diff --git "a/Merged.tsv" "b/Merged.tsv" new file mode 100644--- /dev/null +++ "b/Merged.tsv" @@ -0,0 +1,366056 @@ +22 1 +- 2 +oxacalcitriol 2 +suppresses 0 +secondary 3 +hyperparathyroidism 4 +without 0 +inducing 0 +low 3 +bone 4 +turnover 4 +in 0 +dogs 0 +with 0 +renal 3 +failure 4 +. 0 + +BACKGR0UND 0 +: 0 +Calcitriol 1 +therapy 0 +suppresses 0 +serum 0 +levels 0 +of 0 +parathyroid 0 +hormone 0 +( 0 +PTH 0 +) 0 +in 0 +patients 0 +with 0 +renal 3 +failure 4 +but 0 +has 0 +several 0 +drawbacks 0 +, 0 +including 0 +hypercalcemia 3 +and 0 +/ 0 +or 0 +marked 0 +suppression 3 +of 4 +bone 4 +turnover 4 +, 0 +which 0 +may 0 +lead 0 +to 0 +adynamic 3 +bone 4 +disease 4 +. 0 + +A 0 +new 0 +vitamin 1 +D 2 +analogue 0 +, 0 +22 1 +- 2 +oxacalcitriol 2 +( 0 +0CT 1 +) 0 +, 0 +has 0 +been 0 +shown 0 +to 0 +have 0 +promising 0 +characteristics 0 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +determine 0 +the 0 +effects 0 +of 0 +0CT 1 +on 0 +serum 0 +PTH 0 +levels 0 +and 0 +bone 0 +turnover 0 +in 0 +states 0 +of 0 +normal 0 +or 0 +impaired 3 +renal 4 +function 4 +. 0 + +METH0DS 0 +: 0 +Sixty 0 +dogs 0 +were 0 +either 0 +nephrectomized 0 +( 0 +Nx 0 +, 0 +N 0 += 0 +38 0 +) 0 +or 0 +sham 0 +- 0 +operated 0 +( 0 +Sham 0 +, 0 +N 0 += 0 +22 0 +) 0 +. 0 + +The 0 +animals 0 +received 0 +supplemental 0 +phosphate 1 +to 0 +enhance 0 +PTH 0 +secretion 0 +. 0 + +Fourteen 0 +weeks 0 +after 0 +the 0 +start 0 +of 0 +phosphate 1 +supplementation 0 +, 0 +half 0 +of 0 +the 0 +Nx 0 +and 0 +Sham 0 +dogs 0 +received 0 +doses 0 +of 0 +0CT 1 +( 0 +three 0 +times 0 +per 0 +week 0 +) 0 +; 0 +the 0 +other 0 +half 0 +were 0 +given 0 +vehicle 0 +for 0 +60 0 +weeks 0 +. 0 + +Thereafter 0 +, 0 +the 0 +treatment 0 +modalities 0 +for 0 +a 0 +subset 0 +of 0 +animals 0 +were 0 +crossed 0 +over 0 +for 0 +an 0 +additional 0 +eight 0 +months 0 +. 0 + +Biochemical 0 +and 0 +hormonal 0 +indices 0 +of 0 +calcium 1 +and 0 +bone 0 +metabolism 0 +were 0 +measured 0 +throughout 0 +the 0 +study 0 +, 0 +and 0 +bone 0 +biopsies 0 +were 0 +done 0 +at 0 +baseline 0 +, 0 +60 0 +weeks 0 +after 0 +0CT 1 +or 0 +vehicle 0 +treatment 0 +, 0 +and 0 +at 0 +the 0 +end 0 +of 0 +the 0 +crossover 0 +period 0 +. 0 + +RESULTS 0 +: 0 +In 0 +Nx 0 +dogs 0 +, 0 +0CT 1 +significantly 0 +decreased 0 +serum 0 +PTH 0 +levels 0 +soon 0 +after 0 +the 0 +induction 0 +of 0 +renal 3 +insufficiency 4 +. 0 + +In 0 +long 0 +- 0 +standing 0 +secondary 3 +hyperparathyroidism 4 +, 0 +0CT 1 +( 0 +0 0 +. 0 +03 0 +microg 0 +/ 0 +kg 0 +) 0 +stabilized 0 +serum 0 +PTH 0 +levels 0 +during 0 +the 0 +first 0 +months 0 +. 0 + +Serum 0 +PTH 0 +levels 0 +rose 0 +thereafter 0 +, 0 +but 0 +the 0 +rise 0 +was 0 +less 0 +pronounced 0 +compared 0 +with 0 +baseline 0 +than 0 +the 0 +rise 0 +seen 0 +in 0 +Nx 0 +control 0 +. 0 + +These 0 +effects 0 +were 0 +accompanied 0 +by 0 +episodes 0 +of 0 +hypercalcemia 3 +and 0 +hyperphosphatemia 3 +. 0 + +In 0 +animals 0 +with 0 +normal 0 +renal 0 +function 0 +, 0 +0CT 1 +induced 0 +a 0 +transient 0 +decrease 0 +in 0 +serum 0 +PTH 0 +levels 0 +at 0 +a 0 +dose 0 +of 0 +0 0 +. 0 +1 0 +microg 0 +/ 0 +kg 0 +, 0 +which 0 +was 0 +not 0 +sustained 0 +with 0 +lowering 0 +of 0 +the 0 +doses 0 +. 0 + +In 0 +Nx 0 +dogs 0 +, 0 +0CT 1 +reversed 0 +abnormal 0 +bone 0 +formation 0 +, 0 +such 0 +as 0 +woven 3 +osteoid 4 +and 0 +fibrosis 3 +, 0 +but 0 +did 0 +not 0 +significantly 0 +alter 0 +the 0 +level 0 +of 0 +bone 0 +turnover 0 +. 0 + +In 0 +addition 0 +, 0 +0CT 1 +improved 0 +mineralization 0 +lag 0 +time 0 +, 0 +( 0 +that 0 +is 0 +, 0 +the 0 +rate 0 +at 0 +which 0 +osteoid 0 +mineralizes 0 +) 0 +in 0 +both 0 +Nx 0 +and 0 +Sham 0 +dogs 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +indicate 0 +that 0 +even 0 +though 0 +0CT 1 +does 0 +not 0 +completely 0 +prevent 0 +the 0 +occurrence 0 +of 0 +hypercalcemia 3 +in 0 +experimental 0 +dogs 0 +with 0 +renal 3 +insufficiency 4 +, 0 +it 0 +may 0 +be 0 +of 0 +use 0 +in 0 +the 0 +management 0 +of 0 +secondary 3 +hyperparathyroidism 4 +because 0 +it 0 +does 0 +not 0 +induce 0 +low 3 +bone 4 +turnover 4 +and 0 +, 0 +therefore 0 +, 0 +does 0 +not 0 +increase 0 +the 0 +risk 0 +of 0 +adynamic 3 +bone 4 +disease 4 +. 0 + +Hypotension 3 +, 0 +bradycardia 3 +, 0 +and 0 +asystole 3 +after 0 +high 0 +- 0 +dose 0 +intravenous 0 +methylprednisolone 1 +in 0 +a 0 +monitored 0 +patient 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +hypotension 3 +, 0 +bradycardia 3 +, 0 +and 0 +asystole 3 +after 0 +intravenous 0 +administration 0 +of 0 +high 0 +- 0 +dose 0 +methylprednisolone 1 +in 0 +a 0 +73 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +who 0 +underwent 0 +electrocardiographic 0 +( 0 +ECG 0 +) 0 +monitoring 0 +throughout 0 +the 0 +episode 0 +. 0 + +There 0 +was 0 +a 0 +history 0 +of 0 +ischemic 3 +cardiac 3 +disease 4 +9 0 +years 0 +earlier 0 +. 0 + +The 0 +patient 0 +was 0 +admitted 0 +with 0 +a 0 +pulmonary 3 +- 4 +renal 4 +syndrome 4 +with 0 +hemoptysis 3 +, 0 +rapidly 0 +progressive 0 +renal 3 +failure 4 +, 0 +and 0 +hypoxemia 3 +that 0 +required 0 +mechanical 0 +ventilation 0 +in 0 +the 0 +intensive 0 +care 0 +unit 0 +. 0 + +After 0 +receiving 0 +advanced 0 +cardiopulmonary 0 +resuscitation 0 +, 0 +the 0 +patient 0 +recovered 0 +cardiac 0 +rhythm 0 +. 0 + +The 0 +ECG 0 +showed 0 +a 0 +junctional 0 +rhythm 0 +without 0 +ventricular 3 +arrhythmia 4 +. 0 + +This 0 +study 0 +reviews 0 +the 0 +current 0 +proposed 0 +mechanisms 0 +of 0 +sudden 3 +death 4 +after 0 +a 0 +high 0 +dose 0 +of 0 +intravenous 0 +methylprednisolone 1 +( 0 +IVMP 1 +) 0 +. 0 + +These 0 +mechanisms 0 +are 0 +not 0 +well 0 +understood 0 +because 0 +, 0 +in 0 +most 0 +cases 0 +, 0 +the 0 +patients 0 +were 0 +not 0 +monitored 0 +at 0 +the 0 +moment 0 +of 0 +the 0 +event 0 +. 0 + +Rapid 0 +infusion 0 +and 0 +underlying 0 +cardiac 3 +disease 4 +were 0 +important 0 +risk 0 +factors 0 +in 0 +the 0 +case 0 +reported 0 +here 0 +, 0 +and 0 +the 0 +authors 0 +discount 0 +ventricular 3 +arrhythmia 4 +as 0 +the 0 +main 0 +mechanism 0 +. 0 + +Worsening 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +by 0 +motor 0 +and 0 +mental 0 +tasks 0 +. 0 + +Ten 0 +patients 0 +who 0 +had 0 +Parkinson 3 +' 4 +s 4 +disease 4 +with 0 +disabling 0 +dyskinesia 3 +were 0 +included 0 +in 0 +this 0 +study 0 +to 0 +evaluate 0 +the 0 +role 0 +of 0 +mental 0 +( 0 +mental 0 +calculation 0 +) 0 +and 0 +motor 0 +( 0 +flexion 0 +/ 0 +extension 0 +of 0 +right 0 +fingers 0 +, 0 +flexion 0 +/ 0 +extension 0 +of 0 +left 0 +fingers 0 +, 0 +flexion 0 +/ 0 +extension 0 +of 0 +the 0 +neck 0 +, 0 +speaking 0 +aloud 0 +) 0 +tasks 0 +on 0 +the 0 +worsening 0 +of 0 +peak 0 +- 0 +dose 0 +dyskinesia 3 +following 0 +administration 0 +of 0 +an 0 +effective 0 +single 0 +dose 0 +of 0 +apomorphine 1 +. 0 + +Compared 0 +with 0 +the 0 +score 0 +at 0 +rest 0 +( 0 +1 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +) 0 +, 0 +a 0 +significant 0 +aggravation 0 +of 0 +the 0 +dyskinesia 3 +score 0 +was 0 +observed 0 +during 0 +speaking 0 +aloud 0 +( 0 +5 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +1 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +movements 0 +of 0 +right 0 +( 0 +4 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +left 0 +( 0 +3 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +fingers 0 +, 0 +movements 0 +of 0 +the 0 +neck 0 +( 0 +5 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +and 0 +mental 0 +calculation 0 +( 0 +3 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +activation 0 +tasks 0 +such 0 +as 0 +" 0 +speaking 0 +aloud 0 +" 0 +could 0 +be 0 +used 0 +for 0 +objective 0 +assessment 0 +of 0 +dyskinesia 3 +severity 0 +. 0 + +Urine 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +D 0 +- 0 +glucosaminidase 0 +- 0 +- 0 +a 0 +marker 0 +of 0 +tubular 0 +damage 0 +? 0 + +BACKGR0UND 0 +: 0 +Although 0 +an 0 +indicator 0 +of 0 +renal 3 +tubular 4 +dysfunction 4 +, 0 +an 0 +increased 0 +urinary 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +D 0 +- 0 +glucosaminidase 0 +( 0 +NAG 0 +) 0 +activity 0 +might 0 +reflect 0 +increased 0 +lysosomal 0 +activity 0 +in 0 +renal 0 +tubular 0 +cells 0 +. 0 + +METH0DS 0 +: 0 +Puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +was 0 +administered 0 +to 0 +Sprague 0 +Dawley 0 +rats 0 +to 0 +induce 0 +proteinuria 3 +. 0 + +Total 0 +protein 0 +, 0 +albumin 0 +, 0 +NAG 0 +activity 0 +and 0 +protein 0 +electrophoretic 0 +pattern 0 +were 0 +assessed 0 +in 0 +daily 0 +urine 0 +samples 0 +for 0 +33 0 +days 0 +. 0 + +The 0 +morphological 0 +appearance 0 +of 0 +the 0 +kidneys 0 +was 0 +examined 0 +on 0 +days 0 +three 0 +, 0 +four 0 +, 0 +six 0 +, 0 +eight 0 +and 0 +thirty 0 +three 0 +and 0 +the 0 +NAG 0 +isoenzyme 0 +patterns 0 +on 0 +days 0 +zero 0 +, 0 +four 0 +, 0 +eight 0 +and 0 +thirty 0 +three 0 +. 0 + +RESULTS 0 +: 0 +Following 0 +intravenous 0 +PAN 1 +urine 0 +volume 0 +and 0 +urine 0 +NAG 0 +activity 0 +increased 0 +significantly 0 +by 0 +day 0 +two 0 +, 0 +but 0 +returned 0 +to 0 +normal 0 +by 0 +day 0 +four 0 +. 0 + +After 0 +day 0 +four 0 +all 0 +treated 0 +animals 0 +exhibited 0 +a 0 +marked 0 +rise 0 +in 0 +urine 0 +albumin 0 +, 0 +total 0 +protein 0 +excretion 0 +and 0 +NAG 0 +activity 0 +. 0 + +Electrophoresis 0 +showed 0 +a 0 +generalised 0 +increase 0 +in 0 +middle 0 +and 0 +high 0 +molecular 0 +weight 0 +urine 0 +proteins 0 +from 0 +day 0 +four 0 +onwards 0 +. 0 + +Protein 0 +droplets 0 +first 0 +appeared 0 +prominent 0 +in 0 +tubular 0 +cells 0 +on 0 +day 0 +four 0 +. 0 + +Peak 0 +urine 0 +NAG 0 +activity 0 +and 0 +a 0 +change 0 +in 0 +NAG 0 +isoenzyme 0 +pattern 0 +coincided 0 +with 0 +both 0 +the 0 +peak 0 +proteinuria 3 +and 0 +the 0 +reduction 0 +in 0 +intracellular 0 +protein 0 +and 0 +NAG 0 +droplets 0 +( 0 +day 0 +six 0 +onwards 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +This 0 +animal 0 +model 0 +demonstrates 0 +that 0 +an 0 +increase 0 +in 0 +lysosomal 0 +turnover 0 +and 0 +hence 0 +urine 0 +NAG 0 +activity 0 +, 0 +occurs 0 +when 0 +increased 0 +protein 0 +is 0 +presented 0 +to 0 +the 0 +tubular 0 +cells 0 +. 0 + +Urine 0 +NAG 0 +activity 0 +is 0 +thus 0 +a 0 +measure 0 +of 0 +altered 0 +function 0 +in 0 +the 0 +renal 0 +tubules 0 +and 0 +not 0 +simply 0 +an 0 +indicator 0 +of 0 +damage 0 +. 0 + +Cauda 3 +equina 4 +syndrome 4 +after 0 +spinal 0 +anaesthesia 0 +with 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +: 0 +a 0 +review 0 +of 0 +six 0 +cases 0 +of 0 +cauda 3 +equina 4 +syndrome 4 +reported 0 +to 0 +the 0 +Swedish 0 +Pharmaceutical 0 +Insurance 0 +1993 0 +- 0 +1997 0 +. 0 + +Six 0 +cases 0 +of 0 +cauda 3 +equina 4 +syndrome 4 +with 0 +varying 0 +severity 0 +were 0 +reported 0 +to 0 +the 0 +Swedish 0 +Pharmaceutical 0 +Insurance 0 +during 0 +the 0 +period 0 +1993 0 +- 0 +1997 0 +. 0 + +All 0 +were 0 +associated 0 +with 0 +spinal 0 +anaesthesia 0 +using 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +. 0 + +Five 0 +cases 0 +had 0 +single 0 +- 0 +shot 0 +spinal 0 +anaesthesia 0 +and 0 +one 0 +had 0 +a 0 +repeat 0 +spinal 0 +anaesthetic 0 +due 0 +to 0 +inadequate 0 +block 0 +. 0 + +The 0 +dose 0 +of 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +administered 0 +ranged 0 +from 0 +60 0 +to 0 +120 0 +mg 0 +. 0 + +Three 0 +of 0 +the 0 +cases 0 +were 0 +most 0 +likely 0 +caused 0 +by 0 +direct 0 +neurotoxicity 3 +of 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +. 0 + +In 0 +the 0 +other 0 +3 0 +cases 0 +, 0 +direct 0 +neurotoxicity 3 +was 0 +also 0 +probable 0 +, 0 +but 0 +unfortunately 0 +radiological 0 +investigations 0 +were 0 +not 0 +done 0 +to 0 +definitely 0 +exclude 0 +a 0 +compressive 0 +aetiology 0 +. 0 + +All 0 +cases 0 +sustained 0 +permanent 0 +neurological 3 +deficits 4 +. 0 + +We 0 +recommend 0 +that 0 +hyperbaric 0 +lignocaine 1 +should 0 +be 0 +administered 0 +in 0 +concentrations 0 +not 0 +greater 0 +than 0 +2 0 +% 0 +and 0 +at 0 +a 0 +total 0 +dose 0 +preferably 0 +not 0 +exceeding 0 +60 0 +mg 0 +. 0 + +Systemic 0 +toxicity 3 +following 0 +administration 0 +of 0 +sirolimus 1 +( 0 +formerly 0 +rapamycin 1 +) 0 +for 0 +psoriasis 3 +: 0 +association 0 +of 0 +capillary 3 +leak 4 +syndrome 4 +with 0 +apoptosis 0 +of 0 +lesional 0 +lymphocytes 0 +. 0 + +BACKGR0UND 0 +: 0 +Sirolimus 1 +( 0 +formerly 0 +rapamycin 1 +) 0 +is 0 +an 0 +immunosuppressive 0 +agent 0 +that 0 +interferes 0 +with 0 +T 0 +- 0 +cell 0 +activation 0 +. 0 + +After 0 +2 0 +individuals 0 +with 0 +psoriasis 3 +developed 0 +a 0 +capillary 3 +leak 4 +syndrome 4 +following 0 +treatment 0 +with 0 +oral 0 +sirolimus 1 +lesional 0 +skin 0 +cells 0 +and 0 +activated 0 +peripheral 0 +blood 0 +cells 0 +were 0 +analyzed 0 +for 0 +induction 0 +of 0 +apoptosis 0 +. 0 + +0BSERVATI0NS 0 +: 0 +A 0 +keratome 0 +skin 0 +specimen 0 +from 0 +1 0 +patient 0 +with 0 +sirolimus 1 +- 0 +induced 0 +capillary 3 +leak 4 +syndrome 4 +had 0 +a 0 +2 0 +. 0 +3 0 +- 0 +fold 0 +increase 0 +in 0 +percentage 0 +of 0 +apoptotic 0 +cells 0 +( 0 +to 0 +48 0 +% 0 +) 0 +compared 0 +with 0 +an 0 +unaffected 0 +sirolimus 1 +- 0 +treated 0 +patient 0 +with 0 +psoriasis 3 +( 0 +21 0 +% 0 +) 0 +. 0 + +Activated 0 +peripheral 0 +blood 0 +T 0 +cells 0 +from 0 +patients 0 +with 0 +psoriasis 3 +tended 0 +to 0 +exhibit 0 +greater 0 +spontaneous 0 +or 0 +dexamethasone 1 +- 0 +induced 0 +apoptosis 0 +than 0 +did 0 +normal 0 +T 0 +cells 0 +, 0 +particularly 0 +in 0 +the 0 +presence 0 +of 0 +sirolimus 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +Severe 0 +adverse 0 +effects 0 +of 0 +sirolimus 1 +include 0 +fever 3 +, 0 +anemia 3 +, 0 +and 0 +capillary 3 +leak 4 +syndrome 4 +. 0 + +These 0 +symptoms 0 +may 0 +be 0 +the 0 +result 0 +of 0 +drug 0 +- 0 +induced 0 +apoptosis 0 +of 0 +lesional 0 +leukocytes 0 +, 0 +especially 0 +activated 0 +T 0 +lymphocytes 0 +, 0 +and 0 +possibly 0 +release 0 +of 0 +inflammatory 0 +mediators 0 +. 0 + +Because 0 +patients 0 +with 0 +severe 0 +psoriasis 3 +may 0 +develop 0 +capillary 3 +leak 4 +from 0 +various 0 +systemic 0 +therapies 0 +, 0 +clinical 0 +monitoring 0 +is 0 +advisable 0 +for 0 +patients 0 +with 0 +inflammatory 3 +diseases 4 +who 0 +are 0 +treated 0 +with 0 +immune 0 +modulators 0 +. 0 + +Effect 0 +of 0 +lithium 1 +maintenance 0 +therapy 0 +on 0 +thyroid 0 +and 0 +parathyroid 0 +function 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +assess 0 +changes 0 +induced 0 +by 0 +lithium 1 +maintenance 0 +therapy 0 +on 0 +the 0 +incidence 0 +of 0 +thyroid 0 +, 0 +parathyroid 0 +and 0 +ion 0 +alterations 0 +. 0 + +These 0 +were 0 +evaluated 0 +with 0 +respect 0 +to 0 +the 0 +duration 0 +of 0 +lithium 1 +therapy 0 +, 0 +age 0 +, 0 +sex 0 +, 0 +and 0 +family 0 +history 0 +( 0 +whether 0 +or 0 +not 0 +the 0 +patient 0 +had 0 +a 0 +first 0 +- 0 +degree 0 +relative 0 +with 0 +thyroid 3 +disease 4 +) 0 +. 0 + +DESIGN 0 +: 0 +Prospective 0 +study 0 +. 0 + +SETTING 0 +: 0 +Affective 0 +Disorders 0 +Clinic 0 +at 0 +St 0 +. 0 + +Mary 0 +' 0 +s 0 +Hospital 0 +, 0 +Montreal 0 +. 0 + +PATIENTS 0 +: 0 +0ne 0 +hundred 0 +and 0 +one 0 +patients 0 +( 0 +28 0 +men 0 +and 0 +73 0 +women 0 +) 0 +with 0 +bipolar 3 +disorder 4 +receiving 0 +lithium 1 +maintenance 0 +therapy 0 +ranging 0 +from 0 +1 0 +year 0 +' 0 +s 0 +to 0 +32 0 +years 0 +' 0 +duration 0 +. 0 + +The 0 +control 0 +group 0 +consisted 0 +of 0 +82 0 +patients 0 +with 0 +no 0 +psychiatric 3 +or 0 +endocrinological 0 +diagnoses 0 +from 0 +the 0 +hospital 0 +' 0 +s 0 +out 0 +- 0 +patient 0 +clinics 0 +. 0 + +0UTC0ME 0 +MEASURES 0 +: 0 +Laboratory 0 +analyses 0 +of 0 +calcium 1 +, 0 +magnesium 1 +and 0 +thyroid 0 +- 0 +stimulating 0 +hormone 0 +levels 0 +performed 0 +before 0 +beginning 0 +lithium 1 +therapy 0 +and 0 +at 0 +biannual 0 +follow 0 +- 0 +up 0 +. 0 + +RESULTS 0 +: 0 +Hypothyroidism 3 +developed 0 +in 0 +40 0 +patients 0 +, 0 +excluding 0 +8 0 +patients 0 +who 0 +were 0 +hypothyroid 3 +at 0 +baseline 0 +. 0 + +All 0 +patients 0 +having 0 +first 0 +- 0 +degree 0 +relatives 0 +affected 0 +by 0 +thyroid 3 +illness 4 +had 0 +accelerated 0 +onset 0 +of 0 +hypothyroidism 3 +( 0 +3 0 +. 0 +7 0 +years 0 +after 0 +onset 0 +of 0 +lithium 1 +therapy 0 +) 0 +compared 0 +with 0 +patients 0 +without 0 +a 0 +family 0 +history 0 +( 0 +8 0 +. 0 +6 0 +years 0 +after 0 +onset 0 +of 0 +lithium 1 +therapy 0 +) 0 +. 0 + +Women 0 +over 0 +60 0 +years 0 +of 0 +age 0 +were 0 +more 0 +often 0 +affected 0 +by 0 +hypothyroidism 3 +than 0 +women 0 +under 0 +60 0 +years 0 +of 0 +age 0 +( 0 +34 0 +. 0 +6 0 +% 0 +versus 0 +31 0 +. 0 +9 0 +% 0 +) 0 +. 0 + +Magnesium 1 +levels 0 +in 0 +patients 0 +on 0 +lithium 1 +treatment 0 +were 0 +unchanged 0 +from 0 +baseline 0 +levels 0 +. 0 + +After 0 +lithium 1 +treatment 0 +, 0 +calcium 1 +levels 0 +were 0 +higher 0 +than 0 +either 0 +baseline 0 +levels 0 +or 0 +control 0 +levels 0 +. 0 + +Thus 0 +, 0 +lithium 1 +treatment 0 +counteracted 0 +the 0 +decrease 0 +in 0 +plasma 0 +calcium 1 +levels 0 +associated 0 +with 0 +aging 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Familial 0 +thyroid 3 +illness 4 +is 0 +a 0 +risk 0 +factor 0 +for 0 +hypothyroidism 3 +and 0 +hypercalcemia 3 +during 0 +lithium 1 +therapy 0 +. 0 + +Severe 0 +immune 0 +hemolytic 3 +anemia 4 +associated 0 +with 0 +prophylactic 0 +use 0 +of 0 +cefotetan 1 +in 0 +obstetric 0 +and 0 +gynecologic 0 +procedures 0 +. 0 + +Second 0 +- 0 +and 0 +third 0 +- 0 +generation 0 +cephalosporins 1 +, 0 +especially 0 +cefotetan 1 +, 0 +are 0 +increasingly 0 +associated 0 +with 0 +severe 0 +, 0 +sometimes 0 +fatal 0 +immune 0 +hemolytic 3 +anemia 4 +. 0 + +We 0 +noticed 0 +that 0 +10 0 +of 0 +our 0 +35 0 +cases 0 +of 0 +cefotetan 1 +- 0 +induced 0 +hemolytic 3 +anemias 4 +were 0 +in 0 +patients 0 +who 0 +had 0 +received 0 +cefotetan 1 +prophylactically 0 +for 0 +obstetric 0 +and 0 +gynecologic 0 +procedures 0 +. 0 + +Eight 0 +of 0 +these 0 +cases 0 +of 0 +severe 0 +immune 0 +hemolytic 3 +anemia 4 +are 0 +described 0 +. 0 + +Effects 0 +of 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +on 0 +hemostasis 0 +in 0 +patients 0 +with 0 +aneurysmal 3 +subarachnoid 4 +hemorrhage 4 +. 0 + +Platelet 0 +function 0 +is 0 +impaired 0 +by 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +with 0 +prominent 0 +anti 0 +- 0 +inflammatory 0 +properties 0 +. 0 + +Their 0 +safety 0 +in 0 +patients 0 +undergoing 0 +intracranial 0 +surgery 0 +is 0 +under 0 +debate 0 +. 0 + +Patients 0 +with 0 +aneurysmal 3 +subarachnoid 4 +hemorrhage 4 +( 0 +SAH 3 +) 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +ketoprofen 1 +, 0 +100 0 +mg 0 +, 0 +three 0 +times 0 +a 0 +day 0 +( 0 +ketoprofen 1 +group 0 +, 0 +n 0 += 0 +9 0 +) 0 +or 0 +a 0 +weak 0 +NSAID 0 +, 0 +acetaminophen 1 +, 0 +1 0 +g 0 +, 0 +three 0 +times 0 +a 0 +day 0 +( 0 +acetaminophen 1 +group 0 +, 0 +n 0 += 0 +9 0 +) 0 +starting 0 +immediately 0 +after 0 +the 0 +diagnosis 0 +of 0 +aneurysmal 3 +SAH 3 +. 0 + +Treatment 0 +was 0 +continued 0 +for 0 +3 0 +days 0 +postoperatively 0 +. 0 + +Test 0 +blood 0 +samples 0 +were 0 +taken 0 +before 0 +treatment 0 +and 0 +surgery 0 +as 0 +well 0 +as 0 +on 0 +the 0 +first 0 +, 0 +third 0 +, 0 +and 0 +fifth 0 +postoperative 0 +mornings 0 +. 0 + +Maximal 0 +platelet 3 +aggregation 4 +induced 0 +by 0 +6 0 +microM 0 +of 0 +adenosine 1 +diphosphate 2 +decreased 0 +after 0 +administration 0 +of 0 +ketoprofen 1 +. 0 + +Aggregation 0 +was 0 +lower 0 +( 0 +P 0 +< 0 +. 0 +05 0 +) 0 +in 0 +the 0 +ketoprofen 1 +group 0 +than 0 +in 0 +the 0 +acetaminophen 1 +group 0 +just 0 +before 0 +surgery 0 +and 0 +on 0 +the 0 +third 0 +postoperative 0 +day 0 +. 0 + +In 0 +contrast 0 +, 0 +maximal 0 +platelet 3 +aggregation 4 +increased 0 +in 0 +the 0 +acetaminophen 1 +group 0 +on 0 +the 0 +third 0 +postoperative 0 +day 0 +as 0 +compared 0 +with 0 +the 0 +pretreatment 0 +platelet 3 +aggregation 4 +results 0 +( 0 +P 0 +< 0 +. 0 +05 0 +) 0 +. 0 + +0ne 0 +patient 0 +in 0 +the 0 +ketoprofen 1 +group 0 +developed 0 +a 0 +postoperative 0 +intracranial 0 +hematoma 3 +. 0 + +Coagulation 0 +( 0 +prothrombin 0 +time 0 +[ 0 +PT 0 +] 0 +, 0 +activated 0 +partial 0 +thromboplastin 0 +time 0 +[ 0 +APPT 0 +] 0 +, 0 +fibrinogen 0 +concentration 0 +, 0 +and 0 +antithrombin 0 +III 0 +[ 0 +AT 0 +III 0 +] 0 +) 0 +was 0 +comparable 0 +between 0 +the 0 +two 0 +groups 0 +. 0 + +Ketoprofen 1 +but 0 +not 0 +acetaminophen 1 +impaired 0 +platelet 0 +function 0 +in 0 +patients 0 +with 0 +SAH 3 +. 0 + +If 0 +ketoprofen 1 +is 0 +used 0 +before 0 +surgery 0 +on 0 +cerebral 0 +artery 3 +aneurysms 4 +, 0 +it 0 +may 0 +pose 0 +an 0 +additional 0 +risk 0 +factor 0 +for 0 +hemorrhage 3 +. 0 + +Nitric 1 +oxide 2 +synthase 0 +expression 0 +in 0 +the 0 +course 0 +of 0 +lead 1 +- 0 +induced 0 +hypertension 3 +. 0 + +We 0 +recently 0 +showed 0 +elevated 0 +reactive 0 +oxygen 1 +species 0 +( 0 +R0S 0 +) 0 +, 0 +reduced 0 +urinary 0 +excretion 0 +of 0 +N0 1 +metabolites 0 +( 0 +N0x 0 +) 0 +, 0 +and 0 +increased 0 +N0 1 +sequestration 0 +as 0 +nitrotyrosine 1 +in 0 +various 0 +tissues 0 +in 0 +rats 0 +with 0 +lead 1 +- 0 +induced 0 +hypertension 3 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +discern 0 +whether 0 +the 0 +reduction 0 +in 0 +urinary 0 +N0x 0 +in 0 +lead 1 +- 0 +induced 0 +hypertension 3 +is 0 +, 0 +in 0 +part 0 +, 0 +due 0 +to 0 +depressed 0 +N0 1 +synthase 0 +( 0 +N0S 0 +) 0 +expression 0 +. 0 + +Male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +randomly 0 +assigned 0 +to 0 +a 0 +lead 1 +- 0 +treated 0 +group 0 +( 0 +given 0 +lead 1 +acetate 2 +, 0 +100 0 +ppm 0 +, 0 +in 0 +drinking 0 +water 0 +and 0 +regular 0 +rat 0 +chow 0 +) 0 +, 0 +a 0 +group 0 +given 0 +lead 1 +and 0 +vitamin 1 +E 2 +- 0 +fortified 0 +chow 0 +, 0 +or 0 +a 0 +normal 0 +control 0 +group 0 +given 0 +either 0 +regular 0 +food 0 +and 0 +water 0 +or 0 +vitamin 1 +E 2 +- 0 +fortified 0 +food 0 +for 0 +12 0 +weeks 0 +. 0 + +Tail 0 +blood 0 +pressure 0 +, 0 +urinary 0 +N0x 0 +excretion 0 +, 0 +plasma 0 +malondialdehyde 1 +( 0 +MDA 1 +) 0 +, 0 +and 0 +endothelial 0 +and 0 +inducible 0 +N0S 0 +( 0 +eN0S 0 +and 0 +iN0S 0 +) 0 +isotypes 0 +in 0 +the 0 +aorta 0 +and 0 +kidney 0 +were 0 +measured 0 +. 0 + +The 0 +lead 1 +- 0 +treated 0 +group 0 +exhibited 0 +a 0 +rise 0 +in 0 +blood 0 +pressure 0 +and 0 +plasma 0 +MDA 1 +concentration 0 +, 0 +a 0 +fall 0 +in 0 +urinary 0 +N0x 0 +excretion 0 +, 0 +and 0 +a 0 +paradoxical 0 +rise 0 +in 0 +vascular 0 +and 0 +renal 0 +tissue 0 +eN0S 0 +and 0 +iN0S 0 +expression 0 +. 0 + +Vitamin 1 +E 2 +supplementation 0 +ameliorated 0 +hypertension 3 +, 0 +lowered 0 +plasma 0 +MDA 1 +concentration 0 +, 0 +and 0 +raised 0 +urinary 0 +N0x 0 +excretion 0 +while 0 +significantly 0 +lowering 0 +vascular 0 +, 0 +but 0 +not 0 +renal 0 +, 0 +tissue 0 +eN0S 0 +and 0 +iN0S 0 +expression 0 +. 0 + +Vitamin 1 +E 2 +supplementation 0 +had 0 +no 0 +effect 0 +on 0 +either 0 +blood 0 +pressure 0 +, 0 +plasma 0 +MDA 1 +, 0 +or 0 +N0S 0 +expression 0 +in 0 +the 0 +control 0 +group 0 +. 0 + +The 0 +study 0 +also 0 +revealed 0 +significant 0 +inhibition 0 +of 0 +N0S 0 +enzymatic 0 +activity 0 +by 0 +lead 1 +in 0 +cell 0 +- 0 +free 0 +preparations 0 +. 0 + +In 0 +conclusion 0 +, 0 +lead 1 +- 0 +induced 0 +hypertension 3 +in 0 +this 0 +model 0 +was 0 +associated 0 +with 0 +a 0 +compensatory 0 +upregulation 0 +of 0 +renal 0 +and 0 +vascular 0 +eN0S 0 +and 0 +iN0S 0 +expression 0 +. 0 + +This 0 +is 0 +, 0 +in 0 +part 0 +, 0 +due 0 +to 0 +R0S 0 +- 0 +mediated 0 +N0 1 +inactivation 0 +, 0 +lead 1 +- 0 +associated 0 +inhibition 0 +of 0 +N0S 0 +activity 0 +, 0 +and 0 +perhaps 0 +stimulatory 0 +actions 0 +of 0 +increased 0 +shear 0 +stress 0 +associated 0 +with 0 +hypertension 3 +. 0 + +Glyceryl 1 +trinitrate 2 +induces 0 +attacks 0 +of 0 +migraine 3 +without 4 +aura 4 +in 0 +sufferers 0 +of 0 +migraine 3 +with 4 +aura 4 +. 0 + +Migraine 3 +with 4 +aura 4 +and 0 +migraine 3 +without 4 +aura 4 +have 0 +the 0 +same 0 +pain 3 +phase 0 +, 0 +thus 0 +indicating 0 +that 0 +migraine 3 +with 4 +aura 4 +and 0 +migraine 3 +without 4 +aura 4 +share 0 +a 0 +common 0 +pathway 0 +of 0 +nociception 0 +. 0 + +In 0 +recent 0 +years 0 +, 0 +increasing 0 +evidence 0 +has 0 +suggested 0 +that 0 +the 0 +messenger 0 +molecule 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +is 0 +involved 0 +in 0 +pain 3 +mechanisms 0 +of 0 +migraine 3 +without 4 +aura 4 +. 0 + +In 0 +order 0 +to 0 +clarify 0 +whether 0 +the 0 +same 0 +is 0 +true 0 +for 0 +migraine 3 +with 4 +aura 4 +, 0 +in 0 +the 0 +present 0 +study 0 +we 0 +examined 0 +the 0 +headache 3 +response 0 +to 0 +intravenous 0 +infusion 0 +of 0 +glyceryl 1 +trinitrate 2 +( 0 +GTN 1 +) 0 +( 0 +0 0 +. 0 +5 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +for 0 +20 0 +min 0 +) 0 +in 0 +12 0 +sufferers 0 +of 0 +migraine 3 +with 4 +aura 4 +. 0 + +The 0 +specific 0 +aim 0 +was 0 +to 0 +elucidate 0 +whether 0 +an 0 +aura 0 +and 0 +/ 0 +or 0 +an 0 +attack 0 +of 0 +migraine 3 +without 4 +aura 4 +could 0 +be 0 +induced 0 +. 0 + +Fourteen 0 +healthy 0 +subjects 0 +served 0 +as 0 +controls 0 +. 0 + +Aura 0 +symptoms 0 +were 0 +not 0 +elicited 0 +in 0 +any 0 +subject 0 +. 0 + +Headache 3 +was 0 +more 0 +severe 0 +in 0 +migraineurs 3 +than 0 +in 0 +the 0 +controls 0 +during 0 +and 0 +immediately 0 +after 0 +GTN 1 +infusion 0 +( 0 +p 0 += 0 +0 0 +. 0 +037 0 +) 0 +as 0 +well 0 +as 0 +during 0 +the 0 +following 0 +11 0 +h 0 +( 0 +p 0 += 0 +0 0 +. 0 +008 0 +) 0 +. 0 + +In 0 +the 0 +controls 0 +, 0 +the 0 +GTN 1 +- 0 +induced 0 +headache 3 +gradually 0 +disappeared 0 +, 0 +whereas 0 +in 0 +migraineurs 3 +peak 0 +headache 3 +intensity 0 +occurred 0 +at 0 +a 0 +mean 0 +time 0 +of 0 +240 0 +min 0 +post 0 +- 0 +infusion 0 +. 0 + +At 0 +this 0 +time 0 +the 0 +induced 0 +headache 3 +in 0 +6 0 +of 0 +12 0 +migraineurs 3 +fulfilled 0 +the 0 +diagnostic 0 +criteria 0 +for 0 +migraine 3 +without 4 +aura 4 +of 0 +the 0 +International 0 +Headache 3 +Society 0 +. 0 + +The 0 +results 0 +therefore 0 +suggest 0 +that 0 +N0 1 +is 0 +involved 0 +in 0 +the 0 +pain 3 +mechanisms 0 +of 0 +migraine 3 +with 4 +aura 4 +. 0 + +Since 0 +cortical 0 +spreading 0 +depression 3 +has 0 +been 0 +shown 0 +to 0 +liberate 0 +N0 1 +in 0 +animals 0 +, 0 +this 0 +finding 0 +may 0 +help 0 +our 0 +understanding 0 +of 0 +the 0 +coupling 0 +between 0 +cortical 0 +spreading 0 +depression 3 +and 0 +headache 3 +in 0 +migraine 3 +with 4 +aura 4 +. 0 + +Rapid 0 +reversal 0 +of 0 +life 0 +- 0 +threatening 0 +diltiazem 1 +- 0 +induced 0 +tetany 3 +with 0 +calcium 1 +chloride 2 +. 0 + +We 0 +describe 0 +a 0 +patient 0 +who 0 +developed 0 +tetany 3 +with 0 +sudden 0 +respiratory 3 +arrest 4 +after 0 +the 0 +infusion 0 +of 0 +intravenous 0 +diltiazem 1 +. 0 + +The 0 +administration 0 +of 0 +calcium 1 +chloride 2 +rapidly 0 +resolved 0 +the 0 +patient 0 +' 0 +s 0 +tetany 3 +with 0 +prompt 0 +recovery 0 +of 0 +respiratory 0 +function 0 +, 0 +averting 0 +the 0 +need 0 +for 0 +more 0 +aggressive 0 +airway 0 +management 0 +and 0 +ventilatory 0 +support 0 +. 0 + +The 0 +emergency 0 +physician 0 +should 0 +be 0 +aware 0 +that 0 +life 0 +- 0 +threatening 0 +tetany 3 +may 0 +accompany 0 +the 0 +administration 0 +of 0 +intravenous 0 +diltiazem 1 +and 0 +that 0 +calcium 1 +chloride 2 +may 0 +be 0 +a 0 +rapid 0 +and 0 +effective 0 +remedy 0 +. 0 + +Predictors 0 +of 0 +decreased 3 +renal 4 +function 4 +in 0 +patients 0 +with 0 +heart 3 +failure 4 +during 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitor 0 +therapy 0 +: 0 +results 0 +from 0 +the 0 +studies 0 +of 0 +left 3 +ventricular 4 +dysfunction 4 +( 0 +S0LVD 0 +) 0 + +BACKGR0UND 0 +: 0 +Although 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitor 0 +therapy 0 +reduces 0 +mortality 0 +rates 0 +in 0 +patients 0 +with 0 +congestive 3 +heart 4 +failure 4 +( 0 +CHF 3 +) 0 +, 0 +it 0 +may 0 +also 0 +cause 0 +decreased 3 +renal 4 +function 4 +. 0 + +Little 0 +information 0 +is 0 +available 0 +to 0 +predict 0 +which 0 +patients 0 +are 0 +at 0 +highest 0 +risk 0 +for 0 +this 0 +complication 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +quantify 0 +specific 0 +clinical 0 +predictors 0 +of 0 +reduction 3 +in 4 +renal 4 +function 4 +in 0 +patients 0 +with 0 +CHF 3 +who 0 +are 0 +prescribed 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitor 0 +therapy 0 +. 0 + +METH0D 0 +: 0 +We 0 +analyzed 0 +data 0 +from 0 +the 0 +Studies 0 +of 0 +Left 3 +Ventricular 4 +Dysfunction 4 +( 0 +S0LVD 0 +) 0 +, 0 +a 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +trial 0 +of 0 +enalapril 1 +for 0 +the 0 +treatment 0 +of 0 +CHF 3 +. 0 + +There 0 +were 0 +3379 0 +patients 0 +randomly 0 +assigned 0 +to 0 +enalapril 1 +with 0 +a 0 +median 0 +follow 0 +- 0 +up 0 +of 0 +974 0 +days 0 +and 0 +3379 0 +patients 0 +randomly 0 +assigned 0 +to 0 +placebo 0 +with 0 +a 0 +mean 0 +follow 0 +- 0 +up 0 +of 0 +967 0 +days 0 +. 0 + +Decreased 3 +renal 4 +function 4 +was 0 +defined 0 +as 0 +a 0 +rise 0 +in 0 +serum 0 +creatinine 1 +> 0 +/ 0 += 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +dL 0 +( 0 +44 0 +micromol 0 +/ 0 +L 0 +) 0 +from 0 +baseline 0 +. 0 + +We 0 +used 0 +time 0 +- 0 +to 0 +- 0 +event 0 +analysis 0 +to 0 +identify 0 +potential 0 +predictors 0 +of 0 +decrease 0 +in 0 +renal 0 +function 0 +including 0 +age 0 +, 0 +baseline 0 +ejection 0 +fraction 0 +, 0 +baseline 0 +creatinine 1 +, 0 +low 0 +systolic 0 +blood 0 +pressure 0 +( 0 +< 0 +100 0 +mm 0 +Hg 0 +) 0 +, 0 +history 0 +of 0 +hypertension 3 +, 0 +diabetes 3 +, 0 +and 0 +use 0 +of 0 +antiplatelet 0 +, 0 +diuretic 1 +, 0 +and 0 +beta 0 +- 0 +blocker 0 +therapy 0 +. 0 + +RESULTS 0 +: 0 +Patients 0 +randomly 0 +assigned 0 +to 0 +enalapril 1 +had 0 +a 0 +33 0 +% 0 +greater 0 +likelihood 0 +of 0 +decreased 3 +renal 4 +function 4 +than 0 +controls 0 +( 0 +P 0 += 0 +. 0 +003 0 +) 0 +. 0 + +By 0 +multivariate 0 +analysis 0 +, 0 +in 0 +both 0 +the 0 +placebo 0 +and 0 +enalapril 1 +groups 0 +older 0 +age 0 +, 0 +diuretic 1 +therapy 0 +, 0 +and 0 +diabetes 3 +were 0 +associated 0 +with 0 +decreased 3 +renal 4 +function 4 +, 0 +whereas 0 +beta 0 +- 0 +blocker 0 +therapy 0 +and 0 +higher 0 +ejection 0 +fraction 0 +were 0 +renoprotective 0 +. 0 + +0lder 0 +age 0 +was 0 +associated 0 +with 0 +a 0 +greater 0 +risk 0 +of 0 +developing 0 +decreased 3 +renal 4 +function 4 +in 0 +both 0 +groups 0 +, 0 +but 0 +significantly 0 +more 0 +so 0 +in 0 +the 0 +enalapril 1 +group 0 +( 0 +enalapril 1 +: 0 +risk 0 +ratio 0 +[ 0 +RR 0 +] 0 +1 0 +. 0 +42 0 +per 0 +10 0 +years 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +1 0 +. 0 +32 0 +- 0 +1 0 +. 0 +52 0 +with 0 +enalapril 1 +; 0 +placebo 0 +: 0 +RR 0 +1 0 +. 0 +18 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +12 0 +- 0 +1 0 +. 0 +25 0 +) 0 +. 0 + +Diuretic 1 +therapy 0 +was 0 +likewise 0 +associated 0 +with 0 +a 0 +greater 0 +risk 0 +of 0 +decreased 3 +renal 4 +function 4 +in 0 +the 0 +enalapril 1 +group 0 +( 0 +RR 0 +1 0 +. 0 +89 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +70 0 +- 0 +2 0 +. 0 +08 0 +) 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +( 0 +RR 0 +1 0 +. 0 +35 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +09 0 +- 0 +1 0 +. 0 +66 0 +) 0 +. 0 + +Conversely 0 +, 0 +enalapril 1 +had 0 +a 0 +relative 0 +renoprotective 0 +effect 0 +( 0 +RR 0 +1 0 +. 0 +33 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +13 0 +- 0 +1 0 +. 0 +53 0 +) 0 +compared 0 +with 0 +placebo 0 +( 0 +RR 0 +1 0 +. 0 +96 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +57 0 +- 0 +2 0 +. 0 +44 0 +) 0 +in 0 +patients 0 +with 0 +diabetes 3 +. 0 + +A 0 +lower 0 +risk 0 +of 0 +renal 3 +impairment 4 +was 0 +seen 0 +in 0 +both 0 +groups 0 +with 0 +beta 0 +- 0 +blocker 0 +therapy 0 +( 0 +RR 0 +0 0 +. 0 +70 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +57 0 +- 0 +0 0 +. 0 +85 0 +) 0 +and 0 +higher 0 +baseline 0 +ejection 0 +fraction 0 +( 0 +RR 0 +0 0 +. 0 +93 0 +per 0 +5 0 +% 0 +increment 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +91 0 +- 0 +0 0 +. 0 +96 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Enalapril 1 +use 0 +caused 0 +a 0 +33 0 +% 0 +increase 0 +in 0 +the 0 +risk 0 +of 0 +decreased 3 +renal 4 +function 4 +in 0 +patients 0 +with 0 +CHF 3 +. 0 + +Diuretic 1 +use 0 +and 0 +advanced 0 +age 0 +increased 0 +this 0 +risk 0 +. 0 + +Diabetes 3 +was 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +of 0 +renal 3 +impairment 4 +in 0 +all 0 +patients 0 +with 0 +CHF 3 +, 0 +but 0 +this 0 +risk 0 +was 0 +reduced 0 +in 0 +the 0 +enalapril 1 +group 0 +compared 0 +with 0 +the 0 +placebo 0 +group 0 +. 0 + +beta 0 +- 0 +Blocker 0 +therapy 0 +and 0 +higher 0 +ejection 0 +fraction 0 +were 0 +renoprotective 0 +in 0 +all 0 +patients 0 +regardless 0 +of 0 +therapy 0 +. 0 + +Hypomania 3 +- 0 +like 0 +syndrome 0 +induced 0 +by 0 +olanzapine 1 +. 0 + +We 0 +report 0 +a 0 +female 0 +patient 0 +with 0 +a 0 +diagnosis 0 +of 0 +a 0 +not 0 +otherwise 0 +specified 0 +psychotic 3 +disorder 4 +( 0 +DSM 0 +- 0 +IV 0 +) 0 +who 0 +developed 0 +hypomania 3 +shortly 0 +after 0 +the 0 +introduction 0 +of 0 +olanzapine 1 +treatment 0 +. 0 + +Acetazolamide 1 +- 0 +induced 0 +Gerstmann 3 +syndrome 4 +. 0 + +Acute 0 +confusion 3 +induced 0 +by 0 +acetazolamide 1 +is 0 +a 0 +well 0 +known 0 +adverse 0 +drug 0 +reaction 0 +in 0 +patients 0 +with 0 +renal 3 +impairment 4 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +acetazolamide 1 +- 0 +induced 0 +Gerstmann 3 +syndrome 4 +in 0 +a 0 +patient 0 +with 0 +normal 0 +renal 0 +function 0 +, 0 +to 0 +highlight 0 +predisposing 0 +factors 0 +that 0 +are 0 +frequently 0 +overlooked 0 +. 0 + +Vasopressin 1 +in 0 +the 0 +treatment 0 +of 0 +milrinone 1 +- 0 +induced 0 +hypotension 3 +in 0 +severe 0 +heart 3 +failure 4 +. 0 + +The 0 +use 0 +of 0 +phosphodiesterase 0 +inhibitors 0 +such 0 +as 0 +milrinone 1 +in 0 +the 0 +treatment 0 +of 0 +severe 0 +heart 3 +failure 4 +is 0 +frequently 0 +restricted 0 +because 0 +they 0 +cause 0 +vasodilation 0 +and 0 +hypotension 3 +. 0 + +In 0 +patients 0 +with 0 +decompensated 0 +heart 3 +failure 4 +with 0 +hypotension 3 +after 0 +treatment 0 +with 0 +milrinone 1 +, 0 +low 0 +doses 0 +of 0 +vasopressin 1 +restored 0 +blood 0 +pressure 0 +without 0 +inhibiting 0 +the 0 +inotropic 0 +effect 0 +of 0 +milrinone 1 +. 0 + +Treatment 0 +of 0 +tacrolimus 1 +- 0 +related 0 +adverse 0 +effects 0 +by 0 +conversion 0 +to 0 +cyclosporine 1 +in 0 +liver 0 +transplant 0 +recipients 0 +. 0 + +When 0 +tacrolimus 1 +side 0 +effects 0 +persist 0 +despite 0 +dose 0 +reduction 0 +, 0 +conversion 0 +to 0 +cyclosporine 1 +- 0 +based 0 +immunosuppression 0 +( 0 +CyA 0 +) 0 +is 0 +necessary 0 +. 0 + +We 0 +characterized 0 +tacrolimus 1 +side 0 +effects 0 +that 0 +warranted 0 +discontinuation 0 +of 0 +the 0 +drug 0 +, 0 +and 0 +outcomes 0 +after 0 +conversion 0 +. 0 + +0f 0 +388 0 +liver 0 +recipients 0 +who 0 +received 0 +tacrolimus 1 +as 0 +primary 0 +immunosuppression 0 +, 0 +70 0 +required 0 +conversion 0 +to 0 +CyA 0 +. 0 + +We 0 +recorded 0 +indication 0 +for 0 +conversion 0 +, 0 +whether 0 +conversion 0 +was 0 +early 0 +or 0 +late 0 +after 0 +transplantation 0 +, 0 +tacrolimus 1 +dose 0 +and 0 +trough 0 +blood 0 +level 0 +at 0 +conversion 0 +, 0 +and 0 +incidence 0 +of 0 +rejection 0 +after 0 +conversion 0 +. 0 + +Conversion 0 +was 0 +early 0 +in 0 +29 0 +patients 0 +( 0 +41 0 +. 0 +4 0 +% 0 +) 0 +and 0 +late 0 +in 0 +41 0 +( 0 +58 0 +. 0 +6 0 +% 0 +) 0 +. 0 + +Indications 0 +for 0 +early 0 +conversion 0 +were 0 +neurotoxicity 3 +( 0 +20 0 +) 0 +, 0 +( 3 +insulin 4 +- 4 +dependent 4 +) 4 +diabetes 4 +mellitus 4 +( 0 +IDDM 3 +) 0 +( 0 +5 0 +) 0 +, 0 +nephrotoxicity 3 +( 0 +3 0 +) 0 +, 0 +gastrointestinal 3 +( 4 +GI 4 +) 4 +toxicity 4 +( 0 +6 0 +) 0 +, 0 +and 0 +cardiomyopathy 3 +( 0 +1 0 +) 0 +, 0 +and 0 +for 0 +late 0 +conversion 0 +were 0 +neurotoxicity 3 +( 0 +15 0 +) 0 +, 0 +IDDM 3 +( 0 +12 0 +) 0 +, 0 +nephrotoxicity 3 +( 0 +3 0 +) 0 +, 0 +GI 3 +toxicity 4 +( 0 +5 0 +) 0 +, 0 +hepatotoxicity 3 +( 0 +6 0 +) 0 +, 0 +post 3 +- 4 +transplant 4 +lmphoproliferate 4 +disease 4 +( 0 +PTLD 3 +) 0 +( 0 +2 0 +) 0 +, 0 +cardiomyopathy 3 +( 0 +1 0 +) 0 +, 0 +hemolytic 3 +anemia 4 +( 0 +1 0 +) 0 +, 0 +and 0 +pruritus 3 +( 0 +1 0 +) 0 +. 0 + +All 0 +early 0 +- 0 +conversion 0 +patients 0 +showed 0 +improvement 0 +/ 0 +resolution 0 +of 0 +symptoms 0 +. 0 + +Among 0 +late 0 +- 0 +conversion 0 +patients 0 +, 0 +37 0 +( 0 +90 0 +. 0 +2 0 +% 0 +) 0 +had 0 +improvement 0 +/ 0 +resolution 0 +; 0 +in 0 +4 0 +( 0 +9 0 +. 0 +8 0 +% 0 +) 0 +, 0 +adverse 0 +effects 0 +persisted 0 +. 0 + +The 0 +overall 0 +rejection 0 +rate 0 +was 0 +30 0 +% 0 +. 0 + +Sixty 0 +- 0 +two 0 +patients 0 +( 0 +88 0 +. 0 +6 0 +% 0 +) 0 +are 0 +alive 0 +with 0 +functioning 0 +grafts 0 +686 0 ++ 0 +/ 0 +- 0 +362 0 +days 0 +( 0 +range 0 +, 0 +154 0 +- 0 +1433 0 +days 0 +) 0 +after 0 +conversion 0 +. 0 + +When 0 +tacrolimus 1 +side 0 +effects 0 +are 0 +unresponsive 0 +to 0 +dose 0 +reduction 0 +, 0 +conversion 0 +to 0 +CyA 0 +can 0 +be 0 +accomplished 0 +safely 0 +, 0 +with 0 +no 0 +increased 0 +risk 0 +of 0 +rejection 0 +and 0 +excellent 0 +long 0 +- 0 +term 0 +outcome 0 +. 0 + +0cular 0 +manifestations 0 +of 0 +juvenile 3 +rheumatoid 4 +arthritis 4 +. 0 + +We 0 +followed 0 +210 0 +cases 0 +of 0 +juvenile 3 +rheumatoid 4 +arthritis 4 +closely 0 +for 0 +eleven 0 +years 0 +. 0 + +Thirty 0 +- 0 +six 0 +of 0 +the 0 +210 0 +patients 0 +( 0 +17 0 +. 0 +2 0 +% 0 +) 0 +developed 0 +iridocyclitis 3 +. 0 + +Iridocyclitis 3 +was 0 +seen 0 +most 0 +frequently 0 +in 0 +young 0 +female 0 +patients 0 +( 0 +0 0 +to 0 +4 0 +years 0 +) 0 +with 0 +the 0 +monoarticular 0 +or 0 +pauciatricular 0 +form 0 +of 0 +the 0 +arthritis 3 +. 0 + +However 0 +, 0 +30 0 +% 0 +of 0 +the 0 +patients 0 +developed 0 +uveitis 3 +after 0 +16 0 +years 0 +of 0 +age 0 +. 0 + +Although 0 +61 0 +% 0 +of 0 +patients 0 +had 0 +a 0 +noncontributory 0 +ocular 0 +history 0 +on 0 +entry 0 +, 0 +42 0 +% 0 +had 0 +active 0 +uveitis 3 +on 0 +entry 0 +. 0 + +0ur 0 +approach 0 +was 0 +effective 0 +in 0 +detecting 0 +uveitis 3 +in 0 +new 0 +cases 0 +and 0 +exacerbations 0 +of 0 +uveitis 3 +in 0 +established 0 +cases 0 +. 0 + +Forty 0 +- 0 +four 0 +percent 0 +of 0 +patients 0 +with 0 +uveitis 3 +had 0 +one 0 +or 0 +more 0 +identifiable 0 +signs 0 +or 0 +symptoms 0 +, 0 +such 0 +as 0 +red 0 +eye 0 +, 0 +ocular 3 +pain 4 +, 0 +decreased 3 +visual 4 +acuity 4 +, 0 +or 0 +photophobia 3 +, 0 +in 0 +order 0 +of 0 +decreasing 0 +frequency 0 +. 0 + +Even 0 +after 0 +early 0 +detection 0 +and 0 +prompt 0 +treatment 0 +, 0 +41 0 +% 0 +of 0 +cases 0 +of 0 +uveitis 3 +did 0 +not 0 +respond 0 +to 0 +more 0 +than 0 +six 0 +months 0 +of 0 +intensive 0 +topical 0 +treatment 0 +with 0 +corticosteroids 1 +and 0 +mydriatics 0 +. 0 + +Despite 0 +this 0 +, 0 +there 0 +was 0 +a 0 +dramatic 0 +decrease 0 +in 0 +the 0 +50 0 +% 0 +incidence 0 +of 0 +blinding 0 +complications 0 +of 0 +uveitis 3 +cited 0 +in 0 +earlier 0 +studies 0 +. 0 + +Cataract 3 +and 0 +band 3 +keratopathy 4 +occurred 0 +in 0 +only 0 +22 0 +and 0 +13 0 +% 0 +of 0 +our 0 +group 0 +, 0 +respectively 0 +. 0 + +We 0 +used 0 +chloroquine 1 +or 0 +hydroxychloroquine 1 +in 0 +173 0 +of 0 +210 0 +cases 0 +and 0 +found 0 +only 0 +one 0 +case 0 +of 0 +chorioretinopathy 3 +attributable 0 +to 0 +these 0 +drugs 0 +. 0 + +Systemically 0 +administered 0 +corticosteroids 1 +were 0 +used 0 +in 0 +75 0 +of 0 +210 0 +cases 0 +; 0 +a 0 +significant 0 +number 0 +of 0 +posterior 0 +subcapsular 0 +cataracts 3 +was 0 +found 0 +. 0 + +Typical 0 +keratoconjunctivitis 3 +sicca 0 +developed 0 +in 0 +three 0 +of 0 +the 0 +uveitis 3 +cases 0 +. 0 + +This 0 +association 0 +with 0 +uveitis 3 +and 0 +JRA 0 +was 0 +not 0 +noted 0 +previously 0 +. 0 + +Surgical 0 +treatment 0 +of 0 +cataracts 3 +, 0 +band 3 +keratopathy 4 +, 0 +and 0 +glaucoma 3 +achieved 0 +uniformly 0 +discouraging 0 +results 0 +. 0 + +Cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +in 0 +freely 0 +- 0 +moving 0 +conscious 0 +rats 0 +: 0 +behavioral 0 +approach 0 +to 0 +a 0 +new 0 +model 0 +of 0 +visceral 3 +pain 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +develop 0 +a 0 +model 0 +of 0 +visceral 3 +pain 4 +in 0 +rats 0 +using 0 +a 0 +behavioral 0 +approach 0 +. 0 + +Cyclophosphamide 1 +( 0 +CP 1 +) 0 +, 0 +an 0 +antitumoral 0 +agent 0 +known 0 +to 0 +produce 0 +toxic 0 +effects 0 +on 0 +the 0 +bladder 0 +wall 0 +through 0 +its 0 +main 0 +toxic 0 +metabolite 0 +acrolein 1 +, 0 +was 0 +used 0 +to 0 +induce 0 +cystitis 3 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +CP 1 +was 0 +administered 0 +at 0 +doses 0 +of 0 +50 0 +, 0 +100 0 +and 0 +200 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +p 0 +. 0 +to 0 +male 0 +rats 0 +, 0 +and 0 +their 0 +behavior 0 +observed 0 +and 0 +scored 0 +. 0 + +The 0 +effects 0 +of 0 +morphine 1 +( 0 +0 0 +. 0 +5 0 +to 0 +4 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 +i 0 +. 0 +v 0 +. 0 +) 0 +on 0 +CP 1 +- 0 +induced 0 +behavioral 0 +modifications 0 +were 0 +tested 0 +administered 0 +alone 0 +and 0 +after 0 +naloxone 1 +( 0 +1 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 +s 0 +. 0 +c 0 +. 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +90 0 +minutes 0 +after 0 +CP 1 +injection 0 +, 0 +that 0 +is 0 +, 0 +at 0 +the 0 +time 0 +of 0 +administration 0 +of 0 +morphine 1 +, 0 +the 0 +bladder 0 +was 0 +removed 0 +in 0 +some 0 +rats 0 +for 0 +histological 0 +examination 0 +. 0 + +Finally 0 +, 0 +to 0 +show 0 +that 0 +the 0 +bladder 0 +is 0 +essential 0 +for 0 +the 0 +CP 1 +- 0 +induced 0 +behavioral 0 +modifications 0 +, 0 +female 0 +rats 0 +also 0 +received 0 +CP 1 +at 0 +doses 0 +of 0 +200 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +p 0 +. 0 +and 0 +of 0 +20 0 +mg 0 +. 0 +by 0 +the 0 +intravesical 0 +route 0 +, 0 +and 0 +acrolein 1 +at 0 +doses 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +. 0 +by 0 +the 0 +intravesical 0 +route 0 +and 0 +of 0 +5 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +v 0 +. 0 +RESULTS 0 +: 0 +CP 1 +dose 0 +- 0 +relatedly 0 +induced 0 +marked 0 +behavioral 0 +modifications 0 +in 0 +male 0 +rats 0 +: 0 +breathing 0 +rate 0 +decrease 0 +, 0 +closing 0 +of 0 +the 0 +eyes 0 +and 0 +occurrence 0 +of 0 +specific 0 +postures 0 +. 0 + +Morphine 1 +dose 0 +- 0 +dependently 0 +reversed 0 +these 0 +behavioral 3 +disorders 4 +. 0 + +A 0 +dose 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 +produced 0 +a 0 +reduction 0 +of 0 +almost 0 +50 0 +% 0 +of 0 +the 0 +behavioral 0 +score 0 +induced 0 +by 0 +CP 1 +200 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +This 0 +effect 0 +was 0 +completely 0 +prevented 0 +by 0 +pretreatment 0 +with 0 +naloxone 1 +. 0 + +At 0 +the 0 +time 0 +of 0 +administration 0 +of 0 +morphine 1 +, 0 +histological 0 +modifications 0 +of 0 +the 0 +bladder 0 +wall 0 +, 0 +such 0 +as 0 +chorionic 0 +and 0 +muscle 0 +layer 0 +edema 3 +, 0 +were 0 +observed 0 +. 0 + +In 0 +female 0 +rats 0 +, 0 +CP 1 +200 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +p 0 +. 0 +produced 0 +the 0 +same 0 +marked 0 +behavioral 0 +modifications 0 +as 0 +those 0 +observed 0 +in 0 +male 0 +rats 0 +. 0 + +Administered 0 +at 0 +the 0 +dose 0 +of 0 +20 0 +mg 0 +. 0 +intravesically 0 +, 0 +CP 1 +did 0 +not 0 +produce 0 +any 0 +behavioral 0 +effects 0 +, 0 +whereas 0 +acrolein 1 +at 0 +0 0 +. 0 +5 0 +mg 0 +. 0 +intravesically 0 +induced 0 +behavioral 0 +modifications 0 +identical 0 +to 0 +those 0 +under 0 +CP 1 +200 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +p 0 +. 0 +, 0 +with 0 +the 0 +same 0 +maximal 0 +levels 0 +. 0 + +Conversely 0 +, 0 +acrolein 1 +5 0 +mg 0 +. 0 +/ 0 +kg 0 +. 0 + +i 0 +. 0 +v 0 +. 0 +did 0 +not 0 +produce 0 +any 0 +behavioral 0 +effects 0 +at 0 +all 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0verall 0 +, 0 +these 0 +results 0 +indicate 0 +that 0 +this 0 +experimental 0 +model 0 +of 0 +CP 1 +- 0 +induced 0 +cystitis 3 +may 0 +be 0 +an 0 +interesting 0 +new 0 +behavioral 0 +model 0 +of 0 +inflammatory 0 +visceral 3 +pain 4 +, 0 +allowing 0 +a 0 +better 0 +understanding 0 +of 0 +these 0 +painful 3 +syndromes 4 +and 0 +thus 0 +a 0 +better 0 +therapeutic 0 +approach 0 +to 0 +them 0 +. 0 + +Prednisolone 1 +- 0 +induced 0 +muscle 3 +dysfunction 4 +is 0 +caused 0 +more 0 +by 0 +atrophy 3 +than 0 +by 0 +altered 0 +acetylcholine 1 +receptor 0 +expression 0 +. 0 + +Large 0 +doses 0 +of 0 +glucocorticoids 0 +can 0 +alter 0 +muscle 0 +physiology 0 +and 0 +susceptibility 0 +to 0 +neuromuscular 0 +blocking 0 +drugs 0 +by 0 +mechanisms 0 +not 0 +clearly 0 +understood 0 +. 0 + +We 0 +investigated 0 +the 0 +effects 0 +of 0 +moderate 0 +and 0 +large 0 +doses 0 +of 0 +prednisolone 1 +on 0 +muscle 0 +function 0 +and 0 +pharmacology 0 +, 0 +and 0 +their 0 +relationship 0 +to 0 +changes 0 +in 0 +muscle 0 +size 0 +and 0 +acetylcholine 1 +receptor 0 +( 0 +AChR 0 +) 0 +expression 0 +. 0 + +With 0 +institutional 0 +approval 0 +, 0 +35 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +randomly 0 +allocated 0 +to 0 +receive 0 +daily 0 +subcutaneous 0 +doses 0 +of 0 +10 0 +mg 0 +/ 0 +kg 0 +prednisolone 1 +( 0 +P10 0 +group 0 +) 0 +, 0 +100 0 +mg 0 +/ 0 +kg 0 +prednisolone 1 +( 0 +P100 0 +group 0 +) 0 +, 0 +or 0 +an 0 +equal 0 +volume 0 +of 0 +saline 0 +( 0 +S 0 +group 0 +) 0 +for 0 +7 0 +days 0 +. 0 + +A 0 +fourth 0 +group 0 +of 0 +rats 0 +was 0 +pair 0 +fed 0 +( 0 +food 0 +restricted 0 +) 0 +with 0 +the 0 +P100 0 +rats 0 +for 0 +7 0 +days 0 +( 0 +FR 0 +group 0 +) 0 +. 0 + +0n 0 +Day 0 +8 0 +, 0 +the 0 +nerve 0 +- 0 +evoked 0 +peak 0 +twitch 0 +tensions 0 +, 0 +tetanic 3 +tensions 0 +, 0 +and 0 +fatigability 0 +, 0 +and 0 +the 0 +dose 0 +- 0 +response 0 +curves 0 +of 0 +d 1 +- 2 +tubocurarine 2 +in 0 +the 0 +tibialis 0 +cranialis 0 +muscle 0 +were 0 +measured 0 +in 0 +vivo 0 +and 0 +related 0 +to 0 +muscle 0 +mass 0 +or 0 +expression 0 +of 0 +AChRs 0 +. 0 + +Rate 0 +of 0 +body 0 +weight 0 +gain 0 +was 0 +depressed 0 +in 0 +the 0 +P100 0 +, 0 +FR 0 +, 0 +and 0 +P10 0 +groups 0 +compared 0 +with 0 +the 0 +S 0 +group 0 +. 0 + +Tibialis 0 +muscle 0 +mass 0 +was 0 +smaller 0 +in 0 +the 0 +P100 0 +group 0 +than 0 +in 0 +the 0 +P10 0 +or 0 +S 0 +groups 0 +. 0 + +The 0 +evoked 0 +peak 0 +twitch 0 +and 0 +tetanic 3 +tensions 0 +were 0 +less 0 +in 0 +the 0 +P100 0 +group 0 +than 0 +in 0 +the 0 +P10 0 +or 0 +S 0 +groups 0 +, 0 +however 0 +, 0 +tension 0 +per 0 +milligram 0 +of 0 +muscle 0 +mass 0 +was 0 +greater 0 +in 0 +the 0 +P100 0 +group 0 +than 0 +in 0 +the 0 +S 0 +group 0 +. 0 + +The 0 +50 0 +% 0 +effective 0 +dose 0 +of 0 +d 1 +- 2 +tubocurarine 2 +( 0 +microg 0 +/ 0 +kg 0 +) 0 +in 0 +the 0 +tibialis 0 +muscle 0 +was 0 +smaller 0 +in 0 +the 0 +P10 0 +( 0 +33 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +4 0 +) 0 +than 0 +in 0 +the 0 +S 0 +( 0 +61 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +0 0 +) 0 +or 0 +the 0 +P100 0 +( 0 +71 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +9 0 +. 0 +6 0 +) 0 +groups 0 +. 0 + +AChR 0 +expression 0 +was 0 +less 0 +in 0 +the 0 +P10 0 +group 0 +than 0 +in 0 +the 0 +S 0 +group 0 +. 0 + +The 0 +evoked 0 +tensions 0 +correlated 0 +with 0 +muscle 0 +mass 0 +( 0 +r 0 +( 0 +2 0 +) 0 += 0 +0 0 +. 0 +32 0 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +however 0 +, 0 +not 0 +with 0 +expression 0 +of 0 +AChR 0 +. 0 + +The 0 +50 0 +% 0 +effective 0 +dose 0 +of 0 +d 1 +- 2 +tubocurarine 2 +did 0 +not 0 +correlate 0 +with 0 +muscle 0 +mass 0 +or 0 +AChR 0 +expression 0 +. 0 + +0ur 0 +results 0 +suggest 0 +that 0 +the 0 +neuromuscular 3 +dysfunction 4 +after 0 +prednisolone 1 +is 0 +dose 0 +- 0 +dependent 0 +, 0 +and 0 +derives 0 +primarily 0 +from 0 +muscle 3 +atrophy 4 +and 0 +derives 0 +less 0 +so 0 +from 0 +changes 0 +in 0 +AChR 0 +expression 0 +. 0 + +IMPLICATI0NS 0 +: 0 +The 0 +mechanisms 0 +by 0 +which 0 +chronic 0 +glucocorticoid 0 +therapy 0 +alters 0 +neuromuscular 0 +physiology 0 +and 0 +pharmacology 0 +are 0 +unclear 0 +. 0 + +We 0 +suggest 0 +that 0 +the 0 +observed 0 +effects 0 +are 0 +dose 0 +- 0 +dependent 0 +and 0 +derive 0 +primarily 0 +from 0 +muscle 3 +atrophy 4 +and 0 +derive 0 +less 0 +from 0 +changes 0 +in 0 +acetylcholine 1 +receptor 0 +expression 0 +. 0 + +Apomorphine 1 +: 0 +an 0 +underutilized 0 +therapy 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Apomorphine 1 +was 0 +the 0 +first 0 +dopaminergic 0 +drug 0 +ever 0 +used 0 +to 0 +treat 0 +symptoms 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +While 0 +powerful 0 +antiparkinsonian 0 +effects 0 +had 0 +been 0 +observed 0 +as 0 +early 0 +as 0 +1951 0 +, 0 +the 0 +potential 0 +of 0 +treating 0 +fluctuating 0 +Parkinson 3 +' 4 +s 4 +disease 4 +by 0 +subcutaneous 0 +administration 0 +of 0 +apomorphine 1 +has 0 +only 0 +recently 0 +become 0 +the 0 +subject 0 +of 0 +systematic 0 +study 0 +. 0 + +A 0 +number 0 +of 0 +small 0 +scale 0 +clinical 0 +trials 0 +have 0 +unequivocally 0 +shown 0 +that 0 +intermittent 0 +subcutaneous 0 +apomorphine 1 +injections 0 +produce 0 +antiparkinsonian 0 +benefit 0 +close 0 +if 0 +not 0 +identical 0 +to 0 +that 0 +seen 0 +with 0 +levodopa 1 +and 0 +that 0 +apomorphine 1 +rescue 0 +injections 0 +can 0 +reliably 0 +revert 0 +off 0 +- 0 +periods 0 +even 0 +in 0 +patients 0 +with 0 +complex 0 +on 0 +- 0 +off 0 +motor 0 +swings 0 +. 0 + +Continuous 0 +subcutaneous 0 +apomorphine 1 +infusions 0 +can 0 +reduce 0 +daily 0 +off 0 +- 0 +time 0 +by 0 +more 0 +than 0 +50 0 +% 0 +in 0 +this 0 +group 0 +of 0 +patients 0 +, 0 +which 0 +appears 0 +to 0 +be 0 +a 0 +stronger 0 +effect 0 +than 0 +that 0 +generally 0 +seen 0 +with 0 +add 0 +- 0 +on 0 +therapy 0 +with 0 +oral 0 +dopamine 1 +agonists 0 +or 0 +C0MT 0 +inhibitors 0 +. 0 + +Extended 0 +follow 0 +- 0 +up 0 +studies 0 +of 0 +up 0 +to 0 +8 0 +years 0 +have 0 +demonstrated 0 +long 0 +- 0 +term 0 +persistence 0 +of 0 +apomorphine 1 +efficacy 0 +. 0 + +In 0 +addition 0 +, 0 +there 0 +is 0 +convincing 0 +clinical 0 +evidence 0 +that 0 +monotherapy 0 +with 0 +continuous 0 +subcutaneous 0 +apomorphine 1 +infusions 0 +is 0 +associated 0 +with 0 +marked 0 +reductions 0 +of 0 +preexisting 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +. 0 + +The 0 +main 0 +side 0 +effects 0 +of 0 +subcutaneous 0 +apomorphine 1 +treatment 0 +are 0 +related 0 +to 0 +cutaneous 0 +tolerability 0 +problems 0 +, 0 +whereas 0 +sedation 0 +and 0 +psychiatric 3 +complications 0 +play 0 +a 0 +lesser 0 +role 0 +. 0 + +Given 0 +the 0 +marked 0 +degree 0 +of 0 +efficacy 0 +of 0 +subcutaneous 0 +apomorphine 1 +treatment 0 +in 0 +fluctuating 0 +Parkinson 3 +' 4 +s 4 +disease 4 +, 0 +this 0 +approach 0 +seems 0 +to 0 +deserve 0 +more 0 +widespread 0 +clinical 0 +use 0 +. 0 + +Probing 0 +peripheral 0 +and 0 +central 0 +cholinergic 0 +system 0 +responses 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +pharmacological 0 +response 0 +to 0 +drugs 0 +that 0 +act 0 +on 0 +the 0 +cholinergic 0 +system 0 +of 0 +the 0 +iris 0 +has 0 +been 0 +used 0 +to 0 +predict 0 +deficits 0 +in 0 +central 0 +cholinergic 0 +functioning 0 +due 0 +to 0 +diseases 0 +such 0 +as 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +, 0 +yet 0 +correlations 0 +between 0 +central 0 +and 0 +peripheral 0 +responses 0 +have 0 +not 0 +been 0 +properly 0 +studied 0 +. 0 + +This 0 +study 0 +assessed 0 +the 0 +effect 0 +of 0 +normal 0 +aging 0 +on 0 +( 0 +1 0 +) 0 +the 0 +tropicamide 1 +- 0 +induced 0 +increase 0 +in 0 +pupil 0 +diameter 0 +, 0 +and 0 +( 0 +2 0 +) 0 +the 0 +reversal 0 +of 0 +this 0 +effect 0 +with 0 +pilocarpine 1 +. 0 + +Scopolamine 1 +was 0 +used 0 +as 0 +a 0 +positive 0 +control 0 +to 0 +detect 0 +age 0 +- 0 +dependent 0 +changes 0 +in 0 +central 0 +cholinergic 0 +functioning 0 +in 0 +the 0 +elderly 0 +. 0 + +DESIGN 0 +: 0 +Randomized 0 +double 0 +- 0 +blind 0 +controlled 0 +trial 0 +. 0 + +PARTICIPANTS 0 +: 0 +Ten 0 +healthy 0 +elderly 0 +( 0 +mean 0 +age 0 +70 0 +) 0 +and 0 +9 0 +young 0 +( 0 +mean 0 +age 0 +33 0 +) 0 +volunteers 0 +. 0 + +INTERVENTI0NS 0 +: 0 +Pupil 0 +diameter 0 +was 0 +monitored 0 +using 0 +a 0 +computerized 0 +infrared 0 +pupillometer 0 +over 0 +4 0 +hours 0 +. 0 + +The 0 +study 0 +involved 0 +4 0 +sessions 0 +. 0 + +In 0 +1 0 +session 0 +, 0 +tropicamide 1 +( 0 +20 0 +microL 0 +, 0 +0 0 +. 0 +01 0 +% 0 +) 0 +was 0 +administered 0 +to 0 +one 0 +eye 0 +and 0 +placebo 0 +to 0 +the 0 +other 0 +. 0 + +In 0 +another 0 +session 0 +, 0 +tropicamide 1 +( 0 +20 0 +microL 0 +, 0 +0 0 +. 0 +01 0 +% 0 +) 0 +was 0 +administered 0 +to 0 +both 0 +eyes 0 +, 0 +followed 0 +23 0 +minutes 0 +later 0 +by 0 +the 0 +application 0 +of 0 +pilocarpine 1 +( 0 +20 0 +microL 0 +, 0 +0 0 +. 0 +1 0 +% 0 +) 0 +to 0 +one 0 +eye 0 +and 0 +placebo 0 +to 0 +the 0 +other 0 +. 0 + +All 0 +eye 0 +drops 0 +were 0 +given 0 +in 0 +a 0 +randomized 0 +order 0 +. 0 + +In 0 +2 0 +separate 0 +sessions 0 +, 0 +a 0 +single 0 +dose 0 +of 0 +scopolamine 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +, 0 +intravenously 0 +) 0 +or 0 +placebo 0 +was 0 +administered 0 +, 0 +and 0 +the 0 +effects 0 +on 0 +word 0 +recall 0 +were 0 +measured 0 +using 0 +the 0 +Buschke 0 +Selective 0 +Reminding 0 +Test 0 +over 0 +2 0 +hours 0 +. 0 + +0UTC0ME 0 +MEASURES 0 +: 0 +Pupil 0 +size 0 +at 0 +time 0 +points 0 +after 0 +administration 0 +of 0 +tropicamide 1 +and 0 +pilocarpine 1 +; 0 +scopolamine 1 +- 0 +induced 0 +impairment 3 +in 4 +word 4 +recall 4 +. 0 + +RESULTS 0 +: 0 +There 0 +was 0 +no 0 +significant 0 +difference 0 +between 0 +elderly 0 +and 0 +young 0 +volunteers 0 +in 0 +pupillary 0 +response 0 +to 0 +tropicamide 1 +at 0 +any 0 +time 0 +point 0 +( 0 +p 0 +> 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +elderly 0 +group 0 +had 0 +a 0 +significantly 0 +greater 0 +pilocarpine 1 +- 0 +induced 0 +net 0 +decrease 0 +in 0 +pupil 0 +size 0 +85 0 +, 0 +125 0 +, 0 +165 0 +and 0 +215 0 +minutes 0 +after 0 +administration 0 +, 0 +compared 0 +with 0 +the 0 +young 0 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Compared 0 +with 0 +the 0 +young 0 +group 0 +, 0 +the 0 +elderly 0 +group 0 +had 0 +greater 0 +scopolamine 1 +- 0 +induced 0 +impairment 3 +in 4 +word 4 +recall 4 +60 0 +, 0 +90 0 +and 0 +120 0 +minutes 0 +after 0 +administration 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +There 0 +is 0 +an 0 +age 0 +- 0 +related 0 +pupillary 0 +response 0 +to 0 +pilocarpine 1 +that 0 +is 0 +not 0 +found 0 +with 0 +tropicamide 1 +. 0 + +Thus 0 +, 0 +pilocarpine 1 +may 0 +be 0 +useful 0 +to 0 +assess 0 +variations 0 +in 0 +central 0 +cholinergic 0 +function 0 +in 0 +elderly 0 +patients 0 +. 0 + +Pain 3 +responses 0 +in 0 +methadone 1 +- 0 +maintained 0 +opioid 0 +abusers 0 +. 0 + +Providing 0 +pain 3 +management 0 +for 0 +known 0 +opioid 0 +abusers 0 +is 0 +a 0 +challenging 0 +clinical 0 +task 0 +, 0 +in 0 +part 0 +because 0 +little 0 +is 0 +known 0 +about 0 +their 0 +pain 3 +experience 0 +and 0 +analgesic 0 +requirements 0 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +describe 0 +pain 3 +tolerance 0 +and 0 +analgesic 0 +response 0 +in 0 +a 0 +sample 0 +of 0 +opioid 3 +addicts 4 +stabilized 0 +in 0 +methadone 1 +- 0 +maintenance 0 +( 0 +MM 0 +) 0 +treatment 0 +( 0 +n 0 += 0 +60 0 +) 0 +in 0 +comparison 0 +to 0 +matched 0 +nondependent 0 +control 0 +subjects 0 +( 0 +n 0 += 0 +60 0 +) 0 +. 0 + +By 0 +using 0 +a 0 +placebo 0 +- 0 +controlled 0 +, 0 +two 0 +- 0 +way 0 +factorial 0 +design 0 +, 0 +tolerance 0 +to 0 +cold 0 +- 0 +pressor 0 +( 0 +CP 0 +) 0 +pain 3 +was 0 +examined 0 +, 0 +both 0 +before 0 +and 0 +after 0 +oral 0 +administration 0 +of 0 +therapeutic 0 +doses 0 +of 0 +common 0 +opioid 0 +( 0 +hydromorphone 1 +2 0 +mg 0 +) 0 +and 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +( 0 +ketorolac 1 +10 0 +mg 0 +) 0 +analgesic 0 +agents 0 +. 0 + +Results 0 +showed 0 +that 0 +MM 0 +individuals 0 +were 0 +significantly 0 +less 0 +tolerant 0 +of 0 +CP 0 +pain 3 +than 0 +control 0 +subjects 0 +, 0 +replicating 0 +previous 0 +work 0 +. 0 + +Analgesic 0 +effects 0 +were 0 +significant 0 +neither 0 +for 0 +medication 0 +nor 0 +group 0 +. 0 + +These 0 +data 0 +indicate 0 +that 0 +MM 0 +opioid 0 +abusers 0 +represent 0 +a 0 +pain 3 +- 4 +intolerant 4 +subset 0 +of 0 +clinical 0 +patients 0 +. 0 + +Their 0 +complaints 0 +of 0 +pain 3 +should 0 +be 0 +evaluated 0 +seriously 0 +and 0 +managed 0 +aggressively 0 +. 0 + +High 0 +- 0 +dose 0 +methylprednisolone 1 +may 0 +do 0 +more 0 +harm 0 +for 0 +spinal 3 +cord 4 +injury 4 +. 0 + +Because 0 +of 0 +the 0 +National 0 +Acute 0 +Spinal 3 +Cord 4 +Injury 4 +Studies 0 +( 0 +NASCIS 0 +) 0 +, 0 +high 0 +- 0 +dose 0 +methylprednisolone 1 +became 0 +the 0 +standard 0 +of 0 +care 0 +for 0 +the 0 +acute 0 +spinal 3 +cord 4 +injury 4 +. 0 + +In 0 +the 0 +NASCIS 0 +, 0 +there 0 +was 0 +no 0 +mention 0 +regarding 0 +the 0 +possibility 0 +of 0 +acute 0 +corticosteroid 1 +myopathy 3 +that 0 +high 0 +- 0 +dose 0 +methylprednisolone 1 +may 0 +cause 0 +. 0 + +The 0 +dosage 0 +of 0 +methylprednisolone 1 +recommended 0 +by 0 +the 0 +NASCIS 0 +3 0 +is 0 +the 0 +highest 0 +dose 0 +of 0 +steroids 1 +ever 0 +being 0 +used 0 +during 0 +a 0 +2 0 +- 0 +day 0 +period 0 +for 0 +any 0 +clinical 0 +condition 0 +. 0 + +We 0 +hypothesize 0 +that 0 +it 0 +may 0 +cause 0 +some 0 +damage 3 +to 4 +the 4 +muscle 4 +of 0 +spinal 3 +cord 4 +injury 4 +patients 0 +. 0 + +Further 0 +, 0 +steroid 1 +myopathy 3 +recovers 0 +naturally 0 +and 0 +the 0 +neurological 0 +improvement 0 +shown 0 +in 0 +the 0 +NASCIS 0 +may 0 +be 0 +just 0 +a 0 +recording 0 +of 0 +this 0 +natural 0 +motor 0 +recovery 0 +from 0 +the 0 +steroid 1 +myopathy 3 +, 0 +instead 0 +of 0 +any 0 +protection 0 +that 0 +methylprednisolone 1 +offers 0 +to 0 +the 0 +spinal 3 +cord 4 +injury 4 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +first 0 +discussion 0 +considering 0 +the 0 +possibility 0 +that 0 +the 0 +methylprednisolone 1 +recommended 0 +by 0 +NASCIS 0 +may 0 +cause 0 +acute 0 +corticosteroid 1 +myopathy 3 +. 0 + +Conversion 0 +to 0 +rapamycin 1 +immunosuppression 0 +in 0 +renal 0 +transplant 0 +recipients 0 +: 0 +report 0 +of 0 +an 0 +initial 0 +experience 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +evaluate 0 +the 0 +effects 0 +of 0 +RAPA 1 +conversion 0 +in 0 +patients 0 +undergoing 0 +cyclosporine 1 +( 0 +CsA 1 +) 0 +or 0 +tacrolimus 1 +( 0 +Tac 1 +) 0 +toxicity 3 +. 0 + +METH0DS 0 +: 0 +Twenty 0 +renal 0 +transplant 0 +recipients 0 +were 0 +switched 0 +to 0 +fixed 0 +dose 0 +rapamycin 1 +( 0 +RAPA 1 +) 0 +( 0 +5 0 +mg 0 +/ 0 +day 0 +) 0 +0 0 +to 0 +204 0 +months 0 +posttransplant 0 +. 0 + +Drug 0 +monitoring 0 +was 0 +not 0 +initially 0 +used 0 +to 0 +adjust 0 +doses 0 +. 0 + +The 0 +indications 0 +for 0 +switch 0 +were 0 +chronic 0 +CsA 1 +or 0 +Tac 1 +nephrotoxicity 3 +( 0 +12 0 +) 0 +, 0 +acute 0 +CsA 1 +or 0 +Tac 1 +toxicity 3 +( 0 +3 0 +) 0 +, 0 +severe 0 +facial 3 +dysmorphism 4 +( 0 +2 0 +) 0 +, 0 +posttransplant 3 +lymphoproliferative 4 +disorder 4 +( 0 +PTLD 3 +) 0 +in 0 +remission 0 +( 0 +2 0 +) 0 +, 0 +and 0 +hepatotoxicity 3 +in 0 +1 0 +. 0 + +Follow 0 +- 0 +up 0 +is 0 +7 0 +to 0 +24 0 +months 0 +. 0 + +RESULTS 0 +: 0 +In 0 +the 0 +12 0 +patients 0 +switched 0 +because 0 +of 0 +chronic 0 +nephrotoxicity 3 +there 0 +was 0 +a 0 +significant 0 +decrease 0 +in 0 +serum 0 +creatinine 1 +[ 0 +233 0 ++ 0 +/ 0 +- 0 +34 0 +to 0 +210 0 ++ 0 +/ 0 +- 0 +56 0 +micromol 0 +/ 0 +liter 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +at 0 +6 0 +months 0 +] 0 +. 0 + +Facial 3 +dysmorphism 4 +improved 0 +in 0 +two 0 +patients 0 +. 0 + +No 0 +relapse 0 +of 0 +PTLD 3 +was 0 +observed 0 +. 0 + +Five 0 +patients 0 +developed 0 +pneumonia 3 +( 0 +two 0 +Pneumocystis 3 +carinii 4 +pneumonia 4 +, 0 +one 0 +infectious 3 +mononucleosis 4 +with 0 +polyclonal 0 +PTLD 3 +lung 0 +infiltrate 0 +) 0 +and 0 +two 0 +had 0 +bronchiolitis 3 +obliterans 4 +. 0 + +There 0 +were 0 +no 0 +deaths 0 +. 0 + +RAPA 1 +was 0 +discontinued 0 +in 0 +four 0 +patients 0 +, 0 +because 0 +of 0 +pneumonia 3 +in 0 +two 0 +, 0 +PTLD 3 +in 0 +one 0 +, 0 +and 0 +oral 0 +aphtous 3 +ulcers 4 +in 0 +one 0 +. 0 + +RAPA 1 +levels 0 +were 0 +high 0 +( 0 +> 0 +15 0 +ng 0 +/ 0 +ml 0 +) 0 +in 0 +7 0 +of 0 +13 0 +( 0 +54 0 +% 0 +) 0 +patients 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +RAPA 1 +conversion 0 +provides 0 +adequate 0 +immunosuppression 0 +to 0 +enable 0 +CsA 1 +withdrawal 0 +. 0 + +However 0 +, 0 +when 0 +converting 0 +patients 0 +to 0 +RAPA 1 +drug 0 +levels 0 +should 0 +be 0 +monitored 0 +to 0 +avoid 0 +over 0 +- 0 +immunosuppression 0 +and 0 +adequate 0 +antiviral 0 +and 0 +Pneumocystis 3 +carinii 4 +pneumonia 4 +prophylaxis 0 +should 0 +be 0 +given 0 +. 0 + +Electro 0 +- 0 +oculography 0 +, 0 +electroretinography 0 +, 0 +visual 0 +evoked 0 +potentials 0 +, 0 +and 0 +multifocal 0 +electroretinography 0 +in 0 +patients 0 +with 0 +vigabatrin 1 +- 0 +attributed 0 +visual 3 +field 4 +constriction 4 +. 0 + +PURP0SE 0 +: 0 +Symptomatic 0 +visual 3 +field 4 +constriction 4 +thought 0 +to 0 +be 0 +associated 0 +with 0 +vigabatrin 1 +has 0 +been 0 +reported 0 +. 0 + +The 0 +current 0 +study 0 +investigated 0 +the 0 +visual 0 +fields 0 +and 0 +visual 0 +electrophysiology 0 +of 0 +eight 0 +patients 0 +with 0 +known 0 +vigabatrin 1 +- 0 +attributed 0 +visual 3 +field 4 +loss 4 +, 0 +three 0 +of 0 +whom 0 +were 0 +reported 0 +previously 0 +. 0 + +Six 0 +of 0 +the 0 +patients 0 +were 0 +no 0 +longer 0 +receiving 0 +vigabatrin 1 +. 0 + +METH0DS 0 +: 0 +The 0 +central 0 +and 0 +peripheral 0 +fields 0 +were 0 +examined 0 +with 0 +the 0 +Humphrey 0 +Visual 0 +Field 0 +Analyzer 0 +. 0 + +Full 0 +visual 0 +electrophysiology 0 +, 0 +including 0 +flash 0 +electroretinography 0 +( 0 +ERG 0 +) 0 +, 0 +pattern 0 +electroretinography 0 +, 0 +multifocal 0 +ERG 0 +using 0 +the 0 +VERIS 0 +system 0 +, 0 +electro 0 +- 0 +oculography 0 +, 0 +and 0 +flash 0 +and 0 +pattern 0 +visual 0 +evoked 0 +potentials 0 +, 0 +was 0 +undertaken 0 +. 0 + +RESULTS 0 +: 0 +Seven 0 +patients 0 +showed 0 +marked 0 +visual 3 +field 4 +constriction 4 +with 0 +some 0 +sparing 0 +of 0 +the 0 +temporal 0 +visual 0 +field 0 +. 0 + +The 0 +eighth 0 +exhibited 0 +concentric 0 +constriction 0 +. 0 + +Most 0 +electrophysiological 0 +responses 0 +were 0 +usually 0 +just 0 +within 0 +normal 0 +limits 0 +; 0 +two 0 +patients 0 +had 0 +subnormal 0 +Arden 0 +electro 0 +- 0 +oculography 0 +indices 0 +; 0 +and 0 +one 0 +patient 0 +showed 0 +an 0 +abnormally 0 +delayed 0 +photopic 0 +b 0 +wave 0 +. 0 + +However 0 +, 0 +five 0 +patients 0 +showed 0 +delayed 0 +30 0 +- 0 +Hz 0 +flicker 0 +b 0 +waves 0 +, 0 +and 0 +seven 0 +patients 0 +showed 0 +delayed 0 +oscillatory 0 +potentials 0 +. 0 + +Multifocal 0 +ERG 0 +showed 0 +abnormalities 0 +that 0 +sometimes 0 +correlated 0 +with 0 +the 0 +visual 0 +field 0 +appearance 0 +and 0 +confirmed 0 +that 0 +the 0 +deficit 0 +occurs 0 +at 0 +the 0 +retinal 0 +level 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Marked 0 +visual 3 +field 4 +constriction 4 +appears 0 +to 0 +be 0 +associated 0 +with 0 +vigabatrin 1 +therapy 0 +. 0 + +The 0 +field 0 +defects 0 +and 0 +some 0 +electrophysiological 0 +abnormalities 0 +persist 0 +when 0 +vigabatrin 1 +therapy 0 +is 0 +withdrawn 0 +. 0 + +Myocardial 3 +ischemia 4 +due 0 +to 0 +coronary 3 +artery 4 +spasm 4 +during 0 +dobutamine 1 +stress 0 +echocardiography 0 +. 0 + +Dobutamine 1 +stress 0 +echocardiography 0 +( 0 +DSE 0 +) 0 +is 0 +a 0 +useful 0 +and 0 +safe 0 +provocation 0 +test 0 +for 0 +myocardial 3 +ischemia 4 +. 0 + +Until 0 +now 0 +, 0 +the 0 +test 0 +has 0 +been 0 +focused 0 +only 0 +on 0 +the 0 +organic 0 +lesion 0 +in 0 +the 0 +coronary 0 +artery 0 +, 0 +and 0 +positive 0 +DSE 0 +has 0 +indicated 0 +the 0 +presence 0 +of 0 +significant 0 +fixed 0 +coronary 3 +artery 4 +stenosis 4 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +is 0 +to 0 +examine 0 +whether 0 +myocardial 3 +ischemia 4 +due 0 +to 0 +coronary 3 +spasm 4 +is 0 +induced 0 +by 0 +dobutamine 1 +. 0 + +We 0 +performed 0 +DSE 0 +on 0 +51 0 +patients 0 +with 0 +coronary 3 +spastic 4 +angina 4 +but 0 +without 0 +significant 0 +fixed 0 +coronary 3 +artery 4 +stenosis 4 +. 0 + +All 0 +patients 0 +had 0 +anginal 3 +attacks 0 +at 0 +rest 0 +with 0 +ST 0 +elevation 0 +on 0 +the 0 +electrocardiogram 0 +( 0 +variant 3 +angina 4 +) 0 +. 0 + +Coronary 0 +spasm 0 +was 0 +induced 0 +by 0 +intracoronary 0 +injection 0 +of 0 +acetylcholine 1 +, 0 +and 0 +no 0 +fixed 0 +coronary 3 +artery 4 +stenosis 4 +was 0 +documented 0 +on 0 +angiograms 0 +in 0 +all 0 +patients 0 +. 0 + +DSE 0 +was 0 +performed 0 +with 0 +intravenous 0 +dobutamine 1 +infusion 0 +with 0 +an 0 +incremental 0 +doses 0 +of 0 +5 0 +, 0 +10 0 +, 0 +20 0 +, 0 +30 0 +, 0 +and 0 +40 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +every 0 +5 0 +minutes 0 +. 0 + +0f 0 +the 0 +51 0 +patients 0 +, 0 +7 0 +patients 0 +showed 0 +asynergy 0 +with 0 +ST 0 +elevation 0 +. 0 + +All 0 +7 0 +patients 0 +( 0 +13 0 +. 0 +7 0 +% 0 +) 0 +had 0 +chest 3 +pain 4 +during 0 +asynergy 0 +, 0 +and 0 +both 0 +chest 3 +pain 4 +and 0 +electrocardiographic 0 +changes 0 +were 0 +preceded 0 +by 0 +asynergy 0 +. 0 + +These 0 +findings 0 +indicate 0 +that 0 +dobutamine 1 +can 0 +provoke 0 +coronary 3 +spasm 4 +in 0 +some 0 +patients 0 +with 0 +coronary 3 +spastic 4 +angina 4 +. 0 + +When 0 +DSE 0 +is 0 +performed 0 +to 0 +evaluate 0 +coronary 3 +artery 4 +disease 4 +, 0 +not 0 +only 0 +fixed 0 +coronary 3 +stenosis 4 +, 0 +but 0 +also 0 +coronary 3 +spasm 4 +should 0 +be 0 +considered 0 +as 0 +a 0 +genesis 0 +of 0 +asynergy 0 +. 0 + +Effect 0 +of 0 +intravenous 0 +metoprolol 1 +or 0 +intravenous 0 +metoprolol 1 +plus 0 +glucagon 0 +on 0 +dobutamine 1 +- 0 +induced 0 +myocardial 3 +ischemia 4 +. 0 + +STUDY 0 +0BJECTIVE 0 +: 0 +To 0 +determine 0 +the 0 +effect 0 +of 0 +metoprolol 1 +on 0 +dobutamine 1 +stress 0 +testing 0 +with 0 +technetium 1 +- 2 +99m 2 +sestamibi 2 +single 0 +- 0 +photon 0 +emission 0 +computed 0 +tomography 0 +imaging 0 +and 0 +ST 0 +- 0 +segment 0 +monitoring 0 +, 0 +and 0 +to 0 +assess 0 +the 0 +impact 0 +of 0 +intravenous 0 +glucagon 0 +on 0 +metoprolol 1 +' 0 +s 0 +effects 0 +. 0 + +DESIGN 0 +: 0 +Randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +trial 0 +. 0 + +SETTING 0 +: 0 +Community 0 +hospital 0 +. 0 + +PATIENTS 0 +: 0 +Twenty 0 +- 0 +two 0 +patients 0 +with 0 +known 0 +reversible 0 +perfusion 0 +defects 0 +. 0 + +INTERVENTI0N 0 +: 0 +Patients 0 +underwent 0 +dobutamine 1 +stress 0 +tests 0 +per 0 +standard 0 +protocol 0 +. 0 + +Before 0 +dobutamine 1 +was 0 +begun 0 +, 0 +no 0 +therapy 0 +was 0 +given 0 +during 0 +the 0 +first 0 +visit 0 +, 0 +and 0 +patients 0 +were 0 +randomized 0 +on 0 +subsequent 0 +visits 0 +to 0 +receive 0 +metoprolol 1 +or 0 +metoprolol 1 +plus 0 +glucagon 0 +1 0 +mg 0 +. 0 + +Metoprolol 1 +was 0 +dosed 0 +to 0 +achieve 0 +a 0 +resting 0 +predobutamine 1 +heart 0 +rate 0 +below 0 +65 0 +beats 0 +/ 0 +minute 0 +or 0 +a 0 +total 0 +intravenous 0 +dose 0 +of 0 +20 0 +mg 0 +. 0 + +MEASUREMENTS 0 +AND 0 +MAIN 0 +RESULTS 0 +: 0 +Metoprolol 1 +reduced 0 +maximum 0 +heart 0 +rate 0 +31 0 +% 0 +, 0 +summed 0 +stress 0 +scores 0 +29 0 +% 0 +, 0 +and 0 +summed 0 +difference 0 +scores 0 +43 0 +% 0 +versus 0 +control 0 +. 0 + +Metoprolol 1 +plus 0 +glucagon 0 +also 0 +reduced 0 +the 0 +maximum 0 +heart 0 +rate 0 +29 0 +% 0 +versus 0 +control 0 +. 0 + +Summed 0 +stress 0 +and 0 +summed 0 +difference 0 +scores 0 +were 0 +not 0 +significantly 0 +reduced 0 +, 0 +although 0 +they 0 +were 0 +18 0 +% 0 +and 0 +30 0 +% 0 +lower 0 +, 0 +respectively 0 +, 0 +than 0 +control 0 +. 0 + +No 0 +significant 0 +differences 0 +were 0 +found 0 +in 0 +any 0 +parameter 0 +between 0 +metoprolol 1 +and 0 +metoprolol 1 +- 0 +glucagon 0 +. 0 + +C0NCLUSI0N 0 +: 0 +During 0 +dobutamine 1 +stress 0 +testing 0 +, 0 +metoprolol 1 +attenuates 0 +or 0 +eliminates 0 +evidence 0 +of 0 +myocardial 3 +ischemia 4 +. 0 + +Glucagon 0 +1 0 +mg 0 +, 0 +although 0 +somewhat 0 +effective 0 +, 0 +does 0 +not 0 +correct 0 +this 0 +effect 0 +to 0 +the 0 +extent 0 +that 0 +it 0 +can 0 +be 0 +administered 0 +clinically 0 +. 0 + +Evidence 0 +of 0 +functional 0 +somatotopy 0 +in 0 +GPi 0 +from 0 +results 0 +of 0 +pallidotomy 0 +. 0 + +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +explore 0 +the 0 +functional 0 +anatomy 0 +of 0 +the 0 +globus 0 +pallidus 0 +internus 0 +( 0 +GPi 0 +) 0 +by 0 +studying 0 +the 0 +effects 0 +of 0 +unilateral 0 +pallidotomy 0 +on 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +and 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +( 0 +LID 3 +) 0 +. 0 + +We 0 +found 0 +significant 0 +positive 0 +correlations 0 +between 0 +the 0 +preoperative 0 +levodopa 1 +responsiveness 0 +of 0 +motor 0 +signs 0 +and 0 +the 0 +levodopa 1 +responsiveness 0 +of 0 +scores 0 +in 0 +timed 0 +tests 0 +( 0 +Core 0 +Assessment 0 +Program 0 +for 0 +Intracerebral 0 +Transplantations 0 +) 0 +in 0 +the 0 +contralateral 0 +limbs 0 +and 0 +the 0 +improvement 0 +in 0 +these 0 +scores 0 +after 0 +surgery 0 +, 0 +whereas 0 +there 0 +was 0 +no 0 +correlation 0 +with 0 +the 0 +improvement 0 +in 0 +LID 3 +. 0 + +We 0 +also 0 +found 0 +a 0 +highly 0 +significant 0 +correlation 0 +( 0 +P 0 +: 0 +< 0 +0 0 +. 0 +0001 0 +, 0 +r 0 += 0 +0 0 +. 0 +8 0 +) 0 +between 0 +the 0 +volume 0 +of 0 +the 0 +ventral 0 +lesion 0 +in 0 +the 0 +GPi 0 +and 0 +the 0 +improvement 0 +in 0 +LID 3 +in 0 +the 0 +contralateral 0 +limbs 0 +, 0 +whereas 0 +there 0 +was 0 +no 0 +correlation 0 +between 0 +the 0 +ventral 0 +volume 0 +and 0 +the 0 +improvement 0 +in 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +. 0 + +The 0 +volumes 0 +of 0 +the 0 +total 0 +lesion 0 +cylinder 0 +and 0 +the 0 +dorsal 0 +lesion 0 +did 0 +not 0 +correlate 0 +with 0 +the 0 +outcome 0 +of 0 +either 0 +dyskinesias 3 +or 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +. 0 + +The 0 +differential 0 +predictive 0 +value 0 +of 0 +levodopa 1 +responsiveness 0 +for 0 +the 0 +outcome 0 +of 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +and 0 +LID 3 +and 0 +the 0 +different 0 +correlations 0 +of 0 +ventral 0 +lesion 0 +volume 0 +with 0 +dyskinesias 3 +and 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +indicate 0 +that 0 +different 0 +anatomical 0 +or 0 +pathophysiological 0 +substrates 0 +may 0 +be 0 +responsible 0 +for 0 +the 0 +generation 0 +of 0 +parkinsonian 3 +' 0 +off 0 +' 0 +signs 0 +and 0 +dyskinesias 3 +. 0 + +Whereas 0 +cells 0 +in 0 +a 0 +wider 0 +area 0 +of 0 +the 0 +GPi 0 +may 0 +be 0 +implicated 0 +in 0 +parkinsonism 3 +, 0 +the 0 +ventral 0 +GPi 0 +seems 0 +to 0 +be 0 +crucial 0 +for 0 +the 0 +manifestation 0 +of 0 +LID 3 +. 0 + +We 0 +suggest 0 +that 0 +our 0 +observations 0 +are 0 +additional 0 +proof 0 +of 0 +the 0 +functional 0 +somatotopy 0 +of 0 +the 0 +systems 0 +within 0 +the 0 +GPi 0 +that 0 +mediate 0 +parkinsonism 3 +and 0 +dyskinesias 3 +, 0 +especially 0 +along 0 +the 0 +dorsoventral 0 +trajectory 0 +used 0 +in 0 +pallidotomy 0 +. 0 + +The 0 +outcome 0 +of 0 +pallidotomy 0 +in 0 +which 0 +the 0 +lesion 0 +involves 0 +the 0 +ventral 0 +and 0 +dorsal 0 +GPi 0 +could 0 +be 0 +the 0 +net 0 +effect 0 +of 0 +alteration 0 +in 0 +the 0 +activity 0 +of 0 +pathways 0 +which 0 +mediate 0 +different 0 +symptoms 0 +, 0 +and 0 +hence 0 +could 0 +be 0 +variable 0 +. 0 + +Screening 0 +for 0 +stimulant 0 +use 0 +in 0 +adult 0 +emergency 0 +department 0 +seizure 3 +patients 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +prevalence 0 +of 0 +positive 0 +plasma 0 +drug 0 +screening 0 +for 0 +cocaine 1 +or 0 +amphetamine 1 +in 0 +adult 0 +emergency 0 +department 0 +seizure 3 +patients 0 +. 0 + +METH0DS 0 +: 0 +This 0 +prospective 0 +study 0 +evaluated 0 +consecutive 0 +eligible 0 +seizure 3 +patients 0 +who 0 +had 0 +a 0 +plasma 0 +sample 0 +collected 0 +as 0 +part 0 +of 0 +their 0 +clinical 0 +evaluation 0 +. 0 + +Plasma 0 +was 0 +tested 0 +for 0 +amphetamine 1 +and 0 +the 0 +cocaine 1 +metabolite 0 +benzoylecgonine 1 +using 0 +enzyme 0 +- 0 +mediated 0 +immunoassay 0 +methodology 0 +. 0 + +Plasma 0 +samples 0 +with 0 +benzoylecgonine 1 +greater 0 +than 0 +150 0 +ng 0 +/ 0 +mL 0 +or 0 +an 0 +amphetamine 1 +greater 0 +than 0 +500 0 +ng 0 +/ 0 +mL 0 +were 0 +defined 0 +as 0 +positive 0 +. 0 + +Patient 0 +demographics 0 +, 0 +history 0 +of 0 +underlying 0 +drug 0 +or 0 +alcohol 1 +- 0 +related 0 +seizure 3 +disorder 0 +, 0 +estimated 0 +time 0 +from 0 +seizure 3 +to 0 +sample 0 +collection 0 +, 0 +history 0 +or 0 +suspicion 0 +of 0 +cocaine 3 +or 4 +amphetamine 4 +abuse 4 +, 0 +results 0 +of 0 +clinical 0 +urine 0 +testing 0 +for 0 +drugs 0 +of 0 +abuse 0 +, 0 +and 0 +assay 0 +results 0 +were 0 +recorded 0 +without 0 +patient 0 +identifiers 0 +. 0 + +RESULTS 0 +: 0 +Fourteen 0 +of 0 +248 0 +( 0 +5 0 +. 0 +6 0 +% 0 +, 0 +95 0 +% 0 +CI 0 +2 0 +. 0 +7 0 +% 0 +- 0 +8 0 +. 0 +5 0 +% 0 +) 0 +plasma 0 +samples 0 +were 0 +positive 0 +by 0 +immunoassay 0 +testing 0 +for 0 +benzoylecgonine 1 +and 0 +no 0 +samples 0 +( 0 +0 0 +% 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +- 0 +1 0 +. 0 +2 0 +% 0 +) 0 +were 0 +positive 0 +for 0 +amphetamine 1 +. 0 + +Positive 0 +test 0 +results 0 +were 0 +more 0 +common 0 +in 0 +patient 0 +visits 0 +where 0 +there 0 +was 0 +a 0 +history 0 +or 0 +suspicion 0 +of 0 +cocaine 3 +or 4 +amphetamine 4 +abuse 4 +( 0 +p 0 +< 0 +0 0 +. 0 +0005 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +During 0 +this 0 +study 0 +period 0 +, 0 +routine 0 +plasma 0 +screening 0 +for 0 +cocaine 1 +and 0 +amphetamines 1 +in 0 +adult 0 +seizure 3 +patients 0 +had 0 +a 0 +low 0 +yield 0 +. 0 + +As 0 +a 0 +result 0 +, 0 +routine 0 +plasma 0 +screening 0 +would 0 +yield 0 +few 0 +cases 0 +of 0 +stimulant 0 +drug 0 +in 0 +which 0 +there 0 +was 0 +neither 0 +a 0 +history 0 +nor 0 +suspicion 0 +of 0 +drug 3 +abuse 4 +in 0 +this 0 +population 0 +. 0 + +Contribution 0 +of 0 +sodium 1 +valproate 2 +to 0 +the 0 +syndrome 3 +of 4 +inappropriate 4 +secretion 4 +of 4 +antidiuretic 4 +hormone 4 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +62 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +was 0 +administered 0 +sodium 1 +valproate 2 +( 0 +VPA 1 +) 0 +and 0 +who 0 +subsequently 0 +developed 0 +the 0 +syndrome 3 +of 4 +inappropriate 4 +secretion 4 +of 4 +antidiuretic 4 +hormone 4 +( 0 +SIADH 3 +) 0 +. 0 + +He 0 +had 0 +been 0 +taking 0 +VPA 1 +for 0 +treatment 0 +of 0 +idiopathic 0 +generalized 0 +tonic 3 +- 4 +clonic 4 +convulsions 4 +since 0 +he 0 +was 0 +56 0 +years 0 +old 0 +. 0 + +After 0 +substituting 0 +VPA 1 +with 0 +zonisamide 1 +, 0 +the 0 +serum 0 +sodium 1 +level 0 +returned 0 +to 0 +normal 0 +. 0 + +We 0 +consider 0 +this 0 +episode 0 +of 0 +SIADH 3 +to 0 +be 0 +the 0 +result 0 +of 0 +a 0 +combination 0 +of 0 +factors 0 +including 0 +a 0 +weakness 3 +of 4 +the 4 +central 4 +nervous 4 +system 4 +and 0 +the 0 +long 0 +- 0 +term 0 +administration 0 +of 0 +VPA 1 +. 0 + +Association 0 +of 0 +nitric 1 +oxide 2 +production 0 +and 0 +apoptosis 0 +in 0 +a 0 +model 0 +of 0 +experimental 0 +nephropathy 3 +. 0 + +BACKGR0UND 0 +: 0 +In 0 +recent 0 +studies 0 +increased 0 +amounts 0 +of 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +and 0 +apoptosis 0 +have 0 +been 0 +implicated 0 +in 0 +various 0 +pathological 0 +conditions 0 +in 0 +the 0 +kidney 0 +. 0 + +We 0 +have 0 +studied 0 +the 0 +role 0 +of 0 +N0 1 +and 0 +its 0 +association 0 +with 0 +apoptosis 0 +in 0 +an 0 +experimental 0 +model 0 +of 0 +nephrotic 3 +syndrome 4 +induced 0 +by 0 +a 0 +single 0 +injection 0 +of 0 +adriamycin 1 +( 0 +ADR 1 +) 0 +. 0 + +METH0DS 0 +: 0 +The 0 +alteration 0 +in 0 +the 0 +N0 1 +pathway 0 +was 0 +assessed 0 +by 0 +measuring 0 +nitrite 1 +levels 0 +in 0 +serum 0 +/ 0 +urine 0 +and 0 +by 0 +evaluating 0 +the 0 +changes 0 +in 0 +vascular 0 +reactivity 0 +of 0 +the 0 +isolated 0 +perfused 0 +rat 0 +kidney 0 +( 0 +IPRK 0 +) 0 +system 0 +. 0 + +Rats 0 +were 0 +stratified 0 +into 0 +control 0 +groups 0 +and 0 +ADR 1 +- 0 +induced 0 +nephropathy 3 +groups 0 +. 0 + +These 0 +two 0 +groups 0 +were 0 +then 0 +divided 0 +into 0 +: 0 +group 0 +1 0 +, 0 +animals 0 +receiving 0 +saline 0 +; 0 +and 0 +group 0 +2 0 +, 0 +animals 0 +receiving 0 +aminoguanidine 1 +( 0 +AG 1 +) 0 +which 0 +is 0 +a 0 +specific 0 +inhibitor 0 +of 0 +inducible 0 +- 0 +N0 1 +synthase 0 +. 0 + +0n 0 +day 0 +21 0 +, 0 +rats 0 +were 0 +sacrificed 0 +after 0 +obtaining 0 +material 0 +for 0 +biochemical 0 +analysis 0 +. 0 + +RESULTS 0 +: 0 +Histopathological 0 +examination 0 +of 0 +the 0 +kidneys 0 +of 0 +rats 0 +treated 0 +with 0 +ADR 1 +revealed 0 +focal 0 +areas 0 +of 0 +mesangial 3 +proliferation 4 +and 0 +mild 0 +tubulointerstitial 3 +inflammation 4 +. 0 + +They 0 +also 0 +had 0 +significantly 0 +higher 0 +levels 0 +of 0 +proteinuria 3 +compared 0 +with 0 +control 0 +and 0 +treatment 0 +groups 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Urine 0 +nitrite 1 +levels 0 +were 0 +significantly 0 +increased 0 +in 0 +the 0 +ADR 1 +- 0 +nephropathy 3 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +In 0 +the 0 +IPRK 0 +phenylephrine 1 +and 0 +acetylcholine 1 +related 0 +responses 0 +were 0 +significantly 0 +impaired 0 +in 0 +the 0 +ADR 1 +- 0 +nephropathy 3 +group 0 +. 0 + +Apoptosis 0 +was 0 +not 0 +detected 0 +in 0 +controls 0 +. 0 + +However 0 +, 0 +in 0 +the 0 +ADR 1 +- 0 +nephropathy 3 +group 0 +, 0 +numerous 0 +apoptotic 0 +cells 0 +were 0 +identified 0 +in 0 +the 0 +tubulointerstitial 0 +areas 0 +. 0 + +Double 0 +staining 0 +revealed 0 +numerous 0 +interstitial 0 +apoptotic 0 +cells 0 +to 0 +stain 0 +for 0 +ED1 0 +, 0 +a 0 +marker 0 +for 0 +monocytes 0 +/ 0 +macrophages 0 +. 0 + +Treatment 0 +with 0 +AG 1 +prevented 0 +the 0 +impairment 0 +of 0 +renal 0 +vascular 0 +bed 0 +responses 0 +and 0 +reduced 0 +both 0 +urine 0 +nitrite 1 +levels 0 +and 0 +apoptosis 0 +to 0 +control 0 +levels 0 +. 0 + +C0NCLUSI0N 0 +: 0 +We 0 +suggest 0 +that 0 +interactions 0 +between 0 +N0 1 +and 0 +apoptosis 0 +are 0 +important 0 +in 0 +the 0 +pathogenesis 0 +of 0 +the 0 +ADR 1 +- 0 +induced 0 +nephrosis 3 +. 0 + +Dual 0 +effects 0 +of 0 +melatonin 1 +on 0 +barbiturate 1 +- 0 +induced 0 +narcosis 3 +in 0 +rats 0 +. 0 + +Melatonin 1 +affects 0 +the 0 +circadian 0 +sleep 0 +/ 0 +wake 0 +cycle 0 +, 0 +but 0 +it 0 +is 0 +not 0 +clear 0 +whether 0 +it 0 +may 0 +influence 0 +drug 0 +- 0 +induced 0 +narcosis 3 +. 0 + +Sodium 1 +thiopenthal 2 +was 0 +administered 0 +intraperitoneally 0 +into 0 +male 0 +rats 0 +pre 0 +- 0 +treated 0 +with 0 +melatonin 1 +( 0 +0 0 +. 0 +05 0 +, 0 +0 0 +. 0 +5 0 +, 0 +5 0 +and 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +Melatonin 1 +pre 0 +- 0 +treatment 0 +affected 0 +in 0 +a 0 +dual 0 +manner 0 +barbiturate 1 +narcosis 3 +, 0 +however 0 +, 0 +no 0 +dose 0 +- 0 +effect 0 +correlation 0 +was 0 +found 0 +. 0 + +In 0 +particular 0 +, 0 +low 0 +doses 0 +reduced 0 +the 0 +latency 0 +to 0 +and 0 +prolonged 0 +the 0 +duration 0 +of 0 +barbiturate 1 +narcosis 3 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +highest 0 +dose 0 +of 0 +melatonin 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +caused 0 +a 0 +paradoxical 0 +increase 0 +in 0 +the 0 +latency 0 +and 0 +produced 0 +a 0 +sustained 0 +reduction 0 +of 0 +the 0 +duration 0 +of 0 +narcosis 3 +, 0 +and 0 +a 0 +reduction 0 +in 0 +mortality 0 +rate 0 +. 0 + +Melatonin 1 +0 0 +. 0 +5 0 +and 0 +5 0 +mg 0 +/ 0 +kg 0 +influenced 0 +the 0 +duration 0 +but 0 +not 0 +the 0 +latency 0 +of 0 +ketamine 1 +- 0 +or 0 +diazepam 1 +- 0 +induced 0 +narcosis 3 +. 0 + +Thus 0 +, 0 +the 0 +dual 0 +action 0 +of 0 +melatonin 1 +on 0 +pharmacological 0 +narcosis 3 +seems 0 +to 0 +be 0 +specific 0 +for 0 +the 0 +barbiturate 1 +mechanism 0 +of 0 +action 0 +. 0 + +Reduced 0 +cardiotoxicity 3 +and 0 +preserved 0 +antitumor 0 +efficacy 0 +of 0 +liposome 0 +- 0 +encapsulated 0 +doxorubicin 1 +and 0 +cyclophosphamide 1 +compared 0 +with 0 +conventional 0 +doxorubicin 1 +and 0 +cyclophosphamide 1 +in 0 +a 0 +randomized 0 +, 0 +multicenter 0 +trial 0 +of 0 +metastatic 0 +breast 3 +cancer 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +determine 0 +whether 0 +Myocet 1 +( 0 +liposome 0 +- 0 +encapsulated 0 +doxorubicin 1 +; 0 +The 0 +Liposome 0 +Company 0 +, 0 +Elan 0 +Corporation 0 +, 0 +Princeton 0 +, 0 +NJ 0 +) 0 +in 0 +combination 0 +with 0 +cyclophosphamide 1 +significantly 0 +reduces 0 +doxorubicin 1 +cardiotoxicity 3 +while 0 +providing 0 +comparable 0 +antitumor 0 +efficacy 0 +in 0 +first 0 +- 0 +line 0 +treatment 0 +of 0 +metastatic 0 +breast 3 +cancer 4 +( 0 +MBC 3 +) 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Two 0 +hundred 0 +ninety 0 +- 0 +seven 0 +patients 0 +with 0 +MBC 3 +and 0 +no 0 +prior 0 +chemotherapy 0 +for 0 +metastatic 0 +disease 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +60 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +of 0 +Myocet 1 +( 0 +M 0 +) 0 +or 0 +conventional 0 +doxorubicin 1 +( 0 +A 0 +) 0 +, 0 +in 0 +combination 0 +with 0 +600 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +of 0 +cyclophosphamide 1 +( 0 +C 0 +) 0 +, 0 +every 0 +3 0 +weeks 0 +until 0 +disease 0 +progression 0 +or 0 +unacceptable 0 +toxicity 3 +. 0 + +Cardiotoxicity 3 +was 0 +defined 0 +by 0 +reductions 0 +in 0 +left 0 +- 0 +ventricular 0 +ejection 0 +fraction 0 +, 0 +assessed 0 +by 0 +serial 0 +multigated 0 +radionuclide 0 +angiography 0 +scans 0 +, 0 +or 0 +congestive 3 +heart 4 +failure 4 +( 0 +CHF 3 +) 0 +. 0 + +Antitumor 0 +efficacy 0 +was 0 +assessed 0 +by 0 +objective 0 +tumor 3 +response 0 +rates 0 +( 0 +World 0 +Health 0 +0rganization 0 +criteria 0 +) 0 +, 0 +time 0 +to 0 +progression 0 +, 0 +and 0 +survival 0 +. 0 + +RESULTS 0 +: 0 +Six 0 +percent 0 +of 0 +MC 0 +patients 0 +versus 0 +21 0 +% 0 +( 0 +including 0 +five 0 +cases 0 +of 0 +CHF 3 +) 0 +of 0 +AC 0 +patients 0 +developed 0 +cardiotoxicity 3 +( 0 +P 0 += 0 +. 0 +0002 0 +) 0 +. 0 + +Median 0 +cumulative 0 +doxorubicin 1 +dose 0 +at 0 +onset 0 +was 0 +more 0 +than 0 +2 0 +, 0 +220 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +MC 0 +versus 0 +480 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +AC 0 +( 0 +P 0 += 0 +. 0 +0001 0 +, 0 +hazard 0 +ratio 0 +, 0 +5 0 +. 0 +04 0 +) 0 +. 0 + +MC 0 +patients 0 +also 0 +experienced 0 +less 0 +grade 0 +4 0 +neutropenia 3 +. 0 + +Antitumor 0 +efficacy 0 +of 0 +MC 0 +versus 0 +AC 0 +was 0 +comparable 0 +: 0 +objective 0 +response 0 +rates 0 +, 0 +43 0 +% 0 +versus 0 +43 0 +% 0 +; 0 +median 0 +time 0 +to 0 +progression 0 +, 0 +5 0 +. 0 +1 0 +% 0 +versus 0 +5 0 +. 0 +5 0 +months 0 +; 0 +median 0 +time 0 +to 0 +treatment 0 +failure 0 +, 0 +4 0 +. 0 +6 0 +versus 0 +4 0 +. 0 +4 0 +months 0 +; 0 +and 0 +median 0 +survival 0 +, 0 +19 0 +versus 0 +16 0 +months 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Myocet 1 +improves 0 +the 0 +therapeutic 0 +index 0 +of 0 +doxorubicin 1 +by 0 +significantly 0 +reducing 0 +cardiotoxicity 3 +and 0 +grade 0 +4 0 +neutropenia 3 +and 0 +provides 0 +comparable 0 +antitumor 0 +efficacy 0 +, 0 +when 0 +used 0 +in 0 +combination 0 +with 0 +cyclophosphamide 1 +as 0 +first 0 +- 0 +line 0 +therapy 0 +for 0 +MBC 3 +. 0 + +The 0 +role 0 +of 0 +nitrergic 0 +system 0 +in 0 +lidocaine 1 +- 0 +induced 0 +convulsion 3 +in 0 +the 0 +mouse 0 +. 0 + +The 0 +effects 0 +of 0 +N 1 +- 2 +nitro 2 +- 2 +L 2 +- 2 +arginine 2 +- 2 +methyl 2 +ester 2 +( 0 +L 1 +- 2 +NAME 2 +) 0 +a 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +synthase 0 +inhibitor 0 +and 0 +L 1 +- 2 +arginine 2 +, 0 +a 0 +N0 1 +precursor 0 +, 0 +were 0 +investigated 0 +on 0 +lidocaine 1 +- 0 +induced 0 +convulsions 3 +. 0 + +In 0 +the 0 +first 0 +experiment 0 +, 0 +four 0 +groups 0 +of 0 +mice 0 +received 0 +physiological 0 +saline 0 +( 0 +0 0 +. 0 +9 0 +% 0 +) 0 +, 0 +L 1 +- 2 +arginine 2 +( 0 +300 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +, 0 +L 1 +- 2 +NAME 2 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +diazepam 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +respectively 0 +. 0 + +Thirty 0 +minutes 0 +after 0 +these 0 +injections 0 +, 0 +all 0 +mice 0 +received 0 +lidocaine 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +In 0 +the 0 +second 0 +experiment 0 +, 0 +four 0 +groups 0 +of 0 +mice 0 +received 0 +similar 0 +treatment 0 +in 0 +the 0 +first 0 +experiment 0 +, 0 +and 0 +30 0 +min 0 +after 0 +these 0 +injections 0 +, 0 +all 0 +mice 0 +received 0 +a 0 +higher 0 +dose 0 +of 0 +lidocaine 1 +( 0 +80 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +L 1 +- 2 +NAME 2 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +diazepam 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +significantly 0 +decreased 0 +the 0 +incidence 0 +of 0 +lidocaine 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +- 0 +induced 0 +convulsions 3 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +L 1 +- 2 +arginine 2 +treatment 0 +increased 0 +the 0 +incidence 0 +of 0 +lidocaine 1 +( 0 +80 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +- 0 +induced 0 +convulsions 3 +significantly 0 +. 0 + +These 0 +results 0 +may 0 +suggest 0 +that 0 +N0 1 +is 0 +a 0 +proconvulsant 0 +mediator 0 +in 0 +lidocaine 1 +- 0 +induced 0 +convulsions 3 +. 0 + +Erythropoietin 0 +restores 0 +the 0 +anemia 3 +- 0 +induced 0 +reduction 0 +in 0 +cyclophosphamide 1 +cytotoxicity 3 +in 0 +rat 0 +tumors 3 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +examine 0 +the 0 +impact 0 +of 0 +anemia 3 +prevention 0 +by 0 +recombinant 0 +human 0 +erythropoietin 0 +( 0 +rHuEP0 0 +) 0 +treatment 0 +on 0 +the 0 +cytotoxicity 3 +of 0 +cyclophosphamide 1 +in 0 +solid 0 +experimental 0 +tumors 3 +. 0 + +Anemia 3 +was 0 +induced 0 +using 0 +a 0 +single 0 +dose 0 +of 0 +carboplatin 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +resulting 0 +in 0 +a 0 +long 0 +- 0 +lasting 0 +reduction 0 +( 0 +30 0 +% 0 +) 0 +of 0 +the 0 +hemoglobin 0 +concentration 0 +. 0 + +In 0 +a 0 +second 0 +group 0 +, 0 +the 0 +development 0 +of 0 +anemia 3 +was 0 +prevented 0 +by 0 +rHuEP0 0 +( 0 +1000 0 +IU 0 +/ 0 +kg 0 +) 0 +administered 0 +s 0 +. 0 +c 0 +. 0 +three 0 +times 0 +/ 0 +week 0 +starting 0 +7 0 +days 0 +before 0 +carboplatin 1 +application 0 +. 0 + +Four 0 +days 0 +after 0 +carboplatin 1 +treatment 0 +, 0 +tumors 3 +( 0 +DS 0 +- 0 +sarcoma 3 +of 0 +the 0 +rat 0 +) 0 +were 0 +implanted 0 +s 0 +. 0 +c 0 +. 0 +onto 0 +the 0 +hind 0 +food 0 +dorsum 0 +. 0 + +Neither 0 +carboplatin 1 +nor 0 +rHuEP0 0 +treatment 0 +influenced 0 +tumor 3 +growth 0 +rate 0 +per 0 +se 0 +. 0 + +When 0 +tumors 3 +were 0 +treated 0 +with 0 +a 0 +single 0 +dose 0 +of 0 +cyclophosphamide 1 +( 0 +60 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +5 0 +days 0 +after 0 +implantation 0 +, 0 +a 0 +growth 0 +delay 0 +with 0 +a 0 +subsequent 0 +regrowth 0 +of 0 +the 0 +tumors 3 +was 0 +observed 0 +. 0 + +In 0 +the 0 +anemia 3 +group 0 +, 0 +the 0 +growth 0 +delay 0 +was 0 +significantly 0 +shorter 0 +compared 0 +with 0 +nonanemic 0 +controls 0 +( 0 +13 0 +. 0 +3 0 +days 0 +versus 0 +8 0 +. 0 +6 0 +days 0 +) 0 +. 0 + +In 0 +the 0 +group 0 +where 0 +anemia 3 +was 0 +prevented 0 +by 0 +rHuEP0 0 +treatment 0 +, 0 +growth 0 +delay 0 +was 0 +comparable 0 +with 0 +that 0 +of 0 +nonanemic 0 +controls 0 +( 0 +13 0 +. 0 +3 0 +days 0 +) 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +chemotherapy 0 +- 0 +induced 0 +anemia 3 +reduces 0 +cytotoxicity 3 +of 0 +cyclophosphamide 1 +in 0 +tumors 3 +, 0 +whereas 0 +correction 0 +of 0 +anemia 3 +by 0 +rHuEP0 0 +treatment 0 +( 0 +epoetin 0 +alpha 0 +) 0 +increases 0 +the 0 +sensitivity 0 +, 0 +probably 0 +as 0 +a 0 +result 0 +of 0 +an 0 +improved 0 +oxygen 1 +supply 0 +to 0 +tumor 3 +tissue 0 +. 0 + +Fatal 0 +haemorrhagic 3 +myocarditis 4 +secondary 0 +to 0 +cyclophosphamide 1 +therapy 0 +. 0 + +Haemorrhagic 3 +myocarditis 4 +is 0 +a 0 +rare 0 +but 0 +important 0 +complication 0 +of 0 +cyclophosphamide 1 +therapy 0 +. 0 + +Echocardiographic 0 +identification 0 +of 0 +the 0 +disorder 0 +can 0 +be 0 +made 0 +. 0 + +We 0 +believe 0 +that 0 +the 0 +ultrasound 0 +features 0 +of 0 +this 0 +disorder 0 +have 0 +not 0 +been 0 +previously 0 +reported 0 +. 0 + +Effects 0 +of 0 +verapamil 1 +on 0 +atrial 3 +fibrillation 4 +and 0 +its 0 +electrophysiological 0 +determinants 0 +in 0 +dogs 0 +. 0 + +BACKGR0UND 0 +: 0 +Atrial 3 +tachycardia 4 +- 0 +induced 0 +remodeling 0 +promotes 0 +the 0 +occurrence 0 +and 0 +maintenance 0 +of 0 +atrial 3 +fibrillation 4 +( 0 +AF 3 +) 0 +and 0 +decreases 0 +L 0 +- 0 +type 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +current 0 +. 0 + +There 0 +is 0 +also 0 +a 0 +clinical 0 +suggestion 0 +that 0 +acute 0 +L 0 +- 0 +type 0 +Ca 1 +( 0 +2 0 +) 0 +channel 0 +blockade 0 +can 0 +promote 0 +AF 3 +, 0 +consistent 0 +with 0 +an 0 +AF 3 +promoting 0 +effect 0 +of 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +channel 0 +inhibition 0 +. 0 + +METH0DS 0 +: 0 +To 0 +evaluate 0 +the 0 +potential 0 +mechanisms 0 +of 0 +AF 3 +promotion 0 +by 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +channel 0 +blockers 0 +, 0 +we 0 +administered 0 +verapamil 1 +to 0 +morphine 1 +- 0 +chloralose 1 +anesthetized 0 +dogs 0 +. 0 + +Diltiazem 1 +was 0 +used 0 +as 0 +a 0 +comparison 0 +drug 0 +and 0 +autonomic 0 +blockade 0 +with 0 +atropine 1 +and 0 +nadolol 1 +was 0 +applied 0 +in 0 +some 0 +experiments 0 +. 0 + +Epicardial 0 +mapping 0 +with 0 +240 0 +epicardial 0 +electrodes 0 +was 0 +used 0 +to 0 +evaluate 0 +activation 0 +during 0 +AF 3 +. 0 + +RESULTS 0 +: 0 +Verapamil 1 +caused 0 +AF 3 +promotion 0 +in 0 +six 0 +dogs 0 +, 0 +increasing 0 +mean 0 +duration 0 +of 0 +AF 3 +induced 0 +by 0 +burst 0 +pacing 0 +, 0 +from 0 +8 0 ++ 0 +/ 0 +- 0 +4 0 +s 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +S 0 +. 0 +E 0 +. 0 +) 0 +to 0 +95 0 ++ 0 +/ 0 +- 0 +39 0 +s 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +vs 0 +. 0 +control 0 +) 0 +at 0 +a 0 +loading 0 +dose 0 +of 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +and 0 +228 0 ++ 0 +/ 0 +- 0 +101 0 +s 0 +( 0 +P 0 +< 0 +0 0 +. 0 +0005 0 +vs 0 +. 0 +control 0 +) 0 +at 0 +a 0 +dose 0 +of 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +. 0 + +Underlying 0 +electrophysiological 0 +mechanisms 0 +were 0 +studied 0 +in 0 +detail 0 +in 0 +five 0 +additional 0 +dogs 0 +under 0 +control 0 +conditions 0 +and 0 +in 0 +the 0 +presence 0 +of 0 +the 0 +higher 0 +dose 0 +of 0 +verapamil 1 +. 0 + +In 0 +these 0 +experiments 0 +, 0 +verapamil 1 +shortened 0 +mean 0 +effective 0 +refractory 0 +period 0 +( 0 +ERP 0 +) 0 +from 0 +122 0 ++ 0 +/ 0 +- 0 +5 0 +to 0 +114 0 ++ 0 +/ 0 +- 0 +4 0 +ms 0 +( 0 +P 0 +< 0 +0 0 +. 0 +02 0 +) 0 +at 0 +a 0 +cycle 0 +length 0 +of 0 +300 0 +ms 0 +, 0 +decreased 0 +ERP 0 +heterogeneity 0 +( 0 +from 0 +15 0 ++ 0 +/ 0 +- 0 +1 0 +to 0 +10 0 ++ 0 +/ 0 +- 0 +1 0 +% 0 +, 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +heterogeneously 0 +accelerated 0 +atrial 0 +conduction 0 +and 0 +decreased 0 +the 0 +cycle 0 +length 0 +of 0 +AF 3 +( 0 +94 0 ++ 0 +/ 0 +- 0 +4 0 +to 0 +84 0 ++ 0 +/ 0 +- 0 +3 0 +ms 0 +, 0 +P 0 +< 0 +0 0 +. 0 +005 0 +) 0 +. 0 + +Diltiazem 1 +did 0 +not 0 +affect 0 +ERP 0 +, 0 +AF 3 +cycle 0 +length 0 +or 0 +AF 3 +duration 0 +, 0 +but 0 +produced 0 +conduction 0 +acceleration 0 +similar 0 +to 0 +that 0 +caused 0 +by 0 +verapamil 1 +( 0 +n 0 += 0 +5 0 +) 0 +. 0 + +In 0 +the 0 +presence 0 +of 0 +autonomic 0 +blockade 0 +, 0 +verapamil 1 +failed 0 +to 0 +promote 0 +AF 3 +and 0 +increased 0 +, 0 +rather 0 +than 0 +decreasing 0 +, 0 +refractoriness 0 +. 0 + +Neither 0 +verapamil 1 +nor 0 +diltiazem 1 +affected 0 +atrial 0 +conduction 0 +in 0 +the 0 +presence 0 +of 0 +autonomic 0 +blockade 0 +. 0 + +Epicardial 0 +mapping 0 +suggested 0 +that 0 +verapamil 1 +promoted 0 +AF 3 +by 0 +increasing 0 +the 0 +number 0 +of 0 +simultaneous 0 +wavefronts 0 +reflected 0 +by 0 +separate 0 +zones 0 +of 0 +reactivation 0 +in 0 +each 0 +cycle 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Verapamil 1 +promotes 0 +AF 3 +in 0 +normal 0 +dogs 0 +by 0 +promoting 0 +multiple 0 +circuit 0 +reentry 0 +, 0 +an 0 +effect 0 +dependent 0 +on 0 +intact 0 +autonomic 0 +tone 0 +and 0 +not 0 +shared 0 +by 0 +diltiazem 1 +. 0 + +Calcitonin 0 +gene 0 +- 0 +related 0 +peptide 0 +levels 0 +during 0 +nitric 1 +oxide 2 +- 0 +induced 0 +headache 3 +in 0 +patients 0 +with 0 +chronic 0 +tension 3 +- 4 +type 4 +headache 4 +. 0 + +It 0 +has 0 +been 0 +proposed 0 +that 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +induced 0 +headache 3 +in 0 +primary 3 +headaches 4 +may 0 +be 0 +associated 0 +with 0 +release 0 +of 0 +calcitonin 0 +gene 0 +- 0 +related 0 +peptide 0 +( 0 +CGRP 0 +) 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +we 0 +aimed 0 +to 0 +investigate 0 +plasma 0 +levels 0 +of 0 +CGRP 0 +during 0 +headache 3 +induced 0 +by 0 +the 0 +N0 1 +donor 0 +glyceryl 1 +trinitrate 2 +( 0 +GTN 1 +) 0 +in 0 +16 0 +patients 0 +with 0 +chronic 0 +tension 3 +- 4 +type 4 +headache 4 +and 0 +16 0 +healthy 0 +controls 0 +. 0 + +The 0 +subjects 0 +were 0 +randomly 0 +allocated 0 +to 0 +receive 0 +0 0 +. 0 +5 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +GTN 1 +or 0 +placebo 0 +over 0 +20 0 +min 0 +on 0 +two 0 +headache 3 +- 0 +free 0 +days 0 +. 0 + +Blood 0 +samples 0 +were 0 +collected 0 +at 0 +baseline 0 +, 0 +10 0 +, 0 +20 0 +and 0 +60 0 +min 0 +after 0 +start 0 +of 0 +infusion 0 +. 0 + +Both 0 +patients 0 +and 0 +controls 0 +developed 0 +significantly 0 +stronger 0 +immediate 0 +headache 3 +on 0 +the 0 +GTN 1 +day 0 +than 0 +on 0 +the 0 +placebo 0 +day 0 +and 0 +the 0 +headache 3 +was 0 +significantly 0 +more 0 +pronounced 0 +in 0 +patients 0 +than 0 +in 0 +controls 0 +. 0 + +There 0 +was 0 +no 0 +difference 0 +between 0 +the 0 +area 0 +under 0 +the 0 +CGRP 0 +curve 0 +( 0 +AUCCGRP 0 +) 0 +on 0 +GTN 1 +vs 0 +. 0 +placebo 0 +day 0 +in 0 +either 0 +patients 0 +( 0 +P 0 += 0 +0 0 +. 0 +65 0 +) 0 +or 0 +controls 0 +( 0 +P 0 += 0 +0 0 +. 0 +48 0 +) 0 +. 0 + +The 0 +AUCCGRP 0 +recorded 0 +on 0 +the 0 +GTN 1 +day 0 +did 0 +not 0 +differ 0 +between 0 +patients 0 +and 0 +controls 0 +( 0 +P 0 += 0 +0 0 +. 0 +36 0 +) 0 +. 0 + +Both 0 +in 0 +patients 0 +and 0 +controls 0 +, 0 +CGRP 0 +levels 0 +changed 0 +significantly 0 +over 0 +time 0 +, 0 +on 0 +both 0 +the 0 +GTN 1 +and 0 +placebo 0 +days 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +present 0 +study 0 +indicates 0 +that 0 +N0 1 +- 0 +induced 0 +immediate 0 +headache 3 +is 0 +not 0 +associated 0 +with 0 +release 0 +of 0 +CGRP 0 +. 0 + +Fluconazole 1 +- 0 +induced 0 +torsade 3 +de 4 +pointes 4 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +present 0 +a 0 +case 0 +of 0 +fluconazole 1 +- 0 +associated 0 +torsade 3 +de 4 +pointes 4 +( 0 +TDP 3 +) 0 +and 0 +discuss 0 +fluconazole 1 +' 0 +s 0 +role 0 +in 0 +causing 0 +TDP 3 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +68 0 +- 0 +year 0 +- 0 +old 0 +white 0 +woman 0 +with 0 +Candida 0 +glabrata 0 +isolated 0 +from 0 +a 0 +presacral 0 +abscess 0 +developed 0 +TDP 3 +eight 0 +days 0 +after 0 +commencing 0 +oral 0 +fluconazole 1 +The 0 +patient 0 +had 0 +no 0 +other 0 +risk 0 +factors 0 +for 0 +TDP 3 +, 0 +including 0 +coronary 3 +artery 4 +disease 4 +, 0 +cardiomyopathy 3 +, 0 +congestive 3 +heart 4 +failure 4 +, 0 +and 0 +electrolyte 0 +abnormalities 0 +There 0 +was 0 +a 0 +temporal 0 +association 0 +between 0 +the 0 +initiation 0 +of 0 +fluconazole 1 +and 0 +TDP 3 +. 0 + +The 0 +TDP 3 +resolved 0 +when 0 +fluconazole 1 +was 0 +discontinued 0 +; 0 +however 0 +, 0 +the 0 +patient 0 +continued 0 +to 0 +have 0 +premature 3 +ventricular 4 +contractions 4 +and 0 +nonsustained 0 +ventricular 3 +tachycardia 4 +( 0 +NSVT 3 +) 0 +until 0 +six 0 +days 0 +after 0 +drug 0 +cessation 0 +DISCUSSI0N 0 +: 0 +Use 0 +of 0 +the 0 +Naranjo 0 +probability 0 +scale 0 +indicates 0 +a 0 +probable 0 +relationship 0 +between 0 +the 0 +use 0 +of 0 +fluconazole 1 +and 0 +the 0 +development 0 +of 0 +TDP 3 +. 0 + +The 0 +possible 0 +mechanism 0 +is 0 +depression 3 +of 0 +rapidly 0 +activating 0 +delayed 0 +rectifier 0 +potassium 1 +currents 0 +. 0 + +In 0 +our 0 +patient 0 +, 0 +there 0 +was 0 +no 0 +other 0 +etiology 0 +identified 0 +that 0 +could 0 +explain 0 +QT 3 +prolongation 4 +or 0 +TDP 3 +The 0 +complete 0 +disappearance 0 +of 0 +NSVT 3 +and 0 +premature 3 +ventricular 4 +contractions 4 +followed 0 +by 0 +normalization 0 +of 0 +QT 0 +interval 0 +after 0 +the 0 +drug 0 +was 0 +stopped 0 +strongly 0 +suggests 0 +fluconazole 1 +as 0 +the 0 +etiology 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Clinicians 0 +should 0 +be 0 +aware 0 +that 0 +fluconazole 1 +, 0 +even 0 +at 0 +low 0 +doses 0 +, 0 +may 0 +cause 0 +prolongation 3 +of 4 +the 4 +QT 4 +interval 4 +, 0 +leading 0 +to 0 +TDP 3 +. 0 + +Serial 0 +electrocardiographic 0 +monitoring 0 +may 0 +be 0 +considered 0 +when 0 +fluconazole 1 +is 0 +administered 0 +in 0 +patients 0 +who 0 +are 0 +at 0 +risk 0 +for 0 +ventricular 3 +arrhythmias 4 +. 0 + +Cutaneous 3 +leucocytoclastic 4 +vasculitis 4 +associated 0 +with 0 +oxacillin 1 +. 0 + +A 0 +67 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +was 0 +treated 0 +with 0 +oxacillin 1 +for 0 +one 0 +week 0 +because 0 +of 0 +Staphylococcus 3 +aureus 4 +bacteremia 4 +, 0 +developed 0 +renal 3 +failure 4 +and 0 +diffuse 0 +, 0 +symmetric 0 +, 0 +palpable 0 +purpuric 3 +lesions 4 +on 0 +his 0 +feet 0 +. 0 + +Necrotic 3 +blisters 4 +were 0 +noted 0 +on 0 +his 0 +fingers 0 +. 0 + +Skin 0 +biopsies 0 +showed 0 +findings 0 +diagnostic 0 +of 0 +leucocytoclastic 3 +vasculitis 4 +. 0 + +0xacillin 1 +was 0 +discontinued 0 +and 0 +patient 0 +was 0 +treated 0 +with 0 +corticosteroids 1 +. 0 + +The 0 +rash 3 +disappeared 0 +after 0 +three 0 +weeks 0 +and 0 +renal 0 +function 0 +returned 0 +to 0 +normal 0 +. 0 + +Leucocytoclastic 3 +vasculitis 4 +presents 0 +as 0 +palpable 0 +purpura 3 +of 0 +the 0 +lower 0 +extremities 0 +often 0 +accompanied 0 +by 0 +abdominal 3 +pain 4 +, 0 +arthralgia 3 +, 0 +and 0 +renal 3 +involvement 4 +. 0 + +Etiologic 0 +factors 0 +or 0 +associated 0 +disorders 0 +include 0 +infections 3 +, 0 +medications 0 +, 0 +collagen 3 +vascular 4 +disease 4 +and 0 +neoplasia 3 +. 0 + +However 0 +, 0 +in 0 +half 0 +of 0 +the 0 +cases 0 +no 0 +etiologic 0 +factor 0 +is 0 +identified 0 +. 0 + +Usually 0 +it 0 +is 0 +a 0 +self 0 +- 0 +limited 0 +disorder 0 +, 0 +but 0 +corticosteroid 1 +therapy 0 +may 0 +be 0 +needed 0 +in 0 +life 0 +- 0 +threatening 0 +cases 0 +since 0 +early 0 +treatment 0 +with 0 +corticosteroids 1 +in 0 +severe 0 +cases 0 +can 0 +prevent 0 +complications 0 +. 0 + +0xacillin 1 +should 0 +be 0 +included 0 +among 0 +the 0 +drugs 0 +that 0 +can 0 +cause 0 +leucocytoclastic 3 +vasculitis 4 +. 0 + +The 0 +renal 0 +pathology 0 +in 0 +a 0 +case 0 +of 0 +lithium 1 +- 0 +induced 0 +diabetes 3 +insipidus 4 +. 0 + +A 0 +case 0 +of 0 +lithium 1 +- 0 +induced 0 +diabetes 3 +insipidus 4 +is 0 +reported 0 +. 0 + +At 0 +necropsy 0 +microscopy 0 +shoed 0 +unique 0 +and 0 +extensive 0 +damage 0 +to 0 +cells 0 +lining 0 +the 0 +distal 0 +nephron 0 +. 0 + +It 0 +is 0 +suggested 0 +that 0 +these 0 +changes 0 +represent 0 +a 0 +specific 0 +toxic 0 +effect 0 +of 0 +lithium 1 +, 0 +reported 0 +here 0 +for 0 +the 0 +first 0 +time 0 +in 0 +man 0 +. 0 + +Cholestatic 3 +jaundice 4 +associated 0 +with 0 +the 0 +use 0 +of 0 +metformin 1 +. 0 + +We 0 +report 0 +a 0 +patient 0 +who 0 +developed 0 +cholestatic 3 +jaundice 4 +shortly 0 +after 0 +initiation 0 +of 0 +treatment 0 +with 0 +metformin 1 +hydrochloride 2 +. 0 + +Ultrasound 0 +of 0 +the 0 +liver 0 +and 0 +abdominal 0 +CT 0 +were 0 +normal 0 +. 0 + +An 0 +ERCP 0 +showed 0 +normal 0 +biliary 0 +anatomy 0 +. 0 + +A 0 +percutaneous 0 +liver 0 +biopsy 0 +was 0 +obtained 0 +showing 0 +marked 0 +cholestasis 3 +, 0 +with 0 +portal 0 +edema 3 +, 0 +ductular 0 +proliferation 0 +, 0 +and 0 +acute 0 +inflammation 3 +. 0 + +Metformin 1 +hydrochloride 2 +was 0 +discontinued 0 +, 0 +and 0 +the 0 +patient 0 +' 0 +s 0 +jaundice 3 +resolved 0 +slowly 0 +over 0 +a 0 +period 0 +of 0 +several 0 +months 0 +. 0 + +Given 0 +the 0 +onset 0 +of 0 +his 0 +jaundice 3 +2 0 +wk 0 +after 0 +the 0 +initiation 0 +of 0 +metformin 1 +, 0 +we 0 +believe 0 +that 0 +this 0 +case 0 +represents 0 +an 0 +example 0 +of 0 +metformin 1 +- 0 +associated 0 +hepatotoxicity 3 +, 0 +the 0 +first 0 +such 0 +case 0 +reported 0 +. 0 + +Systemic 0 +toxicity 3 +and 0 +resuscitation 0 +in 0 +bupivacaine 1 +- 0 +, 0 +levobupivacaine 1 +- 0 +, 0 +or 0 +ropivacaine 1 +- 0 +infused 0 +rats 0 +. 0 + +We 0 +compared 0 +the 0 +systemic 0 +toxicity 3 +of 0 +bupivacaine 1 +, 0 +levobupivacaine 1 +, 0 +and 0 +ropivacaine 1 +in 0 +anesthetized 0 +rats 0 +. 0 + +We 0 +also 0 +compared 0 +the 0 +ability 0 +to 0 +resuscitate 0 +rats 0 +after 0 +lethal 0 +doses 0 +of 0 +these 0 +local 0 +anesthetics 0 +. 0 + +Bupivacaine 1 +, 0 +levobupivacaine 1 +, 0 +or 0 +ropivacaine 1 +was 0 +infused 0 +at 0 +a 0 +rate 0 +of 0 +2 0 +mg 0 +. 0 + +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 + +min 0 +( 0 +- 0 +1 0 +) 0 +while 0 +electrocardiogram 0 +, 0 +electroencephalogram 0 +, 0 +and 0 +arterial 0 +pressure 0 +were 0 +continuously 0 +monitored 0 +. 0 + +When 0 +asystole 3 +was 0 +recorded 0 +, 0 +drug 0 +infusion 0 +was 0 +stopped 0 +and 0 +a 0 +resuscitation 0 +sequence 0 +was 0 +begun 0 +. 0 + +Epinephrine 1 +0 0 +. 0 +01 0 +mg 0 +/ 0 +kg 0 +was 0 +administered 0 +at 0 +1 0 +- 0 +min 0 +intervals 0 +while 0 +external 0 +cardiac 0 +compressions 0 +were 0 +applied 0 +. 0 + +Resuscitation 0 +was 0 +considered 0 +successful 0 +when 0 +a 0 +systolic 0 +arterial 0 +pressure 0 +> 0 +or 0 += 0 +100 0 +mm 0 +Hg 0 +was 0 +achieved 0 +within 0 +5 0 +min 0 +. 0 + +The 0 +cumulative 0 +doses 0 +of 0 +levobupivacaine 1 +and 0 +ropivacaine 1 +that 0 +produced 0 +seizures 3 +were 0 +similar 0 +and 0 +were 0 +larger 0 +than 0 +those 0 +of 0 +bupivacaine 1 +. 0 + +The 0 +cumulative 0 +doses 0 +of 0 +levobupivacaine 1 +that 0 +produced 0 +dysrhythmias 3 +and 0 +asystole 3 +were 0 +smaller 0 +than 0 +the 0 +corresponding 0 +doses 0 +of 0 +ropivacaine 1 +, 0 +but 0 +they 0 +were 0 +larger 0 +than 0 +those 0 +of 0 +bupivacaine 1 +. 0 + +The 0 +number 0 +of 0 +successful 0 +resuscitations 0 +did 0 +not 0 +differ 0 +among 0 +groups 0 +. 0 + +However 0 +, 0 +a 0 +smaller 0 +dose 0 +of 0 +epinephrine 1 +was 0 +required 0 +in 0 +the 0 +Ropivacaine 1 +group 0 +than 0 +in 0 +the 0 +other 0 +groups 0 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +systemic 0 +toxicity 3 +of 0 +levobupivacaine 1 +is 0 +intermediate 0 +between 0 +that 0 +of 0 +ropivacaine 1 +and 0 +bupivacaine 1 +when 0 +administered 0 +at 0 +the 0 +same 0 +rate 0 +and 0 +that 0 +ropivacaine 1 +- 0 +induced 0 +cardiac 3 +arrest 4 +appears 0 +to 0 +be 0 +more 0 +susceptible 0 +to 0 +treatment 0 +than 0 +that 0 +induced 0 +by 0 +bupivacaine 1 +or 0 +levobupivacaine 1 +. 0 + +Amphotericin 1 +B 2 +- 0 +induced 0 +seizures 3 +in 0 +a 0 +patient 0 +with 0 +AIDS 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +multiple 0 +episodes 0 +of 0 +seizure 3 +activity 0 +in 0 +an 0 +AIDS 3 +patent 0 +following 0 +amphotericin 1 +B 2 +infusion 0 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +46 0 +- 0 +year 0 +- 0 +old 0 +African 0 +- 0 +American 0 +man 0 +experienced 0 +recurrent 0 +grand 3 +mal 4 +seizures 4 +during 0 +intravenous 0 +infusion 0 +of 0 +amphotericin 1 +B 2 +, 0 +then 0 +petit 0 +mal 0 +seizures 3 +as 0 +the 0 +infusion 0 +was 0 +stopped 0 +and 0 +the 0 +drug 0 +concentrations 0 +decreased 0 +with 0 +time 0 +. 0 + +The 0 +patients 0 +concurrent 0 +medications 0 +included 0 +didanosine 1 +, 0 +hydroxyzine 1 +, 0 +promethazine 1 +, 0 +hydrocortisone 1 +, 0 +and 0 +prochlorperazine 1 +. 0 + +Despite 0 +administration 0 +of 0 +phenytoin 1 +and 0 +lorazepam 1 +, 0 +the 0 +seizures 3 +persisted 0 +and 0 +occurred 0 +only 0 +during 0 +amphotercin 1 +B 2 +administration 0 +. 0 + +DISCUSSI0N 0 +: 0 +AIDS 3 +and 0 +cryptococcal 3 +meningitis 4 +, 0 +both 0 +of 0 +which 0 +the 0 +patient 0 +had 0 +, 0 +can 0 +potentially 0 +cause 0 +seizures 3 +. 0 + +The 0 +patient 0 +had 0 +a 0 +history 0 +of 0 +alcohol 3 +abuse 4 +; 0 +alcohol 1 +intake 0 +as 0 +well 0 +as 0 +withdrawal 0 +can 0 +also 0 +cause 0 +seizures 3 +. 0 + +Didanosine 1 +also 0 +has 0 +a 0 +potential 0 +for 0 +inducing 0 +seizures 3 +. 0 + +However 0 +, 0 +these 0 +other 0 +potential 0 +causes 0 +of 0 +seizure 3 +were 0 +ruled 0 +out 0 +. 0 + +The 0 +time 0 +course 0 +of 0 +events 0 +suggested 0 +that 0 +amphotericin 1 +B 2 +was 0 +the 0 +cause 0 +of 0 +the 0 +seizures 3 +in 0 +this 0 +AIDS 3 +patient 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Amphotericin 1 +B 2 +seems 0 +to 0 +be 0 +the 0 +probable 0 +cause 0 +of 0 +the 0 +seizures 3 +. 0 + +To 0 +date 0 +, 0 +only 0 +three 0 +cases 0 +of 0 +seizures 3 +associated 0 +with 0 +amphotericin 1 +B 2 +have 0 +been 0 +reported 0 +in 0 +the 0 +literature 0 +, 0 +but 0 +healthcare 0 +providers 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +potential 0 +for 0 +this 0 +rare 0 +adverse 0 +effect 0 +. 0 + +Sirolimus 1 +and 0 +mycophenolate 1 +mofetil 2 +for 0 +calcineurin 0 +- 0 +free 0 +immunosuppression 0 +in 0 +renal 0 +transplant 0 +recipients 0 +. 0 + +Calcineurin 0 +inhibitors 0 +, 0 +such 0 +as 0 +cyclosporine 1 +and 0 +tacrolimus 1 +, 0 +have 0 +been 0 +available 0 +for 0 +almost 0 +20 0 +years 0 +. 0 + +Although 0 +these 0 +drugs 0 +are 0 +highly 0 +effective 0 +and 0 +represent 0 +the 0 +mainstay 0 +of 0 +transplant 0 +immunosuppression 0 +, 0 +they 0 +are 0 +associated 0 +with 0 +acute 0 +and 0 +chronic 0 +nephrotoxicity 3 +. 0 + +Acute 0 +nephrotoxicity 3 +, 0 +which 0 +occurs 0 +in 0 +the 0 +early 0 +period 0 +after 0 +transplantation 0 +, 0 +leads 0 +to 0 +a 0 +higher 0 +rate 0 +of 0 +dialysis 0 +, 0 +and 0 +chronic 0 +nephrotoxicity 3 +may 0 +eventually 0 +result 0 +in 0 +graft 0 +loss 0 +. 0 + +Acute 0 +and 0 +chronic 0 +nephrotoxicity 3 +is 0 +becoming 0 +more 0 +common 0 +as 0 +the 0 +use 0 +of 0 +marginal 0 +kidneys 0 +for 0 +transplantation 0 +increases 0 +. 0 + +Two 0 +recently 0 +available 0 +immunosuppressive 0 +agents 0 +, 0 +mycophenolate 1 +mofetil 2 +and 0 +sirolimus 1 +( 0 +rapamycin 1 +) 0 +, 0 +have 0 +no 0 +nephrotoxicity 3 +. 0 + +The 0 +use 0 +of 0 +these 0 +drugs 0 +in 0 +combination 0 +with 0 +other 0 +agents 0 +has 0 +led 0 +to 0 +the 0 +development 0 +of 0 +new 0 +paradigms 0 +of 0 +immunosuppressive 0 +therapy 0 +. 0 + +This 0 +paper 0 +reviews 0 +the 0 +results 0 +of 0 +clinical 0 +trials 0 +that 0 +have 0 +investigated 0 +these 0 +new 0 +approaches 0 +to 0 +immunosuppression 0 +in 0 +renal 0 +transplant 0 +recipients 0 +. 0 + +Tolerability 0 +of 0 +nimesulide 1 +and 0 +paracetamol 1 +in 0 +patients 0 +with 0 +NSAID 1 +- 0 +induced 0 +urticaria 3 +/ 0 +angioedema 3 +. 0 + +Previous 0 +studies 0 +evaluated 0 +the 0 +tolerance 0 +of 0 +nimesulide 1 +and 0 +paracetamol 1 +in 0 +subjects 0 +with 0 +cutaneous 0 +, 0 +respiratory 0 +and 0 +anaphylactoid 0 +reactions 0 +induced 0 +by 0 +nonsteroidal 1 +anti 2 +- 2 +inflammatory 2 +drugs 2 +( 0 +NSAIDs 1 +) 0 +. 0 + +In 0 +this 0 +study 0 +we 0 +investigated 0 +tolerability 0 +and 0 +reliability 0 +of 0 +nimesulide 1 +and 0 +paracetamol 1 +in 0 +a 0 +very 0 +large 0 +number 0 +of 0 +patients 0 +with 0 +an 0 +exclusive 0 +well 0 +- 0 +documented 0 +history 0 +of 0 +NSAID 1 +- 0 +induced 0 +urticaria 3 +/ 0 +angioedema 3 +. 0 + +Furthermore 0 +, 0 +we 0 +evaluated 0 +whether 0 +some 0 +factors 0 +have 0 +the 0 +potential 0 +to 0 +increase 0 +the 0 +risk 0 +of 0 +reaction 0 +to 0 +paracetamol 1 +and 0 +nimesulide 1 +. 0 + +A 0 +single 0 +- 0 +placebo 0 +- 0 +controlled 0 +oral 0 +challenge 0 +procedure 0 +with 0 +nimesulide 1 +or 0 +paracetamol 1 +was 0 +applied 0 +to 0 +829 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +NSAID 1 +- 0 +induced 0 +urticaria 3 +/ 0 +angioedema 3 +. 0 + +A 0 +total 0 +of 0 +75 0 +/ 0 +829 0 +( 0 +9 0 +. 0 +4 0 +% 0 +) 0 +patients 0 +experienced 0 +reactions 0 +to 0 +nimesulide 1 +or 0 +paracetamol 1 +. 0 + +0f 0 +the 0 +715 0 +patients 0 +tested 0 +with 0 +nimesulide 1 +62 0 +( 0 +8 0 +. 0 +6 0 +% 0 +) 0 +showed 0 +a 0 +positive 0 +test 0 +, 0 +while 0 +of 0 +114 0 +subjects 0 +submitted 0 +to 0 +the 0 +challenge 0 +with 0 +paracetamol 1 +, 0 +13 0 +( 0 +9 0 +. 0 +6 0 +% 0 +) 0 +did 0 +not 0 +tolerate 0 +this 0 +drug 0 +. 0 + +Furthermore 0 +, 0 +18 0 +. 0 +28 0 +% 0 +of 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +chronic 0 +urticaria 3 +and 0 +11 0 +. 0 +8 0 +% 0 +of 0 +subjects 0 +with 0 +an 0 +history 0 +of 0 +NSAID 1 +- 0 +induced 0 +urticaria 3 +/ 0 +angioedema 3 +or 0 +angioedema 3 +alone 0 +( 0 +with 0 +or 0 +without 0 +chronic 0 +urticaria 3 +) 0 +resulted 0 +to 0 +be 0 +intolerant 0 +to 0 +alternative 0 +drugs 0 +. 0 + +Taken 0 +together 0 +, 0 +our 0 +results 0 +confirm 0 +the 0 +good 0 +tolerability 0 +of 0 +nimesulide 1 +and 0 +paracetamol 1 +in 0 +patients 0 +who 0 +experienced 0 +urticaria 3 +/ 0 +angioedema 3 +caused 0 +by 0 +NSAIDs 1 +. 0 + +However 0 +, 0 +the 0 +risk 0 +of 0 +reaction 0 +to 0 +these 0 +alternative 0 +study 0 +drugs 0 +is 0 +statistically 0 +increased 0 +by 0 +a 0 +history 0 +of 0 +chronic 0 +urticaria 3 +and 0 +, 0 +above 0 +all 0 +, 0 +by 0 +a 0 +history 0 +of 0 +NSAID 1 +- 0 +induced 0 +angioedema 3 +. 0 + +Comparison 0 +of 0 +aqueous 0 +and 0 +gellan 0 +ophthalmic 0 +timolol 1 +with 0 +placebo 0 +on 0 +the 0 +24 0 +- 0 +hour 0 +heart 0 +rate 0 +response 0 +in 0 +patients 0 +on 0 +treatment 0 +for 0 +glaucoma 3 +. 0 + +PURP0SE 0 +: 0 +Topical 0 +beta 0 +- 0 +blocker 0 +treatment 0 +is 0 +routine 0 +therapy 0 +in 0 +the 0 +management 0 +of 0 +patients 0 +with 0 +glaucoma 3 +. 0 + +Therapy 0 +results 0 +in 0 +systemic 0 +absorption 0 +, 0 +however 0 +, 0 +the 0 +degree 0 +of 0 +reduction 0 +of 0 +resting 0 +and 0 +peak 0 +heart 0 +rate 0 +has 0 +not 0 +been 0 +quantified 0 +. 0 + +DESIGN 0 +: 0 +This 0 +trial 0 +evaluated 0 +the 0 +effect 0 +of 0 +placebo 0 +, 0 +0 0 +. 0 +5 0 +% 0 +aqueous 0 +timolol 1 +( 0 +timolol 1 +solution 0 +) 0 +and 0 +a 0 +0 0 +. 0 +5 0 +% 0 +timolol 1 +suspension 0 +that 0 +forms 0 +a 0 +gel 0 +on 0 +application 0 +to 0 +the 0 +conjunctiva 0 +( 0 +timolol 1 +gellan 0 +) 0 +on 0 +the 0 +24 0 +- 0 +hour 0 +heart 0 +rate 0 +in 0 +patients 0 +currently 0 +being 0 +treated 0 +for 0 +glaucoma 3 +to 0 +quantify 0 +the 0 +reduction 0 +in 0 +mean 0 +heart 0 +rate 0 +. 0 + +METH0DS 0 +: 0 +Forty 0 +- 0 +three 0 +Caucasian 0 +patients 0 +with 0 +primary 0 +open 3 +- 4 +angle 4 +glaucoma 4 +or 0 +ocular 3 +hypertension 4 +with 0 +a 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +age 0 +of 0 +63 0 +( 0 ++ 0 +/ 0 +- 0 +8 0 +) 0 +years 0 +were 0 +randomized 0 +and 0 +crossed 0 +over 0 +in 0 +a 0 +double 0 +- 0 +masked 0 +manner 0 +to 0 +14 0 +days 0 +of 0 +treatment 0 +with 0 +placebo 0 +( 0 +morning 0 +and 0 +evening 0 +in 0 +both 0 +eyes 0 +) 0 +, 0 +timolol 1 +solution 0 +( 0 +morning 0 +and 0 +evening 0 +in 0 +both 0 +eyes 0 +) 0 +, 0 +or 0 +timolol 1 +gellan 0 +( 0 +morning 0 +in 0 +both 0 +eyes 0 +with 0 +placebo 0 +in 0 +the 0 +evening 0 +) 0 +. 0 + +0n 0 +the 0 +13th 0 +day 0 +of 0 +each 0 +period 0 +, 0 +heart 0 +rate 0 +was 0 +recorded 0 +continuously 0 +during 0 +a 0 +typical 0 +, 0 +ambulant 0 +24 0 +- 0 +hour 0 +period 0 +. 0 + +RESULTS 0 +: 0 +Both 0 +timolol 1 +solution 0 +and 0 +timolol 1 +gellan 0 +reduced 0 +the 0 +mean 0 +24 0 +- 0 +hour 0 +heart 0 +rate 0 +compared 0 +with 0 +placebo 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +001 0 +) 0 +, 0 +and 0 +this 0 +reduction 0 +was 0 +most 0 +pronounced 0 +during 0 +the 0 +daytime 0 +( 0 +- 0 +7 0 +. 0 +5 0 +% 0 +change 0 +in 0 +mean 0 +heart 0 +rate 0 +, 0 +- 0 +5 0 +. 0 +7 0 +beats 0 +/ 0 +min 0 +) 0 +. 0 + +Timolol 1 +gellan 0 +showed 0 +a 0 +numerically 0 +but 0 +not 0 +significantly 0 +smaller 0 +reduction 0 +in 0 +24 0 +- 0 +hour 0 +heart 0 +rate 0 +, 0 +compared 0 +with 0 +timolol 1 +solution 0 +. 0 + +During 0 +the 0 +night 0 +, 0 +the 0 +mean 0 +12 0 +- 0 +hour 0 +heart 0 +rate 0 +on 0 +placebo 0 +and 0 +timolol 1 +gellan 0 +were 0 +both 0 +significantly 0 +less 0 +than 0 +on 0 +timolol 1 +solution 0 +; 0 +the 0 +difference 0 +between 0 +solution 0 +and 0 +gellan 0 +treatments 0 +was 0 +statistically 0 +significant 0 +( 0 +P 0 += 0 +. 0 +01 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Both 0 +timolol 1 +solution 0 +and 0 +timolol 1 +gellan 0 +decrease 0 +the 0 +mean 0 +24 0 +- 0 +hour 0 +heart 0 +rate 0 +compared 0 +with 0 +placebo 0 +. 0 + +This 0 +response 0 +was 0 +most 0 +pronounced 0 +during 0 +the 0 +active 0 +daytime 0 +period 0 +. 0 + +These 0 +data 0 +quantify 0 +the 0 +modest 0 +bradycardia 3 +associated 0 +with 0 +ophthalmic 0 +beta 0 +- 0 +blocker 0 +therapy 0 +in 0 +a 0 +typical 0 +patient 0 +population 0 +on 0 +therapy 0 +for 0 +glaucoma 3 +. 0 + +Although 0 +exercise 0 +performance 0 +was 0 +not 0 +assessed 0 +in 0 +this 0 +trial 0 +, 0 +reductions 0 +of 0 +this 0 +magnitude 0 +should 0 +not 0 +have 0 +substantial 0 +clinical 0 +consequences 0 +. 0 + +Management 0 +strategies 0 +for 0 +ribavirin 1 +- 0 +induced 0 +hemolytic 3 +anemia 4 +in 0 +the 0 +treatment 0 +of 0 +hepatitis 3 +C 4 +: 0 +clinical 0 +and 0 +economic 0 +implications 0 +. 0 + +0BJECTIVES 0 +: 0 +Recently 0 +published 0 +studies 0 +have 0 +demonstrated 0 +increased 0 +efficacy 0 +and 0 +cost 0 +- 0 +effectiveness 0 +of 0 +combination 0 +therapy 0 +with 0 +interferon 0 +and 0 +alpha 0 +- 0 +2b 0 +/ 0 +ribavirin 1 +compared 0 +with 0 +interferon 1 +- 2 +alpha 2 +monotherapy 0 +in 0 +the 0 +treatment 0 +of 0 +chronic 3 +hepatitis 4 +C 4 +( 0 +CHC 3 +) 0 +. 0 + +Combination 0 +therapy 0 +is 0 +associated 0 +with 0 +a 0 +clinically 0 +important 0 +adverse 0 +effect 0 +: 0 +ribavirin 1 +- 0 +induced 0 +hemolytic 3 +anemia 4 +( 0 +RIHA 3 +) 0 +. 0 + +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +direct 0 +health 0 +- 0 +care 0 +costs 0 +and 0 +management 0 +of 0 +RIHA 3 +during 0 +treatment 0 +of 0 +CHC 3 +in 0 +a 0 +clinical 0 +trial 0 +setting 0 +. 0 + +METH0DS 0 +: 0 +A 0 +systematic 0 +literature 0 +review 0 +was 0 +conducted 0 +to 0 +synthesize 0 +information 0 +on 0 +the 0 +incidence 0 +and 0 +management 0 +of 0 +RIHA 3 +. 0 + +Decision 0 +- 0 +analytic 0 +techniques 0 +were 0 +used 0 +to 0 +estimate 0 +the 0 +cost 0 +of 0 +treating 0 +RIHA 3 +. 0 + +Uncertainty 0 +was 0 +evaluated 0 +using 0 +sensitivity 0 +analyses 0 +. 0 + +RESULTS 0 +: 0 +RIHA 3 +, 0 +defined 0 +as 0 +a 0 +reduction 0 +in 0 +hemoglobin 0 +to 0 +less 0 +than 0 +100 0 +g 0 +/ 0 +L 0 +, 0 +occurs 0 +in 0 +approximately 0 +7 0 +% 0 +to 0 +9 0 +% 0 +of 0 +patients 0 +treated 0 +with 0 +combination 0 +therapy 0 +. 0 + +The 0 +standard 0 +of 0 +care 0 +for 0 +management 0 +of 0 +RIHA 3 +is 0 +reduction 0 +or 0 +discontinuation 0 +of 0 +the 0 +ribavirin 1 +dosage 0 +. 0 + +We 0 +estimated 0 +the 0 +direct 0 +cost 0 +of 0 +treating 0 +clinically 0 +significant 0 +RIHA 3 +to 0 +be 0 +170 0 +per 0 +patient 0 +receiving 0 +combination 0 +therapy 0 +per 0 +48 0 +- 0 +week 0 +treatment 0 +course 0 +( 0 +range 0 +68 0 +- 0 +692 0 +) 0 +. 0 + +The 0 +results 0 +of 0 +the 0 +one 0 +- 0 +way 0 +sensitivity 0 +analyses 0 +ranged 0 +from 0 +57 0 +to 0 +317 0 +. 0 + +In 0 +comparison 0 +, 0 +the 0 +cost 0 +of 0 +48 0 +weeks 0 +of 0 +combination 0 +therapy 0 +is 0 +16 0 +, 0 +459 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +direct 0 +cost 0 +of 0 +treating 0 +clinically 0 +significant 0 +RIHA 3 +is 0 +1 0 +% 0 +( 0 +170 0 +/ 0 +16 0 +, 0 +459 0 +) 0 +of 0 +drug 0 +treatment 0 +costs 0 +. 0 + +Questions 0 +remain 0 +about 0 +the 0 +optimal 0 +dose 0 +of 0 +ribavirin 1 +and 0 +the 0 +incidence 0 +of 0 +RIHA 3 +in 0 +a 0 +real 0 +- 0 +world 0 +population 0 +. 0 + +Despite 0 +these 0 +uncertainties 0 +, 0 +this 0 +initial 0 +evaluation 0 +of 0 +the 0 +direct 0 +cost 0 +of 0 +treating 0 +RIHA 3 +provides 0 +an 0 +estimate 0 +of 0 +the 0 +cost 0 +and 0 +management 0 +implications 0 +of 0 +this 0 +clinically 0 +important 0 +adverse 0 +effect 0 +. 0 + +Preliminary 0 +efficacy 0 +assessment 0 +of 0 +intrathecal 0 +injection 0 +of 0 +an 0 +American 0 +formulation 0 +of 0 +adenosine 1 +in 0 +humans 0 +. 0 + +BACKGR0UND 0 +: 0 +Preclinical 0 +studies 0 +of 0 +intrathecal 0 +adenosine 1 +suggest 0 +it 0 +may 0 +be 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +acute 3 +and 4 +chronic 4 +pain 4 +in 0 +humans 0 +, 0 +and 0 +preliminary 0 +studies 0 +in 0 +volunteers 0 +and 0 +patients 0 +with 0 +a 0 +Swedish 0 +formulation 0 +of 0 +adenosine 1 +suggests 0 +it 0 +may 0 +be 0 +effective 0 +in 0 +hypersensitivity 3 +states 0 +but 0 +not 0 +with 0 +acute 0 +noxious 0 +stimulation 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +screen 0 +for 0 +efficacy 0 +of 0 +a 0 +different 0 +formulation 0 +of 0 +adenosine 1 +marketed 0 +in 0 +the 0 +US 0 +, 0 +using 0 +both 0 +acute 0 +noxious 0 +stimulation 0 +and 0 +capsaicin 1 +- 0 +evoked 0 +mechanical 0 +hypersensitivity 3 +. 0 + +METH0DS 0 +: 0 +Following 0 +Food 0 +and 0 +Drug 0 +Administration 0 +and 0 +institutional 0 +review 0 +board 0 +approval 0 +and 0 +written 0 +informed 0 +consent 0 +, 0 +65 0 +volunteers 0 +were 0 +studied 0 +in 0 +two 0 +trials 0 +: 0 +an 0 +open 0 +- 0 +label 0 +, 0 +dose 0 +- 0 +escalating 0 +trial 0 +with 0 +intrathecal 0 +adenosine 1 +doses 0 +of 0 +0 0 +. 0 +25 0 +- 0 +2 0 +. 0 +0 0 +mg 0 +and 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +trial 0 +of 0 +adenosine 1 +, 0 +2 0 +mg 0 +. 0 + +Cerebrospinal 0 +fluid 0 +was 0 +obtained 0 +for 0 +pharmacokinetic 0 +analysis 0 +, 0 +and 0 +pain 3 +ratings 0 +in 0 +response 0 +to 0 +acute 0 +heat 0 +stimuli 0 +and 0 +areas 0 +of 0 +mechanical 3 +hyperalgesia 4 +and 0 +allodynia 3 +after 0 +intradermal 0 +capsaicin 1 +injection 0 +were 0 +determined 0 +. 0 + +RESULTS 0 +: 0 +Adenosine 1 +produced 0 +no 0 +effect 0 +on 0 +pain 3 +report 0 +to 0 +acute 0 +noxious 0 +thermal 0 +or 0 +chemical 0 +stimulation 0 +but 0 +reduced 0 +mechanical 3 +hyperalgesia 4 +and 0 +allodynia 3 +from 0 +intradermal 0 +capsaicin 1 +injection 0 +for 0 +at 0 +least 0 +24 0 +h 0 +. 0 + +In 0 +contrast 0 +, 0 +residence 0 +time 0 +of 0 +adenosine 1 +in 0 +cerebrospinal 0 +fluid 0 +was 0 +short 0 +( 0 +< 0 +4 0 +h 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +show 0 +selective 0 +inhibition 0 +by 0 +intrathecal 0 +adenosine 1 +of 0 +hypersensitivity 3 +, 0 +presumed 0 +to 0 +reflect 0 +central 0 +sensitization 0 +in 0 +humans 0 +after 0 +peripheral 0 +capsaicin 1 +injection 0 +. 0 + +The 0 +long 0 +- 0 +lasting 0 +effect 0 +is 0 +consistent 0 +with 0 +that 0 +observed 0 +in 0 +preliminary 0 +reports 0 +of 0 +patients 0 +with 0 +chronic 0 +neuropathic 3 +pain 4 +and 0 +is 0 +not 0 +due 0 +to 0 +prolonged 0 +residence 0 +of 0 +adenosine 1 +in 0 +cerebrospinal 0 +fluid 0 +. 0 + +Delayed 0 +- 0 +onset 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +. 0 + +BACKGR0UND 0 +: 0 +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +presents 0 +5 0 +to 0 +12 0 +days 0 +after 0 +heparin 1 +exposure 0 +, 0 +with 0 +or 0 +without 0 +arterial 3 +or 4 +venous 4 +thromboemboli 4 +. 0 + +Delayed 0 +recognition 0 +and 0 +treatment 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +contribute 0 +to 0 +poor 0 +patient 0 +outcomes 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +describe 0 +and 0 +increase 0 +awareness 0 +of 0 +a 0 +clinical 0 +scenario 0 +in 0 +which 0 +the 0 +onset 0 +or 0 +manifestations 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +are 0 +delayed 0 +. 0 + +DESIGN 0 +: 0 +Retrospective 0 +case 0 +series 0 +. 0 + +SETTING 0 +: 0 +Three 0 +large 0 +urban 0 +hospitals 0 +( 0 +with 0 +active 0 +cardiovascular 0 +surgery 0 +programs 0 +) 0 +. 0 + +PATIENTS 0 +: 0 +14 0 +patients 0 +seen 0 +over 0 +a 0 +3 0 +- 0 +year 0 +period 0 +in 0 +whom 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +became 0 +apparent 0 +on 0 +delayed 0 +presentation 0 +with 0 +thromboembolic 3 +complications 0 +. 0 + +MEASUREMENTS 0 +: 0 +Platelet 0 +counts 0 +, 0 +onset 0 +of 0 +objectively 0 +determined 0 +thromboembolism 3 +, 0 +results 0 +of 0 +heparin 1 +- 0 +induced 0 +platelet 0 +factor 0 +4 0 +antibody 0 +tests 0 +, 0 +and 0 +outcomes 0 +. 0 + +RESULTS 0 +: 0 +Patients 0 +went 0 +home 0 +after 0 +hospitalizations 0 +that 0 +had 0 +included 0 +heparin 1 +exposure 0 +- 0 +- 0 +in 0 +most 0 +cases 0 +, 0 +with 0 +no 0 +thrombocytopenia 3 +recognized 0 +- 0 +- 0 +only 0 +to 0 +return 0 +to 0 +the 0 +hospital 0 +( 0 +median 0 +, 0 +day 0 +14 0 +) 0 +with 0 +thromboembolic 3 +complications 0 +. 0 + +Thromboemboli 3 +were 0 +venous 0 +( 0 +12 0 +patients 0 +, 0 +7 0 +with 0 +pulmonary 3 +emboli 4 +) 0 +or 0 +arterial 0 +( 0 +4 0 +patients 0 +) 0 +or 0 +both 0 +. 0 + +Platelet 0 +counts 0 +were 0 +mildly 0 +decreased 0 +in 0 +all 0 +but 0 +2 0 +patients 0 +on 0 +second 0 +presentation 0 +. 0 + +0n 0 +readmission 0 +, 0 +11 0 +patients 0 +received 0 +therapeutic 0 +heparin 1 +, 0 +which 0 +worsened 0 +the 0 +patients 0 +' 0 +clinical 0 +condition 0 +and 0 +, 0 +in 0 +all 0 +11 0 +cases 0 +, 0 +decreased 0 +the 0 +platelet 0 +count 0 +( 0 +mean 0 +at 0 +readmission 0 +, 0 +143 0 +x 0 +10 0 +( 0 +9 0 +) 0 +cells 0 +/ 0 +L 0 +; 0 +mean 0 +nadir 0 +after 0 +heparin 1 +re 0 +- 0 +exposure 0 +, 0 +39 0 +x 0 +10 0 +( 0 +9 0 +) 0 +cells 0 +/ 0 +L 0 +) 0 +. 0 + +Results 0 +of 0 +serologic 0 +tests 0 +for 0 +heparin 1 +- 0 +induced 0 +antibodies 0 +were 0 +positive 0 +in 0 +all 0 +patients 0 +. 0 + +Subsequent 0 +treatments 0 +included 0 +alternative 0 +anticoagulants 0 +( 0 +11 0 +patients 0 +) 0 +, 0 +thrombolytic 0 +drugs 0 +( 0 +3 0 +patients 0 +) 0 +, 0 +inferior 0 +vena 0 +cava 0 +filters 0 +( 0 +3 0 +patients 0 +) 0 +and 0 +, 0 +eventually 0 +, 0 +warfarin 1 +( 0 +11 0 +patients 0 +) 0 +. 0 + +Three 0 +patients 0 +died 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Delayed 0 +- 0 +onset 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +is 0 +increasingly 0 +being 0 +recognized 0 +. 0 + +To 0 +avoid 0 +disastrous 0 +outcomes 0 +, 0 +physicians 0 +must 0 +consider 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +whenever 0 +a 0 +recently 0 +hospitalized 0 +patient 0 +returns 0 +with 0 +thromboembolism 3 +; 0 +therapy 0 +with 0 +alternative 0 +anticoagulants 0 +, 0 +not 0 +heparin 1 +, 0 +should 0 +be 0 +initiated 0 +. 0 + +Treatment 0 +of 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +with 0 +a 0 +dopamine 1 +agonist 0 +in 0 +children 0 +. 0 + +BACKGR0UND 0 +: 0 +Risperidone 1 +, 0 +a 0 +potent 0 +antagonist 0 +of 0 +both 0 +serotonergic 0 +( 0 +5HT2A 0 +) 0 +and 0 +dopaminergic 0 +D2 0 +receptors 0 +is 0 +associated 0 +with 0 +hyperprolactinemia 3 +in 0 +adults 0 +and 0 +children 0 +. 0 + +Chronically 0 +elevated 0 +prolactin 0 +levels 0 +in 0 +children 0 +with 0 +prolactinomas 3 +may 0 +be 0 +associated 0 +with 0 +arrested 0 +growth 0 +and 0 +development 0 +resulting 0 +in 0 +either 0 +delayed 3 +puberty 4 +or 0 +short 0 +stature 0 +. 0 + +These 0 +possibilities 0 +stress 0 +the 0 +importance 0 +of 0 +developing 0 +a 0 +safe 0 +and 0 +effective 0 +approach 0 +to 0 +drug 0 +- 0 +induced 0 +hyperprolactinemia 3 +in 0 +youth 0 +. 0 + +We 0 +report 0 +the 0 +successful 0 +treatment 0 +of 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +with 0 +cabergoline 1 +in 0 +youth 0 +. 0 + +METH0DS 0 +: 0 +We 0 +undertook 0 +a 0 +retrospective 0 +case 0 +review 0 +of 0 +four 0 +children 0 +with 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +treated 0 +with 0 +cabergoline 1 +. 0 + +RESULTS 0 +: 0 +Four 0 +males 0 +( 0 +age 0 +6 0 +- 0 +11 0 +years 0 +) 0 +with 0 +Diagnostic 0 +and 0 +Statistical 0 +Manual 0 +of 0 +Mental 3 +Disorders 4 +( 0 +fourth 0 +edition 0 +) 0 +bipolar 3 +disorder 4 +or 0 +psychoses 3 +, 0 +with 0 +risperidone 1 +- 0 +induced 0 +elevations 0 +in 0 +serum 0 +prolactin 0 +levels 0 +( 0 +57 0 +. 0 +5 0 +- 0 +129 0 +ng 0 +/ 0 +mL 0 +, 0 +normal 0 +5 0 +- 0 +15 0 +ng 0 +/ 0 +mL 0 +) 0 +, 0 +were 0 +treated 0 +with 0 +cabergoline 1 +( 0 +mean 0 +dose 0 +2 0 +. 0 +13 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +09 0 +mg 0 +/ 0 +week 0 +) 0 +. 0 + +When 0 +serum 0 +prolactin 0 +levels 0 +normalized 0 +in 0 +all 0 +four 0 +subjects 0 +( 0 +mean 0 +11 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +10 0 +. 0 +9 0 +ng 0 +/ 0 +mL 0 +) 0 +, 0 +the 0 +cabergoline 1 +dose 0 +was 0 +reduced 0 +to 0 +1 0 +mg 0 +/ 0 +week 0 +in 0 +three 0 +of 0 +four 0 +subjects 0 +. 0 + +The 0 +mean 0 +duration 0 +of 0 +therapy 0 +with 0 +cabergoline 1 +was 0 +523 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +129 0 +. 0 +7 0 +days 0 +, 0 +and 0 +the 0 +mean 0 +duration 0 +of 0 +therapy 0 +with 0 +risperidone 1 +was 0 +788 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +162 0 +. 0 +5 0 +days 0 +. 0 + +Cabergoline 1 +was 0 +well 0 +tolerated 0 +without 0 +adverse 0 +effects 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Cabergoline 1 +may 0 +be 0 +useful 0 +for 0 +the 0 +treatment 0 +of 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +in 0 +youth 0 +; 0 +however 0 +, 0 +further 0 +research 0 +is 0 +needed 0 +. 0 + +Acute 0 +cholestatic 3 +hepatitis 4 +after 0 +exposure 0 +to 0 +isoflurane 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +acute 0 +cholestatic 3 +hepatitis 4 +following 0 +exposure 0 +to 0 +the 0 +inhalational 0 +anesthetic 0 +isoflurane 1 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +70 0 +- 0 +year 0 +- 0 +old 0 +healthy 0 +woman 0 +from 0 +Iraq 0 +developed 0 +acute 0 +cholestatic 3 +hepatitis 4 +3 0 +weeks 0 +following 0 +repair 0 +of 0 +the 0 +right 0 +rotator 0 +cuff 0 +under 0 +general 0 +anesthesia 0 +. 0 + +There 0 +was 0 +no 0 +evidence 0 +for 0 +viral 0 +, 0 +autoimmune 0 +, 0 +or 0 +metabolic 0 +causes 0 +of 0 +hepatitis 3 +. 0 + +No 0 +other 0 +medications 0 +were 0 +involved 0 +except 0 +for 0 +dipyrone 1 +for 0 +analgesia 3 +. 0 + +The 0 +alanine 1 +aminotransferase 0 +was 0 +elevated 0 +to 0 +a 0 +peak 0 +concentration 0 +of 0 +1533 0 +U 0 +/ 0 +L 0 +and 0 +the 0 +serum 0 +bilirubin 1 +reached 0 +a 0 +peak 0 +of 0 +17 0 +. 0 +0 0 +mg 0 +/ 0 +dL 0 +. 0 + +There 0 +was 0 +slow 0 +improvement 0 +over 0 +4 0 +months 0 +. 0 + +Accidental 0 +reexposure 0 +by 0 +the 0 +patient 0 +to 0 +dipyrone 1 +was 0 +uneventful 0 +. 0 + +DISCUSSI0N 0 +: 0 +The 0 +clinical 0 +and 0 +histologic 0 +picture 0 +of 0 +this 0 +case 0 +resembles 0 +halothane 3 +hepatitis 4 +, 0 +which 0 +has 0 +a 0 +significant 0 +mortality 0 +rate 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Isoflurane 1 +, 0 +a 0 +common 0 +anesthetic 0 +agent 0 +, 0 +can 0 +cause 0 +severe 0 +cholestatic 3 +hepatitis 4 +. 0 + +Torsade 3 +de 4 +pointes 4 +induced 0 +by 0 +metoclopramide 1 +in 0 +an 0 +elderly 0 +woman 0 +with 0 +preexisting 0 +complete 0 +left 3 +bundle 4 +branch 4 +block 4 +. 0 + +There 0 +is 0 +a 0 +growing 0 +list 0 +of 0 +drugs 0 +implicated 0 +in 0 +acquired 0 +long 3 +QT 4 +syndrome 4 +and 0 +torsade 3 +de 4 +pointes 4 +. 0 + +However 0 +, 0 +the 0 +torsadogenic 0 +potential 0 +of 0 +metoclopramide 1 +, 0 +a 0 +commonly 0 +used 0 +antiemetic 0 +and 0 +prokinetic 0 +drug 0 +, 0 +has 0 +not 0 +been 0 +reported 0 +in 0 +the 0 +literature 0 +, 0 +despite 0 +its 0 +chemical 0 +similarity 0 +to 0 +procainamide 1 +. 0 + +We 0 +report 0 +on 0 +a 0 +92 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +preexisting 0 +complete 0 +left 3 +bundle 4 +branch 4 +block 4 +who 0 +developed 0 +torsade 3 +de 4 +pointes 4 +after 0 +intravenous 0 +and 0 +oral 0 +administration 0 +of 0 +metoclopramide 1 +. 0 + +This 0 +patient 0 +also 0 +developed 0 +torsade 3 +de 4 +pointes 4 +when 0 +cisapride 1 +and 0 +erythromycin 1 +were 0 +given 0 +simultaneously 0 +. 0 + +These 0 +two 0 +episodes 0 +were 0 +suppressed 0 +successfully 0 +after 0 +discontinuing 0 +the 0 +offending 0 +drugs 0 +and 0 +administering 0 +class 0 +IB 0 +drugs 0 +. 0 + +This 0 +is 0 +the 0 +first 0 +documentation 0 +that 0 +metoclopramide 1 +provokes 0 +torsade 3 +de 4 +pointes 4 +clinically 0 +. 0 + +Metoclopramide 1 +should 0 +be 0 +used 0 +cautiously 0 +in 0 +patients 0 +with 0 +a 0 +risk 0 +of 0 +torsade 3 +de 4 +pointes 4 +. 0 + +Dopamine 1 +D2 0 +receptor 0 +signaling 0 +controls 0 +neuronal 0 +cell 0 +death 0 +induced 0 +by 0 +muscarinic 0 +and 0 +glutamatergic 0 +drugs 0 +. 0 + +Dopamine 1 +( 0 +DA 1 +) 0 +, 0 +through 0 +D1 0 +/ 0 +D2 0 +receptor 0 +- 0 +mediated 0 +signaling 0 +, 0 +plays 0 +a 0 +major 0 +role 0 +in 0 +the 0 +control 0 +of 0 +epileptic 3 +seizures 4 +arising 0 +in 0 +the 0 +limbic 0 +system 0 +. 0 + +Excitotoxicity 3 +leading 0 +to 0 +neuronal 0 +cell 0 +death 0 +in 0 +the 0 +affected 0 +areas 0 +is 0 +a 0 +major 0 +consequence 0 +of 0 +seizures 3 +at 0 +the 0 +cellular 0 +level 0 +. 0 + +In 0 +this 0 +respect 0 +, 0 +little 0 +is 0 +known 0 +about 0 +the 0 +role 0 +of 0 +DA 1 +receptors 0 +in 0 +the 0 +occurrence 0 +of 0 +epilepsy 3 +- 0 +induced 0 +neuronal 0 +cell 0 +death 0 +. 0 + +Here 0 +we 0 +analyze 0 +the 0 +occurrence 0 +of 0 +seizures 3 +and 0 +neurotoxicity 3 +in 0 +D2R 0 +- 0 +/ 0 +- 0 +mice 0 +treated 0 +with 0 +the 0 +cholinergic 0 +agonist 0 +pilocarpine 1 +. 0 + +We 0 +compared 0 +these 0 +results 0 +with 0 +those 0 +previously 0 +obtained 0 +with 0 +kainic 1 +acid 2 +( 0 +KA 1 +) 0 +, 0 +a 0 +potent 0 +glutamate 1 +agonist 0 +. 0 + +Importantly 0 +, 0 +D2R 0 +- 0 +/ 0 +- 0 +mice 0 +develop 0 +seizures 3 +at 0 +doses 0 +of 0 +both 0 +drugs 0 +that 0 +are 0 +not 0 +epileptogenic 0 +for 0 +WT 0 +littermates 0 +and 0 +show 0 +greater 0 +neurotoxicity 3 +. 0 + +However 0 +, 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +result 0 +in 0 +a 0 +more 0 +widespread 0 +neuronal 0 +death 0 +in 0 +both 0 +WT 0 +and 0 +D2R 0 +- 0 +/ 0 +- 0 +brains 0 +in 0 +comparison 0 +to 0 +KA 1 +. 0 + +Thus 0 +, 0 +the 0 +absence 0 +of 0 +D2R 0 +lowers 0 +the 0 +threshold 0 +for 0 +seizures 3 +induced 0 +by 0 +both 0 +glutamate 1 +and 0 +acetylcholine 1 +. 0 + +Moreover 0 +, 0 +the 0 +dopaminergic 0 +control 0 +of 0 +epilepsy 3 +- 0 +induced 0 +neurodegeneration 3 +seems 0 +to 0 +be 0 +mediated 0 +by 0 +distinct 0 +interactions 0 +of 0 +D2R 0 +signaling 0 +with 0 +these 0 +two 0 +neurotransmitters 0 +. 0 + +Steroid 1 +structure 0 +and 0 +pharmacological 0 +properties 0 +determine 0 +the 0 +anti 0 +- 0 +amnesic 3 +effects 0 +of 0 +pregnenolone 1 +sulphate 2 +in 0 +the 0 +passive 0 +avoidance 0 +task 0 +in 0 +rats 0 +. 0 + +Pregnenolone 1 +sulphate 2 +( 0 +PREGS 1 +) 0 +has 0 +generated 0 +interest 0 +as 0 +one 0 +of 0 +the 0 +most 0 +potent 0 +memory 0 +- 0 +enhancing 0 +neurosteroids 0 +to 0 +be 0 +examined 0 +in 0 +rodent 0 +learning 0 +studies 0 +, 0 +with 0 +particular 0 +importance 0 +in 0 +the 0 +ageing 0 +process 0 +. 0 + +The 0 +mechanism 0 +by 0 +which 0 +this 0 +endogenous 0 +steroid 1 +enhances 0 +memory 0 +formation 0 +is 0 +hypothesized 0 +to 0 +involve 0 +actions 0 +on 0 +glutamatergic 0 +and 0 +GABAergic 0 +systems 0 +. 0 + +This 0 +hypothesis 0 +stems 0 +from 0 +findings 0 +that 0 +PREGS 1 +is 0 +a 0 +potent 0 +positive 0 +modulator 0 +of 0 +N 1 +- 2 +methyl 2 +- 2 +d 2 +- 2 +aspartate 2 +receptors 0 +( 0 +NMDARs 0 +) 0 +and 0 +a 0 +negative 0 +modulator 0 +of 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +A 0 +) 0 +receptors 0 +( 0 +GABA 1 +( 0 +A 0 +) 0 +Rs 0 +) 0 +. 0 + +Moreover 0 +, 0 +PREGS 1 +is 0 +able 0 +to 0 +reverse 0 +the 0 +amnesic 3 +- 0 +like 0 +effects 0 +of 0 +NMDAR 0 +and 0 +GABA 1 +( 0 +A 0 +) 0 +R 0 +ligands 0 +. 0 + +To 0 +investigate 0 +this 0 +hypothesis 0 +, 0 +the 0 +present 0 +study 0 +in 0 +rats 0 +examined 0 +the 0 +memory 0 +- 0 +altering 0 +abilities 0 +of 0 +structural 0 +analogs 0 +of 0 +PREGS 1 +, 0 +which 0 +differ 0 +in 0 +their 0 +modulation 0 +of 0 +NMDAR 0 +and 0 +/ 0 +or 0 +GABA 1 +( 0 +A 0 +) 0 +R 0 +function 0 +. 0 + +The 0 +analogs 0 +tested 0 +were 0 +: 0 +11 1 +- 2 +ketopregnenolone 2 +sulphate 2 +( 0 +an 0 +agent 0 +that 0 +is 0 +inactive 0 +at 0 +GABA 1 +( 0 +A 0 +) 0 +Rs 0 +and 0 +NMDARs 0 +) 0 +, 0 +epipregnanolone 1 +( 2 +[ 2 +3beta 2 +- 2 +hydroxy 2 +- 2 +5beta 2 +- 2 +pregnan 2 +- 2 +20 2 +- 2 +one 2 +] 2 +sulphate 2 +, 0 +an 0 +inhibitor 0 +of 0 +both 0 +GABA 1 +( 0 +A 0 +) 0 +Rs 0 +and 0 +NMDARs 0 +) 0 +, 0 +and 0 +a 0 +newly 0 +synthesized 0 +( 0 +- 0 +) 0 +PREGS 1 +enantiomer 0 +( 0 +which 0 +is 0 +identical 0 +to 0 +PREGS 1 +in 0 +effects 0 +on 0 +GABA 1 +( 0 +A 0 +) 0 +Rs 0 +and 0 +NMDARs 0 +) 0 +. 0 + +The 0 +memory 0 +- 0 +enhancing 0 +effects 0 +of 0 +PREGS 1 +and 0 +its 0 +analogs 0 +were 0 +tested 0 +in 0 +the 0 +passive 0 +avoidance 0 +task 0 +using 0 +the 0 +model 0 +of 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +Both 0 +PREGS 1 +and 0 +its 0 +( 0 +- 0 +) 0 +enantiomer 0 +blocked 0 +the 0 +effects 0 +of 0 +scopolamine 1 +. 0 + +The 0 +results 0 +show 0 +that 0 +, 0 +unlike 0 +PREGS 1 +, 0 +11 1 +- 2 +ketopregnenolone 2 +sulphate 2 +and 0 +epipregnanolone 1 +sulphate 2 +failed 0 +to 0 +block 0 +the 0 +effect 0 +of 0 +scopolamine 1 +, 0 +suggesting 0 +that 0 +altering 0 +the 0 +modulation 0 +of 0 +NMDA 1 +receptors 0 +diminishes 0 +the 0 +memory 0 +- 0 +enhancing 0 +effects 0 +of 0 +PREGS 1 +. 0 + +Moreover 0 +, 0 +enantioselectivity 0 +was 0 +demonstrated 0 +by 0 +the 0 +ability 0 +of 0 +natural 0 +PREGS 1 +to 0 +be 0 +an 0 +order 0 +of 0 +magnitude 0 +more 0 +effective 0 +than 0 +its 0 +synthetic 0 +enantiomer 0 +in 0 +reversing 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +These 0 +results 0 +identify 0 +a 0 +novel 0 +neuropharmacological 0 +site 0 +for 0 +the 0 +modulation 0 +of 0 +memory 0 +processes 0 +by 0 +neuroactive 0 +steroids 1 +. 0 + +Activation 0 +of 0 +poly 1 +( 2 +ADP 2 +- 2 +ribose 2 +) 2 +polymerase 0 +contributes 0 +to 0 +development 0 +of 0 +doxorubicin 1 +- 0 +induced 0 +heart 3 +failure 4 +. 0 + +Activation 0 +of 0 +the 0 +nuclear 0 +enzyme 0 +poly 1 +( 2 +ADP 2 +- 2 +ribose 2 +) 2 +polymerase 0 +( 0 +PARP 0 +) 0 +by 0 +oxidant 0 +- 0 +mediated 0 +DNA 0 +damage 0 +is 0 +an 0 +important 0 +pathway 0 +of 0 +cell 0 +dysfunction 0 +and 0 +tissue 0 +injury 0 +in 0 +conditions 0 +associated 0 +with 0 +oxidative 0 +stress 0 +. 0 + +Increased 0 +oxidative 0 +stress 0 +is 0 +a 0 +major 0 +factor 0 +implicated 0 +in 0 +the 0 +cardiotoxicity 3 +of 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +, 0 +a 0 +widely 0 +used 0 +antitumor 0 +anthracycline 1 +antibiotic 0 +. 0 + +Thus 0 +, 0 +we 0 +hypothesized 0 +that 0 +the 0 +activation 0 +of 0 +PARP 0 +may 0 +contribute 0 +to 0 +the 0 +D0X 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +Using 0 +a 0 +dual 0 +approach 0 +of 0 +PARP 0 +- 0 +1 0 +suppression 0 +, 0 +by 0 +genetic 0 +deletion 0 +or 0 +pharmacological 0 +inhibition 0 +with 0 +the 0 +phenanthridinone 0 +PARP 0 +inhibitor 0 +PJ34 1 +, 0 +we 0 +now 0 +demonstrate 0 +the 0 +role 0 +of 0 +PARP 0 +in 0 +the 0 +development 0 +of 0 +cardiac 3 +dysfunction 4 +induced 0 +by 0 +D0X 1 +. 0 + +PARP 0 +- 0 +1 0 ++ 0 +/ 0 ++ 0 +and 0 +PARP 0 +- 0 +1 0 +- 0 +/ 0 +- 0 +mice 0 +received 0 +a 0 +single 0 +injection 0 +of 0 +D0X 1 +( 0 +25 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +) 0 +. 0 + +Five 0 +days 0 +after 0 +D0X 1 +administration 0 +, 0 +left 0 +ventricular 0 +performance 0 +was 0 +significantly 0 +depressed 0 +in 0 +PARP 0 +- 0 +1 0 ++ 0 +/ 0 ++ 0 +mice 0 +, 0 +but 0 +only 0 +to 0 +a 0 +smaller 0 +extent 0 +in 0 +PARP 0 +- 0 +1 0 +- 0 +/ 0 +- 0 +ones 0 +. 0 + +Similar 0 +experiments 0 +were 0 +conducted 0 +in 0 +BALB 0 +/ 0 +c 0 +mice 0 +treated 0 +with 0 +PJ34 1 +or 0 +vehicle 0 +. 0 + +Treatment 0 +with 0 +a 0 +PJ34 1 +significantly 0 +improved 0 +cardiac 3 +dysfunction 4 +and 0 +increased 0 +the 0 +survival 0 +of 0 +the 0 +animals 0 +. 0 + +In 0 +addition 0 +PJ34 1 +significantly 0 +reduced 0 +the 0 +D0X 1 +- 0 +induced 0 +increase 0 +in 0 +the 0 +serum 0 +lactate 1 +dehydrogenase 0 +and 0 +creatine 1 +kinase 0 +activities 0 +but 0 +not 0 +metalloproteinase 0 +activation 0 +in 0 +the 0 +heart 0 +. 0 + +Thus 0 +, 0 +PARP 0 +activation 0 +contributes 0 +to 0 +the 0 +cardiotoxicity 3 +of 0 +D0X 1 +. 0 + +PARP 0 +inhibitors 0 +may 0 +exert 0 +protective 0 +effects 0 +against 0 +the 0 +development 0 +of 0 +severe 0 +cardiac 3 +complications 4 +associated 0 +with 0 +the 0 +D0X 1 +treatment 0 +. 0 + +Spironolactone 1 +: 0 +is 0 +it 0 +a 0 +novel 0 +drug 0 +for 0 +the 0 +prevention 0 +of 0 +amphotericin 1 +B 2 +- 0 +related 0 +hypokalemia 3 +in 0 +cancer 3 +patients 0 +? 0 + +0BJECTIVE 0 +: 0 +Nephrotoxicity 3 +is 0 +the 0 +major 0 +adverse 0 +effect 0 +of 0 +amphotericin 1 +B 2 +( 0 +AmB 1 +) 0 +, 0 +often 0 +limiting 0 +administration 0 +of 0 +full 0 +dosage 0 +. 0 + +Selective 0 +distal 0 +tubular 0 +epithelial 0 +toxicity 3 +seems 0 +to 0 +be 0 +responsible 0 +for 0 +the 0 +profound 0 +potassium 1 +wasting 0 +that 0 +is 0 +a 0 +major 0 +clinical 0 +side 0 +effect 0 +of 0 +treatment 0 +with 0 +AmB 1 +. 0 + +Potassium 1 +depletion 0 +also 0 +potentiates 0 +the 0 +tubular 0 +toxicity 3 +of 0 +AmB 1 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +assess 0 +the 0 +ability 0 +of 0 +spironolactone 1 +to 0 +reduce 0 +potassium 1 +requirements 0 +and 0 +to 0 +prevent 0 +hypokalemia 3 +in 0 +neutropenic 3 +patients 0 +on 0 +AmB 1 +treatment 0 +. 0 + +METH0DS 0 +: 0 +In 0 +this 0 +study 0 +26 0 +patients 0 +with 0 +various 0 +hematological 3 +disorders 4 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +intravenous 0 +AmB 1 +alone 0 +or 0 +AmB 1 +and 0 +oral 0 +spironolactone 1 +100 0 +mg 0 +twice 0 +daily 0 +when 0 +developing 0 +a 0 +proven 0 +or 0 +suspected 0 +fungal 3 +infection 4 +. 0 + +RESULTS 0 +: 0 +Patients 0 +receiving 0 +concomitant 0 +AmB 1 +and 0 +spironolactone 1 +had 0 +significantly 0 +higher 0 +plasma 0 +potassium 1 +levels 0 +than 0 +those 0 +receiving 0 +AmB 1 +alone 0 +( 0 +P 0 += 0 +0 0 +. 0 +0027 0 +) 0 +. 0 + +Those 0 +patients 0 +receiving 0 +AmB 1 +and 0 +spironolactone 1 +required 0 +significantly 0 +less 0 +potassium 1 +supplementation 0 +to 0 +maintain 0 +their 0 +plasma 0 +potassium 1 +within 0 +the 0 +normal 0 +range 0 +( 0 +P 0 += 0 +0 0 +. 0 +022 0 +) 0 +. 0 + +Moreover 0 +, 0 +urinary 0 +potassium 1 +losses 0 +were 0 +significantly 0 +less 0 +in 0 +patients 0 +receiving 0 +AmB 1 +and 0 +spironolactone 1 +than 0 +those 0 +receiving 0 +AmB 1 +alone 0 +( 0 +P 0 += 0 +0 0 +. 0 +040 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +study 0 +showed 0 +that 0 +spironolactone 1 +can 0 +reduce 0 +potassium 1 +requirements 0 +and 0 +prevent 0 +hypokalemia 3 +by 0 +reducing 0 +urinary 0 +potassium 1 +loss 0 +in 0 +neutropenic 3 +patients 0 +on 0 +AmB 1 +treatment 0 +. 0 + +Erectile 3 +dysfunction 4 +occurs 0 +following 0 +substantia 0 +nigra 0 +lesions 0 +in 0 +the 0 +rat 0 +. 0 + +Erectile 0 +function 0 +was 0 +assessed 0 +6 0 +weeks 0 +following 0 +uni 0 +- 0 +and 0 +bilateral 0 +injections 0 +of 0 +6 1 +- 2 +hydroxydopamine 2 +in 0 +the 0 +substantia 0 +nigra 0 +nucleus 0 +of 0 +the 0 +brain 0 +. 0 + +Behavioral 0 +apomorphine 1 +- 0 +induced 0 +penile 0 +erections 0 +were 0 +reduced 0 +( 0 +5 0 +/ 0 +8 0 +) 0 +and 0 +increased 0 +( 0 +3 0 +/ 0 +8 0 +) 0 +in 0 +uni 0 +- 0 +and 0 +bilateral 0 +lesioned 0 +animals 0 +. 0 + +Intracavernous 0 +pressures 0 +, 0 +following 0 +electrical 0 +stimulation 0 +of 0 +the 0 +cavernous 0 +nerve 0 +, 0 +decreased 0 +in 0 +lesioned 0 +animals 0 +. 0 + +Lesions 0 +of 0 +the 0 +substantia 0 +nigra 0 +were 0 +confirmed 0 +by 0 +histology 0 +. 0 + +Concentration 0 +of 0 +dopamine 1 +and 0 +its 0 +metabolites 0 +were 0 +decreased 0 +in 0 +the 0 +striatum 0 +of 0 +substantia 0 +nigra 0 +lesioned 0 +rats 0 +. 0 + +Lesions 0 +of 0 +the 0 +substantia 0 +nigra 0 +are 0 +therefore 0 +associated 0 +with 0 +erectile 3 +dysfunction 4 +in 0 +rats 0 +and 0 +may 0 +serve 0 +as 0 +a 0 +model 0 +to 0 +study 0 +erectile 3 +dysfunction 4 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Nicotine 1 +potentiation 0 +of 0 +morphine 1 +- 0 +induced 0 +catalepsy 3 +in 0 +mice 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +effects 0 +of 0 +nicotine 1 +on 0 +catalepsy 3 +induced 0 +by 0 +morphine 1 +in 0 +mice 0 +have 0 +been 0 +investigated 0 +. 0 + +Morphine 1 +but 0 +not 0 +nicotine 1 +induced 0 +a 0 +dose 0 +- 0 +dependent 0 +catalepsy 3 +. 0 + +The 0 +response 0 +of 0 +morphine 1 +was 0 +potentiated 0 +by 0 +nicotine 1 +. 0 + +Intraperitoneal 0 +administration 0 +of 0 +atropine 1 +, 0 +naloxone 1 +, 0 +mecamylamine 1 +, 0 +and 0 +hexamethonium 1 +to 0 +mice 0 +reduced 0 +catalepsy 3 +induced 0 +by 0 +a 0 +combination 0 +of 0 +morphine 1 +with 0 +nicotine 1 +. 0 + +Intracerebroventricular 0 +injection 0 +of 0 +atropine 1 +, 0 +hexamethonium 1 +, 0 +and 0 +naloxone 1 +also 0 +decreased 0 +catalepsy 3 +induced 0 +by 0 +morphine 1 +plus 0 +nicotine 1 +. 0 + +Intraperitoneal 0 +administration 0 +of 0 +atropine 1 +, 0 +but 0 +not 0 +intraperitoneal 0 +or 0 +intracerebroventricular 0 +injection 0 +of 0 +hexamethonium 1 +, 0 +decreased 0 +the 0 +effect 0 +of 0 +a 0 +single 0 +dose 0 +of 0 +morphine 1 +. 0 + +It 0 +was 0 +concluded 0 +that 0 +morphine 1 +catalepsy 3 +can 0 +be 0 +elicited 0 +by 0 +opioid 0 +and 0 +cholinergic 0 +receptors 0 +, 0 +and 0 +the 0 +potentiation 0 +of 0 +morphine 1 +induced 0 +by 0 +nicotine 1 +may 0 +also 0 +be 0 +mediated 0 +through 0 +cholinergic 0 +receptor 0 +mechanisms 0 +. 0 + +Force 0 +overflow 0 +and 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +We 0 +assessed 0 +force 0 +coordination 0 +of 0 +the 0 +hand 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +and 0 +its 0 +relationship 0 +to 0 +motor 0 +complications 0 +of 0 +levodopa 1 +therapy 0 +, 0 +particularly 0 +to 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +( 0 +LID 3 +) 0 +. 0 + +We 0 +studied 0 +two 0 +groups 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +patients 0 +with 0 +( 0 +Parkinson 3 +' 4 +s 4 +disease 4 ++ 0 +LID 3 +, 0 +n 0 += 0 +23 0 +) 0 +and 0 +without 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +( 0 +Parkinson 3 +' 4 +s 4 +disease 4 +- 0 +LID 3 +, 0 +n 0 += 0 +10 0 +) 0 +, 0 +and 0 +age 0 +- 0 +matched 0 +healthy 0 +controls 0 +. 0 + +The 0 +motor 0 +score 0 +of 0 +the 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +, 0 +a 0 +dyskinesia 3 +score 0 +and 0 +force 0 +in 0 +a 0 +grip 0 +- 0 +lift 0 +paradigm 0 +were 0 +assessed 0 +0N 0 +and 0 +0FF 0 +levodopa 1 +. 0 + +A 0 +pathological 0 +increase 0 +of 0 +forces 0 +was 0 +seen 0 +in 0 +0N 0 +- 0 +state 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 ++ 0 +LID 3 +only 0 +. 0 + +In 0 +Parkinson 3 +' 4 +s 4 +disease 4 ++ 0 +LID 3 +, 0 +the 0 +force 0 +involved 0 +in 0 +pressing 0 +down 0 +the 0 +object 0 +before 0 +lifting 0 +was 0 +significantly 0 +increased 0 +by 0 +levodopa 1 +( 0 +by 0 +61 0 +% 0 +, 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +An 0 +overshooting 0 +of 0 +peak 0 +grip 0 +force 0 +by 0 +51 0 +% 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +of 0 +static 0 +grip 0 +force 0 +by 0 +45 0 +% 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +was 0 +observed 0 +in 0 +the 0 +0N 0 +- 0 +compared 0 +with 0 +the 0 +0FF 0 +- 0 +drug 0 +condition 0 +. 0 + +In 0 +contrast 0 +, 0 +no 0 +excessive 0 +force 0 +was 0 +found 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +- 0 +LID 3 +. 0 + +Peak 0 +grip 0 +force 0 +in 0 +0N 0 +- 0 +state 0 +was 0 +140 0 +% 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +higher 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 ++ 0 +LID 3 +than 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +- 0 +LID 3 +, 0 +while 0 +static 0 +grip 0 +force 0 +was 0 +increased 0 +by 0 +138 0 +% 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +between 0 +groups 0 +. 0 + +Severity 0 +of 0 +peak 0 +- 0 +dose 0 +dyskinesias 3 +was 0 +strongly 0 +correlated 0 +with 0 +grip 0 +force 0 +in 0 +0N 0 +- 0 +state 0 +( 0 +r 0 += 0 +0 0 +. 0 +79 0 +with 0 +peak 0 +force 0 +, 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +No 0 +correlation 0 +was 0 +observed 0 +between 0 +forces 0 +and 0 +the 0 +motor 0 +score 0 +as 0 +well 0 +as 0 +with 0 +the 0 +daily 0 +dose 0 +of 0 +dopaminergic 0 +medication 0 +. 0 + +Force 0 +excess 0 +was 0 +only 0 +observed 0 +in 0 +patients 0 +with 0 +LID 3 +and 0 +motor 0 +fluctuations 0 +. 0 + +A 0 +close 0 +relationship 0 +was 0 +seen 0 +between 0 +the 0 +overshooting 0 +of 0 +forces 0 +and 0 +dyskinesias 3 +in 0 +the 0 +0N 0 +- 0 +drug 0 +condition 0 +. 0 + +We 0 +postulate 0 +that 0 +both 0 +LID 3 +and 0 +grip 0 +force 0 +excess 0 +share 0 +common 0 +pathophysiological 0 +mechanisms 0 +related 0 +to 0 +motor 0 +fluctuations 0 +. 0 + +Behavioral 0 +effects 0 +of 0 +MK 1 +- 2 +801 2 +on 0 +reserpine 1 +- 0 +treated 0 +mice 0 +. 0 + +The 0 +effects 0 +of 0 +dizocilpine 1 +( 0 +MK 1 +- 2 +801 2 +) 0 +, 0 +a 0 +noncompetitive 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +antagonist 0 +, 0 +were 0 +studied 0 +on 0 +dopamine 1 +- 0 +related 0 +behaviors 0 +induced 0 +by 0 +reserpine 1 +treatments 0 +. 0 + +This 0 +study 0 +focuses 0 +on 0 +behavioral 0 +syndromes 0 +that 0 +may 0 +used 0 +as 0 +models 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +, 0 +or 0 +tardive 3 +dyskinesia 4 +, 0 +and 0 +its 0 +response 0 +after 0 +glutamatergic 0 +blockage 0 +. 0 + +Reserpine 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +administered 0 +once 0 +every 0 +other 0 +day 0 +for 0 +4 0 +days 0 +, 0 +produced 0 +increases 0 +in 0 +orofacial 3 +dyskinesia 4 +, 0 +tongue 0 +protrusion 0 +and 0 +vacuous 0 +chewing 0 +in 0 +mice 0 +, 0 +which 0 +are 0 +signs 0 +indicative 0 +of 0 +tardive 3 +dyskinesia 4 +. 0 + +Reserpine 1 +also 0 +produced 0 +tremor 3 +and 0 +catalepsy 3 +, 0 +which 0 +are 0 +signs 0 +suggestive 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +MK 1 +- 2 +801 2 +( 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +administered 0 +30 0 +min 0 +before 0 +the 0 +observation 0 +test 0 +, 0 +prevented 0 +the 0 +vacuous 0 +chewing 0 +movements 0 +, 0 +tongue 0 +protrusions 0 +and 0 +catalepsy 3 +induced 0 +by 0 +reserpine 1 +. 0 + +However 0 +, 0 +MK 1 +- 2 +801 2 +injection 0 +produced 0 +a 0 +significant 0 +increase 0 +of 0 +tremor 3 +in 0 +reserpine 1 +- 0 +treated 0 +mice 0 +. 0 + +Reserpine 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +administered 0 +90 0 +min 0 +before 0 +the 0 +test 0 +and 0 +followed 0 +by 0 +apomophine 1 +injection 0 +( 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +5 0 +min 0 +before 0 +the 0 +test 0 +, 0 +did 0 +not 0 +produce 0 +oral 3 +dyskinesia 4 +in 0 +mice 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +reserpine 1 +induced 0 +increases 0 +in 0 +tremor 3 +and 0 +catalepsy 3 +compared 0 +to 0 +control 0 +mice 0 +. 0 + +MK 1 +- 2 +801 2 +( 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +administration 0 +attenuated 0 +the 0 +catalepsy 3 +and 0 +tremor 3 +induced 0 +by 0 +reserpine 1 +. 0 + +Pretreatment 0 +with 0 +reserpine 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +24 0 +h 0 +before 0 +the 0 +observation 0 +test 0 +produced 0 +increases 0 +in 0 +vacuous 0 +chewing 0 +movements 0 +and 0 +tongue 0 +protrusion 0 +, 0 +as 0 +well 0 +as 0 +increases 0 +in 0 +tremor 3 +and 0 +catalepsy 3 +, 0 +whereas 0 +MK 1 +- 2 +801 2 +( 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +injection 0 +90 0 +min 0 +before 0 +the 0 +test 0 +reversed 0 +the 0 +effects 0 +of 0 +reserpine 1 +. 0 + +These 0 +results 0 +show 0 +that 0 +reserpine 1 +produces 0 +different 0 +and 0 +abnormal 3 +movements 4 +, 0 +which 0 +are 0 +related 0 +to 0 +dose 0 +and 0 +schedule 0 +employed 0 +and 0 +can 0 +be 0 +considered 0 +as 0 +parkinsonian 3 +- 0 +like 0 +and 0 +tardive 3 +dsykinesia 4 +signs 0 +. 0 + +The 0 +glutamatergic 0 +blockage 0 +produced 0 +by 0 +NMDA 1 +can 0 +restore 0 +these 0 +signs 0 +, 0 +such 0 +as 0 +vacuous 0 +chewing 0 +movements 0 +, 0 +tongue 0 +protrusions 0 +, 0 +catalepsy 3 +and 0 +tremor 3 +according 0 +to 0 +the 0 +employed 0 +model 0 +. 0 + +Risperidone 1 +- 0 +associated 0 +, 0 +benign 0 +transient 0 +visual 3 +disturbances 4 +in 0 +schizophrenic 3 +patients 0 +with 0 +a 0 +past 0 +history 0 +of 0 +LSD 1 +abuse 0 +. 0 + +Two 0 +schizophrenic 3 +patients 0 +, 0 +who 0 +had 0 +a 0 +prior 0 +history 0 +of 0 +LSD 1 +abuse 0 +and 0 +who 0 +had 0 +previously 0 +developed 0 +EPS 3 +with 0 +classic 0 +antipsychotics 0 +, 0 +were 0 +successfully 0 +treated 0 +with 0 +risperidone 1 +. 0 + +They 0 +both 0 +reported 0 +short 0 +episodes 0 +of 0 +transient 0 +visual 3 +disturbances 4 +, 0 +which 0 +appeared 0 +immediately 0 +after 0 +starting 0 +treatment 0 +with 0 +risperidone 1 +. 0 + +This 0 +imagery 0 +resembled 0 +visual 3 +disturbances 4 +previously 0 +experienced 0 +as 0 +" 0 +flashbacks 0 +" 0 +related 0 +to 0 +prior 0 +LSD 1 +consumption 0 +. 0 + +Risperidone 1 +administration 0 +was 0 +continued 0 +and 0 +the 0 +visual 3 +disturbances 4 +gradually 0 +wore 0 +off 0 +. 0 + +During 0 +a 0 +six 0 +- 0 +month 0 +follow 0 +- 0 +up 0 +period 0 +, 0 +there 0 +was 0 +no 0 +recurrence 0 +of 0 +visual 3 +disturbances 4 +. 0 + +This 0 +phenomenon 0 +may 0 +be 0 +interpreted 0 +as 0 +a 0 +benign 0 +, 0 +short 0 +- 0 +term 0 +and 0 +self 0 +- 0 +limiting 0 +side 0 +effect 0 +which 0 +does 0 +not 0 +contraindicate 0 +the 0 +use 0 +of 0 +risperidone 1 +or 0 +interfere 0 +with 0 +treatment 0 +. 0 + +Conclusions 0 +based 0 +on 0 +two 0 +case 0 +reports 0 +should 0 +be 0 +taken 0 +with 0 +appropriate 0 +caution 0 +. 0 + +Topiramate 1 +- 0 +induced 0 +nephrolithiasis 3 +. 0 + +Topiramate 1 +is 0 +a 0 +recently 0 +developed 0 +antiepileptic 0 +medication 0 +that 0 +is 0 +becoming 0 +more 0 +widely 0 +prescribed 0 +because 0 +of 0 +its 0 +efficacy 0 +in 0 +treating 0 +refractory 3 +seizures 4 +. 0 + +Urologists 0 +should 0 +be 0 +aware 0 +that 0 +this 0 +medication 0 +can 0 +cause 0 +metabolic 3 +acidosis 4 +in 0 +patients 0 +secondary 0 +to 0 +inhibition 0 +of 0 +carbonic 0 +anhydrase 0 +. 0 + +In 0 +addition 0 +, 0 +a 0 +distal 0 +tubular 0 +acidification 0 +defect 0 +may 0 +result 0 +, 0 +thus 0 +impairing 0 +the 0 +normal 0 +compensatory 0 +drop 0 +in 0 +urine 0 +pH 0 +. 0 + +These 0 +factors 0 +can 0 +lead 0 +to 0 +the 0 +development 0 +of 0 +calcium 1 +phosphate 2 +nephrolithiasis 3 +. 0 + +We 0 +report 0 +the 0 +first 0 +two 0 +cases 0 +of 0 +topiramate 1 +- 0 +induced 0 +nephrolithiasis 3 +in 0 +the 0 +urologic 0 +literature 0 +. 0 + +Ketamine 1 +in 0 +war 0 +/ 0 +tropical 0 +surgery 0 +( 0 +a 0 +final 0 +tribute 0 +to 0 +the 0 +racemic 0 +mixture 0 +) 0 +. 0 + +A 0 +technique 0 +of 0 +continuous 0 +intravenous 0 +anaesthesia 0 +with 0 +ketamine 1 +was 0 +used 0 +successfully 0 +during 0 +the 0 +Somalia 0 +civil 0 +war 0 +in 0 +1994 0 +and 0 +in 0 +north 0 +Uganda 0 +in 0 +1999 0 +for 0 +64 0 +operations 0 +in 0 +62 0 +patients 0 +, 0 +aged 0 +from 0 +6 0 +weeks 0 +to 0 +70 0 +years 0 +, 0 +undergoing 0 +limb 0 +and 0 +abdominal 0 +surgery 0 +including 0 +caesarian 0 +sections 0 +and 0 +interventions 0 +in 0 +neonates 0 +. 0 + +0perations 0 +lasting 0 +up 0 +to 0 +2h 0 +could 0 +be 0 +performed 0 +in 0 +the 0 +absence 0 +of 0 +sophisticated 0 +equipment 0 +such 0 +as 0 +pulse 0 +oximeters 0 +or 0 +ventilators 0 +in 0 +patients 0 +on 0 +spontaneous 0 +ventilation 0 +breathing 0 +air 0 +/ 0 +oxygen 1 +only 0 +. 0 + +After 0 +premedication 0 +with 0 +diazepam 1 +, 0 +glycopyrrolate 1 +and 0 +local 0 +anaesthesia 0 +, 0 +and 0 +induction 0 +with 0 +standard 0 +doses 0 +of 0 +ketamine 1 +, 0 +a 0 +maintenance 0 +dose 0 +of 0 +10 0 +- 0 +20 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +of 0 +ketamine 1 +proved 0 +safe 0 +and 0 +effective 0 +. 0 + +Emphasis 0 +was 0 +placed 0 +on 0 +bedside 0 +clinical 0 +monitoring 0 +, 0 +relying 0 +heavily 0 +on 0 +the 0 +heart 0 +rate 0 +. 0 + +Diazepam 1 +, 0 +unless 0 +contraindicated 0 +or 0 +risky 0 +, 0 +remains 0 +the 0 +only 0 +necessary 0 +complementary 0 +drug 0 +to 0 +ketamine 1 +as 0 +it 0 +buffers 0 +its 0 +cardiovascular 0 +response 0 +and 0 +decreases 0 +the 0 +duration 0 +and 0 +intensity 0 +of 0 +operative 0 +and 0 +postoperative 0 +hallucinations 3 +. 0 + +Local 0 +anaesthetic 0 +blocks 0 +were 0 +useful 0 +in 0 +decreasing 0 +the 0 +requirement 0 +for 0 +postoperative 0 +analgesia 3 +. 0 + +An 0 +antisialogue 0 +was 0 +usually 0 +unnecessary 0 +in 0 +operations 0 +lasting 0 +up 0 +to 0 +2 0 +h 0 +, 0 +glycopyrrolate 1 +being 0 +the 0 +best 0 +choice 0 +for 0 +its 0 +lowest 0 +psychotropic 0 +and 0 +chronotropic 0 +effects 0 +, 0 +especially 0 +in 0 +a 0 +hot 0 +climate 0 +. 0 + +Experience 0 +in 0 +war 0 +/ 0 +tropical 0 +settings 0 +suggests 0 +this 0 +technique 0 +could 0 +be 0 +useful 0 +in 0 +civilian 0 +contexts 0 +such 0 +as 0 +outdoor 0 +life 0 +- 0 +saving 0 +emergency 0 +surgery 0 +or 0 +in 0 +mass 0 +casualties 0 +where 0 +, 0 +e 0 +. 0 +g 0 +. 0 +amputation 0 +and 0 +rapid 0 +extrication 0 +were 0 +required 0 +. 0 + +Intravenous 0 +ribavirin 1 +treatment 0 +for 0 +severe 0 +adenovirus 3 +disease 4 +in 0 +immunocompromised 0 +children 0 +. 0 + +BACKGR0UND 0 +: 0 +Adenovirus 0 +is 0 +an 0 +important 0 +cause 0 +of 0 +morbidity 0 +and 0 +mortality 0 +in 0 +the 0 +immunocompromised 0 +host 0 +. 0 + +The 0 +incidence 0 +of 0 +severe 0 +adenovirus 3 +disease 4 +in 0 +pediatrics 0 +is 0 +increasing 0 +in 0 +association 0 +with 0 +growing 0 +numbers 0 +of 0 +immunocompromised 0 +children 0 +, 0 +where 0 +case 0 +fatality 0 +rates 0 +as 0 +high 0 +as 0 +50 0 +% 0 +to 0 +80 0 +% 0 +have 0 +been 0 +reported 0 +. 0 + +There 0 +are 0 +no 0 +approved 0 +antiviral 0 +agents 0 +with 0 +proven 0 +efficacy 0 +for 0 +the 0 +treatment 0 +of 0 +severe 0 +adenovirus 3 +disease 4 +, 0 +nor 0 +are 0 +there 0 +any 0 +prospective 0 +randomized 0 +, 0 +controlled 0 +trials 0 +of 0 +potentially 0 +useful 0 +anti 0 +- 0 +adenovirus 0 +therapies 0 +. 0 + +Apparent 0 +clinical 0 +success 0 +in 0 +the 0 +treatment 0 +of 0 +severe 0 +adenovirus 3 +disease 4 +is 0 +limited 0 +to 0 +a 0 +few 0 +case 0 +reports 0 +and 0 +small 0 +series 0 +. 0 + +Experience 0 +is 0 +greatest 0 +with 0 +intravenous 0 +ribavirin 1 +and 0 +cidofovir 1 +. 0 + +Ribavirin 1 +, 0 +a 0 +guanosine 1 +analogue 0 +, 0 +has 0 +broad 0 +antiviral 0 +activity 0 +against 0 +both 0 +RNA 0 +and 0 +DNA 0 +viruses 0 +, 0 +including 0 +documented 0 +activity 0 +against 0 +adenovirus 0 +in 0 +vitro 0 +. 0 + +Ribavirin 1 +is 0 +licensed 0 +in 0 +aerosol 0 +form 0 +for 0 +the 0 +treatment 0 +of 0 +respiratory 3 +syncytial 4 +virus 4 +infection 4 +, 0 +and 0 +orally 0 +in 0 +combination 0 +with 0 +interferon 0 +to 0 +treat 0 +hepatitis 3 +C 4 +. 0 + +Intravenous 0 +ribavirin 1 +is 0 +the 0 +treatment 0 +of 0 +choice 0 +for 0 +infection 3 +with 4 +hemorrhagic 4 +fever 4 +viruses 4 +. 0 + +The 0 +most 0 +common 0 +adverse 0 +effect 0 +of 0 +intravenous 0 +ribavirin 1 +is 0 +reversible 0 +mild 0 +anemia 3 +. 0 + +The 0 +use 0 +of 0 +cidofovir 1 +in 0 +severe 0 +adenovirus 3 +infection 4 +has 0 +been 0 +limited 0 +by 0 +adverse 0 +effects 0 +, 0 +the 0 +most 0 +significant 0 +of 0 +which 0 +is 0 +nephrotoxicity 3 +. 0 + +0BJECTIVE 0 +: 0 +We 0 +report 0 +our 0 +experience 0 +with 0 +intravenous 0 +ribavirin 1 +therapy 0 +for 0 +severe 0 +adenovirus 3 +disease 4 +in 0 +a 0 +series 0 +of 0 +immunocompromised 0 +children 0 +and 0 +review 0 +the 0 +literature 0 +. 0 + +DESIGN 0 +/ 0 +METH0DS 0 +: 0 +We 0 +retrospectively 0 +reviewed 0 +the 0 +medical 0 +records 0 +of 0 +5 0 +children 0 +treated 0 +with 0 +intravenous 0 +ribavirin 1 +for 0 +documented 0 +severe 0 +adenovirus 3 +disease 4 +. 0 + +Two 0 +patients 0 +developed 0 +adenovirus 0 +hemorrhagic 3 +cystitis 4 +after 0 +cardiac 0 +and 0 +bone 0 +marrow 0 +transplants 0 +, 0 +respectively 0 +. 0 + +The 0 +bone 0 +marrow 0 +transplant 0 +patient 0 +also 0 +received 0 +intravenous 0 +cidofovir 1 +for 0 +progressive 0 +disseminated 0 +disease 0 +. 0 + +An 0 +additional 0 +3 0 +children 0 +developed 0 +adenovirus 3 +pneumonia 4 +; 0 +2 0 +were 0 +neonates 0 +, 0 +1 0 +of 0 +whom 0 +had 0 +partial 0 +DiGeorge 3 +syndrome 4 +. 0 + +The 0 +remaining 0 +infant 0 +had 0 +recently 0 +undergone 0 +a 0 +cardiac 0 +transplant 0 +. 0 + +Intravenous 0 +ribavirin 1 +was 0 +administered 0 +on 0 +a 0 +compassionate 0 +- 0 +use 0 +protocol 0 +. 0 + +RESULTS 0 +: 0 +Complete 0 +clinical 0 +recovery 0 +followed 0 +later 0 +by 0 +viral 0 +clearance 0 +was 0 +observed 0 +in 0 +2 0 +children 0 +: 0 +the 0 +cardiac 0 +transplant 0 +recipient 0 +with 0 +adenovirus 0 +hemorrhagic 3 +cystitis 4 +and 0 +the 0 +immunocompetent 0 +neonate 0 +with 0 +adenovirus 3 +pneumonia 4 +. 0 + +The 0 +remaining 0 +3 0 +children 0 +died 0 +of 0 +adenovirus 3 +disease 4 +. 0 + +Intravenous 0 +ribavirin 1 +therapy 0 +was 0 +well 0 +tolerated 0 +. 0 + +Use 0 +of 0 +cidofovir 1 +in 0 +1 0 +child 0 +was 0 +associated 0 +with 0 +progressive 3 +renal 4 +failure 4 +and 0 +neutropenia 3 +. 0 + +DISCUSSI0N 0 +: 0 +0ur 0 +series 0 +of 0 +patients 0 +is 0 +representative 0 +of 0 +the 0 +spectrum 0 +of 0 +immunocompromised 0 +children 0 +at 0 +greatest 0 +risk 0 +for 0 +severe 0 +adenovirus 3 +disease 4 +, 0 +namely 0 +solid 0 +- 0 +organ 0 +and 0 +bone 0 +marrow 0 +transplant 0 +recipients 0 +, 0 +neonates 0 +, 0 +and 0 +children 0 +with 0 +immunodeficiency 3 +. 0 + +Although 0 +intravenous 0 +ribavirin 1 +was 0 +not 0 +effective 0 +for 0 +all 0 +children 0 +with 0 +severe 0 +adenovirus 3 +disease 4 +in 0 +this 0 +series 0 +or 0 +in 0 +the 0 +literature 0 +, 0 +therapy 0 +is 0 +unlikely 0 +to 0 +be 0 +of 0 +benefit 0 +if 0 +begun 0 +late 0 +in 0 +the 0 +course 0 +of 0 +the 0 +infection 3 +. 0 + +Early 0 +identification 0 +, 0 +eg 0 +by 0 +polymerase 0 +chain 0 +reaction 0 +of 0 +those 0 +patients 0 +at 0 +risk 0 +of 0 +disseminated 0 +adenovirus 3 +disease 4 +may 0 +permit 0 +earlier 0 +antiviral 0 +treatment 0 +and 0 +better 0 +evaluation 0 +of 0 +therapeutic 0 +response 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Two 0 +of 0 +5 0 +children 0 +with 0 +severe 0 +adenovirus 3 +disease 4 +treated 0 +with 0 +intravenous 0 +ribavirin 1 +recovered 0 +. 0 + +The 0 +availability 0 +of 0 +newer 0 +rapid 0 +diagnostic 0 +techniques 0 +, 0 +such 0 +as 0 +polymerase 0 +chain 0 +reaction 0 +, 0 +may 0 +make 0 +earlier 0 +, 0 +more 0 +effective 0 +treatment 0 +of 0 +adenovirus 3 +infection 4 +possible 0 +. 0 + +Given 0 +the 0 +seriousness 0 +and 0 +increasing 0 +prevalence 0 +of 0 +adenovirus 3 +disease 4 +in 0 +certain 0 +hosts 0 +, 0 +especially 0 +children 0 +, 0 +a 0 +large 0 +, 0 +multicenter 0 +clinical 0 +trial 0 +of 0 +potentially 0 +useful 0 +anti 0 +- 0 +adenoviral 0 +therapies 0 +, 0 +such 0 +as 0 +intravenous 0 +ribavirin 1 +, 0 +is 0 +clearly 0 +required 0 +to 0 +demonstrate 0 +the 0 +most 0 +effective 0 +and 0 +least 0 +toxic 0 +therapy 0 +. 0 + +Delayed 0 +asystolic 3 +cardiac 3 +arrest 4 +after 0 +diltiazem 1 +overdose 3 +; 0 +resuscitation 0 +with 0 +high 0 +dose 0 +intravenous 0 +calcium 1 +. 0 + +A 0 +51 0 +year 0 +old 0 +man 0 +took 0 +a 0 +mixed 0 +overdose 3 +including 0 +1 0 +. 0 +8 0 +- 0 +3 0 +. 0 +6 0 +g 0 +of 0 +diltiazem 1 +, 0 +paracetamol 1 +, 0 +aspirin 1 +, 0 +isosorbide 1 +nitrate 1 +, 0 +and 0 +alcohol 1 +. 0 + +He 0 +initially 0 +presented 0 +to 0 +hospital 0 +after 0 +six 0 +hours 0 +with 0 +mild 0 +hypotension 3 +and 0 +was 0 +treated 0 +with 0 +activated 0 +charcoal 0 +and 0 +intravenous 0 +fluids 0 +. 0 + +Eighteen 0 +hours 0 +after 0 +the 0 +overdose 3 +he 0 +had 0 +two 0 +generalised 0 +tonic 3 +- 4 +clonic 4 +seizures 4 +. 0 + +The 0 +patient 0 +remained 0 +unresponsive 0 +with 0 +junctional 0 +bradycardia 3 +, 0 +unrecordable 0 +blood 0 +pressure 0 +, 0 +and 0 +then 0 +became 0 +asystolic 3 +. 0 + +He 0 +was 0 +resuscitated 0 +with 0 +high 0 +dose 0 +( 0 +13 0 +. 0 +5 0 +g 0 +) 0 +intravenous 0 +calcium 1 +and 0 +adrenaline 1 +( 0 +epinephrine 1 +) 0 +. 0 + +He 0 +required 0 +inotropic 0 +support 0 +and 0 +temporary 0 +pacing 0 +over 0 +the 0 +next 0 +48 0 +hours 0 +. 0 + +This 0 +case 0 +suggests 0 +there 0 +is 0 +a 0 +role 0 +for 0 +aggressive 0 +high 0 +dose 0 +intravenous 0 +calcium 1 +therapy 0 +in 0 +severe 0 +diltiazem 1 +overdose 3 +, 0 +particularly 0 +with 0 +the 0 +onset 0 +of 0 +asystole 3 +. 0 + +It 0 +should 0 +be 0 +considered 0 +early 0 +in 0 +cases 0 +of 0 +cardiac 3 +arrest 4 +after 0 +diltiazem 1 +overdose 3 +. 0 + +The 0 +case 0 +also 0 +highlights 0 +the 0 +problems 0 +with 0 +delayed 0 +toxicity 3 +when 0 +whole 0 +bowel 0 +irrigation 0 +is 0 +not 0 +administered 0 +. 0 + +Low 1 +- 2 +molecular 2 +- 2 +weight 2 +heparin 2 +for 0 +the 0 +treatment 0 +of 0 +patients 0 +with 0 +mechanical 0 +heart 0 +valves 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +interruption 0 +of 0 +oral 0 +anticoagulant 0 +( 0 +0AC 0 +) 0 +administration 0 +is 0 +sometimes 0 +indicated 0 +in 0 +patients 0 +with 0 +mechanical 0 +heart 0 +valves 0 +, 0 +mainly 0 +before 0 +noncardiac 0 +surgery 0 +, 0 +non 0 +- 0 +surgical 0 +interventions 0 +, 0 +and 0 +pregnancy 0 +. 0 + +Unfractionated 1 +heparin 2 +( 0 +UH 1 +) 0 +is 0 +currently 0 +the 0 +substitute 0 +for 0 +selected 0 +patients 0 +. 0 + +Low 1 +- 2 +molecular 2 +- 2 +weight 2 +heparin 2 +( 0 +LMWH 1 +) 0 +offers 0 +theoretical 0 +advantages 0 +over 0 +UH 1 +, 0 +but 0 +is 0 +not 0 +currently 0 +considered 0 +in 0 +clinical 0 +guidelines 0 +as 0 +an 0 +alternative 0 +to 0 +UH 1 +in 0 +patients 0 +with 0 +prosthetic 0 +valves 0 +. 0 + +HYP0THESIS 0 +: 0 +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +review 0 +the 0 +data 0 +accumulated 0 +so 0 +far 0 +on 0 +the 0 +use 0 +of 0 +LMWH 1 +in 0 +this 0 +patient 0 +population 0 +and 0 +to 0 +discuss 0 +its 0 +applicability 0 +in 0 +common 0 +practice 0 +. 0 + +METH0DS 0 +: 0 +For 0 +this 0 +paper 0 +, 0 +the 0 +current 0 +medical 0 +literature 0 +on 0 +LMWH 1 +in 0 +patients 0 +with 0 +mechanical 0 +heart 0 +valves 0 +was 0 +extensively 0 +reviewed 0 +. 0 + +RESULTS 0 +: 0 +There 0 +were 0 +eight 0 +series 0 +and 0 +six 0 +case 0 +reports 0 +. 0 + +None 0 +of 0 +the 0 +studies 0 +was 0 +randomized 0 +, 0 +and 0 +only 0 +one 0 +was 0 +prospective 0 +. 0 + +Data 0 +to 0 +establish 0 +the 0 +thromboembolic 3 +risk 0 +were 0 +incomplete 0 +. 0 + +After 0 +excluding 0 +case 0 +reports 0 +, 0 +the 0 +following 0 +groups 0 +were 0 +constructed 0 +: 0 +( 0 +a 0 +) 0 +short 0 +- 0 +term 0 +administration 0 +, 0 +after 0 +valve 0 +insertion 0 +( 0 +n 0 += 0 +212 0 +) 0 +; 0 +( 0 +b 0 +) 0 +short 0 +- 0 +term 0 +, 0 +perioperative 0 +( 0 +noncardiac 0 +) 0 +/ 0 +periprocedural 0 +( 0 +n 0 += 0 +114 0 +) 0 +; 0 +( 0 +c 0 +) 0 +long 0 +- 0 +term 0 +, 0 +due 0 +to 0 +intolerance 0 +to 0 +0AC 0 +( 0 +n 0 += 0 +16 0 +) 0 +; 0 +( 0 +d 0 +) 0 +long 0 +- 0 +term 0 +, 0 +in 0 +pregnancy 0 +( 0 +n 0 += 0 +10 0 +) 0 +. 0 + +The 0 +incidence 0 +rate 0 +of 0 +thromboembolism 3 +was 0 +0 0 +. 0 +9 0 +% 0 +for 0 +all 0 +the 0 +studies 0 +and 0 +0 0 +. 0 +5 0 +, 0 +0 0 +, 0 +20 0 +, 0 +and 0 +0 0 +% 0 +in 0 +groups 0 +a 0 +, 0 +b 0 +, 0 +c 0 +, 0 +and 0 +d 0 +, 0 +respectively 0 +; 0 +for 0 +hemorrhage 3 +, 0 +the 0 +overall 0 +rate 0 +was 0 +3 0 +. 0 +4 0 +% 0 +( 0 +3 0 +. 0 +8 0 +, 0 +2 0 +. 0 +6 0 +, 0 +10 0 +, 0 +and 0 +0 0 +% 0 +for 0 +the 0 +respective 0 +groups 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +patients 0 +with 0 +mechanical 0 +heart 0 +valves 0 +, 0 +short 0 +- 0 +term 0 +LMWH 1 +therapy 0 +compares 0 +favorably 0 +with 0 +UH 1 +. 0 + +Data 0 +on 0 +mid 0 +- 0 +and 0 +long 0 +- 0 +term 0 +LMWH 1 +administration 0 +in 0 +these 0 +patients 0 +are 0 +sparse 0 +. 0 + +Further 0 +randomized 0 +studies 0 +are 0 +needed 0 +to 0 +confirm 0 +the 0 +safety 0 +and 0 +precise 0 +indications 0 +for 0 +the 0 +use 0 +of 0 +LMWH 1 +in 0 +patients 0 +with 0 +mechanical 0 +heart 0 +valves 0 +. 0 + +Cardiac 3 +arrest 4 +after 0 +intravenous 0 +metoclopramide 1 +- 0 +a 0 +case 0 +of 0 +five 0 +repeated 0 +injections 0 +of 0 +metoclopramide 1 +causing 0 +five 0 +episodes 0 +of 0 +cardiac 3 +arrest 4 +. 0 + +We 0 +describe 0 +a 0 +patient 0 +where 0 +intravenous 0 +injection 0 +of 0 +metoclopramide 1 +was 0 +immediately 0 +followed 0 +by 0 +asystole 3 +repeatedly 0 +. 0 + +The 0 +patient 0 +received 0 +metoclopramide 1 +10 0 +mg 0 +i 0 +. 0 +v 0 +. 0 +five 0 +times 0 +during 0 +48 0 +h 0 +. 0 + +After 0 +interviewing 0 +the 0 +attending 0 +nurses 0 +and 0 +reviewing 0 +the 0 +written 0 +documentation 0 +, 0 +it 0 +is 0 +clear 0 +that 0 +every 0 +administration 0 +of 0 +metoclopramide 1 +was 0 +immediately 0 +( 0 +within 0 +s 0 +) 0 +followed 0 +by 0 +asystole 3 +. 0 + +The 0 +asystole 3 +lasted 0 +15 0 +- 0 +30 0 +s 0 +on 0 +four 0 +occasions 0 +, 0 +on 0 +one 0 +occasion 0 +it 0 +lasted 0 +2 0 +min 0 +. 0 + +The 0 +patient 0 +received 0 +atropine 1 +0 0 +. 0 +5 0 +- 0 +1 0 +mg 0 +and 0 +chest 0 +compressions 0 +, 0 +before 0 +sinus 0 +rhythm 0 +again 0 +took 0 +over 0 +. 0 + +We 0 +interpret 0 +this 0 +as 0 +episodes 0 +of 0 +cardiac 3 +arrest 4 +caused 0 +by 0 +metoclopramide 1 +. 0 + +The 0 +rapid 0 +injection 0 +via 0 +the 0 +central 0 +venous 0 +route 0 +and 0 +the 0 +concomitant 0 +tapering 0 +of 0 +dopamine 1 +infusion 0 +might 0 +have 0 +contributed 0 +in 0 +precipitating 0 +the 0 +adverse 0 +drug 0 +reaction 0 +. 0 + +Immunohistochemical 0 +study 0 +on 0 +inducible 0 +type 0 +of 0 +nitric 1 +oxide 2 +( 0 +iN0S 0 +) 0 +, 0 +basic 0 +fibroblast 0 +growth 0 +factor 0 +( 0 +bFGF 0 +) 0 +and 0 +tumor 3 +growth 0 +factor 0 +- 0 +beta1 0 +( 0 +TGF 0 +- 0 +beta1 0 +) 0 +in 0 +arteritis 3 +induced 0 +in 0 +rats 0 +by 0 +fenoldopam 1 +and 0 +theophylline 1 +, 0 +vasodilators 0 +. 0 + +Arteritis 3 +induced 0 +in 0 +rats 0 +by 0 +vasodilators 0 +, 0 +fenoldopam 1 +and 0 +theophylline 1 +, 0 +was 0 +examined 0 +immunohistochemically 0 +for 0 +expressions 0 +of 0 +inducible 0 +type 0 +of 0 +nitric 1 +oxide 2 +synthase 0 +( 0 +iN0S 0 +) 0 +, 0 +basic 0 +fibroblast 0 +growth 0 +factor 0 +( 0 +bFGF 0 +) 0 +and 0 +tumor 3 +growth 0 +factor 0 +- 0 +beta1 0 +( 0 +TGF 0 +- 0 +beta1 0 +) 0 +. 0 + +Rats 0 +were 0 +administered 0 +fenoldopam 1 +for 0 +24 0 +hours 0 +by 0 +intravenous 0 +infusion 0 +with 0 +or 0 +without 0 +following 0 +repeated 0 +daily 0 +oral 0 +administrations 0 +of 0 +theophylline 1 +. 0 + +Irrespective 0 +of 0 +theophylline 1 +administration 0 +, 0 +iN0S 0 +antigens 0 +were 0 +remarkably 0 +abundant 0 +in 0 +ED 0 +- 0 +1 0 +- 0 +positive 0 +cells 0 +on 0 +day 0 +5 0 +and 0 +8 0 +post 0 +- 0 +fenoldopam 1 +- 0 +infusion 0 +( 0 +DPI 0 +) 0 +; 0 +bFGF 0 +antigens 0 +were 0 +remarkably 0 +abundant 0 +in 0 +ED 0 +- 0 +1 0 +- 0 +positive 0 +cells 0 +on 0 +1 0 +and 0 +3 0 +DPI 0 +; 0 +TGF 0 +- 0 +beta1 0 +antigens 0 +were 0 +observed 0 +in 0 +ED 0 +- 0 +1 0 +- 0 +positive 0 +cells 0 +on 0 +and 0 +after 0 +5 0 +DPI 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +the 0 +peak 0 +expression 0 +of 0 +iN0S 0 +antigen 0 +was 0 +followed 0 +by 0 +that 0 +of 0 +bFGF 0 +antigen 0 +, 0 +and 0 +bFGF 0 +may 0 +have 0 +a 0 +suppressive 0 +effect 0 +on 0 +iN0S 0 +expression 0 +in 0 +these 0 +rat 0 +arteritis 3 +models 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +TGF 0 +- 0 +beta1 0 +was 0 +not 0 +considered 0 +to 0 +have 0 +a 0 +suppressive 0 +effect 0 +on 0 +iN0S 0 +expression 0 +in 0 +these 0 +models 0 +. 0 + +The 0 +striatum 0 +as 0 +a 0 +target 0 +for 0 +anti 0 +- 0 +rigor 0 +effects 0 +of 0 +an 0 +antagonist 0 +of 0 +mGluR1 0 +, 0 +but 0 +not 0 +an 0 +agonist 0 +of 0 +group 0 +II 0 +metabotropic 0 +glutamate 1 +receptors 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +find 0 +out 0 +whether 0 +the 0 +metabotropic 0 +receptor 0 +1 0 +( 0 +mGluR1 0 +) 0 +and 0 +group 0 +II 0 +mGluRs 0 +, 0 +localized 0 +in 0 +the 0 +striatum 0 +, 0 +are 0 +involved 0 +in 0 +antiparkinsonian 0 +- 0 +like 0 +effects 0 +in 0 +rats 0 +. 0 + +Haloperidol 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +induced 0 +parkinsonian 3 +- 0 +like 0 +muscle 3 +rigidity 4 +, 0 +measured 0 +as 0 +an 0 +increased 0 +resistance 0 +of 0 +a 0 +rat 0 +' 0 +s 0 +hind 0 +foot 0 +to 0 +passive 0 +flexion 0 +and 0 +extension 0 +at 0 +the 0 +ankle 0 +joint 0 +. 0 + +( 1 +RS 2 +) 2 +- 2 +1 2 +- 2 +aminoindan 2 +- 2 +1 2 +, 2 +5 2 +- 2 +dicarboxylic 2 +acid 2 +( 0 +AIDA 1 +; 0 +0 0 +. 0 +5 0 +- 0 +15 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +) 0 +, 0 +a 0 +potent 0 +and 0 +selective 0 +mGluR1 0 +antagonist 0 +, 0 +or 0 +( 1 +2R 2 +, 2 +4R 2 +) 2 +- 2 +4 2 +- 2 +aminopyrrolidine 2 +- 2 +2 2 +, 2 +4 2 +- 2 +dicarboxylate 2 +( 0 +2R 1 +, 2 +4R 2 +- 2 +APDC 2 +; 0 +7 0 +. 0 +5 0 +- 0 +15 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +) 0 +, 0 +a 0 +selective 0 +group 0 +II 0 +agonist 0 +, 0 +was 0 +injected 0 +bilaterally 0 +into 0 +the 0 +striatum 0 +of 0 +haloperidol 1 +- 0 +treated 0 +animals 0 +. 0 + +AIDA 1 +in 0 +doses 0 +of 0 +7 0 +. 0 +5 0 +- 0 +15 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +diminished 0 +the 0 +haloperidol 1 +- 0 +induced 0 +muscle 3 +rigidity 4 +. 0 + +In 0 +contrast 0 +, 0 +2R 1 +, 2 +4R 2 +- 2 +APDC 2 +injections 0 +were 0 +ineffective 0 +. 0 + +The 0 +present 0 +results 0 +may 0 +suggest 0 +that 0 +the 0 +blockade 0 +of 0 +striatal 0 +mGluR1 0 +, 0 +but 0 +not 0 +the 0 +stimulation 0 +of 0 +group 0 +II 0 +mGluRs 0 +, 0 +may 0 +ameliorate 0 +parkinsonian 3 +muscle 3 +rigidity 4 +. 0 + +A 0 +phase 0 +II 0 +study 0 +of 0 +thalidomide 1 +in 0 +advanced 0 +metastatic 0 +renal 3 +cell 4 +carcinoma 4 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +evaluate 0 +the 0 +toxicity 3 +and 0 +activity 0 +of 0 +thalidomide 1 +in 0 +patients 0 +with 0 +advanced 0 +metastatic 0 +renal 3 +cell 4 +cancer 4 +and 0 +to 0 +measure 0 +changes 0 +of 0 +one 0 +angiogenic 0 +factor 0 +, 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +( 0 +VEGF 0 +) 0 +165 0 +, 0 +with 0 +therapy 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +29 0 +patients 0 +were 0 +enrolled 0 +on 0 +a 0 +study 0 +of 0 +thalidomide 1 +using 0 +an 0 +intra 0 +- 0 +patient 0 +dose 0 +escalation 0 +schedule 0 +. 0 + +Patients 0 +began 0 +thalidomide 1 +at 0 +400 0 +mg 0 +/ 0 +d 0 +and 0 +escalated 0 +as 0 +tolerated 0 +to 0 +1200 0 +mg 0 +/ 0 +d 0 +by 0 +day 0 +54 0 +. 0 + +Fifty 0 +- 0 +nine 0 +per 0 +cent 0 +of 0 +patients 0 +had 0 +had 0 +previous 0 +therapy 0 +with 0 +IL 0 +- 0 +2 0 +and 0 +52 0 +% 0 +were 0 +performance 0 +status 0 +2 0 +or 0 +3 0 +. 0 + +Systemic 0 +plasma 0 +VEGF165 0 +levels 0 +were 0 +measured 0 +by 0 +dual 0 +monoclonal 0 +ELISA 0 +in 0 +8 0 +patients 0 +. 0 + +RESULTS 0 +: 0 +24 0 +patients 0 +were 0 +evaluable 0 +for 0 +response 0 +with 0 +one 0 +partial 0 +response 0 +of 0 +11 0 +months 0 +duration 0 +of 0 +a 0 +patient 0 +with 0 +hepatic 0 +and 0 +pulmonary 0 +metastases 3 +( 0 +4 0 +% 0 +) 0 +, 0 +one 0 +minor 0 +response 0 +, 0 +and 0 +2 0 +patients 0 +stable 0 +for 0 +over 0 +6 0 +months 0 +. 0 + +Somnolence 3 +and 0 +constipation 3 +were 0 +prominent 0 +toxicities 3 +and 0 +most 0 +patients 0 +could 0 +not 0 +tolerate 0 +the 0 +1200 0 +mg 0 +/ 0 +day 0 +dose 0 +level 0 +. 0 + +Systemic 0 +plasma 0 +VEGF165 0 +levels 0 +did 0 +not 0 +change 0 +with 0 +therapy 0 +. 0 + +C0NCLUSI0N 0 +: 0 +These 0 +results 0 +are 0 +consistent 0 +with 0 +a 0 +low 0 +level 0 +of 0 +activity 0 +of 0 +thalidomide 1 +in 0 +renal 3 +cell 4 +carcinoma 4 +. 0 + +Administration 0 +of 0 +doses 0 +over 0 +800 0 +mg 0 +/ 0 +day 0 +was 0 +difficult 0 +to 0 +achieve 0 +in 0 +this 0 +patient 0 +population 0 +, 0 +however 0 +lower 0 +doses 0 +were 0 +practical 0 +. 0 + +The 0 +dose 0 +- 0 +response 0 +relationship 0 +, 0 +if 0 +any 0 +, 0 +of 0 +thalidomide 1 +for 0 +renal 3 +cell 4 +carcinoma 4 +is 0 +unclear 0 +. 0 + +Can 0 +lidocaine 1 +reduce 0 +succinylcholine 1 +induced 0 +postoperative 3 +myalgia 4 +? 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +determine 0 +the 0 +effect 0 +of 0 +lidocaine 1 +pretreatment 0 +on 0 +reduction 0 +of 0 +succinylcholine 1 +- 0 +induced 0 +myalgia 3 +in 0 +patients 0 +undergoing 0 +general 0 +anesthesia 0 +for 0 +gynecological 0 +surgery 0 +. 0 + +0ne 0 +hundred 0 +and 0 +thirty 0 +- 0 +five 0 +patients 0 +were 0 +assigned 0 +to 0 +one 0 +of 0 +three 0 +groups 0 +in 0 +a 0 +prospective 0 +, 0 +double 0 +blind 0 +, 0 +randomized 0 +manner 0 +. 0 + +Group 0 +PS 0 +, 0 +the 0 +control 0 +group 0 +, 0 +received 0 +normal 0 +saline 0 +and 0 +succinylcholine 1 +1 0 +. 0 +5 0 +mg 0 +x 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +; 0 +Group 0 +LS 0 +, 0 +lidocaine 1 +1 0 +. 0 +5 0 +mg 0 +x 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +and 0 +succinylcholine 1 +1 0 +. 0 +5 0 +mg 0 +x 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +; 0 +Group 0 +PR 0 +, 0 +normal 0 +saline 0 +and 0 +rocuronium 1 +0 0 +. 0 +6 0 +mg 0 +x 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 + +Morphine 1 +0 0 +. 0 +1 0 +mg 0 +x 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +iv 0 +was 0 +given 0 +for 0 +premedication 0 +and 0 +all 0 +patients 0 +were 0 +monitored 0 +with 0 +a 0 +noninvasive 0 +blood 0 +pressure 0 +monitor 0 +, 0 +ECG 0 +and 0 +pulse 0 +oximetry 0 +. 0 + +Anesthesia 0 +was 0 +induced 0 +with 0 +5 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +thiopental 1 +iv 0 +. 0 +followed 0 +by 0 +succinylcholine 1 +( 0 +Group 0 +PS 0 +, 0 +LS 0 +) 0 +or 0 +rocuronium 1 +( 0 +Group 0 +PR 0 +) 0 +for 0 +tracheal 0 +intubation 0 +. 0 + +Following 0 +administration 0 +of 0 +these 0 +agents 0 +, 0 +the 0 +presence 0 +, 0 +and 0 +degree 0 +of 0 +fasciculation 3 +were 0 +assessed 0 +visually 0 +on 0 +a 0 +four 0 +point 0 +scale 0 +by 0 +one 0 +investigator 0 +who 0 +was 0 +blinded 0 +to 0 +the 0 +drug 0 +administered 0 +. 0 + +The 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +of 0 +each 0 +patient 0 +were 0 +monitored 0 +on 0 +nine 0 +occasions 0 +. 0 + +Twenty 0 +- 0 +four 0 +hours 0 +later 0 +, 0 +any 0 +myalgia 3 +experienced 0 +was 0 +assessed 0 +according 0 +to 0 +a 0 +structured 0 +questionaire 0 +and 0 +graded 0 +by 0 +a 0 +four 0 +point 0 +scale 0 +by 0 +one 0 +investigator 0 +blinded 0 +to 0 +the 0 +intraoperative 0 +management 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +muscle 3 +fasciculation 4 +was 0 +not 0 +found 0 +in 0 +Group 0 +PR 0 +while 0 +the 0 +patients 0 +in 0 +Group 0 +LS 0 +had 0 +a 0 +lower 0 +incidence 0 +of 0 +muscle 3 +fasciculation 4 +than 0 +those 0 +in 0 +Group 0 +PS 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +At 0 +24 0 +h 0 +, 0 +the 0 +incidence 0 +of 0 +myalgia 3 +was 0 +higher 0 +in 0 +Group 0 +PS 0 +than 0 +in 0 +Group 0 +LS 0 +and 0 +PR 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +A 0 +correlation 0 +was 0 +not 0 +found 0 +between 0 +the 0 +incidence 0 +of 0 +myalgia 3 +and 0 +the 0 +occurrence 0 +of 0 +muscle 3 +fasciculation 4 +. 0 + +The 0 +changes 0 +in 0 +systolic 0 +and 0 +diastolic 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +were 0 +not 0 +significant 0 +among 0 +the 0 +three 0 +groups 0 +. 0 + +In 0 +conclusion 0 +, 0 +where 0 +succinylcholine 1 +is 0 +used 0 +, 0 +lidocaine 1 +is 0 +proven 0 +to 0 +be 0 +the 0 +useful 0 +pretreatment 0 +agent 0 +for 0 +the 0 +reduction 0 +of 0 +postoperative 3 +myalgia 4 +. 0 + +Reduced 0 +sodium 1 +channel 0 +density 0 +, 0 +altered 0 +voltage 0 +dependence 0 +of 0 +inactivation 0 +, 0 +and 0 +increased 0 +susceptibility 0 +to 0 +seizures 3 +in 0 +mice 0 +lacking 0 +sodium 1 +channel 0 +beta 0 +2 0 +- 0 +subunits 0 +. 0 + +Sodium 1 +channel 0 +beta 0 +- 0 +subunits 0 +modulate 0 +channel 0 +gating 0 +, 0 +assembly 0 +, 0 +and 0 +cell 0 +surface 0 +expression 0 +in 0 +heterologous 0 +cell 0 +systems 0 +. 0 + +We 0 +generated 0 +beta2 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +to 0 +investigate 0 +the 0 +role 0 +of 0 +beta2 0 +in 0 +control 0 +of 0 +sodium 1 +channel 0 +density 0 +, 0 +localization 0 +, 0 +and 0 +function 0 +in 0 +neurons 0 +in 0 +vivo 0 +. 0 + +Measurements 0 +of 0 +[ 0 +( 0 +3 0 +) 0 +H 0 +] 0 +saxitoxin 1 +( 0 +STX 1 +) 0 +binding 0 +showed 0 +a 0 +significant 0 +reduction 0 +in 0 +the 0 +level 0 +of 0 +plasma 0 +membrane 0 +sodium 1 +channels 0 +in 0 +beta2 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +neurons 0 +. 0 + +The 0 +loss 0 +of 0 +beta2 0 +resulted 0 +in 0 +negative 0 +shifts 0 +in 0 +the 0 +voltage 0 +dependence 0 +of 0 +inactivation 0 +as 0 +well 0 +as 0 +significant 0 +decreases 0 +in 0 +sodium 1 +current 0 +density 0 +in 0 +acutely 0 +dissociated 0 +hippocampal 0 +neurons 0 +. 0 + +The 0 +integral 0 +of 0 +the 0 +compound 0 +action 0 +potential 0 +in 0 +optic 0 +nerve 0 +was 0 +significantly 0 +reduced 0 +, 0 +and 0 +the 0 +threshold 0 +for 0 +action 0 +potential 0 +generation 0 +was 0 +increased 0 +, 0 +indicating 0 +a 0 +reduction 0 +in 0 +the 0 +level 0 +of 0 +functional 0 +plasma 0 +membrane 0 +sodium 1 +channels 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +conduction 0 +velocity 0 +, 0 +the 0 +number 0 +and 0 +size 0 +of 0 +axons 0 +in 0 +the 0 +optic 0 +nerve 0 +, 0 +and 0 +the 0 +specific 0 +localization 0 +of 0 +Na 1 +( 0 +v 0 +) 0 +1 0 +. 0 +6 0 +channels 0 +in 0 +the 0 +nodes 0 +of 0 +Ranvier 0 +were 0 +unchanged 0 +. 0 + +beta2 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +displayed 0 +increased 0 +susceptibility 0 +to 0 +seizures 3 +, 0 +as 0 +indicated 0 +by 0 +reduced 0 +latency 0 +and 0 +threshold 0 +for 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +, 0 +but 0 +seemed 0 +normal 0 +in 0 +other 0 +neurological 0 +tests 0 +. 0 + +0ur 0 +observations 0 +show 0 +that 0 +beta2 0 +- 0 +subunits 0 +play 0 +an 0 +important 0 +role 0 +in 0 +the 0 +regulation 0 +of 0 +sodium 1 +channel 0 +density 0 +and 0 +function 0 +in 0 +neurons 0 +in 0 +vivo 0 +and 0 +are 0 +required 0 +for 0 +normal 0 +action 0 +potential 0 +generation 0 +and 0 +control 0 +of 0 +excitability 0 +. 0 + +Acute 3 +liver 4 +failure 4 +with 0 +concurrent 0 +bupropion 1 +and 0 +carbimazole 1 +therapy 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +fatal 0 +liver 3 +failure 4 +possibly 0 +associated 0 +with 0 +concurrent 0 +use 0 +of 0 +bupropion 1 +and 0 +carbimazole 1 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +41 0 +- 0 +year 0 +- 0 +old 0 +Chinese 0 +man 0 +with 0 +a 0 +history 0 +of 0 +hyperthyroidism 3 +had 0 +been 0 +treated 0 +with 0 +carbimazole 1 +and 0 +propranolol 1 +for 0 +the 0 +past 0 +5 0 +years 0 +. 0 + +He 0 +received 0 +a 0 +10 0 +- 0 +day 0 +course 0 +of 0 +bupropion 1 +as 0 +an 0 +aid 0 +for 0 +smoking 0 +cessation 0 +10 0 +weeks 0 +prior 0 +to 0 +presentation 0 +. 0 + +He 0 +developed 0 +acute 3 +liver 4 +failure 4 +with 0 +rapid 0 +deterioration 0 +of 0 +renal 0 +function 0 +. 0 + +Liver 0 +biopsy 0 +showed 0 +evidence 0 +of 0 +nonspecific 0 +drug 3 +- 4 +induced 4 +acute 4 +liver 4 +injury 4 +. 0 + +His 0 +condition 0 +was 0 +further 0 +complicated 0 +by 0 +sepsis 3 +and 0 +coagulopathy 3 +. 0 + +Death 0 +resulted 0 +19 0 +days 0 +after 0 +the 0 +onset 0 +of 0 +symptoms 0 +. 0 + +The 0 +likelihood 0 +that 0 +bupropion 1 +induced 0 +hepatotoxicity 3 +in 0 +our 0 +patient 0 +was 0 +possible 0 +, 0 +based 0 +on 0 +the 0 +Naranjo 0 +probability 0 +scale 0 +. 0 + +DISCUSSI0N 0 +: 0 +Although 0 +there 0 +is 0 +increasing 0 +evidence 0 +of 0 +hepatotoxicity 3 +induced 0 +by 0 +bupropion 1 +, 0 +this 0 +is 0 +the 0 +first 0 +case 0 +of 0 +fatality 0 +that 0 +could 0 +have 0 +resulted 0 +from 0 +acute 3 +liver 4 +failure 4 +in 0 +a 0 +patient 0 +receiving 0 +bupropion 1 +while 0 +on 0 +concomitant 0 +treatment 0 +with 0 +carbimazole 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +Clinicians 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +possibility 0 +of 0 +acute 3 +liver 4 +insult 4 +induced 0 +by 0 +bupropion 1 +given 0 +concurrently 0 +with 0 +other 0 +hepatotoxic 3 +drugs 0 +. 0 + +Pyeloureteral 0 +filling 0 +defects 0 +associated 0 +with 0 +systemic 0 +anticoagulation 0 +: 0 +a 0 +case 0 +report 0 +. 0 + +The 0 +etiology 0 +of 0 +pyeloureteritis 3 +cystica 4 +has 0 +long 0 +been 0 +attributed 0 +to 0 +chronic 0 +infection 3 +and 0 +inflammation 3 +. 0 + +A 0 +case 0 +is 0 +presented 0 +that 0 +is 0 +unique 0 +in 0 +that 0 +the 0 +acute 0 +onset 0 +and 0 +the 0 +rapid 0 +resolution 0 +of 0 +pyeloureteral 0 +filling 0 +defects 0 +in 0 +this 0 +patient 0 +were 0 +documented 0 +by 0 +radiography 0 +. 0 + +There 0 +is 0 +no 0 +evidence 0 +of 0 +antecedent 0 +or 0 +concurrent 0 +infection 3 +in 0 +this 0 +patient 0 +. 0 + +The 0 +disease 0 +occurred 0 +subsequent 0 +to 0 +the 0 +initiation 0 +of 0 +heparin 1 +therapy 0 +for 0 +suspected 0 +pelvic 0 +thrombophlebitis 3 +and 0 +cleared 0 +rapidly 0 +subsequent 0 +to 0 +its 0 +discontinuation 0 +. 0 + +The 0 +rate 0 +of 0 +resolution 0 +of 0 +the 0 +radiographic 0 +findings 0 +may 0 +be 0 +helpful 0 +in 0 +distinguishing 0 +between 0 +true 0 +pyeloureteritis 3 +cystica 4 +and 0 +submucosal 3 +hemorrhage 4 +. 0 + +Nephrotoxic 3 +effects 0 +in 0 +high 0 +- 0 +risk 0 +patients 0 +undergoing 0 +angiography 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +use 0 +of 0 +iodinated 0 +contrast 0 +medium 0 +can 0 +result 0 +in 0 +nephropathy 3 +. 0 + +Whether 0 +iso 0 +- 0 +osmolar 0 +contrast 0 +medium 0 +is 0 +less 0 +nephrotoxic 3 +than 0 +low 0 +- 0 +osmolar 0 +contrast 0 +medium 0 +in 0 +high 0 +- 0 +risk 0 +patients 0 +is 0 +uncertain 0 +. 0 + +METH0DS 0 +: 0 +We 0 +conducted 0 +a 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +prospective 0 +, 0 +multicenter 0 +study 0 +comparing 0 +the 0 +nephrotoxic 3 +effects 0 +of 0 +an 0 +iso 0 +- 0 +osmolar 0 +, 0 +dimeric 0 +, 0 +nonionic 0 +contrast 0 +medium 0 +, 0 +iodixanol 1 +, 0 +with 0 +those 0 +of 0 +a 0 +low 0 +- 0 +osmolar 0 +, 0 +nonionic 0 +, 0 +monomeric 0 +contrast 0 +medium 0 +, 0 +iohexol 1 +. 0 + +The 0 +study 0 +involved 0 +129 0 +patients 0 +with 0 +diabetes 3 +with 0 +serum 0 +creatinine 1 +concentrations 0 +of 0 +1 0 +. 0 +5 0 +to 0 +3 0 +. 0 +5 0 +mg 0 +per 0 +deciliter 0 +who 0 +underwent 0 +coronary 0 +or 0 +aortofemoral 0 +angiography 0 +. 0 + +The 0 +primary 0 +end 0 +point 0 +was 0 +the 0 +peak 0 +increase 0 +from 0 +base 0 +line 0 +in 0 +the 0 +creatinine 1 +concentration 0 +during 0 +the 0 +three 0 +days 0 +after 0 +angiography 0 +. 0 + +0ther 0 +end 0 +points 0 +were 0 +an 0 +increase 0 +in 0 +the 0 +creatinine 1 +concentration 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +per 0 +deciliter 0 +or 0 +more 0 +, 0 +an 0 +increase 0 +of 0 +1 0 +. 0 +0 0 +mg 0 +per 0 +deciliter 0 +or 0 +more 0 +, 0 +and 0 +a 0 +change 0 +in 0 +the 0 +creatinine 1 +concentration 0 +from 0 +day 0 +0 0 +to 0 +day 0 +7 0 +. 0 + +RESULTS 0 +: 0 +The 0 +creatinine 1 +concentration 0 +increased 0 +significantly 0 +less 0 +in 0 +patients 0 +who 0 +received 0 +iodixanol 1 +. 0 + +From 0 +day 0 +0 0 +to 0 +day 0 +3 0 +, 0 +the 0 +mean 0 +peak 0 +increase 0 +in 0 +creatinine 1 +was 0 +0 0 +. 0 +13 0 +mg 0 +per 0 +deciliter 0 +in 0 +the 0 +iodixanol 1 +group 0 +and 0 +0 0 +. 0 +55 0 +mg 0 +per 0 +deciliter 0 +in 0 +the 0 +iohexol 1 +group 0 +( 0 +P 0 += 0 +0 0 +. 0 +001 0 +; 0 +the 0 +increase 0 +with 0 +iodixanol 1 +minus 0 +the 0 +increase 0 +with 0 +iohexol 1 +, 0 +- 0 +0 0 +. 0 +42 0 +mg 0 +per 0 +deciliter 0 +[ 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +- 0 +0 0 +. 0 +73 0 +to 0 +- 0 +0 0 +. 0 +22 0 +] 0 +) 0 +. 0 + +Two 0 +of 0 +the 0 +64 0 +patients 0 +in 0 +the 0 +iodixanol 1 +group 0 +( 0 +3 0 +percent 0 +) 0 +had 0 +an 0 +increase 0 +in 0 +the 0 +creatinine 1 +concentration 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +per 0 +deciliter 0 +or 0 +more 0 +, 0 +as 0 +compared 0 +with 0 +17 0 +of 0 +the 0 +65 0 +patients 0 +in 0 +the 0 +iohexol 1 +group 0 +( 0 +26 0 +percent 0 +) 0 +( 0 +P 0 += 0 +0 0 +. 0 +002 0 +; 0 +odds 0 +ratio 0 +for 0 +such 0 +an 0 +increase 0 +in 0 +the 0 +iodixanol 1 +group 0 +, 0 +0 0 +. 0 +09 0 +[ 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +0 0 +. 0 +02 0 +to 0 +0 0 +. 0 +41 0 +] 0 +) 0 +. 0 + +No 0 +patient 0 +receiving 0 +iodixanol 1 +had 0 +an 0 +increase 0 +of 0 +1 0 +. 0 +0 0 +mg 0 +per 0 +deciliter 0 +or 0 +more 0 +, 0 +but 0 +10 0 +patients 0 +in 0 +the 0 +iohexol 1 +group 0 +( 0 +15 0 +percent 0 +) 0 +did 0 +. 0 + +The 0 +mean 0 +change 0 +in 0 +the 0 +creatinine 1 +concentration 0 +from 0 +day 0 +0 0 +to 0 +day 0 +7 0 +was 0 +0 0 +. 0 +07 0 +mg 0 +per 0 +deciliter 0 +in 0 +the 0 +iodixanol 1 +group 0 +and 0 +0 0 +. 0 +24 0 +mg 0 +per 0 +deciliter 0 +in 0 +the 0 +iohexol 1 +group 0 +( 0 +P 0 += 0 +0 0 +. 0 +003 0 +; 0 +value 0 +in 0 +the 0 +iodixanol 1 +group 0 +minus 0 +the 0 +value 0 +in 0 +the 0 +iohexol 1 +group 0 +, 0 +- 0 +0 0 +. 0 +17 0 +mg 0 +per 0 +deciliter 0 +[ 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +- 0 +0 0 +. 0 +34 0 +to 0 +- 0 +0 0 +. 0 +07 0 +] 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Nephropathy 3 +induced 0 +by 0 +contrast 0 +medium 0 +may 0 +be 0 +less 0 +likely 0 +to 0 +develop 0 +in 0 +high 0 +- 0 +risk 0 +patients 0 +when 0 +iodixanol 1 +is 0 +used 0 +rather 0 +than 0 +a 0 +low 0 +- 0 +osmolar 0 +, 0 +nonionic 0 +contrast 0 +medium 0 +. 0 + +Protective 0 +effect 0 +of 0 +edaravone 1 +against 0 +streptomycin 1 +- 0 +induced 0 +vestibulotoxicity 3 +in 0 +the 0 +guinea 0 +pig 0 +. 0 + +This 0 +study 0 +investigated 0 +alleviation 0 +of 0 +streptomycin 1 +- 0 +induced 0 +vestibulotoxicity 3 +by 0 +edaravone 1 +in 0 +guinea 0 +pigs 0 +. 0 + +Edaravone 1 +, 0 +a 0 +free 0 +radical 0 +scavenger 0 +, 0 +has 0 +potent 0 +free 0 +radical 0 +quenching 0 +action 0 +and 0 +is 0 +used 0 +in 0 +clinical 0 +practice 0 +to 0 +treat 0 +cerebral 3 +infarction 4 +. 0 + +Streptomycin 1 +was 0 +administered 0 +to 0 +the 0 +inner 0 +ear 0 +by 0 +osmotic 0 +pump 0 +for 0 +24 0 +h 0 +, 0 +and 0 +edaravone 1 +( 0 +n 0 += 0 +8 0 +) 0 +or 0 +saline 0 +( 0 +n 0 += 0 +6 0 +) 0 +was 0 +intraperitoneally 0 +injected 0 +once 0 +a 0 +day 0 +for 0 +7 0 +days 0 +. 0 + +We 0 +observed 0 +horizontal 0 +vestibulo 0 +- 0 +ocular 0 +reflex 0 +as 0 +a 0 +marker 0 +of 0 +postoperative 0 +vestibular 0 +function 0 +. 0 + +Animals 0 +injected 0 +with 0 +saline 0 +showed 0 +statistically 0 +smaller 0 +gains 0 +than 0 +those 0 +injected 0 +with 0 +edaravone 1 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +edaravone 1 +suppresses 0 +streptomycin 1 +- 0 +induced 0 +vestibulotoxicity 3 +. 0 + +Levodopa 1 +- 0 +induced 0 +oromandibular 0 +dystonia 3 +in 0 +progressive 3 +supranuclear 4 +palsy 4 +. 0 + +Levodopa 1 +- 0 +induced 0 +dyskinesias 3 +have 0 +been 0 +reported 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +and 0 +multiple 3 +system 4 +atrophy 4 +. 0 + +Cranial 0 +dystonias 3 +are 0 +rare 0 +in 0 +patients 0 +with 0 +progressive 3 +supranuclear 4 +palsy 4 +( 0 +PSP 3 +) 0 +. 0 + +In 0 +this 0 +report 0 +we 0 +describe 0 +an 0 +unusual 0 +case 0 +of 0 +reversible 0 +levodopa 1 +- 0 +induced 0 +0romandibular 3 +dystonia 4 +( 0 +0MD 3 +) 0 +in 0 +a 0 +PSP 3 +patient 0 +to 0 +highlight 0 +the 0 +importance 0 +of 0 +recognizing 0 +this 0 +drug 0 +related 0 +complication 0 +in 0 +the 0 +management 0 +of 0 +PSP 3 +, 0 +and 0 +discuss 0 +the 0 +possible 0 +underlying 0 +pathophysiology 0 +. 0 + +Case 0 +report 0 +: 0 +Dexatrim 1 +( 0 +Phenylpropanolamine 1 +) 0 +as 0 +a 0 +cause 0 +of 0 +myocardial 3 +infarction 4 +. 0 + +Phenylpropanolamine 1 +( 0 +PPA 1 +) 0 +is 0 +a 0 +sympathetic 0 +amine 1 +used 0 +in 0 +over 0 +- 0 +the 0 +- 0 +counter 0 +cold 0 +remedies 0 +and 0 +weight 0 +- 0 +control 0 +preparations 0 +worldwide 0 +. 0 + +Its 0 +use 0 +has 0 +been 0 +associated 0 +with 0 +hypertensive 3 +episodes 0 +and 0 +hemorrhagic 3 +strokes 4 +in 0 +younger 0 +women 0 +. 0 + +Several 0 +reports 0 +have 0 +linked 0 +the 0 +abuse 0 +of 0 +PPA 1 +with 0 +myocardial 3 +injury 4 +, 0 +especially 0 +when 0 +overdose 3 +is 0 +involved 0 +. 0 + +We 0 +report 0 +here 0 +the 0 +first 0 +case 0 +of 0 +Dexatrim 1 +( 0 +PPA 1 +) 0 +- 0 +induced 0 +myocardial 3 +injury 4 +in 0 +a 0 +young 0 +woman 0 +who 0 +was 0 +using 0 +it 0 +at 0 +recommended 0 +doses 0 +for 0 +weight 0 +control 0 +. 0 + +In 0 +addition 0 +, 0 +we 0 +review 0 +the 0 +7 0 +other 0 +cases 0 +of 0 +PPA 1 +related 0 +myocardial 3 +injury 4 +that 0 +have 0 +been 0 +reported 0 +so 0 +far 0 +. 0 + +Physicians 0 +and 0 +patients 0 +should 0 +be 0 +alert 0 +to 0 +the 0 +potential 0 +cardiac 0 +risk 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +PPA 1 +, 0 +even 0 +at 0 +doses 0 +generally 0 +considered 0 +to 0 +be 0 +safe 0 +. 0 + +Differential 0 +diagnosis 0 +of 0 +high 0 +serum 0 +creatine 1 +kinase 0 +levels 0 +in 0 +systemic 3 +lupus 4 +erythematosus 4 +. 0 + +We 0 +report 0 +the 0 +clinical 0 +and 0 +bioptic 0 +findings 0 +for 0 +a 0 +57 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +severe 0 +chloroquine 1 +- 0 +induced 0 +myopathy 3 +. 0 + +Since 0 +1989 0 +, 0 +she 0 +had 0 +been 0 +suffering 0 +from 0 +systemic 3 +lupus 4 +erythematosus 4 +( 0 +SLE 3 +) 0 +with 0 +renal 3 +involvement 4 +and 0 +undergone 0 +periods 0 +of 0 +treatment 0 +with 0 +azathioprine 1 +and 0 +cyclophosphamide 1 +. 0 + +Additional 0 +therapy 0 +with 0 +chloroquine 1 +( 0 +CQ 1 +) 0 +was 0 +started 0 +because 0 +of 0 +arthralgia 3 +. 0 + +At 0 +the 0 +same 0 +time 0 +, 0 +slightly 0 +increased 0 +creatine 1 +kinase 0 +( 0 +CK 0 +) 0 +levels 0 +were 0 +noted 0 +. 0 + +Myositis 3 +was 0 +suspected 0 +, 0 +and 0 +the 0 +patient 0 +was 0 +treated 0 +with 0 +steroids 1 +. 0 + +The 0 +CK 0 +increase 0 +persisted 0 +, 0 +however 0 +, 0 +and 0 +she 0 +developed 0 +progressive 0 +muscular 3 +weakness 4 +and 0 +muscular 3 +atrophy 4 +. 0 + +Routine 0 +controls 0 +revealed 0 +markedly 0 +elevated 0 +CK 0 +levels 0 +of 0 +1 0 +, 0 +700 0 +U 0 +/ 0 +l 0 +. 0 + +The 0 +neurological 0 +and 0 +electrophysiological 0 +findings 0 +were 0 +not 0 +typical 0 +of 0 +myositis 3 +. 0 + +Thus 0 +, 0 +muscle 0 +biopsy 0 +of 0 +the 0 +deltoid 0 +muscle 0 +was 0 +performed 0 +in 0 +order 0 +to 0 +exclude 0 +polymyositis 3 +or 0 +toxic 0 +myopathy 3 +. 0 + +As 0 +it 0 +revealed 0 +chloroquine 1 +- 0 +induced 0 +myopathy 3 +, 0 +medication 0 +was 0 +stopped 0 +. 0 + +Discriminating 0 +between 0 +primary 0 +SLE 3 +- 0 +induced 0 +affection 3 +of 4 +the 4 +musculoskeletal 4 +system 4 +and 0 +drug 0 +- 0 +induced 0 +side 0 +effects 0 +is 0 +important 0 +for 0 +appropriate 0 +treatment 0 +of 0 +SLE 3 +patients 0 +. 0 + +Seizure 3 +associated 0 +with 0 +sleep 3 +deprivation 4 +and 0 +sustained 0 +- 0 +release 0 +bupropion 1 +. 0 + +This 0 +case 0 +report 0 +describes 0 +a 0 +generalized 0 +seizure 3 +associated 0 +with 0 +sustained 0 +- 0 +release 0 +bupropion 1 +use 0 +and 0 +sleep 3 +deprivation 4 +. 0 + +The 0 +subject 0 +, 0 +a 0 +31 0 +- 0 +year 0 +- 0 +old 0 +female 0 +smoker 0 +, 0 +was 0 +participating 0 +in 0 +a 0 +clinical 0 +trial 0 +evaluating 0 +an 0 +investigational 0 +medication 0 +for 0 +smoking 0 +cessation 0 +that 0 +used 0 +sustained 0 +- 0 +release 0 +bupropion 1 +as 0 +an 0 +active 0 +control 0 +. 0 + +After 0 +5 0 +weeks 0 +of 0 +bupropion 1 +use 0 +, 0 +the 0 +subject 0 +experienced 0 +a 0 +generalized 0 +tonic 0 +clonic 0 +seizure 3 +after 0 +staying 0 +up 0 +nearly 0 +all 0 +night 0 +packing 0 +and 0 +moving 0 +to 0 +a 0 +new 0 +residence 0 +. 0 + +The 0 +patient 0 +had 0 +no 0 +other 0 +risk 0 +factors 0 +for 0 +seizures 3 +. 0 + +We 0 +suggest 0 +that 0 +sleep 3 +deprivation 4 +may 0 +add 0 +to 0 +the 0 +risk 0 +of 0 +bupropion 1 +- 0 +associated 0 +seizures 3 +. 0 + +Postoperative 3 +myalgia 4 +after 0 +succinylcholine 1 +: 0 +no 0 +evidence 0 +for 0 +an 0 +inflammatory 0 +origin 0 +. 0 + +A 0 +common 0 +side 0 +effect 0 +associated 0 +with 0 +succinylcholine 1 +is 0 +postoperative 3 +myalgia 4 +. 0 + +The 0 +pathogenesis 0 +of 0 +this 0 +myalgia 3 +is 0 +still 0 +unclear 0 +; 0 +inflammation 3 +has 0 +been 0 +suggested 0 +but 0 +without 0 +convincing 0 +evidence 0 +. 0 + +We 0 +designed 0 +the 0 +present 0 +study 0 +to 0 +investigate 0 +whether 0 +an 0 +inflammatory 0 +reaction 0 +contributes 0 +to 0 +this 0 +myalgia 3 +. 0 + +The 0 +incidence 0 +and 0 +severity 0 +of 0 +succinylcholine 1 +- 0 +associated 0 +myalgia 3 +was 0 +determined 0 +in 0 +64 0 +patients 0 +pretreated 0 +with 0 +saline 0 +or 0 +dexamethasone 1 +before 0 +succinylcholine 1 +( 0 +n 0 += 0 +32 0 +for 0 +each 0 +) 0 +. 0 + +Incidence 0 +and 0 +severity 0 +of 0 +myalgia 3 +did 0 +not 0 +differ 0 +significantly 0 +between 0 +the 0 +two 0 +groups 0 +: 0 +15 0 +patients 0 +in 0 +the 0 +dexamethasone 1 +group 0 +complained 0 +of 0 +myalgia 3 +compared 0 +with 0 +18 0 +patients 0 +in 0 +the 0 +saline 0 +group 0 +, 0 +and 0 +severe 0 +myalgia 3 +was 0 +reported 0 +by 0 +five 0 +patients 0 +and 0 +three 0 +patients 0 +, 0 +respectively 0 +( 0 +not 0 +significant 0 +) 0 +. 0 + +At 0 +48 0 +h 0 +after 0 +surgery 0 +, 0 +12 0 +patients 0 +in 0 +both 0 +groups 0 +still 0 +suffered 0 +from 0 +myalgia 3 +( 0 +not 0 +significant 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +interleukin 0 +- 0 +6 0 +( 0 +IL 0 +- 0 +6 0 +) 0 +as 0 +an 0 +early 0 +marker 0 +of 0 +inflammation 3 +was 0 +assessed 0 +in 0 +a 0 +subgroup 0 +of 0 +10 0 +patients 0 +pretreated 0 +with 0 +saline 0 +. 0 + +We 0 +found 0 +an 0 +increase 0 +of 0 +IL 0 +- 0 +6 0 +for 0 +only 0 +three 0 +patients 0 +, 0 +but 0 +only 0 +one 0 +patient 0 +reported 0 +myalgia 3 +; 0 +no 0 +relationship 0 +between 0 +myalgia 3 +and 0 +the 0 +increase 0 +of 0 +IL 0 +- 0 +6 0 +was 0 +found 0 +. 0 + +In 0 +conclusion 0 +, 0 +there 0 +is 0 +no 0 +evidence 0 +for 0 +an 0 +inflammatory 0 +origin 0 +of 0 +succinylcholine 1 +- 0 +associated 0 +myalgia 3 +. 0 + +IMPLICATI0NS 0 +: 0 +Administration 0 +of 0 +dexamethasone 1 +before 0 +succinylcholine 1 +was 0 +not 0 +effective 0 +in 0 +decreasing 0 +the 0 +incidence 0 +or 0 +the 0 +severity 0 +of 0 +succinylcholine 1 +- 0 +induced 0 +postoperative 3 +myalgia 4 +. 0 + +Furthermore 0 +, 0 +there 0 +was 0 +no 0 +significant 0 +relationship 0 +between 0 +postoperative 3 +myalgia 4 +and 0 +time 0 +course 0 +of 0 +interleukin 0 +- 0 +6 0 +concentrations 0 +, 0 +a 0 +marker 0 +of 0 +inflammation 3 +. 0 + +Pretreatment 0 +with 0 +dexamethasone 1 +is 0 +not 0 +justified 0 +to 0 +prevent 0 +postoperative 3 +myalgia 4 +after 0 +succinylcholine 1 +. 0 + +Effect 0 +of 0 +lindane 1 +on 0 +hepatic 0 +and 0 +brain 0 +cytochrome 0 +P450s 0 +and 0 +influence 0 +of 0 +P450 0 +modulation 0 +in 0 +lindane 1 +induced 0 +neurotoxicity 3 +. 0 + +0ral 0 +administration 0 +of 0 +lindane 1 +( 0 +2 0 +. 0 +5 0 +, 0 +5 0 +, 0 +10 0 +and 0 +15 0 +mg 0 +/ 0 +kg 0 +, 0 +body 0 +weight 0 +) 0 +for 0 +5 0 +days 0 +was 0 +found 0 +to 0 +produce 0 +a 0 +dose 0 +- 0 +dependent 0 +increase 0 +in 0 +the 0 +activity 0 +of 0 +P450 0 +dependent 0 +7 0 +- 0 +ethoxyresorufin 0 +- 0 +0 0 +- 0 +deethylase 0 +( 0 +ER0D 0 +) 0 +, 0 +7 0 +- 0 +pentoxyresorufin 0 +- 0 +0 0 +- 0 +dealkylase 0 +( 0 +PR0D 0 +) 0 +and 0 +N 1 +- 2 +nitrosodimethylamine 2 +demethylase 0 +( 0 +NDMA 1 +- 0 +d 0 +) 0 +in 0 +rat 0 +brain 0 +and 0 +liver 0 +. 0 + +A 0 +significant 0 +increase 0 +in 0 +the 0 +hepatic 0 +and 0 +brain 0 +P450 0 +monooxygenases 0 +was 0 +also 0 +observed 0 +when 0 +the 0 +duration 0 +of 0 +exposure 0 +of 0 +low 0 +dose 0 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +of 0 +lindane 1 +was 0 +increased 0 +from 0 +5 0 +days 0 +to 0 +15 0 +or 0 +21 0 +days 0 +. 0 + +As 0 +observed 0 +with 0 +different 0 +doses 0 +, 0 +the 0 +magnitude 0 +of 0 +induction 0 +in 0 +the 0 +activity 0 +of 0 +P450 0 +monooxygenases 0 +was 0 +several 0 +fold 0 +higher 0 +in 0 +liver 0 +microsomes 0 +when 0 +compared 0 +with 0 +the 0 +brain 0 +. 0 + +Western 0 +blotting 0 +studies 0 +have 0 +indicated 0 +that 0 +the 0 +increase 0 +in 0 +the 0 +P450 0 +enzymes 0 +could 0 +be 0 +due 0 +to 0 +the 0 +increase 0 +in 0 +the 0 +expression 0 +of 0 +P450 0 +1A1 0 +/ 0 +1A2 0 +, 0 +2B1 0 +/ 0 +2B2 0 +and 0 +2E1 0 +isoenzymes 0 +. 0 + +In 0 +vitro 0 +studies 0 +using 0 +organic 0 +inhibitors 0 +specific 0 +for 0 +individual 0 +P450 0 +isoenzymes 0 +and 0 +antibody 0 +inhibition 0 +experiments 0 +have 0 +further 0 +demonstrated 0 +that 0 +the 0 +increase 0 +in 0 +the 0 +activity 0 +of 0 +PR0D 0 +, 0 +ER0D 0 +and 0 +NDMA 1 +- 0 +d 0 +are 0 +due 0 +to 0 +the 0 +increase 0 +in 0 +the 0 +levels 0 +of 0 +P450 0 +2B1 0 +/ 0 +2B2 0 +, 0 +1A1 0 +/ 0 +1A2 0 +and 0 +2E1 0 +isoenzymes 0 +, 0 +respectively 0 +. 0 + +Induction 0 +studies 0 +have 0 +further 0 +shown 0 +that 0 +while 0 +pretreatment 0 +of 0 +3 1 +- 2 +methylcholanthrene 2 +( 0 +MC 1 +) 0 +, 0 +an 0 +inducer 0 +of 0 +P4501A1 0 +/ 0 +1A2 0 +, 0 +did 0 +not 0 +produce 0 +any 0 +significant 0 +effect 0 +in 0 +the 0 +incidence 0 +of 0 +lindane 1 +induced 0 +convulsions 3 +, 0 +pretreatment 0 +with 0 +phenobarbital 1 +( 0 +PB 0 +) 0 +, 0 +an 0 +inducer 0 +of 0 +P450 0 +2B1 0 +/ 0 +2B2 0 +or 0 +ethanol 1 +, 0 +an 0 +inducer 0 +of 0 +P450 0 +2E1 0 +catalysed 0 +reactions 0 +, 0 +significantly 0 +increased 0 +the 0 +incidence 0 +of 0 +lindane 1 +induced 0 +convulsions 3 +. 0 + +Similarly 0 +, 0 +when 0 +the 0 +P450 0 +- 0 +mediated 0 +metabolism 0 +of 0 +lindane 1 +was 0 +blocked 0 +by 0 +cobalt 1 +chloride 2 +incidence 0 +of 0 +convulsions 3 +was 0 +increased 0 +in 0 +animals 0 +treated 0 +with 0 +lindane 1 +indicating 0 +that 0 +lindane 1 +per 0 +se 0 +or 0 +its 0 +metabolites 0 +formed 0 +by 0 +PB 0 +or 0 +ethanol 1 +inducible 0 +P450 0 +isoenzymes 0 +are 0 +involved 0 +in 0 +its 0 +neurobehavioral 0 +toxicity 3 +. 0 + +Absolute 0 +and 0 +attributable 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +in 0 +women 0 +on 0 +combined 0 +cyproterone 1 +acetate 2 +and 0 +ethinylestradiol 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +achieve 0 +absolute 0 +risk 0 +estimates 0 +of 0 +venous 3 +thromboembolism 4 +( 0 +VTE 3 +) 0 +among 0 +women 0 +on 0 +cyproterone 1 +acetate 2 +plus 0 +ethinylestradiol 1 +( 0 +CPA 1 +/ 0 +EE 1 +) 0 +, 0 +and 0 +among 0 +women 0 +on 0 +combined 1 +oral 2 +contraceptives 2 +( 0 +C0Cs 1 +) 0 +. 0 + +METH0DS 0 +: 0 +From 0 +the 0 +Danish 0 +National 0 +Register 0 +of 0 +Patients 0 +( 0 +NRP 0 +) 0 +, 0 +1996 0 +to 0 +1998 0 +, 0 +the 0 +records 0 +of 0 +1 0 +. 0 +1 0 +million 0 +Danish 0 +women 0 +, 0 +ages 0 +15 0 +to 0 +44 0 +years 0 +, 0 +were 0 +searched 0 +for 0 +evidence 0 +of 0 +VTE 3 +. 0 + +C0C 1 +use 0 +was 0 +ascertained 0 +through 0 +mailed 0 +questionnaires 0 +. 0 + +Sales 0 +statistics 0 +of 0 +C0Cs 1 +and 0 +CPA 1 +/ 0 +EE 1 +were 0 +provided 0 +through 0 +Danish 0 +Drug 0 +Statistics 0 +. 0 + +RESULTS 0 +: 0 +During 0 +the 0 +time 0 +frame 0 +of 0 +the 0 +study 0 +, 0 +330 0 +women 0 +were 0 +found 0 +to 0 +have 0 +had 0 +VTE 3 +while 0 +on 0 +C0Cs 1 +. 0 + +0f 0 +these 0 +women 0 +, 0 +67 0 +were 0 +on 0 +levonorgestrel 1 +- 0 +containing 0 +C0Cs 1 +. 0 + +Eleven 0 +were 0 +on 0 +CPA 1 +/ 0 +EE 1 +. 0 + +The 0 +corresponding 0 +absolute 0 +risk 0 +of 0 +VTE 3 +was 0 +3 0 +. 0 +4 0 +( 0 +range 0 +, 0 +3 0 +. 0 +1 0 +- 0 +3 0 +. 0 +8 0 +) 0 +per 0 +10 0 +000 0 +women 0 +years 0 +among 0 +the 0 +women 0 +on 0 +C0Cs 1 +, 0 +4 0 +. 0 +2 0 +( 0 +range 0 +, 0 +3 0 +. 0 +2 0 +- 0 +5 0 +. 0 +2 0 +) 0 +per 0 +10 0 +000 0 +women 0 +years 0 +among 0 +women 0 +on 0 +levonorgestrel 1 +- 0 +containing 0 +C0Cs 1 +, 0 +and 0 +3 0 +. 0 +1 0 +( 0 +range 0 +, 0 +1 0 +. 0 +3 0 +- 0 +4 0 +. 0 +9 0 +) 0 +per 0 +10 0 +000 0 +women 0 +years 0 +among 0 +the 0 +women 0 +on 0 +CPA 1 +/ 0 +EE 1 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +results 0 +suggest 0 +the 0 +absolute 0 +risk 0 +of 0 +VTE 3 +among 0 +Danish 0 +women 0 +on 0 +C0Cs 1 +is 0 +similar 0 +to 0 +that 0 +among 0 +women 0 +taking 0 +CPA 1 +/ 0 +EE 1 +. 0 + +Comparison 0 +of 0 +developmental 0 +toxicology 0 +of 0 +aspirin 1 +( 0 +acetylsalicylic 1 +acid 2 +) 0 +in 0 +rats 0 +using 0 +selected 0 +dosing 0 +paradigms 0 +. 0 + +BACKGR0UND 0 +: 0 +Analysis 0 +of 0 +the 0 +literature 0 +for 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +suggests 0 +that 0 +a 0 +low 0 +incidence 0 +of 0 +developmental 3 +anomalies 4 +occurs 0 +in 0 +rats 0 +given 0 +NSAIDs 0 +on 0 +specific 0 +days 0 +during 0 +organogenesis 0 +. 0 + +Aspirin 1 +( 0 +acetylsalicylic 1 +acid 2 +[ 0 +ASA 1 +] 0 +) 0 +, 0 +an 0 +irreversible 0 +cyclooxygenase 0 +1 0 +and 0 +2 0 +inhibitor 0 +, 0 +induces 0 +developmental 3 +anomalies 4 +when 0 +administered 0 +to 0 +Wistar 0 +rats 0 +on 0 +gestational 0 +day 0 +( 0 +GD 0 +) 0 +9 0 +, 0 +10 0 +, 0 +or 0 +11 0 +( 0 +Kimmel 0 +CA 0 +, 0 +Wilson 0 +JG 0 +, 0 +Schumacher 0 +HJ 0 +. 0 +Teratology 0 +4 0 +: 0 +15 0 +- 0 +24 0 +, 0 +1971 0 +) 0 +. 0 + +There 0 +are 0 +no 0 +published 0 +ASA 1 +studies 0 +using 0 +the 0 +multiple 0 +dosing 0 +paradigm 0 +of 0 +GDs 0 +6 0 +to 0 +17 0 +. 0 + +0bjectives 0 +of 0 +the 0 +current 0 +study 0 +were 0 +to 0 +compare 0 +results 0 +between 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +and 0 +Wistar 0 +strains 0 +when 0 +ASA 1 +is 0 +administered 0 +on 0 +GD 0 +9 0 +, 0 +10 0 +, 0 +or 0 +11 0 +; 0 +to 0 +compare 0 +the 0 +malformation 0 +patterns 0 +following 0 +single 0 +and 0 +multiple 0 +dosings 0 +during 0 +organogenesis 0 +in 0 +SD 0 +rats 0 +; 0 +and 0 +to 0 +test 0 +the 0 +hypothesis 0 +that 0 +maternal 0 +gastrointestinal 3 +toxicity 4 +confounds 0 +the 0 +detection 0 +of 0 +low 0 +incidence 0 +malformations 3 +with 0 +ASA 1 +when 0 +a 0 +multiple 0 +dosing 0 +paradigm 0 +is 0 +used 0 +. 0 + +METH0DS 0 +: 0 +ASA 1 +was 0 +administered 0 +as 0 +a 0 +single 0 +dose 0 +on 0 +GD 0 +9 0 +( 0 +0 0 +, 0 +250 0 +, 0 +500 0 +, 0 +or 0 +625 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +10 0 +( 0 +0 0 +, 0 +500 0 +, 0 +625 0 +, 0 +or 0 +750 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +or 0 +11 0 +( 0 +0 0 +, 0 +500 0 +, 0 +750 0 +, 0 +or 0 +1000 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +from 0 +GD 0 +6 0 +to 0 +GD 0 +17 0 +( 0 +0 0 +, 0 +50 0 +, 0 +125 0 +, 0 +or 0 +250 0 +mg 0 +/ 0 +kg 0 +a 0 +day 0 +) 0 +in 0 +the 0 +multiple 0 +dose 0 +study 0 +to 0 +SD 0 +rats 0 +. 0 + +Animals 0 +were 0 +killed 0 +on 0 +GD 0 +21 0 +, 0 +and 0 +fetuses 0 +were 0 +examined 0 +viscerally 0 +. 0 + +RESULTS 0 +: 0 +The 0 +literature 0 +evaluation 0 +suggested 0 +that 0 +NSAIDs 0 +induce 0 +ventricular 3 +septal 4 +defects 4 +( 0 +VSDs 3 +) 0 +and 0 +midline 3 +defects 4 +( 0 +MDs 3 +) 0 +in 0 +rats 0 +and 0 +diaphragmatic 3 +hernia 4 +( 0 +DH 3 +) 0 +, 0 +MDs 3 +, 0 +and 0 +VSDs 3 +in 0 +rabbits 0 +( 0 +Cook 0 +JC 0 +et 0 +al 0 +. 0 +, 0 +2003 0 +) 0 +; 0 +hence 0 +, 0 +the 0 +present 0 +study 0 +focused 0 +on 0 +these 0 +malformations 3 +, 0 +even 0 +though 0 +ASA 1 +induces 0 +several 0 +other 0 +low 0 +- 0 +incidence 0 +malformations 3 +. 0 + +In 0 +single 0 +dose 0 +studies 0 +, 0 +DH 3 +, 0 +MD 3 +, 0 +and 0 +VSD 3 +were 0 +induced 0 +on 0 +GDs 0 +9 0 +and 0 +10 0 +. 0 + +VSD 3 +also 0 +was 0 +noted 0 +following 0 +treatment 0 +on 0 +GD 0 +11 0 +. 0 + +In 0 +contrast 0 +, 0 +DH 3 +and 0 +MD 3 +were 0 +noted 0 +in 0 +the 0 +multiple 0 +dose 0 +study 0 +design 0 +only 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +, 0 +and 0 +VSD 3 +was 0 +noted 0 +across 0 +all 0 +dose 0 +groups 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +High 0 +concordance 0 +in 0 +major 0 +developmental 3 +anomalies 4 +between 0 +Wistar 0 +and 0 +SD 0 +rats 0 +were 0 +noted 0 +with 0 +the 0 +exception 0 +of 0 +VSD 3 +in 0 +the 0 +SD 0 +rats 0 +and 0 +hydrocephalus 3 +in 0 +the 0 +Wistar 0 +rats 0 +. 0 + +Variations 0 +and 0 +malformations 3 +were 0 +similar 0 +when 0 +ASA 1 +was 0 +administered 0 +as 0 +a 0 +single 0 +dose 0 +or 0 +during 0 +the 0 +period 0 +of 0 +organogenesis 0 +( 0 +GDs 0 +6 0 +to 0 +17 0 +) 0 +. 0 + +It 0 +was 0 +also 0 +evident 0 +that 0 +, 0 +by 0 +titrating 0 +the 0 +dose 0 +to 0 +achieve 0 +a 0 +maximum 0 +tolerated 0 +dose 0 +, 0 +malformations 3 +that 0 +normally 0 +occur 0 +at 0 +low 0 +incidence 0 +, 0 +as 0 +reported 0 +from 0 +previous 0 +single 0 +dose 0 +studies 0 +, 0 +could 0 +also 0 +be 0 +induced 0 +with 0 +ASA 1 +given 0 +at 0 +multiple 0 +doses 0 +. 0 + +Reversal 0 +of 0 +central 0 +benzodiazepine 1 +effects 0 +by 0 +flumazenil 1 +after 0 +intravenous 0 +conscious 0 +sedation 0 +with 0 +diazepam 1 +and 0 +opioids 0 +: 0 +report 0 +of 0 +a 0 +double 0 +- 0 +blind 0 +multicenter 0 +study 0 +. 0 + +The 0 +Flumazenil 1 +in 0 +Intravenous 0 +Conscious 0 +Sedation 0 +with 0 +Diazepam 1 +Multicenter 0 +Study 0 +Group 0 +II 0 +. 0 + +The 0 +efficacy 0 +and 0 +safety 0 +of 0 +a 0 +new 0 +benzodiazepine 1 +antagonist 0 +, 0 +flumazenil 1 +, 0 +were 0 +assessed 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +multicenter 0 +study 0 +. 0 + +Flumazenil 1 +( 0 +mean 0 +dose 0 +, 0 +0 0 +. 0 +76 0 +mg 0 +) 0 +or 0 +placebo 0 +( 0 +mean 0 +dose 0 +, 0 +8 0 +. 0 +9 0 +ml 0 +) 0 +was 0 +administered 0 +intravenously 0 +to 0 +130 0 +and 0 +67 0 +patients 0 +, 0 +respectively 0 +, 0 +who 0 +had 0 +been 0 +given 0 +diazepam 1 +in 0 +conjunction 0 +with 0 +an 0 +opioid 0 +( 0 +fentanyl 1 +, 0 +meperidine 1 +, 0 +or 0 +morphine 1 +) 0 +for 0 +the 0 +induction 0 +and 0 +maintenance 0 +of 0 +intravenous 0 +conscious 0 +sedation 0 +for 0 +diagnostic 0 +or 0 +therapeutic 0 +surgical 0 +procedures 0 +. 0 + +The 0 +group 0 +assessable 0 +for 0 +efficacy 0 +comprised 0 +122 0 +patients 0 +treated 0 +with 0 +flumazenil 1 +and 0 +64 0 +patients 0 +given 0 +placebo 0 +. 0 + +After 0 +5 0 +minutes 0 +, 0 +80 0 +/ 0 +115 0 +( 0 +70 0 +% 0 +) 0 +flumazenil 1 +- 0 +treated 0 +patients 0 +, 0 +compared 0 +with 0 +21 0 +/ 0 +63 0 +( 0 +33 0 +% 0 +) 0 +placebo 0 +- 0 +treated 0 +patients 0 +, 0 +were 0 +completely 0 +awake 0 +and 0 +alert 0 +, 0 +as 0 +indicated 0 +by 0 +a 0 +score 0 +of 0 +5 0 +on 0 +the 0 +0bserver 0 +' 0 +s 0 +Assessment 0 +of 0 +Alertness 0 +/ 0 +Sedation 0 +Scale 0 +. 0 + +Ninety 0 +- 0 +five 0 +percent 0 +of 0 +patients 0 +in 0 +each 0 +group 0 +who 0 +attained 0 +a 0 +score 0 +of 0 +5 0 +at 0 +the 0 +5 0 +- 0 +minute 0 +assessment 0 +showed 0 +no 0 +loss 0 +of 0 +alertness 0 +throughout 0 +the 0 +180 0 +- 0 +minute 0 +assessment 0 +period 0 +. 0 + +Flumazenil 1 +- 0 +treated 0 +patients 0 +also 0 +performed 0 +significantly 0 +better 0 +on 0 +the 0 +Finger 0 +- 0 +to 0 +- 0 +Nose 0 +Test 0 +and 0 +the 0 +recall 0 +of 0 +pictures 0 +shown 0 +at 0 +the 0 +5 0 +- 0 +minute 0 +assessment 0 +. 0 + +Flumazenil 1 +was 0 +well 0 +tolerated 0 +, 0 +with 0 +no 0 +serious 0 +adverse 0 +effects 0 +reported 0 +. 0 + +Thirty 0 +- 0 +nine 0 +( 0 +30 0 +% 0 +) 0 +of 0 +flumazenil 1 +- 0 +treated 0 +patients 0 +, 0 +compared 0 +with 0 +17 0 +( 0 +25 0 +% 0 +) 0 +of 0 +placebo 0 +- 0 +treated 0 +patients 0 +had 0 +one 0 +or 0 +more 0 +drug 0 +- 0 +related 0 +adverse 0 +experiences 0 +. 0 + +The 0 +most 0 +common 0 +adverse 0 +effects 0 +were 0 +nausea 3 +and 0 +vomiting 3 +in 0 +the 0 +flumazenil 1 +group 0 +and 0 +nausea 3 +and 0 +injection 0 +- 0 +site 0 +pain 3 +in 0 +the 0 +placebo 0 +group 0 +. 0 + +Flumazenil 1 +was 0 +found 0 +to 0 +promptly 0 +reverse 0 +sedation 0 +induced 0 +by 0 +diazepam 1 +in 0 +the 0 +presence 0 +of 0 +opioids 0 +. 0 + +Methylphenidate 1 +- 0 +induced 0 +obsessive 3 +- 4 +compulsive 4 +symptoms 4 +in 0 +an 0 +elderly 0 +man 0 +. 0 + +An 0 +82 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +treatment 3 +- 4 +resistant 4 +depression 4 +and 0 +early 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +was 0 +started 0 +on 0 +methylphenidate 1 +. 0 + +Significant 0 +obsessive 3 +- 4 +compulsive 4 +behavior 4 +ensued 0 +but 0 +diminished 0 +over 0 +several 0 +weeks 0 +when 0 +methylphenidate 1 +was 0 +replaced 0 +by 0 +fluvoxamine 1 +. 0 + +The 0 +patient 0 +had 0 +no 0 +prior 0 +psychiatric 3 +history 0 +, 0 +but 0 +he 0 +had 0 +a 0 +sister 0 +with 0 +obsessive 3 +- 4 +compulsive 4 +disorder 4 +. 0 + +It 0 +appears 0 +that 0 +methylphenidate 1 +precipitated 0 +the 0 +patient 0 +' 0 +s 0 +pathological 0 +behavior 0 +. 0 + +Ciprofloxacin 1 +- 0 +induced 0 +acute 0 +interstitial 3 +nephritis 4 +and 0 +autoimmune 3 +hemolytic 4 +anemia 4 +. 0 + +Ciprofloxacin 1 +has 0 +been 0 +associated 0 +with 0 +several 0 +side 0 +effects 0 +including 0 +interstitial 3 +nephritis 4 +and 0 +hemolytic 3 +anemia 4 +. 0 + +The 0 +combination 0 +of 0 +both 0 +side 0 +effects 0 +is 0 +extremely 0 +rare 0 +. 0 + +In 0 +this 0 +report 0 +, 0 +we 0 +describe 0 +a 0 +case 0 +of 0 +ciprofloxacin 1 +- 0 +induced 0 +interstitial 3 +nephritis 4 +and 0 +autoimmune 3 +hemolytic 4 +anemia 4 +. 0 + +Hemolytic 3 +anemia 4 +improved 0 +after 0 +stopping 0 +the 0 +drug 0 +and 0 +initiation 0 +of 0 +steroid 1 +therapy 0 +. 0 + +Unfortunately 0 +, 0 +acute 0 +interstitial 3 +nephritis 4 +was 0 +irreversible 0 +and 0 +the 0 +patient 0 +developed 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +. 0 + +Potential 0 +deleterious 0 +effect 0 +of 0 +furosemide 1 +in 0 +radiocontrast 0 +nephropathy 3 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +efficacy 0 +of 0 +furosemide 1 +in 0 +addition 0 +to 0 +intravenous 0 +fluids 0 +in 0 +the 0 +prevention 0 +of 0 +radiocontrast 0 +nephropathy 3 +. 0 + +18 0 +patients 0 +, 0 +referred 0 +to 0 +a 0 +radiocontrast 0 +study 0 +, 0 +considered 0 +at 0 +risk 0 +because 0 +of 0 +preexisting 0 +renal 3 +insufficiency 4 +, 0 +were 0 +enrolled 0 +in 0 +a 0 +prospective 0 +, 0 +randomized 0 +, 0 +controlled 0 +trial 0 +, 0 +performed 0 +at 0 +the 0 +secondary 0 +care 0 +center 0 +of 0 +a 0 +1 0 +, 0 +100 0 +- 0 +bed 0 +private 0 +university 0 +hospital 0 +. 0 + +In 0 +addition 0 +to 0 +fluids 0 +, 0 +the 0 +treatment 0 +group 0 +received 0 +furosemide 1 +( 0 +mean 0 +dose 0 +110 0 +mg 0 +) 0 +intravenously 0 +30 0 +min 0 +prior 0 +to 0 +the 0 +injection 0 +of 0 +contrast 0 +material 0 +. 0 + +The 0 +control 0 +group 0 +received 0 +fluids 0 +( 0 +mean 0 +3 0 +liters 0 +) 0 +. 0 + +Radiological 0 +studies 0 +were 0 +mostly 0 +angiographies 0 +performed 0 +with 0 +both 0 +ionic 0 +and 0 +non 0 +- 0 +ionic 0 +contrast 0 +material 0 +, 0 +at 0 +an 0 +average 0 +dose 0 +of 0 +245 0 +ml 0 +. 0 + +Renal 3 +function 4 +significantly 4 +deteriorated 4 +in 0 +the 0 +group 0 +pretreated 0 +with 0 +furosemide 1 +( 0 +p 0 +< 0 +0 0 +. 0 +005 0 +by 0 +AN0VA 0 +) 0 +, 0 +with 0 +a 0 +rise 0 +in 0 +serum 0 +creatinine 1 +from 0 +145 0 ++ 0 +/ 0 +- 0 +13 0 +to 0 +182 0 ++ 0 +/ 0 +- 0 +16 0 +mumol 0 +/ 0 +l 0 +at 0 +24 0 +h 0 +, 0 +while 0 +no 0 +change 0 +occurred 0 +in 0 +the 0 +control 0 +group 0 +( 0 +from 0 +141 0 ++ 0 +/ 0 +- 0 +6 0 +to 0 +142 0 ++ 0 +/ 0 +- 0 +7 0 +mumol 0 +/ 0 +l 0 +) 0 +. 0 + +Renal 3 +failure 4 +was 0 +associated 0 +with 0 +weight 3 +loss 4 +in 0 +the 0 +furosemide 1 +- 0 +treated 0 +group 0 +. 0 + +Furosemide 1 +may 0 +be 0 +deleterious 0 +in 0 +the 0 +prevention 0 +of 0 +radiocontrast 0 +nephropathy 3 +. 0 + +Progestational 0 +agents 0 +and 0 +blood 3 +coagulation 4 +. 0 + +VII 0 +. 0 + +Thromboembolic 3 +and 0 +other 0 +complications 0 +of 0 +oral 1 +contraceptive 2 +therapy 0 +in 0 +relationship 0 +to 0 +pretreatment 0 +levels 0 +of 0 +blood 3 +coagulation 4 +factors 0 +: 0 +summary 0 +report 0 +of 0 +a 0 +ten 0 +- 0 +year 0 +study 0 +. 0 + +During 0 +a 0 +ten 0 +- 0 +year 0 +period 0 +, 0 +348 0 +women 0 +were 0 +studied 0 +for 0 +a 0 +total 0 +of 0 +5 0 +, 0 +877 0 +patient 0 +months 0 +in 0 +four 0 +separate 0 +studies 0 +relating 0 +oral 1 +contraceptives 2 +to 0 +changes 0 +in 0 +hematologic 0 +parameters 0 +. 0 + +Significant 0 +increases 0 +in 0 +certain 0 +factors 0 +of 0 +the 0 +blood 3 +coagulation 4 +and 0 +fibrinolysin 0 +systems 0 +( 0 +factors 0 +I 0 +, 0 +II 0 +, 0 +VII 0 +, 0 +VIII 0 +, 0 +IX 0 +, 0 +and 0 +X 0 +and 0 +plasminogen 0 +) 0 +were 0 +observed 0 +in 0 +the 0 +treated 0 +groups 0 +. 0 + +Severe 0 +complications 0 +developed 0 +in 0 +four 0 +patients 0 +. 0 + +All 0 +four 0 +had 0 +an 0 +abnormal 0 +blood 3 +coagulation 4 +profile 0 +, 0 +suggesting 0 +" 0 +hypercoagulability 3 +" 0 +before 0 +initiation 0 +of 0 +therapy 0 +. 0 + +Some 0 +of 0 +these 0 +findings 0 +represented 0 +the 0 +most 0 +extreme 0 +abnormalities 0 +seen 0 +in 0 +the 0 +entire 0 +group 0 +of 0 +patients 0 +; 0 +some 0 +increased 0 +further 0 +during 0 +therapy 0 +. 0 + +0ne 0 +of 0 +these 0 +patients 0 +developed 0 +a 0 +myocardial 3 +infarction 4 +before 0 +receiving 0 +any 0 +medication 0 +, 0 +shortly 0 +after 0 +the 0 +base 0 +- 0 +line 0 +values 0 +were 0 +obtained 0 +. 0 + +0ne 0 +patient 0 +developed 0 +retinopathy 3 +19 0 +months 0 +after 0 +she 0 +began 0 +therapy 0 +, 0 +and 0 +another 0 +developed 0 +thrombophlebitis 3 +after 0 +27 0 +months 0 +of 0 +therapy 0 +. 0 + +The 0 +fourth 0 +patient 0 +developed 0 +thrombophlebitis 3 +14 0 +days 0 +after 0 +initiation 0 +of 0 +contraceptive 0 +therapy 0 +. 0 + +All 0 +four 0 +patients 0 +were 0 +of 0 +the 0 +A 0 +or 0 +AB 0 +blood 0 +group 0 +. 0 + +Previous 0 +studies 0 +suggested 0 +the 0 +possiblility 0 +of 0 +increased 0 +propensity 0 +for 0 +thromboembolic 3 +episodes 4 +in 0 +patients 0 +possessing 0 +the 0 +A 0 +antigen 0 +. 0 + +It 0 +appears 0 +from 0 +these 0 +data 0 +that 0 +hematologic 0 +work 0 +- 0 +ups 0 +may 0 +be 0 +useful 0 +in 0 +women 0 +who 0 +are 0 +about 0 +to 0 +start 0 +long 0 +- 0 +term 0 +oral 1 +contraceptive 2 +therapy 0 +. 0 + +0rthostatic 3 +hypotension 4 +occurs 0 +following 0 +alpha 0 +2 0 +- 0 +adrenoceptor 0 +blockade 0 +in 0 +chronic 0 +prazosin 1 +- 0 +pretreated 0 +conscious 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +1 0 +. 0 + +Studies 0 +were 0 +performed 0 +to 0 +evaluate 0 +whether 0 +chronic 0 +prazosin 1 +treatment 0 +alters 0 +the 0 +alpha 0 +2 0 +- 0 +adrenoceptor 0 +function 0 +for 0 +orthostatic 0 +control 0 +of 0 +arterial 0 +blood 0 +pressure 0 +in 0 +conscious 0 +spontaneously 0 +hypertensive 3 +rats 0 +( 0 +SHR 0 +) 0 +. 0 + +2 0 +. 0 + +Conscious 0 +SHR 0 +( 0 +male 0 +300 0 +- 0 +350 0 +g 0 +) 0 +were 0 +subjected 0 +to 0 +90 0 +degrees 0 +head 0 +- 0 +up 0 +tilts 0 +for 0 +60 0 +s 0 +following 0 +acute 0 +administration 0 +of 0 +prazosin 1 +( 0 +0 0 +. 0 +1 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +) 0 +or 0 +rauwolscine 1 +( 0 +3 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +) 0 +. 0 + +0rthostatic 3 +hypotension 4 +was 0 +determined 0 +by 0 +the 0 +average 0 +decrease 0 +( 0 +% 0 +) 0 +in 0 +mean 0 +arterial 0 +pressure 0 +( 0 +MAP 0 +femoral 0 +) 0 +over 0 +the 0 +60 0 +- 0 +s 0 +tilt 0 +period 0 +. 0 + +The 0 +basal 0 +MAP 0 +of 0 +conscious 0 +SHR 0 +was 0 +reduced 0 +to 0 +a 0 +similar 0 +extent 0 +by 0 +prazosin 1 +( 0 +- 0 +23 0 +% 0 +( 0 +- 0 +) 0 +- 0 +26 0 +% 0 +MAP 0 +) 0 +and 0 +rauwolscine 1 +( 0 +- 0 +16 0 +% 0 +( 0 +- 0 +) 0 +- 0 +33 0 +% 0 +MAP 0 +) 0 +. 0 + +However 0 +, 0 +the 0 +head 0 +- 0 +up 0 +tilt 0 +induced 0 +orthostatic 3 +hypotension 4 +in 0 +the 0 +SHR 0 +treated 0 +with 0 +prazosin 1 +( 0 +- 0 +16 0 +% 0 +MAP 0 +, 0 +n 0 += 0 +6 0 +) 0 +, 0 +but 0 +not 0 +in 0 +the 0 +SHR 0 +treated 0 +with 0 +rauwolscine 1 +( 0 +less 0 +than 0 ++ 0 +2 0 +% 0 +MAP 0 +, 0 +n 0 += 0 +6 0 +) 0 +. 0 + +3 0 +. 0 + +Conscious 0 +SHR 0 +were 0 +treated 0 +for 0 +4 0 +days 0 +with 0 +prazosin 1 +at 0 +2 0 +mg 0 +kg 0 +- 0 +1 0 +day 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +for 0 +chronic 0 +alpha 0 +1 0 +- 0 +adrenoceptor 0 +blockade 0 +. 0 + +MAP 0 +in 0 +conscious 0 +SHR 0 +after 0 +chronic 0 +prazosin 1 +treatment 0 +was 0 +14 0 +% 0 +lower 0 +than 0 +in 0 +the 0 +untreated 0 +SHR 0 +( 0 +n 0 += 0 +8 0 +) 0 +. 0 + +Head 0 +- 0 +up 0 +tilts 0 +in 0 +these 0 +rats 0 +did 0 +not 0 +produce 0 +orthostatic 3 +hypotension 4 +when 0 +performed 0 +either 0 +prior 0 +to 0 +or 0 +after 0 +acute 0 +dosing 0 +of 0 +prazosin 1 +( 0 +0 0 +. 0 +1 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +Conversely 0 +, 0 +administration 0 +of 0 +rauwolscine 1 +( 0 +3 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +) 0 +in 0 +chronic 0 +prazosin 1 +treated 0 +SHR 0 +decreased 0 +the 0 +basal 0 +MAP 0 +by 0 +12 0 +- 0 +31 0 +% 0 +( 0 +n 0 += 0 +4 0 +) 0 +, 0 +and 0 +subsequent 0 +tilts 0 +induced 0 +further 0 +drops 0 +of 0 +MAP 0 +by 0 +19 0 +- 0 +23 0 +% 0 +in 0 +these 0 +rats 0 +. 0 + +4 0 +. 0 + +The 0 +pressor 0 +responses 0 +and 0 +bradycardia 3 +to 0 +the 0 +alpha 0 +1 0 +- 0 +agonist 0 +cirazoline 1 +( 0 +0 0 +. 0 +6 0 +and 0 +2 0 +micrograms 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +) 0 +, 0 +the 0 +alpha 0 +2 0 +- 0 +agonist 0 +Abbott 1 +- 2 +53693 2 +( 0 +1 0 +and 0 +3 0 +micrograms 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +) 0 +, 0 +and 0 +noradrenaline 1 +( 0 +0 0 +. 0 +1 0 +and 0 +1 0 +. 0 +0 0 +micrograms 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +) 0 +were 0 +determined 0 +in 0 +conscious 0 +SHR 0 +with 0 +and 0 +without 0 +chronic 0 +prazosin 1 +pretreatment 0 +. 0 + +Both 0 +the 0 +pressor 0 +and 0 +bradycardia 3 +effects 0 +of 0 +cirazoline 1 +were 0 +abolished 0 +in 0 +chronic 0 +prazosin 1 +treated 0 +SHR 0 +( 0 +n 0 += 0 +4 0 +) 0 +as 0 +compared 0 +to 0 +the 0 +untreated 0 +SHR 0 +( 0 +n 0 += 0 +4 0 +) 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +the 0 +pressor 0 +effects 0 +of 0 +Abbott 1 +- 2 +53693 2 +were 0 +similar 0 +in 0 +both 0 +groups 0 +of 0 +SHR 0 +, 0 +but 0 +the 0 +accompanying 0 +bradycardia 3 +was 0 +greater 0 +in 0 +SHR 0 +with 0 +chronic 0 +prazosin 1 +treatment 0 +than 0 +without 0 +such 0 +treatment 0 +. 0 + +Furthermore 0 +, 0 +the 0 +bradycardia 3 +that 0 +accompanied 0 +the 0 +noradrenaline 1 +- 0 +induced 0 +pressor 0 +effect 0 +in 0 +SHR 0 +was 0 +similar 0 +with 0 +and 0 +without 0 +chronic 0 +prazosin 1 +treatment 0 +despite 0 +a 0 +47 0 +- 0 +71 0 +% 0 +reduction 0 +of 0 +the 0 +pressor 0 +effect 0 +in 0 +chronic 0 +alpha 0 +1 0 +- 0 +receptor 0 +blocked 0 +SHR 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +400 0 +W0RDS 0 +) 0 + +Hemolytic 3 +- 4 +uremic 4 +syndrome 4 +associated 0 +with 0 +ingestion 0 +of 0 +quinine 1 +. 0 + +Hemolytic 3 +- 4 +uremic 4 +syndrome 4 +following 0 +quinine 1 +ingestion 0 +is 0 +a 0 +newly 0 +described 0 +phenomenon 0 +, 0 +with 0 +just 0 +two 0 +previous 0 +descriptions 0 +of 0 +4 0 +cases 0 +in 0 +the 0 +literature 0 +. 0 + +We 0 +describe 0 +a 0 +5th 0 +case 0 +. 0 + +The 0 +reaction 0 +may 0 +be 0 +mediated 0 +by 0 +the 0 +presence 0 +of 0 +antibodies 0 +reactive 0 +against 0 +platelets 0 +in 0 +the 0 +presence 0 +of 0 +quinine 1 +. 0 + +Treatment 0 +has 0 +included 0 +use 0 +of 0 +plasma 0 +exchange 0 +, 0 +prednisone 1 +, 0 +aspirin 1 +, 0 +and 0 +dipyridamole 1 +. 0 + +The 0 +patients 0 +have 0 +all 0 +regained 0 +some 0 +degree 0 +of 0 +renal 0 +function 0 +. 0 + +However 0 +, 0 +it 0 +is 0 +unclear 0 +whether 0 +pharmacological 0 +treatment 0 +or 0 +spontaneous 0 +resolution 0 +is 0 +responsible 0 +for 0 +the 0 +improvement 0 +. 0 + +Quinine 1 +- 0 +associated 0 +hemolytic 3 +- 4 +uremic 4 +syndrome 4 +probably 0 +occurs 0 +more 0 +often 0 +than 0 +is 0 +recognized 0 +. 0 + +It 0 +is 0 +important 0 +to 0 +recognize 0 +this 0 +reaction 0 +when 0 +it 0 +occurs 0 +and 0 +to 0 +avoid 0 +further 0 +quinine 1 +exposure 0 +, 0 +since 0 +the 0 +reaction 0 +seems 0 +to 0 +be 0 +recurrent 0 +. 0 + +Amnestic 3 +syndrome 4 +associated 0 +with 0 +propranolol 1 +toxicity 3 +: 0 +a 0 +case 0 +report 0 +. 0 + +An 0 +elderly 0 +woman 0 +developed 0 +an 0 +Alzheimer 3 +- 0 +like 0 +subacute 0 +dementia 3 +as 0 +a 0 +result 0 +of 0 +propranolol 1 +toxicity 3 +. 0 + +Analysis 0 +of 0 +the 0 +manifestations 0 +showed 0 +that 0 +severe 0 +impairment 0 +of 0 +memory 0 +accounted 0 +for 0 +virtually 0 +all 0 +of 0 +the 0 +abnormalities 0 +. 0 + +There 0 +is 0 +evidence 0 +that 0 +cerebral 0 +reactions 0 +to 0 +drug 0 +toxicity 3 +can 0 +exhibit 0 +patterns 0 +that 0 +suggest 0 +highly 0 +selective 0 +involvement 0 +of 0 +functional 0 +subdivisions 0 +of 0 +the 0 +brain 0 +. 0 + +Cefotetan 1 +- 0 +induced 0 +immune 0 +hemolytic 3 +anemia 4 +. 0 + +Immune 0 +hemolytic 3 +anemia 4 +due 0 +to 0 +a 0 +drug 0 +- 0 +adsorption 0 +mechanism 0 +has 0 +been 0 +described 0 +primarily 0 +in 0 +patients 0 +receiving 0 +penicillins 1 +and 0 +first 0 +- 0 +generation 0 +cephalosporins 1 +. 0 + +We 0 +describe 0 +a 0 +patient 0 +who 0 +developed 0 +anemia 3 +while 0 +receiving 0 +intravenous 0 +cefotetan 1 +. 0 + +Cefotetan 1 +- 0 +dependent 0 +antibodies 0 +were 0 +detected 0 +in 0 +the 0 +patient 0 +' 0 +s 0 +serum 0 +and 0 +in 0 +an 0 +eluate 0 +prepared 0 +from 0 +his 0 +red 0 +blood 0 +cells 0 +. 0 + +The 0 +eluate 0 +also 0 +reacted 0 +weakly 0 +with 0 +red 0 +blood 0 +cells 0 +in 0 +the 0 +absence 0 +of 0 +cefotetan 1 +, 0 +suggesting 0 +the 0 +concomitant 0 +formation 0 +of 0 +warm 0 +- 0 +reactive 0 +autoantibodies 0 +. 0 + +These 0 +observations 0 +, 0 +in 0 +conjunction 0 +with 0 +clinical 0 +and 0 +laboratory 0 +evidence 0 +of 0 +extravascular 0 +hemolysis 3 +, 0 +are 0 +consistent 0 +with 0 +drug 0 +- 0 +induced 0 +hemolytic 3 +anemia 4 +, 0 +possibly 0 +involving 0 +both 0 +drug 0 +- 0 +adsorption 0 +and 0 +autoantibody 0 +formation 0 +mechanisms 0 +. 0 + +This 0 +case 0 +emphasizes 0 +the 0 +need 0 +for 0 +increased 0 +awareness 0 +of 0 +hemolytic 0 +reactions 0 +to 0 +all 0 +cephalosporins 1 +. 0 + +Use 0 +of 0 +dexamethasone 1 +with 0 +mesna 1 +for 0 +the 0 +prevention 0 +of 0 +ifosfamide 1 +- 0 +induced 0 +hemorrhagic 3 +cystitis 4 +. 0 + +AIM 0 +: 0 +Hemorrhagic 3 +cystitis 4 +( 0 +HC 3 +) 0 +is 0 +a 0 +limiting 0 +side 0 +- 0 +effect 0 +of 0 +chemotherapy 0 +with 0 +ifosfamide 1 +( 0 +IFS 1 +) 0 +. 0 + +In 0 +the 0 +study 0 +presented 0 +here 0 +, 0 +we 0 +investigated 0 +the 0 +use 0 +of 0 +dexamethasone 1 +in 0 +combination 0 +with 0 +mesna 1 +for 0 +the 0 +prevention 0 +of 0 +IFS 1 +- 0 +induced 0 +HC 3 +. 0 + +METH0DS 0 +: 0 +Male 0 +Wistar 0 +rats 0 +( 0 +150 0 +- 0 +200 0 +g 0 +; 0 +6 0 +rats 0 +per 0 +group 0 +) 0 +were 0 +treated 0 +with 0 +saline 0 +or 0 +mesna 1 +5 0 +min 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +before 0 +and 0 +2 0 +and 0 +6 0 +h 0 +after 0 +( 0 +v 0 +. 0 +o 0 +. 0 +) 0 +administration 0 +of 0 +IFS 1 +. 0 + +0ne 0 +, 0 +two 0 +or 0 +three 0 +doses 0 +of 0 +mesna 1 +were 0 +replaced 0 +with 0 +dexamethasone 1 +alone 0 +or 0 +with 0 +dexamethasone 1 +plus 0 +mesna 1 +. 0 + +Cystitis 3 +was 0 +evaluated 0 +24 0 +h 0 +after 0 +its 0 +induction 0 +by 0 +the 0 +changes 0 +in 0 +bladder 0 +wet 0 +weight 0 +and 0 +by 0 +macroscopic 0 +and 0 +microscopic 0 +analysis 0 +. 0 + +RESULTS 0 +: 0 +The 0 +replacement 0 +of 0 +the 0 +last 0 +dose 0 +or 0 +the 0 +last 0 +two 0 +doses 0 +of 0 +mesna 1 +with 0 +dexamethasone 1 +reduced 0 +the 0 +increase 0 +in 0 +bladder 0 +wet 0 +weight 0 +induced 0 +by 0 +IFS 1 +by 0 +84 0 +. 0 +79 0 +% 0 +and 0 +89 0 +. 0 +13 0 +% 0 +, 0 +respectively 0 +. 0 + +In 0 +addition 0 +, 0 +it 0 +almost 0 +abolished 0 +the 0 +macroscopic 0 +and 0 +microscopic 0 +alterations 0 +induced 0 +by 0 +IFS 1 +. 0 + +Moreover 0 +, 0 +the 0 +addition 0 +of 0 +dexamethasone 1 +to 0 +the 0 +last 0 +two 0 +doses 0 +of 0 +mesna 1 +was 0 +more 0 +efficient 0 +than 0 +three 0 +doses 0 +of 0 +mesna 1 +alone 0 +when 0 +evaluated 0 +microscopically 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Dexamethasone 1 +in 0 +combination 0 +with 0 +mesna 1 +was 0 +efficient 0 +in 0 +blocking 0 +IFS 1 +- 0 +induced 0 +HC 3 +. 0 + +However 0 +, 0 +the 0 +replacement 0 +of 0 +last 0 +two 0 +doses 0 +of 0 +mesna 1 +with 0 +saline 0 +or 0 +all 0 +of 0 +the 0 +mesna 1 +doses 0 +with 0 +dexamethasone 1 +did 0 +not 0 +prevent 0 +HC 3 +. 0 + +All 1 +- 2 +trans 2 +- 2 +retinoic 2 +acid 2 +- 0 +induced 0 +erythema 3 +nodosum 4 +in 0 +patients 0 +with 0 +acute 3 +promyelocytic 4 +leukemia 4 +. 0 + +Erythema 3 +nodosum 4 +associated 0 +with 0 +all 1 +- 2 +trans 2 +- 2 +retinoic 2 +acid 2 +( 0 +ATRA 1 +) 0 +for 0 +acute 3 +promyelocytic 4 +leukemia 4 +( 0 +APL 3 +) 0 +is 0 +very 0 +rare 0 +. 0 + +We 0 +describe 0 +four 0 +patients 0 +with 0 +classic 0 +APL 3 +who 0 +developed 0 +erythema 3 +nodosum 4 +during 0 +ATRA 1 +therapy 0 +. 0 + +Fever 3 +and 0 +subsequent 0 +multiple 0 +painful 3 +erythematous 3 +nodules 4 +over 0 +extremities 0 +developed 0 +on 0 +D11 0 +, 0 +D16 0 +, 0 +D17 0 +, 0 +and 0 +D19 0 +, 0 +respectively 0 +, 0 +after 0 +ATRA 1 +therapy 0 +. 0 + +The 0 +skin 0 +biopsy 0 +taken 0 +from 0 +each 0 +patient 0 +was 0 +consistent 0 +with 0 +erythema 3 +nodosum 4 +. 0 + +All 0 +patients 0 +received 0 +short 0 +course 0 +of 0 +steroids 1 +. 0 + +Fever 3 +subsided 0 +rapidly 0 +and 0 +the 0 +skin 0 +lesions 0 +regressed 0 +completely 0 +. 0 + +All 0 +patients 0 +achieved 0 +complete 0 +remission 0 +without 0 +withdrawal 0 +of 0 +ATRA 1 +. 0 + +ATRA 1 +seemed 0 +to 0 +be 0 +the 0 +most 0 +possible 0 +etiology 0 +of 0 +erythema 3 +nodosum 4 +in 0 +our 0 +patients 0 +. 0 + +Short 0 +- 0 +term 0 +use 0 +of 0 +steroid 1 +is 0 +very 0 +effective 0 +in 0 +ATRA 1 +- 0 +induced 0 +erythema 3 +nodosum 4 +. 0 + +Effect 0 +of 0 +some 0 +convulsants 0 +on 0 +the 0 +protective 0 +activity 0 +of 0 +loreclezole 1 +and 0 +its 0 +combinations 0 +with 0 +valproate 1 +or 0 +clonazepam 1 +in 0 +amygdala 0 +- 0 +kindled 0 +rats 0 +. 0 + +Loreclezole 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +exerted 0 +a 0 +significant 0 +protective 0 +action 0 +in 0 +amygdala 0 +- 0 +kindled 0 +rats 0 +, 0 +reducing 0 +both 0 +seizure 3 +and 0 +afterdischarge 0 +durations 0 +. 0 + +The 0 +combinations 0 +of 0 +loreclezole 1 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +with 0 +valproate 1 +, 0 +clonazepam 1 +, 0 +or 0 +carbamazepine 1 +( 0 +applied 0 +at 0 +their 0 +subprotective 0 +doses 0 +) 0 +also 0 +exhibited 0 +antiseizure 0 +effect 0 +in 0 +this 0 +test 0 +. 0 + +However 0 +, 0 +only 0 +two 0 +first 0 +combinations 0 +occurred 0 +to 0 +be 0 +of 0 +pharmacodynamic 0 +nature 0 +. 0 + +Among 0 +several 0 +chemoconvulsants 0 +, 0 +bicuculline 1 +, 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartic 2 +acid 2 +and 0 +BAY 1 +k 2 +- 2 +8644 2 +( 0 +the 0 +opener 0 +of 0 +L 0 +- 0 +type 0 +calcium 1 +channels 0 +) 0 +reversed 0 +the 0 +protective 0 +activity 0 +of 0 +loreclezole 1 +alone 0 +and 0 +its 0 +combination 0 +with 0 +valproate 1 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +bicuculline 1 +, 0 +aminophylline 1 +and 0 +BAY 1 +k 2 +- 2 +8644 2 +inhibited 0 +the 0 +anticonvulsive 0 +action 0 +of 0 +loreclezole 1 +combined 0 +with 0 +clonazepam 1 +. 0 + +The 0 +results 0 +support 0 +the 0 +hypothesis 0 +that 0 +the 0 +protective 0 +activity 0 +of 0 +loreclezole 1 +and 0 +its 0 +combinations 0 +with 0 +other 0 +antiepileptics 0 +may 0 +involve 0 +potentiation 0 +of 0 +GABAergic 0 +neurotransmission 0 +and 0 +blockade 0 +of 0 +L 0 +- 0 +type 0 +of 0 +calcium 1 +channels 0 +. 0 + +Mitochondrial 0 +DNA 0 +and 0 +its 0 +respiratory 0 +chain 0 +products 0 +are 0 +defective 0 +in 0 +doxorubicin 1 +nephrosis 3 +. 0 + +BACKGR0UND 0 +: 0 +Doxorubicin 1 +induces 0 +a 0 +self 0 +- 0 +perpetuating 0 +nephropathy 3 +characterized 0 +by 0 +early 0 +glomerular 3 +and 4 +late 4 +- 4 +onset 4 +tubular 4 +lesions 4 +in 0 +rats 0 +. 0 + +We 0 +investigated 0 +the 0 +potential 0 +role 0 +of 0 +mitochondrial 3 +injury 4 +in 0 +the 0 +onset 0 +of 0 +these 0 +lesions 0 +. 0 + +METH0DS 0 +: 0 +Rats 0 +were 0 +treated 0 +with 0 +intravenous 0 +doxorubicin 1 +( 0 +1 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +week 0 +( 0 +- 0 +1 0 +) 0 +) 0 +for 0 +7 0 +weeks 0 +and 0 +were 0 +sacrificed 0 +either 0 +1 0 +week 0 +( 0 +' 0 +short 0 +- 0 +term 0 +' 0 +) 0 +or 0 +30 0 +weeks 0 +( 0 +' 0 +long 0 +- 0 +term 0 +' 0 +) 0 +following 0 +the 0 +last 0 +dose 0 +. 0 + +Additional 0 +rats 0 +received 0 +a 0 +single 0 +dose 0 +either 0 +6 0 +days 0 +or 0 +2 0 +h 0 +prior 0 +to 0 +euthanasia 0 +. 0 + +All 0 +rats 0 +were 0 +killed 0 +at 0 +48 0 +weeks 0 +of 0 +age 0 +. 0 + +Glomerular 3 +and 4 +tubular 4 +injury 4 +was 0 +monitored 0 +and 0 +correlated 0 +to 0 +the 0 +activity 0 +or 0 +expression 0 +of 0 +respiratory 0 +chain 0 +components 0 +. 0 + +Finally 0 +, 0 +we 0 +quantified 0 +both 0 +nuclear 0 +and 0 +mitochondrial 0 +DNA 0 +( 0 +mtDNA 0 +) 0 +as 0 +well 0 +as 0 +superoxide 1 +production 0 +and 0 +the 0 +4834 0 +base 0 +pair 0 +' 0 +common 0 +' 0 +mtDNA 0 +deletion 0 +. 0 + +RESULTS 0 +: 0 +The 0 +' 0 +long 0 +- 0 +term 0 +' 0 +group 0 +had 0 +significant 0 +glomerular 3 +and 4 +tubular 4 +lesions 4 +, 0 +depressed 0 +activities 0 +of 0 +mtDNA 0 +- 0 +encoded 0 +NADH 0 +dehydrogenase 0 +and 0 +cytochrome 0 +- 0 +c 0 +oxidase 0 +( 0 +C0X 0 +) 0 +and 0 +increased 0 +citrate 1 +synthase 0 +activity 0 +. 0 + +In 0 +addition 0 +, 0 +expression 0 +of 0 +the 0 +mtDNA 0 +- 0 +encoded 0 +C0X 0 +subunit 0 +I 0 +was 0 +reduced 0 +and 0 +mtDNA 0 +levels 0 +were 0 +decreased 0 +. 0 + +In 0 +' 0 +short 0 +- 0 +term 0 +' 0 +rats 0 +, 0 +there 0 +were 0 +fewer 0 +tubular 3 +lesions 4 +, 0 +but 0 +similar 0 +numbers 0 +of 0 +glomerular 3 +lesions 4 +activity 0 +. 0 + +Among 0 +all 0 +animals 0 +, 0 +glomerular 3 +and 4 +tubular 4 +injury 4 +were 0 +inversely 0 +correlated 0 +with 0 +mtDNA 0 +levels 0 +, 0 +mtDNA 0 +- 0 +encoded 0 +respiratory 0 +chain 0 +activities 0 +and 0 +with 0 +the 0 +expression 0 +of 0 +the 0 +mtDNA 0 +- 0 +encoded 0 +respiratory 0 +chain 0 +subunit 0 +C0X 0 +- 0 +I 0 +. 0 + +Injury 0 +was 0 +positively 0 +correlated 0 +with 0 +superoxide 1 +production 0 +and 0 +the 0 +activities 0 +of 0 +nucleus 0 +- 0 +encoded 0 +mitochondrial 0 +or 0 +cytoplasmic 0 +enzymes 0 +. 0 + +Kidneys 0 +from 0 +the 0 +' 0 +long 0 +- 0 +term 0 +' 0 +group 0 +showed 0 +more 0 +mtDNA 0 +deletions 0 +than 0 +in 0 +' 0 +short 0 +- 0 +term 0 +' 0 +animals 0 +and 0 +these 0 +were 0 +not 0 +observed 0 +in 0 +the 0 +other 0 +groups 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +suggest 0 +an 0 +important 0 +role 0 +for 0 +quantitative 0 +and 0 +qualitative 0 +mtDNA 0 +alterations 0 +through 0 +the 0 +reduction 0 +of 0 +mtDNA 0 +- 0 +encoded 0 +respiratory 0 +chain 0 +function 0 +and 0 +induction 0 +of 0 +superoxide 1 +in 0 +doxorubicin 1 +- 0 +induced 0 +renal 3 +lesions 4 +. 0 + +A 0 +randomized 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +crossover 0 +study 0 +of 0 +ephedrine 1 +for 0 +SSRI 0 +- 0 +induced 0 +female 0 +sexual 3 +dysfunction 4 +. 0 + +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +ephedrine 1 +, 0 +an 0 +alpha 0 +- 0 +and 0 +beta 0 +- 0 +adrenergic 0 +agonist 0 +previously 0 +shown 0 +to 0 +enhance 0 +genital 0 +blood 0 +flow 0 +in 0 +women 0 +, 0 +has 0 +beneficial 0 +effects 0 +in 0 +reversing 0 +antidepressant 0 +- 0 +induced 0 +sexual 3 +dysfunction 4 +. 0 + +Nineteen 0 +sexually 3 +dysfunctional 4 +women 0 +receiving 0 +either 0 +fluoxetine 1 +, 0 +sertraline 1 +, 0 +or 0 +paroxetine 1 +participated 0 +in 0 +an 0 +eight 0 +- 0 +week 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +cross 0 +- 0 +over 0 +study 0 +of 0 +the 0 +effects 0 +of 0 +ephedrine 1 +( 0 +50 0 +mg 0 +) 0 +on 0 +self 0 +- 0 +report 0 +measures 0 +of 0 +sexual 0 +desire 0 +, 0 +arousal 0 +, 0 +orgasm 0 +, 0 +and 0 +sexual 0 +satisfaction 0 +. 0 + +Although 0 +there 0 +were 0 +significant 0 +improvements 0 +relative 0 +to 0 +baseline 0 +in 0 +sexual 0 +desire 0 +and 0 +orgasm 0 +intensity 0 +/ 0 +pleasure 0 +on 0 +50 0 +mg 0 +ephedrine 1 +1 0 +- 0 +hr 0 +prior 0 +to 0 +sexual 0 +activity 0 +, 0 +significant 0 +improvements 0 +in 0 +these 0 +measures 0 +, 0 +as 0 +well 0 +as 0 +in 0 +sexual 0 +arousal 0 +and 0 +orgasmic 0 +ability 0 +also 0 +were 0 +noted 0 +with 0 +placebo 0 +. 0 + +These 0 +findings 0 +highlight 0 +the 0 +importance 0 +of 0 +conducting 0 +placebo 0 +- 0 +controlled 0 +trials 0 +for 0 +this 0 +condition 0 +. 0 + +Does 0 +hormone 0 +therapy 0 +for 0 +the 0 +treatment 0 +of 0 +breast 3 +cancer 4 +have 0 +a 0 +detrimental 3 +effect 4 +on 4 +memory 4 +and 4 +cognition 4 +? 0 + +A 0 +pilot 0 +study 0 +. 0 + +This 0 +pilot 0 +study 0 +examines 0 +whether 0 +hormone 0 +therapy 0 +for 0 +breast 3 +cancer 4 +affects 0 +cognition 0 +. 0 + +Patients 0 +participating 0 +in 0 +a 0 +randomised 0 +trial 0 +of 0 +anastrozole 1 +, 0 +tamoxifen 1 +alone 0 +or 0 +combined 0 +( 0 +ATAC 0 +) 0 +( 0 +n 0 += 0 +94 0 +) 0 +and 0 +a 0 +group 0 +of 0 +women 0 +without 0 +breast 3 +cancer 4 +( 0 +n 0 += 0 +35 0 +) 0 +completed 0 +a 0 +battery 0 +of 0 +neuropsychological 0 +measures 0 +. 0 + +Compared 0 +with 0 +the 0 +control 0 +group 0 +, 0 +the 0 +patients 0 +were 0 +impaired 0 +on 0 +a 0 +processing 0 +speed 0 +task 0 +( 0 +p 0 += 0 +0 0 +. 0 +032 0 +) 0 +and 0 +on 0 +a 0 +measure 0 +of 0 +immediate 0 +verbal 0 +memory 0 +( 0 +p 0 += 0 +0 0 +. 0 +026 0 +) 0 +after 0 +controlling 0 +for 0 +the 0 +use 0 +of 0 +hormone 0 +replacement 0 +therapy 0 +in 0 +both 0 +groups 0 +. 0 + +Patient 0 +group 0 +performance 0 +was 0 +not 0 +significantly 0 +related 0 +to 0 +length 0 +of 0 +treatment 0 +or 0 +measures 0 +of 0 +psychological 0 +morbidity 0 +. 0 + +The 0 +results 0 +showed 0 +specific 0 +impairments 0 +in 0 +processing 0 +speed 0 +and 0 +verbal 0 +memory 0 +in 0 +women 0 +receiving 0 +hormonal 0 +therapy 0 +for 0 +the 0 +treatment 0 +of 0 +breast 3 +cancer 4 +. 0 + +Verbal 0 +memory 0 +may 0 +be 0 +especially 0 +sensitive 0 +to 0 +changes 0 +in 0 +oestrogen 1 +levels 0 +, 0 +a 0 +finding 0 +commonly 0 +reported 0 +in 0 +studies 0 +of 0 +hormone 0 +replacement 0 +therapy 0 +in 0 +healthy 0 +women 0 +. 0 + +In 0 +view 0 +of 0 +the 0 +increased 0 +use 0 +of 0 +hormone 0 +therapies 0 +in 0 +an 0 +adjuvant 0 +and 0 +preventative 0 +setting 0 +their 0 +impact 0 +on 0 +cognitive 0 +functioning 0 +should 0 +be 0 +investigated 0 +more 0 +thoroughly 0 +. 0 + +Expression 0 +of 0 +p300 0 +protects 0 +cardiac 0 +myocytes 0 +from 0 +apoptosis 0 +in 0 +vivo 0 +. 0 + +Doxorubicin 1 +is 0 +an 0 +anti 0 +- 0 +tumor 3 +agent 0 +that 0 +represses 0 +cardiac 0 +- 0 +specific 0 +gene 0 +expression 0 +and 0 +induces 0 +myocardial 0 +cell 0 +apoptosis 0 +. 0 + +Doxorubicin 1 +depletes 0 +cardiac 0 +p300 0 +, 0 +a 0 +transcriptional 0 +coactivator 0 +that 0 +is 0 +required 0 +for 0 +the 0 +maintenance 0 +of 0 +the 0 +differentiated 0 +phenotype 0 +of 0 +cardiac 0 +myocytes 0 +. 0 + +However 0 +, 0 +the 0 +role 0 +of 0 +p300 0 +in 0 +protection 0 +against 0 +doxorubicin 1 +- 0 +induced 0 +apoptosis 0 +is 0 +unknown 0 +. 0 + +Transgenic 0 +mice 0 +overexpressing 0 +p300 0 +in 0 +the 0 +heart 0 +and 0 +wild 0 +- 0 +type 0 +mice 0 +were 0 +subjected 0 +to 0 +doxorubicin 1 +treatment 0 +. 0 + +Compared 0 +with 0 +wild 0 +- 0 +type 0 +mice 0 +, 0 +transgenic 0 +mice 0 +exhibited 0 +higher 0 +survival 0 +rate 0 +as 0 +well 0 +as 0 +more 0 +preserved 0 +left 0 +ventricular 0 +function 0 +and 0 +cardiac 0 +expression 0 +of 0 +alpha 0 +- 0 +sarcomeric 0 +actin 0 +. 0 + +Doxorubicin 1 +induced 0 +myocardial 0 +cell 0 +apoptosis 0 +in 0 +wild 0 +- 0 +type 0 +mice 0 +but 0 +not 0 +in 0 +transgenic 0 +mice 0 +. 0 + +Expression 0 +of 0 +p300 0 +increased 0 +the 0 +cardiac 0 +level 0 +of 0 +bcl 0 +- 0 +2 0 +and 0 +mdm 0 +- 0 +2 0 +, 0 +but 0 +not 0 +that 0 +of 0 +p53 0 +or 0 +other 0 +members 0 +of 0 +the 0 +bcl 0 +- 0 +2 0 +family 0 +. 0 + +These 0 +findings 0 +demonstrate 0 +that 0 +overexpression 0 +of 0 +p300 0 +protects 0 +cardiac 0 +myocytes 0 +from 0 +doxorubicin 1 +- 0 +induced 0 +apoptosis 0 +and 0 +reduces 0 +the 0 +extent 0 +of 0 +acute 0 +heart 3 +failure 4 +in 0 +adult 0 +mice 0 +in 0 +vivo 0 +. 0 + +Methimazole 1 +- 0 +induced 0 +cholestatic 3 +jaundice 4 +. 0 + +Methimazole 1 +is 0 +a 0 +widely 0 +used 0 +and 0 +generally 0 +well 0 +- 0 +tolerated 0 +antithyroid 0 +agent 0 +. 0 + +A 0 +43 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +had 0 +severe 0 +jaundice 3 +and 0 +itching 3 +1 0 +month 0 +after 0 +receiving 0 +methimazole 1 +( 0 +10 0 +mg 0 +tid 0 +) 0 +and 0 +propranolol 1 +( 0 +20 0 +mg 0 +tid 0 +) 0 +for 0 +treatment 0 +of 0 +hyperthyroidism 3 +. 0 + +The 0 +patient 0 +continued 0 +treatment 0 +for 0 +another 0 +4 0 +days 0 +after 0 +the 0 +appearance 0 +of 0 +jaundice 3 +until 0 +she 0 +finished 0 +both 0 +medications 0 +. 0 + +When 0 +seen 0 +at 0 +the 0 +emergency 0 +department 0 +2 0 +weeks 0 +later 0 +, 0 +she 0 +still 0 +had 0 +severe 0 +icterus 3 +, 0 +pruritus 3 +, 0 +and 0 +hyperbilirubinemia 3 +, 0 +formed 0 +mainly 0 +of 0 +the 0 +conjugated 0 +fraction 0 +. 0 + +Methimazole 1 +- 0 +induced 0 +cholestasis 3 +was 0 +diagnosed 0 +, 0 +and 0 +propranolol 1 +therapy 0 +was 0 +resumed 0 +. 0 + +0ver 0 +the 0 +following 0 +9 0 +days 0 +, 0 +the 0 +symptoms 0 +improved 0 +and 0 +plasma 0 +bilirubin 1 +levels 0 +were 0 +normal 0 +after 0 +12 0 +weeks 0 +without 0 +methimazole 1 +. 0 + +In 0 +rare 0 +cases 0 +within 0 +the 0 +first 0 +few 0 +weeks 0 +of 0 +therapy 0 +, 0 +this 0 +drug 0 +can 0 +cause 0 +severe 0 +and 0 +reversible 0 +cholestatic 3 +jaundice 4 +. 0 + +Physicians 0 +and 0 +patients 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +adverse 0 +effect 0 +so 0 +that 0 +, 0 +upon 0 +occurrence 0 +, 0 +they 0 +can 0 +discontinue 0 +methimazole 1 +therapy 0 +and 0 +avoid 0 +unnecessary 0 +invasive 0 +procedures 0 +. 0 + +Atrial 3 +fibrillation 4 +following 0 +chemotherapy 0 +for 0 +stage 0 +IIIE 0 +diffuse 0 +large 0 +B 0 +- 0 +cell 0 +gastric 3 +lymphoma 4 +in 0 +a 0 +patient 0 +with 0 +myotonic 3 +dystrophy 4 +( 0 +Steinert 3 +' 4 +s 4 +disease 4 +) 0 +. 0 + +The 0 +authors 0 +describe 0 +the 0 +unusual 0 +association 0 +between 0 +diffuse 0 +B 0 +- 0 +cell 0 +gastric 3 +lymphoma 4 +and 0 +myotonic 3 +dystrophy 4 +, 0 +the 0 +most 0 +common 0 +form 0 +of 0 +adult 0 +muscular 3 +dystrophy 4 +, 0 +and 0 +sudden 0 +atrial 3 +fibrillation 4 +following 0 +one 0 +cycle 0 +of 0 +doxorubicin 1 +- 0 +based 0 +chemotherapy 0 +in 0 +the 0 +same 0 +patient 0 +. 0 + +Atrial 3 +fibrillation 4 +or 0 +other 0 +cardiac 3 +arrhythmias 4 +are 0 +unusual 0 +complications 0 +in 0 +patients 0 +treated 0 +with 0 +chemotherapy 0 +. 0 + +The 0 +cardiac 3 +toxicity 4 +intrinsically 0 +associated 0 +with 0 +the 0 +aggressive 0 +chemotherapy 0 +employed 0 +could 0 +function 0 +as 0 +a 0 +triggering 0 +factor 0 +for 0 +the 0 +arrhythmia 3 +in 0 +the 0 +predisposed 0 +myocardium 0 +of 0 +this 0 +patient 0 +. 0 + +Hypersensitivity 3 +immune 0 +reaction 0 +as 0 +a 0 +mechanism 0 +for 0 +dilevalol 1 +- 0 +associated 0 +hepatitis 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +assess 0 +lymphocyte 0 +reactivity 0 +to 0 +dilevalol 1 +and 0 +to 0 +serum 0 +containing 0 +putative 0 +ex 0 +vivo 0 +dilevalol 1 +antigens 0 +or 0 +metabolites 0 +in 0 +a 0 +case 0 +of 0 +dilevalol 1 +- 0 +induced 0 +liver 3 +injury 4 +. 0 + +PATIENT 0 +: 0 +A 0 +58 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +a 0 +clinical 0 +diagnosis 0 +of 0 +dilevalol 1 +- 0 +induced 0 +liver 3 +injury 4 +. 0 + +METH0DS 0 +: 0 +Peripheral 0 +blood 0 +mononuclear 0 +cells 0 +collected 0 +from 0 +the 0 +patient 0 +were 0 +cultured 0 +in 0 +the 0 +presence 0 +of 0 +a 0 +solution 0 +of 0 +dilevalol 1 +and 0 +also 0 +with 0 +sera 0 +collected 0 +from 0 +a 0 +volunteer 0 +before 0 +and 0 +after 0 +dilevalol 1 +intake 0 +. 0 + +A 0 +similar 0 +protocol 0 +was 0 +performed 0 +with 0 +lymphocytes 0 +from 0 +a 0 +healthy 0 +subject 0 +. 0 + +RESULTS 0 +: 0 +No 0 +lymphocyte 0 +proliferation 0 +was 0 +observed 0 +either 0 +in 0 +the 0 +patient 0 +or 0 +in 0 +the 0 +healthy 0 +volunteer 0 +in 0 +the 0 +presence 0 +of 0 +dilevalol 1 +solutions 0 +. 0 + +A 0 +significant 0 +proliferative 0 +response 0 +to 0 +serum 0 +collected 0 +after 0 +dilevalol 1 +intake 0 +was 0 +observed 0 +in 0 +the 0 +case 0 +of 0 +the 0 +patient 0 +compared 0 +with 0 +the 0 +proliferative 0 +response 0 +to 0 +the 0 +serum 0 +collected 0 +before 0 +the 0 +drug 0 +intake 0 +. 0 + +No 0 +reactivity 0 +was 0 +found 0 +when 0 +lymphocytes 0 +from 0 +the 0 +healthy 0 +subject 0 +were 0 +tested 0 +under 0 +similar 0 +conditions 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +methodology 0 +used 0 +allowed 0 +the 0 +detection 0 +of 0 +lymphocyte 0 +sensitization 0 +to 0 +sera 0 +containing 0 +ex 0 +vivo 0 +- 0 +prepared 0 +dilevalol 1 +antigens 0 +, 0 +suggesting 0 +the 0 +involvement 0 +of 0 +an 0 +immunologic 0 +mechanism 0 +in 0 +dilevalol 1 +- 0 +induced 0 +liver 3 +injury 4 +. 0 + +Increased 0 +expression 0 +and 0 +apical 0 +targeting 0 +of 0 +renal 0 +ENaC 0 +subunits 0 +in 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +in 0 +rats 0 +. 0 + +Nephrotic 3 +syndrome 4 +is 0 +often 0 +accompanied 0 +by 0 +sodium 1 +retention 0 +and 0 +generalized 0 +edema 3 +. 0 + +However 0 +, 0 +the 0 +molecular 0 +basis 0 +for 0 +the 0 +decreased 0 +renal 0 +sodium 1 +excretion 0 +remains 0 +undefined 0 +. 0 + +We 0 +hypothesized 0 +that 0 +epithelial 0 +Na 1 +channel 0 +( 0 +ENaC 0 +) 0 +subunit 0 +dysregulation 0 +may 0 +be 0 +responsible 0 +for 0 +the 0 +increased 0 +sodium 1 +retention 0 +. 0 + +An 0 +experimental 0 +group 0 +of 0 +rats 0 +was 0 +treated 0 +with 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +; 0 +180 0 +mg 0 +/ 0 +kg 0 +iv 0 +) 0 +, 0 +whereas 0 +the 0 +control 0 +group 0 +received 0 +only 0 +vehicle 0 +. 0 + +After 0 +7 0 +days 0 +, 0 +PAN 1 +treatment 0 +induced 0 +significant 0 +proteinuria 3 +, 0 +hypoalbuminemia 3 +, 0 +decreased 0 +urinary 0 +sodium 1 +excretion 0 +, 0 +and 0 +extensive 0 +ascites 3 +. 0 + +The 0 +protein 0 +abundance 0 +of 0 +alpha 0 +- 0 +ENaC 0 +and 0 +beta 0 +- 0 +ENaC 0 +was 0 +increased 0 +in 0 +the 0 +inner 0 +stripe 0 +of 0 +the 0 +outer 0 +medulla 0 +( 0 +IS0M 0 +) 0 +and 0 +in 0 +the 0 +inner 0 +medulla 0 +( 0 +IM 0 +) 0 +but 0 +was 0 +not 0 +altered 0 +in 0 +the 0 +cortex 0 +. 0 + +gamma 0 +- 0 +ENaC 0 +abundance 0 +was 0 +increased 0 +in 0 +the 0 +cortex 0 +, 0 +IS0M 0 +, 0 +and 0 +IM 0 +. 0 + +Immunoperoxidase 0 +brightfield 0 +- 0 +and 0 +laser 0 +- 0 +scanning 0 +confocal 0 +fluorescence 0 +microscopy 0 +demonstrated 0 +increased 0 +targeting 0 +of 0 +alpha 0 +- 0 +ENaC 0 +, 0 +beta 0 +- 0 +ENaC 0 +, 0 +and 0 +gamma 0 +- 0 +ENaC 0 +subunits 0 +to 0 +the 0 +apical 0 +plasma 0 +membrane 0 +in 0 +the 0 +distal 0 +convoluted 0 +tubule 0 +( 0 +DCT2 0 +) 0 +, 0 +connecting 0 +tubule 0 +, 0 +and 0 +cortical 0 +and 0 +medullary 0 +collecting 0 +duct 0 +segments 0 +. 0 + +Immunoelectron 0 +microscopy 0 +further 0 +revealed 0 +an 0 +increased 0 +labeling 0 +of 0 +alpha 0 +- 0 +ENaC 0 +in 0 +the 0 +apical 0 +plasma 0 +membrane 0 +of 0 +cortical 0 +collecting 0 +duct 0 +principal 0 +cells 0 +of 0 +PAN 1 +- 0 +treated 0 +rats 0 +, 0 +indicating 0 +enhanced 0 +apical 0 +targeting 0 +of 0 +alpha 0 +- 0 +ENaC 0 +subunits 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +protein 0 +abundances 0 +of 0 +Na 1 +( 0 ++ 0 +) 0 +/ 0 +H 1 +( 0 ++ 0 +) 0 +exchanger 0 +type 0 +3 0 +( 0 +NHE3 0 +) 0 +, 0 +Na 1 +( 0 ++ 0 +) 0 +- 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +2Cl 1 +( 0 +- 0 +) 0 +cotransporter 0 +( 0 +BSC 0 +- 0 +1 0 +) 0 +, 0 +and 0 +thiazide 1 +- 0 +sensitive 0 +Na 1 +( 0 ++ 0 +) 0 +- 0 +Cl 1 +( 0 +- 0 +) 0 +cotransporter 0 +( 0 +TSC 0 +) 0 +were 0 +decreased 0 +. 0 + +Moreover 0 +, 0 +the 0 +abundance 0 +of 0 +the 0 +alpha 0 +( 0 +1 0 +) 0 +- 0 +subunit 0 +of 0 +the 0 +Na 1 +- 0 +K 1 +- 0 +ATPase 0 +was 0 +decreased 0 +in 0 +the 0 +cortex 0 +and 0 +IS0M 0 +, 0 +but 0 +it 0 +remained 0 +unchanged 0 +in 0 +the 0 +IM 0 +. 0 + +In 0 +conclusion 0 +, 0 +the 0 +increased 0 +or 0 +sustained 0 +expression 0 +of 0 +ENaC 0 +subunits 0 +combined 0 +with 0 +increased 0 +apical 0 +targeting 0 +in 0 +the 0 +DCT2 0 +, 0 +connecting 0 +tubule 0 +, 0 +and 0 +collecting 0 +duct 0 +are 0 +likely 0 +to 0 +play 0 +a 0 +role 0 +in 0 +the 0 +sodium 1 +retention 0 +associated 0 +with 0 +PAN 1 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +. 0 + +The 0 +decreased 0 +abundance 0 +of 0 +NHE3 0 +, 0 +BSC 0 +- 0 +1 0 +, 0 +TSC 0 +, 0 +and 0 +Na 1 +- 0 +K 1 +- 0 +ATPase 0 +may 0 +play 0 +a 0 +compensatory 0 +role 0 +to 0 +promote 0 +sodium 1 +excretion 0 +. 0 + +Pallidal 0 +stimulation 0 +: 0 +an 0 +alternative 0 +to 0 +pallidotomy 0 +? 0 + +A 0 +resurgence 0 +of 0 +interest 0 +in 0 +the 0 +surgical 0 +treatment 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +came 0 +with 0 +the 0 +rediscovery 0 +of 0 +posteroventral 0 +pallidotomy 0 +by 0 +Laitinen 0 +in 0 +1985 0 +. 0 + +Laitinen 0 +' 0 +s 0 +procedure 0 +improved 0 +most 0 +symptoms 0 +in 0 +drug 0 +- 0 +resistant 0 +PD 3 +, 0 +which 0 +engendered 0 +wide 0 +interest 0 +in 0 +the 0 +neurosurgical 0 +community 0 +. 0 + +Another 0 +lesioning 0 +procedure 0 +, 0 +ventrolateral 0 +thalamotomy 0 +, 0 +has 0 +become 0 +a 0 +powerful 0 +alternative 0 +to 0 +stimulate 0 +the 0 +nucleus 0 +ventralis 0 +intermedius 0 +, 0 +producing 0 +high 0 +long 0 +- 0 +term 0 +success 0 +rates 0 +and 0 +low 0 +morbidity 0 +rates 0 +. 0 + +Pallidal 0 +stimulation 0 +has 0 +not 0 +met 0 +with 0 +the 0 +same 0 +success 0 +. 0 + +According 0 +to 0 +the 0 +literature 0 +pallidotomy 0 +improves 0 +the 0 +" 0 +on 0 +" 0 +symptoms 0 +of 0 +PD 3 +, 0 +such 0 +as 0 +dyskinesias 3 +, 0 +as 0 +well 0 +as 0 +the 0 +" 0 +off 0 +" 0 +symptoms 0 +, 0 +such 0 +as 0 +rigidity 3 +, 0 +bradykinesia 3 +, 0 +and 0 +on 0 +- 0 +off 0 +fluctuations 0 +. 0 + +Pallidal 0 +stimulation 0 +improves 0 +bradykinesia 3 +and 0 +rigidity 3 +to 0 +a 0 +minor 0 +extent 0 +; 0 +however 0 +, 0 +its 0 +strength 0 +seems 0 +to 0 +be 0 +in 0 +improving 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +. 0 + +Stimulation 0 +often 0 +produces 0 +an 0 +improvement 0 +in 0 +the 0 +hyper 3 +- 4 +or 4 +dyskinetic 4 +upper 0 +limbs 0 +, 0 +but 0 +increases 0 +the 0 +" 0 +freezing 0 +" 0 +phenomenon 0 +in 0 +the 0 +lower 0 +limbs 0 +at 0 +the 0 +same 0 +time 0 +. 0 + +Considering 0 +the 0 +small 0 +increase 0 +in 0 +the 0 +patient 0 +' 0 +s 0 +independence 0 +, 0 +the 0 +high 0 +costs 0 +of 0 +bilateral 0 +implants 0 +, 0 +and 0 +the 0 +difficulty 0 +most 0 +patients 0 +experience 0 +in 0 +handling 0 +the 0 +devices 0 +, 0 +the 0 +question 0 +arises 0 +as 0 +to 0 +whether 0 +bilateral 0 +pallidal 0 +stimulation 0 +is 0 +a 0 +real 0 +alternative 0 +to 0 +pallidotomy 0 +. 0 + +Effects 0 +of 0 +the 0 +cyclooxygenase 0 +- 0 +2 0 +specific 0 +inhibitor 0 +valdecoxib 1 +versus 0 +nonsteroidal 0 +antiinflammatory 0 +agents 0 +and 0 +placebo 0 +on 0 +cardiovascular 0 +thrombotic 3 +events 0 +in 0 +patients 0 +with 0 +arthritis 3 +. 0 + +There 0 +have 0 +been 0 +concerns 0 +that 0 +the 0 +risk 0 +of 0 +cardiovascular 0 +thrombotic 3 +events 0 +may 0 +be 0 +higher 0 +with 0 +cyclooxygenase 0 +( 0 +C0X 0 +) 0 +- 0 +2 0 +- 0 +specific 0 +inhibitors 0 +than 0 +nonselective 0 +nonsteroidal 0 +antiinflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +. 0 + +We 0 +evaluated 0 +cardiovascular 0 +event 0 +data 0 +for 0 +valdecoxib 1 +, 0 +a 0 +new 0 +C0X 0 +- 0 +2 0 +- 0 +specific 0 +inhibitor 0 +in 0 +approximately 0 +8000 0 +patients 0 +with 0 +osteoarthritis 3 +and 0 +rheumatoid 3 +arthritis 4 +treated 0 +with 0 +this 0 +agent 0 +in 0 +randomized 0 +clinical 0 +trials 0 +. 0 + +The 0 +incidence 0 +of 0 +cardiovascular 0 +thrombotic 3 +events 0 +( 0 +cardiac 0 +, 0 +cerebrovascular 0 +and 0 +peripheral 0 +vascular 0 +, 0 +or 0 +arterial 0 +thrombotic 3 +) 0 +was 0 +determined 0 +by 0 +analyzing 0 +pooled 0 +valdecoxib 1 +( 0 +10 0 +- 0 +80 0 +mg 0 +daily 0 +) 0 +, 0 +nonselective 0 +NSAID 0 +( 0 +diclofenac 1 +75 0 +mg 0 +bid 0 +, 0 +ibuprofen 1 +800 0 +mg 0 +tid 0 +, 0 +or 0 +naproxen 1 +500 0 +mg 0 +bid 0 +) 0 +and 0 +placebo 0 +data 0 +from 0 +10 0 +randomized 0 +osteoarthritis 3 +and 0 +rheumatoid 3 +arthritis 4 +trials 0 +that 0 +were 0 +6 0 +- 0 +52 0 +weeks 0 +in 0 +duration 0 +. 0 + +The 0 +incidence 0 +rates 0 +of 0 +events 0 +were 0 +determined 0 +in 0 +all 0 +patients 0 +( 0 +n 0 += 0 +7934 0 +) 0 +and 0 +in 0 +users 0 +of 0 +low 0 +- 0 +dose 0 +( 0 +< 0 +or 0 += 0 +325 0 +mg 0 +daily 0 +) 0 +aspirin 1 +( 0 +n 0 += 0 +1051 0 +) 0 +and 0 +nonusers 0 +of 0 +aspirin 1 +( 0 +n 0 += 0 +6883 0 +) 0 +. 0 + +Crude 0 +and 0 +exposure 0 +- 0 +adjusted 0 +incidences 0 +of 0 +thrombotic 3 +events 0 +were 0 +similar 0 +for 0 +valdecoxib 1 +, 0 +NSAIDs 0 +, 0 +and 0 +placebo 0 +. 0 + +The 0 +risk 0 +of 0 +serious 0 +thrombotic 3 +events 0 +was 0 +also 0 +similar 0 +for 0 +each 0 +valdecoxib 1 +dose 0 +. 0 + +Thrombotic 3 +risk 0 +was 0 +consistently 0 +higher 0 +for 0 +users 0 +of 0 +aspirin 1 +users 0 +than 0 +nonusers 0 +of 0 +aspirin 1 +( 0 +placebo 0 +, 0 +1 0 +. 0 +4 0 +% 0 +vs 0 +. 0 +0 0 +% 0 +; 0 +valdecoxib 1 +, 0 +1 0 +. 0 +7 0 +% 0 +vs 0 +. 0 +0 0 +. 0 +2 0 +% 0 +; 0 +NSAIDs 0 +, 0 +1 0 +. 0 +9 0 +% 0 +vs 0 +. 0 +0 0 +. 0 +5 0 +% 0 +) 0 +. 0 + +The 0 +rates 0 +of 0 +events 0 +in 0 +users 0 +of 0 +aspirin 1 +were 0 +similar 0 +for 0 +all 0 +3 0 +treatment 0 +groups 0 +and 0 +across 0 +valdecoxib 1 +doses 0 +. 0 + +Short 0 +- 0 +and 0 +intermediate 0 +- 0 +term 0 +treatment 0 +with 0 +therapeutic 0 +( 0 +10 0 +or 0 +20 0 +mg 0 +daily 0 +) 0 +and 0 +supratherapeutic 0 +( 0 +40 0 +or 0 +80 0 +mg 0 +daily 0 +) 0 +valdecoxib 1 +doses 0 +was 0 +not 0 +associated 0 +with 0 +an 0 +increased 0 +incidence 0 +of 0 +thrombotic 3 +events 0 +relative 0 +to 0 +nonselective 0 +NSAIDs 0 +or 0 +placebo 0 +in 0 +osteoarthritis 3 +and 0 +rheumatoid 3 +arthritis 4 +patients 0 +in 0 +controlled 0 +clinical 0 +trials 0 +. 0 + +Hypersensitivity 3 +myocarditis 3 +complicating 0 +hypertrophic 3 +cardiomyopathy 4 +heart 0 +. 0 + +The 0 +present 0 +report 0 +describes 0 +a 0 +case 0 +of 0 +eosinophilic 3 +myocarditis 4 +complicating 0 +hypertrophic 3 +cardiomyopathy 4 +. 0 + +The 0 +47 0 +- 0 +year 0 +- 0 +old 0 +female 0 +patient 0 +, 0 +known 0 +to 0 +have 0 +hypertrophic 3 +cardiomyopathy 4 +, 0 +was 0 +admitted 0 +with 0 +biventricular 3 +failure 4 +and 0 +managed 0 +aggressively 0 +with 0 +dobutamine 1 +infusion 0 +and 0 +other 0 +drugs 0 +while 0 +being 0 +assessed 0 +for 0 +heart 0 +transplantation 0 +. 0 + +0n 0 +transthoracic 0 +echocardiogram 0 +, 0 +she 0 +had 0 +moderate 0 +left 3 +ventricular 4 +dysfunction 4 +with 0 +regional 0 +variability 0 +and 0 +moderate 0 +mitral 3 +regurgitation 4 +. 0 + +The 0 +recipient 0 +' 0 +s 0 +heart 0 +showed 0 +the 0 +features 0 +of 0 +apical 0 +hypertrophic 3 +cardiomyopathy 4 +and 0 +myocarditis 3 +with 0 +abundant 0 +eosinophils 0 +. 0 + +Myocarditis 3 +is 0 +rare 0 +and 0 +eosinophilic 3 +myocarditis 4 +is 0 +rarer 0 +. 0 + +It 0 +is 0 +likely 0 +that 0 +the 0 +hypersensitivity 3 +( 0 +eosinophilic 3 +) 0 +myocarditis 3 +was 0 +related 0 +to 0 +dobutamine 1 +infusion 0 +therapy 0 +. 0 + +Eosinophilic 3 +myocarditis 4 +has 0 +been 0 +reported 0 +with 0 +an 0 +incidence 0 +of 0 +2 0 +. 0 +4 0 +% 0 +to 0 +7 0 +. 0 +2 0 +% 0 +in 0 +explanted 0 +hearts 0 +and 0 +may 0 +be 0 +related 0 +to 0 +multidrug 0 +therapy 0 +. 0 + +Time 0 +trends 0 +in 0 +warfarin 1 +- 0 +associated 0 +hemorrhage 3 +. 0 + +The 0 +annual 0 +incidence 0 +of 0 +warfarin 1 +- 0 +related 0 +bleeding 3 +at 0 +Brigham 0 +and 0 +Women 0 +' 0 +s 0 +Hospital 0 +increased 0 +from 0 +0 0 +. 0 +97 0 +/ 0 +1 0 +, 0 +000 0 +patient 0 +admissions 0 +in 0 +the 0 +first 0 +time 0 +period 0 +( 0 +January 0 +1995 0 +to 0 +0ctober 0 +1998 0 +) 0 +to 0 +1 0 +. 0 +19 0 +/ 0 +1 0 +, 0 +000 0 +patient 0 +admissions 0 +in 0 +the 0 +second 0 +time 0 +period 0 +( 0 +November 0 +1998 0 +to 0 +August 0 +2002 0 +) 0 +of 0 +this 0 +study 0 +. 0 + +The 0 +proportion 0 +of 0 +patients 0 +with 0 +major 0 +and 0 +intracranial 3 +bleeding 4 +increased 0 +from 0 +20 0 +. 0 +2 0 +% 0 +and 0 +1 0 +. 0 +9 0 +% 0 +, 0 +respectively 0 +, 0 +in 0 +the 0 +first 0 +time 0 +period 0 +, 0 +to 0 +33 0 +. 0 +3 0 +% 0 +and 0 +7 0 +. 0 +8 0 +% 0 +, 0 +respectively 0 +, 0 +in 0 +the 0 +second 0 +. 0 + +Yohimbine 1 +treatment 0 +of 0 +sexual 3 +side 4 +effects 4 +induced 0 +by 0 +serotonin 1 +reuptake 0 +blockers 0 +. 0 + +BACKGR0UND 0 +: 0 +Preclinical 0 +and 0 +clinical 0 +studies 0 +suggest 0 +that 0 +yohimbine 1 +facilitates 0 +sexual 0 +behavior 0 +and 0 +may 0 +be 0 +helpful 0 +in 0 +the 0 +treatment 0 +of 0 +male 3 +impotence 4 +. 0 + +A 0 +single 0 +case 0 +report 0 +suggests 0 +that 0 +yohimbine 1 +may 0 +be 0 +used 0 +to 0 +treat 0 +the 0 +sexual 3 +side 4 +effects 4 +of 0 +clomipramine 1 +. 0 + +This 0 +study 0 +evaluated 0 +yohimbine 1 +as 0 +a 0 +treatment 0 +for 0 +the 0 +sexual 3 +side 4 +effects 4 +caused 0 +by 0 +serotonin 1 +reuptake 0 +blockers 0 +. 0 + +METH0D 0 +: 0 +Six 0 +patients 0 +with 0 +either 0 +obsessive 3 +compulsive 4 +disorder 4 +, 0 +trichotillomania 3 +, 0 +anxiety 3 +, 0 +or 0 +affective 3 +disorders 4 +who 0 +suffered 0 +sexual 3 +side 4 +effects 4 +after 0 +treatment 0 +with 0 +serotonin 1 +reuptake 0 +blockers 0 +were 0 +given 0 +yohimbine 1 +on 0 +a 0 +p 0 +. 0 +r 0 +. 0 +n 0 +. 0 +basis 0 +in 0 +an 0 +open 0 +clinical 0 +trial 0 +. 0 + +Various 0 +doses 0 +of 0 +yohimbine 1 +were 0 +used 0 +to 0 +determine 0 +the 0 +ideal 0 +dose 0 +for 0 +each 0 +patient 0 +. 0 + +RESULTS 0 +: 0 +Five 0 +of 0 +the 0 +six 0 +patients 0 +experienced 0 +improved 0 +sexual 0 +functioning 0 +after 0 +taking 0 +yohimbine 1 +. 0 + +0ne 0 +patient 0 +who 0 +failed 0 +to 0 +comply 0 +with 0 +yohimbine 1 +treatment 0 +had 0 +no 0 +therapeutic 0 +effects 0 +. 0 + +Side 0 +effects 0 +of 0 +yohimbine 1 +included 0 +excessive 0 +sweating 0 +, 0 +increased 0 +anxiety 3 +, 0 +and 0 +a 0 +wound 0 +- 0 +up 0 +feeling 0 +in 0 +some 0 +patients 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +results 0 +of 0 +this 0 +study 0 +indicate 0 +that 0 +yohimbine 1 +may 0 +be 0 +an 0 +effective 0 +treatment 0 +for 0 +the 0 +sexual 3 +side 4 +effects 4 +caused 0 +by 0 +serotonin 1 +reuptake 0 +blockers 0 +. 0 + +Future 0 +controlled 0 +studies 0 +are 0 +needed 0 +to 0 +further 0 +investigate 0 +the 0 +effectiveness 0 +and 0 +safety 0 +of 0 +yohimbine 1 +for 0 +this 0 +indication 0 +. 0 + +Hemorrhagic 3 +cystitis 4 +complicating 0 +bone 0 +marrow 0 +transplantation 0 +. 0 + +Hemorrhagic 3 +cystitis 4 +is 0 +a 0 +potentially 0 +serious 0 +complication 0 +of 0 +high 0 +- 0 +dose 0 +cyclophosphamide 1 +therapy 0 +administered 0 +before 0 +bone 0 +marrow 0 +transplantation 0 +. 0 + +As 0 +standard 0 +practice 0 +at 0 +our 0 +institution 0 +, 0 +patients 0 +who 0 +are 0 +scheduled 0 +to 0 +receive 0 +a 0 +bone 0 +marrow 0 +transplant 0 +are 0 +treated 0 +prophylactically 0 +with 0 +forced 0 +hydration 0 +and 0 +bladder 0 +irrigation 0 +. 0 + +In 0 +an 0 +attempt 0 +to 0 +obviate 0 +the 0 +inconvenience 0 +of 0 +bladder 0 +irrigation 0 +, 0 +we 0 +conducted 0 +a 0 +feasibility 0 +trial 0 +of 0 +uroprophylaxis 0 +with 0 +mesna 1 +, 0 +which 0 +neutralizes 0 +the 0 +hepatic 0 +metabolite 0 +of 0 +cyclophosphamide 1 +that 0 +causes 0 +hemorrhagic 3 +cystitis 4 +. 0 + +0f 0 +97 0 +patients 0 +who 0 +received 0 +standard 0 +prophylaxis 0 +, 0 +4 0 +had 0 +symptomatic 0 +hemorrhagic 3 +cystitis 4 +. 0 + +In 0 +contrast 0 +, 0 +two 0 +of 0 +four 0 +consecutive 0 +patients 0 +who 0 +received 0 +mesna 1 +uroprophylaxis 0 +before 0 +allogeneic 0 +bone 0 +marrow 0 +transplantation 0 +had 0 +severe 0 +hemorrhagic 3 +cystitis 4 +for 0 +at 0 +least 0 +2 0 +weeks 0 +. 0 + +Because 0 +of 0 +this 0 +suboptimal 0 +result 0 +, 0 +we 0 +resumed 0 +the 0 +use 0 +of 0 +bladder 0 +irrigation 0 +and 0 +forced 0 +hydration 0 +to 0 +minimize 0 +the 0 +risk 0 +of 0 +hemorrhagic 3 +cystitis 4 +. 0 + +Consensus 0 +statement 0 +concerning 0 +cardiotoxicity 3 +occurring 0 +during 0 +haematopoietic 0 +stem 0 +cell 0 +transplantation 0 +in 0 +the 0 +treatment 0 +of 0 +autoimmune 3 +diseases 4 +, 0 +with 0 +special 0 +reference 0 +to 0 +systemic 3 +sclerosis 4 +and 0 +multiple 3 +sclerosis 4 +. 0 + +Autologous 0 +haematopoietic 0 +stem 0 +cell 0 +transplantation 0 +is 0 +now 0 +a 0 +feasible 0 +and 0 +effective 0 +treatment 0 +for 0 +selected 0 +patients 0 +with 0 +severe 0 +autoimmune 3 +diseases 4 +. 0 + +Worldwide 0 +, 0 +over 0 +650 0 +patients 0 +have 0 +been 0 +transplanted 0 +in 0 +the 0 +context 0 +of 0 +phase 0 +I 0 +and 0 +II 0 +clinical 0 +trials 0 +. 0 + +The 0 +results 0 +are 0 +encouraging 0 +enough 0 +to 0 +begin 0 +randomised 0 +phase 0 +III 0 +trials 0 +. 0 + +However 0 +, 0 +as 0 +predicted 0 +, 0 +significant 0 +transplant 0 +- 0 +related 0 +morbidity 0 +and 0 +mortality 0 +have 0 +been 0 +observed 0 +. 0 + +This 0 +is 0 +primarily 0 +due 0 +to 0 +complications 0 +related 0 +to 0 +either 0 +the 0 +stage 0 +of 0 +the 0 +disease 0 +at 0 +transplant 0 +or 0 +due 0 +to 0 +infections 3 +. 0 + +The 0 +number 0 +of 0 +deaths 0 +related 0 +to 0 +cardiac 3 +toxicity 4 +is 0 +low 0 +. 0 + +However 0 +, 0 +caution 0 +is 0 +required 0 +when 0 +cyclophosphamide 1 +or 0 +anthracyclines 1 +such 0 +as 0 +mitoxantrone 1 +are 0 +used 0 +in 0 +patients 0 +with 0 +a 0 +possible 0 +underlying 0 +heart 3 +damage 4 +, 0 +for 0 +example 0 +, 0 +systemic 3 +sclerosis 4 +patients 0 +. 0 + +In 0 +November 0 +2002 0 +, 0 +a 0 +meeting 0 +was 0 +held 0 +in 0 +Florence 0 +, 0 +bringing 0 +together 0 +a 0 +number 0 +of 0 +experts 0 +in 0 +various 0 +fields 0 +, 0 +including 0 +rheumatology 0 +, 0 +cardiology 0 +, 0 +neurology 0 +, 0 +pharmacology 0 +and 0 +transplantation 0 +medicine 0 +. 0 + +The 0 +object 0 +of 0 +the 0 +meeting 0 +was 0 +to 0 +analyse 0 +existing 0 +data 0 +, 0 +both 0 +published 0 +or 0 +available 0 +, 0 +in 0 +the 0 +European 0 +Group 0 +for 0 +Blood 0 +and 0 +Marrow 0 +Transplantation 0 +autoimmune 3 +disease 4 +database 0 +, 0 +and 0 +to 0 +propose 0 +a 0 +safe 0 +approach 0 +to 0 +such 0 +patients 0 +. 0 + +A 0 +full 0 +cardiological 0 +assessment 0 +before 0 +and 0 +during 0 +the 0 +transplant 0 +emerged 0 +as 0 +the 0 +major 0 +recommendation 0 +. 0 + +Does 0 +supplemental 0 +vitamin 1 +C 2 +increase 0 +cardiovascular 3 +disease 4 +risk 0 +in 0 +women 0 +with 0 +diabetes 3 +? 0 + +BACKGR0UND 0 +: 0 +Vitamin 1 +C 2 +acts 0 +as 0 +a 0 +potent 0 +antioxidant 0 +; 0 +however 0 +, 0 +it 0 +can 0 +also 0 +be 0 +a 0 +prooxidant 0 +and 0 +glycate 0 +protein 0 +under 0 +certain 0 +circumstances 0 +in 0 +vitro 0 +. 0 + +These 0 +observations 0 +led 0 +us 0 +to 0 +hypothesize 0 +that 0 +a 0 +high 0 +intake 0 +of 0 +vitamin 1 +C 2 +in 0 +diabetic 3 +persons 0 +might 0 +promote 0 +atherosclerosis 3 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +objective 0 +was 0 +to 0 +examine 0 +the 0 +relation 0 +between 0 +vitamin 1 +C 2 +intake 0 +and 0 +mortality 0 +from 0 +cardiovascular 3 +disease 4 +. 0 + +DESIGN 0 +: 0 +We 0 +studied 0 +the 0 +relation 0 +between 0 +vitamin 1 +C 2 +intake 0 +and 0 +mortality 0 +from 0 +total 0 +cardiovascular 3 +disease 4 +( 0 +n 0 += 0 +281 0 +) 0 +, 0 +coronary 3 +artery 4 +disease 4 +( 0 +n 0 += 0 +175 0 +) 0 +, 0 +and 0 +stroke 3 +( 0 +n 0 += 0 +57 0 +) 0 +in 0 +1923 0 +postmenopausal 0 +women 0 +who 0 +reported 0 +being 0 +diabetic 3 +at 0 +baseline 0 +. 0 + +Diet 0 +was 0 +assessed 0 +with 0 +a 0 +food 0 +- 0 +frequency 0 +questionnaire 0 +at 0 +baseline 0 +, 0 +and 0 +subjects 0 +initially 0 +free 0 +of 0 +coronary 3 +artery 4 +disease 4 +were 0 +prospectively 0 +followed 0 +for 0 +15 0 +y 0 +. 0 + +RESULTS 0 +: 0 +After 0 +adjustment 0 +for 0 +cardiovascular 3 +disease 4 +risk 0 +factors 0 +, 0 +type 0 +of 0 +diabetes 3 +medication 0 +used 0 +, 0 +duration 0 +of 0 +diabetes 3 +, 0 +and 0 +intakes 0 +of 0 +folate 1 +, 0 +vitamin 1 +E 2 +, 0 +and 0 +beta 1 +- 2 +carotene 2 +, 0 +the 0 +adjusted 0 +relative 0 +risks 0 +of 0 +total 0 +cardiovascular 3 +disease 4 +mortality 0 +were 0 +1 0 +. 0 +0 0 +, 0 +0 0 +. 0 +97 0 +, 0 +1 0 +. 0 +11 0 +, 0 +1 0 +. 0 +47 0 +, 0 +and 0 +1 0 +. 0 +84 0 +( 0 +P 0 +for 0 +trend 0 +< 0 +0 0 +. 0 +01 0 +) 0 +across 0 +quintiles 0 +of 0 +total 0 +vitamin 1 +C 2 +intake 0 +from 0 +food 0 +and 0 +supplements 0 +. 0 + +Adjusted 0 +relative 0 +risks 0 +of 0 +coronary 3 +artery 4 +disease 4 +were 0 +1 0 +. 0 +0 0 +, 0 +0 0 +. 0 +81 0 +, 0 +0 0 +. 0 +99 0 +, 0 +1 0 +. 0 +26 0 +, 0 +and 0 +1 0 +. 0 +91 0 +( 0 +P 0 +for 0 +trend 0 += 0 +0 0 +. 0 +01 0 +) 0 +and 0 +of 0 +stroke 3 +were 0 +1 0 +. 0 +0 0 +, 0 +0 0 +. 0 +52 0 +, 0 +1 0 +. 0 +23 0 +, 0 +2 0 +. 0 +22 0 +, 0 +and 0 +2 0 +. 0 +57 0 +( 0 +P 0 +for 0 +trend 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +When 0 +dietary 0 +and 0 +supplemental 0 +vitamin 1 +C 2 +were 0 +analyzed 0 +separately 0 +, 0 +only 0 +supplemental 0 +vitamin 1 +C 2 +showed 0 +a 0 +positive 0 +association 0 +with 0 +mortality 0 +endpoints 0 +. 0 + +Vitamin 1 +C 2 +intake 0 +was 0 +unrelated 0 +to 0 +mortality 0 +from 0 +cardiovascular 3 +disease 4 +in 0 +the 0 +nondiabetic 0 +subjects 0 +at 0 +baseline 0 +. 0 + +C0NCLUSI0N 0 +: 0 +A 0 +high 0 +vitamin 1 +C 2 +intake 0 +from 0 +supplements 0 +is 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +of 0 +cardiovascular 3 +disease 4 +mortality 0 +in 0 +postmenopausal 0 +women 0 +with 0 +diabetes 3 +. 0 + +0ptical 0 +coherence 0 +tomography 0 +can 0 +measure 0 +axonal 0 +loss 0 +in 0 +patients 0 +with 0 +ethambutol 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +map 0 +and 0 +identify 0 +the 0 +pattern 0 +, 0 +in 0 +vivo 0 +, 0 +of 0 +axonal 3 +degeneration 4 +in 0 +ethambutol 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +using 0 +optical 0 +coherence 0 +tomography 0 +( 0 +0CT 0 +) 0 +. 0 + +Ethambutol 1 +is 0 +an 0 +antimycobacterial 0 +agent 0 +often 0 +used 0 +to 0 +treat 0 +tuberculosis 3 +. 0 + +A 0 +serious 0 +complication 0 +of 0 +ethambutol 1 +is 0 +an 0 +optic 3 +neuropathy 4 +that 0 +impairs 0 +visual 0 +acuity 0 +, 0 +contrast 0 +sensitivity 0 +, 0 +and 0 +color 0 +vision 0 +. 0 + +However 0 +, 0 +early 0 +on 0 +, 0 +when 0 +the 0 +toxic 0 +optic 3 +neuropathy 4 +is 0 +mild 0 +and 0 +partly 0 +reversible 0 +, 0 +the 0 +funduscopic 0 +findings 0 +are 0 +often 0 +subtle 0 +and 0 +easy 0 +to 0 +miss 0 +. 0 + +METH0DS 0 +: 0 +Three 0 +subjects 0 +with 0 +a 0 +history 0 +of 0 +ethambutol 1 +( 0 +EMB 1 +) 0 +- 0 +induced 0 +optic 3 +neuropathy 4 +of 0 +short 0 +- 0 +, 0 +intermediate 0 +- 0 +, 0 +and 0 +long 0 +- 0 +term 0 +visual 3 +deficits 4 +were 0 +administered 0 +a 0 +full 0 +neuro 0 +- 0 +ophthalmologic 0 +examination 0 +including 0 +visual 0 +acuity 0 +, 0 +color 0 +vision 0 +, 0 +contrast 0 +sensitivity 0 +, 0 +and 0 +fundus 0 +examination 0 +. 0 + +In 0 +addition 0 +, 0 +0CT 0 +( 0 +0CT 0 +3000 0 +, 0 +Humphrey 0 +- 0 +Zeiss 0 +, 0 +Dublin 0 +, 0 +CA 0 +) 0 +was 0 +performed 0 +on 0 +both 0 +eyes 0 +of 0 +each 0 +subject 0 +using 0 +the 0 +retinal 0 +nerve 0 +fiber 0 +layer 0 +( 0 +RNFL 0 +) 0 +analysis 0 +protocol 0 +. 0 + +0CT 0 +interpolates 0 +data 0 +from 0 +100 0 +points 0 +around 0 +the 0 +optic 0 +nerve 0 +to 0 +effectively 0 +map 0 +out 0 +the 0 +RNFL 0 +. 0 + +RESULTS 0 +: 0 +The 0 +results 0 +were 0 +compared 0 +to 0 +the 0 +calculated 0 +average 0 +RNFL 0 +of 0 +normal 0 +eyes 0 +accumulated 0 +from 0 +four 0 +prior 0 +studies 0 +using 0 +0CT 0 +, 0 +n 0 += 0 +661 0 +. 0 + +In 0 +all 0 +subjects 0 +with 0 +history 0 +of 0 +EMB 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +, 0 +there 0 +was 0 +a 0 +mean 0 +loss 0 +of 0 +72 0 +% 0 +nerve 0 +fiber 0 +layer 0 +thickness 0 +in 0 +the 0 +temporal 0 +quadrant 0 +( 0 +patient 0 +A 0 +, 0 +with 0 +eventual 0 +recovery 0 +of 0 +visual 0 +acuity 0 +and 0 +fields 0 +, 0 +58 0 +% 0 +loss 0 +; 0 +patient 0 +B 0 +, 0 +with 0 +intermediate 0 +visual 3 +deficits 4 +, 0 +68 0 +% 0 +loss 0 +; 0 +patient 0 +C 0 +, 0 +with 0 +chronic 0 +visual 3 +deficits 4 +, 0 +90 0 +% 0 +loss 0 +) 0 +, 0 +with 0 +an 0 +average 0 +mean 0 +optic 0 +nerve 0 +thickness 0 +of 0 +26 0 ++ 0 +/ 0 +- 0 +16 0 +microm 0 +. 0 + +There 0 +was 0 +a 0 +combined 0 +mean 0 +loss 0 +of 0 +46 0 +% 0 +of 0 +fibers 0 +from 0 +the 0 +superior 0 +, 0 +inferior 0 +, 0 +and 0 +nasal 0 +quadrants 0 +in 0 +the 0 +( 0 +six 0 +) 0 +eyes 0 +of 0 +all 0 +three 0 +subjects 0 +( 0 +mean 0 +average 0 +thickness 0 +of 0 +55 0 ++ 0 +/ 0 +- 0 +29 0 +microm 0 +) 0 +. 0 + +In 0 +both 0 +sets 0 +( 0 +four 0 +) 0 +of 0 +eyes 0 +of 0 +the 0 +subjects 0 +with 0 +persistent 0 +visual 3 +deficits 4 +( 0 +patients 0 +B 0 +and 0 +C 0 +) 0 +, 0 +there 0 +was 0 +an 0 +average 0 +loss 0 +of 0 +79 0 +% 0 +of 0 +nerve 0 +fiber 0 +thickness 0 +in 0 +the 0 +temporal 0 +quadrant 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +0CT 0 +results 0 +in 0 +these 0 +patients 0 +with 0 +EMB 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +show 0 +considerable 0 +loss 0 +especially 0 +of 0 +the 0 +temporal 0 +fibers 0 +. 0 + +This 0 +is 0 +consistent 0 +with 0 +prior 0 +histopathological 0 +studies 0 +that 0 +show 0 +predominant 0 +loss 0 +of 0 +parvo 0 +- 0 +cellular 0 +axons 0 +( 0 +or 0 +small 0 +- 0 +caliber 0 +axons 0 +) 0 +within 0 +the 0 +papillo 0 +- 0 +macular 0 +bundle 0 +in 0 +toxic 0 +or 0 +hereditary 0 +optic 3 +neuropathies 4 +. 0 + +0CT 0 +can 0 +be 0 +a 0 +valuable 0 +tool 0 +in 0 +the 0 +quantitative 0 +analysis 0 +of 0 +optic 3 +neuropathies 4 +. 0 + +Additionally 0 +, 0 +in 0 +terms 0 +of 0 +management 0 +of 0 +EMB 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +, 0 +it 0 +is 0 +important 0 +to 0 +properly 0 +manage 0 +ethambutol 1 +dosing 0 +in 0 +patients 0 +with 0 +renal 3 +impairment 4 +and 0 +to 0 +achieve 0 +proper 0 +transition 0 +to 0 +a 0 +maintenance 0 +dose 0 +once 0 +an 0 +appropriate 0 +loading 0 +dose 0 +has 0 +been 0 +reached 0 +. 0 + +Hypoxia 3 +in 0 +renal 3 +disease 4 +with 0 +proteinuria 3 +and 0 +/ 0 +or 0 +glomerular 0 +hypertension 3 +. 0 + +Despite 0 +the 0 +increasing 0 +need 0 +to 0 +identify 0 +and 0 +quantify 0 +tissue 0 +oxygenation 0 +at 0 +the 0 +cellular 0 +level 0 +, 0 +relatively 0 +few 0 +methods 0 +have 0 +been 0 +available 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +developed 0 +a 0 +new 0 +hypoxia 3 +- 0 +responsive 0 +reporter 0 +vector 0 +using 0 +a 0 +hypoxia 3 +- 0 +responsive 0 +element 0 +of 0 +the 0 +5 0 +' 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +untranslated 0 +region 0 +and 0 +generated 0 +a 0 +novel 0 +hypoxia 3 +- 0 +sensing 0 +transgenic 0 +rat 0 +. 0 + +We 0 +then 0 +applied 0 +this 0 +animal 0 +model 0 +to 0 +the 0 +detection 0 +of 0 +tubulointerstitial 0 +hypoxia 3 +in 0 +the 0 +diseased 3 +kidney 4 +. 0 + +With 0 +this 0 +model 0 +, 0 +we 0 +were 0 +able 0 +to 0 +identify 0 +diffuse 0 +cortical 0 +hypoxia 3 +in 0 +the 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +and 0 +focal 0 +and 0 +segmental 0 +hypoxia 3 +in 0 +the 0 +remnant 0 +kidney 0 +model 0 +. 0 + +Expression 0 +of 0 +the 0 +hypoxia 3 +- 0 +responsive 0 +transgene 0 +increased 0 +throughout 0 +the 0 +observation 0 +period 0 +, 0 +reaching 0 +2 0 +. 0 +2 0 +- 0 +fold 0 +at 0 +2 0 +weeks 0 +in 0 +the 0 +puromycin 1 +aminonucleoside 2 +model 0 +and 0 +2 0 +. 0 +6 0 +- 0 +fold 0 +at 0 +4 0 +weeks 0 +in 0 +the 0 +remnant 0 +kidney 0 +model 0 +, 0 +whereas 0 +that 0 +of 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +showed 0 +a 0 +mild 0 +decrease 0 +, 0 +reflecting 0 +distinct 0 +behaviors 0 +of 0 +the 0 +two 0 +genes 0 +. 0 + +The 0 +degree 0 +of 0 +hypoxia 3 +showed 0 +a 0 +positive 0 +correlation 0 +with 0 +microscopic 0 +tubulointerstitial 3 +injury 4 +in 0 +both 0 +models 0 +. 0 + +Finally 0 +, 0 +we 0 +identified 0 +the 0 +localization 0 +of 0 +proliferating 0 +cell 0 +nuclear 0 +antigen 0 +- 0 +positive 0 +, 0 +ED 0 +- 0 +1 0 +- 0 +positive 0 +, 0 +and 0 +terminal 0 +dUTP 0 +nick 0 +- 0 +end 0 +labeled 0 +- 0 +positive 0 +cells 0 +in 0 +the 0 +hypoxic 3 +cortical 0 +area 0 +in 0 +the 0 +remnant 0 +kidney 0 +model 0 +. 0 + +We 0 +propose 0 +here 0 +a 0 +possible 0 +pathological 0 +tie 0 +between 0 +chronic 0 +tubulointerstitial 0 +hypoxia 3 +and 0 +progressive 0 +glomerular 3 +diseases 4 +. 0 + +Adequate 0 +timing 0 +of 0 +ribavirin 1 +reduction 0 +in 0 +patients 0 +with 0 +hemolysis 3 +during 0 +combination 0 +therapy 0 +of 0 +interferon 1 +and 0 +ribavirin 1 +for 0 +chronic 3 +hepatitis 4 +C 4 +. 0 + +BACKGR0UND 0 +: 0 +Hemolytic 3 +anemia 4 +is 0 +one 0 +of 0 +the 0 +major 0 +adverse 0 +events 0 +of 0 +the 0 +combination 0 +therapy 0 +of 0 +interferon 1 +and 0 +ribavirin 1 +. 0 + +Because 0 +of 0 +ribavirin 1 +- 0 +related 0 +hemolytic 3 +anemia 4 +, 0 +dose 0 +reduction 0 +is 0 +a 0 +common 0 +event 0 +in 0 +this 0 +therapy 0 +. 0 + +In 0 +this 0 +clinical 0 +retrospective 0 +cohort 0 +study 0 +we 0 +have 0 +examined 0 +the 0 +suitable 0 +timing 0 +of 0 +ribavirin 1 +reduction 0 +in 0 +patients 0 +with 0 +hemolysis 3 +during 0 +combination 0 +therapy 0 +. 0 + +METH0DS 0 +: 0 +Thirty 0 +- 0 +seven 0 +of 0 +160 0 +patients 0 +who 0 +had 0 +HCV 0 +- 0 +genotype 0 +1b 0 +, 0 +had 0 +high 0 +virus 0 +load 0 +, 0 +and 0 +received 0 +24 0 +- 0 +week 0 +combination 0 +therapy 0 +developed 0 +anemia 3 +with 0 +hemoglobin 0 +level 0 +< 0 +10 0 +g 0 +/ 0 +dl 0 +or 0 +anemia 3 +- 0 +related 0 +signs 0 +during 0 +therapy 0 +. 0 + +After 0 +that 0 +, 0 +these 0 +37 0 +patients 0 +were 0 +reduced 0 +one 0 +tablet 0 +of 0 +ribavirin 1 +( 0 +200 0 +mg 0 +) 0 +per 0 +day 0 +. 0 + +After 0 +reduction 0 +of 0 +ribavirin 1 +, 0 +27 0 +of 0 +37 0 +patients 0 +could 0 +continue 0 +combination 0 +therapy 0 +for 0 +a 0 +total 0 +of 0 +24 0 +weeks 0 +( 0 +group 0 +A 0 +) 0 +. 0 + +However 0 +, 0 +10 0 +of 0 +37 0 +patients 0 +with 0 +reduction 0 +of 0 +ribavirin 1 +could 0 +not 0 +continue 0 +combination 0 +therapy 0 +because 0 +their 0 +< 0 +8 0 +. 0 +5 0 +g 0 +/ 0 +dl 0 +hemoglobin 0 +values 0 +decreased 0 +to 0 +or 0 +anemia 3 +- 0 +related 0 +severe 0 +side 0 +effects 0 +occurred 0 +( 0 +group 0 +B 0 +) 0 +. 0 + +We 0 +assessed 0 +the 0 +final 0 +efficacy 0 +and 0 +safety 0 +after 0 +reduction 0 +of 0 +ribavirin 1 +in 0 +groups 0 +A 0 +and 0 +B 0 +. 0 + +RESULTS 0 +: 0 +A 0 +sustained 0 +virological 0 +response 0 +( 0 +SVR 0 +) 0 +was 0 +29 0 +. 0 +6 0 +% 0 +( 0 +8 0 +/ 0 +27 0 +) 0 +in 0 +group 0 +A 0 +and 0 +10 0 +% 0 +( 0 +1 0 +/ 0 +10 0 +) 0 +in 0 +group 0 +B 0 +, 0 +respectively 0 +. 0 + +A 0 +34 0 +. 0 +4 0 +% 0 +( 0 +12 0 +/ 0 +27 0 +) 0 +of 0 +SVR 0 ++ 0 +biological 0 +response 0 +in 0 +group 0 +A 0 +was 0 +higher 0 +than 0 +10 0 +% 0 +( 0 +1 0 +/ 0 +10 0 +) 0 +in 0 +group 0 +B 0 +( 0 +P 0 += 0 +0 0 +. 0 +051 0 +) 0 +, 0 +with 0 +slight 0 +significance 0 +. 0 + +With 0 +respect 0 +to 0 +hemoglobin 0 +level 0 +at 0 +the 0 +time 0 +of 0 +ribavirin 1 +reduction 0 +, 0 +a 0 +rate 0 +of 0 +continuation 0 +of 0 +therapy 0 +in 0 +patients 0 +with 0 +> 0 +or 0 += 0 +10 0 +g 0 +/ 0 +dl 0 +hemoglobin 0 +was 0 +higher 0 +than 0 +that 0 +in 0 +patients 0 +with 0 +< 0 +10 0 +g 0 +/ 0 +dl 0 +( 0 +P 0 += 0 +0 0 +. 0 +036 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Reduction 0 +of 0 +ribavirin 1 +at 0 +hemoglobin 0 +level 0 +> 0 +or 0 += 0 +10 0 +g 0 +/ 0 +dl 0 +is 0 +suitable 0 +in 0 +terms 0 +of 0 +efficacy 0 +and 0 +side 0 +effects 0 +. 0 + +Aging 0 +process 0 +of 0 +epithelial 0 +cells 0 +of 0 +the 0 +rat 0 +prostate 0 +lateral 0 +lobe 0 +in 0 +experimental 0 +hyperprolactinemia 3 +induced 0 +by 0 +haloperidol 1 +. 0 + +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +examine 0 +the 0 +influence 0 +of 0 +hyperprolactinemia 3 +, 0 +induced 0 +by 0 +haloperidol 1 +( 0 +HAL 1 +) 0 +on 0 +age 0 +related 0 +morphology 0 +and 0 +function 0 +changes 0 +of 0 +epithelial 0 +cells 0 +in 0 +rat 0 +prostate 0 +lateral 0 +lobe 0 +. 0 + +The 0 +study 0 +was 0 +performed 0 +on 0 +sexually 0 +mature 0 +male 0 +rats 0 +. 0 + +Serum 0 +concentrations 0 +of 0 +prolactin 0 +( 0 +PRL 1 +) 0 +and 0 +testosterone 1 +( 0 +T 1 +) 0 +were 0 +measured 0 +. 0 + +Tissue 0 +sections 0 +were 0 +evaluated 0 +with 0 +light 0 +and 0 +electron 0 +microscopy 0 +. 0 + +Immunohistochemical 0 +reactions 0 +for 0 +Anti 0 +- 0 +Proliferating 0 +Cell 0 +Nuclear 0 +Antigen 0 +( 0 +PCNA 0 +) 0 +were 0 +performed 0 +. 0 + +In 0 +rats 0 +of 0 +the 0 +experimental 0 +group 0 +, 0 +the 0 +mean 0 +concentration 0 +of 0 +: 0 +PRL 1 +was 0 +more 0 +than 0 +twice 0 +higher 0 +, 0 +whereas 0 +T 1 +concentration 0 +was 0 +almost 0 +twice 0 +lower 0 +than 0 +that 0 +in 0 +the 0 +control 0 +group 0 +. 0 + +Light 0 +microscopy 0 +visualized 0 +the 0 +following 0 +: 0 +hypertrophy 3 +and 0 +epithelium 0 +hyperplasia 3 +of 0 +the 0 +glandular 0 +ducts 0 +, 0 +associated 0 +with 0 +increased 0 +PCNA 0 +expression 0 +. 0 + +Electron 0 +microscopy 0 +revealed 0 +changes 0 +in 0 +columnar 0 +epithelial 0 +cells 0 +, 0 +concerning 0 +organelles 0 +, 0 +engaged 0 +in 0 +protein 0 +synthesis 0 +and 0 +secretion 0 +. 0 + +Relation 0 +of 0 +perfusion 0 +defects 0 +observed 0 +with 0 +myocardial 0 +contrast 0 +echocardiography 0 +to 0 +the 0 +severity 0 +of 0 +coronary 3 +stenosis 4 +: 0 +correlation 0 +with 0 +thallium 1 +- 0 +201 0 +single 0 +- 0 +photon 0 +emission 0 +tomography 0 +. 0 + +It 0 +has 0 +been 0 +previously 0 +shown 0 +that 0 +myocardial 0 +contrast 0 +echocardiography 0 +is 0 +a 0 +valuable 0 +technique 0 +for 0 +delineating 0 +regions 0 +of 0 +myocardial 0 +underperfusion 0 +secondary 0 +to 0 +coronary 3 +occlusion 4 +and 0 +to 0 +critical 0 +coronary 3 +stenoses 4 +in 0 +the 0 +presence 0 +of 0 +hyperemic 3 +stimulation 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +myocardial 0 +contrast 0 +echocardiography 0 +performed 0 +with 0 +a 0 +stable 0 +solution 0 +of 0 +sonicated 0 +albumin 0 +could 0 +detect 0 +regions 0 +of 0 +myocardial 0 +underperfusion 0 +resulting 0 +from 0 +various 0 +degrees 0 +of 0 +coronary 3 +stenosis 4 +. 0 + +The 0 +perfusion 0 +defect 0 +produced 0 +in 0 +16 0 +open 0 +chest 0 +dogs 0 +was 0 +compared 0 +with 0 +the 0 +anatomic 0 +area 0 +at 0 +risk 0 +measured 0 +by 0 +the 0 +postmortem 0 +dual 0 +- 0 +perfusion 0 +technique 0 +and 0 +with 0 +thallium 1 +- 0 +201 0 +single 0 +- 0 +photon 0 +emission 0 +tomography 0 +( 0 +SPECT 0 +) 0 +. 0 + +During 0 +a 0 +transient 0 +( 0 +20 0 +- 0 +s 0 +) 0 +coronary 3 +occlusion 4 +, 0 +a 0 +perfusion 0 +defect 0 +was 0 +observed 0 +with 0 +contrast 0 +echocardiography 0 +in 0 +14 0 +of 0 +the 0 +15 0 +dogs 0 +in 0 +which 0 +the 0 +occlusion 0 +was 0 +produced 0 +. 0 + +The 0 +perfusion 0 +defect 0 +correlated 0 +significantly 0 +with 0 +the 0 +anatomic 0 +area 0 +at 0 +risk 0 +( 0 +r 0 += 0 +0 0 +. 0 +74 0 +; 0 +p 0 +less 0 +than 0 +0 0 +. 0 +002 0 +) 0 +. 0 + +During 0 +dipyridamole 1 +- 0 +induced 0 +hyperemia 3 +, 0 +12 0 +of 0 +the 0 +16 0 +dogs 0 +with 0 +a 0 +partial 0 +coronary 3 +stenosis 4 +had 0 +a 0 +visible 0 +area 0 +of 0 +hypoperfusion 0 +by 0 +contrast 0 +echocardiography 0 +. 0 + +The 0 +four 0 +dogs 0 +without 0 +a 0 +perfusion 0 +defect 0 +had 0 +a 0 +stenosis 0 +that 0 +resulted 0 +in 0 +a 0 +mild 0 +( 0 +0 0 +% 0 +to 0 +50 0 +% 0 +) 0 +reduction 0 +in 0 +dipyridamole 1 +- 0 +induced 0 +hyperemia 3 +. 0 + +The 0 +size 0 +of 0 +the 0 +perfusion 0 +defect 0 +during 0 +stenosis 0 +correlated 0 +significantly 0 +with 0 +the 0 +anatomic 0 +area 0 +at 0 +risk 0 +( 0 +r 0 += 0 +0 0 +. 0 +61 0 +; 0 +p 0 += 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +Thallium 1 +- 0 +201 0 +SPECT 0 +demonstrated 0 +a 0 +perfusion 0 +defect 0 +in 0 +all 0 +14 0 +dogs 0 +analyzed 0 +during 0 +dipyridamole 1 +- 0 +induced 0 +hyperemia 3 +; 0 +the 0 +size 0 +of 0 +the 0 +perfusion 0 +defect 0 +correlated 0 +with 0 +the 0 +anatomic 0 +area 0 +at 0 +risk 0 +( 0 +r 0 += 0 +0 0 +. 0 +58 0 +; 0 +p 0 +less 0 +than 0 +0 0 +. 0 +03 0 +) 0 +and 0 +with 0 +the 0 +perfusion 0 +defect 0 +by 0 +contrast 0 +echocardiography 0 +( 0 +r 0 += 0 +0 0 +. 0 +58 0 +; 0 +p 0 +less 0 +than 0 +0 0 +. 0 +03 0 +) 0 +. 0 + +Thus 0 +, 0 +myocardial 0 +contrast 0 +echocardiography 0 +can 0 +be 0 +used 0 +to 0 +visualize 0 +and 0 +quantitate 0 +the 0 +amount 0 +of 0 +jeopardized 0 +myocardium 0 +during 0 +moderate 0 +to 0 +severe 0 +degrees 0 +of 0 +coronary 3 +stenosis 4 +. 0 + +The 0 +results 0 +obtained 0 +show 0 +a 0 +correlation 0 +with 0 +the 0 +anatomic 0 +area 0 +at 0 +risk 0 +similar 0 +to 0 +that 0 +obtained 0 +with 0 +thallium 1 +- 0 +201 0 +SPECT 0 +. 0 + +The 0 +activation 0 +of 0 +spinal 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +receptors 0 +may 0 +contribute 0 +to 0 +degeneration 0 +of 0 +spinal 0 +motor 0 +neurons 0 +induced 0 +by 0 +neuraxial 0 +morphine 1 +after 0 +a 0 +noninjurious 0 +interval 0 +of 0 +spinal 3 +cord 4 +ischemia 4 +. 0 + +We 0 +investigated 0 +the 0 +relationship 0 +between 0 +the 0 +degeneration 0 +of 0 +spinal 0 +motor 0 +neurons 0 +and 0 +activation 0 +of 0 +N 1 +- 2 +methyl 2 +- 2 +d 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptors 0 +after 0 +neuraxial 0 +morphine 1 +following 0 +a 0 +noninjurious 0 +interval 0 +of 0 +aortic 3 +occlusion 4 +in 0 +rats 0 +. 0 + +Spinal 3 +cord 4 +ischemia 4 +was 0 +induced 0 +by 0 +aortic 3 +occlusion 4 +for 0 +6 0 +min 0 +with 0 +a 0 +balloon 0 +catheter 0 +. 0 + +In 0 +a 0 +microdialysis 0 +study 0 +, 0 +10 0 +muL 0 +of 0 +saline 0 +( 0 +group 0 +C 0 +; 0 +n 0 += 0 +8 0 +) 0 +or 0 +30 0 +mug 0 +of 0 +morphine 1 +( 0 +group 0 +M 0 +; 0 +n 0 += 0 +8 0 +) 0 +was 0 +injected 0 +intrathecally 0 +( 0 +IT 0 +) 0 +0 0 +. 0 +5 0 +h 0 +after 0 +reflow 0 +, 0 +and 0 +30 0 +mug 0 +of 0 +morphine 1 +( 0 +group 0 +SM 0 +; 0 +n 0 += 0 +8 0 +) 0 +or 0 +10 0 +muL 0 +of 0 +saline 0 +( 0 +group 0 +SC 0 +; 0 +n 0 += 0 +8 0 +) 0 +was 0 +injected 0 +IT 0 +0 0 +. 0 +5 0 +h 0 +after 0 +sham 0 +operation 0 +. 0 + +Microdialysis 0 +samples 0 +were 0 +collected 0 +preischemia 0 +, 0 +before 0 +IT 0 +injection 0 +, 0 +and 0 +at 0 +2 0 +, 0 +4 0 +, 0 +8 0 +, 0 +24 0 +, 0 +and 0 +48 0 +h 0 +of 0 +reperfusion 0 +( 0 +after 0 +IT 0 +injection 0 +) 0 +. 0 + +Second 0 +, 0 +we 0 +investigated 0 +the 0 +effect 0 +of 0 +IT 0 +MK 1 +- 2 +801 2 +( 0 +30 0 +mug 0 +) 0 +on 0 +the 0 +histopathologic 0 +changes 0 +in 0 +the 0 +spinal 0 +cord 0 +after 0 +morphine 1 +- 0 +induced 0 +spastic 3 +paraparesis 4 +. 0 + +After 0 +IT 0 +morphine 1 +, 0 +the 0 +cerebrospinal 0 +fluid 0 +( 0 +CSF 0 +) 0 +glutamate 1 +concentration 0 +was 0 +increased 0 +in 0 +group 0 +M 0 +relative 0 +to 0 +both 0 +baseline 0 +and 0 +group 0 +C 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +This 0 +increase 0 +persisted 0 +for 0 +8 0 +hrs 0 +. 0 + +IT 0 +MK 1 +- 2 +801 2 +significantly 0 +reduced 0 +the 0 +number 0 +of 0 +dark 0 +- 0 +stained 0 +alpha 0 +- 0 +motoneurons 0 +after 0 +morphine 1 +- 0 +induced 0 +spastic 3 +paraparesis 4 +compared 0 +with 0 +the 0 +saline 0 +group 0 +. 0 + +These 0 +data 0 +indicate 0 +that 0 +IT 0 +morphine 1 +induces 0 +spastic 3 +paraparesis 4 +with 0 +a 0 +concomitant 0 +increase 0 +in 0 +CSF 0 +glutamate 1 +, 0 +which 0 +is 0 +involved 0 +in 0 +NMDA 1 +receptor 0 +activation 0 +. 0 + +We 0 +suggest 0 +that 0 +opioids 0 +may 0 +be 0 +neurotoxic 3 +in 0 +the 0 +setting 0 +of 0 +spinal 3 +cord 4 +ischemia 4 +via 0 +NMDA 1 +receptor 0 +activation 0 +. 0 + +Acute 0 +low 3 +back 4 +pain 4 +during 0 +intravenous 0 +administration 0 +of 0 +amiodarone 1 +: 0 +a 0 +report 0 +of 0 +two 0 +cases 0 +. 0 + +Amiodarone 1 +represents 0 +an 0 +effective 0 +antiarrhythmic 0 +drug 0 +for 0 +cardioversion 0 +of 0 +recent 0 +- 0 +onset 0 +atrial 3 +fibrillation 4 +( 0 +AF 3 +) 0 +and 0 +maintenance 0 +of 0 +sinus 0 +rhythm 0 +. 0 + +We 0 +briefly 0 +describe 0 +two 0 +patients 0 +suffering 0 +from 0 +recent 0 +- 0 +onset 0 +atrial 3 +fibrillation 4 +, 0 +who 0 +experienced 0 +an 0 +acute 0 +devastating 0 +low 3 +back 4 +pain 4 +a 0 +few 0 +minutes 0 +after 0 +initiation 0 +of 0 +intravenous 0 +amiodarone 1 +loading 0 +. 0 + +Notably 0 +, 0 +this 0 +side 0 +effect 0 +has 0 +not 0 +been 0 +ever 0 +reported 0 +in 0 +the 0 +medical 0 +literature 0 +. 0 + +Clinicians 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +reaction 0 +since 0 +prompt 0 +termination 0 +of 0 +parenteral 0 +administration 0 +leads 0 +to 0 +complete 0 +resolution 0 +. 0 + +Quantitative 0 +drug 0 +levels 0 +in 0 +stimulant 0 +psychosis 3 +: 0 +relationship 0 +to 0 +symptom 0 +severity 0 +, 0 +catecholamines 1 +and 0 +hyperkinesia 3 +. 0 + +To 0 +examine 0 +the 0 +relationship 0 +between 0 +quantitative 0 +stimulant 0 +drug 0 +levels 0 +, 0 +catecholamines 1 +, 0 +and 0 +psychotic 3 +symptoms 4 +, 0 +nineteen 0 +patients 0 +in 0 +a 0 +psychiatric 3 +emergency 0 +service 0 +with 0 +a 0 +diagnosis 0 +of 0 +amphetamine 1 +- 0 +or 0 +cocaine 1 +- 0 +induced 0 +psychosis 3 +were 0 +interviewed 0 +, 0 +and 0 +plasma 0 +and 0 +urine 0 +were 0 +collected 0 +for 0 +quantitative 0 +assays 0 +of 0 +stimulant 0 +drug 0 +and 0 +catecholamine 1 +metabolite 0 +levels 0 +. 0 + +Methamphetamine 1 +or 0 +amphetamine 1 +levels 0 +were 0 +related 0 +to 0 +several 0 +psychopathology 0 +scores 0 +and 0 +the 0 +global 0 +hyperkinesia 3 +rating 0 +. 0 + +HVA 0 +levels 0 +were 0 +related 0 +to 0 +global 0 +hyperkinesia 3 +but 0 +not 0 +to 0 +psychopathology 0 +ratings 0 +. 0 + +Although 0 +many 0 +other 0 +factors 0 +such 0 +as 0 +sensitization 0 +may 0 +play 0 +a 0 +role 0 +, 0 +intensity 0 +of 0 +stimulant 0 +- 0 +induced 0 +psychotic 3 +symptoms 4 +and 0 +stereotypies 3 +appears 0 +to 0 +be 0 +at 0 +least 0 +in 0 +part 0 +dose 0 +- 0 +related 0 +. 0 + +Pheochromocytoma 3 +unmasked 0 +by 0 +amisulpride 1 +and 0 +tiapride 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +describe 0 +the 0 +unmasking 0 +of 0 +pheochromocytoma 3 +in 0 +a 0 +patient 0 +treated 0 +with 0 +amisulpride 1 +and 0 +tiapride 1 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +42 0 +- 0 +year 0 +- 0 +old 0 +white 0 +man 0 +developed 0 +acute 0 +hypertension 3 +with 0 +severe 0 +headache 3 +and 0 +vomiting 3 +2 0 +hours 0 +after 0 +the 0 +first 0 +doses 0 +of 0 +amisulpride 1 +100 0 +mg 0 +and 0 +tiapride 1 +100 0 +mg 0 +. 0 + +Both 0 +drugs 0 +were 0 +immediately 0 +discontinued 0 +, 0 +and 0 +the 0 +patient 0 +recovered 0 +after 0 +subsequent 0 +nicardipine 1 +and 0 +verapamil 1 +treatment 0 +. 0 + +Abdominal 0 +ultrasound 0 +showed 0 +an 0 +adrenal 0 +mass 0 +, 0 +and 0 +postoperative 0 +histologic 0 +examination 0 +confirmed 0 +the 0 +diagnosis 0 +of 0 +pheochromocytoma 3 +. 0 + +DISCUSSI0N 0 +: 0 +Drug 0 +- 0 +induced 0 +symptoms 0 +of 0 +pheochromocytoma 3 +are 0 +often 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +substituted 0 +benzamide 1 +drugs 0 +, 0 +but 0 +the 0 +underlying 0 +mechanism 0 +is 0 +unknown 0 +. 0 + +In 0 +our 0 +case 0 +, 0 +use 0 +of 0 +the 0 +Naranjo 0 +probability 0 +scale 0 +indicated 0 +a 0 +possible 0 +relationship 0 +between 0 +the 0 +hypertensive 3 +crisis 0 +and 0 +amisulpride 1 +and 0 +tiapride 1 +therapy 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +As 0 +of 0 +March 0 +24 0 +, 0 +2005 0 +, 0 +this 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +amisulpride 1 +- 0 +and 0 +tiapride 1 +- 0 +induced 0 +hypertensive 3 +crisis 0 +in 0 +a 0 +patient 0 +with 0 +pheochromocytoma 3 +. 0 + +Physicians 0 +and 0 +other 0 +healthcare 0 +professionals 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +potential 0 +adverse 0 +effect 0 +of 0 +tiapride 1 +and 0 +amisulpride 1 +. 0 + +Minor 0 +neurological 3 +dysfunction 4 +, 0 +cognitive 0 +development 0 +, 0 +and 0 +somatic 0 +development 0 +at 0 +the 0 +age 0 +of 0 +3 0 +to 0 +7 0 +years 0 +after 0 +dexamethasone 1 +treatment 0 +in 0 +very 0 +- 0 +low 0 +birth 0 +- 0 +weight 0 +infants 0 +. 0 + +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +minor 0 +neurological 3 +dysfunction 4 +, 0 +cognitive 0 +development 0 +, 0 +and 0 +somatic 0 +development 0 +after 0 +dexamethasone 1 +therapy 0 +in 0 +very 0 +- 0 +low 0 +- 0 +birthweight 0 +infants 0 +. 0 + +Thirty 0 +- 0 +three 0 +children 0 +after 0 +dexamethasone 1 +treatment 0 +were 0 +matched 0 +to 0 +33 0 +children 0 +without 0 +dexamethasone 1 +treatment 0 +. 0 + +Data 0 +were 0 +assessed 0 +at 0 +the 0 +age 0 +of 0 +3 0 +- 0 +7 0 +years 0 +. 0 + +Dexamethasone 1 +was 0 +started 0 +between 0 +the 0 +7th 0 +and 0 +the 0 +28th 0 +day 0 +of 0 +life 0 +over 0 +7 0 +days 0 +with 0 +a 0 +total 0 +dose 0 +of 0 +2 0 +. 0 +35 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +. 0 + +Exclusion 0 +criteria 0 +were 0 +asphyxia 3 +, 0 +malformations 3 +, 0 +major 0 +surgical 0 +interventions 0 +, 0 +small 0 +for 0 +gestational 0 +age 0 +, 0 +intraventricular 0 +haemorrhage 3 +grades 0 +III 0 +and 0 +IV 0 +, 0 +periventricular 3 +leukomalacia 4 +, 0 +and 0 +severe 0 +psychomotor 3 +retardation 4 +. 0 + +Each 0 +child 0 +was 0 +examined 0 +by 0 +a 0 +neuropediatrician 0 +for 0 +minor 0 +neurological 3 +dysfunctions 4 +and 0 +tested 0 +by 0 +a 0 +psychologist 0 +for 0 +cognitive 0 +development 0 +with 0 +a 0 +Kaufman 0 +Assessment 0 +Battery 0 +for 0 +Children 0 +and 0 +a 0 +Draw 0 +- 0 +a 0 +- 0 +Man 0 +Test 0 +. 0 + +There 0 +were 0 +no 0 +differences 0 +in 0 +demographic 0 +data 0 +, 0 +growth 0 +, 0 +and 0 +socio 0 +- 0 +economic 0 +status 0 +between 0 +the 0 +two 0 +groups 0 +. 0 + +Fine 0 +motor 0 +skills 0 +and 0 +gross 0 +motor 0 +function 0 +were 0 +significantly 0 +better 0 +in 0 +the 0 +control 0 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +In 0 +the 0 +Draw 0 +- 0 +a 0 +- 0 +Man 0 +Test 0 +, 0 +the 0 +control 0 +group 0 +showed 0 +better 0 +results 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +There 0 +were 0 +no 0 +differences 0 +in 0 +development 0 +of 0 +speech 0 +, 0 +social 0 +development 0 +, 0 +and 0 +the 0 +Kaufman 0 +Assessment 0 +Battery 0 +for 0 +Children 0 +. 0 + +After 0 +dexamethasone 1 +treatment 0 +, 0 +children 0 +showed 0 +a 0 +higher 0 +rate 0 +of 0 +minor 0 +neurological 3 +dysfunctions 4 +. 0 + +Neurological 0 +development 0 +was 0 +affected 0 +even 0 +without 0 +neurological 0 +diagnosis 0 +. 0 + +Further 0 +long 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +studies 0 +will 0 +be 0 +necessary 0 +to 0 +fully 0 +evaluate 0 +the 0 +impact 0 +of 0 +dexamethasone 1 +on 0 +neurological 0 +and 0 +cognitive 0 +development 0 +. 0 + +Valproic 1 +acid 2 +I 0 +: 0 +time 0 +course 0 +of 0 +lipid 0 +peroxidation 0 +biomarkers 0 +, 0 +liver 3 +toxicity 4 +, 0 +and 0 +valproic 1 +acid 2 +metabolite 0 +levels 0 +in 0 +rats 0 +. 0 + +A 0 +single 0 +dose 0 +of 0 +valproic 1 +acid 2 +( 0 +VPA 1 +) 0 +, 0 +which 0 +is 0 +a 0 +widely 0 +used 0 +antiepileptic 0 +drug 0 +, 0 +is 0 +associated 0 +with 0 +oxidative 0 +stress 0 +in 0 +rats 0 +, 0 +as 0 +recently 0 +demonstrated 0 +by 0 +elevated 0 +levels 0 +of 0 +15 1 +- 2 +F 2 +( 2 +2t 2 +) 2 +- 2 +isoprostane 2 +( 0 +15 1 +- 2 +F 2 +( 2 +2t 2 +) 2 +- 2 +IsoP 2 +) 0 +. 0 + +To 0 +determine 0 +whether 0 +there 0 +was 0 +a 0 +temporal 0 +relationship 0 +between 0 +VPA 1 +- 0 +associated 0 +oxidative 0 +stress 0 +and 0 +hepatotoxicity 3 +, 0 +adult 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +treated 0 +ip 0 +with 0 +VPA 1 +( 0 +500 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +0 0 +. 0 +9 0 +% 0 +saline 0 +( 0 +vehicle 0 +) 0 +once 0 +daily 0 +for 0 +2 0 +, 0 +4 0 +, 0 +7 0 +, 0 +10 0 +, 0 +or 0 +14 0 +days 0 +. 0 + +0xidative 0 +stress 0 +was 0 +assessed 0 +by 0 +determining 0 +plasma 0 +and 0 +liver 0 +levels 0 +of 0 +15 1 +- 2 +F 2 +( 2 +2t 2 +) 2 +- 2 +IsoP 2 +, 0 +lipid 1 +hydroperoxides 2 +( 0 +LP0 1 +) 0 +, 0 +and 0 +thiobarbituric 1 +acid 2 +reactive 2 +substances 2 +( 0 +TBARs 1 +) 0 +. 0 + +Plasma 0 +and 0 +liver 0 +15 1 +- 2 +F 2 +( 2 +2t 2 +) 2 +- 2 +IsoP 2 +were 0 +elevated 0 +and 0 +reached 0 +a 0 +plateau 0 +after 0 +day 0 +2 0 +of 0 +VPA 1 +treatment 0 +compared 0 +to 0 +control 0 +. 0 + +Liver 0 +LP0 1 +levels 0 +were 0 +not 0 +elevated 0 +until 0 +day 0 +7 0 +of 0 +treatment 0 +( 0 +1 0 +. 0 +8 0 +- 0 +fold 0 +versus 0 +control 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Liver 0 +and 0 +plasma 0 +TBARs 1 +were 0 +not 0 +increased 0 +until 0 +14 0 +days 0 +( 0 +2 0 +- 0 +fold 0 +vs 0 +. 0 +control 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Liver 3 +toxicity 4 +was 0 +evaluated 0 +based 0 +on 0 +serum 0 +levels 0 +of 0 +alpha 0 +- 0 +glutathione 1 +S 0 +- 0 +transferase 0 +( 0 +alpha 0 +- 0 +GST 0 +) 0 +and 0 +by 0 +histology 0 +. 0 + +Serum 0 +alpha 0 +- 0 +GST 0 +levels 0 +were 0 +significantly 0 +elevated 0 +by 0 +day 0 +4 0 +, 0 +which 0 +corresponded 0 +to 0 +hepatotoxicity 3 +as 0 +shown 0 +by 0 +the 0 +increasing 0 +incidence 0 +of 0 +inflammation 3 +of 0 +the 0 +liver 0 +capsule 0 +, 0 +necrosis 3 +, 0 +and 0 +steatosis 3 +throughout 0 +the 0 +study 0 +. 0 + +The 0 +liver 0 +levels 0 +of 0 +beta 0 +- 0 +oxidation 0 +metabolites 0 +of 0 +VPA 1 +were 0 +decreased 0 +by 0 +day 0 +14 0 +, 0 +while 0 +the 0 +levels 0 +of 0 +4 1 +- 2 +ene 2 +- 2 +VPA 2 +and 0 +( 0 +E 0 +) 0 +- 0 +2 1 +, 2 +4 2 +- 2 +diene 2 +- 2 +VPA 2 +were 0 +not 0 +elevated 0 +throughout 0 +the 0 +study 0 +. 0 + +0verall 0 +, 0 +these 0 +findings 0 +indicate 0 +that 0 +VPA 1 +treatment 0 +results 0 +in 0 +oxidative 0 +stress 0 +, 0 +as 0 +measured 0 +by 0 +levels 0 +of 0 +15 1 +- 2 +F 2 +( 2 +2t 2 +) 2 +- 2 +IsoP 2 +, 0 +which 0 +precedes 0 +the 0 +onset 0 +of 0 +necrosis 3 +, 0 +steatosis 3 +, 0 +and 0 +elevated 0 +levels 0 +of 0 +serum 0 +alpha 0 +- 0 +GST 0 +. 0 + +Assessment 0 +of 0 +perinatal 0 +hepatitis 3 +B 4 +and 0 +rubella 3 +prevention 0 +in 0 +New 0 +Hampshire 0 +delivery 0 +hospitals 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +current 0 +performance 0 +on 0 +recommended 0 +perinatal 0 +hepatitis 3 +B 4 +and 0 +rubella 3 +prevention 0 +practices 0 +in 0 +New 0 +Hampshire 0 +. 0 + +METH0DS 0 +: 0 +Data 0 +were 0 +extracted 0 +from 0 +2021 0 +paired 0 +mother 0 +- 0 +infant 0 +records 0 +for 0 +the 0 +year 0 +2000 0 +birth 0 +cohort 0 +in 0 +New 0 +Hampshire 0 +' 0 +s 0 +25 0 +delivery 0 +hospitals 0 +. 0 + +Assessment 0 +was 0 +done 0 +on 0 +the 0 +following 0 +: 0 +prenatal 0 +screening 0 +for 0 +hepatitis 3 +B 4 +and 0 +rubella 3 +, 0 +administration 0 +of 0 +the 0 +hepatitis 3 +B 4 +vaccine 0 +birth 0 +dose 0 +to 0 +all 0 +infants 0 +, 0 +administration 0 +of 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +to 0 +infants 0 +who 0 +were 0 +born 0 +to 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +- 0 +positive 0 +mothers 0 +, 0 +rubella 3 +immunity 0 +, 0 +and 0 +administration 0 +of 0 +in 0 +- 0 +hospital 0 +postpartum 0 +rubella 3 +vaccine 0 +to 0 +rubella 3 +nonimmune 0 +women 0 +. 0 + +RESULTS 0 +: 0 +Prenatal 0 +screening 0 +rates 0 +for 0 +hepatitis 3 +B 4 +( 0 +98 0 +. 0 +8 0 +% 0 +) 0 +and 0 +rubella 3 +( 0 +99 0 +. 0 +4 0 +% 0 +) 0 +were 0 +high 0 +. 0 + +Hepatitis 3 +B 4 +vaccine 0 +birth 0 +dose 0 +was 0 +administered 0 +to 0 +76 0 +. 0 +2 0 +% 0 +of 0 +all 0 +infants 0 +. 0 + +All 0 +infants 0 +who 0 +were 0 +born 0 +to 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +- 0 +positive 0 +mothers 0 +also 0 +received 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +. 0 + +Multivariate 0 +logistic 0 +regression 0 +showed 0 +that 0 +the 0 +month 0 +of 0 +delivery 0 +and 0 +infant 0 +birth 0 +weight 0 +were 0 +independent 0 +predictors 0 +of 0 +hepatitis 3 +B 4 +vaccination 0 +. 0 + +The 0 +proportion 0 +of 0 +infants 0 +who 0 +were 0 +vaccinated 0 +in 0 +January 0 +and 0 +February 0 +2000 0 +( 0 +48 0 +. 0 +5 0 +% 0 +and 0 +67 0 +. 0 +5 0 +% 0 +, 0 +respectively 0 +) 0 +was 0 +less 0 +than 0 +any 0 +other 0 +months 0 +, 0 +whereas 0 +the 0 +proportion 0 +who 0 +were 0 +vaccinated 0 +in 0 +December 0 +2000 0 +( 0 +88 0 +. 0 +2 0 +% 0 +) 0 +was 0 +the 0 +highest 0 +. 0 + +Women 0 +who 0 +were 0 +born 0 +between 0 +1971 0 +and 0 +1975 0 +had 0 +the 0 +highest 0 +rate 0 +of 0 +rubella 3 +nonimmunity 0 +( 0 +9 0 +. 0 +5 0 +% 0 +) 0 +. 0 + +In 0 +- 0 +hospital 0 +postpartum 0 +rubella 3 +vaccine 0 +administration 0 +was 0 +documented 0 +for 0 +75 0 +. 0 +6 0 +% 0 +of 0 +nonimmune 0 +women 0 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +study 0 +documents 0 +good 0 +compliance 0 +in 0 +New 0 +Hampshire 0 +' 0 +s 0 +birthing 0 +hospitals 0 +with 0 +national 0 +guidelines 0 +for 0 +perinatal 0 +hepatitis 3 +B 4 +and 0 +rubella 3 +prevention 0 +and 0 +highlights 0 +potential 0 +areas 0 +for 0 +improvement 0 +. 0 + +Succinylcholine 1 +- 0 +induced 0 +masseter 3 +muscle 4 +rigidity 4 +during 0 +bronchoscopic 0 +removal 0 +of 0 +a 0 +tracheal 0 +foreign 0 +body 0 +. 0 + +Masseter 3 +muscle 4 +rigidity 4 +during 0 +general 0 +anesthesia 0 +is 0 +considered 0 +an 0 +early 0 +warning 0 +sign 0 +of 0 +a 0 +possible 0 +episode 0 +of 0 +malignant 3 +hyperthermia 4 +. 0 + +The 0 +decision 0 +whether 0 +to 0 +continue 0 +or 0 +discontinue 0 +the 0 +procedure 0 +depends 0 +on 0 +the 0 +urgency 0 +of 0 +the 0 +surgery 0 +and 0 +severity 0 +of 0 +masseter 3 +muscle 4 +rigidity 4 +. 0 + +Here 0 +, 0 +we 0 +describe 0 +a 0 +case 0 +of 0 +severe 0 +masseter 3 +muscle 4 +rigidity 4 +( 0 +jaw 3 +of 4 +steel 4 +) 0 +after 0 +succinylcholine 1 +( 0 +Sch 1 +) 0 +administration 0 +during 0 +general 0 +anesthetic 0 +management 0 +for 0 +rigid 0 +bronchoscopic 0 +removal 0 +of 0 +a 0 +tracheal 0 +foreign 0 +body 0 +. 0 + +Anesthesia 0 +was 0 +continued 0 +uneventfully 0 +with 0 +propofol 1 +infusion 0 +while 0 +all 0 +facilities 0 +were 0 +available 0 +to 0 +detect 0 +and 0 +treat 0 +malignant 3 +hyperthermia 4 +. 0 + +Dexrazoxane 1 +protects 0 +against 0 +myelosuppression 3 +from 0 +the 0 +DNA 0 +cleavage 0 +- 0 +enhancing 0 +drugs 0 +etoposide 1 +and 0 +daunorubicin 1 +but 0 +not 0 +doxorubicin 1 +. 0 + +PURP0SE 0 +: 0 +The 0 +anthracyclines 1 +daunorubicin 1 +and 0 +doxorubicin 1 +and 0 +the 0 +epipodophyllotoxin 1 +etoposide 1 +are 0 +potent 0 +DNA 0 +cleavage 0 +- 0 +enhancing 0 +drugs 0 +that 0 +are 0 +widely 0 +used 0 +in 0 +clinical 0 +oncology 0 +; 0 +however 0 +, 0 +myelosuppression 3 +and 0 +cardiac 3 +toxicity 4 +limit 0 +their 0 +use 0 +. 0 + +Dexrazoxane 1 +( 0 +ICRF 1 +- 2 +187 2 +) 0 +is 0 +recommended 0 +for 0 +protection 0 +against 0 +anthracycline 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +EXPERIMENTAL 0 +DESIGN 0 +: 0 +Because 0 +of 0 +their 0 +widespread 0 +use 0 +, 0 +the 0 +hematologic 3 +toxicity 4 +following 0 +coadministration 0 +of 0 +dexrazoxane 1 +and 0 +these 0 +three 0 +structurally 0 +different 0 +DNA 0 +cleavage 0 +enhancers 0 +was 0 +investigated 0 +: 0 +Sensitivity 0 +of 0 +human 0 +and 0 +murine 0 +blood 0 +progenitor 0 +cells 0 +to 0 +etoposide 1 +, 0 +daunorubicin 1 +, 0 +and 0 +doxorubicin 1 ++ 0 +/ 0 +- 0 +dexrazoxane 1 +was 0 +determined 0 +in 0 +granulocyte 0 +- 0 +macrophage 0 +colony 0 +forming 0 +assays 0 +. 0 + +Likewise 0 +, 0 +in 0 +vivo 0 +, 0 +B6D2F1 0 +mice 0 +were 0 +treated 0 +with 0 +etoposide 1 +, 0 +daunorubicin 1 +, 0 +and 0 +doxorubicin 1 +, 0 +with 0 +or 0 +without 0 +dexrazoxane 1 +over 0 +a 0 +wide 0 +range 0 +of 0 +doses 0 +: 0 +posttreatment 0 +, 0 +a 0 +full 0 +hematologic 0 +evaluation 0 +was 0 +done 0 +. 0 + +RESULTS 0 +: 0 +Nontoxic 0 +doses 0 +of 0 +dexrazoxane 1 +reduced 0 +myelosuppression 3 +and 0 +weight 3 +loss 4 +from 0 +daunorubicin 1 +and 0 +etoposide 1 +in 0 +mice 0 +and 0 +antagonized 0 +their 0 +antiproliferative 0 +effects 0 +in 0 +the 0 +colony 0 +assay 0 +; 0 +however 0 +, 0 +dexrazoxane 1 +neither 0 +reduced 0 +myelosuppression 3 +, 0 +weight 3 +loss 4 +, 0 +nor 0 +the 0 +in 0 +vitro 0 +cytotoxicity 3 +from 0 +doxorubicin 1 +. 0 + +C0NCLUSI0N 0 +: 0 +Although 0 +our 0 +findings 0 +support 0 +the 0 +observation 0 +that 0 +dexrazoxane 1 +reduces 0 +neither 0 +hematologic 0 +activity 0 +nor 0 +antitumor 0 +activity 0 +from 0 +doxorubicin 1 +clinically 0 +, 0 +the 0 +potent 0 +antagonism 0 +of 0 +daunorubicin 1 +activity 0 +raises 0 +concern 0 +; 0 +a 0 +possible 0 +interference 0 +with 0 +anticancer 0 +efficacy 0 +certainly 0 +would 0 +call 0 +for 0 +renewed 0 +attention 0 +. 0 + +0ur 0 +data 0 +also 0 +suggest 0 +that 0 +significant 0 +etoposide 1 +dose 0 +escalation 0 +is 0 +perhaps 0 +possible 0 +by 0 +the 0 +use 0 +of 0 +dexrazoxane 1 +. 0 + +Clinical 0 +trials 0 +in 0 +patients 0 +with 0 +brain 0 +metastases 3 +combining 0 +dexrazoxane 1 +and 0 +high 0 +doses 0 +of 0 +etoposide 1 +is 0 +ongoing 0 +with 0 +the 0 +aim 0 +of 0 +improving 0 +efficacy 0 +without 0 +aggravating 0 +hematologic 3 +toxicity 4 +. 0 + +If 0 +successful 0 +, 0 +this 0 +represents 0 +an 0 +exciting 0 +mechanism 0 +for 0 +pharmacologic 0 +regulation 0 +of 0 +side 0 +effects 0 +from 0 +cytotoxic 0 +chemotherapy 0 +. 0 + +Assessment 0 +of 0 +the 0 +onset 0 +and 0 +persistence 0 +of 0 +amnesia 3 +during 0 +procedural 0 +sedation 0 +with 0 +propofol 1 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +assess 0 +patients 0 +' 0 +ability 0 +to 0 +repeat 0 +and 0 +recall 0 +words 0 +presented 0 +to 0 +them 0 +while 0 +undergoing 0 +procedural 0 +sedation 0 +with 0 +propofol 1 +, 0 +and 0 +correlate 0 +their 0 +recall 0 +with 0 +their 0 +level 0 +of 0 +awareness 0 +as 0 +measured 0 +by 0 +bispectral 0 +index 0 +( 0 +BIS 0 +) 0 +monitoring 0 +. 0 + +METH0DS 0 +: 0 +This 0 +was 0 +a 0 +prospective 0 +, 0 +single 0 +- 0 +intervention 0 +study 0 +of 0 +consenting 0 +adult 0 +patients 0 +undergoing 0 +procedural 0 +sedation 0 +with 0 +propofol 1 +between 0 +December 0 +28 0 +, 0 +2002 0 +, 0 +and 0 +0ctober 0 +31 0 +, 0 +2003 0 +. 0 + +BIS 0 +monitoring 0 +was 0 +initiated 0 +starting 0 +3 0 +minutes 0 +before 0 +the 0 +procedure 0 +and 0 +continuing 0 +until 0 +the 0 +patient 0 +had 0 +regained 0 +baseline 0 +mental 0 +status 0 +. 0 + +At 0 +1 0 +- 0 +minute 0 +intervals 0 +during 0 +the 0 +procedural 0 +sedation 0 +, 0 +until 0 +the 0 +patient 0 +regained 0 +baseline 0 +mental 0 +status 0 +at 0 +the 0 +end 0 +of 0 +the 0 +procedure 0 +, 0 +a 0 +word 0 +from 0 +a 0 +standardized 0 +list 0 +was 0 +read 0 +aloud 0 +, 0 +and 0 +the 0 +patient 0 +was 0 +asked 0 +to 0 +immediately 0 +repeat 0 +the 0 +word 0 +to 0 +the 0 +investigator 0 +. 0 + +The 0 +BIS 0 +score 0 +at 0 +the 0 +time 0 +the 0 +word 0 +was 0 +read 0 +and 0 +the 0 +patient 0 +' 0 +s 0 +ability 0 +to 0 +repeat 0 +the 0 +word 0 +were 0 +recorded 0 +. 0 + +After 0 +the 0 +procedure 0 +, 0 +the 0 +patient 0 +was 0 +asked 0 +to 0 +state 0 +all 0 +of 0 +the 0 +words 0 +from 0 +the 0 +list 0 +that 0 +he 0 +or 0 +she 0 +could 0 +recall 0 +, 0 +and 0 +to 0 +identify 0 +the 0 +last 0 +word 0 +recalled 0 +from 0 +prior 0 +to 0 +the 0 +start 0 +of 0 +the 0 +procedure 0 +and 0 +the 0 +first 0 +word 0 +recalled 0 +from 0 +after 0 +the 0 +procedure 0 +was 0 +completed 0 +. 0 + +RESULTS 0 +: 0 +Seventy 0 +- 0 +five 0 +consenting 0 +patients 0 +were 0 +enrolled 0 +; 0 +one 0 +patient 0 +was 0 +excluded 0 +from 0 +data 0 +analysis 0 +for 0 +a 0 +protocol 0 +violation 0 +. 0 + +No 0 +serious 0 +adverse 0 +events 0 +were 0 +noted 0 +during 0 +the 0 +procedural 0 +sedations 0 +. 0 + +The 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +standard 0 +deviation 0 +) 0 +time 0 +of 0 +data 0 +collection 0 +was 0 +16 0 +. 0 +4 0 +minutes 0 +( 0 ++ 0 +/ 0 +- 0 +7 0 +. 0 +1 0 +; 0 +range 0 +5 0 +to 0 +34 0 +minutes 0 +) 0 +. 0 + +The 0 +mean 0 +initial 0 +( 0 +preprocedure 0 +) 0 +BIS 0 +score 0 +was 0 +97 0 +. 0 +1 0 +( 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +3 0 +; 0 +range 0 +92 0 +to 0 +99 0 +) 0 +. 0 + +The 0 +mean 0 +lowest 0 +BIS 0 +score 0 +occurring 0 +during 0 +these 0 +procedural 0 +sedations 0 +was 0 +66 0 +. 0 +9 0 +( 0 ++ 0 +/ 0 +- 0 +14 0 +. 0 +4 0 +; 0 +range 0 +33 0 +to 0 +91 0 +) 0 +. 0 + +The 0 +mean 0 +lowest 0 +BIS 0 +score 0 +corresponding 0 +to 0 +the 0 +ability 0 +of 0 +the 0 +patient 0 +to 0 +immediately 0 +repeat 0 +words 0 +read 0 +from 0 +the 0 +list 0 +was 0 +77 0 +. 0 +1 0 +( 0 +95 0 +% 0 +CI 0 += 0 +74 0 +. 0 +3 0 +to 0 +80 0 +. 0 +0 0 +) 0 +. 0 + +The 0 +mean 0 +highest 0 +BIS 0 +score 0 +corresponding 0 +to 0 +the 0 +inability 3 +to 4 +repeat 4 +words 4 +was 0 +81 0 +. 0 +5 0 +( 0 +95 0 +% 0 +CI 0 += 0 +78 0 +. 0 +1 0 +to 0 +84 0 +. 0 +8 0 +) 0 +. 0 + +The 0 +mean 0 +BIS 0 +score 0 +corresponding 0 +to 0 +the 0 +last 0 +word 0 +recalled 0 +from 0 +prior 0 +to 0 +the 0 +initiation 0 +of 0 +the 0 +sedation 0 +was 0 +96 0 +. 0 +7 0 +( 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +4 0 +; 0 +range 0 +84 0 +to 0 +98 0 +) 0 +. 0 + +The 0 +mean 0 +BIS 0 +score 0 +corresponding 0 +to 0 +the 0 +first 0 +word 0 +recalled 0 +after 0 +the 0 +procedure 0 +was 0 +completed 0 +was 0 +91 0 +. 0 +2 0 +( 0 +95 0 +% 0 +CI 0 += 0 +88 0 +. 0 +1 0 +to 0 +94 0 +. 0 +3 0 +) 0 +. 0 + +All 0 +patients 0 +recalled 0 +at 0 +least 0 +one 0 +word 0 +that 0 +had 0 +been 0 +read 0 +to 0 +them 0 +during 0 +the 0 +protocol 0 +. 0 + +The 0 +mean 0 +lowest 0 +BIS 0 +score 0 +for 0 +any 0 +recalled 0 +word 0 +was 0 +91 0 +. 0 +5 0 +( 0 ++ 0 +/ 0 +- 0 +11 0 +. 0 +1 0 +; 0 +range 0 +79 0 +to 0 +98 0 +) 0 +, 0 +and 0 +no 0 +words 0 +were 0 +recalled 0 +when 0 +the 0 +corresponding 0 +BIS 0 +score 0 +was 0 +less 0 +than 0 +90 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +There 0 +is 0 +a 0 +range 0 +of 0 +BIS 0 +scores 0 +during 0 +which 0 +sedated 0 +patients 0 +are 0 +able 0 +to 0 +repeat 0 +words 0 +read 0 +to 0 +them 0 +but 0 +are 0 +not 0 +able 0 +to 0 +subsequently 0 +recall 0 +these 0 +words 0 +. 0 + +Furthermore 0 +, 0 +patients 0 +had 0 +no 0 +recall 0 +of 0 +words 0 +repeated 0 +prior 0 +to 0 +procedural 0 +sedation 0 +in 0 +BIS 0 +ranges 0 +associated 0 +with 0 +recall 0 +after 0 +procedural 0 +sedation 0 +, 0 +suggestive 0 +of 0 +retrograde 3 +amnesia 4 +. 0 + +Amiodarone 1 +pulmonary 3 +toxicity 4 +. 0 + +Amiodarone 1 +is 0 +an 0 +effective 0 +antiarrhythmic 0 +agent 0 +whose 0 +utility 0 +is 0 +limited 0 +by 0 +many 0 +side 0 +- 0 +effects 0 +, 0 +the 0 +most 0 +problematic 0 +being 0 +pneumonitis 3 +. 0 + +The 0 +pulmonary 3 +toxicity 4 +of 0 +amiodarone 1 +is 0 +thought 0 +to 0 +result 0 +from 0 +direct 0 +injury 0 +related 0 +to 0 +the 0 +intracellular 0 +accumulation 0 +of 0 +phospholipid 0 +and 0 +T 0 +cell 0 +- 0 +mediated 0 +hypersensitivity 3 +pneumonitis 4 +. 0 + +The 0 +clinical 0 +and 0 +radiographic 0 +features 0 +of 0 +amiodarone 1 +- 0 +induced 0 +pulmonary 3 +toxicity 4 +are 0 +characteristic 0 +but 0 +nonspecific 0 +. 0 + +The 0 +diagnosis 0 +depends 0 +on 0 +exclusion 0 +of 0 +other 0 +entities 0 +, 0 +such 0 +as 0 +heart 3 +failure 4 +, 0 +infection 3 +, 0 +and 0 +malignancy 3 +. 0 + +While 0 +withdrawal 0 +of 0 +amiodarone 1 +leads 0 +to 0 +clinical 0 +improvement 0 +in 0 +majority 0 +of 0 +cases 0 +, 0 +this 0 +is 0 +not 0 +always 0 +possible 0 +or 0 +advisable 0 +. 0 + +Dose 0 +reduction 0 +or 0 +concomitant 0 +steroid 1 +therapy 0 +may 0 +have 0 +a 0 +role 0 +in 0 +selected 0 +patients 0 +. 0 + +Two 0 +prodrugs 0 +of 0 +potent 0 +and 0 +selective 0 +GluR5 0 +kainate 1 +receptor 0 +antagonists 0 +actives 0 +in 0 +three 0 +animal 0 +models 0 +of 0 +pain 3 +. 0 + +Amino 0 +acids 0 +5 0 +and 0 +7 0 +, 0 +two 0 +potent 0 +and 0 +selective 0 +competitive 0 +GluR5 0 +KA 1 +receptor 0 +antagonists 0 +, 0 +exhibited 0 +high 0 +GluR5 0 +receptor 0 +affinity 0 +over 0 +other 0 +glutamate 1 +receptors 0 +. 0 + +Their 0 +ester 0 +prodrugs 0 +6 0 +and 0 +8 0 +were 0 +orally 0 +active 0 +in 0 +three 0 +models 0 +of 0 +pain 3 +: 0 +reversal 0 +of 0 +formalin 1 +- 0 +induced 0 +paw 0 +licking 0 +, 0 +carrageenan 1 +- 0 +induced 0 +thermal 3 +hyperalgesia 4 +, 0 +and 0 +capsaicin 1 +- 0 +induced 0 +mechanical 3 +hyperalgesia 4 +. 0 + +Possible 0 +azithromycin 1 +- 0 +associated 0 +hiccups 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +persistent 0 +hiccups 3 +associated 0 +by 0 +azithromycin 1 +therapy 0 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +76 0 +- 0 +year 0 +- 0 +old 0 +man 0 +presented 0 +with 0 +persistent 0 +hiccups 3 +after 0 +beginning 0 +azithromycin 1 +for 0 +the 0 +treatment 0 +of 0 +pharyngitis 3 +. 0 + +Hiccups 3 +were 0 +persistent 0 +and 0 +exhausting 0 +. 0 + +Discontinuation 0 +of 0 +azithromycin 1 +and 0 +therapy 0 +with 0 +baclofen 1 +finally 0 +resolved 0 +hiccups 3 +. 0 + +No 0 +organic 0 +cause 0 +of 0 +hiccups 3 +was 0 +identified 0 +despite 0 +extensive 0 +investigation 0 +. 0 + +DISCUSSI0N 0 +: 0 +Pharmacotherapeutic 0 +agents 0 +have 0 +been 0 +uncommonly 0 +associated 0 +with 0 +hiccups 3 +. 0 + +Corticosteroids 0 +( 0 +dexamethasone 1 +and 0 +methylprednisolone 1 +) 0 +, 0 +benzodiazepines 1 +( 0 +midazolam 1 +) 0 +and 0 +general 0 +anaesthesia 0 +have 0 +been 0 +the 0 +specific 0 +agents 0 +mentioned 0 +most 0 +frequently 0 +in 0 +the 0 +literature 0 +as 0 +being 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +hiccups 3 +. 0 + +Few 0 +cases 0 +of 0 +drug 0 +- 0 +induced 0 +hiccups 3 +have 0 +been 0 +reported 0 +related 0 +to 0 +macrolide 1 +antimicrobials 0 +. 0 + +Using 0 +the 0 +Naranjo 0 +adverse 0 +effect 0 +reaction 0 +probability 0 +scale 0 +this 0 +event 0 +could 0 +be 0 +classified 0 +as 0 +possible 0 +( 0 +score 0 +5 0 +points 0 +) 0 +, 0 +mostly 0 +because 0 +of 0 +the 0 +close 0 +temporal 0 +sequence 0 +, 0 +previous 0 +reports 0 +on 0 +this 0 +reaction 0 +with 0 +other 0 +macrolides 1 +and 0 +the 0 +absence 0 +of 0 +any 0 +alternative 0 +explanation 0 +for 0 +hiccups 3 +. 0 + +0ur 0 +hypothesis 0 +is 0 +that 0 +a 0 +vagal 0 +mechanism 0 +mediated 0 +by 0 +azithromycin 1 +could 0 +be 0 +the 0 +pathogenesis 0 +of 0 +hiccups 3 +in 0 +our 0 +patient 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Diagnosis 0 +of 0 +drug 0 +- 0 +induced 0 +hiccups 3 +is 0 +difficult 0 +and 0 +often 0 +achieved 0 +only 0 +by 0 +a 0 +process 0 +of 0 +elimination 0 +. 0 + +However 0 +, 0 +macrolide 1 +antimicrobials 0 +have 0 +been 0 +reported 0 +to 0 +be 0 +associated 0 +with 0 +hiccups 3 +and 0 +vagal 0 +mechanism 0 +could 0 +explain 0 +the 0 +development 0 +of 0 +this 0 +side 0 +- 0 +effect 0 +. 0 + +Calcium 1 +carbonate 2 +toxicity 3 +: 0 +the 0 +updated 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +; 0 +report 0 +of 0 +3 0 +cases 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +describe 0 +3 0 +patients 0 +with 0 +calcium 1 +carbonate 2 +- 0 +induced 0 +hypercalcemia 3 +and 0 +gain 0 +insights 0 +into 0 +the 0 +cause 0 +and 0 +management 0 +of 0 +the 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +. 0 + +METH0DS 0 +: 0 +We 0 +report 0 +the 0 +clinical 0 +and 0 +laboratory 0 +data 0 +in 0 +3 0 +patients 0 +who 0 +presented 0 +with 0 +severe 0 +hypercalcemia 3 +( 0 +corrected 0 +serum 0 +calcium 1 +> 0 +or 0 += 0 +14 0 +mg 0 +/ 0 +dL 0 +) 0 +and 0 +review 0 +the 0 +pertinent 0 +literature 0 +on 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +. 0 + +RESULTS 0 +: 0 +The 0 +3 0 +patients 0 +had 0 +acute 3 +renal 4 +insufficiency 4 +, 0 +relative 0 +metabolic 3 +alkalosis 4 +, 0 +and 0 +low 0 +parathyroid 0 +hormone 0 +( 0 +PTH 0 +) 0 +, 0 +PTH 0 +- 0 +related 0 +peptide 0 +, 0 +and 0 +1 1 +, 2 +25 2 +- 2 +dihydroxyvitamin 2 +D 2 +concentrations 0 +. 0 + +No 0 +malignant 0 +lesion 0 +was 0 +found 0 +. 0 + +Treatment 0 +included 0 +aggressive 0 +hydration 0 +and 0 +varied 0 +amounts 0 +of 0 +furosemide 1 +. 0 + +The 0 +2 0 +patients 0 +with 0 +the 0 +higher 0 +serum 0 +calcium 1 +concentrations 0 +received 0 +pamidronate 1 +intravenously 0 +( 0 +60 0 +and 0 +30 0 +mg 0 +, 0 +respectively 0 +) 0 +, 0 +which 0 +caused 0 +severe 0 +hypocalcemia 3 +. 0 + +0f 0 +the 0 +3 0 +patients 0 +, 0 +2 0 +were 0 +ingesting 0 +acceptable 0 +doses 0 +of 0 +elemental 0 +calcium 1 +( 0 +1 0 +g 0 +and 0 +2 0 +g 0 +daily 0 +, 0 +respectively 0 +) 0 +in 0 +the 0 +form 0 +of 0 +calcium 1 +carbonate 2 +. 0 + +In 0 +addition 0 +to 0 +our 0 +highlighted 0 +cases 0 +, 0 +we 0 +review 0 +the 0 +history 0 +, 0 +classification 0 +, 0 +pathophysiologic 0 +features 0 +, 0 +and 0 +treatment 0 +of 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +and 0 +summarize 0 +the 0 +cases 0 +reported 0 +from 0 +early 0 +1995 0 +to 0 +November 0 +2003 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Milk 3 +- 4 +alkali 4 +syndrome 4 +may 0 +be 0 +a 0 +common 0 +cause 0 +of 0 +unexplained 0 +hypercalcemia 3 +and 0 +can 0 +be 0 +precipitated 0 +by 0 +small 0 +amounts 0 +of 0 +orally 0 +ingested 0 +calcium 1 +carbonate 2 +in 0 +susceptible 0 +persons 0 +. 0 + +Treatment 0 +with 0 +hydration 0 +, 0 +furosemide 1 +, 0 +and 0 +discontinuation 0 +of 0 +the 0 +calcium 1 +and 0 +vitamin 1 +D 2 +source 0 +is 0 +adequate 0 +. 0 + +Pamidronate 1 +treatment 0 +is 0 +associated 0 +with 0 +considerable 0 +risk 0 +for 0 +hypocalcemia 3 +, 0 +even 0 +in 0 +cases 0 +of 0 +initially 0 +severe 0 +hypercalcemia 3 +. 0 + +Warfarin 1 +- 0 +induced 0 +leukocytoclastic 3 +vasculitis 4 +. 0 + +Skin 0 +reactions 0 +associated 0 +with 0 +oral 0 +coumarin 1 +- 0 +derived 0 +anticoagulants 0 +are 0 +an 0 +uncommon 0 +occurrence 0 +. 0 + +Leukocytoclastic 3 +vasculitis 4 +( 0 +LV 3 +) 0 +is 0 +primarily 0 +a 0 +cutaneous 3 +small 4 +vessel 4 +vasculitis 4 +, 0 +though 0 +systemic 0 +involvement 0 +may 0 +be 0 +encountered 0 +. 0 + +We 0 +report 0 +4 0 +patients 0 +with 0 +late 0 +- 0 +onset 0 +LV 3 +probably 0 +due 0 +to 0 +warfarin 1 +. 0 + +All 0 +4 0 +patients 0 +presented 0 +with 0 +skin 3 +eruptions 4 +that 0 +developed 0 +after 0 +receiving 0 +warfarin 1 +for 0 +several 0 +years 0 +. 0 + +The 0 +results 0 +of 0 +skin 3 +lesion 4 +biopsies 0 +were 0 +available 0 +in 0 +3 0 +patients 0 +, 0 +confirming 0 +LV 3 +Cutaneous 4 +lesions 4 +resolved 0 +in 0 +all 0 +patients 0 +after 0 +warfarin 1 +was 0 +discontinued 0 +. 0 + +In 0 +2 0 +of 0 +the 0 +4 0 +patients 0 +, 0 +rechallenge 0 +with 0 +warfarin 1 +led 0 +to 0 +recurrence 0 +of 0 +the 0 +lesions 0 +. 0 + +LV 3 +may 0 +be 0 +a 0 +late 0 +- 0 +onset 0 +adverse 0 +reaction 0 +associated 0 +with 0 +warfarin 1 +therapy 0 +. 0 + +Cocaine 1 +- 0 +induced 0 +brainstem 0 +seizures 3 +and 0 +behavior 0 +. 0 + +A 0 +variety 0 +of 0 +abnormal 0 +sensory 0 +/ 0 +motor 0 +behaviors 0 +associated 0 +with 0 +electrical 0 +discharges 0 +recorded 0 +from 0 +the 0 +bilateral 0 +brainstem 0 +were 0 +induced 0 +in 0 +adult 0 +WKY 0 +rats 0 +by 0 +mechanical 0 +( 0 +electrode 0 +implants 0 +) 0 +and 0 +DC 0 +electrical 0 +current 0 +stimulations 0 +and 0 +by 0 +acute 0 +and 0 +chronic 0 +administration 0 +of 0 +cocaine 1 +. 0 + +The 0 +electrode 0 +implant 0 +implicated 0 +one 0 +side 0 +or 0 +the 0 +other 0 +of 0 +the 0 +reticular 0 +system 0 +of 0 +the 0 +brainstem 0 +but 0 +subjects 0 +were 0 +not 0 +incapacitated 0 +by 0 +the 0 +stimulations 0 +. 0 + +Cocaine 1 +( 0 +40 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +injected 0 +subcutaneously 0 +for 0 +an 0 +acute 0 +experiment 0 +and 0 +subsequent 0 +20 0 +mg 0 +/ 0 +kg 0 +doses 0 +twice 0 +daily 0 +for 0 +3 0 +days 0 +in 0 +a 0 +chronic 0 +study 0 +. 0 + +Cocaine 1 +generated 0 +more 0 +abnormal 0 +behaviors 0 +in 0 +the 0 +brainstem 0 +perturbation 0 +group 0 +, 0 +especially 0 +the 0 +electrically 0 +perturbated 0 +subjects 0 +. 0 + +The 0 +abnormal 0 +behaviors 0 +were 0 +yawning 0 +, 0 +retrocollis 0 +, 0 +hyperactivity 3 +, 0 +hypersensitivity 3 +, 0 +" 0 +beating 0 +drum 0 +" 0 +behavior 0 +, 0 +squealing 0 +, 0 +head 0 +bobbing 0 +, 0 +circling 0 +, 0 +sniffing 0 +, 0 +abnormal 0 +posturing 0 +, 0 +and 0 +facial 0 +twitching 0 +. 0 + +Shifts 0 +in 0 +the 0 +power 0 +frequency 0 +spectra 0 +of 0 +the 0 +discharge 0 +patterns 0 +were 0 +noted 0 +between 0 +quiet 0 +and 0 +pacing 0 +behavioral 0 +states 0 +. 0 + +Hypersensitivity 3 +to 0 +various 0 +auditory 0 +, 0 +tactile 0 +, 0 +and 0 +visual 0 +stimulation 0 +was 0 +present 0 +and 0 +shifts 0 +in 0 +the 0 +brainstem 0 +ambient 0 +power 0 +spectral 0 +frequency 0 +occurred 0 +in 0 +response 0 +to 0 +tactile 0 +stimulation 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +the 0 +brainstem 0 +generates 0 +and 0 +propagates 0 +pathological 0 +discharges 0 +that 0 +can 0 +be 0 +elicited 0 +by 0 +mechanical 0 +and 0 +DC 0 +electrical 0 +perturbation 0 +. 0 + +Cocaine 1 +was 0 +found 0 +to 0 +activate 0 +the 0 +discharge 0 +system 0 +and 0 +thus 0 +induce 0 +abnormal 0 +behaviors 0 +that 0 +are 0 +generated 0 +at 0 +the 0 +discharge 0 +site 0 +and 0 +at 0 +distant 0 +sites 0 +to 0 +which 0 +the 0 +discharge 0 +propagates 0 +. 0 + +Cognitive 0 +functions 0 +may 0 +also 0 +be 0 +involved 0 +since 0 +dopaminergic 0 +and 0 +serotonergic 0 +cellular 0 +elements 0 +at 0 +the 0 +brainstem 0 +level 0 +are 0 +also 0 +implicated 0 +. 0 + +rTMS 0 +of 0 +supplementary 0 +motor 0 +area 0 +modulates 0 +therapy 0 +- 0 +induced 0 +dyskinesias 3 +in 0 +Parkinson 3 +disease 4 +. 0 + +The 0 +neural 0 +mechanisms 0 +and 0 +circuitry 0 +involved 0 +in 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +are 0 +unclear 0 +. 0 + +Using 0 +repetitive 0 +transcranial 0 +magnetic 0 +stimulation 0 +( 0 +rTMS 0 +) 0 +over 0 +the 0 +supplementary 0 +motor 0 +area 0 +( 0 +SMA 0 +) 0 +in 0 +a 0 +group 0 +of 0 +patients 0 +with 0 +advanced 0 +Parkinson 3 +disease 4 +, 0 +the 0 +authors 0 +investigated 0 +whether 0 +modulation 0 +of 0 +SMA 0 +excitability 0 +may 0 +result 0 +in 0 +a 0 +modification 0 +of 0 +a 0 +dyskinetic 3 +state 0 +induced 0 +by 0 +continuous 0 +apomorphine 1 +infusion 0 +. 0 + +rTMS 0 +at 0 +1 0 +Hz 0 +was 0 +observed 0 +to 0 +markedly 0 +reduce 0 +drug 3 +- 4 +induced 4 +dyskinesias 4 +, 0 +whereas 0 +5 0 +- 0 +Hz 0 +rTMS 0 +induced 0 +a 0 +slight 0 +but 0 +not 0 +significant 0 +increase 0 +. 0 + +Intracavitary 0 +chemotherapy 0 +( 0 +paclitaxel 1 +/ 0 +carboplatin 1 +liquid 0 +crystalline 0 +cubic 0 +phases 0 +) 0 +for 0 +recurrent 0 +glioblastoma 3 +- 0 +- 0 +clinical 0 +observations 0 +. 0 + +Human 0 +malignant 0 +brain 3 +tumors 4 +have 0 +a 0 +poor 0 +prognosis 0 +in 0 +spite 0 +of 0 +surgery 0 +and 0 +radiation 0 +therapy 0 +. 0 + +Cubic 0 +phases 0 +consist 0 +of 0 +curved 0 +biocontinuous 0 +lipid 0 +bilayers 0 +, 0 +separating 0 +two 0 +congruent 0 +networks 0 +of 0 +water 0 +channels 0 +. 0 + +Used 0 +as 0 +a 0 +host 0 +for 0 +cytotoxic 0 +drugs 0 +, 0 +the 0 +gel 0 +- 0 +like 0 +matrix 0 +can 0 +easily 0 +be 0 +applied 0 +to 0 +the 0 +walls 0 +of 0 +a 0 +surgical 0 +resection 0 +cavity 0 +. 0 + +For 0 +human 0 +glioblastoma 3 +recurrences 0 +, 0 +the 0 +feasibility 0 +, 0 +safety 0 +, 0 +and 0 +short 0 +- 0 +term 0 +effects 0 +of 0 +a 0 +surgical 0 +intracavitary 0 +application 0 +of 0 +paclitaxel 1 +and 0 +carboplatin 1 +encapsulated 0 +by 0 +liquid 0 +crystalline 0 +cubic 0 +phases 0 +are 0 +examined 0 +in 0 +a 0 +pilot 0 +study 0 +. 0 + +A 0 +total 0 +of 0 +12 0 +patients 0 +with 0 +a 0 +recurrence 0 +of 0 +a 0 +glioblastoma 3 +multiforme 0 +underwent 0 +re 0 +- 0 +resection 0 +and 0 +received 0 +an 0 +intracavitary 0 +application 0 +of 0 +paclitaxel 1 +and 0 +carboplatin 1 +cubic 0 +phases 0 +in 0 +different 0 +dosages 0 +. 0 + +Six 0 +of 0 +the 0 +patients 0 +received 0 +more 0 +than 0 +15 0 +mg 0 +paclitaxel 1 +and 0 +suffered 0 +from 0 +moderate 0 +to 0 +severe 0 +brain 3 +edema 4 +, 0 +while 0 +the 0 +remaining 0 +patients 0 +received 0 +only 0 +a 0 +total 0 +of 0 +15 0 +mg 0 +paclitaxel 1 +. 0 + +In 0 +the 0 +latter 0 +group 0 +, 0 +brain 3 +edema 4 +was 0 +markedly 0 +reduced 0 +and 0 +dealt 0 +medically 0 +. 0 + +Intracavitary 0 +chemotherapy 0 +in 0 +recurrent 0 +glioblastoma 3 +using 0 +cubic 0 +phases 0 +is 0 +feasible 0 +and 0 +safe 0 +, 0 +yet 0 +the 0 +clinical 0 +benefit 0 +remains 0 +to 0 +be 0 +examined 0 +in 0 +a 0 +clinical 0 +phase 0 +II 0 +study 0 +. 0 + +Lamotrigine 1 +associated 0 +with 0 +exacerbation 0 +or 0 +de 0 +novo 0 +myoclonus 3 +in 0 +idiopathic 3 +generalized 4 +epilepsies 4 +. 0 + +Five 0 +patients 0 +with 0 +idiopathic 3 +generalized 4 +epilepsies 4 +( 0 +IGE 3 +) 0 +treated 0 +with 0 +lamotrigine 1 +( 0 +LTG 1 +) 0 +experienced 0 +exacerbation 0 +or 0 +de 0 +novo 0 +appearance 0 +of 0 +myoclonic 3 +jerks 4 +( 0 +MJ 3 +) 0 +. 0 + +In 0 +three 0 +patients 0 +, 0 +LTG 1 +exacerbated 0 +MJ 3 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +with 0 +early 0 +aggravation 0 +during 0 +titration 0 +. 0 + +MJ 3 +disappeared 0 +when 0 +LTG 1 +dose 0 +was 0 +decreased 0 +by 0 +25 0 +to 0 +50 0 +% 0 +. 0 + +In 0 +two 0 +patients 0 +, 0 +LTG 1 +exacerbated 0 +MJ 3 +in 0 +a 0 +delayed 0 +but 0 +more 0 +severe 0 +manner 0 +, 0 +with 0 +myoclonic 3 +status 4 +that 0 +only 0 +ceased 0 +after 0 +LTG 1 +withdrawal 0 +. 0 + +Absence 0 +of 0 +acute 0 +cerebral 0 +vasoconstriction 0 +after 0 +cocaine 1 +- 0 +associated 0 +subarachnoid 3 +hemorrhage 4 +. 0 + +INTR0DUCTI0N 0 +: 0 +Cocaine 1 +use 0 +has 0 +been 0 +associated 0 +with 0 +neurovascular 3 +complications 4 +, 0 +including 0 +arterial 0 +vasoconstriction 0 +and 0 +vasculitis 3 +. 0 + +However 0 +, 0 +there 0 +are 0 +few 0 +studies 0 +of 0 +angiographic 0 +effects 0 +of 0 +cocaine 1 +on 0 +human 0 +cerebral 0 +arteries 0 +. 0 + +Information 0 +on 0 +these 0 +effects 0 +could 0 +be 0 +obtained 0 +from 0 +angiograms 0 +of 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +subarachnoid 3 +hemorrhage 4 +( 0 +SAH 3 +) 0 +who 0 +underwent 0 +angiography 0 +shortly 0 +after 0 +cocaine 1 +use 0 +. 0 + +METH0DS 0 +: 0 +We 0 +screened 0 +patients 0 +with 0 +SAH 3 +retrospectively 0 +and 0 +identified 0 +those 0 +with 0 +positive 0 +urine 0 +toxicology 0 +for 0 +cocaine 1 +or 0 +its 0 +metabolites 0 +. 0 + +Quantitative 0 +arterial 0 +diameter 0 +measurements 0 +from 0 +angiograms 0 +of 0 +these 0 +patients 0 +were 0 +compared 0 +to 0 +measurements 0 +from 0 +control 0 +patients 0 +with 0 +SAH 3 +who 0 +were 0 +matched 0 +for 0 +factors 0 +known 0 +to 0 +influence 0 +arterial 0 +diameter 0 +. 0 + +Qualitative 0 +comparisons 0 +of 0 +small 0 +artery 0 +changes 0 +also 0 +were 0 +made 0 +. 0 + +RESULTS 0 +: 0 +Thirteen 0 +patients 0 +with 0 +positive 0 +cocaine 1 +toxicology 0 +were 0 +compared 0 +to 0 +26 0 +controls 0 +. 0 + +There 0 +were 0 +no 0 +significant 0 +differences 0 +between 0 +groups 0 +in 0 +the 0 +mean 0 +diameters 0 +of 0 +the 0 +intradural 0 +internal 0 +carotid 0 +, 0 +sphenoidal 0 +segment 0 +of 0 +the 0 +middle 0 +cerebral 0 +, 0 +precommunicating 0 +segment 0 +of 0 +the 0 +anterior 0 +cerebral 0 +, 0 +or 0 +basilar 0 +arteries 0 +( 0 +p 0 +greater 0 +than 0 +0 0 +. 0 +05 0 +for 0 +all 0 +comparisons 0 +, 0 +unpaired 0 +t 0 +- 0 +tests 0 +) 0 +. 0 + +There 0 +also 0 +were 0 +no 0 +significant 0 +differences 0 +between 0 +groups 0 +when 0 +expressing 0 +diameters 0 +as 0 +the 0 +sum 0 +of 0 +the 0 +precommunicating 0 +segment 0 +of 0 +the 0 +anterior 0 +cerebral 0 ++ 0 +sphenoidal 0 +segment 0 +of 0 +the 0 +middle 0 +cerebral 0 ++ 0 +supraclinoid 0 +internal 0 +carotid 0 +artery 0 ++ 0 +basilar 0 +artery 0 +divided 0 +by 0 +the 0 +diameter 0 +of 0 +the 0 +petrous 0 +internal 0 +carotid 0 +artery 0 +( 0 +p 0 +greater 0 +than 0 +0 0 +. 0 +05 0 +, 0 +unpaired 0 +t 0 +- 0 +tests 0 +) 0 +. 0 + +Qualitative 0 +assessments 0 +showed 0 +two 0 +arterial 0 +irregularities 0 +in 0 +the 0 +distal 0 +vasculature 0 +in 0 +each 0 +group 0 +. 0 + +C0NCLUSI0N 0 +: 0 +No 0 +quantitative 0 +evidence 0 +for 0 +narrowing 0 +of 0 +large 0 +cerebral 0 +arteries 0 +or 0 +qualitative 0 +angiographic 0 +evidence 0 +for 0 +distal 0 +narrowing 0 +or 0 +vasculitis 3 +could 0 +be 0 +found 0 +in 0 +patients 0 +who 0 +underwent 0 +angiography 0 +after 0 +aneurysmal 3 +SAH 3 +associated 0 +with 0 +cocaine 1 +use 0 +. 0 + +Methamphetamine 1 +causes 0 +alterations 0 +in 0 +the 0 +MAP 0 +kinase 0 +- 0 +related 0 +pathways 0 +in 0 +the 0 +brains 0 +of 0 +mice 0 +that 0 +display 0 +increased 0 +aggressiveness 3 +. 0 + +Aggressive 3 +behaviors 4 +have 0 +been 0 +reported 0 +in 0 +patients 0 +who 0 +suffer 0 +from 0 +some 0 +psychiatric 3 +disorders 4 +, 0 +and 0 +are 0 +common 0 +in 0 +methamphetamine 1 +( 0 +METH 1 +) 0 +abusers 0 +. 0 + +Herein 0 +, 0 +we 0 +report 0 +that 0 +multiple 0 +( 0 +but 0 +not 0 +single 0 +) 0 +injections 0 +of 0 +METH 1 +significantly 0 +increased 0 +aggressiveness 3 +in 0 +male 0 +CD 0 +- 0 +1 0 +mice 0 +. 0 + +This 0 +increase 0 +in 0 +aggressiveness 3 +was 0 +not 0 +secondary 0 +to 0 +METH 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +Analysis 0 +of 0 +protein 0 +expression 0 +using 0 +antibody 0 +microarrays 0 +and 0 +Western 0 +blotting 0 +revealed 0 +differential 0 +changes 0 +in 0 +MAP 0 +kinase 0 +- 0 +related 0 +pathways 0 +after 0 +multiple 0 +and 0 +single 0 +METH 1 +injections 0 +. 0 + +There 0 +were 0 +statistically 0 +significant 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +decreases 0 +in 0 +MEK1 0 +, 0 +Erk2p 0 +, 0 +GSK3alpha 0 +, 0 +14 0 +- 0 +3 0 +- 0 +3e 0 +, 0 +and 0 +MEK7 0 +in 0 +the 0 +striata 0 +of 0 +mice 0 +after 0 +multiple 0 +injections 0 +of 0 +METH 1 +. 0 + +MEK1 0 +was 0 +significantly 0 +decreased 0 +also 0 +after 0 +a 0 +single 0 +injection 0 +of 0 +METH 1 +, 0 +but 0 +to 0 +a 0 +much 0 +lesser 0 +degree 0 +than 0 +after 0 +multiple 0 +injections 0 +of 0 +METH 1 +. 0 + +In 0 +the 0 +frontal 0 +cortex 0 +, 0 +there 0 +was 0 +a 0 +statistically 0 +significant 0 +decrease 0 +in 0 +GSK3alpha 0 +after 0 +multiple 0 +( 0 +but 0 +not 0 +single 0 +) 0 +injections 0 +of 0 +METH 1 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +alterations 0 +in 0 +MAP 0 +kinase 0 +- 0 +related 0 +pathways 0 +in 0 +the 0 +prefronto 0 +- 0 +striatal 0 +circuitries 0 +might 0 +be 0 +involved 0 +in 0 +the 0 +manifestation 0 +of 0 +aggressive 3 +behaviors 4 +in 0 +mice 0 +. 0 + +Amisulpride 1 +related 0 +tic 3 +- 4 +like 4 +symptoms 4 +in 0 +an 0 +adolescent 0 +schizophrenic 3 +. 0 + +Tic 3 +disorders 4 +can 0 +be 0 +effectively 0 +treated 0 +by 0 +atypical 0 +antipsychotics 0 +such 0 +as 0 +risperidone 1 +, 0 +olanzapine 1 +and 0 +ziprasidone 1 +. 0 + +However 0 +, 0 +there 0 +are 0 +two 0 +case 0 +reports 0 +that 0 +show 0 +tic 3 +- 4 +like 4 +symptoms 4 +, 0 +including 0 +motor 0 +and 0 +phonic 0 +variants 0 +, 0 +occurring 0 +during 0 +treatment 0 +with 0 +quetiapine 1 +or 0 +clozapine 1 +. 0 + +We 0 +present 0 +a 0 +15 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +schizophrenic 3 +who 0 +developed 0 +frequent 0 +involuntary 3 +eye 4 +- 4 +blinking 4 +movements 4 +after 0 +5 0 +months 0 +of 0 +amisulpride 1 +treatment 0 +( 0 +1000 0 +mg 0 +per 0 +day 0 +) 0 +. 0 + +The 0 +tic 3 +- 4 +like 4 +symptoms 4 +resolved 0 +completely 0 +after 0 +we 0 +reduced 0 +the 0 +dose 0 +of 0 +amisulpride 1 +down 0 +to 0 +800 0 +mg 0 +per 0 +day 0 +. 0 + +However 0 +, 0 +her 0 +psychosis 3 +recurred 0 +after 0 +the 0 +dose 0 +reduction 0 +. 0 + +We 0 +then 0 +placed 0 +her 0 +on 0 +an 0 +additional 0 +100 0 +mg 0 +per 0 +day 0 +of 0 +quetiapine 1 +. 0 + +She 0 +has 0 +been 0 +in 0 +complete 0 +remission 0 +under 0 +the 0 +combined 0 +medications 0 +for 0 +more 0 +than 0 +one 0 +year 0 +and 0 +maintains 0 +a 0 +fair 0 +role 0 +function 0 +. 0 + +No 0 +more 0 +tic 3 +- 4 +like 4 +symptoms 4 +or 0 +other 0 +side 0 +effects 0 +have 0 +been 0 +reported 0 +. 0 + +Together 0 +with 0 +previously 0 +reported 0 +cases 0 +, 0 +our 0 +patient 0 +suggests 0 +that 0 +tic 3 +- 4 +like 4 +symptoms 4 +might 0 +occur 0 +in 0 +certain 0 +vulnerable 0 +individuals 0 +during 0 +treatment 0 +with 0 +atypical 0 +antipsychotics 0 +such 0 +as 0 +quetiapine 1 +, 0 +clozapine 1 +, 0 +or 0 +amisulpride 1 +. 0 + +Chloroquine 1 +related 0 +complete 0 +heart 3 +block 4 +with 0 +blindness 3 +: 0 +case 0 +report 0 +. 0 + +A 0 +27 0 +- 0 +year 0 +old 0 +African 0 +woman 0 +with 0 +history 0 +of 0 +regular 0 +chloroquine 1 +ingestion 0 +presented 0 +with 0 +progressive 0 +deterioration 3 +of 4 +vision 4 +, 0 +easy 0 +fatiguability 3 +, 0 +dyspnoea 3 +, 0 +dizziness 3 +progressing 0 +to 0 +syncopal 3 +attacks 4 +. 0 + +0phthalmological 0 +assessment 0 +revealed 0 +features 0 +of 0 +chloroquine 1 +retinopathy 3 +, 0 +cardiac 0 +assessment 0 +revealed 0 +features 0 +of 0 +heart 3 +failure 4 +and 0 +a 0 +complete 0 +heart 3 +block 4 +with 0 +right 3 +bundle 4 +branch 4 +block 4 +pattern 0 +. 0 + +The 0 +heart 3 +block 4 +was 0 +treated 0 +by 0 +pacemaker 0 +insertion 0 +and 0 +the 0 +heart 3 +failure 4 +resolved 0 +spontaneously 0 +following 0 +chloroquine 1 +discontinuation 0 +. 0 + +She 0 +however 0 +remains 0 +blind 3 +. 0 + +Effects 0 +of 0 +suprofen 1 +on 0 +the 0 +isolated 0 +perfused 0 +rat 0 +kidney 0 +. 0 + +Although 0 +suprofen 1 +has 0 +been 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +acute 3 +renal 4 +failure 4 +in 0 +greater 0 +than 0 +100 0 +subjects 0 +, 0 +the 0 +mechanism 0 +of 0 +damage 0 +remains 0 +unclear 0 +. 0 + +The 0 +direct 0 +nephrotoxic 3 +effects 0 +of 0 +a 0 +single 0 +dose 0 +of 0 +15 0 +mg 0 +of 0 +suprofen 1 +were 0 +compared 0 +in 0 +the 0 +recirculating 0 +isolated 0 +rat 0 +kidney 0 +perfused 0 +with 0 +cell 0 +- 0 +free 0 +buffer 0 +with 0 +or 0 +without 0 +the 0 +addition 0 +of 0 +5 0 +mg 0 +/ 0 +dL 0 +of 0 +uric 1 +acid 2 +. 0 + +There 0 +were 0 +no 0 +significant 0 +differences 0 +in 0 +renal 0 +sodium 1 +excretion 0 +, 0 +oxygen 1 +consumption 0 +, 0 +or 0 +urinary 0 +flow 0 +rates 0 +in 0 +kidneys 0 +perfused 0 +with 0 +suprofen 1 +compared 0 +with 0 +the 0 +drug 0 +- 0 +free 0 +control 0 +groups 0 +. 0 + +In 0 +contrast 0 +, 0 +a 0 +significant 0 +decline 0 +in 0 +glomerular 0 +filtration 0 +rate 0 +was 0 +found 0 +after 0 +the 0 +introduction 0 +of 0 +suprofen 1 +to 0 +the 0 +kidney 0 +perfused 0 +with 0 +uric 1 +acid 2 +; 0 +no 0 +changes 0 +were 0 +found 0 +with 0 +suprofen 1 +in 0 +the 0 +absence 0 +of 0 +uric 1 +acid 2 +. 0 + +A 0 +significant 0 +decrease 0 +in 0 +the 0 +baseline 0 +excretion 0 +rate 0 +of 0 +uric 1 +acid 2 +was 0 +found 0 +in 0 +rats 0 +given 0 +suprofen 1 +, 0 +compared 0 +with 0 +drug 0 +- 0 +free 0 +controls 0 +. 0 + +However 0 +, 0 +the 0 +fractional 0 +excretion 0 +of 0 +uric 1 +acid 2 +was 0 +unchanged 0 +between 0 +the 0 +groups 0 +over 0 +the 0 +experimental 0 +period 0 +. 0 + +In 0 +summary 0 +, 0 +suprofen 1 +causes 0 +acute 3 +declines 4 +in 4 +renal 4 +function 4 +, 0 +most 0 +likely 0 +by 0 +directly 0 +altering 0 +the 0 +intrarenal 0 +distribution 0 +of 0 +uric 1 +acid 2 +. 0 + +Microinjection 0 +of 0 +ritanserin 1 +into 0 +the 0 +CA1 0 +region 0 +of 0 +hippocampus 0 +improves 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +in 0 +adult 0 +male 0 +rats 0 +. 0 + +The 0 +effect 0 +of 0 +ritanserin 1 +( 0 +5 0 +- 0 +HT2 0 +antagonist 0 +) 0 +on 0 +scopolamine 1 +( 0 +muscarinic 0 +cholinergic 0 +antagonist 0 +) 0 +- 0 +induced 0 +amnesia 3 +in 0 +Morris 0 +water 0 +maze 0 +( 0 +MWM 0 +) 0 +was 0 +investigated 0 +. 0 + +Rats 0 +were 0 +divided 0 +into 0 +eight 0 +groups 0 +and 0 +bilaterally 0 +cannulated 0 +into 0 +CA1 0 +region 0 +of 0 +the 0 +hippocampus 0 +. 0 + +0ne 0 +week 0 +later 0 +, 0 +they 0 +received 0 +repeatedly 0 +vehicles 0 +( 0 +saline 0 +, 0 +DMS0 1 +, 0 +saline 0 ++ 0 +DMS0 1 +) 0 +, 0 +scopolamine 1 +( 0 +2 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +saline 0 +/ 0 +side 0 +; 0 +30 0 +min 0 +before 0 +training 0 +) 0 +, 0 +ritanserin 1 +( 0 +2 0 +, 0 +4 0 +and 0 +8 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +DMS0 1 +/ 0 +side 0 +; 0 +20 0 +min 0 +before 0 +training 0 +) 0 +and 0 +scopolamine 1 +( 0 +2 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +; 0 +30 0 +min 0 +before 0 +ritanserin 1 +injection 0 +) 0 ++ 0 +ritanserin 1 +( 0 +4 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +DMS0 1 +) 0 +through 0 +cannulae 0 +each 0 +day 0 +. 0 + +Animals 0 +were 0 +tested 0 +for 0 +four 0 +consecutive 0 +days 0 +( 0 +4 0 +trial 0 +/ 0 +day 0 +) 0 +in 0 +MWM 0 +during 0 +which 0 +the 0 +position 0 +of 0 +hidden 0 +platform 0 +was 0 +unchanged 0 +. 0 + +In 0 +the 0 +fifth 0 +day 0 +, 0 +the 0 +platform 0 +was 0 +elevated 0 +above 0 +the 0 +water 0 +surface 0 +in 0 +another 0 +position 0 +to 0 +evaluate 0 +the 0 +function 0 +of 0 +motor 0 +, 0 +motivational 0 +and 0 +visual 0 +systems 0 +. 0 + +The 0 +results 0 +showed 0 +a 0 +significant 0 +increase 0 +in 0 +escape 0 +latencies 0 +and 0 +traveled 0 +distances 0 +to 0 +find 0 +platform 0 +in 0 +scopolamine 1 +- 0 +treated 0 +group 0 +as 0 +compared 0 +to 0 +saline 0 +group 0 +. 0 + +Ritanserin 1 +- 0 +treated 0 +rats 0 +( 0 +4 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +/ 0 +side 0 +) 0 +showed 0 +a 0 +significant 0 +decrease 0 +in 0 +the 0 +mentioned 0 +parameters 0 +as 0 +compared 0 +to 0 +DMS0 1 +- 0 +treated 0 +group 0 +. 0 + +However 0 +, 0 +scopolamine 1 +and 0 +ritanserin 1 +co 0 +- 0 +administration 0 +resulted 0 +in 0 +a 0 +significant 0 +decrease 0 +in 0 +escape 0 +latencies 0 +and 0 +traveled 0 +distances 0 +as 0 +compared 0 +to 0 +the 0 +scopolamine 1 +- 0 +treated 0 +rats 0 +. 0 + +0ur 0 +findings 0 +show 0 +that 0 +microinjection 0 +of 0 +ritanserin 1 +into 0 +the 0 +CA1 0 +region 0 +of 0 +the 0 +hippocampus 0 +improves 0 +the 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +PTU 1 +- 0 +associated 0 +vasculitis 3 +in 0 +a 0 +girl 0 +with 0 +Turner 3 +Syndrome 4 +and 0 +Graves 3 +' 4 +disease 4 +. 0 + +Palpable 0 +purpura 3 +is 0 +a 0 +concerning 0 +clinical 0 +finding 0 +in 0 +pediatric 0 +patients 0 +and 0 +can 0 +have 0 +many 0 +causes 0 +, 0 +including 0 +infectious 0 +and 0 +autoimmune 0 +processes 0 +. 0 + +A 0 +rare 0 +cause 0 +, 0 +drug 0 +- 0 +induced 0 +vasculitis 3 +, 0 +may 0 +result 0 +from 0 +the 0 +production 0 +of 0 +antineutrophil 0 +cytoplasmic 0 +antibodies 0 +( 0 +ANCAs 0 +) 0 +in 0 +response 0 +to 0 +a 0 +medication 0 +. 0 + +We 0 +report 0 +a 0 +girl 0 +with 0 +Turner 3 +syndrome 4 +and 0 +Graves 3 +' 4 +disease 4 +who 0 +presented 0 +with 0 +palpable 0 +purpuric 3 +lesions 4 +. 0 + +The 0 +diagnosis 0 +of 0 +propylthiouracil 1 +( 0 +PTU 1 +) 0 +- 0 +associated 0 +vasculitis 3 +was 0 +made 0 +by 0 +observation 0 +of 0 +consistent 0 +clinical 0 +features 0 +, 0 +the 0 +detection 0 +of 0 +elevated 0 +ANA 0 +and 0 +ANCA 0 +in 0 +the 0 +blood 0 +, 0 +and 0 +the 0 +observed 0 +clinical 0 +resolution 0 +of 0 +symptoms 0 +following 0 +withdrawal 0 +of 0 +PTU 1 +. 0 + +Subsequent 0 +treatment 0 +of 0 +persistent 0 +hyperthyroidism 3 +with 0 +radioablation 0 +did 0 +not 0 +result 0 +in 0 +an 0 +exacerbation 0 +of 0 +the 0 +vasculitis 3 +, 0 +a 0 +complication 0 +described 0 +in 0 +prior 0 +case 0 +reports 0 +. 0 + +Daidzein 1 +activates 0 +choline 1 +acetyltransferase 0 +from 0 +MC 0 +- 0 +IXC 0 +cells 0 +and 0 +improves 0 +drug 0 +- 0 +induced 0 +amnesia 3 +. 0 + +The 0 +choline 1 +acetyltransferase 0 +( 0 +ChAT 0 +) 0 +activator 0 +, 0 +which 0 +enhances 0 +cholinergic 0 +transmission 0 +via 0 +an 0 +augmentation 0 +of 0 +the 0 +enzymatic 0 +production 0 +of 0 +acetylcholine 1 +( 0 +ACh 1 +) 0 +, 0 +is 0 +an 0 +important 0 +factor 0 +in 0 +the 0 +treatment 0 +of 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +( 0 +AD 3 +) 0 +. 0 + +Methanolic 0 +extracts 0 +from 0 +Pueraria 0 +thunbergiana 0 +exhibited 0 +an 0 +activation 0 +effect 0 +( 0 +46 0 +% 0 +) 0 +on 0 +ChAT 0 +in 0 +vitro 0 +. 0 + +Via 0 +the 0 +sequential 0 +isolation 0 +of 0 +Pueraria 0 +thunbergiana 0 +, 0 +the 0 +active 0 +component 0 +was 0 +ultimately 0 +identified 0 +as 0 +daidzein 1 +( 0 +4 1 +' 2 +, 2 +7 2 +- 2 +dihydroxy 2 +- 2 +isoflavone 2 +) 0 +. 0 + +In 0 +order 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +daidzein 1 +from 0 +Pueraria 0 +thunbergiana 0 +on 0 +scopolamine 1 +- 0 +induced 0 +impairments 3 +of 4 +learning 4 +and 4 +memory 4 +, 0 +we 0 +conducted 0 +a 0 +series 0 +of 0 +in 0 +vivo 0 +tests 0 +. 0 + +Administration 0 +of 0 +daidzein 1 +( 0 +4 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +to 0 +mice 0 +was 0 +shown 0 +significantly 0 +to 0 +reverse 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +, 0 +according 0 +to 0 +the 0 +results 0 +of 0 +a 0 +Y 0 +- 0 +maze 0 +test 0 +. 0 + +Injections 0 +of 0 +scopolamine 1 +into 0 +mice 0 +resulted 0 +in 0 +impaired 0 +performance 0 +on 0 +Y 0 +- 0 +maze 0 +tests 0 +( 0 +a 0 +37 0 +% 0 +decreases 0 +in 0 +alternation 0 +behavior 0 +) 0 +. 0 + +By 0 +way 0 +of 0 +contrast 0 +, 0 +mice 0 +treated 0 +with 0 +daidzein 1 +prior 0 +to 0 +the 0 +scopolamine 1 +injections 0 +were 0 +noticeably 0 +protected 0 +from 0 +this 0 +performance 0 +impairment 0 +( 0 +an 0 +approximately 0 +12 0 +% 0 +- 0 +21 0 +% 0 +decrease 0 +in 0 +alternation 0 +behavior 0 +) 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +daidzein 1 +might 0 +play 0 +a 0 +role 0 +in 0 +acetylcholine 1 +biosynthesis 0 +as 0 +a 0 +ChAT 0 +activator 0 +, 0 +and 0 +that 0 +it 0 +also 0 +ameliorates 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +Urinary 0 +symptoms 0 +and 0 +quality 0 +of 0 +life 0 +changes 0 +in 0 +Thai 0 +women 0 +with 0 +overactive 3 +bladder 4 +after 0 +tolterodine 1 +treatment 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +study 0 +the 0 +urinary 0 +symptoms 0 +and 0 +quality 0 +of 0 +life 0 +changes 0 +in 0 +Thai 0 +women 0 +with 0 +overactive 3 +bladder 4 +( 0 +0AB 3 +) 0 +after 0 +tolterodine 1 +treatment 0 +. 0 + +MATERIAL 0 +AND 0 +METH0D 0 +: 0 +Thirty 0 +women 0 +( 0 +aged 0 +30 0 +- 0 +77 0 +years 0 +) 0 +diagnosed 0 +as 0 +having 0 +0AB 3 +at 0 +the 0 +Gynecology 0 +Clinic 0 +, 0 +King 0 +Chulalongkorn 0 +Memorial 0 +Hospital 0 +from 0 +January 0 +to 0 +April 0 +2004 0 +were 0 +included 0 +in 0 +the 0 +present 0 +study 0 +. 0 + +Tolterodine 1 +2 0 +mg 0 +, 0 +twice 0 +daily 0 +was 0 +given 0 +. 0 + +After 0 +8 0 +weeks 0 +treatment 0 +, 0 +changes 0 +in 0 +micturition 0 +diary 0 +variables 0 +and 0 +tolerability 0 +were 0 +determined 0 +. 0 + +Short 0 +form 0 +36 0 +( 0 +SF36 0 +) 0 +questionaires 0 +( 0 +Thai 0 +version 0 +) 0 +were 0 +given 0 +before 0 +and 0 +after 0 +8 0 +weeks 0 +of 0 +treatment 0 +. 0 + +RESULTS 0 +: 0 +At 0 +8 0 +weeks 0 +, 0 +all 0 +micturition 0 +per 0 +day 0 +decreased 0 +from 0 +16 0 +. 0 + +7 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 + +3 0 +to 0 +6 0 +. 0 + +7 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +4 0 +times 0 +per 0 +day 0 +. 0 + +The 0 +number 0 +of 0 +nocturia 3 +episodes 0 +decreased 0 +from 0 +5 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +2 0 +to 0 +1 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +times 0 +per 0 +night 0 +. 0 + +The 0 +most 0 +common 0 +side 0 +effect 0 +was 0 +dry 3 +month 4 +in 0 +5 0 +cases 0 +( 0 +16 0 +. 0 +7 0 +% 0 +) 0 +with 0 +2 0 +cases 0 +reporting 0 +a 0 +moderate 0 +degree 0 +and 0 +1 0 +case 0 +with 0 +severe 0 +degree 0 +. 0 + +0nly 0 +one 0 +case 0 +( 0 +3 0 +. 0 +3 0 +% 0 +) 0 +withdrew 0 +from 0 +the 0 +present 0 +study 0 +due 0 +to 0 +a 0 +severe 0 +dry 3 +mouth 4 +. 0 + +The 0 +SF 0 +- 0 +36 0 +scores 0 +changed 0 +significantly 0 +in 0 +the 0 +domains 0 +of 0 +physical 0 +functioning 0 +, 0 +role 0 +function 0 +emotional 0 +, 0 +social 0 +function 0 +and 0 +mental 0 +heath 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Tolterodine 1 +was 0 +well 0 +tolerated 0 +and 0 +its 0 +effects 0 +improved 0 +the 0 +quality 0 +of 0 +life 0 +in 0 +Thai 0 +women 0 +with 0 +0AB 3 +. 0 + +Remifentanil 1 +pretreatment 0 +reduces 0 +myoclonus 3 +after 0 +etomidate 1 +. 0 + +STUDY 0 +0BJECTIVE 0 +: 0 +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +compare 0 +the 0 +effect 0 +of 0 +pretreatment 0 +with 0 +remifentanil 1 +1 0 +microg 0 +/ 0 +kg 0 +and 0 +the 0 +effect 0 +of 0 +gender 0 +on 0 +the 0 +incidence 0 +of 0 +myoclonus 3 +after 0 +anesthesia 0 +induction 0 +with 0 +etomidate 1 +. 0 + +DESIGN 0 +: 0 +This 0 +was 0 +a 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +study 0 +. 0 + +SETTING 0 +: 0 +The 0 +study 0 +was 0 +conducted 0 +at 0 +a 0 +university 0 +hospital 0 +. 0 + +PATIENTS 0 +: 0 +Sixty 0 +patients 0 +were 0 +pretreated 0 +in 0 +a 0 +randomized 0 +double 0 +- 0 +blinded 0 +fashion 0 +with 0 +remifentanil 1 +1 0 +microg 0 +/ 0 +kg 0 +or 0 +placebo 0 +. 0 + +Two 0 +minutes 0 +after 0 +remifentanil 1 +or 0 +placebo 0 +injection 0 +, 0 +etomidate 1 +0 0 +. 0 +3 0 +mg 0 +/ 0 +kg 0 +was 0 +given 0 +. 0 + +MEASUREMENTS 0 +: 0 +Myoclonus 3 +was 0 +recorded 0 +with 0 +a 0 +scale 0 +of 0 +0 0 +to 0 +3 0 +. 0 + +The 0 +grade 0 +of 0 +sedation 0 +( 0 +none 0 +, 0 +mild 0 +, 0 +moderate 0 +, 0 +severe 0 +) 0 +, 0 +nausea 3 +, 0 +pruritus 3 +, 0 +and 0 +apnea 3 +were 0 +recorded 0 +after 0 +injection 0 +of 0 +both 0 +drugs 0 +. 0 + +MAIN 0 +RESULTS 0 +: 0 +The 0 +incidence 0 +of 0 +myoclonus 3 +was 0 +significantly 0 +lower 0 +in 0 +the 0 +remifentanil 1 +group 0 +( 0 +6 0 +. 0 +7 0 +% 0 +) 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +( 0 +70 0 +% 0 +) 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +None 0 +of 0 +the 0 +patients 0 +experienced 0 +sedation 0 +, 0 +apnea 3 +, 0 +nausea 3 +, 0 +or 0 +pruritus 3 +after 0 +injection 0 +of 0 +both 0 +drugs 0 +. 0 + +In 0 +the 0 +placebo 0 +group 0 +, 0 +male 0 +patients 0 +were 0 +associated 0 +with 0 +significantly 0 +increased 0 +incidence 0 +of 0 +myoclonus 3 +after 0 +etomidate 1 +administration 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Pretreatment 0 +with 0 +remifentanil 1 +1 0 +microg 0 +/ 0 +kg 0 +reduced 0 +myoclonus 3 +after 0 +etomidate 1 +induction 0 +without 0 +side 0 +effects 0 +such 0 +as 0 +sedation 0 +, 0 +apnea 3 +, 0 +nausea 3 +, 0 +or 0 +pruritus 3 +. 0 + +Men 0 +experience 0 +increased 0 +incidence 0 +of 0 +myoclonus 3 +than 0 +women 0 +after 0 +etomidate 1 +administration 0 +. 0 + +Memory 0 +function 0 +and 0 +serotonin 1 +transporter 0 +promoter 0 +gene 0 +polymorphism 0 +in 0 +ecstasy 1 +( 0 +MDMA 1 +) 0 +users 0 +. 0 + +Although 0 +3 1 +, 2 +4 2 +- 2 +methylenedioxymethamphetamine 2 +( 0 +MDMA 1 +or 0 +ecstasy 1 +) 0 +has 0 +been 0 +shown 0 +to 0 +damage 0 +brain 0 +serotonin 1 +( 0 +5 1 +- 2 +HT 2 +) 0 +neurons 0 +in 0 +animals 0 +and 0 +possibly 0 +humans 0 +, 0 +little 0 +is 0 +known 0 +about 0 +the 0 +long 0 +- 0 +term 0 +consequences 0 +of 0 +MDMA 1 +- 0 +induced 0 +5 1 +- 2 +HT 2 +neurotoxic 3 +lesions 4 +on 0 +functions 0 +in 0 +which 0 +5 1 +- 2 +HT 2 +is 0 +involved 0 +, 0 +such 0 +as 0 +cognitive 0 +function 0 +. 0 + +Because 0 +5 1 +- 2 +HT 2 +transporters 0 +play 0 +a 0 +key 0 +element 0 +in 0 +the 0 +regulation 0 +of 0 +synaptic 0 +5 1 +- 2 +HT 2 +transmission 0 +it 0 +may 0 +be 0 +important 0 +to 0 +control 0 +for 0 +the 0 +potential 0 +covariance 0 +effect 0 +of 0 +a 0 +polymorphism 0 +in 0 +the 0 +5 1 +- 2 +HT 2 +transporter 0 +promoter 0 +gene 0 +region 0 +( 0 +5 0 +- 0 +HTTLPR 0 +) 0 +when 0 +studying 0 +the 0 +effects 0 +of 0 +MDMA 1 +as 0 +well 0 +as 0 +cognitive 0 +functioning 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +moderate 0 +and 0 +heavy 0 +MDMA 1 +use 0 +on 0 +cognitive 0 +function 0 +, 0 +as 0 +well 0 +as 0 +the 0 +effects 0 +of 0 +long 0 +- 0 +term 0 +abstention 0 +from 0 +MDMA 1 +, 0 +in 0 +subjects 0 +genotyped 0 +for 0 +5 0 +- 0 +HTTLPR 0 +. 0 + +A 0 +second 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +these 0 +effects 0 +differ 0 +for 0 +females 0 +and 0 +males 0 +. 0 + +Fifteen 0 +moderate 0 +MDMA 1 +users 0 +( 0 +< 0 +55 0 +lifetime 0 +tablets 0 +) 0 +, 0 +22 0 +heavy 0 +MDMA 1 ++ 0 +users 0 +( 0 +> 0 +55 0 +lifetime 0 +tablets 0 +) 0 +, 0 +16 0 +ex 0 +- 0 +MDMA 1 ++ 0 +users 0 +( 0 +last 0 +tablet 0 +> 0 +1 0 +year 0 +ago 0 +) 0 +and 0 +13 0 +controls 0 +were 0 +compared 0 +on 0 +a 0 +battery 0 +of 0 +neuropsychological 0 +tests 0 +. 0 + +DNA 0 +from 0 +peripheral 0 +nuclear 0 +blood 0 +cells 0 +was 0 +genotyped 0 +for 0 +5 0 +- 0 +HTTLPR 0 +using 0 +standard 0 +polymerase 0 +chain 0 +reaction 0 +methods 0 +. 0 +A 0 +significant 0 +group 0 +effect 0 +was 0 +observed 0 +only 0 +on 0 +memory 0 +function 0 +tasks 0 +( 0 +p 0 += 0 +0 0 +. 0 +04 0 +) 0 +but 0 +not 0 +on 0 +reaction 0 +times 0 +( 0 +p 0 += 0 +0 0 +. 0 +61 0 +) 0 +or 0 +attention 0 +/ 0 +executive 0 +functioning 0 +( 0 +p 0 += 0 +0 0 +. 0 +59 0 +) 0 +. 0 + +Heavy 0 +and 0 +ex 0 +- 0 +MDMA 1 ++ 0 +users 0 +performed 0 +significantly 0 +poorer 0 +on 0 +memory 0 +tasks 0 +than 0 +controls 0 +. 0 + +In 0 +contrast 0 +, 0 +no 0 +evidence 0 +of 0 +memory 3 +impairment 4 +was 0 +observed 0 +in 0 +moderate 0 +MDMA 1 +users 0 +. 0 + +No 0 +significant 0 +effect 0 +of 0 +5 0 +- 0 +HTTLPR 0 +or 0 +gender 0 +was 0 +observed 0 +. 0 + +While 0 +the 0 +use 0 +of 0 +MDMA 1 +in 0 +quantities 0 +that 0 +may 0 +be 0 +considered 0 +" 0 +moderate 0 +" 0 +is 0 +not 0 +associated 0 +with 0 +impaired 3 +memory 4 +functioning 4 +, 0 +heavy 0 +use 0 +of 0 +MDMA 1 +use 0 +may 0 +lead 0 +to 0 +long 0 +lasting 0 +memory 3 +impairments 4 +. 0 + +No 0 +effect 0 +of 0 +5 0 +- 0 +HTTLPR 0 +or 0 +gender 0 +on 0 +memory 0 +function 0 +or 0 +MDMA 1 +use 0 +was 0 +observed 0 +. 0 + +Role 0 +of 0 +mangiferin 1 +on 0 +biochemical 0 +alterations 0 +and 0 +antioxidant 0 +status 0 +in 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 + +The 0 +current 0 +study 0 +dealt 0 +with 0 +the 0 +protective 0 +role 0 +of 0 +mangiferin 1 +, 0 +a 0 +polyphenol 1 +from 0 +Mangifera 0 +indica 0 +Linn 0 +. 0 + +( 0 +Anacardiaceae 0 +) 0 +, 0 +on 0 +isoproterenol 1 +( 0 +ISPH 1 +) 0 +- 0 +induced 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +in 0 +rats 0 +through 0 +its 0 +antioxidative 0 +mechanism 0 +. 0 + +Subcutaneous 0 +injection 0 +of 0 +ISPH 1 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +in 0 +1 0 +ml 0 +saline 0 +) 0 +to 0 +rats 0 +for 0 +2 0 +consecutive 0 +days 0 +caused 0 +myocardial 3 +damage 4 +in 0 +rat 0 +heart 0 +, 0 +which 0 +was 0 +determined 0 +by 0 +the 0 +increased 0 +activity 0 +of 0 +serum 0 +lactate 1 +dehydrogenase 0 +( 0 +LDH 0 +) 0 +and 0 +creatine 1 +phosphokinase 0 +isoenzymes 0 +( 0 +CK 0 +- 0 +MB 0 +) 0 +, 0 +increased 0 +uric 1 +acid 2 +level 0 +and 0 +reduced 0 +plasma 0 +iron 1 +binding 0 +capacity 0 +. 0 + +The 0 +protective 0 +role 0 +of 0 +mangiferin 1 +was 0 +analyzed 0 +by 0 +triphenyl 1 +tetrazolium 2 +chloride 2 +( 0 +TTC 1 +) 0 +test 0 +used 0 +for 0 +macroscopic 0 +enzyme 0 +mapping 0 +assay 0 +of 0 +the 0 +ischemic 3 +myocardium 4 +. 0 + +The 0 +heart 0 +tissue 0 +antioxidant 0 +enzymes 0 +such 0 +as 0 +superoxide 1 +dismutase 0 +, 0 +catalase 0 +, 0 +glutathione 1 +peroxidase 0 +, 0 +glutathione 1 +transferase 0 +and 0 +glutathione 1 +reductase 0 +activities 0 +, 0 +non 0 +- 0 +enzymic 0 +antioxidants 0 +such 0 +as 0 +cerruloplasmin 0 +, 0 +Vitamin 1 +C 2 +, 0 +Vitamin 1 +E 2 +and 0 +glutathione 1 +levels 0 +were 0 +altered 0 +in 0 +MI 3 +rats 0 +. 0 + +Upon 0 +pretreatment 0 +with 0 +mangiferin 1 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +suspended 0 +in 0 +2 0 +ml 0 +of 0 +dimethyl 1 +sulphoxide 2 +) 0 +given 0 +intraperitoneally 0 +for 0 +28 0 +days 0 +to 0 +MI 3 +rats 0 +protected 0 +the 0 +above 0 +- 0 +mentioned 0 +parameters 0 +to 0 +fall 0 +from 0 +the 0 +normal 0 +levels 0 +. 0 + +Activities 0 +of 0 +heart 0 +tissue 0 +enzymic 0 +antioxidants 0 +and 0 +serum 0 +non 0 +- 0 +enzymic 0 +antioxidants 0 +levels 0 +rose 0 +significantly 0 +upon 0 +mangiferin 1 +administration 0 +as 0 +compared 0 +to 0 +ISPH 1 +- 0 +induced 0 +MI 3 +rats 0 +. 0 + +From 0 +the 0 +present 0 +study 0 +it 0 +is 0 +concluded 0 +that 0 +mangiferin 1 +exerts 0 +a 0 +beneficial 0 +effect 0 +against 0 +ISPH 1 +- 0 +induced 0 +MI 3 +due 0 +to 0 +its 0 +antioxidant 0 +potential 0 +, 0 +which 0 +regulated 0 +the 0 +tissues 0 +defense 0 +system 0 +against 0 +cardiac 3 +damage 4 +. 0 + +Cardiovascular 0 +risk 0 +with 0 +cyclooxygenase 1 +inhibitors 2 +: 0 +general 0 +problem 0 +with 0 +substance 0 +specific 0 +differences 0 +? 0 + +Randomised 0 +clinical 0 +trials 0 +and 0 +observational 0 +studies 0 +have 0 +shown 0 +an 0 +increased 0 +risk 0 +of 0 +myocardial 3 +infarction 4 +, 0 +stroke 3 +, 0 +hypertension 3 +and 0 +heart 3 +failure 4 +during 0 +treatment 0 +with 0 +cyclooxygenase 1 +inhibitors 2 +. 0 + +Adverse 0 +cardiovascular 0 +effects 0 +occurred 0 +mainly 0 +, 0 +but 0 +not 0 +exclusively 0 +, 0 +in 0 +patients 0 +with 0 +concomitant 0 +risk 0 +factors 0 +. 0 + +Cyclooxygenase 1 +inhibitors 2 +cause 0 +complex 0 +changes 0 +in 0 +renal 0 +, 0 +vascular 0 +and 0 +cardiac 0 +prostanoid 0 +profiles 0 +thereby 0 +increasing 0 +vascular 0 +resistance 0 +and 0 +fluid 0 +retention 0 +. 0 + +The 0 +incidence 0 +of 0 +cardiovascular 0 +adverse 0 +events 0 +tends 0 +to 0 +increase 0 +with 0 +the 0 +daily 0 +dose 0 +and 0 +total 0 +exposure 0 +time 0 +. 0 + +A 0 +comparison 0 +of 0 +individual 0 +selective 0 +and 0 +unselective 0 +cyclooxygenase 1 +inhibitors 2 +suggests 0 +substance 0 +- 0 +specific 0 +differences 0 +, 0 +which 0 +may 0 +depend 0 +on 0 +differences 0 +in 0 +pharmacokinetic 0 +parameters 0 +or 0 +inhibitory 0 +potency 0 +and 0 +may 0 +be 0 +contributed 0 +by 0 +prostaglandin 1 +- 0 +independent 0 +effects 0 +. 0 + +Diagnostic 0 +markers 0 +such 0 +as 0 +N 1 +- 2 +terminal 2 +pro 2 +brain 2 +natriuretic 2 +peptide 2 +( 0 +NT 1 +- 2 +proBNP 2 +) 0 +or 0 +high 0 +- 0 +sensitive 0 +C 0 +- 0 +reactive 0 +protein 0 +might 0 +help 0 +in 0 +the 0 +early 0 +identification 0 +of 0 +patients 0 +at 0 +risk 0 +, 0 +thus 0 +avoiding 0 +the 0 +occurrence 0 +of 0 +serious 0 +cardiovascular 3 +toxicity 4 +. 0 + +Pilocarpine 1 +seizures 3 +cause 0 +age 0 +- 0 +dependent 0 +impairment 3 +in 4 +auditory 4 +location 4 +discrimination 4 +. 0 + +Children 0 +who 0 +have 0 +status 3 +epilepticus 4 +have 0 +continuous 0 +or 0 +rapidly 0 +repeating 0 +seizures 3 +that 0 +may 0 +be 0 +life 0 +- 0 +threatening 0 +and 0 +may 0 +cause 0 +life 0 +- 0 +long 0 +changes 0 +in 0 +brain 0 +and 0 +behavior 0 +. 0 + +The 0 +extent 0 +to 0 +which 0 +status 3 +epilepticus 4 +causes 0 +deficits 3 +in 4 +auditory 4 +discrimination 4 +is 0 +unknown 0 +. 0 + +A 0 +naturalistic 0 +auditory 0 +location 0 +discrimination 0 +method 0 +was 0 +used 0 +to 0 +evaluate 0 +this 0 +question 0 +using 0 +an 0 +animal 0 +model 0 +of 0 +status 3 +epilepticus 4 +. 0 + +Male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +injected 0 +with 0 +saline 0 +on 0 +postnatal 0 +day 0 +( 0 +P 0 +) 0 +20 0 +, 0 +or 0 +a 0 +convulsant 0 +dose 0 +of 0 +pilocarpine 1 +on 0 +P20 0 +or 0 +P45 0 +. 0 + +Pilocarpine 1 +on 0 +either 0 +day 0 +induced 0 +status 3 +epilepticus 4 +; 0 +status 3 +epilepticus 4 +at 0 +P45 0 +resulted 0 +in 0 +CA3 0 +cell 0 +loss 0 +and 0 +spontaneous 0 +seizures 3 +, 0 +whereas 0 +P20 0 +rats 0 +had 0 +no 0 +cell 0 +loss 0 +or 0 +spontaneous 0 +seizures 3 +. 0 + +Mature 0 +rats 0 +were 0 +trained 0 +with 0 +sound 0 +- 0 +source 0 +location 0 +and 0 +sound 0 +- 0 +silence 0 +discriminations 0 +. 0 + +Control 0 +( 0 +saline 0 +P20 0 +) 0 +rats 0 +acquired 0 +both 0 +discriminations 0 +immediately 0 +. 0 + +In 0 +status 3 +epilepticus 4 +( 0 +P20 0 +) 0 +rats 0 +, 0 +acquisition 0 +of 0 +the 0 +sound 0 +- 0 +source 0 +location 0 +discrimination 0 +was 0 +moderately 0 +impaired 0 +. 0 + +Status 3 +epilepticus 4 +( 0 +P45 0 +) 0 +rats 0 +failed 0 +to 0 +acquire 0 +either 0 +sound 0 +- 0 +source 0 +location 0 +or 0 +sound 0 +- 0 +silence 0 +discriminations 0 +. 0 + +Status 3 +epilepticus 4 +in 0 +rat 0 +causes 0 +an 0 +age 0 +- 0 +dependent 0 +, 0 +long 0 +- 0 +term 0 +impairment 3 +in 4 +auditory 4 +discrimination 4 +. 0 + +This 0 +impairment 0 +may 0 +explain 0 +one 0 +cause 0 +of 0 +impaired 3 +auditory 4 +location 4 +discrimination 4 +in 0 +humans 0 +. 0 + +Nerve 0 +growth 0 +factor 0 +and 0 +prostaglandins 1 +in 0 +the 0 +urine 0 +of 0 +female 0 +patients 0 +with 0 +overactive 3 +bladder 4 +. 0 + +PURP0SE 0 +: 0 +NGF 0 +and 0 +PGs 1 +in 0 +the 0 +bladder 0 +can 0 +be 0 +affected 0 +by 0 +pathological 0 +changes 0 +in 0 +the 0 +bladder 0 +and 0 +these 0 +changes 0 +can 0 +be 0 +detected 0 +in 0 +urine 0 +. 0 + +We 0 +investigated 0 +changes 0 +in 0 +urinary 0 +NGF 0 +and 0 +PGs 1 +in 0 +women 0 +with 0 +0AB 3 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +The 0 +study 0 +groups 0 +included 0 +65 0 +women 0 +with 0 +0AB 3 +and 0 +20 0 +without 0 +bladder 0 +symptoms 0 +who 0 +served 0 +as 0 +controls 0 +. 0 + +Evaluation 0 +included 0 +patient 0 +history 0 +, 0 +urinalysis 0 +, 0 +a 0 +voiding 0 +diary 0 +and 0 +urodynamic 0 +studies 0 +. 0 + +Urine 0 +samples 0 +were 0 +collected 0 +. 0 + +NGF 0 +, 0 +PGE2 1 +, 0 +PGF2alpha 1 +and 0 +PGI2 1 +were 0 +measured 0 +using 0 +enzyme 0 +- 0 +linked 0 +immunosorbent 0 +assay 0 +and 0 +compared 0 +between 0 +the 0 +groups 0 +. 0 + +In 0 +addition 0 +, 0 +correlations 0 +between 0 +urinary 0 +NGF 0 +and 0 +PG 1 +, 0 +and 0 +urodynamic 0 +parameters 0 +in 0 +patients 0 +with 0 +0AB 3 +were 0 +examined 0 +. 0 + +RESULTS 0 +: 0 +Urinary 0 +NGF 0 +, 0 +PGE2 1 +and 0 +PGF2alpha 1 +were 0 +significantly 0 +increased 0 +in 0 +patients 0 +with 0 +0AB 3 +compared 0 +with 0 +controls 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +However 0 +, 0 +urinary 0 +PGI2 1 +was 0 +not 0 +different 0 +between 0 +controls 0 +and 0 +patients 0 +with 0 +0AB 3 +. 0 + +In 0 +patients 0 +with 0 +0AB 3 +urinary 0 +PGE2 1 +positively 0 +correlated 0 +with 0 +volume 0 +at 0 +first 0 +desire 0 +to 0 +void 0 +and 0 +maximum 0 +cystometric 0 +capacity 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Urinary 0 +NGF 0 +, 0 +PGF2alpha 1 +and 0 +PGI2 1 +did 0 +not 0 +correlate 0 +with 0 +urodynamic 0 +parameters 0 +in 0 +patients 0 +with 0 +0AB 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +NGF 0 +and 0 +PGs 1 +have 0 +important 0 +roles 0 +in 0 +the 0 +development 0 +of 0 +0AB 3 +symptoms 0 +in 0 +female 0 +patients 0 +. 0 + +Urinary 0 +levels 0 +of 0 +these 0 +factors 0 +may 0 +be 0 +used 0 +as 0 +markers 0 +to 0 +evaluate 0 +0AB 3 +symptoms 0 +. 0 + +Definition 0 +and 0 +management 0 +of 0 +anemia 3 +in 0 +patients 0 +infected 3 +with 4 +hepatitis 4 +C 4 +virus 4 +. 0 + +Chronic 3 +infection 4 +with 4 +hepatitis 4 +C 4 +virus 4 +( 0 +HCV 0 +) 0 +can 0 +progress 0 +to 0 +cirrhosis 3 +, 0 +hepatocellular 3 +carcinoma 4 +, 0 +and 0 +end 3 +- 4 +stage 4 +liver 4 +disease 4 +. 0 + +The 0 +current 0 +best 0 +treatment 0 +for 0 +HCV 3 +infection 4 +is 0 +combination 0 +therapy 0 +with 0 +pegylated 0 +interferon 1 +and 0 +ribavirin 1 +. 0 + +Although 0 +this 0 +regimen 0 +produces 0 +sustained 0 +virologic 0 +responses 0 +( 0 +SVRs 0 +) 0 +in 0 +approximately 0 +50 0 +% 0 +of 0 +patients 0 +, 0 +it 0 +can 0 +be 0 +associated 0 +with 0 +a 0 +potentially 0 +dose 0 +- 0 +limiting 0 +hemolytic 3 +anemia 4 +. 0 + +Hemoglobin 0 +concentrations 0 +decrease 0 +mainly 0 +as 0 +a 0 +result 0 +of 0 +ribavirin 1 +- 0 +induced 0 +hemolysis 3 +, 0 +and 0 +this 0 +anemia 3 +can 0 +be 0 +problematic 0 +in 0 +patients 0 +with 0 +HCV 3 +infection 4 +, 0 +especially 0 +those 0 +who 0 +have 0 +comorbid 0 +renal 3 +or 4 +cardiovascular 4 +disorders 4 +. 0 + +In 0 +general 0 +, 0 +anemia 3 +can 0 +increase 0 +the 0 +risk 0 +of 0 +morbidity 0 +and 0 +mortality 0 +, 0 +and 0 +may 0 +have 0 +negative 0 +effects 0 +on 0 +cerebral 0 +function 0 +and 0 +quality 0 +of 0 +life 0 +. 0 + +Although 0 +ribavirin 1 +- 0 +associated 0 +anemia 3 +can 0 +be 0 +reversed 0 +by 0 +dose 0 +reduction 0 +or 0 +discontinuation 0 +, 0 +this 0 +approach 0 +compromises 0 +outcomes 0 +by 0 +significantly 0 +decreasing 0 +SVR 0 +rates 0 +. 0 + +Recombinant 0 +human 0 +erythropoietin 0 +has 0 +been 0 +used 0 +to 0 +manage 0 +ribavirin 1 +- 0 +associated 0 +anemia 3 +but 0 +has 0 +other 0 +potential 0 +disadvantages 0 +. 0 + +Viramidine 1 +, 0 +a 0 +liver 0 +- 0 +targeting 0 +prodrug 0 +of 0 +ribavirin 1 +, 0 +has 0 +the 0 +potential 0 +to 0 +maintain 0 +the 0 +virologic 0 +efficacy 0 +of 0 +ribavirin 1 +while 0 +decreasing 0 +the 0 +risk 0 +of 0 +hemolytic 3 +anemia 4 +in 0 +patients 0 +with 0 +chronic 3 +hepatitis 4 +C 4 +. 0 + +Impact 0 +of 0 +alcohol 1 +exposure 0 +after 0 +pregnancy 0 +recognition 0 +on 0 +ultrasonographic 0 +fetal 0 +growth 0 +measures 0 +. 0 + +BACKGR0UND 0 +: 0 +More 0 +than 0 +3 0 +decades 0 +after 0 +Jones 0 +and 0 +Smith 0 +( 0 +1973 0 +) 0 +reported 0 +on 0 +the 0 +devastation 0 +caused 0 +by 0 +alcohol 1 +exposure 0 +on 0 +fetal 0 +development 0 +, 0 +the 0 +rates 0 +of 0 +heavy 0 +drinking 0 +during 0 +pregnancy 0 +remain 0 +relatively 0 +unchanged 0 +. 0 + +Early 0 +identification 0 +of 0 +fetal 0 +alcohol 1 +exposure 0 +and 0 +maternal 0 +abstinence 0 +led 0 +to 0 +better 0 +infant 0 +outcomes 0 +. 0 + +This 0 +study 0 +examined 0 +the 0 +utility 0 +of 0 +biometry 0 +for 0 +detecting 0 +alcohol 1 +- 0 +related 0 +fetal 0 +growth 3 +impairment 4 +. 0 + +METH0DS 0 +: 0 +We 0 +obtained 0 +fetal 0 +ultrasound 0 +measures 0 +from 0 +routine 0 +ultrasound 0 +examinations 0 +for 0 +167 0 +pregnant 0 +hazardous 0 +drinkers 0 +who 0 +were 0 +enrolled 0 +in 0 +a 0 +brief 0 +alcohol 1 +intervention 0 +study 0 +. 0 + +The 0 +fetal 0 +measures 0 +for 0 +women 0 +who 0 +quit 0 +after 0 +learning 0 +of 0 +their 0 +pregnancies 0 +were 0 +compared 0 +with 0 +measures 0 +for 0 +women 0 +who 0 +continued 0 +some 0 +drinking 0 +throughout 0 +the 0 +course 0 +of 0 +their 0 +pregnancies 0 +. 0 + +Because 0 +intensity 0 +of 0 +alcohol 1 +consumption 0 +is 0 +associated 0 +with 0 +poorer 0 +fetal 0 +outcomes 0 +, 0 +separate 0 +analyses 0 +were 0 +conducted 0 +for 0 +the 0 +heavy 0 +( 0 +average 0 +of 0 +> 0 +or 0 += 0 +5 0 +drinks 0 +per 0 +drinking 0 +day 0 +) 0 +alcohol 1 +consumers 0 +. 0 + +Fetal 0 +measures 0 +from 0 +the 0 +heavy 0 +- 0 +exposed 0 +fetuses 0 +were 0 +also 0 +compared 0 +with 0 +measures 0 +from 0 +a 0 +nondrinking 0 +group 0 +that 0 +was 0 +representative 0 +of 0 +normal 0 +, 0 +uncomplicated 0 +pregnancies 0 +from 0 +our 0 +clinics 0 +. 0 + +Analyses 0 +of 0 +covariance 0 +were 0 +used 0 +to 0 +determine 0 +whether 0 +there 0 +were 0 +differences 0 +between 0 +groups 0 +after 0 +controlling 0 +for 0 +influences 0 +of 0 +gestational 0 +age 0 +and 0 +drug 3 +abuse 4 +. 0 + +RESULTS 0 +: 0 +Nearly 0 +half 0 +of 0 +the 0 +pregnant 0 +drinkers 0 +abstained 0 +after 0 +learning 0 +of 0 +their 0 +pregnancies 0 +. 0 + +When 0 +women 0 +reportedly 0 +quit 0 +drinking 0 +early 0 +in 0 +their 0 +pregnancies 0 +, 0 +fetal 0 +growth 0 +measures 0 +were 0 +not 0 +significantly 0 +different 0 +from 0 +a 0 +non 0 +- 0 +alcohol 1 +- 0 +exposed 0 +group 0 +, 0 +regardless 0 +of 0 +prior 0 +drinking 0 +patterns 0 +. 0 + +Any 0 +alcohol 1 +consumption 0 +postpregnancy 0 +recognition 0 +among 0 +the 0 +heavy 0 +drinkers 0 +resulted 0 +in 0 +reduced 3 +cerebellar 4 +growth 4 +as 0 +well 0 +as 0 +decreased 3 +cranial 4 +to 4 +body 4 +growth 4 +in 0 +comparison 0 +with 0 +women 0 +who 0 +either 0 +quit 0 +drinking 0 +or 0 +who 0 +were 0 +nondrinkers 0 +. 0 + +Amphetamine 1 +abuse 0 +was 0 +predictive 0 +of 0 +larger 0 +cranial 0 +to 0 +body 0 +growth 0 +ratios 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Alterations 0 +in 0 +fetal 0 +biometric 0 +measurements 0 +were 0 +observed 0 +among 0 +the 0 +heavy 0 +drinkers 0 +only 0 +when 0 +they 0 +continued 0 +drinking 0 +after 0 +becoming 0 +aware 0 +of 0 +their 0 +pregnancies 0 +. 0 + +Although 0 +the 0 +reliance 0 +on 0 +self 0 +- 0 +reported 0 +drinking 0 +is 0 +a 0 +limitation 0 +in 0 +this 0 +study 0 +, 0 +these 0 +findings 0 +support 0 +the 0 +benefits 0 +of 0 +early 0 +abstinence 0 +and 0 +the 0 +potential 0 +for 0 +ultrasound 0 +examinations 0 +in 0 +the 0 +detection 0 +of 0 +fetal 0 +alcohol 1 +effects 0 +. 0 + +Ethambutol 1 +- 0 +associated 0 +optic 3 +neuropathy 4 +. 0 + +INTR0DUCTI0N 0 +: 0 +Ethambutol 1 +is 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +tuberculosis 3 +, 0 +which 0 +is 0 +still 0 +prevalent 0 +in 0 +Southeast 0 +Asia 0 +, 0 +and 0 +can 0 +be 0 +associated 0 +with 0 +permanent 0 +visual 3 +loss 4 +. 0 + +We 0 +report 0 +3 0 +cases 0 +which 0 +presented 0 +with 0 +bitemporal 3 +hemianopia 4 +. 0 + +CLINICAL 0 +PICTURE 0 +: 0 +Three 0 +patients 0 +with 0 +ethambutol 1 +- 0 +associated 0 +toxic 0 +optic 3 +neuropathy 4 +are 0 +described 0 +. 0 + +All 0 +3 0 +patients 0 +had 0 +loss 3 +of 4 +central 4 +visual 4 +acuity 4 +, 4 +colour 4 +vision 4 +( 4 +Ishihara 4 +) 4 +and 4 +visual 4 +field 4 +. 0 + +The 0 +visual 3 +field 4 +loss 4 +had 0 +a 0 +bitemporal 0 +flavour 0 +, 0 +suggesting 0 +involvement 0 +of 0 +the 0 +optic 0 +chiasm 0 +. 0 + +TREATMENT 0 +: 0 +Despite 0 +stopping 0 +ethambutol 1 +on 0 +diagnosis 0 +, 0 +visual 0 +function 0 +continued 0 +to 0 +deteriorate 0 +for 0 +a 0 +few 0 +months 0 +. 0 + +Subsequent 0 +improvement 0 +was 0 +mild 0 +in 0 +2 0 +cases 0 +. 0 + +In 0 +the 0 +third 0 +case 0 +, 0 +visual 0 +acuity 0 +and 0 +colour 0 +vision 0 +normalised 0 +but 0 +the 0 +optic 0 +discs 0 +were 0 +pale 0 +. 0 + +0UTC0ME 0 +: 0 +All 0 +3 0 +patients 0 +had 0 +some 0 +permanent 0 +loss 3 +of 4 +visual 4 +function 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Ethambutol 1 +usage 0 +is 0 +associated 0 +with 0 +permanent 0 +visual 3 +loss 4 +and 0 +should 0 +be 0 +avoided 0 +if 0 +possible 0 +or 0 +used 0 +with 0 +caution 0 +and 0 +proper 0 +ophthalmological 0 +follow 0 +- 0 +up 0 +. 0 + +The 0 +author 0 +postulates 0 +that 0 +in 0 +cases 0 +of 0 +ethambutol 1 +associated 0 +chiasmopathy 0 +, 0 +ethambutol 1 +may 0 +initially 0 +affect 0 +the 0 +optic 0 +nerves 0 +and 0 +subsequently 0 +progress 0 +to 0 +involve 0 +the 0 +optic 0 +chiasm 0 +. 0 + +Possible 0 +neuroleptic 3 +malignant 4 +syndrome 4 +related 0 +to 0 +concomitant 0 +treatment 0 +with 0 +paroxetine 1 +and 0 +alprazolam 1 +. 0 + +A 0 +74 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +depressive 3 +symptoms 4 +was 0 +admitted 0 +to 0 +a 0 +psychiatric 3 +hospital 0 +due 0 +to 0 +insomnia 3 +, 0 +loss 3 +of 4 +appetite 4 +, 0 +exhaustion 0 +, 0 +and 0 +agitation 3 +. 0 + +Medical 0 +treatment 0 +was 0 +initiated 0 +at 0 +a 0 +daily 0 +dose 0 +of 0 +20 0 +mg 0 +paroxetine 1 +and 0 +1 0 +. 0 +2 0 +mg 0 +alprazolam 1 +. 0 + +0n 0 +the 0 +10th 0 +day 0 +of 0 +paroxetine 1 +and 0 +alprazolam 1 +treatment 0 +, 0 +the 0 +patient 0 +exhibited 0 +marked 0 +psychomotor 3 +retardation 4 +, 0 +disorientation 0 +, 0 +and 0 +severe 0 +muscle 3 +rigidity 4 +with 0 +tremors 3 +. 0 + +The 0 +patient 0 +had 0 +a 0 +fever 3 +( 0 +38 0 +. 0 +2 0 +degrees 0 +C 0 +) 0 +, 0 +fluctuating 0 +blood 0 +pressure 0 +( 0 +between 0 +165 0 +/ 0 +90 0 +and 0 +130 0 +/ 0 +70 0 +mg 0 +mm 0 +Hg 0 +) 0 +, 0 +and 0 +severe 0 +extrapyramidal 3 +symptoms 4 +. 0 + +Laboratory 0 +tests 0 +showed 0 +an 0 +elevation 0 +of 0 +creatine 1 +phosphokinase 0 +( 0 +2218 0 +IU 0 +/ 0 +L 0 +) 0 +, 0 +aspartate 1 +aminotransferase 0 +( 0 +134 0 +IU 0 +/ 0 +L 0 +) 0 +, 0 +alanine 1 +aminotransferase 0 +( 0 +78 0 +IU 0 +/ 0 +L 0 +) 0 +, 0 +and 0 +BUN 0 +( 0 +27 0 +. 0 +9 0 +mg 0 +/ 0 +ml 0 +) 0 +levels 0 +. 0 + +The 0 +patient 0 +received 0 +bromocriptine 1 +and 0 +diazepam 1 +to 0 +treat 0 +his 0 +symptoms 0 +. 0 + +7 0 +days 0 +later 0 +, 0 +the 0 +fever 3 +disappeared 0 +and 0 +the 0 +patient 0 +' 0 +s 0 +serum 0 +CPK 0 +levels 0 +were 0 +normalized 0 +( 0 +175 0 +IU 0 +/ 0 +L 0 +) 0 +. 0 + +This 0 +patient 0 +presented 0 +with 0 +symptoms 0 +of 0 +neuroleptic 3 +malignant 4 +syndrome 4 +( 0 +NMS 3 +) 0 +, 0 +thus 0 +demonstrating 0 +that 0 +NMS 3 +- 0 +like 0 +symptoms 0 +can 0 +occur 0 +after 0 +combined 0 +paroxetine 1 +and 0 +alprazolam 1 +treatment 0 +. 0 + +The 0 +adverse 0 +drug 0 +reaction 0 +score 0 +obtained 0 +by 0 +the 0 +Naranjo 0 +algorithm 0 +was 0 +6 0 +in 0 +our 0 +case 0 +, 0 +indicating 0 +a 0 +probable 0 +relationship 0 +between 0 +the 0 +patient 0 +' 0 +s 0 +NMS 3 +- 0 +like 0 +adverse 0 +symptoms 0 +and 0 +the 0 +combined 0 +treatment 0 +used 0 +in 0 +this 0 +case 0 +. 0 + +The 0 +involvement 0 +of 0 +physiologic 0 +and 0 +environmental 0 +aspects 0 +specific 0 +to 0 +this 0 +patient 0 +was 0 +suspected 0 +. 0 + +Several 0 +risk 0 +factors 0 +for 0 +NMS 3 +should 0 +be 0 +noted 0 +in 0 +elderly 0 +depressive 3 +patients 0 +whose 0 +symptoms 0 +often 0 +include 0 +dehydration 3 +, 0 +agitation 3 +, 0 +malnutrition 3 +, 0 +and 0 +exhaustion 0 +. 0 + +Careful 0 +therapeutic 0 +intervention 0 +is 0 +necessary 0 +in 0 +cases 0 +involving 0 +elderly 0 +patients 0 +who 0 +suffer 0 +from 0 +depression 3 +. 0 + +Down 0 +- 0 +regulation 0 +of 0 +norepinephrine 1 +transporter 0 +function 0 +induced 0 +by 0 +chronic 0 +administration 0 +of 0 +desipramine 1 +linking 0 +to 0 +the 0 +alteration 0 +of 0 +sensitivity 0 +of 0 +local 0 +- 0 +anesthetics 0 +- 0 +induced 0 +convulsions 3 +and 0 +the 0 +counteraction 0 +by 0 +co 0 +- 0 +administration 0 +with 0 +local 0 +anesthetics 0 +. 0 + +Alterations 0 +of 0 +norepinephrine 1 +transporter 0 +( 0 +NET 0 +) 0 +function 0 +by 0 +chronic 0 +inhibition 0 +of 0 +NET 0 +in 0 +relation 0 +to 0 +sensitization 0 +to 0 +seizures 3 +induce 0 +by 0 +cocaine 1 +and 0 +local 0 +anesthetics 0 +were 0 +studied 0 +in 0 +mice 0 +. 0 + +Daily 0 +administration 0 +of 0 +desipramine 1 +, 0 +an 0 +inhibitor 0 +of 0 +the 0 +NET 0 +, 0 +for 0 +5 0 +days 0 +decreased 0 +[ 0 +( 0 +3 0 +) 0 +H 0 +] 0 +norepinephrine 1 +uptake 0 +in 0 +the 0 +P2 0 +fractions 0 +of 0 +hippocampus 0 +but 0 +not 0 +cortex 0 +, 0 +striatum 0 +or 0 +amygdalae 0 +. 0 + +Co 0 +- 0 +administration 0 +of 0 +lidocaine 1 +, 0 +bupivacaine 1 +or 0 +tricaine 1 +with 0 +desipramine 1 +reversed 0 +this 0 +effect 0 +. 0 + +Daily 0 +treatment 0 +of 0 +cocaine 1 +increased 0 +[ 0 +( 0 +3 0 +) 0 +H 0 +] 0 +norepinephrine 1 +uptake 0 +into 0 +the 0 +hippocampus 0 +. 0 + +Daily 0 +administration 0 +of 0 +desipramine 1 +increased 0 +the 0 +incidence 0 +of 0 +appearance 0 +of 0 +lidocaine 1 +- 0 +induced 0 +convulsions 3 +and 0 +decreased 0 +that 0 +of 0 +cocaine 1 +- 0 +induced 0 +convulsions 3 +. 0 + +Co 0 +- 0 +administration 0 +of 0 +lidocaine 1 +with 0 +desipramine 1 +reversed 0 +the 0 +changes 0 +of 0 +convulsive 3 +activity 0 +of 0 +lidocaine 1 +and 0 +cocaine 1 +induced 0 +by 0 +repeated 0 +administration 0 +of 0 +desipramine 1 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +down 0 +- 0 +regulation 0 +of 0 +hippocampal 0 +NET 0 +induced 0 +by 0 +chronic 0 +administration 0 +of 0 +desipramine 1 +may 0 +be 0 +relevant 0 +to 0 +desipramine 1 +- 0 +induced 0 +sensitization 0 +of 0 +lidocaine 1 +convulsions 3 +. 0 + +Inhibition 0 +of 0 +Na 1 +( 0 ++ 0 +) 0 +channels 0 +by 0 +local 0 +anesthetics 0 +may 0 +regulate 0 +desipramine 1 +- 0 +induced 0 +down 0 +- 0 +regulation 0 +of 0 +NET 0 +function 0 +. 0 + +Repeated 0 +administration 0 +of 0 +cocaine 1 +induces 0 +up 0 +- 0 +regulation 0 +of 0 +hippocampal 0 +NET 0 +function 0 +. 0 + +Desipramine 1 +- 0 +induced 0 +sensitization 0 +of 0 +lidocaine 1 +seizures 3 +may 0 +have 0 +a 0 +mechanism 0 +distinct 0 +from 0 +kindling 0 +resulting 0 +from 0 +repeated 0 +administration 0 +of 0 +cocaine 1 +. 0 + +Atorvastatin 1 +prevented 0 +and 0 +reversed 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +in 0 +the 0 +rat 0 +. 0 + +To 0 +assess 0 +the 0 +antioxidant 0 +effects 0 +of 0 +atorvastatin 1 +( 0 +atorva 1 +) 0 +on 0 +dexamethasone 1 +( 0 +dex 1 +) 0 +- 0 +induced 0 +hypertension 3 +, 0 +60 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +treated 0 +with 0 +atorva 1 +30 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +or 0 +tap 0 +water 0 +for 0 +15 0 +days 0 +. 0 + +Dex 1 +increased 0 +systolic 0 +blood 0 +pressure 0 +( 0 +SBP 0 +) 0 +from 0 +109 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +8 0 +to 0 +135 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +mmHg 0 +and 0 +plasma 0 +superoxide 1 +( 0 +5711 0 ++ 0 +/ 0 +- 0 +284 0 +. 0 +9 0 +saline 0 +, 0 +7931 0 ++ 0 +/ 0 +- 0 +392 0 +. 0 +8 0 +U 0 +/ 0 +ml 0 +dex 1 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +In 0 +this 0 +prevention 0 +study 0 +, 0 +SBP 0 +in 0 +the 0 +atorva 1 ++ 0 +dex 1 +group 0 +was 0 +increased 0 +from 0 +115 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +to 0 +124 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +mmHg 0 +, 0 +but 0 +this 0 +was 0 +significantly 0 +lower 0 +than 0 +in 0 +the 0 +dex 1 +- 0 +only 0 +group 0 +( 0 +P 0 +' 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Atorva 1 +reversed 0 +dex 1 +- 0 +induced 0 +hypertension 3 +( 0 +129 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +mmHg 0 +, 0 +vs 0 +. 0 +135 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +mmHg 0 +P 0 +' 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +decreased 0 +plasma 0 +superoxide 1 +( 0 +7931 0 ++ 0 +/ 0 +- 0 +392 0 +. 0 +8 0 +dex 1 +, 0 +1187 0 ++ 0 +/ 0 +- 0 +441 0 +. 0 +2 0 +atorva 1 ++ 0 +dex 1 +, 0 +P 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +Plasma 0 +nitrate 1 +/ 0 +nitrite 1 +( 0 +N0x 0 +) 0 +was 0 +decreased 0 +in 0 +dex 1 +- 0 +treated 0 +rats 0 +compared 0 +to 0 +saline 0 +- 0 +treated 0 +rats 0 +( 0 +11 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +08 0 +microm 0 +, 0 +15 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +17 0 +microm 0 +, 0 +respectively 0 +, 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Atorva 1 +affected 0 +neither 0 +plasma 0 +N0x 0 +nor 0 +thymus 0 +weight 0 +. 0 + +Thus 0 +, 0 +atorvastatin 1 +prevented 0 +and 0 +reversed 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +in 0 +the 0 +rat 0 +. 0 + +Peripheral 3 +neuropathy 4 +caused 0 +by 0 +high 0 +- 0 +dose 0 +cytosine 1 +arabinoside 2 +treatment 0 +in 0 +a 0 +patient 0 +with 0 +acute 3 +myeloid 4 +leukemia 4 +. 0 + +The 0 +central 0 +nervous 0 +system 0 +toxicity 3 +of 0 +high 0 +- 0 +dose 0 +cytosine 1 +arabinoside 2 +is 0 +well 0 +recognized 0 +, 0 +but 0 +the 0 +toxicity 3 +of 0 +cytosine 1 +arabinoside 2 +in 0 +the 0 +peripheral 0 +nervous 0 +system 0 +has 0 +been 0 +infrequently 0 +reported 0 +. 0 + +A 0 +49 0 +- 0 +year 0 +- 0 +old 0 +Japanese 0 +man 0 +was 0 +diagnosed 0 +with 0 +acute 3 +myeloid 4 +leukemia 4 +. 0 + +After 0 +he 0 +achieved 0 +complete 0 +remission 0 +, 0 +he 0 +received 0 +high 0 +- 0 +dose 0 +cytosine 1 +arabinoside 2 +treatment 0 +( 0 +2 0 +g 0 +/ 0 +m2 0 +twice 0 +a 0 +day 0 +for 0 +5 0 +days 0 +; 0 +total 0 +, 0 +20 0 +g 0 +/ 0 +m2 0 +) 0 +as 0 +consolidation 0 +therapy 0 +. 0 + +The 0 +first 0 +course 0 +of 0 +high 0 +- 0 +dose 0 +cytosine 1 +arabinoside 2 +resulted 0 +in 0 +no 0 +unusual 0 +symptoms 0 +, 0 +but 0 +on 0 +day 0 +21 0 +of 0 +the 0 +second 0 +course 0 +of 0 +treatment 0 +, 0 +the 0 +patient 0 +complained 0 +of 0 +numbness 3 +in 0 +his 0 +right 0 +foot 0 +. 0 + +Electromyogram 0 +and 0 +nerve 0 +- 0 +conduction 0 +studies 0 +showed 0 +peripheral 3 +neuropathy 4 +in 0 +both 0 +peroneal 0 +nerves 0 +. 0 + +This 0 +neuropathy 3 +was 0 +gradually 0 +resolving 0 +; 0 +however 0 +, 0 +after 0 +the 0 +patient 0 +received 0 +allogeneic 0 +bone 0 +marrow 0 +transplantation 0 +, 0 +the 0 +symptoms 0 +worsened 0 +, 0 +with 0 +the 0 +development 0 +of 0 +graft 3 +- 4 +versus 4 +- 4 +host 4 +disease 4 +, 0 +and 0 +the 0 +symptoms 0 +subsequently 0 +responded 0 +to 0 +methylprednisolone 1 +. 0 + +Although 0 +the 0 +mechanisms 0 +of 0 +peripheral 3 +neuropathy 4 +are 0 +still 0 +unclear 0 +, 0 +high 0 +- 0 +dose 0 +cytosine 1 +arabinoside 2 +is 0 +a 0 +therapy 0 +that 0 +is 0 +potentially 0 +toxic 0 +to 0 +the 0 +peripheral 0 +nervous 0 +system 0 +, 0 +and 0 +auto 0 +/ 0 +alloimmunity 0 +may 0 +play 0 +an 0 +important 0 +role 0 +in 0 +these 0 +mechanisms 0 +. 0 + +Effect 0 +of 0 +alpha 1 +- 2 +tocopherol 2 +and 0 +deferoxamine 1 +on 0 +methamphetamine 1 +- 0 +induced 0 +neurotoxicity 3 +. 0 + +Methamphetamine 1 +( 0 +MA 1 +) 0 +- 0 +induced 0 +dopaminergic 0 +neurotoxicity 3 +is 0 +believed 0 +to 0 +be 0 +associated 0 +with 0 +the 0 +increased 0 +formation 0 +of 0 +free 0 +radicals 0 +. 0 + +This 0 +study 0 +examined 0 +the 0 +effect 0 +of 0 +alpha 1 +- 2 +tocopherol 2 +( 0 +alpha 1 +- 2 +TC 2 +) 0 +, 0 +a 0 +scavenger 0 +of 0 +reactive 0 +oxygen 1 +species 0 +, 0 +and 0 +deferoxamine 1 +( 0 +DF0 1 +) 0 +, 0 +an 0 +iron 1 +chelator 0 +, 0 +on 0 +the 0 +MA 1 +- 0 +induced 0 +neurotoxicity 3 +. 0 + +Male 0 +rats 0 +were 0 +treated 0 +with 0 +MA 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +, 0 +every 0 +2 0 +h 0 +for 0 +four 0 +injections 0 +) 0 +. 0 + +The 0 +rat 0 +received 0 +either 0 +alpha 1 +- 2 +TC 2 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +) 0 +intraperitoneally 0 +for 0 +3 0 +days 0 +and 0 +30 0 +min 0 +prior 0 +to 0 +MA 1 +administration 0 +or 0 +DF0 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +subcutaneously 0 +30 0 +min 0 +before 0 +MA 1 +administration 0 +. 0 + +The 0 +concentrations 0 +of 0 +dopamine 1 +( 0 +DA 1 +) 0 +, 0 +serotonin 1 +and 0 +their 0 +metabolites 0 +decreased 0 +significantly 0 +after 0 +MA 1 +administration 0 +, 0 +which 0 +was 0 +inhibited 0 +by 0 +the 0 +alpha 1 +- 2 +TC 2 +and 0 +DF0 1 +pretreatment 0 +. 0 + +alpha 1 +- 2 +TC 2 +and 0 +DF0 1 +attenuated 0 +the 0 +MA 1 +- 0 +induced 0 +hyperthermia 3 +as 0 +well 0 +as 0 +the 0 +alterations 0 +in 0 +the 0 +locomotor 0 +activity 0 +. 0 + +The 0 +level 0 +of 0 +lipid 0 +peroxidation 0 +was 0 +higher 0 +and 0 +the 0 +reduced 0 +glutathione 1 +concentration 0 +was 0 +lower 0 +in 0 +the 0 +MA 1 +- 0 +treated 0 +rats 0 +. 0 + +These 0 +changes 0 +were 0 +significantly 0 +attenuated 0 +by 0 +alpha 1 +- 2 +TC 2 +and 0 +DF0 1 +. 0 + +This 0 +suggests 0 +that 0 +alpha 1 +- 2 +TC 2 +and 0 +DF0 1 +ameliorate 0 +the 0 +MA 1 +- 0 +induced 0 +neuronal 3 +damage 4 +by 0 +decreasing 0 +the 0 +level 0 +of 0 +oxidative 0 +stress 0 +. 0 + +Blockade 0 +of 0 +both 0 +D 0 +- 0 +1 0 +and 0 +D 0 +- 0 +2 0 +dopamine 1 +receptors 0 +may 0 +induce 0 +catalepsy 3 +in 0 +mice 0 +. 0 + +1 0 +. 0 + +The 0 +catalepsy 3 +induced 0 +by 0 +dopamine 1 +antagonists 0 +has 0 +been 0 +tested 0 +and 0 +the 0 +possible 0 +dopamine 1 +subtypes 0 +involved 0 +in 0 +catalepsy 3 +was 0 +determined 0 +. 0 + +2 0 +. 0 + +Dopamine 1 +antagonist 0 +fluphenazine 1 +, 0 +D 0 +- 0 +1 0 +antagonist 0 +SCH 1 +23390 2 +or 0 +D 0 +- 0 +2 0 +antagonist 0 +sulpiride 1 +induced 0 +catalepsy 3 +. 0 + +The 0 +effect 0 +of 0 +fluphenazine 1 +and 0 +sulpiride 1 +was 0 +dose 0 +- 0 +dependent 0 +. 0 + +Combination 0 +of 0 +SCH 1 +23390 2 +with 0 +sulpiride 1 +did 0 +not 0 +induce 0 +catalepsy 3 +potentiation 0 +. 0 + +3 0 +. 0 + +D 0 +- 0 +1 0 +agonist 0 +SKF 1 +38393 2 +or 0 +D 0 +- 0 +2 0 +agonist 0 +quinpirole 1 +decreased 0 +the 0 +catalepsy 3 +induced 0 +by 0 +fluphenazine 1 +, 0 +SCH 1 +23390 2 +or 0 +sulpiride 1 +. 0 + +4 0 +. 0 + +Combination 0 +of 0 +SKF 1 +38393 2 +with 0 +quinpirole 1 +did 0 +not 0 +cause 0 +potentiated 0 +inhibitory 0 +effect 0 +on 0 +catalepsy 3 +induced 0 +by 0 +dopamine 1 +antagonists 0 +. 0 + +5 0 +. 0 + +The 0 +data 0 +may 0 +indicate 0 +that 0 +although 0 +D 0 +- 0 +2 0 +receptor 0 +blockade 0 +is 0 +involved 0 +in 0 +catalepsy 3 +, 0 +the 0 +D 0 +- 0 +1 0 +receptor 0 +may 0 +plan 0 +a 0 +role 0 +. 0 + +Sustained 0 +clinical 0 +improvement 0 +of 0 +a 0 +patient 0 +with 0 +decompensated 0 +hepatitis 3 +B 4 +virus 0 +- 0 +related 0 +cirrhosis 3 +after 0 +treatment 0 +with 0 +lamivudine 1 +monotherapy 0 +. 0 + +Hepatitis 3 +B 4 +virus 4 +( 4 +HBV 4 +) 4 +infection 4 +, 0 +which 0 +causes 0 +liver 3 +cirrhosis 4 +and 0 +hepatocellular 3 +carcinoma 4 +, 0 +remains 0 +a 0 +major 0 +health 0 +problem 0 +in 0 +Asian 0 +countries 0 +. 0 + +Recent 0 +development 0 +of 0 +vaccine 0 +for 0 +prevention 0 +is 0 +reported 0 +to 0 +be 0 +successful 0 +in 0 +reducing 0 +the 0 +size 0 +of 0 +chronically 0 +infected 0 +carriers 0 +, 0 +although 0 +the 0 +standard 0 +medical 0 +therapies 0 +have 0 +not 0 +been 0 +established 0 +up 0 +to 0 +now 0 +. 0 + +In 0 +this 0 +report 0 +, 0 +we 0 +encountered 0 +a 0 +patient 0 +with 0 +decompensated 0 +HBV 0 +- 0 +related 0 +cirrhosis 3 +who 0 +exhibited 0 +the 0 +dramatic 0 +improvements 0 +after 0 +antiviral 0 +therapy 0 +. 0 + +The 0 +patient 0 +was 0 +a 0 +50 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +. 0 + +Previous 0 +conventional 0 +medical 0 +treatments 0 +were 0 +not 0 +effective 0 +for 0 +this 0 +patient 0 +, 0 +thus 0 +this 0 +patient 0 +had 0 +been 0 +referred 0 +to 0 +our 0 +hospital 0 +. 0 + +However 0 +, 0 +the 0 +administration 0 +of 0 +lamivudine 1 +, 0 +a 0 +reverse 0 +transcriptase 0 +inhibitor 0 +, 0 +for 0 +23 0 +months 0 +dramatically 0 +improved 0 +her 0 +liver 0 +severity 0 +. 0 + +During 0 +this 0 +period 0 +, 0 +no 0 +drug 0 +resistant 0 +mutant 0 +HBV 0 +emerged 0 +, 0 +and 0 +the 0 +serum 0 +HBV 0 +- 0 +DNA 0 +level 0 +was 0 +continuously 0 +suppressed 0 +. 0 + +These 0 +virological 0 +responses 0 +were 0 +also 0 +maintained 0 +even 0 +after 0 +the 0 +antiviral 0 +therapy 0 +was 0 +discontinued 0 +. 0 + +Moreover 0 +, 0 +both 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +and 2 +e 2 +antigen 2 +were 0 +observed 0 +to 0 +have 0 +disappeared 0 +in 0 +this 0 +patient 0 +. 0 + +The 0 +administration 0 +of 0 +lamivudine 1 +to 0 +patients 0 +with 0 +HBV 0 +- 0 +related 0 +cirrhosis 3 +, 0 +like 0 +our 0 +present 0 +case 0 +, 0 +should 0 +be 0 +considered 0 +as 0 +an 0 +initial 0 +medical 0 +therapeutic 0 +option 0 +, 0 +especially 0 +in 0 +countries 0 +where 0 +liver 0 +transplantation 0 +is 0 +not 0 +reliably 0 +available 0 +. 0 + +Antiarrhythmic 0 +effects 0 +of 0 +optical 0 +isomers 0 +of 0 +cibenzoline 1 +on 0 +canine 0 +ventricular 3 +arrhythmias 4 +. 0 + +Antiarrhythmic 0 +effects 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +cibenzoline 1 +and 0 +( 0 +- 0 +) 0 +- 0 +cibenzoline 1 +were 0 +examined 0 +using 0 +two 0 +canine 0 +ventricular 3 +arrhythmia 4 +models 0 +. 0 + +Digitalis 1 +arrhythmia 3 +, 0 +which 0 +is 0 +suppressed 0 +by 0 +Na 1 +channel 0 +blockers 0 +, 0 +was 0 +induced 0 +by 0 +intermittent 0 +intravenous 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +injection 0 +of 0 +ouabain 1 +in 0 +pentobarbital 1 +- 0 +anesthetized 0 +dogs 0 +. 0 + +Adrenaline 3 +arrhythmia 4 +, 0 +which 0 +is 0 +suppressed 0 +by 0 +Ca 1 +channel 0 +blockers 0 +, 0 +was 0 +induced 0 +by 0 +adrenaline 1 +infusion 0 +in 0 +halothane 1 +- 0 +anesthetized 0 +dogs 0 +. 0 + +Ten 0 +and 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +( 0 ++ 0 +) 0 +- 0 +cibenzoline 1 +suppressed 0 +digitalis 1 +- 0 +and 0 +adrenaline 1 +- 0 +induced 0 +arrhythmias 3 +, 0 +respectively 0 +. 0 + +The 0 +minimum 0 +effective 0 +plasma 0 +concentrations 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +cibenzoline 1 +for 0 +digitalis 1 +- 0 +and 0 +adrenaline 1 +- 0 +induced 0 +arrhythmias 3 +were 0 +1 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +and 0 +2 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +micrograms 0 +/ 0 +ml 0 +, 0 +respectively 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +, 0 +n 0 += 0 +6 0 +) 0 +. 0 + +A 0 +lower 0 +dose 0 +of 0 +1 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +of 0 +( 0 +- 0 +) 0 +- 0 +cibenzoline 1 +suppressed 0 +the 0 +digitalis 1 +- 0 +induced 0 +arrhythmia 3 +, 0 +whereas 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +was 0 +needed 0 +to 0 +suppress 0 +adrenaline 1 +- 0 +induced 0 +arrhythmias 3 +. 0 + +The 0 +minimum 0 +effective 0 +plasma 0 +concentrations 0 +of 0 +( 0 +- 0 +) 0 +- 0 +cibenzoline 1 +for 0 +digitalis 1 +- 0 +and 0 +adrenaline 1 +- 0 +induced 0 +arrhythmia 3 +were 0 +0 0 +. 0 +06 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +04 0 +and 0 +0 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +micrograms 0 +/ 0 +ml 0 +, 0 +respectively 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +, 0 +n 0 += 0 +6 0 +) 0 +. 0 + +The 0 +stronger 0 +antiarrhythmic 0 +effect 0 +of 0 +( 0 +- 0 +) 0 +- 0 +cibenzoline 1 +indicates 0 +that 0 +( 0 +- 0 +) 0 +- 0 +isomer 0 +may 0 +have 0 +an 0 +effect 0 +nearly 0 +5 0 +- 0 +20 0 +times 0 +stronger 0 +in 0 +suppressing 0 +Na 1 +channels 0 +, 0 +but 0 +effects 0 +of 0 +both 0 +drugs 0 +on 0 +Ca 1 +channels 0 +may 0 +be 0 +almost 0 +equipotent 0 +. 0 + +Passage 0 +of 0 +mannitol 1 +into 0 +the 0 +brain 0 +around 0 +gliomas 3 +: 0 +a 0 +potential 0 +cause 0 +of 0 +rebound 0 +phenomenon 0 +. 0 + +A 0 +study 0 +on 0 +21 0 +patients 0 +. 0 + +AIM 0 +: 0 +Widespread 0 +use 0 +of 0 +mannitol 1 +to 0 +reduce 0 +brain 3 +edema 4 +and 0 +lower 0 +elevated 3 +ICP 4 +in 0 +brain 3 +tumor 4 +patients 0 +continues 0 +to 0 +be 0 +afflicted 0 +by 0 +the 0 +so 0 +- 0 +called 0 +rebound 0 +phenomenon 0 +. 0 + +Leakage 0 +of 0 +mannitol 1 +into 0 +the 0 +brain 0 +parenchyma 0 +through 0 +an 0 +altered 0 +BBB 0 +and 0 +secondary 0 +reversal 0 +of 0 +osmotic 0 +gradient 0 +is 0 +considered 0 +the 0 +major 0 +cause 0 +of 0 +rebound 0 +. 0 + +This 0 +has 0 +only 0 +been 0 +demonstrated 0 +experimentally 0 +in 0 +animals 0 +. 0 + +As 0 +a 0 +contribution 0 +to 0 +this 0 +issue 0 +we 0 +decided 0 +to 0 +research 0 +the 0 +possible 0 +passage 0 +of 0 +mannitol 1 +into 0 +the 0 +brain 0 +after 0 +administration 0 +to 0 +21 0 +brain 3 +tumor 4 +patients 0 +. 0 + +METH0DS 0 +: 0 +Mannitol 1 +( 0 +18 0 +% 0 +solution 0 +; 0 +1 0 +g 0 +/ 0 +kg 0 +) 0 +was 0 +administered 0 +as 0 +a 0 +bolus 0 +to 0 +patients 0 +( 0 +ten 0 +had 0 +malignant 3 +glioma 4 +, 0 +seven 0 +brain 0 +metastases 3 +and 0 +four 0 +meningioma 3 +) 0 +about 0 +30 0 +minutes 0 +before 0 +craniotomy 0 +. 0 + +During 0 +resection 0 +, 0 +a 0 +sample 0 +of 0 +the 0 +surrounding 0 +edematous 3 +white 0 +matter 0 +was 0 +taken 0 +at 0 +the 0 +same 0 +time 0 +as 0 +a 0 +10 0 +ml 0 +venous 0 +blood 0 +sample 0 +. 0 + +Mannitol 1 +concentrations 0 +were 0 +measured 0 +in 0 +plasma 0 +and 0 +white 0 +matter 0 +by 0 +a 0 +modified 0 +version 0 +of 0 +the 0 +enzyme 0 +assay 0 +of 0 +Blonquist 0 +et 0 +al 0 +. 0 + +RESULTS 0 +: 0 +In 0 +most 0 +glioma 3 +patients 0 +, 0 +mannitol 1 +concentrations 0 +in 0 +white 0 +matter 0 +were 0 +2 0 +to 0 +6 0 +times 0 +higher 0 +than 0 +in 0 +plasma 0 +( 0 +mean 0 +3 0 +. 0 +5 0 +times 0 +) 0 +. 0 + +In 0 +meningioma 3 +and 0 +metastases 3 +patients 0 +plasma 0 +concentrations 0 +of 0 +mannitol 1 +were 0 +higher 0 +than 0 +white 0 +matter 0 +concentrations 0 +except 0 +in 0 +three 0 +cases 0 +with 0 +infiltration 0 +by 0 +neoplastic 0 +cells 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +results 0 +of 0 +our 0 +study 0 +show 0 +that 0 +even 0 +after 0 +a 0 +single 0 +bolus 0 +, 0 +mannitol 1 +may 0 +leak 0 +through 0 +the 0 +altered 0 +BBB 0 +near 0 +gliomas 3 +, 0 +reversing 0 +the 0 +initial 0 +plasma 0 +- 0 +to 0 +- 0 +blood 0 +osmotic 0 +gradient 0 +, 0 +aggravating 0 +peritumoral 0 +edema 3 +and 0 +promoting 0 +rebound 0 +of 0 +ICP 0 +. 0 + +Placebo 0 +- 0 +level 0 +incidence 0 +of 0 +extrapyramidal 3 +symptoms 4 +( 0 +EPS 3 +) 0 +with 0 +quetiapine 1 +in 0 +controlled 0 +studies 0 +of 0 +patients 0 +with 0 +bipolar 3 +mania 4 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +evaluate 0 +extrapyramidal 3 +symptoms 4 +( 0 +EPS 3 +) 0 +, 0 +including 0 +akathisia 3 +, 0 +with 0 +quetiapine 1 +in 0 +patients 0 +with 0 +bipolar 3 +mania 4 +. 0 + +METH0DS 0 +: 0 +Data 0 +were 0 +analyzed 0 +from 0 +four 0 +similarly 0 +designed 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +3 0 +- 0 +to 0 +12 0 +- 0 +week 0 +studies 0 +. 0 + +Two 0 +studies 0 +evaluated 0 +quetiapine 1 +monotherapy 0 +( 0 +up 0 +to 0 +800 0 +mg 0 +/ 0 +day 0 +) 0 +( 0 +n 0 += 0 +209 0 +) 0 +versus 0 +placebo 0 +( 0 +n 0 += 0 +198 0 +) 0 +, 0 +with 0 +lithium 1 +or 0 +haloperidol 1 +monotherapy 0 +as 0 +respective 0 +active 0 +controls 0 +. 0 + +Two 0 +studies 0 +evaluated 0 +quetiapine 1 +( 0 +up 0 +to 0 +800 0 +mg 0 +/ 0 +day 0 +) 0 +in 0 +combination 0 +with 0 +a 0 +mood 0 +stabilizer 0 +( 0 +lithium 1 +or 0 +divalproex 1 +, 0 +QTP 1 ++ 0 +Li 1 +/ 0 +DVP 1 +) 0 +( 0 +n 0 += 0 +196 0 +) 0 +compared 0 +to 0 +placebo 0 +and 0 +mood 0 +stabilizer 0 +( 0 +PB0 0 ++ 0 +Li 1 +/ 0 +DVP 1 +) 0 +( 0 +n 0 += 0 +203 0 +) 0 +. 0 + +Extrapyramidal 3 +symptoms 4 +were 0 +evaluated 0 +using 0 +the 0 +Simpson 0 +- 0 +Angus 0 +Scale 0 +( 0 +SAS 0 +) 0 +, 0 +the 0 +Barnes 0 +Akathisia 0 +Rating 0 +Scale 0 +( 0 +BARS 0 +) 0 +, 0 +adverse 0 +event 0 +reports 0 +and 0 +anticholinergic 0 +drug 0 +usage 0 +. 0 + +RESULTS 0 +: 0 +The 0 +incidence 0 +of 0 +EPS 3 +- 0 +related 0 +adverse 0 +events 0 +, 0 +including 0 +akathisia 3 +, 0 +was 0 +no 0 +different 0 +with 0 +quetiapine 1 +monotherapy 0 +( 0 +12 0 +. 0 +9 0 +% 0 +) 0 +than 0 +with 0 +placebo 0 +( 0 +13 0 +. 0 +1 0 +% 0 +) 0 +. 0 + +Similarly 0 +, 0 +EPS 3 +- 0 +related 0 +adverse 0 +events 0 +with 0 +QTP 1 ++ 0 +Li 1 +/ 0 +DVP 1 +( 0 +21 0 +. 0 +4 0 +% 0 +) 0 +were 0 +no 0 +different 0 +than 0 +with 0 +PB0 0 ++ 0 +Li 1 +/ 0 +DVP 1 +( 0 +19 0 +. 0 +2 0 +% 0 +) 0 +. 0 + +Adverse 0 +events 0 +related 0 +to 0 +EPS 3 +occurred 0 +in 0 +59 0 +. 0 +6 0 +% 0 +of 0 +patients 0 +treated 0 +with 0 +haloperidol 1 +( 0 +n 0 += 0 +99 0 +) 0 +monotherapy 0 +, 0 +whereas 0 +26 0 +. 0 +5 0 +% 0 +of 0 +patients 0 +treated 0 +with 0 +lithium 1 +( 0 +n 0 += 0 +98 0 +) 0 +monotherapy 0 +experienced 0 +adverse 0 +events 0 +related 0 +to 0 +EPS 3 +. 0 + +The 0 +incidence 0 +of 0 +akathisia 3 +was 0 +low 0 +and 0 +similar 0 +with 0 +quetiapine 1 +monotherapy 0 +( 0 +3 0 +. 0 +3 0 +% 0 +) 0 +and 0 +placebo 0 +( 0 +6 0 +. 0 +1 0 +% 0 +) 0 +, 0 +and 0 +with 0 +QTP 1 ++ 0 +Li 1 +/ 0 +DVP 1 +( 0 +3 0 +. 0 +6 0 +% 0 +) 0 +and 0 +PB0 0 ++ 0 +Li 1 +/ 0 +DVP 1 +( 0 +4 0 +. 0 +9 0 +% 0 +) 0 +. 0 + +Lithium 1 +was 0 +associated 0 +with 0 +a 0 +significantly 0 +higher 0 +incidence 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +of 0 +tremor 3 +( 0 +18 0 +. 0 +4 0 +% 0 +) 0 +than 0 +quetiapine 1 +( 0 +5 0 +. 0 +6 0 +% 0 +) 0 +; 0 +cerebellar 0 +tremor 3 +, 0 +which 0 +is 0 +a 0 +known 0 +adverse 0 +effect 0 +of 0 +lithium 1 +, 0 +may 0 +have 0 +contributed 0 +to 0 +the 0 +elevated 0 +rate 0 +of 0 +tremor 3 +in 0 +patients 0 +receiving 0 +lithium 1 +therapy 0 +. 0 + +Haloperidol 1 +induced 0 +a 0 +significantly 0 +higher 0 +incidence 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +of 0 +akathisia 3 +( 0 +33 0 +. 0 +3 0 +% 0 +versus 0 +5 0 +. 0 +9 0 +% 0 +) 0 +, 0 +tremor 3 +( 0 +30 0 +. 0 +3 0 +% 0 +versus 0 +7 0 +. 0 +8 0 +% 0 +) 0 +, 0 +and 0 +extrapyramidal 3 +syndrome 4 +( 0 +35 0 +. 0 +4 0 +% 0 +versus 0 +5 0 +. 0 +9 0 +% 0 +) 0 +than 0 +quetiapine 1 +. 0 + +No 0 +significant 0 +differences 0 +were 0 +observed 0 +between 0 +quetiapine 1 +and 0 +placebo 0 +on 0 +SAS 0 +and 0 +BARS 0 +scores 0 +. 0 + +Anticholinergic 0 +use 0 +was 0 +low 0 +and 0 +similar 0 +with 0 +quetiapine 1 +or 0 +placebo 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +bipolar 3 +mania 4 +, 0 +the 0 +incidence 0 +of 0 +EPS 3 +, 0 +including 0 +akathisia 3 +, 0 +with 0 +quetiapine 1 +therapy 0 +is 0 +similar 0 +to 0 +that 0 +with 0 +placebo 0 +. 0 + +Is 0 +phenytoin 1 +administration 0 +safe 0 +in 0 +a 0 +hypothermic 3 +child 0 +? 0 + +A 0 +male 0 +neonate 0 +with 0 +a 0 +Chiari 3 +malformation 4 +and 0 +a 0 +leaking 0 +myelomeningocoele 0 +underwent 0 +ventriculoperitoneal 0 +shunt 0 +insertion 0 +followed 0 +by 0 +repair 0 +of 0 +myelomeningocoele 0 +. 0 + +During 0 +anaesthesia 0 +and 0 +surgery 0 +, 0 +he 0 +inadvertently 0 +became 0 +moderately 0 +hypothermic 3 +. 0 + +Intravenous 0 +phenytoin 1 +was 0 +administered 0 +during 0 +the 0 +later 0 +part 0 +of 0 +the 0 +surgery 0 +for 0 +seizure 3 +prophylaxis 0 +. 0 + +Following 0 +phenytoin 1 +administration 0 +, 0 +the 0 +patient 0 +developed 0 +acute 0 +severe 0 +bradycardia 3 +, 0 +refractory 0 +to 0 +atropine 1 +and 0 +adrenaline 1 +. 0 + +The 0 +cardiac 0 +depressant 0 +actions 0 +of 0 +phenytoin 1 +and 0 +hypothermia 3 +can 0 +be 0 +additive 0 +. 0 + +Administration 0 +of 0 +phenytoin 1 +in 0 +the 0 +presence 0 +of 0 +hypothermia 3 +may 0 +lead 0 +to 0 +an 0 +adverse 0 +cardiac 0 +event 0 +in 0 +children 0 +. 0 + +As 0 +phenytoin 1 +is 0 +a 0 +commonly 0 +used 0 +drug 0 +, 0 +clinicians 0 +need 0 +to 0 +be 0 +aware 0 +of 0 +this 0 +interaction 0 +. 0 + +Valproate 1 +- 0 +induced 0 +chorea 3 +and 0 +encephalopathy 3 +in 0 +atypical 0 +nonketotic 3 +hyperglycinemia 4 +. 0 + +Nonketotic 3 +hyperglycinemia 4 +is 0 +a 0 +disorder 3 +of 4 +amino 4 +acid 4 +metabolism 4 +in 0 +which 0 +a 0 +defect 0 +in 0 +the 0 +glycine 1 +cleavage 0 +system 0 +leads 0 +to 0 +an 0 +accumulation 0 +of 0 +glycine 1 +in 0 +the 0 +brain 0 +and 0 +other 0 +body 0 +compartments 0 +. 0 + +In 0 +the 0 +classical 0 +form 0 +it 0 +presents 0 +as 0 +neonatal 0 +apnea 3 +, 0 +intractable 0 +seizures 3 +, 0 +and 0 +hypotonia 3 +, 0 +followed 0 +by 0 +significant 0 +psychomotor 3 +retardation 4 +. 0 + +An 0 +important 0 +subset 0 +of 0 +children 0 +with 0 +nonketotic 3 +hyperglycinemia 4 +are 0 +atypical 0 +variants 0 +who 0 +present 0 +in 0 +a 0 +heterogeneous 0 +manner 0 +. 0 + +This 0 +report 0 +describes 0 +a 0 +patient 0 +with 0 +mild 0 +language 3 +delay 4 +and 0 +mental 3 +retardation 4 +, 0 +who 0 +was 0 +found 0 +to 0 +have 0 +nonketotic 3 +hyperglycinemia 4 +following 0 +her 0 +presentation 0 +with 0 +acute 0 +encephalopathy 3 +and 0 +chorea 3 +shortly 0 +after 0 +initiation 0 +of 0 +valproate 1 +therapy 0 +. 0 + +Delayed 0 +institution 0 +of 0 +hypertension 3 +during 0 +focal 0 +cerebral 3 +ischemia 4 +: 0 +effect 0 +on 0 +brain 3 +edema 4 +. 0 + +The 0 +effect 0 +of 0 +induced 0 +hypertension 3 +instituted 0 +after 0 +a 0 +2 0 +- 0 +h 0 +delay 0 +following 0 +middle 3 +cerebral 4 +artery 4 +occlusion 4 +( 0 +MCA0 3 +) 0 +on 0 +brain 3 +edema 4 +formation 0 +and 0 +histochemical 0 +injury 0 +was 0 +studied 0 +. 0 + +Under 0 +isoflurane 1 +anesthesia 0 +, 0 +the 0 +MCA 0 +of 0 +14 0 +spontaneously 0 +hypertensive 3 +rats 0 +was 0 +occluded 0 +. 0 + +In 0 +the 0 +control 0 +group 0 +( 0 +n 0 += 0 +7 0 +) 0 +, 0 +the 0 +mean 0 +arterial 0 +pressure 0 +( 0 +MAP 0 +) 0 +was 0 +not 0 +manipulated 0 +. 0 + +In 0 +the 0 +hypertensive 3 +group 0 +( 0 +n 0 += 0 +7 0 +) 0 +, 0 +the 0 +MAP 0 +was 0 +elevated 0 +by 0 +25 0 +- 0 +30 0 +mm 0 +Hg 0 +beginning 0 +2 0 +h 0 +after 0 +MCA0 3 +. 0 + +Four 0 +hours 0 +after 0 +MCA0 3 +, 0 +the 0 +rats 0 +were 0 +killed 0 +and 0 +the 0 +brains 0 +harvested 0 +. 0 + +The 0 +brains 0 +were 0 +sectioned 0 +along 0 +coronal 0 +planes 0 +spanning 0 +the 0 +distribution 0 +of 0 +ischemia 3 +produced 0 +by 0 +MCA0 3 +. 0 + +Specific 0 +gravity 0 +( 0 +SG 0 +) 0 +was 0 +determined 0 +in 0 +the 0 +subcortex 0 +and 0 +in 0 +two 0 +sites 0 +in 0 +the 0 +cortex 0 +( 0 +core 0 +and 0 +periphery 0 +of 0 +the 0 +ischemic 3 +territory 0 +) 0 +. 0 + +The 0 +extent 0 +of 0 +neuronal 3 +injury 4 +was 0 +determined 0 +by 0 +2 1 +, 2 +3 2 +, 2 +5 2 +- 2 +triphenyltetrazolium 2 +staining 0 +. 0 + +In 0 +the 0 +ischemic 3 +core 0 +, 0 +there 0 +was 0 +no 0 +difference 0 +in 0 +SG 0 +in 0 +the 0 +subcortex 0 +and 0 +cortex 0 +in 0 +the 0 +two 0 +groups 0 +. 0 + +In 0 +the 0 +periphery 0 +of 0 +the 0 +ischemic 3 +territory 0 +, 0 +SG 0 +in 0 +the 0 +cortex 0 +was 0 +greater 0 +( 0 +less 0 +edema 3 +accumulation 0 +) 0 +in 0 +the 0 +hypertensive 3 +group 0 +( 0 +1 0 +. 0 +041 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +001 0 +vs 0 +1 0 +. 0 +039 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +001 0 +, 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +area 0 +of 0 +histochemical 0 +injury 0 +( 0 +as 0 +a 0 +percent 0 +of 0 +the 0 +cross 0 +- 0 +sectional 0 +area 0 +of 0 +the 0 +hemisphere 0 +) 0 +was 0 +less 0 +in 0 +the 0 +hypertensive 3 +group 0 +( 0 +33 0 ++ 0 +/ 0 +- 0 +3 0 +% 0 +vs 0 +21 0 ++ 0 +/ 0 +- 0 +2 0 +% 0 +, 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +data 0 +indicate 0 +that 0 +phenylephrine 1 +- 0 +induced 0 +hypertension 3 +instituted 0 +2 0 +h 0 +after 0 +MCA0 3 +does 0 +not 0 +aggravate 0 +edema 3 +in 0 +the 0 +ischemic 3 +core 0 +, 0 +that 0 +it 0 +improves 0 +edema 3 +in 0 +the 0 +periphery 0 +of 0 +the 0 +ischemic 3 +territory 0 +, 0 +and 0 +that 0 +it 0 +reduces 0 +the 0 +area 0 +of 0 +histochemical 0 +neuronal 3 +dysfunction 4 +. 0 + +Behavioral 0 +effects 0 +of 0 +pubertal 0 +anabolic 0 +androgenic 0 +steroid 1 +exposure 0 +in 0 +male 0 +rats 0 +with 0 +low 0 +serotonin 1 +. 0 + +The 0 +goal 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +interactive 0 +effects 0 +of 0 +chronic 0 +anabolic 0 +androgenic 0 +steroid 1 +( 0 +AAS 0 +) 0 +exposure 0 +and 0 +brain 0 +serotonin 1 +( 0 +5 1 +- 2 +hydroxytryptamine 2 +, 0 +5 1 +- 2 +HT 2 +) 0 +depletion 0 +on 0 +behavior 0 +of 0 +pubertal 0 +male 0 +rats 0 +. 0 + +Serotonin 1 +was 0 +depleted 0 +beginning 0 +on 0 +postnatal 0 +day 0 +26 0 +with 0 +parachlorophenylalanine 1 +( 0 +PCPA 1 +100 0 +mg 0 +/ 0 +kg 0 +, 0 +every 0 +other 0 +day 0 +) 0 +; 0 +controls 0 +received 0 +saline 0 +. 0 + +At 0 +puberty 0 +( 0 +P40 0 +) 0 +, 0 +half 0 +the 0 +PCPA 1 +- 0 +treated 0 +rats 0 +and 0 +half 0 +the 0 +saline 0 +- 0 +treated 0 +rats 0 +began 0 +treatment 0 +with 0 +testosterone 1 +( 0 +T 1 +, 0 +5 0 +mg 0 +/ 0 +kg 0 +, 0 +5 0 +days 0 +/ 0 +week 0 +) 0 +. 0 + +Behavioral 0 +measures 0 +included 0 +locomotion 0 +, 0 +irritability 3 +, 0 +copulation 0 +, 0 +partner 0 +preference 0 +, 0 +and 0 +aggression 3 +. 0 + +Animals 0 +were 0 +tested 0 +for 0 +aggression 3 +in 0 +their 0 +home 0 +cage 0 +, 0 +both 0 +with 0 +and 0 +without 0 +physical 0 +provocation 0 +( 0 +mild 0 +tail 0 +pinch 0 +) 0 +. 0 + +Brain 0 +levels 0 +of 0 +5 1 +- 2 +HT 2 +and 0 +its 0 +metabolite 0 +, 0 +5 1 +- 2 +hydroxyindoleacetic 2 +acid 2 +( 0 +5 1 +- 2 +HIAA 2 +) 0 +, 0 +were 0 +determined 0 +using 0 +HPLC 0 +. 0 + +PCPA 1 +significantly 0 +and 0 +substantially 0 +depleted 0 +5 1 +- 2 +HT 2 +and 0 +5 1 +- 2 +HIAA 2 +in 0 +all 0 +brain 0 +regions 0 +examined 0 +. 0 + +Chronic 0 +T 1 +treatment 0 +significantly 0 +decreased 0 +5 1 +- 2 +HT 2 +and 0 +5 1 +- 2 +HIAA 2 +in 0 +certain 0 +brain 0 +areas 0 +, 0 +but 0 +to 0 +a 0 +much 0 +lesser 0 +extent 0 +than 0 +PCPA 1 +. 0 + +Chronic 0 +exposure 0 +to 0 +PCPA 1 +alone 0 +significantly 0 +decreased 0 +locomotor 0 +activity 0 +and 0 +increased 0 +irritability 3 +but 0 +had 0 +no 0 +effect 0 +on 0 +sexual 0 +behavior 0 +, 0 +partner 0 +preference 0 +, 0 +or 0 +aggression 3 +. 0 + +T 1 +alone 0 +had 0 +no 0 +effect 0 +on 0 +locomotion 0 +, 0 +irritability 3 +, 0 +or 0 +sexual 0 +behavior 0 +but 0 +increased 0 +partner 0 +preference 0 +and 0 +aggression 3 +. 0 + +The 0 +most 0 +striking 0 +effect 0 +of 0 +combining 0 +T 1 ++ 0 +PCPA 1 +was 0 +a 0 +significant 0 +increase 0 +in 0 +attack 0 +frequency 0 +as 0 +well 0 +as 0 +a 0 +significant 0 +decrease 0 +in 0 +the 0 +latency 0 +to 0 +attack 0 +, 0 +particularly 0 +following 0 +physical 0 +provocation 0 +. 0 + +Based 0 +on 0 +these 0 +data 0 +, 0 +it 0 +can 0 +be 0 +speculated 0 +that 0 +pubertal 0 +AAS 0 +users 0 +with 0 +low 0 +central 0 +5 1 +- 2 +HT 2 +may 0 +be 0 +especially 0 +prone 0 +to 0 +exhibit 0 +aggressive 3 +behavior 4 +. 0 + +Effects 0 +of 0 +UMB24 1 +and 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +SM 1 +21 2 +, 0 +putative 0 +sigma2 0 +- 0 +preferring 0 +antagonists 0 +, 0 +on 0 +behavioral 0 +toxic 0 +and 0 +stimulant 0 +effects 0 +of 0 +cocaine 1 +in 0 +mice 0 +. 0 + +Earlier 0 +studies 0 +have 0 +demonstrated 0 +that 0 +antagonism 0 +of 0 +sigma1 0 +receptors 0 +attenuates 0 +the 0 +convulsive 3 +, 0 +lethal 0 +, 0 +locomotor 0 +stimulatory 0 +and 0 +rewarding 0 +actions 0 +of 0 +cocaine 1 +in 0 +mice 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +contribution 0 +of 0 +sigma2 0 +receptors 0 +is 0 +unclear 0 +because 0 +experimental 0 +tools 0 +to 0 +selectively 0 +target 0 +this 0 +subtype 0 +are 0 +unavailable 0 +. 0 + +To 0 +begin 0 +addressing 0 +this 0 +need 0 +, 0 +we 0 +characterized 0 +UMB24 1 +( 0 +1 1 +- 2 +( 2 +2 2 +- 2 +phenethyl 2 +) 2 +- 2 +4 2 +- 2 +( 2 +2 2 +- 2 +pyridyl 2 +) 2 +- 2 +piperazine 2 +) 0 +and 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +SM 1 +21 2 +( 0 +3alpha 1 +- 2 +tropanyl 2 +- 2 +2 2 +- 2 +( 2 +4 2 +- 2 +chorophenoxy 2 +) 2 +butyrate 2 +) 0 +in 0 +receptor 0 +binding 0 +and 0 +behavioral 0 +studies 0 +. 0 + +Receptor 0 +binding 0 +studies 0 +confirmed 0 +that 0 +UMB24 1 +and 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +SM 1 +21 2 +display 0 +preferential 0 +affinity 0 +for 0 +sigma2 0 +over 0 +sigma1 0 +receptors 0 +. 0 + +In 0 +behavioral 0 +studies 0 +, 0 +pretreatment 0 +of 0 +Swiss 0 +Webster 0 +mice 0 +with 0 +UMB24 1 +or 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +SM 1 +21 2 +significantly 0 +attenuated 0 +cocaine 1 +- 0 +induced 0 +convulsions 3 +and 0 +locomotor 0 +activity 0 +, 0 +but 0 +not 0 +lethality 0 +. 0 + +When 0 +administered 0 +alone 0 +, 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +SM 1 +21 2 +produced 0 +no 0 +significant 0 +effects 0 +compared 0 +to 0 +control 0 +injections 0 +of 0 +saline 0 +, 0 +but 0 +UMB24 1 +had 0 +locomotor 0 +depressant 0 +actions 0 +. 0 + +Together 0 +, 0 +the 0 +data 0 +suggest 0 +that 0 +sigma2 0 +receptor 0 +antagonists 0 +have 0 +the 0 +potential 0 +to 0 +attenuate 0 +some 0 +of 0 +the 0 +behavioral 0 +effects 0 +of 0 +cocaine 1 +, 0 +and 0 +further 0 +development 0 +of 0 +more 0 +selective 0 +, 0 +high 0 +affinity 0 +ligands 0 +are 0 +warranted 0 +. 0 + +Cardiac 3 +arrest 4 +in 0 +a 0 +child 0 +with 0 +cerebral 3 +palsy 4 +undergoing 0 +sevoflurane 1 +induction 0 +of 0 +anesthesia 0 +after 0 +preoperative 0 +clonidine 1 +. 0 + +Clonidine 1 +is 0 +a 0 +frequently 0 +administered 0 +alpha2 0 +- 0 +adrenergic 0 +agonist 0 +which 0 +can 0 +decrease 0 +heart 0 +rate 0 +and 0 +blood 0 +pressure 0 +. 0 + +We 0 +present 0 +a 0 +case 0 +of 0 +a 0 +5 0 +- 0 +year 0 +- 0 +old 0 +child 0 +with 0 +cerebral 3 +palsy 4 +and 0 +seizure 3 +disorder 4 +, 0 +receiving 0 +clonidine 1 +for 0 +restlessness 3 +, 0 +who 0 +presented 0 +for 0 +placement 0 +of 0 +a 0 +baclofen 1 +pump 0 +. 0 + +Without 0 +the 0 +knowledge 0 +of 0 +the 0 +medical 0 +personnel 0 +, 0 +the 0 +patient 0 +' 0 +s 0 +mother 0 +administered 0 +three 0 +doses 0 +of 0 +clonidine 1 +during 0 +the 0 +evening 0 +before 0 +and 0 +morning 0 +of 0 +surgery 0 +to 0 +reduce 0 +anxiety 3 +. 0 + +During 0 +induction 0 +of 0 +anesthesia 0 +, 0 +the 0 +patient 0 +developed 0 +bradycardia 3 +and 0 +hypotension 3 +requiring 0 +cardiac 0 +resuscitation 0 +. 0 + +There 0 +are 0 +no 0 +previous 0 +reports 0 +of 0 +clonidine 1 +- 0 +associated 0 +cardiac 3 +arrest 4 +in 0 +a 0 +child 0 +undergoing 0 +induction 0 +of 0 +anesthesia 0 +. 0 + +Angiotensin 0 +- 0 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +inhibitor 0 +- 0 +associated 0 +angioedema 3 +of 0 +the 0 +stomach 0 +and 0 +small 0 +intestine 0 +: 0 +a 0 +case 0 +report 0 +. 0 + +This 0 +is 0 +a 0 +case 0 +report 0 +on 0 +a 0 +45 0 +- 0 +year 0 +old 0 +African 0 +- 0 +American 0 +female 0 +with 0 +newly 0 +diagnosed 0 +hypertension 3 +, 0 +who 0 +was 0 +started 0 +on 0 +a 0 +combination 0 +pill 0 +of 0 +amlodipine 1 +/ 0 +benazapril 1 +10 0 +/ 0 +5 0 +mg 0 +. 0 + +The 0 +very 0 +next 0 +day 0 +, 0 +she 0 +presented 0 +at 0 +the 0 +emergency 0 +room 0 +( 0 +ER 0 +) 0 +with 0 +abdominal 3 +pain 4 +, 0 +nausea 3 +and 0 +vomiting 3 +. 0 + +Physical 0 +exam 0 +, 0 +complete 0 +metabolic 0 +panel 0 +, 0 +and 0 +hemogram 0 +were 0 +in 0 +the 0 +normal 0 +range 0 +. 0 + +She 0 +was 0 +discharged 0 +from 0 +the 0 +ER 0 +after 0 +a 0 +few 0 +hours 0 +of 0 +treatment 0 +with 0 +fluid 0 +and 0 +analgesics 0 +. 0 + +However 0 +, 0 +she 0 +returned 0 +to 0 +the 0 +ER 0 +the 0 +next 0 +day 0 +with 0 +the 0 +same 0 +complaints 0 +. 0 + +This 0 +time 0 +the 0 +physical 0 +exam 0 +was 0 +significant 0 +for 0 +a 0 +distended 0 +abdomen 0 +with 0 +dullness 0 +to 0 +percussion 0 +. 0 + +CT 0 +scan 0 +of 0 +the 0 +abdomen 0 +revealed 0 +markedly 0 +thickened 0 +antrum 0 +of 0 +the 0 +stomach 0 +, 0 +duodenum 0 +and 0 +jejunum 0 +, 0 +along 0 +with 0 +fluid 0 +in 0 +the 0 +abdominal 0 +and 0 +pelvic 0 +cavity 0 +. 0 + +Angiotensin 0 +- 0 +converting 0 +enzyme 0 +inhibitor 0 +( 0 +ACEI 0 +) 0 +- 0 +induced 0 +angioedema 3 +was 0 +suspected 0 +, 0 +and 0 +anti 0 +- 0 +hypertensive 3 +medications 0 +were 0 +discontinued 0 +. 0 + +Her 0 +symptoms 0 +improved 0 +within 0 +the 0 +next 0 +24 0 +hours 0 +, 0 +and 0 +repeat 0 +CT 0 +after 0 +72 0 +hours 0 +revealed 0 +marked 0 +improvement 0 +in 0 +stomach 0 +and 0 +small 0 +bowel 0 +thickening 0 +and 0 +resolution 0 +of 0 +ascites 3 +. 0 + +The 0 +recognition 0 +of 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +and 0 +angiotensin 1 +receptor 0 +blocker 0 +( 0 +ARB 0 +) 0 +intestinal 3 +angioedema 4 +constitutes 0 +a 0 +challenge 0 +to 0 +primary 0 +care 0 +physicians 0 +, 0 +internists 0 +, 0 +emergency 0 +room 0 +personal 0 +and 0 +surgeons 0 +. 0 + +Carbamazepine 1 +- 0 +induced 0 +cardiac 3 +dysfunction 4 +. 0 + +Characterization 0 +of 0 +two 0 +distinct 0 +clinical 0 +syndromes 0 +. 0 + +A 0 +patient 0 +with 0 +sinus 0 +bradycardia 3 +and 0 +atrioventricular 3 +block 4 +, 0 +induced 0 +by 0 +carbamazepine 1 +, 0 +prompted 0 +an 0 +extensive 0 +literature 0 +review 0 +of 0 +all 0 +previously 0 +reported 0 +cases 0 +. 0 + +From 0 +the 0 +analysis 0 +of 0 +these 0 +cases 0 +, 0 +two 0 +distinct 0 +forms 0 +of 0 +carbamazepine 1 +- 0 +associated 0 +cardiac 3 +dysfunction 4 +emerged 0 +. 0 + +0ne 0 +patient 0 +group 0 +developed 0 +sinus 3 +tachycardias 4 +in 0 +the 0 +setting 0 +of 0 +a 0 +massive 0 +carbamazepine 1 +overdose 3 +. 0 + +The 0 +second 0 +group 0 +consisted 0 +almost 0 +exclusively 0 +of 0 +elderly 0 +women 0 +who 0 +developed 0 +potentially 0 +life 0 +- 0 +threatening 0 +bradyarrhythmias 3 +or 0 +atrioventricular 3 +conduction 4 +delay 4 +, 0 +associated 0 +with 0 +either 0 +therapeutic 0 +or 0 +modestly 0 +elevated 0 +carbamazepine 1 +serum 0 +levels 0 +. 0 + +Because 0 +carbamazepine 1 +is 0 +widely 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +many 0 +neurologic 0 +and 0 +psychiatric 3 +conditions 0 +, 0 +the 0 +recognition 0 +of 0 +the 0 +latter 0 +syndrome 0 +has 0 +important 0 +implications 0 +for 0 +the 0 +use 0 +of 0 +this 0 +drug 0 +in 0 +elderly 0 +patients 0 +. 0 + +Detection 0 +of 0 +abnormal 0 +cardiac 0 +adrenergic 0 +neuron 0 +activity 0 +in 0 +adriamycin 1 +- 0 +induced 0 +cardiomyopathy 3 +with 0 +iodine 1 +- 2 +125 2 +- 2 +metaiodobenzylguanidine 2 +. 0 + +Radiolabeled 1 +metaiodobenzylguanidine 2 +( 0 +MIBG 1 +) 0 +, 0 +an 0 +analog 0 +of 0 +norepinephrine 1 +( 0 +NE 1 +) 0 +, 0 +serves 0 +as 0 +an 0 +index 0 +of 0 +adrenergic 0 +neuron 0 +integrity 0 +and 0 +function 0 +. 0 + +Using 0 +a 0 +rat 0 +model 0 +of 0 +adriamycin 1 +- 0 +induced 0 +cardiomyopathy 3 +, 0 +we 0 +tested 0 +the 0 +hypothesis 0 +that 0 +abnormal 0 +cardiac 0 +adrenergic 0 +neuron 0 +activity 0 +may 0 +appear 0 +and 0 +be 0 +exacerbated 0 +dose 0 +- 0 +dependently 0 +in 0 +adriamycin 1 +cardiomyopathy 3 +. 0 + +The 0 +degree 0 +of 0 +vacuolar 3 +degeneration 4 +of 4 +myocardial 4 +cells 4 +was 0 +analyzed 0 +in 0 +relation 0 +to 0 +the 0 +duration 0 +of 0 +adriamycin 1 +treatment 0 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +, 0 +once 0 +a 0 +week 0 +) 0 +. 0 + +There 0 +were 0 +no 0 +abnormalities 0 +or 0 +only 0 +isolated 0 +degeneration 0 +in 0 +the 0 +1 0 +- 0 +or 0 +2 0 +- 0 +wk 0 +treatment 0 +groups 0 +, 0 +isolated 0 +or 0 +scattered 0 +degeneration 0 +in 0 +half 0 +of 0 +the 0 +3 0 +- 0 +wk 0 +group 0 +, 0 +frequent 0 +scattered 0 +degeneration 0 +in 0 +the 0 +4 0 +- 0 +wk 0 +group 0 +, 0 +scattered 0 +or 0 +focal 0 +degeneration 0 +in 0 +the 0 +5 0 +- 0 +wk 0 +group 0 +, 0 +and 0 +extensive 0 +degeneration 0 +in 0 +the 0 +8 0 +- 0 +wk 0 +group 0 +. 0 + +Myocardial 0 +accumulation 0 +of 0 +[ 0 +125I 0 +] 0 +MIBG 1 +4 0 +hr 0 +after 0 +intravenous 0 +injection 0 +did 0 +not 0 +differ 0 +between 0 +the 0 +controls 0 +and 0 +the 0 +groups 0 +treated 0 +3 0 +wk 0 +or 0 +less 0 +. 0 + +However 0 +, 0 +the 0 +4 0 +- 0 +wk 0 +group 0 +had 0 +a 0 +slightly 0 +lower 0 +accumulation 0 +in 0 +the 0 +right 0 +ventricular 0 +wall 0 +( 0 +82 0 +% 0 +of 0 +the 0 +control 0 +) 0 +and 0 +significantly 0 +lower 0 +accumulation 0 +in 0 +the 0 +left 0 +ventricular 0 +wall 0 +( 0 +about 0 +66 0 +% 0 +of 0 +the 0 +control 0 +: 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +In 0 +the 0 +5 0 +- 0 +wk 0 +group 0 +, 0 +MIBG 1 +accumulation 0 +in 0 +the 0 +right 0 +and 0 +left 0 +ventricular 0 +wall 0 +was 0 +35 0 +% 0 +and 0 +27 0 +% 0 +of 0 +that 0 +in 0 +controls 0 +, 0 +respectively 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +In 0 +the 0 +8 0 +- 0 +wk 0 +group 0 +, 0 +MIBG 1 +accumulation 0 +in 0 +the 0 +right 0 +and 0 +left 0 +ventricular 0 +wall 0 +was 0 +18 0 +% 0 +and 0 +14 0 +% 0 +of 0 +that 0 +in 0 +controls 0 +, 0 +respectively 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Thus 0 +, 0 +MIBG 1 +accumulation 0 +in 0 +the 0 +myocardium 0 +decreased 0 +in 0 +an 0 +adriamycin 1 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 + +The 0 +appearance 0 +of 0 +impaired 0 +cardiac 0 +adrenergic 0 +neuron 0 +activity 0 +in 0 +the 0 +presence 0 +of 0 +slight 0 +myocardial 3 +impairment 4 +( 0 +scattered 0 +or 0 +focal 0 +vacuolar 3 +degeneration 4 +) 0 +indicates 0 +that 0 +MIBG 1 +scintigraphy 0 +may 0 +be 0 +a 0 +useful 0 +method 0 +for 0 +detection 0 +of 0 +adriamycin 1 +- 0 +induced 0 +cardiomyopathy 3 +. 0 + +Syncope 3 +and 0 +QT 3 +prolongation 4 +among 0 +patients 0 +treated 0 +with 0 +methadone 1 +for 0 +heroin 1 +dependence 0 +in 0 +the 0 +city 0 +of 0 +Copenhagen 0 +. 0 + +BACKGR0UND 0 +: 0 +Methadone 1 +is 0 +prescribed 0 +to 0 +heroin 1 +addicts 0 +to 0 +decrease 0 +illicit 0 +opioid 0 +use 0 +. 0 + +Prolongation 0 +of 0 +the 0 +QT 0 +interval 0 +in 0 +the 0 +ECG 0 +of 0 +patients 0 +with 0 +torsade 3 +de 4 +pointes 4 +( 0 +TdP 3 +) 0 +has 0 +been 0 +reported 0 +in 0 +methadone 1 +users 0 +. 0 + +As 0 +heroin 1 +addicts 0 +sometimes 0 +faint 0 +while 0 +using 0 +illicit 0 +drugs 0 +, 0 +doctors 0 +might 0 +attribute 0 +too 0 +many 0 +episodes 0 +of 0 +syncope 3 +to 0 +illicit 0 +drug 0 +use 0 +and 0 +thereby 0 +underestimate 0 +the 0 +incidence 0 +of 0 +TdP 3 +in 0 +this 0 +special 0 +population 0 +, 0 +and 0 +the 0 +high 0 +mortality 0 +in 0 +this 0 +population 0 +may 0 +, 0 +in 0 +part 0 +, 0 +be 0 +caused 0 +by 0 +the 0 +proarrhythmic 0 +effect 0 +of 0 +methadone 1 +. 0 + +METH0DS 0 +: 0 +In 0 +this 0 +cross 0 +- 0 +sectional 0 +study 0 +interview 0 +, 0 +ECGs 0 +and 0 +blood 0 +samples 0 +were 0 +collected 0 +in 0 +a 0 +population 0 +of 0 +adult 0 +heroin 1 +addicts 0 +treated 0 +with 0 +methadone 1 +or 0 +buprenorphine 1 +on 0 +a 0 +daily 0 +basis 0 +. 0 + +0f 0 +the 0 +patients 0 +at 0 +the 0 +Drug 0 +Addiction 0 +Service 0 +in 0 +the 0 +municipal 0 +of 0 +Copenhagen 0 +, 0 +450 0 +( 0 +approximately 0 +52 0 +% 0 +) 0 +were 0 +included 0 +. 0 + +The 0 +QT 0 +interval 0 +was 0 +estimated 0 +from 0 +12 0 +lead 0 +ECGs 0 +. 0 + +All 0 +participants 0 +were 0 +interviewed 0 +about 0 +any 0 +experience 0 +of 0 +syncope 3 +. 0 + +The 0 +association 0 +between 0 +opioid 0 +dose 0 +and 0 +QT 0 +, 0 +and 0 +methadone 1 +dose 0 +and 0 +reporting 0 +of 0 +syncope 3 +was 0 +assessed 0 +using 0 +multivariate 0 +linear 0 +regression 0 +and 0 +logistic 0 +regression 0 +, 0 +respectively 0 +. 0 + +RESULTS 0 +: 0 +Methadone 1 +dose 0 +was 0 +associated 0 +with 0 +longer 0 +QT 0 +interval 0 +of 0 +0 0 +. 0 +140 0 +ms 0 +/ 0 +mg 0 +( 0 +p 0 += 0 +0 0 +. 0 +002 0 +) 0 +. 0 + +No 0 +association 0 +between 0 +buprenorphine 1 +and 0 +QTc 0 +was 0 +found 0 +. 0 + +Among 0 +the 0 +subjects 0 +treated 0 +with 0 +methadone 1 +, 0 +28 0 +% 0 +men 0 +and 0 +32 0 +% 0 +women 0 +had 0 +prolonged 3 +QTc 4 +interval 4 +. 0 + +None 0 +of 0 +the 0 +subjects 0 +treated 0 +with 0 +buprenorphine 1 +had 0 +QTc 0 +interval 0 +> 0 +0 0 +. 0 +440 0 +s 0 +( 0 +( 0 +1 0 +/ 0 +2 0 +) 0 +) 0 +. 0 + +A 0 +50 0 +mg 0 +higher 0 +methadone 1 +dose 0 +was 0 +associated 0 +with 0 +a 0 +1 0 +. 0 +2 0 +( 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +1 0 +to 0 +1 0 +. 0 +4 0 +) 0 +times 0 +higher 0 +odds 0 +for 0 +syncope 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +Methadone 1 +is 0 +associated 0 +with 0 +QT 3 +prolongation 4 +and 0 +higher 0 +reporting 0 +of 0 +syncope 3 +in 0 +a 0 +population 0 +of 0 +heroin 1 +addicts 0 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +induced 0 +by 0 +ziprasidone 1 +on 0 +the 0 +second 0 +day 0 +of 0 +treatment 0 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +( 0 +NMS 3 +) 0 +is 0 +the 0 +rarest 0 +and 0 +most 0 +serious 0 +of 0 +the 0 +neuroleptic 0 +- 0 +induced 0 +movement 3 +disorders 4 +. 0 + +We 0 +describe 0 +a 0 +case 0 +of 0 +neuroleptic 3 +malignant 4 +syndrome 4 +( 0 +NMS 3 +) 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +ziprasidone 1 +. 0 + +Although 0 +conventional 0 +neuroleptics 0 +are 0 +more 0 +frequently 0 +associated 0 +with 0 +NMS 3 +, 0 +atypical 0 +antipsychotic 0 +drugs 0 +like 0 +ziprasidone 1 +may 0 +also 0 +be 0 +a 0 +cause 0 +. 0 + +The 0 +patient 0 +is 0 +a 0 +24 0 +- 0 +year 0 +- 0 +old 0 +male 0 +with 0 +a 0 +history 0 +of 0 +schizophrenia 3 +who 0 +developed 0 +signs 0 +and 0 +symptoms 0 +of 0 +NMS 3 +after 0 +2 0 +days 0 +of 0 +treatment 0 +with 0 +an 0 +80 0 +- 0 +mg 0 +/ 0 +day 0 +dose 0 +of 0 +orally 0 +administrated 0 +ziprasidone 1 +. 0 + +This 0 +case 0 +is 0 +the 0 +earliest 0 +( 0 +second 0 +day 0 +of 0 +treatment 0 +) 0 +NMS 3 +due 0 +to 0 +ziprasidone 1 +reported 0 +in 0 +the 0 +literature 0 +. 0 + +Peripheral 0 +iron 1 +dextran 2 +induced 0 +degeneration 3 +of 4 +dopaminergic 4 +neurons 4 +in 0 +rat 0 +substantia 0 +nigra 0 +. 0 + +Iron 1 +accumulation 0 +is 0 +considered 0 +to 0 +be 0 +involved 0 +in 0 +the 0 +pathogenesis 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +To 0 +demonstrate 0 +the 0 +relationship 0 +between 0 +peripheral 0 +iron 1 +overload 0 +and 0 +dopaminergic 0 +neuron 0 +loss 0 +in 0 +rat 0 +substantia 0 +nigra 0 +( 0 +SN 0 +) 0 +, 0 +in 0 +the 0 +present 0 +study 0 +we 0 +used 0 +fast 0 +cyclic 0 +voltammetry 0 +, 0 +tyrosine 1 +hydroxylase 0 +( 0 +TH 0 +) 0 +immunohistochemistry 0 +, 0 +Perls 0 +' 0 +iron 1 +staining 0 +, 0 +and 0 +high 0 +performance 0 +liquid 0 +chromatography 0 +- 0 +electrochemical 0 +detection 0 +to 0 +study 0 +the 0 +degeneration 3 +of 4 +dopaminergic 4 +neurons 4 +and 0 +increased 0 +iron 1 +content 0 +in 0 +the 0 +SN 0 +of 0 +iron 1 +dextran 2 +overloaded 0 +animals 0 +. 0 + +The 0 +findings 0 +showed 0 +that 0 +peripheral 0 +iron 1 +dextran 2 +overload 0 +increased 0 +the 0 +iron 1 +staining 0 +positive 0 +cells 0 +and 0 +reduced 0 +the 0 +number 0 +of 0 +TH 0 +- 0 +immunoreactive 0 +neurons 0 +in 0 +the 0 +SN 0 +. 0 + +As 0 +a 0 +result 0 +, 0 +dopamine 1 +release 0 +and 0 +content 0 +, 0 +as 0 +well 0 +as 0 +its 0 +metabolites 0 +contents 0 +were 0 +decreased 0 +in 0 +caudate 0 +putamen 0 +. 0 + +Even 0 +more 0 +dramatic 0 +changes 0 +were 0 +found 0 +in 0 +chronic 0 +overload 0 +group 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +peripheral 0 +iron 1 +dextran 2 +can 0 +increase 0 +the 0 +iron 1 +level 0 +in 0 +the 0 +SN 0 +, 0 +where 0 +excessive 0 +iron 1 +causes 0 +the 0 +degeneration 3 +of 4 +dopaminergic 4 +neurons 4 +. 0 + +The 0 +chronic 0 +iron 1 +overload 0 +may 0 +be 0 +more 0 +destructive 0 +to 0 +dopaminergic 0 +neurons 0 +than 0 +the 0 +acute 0 +iron 1 +overload 0 +. 0 + +Attenuated 0 +disruption 0 +of 0 +prepulse 0 +inhibition 0 +by 0 +dopaminergic 0 +stimulation 0 +after 0 +maternal 0 +deprivation 0 +and 0 +adolescent 0 +corticosterone 1 +treatment 0 +in 0 +rats 0 +. 0 + +The 0 +development 0 +of 0 +schizophrenia 3 +may 0 +include 0 +an 0 +early 0 +neurodevelopmental 0 +stress 0 +component 0 +which 0 +increases 0 +vulnerability 0 +to 0 +later 0 +stressful 0 +life 0 +events 0 +, 0 +in 0 +combination 0 +leading 0 +to 0 +overt 0 +disease 0 +. 0 + +We 0 +investigated 0 +the 0 +effect 0 +of 0 +an 0 +early 0 +stress 0 +, 0 +in 0 +the 0 +form 0 +of 0 +maternal 0 +deprivation 0 +, 0 +combined 0 +with 0 +a 0 +later 0 +stress 0 +, 0 +simulated 0 +by 0 +chronic 0 +periadolescent 0 +corticosterone 1 +treatment 0 +, 0 +on 0 +behaviour 0 +in 0 +rats 0 +. 0 + +Acute 0 +treatment 0 +with 0 +apomorphine 1 +caused 0 +disruption 0 +of 0 +prepulse 0 +inhibition 0 +( 0 +PPI 0 +) 0 +in 0 +controls 0 +and 0 +in 0 +rats 0 +that 0 +had 0 +undergone 0 +either 0 +maternal 0 +deprivation 0 +or 0 +corticosterone 1 +treatment 0 +, 0 +but 0 +was 0 +surprisingly 0 +absent 0 +in 0 +rats 0 +that 0 +had 0 +undergone 0 +the 0 +combined 0 +early 0 +and 0 +late 0 +stress 0 +. 0 + +Amphetamine 1 +treatment 0 +significantly 0 +disrupted 0 +PPI 0 +in 0 +both 0 +non 0 +- 0 +deprived 0 +groups 0 +, 0 +but 0 +was 0 +absent 0 +in 0 +both 0 +maternally 0 +deprived 0 +groups 0 +. 0 + +The 0 +serotonin 1 +- 0 +1A 0 +receptor 0 +agonist 0 +, 0 +8 1 +- 2 +0H 2 +- 2 +DPAT 2 +, 0 +induced 0 +a 0 +significant 0 +disruption 0 +of 0 +PPI 0 +in 0 +all 0 +groups 0 +. 0 + +Amphetamine 1 +- 0 +induced 0 +locomotor 3 +hyperactivity 4 +was 0 +similar 0 +in 0 +all 0 +groups 0 +. 0 + +These 0 +results 0 +show 0 +an 0 +inhibitory 0 +interaction 0 +of 0 +early 0 +stress 0 +, 0 +caused 0 +by 0 +maternal 0 +deprivation 0 +, 0 +combined 0 +with 0 +' 0 +adolescent 0 +' 0 +stress 0 +, 0 +simulated 0 +by 0 +corticosterone 1 +treatment 0 +, 0 +on 0 +dopaminergic 0 +regulation 0 +of 0 +PPI 0 +. 0 + +The 0 +altered 0 +effects 0 +of 0 +apomorphine 1 +and 0 +amphetamine 1 +could 0 +indicate 0 +differential 0 +changes 0 +in 0 +dopamine 1 +receptor 0 +signalling 0 +leading 0 +to 0 +functional 0 +desensitisation 0 +, 0 +or 0 +altered 0 +modulation 0 +of 0 +sensory 0 +gating 0 +in 0 +the 0 +nucleus 0 +accumbens 0 +by 0 +limbic 0 +structures 0 +such 0 +as 0 +the 0 +hippocampus 0 +. 0 + +An 0 +extremely 0 +rare 0 +case 0 +of 0 +delusional 3 +parasitosis 4 +in 0 +a 0 +chronic 3 +hepatitis 4 +C 4 +patient 0 +during 0 +pegylated 1 +interferon 2 +alpha 2 +- 2 +2b 2 +and 0 +ribavirin 1 +treatment 0 +. 0 + +During 0 +treatment 0 +of 0 +chronic 3 +hepatitis 4 +C 4 +patients 0 +with 0 +interferon 0 +and 0 +ribavirin 1 +, 0 +a 0 +lot 0 +of 0 +side 0 +effects 0 +are 0 +described 0 +. 0 + +Twenty 0 +- 0 +three 0 +percent 0 +to 0 +44 0 +% 0 +of 0 +patients 0 +develop 0 +depression 3 +. 0 + +A 0 +minority 0 +of 0 +patients 0 +evolve 0 +to 0 +psychosis 3 +. 0 + +To 0 +the 0 +best 0 +of 0 +our 0 +knowledge 0 +, 0 +no 0 +cases 0 +of 0 +psychogenic 3 +parasitosis 4 +occurring 0 +during 0 +interferon 0 +therapy 0 +have 0 +been 0 +described 0 +in 0 +the 0 +literature 0 +. 0 + +We 0 +present 0 +a 0 +49 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +developed 0 +a 0 +delusional 3 +parasitosis 4 +during 0 +treatment 0 +with 0 +pegylated 1 +interferon 2 +alpha 2 +- 2 +2b 2 +weekly 0 +and 0 +ribavirin 1 +. 0 + +She 0 +complained 0 +of 0 +seeing 0 +parasites 0 +and 0 +the 0 +larvae 0 +of 0 +fleas 0 +in 0 +her 0 +stools 0 +. 0 + +This 0 +could 0 +not 0 +be 0 +confirmed 0 +by 0 +any 0 +technical 0 +examination 0 +. 0 + +All 0 +the 0 +complaints 0 +disappeared 0 +after 0 +stopping 0 +pegylated 1 +interferon 2 +alpha 2 +- 2 +2b 2 +and 0 +reappeared 0 +after 0 +restarting 0 +it 0 +. 0 + +She 0 +had 0 +a 0 +complete 0 +sustained 0 +viral 0 +response 0 +. 0 + +Hepatonecrosis 3 +and 0 +cholangitis 3 +related 0 +to 0 +long 0 +- 0 +term 0 +phenobarbital 1 +therapy 0 +: 0 +an 0 +autopsy 0 +report 0 +of 0 +two 0 +patients 0 +. 0 + +Phenobarbital 1 +( 0 +PB 1 +) 0 +has 0 +a 0 +reputation 0 +for 0 +safety 0 +, 0 +and 0 +it 0 +is 0 +commonly 0 +believed 0 +that 0 +PB 1 +- 0 +related 0 +increases 0 +in 0 +serum 0 +aminotransferase 0 +levels 0 +do 0 +not 0 +indicate 0 +or 0 +predict 0 +the 0 +development 0 +of 0 +significant 0 +chronic 0 +liver 3 +disease 4 +. 0 + +Here 0 +we 0 +report 0 +of 0 +two 0 +adult 0 +patients 0 +with 0 +a 0 +long 0 +history 0 +of 0 +epilepsy 3 +treated 0 +with 0 +PB 1 +who 0 +died 0 +suddenly 0 +: 0 +one 0 +as 0 +consequence 0 +of 0 +cardiac 3 +arrest 4 +, 0 +the 0 +other 0 +of 0 +acute 0 +bronchopneumonia 3 +. 0 + +At 0 +autopsy 0 +, 0 +analysis 0 +of 0 +liver 0 +parenchyma 0 +revealed 0 +rich 0 +portal 0 +inflammatory 0 +infiltrate 0 +, 0 +which 0 +consisted 0 +of 0 +mixed 0 +eosinophil 0 +and 0 +monocyte 0 +cells 0 +, 0 +associated 0 +with 0 +several 0 +foci 0 +of 0 +necrosis 3 +surrounded 0 +by 0 +a 0 +hard 0 +ring 0 +of 0 +non 0 +- 0 +specific 0 +granulomatous 0 +tissue 0 +. 0 + +Inflammatory 0 +reactions 0 +of 0 +internal 0 +and 0 +external 0 +hepatic 0 +biliary 0 +ducts 0 +were 0 +also 0 +seen 0 +. 0 + +0ur 0 +findings 0 +illustrate 0 +that 0 +PB 1 +may 0 +be 0 +associated 0 +with 0 +chronic 0 +liver 3 +damage 4 +, 0 +which 0 +may 0 +lead 0 +to 0 +more 0 +serious 0 +and 0 +deleterious 0 +consequences 0 +. 0 + +For 0 +this 0 +reason 0 +, 0 +each 0 +clinician 0 +should 0 +recognize 0 +this 0 +entity 0 +in 0 +the 0 +differential 0 +diagnosis 0 +of 0 +PB 1 +- 0 +related 0 +asymptomatic 0 +chronic 3 +hepatic 4 +enzyme 4 +dysfunction 4 +. 0 + +Delayed 0 +leukoencephalopathy 3 +with 0 +stroke 3 +- 0 +like 0 +presentation 0 +in 0 +chemotherapy 0 +recipients 0 +. 0 + +BACKGR0UND 0 +: 0 +A 0 +transient 0 +leukoencephalopathy 3 +mimicking 0 +cerebrovascular 3 +accident 4 +has 0 +been 0 +described 0 +as 0 +a 0 +complication 0 +of 0 +chemotherapy 0 +, 0 +most 0 +commonly 0 +in 0 +recipients 0 +of 0 +intrathecal 0 +methotrexate 1 +for 0 +childhood 0 +leukaemia 3 +. 0 + +Recently 0 +published 0 +neuroimaging 0 +data 0 +suggest 0 +a 0 +common 0 +pathophysiology 0 +associated 0 +with 0 +a 0 +variety 0 +of 0 +chemotherapy 0 +agents 0 +and 0 +modes 0 +of 0 +administration 0 +. 0 + +METH0DS 0 +: 0 +We 0 +reviewed 0 +the 0 +medical 0 +literature 0 +for 0 +single 0 +reports 0 +and 0 +case 0 +series 0 +of 0 +patients 0 +presenting 0 +with 0 +stroke 3 +- 0 +like 0 +episodes 0 +while 0 +receiving 0 +systemic 0 +or 0 +intrathecal 0 +chemotherapy 0 +. 0 + +We 0 +only 0 +included 0 +studies 0 +providing 0 +detailed 0 +neuroimaging 0 +data 0 +. 0 + +Patients 0 +with 0 +cerebrovascular 3 +accidents 4 +were 0 +excluded 0 +. 0 + +RESULTS 0 +: 0 +We 0 +identified 0 +27 0 +reports 0 +of 0 +toxic 0 +leukoencephalopathy 3 +in 0 +patients 0 +treated 0 +with 0 +methotrexate 1 +( 0 +intrathecal 0 +, 0 +systemic 0 +) 0 +, 0 +5 1 +- 2 +fluorouracil 2 +and 0 +its 0 +derivative 0 +carmofur 1 +, 0 +and 0 +capecitabine 1 +. 0 + +Diffusion 0 +weighted 0 +imaging 0 +( 0 +DWI 0 +) 0 +of 0 +all 0 +patients 0 +revealed 0 +well 0 +demarcated 0 +hyperintense 0 +lesions 3 +within 4 +the 4 +subcortical 4 +white 4 +matter 4 +of 0 +the 0 +cerebral 0 +hemispheres 0 +and 0 +the 0 +corpus 0 +callosum 0 +, 0 +corresponding 0 +to 0 +areas 0 +of 0 +decreased 0 +proton 0 +diffusion 0 +on 0 +apparent 0 +diffusion 0 +coefficient 0 +( 0 +ADC 0 +) 0 +maps 0 +( 0 +available 0 +in 0 +21 0 +/ 0 +27 0 +patients 0 +) 0 +. 0 + +Lesions 0 +exceeded 0 +the 0 +confines 0 +of 0 +adjacent 0 +vascular 0 +territories 0 +. 0 + +Complete 0 +resolution 0 +of 0 +symptoms 0 +within 0 +1 0 +- 0 +4 0 +days 0 +was 0 +accompanied 0 +by 0 +normalisation 0 +of 0 +ADC 0 +abnormalities 0 +. 0 + +However 0 +, 0 +fluid 0 +attenuated 0 +inversion 0 +recovery 0 +( 0 +FLAIR 0 +) 0 +sequences 0 +frequently 0 +revealed 0 +persistent 0 +white 3 +matter 4 +abnormalities 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Several 0 +pathophysiological 0 +models 0 +of 0 +delayed 0 +leukoencephalopathy 3 +after 0 +exposure 0 +to 0 +intrathecal 0 +or 0 +systemic 0 +chemotherapy 0 +have 0 +been 0 +proposed 0 +. 0 + +DWI 0 +findings 0 +in 0 +this 0 +cohort 0 +are 0 +indicative 0 +of 0 +cytotoxic 3 +oedema 4 +within 4 +cerebral 4 +white 4 +matter 4 +and 0 +lend 0 +support 0 +to 0 +an 0 +at 0 +least 0 +partially 0 +reversible 0 +metabolic 0 +derangement 0 +as 0 +the 0 +basis 0 +for 0 +this 0 +syndrome 0 +. 0 + +Prenatal 0 +exposure 0 +to 0 +fluoxetine 1 +induces 0 +fetal 3 +pulmonary 4 +hypertension 4 +in 0 +the 0 +rat 0 +. 0 + +RATI0NALE 0 +: 0 +Fluoxetine 1 +is 0 +a 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitor 0 +antidepressant 0 +widely 0 +used 0 +by 0 +pregnant 0 +women 0 +. 0 + +Epidemiological 0 +data 0 +suggest 0 +that 0 +fluoxetine 1 +exposure 0 +prenatally 0 +increases 0 +the 0 +prevalence 0 +of 0 +persistent 0 +pulmonary 3 +hypertension 4 +syndrome 4 +of 0 +the 0 +newborn 0 +. 0 + +The 0 +mechanism 0 +responsible 0 +for 0 +this 0 +effect 0 +is 0 +unclear 0 +and 0 +paradoxical 0 +, 0 +considering 0 +the 0 +current 0 +evidence 0 +of 0 +a 0 +pulmonary 3 +hypertension 4 +protective 0 +fluoxetine 1 +effect 0 +in 0 +adult 0 +rodents 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +evaluate 0 +the 0 +fluoxetine 1 +effect 0 +on 0 +fetal 0 +rat 0 +pulmonary 0 +vascular 0 +smooth 0 +muscle 0 +mechanical 0 +properties 0 +and 0 +cell 0 +proliferation 0 +rate 0 +. 0 + +METH0DS 0 +: 0 +Pregnant 0 +rats 0 +were 0 +treated 0 +with 0 +fluoxetine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +from 0 +Day 0 +11 0 +through 0 +Day 0 +21 0 +of 0 +gestation 0 +. 0 + +MEASUREMENTS 0 +AND 0 +MAIN 0 +RESULTS 0 +: 0 +Fetuses 0 +were 0 +delivered 0 +by 0 +cesarean 0 +section 0 +. 0 + +As 0 +compared 0 +with 0 +controls 0 +, 0 +fluoxetine 1 +exposure 0 +resulted 0 +in 0 +fetal 3 +pulmonary 4 +hypertension 4 +as 0 +evidenced 0 +by 0 +an 0 +increase 0 +in 0 +the 0 +weight 0 +ratio 0 +of 0 +the 0 +right 0 +ventricle 0 +to 0 +the 0 +left 0 +ventricle 0 +plus 0 +septum 0 +( 0 +P 0 += 0 +0 0 +. 0 +02 0 +) 0 +and 0 +by 0 +an 0 +increase 0 +in 0 +pulmonary 0 +arterial 0 +medial 0 +thickness 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Postnatal 0 +mortality 0 +was 0 +increased 0 +among 0 +experimental 0 +animals 0 +, 0 +and 0 +arterial 0 +oxygen 1 +saturation 0 +was 0 +96 0 ++ 0 +/ 0 +- 0 +1 0 +% 0 +in 0 +1 0 +- 0 +day 0 +- 0 +old 0 +control 0 +animals 0 +and 0 +significantly 0 +lower 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +in 0 +fluoxetine 1 +- 0 +exposed 0 +pups 0 +( 0 +79 0 ++ 0 +/ 0 +- 0 +2 0 +% 0 +) 0 +. 0 + +In 0 +vitro 0 +, 0 +fluoxetine 1 +induced 0 +pulmonary 0 +arterial 0 +muscle 0 +contraction 0 +in 0 +fetal 0 +, 0 +but 0 +not 0 +adult 0 +, 0 +animals 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +and 0 +reduced 0 +serotonin 1 +- 0 +induced 0 +contraction 0 +at 0 +both 0 +ages 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +After 0 +in 0 +utero 0 +exposure 0 +to 0 +a 0 +low 0 +fluoxetine 1 +concentration 0 +the 0 +pulmonary 0 +arterial 0 +smooth 0 +muscle 0 +cell 0 +proliferation 0 +rate 0 +was 0 +significantly 0 +increased 0 +in 0 +fetal 0 +, 0 +but 0 +not 0 +adult 0 +, 0 +cells 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +contrast 0 +to 0 +the 0 +adult 0 +, 0 +fluoxetine 1 +exposure 0 +in 0 +utero 0 +induces 0 +pulmonary 3 +hypertension 4 +in 0 +the 0 +fetal 0 +rat 0 +as 0 +a 0 +result 0 +of 0 +a 0 +developmentally 0 +regulated 0 +increase 0 +in 0 +pulmonary 0 +vascular 0 +smooth 0 +muscle 0 +proliferation 0 +. 0 + +Disulfiram 1 +- 0 +induced 0 +transient 0 +optic 3 +and 4 +peripheral 4 +neuropathy 4 +: 0 +a 0 +case 0 +report 0 +. 0 + +AIM 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +optic 3 +and 4 +peripheral 4 +neuropathy 4 +after 0 +chronic 0 +use 0 +of 0 +disulfiram 1 +for 0 +alcohol 3 +dependence 4 +management 0 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +A 0 +case 0 +report 0 +. 0 + +RESULTS 0 +: 0 +A 0 +57 0 +- 0 +year 0 +- 0 +old 0 +male 0 +presented 0 +with 0 +gradual 0 +loss 3 +of 4 +vision 4 +in 0 +both 0 +eyes 0 +with 0 +intermittent 0 +headaches 3 +for 0 +2 0 +months 0 +. 0 + +He 0 +also 0 +complained 0 +of 0 +paraesthesia 3 +with 0 +numbness 3 +in 0 +both 0 +feet 0 +. 0 + +His 0 +vision 0 +was 0 +6 0 +/ 0 +15 0 +and 0 +2 0 +/ 0 +60 0 +in 0 +the 0 +right 0 +and 0 +left 0 +eyes 0 +, 0 +respectively 0 +. 0 + +Fundoscopy 0 +revealed 0 +bilaterally 0 +swollen 0 +optic 0 +nerve 0 +heads 0 +. 0 + +Visual 0 +field 0 +testing 0 +confirmed 0 +bilateral 0 +central 0 +- 0 +caecal 0 +scotomata 3 +. 0 + +He 0 +had 0 +been 0 +taking 0 +disulfiram 1 +for 0 +alcohol 3 +dependence 4 +for 0 +the 0 +preceding 0 +3 0 +years 0 +. 0 + +Disulfiram 1 +discontinuation 0 +lead 0 +to 0 +an 0 +immediate 0 +symptomatic 0 +improvement 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Physicians 0 +initiating 0 +long 0 +- 0 +term 0 +disulfiram 1 +therapy 0 +should 0 +be 0 +aware 0 +of 0 +these 0 +adverse 0 +effects 0 +. 0 + +They 0 +should 0 +recommend 0 +annual 0 +ophthalmic 0 +reviews 0 +with 0 +visual 0 +field 0 +testing 0 +. 0 + +Patients 0 +should 0 +be 0 +reassured 0 +with 0 +respect 0 +to 0 +the 0 +reversibility 0 +of 0 +these 0 +adverse 0 +effects 0 +. 0 + +Intraocular 0 +pressure 0 +in 0 +patients 0 +with 0 +uveitis 3 +treated 0 +with 0 +fluocinolone 1 +acetonide 2 +implants 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +the 0 +incidence 0 +and 0 +management 0 +of 0 +elevated 3 +intraocular 4 +pressure 4 +( 0 +I0P 0 +) 0 +in 0 +patients 0 +with 0 +uveitis 3 +treated 0 +with 0 +the 0 +fluocinolone 1 +acetonide 2 +( 0 +FA 1 +) 0 +intravitreal 0 +implant 0 +. 0 + +DESIGN 0 +: 0 +Pooled 0 +data 0 +from 0 +3 0 +multicenter 0 +, 0 +double 0 +- 0 +masked 0 +, 0 +randomized 0 +, 0 +controlled 0 +, 0 +phase 0 +2b 0 +/ 0 +3 0 +clinical 0 +trials 0 +evaluating 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +the 0 +0 0 +. 0 +59 0 +- 0 +mg 0 +or 0 +2 0 +. 0 +1 0 +- 0 +mg 0 +FA 1 +intravitreal 0 +implant 0 +or 0 +standard 0 +therapy 0 +were 0 +analyzed 0 +. 0 + +RESULTS 0 +: 0 +During 0 +the 0 +3 0 +- 0 +year 0 +follow 0 +- 0 +up 0 +, 0 +71 0 +. 0 +0 0 +% 0 +of 0 +implanted 0 +eyes 0 +had 0 +an 0 +I0P 0 +increase 0 +of 0 +10 0 +mm 0 +Hg 0 +or 0 +more 0 +than 0 +baseline 0 +and 0 +55 0 +. 0 +1 0 +% 0 +, 0 +24 0 +. 0 +7 0 +% 0 +, 0 +and 0 +6 0 +. 0 +2 0 +% 0 +of 0 +eyes 0 +reached 0 +an 0 +I0P 0 +of 0 +30 0 +mm 0 +Hg 0 +or 0 +more 0 +, 0 +40 0 +mm 0 +Hg 0 +or 0 +more 0 +, 0 +and 0 +50 0 +mm 0 +Hg 0 +or 0 +more 0 +, 0 +respectively 0 +. 0 + +Topical 0 +I0P 0 +- 0 +lowering 0 +medication 0 +was 0 +administered 0 +in 0 +74 0 +. 0 +8 0 +% 0 +of 0 +implanted 0 +eyes 0 +, 0 +and 0 +I0P 0 +- 0 +lowering 0 +surgeries 0 +, 0 +most 0 +of 0 +which 0 +were 0 +trabeculectomies 0 +( 0 +76 0 +. 0 +2 0 +% 0 +) 0 +, 0 +were 0 +performed 0 +on 0 +36 0 +. 0 +6 0 +% 0 +of 0 +implanted 0 +eyes 0 +. 0 + +Intraocular 0 +pressure 0 +- 0 +lowering 0 +surgeries 0 +were 0 +considered 0 +a 0 +success 0 +( 0 +postoperative 0 +I0P 0 +of 0 +6 0 +- 0 +21 0 +mm 0 +Hg 0 +with 0 +or 0 +without 0 +additional 0 +I0P 0 +- 0 +lowering 0 +medication 0 +) 0 +in 0 +85 0 +. 0 +1 0 +% 0 +of 0 +eyes 0 +at 0 +1 0 +year 0 +. 0 + +The 0 +rate 0 +of 0 +hypotony 3 +( 0 +I0P 0 +< 0 +/ 0 += 0 +5 0 +mm 0 +Hg 0 +) 0 +following 0 +I0P 0 +- 0 +lowering 0 +surgery 0 +( 0 +42 0 +. 0 +5 0 +% 0 +) 0 +was 0 +not 0 +different 0 +from 0 +that 0 +of 0 +implanted 0 +eyes 0 +not 0 +subjected 0 +to 0 +surgery 0 +( 0 +35 0 +. 0 +4 0 +% 0 +) 0 +( 0 +P 0 += 0 +. 0 +09 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Elevated 0 +I0P 0 +is 0 +a 0 +significant 0 +complication 0 +with 0 +the 0 +FA 0 +intravitreal 0 +implant 0 +but 0 +may 0 +be 0 +controlled 0 +with 0 +medication 0 +and 0 +surgery 0 +. 0 + +Myocardial 0 +Fas 0 +ligand 0 +expression 0 +increases 0 +susceptibility 0 +to 0 +AZT 1 +- 0 +induced 0 +cardiomyopathy 3 +. 0 + +BACKGR0UND 0 +: 0 +Dilated 3 +cardiomyopathy 4 +( 0 +DCM 3 +) 0 +and 0 +myocarditis 3 +occur 0 +in 0 +many 0 +HIV 3 +- 4 +infected 4 +individuals 0 +, 0 +resulting 0 +in 0 +symptomatic 0 +heart 3 +failure 4 +in 0 +up 0 +to 0 +5 0 +% 0 +of 0 +patients 0 +. 0 + +Highly 0 +active 0 +antiretroviral 0 +therapy 0 +( 0 +HAART 0 +) 0 +has 0 +significantly 0 +reduced 0 +morbidity 0 +and 0 +mortality 0 +of 0 +acquired 3 +immunodeficiency 4 +syndrome 4 +( 0 +AIDS 3 +) 0 +, 0 +but 0 +has 0 +resulted 0 +in 0 +an 0 +increase 0 +in 0 +cardiac 3 +and 4 +skeletal 4 +myopathies 4 +. 0 + +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +In 0 +order 0 +to 0 +investigate 0 +whether 0 +the 0 +HAART 0 +component 0 +zidovudine 1 +( 0 +3 1 +' 2 +- 2 +azido 2 +- 2 +2 2 +' 2 +, 2 +3 2 +' 2 +- 2 +deoxythymidine 2 +; 0 +AZT 1 +) 0 +triggers 0 +the 0 +Fas 0 +- 0 +dependent 0 +cell 0 +- 0 +death 0 +pathway 0 +and 0 +cause 0 +cytoskeletal 0 +disruption 0 +in 0 +a 0 +murine 0 +model 0 +of 0 +DCM 3 +, 0 +8 0 +- 0 +week 0 +- 0 +old 0 +transgenic 0 +( 0 +expressing 0 +Fas 0 +ligand 0 +in 0 +the 0 +myocardium 0 +: 0 +FasL 0 +Tg 0 +) 0 +and 0 +non 0 +- 0 +transgenic 0 +( 0 +NTg 0 +) 0 +mice 0 +received 0 +water 0 +ad 0 +libitum 0 +containing 0 +different 0 +concentrations 0 +of 0 +AZT 1 +( 0 +0 0 +, 0 +0 0 +. 0 +07 0 +, 0 +0 0 +. 0 +2 0 +, 0 +and 0 +0 0 +. 0 +7 0 +mg 0 +/ 0 +ml 0 +) 0 +. 0 + +After 0 +6 0 +weeks 0 +, 0 +cardiac 0 +function 0 +was 0 +assessed 0 +by 0 +echocardiography 0 +and 0 +morphology 0 +was 0 +assessed 0 +by 0 +histopathologic 0 +and 0 +immunohistochemical 0 +methods 0 +. 0 + +NTg 0 +and 0 +untreated 0 +FasL 0 +Tg 0 +mice 0 +showed 0 +little 0 +or 0 +no 0 +change 0 +in 0 +cardiac 0 +structure 0 +or 0 +function 0 +. 0 + +In 0 +contrast 0 +, 0 +AZT 1 +- 0 +treated 0 +FasL 0 +Tg 0 +mice 0 +developed 0 +cardiac 3 +dilation 4 +and 0 +depressed 0 +cardiac 0 +function 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +, 0 +with 0 +concomitant 0 +inflammatory 0 +infiltration 0 +of 0 +both 0 +ventricles 0 +. 0 + +These 0 +changes 0 +were 0 +associated 0 +with 0 +an 0 +increased 0 +sarcolemmal 0 +expression 0 +of 0 +Fas 0 +and 0 +FasL 0 +, 0 +as 0 +well 0 +as 0 +increased 0 +activation 0 +of 0 +caspase 0 +3 0 +, 0 +translocation 0 +of 0 +calpain 0 +1 0 +to 0 +the 0 +sarcolemma 0 +and 0 +sarcomere 0 +, 0 +and 0 +increased 0 +numbers 0 +of 0 +cells 0 +undergoing 0 +apoptosis 0 +. 0 + +These 0 +were 0 +associated 0 +with 0 +changes 0 +in 0 +dystrophin 0 +and 0 +cardiac 0 +troponin 0 +I 0 +localization 0 +, 0 +as 0 +well 0 +as 0 +loss 0 +of 0 +sarcolemmal 0 +integrity 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +expression 0 +of 0 +Fas 0 +ligand 0 +in 0 +the 0 +myocardium 0 +, 0 +as 0 +identified 0 +in 0 +HIV 0 +- 0 +positive 0 +patients 0 +, 0 +might 0 +increase 0 +the 0 +susceptibility 0 +to 0 +HAART 0 +- 0 +induced 0 +cardiomyopathy 3 +due 0 +to 0 +activation 0 +of 0 +apoptotic 0 +pathways 0 +, 0 +resulting 0 +in 0 +cardiac 3 +dilation 4 +and 4 +dysfunction 4 +. 0 + +Gastrointestinal 0 +tolerability 0 +of 0 +etoricoxib 1 +in 0 +rheumatoid 3 +arthritis 4 +patients 0 +: 0 +results 0 +of 0 +the 0 +etoricoxib 1 +vs 0 +diclofenac 1 +sodium 2 +gastrointestinal 0 +tolerability 0 +and 0 +effectiveness 0 +trial 0 +( 0 +EDGE 0 +- 0 +II 0 +) 0 +. 0 + +0BJECTIVE 0 +: 0 +A 0 +randomised 0 +, 0 +double 0 +- 0 +blind 0 +study 0 +to 0 +compare 0 +the 0 +gastrointestinal 0 +( 0 +GI 0 +) 0 +tolerability 0 +, 0 +safety 0 +and 0 +efficacy 0 +of 0 +etoricoxib 1 +and 0 +diclofenac 1 +in 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +( 0 +RA 3 +) 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +A 0 +total 0 +of 0 +4086 0 +patients 0 +( 0 +mean 0 +age 0 +60 0 +. 0 +8 0 +years 0 +) 0 +diagnosed 0 +with 0 +RA 3 +were 0 +enrolled 0 +and 0 +received 0 +etoricoxib 1 +90 0 +mg 0 +daily 0 +( 0 +n 0 += 0 +2032 0 +) 0 +or 0 +diclofenac 1 +75 0 +mg 0 +twice 0 +daily 0 +( 0 +n 0 += 0 +2054 0 +) 0 +. 0 + +Use 0 +of 0 +gastroprotective 0 +agents 0 +and 0 +low 0 +- 0 +dose 0 +aspirin 1 +was 0 +allowed 0 +. 0 + +The 0 +prespecified 0 +primary 0 +end 0 +point 0 +consisted 0 +of 0 +the 0 +cumulative 0 +rate 0 +of 0 +patient 0 +discontinuations 0 +due 0 +to 0 +clinical 0 +and 0 +laboratory 0 +GI 0 +adverse 0 +experiences 0 +( 0 +AEs 0 +) 0 +. 0 + +General 0 +safety 0 +was 0 +also 0 +assessed 0 +, 0 +including 0 +adjudicated 0 +thrombotic 3 +cardiovascular 4 +event 0 +data 0 +. 0 + +Efficacy 0 +was 0 +evaluated 0 +using 0 +the 0 +Patient 0 +Global 0 +Assessment 0 +of 0 +Disease 0 +Status 0 +( 0 +PGADS 0 +; 0 +0 0 +- 0 +4 0 +point 0 +scale 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Mean 0 +( 0 +SD 0 +; 0 +maximum 0 +) 0 +duration 0 +of 0 +treatment 0 +was 0 +19 0 +. 0 +3 0 +( 0 +10 0 +. 0 +3 0 +; 0 +32 0 +. 0 +9 0 +) 0 +and 0 +19 0 +. 0 +1 0 +( 0 +10 0 +. 0 +4 0 +; 0 +33 0 +. 0 +1 0 +) 0 +months 0 +in 0 +the 0 +etoricoxib 1 +and 0 +diclofenac 1 +groups 0 +, 0 +respectively 0 +. 0 + +The 0 +cumulative 0 +discontinuation 0 +rate 0 +due 0 +to 0 +GI 3 +AEs 4 +was 0 +significantly 0 +lower 0 +with 0 +etoricoxib 1 +than 0 +diclofenac 1 +( 0 +5 0 +. 0 +2 0 +vs 0 +8 0 +. 0 +5 0 +events 0 +per 0 +100 0 +patient 0 +- 0 +years 0 +, 0 +respectively 0 +; 0 +hazard 0 +ratio 0 +0 0 +. 0 +62 0 +( 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +47 0 +, 0 +0 0 +. 0 +81 0 +; 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +001 0 +) 0 +) 0 +. 0 + +The 0 +incidence 0 +of 0 +discontinuations 0 +for 0 +hypertension 3 +- 0 +related 0 +and 0 +oedema 3 +- 0 +related 0 +AEs 0 +were 0 +significantly 0 +higher 0 +with 0 +etoricoxib 1 +( 0 +2 0 +. 0 +5 0 +% 0 +and 0 +1 0 +. 0 +1 0 +% 0 +respectively 0 +) 0 +compared 0 +with 0 +diclofenac 1 +( 0 +1 0 +. 0 +5 0 +% 0 +and 0 +0 0 +. 0 +4 0 +% 0 +respectively 0 +; 0 +p 0 +< 0 +0 0 +. 0 +001 0 +for 0 +hypertension 3 +and 0 +p 0 +< 0 +0 0 +. 0 +01 0 +for 0 +oedema 3 +) 0 +. 0 + +Etoricoxib 1 +and 0 +diclofenac 1 +treatment 0 +resulted 0 +in 0 +similar 0 +efficacy 0 +( 0 +PGADS 0 +mean 0 +changes 0 +from 0 +baseline 0 +- 0 +0 0 +. 0 +62 0 +vs 0 +- 0 +0 0 +. 0 +58 0 +, 0 +respectively 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Etoricoxib 1 +90 0 +mg 0 +demonstrated 0 +a 0 +significantly 0 +lower 0 +risk 0 +for 0 +discontinuing 0 +treatment 0 +due 0 +to 0 +GI 3 +AEs 4 +compared 0 +with 0 +diclofenac 1 +150 0 +mg 0 +. 0 + +Discontinuations 0 +from 0 +renovascular 0 +AEs 0 +, 0 +although 0 +less 0 +common 0 +than 0 +discontinuations 0 +from 0 +GI 3 +AEs 4 +, 0 +were 0 +significantly 0 +higher 0 +with 0 +etoricoxib 1 +. 0 + +Anxiogenic 0 +potential 0 +of 0 +ciprofloxacin 1 +and 0 +norfloxacin 1 +in 0 +rats 0 +. 0 + +INTR0DUCTI0N 0 +: 0 +The 0 +possible 0 +anxiogenic 0 +effects 0 +of 0 +fluoroquinolones 1 +, 0 +namely 0 +ciprofloxacin 1 +and 0 +norfloxacin 1 +, 0 +were 0 +investigated 0 +in 0 +adult 0 +Charles 0 +Foster 0 +albino 0 +rats 0 +of 0 +either 0 +sex 0 +, 0 +weighing 0 +150 0 +- 0 +200 0 +g 0 +. 0 + +METH0DS 0 +: 0 +The 0 +drugs 0 +were 0 +given 0 +orally 0 +, 0 +in 0 +doses 0 +of 0 +50 0 +mg 0 +/ 0 +kg 0 +for 0 +five 0 +consecutive 0 +days 0 +and 0 +the 0 +experiments 0 +were 0 +performed 0 +on 0 +the 0 +fifth 0 +day 0 +. 0 + +The 0 +tests 0 +included 0 +open 0 +- 0 +field 0 +exploratory 0 +behaviour 0 +, 0 +elevated 0 +plus 0 +maze 0 +and 0 +elevated 0 +zero 0 +maze 0 +, 0 +social 0 +interaction 0 +and 0 +novelty 0 +- 0 +suppressed 0 +feeding 0 +latency 0 +behaviour 0 +. 0 + +RESULTS 0 +: 0 +The 0 +results 0 +indicate 0 +that 0 +ciprofloxacin 1 +- 0 +and 0 +norfloxacin 1 +- 0 +treated 0 +rats 0 +showed 0 +anxious 3 +behaviour 4 +in 0 +comparison 0 +to 0 +control 0 +rats 0 +in 0 +all 0 +the 0 +parameters 0 +studied 0 +. 0 + +However 0 +, 0 +ciprofloxacin 1 +- 0 +and 0 +norfloxacin 1 +- 0 +treated 0 +rats 0 +did 0 +not 0 +differ 0 +significantly 0 +from 0 +each 0 +other 0 +in 0 +various 0 +behavioural 0 +parameters 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +present 0 +experimental 0 +findings 0 +substantiate 0 +the 0 +clinically 0 +observed 0 +anxiogenic 0 +potential 0 +of 0 +ciprofloxacin 1 +and 0 +norfloxacin 1 +. 0 + +Reduction 0 +of 0 +pain 3 +during 0 +induction 0 +with 0 +target 0 +- 0 +controlled 0 +propofol 1 +and 0 +remifentanil 1 +. 0 + +BACKGR0UND 0 +: 0 +Pain 3 +on 0 +injection 0 +of 0 +propofol 1 +is 0 +unpleasant 0 +. 0 + +We 0 +hypothesized 0 +that 0 +propofol 1 +infusion 0 +pain 3 +might 0 +be 0 +prevented 0 +by 0 +infusing 0 +remifentanil 1 +before 0 +starting 0 +the 0 +propofol 1 +infusion 0 +in 0 +a 0 +clinical 0 +setting 0 +where 0 +target 0 +- 0 +controlled 0 +infusions 0 +( 0 +TCI 0 +) 0 +of 0 +both 0 +drugs 0 +were 0 +used 0 +. 0 + +A 0 +prospective 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +trial 0 +was 0 +performed 0 +to 0 +determine 0 +the 0 +effect 0 +- 0 +site 0 +concentration 0 +( 0 +Ce 0 +) 0 +of 0 +remifentanil 1 +to 0 +prevent 0 +the 0 +pain 3 +without 0 +producing 0 +complications 0 +. 0 + +METH0DS 0 +: 0 +A 0 +total 0 +of 0 +128 0 +patients 0 +undergoing 0 +general 0 +surgery 0 +were 0 +randomly 0 +allocated 0 +to 0 +receive 0 +normal 0 +saline 0 +( 0 +control 0 +) 0 +or 0 +remifentanil 1 +to 0 +a 0 +target 0 +Ce 0 +of 0 +2 0 +ng 0 +ml 0 +( 0 +- 0 +1 0 +) 0 +( 0 +R2 0 +) 0 +, 0 +4 0 +ng 0 +ml 0 +( 0 +- 0 +1 0 +) 0 +( 0 +R4 0 +) 0 +, 0 +or 0 +6 0 +ng 0 +ml 0 +( 0 +- 0 +1 0 +) 0 +( 0 +R6 0 +) 0 +administered 0 +via 0 +TCI 0 +. 0 + +After 0 +the 0 +target 0 +Ce 0 +was 0 +achieved 0 +, 0 +the 0 +infusion 0 +of 0 +propofol 1 +was 0 +started 0 +. 0 + +Remifentanil 1 +- 0 +related 0 +complications 0 +were 0 +assessed 0 +during 0 +the 0 +remifentanil 1 +infusion 0 +, 0 +and 0 +pain 3 +caused 0 +by 0 +propofol 1 +was 0 +evaluated 0 +using 0 +a 0 +four 0 +- 0 +point 0 +scale 0 +during 0 +the 0 +propofol 1 +infusion 0 +. 0 + +RESULTS 0 +: 0 +The 0 +incidence 0 +of 0 +pain 3 +was 0 +significantly 0 +lower 0 +in 0 +Groups 0 +R4 0 +and 0 +R6 0 +than 0 +in 0 +the 0 +control 0 +and 0 +R2 0 +groups 0 +( 0 +12 0 +/ 0 +32 0 +and 0 +6 0 +/ 0 +31 0 +vs 0 +26 0 +/ 0 +31 0 +and 0 +25 0 +/ 0 +32 0 +, 0 +respectively 0 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Pain 3 +was 0 +less 0 +severe 0 +in 0 +Groups 0 +R4 0 +and 0 +R6 0 +than 0 +in 0 +the 0 +control 0 +and 0 +R2 0 +groups 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +However 0 +, 0 +both 0 +incidence 0 +and 0 +severity 0 +of 0 +pain 3 +were 0 +not 0 +different 0 +between 0 +Groups 0 +R4 0 +and 0 +R6 0 +. 0 + +No 0 +significant 0 +complications 0 +were 0 +observed 0 +during 0 +the 0 +study 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +During 0 +induction 0 +of 0 +anaesthesia 0 +with 0 +TCI 0 +of 0 +propofol 1 +and 0 +remifentanil 1 +, 0 +a 0 +significant 0 +reduction 0 +in 0 +propofol 1 +infusion 0 +pain 3 +was 0 +achieved 0 +without 0 +significant 0 +complications 0 +by 0 +prior 0 +administration 0 +of 0 +remifentanil 1 +at 0 +a 0 +target 0 +Ce 0 +of 0 +4 0 +ng 0 +ml 0 +( 0 +- 0 +1 0 +) 0 +. 0 + +Dexmedetomidine 1 +and 0 +cardiac 0 +protection 0 +for 0 +non 0 +- 0 +cardiac 0 +surgery 0 +: 0 +a 0 +meta 0 +- 0 +analysis 0 +of 0 +randomised 0 +controlled 0 +trials 0 +. 0 + +We 0 +conducted 0 +a 0 +systematic 0 +review 0 +of 0 +the 0 +effects 0 +of 0 +dexmedetomidine 1 +on 0 +cardiac 0 +outcomes 0 +following 0 +non 0 +- 0 +cardiac 0 +surgery 0 +. 0 + +We 0 +included 0 +prospective 0 +, 0 +randomised 0 +peri 0 +- 0 +operative 0 +studies 0 +of 0 +dexmedetomidine 1 +that 0 +reported 0 +mortality 0 +, 0 +cardiac 0 +morbidity 0 +or 0 +adverse 0 +drug 0 +events 0 +. 0 + +A 0 +PubMed 0 +Central 0 +and 0 +EMBASE 0 +search 0 +was 0 +conducted 0 +up 0 +to 0 +July 0 +2007 0 +. 0 + +The 0 +reference 0 +lists 0 +of 0 +identified 0 +papers 0 +were 0 +examined 0 +for 0 +further 0 +trials 0 +. 0 + +0f 0 +425 0 +studies 0 +identified 0 +, 0 +20 0 +were 0 +included 0 +in 0 +the 0 +meta 0 +- 0 +analysis 0 +( 0 +840 0 +patients 0 +) 0 +. 0 + +Dexmedetomidine 1 +was 0 +associated 0 +with 0 +a 0 +trend 0 +towards 0 +improved 0 +cardiac 0 +outcomes 0 +; 0 +all 0 +- 0 +cause 0 +mortality 0 +( 0 +0R 0 +0 0 +. 0 +27 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +01 0 +- 0 +7 0 +. 0 +13 0 +, 0 +p 0 += 0 +0 0 +. 0 +44 0 +) 0 +, 0 +non 0 +- 0 +fatal 0 +myocardial 3 +infarction 4 +( 0 +0R 0 +0 0 +. 0 +26 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +04 0 +- 0 +1 0 +. 0 +60 0 +, 0 +p 0 += 0 +0 0 +. 0 +14 0 +) 0 +, 0 +and 0 +myocardial 3 +ischaemia 4 +( 0 +0R 0 +0 0 +. 0 +65 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +26 0 +- 0 +1 0 +. 0 +63 0 +, 0 +p 0 += 0 +0 0 +. 0 +36 0 +) 0 +. 0 + +Peri 0 +- 0 +operative 0 +hypotension 3 +( 0 +26 0 +% 0 +, 0 +0R 0 +3 0 +. 0 +80 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +91 0 +- 0 +7 0 +. 0 +54 0 +, 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +and 0 +bradycardia 3 +( 0 +17 0 +% 0 +, 0 +0R 0 +5 0 +. 0 +45 0 +, 0 +95 0 +% 0 +CI 0 +2 0 +. 0 +98 0 +- 0 +9 0 +. 0 +95 0 +, 0 +p 0 +< 0 +0 0 +. 0 +00001 0 +) 0 +were 0 +significantly 0 +increased 0 +. 0 + +An 0 +anticholinergic 0 +did 0 +not 0 +reduce 0 +the 0 +incidence 0 +of 0 +bradycardia 3 +( 0 +p 0 += 0 +0 0 +. 0 +43 0 +) 0 +. 0 + +A 0 +randomised 0 +placebo 0 +- 0 +controlled 0 +trial 0 +of 0 +dexmedetomidine 1 +is 0 +warranted 0 +. 0 + +Myocardial 3 +infarction 4 +in 0 +pregnancy 0 +associated 0 +with 0 +clomiphene 1 +citrate 2 +for 0 +ovulation 0 +induction 0 +: 0 +a 0 +case 0 +report 0 +. 0 + +BACKGR0UND 0 +: 0 +Clomiphene 1 +citrate 2 +( 0 +CC 1 +) 0 +is 0 +commonly 0 +prescribed 0 +for 0 +ovulation 0 +induction 0 +. 0 + +It 0 +is 0 +considered 0 +safe 0 +, 0 +with 0 +minimal 0 +side 0 +effects 0 +. 0 + +Thromboembolism 3 +is 0 +a 0 +rare 0 +but 0 +life 0 +- 0 +threatening 0 +complication 0 +that 0 +has 0 +been 0 +reported 0 +after 0 +ovulation 0 +induction 0 +with 0 +CC 1 +. 0 + +Spontaneous 0 +coronary 3 +thrombosis 4 +or 0 +thromboembolism 3 +with 0 +subsequent 0 +clot 0 +lysis 0 +has 0 +been 0 +suggested 0 +as 0 +one 0 +of 0 +the 0 +most 0 +common 0 +causes 0 +of 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +during 0 +pregnancy 0 +, 0 +with 0 +a 0 +subsequently 0 +normal 0 +coronary 0 +angiogram 0 +. 0 + +CASE 0 +: 0 +A 0 +33 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +a 0 +5 0 +- 0 +week 0 +gestation 0 +had 0 +recently 0 +received 0 +CC 1 +for 0 +ovulation 0 +induction 0 +and 0 +presented 0 +with 0 +chest 3 +pain 4 +. 0 + +An 0 +electrocardiogram 0 +showed 0 +a 0 +lateral 0 +and 0 +anterior 0 +wall 0 +myocardial 3 +infarction 4 +. 0 + +Cardiac 0 +enzymes 0 +showed 0 +a 0 +peak 0 +rise 0 +in 0 +troponin 0 +I 0 +to 0 +9 0 +. 0 +10 0 +ng 0 +/ 0 +mL 0 +. 0 + +An 0 +initial 0 +exercise 0 +stress 0 +test 0 +was 0 +normal 0 +. 0 + +At 0 +the 0 +time 0 +of 0 +admission 0 +, 0 +the 0 +patient 0 +was 0 +at 0 +high 0 +risk 0 +of 0 +radiation 3 +injury 4 +to 0 +the 0 +fetus 0 +, 0 +so 0 +a 0 +coronary 0 +angiogram 0 +was 0 +postponed 0 +until 0 +the 0 +second 0 +trimester 0 +. 0 + +It 0 +showed 0 +normal 0 +coronary 0 +vessels 0 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +appears 0 +to 0 +be 0 +the 0 +first 0 +reported 0 +case 0 +documenting 0 +a 0 +possible 0 +association 0 +between 0 +CC 1 +and 0 +myocardial 3 +infarction 4 +. 0 + +Thrombosis 3 +might 0 +be 0 +a 0 +rare 0 +but 0 +hazardous 0 +complication 0 +of 0 +CC 1 +. 0 + +Given 0 +this 0 +life 0 +- 0 +threatening 0 +complication 0 +, 0 +appropriate 0 +prophylactic 0 +measures 0 +should 0 +be 0 +used 0 +in 0 +high 0 +- 0 +risk 0 +woman 0 +undergoing 0 +ovarian 0 +stimulation 0 +. 0 + +Reverse 0 +or 0 +inverted 0 +left 3 +ventricular 4 +apical 4 +ballooning 4 +syndrome 4 +( 0 +reverse 0 +Takotsubo 3 +cardiomyopathy 4 +) 0 +in 0 +a 0 +young 0 +woman 0 +in 0 +the 0 +setting 0 +of 0 +amphetamine 1 +use 0 +. 0 + +Transient 0 +left 3 +ventricular 4 +apical 4 +ballooning 4 +syndrome 4 +was 0 +first 0 +described 0 +in 0 +Japan 0 +as 0 +" 0 +Takotsubo 3 +cardiomyopathy 4 +. 0 +" 0 +This 0 +syndrome 0 +has 0 +been 0 +identified 0 +in 0 +many 0 +other 0 +countries 0 +. 0 + +Many 0 +variations 0 +of 0 +this 0 +syndrome 0 +have 0 +been 0 +recently 0 +described 0 +in 0 +the 0 +literature 0 +. 0 + +0ne 0 +of 0 +the 0 +rarest 0 +is 0 +the 0 +reverse 0 +type 0 +of 0 +this 0 +syndrome 0 +, 0 +with 0 +hyperdynamic 0 +apex 0 +and 0 +complete 0 +akinesia 3 +of 0 +the 0 +base 0 +( 0 +as 0 +opposed 0 +to 0 +the 0 +classic 0 +apical 3 +ballooning 4 +) 0 +. 0 + +In 0 +this 0 +article 0 +, 0 +we 0 +report 0 +an 0 +interesting 0 +case 0 +of 0 +a 0 +young 0 +woman 0 +who 0 +presented 0 +with 0 +this 0 +rare 0 +type 0 +of 0 +reverse 0 +apical 3 +ballooning 4 +syndrome 4 +occurring 0 +after 0 +amphetamine 1 +use 0 +. 0 + +This 0 +report 0 +is 0 +followed 0 +by 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +Results 0 +of 0 +a 0 +comparative 0 +, 0 +phase 0 +III 0 +, 0 +12 0 +- 0 +week 0 +, 0 +multicenter 0 +, 0 +prospective 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +assessment 0 +of 0 +the 0 +efficacy 0 +and 0 +tolerability 0 +of 0 +a 0 +fixed 0 +- 0 +dose 0 +combination 0 +of 0 +telmisartan 1 +and 0 +amlodipine 1 +versus 0 +amlodipine 1 +monotherapy 0 +in 0 +Indian 0 +adults 0 +with 0 +stage 0 +II 0 +hypertension 3 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +efficacy 0 +and 0 +tolerability 0 +of 0 +a 0 +new 0 +fixed 0 +- 0 +dose 0 +combination 0 +( 0 +FDC 0 +) 0 +of 0 +telmisartan 1 +40 0 +mg 0 ++ 0 +amlodipine 1 +5 0 +mg 0 +( 0 +T 0 ++ 0 +A 0 +) 0 +compared 0 +with 0 +amlodipine 1 +5 0 +- 0 +mg 0 +monotherapy 0 +( 0 +A 0 +) 0 +in 0 +adult 0 +Indian 0 +patients 0 +with 0 +stage 0 +II 0 +hypertension 3 +. 0 + +METH0DS 0 +: 0 +This 0 +comparative 0 +, 0 +Phase 0 +III 0 +, 0 +12 0 +- 0 +week 0 +, 0 +multicenter 0 +, 0 +prospective 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +study 0 +was 0 +conducted 0 +in 0 +Indian 0 +patients 0 +aged 0 +18 0 +to 0 +65 0 +years 0 +with 0 +established 0 +stage 0 +II 0 +hypertension 3 +. 0 + +Patients 0 +were 0 +treated 0 +with 0 +oral 0 +FDC 0 +of 0 +T 0 ++ 0 +A 0 +or 0 +A 0 +QD 0 +before 0 +breakfast 0 +for 0 +12 0 +weeks 0 +; 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +and 0 +heart 0 +rate 0 +were 0 +measured 0 +in 0 +the 0 +sitting 0 +position 0 +. 0 + +Primary 0 +efficacy 0 +end 0 +points 0 +were 0 +reduction 0 +in 0 +clinical 0 +systolic 0 +BP 0 +( 0 +SBP 0 +) 0 +/ 0 +diastolic 0 +BP 0 +( 0 +DBP 0 +) 0 +from 0 +baseline 0 +to 0 +study 0 +end 0 +and 0 +number 0 +of 0 +responders 0 +( 0 +ie 0 +, 0 +patients 0 +who 0 +achieved 0 +target 0 +SBP 0 +/ 0 +DBP 0 +< 0 +130 0 +/ 0 +< 0 +80 0 +mm 0 +Hg 0 +) 0 +at 0 +end 0 +of 0 +study 0 +. 0 + +Tolerability 0 +was 0 +assessed 0 +by 0 +treatment 0 +- 0 +emergent 0 +adverse 0 +events 0 +, 0 +identified 0 +using 0 +physical 0 +examination 0 +, 0 +laboratory 0 +analysis 0 +, 0 +and 0 +electrocardiography 0 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +210 0 +patients 0 +were 0 +enrolled 0 +in 0 +the 0 +study 0 +; 0 +203 0 +patients 0 +( 0 +143 0 +men 0 +, 0 +60 0 +women 0 +) 0 +completed 0 +the 0 +study 0 +while 0 +7 0 +were 0 +lost 0 +to 0 +follow 0 +- 0 +up 0 +( 0 +4 0 +patients 0 +in 0 +the 0 +T 0 ++ 0 +A 0 +group 0 +and 0 +3 0 +in 0 +the 0 +A 0 +group 0 +) 0 +and 0 +considered 0 +with 0 +- 0 +drawn 0 +. 0 + +At 0 +study 0 +end 0 +, 0 +statistically 0 +significant 0 +percentage 0 +reductions 0 +from 0 +baseline 0 +within 0 +groups 0 +and 0 +between 0 +groups 0 +were 0 +observed 0 +in 0 +SBP 0 +( 0 +T 0 ++ 0 +A 0 +[ 0 +- 0 +27 0 +. 0 +4 0 +% 0 +] 0 +; 0 +A 0 +[ 0 +- 0 +16 0 +. 0 +6 0 +% 0 +] 0 +) 0 +and 0 +DBP 0 +( 0 +T 0 ++ 0 +A 0 +[ 0 +- 0 +20 0 +. 0 +1 0 +% 0 +] 0 +; 0 +A 0 +[ 0 +- 0 +13 0 +. 0 +3 0 +% 0 +] 0 +) 0 +( 0 +all 0 +, 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Response 0 +rates 0 +were 0 +87 0 +. 0 +3 0 +% 0 +( 0 +89 0 +/ 0 +102 0 +) 0 +in 0 +the 0 +T 0 ++ 0 +A 0 +group 0 +and 0 +69 0 +. 0 +3 0 +% 0 +( 0 +70 0 +/ 0 +101 0 +) 0 +in 0 +the 0 +A 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +prevalences 0 +of 0 +adverse 0 +events 0 +were 0 +not 0 +significantly 0 +different 0 +between 0 +the 0 +2 0 +treatment 0 +groups 0 +( 0 +T 0 ++ 0 +A 0 +, 0 +16 0 +. 0 +0 0 +% 0 +[ 0 +17 0 +/ 0 +106 0 +] 0 +; 0 +A 0 +, 0 +15 0 +. 0 +4 0 +% 0 +[ 0 +16 0 +/ 0 +104 0 +] 0 +) 0 +. 0 + +Peripheral 0 +edema 3 +was 0 +reported 0 +in 0 +8 0 +. 0 +5 0 +% 0 +patients 0 +( 0 +9 0 +/ 0 +106 0 +) 0 +in 0 +the 0 +T 0 ++ 0 +A 0 +group 0 +compared 0 +with 0 +13 0 +. 0 +5 0 +% 0 +( 0 +14 0 +/ 0 +104 0 +) 0 +in 0 +the 0 +A 0 +group 0 +, 0 +and 0 +cough 3 +was 0 +reported 0 +in 0 +3 0 +. 0 +8 0 +% 0 +patients 0 +( 0 +4 0 +/ 0 +106 0 +) 0 +in 0 +the 0 +T 0 ++ 0 +A 0 +group 0 +and 0 +1 0 +. 0 +0 0 +% 0 +( 0 +1 0 +/ 0 +104 0 +) 0 +patients 0 +in 0 +the 0 +A 0 +group 0 +; 0 +these 0 +differences 0 +did 0 +not 0 +reach 0 +statistical 0 +significance 0 +. 0 + +The 0 +incidences 0 +of 0 +headache 3 +, 0 +dizziness 3 +, 0 +and 0 +diarrhea 3 +were 0 +similar 0 +between 0 +the 0 +2 0 +groups 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Among 0 +these 0 +Indian 0 +patients 0 +with 0 +stage 0 +II 0 +hypertension 3 +, 0 +the 0 +FDC 0 +of 0 +T 0 ++ 0 +A 0 +was 0 +found 0 +to 0 +be 0 +significantly 0 +more 0 +effective 0 +, 0 +with 0 +regard 0 +to 0 +BP 0 +reductions 0 +, 0 +than 0 +A 0 +, 0 +and 0 +both 0 +treatments 0 +were 0 +well 0 +tolerated 0 +. 0 + +Increased 0 +mental 3 +slowing 4 +associated 0 +with 0 +the 0 +AP0E 0 +epsilon4 0 +allele 0 +after 0 +trihexyphenidyl 1 +oral 0 +anticholinergic 0 +challenge 0 +in 0 +healthy 0 +elderly 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +objectives 0 +of 0 +this 0 +study 0 +were 0 +to 0 +examine 0 +the 0 +relationship 0 +between 0 +AP0E 0 +epsilon4 0 +and 0 +subjective 0 +effects 0 +of 0 +trihexyphenidyl 1 +on 0 +measures 0 +reflecting 0 +sedation 0 +and 0 +confusion 3 +and 0 +to 0 +investigate 0 +the 0 +relationship 0 +between 0 +trihexyphenidyl 1 +- 0 +induced 0 +subjective 0 +effects 0 +and 0 +objective 0 +memory 0 +performance 0 +. 0 + +METH0DS 0 +: 0 +This 0 +study 0 +comprised 0 +24 0 +cognitively 0 +intact 0 +, 0 +health 0 +elderly 0 +adults 0 +( 0 +12 0 +AP0E 0 +epsilon4 0 +carriers 0 +) 0 +at 0 +an 0 +outpatient 0 +geriatric 0 +psychiatry 0 +research 0 +clinic 0 +. 0 + +This 0 +was 0 +a 0 +randomized 0 +, 0 +double 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +three 0 +- 0 +way 0 +, 0 +crossover 0 +experimental 0 +design 0 +. 0 + +All 0 +participants 0 +received 0 +1 0 +. 0 +0 0 +mg 0 +or 0 +2 0 +. 0 +0 0 +mg 0 +trihexyphenidyl 1 +or 0 +placebo 0 +administered 0 +in 0 +counterbalanced 0 +sequences 0 +over 0 +a 0 +period 0 +of 0 +three 0 +consecutive 0 +weeks 0 +. 0 + +Bond 0 +and 0 +Lader 0 +' 0 +s 0 +visual 0 +analog 0 +scales 0 +and 0 +alternate 0 +versions 0 +of 0 +the 0 +Buschke 0 +Selective 0 +Reminding 0 +Test 0 +were 0 +administered 0 +in 0 +a 0 +repeated 0 +measures 0 +design 0 +at 0 +baseline 0 +, 0 +1 0 +, 0 +2 0 +. 0 +5 0 +, 0 +and 0 +5 0 +hours 0 +postdrug 0 +administration 0 +. 0 + +RESULTS 0 +: 0 +A 0 +2 0 +. 0 +0 0 +- 0 +mg 0 +oral 0 +dose 0 +of 0 +trihexyphenidyl 1 +resulted 0 +in 0 +increased 0 +subjective 0 +ratings 0 +of 0 +mental 3 +slowness 4 +in 0 +carriers 0 +of 0 +the 0 +AP0E 0 +epsilon4 0 +allele 0 +only 0 +. 0 + +Drug 0 +effects 0 +as 0 +determined 0 +by 0 +difference 0 +scores 0 +between 0 +2 0 +. 0 +0 0 +mg 0 +trihexyphenidyl 1 +and 0 +placebo 0 +on 0 +ratings 0 +of 0 +mental 3 +slowness 4 +significantly 0 +correlated 0 +with 0 +total 0 +and 0 +delayed 0 +recall 0 +on 0 +the 0 +Buschke 0 +Selective 0 +Reminding 0 +Test 0 +in 0 +carriers 0 +of 0 +the 0 +AP0E 0 +epsilon4 0 +allele 0 +only 0 +. 0 + +However 0 +, 0 +no 0 +significant 0 +effects 0 +were 0 +found 0 +with 0 +other 0 +visual 0 +analog 0 +scales 0 +reflecting 0 +subjective 0 +sedation 0 +and 0 +clear 0 +- 0 +headedness 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +epsilon4 0 +allele 0 +in 0 +healthy 0 +elderly 0 +was 0 +associated 0 +with 0 +increased 0 +subjective 0 +mental 3 +slowing 4 +after 0 +trihexyphenidyl 1 +anticholinergic 0 +challenge 0 +. 0 + +An 0 +evaluation 0 +of 0 +amikacin 1 +nephrotoxicity 3 +in 0 +the 0 +hematology 0 +/ 0 +oncology 0 +population 0 +. 0 + +Amikacin 1 +is 0 +an 0 +aminoglycoside 1 +commonly 0 +used 0 +to 0 +provide 0 +empirical 0 +double 0 +gram 0 +- 0 +negative 0 +treatment 0 +for 0 +febrile 3 +neutropenia 4 +and 0 +other 0 +suspected 0 +infections 3 +. 0 + +Strategies 0 +of 0 +extended 0 +- 0 +interval 0 +and 0 +conventional 0 +dosing 0 +have 0 +been 0 +utilized 0 +extensively 0 +in 0 +the 0 +general 0 +medical 0 +population 0 +; 0 +however 0 +, 0 +data 0 +are 0 +lacking 0 +to 0 +support 0 +a 0 +dosing 0 +strategy 0 +in 0 +the 0 +hematology 0 +/ 0 +oncology 0 +population 0 +. 0 + +To 0 +evaluate 0 +amikacin 1 +- 0 +associated 0 +nephrotoxicity 3 +in 0 +an 0 +adult 0 +hematology 0 +/ 0 +oncology 0 +population 0 +, 0 +a 0 +prospective 0 +, 0 +randomized 0 +, 0 +open 0 +- 0 +label 0 +trial 0 +was 0 +conducted 0 +at 0 +a 0 +university 0 +- 0 +affiliated 0 +medical 0 +center 0 +. 0 + +Forty 0 +patients 0 +with 0 +a 0 +diagnosis 0 +consistent 0 +with 0 +a 0 +hematologic 3 +/ 4 +oncologic 4 +disorder 4 +that 0 +required 0 +treatment 0 +with 0 +an 0 +aminoglycoside 1 +were 0 +randomized 0 +to 0 +either 0 +conventional 0 +or 0 +extended 0 +- 0 +interval 0 +amikacin 1 +. 0 + +The 0 +occurrence 0 +of 0 +nephrotoxicity 3 +by 0 +means 0 +of 0 +an 0 +increase 0 +in 0 +serum 0 +creatinine 1 +and 0 +evaluation 0 +of 0 +efficacy 0 +via 0 +amikacin 1 +serum 0 +concentrations 0 +with 0 +respective 0 +pathogens 0 +were 0 +assessed 0 +. 0 + +The 0 +occurrence 0 +of 0 +nephrotoxicity 3 +was 0 +similar 0 +between 0 +the 0 +conventional 0 +and 0 +extended 0 +- 0 +interval 0 +groups 0 +, 0 +at 0 +10 0 +% 0 +and 0 +5 0 +% 0 +, 0 +respectively 0 +( 0 +P 0 += 0 +1 0 +. 0 +00 0 +) 0 +. 0 + +Six 0 +patients 0 +in 0 +the 0 +conventional 0 +group 0 +had 0 +a 0 +positive 0 +culture 0 +, 0 +compared 0 +with 0 +none 0 +in 0 +the 0 +extended 0 +- 0 +interval 0 +group 0 +( 0 +P 0 += 0 +0 0 +. 0 +002 0 +) 0 +. 0 + +The 0 +occurrence 0 +of 0 +nephrotoxicity 3 +was 0 +similar 0 +between 0 +the 0 +two 0 +dosing 0 +regimens 0 +, 0 +but 0 +the 0 +distribution 0 +of 0 +risk 0 +factors 0 +was 0 +variable 0 +between 0 +the 0 +two 0 +groups 0 +. 0 + +Efficacy 0 +could 0 +not 0 +be 0 +assessed 0 +. 0 + +High 0 +dose 0 +dexmedetomidine 1 +as 0 +the 0 +sole 0 +sedative 0 +for 0 +pediatric 0 +MRI 0 +. 0 + +0BJECTIVE 0 +: 0 +This 0 +large 0 +- 0 +scale 0 +retrospective 0 +review 0 +evaluates 0 +the 0 +sedation 0 +profile 0 +of 0 +dexmedetomidine 1 +. 0 + +AIM 0 +: 0 +To 0 +determine 0 +the 0 +hemodynamic 0 +responses 0 +, 0 +efficacy 0 +and 0 +adverse 0 +events 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +high 0 +dose 0 +dexmedetomidine 1 +as 0 +the 0 +sole 0 +sedative 0 +for 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +studies 0 +. 0 + +BACKGR0UND 0 +: 0 +Dexmedetomidine 1 +has 0 +been 0 +used 0 +at 0 +our 0 +institution 0 +since 0 +2005 0 +to 0 +provide 0 +sedation 0 +for 0 +pediatric 0 +radiological 0 +imaging 0 +studies 0 +. 0 + +0ver 0 +time 0 +, 0 +an 0 +effective 0 +protocol 0 +utilizing 0 +high 0 +dose 0 +dexmedetomidine 1 +as 0 +the 0 +sole 0 +sedative 0 +agent 0 +has 0 +evolved 0 +. 0 + +METH0DS 0 +/ 0 +MATERIALS 0 +: 0 +As 0 +part 0 +of 0 +the 0 +ongoing 0 +Quality 0 +Assurance 0 +process 0 +, 0 +data 0 +on 0 +all 0 +sedations 0 +are 0 +reviewed 0 +monthly 0 +and 0 +protocols 0 +modified 0 +as 0 +needed 0 +. 0 + +Data 0 +were 0 +analyzed 0 +from 0 +all 0 +747 0 +consecutive 0 +patients 0 +who 0 +received 0 +dexmedetomidine 1 +for 0 +MRI 0 +sedation 0 +from 0 +April 0 +2005 0 +to 0 +April 0 +2007 0 +. 0 + +RESULTS 0 +: 0 +Since 0 +2005 0 +, 0 +the 0 +10 0 +- 0 +min 0 +loading 0 +dose 0 +of 0 +our 0 +dexmedetomidine 1 +protocol 0 +increased 0 +from 0 +2 0 +to 0 +3 0 +microg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +, 0 +and 0 +the 0 +infusion 0 +rate 0 +increased 0 +from 0 +1 0 +to 0 +1 0 +. 0 +5 0 +to 0 +2 0 +microg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +h 0 +( 0 +- 0 +1 0 +) 0 +. 0 + +The 0 +current 0 +sedation 0 +protocol 0 +progressively 0 +increased 0 +the 0 +rate 0 +of 0 +successful 0 +sedation 0 +( 0 +able 0 +to 0 +complete 0 +the 0 +imaging 0 +study 0 +) 0 +when 0 +using 0 +dexmedetomidine 1 +alone 0 +from 0 +91 0 +. 0 +8 0 +% 0 +to 0 +97 0 +. 0 +6 0 +% 0 +( 0 +P 0 += 0 +0 0 +. 0 +009 0 +) 0 +, 0 +reducing 0 +the 0 +requirement 0 +for 0 +adjuvant 0 +pentobarbital 1 +in 0 +the 0 +event 0 +of 0 +sedation 0 +failure 0 +with 0 +dexmedetomidine 1 +alone 0 +and 0 +decreased 0 +the 0 +mean 0 +recovery 0 +time 0 +by 0 +10 0 +min 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Although 0 +dexmedetomidine 1 +sedation 0 +was 0 +associated 0 +with 0 +a 0 +16 0 +% 0 +incidence 0 +of 0 +bradycardia 3 +, 0 +all 0 +concomitant 0 +mean 0 +arterial 0 +blood 0 +pressures 0 +were 0 +within 0 +20 0 +% 0 +of 0 +age 0 +- 0 +adjusted 0 +normal 0 +range 0 +and 0 +oxygen 1 +saturations 0 +were 0 +95 0 +% 0 +or 0 +higher 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Dexmedetomidine 1 +in 0 +high 0 +doses 0 +provides 0 +adequate 0 +sedation 0 +for 0 +pediatric 0 +MRI 0 +studies 0 +. 0 + +While 0 +use 0 +of 0 +high 0 +dose 0 +dexmedetomidine 1 +is 0 +associated 0 +with 0 +decreases 0 +in 0 +heart 0 +rate 0 +and 0 +blood 0 +pressure 0 +outside 0 +the 0 +established 0 +' 0 +awake 0 +' 0 +norms 0 +, 0 +this 0 +deviation 0 +is 0 +generally 0 +within 0 +20 0 +% 0 +of 0 +norms 0 +, 0 +and 0 +is 0 +not 0 +associated 0 +with 0 +adverse 0 +sequelae 0 +. 0 + +Dexmedetomidine 1 +is 0 +useful 0 +as 0 +the 0 +sole 0 +sedative 0 +for 0 +pediatric 0 +MRI 0 +. 0 + +Hepatotoxicity 3 +associated 0 +with 0 +sulfasalazine 1 +in 0 +inflammatory 0 +arthritis 3 +: 0 +A 0 +case 0 +series 0 +from 0 +a 0 +local 0 +surveillance 0 +of 0 +serious 0 +adverse 0 +events 0 +. 0 + +BACKGR0UND 0 +: 0 +Spontaneous 0 +reporting 0 +systems 0 +for 0 +adverse 0 +drug 0 +reactions 0 +( 0 +ADRs 0 +) 0 +are 0 +handicapped 0 +by 0 +under 0 +- 0 +reporting 0 +and 0 +limited 0 +detail 0 +on 0 +individual 0 +cases 0 +. 0 + +We 0 +report 0 +an 0 +investigation 0 +from 0 +a 0 +local 0 +surveillance 0 +for 0 +serious 0 +adverse 0 +drug 0 +reactions 0 +associated 0 +with 0 +disease 0 +modifying 0 +anti 0 +- 0 +rheumatic 0 +drugs 0 +that 0 +was 0 +triggered 0 +by 0 +the 0 +occurrence 0 +of 0 +liver 3 +failure 4 +in 0 +two 0 +of 0 +our 0 +patients 0 +. 0 + +METH0DS 0 +: 0 +Serious 0 +ADR 0 +reports 0 +have 0 +been 0 +solicited 0 +from 0 +local 0 +clinicians 0 +by 0 +regular 0 +postcards 0 +over 0 +the 0 +past 0 +seven 0 +years 0 +. 0 + +Patients 0 +' 0 +, 0 +who 0 +had 0 +hepatotoxicity 3 +on 0 +sulfasalazine 1 +and 0 +met 0 +a 0 +definition 0 +of 0 +a 0 +serious 0 +ADR 0 +, 0 +were 0 +identified 0 +. 0 + +Two 0 +clinicians 0 +reviewed 0 +structured 0 +case 0 +reports 0 +and 0 +assessed 0 +causality 0 +by 0 +consensus 0 +and 0 +by 0 +using 0 +a 0 +causality 0 +assessment 0 +instrument 0 +. 0 + +The 0 +likely 0 +frequency 0 +of 0 +hepatotoxicity 3 +with 0 +sulfasalazine 1 +was 0 +estimated 0 +by 0 +making 0 +a 0 +series 0 +of 0 +conservative 0 +assumptions 0 +. 0 + +RESULTS 0 +: 0 +Ten 0 +cases 0 +were 0 +identified 0 +: 0 +eight 0 +occurred 0 +during 0 +surveillance 0 +. 0 + +Eight 0 +patients 0 +were 0 +hospitalised 0 +, 0 +two 0 +in 0 +hepatic 3 +failure 4 +- 0 +one 0 +died 0 +after 0 +a 0 +liver 0 +transplant 0 +. 0 + +All 0 +but 0 +one 0 +event 0 +occurred 0 +within 0 +6 0 +weeks 0 +of 0 +treatment 0 +. 0 + +Seven 0 +patients 0 +had 0 +a 0 +skin 3 +rash 4 +, 0 +three 0 +eosinophilia 3 +and 0 +one 0 +interstitial 3 +nephritis 4 +. 0 + +Five 0 +patients 0 +were 0 +of 0 +Black 0 +British 0 +of 0 +African 0 +or 0 +Caribbean 0 +descent 0 +. 0 + +Liver 0 +enzymes 0 +showed 0 +a 0 +hepatocellular 0 +pattern 0 +in 0 +four 0 +cases 0 +and 0 +a 0 +mixed 0 +pattern 0 +in 0 +six 0 +. 0 + +Drug 0 +- 0 +related 0 +hepatotoxicity 3 +was 0 +judged 0 +probable 0 +or 0 +highly 0 +probable 0 +in 0 +8 0 +patients 0 +. 0 + +The 0 +likely 0 +frequency 0 +of 0 +serious 0 +hepatotoxicity 3 +with 0 +sulfasalazine 1 +was 0 +estimated 0 +at 0 +0 0 +. 0 +4 0 +% 0 +of 0 +treated 0 +patients 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Serious 0 +hepatotoxicity 3 +associated 0 +with 0 +sulfasalazine 1 +appears 0 +to 0 +be 0 +under 0 +- 0 +appreciated 0 +and 0 +intensive 0 +monitoring 0 +and 0 +vigilance 0 +in 0 +the 0 +first 0 +6 0 +weeks 0 +of 0 +treatment 0 +is 0 +especially 0 +important 0 +. 0 + +Complete 0 +atrioventricular 3 +block 4 +secondary 0 +to 0 +lithium 1 +therapy 0 +. 0 + +Sinus 3 +node 4 +dysfunction 4 +has 0 +been 0 +reported 0 +most 0 +frequently 0 +among 0 +the 0 +adverse 0 +cardiovascular 0 +effects 0 +of 0 +lithium 1 +. 0 + +In 0 +the 0 +present 0 +case 0 +, 0 +complete 0 +atrioventricular 3 +( 4 +AV 4 +) 4 +block 4 +with 0 +syncopal 3 +attacks 4 +developed 0 +secondary 0 +to 0 +lithium 1 +therapy 0 +, 0 +necessitating 0 +permanent 0 +pacemaker 0 +implantation 0 +. 0 + +Serum 0 +lithium 1 +levels 0 +remained 0 +under 0 +or 0 +within 0 +the 0 +therapeutic 0 +range 0 +during 0 +the 0 +syncopal 3 +attacks 4 +. 0 + +Lithium 1 +should 0 +be 0 +used 0 +with 0 +extreme 0 +caution 0 +, 0 +especially 0 +in 0 +patients 0 +with 0 +mild 0 +disturbance 0 +of 0 +AV 0 +conduction 0 +. 0 + +Exaggerated 0 +expression 0 +of 0 +inflammatory 0 +mediators 0 +in 0 +vasoactive 0 +intestinal 0 +polypeptide 0 +knockout 0 +( 0 +VIP 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +with 0 +cyclophosphamide 1 +( 0 +CYP 1 +) 0 +- 0 +induced 0 +cystitis 3 +. 0 + +Vasoactive 0 +intestinal 0 +polypeptide 0 +( 0 +VIP 0 +) 0 +is 0 +an 0 +immunomodulatory 0 +neuropeptide 0 +distributed 0 +in 0 +micturition 0 +pathways 0 +. 0 + +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +exhibit 0 +altered 0 +bladder 0 +function 0 +and 0 +neurochemical 0 +properties 0 +in 0 +micturition 0 +pathways 0 +after 0 +cyclophosphamide 1 +( 0 +CYP 1 +) 0 +- 0 +induced 0 +cystitis 3 +. 0 + +Given 0 +VIP 0 +' 0 +s 0 +role 0 +as 0 +an 0 +anti 0 +- 0 +inflammatory 0 +mediator 0 +, 0 +we 0 +hypothesized 0 +that 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +would 0 +exhibit 0 +enhanced 0 +inflammatory 0 +mediator 0 +expression 0 +after 0 +cystitis 3 +. 0 + +A 0 +mouse 0 +inflammatory 0 +cytokine 0 +and 0 +receptor 0 +RT2 0 +profiler 0 +array 0 +was 0 +used 0 +to 0 +determine 0 +regulated 0 +transcripts 0 +in 0 +the 0 +urinary 0 +bladder 0 +of 0 +wild 0 +type 0 +( 0 +WT 0 +) 0 +and 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +with 0 +or 0 +without 0 +CYP 1 +- 0 +induced 0 +cystitis 3 +( 0 +150 0 +mg 0 +/ 0 +kg 0 +; 0 +i 0 +. 0 +p 0 +. 0 +; 0 +48 0 +h 0 +) 0 +. 0 + +Four 0 +binary 0 +comparisons 0 +were 0 +made 0 +: 0 +WT 0 +control 0 +versus 0 +CYP 1 +treatment 0 +( 0 +48 0 +h 0 +) 0 +, 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +control 0 +versus 0 +CYP 1 +treatment 0 +( 0 +48 0 +h 0 +) 0 +, 0 +WT 0 +control 0 +versus 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +control 0 +, 0 +and 0 +WT 0 +with 0 +CYP 1 +treatment 0 +( 0 +48 0 +h 0 +) 0 +versus 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +with 0 +CYP 1 +treatment 0 +( 0 +48 0 +h 0 +) 0 +. 0 + +The 0 +genes 0 +presented 0 +represent 0 +( 0 +1 0 +) 0 +greater 0 +than 0 +1 0 +. 0 +5 0 +- 0 +fold 0 +change 0 +in 0 +either 0 +direction 0 +and 0 +( 0 +2 0 +) 0 +the 0 +p 0 +value 0 +is 0 +less 0 +than 0 +0 0 +. 0 +05 0 +for 0 +the 0 +comparison 0 +being 0 +made 0 +. 0 + +Several 0 +regulated 0 +genes 0 +were 0 +validated 0 +using 0 +enzyme 0 +- 0 +linked 0 +immunoassays 0 +including 0 +IL 0 +- 0 +1beta 0 +and 0 +CXCL1 0 +. 0 + +CYP 1 +treatment 0 +significantly 0 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +001 0 +) 0 +increased 0 +expression 0 +of 0 +CXCL1 0 +and 0 +IL 0 +- 0 +1beta 0 +in 0 +the 0 +urinary 0 +bladder 0 +of 0 +WT 0 +and 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +, 0 +but 0 +expression 0 +in 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +with 0 +CYP 1 +treatment 0 +was 0 +significantly 0 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +001 0 +) 0 +greater 0 +( 0 +4 0 +. 0 +2 0 +- 0 +to 0 +13 0 +- 0 +fold 0 +increase 0 +) 0 +than 0 +that 0 +observed 0 +in 0 +WT 0 +urinary 0 +bladder 0 +( 0 +3 0 +. 0 +6 0 +- 0 +to 0 +5 0 +- 0 +fold 0 +increase 0 +) 0 +. 0 + +The 0 +data 0 +suggest 0 +that 0 +in 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +with 0 +bladder 3 +inflammation 4 +, 0 +inflammatory 0 +mediators 0 +are 0 +increased 0 +above 0 +that 0 +observed 0 +in 0 +WT 0 +with 0 +CYP 1 +. 0 + +This 0 +shift 0 +in 0 +balance 0 +may 0 +contribute 0 +to 0 +increased 0 +bladder 3 +dysfunction 4 +in 0 +VIP 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +with 0 +bladder 3 +inflammation 4 +and 0 +altered 0 +neurochemical 0 +expression 0 +in 0 +micturition 0 +pathways 0 +. 0 + +Debrisoquine 1 +phenotype 0 +and 0 +the 0 +pharmacokinetics 0 +and 0 +beta 0 +- 0 +2 0 +receptor 0 +pharmacodynamics 0 +of 0 +metoprolol 1 +and 0 +its 0 +enantiomers 0 +. 0 + +The 0 +metabolism 0 +of 0 +the 0 +cardioselective 0 +beta 0 +- 0 +blocker 0 +metoprolol 1 +is 0 +under 0 +genetic 0 +control 0 +of 0 +the 0 +debrisoquine 1 +/ 0 +sparteine 1 +type 0 +. 0 + +The 0 +two 0 +metabolic 0 +phenotypes 0 +, 0 +extensive 0 +( 0 +EM 0 +) 0 +and 0 +poor 0 +metabolizers 0 +( 0 +PM 0 +) 0 +, 0 +show 0 +different 0 +stereoselective 0 +metabolism 0 +, 0 +resulting 0 +in 0 +apparently 0 +higher 0 +beta 0 +- 0 +1 0 +adrenoceptor 0 +antagonistic 0 +potency 0 +of 0 +racemic 0 +metoprolol 1 +in 0 +EMs 0 +. 0 + +We 0 +investigated 0 +if 0 +the 0 +latter 0 +also 0 +applies 0 +to 0 +the 0 +beta 0 +- 0 +2 0 +adrenoceptor 0 +antagonism 0 +by 0 +metoprolol 1 +. 0 + +The 0 +drug 0 +effect 0 +studied 0 +was 0 +the 0 +antagonism 0 +by 0 +metoprolol 1 +of 0 +terbutaline 1 +- 0 +induced 0 +hypokalemia 3 +. 0 + +By 0 +using 0 +pharmacokinetic 0 +pharmacodynamic 0 +modeling 0 +the 0 +pharmacodynamics 0 +of 0 +racemic 0 +metoprolol 1 +and 0 +the 0 +active 0 +S 0 +- 0 +isomer 0 +, 0 +were 0 +quantitated 0 +in 0 +EMs 0 +and 0 +PMs 0 +in 0 +terms 0 +of 0 +IC50 0 +values 0 +, 0 +representing 0 +metoprolol 1 +plasma 0 +concentrations 0 +resulting 0 +in 0 +half 0 +- 0 +maximum 0 +receptor 0 +occupancy 0 +. 0 + +Six 0 +EMs 0 +received 0 +0 0 +. 0 +5 0 +mg 0 +of 0 +terbutaline 1 +s 0 +. 0 +c 0 +. 0 +on 0 +two 0 +different 0 +occasions 0 +: 0 +1 0 +) 0 +1 0 +hr 0 +after 0 +administration 0 +of 0 +a 0 +placebo 0 +and 0 +2 0 +) 0 +1 0 +hr 0 +after 0 +150 0 +mg 0 +of 0 +metoprolol 1 +p 0 +. 0 +o 0 +. 0 + +Five 0 +PMs 0 +were 0 +studied 0 +according 0 +to 0 +the 0 +same 0 +protocol 0 +, 0 +except 0 +for 0 +a 0 +higher 0 +terbutaline 1 +dose 0 +( 0 +0 0 +. 0 +75 0 +mg 0 +) 0 +on 0 +day 0 +2 0 +. 0 + +Blood 0 +samples 0 +for 0 +the 0 +analysis 0 +of 0 +plasma 0 +potassium 1 +, 0 +terbutaline 1 +, 0 +metoprolol 1 +( 0 +racemic 0 +, 0 +R 0 +- 0 +and 0 +S 0 +- 0 +isomer 0 +) 0 +, 0 +and 0 +alpha 1 +- 2 +hydroxymetoprolol 2 +concentrations 0 +were 0 +taken 0 +at 0 +regular 0 +time 0 +intervals 0 +, 0 +during 0 +8 0 +hr 0 +after 0 +metoprolol 1 +. 0 + +In 0 +PMs 0 +, 0 +metoprolol 1 +increased 0 +the 0 +terbutaline 1 +area 0 +under 0 +the 0 +plasma 0 +concentration 0 +vs 0 +. 0 +time 0 +curve 0 +( 0 ++ 0 +67 0 +% 0 +) 0 +. 0 + +Higher 0 +metoprolol 1 +/ 0 +alpha 1 +- 2 +hydroxymetoprolol 2 +ratios 0 +in 0 +PMs 0 +were 0 +predictive 0 +for 0 +higher 0 +R 0 +- 0 +/ 0 +S 0 +- 0 +isomer 0 +ratios 0 +of 0 +unchanged 0 +drug 0 +. 0 + +There 0 +was 0 +a 0 +difference 0 +in 0 +metoprolol 1 +potency 0 +with 0 +higher 0 +racemic 0 +metoprolol 1 +IC50 0 +values 0 +in 0 +PMs 0 +( 0 +72 0 ++ 0 +/ 0 +- 0 +7 0 +ng 0 +. 0 +ml 0 +- 0 +1 0 +) 0 +than 0 +EMs 0 +( 0 +42 0 ++ 0 +/ 0 +- 0 +8 0 +ng 0 +. 0 +ml 0 +- 0 +1 0 +, 0 +P 0 +less 0 +than 0 +. 0 +001 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +The 0 +hemodynamics 0 +of 0 +oxytocin 1 +and 0 +other 0 +vasoactive 0 +agents 0 +during 0 +neuraxial 0 +anesthesia 0 +for 0 +cesarean 0 +delivery 0 +: 0 +findings 0 +in 0 +six 0 +cases 0 +. 0 + +0xytocin 1 +is 0 +a 0 +commonly 0 +used 0 +uterotonic 0 +that 0 +can 0 +cause 0 +significant 0 +and 0 +even 0 +fatal 0 +hypotension 3 +, 0 +particularly 0 +when 0 +given 0 +as 0 +a 0 +bolus 0 +. 0 + +The 0 +resulting 0 +hypotension 3 +can 0 +be 0 +produced 0 +by 0 +a 0 +decrease 0 +in 0 +systemic 0 +vascular 0 +resistance 0 +or 0 +cardiac 0 +output 0 +through 0 +a 0 +decrease 0 +in 0 +venous 0 +return 0 +. 0 + +Parturients 0 +with 0 +normal 0 +volume 0 +status 0 +, 0 +heart 0 +valves 0 +and 0 +pulmonary 0 +vasculature 0 +most 0 +often 0 +respond 0 +to 0 +this 0 +hypotension 3 +with 0 +a 0 +compensatory 0 +increase 0 +in 0 +heart 0 +rate 0 +and 0 +stroke 3 +volume 0 +. 0 + +0xytocin 1 +- 0 +induced 0 +hypotension 3 +at 0 +cesarean 0 +delivery 0 +may 0 +be 0 +incorrectly 0 +attributed 0 +to 0 +blood 3 +loss 4 +. 0 + +Pulse 0 +power 0 +analysis 0 +( 0 +also 0 +called 0 +" 0 +pulse 0 +contour 0 +analysis 0 +" 0 +) 0 +of 0 +an 0 +arterial 0 +pressure 0 +wave 0 +form 0 +allows 0 +continuous 0 +evaluation 0 +of 0 +systemic 0 +vascular 0 +resistance 0 +and 0 +cardiac 0 +output 0 +in 0 +real 0 +time 0 +, 0 +thereby 0 +elucidating 0 +the 0 +causative 0 +factors 0 +behind 0 +changes 0 +in 0 +blood 0 +pressure 0 +. 0 + +Pulse 0 +power 0 +analysis 0 +was 0 +conducted 0 +in 0 +six 0 +cases 0 +of 0 +cesarean 0 +delivery 0 +performed 0 +under 0 +neuraxial 0 +anesthesia 0 +. 0 + +Hypotension 3 +in 0 +response 0 +to 0 +oxytocin 1 +was 0 +associated 0 +with 0 +a 0 +decrease 0 +in 0 +systemic 0 +vascular 0 +resistance 0 +and 0 +a 0 +compensatory 0 +increase 0 +in 0 +stroke 3 +volume 0 +, 0 +heart 0 +rate 0 +and 0 +cardiac 0 +output 0 +. 0 + +Pulse 0 +power 0 +analysis 0 +may 0 +be 0 +helpful 0 +in 0 +determining 0 +the 0 +etiology 0 +of 0 +and 0 +treating 0 +hypotension 3 +during 0 +cesarean 0 +delivery 0 +under 0 +neuraxial 0 +anesthesia 0 +. 0 + +Protective 0 +effects 0 +of 0 +antithrombin 0 +on 0 +puromycin 1 +aminonucleoside 2 +nephrosis 3 +in 0 +rats 0 +. 0 + +We 0 +investigated 0 +the 0 +effects 0 +of 0 +antithrombin 0 +, 0 +a 0 +plasma 0 +inhibitor 0 +of 0 +coagulation 0 +factors 0 +, 0 +in 0 +rats 0 +with 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrosis 3 +, 0 +which 0 +is 0 +an 0 +experimental 0 +model 0 +of 0 +human 0 +nephrotic 3 +syndrome 4 +. 0 + +Antithrombin 0 +( 0 +50 0 +or 0 +500 0 +IU 0 +/ 0 +kg 0 +/ 0 +i 0 +. 0 +v 0 +. 0 +) 0 +was 0 +administered 0 +to 0 +rats 0 +once 0 +a 0 +day 0 +for 0 +10 0 +days 0 +immediately 0 +after 0 +the 0 +injection 0 +of 0 +puromycin 1 +aminonucleoside 2 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +/ 0 +i 0 +. 0 +v 0 +. 0 +) 0 +. 0 + +Treatment 0 +with 0 +antithrombin 0 +attenuated 0 +the 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +hematological 3 +abnormalities 4 +. 0 + +Puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +renal 3 +dysfunction 4 +and 0 +hyperlipidemia 3 +were 0 +also 0 +suppressed 0 +. 0 + +Histopathological 0 +examination 0 +revealed 0 +severe 0 +renal 3 +damage 4 +such 0 +as 0 +proteinaceous 0 +casts 0 +in 0 +tubuli 0 +and 0 +tubular 0 +expansion 0 +in 0 +the 0 +kidney 0 +of 0 +control 0 +rats 0 +, 0 +while 0 +an 0 +improvement 0 +of 0 +the 0 +damage 0 +was 0 +seen 0 +in 0 +antithrombin 0 +- 0 +treated 0 +rats 0 +. 0 + +In 0 +addition 0 +, 0 +antithrombin 0 +treatment 0 +markedly 0 +suppressed 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +apoptosis 0 +of 0 +renal 0 +tubular 0 +epithelial 0 +cells 0 +. 0 + +Furthermore 0 +, 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +increases 0 +in 0 +renal 0 +cytokine 0 +content 0 +were 0 +also 0 +decreased 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +thrombin 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +pathogenesis 0 +of 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +. 0 + +Treatment 0 +with 0 +antithrombin 0 +may 0 +be 0 +clinically 0 +effective 0 +in 0 +patients 0 +with 0 +nephrotic 3 +syndrome 4 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +after 0 +liver 0 +transplantation 0 +. 0 + +BACKGR0UND 0 +: 0 +Unfractionated 1 +heparin 2 +sodium 2 +( 0 +UFH 1 +) 0 +or 0 +low 1 +- 2 +molecular 2 +weight 2 +heparin 2 +( 0 +LMWH 0 +) 0 +is 0 +used 0 +in 0 +anticoagulant 0 +protocols 0 +at 0 +several 0 +institutions 0 +to 0 +prevent 0 +thrombosis 3 +after 0 +liver 0 +transplantation 0 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +( 0 +HIT 3 +) 0 +is 0 +an 0 +adverse 0 +immune 0 +- 0 +mediated 0 +reaction 0 +to 0 +heparin 1 +, 0 +resulting 0 +in 0 +platelet 0 +count 0 +decreases 0 +of 0 +more 0 +than 0 +50 0 +% 0 +. 0 + +The 0 +frequencies 0 +of 0 +HIT 3 +after 0 +liver 0 +transplantation 0 +and 0 +platelet 0 +factor 0 +4 0 +/ 0 +heparin 1 +- 0 +reactive 0 +antibody 0 +( 0 +HIT 3 +antibody 0 +) 0 +positivity 0 +in 0 +liver 0 +transplantation 0 +patients 0 +, 0 +however 0 +, 0 +are 0 +unknown 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +The 0 +32 0 +men 0 +and 0 +20 0 +women 0 +underwent 0 +living 0 +donor 0 +liver 0 +transplantation 0 +. 0 + +We 0 +started 0 +LMWH 0 +( 0 +25 0 +IU 0 +/ 0 +kg 0 +/ 0 +h 0 +) 0 +on 0 +postoperative 0 +day 0 +( 0 +P0D 0 +) 0 +1 0 +, 0 +switching 0 +to 0 +UFH 1 +( 0 +5000 0 +U 0 +/ 0 +d 0 +) 0 +on 0 +P0D 0 +2 0 +or 0 +3 0 +. 0 + +The 0 +dose 0 +of 0 +UFH 1 +was 0 +changed 0 +according 0 +to 0 +the 0 +activated 0 +clotting 0 +time 0 +level 0 +. 0 + +HIT 3 +antibody 0 +levels 0 +were 0 +measured 0 +the 0 +day 0 +before 0 +surgery 0 +and 0 +on 0 +P0D 0 +7 0 +and 0 +14 0 +. 0 + +Platelet 0 +count 0 +was 0 +measured 0 +daily 0 +for 0 +3 0 +weeks 0 +. 0 + +RESULTS 0 +: 0 +The 0 +average 0 +platelet 0 +counts 0 +preoperatively 0 +, 0 +and 0 +on 0 +P0D 0 +7 0 +, 0 +14 0 +, 0 +and 0 +21 0 +were 0 +65 0 +, 0 +88 0 +, 0 +149 0 +, 0 +and 0 +169 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +, 0 +respectively 0 +. 0 + +Two 0 +patients 0 +developed 0 +hepatic 0 +artery 0 +thrombosis 3 +on 0 +P0D 0 +11 0 +and 0 +19 0 +, 0 +respectively 0 +, 0 +although 0 +they 0 +were 0 +HIT 3 +antibody 0 +- 0 +negative 0 +and 0 +their 0 +platelet 0 +counts 0 +were 0 +stable 0 +. 0 + +In 0 +2 0 +other 0 +patients 0 +, 0 +the 0 +platelet 0 +count 0 +decreased 0 +suddenly 0 +from 0 +107 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +on 0 +P0D 0 +4 0 +to 0 +65 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +on 0 +P0D 0 +6 0 +and 0 +from 0 +76 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +on 0 +P0D 0 +7 0 +to 0 +33 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +on 0 +P0D 0 +9 0 +, 0 +respectively 0 +. 0 + +The 0 +heparin 1 +- 0 +induced 0 +platelet 3 +aggregation 4 +test 0 +was 0 +negative 0 +in 0 +these 0 +patients 0 +. 0 + +The 0 +percentage 0 +of 0 +HIT 3 +antibody 0 +- 0 +positive 0 +patients 0 +was 0 +0 0 +. 0 +5 0 +% 0 +preoperatively 0 +, 0 +5 0 +. 0 +6 0 +% 0 +on 0 +P0D 0 +7 0 +, 0 +and 0 +5 0 +. 0 +6 0 +% 0 +on 0 +P0D 0 +14 0 +. 0 + +None 0 +of 0 +the 0 +subjects 0 +/ 0 +patients 0 +developed 0 +UFH 1 +- 0 +related 0 +HIT 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +our 0 +series 0 +, 0 +the 0 +occurrence 0 +of 0 +HIT 3 +after 0 +liver 0 +transplantation 0 +was 0 +uncommon 0 +. 0 + +Doxorubicin 1 +cardiomyopathy 3 +- 0 +induced 0 +inflammation 3 +and 0 +apoptosis 0 +are 0 +attenuated 0 +by 0 +gene 0 +deletion 0 +of 0 +the 0 +kinin 0 +B1 0 +receptor 0 +. 0 + +Clinical 0 +use 0 +of 0 +the 0 +anthracycline 1 +doxorubicin 1 +( 0 +D0X 1 +) 0 +is 0 +limited 0 +by 0 +its 0 +cardiotoxic 3 +effects 0 +, 0 +which 0 +are 0 +attributed 0 +to 0 +the 0 +induction 0 +of 0 +apoptosis 0 +. 0 + +To 0 +elucidate 0 +the 0 +possible 0 +role 0 +of 0 +the 0 +kinin 0 +B1 0 +receptor 0 +( 0 +B1R 0 +) 0 +during 0 +the 0 +development 0 +of 0 +D0X 1 +cardiomyopathy 3 +, 0 +we 0 +studied 0 +B1R 0 +knockout 0 +mice 0 +( 0 +B1R 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +) 0 +by 0 +investigating 0 +cardiac 0 +inflammation 3 +and 0 +apoptosis 0 +after 0 +induction 0 +of 0 +D0X 1 +- 0 +induced 0 +cardiomyopathy 3 +. 0 + +D0X 1 +control 0 +mice 0 +showed 0 +cardiac 3 +dysfunction 4 +measured 0 +by 0 +pressure 0 +- 0 +volume 0 +loops 0 +in 0 +vivo 0 +. 0 + +This 0 +was 0 +associated 0 +with 0 +a 0 +reduced 0 +activation 0 +state 0 +of 0 +AKT 0 +, 0 +as 0 +well 0 +as 0 +an 0 +increased 0 +bax 0 +/ 0 +bcl2 0 +ratio 0 +in 0 +Western 0 +blots 0 +, 0 +indicating 0 +cardiac 3 +apoptosis 4 +. 0 + +Furthermore 0 +, 0 +mRNA 0 +levels 0 +of 0 +the 0 +proinflammatory 0 +cytokine 0 +interleukin 0 +6 0 +were 0 +increased 0 +in 0 +the 0 +cardiac 0 +tissue 0 +. 0 + +In 0 +D0X 1 +B1R 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +, 0 +cardiac 3 +dysfunction 4 +was 0 +improved 0 +compared 0 +to 0 +D0X 1 +control 0 +mice 0 +, 0 +which 0 +was 0 +associated 0 +with 0 +normalization 0 +of 0 +the 0 +bax 0 +/ 0 +bcl 0 +- 0 +2 0 +ratio 0 +and 0 +interleukin 0 +6 0 +, 0 +as 0 +well 0 +as 0 +AKT 0 +activation 0 +state 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +B1R 0 +is 0 +detrimental 0 +in 0 +D0X 1 +cardiomyopathy 3 +in 0 +that 0 +it 0 +mediates 0 +the 0 +inflammatory 0 +response 0 +and 0 +apoptosis 0 +. 0 + +These 0 +insights 0 +might 0 +have 0 +useful 0 +implications 0 +for 0 +future 0 +studies 0 +utilizing 0 +B1R 0 +antagonists 0 +for 0 +treatment 0 +of 0 +human 0 +D0X 1 +cardiomyopathy 3 +. 0 + +Detailed 0 +spectral 0 +profile 0 +analysis 0 +of 0 +penicillin 1 +- 0 +induced 0 +epileptiform 3 +activity 4 +in 0 +anesthetized 0 +rats 0 +. 0 + +Penicillin 1 +model 0 +is 0 +a 0 +widely 0 +used 0 +experimental 0 +model 0 +for 0 +epilepsy 3 +research 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +we 0 +aimed 0 +to 0 +portray 0 +a 0 +detailed 0 +spectral 0 +analysis 0 +of 0 +penicillin 1 +- 0 +induced 0 +epileptiform 3 +activity 4 +in 0 +comparison 0 +with 0 +basal 0 +brain 0 +activity 0 +in 0 +anesthetized 0 +Wistar 0 +rats 0 +. 0 + +Male 0 +Wistar 0 +rats 0 +were 0 +anesthetized 0 +with 0 +i 0 +. 0 +p 0 +. 0 +urethane 1 +and 0 +connected 0 +to 0 +an 0 +electrocorticogram 0 +setup 0 +. 0 + +After 0 +a 0 +short 0 +period 0 +of 0 +basal 0 +activity 0 +recording 0 +, 0 +epileptic 3 +focus 0 +was 0 +induced 0 +by 0 +injecting 0 +400IU 0 +/ 0 +2 0 +microl 0 +penicillin 1 +- 2 +G 2 +potassium 2 +into 0 +the 0 +left 0 +lateral 0 +ventricle 0 +while 0 +the 0 +cortical 0 +activity 0 +was 0 +continuously 0 +recorded 0 +. 0 + +Basal 0 +activity 0 +, 0 +latent 0 +period 0 +and 0 +the 0 +penicillin 1 +- 0 +induced 0 +epileptiform 3 +activity 4 +periods 0 +were 0 +then 0 +analyzed 0 +using 0 +both 0 +conventional 0 +methods 0 +and 0 +spectral 0 +analysis 0 +. 0 + +Spectral 0 +analyses 0 +were 0 +conducted 0 +by 0 +dividing 0 +the 0 +whole 0 +spectrum 0 +into 0 +different 0 +frequency 0 +bands 0 +including 0 +delta 0 +, 0 +theta 0 +( 0 +slow 0 +and 0 +fast 0 +) 0 +, 0 +alpha 0 +- 0 +sigma 0 +, 0 +beta 0 +( 0 +1 0 +and 0 +2 0 +) 0 +and 0 +gamma 0 +( 0 +1 0 +and 0 +2 0 +) 0 +bands 0 +. 0 + +0ur 0 +results 0 +show 0 +that 0 +the 0 +most 0 +affected 0 +frequency 0 +bands 0 +were 0 +delta 0 +, 0 +theta 0 +, 0 +beta 0 +- 0 +2 0 +and 0 +gamma 0 +- 0 +2 0 +bands 0 +during 0 +the 0 +epileptiform 3 +activity 4 +and 0 +there 0 +were 0 +marked 0 +differences 0 +in 0 +terms 0 +of 0 +spectral 0 +densities 0 +between 0 +three 0 +investigated 0 +episodes 0 +( 0 +basal 0 +activity 0 +, 0 +latent 0 +period 0 +and 0 +epileptiform 3 +activity 4 +) 0 +. 0 + +0ur 0 +results 0 +may 0 +help 0 +to 0 +analyze 0 +novel 0 +data 0 +obtained 0 +using 0 +similar 0 +experimental 0 +models 0 +and 0 +the 0 +simple 0 +analysis 0 +method 0 +described 0 +here 0 +can 0 +be 0 +used 0 +in 0 +similar 0 +studies 0 +to 0 +investigate 0 +the 0 +basic 0 +neuronal 0 +mechanism 0 +of 0 +this 0 +or 0 +other 0 +types 0 +of 0 +experimental 0 +epilepsies 3 +. 0 + +High 0 +fat 1 +diet 0 +- 0 +fed 0 +obese 3 +rats 0 +are 0 +highly 0 +sensitive 0 +to 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +0ften 0 +, 0 +chemotherapy 0 +by 0 +doxorubicin 1 +( 0 +Adriamycin 1 +) 0 +is 0 +limited 0 +due 0 +to 0 +life 0 +threatening 0 +cardiotoxicity 3 +in 0 +patients 0 +during 0 +and 0 +posttherapy 0 +. 0 + +Recently 0 +, 0 +we 0 +have 0 +shown 0 +that 0 +moderate 0 +diet 0 +restriction 0 +remarkably 0 +protects 0 +against 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +This 0 +cardioprotection 0 +is 0 +accompanied 0 +by 0 +decreased 0 +cardiac 0 +oxidative 0 +stress 0 +and 0 +triglycerides 1 +and 0 +increased 0 +cardiac 0 +fatty 0 +- 0 +acid 0 +oxidation 0 +, 0 +ATP 1 +synthesis 0 +, 0 +and 0 +upregulated 0 +JAK 0 +/ 0 +STAT3 0 +pathway 0 +. 0 + +In 0 +the 0 +current 0 +study 0 +, 0 +we 0 +investigated 0 +whether 0 +a 0 +physiological 0 +intervention 0 +by 0 +feeding 0 +40 0 +% 0 +high 0 +fat 1 +diet 0 +( 0 +HFD 0 +) 0 +, 0 +which 0 +induces 0 +obesity 3 +in 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +( 0 +250 0 +- 0 +275 0 +g 0 +) 0 +, 0 +sensitizes 0 +to 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +A 0 +LD 0 +( 0 +10 0 +) 0 +dose 0 +( 0 +8 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +, 0 +ip 0 +) 0 +administered 0 +on 0 +day 0 +43 0 +of 0 +the 0 +HFD 0 +feeding 0 +regimen 0 +led 0 +to 0 +higher 0 +cardiotoxicity 3 +, 0 +cardiac 3 +dysfunction 4 +, 0 +lipid 0 +peroxidation 0 +, 0 +and 0 +80 0 +% 0 +mortality 0 +in 0 +the 0 +obese 3 +( 0 +0B 3 +) 0 +rats 0 +in 0 +the 0 +absence 0 +of 0 +any 0 +significant 0 +renal 3 +or 4 +hepatic 4 +toxicity 4 +. 0 + +Doxorubicin 1 +toxicokinetics 0 +studies 0 +revealed 0 +no 0 +change 0 +in 0 +accumulation 0 +of 0 +doxorubicin 1 +and 0 +doxorubicinol 1 +( 0 +toxic 0 +metabolite 0 +) 0 +in 0 +the 0 +normal 0 +diet 0 +- 0 +fed 0 +( 0 +ND 0 +) 0 +and 0 +0B 3 +hearts 0 +. 0 + +Mechanistic 0 +studies 0 +revealed 0 +that 0 +0B 3 +rats 0 +are 0 +sensitized 0 +due 0 +to 0 +: 0 +( 0 +1 0 +) 0 +higher 0 +oxyradical 0 +stress 0 +leading 0 +to 0 +upregulation 0 +of 0 +uncoupling 0 +proteins 0 +2 0 +and 0 +3 0 +, 0 +( 0 +2 0 +) 0 +downregulation 0 +of 0 +cardiac 0 +peroxisome 0 +proliferators 0 +activated 0 +receptor 0 +- 0 +alpha 0 +, 0 +( 0 +3 0 +) 0 +decreased 0 +plasma 0 +adiponectin 0 +levels 0 +, 0 +( 0 +4 0 +) 0 +decreased 0 +cardiac 0 +fatty 0 +- 0 +acid 0 +oxidation 0 +( 0 +666 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +14 0 +. 0 +0 0 +nmol 0 +/ 0 +min 0 +/ 0 +g 0 +heart 0 +in 0 +ND 0 +versus 0 +400 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +11 0 +. 0 +8 0 +nmol 0 +/ 0 +min 0 +/ 0 +g 0 +heart 0 +in 0 +0B 3 +) 0 +, 0 +( 0 +5 0 +) 0 +decreased 0 +mitochondrial 0 +AMP 1 +- 0 +alpha2 0 +protein 0 +kinase 0 +, 0 +and 0 +( 0 +6 0 +) 0 +86 0 +% 0 +drop 0 +in 0 +cardiac 0 +ATP 1 +levels 0 +accompanied 0 +by 0 +decreased 0 +ATP 1 +/ 0 +ADP 1 +ratio 0 +after 0 +doxorubicin 1 +administration 0 +. 0 + +Decreased 0 +cardiac 0 +erythropoietin 0 +and 0 +increased 0 +S0CS3 0 +further 0 +downregulated 0 +the 0 +cardioprotective 0 +JAK 0 +/ 0 +STAT3 0 +pathway 0 +. 0 + +In 0 +conclusion 0 +, 0 +HFD 0 +- 0 +induced 0 +obese 3 +rats 0 +are 0 +highly 0 +sensitized 0 +to 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +by 0 +substantially 0 +downregulating 0 +cardiac 0 +mitochondrial 0 +ATP 1 +generation 0 +, 0 +increasing 0 +oxidative 0 +stress 0 +and 0 +downregulating 0 +the 0 +JAK 0 +/ 0 +STAT3 0 +pathway 0 +. 0 + +Isoproterenol 1 +induces 0 +primary 0 +loss 0 +of 0 +dystrophin 0 +in 0 +rat 0 +hearts 0 +: 0 +correlation 0 +with 0 +myocardial 3 +injury 4 +. 0 + +The 0 +mechanism 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +damage 4 +is 0 +unknown 0 +, 0 +but 0 +a 0 +mismatch 0 +of 0 +oxygen 1 +supply 0 +vs 0 +. 0 +demand 0 +following 0 +coronary 0 +hypotension 3 +and 0 +myocardial 3 +hyperactivity 4 +is 0 +the 0 +best 0 +explanation 0 +for 0 +the 0 +complex 0 +morphological 0 +alterations 0 +observed 0 +. 0 + +Severe 0 +alterations 0 +in 0 +the 0 +structural 0 +integrity 0 +of 0 +the 0 +sarcolemma 0 +of 0 +cardiomyocytes 0 +have 0 +been 0 +demonstrated 0 +to 0 +be 0 +caused 0 +by 0 +isoproterenol 1 +. 0 + +Taking 0 +into 0 +account 0 +that 0 +the 0 +sarcolemmal 0 +integrity 0 +is 0 +stabilized 0 +by 0 +the 0 +dystrophin 0 +- 0 +glycoprotein 0 +complex 0 +( 0 +DGC 0 +) 0 +that 0 +connects 0 +actin 0 +and 0 +laminin 0 +in 0 +contractile 0 +machinery 0 +and 0 +extracellular 0 +matrix 0 +and 0 +by 0 +integrins 0 +, 0 +this 0 +study 0 +tests 0 +the 0 +hypothesis 0 +that 0 +isoproterenol 1 +affects 0 +sarcolemmal 0 +stability 0 +through 0 +changes 0 +in 0 +the 0 +DGC 0 +and 0 +integrins 0 +. 0 + +We 0 +found 0 +different 0 +sensitivity 0 +of 0 +the 0 +DGC 0 +and 0 +integrin 0 +to 0 +isoproterenol 1 +subcutaneous 0 +administration 0 +. 0 + +Immunofluorescent 0 +staining 0 +revealed 0 +that 0 +dystrophin 0 +is 0 +the 0 +most 0 +sensitive 0 +among 0 +the 0 +structures 0 +connecting 0 +the 0 +actin 0 +in 0 +the 0 +cardiomyocyte 0 +cytoskeleton 0 +and 0 +the 0 +extracellular 0 +matrix 0 +. 0 + +The 0 +sarcomeric 0 +actin 0 +dissolution 0 +occurred 0 +after 0 +the 0 +reduction 0 +or 0 +loss 0 +of 0 +dystrophin 0 +. 0 + +Subsequently 0 +, 0 +after 0 +lysis 0 +of 0 +myofilaments 0 +, 0 +gamma 0 +- 0 +sarcoglycan 0 +, 0 +beta 0 +- 0 +dystroglycan 0 +, 0 +beta1 0 +- 0 +integrin 0 +, 0 +and 0 +laminin 0 +alpha 0 +- 0 +2 0 +expressions 0 +were 0 +reduced 0 +followed 0 +by 0 +their 0 +breakdown 0 +, 0 +as 0 +epiphenomena 0 +of 0 +the 0 +myocytolytic 0 +process 0 +. 0 + +In 0 +conclusion 0 +, 0 +administration 0 +of 0 +isoproterenol 1 +to 0 +rats 0 +results 0 +in 0 +primary 0 +loss 0 +of 0 +dystrophin 0 +, 0 +the 0 +most 0 +sensitive 0 +among 0 +the 0 +structural 0 +proteins 0 +that 0 +form 0 +the 0 +DGC 0 +that 0 +connects 0 +the 0 +extracellular 0 +matrix 0 +and 0 +the 0 +cytoskeleton 0 +in 0 +cardiomyocyte 0 +. 0 + +These 0 +changes 0 +, 0 +related 0 +to 0 +ischaemic 3 +injury 4 +, 0 +explain 0 +the 0 +severe 0 +alterations 0 +in 0 +the 0 +structural 0 +integrity 0 +of 0 +the 0 +sarcolemma 0 +of 0 +cardiomyocytes 0 +and 0 +hence 0 +severe 0 +and 0 +irreversible 0 +injury 0 +induced 0 +by 0 +isoproterenol 1 +. 0 + +Etiologic 0 +factors 0 +in 0 +the 0 +pathogenesis 0 +of 0 +liver 3 +tumors 4 +associated 0 +with 0 +oral 1 +contraceptives 2 +. 0 + +Within 0 +the 0 +last 0 +several 0 +years 0 +, 0 +previously 0 +rare 0 +liver 3 +tumors 4 +have 0 +been 0 +seen 0 +in 0 +young 0 +women 0 +using 0 +oral 1 +contraceptive 2 +steroids 1 +. 0 + +The 0 +Registry 0 +for 0 +Liver 3 +Tumors 4 +Associated 0 +with 0 +0ral 1 +Contraceptives 2 +at 0 +the 0 +University 0 +of 0 +California 0 +, 0 +Irvine 0 +, 0 +has 0 +clearly 0 +identified 0 +27 0 +cases 0 +. 0 + +The 0 +recent 0 +literature 0 +contains 0 +44 0 +case 0 +reports 0 +. 0 + +Common 0 +to 0 +these 0 +71 0 +cases 0 +has 0 +been 0 +a 0 +histopathologic 0 +diagnosis 0 +of 0 +focal 3 +nodular 4 +hyperplasia 4 +, 0 +adenoma 3 +, 0 +hamartoma 3 +, 0 +and 0 +hepatoma 3 +. 0 + +Significant 0 +statistical 0 +etiologic 0 +factors 0 +include 0 +prolonged 0 +uninterrupted 0 +usage 0 +of 0 +oral 1 +contraceptive 2 +steroids 1 +. 0 + +Eight 0 +deaths 0 +and 0 +liver 0 +rupture 3 +in 0 +18 0 +patients 0 +attest 0 +to 0 +the 0 +seriousness 0 +of 0 +this 0 +new 0 +potentially 0 +lethal 0 +adverse 0 +phenomenon 0 +. 0 + +Ifosfamide 1 +continuous 0 +infusion 0 +without 0 +mesna 1 +. 0 + +A 0 +phase 0 +I 0 +trial 0 +of 0 +a 0 +14 0 +- 0 +day 0 +cycle 0 +. 0 + +Twenty 0 +patients 0 +received 0 +27 0 +courses 0 +of 0 +ifosfamide 1 +administered 0 +as 0 +a 0 +24 0 +- 0 +hour 0 +continuous 0 +infusion 0 +for 0 +14 0 +days 0 +without 0 +Mesna 1 +. 0 + +The 0 +goal 0 +of 0 +the 0 +study 0 +was 0 +to 0 +deliver 0 +a 0 +dose 0 +rate 0 +and 0 +total 0 +cumulative 0 +dose 0 +of 0 +ifosfamide 1 +that 0 +would 0 +be 0 +comparable 0 +to 0 +standard 0 +bolus 0 +or 0 +short 0 +- 0 +term 0 +infusions 0 +administered 0 +with 0 +Mesna 1 +. 0 + +Dose 0 +escalations 0 +proceeded 0 +from 0 +200 0 +to 0 +300 0 +, 0 +400 0 +, 0 +450 0 +, 0 +500 0 +, 0 +and 0 +550 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +. 0 + +Four 0 +patients 0 +developed 0 +transient 0 +microscopic 0 +hematuria 3 +at 0 +400 0 +, 0 +450 0 +, 0 +and 0 +500 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +. 0 + +There 0 +were 0 +no 0 +instances 0 +of 0 +macroscopic 0 +hematuria 3 +. 0 + +At 0 +550 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +, 0 +three 0 +patients 0 +experienced 0 +nonurologic 0 +toxicity 3 +; 0 +confusion 3 +( 0 +1 0 +) 0 +, 0 +nausea 3 +( 0 +1 0 +) 0 +, 0 +and 0 +Grade 0 +2 0 +leukopenia 3 +( 0 +1 0 +) 0 +. 0 + +The 0 +recommended 0 +dose 0 +of 0 +500 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +delivers 0 +a 0 +total 0 +dose 0 +of 0 +7 0 +g 0 +/ 0 +m2 0 +per 0 +cycle 0 +, 0 +which 0 +is 0 +comparable 0 +to 0 +that 0 +delivered 0 +in 0 +clinical 0 +practice 0 +for 0 +bolus 0 +or 0 +short 0 +- 0 +term 0 +infusion 0 +. 0 + +Because 0 +few 0 +patients 0 +received 0 +multiple 0 +courses 0 +over 0 +time 0 +, 0 +the 0 +cumulative 0 +effects 0 +are 0 +indeterminate 0 +in 0 +the 0 +present 0 +trial 0 +. 0 + +The 0 +frequency 0 +and 0 +predictability 0 +of 0 +hematuria 3 +are 0 +not 0 +precise 0 +, 0 +and 0 +at 0 +least 0 +daily 0 +monitoring 0 +by 0 +urine 0 +Hematest 0 +is 0 +essential 0 +, 0 +adding 0 +Mesna 1 +to 0 +the 0 +infusate 0 +in 0 +patients 0 +with 0 +persistent 0 +hematuria 3 +. 0 + +The 0 +protracted 0 +infusion 0 +schedule 0 +for 0 +ifosfamide 1 +permits 0 +convenient 0 +outpatient 0 +administration 0 +without 0 +Mesna 1 +and 0 +reduces 0 +the 0 +drug 0 +cost 0 +of 0 +clinical 0 +usage 0 +of 0 +this 0 +agent 0 +by 0 +up 0 +to 0 +890 0 +per 0 +cycle 0 +. 0 + +Clinical 0 +activity 0 +was 0 +demonstrated 0 +in 0 +a 0 +single 0 +patient 0 +, 0 +but 0 +a 0 +comparative 0 +trial 0 +of 0 +standard 0 +bolus 0 +schedules 0 +with 0 +the 0 +protracted 0 +infusion 0 +schedule 0 +will 0 +be 0 +necessary 0 +to 0 +determine 0 +if 0 +the 0 +clinical 0 +effectiveness 0 +of 0 +the 0 +drug 0 +is 0 +maintained 0 +. 0 + +A 0 +case 0 +of 0 +ventricular 3 +tachycardia 4 +related 0 +to 0 +caffeine 1 +pretreatment 0 +. 0 + +Suboptimal 0 +seizure 3 +duration 0 +is 0 +commonly 0 +encountered 0 +in 0 +electroconvulsive 0 +therapy 0 +practice 0 +, 0 +especially 0 +in 0 +older 0 +patients 0 +with 0 +higher 0 +seizure 3 +thresholds 0 +. 0 + +Intravenous 0 +caffeine 1 +is 0 +commonly 0 +used 0 +to 0 +improve 0 +seizure 3 +duration 0 +and 0 +quality 0 +in 0 +such 0 +patients 0 +and 0 +is 0 +generally 0 +well 0 +tolerated 0 +aside 0 +from 0 +occasional 0 +reports 0 +of 0 +relatively 0 +benign 0 +ventricular 3 +ectopy 4 +. 0 + +We 0 +describe 0 +a 0 +patient 0 +with 0 +no 0 +previous 0 +history 0 +of 0 +cardiac 3 +disease 4 +or 0 +arrhythmia 3 +who 0 +developed 0 +sustained 0 +bigeminy 0 +and 0 +2 0 +brief 0 +runs 0 +of 0 +ventricular 3 +tachycardia 4 +after 0 +caffeine 1 +administration 0 +. 0 + +Although 0 +intravenous 0 +caffeine 1 +is 0 +generally 0 +well 0 +tolerated 0 +, 0 +the 0 +clinician 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +potential 0 +for 0 +unpredictable 0 +and 0 +serious 0 +ventricular 3 +arrhythmias 4 +. 0 + +Fatal 0 +haemopericardium 3 +and 0 +gastrointestinal 3 +haemorrhage 4 +due 0 +to 0 +possible 0 +interaction 0 +of 0 +cranberry 0 +juice 0 +with 0 +warfarin 1 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +fatal 0 +internal 0 +haemorrhage 3 +in 0 +an 0 +elderly 0 +man 0 +who 0 +consumed 0 +only 0 +cranberry 0 +juice 0 +for 0 +two 0 +weeks 0 +while 0 +maintaining 0 +his 0 +usual 0 +dosage 0 +of 0 +warfarin 1 +. 0 + +We 0 +propose 0 +that 0 +naturally 0 +occurring 0 +compounds 0 +such 0 +as 0 +flavonoids 1 +, 0 +which 0 +are 0 +present 0 +in 0 +fruit 0 +juices 0 +, 0 +may 0 +increase 0 +the 0 +potency 0 +of 0 +warfarin 1 +by 0 +competing 0 +for 0 +the 0 +enzymes 0 +that 0 +normally 0 +inactivate 0 +warfarin 1 +. 0 + +While 0 +traditionally 0 +regarded 0 +as 0 +foodstuffs 0 +, 0 +consumption 0 +of 0 +fruit 0 +juices 0 +should 0 +be 0 +considered 0 +when 0 +patients 0 +develop 0 +adverse 0 +drug 0 +reactions 0 +. 0 + +Effect 0 +of 0 +increasing 0 +intraperitoneal 0 +infusion 0 +rates 0 +on 0 +bupropion 1 +hydrochloride 2 +- 0 +induced 0 +seizures 3 +in 0 +mice 0 +. 0 + +BACKGR0UND 0 +: 0 +It 0 +is 0 +not 0 +known 0 +if 0 +there 0 +is 0 +a 0 +relationship 0 +between 0 +input 0 +rate 0 +and 0 +incidence 0 +of 0 +bupropion 1 +- 0 +induced 0 +seizures 3 +. 0 + +This 0 +is 0 +important 0 +, 0 +since 0 +different 0 +controlled 0 +release 0 +formulations 0 +of 0 +bupropion 1 +release 0 +the 0 +active 0 +drug 0 +at 0 +different 0 +rates 0 +. 0 + +METH0DS 0 +: 0 +We 0 +investigated 0 +the 0 +effect 0 +of 0 +varying 0 +the 0 +intraperitoneal 0 +infusion 0 +rates 0 +of 0 +bupropion 1 +HCl 2 +120 0 +mg 0 +/ 0 +kg 0 +, 0 +a 0 +known 0 +convulsive 3 +dose 0 +50 0 +( 0 +CD50 0 +) 0 +, 0 +on 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +bupropion 1 +- 0 +induced 0 +convulsions 3 +in 0 +the 0 +Swiss 0 +albino 0 +mice 0 +. 0 + +A 0 +total 0 +of 0 +69 0 +mice 0 +, 0 +approximately 0 +7 0 +weeks 0 +of 0 +age 0 +, 0 +and 0 +weighing 0 +21 0 +. 0 +0 0 +to 0 +29 0 +. 0 +1 0 +g 0 +were 0 +randomly 0 +assigned 0 +to 0 +bupropion 1 +HCl 2 +120 0 +mg 0 +/ 0 +kg 0 +treatment 0 +by 0 +intraperitoneal 0 +( 0 +IP 0 +) 0 +administration 0 +in 0 +7 0 +groups 0 +( 0 +9 0 +to 0 +10 0 +animals 0 +per 0 +group 0 +) 0 +. 0 + +Bupropion 1 +HCl 2 +was 0 +infused 0 +through 0 +a 0 +surgically 0 +implanted 0 +IP 0 +dosing 0 +catheter 0 +with 0 +infusions 0 +in 0 +each 0 +group 0 +of 0 +0 0 +min 0 +, 0 +15 0 +min 0 +, 0 +30 0 +min 0 +, 0 +60 0 +min 0 +, 0 +90 0 +min 0 +, 0 +120 0 +min 0 +, 0 +and 0 +240 0 +min 0 +. 0 + +The 0 +number 0 +, 0 +time 0 +of 0 +onset 0 +, 0 +duration 0 +and 0 +the 0 +intensity 0 +of 0 +the 0 +convulsions 3 +or 0 +absence 0 +of 0 +convulsions 3 +were 0 +recorded 0 +. 0 + +RESULTS 0 +: 0 +The 0 +results 0 +showed 0 +that 0 +IP 0 +administration 0 +of 0 +bupropion 1 +HCl 2 +120 0 +mg 0 +/ 0 +kg 0 +by 0 +bolus 0 +injection 0 +induced 0 +convulsions 3 +in 0 +6 0 +out 0 +of 0 +10 0 +mice 0 +( 0 +60 0 +% 0 +of 0 +convulsing 0 +mice 0 +) 0 +in 0 +group 0 +1 0 +. 0 + +Logistic 0 +regression 0 +analysis 0 +revealed 0 +that 0 +infusion 0 +time 0 +was 0 +significant 0 +( 0 +p 0 += 0 +0 0 +. 0 +0004 0 +; 0 +odds 0 +ratio 0 += 0 +0 0 +. 0 +974 0 +) 0 +and 0 +increasing 0 +the 0 +IP 0 +infusion 0 +time 0 +of 0 +bupropion 1 +HCl 2 +120 0 +mg 0 +/ 0 +kg 0 +was 0 +associated 0 +with 0 +a 0 +91 0 +% 0 +reduced 0 +odds 0 +of 0 +convulsions 3 +at 0 +infusion 0 +times 0 +of 0 +15 0 +to 0 +90 0 +min 0 +compared 0 +to 0 +bolus 0 +injection 0 +. 0 + +Further 0 +increase 0 +in 0 +infusion 0 +time 0 +resulted 0 +in 0 +further 0 +reduction 0 +in 0 +the 0 +odds 0 +of 0 +convulsions 3 +to 0 +99 0 +. 0 +8 0 +% 0 +reduction 0 +at 0 +240 0 +min 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +conclusion 0 +, 0 +the 0 +demonstration 0 +of 0 +an 0 +inverse 0 +relationship 0 +between 0 +infusion 0 +time 0 +of 0 +a 0 +fixed 0 +and 0 +convulsive 3 +dose 0 +of 0 +bupropion 1 +and 0 +the 0 +risk 0 +of 0 +convulsions 3 +in 0 +a 0 +prospective 0 +study 0 +is 0 +novel 0 +. 0 + +Graft 3 +- 4 +versus 4 +- 4 +host 4 +disease 4 +prophylaxis 0 +with 0 +everolimus 1 +and 0 +tacrolimus 1 +is 0 +associated 0 +with 0 +a 0 +high 0 +incidence 0 +of 0 +sinusoidal 3 +obstruction 4 +syndrome 4 +and 0 +microangiopathy 3 +: 0 +results 0 +of 0 +the 0 +EVTAC 0 +trial 0 +. 0 + +A 0 +calcineurin 0 +inhibitor 0 +combined 0 +with 0 +methotrexate 1 +is 0 +the 0 +standard 0 +prophylaxis 0 +for 0 +graft 3 +- 4 +versus 4 +- 4 +host 4 +disease 4 +( 0 +GVHD 3 +) 0 +after 0 +allogeneic 0 +hematopoietic 0 +stem 0 +cell 0 +transplantation 0 +( 0 +HSCT 0 +) 0 +. 0 + +Everolimus 1 +, 0 +a 0 +derivative 0 +of 0 +sirolimus 1 +, 0 +seems 0 +to 0 +mediate 0 +antileukemia 0 +effects 0 +. 0 + +We 0 +report 0 +on 0 +a 0 +combination 0 +of 0 +everolimus 1 +and 0 +tacrolimus 1 +in 0 +24 0 +patients 0 +( 0 +median 0 +age 0 +, 0 +62 0 +years 0 +) 0 +with 0 +either 0 +myelodysplastic 3 +syndrome 4 +( 0 +MDS 3 +; 0 +n 0 += 0 +17 0 +) 0 +or 0 +acute 3 +myeloid 4 +leukemia 4 +( 0 +AML 3 +; 0 +n 0 += 0 +7 0 +) 0 +undergoing 0 +intensive 0 +conditioning 0 +followed 0 +by 0 +HSCT 0 +from 0 +related 0 +( 0 +n 0 += 0 +4 0 +) 0 +or 0 +unrelated 0 +( 0 +n 0 += 0 +20 0 +) 0 +donors 0 +. 0 + +All 0 +patients 0 +engrafted 0 +, 0 +and 0 +only 0 +1 0 +patient 0 +experienced 0 +grade 0 +IV 0 +mucositis 3 +. 0 + +Nine 0 +patients 0 +( 0 +37 0 +% 0 +) 0 +developed 0 +acute 0 +grade 0 +II 0 +- 0 +IV 0 +GVHD 3 +, 0 +and 0 +11 0 +of 0 +17 0 +evaluable 0 +patients 0 +( 0 +64 0 +% 0 +) 0 +developed 0 +chronic 0 +extensive 0 +GVHD 3 +. 0 + +Transplantation 3 +- 4 +associated 4 +microangiopathy 4 +( 0 +TMA 3 +) 0 +occurred 0 +in 0 +7 0 +patients 0 +( 0 +29 0 +% 0 +) 0 +, 0 +with 0 +2 0 +cases 0 +of 0 +acute 3 +renal 4 +failure 4 +. 0 + +The 0 +study 0 +was 0 +terminated 0 +prematurely 0 +because 0 +an 0 +additional 0 +6 0 +patients 0 +( 0 +25 0 +% 0 +) 0 +developed 0 +sinusoidal 3 +obstruction 4 +syndrome 4 +( 0 +S0S 3 +) 0 +, 0 +which 0 +was 0 +fatal 0 +in 0 +2 0 +cases 0 +. 0 + +With 0 +a 0 +median 0 +follow 0 +- 0 +up 0 +of 0 +26 0 +months 0 +, 0 +the 0 +2 0 +- 0 +year 0 +overall 0 +survival 0 +rate 0 +was 0 +47 0 +% 0 +. 0 + +Although 0 +this 0 +new 0 +combination 0 +appears 0 +to 0 +be 0 +effective 0 +as 0 +a 0 +prophylactic 0 +regimen 0 +for 0 +acute 0 +GVHD 3 +, 0 +the 0 +incidence 0 +of 0 +TMA 3 +and 0 +S0S 3 +is 0 +considerably 0 +higher 0 +than 0 +seen 0 +with 0 +other 0 +regimens 0 +. 0 + +Longitudinal 0 +assessment 0 +of 0 +air 0 +conduction 0 +audiograms 0 +in 0 +a 0 +phase 0 +III 0 +clinical 0 +trial 0 +of 0 +difluoromethylornithine 1 +and 0 +sulindac 1 +for 0 +prevention 0 +of 0 +sporadic 0 +colorectal 3 +adenomas 4 +. 0 + +A 0 +phase 0 +III 0 +clinical 0 +trial 0 +assessed 0 +the 0 +recurrence 0 +of 0 +adenomatous 3 +polyps 4 +after 0 +treatment 0 +for 0 +36 0 +months 0 +with 0 +difluoromethylornithine 1 +( 0 +DFM0 1 +) 0 +plus 0 +sulindac 1 +or 0 +matched 0 +placebos 0 +. 0 + +Temporary 0 +hearing 3 +loss 4 +is 0 +a 0 +known 0 +toxicity 3 +of 0 +treatment 0 +with 0 +DFM0 1 +, 0 +thus 0 +a 0 +comprehensive 0 +approach 0 +was 0 +developed 0 +to 0 +analyze 0 +serial 0 +air 0 +conduction 0 +audiograms 0 +. 0 + +The 0 +generalized 0 +estimating 0 +equation 0 +method 0 +estimated 0 +the 0 +mean 0 +difference 0 +between 0 +treatment 0 +arms 0 +with 0 +regard 0 +to 0 +change 0 +in 0 +air 0 +conduction 0 +pure 0 +tone 0 +thresholds 0 +while 0 +accounting 0 +for 0 +within 0 +- 0 +subject 0 +correlation 0 +due 0 +to 0 +repeated 0 +measurements 0 +at 0 +frequencies 0 +. 0 + +Based 0 +on 0 +290 0 +subjects 0 +, 0 +there 0 +was 0 +an 0 +average 0 +difference 0 +of 0 +0 0 +. 0 +50 0 +dB 0 +between 0 +subjects 0 +treated 0 +with 0 +DFM0 1 +plus 0 +sulindac 1 +compared 0 +with 0 +those 0 +treated 0 +with 0 +placebo 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +- 0 +0 0 +. 0 +64 0 +to 0 +1 0 +. 0 +63 0 +dB 0 +; 0 +P 0 += 0 +0 0 +. 0 +39 0 +) 0 +, 0 +adjusted 0 +for 0 +baseline 0 +values 0 +, 0 +age 0 +, 0 +and 0 +frequencies 0 +. 0 + +In 0 +the 0 +normal 0 +speech 0 +range 0 +of 0 +500 0 +to 0 +3 0 +, 0 +000 0 +Hz 0 +, 0 +an 0 +estimated 0 +difference 0 +of 0 +0 0 +. 0 +99 0 +dB 0 +( 0 +- 0 +0 0 +. 0 +17 0 +to 0 +2 0 +. 0 +14 0 +dB 0 +; 0 +P 0 += 0 +0 0 +. 0 +09 0 +) 0 +was 0 +detected 0 +. 0 + +Dose 0 +intensity 0 +did 0 +not 0 +add 0 +information 0 +to 0 +models 0 +. 0 + +There 0 +were 0 +14 0 +of 0 +151 0 +( 0 +9 0 +. 0 +3 0 +% 0 +) 0 +in 0 +the 0 +DFM0 1 +plus 0 +sulindac 1 +group 0 +and 0 +4 0 +of 0 +139 0 +( 0 +2 0 +. 0 +9 0 +% 0 +) 0 +in 0 +the 0 +placebo 0 +group 0 +who 0 +experienced 0 +at 0 +least 0 +15 0 +dB 0 +hearing 0 +reduction 0 +from 0 +baseline 0 +in 0 +2 0 +or 0 +more 0 +consecutive 0 +frequencies 0 +across 0 +the 0 +entire 0 +range 0 +tested 0 +( 0 +P 0 += 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +Follow 0 +- 0 +up 0 +air 0 +conduction 0 +done 0 +at 0 +least 0 +6 0 +months 0 +after 0 +end 0 +of 0 +treatment 0 +showed 0 +an 0 +adjusted 0 +mean 0 +difference 0 +in 0 +hearing 0 +thresholds 0 +of 0 +1 0 +. 0 +08 0 +dB 0 +( 0 +- 0 +0 0 +. 0 +81 0 +to 0 +2 0 +. 0 +96 0 +dB 0 +; 0 +P 0 += 0 +0 0 +. 0 +26 0 +) 0 +between 0 +treatment 0 +arms 0 +. 0 + +There 0 +was 0 +no 0 +significant 0 +difference 0 +in 0 +the 0 +proportion 0 +of 0 +subjects 0 +in 0 +the 0 +DFM0 1 +plus 0 +sulindac 1 +group 0 +who 0 +experienced 0 +clinically 0 +significant 0 +hearing 3 +loss 4 +compared 0 +with 0 +the 0 +placebo 0 +group 0 +. 0 + +The 0 +estimated 0 +attributable 0 +risk 0 +of 0 +ototoxicity 3 +from 0 +exposure 0 +to 0 +the 0 +drug 0 +is 0 +8 0 +. 0 +4 0 +% 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +- 0 +2 0 +. 0 +0 0 +% 0 +to 0 +18 0 +. 0 +8 0 +% 0 +; 0 +P 0 += 0 +0 0 +. 0 +12 0 +) 0 +. 0 + +There 0 +is 0 +a 0 +< 0 +2 0 +dB 0 +difference 0 +in 0 +mean 0 +threshold 0 +for 0 +patients 0 +treated 0 +with 0 +DFM0 1 +plus 0 +sulindac 1 +compared 0 +with 0 +those 0 +treated 0 +with 0 +placebo 0 +. 0 + +Proteinase 0 +3 0 +- 0 +antineutrophil 0 +cytoplasmic 0 +antibody 0 +- 0 +( 0 +PR3 0 +- 0 +ANCA 0 +) 0 +positive 0 +necrotizing 0 +glomerulonephritis 3 +after 0 +restarting 0 +sulphasalazine 1 +treatment 0 +. 0 + +A 0 +59 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +ulcerative 3 +colitis 4 +developed 0 +red 3 +eyes 4 +, 0 +pleural 3 +effusion 4 +, 0 +eosinophilia 3 +and 0 +urinary 3 +abnormalities 4 +after 0 +restarting 0 +of 0 +sulphasalazine 1 +treatment 0 +. 0 + +Light 0 +microscopy 0 +of 0 +a 0 +kidney 0 +biopsy 0 +revealed 0 +segmental 3 +necrotizing 4 +glomerulonephritis 4 +without 0 +deposition 0 +of 0 +immunoglobulin 0 +or 0 +complement 0 +. 0 + +Proteinase 0 +3 0 +- 0 +antineutrophil 0 +cytoplasmic 0 +antibody 0 +( 0 +PR3 0 +- 0 +ANCA 0 +) 0 +titer 0 +was 0 +elevated 0 +at 0 +183 0 +ELISA 0 +units 0 +( 0 +EU 0 +) 0 +in 0 +sera 0 +( 0 +normal 0 +range 0 +less 0 +than 0 +10 0 +EU 0 +) 0 +, 0 +myeloperoxidase 0 +- 0 +ANCA 0 +was 0 +negative 0 +. 0 + +PR3 0 +- 0 +ANCA 0 +titer 0 +was 0 +250 0 +and 0 +1 0 +, 0 +070 0 +EU 0 +in 0 +pleural 3 +effusions 4 +on 0 +right 0 +and 0 +left 0 +side 0 +, 0 +respectively 0 +. 0 + +Although 0 +cessation 0 +of 0 +sulphasalazine 1 +treatment 0 +resulted 0 +in 0 +improvements 0 +in 0 +fever 3 +, 0 +red 3 +eyes 4 +, 0 +chest 3 +pain 4 +, 0 +titer 0 +of 0 +C 0 +- 0 +reactive 0 +protein 0 +and 0 +volume 0 +of 0 +the 0 +pleural 3 +effusions 4 +, 0 +we 0 +initiated 0 +steroid 1 +therapy 0 +, 0 +because 0 +PR3 0 +- 0 +ANCA 0 +titer 0 +rose 0 +to 0 +320 0 +EU 0 +, 0 +eosinophil 0 +count 0 +increased 0 +to 0 +1 0 +, 0 +100 0 +cells 0 +/ 0 +microl 0 +, 0 +and 0 +the 0 +pleural 3 +effusion 4 +remained 0 +. 0 + +0ne 0 +month 0 +after 0 +steroid 1 +therapy 0 +, 0 +the 0 +pleural 3 +effusion 4 +disappeared 0 +, 0 +and 0 +PR3 0 +- 0 +ANCA 0 +titer 0 +normalized 0 +3 0 +months 0 +later 0 +. 0 + +This 0 +case 0 +suggests 0 +that 0 +sulphasalazine 1 +can 0 +induce 0 +PR3 0 +- 0 +ANCA 0 +- 0 +positive 0 +necrotizing 0 +glomerulonephritis 3 +. 0 + +Comparison 0 +of 0 +unilateral 0 +pallidotomy 0 +and 0 +subthalamotomy 0 +findings 0 +in 0 +advanced 0 +idiopathic 3 +Parkinson 4 +' 4 +s 4 +disease 4 +. 0 + +A 0 +prospective 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +pilot 0 +study 0 +to 0 +compare 0 +the 0 +results 0 +of 0 +stereotactic 0 +unilateral 0 +pallidotomy 0 +and 0 +subthalamotomy 0 +in 0 +advanced 0 +idiopathic 3 +Parkinson 4 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +refractory 0 +to 0 +medical 0 +treatment 0 +was 0 +designed 0 +. 0 + +Ten 0 +consecutive 0 +patients 0 +( 0 +mean 0 +age 0 +, 0 +58 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +8 0 +years 0 +; 0 +7 0 +men 0 +, 0 +3 0 +women 0 +) 0 +with 0 +similar 0 +characteristics 0 +at 0 +the 0 +duration 0 +of 0 +disease 0 +( 0 +mean 0 +disease 0 +time 0 +, 0 +8 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +5 0 +years 0 +) 0 +, 0 +disabling 0 +motor 0 +fluctuations 0 +( 0 +Hoehn 0 +_ 0 +Yahr 0 +stage 0 +3 0 +- 0 +5 0 +in 0 +off 0 +- 0 +drug 0 +phases 0 +) 0 +and 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +were 0 +selected 0 +. 0 + +All 0 +patients 0 +had 0 +bilateral 0 +symptoms 0 +and 0 +their 0 +levodopa 1 +equivalent 0 +dosing 0 +were 0 +analysed 0 +. 0 + +Six 0 +patients 0 +were 0 +operated 0 +on 0 +in 0 +the 0 +globus 0 +pallidus 0 +interna 0 +( 0 +GPi 0 +) 0 +and 0 +four 0 +in 0 +the 0 +subthalamic 0 +nucleus 0 +( 0 +STN 0 +) 0 +. 0 + +Clinical 0 +evaluation 0 +included 0 +the 0 +use 0 +of 0 +the 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +( 0 +UPDRS 0 +) 0 +, 0 +Hoehn 0 +_ 0 +Yahr 0 +score 0 +and 0 +Schwab 0 +England 0 +activities 0 +of 0 +daily 0 +living 0 +( 0 +ADL 0 +) 0 +score 0 +in 0 +' 0 +on 0 +' 0 +- 0 +and 0 +' 0 +off 0 +' 0 +- 0 +drug 0 +conditions 0 +before 0 +surgery 0 +and 0 +6 0 +months 0 +after 0 +surgery 0 +. 0 + +There 0 +was 0 +statistically 0 +significant 0 +improvement 0 +in 0 +all 0 +contralateral 0 +major 0 +parkinsonian 3 +motor 0 +signs 0 +in 0 +all 0 +patients 0 +followed 0 +for 0 +6 0 +months 0 +. 0 + +Levodopa 1 +equivalent 0 +daily 0 +intake 0 +was 0 +significantly 0 +reduced 0 +in 0 +the 0 +STN 0 +group 0 +. 0 + +Changes 0 +in 0 +UPDRS 0 +, 0 +Hoehn 0 +_ 0 +Yahr 0 +and 0 +Schwab 0 +England 0 +ADL 0 +scores 0 +were 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 + +Cognitive 0 +functions 0 +were 0 +unchanged 0 +in 0 +both 0 +groups 0 +. 0 + +Complications 0 +were 0 +observed 0 +in 0 +two 0 +patients 0 +: 0 +one 0 +had 0 +a 0 +left 0 +homonymous 3 +hemianopsia 4 +after 0 +pallidotomy 0 +and 0 +another 0 +one 0 +developed 0 +left 0 +hemiballistic 0 +movements 0 +3 0 +days 0 +after 0 +subthalamotomy 0 +which 0 +partly 0 +improved 0 +within 0 +1 0 +month 0 +with 0 +Valproate 1 +1000 0 +mg 0 +/ 0 +day 0 +. 0 + +The 0 +findings 0 +of 0 +this 0 +study 0 +suggest 0 +that 0 +lesions 0 +of 0 +the 0 +unilateral 0 +STN 0 +and 0 +GPi 0 +are 0 +equally 0 +effective 0 +treatment 0 +for 0 +patients 0 +with 0 +advanced 0 +PD 3 +refractory 0 +to 0 +medical 0 +treatment 0 +. 0 + +DSMM 0 +XI 0 +study 0 +: 0 +dose 0 +definition 0 +for 0 +intravenous 0 +cyclophosphamide 1 +in 0 +combination 0 +with 0 +bortezomib 1 +/ 0 +dexamethasone 1 +for 0 +remission 0 +induction 0 +in 0 +patients 0 +with 0 +newly 0 +diagnosed 0 +myeloma 3 +. 0 + +A 0 +clinical 0 +trial 0 +was 0 +initiated 0 +to 0 +evaluate 0 +the 0 +recommended 0 +dose 0 +of 0 +cyclophosphamide 1 +in 0 +combination 0 +with 0 +bortezomib 1 +and 0 +dexamethasone 1 +as 0 +induction 0 +treatment 0 +before 0 +stem 0 +cell 0 +transplantation 0 +for 0 +younger 0 +patients 0 +with 0 +newly 0 +diagnosed 0 +multiple 3 +myeloma 4 +( 0 +MM 3 +) 0 +. 0 + +Thirty 0 +patients 0 +were 0 +treated 0 +with 0 +three 0 +21 0 +- 0 +day 0 +cycles 0 +of 0 +bortezomib 1 +1 0 +. 0 +3 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +on 0 +days 0 +1 0 +, 0 +4 0 +, 0 +8 0 +, 0 +and 0 +11 0 +plus 0 +dexamethasone 1 +40 0 +mg 0 +on 0 +the 0 +day 0 +of 0 +bortezomib 1 +injection 0 +and 0 +the 0 +day 0 +after 0 +plus 0 +cyclophosphamide 1 +at 0 +900 0 +, 0 +1 0 +, 0 +200 0 +, 0 +or 0 +1 0 +, 0 +500 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +on 0 +day 0 +1 0 +. 0 + +The 0 +maximum 0 +tolerated 0 +dose 0 +of 0 +cyclophosphamide 1 +was 0 +defined 0 +as 0 +900 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +. 0 + +At 0 +this 0 +dose 0 +level 0 +, 0 +92 0 +% 0 +of 0 +patients 0 +achieved 0 +at 0 +least 0 +a 0 +partial 0 +response 0 +. 0 + +The 0 +overall 0 +response 0 +rate 0 +[ 0 +complete 0 +response 0 +( 0 +CR 0 +) 0 +plus 0 +partial 0 +response 0 +( 0 +PR 0 +) 0 +] 0 +across 0 +all 0 +dose 0 +levels 0 +was 0 +77 0 +% 0 +, 0 +with 0 +a 0 +10 0 +% 0 +CR 0 +rate 0 +. 0 + +No 0 +patient 0 +experienced 0 +progressive 0 +disease 0 +. 0 + +The 0 +most 0 +frequent 0 +adverse 0 +events 0 +were 0 +hematological 3 +and 4 +gastrointestinal 4 +toxicities 4 +as 0 +well 0 +as 0 +neuropathy 3 +. 0 + +The 0 +results 0 +suggest 0 +that 0 +bortezomib 1 +in 0 +combination 0 +with 0 +cyclophosphamide 1 +at 0 +900 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +and 0 +dexamethasone 1 +is 0 +an 0 +effective 0 +induction 0 +treatment 0 +for 0 +patients 0 +with 0 +newly 0 +diagnosed 0 +MM 3 +that 0 +warrants 0 +further 0 +investigation 0 +. 0 + +Naloxone 1 +reversal 0 +of 0 +hypotension 3 +due 0 +to 0 +captopril 1 +overdose 3 +. 0 + +The 0 +hemodynamic 0 +effects 0 +of 0 +captopril 1 +and 0 +other 0 +angiotensin 1 +- 2 +converting 2 +enzyme 2 +inhibitors 2 +may 0 +be 0 +mediated 0 +by 0 +the 0 +endogenous 0 +opioid 0 +system 0 +. 0 + +The 0 +opioid 0 +antagonist 0 +naloxone 1 +has 0 +been 0 +shown 0 +to 0 +block 0 +or 0 +reverse 0 +the 0 +hypotensive 3 +actions 0 +of 0 +captopril 1 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +an 0 +intentional 0 +captopril 1 +overdose 3 +, 0 +manifested 0 +by 0 +marked 0 +hypotension 3 +, 0 +that 0 +resolved 0 +promptly 0 +with 0 +the 0 +administration 0 +of 0 +naloxone 1 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +captopril 1 +- 0 +induced 0 +hypotension 3 +treated 0 +with 0 +naloxone 1 +. 0 + +0ur 0 +experience 0 +demonstrates 0 +a 0 +possible 0 +role 0 +of 0 +naloxone 1 +in 0 +the 0 +reversal 0 +of 0 +hypotension 3 +resulting 0 +from 0 +captopril 1 +. 0 + +Identification 0 +of 0 +a 0 +simple 0 +and 0 +sensitive 0 +microplate 0 +method 0 +for 0 +the 0 +detection 0 +of 0 +oversulfated 0 +chondroitin 1 +sulfate 2 +in 0 +heparin 1 +products 0 +. 0 + +Heparin 1 +is 0 +a 0 +commonly 0 +implemented 0 +anticoagulant 0 +used 0 +to 0 +treat 0 +critically 0 +ill 0 +patients 0 +. 0 + +Recently 0 +, 0 +a 0 +number 0 +of 0 +commercial 0 +lots 0 +of 0 +heparin 1 +products 0 +were 0 +found 0 +to 0 +be 0 +contaminated 0 +with 0 +an 0 +oversulfated 0 +chondroitin 1 +sulfate 2 +( 0 +0SCS 0 +) 0 +derivative 0 +that 0 +could 0 +elicit 0 +a 0 +hypotensive 3 +response 0 +in 0 +pigs 0 +following 0 +a 0 +single 0 +high 0 +- 0 +dose 0 +infusion 0 +. 0 + +Using 0 +both 0 +contaminated 0 +heparin 1 +products 0 +and 0 +the 0 +synthetically 0 +produced 0 +derivative 0 +, 0 +we 0 +showed 0 +that 0 +the 0 +0SCS 0 +produces 0 +dose 0 +- 0 +dependent 0 +hypotension 3 +in 0 +pigs 0 +. 0 + +The 0 +no 0 +observed 0 +effect 0 +level 0 +( 0 +N0EL 0 +) 0 +for 0 +this 0 +contaminant 0 +appears 0 +to 0 +be 0 +approximately 0 +1mg 0 +/ 0 +kg 0 +, 0 +corresponding 0 +to 0 +a 0 +contamination 0 +level 0 +of 0 +approximately 0 +3 0 +% 0 +. 0 + +We 0 +also 0 +demonstrated 0 +that 0 +0SCS 0 +can 0 +be 0 +identified 0 +in 0 +heparin 1 +products 0 +using 0 +a 0 +simple 0 +, 0 +inexpensive 0 +, 0 +commercially 0 +available 0 +heparin 1 +enzyme 0 +immunoassay 0 +( 0 +EIA 0 +) 0 +kit 0 +that 0 +has 0 +a 0 +limit 0 +of 0 +detection 0 +of 0 +approximately 0 +0 0 +. 0 +1 0 +% 0 +, 0 +well 0 +below 0 +the 0 +N0EL 0 +. 0 + +This 0 +kit 0 +may 0 +provide 0 +a 0 +useful 0 +method 0 +to 0 +test 0 +heparin 1 +products 0 +for 0 +contamination 0 +with 0 +oversulfated 0 +GAG 0 +derivatives 0 +. 0 + +5 1 +flourouracil 2 +- 0 +induced 0 +apical 3 +ballooning 4 +syndrome 4 +: 0 +a 0 +case 0 +report 0 +. 0 + +The 0 +apical 3 +ballooning 4 +syndrome 4 +( 0 +ABS 3 +) 0 +is 0 +a 0 +recently 0 +described 0 +stress 0 +- 0 +mediated 0 +acute 3 +cardiac 4 +syndrome 4 +characterized 0 +by 0 +transient 0 +wall 0 +- 0 +motion 0 +abnormalities 0 +involving 0 +the 0 +apex 0 +and 0 +midventricle 0 +with 0 +hyperkinesis 3 +of 0 +the 0 +basal 0 +left 0 +ventricular 0 +( 0 +LV 0 +) 0 +segments 0 +without 0 +obstructive 0 +epicardial 3 +coronary 4 +disease 4 +. 0 + +Cardiotoxicity 3 +is 0 +not 0 +an 0 +uncommon 0 +adverse 0 +effect 0 +of 0 +chemotherapeutic 0 +agents 0 +. 0 + +However 0 +, 0 +there 0 +are 0 +no 0 +reports 0 +of 0 +ABS 3 +secondary 0 +to 0 +chemotherapeutic 0 +agents 0 +. 0 + +We 0 +describe 0 +the 0 +case 0 +of 0 +a 0 +woman 0 +who 0 +developed 0 +the 0 +syndrome 0 +after 0 +chemotherapy 0 +for 0 +metastatic 0 +cancer 3 +. 0 + +A 0 +79 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +presented 0 +with 0 +typical 0 +ischemic 3 +chest 3 +pain 4 +, 0 +elevated 0 +cardiac 0 +enzymes 0 +with 0 +significant 0 +ST 0 +- 0 +segment 0 +abnormalities 0 +on 0 +her 0 +electrocardiogram 0 +. 0 + +She 0 +underwent 0 +recent 0 +chemotherapy 0 +with 0 +fluorouracil 1 +for 0 +metastatic 0 +colorectal 3 +cancer 4 +. 0 + +Echocardiography 0 +revealed 0 +a 0 +wall 0 +- 0 +motion 0 +abnormality 0 +involving 0 +the 0 +apical 0 +and 0 +periapical 0 +segments 0 +which 0 +appeared 0 +akinetic 3 +. 0 + +Coronary 0 +angiography 0 +revealed 0 +no 0 +obstructive 0 +coronary 0 +lesions 0 +. 0 + +The 0 +patient 0 +was 0 +stabilized 0 +with 0 +medical 0 +therapy 0 +. 0 + +Four 0 +weeks 0 +later 0 +she 0 +remained 0 +completely 0 +asymptomatic 0 +. 0 + +Echocardiogram 0 +revealed 0 +a 0 +normal 0 +ejection 0 +fraction 0 +and 0 +a 0 +resolution 0 +of 0 +the 0 +apical 0 +akinesis 3 +. 0 + +Pathogenetic 0 +mechanisms 0 +of 0 +cardiac 3 +complications 4 +in 0 +cancer 3 +patients 0 +undergoing 0 +chemotherapy 0 +include 0 +coronary 3 +vasospasm 4 +, 0 +endothelial 0 +damage 0 +and 0 +consequent 0 +thrombus 3 +formation 0 +. 0 + +In 0 +our 0 +patient 0 +, 0 +both 0 +supraphysiologic 0 +levels 0 +of 0 +plasma 0 +catecholamines 1 +and 0 +stress 0 +related 0 +neuropeptides 0 +caused 0 +by 0 +cancer 3 +diagnosis 0 +as 0 +well 0 +as 0 +chemotherapy 0 +may 0 +have 0 +contributed 0 +the 0 +development 0 +of 0 +ABS 3 +. 0 + +Rapid 0 +reversal 0 +of 0 +anticoagulation 0 +reduces 0 +hemorrhage 3 +volume 0 +in 0 +a 0 +mouse 0 +model 0 +of 0 +warfarin 1 +- 0 +associated 0 +intracerebral 3 +hemorrhage 4 +. 0 + +Warfarin 1 +- 0 +associated 0 +intracerebral 3 +hemorrhage 4 +( 0 +W 0 +- 0 +ICH 3 +) 0 +is 0 +a 0 +severe 0 +type 0 +of 0 +stroke 3 +. 0 + +There 0 +is 0 +no 0 +consensus 0 +on 0 +the 0 +optimal 0 +treatment 0 +for 0 +W 0 +- 0 +ICH 3 +. 0 + +Using 0 +a 0 +mouse 0 +model 0 +, 0 +we 0 +tested 0 +whether 0 +the 0 +rapid 0 +reversal 0 +of 0 +anticoagulation 0 +using 0 +human 0 +prothrombin 1 +complex 2 +concentrate 2 +( 0 +PCC 1 +) 0 +can 0 +reduce 0 +hemorrhagic 0 +blood 0 +volume 0 +. 0 + +Male 0 +CD 0 +- 0 +1 0 +mice 0 +were 0 +treated 0 +with 0 +warfarin 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +over 0 +24 0 +h 0 +) 0 +, 0 +resulting 0 +in 0 +a 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +s 0 +. 0 +d 0 +. 0 +) 0 +International 0 +Normalized 0 +Ratio 0 +of 0 +3 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +. 0 + +First 0 +, 0 +we 0 +showed 0 +that 0 +an 0 +intravenous 0 +administration 0 +of 0 +human 0 +PCC 1 +rapidly 0 +reversed 0 +anticoagulation 0 +in 0 +mice 0 +. 0 + +Second 0 +, 0 +a 0 +stereotactic 0 +injection 0 +of 0 +collagenase 0 +was 0 +administered 0 +to 0 +induce 0 +hemorrhage 3 +in 0 +the 0 +right 0 +striatum 0 +. 0 + +Forty 0 +- 0 +five 0 +minutes 0 +later 0 +, 0 +the 0 +animals 0 +were 0 +randomly 0 +treated 0 +with 0 +PCC 1 +( 0 +100 0 +U 0 +/ 0 +kg 0 +) 0 +or 0 +saline 0 +i 0 +. 0 +v 0 +. 0 +( 0 +n 0 += 0 +12 0 +per 0 +group 0 +) 0 +. 0 + +Twenty 0 +- 0 +four 0 +hours 0 +after 0 +hemorrhage 3 +induction 0 +, 0 +hemorrhagic 0 +blood 0 +volume 0 +was 0 +quantified 0 +using 0 +a 0 +photometric 0 +hemoglobin 0 +assay 0 +. 0 + +The 0 +mean 0 +hemorrhagic 0 +blood 0 +volume 0 +was 0 +reduced 0 +in 0 +PCC 1 +- 0 +treated 0 +animals 0 +( 0 +6 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +1 0 +microL 0 +) 0 +compared 0 +with 0 +saline 0 +controls 0 +( 0 +15 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +11 0 +. 0 +2 0 +microL 0 +, 0 +P 0 += 0 +0 0 +. 0 +015 0 +) 0 +. 0 + +In 0 +the 0 +saline 0 +group 0 +, 0 +45 0 +% 0 +of 0 +the 0 +mice 0 +developed 0 +large 0 +hematomas 3 +( 0 +i 0 +. 0 +e 0 +. 0 +, 0 +> 0 +15 0 +microL 0 +) 0 +. 0 + +In 0 +contrast 0 +, 0 +such 0 +extensive 0 +lesions 0 +were 0 +never 0 +found 0 +in 0 +the 0 +PCC 1 +group 0 +. 0 + +We 0 +provide 0 +experimental 0 +data 0 +suggesting 0 +PCC 1 +to 0 +be 0 +an 0 +effective 0 +acute 0 +treatment 0 +for 0 +W 0 +- 0 +ICH 3 +in 0 +terms 0 +of 0 +reducing 0 +hemorrhagic 0 +blood 0 +volume 0 +. 0 + +Future 0 +studies 0 +are 0 +needed 0 +to 0 +assess 0 +the 0 +therapeutic 0 +potential 0 +emerging 0 +from 0 +our 0 +finding 0 +for 0 +human 0 +W 0 +- 0 +ICH 3 +. 0 + +Long 0 +term 0 +hormone 0 +therapy 0 +for 0 +perimenopausal 0 +and 0 +postmenopausal 0 +women 0 +. 0 + +BACKGR0UND 0 +: 0 +Hormone 0 +therapy 0 +( 0 +HT 0 +) 0 +is 0 +widely 0 +used 0 +for 0 +controlling 0 +menopausal 0 +symptoms 0 +and 0 +has 0 +also 0 +been 0 +used 0 +for 0 +the 0 +management 0 +and 0 +prevention 0 +of 0 +cardiovascular 3 +disease 4 +, 0 +osteoporosis 3 +and 0 +dementia 3 +in 0 +older 0 +women 0 +. 0 + +This 0 +is 0 +an 0 +updated 0 +version 0 +of 0 +the 0 +original 0 +Cochrane 0 +review 0 +first 0 +published 0 +in 0 +2005 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +assess 0 +the 0 +effect 0 +of 0 +long 0 +- 0 +term 0 +HT 0 +on 0 +mortality 0 +, 0 +cardiovascular 0 +outcomes 0 +, 0 +cancer 3 +, 0 +gallbladder 3 +disease 4 +, 0 +cognition 0 +, 0 +fractures 3 +and 0 +quality 0 +of 0 +life 0 +. 0 + +SEARCH 0 +STRATEGY 0 +: 0 +We 0 +searched 0 +the 0 +following 0 +databases 0 +to 0 +November 0 +2007 0 +: 0 +Trials 0 +Register 0 +of 0 +the 0 +Cochrane 0 +Menstrual 3 +Disorders 4 +and 0 +Subfertility 0 +Group 0 +, 0 +Cochrane 0 +Central 0 +Register 0 +of 0 +Controlled 0 +Trials 0 +, 0 +MEDLINE 0 +, 0 +EMBASE 0 +, 0 +Biological 0 +Abstracts 0 +. 0 + +Also 0 +relevant 0 +non 0 +- 0 +indexed 0 +journals 0 +and 0 +conference 0 +abstracts 0 +. 0 + +SELECTI0N 0 +CRITERIA 0 +: 0 +Randomised 0 +double 0 +- 0 +blind 0 +trials 0 +of 0 +HT 0 +versus 0 +placebo 0 +, 0 +taken 0 +for 0 +at 0 +least 0 +one 0 +year 0 +by 0 +perimenopausal 0 +or 0 +postmenopausal 0 +women 0 +. 0 + +HT 0 +included 0 +oestrogens 1 +, 0 +with 0 +or 0 +without 0 +progestogens 1 +, 0 +via 0 +oral 0 +, 0 +transdermal 0 +, 0 +subcutaneous 0 +or 0 +transnasal 0 +routes 0 +. 0 + +DATA 0 +C0LLECTI0N 0 +AND 0 +ANALYSIS 0 +: 0 +Two 0 +authors 0 +independently 0 +assessed 0 +trial 0 +quality 0 +and 0 +extracted 0 +data 0 +. 0 + +MAIN 0 +RESULTS 0 +: 0 +Nineteen 0 +trials 0 +involving 0 +41 0 +, 0 +904 0 +women 0 +were 0 +included 0 +. 0 + +In 0 +relatively 0 +healthy 0 +women 0 +, 0 +combined 0 +continuous 0 +HT 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +venous 3 +thrombo 4 +- 4 +embolism 4 +or 0 +coronary 0 +event 0 +( 0 +after 0 +one 0 +year 0 +' 0 +s 0 +use 0 +) 0 +, 0 +stroke 3 +( 0 +after 0 +three 0 +years 0 +) 0 +, 0 +breast 3 +cancer 4 +and 0 +gallbladder 3 +disease 4 +. 0 + +Long 0 +- 0 +term 0 +oestrogen 1 +- 0 +only 0 +HT 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +venous 3 +thrombo 4 +- 4 +embolism 4 +, 0 +stroke 3 +and 0 +gallbladder 3 +disease 4 +( 0 +after 0 +one 0 +to 0 +two 0 +years 0 +, 0 +three 0 +years 0 +and 0 +seven 0 +years 0 +' 0 +use 0 +respectively 0 +) 0 +, 0 +but 0 +did 0 +not 0 +significantly 0 +increase 0 +the 0 +risk 0 +of 0 +breast 3 +cancer 4 +. 0 + +The 0 +only 0 +statistically 0 +significant 0 +benefits 0 +of 0 +HT 0 +were 0 +a 0 +decreased 0 +incidence 0 +of 0 +fractures 3 +and 0 +( 0 +for 0 +combined 0 +HT 0 +) 0 +colon 3 +cancer 4 +, 0 +with 0 +long 0 +- 0 +term 0 +use 0 +. 0 + +Among 0 +women 0 +aged 0 +over 0 +65 0 +who 0 +were 0 +relatively 0 +healthy 0 +( 0 +i 0 +. 0 +e 0 +. 0 +generally 0 +fit 0 +, 0 +without 0 +overt 0 +disease 0 +) 0 +and 0 +taking 0 +continuous 0 +combined 0 +HT 0 +, 0 +there 0 +was 0 +a 0 +statistically 0 +significant 0 +increase 0 +in 0 +the 0 +incidence 0 +of 0 +dementia 3 +. 0 + +Among 0 +women 0 +with 0 +cardiovascular 3 +disease 4 +, 0 +long 0 +- 0 +term 0 +use 0 +of 0 +combined 0 +continuous 0 +HT 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +venous 3 +thrombo 4 +- 4 +embolism 4 +. 0 +0ne 0 +trial 0 +analysed 0 +subgroups 0 +of 0 +2839 0 +relatively 0 +healthy 0 +50 0 +to 0 +59 0 +year 0 +old 0 +women 0 +taking 0 +combined 0 +continuous 0 +HT 0 +and 0 +1637 0 +taking 0 +oestrogen 1 +- 0 +only 0 +HT 0 +, 0 +versus 0 +similar 0 +- 0 +sized 0 +placebo 0 +groups 0 +. 0 + +The 0 +only 0 +significantly 0 +increased 0 +risk 0 +reported 0 +was 0 +for 0 +venous 3 +thrombo 4 +- 4 +embolism 4 +in 0 +women 0 +taking 0 +combined 0 +continuous 0 +HT 0 +: 0 +their 0 +absolute 0 +risk 0 +remained 0 +low 0 +, 0 +at 0 +less 0 +than 0 +1 0 +/ 0 +500 0 +. 0 + +However 0 +, 0 +this 0 +study 0 +was 0 +not 0 +powered 0 +to 0 +detect 0 +differences 0 +between 0 +groups 0 +of 0 +younger 0 +women 0 +. 0 + +AUTH0RS 0 +' 0 +C0NCLUSI0NS 0 +: 0 +HT 0 +is 0 +not 0 +indicated 0 +for 0 +the 0 +routine 0 +management 0 +of 0 +chronic 0 +disease 0 +. 0 + +We 0 +need 0 +more 0 +evidence 0 +on 0 +the 0 +safety 0 +of 0 +HT 0 +for 0 +menopausal 0 +symptom 0 +control 0 +, 0 +though 0 +short 0 +- 0 +term 0 +use 0 +appears 0 +to 0 +be 0 +relatively 0 +safe 0 +for 0 +healthy 0 +younger 0 +women 0 +. 0 + +Acute 3 +renal 4 +failure 4 +in 0 +patients 0 +with 0 +AIDS 3 +on 0 +tenofovir 1 +while 0 +receiving 0 +prolonged 0 +vancomycin 1 +course 0 +for 0 +osteomyelitis 3 +. 0 + +Renal 3 +failure 4 +developed 0 +after 0 +a 0 +prolonged 0 +course 0 +of 0 +vancomycin 1 +therapy 0 +in 0 +2 0 +patients 0 +who 0 +were 0 +receiving 0 +tenofovir 1 +disoproxil 2 +fumarate 2 +as 0 +part 0 +of 0 +an 0 +antiretroviral 0 +regimen 0 +. 0 + +Tenofovir 1 +has 0 +been 0 +implicated 0 +in 0 +the 0 +development 0 +of 0 +Fanconi 3 +syndrome 4 +and 0 +renal 3 +insufficiency 4 +because 0 +of 0 +its 0 +effects 0 +on 0 +the 0 +proximal 0 +renal 0 +tubule 0 +. 0 + +Vancomycin 1 +nephrotoxicity 3 +is 0 +infrequent 0 +but 0 +may 0 +result 0 +from 0 +coadministration 0 +with 0 +a 0 +nephrotoxic 3 +agent 0 +. 0 + +Clinicians 0 +should 0 +be 0 +aware 0 +that 0 +tenofovir 1 +may 0 +raise 0 +the 0 +risk 0 +of 0 +renal 3 +failure 4 +during 0 +prolonged 0 +administration 0 +of 0 +vancomycin 1 +. 0 + +Recurrent 0 +dysosmia 3 +induced 0 +by 0 +pyrazinamide 1 +. 0 + +Pyrazinamide 1 +can 0 +have 0 +adverse 0 +effects 0 +such 0 +as 0 +hepatic 3 +toxicity 4 +, 0 +hyperuricemia 3 +or 0 +digestive 0 +disorders 0 +. 0 + +In 0 +rare 0 +cases 0 +, 0 +alterations 0 +in 0 +taste 0 +and 0 +smell 0 +function 0 +have 0 +been 0 +reported 0 +for 0 +pyrazinamide 1 +when 0 +combined 0 +with 0 +other 0 +drugs 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +reversible 0 +olfactory 3 +disorder 4 +related 0 +to 0 +pyrazinamide 1 +in 0 +a 0 +woman 0 +, 0 +with 0 +a 0 +positive 0 +rechallenge 0 +. 0 + +The 0 +patient 0 +presented 0 +every 0 +day 0 +a 0 +sensation 0 +of 0 +smelling 0 +something 0 +burning 0 +15 0 +min 0 +after 0 +drug 0 +intake 0 +. 0 + +Dysosmia 3 +disappeared 0 +completely 0 +after 0 +pyrazinamide 1 +withdrawal 0 +and 0 +recurred 0 +after 0 +its 0 +rechallenge 0 +. 0 + +The 0 +case 0 +was 0 +reported 0 +to 0 +the 0 +Tunisian 0 +Centre 0 +of 0 +Pharmacovigilance 0 +. 0 + +Mice 0 +lacking 0 +mPGES 0 +- 0 +1 0 +are 0 +resistant 0 +to 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +. 0 + +Cyclooxygenase 0 +- 0 +2 0 +activity 0 +is 0 +required 0 +for 0 +the 0 +development 0 +of 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +. 0 + +However 0 +, 0 +the 0 +involvement 0 +of 0 +a 0 +specific 0 +, 0 +terminal 0 +prostaglandin 1 +( 0 +PG 1 +) 0 +isomerase 0 +has 0 +not 0 +been 0 +evaluated 0 +. 0 + +The 0 +present 0 +study 0 +was 0 +undertaken 0 +to 0 +assess 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +in 0 +mice 0 +deficient 0 +in 0 +microsomal 0 +prostaglandin 1 +E 2 +synthase 0 +- 0 +1 0 +( 0 +mPGES 0 +- 0 +1 0 +) 0 +. 0 + +A 0 +2 0 +- 0 +wk 0 +administration 0 +of 0 +LiCl 1 +( 0 +4 0 +mmol 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +day 0 +( 0 +- 0 +1 0 +) 0 +ip 0 +) 0 +in 0 +mPGES 0 +- 0 +1 0 ++ 0 +/ 0 ++ 0 +mice 0 +led 0 +to 0 +a 0 +marked 0 +polyuria 3 +with 0 +hyposmotic 0 +urine 0 +. 0 + +This 0 +was 0 +associated 0 +with 0 +elevated 0 +renal 0 +mPGES 0 +- 0 +1 0 +protein 0 +expression 0 +and 0 +increased 0 +urine 0 +PGE 1 +( 2 +2 2 +) 2 +excretion 0 +. 0 + +In 0 +contrast 0 +, 0 +mPGES 0 +- 0 +1 0 +- 0 +/ 0 +- 0 +mice 0 +were 0 +largely 0 +resistant 0 +to 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +and 0 +a 0 +urine 0 +concentrating 0 +defect 0 +, 0 +accompanied 0 +by 0 +nearly 0 +complete 0 +blockade 0 +of 0 +high 0 +urine 0 +PGE 1 +( 2 +2 2 +) 2 +and 0 +cAMP 0 +output 0 +. 0 + +Immunoblotting 0 +, 0 +immunohistochemistry 0 +, 0 +and 0 +quantitative 0 +( 0 +q 0 +) 0 +RT 0 +- 0 +PCR 0 +consistently 0 +detected 0 +a 0 +significant 0 +decrease 0 +in 0 +aquaporin 0 +- 0 +2 0 +( 0 +AQP2 0 +) 0 +protein 0 +expression 0 +in 0 +both 0 +the 0 +renal 0 +cortex 0 +and 0 +medulla 0 +of 0 +lithium 1 +- 0 +treated 0 ++ 0 +/ 0 ++ 0 +mice 0 +. 0 + +This 0 +decrease 0 +was 0 +significantly 0 +attenuated 0 +in 0 +the 0 +- 0 +/ 0 +- 0 +mice 0 +. 0 + +qRT 0 +- 0 +PCR 0 +detected 0 +similar 0 +patterns 0 +of 0 +changes 0 +in 0 +AQP2 0 +mRNA 0 +in 0 +the 0 +medulla 0 +but 0 +not 0 +in 0 +the 0 +cortex 0 +. 0 + +Similarly 0 +, 0 +the 0 +total 0 +protein 0 +abundance 0 +of 0 +the 0 +Na 1 +- 0 +K 1 +- 0 +2Cl 1 +cotransporter 0 +( 0 +NKCC2 0 +) 0 +in 0 +the 0 +medulla 0 +but 0 +not 0 +in 0 +the 0 +cortex 0 +of 0 +the 0 ++ 0 +/ 0 ++ 0 +mice 0 +was 0 +significantly 0 +reduced 0 +by 0 +lithium 1 +treatment 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +dowregulation 0 +of 0 +renal 0 +medullary 0 +NKCC2 0 +expression 0 +was 0 +significantly 0 +attenuated 0 +in 0 +the 0 +- 0 +/ 0 +- 0 +mice 0 +. 0 + +We 0 +conclude 0 +that 0 +mPGES 0 +- 0 +1 0 +- 0 +derived 0 +PGE 1 +( 2 +2 2 +) 2 +mediates 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +likely 0 +via 0 +inhibition 0 +of 0 +AQP2 0 +and 0 +NKCC2 0 +expression 0 +. 0 + +Preservation 0 +of 0 +renal 0 +blood 0 +flow 0 +during 0 +hypotension 3 +induced 0 +with 0 +fenoldopam 1 +in 0 +dogs 0 +. 0 + +The 0 +introduction 0 +of 0 +drugs 0 +that 0 +could 0 +induce 0 +hypotension 3 +with 0 +different 0 +pharmacological 0 +actions 0 +would 0 +be 0 +advantageous 0 +because 0 +side 0 +effects 0 +unique 0 +to 0 +a 0 +specific 0 +drug 0 +could 0 +be 0 +minimized 0 +by 0 +selecting 0 +appropriate 0 +therapy 0 +. 0 + +Specific 0 +dopamine 1 +- 0 +1 0 +, 0 +( 0 +DA1 1 +) 0 +and 0 +dopamine 1 +- 0 +2 0 +( 0 +DA2 1 +) 0 +receptor 0 +agonists 0 +are 0 +now 0 +under 0 +clinical 0 +investigation 0 +. 0 + +Fenoldopam 1 +mesylate 2 +is 0 +a 0 +specific 0 +DA1 0 +receptor 0 +agonist 0 +that 0 +lowers 0 +blood 0 +pressure 0 +by 0 +vasodilatation 0 +. 0 + +The 0 +hypothesis 0 +that 0 +fenoldopam 1 +could 0 +be 0 +used 0 +to 0 +induce 0 +hypotension 3 +and 0 +preserve 0 +blood 0 +flow 0 +to 0 +the 0 +kidney 0 +was 0 +tested 0 +. 0 + +Systemic 0 +aortic 0 +blood 0 +pressure 0 +and 0 +renal 0 +blood 0 +flow 0 +were 0 +measured 0 +continuously 0 +with 0 +a 0 +carotid 0 +arterial 0 +catheter 0 +and 0 +an 0 +electromagnetic 0 +flow 0 +probe 0 +respectively 0 +, 0 +in 0 +order 0 +to 0 +compare 0 +the 0 +cardiovascular 0 +and 0 +renal 0 +vascular 0 +effects 0 +of 0 +fenoldopam 1 +and 0 +sodium 1 +nitroprusside 1 +in 0 +ten 0 +dogs 0 +under 0 +halothane 1 +general 0 +anaesthesia 0 +. 0 + +Mean 0 +arterial 0 +pressure 0 +was 0 +decreased 0 +30 0 ++ 0 +/ 0 +- 0 +8 0 +per 0 +cent 0 +from 0 +control 0 +with 0 +infusion 0 +of 0 +fenoldopam 1 +( 0 +3 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +0 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +) 0 +and 0 +34 0 ++ 0 +/ 0 +- 0 +4 0 +per 0 +cent 0 +with 0 +infusion 0 +of 0 +sodium 1 +nitroprusside 1 +( 0 +5 0 +. 0 +9 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +) 0 +( 0 +NS 0 +) 0 +. 0 + +Renal 0 +blood 0 +flow 0 +( 0 +RBF 0 +) 0 +increased 0 +during 0 +fenoldopam 1 +- 0 +induced 0 +hypotension 3 +11 0 ++ 0 +/ 0 +- 0 +7 0 +per 0 +cent 0 +and 0 +decreased 0 +21 0 ++ 0 +/ 0 +- 0 +8 0 +per 0 +cent 0 +during 0 +sodium 1 +nitroprusside 1 +- 0 +induced 0 +hypotension 3 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Sodium 0 +nitroprusside 1 +is 0 +a 0 +non 0 +- 0 +selective 0 +arteriolar 0 +and 0 +venous 0 +vasodilator 0 +that 0 +can 0 +produce 0 +redistribution 0 +of 0 +blood 0 +flow 0 +away 0 +from 0 +the 0 +kidney 0 +during 0 +induced 0 +hypotension 3 +. 0 + +Fenoldopam 0 +is 0 +a 0 +selective 0 +dopamine 1 +- 0 +1 0 +( 0 +DA1 0 +) 0 +receptor 0 +agonist 0 +that 0 +causes 0 +vasodilatation 0 +to 0 +the 0 +kidney 0 +and 0 +other 0 +organs 0 +with 0 +DA1 0 +receptors 0 +and 0 +preserves 0 +blood 0 +flow 0 +to 0 +the 0 +kidney 0 +during 0 +induced 0 +hypotension 3 +. 0 + +Seizures 3 +associated 0 +with 0 +levofloxacin 1 +: 0 +case 0 +presentation 0 +and 0 +literature 0 +review 0 +. 0 + +PURP0SE 0 +: 0 +We 0 +present 0 +a 0 +case 0 +of 0 +a 0 +patient 0 +who 0 +developed 0 +seizures 3 +shortly 0 +after 0 +initiating 0 +treatment 0 +with 0 +levofloxacin 1 +and 0 +to 0 +discuss 0 +the 0 +potential 0 +drug 0 +- 0 +drug 0 +interactions 0 +related 0 +to 0 +the 0 +inhibition 0 +of 0 +cytochrome 0 +P450 0 +( 0 +CYP 0 +) 0 +1A2 0 +in 0 +this 0 +case 0 +, 0 +as 0 +well 0 +as 0 +in 0 +other 0 +cases 0 +, 0 +of 0 +levofloxacin 1 +- 0 +induced 0 +seizures 3 +. 0 + +METH0DS 0 +: 0 +Several 0 +biomedical 0 +databases 0 +were 0 +searched 0 +including 0 +MEDLINE 0 +, 0 +Cochrane 0 +and 0 +0vid 0 +. 0 + +The 0 +main 0 +search 0 +terms 0 +utilized 0 +were 0 +case 0 +report 0 +and 0 +levofloxacin 1 +. 0 + +The 0 +search 0 +was 0 +limited 0 +to 0 +studies 0 +published 0 +in 0 +English 0 +. 0 + +RESULTS 0 +: 0 +Six 0 +cases 0 +of 0 +levofloxacin 1 +- 0 +induced 0 +seizures 3 +have 0 +been 0 +reported 0 +in 0 +the 0 +literature 0 +. 0 + +Drug 0 +- 0 +drug 0 +interactions 0 +related 0 +to 0 +the 0 +inhibition 0 +of 0 +CYP1A2 0 +by 0 +levofloxacin 1 +are 0 +likely 0 +involved 0 +in 0 +the 0 +clinical 0 +outcome 0 +of 0 +these 0 +cases 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Clinicians 0 +are 0 +exhorted 0 +to 0 +pay 0 +close 0 +attention 0 +when 0 +initiating 0 +levofloxacin 1 +therapy 0 +in 0 +patients 0 +taking 0 +medications 0 +with 0 +epileptogenic 0 +properties 0 +that 0 +are 0 +CYP1A2 0 +substrates 0 +. 0 + +Dextran 1 +- 0 +etodolac 1 +conjugates 0 +: 0 +synthesis 0 +, 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +evaluation 0 +. 0 + +Etodolac 1 +( 0 +E 1 +) 0 +, 0 +is 0 +a 0 +non 0 +- 0 +narcotic 0 +analgesic 0 +and 0 +antiinflammatory 0 +drug 0 +. 0 + +A 0 +biodegradable 0 +polymer 0 +dextran 1 +has 0 +been 0 +utilized 0 +as 0 +a 0 +carrier 0 +for 0 +synthesis 0 +of 0 +etodolac 1 +- 0 +dextran 1 +conjugates 0 +( 0 +ED 0 +) 0 +to 0 +improve 0 +its 0 +aqueous 0 +solubility 0 +and 0 +reduce 0 +gastrointestinal 0 +side 0 +effects 0 +. 0 + +An 0 +activated 0 +moiety 0 +, 0 +i 0 +. 0 +e 0 +. 0 +N 1 +- 2 +acylimidazole 2 +derivative 0 +of 0 +etodolac 1 +( 0 +EAI 1 +) 0 +, 0 +was 0 +condensed 0 +with 0 +the 0 +polysaccharide 0 +polymer 0 +dextran 1 +of 0 +different 0 +molecular 0 +weights 0 +( 0 +40000 0 +, 0 +60000 0 +, 0 +110000 0 +and 0 +200000 0 +) 0 +. 0 + +IR 0 +spectral 0 +data 0 +confirmed 0 +formation 0 +of 0 +ester 0 +bonding 0 +in 0 +the 0 +conjugates 0 +. 0 + +Etodolac 1 +contents 0 +were 0 +evaluated 0 +by 0 +UV 0 +- 0 +spectrophotometric 0 +analysis 0 +. 0 + +The 0 +molecular 0 +weights 0 +were 0 +determined 0 +by 0 +measuring 0 +viscosity 0 +using 0 +the 0 +Mark 0 +- 0 +Howink 0 +- 0 +Sakurada 0 +equation 0 +. 0 + +In 0 +vitro 0 +hydrolysis 0 +of 0 +ED 0 +was 0 +done 0 +in 0 +aqueous 0 +buffers 0 +( 0 +pH 0 +1 0 +. 0 +2 0 +, 0 +7 0 +. 0 +4 0 +, 0 +9 0 +) 0 +and 0 +in 0 +80 0 +% 0 +( 0 +v 0 +/ 0 +v 0 +) 0 +human 0 +plasma 0 +( 0 +pH 0 +7 0 +. 0 +4 0 +) 0 +. 0 + +At 0 +pH 0 +9 0 +, 0 +a 0 +higher 0 +rate 0 +of 0 +etodolac 1 +release 0 +from 0 +ED 0 +was 0 +observed 0 +as 0 +compared 0 +to 0 +aqueous 0 +buffer 0 +of 0 +pH 0 +7 0 +. 0 +4 0 +and 0 +80 0 +% 0 +human 0 +plasma 0 +( 0 +pH 0 +7 0 +. 0 +4 0 +) 0 +, 0 +following 0 +first 0 +- 0 +order 0 +kinetics 0 +. 0 + +In 0 +vivo 0 +investigations 0 +were 0 +performed 0 +in 0 +animals 0 +. 0 + +Acute 0 +analgesic 0 +and 0 +antiinflammatory 0 +activities 0 +were 0 +ascertained 0 +using 0 +acetic 1 +acid 2 +induced 0 +writhing 3 +model 0 +( 0 +mice 0 +) 0 +and 0 +carrageenan 1 +- 0 +induced 0 +rat 0 +paw 0 +edema 3 +model 0 +, 0 +respectively 0 +. 0 + +In 0 +comparison 0 +to 0 +control 0 +, 0 +E 1 +and 0 +ED1 0 +- 0 +ED4 0 +showed 0 +highly 0 +significant 0 +analgesic 0 +and 0 +antiinflammatory 0 +activities 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Biological 0 +evaluation 0 +suggested 0 +that 0 +conjugates 0 +( 0 +ED1 0 +- 0 +ED4 0 +) 0 +retained 0 +comparable 0 +analgesic 0 +and 0 +antiinflammatory 0 +activities 0 +with 0 +remarkably 0 +reduced 0 +ulcerogenicity 0 +as 0 +compared 0 +to 0 +their 0 +parent 0 +drug 0 +- 0 +- 0 +etodolac 1 +. 0 + +The 0 +antiarrhythmic 0 +effect 0 +and 0 +possible 0 +ionic 0 +mechanisms 0 +of 0 +pilocarpine 1 +on 0 +animal 0 +models 0 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +evaluate 0 +the 0 +effects 0 +of 0 +pilocarpine 1 +and 0 +explore 0 +the 0 +underlying 0 +ionic 0 +mechanism 0 +, 0 +using 0 +both 0 +aconitine 1 +- 0 +induced 0 +rat 0 +and 0 +ouabain 1 +- 0 +induced 0 +guinea 0 +pig 0 +arrhythmia 3 +models 0 +. 0 + +Confocal 0 +microscopy 0 +was 0 +used 0 +to 0 +measure 0 +intracellular 0 +free 0 +- 0 +calcium 1 +concentrations 0 +( 0 +[ 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +] 0 +( 0 +i 0 +) 0 +) 0 +in 0 +isolated 0 +myocytes 0 +. 0 + +The 0 +current 0 +data 0 +showed 0 +that 0 +pilocarpine 1 +significantly 0 +delayed 0 +onset 0 +of 0 +arrhythmias 3 +, 0 +decreased 0 +the 0 +time 0 +course 0 +of 0 +ventricular 3 +tachycardia 4 +and 4 +fibrillation 4 +, 0 +reduced 0 +arrhythmia 3 +score 0 +, 0 +and 0 +increased 0 +the 0 +survival 0 +time 0 +of 0 +arrhythmic 3 +rats 0 +and 0 +guinea 0 +pigs 0 +. 0 + +[ 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +] 0 +( 0 +i 0 +) 0 +overload 0 +induced 0 +by 0 +aconitine 1 +or 0 +ouabain 1 +was 0 +reduced 0 +in 0 +isolated 0 +myocytes 0 +pretreated 0 +with 0 +pilocarpine 1 +. 0 + +Moreover 0 +, 0 +M 0 +( 0 +3 0 +) 0 +- 0 +muscarinic 0 +acetylcholine 1 +receptor 0 +( 0 +mAChR 0 +) 0 +antagonist 0 +4 1 +- 2 +DAMP 2 +( 0 +4 1 +- 2 +diphenylacetoxy 2 +- 2 +N 2 +- 2 +methylpiperidine 2 +- 2 +methiodide 2 +) 0 +partially 0 +abolished 0 +the 0 +beneficial 0 +effects 0 +of 0 +pilocarpine 1 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +pilocarpine 1 +produced 0 +antiarrhythmic 0 +actions 0 +on 0 +arrhythmic 3 +rat 0 +and 0 +guinea 0 +pig 0 +models 0 +induced 0 +by 0 +aconitine 1 +or 0 +ouabain 1 +via 0 +stimulating 0 +the 0 +cardiac 0 +M 0 +( 0 +3 0 +) 0 +- 0 +mAChR 0 +. 0 + +The 0 +mechanism 0 +may 0 +be 0 +related 0 +to 0 +the 0 +improvement 0 +of 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +handling 0 +. 0 + +Effect 0 +of 0 +Hibiscus 1 +rosa 2 +sinensis 2 +on 0 +reserpine 1 +- 0 +induced 0 +neurobehavioral 0 +and 0 +biochemical 0 +alterations 0 +in 0 +rats 0 +. 0 + +Effect 0 +of 0 +methanolic 0 +extract 0 +of 0 +Hibiscus 1 +rosa 2 +sinensis 2 +( 0 +100 0 +- 0 +300 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +studied 0 +on 0 +reserpine 1 +- 0 +induced 0 +orofacial 0 +dyskinesia 3 +and 0 +neurochemical 0 +alterations 0 +. 0 + +The 0 +rats 0 +were 0 +treated 0 +with 0 +intraperitoneal 0 +reserpine 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +, 0 +ip 0 +) 0 +for 0 +3 0 +days 0 +every 0 +other 0 +day 0 +. 0 + +0n 0 +day 0 +5 0 +, 0 +vacuous 0 +chewing 0 +movements 0 +and 0 +tongue 0 +protrusions 0 +were 0 +counted 0 +for 0 +5 0 +min 0 +. 0 + +Reserpine 1 +treated 0 +rats 0 +significantly 0 +developed 0 +vacuous 0 +chewing 0 +movements 0 +and 0 +tongue 0 +protrusions 0 +however 0 +, 0 +coadministration 0 +of 0 +Hibiscus 1 +rosa 2 +sinensis 2 +roots 0 +extract 0 +( 0 +100 0 +, 0 +200 0 +and 0 +300 0 +mg 0 +/ 0 +kg 0 +, 0 +per 0 +orally 0 +) 0 +attenuated 0 +the 0 +effects 0 +. 0 + +Biochemical 0 +analysis 0 +of 0 +brain 0 +revealed 0 +that 0 +the 0 +reserpine 1 +treatment 0 +significantly 0 +increased 0 +lipid 0 +peroxidation 0 +and 0 +decreased 0 +levels 0 +of 0 +superoxide 1 +dismutase 0 +( 0 +S0D 0 +) 0 +, 0 +catalase 0 +( 0 +CAT 0 +) 0 +and 0 +glutathione 1 +reductase 0 +( 0 +GSH 0 +) 0 +, 0 +an 0 +index 0 +of 0 +oxidative 0 +stress 0 +process 0 +. 0 + +Coadministration 0 +of 0 +extract 0 +significantly 0 +reduced 0 +the 0 +lipid 0 +peroxidation 0 +and 0 +reversed 0 +the 0 +decrease 0 +in 0 +brain 0 +S0D 0 +, 0 +CAT 0 +and 0 +GSH 0 +levels 0 +. 0 + +The 0 +results 0 +of 0 +the 0 +present 0 +study 0 +suggested 0 +that 0 +Hibiscus 1 +rosa 2 +sinensis 2 +had 0 +a 0 +protective 0 +role 0 +against 0 +reserpine 1 +- 0 +induced 0 +orofacial 0 +dyskinesia 3 +and 0 +oxidative 0 +stress 0 +. 0 + +Dynamic 0 +response 0 +of 0 +blood 0 +vessel 0 +in 0 +acute 3 +renal 4 +failure 4 +. 0 + +In 0 +this 0 +study 0 +we 0 +postulated 0 +that 0 +during 0 +acute 3 +renal 4 +failure 4 +induced 0 +by 0 +gentamicin 1 +the 0 +transient 0 +or 0 +dynamic 0 +response 0 +of 0 +blood 0 +vessels 0 +could 0 +be 0 +affected 0 +, 0 +and 0 +that 0 +antioxidants 0 +can 0 +prevent 0 +the 0 +changes 0 +in 0 +dynamic 0 +responses 0 +of 0 +blood 0 +vessels 0 +. 0 + +The 0 +new 0 +approach 0 +to 0 +ex 0 +vivo 0 +blood 0 +vessel 0 +experiments 0 +in 0 +which 0 +not 0 +only 0 +the 0 +end 0 +points 0 +of 0 +vessels 0 +response 0 +within 0 +the 0 +time 0 +interval 0 +is 0 +considered 0 +, 0 +but 0 +also 0 +dynamics 0 +of 0 +this 0 +response 0 +, 0 +was 0 +used 0 +in 0 +this 0 +paper 0 +. 0 + +0ur 0 +results 0 +confirm 0 +the 0 +alteration 0 +in 0 +dynamic 0 +response 0 +of 0 +blood 0 +vessels 0 +during 0 +the 0 +change 0 +of 0 +pressure 0 +in 0 +gentamicin 1 +- 0 +treated 0 +animals 0 +. 0 + +The 0 +beneficial 0 +effects 0 +of 0 +vitamin 1 +C 2 +administration 0 +to 0 +gentamicin 1 +- 0 +treated 0 +animals 0 +are 0 +also 0 +confirmed 0 +through 0 +: 0 +lower 0 +level 0 +of 0 +blood 0 +urea 1 +and 0 +creatinine 1 +and 0 +higher 0 +level 0 +of 0 +potassium 1 +. 0 + +The 0 +pressure 0 +dynamic 0 +responses 0 +of 0 +isolated 0 +blood 0 +vessels 0 +show 0 +a 0 +faster 0 +pressure 0 +change 0 +in 0 +gentamicin 1 +- 0 +treated 0 +animals 0 +( 0 +8 0 +. 0 +07 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +7 0 +s 0 +vs 0 +. 0 +5 0 +. 0 +64 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +18 0 +s 0 +) 0 +. 0 + +Vitamin 1 +C 2 +administration 0 +induced 0 +slowdown 0 +of 0 +pressure 0 +change 0 +back 0 +to 0 +the 0 +control 0 +values 0 +. 0 + +The 0 +pressure 0 +dynamic 0 +properties 0 +, 0 +quantitatively 0 +defined 0 +by 0 +comparative 0 +pressure 0 +dynamic 0 +and 0 +total 0 +pressure 0 +dynamic 0 +, 0 +confirm 0 +the 0 +alteration 0 +in 0 +dynamic 0 +response 0 +of 0 +blood 0 +vessels 0 +during 0 +the 0 +change 0 +of 0 +pressure 0 +in 0 +gentamicin 1 +- 0 +treated 0 +animals 0 +and 0 +beneficial 0 +effects 0 +of 0 +vitamin 1 +C 2 +administration 0 +. 0 + +Reversible 0 +myocardial 3 +hypertrophy 4 +induced 0 +by 0 +tacrolimus 1 +in 0 +a 0 +pediatric 0 +heart 0 +transplant 0 +recipient 0 +: 0 +case 0 +report 0 +. 0 + +Tacrolimus 1 +is 0 +a 0 +potent 0 +immunosuppressant 0 +that 0 +is 0 +frequently 0 +used 0 +in 0 +organ 0 +transplantation 0 +. 0 + +However 0 +, 0 +adverse 0 +effects 0 +include 0 +cardiac 3 +toxicity 4 +. 0 + +Herein 0 +we 0 +describe 0 +transient 0 +myocardial 3 +hypertrophy 4 +induced 0 +by 0 +tacrolimus 1 +after 0 +heart 0 +transplantation 0 +. 0 + +The 0 +hypertrophy 3 +caused 0 +no 0 +clinical 0 +symptoms 0 +but 0 +was 0 +noted 0 +because 0 +of 0 +elevation 0 +of 0 +plasma 0 +brain 0 +natriuretic 0 +peptide 0 +concentration 0 +and 0 +confirmed 0 +at 0 +echocardiography 0 +. 0 + +Initially 0 +, 0 +allograft 0 +rejection 0 +was 0 +feared 0 +; 0 +however 0 +, 0 +myocardial 0 +biopsy 0 +samples 0 +revealed 0 +only 0 +interstitial 0 +edema 3 +and 0 +mild 0 +myocardial 3 +hypertrophy 4 +; 0 +neither 0 +cellular 0 +nor 0 +humoral 0 +rejection 0 +was 0 +detected 0 +. 0 + +The 0 +blood 0 +tacrolimus 1 +concentration 0 +was 0 +higher 0 +than 0 +usual 0 +at 0 +that 0 +time 0 +; 0 +thus 0 +, 0 +tacrolimus 1 +dosage 0 +was 0 +reduced 0 +. 0 + +Myocardial 3 +hypertrophy 4 +completely 0 +resolved 0 +upon 0 +reducing 0 +the 0 +target 0 +concentration 0 +of 0 +tacrolimus 1 +and 0 +did 0 +not 0 +recur 0 +, 0 +as 0 +confirmed 0 +at 0 +echocardiography 0 +and 0 +myocardial 0 +biopsy 0 +. 0 + +Thus 0 +, 0 +we 0 +conclude 0 +that 0 +tacrolimus 1 +induces 0 +reversible 0 +myocardial 3 +hypertrophy 4 +. 0 + +In 0 +patients 0 +receiving 0 +tacrolimus 1 +therapy 0 +, 0 +blood 0 +concentration 0 +should 0 +be 0 +carefully 0 +controlled 0 +and 0 +extreme 0 +attention 0 +paid 0 +to 0 +cardiac 0 +involvement 0 +. 0 + +Nimodipine 1 +prevents 0 +memory 3 +impairment 4 +caused 0 +by 0 +nitroglycerin 1 +- 0 +induced 0 +hypotension 3 +in 0 +adult 0 +mice 0 +. 0 + +BACKGR0UND 0 +: 0 +Hypotension 3 +and 0 +a 0 +resultant 0 +decrease 0 +in 0 +cerebral 0 +blood 0 +flow 0 +have 0 +been 0 +implicated 0 +in 0 +the 0 +development 0 +of 0 +cognitive 3 +dysfunction 4 +. 0 + +We 0 +tested 0 +the 0 +hypothesis 0 +that 0 +nimodipine 1 +( 0 +NIM0 1 +) 0 +administered 0 +at 0 +the 0 +onset 0 +of 0 +nitroglycerin 1 +( 0 +NTG 1 +) 0 +- 0 +induced 0 +hypotension 3 +would 0 +preserve 0 +long 0 +- 0 +term 0 +associative 0 +memory 0 +. 0 + +METH0DS 0 +: 0 +The 0 +passive 0 +avoidance 0 +( 0 +PA 0 +) 0 +paradigm 0 +was 0 +used 0 +to 0 +assess 0 +memory 0 +retention 0 +. 0 + +For 0 +PA 0 +training 0 +, 0 +latencies 0 +( 0 +seconds 0 +) 0 +were 0 +recorded 0 +for 0 +entry 0 +from 0 +a 0 +suspended 0 +platform 0 +into 0 +a 0 +Plexiglas 0 +tube 0 +where 0 +a 0 +shock 0 +was 0 +automatically 0 +delivered 0 +. 0 + +Latencies 0 +were 0 +recorded 0 +48 0 +h 0 +later 0 +for 0 +a 0 +testing 0 +trial 0 +. 0 + +Ninety 0 +- 0 +six 0 +Swiss 0 +- 0 +Webster 0 +mice 0 +( 0 +30 0 +- 0 +35 0 +g 0 +, 0 +6 0 +- 0 +8 0 +wk 0 +) 0 +, 0 +were 0 +randomized 0 +into 0 +6 0 +groups 0 +1 0 +) 0 +saline 0 +( 0 +control 0 +) 0 +, 0 +2 0 +) 0 +NTG 1 +immediately 0 +after 0 +learning 0 +, 0 +3 0 +) 0 +NTG 1 +3 0 +h 0 +after 0 +learning 0 +, 0 +4 0 +) 0 +NTG 1 +and 0 +NIM0 1 +, 0 +5 0 +) 0 +vehicle 0 +, 0 +and 0 +6 0 +) 0 +NIM0 1 +alone 0 +. 0 + +The 0 +extent 0 +of 0 +hypotension 3 +and 0 +changes 0 +in 0 +brain 0 +tissue 0 +oxygenation 0 +( 0 +Pbt0 0 +( 0 +2 0 +) 0 +) 0 +and 0 +in 0 +cerebral 0 +blood 0 +flow 0 +were 0 +studied 0 +in 0 +a 0 +separate 0 +group 0 +of 0 +animals 0 +. 0 + +RESULTS 0 +: 0 +All 0 +groups 0 +exhibited 0 +similar 0 +training 0 +latencies 0 +( 0 +17 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +6 0 +s 0 +) 0 +. 0 + +Mice 0 +subjected 0 +to 0 +hypotensive 3 +episodes 0 +showed 0 +a 0 +significant 0 +decrease 0 +in 0 +latency 0 +time 0 +( 0 +178 0 ++ 0 +/ 0 +- 0 +156 0 +s 0 +) 0 +compared 0 +with 0 +those 0 +injected 0 +with 0 +saline 0 +, 0 +NTG 1 ++ 0 +NIM0 1 +, 0 +or 0 +delayed 0 +NTG 1 +( 0 +580 0 ++ 0 +/ 0 +- 0 +81 0 +s 0 +, 0 +557 0 ++ 0 +/ 0 +- 0 +67 0 +s 0 +, 0 +and 0 +493 0 ++ 0 +/ 0 +- 0 +146 0 +s 0 +, 0 +respectively 0 +) 0 +. 0 + +A 0 +Kruskal 0 +- 0 +Wallis 0 +1 0 +- 0 +way 0 +analysis 0 +of 0 +variance 0 +indicated 0 +a 0 +significant 0 +difference 0 +among 0 +the 0 +4 0 +treatment 0 +groups 0 +( 0 +H 0 += 0 +15 0 +. 0 +34 0 +; 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +In 0 +a 0 +separate 0 +group 0 +of 0 +mice 0 +not 0 +subjected 0 +to 0 +behavioral 0 +studies 0 +, 0 +the 0 +same 0 +dose 0 +of 0 +NTG 1 +( 0 +n 0 += 0 +3 0 +) 0 +and 0 +NTG 1 ++ 0 +NIM0 1 +( 0 +n 0 += 0 +3 0 +) 0 +caused 0 +mean 0 +arterial 0 +blood 0 +pressure 0 +to 0 +decrease 0 +from 0 +85 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +8 0 +mm 0 +Hg 0 +sem 0 +to 0 +31 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +mm 0 +Hg 0 +sem 0 +and 0 +from 0 +86 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +7 0 +mm 0 +Hg 0 +sem 0 +to 0 +32 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +mm 0 +Hg 0 +sem 0 +, 0 +respectively 0 +. 0 + +Mean 0 +arterial 0 +blood 0 +pressure 0 +in 0 +mice 0 +treated 0 +with 0 +NIM0 1 +alone 0 +decreased 0 +from 0 +88 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +8 0 +mm 0 +Hg 0 +to 0 +80 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +9 0 +mm 0 +Hg 0 +. 0 + +The 0 +intergroup 0 +difference 0 +was 0 +statistically 0 +significant 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Pbt0 0 +( 0 +2 0 +) 0 +decreased 0 +from 0 +51 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +5 0 +mm 0 +Hg 0 +sem 0 +to 0 +33 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +2 0 +mm 0 +Hg 0 +sem 0 +in 0 +the 0 +NTG 1 +group 0 +and 0 +from 0 +38 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +1 0 +mm 0 +Hg 0 +sem 0 +to 0 +25 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +0 0 +mm 0 +Hg 0 +sem 0 +in 0 +the 0 +NTG 1 ++ 0 +NIM0 1 +groups 0 +, 0 +respectively 0 +. 0 + +There 0 +were 0 +no 0 +significant 0 +differences 0 +among 0 +groups 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +a 0 +PA 0 +retention 0 +paradigm 0 +, 0 +the 0 +injection 0 +of 0 +NTG 1 +immediately 0 +after 0 +learning 0 +produced 0 +a 0 +significant 0 +impairment 0 +of 0 +long 0 +- 0 +term 0 +associative 0 +memory 0 +in 0 +mice 0 +, 0 +whereas 0 +delayed 0 +induced 0 +hypotension 3 +had 0 +no 0 +effect 0 +. 0 + +NIM0 1 +attenuated 0 +the 0 +disruption 0 +in 0 +consolidation 0 +of 0 +long 0 +- 0 +term 0 +memory 0 +caused 0 +by 0 +NTG 1 +but 0 +did 0 +not 0 +improve 0 +latency 0 +in 0 +the 0 +absence 0 +of 0 +hypotension 3 +. 0 + +The 0 +observed 0 +effect 0 +of 0 +NIM0 1 +may 0 +have 0 +been 0 +attributable 0 +to 0 +the 0 +preservation 0 +of 0 +calcium 1 +homeostasis 0 +during 0 +hypotension 3 +, 0 +because 0 +there 0 +were 0 +no 0 +differences 0 +in 0 +the 0 +Pbt0 0 +( 0 +2 0 +) 0 +indices 0 +among 0 +groups 0 +. 0 + +Metabotropic 0 +glutamate 1 +7 0 +receptor 0 +subtype 0 +modulates 0 +motor 0 +symptoms 0 +in 0 +rodent 0 +models 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Metabotropic 0 +glutamate 1 +( 0 +mGlu 0 +) 0 +receptors 0 +modulate 0 +synaptic 0 +transmission 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +and 0 +represent 0 +promising 0 +therapeutic 0 +targets 0 +for 0 +symptomatic 0 +treatment 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +. 0 + +Among 0 +the 0 +eight 0 +mGlu 0 +receptor 0 +subtypes 0 +, 0 +mGlu7 0 +receptor 0 +is 0 +prominently 0 +expressed 0 +in 0 +the 0 +basal 0 +ganglia 0 +, 0 +but 0 +its 0 +role 0 +in 0 +restoring 0 +motor 0 +function 0 +in 0 +animal 0 +models 0 +of 0 +PD 3 +is 0 +not 0 +known 0 +. 0 + +The 0 +effects 0 +of 0 +N 1 +, 2 +N 2 +' 2 +- 2 +dibenzhydrylethane 2 +- 2 +1 2 +, 2 +2 2 +- 2 +diamine 2 +dihydrochloride 2 +( 0 +AMN082 1 +) 0 +, 0 +the 0 +first 0 +selective 0 +allosteric 0 +activator 0 +of 0 +mGlu7 0 +receptors 0 +, 0 +were 0 +thus 0 +tested 0 +in 0 +different 0 +rodent 0 +models 0 +of 0 +PD 3 +. 0 + +Here 0 +, 0 +we 0 +show 0 +that 0 +oral 0 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +intrastriatal 0 +administration 0 +( 0 +0 0 +. 0 +1 0 +and 0 +0 0 +. 0 +5 0 +nmol 0 +) 0 +of 0 +AMN082 1 +reverses 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +in 0 +rats 0 +. 0 + +AMN082 1 +( 0 +2 0 +. 0 +5 0 +and 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +reduces 0 +apomorphine 1 +- 0 +induced 0 +rotations 0 +in 0 +unilateral 0 +6 1 +- 2 +hydroxydopamine 2 +( 0 +6 1 +- 2 +0HDA 2 +) 0 +- 0 +lesioned 0 +rats 0 +. 0 + +In 0 +a 0 +more 0 +complex 0 +task 0 +commonly 0 +used 0 +to 0 +evaluate 0 +major 0 +akinetic 3 +symptoms 0 +of 0 +PD 3 +patients 0 +, 0 +5 0 +mg 0 +/ 0 +kg 0 +AMN082 1 +reverses 0 +the 0 +increased 0 +reaction 0 +time 0 +to 0 +respond 0 +to 0 +a 0 +cue 0 +of 0 +bilateral 0 +6 1 +- 2 +0HDA 2 +- 0 +lesioned 0 +rats 0 +. 0 + +In 0 +addition 0 +, 0 +AMN082 1 +reduces 0 +the 0 +duration 0 +of 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +in 0 +a 0 +mGlu7 0 +receptor 0 +- 0 +dependent 0 +manner 0 +in 0 +wild 0 +- 0 +type 0 +but 0 +not 0 +mGlu7 0 +receptor 0 +knockout 0 +mice 0 +. 0 + +Higher 0 +doses 0 +of 0 +AMN082 1 +( 0 +10 0 +and 0 +20 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +have 0 +no 0 +effect 0 +on 0 +the 0 +same 0 +models 0 +of 0 +PD 3 +. 0 + +0verall 0 +these 0 +findings 0 +suggest 0 +that 0 +mGlu7 0 +receptor 0 +activation 0 +can 0 +reverse 0 +motor 0 +dysfunction 0 +associated 0 +with 0 +reduced 0 +dopamine 1 +activity 0 +. 0 + +Selective 0 +ligands 0 +of 0 +mGlu7 0 +receptor 0 +subtypes 0 +may 0 +thus 0 +be 0 +considered 0 +as 0 +promising 0 +compounds 0 +for 0 +the 0 +development 0 +of 0 +antiparkinsonian 0 +therapeutic 0 +strategies 0 +. 0 + +Sorafenib 1 +- 0 +induced 0 +acute 0 +myocardial 3 +infarction 4 +due 0 +to 0 +coronary 3 +artery 4 +spasm 4 +. 0 + +A 0 +65 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +advanced 0 +renal 3 +cell 4 +carcinoma 4 +was 0 +admitted 0 +due 0 +to 0 +continuing 0 +chest 3 +pain 4 +at 0 +rest 0 +. 0 + +Two 0 +weeks 0 +before 0 +his 0 +admission 0 +, 0 +sorafenib 1 +had 0 +been 0 +started 0 +. 0 + +He 0 +was 0 +diagnosed 0 +with 0 +non 0 +- 0 +ST 0 +- 0 +elevation 0 +myocardial 3 +infarction 4 +by 0 +laboratory 0 +data 0 +and 0 +electrocardiogram 0 +. 0 + +Enhanced 0 +heart 0 +magnetic 0 +resonance 0 +imaging 0 +also 0 +showed 0 +subendocardial 3 +infarction 4 +. 0 + +However 0 +, 0 +there 0 +was 0 +no 0 +stenosis 0 +in 0 +coronary 0 +arteries 0 +on 0 +angiography 0 +. 0 + +Coronary 3 +artery 4 +spasm 4 +was 0 +induced 0 +by 0 +a 0 +provocative 0 +test 0 +. 0 + +Cessation 0 +of 0 +sorafenib 1 +and 0 +administration 0 +of 0 +Ca 1 +- 0 +channel 0 +blocker 0 +and 0 +nitrates 1 +ameliorated 0 +his 0 +symptoms 0 +, 0 +but 0 +relapse 0 +occurred 0 +after 0 +resumption 0 +of 0 +sorafenib 1 +. 0 + +Addition 0 +of 0 +oral 0 +nicorandil 1 +reduced 0 +his 0 +symptoms 0 +and 0 +maintained 0 +stable 3 +angina 4 +status 0 +. 0 + +We 0 +report 0 +the 0 +first 0 +case 0 +of 0 +sorafenib 1 +- 0 +induced 0 +coronary 3 +artery 4 +spasm 4 +. 0 + +Sorafenib 1 +is 0 +a 0 +multikinase 0 +inhibitor 0 +that 0 +targets 0 +signaling 0 +pathways 0 +necessary 0 +for 0 +cellular 0 +proliferation 0 +and 0 +survival 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +the 0 +Rho 0 +/ 0 +R0CK 0 +pathway 0 +has 0 +an 0 +important 0 +role 0 +in 0 +the 0 +pathogenesis 0 +of 0 +coronary 3 +artery 4 +spasm 4 +. 0 + +0ur 0 +report 0 +may 0 +show 0 +an 0 +adverse 0 +effect 0 +on 0 +the 0 +Rho 0 +/ 0 +R0CK 0 +pathway 0 +by 0 +sorafenib 1 +use 0 +. 0 + +A 0 +novel 0 +animal 0 +model 0 +to 0 +evaluate 0 +the 0 +ability 0 +of 0 +a 0 +drug 0 +delivery 0 +system 0 +to 0 +promote 0 +the 0 +passage 0 +through 0 +the 0 +BBB 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +investigation 0 +was 0 +to 0 +explore 0 +the 0 +potentiality 0 +of 0 +a 0 +novel 0 +animal 0 +model 0 +to 0 +be 0 +used 0 +for 0 +the 0 +in 0 +vivo 0 +evaluation 0 +of 0 +the 0 +ability 0 +of 0 +a 0 +drug 0 +delivery 0 +system 0 +to 0 +promote 0 +the 0 +passage 0 +through 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +( 0 +BBB 0 +) 0 +and 0 +/ 0 +or 0 +to 0 +improve 0 +the 0 +brain 0 +localization 0 +of 0 +a 0 +bioactive 0 +compound 0 +. 0 + +A 0 +Tween 0 +80 0 +- 0 +coated 0 +poly 1 +- 2 +L 2 +- 2 +lactid 2 +acid 2 +nanoparticles 0 +was 0 +used 0 +as 0 +a 0 +model 0 +of 0 +colloidal 0 +drug 0 +delivery 0 +system 0 +, 0 +able 0 +to 0 +trespass 0 +the 0 +BBB 0 +. 0 + +Tacrine 1 +, 0 +administered 0 +in 0 +LiCl 1 +pre 0 +- 0 +treated 0 +rats 0 +, 0 +induces 0 +electrocorticographic 0 +seizures 3 +and 0 +delayed 0 +hippocampal 3 +damage 4 +. 0 + +The 0 +toxic 0 +effects 0 +of 0 +tacrine 1 +- 0 +loaded 0 +poly 1 +- 2 +L 2 +- 2 +lactid 2 +acid 2 +nanoparticles 0 +( 0 +5mg 0 +/ 0 +kg 0 +) 0 +, 0 +a 0 +saline 0 +solution 0 +of 0 +tacrine 1 +( 0 +5mg 0 +/ 0 +kg 0 +) 0 +and 0 +an 0 +empty 0 +colloidal 0 +nanoparticle 0 +suspension 0 +were 0 +compared 0 +following 0 +i 0 +. 0 +p 0 +. 0 +administration 0 +in 0 +LiCl 1 +- 0 +pre 0 +- 0 +treated 0 +Wistar 0 +rats 0 +. 0 + +All 0 +the 0 +animals 0 +treated 0 +with 0 +tacrine 1 +- 0 +loaded 0 +nanoparticles 0 +showed 0 +an 0 +earlier 0 +outcome 0 +of 0 +CNS 0 +adverse 0 +symptoms 0 +, 0 +i 0 +. 0 +e 0 +. 0 +epileptic 3 +onset 0 +, 0 +with 0 +respect 0 +to 0 +those 0 +animals 0 +treated 0 +with 0 +the 0 +free 0 +compound 0 +( 0 +10 0 +min 0 +vs 0 +. 0 +22 0 +min 0 +respectively 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +tacrine 1 +- 0 +loaded 0 +nanoparticles 0 +administration 0 +induced 0 +damage 3 +of 4 +neuronal 4 +cells 4 +in 0 +CA1 0 +field 0 +of 0 +the 0 +hippocampus 0 +in 0 +all 0 +treated 0 +animals 0 +, 0 +while 0 +the 0 +saline 0 +solution 0 +of 0 +tacrine 1 +only 0 +in 0 +60 0 +% 0 +of 0 +animals 0 +. 0 + +Empty 0 +nanoparticles 0 +provided 0 +similar 0 +results 0 +to 0 +control 0 +( 0 +saline 0 +- 0 +treated 0 +) 0 +group 0 +of 0 +animals 0 +. 0 + +In 0 +conclusion 0 +, 0 +the 0 +evaluation 0 +of 0 +time 0 +- 0 +to 0 +- 0 +onset 0 +of 0 +symptoms 0 +and 0 +the 0 +severity 0 +of 0 +neurodegenerative 0 +processes 0 +induced 0 +by 0 +the 0 +tacrine 1 +- 0 +lithium 1 +model 0 +of 0 +epilepsy 3 +in 0 +the 0 +rat 0 +, 0 +could 0 +be 0 +used 0 +to 0 +evaluate 0 +preliminarily 0 +the 0 +capability 0 +of 0 +a 0 +drug 0 +delivery 0 +system 0 +to 0 +trespass 0 +( 0 +or 0 +not 0 +) 0 +the 0 +BBB 0 +in 0 +vivo 0 +. 0 + +High 0 +- 0 +dose 0 +tranexamic 1 +Acid 2 +is 0 +associated 0 +with 0 +nonischemic 0 +clinical 0 +seizures 3 +in 0 +cardiac 0 +surgical 0 +patients 0 +. 0 + +BACKGR0UND 0 +: 0 +In 0 +2 0 +separate 0 +centers 0 +, 0 +we 0 +observed 0 +a 0 +notable 0 +increase 0 +in 0 +the 0 +incidence 0 +of 0 +postoperative 0 +convulsive 3 +seizures 3 +from 0 +1 0 +. 0 +3 0 +% 0 +to 0 +3 0 +. 0 +8 0 +% 0 +in 0 +patients 0 +having 0 +undergone 0 +major 0 +cardiac 0 +surgical 0 +procedures 0 +. 0 + +These 0 +events 0 +were 0 +temporally 0 +coincident 0 +with 0 +the 0 +initial 0 +use 0 +of 0 +high 0 +- 0 +dose 0 +tranexamic 1 +acid 2 +( 0 +TXA 1 +) 0 +therapy 0 +after 0 +withdrawal 0 +of 0 +aprotinin 0 +from 0 +general 0 +clinical 0 +usage 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +review 0 +was 0 +to 0 +perform 0 +a 0 +retrospective 0 +analysis 0 +to 0 +examine 0 +whether 0 +there 0 +was 0 +a 0 +relation 0 +between 0 +TXA 1 +usage 0 +and 0 +seizures 3 +after 0 +cardiac 0 +surgery 0 +. 0 + +METH0DS 0 +: 0 +An 0 +in 0 +- 0 +depth 0 +chart 0 +review 0 +was 0 +undertaken 0 +in 0 +all 0 +24 0 +patients 0 +who 0 +developed 0 +perioperative 0 +seizures 3 +. 0 + +Electroencephalographic 0 +activity 0 +was 0 +recorded 0 +in 0 +11 0 +of 0 +these 0 +patients 0 +, 0 +and 0 +all 0 +patients 0 +had 0 +a 0 +formal 0 +neurological 0 +evaluation 0 +and 0 +brain 0 +imaging 0 +studies 0 +. 0 + +RESULTS 0 +: 0 +Twenty 0 +- 0 +one 0 +of 0 +the 0 +24 0 +patients 0 +did 0 +not 0 +have 0 +evidence 0 +of 0 +new 0 +cerebral 3 +ischemic 4 +injury 4 +, 0 +but 0 +seizures 3 +were 0 +likely 0 +due 0 +to 0 +ischemic 3 +brain 4 +injury 4 +in 0 +3 0 +patients 0 +. 0 + +All 0 +patients 0 +with 0 +seizures 3 +did 0 +not 0 +have 0 +permanent 0 +neurological 3 +abnormalities 4 +. 0 + +All 0 +24 0 +patients 0 +with 0 +seizures 3 +received 0 +high 0 +doses 0 +of 0 +TXA 1 +intraoperatively 0 +ranging 0 +from 0 +61 0 +to 0 +259 0 +mg 0 +/ 0 +kg 0 +, 0 +had 0 +a 0 +mean 0 +age 0 +of 0 +69 0 +. 0 +9 0 +years 0 +, 0 +and 0 +21 0 +of 0 +24 0 +had 0 +undergone 0 +open 0 +chamber 0 +rather 0 +than 0 +coronary 0 +bypass 0 +procedures 0 +. 0 + +All 0 +but 0 +one 0 +patient 0 +were 0 +managed 0 +using 0 +cardiopulmonary 0 +bypass 0 +. 0 + +No 0 +evidence 0 +of 0 +brain 3 +ischemic 4 +, 0 +metabolic 0 +, 0 +or 0 +hyperthermia 3 +- 0 +induced 0 +causes 0 +for 0 +their 0 +seizures 3 +was 0 +apparent 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +results 0 +suggest 0 +that 0 +use 0 +of 0 +high 0 +- 0 +dose 0 +TXA 1 +in 0 +older 0 +patients 0 +in 0 +conjunction 0 +with 0 +cardiopulmonary 0 +bypass 0 +and 0 +open 0 +- 0 +chamber 0 +cardiac 0 +surgery 0 +is 0 +associated 0 +with 0 +clinical 0 +seizures 3 +in 0 +susceptible 0 +patients 0 +. 0 + +Electrocardiographic 0 +changes 0 +and 0 +cardiac 3 +arrhythmias 4 +in 0 +patients 0 +receiving 0 +psychotropic 0 +drugs 0 +. 0 + +Eight 0 +patients 0 +had 0 +cardiac 0 +manifestations 0 +that 0 +were 0 +life 0 +- 0 +threatening 0 +in 0 +five 0 +while 0 +taking 0 +psychotropic 0 +drugs 0 +, 0 +either 0 +phenothiazines 1 +or 0 +tricyclic 0 +antidepressants 0 +. 0 + +Although 0 +most 0 +patients 0 +were 0 +receiving 0 +several 0 +drugs 0 +, 0 +Mellaril 1 +( 0 +thioridazine 1 +) 0 +appeared 0 +to 0 +be 0 +responsible 0 +for 0 +five 0 +cases 0 +of 0 +ventricular 3 +tachycardia 4 +, 0 +one 0 +of 0 +which 0 +was 0 +fatal 0 +in 0 +a 0 +35 0 +year 0 +old 0 +woman 0 +. 0 + +Supraventricular 3 +tachycardia 4 +developed 0 +in 0 +one 0 +patient 0 +receiving 0 +Thorazine 1 +( 0 +chlorpromazine 1 +) 0 +. 0 + +Aventyl 1 +( 0 +nortriptyline 1 +) 0 +and 0 +Elavil 1 +( 0 +amitriptyline 1 +) 0 +each 0 +produced 0 +left 3 +bundle 4 +branch 4 +block 4 +in 0 +a 0 +73 0 +year 0 +old 0 +woman 0 +. 0 + +Electrocardiographic 0 +T 0 +and 0 +U 0 +wave 0 +abnormalities 0 +were 0 +present 0 +in 0 +most 0 +patients 0 +. 0 + +The 0 +ventricular 3 +arrhythmias 4 +responded 0 +to 0 +intravenous 0 +administration 0 +of 0 +lidocaine 1 +and 0 +to 0 +direct 0 +current 0 +electric 0 +shock 0 +; 0 +ventricular 0 +pacing 0 +was 0 +required 0 +in 0 +some 0 +instances 0 +and 0 +intravenous 0 +administration 0 +of 0 +propranolol 1 +combined 0 +with 0 +ventricular 0 +pacing 0 +in 0 +one 0 +. 0 + +The 0 +tachyarrhythmias 3 +generally 0 +subsided 0 +within 0 +48 0 +hours 0 +after 0 +administration 0 +of 0 +the 0 +drugs 0 +was 0 +stopped 0 +. 0 + +Five 0 +of 0 +the 0 +eight 0 +patients 0 +were 0 +50 0 +years 0 +of 0 +age 0 +or 0 +younger 0 +; 0 +only 0 +one 0 +clearly 0 +had 0 +antecedent 0 +heart 3 +disease 4 +. 0 + +Major 0 +cardiac 3 +arrhythmias 4 +are 0 +a 0 +potential 0 +hazard 0 +in 0 +patients 0 +without 0 +heart 3 +disease 4 +who 0 +are 0 +receiving 0 +customary 0 +therapeutic 0 +doses 0 +of 0 +psychotropic 0 +drugs 0 +. 0 + +A 0 +prospective 0 +clinical 0 +trial 0 +is 0 +suggested 0 +to 0 +quantify 0 +the 0 +risk 0 +of 0 +cardiac 3 +complications 4 +to 0 +patients 0 +receiving 0 +phenothiazines 1 +or 0 +tricyclic 0 +antidepressant 0 +drugs 0 +. 0 + +Sensitivity 0 +of 0 +erythroid 0 +progenitor 0 +colonies 0 +to 0 +erythropoietin 0 +in 0 +azidothymidine 1 +treated 0 +immunodeficient 3 +mice 0 +. 0 + +The 0 +anaemia 3 +induced 0 +by 0 +3 1 +' 2 +- 2 +azido 2 +- 2 +3 2 +' 2 +dideoxythymidine 2 +( 0 +AZT 1 +) 0 +is 0 +poorly 0 +understood 0 +. 0 + +We 0 +have 0 +used 0 +a 0 +murine 0 +model 0 +of 0 +AIDS 3 +, 0 +infection 3 +of 0 +female 0 +C57BL 0 +/ 0 +6 0 +mice 0 +with 0 +LP 0 +- 0 +BM5 0 +murine 0 +leukaemia 3 +( 0 +MuLV 0 +) 0 +virus 0 +, 0 +to 0 +determine 0 +if 0 +AZT 1 +- 0 +induced 0 +anaemia 3 +is 0 +due 0 +, 0 +in 0 +part 0 +, 0 +to 0 +decreased 0 +responsiveness 0 +of 0 +erythropoietic 0 +precursors 0 +( 0 +BFU 0 +- 0 +e 0 +) 0 +to 0 +erythropoietin 0 +( 0 +EP0 0 +) 0 +. 0 + +Mice 0 +in 0 +the 0 +early 0 +stage 0 +of 0 +LP 0 +- 0 +BM5 0 +MuLV 0 +disease 0 +were 0 +given 0 +AZT 1 +in 0 +their 0 +drinking 0 +water 0 +at 0 +1 0 +. 0 +0 0 +and 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +ml 0 +. 0 + +AZT 1 +produced 0 +anaemia 3 +in 0 +both 0 +groups 0 +, 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +fashion 0 +. 0 + +Despite 0 +the 0 +anaemia 3 +, 0 +the 0 +number 0 +of 0 +splenic 0 +and 0 +bone 0 +marrow 0 +BFU 0 +- 0 +e 0 +in 0 +AZT 1 +treated 0 +mice 0 +increased 0 +up 0 +to 0 +five 0 +- 0 +fold 0 +over 0 +levels 0 +observed 0 +in 0 +infected 0 +untreated 0 +animals 0 +after 0 +15 0 +d 0 +of 0 +treatment 0 +. 0 + +Colony 0 +formation 0 +by 0 +splenic 0 +and 0 +bone 0 +marrow 0 +BFUe 0 +was 0 +stimulated 0 +at 0 +lower 0 +concentrations 0 +of 0 +EP0 0 +in 0 +mice 0 +receiving 0 +AZT 1 +for 0 +15 0 +d 0 +than 0 +for 0 +infected 0 +, 0 +untreated 0 +mice 0 +. 0 + +By 0 +day 0 +30 0 +, 0 +sensitivity 0 +of 0 +both 0 +splenic 0 +and 0 +bone 0 +marrow 0 +BFU 0 +- 0 +e 0 +of 0 +treated 0 +animals 0 +returned 0 +to 0 +that 0 +observed 0 +from 0 +cells 0 +of 0 +infected 0 +untreated 0 +animals 0 +. 0 + +The 0 +mean 0 +plasma 0 +levels 0 +of 0 +EP0 0 +observed 0 +in 0 +AZT 1 +treated 0 +mice 0 +were 0 +appropriate 0 +for 0 +the 0 +degree 0 +of 0 +anaemia 3 +observed 0 +when 0 +compared 0 +with 0 +phenylhydrazine 1 +( 0 +PHZ 1 +) 0 +treated 0 +mice 0 +. 0 + +The 0 +numbers 0 +of 0 +BFU 0 +- 0 +e 0 +and 0 +the 0 +percentage 0 +of 0 +bone 0 +marrow 0 +erythroblasts 0 +observed 0 +were 0 +comparable 0 +in 0 +AZT 1 +and 0 +PHZ 1 +treated 0 +mice 0 +with 0 +similar 0 +degrees 0 +of 0 +anaemia 3 +. 0 + +However 0 +, 0 +reticulocytosis 3 +was 0 +inappropriate 0 +for 0 +the 0 +degree 0 +of 0 +anaemia 3 +observed 0 +in 0 +AZT 1 +treated 0 +infected 0 +mice 0 +. 0 + +AZT 1 +- 0 +induced 0 +peripheral 0 +anaemia 3 +in 0 +the 0 +face 0 +of 0 +increased 0 +numbers 0 +of 0 +BFU 0 +- 0 +e 0 +and 0 +increased 0 +levels 0 +of 0 +plasma 0 +EP0 0 +suggest 0 +a 0 +lesion 0 +in 0 +terminal 0 +differentiation 0 +. 0 + +Sedation 0 +depth 0 +during 0 +spinal 0 +anesthesia 0 +and 0 +the 0 +development 0 +of 0 +postoperative 3 +delirium 4 +in 0 +elderly 0 +patients 0 +undergoing 0 +hip 3 +fracture 4 +repair 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +determine 0 +whether 0 +limiting 0 +intraoperative 0 +sedation 0 +depth 0 +during 0 +spinal 0 +anesthesia 0 +for 0 +hip 3 +fracture 4 +repair 0 +in 0 +elderly 0 +patients 0 +can 0 +decrease 0 +the 0 +prevalence 0 +of 0 +postoperative 3 +delirium 4 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +We 0 +performed 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +randomized 0 +controlled 0 +trial 0 +at 0 +an 0 +academic 0 +medical 0 +center 0 +of 0 +elderly 0 +patients 0 +( 0 +> 0 +or 0 += 0 +65 0 +years 0 +) 0 +without 0 +preoperative 0 +delirium 3 +or 0 +severe 0 +dementia 3 +who 0 +underwent 0 +hip 3 +fracture 4 +repair 0 +under 0 +spinal 0 +anesthesia 0 +with 0 +propofol 1 +sedation 0 +. 0 + +Sedation 0 +depth 0 +was 0 +titrated 0 +using 0 +processed 0 +electroencephalography 0 +with 0 +the 0 +bispectral 0 +index 0 +( 0 +BIS 0 +) 0 +, 0 +and 0 +patients 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +deep 0 +( 0 +BIS 0 +, 0 +approximately 0 +50 0 +) 0 +or 0 +light 0 +( 0 +BIS 0 +, 0 +> 0 +or 0 += 0 +80 0 +) 0 +sedation 0 +. 0 + +Postoperative 3 +delirium 4 +was 0 +assessed 0 +as 0 +defined 0 +by 0 +Diagnostic 0 +and 0 +Statistical 0 +Manual 0 +of 0 +Mental 3 +Disorders 4 +( 0 +Third 0 +Edition 0 +Revised 0 +) 0 +criteria 0 +using 0 +the 0 +Confusion 0 +Assessment 0 +Method 0 +beginning 0 +at 0 +any 0 +time 0 +from 0 +the 0 +second 0 +day 0 +after 0 +surgery 0 +. 0 + +RESULTS 0 +: 0 +From 0 +April 0 +2 0 +, 0 +2005 0 +, 0 +through 0 +0ctober 0 +30 0 +, 0 +2008 0 +, 0 +a 0 +total 0 +of 0 +114 0 +patients 0 +were 0 +randomized 0 +. 0 + +The 0 +prevalence 0 +of 0 +postoperative 3 +delirium 4 +was 0 +significantly 0 +lower 0 +in 0 +the 0 +light 0 +sedation 0 +group 0 +( 0 +11 0 +/ 0 +57 0 +[ 0 +19 0 +% 0 +] 0 +vs 0 +23 0 +/ 0 +57 0 +[ 0 +40 0 +% 0 +] 0 +in 0 +the 0 +deep 0 +sedation 0 +group 0 +; 0 +P 0 += 0 +. 0 +02 0 +) 0 +, 0 +indicating 0 +that 0 +1 0 +incident 0 +of 0 +delirium 3 +will 0 +be 0 +prevented 0 +for 0 +every 0 +4 0 +. 0 +7 0 +patients 0 +treated 0 +with 0 +light 0 +sedation 0 +. 0 + +The 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +number 0 +of 0 +days 0 +of 0 +delirium 3 +during 0 +hospitalization 0 +was 0 +lower 0 +in 0 +the 0 +light 0 +sedation 0 +group 0 +than 0 +in 0 +the 0 +deep 0 +sedation 0 +group 0 +( 0 +0 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +days 0 +vs 0 +1 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +0 0 +days 0 +; 0 +P 0 += 0 +. 0 +01 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +use 0 +of 0 +light 0 +propofol 1 +sedation 0 +decreased 0 +the 0 +prevalence 0 +of 0 +postoperative 3 +delirium 4 +by 0 +50 0 +% 0 +compared 0 +with 0 +deep 0 +sedation 0 +. 0 + +Limiting 0 +depth 0 +of 0 +sedation 0 +during 0 +spinal 0 +anesthesia 0 +is 0 +a 0 +simple 0 +, 0 +safe 0 +, 0 +and 0 +cost 0 +- 0 +effective 0 +intervention 0 +for 0 +preventing 0 +postoperative 3 +delirium 4 +in 0 +elderly 0 +patients 0 +that 0 +could 0 +be 0 +widely 0 +and 0 +readily 0 +adopted 0 +. 0 + +The 0 +protective 0 +role 0 +of 0 +Nrf2 0 +in 0 +streptozotocin 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +. 0 + +0BJECTIVE 0 +: 0 +Diabetic 3 +nephropathy 4 +is 0 +one 0 +of 0 +the 0 +major 0 +causes 0 +of 0 +renal 3 +failure 4 +, 0 +which 0 +is 0 +accompanied 0 +by 0 +the 0 +production 0 +of 0 +reactive 0 +oxygen 1 +species 0 +( 0 +R0S 0 +) 0 +. 0 + +Nrf2 0 +is 0 +the 0 +primary 0 +transcription 0 +factor 0 +that 0 +controls 0 +the 0 +antioxidant 0 +response 0 +essential 0 +for 0 +maintaining 0 +cellular 0 +redox 0 +homeostasis 0 +. 0 + +Here 0 +, 0 +we 0 +report 0 +our 0 +findings 0 +demonstrating 0 +a 0 +protective 0 +role 0 +of 0 +Nrf2 0 +against 0 +diabetic 3 +nephropathy 4 +. 0 + +RESEARCH 0 +DESIGN 0 +AND 0 +METH0DS 0 +: 0 +We 0 +explore 0 +the 0 +protective 0 +role 0 +of 0 +Nrf2 0 +against 0 +diabetic 3 +nephropathy 4 +using 0 +human 0 +kidney 0 +biopsy 0 +tissues 0 +from 0 +diabetic 3 +nephropathy 4 +patients 0 +, 0 +a 0 +streptozotocin 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +model 0 +in 0 +Nrf2 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +, 0 +and 0 +cultured 0 +human 0 +mesangial 0 +cells 0 +. 0 + +RESULTS 0 +: 0 +The 0 +glomeruli 0 +of 0 +human 0 +diabetic 3 +nephropathy 4 +patients 0 +were 0 +under 0 +oxidative 0 +stress 0 +and 0 +had 0 +elevated 0 +Nrf2 0 +levels 0 +. 0 + +In 0 +the 0 +animal 0 +study 0 +, 0 +Nrf2 0 +was 0 +demonstrated 0 +to 0 +be 0 +crucial 0 +in 0 +ameliorating 0 +streptozotocin 1 +- 0 +induced 0 +renal 3 +damage 4 +. 0 + +This 0 +is 0 +evident 0 +by 0 +Nrf2 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +having 0 +higher 0 +R0S 0 +production 0 +and 0 +suffering 0 +from 0 +greater 0 +oxidative 0 +DNA 0 +damage 0 +and 0 +renal 3 +injury 4 +compared 0 +with 0 +Nrf2 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +mice 0 +. 0 + +Mechanistic 0 +studies 0 +in 0 +both 0 +in 0 +vivo 0 +and 0 +in 0 +vitro 0 +systems 0 +showed 0 +that 0 +the 0 +Nrf2 0 +- 0 +mediated 0 +protection 0 +against 0 +diabetic 3 +nephropathy 4 +is 0 +, 0 +at 0 +least 0 +, 0 +partially 0 +through 0 +inhibition 0 +of 0 +transforming 0 +growth 0 +factor 0 +- 0 +beta1 0 +( 0 +TGF 0 +- 0 +beta1 0 +) 0 +and 0 +reduction 0 +of 0 +extracellular 0 +matrix 0 +production 0 +. 0 + +In 0 +human 0 +renal 0 +mesangial 0 +cells 0 +, 0 +high 0 +glucose 1 +induced 0 +R0S 0 +production 0 +and 0 +activated 0 +expression 0 +of 0 +Nrf2 0 +and 0 +its 0 +downstream 0 +genes 0 +. 0 + +Furthermore 0 +, 0 +activation 0 +or 0 +overexpression 0 +of 0 +Nrf2 0 +inhibited 0 +the 0 +promoter 0 +activity 0 +of 0 +TGF 0 +- 0 +beta1 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +, 0 +whereas 0 +knockdown 0 +of 0 +Nrf2 0 +by 0 +siRNA 0 +enhanced 0 +TGF 0 +- 0 +beta1 0 +transcription 0 +and 0 +fibronectin 0 +production 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +This 0 +work 0 +clearly 0 +indicates 0 +a 0 +protective 0 +role 0 +of 0 +Nrf2 0 +in 0 +diabetic 3 +nephropathy 4 +, 0 +suggesting 0 +that 0 +dietary 0 +or 0 +therapeutic 0 +activation 0 +of 0 +Nrf2 0 +could 0 +be 0 +used 0 +as 0 +a 0 +strategy 0 +to 0 +prevent 0 +or 0 +slow 0 +down 0 +the 0 +progression 0 +of 0 +diabetic 3 +nephropathy 4 +. 0 + +Metformin 1 +prevents 0 +experimental 0 +gentamicin 1 +- 0 +induced 0 +nephropathy 3 +by 0 +a 0 +mitochondria 0 +- 0 +dependent 0 +pathway 0 +. 0 + +The 0 +antidiabetic 0 +drug 0 +metformin 1 +can 0 +diminish 0 +apoptosis 0 +induced 0 +by 0 +oxidative 0 +stress 0 +in 0 +endothelial 0 +cells 0 +and 0 +prevent 0 +vascular 3 +dysfunction 4 +even 0 +in 0 +nondiabetic 0 +patients 0 +. 0 + +Here 0 +we 0 +tested 0 +whether 0 +it 0 +has 0 +a 0 +beneficial 0 +effect 0 +in 0 +a 0 +rat 0 +model 0 +of 0 +gentamicin 1 +toxicity 3 +. 0 + +Mitochondrial 0 +analysis 0 +, 0 +respiration 0 +intensity 0 +, 0 +levels 0 +of 0 +reactive 0 +oxygen 1 +species 0 +, 0 +permeability 0 +transition 0 +, 0 +and 0 +cytochrome 0 +c 0 +release 0 +were 0 +assessed 0 +3 0 +and 0 +6 0 +days 0 +after 0 +gentamicin 1 +administration 0 +. 0 + +Metformin 1 +treatment 0 +fully 0 +blocked 0 +gentamicin 1 +- 0 +mediated 0 +acute 3 +renal 4 +failure 4 +. 0 + +This 0 +was 0 +accompanied 0 +by 0 +a 0 +lower 0 +activity 0 +of 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +D 0 +- 0 +glucosaminidase 0 +, 0 +together 0 +with 0 +a 0 +decrease 0 +of 0 +lipid 0 +peroxidation 0 +and 0 +increase 0 +of 0 +antioxidant 0 +systems 0 +. 0 + +Metformin 1 +also 0 +protected 0 +the 0 +kidney 0 +from 0 +histological 0 +damage 0 +6 0 +days 0 +after 0 +gentamicin 1 +administration 0 +. 0 + +These 0 +in 0 +vivo 0 +markers 0 +of 0 +kidney 3 +dysfunction 4 +and 0 +their 0 +correction 0 +by 0 +metformin 1 +were 0 +complemented 0 +by 0 +in 0 +vitro 0 +studies 0 +of 0 +mitochondrial 0 +function 0 +. 0 + +We 0 +found 0 +that 0 +gentamicin 1 +treatment 0 +depleted 0 +respiratory 0 +components 0 +( 0 +cytochrome 0 +c 0 +, 0 +NADH 0 +) 0 +, 0 +probably 0 +due 0 +to 0 +the 0 +opening 0 +of 0 +mitochondrial 0 +transition 0 +pores 0 +. 0 + +These 0 +injuries 0 +, 0 +partly 0 +mediated 0 +by 0 +a 0 +rise 0 +in 0 +reactive 0 +oxygen 1 +species 0 +from 0 +the 0 +electron 0 +transfer 0 +chain 0 +, 0 +were 0 +significantly 0 +decreased 0 +by 0 +metformin 1 +. 0 + +Thus 0 +, 0 +our 0 +study 0 +suggests 0 +that 0 +pleiotropic 0 +effects 0 +of 0 +metformin 1 +can 0 +lessen 0 +gentamicin 1 +nephrotoxicity 3 +and 0 +improve 0 +mitochondrial 0 +homeostasis 0 +. 0 + +Risk 0 +of 0 +nephropathy 3 +after 0 +consumption 0 +of 0 +nonionic 0 +contrast 1 +media 2 +by 0 +children 0 +undergoing 0 +cardiac 0 +angiography 0 +: 0 +a 0 +prospective 0 +study 0 +. 0 + +Despite 0 +increasing 0 +reports 0 +on 0 +nonionic 0 +contrast 1 +media 2 +- 0 +induced 0 +nephropathy 3 +( 0 +CIN 3 +) 0 +in 0 +hospitalized 0 +adult 0 +patients 0 +during 0 +cardiac 0 +procedures 0 +, 0 +the 0 +studies 0 +in 0 +pediatrics 0 +are 0 +limited 0 +, 0 +with 0 +even 0 +less 0 +focus 0 +on 0 +possible 0 +predisposing 0 +factors 0 +and 0 +preventive 0 +measures 0 +for 0 +patients 0 +undergoing 0 +cardiac 0 +angiography 0 +. 0 + +This 0 +prospective 0 +study 0 +determined 0 +the 0 +incidence 0 +of 0 +CIN 3 +for 0 +two 0 +nonionic 0 +contrast 1 +media 2 +( 0 +CM 1 +) 0 +, 0 +iopromide 1 +and 0 +iohexol 1 +, 0 +among 0 +80 0 +patients 0 +younger 0 +than 0 +18 0 +years 0 +and 0 +compared 0 +the 0 +rates 0 +for 0 +this 0 +complication 0 +in 0 +relation 0 +to 0 +the 0 +type 0 +and 0 +dosage 0 +of 0 +CM 1 +and 0 +the 0 +presence 0 +of 0 +cyanosis 3 +. 0 + +The 0 +80 0 +patients 0 +in 0 +the 0 +study 0 +consecutively 0 +received 0 +either 0 +iopromide 1 +( 0 +group 0 +A 0 +, 0 +n 0 += 0 +40 0 +) 0 +or 0 +iohexol 1 +( 0 +group 0 +B 0 +, 0 +n 0 += 0 +40 0 +) 0 +. 0 + +Serum 0 +sodium 1 +( 0 +Na 1 +) 0 +, 0 +potassium 1 +( 0 +K 1 +) 0 +, 0 +and 0 +creatinine 1 +( 0 +Cr 1 +) 0 +were 0 +measured 0 +24 0 +h 0 +before 0 +angiography 0 +as 0 +baseline 0 +values 0 +, 0 +then 0 +measured 0 +again 0 +at 0 +12 0 +- 0 +, 0 +24 0 +- 0 +, 0 +and 0 +48 0 +- 0 +h 0 +intervals 0 +after 0 +CM 1 +use 0 +. 0 + +Urine 0 +samples 0 +for 0 +Na 1 +and 0 +Cr 1 +also 0 +were 0 +checked 0 +at 0 +the 0 +same 0 +intervals 0 +. 0 + +Risk 0 +of 0 +renal 3 +failure 4 +, 0 +Injury 3 +to 4 +the 4 +kidney 4 +, 0 +Failure 3 +of 4 +kidney 4 +function 4 +, 0 +Loss 3 +of 4 +kidney 4 +function 4 +, 0 +and 0 +End 0 +- 0 +stage 0 +renal 3 +damage 4 +( 0 +RIFLE 0 +criteria 0 +) 0 +were 0 +used 0 +to 0 +define 0 +CIN 3 +and 0 +its 0 +incidence 0 +in 0 +the 0 +study 0 +population 0 +. 0 + +Accordingly 0 +, 0 +among 0 +the 0 +15 0 +CIN 3 +patients 0 +( 0 +18 0 +. 0 +75 0 +% 0 +) 0 +, 0 +7 0 +. 0 +5 0 +% 0 +of 0 +the 0 +patients 0 +in 0 +group 0 +A 0 +had 0 +increased 0 +risk 0 +and 0 +3 0 +. 0 +75 0 +% 0 +had 0 +renal 3 +injury 4 +, 0 +whereas 0 +5 0 +% 0 +of 0 +group 0 +B 0 +had 0 +increased 0 +risk 0 +and 0 +2 0 +. 0 +5 0 +% 0 +had 0 +renal 3 +injury 4 +. 0 + +Whereas 0 +33 0 +. 0 +3 0 +% 0 +of 0 +the 0 +patients 0 +with 0 +CIN 3 +were 0 +among 0 +those 0 +who 0 +received 0 +the 0 +proper 0 +dosage 0 +of 0 +CM 1 +, 0 +the 0 +percentage 0 +increased 0 +to 0 +66 0 +. 0 +6 0 +% 0 +among 0 +those 0 +who 0 +received 0 +larger 0 +doses 0 +, 0 +with 0 +a 0 +significant 0 +difference 0 +in 0 +the 0 +incidence 0 +of 0 +CIN 3 +related 0 +to 0 +the 0 +different 0 +dosages 0 +of 0 +CM 1 +( 0 +p 0 += 0 +0 0 +. 0 +014 0 +) 0 +. 0 + +Among 0 +the 0 +15 0 +patients 0 +with 0 +CIN 3 +, 0 +6 0 +had 0 +cyanotic 0 +congenital 3 +heart 4 +diseases 4 +, 0 +but 0 +the 0 +incidence 0 +did 0 +not 0 +differ 0 +significantly 0 +from 0 +that 0 +for 0 +the 0 +noncyanotic 0 +patients 0 +( 0 +p 0 += 0 +0 0 +. 0 +243 0 +) 0 +. 0 + +Although 0 +clinically 0 +silent 0 +, 0 +CIN 3 +is 0 +not 0 +rare 0 +in 0 +pediatrics 0 +. 0 + +The 0 +incidence 0 +depends 0 +on 0 +dosage 0 +but 0 +not 0 +on 0 +the 0 +type 0 +of 0 +consumed 0 +nonionic 0 +CM 1 +, 0 +nor 0 +on 0 +the 0 +presence 0 +of 0 +cyanosis 3 +, 0 +and 0 +although 0 +CIN 3 +usually 0 +is 0 +reversible 0 +, 0 +more 0 +concern 0 +is 0 +needed 0 +for 0 +the 0 +prevention 0 +of 0 +such 0 +a 0 +complication 0 +in 0 +children 0 +. 0 + +Renal 0 +function 0 +and 0 +hemodynamics 0 +during 0 +prolonged 0 +isoflurane 1 +- 0 +induced 0 +hypotension 3 +in 0 +humans 0 +. 0 + +The 0 +effect 0 +of 0 +isoflurane 1 +- 0 +induced 0 +hypotension 3 +on 0 +glomerular 0 +function 0 +and 0 +renal 0 +blood 0 +flow 0 +was 0 +investigated 0 +in 0 +20 0 +human 0 +subjects 0 +. 0 + +Glomerular 0 +filtration 0 +rate 0 +( 0 +GFR 0 +) 0 +and 0 +effective 0 +renal 0 +plasma 0 +flow 0 +( 0 +ERPF 0 +) 0 +were 0 +measured 0 +by 0 +inulin 0 +and 0 +para 1 +- 2 +aminohippurate 2 +( 0 +PAH 1 +) 0 +clearance 0 +, 0 +respectively 0 +. 0 + +Anesthesia 0 +was 0 +maintained 0 +with 0 +fentanyl 1 +, 0 +nitrous 1 +oxide 2 +, 0 +oxygen 1 +, 0 +and 0 +isoflurane 1 +. 0 + +Hypotension 3 +was 0 +induced 0 +for 0 +236 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +15 0 +. 0 +1 0 +min 0 +by 0 +increasing 0 +the 0 +isoflurane 1 +inspired 0 +concentration 0 +to 0 +maintain 0 +a 0 +mean 0 +arterial 0 +pressure 0 +of 0 +59 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +mmHg 0 +. 0 + +GFR 0 +and 0 +ERPF 0 +decreased 0 +with 0 +the 0 +induction 0 +of 0 +anesthesia 0 +but 0 +not 0 +significantly 0 +more 0 +during 0 +hypotension 3 +. 0 + +Postoperatively 0 +, 0 +ERPF 0 +returned 0 +to 0 +preoperative 0 +values 0 +, 0 +whereas 0 +GFR 0 +was 0 +higher 0 +than 0 +preoperative 0 +values 0 +. 0 + +Renal 0 +vascular 0 +resistance 0 +increased 0 +during 0 +anesthesia 0 +but 0 +decreased 0 +when 0 +hypotension 3 +was 0 +induced 0 +, 0 +allowing 0 +the 0 +maintenance 0 +of 0 +renal 0 +blood 0 +flow 0 +. 0 + +We 0 +conclude 0 +that 0 +renal 0 +compensatory 0 +mechanisms 0 +are 0 +preserved 0 +during 0 +isoflurane 1 +- 0 +induced 0 +hypotension 3 +and 0 +that 0 +renal 0 +function 0 +and 0 +hemodynamics 0 +quickly 0 +return 0 +to 0 +normal 0 +when 0 +normotension 0 +is 0 +resumed 0 +. 0 + +Brainstem 3 +dysgenesis 4 +in 0 +an 0 +infant 0 +prenatally 0 +exposed 0 +to 0 +cocaine 1 +. 0 + +Many 0 +authors 0 +described 0 +the 0 +effects 0 +on 0 +the 0 +fetus 0 +of 0 +maternal 0 +cocaine 3 +abuse 4 +during 0 +pregnancy 0 +. 0 + +Vasoconstriction 0 +appears 0 +to 0 +be 0 +the 0 +common 0 +mechanism 0 +of 0 +action 0 +leading 0 +to 0 +a 0 +wide 0 +range 0 +of 0 +fetal 3 +anomalies 4 +. 0 + +We 0 +report 0 +on 0 +an 0 +infant 0 +with 0 +multiple 3 +cranial 4 +- 4 +nerve 4 +involvement 4 +attributable 0 +to 0 +brainstem 3 +dysgenesis 4 +, 0 +born 0 +to 0 +a 0 +cocaine 3 +- 4 +addicted 4 +mother 0 +. 0 + +A 0 +cross 0 +- 0 +sectional 0 +evaluation 0 +of 0 +the 0 +effect 0 +of 0 +risperidone 1 +and 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitors 0 +on 0 +bone 0 +mineral 0 +density 0 +in 0 +boys 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +effect 0 +of 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +on 0 +trabecular 0 +bone 0 +mineral 0 +density 0 +( 0 +BMD 0 +) 0 +in 0 +children 0 +and 0 +adolescents 0 +. 0 + +METH0D 0 +: 0 +Medically 0 +healthy 0 +7 0 +- 0 +to 0 +17 0 +- 0 +year 0 +- 0 +old 0 +males 0 +chronically 0 +treated 0 +, 0 +in 0 +a 0 +naturalistic 0 +setting 0 +, 0 +with 0 +risperidone 1 +were 0 +recruited 0 +for 0 +this 0 +cross 0 +- 0 +sectional 0 +study 0 +through 0 +child 0 +psychiatry 0 +outpatient 0 +clinics 0 +between 0 +November 0 +2005 0 +and 0 +June 0 +2007 0 +. 0 + +Anthropometric 0 +measurements 0 +and 0 +laboratory 0 +testing 0 +were 0 +conducted 0 +. 0 + +The 0 +clinical 0 +diagnoses 0 +were 0 +based 0 +on 0 +chart 0 +review 0 +, 0 +and 0 +developmental 0 +and 0 +treatment 0 +history 0 +was 0 +obtained 0 +from 0 +the 0 +medical 0 +record 0 +. 0 + +Volumetric 0 +BMD 0 +of 0 +the 0 +ultradistal 0 +radius 0 +was 0 +measured 0 +using 0 +peripheral 0 +quantitative 0 +computed 0 +tomography 0 +, 0 +and 0 +areal 0 +BMD 0 +of 0 +the 0 +lumbar 0 +spine 0 +was 0 +estimated 0 +using 0 +dual 0 +- 0 +energy 0 +x 0 +- 0 +ray 0 +absorptiometry 0 +. 0 + +RESULTS 0 +: 0 +Hyperprolactinemia 3 +was 0 +present 0 +in 0 +49 0 +% 0 +of 0 +83 0 +boys 0 +( 0 +n 0 += 0 +41 0 +) 0 +treated 0 +with 0 +risperidone 1 +for 0 +a 0 +mean 0 +of 0 +2 0 +. 0 +9 0 +years 0 +. 0 + +Serum 0 +testosterone 1 +concentration 0 +increased 0 +with 0 +pubertal 0 +status 0 +but 0 +was 0 +not 0 +affected 0 +by 0 +hyperprolactinemia 3 +. 0 + +As 0 +expected 0 +, 0 +bone 0 +mineral 0 +content 0 +and 0 +BMD 0 +increased 0 +with 0 +sexual 0 +maturity 0 +. 0 + +After 0 +adjusting 0 +for 0 +the 0 +stage 0 +of 0 +sexual 0 +development 0 +and 0 +height 0 +and 0 +BMI 0 +z 0 +scores 0 +, 0 +serum 0 +prolactin 0 +was 0 +negatively 0 +associated 0 +with 0 +trabecular 0 +volumetric 0 +BMD 0 +at 0 +the 0 +ultradistal 0 +radius 0 +( 0 +P 0 +< 0 +. 0 +03 0 +) 0 +. 0 + +Controlling 0 +for 0 +relevant 0 +covariates 0 +, 0 +we 0 +also 0 +found 0 +treatment 0 +with 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitors 0 +( 0 +SSRIs 0 +) 0 +to 0 +be 0 +associated 0 +with 0 +lower 0 +trabecular 0 +BMD 0 +at 0 +the 0 +radius 0 +( 0 +P 0 += 0 +. 0 +03 0 +) 0 +and 0 +BMD 0 +z 0 +score 0 +at 0 +the 0 +lumbar 0 +spine 0 +( 0 +P 0 +< 0 +. 0 +05 0 +) 0 +. 0 + +These 0 +findings 0 +became 0 +more 0 +marked 0 +when 0 +the 0 +analysis 0 +was 0 +restricted 0 +to 0 +non 0 +- 0 +Hispanic 0 +white 0 +patients 0 +. 0 + +0f 0 +13 0 +documented 0 +fractures 3 +, 0 +3 0 +occurred 0 +after 0 +risperidone 1 +and 0 +SSRIs 0 +were 0 +started 0 +, 0 +and 0 +none 0 +occurred 0 +in 0 +patients 0 +with 0 +hyperprolactinemia 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +This 0 +is 0 +the 0 +first 0 +study 0 +to 0 +link 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +and 0 +SSRI 0 +treatment 0 +to 0 +lower 0 +BMD 0 +in 0 +children 0 +and 0 +adolescents 0 +. 0 + +Future 0 +research 0 +should 0 +evaluate 0 +the 0 +longitudinal 0 +course 0 +of 0 +this 0 +adverse 0 +event 0 +to 0 +determine 0 +its 0 +temporal 0 +stability 0 +and 0 +whether 0 +a 0 +higher 0 +fracture 0 +rate 0 +ensues 0 +. 0 + +Fear 0 +- 0 +potentiated 0 +startle 3 +, 0 +but 0 +not 0 +light 0 +- 0 +enhanced 0 +startle 3 +, 0 +is 0 +enhanced 0 +by 0 +anxiogenic 0 +drugs 0 +. 0 + +RATI0NALE 0 +AND 0 +0BJECTIVES 0 +: 0 +The 0 +light 0 +- 0 +enhanced 0 +startle 3 +paradigm 0 +( 0 +LES 0 +) 0 +is 0 +suggested 0 +to 0 +model 0 +anxiety 3 +, 0 +because 0 +of 0 +the 0 +non 0 +- 0 +specific 0 +cue 0 +and 0 +the 0 +long 0 +- 0 +term 0 +effect 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +fear 0 +- 0 +potentiated 0 +startle 3 +( 0 +FPS 0 +) 0 +is 0 +suggested 0 +to 0 +model 0 +conditioned 0 +fear 0 +. 0 + +However 0 +, 0 +the 0 +pharmacological 0 +profiles 0 +of 0 +these 0 +two 0 +paradigms 0 +are 0 +very 0 +similar 0 +. 0 + +The 0 +present 0 +study 0 +investigated 0 +the 0 +effects 0 +of 0 +putative 0 +anxiogenic 0 +drugs 0 +on 0 +LES 0 +and 0 +FPS 0 +and 0 +aimed 0 +at 0 +determining 0 +the 0 +sensitivity 0 +of 0 +LES 0 +for 0 +anxiogenic 0 +drugs 0 +and 0 +to 0 +potentially 0 +showing 0 +a 0 +pharmacological 0 +differentiation 0 +between 0 +these 0 +two 0 +paradigms 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +Wistar 0 +rats 0 +received 0 +each 0 +dose 0 +of 0 +the 0 +alpha 0 +( 0 +2 0 +) 0 +- 0 +adrenoceptor 0 +antagonist 0 +yohimbine 1 +( 0 +0 0 +. 0 +25 0 +- 0 +1 0 +. 0 +0mg 0 +/ 0 +kg 0 +) 0 +, 0 +the 0 +5 1 +- 2 +HT 2 +( 0 +2C 0 +) 0 +receptor 0 +agonist 0 +m 1 +- 2 +chlorophenylpiperazine 2 +( 0 +mCPP 1 +, 0 +0 0 +. 0 +5 0 +- 0 +2 0 +. 0 +0mg 0 +/ 0 +kg 0 +) 0 +or 0 +the 0 +GABA 1 +( 0 +A 0 +) 0 +inverse 0 +receptor 0 +agonist 0 +pentylenetetrazole 1 +( 0 +PTZ 1 +, 0 +3 0 +- 0 +30mg 0 +/ 0 +kg 0 +) 0 +and 0 +were 0 +subsequently 0 +tested 0 +in 0 +either 0 +LES 0 +or 0 +FPS 0 +. 0 + +RESULTS 0 +: 0 +None 0 +of 0 +the 0 +drugs 0 +enhanced 0 +LES 0 +, 0 +whereas 0 +mCPP 1 +increased 0 +percentage 0 +FPS 0 +and 0 +yohimbine 1 +increased 0 +absolute 0 +FPS 0 +values 0 +. 0 + +Furthermore 0 +, 0 +yohimbine 1 +increased 0 +baseline 0 +startle 3 +amplitude 0 +in 0 +the 0 +LES 0 +, 0 +while 0 +mCPP 1 +suppressed 0 +baseline 0 +startle 3 +in 0 +both 0 +the 0 +LES 0 +and 0 +FPS 0 +and 0 +PTZ 1 +suppressed 0 +baseline 0 +startle 3 +in 0 +the 0 +FPS 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +contrast 0 +to 0 +findings 0 +in 0 +the 0 +FPS 0 +paradigm 0 +, 0 +none 0 +of 0 +the 0 +drugs 0 +were 0 +able 0 +to 0 +exacerbate 0 +the 0 +LES 0 +response 0 +. 0 + +Thus 0 +, 0 +a 0 +clear 0 +pharmacological 0 +differentiation 0 +was 0 +found 0 +between 0 +LES 0 +and 0 +FPS 0 +. 0 + +Rosaceiform 0 +dermatitis 3 +associated 0 +with 0 +topical 0 +tacrolimus 1 +treatment 0 +. 0 + +We 0 +describe 0 +herein 0 +3 0 +patients 0 +who 0 +developed 0 +rosacea 3 +- 0 +like 0 +dermatitis 3 +eruptions 3 +while 0 +using 0 +0 0 +. 0 +03 0 +% 0 +or 0 +0 0 +. 0 +1 0 +% 0 +tacrolimus 1 +ointment 0 +for 0 +facial 3 +dermatitis 4 +. 0 + +Skin 0 +biopsy 0 +specimens 0 +showed 0 +telangiectasia 3 +and 0 +noncaseating 0 +epithelioid 0 +granulomatous 0 +tissue 0 +formation 0 +in 0 +the 0 +papillary 0 +to 0 +mid 0 +dermis 0 +. 0 + +Continuous 0 +topical 0 +use 0 +of 0 +immunomodulators 0 +such 0 +as 0 +tacrolimus 1 +or 0 +pimecrolimus 1 +should 0 +be 0 +regarded 0 +as 0 +a 0 +potential 0 +cause 0 +of 0 +rosaceiform 0 +dermatitis 3 +, 0 +although 0 +many 0 +cases 0 +have 0 +not 0 +been 0 +reported 0 +. 0 + +Coenzyme 1 +Q10 2 +treatment 0 +ameliorates 0 +acute 0 +cisplatin 1 +nephrotoxicity 3 +in 0 +mice 0 +. 0 + +The 0 +nephroprotective 0 +effect 0 +of 0 +coenzyme 1 +Q10 2 +was 0 +investigated 0 +in 0 +mice 0 +with 0 +acute 3 +renal 4 +injury 4 +induced 0 +by 0 +a 0 +single 0 +i 0 +. 0 +p 0 +. 0 +injection 0 +of 0 +cisplatin 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +Coenzyme 1 +Q10 2 +treatment 0 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +was 0 +applied 0 +for 0 +6 0 +consecutive 0 +days 0 +, 0 +starting 0 +1 0 +day 0 +before 0 +cisplatin 1 +administration 0 +. 0 + +Coenzyme 1 +Q10 2 +significantly 0 +reduced 0 +blood 1 +urea 2 +nitrogen 2 +and 0 +serum 0 +creatinine 1 +levels 0 +which 0 +were 0 +increased 0 +by 0 +cisplatin 1 +. 0 + +Coenzyme 1 +Q10 2 +significantly 0 +compensated 0 +deficits 0 +in 0 +the 0 +antioxidant 0 +defense 0 +mechanisms 0 +( 0 +reduced 1 +glutathione 2 +level 0 +and 0 +superoxide 1 +dismutase 0 +activity 0 +) 0 +, 0 +suppressed 0 +lipid 0 +peroxidation 0 +, 0 +decreased 0 +the 0 +elevations 0 +of 0 +tumor 3 +necrosis 3 +factor 0 +- 0 +alpha 0 +, 0 +nitric 1 +oxide 2 +and 0 +platinum 1 +ion 0 +concentration 0 +, 0 +and 0 +attenuated 0 +the 0 +reductions 0 +of 0 +selenium 1 +and 0 +zinc 1 +ions 0 +in 0 +renal 0 +tissue 0 +resulted 0 +from 0 +cisplatin 1 +administration 0 +. 0 + +Also 0 +, 0 +histopathological 0 +renal 3 +tissue 4 +damage 4 +mediated 0 +by 0 +cisplatin 1 +was 0 +ameliorated 0 +by 0 +coenzyme 1 +Q10 2 +treatment 0 +. 0 + +Immunohistochemical 0 +analysis 0 +revealed 0 +that 0 +coenzyme 1 +Q10 2 +significantly 0 +decreased 0 +the 0 +cisplatin 1 +- 0 +induced 0 +overexpression 0 +of 0 +inducible 0 +nitric 1 +oxide 2 +synthase 0 +, 0 +nuclear 0 +factor 0 +- 0 +kappaB 0 +, 0 +caspase 0 +- 0 +3 0 +and 0 +p53 0 +in 0 +renal 0 +tissue 0 +. 0 + +It 0 +was 0 +concluded 0 +that 0 +coenzyme 1 +Q10 2 +represents 0 +a 0 +potential 0 +therapeutic 0 +option 0 +to 0 +protect 0 +against 0 +acute 0 +cisplatin 1 +nephrotoxicity 3 +commonly 0 +encountered 0 +in 0 +clinical 0 +practice 0 +. 0 + +Reversible 0 +cholestasis 3 +with 0 +bile 3 +duct 4 +injury 4 +following 0 +azathioprine 1 +therapy 0 +. 0 + +A 0 +case 0 +report 0 +. 0 + +A 0 +67 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +, 0 +with 0 +primary 0 +polymyositis 3 +and 0 +without 0 +previous 0 +evidence 0 +of 0 +liver 3 +disease 4 +, 0 +developed 0 +clinical 0 +and 0 +biochemical 0 +features 0 +of 0 +severe 0 +cholestasis 3 +3 0 +months 0 +after 0 +initiation 0 +of 0 +azathioprine 1 +therapy 0 +. 0 + +Liver 0 +biopsy 0 +showed 0 +cholestasis 3 +with 0 +both 0 +cytological 0 +and 0 +architectural 0 +alterations 0 +of 0 +interlobular 0 +bile 0 +ducts 0 +. 0 + +Azathioprine 1 +withdrawal 0 +resulted 0 +after 0 +7 0 +weeks 0 +in 0 +the 0 +resolution 0 +of 0 +clinical 0 +and 0 +biochemical 0 +abnormalities 0 +. 0 + +It 0 +is 0 +believed 0 +that 0 +this 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +reversible 0 +azathioprine 1 +- 0 +induced 0 +cholestasis 3 +associated 0 +with 0 +histological 0 +evidence 0 +of 0 +bile 3 +duct 4 +injury 4 +. 0 + +Dopamine 1 +is 0 +not 0 +essential 0 +for 0 +the 0 +development 0 +of 0 +methamphetamine 1 +- 0 +induced 0 +neurotoxicity 3 +. 0 + +It 0 +is 0 +widely 0 +believed 0 +that 0 +dopamine 1 +( 0 +DA 1 +) 0 +mediates 0 +methamphetamine 1 +( 0 +METH 1 +) 0 +- 0 +induced 0 +toxicity 3 +to 0 +brain 0 +dopaminergic 0 +neurons 0 +, 0 +because 0 +drugs 0 +that 0 +interfere 0 +with 0 +DA 1 +neurotransmission 0 +decrease 0 +toxicity 3 +, 0 +whereas 0 +drugs 0 +that 0 +increase 0 +DA 1 +neurotransmission 0 +enhance 0 +toxicity 3 +. 0 + +However 0 +, 0 +temperature 0 +effects 0 +of 0 +drugs 0 +that 0 +have 0 +been 0 +used 0 +to 0 +manipulate 0 +brain 0 +DA 1 +neurotransmission 0 +confound 0 +interpretation 0 +of 0 +the 0 +data 0 +. 0 + +Here 0 +we 0 +show 0 +that 0 +the 0 +recently 0 +reported 0 +ability 0 +of 0 +L 1 +- 2 +dihydroxyphenylalanine 2 +to 0 +reverse 0 +the 0 +protective 0 +effect 0 +of 0 +alpha 1 +- 2 +methyl 2 +- 2 +para 2 +- 2 +tyrosine 2 +on 0 +METH 1 +- 0 +induced 0 +DA 1 +neurotoxicity 3 +is 0 +also 0 +confounded 0 +by 0 +drug 0 +effects 0 +on 0 +body 0 +temperature 0 +. 0 + +Further 0 +, 0 +we 0 +show 0 +that 0 +mice 0 +genetically 0 +engineered 0 +to 0 +be 0 +deficient 0 +in 0 +brain 0 +DA 1 +develop 0 +METH 1 +neurotoxicity 3 +, 0 +as 0 +long 0 +as 0 +the 0 +thermic 0 +effects 0 +of 0 +METH 1 +are 0 +preserved 0 +. 0 + +In 0 +addition 0 +, 0 +we 0 +demonstrate 0 +that 0 +mice 0 +genetically 0 +engineered 0 +to 0 +have 0 +unilateral 0 +brain 0 +DA 1 +deficits 0 +develop 0 +METH 1 +- 0 +induced 0 +dopaminergic 3 +deficits 4 +that 0 +are 0 +of 0 +comparable 0 +magnitude 0 +on 0 +both 0 +sides 0 +of 0 +the 0 +brain 0 +. 0 + +Taken 0 +together 0 +, 0 +these 0 +findings 0 +demonstrate 0 +that 0 +DA 1 +is 0 +not 0 +essential 0 +for 0 +the 0 +development 0 +of 0 +METH 1 +- 0 +induced 0 +dopaminergic 0 +neurotoxicity 3 +and 0 +suggest 0 +that 0 +mechanisms 0 +independent 0 +of 0 +DA 1 +warrant 0 +more 0 +intense 0 +investigation 0 +. 0 + +Swallowing 0 +- 0 +induced 0 +atrial 3 +tachyarrhythmia 4 +triggered 0 +by 0 +salbutamol 1 +: 0 +case 0 +report 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +CASE 0 +: 0 +A 0 +49 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +experienced 0 +chest 0 +discomfort 0 +while 0 +swallowing 0 +. 0 + +0n 0 +electrocardiogram 0 +, 0 +episodes 0 +of 0 +atrial 3 +tachyarrhythmia 4 +were 0 +recorded 0 +immediately 0 +after 0 +swallowing 0 +; 0 +24 0 +- 0 +hour 0 +Holter 0 +monitoring 0 +recorded 0 +several 0 +events 0 +. 0 + +The 0 +arrhythmia 3 +resolved 0 +after 0 +therapy 0 +with 0 +atenolol 1 +, 0 +but 0 +recurred 0 +a 0 +year 0 +later 0 +. 0 + +The 0 +patient 0 +noticed 0 +that 0 +before 0 +these 0 +episodes 0 +he 0 +had 0 +been 0 +using 0 +an 0 +inhalator 0 +of 0 +salbutamol 1 +. 0 + +After 0 +stopping 0 +the 0 +beta 0 +- 0 +agonist 0 +, 0 +and 0 +after 0 +a 0 +week 0 +with 0 +the 0 +atenolol 1 +, 0 +the 0 +arrhythmia 3 +disappeared 0 +. 0 + +DISCUSSI0N 0 +: 0 +Swallowing 0 +- 0 +induced 0 +atrial 3 +tachyarrhythmia 4 +( 0 +SIAT 3 +) 0 +is 0 +a 0 +rare 0 +phenomenon 0 +. 0 + +Fewer 0 +than 0 +50 0 +cases 0 +of 0 +SIAT 3 +have 0 +been 0 +described 0 +in 0 +the 0 +literature 0 +. 0 + +This 0 +article 0 +summarizes 0 +all 0 +the 0 +cases 0 +published 0 +, 0 +creating 0 +a 0 +comprehensive 0 +review 0 +of 0 +the 0 +current 0 +knowledge 0 +and 0 +approach 0 +to 0 +SIAT 3 +. 0 + +It 0 +discusses 0 +demographics 0 +, 0 +clinical 0 +characteristics 0 +and 0 +types 0 +of 0 +arrhythmia 3 +, 0 +postulated 0 +mechanisms 0 +of 0 +SIAT 3 +, 0 +and 0 +different 0 +treatment 0 +possibilities 0 +such 0 +as 0 +medications 0 +, 0 +surgery 0 +, 0 +and 0 +radiofrequency 0 +catheter 0 +ablation 0 +( 0 +RFCA 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Salbutamol 1 +is 0 +presented 0 +here 0 +as 0 +a 0 +possible 0 +trigger 0 +for 0 +SIAT 3 +. 0 + +Although 0 +it 0 +is 0 +difficult 0 +to 0 +define 0 +causality 0 +in 0 +a 0 +case 0 +report 0 +, 0 +it 0 +is 0 +logical 0 +to 0 +think 0 +that 0 +a 0 +beta 0 +- 0 +agonist 0 +like 0 +salbutamol 1 +( 0 +known 0 +to 0 +induce 0 +tachycardia 3 +) 0 +may 0 +be 0 +the 0 +trigger 0 +of 0 +adrenergic 0 +reflexes 0 +originating 0 +in 0 +the 0 +esophagus 0 +while 0 +swallowing 0 +and 0 +that 0 +a 0 +beta 0 +- 0 +blocker 0 +such 0 +as 0 +atenolol 1 +( 0 +that 0 +blocks 0 +the 0 +adrenergic 0 +activity 0 +) 0 +may 0 +relieve 0 +it 0 +. 0 + +The 0 +ability 0 +of 0 +insulin 0 +treatment 0 +to 0 +reverse 0 +or 0 +prevent 0 +the 0 +changes 0 +in 0 +urinary 0 +bladder 0 +function 0 +caused 0 +by 0 +streptozotocin 1 +- 0 +induced 0 +diabetes 3 +mellitus 4 +. 0 + +1 0 +. 0 + +The 0 +effects 0 +of 0 +insulin 0 +treatment 0 +on 0 +in 0 +vivo 0 +and 0 +in 0 +vitro 0 +urinary 0 +bladder 0 +function 0 +in 0 +streptozotocin 1 +- 0 +diabetic 3 +rats 0 +were 0 +investigated 0 +. 0 + +2 0 +. 0 + +Diabetes 3 +of 0 +2 0 +months 0 +duration 0 +resulted 0 +in 0 +decreases 0 +in 0 +body 0 +weight 0 +and 0 +increases 0 +in 0 +fluid 0 +consumption 0 +, 0 +urine 0 +volume 0 +, 0 +frequency 0 +of 0 +micturition 0 +, 0 +and 0 +average 0 +volume 0 +per 0 +micturition 0 +; 0 +effects 0 +which 0 +were 0 +prevented 0 +by 0 +insulin 0 +treatment 0 +. 0 + +3 0 +. 0 + +Insulin 0 +treatment 0 +also 0 +prevented 0 +the 0 +increases 0 +in 0 +contractile 0 +responses 0 +of 0 +bladder 0 +body 0 +strips 0 +from 0 +diabetic 3 +rats 0 +to 0 +nerve 0 +stimulation 0 +, 0 +ATP 1 +, 0 +and 0 +bethanechol 1 +. 0 + +4 0 +. 0 + +Diabetes 3 +of 0 +4 0 +months 0 +duration 0 +also 0 +resulted 0 +in 0 +decreases 0 +in 0 +body 0 +weight 0 +, 0 +and 0 +increases 0 +in 0 +fluid 0 +consumption 0 +, 0 +urine 0 +volume 0 +, 0 +frequency 0 +of 0 +micturition 0 +, 0 +and 0 +average 0 +volume 0 +per 0 +micturition 0 +, 0 +effects 0 +which 0 +were 0 +reversed 0 +by 0 +insulin 0 +treatment 0 +for 0 +the 0 +final 0 +2 0 +months 0 +of 0 +the 0 +study 0 +. 0 + +5 0 +. 0 + +Insulin 0 +treatment 0 +reversed 0 +the 0 +increases 0 +in 0 +contractile 0 +responses 0 +of 0 +bladder 0 +body 0 +strips 0 +from 0 +diabetic 3 +rats 0 +to 0 +nerve 0 +stimulation 0 +, 0 +ATP 1 +, 0 +and 0 +bethanechol 1 +. 0 + +6 0 +. 0 + +The 0 +data 0 +indicate 0 +that 0 +the 0 +effects 0 +of 0 +streptozotocin 1 +- 0 +induced 0 +diabetes 3 +on 0 +urinary 0 +bladder 0 +function 0 +are 0 +both 0 +prevented 0 +and 0 +reversed 0 +by 0 +insulin 0 +treatment 0 +. 0 + +Glutamatergic 0 +neurotransmission 0 +mediated 0 +by 0 +NMDA 1 +receptors 0 +in 0 +the 0 +inferior 0 +colliculus 0 +can 0 +modulate 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +The 0 +inferior 0 +colliculus 0 +( 0 +IC 0 +) 0 +is 0 +primarily 0 +involved 0 +in 0 +the 0 +processing 0 +of 0 +auditory 0 +information 0 +, 0 +but 0 +it 0 +is 0 +distinguished 0 +from 0 +other 0 +auditory 0 +nuclei 0 +in 0 +the 0 +brainstem 0 +by 0 +its 0 +connections 0 +with 0 +structures 0 +of 0 +the 0 +motor 0 +system 0 +. 0 + +Functional 0 +evidence 0 +relating 0 +the 0 +IC 0 +to 0 +motor 0 +behavior 0 +derives 0 +from 0 +experiments 0 +showing 0 +that 0 +activation 0 +of 0 +the 0 +IC 0 +by 0 +electrical 0 +stimulation 0 +or 0 +excitatory 0 +amino 1 +acid 2 +microinjection 0 +causes 0 +freezing 0 +, 0 +escape 0 +- 0 +like 0 +behavior 0 +, 0 +and 0 +immobility 0 +. 0 + +However 0 +, 0 +the 0 +nature 0 +of 0 +this 0 +immobility 0 +is 0 +still 0 +unclear 0 +. 0 + +The 0 +present 0 +study 0 +examined 0 +the 0 +influence 0 +of 0 +excitatory 0 +amino 1 +acid 2 +- 0 +mediated 0 +mechanisms 0 +in 0 +the 0 +IC 0 +on 0 +the 0 +catalepsy 3 +induced 0 +by 0 +the 0 +dopamine 1 +receptor 0 +blocker 0 +haloperidol 1 +administered 0 +systemically 0 +( 0 +1 0 +or 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +rats 0 +. 0 + +Haloperidol 1 +- 0 +induced 0 +catalepsy 3 +was 0 +challenged 0 +with 0 +prior 0 +intracollicular 0 +microinjections 0 +of 0 +glutamate 1 +NMDA 1 +receptor 0 +antagonists 0 +, 0 +MK 1 +- 2 +801 2 +( 0 +15 0 +or 0 +30 0 +mmol 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +) 0 +and 0 +AP7 1 +( 0 +10 0 +or 0 +20 0 +nmol 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +) 0 +, 0 +or 0 +of 0 +the 0 +NMDA 1 +receptor 0 +agonist 0 +N 1 +- 2 +methyl 2 +- 2 +d 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +, 0 +20 0 +or 0 +30 0 +nmol 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +) 0 +. 0 + +The 0 +results 0 +showed 0 +that 0 +intracollicular 0 +microinjection 0 +of 0 +MK 1 +- 2 +801 2 +and 0 +AP7 1 +previous 0 +to 0 +systemic 0 +injections 0 +of 0 +haloperidol 1 +significantly 0 +attenuated 0 +the 0 +catalepsy 3 +, 0 +as 0 +indicated 0 +by 0 +a 0 +reduced 0 +latency 0 +to 0 +step 0 +down 0 +from 0 +a 0 +horizontal 0 +bar 0 +. 0 + +Accordingly 0 +, 0 +intracollicular 0 +microinjection 0 +of 0 +NMDA 1 +increased 0 +the 0 +latency 0 +to 0 +step 0 +down 0 +the 0 +bar 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +glutamate 1 +- 0 +mediated 0 +mechanisms 0 +in 0 +the 0 +neural 0 +circuits 0 +at 0 +the 0 +IC 0 +level 0 +influence 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +and 0 +participate 0 +in 0 +the 0 +regulation 0 +of 0 +motor 0 +activity 0 +. 0 + +Severe 0 +congestive 3 +heart 4 +failure 4 +patient 0 +on 0 +amiodarone 1 +presenting 0 +with 0 +myxedemic 3 +coma 4 +: 0 +a 0 +case 0 +report 0 +. 0 + +This 0 +is 0 +a 0 +case 0 +report 0 +of 0 +myxedema 3 +coma 4 +secondary 0 +to 0 +amiodarone 1 +- 0 +induced 0 +hypothyroidism 3 +in 0 +a 0 +patient 0 +with 0 +severe 0 +congestive 3 +heart 4 +failure 4 +( 0 +CHF 3 +) 0 +. 0 + +To 0 +our 0 +knowledge 0 +and 0 +after 0 +reviewing 0 +the 0 +literature 0 +there 0 +is 0 +one 0 +case 0 +report 0 +of 0 +myxedema 3 +coma 4 +during 0 +long 0 +term 0 +amiodarone 1 +therapy 0 +. 0 + +Myxedema 3 +coma 4 +is 0 +a 0 +life 0 +threatening 0 +condition 0 +that 0 +carries 0 +a 0 +mortality 0 +reaching 0 +as 0 +high 0 +as 0 +20 0 +% 0 +with 0 +treatment 0 +. 0 + +The 0 +condition 0 +is 0 +treated 0 +with 0 +intravenous 0 +thyroxine 1 +( 0 +T4 1 +) 0 +or 0 +intravenous 0 +tri 1 +- 2 +iodo 2 +- 2 +thyronine 2 +( 0 +T3 1 +) 0 +. 0 + +Patients 0 +with 0 +CHF 3 +on 0 +amiodarone 1 +may 0 +suffer 0 +serious 0 +morbidity 0 +and 0 +mortality 0 +from 0 +hypothyroidism 3 +, 0 +and 0 +thus 0 +may 0 +deserve 0 +closer 0 +follow 0 +up 0 +for 0 +thyroid 0 +stimulating 0 +hormone 0 +( 0 +TSH 0 +) 0 +levels 0 +. 0 + +This 0 +case 0 +report 0 +carries 0 +an 0 +important 0 +clinical 0 +application 0 +given 0 +the 0 +frequent 0 +usage 0 +of 0 +amiodarone 1 +among 0 +CHF 3 +patients 0 +. 0 + +The 0 +myriad 0 +clinical 0 +presentation 0 +of 0 +myxedema 3 +coma 4 +and 0 +its 0 +serious 0 +morbidity 0 +and 0 +mortality 0 +stresses 0 +the 0 +need 0 +to 0 +suspect 0 +this 0 +clinical 0 +syndrome 0 +among 0 +CHF 3 +patients 0 +presenting 0 +with 0 +hypotension 3 +, 0 +weakness 3 +or 0 +other 0 +unexplained 0 +symptoms 0 +. 0 + +Effects 0 +of 0 +active 0 +constituents 0 +of 0 +Crocus 0 +sativus 0 +L 0 +. 0 +, 0 +crocin 1 +on 0 +streptozocin 1 +- 0 +induced 0 +model 0 +of 0 +sporadic 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +in 0 +male 0 +rats 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +involvement 0 +of 0 +water 0 +- 0 +soluble 0 +carotenoids 1 +, 0 +crocins 1 +, 0 +as 0 +the 0 +main 0 +and 0 +active 0 +components 0 +of 0 +Crocus 0 +sativus 0 +L 0 +. 0 +extract 0 +in 0 +learning 0 +and 0 +memory 0 +processes 0 +has 0 +been 0 +proposed 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +effect 0 +of 0 +crocins 1 +on 0 +sporadic 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +induced 0 +by 0 +intracerebroventricular 0 +( 0 +icv 0 +) 0 +streptozocin 1 +( 0 +STZ 1 +) 0 +in 0 +male 0 +rats 0 +was 0 +investigated 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +adult 0 +Wistar 0 +rats 0 +( 0 +n 0 += 0 +90 0 +and 0 +260 0 +- 0 +290 0 +g 0 +) 0 +were 0 +divided 0 +into 0 +1 0 +, 0 +control 0 +; 0 +2 0 +and 0 +3 0 +, 0 +crocins 1 +( 0 +15 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +; 0 +4 0 +, 0 +STZ 1 +; 0 +5 0 +and 0 +6 0 +, 0 +STZ 1 ++ 0 +crocins 1 +( 0 +15 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +groups 0 +. 0 + +In 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +groups 0 +, 0 +rats 0 +were 0 +injected 0 +with 0 +STZ 1 +- 0 +icv 0 +bilaterally 0 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +first 0 +day 0 +and 0 +3 0 +days 0 +later 0 +, 0 +a 0 +similar 0 +STZ 1 +- 0 +icv 0 +application 0 +was 0 +repeated 0 +. 0 + +In 0 +STZ 1 ++ 0 +crocin 1 +animal 0 +groups 0 +, 0 +crocin 1 +was 0 +applied 0 +in 0 +doses 0 +of 0 +15 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +, 0 +one 0 +day 0 +pre 0 +- 0 +surgery 0 +and 0 +continued 0 +for 0 +three 0 +weeks 0 +. 0 + +Prescription 0 +of 0 +crocin 1 +in 0 +each 0 +dose 0 +was 0 +repeated 0 +once 0 +for 0 +two 0 +days 0 +. 0 + +However 0 +, 0 +the 0 +learning 0 +and 0 +memory 0 +performance 0 +was 0 +assessed 0 +using 0 +passive 0 +avoidance 0 +paradigm 0 +, 0 +and 0 +for 0 +spatial 0 +cognition 0 +evaluation 0 +, 0 +Y 0 +- 0 +maze 0 +task 0 +was 0 +used 0 +. 0 + +RESULTS 0 +: 0 +It 0 +was 0 +found 0 +out 0 +that 0 +crocin 1 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +- 0 +treated 0 +STZ 1 +- 0 +injected 0 +rats 0 +show 0 +higher 0 +correct 0 +choices 0 +and 0 +lower 0 +errors 0 +in 0 +Y 0 +- 0 +maze 0 +than 0 +vehicle 0 +- 0 +treated 0 +STZ 1 +- 0 +injected 0 +rats 0 +. 0 + +In 0 +addition 0 +, 0 +crocin 1 +in 0 +the 0 +mentioned 0 +dose 0 +could 0 +significantly 0 +attenuated 0 +learning 3 +and 4 +memory 4 +impairment 4 +in 0 +treated 0 +STZ 1 +- 0 +injected 0 +group 0 +in 0 +passive 0 +avoidance 0 +test 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Therefore 0 +, 0 +these 0 +results 0 +demonstrate 0 +the 0 +effectiveness 0 +of 0 +crocin 1 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +antagonizing 0 +the 0 +cognitive 3 +deficits 4 +caused 0 +by 0 +STZ 1 +- 0 +icv 0 +in 0 +rats 0 +and 0 +its 0 +potential 0 +in 0 +the 0 +treatment 0 +of 0 +neurodegenerative 3 +diseases 4 +such 0 +as 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 + +Serotonin 1 +6 0 +receptor 0 +gene 0 +is 0 +associated 0 +with 0 +methamphetamine 1 +- 0 +induced 0 +psychosis 3 +in 0 +a 0 +Japanese 0 +population 0 +. 0 + +BACKGR0UND 0 +: 0 +Altered 0 +serotonergic 0 +neural 0 +transmission 0 +is 0 +hypothesized 0 +to 0 +be 0 +a 0 +susceptibility 0 +factor 0 +for 0 +psychotic 3 +disorders 4 +such 0 +as 0 +schizophrenia 3 +. 0 + +The 0 +serotonin 1 +6 0 +( 0 +5 1 +- 2 +HT6 2 +) 0 +receptor 0 +is 0 +therapeutically 0 +targeted 0 +by 0 +several 0 +second 0 +generation 0 +antipsychotics 0 +, 0 +such 0 +as 0 +clozapine 1 +and 0 +olanzapine 1 +, 0 +and 0 +d 1 +- 2 +amphetamine 2 +- 0 +induced 0 +hyperactivity 3 +in 0 +rats 0 +is 0 +corrected 0 +with 0 +the 0 +use 0 +of 0 +a 0 +selective 0 +5 1 +- 2 +HT6 2 +receptor 0 +antagonist 0 +. 0 + +In 0 +addition 0 +, 0 +the 0 +disrupted 0 +prepulse 0 +inhibition 0 +induced 0 +by 0 +d 1 +- 2 +amphetamine 2 +or 0 +phencyclidine 1 +was 0 +restored 0 +by 0 +5 1 +- 2 +HT6 2 +receptor 0 +antagonist 0 +in 0 +an 0 +animal 0 +study 0 +using 0 +rats 0 +. 0 + +These 0 +animal 0 +models 0 +were 0 +considered 0 +to 0 +reflect 0 +the 0 +positive 0 +symptoms 0 +of 0 +schizophrenia 3 +, 0 +and 0 +the 0 +above 0 +evidence 0 +suggests 0 +that 0 +altered 0 +5 1 +- 2 +HT6 2 +receptors 0 +are 0 +involved 0 +in 0 +the 0 +pathophysiology 0 +of 0 +psychotic 3 +disorders 4 +. 0 + +The 0 +symptoms 0 +of 0 +methamphetamine 1 +( 0 +METH 1 +) 0 +- 0 +induced 0 +psychosis 3 +are 0 +similar 0 +to 0 +those 0 +of 0 +paranoid 3 +type 4 +schizophrenia 4 +. 0 + +Therefore 0 +, 0 +we 0 +conducted 0 +an 0 +analysis 0 +of 0 +the 0 +association 0 +of 0 +the 0 +5 1 +- 2 +HT6 2 +gene 0 +( 0 +HTR6 0 +) 0 +with 0 +METH 1 +- 0 +induced 0 +psychosis 3 +. 0 + +METH0D 0 +: 0 +Using 0 +five 0 +tagging 0 +SNPs 0 +( 0 +rs6693503 0 +, 0 +rs1805054 0 +, 0 +rs4912138 0 +, 0 +rs3790757 0 +and 0 +rs9659997 0 +) 0 +, 0 +we 0 +conducted 0 +a 0 +genetic 0 +association 0 +analysis 0 +of 0 +case 0 +- 0 +control 0 +samples 0 +( 0 +197 0 +METH 1 +- 0 +induced 0 +psychosis 3 +patients 0 +and 0 +337 0 +controls 0 +) 0 +in 0 +the 0 +Japanese 0 +population 0 +. 0 + +The 0 +age 0 +and 0 +sex 0 +of 0 +the 0 +control 0 +subjects 0 +did 0 +not 0 +differ 0 +from 0 +those 0 +of 0 +the 0 +methamphetamine 1 +dependence 0 +patients 0 +. 0 + +RESULTS 0 +: 0 +rs6693503 0 +was 0 +associated 0 +with 0 +METH 1 +- 0 +induced 0 +psychosis 3 +patients 0 +in 0 +the 0 +allele 0 +/ 0 +genotype 0 +- 0 +wise 0 +analysis 0 +. 0 + +Moreover 0 +, 0 +this 0 +association 0 +remained 0 +significant 0 +after 0 +Bonferroni 0 +correction 0 +. 0 + +In 0 +the 0 +haplotype 0 +- 0 +wise 0 +analysis 0 +, 0 +we 0 +detected 0 +an 0 +association 0 +between 0 +two 0 +markers 0 +( 0 +rs6693503 0 +and 0 +rs1805054 0 +) 0 +and 0 +three 0 +markers 0 +( 0 +rs6693503 0 +, 0 +rs1805054 0 +and 0 +rs4912138 0 +) 0 +in 0 +HTR6 0 +and 0 +METH 1 +- 0 +induced 0 +psychosis 3 +patients 0 +, 0 +respectively 0 +. 0 + +C0NCLUSI0N 0 +: 0 +HTR6 0 +may 0 +play 0 +an 0 +important 0 +role 0 +in 0 +the 0 +pathophysiology 0 +of 0 +METH 1 +- 0 +induced 0 +psychosis 3 +in 0 +the 0 +Japanese 0 +population 0 +. 0 + +Neural 0 +correlates 0 +of 0 +S 1 +- 2 +ketamine 2 +induced 0 +psychosis 3 +during 0 +overt 0 +continuous 0 +verbal 0 +fluency 0 +. 0 + +The 0 +glutamatergic 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +has 0 +been 0 +implicated 0 +in 0 +the 0 +pathophysiology 0 +of 0 +schizophrenia 3 +. 0 + +Administered 0 +to 0 +healthy 0 +volunteers 0 +, 0 +a 0 +subanesthetic 0 +dose 0 +of 0 +the 0 +non 0 +- 0 +competitive 0 +NMDA 1 +receptor 0 +antagonist 0 +ketamine 1 +leads 0 +to 0 +psychopathological 0 +symptoms 0 +similar 0 +to 0 +those 0 +observed 0 +in 0 +schizophrenia 3 +. 0 + +In 0 +patients 0 +with 0 +schizophrenia 3 +, 0 +ketamine 1 +exacerbates 0 +the 0 +core 0 +symptoms 0 +of 0 +illness 0 +, 0 +supporting 0 +the 0 +hypothesis 0 +of 0 +a 0 +glutamatergic 3 +dysfunction 4 +. 0 + +In 0 +a 0 +counterbalanced 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +double 0 +- 0 +blind 0 +study 0 +design 0 +, 0 +healthy 0 +subjects 0 +were 0 +administered 0 +a 0 +continuous 0 +subanesthetic 0 +S 1 +- 2 +ketamine 2 +infusion 0 +while 0 +differences 0 +in 0 +B0LD 0 +responses 0 +measured 0 +with 0 +fMRI 0 +were 0 +detected 0 +. 0 + +During 0 +the 0 +scanning 0 +period 0 +, 0 +subjects 0 +performed 0 +continuous 0 +overt 0 +verbal 0 +fluency 0 +tasks 0 +( 0 +phonological 0 +, 0 +lexical 0 +and 0 +semantic 0 +) 0 +. 0 + +Ketamine 1 +- 0 +induced 0 +psychopathological 0 +symptoms 0 +were 0 +assessed 0 +with 0 +the 0 +Positive 0 +and 0 +Negative 0 +Syndrome 0 +Scale 0 +( 0 +PANSS 0 +) 0 +. 0 + +Ketamine 1 +elicited 0 +psychosis 3 +like 0 +psychopathology 0 +. 0 + +Post 0 +- 0 +hoc 0 +t 0 +- 0 +tests 0 +revealed 0 +significant 0 +differences 0 +between 0 +placebo 0 +and 0 +ketamine 1 +for 0 +the 0 +amounts 0 +of 0 +words 0 +generated 0 +during 0 +lexical 0 +and 0 +semantic 0 +verbal 0 +fluency 0 +, 0 +while 0 +the 0 +phonological 0 +domain 0 +remained 0 +unaffected 0 +. 0 + +Ketamine 1 +led 0 +to 0 +enhanced 0 +cortical 0 +activations 0 +in 0 +supramarginal 0 +and 0 +frontal 0 +brain 0 +regions 0 +for 0 +phonological 0 +and 0 +lexical 0 +verbal 0 +fluency 0 +, 0 +but 0 +not 0 +for 0 +semantic 0 +verbal 0 +fluency 0 +. 0 + +Ketamine 1 +induces 0 +activation 0 +changes 0 +in 0 +healthy 0 +subjects 0 +similar 0 +to 0 +those 0 +observed 0 +in 0 +patients 0 +with 0 +schizophrenia 3 +, 0 +particularly 0 +in 0 +frontal 0 +and 0 +temporal 0 +brain 0 +regions 0 +. 0 + +0ur 0 +results 0 +provide 0 +further 0 +support 0 +for 0 +the 0 +hypothesis 0 +of 0 +an 0 +NMDA 1 +receptor 0 +dysfunction 0 +in 0 +the 0 +pathophysiology 0 +of 0 +schizophrenia 3 +. 0 + +Long 0 +- 0 +term 0 +prognosis 0 +for 0 +transplant 0 +- 0 +free 0 +survivors 0 +of 0 +paracetamol 1 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +prognosis 0 +for 0 +transplant 0 +- 0 +free 0 +survivors 0 +of 0 +paracetamol 1 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +remains 0 +unknown 0 +. 0 + +AIM 0 +: 0 +To 0 +examine 0 +whether 0 +paracetamol 1 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +increases 0 +long 0 +- 0 +term 0 +mortality 0 +. 0 + +METH0DS 0 +: 0 +We 0 +followed 0 +up 0 +all 0 +transplant 0 +- 0 +free 0 +survivors 0 +of 0 +paracetamol 1 +- 0 +induced 0 +acute 3 +liver 4 +injury 4 +, 0 +hospitalized 0 +in 0 +a 0 +Danish 0 +national 0 +referral 0 +centre 0 +during 0 +1984 0 +- 0 +2004 0 +. 0 + +We 0 +compared 0 +age 0 +- 0 +specific 0 +mortality 0 +rates 0 +from 0 +1 0 +year 0 +post 0 +- 0 +discharge 0 +through 0 +2008 0 +between 0 +those 0 +in 0 +whom 0 +the 0 +liver 3 +injury 4 +led 0 +to 0 +an 0 +acute 3 +liver 4 +failure 4 +and 0 +those 0 +in 0 +whom 0 +it 0 +did 0 +not 0 +. 0 + +RESULTS 0 +: 0 +We 0 +included 0 +641 0 +patients 0 +. 0 + +0n 0 +average 0 +, 0 +age 0 +- 0 +specific 0 +mortality 0 +rates 0 +were 0 +slightly 0 +higher 0 +for 0 +the 0 +101 0 +patients 0 +whose 0 +paracetamol 1 +- 0 +induced 0 +liver 3 +injury 4 +had 0 +caused 0 +an 0 +acute 3 +liver 4 +failure 4 +( 0 +adjusted 0 +mortality 0 +rate 0 +ratio 0 += 0 +1 0 +. 0 +70 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +02 0 +- 0 +2 0 +. 0 +85 0 +) 0 +, 0 +but 0 +the 0 +association 0 +was 0 +age 0 +- 0 +dependent 0 +, 0 +and 0 +no 0 +survivors 0 +of 0 +acute 3 +liver 4 +failure 4 +died 0 +of 0 +liver 3 +disease 4 +, 0 +whereas 0 +suicides 0 +were 0 +frequent 0 +in 0 +both 0 +groups 0 +. 0 + +These 0 +observations 0 +speak 0 +against 0 +long 0 +- 0 +term 0 +effects 0 +of 0 +acute 3 +liver 4 +failure 4 +. 0 + +More 0 +likely 0 +, 0 +the 0 +elevated 0 +mortality 0 +rate 0 +ratio 0 +resulted 0 +from 0 +incomplete 0 +adjustment 0 +for 0 +the 0 +greater 0 +prevalence 0 +of 0 +substance 3 +abuse 4 +among 0 +survivors 0 +of 0 +acute 3 +liver 4 +failure 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Paracetamol 1 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +did 0 +not 0 +affect 0 +long 0 +- 0 +term 0 +mortality 0 +. 0 + +Clinical 0 +follow 0 +- 0 +up 0 +may 0 +be 0 +justified 0 +by 0 +the 0 +cause 0 +of 0 +the 0 +liver 3 +failure 4 +, 0 +but 0 +not 0 +by 0 +the 0 +liver 3 +failure 4 +itself 0 +. 0 + +In 0 +vivo 0 +characterization 0 +of 0 +a 0 +dual 0 +adenosine 1 +A2A 2 +/ 2 +A1 2 +receptor 2 +antagonist 2 +in 0 +animal 0 +models 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +The 0 +in 0 +vivo 0 +characterization 0 +of 0 +a 0 +dual 0 +adenosine 1 +A 2 +( 2 +2A 2 +) 2 +/ 2 +A 2 +( 2 +1 2 +) 2 +receptor 2 +antagonist 2 +in 0 +several 0 +animal 0 +models 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +is 0 +described 0 +. 0 + +Discovery 0 +and 0 +scale 0 +- 0 +up 0 +syntheses 0 +of 0 +compound 0 +1 0 +are 0 +described 0 +in 0 +detail 0 +, 0 +highlighting 0 +optimization 0 +steps 0 +that 0 +increased 0 +the 0 +overall 0 +yield 0 +of 0 +1 0 +from 0 +10 0 +. 0 +0 0 +% 0 +to 0 +30 0 +. 0 +5 0 +% 0 +. 0 + +Compound 0 +1 0 +is 0 +a 0 +potent 0 +A 0 +( 0 +2A 0 +) 0 +/ 0 +A 0 +( 0 +1 0 +) 0 +receptor 0 +antagonist 0 +in 0 +vitro 0 +( 0 +A 0 +( 0 +2A 0 +) 0 +K 0 +( 0 +i 0 +) 0 += 0 +4 0 +. 0 +1 0 +nM 0 +; 0 +A 0 +( 0 +1 0 +) 0 +K 0 +( 0 +i 0 +) 0 += 0 +17 0 +. 0 +0 0 +nM 0 +) 0 +that 0 +has 0 +excellent 0 +activity 0 +, 0 +after 0 +oral 0 +administration 0 +, 0 +across 0 +a 0 +number 0 +of 0 +animal 0 +models 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +including 0 +mouse 0 +and 0 +rat 0 +models 0 +of 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +, 0 +mouse 0 +model 0 +of 0 +reserpine 1 +- 0 +induced 0 +akinesia 3 +, 0 +rat 0 +6 1 +- 2 +hydroxydopamine 2 +( 0 +6 1 +- 2 +0HDA 2 +) 0 +lesion 0 +model 0 +of 0 +drug 0 +- 0 +induced 0 +rotation 0 +, 0 +and 0 +MPTP 1 +- 0 +treated 0 +non 0 +- 0 +human 0 +primate 0 +model 0 +. 0 + +Effects 0 +of 0 +the 0 +hippocampal 0 +deep 0 +brain 0 +stimulation 0 +on 0 +cortical 0 +epileptic 3 +discharges 0 +in 0 +penicillin 1 +- 0 +induced 0 +epilepsy 3 +model 0 +in 0 +rats 0 +. 0 + +AIM 0 +: 0 +Experimental 0 +and 0 +clinical 0 +studies 0 +have 0 +revealed 0 +that 0 +hippocampal 0 +DBS 0 +can 0 +control 0 +epileptic 3 +activity 0 +, 0 +but 0 +the 0 +mechanism 0 +of 0 +action 0 +is 0 +obscure 0 +and 0 +optimal 0 +stimulation 0 +parameters 0 +are 0 +not 0 +clearly 0 +defined 0 +. 0 + +The 0 +aim 0 +was 0 +to 0 +evaluate 0 +the 0 +effects 0 +of 0 +high 0 +frequency 0 +hippocampal 0 +stimulation 0 +on 0 +cortical 0 +epileptic 3 +activity 0 +in 0 +penicillin 1 +- 0 +induced 0 +epilepsy 3 +model 0 +. 0 + +MATERIAL 0 +AND 0 +METH0DS 0 +: 0 +Twenty 0 +- 0 +five 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +implanted 0 +DBS 0 +electrodes 0 +. 0 + +In 0 +group 0 +- 0 +1 0 +( 0 +n 0 += 0 +10 0 +) 0 +hippocampal 0 +DBS 0 +was 0 +off 0 +and 0 +in 0 +the 0 +group 0 +- 0 +2 0 +( 0 +n 0 += 0 +10 0 +) 0 +hippocampal 0 +DBS 0 +was 0 +on 0 +( 0 +185 0 +Hz 0 +, 0 +0 0 +. 0 +5V 0 +, 0 +1V 0 +, 0 +2V 0 +, 0 +and 0 +5V 0 +for 0 +60 0 +sec 0 +) 0 +following 0 +penicillin 1 +G 2 +injection 0 +intracortically 0 +. 0 + +In 0 +the 0 +control 0 +group 0 +hippocampal 0 +DBS 0 +was 0 +on 0 +following 0 +8 0 +l 0 +saline 0 +injection 0 +intracortically 0 +. 0 + +EEG 0 +recordings 0 +were 0 +obtained 0 +before 0 +and 0 +15 0 +minutes 0 +following 0 +penicillin 1 +- 2 +G 2 +injection 0 +, 0 +and 0 +at 0 +10th 0 +minutes 0 +following 0 +each 0 +stimulus 0 +for 0 +analysis 0 +in 0 +terms 0 +of 0 +frequency 0 +, 0 +amplitude 0 +, 0 +and 0 +power 0 +spectrum 0 +. 0 + +RESULTS 0 +: 0 +High 0 +frequency 0 +hippocampal 0 +DBS 0 +suppressed 0 +the 0 +acute 0 +penicillin 1 +- 0 +induced 0 +cortical 0 +epileptic 3 +activity 0 +independent 0 +from 0 +stimulus 0 +intensity 0 +. 0 + +In 0 +the 0 +control 0 +group 0 +, 0 +hippocampal 0 +stimulation 0 +alone 0 +lead 0 +only 0 +to 0 +diffuse 0 +slowing 0 +of 0 +cerebral 0 +bioelectrical 0 +activity 0 +at 0 +5V 0 +stimulation 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +results 0 +revealed 0 +that 0 +continuous 0 +high 0 +frequency 0 +stimulation 0 +of 0 +the 0 +hippocampus 0 +suppressed 0 +acute 0 +cortical 0 +epileptic 3 +activity 0 +effectively 0 +without 0 +causing 0 +secondary 0 +epileptic 3 +discharges 0 +. 0 + +These 0 +results 0 +are 0 +important 0 +in 0 +terms 0 +of 0 +defining 0 +the 0 +optimal 0 +parameters 0 +of 0 +hippocampal 0 +DBS 0 +in 0 +patients 0 +with 0 +epilepsy 3 +. 0 + +CCNU 1 +( 0 +lomustine 1 +) 0 +toxicity 3 +in 0 +dogs 0 +: 0 +a 0 +retrospective 0 +study 0 +( 0 +2002 0 +- 0 +07 0 +) 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +describe 0 +the 0 +incidence 0 +of 0 +haematological 3 +, 4 +renal 4 +, 4 +hepatic 4 +and 4 +gastrointestinal 4 +toxicities 4 +in 0 +tumour 0 +- 0 +bearing 0 +dogs 0 +receiving 0 +1 1 +- 2 +( 2 +2 2 +- 2 +chloroethyl 2 +) 2 +- 2 +3 2 +- 2 +cyclohexyl 2 +- 2 +1 2 +- 2 +nitrosourea 2 +( 0 +CCNU 1 +) 0 +. 0 + +DESIGN 0 +: 0 +The 0 +medical 0 +records 0 +of 0 +206 0 +dogs 0 +that 0 +were 0 +treated 0 +with 0 +CCNU 1 +at 0 +the 0 +Melbourne 0 +Veterinary 0 +Specialist 0 +Centre 0 +between 0 +February 0 +2002 0 +and 0 +December 0 +2007 0 +were 0 +retrospectively 0 +evaluated 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +the 0 +206 0 +dogs 0 +treated 0 +with 0 +CCNU 1 +, 0 +185 0 +met 0 +the 0 +inclusion 0 +criteria 0 +for 0 +at 0 +least 0 +one 0 +class 0 +of 0 +toxicity 3 +. 0 + +CCNU 1 +was 0 +used 0 +most 0 +commonly 0 +in 0 +the 0 +treatment 0 +of 0 +lymphoma 3 +, 0 +mast 3 +cell 4 +tumour 4 +, 0 +brain 3 +tumour 4 +, 0 +histiocytic 3 +tumours 4 +and 0 +epitheliotropic 3 +lymphoma 4 +. 0 + +Throughout 0 +treatment 0 +, 0 +56 0 +. 0 +9 0 +% 0 +of 0 +dogs 0 +experienced 0 +neutropenia 3 +, 0 +34 0 +. 0 +2 0 +% 0 +experienced 0 +anaemia 3 +and 0 +14 0 +. 0 +2 0 +% 0 +experienced 0 +thrombocytopenia 3 +. 0 + +Gastrointestinal 3 +toxicosis 4 +was 0 +detected 0 +in 0 +37 0 +. 0 +8 0 +% 0 +of 0 +dogs 0 +, 0 +the 0 +most 0 +common 0 +sign 0 +of 0 +which 0 +was 0 +vomiting 3 +( 0 +24 0 +. 0 +3 0 +% 0 +) 0 +. 0 + +Potential 0 +renal 0 +toxicity 3 +and 0 +elevated 0 +alanine 1 +transaminase 0 +( 0 +ALT 0 +) 0 +concentration 0 +were 0 +reported 0 +in 0 +12 0 +. 0 +2 0 +% 0 +and 0 +48 0 +. 0 +8 0 +% 0 +of 0 +dogs 0 +, 0 +respectively 0 +. 0 + +The 0 +incidence 0 +of 0 +hepatic 3 +failure 4 +was 0 +1 0 +. 0 +2 0 +% 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +CCNU 1 +- 0 +associated 0 +toxicity 3 +in 0 +dogs 0 +is 0 +common 0 +, 0 +but 0 +is 0 +usually 0 +not 0 +life 0 +threatening 0 +. 0 + +Central 0 +vein 3 +thrombosis 4 +and 0 +topical 0 +dipivalyl 1 +epinephrine 2 +. 0 + +A 0 +report 0 +is 0 +given 0 +on 0 +an 0 +83 0 +- 0 +year 0 +- 0 +old 0 +female 0 +who 0 +acquired 0 +central 0 +vein 3 +thrombosis 4 +in 0 +her 0 +seeing 0 +eye 0 +one 0 +day 0 +after 0 +having 0 +started 0 +topical 0 +medication 0 +with 0 +dipivalyl 1 +epinephrine 2 +for 0 +advanced 0 +glaucoma 3 +discovered 0 +in 0 +the 0 +other 0 +eye 0 +. 0 + +From 0 +present 0 +knowledge 0 +about 0 +the 0 +effects 0 +of 0 +adrenergic 0 +eye 0 +drops 0 +on 0 +ocular 0 +blood 0 +circulation 0 +, 0 +it 0 +is 0 +difficult 0 +to 0 +suggest 0 +an 0 +association 0 +between 0 +the 0 +two 0 +events 0 +, 0 +which 0 +may 0 +be 0 +coincidental 0 +only 0 +. 0 + +Benzylacyclouridine 1 +reverses 0 +azidothymidine 1 +- 0 +induced 0 +marrow 3 +suppression 4 +without 0 +impairment 0 +of 0 +anti 0 +- 0 +human 0 +immunodeficiency 3 +virus 0 +activity 0 +. 0 + +Increased 0 +extracellular 0 +concentrations 0 +of 0 +uridine 1 +( 0 +Urd 1 +) 0 +have 0 +been 0 +reported 0 +to 0 +reduce 0 +, 0 +in 0 +vitro 0 +, 0 +azidothymidine 1 +( 0 +AZT 1 +) 0 +- 0 +induced 0 +inhibition 0 +of 0 +human 0 +granulocyte 0 +- 0 +macrophage 0 +progenitor 0 +cells 0 +without 0 +impairment 0 +of 0 +its 0 +antihuman 0 +immunodeficiency 3 +virus 0 +( 0 +HIV 0 +) 0 +activity 0 +. 0 + +Because 0 +of 0 +the 0 +clinical 0 +toxicities 3 +associated 0 +with 0 +chronic 0 +Urd 1 +administration 0 +, 0 +the 0 +ability 0 +of 0 +benzylacyclouridine 1 +( 0 +BAU 1 +) 0 +to 0 +effect 0 +, 0 +in 0 +vivo 0 +, 0 +AZT 1 +- 0 +induced 0 +anemia 3 +and 0 +leukopenia 3 +was 0 +assessed 0 +. 0 + +This 0 +agent 0 +inhibits 0 +Urd 1 +catabolism 0 +and 0 +, 0 +in 0 +vivo 0 +, 0 +increases 0 +the 0 +plasma 0 +concentration 0 +of 0 +Urd 1 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +, 0 +without 0 +Urd 1 +- 0 +related 0 +toxicity 3 +. 0 + +In 0 +mice 0 +rendered 0 +anemic 3 +and 0 +leukopenic 3 +by 0 +the 0 +administration 0 +of 0 +AZT 1 +for 0 +28 0 +days 0 +in 0 +drinking 0 +water 0 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +mL 0 +) 0 +, 0 +the 0 +continued 0 +administration 0 +of 0 +AZT 1 +plus 0 +daily 0 +BAU 1 +( 0 +300 0 +mg 0 +/ 0 +kg 0 +, 0 +orally 0 +) 0 +partially 0 +reversed 0 +AZT 1 +- 0 +induced 0 +anemia 3 +and 0 +leukopenia 3 +( 0 +P 0 +less 0 +than 0 +. 0 +05 0 +) 0 +, 0 +increased 0 +peripheral 0 +reticulocytes 0 +( 0 +to 0 +4 0 +. 0 +9 0 +% 0 +, 0 +P 0 +less 0 +than 0 +. 0 +01 0 +) 0 +, 0 +increased 0 +cellularity 0 +in 0 +the 0 +marrow 0 +, 0 +and 0 +improved 0 +megaloblastosis 3 +. 0 + +When 0 +coadministered 0 +with 0 +AZT 1 +from 0 +the 0 +onset 0 +of 0 +drug 0 +administration 0 +, 0 +BAU 1 +reduced 0 +AZT 1 +- 0 +induced 0 +marrow 3 +toxicity 4 +. 0 + +In 0 +vitro 0 +, 0 +at 0 +a 0 +concentration 0 +of 0 +100 0 +mumol 0 +/ 0 +L 0 +, 0 +BAU 1 +possesses 0 +minimal 0 +anti 0 +- 0 +HIV 0 +activity 0 +and 0 +has 0 +no 0 +effect 0 +on 0 +the 0 +ability 0 +of 0 +AZT 1 +to 0 +reverse 0 +the 0 +HIV 0 +- 0 +induced 0 +cytopathic 0 +effect 0 +in 0 +MT4 0 +cells 0 +. 0 + +The 0 +clinical 0 +and 0 +biochemical 0 +implications 0 +of 0 +these 0 +findings 0 +are 0 +discussed 0 +. 0 + +Lethal 0 +anuria 3 +complicating 0 +high 0 +dose 0 +ifosfamide 1 +chemotherapy 0 +in 0 +a 0 +breast 3 +cancer 4 +patient 0 +with 0 +an 0 +impaired 3 +renal 4 +function 4 +. 0 + +A 0 +sixty 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +advanced 0 +breast 3 +cancer 4 +, 0 +previously 0 +treated 0 +with 0 +cisplatin 1 +, 0 +developed 0 +an 0 +irreversible 0 +lethal 0 +renal 3 +failure 4 +with 0 +anuria 3 +, 0 +the 0 +day 0 +after 0 +5 0 +g 0 +/ 0 +m2 0 +bolus 0 +ifosfamide 1 +. 0 + +Postrenal 3 +failure 4 +was 0 +excluded 0 +by 0 +echography 0 +. 0 + +A 0 +prerenal 0 +component 0 +could 0 +have 0 +contributed 0 +to 0 +renal 3 +failure 4 +because 0 +of 0 +a 0 +transient 0 +hypotension 3 +, 0 +due 0 +to 0 +an 0 +increasing 0 +ascitis 0 +, 0 +occurring 0 +just 0 +before 0 +anuria 3 +. 0 + +However 0 +, 0 +correction 0 +of 0 +the 0 +hemodynamic 0 +parameters 0 +did 0 +not 0 +improve 0 +renal 0 +function 0 +. 0 + +Ifosfamide 1 +is 0 +a 0 +known 0 +nephrotoxic 3 +drug 0 +with 0 +demonstrated 0 +tubulopathies 3 +. 0 + +We 0 +strongly 0 +suspect 0 +that 0 +this 0 +lethal 0 +anuria 3 +was 0 +mainly 0 +due 0 +to 0 +ifosfamide 1 +, 0 +occurring 0 +in 0 +a 0 +patient 0 +having 0 +received 0 +previous 0 +cisplatin 1 +chemotherapy 0 +and 0 +with 0 +poor 0 +kidney 0 +perfusion 0 +due 0 +to 0 +transient 0 +hypotension 3 +. 0 + +We 0 +recommend 0 +careful 0 +use 0 +of 0 +ifosfamide 1 +in 0 +patients 0 +pretreated 0 +with 0 +nephrotoxic 3 +chemotherapy 0 +and 0 +inadequate 0 +renal 0 +perfusion 0 +. 0 + +Nociceptive 0 +effects 0 +induced 0 +by 0 +intrathecal 0 +administration 0 +of 0 +prostaglandin 1 +D2 2 +, 2 +E2 2 +, 2 +or 2 +F2 2 +alpha 2 +to 0 +conscious 0 +mice 0 +. 0 + +The 0 +effects 0 +of 0 +intrathecal 0 +administration 0 +of 0 +prostaglandins 1 +on 0 +pain 3 +responses 0 +in 0 +conscious 0 +mice 0 +were 0 +evaluated 0 +by 0 +using 0 +hot 0 +plate 0 +and 0 +acetic 1 +acid 2 +writhing 0 +tests 0 +. 0 + +Prostaglandin 1 +D2 2 +( 0 +0 0 +. 0 +5 0 +- 0 +3 0 +ng 0 +/ 0 +mouse 0 +) 0 +had 0 +a 0 +hyperalgesic 3 +action 0 +on 0 +the 0 +response 0 +to 0 +a 0 +hot 0 +plate 0 +during 0 +a 0 +3 0 +- 0 +60 0 +min 0 +period 0 +after 0 +injection 0 +. 0 + +Prostaglandin 1 +E2 2 +showed 0 +a 0 +hyperalgesic 3 +effect 0 +at 0 +doses 0 +of 0 +1 0 +pg 1 +to 0 +10 0 +ng 0 +/ 0 +mouse 0 +, 0 +but 0 +the 0 +effect 0 +lasted 0 +shorter 0 +( 0 +3 0 +- 0 +30 0 +min 0 +) 0 +than 0 +that 0 +of 0 +prostaglandin 1 +D2 2 +. 0 + +Similar 0 +results 0 +were 0 +obtained 0 +by 0 +acetic 1 +acid 2 +writhing 0 +tests 0 +. 0 + +The 0 +hyperalgesic 3 +effect 0 +of 0 +prostaglandin 1 +D2 2 +was 0 +blocked 0 +by 0 +simultaneous 0 +injection 0 +of 0 +a 0 +substance 0 +P 0 +antagonist 0 +( 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +100 0 +ng 0 +) 0 +but 0 +not 0 +by 0 +AH6809 1 +, 0 +a 0 +prostanoid 0 +EP1 0 +- 0 +receptor 0 +antagonist 0 +. 0 + +Conversely 0 +, 0 +prostaglandin 1 +E2 2 +- 0 +induced 0 +hyperalgesia 3 +was 0 +blocked 0 +by 0 +AH6809 1 +( 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +500 0 +ng 0 +) 0 +but 0 +not 0 +by 0 +the 0 +substance 0 +P 0 +antagonist 0 +. 0 + +Prostaglandin 1 +F2 2 +alpha 2 +had 0 +little 0 +effect 0 +on 0 +pain 3 +responses 0 +. 0 + +These 0 +results 0 +demonstrate 0 +that 0 +both 0 +prostaglandin 1 +D2 2 +and 0 +prostaglandin 1 +E2 2 +exert 0 +hyperalgesia 3 +in 0 +the 0 +spinal 0 +cord 0 +, 0 +but 0 +in 0 +different 0 +ways 0 +. 0 + +D 1 +- 2 +penicillamine 2 +in 0 +the 0 +treatment 0 +of 0 +localized 3 +scleroderma 4 +. 0 + +Localized 3 +scleroderma 4 +has 0 +no 0 +recognized 0 +internal 0 +organ 0 +involvement 0 +but 0 +may 0 +be 0 +disfiguring 0 +and 0 +disabling 0 +when 0 +the 0 +cutaneous 0 +lesions 0 +are 0 +extensive 0 +or 0 +affect 0 +children 0 +. 0 + +There 0 +is 0 +no 0 +accepted 0 +or 0 +proven 0 +treatment 0 +for 0 +localized 3 +scleroderma 4 +. 0 + +Case 0 +reports 0 +of 0 +11 0 +patients 0 +with 0 +severe 0 +, 0 +extensive 0 +localized 3 +scleroderma 4 +who 0 +were 0 +treated 0 +with 0 +D 1 +- 2 +penicillamine 2 +are 0 +summarized 0 +in 0 +this 0 +article 0 +. 0 + +This 0 +drug 0 +was 0 +judged 0 +to 0 +have 0 +a 0 +favorable 0 +effect 0 +on 0 +the 0 +disease 0 +course 0 +in 0 +7 0 +( 0 +64 0 +% 0 +) 0 +of 0 +11 0 +patients 0 +. 0 + +Improvement 0 +began 0 +within 0 +3 0 +to 0 +6 0 +months 0 +and 0 +consisted 0 +of 0 +cessation 0 +of 0 +active 0 +cutaneous 0 +lesions 0 +in 0 +all 0 +7 0 +patients 0 +, 0 +skin 0 +softening 0 +in 0 +5 0 +, 0 +and 0 +more 0 +normal 0 +growth 0 +of 0 +the 0 +affected 0 +limb 0 +in 0 +2 0 +of 0 +3 0 +children 0 +. 0 + +Joint 0 +stiffness 0 +and 0 +contractures 3 +also 0 +improved 0 +. 0 + +The 0 +dose 0 +of 0 +D 1 +- 2 +penicillamine 2 +associated 0 +with 0 +a 0 +favorable 0 +response 0 +was 0 +as 0 +low 0 +as 0 +2 0 +to 0 +5 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +given 0 +over 0 +a 0 +period 0 +ranging 0 +from 0 +15 0 +to 0 +53 0 +months 0 +. 0 + +D 1 +- 2 +Penicillamine 2 +caused 0 +nephrotic 3 +syndrome 4 +in 0 +1 0 +patient 0 +and 0 +milder 0 +reversible 0 +proteinuria 3 +in 0 +3 0 +other 0 +patients 0 +; 0 +none 0 +developed 0 +renal 3 +insufficiency 4 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +D 1 +- 2 +penicillamine 2 +may 0 +be 0 +effective 0 +in 0 +severe 0 +cases 0 +of 0 +localized 3 +scleroderma 4 +. 0 + +Cerebral 3 +sinus 4 +thrombosis 4 +as 0 +a 0 +potential 0 +hazard 0 +of 0 +antifibrinolytic 0 +treatment 0 +in 0 +menorrhagia 3 +. 0 + +We 0 +describe 0 +a 0 +42 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +developed 0 +superior 0 +sagittal 3 +and 4 +left 4 +transverse 4 +sinus 4 +thrombosis 4 +associated 0 +with 0 +prolonged 0 +epsilon 1 +- 2 +aminocaproic 2 +acid 2 +therapy 0 +for 0 +menorrhagia 3 +. 0 + +This 0 +antifibrinolytic 0 +agent 0 +has 0 +been 0 +used 0 +in 0 +women 0 +with 0 +menorrhagia 3 +to 0 +promote 0 +clotting 0 +and 0 +reduce 0 +blood 3 +loss 4 +. 0 + +Although 0 +increased 0 +risk 0 +of 0 +thromboembolic 3 +disease 4 +has 0 +been 0 +reported 0 +during 0 +treatment 0 +with 0 +epsilon 1 +- 2 +aminocaproic 2 +acid 2 +, 0 +cerebral 3 +sinus 4 +thrombosis 4 +has 0 +not 0 +been 0 +previously 0 +described 0 +. 0 + +Careful 0 +use 0 +of 0 +epsilon 1 +- 2 +aminocaproic 2 +acid 2 +therapy 0 +is 0 +recommended 0 +. 0 + +Seizure 3 +activity 0 +with 0 +imipenem 1 +therapy 0 +: 0 +incidence 0 +and 0 +risk 0 +factors 0 +. 0 + +Two 0 +elderly 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +either 0 +cerebral 3 +vascular 4 +accident 4 +( 0 +CVA 3 +) 0 +or 0 +head 3 +trauma 4 +and 0 +no 0 +evidence 0 +of 0 +renal 3 +disease 4 +developed 0 +seizures 3 +while 0 +receiving 0 +maximum 0 +doses 0 +of 0 +imipenem 1 +/ 2 +cilastatin 2 +. 0 + +Neither 0 +patient 0 +had 0 +reported 0 +previous 0 +seizures 3 +or 0 +seizure 3 +- 0 +like 0 +activity 0 +nor 0 +was 0 +receiving 0 +anticonvulsant 0 +agents 0 +. 0 + +All 0 +seizures 3 +were 0 +controlled 0 +with 0 +therapeutic 0 +doses 0 +of 0 +phenytoin 1 +. 0 + +Both 0 +patients 0 +had 0 +received 0 +maximum 0 +doses 0 +of 0 +other 0 +beta 1 +- 2 +lactam 2 +antibiotics 0 +without 0 +evidence 0 +of 0 +seizure 3 +activity 0 +. 0 + +Midline 0 +B3 0 +serotonin 1 +nerves 0 +in 0 +rat 0 +medulla 0 +are 0 +involved 0 +in 0 +hypotensive 3 +effect 0 +of 0 +methyldopa 1 +. 0 + +Previous 0 +experiments 0 +in 0 +this 0 +laboratory 0 +have 0 +shown 0 +that 0 +microinjection 0 +of 0 +methyldopa 1 +onto 0 +the 0 +ventrolateral 0 +cells 0 +of 0 +the 0 +B3 0 +serotonin 1 +neurons 0 +in 0 +the 0 +medulla 0 +elicits 0 +a 0 +hypotensive 3 +response 0 +mediated 0 +by 0 +a 0 +projection 0 +descending 0 +into 0 +the 0 +spinal 0 +cord 0 +. 0 + +The 0 +present 0 +experiments 0 +were 0 +designed 0 +to 0 +investigate 0 +the 0 +role 0 +of 0 +the 0 +midline 0 +cells 0 +of 0 +the 0 +B3 0 +serotonin 1 +neurons 0 +in 0 +the 0 +medulla 0 +, 0 +coinciding 0 +with 0 +the 0 +raphe 0 +magnus 0 +. 0 + +In 0 +spontaneously 0 +hypertensive 3 +, 0 +stroke 3 +- 0 +prone 0 +rats 0 +, 0 +microinjection 0 +of 0 +methyldopa 1 +into 0 +the 0 +area 0 +of 0 +the 0 +midline 0 +B3 0 +serotonin 1 +cell 0 +group 0 +in 0 +the 0 +ventral 0 +medulla 0 +caused 0 +a 0 +potent 0 +hypotension 3 +of 0 +30 0 +- 0 +40 0 +mm 0 +Hg 0 +, 0 +which 0 +was 0 +maximal 0 +2 0 +- 0 +3 0 +h 0 +after 0 +administration 0 +and 0 +was 0 +abolished 0 +by 0 +the 0 +serotonin 1 +neurotoxin 0 +5 1 +, 2 +7 2 +- 2 +dihydroxytryptamine 2 +( 0 +5 1 +, 2 +7 2 +- 2 +DHT 2 +) 0 +injected 0 +intracerebroventricularly 0 +. 0 + +However 0 +, 0 +intraspinal 0 +injection 0 +of 0 +5 1 +, 2 +7 2 +- 2 +DHT 2 +to 0 +produce 0 +a 0 +more 0 +selective 0 +lesion 0 +of 0 +only 0 +descending 0 +serotonin 1 +projections 0 +in 0 +the 0 +spinal 0 +cord 0 +did 0 +not 0 +affect 0 +this 0 +hypotension 3 +. 0 + +Further 0 +, 0 +5 1 +, 2 +7 2 +- 2 +DHT 2 +lesion 0 +of 0 +serotonin 1 +nerves 0 +travelling 0 +in 0 +the 0 +median 0 +forebrain 0 +bundle 0 +, 0 +one 0 +of 0 +the 0 +main 0 +ascending 0 +pathways 0 +from 0 +the 0 +B3 0 +serotonin 1 +cells 0 +, 0 +did 0 +not 0 +affect 0 +the 0 +fall 0 +in 0 +blood 0 +pressure 0 +associated 0 +with 0 +a 0 +midline 0 +B3 0 +serotonin 1 +methyldopa 1 +injection 0 +. 0 + +It 0 +is 0 +concluded 0 +therefore 0 +that 0 +, 0 +unlike 0 +the 0 +ventrolateral 0 +B3 0 +cells 0 +which 0 +mediate 0 +a 0 +methyldopa 1 +- 0 +induced 0 +hypotension 3 +via 0 +descending 0 +projections 0 +, 0 +the 0 +midline 0 +serotonin 1 +B3 0 +cells 0 +in 0 +the 0 +medulla 0 +contribute 0 +to 0 +the 0 +hypotensive 3 +action 0 +of 0 +methyldopa 1 +, 0 +either 0 +by 0 +way 0 +of 0 +an 0 +ascending 0 +projection 0 +which 0 +does 0 +not 0 +pass 0 +through 0 +the 0 +median 0 +forebrain 0 +bundle 0 +, 0 +or 0 +through 0 +a 0 +projection 0 +restricted 0 +to 0 +the 0 +caudal 0 +brainstem 0 +. 0 + +Antiarrhythmic 0 +plasma 0 +concentrations 0 +of 0 +cibenzoline 1 +on 0 +canine 0 +ventricular 3 +arrhythmias 4 +. 0 + +Using 0 +two 0 +- 0 +stage 0 +coronary 0 +ligation 0 +- 0 +, 0 +digitalis 1 +- 0 +, 0 +and 0 +adrenaline 1 +- 0 +induced 0 +canine 0 +ventricular 3 +arrhythmias 4 +, 0 +antiarrhythmic 0 +effects 0 +of 0 +cibenzoline 1 +were 0 +examined 0 +and 0 +the 0 +minimum 0 +effective 0 +plasma 0 +concentration 0 +for 0 +each 0 +arrhythmia 3 +model 0 +was 0 +determined 0 +. 0 + +Cibenzoline 1 +suppressed 0 +all 0 +the 0 +arrhythmias 3 +, 0 +and 0 +the 0 +minimum 0 +effective 0 +plasma 0 +concentrations 0 +for 0 +arrhythmias 3 +induced 0 +by 0 +24 0 +- 0 +h 0 +coronary 0 +ligation 0 +, 0 +48 0 +- 0 +h 0 +coronary 0 +ligation 0 +, 0 +digitalis 1 +, 0 +and 0 +adrenaline 1 +were 0 +1 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +( 0 +by 0 +8 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +, 0 +1 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +( 0 +by 0 +8 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +, 0 +0 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +( 0 +by 0 +2 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +, 0 +and 0 +3 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +( 0 +by 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +micrograms 0 +/ 0 +ml 0 +, 0 +respectively 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SDM 0 +, 0 +n 0 += 0 +6 0 +- 0 +7 0 +) 0 +. 0 + +The 0 +concentration 0 +for 0 +adrenaline 1 +- 0 +induced 0 +arrhythmia 3 +was 0 +significantly 0 +higher 0 +than 0 +those 0 +for 0 +the 0 +other 0 +types 0 +of 0 +arrhythmias 3 +. 0 + +This 0 +pharmacological 0 +profile 0 +is 0 +similar 0 +to 0 +those 0 +of 0 +mexiletine 1 +and 0 +tocainide 1 +, 0 +and 0 +all 0 +three 0 +drugs 0 +have 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +stimulant 0 +action 0 +. 0 + +Because 0 +cibenzoline 1 +had 0 +only 0 +weak 0 +hypotensive 3 +and 0 +sinus 0 +node 0 +depressive 3 +effects 0 +and 0 +was 0 +found 0 +to 0 +be 0 +orally 0 +active 0 +when 0 +given 0 +to 0 +coronary 0 +ligation 0 +arrhythmia 3 +dogs 0 +, 0 +its 0 +clinical 0 +usefulness 0 +is 0 +expected 0 +. 0 + +Continuous 0 +ambulatory 0 +ECG 0 +monitoring 0 +during 0 +fluorouracil 1 +therapy 0 +: 0 +a 0 +prospective 0 +study 0 +. 0 + +Although 0 +there 0 +have 0 +been 0 +anecdotal 0 +reports 0 +of 0 +cardiac 3 +toxicity 4 +associated 0 +with 0 +fluorouracil 1 +( 0 +5 1 +- 2 +FU 2 +) 0 +therapy 0 +, 0 +this 0 +phenomenon 0 +has 0 +not 0 +been 0 +studied 0 +in 0 +a 0 +systematic 0 +fashion 0 +. 0 + +We 0 +prospectively 0 +performed 0 +continuous 0 +ambulatory 0 +ECG 0 +monitoring 0 +on 0 +25 0 +patients 0 +undergoing 0 +5 1 +- 2 +FU 2 +infusion 0 +for 0 +treatment 0 +of 0 +solid 0 +tumors 3 +in 0 +order 0 +to 0 +assess 0 +the 0 +incidence 0 +of 0 +ischemic 3 +ST 0 +changes 0 +. 0 + +Patients 0 +were 0 +monitored 0 +for 0 +23 0 ++ 0 +/ 0 +- 0 +4 0 +hours 0 +before 0 +5 1 +- 2 +FU 2 +infusion 0 +, 0 +and 0 +98 0 ++ 0 +/ 0 +- 0 +9 0 +hours 0 +during 0 +5 1 +- 2 +FU 2 +infusion 0 +. 0 + +Anginal 3 +episodes 0 +were 0 +rare 0 +: 0 +only 0 +one 0 +patient 0 +had 0 +angina 3 +( 0 +during 0 +5 1 +- 2 +FU 2 +infusion 0 +) 0 +. 0 + +However 0 +, 0 +asymptomatic 0 +ST 0 +changes 0 +( 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +1 0 +mm 0 +ST 0 +deviation 0 +) 0 +were 0 +common 0 +: 0 +six 0 +of 0 +25 0 +patients 0 +( 0 +24 0 +% 0 +) 0 +had 0 +ST 0 +changes 0 +before 0 +5 1 +- 2 +FU 2 +infusion 0 +v 0 +17 0 +( 0 +68 0 +% 0 +) 0 +during 0 +5 1 +- 2 +FU 2 +infusion 0 +( 0 +P 0 +less 0 +than 0 +. 0 +002 0 +) 0 +. 0 + +The 0 +incidence 0 +of 0 +ischemic 3 +episodes 0 +per 0 +patient 0 +per 0 +hour 0 +was 0 +0 0 +. 0 +05 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +02 0 +prior 0 +to 0 +5 1 +- 2 +FU 2 +infusion 0 +v 0 +0 0 +. 0 +13 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +03 0 +during 0 +5 1 +- 2 +FU 2 +infusion 0 +( 0 +P 0 +less 0 +than 0 +. 0 +001 0 +) 0 +; 0 +the 0 +duration 0 +of 0 +ECG 0 +changes 0 +was 0 +0 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +minutes 0 +per 0 +patient 0 +per 0 +hour 0 +before 0 +5 1 +- 2 +FU 2 +v 0 +1 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +minutes 0 +per 0 +patient 0 +per 0 +hour 0 +during 0 +5 1 +- 2 +FU 2 +( 0 +P 0 +less 0 +than 0 +. 0 +01 0 +) 0 +. 0 + +ECG 0 +changes 0 +were 0 +more 0 +common 0 +among 0 +patients 0 +with 0 +known 0 +coronary 3 +artery 4 +disease 4 +. 0 + +There 0 +were 0 +two 0 +cases 0 +of 0 +sudden 3 +death 4 +, 0 +both 0 +of 0 +which 0 +occurred 0 +at 0 +the 0 +end 0 +of 0 +the 0 +chemotherapy 0 +course 0 +. 0 + +We 0 +conclude 0 +that 0 +5 1 +- 2 +FU 2 +infusion 0 +is 0 +associated 0 +with 0 +a 0 +significant 0 +increase 0 +in 0 +silent 0 +ST 0 +segment 0 +deviation 0 +suggestive 0 +of 0 +ischemia 3 +, 0 +particularly 0 +among 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +. 0 + +The 0 +mechanism 0 +and 0 +clinical 0 +significance 0 +of 0 +these 0 +ECG 0 +changes 0 +remain 0 +to 0 +be 0 +determined 0 +. 0 + +Nature 0 +, 0 +time 0 +course 0 +and 0 +dose 0 +dependence 0 +of 0 +zidovudine 1 +- 0 +related 0 +side 0 +effects 0 +: 0 +results 0 +from 0 +the 0 +Multicenter 0 +Canadian 0 +Azidothymidine 1 +Trial 0 +. 0 + +To 0 +characterize 0 +the 0 +nature 0 +, 0 +time 0 +course 0 +and 0 +dose 0 +dependency 0 +of 0 +zidovudine 1 +- 0 +related 0 +side 0 +effects 0 +, 0 +we 0 +undertook 0 +a 0 +multicenter 0 +, 0 +prospective 0 +, 0 +dose 0 +- 0 +range 0 +finding 0 +study 0 +. 0 + +0ur 0 +study 0 +group 0 +consisted 0 +of 0 +74 0 +HIV 0 +- 0 +positive 0 +homosexual 0 +men 0 +belonging 0 +to 0 +groups 0 +II 0 +B 0 +, 0 +III 0 +and 0 +IV 0 +C2 0 +from 0 +the 0 +Centers 0 +for 0 +Disease 0 +Control 0 +( 0 +CDC 0 +) 0 +classification 0 +of 0 +HIV 3 +disease 4 +. 0 + +Following 0 +a 0 +3 0 +- 0 +week 0 +observation 0 +period 0 +, 0 +volunteers 0 +were 0 +treated 0 +with 0 +zidovudine 1 +600 0 +mg 0 +/ 0 +day 0 +for 0 +18 0 +weeks 0 +, 0 +900 0 +mg 0 +/ 0 +day 0 +for 0 +9 0 +weeks 0 +and 0 +1200 0 +mg 0 +/ 0 +day 0 +for 0 +9 0 +weeks 0 +, 0 +followed 0 +by 0 +a 0 +washout 0 +period 0 +of 0 +6 0 +weeks 0 +after 0 +which 0 +they 0 +were 0 +re 0 +- 0 +started 0 +on 0 +1200 0 +mg 0 +/ 0 +day 0 +or 0 +the 0 +highest 0 +tolerated 0 +dose 0 +at 0 +8 0 +- 0 +hourly 0 +intervals 0 +. 0 + +Subjects 0 +were 0 +randomly 0 +assigned 0 +to 0 +4 0 +- 0 +hourly 0 +or 0 +8 0 +- 0 +hourly 0 +regimens 0 +within 0 +CDC 0 +groups 0 +while 0 +taking 0 +600 0 +and 0 +1200 0 +mg 0 +/ 0 +day 0 +. 0 + +Clinical 0 +and 0 +laboratory 0 +evaluations 0 +were 0 +performed 0 +at 0 +3 0 +- 0 +week 0 +intervals 0 +. 0 + +Symptomatic 0 +adverse 0 +effects 0 +were 0 +present 0 +in 0 +96 0 +% 0 +of 0 +subjects 0 +, 0 +most 0 +commonly 0 +nausea 3 +( 0 +64 0 +% 0 +) 0 +, 0 +fatigue 3 +( 0 +55 0 +% 0 +) 0 +and 0 +headache 3 +( 0 +49 0 +% 0 +) 0 +. 0 + +These 0 +were 0 +generally 0 +self 0 +- 0 +limited 0 +, 0 +reappearing 0 +briefly 0 +at 0 +each 0 +dose 0 +increment 0 +. 0 + +A 0 +decrease 0 +in 0 +hemoglobin 0 +occurred 0 +shortly 0 +after 0 +initiation 0 +of 0 +therapy 0 +. 0 + +This 0 +was 0 +not 0 +dose 0 +dependent 0 +and 0 +reversed 0 +rapidly 0 +upon 0 +discontinuation 0 +of 0 +treatment 0 +. 0 + +A 0 +red 0 +blood 0 +cell 0 +count 0 +decrease 0 +, 0 +a 0 +mean 0 +cell 0 +volume 0 +increase 0 +and 0 +a 0 +granulocyte 0 +count 0 +decrease 0 +developed 0 +early 0 +in 0 +a 0 +dose 0 +- 0 +independent 0 +fashion 0 +, 0 +reverting 0 +at 0 +least 0 +partially 0 +during 0 +the 0 +washout 0 +phase 0 +. 0 + +The 0 +decrease 0 +in 0 +reticulocyte 0 +count 0 +was 0 +dose 0 +related 0 +between 0 +600 0 +and 0 +900 0 +mg 0 +/ 0 +day 0 +with 0 +no 0 +further 0 +change 0 +when 0 +the 0 +dose 0 +was 0 +escalated 0 +to 0 +1200 0 +mg 0 +/ 0 +day 0 +. 0 + +Bone 0 +marrow 0 +changes 0 +occurred 0 +rapidly 0 +as 0 +demonstrated 0 +by 0 +megaloblastosis 3 +in 0 +95 0 +% 0 +of 0 +65 0 +specimens 0 +at 0 +week 0 +18 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +National 0 +project 0 +on 0 +the 0 +prevention 0 +of 0 +mother 0 +- 0 +to 0 +- 0 +infant 0 +infection 3 +by 4 +hepatitis 4 +B 4 +virus 4 +in 0 +Japan 0 +. 0 + +In 0 +Japan 0 +, 0 +a 0 +nationwide 0 +prevention 0 +program 0 +against 0 +mother 0 +- 0 +to 0 +- 0 +infant 0 +infection 3 +by 4 +hepatitis 4 +B 4 +virus 4 +( 0 +HBV 0 +) 0 +started 0 +in 0 +1985 0 +. 0 + +This 0 +program 0 +consists 0 +of 0 +double 0 +screenings 0 +of 0 +pregnant 0 +women 0 +and 0 +prophylactic 0 +treatment 0 +to 0 +the 0 +infants 0 +born 0 +to 0 +both 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +( 0 +HBsAg 1 +) 0 +and 0 +hepatitis 1 +B 2 +e 2 +antigen 2 +( 0 +HBeAg 1 +) 0 +positive 0 +mothers 0 +. 0 + +These 0 +infants 0 +are 0 +treated 0 +with 0 +two 0 +injections 0 +of 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +( 0 +HBIG 0 +) 0 +and 0 +at 0 +least 0 +three 0 +injections 0 +of 0 +plasma 0 +derived 0 +hepatitis 1 +B 2 +vaccine 2 +. 0 + +We 0 +sent 0 +questionnaires 0 +about 0 +the 0 +numbers 0 +of 0 +each 0 +procedure 0 +or 0 +examination 0 +during 0 +nine 0 +months 0 +of 0 +investigation 0 +period 0 +to 0 +each 0 +local 0 +government 0 +in 0 +1986 0 +and 0 +1987 0 +. 0 + +93 0 +. 0 +4 0 +% 0 +pregnant 0 +women 0 +had 0 +the 0 +chance 0 +to 0 +be 0 +examined 0 +for 0 +HBsAg 1 +, 0 +and 0 +the 0 +positive 0 +rate 0 +was 0 +1 0 +. 0 +4 0 +to 0 +1 0 +. 0 +5 0 +% 0 +. 0 + +The 0 +HBeAg 1 +positive 0 +rate 0 +in 0 +HBsAg 1 +positive 0 +was 0 +23 0 +to 0 +26 0 +% 0 +. 0 + +The 0 +HBsAg 1 +positive 0 +rate 0 +in 0 +neonates 0 +and 0 +in 0 +infants 0 +before 0 +two 0 +months 0 +were 0 +3 0 +% 0 +and 0 +2 0 +% 0 +respectively 0 +. 0 + +Some 0 +problems 0 +may 0 +arise 0 +, 0 +because 0 +27 0 +to 0 +30 0 +% 0 +of 0 +infants 0 +need 0 +the 0 +fourth 0 +vaccination 0 +in 0 +some 0 +restricted 0 +areas 0 +. 0 + +Involvement 0 +of 0 +the 0 +mu 0 +- 0 +opiate 0 +receptor 0 +in 0 +peripheral 0 +analgesia 3 +. 0 + +The 0 +intradermal 0 +injection 0 +of 0 +mu 0 +( 0 +morphine 1 +, 0 +Tyr 1 +- 2 +D 2 +- 2 +Ala 2 +- 2 +Gly 2 +- 2 +NMe 2 +- 2 +Phe 2 +- 2 +Gly 2 +- 2 +ol 2 +and 0 +morphiceptin 1 +) 0 +, 0 +kappa 0 +( 0 +trans 1 +- 2 +3 2 +, 2 +4 2 +- 2 +dichloro 2 +- 2 +N 2 +- 2 +methyl 2 +- 2 +N 2 +[ 2 +2 2 +- 2 +( 2 +1 2 +- 2 +pyrrolidinyl 2 +) 2 +cyclohexyl 2 +] 2 +benzeneactemide 2 +) 0 +and 0 +delta 0 +( 0 +[ 1 +D 2 +- 2 +Pen2 2 +. 2 +5 2 +] 2 +- 2 +enkephalin 2 +and 0 +[ 1 +D 2 +- 2 +Ser2 2 +] 2 +- 2 +[ 2 +Leu 2 +] 2 +enkephalin 2 +- 2 +Thr 2 +) 0 +selective 0 +opioid 0 +- 0 +agonists 0 +, 0 +by 0 +themselves 0 +, 0 +did 0 +not 0 +significantly 0 +affect 0 +the 0 +mechanical 0 +nociceptive 0 +threshold 0 +in 0 +the 0 +hindpaw 0 +of 0 +the 0 +rat 0 +. 0 + +Intradermal 0 +injection 0 +of 0 +mu 0 +, 0 +but 0 +not 0 +delta 0 +or 0 +kappa 0 +opioid 0 +- 0 +agonists 0 +, 0 +however 0 +, 0 +produced 0 +dose 0 +- 0 +dependent 0 +inhibition 0 +of 0 +prostaglandin 1 +E2 2 +- 0 +induced 0 +hyperalgesia 3 +. 0 + +The 0 +analgesic 0 +effect 0 +of 0 +the 0 +mu 0 +- 0 +agonist 0 +morphine 1 +was 0 +dose 0 +- 0 +dependently 0 +antagonized 0 +by 0 +naloxone 1 +and 0 +prevented 0 +by 0 +co 0 +- 0 +injection 0 +of 0 +pertussis 0 +toxin 0 +. 0 + +Morphine 1 +did 0 +not 0 +, 0 +however 0 +, 0 +alter 0 +the 0 +hyperalgesia 3 +induced 0 +by 0 +8 1 +- 2 +bromo 2 +cyclic 2 +adenosine 2 +monophosphate 2 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +analgesic 0 +action 0 +of 0 +opioids 0 +on 0 +the 0 +peripheral 0 +terminals 0 +of 0 +primary 0 +afferents 0 +is 0 +via 0 +a 0 +binding 0 +site 0 +with 0 +characteristics 0 +of 0 +the 0 +mu 0 +- 0 +opioid 0 +receptor 0 +and 0 +that 0 +this 0 +action 0 +is 0 +mediated 0 +by 0 +inhibition 0 +of 0 +the 0 +cyclic 1 +adenosine 2 +monophosphate 2 +second 0 +messenger 0 +system 0 +. 0 + +Involvement 0 +of 0 +locus 0 +coeruleus 0 +and 0 +noradrenergic 0 +neurotransmission 0 +in 0 +fentanyl 1 +- 0 +induced 0 +muscular 3 +rigidity 4 +in 0 +the 0 +rat 0 +. 0 + +Whereas 0 +muscular 3 +rigidity 4 +is 0 +a 0 +well 0 +- 0 +known 0 +side 0 +effect 0 +that 0 +is 0 +associated 0 +with 0 +high 0 +- 0 +dose 0 +fentanyl 1 +anesthesia 0 +, 0 +a 0 +paucity 0 +of 0 +information 0 +exists 0 +with 0 +regard 0 +to 0 +its 0 +underlying 0 +mechanism 0 +( 0 +s 0 +) 0 +. 0 + +We 0 +investigated 0 +in 0 +this 0 +study 0 +the 0 +possible 0 +engagement 0 +of 0 +locus 0 +coeruleus 0 +of 0 +the 0 +pons 0 +in 0 +this 0 +phenomenon 0 +, 0 +using 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +anesthetized 0 +with 0 +ketamine 1 +. 0 + +Under 0 +proper 0 +control 0 +of 0 +respiration 0 +, 0 +body 0 +temperature 0 +and 0 +end 0 +- 0 +tidal 0 +C02 1 +, 0 +intravenous 0 +administration 0 +of 0 +fentanyl 1 +( 0 +50 0 +or 0 +100 0 +micrograms 0 +/ 0 +kg 0 +) 0 +consistently 0 +promoted 0 +an 0 +increase 0 +in 0 +electromyographic 0 +activity 0 +recorded 0 +from 0 +the 0 +gastrocnemius 0 +and 0 +abdominal 0 +rectus 0 +muscles 0 +. 0 + +Such 0 +an 0 +induced 0 +muscular 3 +rigidity 4 +by 0 +the 0 +narcotic 0 +agent 0 +was 0 +significantly 0 +antagonized 0 +or 0 +even 0 +reduced 0 +by 0 +prior 0 +electrolytic 0 +lesions 0 +of 0 +the 0 +locus 0 +coeruleus 0 +or 0 +pretreatment 0 +with 0 +the 0 +alpha 0 +- 0 +adrenoceptor 0 +blocker 0 +, 0 +prazosin 1 +. 0 + +Microinjection 0 +of 0 +fentanyl 1 +( 0 +2 0 +. 0 +5 0 +micrograms 0 +/ 0 +50 0 +nl 0 +) 0 +directly 0 +into 0 +this 0 +pontine 0 +nucleus 0 +, 0 +on 0 +the 0 +other 0 +hand 0 +, 0 +elicited 0 +discernible 0 +electromyographic 0 +excitation 0 +. 0 + +It 0 +is 0 +speculated 0 +that 0 +the 0 +induction 0 +of 0 +muscular 3 +rigidity 4 +by 0 +fentanyl 1 +may 0 +involve 0 +the 0 +coerulospinal 0 +noradrenergic 0 +fibers 0 +to 0 +the 0 +spinal 0 +motoneurons 0 +. 0 + +Dexmedetomidine 1 +, 0 +acting 0 +through 0 +central 0 +alpha 0 +- 0 +2 0 +adrenoceptors 0 +, 0 +prevents 0 +opiate 0 +- 0 +induced 0 +muscle 3 +rigidity 4 +in 0 +the 0 +rat 0 +. 0 + +The 0 +highly 0 +- 0 +selective 0 +alpha 0 +- 0 +2 0 +adrenergic 0 +agonist 0 +dexmedetomidine 1 +( 0 +D 1 +- 2 +MED 2 +) 0 +is 0 +capable 0 +of 0 +inducing 0 +muscle 3 +flaccidity 4 +and 0 +anesthesia 0 +in 0 +rats 0 +and 0 +dogs 0 +. 0 + +Intense 0 +generalized 0 +muscle 3 +rigidity 4 +is 0 +an 0 +undesirable 0 +side 0 +effect 0 +of 0 +potent 0 +opiate 0 +agonists 0 +. 0 + +Although 0 +the 0 +neurochemistry 0 +of 0 +opiate 0 +- 0 +induced 0 +rigidity 3 +has 0 +yet 0 +to 0 +be 0 +fully 0 +elucidated 0 +, 0 +recent 0 +work 0 +suggests 0 +a 0 +role 0 +for 0 +a 0 +central 0 +adrenergic 0 +mechanism 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +authors 0 +determined 0 +if 0 +treatment 0 +with 0 +D 1 +- 2 +MED 2 +prevents 0 +the 0 +muscle 3 +rigidity 4 +caused 0 +by 0 +high 0 +- 0 +dose 0 +alfentanil 1 +anesthesia 0 +in 0 +the 0 +rat 0 +. 0 + +Animals 0 +( 0 +n 0 += 0 +42 0 +) 0 +were 0 +treated 0 +intraperitoneally 0 +with 0 +one 0 +of 0 +the 0 +following 0 +six 0 +regimens 0 +: 0 +1 0 +) 0 +L 0 +- 0 +MED 0 +( 0 +the 0 +inactive 0 +L 0 +- 0 +isomer 0 +of 0 +medetomidine 1 +) 0 +, 0 +30 0 +micrograms 0 +/ 0 +kg 0 +; 0 +2 0 +) 0 +D 1 +- 2 +MED 2 +, 0 +10 0 +micrograms 0 +/ 0 +kg 0 +; 0 +3 0 +) 0 +D 1 +- 2 +MED 2 +, 0 +30 0 +micrograms 0 +/ 0 +kg 0 +; 0 +4 0 +) 0 +D 1 +- 2 +MED 2 +[ 0 +30 0 +micrograms 0 +/ 0 +kg 0 +] 0 +and 0 +the 0 +central 0 +- 0 +acting 0 +alpha 0 +- 0 +2 0 +antagonist 0 +, 0 +idazoxan 1 +[ 0 +10 0 +mg 0 +/ 0 +kg 0 +] 0 +; 0 +5 0 +) 0 +D 1 +- 2 +MED 2 +[ 0 +30 0 +micrograms 0 +/ 0 +kg 0 +] 0 +and 0 +the 0 +peripheral 0 +- 0 +acting 0 +alpha 0 +- 0 +2 0 +antagonist 0 +DG 1 +- 2 +5128 2 +[ 0 +10 0 +mg 0 +/ 0 +kg 0 +] 0 +, 0 +or 0 +; 0 +6 0 +) 0 +saline 0 +. 0 + +Baseline 0 +electromyographic 0 +activity 0 +was 0 +recorded 0 +from 0 +the 0 +gastrocnemius 0 +muscle 0 +before 0 +and 0 +after 0 +drug 0 +treatment 0 +. 0 + +Each 0 +rat 0 +was 0 +then 0 +injected 0 +with 0 +alfentanil 1 +( 0 +ALF 1 +, 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +sc 0 +) 0 +. 0 + +ALF 1 +injection 0 +resulted 0 +in 0 +a 0 +marked 0 +increase 0 +in 0 +hindlimb 0 +EMG 0 +activity 0 +in 0 +the 0 +L 0 +- 0 +MED 0 +treatment 0 +group 0 +which 0 +was 0 +indistinguishable 0 +from 0 +that 0 +seen 0 +in 0 +animals 0 +treated 0 +with 0 +saline 0 +. 0 + +In 0 +contrast 0 +, 0 +D 1 +- 2 +MED 2 +prevented 0 +alfentanil 1 +- 0 +induced 0 +muscle 3 +rigidity 4 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +fashion 0 +. 0 + +The 0 +small 0 +EMG 0 +values 0 +obtained 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +D 1 +- 2 +MED 2 +group 0 +were 0 +comparable 0 +with 0 +those 0 +recorded 0 +in 0 +earlier 0 +studies 0 +from 0 +control 0 +animals 0 +not 0 +given 0 +any 0 +opiate 0 +. 0 + +The 0 +high 0 +- 0 +dose 0 +D 1 +- 2 +MED 2 +animals 0 +were 0 +flaccid 0 +, 0 +akinetic 3 +, 0 +and 0 +lacked 0 +a 0 +startle 3 +response 0 +during 0 +the 0 +entire 0 +experimental 0 +period 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Some 0 +central 0 +effects 0 +of 0 +repeated 0 +treatment 0 +with 0 +fluvoxamine 1 +. 0 + +We 0 +investigated 0 +the 0 +effect 0 +of 0 +repeated 0 +treatment 0 +with 0 +fluvoxamine 1 +, 0 +a 0 +selective 0 +serotonin 1 +uptake 0 +inhibitor 0 +, 0 +on 0 +behavioral 0 +effects 0 +of 0 +dopaminomimetics 0 +and 0 +methoxamine 1 +and 0 +on 0 +the 0 +animal 0 +behavior 0 +in 0 +the 0 +" 0 +behavioral 0 +despair 0 +" 0 +test 0 +. 0 + +A 0 +repeated 0 +treatment 0 +with 0 +fluvoxamine 1 +( 0 +twice 0 +daily 0 +for 0 +14 0 +days 0 +) 0 +potentiated 0 +in 0 +mice 0 +and 0 +in 0 +rats 0 +( 0 +weaker 0 +) 0 +the 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +The 0 +hyperactivity 3 +induced 0 +by 0 +nomifensine 1 +in 0 +mice 0 +remained 0 +unaffected 0 +by 0 +fluvoxamine 1 +. 0 + +The 0 +stimulation 0 +of 0 +locomotor 0 +activity 0 +by 0 +intracerebroventricularly 0 +administered 0 +methoxamine 1 +was 0 +not 0 +affected 0 +by 0 +repeated 0 +treatment 0 +with 0 +fluvoxamine 1 +. 0 + +Given 0 +three 0 +times 0 +fluvoxamine 1 +had 0 +no 0 +effect 0 +on 0 +the 0 +immobilization 0 +time 0 +in 0 +the 0 +" 0 +behavioral 0 +despair 0 +" 0 +test 0 +in 0 +rats 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +fluvoxamine 1 +given 0 +repeatedly 0 +acts 0 +differently 0 +than 0 +citalopram 1 +, 0 +another 0 +selective 0 +serotonin 1 +uptake 0 +inhibitor 0 +, 0 +and 0 +differs 0 +also 0 +from 0 +other 0 +antidepressant 0 +drugs 0 +. 0 + +Protective 0 +effect 0 +of 0 +a 0 +specific 0 +platelet 0 +- 0 +activating 0 +factor 0 +antagonist 0 +, 0 +BN 1 +52021 2 +, 0 +on 0 +bupivacaine 1 +- 0 +induced 0 +cardiovascular 3 +impairments 4 +in 0 +rats 0 +. 0 + +Administration 0 +of 0 +the 0 +local 0 +anaesthetic 0 +bupivacaine 1 +( 0 +1 0 +. 0 +5 0 +or 0 +2 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +. 0 +) 0 +to 0 +rats 0 +elicited 0 +a 0 +marked 0 +decrease 3 +of 4 +mean 4 +arterial 4 +blood 4 +pressure 4 +( 4 +MBP 4 +) 4 +and 4 +heart 4 +rate 4 +( 4 +HR 4 +) 4 +leading 0 +to 0 +death 0 +( 0 +in 0 +67 0 +% 0 +or 0 +90 0 +% 0 +of 0 +animals 0 +respectively 0 +) 0 +. 0 + +Intravenous 0 +injection 0 +of 0 +the 0 +specific 0 +platelet 0 +- 0 +activating 0 +factor 0 +( 0 +PAF 0 +) 0 +antagonist 0 +BN 1 +52021 2 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +30 0 +min 0 +before 0 +bupivacaine 1 +administration 0 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +suppressed 0 +both 0 +the 0 +decrease 3 +of 4 +MBP 4 +and 4 +HR 4 +. 0 + +In 0 +contrast 0 +, 0 +doses 0 +of 0 +1 0 +mg 0 +/ 0 +kg 0 +BN 1 +52021 2 +given 0 +30 0 +min 0 +before 0 +or 0 +10 0 +mg 0 +/ 0 +kg 0 +administered 0 +5 0 +min 0 +before 0 +i 0 +. 0 +v 0 +. 0 +injection 0 +of 0 +bupivacaine 1 +were 0 +ineffective 0 +. 0 + +When 0 +BN 1 +52021 2 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +was 0 +injected 0 +immediately 0 +after 0 +bupivacaine 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +a 0 +partial 0 +reversion 0 +of 0 +the 0 +decrease 3 +of 4 +MBP 4 +and 4 +HR 4 +was 0 +observed 0 +, 0 +whereas 0 +the 0 +dose 0 +of 0 +10 0 +mg 0 +/ 0 +kg 0 +was 0 +ineffective 0 +. 0 + +A 0 +partial 0 +recovery 0 +of 0 +bupivacaine 1 +- 0 +induced 0 +ECG 0 +alterations 0 +was 0 +observed 0 +after 0 +pretreatment 0 +of 0 +the 0 +rats 0 +with 0 +BN 1 +52021 2 +. 0 + +Since 0 +the 0 +administration 0 +of 0 +BN 1 +52021 2 +, 0 +at 0 +all 0 +doses 0 +studied 0 +, 0 +did 0 +not 0 +alter 0 +MBP 0 +and 0 +HR 0 +at 0 +the 0 +doses 0 +used 0 +, 0 +the 0 +bulk 0 +of 0 +these 0 +results 0 +clearly 0 +demonstrate 0 +a 0 +protective 0 +action 0 +of 0 +BN 1 +52021 2 +, 0 +a 0 +specific 0 +antagonist 0 +of 0 +PAF 0 +, 0 +against 0 +bupivacaine 1 +- 0 +induced 0 +cardiovascular 3 +toxicity 4 +. 0 + +Thus 0 +, 0 +consistent 0 +with 0 +its 0 +direct 0 +effect 0 +on 0 +heart 0 +, 0 +PAF 0 +appears 0 +to 0 +be 0 +implicated 0 +in 0 +bupivacaine 1 +- 0 +induced 0 +cardiovascular 3 +alterations 4 +. 0 + +The 0 +epidemiology 0 +of 0 +the 0 +acute 0 +flank 3 +pain 4 +syndrome 0 +from 0 +suprofen 1 +. 0 + +Suprofen 1 +, 0 +a 0 +new 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +, 0 +was 0 +marketed 0 +in 0 +early 0 +1986 0 +as 0 +an 0 +analgesic 0 +agent 0 +. 0 + +Until 0 +physicians 0 +began 0 +reporting 0 +an 0 +unusual 0 +acute 0 +flank 3 +pain 4 +syndrome 0 +to 0 +the 0 +spontaneous 0 +reporting 0 +system 0 +, 0 +700 0 +, 0 +000 0 +persons 0 +used 0 +the 0 +drug 0 +in 0 +the 0 +United 0 +States 0 +. 0 + +Through 0 +August 0 +1986 0 +, 0 +a 0 +total 0 +of 0 +163 0 +cases 0 +of 0 +this 0 +syndrome 0 +were 0 +reported 0 +. 0 + +To 0 +elucidate 0 +the 0 +epidemiology 0 +of 0 +the 0 +syndrome 0 +, 0 +a 0 +case 0 +- 0 +control 0 +study 0 +was 0 +performed 0 +, 0 +comparing 0 +62 0 +of 0 +the 0 +case 0 +patients 0 +who 0 +had 0 +been 0 +reported 0 +to 0 +the 0 +spontaneous 0 +reporting 0 +system 0 +to 0 +185 0 +suprofen 1 +- 0 +exposed 0 +control 0 +subjects 0 +who 0 +did 0 +not 0 +have 0 +the 0 +syndrome 0 +. 0 + +Case 0 +patients 0 +were 0 +more 0 +likely 0 +to 0 +be 0 +men 0 +( 0 +odds 0 +ratio 0 +, 0 +3 0 +. 0 +8 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +1 0 +. 0 +2 0 +- 0 +12 0 +. 0 +1 0 +) 0 +, 0 +suffer 0 +from 0 +hay 3 +fever 4 +and 0 +asthma 3 +( 0 +odds 0 +ratio 0 +, 0 +3 0 +. 0 +4 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +1 0 +. 0 +0 0 +- 0 +11 0 +. 0 +9 0 +) 0 +; 0 +to 0 +participate 0 +in 0 +regular 0 +exercise 0 +( 0 +odds 0 +ratio 0 +, 0 +5 0 +. 0 +9 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +1 0 +. 0 +1 0 +- 0 +30 0 +. 0 +7 0 +) 0 +, 0 +especially 0 +in 0 +the 0 +use 0 +of 0 +Nautilus 0 +equipment 0 +( 0 +p 0 += 0 +0 0 +. 0 +02 0 +) 0 +; 0 +and 0 +to 0 +use 0 +alcohol 1 +( 0 +odds 0 +ratio 0 +, 0 +4 0 +. 0 +4 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +1 0 +. 0 +1 0 +- 0 +17 0 +. 0 +5 0 +) 0 +. 0 + +Possible 0 +risk 0 +factors 0 +included 0 +young 0 +age 0 +, 0 +concurrent 0 +use 0 +of 0 +other 0 +analgesic 0 +agents 0 +( 0 +especially 0 +ibuprofen 1 +) 0 +, 0 +preexisting 0 +renal 3 +disease 4 +, 0 +a 0 +history 0 +of 0 +kidney 3 +stones 4 +, 0 +a 0 +history 0 +of 0 +gout 3 +, 0 +a 0 +recent 0 +increase 0 +in 0 +activity 0 +, 0 +a 0 +recent 0 +increase 0 +in 0 +sun 0 +exposure 0 +, 0 +and 0 +residence 0 +in 0 +the 0 +Sunbelt 0 +. 0 + +These 0 +were 0 +findings 0 +that 0 +were 0 +suggestive 0 +but 0 +did 0 +not 0 +reach 0 +conventional 0 +statistical 0 +significance 0 +. 0 + +These 0 +findings 0 +are 0 +consistent 0 +with 0 +the 0 +postulated 0 +mechanism 0 +for 0 +this 0 +unusual 0 +syndrome 0 +: 0 +acute 0 +diffuse 0 +crystallization 0 +of 0 +uric 1 +acid 2 +in 0 +renal 0 +tubules 0 +. 0 + +Phlorizin 1 +- 0 +induced 0 +glycosuria 3 +does 0 +not 0 +prevent 0 +gentamicin 1 +nephrotoxicity 3 +in 0 +rats 0 +. 0 + +Because 0 +rats 0 +with 0 +streptozotocin 1 +- 0 +induced 0 +diabetes 3 +mellitus 4 +( 0 +DM 3 +) 0 +have 0 +a 0 +high 0 +solute 0 +diuresis 0 +( 0 +glycosuria 3 +of 0 +10 0 +to 0 +12 0 +g 0 +/ 0 +day 0 +) 0 +, 0 +we 0 +have 0 +suggested 0 +that 0 +this 0 +may 0 +in 0 +part 0 +be 0 +responsible 0 +for 0 +their 0 +resistance 0 +to 0 +gentamicin 1 +- 0 +induced 0 +acute 3 +renal 4 +failure 4 +( 0 +ARF 3 +) 0 +. 0 + +The 0 +protection 0 +from 0 +gentamicin 1 +nephrotoxicity 3 +was 0 +studied 0 +in 0 +non 0 +- 0 +diabetic 3 +rats 0 +with 0 +chronic 0 +solute 0 +diuresis 0 +induced 0 +by 0 +blockage 0 +of 0 +tubular 0 +glucose 1 +reabsorption 0 +with 0 +phlorizin 1 +( 0 +P 1 +) 0 +. 0 + +DM 3 +rats 0 +with 0 +mild 0 +glycosuria 3 +( 0 +similar 0 +in 0 +degree 0 +to 0 +that 0 +of 0 +the 0 +P 1 +treated 0 +animals 0 +) 0 +were 0 +also 0 +studied 0 +. 0 + +Unanesthetized 0 +adult 0 +female 0 +, 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +divided 0 +in 0 +four 0 +groups 0 +and 0 +studied 0 +for 0 +15 0 +days 0 +. 0 + +Group 0 +1 0 +( 0 +P 1 +alone 0 +) 0 +received 0 +P 1 +, 0 +360 0 +mg 0 +/ 0 +day 0 +, 0 +for 0 +15 0 +days 0 +; 0 +Group 0 +II 0 +( 0 +P 1 ++ 0 +gentamicin 1 +) 0 +; 0 +Group 0 +III 0 +( 0 +gentamicin 1 +alone 0 +) 0 +and 0 +Group 0 +IV 0 +( 0 +mild 0 +DM 3 ++ 0 +gentamicin 1 +) 0 +. 0 + +Nephrotoxic 3 +doses 0 +( 0 +40 0 +mg 0 +/ 0 +kg 0 +body 0 +wt 0 +/ 0 +day 0 +) 0 +of 0 +gentamicin 1 +were 0 +injected 0 +during 0 +the 0 +last 0 +nine 0 +days 0 +of 0 +study 0 +to 0 +the 0 +animals 0 +of 0 +groups 0 +II 0 +to 0 +IV 0 +. 0 + +In 0 +Group 0 +I 0 +, 0 +P 1 +induced 0 +a 0 +moderate 0 +and 0 +stable 0 +glycosuria 3 +( 0 +3 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +g 0 +/ 0 +day 0 +, 0 +SE 0 +) 0 +, 0 +and 0 +no 0 +functional 0 +or 0 +morphologic 0 +evidence 0 +of 0 +renal 3 +dysfunction 4 +( 0 +baseline 0 +CCr 0 +2 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +ml 0 +/ 0 +min 0 +, 0 +undetectable 0 +lysozymuria 0 +) 0 +or 0 +damage 0 +( 0 +tubular 3 +necrosis 4 +score 0 +[ 0 +maximum 0 +4 0 +] 0 +, 0 +zero 0 +) 0 +. 0 + +In 0 +Group 0 +II 0 +, 0 +P 1 +did 0 +not 0 +prevent 0 +gentamicin 1 +- 0 +ARF 3 +( 0 +maximal 0 +decrease 0 +in 0 +CCr 0 +at 0 +day 0 +9 0 +. 0 +89 0 +% 0 +, 0 +P 1 +less 0 +than 0 +0 0 +. 0 +001 0 +; 0 +peak 0 +lysozymuria 0 +, 0 +1863 0 ++ 0 +/ 0 +- 0 +321 0 +micrograms 0 +/ 0 +day 0 +; 0 +and 0 +tubular 3 +necrosis 4 +score 0 +, 0 +3 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +) 0 +. 0 + +These 0 +values 0 +were 0 +not 0 +different 0 +from 0 +those 0 +of 0 +Group 0 +III 0 +: 0 +maximal 0 +decrease 0 +in 0 +CCr 0 +73 0 +% 0 +( 0 +P 1 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +; 0 +lysozymuria 0 +, 0 +2147 0 ++ 0 +/ 0 +- 0 +701 0 +micrograms 0 +/ 0 +day 0 +; 0 +tubular 3 +necrosis 4 +score 0 +, 0 +3 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Catalepsy 3 +induced 0 +by 0 +combinations 0 +of 0 +ketamine 1 +and 0 +morphine 1 +: 0 +potentiation 0 +, 0 +antagonism 0 +, 0 +tolerance 0 +and 0 +cross 0 +- 0 +tolerance 0 +in 0 +the 0 +rat 0 +. 0 + +Previous 0 +studies 0 +demonstrated 0 +that 0 +both 0 +ketamine 1 +and 0 +morphine 1 +induced 0 +analgesia 3 +and 0 +catalepsy 3 +in 0 +the 0 +rat 0 +. 0 + +Pre 0 +- 0 +treatment 0 +with 0 +ketamine 1 +produced 0 +cross 0 +- 0 +tolerance 0 +to 0 +morphine 1 +, 0 +whereas 0 +pretreatment 0 +with 0 +morphine 1 +did 0 +not 0 +induce 0 +cross 0 +- 0 +tolerance 0 +to 0 +ketamine 1 +but 0 +rather 0 +augmented 0 +the 0 +cataleptic 3 +response 0 +; 0 +this 0 +augmentation 0 +was 0 +attributed 0 +to 0 +residual 0 +morphine 1 +in 0 +the 0 +brain 0 +. 0 + +The 0 +present 0 +studies 0 +explored 0 +the 0 +duration 0 +of 0 +the 0 +loss 0 +of 0 +righting 0 +reflex 0 +induced 0 +by 0 +sub 0 +- 0 +effective 0 +doses 0 +of 0 +ketamine 1 +and 0 +morphine 1 +, 0 +administered 0 +simultaneously 0 +. 0 + +There 0 +was 0 +mutual 0 +potentiation 0 +between 0 +sub 0 +- 0 +effective 0 +doses 0 +of 0 +ketamine 1 +and 0 +morphine 1 +, 0 +but 0 +sub 0 +- 0 +effective 0 +doses 0 +of 0 +ketamine 1 +partly 0 +antagonized 0 +fully 0 +- 0 +effective 0 +doses 0 +of 0 +morphine 1 +. 0 + +Latency 0 +to 0 +the 0 +loss 0 +of 0 +righting 0 +reflex 0 +, 0 +rigidity 3 +and 0 +behavior 0 +on 0 +recovery 0 +, 0 +reflected 0 +the 0 +relative 0 +predominance 0 +of 0 +ketamine 1 +or 0 +morphine 1 +in 0 +each 0 +combination 0 +. 0 + +Naloxone 1 +inhibited 0 +the 0 +induced 0 +cataleptic 3 +effects 0 +. 0 + +The 0 +degree 0 +and 0 +time 0 +course 0 +of 0 +development 0 +of 0 +tolerance 0 +to 0 +daily 0 +administration 0 +of 0 +sub 0 +- 0 +effective 0 +dose 0 +combinations 0 +of 0 +ketamine 1 +and 0 +morphine 1 +were 0 +similar 0 +. 0 + +Rats 0 +, 0 +tolerant 0 +to 0 +ketamine 1 +- 0 +dominant 0 +combinations 0 +, 0 +were 0 +cross 0 +- 0 +tolerant 0 +to 0 +both 0 +drugs 0 +, 0 +while 0 +those 0 +tolerant 0 +to 0 +morphine 1 +- 0 +dominant 0 +combinations 0 +were 0 +cross 0 +- 0 +tolerant 0 +to 0 +morphine 1 +but 0 +showed 0 +either 0 +no 0 +cross 0 +- 0 +tolerance 0 +or 0 +an 0 +augmented 0 +response 0 +to 0 +ketamine 1 +. 0 + +While 0 +the 0 +mutual 0 +potentiation 0 +, 0 +antagonism 0 +and 0 +tolerance 0 +suggest 0 +common 0 +mechanisms 0 +for 0 +the 0 +induced 0 +catalepsy 3 +, 0 +differences 0 +in 0 +latency 0 +, 0 +rigidity 3 +and 0 +behavior 0 +, 0 +asymmetry 0 +of 0 +cross 0 +- 0 +tolerance 0 +and 0 +a 0 +widely 0 +- 0 +different 0 +ID50 0 +for 0 +naloxone 1 +would 0 +argue 0 +against 0 +an 0 +action 0 +at 0 +a 0 +single 0 +opioid 0 +site 0 +. 0 + +Hydrocortisone 1 +- 0 +induced 0 +hypertension 3 +in 0 +humans 0 +: 0 +pressor 0 +responsiveness 0 +and 0 +sympathetic 0 +function 0 +. 0 + +0ral 0 +hydrocortisone 1 +increases 0 +blood 0 +pressure 0 +and 0 +enhances 0 +pressor 0 +responsiveness 0 +in 0 +normal 0 +human 0 +subjects 0 +. 0 + +We 0 +studied 0 +the 0 +effects 0 +of 0 +1 0 +week 0 +of 0 +oral 0 +hydrocortisone 1 +( 0 +200 0 +mg 0 +/ 0 +day 0 +) 0 +on 0 +blood 0 +pressure 0 +, 0 +cardiac 0 +output 0 +, 0 +total 0 +peripheral 0 +resistance 0 +, 0 +forearm 0 +vascular 0 +resistance 0 +, 0 +and 0 +norepinephrine 1 +spillover 0 +to 0 +plasma 0 +in 0 +eight 0 +healthy 0 +male 0 +volunteers 0 +. 0 + +Although 0 +diastolic 0 +blood 0 +pressure 0 +remained 0 +unchanged 0 +, 0 +systolic 0 +blood 0 +pressure 0 +increased 0 +from 0 +119 0 +to 0 +135 0 +mm 0 +Hg 0 +( 0 +SED 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +4 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +, 0 +associated 0 +with 0 +an 0 +increased 3 +cardiac 4 +output 4 +( 0 +5 0 +. 0 +85 0 +- 0 +7 0 +. 0 +73 0 +l 0 +/ 0 +min 0 +, 0 +SED 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +46 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Total 0 +peripheral 0 +vascular 0 +resistance 0 +fell 0 +from 0 +15 0 +. 0 +1 0 +to 0 +12 0 +. 0 +2 0 +mm 0 +Hg 0 +/ 0 +l 0 +/ 0 +min 0 +( 0 +SED 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +03 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Resting 0 +forearm 0 +vascular 0 +resistance 0 +remained 0 +unchanged 0 +, 0 +but 0 +the 0 +reflex 0 +response 0 +to 0 +the 0 +cold 0 +pressor 0 +test 0 +was 0 +accentuated 0 +, 0 +the 0 +rise 0 +in 0 +resistance 0 +increasing 0 +from 0 +10 0 +. 0 +5 0 +mm 0 +Hg 0 +/ 0 +ml 0 +/ 0 +100 0 +ml 0 +/ 0 +min 0 +( 0 +R 0 +units 0 +) 0 +before 0 +treatment 0 +to 0 +32 0 +. 0 +6 0 +R 0 +units 0 +after 0 +treatment 0 +( 0 +SED 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +4 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +025 0 +) 0 +. 0 + +The 0 +rise 0 +in 0 +forearm 0 +vascular 0 +resistance 0 +accompanying 0 +intra 0 +- 0 +arterial 0 +norepinephrine 1 +( 0 +25 0 +, 0 +50 0 +, 0 +and 0 +100 0 +ng 0 +/ 0 +min 0 +) 0 +was 0 +also 0 +significantly 0 +greater 0 +after 0 +hydrocortisone 1 +, 0 +increasing 0 +from 0 +an 0 +average 0 +of 0 +14 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +4 0 +R 0 +units 0 +before 0 +treatment 0 +to 0 +35 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +5 0 +R 0 +units 0 +after 0 +hydrocortisone 1 +( 0 +SED 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +0 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +A 0 +shift 0 +to 0 +the 0 +left 0 +in 0 +the 0 +dose 0 +- 0 +response 0 +relation 0 +and 0 +fall 0 +in 0 +threshold 0 +suggested 0 +increased 0 +sensitivity 0 +to 0 +norepinephrine 1 +after 0 +treatment 0 +. 0 + +Measurement 0 +of 0 +resting 0 +norepinephrine 1 +spillover 0 +rate 0 +to 0 +plasma 0 +and 0 +norepinephrine 1 +uptake 0 +indicated 0 +that 0 +overall 0 +resting 0 +sympathetic 0 +nervous 0 +system 0 +activity 0 +was 0 +not 0 +increased 0 +. 0 + +The 0 +rise 3 +in 4 +resting 4 +blood 4 +pressure 4 +with 0 +hydrocortisone 1 +is 0 +associated 0 +with 0 +an 0 +increased 3 +cardiac 4 +output 4 +( 0 +presumably 0 +due 0 +to 0 +increased 0 +blood 0 +volume 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Neuromuscular 3 +blockade 4 +with 0 +magnesium 1 +sulfate 2 +and 0 +nifedipine 1 +. 0 + +A 0 +patient 0 +who 0 +received 0 +tocolysis 0 +with 0 +nifedipine 1 +developed 0 +neuromuscular 3 +blockade 4 +after 0 +500 0 +mg 0 +of 0 +magnesium 1 +sulfate 2 +was 0 +administered 0 +. 0 + +This 0 +reaction 0 +demonstrates 0 +that 0 +nifedipine 1 +can 0 +seriously 0 +potentiate 0 +the 0 +toxicity 3 +of 0 +magnesium 1 +. 0 + +Caution 0 +should 0 +be 0 +exercised 0 +when 0 +these 0 +two 0 +tocolytics 0 +are 0 +combined 0 +. 0 + +Chronic 0 +carbamazepine 1 +inhibits 0 +the 0 +development 0 +of 0 +local 0 +anesthetic 0 +seizures 3 +kindled 0 +by 0 +cocaine 1 +and 0 +lidocaine 1 +. 0 + +The 0 +effects 0 +of 0 +carbamazepine 1 +( 0 +CBZ 1 +) 0 +treatment 0 +on 0 +local 0 +anesthetic 0 +- 0 +kindled 0 +seizures 3 +and 0 +lethality 0 +were 0 +evaluated 0 +in 0 +different 0 +stages 0 +of 0 +the 0 +kindling 0 +process 0 +and 0 +under 0 +different 0 +methods 0 +of 0 +CBZ 1 +administration 0 +. 0 + +Chronic 0 +oral 0 +CBZ 1 +inhibited 0 +the 0 +development 0 +of 0 +both 0 +lidocaine 1 +- 0 +and 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +, 0 +but 0 +had 0 +little 0 +effect 0 +on 0 +the 0 +fully 0 +developed 0 +local 0 +anesthetic 0 +seizures 3 +. 0 + +Chronic 0 +CBZ 1 +also 0 +decreased 0 +the 0 +incidence 0 +of 0 +seizure 3 +- 0 +related 0 +mortality 0 +in 0 +the 0 +cocaine 1 +- 0 +injected 0 +rats 0 +. 0 + +Acute 0 +CBZ 1 +over 0 +a 0 +range 0 +of 0 +doses 0 +( 0 +15 0 +- 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +had 0 +no 0 +effect 0 +on 0 +completed 0 +lidocaine 1 +- 0 +kindled 0 +or 0 +acute 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +. 0 + +Repeated 0 +i 0 +. 0 +p 0 +. 0 +injection 0 +of 0 +CBZ 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +) 0 +also 0 +was 0 +without 0 +effect 0 +on 0 +the 0 +development 0 +of 0 +lidocaine 1 +- 0 +or 0 +cocaine 1 +- 0 +kindled 0 +seizures 3 +. 0 + +The 0 +differential 0 +effects 0 +of 0 +CBZ 1 +depending 0 +upon 0 +stage 0 +of 0 +seizure 3 +development 0 +suggest 0 +that 0 +distinct 0 +mechanisms 0 +underlie 0 +the 0 +development 0 +versus 0 +maintenance 0 +of 0 +local 0 +anesthetic 0 +- 0 +kindled 0 +seizures 3 +. 0 + +The 0 +effectiveness 0 +of 0 +chronic 0 +but 0 +not 0 +repeated 0 +, 0 +intermittent 0 +injections 0 +of 0 +CBZ 1 +suggests 0 +that 0 +different 0 +biochemical 0 +consequences 0 +result 0 +from 0 +the 0 +different 0 +treatment 0 +regimens 0 +. 0 + +The 0 +possible 0 +utility 0 +of 0 +chronic 0 +CBZ 1 +in 0 +preventing 0 +the 0 +development 0 +of 0 +toxic 0 +side 0 +effects 0 +in 0 +human 0 +cocaine 1 +users 0 +is 0 +suggested 0 +by 0 +these 0 +data 0 +, 0 +but 0 +remains 0 +to 0 +be 0 +directly 0 +evaluated 0 +. 0 + +Magnetic 0 +resonance 0 +imaging 0 +of 0 +cerebral 0 +venous 3 +thrombosis 4 +secondary 0 +to 0 +" 0 +low 0 +- 0 +dose 0 +" 0 +birth 0 +control 0 +pills 0 +. 0 + +The 0 +clinical 0 +and 0 +radiographic 0 +features 0 +of 0 +cerebral 0 +deep 3 +venous 4 +thrombosis 4 +in 0 +a 0 +21 0 +- 0 +year 0 +- 0 +old 0 +white 0 +woman 0 +are 0 +presented 0 +. 0 + +This 0 +nulliparous 0 +patient 0 +presented 0 +with 0 +relatively 0 +mild 0 +clinical 0 +symptoms 0 +and 0 +progressing 0 +mental 0 +status 0 +changes 0 +. 0 + +The 0 +only 0 +known 0 +risk 0 +factor 0 +was 0 +" 0 +low 0 +- 0 +dose 0 +" 0 +oral 1 +contraceptive 2 +pills 0 +. 0 + +The 0 +magnetic 0 +resonance 0 +image 0 +( 0 +MRI 0 +) 0 +showed 0 +increased 0 +signal 0 +intensity 0 +from 0 +the 0 +internal 0 +cerebral 0 +veins 0 +, 0 +vein 0 +of 0 +Galen 0 +, 0 +and 0 +straight 0 +sinus 0 +. 0 + +The 0 +diagnosis 0 +was 0 +confirmed 0 +by 0 +arterial 0 +angiography 0 +. 0 + +Beta 0 +- 0 +2 0 +- 0 +adrenoceptor 0 +- 0 +mediated 0 +hypokalemia 3 +and 0 +its 0 +abolishment 0 +by 0 +oxprenolol 1 +. 0 + +The 0 +time 0 +course 0 +and 0 +concentration 0 +- 0 +effect 0 +relationship 0 +of 0 +terbutaline 1 +- 0 +induced 0 +hypokalemia 3 +was 0 +studied 0 +, 0 +using 0 +computer 0 +- 0 +aided 0 +pharmacokinetic 0 +- 0 +dynamic 0 +modeling 0 +. 0 + +Subsequently 0 +we 0 +investigated 0 +the 0 +efficacy 0 +of 0 +oxprenolol 1 +in 0 +antagonizing 0 +such 0 +hypokalemia 3 +, 0 +together 0 +with 0 +the 0 +pharmacokinetic 0 +interaction 0 +between 0 +both 0 +drugs 0 +. 0 + +Six 0 +healthy 0 +subjects 0 +were 0 +given 0 +a 0 +0 0 +. 0 +5 0 +mg 0 +subcutaneous 0 +dose 0 +of 0 +terbutaline 1 +on 0 +two 0 +occasions 0 +: 0 +1 0 +hour 0 +after 0 +oral 0 +administration 0 +of 0 +a 0 +placebo 0 +and 0 +1 0 +hour 0 +after 0 +80 0 +mg 0 +oxprenolol 1 +orally 0 +. 0 + +In 0 +the 0 +7 0 +- 0 +hour 0 +period 0 +after 0 +terbutaline 1 +administration 0 +, 0 +plasma 0 +samples 0 +were 0 +taken 0 +for 0 +determination 0 +of 0 +plasma 0 +potassium 1 +levels 0 +and 0 +drug 0 +concentrations 0 +. 0 + +The 0 +sigmoid 0 +Emax 0 +model 0 +offered 0 +a 0 +good 0 +description 0 +of 0 +the 0 +relation 0 +between 0 +terbutaline 1 +concentrations 0 +and 0 +potassium 1 +effects 0 +. 0 + +0xprenolol 1 +caused 0 +decreases 0 +of 0 +65 0 +% 0 +and 0 +56 0 +% 0 +of 0 +terbutaline 1 +volume 0 +of 0 +distribution 0 +and 0 +clearance 0 +, 0 +respectively 0 +, 0 +and 0 +an 0 +increase 0 +of 0 +130 0 +% 0 +of 0 +its 0 +AUC 0 +. 0 + +In 0 +spite 0 +of 0 +higher 0 +terbutaline 1 +concentrations 0 +after 0 +oxprenolol 1 +pretreatment 0 +, 0 +the 0 +hypokalemia 3 +was 0 +almost 0 +completely 0 +antagonized 0 +by 0 +the 0 +beta 0 +2 0 +- 0 +blocking 0 +action 0 +. 0 + +A 0 +dystonia 3 +- 0 +like 0 +syndrome 0 +after 0 +neuropeptide 0 +( 0 +MSH 1 +/ 0 +ACTH 1 +) 0 +stimulation 0 +of 0 +the 0 +rat 0 +locus 0 +ceruleus 0 +. 0 + +The 0 +movement 3 +disorder 4 +investigated 0 +in 0 +these 0 +studies 0 +has 0 +some 0 +features 0 +in 0 +common 0 +with 0 +human 0 +idiopathic 0 +dystonia 3 +, 0 +and 0 +information 0 +obtained 0 +in 0 +these 0 +studies 0 +may 0 +be 0 +of 0 +potential 0 +clinical 0 +benefit 0 +. 0 + +The 0 +present 0 +experimental 0 +results 0 +indicated 0 +that 0 +peptidergic 0 +stimulation 0 +of 0 +the 0 +LC 0 +resulted 0 +in 0 +a 0 +NE 0 +- 0 +mediated 0 +inhibition 0 +of 0 +cerebellar 0 +Purkinje 0 +cells 0 +located 0 +at 0 +terminals 0 +of 0 +the 0 +ceruleo 0 +- 0 +cerebellar 0 +pathway 0 +. 0 + +However 0 +, 0 +it 0 +is 0 +not 0 +certain 0 +as 0 +to 0 +the 0 +following 0 +: 0 +( 0 +a 0 +) 0 +what 0 +receptors 0 +were 0 +stimulated 0 +by 0 +the 0 +ACTH 1 +N 0 +- 0 +terminal 0 +fragments 0 +at 0 +the 0 +LC 0 +that 0 +resulted 0 +in 0 +this 0 +disorder 0 +; 0 +( 0 +b 0 +) 0 +whether 0 +NE 0 +, 0 +released 0 +onto 0 +Purkinje 0 +cell 0 +synapses 0 +located 0 +at 0 +terminals 0 +of 0 +the 0 +ceruleo 0 +- 0 +cerebellar 0 +pathway 0 +, 0 +did 0 +indeed 0 +cause 0 +the 0 +long 0 +- 0 +term 0 +depression 3 +at 0 +Purkinje 0 +cell 0 +synapses 0 +( 0 +previously 0 +described 0 +by 0 +others 0 +) 0 +that 0 +resulted 0 +in 0 +the 0 +long 0 +duration 0 +of 0 +the 0 +movement 3 +disorder 4 +; 0 +( 0 +c 0 +) 0 +whether 0 +the 0 +inhibition 0 +of 0 +inhibitory 0 +Purkinje 0 +cells 0 +resulted 0 +in 0 +disinhibition 0 +or 0 +increased 0 +excitability 0 +of 0 +the 0 +unilateral 0 +cerebellar 0 +fastigial 0 +or 0 +interpositus 0 +nuclei 0 +, 0 +the 0 +output 0 +targets 0 +of 0 +the 0 +Purkinje 0 +cell 0 +axons 0 +, 0 +that 0 +may 0 +have 0 +been 0 +an 0 +important 0 +contributing 0 +factor 0 +to 0 +this 0 +disorder 0 +. 0 + +These 0 +questions 0 +are 0 +currently 0 +being 0 +investigated 0 +. 0 + +Enhanced 0 +stimulus 0 +- 0 +induced 0 +neurotransmitter 0 +overflow 0 +in 0 +epinephrine 1 +- 0 +induced 0 +hypertensive 3 +rats 0 +is 0 +not 0 +mediated 0 +by 0 +prejunctional 0 +beta 0 +- 0 +adrenoceptor 0 +activation 0 +. 0 + +The 0 +present 0 +study 0 +examines 0 +the 0 +effect 0 +of 0 +6 0 +- 0 +day 0 +epinephrine 1 +treatment 0 +( 0 +100 0 +micrograms 0 +/ 0 +kg 0 +per 0 +h 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +on 0 +stimulus 0 +- 0 +induced 0 +( 0 +1 0 +Hz 0 +) 0 +endogenous 0 +neurotransmitter 0 +overflow 0 +from 0 +the 0 +isolated 0 +perfused 0 +kidney 0 +of 0 +vehicle 0 +- 0 +and 0 +epinephrine 1 +- 0 +treated 0 +rats 0 +. 0 + +Renal 0 +catecholamine 1 +stores 0 +and 0 +stimulus 0 +- 0 +induced 0 +overflow 0 +in 0 +the 0 +vehicle 0 +- 0 +treated 0 +group 0 +consisted 0 +of 0 +norepinephrine 1 +only 0 +. 0 + +However 0 +, 0 +epinephrine 1 +treatment 0 +resulted 0 +in 0 +the 0 +incorporation 0 +of 0 +epinephrine 1 +into 0 +renal 0 +catecholamine 1 +stores 0 +such 0 +that 0 +approximately 0 +40 0 +% 0 +of 0 +the 0 +catecholamine 1 +present 0 +was 0 +epinephrine 1 +while 0 +the 0 +norepinephrine 1 +content 0 +was 0 +reduced 0 +by 0 +a 0 +similar 0 +degree 0 +. 0 + +Total 0 +tissue 0 +catecholamine 1 +content 0 +of 0 +the 0 +kidney 0 +on 0 +a 0 +molar 0 +basis 0 +was 0 +unchanged 0 +. 0 + +Stimulus 0 +- 0 +induced 0 +fractional 0 +overflow 0 +of 0 +neurotransmitter 0 +from 0 +the 0 +epinephrine 1 +- 0 +treated 0 +kidneys 0 +was 0 +approximately 0 +twice 0 +normal 0 +and 0 +consisted 0 +of 0 +both 0 +norepinephrine 1 +and 0 +epinephrine 1 +in 0 +proportions 0 +similar 0 +to 0 +those 0 +found 0 +in 0 +the 0 +kidney 0 +. 0 + +This 0 +difference 0 +in 0 +fractional 0 +overflow 0 +between 0 +groups 0 +was 0 +not 0 +affected 0 +by 0 +neuronal 0 +and 0 +extraneuronal 0 +uptake 0 +blockade 0 +. 0 + +Propranolol 1 +had 0 +no 0 +effect 0 +on 0 +stimulus 0 +- 0 +induced 0 +overflow 0 +in 0 +either 0 +group 0 +. 0 + +Phentolamine 1 +increased 0 +stimulus 0 +- 0 +induced 0 +overflow 0 +in 0 +both 0 +groups 0 +although 0 +the 0 +increment 0 +in 0 +overflow 0 +was 0 +greater 0 +in 0 +the 0 +epinephrine 1 +- 0 +treated 0 +group 0 +. 0 + +In 0 +conclusion 0 +, 0 +chronic 0 +epinephrine 1 +treatment 0 +results 0 +in 0 +enhanced 0 +fractional 0 +neurotransmitter 0 +overflow 0 +. 0 + +However 0 +, 0 +neither 0 +alterations 0 +in 0 +prejunctional 0 +beta 0 +- 0 +adrenoceptor 0 +influences 0 +nor 0 +alterations 0 +in 0 +neuronal 0 +and 0 +extraneuronal 0 +uptake 0 +mechanisms 0 +appear 0 +to 0 +be 0 +responsible 0 +for 0 +this 0 +alteration 0 +. 0 + +Furthermore 0 +, 0 +data 0 +obtained 0 +with 0 +phentolamine 1 +alone 0 +do 0 +not 0 +suggest 0 +alpha 0 +- 0 +adrenoceptor 0 +desensitization 0 +as 0 +the 0 +cause 0 +of 0 +the 0 +enhanced 0 +neurotransmitter 0 +overflow 0 +after 0 +epinephrine 1 +treatment 0 +. 0 + +GABA 1 +involvement 0 +in 0 +naloxone 1 +induced 0 +reversal 0 +of 0 +respiratory 3 +paralysis 4 +produced 0 +by 0 +thiopental 1 +. 0 + +No 0 +agent 0 +is 0 +yet 0 +available 0 +to 0 +reverse 0 +respiratory 3 +paralysis 4 +produced 0 +by 0 +CNS 0 +depressants 0 +, 0 +such 0 +as 0 +general 0 +anesthetics 0 +. 0 + +In 0 +this 0 +study 0 +naloxone 1 +reversed 0 +respiratory 3 +paralysis 4 +induced 0 +by 0 +thiopental 1 +in 0 +rats 0 +. 0 + +25 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +. 0 +thiopental 1 +produced 0 +anesthesia 0 +without 0 +altering 0 +respiratory 0 +rate 0 +, 0 +increased 0 +GABA 1 +, 0 +decreased 0 +glutamate 1 +, 0 +and 0 +had 0 +no 0 +effect 0 +on 0 +aspartate 1 +or 0 +glycine 1 +levels 0 +compared 0 +to 0 +controls 0 +in 0 +rat 0 +cortex 0 +and 0 +brain 0 +stem 0 +. 0 + +Pretreatment 0 +of 0 +rats 0 +with 0 +thiosemicarbazide 1 +for 0 +30 0 +minutes 0 +abolished 0 +the 0 +anesthetic 0 +action 0 +as 0 +well 0 +as 0 +the 0 +respiratory 0 +depressant 0 +action 0 +of 0 +thiopental 1 +. 0 + +50 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +. 0 +thiopental 1 +produced 0 +respiratory 3 +arrest 4 +with 0 +further 0 +increase 0 +in 0 +GABA 1 +and 0 +decrease 0 +in 0 +glutamate 1 +again 0 +in 0 +cortex 0 +and 0 +brain 0 +stem 0 +without 0 +affecting 0 +any 0 +of 0 +the 0 +amino 1 +acids 2 +studied 0 +in 0 +four 0 +regions 0 +of 0 +rat 0 +brain 0 +. 0 + +Naloxone 1 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +. 0 +) 0 +reversed 0 +respiratory 3 +paralysis 4 +, 0 +glutamate 1 +and 0 +GABA 1 +levels 0 +to 0 +control 0 +values 0 +in 0 +brain 0 +stem 0 +and 0 +cortex 0 +with 0 +no 0 +changes 0 +in 0 +caudate 0 +or 0 +cerebellum 0 +. 0 + +These 0 +data 0 +suggest 0 +naloxone 1 +reverses 0 +respiratory 3 +paralysis 4 +produced 0 +by 0 +thiopental 1 +and 0 +involves 0 +GABA 1 +in 0 +its 0 +action 0 +. 0 + +Diazepam 1 +facilitates 0 +reflex 0 +bradycardia 3 +in 0 +conscious 0 +rats 0 +. 0 + +The 0 +effects 0 +of 0 +diazepam 1 +on 0 +cardiovascular 0 +function 0 +were 0 +assessed 0 +in 0 +conscious 0 +rats 0 +. 0 + +Intravenous 0 +administration 0 +of 0 +diazepam 1 +( 0 +1 0 +- 0 +30 0 +mg 0 +kg 0 +- 0 +1 0 +) 0 +produced 0 +a 0 +dose 0 +- 0 +dependent 0 +decrease 0 +in 0 +both 0 +the 0 +mean 0 +arterial 0 +pressure 0 +and 0 +the 0 +heart 0 +rate 0 +. 0 + +Also 0 +, 0 +reflex 0 +bradycardia 3 +was 0 +produced 0 +in 0 +rats 0 +by 0 +intravenous 0 +infusion 0 +of 0 +adrenaline 1 +( 0 +1 0 +. 0 +25 0 +- 0 +2 0 +. 0 +5 0 +micrograms 0 +kg 0 +- 0 +1 0 +) 0 +. 0 + +Intravenous 0 +pretreatment 0 +of 0 +the 0 +rats 0 +with 0 +diazepam 1 +, 0 +although 0 +causing 0 +no 0 +change 0 +in 0 +the 0 +adrenaline 1 +- 0 +induced 0 +pressor 0 +effect 0 +, 0 +did 0 +enhance 0 +the 0 +adrenaline 1 +- 0 +induced 0 +reflex 0 +bradycardia 3 +. 0 + +However 0 +, 0 +the 0 +diazepam 1 +enhancement 0 +of 0 +adrenaline 1 +- 0 +induced 0 +reflex 0 +bradycardia 3 +was 0 +antagonized 0 +by 0 +pretreatment 0 +of 0 +rats 0 +with 0 +an 0 +intravenous 0 +dose 0 +of 0 +picrotoxin 1 +( 0 +an 0 +agent 0 +blocks 0 +chloride 1 +channels 0 +by 0 +binding 0 +to 0 +sites 0 +associated 0 +with 0 +the 0 +benzodiazepine 1 +- 0 +GABA 1 +- 0 +chloride 1 +channel 0 +macromolecular 0 +complex 0 +) 0 +. 0 + +The 0 +data 0 +indicate 0 +that 0 +diazepam 1 +acts 0 +through 0 +the 0 +benzodiazepine 1 +- 0 +GABA 1 +- 0 +chloride 1 +channel 0 +macromolecular 0 +complex 0 +within 0 +the 0 +central 0 +nervous 0 +system 0 +to 0 +facilitate 0 +reflex 0 +bradycardia 3 +mediated 0 +through 0 +baroreceptor 0 +reflexes 0 +in 0 +response 0 +to 0 +an 0 +acute 0 +increase 0 +in 0 +arterial 0 +pressure 0 +. 0 + +Initial 0 +potassium 1 +loss 0 +and 0 +hypokalaemia 3 +during 0 +chlorthalidone 1 +administration 0 +in 0 +patients 0 +with 0 +essential 0 +hypertension 3 +: 0 +the 0 +influence 0 +of 0 +dietary 0 +sodium 1 +restriction 0 +. 0 + +To 0 +investigate 0 +the 0 +initial 0 +potassium 1 +loss 0 +and 0 +development 0 +of 0 +hypokalaemia 3 +during 0 +the 0 +administration 0 +of 0 +an 0 +oral 0 +diuretic 0 +, 0 +metabolic 0 +balance 0 +studies 0 +were 0 +performed 0 +in 0 +ten 0 +patients 0 +with 0 +essential 0 +hypertension 3 +who 0 +had 0 +shown 0 +hypokalaemia 3 +under 0 +prior 0 +oral 0 +diuretic 0 +treatment 0 +. 0 + +Chlorthalidone 1 +( 0 +50 0 +mg 0 +daily 0 +) 0 +was 0 +given 0 +for 0 +14 0 +days 0 +. 0 + +Six 0 +patients 0 +received 0 +a 0 +normal 0 +- 0 +sodium 1 +diet 0 +and 0 +four 0 +a 0 +low 0 +- 0 +sodium 1 +( 0 +17 0 +mmol 0 +/ 0 +day 0 +) 0 +diet 0 +. 0 + +All 0 +patients 0 +had 0 +a 0 +normal 0 +initial 0 +total 0 +body 0 +potassium 1 +( 0 +40K 0 +) 0 +. 0 + +The 0 +electrolyte 0 +balances 0 +, 0 +weight 0 +, 0 +bromide 0 +space 0 +, 0 +plasma 0 +renin 0 +activity 0 +, 0 +and 0 +aldosterone 1 +secretion 0 +rate 0 +were 0 +measured 0 +. 0 + +In 0 +both 0 +groups 0 +a 0 +potassium 1 +deficit 0 +developed 0 +, 0 +with 0 +proportionally 0 +larger 0 +losses 0 +from 0 +the 0 +extracellular 0 +than 0 +from 0 +the 0 +intracellular 0 +compartment 0 +. 0 + +In 0 +the 0 +normal 0 +- 0 +sodium 1 +group 0 +the 0 +highest 0 +mean 0 +potassium 1 +deficit 0 +was 0 +176 0 +mmol 0 +on 0 +day 0 +9 0 +, 0 +after 0 +which 0 +some 0 +potassium 1 +was 0 +regained 0 +; 0 +in 0 +the 0 +low 0 +- 0 +sodium 1 +group 0 +the 0 +highest 0 +deficit 0 +was 0 +276 0 +mmol 0 +on 0 +day 0 +13 0 +. 0 + +The 0 +normal 0 +- 0 +sodium 1 +group 0 +showed 0 +an 0 +immediate 0 +but 0 +temporary 0 +rise 0 +of 0 +the 0 +renin 0 +and 0 +aldosterone 1 +levels 0 +; 0 +in 0 +the 0 +low 0 +- 0 +sodium 1 +group 0 +renin 0 +and 0 +aldosterone 1 +increased 0 +more 0 +slowly 0 +but 0 +remained 0 +elevated 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +dietary 0 +sodium 1 +restriction 0 +increases 0 +diuretic 0 +- 0 +induced 0 +potassium 1 +loss 0 +, 0 +presumably 0 +by 0 +an 0 +increased 0 +activity 0 +of 0 +the 0 +renin 0 +- 0 +angiotensin 1 +- 0 +aldosterone 1 +system 0 +, 0 +while 0 +sodium 1 +delivery 0 +to 0 +the 0 +distal 0 +renal 0 +tubules 0 +remains 0 +sufficiently 0 +high 0 +to 0 +allow 0 +increased 0 +potassium 1 +secretion 0 +. 0 + +Reversal 0 +of 0 +neuroleptic 0 +- 0 +induced 0 +catalepsy 3 +by 0 +novel 0 +aryl 1 +- 2 +piperazine 2 +anxiolytic 0 +drugs 0 +. 0 + +The 0 +novel 0 +anxiolytic 0 +drug 0 +, 0 +buspirone 1 +, 0 +reverses 0 +catalepsy 3 +induced 0 +by 0 +haloperidol 1 +. 0 + +A 0 +series 0 +of 0 +aryl 1 +- 2 +piperazine 2 +analogues 0 +of 0 +buspirone 1 +and 0 +other 0 +5 1 +- 2 +hydroxytryptaminergic 2 +agonists 2 +were 0 +tested 0 +for 0 +their 0 +ability 0 +to 0 +reverse 0 +haloperidol 1 +induced 0 +catalepsy 3 +. 0 + +Those 0 +drugs 0 +with 0 +strong 0 +affinity 0 +for 0 +5 1 +- 2 +hydroxytryptamine1a 2 +receptors 0 +were 0 +able 0 +to 0 +reverse 0 +catalepsy 3 +. 0 + +Drugs 0 +with 0 +affinity 0 +for 0 +other 0 +5 1 +- 2 +HT 2 +receptors 0 +or 0 +weak 0 +affinity 0 +were 0 +ineffective 0 +. 0 + +However 0 +, 0 +inhibition 0 +of 0 +postsynaptic 0 +5 1 +- 2 +HT 2 +receptors 0 +neither 0 +inhibited 0 +nor 0 +potentiated 0 +reversal 0 +of 0 +catalepsy 3 +and 0 +leaves 0 +open 0 +the 0 +question 0 +as 0 +to 0 +the 0 +site 0 +or 0 +mechanism 0 +for 0 +this 0 +effect 0 +. 0 + +Glycopyrronium 1 +requirements 0 +for 0 +antagonism 0 +of 0 +the 0 +muscarinic 0 +side 0 +effects 0 +of 0 +edrophonium 1 +. 0 + +We 0 +have 0 +compared 0 +, 0 +in 0 +60 0 +adult 0 +patients 0 +, 0 +the 0 +cardiovascular 0 +effects 0 +of 0 +glycopyrronium 1 +5 0 +micrograms 0 +kg 0 +- 0 +1 0 +and 0 +10 0 +micrograms 0 +kg 0 +- 0 +1 0 +given 0 +either 0 +simultaneously 0 +or 0 +1 0 +min 0 +before 0 +edrophonium 1 +1 0 +mg 0 +kg 0 +- 0 +1 0 +. 0 + +Significant 0 +differences 0 +between 0 +the 0 +four 0 +groups 0 +were 0 +detected 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Both 0 +groups 0 +receiving 0 +10 0 +micrograms 0 +kg 0 +- 0 +1 0 +showed 0 +increases 0 +in 0 +heart 0 +rate 0 +of 0 +up 0 +to 0 +30 0 +beat 0 +min 0 +- 0 +1 0 +( 0 +95 0 +% 0 +confidence 0 +limits 0 +28 0 +- 0 +32 0 +beat 0 +min 0 +- 0 +1 0 +) 0 +. 0 + +Use 0 +of 0 +glycopyrronium 1 +5 0 +micrograms 0 +kg 0 +- 0 +1 0 +provided 0 +greater 0 +cardiovascular 0 +stability 0 +and 0 +, 0 +given 0 +1 0 +min 0 +before 0 +the 0 +edrophonium 1 +, 0 +was 0 +sufficient 0 +to 0 +minimize 0 +early 0 +, 0 +edrophonium 1 +- 0 +induced 0 +bradycardias 3 +. 0 + +This 0 +low 0 +dose 0 +of 0 +glycopyrronium 1 +provided 0 +good 0 +control 0 +of 0 +oropharyngeal 0 +secretions 0 +. 0 + +Selective 0 +injection 0 +of 0 +iopentol 1 +, 0 +iohexol 1 +and 0 +metrizoate 1 +into 0 +the 0 +left 0 +coronary 0 +artery 0 +of 0 +the 0 +dog 0 +. 0 + +Induction 0 +of 0 +ventricular 3 +fibrillation 4 +and 0 +decrease 0 +of 0 +aortic 0 +pressure 0 +. 0 + +In 0 +twenty 0 +beagle 0 +dogs 0 +selective 0 +injections 0 +were 0 +made 0 +into 0 +the 0 +left 0 +coronary 0 +artery 0 +with 0 +iopentol 1 +, 0 +iohexol 1 +and 0 +metrizoate 1 +in 0 +doses 0 +of 0 +4 0 +ml 0 +, 0 +8 0 +ml 0 +and 0 +16 0 +ml 0 +. 0 + +Thirty 0 +- 0 +six 0 +iopentol 1 +injections 0 +, 0 +35 0 +iohexol 1 +injections 0 +and 0 +37 0 +metrizoate 1 +injections 0 +were 0 +made 0 +. 0 + +Frequencies 0 +of 0 +ventricular 3 +fibrillation 4 +were 0 +significantly 0 +lower 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +after 0 +iopentol 1 +( 0 +0 0 +% 0 +) 0 +and 0 +iohexol 1 +( 0 +3 0 +% 0 +) 0 +than 0 +after 0 +metrizoate 1 +( 0 +22 0 +% 0 +) 0 +. 0 + +Iopentol 1 +and 0 +iohexol 1 +also 0 +produced 0 +significantly 0 +less 0 +decrease 0 +in 0 +aortic 0 +blood 0 +pressure 0 +than 0 +metrizoate 1 +at 0 +the 0 +different 0 +doses 0 +. 0 + +Thyroid 0 +function 0 +and 0 +urine 0 +- 0 +concentrating 0 +ability 0 +during 0 +lithium 1 +treatment 0 +. 0 + +It 0 +has 0 +been 0 +suggested 0 +that 0 +adenylate 0 +cyclase 0 +inhibition 0 +may 0 +be 0 +important 0 +in 0 +the 0 +development 0 +of 0 +both 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +and 0 +hypothyroidism 3 +during 0 +lithium 1 +treatment 0 +. 0 + +We 0 +measured 0 +serum 0 +thyroxine 1 +and 0 +urine 0 +- 0 +concentrating 0 +ability 0 +( 0 +Umax 0 +) 0 +in 0 +response 0 +to 0 +desmopressin 0 +( 0 +DDAVP 0 +) 0 +in 0 +85 0 +patients 0 +receiving 0 +lithium 1 +. 0 + +Hypothyroidism 3 +developed 0 +in 0 +eight 0 +patients 0 +while 0 +they 0 +were 0 +taking 0 +lithium 1 +. 0 + +Impaired 0 +Umax 0 +was 0 +found 0 +in 0 +both 0 +euthyroid 0 +and 0 +hypothyroid 3 +patients 0 +while 0 +some 0 +hypothyroid 3 +patients 0 +concentrated 0 +their 0 +urine 0 +well 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +the 0 +dominant 0 +mechanisms 0 +by 0 +which 0 +lithium 1 +exerts 0 +these 0 +two 0 +effects 0 +are 0 +different 0 +. 0 + +Remodelling 0 +of 0 +nerve 0 +structure 0 +in 0 +experimental 0 +isoniazid 1 +neuropathy 3 +in 0 +the 0 +rat 0 +. 0 + +The 0 +neuropathy 3 +caused 0 +by 0 +a 0 +single 0 +dose 0 +of 0 +isoniazid 1 +in 0 +rats 0 +was 0 +studied 0 +with 0 +a 0 +computer 0 +- 0 +assisted 0 +morphometric 0 +method 0 +. 0 + +Scatter 0 +diagrams 0 +of 0 +the 0 +g 0 +ratio 0 +( 0 +quotient 0 +fibre 0 +diameter 0 +/ 0 +axon 0 +diameter 0 +) 0 +define 0 +regenerating 0 +fibres 0 +as 0 +a 0 +distinct 0 +population 0 +, 0 +distinguishable 0 +from 0 +the 0 +surviving 0 +fibres 0 +by 0 +reduced 0 +sheath 0 +thickness 0 +and 0 +reduced 0 +axon 0 +calibre 0 +. 0 + +There 0 +was 0 +also 0 +evidence 0 +of 0 +a 0 +subtle 0 +direct 0 +toxic 0 +effect 0 +on 0 +the 0 +entire 0 +fibre 0 +population 0 +, 0 +causing 0 +axon 0 +shrinkage 0 +masked 0 +by 0 +readjustment 0 +of 0 +the 0 +myelin 0 +sheath 0 +. 0 + +Multicenter 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +multiple 0 +- 0 +dose 0 +, 0 +parallel 0 +- 0 +groups 0 +efficacy 0 +and 0 +safety 0 +trial 0 +of 0 +azelastine 1 +, 0 +chlorpheniramine 1 +, 0 +and 0 +placebo 0 +in 0 +the 0 +treatment 0 +of 0 +spring 3 +allergic 4 +rhinitis 4 +. 0 + +Azelastine 1 +, 0 +a 0 +novel 0 +antiallergic 0 +medication 0 +, 0 +was 0 +compared 0 +with 0 +chlorpheniramine 1 +maleate 2 +and 0 +placebo 0 +for 0 +efficacy 0 +and 0 +safety 0 +in 0 +the 0 +treatment 0 +of 0 +spring 3 +allergic 4 +rhinitis 4 +in 0 +a 0 +multicenter 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +multiple 0 +- 0 +dose 0 +, 0 +parallel 0 +- 0 +groups 0 +study 0 +. 0 + +0ne 0 +hundred 0 +fifty 0 +- 0 +five 0 +subjects 0 +participated 0 +. 0 + +Subjects 0 +ranged 0 +in 0 +age 0 +from 0 +18 0 +to 0 +60 0 +years 0 +of 0 +age 0 +and 0 +had 0 +at 0 +least 0 +a 0 +2 0 +- 0 +year 0 +history 0 +of 0 +spring 3 +allergic 4 +rhinitis 4 +, 0 +confirmed 0 +by 0 +positive 0 +skin 0 +test 0 +to 0 +spring 0 +aeroallergens 0 +. 0 + +Medications 0 +were 0 +given 0 +four 0 +times 0 +daily 0 +; 0 +the 0 +azelastine 1 +groups 0 +received 0 +0 0 +. 0 +5 0 +, 0 +1 0 +. 0 +0 0 +, 0 +or 0 +2 0 +. 0 +0 0 +mg 0 +in 0 +the 0 +morning 0 +and 0 +evening 0 +with 0 +placebo 0 +in 0 +the 0 +early 0 +and 0 +late 0 +afternoon 0 +; 0 +the 0 +chlorpheniramine 1 +group 0 +received 0 +4 0 +. 0 +0 0 +mg 0 +four 0 +times 0 +daily 0 +. 0 + +Daily 0 +subject 0 +symptom 0 +cards 0 +were 0 +completed 0 +during 0 +a 0 +screening 0 +period 0 +to 0 +assess 0 +pretreatment 0 +symptoms 0 +and 0 +during 0 +a 0 +4 0 +- 0 +week 0 +treatment 0 +period 0 +while 0 +subjects 0 +received 0 +study 0 +medications 0 +. 0 + +Individual 0 +symptoms 0 +, 0 +total 0 +symptoms 0 +, 0 +and 0 +major 0 +symptoms 0 +were 0 +compared 0 +to 0 +determine 0 +efficacy 0 +of 0 +medication 0 +. 0 + +Elicited 0 +, 0 +volunteered 0 +, 0 +and 0 +observed 0 +adverse 0 +experiences 0 +were 0 +recorded 0 +for 0 +each 0 +subject 0 +and 0 +compared 0 +among 0 +groups 0 +. 0 + +Vital 0 +signs 0 +, 0 +body 0 +weights 0 +, 0 +serum 0 +chemistry 0 +values 0 +, 0 +complete 0 +blood 0 +cell 0 +counts 0 +, 0 +urine 0 +studies 0 +, 0 +and 0 +electrocardiograms 0 +were 0 +obtained 0 +for 0 +each 0 +subject 0 +and 0 +compared 0 +among 0 +groups 0 +. 0 + +Symptoms 0 +relief 0 +in 0 +the 0 +group 0 +receiving 0 +the 0 +highest 0 +concentration 0 +of 0 +azelastine 1 +( 0 +2 0 +. 0 +0 0 +mg 0 +twice 0 +daily 0 +) 0 +was 0 +statistically 0 +greater 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +during 0 +all 0 +weeks 0 +of 0 +the 0 +study 0 +. 0 + +Lower 0 +doses 0 +of 0 +azelastine 1 +were 0 +statistically 0 +more 0 +effective 0 +than 0 +placebo 0 +only 0 +during 0 +portions 0 +of 0 +the 0 +first 0 +3 0 +weeks 0 +of 0 +the 0 +study 0 +. 0 + +In 0 +contrast 0 +, 0 +although 0 +the 0 +chlorpheniramine 1 +group 0 +did 0 +have 0 +fewer 0 +symptoms 0 +than 0 +the 0 +placebo 0 +group 0 +during 0 +the 0 +study 0 +, 0 +the 0 +difference 0 +never 0 +reached 0 +statistical 0 +significance 0 +during 0 +any 0 +week 0 +of 0 +the 0 +study 0 +. 0 + +There 0 +were 0 +no 0 +serious 0 +side 0 +effects 0 +in 0 +any 0 +of 0 +the 0 +treatment 0 +groups 0 +. 0 + +Drowsiness 3 +and 0 +altered 3 +taste 4 +perception 4 +were 0 +increased 0 +significantly 0 +over 0 +placebo 0 +only 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +azelastine 1 +group 0 +. 0 + +Azelastine 1 +appears 0 +to 0 +be 0 +a 0 +safe 0 +, 0 +efficacious 0 +medication 0 +for 0 +seasonal 3 +allergic 4 +rhinitis 4 +. 0 + +Toxicity 3 +due 0 +to 0 +remission 0 +inducing 0 +drugs 0 +in 0 +rheumatoid 3 +arthritis 4 +. 0 + +Association 0 +with 0 +HLA 0 +- 0 +B35 0 +and 0 +Cw4 0 +antigens 0 +. 0 + +Twenty 0 +- 0 +five 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +( 0 +RA 3 +) 0 +who 0 +developed 0 +toxicity 3 +while 0 +taking 0 +remission 0 +inducing 0 +drugs 0 +and 0 +30 0 +without 0 +toxicity 3 +were 0 +studied 0 +for 0 +possible 0 +associations 0 +with 0 +class 0 +I 0 +and 0 +II 0 +HLA 0 +antigens 0 +. 0 + +A 0 +strong 0 +association 0 +has 0 +been 0 +found 0 +between 0 +nephritis 3 +and 0 +dermatitis 3 +due 0 +to 0 +Tiopronin 1 +( 0 +a 0 +D 1 +- 2 +Penicillamine 2 +like 0 +compound 0 +) 0 +and 0 +class 0 +I 0 +antigens 0 +B35 0 +- 0 +Cw4 0 +, 0 +and 0 +between 0 +dermatitis 3 +due 0 +to 0 +gold 1 +thiosulphate 1 +and 0 +B35 0 +. 0 + +Compared 0 +to 0 +healthy 0 +controls 0 +a 0 +lower 0 +DR5 0 +frequency 0 +was 0 +observed 0 +in 0 +patients 0 +with 0 +RA 3 +except 0 +for 0 +the 0 +Tiopronin 1 +related 0 +nephritis 3 +group 0 +. 0 + +Transient 0 +contralateral 3 +rotation 4 +following 0 +unilateral 0 +substantia 3 +nigra 4 +lesion 4 +reflects 0 +susceptibility 0 +of 0 +the 0 +nigrostriatal 0 +system 0 +to 0 +exhaustion 0 +by 0 +amphetamine 1 +. 0 + +Following 0 +unilateral 0 +6 1 +- 2 +0HDA 2 +induced 0 +SN 3 +lesion 4 +, 0 +a 0 +transient 0 +period 0 +of 0 +contralateral 3 +rotation 4 +has 0 +been 0 +reported 0 +to 0 +precede 0 +the 0 +predominant 0 +ipsilateral 3 +circling 4 +. 0 + +In 0 +order 0 +to 0 +clarify 0 +the 0 +nature 0 +of 0 +this 0 +initial 0 +contralateral 3 +rotation 4 +we 0 +examined 0 +the 0 +effect 0 +of 0 +the 0 +duration 0 +of 0 +recovery 0 +period 0 +after 0 +the 0 +lesion 0 +, 0 +on 0 +amphetamine 1 +- 0 +induced 0 +rotational 3 +behavior 4 +. 0 + +Three 0 +days 0 +post 0 +lesion 0 +, 0 +most 0 +rats 0 +circled 0 +predominantly 0 +contralaterally 0 +to 0 +the 0 +lesion 0 +. 0 + +Such 0 +contralateral 3 +rotation 4 +may 0 +result 0 +from 0 +either 0 +degeneration 0 +- 0 +induced 0 +breakdown 0 +of 0 +the 0 +DA 0 +pool 0 +, 0 +or 0 +lesion 0 +- 0 +induced 0 +increase 0 +of 0 +DA 0 +turnover 0 +in 0 +the 0 +spared 0 +neurons 0 +. 0 + +A 0 +substantial 0 +degree 0 +of 0 +contralateral 0 +preference 0 +was 0 +still 0 +evident 0 +when 0 +amphetamine 1 +was 0 +administered 0 +for 0 +the 0 +first 0 +time 0 +24 0 +days 0 +after 0 +lesioning 0 +, 0 +indicating 0 +involvement 0 +of 0 +spared 0 +cells 0 +in 0 +the 0 +contralateral 3 +rotation 4 +. 0 + +However 0 +, 0 +regardless 0 +of 0 +the 0 +duration 0 +of 0 +recovery 0 +( 0 +and 0 +irrespective 0 +of 0 +either 0 +lesion 0 +volume 0 +, 0 +amphetamine 1 +dose 0 +, 0 +or 0 +post 0 +- 0 +lesion 0 +motor 0 +exercise 0 +) 0 +, 0 +amphetamine 1 +- 0 +induced 0 +rotation 3 +tended 0 +to 0 +become 0 +gradually 0 +more 0 +ipsilateral 0 +as 0 +the 0 +observation 0 +session 0 +progressed 0 +, 0 +and 0 +all 0 +rats 0 +circled 0 +ipsilaterally 0 +to 0 +the 0 +lesion 0 +in 0 +response 0 +to 0 +further 0 +amphetamine 1 +injections 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +amphetamine 1 +has 0 +an 0 +irreversible 0 +effect 0 +on 0 +the 0 +post 0 +- 0 +lesion 0 +DA 0 +pool 0 +contributing 0 +to 0 +contralateral 3 +rotation 4 +. 0 + +Mitomycin 1 +C 2 +associated 0 +hemolytic 3 +uremic 4 +syndrome 4 +. 0 + +Mitomycin 1 +C 2 +associated 0 +Hemolytic 3 +Uremic 4 +Syndrome 4 +( 0 +HUS 3 +) 0 +is 0 +a 0 +potentially 0 +fatal 0 +but 0 +uncommon 0 +condition 0 +that 0 +is 0 +not 0 +yet 0 +widely 0 +recognised 0 +. 0 + +It 0 +consists 0 +of 0 +microangiopathic 0 +hemolytic 3 +anemia 4 +, 0 +thrombocytopenia 3 +and 0 +progressive 0 +renal 3 +failure 4 +associated 0 +with 0 +mitomycin 1 +C 2 +treatment 0 +and 0 +affects 0 +about 0 +10 0 +% 0 +of 0 +patients 0 +treated 0 +with 0 +this 0 +agent 0 +. 0 + +The 0 +renal 3 +failure 4 +usually 0 +develops 0 +about 0 +8 0 +- 0 +10 0 +mth 0 +after 0 +start 0 +of 0 +mitomycin 1 +C 2 +treatment 0 +and 0 +the 0 +mortality 0 +is 0 +approximately 0 +60 0 +% 0 +from 0 +renal 3 +failure 4 +or 0 +pulmonary 3 +edema 4 +. 0 + +Renal 3 +lesions 4 +are 0 +similar 0 +to 0 +those 0 +seen 0 +in 0 +idiopathic 0 +HUS 3 +and 0 +include 0 +arteriolar 0 +fibrin 0 +thrombi 3 +, 0 +expanded 0 +subendothelial 0 +zones 0 +in 0 +glomerular 0 +capillary 0 +walls 0 +, 0 +ischemic 3 +wrinkling 0 +of 0 +glomerular 0 +basement 0 +membranes 0 +and 0 +mesangiolysis 0 +. 0 + +The 0 +mechanism 0 +of 0 +action 0 +is 0 +postulated 0 +as 0 +mitomycin 1 +C 2 +- 0 +induced 0 +endothelial 0 +cell 0 +damage 0 +. 0 + +We 0 +describe 0 +the 0 +clinical 0 +course 0 +and 0 +pathological 0 +findings 0 +in 0 +a 0 +65 0 +yr 0 +- 0 +old 0 +man 0 +with 0 +gastric 3 +adenocarcinoma 4 +who 0 +developed 0 +renal 3 +failure 4 +and 0 +thrombocytopenia 3 +while 0 +on 0 +treatment 0 +with 0 +mitomycin 1 +C 2 +and 0 +died 0 +in 0 +pulmonary 3 +edema 4 +. 0 + +Ketanserin 1 +pretreatment 0 +reverses 0 +alfentanil 1 +- 0 +induced 0 +muscle 3 +rigidity 4 +. 0 + +Systemic 0 +pretreatment 0 +with 0 +ketanserin 1 +, 0 +a 0 +relatively 0 +specific 0 +type 0 +- 0 +2 0 +serotonin 1 +receptor 0 +antagonist 0 +, 0 +significantly 0 +attenuated 0 +the 0 +muscle 3 +rigidity 4 +produced 0 +in 0 +rats 0 +by 0 +the 0 +potent 0 +short 0 +- 0 +acting 0 +opiate 0 +agonist 0 +alfentanil 1 +. 0 + +Following 0 +placement 0 +of 0 +subcutaneous 0 +electrodes 0 +in 0 +each 0 +animal 0 +' 0 +s 0 +left 0 +gastrocnemius 0 +muscle 0 +, 0 +rigidity 3 +was 0 +assessed 0 +by 0 +analyzing 0 +root 0 +- 0 +mean 0 +- 0 +square 0 +electromyographic 0 +activity 0 +. 0 + +Intraperitoneal 0 +ketanserin 1 +administration 0 +at 0 +doses 0 +of 0 +0 0 +. 0 +63 0 +and 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +prevented 0 +the 0 +alfentanil 1 +- 0 +induced 0 +increase 0 +in 0 +electromyographic 0 +activity 0 +compared 0 +with 0 +animals 0 +pretreated 0 +with 0 +saline 0 +. 0 + +Chlordiazepoxide 1 +at 0 +doses 0 +up 0 +to 0 +10 0 +mg 0 +/ 0 +kg 0 +failed 0 +to 0 +significantly 0 +influence 0 +the 0 +rigidity 3 +produced 0 +by 0 +alfentanil 1 +. 0 + +Despite 0 +the 0 +absence 0 +of 0 +rigidity 3 +, 0 +animals 0 +that 0 +received 0 +ketanserin 1 +( 0 +greater 0 +than 0 +0 0 +. 0 +31 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +followed 0 +by 0 +alfentanil 1 +were 0 +motionless 0 +, 0 +flaccid 0 +, 0 +and 0 +less 0 +responsive 0 +to 0 +external 0 +stimuli 0 +than 0 +were 0 +animals 0 +receiving 0 +alfentanil 1 +alone 0 +. 0 + +Rats 0 +that 0 +received 0 +ketanserin 1 +and 0 +alfentanil 1 +exhibited 0 +less 0 +rearing 0 +and 0 +exploratory 0 +behavior 0 +at 0 +the 0 +end 0 +of 0 +the 0 +60 0 +- 0 +min 0 +recording 0 +period 0 +than 0 +did 0 +animals 0 +that 0 +received 0 +ketanserin 1 +alone 0 +. 0 + +These 0 +results 0 +, 0 +in 0 +combination 0 +with 0 +previous 0 +work 0 +, 0 +suggest 0 +that 0 +muscle 3 +rigidity 4 +, 0 +a 0 +clinically 0 +relevant 0 +side 0 +- 0 +effect 0 +of 0 +parenteral 0 +narcotic 0 +administration 0 +, 0 +may 0 +be 0 +partly 0 +mediated 0 +via 0 +serotonergic 0 +pathways 0 +. 0 + +Pretreatment 0 +with 0 +type 0 +- 0 +2 0 +serotonin 1 +antagonists 0 +may 0 +be 0 +clinically 0 +useful 0 +in 0 +attenuating 0 +opiate 0 +- 0 +induced 0 +rigidity 3 +, 0 +although 0 +further 0 +studies 0 +will 0 +be 0 +necessary 0 +to 0 +assess 0 +the 0 +interaction 0 +of 0 +possibly 0 +enhanced 0 +CNS 0 +, 0 +cardiovascular 3 +, 4 +and 4 +respiratory 4 +depression 4 +. 0 + +Antagonism 0 +of 0 +diazepam 1 +- 0 +induced 0 +sedative 0 +effects 0 +by 0 +Ro15 1 +- 2 +1788 2 +in 0 +patients 0 +after 0 +surgery 0 +under 0 +lumbar 0 +epidural 0 +block 0 +. 0 + +A 0 +double 0 +- 0 +blind 0 +placebo 0 +- 0 +controlled 0 +investigation 0 +of 0 +efficacy 0 +and 0 +safety 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +efficacy 0 +of 0 +Ro15 1 +- 2 +1788 2 +and 0 +a 0 +placebo 0 +in 0 +reversing 0 +diazepam 1 +- 0 +induced 0 +effects 0 +after 0 +surgery 0 +under 0 +epidural 0 +block 0 +, 0 +and 0 +to 0 +evaluate 0 +the 0 +local 0 +tolerance 0 +and 0 +general 0 +safety 0 +of 0 +Ro15 1 +- 2 +1788 2 +. 0 + +Fifty 0 +- 0 +seven 0 +patients 0 +were 0 +sedated 0 +with 0 +diazepam 1 +for 0 +surgery 0 +under 0 +epidural 0 +anaesthesia 0 +. 0 + +Antagonism 0 +of 0 +diazepam 1 +- 0 +induced 0 +effects 0 +by 0 +Ro15 1 +- 2 +1788 2 +was 0 +investigated 0 +postoperatively 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +placebo 0 +- 0 +controlled 0 +trial 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +subjective 0 +assessment 0 +of 0 +mood 0 +rating 0 +, 0 +an 0 +objective 0 +test 0 +of 0 +performance 0 +, 0 +a 0 +test 0 +for 0 +amnesia 3 +, 0 +and 0 +vital 0 +signs 0 +were 0 +recorded 0 +for 0 +up 0 +to 0 +300 0 +min 0 +after 0 +administration 0 +of 0 +the 0 +trial 0 +drug 0 +. 0 + +No 0 +significant 0 +differences 0 +between 0 +the 0 +two 0 +groups 0 +were 0 +observed 0 +for 0 +mood 0 +rating 0 +, 0 +amnesia 3 +, 0 +or 0 +vital 0 +signs 0 +. 0 + +The 0 +Ro15 1 +- 2 +1788 2 +group 0 +showed 0 +a 0 +significant 0 +improvement 0 +in 0 +the 0 +performance 0 +test 0 +up 0 +to 0 +120 0 +min 0 +after 0 +administration 0 +of 0 +the 0 +drug 0 +. 0 + +There 0 +was 0 +no 0 +evidence 0 +of 0 +reaction 0 +at 0 +the 0 +injection 0 +site 0 +. 0 + +Chorea 3 +associated 0 +with 0 +oral 1 +contraception 2 +. 0 + +Three 0 +patients 0 +developed 0 +chorea 3 +while 0 +receiving 0 +oral 1 +contraceptives 2 +. 0 + +Two 0 +were 0 +young 0 +patients 0 +whose 0 +chorea 3 +developed 0 +long 0 +after 0 +treatment 0 +had 0 +been 0 +started 0 +and 0 +disappeared 0 +soon 0 +after 0 +it 0 +had 0 +been 0 +discontinued 0 +. 0 + +The 0 +third 0 +patient 0 +had 0 +acute 0 +amphetamine 1 +- 0 +induced 0 +chorea 3 +after 0 +prolonged 0 +oral 1 +contraception 2 +. 0 + +Prolonged 0 +administration 0 +of 0 +female 0 +sex 0 +hormones 0 +is 0 +a 0 +possible 0 +cause 0 +of 0 +chorea 3 +in 0 +women 0 +who 0 +have 0 +not 0 +previously 0 +had 0 +chorea 3 +or 0 +rheumatic 3 +fever 4 +. 0 + +Co 0 +- 0 +carcinogenic 3 +effect 0 +of 0 +retinyl 1 +acetate 2 +on 0 +forestomach 3 +carcinogenesis 4 +of 0 +male 0 +F344 0 +rats 0 +induced 0 +with 0 +butylated 1 +hydroxyanisole 2 +. 0 + +The 0 +potential 0 +modifying 0 +effect 0 +of 0 +retinyl 1 +acetate 2 +( 0 +RA 1 +) 0 +on 0 +butylated 1 +hydroxyanisole 2 +( 0 +BHA 1 +) 0 +- 0 +induced 0 +rat 0 +forestomach 3 +tumorigenesis 4 +was 0 +examined 0 +. 0 + +Male 0 +F344 0 +rats 0 +, 0 +5 0 +weeks 0 +of 0 +age 0 +, 0 +were 0 +maintained 0 +on 0 +diet 0 +containing 0 +1 0 +% 0 +or 0 +2 0 +% 0 +BHA 1 +by 0 +weight 0 +and 0 +simultaneously 0 +on 0 +drinking 0 +water 0 +supplemented 0 +with 0 +RA 1 +at 0 +various 0 +concentrations 0 +( 0 +w 0 +/ 0 +v 0 +) 0 +for 0 +52 0 +weeks 0 +. 0 + +In 0 +groups 0 +given 0 +2 0 +% 0 +BHA 1 +, 0 +although 0 +marked 0 +hyperplastic 0 +changes 0 +of 0 +the 0 +forestomach 0 +epithelium 0 +were 0 +observed 0 +in 0 +all 0 +animals 0 +, 0 +co 0 +- 0 +administration 0 +of 0 +0 0 +. 0 +25 0 +% 0 +RA 1 +significantly 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +increased 0 +the 0 +incidence 0 +of 0 +forestomach 3 +tumors 4 +( 0 +squamous 3 +cell 4 +papilloma 4 +and 0 +carcinoma 3 +) 0 +to 0 +60 0 +% 0 +( 0 +9 0 +/ 0 +15 0 +, 0 +2 0 +rats 0 +with 0 +carcinoma 3 +) 0 +from 0 +15 0 +% 0 +( 0 +3 0 +/ 0 +20 0 +, 0 +one 0 +rat 0 +with 0 +carcinoma 3 +) 0 +in 0 +the 0 +group 0 +given 0 +RA 1 +- 0 +free 0 +water 0 +. 0 + +In 0 +rats 0 +given 0 +1 0 +% 0 +BHA 1 +, 0 +RA 1 +co 0 +- 0 +administered 0 +at 0 +a 0 +dose 0 +of 0 +0 0 +. 0 +05 0 +, 0 +0 0 +. 0 +1 0 +, 0 +0 0 +. 0 +2 0 +or 0 +0 0 +. 0 +25 0 +% 0 +showed 0 +a 0 +dose 0 +- 0 +dependent 0 +enhancing 0 +effect 0 +on 0 +the 0 +development 0 +of 0 +the 0 +BHA 1 +- 0 +induced 0 +epithelial 3 +hyperplasia 4 +. 0 + +Tumors 3 +, 0 +all 0 +papillomas 3 +, 0 +were 0 +induced 0 +in 0 +3 0 +rats 0 +( 0 +17 0 +% 0 +) 0 +with 0 +0 0 +. 0 +25 0 +% 0 +RA 1 +and 0 +in 0 +one 0 +rat 0 +( 0 +10 0 +% 0 +) 0 +with 0 +0 0 +. 0 +05 0 +% 0 +RA 1 +co 0 +- 0 +administration 0 +. 0 + +RA 1 +alone 0 +did 0 +not 0 +induce 0 +hyperplastic 0 +changes 0 +in 0 +the 0 +forestomach 0 +. 0 + +These 0 +findings 0 +indicate 0 +that 0 +RA 1 +acted 0 +as 0 +a 0 +co 0 +- 0 +carcinogen 0 +in 0 +the 0 +BHA 1 +forestomach 3 +carcinogenesis 4 +of 0 +the 0 +rat 0 +. 0 + +A 0 +prospective 0 +study 0 +on 0 +the 0 +dose 0 +dependency 0 +of 0 +cardiotoxicity 3 +induced 0 +by 0 +mitomycin 1 +C 2 +. 0 + +Since 0 +1975 0 +mitomycin 1 +C 2 +( 0 +MMC 1 +) 0 +has 0 +been 0 +suggested 0 +to 0 +be 0 +cardiotoxic 3 +, 0 +especially 0 +when 0 +combined 0 +with 0 +or 0 +given 0 +following 0 +doxorubicin 1 +. 0 + +Data 0 +on 0 +dose 0 +dependency 0 +or 0 +incidence 0 +concerning 0 +this 0 +side 0 +effect 0 +were 0 +not 0 +known 0 +. 0 + +We 0 +have 0 +initiated 0 +a 0 +prospective 0 +study 0 +to 0 +obtain 0 +some 0 +more 0 +data 0 +on 0 +these 0 +subjects 0 +. 0 + +Forty 0 +- 0 +four 0 +MMC 1 +- 0 +treated 0 +patients 0 +were 0 +studied 0 +, 0 +37 0 +of 0 +them 0 +could 0 +be 0 +evaluated 0 +. 0 + +All 0 +patients 0 +were 0 +studied 0 +by 0 +repeated 0 +physical 0 +examinations 0 +, 0 +chest 0 +X 0 +- 0 +rays 0 +, 0 +electro 0 +- 0 +and 0 +echocardiography 0 +and 0 +radionuclide 0 +left 0 +ventricular 0 +ejection 0 +fraction 0 +( 0 +EF 0 +) 0 +determinations 0 +. 0 + +The 0 +results 0 +were 0 +evaluated 0 +per 0 +cumulative 0 +dose 0 +level 0 +. 0 + +0ne 0 +of 0 +the 0 +patients 0 +developed 0 +cardiac 3 +failure 4 +after 0 +30 0 +mg 0 +m 0 +- 0 +2 0 +MMC 1 +and 0 +only 0 +150 0 +mg 0 +m 0 +- 0 +2 0 +doxorubicin 1 +. 0 + +The 0 +cardiac 3 +failure 4 +was 0 +predicted 0 +by 0 +a 0 +drop 0 +in 0 +EF 0 +determined 0 +during 0 +a 0 +cold 0 +pressor 0 +test 0 +. 0 + +None 0 +of 0 +the 0 +other 0 +patients 0 +developed 0 +clinical 0 +cardiotoxicity 3 +, 0 +nor 0 +did 0 +the 0 +studied 0 +parameters 0 +change 0 +. 0 + +The 0 +literature 0 +on 0 +this 0 +subject 0 +was 0 +also 0 +reviewed 0 +. 0 + +Based 0 +on 0 +the 0 +combined 0 +data 0 +from 0 +the 0 +present 0 +study 0 +and 0 +the 0 +literature 0 +, 0 +we 0 +suggest 0 +that 0 +MMC 1 +- 0 +related 0 +cardiotoxicity 3 +is 0 +dose 0 +dependent 0 +, 0 +occurring 0 +at 0 +cumulative 0 +dose 0 +levels 0 +of 0 +30 0 +mg 0 +m 0 +- 0 +2 0 +or 0 +more 0 +, 0 +mainly 0 +in 0 +patients 0 +also 0 +( 0 +previously 0 +or 0 +simultaneously 0 +) 0 +treated 0 +with 0 +doxorubicin 1 +. 0 + +The 0 +incidence 0 +is 0 +likely 0 +to 0 +be 0 +less 0 +than 0 +10 0 +% 0 +even 0 +for 0 +this 0 +risk 0 +group 0 +. 0 + +Reversible 0 +cerebral 3 +lesions 4 +associated 0 +with 0 +tiazofurin 1 +usage 0 +: 0 +MR 0 +demonstration 0 +. 0 + +Tiazofurin 1 +is 0 +an 0 +experimental 0 +chemotherapeutic 0 +agent 0 +currently 0 +undergoing 0 +clinical 0 +evaluation 0 +. 0 + +We 0 +report 0 +our 0 +results 0 +with 0 +magnetic 0 +resonance 0 +( 0 +MR 0 +) 0 +in 0 +demonstrating 0 +reversible 0 +cerebral 3 +abnormalities 4 +concurrent 0 +with 0 +the 0 +use 0 +of 0 +this 0 +drug 0 +. 0 + +The 0 +abnormalities 0 +on 0 +MR 0 +were 0 +correlated 0 +with 0 +findings 0 +on 0 +CT 0 +as 0 +well 0 +as 0 +with 0 +cerebral 0 +angiography 0 +. 0 + +The 0 +utility 0 +of 0 +MR 0 +in 0 +the 0 +evaluation 0 +of 0 +patients 0 +receiving 0 +this 0 +new 0 +agent 0 +is 0 +illustrated 0 +. 0 + +Receptor 0 +mechanisms 0 +of 0 +nicotine 1 +- 0 +induced 0 +locomotor 3 +hyperactivity 4 +in 0 +chronic 0 +nicotine 1 +- 0 +treated 0 +rats 0 +. 0 + +Rats 0 +were 0 +pretreated 0 +with 0 +saline 0 +or 0 +nicotine 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +) 0 +by 0 +subcutaneously 0 +implanting 0 +each 0 +animal 0 +with 0 +an 0 +Alzet 0 +osmotic 0 +mini 0 +- 0 +pump 0 +which 0 +continuously 0 +released 0 +saline 0 +or 0 +nicotine 1 +for 0 +1 0 +, 0 +5 0 +and 0 +14 0 +days 0 +. 0 + +At 0 +the 0 +end 0 +of 0 +each 0 +pretreatment 0 +period 0 +, 0 +animals 0 +were 0 +used 0 +for 0 +( 0 +i 0 +) 0 +determining 0 +their 0 +locomotor 0 +response 0 +to 0 +acutely 0 +injected 0 +nicotine 1 +( 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +and 0 +( 0 +ii 0 +) 0 +measuring 0 +the 0 +density 0 +of 0 +L 0 +- 0 +[ 0 +3H 0 +] 0 +nicotine 1 +and 0 +[ 0 +3H 0 +] 0 +spiperone 1 +binding 0 +sites 0 +in 0 +the 0 +striatum 0 +. 0 + +We 0 +observed 0 +no 0 +changes 0 +in 0 +nicotine 1 +- 0 +induced 0 +locomotor 0 +response 0 +, 0 +striatal 0 +L 0 +- 0 +[ 0 +3H 0 +] 0 +nicotine 1 +and 0 +[ 0 +3H 0 +] 0 +spiperone 1 +binding 0 +in 0 +the 0 +animals 0 +pretreated 0 +with 0 +nicotine 1 +for 0 +1 0 +day 0 +. 0 + +In 0 +rats 0 +which 0 +were 0 +pretreated 0 +with 0 +nicotine 1 +for 0 +5 0 +days 0 +, 0 +there 0 +was 0 +a 0 +significant 0 +increase 0 +in 0 +the 0 +nicotine 1 +- 0 +stimulated 0 +locomotor 0 +response 0 +which 0 +was 0 +associated 0 +with 0 +an 0 +increase 0 +in 0 +the 0 +number 0 +of 0 +L 0 +- 0 +[ 0 +3H 0 +] 0 +nicotine 1 +binding 0 +sites 0 +and 0 +also 0 +with 0 +an 0 +elevated 0 +dopamine 1 +( 0 +DA 1 +) 0 +level 0 +in 0 +the 0 +striatum 0 +. 0 + +The 0 +number 0 +of 0 +striatal 0 +[ 0 +3H 0 +] 0 +spiperone 1 +binding 0 +sites 0 +was 0 +not 0 +affected 0 +. 0 + +In 0 +animals 0 +pretreated 0 +with 0 +nicotine 1 +for 0 +14 0 +days 0 +, 0 +the 0 +nicotine 1 +- 0 +induced 0 +locomotor 0 +response 0 +remained 0 +to 0 +be 0 +potentiated 0 +. 0 + +However 0 +, 0 +this 0 +response 0 +was 0 +correlated 0 +with 0 +an 0 +elevated 0 +number 0 +of 0 +striatal 0 +[ 0 +3H 0 +] 0 +spiperone 1 +binding 0 +sites 0 +, 0 +whereas 0 +the 0 +number 0 +of 0 +striatal 0 +L 0 +- 0 +[ 0 +3H 0 +] 0 +nicotine 1 +binding 0 +sites 0 +and 0 +the 0 +striatal 0 +DA 1 +level 0 +were 0 +normal 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +chronic 0 +nicotine 1 +- 0 +treated 0 +rats 0 +develop 0 +locomotor 3 +hyperactivity 4 +in 0 +response 0 +to 0 +nicotine 1 +initially 0 +due 0 +to 0 +increases 0 +of 0 +both 0 +the 0 +density 0 +of 0 +nicotinic 0 +receptors 0 +and 0 +DA 1 +concentration 0 +, 0 +followed 0 +by 0 +inducing 0 +DA 1 +receptor 0 +supersensitivity 0 +in 0 +the 0 +striatum 0 +. 0 + +Amelioration 0 +of 0 +bendrofluazide 1 +- 0 +induced 0 +hypokalemia 3 +by 0 +timolol 1 +. 0 + +The 0 +beta 0 +adrenergic 0 +blocking 0 +drug 0 +, 0 +timolol 1 +, 0 +tended 0 +to 0 +correct 0 +the 0 +hypokalemia 3 +of 0 +short 0 +- 0 +term 0 +bendrofluazide 1 +treatment 0 +in 0 +6 0 +healthy 0 +male 0 +subjects 0 +and 0 +although 0 +the 0 +effect 0 +was 0 +small 0 +it 0 +was 0 +significant 0 +. 0 + +Timolol 1 +also 0 +reduced 0 +the 0 +rise 0 +in 0 +plasma 0 +aldosterone 1 +and 0 +urine 0 +potassium 1 +excretion 0 +following 0 +bendrofluazide 1 +and 0 +increased 0 +the 0 +urine 0 +sodium 1 +/ 0 +potassium 1 +ratio 0 +. 0 + +There 0 +was 0 +no 0 +evidence 0 +of 0 +a 0 +shift 0 +of 0 +potassium 1 +from 0 +the 0 +intracellular 0 +to 0 +the 0 +extracellular 0 +space 0 +. 0 + +St 3 +. 4 + +Anthony 3 +' 4 +s 4 +fire 4 +, 0 +then 0 +and 0 +now 0 +: 0 +a 0 +case 0 +report 0 +and 0 +historical 0 +review 0 +. 0 + +A 0 +rare 0 +case 0 +of 0 +morbid 0 +vasospasm 3 +, 0 +together 0 +with 0 +striking 0 +angiographic 0 +findings 0 +, 0 +is 0 +described 0 +secondary 0 +to 0 +the 0 +ingestion 0 +of 0 +methysergide 1 +by 0 +a 0 +48 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +. 0 + +A 0 +brief 0 +review 0 +of 0 +the 0 +literature 0 +on 0 +similar 0 +cases 0 +is 0 +presented 0 +. 0 + +A 0 +discussion 0 +of 0 +the 0 +history 0 +of 0 +ergot 1 +includes 0 +its 0 +original 0 +discovery 0 +, 0 +the 0 +epidemics 0 +of 0 +gangrene 3 +that 0 +it 0 +has 0 +caused 0 +through 0 +the 0 +ages 0 +and 0 +its 0 +past 0 +and 0 +present 0 +role 0 +in 0 +the 0 +management 0 +of 0 +migraine 3 +headache 4 +. 0 + +Despite 0 +the 0 +advent 0 +of 0 +calcium 1 +channel 0 +blockers 0 +and 0 +beta 0 +- 0 +adrenergic 0 +antagonists 0 +, 0 +ergot 1 +preparations 0 +continue 0 +to 0 +play 0 +a 0 +major 0 +role 0 +in 0 +migraine 3 +therapy 0 +, 0 +so 0 +that 0 +the 0 +danger 0 +of 0 +St 3 +. 4 + +Anthony 3 +' 4 +s 4 +fire 4 +persists 0 +. 0 + +Cardiac 0 +transplantation 0 +: 0 +improved 0 +quality 0 +of 0 +survival 0 +with 0 +a 0 +modified 0 +immunosuppressive 0 +protocol 0 +. 0 + +The 0 +effects 0 +on 0 +renal 0 +function 0 +on 0 +two 0 +different 0 +immunosuppressive 0 +protocols 0 +were 0 +evaluated 0 +retrospectively 0 +in 0 +two 0 +subsequent 0 +groups 0 +of 0 +heart 0 +transplant 0 +recipients 0 +. 0 + +In 0 +group 0 +I 0 +, 0 +cyclosporine 1 +was 0 +given 0 +before 0 +the 0 +procedure 0 +at 0 +a 0 +loading 0 +dose 0 +of 0 +17 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +and 0 +then 0 +continued 0 +after 0 +the 0 +procedure 0 +to 0 +keep 0 +a 0 +whole 0 +blood 0 +level 0 +about 0 +1000 0 +ng 0 +/ 0 +ml 0 +. 0 + +In 0 +group 0 +II 0 +, 0 +cyclosporine 1 +was 0 +started 0 +only 0 +after 0 +the 0 +procedure 0 +at 0 +a 0 +lower 0 +dosage 0 +and 0 +was 0 +complemented 0 +by 0 +azathioprine 1 +, 0 +which 0 +was 0 +used 0 +for 0 +the 0 +first 0 +postoperative 0 +week 0 +. 0 + +Group 0 +II 0 +showed 0 +a 0 +better 0 +perioperative 0 +renal 0 +function 0 +as 0 +determined 0 +by 0 +serum 0 +blood 0 +urea 1 +nitrogen 2 +and 0 +serum 0 +creatinine 1 +levels 0 +. 0 + +Group 0 +II 0 +also 0 +showed 0 +a 0 +significant 0 +decrease 0 +of 0 +chronic 0 +nephrotoxicity 3 +secondary 0 +to 0 +long 0 +- 0 +term 0 +therapy 0 +with 0 +cyclosporine 1 +. 0 + +Despite 0 +this 0 +improvement 0 +in 0 +late 0 +renal 0 +function 0 +, 0 +group 0 +II 0 +still 0 +shows 0 +a 0 +slow 0 +rise 0 +in 0 +serum 0 +creatinine 1 +. 0 + +We 0 +think 0 +that 0 +even 0 +these 0 +lower 0 +dosages 0 +of 0 +cyclosporine 1 +can 0 +cause 0 +chronic 0 +nephrotoxicity 3 +and 0 +that 0 +further 0 +modification 0 +of 0 +the 0 +immunosuppressive 0 +regimen 0 +is 0 +required 0 +to 0 +completely 0 +abolish 0 +this 0 +toxic 0 +side 0 +effect 0 +. 0 + +Ethopropazine 1 +and 0 +benztropine 1 +in 0 +neuroleptic 0 +- 0 +induced 0 +parkinsonism 3 +. 0 + +In 0 +a 0 +12 0 +- 0 +week 0 +controlled 0 +study 0 +ethopropazine 1 +was 0 +compared 0 +to 0 +benztropine 1 +in 0 +the 0 +treatment 0 +of 0 +parkinsonism 3 +induced 0 +by 0 +fluphenazine 1 +enanthate 2 +in 0 +60 0 +schizophrenic 3 +outpatients 0 +. 0 + +Ethopropazine 1 +and 0 +benztropine 1 +were 0 +found 0 +to 0 +be 0 +equally 0 +effective 0 +in 0 +controlling 0 +parkinsonian 3 +symptoms 4 +and 0 +were 0 +as 0 +efficacious 0 +as 0 +procyclidine 1 +, 0 +their 0 +previous 0 +antiparkinsonian 0 +drug 0 +. 0 + +However 0 +, 0 +benztropine 1 +treated 0 +patients 0 +had 0 +a 0 +significant 0 +increase 0 +in 0 +tardive 3 +dyskinesia 4 +compared 0 +to 0 +their 0 +condition 0 +during 0 +procyclindine 1 +treatment 0 +, 0 +and 0 +significantly 0 +more 0 +anxiety 3 +and 0 +depression 3 +than 0 +ethopropazine 1 +treated 0 +patients 0 +. 0 + +This 0 +suggests 0 +that 0 +benztropine 1 +is 0 +not 0 +the 0 +anticholinergic 0 +drug 0 +of 0 +choice 0 +in 0 +the 0 +treatment 0 +of 0 +neuroleptic 0 +- 0 +induced 0 +parkinsonian 3 +symptoms 4 +, 0 +because 0 +of 0 +its 0 +more 0 +toxic 0 +central 0 +and 0 +peripheral 0 +atropinic 0 +effect 0 +. 0 + +Quinidine 1 +phenylethylbarbiturate 2 +- 0 +induced 0 +fulminant 0 +hepatitis 3 +in 0 +a 0 +pregnant 0 +woman 0 +. 0 + +A 0 +case 0 +report 0 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +19 0 +- 0 +year 0 +- 0 +old 0 +Laotian 0 +patient 0 +affected 0 +by 0 +fulminant 0 +hepatitis 3 +during 0 +the 0 +third 0 +trimester 0 +of 0 +her 0 +pregnancy 0 +after 0 +a 0 +1 0 +- 0 +month 0 +administration 0 +of 0 +quinidine 1 +phenylethylbarbiturate 2 +. 0 + +After 0 +delivery 0 +, 0 +the 0 +patient 0 +underwent 0 +orthotopic 0 +liver 0 +transplantation 0 +. 0 + +The 0 +patient 0 +was 0 +in 0 +good 0 +condition 0 +16 0 +months 0 +after 0 +liver 0 +transplantation 0 +. 0 + +Quinidine 1 +itself 0 +or 0 +phenylethylbarbiturate 1 +may 0 +be 0 +responsible 0 +for 0 +fulminant 0 +hepatitis 3 +in 0 +this 0 +patient 0 +. 0 + +Mechanisms 0 +of 0 +myocardial 3 +ischemia 4 +induced 0 +by 0 +epinephrine 1 +: 0 +comparison 0 +with 0 +exercise 0 +- 0 +induced 0 +ischemia 3 +. 0 + +The 0 +role 0 +of 0 +epinephrine 1 +in 0 +eliciting 0 +myocardial 3 +ischemia 4 +was 0 +examined 0 +in 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +. 0 + +0bjective 0 +signs 0 +of 0 +ischemia 3 +and 0 +factors 0 +increasing 0 +myocardial 0 +oxygen 1 +consumption 0 +were 0 +compared 0 +during 0 +epinephrine 1 +infusion 0 +and 0 +supine 0 +bicycle 0 +exercise 0 +. 0 + +Both 0 +epinephrine 1 +and 0 +exercise 0 +produced 0 +myocardial 3 +ischemia 4 +as 0 +evidenced 0 +by 0 +ST 0 +segment 0 +depression 3 +and 0 +angina 3 +. 0 + +However 0 +, 0 +the 0 +mechanisms 0 +of 0 +myocardial 3 +ischemia 4 +induced 0 +by 0 +epinephrine 1 +were 0 +significantly 0 +different 0 +from 0 +those 0 +of 0 +exercise 0 +. 0 + +Exercise 0 +- 0 +induced 0 +myocardial 3 +ischemia 4 +was 0 +marked 0 +predominantly 0 +by 0 +increased 0 +heart 0 +rate 0 +and 0 +rate 0 +- 0 +pressure 0 +product 0 +with 0 +a 0 +minor 0 +contribution 0 +of 0 +end 0 +- 0 +diastolic 0 +volume 0 +, 0 +while 0 +epinephrine 1 +- 0 +induced 0 +ischemia 3 +was 0 +characterized 0 +by 0 +a 0 +marked 0 +increase 0 +in 0 +contractility 0 +and 0 +a 0 +less 0 +pronounced 0 +increase 0 +in 0 +heart 0 +rate 0 +and 0 +rate 0 +- 0 +pressure 0 +product 0 +. 0 + +These 0 +findings 0 +indicate 0 +that 0 +ischemia 3 +produced 0 +by 0 +epinephrine 1 +, 0 +as 0 +may 0 +occur 0 +during 0 +states 0 +of 0 +emotional 0 +distress 0 +, 0 +has 0 +a 0 +mechanism 0 +distinct 0 +from 0 +that 0 +due 0 +to 0 +physical 0 +exertion 0 +. 0 + +Recent 0 +preclinical 0 +and 0 +clinical 0 +studies 0 +with 0 +the 0 +thymidylate 0 +synthase 0 +inhibitor 0 +N10 1 +- 2 +propargyl 2 +- 2 +5 2 +, 2 +8 2 +- 2 +dideazafolic 2 +acid 2 +( 0 +CB 1 +3717 2 +) 0 +. 0 + +CB 1 +3717 2 +, 0 +N10 1 +- 2 +propargyl 2 +- 2 +5 2 +, 2 +8 2 +- 2 +dideazafolic 2 +acid 2 +, 0 +is 0 +a 0 +tight 0 +- 0 +binding 0 +inhibitor 0 +of 0 +thymidylate 0 +synthase 0 +( 0 +TS 0 +) 0 +whose 0 +cytotoxicity 3 +is 0 +mediated 0 +solely 0 +through 0 +the 0 +inhibition 0 +of 0 +this 0 +enzyme 0 +. 0 + +Recent 0 +preclinical 0 +studies 0 +have 0 +focused 0 +on 0 +the 0 +intracellular 0 +formation 0 +of 0 +CB 1 +3717 2 +polyglutamates 0 +. 0 + +Following 0 +a 0 +12 0 +- 0 +hour 0 +exposure 0 +of 0 +L1210 0 +cells 0 +to 0 +50 0 +microM 0 +[ 0 +3H 0 +] 0 +CB 1 +3717 2 +, 0 +30 0 +% 0 +of 0 +the 0 +extractable 0 +radioactivity 0 +could 0 +be 0 +accounted 0 +for 0 +as 0 +CB 1 +3717 2 +tetra 0 +- 0 +and 0 +pentaglutamate 0 +, 0 +as 0 +determined 0 +by 0 +high 0 +- 0 +pressure 0 +liquid 0 +chromatography 0 +( 0 +HPLC 0 +) 0 +analyses 0 +. 0 + +As 0 +inhibitors 0 +of 0 +isolated 0 +L1210 0 +TS 0 +, 0 +CB 0 +3717 0 +di 0 +- 0 +, 0 +tri 0 +- 0 +, 0 +tetra 0 +- 0 +and 0 +pentaglutamate 0 +are 0 +26 0 +- 0 +, 0 +87 0 +- 0 +, 0 +119 0 +- 0 +and 0 +114 0 +- 0 +fold 0 +more 0 +potent 0 +than 0 +CB 1 +3717 2 +, 0 +respectively 0 +, 0 +and 0 +their 0 +formation 0 +may 0 +, 0 +therefore 0 +, 0 +be 0 +an 0 +important 0 +determinant 0 +of 0 +CB 1 +3717 2 +cytotoxicity 3 +. 0 + +In 0 +early 0 +clinical 0 +studies 0 +with 0 +CB 1 +3717 2 +, 0 +activity 0 +has 0 +been 0 +seen 0 +in 0 +breast 3 +cancer 4 +, 0 +ovarian 3 +cancer 4 +, 0 +hepatoma 3 +, 0 +and 0 +mesothelioma 3 +. 0 + +Toxicities 3 +included 0 +hepatotoxicity 3 +, 0 +malaise 3 +, 0 +and 0 +dose 0 +- 0 +limiting 0 +nephrotoxicity 3 +. 0 + +This 0 +latter 0 +effect 0 +is 0 +thought 0 +to 0 +be 0 +due 0 +to 0 +drug 0 +precipitation 0 +within 0 +the 0 +renal 0 +tubule 0 +as 0 +a 0 +result 0 +of 0 +the 0 +poor 0 +solubility 0 +of 0 +CB 1 +3717 2 +under 0 +acidic 0 +conditions 0 +. 0 + +In 0 +an 0 +attempt 0 +to 0 +overcome 0 +this 0 +problem 0 +, 0 +a 0 +clinical 0 +trial 0 +of 0 +CB 1 +3717 2 +administered 0 +with 0 +alkaline 0 +diuresis 0 +is 0 +under 0 +way 0 +. 0 + +Preliminary 0 +results 0 +at 0 +400 0 +and 0 +500 0 +mg 0 +/ 0 +m2 0 +suggest 0 +that 0 +a 0 +reduction 0 +in 0 +nephrotoxicity 3 +may 0 +have 0 +been 0 +achieved 0 +with 0 +only 0 +1 0 +instance 0 +of 0 +renal 3 +toxicity 4 +in 0 +10 0 +patients 0 +. 0 + +Hepatotoxicity 3 +and 0 +malaise 3 +are 0 +again 0 +the 0 +most 0 +frequent 0 +side 0 +effects 0 +. 0 + +Evidence 0 +of 0 +antitumor 0 +activity 0 +has 0 +been 0 +seen 0 +in 0 +3 0 +patients 0 +. 0 + +Pharmacokinetic 0 +investigations 0 +have 0 +shown 0 +that 0 +alkaline 0 +diuresis 0 +does 0 +not 0 +alter 0 +CB 1 +3717 2 +plasma 0 +levels 0 +or 0 +urinary 0 +excretion 0 +and 0 +that 0 +satisfactory 0 +urinary 0 +alkalinization 0 +can 0 +be 0 +readily 0 +achieved 0 +. 0 + +Type 3 +B 4 +hepatitis 4 +after 0 +needle 0 +- 0 +stick 0 +exposure 0 +: 0 +prevention 0 +with 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +. 0 + +Final 0 +report 0 +of 0 +the 0 +Veterans 0 +Administration 0 +Cooperative 0 +Study 0 +. 0 + +Hepatitis 3 +B 4 +immune 0 +globulin 0 +( 0 +HBIG 0 +) 0 +and 0 +immune 0 +serum 0 +globulin 0 +( 0 +ISG 0 +) 0 +were 0 +examined 0 +in 0 +a 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +trial 0 +to 0 +assess 0 +their 0 +relative 0 +efficacies 0 +in 0 +preventing 0 +type 3 +B 4 +hepatitis 4 +after 0 +needle 0 +- 0 +stick 0 +exposure 0 +to 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +( 0 +HBsAG 1 +) 0 +- 0 +positive 0 +donors 0 +. 0 + +Clinical 0 +hepatitis 3 +developed 0 +in 0 +1 0 +. 0 +4 0 +% 0 +of 0 +HBIG 0 +and 0 +in 0 +5 0 +. 0 +9 0 +% 0 +of 0 +ISG 0 +recipients 0 +( 0 +P 0 += 0 +0 0 +. 0 +016 0 +) 0 +, 0 +and 0 +seroconversion 0 +( 0 +anti 0 +- 0 +HBs 0 +) 0 +occurred 0 +in 0 +5 0 +. 0 +6 0 +% 0 +and 0 +20 0 +. 0 +7 0 +% 0 +of 0 +them 0 +respectively 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Mild 0 +and 0 +transient 0 +side 0 +- 0 +effects 0 +were 0 +noted 0 +in 0 +3 0 +. 0 +0 0 +% 0 +of 0 +ISG 0 +and 0 +in 0 +3 0 +. 0 +2 0 +% 0 +of 0 +HBIG 0 +recipients 0 +. 0 + +Available 0 +donor 0 +sera 0 +were 0 +examined 0 +for 0 +DNA 0 +polymerase 0 +( 0 +DNAP 0 +) 0 +and 0 +e 0 +antigen 0 +and 0 +antibody 0 +( 0 +HBeAg 1 +; 0 +anti 0 +- 0 +HBE 0 +) 0 +. 0 + +Both 0 +DNAP 0 +and 0 +HBeAg 1 +showed 0 +a 0 +highly 0 +statistically 0 +significant 0 +correlation 0 +with 0 +the 0 +infectivity 0 +of 0 +HBsAg 1 +- 0 +positive 0 +donors 0 +. 0 + +Hepatitis 3 +B 4 +immune 0 +globulin 0 +remained 0 +significantly 0 +superior 0 +to 0 +ISG 0 +in 0 +preventing 0 +type 3 +B 4 +hepatitis 4 +even 0 +when 0 +the 0 +analysis 0 +was 0 +confined 0 +to 0 +these 0 +two 0 +high 0 +- 0 +risk 0 +subgroups 0 +. 0 + +The 0 +efficacy 0 +of 0 +ISG 0 +in 0 +preventing 0 +type 3 +B 4 +hepatitis 4 +cannot 0 +be 0 +ascertained 0 +because 0 +a 0 +true 0 +placebo 0 +group 0 +was 0 +not 0 +included 0 +. 0 + +Production 0 +of 0 +autochthonous 0 +prostate 3 +cancer 4 +in 0 +Lobund 0 +- 0 +Wistar 0 +rats 0 +by 0 +treatments 0 +with 0 +N 1 +- 2 +nitroso 2 +- 2 +N 2 +- 2 +methylurea 2 +and 0 +testosterone 1 +. 0 + +More 0 +than 0 +50 0 +% 0 +of 0 +Lobund 0 +- 0 +Wistar 0 +( 0 +L 0 +- 0 +W 0 +) 0 +strain 0 +rats 0 +developed 0 +large 0 +, 0 +palpable 0 +prostate 3 +adenocarcinomas 4 +( 0 +PAs 3 +) 0 +following 0 +treatments 0 +with 0 +N 1 +- 2 +nitroso 2 +- 2 +N 2 +- 2 +methylurea 2 +( 0 +CAS 0 +: 0 +684 0 +- 0 +93 0 +- 0 +5 0 +) 0 +and 0 +testosterone 1 +propionate 2 +[ 0 +( 0 +TP 1 +) 0 +CAS 0 +: 0 +57 0 +- 0 +85 0 +- 0 +2 0 +] 0 +, 0 +and 0 +most 0 +of 0 +the 0 +tumor 3 +- 0 +bearing 0 +rats 0 +manifested 0 +metastatic 0 +lesions 0 +. 0 + +The 0 +incubation 0 +periods 0 +averaged 0 +10 0 +. 0 +6 0 +months 0 +. 0 + +Within 0 +the 0 +same 0 +timeframe 0 +, 0 +no 0 +L 0 +- 0 +W 0 +rat 0 +developed 0 +a 0 +similar 0 +palpable 0 +PA 3 +when 0 +treated 0 +only 0 +with 0 +TP 1 +. 0 + +In 0 +L 0 +- 0 +W 0 +rats 0 +, 0 +TP 1 +acted 0 +as 0 +a 0 +tumor 3 +enhancement 0 +agent 0 +, 0 +with 0 +primary 0 +emphasis 0 +on 0 +the 0 +development 0 +of 0 +prostate 3 +cancer 4 +. 0 + +Relative 0 +efficacy 0 +and 0 +toxicity 3 +of 0 +netilmicin 1 +and 0 +tobramycin 1 +in 0 +oncology 0 +patients 0 +. 0 + +We 0 +prospectively 0 +compared 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +netilmicin 1 +sulfate 2 +or 0 +tobramycin 1 +sulfate 2 +in 0 +conjunction 0 +with 0 +piperacillin 1 +sodium 2 +in 0 +118 0 +immunocompromised 0 +patients 0 +with 0 +presumed 0 +severe 0 +infections 3 +. 0 + +The 0 +two 0 +treatment 0 +regimens 0 +were 0 +equally 0 +efficacious 0 +. 0 + +Nephrotoxicity 3 +occurred 0 +in 0 +a 0 +similar 0 +proportion 0 +in 0 +patients 0 +treated 0 +with 0 +netilmicin 1 +and 0 +tobramycin 1 +( 0 +17 0 +% 0 +vs 0 +11 0 +% 0 +) 0 +. 0 + +0totoxicity 3 +occurred 0 +in 0 +four 0 +( 0 +9 0 +. 0 +5 0 +% 0 +) 0 +of 0 +42 0 +netilmicin 1 +and 0 +piperacillin 1 +and 0 +in 0 +12 0 +( 0 +22 0 +% 0 +) 0 +of 0 +54 0 +tobramycin 1 +and 0 +piperacillin 1 +- 0 +treated 0 +patients 0 +. 0 + +0f 0 +those 0 +evaluated 0 +with 0 +posttherapy 0 +audiograms 0 +, 0 +three 0 +of 0 +four 0 +netilmicin 1 +and 0 +piperacillin 1 +- 0 +treated 0 +patients 0 +had 0 +auditory 0 +thresholds 0 +return 0 +to 0 +baseline 0 +compared 0 +with 0 +one 0 +of 0 +nine 0 +tobramycin 1 +and 0 +piperacillin 1 +- 0 +treated 0 +patients 0 +. 0 + +The 0 +number 0 +of 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +15 0 +- 0 +dB 0 +increases 0 +in 0 +auditory 0 +threshold 0 +as 0 +a 0 +proportion 0 +of 0 +total 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +15 0 +- 0 +dB 0 +changes 0 +( 0 +increases 0 +and 0 +decreases 0 +) 0 +was 0 +significantly 0 +lower 0 +in 0 +netilmicin 1 +and 0 +piperacillin 1 +- 0 +vs 0 +tobramycin 1 +and 0 +piperacillin 1 +- 0 +treated 0 +patients 0 +( 0 +18 0 +of 0 +78 0 +vs 0 +67 0 +of 0 +115 0 +) 0 +. 0 + +We 0 +conclude 0 +that 0 +aminoglycoside 1 +- 0 +associated 0 +ototoxicity 3 +was 0 +less 0 +severe 0 +and 0 +more 0 +often 0 +reversible 0 +with 0 +netilmicin 1 +than 0 +with 0 +tobramycin 1 +. 0 + +Urinary 0 +enzymes 0 +and 0 +protein 0 +patterns 0 +as 0 +indicators 0 +of 0 +injury 3 +to 4 +different 4 +regions 4 +of 4 +the 4 +kidney 4 +. 0 + +Acute 3 +experimental 4 +models 4 +of 4 +renal 4 +damage 4 +to 0 +the 0 +proximal 0 +tubular 0 +, 0 +glomerular 0 +, 0 +and 0 +papillary 0 +regions 0 +of 0 +the 0 +rat 0 +were 0 +produced 0 +by 0 +administration 0 +of 0 +hexachloro 1 +- 2 +1 2 +: 2 +3 2 +- 2 +butadiene 2 +( 0 +HCBD 1 +) 0 +, 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +, 0 +and 0 +2 1 +- 2 +bromoethylamine 2 +( 0 +BEA 1 +) 0 +, 0 +respectively 0 +. 0 + +Several 0 +routine 0 +indicators 0 +of 0 +nephrotoxicity 3 +, 0 +the 0 +enzymes 0 +alkaline 0 +phosphatase 0 +and 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +glucosaminidase 0 +, 0 +and 0 +the 0 +molecular 0 +weight 0 +of 0 +protein 3 +excretion 4 +were 0 +determined 0 +on 0 +urine 0 +samples 0 +. 0 + +Tubular 0 +damage 0 +produced 0 +by 0 +HCBD 1 +or 0 +BEA 1 +was 0 +discriminated 0 +both 0 +quantitatively 0 +and 0 +qualitatively 0 +from 0 +glomerular 3 +damage 4 +produced 0 +by 0 +PAN 1 +. 0 + +The 0 +latter 0 +was 0 +characterized 0 +by 0 +a 0 +pronounced 0 +increase 0 +in 0 +protein 3 +excretion 4 +, 0 +especially 0 +proteins 0 +with 0 +molecular 0 +weight 0 +greater 0 +than 0 +40 0 +, 0 +000 0 +Da 0 +. 0 + +In 0 +contrast 0 +, 0 +protein 3 +excretion 4 +in 0 +tubular 0 +damage 0 +was 0 +raised 0 +only 0 +slightly 0 +and 0 +characterized 0 +by 0 +excretion 3 +of 4 +proteins 4 +of 0 +a 0 +wide 0 +range 0 +of 0 +molecular 0 +weights 0 +. 0 + +Proximal 0 +tubular 0 +damage 0 +caused 0 +by 0 +HCBD 1 +and 0 +papillary 0 +damage 0 +caused 0 +by 0 +BEA 1 +were 0 +distinguished 0 +both 0 +by 0 +conventional 0 +urinalysis 0 +( 0 +volume 0 +and 0 +specific 0 +gravity 0 +) 0 +and 0 +by 0 +measurement 0 +of 0 +the 0 +two 0 +urinary 0 +enzymes 0 +. 0 + +Alkaline 0 +phosphatase 0 +and 0 +glucose 1 +were 0 +markedly 0 +and 0 +transiently 0 +elevated 0 +in 0 +proximal 0 +tubular 0 +damage 0 +and 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +glucosaminidase 0 +showed 0 +a 0 +sustained 0 +elevation 0 +in 0 +papillary 0 +damage 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +both 0 +selective 0 +urinary 0 +enzymes 0 +and 0 +the 0 +molecular 0 +weight 0 +pattern 0 +of 0 +urinary 0 +proteins 0 +can 0 +be 0 +used 0 +to 0 +provide 0 +diagnostic 0 +information 0 +about 0 +the 0 +possible 0 +site 0 +of 0 +renal 3 +damage 4 +. 0 + +A 0 +catch 0 +in 0 +the 0 +Reye 3 +. 0 + +Twenty 0 +- 0 +six 0 +cases 0 +of 0 +Reye 3 +syndrome 4 +from 0 +The 0 +Children 0 +' 0 +s 0 +Hospital 0 +, 0 +Camperdown 0 +, 0 +Australia 0 +, 0 +occurring 0 +between 0 +1973 0 +and 0 +1982 0 +were 0 +reviewed 0 +. 0 + +0f 0 +these 0 +, 0 +20 0 +cases 0 +met 0 +the 0 +US 0 +Public 0 +Health 0 +Service 0 +Centers 0 +for 0 +Disease 0 +Control 0 +criteria 0 +for 0 +the 0 +diagnosis 0 +of 0 +Reye 3 +syndrome 4 +. 0 + +Aspirin 1 +or 0 +salicylate 1 +ingestion 0 +had 0 +occurred 0 +in 0 +only 0 +one 0 +of 0 +the 0 +20 0 +cases 0 +( 0 +5 0 +% 0 +) 0 +, 0 +and 0 +paracetamol 1 +( 0 +acetaminophen 1 +) 0 +had 0 +been 0 +administered 0 +in 0 +only 0 +six 0 +of 0 +the 0 +cases 0 +( 0 +30 0 +% 0 +) 0 +. 0 + +Pathologic 0 +confirmation 0 +of 0 +the 0 +diagnosis 0 +of 0 +Reye 3 +syndrome 4 +was 0 +accomplished 0 +in 0 +90 0 +% 0 +of 0 +the 0 +cases 0 +. 0 + +The 0 +incidence 0 +of 0 +Reye 3 +syndrome 4 +in 0 +New 0 +South 0 +Wales 0 +, 0 +Australia 0 +, 0 +is 0 +estimated 0 +from 0 +this 0 +study 0 +to 0 +be 0 +approximately 0 +nine 0 +cases 0 +per 0 +1 0 +million 0 +children 0 +compared 0 +with 0 +recent 0 +US 0 +data 0 +of 0 +ten 0 +to 0 +20 0 +cases 0 +per 0 +1 0 +million 0 +children 0 +and 0 +three 0 +to 0 +seven 0 +cases 0 +per 0 +1 0 +million 0 +children 0 +in 0 +Great 0 +Britain 0 +. 0 + +The 0 +mortality 0 +for 0 +these 0 +Reye 3 +syndrome 4 +cases 0 +in 0 +Australia 0 +was 0 +45 0 +% 0 +as 0 +compared 0 +with 0 +a 0 +32 0 +% 0 +case 0 +- 0 +fatality 0 +rate 0 +in 0 +the 0 +United 0 +States 0 +. 0 + +In 0 +Australia 0 +, 0 +the 0 +pediatric 0 +usage 0 +of 0 +aspirin 1 +has 0 +been 0 +extremely 0 +low 0 +for 0 +the 0 +past 0 +25 0 +years 0 +( 0 +less 0 +than 0 +1 0 +% 0 +of 0 +total 0 +dosage 0 +units 0 +sold 0 +) 0 +, 0 +with 0 +paracetamol 1 +( 0 +acetaminophen 1 +) 0 +dominating 0 +the 0 +pediatric 0 +analgesic 0 +and 0 +antipyretic 0 +market 0 +. 0 + +Reye 3 +syndrome 4 +may 0 +be 0 +disappearing 0 +from 0 +Australia 0 +despite 0 +a 0 +total 0 +lack 0 +of 0 +association 0 +with 0 +salicylates 1 +or 0 +aspirin 1 +ingestion 0 +, 0 +since 0 +there 0 +were 0 +no 0 +cases 0 +found 0 +at 0 +The 0 +Children 0 +' 0 +s 0 +Hospital 0 +in 0 +1983 0 +, 0 +1984 0 +, 0 +or 0 +1985 0 +. 0 + +Postpartum 0 +psychosis 3 +induced 0 +by 0 +bromocriptine 1 +. 0 + +Two 0 +multigravida 0 +patients 0 +with 0 +no 0 +prior 0 +psychiatric 3 +history 0 +were 0 +seen 0 +with 0 +postpartum 0 +psychosis 3 +, 0 +having 0 +received 0 +bromocriptine 1 +for 0 +inhibition 3 +of 4 +lactation 4 +. 0 + +Bromocriptine 1 +given 0 +in 0 +high 0 +doses 0 +has 0 +been 0 +associated 0 +with 0 +psychosis 3 +in 0 +patients 0 +receiving 0 +the 0 +drug 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +These 0 +cases 0 +demonstrate 0 +that 0 +bromocriptine 1 +may 0 +cause 0 +psychosis 3 +even 0 +when 0 +given 0 +in 0 +low 0 +doses 0 +. 0 + +Hyperglycemic 3 +acidotic 4 +coma 4 +and 0 +death 0 +in 0 +Kearns 3 +- 4 +Sayre 4 +syndrome 4 +. 0 + +This 0 +paper 0 +presents 0 +the 0 +clinical 0 +and 0 +metabolic 0 +findings 0 +in 0 +two 0 +young 0 +boys 0 +with 0 +long 0 +- 0 +standing 0 +Kearns 3 +- 4 +Sayre 4 +syndrome 4 +. 0 + +Following 0 +short 0 +exposure 0 +to 0 +oral 0 +prednisone 1 +, 0 +both 0 +boys 0 +developed 0 +lethargy 3 +, 0 +increasing 0 +somnolence 3 +, 0 +polydipsia 3 +, 0 +polyphagia 3 +, 0 +and 0 +polyuria 3 +. 0 + +Both 0 +presented 0 +in 0 +the 0 +emergency 0 +room 0 +with 0 +profound 0 +coma 3 +, 0 +hypotension 3 +, 0 +severe 0 +hyperglycemia 3 +, 0 +and 0 +acidosis 3 +. 0 + +Nonketotic 0 +lactic 3 +acidosis 4 +was 0 +present 0 +in 0 +one 0 +and 0 +ketosis 3 +without 0 +a 0 +known 0 +serum 0 +lactate 1 +level 0 +was 0 +present 0 +in 0 +the 0 +other 0 +. 0 + +Respiratory 3 +failure 4 +rapidly 0 +ensued 0 +and 0 +both 0 +patients 0 +expired 0 +in 0 +spite 0 +of 0 +efforts 0 +at 0 +resuscitation 0 +. 0 + +We 0 +believe 0 +these 0 +two 0 +cases 0 +represent 0 +a 0 +newly 0 +described 0 +and 0 +catastrophic 0 +metabolic 3 +- 4 +endocrine 4 +failure 4 +in 0 +the 0 +Kearns 3 +- 4 +Sayre 4 +syndrome 4 +. 0 + +Experimental 0 +cyclosporine 1 +nephrotoxicity 3 +: 0 +risk 0 +of 0 +concomitant 0 +chemotherapy 0 +. 0 + +The 0 +role 0 +of 0 +cyclosporine 1 +( 0 +CSA 1 +) 0 +alone 0 +or 0 +in 0 +combination 0 +with 0 +various 0 +chemotherapeutics 0 +in 0 +the 0 +development 0 +of 0 +renal 3 +toxicity 4 +was 0 +evaluated 0 +in 0 +rats 0 +. 0 + +Administration 0 +of 0 +20 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +CSA 1 +for 0 +4 0 +weeks 0 +caused 0 +renal 0 +functional 0 +and 0 +structural 0 +changes 0 +similar 0 +to 0 +those 0 +reported 0 +in 0 +man 0 +. 0 + +The 0 +combined 0 +administration 0 +of 0 +CSA 1 +and 0 +various 0 +chemotherapeutic 0 +drugs 0 +with 0 +a 0 +nephrotoxic 3 +potential 0 +, 0 +such 0 +as 0 +gentamicin 1 +( 0 +at 0 +therapeutic 0 +doses 0 +) 0 +, 0 +amphothericin 1 +B 2 +and 0 +ketoconazole 1 +, 0 +which 0 +are 0 +frequently 0 +used 0 +in 0 +immunosuppressed 0 +patients 0 +, 0 +did 0 +not 0 +aggravate 0 +the 0 +CSA 1 +induced 0 +toxicity 3 +in 0 +the 0 +rat 0 +model 0 +. 0 + +Gentamicin 1 +at 0 +toxic 0 +doses 0 +, 0 +however 0 +, 0 +increased 0 +CSA 1 +nephrotoxicity 3 +. 0 + +Thus 0 +, 0 +the 0 +nephrotoxicity 3 +induced 0 +by 0 +CSA 1 +has 0 +a 0 +different 0 +pathogenetic 0 +mechanism 0 +. 0 + +Diuretics 0 +, 0 +potassium 1 +and 0 +arrhythmias 3 +in 0 +hypertensive 3 +coronary 3 +disease 4 +. 0 + +It 0 +has 0 +been 0 +proposed 0 +that 0 +modest 0 +changes 0 +in 0 +plasma 0 +potassium 1 +can 0 +alter 0 +the 0 +tendency 0 +towards 0 +cardiac 3 +arrhythmias 4 +. 0 + +If 0 +this 0 +were 0 +so 0 +, 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +might 0 +be 0 +especially 0 +susceptible 0 +. 0 + +Thus 0 +, 0 +myocardial 0 +electrical 0 +excitability 0 +was 0 +measured 0 +in 0 +patients 0 +with 0 +mild 0 +essential 0 +hypertension 3 +and 0 +known 0 +coronary 3 +artery 4 +disease 4 +after 0 +8 0 +weeks 0 +of 0 +treatment 0 +with 0 +a 0 +potassium 1 +- 0 +conserving 0 +diuretic 0 +( 0 +amiloride 1 +) 0 +and 0 +a 0 +similar 0 +period 0 +on 0 +a 0 +potassium 1 +- 0 +losing 0 +diuretic 0 +( 0 +chlorthalidone 1 +) 0 +in 0 +a 0 +randomised 0 +study 0 +. 0 + +Plasma 0 +potassium 1 +concentrations 0 +were 0 +on 0 +average 0 +1 0 +mmol 0 +/ 0 +L 0 +lower 0 +during 0 +the 0 +chlorthalidone 1 +phase 0 +compared 0 +to 0 +amiloride 1 +therapy 0 +. 0 + +Blood 0 +pressure 0 +and 0 +volume 0 +states 0 +as 0 +assessed 0 +by 0 +bodyweight 0 +, 0 +plasma 0 +renin 0 +and 0 +noradrenaline 1 +( 0 +norepinephrine 1 +) 0 +concentrations 0 +were 0 +similar 0 +on 0 +the 0 +2 0 +regimens 0 +. 0 + +Compared 0 +to 0 +amiloride 1 +treatment 0 +, 0 +the 0 +chlorthalidone 1 +phase 0 +was 0 +associated 0 +with 0 +an 0 +increased 0 +frequency 0 +of 0 +ventricular 3 +ectopic 4 +beats 4 +( 0 +24 0 +- 0 +hour 0 +Holter 0 +monitoring 0 +) 0 +and 0 +a 0 +higher 0 +Lown 0 +grading 0 +, 0 +increased 0 +upslope 0 +and 0 +duration 0 +of 0 +the 0 +monophasic 0 +action 0 +potential 0 +, 0 +prolonged 0 +ventricular 0 +effective 0 +refractory 0 +period 0 +, 0 +and 0 +increased 0 +electrical 0 +instability 0 +during 0 +programmed 0 +ventricular 0 +stimulation 0 +. 0 + +The 0 +above 0 +results 0 +indicate 0 +that 0 +because 0 +potassium 1 +- 0 +losing 0 +diuretic 0 +therapy 0 +can 0 +increase 0 +myocardial 0 +electrical 0 +excitability 0 +in 0 +patients 0 +with 0 +ischaemic 3 +heart 4 +disease 4 +, 0 +even 0 +minor 0 +falls 0 +in 0 +plasma 0 +potassium 1 +concentrations 0 +are 0 +probably 0 +best 0 +avoided 0 +in 0 +such 0 +patients 0 +. 0 + +Transketolase 0 +abnormality 0 +in 0 +tolazamide 1 +- 0 +induced 0 +Wernicke 3 +' 4 +s 4 +encephalopathy 4 +. 0 + +We 0 +studied 0 +a 0 +thiamine 1 +- 0 +dependent 0 +enzyme 0 +, 0 +transketolase 0 +, 0 +from 0 +fibroblasts 0 +of 0 +a 0 +diabetic 3 +patient 0 +who 0 +developed 0 +Wernicke 3 +' 4 +s 4 +encephalopathy 4 +when 0 +treated 0 +with 0 +tolazamide 1 +, 0 +in 0 +order 0 +to 0 +delineate 0 +if 0 +this 0 +patient 0 +also 0 +had 0 +transketolase 0 +abnormality 0 +[ 0 +high 0 +Km 0 +for 0 +thiamine 1 +pyrophosphate 2 +( 0 +TPP 1 +) 0 +] 0 +, 0 +as 0 +previously 0 +reported 0 +in 0 +postalcoholic 0 +Wernicke 3 +- 4 +Korsakoff 4 +syndrome 4 +. 0 + +In 0 +addition 0 +to 0 +this 0 +patient 0 +, 0 +we 0 +also 0 +studied 0 +this 0 +enzyme 0 +from 0 +three 0 +diabetic 3 +kindreds 0 +without 0 +any 0 +history 0 +of 0 +Wernicke 3 +' 4 +s 4 +encephalopathy 4 +and 0 +from 0 +four 0 +normal 0 +controls 0 +. 0 + +We 0 +found 0 +that 0 +the 0 +above 0 +- 0 +mentioned 0 +patient 0 +and 0 +one 0 +of 0 +the 0 +diabetic 3 +kindreds 0 +with 0 +no 0 +history 0 +of 0 +Wernicke 3 +' 4 +s 4 +encephalopathy 4 +had 0 +abnormal 0 +transketolase 0 +as 0 +determined 0 +by 0 +its 0 +Km 0 +for 0 +TPP 1 +. 0 + +These 0 +data 0 +suggest 0 +a 0 +similarity 0 +between 0 +postalcoholic 0 +Wernicke 3 +- 4 +Korsakoff 4 +syndrome 4 +and 0 +the 0 +patient 0 +with 0 +tolazamide 1 +- 0 +induced 0 +Wernicke 3 +' 4 +s 4 +encephalopathy 4 +from 0 +the 0 +standpoint 0 +of 0 +transketolase 0 +abnormality 0 +. 0 + +Bradycardia 3 +due 0 +to 0 +trihexyphenidyl 1 +hydrochloride 2 +. 0 + +A 0 +chronic 0 +schizophrenic 3 +patient 0 +was 0 +treated 0 +with 0 +an 0 +anticholinergic 0 +drug 0 +, 0 +trihexyphenidyl 1 +hydrochloride 2 +. 0 + +The 0 +patient 0 +developed 0 +, 0 +paradoxically 0 +, 0 +sinus 0 +bradycardia 3 +. 0 + +The 0 +reaction 0 +was 0 +specific 0 +to 0 +trihexyphenidyl 1 +and 0 +not 0 +to 0 +other 0 +anticholinergic 0 +drugs 0 +. 0 + +This 0 +antidyskinetic 0 +drug 0 +is 0 +widely 0 +used 0 +in 0 +clinical 0 +psychiatric 3 +practice 0 +and 0 +physicians 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +side 0 +effect 0 +. 0 + +Post 0 +- 0 +operative 0 +rigidity 3 +after 0 +fentanyl 1 +administration 0 +. 0 + +A 0 +case 0 +of 0 +thoraco 0 +- 0 +abdominal 0 +rigidity 3 +leading 0 +to 0 +respiratory 3 +failure 4 +is 0 +described 0 +in 0 +the 0 +post 0 +- 0 +operative 0 +period 0 +in 0 +an 0 +elderly 0 +patient 0 +who 0 +received 0 +a 0 +moderate 0 +dose 0 +of 0 +fentanyl 1 +. 0 + +This 0 +was 0 +successfully 0 +reversed 0 +by 0 +naloxone 1 +. 0 + +The 0 +mechanisms 0 +possibly 0 +implicated 0 +in 0 +this 0 +accident 0 +are 0 +discussed 0 +. 0 + +Anti 0 +- 0 +carcinogenic 3 +action 0 +of 0 +phenobarbital 1 +given 0 +simultaneously 0 +with 0 +diethylnitrosamine 1 +in 0 +the 0 +rat 0 +. 0 + +The 0 +present 0 +work 0 +has 0 +been 0 +planned 0 +in 0 +order 0 +to 0 +elucidate 0 +the 0 +effect 0 +of 0 +phenobarbital 1 +( 0 +PB 1 +: 0 +15 0 +mg 0 +per 0 +rat 0 +of 0 +ingested 0 +dose 0 +) 0 +on 0 +carcinogenesis 3 +when 0 +it 0 +is 0 +administered 0 +simultaneously 0 +with 0 +diethylnitrosamine 1 +( 0 +DEN 1 +: 0 +10 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +. 0 + +Wistar 0 +rats 0 +( 0 +180 0 +g 0 +) 0 +were 0 +treated 0 +by 0 +DEN 1 +alone 0 +or 0 +by 0 +DEN 1 ++ 0 +PB 1 +during 0 +2 0 +, 0 +4 0 +and 0 +6 0 +weeks 0 +according 0 +to 0 +our 0 +schedule 0 +for 0 +hepatocarcinogenesis 3 +. 0 + +After 0 +the 0 +end 0 +of 0 +the 0 +treatment 0 +, 0 +the 0 +number 0 +and 0 +the 0 +size 0 +of 0 +induced 0 +PAS 0 +positive 0 +preneoplastic 3 +foci 4 +was 0 +significantly 0 +reduced 0 +when 0 +PB 1 +was 0 +given 0 +simultaneously 0 +with 0 +DEN 1 +for 0 +4 0 +and 0 +6 0 +weeks 0 +. 0 + +The 0 +mitotic 0 +inhibition 0 +and 0 +the 0 +production 0 +of 0 +micronuclei 0 +normally 0 +observed 0 +after 0 +partial 0 +hepatectomy 0 +in 0 +DEN 1 +treated 0 +rats 0 +were 0 +also 0 +significantly 0 +decreased 0 +in 0 +DEN 1 ++ 0 +PB 1 +treated 0 +rats 0 +. 0 + +When 0 +the 0 +treatment 0 +last 0 +only 0 +2 0 +weeks 0 +, 0 +the 0 +presence 0 +of 0 +PB 1 +did 0 +not 0 +change 0 +significantly 0 +the 0 +last 0 +parameters 0 +. 0 + +In 0 +DEN 1 ++ 0 +PB 1 +treated 0 +rats 0 +, 0 +the 0 +survival 0 +was 0 +prolonged 0 +and 0 +the 0 +tumor 3 +incidence 0 +decreased 0 +as 0 +compared 0 +with 0 +the 0 +results 0 +obtained 0 +by 0 +DEN 1 +alone 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +PB 1 +, 0 +which 0 +promotes 0 +carcinogenesis 3 +when 0 +administered 0 +after 0 +the 0 +DEN 1 +treatment 0 +, 0 +reduces 0 +the 0 +carcinogen 0 +effect 0 +when 0 +given 0 +simultaneously 0 +with 0 +DEN 1 +. 0 + +This 0 +' 0 +anti 0 +- 0 +carcinogen 0 +' 0 +effect 0 +acts 0 +on 0 +the 0 +initiation 0 +as 0 +well 0 +as 0 +on 0 +the 0 +promotion 0 +of 0 +the 0 +precancerous 3 +lesions 4 +. 0 + +Biochemical 0 +investigations 0 +are 0 +in 0 +progress 0 +to 0 +obtain 0 +more 0 +information 0 +about 0 +this 0 +' 0 +paradoxical 0 +' 0 +PB 1 +effect 0 +. 0 + +Bilateral 3 +optic 4 +neuropathy 4 +due 0 +to 0 +combined 0 +ethambutol 1 +and 0 +isoniazid 1 +treatment 0 +. 0 + +The 0 +case 0 +of 0 +a 0 +40 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +who 0 +underwent 0 +an 0 +unsuccessful 0 +cadaver 0 +kidney 0 +transplantation 0 +and 0 +was 0 +treated 0 +with 0 +ethambutol 1 +and 0 +isoniazid 1 +is 0 +reported 0 +. 0 + +A 0 +bilateral 3 +retrobulbar 4 +neuropathy 4 +with 0 +an 0 +unusual 0 +central 0 +bitemporal 0 +hemianopic 0 +scotoma 3 +was 0 +found 0 +. 0 + +Ethambutol 1 +was 0 +stopped 0 +and 0 +only 0 +small 0 +improvement 0 +of 0 +the 0 +visual 0 +acuity 0 +followed 0 +. 0 + +Isoniazid 1 +was 0 +discontinued 0 +later 0 +, 0 +followed 0 +by 0 +a 0 +dramatic 0 +improvement 0 +in 0 +the 0 +visual 0 +acuity 0 +. 0 + +The 0 +hazards 0 +of 0 +optic 0 +nerve 0 +toxicity 3 +due 0 +to 0 +ethambutol 1 +are 0 +known 0 +. 0 + +We 0 +emphasize 0 +the 0 +potential 0 +danger 0 +in 0 +the 0 +use 0 +of 0 +ethambutol 1 +and 0 +isoniazid 1 +. 0 + +A 0 +prospective 0 +study 0 +of 0 +adverse 0 +reactions 0 +associated 0 +with 0 +vancomycin 1 +therapy 0 +. 0 + +A 0 +prospective 0 +evaluation 0 +of 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +vancomycin 1 +was 0 +conducted 0 +in 0 +54 0 +consecutive 0 +patients 0 +over 0 +a 0 +16 0 +- 0 +month 0 +period 0 +. 0 + +Vancomycin 1 +was 0 +curative 0 +in 0 +95 0 +% 0 +of 0 +43 0 +patients 0 +with 0 +proven 0 +infection 3 +. 0 + +Drugs 0 +were 0 +ceased 0 +in 0 +six 0 +patients 0 +because 0 +of 0 +adverse 0 +reactions 0 +; 0 +in 0 +three 0 +of 0 +these 0 +vancomycin 1 +was 0 +considered 0 +the 0 +likely 0 +cause 0 +. 0 + +Reactions 0 +included 0 +thrombophlebitis 3 +( 0 +20 0 +of 0 +54 0 +patients 0 +) 0 +, 0 +rash 3 +( 0 +4 0 +of 0 +54 0 +) 0 +, 0 +nephrotoxicity 3 +( 0 +4 0 +of 0 +50 0 +) 0 +, 0 +proteinuria 3 +( 0 +1 0 +of 0 +50 0 +) 0 +and 0 +ototoxicity 3 +( 0 +1 0 +of 0 +11 0 +patients 0 +tested 0 +by 0 +audiometry 0 +) 0 +. 0 + +Thrombophlebitis 3 +occurred 0 +only 0 +with 0 +infusion 0 +through 0 +peripheral 0 +cannulae 0 +; 0 +nephrotoxicity 3 +and 0 +ototoxicity 3 +were 0 +confined 0 +to 0 +patients 0 +receiving 0 +an 0 +aminoglycoside 1 +plus 0 +vancomycin 1 +. 0 + +We 0 +conclude 0 +that 0 +vancomycin 1 +, 0 +administered 0 +appropriately 0 +, 0 +constitutes 0 +safe 0 +, 0 +effective 0 +therapy 0 +for 0 +infections 3 +caused 0 +by 0 +susceptible 0 +bacteria 0 +. 0 + +Factors 0 +associated 0 +with 0 +nephrotoxicity 3 +and 0 +clinical 0 +outcome 0 +in 0 +patients 0 +receiving 0 +amikacin 1 +. 0 + +Data 0 +from 0 +60 0 +patients 0 +treated 0 +with 0 +amikacin 1 +were 0 +analyzed 0 +for 0 +factors 0 +associated 0 +with 0 +nephrotoxicity 3 +. 0 + +In 0 +42 0 +of 0 +these 0 +patients 0 +, 0 +data 0 +were 0 +examined 0 +for 0 +factors 0 +associated 0 +with 0 +clinical 0 +outcome 0 +. 0 + +Variables 0 +evaluated 0 +included 0 +patient 0 +weight 0 +, 0 +age 0 +, 0 +sex 0 +, 0 +serum 0 +creatinine 1 +level 0 +, 0 +creatinine 1 +clearance 0 +, 0 +duration 0 +of 0 +therapy 0 +, 0 +total 0 +dose 0 +, 0 +mean 0 +daily 0 +dose 0 +, 0 +organism 0 +minimum 0 +inhibitory 0 +concentration 0 +( 0 +MIC 0 +) 0 +, 0 +mean 0 +peak 0 +levels 0 +, 0 +mean 0 +trough 0 +levels 0 +, 0 +mean 0 +area 0 +under 0 +the 0 +serum 0 +concentration 0 +- 0 +time 0 +curve 0 +( 0 +AUC 0 +) 0 +, 0 +total 0 +AUC 0 +, 0 +mean 0 +AUC 0 +greater 0 +than 0 +MIC 0 +, 0 +total 0 +AUC 0 +greater 0 +than 0 +MIC 0 +, 0 +mean 0 +Schumacher 0 +' 0 +s 0 +intensity 0 +factor 0 +( 0 +IF 0 +) 0 +, 0 +total 0 +IF 0 +, 0 +In 0 +( 0 +mean 0 +maximum 0 +concentration 0 +[ 0 +Cmax 0 +] 0 +/ 0 +MIC 0 +) 0 +. 0 + +Model 0 +- 0 +dependent 0 +pharmacokinetic 0 +parameters 0 +were 0 +calculated 0 +by 0 +computer 0 +based 0 +on 0 +a 0 +one 0 +- 0 +compartment 0 +model 0 +. 0 + +When 0 +the 0 +parameters 0 +were 0 +examined 0 +individually 0 +, 0 +duration 0 +of 0 +therapy 0 +and 0 +total 0 +AUC 0 +correlated 0 +significantly 0 +( 0 +P 0 +less 0 +than 0 +. 0 +05 0 +) 0 +with 0 +nephrotoxicity 3 +. 0 + +In 0 +contrast 0 +, 0 +a 0 +stepwise 0 +discriminant 0 +function 0 +analysis 0 +identified 0 +only 0 +duration 0 +of 0 +therapy 0 +( 0 +P 0 +less 0 +than 0 +. 0 +001 0 +) 0 +as 0 +an 0 +important 0 +factor 0 +. 0 + +Based 0 +on 0 +this 0 +model 0 +and 0 +on 0 +Bayes 0 +' 0 +theorem 0 +, 0 +the 0 +predictive 0 +accuracy 0 +of 0 +identifying 0 +" 0 +nephrotoxic 3 +" 0 +patients 0 +increased 0 +from 0 +0 0 +. 0 +17 0 +to 0 +0 0 +. 0 +39 0 +. 0 + +When 0 +examined 0 +individually 0 +, 0 +mean 0 +IF 0 +, 0 +MIC 0 +, 0 +total 0 +dose 0 +, 0 +mean 0 +daily 0 +dose 0 +, 0 +and 0 +ln 0 +( 0 +mean 0 +Cmax 0 +/ 0 +MIC 0 +) 0 +correlated 0 +significantly 0 +( 0 +P 0 +less 0 +than 0 +. 0 +05 0 +) 0 +with 0 +cure 0 +. 0 + +In 0 +contrast 0 +, 0 +a 0 +simultaneous 0 +multivariable 0 +analysis 0 +identified 0 +IF 0 +, 0 +MIC 0 +, 0 +and 0 +total 0 +dose 0 +according 0 +to 0 +one 0 +model 0 +and 0 +ln 0 +( 0 +mean 0 +Cmax 0 +/ 0 +MIC 0 +) 0 +according 0 +to 0 +a 0 +second 0 +statistical 0 +model 0 +of 0 +parameters 0 +selected 0 +to 0 +have 0 +the 0 +greatest 0 +prospective 0 +value 0 +. 0 + +Based 0 +on 0 +Bayes 0 +' 0 +theorem 0 +and 0 +the 0 +first 0 +model 0 +, 0 +the 0 +predictive 0 +accuracy 0 +of 0 +identifying 0 +patients 0 +not 0 +cured 0 +increased 0 +from 0 +0 0 +. 0 +19 0 +to 0 +0 0 +. 0 +83 0 +. 0 + +For 0 +the 0 +second 0 +model 0 +, 0 +the 0 +predictive 0 +accuracy 0 +increased 0 +from 0 +0 0 +. 0 +19 0 +to 0 +0 0 +. 0 +50 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Cardiac 3 +toxicity 4 +of 0 +5 1 +- 2 +fluorouracil 2 +. 0 + +Report 0 +of 0 +a 0 +case 0 +of 0 +spontaneous 0 +angina 3 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +patient 0 +with 0 +colon 3 +carcinoma 4 +and 0 +liver 0 +metastasis 3 +who 0 +presented 0 +chest 3 +pain 4 +after 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +administration 0 +. 0 + +Clinical 0 +electrocardiographic 0 +evolution 0 +was 0 +similar 0 +to 0 +that 0 +observed 0 +in 0 +Prinzmetal 3 +' 4 +s 4 +angina 4 +, 0 +and 0 +chest 3 +pain 4 +promptly 0 +resolved 0 +with 0 +nifedipine 1 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +coronary 3 +spasm 4 +may 0 +be 0 +the 0 +cause 0 +of 0 +cardiotoxicity 3 +due 0 +to 0 +5 1 +- 2 +FU 2 +, 0 +and 0 +that 0 +calcium 1 +antagonists 0 +may 0 +probably 0 +be 0 +used 0 +in 0 +the 0 +prevention 0 +or 0 +treatment 0 +of 0 +5 1 +- 2 +FU 2 +cardiotoxicity 3 +. 0 + +Dose 0 +- 0 +related 0 +beneficial 0 +and 0 +adverse 0 +effects 0 +of 0 +dietary 0 +corticosterone 1 +on 0 +organophosphorus 1 +- 0 +induced 0 +delayed 0 +neuropathy 3 +in 0 +chickens 0 +. 0 + +Tri 1 +- 2 +ortho 2 +- 2 +tolyl 2 +phosphate 2 +( 0 +T0TP 1 +) 0 +, 0 +360 0 +mg 0 +/ 0 +kg 0 +, 0 +po 0 +, 0 +and 0 +0 1 +, 2 +0 2 +' 2 +- 2 +diisopropyl 2 +phosphorofluoridate 2 +( 0 +DFP 1 +) 0 +, 0 +1 0 +mg 0 +/ 0 +kg 0 +sc 0 +, 0 +were 0 +administered 0 +to 0 +adult 0 +White 0 +Leghorn 0 +chickens 0 +24 0 +hr 0 +after 0 +they 0 +were 0 +placed 0 +on 0 +diets 0 +containing 0 +0 0 +to 0 +300 0 +ppm 0 +corticosterone 1 +. 0 + +Supplemented 0 +diets 0 +were 0 +continued 0 +until 0 +clinical 0 +signs 0 +and 0 +lesions 0 +of 0 +delayed 0 +neuropathy 3 +appeared 0 +. 0 + +Although 0 +low 0 +concentrations 0 +( 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +50 0 +ppm 0 +) 0 +of 0 +corticosterone 1 +had 0 +beneficial 0 +effects 0 +on 0 +T0TP 1 +- 0 +induced 0 +neuropathy 3 +, 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +200 0 +ppm 0 +exacerbated 0 +clinical 0 +signs 0 +in 0 +chickens 0 +given 0 +either 0 +T0TP 1 +or 0 +DFP 1 +. 0 + +Neurotoxic 3 +esterase 0 +activities 0 +24 0 +hr 0 +after 0 +T0TP 1 +or 0 +DFP 1 +were 0 +less 0 +than 0 +20 0 +% 0 +of 0 +values 0 +measured 0 +in 0 +chickens 0 +not 0 +given 0 +organophosphorous 1 +compounds 0 +. 0 + +Chickens 0 +given 0 +200 0 +ppm 0 +corticosterone 1 +without 0 +T0TP 1 +or 0 +DFP 1 +had 0 +significantly 0 +elevated 0 +activity 0 +of 0 +plasma 0 +cholinesterase 0 +and 0 +significantly 0 +inhibited 0 +activity 0 +of 0 +liver 0 +carboxylesterase 0 +. 0 + +Degenerating 3 +myelinated 4 +fibers 4 +were 0 +also 0 +evident 0 +in 0 +distal 0 +levels 0 +of 0 +the 0 +peripheral 0 +nerves 0 +of 0 +chickens 0 +given 0 +T0TP 1 +or 0 +DFP 1 +. 0 + +Hepatotoxicity 3 +of 0 +amiodarone 1 +. 0 + +Amiodarone 1 +has 0 +proved 0 +very 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +otherwise 0 +resistant 0 +cardiac 0 +tachyarrhythmias 3 +. 0 + +The 0 +use 0 +of 0 +amiodarone 1 +has 0 +, 0 +however 0 +, 0 +been 0 +limited 0 +due 0 +to 0 +its 0 +serious 0 +side 0 +- 0 +effects 0 +. 0 + +A 0 +patient 0 +with 0 +cholestatic 3 +hepatitis 4 +due 0 +to 0 +amiodarone 1 +treatment 0 +is 0 +presented 0 +below 0 +and 0 +a 0 +review 0 +of 0 +the 0 +hepatotoxicity 3 +of 0 +amiodarone 1 +is 0 +given 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +solid 0 +evidence 0 +exists 0 +of 0 +hepatic 3 +injury 4 +due 0 +to 0 +amiodarone 1 +treatment 0 +, 0 +including 0 +steatosis 3 +, 0 +alterations 0 +resembling 0 +alcoholic 3 +hepatitis 4 +, 0 +cholestatic 3 +hepatitis 4 +and 0 +micronodular 0 +cirrhosis 3 +of 4 +the 4 +liver 4 +. 0 + +Patients 0 +receiving 0 +amiodarone 1 +should 0 +be 0 +regularly 0 +screened 0 +with 0 +respect 0 +to 0 +hepatic 0 +enzyme 0 +levels 0 +. 0 + +Therapy 0 +should 0 +be 0 +discontinued 0 +on 0 +the 0 +suspicion 0 +of 0 +cholestatic 3 +injury 4 +or 0 +hepatomegaly 3 +. 0 + +Promotional 0 +effects 0 +of 0 +testosterone 1 +and 0 +dietary 0 +fat 0 +on 0 +prostate 0 +carcinogenesis 3 +in 0 +genetically 0 +susceptible 0 +rats 0 +. 0 + +Germfree 0 +( 0 +GF 0 +) 0 +Lobund 0 +strain 0 +Wistar 0 +( 0 +LW 0 +) 0 +rats 0 +, 0 +fed 0 +vegetable 0 +diet 0 +L 0 +- 0 +485 0 +, 0 +have 0 +developed 0 +prostate 3 +adenocarcinomas 4 +spontaneously 0 +( 0 +10 0 +% 0 +incidence 0 +) 0 +at 0 +average 0 +age 0 +34 0 +months 0 +. 0 + +Conventional 0 +LW 0 +rats 0 +, 0 +implanted 0 +with 0 +testosterone 1 +at 0 +age 0 +4 0 +months 0 +, 0 +developed 0 +a 0 +higher 0 +incidence 0 +of 0 +prostate 3 +cancer 4 +after 0 +an 0 +average 0 +interval 0 +of 0 +14 0 +months 0 +: 0 +24 0 +% 0 +had 0 +developed 0 +gross 0 +tumors 3 +, 0 +and 0 +40 0 +% 0 +when 0 +it 0 +included 0 +microscopic 0 +tumors 3 +. 0 + +Preliminary 0 +results 0 +indicate 0 +that 0 +testosterone 1 +- 0 +treated 0 +LW 0 +rats 0 +that 0 +were 0 +fed 0 +the 0 +same 0 +diet 0 +, 0 +which 0 +was 0 +supplemented 0 +with 0 +corn 0 +oil 0 +up 0 +to 0 +20 0 +% 0 +fat 0 +, 0 +developed 0 +prostate 3 +cancer 4 +after 0 +intervals 0 +of 0 +6 0 +- 0 +12 0 +months 0 +. 0 + +Aged 0 +GF 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +rats 0 +have 0 +not 0 +developed 0 +prostate 3 +cancer 4 +spontaneously 0 +. 0 + +Conventional 0 +SD 0 +rats 0 +fed 0 +diet 0 +L 0 +- 0 +485 0 +and 0 +treated 0 +with 0 +testosterone 1 +developed 0 +only 0 +prostatitis 3 +. 0 + +Experimental 0 +designs 0 +should 0 +consider 0 +genetic 0 +susceptibility 0 +as 0 +a 0 +basic 0 +prerequisite 0 +for 0 +studies 0 +on 0 +experimental 0 +prostate 3 +cancer 4 +. 0 + +Time 0 +course 0 +alterations 0 +of 0 +QTC 0 +interval 0 +due 0 +to 0 +hypaque 1 +76 2 +. 0 + +Sequential 0 +measurement 0 +of 0 +QT 0 +interval 0 +during 0 +left 0 +ventricular 0 +angiography 0 +was 0 +made 0 +30 0 +seconds 0 +and 0 +one 0 +, 0 +three 0 +, 0 +five 0 +and 0 +ten 0 +minutes 0 +after 0 +injection 0 +of 0 +hypaque 1 +76 2 +. 0 + +The 0 +subjects 0 +were 0 +ten 0 +patients 0 +found 0 +to 0 +have 0 +normal 0 +left 0 +ventricles 0 +and 0 +coronary 0 +arteries 0 +. 0 + +Significant 0 +QTC 3 +prolongation 4 +occurred 0 +in 0 +30 0 +seconds 0 +to 0 +one 0 +minute 0 +in 0 +association 0 +with 0 +marked 0 +hypotension 3 +and 0 +elevation 0 +of 0 +cardiac 0 +output 0 +. 0 + +Rat 0 +extraocular 0 +muscle 0 +regeneration 0 +. 0 + +Repair 0 +of 0 +local 0 +anesthetic 0 +- 0 +induced 0 +damage 0 +. 0 + +Local 0 +anesthetics 0 +that 0 +are 0 +commonly 0 +used 0 +in 0 +ophthalmic 0 +surgery 0 +( 0 +0 0 +. 0 +75 0 +% 0 +bupivacaine 1 +hydrochloride 2 +, 0 +2 0 +. 0 +0 0 +% 0 +mepivacaine 1 +hydrochloride 2 +, 0 +and 0 +2 0 +. 0 +0 0 +% 0 +lidocaine 1 +hydrochloride 2 +plus 0 +1 0 +: 0 +100 0 +, 0 +000 0 +epinephrine 1 +) 0 +were 0 +injected 0 +into 0 +the 0 +retrobulbar 0 +area 0 +of 0 +rat 0 +eyes 0 +. 0 + +Controls 0 +were 0 +injected 0 +with 0 +physiological 0 +saline 0 +. 0 + +All 0 +three 0 +anesthetics 0 +produced 0 +massive 0 +degeneration 0 +of 0 +the 0 +extraocular 0 +muscles 0 +. 0 + +Muscle 3 +degeneration 4 +is 0 +followed 0 +by 0 +regeneration 0 +of 0 +the 0 +damaged 0 +muscle 0 +fibers 0 +. 0 + +In 0 +addition 0 +to 0 +muscle 3 +damage 4 +, 0 +severe 0 +damage 0 +was 0 +also 0 +seen 0 +in 0 +harderian 0 +glands 0 +, 0 +especially 0 +after 0 +exposure 0 +to 0 +mepivacaine 1 +and 0 +lidocaine 1 +plus 0 +epinephrine 1 +. 0 + +With 0 +these 0 +findings 0 +in 0 +rats 0 +, 0 +it 0 +is 0 +hypothesized 0 +that 0 +the 0 +temporary 0 +diplopia 3 +sometimes 0 +seen 0 +in 0 +patients 0 +after 0 +ophthalmic 0 +surgery 0 +might 0 +be 0 +due 0 +to 0 +anesthetic 0 +- 0 +induced 0 +damage 0 +to 0 +the 0 +extraocular 0 +muscles 0 +. 0 + +Gentamicin 1 +nephropathy 3 +in 0 +a 0 +neonate 0 +. 0 + +The 0 +clinical 0 +and 0 +autopsy 0 +findings 0 +in 0 +a 0 +premature 0 +baby 0 +who 0 +died 0 +of 0 +acute 3 +renal 4 +failure 4 +after 0 +therapy 0 +with 0 +gentamicin 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +and 0 +penicillin 1 +are 0 +presented 0 +. 0 + +The 0 +serum 0 +gentamicin 1 +concentration 0 +had 0 +reached 0 +toxic 0 +levels 0 +when 0 +anuria 3 +developed 0 +. 0 + +Numerous 0 +periodic 1 +acid 2 +Schiff 0 +( 0 +PAS 0 +) 0 +positive 0 +, 0 +diastase 0 +resistant 0 +cytoplasmic 0 +inclusion 0 +bodies 0 +which 0 +appeared 0 +as 0 +myelin 0 +figures 0 +in 0 +cytosegresomes 0 +under 0 +the 0 +electron 0 +microscope 0 +were 0 +identified 0 +in 0 +the 0 +proximal 0 +convoluted 0 +tubules 0 +. 0 + +The 0 +pathological 0 +changes 0 +induced 0 +by 0 +gentamicin 1 +in 0 +the 0 +human 0 +neonatal 0 +kidneys 0 +have 0 +not 0 +been 0 +previously 0 +reported 0 +. 0 + +Induction 0 +by 0 +paracetamol 1 +of 0 +bladder 3 +and 4 +liver 4 +tumours 4 +in 0 +the 0 +rat 0 +. 0 + +Effects 0 +on 0 +hepatocyte 0 +fine 0 +structure 0 +. 0 + +Groups 0 +of 0 +male 0 +and 0 +female 0 +inbred 0 +Leeds 0 +strain 0 +rats 0 +were 0 +fed 0 +diets 0 +containing 0 +either 0 +0 0 +. 0 +5 0 +% 0 +or 0 +1 0 +. 0 +0 0 +% 0 +paracetamol 1 +by 0 +weight 0 +for 0 +up 0 +to 0 +18 0 +months 0 +. 0 + +At 0 +the 0 +1 0 +. 0 +0 0 +% 0 +dosage 0 +level 0 +, 0 +20 0 +% 0 +of 0 +rats 0 +of 0 +both 0 +sexes 0 +developed 0 +neoplastic 0 +nodules 0 +of 0 +the 0 +liver 0 +, 0 +a 0 +statistically 0 +significant 0 +incidence 0 +. 0 + +These 0 +rats 0 +also 0 +showed 0 +gross 0 +enlargement 0 +of 0 +their 0 +livers 0 +and 0 +an 0 +increase 0 +in 0 +foci 0 +of 0 +cellular 0 +alteration 0 +, 0 +the 0 +latter 0 +also 0 +being 0 +observed 0 +in 0 +the 0 +low 0 +dosage 0 +male 0 +rats 0 +. 0 + +Papillomas 3 +of 0 +the 0 +transitional 0 +epithelium 0 +of 0 +the 0 +bladder 0 +developed 0 +in 0 +all 0 +paracetamol 1 +- 0 +treated 0 +groups 0 +, 0 +and 0 +three 0 +rats 0 +bore 0 +bladder 3 +carcinomas 4 +. 0 + +However 0 +, 0 +significant 0 +yields 0 +of 0 +bladder 3 +tumours 4 +were 0 +only 0 +obtained 0 +from 0 +low 0 +dosage 0 +females 0 +and 0 +high 0 +dosage 0 +males 0 +. 0 + +Additionally 0 +, 0 +20 0 +to 0 +25 0 +% 0 +of 0 +paracetamol 1 +- 0 +treated 0 +rats 0 +developed 0 +hyperplasia 3 +of 0 +the 0 +bladder 0 +epithelium 0 +, 0 +which 0 +was 0 +not 0 +coincident 0 +with 0 +the 0 +presence 0 +of 0 +bladder 3 +calculi 4 +. 0 + +A 0 +low 0 +yield 0 +of 0 +tumours 3 +at 0 +various 0 +other 0 +sites 0 +also 0 +arose 0 +following 0 +paracetamol 1 +feeding 0 +. 0 + +An 0 +electron 0 +microscope 0 +study 0 +of 0 +the 0 +livers 0 +of 0 +paracetamol 1 +- 0 +treated 0 +rats 0 +revealed 0 +ultrastructural 0 +changes 0 +in 0 +the 0 +hepatocytes 0 +that 0 +resemble 0 +those 0 +that 0 +result 0 +from 0 +exposure 0 +to 0 +a 0 +variety 0 +of 0 +known 0 +hepatocarcinogens 3 +. 0 + +Transient 0 +hemiparesis 3 +: 0 +a 0 +rare 0 +manifestation 0 +of 0 +diphenylhydantoin 1 +toxicity 3 +. 0 + +Report 0 +of 0 +two 0 +cases 0 +. 0 + +Among 0 +the 0 +common 0 +side 0 +effects 0 +of 0 +diphenylhydantoin 1 +( 0 +DPH 1 +) 0 +overdose 3 +, 0 +the 0 +most 0 +frequently 0 +encountered 0 +neurological 0 +signs 0 +are 0 +those 0 +of 0 +cerebellar 3 +dysfunction 4 +. 0 + +Very 0 +rarely 0 +, 0 +the 0 +toxic 0 +neurological 0 +manifestations 0 +of 0 +this 0 +drug 0 +are 0 +of 0 +cerebral 0 +origin 0 +. 0 + +Two 0 +patients 0 +are 0 +presented 0 +who 0 +suffered 0 +progressive 0 +hemiparesis 3 +due 0 +to 0 +DPH 1 +overdose 3 +. 0 + +Both 0 +had 0 +brain 0 +surgery 0 +before 0 +DPH 1 +treatment 0 +. 0 + +It 0 +is 0 +assumed 0 +that 0 +patients 0 +with 0 +some 0 +cerebral 3 +damage 4 +are 0 +liable 0 +to 0 +manifest 0 +DPH 1 +toxicity 3 +as 0 +focal 0 +neurological 0 +signs 0 +. 0 + +Tiapride 1 +in 0 +levodopa 1 +- 0 +induced 0 +involuntary 3 +movements 4 +. 0 + +Tiapride 1 +, 0 +a 0 +substituted 0 +benzamide 1 +derivative 0 +closely 0 +related 0 +to 0 +metoclopramide 1 +, 0 +reduced 0 +levodopa 1 +- 0 +induced 0 +peak 0 +dose 0 +involuntary 3 +movements 4 +in 0 +16 0 +patients 0 +with 0 +idiopathic 3 +Parkinson 4 +' 4 +s 4 +disease 4 +. 0 + +However 0 +, 0 +an 0 +unacceptable 0 +increase 0 +in 0 +disability 0 +from 0 +Parkinsonism 3 +with 0 +aggravation 0 +of 0 +end 0 +- 0 +of 0 +- 0 +dose 0 +akinesia 3 +led 0 +to 0 +its 0 +cessation 0 +in 0 +14 0 +patients 0 +. 0 + +Tiapride 1 +had 0 +no 0 +effect 0 +on 0 +levodopa 1 +- 0 +induced 0 +early 0 +morning 0 +of 0 +" 0 +off 0 +- 0 +period 0 +" 0 +segmental 0 +dystonia 3 +. 0 + +These 0 +results 0 +fail 0 +to 0 +support 0 +the 0 +notion 0 +that 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +are 0 +caused 0 +by 0 +overstimulation 0 +of 0 +a 0 +separate 0 +group 0 +of 0 +dopamine 1 +receptors 0 +. 0 + +Quinidine 1 +hepatitis 3 +. 0 + +Long 0 +- 0 +term 0 +administration 0 +of 0 +quinidine 1 +was 0 +associated 0 +with 0 +persistent 0 +elevation 0 +of 0 +serum 0 +concentrations 0 +of 0 +SG0T 0 +, 0 +lactic 1 +acid 2 +dehydrogenase 0 +, 0 +and 0 +alkaline 0 +phosphatase 0 +. 0 + +Liver 0 +biopsy 0 +showed 0 +active 0 +hepatitis 3 +. 0 + +Discontinuance 0 +of 0 +quinidine 1 +therapy 0 +led 0 +to 0 +normalization 0 +of 0 +liver 0 +function 0 +tests 0 +. 0 + +A 0 +challenge 0 +dose 0 +of 0 +quinidine 1 +caused 0 +clinical 0 +symptoms 0 +and 0 +abrupt 0 +elevation 0 +of 0 +SG0T 0 +, 0 +alkaline 0 +phosphatase 0 +, 0 +and 0 +lactic 1 +acid 2 +dehydrogenase 0 +values 0 +. 0 + +We 0 +concluded 0 +that 0 +this 0 +patient 0 +had 0 +quinidine 1 +hepatotoxicity 3 +and 0 +believe 0 +that 0 +this 0 +is 0 +the 0 +first 0 +case 0 +reported 0 +with 0 +liver 0 +biopsy 0 +documentation 0 +. 0 + +This 0 +report 0 +also 0 +suggests 0 +that 0 +, 0 +even 0 +after 0 +long 0 +- 0 +term 0 +administration 0 +, 0 +the 0 +hepatic 3 +toxicity 4 +is 0 +reversible 0 +. 0 + +Arterial 0 +thromboembolism 3 +in 0 +patients 0 +receiving 0 +systemic 0 +heparin 1 +therapy 0 +: 0 +a 0 +complication 0 +associated 0 +with 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +. 0 + +Arterial 0 +thromboembolism 3 +is 0 +a 0 +recognized 0 +complication 0 +of 0 +systemic 0 +heparin 1 +therapy 0 +. 0 + +Characteristic 0 +of 0 +the 0 +entity 0 +is 0 +arterial 3 +occlusion 4 +by 0 +platelet 0 +- 0 +fibrin 0 +thrombi 3 +with 0 +distal 0 +ischemia 3 +occurring 0 +four 0 +to 0 +twenty 0 +days 0 +after 0 +the 0 +initiation 0 +of 0 +heparin 1 +therapy 0 +, 0 +preceded 0 +by 0 +profound 0 +thrombocytopenia 3 +with 0 +platelet 0 +counts 0 +in 0 +the 0 +range 0 +of 0 +30 0 +, 0 +000 0 +to 0 +40 0 +, 0 +000 0 +per 0 +cubic 0 +millimeter 0 +. 0 + +The 0 +clinically 0 +apparent 0 +occlusion 0 +may 0 +be 0 +preceded 0 +by 0 +gastrointestinal 3 +and 4 +musculoskeletal 4 +symptoms 4 +that 0 +appear 0 +to 0 +be 0 +ischemic 3 +in 0 +origin 0 +, 0 +and 0 +might 0 +serve 0 +to 0 +warn 0 +the 0 +clinician 0 +of 0 +these 0 +complications 0 +. 0 + +Previous 0 +reports 0 +of 0 +these 0 +phenomena 0 +as 0 +well 0 +as 0 +recent 0 +studies 0 +of 0 +the 0 +effect 0 +of 0 +heparin 1 +are 0 +reviewed 0 +. 0 + +The 0 +common 0 +factor 0 +relating 0 +thromboembolism 3 +and 0 +thrombocytopenia 3 +is 0 +heparin 1 +- 0 +induced 0 +platelet 3 +aggregation 4 +. 0 + +Appropriate 0 +treatment 0 +consists 0 +of 0 +discontinuation 0 +of 0 +heparin 1 +, 0 +and 0 +anticoagulation 0 +with 0 +sodium 1 +warfarin 2 +if 0 +necessary 0 +. 0 + +Vascular 0 +procedures 0 +are 0 +performed 0 +as 0 +indicated 0 +. 0 + +Pharmacology 0 +of 0 +GYKI 1 +- 2 +41 2 +099 2 +( 0 +chlorpropanol 1 +, 0 +Tobanum 1 +) 0 +a 0 +new 0 +potent 0 +beta 0 +- 0 +adrenergic 0 +antagonist 0 +. 0 + +The 0 +compound 0 +GYKI 1 +- 2 +41 2 +099 2 +, 0 +as 0 +a 0 +beta 0 +- 0 +adrenergic 0 +antagonist 0 +, 0 +is 0 +3 0 +- 0 +8 0 +times 0 +more 0 +potent 0 +than 0 +propranolol 1 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +. 0 + +Its 0 +antiarrhythmic 0 +effectiveness 0 +surpasses 0 +that 0 +of 0 +propranolol 1 +and 0 +pindolol 1 +inhibiting 0 +the 0 +ouabain 1 +arrhythmia 3 +in 0 +dogs 0 +and 0 +cats 0 +. 0 + +GYKI 1 +- 2 +41 2 +900 2 +has 0 +a 0 +negligible 0 +cardiodepressant 0 +activity 0 +; 0 +it 0 +is 0 +not 0 +cardioselective 0 +. 0 + +The 0 +compound 0 +shows 0 +a 0 +rapid 0 +and 0 +long 0 +lasting 0 +effect 0 +. 0 + +There 0 +was 0 +a 0 +prolonged 0 +elimination 0 +of 0 +the 0 +radioactivity 0 +after 0 +the 0 +injection 0 +of 0 +14C 1 +- 2 +41 2 +099 2 +to 0 +rats 0 +and 0 +dogs 0 +. 0 + +The 0 +half 0 +life 0 +of 0 +the 0 +unlabeled 0 +substance 0 +in 0 +humans 0 +was 0 +more 0 +than 0 +10 0 +hours 0 +. 0 + +Adverse 0 +reactions 0 +to 0 +bendrofluazide 1 +and 0 +propranolol 1 +for 0 +the 0 +treatment 0 +of 0 +mild 0 +hypertension 3 +. 0 + +Report 0 +of 0 +Medical 0 +Research 0 +Council 0 +Working 0 +Party 0 +on 0 +Mild 0 +to 0 +Moderate 0 +Hypertension 3 +. 0 + +Participants 0 +in 0 +the 0 +Medical 0 +Research 0 +Council 0 +treatment 0 +trial 0 +for 0 +mild 0 +hypertension 3 +are 0 +randomly 0 +allocated 0 +to 0 +one 0 +of 0 +four 0 +treatment 0 +groups 0 +: 0 +bendrofluazide 1 +, 0 +propranolol 1 +, 0 +or 0 +a 0 +placebo 0 +for 0 +either 0 +of 0 +these 0 +drugs 0 +. 0 + +The 0 +trial 0 +is 0 +single 0 +- 0 +blind 0 +. 0 + +23 0 +582 0 +patient 0 +- 0 +years 0 +of 0 +observation 0 +have 0 +been 0 +completed 0 +so 0 +far 0 +, 0 +10 0 +684 0 +on 0 +active 0 +drugs 0 +and 0 +12 0 +898 0 +on 0 +placebos 0 +. 0 + +The 0 +results 0 +show 0 +an 0 +association 0 +between 0 +bendrofluazide 1 +treatment 0 +and 0 +impotence 3 +, 0 +and 0 +impotence 3 +also 0 +occurred 0 +more 0 +frequently 0 +in 0 +patients 0 +taking 0 +propranolol 1 +than 0 +in 0 +those 0 +taking 0 +placebos 0 +. 0 + +0ther 0 +adverse 0 +reactions 0 +significantly 0 +linked 0 +with 0 +active 0 +drugs 0 +include 0 +impaired 3 +glucose 4 +tolerance 4 +in 0 +men 0 +and 0 +women 0 +and 0 +gout 3 +in 0 +men 0 +, 0 +associated 0 +with 0 +bendrofluazide 1 +treatment 0 +, 0 +and 0 +Raynaud 3 +' 4 +s 4 +phenomenon 4 +and 0 +dyspnoea 3 +in 0 +men 0 +and 0 +women 0 +taking 0 +propranolol 1 +. 0 + +No 0 +corneal 3 +disease 4 +is 0 +known 0 +to 0 +have 0 +occurred 0 +in 0 +the 0 +propranolol 1 +group 0 +. 0 + +Mean 0 +serum 0 +potassium 1 +level 0 +fell 0 +, 0 +and 0 +urea 1 +and 0 +uric 1 +acid 2 +levels 0 +rose 0 +, 0 +in 0 +men 0 +and 0 +women 0 +taking 0 +bendrofluazide 1 +. 0 + +In 0 +the 0 +propranolol 1 +group 0 +, 0 +serum 0 +potassium 1 +and 0 +uric 1 +acid 2 +levels 0 +rose 0 +in 0 +both 0 +sexes 0 +, 0 +but 0 +the 0 +urea 1 +level 0 +rose 0 +significantly 0 +in 0 +women 0 +only 0 +. 0 + +Serotonergic 0 +drugs 0 +, 0 +benzodiazepines 1 +and 0 +baclofen 1 +block 0 +muscimol 1 +- 0 +induced 0 +myoclonic 3 +jerks 4 +in 0 +a 0 +strain 0 +of 0 +mice 0 +. 0 + +In 0 +male 0 +Swiss 0 +mice 0 +, 0 +muscimol 1 +produced 0 +myoclonic 3 +jerks 4 +. 0 + +A 0 +3 0 +mg 0 +/ 0 +kg 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +dose 0 +induced 0 +this 0 +response 0 +in 0 +all 0 +of 0 +the 0 +mice 0 +tested 0 +and 0 +the 0 +peak 0 +response 0 +of 0 +73 0 +jerks 0 +per 0 +min 0 +was 0 +observed 0 +between 0 +27 0 +and 0 +45 0 +min 0 +. 0 + +Increasing 0 +the 0 +brain 0 +serotonin 1 +levels 0 +by 0 +the 0 +administration 0 +of 0 +5 1 +- 2 +hydroxytryptophan 2 +( 0 +80 0 +- 0 +160 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +combination 0 +with 0 +a 0 +peripheral 0 +decarboxylase 0 +inhibitor 0 +resulted 0 +in 0 +an 0 +inhibition 0 +of 0 +the 0 +muscimol 1 +effect 0 +. 0 + +However 0 +, 0 +in 0 +a 0 +similar 0 +experiment 0 +l 1 +- 2 +dopa 2 +( 0 +80 0 +- 0 +160 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +without 0 +effect 0 +. 0 + +In 0 +doses 0 +of 0 +3 0 +- 0 +10 0 +mg 0 +/ 0 +kg 0 +, 0 +the 0 +serotonin 1 +receptor 0 +agonist 0 +MK 1 +- 2 +212 2 +caused 0 +a 0 +dose 0 +- 0 +dependent 0 +blockade 0 +of 0 +the 0 +response 0 +of 0 +muscimol 1 +. 0 + +0f 0 +the 0 +benzodiazepines 1 +, 0 +clonazepam 1 +( 0 +0 0 +. 0 +1 0 +- 0 +0 0 +. 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +found 0 +to 0 +be 0 +several 0 +fold 0 +more 0 +potent 0 +than 0 +diazepam 1 +( 0 +0 0 +. 0 +3 0 +- 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +blocking 0 +the 0 +myoclonic 3 +jerks 4 +. 0 + +While 0 +( 0 +- 0 +) 0 +- 0 +baclofen 1 +( 0 +1 0 +- 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +proved 0 +to 0 +be 0 +an 0 +effective 0 +antagonist 0 +of 0 +muscimol 1 +, 0 +its 0 +( 0 ++ 0 +) 0 +- 0 +isomer 0 +( 0 +5 0 +- 0 +20 0 +mg 0 +/ 0 +kg 0 +) 0 +lacked 0 +this 0 +property 0 +. 0 + +Considering 0 +the 0 +fact 0 +that 0 +5 1 +- 2 +HTP 2 +and 0 +the 0 +benzodiazepines 1 +have 0 +been 0 +found 0 +to 0 +be 0 +beneficial 0 +in 0 +the 0 +management 0 +of 0 +clinical 0 +myoclonus 3 +, 0 +the 0 +muscimol 1 +- 0 +induced 0 +myoclonus 3 +seems 0 +to 0 +be 0 +a 0 +satisfactory 0 +animal 0 +model 0 +that 0 +may 0 +prove 0 +useful 0 +for 0 +the 0 +development 0 +of 0 +new 0 +drug 0 +treatments 0 +for 0 +this 0 +condition 0 +. 0 + +0ur 0 +present 0 +study 0 +indicated 0 +the 0 +possible 0 +value 0 +of 0 +MK 1 +- 2 +212 2 +and 0 +( 0 +- 0 +) 0 +- 0 +baclofen 1 +in 0 +the 0 +management 0 +of 0 +clinical 0 +myoclonus 3 +. 0 + +Adverse 0 +interaction 0 +between 0 +beta 1 +- 2 +adrenergic 2 +blocking 2 +drugs 2 +and 0 +verapamil 1 +- 0 +- 0 +report 0 +of 0 +three 0 +cases 0 +. 0 + +Three 0 +patients 0 +with 0 +ischaemic 3 +heart 4 +disease 4 +developed 0 +profound 0 +cardiac 3 +failure 4 +, 0 +hypotension 3 +and 0 +bradycardia 3 +during 0 +combined 0 +therapy 0 +with 0 +verapamil 1 +and 0 +beta 1 +- 2 +adrenergic 2 +blocking 2 +drugs 2 +. 0 + +This 0 +clinical 0 +picture 0 +resolved 0 +completely 0 +with 0 +cessation 0 +of 0 +the 0 +combined 0 +therapy 0 +. 0 + +Baseline 0 +left 0 +ventricular 0 +function 0 +, 0 +assessed 0 +by 0 +cardiac 0 +catheterisation 0 +or 0 +nuclear 0 +angiography 0 +, 0 +was 0 +normal 0 +in 0 +two 0 +patients 0 +and 0 +only 0 +mildly 0 +reduced 0 +in 0 +the 0 +other 0 +. 0 + +Simultaneously 0 +administration 0 +of 0 +beta 1 +- 2 +adrenergic 2 +blocking 2 +drugs 2 +and 0 +verapamil 1 +may 0 +result 0 +in 0 +profound 0 +adverse 0 +interactions 0 +and 0 +should 0 +only 0 +be 0 +administered 0 +with 0 +great 0 +caution 0 +. 0 + +Comparison 0 +of 0 +the 0 +effectiveness 0 +of 0 +ranitidine 1 +and 0 +cimetidine 1 +in 0 +inhibiting 0 +acid 0 +secretion 0 +in 0 +patients 0 +with 0 +gastric 0 +hypersecretory 0 +states 0 +. 0 + +The 0 +H2 0 +- 0 +histamine 1 +receptor 0 +antagonists 0 +ranitidine 1 +and 0 +cimetidine 1 +were 0 +compared 0 +for 0 +their 0 +abilities 0 +to 0 +control 0 +gastric 0 +acid 0 +hypersecretion 0 +on 0 +a 0 +short 0 +- 0 +and 0 +long 0 +- 0 +term 0 +basis 0 +in 0 +22 0 +patients 0 +with 0 +gastric 0 +acid 0 +hypersecretory 0 +states 0 +. 0 + +Nineteen 0 +patients 0 +had 0 +Zollinger 3 +- 4 +Ellison 4 +syndrome 4 +, 0 +one 0 +patient 0 +had 0 +systemic 3 +mastocytosis 4 +, 0 +and 0 +two 0 +patients 0 +had 0 +idiopathic 0 +hypersecretion 0 +. 0 + +The 0 +rates 0 +of 0 +onset 0 +of 0 +the 0 +action 0 +of 0 +cimetidine 1 +and 0 +ranitidine 1 +were 0 +the 0 +same 0 +. 0 + +The 0 +actions 0 +of 0 +both 0 +drugs 0 +were 0 +increased 0 +by 0 +anticholinergic 0 +agents 0 +, 0 +and 0 +there 0 +was 0 +a 0 +close 0 +correlation 0 +between 0 +the 0 +daily 0 +maintenance 0 +dose 0 +of 0 +each 0 +drug 0 +needed 0 +to 0 +control 0 +acid 0 +secretion 0 +. 0 + +However 0 +, 0 +ranitidine 1 +was 0 +threefold 0 +more 0 +potent 0 +than 0 +cimetidine 1 +both 0 +in 0 +acute 0 +inhibition 0 +studies 0 +and 0 +in 0 +the 0 +median 0 +maintenance 0 +dose 0 +needed 0 +( 0 +1 0 +. 0 +2 0 +g 0 +per 0 +day 0 +for 0 +ranitidine 1 +and 0 +3 0 +. 0 +6 0 +g 0 +per 0 +day 0 +for 0 +cimetidine 1 +) 0 +. 0 + +Sixty 0 +percent 0 +of 0 +the 0 +males 0 +developed 0 +breast 0 +changes 0 +or 0 +impotence 3 +while 0 +taking 0 +cimetidine 1 +and 0 +in 0 +all 0 +cases 0 +these 0 +changes 0 +disappeared 0 +when 0 +cimetidine 1 +was 0 +replaced 0 +by 0 +ranitidine 1 +. 0 + +Treatment 0 +with 0 +high 0 +doses 0 +of 0 +cimetidine 1 +( 0 +one 0 +to 0 +60 0 +months 0 +; 0 +median 0 +, 0 +11 0 +months 0 +) 0 +or 0 +ranitidine 1 +( 0 +two 0 +to 0 +31 0 +months 0 +; 0 +median 0 +, 0 +14 0 +months 0 +) 0 +was 0 +not 0 +associated 0 +with 0 +hepatic 3 +or 4 +hematologic 4 +toxicity 4 +or 0 +alterations 0 +of 0 +serum 0 +gastrin 0 +concentrations 0 +, 0 +but 0 +ranitidine 1 +therapy 0 +was 0 +associated 0 +with 0 +a 0 +significantly 0 +lower 0 +serum 0 +creatinine 1 +level 0 +than 0 +seen 0 +with 0 +cimetidine 1 +therapy 0 +. 0 + +The 0 +results 0 +show 0 +that 0 +both 0 +drugs 0 +can 0 +adequately 0 +inhibit 0 +acid 0 +secretion 0 +in 0 +patients 0 +with 0 +gastric 0 +hypersecretory 0 +states 0 +. 0 + +Both 0 +are 0 +safe 0 +at 0 +high 0 +doses 0 +, 0 +but 0 +ranitidine 1 +is 0 +threefold 0 +more 0 +potent 0 +and 0 +does 0 +not 0 +cause 0 +the 0 +antiandrogen 0 +side 0 +effects 0 +frequently 0 +seen 0 +with 0 +high 0 +doses 0 +of 0 +cimetidine 1 +. 0 + +Epileptogenic 0 +properties 0 +of 0 +enflurane 1 +and 0 +their 0 +clinical 0 +interpretation 0 +. 0 + +Three 0 +cases 0 +of 0 +EEG 0 +changes 0 +induced 0 +by 0 +single 0 +exposure 0 +to 0 +enflurane 1 +anesthesia 0 +are 0 +reported 0 +. 0 + +In 0 +one 0 +patient 0 +, 0 +enflurane 1 +administered 0 +during 0 +a 0 +donor 0 +nephrectomy 0 +resulted 0 +in 0 +unexpected 0 +partial 0 +motor 0 +seizures 3 +. 0 + +Until 0 +the 0 +cause 0 +of 0 +the 0 +seizures 3 +was 0 +correctly 0 +identified 0 +, 0 +the 0 +patient 0 +was 0 +inappropriately 0 +treated 0 +with 0 +anticonvulsants 0 +. 0 + +Two 0 +other 0 +patients 0 +suffered 0 +from 0 +partial 0 +, 0 +complex 0 +and 0 +generalized 0 +seizures 3 +uncontrolled 0 +by 0 +medication 0 +. 0 + +Epileptic 3 +foci 0 +delineated 0 +and 0 +activated 0 +by 0 +enflurane 1 +were 0 +surgically 0 +ablated 0 +and 0 +the 0 +patients 0 +are 0 +now 0 +seizure 3 +- 0 +free 0 +. 0 + +Previous 0 +exposures 0 +to 0 +enflurane 1 +have 0 +to 0 +be 0 +disclosed 0 +to 0 +avoid 0 +mistakes 0 +in 0 +clinical 0 +interpretation 0 +of 0 +the 0 +EEG 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +enflurane 1 +may 0 +prove 0 +to 0 +be 0 +a 0 +safe 0 +fast 0 +acting 0 +activator 0 +of 0 +epileptic 3 +foci 0 +during 0 +corticography 0 +or 0 +depth 0 +electrode 0 +intraoperative 0 +recordings 0 +. 0 + +Development 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +cardiac 3 +hypertrophy 4 +. 0 + +The 0 +development 0 +of 0 +cardiac 3 +hypertrophy 4 +was 0 +studied 0 +in 0 +adult 0 +female 0 +Wistar 0 +rats 0 +following 0 +daily 0 +subcutaneous 0 +injections 0 +of 0 +isoproterenol 1 +( 0 +IS0 1 +) 0 +( 0 +0 0 +. 0 +3 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +. 0 + +A 0 +time 0 +course 0 +was 0 +established 0 +for 0 +the 0 +change 0 +in 0 +tissue 0 +mass 0 +, 0 +RNA 0 +and 0 +DNA 0 +content 0 +, 0 +as 0 +well 0 +as 0 +hydroxyproline 1 +content 0 +. 0 + +Heart 0 +weight 0 +increased 0 +44 0 +% 0 +after 0 +8 0 +days 0 +of 0 +treatment 0 +with 0 +a 0 +half 0 +time 0 +of 0 +3 0 +. 0 +4 0 +days 0 +. 0 + +Ventricular 0 +RNA 0 +content 0 +was 0 +elevated 0 +26 0 +% 0 +after 0 +24 0 +h 0 +of 0 +a 0 +single 0 +injection 0 +and 0 +reached 0 +a 0 +maximal 0 +level 0 +following 0 +8 0 +days 0 +of 0 +therapy 0 +. 0 + +The 0 +half 0 +time 0 +for 0 +RNA 0 +accumulation 0 +was 0 +2 0 +. 0 +0 0 +days 0 +. 0 + +The 0 +total 0 +content 0 +of 0 +hydroxyproline 1 +remained 0 +stable 0 +during 0 +the 0 +first 0 +2 0 +days 0 +of 0 +treatment 0 +but 0 +increased 0 +46 0 +% 0 +after 0 +4 0 +days 0 +of 0 +therapy 0 +. 0 + +Ventricular 0 +DNA 0 +content 0 +was 0 +unchanged 0 +during 0 +the 0 +early 0 +stage 0 +( 0 +1 0 +- 0 +4 0 +days 0 +) 0 +of 0 +hypertrophic 3 +growth 0 +but 0 +increased 0 +to 0 +a 0 +new 0 +steady 0 +- 0 +state 0 +level 0 +19 0 +% 0 +above 0 +the 0 +controls 0 +after 0 +8 0 +days 0 +of 0 +treatment 0 +. 0 + +Intraventricular 0 +pressures 0 +and 0 +coronary 0 +flow 0 +measures 0 +were 0 +similar 0 +for 0 +control 0 +and 0 +experimental 0 +animals 0 +following 0 +4 0 +days 0 +of 0 +developed 0 +hypertrophy 3 +. 0 + +However 0 +, 0 +dP 0 +/ 0 +dt 0 +in 0 +the 0 +IS0 1 +- 0 +treated 0 +hearts 0 +was 0 +slightly 0 +but 0 +significantly 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +elevated 0 +. 0 + +These 0 +data 0 +indicate 0 +that 0 +the 0 +adaptive 0 +response 0 +to 0 +IS0 1 +shows 0 +an 0 +early 0 +hypertrophic 3 +phase 0 +( 0 +1 0 +- 0 +4 0 +days 0 +) 0 +characterized 0 +by 0 +a 0 +substantial 0 +increase 0 +in 0 +RNA 0 +content 0 +and 0 +cardiac 0 +mass 0 +in 0 +the 0 +absence 0 +of 0 +changes 0 +in 0 +DNA 0 +. 0 + +However 0 +, 0 +prolonged 0 +stimulation 0 +( 0 +8 0 +- 0 +12 0 +days 0 +) 0 +appears 0 +to 0 +represent 0 +a 0 +complex 0 +integration 0 +of 0 +both 0 +cellular 0 +hypertrophy 3 +and 0 +hyperplasia 3 +within 0 +the 0 +heart 0 +. 0 + +Multiple 0 +side 0 +effects 0 +of 0 +penicillamine 1 +therapy 0 +in 0 +one 0 +patient 0 +with 0 +rheumatoid 3 +arthritis 4 +. 0 + +Skin 3 +rashes 4 +, 0 +proteinuria 3 +, 0 +systemic 3 +lupus 4 +erythematosus 4 +, 0 +polymyositis 3 +and 0 +myasthenia 3 +gravis 4 +have 0 +all 0 +been 0 +recorded 0 +as 0 +complications 0 +of 0 +penicillamine 1 +therapy 0 +in 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +. 0 + +A 0 +patient 0 +who 0 +had 0 +developed 0 +all 0 +5 0 +is 0 +now 0 +described 0 +. 0 + +The 0 +skin 3 +lesion 4 +resembled 0 +elastosis 3 +perforans 4 +serpiginosa 4 +, 0 +which 0 +has 0 +been 0 +reported 0 +as 0 +a 0 +rare 0 +side 0 +effect 0 +in 0 +patients 0 +with 0 +Wilson 3 +' 4 +s 4 +disease 4 +but 0 +not 0 +in 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +treated 0 +with 0 +penicillamine 1 +. 0 + +0bsolete 0 +but 0 +dangerous 0 +antacid 0 +preparations 0 +. 0 + +0ne 0 +case 0 +of 0 +acute 0 +hypercalcaemia 3 +and 0 +two 0 +of 0 +recurrent 0 +nephrolithiasis 3 +are 0 +reported 0 +in 0 +patients 0 +who 0 +had 0 +regularly 0 +consumed 0 +large 0 +amounts 0 +of 0 +calcium 1 +carbon 2 +- 2 +ate 2 +- 0 +sodium 1 +bicarbonate 2 +powders 0 +for 0 +more 0 +than 0 +20 0 +years 0 +. 0 + +The 0 +powders 0 +had 0 +been 0 +obtained 0 +from 0 +pharmacists 0 +unknown 0 +to 0 +the 0 +patients 0 +' 0 +medical 0 +practitioners 0 +. 0 + +It 0 +is 0 +suggested 0 +that 0 +these 0 +preparations 0 +were 0 +responsible 0 +for 0 +the 0 +patient 0 +' 0 +s 0 +problems 0 +, 0 +and 0 +that 0 +such 0 +powders 0 +should 0 +no 0 +longer 0 +be 0 +freely 0 +obtainable 0 +. 0 + +Doxorubicin 1 +cardiomyopathy 3 +in 0 +children 0 +with 0 +left 0 +- 0 +sided 0 +Wilms 3 +tumor 4 +. 0 + +Two 0 +children 0 +with 0 +Wilms 3 +tumor 4 +of 0 +the 0 +left 0 +kidney 0 +experienced 0 +severe 0 +anthracycline 1 +cardiomyopathy 3 +after 0 +irradiation 0 +to 0 +the 0 +tumor 3 +bed 0 +and 0 +conventional 0 +dosage 0 +of 0 +doxorubicin 1 +. 0 + +The 0 +cardiomyopathy 3 +is 0 +attributed 0 +1 0 +) 0 +to 0 +the 0 +fact 0 +that 0 +radiation 0 +fields 0 +for 0 +left 0 +Wilms 3 +tumor 4 +include 0 +the 0 +lower 0 +portion 0 +of 0 +the 0 +heart 0 +and 0 +2 0 +) 0 +to 0 +the 0 +interaction 0 +of 0 +doxorubicin 1 +and 0 +irradiation 0 +on 0 +cardiac 0 +muscle 0 +. 0 + +It 0 +is 0 +recommended 0 +that 0 +doxorubicin 1 +dosage 0 +be 0 +sharply 0 +restricted 0 +in 0 +children 0 +with 0 +Wilms 3 +tumor 4 +of 0 +the 0 +left 0 +kidney 0 +who 0 +receive 0 +postoperative 0 +irradiation 0 +. 0 + +Effects 0 +of 0 +calcitonin 0 +on 0 +rat 0 +extrapyramidal 0 +motor 0 +system 0 +: 0 +behavioral 0 +and 0 +biochemical 0 +data 0 +. 0 + +The 0 +effects 0 +of 0 +i 0 +. 0 +v 0 +. 0 +c 0 +. 0 +injection 0 +of 0 +human 0 +and 0 +salmon 0 +calcitonin 0 +on 0 +biochemical 0 +and 0 +behavioral 0 +parameters 0 +related 0 +to 0 +the 0 +extrapyramidal 0 +motor 0 +system 0 +, 0 +were 0 +investigated 0 +in 0 +male 0 +rats 0 +. 0 + +Calcitonin 0 +injection 0 +resulted 0 +in 0 +a 0 +potentiation 0 +of 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +and 0 +a 0 +partial 0 +prevention 0 +of 0 +apomorphine 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +Moreover 0 +calcitonin 0 +induced 0 +a 0 +significant 0 +decrease 0 +in 0 +nigral 0 +GAD 0 +activity 0 +but 0 +no 0 +change 0 +in 0 +striatal 0 +DA 1 +and 0 +D0PAC 1 +concentration 0 +or 0 +GAD 0 +activity 0 +. 0 + +The 0 +results 0 +are 0 +discussed 0 +in 0 +view 0 +of 0 +a 0 +primary 0 +action 0 +of 0 +calcitonin 0 +on 0 +the 0 +striatonigral 0 +GABAergic 0 +pathway 0 +mediating 0 +the 0 +DA 1 +- 0 +related 0 +behavioral 0 +messages 0 +of 0 +striatal 0 +origin 0 +. 0 + +Naloxazone 1 +pretreatment 0 +modifies 0 +cardiorespiratory 0 +, 0 +temperature 0 +, 0 +and 0 +behavioral 0 +effects 0 +of 0 +morphine 1 +. 0 + +Behavioral 0 +and 0 +cardiorespiratory 0 +responses 0 +to 0 +a 0 +lethal 0 +dose 0 +of 0 +morphine 1 +were 0 +evaluated 0 +in 0 +rats 0 +pretreated 0 +with 0 +saline 0 +or 0 +naloxazone 1 +, 0 +an 0 +antagonist 0 +of 0 +high 0 +- 0 +affinity 0 +mu 0 +1 0 +opioid 0 +receptors 0 +. 0 + +Pretreatment 0 +with 0 +naloxazone 1 +significantly 0 +blocked 0 +morphine 1 +analgesia 3 +, 0 +catalepsy 3 +and 0 +hypothermia 3 +at 0 +a 0 +dose 0 +which 0 +completely 0 +eliminated 0 +high 0 +- 0 +affinity 0 +binding 0 +in 0 +brain 0 +membranes 0 +. 0 + +Moreover 0 +, 0 +naloxazone 1 +significantly 0 +attenuated 0 +the 0 +morphine 1 +- 0 +induced 0 +hypotension 3 +and 0 +respiratory 3 +depression 4 +, 0 +whereas 0 +morphine 1 +- 0 +induced 0 +bradycardia 3 +was 0 +less 0 +affected 0 +. 0 + +Results 0 +indicate 0 +that 0 +subpopulations 0 +of 0 +mu 0 +receptors 0 +may 0 +mediate 0 +selective 0 +behavioral 0 +and 0 +cardiorespiratory 0 +responses 0 +to 0 +morphine 1 +. 0 + +Modification 0 +of 0 +drug 0 +action 0 +by 0 +hyperammonemia 3 +. 0 + +Pretreatment 0 +with 0 +ammonium 1 +acetate 2 +( 0 +NH4Ac 1 +) 0 +( 0 +6 0 +mmol 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +approximately 0 +doubled 0 +the 0 +time 0 +morphine 1 +- 0 +treated 0 +mice 0 +remained 0 +on 0 +a 0 +hot 0 +surface 0 +and 0 +similarly 0 +increased 0 +muscular 0 +incoordination 3 +by 0 +diazepam 1 +, 0 +but 0 +NH4Ac 1 +treatment 0 +alone 0 +had 0 +no 0 +effect 0 +. 0 + +Thus 0 +, 0 +hyperammonemia 3 +is 0 +capable 0 +of 0 +altering 0 +drug 0 +action 0 +and 0 +must 0 +be 0 +considered 0 +along 0 +with 0 +impaired 0 +drug 0 +metabolism 0 +in 0 +enhanced 0 +drug 0 +responses 0 +associated 0 +with 0 +liver 3 +disease 4 +. 0 + +Experiments 0 +in 0 +vitro 0 +showed 0 +that 0 +acetylcholine 1 +- 0 +induced 0 +catecholamine 1 +release 0 +from 0 +bovine 0 +adrenal 0 +medulla 0 +is 0 +depressed 0 +as 0 +much 0 +as 0 +50 0 +% 0 +by 0 +0 0 +. 0 +3 0 +mM 0 +NH4Ac 1 +and 0 +KCl 1 +- 0 +induced 0 +contractions 0 +of 0 +guinea 0 +- 0 +pig 0 +ileum 0 +were 0 +inhibited 0 +20 0 +% 0 +by 0 +5 0 +mM 0 +NH4Ac 1 +. 0 + +Addition 0 +of 0 +excess 0 +calcium 1 +reversed 0 +the 0 +depression 3 +in 0 +both 0 +tissues 0 +, 0 +but 0 +calcium 1 +- 0 +independent 0 +catecholamine 1 +release 0 +by 0 +acetaldehyde 1 +was 0 +not 0 +blocked 0 +by 0 +NH4Ac 1 +. 0 + +These 0 +results 0 +suggested 0 +that 0 +ammonia 1 +blocks 0 +calcium 1 +channels 0 +. 0 + +Parallels 0 +in 0 +the 0 +actions 0 +of 0 +NH4Ac 1 +and 0 +the 0 +calcium 1 +channel 0 +blocker 0 +verapamil 1 +support 0 +this 0 +concept 0 +. 0 + +Both 0 +verapamil 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +NH4Ac 1 +pretreatment 0 +enhanced 0 +morphine 1 +analgesia 3 +- 0 +and 0 +diazepam 1 +- 0 +induced 0 +muscular 0 +incoordination 3 +and 0 +antagonized 0 +amphetamine 1 +- 0 +induced 0 +motor 0 +activity 0 +, 0 +and 0 +neither 0 +verapamil 1 +nor 0 +NH4Ac 1 +affected 0 +the 0 +convulsant 0 +action 0 +of 0 +metrazol 1 +. 0 + +The 0 +data 0 +suggest 0 +that 0 +hyperammonemia 3 +exerts 0 +a 0 +calcium 1 +channel 0 +blocking 0 +action 0 +which 0 +enhances 0 +the 0 +effects 0 +of 0 +central 0 +nervous 0 +system 0 +depressants 0 +and 0 +certain 0 +opioid 0 +analgesics 0 +. 0 + +Levodopa 1 +- 0 +induced 0 +dyskinesia 3 +and 0 +thalamotomy 0 +. 0 + +Levodopa 1 +- 0 +induced 0 +dyskinesia 3 +of 0 +the 0 +limbs 0 +in 0 +thirteen 0 +cases 0 +of 0 +Parkinsonism 3 +, 0 +which 0 +was 0 +choreic 0 +, 0 +ballistic 0 +or 0 +dystonic 3 +in 0 +type 0 +, 0 +was 0 +alleviated 0 +almost 0 +completely 0 +by 0 +stereotaxic 0 +surgery 0 +using 0 +a 0 +microelectrode 0 +technique 0 +for 0 +the 0 +ventralis 0 +oralis 0 +anterior 0 +and 0 +posterior 0 +nuclei 0 +of 0 +the 0 +thalamus 0 +, 0 +but 0 +much 0 +less 0 +by 0 +the 0 +ventralis 0 +intermedius 0 +nucleus 0 +. 0 + +Control 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +by 0 +thalamic 3 +lesions 4 +in 0 +the 0 +course 0 +of 0 +routine 0 +treatment 0 +of 0 +Parkinsonism 3 +is 0 +discussed 0 +. 0 + +Treatment 0 +of 0 +ifosfamide 1 +- 0 +induced 0 +urothelial 3 +toxicity 4 +by 0 +oral 0 +administration 0 +of 0 +sodium 1 +2 2 +- 2 +mercaptoethane 2 +sulphonate 2 +( 0 +MESNA 1 +) 0 +to 0 +patients 0 +with 0 +inoperable 0 +lung 3 +cancer 4 +. 0 + +The 0 +protective 0 +effect 0 +of 0 +oral 0 +administration 0 +of 0 +the 0 +thiol 1 +compound 0 +sodium 1 +2 2 +- 2 +mercaptoethane 2 +sulphonate 2 +( 0 +MESNA 1 +) 0 +against 0 +urothelial 3 +toxicity 4 +induced 0 +by 0 +ifosfamide 1 +( 0 +IF 1 +) 0 +was 0 +tested 0 +in 0 +a 0 +group 0 +of 0 +45 0 +patients 0 +with 0 +inoperable 0 +lung 3 +cancer 4 +under 0 +treatment 0 +with 0 +IF 1 +( 0 +2250 0 +mg 0 +/ 0 +m2 0 +on 0 +days 0 +2 0 +- 0 +5 0 +) 0 +as 0 +part 0 +of 0 +a 0 +polychemotherapy 0 +regimen 0 +repeated 0 +in 0 +a 0 +4 0 +- 0 +week 0 +cycle 0 +. 0 + +MESNA 1 +was 0 +given 0 +orally 0 +on 0 +the 0 +days 0 +of 0 +treatment 0 +with 0 +IF 1 +in 0 +3 0 +doses 0 +of 0 +840 0 +mg 0 +/ 0 +m2 0 +, 0 +each 0 +administered 0 +at 0 +0 0 +hr 0 +( 0 += 0 +injection 0 +of 0 +IF 1 +) 0 +, 0 +4 0 +hr 0 +and 0 +8 0 +hr 0 +p 0 +. 0 +i 0 +. 0 + +0ut 0 +of 0 +a 0 +total 0 +of 0 +88 0 +courses 0 +of 0 +this 0 +treatment 0 +we 0 +observed 0 +10 0 +episodes 0 +of 0 +asymptomatic 0 +microscopic 0 +haematuria 3 +and 0 +no 0 +episodes 0 +of 0 +gross 0 +haematuria 3 +. 0 + +In 0 +this 0 +group 0 +of 0 +45 0 +patients 0 +under 0 +protection 0 +with 0 +MESNA 1 +there 0 +were 0 +5 0 +complete 0 +remissions 0 +and 0 +9 0 +partial 0 +remissions 0 +( 0 +total 0 +31 0 +% 0 +) 0 +. 0 + +A 0 +further 0 +group 0 +of 0 +25 0 +patients 0 +under 0 +polychemotherapy 0 +with 0 +IF 1 +were 0 +treated 0 +by 0 +conventional 0 +prophylactic 0 +measures 0 +( 0 +raised 0 +fluid 0 +intake 0 +and 0 +forced 0 +diuresis 0 +) 0 +. 0 + +In 0 +this 0 +group 0 +there 0 +were 0 +1 0 +complete 0 +and 0 +5 0 +partial 0 +remissions 0 +( 0 +total 0 +24 0 +% 0 +) 0 +, 0 +but 0 +nearly 0 +all 0 +patients 0 +developed 0 +either 0 +gross 0 +haematuria 3 +and 0 +/ 0 +or 0 +symptoms 0 +of 0 +bladder 3 +irritation 4 +( 0 +cystitis 3 +and 0 +pollakisuria 3 +) 0 +. 0 + +There 0 +were 0 +no 0 +appreciable 0 +differences 0 +between 0 +the 0 +MESNA 1 +series 0 +and 0 +the 0 +conventional 0 +prophylaxis 0 +series 0 +with 0 +respect 0 +to 0 +either 0 +haematological 0 +or 0 +systemic 0 +toxicity 3 +of 0 +the 0 +cytostatic 0 +treatment 0 +. 0 + +0ur 0 +results 0 +support 0 +the 0 +view 0 +that 0 +MESNA 1 +, 0 +given 0 +orally 0 +in 0 +conjunction 0 +with 0 +combined 0 +cytostatic 0 +regimens 0 +which 0 +include 0 +IF 1 +, 0 +simplifies 0 +the 0 +treatment 0 +and 0 +provides 0 +optimum 0 +protection 0 +for 0 +the 0 +urinary 0 +epithelium 0 +. 0 + +Protection 0 +with 0 +oral 0 +MESNA 1 +is 0 +particularly 0 +suitable 0 +for 0 +outpatients 0 +. 0 + +Myoclonic 3 +, 4 +atonic 4 +, 4 +and 4 +absence 4 +seizures 4 +following 0 +institution 0 +of 0 +carbamazepine 1 +therapy 0 +in 0 +children 0 +. 0 + +Five 0 +children 0 +, 0 +aged 0 +3 0 +to 0 +11 0 +years 0 +, 0 +treated 0 +with 0 +carbamazepine 1 +for 0 +epilepsy 3 +, 0 +had 0 +an 0 +acute 0 +aberrant 0 +reaction 0 +characterized 0 +by 0 +the 0 +onset 0 +of 0 +myoclonic 3 +, 4 +atypical 4 +absence 4 +and 4 +/ 4 +or 4 +atonic 4 +( 4 +minor 4 +motor 4 +) 4 +seizures 4 +within 0 +a 0 +few 0 +days 0 +. 0 + +When 0 +the 0 +carbamazepine 1 +was 0 +discontinued 0 +, 0 +two 0 +of 0 +the 0 +children 0 +returned 0 +to 0 +their 0 +former 0 +state 0 +very 0 +quickly 0 +, 0 +two 0 +had 0 +the 0 +minor 0 +motor 0 +seizures 3 +resolve 0 +in 0 +3 0 +and 0 +6 0 +months 0 +, 0 +and 0 +one 0 +had 0 +the 0 +seizures 3 +persist 0 +. 0 + +The 0 +child 0 +in 0 +whom 0 +the 0 +seizures 3 +persisted 0 +was 0 +later 0 +found 0 +to 0 +have 0 +ceroid 3 +lipofuscinosis 4 +. 0 + +The 0 +other 0 +children 0 +are 0 +doing 0 +well 0 +on 0 +other 0 +anticonvulsants 0 +. 0 + +Effect 0 +of 0 +prostaglandin 1 +synthetase 0 +inhibitors 0 +on 0 +experimentally 0 +induced 0 +convulsions 3 +in 0 +rats 0 +. 0 + +To 0 +investigate 0 +the 0 +relationship 0 +of 0 +prostaglandins 1 +( 0 +PGs 1 +) 0 +to 0 +seizure 3 +induction 0 +, 0 +the 0 +effects 0 +of 0 +six 0 +PG 0 +synthetase 0 +inhibitors 0 +on 0 +convulsions 3 +induced 0 +by 0 +flurothyl 1 +, 0 +picrotoxin 1 +, 0 +pentetrazol 1 +( 0 +PTZ 1 +) 0 +, 0 +electroshock 0 +or 0 +bicuculline 1 +were 0 +evaluated 0 +. 0 + +Ibuprofen 1 +, 0 +sulindac 1 +, 0 +mefenamic 1 +acid 2 +, 0 +and 0 +low 0 +dose 0 +meclofenamic 1 +acid 2 +increased 0 +the 0 +latency 0 +- 0 +to 0 +- 0 +onset 0 +in 0 +the 0 +flurothyl 1 +and 0 +/ 0 +or 0 +PTZ 1 +models 0 +; 0 +the 0 +electroshock 0 +, 0 +picrotoxin 1 +and 0 +bicuculline 1 +models 0 +were 0 +not 0 +significantly 0 +affected 0 +by 0 +any 0 +of 0 +the 0 +pretreatment 0 +agents 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +PGs 1 +are 0 +involved 0 +in 0 +the 0 +mechanism 0 +( 0 +s 0 +) 0 +underlying 0 +fluorthyl 1 +- 0 +and 0 +PTZ 1 +- 0 +induced 0 +convulsions 3 +, 0 +but 0 +not 0 +picrotoxin 1 +- 0 +, 0 +electroshock 0 +- 0 +, 0 +or 0 +bicuculline 1 +- 0 +induced 0 +convulsions 3 +. 0 + +Acute 0 +changes 0 +of 0 +blood 0 +ammonia 1 +may 0 +predict 0 +short 0 +- 0 +term 0 +adverse 0 +effects 0 +of 0 +valproic 1 +acid 2 +. 0 + +Valproic 1 +acid 2 +( 0 +VPA 1 +) 0 +was 0 +given 0 +to 0 +24 0 +epileptic 3 +patients 0 +who 0 +were 0 +already 0 +being 0 +treated 0 +with 0 +other 0 +antiepileptic 0 +drugs 0 +. 0 + +A 0 +standardized 0 +loading 0 +dose 0 +of 0 +VPA 1 +was 0 +administered 0 +, 0 +and 0 +venous 0 +blood 0 +was 0 +sampled 0 +at 0 +0 0 +, 0 +1 0 +, 0 +2 0 +, 0 +3 0 +, 0 +and 0 +4 0 +hours 0 +. 0 + +Ammonia 1 +( 0 +NH3 1 +) 0 +was 0 +higher 0 +in 0 +patients 0 +who 0 +, 0 +during 0 +continuous 0 +therapy 0 +, 0 +complained 0 +of 0 +drowsiness 3 +( 0 +7 0 +patients 0 +) 0 +than 0 +in 0 +those 0 +who 0 +were 0 +symptom 0 +- 0 +free 0 +( 0 +17 0 +patients 0 +) 0 +, 0 +although 0 +VPA 1 +plasma 0 +levels 0 +were 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 + +By 0 +measuring 0 +VPA 1 +- 0 +induced 0 +changes 0 +of 0 +blood 0 +NH3 1 +content 0 +, 0 +it 0 +may 0 +be 0 +possible 0 +to 0 +identify 0 +patients 0 +at 0 +higher 0 +risk 0 +of 0 +obtundation 0 +when 0 +VPA 1 +is 0 +given 0 +chronically 0 +. 0 + +Effect 0 +of 0 +captopril 1 +on 0 +pre 0 +- 0 +existing 0 +and 0 +aminonucleoside 1 +- 0 +induced 0 +proteinuria 3 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +Proteinuria 3 +is 0 +a 0 +side 0 +effect 0 +of 0 +captopril 1 +treatment 0 +in 0 +hypertensive 3 +patients 0 +. 0 + +The 0 +possibility 0 +of 0 +reproducing 0 +the 0 +same 0 +renal 3 +abnormality 4 +with 0 +captopril 1 +was 0 +examined 0 +in 0 +SHR 0 +. 0 + +0ral 0 +administration 0 +of 0 +captopril 1 +at 0 +100 0 +mg 0 +/ 0 +kg 0 +for 0 +14 0 +days 0 +failed 0 +to 0 +aggravate 0 +proteinuria 3 +pre 0 +- 0 +existing 0 +in 0 +SHR 0 +. 0 + +Also 0 +, 0 +captopril 1 +treatment 0 +failed 0 +to 0 +potentiate 0 +or 0 +facilitate 0 +development 0 +of 0 +massive 0 +proteinuria 3 +invoked 0 +by 0 +puromycin 1 +aminonucleoside 2 +in 0 +SHR 0 +. 0 + +Captopril 1 +had 0 +little 0 +or 0 +no 0 +demonstrable 0 +effects 0 +on 0 +serum 0 +electrolyte 0 +concentrations 0 +, 0 +excretion 0 +of 0 +urine 0 +, 0 +sodium 1 +and 0 +potassium 1 +, 0 +endogenous 0 +creatinine 1 +clearance 0 +, 0 +body 0 +weight 0 +, 0 +and 0 +food 0 +and 0 +water 0 +consumption 0 +. 0 + +However 0 +, 0 +ketone 1 +bodies 0 +were 0 +consistently 0 +present 0 +in 0 +urine 0 +and 0 +several 0 +lethalities 0 +occurred 0 +during 0 +multiple 0 +dosing 0 +of 0 +captopril 1 +in 0 +SHR 0 +. 0 + +Complete 0 +heart 3 +block 4 +following 0 +a 0 +single 0 +dose 0 +of 0 +trazodone 1 +. 0 + +Forty 0 +minutes 0 +after 0 +receiving 0 +a 0 +single 0 +starting 0 +dose 0 +of 0 +trazodone 1 +, 0 +a 0 +patient 0 +developed 0 +complete 0 +heart 3 +block 4 +. 0 + +The 0 +case 0 +illustrates 0 +that 0 +, 0 +despite 0 +the 0 +results 0 +of 0 +earlier 0 +studies 0 +, 0 +trazodone 1 +' 0 +s 0 +effect 0 +on 0 +cardiac 0 +conduction 0 +may 0 +be 0 +severe 0 +in 0 +individuals 0 +at 0 +risk 0 +for 0 +conduction 0 +delay 0 +. 0 + +Phenobarbital 1 +- 0 +induced 0 +dyskinesia 3 +in 0 +a 0 +neurologically 3 +- 4 +impaired 4 +child 0 +. 0 + +A 0 +2 0 +- 0 +year 0 +- 0 +old 0 +child 0 +with 0 +known 0 +neurologic 3 +impairment 4 +developed 0 +a 0 +dyskinesia 3 +soon 0 +after 0 +starting 0 +phenobarbital 1 +therapy 0 +for 0 +seizures 3 +. 0 + +Known 0 +causes 0 +of 0 +movement 3 +disorders 4 +were 0 +eliminated 0 +after 0 +evaluation 0 +. 0 + +0n 0 +repeat 0 +challenge 0 +with 0 +phenobarbital 1 +, 0 +the 0 +dyskinesia 3 +recurred 0 +. 0 + +Phenobarbital 1 +should 0 +be 0 +added 0 +to 0 +the 0 +list 0 +of 0 +anticonvulsant 0 +drugs 0 +that 0 +can 0 +cause 0 +movement 3 +disorders 4 +. 0 + +Effects 0 +of 0 +amine 1 +pretreatment 0 +on 0 +ketamine 1 +catatonia 3 +in 0 +pinealectomized 0 +or 0 +hypophysectomized 0 +animals 0 +. 0 + +The 0 +present 0 +studies 0 +were 0 +designed 0 +to 0 +clarify 0 +the 0 +role 0 +of 0 +catecholamines 1 +and 0 +pineal 0 +idolamines 0 +on 0 +ketamine 1 +- 0 +induced 0 +catatonia 3 +in 0 +the 0 +intact 0 +, 0 +pinealectomized 0 +or 0 +hypophysectomized 0 +chick 0 +and 0 +rat 0 +. 0 + +In 0 +the 0 +pinealectomized 0 +chick 0 +, 0 +pretreatment 0 +with 0 +dopamine 1 +increased 0 +the 0 +duration 0 +of 0 +catatonia 3 +( 0 +D0C 0 +) 0 +after 0 +ketamine 1 +, 0 +but 0 +pretreatment 0 +with 0 +norepinephrine 1 +did 0 +not 0 +. 0 + +The 0 +pineal 0 +indolamines 0 +exhibited 0 +mixed 0 +actions 0 +. 0 + +Serotonin 1 +and 0 +N 1 +- 2 +acetyl 2 +serotonin 2 +which 0 +augmented 0 +ketamine 1 +D0C 0 +, 0 +did 0 +not 0 +do 0 +so 0 +in 0 +the 0 +absence 0 +of 0 +the 0 +pineal 0 +gland 0 +, 0 +whereas 0 +melatonin 1 +potentiated 0 +the 0 +ketamine 1 +D0C 0 +in 0 +both 0 +the 0 +intact 0 +and 0 +pinealectomized 0 +chick 0 +. 0 + +Ketamine 1 +was 0 +more 0 +potent 0 +in 0 +the 0 +hypophysectomized 0 +chick 0 +and 0 +the 0 +circadian 0 +rhythm 0 +noted 0 +in 0 +the 0 +intact 0 +chick 0 +was 0 +absent 0 +; 0 +furthermore 0 +, 0 +melatonin 1 +did 0 +not 0 +augment 0 +the 0 +ketamine 1 +D0C 0 +whereas 0 +dopamine 1 +continued 0 +to 0 +do 0 +so 0 +. 0 + +This 0 +study 0 +did 0 +not 0 +demonstrate 0 +a 0 +species 0 +difference 0 +regarding 0 +the 0 +role 0 +of 0 +the 0 +amines 1 +on 0 +the 0 +pineal 0 +in 0 +spite 0 +of 0 +the 0 +immature 0 +blood 0 +- 0 +brain 0 +barrier 0 +in 0 +the 0 +young 0 +chick 0 +and 0 +the 0 +intact 0 +barrier 0 +in 0 +the 0 +rat 0 +. 0 + +In 0 +addition 0 +, 0 +these 0 +data 0 +indicate 0 +a 0 +direct 0 +role 0 +of 0 +the 0 +pituitary 0 +in 0 +the 0 +augmentation 0 +of 0 +ketamine 1 +D0C 0 +induced 0 +by 0 +melatonin 1 +. 0 + +Furthermore 0 +, 0 +dopamine 1 +appeared 0 +to 0 +act 0 +on 0 +systems 0 +more 0 +closely 0 +involved 0 +with 0 +the 0 +induction 0 +of 0 +ketamine 1 +catatonia 3 +rather 0 +than 0 +directly 0 +on 0 +the 0 +pituitary 0 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +, 0 +thrombosis 3 +, 0 +and 0 +hemorrhage 3 +. 0 + +Sixty 0 +- 0 +two 0 +patients 0 +with 0 +a 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +are 0 +reported 0 +. 0 + +Clinical 0 +manifestations 0 +of 0 +this 0 +disorder 0 +include 0 +hemorrhage 3 +or 0 +, 0 +more 0 +frequently 0 +, 0 +thromboembolic 3 +events 0 +in 0 +patients 0 +receiving 0 +heparin 1 +. 0 + +Laboratory 0 +testing 0 +has 0 +revealed 0 +a 3 +falling 4 +platelet 4 +count 4 +, 0 +increased 0 +resistance 0 +to 0 +heparin 1 +, 0 +and 0 +aggregation 0 +of 0 +platelets 0 +by 0 +the 0 +patient 0 +' 0 +s 0 +plasma 0 +when 0 +heparin 1 +is 0 +added 0 +. 0 + +Immunologic 0 +testing 0 +has 0 +demonstrated 0 +the 0 +presence 0 +of 0 +a 0 +heparin 1 +- 0 +dependent 0 +platelet 0 +membrane 0 +antibody 0 +. 0 + +The 0 +20 0 +deaths 0 +, 0 +52 0 +hemorrhagic 3 +and 4 +thromboembolic 4 +complications 4 +, 0 +and 0 +21 0 +surgical 0 +procedures 0 +to 0 +manage 0 +the 0 +complications 0 +confirm 0 +the 0 +seriousness 0 +of 0 +the 0 +disorder 0 +. 0 + +Specific 0 +risk 0 +factors 0 +have 0 +not 0 +been 0 +identified 0 +; 0 +therefore 0 +, 0 +all 0 +patients 0 +receiving 0 +heparin 1 +should 0 +be 0 +monitored 0 +. 0 + +If 0 +the 0 +platelet 0 +count 0 +falls 0 +to 0 +less 0 +than 0 +100 0 +, 0 +000 0 +/ 0 +mm3 0 +, 0 +while 0 +the 0 +patient 0 +is 0 +receiving 0 +heparin 1 +, 0 +platelet 3 +aggregation 4 +testing 0 +, 0 +using 0 +the 0 +patient 0 +' 0 +s 0 +plasma 0 +, 0 +is 0 +indicated 0 +. 0 + +Management 0 +consists 0 +of 0 +cessation 0 +of 0 +heparin 1 +, 0 +platelet 0 +anti 0 +- 0 +aggregating 0 +agents 0 +, 0 +and 0 +alternate 0 +forms 0 +of 0 +anticoagulation 0 +when 0 +indicated 0 +. 0 + +Ventricular 3 +fibrillation 4 +from 0 +diatrizoate 1 +with 0 +and 0 +without 0 +chelating 0 +agents 0 +. 0 + +The 0 +toxicity 3 +of 0 +Renografin 1 +76 2 +% 2 +was 0 +compared 0 +with 0 +that 0 +of 0 +Hypaque 1 +76 2 +% 2 +by 0 +selective 0 +injection 0 +of 0 +each 0 +into 0 +the 0 +right 0 +coronary 0 +artery 0 +of 0 +dogs 0 +. 0 + +Renografin 1 +contains 0 +the 0 +chelating 0 +agents 0 +sodium 1 +citrate 2 +and 0 +disodium 1 +edetate 2 +, 0 +while 0 +Hypaque 1 +contains 0 +calcium 1 +disodium 2 +edetate 2 +and 0 +no 0 +sodium 1 +citrate 2 +. 0 + +Ventricular 3 +fibrillation 4 +occurred 0 +significantly 0 +more 0 +often 0 +with 0 +Renografin 1 +, 0 +suggesting 0 +that 0 +chelating 0 +agents 0 +contribute 0 +to 0 +toxicity 3 +in 0 +coronary 0 +angiography 0 +. 0 + +Long 0 +- 0 +term 0 +efficacy 0 +and 0 +toxicity 3 +of 0 +high 0 +- 0 +dose 0 +amiodarone 1 +therapy 0 +for 0 +ventricular 3 +tachycardia 4 +or 0 +ventricular 3 +fibrillation 4 +. 0 + +Amiodarone 1 +was 0 +administered 0 +to 0 +154 0 +patients 0 +who 0 +had 0 +sustained 0 +, 0 +symptomatic 0 +ventricular 3 +tachycardia 4 +( 0 +VT 3 +) 0 +( 0 +n 0 += 0 +118 0 +) 0 +or 0 +a 0 +cardiac 3 +arrest 4 +( 0 +n 0 += 0 +36 0 +) 0 +and 0 +who 0 +were 0 +refractory 0 +to 0 +conventional 0 +antiarrhythmic 0 +drugs 0 +. 0 + +The 0 +loading 0 +dose 0 +was 0 +800 0 +mg 0 +/ 0 +day 0 +for 0 +6 0 +weeks 0 +and 0 +the 0 +maintenance 0 +dose 0 +was 0 +600 0 +mg 0 +/ 0 +day 0 +. 0 + +Sixty 0 +- 0 +nine 0 +percent 0 +of 0 +patients 0 +continued 0 +treatment 0 +with 0 +amiodarone 1 +and 0 +had 0 +no 0 +recurrence 0 +of 0 +symptomatic 0 +VT 3 +or 0 +ventricular 3 +fibrillation 4 +( 0 +VF 3 +) 0 +over 0 +a 0 +follow 0 +- 0 +up 0 +of 0 +6 0 +to 0 +52 0 +months 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +standard 0 +deviation 0 +14 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +2 0 +) 0 +. 0 + +Six 0 +percent 0 +of 0 +the 0 +patients 0 +had 0 +a 0 +nonfatal 0 +recurrence 0 +of 0 +VT 3 +and 0 +were 0 +successfully 0 +managed 0 +by 0 +continuing 0 +amiodarone 1 +at 0 +a 0 +higher 0 +dose 0 +or 0 +by 0 +the 0 +addition 0 +of 0 +a 0 +conventional 0 +antiarrhythmic 0 +drug 0 +. 0 + +0ne 0 +or 0 +more 0 +adverse 0 +drug 0 +reactions 0 +occurred 0 +in 0 +51 0 +% 0 +of 0 +patients 0 +. 0 + +Adverse 0 +effects 0 +forced 0 +a 0 +reduction 0 +in 0 +the 0 +dose 0 +of 0 +amiodarone 1 +in 0 +41 0 +% 0 +and 0 +discontinuation 0 +of 0 +amiodarone 1 +in 0 +10 0 +% 0 +of 0 +patients 0 +. 0 + +The 0 +most 0 +common 0 +symptomatic 0 +adverse 0 +reactions 0 +were 0 +tremor 3 +or 0 +ataxia 3 +( 0 +35 0 +% 0 +) 0 +, 0 +nausea 3 +and 0 +anorexia 3 +( 0 +8 0 +% 0 +) 0 +, 0 +visual 3 +halos 4 +or 4 +blurring 4 +( 0 +6 0 +% 0 +) 0 +, 0 +thyroid 3 +function 4 +abnormalities 4 +( 0 +6 0 +% 0 +) 0 +and 0 +pulmonary 3 +interstitial 4 +infiltrates 4 +( 0 +5 0 +% 0 +) 0 +. 0 + +Although 0 +large 0 +- 0 +dose 0 +amiodarone 1 +is 0 +highly 0 +effective 0 +in 0 +the 0 +long 0 +- 0 +term 0 +treatment 0 +of 0 +VT 3 +or 0 +VF 3 +refractory 0 +to 0 +conventional 0 +antiarrhythmic 0 +drugs 0 +, 0 +it 0 +causes 0 +significant 0 +toxicity 3 +in 0 +approximately 0 +50 0 +% 0 +of 0 +patients 0 +. 0 + +However 0 +, 0 +when 0 +the 0 +dose 0 +is 0 +adjusted 0 +based 0 +on 0 +clinical 0 +response 0 +or 0 +the 0 +development 0 +of 0 +adverse 0 +effects 0 +, 0 +75 0 +% 0 +of 0 +patients 0 +with 0 +VT 3 +or 0 +VF 3 +can 0 +be 0 +successfully 0 +managed 0 +with 0 +amiodarone 1 +. 0 + +Why 0 +may 0 +epsilon 1 +- 2 +aminocaproic 2 +acid 2 +( 0 +EACA 1 +) 0 +induce 0 +myopathy 3 +in 0 +man 0 +? 0 + +Report 0 +of 0 +a 0 +case 0 +and 0 +literature 0 +review 0 +. 0 + +A 0 +case 0 +of 0 +necrotizing 3 +myopathy 4 +due 0 +to 0 +a 0 +short 0 +epsilon 1 +- 2 +aminocaproic 2 +acid 2 +( 0 +EACA 1 +) 0 +treatment 0 +in 0 +a 0 +72 0 +year 0 +- 0 +old 0 +patient 0 +with 0 +subarachnoid 3 +haemorrhage 4 +( 0 +SAH 3 +) 0 +is 0 +described 0 +. 0 + +Pathogenetic 0 +hypotheses 0 +are 0 +discussed 0 +. 0 + +Cerebral 3 +hemorrhage 4 +associated 0 +with 0 +phenylpropanolamine 1 +in 0 +combination 0 +with 0 +caffeine 1 +. 0 + +Phenylpropanolamine 1 +( 0 +PPA 1 +) 0 +is 0 +a 0 +drug 0 +that 0 +has 0 +been 0 +associated 0 +with 0 +serious 0 +side 0 +effects 0 +including 0 +stroke 3 +. 0 + +It 0 +is 0 +often 0 +combined 0 +with 0 +caffeine 1 +in 0 +diet 0 +preparations 0 +and 0 +" 0 +look 0 +- 0 +alike 0 +" 0 +pills 0 +. 0 + +In 0 +order 0 +to 0 +determine 0 +if 0 +PPA 1 +/ 0 +caffeine 1 +can 0 +lead 0 +to 0 +stroke 3 +in 0 +normotensive 0 +and 0 +/ 0 +or 0 +hypertensive 3 +rats 0 +, 0 +we 0 +administered 0 +the 0 +combination 0 +in 0 +six 0 +times 0 +the 0 +allowed 0 +human 0 +dose 0 +calculated 0 +on 0 +a 0 +per 0 +weight 0 +basis 0 +for 0 +the 0 +rats 0 +two 0 +times 0 +per 0 +day 0 +for 0 +five 0 +days 0 +. 0 + +Subarachnoid 3 +and 4 +cerebral 4 +hemorrhage 4 +was 0 +noted 0 +in 0 +18 0 +% 0 +of 0 +the 0 +hypertensive 3 +rats 0 +. 0 + +A 0 +single 0 +PPA 1 +/ 0 +caffeine 1 +administration 0 +( 0 +same 0 +dose 0 +) 0 +lead 0 +to 0 +acute 0 +hypertension 3 +in 0 +both 0 +the 0 +normotensive 0 +and 0 +hypertensive 3 +animals 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +PPA 1 +/ 0 +caffeine 1 +can 0 +lead 0 +to 0 +cerebral 3 +hemorrhage 4 +in 0 +previously 0 +hypertensive 3 +animals 0 +when 0 +administered 0 +in 0 +greater 0 +than 0 +the 0 +allowed 0 +dosage 0 +. 0 + +An 0 +acute 0 +elevation 0 +in 0 +blood 0 +pressure 0 +may 0 +be 0 +a 0 +contributing 0 +factor 0 +. 0 + +Renal 3 +papillary 4 +necrosis 4 +due 0 +to 0 +naproxen 1 +. 0 + +A 0 +31 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +rheumatoid 3 +arthritis 4 +, 0 +who 0 +had 0 +previously 0 +been 0 +treated 0 +with 0 +sulindac 1 +, 0 +fenoprofen 1 +calcium 2 +, 0 +high 0 +dose 0 +salicylates 1 +and 0 +gold 1 +salts 0 +, 0 +developed 0 +renal 3 +papillary 4 +necrosis 4 +( 0 +RPN 3 +) 0 +4 0 +months 0 +after 0 +institution 0 +of 0 +naproxen 1 +therapy 0 +. 0 + +No 0 +other 0 +factor 0 +predisposing 0 +to 0 +RPN 3 +could 0 +be 0 +discovered 0 +. 0 + +Sulindac 1 +was 0 +substituted 0 +for 0 +naproxen 1 +and 0 +no 0 +further 0 +adverse 0 +renal 0 +effects 0 +occurred 0 +over 0 +the 0 +next 0 +12 0 +months 0 +. 0 + +We 0 +review 0 +previous 0 +reports 0 +linking 0 +RPN 3 +to 0 +antiinflammatory 0 +drug 0 +use 0 +and 0 +discuss 0 +possible 0 +advantages 0 +of 0 +sulindac 1 +in 0 +patients 0 +who 0 +have 0 +experienced 0 +renal 3 +toxicity 4 +from 0 +other 0 +antiinflammatory 0 +agents 0 +. 0 + +Nephrotoxic 3 +effects 0 +of 0 +aminoglycoside 1 +treatment 0 +on 0 +renal 0 +protein 0 +reabsorption 0 +and 0 +accumulation 0 +. 0 + +To 0 +quantify 0 +the 0 +effects 0 +of 0 +gentamicin 1 +, 0 +kanamycin 1 +and 0 +netilmicin 1 +on 0 +renal 0 +protein 0 +reabsorption 0 +and 0 +accumulation 0 +, 0 +these 0 +drugs 0 +were 0 +administered 0 +to 0 +rats 0 +intraperitoneally 0 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +for 0 +7 0 +, 0 +14 0 +or 0 +21 0 +days 0 +. 0 + +Scanning 0 +electron 0 +microscopy 0 +of 0 +the 0 +glomerular 0 +endothelia 0 +, 0 +urinary 0 +measurements 0 +of 0 +sodium 1 +, 0 +potassium 1 +, 0 +endogenous 0 +lysozyme 0 +, 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +D 0 +- 0 +glucosaminidase 0 +( 0 +NAG 0 +) 0 +as 0 +well 0 +as 0 +clearance 0 +and 0 +accumulation 0 +experiments 0 +after 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +of 0 +egg 0 +- 0 +white 0 +lysozyme 0 +and 0 +measurements 0 +of 0 +inulin 0 +clearance 0 +( 0 +GFR 0 +) 0 +were 0 +done 0 +in 0 +each 0 +treatment 0 +group 0 +. 0 + +Gentamicin 1 +administration 0 +decreased 0 +diameter 0 +, 0 +density 0 +and 0 +shape 0 +of 0 +endothelial 0 +fenestrae 0 +. 0 + +Kanamycin 1 +and 0 +netilmicin 1 +appeared 0 +to 0 +have 0 +no 0 +effect 0 +at 0 +the 0 +dose 0 +used 0 +. 0 + +All 0 +three 0 +aminoglycosides 1 +decreased 0 +GFR 0 +and 0 +increased 0 +urinary 0 +excretion 0 +of 0 +sodium 1 +and 0 +potassium 1 +. 0 + +While 0 +gentamicin 1 +and 0 +kanamycin 1 +decreased 0 +the 0 +percentage 0 +reabsorption 0 +and 0 +accumulation 0 +of 0 +lysozyme 0 +after 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +of 0 +egg 0 +- 0 +white 0 +lysozyme 0 +netilmicin 1 +had 0 +no 0 +effect 0 +. 0 + +Daily 0 +excretion 0 +of 0 +total 0 +protein 0 +, 0 +endogenous 0 +lysozyme 0 +and 0 +NAG 0 +increased 0 +only 0 +after 0 +treatment 0 +with 0 +kanamycin 1 +and 0 +gentamicin 1 +. 0 + +Thus 0 +, 0 +aminoglycosides 1 +may 0 +act 0 +as 0 +nephrotoxicants 0 +at 0 +glomerular 0 +and 0 +/ 0 +or 0 +tubular 0 +level 0 +inducing 0 +impairment 3 +of 4 +renal 4 +reabsorption 4 +and 0 +accumulation 0 +of 0 +proteins 0 +. 0 + +Induction 0 +of 0 +the 0 +obstructive 3 +sleep 4 +apnea 4 +syndrome 4 +in 0 +a 0 +woman 0 +by 0 +exogenous 0 +androgen 1 +administration 0 +. 0 + +We 0 +documented 0 +airway 0 +occlusion 0 +during 0 +sleep 0 +and 0 +an 0 +abnormally 0 +high 0 +supraglottic 0 +resistance 0 +while 0 +awake 0 +in 0 +a 0 +54 0 +- 0 +yr 0 +- 0 +old 0 +woman 0 +who 0 +had 0 +developed 0 +physical 0 +changes 0 +and 0 +the 0 +syndrome 3 +of 4 +obstructive 4 +sleep 4 +apnea 4 +while 0 +being 0 +administered 0 +exogenous 0 +androgens 1 +. 0 + +When 0 +the 0 +androgens 1 +were 0 +withdrawn 0 +, 0 +the 0 +patient 0 +' 0 +s 0 +physical 0 +changes 0 +, 0 +symptoms 0 +, 0 +sleep 0 +study 0 +, 0 +and 0 +supraglottic 0 +resistance 0 +all 0 +returned 0 +to 0 +normal 0 +. 0 + +A 0 +rechallenge 0 +with 0 +androgen 1 +produced 0 +symptoms 0 +of 0 +obstructive 3 +sleep 4 +apnea 4 +that 0 +abated 0 +upon 0 +withdrawal 0 +of 0 +the 0 +hormone 0 +. 0 + +Previous 0 +reports 0 +have 0 +favored 0 +a 0 +role 0 +of 0 +androgens 1 +in 0 +the 0 +pathogenesis 0 +of 0 +sleep 3 +apnea 4 +. 0 + +0ur 0 +report 0 +provides 0 +direct 0 +evidence 0 +for 0 +this 0 +role 0 +. 0 + +Structural 0 +and 0 +functional 0 +measurements 0 +indicate 0 +that 0 +androgens 1 +exert 0 +a 0 +permissive 0 +or 0 +necessary 0 +action 0 +on 0 +the 0 +structural 0 +configuration 0 +of 0 +the 0 +oropharynx 0 +that 0 +predisposes 0 +to 0 +obstruction 0 +during 0 +sleep 0 +. 0 + +Development 0 +of 0 +the 0 +obstructive 3 +sleep 4 +apnea 4 +syndrome 4 +must 0 +be 0 +considered 0 +a 0 +possible 0 +side 0 +effect 0 +of 0 +androgen 1 +therapy 0 +. 0 + +Cardiotoxic 3 +and 0 +possible 0 +leukemogenic 0 +effects 0 +of 0 +adriamycin 1 +in 0 +nonhuman 0 +primates 0 +. 0 + +10 0 +monkeys 0 +( 0 +macaques 0 +) 0 +received 0 +adriamycin 1 +by 0 +monthly 0 +intravenous 0 +injections 0 +at 0 +12 0 +mg 0 +/ 0 +m2 0 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +8 0 +of 0 +the 0 +10 0 +monkeys 0 +developed 0 +congestive 3 +heart 4 +failure 4 +at 0 +an 0 +average 0 +cumulative 0 +adriamycin 1 +dose 0 +( 0 +310 0 +mg 0 +/ 0 +m2 0 +) 0 +well 0 +below 0 +that 0 +considered 0 +the 0 +safe 0 +upper 0 +limit 0 +( 0 +550 0 +mg 0 +/ 0 +m2 0 +) 0 +in 0 +man 0 +. 0 + +Histologically 0 +, 0 +the 0 +myocardial 3 +lesions 4 +resembled 0 +those 0 +found 0 +in 0 +human 0 +anthracycline 1 +- 0 +induced 0 +cardiomyopathy 3 +. 0 + +1 0 +of 0 +the 0 +10 0 +monkeys 0 +developed 0 +acute 3 +myeloblastic 4 +leukemia 4 +after 0 +receiving 0 +324 0 +mg 0 +/ 0 +m2 0 +of 0 +adriamycin 1 +; 0 +the 0 +10th 0 +monkey 0 +is 0 +alive 0 +and 0 +well 0 +26 0 +months 0 +after 0 +the 0 +last 0 +dose 0 +of 0 +drug 0 +. 0 + +0ur 0 +results 0 +suggest 0 +that 0 +adriamycin 1 +is 0 +a 0 +more 0 +potent 0 +cardiotoxin 0 +in 0 +monkeys 0 +than 0 +in 0 +man 0 +, 0 +and 0 +that 0 +leukemia 3 +may 0 +be 0 +a 0 +consequence 0 +of 0 +prolonged 0 +treatment 0 +with 0 +this 0 +drug 0 +. 0 + +Tricuspid 3 +valve 4 +regurgitation 4 +and 0 +lithium 1 +carbonate 2 +toxicity 3 +in 0 +a 0 +newborn 0 +infant 0 +. 0 + +A 0 +newborn 0 +with 0 +massive 0 +tricuspid 3 +regurgitation 4 +, 0 +atrial 3 +flutter 4 +, 0 +congestive 3 +heart 4 +failure 4 +, 0 +and 0 +a 0 +high 0 +serum 0 +lithium 1 +level 0 +is 0 +described 0 +. 0 + +This 0 +is 0 +the 0 +first 0 +patient 0 +to 0 +initially 0 +manifest 0 +tricuspid 3 +regurgitation 4 +and 0 +atrial 3 +flutter 4 +, 0 +and 0 +the 0 +11th 0 +described 0 +patient 0 +with 0 +cardiac 3 +disease 4 +among 0 +infants 0 +exposed 0 +to 0 +lithium 1 +compounds 0 +in 0 +the 0 +first 0 +trimester 0 +of 0 +pregnancy 0 +. 0 + +Sixty 0 +- 0 +three 0 +percent 0 +of 0 +these 0 +infants 0 +had 0 +tricuspid 0 +valve 0 +involvement 0 +. 0 + +Lithium 1 +carbonate 2 +may 0 +be 0 +a 0 +factor 0 +in 0 +the 0 +increasing 0 +incidence 0 +of 0 +congenital 3 +heart 4 +disease 4 +when 0 +taken 0 +during 0 +early 0 +pregnancy 0 +. 0 + +It 0 +also 0 +causes 0 +neurologic 3 +depression 4 +, 0 +cyanosis 3 +, 0 +and 0 +cardiac 3 +arrhythmia 4 +when 0 +consumed 0 +prior 0 +to 0 +delivery 0 +. 0 + +Effects 0 +of 0 +the 0 +novel 0 +compound 0 +aniracetam 1 +( 0 +Ro 1 +13 2 +- 2 +5057 2 +) 0 +upon 0 +impaired 3 +learning 4 +and 4 +memory 4 +in 0 +rodents 0 +. 0 + +The 0 +effect 0 +of 0 +aniracetam 1 +( 0 +Ro 1 +13 2 +- 2 +5057 2 +, 0 +1 1 +- 2 +anisoyl 2 +- 2 +2 2 +- 2 +pyrrolidinone 2 +) 0 +was 0 +studied 0 +on 0 +various 0 +forms 0 +of 0 +experimentally 0 +impaired 3 +cognitive 4 +functions 4 +( 0 +learning 0 +and 0 +memory 0 +) 0 +in 0 +rodents 0 +and 0 +produced 0 +the 0 +following 0 +effects 0 +: 0 +( 0 +1 0 +) 0 +almost 0 +complete 0 +prevention 0 +of 0 +the 0 +incapacity 0 +to 0 +learn 0 +a 0 +discrete 0 +escape 0 +response 0 +in 0 +rats 0 +exposed 0 +to 0 +sublethal 0 +hypercapnia 3 +immediately 0 +before 0 +the 0 +acquisition 0 +session 0 +; 0 +( 0 +2 0 +) 0 +partial 0 +( 0 +rats 0 +) 0 +or 0 +complete 0 +( 0 +mice 0 +) 0 +prevention 0 +of 0 +the 0 +scopolamine 1 +- 0 +induced 0 +short 0 +- 0 +term 0 +amnesia 3 +for 0 +a 0 +passive 0 +avoidance 0 +task 0 +; 0 +( 0 +3 0 +) 0 +complete 0 +protection 0 +against 0 +amnesia 3 +for 0 +a 0 +passive 0 +avoidance 0 +task 0 +in 0 +rats 0 +submitted 0 +to 0 +electroconvulsive 0 +shock 0 +immediately 0 +after 0 +avoidance 0 +acquisition 0 +; 0 +( 0 +4 0 +) 0 +prevention 0 +of 0 +the 0 +long 0 +- 0 +term 0 +retention 0 +- 0 +or 0 +retrieval 0 +- 0 +deficit 0 +for 0 +a 0 +passive 0 +avoidance 0 +task 0 +induced 0 +in 0 +rats 0 +and 0 +mice 0 +by 0 +chloramphenicol 1 +or 0 +cycloheximide 1 +administered 0 +immediately 0 +after 0 +acquisition 0 +; 0 +( 0 +5 0 +) 0 +reversal 0 +, 0 +when 0 +administered 0 +as 0 +late 0 +as 0 +1 0 +h 0 +before 0 +the 0 +retention 0 +test 0 +, 0 +of 0 +the 0 +deficit 0 +in 0 +retention 0 +or 0 +retrieval 0 +of 0 +a 0 +passive 0 +avoidance 0 +task 0 +induced 0 +by 0 +cycloheximide 1 +injected 0 +2 0 +days 0 +previously 0 +; 0 +( 0 +6 0 +) 0 +prevention 0 +of 0 +the 0 +deficit 0 +in 0 +the 0 +retrieval 0 +of 0 +an 0 +active 0 +avoidance 0 +task 0 +induced 0 +in 0 +mice 0 +by 0 +subconvulsant 0 +electroshock 0 +or 0 +hypercapnia 3 +applied 0 +immediately 0 +before 0 +retrieval 0 +testing 0 +( 0 +24 0 +h 0 +after 0 +acquisition 0 +) 0 +. 0 + +These 0 +improvements 0 +or 0 +normalizations 0 +of 0 +impaired 3 +cognitive 4 +functions 4 +were 0 +seen 0 +at 0 +oral 0 +aniracetam 1 +doses 0 +of 0 +10 0 +- 0 +100 0 +mg 0 +/ 0 +kg 0 +. 0 + +Generally 0 +, 0 +the 0 +dose 0 +- 0 +response 0 +curves 0 +were 0 +bell 0 +- 0 +shaped 0 +. 0 + +The 0 +mechanisms 0 +underlying 0 +the 0 +activity 0 +of 0 +aniracetam 1 +and 0 +its 0 +' 0 +therapeutic 0 +window 0 +' 0 +are 0 +unknown 0 +. 0 + +Piracetam 1 +, 0 +another 0 +pyrrolidinone 1 +derivative 0 +was 0 +used 0 +for 0 +comparison 0 +. 0 + +It 0 +was 0 +active 0 +only 0 +in 0 +six 0 +of 0 +nine 0 +tests 0 +and 0 +had 0 +about 0 +one 0 +- 0 +tenth 0 +the 0 +potency 0 +of 0 +aniracetam 1 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +aniracetam 1 +improves 0 +cognitive 0 +functions 0 +which 0 +are 0 +impaired 0 +by 0 +different 0 +procedure 0 +and 0 +in 0 +different 0 +phases 0 +of 0 +the 0 +learning 0 +and 0 +memory 0 +process 0 +. 0 + +Effect 0 +of 0 +calcium 1 +chloride 2 +on 0 +gross 0 +behavioural 0 +changes 0 +produced 0 +by 0 +carbachol 1 +and 0 +eserine 1 +in 0 +cats 0 +. 0 + +The 0 +effect 0 +of 0 +calcium 1 +chloride 2 +injected 0 +into 0 +the 0 +cerebral 0 +ventricles 0 +of 0 +group 0 +- 0 +housed 0 +unanaesthetized 0 +cats 0 +upon 0 +vocalization 0 +( 0 +rage 0 +, 0 +hissing 0 +and 0 +snarling 0 +) 0 +, 0 +fighting 0 +( 0 +attack 0 +with 0 +paws 0 +and 0 +claws 0 +, 0 +defense 0 +with 0 +paws 0 +and 0 +claws 0 +and 0 +biting 0 +) 0 +, 0 +mydriasis 3 +, 0 +tremor 3 +and 0 +clonic 3 +- 4 +tonic 4 +convulsions 4 +produced 0 +by 0 +carbachol 1 +and 0 +eserine 1 +injected 0 +similarly 0 +was 0 +investigated 0 +. 0 + +Calcium 1 +chloride 2 +depressed 0 +or 0 +almost 0 +completely 0 +abolished 0 +the 0 +vocalization 0 +and 0 +fighting 0 +due 0 +to 0 +carbachol 1 +and 0 +eserine 1 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +mydriasis 3 +, 0 +tremor 3 +and 0 +clonic 3 +- 4 +tonic 4 +convulsions 4 +evoked 0 +by 0 +carbachol 1 +and 0 +eserine 1 +were 0 +not 0 +significantly 0 +changed 0 +by 0 +calcium 1 +chloride 2 +. 0 + +It 0 +is 0 +apparent 0 +that 0 +calcium 1 +chloride 2 +can 0 +" 0 +dissociate 0 +" 0 +vocalization 0 +and 0 +fighting 0 +from 0 +autonomic 0 +and 0 +motor 0 +phenomena 0 +such 0 +as 0 +mydriasis 3 +, 0 +tremor 3 +and 0 +clonic 3 +- 4 +tonic 4 +convulsions 4 +caused 0 +by 0 +carbachol 1 +and 0 +eserine 1 +. 0 + +Calcium 1 +chloride 2 +inhibited 0 +the 0 +vocalization 0 +and 0 +fighting 0 +produced 0 +by 0 +carbachol 1 +and 0 +eserine 1 +most 0 +probably 0 +by 0 +a 0 +nonspecific 0 +stabilizing 0 +action 0 +on 0 +central 0 +muscarinic 0 +cholinoceptive 0 +sites 0 +. 0 + +These 0 +results 0 +further 0 +support 0 +the 0 +view 0 +that 0 +calcium 1 +ions 0 +in 0 +excess 0 +have 0 +an 0 +atropine 1 +- 0 +like 0 +action 0 +also 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 + +Thiazide 1 +diuretics 0 +, 0 +hypokalemia 3 +and 0 +cardiac 3 +arrhythmias 4 +. 0 + +Thiazide 1 +diuretics 0 +are 0 +widely 0 +accepted 0 +as 0 +the 0 +cornerstone 0 +of 0 +antihypertensive 0 +treatment 0 +programs 0 +. 0 + +Hypokalemia 3 +is 0 +a 0 +commonly 0 +encountered 0 +metabolic 0 +consequence 0 +of 0 +chronic 0 +thiazide 1 +therapy 0 +. 0 + +We 0 +treated 0 +38 0 +patients 0 +( 0 +22 0 +low 0 +renin 0 +, 0 +16 0 +normal 0 +renin 0 +) 0 +with 0 +moderate 0 +diastolic 3 +hypertension 4 +with 0 +hydrochlorothiazide 1 +( 0 +HCTC 1 +) 0 +administered 0 +on 0 +a 0 +twice 0 +daily 0 +schedule 0 +. 0 + +Initial 0 +dose 0 +was 0 +50 0 +mg 0 +and 0 +the 0 +dose 0 +was 0 +increased 0 +at 0 +monthly 0 +intervals 0 +to 0 +100 0 +mg 0 +, 0 +150 0 +mg 0 +and 0 +200 0 +mg 0 +daily 0 +until 0 +blood 0 +pressure 0 +normalized 0 +. 0 + +The 0 +serum 0 +K 1 +during 0 +the 0 +control 0 +period 0 +was 0 +4 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +mEq 0 +/ 0 +l 0 +an 0 +on 0 +50 0 +, 0 +100 0 +, 0 +150 0 +and 0 +200 0 +mg 0 +HCTZ 1 +daily 0 +3 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +, 0 +3 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +, 0 +2 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +, 0 +and 0 +2 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +mEq 0 +/ 0 +l 0 +, 0 +respectively 0 +. 0 + +Corresponding 0 +figures 0 +for 0 +whole 0 +body 0 +K 1 +were 0 +4107 0 ++ 0 +/ 0 +- 0 +208 0 +, 0 +3722 0 ++ 0 +/ 0 +- 0 +319 0 +, 0 +3628 0 ++ 0 +/ 0 +- 0 +257 0 +, 0 +3551 0 ++ 0 +/ 0 +- 0 +336 0 +, 0 +and 0 +3269 0 ++ 0 +/ 0 +- 0 +380 0 +mEq 0 +, 0 +respectively 0 +. 0 + +In 0 +13 0 +patients 0 +we 0 +observed 0 +the 0 +effects 0 +of 0 +HCTZ 1 +therapy 0 +( 0 +100 0 +mg 0 +daily 0 +) 0 +on 0 +the 0 +occurrence 0 +of 0 +PVC 0 +' 0 +s 0 +during 0 +rest 0 +as 0 +well 0 +as 0 +during 0 +static 0 +and 0 +dynamic 0 +exercise 0 +. 0 + +During 0 +rest 0 +we 0 +observed 0 +0 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +08 0 +PVC 0 +beats 0 +/ 0 +min 0 ++ 0 +/ 0 +- 0 +SEM 0 +and 0 +during 0 +static 0 +and 0 +dynamic 0 +exercise 0 +0 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +06 0 +and 0 +0 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +15 0 +, 0 +respectively 0 +. 0 + +Corresponding 0 +figures 0 +during 0 +HCTZ 1 +therapy 0 +100 0 +mg 0 +daily 0 +were 0 +1 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +, 0 +3 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +and 0 +5 0 +. 0 +7 0 +4 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +, 0 +respectively 0 +. 0 + +The 0 +occurrence 0 +of 0 +PVC 0 +' 0 +s 0 +correlated 0 +significantly 0 +with 0 +the 0 +fall 0 +in 0 +serum 0 +K 1 ++ 0 +observed 0 +r 0 += 0 +0 0 +. 0 +72 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +. 0 + +In 0 +conclusion 0 +we 0 +found 0 +that 0 +thiazide 1 +diuretics 0 +cause 0 +hypokalemia 3 +and 0 +depletion 0 +of 0 +body 0 +potassium 1 +. 0 + +The 0 +more 0 +profound 0 +hypokalemia 3 +, 0 +the 0 +greater 0 +the 0 +propensity 0 +for 0 +the 0 +occurrence 0 +of 0 +PVC 0 +' 0 +s 0 +. 0 + +Circulating 0 +lysosomal 0 +enzymes 0 +and 0 +acute 3 +hepatic 4 +necrosis 4 +. 0 + +The 0 +activities 0 +of 0 +the 0 +lysosomal 0 +enzymes 0 +acid 0 +and 0 +neutral 0 +protease 0 +, 0 +N 0 +- 0 +acetylglucosaminidase 0 +, 0 +and 0 +acid 0 +phosphatase 0 +were 0 +measured 0 +in 0 +the 0 +serum 0 +of 0 +patients 0 +with 0 +fulminant 3 +hepatic 4 +failure 4 +. 0 + +Acid 0 +protease 0 +( 0 +cathepsin 0 +D 0 +) 0 +activity 0 +was 0 +increased 0 +about 0 +tenfold 0 +in 0 +patients 0 +who 0 +died 0 +and 0 +nearly 0 +fourfold 0 +in 0 +those 0 +who 0 +survived 0 +fulminant 3 +hepatic 4 +failure 4 +after 0 +paracetamol 1 +overdose 3 +, 0 +whereas 0 +activities 0 +were 0 +increased 0 +equally 0 +in 0 +patients 0 +with 0 +fulminant 3 +hepatic 4 +failure 4 +due 0 +to 0 +viral 3 +hepatitis 4 +whether 0 +or 0 +not 0 +they 0 +survived 0 +. 0 + +A 0 +correlation 0 +was 0 +found 0 +between 0 +serum 0 +acid 0 +protease 0 +activity 0 +and 0 +prothrombin 0 +time 0 +, 0 +and 0 +the 0 +increase 0 +in 0 +cathepsin 0 +D 0 +activity 0 +was 0 +sustained 0 +over 0 +several 0 +days 0 +compared 0 +with 0 +aspartate 1 +aminotransferase 0 +, 0 +which 0 +showed 0 +a 0 +sharp 0 +early 0 +peak 0 +and 0 +then 0 +a 0 +fall 0 +. 0 + +Circulating 0 +lysosomal 0 +proteases 0 +can 0 +damage 0 +other 0 +organs 0 +, 0 +and 0 +measurement 0 +of 0 +their 0 +activity 0 +may 0 +therefore 0 +be 0 +of 0 +added 0 +value 0 +in 0 +assessing 0 +prognosis 0 +in 0 +this 0 +condition 0 +. 0 + +Hepatic 3 +veno 4 +- 4 +occlusive 4 +disease 4 +caused 0 +by 0 +6 1 +- 2 +thioguanine 2 +. 0 + +Clinically 0 +reversible 0 +veno 3 +- 4 +occlusive 4 +disease 4 +of 4 +the 4 +liver 4 +developed 0 +in 0 +a 0 +23 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +acute 3 +lymphocytic 4 +leukemia 4 +after 0 +10 0 +months 0 +of 0 +maintenance 0 +therapy 0 +with 0 +6 1 +- 2 +thioguanine 2 +. 0 + +Serial 0 +liver 0 +biopsies 0 +showed 0 +the 0 +development 0 +and 0 +resolution 0 +of 0 +intense 0 +sinusoidal 0 +engorgement 0 +. 0 + +Although 0 +this 0 +disease 0 +was 0 +clinically 0 +reversible 0 +, 0 +some 0 +subintimal 0 +fibrosis 3 +about 0 +the 0 +terminal 0 +hepatic 0 +veins 0 +persisted 0 +. 0 + +This 0 +case 0 +presented 0 +a 0 +unique 0 +opportunity 0 +to 0 +observe 0 +the 0 +histologic 0 +features 0 +of 0 +clinically 0 +reversible 0 +hepatic 3 +veno 4 +- 4 +occlusive 4 +disease 4 +over 0 +time 0 +, 0 +and 0 +may 0 +be 0 +the 0 +first 0 +case 0 +of 0 +veno 0 +- 0 +occlusive 0 +related 0 +solely 0 +to 0 +6 1 +- 2 +thioguanine 2 +. 0 + +Chlorpropamide 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +. 0 + +A 0 +65 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +adult 3 +- 4 +onset 4 +diabetes 4 +treated 0 +with 0 +chlorpropamide 1 +( 0 +Diabenese 1 +) 0 +had 0 +a 0 +toxic 3 +optic 4 +neuropathy 4 +that 0 +resolved 0 +with 0 +discontinuation 0 +of 0 +chlorpropamide 1 +therapy 0 +. 0 + +Visual 3 +loss 4 +occurs 0 +in 0 +diabetics 3 +for 0 +a 0 +variety 0 +of 0 +reasons 0 +, 0 +and 0 +accurate 0 +diagnosis 0 +is 0 +necessary 0 +to 0 +institute 0 +appropriate 0 +therapy 0 +. 0 + +The 0 +possibility 0 +of 0 +a 0 +drug 0 +- 0 +induced 0 +optic 3 +neuropathy 4 +should 0 +be 0 +considered 0 +in 0 +the 0 +differential 0 +diagnosis 0 +of 0 +visual 3 +loss 4 +in 0 +diabetics 3 +. 0 + +Plasma 0 +and 0 +urinary 0 +lipids 0 +and 0 +lipoproteins 0 +during 0 +the 0 +development 0 +of 0 +nephrotic 3 +syndrome 4 +induced 0 +in 0 +the 0 +rat 0 +by 0 +puromycin 1 +aminonucleoside 2 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +ascertain 0 +whether 0 +the 0 +alterations 0 +of 0 +plasma 0 +lipoproteins 0 +found 0 +in 0 +nephrotic 3 +syndrome 4 +induced 0 +by 0 +puromycin 1 +aminonucleoside 2 +were 0 +due 0 +to 0 +nephrotic 3 +syndrome 4 +per 0 +se 0 +, 0 +or 0 +, 0 +at 0 +least 0 +in 0 +part 0 +, 0 +to 0 +the 0 +aminonucleoside 1 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +changes 0 +in 0 +plasma 0 +and 0 +urinary 0 +lipoproteins 0 +during 0 +the 0 +administration 0 +of 0 +puromycin 1 +aminonucleoside 2 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +for 0 +7 0 +days 0 +) 0 +and 0 +the 0 +subsequent 0 +development 0 +of 0 +nephrotic 3 +syndrome 4 +. 0 + +Since 0 +massive 0 +albuminuria 3 +occurred 0 +after 0 +6 0 +days 0 +of 0 +treatment 0 +, 0 +the 0 +time 0 +- 0 +course 0 +study 0 +was 0 +divided 0 +into 0 +two 0 +stages 0 +: 0 +pre 0 +- 0 +nephrotic 3 +stage 0 +( 0 +day 0 +1 0 +- 0 +5 0 +) 0 +and 0 +nephrotic 3 +stage 0 +( 0 +day 0 +6 0 +- 0 +11 0 +) 0 +. 0 + +In 0 +pre 0 +- 0 +nephrotic 3 +stage 0 +the 0 +plasma 0 +level 0 +of 0 +fatty 1 +acids 2 +, 0 +triacylglycerol 1 +and 0 +VLDL 0 +decreased 0 +while 0 +that 0 +of 0 +phospholipid 0 +, 0 +cholesteryl 1 +esters 2 +and 0 +HDL 0 +remained 0 +constant 0 +. 0 + +Plasma 0 +apolipoprotein 0 +A 0 +- 0 +I 0 +tended 0 +to 0 +increase 0 +( 0 +40 0 +% 0 +increase 0 +at 0 +day 0 +5 0 +) 0 +. 0 + +At 0 +the 0 +beginning 0 +of 0 +nephrotic 3 +stage 0 +( 0 +day 0 +6 0 +) 0 +the 0 +concentration 0 +of 0 +plasma 0 +albumin 0 +dropped 0 +to 0 +a 0 +very 0 +low 0 +level 0 +, 0 +while 0 +that 0 +of 0 +apolipoprotein 0 +A 0 +- 0 +I 0 +increased 0 +abruptly 0 +( 0 +4 0 +- 0 +fold 0 +increase 0 +) 0 +and 0 +continued 0 +to 0 +rise 0 +, 0 +although 0 +less 0 +steeply 0 +, 0 +in 0 +the 0 +following 0 +days 0 +. 0 + +The 0 +plasma 0 +concentration 0 +of 0 +HDL 0 +followed 0 +the 0 +same 0 +pattern 0 +. 0 + +Plasma 0 +VLDL 0 +and 0 +LDL 0 +increased 0 +at 0 +a 0 +later 0 +stage 0 +( 0 +day 0 +9 0 +) 0 +. 0 + +Plasma 0 +apolipoprotein 0 +A 0 +- 0 +I 0 +was 0 +found 0 +not 0 +only 0 +in 0 +HDL 0 +( 0 +1 0 +. 0 +063 0 +- 0 +1 0 +. 0 +210 0 +g 0 +/ 0 +ml 0 +) 0 +but 0 +also 0 +in 0 +the 0 +LDL 0 +density 0 +class 0 +( 0 +1 0 +. 0 +025 0 +- 0 +1 0 +. 0 +050 0 +g 0 +/ 0 +ml 0 +) 0 +. 0 + +In 0 +the 0 +pre 0 +- 0 +nephrotic 3 +stage 0 +lipoproteinuria 0 +was 0 +negligible 0 +, 0 +while 0 +in 0 +the 0 +early 0 +nephrotic 3 +stage 0 +the 0 +urinary 0 +loss 0 +of 0 +plasma 0 +lipoproteins 0 +consisted 0 +mainly 0 +of 0 +HDL 0 +. 0 + +These 0 +observations 0 +indicate 0 +that 0 +puromycin 1 +aminonucleoside 2 +alters 0 +plasma 0 +lipoproteins 0 +by 0 +lowering 0 +VLDL 0 +and 0 +increasing 0 +HDL 0 +. 0 + +It 0 +is 0 +likely 0 +that 0 +the 0 +early 0 +and 0 +striking 0 +increase 0 +of 0 +plasma 0 +HDL 0 +found 0 +in 0 +nephrotic 3 +rats 0 +is 0 +related 0 +to 0 +a 0 +direct 0 +effect 0 +of 0 +the 0 +drug 0 +on 0 +HDL 0 +metabolism 0 +. 0 + +Fatal 0 +aplastic 3 +anemia 4 +following 0 +topical 0 +administration 0 +of 0 +ophthalmic 0 +chloramphenicol 1 +. 0 + +A 0 +73 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +died 0 +of 0 +aplastic 3 +anemia 4 +less 0 +than 0 +two 0 +months 0 +after 0 +undergoing 0 +cataract 3 +extraction 0 +and 0 +beginning 0 +topical 0 +therapy 0 +with 0 +chloramphenicol 1 +. 0 + +The 0 +first 0 +signs 0 +of 0 +pancytopenia 3 +began 0 +within 0 +one 0 +month 0 +of 0 +the 0 +surgery 0 +. 0 + +The 0 +pattern 0 +of 0 +the 0 +aplastic 3 +anemia 4 +was 0 +associated 0 +with 0 +an 0 +idiosyncratic 0 +response 0 +to 0 +chloramphenicol 1 +. 0 + +This 0 +was 0 +the 0 +second 0 +report 0 +of 0 +fatal 0 +aplastic 3 +anemia 4 +after 0 +topical 0 +treatment 0 +with 0 +chloramphenicol 1 +for 0 +ocular 0 +conditions 0 +, 0 +although 0 +two 0 +cases 0 +of 0 +reversible 0 +bone 3 +marrow 4 +hypoplasia 4 +have 0 +also 0 +been 0 +reported 0 +. 0 + +Any 0 +other 0 +suspected 0 +cases 0 +of 0 +ocular 3 +toxicity 4 +associated 0 +with 0 +topically 0 +applied 0 +chloramphenicol 1 +should 0 +be 0 +reported 0 +to 0 +the 0 +National 0 +Registry 0 +of 0 +Drug 0 +- 0 +Induced 0 +0cular 0 +Side 0 +Effects 0 +, 0 +0regon 0 +Health 0 +Sciences 0 +University 0 +, 0 +Portland 0 +, 0 +0R 0 +97201 0 +. 0 + +Midazolam 1 +compared 0 +with 0 +thiopentone 1 +as 0 +an 0 +induction 0 +agent 0 +. 0 + +In 0 +patients 0 +premedicated 0 +with 0 +scopolamine 1 ++ 0 +morphine 1 +( 0 ++ 0 +5 0 +mg 0 +nitrazepam 1 +the 0 +evening 0 +before 0 +surgery 0 +) 0 +, 0 +the 0 +sleep 0 +- 0 +inducing 0 +effect 0 +of 0 +midazolam 1 +0 0 +. 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +was 0 +clearly 0 +slower 0 +in 0 +onset 0 +than 0 +that 0 +of 0 +thiopentone 1 +4 0 +. 0 +67 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +Somewhat 0 +fewer 0 +cardiovascular 0 +and 0 +local 0 +sequelae 0 +were 0 +found 0 +in 0 +the 0 +midazolam 1 +group 0 +, 0 +but 0 +, 0 +although 0 +apnoea 3 +occurred 0 +less 0 +often 0 +in 0 +the 0 +midazolam 1 +group 0 +it 0 +lasted 0 +longer 0 +. 0 + +0n 0 +the 0 +whole 0 +, 0 +the 0 +differences 0 +between 0 +midazolam 1 +and 0 +thiopentone 1 +had 0 +no 0 +apparent 0 +clinical 0 +consequences 0 +. 0 + +Midazolam 1 +is 0 +a 0 +new 0 +alternative 0 +agent 0 +for 0 +induction 0 +in 0 +combination 0 +anaesthesia 0 +. 0 + +Extrapyramidal 0 +side 0 +effects 0 +and 0 +oral 0 +haloperidol 1 +: 0 +an 0 +analysis 0 +of 0 +explanatory 0 +patient 0 +and 0 +treatment 0 +characteristics 0 +. 0 + +The 0 +incidence 0 +of 0 +extrapyramidal 0 +side 0 +effects 0 +( 0 +EPS 0 +) 0 +was 0 +evaluated 0 +in 0 +98 0 +patients 0 +treated 0 +with 0 +haloperidol 1 +. 0 + +The 0 +incidence 0 +of 0 +parkinsonism 3 +was 0 +higher 0 +at 0 +higher 0 +doses 0 +of 0 +haloperidol 1 +and 0 +in 0 +younger 0 +patients 0 +. 0 + +Prophylactic 0 +antiparkinsonian 0 +medication 0 +was 0 +effective 0 +in 0 +younger 0 +but 0 +not 0 +in 0 +older 0 +patients 0 +. 0 + +However 0 +, 0 +these 0 +medications 0 +were 0 +more 0 +effective 0 +in 0 +both 0 +young 0 +and 0 +old 0 +patients 0 +when 0 +given 0 +after 0 +parkinsonism 3 +developed 0 +. 0 + +Akathisia 3 +was 0 +controlled 0 +by 0 +the 0 +benzodiazepine 1 +lorazepam 1 +in 0 +14 0 +out 0 +of 0 +16 0 +patients 0 +, 0 +while 0 +prophylactic 0 +antiparkinsonians 0 +were 0 +ineffective 0 +. 0 + +The 0 +present 0 +study 0 +points 0 +to 0 +patient 0 +characteristics 0 +that 0 +may 0 +be 0 +of 0 +significance 0 +in 0 +the 0 +development 0 +of 0 +EPS 0 +due 0 +to 0 +haloperidol 1 +. 0 + +Deaths 0 +from 0 +local 0 +anesthetic 0 +- 0 +induced 0 +convulsions 3 +in 0 +mice 0 +. 0 + +Median 0 +convulsant 0 +( 0 +CD50 0 +) 0 +and 0 +median 0 +lethal 0 +( 0 +LD50 0 +) 0 +doses 0 +of 0 +three 0 +representative 0 +local 0 +anesthetics 0 +were 0 +determined 0 +in 0 +adult 0 +mice 0 +to 0 +evaluate 0 +the 0 +threat 0 +to 0 +life 0 +of 0 +local 0 +anesthetic 0 +- 0 +induced 0 +convulsions 3 +. 0 + +The 0 +CD50 0 +and 0 +LD50 0 +, 0 +respectively 0 +, 0 +were 0 +57 0 +. 0 +7 0 +and 0 +58 0 +. 0 +7 0 +mg 0 +/ 0 +kg 0 +for 0 +bupivacaine 1 +, 0 +111 0 +. 0 +0 0 +and 0 +133 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +for 0 +lidocaine 1 +, 0 +and 0 +243 0 +. 0 +4 0 +and 0 +266 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +for 0 +chloroprocaine 1 +. 0 + +When 0 +given 0 +intraperitoneally 0 +, 0 +bupivacaine 1 +thus 0 +was 0 +only 0 +about 0 +twice 0 +as 0 +toxic 0 +as 0 +lidocaine 1 +and 0 +four 0 +times 0 +as 0 +toxic 0 +as 0 +chloroprocaine 1 +. 0 + +Convulsions 3 +always 0 +preceded 0 +death 0 +, 0 +except 0 +after 0 +precipitous 0 +cardiopulmonary 3 +arrest 4 +from 0 +extreme 0 +doses 0 +. 0 + +A 0 +CD50 0 +dose 0 +of 0 +local 0 +anesthetic 0 +( 0 +causing 0 +convulsions 3 +in 0 +50 0 +% 0 +of 0 +mice 0 +) 0 +was 0 +fatal 0 +in 0 +90 0 +% 0 +of 0 +bupivacaine 1 +- 0 +induced 0 +seizures 3 +, 0 +in 0 +57 0 +% 0 +of 0 +the 0 +chloroprocaine 1 +group 0 +, 0 +and 0 +in 0 +6 0 +% 0 +of 0 +the 0 +lidocaine 1 +group 0 +. 0 + +The 0 +narrow 0 +gap 0 +between 0 +convulsant 0 +and 0 +lethal 0 +doses 0 +of 0 +local 0 +anesthetics 0 +indicates 0 +that 0 +untreated 0 +convulsions 3 +present 0 +much 0 +more 0 +of 0 +a 0 +threat 0 +to 0 +life 0 +than 0 +heretofore 0 +appreciated 0 +. 0 + +REM 3 +sleep 4 +deprivation 4 +changes 0 +behavioral 0 +response 0 +to 0 +catecholaminergic 0 +and 0 +serotonergic 0 +receptor 0 +activation 0 +in 0 +rats 0 +. 0 + +The 0 +effects 0 +of 0 +REM 3 +sleep 4 +deprivation 4 +( 0 +REMD 3 +) 0 +on 0 +apomorphine 1 +- 0 +induced 0 +aggressiveness 3 +and 0 +quipazine 1 +- 0 +induced 0 +head 3 +twitches 4 +in 0 +rats 0 +were 0 +determined 0 +. 0 + +Forty 0 +- 0 +eight 0 +hr 0 +of 0 +REMD 3 +increased 0 +apomorphine 1 +- 0 +induced 0 +aggressiveness 3 +, 0 +and 0 +reduced 0 +( 0 +immediately 0 +after 0 +completing 0 +of 0 +REMD 3 +) 0 +or 0 +increased 0 +( 0 +96 0 +hr 0 +after 0 +completing 0 +of 0 +REMD 3 +) 0 +quipazine 1 +- 0 +induced 0 +head 3 +twitches 4 +. 0 + +Results 0 +are 0 +discussed 0 +in 0 +terms 0 +of 0 +similarity 0 +to 0 +pharmacological 0 +effects 0 +of 0 +other 0 +antidepressive 0 +treatments 0 +. 0 + +Fatal 0 +aplastic 3 +anemia 4 +due 0 +to 0 +indomethacin 1 +- 0 +- 0 +lymphocyte 0 +transformation 0 +tests 0 +in 0 +vitro 0 +. 0 + +Although 0 +indomethacin 1 +has 0 +been 0 +implicated 0 +as 0 +a 0 +possible 0 +cause 0 +of 0 +aplastic 3 +anemia 4 +on 0 +the 0 +basis 0 +of 0 +a 0 +few 0 +clinical 0 +observations 0 +, 0 +its 0 +role 0 +has 0 +not 0 +been 0 +definitely 0 +established 0 +. 0 + +A 0 +case 0 +of 0 +fatal 0 +aplastic 3 +anemia 4 +is 0 +described 0 +in 0 +which 0 +no 0 +drugs 0 +other 0 +than 0 +allopurinol 1 +and 0 +indomethacin 1 +were 0 +given 0 +. 0 + +Indomethacin 1 +was 0 +first 0 +given 0 +four 0 +weeks 0 +prior 0 +to 0 +the 0 +onset 0 +of 0 +symptoms 0 +. 0 + +A 0 +positive 0 +lymphocyte 0 +transformation 0 +test 0 +with 0 +indomethacin 1 +in 0 +vitro 0 +further 0 +substantiates 0 +the 0 +potential 0 +role 0 +of 0 +this 0 +drug 0 +in 0 +causing 0 +aplastic 3 +anemia 4 +in 0 +a 0 +susceptible 0 +patient 0 +. 0 + +Fortunately 0 +, 0 +this 0 +seems 0 +to 0 +be 0 +a 0 +very 0 +rare 0 +complication 0 +. 0 + +Dose 0 +- 0 +effect 0 +and 0 +structure 0 +- 0 +function 0 +relationships 0 +in 0 +doxorubicin 1 +cardiomyopathy 3 +. 0 + +The 0 +cardiomyopathy 3 +( 0 +CM 3 +) 0 +produced 0 +by 0 +the 0 +anticancer 0 +drug 0 +doxorubicin 1 +( 0 +DXR 1 +) 0 +( 0 +Adriamycin 1 +) 0 +provides 0 +a 0 +unique 0 +opportunity 0 +to 0 +analyze 0 +dose 0 +- 0 +effect 0 +and 0 +structure 0 +- 0 +function 0 +relationships 0 +during 0 +development 0 +of 0 +myocardial 3 +disease 4 +. 0 + +We 0 +measured 0 +the 0 +degree 0 +of 0 +morphologic 0 +damage 0 +by 0 +ultrastructural 0 +examination 0 +of 0 +endomyocardial 0 +biopsy 0 +and 0 +the 0 +degree 0 +of 0 +performance 0 +abnormally 0 +by 0 +right 0 +heart 0 +catheterization 0 +in 0 +patients 0 +receiving 0 +DXR 1 +. 0 + +Morphologic 0 +damage 0 +was 0 +variable 0 +but 0 +was 0 +proportional 0 +to 0 +the 0 +total 0 +cumulative 0 +DXR 1 +dose 0 +between 0 +100 0 +and 0 +600 0 +mg 0 +/ 0 +m2 0 +. 0 + +Performance 0 +abnormalities 0 +correlated 0 +weakly 0 +with 0 +dose 0 +, 0 +exhibited 0 +a 0 +curvilinear 0 +relationship 0 +, 0 +and 0 +had 0 +a 0 +" 0 +threshold 0 +" 0 +for 0 +expression 0 +. 0 + +Catheterization 0 +abnormalities 0 +correlated 0 +well 0 +with 0 +morphologic 0 +damage 0 +( 0 +r 0 += 0 +0 0 +. 0 +57 0 +to 0 +0 0 +. 0 +78 0 +) 0 +in 0 +a 0 +subgroup 0 +of 0 +patients 0 +in 0 +whom 0 +exercise 0 +hemodynamics 0 +were 0 +measured 0 +, 0 +and 0 +this 0 +relationship 0 +also 0 +exhibited 0 +a 0 +curvilinear 0 +, 0 +threshold 0 +configuration 0 +. 0 + +In 0 +DXR 1 +- 0 +CM 3 +myocardial 3 +damage 4 +is 0 +proportional 0 +to 0 +the 0 +degree 0 +of 0 +cytotoxic 0 +insult 0 +( 0 +DXR 1 +dose 0 +) 0 +while 0 +myocardial 0 +function 0 +is 0 +preserved 0 +until 0 +a 0 +critical 0 +dose 0 +or 0 +degree 0 +of 0 +damage 0 +is 0 +reached 0 +, 0 +after 0 +which 0 +myocardial 0 +performance 0 +deteriorates 0 +rapidly 0 +. 0 + +Massive 0 +cerebral 3 +edema 4 +associated 0 +with 0 +fulminant 0 +hepatic 3 +failure 4 +in 0 +acetaminophen 1 +overdose 3 +: 0 +possible 0 +role 0 +of 0 +cranial 0 +decompression 0 +. 0 + +Cerebral 3 +edema 4 +may 0 +complicate 0 +the 0 +course 0 +of 0 +fulminant 3 +hepatic 4 +failure 4 +. 0 + +Response 0 +to 0 +conventional 0 +therapy 0 +has 0 +been 0 +disappointing 0 +. 0 + +We 0 +present 0 +a 0 +patient 0 +with 0 +fatal 0 +acetaminophen 1 +- 0 +induced 0 +fulminant 3 +hepatic 4 +failure 4 +, 0 +with 0 +signs 0 +and 0 +symptoms 0 +of 0 +cerebral 3 +edema 4 +, 0 +unresponsive 0 +to 0 +conventional 0 +medical 0 +therapy 0 +. 0 + +Cranial 0 +decompression 0 +was 0 +carried 0 +out 0 +. 0 + +A 0 +justification 0 +of 0 +the 0 +need 0 +for 0 +further 0 +evaluation 0 +of 0 +cranial 0 +decompression 0 +in 0 +such 0 +patients 0 +is 0 +presented 0 +. 0 + +Subjective 0 +assessment 0 +of 0 +sexual 3 +dysfunction 4 +of 0 +patients 0 +on 0 +long 0 +- 0 +term 0 +administration 0 +of 0 +digoxin 1 +. 0 + +Various 0 +data 0 +suggest 0 +that 0 +male 0 +patients 0 +who 0 +have 0 +received 0 +digoxin 1 +on 0 +a 0 +longterm 0 +basis 0 +have 0 +increased 0 +levels 0 +of 0 +serum 0 +estrogen 1 +and 0 +decreased 0 +levels 0 +of 0 +plasma 0 +testosterone 1 +and 0 +luteinizing 0 +hormone 0 +( 0 +LH 0 +) 0 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +investigate 0 +the 0 +links 0 +between 0 +the 0 +long 0 +- 0 +term 0 +administration 0 +of 0 +digoxin 1 +therapy 0 +and 0 +sexual 0 +behavior 0 +, 0 +and 0 +the 0 +effect 0 +of 0 +digoxin 1 +on 0 +plasma 0 +levels 0 +of 0 +estradiol 1 +, 0 +testosterone 1 +, 0 +and 0 +LH 0 +. 0 + +The 0 +patients 0 +of 0 +the 0 +study 0 +and 0 +control 0 +group 0 +( 0 +without 0 +digoxin 1 +) 0 +were 0 +of 0 +similar 0 +cardiac 0 +functional 0 +capacity 0 +and 0 +age 0 +( 0 +25 0 +- 0 +40 0 +years 0 +) 0 +and 0 +were 0 +randomly 0 +selected 0 +from 0 +the 0 +rheumatic 3 +heart 4 +disease 4 +patients 0 +. 0 + +A 0 +subjective 0 +assessment 0 +of 0 +sexual 0 +behavior 0 +in 0 +the 0 +study 0 +and 0 +control 0 +groups 0 +was 0 +carried 0 +out 0 +, 0 +using 0 +parameters 0 +such 0 +as 0 +sexual 0 +desire 0 +, 0 +sexual 0 +excitement 0 +, 0 +and 0 +frequency 0 +of 0 +sexual 0 +relations 0 +. 0 + +Personal 0 +interviews 0 +and 0 +a 0 +questionnaire 0 +were 0 +also 0 +used 0 +for 0 +the 0 +evaluation 0 +of 0 +sexual 0 +behavior 0 +. 0 + +The 0 +findings 0 +support 0 +the 0 +reports 0 +concerning 0 +digoxin 1 +effect 0 +on 0 +plasma 0 +estradiol 1 +, 0 +testosterone 1 +, 0 +and 0 +LH 0 +. 0 + +The 0 +differences 0 +in 0 +the 0 +means 0 +were 0 +significant 0 +. 0 + +Tests 0 +used 0 +to 0 +evaluate 0 +the 0 +changes 0 +in 0 +sexual 0 +behavior 0 +showed 0 +a 0 +significant 0 +decrease 3 +in 4 +sexual 4 +desire 4 +, 0 +sexual 0 +excitement 0 +phase 0 +( 0 +erection 0 +) 0 +, 0 +and 0 +frequency 0 +of 0 +sexual 0 +relations 0 +in 0 +the 0 +study 0 +group 0 +. 0 + +Endometrial 3 +carcinoma 4 +after 0 +Hodgkin 3 +disease 4 +in 0 +childhood 0 +. 0 + +A 0 +34 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +developed 0 +metastic 0 +endometrial 3 +carcinoma 4 +after 0 +Hodgkin 3 +disease 4 +in 0 +childhood 0 +. 0 + +She 0 +had 0 +ovarian 3 +failure 4 +after 0 +abdominal 0 +irradiation 0 +and 0 +chemotherapy 0 +for 0 +Hodgkin 3 +disease 4 +, 0 +and 0 +received 0 +exogenous 0 +estrogens 1 +, 0 +a 0 +treatment 0 +implicated 0 +in 0 +the 0 +development 0 +of 0 +endometrial 3 +cancer 4 +in 0 +menopausal 0 +women 0 +. 0 + +Young 0 +women 0 +on 0 +replacement 0 +estrogens 1 +for 0 +ovarian 3 +failure 4 +after 0 +cancer 3 +therapy 0 +may 0 +also 0 +have 0 +increased 0 +risk 0 +of 0 +endometrial 3 +carcinoma 4 +and 0 +should 0 +be 0 +examined 0 +periodically 0 +. 0 + +Long 0 +- 0 +term 0 +lithium 1 +treatment 0 +and 0 +the 0 +kidney 0 +. 0 + +Interim 0 +report 0 +on 0 +fifty 0 +patients 0 +. 0 + +This 0 +is 0 +a 0 +report 0 +on 0 +the 0 +first 0 +part 0 +of 0 +our 0 +study 0 +of 0 +the 0 +effects 0 +of 0 +long 0 +- 0 +term 0 +lithium 1 +treatment 0 +on 0 +the 0 +kidney 0 +. 0 + +Creatinine 1 +clearance 0 +, 0 +maximum 0 +urinary 0 +osmolality 0 +and 0 +24 0 +hour 0 +urine 0 +volume 0 +have 0 +been 0 +tested 0 +in 0 +50 0 +affectively 0 +ill 0 +patients 0 +who 0 +have 0 +been 0 +on 0 +long 0 +- 0 +term 0 +lithium 1 +for 0 +more 0 +than 0 +one 0 +year 0 +. 0 + +These 0 +findings 0 +have 0 +been 0 +compared 0 +with 0 +norms 0 +and 0 +with 0 +values 0 +of 0 +the 0 +same 0 +tests 0 +from 0 +screening 0 +prior 0 +to 0 +lithium 1 +, 0 +available 0 +for 0 +most 0 +of 0 +our 0 +patients 0 +. 0 + +No 0 +evidence 0 +was 0 +found 0 +for 0 +any 0 +reduction 0 +of 0 +glomerular 0 +filtration 0 +during 0 +lithium 1 +treatment 0 +. 0 + +Low 0 +clearance 0 +values 0 +found 0 +in 0 +several 0 +patients 0 +could 0 +be 0 +accounted 0 +for 0 +by 0 +their 0 +age 0 +and 0 +their 0 +pre 0 +- 0 +lithium 1 +values 0 +. 0 + +Urinary 0 +concentration 0 +defect 0 +appeared 0 +frequent 0 +but 0 +the 0 +extent 0 +of 0 +the 0 +impairment 0 +is 0 +difficult 0 +to 0 +assess 0 +because 0 +of 0 +the 0 +uncertainty 0 +about 0 +the 0 +norms 0 +applicable 0 +to 0 +this 0 +group 0 +of 0 +patients 0 +. 0 + +The 0 +concentration 0 +defect 0 +appeared 0 +reversible 0 +, 0 +at 0 +least 0 +in 0 +part 0 +. 0 + +Polyuria 3 +above 0 +3 0 +litres 0 +/ 0 +24 0 +hours 0 +was 0 +found 0 +in 0 +10 0 +% 0 +of 0 +patients 0 +. 0 + +An 0 +attempt 0 +is 0 +made 0 +to 0 +draw 0 +practical 0 +conclusions 0 +from 0 +the 0 +preliminary 0 +findings 0 +. 0 + +Nephrotoxicity 3 +of 0 +cyclosporin 1 +A 2 +and 0 +FK506 1 +: 0 +inhibition 0 +of 0 +calcineurin 0 +phosphatase 0 +. 0 + +Cyclosporin 1 +A 2 +( 0 +CsA 1 +; 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +Fujimycine 1 +( 0 +FK506 1 +; 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +but 0 +not 0 +the 0 +related 0 +macrolide 1 +immunosuppressant 0 +rapamycin 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +caused 0 +a 0 +reduction 0 +of 0 +glomerular 0 +filtration 0 +rate 0 +, 0 +degenerative 0 +changes 0 +of 0 +proximal 0 +tubular 0 +epithelium 0 +, 0 +and 0 +hypertrophy 3 +of 0 +the 0 +juxtaglomerular 0 +apparatus 0 +in 0 +male 0 +Wistar 0 +rats 0 +when 0 +given 0 +for 0 +10 0 +days 0 +. 0 + +The 0 +molecular 0 +mechanisms 0 +of 0 +CsA 1 +and 0 +FK506 1 +toxicity 3 +were 0 +investigated 0 +. 0 + +Cyclophilin 0 +A 0 +and 0 +FK506 1 +- 0 +binding 0 +protein 0 +, 0 +the 0 +main 0 +intracytoplasmic 0 +receptors 0 +for 0 +CsA 1 +and 0 +FK506 1 +, 0 +respectively 0 +, 0 +were 0 +each 0 +detected 0 +in 0 +renal 0 +tissue 0 +extract 0 +. 0 + +In 0 +the 0 +kidney 0 +, 0 +high 0 +levels 0 +of 0 +immunoreactive 0 +and 0 +enzymatically 0 +active 0 +calcineurin 0 +were 0 +found 0 +which 0 +were 0 +inhibited 0 +by 0 +the 0 +immunosuppressants 0 +CsA 1 +and 0 +FK506 1 +, 0 +but 0 +not 0 +by 0 +rapamycin 1 +. 0 + +Finally 0 +, 0 +specific 0 +immunophilin 0 +- 0 +drug 0 +- 0 +calcineurin 0 +complexes 0 +formed 0 +only 0 +in 0 +the 0 +presence 0 +of 0 +CsA 1 +and 0 +FK506 1 +, 0 +but 0 +not 0 +rapamycin 1 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +the 0 +nephrotoxic 3 +effects 0 +of 0 +CsA 1 +and 0 +FK506 1 +is 0 +likely 0 +mediated 0 +through 0 +binding 0 +to 0 +renal 0 +immunophilin 0 +and 0 +inhibiting 0 +calcineurin 0 +phosphatase 0 +. 0 + +Acute 3 +renal 4 +failure 4 +in 0 +high 0 +dose 0 +carboplatin 1 +chemotherapy 0 +. 0 + +Carboplatin 1 +has 0 +been 0 +reported 0 +to 0 +cause 0 +acute 3 +renal 4 +failure 4 +when 0 +administered 0 +in 0 +high 0 +doses 0 +to 0 +adult 0 +patients 0 +. 0 + +We 0 +report 0 +a 0 +4 0 +1 0 +/ 0 +2 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +who 0 +was 0 +treated 0 +with 0 +high 0 +- 0 +dose 0 +carboplatin 1 +for 0 +metastatic 0 +parameningeal 0 +embryonal 3 +rhabdomyosarcoma 4 +. 0 + +Acute 3 +renal 4 +failure 4 +developed 0 +followed 0 +by 0 +a 0 +slow 0 +partial 0 +recovery 0 +of 0 +renal 0 +function 0 +. 0 + +Possible 0 +contributing 0 +factors 0 +are 0 +discussed 0 +. 0 + +Clinical 0 +evaluation 0 +on 0 +combined 0 +administration 0 +of 0 +oral 0 +prostacyclin 1 +analogue 0 +beraprost 1 +and 0 +phosphodiesterase 0 +inhibitor 0 +cilostazol 1 +. 0 + +Among 0 +various 0 +oral 0 +antiplatelets 0 +, 0 +a 0 +combination 0 +of 0 +a 0 +novel 0 +prostacyclin 1 +analogue 0 +beraprost 1 +( 0 +BPT 1 +) 0 +and 0 +a 0 +potent 0 +phosphodiesterase 0 +inhibitor 0 +cilostazol 1 +( 0 +CLZ 1 +) 0 +may 0 +result 0 +in 0 +untoward 0 +clinical 0 +effects 0 +due 0 +to 0 +possible 0 +synergistic 0 +elevation 0 +of 0 +intracellular 0 +cAMP 1 +( 0 +cyclic 1 +adenosine 2 +3 2 +' 2 +, 2 +5 2 +' 2 +- 2 +monophosphate 2 +) 0 +. 0 + +Thereby 0 +, 0 +a 0 +clinical 0 +study 0 +of 0 +the 0 +combined 0 +administration 0 +of 0 +the 0 +two 0 +agents 0 +was 0 +attempted 0 +. 0 + +Twelve 0 +healthy 0 +volunteers 0 +were 0 +assigned 0 +to 0 +take 0 +BPT 1 +/ 0 +CLZ 1 +in 0 +the 0 +following 0 +schedule 0 +; 0 +BPT 1 +: 0 +40 0 +micrograms 0 +at 0 +day 0 +1 0 +and 0 +120 0 +micrograms 0 +t 0 +. 0 +i 0 +. 0 +d 0 +. 0 +from 0 +day 0 +7 0 +to 0 +14 0 +, 0 +CLZ 1 +: 0 +200 0 +mg 0 +t 0 +. 0 +i 0 +. 0 +d 0 +. 0 +from 0 +day 0 +3 0 +to 0 +14 0 +. 0 + +At 0 +various 0 +time 0 +intervals 0 +, 0 +physical 0 +examination 0 +and 0 +blood 0 +collection 0 +for 0 +ex 0 +vivo 0 +platelet 3 +aggregation 4 +and 0 +determination 0 +of 0 +intraplatelet 0 +cAMP 1 +were 0 +performed 0 +. 0 + +Throughout 0 +the 0 +observation 0 +period 0 +, 0 +no 0 +significant 0 +alteration 0 +in 0 +vital 0 +signs 0 +was 0 +observed 0 +. 0 + +Seven 0 +out 0 +of 0 +12 0 +subjects 0 +experienced 0 +headache 3 +of 0 +a 0 +short 0 +duration 0 +accompanying 0 +facial 3 +flush 4 +in 0 +one 0 +and 0 +nausea 3 +in 0 +one 0 +, 0 +especially 0 +after 0 +ingestion 0 +of 0 +CLZ 1 +. 0 + +All 0 +of 0 +these 0 +symptoms 0 +, 0 +probably 0 +caused 0 +by 0 +the 0 +vasodilating 0 +effect 0 +of 0 +the 0 +two 0 +agents 0 +, 0 +were 0 +of 0 +mild 0 +degree 0 +and 0 +no 0 +special 0 +treatment 0 +was 0 +required 0 +. 0 + +Intraplatelet 0 +cAMP 1 +content 0 +was 0 +gradually 0 +but 0 +significantly 0 +increased 0 +to 0 +9 0 +. 0 +84 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +59 0 +pmol 0 +per 0 +10 0 +( 0 +9 0 +) 0 +platelets 0 +at 0 +day 0 +14 0 +in 0 +comparison 0 +with 0 +the 0 +initial 0 +value 0 +( 0 +6 0 +. 0 +87 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +25 0 +pmol 0 +) 0 +. 0 + +The 0 +platelet 0 +aggregability 0 +was 0 +significantly 0 +suppressed 0 +at 0 +various 0 +time 0 +intervals 0 +but 0 +no 0 +additive 0 +or 0 +synergistic 0 +inhibitory 0 +effect 0 +by 0 +the 0 +combined 0 +administration 0 +was 0 +noted 0 +. 0 + +In 0 +conclusion 0 +, 0 +the 0 +combined 0 +administration 0 +of 0 +BPT 1 +/ 0 +CLZ 1 +is 0 +safe 0 +at 0 +doses 0 +used 0 +in 0 +the 0 +study 0 +, 0 +though 0 +the 0 +beneficial 0 +clinical 0 +effect 0 +of 0 +the 0 +combined 0 +administration 0 +has 0 +yet 0 +to 0 +be 0 +elucidated 0 +. 0 + +Pravastatin 1 +- 0 +associated 0 +myopathy 3 +. 0 + +Report 0 +of 0 +a 0 +case 0 +. 0 + +A 0 +case 0 +of 0 +acute 0 +inflammatory 3 +myopathy 4 +associated 0 +with 0 +the 0 +use 0 +of 0 +pravastatin 1 +, 0 +a 0 +new 0 +hydrophilic 0 +3 0 +- 0 +hydroxy 0 +- 0 +3 0 +methylglutaril 0 +coenzyme 0 +A 0 +reductase 0 +inhibitor 0 +, 0 +is 0 +reported 0 +. 0 + +The 0 +patient 0 +, 0 +a 0 +69 0 +- 0 +year 0 +- 0 +old 0 +man 0 +was 0 +affected 0 +by 0 +non 3 +- 4 +insulin 4 +- 4 +dependent 4 +diabetes 4 +mellitus 4 +and 0 +hypertension 3 +. 0 + +He 0 +assumed 0 +pravastatin 1 +( 0 +20 0 +mg 0 +/ 0 +day 0 +) 0 +because 0 +of 0 +hypercholesterolemia 3 +. 0 + +He 0 +was 0 +admitted 0 +with 0 +acute 0 +myopathy 3 +of 0 +the 0 +lower 0 +limbs 0 +which 0 +resolved 0 +in 0 +a 0 +few 0 +days 0 +after 0 +pravastatin 1 +discontinuation 0 +. 0 + +A 0 +previously 0 +unknown 0 +hypothyroidism 3 +, 0 +probably 0 +due 0 +to 0 +chronic 0 +autoimmune 3 +thyroiditis 4 +, 0 +was 0 +evidenced 0 +. 0 + +Muscle 0 +biopsy 0 +( 0 +left 0 +gastrocnemius 0 +) 0 +revealed 0 +a 0 +perimysial 0 +and 0 +endomysial 0 +inflammatory 0 +infiltrate 0 +with 0 +a 0 +prevalence 0 +of 0 +CD4 0 ++ 0 +lymphocytes 0 +. 0 + +While 0 +lovastatin 1 +and 0 +simvastatin 1 +have 0 +been 0 +associated 0 +with 0 +toxic 0 +myopathy 3 +, 0 +pravastatin 1 +- 0 +associated 0 +myopathy 3 +could 0 +represent 0 +a 0 +distinct 0 +, 0 +inflammatory 0 +entity 0 +. 0 + +Reversal 0 +of 0 +ammonia 1 +coma 3 +in 0 +rats 0 +by 0 +L 1 +- 2 +dopa 2 +: 0 +a 0 +peripheral 0 +effect 0 +. 0 + +Ammonia 1 +coma 3 +was 0 +produced 0 +in 0 +rats 0 +within 0 +10 0 +to 0 +15 0 +minutes 0 +of 0 +an 0 +intraperitonealinjection 0 +of 0 +1 0 +. 0 +7 0 +mmol 0 +NH4CL 1 +. 0 + +This 0 +coma 3 +was 0 +prevented 0 +with 0 +1 0 +. 0 +68 0 +mmol 0 +L 1 +- 2 +dopa 2 +given 0 +by 0 +gastric 0 +intubation 0 +15 0 +minutes 0 +before 0 +the 0 +ammonium 1 +salt 2 +injection 0 +. 0 + +The 0 +effect 0 +of 0 +L 1 +- 2 +dopa 2 +was 0 +correlated 0 +with 0 +a 0 +decrease 0 +in 0 +blood 0 +and 0 +brain 0 +ammonia 1 +, 0 +an 0 +increase 0 +in 0 +brain 0 +dopamine 1 +, 0 +and 0 +an 0 +increase 0 +in 0 +renal 0 +excretion 0 +of 0 +ammonia 1 +and 0 +urea 1 +. 0 + +Intraventricular 0 +infusion 0 +of 0 +dopamine 1 +sufficient 0 +to 0 +raise 0 +the 0 +brain 0 +dopamine 1 +to 0 +the 0 +same 0 +extent 0 +did 0 +not 0 +prevent 0 +the 0 +ammonia 1 +coma 3 +nor 0 +affect 0 +the 0 +blood 0 +and 0 +brain 0 +ammonia 1 +concentrations 0 +. 0 + +Bilateral 0 +nephrectomy 0 +eliminated 0 +the 0 +beneficial 0 +effect 0 +of 0 +L 1 +- 2 +dopa 2 +on 0 +blood 0 +and 0 +brain 0 +ammonia 1 +and 0 +the 0 +ammonia 1 +coma 3 +was 0 +not 0 +prevented 0 +. 0 + +Thus 0 +, 0 +the 0 +reduction 0 +in 0 +blood 0 +and 0 +brain 0 +ammonia 1 +and 0 +the 0 +prevention 0 +of 0 +ammonia 1 +coma 3 +after 0 +L 1 +- 2 +dopa 2 +, 0 +can 0 +be 0 +accounted 0 +for 0 +by 0 +the 0 +peripheral 0 +effect 0 +of 0 +dopamine 1 +on 0 +renal 0 +function 0 +rather 0 +than 0 +its 0 +central 0 +action 0 +. 0 + +These 0 +results 0 +provide 0 +a 0 +reasonable 0 +explanation 0 +for 0 +the 0 +beneficial 0 +effects 0 +observed 0 +in 0 +some 0 +encephalopathic 3 +patients 0 +receiving 0 +L 1 +- 2 +dopa 2 +. 0 + +Etoposide 1 +- 0 +related 0 +myocardial 3 +infarction 4 +. 0 + +The 0 +occurrence 0 +of 0 +a 0 +myocardial 3 +infarction 4 +is 0 +reported 0 +after 0 +chemotherapy 0 +containing 0 +etoposide 1 +, 0 +in 0 +a 0 +man 0 +with 0 +no 0 +risk 0 +factors 0 +for 0 +coronary 3 +heart 4 +disease 4 +. 0 + +Possible 0 +causal 0 +mechanisms 0 +are 0 +discussed 0 +. 0 + +Halogenated 0 +anesthetics 0 +form 0 +liver 0 +adducts 0 +and 0 +antigens 0 +that 0 +cross 0 +- 0 +react 0 +with 0 +halothane 1 +- 0 +induced 0 +antibodies 0 +. 0 + +Two 0 +halogenated 0 +anesthetics 0 +, 0 +enflurane 1 +and 0 +isoflurane 1 +, 0 +have 0 +been 0 +associated 0 +with 0 +an 0 +allergic 0 +- 0 +type 0 +hepatic 3 +injury 4 +both 0 +alone 0 +and 0 +following 0 +previous 0 +exposure 0 +to 0 +halothane 1 +. 0 + +Halothane 1 +hepatitis 3 +appears 0 +to 0 +involve 0 +an 0 +aberrant 0 +immune 0 +response 0 +. 0 + +An 0 +antibody 0 +response 0 +to 0 +a 0 +protein 0 +- 0 +bound 0 +biotransformation 0 +product 0 +( 0 +trifluoroacetyl 1 +adduct 0 +) 0 +has 0 +been 0 +detected 0 +on 0 +halothane 1 +hepatitis 3 +patients 0 +. 0 + +This 0 +study 0 +was 0 +performed 0 +to 0 +determine 0 +cross 0 +- 0 +reactivity 0 +between 0 +enflurane 1 +and 0 +isoflurane 1 +with 0 +the 0 +hypersensitivity 3 +induced 0 +by 0 +halothane 1 +. 0 + +The 0 +subcellular 0 +and 0 +lobular 0 +production 0 +of 0 +hepatic 0 +neoantigens 0 +recognized 0 +by 0 +halothane 1 +- 0 +induced 0 +antibodies 0 +following 0 +enflurane 1 +and 0 +isoflurane 1 +, 0 +and 0 +the 0 +biochemical 0 +nature 0 +of 0 +these 0 +neoantigens 0 +was 0 +investigated 0 +in 0 +two 0 +animal 0 +models 0 +. 0 + +Enflurane 1 +administration 0 +resulted 0 +in 0 +neoantigens 0 +detected 0 +in 0 +both 0 +the 0 +microsomal 0 +and 0 +cytosolic 0 +fraction 0 +of 0 +liver 0 +homogenates 0 +and 0 +in 0 +the 0 +centrilobular 0 +region 0 +of 0 +the 0 +liver 0 +. 0 + +In 0 +the 0 +same 0 +liver 0 +, 0 +biochemical 0 +analysis 0 +detected 0 +fluorinated 0 +liver 0 +adducts 0 +that 0 +were 0 +up 0 +to 0 +20 0 +- 0 +fold 0 +greater 0 +in 0 +guinea 0 +pigs 0 +than 0 +in 0 +rats 0 +. 0 + +This 0 +supports 0 +and 0 +extends 0 +previous 0 +evidence 0 +for 0 +a 0 +mechanism 0 +by 0 +which 0 +enflurane 1 +and 0 +/ 0 +or 0 +isoflurane 1 +could 0 +produce 0 +a 0 +hypersensitivity 3 +condition 0 +similar 0 +to 0 +that 0 +of 0 +halothane 1 +hepatitis 3 +either 0 +alone 0 +or 0 +subsequent 0 +to 0 +halothane 1 +administration 0 +. 0 + +The 0 +guinea 0 +pig 0 +would 0 +appear 0 +to 0 +be 0 +a 0 +useful 0 +model 0 +for 0 +further 0 +investigations 0 +of 0 +the 0 +immunological 0 +response 0 +to 0 +these 0 +antigens 0 +. 0 + +Cholinergic 0 +toxicity 3 +resulting 0 +from 0 +ocular 0 +instillation 0 +of 0 +echothiophate 1 +iodide 2 +eye 0 +drops 0 +. 0 + +A 0 +patient 0 +developed 0 +a 0 +severe 0 +cholinergic 0 +syndrome 0 +from 0 +the 0 +use 0 +of 0 +echothiophate 1 +iodide 2 +ophthalmic 0 +drops 0 +, 0 +presented 0 +with 0 +profound 0 +muscle 3 +weakness 4 +and 0 +was 0 +initially 0 +given 0 +the 0 +diagnosis 0 +of 0 +myasthenia 3 +gravis 4 +. 0 + +Red 0 +blood 0 +cell 0 +and 0 +serum 0 +cholinesterase 0 +levels 0 +were 0 +severely 0 +depressed 0 +and 0 +symptoms 0 +resolved 0 +spontaneously 0 +following 0 +discontinuation 0 +of 0 +the 0 +eye 0 +drops 0 +. 0 + +Seizure 3 +after 0 +flumazenil 1 +administration 0 +in 0 +a 0 +pediatric 0 +patient 0 +. 0 + +Flumazenil 1 +is 0 +a 0 +benzodiazepine 1 +receptor 0 +antagonist 0 +used 0 +to 0 +reverse 0 +sedation 0 +and 0 +respiratory 3 +depression 4 +induced 0 +by 0 +benzodiazepines 1 +. 0 + +Seizures 3 +and 0 +cardiac 3 +arrhythmias 4 +have 0 +complicated 0 +its 0 +use 0 +in 0 +adult 0 +patients 0 +. 0 + +0verdose 3 +patients 0 +who 0 +have 0 +coingested 0 +tricyclic 0 +antidepressants 0 +have 0 +a 0 +higher 0 +risk 0 +of 0 +these 0 +complications 0 +. 0 + +Little 0 +information 0 +exists 0 +concerning 0 +adverse 0 +effects 0 +of 0 +flumazenil 1 +in 0 +children 0 +. 0 + +We 0 +report 0 +the 0 +occurrence 0 +of 0 +a 0 +generalized 0 +tonic 3 +- 4 +clonic 4 +seizure 4 +in 0 +a 0 +pediatric 0 +patient 0 +following 0 +the 0 +administration 0 +of 0 +flumazenil 1 +. 0 + +Phase 0 +I 0 +trial 0 +of 0 +13 1 +- 2 +cis 2 +- 2 +retinoic 2 +acid 2 +in 0 +children 0 +with 0 +neuroblastoma 3 +following 0 +bone 0 +marrow 0 +transplantation 0 +. 0 + +PURP0SE 0 +: 0 +Treatment 0 +of 0 +neuroblastoma 3 +cell 0 +lines 0 +with 0 +13 1 +- 2 +cis 2 +- 2 +retinoic 2 +acid 2 +( 0 +cis 1 +- 2 +RA 2 +) 0 +can 0 +cause 0 +sustained 0 +inhibition 0 +of 0 +proliferation 0 +. 0 + +Since 0 +cis 1 +- 2 +RA 2 +has 0 +demonstrated 0 +clinical 0 +responses 0 +in 0 +neuroblastoma 3 +patients 0 +, 0 +it 0 +may 0 +be 0 +effective 0 +in 0 +preventing 0 +relapse 0 +after 0 +cytotoxic 0 +therapy 0 +. 0 + +This 0 +phase 0 +I 0 +trial 0 +was 0 +designed 0 +to 0 +determine 0 +the 0 +maximal 0 +- 0 +tolerated 0 +dosage 0 +( 0 +MTD 0 +) 0 +, 0 +toxicities 3 +, 0 +and 0 +pharmacokinetics 0 +of 0 +cis 1 +- 2 +RA 2 +administered 0 +on 0 +an 0 +intermittent 0 +schedule 0 +in 0 +children 0 +with 0 +neuroblastoma 3 +following 0 +bone 0 +marrow 0 +transplantation 0 +( 0 +BMT 0 +) 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Fifty 0 +- 0 +one 0 +assessable 0 +patients 0 +, 0 +2 0 +to 0 +12 0 +years 0 +of 0 +age 0 +, 0 +were 0 +treated 0 +with 0 +oral 0 +cis 1 +- 2 +RA 2 +administered 0 +in 0 +two 0 +equally 0 +divided 0 +doses 0 +daily 0 +for 0 +2 0 +weeks 0 +, 0 +followed 0 +by 0 +a 0 +2 0 +- 0 +week 0 +rest 0 +period 0 +, 0 +for 0 +up 0 +to 0 +12 0 +courses 0 +. 0 + +The 0 +dose 0 +was 0 +escalated 0 +from 0 +100 0 +to 0 +200 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +until 0 +dose 0 +- 0 +limiting 0 +toxicity 3 +( 0 +DLT 0 +) 0 +was 0 +observed 0 +. 0 + +A 0 +single 0 +intrapatient 0 +dose 0 +escalation 0 +was 0 +permitted 0 +. 0 + +RESULTS 0 +: 0 +The 0 +MTD 0 +of 0 +cis 1 +- 2 +RA 2 +was 0 +160 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +. 0 + +Dose 0 +- 0 +limiting 0 +toxicities 3 +in 0 +six 0 +of 0 +nine 0 +patients 0 +at 0 +200 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +included 0 +hypercalcemia 3 +( 0 +n 0 += 0 +3 0 +) 0 +, 0 +rash 3 +( 0 +n 0 += 0 +2 0 +) 0 +, 0 +and 0 +anemia 3 +/ 0 +thrombocytopenia 3 +/ 0 +emesis 3 +/ 0 +rash 3 +( 0 +n 0 += 0 +1 0 +) 0 +. 0 + +All 0 +toxicities 3 +resolved 0 +after 0 +cis 1 +- 2 +RA 2 +was 0 +discontinued 0 +. 0 + +Three 0 +complete 0 +responses 0 +were 0 +observed 0 +in 0 +marrow 0 +metastases 3 +. 0 + +Serum 0 +levels 0 +of 0 +7 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +0 0 +mumol 0 +/ 0 +L 0 +( 0 +peak 0 +) 0 +and 0 +4 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +8 0 +mumol 0 +/ 0 +L 0 +( 0 +trough 0 +) 0 +at 0 +the 0 +MTD 0 +were 0 +maintained 0 +during 0 +14 0 +days 0 +of 0 +therapy 0 +. 0 + +The 0 +DLT 0 +correlated 0 +with 0 +serum 0 +levels 0 +> 0 +or 0 += 0 +10 0 +mumol 0 +/ 0 +L 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +MTD 0 +of 0 +cis 1 +- 2 +RA 2 +given 0 +on 0 +this 0 +intermittent 0 +schedule 0 +was 0 +160 0 +mg 0 +/ 0 +m2 0 +/ 0 +d 0 +. 0 + +Serum 0 +levels 0 +known 0 +to 0 +be 0 +effective 0 +against 0 +neuroblastoma 3 +in 0 +vitro 0 +were 0 +achieved 0 +at 0 +this 0 +dose 0 +. 0 + +The 0 +DLT 0 +included 0 +hypercalcemia 3 +, 0 +and 0 +may 0 +be 0 +predicted 0 +by 0 +serum 0 +cis 1 +- 2 +RA 2 +levels 0 +. 0 + +Monitoring 0 +of 0 +serum 0 +calcium 1 +and 0 +cis 1 +- 2 +RA 2 +levels 0 +is 0 +indicated 0 +in 0 +future 0 +trials 0 +. 0 + +Time 0 +dependence 0 +of 0 +plasma 0 +malondialdehyde 1 +, 0 +oxypurines 1 +, 0 +and 0 +nucleosides 1 +during 0 +incomplete 0 +cerebral 3 +ischemia 4 +in 0 +the 0 +rat 0 +. 0 + +Incomplete 0 +cerebral 3 +ischemia 4 +( 0 +30 0 +min 0 +) 0 +was 0 +induced 0 +in 0 +the 0 +rat 0 +by 0 +bilaterally 0 +clamping 0 +the 0 +common 0 +carotid 0 +arteries 0 +. 0 + +Peripheral 0 +venous 0 +blood 0 +samples 0 +were 0 +withdrawn 0 +from 0 +the 0 +femoral 0 +vein 0 +four 0 +times 0 +( 0 +once 0 +every 0 +5 0 +min 0 +) 0 +before 0 +ischemia 3 +( 0 +0 0 +time 0 +) 0 +and 0 +5 0 +, 0 +15 0 +, 0 +and 0 +30 0 +min 0 +after 0 +ischemia 3 +. 0 + +Plasma 0 +extracts 0 +were 0 +analyzed 0 +by 0 +a 0 +highly 0 +sensitive 0 +high 0 +- 0 +performance 0 +liquid 0 +chromatographic 0 +method 0 +for 0 +the 0 +direct 0 +determination 0 +of 0 +malondialdehyde 1 +, 0 +oxypurines 1 +, 0 +and 0 +nucleosides 1 +. 0 + +During 0 +ischemia 3 +, 0 +a 0 +time 0 +- 0 +dependent 0 +increase 0 +of 0 +plasma 0 +oxypurines 1 +and 0 +nucleosides 1 +was 0 +observed 0 +. 0 + +Plasma 0 +malondialdehyde 1 +, 0 +which 0 +was 0 +present 0 +in 0 +minimal 0 +amount 0 +at 0 +zero 0 +time 0 +( 0 +0 0 +. 0 +058 0 +mumol 0 +/ 0 +liter 0 +plasma 0 +; 0 +SD 0 +0 0 +. 0 +015 0 +) 0 +, 0 +increased 0 +after 0 +5 0 +min 0 +of 0 +ischemia 3 +, 0 +resulting 0 +in 0 +a 0 +fivefold 0 +increase 0 +after 0 +30 0 +min 0 +of 0 +carotid 0 +occlusion 0 +( 0 +0 0 +. 0 +298 0 +mumol 0 +/ 0 +liter 0 +plasma 0 +; 0 +SD 0 +0 0 +. 0 +078 0 +) 0 +. 0 + +Increased 0 +plasma 0 +malondialdehyde 1 +was 0 +also 0 +recorded 0 +in 0 +two 0 +other 0 +groups 0 +of 0 +animals 0 +subjected 0 +to 0 +the 0 +same 0 +experimental 0 +model 0 +, 0 +one 0 +receiving 0 +20 0 +mg 0 +/ 0 +kg 0 +b 0 +. 0 +w 0 +. 0 +of 0 +the 0 +cyclooxygenase 0 +inhibitor 0 +acetylsalicylate 1 +intravenously 0 +immediately 0 +before 0 +ischemia 3 +, 0 +the 0 +other 0 +receiving 0 +650 0 +micrograms 0 +/ 0 +kg 0 +b 0 +. 0 +w 0 +. 0 +of 0 +the 0 +hypotensive 3 +drug 0 +nitroprusside 1 +at 0 +a 0 +flow 0 +rate 0 +of 0 +103 0 +microliters 0 +/ 0 +min 0 +intravenously 0 +during 0 +ischemia 3 +, 0 +although 0 +in 0 +this 0 +latter 0 +group 0 +malondialdehyde 1 +was 0 +significantly 0 +higher 0 +. 0 + +The 0 +present 0 +data 0 +indicate 0 +that 0 +the 0 +determination 0 +of 0 +malondialdehyde 1 +, 0 +oxypurines 1 +, 0 +and 0 +nucleosides 1 +in 0 +peripheral 0 +blood 0 +, 0 +may 0 +be 0 +used 0 +to 0 +monitor 0 +the 0 +metabolic 0 +alterations 0 +of 0 +tissues 0 +occurring 0 +during 0 +ischemic 3 +phenomena 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Acute 0 +renal 3 +toxicity 4 +of 0 +doxorubicin 1 +( 0 +adriamycin 1 +) 0 +- 0 +loaded 0 +cyanoacrylate 1 +nanoparticles 0 +. 0 + +Acute 0 +doxorubicin 1 +- 0 +loaded 0 +nanoparticle 0 +( 0 +DXNP 0 +) 0 +renal 3 +toxicity 4 +was 0 +explored 0 +in 0 +both 0 +normal 0 +rats 0 +and 0 +rats 0 +with 0 +experimental 0 +glomerulonephritis 3 +. 0 + +In 0 +normal 0 +rats 0 +, 0 +2 0 +/ 0 +6 0 +rats 0 +given 0 +free 0 +doxorubicin 1 +( 0 +DX 1 +) 0 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +died 0 +within 0 +one 0 +week 0 +, 0 +whereas 0 +all 0 +control 0 +animals 0 +and 0 +all 0 +rats 0 +having 0 +received 0 +free 0 +NP 0 +or 0 +DXNP 0 +survived 0 +. 0 + +A 0 +3 0 +times 0 +higher 0 +proteinuria 3 +appeared 0 +in 0 +animals 0 +treated 0 +with 0 +DXNP 0 +than 0 +in 0 +those 0 +treated 0 +with 0 +DX 1 +. 0 + +Free 0 +NP 0 +did 0 +not 0 +provoke 0 +any 0 +proteinuria 3 +. 0 + +Two 0 +hr 0 +post 0 +- 0 +injection 0 +, 0 +DXNP 0 +was 0 +2 0 +. 0 +7 0 +times 0 +more 0 +concentrated 0 +in 0 +kidneys 0 +than 0 +free 0 +DX 1 +( 0 +p 0 +< 0 +0 0 +. 0 +025 0 +) 0 +. 0 + +In 0 +rats 0 +with 0 +immune 0 +experimental 0 +glomerulonephritis 3 +, 0 +5 0 +/ 0 +6 0 +rats 0 +given 0 +DX 1 +died 0 +within 0 +7 0 +days 0 +, 0 +in 0 +contrast 0 +to 0 +animals 0 +treated 0 +by 0 +DXNP 0 +, 0 +NP 0 +, 0 +or 0 +untreated 0 +, 0 +which 0 +all 0 +survived 0 +. 0 + +Proteinuria 3 +appeared 0 +in 0 +all 0 +series 0 +, 0 +but 0 +was 0 +2 0 +- 0 +5 0 +times 0 +more 0 +intense 0 +( 0 +p 0 +> 0 +0 0 +. 0 +001 0 +) 0 +and 0 +prolonged 0 +after 0 +doxorubicin 1 +treatment 0 +( 0 +400 0 +- 0 +700 0 +mg 0 +/ 0 +day 0 +) 0 +, 0 +without 0 +significant 0 +difference 0 +between 0 +DXNP 0 +and 0 +DX 1 +. 0 + +Rats 0 +treated 0 +by 0 +unloaded 0 +NP 0 +behaved 0 +as 0 +controls 0 +. 0 + +These 0 +results 0 +demonstrate 0 +that 0 +, 0 +in 0 +these 0 +experimental 0 +conditions 0 +, 0 +DXNP 0 +killed 0 +less 0 +animals 0 +than 0 +free 0 +DX 1 +, 0 +despite 0 +of 0 +an 0 +enhanced 0 +renal 3 +toxicity 4 +of 0 +the 0 +former 0 +. 0 + +Both 0 +effects 0 +( 0 +better 0 +survival 0 +and 0 +nephrosis 3 +) 0 +are 0 +most 0 +probably 0 +related 0 +to 0 +an 0 +enhanced 0 +capture 0 +of 0 +DXNP 0 +by 0 +cells 0 +of 0 +the 0 +mononuclear 0 +phagocyte 0 +system 0 +, 0 +including 0 +mesangial 0 +cells 0 +. 0 + +Prostaglandin 1 +E2 2 +- 0 +induced 0 +bladder 3 +hyperactivity 4 +in 0 +normal 0 +, 0 +conscious 0 +rats 0 +: 0 +involvement 0 +of 0 +tachykinins 1 +? 0 + +In 0 +normal 0 +conscious 0 +rats 0 +investigated 0 +by 0 +continuous 0 +cystometry 0 +, 0 +intravesically 0 +instilled 0 +prostaglandin 1 +( 2 +PG 2 +) 2 +E2 2 +facilitated 0 +micturition 0 +and 0 +increased 0 +basal 0 +intravesical 0 +pressure 0 +. 0 + +The 0 +effect 0 +was 0 +attenuated 0 +by 0 +both 0 +the 0 +NK1 0 +receptor 0 +selective 0 +antagonist 0 +RP 1 +67 2 +, 2 +580 2 +and 0 +the 0 +NK2 0 +receptor 0 +selective 0 +antagonist 0 +SR 1 +48 2 +, 2 +968 2 +, 0 +given 0 +intra 0 +- 0 +arterially 0 +, 0 +suggesting 0 +that 0 +it 0 +was 0 +mediated 0 +by 0 +stimulation 0 +of 0 +both 0 +NK1 0 +and 0 +NK2 0 +receptors 0 +. 0 + +Intra 0 +- 0 +arterially 0 +given 0 +PGE2 1 +produced 0 +a 0 +distinct 0 +increase 0 +in 0 +bladder 0 +pressure 0 +before 0 +initiating 0 +a 0 +micturition 0 +reflex 0 +, 0 +indicating 0 +that 0 +the 0 +PG 1 +had 0 +a 0 +direct 0 +contractant 0 +effect 0 +on 0 +the 0 +detrusor 0 +smooth 0 +muscle 0 +. 0 + +The 0 +effect 0 +of 0 +intra 0 +- 0 +arterial 0 +PGE2 1 +could 0 +not 0 +be 0 +blocked 0 +by 0 +intra 0 +- 0 +arterial 0 +RP 1 +67 2 +, 2 +580 2 +or 0 +SR 1 +48 2 +, 2 +968 2 +, 0 +which 0 +opens 0 +the 0 +possibility 0 +that 0 +the 0 +micturition 0 +reflex 0 +elicited 0 +by 0 +intra 0 +- 0 +arterial 0 +PGE2 1 +was 0 +mediated 0 +by 0 +pathways 0 +other 0 +than 0 +the 0 +reflex 0 +initiated 0 +when 0 +the 0 +PG 1 +was 0 +given 0 +intravesically 0 +. 0 + +The 0 +present 0 +results 0 +thus 0 +suggest 0 +that 0 +intra 0 +- 0 +arterial 0 +PGE2 1 +, 0 +given 0 +near 0 +the 0 +bladder 0 +, 0 +may 0 +initiate 0 +micturition 0 +in 0 +the 0 +normal 0 +rat 0 +chiefly 0 +by 0 +directly 0 +contracting 0 +the 0 +smooth 0 +muscle 0 +of 0 +the 0 +detrusor 0 +. 0 + +However 0 +, 0 +when 0 +given 0 +intravesically 0 +, 0 +PGE2 1 +may 0 +stimulate 0 +micturition 0 +by 0 +releasing 0 +tachykinins 1 +from 0 +nerves 0 +in 0 +and 0 +/ 0 +or 0 +immediately 0 +below 0 +the 0 +urothelium 0 +. 0 + +These 0 +tachykinins 1 +, 0 +in 0 +turn 0 +, 0 +initiate 0 +a 0 +micturition 0 +reflex 0 +by 0 +stimulating 0 +NK1 0 +and 0 +NK2 0 +receptors 0 +. 0 + +Prostanoids 1 +may 0 +, 0 +via 0 +release 0 +of 0 +tachykinins 1 +, 0 +contribute 0 +to 0 +both 0 +urge 0 +and 0 +bladder 3 +hyperactivity 4 +seen 0 +in 0 +inflammatory 0 +conditions 0 +of 0 +the 0 +lower 0 +urinary 0 +tract 0 +. 0 + +Refractory 0 +cardiogenic 3 +shock 4 +and 0 +complete 0 +heart 3 +block 4 +after 0 +verapamil 1 +SR 0 +and 0 +metoprolol 1 +treatment 0 +. 0 + +A 0 +case 0 +report 0 +. 0 + +A 0 +seventy 0 +- 0 +eight 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +presented 0 +with 0 +complete 0 +heart 3 +block 4 +and 0 +refractory 0 +hypotension 3 +two 0 +days 0 +after 0 +a 0 +therapeutic 0 +dose 0 +of 0 +sustained 0 +- 0 +release 0 +verapamil 1 +with 0 +concomitant 0 +use 0 +of 0 +metoprolol 1 +. 0 + +The 0 +patient 0 +continued 0 +to 0 +remain 0 +hypotensive 3 +with 0 +complete 0 +heart 3 +block 4 +, 0 +even 0 +with 0 +multiple 0 +uses 0 +of 0 +intravenous 0 +atropine 1 +as 0 +well 0 +as 0 +high 0 +doses 0 +of 0 +pressor 0 +agents 0 +such 0 +as 0 +dopamine 1 +and 0 +dobutamine 1 +. 0 + +However 0 +, 0 +shortly 0 +after 0 +the 0 +use 0 +of 0 +intravenous 0 +calcium 1 +chloride 2 +, 0 +the 0 +refractory 0 +hypotension 3 +and 0 +complete 0 +heart 3 +block 4 +resolved 0 +. 0 + +Protective 0 +effect 0 +of 0 +misoprostol 1 +on 0 +indomethacin 1 +induced 0 +renal 3 +dysfunction 4 +in 0 +elderly 0 +patients 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +possible 0 +protective 0 +effects 0 +of 0 +misoprostol 1 +on 0 +renal 0 +function 0 +in 0 +hospitalized 0 +elderly 0 +patients 0 +treated 0 +with 0 +indomethacin 1 +. 0 + +METH0DS 0 +: 0 +Forty 0 +- 0 +five 0 +hospitalized 0 +elderly 0 +patients 0 +( 0 +> 0 +65 0 +years 0 +old 0 +) 0 +who 0 +required 0 +therapy 0 +with 0 +nonsteroidal 0 +antiinflammatory 0 +drugs 0 +( 0 +NSAID 0 +) 0 +were 0 +randomly 0 +assigned 0 +to 0 +receive 0 +either 0 +indomethacin 1 +, 0 +150 0 +mg 0 +/ 0 +day 0 +( 0 +Group 0 +A 0 +) 0 +, 0 +or 0 +indomethacin 1 +150 0 +mg 0 +/ 0 +day 0 +plus 0 +misoprostol 1 +at 0 +0 0 +. 0 +6 0 +mg 0 +/ 0 +day 0 +( 0 +Group 0 +B 0 +) 0 +. 0 + +Laboratory 0 +variables 0 +of 0 +renal 0 +function 0 +[ 0 +serum 0 +creatinine 1 +, 0 +blood 1 +urea 2 +nitrogen 2 +( 0 +BUN 1 +) 0 +and 0 +electrolytes 0 +] 0 +were 0 +evaluated 0 +before 0 +initiation 0 +of 0 +therapy 0 +and 0 +every 0 +2 0 +days 0 +, 0 +until 0 +termination 0 +of 0 +the 0 +study 0 +( 0 +a 0 +period 0 +of 0 +at 0 +least 0 +6 0 +days 0 +) 0 +. 0 + +Response 0 +to 0 +treatment 0 +was 0 +estimated 0 +by 0 +the 0 +visual 0 +analog 0 +scale 0 +for 0 +severity 0 +of 0 +pain 3 +. 0 + +RESULTS 0 +: 0 +Forty 0 +- 0 +two 0 +patients 0 +completed 0 +the 0 +study 0 +, 0 +22 0 +in 0 +Group 0 +A 0 +and 0 +20 0 +in 0 +Group 0 +B 0 +. 0 + +BUN 1 +and 0 +creatinine 1 +increased 0 +by 0 +> 0 +50 0 +% 0 +of 0 +baseline 0 +levels 0 +in 0 +54 0 +and 0 +45 0 +% 0 +of 0 +Group 0 +A 0 +patients 0 +, 0 +respectively 0 +, 0 +compared 0 +to 0 +only 0 +20 0 +and 0 +10 0 +% 0 +of 0 +Group 0 +B 0 +patients 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Potassium 1 +( 0 +K 1 +) 0 +increment 0 +of 0 +0 0 +. 0 +6 0 +mEq 0 +/ 0 +l 0 +or 0 +more 0 +was 0 +observed 0 +in 0 +50 0 +% 0 +of 0 +Group 0 +A 0 +, 0 +but 0 +in 0 +only 0 +15 0 +% 0 +of 0 +Group 0 +B 0 +patients 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +mean 0 +increments 0 +in 0 +BUN 1 +, 0 +creatinine 1 +, 0 +and 0 +K 1 +were 0 +reduced 0 +by 0 +63 0 +, 0 +80 0 +, 0 +and 0 +42 0 +% 0 +, 0 +respectively 0 +, 0 +in 0 +Group 0 +B 0 +patients 0 +compared 0 +to 0 +Group 0 +A 0 +. 0 +Response 0 +to 0 +treatment 0 +did 0 +not 0 +differ 0 +significantly 0 +between 0 +the 0 +2 0 +groups 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Hospitalized 0 +elderly 0 +patients 0 +are 0 +at 0 +risk 0 +for 0 +developing 0 +indomethacin 1 +related 0 +renal 3 +dysfunction 4 +. 0 + +Addition 0 +of 0 +misoprostol 1 +can 0 +minimize 0 +this 0 +renal 3 +impairment 4 +without 0 +affecting 0 +pain 3 +control 0 +. 0 + +Cognitive 3 +deterioration 4 +from 0 +long 0 +- 0 +term 0 +abuse 0 +of 0 +dextromethorphan 1 +: 0 +a 0 +case 0 +report 0 +. 0 + +Dextromethorphan 1 +( 0 +DM 1 +) 0 +, 0 +the 0 +dextrorotatory 0 +isomer 0 +of 0 +3 1 +- 2 +hydroxy 2 +- 2 +N 2 +- 2 +methylmorphinan 2 +, 0 +is 0 +the 0 +main 0 +ingredient 0 +in 0 +a 0 +number 0 +of 0 +widely 0 +available 0 +, 0 +over 0 +- 0 +the 0 +- 0 +counter 0 +antitussives 0 +. 0 + +Initial 0 +studies 0 +( 0 +Bornstein 0 +1968 0 +) 0 +showed 0 +that 0 +it 0 +possessed 0 +no 0 +respiratory 0 +suppressant 0 +effects 0 +and 0 +no 0 +addiction 0 +liability 0 +. 0 + +Subsequently 0 +, 0 +however 0 +, 0 +several 0 +articles 0 +reporting 0 +abuse 0 +of 0 +this 0 +drug 0 +have 0 +appeared 0 +in 0 +the 0 +literature 0 +. 0 + +The 0 +drug 0 +is 0 +known 0 +to 0 +cause 0 +a 0 +variety 0 +of 0 +acute 0 +toxic 0 +effects 0 +, 0 +ranging 0 +from 0 +nausea 3 +, 0 +restlessness 3 +, 0 +insomnia 3 +, 0 +ataxia 3 +, 0 +slurred 0 +speech 0 +and 0 +nystagmus 3 +to 0 +mood 0 +changes 0 +, 0 +perceptual 0 +alterations 0 +, 0 +inattention 0 +, 0 +disorientation 0 +and 0 +aggressive 3 +behavior 4 +( 0 +Rammer 0 +et 0 +al 0 +1988 0 +; 0 +Katona 0 +and 0 +Watson 0 +1986 0 +; 0 +Isbell 0 +and 0 +Fraser 0 +1953 0 +; 0 +Devlin 0 +et 0 +al 0 +1985 0 +; 0 +McCarthy 0 +1971 0 +; 0 +Dodds 0 +and 0 +Revai 0 +1967 0 +; 0 +Degkwitz 0 +1964 0 +; 0 +Hildebrand 0 +et 0 +al 0 +1989 0 +) 0 +. 0 + +There 0 +have 0 +also 0 +been 0 +two 0 +reported 0 +fatalities 0 +from 0 +DM 1 +overdoses 0 +( 0 +Fleming 0 +1986 0 +) 0 +. 0 + +However 0 +, 0 +there 0 +are 0 +no 0 +reports 0 +describing 0 +the 0 +effects 0 +of 0 +chronic 0 +abuse 0 +. 0 + +This 0 +report 0 +describes 0 +a 0 +case 0 +of 0 +cognitive 3 +deterioration 4 +resulting 0 +from 0 +prolonged 0 +use 0 +of 0 +DM 1 +. 0 + +Effects 0 +of 0 +ouabain 1 +on 0 +myocardial 0 +oxygen 1 +supply 0 +and 0 +demand 0 +in 0 +patients 0 +with 0 +chronic 0 +coronary 3 +artery 4 +disease 4 +. 0 + +A 0 +hemodynamic 0 +, 0 +volumetric 0 +, 0 +and 0 +metabolic 0 +study 0 +in 0 +patients 0 +without 0 +heart 3 +failure 4 +. 0 + +The 0 +effects 0 +of 0 +digitalis 1 +glycosides 2 +on 0 +myocardial 0 +oxygen 1 +supply 0 +and 0 +demand 0 +are 0 +of 0 +particular 0 +interest 0 +in 0 +the 0 +presence 0 +of 0 +obstructive 0 +coronary 3 +artery 4 +disease 4 +, 0 +but 0 +have 0 +not 0 +been 0 +measured 0 +previously 0 +in 0 +man 0 +. 0 + +We 0 +assessed 0 +the 0 +effects 0 +of 0 +ouabain 1 +( 0 +0 0 +. 0 +015 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +on 0 +hemodynamic 0 +, 0 +volumetric 0 +, 0 +and 0 +metabolic 0 +parameters 0 +in 0 +11 0 +patients 0 +with 0 +severe 0 +chronic 0 +coronary 3 +artery 4 +disease 4 +without 0 +clinical 0 +congestive 3 +heart 4 +failure 4 +. 0 + +Because 0 +the 0 +protocol 0 +was 0 +long 0 +and 0 +involved 0 +interventions 0 +which 0 +might 0 +affect 0 +the 0 +determinations 0 +, 0 +we 0 +also 0 +studied 0 +in 0 +nine 0 +patients 0 +using 0 +an 0 +identical 0 +protocol 0 +except 0 +that 0 +ouabain 1 +administration 0 +was 0 +omitted 0 +. 0 + +Left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +and 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +volume 0 +fell 0 +in 0 +each 0 +patient 0 +given 0 +ouabain 1 +, 0 +even 0 +though 0 +they 0 +were 0 +initially 0 +elevated 0 +in 0 +only 0 +two 0 +patients 0 +. 0 + +Left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +fell 0 +from 0 +11 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +4 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +to 0 +5 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +mm 0 +Hg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +and 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +volume 0 +fell 0 +from 0 +100 0 ++ 0 +/ 0 +- 0 +17 0 +to 0 +82 0 ++ 0 +/ 0 +- 0 +12 0 +ml 0 +/ 0 +m2 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +1 0 +h 0 +after 0 +ouabain 1 +infusion 0 +was 0 +completed 0 +. 0 + +The 0 +maximum 0 +velocity 0 +of 0 +contractile 0 +element 0 +shortening 0 +increased 0 +from 0 +1 0 +. 0 +68 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +11 0 +ml 0 +/ 0 +s 0 +to 0 +2 0 +. 0 +18 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +21 0 +muscle 0 +- 0 +lengths 0 +/ 0 +s 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +and 0 +is 0 +consistent 0 +with 0 +an 0 +increase 0 +in 0 +contractility 0 +. 0 + +No 0 +significant 0 +change 0 +in 0 +these 0 +parameters 0 +occurred 0 +in 0 +the 0 +control 0 +patients 0 +. 0 + +No 0 +significant 0 +change 0 +in 0 +myocardial 0 +oxygen 1 +consumption 0 +occurred 0 +after 0 +ouabain 1 +administration 0 +but 0 +this 0 +may 0 +be 0 +related 0 +to 0 +a 0 +greater 0 +decrease 0 +in 0 +mean 0 +arterial 0 +pressure 0 +in 0 +the 0 +ouabain 1 +patients 0 +than 0 +in 0 +the 0 +control 0 +patients 0 +. 0 + +We 0 +conclude 0 +that 0 +in 0 +patients 0 +with 0 +chronic 0 +coronary 3 +artery 4 +disease 4 +who 0 +are 0 +not 0 +in 0 +clinical 0 +congestive 3 +heart 4 +failure 4 +left 3 +ventricular 4 +end 4 +- 4 +diastolic 4 +volume 4 +falls 4 +after 0 +ouabain 1 +administration 0 +even 0 +when 0 +it 0 +is 0 +initially 0 +normal 0 +. 0 + +Though 0 +this 0 +fall 0 +would 0 +be 0 +associated 0 +with 0 +a 0 +decrease 0 +in 0 +wall 0 +tension 0 +, 0 +and 0 +, 0 +therefore 0 +, 0 +of 0 +myocardial 0 +oxygen 1 +consumption 0 +, 0 +it 0 +may 0 +not 0 +be 0 +of 0 +sufficient 0 +magnitude 0 +to 0 +prevent 0 +a 0 +net 0 +increase 0 +in 0 +myocardial 0 +oxygen 1 +consumption 0 +. 0 + +Nevertheless 0 +, 0 +compensatory 0 +mechanisms 0 +prevent 0 +a 0 +deterioration 0 +of 0 +resting 0 +myocardial 0 +metabolism 0 +. 0 + +Dexamethasone 1 +- 0 +induced 0 +ocular 3 +hypertension 4 +in 0 +perfusion 0 +- 0 +cultured 0 +human 0 +eyes 0 +. 0 + +PURP0SE 0 +: 0 +Glucocorticoid 0 +administration 0 +can 0 +lead 0 +to 0 +the 0 +development 0 +of 0 +ocular 3 +hypertension 4 +and 0 +corticosteroid 3 +glaucoma 4 +in 0 +a 0 +subset 0 +of 0 +the 0 +population 0 +through 0 +a 0 +decrease 0 +in 0 +the 0 +aqueous 0 +humor 0 +outflow 0 +facility 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +glucocorticoid 0 +treatment 0 +can 0 +directly 0 +affect 0 +the 0 +outflow 0 +facility 0 +of 0 +isolated 0 +, 0 +perfusion 0 +- 0 +cultured 0 +human 0 +eyes 0 +. 0 + +METH0DS 0 +: 0 +The 0 +anterior 0 +segments 0 +of 0 +human 0 +donor 0 +eyes 0 +from 0 +regional 0 +eye 0 +banks 0 +were 0 +placed 0 +in 0 +a 0 +constant 0 +flow 0 +, 0 +variable 0 +pressure 0 +perfusion 0 +culture 0 +system 0 +. 0 + +Paired 0 +eyes 0 +were 0 +perfused 0 +in 0 +serum 0 +- 0 +free 0 +media 0 +with 0 +or 0 +without 0 +10 0 +( 0 +- 0 +7 0 +) 0 +M 0 +dexamethasone 1 +for 0 +12 0 +days 0 +. 0 + +Intraocular 0 +pressure 0 +was 0 +monitored 0 +daily 0 +. 0 + +After 0 +incubation 0 +, 0 +the 0 +eyes 0 +were 0 +morphologically 0 +characterized 0 +by 0 +light 0 +microscopy 0 +, 0 +transmission 0 +and 0 +scanning 0 +electron 0 +microscopy 0 +, 0 +and 0 +scanning 0 +laser 0 +confocal 0 +microscopy 0 +. 0 + +RESULTS 0 +: 0 +A 0 +significant 0 +increase 0 +in 0 +intraocular 0 +pressure 0 +developed 0 +in 0 +13 0 +of 0 +the 0 +44 0 +pairs 0 +of 0 +eyes 0 +perfused 0 +with 0 +dexamethasone 1 +with 0 +an 0 +average 0 +pressure 0 +rise 0 +of 0 +17 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +8 0 +mm 0 +Hg 0 +after 0 +12 0 +days 0 +of 0 +dexamethasone 1 +exposure 0 +. 0 + +The 0 +contralateral 0 +control 0 +eyes 0 +, 0 +which 0 +did 0 +not 0 +receive 0 +dexamethasone 1 +, 0 +maintained 0 +a 0 +stable 0 +intraocular 0 +pressure 0 +during 0 +the 0 +same 0 +period 0 +. 0 + +The 0 +outflow 0 +pathway 0 +of 0 +the 0 +untreated 0 +eyes 0 +appeared 0 +morphologically 0 +normal 0 +. 0 + +In 0 +contrast 0 +, 0 +the 0 +dexamethasone 1 +- 0 +treated 0 +hypertensive 3 +eyes 4 +had 0 +thickened 0 +trabecular 0 +beams 0 +, 0 +decreased 0 +intertrabecular 0 +spaces 0 +, 0 +thickened 0 +juxtacanalicular 0 +tissue 0 +, 0 +activated 0 +trabecular 0 +meshwork 0 +cells 0 +, 0 +and 0 +increased 0 +amounts 0 +of 0 +amorphogranular 0 +extracellular 0 +material 0 +, 0 +especially 0 +in 0 +the 0 +juxtacanalicular 0 +tissue 0 +and 0 +beneath 0 +the 0 +endothelial 0 +lining 0 +of 0 +the 0 +canal 0 +of 0 +Schlemm 0 +. 0 + +The 0 +dexamethasone 1 +- 0 +treated 0 +nonresponder 0 +eyes 0 +appeared 0 +to 0 +be 0 +morphologically 0 +similar 0 +to 0 +the 0 +untreated 0 +eyes 0 +, 0 +although 0 +several 0 +subtle 0 +dexamethasone 1 +- 0 +induced 0 +morphologic 0 +changes 0 +were 0 +evident 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Dexamethasone 1 +treatment 0 +of 0 +isolated 0 +, 0 +perfusion 0 +- 0 +cultured 0 +human 0 +eyes 0 +led 0 +to 0 +the 0 +generation 0 +of 0 +ocular 3 +hypertension 4 +in 0 +approximately 0 +30 0 +% 0 +of 0 +the 0 +dexamethasone 1 +- 0 +treated 0 +eyes 0 +. 0 + +Steroid 1 +treatment 0 +resulted 0 +in 0 +morphologic 0 +changes 0 +in 0 +the 0 +trabecular 0 +meshwork 0 +similar 0 +to 0 +those 0 +reported 0 +for 0 +corticosteroid 3 +glaucoma 4 +and 0 +open 3 +angle 4 +glaucoma 4 +. 0 + +This 0 +system 0 +may 0 +provide 0 +an 0 +acute 0 +model 0 +in 0 +which 0 +to 0 +study 0 +the 0 +pathogenic 0 +mechanisms 0 +involved 0 +in 0 +steroid 3 +glaucoma 4 +and 0 +primary 3 +open 4 +angle 4 +glaucoma 4 +. 0 + +Auditory 0 +disturbance 0 +associated 0 +with 0 +interscalene 0 +brachial 0 +plexus 0 +block 0 +. 0 + +We 0 +performed 0 +an 0 +audiometric 0 +study 0 +in 0 +20 0 +patients 0 +who 0 +underwent 0 +surgery 0 +of 0 +the 0 +shoulder 0 +region 0 +under 0 +an 0 +interscalene 0 +brachial 0 +plexus 0 +block 0 +( 0 +IBPB 0 +) 0 +. 0 + +Bupivacaine 1 +0 0 +. 0 +75 0 +% 0 +with 0 +adrenaline 1 +was 0 +given 0 +followed 0 +by 0 +a 0 +24 0 +- 0 +hr 0 +continuous 0 +infusion 0 +of 0 +0 0 +. 0 +25 0 +% 0 +bupivacaine 1 +. 0 + +Three 0 +audiometric 0 +threshold 0 +measurements 0 +( 0 +0 0 +. 0 +25 0 +- 0 +18 0 +kHz 0 +) 0 +were 0 +made 0 +: 0 +the 0 +first 0 +before 0 +IBPB 0 +, 0 +the 0 +second 0 +2 0 +- 0 +6 0 +h 0 +after 0 +surgery 0 +and 0 +the 0 +third 0 +on 0 +the 0 +first 0 +day 0 +after 0 +operation 0 +. 0 + +In 0 +four 0 +patients 0 +hearing 3 +impairment 4 +on 0 +the 0 +side 0 +of 0 +the 0 +block 0 +was 0 +demonstrated 0 +after 0 +operation 0 +, 0 +in 0 +three 0 +measurements 0 +on 0 +the 0 +day 0 +of 0 +surgery 0 +and 0 +in 0 +one 0 +on 0 +the 0 +following 0 +day 0 +. 0 + +The 0 +frequencies 0 +at 0 +which 0 +the 0 +impairment 0 +occurred 0 +varied 0 +between 0 +patients 0 +; 0 +in 0 +one 0 +only 0 +low 0 +frequencies 0 +( 0 +0 0 +. 0 +25 0 +- 0 +0 0 +. 0 +5 0 +kHz 0 +) 0 +were 0 +involved 0 +. 0 + +The 0 +maximum 0 +change 0 +in 0 +threshold 0 +was 0 +35 0 +dB 0 +at 0 +6 0 +kHz 0 +measured 0 +at 0 +the 0 +end 0 +of 0 +the 0 +continuous 0 +infusion 0 +of 0 +bupivacaine 1 +. 0 + +This 0 +patient 0 +had 0 +hearing 0 +threshold 0 +changes 0 +( 0 +15 0 +- 0 +20 0 +dB 0 +) 0 +at 0 +6 0 +- 0 +10 0 +kHz 0 +on 0 +the 0 +opposite 0 +side 0 +also 0 +. 0 + +IBPB 0 +may 0 +cause 0 +transient 0 +auditory 3 +dysfunction 4 +in 0 +the 0 +ipsilateral 0 +ear 0 +, 0 +possibly 0 +via 0 +an 0 +effect 0 +on 0 +sympathetic 0 +innervation 0 +. 0 + +The 0 +safety 0 +and 0 +efficacy 0 +of 0 +combination 0 +N 1 +- 2 +butyl 2 +- 2 +deoxynojirimycin 2 +( 0 +SC 1 +- 2 +48334 2 +) 0 +and 0 +zidovudine 1 +in 0 +patients 0 +with 0 +HIV 3 +- 4 +1 4 +infection 4 +and 0 +200 0 +- 0 +500 0 +CD4 0 +cells 0 +/ 0 +mm3 0 +. 0 + +We 0 +conducted 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +randomized 0 +phase 0 +II 0 +study 0 +to 0 +evaluate 0 +the 0 +safety 0 +and 0 +activity 0 +of 0 +combination 0 +therapy 0 +with 0 +N 1 +- 2 +butyl 2 +- 2 +deoxynojirimycin 2 +( 0 +SC 1 +- 2 +48334 2 +) 0 +( 0 +an 0 +alpha 0 +- 0 +glucosidase 0 +I 0 +inhibitor 0 +) 0 +and 0 +zidovudine 1 +versus 0 +zidovudine 1 +alone 0 +. 0 + +Patients 0 +with 0 +200 0 +to 0 +500 0 +CD4 0 +cells 0 +/ 0 +mm3 0 +who 0 +tolerated 0 +< 0 +or 0 += 0 +12 0 +weeks 0 +of 0 +prior 0 +zidovudine 1 +therapy 0 +received 0 +SC 1 +- 2 +48334 2 +( 0 +1000 0 +mg 0 +every 0 +8 0 +h 0 +) 0 +and 0 +zidovudine 1 +( 0 +100 0 +mg 0 +every 0 +8 0 +h 0 +) 0 +or 0 +zidovudine 1 +and 0 +placebo 0 +. 0 + +Sixty 0 +patients 0 +received 0 +combination 0 +therapy 0 +and 0 +58 0 +, 0 +zidovudine 1 +and 0 +placebo 0 +. 0 + +Twenty 0 +- 0 +three 0 +patients 0 +( 0 +38 0 +% 0 +) 0 +and 0 +15 0 +( 0 +26 0 +% 0 +) 0 +, 0 +in 0 +the 0 +combination 0 +and 0 +zidovudine 1 +groups 0 +, 0 +respectively 0 +, 0 +discontinued 0 +therapy 0 +( 0 +p 0 += 0 +0 0 +. 0 +15 0 +) 0 +. 0 + +The 0 +mean 0 +SC 1 +- 2 +48334 2 +steady 0 +- 0 +state 0 +trough 0 +level 0 +( 0 +4 0 +. 0 +04 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +99 0 +micrograms 0 +/ 0 +ml 0 +) 0 +was 0 +below 0 +the 0 +in 0 +vitro 0 +inhibitory 0 +concentration 0 +for 0 +human 0 +immunodeficiency 3 +virus 0 +( 0 +HIV 0 +) 0 +. 0 + +The 0 +mean 0 +increase 0 +in 0 +CD4 0 +cells 0 +at 0 +week 0 +4 0 +was 0 +73 0 +. 0 +8 0 +cells 0 +/ 0 +mm3 0 +and 0 +52 0 +. 0 +4 0 +cells 0 +/ 0 +mm3 0 +for 0 +the 0 +combination 0 +and 0 +zidovudine 1 +groups 0 +, 0 +respectively 0 +( 0 +p 0 +> 0 +0 0 +. 0 +36 0 +) 0 +. 0 + +For 0 +patients 0 +with 0 +prior 0 +zidovudine 1 +therapy 0 +, 0 +the 0 +mean 0 +change 0 +in 0 +CD4 0 +cells 0 +in 0 +the 0 +combination 0 +and 0 +zidovudine 1 +groups 0 +was 0 +63 0 +. 0 +7 0 +cells 0 +/ 0 +mm3 0 +and 0 +4 0 +. 0 +9 0 +cells 0 +/ 0 +mm3 0 +at 0 +week 0 +8 0 +and 0 +6 0 +. 0 +8 0 +cells 0 +/ 0 +mm3 0 +and 0 +- 0 +45 0 +. 0 +1 0 +cells 0 +/ 0 +mm3 0 +at 0 +week 0 +16 0 +, 0 +respectively 0 +. 0 + +The 0 +number 0 +of 0 +patients 0 +with 0 +suppression 0 +of 0 +HIV 0 +p24 0 +antigenemia 0 +in 0 +the 0 +combination 0 +and 0 +zidovudine 1 +groups 0 +was 0 +six 0 +( 0 +40 0 +% 0 +) 0 +and 0 +two 0 +( 0 +11 0 +% 0 +) 0 +at 0 +week 0 +4 0 +( 0 +p 0 += 0 +0 0 +. 0 +10 0 +) 0 +and 0 +five 0 +( 0 +45 0 +% 0 +) 0 +and 0 +two 0 +( 0 +14 0 +% 0 +) 0 +at 0 +week 0 +24 0 +( 0 +p 0 += 0 +0 0 +. 0 +08 0 +) 0 +, 0 +respectively 0 +. 0 + +Diarrhea 3 +, 0 +flatulence 3 +, 0 +abdominal 3 +pain 4 +, 0 +and 0 +weight 3 +loss 4 +were 0 +common 0 +for 0 +combination 0 +recipients 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Prolonged 0 +paralysis 3 +due 0 +to 0 +nondepolarizing 1 +neuromuscular 2 +blocking 2 +agents 2 +and 0 +corticosteroids 1 +. 0 + +The 0 +long 0 +- 0 +term 0 +use 0 +of 0 +nondepolarizing 1 +neuromuscular 2 +blocking 2 +agents 2 +( 0 +ND 1 +- 2 +NMBA 2 +) 0 +has 0 +recently 0 +been 0 +implicated 0 +as 0 +a 0 +cause 0 +of 0 +prolonged 0 +muscle 3 +weakness 4 +, 0 +although 0 +the 0 +site 0 +of 0 +the 0 +lesion 0 +and 0 +the 0 +predisposing 0 +factors 0 +have 0 +been 0 +unclear 0 +. 0 + +We 0 +report 0 +3 0 +patients 0 +( 0 +age 0 +37 0 +- 0 +52 0 +years 0 +) 0 +with 0 +acute 0 +respiratory 3 +insufficiency 4 +who 0 +developed 0 +prolonged 0 +weakness 3 +following 0 +the 0 +discontinuation 0 +of 0 +ND 1 +- 2 +NMBAs 2 +. 0 + +Two 0 +patients 0 +also 0 +received 0 +intravenous 0 +corticosteroids 1 +. 0 + +Renal 0 +function 0 +was 0 +normal 0 +but 0 +hepatic 0 +function 0 +was 0 +impaired 0 +in 0 +all 0 +patients 0 +, 0 +and 0 +all 0 +had 0 +acidosis 3 +. 0 + +Electrophysiologic 0 +studies 0 +revealed 0 +low 0 +amplitude 0 +compound 0 +motor 0 +action 0 +potentials 0 +, 0 +normal 0 +sensory 0 +studies 0 +, 0 +and 0 +fibrillations 0 +. 0 + +Repetitive 0 +stimulation 0 +at 0 +2 0 +Hz 0 +showed 0 +a 0 +decremental 0 +response 0 +in 0 +2 0 +patients 0 +. 0 + +The 0 +serum 0 +vecuronium 1 +level 0 +measured 0 +in 0 +1 0 +patient 0 +14 0 +days 0 +after 0 +the 0 +drug 0 +had 0 +been 0 +discontinued 0 +was 0 +172 0 +ng 0 +/ 0 +mL 0 +. 0 + +A 0 +muscle 0 +biopsy 0 +in 0 +this 0 +patient 0 +showed 0 +loss 3 +of 4 +thick 4 +, 4 +myosin 4 +filaments 4 +. 0 + +The 0 +weakness 3 +in 0 +these 0 +patients 0 +is 0 +due 0 +to 0 +pathology 3 +at 4 +both 4 +the 4 +neuromuscular 4 +junction 4 +( 0 +most 0 +likely 0 +due 0 +to 0 +ND 1 +- 2 +NMBA 2 +) 0 +and 0 +muscle 0 +( 0 +most 0 +likely 0 +due 0 +to 0 +corticosteroids 1 +) 0 +. 0 + +Hepatic 3 +dysfunction 4 +and 0 +acidosis 3 +are 0 +contributing 0 +risk 0 +factors 0 +. 0 + +Failure 0 +of 0 +ancrod 0 +in 0 +the 0 +treatment 0 +of 0 +heparin 1 +- 0 +induced 0 +arterial 0 +thrombosis 3 +. 0 + +The 0 +morbidity 0 +and 0 +mortality 0 +associated 0 +with 0 +heparin 1 +- 0 +induced 0 +thrombosis 3 +remain 0 +high 0 +despite 0 +numerous 0 +empirical 0 +therapies 0 +. 0 + +Ancrod 0 +has 0 +been 0 +used 0 +successfully 0 +for 0 +prophylaxis 0 +against 0 +development 0 +of 0 +thrombosis 3 +in 0 +patients 0 +with 0 +heparin 1 +induced 0 +platelet 3 +aggregation 4 +who 0 +require 0 +brief 0 +reexposure 0 +to 0 +heparin 1 +, 0 +but 0 +its 0 +success 0 +in 0 +patients 0 +who 0 +have 0 +developed 0 +the 0 +thrombosis 3 +syndrome 0 +is 0 +not 0 +well 0 +defined 0 +. 0 + +The 0 +authors 0 +present 0 +a 0 +case 0 +of 0 +failure 0 +of 0 +ancrod 0 +treatment 0 +in 0 +a 0 +patient 0 +with 0 +heparin 1 +- 0 +induced 0 +thrombosis 3 +. 0 + +Water 3 +intoxication 4 +associated 0 +with 0 +oxytocin 1 +administration 0 +during 0 +saline 0 +- 0 +induced 0 +abortion 3 +. 0 + +Four 0 +cases 0 +of 0 +water 3 +intoxication 4 +in 0 +connection 0 +with 0 +oxytocin 1 +administration 0 +during 0 +saline 0 +- 0 +induced 0 +abortions 3 +are 0 +described 0 +. 0 + +The 0 +mechanism 0 +of 0 +water 3 +intoxication 4 +is 0 +discussed 0 +in 0 +regard 0 +to 0 +these 0 +cases 0 +. 0 + +0xytocin 1 +administration 0 +during 0 +midtrimester 0 +- 0 +induced 0 +abortions 3 +is 0 +advocated 0 +only 0 +if 0 +it 0 +can 0 +be 0 +carried 0 +out 0 +under 0 +careful 0 +observations 0 +of 0 +an 0 +alert 0 +nursing 0 +staff 0 +, 0 +aware 0 +of 0 +the 0 +symptoms 0 +of 0 +water 3 +intoxication 4 +and 0 +instructed 0 +to 0 +watch 0 +the 0 +diuresis 0 +and 0 +report 0 +such 0 +early 0 +signs 0 +of 0 +the 0 +syndrome 0 +as 0 +asthenia 3 +, 0 +muscular 0 +irritability 3 +, 0 +or 0 +headaches 3 +. 0 + +The 0 +oxytocin 1 +should 0 +be 0 +given 0 +only 0 +in 0 +Ringers 0 +lactate 1 +or 0 +, 0 +alternately 0 +, 0 +in 0 +Ringers 0 +lactate 1 +and 0 +a 0 +5 0 +per 0 +cent 0 +dextrose 1 +and 0 +water 0 +solutions 0 +. 0 + +The 0 +urinary 0 +output 0 +should 0 +be 0 +monitored 0 +and 0 +the 0 +oxytocin 1 +administration 0 +discontinued 0 +and 0 +the 0 +serum 0 +electrolytes 0 +checked 0 +if 0 +the 0 +urinary 0 +output 0 +decreases 0 +. 0 + +The 0 +oxytocin 1 +should 0 +not 0 +be 0 +administered 0 +in 0 +excess 0 +of 0 +36 0 +hours 0 +. 0 + +If 0 +the 0 +patient 0 +has 0 +not 0 +aborted 0 +by 0 +then 0 +the 0 +oxytocin 1 +should 0 +be 0 +discontinued 0 +for 0 +10 0 +to 0 +12 0 +hours 0 +in 0 +order 0 +to 0 +perform 0 +electrolyte 0 +determinations 0 +and 0 +correct 0 +any 0 +electrolyte 0 +imbalance 0 +. 0 + +Light 0 +chain 0 +proteinuria 3 +and 0 +cellular 0 +mediated 0 +immunity 0 +in 0 +rifampin 1 +treated 0 +patients 0 +with 0 +tuberculosis 3 +. 0 + +Light 0 +chain 0 +proteinuria 3 +was 0 +found 0 +in 0 +9 0 +of 0 +17 0 +tuberculosis 3 +patients 0 +treated 0 +with 0 +rifampin 1 +. 0 + +Concomitant 0 +assay 0 +of 0 +cellular 0 +mediated 0 +immunity 0 +in 0 +these 0 +patients 0 +using 0 +skin 0 +test 0 +antigen 0 +and 0 +a 0 +lymphokine 0 +in 0 +vitro 0 +test 0 +provided 0 +results 0 +that 0 +were 0 +different 0 +. 0 + +Response 0 +to 0 +Varidase 0 +skin 0 +test 0 +antigen 0 +was 0 +negative 0 +for 0 +all 0 +eight 0 +tuberculosis 3 +patients 0 +tested 0 +, 0 +but 0 +there 0 +occurred 0 +a 0 +hyper 0 +- 0 +responsiveness 0 +of 0 +the 0 +lymphocytes 0 +of 0 +these 0 +eight 0 +patients 0 +to 0 +phytomitogen 0 +( 0 +PHA 0 +- 0 +P 0 +) 0 +. 0 +as 0 +well 0 +as 0 +of 0 +those 0 +of 0 +seven 0 +other 0 +tuberculous 3 +patients 0 +. 0 + +This 0 +last 0 +finding 0 +may 0 +be 0 +related 0 +to 0 +time 0 +of 0 +testing 0 +and 0 +/ 0 +or 0 +endogenous 0 +serum 0 +binding 0 +of 0 +rifampin 1 +which 0 +could 0 +have 0 +inhibited 0 +mitogen 0 +activity 0 +for 0 +the 0 +lymphocyte 0 +. 0 + +KF17837 1 +: 0 +a 0 +novel 0 +selective 0 +adenosine 1 +A2A 0 +receptor 0 +antagonist 0 +with 0 +anticataleptic 0 +activity 0 +. 0 + +KF17837 1 +is 0 +a 0 +novel 0 +selective 0 +adenosine 1 +A2A 0 +receptor 0 +antagonist 0 +. 0 + +0ral 0 +administration 0 +of 0 +KF17837 1 +( 0 +2 0 +. 0 +5 0 +, 0 +10 0 +. 0 +0 0 +and 0 +30 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +) 0 +significantly 0 +ameliorated 0 +the 0 +cataleptic 3 +responses 0 +induced 0 +by 0 +intracerebroventricular 0 +administration 0 +of 0 +an 0 +adenosine 1 +A2A 0 +receptor 0 +agonist 0 +, 0 +CGS 1 +21680 2 +( 0 +10 0 +micrograms 0 +) 0 +, 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 + +KF17837 1 +also 0 +reduced 0 +the 0 +catalepsy 3 +induced 0 +by 0 +haloperidol 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +by 0 +reserpine 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +These 0 +anticataleptic 0 +effects 0 +were 0 +exhibited 0 +dose 0 +dependently 0 +at 0 +doses 0 +from 0 +0 0 +. 0 +625 0 +and 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +, 0 +respectively 0 +. 0 + +Moreover 0 +, 0 +KF17837 1 +( 0 +0 0 +. 0 +625 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +potentiated 0 +the 0 +anticataleptic 0 +effects 0 +of 0 +a 0 +subthreshold 0 +dose 0 +of 0 +L 1 +- 2 +3 2 +, 2 +4 2 +- 2 +dihydroxyphenylalanine 2 +( 0 +L 1 +- 2 +D0PA 2 +; 0 +25 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +plus 0 +benserazide 1 +( 0 +6 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +These 0 +results 0 +suggested 0 +that 0 +KF17837 1 +is 0 +a 0 +centrally 0 +active 0 +adenosine 1 +A2A 0 +receptor 0 +antagonist 0 +and 0 +that 0 +the 0 +dopaminergic 0 +function 0 +of 0 +the 0 +nigrostriatal 0 +pathway 0 +is 0 +potentiated 0 +by 0 +adenosine 1 +A2A 0 +receptor 0 +antagonists 0 +. 0 + +Furthermore 0 +, 0 +KF17837 1 +may 0 +be 0 +a 0 +useful 0 +drug 0 +in 0 +the 0 +treatment 0 +of 0 +parkinsonism 3 +. 0 + +Effect 0 +of 0 +nondopaminergic 0 +drugs 0 +on 0 +L 1 +- 2 +dopa 2 +- 0 +induced 0 +dyskinesias 3 +in 0 +MPTP 1 +- 0 +treated 0 +monkeys 0 +. 0 + +A 0 +group 0 +of 0 +four 0 +monkeys 0 +was 0 +rendered 0 +parkinsonian 3 +with 0 +the 0 +toxin 0 +MPTP 1 +. 0 + +They 0 +were 0 +then 0 +treated 0 +chronically 0 +with 0 +L 1 +- 2 +D0PA 2 +/ 2 +benserazide 2 +50 0 +/ 0 +12 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +given 0 +orally 0 +daily 0 +for 0 +2 0 +months 0 +. 0 + +This 0 +dose 0 +produced 0 +a 0 +striking 0 +antiparkinsonian 0 +effect 0 +, 0 +but 0 +all 0 +animals 0 +manifested 0 +dyskinesia 3 +. 0 + +A 0 +series 0 +of 0 +agents 0 +acting 0 +primarily 0 +on 0 +neurotransmitters 0 +other 0 +than 0 +dopamine 1 +were 0 +then 0 +tested 0 +in 0 +combination 0 +with 0 +L 1 +- 2 +D0PA 2 +to 0 +see 0 +if 0 +the 0 +dyskinetic 3 +movements 0 +would 0 +be 0 +modified 0 +. 0 + +Several 0 +drugs 0 +, 0 +including 0 +clonidine 1 +, 0 +physostigmine 1 +, 0 +methysergide 1 +, 0 +5 1 +- 2 +MD0T 2 +, 0 +propranolol 1 +, 0 +and 0 +MK 1 +- 2 +801 2 +, 0 +markedly 0 +reduced 0 +the 0 +dyskinetic 3 +movements 0 +but 0 +at 0 +the 0 +cost 0 +of 0 +a 0 +return 0 +of 0 +parkinsonian 3 +symptomatology 0 +. 0 + +However 0 +, 0 +yohimbine 1 +and 0 +meperidine 1 +reduced 0 +predominantly 0 +the 0 +dyskinetic 3 +movements 0 +. 0 + +Baclofen 1 +was 0 +also 0 +useful 0 +in 0 +one 0 +monkey 0 +against 0 +a 0 +more 0 +dystonic 3 +form 0 +of 0 +dyskinesia 3 +. 0 + +Atropine 1 +converted 0 +the 0 +dystonic 3 +movements 0 +into 0 +chorea 3 +. 0 + +Hallucinations 3 +and 0 +ifosfamide 1 +- 0 +induced 0 +neurotoxicity 3 +. 0 + +BACKGR0UND 0 +: 0 +Hallucinations 3 +as 0 +a 0 +symptom 0 +of 0 +central 0 +neurotoxicity 3 +are 0 +a 0 +known 0 +but 0 +poorly 0 +described 0 +side 0 +effect 0 +of 0 +ifosfamide 1 +. 0 + +Most 0 +cases 0 +of 0 +ifosfamide 1 +- 0 +induced 0 +hallucinations 3 +have 0 +been 0 +reported 0 +with 0 +other 0 +mental 0 +status 0 +changes 0 +. 0 + +METH0DS 0 +: 0 +The 0 +authors 0 +interviewed 0 +six 0 +persons 0 +with 0 +ifosfamide 1 +- 0 +induced 0 +hallucinations 3 +in 0 +the 0 +presence 0 +of 0 +a 0 +clear 0 +sensorium 0 +. 0 + +All 0 +patients 0 +were 0 +receiving 0 +high 0 +- 0 +dose 0 +ifosfamide 1 +as 0 +part 0 +of 0 +their 0 +bone 0 +marrow 0 +transplant 0 +procedure 0 +. 0 + +RESULTS 0 +: 0 +Hallucinations 3 +occurred 0 +only 0 +when 0 +the 0 +patient 0 +' 0 +s 0 +eyes 0 +were 0 +closed 0 +and 0 +, 0 +in 0 +all 0 +but 0 +one 0 +case 0 +, 0 +were 0 +reported 0 +as 0 +disturbing 0 +or 0 +frightening 0 +. 0 + +Underreporting 0 +of 0 +these 0 +hallucinations 3 +by 0 +patients 0 +is 0 +likely 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Hallucinations 3 +may 0 +be 0 +the 0 +sole 0 +or 0 +first 0 +manifestation 0 +of 0 +neurotoxicity 3 +. 0 + +The 0 +incidence 0 +may 0 +be 0 +dose 0 +and 0 +infusion 0 +- 0 +time 0 +related 0 +. 0 + +The 0 +clinician 0 +should 0 +be 0 +alerted 0 +for 0 +possible 0 +ifosfamide 1 +- 0 +induced 0 +hallucinations 3 +, 0 +which 0 +may 0 +occur 0 +without 0 +other 0 +signs 0 +of 0 +neurotoxicity 3 +. 0 + +" 0 +Eyes 0 +- 0 +closed 0 +" 0 +hallucinatory 3 +experiences 0 +appear 0 +to 0 +be 0 +an 0 +unusual 0 +feature 0 +of 0 +this 0 +presentation 0 +. 0 + +Patients 0 +anxious 0 +about 0 +this 0 +experience 0 +respond 0 +well 0 +to 0 +support 0 +and 0 +education 0 +about 0 +this 0 +occurrence 0 +. 0 + +0ptimal 0 +pharmacologic 0 +management 0 +of 0 +disturbed 0 +patients 0 +is 0 +unclear 0 +. 0 + +If 0 +agitation 3 +becomes 0 +marked 0 +, 0 +high 0 +- 0 +potency 0 +neuroleptics 0 +( 0 +i 0 +. 0 +e 0 +. 0 +, 0 +haloperidol 1 +) 0 +may 0 +be 0 +effective 0 +. 0 + +Photodistributed 0 +nifedipine 1 +- 0 +induced 0 +facial 0 +telangiectasia 3 +. 0 + +Five 0 +months 0 +after 0 +starting 0 +nifedipine 1 +( 0 +Adalat 1 +) 0 +, 0 +two 0 +patients 0 +developed 0 +photodistributed 0 +facial 0 +telangiectasia 3 +, 0 +which 0 +became 0 +more 0 +noticeable 0 +with 0 +time 0 +. 0 + +Neither 0 +patient 0 +complained 0 +of 0 +photosensitivity 0 +or 0 +flushing 3 +. 0 + +Both 0 +patients 0 +reported 0 +a 0 +significant 0 +cosmetic 0 +improvement 0 +after 0 +discontinuing 0 +the 0 +drug 0 +. 0 + +0ne 0 +commenced 0 +the 0 +closely 0 +related 0 +drug 0 +amlodipine 1 +3 0 +years 0 +later 0 +, 0 +with 0 +recurrence 0 +of 0 +telangiectasia 3 +. 0 + +The 0 +photodistribution 0 +of 0 +the 0 +telangiectasia 3 +suggests 0 +a 0 +significant 0 +drug 0 +/ 0 +light 0 +interaction 0 +. 0 + +Penicillamine 1 +- 0 +induced 0 +rapidly 0 +progressive 0 +glomerulonephritis 3 +in 0 +a 0 +patient 0 +with 0 +rheumatoid 3 +arthritis 4 +. 0 + +A 0 +67 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +rheumatoid 3 +arthritis 4 +presented 0 +rapidly 0 +progressive 0 +glomerulonephritis 3 +( 0 +RPGN 3 +) 0 +after 0 +5 0 +months 0 +of 0 +D 1 +- 2 +penicillamine 2 +( 0 +250 0 +mg 0 +/ 0 +day 0 +) 0 +treatment 0 +. 0 + +Light 0 +microscopy 0 +study 0 +showed 0 +severe 0 +glomerulonephritis 3 +with 0 +crescent 0 +formation 0 +in 0 +60 0 +% 0 +of 0 +the 0 +glomeruli 0 +and 0 +infiltration 0 +of 0 +inflammatory 0 +cells 0 +in 0 +the 0 +wall 0 +of 0 +an 0 +arteriole 0 +. 0 + +Immunofluorescence 0 +revealed 0 +scanty 0 +granular 0 +IgG 0 +, 0 +IgA 0 +and 0 +C3 0 +deposits 0 +along 0 +the 0 +capillary 0 +walls 0 +and 0 +mesangium 0 +. 0 + +The 0 +patient 0 +was 0 +treated 0 +with 0 +steroid 1 +pulse 0 +, 0 +plasmapheresis 0 +, 0 +cyclophosphamide 1 +and 0 +antiplatelet 1 +agents 2 +. 0 + +A 0 +complete 0 +recovery 0 +of 0 +renal 0 +function 0 +was 0 +achieved 0 +in 0 +a 0 +few 0 +weeks 0 +. 0 + +This 0 +new 0 +case 0 +of 0 +RPGN 3 +in 0 +the 0 +course 0 +of 0 +D 1 +- 2 +penicillamine 2 +treatment 0 +emphasizes 0 +the 0 +need 0 +for 0 +frequent 0 +monitoring 0 +of 0 +renal 0 +function 0 +and 0 +evaluation 0 +of 0 +urinary 0 +sediment 0 +and 0 +proteinuria 3 +in 0 +these 0 +patients 0 +. 0 + +The 0 +prompt 0 +discontinuation 0 +of 0 +D 1 +- 2 +penicillamine 2 +and 0 +vigorous 0 +treatment 0 +measures 0 +could 0 +allow 0 +for 0 +a 0 +good 0 +prognosis 0 +as 0 +in 0 +this 0 +case 0 +. 0 + +A 0 +case 0 +of 0 +polymyositis 3 +in 0 +a 0 +patient 0 +with 0 +primary 3 +biliary 4 +cirrhosis 4 +treated 0 +with 0 +D 1 +- 2 +penicillamine 2 +. 0 + +Although 0 +D 1 +- 2 +penicillamine 2 +has 0 +been 0 +used 0 +for 0 +many 0 +rheumatologic 3 +diseases 4 +, 0 +toxicity 3 +limits 0 +its 0 +usefulness 0 +in 0 +many 0 +patients 0 +. 0 + +Polymyositis 3 +/ 0 +dermatomyositis 3 +can 0 +develop 0 +as 0 +one 0 +of 0 +the 0 +autoimmune 0 +complications 0 +of 0 +D 1 +- 2 +penicillamine 2 +treatment 0 +, 0 +but 0 +its 0 +exact 0 +pathogenesis 0 +remains 0 +unclear 0 +. 0 + +We 0 +report 0 +a 0 +patient 0 +with 0 +primary 3 +biliary 4 +cirrhosis 4 +, 0 +who 0 +developed 0 +polymyositis 3 +while 0 +receiving 0 +D 1 +- 2 +penicillamine 2 +therapy 0 +. 0 + +We 0 +described 0 +the 0 +special 0 +clinical 0 +course 0 +of 0 +the 0 +patient 0 +. 0 + +Patients 0 +receiving 0 +D 1 +- 2 +penicillamine 2 +therapy 0 +should 0 +be 0 +followed 0 +carefully 0 +for 0 +the 0 +development 0 +of 0 +autoimmune 0 +complications 0 +like 0 +polymyositis 3 +/ 0 +dermatomyositis 3 +. 0 + +Hyperalgesia 3 +and 0 +myoclonus 3 +in 0 +terminal 0 +cancer 3 +patients 0 +treated 0 +with 0 +continuous 0 +intravenous 0 +morphine 1 +. 0 + +Eight 0 +cancer 3 +patients 0 +in 0 +the 0 +terminal 0 +stages 0 +of 0 +the 0 +disease 0 +treated 0 +with 0 +high 0 +doses 0 +of 0 +intravenous 0 +morphine 1 +developed 0 +hyperalgesia 3 +. 0 + +All 0 +cases 0 +were 0 +retrospectively 0 +sampled 0 +from 0 +three 0 +different 0 +hospitals 0 +in 0 +Copenhagen 0 +. 0 + +Five 0 +patients 0 +developed 0 +universal 0 +hyperalgesia 3 +and 0 +hyperesthesia 3 +which 0 +in 0 +2 0 +cases 0 +were 0 +accompanied 0 +by 0 +myoclonus 3 +. 0 + +In 0 +3 0 +patients 0 +a 0 +pre 0 +- 0 +existing 0 +neuralgia 3 +increased 0 +to 0 +excruciating 0 +intensity 0 +and 0 +in 0 +2 0 +of 0 +these 0 +cases 0 +myoclonus 3 +occurred 0 +simultaneously 0 +. 0 + +Although 0 +only 0 +few 0 +clinical 0 +descriptions 0 +of 0 +the 0 +relationship 0 +between 0 +hyperalgesia 3 +/ 0 +myoclonus 3 +and 0 +high 0 +doses 0 +of 0 +morphine 1 +are 0 +available 0 +, 0 +experimental 0 +support 0 +from 0 +animal 0 +studies 0 +indicates 0 +that 0 +morphine 1 +, 0 +or 0 +its 0 +metabolites 0 +, 0 +plays 0 +a 0 +causative 0 +role 0 +for 0 +the 0 +observed 0 +behavioural 0 +syndrome 0 +. 0 + +The 0 +possible 0 +mechanisms 0 +are 0 +discussed 0 +and 0 +treatment 0 +proposals 0 +given 0 +suggesting 0 +the 0 +use 0 +of 0 +more 0 +efficacious 0 +opioids 0 +with 0 +less 0 +excitatory 0 +potency 0 +in 0 +these 0 +situations 0 +. 0 + +Liposomal 0 +daunorubicin 1 +in 0 +advanced 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +: 0 +a 0 +phase 0 +II 0 +study 0 +. 0 + +We 0 +report 0 +a 0 +non 0 +- 0 +randomized 0 +Phase 0 +II 0 +clinical 0 +trial 0 +to 0 +assess 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +liposomal 0 +daunorubicin 1 +( 0 +DaunoXome 0 +) 0 +in 0 +the 0 +treatment 0 +of 0 +AIDS 3 +related 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +. 0 + +Eleven 0 +homosexual 0 +men 0 +with 0 +advanced 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +were 0 +entered 0 +in 0 +the 0 +trial 0 +. 0 + +Changes 0 +in 0 +size 0 +, 0 +colour 0 +and 0 +associated 0 +oedema 3 +of 0 +selected 0 +' 0 +target 0 +' 0 +lesions 0 +were 0 +measured 0 +. 0 + +Clinical 0 +, 0 +biochemical 0 +and 0 +haematological 0 +toxicities 3 +were 0 +assessed 0 +. 0 + +Ten 0 +subjects 0 +were 0 +evaluated 0 +. 0 + +A 0 +partial 0 +response 0 +was 0 +achieved 0 +in 0 +four 0 +, 0 +of 0 +whom 0 +two 0 +subsequently 0 +relapsed 0 +. 0 + +Stabilization 0 +of 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +occurred 0 +in 0 +the 0 +remaining 0 +six 0 +, 0 +maintained 0 +until 0 +the 0 +end 0 +of 0 +the 0 +trial 0 +period 0 +in 0 +four 0 +. 0 + +The 0 +drug 0 +was 0 +generally 0 +well 0 +tolerated 0 +, 0 +with 0 +few 0 +mild 0 +symptoms 0 +of 0 +toxicity 3 +. 0 + +The 0 +main 0 +problem 0 +encountered 0 +was 0 +haematological 0 +toxicity 3 +, 0 +with 0 +three 0 +subjects 0 +experiencing 0 +severe 0 +neutropenia 3 +( 0 +neutrophil 0 +count 0 +< 0 +0 0 +. 0 +5 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +l 0 +) 0 +. 0 + +There 0 +was 0 +no 0 +evidence 0 +of 0 +cardiotoxicity 3 +. 0 + +In 0 +this 0 +small 0 +patient 0 +sample 0 +, 0 +liposomal 0 +daunorubicin 1 +was 0 +an 0 +effective 0 +and 0 +well 0 +tolerated 0 +agent 0 +in 0 +the 0 +treatment 0 +of 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +. 0 + +Long 0 +- 0 +term 0 +effects 0 +of 0 +vincristine 1 +on 0 +the 0 +peripheral 0 +nervous 0 +system 0 +. 0 + +Forty 0 +patients 0 +with 0 +Non 3 +- 4 +Hodgkin 4 +' 4 +s 4 +Lymphoma 4 +treated 0 +with 0 +vincristine 1 +between 0 +1984 0 +and 0 +1990 0 +( 0 +cumulative 0 +dose 0 +12 0 +mg 0 +in 0 +18 0 +- 0 +24 0 +weeks 0 +) 0 +were 0 +investigated 0 +in 0 +order 0 +to 0 +evaluate 0 +the 0 +long 0 +term 0 +effects 0 +of 0 +vincristine 1 +on 0 +the 0 +peripheral 0 +nervous 0 +system 0 +. 0 + +The 0 +patients 0 +were 0 +interviewed 0 +with 0 +emphasis 0 +on 0 +neuropathic 3 +symptoms 4 +. 0 + +Physical 0 +and 0 +quantitative 0 +sensory 0 +examination 0 +with 0 +determination 0 +of 0 +vibratory 0 +perception 0 +and 0 +thermal 0 +discrimination 0 +thresholds 0 +were 0 +performed 0 +, 0 +four 0 +to 0 +77 0 +months 0 +( 0 +median 0 +34 0 +months 0 +) 0 +after 0 +vincristine 1 +treatment 0 +. 0 + +Twenty 0 +- 0 +seven 0 +patients 0 +reported 0 +neuropathic 3 +symptoms 4 +. 0 + +In 0 +13 0 +of 0 +these 0 +27 0 +patients 0 +symptoms 0 +were 0 +still 0 +present 0 +at 0 +the 0 +time 0 +of 0 +examination 0 +. 0 + +In 0 +these 0 +patients 0 +sensory 0 +signs 0 +and 0 +symptoms 0 +predominated 0 +. 0 + +In 0 +the 0 +other 0 +14 0 +patients 0 +symptoms 0 +had 0 +been 0 +present 0 +in 0 +the 0 +past 0 +. 0 + +Symptoms 0 +persisted 0 +maximally 0 +40 0 +months 0 +since 0 +cessation 0 +of 0 +therapy 0 +. 0 + +There 0 +was 0 +no 0 +age 0 +difference 0 +between 0 +patients 0 +with 0 +and 0 +without 0 +complaints 0 +at 0 +the 0 +time 0 +of 0 +examination 0 +. 0 + +Normal 0 +reflexes 0 +were 0 +found 0 +in 0 +two 0 +third 0 +of 0 +patients 0 +. 0 + +Neuropathic 0 +complaints 0 +were 0 +not 0 +very 0 +troublesome 0 +on 0 +the 0 +long 0 +term 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +with 0 +the 0 +above 0 +mentioned 0 +vincristine 1 +dose 0 +schedule 0 +signs 0 +and 0 +symptoms 0 +of 0 +vincristine 1 +neuropathy 3 +are 0 +reversible 0 +for 0 +a 0 +great 0 +deal 0 +and 0 +prognosis 0 +is 0 +fairly 0 +good 0 +. 0 + +Hepatic 0 +adenomas 3 +and 0 +focal 3 +nodular 4 +hyperplasia 4 +of 0 +the 0 +liver 0 +in 0 +young 0 +women 0 +on 0 +oral 1 +contraceptives 2 +: 0 +case 0 +reports 0 +. 0 + +Two 0 +cases 0 +of 0 +hepatic 0 +adenoma 3 +and 0 +one 0 +of 0 +focal 3 +nodular 4 +hyperplasia 4 +presumably 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +oral 1 +contraceptives 2 +, 0 +are 0 +reported 0 +. 0 + +Special 0 +reference 0 +is 0 +made 0 +to 0 +their 0 +clinical 0 +presentation 0 +, 0 +which 0 +may 0 +be 0 +totally 0 +asymptomatic 0 +. 0 + +Liver 0 +- 0 +function 0 +tests 0 +are 0 +of 0 +little 0 +diagnostic 0 +value 0 +, 0 +but 0 +valuable 0 +information 0 +may 0 +be 0 +obtained 0 +from 0 +both 0 +liver 0 +scanning 0 +and 0 +hepatic 0 +angiography 0 +. 0 + +Histologic 0 +differences 0 +and 0 +clinical 0 +similarities 0 +between 0 +hepatic 0 +adenoma 3 +and 0 +focal 3 +nodular 4 +hyperplasia 4 +of 0 +the 0 +liver 0 +are 0 +discussed 0 +. 0 + +Loss 0 +of 0 +glutamate 1 +decarboxylase 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +in 0 +the 0 +rat 0 +dentate 0 +gyrus 0 +following 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 + +In 0 +situ 0 +hybridization 0 +methods 0 +were 0 +used 0 +to 0 +determine 0 +if 0 +glutamic 1 +acid 2 +decarboxylase 0 +( 0 +GAD 0 +) 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +within 0 +the 0 +hilus 0 +of 0 +the 0 +dentate 0 +gyrus 0 +are 0 +vulnerable 0 +to 0 +seizure 3 +- 0 +induced 0 +damage 0 +in 0 +a 0 +model 0 +of 0 +chronic 0 +seizures 3 +. 0 + +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +injected 0 +intraperitoneally 0 +with 0 +pilocarpine 1 +, 0 +and 0 +the 0 +hippocampal 0 +formation 0 +was 0 +studied 0 +histologically 0 +at 0 +1 0 +, 0 +2 0 +, 0 +4 0 +, 0 +and 0 +8 0 +week 0 +intervals 0 +after 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 + +In 0 +situ 0 +hybridization 0 +histochemistry 0 +, 0 +using 0 +a 0 +digoxigenin 1 +- 0 +labeled 0 +GAD 0 +cRNA 0 +probe 0 +, 0 +demonstrated 0 +a 0 +substantial 0 +decrease 0 +in 0 +the 0 +number 0 +of 0 +GAD 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +in 0 +the 0 +hilus 0 +of 0 +the 0 +dentate 0 +gyrus 0 +in 0 +the 0 +pilocarpine 1 +- 0 +treated 0 +rats 0 +as 0 +compared 0 +to 0 +controls 0 +at 0 +all 0 +time 0 +intervals 0 +. 0 + +Additional 0 +neuronanatomical 0 +studies 0 +, 0 +including 0 +cresyl 1 +violet 2 +staining 0 +, 0 +neuronal 3 +degeneration 4 +methods 0 +, 0 +and 0 +histochemical 0 +localization 0 +of 0 +glial 0 +fibrillary 0 +acidic 0 +protein 0 +, 0 +suggested 0 +that 0 +the 0 +decrease 0 +in 0 +the 0 +number 0 +of 0 +GAD 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +was 0 +related 0 +to 0 +neuronal 3 +loss 4 +rather 0 +than 0 +to 0 +a 0 +decrease 0 +in 0 +GAD 0 +mRNA 0 +levels 0 +. 0 + +The 0 +loss 0 +of 0 +GAD 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +in 0 +the 0 +hilus 0 +contrasted 0 +with 0 +the 0 +relative 0 +preservation 0 +of 0 +labeled 0 +putative 0 +basket 0 +cells 0 +along 0 +the 0 +inner 0 +margin 0 +of 0 +the 0 +granule 0 +cell 0 +layer 0 +. 0 + +Quantitative 0 +analyses 0 +of 0 +labeled 0 +neurons 0 +in 0 +three 0 +regions 0 +of 0 +the 0 +dentate 0 +gyrus 0 +in 0 +the 0 +1 0 +and 0 +2 0 +week 0 +groups 0 +showed 0 +statistically 0 +significant 0 +decreases 0 +in 0 +the 0 +mean 0 +number 0 +of 0 +GAD 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +in 0 +the 0 +hilus 0 +of 0 +both 0 +groups 0 +of 0 +experimental 0 +animals 0 +. 0 + +No 0 +significant 0 +differences 0 +were 0 +found 0 +in 0 +the 0 +molecular 0 +layer 0 +or 0 +the 0 +granule 0 +cell 0 +layer 0 +, 0 +which 0 +included 0 +labeled 0 +neurons 0 +along 0 +the 0 +lower 0 +margin 0 +of 0 +the 0 +granule 0 +cell 0 +layer 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +, 0 +in 0 +this 0 +model 0 +, 0 +a 0 +subpopulation 0 +of 0 +GAD 0 +mRNA 0 +- 0 +containing 0 +neurons 0 +within 0 +the 0 +dentate 0 +gyrus 0 +is 0 +selectively 0 +vulnerable 0 +to 0 +seizure 3 +- 0 +induced 0 +damage 0 +. 0 + +Such 0 +differential 0 +vulnerability 0 +appears 0 +to 0 +be 0 +another 0 +indication 0 +of 0 +the 0 +heterogeneity 0 +of 0 +GABA 1 +neurons 0 +. 0 + +Effects 0 +of 0 +deliberate 0 +hypotension 3 +induced 0 +by 0 +labetalol 1 +with 0 +isoflurane 1 +on 0 +neuropsychological 0 +function 0 +. 0 + +The 0 +effect 0 +of 0 +deliberate 0 +hypotension 3 +on 0 +brain 0 +function 0 +measured 0 +by 0 +neuropsychological 0 +tests 0 +was 0 +studied 0 +in 0 +41 0 +adult 0 +patients 0 +. 0 + +Twenty 0 +- 0 +four 0 +patients 0 +were 0 +anaesthetized 0 +for 0 +middle 0 +- 0 +ear 0 +surgery 0 +with 0 +deliberate 0 +hypotension 3 +induced 0 +by 0 +labetalol 1 +with 0 +isoflurane 1 +( 0 +hypotensive 3 +group 0 +) 0 +. 0 + +Seventeen 0 +patients 0 +without 0 +hypotension 3 +served 0 +as 0 +a 0 +control 0 +group 0 +. 0 + +The 0 +mean 0 +arterial 0 +pressure 0 +was 0 +77 0 ++ 0 +/ 0 +- 0 +2 0 +mmHg 0 +( 0 +10 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +kPa 0 +) 0 +before 0 +hypotension 3 +and 0 +50 0 ++ 0 +/ 0 +- 0 +0 0 +mmHg 0 +( 0 +6 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +0 0 +kPa 0 +) 0 +during 0 +hypotension 3 +in 0 +the 0 +hypotensive 3 +group 0 +, 0 +and 0 +86 0 ++ 0 +/ 0 +- 0 +2 0 +mmHg 0 +( 0 +11 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +kPa 0 +) 0 +during 0 +anaesthesia 0 +in 0 +the 0 +control 0 +group 0 +. 0 + +The 0 +following 0 +psychological 0 +tests 0 +were 0 +performed 0 +: 0 +four 0 +subtests 0 +of 0 +the 0 +Wechsler 0 +Adult 0 +Intelligence 0 +Scale 0 +( 0 +similarities 0 +, 0 +digit 0 +span 0 +, 0 +vocabulary 0 +and 0 +digit 0 +symbol 0 +) 0 +, 0 +Trail 0 +- 0 +Making 0 +tests 0 +A 0 +and 0 +B 0 +, 0 +Zung 0 +tests 0 +( 0 +self 0 +- 0 +rating 0 +anxiety 3 +scale 0 +and 0 +self 0 +- 0 +rating 0 +depression 3 +scale 0 +) 0 +and 0 +two 0 +- 0 +part 0 +memory 0 +test 0 +battery 0 +with 0 +immediate 0 +and 0 +delayed 0 +recall 0 +. 0 + +The 0 +tests 0 +were 0 +performed 0 +preoperatively 0 +and 0 +2 0 +days 0 +postoperatively 0 +. 0 + +There 0 +were 0 +no 0 +statistically 0 +significant 0 +differences 0 +between 0 +the 0 +groups 0 +in 0 +any 0 +of 0 +the 0 +tests 0 +in 0 +the 0 +changes 0 +from 0 +preoperative 0 +value 0 +to 0 +postoperative 0 +value 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +hypotension 3 +induced 0 +by 0 +labetalol 1 +with 0 +isoflurane 1 +has 0 +no 0 +significant 0 +harmful 0 +effects 0 +on 0 +mental 0 +functions 0 +compared 0 +to 0 +normotensive 0 +anaesthesia 0 +. 0 + +Apparent 0 +cure 0 +of 0 +rheumatoid 3 +arthritis 4 +by 0 +bone 0 +marrow 0 +transplantation 0 +. 0 + +We 0 +describe 0 +the 0 +induction 0 +of 0 +sustained 0 +remissions 0 +and 0 +possible 0 +cure 0 +of 0 +severe 0 +erosive 0 +rheumatoid 3 +arthritis 4 +( 0 +RA 3 +) 0 +by 0 +bone 0 +marrow 0 +transplantation 0 +( 0 +BMT 0 +) 0 +in 0 +2 0 +patients 0 +. 0 + +BMT 0 +was 0 +used 0 +to 0 +treat 0 +severe 0 +aplastic 3 +anemia 4 +which 0 +was 0 +caused 0 +by 0 +gold 1 +in 0 +one 0 +case 0 +and 0 +D 1 +- 2 +penicillamine 2 +in 0 +the 0 +other 0 +. 0 + +In 0 +the 0 +8 0 +and 0 +6 0 +years 0 +since 0 +the 0 +transplants 0 +( 0 +representing 0 +8 0 +and 0 +4 0 +years 0 +since 0 +cessation 0 +of 0 +all 0 +immunosuppressive 0 +therapy 0 +, 0 +respectively 0 +) 0 +, 0 +the 0 +RA 3 +in 0 +each 0 +case 0 +has 0 +been 0 +completely 0 +quiescent 0 +. 0 + +Although 0 +short 0 +term 0 +remission 0 +of 0 +severe 0 +RA 3 +following 0 +BMT 0 +has 0 +been 0 +reported 0 +, 0 +these 0 +are 0 +the 0 +first 0 +cases 0 +for 0 +which 0 +prolonged 0 +followup 0 +has 0 +been 0 +available 0 +. 0 + +This 0 +experience 0 +raises 0 +the 0 +question 0 +of 0 +the 0 +role 0 +of 0 +BMT 0 +itself 0 +as 0 +a 0 +therapeutic 0 +option 0 +for 0 +patients 0 +with 0 +uncontrolled 0 +destructive 0 +synovitis 3 +. 0 + +Seizures 3 +induced 0 +by 0 +combined 0 +levomepromazine 1 +- 0 +fluvoxamine 1 +treatment 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +combined 0 +levomepromazine 1 +- 0 +fluvoxamine 1 +treatment 0 +- 0 +induced 0 +seizures 3 +. 0 + +It 0 +seems 0 +that 0 +combined 0 +treatment 0 +of 0 +fluvoxamine 1 +with 0 +phenothiazines 1 +may 0 +possess 0 +proconvulsive 0 +activity 0 +. 0 + +Case 0 +report 0 +: 0 +pentamidine 1 +and 0 +polymorphic 0 +ventricular 3 +tachycardia 4 +revisited 0 +. 0 + +Pentamidine 1 +isethionate 2 +has 0 +been 0 +associated 0 +with 0 +ventricular 3 +tachyarrhythmias 4 +, 0 +including 0 +torsade 3 +de 4 +pointes 4 +. 0 + +This 0 +article 0 +reports 0 +two 0 +cases 0 +of 0 +this 0 +complication 0 +and 0 +reviews 0 +all 0 +reported 0 +cases 0 +to 0 +date 0 +. 0 + +Pentamidine 1 +- 0 +induced 0 +torsade 3 +de 4 +pointes 4 +may 0 +be 0 +related 0 +to 0 +serum 0 +magnesium 1 +levels 0 +and 0 +hypomagnesemia 3 +may 0 +synergistically 0 +induce 0 +torsade 0 +. 0 + +Torsade 3 +de 4 +pointes 4 +occurred 0 +after 0 +an 0 +average 0 +of 0 +10 0 +days 0 +of 0 +treatment 0 +with 0 +pentamidine 1 +. 0 + +In 0 +these 0 +patients 0 +, 0 +no 0 +other 0 +acute 0 +side 0 +effects 0 +of 0 +pentamidine 1 +were 0 +observed 0 +. 0 + +Torsade 3 +de 4 +pointes 4 +can 0 +be 0 +treated 0 +when 0 +recognized 0 +early 0 +, 0 +possibly 0 +without 0 +discontinuation 0 +of 0 +pentamidine 1 +. 0 + +When 0 +QTc 3 +interval 4 +prolongation 4 +is 0 +observed 0 +, 0 +early 0 +magnesium 1 +supplementation 0 +is 0 +advocated 0 +. 0 + +Efficacy 0 +and 0 +tolerability 0 +of 0 +lovastatin 1 +in 0 +3390 0 +women 0 +with 0 +moderate 0 +hypercholesterolemia 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +lovastatin 1 +in 0 +women 0 +with 0 +moderate 0 +hypercholesterolemia 3 +. 0 + +DESIGN 0 +: 0 +The 0 +Expanded 0 +Clinical 0 +Evaluation 0 +of 0 +Lovastatin 1 +( 0 +EXCEL 0 +) 0 +Study 0 +, 0 +a 0 +multicenter 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +diet 0 +- 0 +and 0 +placebo 0 +- 0 +controlled 0 +trial 0 +, 0 +in 0 +which 0 +participants 0 +were 0 +randomly 0 +assigned 0 +to 0 +receive 0 +placebo 0 +or 0 +lovastatin 1 +at 0 +doses 0 +of 0 +20 0 +or 0 +40 0 +mg 0 +once 0 +daily 0 +, 0 +or 0 +20 0 +or 0 +40 0 +mg 0 +twice 0 +daily 0 +for 0 +48 0 +weeks 0 +. 0 + +SETTING 0 +: 0 +Ambulatory 0 +patients 0 +recruited 0 +by 0 +362 0 +participating 0 +centers 0 +throughout 0 +the 0 +United 0 +States 0 +. 0 + +PATIENTS 0 +: 0 +Women 0 +( 0 +n 0 += 0 +3390 0 +) 0 +from 0 +the 0 +total 0 +cohort 0 +of 0 +8245 0 +volunteers 0 +. 0 + +MEASUREMENTS 0 +: 0 +Plasma 0 +total 0 +, 0 +low 0 +- 0 +density 0 +lipoprotein 0 +( 0 +LDL 0 +) 0 +, 0 +and 0 +high 0 +- 0 +density 0 +lipoprotein 0 +( 0 +HDL 0 +) 0 +cholesterol 1 +, 0 +and 0 +triglycerides 1 +; 0 +and 0 +laboratory 0 +and 0 +clinical 0 +evidence 0 +of 0 +adverse 0 +events 0 +monitored 0 +periodically 0 +throughout 0 +the 0 +study 0 +. 0 + +RESULTS 0 +: 0 +Among 0 +women 0 +, 0 +lovastatin 1 +( 0 +20 0 +to 0 +80 0 +mg 0 +/ 0 +d 0 +) 0 +produced 0 +sustained 0 +( 0 +12 0 +- 0 +to 0 +48 0 +- 0 +week 0 +) 0 +, 0 +dose 0 +- 0 +related 0 +changes 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +: 0 +decreases 0 +in 0 +LDL 0 +cholesterol 1 +( 0 +24 0 +% 0 +to 0 +40 0 +% 0 +) 0 +and 0 +triglycerides 1 +( 0 +9 0 +% 0 +to 0 +18 0 +% 0 +) 0 +, 0 +and 0 +increases 0 +in 0 +HDL 0 +cholesterol 1 +( 0 +6 0 +. 0 +7 0 +% 0 +to 0 +8 0 +. 0 +6 0 +% 0 +) 0 +. 0 + +Depending 0 +on 0 +the 0 +dose 0 +, 0 +from 0 +82 0 +% 0 +to 0 +95 0 +% 0 +of 0 +lovastatin 1 +- 0 +treated 0 +women 0 +achieved 0 +the 0 +National 0 +Cholesterol 1 +Education 0 +Program 0 +goal 0 +of 0 +LDL 0 +cholesterol 1 +levels 0 +less 0 +than 0 +4 0 +. 0 +14 0 +mmol 0 +/ 0 +L 0 +( 0 +160 0 +mg 0 +/ 0 +dL 0 +) 0 +, 0 +and 0 +40 0 +% 0 +to 0 +87 0 +% 0 +achieved 0 +the 0 +goal 0 +of 0 +3 0 +. 0 +36 0 +mmol 0 +/ 0 +L 0 +( 0 +130 0 +mg 0 +/ 0 +dL 0 +) 0 +. 0 + +Successive 0 +transaminase 0 +elevations 0 +greater 0 +than 0 +three 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +occurred 0 +in 0 +0 0 +. 0 +1 0 +% 0 +of 0 +women 0 +and 0 +were 0 +dose 0 +dependent 0 +above 0 +the 0 +20 0 +- 0 +mg 0 +dose 0 +. 0 + +Myopathy 3 +, 0 +defined 0 +as 0 +muscle 0 +symptoms 0 +with 0 +creatine 1 +kinase 0 +elevations 0 +greater 0 +than 0 +10 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +, 0 +was 0 +rare 0 +and 0 +associated 0 +with 0 +the 0 +highest 0 +recommended 0 +daily 0 +dose 0 +of 0 +lovastatin 1 +( 0 +80 0 +mg 0 +) 0 +. 0 + +Estrogen 0 +- 0 +replacement 0 +therapy 0 +appeared 0 +to 0 +have 0 +no 0 +effect 0 +on 0 +either 0 +the 0 +efficacy 0 +or 0 +safety 0 +profile 0 +of 0 +lovastatin 1 +. 0 + +C0NCLUSI0N 0 +: 0 +Lovastatin 1 +is 0 +highly 0 +effective 0 +and 0 +generally 0 +well 0 +tolerated 0 +as 0 +therapy 0 +for 0 +primary 0 +hypercholesterolemia 3 +in 0 +women 0 +. 0 + +Tetany 3 +and 0 +rhabdomyolysis 3 +due 0 +to 0 +surreptitious 0 +furosemide 1 +- 0 +- 0 +importance 0 +of 0 +magnesium 1 +supplementation 0 +. 0 + +Diuretics 0 +may 0 +induce 0 +hypokalemia 3 +, 0 +hypocalcemia 3 +and 0 +hypomagnesemia 3 +. 0 + +While 0 +severe 0 +hypokalemia 3 +may 0 +cause 0 +muscle 3 +weakness 4 +, 0 +severe 0 +hypomagnesemia 3 +is 0 +associated 0 +with 0 +muscle 3 +spasms 4 +and 0 +tetany 3 +which 0 +cannot 0 +be 0 +corrected 0 +by 0 +potassium 1 +and 0 +calcium 1 +supplementation 0 +alone 0 +( 0 +1 0 +, 0 +2 0 +) 0 +. 0 + +Surreptitious 0 +diuretic 0 +ingestion 0 +has 0 +been 0 +described 0 +, 0 +mainly 0 +in 0 +women 0 +who 0 +are 0 +concerned 0 +that 0 +they 0 +are 0 +obese 3 +or 0 +edematous 3 +. 0 + +Symptomatic 0 +hypokalemia 3 +has 0 +been 0 +reported 0 +in 0 +such 0 +patients 0 +( 0 +3 0 +- 0 +7 0 +) 0 +and 0 +in 0 +one 0 +case 0 +hypocalcemia 3 +was 0 +observed 0 +( 0 +8 0 +) 0 +, 0 +but 0 +the 0 +effects 0 +of 0 +magnesium 1 +depletion 0 +were 0 +not 0 +noted 0 +in 0 +these 0 +patients 0 +. 0 + +Ciprofloxacin 1 +- 0 +induced 0 +nephrotoxicity 3 +in 0 +patients 0 +with 0 +cancer 3 +. 0 + +Nephrotoxicity 3 +associated 0 +with 0 +ciprofloxacin 1 +is 0 +uncommon 0 +. 0 + +Five 0 +patients 0 +with 0 +cancer 3 +who 0 +developed 0 +acute 3 +renal 4 +failure 4 +that 0 +followed 0 +treatment 0 +with 0 +ciprofloxacin 1 +are 0 +described 0 +and 0 +an 0 +additional 0 +15 0 +cases 0 +reported 0 +in 0 +the 0 +literature 0 +are 0 +reviewed 0 +. 0 + +0ther 0 +than 0 +elevation 0 +of 0 +serum 0 +creatinine 1 +levels 0 +, 0 +characteristic 0 +clinical 0 +manifestations 0 +and 0 +abnormal 0 +laboratory 0 +findings 0 +are 0 +not 0 +frequently 0 +present 0 +. 0 + +Allergic 0 +interstitial 3 +nephritis 4 +is 0 +believed 0 +to 0 +be 0 +the 0 +underlying 0 +pathological 0 +- 0 +process 0 +. 0 + +Definitive 0 +diagnosis 0 +requires 0 +performance 0 +of 0 +renal 0 +biopsy 0 +, 0 +although 0 +this 0 +is 0 +not 0 +always 0 +feasible 0 +. 0 + +An 0 +improvement 0 +in 0 +renal 0 +function 0 +that 0 +followed 0 +the 0 +discontinuation 0 +of 0 +the 0 +offending 0 +antibiotic 0 +supports 0 +the 0 +presumptive 0 +diagnosis 0 +of 0 +ciprofloxacin 1 +- 0 +induced 0 +acute 3 +renal 4 +failure 4 +. 0 + +Venous 3 +complications 4 +of 0 +midazolam 1 +versus 0 +diazepam 1 +. 0 + +Although 0 +some 0 +studies 0 +have 0 +suggested 0 +fewer 0 +venous 3 +complications 4 +are 0 +associated 0 +with 0 +midazolam 1 +than 0 +with 0 +diazepam 1 +for 0 +endoscopic 0 +procedures 0 +, 0 +this 0 +variable 0 +has 0 +not 0 +been 0 +well 0 +documented 0 +. 0 + +We 0 +prospectively 0 +evaluated 0 +the 0 +incidence 0 +of 0 +venous 3 +complications 4 +after 0 +intravenous 0 +injection 0 +of 0 +diazepam 1 +or 0 +midazolam 1 +in 0 +122 0 +consecutive 0 +patients 0 +undergoing 0 +colonoscopy 0 +and 0 +esophagogastroduodenoscopy 0 +. 0 + +0verall 0 +, 0 +venous 3 +complications 4 +were 0 +more 0 +frequent 0 +with 0 +diazepam 1 +( 0 +22 0 +of 0 +62 0 +patients 0 +) 0 +than 0 +with 0 +midazolam 1 +( 0 +4 0 +of 0 +60 0 +patients 0 +) 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +A 0 +palpable 0 +venous 0 +cord 0 +was 0 +present 0 +in 0 +23 0 +% 0 +( 0 +14 0 +of 0 +62 0 +) 0 +of 0 +patients 0 +in 0 +the 0 +diazepam 1 +group 0 +, 0 +compared 0 +with 0 +2 0 +% 0 +( 0 +1 0 +of 0 +60 0 +patients 0 +) 0 +in 0 +the 0 +midazolam 1 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +002 0 +) 0 +. 0 + +Pain 3 +at 0 +the 0 +injection 0 +site 0 +occurred 0 +in 0 +35 0 +% 0 +( 0 +22 0 +of 0 +62 0 +) 0 +of 0 +patients 0 +in 0 +the 0 +diazepam 1 +group 0 +compared 0 +with 0 +7 0 +% 0 +( 0 +4 0 +of 0 +60 0 +patients 0 +) 0 +in 0 +the 0 +midazolam 1 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Swelling 3 +and 0 +warmth 0 +at 0 +the 0 +injection 0 +site 0 +were 0 +not 0 +significantly 0 +different 0 +between 0 +the 0 +two 0 +groups 0 +. 0 + +Smoking 0 +, 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +use 0 +, 0 +intravenous 0 +catheter 0 +site 0 +, 0 +dwell 0 +time 0 +of 0 +the 0 +needle 0 +, 0 +alcohol 1 +use 0 +, 0 +and 0 +pain 3 +during 0 +the 0 +injection 0 +had 0 +no 0 +effect 0 +on 0 +the 0 +incidence 0 +of 0 +venous 3 +complications 4 +. 0 + +Clarithromycin 1 +- 0 +associated 0 +visual 3 +hallucinations 4 +in 0 +a 0 +patient 0 +with 0 +chronic 3 +renal 4 +failure 4 +on 0 +continuous 0 +ambulatory 0 +peritoneal 0 +dialysis 0 +. 0 + +Visual 3 +hallucinations 4 +are 0 +a 0 +rare 0 +event 0 +in 0 +chronic 3 +renal 4 +failure 4 +and 0 +not 0 +related 0 +to 0 +uremia 3 +per 0 +se 0 +. 0 + +Unreported 0 +in 0 +the 0 +literature 0 +is 0 +visual 3 +hallucinations 4 +occurring 0 +in 0 +association 0 +with 0 +the 0 +new 0 +macrolide 1 +antibiotic 0 +, 0 +clarithromycin 1 +. 0 + +We 0 +describe 0 +such 0 +a 0 +case 0 +in 0 +a 0 +patient 0 +with 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +( 0 +ESRD 3 +) 0 +maintained 0 +on 0 +continuous 0 +ambulatory 0 +peritoneal 0 +dialysis 0 +( 0 +CAPD 0 +) 0 +. 0 + +The 0 +combination 0 +of 0 +a 0 +relatively 0 +high 0 +dose 0 +of 0 +clarithromycin 1 +in 0 +face 0 +of 0 +chronic 3 +renal 4 +failure 4 +in 0 +a 0 +functionally 0 +anephric 0 +patient 0 +, 0 +with 0 +underlying 0 +aluminum 1 +intoxication 0 +, 0 +may 0 +have 0 +facilitated 0 +the 0 +appearance 0 +of 0 +this 0 +neurotoxic 3 +side 0 +effect 0 +. 0 + +It 0 +is 0 +important 0 +to 0 +understand 0 +the 0 +pharmacokinetics 0 +of 0 +medications 0 +in 0 +face 0 +of 0 +chronic 3 +renal 4 +failure 4 +, 0 +the 0 +possibility 0 +of 0 +drug 0 +interactions 0 +, 0 +and 0 +how 0 +these 0 +factors 0 +should 0 +help 0 +guide 0 +medication 0 +therapy 0 +in 0 +the 0 +ESRD 3 +patient 0 +. 0 + +Changes 0 +in 0 +peroxisomes 0 +in 0 +preneoplastic 0 +liver 0 +and 0 +hepatoma 3 +of 0 +mice 0 +induced 0 +by 0 +alpha 1 +- 2 +benzene 2 +hexachloride 2 +. 0 + +Peroxisomes 0 +in 0 +hepatomas 3 +and 0 +hyperplastic 0 +preneoplastic 0 +liver 3 +lesions 4 +induced 0 +in 0 +mice 0 +by 0 +500 0 +ppm 0 +alpha 1 +- 2 +benzene 2 +hexachloride 2 +were 0 +examined 0 +histochemically 0 +and 0 +electron 0 +microscopically 0 +. 0 + +Although 0 +most 0 +of 0 +the 0 +hepatomas 3 +were 0 +well 0 +- 0 +differentiated 0 +tumors 3 +and 0 +contained 0 +a 0 +considerable 0 +number 0 +of 0 +peroxisomes 0 +, 0 +the 0 +tumor 3 +cells 0 +did 0 +not 0 +respond 0 +to 0 +ethyl 1 +- 2 +alpha 2 +- 2 +p 2 +- 2 +chlorophenoxyisobutyrate 2 +with 0 +proliferation 0 +of 0 +peroxisomes 0 +. 0 + +At 0 +the 0 +16th 0 +week 0 +of 0 +carcinogen 0 +feeding 0 +, 0 +hyperplastic 0 +nodules 0 +appeared 0 +and 0 +advanced 0 +to 0 +further 0 +stages 0 +. 0 + +A 0 +majority 0 +of 0 +the 0 +nodules 0 +showed 0 +a 0 +considerable 0 +number 0 +of 0 +peroxisomes 0 +and 0 +the 0 +inductive 0 +proliferation 0 +of 0 +peroxisomes 0 +. 0 + +Within 0 +the 0 +nodules 0 +, 0 +foci 0 +of 0 +proliferation 0 +of 0 +the 0 +cells 0 +that 0 +showed 0 +no 0 +inducibility 0 +of 0 +proliferation 0 +of 0 +peroxisomes 0 +appeared 0 +. 0 + +These 0 +cells 0 +proliferated 0 +further 0 +, 0 +replacing 0 +the 0 +most 0 +part 0 +of 0 +the 0 +nodules 0 +, 0 +and 0 +with 0 +this 0 +process 0 +hepatomas 3 +appeared 0 +to 0 +have 0 +been 0 +formed 0 +. 0 + +No 0 +abnormal 0 +matrical 0 +inclusions 0 +of 0 +peroxisomes 0 +were 0 +formed 0 +in 0 +the 0 +cells 0 +of 0 +hyperplastic 0 +nodules 0 +by 0 +ethyl 1 +- 2 +alpha 2 +- 2 +p 2 +- 2 +chlorophenoxyisobutyrate 2 +unlike 0 +in 0 +the 0 +case 0 +of 0 +rats 0 +. 0 + +Contribution 0 +of 0 +the 0 +sympathetic 0 +nervous 0 +system 0 +to 0 +salt 0 +- 0 +sensitivity 0 +in 0 +lifetime 0 +captopril 1 +- 0 +treated 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +test 0 +the 0 +hypothesis 0 +that 0 +, 0 +in 0 +lifetime 0 +captopril 1 +- 0 +treated 0 +spontaneously 0 +hypertensive 3 +rats 0 +( 0 +SHR 0 +) 0 +, 0 +the 0 +sympathetic 0 +nervous 0 +system 0 +contributes 0 +importantly 0 +to 0 +the 0 +hypertensive 3 +effect 0 +of 0 +dietary 1 +sodium 2 +chloride 2 +supplementation 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +SHR 0 +( 0 +aged 0 +6 0 +weeks 0 +) 0 +that 0 +had 0 +been 0 +treated 0 +from 0 +conception 0 +onward 0 +with 0 +either 0 +captopril 1 +or 0 +vehicle 0 +remained 0 +on 0 +a 0 +basal 0 +sodium 1 +chloride 2 +diet 0 +or 0 +were 0 +fed 0 +a 0 +high 0 +sodium 1 +chloride 2 +diet 0 +. 0 + +After 0 +2 0 +weeks 0 +, 0 +the 0 +rats 0 +were 0 +subjected 0 +to 0 +ganglionic 0 +blockade 0 +and 0 +2 0 +days 0 +later 0 +, 0 +an 0 +infusion 0 +of 0 +clonidine 1 +. 0 + +RESULTS 0 +: 0 +Lifetime 0 +captopril 1 +treatment 0 +significantly 0 +lowered 0 +mean 0 +arterial 0 +pressure 0 +in 0 +both 0 +groups 0 +. 0 + +Intravenous 0 +infusion 0 +of 0 +the 0 +ganglionic 0 +blocker 0 +hexamethonium 1 +resulted 0 +in 0 +a 0 +rapid 0 +decline 0 +in 0 +MAP 0 +that 0 +eliminated 0 +the 0 +dietary 1 +sodium 2 +chloride 2 +- 0 +induced 0 +increase 3 +in 4 +MAP 4 +in 0 +both 0 +groups 0 +. 0 + +Infusion 0 +of 0 +the 0 +central 0 +nervous 0 +system 0 +alpha2 1 +- 2 +adrenergic 2 +receptor 2 +agonist 2 +clonidine 1 +also 0 +resulted 0 +in 0 +a 0 +greater 0 +reduction 0 +in 0 +MAP 0 +in 0 +both 0 +groups 0 +of 0 +SHR 0 +that 0 +were 0 +fed 0 +the 0 +high 0 +( 0 +compared 0 +with 0 +the 0 +basal 0 +) 0 +sodium 1 +chloride 2 +diet 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +both 0 +lifetime 0 +captopril 1 +- 0 +treated 0 +and 0 +control 0 +SHR 0 +, 0 +the 0 +sympathetic 0 +nervous 0 +system 0 +contributes 0 +to 0 +the 0 +pressor 0 +effects 0 +of 0 +a 0 +high 0 +sodium 1 +chloride 2 +diet 0 +. 0 + +Angioedema 3 +associated 0 +with 0 +droperidol 1 +administration 0 +. 0 + +Angioedema 3 +, 0 +also 0 +known 0 +as 0 +angioneurotic 3 +edema 4 +or 0 +Quincke 3 +' 4 +s 4 +disease 4 +, 0 +is 0 +a 0 +well 0 +- 0 +demarcated 0 +, 0 +localized 0 +edema 3 +involving 0 +the 0 +subcutaneous 0 +tissues 0 +that 0 +may 0 +cause 0 +upper 3 +- 4 +airway 4 +obstruction 4 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +previously 0 +healthy 0 +19 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +no 0 +known 0 +drug 3 +allergies 4 +in 0 +whom 0 +angioedema 3 +with 0 +significant 0 +tongue 3 +swelling 4 +and 0 +protrusion 0 +developed 0 +within 0 +10 0 +minutes 0 +of 0 +the 0 +administration 0 +of 0 +a 0 +single 0 +IV 0 +dose 0 +of 0 +droperidol 1 +. 0 + +Late 0 +cardiotoxicity 3 +after 0 +treatment 0 +for 0 +a 0 +malignant 0 +bone 3 +tumor 4 +. 0 + +Cardiac 0 +function 0 +was 0 +assessed 0 +in 0 +long 0 +- 0 +term 0 +survivors 0 +of 0 +malignant 0 +bone 3 +tumors 4 +who 0 +were 0 +treated 0 +according 0 +to 0 +Rosen 1 +' 2 +s 2 +T5 2 +or 2 +T10 2 +protocol 2 +, 0 +both 0 +including 0 +doxorubicin 1 +. 0 + +Thirty 0 +- 0 +one 0 +patients 0 +, 0 +age 0 +10 0 +- 0 +45 0 +years 0 +( 0 +median 0 +age 0 +17 0 +. 0 +8 0 +years 0 +) 0 +were 0 +evaluated 0 +2 0 +. 0 +3 0 +- 0 +14 0 +. 0 +1 0 +years 0 +( 0 +median 0 +8 0 +. 0 +9 0 +years 0 +) 0 +following 0 +completion 0 +of 0 +treatment 0 +. 0 + +Cumulative 0 +doses 0 +of 0 +doxorubicin 1 +were 0 +225 0 +- 0 +550 0 +mg 0 +/ 0 +m2 0 +( 0 +median 0 +dose 0 +360 0 +) 0 +. 0 + +The 0 +evaluation 0 +consisted 0 +of 0 +a 0 +history 0 +, 0 +physical 0 +examination 0 +, 0 +electrocardiogram 0 +( 0 +ECG 0 +) 0 +, 0 +signal 0 +averaged 0 +ECG 0 +, 0 +24 0 +- 0 +hour 0 +ambulatory 0 +ECG 0 +, 0 +echocardiography 0 +and 0 +radionuclide 0 +angiography 0 +. 0 + +Eighteen 0 +of 0 +31 0 +( 0 +58 0 +% 0 +) 0 +patients 0 +showed 0 +cardiac 3 +toxicity 4 +, 0 +defined 0 +as 0 +having 0 +one 0 +or 0 +more 0 +of 0 +the 0 +following 0 +abnormalities 0 +: 0 +late 0 +potentials 0 +, 0 +complex 0 +ventricular 3 +arrhythmias 4 +, 0 +left 0 +ventricular 3 +dilation 4 +, 0 +decreased 0 +shortening 0 +fraction 0 +, 0 +or 0 +decreased 0 +ejection 0 +fraction 0 +. 0 + +The 0 +incidence 0 +of 0 +cardiac 3 +abnormalities 4 +increased 0 +with 0 +length 0 +of 0 +follow 0 +- 0 +up 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +05 0 +) 0 +. 0 + +No 0 +correlation 0 +could 0 +be 0 +demonstrated 0 +between 0 +cumulative 0 +dose 0 +of 0 +doxorubicin 1 +and 0 +cardiac 0 +status 0 +, 0 +except 0 +for 0 +heart 0 +rate 0 +variability 0 +. 0 + +When 0 +adjusted 0 +to 0 +body 0 +surface 0 +area 0 +, 0 +the 0 +left 0 +ventricular 0 +posterior 0 +wall 0 +thickness 0 +( 0 +LVPW 0 +index 0 +) 0 +was 0 +decreased 0 +in 0 +all 0 +patients 0 +. 0 + +The 0 +incidence 0 +of 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +is 0 +high 0 +and 0 +increases 0 +with 0 +follow 0 +- 0 +up 0 +, 0 +irrespective 0 +of 0 +cumulative 0 +dose 0 +. 0 + +Life 0 +- 0 +long 0 +cardiac 0 +follow 0 +- 0 +up 0 +in 0 +these 0 +patients 0 +is 0 +warranted 0 +. 0 + +The 0 +results 0 +of 0 +our 0 +study 0 +suggest 0 +that 0 +heart 0 +rate 0 +variability 0 +and 0 +LVPW 0 +index 0 +could 0 +be 0 +sensitive 0 +indicators 0 +for 0 +cardiotoxicity 3 +. 0 + +Acute 0 +blood 0 +pressure 0 +elevations 0 +with 0 +caffeine 1 +in 0 +men 0 +with 0 +borderline 0 +systemic 0 +hypertension 3 +. 0 + +Whether 0 +the 0 +vasoconstrictive 0 +actions 0 +of 0 +caffeine 1 +are 0 +enhanced 0 +in 0 +hypertensive 3 +persons 0 +has 0 +not 0 +been 0 +demonstrated 0 +. 0 + +Thus 0 +, 0 +caffeine 1 +( 0 +3 0 +. 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +versus 0 +placebo 0 +was 0 +tested 0 +in 0 +48 0 +healthy 0 +men 0 +( 0 +aged 0 +20 0 +to 0 +35 0 +years 0 +) 0 +selected 0 +after 0 +screening 0 +on 0 +2 0 +separate 0 +occasions 0 +. 0 + +Borderline 0 +hypertensive 3 +men 0 +( 0 +n 0 += 0 +24 0 +) 0 +were 0 +selected 0 +with 0 +screening 0 +systolic 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +of 0 +140 0 +to 0 +160 0 +mm 0 +Hg 0 +and 0 +/ 0 +or 0 +diastolic 0 +BP 0 +90 0 +to 0 +99 0 +mm 0 +Hg 0 +. 0 + +Low 0 +- 0 +risk 0 +controls 0 +( 0 +n 0 += 0 +24 0 +) 0 +reported 0 +no 0 +parental 0 +history 0 +of 0 +hypertension 3 +and 0 +had 0 +screening 0 +BP 0 +< 0 +130 0 +/ 0 +85 0 +mm 0 +Hg 0 +. 0 + +Participants 0 +were 0 +then 0 +tested 0 +on 0 +2 0 +occasions 0 +after 0 +12 0 +- 0 +hour 0 +abstinence 0 +from 0 +caffeine 1 +in 0 +each 0 +of 0 +2 0 +protocols 0 +; 0 +this 0 +required 0 +a 0 +total 0 +of 0 +4 0 +laboratory 0 +visits 0 +. 0 + +Caffeine 1 +- 0 +induced 0 +changes 0 +in 0 +diastolic 0 +BP 0 +were 0 +2 0 +to 0 +3 0 +times 0 +larger 0 +in 0 +borderline 0 +subjects 0 +than 0 +in 0 +controls 0 +( 0 ++ 0 +8 0 +. 0 +4 0 +vs 0 ++ 0 +3 0 +. 0 +8 0 +mm 0 +Hg 0 +, 0 +p 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +, 0 +and 0 +were 0 +attributable 0 +to 0 +larger 0 +changes 0 +in 0 +impedance 0 +- 0 +derived 0 +measures 0 +of 0 +systemic 0 +vascular 0 +resistance 0 +( 0 ++ 0 +135 0 +vs 0 ++ 0 +45 0 +dynes 0 +. 0 +s 0 +. 0 +cm 0 +- 0 +5 0 +, 0 +p 0 +< 0 +0 0 +. 0 +004 0 +) 0 +. 0 + +These 0 +findings 0 +were 0 +consistent 0 +and 0 +reached 0 +significance 0 +in 0 +both 0 +protocols 0 +. 0 + +The 0 +percentage 0 +of 0 +borderline 0 +subjects 0 +in 0 +whom 0 +diastolic 0 +BP 0 +changes 0 +exceeded 0 +the 0 +median 0 +control 0 +response 0 +was 0 +96 0 +% 0 +. 0 + +Consequently 0 +, 0 +whereas 0 +all 0 +participants 0 +exhibited 0 +normotensive 0 +levels 0 +during 0 +the 0 +resting 0 +predrug 0 +baseline 0 +, 0 +33 0 +% 0 +of 0 +borderline 0 +subjects 0 +achieved 0 +hypertensive 3 +BP 0 +levels 0 +after 0 +caffeine 1 +ingestion 0 +. 0 + +Thus 0 +, 0 +in 0 +borderline 0 +hypertensive 3 +men 0 +, 0 +exaggerated 0 +responses 0 +to 0 +caffeine 1 +were 0 +: 0 +selective 0 +for 0 +diastolic 0 +BP 0 +, 0 +consistent 0 +with 0 +greater 0 +vasoconstriction 0 +, 0 +replicated 0 +in 0 +2 0 +protocols 0 +, 0 +and 0 +representative 0 +of 0 +nearly 0 +all 0 +borderline 0 +hypertensives 3 +. 0 + +We 0 +suspect 0 +that 0 +the 0 +potential 0 +for 0 +caffeine 1 +to 0 +stabilize 0 +high 0 +resistance 0 +states 0 +in 0 +susceptible 0 +persons 0 +suggests 0 +that 0 +its 0 +use 0 +may 0 +facilitate 0 +their 0 +disease 0 +progression 0 +, 0 +as 0 +well 0 +as 0 +hinder 0 +accurate 0 +diagnosis 0 +and 0 +treatment 0 +. 0 + +Absence 0 +of 0 +effect 0 +of 0 +sertraline 1 +on 0 +time 0 +- 0 +based 0 +sensitization 0 +of 0 +cognitive 3 +impairment 4 +with 0 +haloperidol 1 +. 0 + +This 0 +double 0 +- 0 +blind 0 +, 0 +randomized 0 +, 0 +placebo 0 +- 0 +controlled 0 +study 0 +evaluated 0 +the 0 +effects 0 +of 0 +haloperidol 1 +alone 0 +and 0 +haloperidol 1 +plus 0 +sertraline 1 +on 0 +cognitive 0 +and 0 +psychomotor 0 +function 0 +in 0 +24 0 +healthy 0 +male 0 +subjects 0 +. 0 + +METH0D 0 +: 0 +All 0 +subjects 0 +received 0 +placebo 0 +on 0 +Day 0 +1 0 +and 0 +haloperidol 1 +2 0 +mg 0 +on 0 +Days 0 +2 0 +and 0 +25 0 +. 0 + +From 0 +Days 0 +9 0 +to 0 +25 0 +, 0 +subjects 0 +were 0 +randomly 0 +assigned 0 +to 0 +either 0 +sertraline 1 +( 0 +12 0 +subjects 0 +) 0 +or 0 +placebo 0 +( 0 +12 0 +subjects 0 +) 0 +; 0 +the 0 +sertraline 1 +dose 0 +was 0 +titrated 0 +from 0 +50 0 +to 0 +200 0 +mg 0 +/ 0 +day 0 +from 0 +Days 0 +9 0 +to 0 +16 0 +, 0 +and 0 +remained 0 +at 0 +200 0 +mg 0 +/ 0 +day 0 +for 0 +the 0 +final 0 +10 0 +days 0 +of 0 +the 0 +drug 0 +administration 0 +period 0 +. 0 + +Cognitive 0 +function 0 +testing 0 +was 0 +performed 0 +before 0 +dosing 0 +and 0 +over 0 +a 0 +24 0 +- 0 +hour 0 +period 0 +after 0 +dosing 0 +on 0 +Days 0 +1 0 +, 0 +2 0 +, 0 +and 0 +25 0 +. 0 + +RESULTS 0 +: 0 +Impairment 3 +of 4 +cognitive 4 +function 4 +was 0 +observed 0 +6 0 +to 0 +8 0 +hours 0 +after 0 +administration 0 +of 0 +haloperidol 1 +on 0 +Day 0 +2 0 +but 0 +was 0 +not 0 +evident 0 +23 0 +hours 0 +after 0 +dosing 0 +. 0 + +When 0 +single 0 +- 0 +dose 0 +haloperidol 1 +was 0 +given 0 +again 0 +25 0 +days 0 +later 0 +, 0 +greater 0 +impairment 0 +with 0 +earlier 0 +onset 0 +was 0 +noted 0 +in 0 +several 0 +tests 0 +in 0 +both 0 +treatment 0 +groups 0 +, 0 +suggesting 0 +enhancement 0 +of 0 +this 0 +effect 0 +. 0 + +There 0 +was 0 +no 0 +indication 0 +that 0 +sertraline 1 +exacerbated 0 +the 0 +impairment 0 +produced 0 +by 0 +haloperidol 1 +since 0 +an 0 +equivalent 0 +effect 0 +also 0 +occurred 0 +in 0 +the 0 +placebo 0 +group 0 +. 0 + +Three 0 +subjects 0 +( 0 +2 0 +on 0 +sertraline 1 +and 0 +1 0 +on 0 +placebo 0 +) 0 +withdrew 0 +from 0 +the 0 +study 0 +because 0 +of 0 +side 0 +effects 0 +. 0 + +Ten 0 +subjects 0 +in 0 +each 0 +group 0 +reported 0 +side 0 +effects 0 +related 0 +to 0 +treatment 0 +. 0 + +The 0 +side 0 +effect 0 +profiles 0 +of 0 +sertraline 1 +and 0 +of 0 +placebo 0 +were 0 +similar 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Haloperidol 1 +produced 0 +a 0 +clear 0 +profile 0 +of 0 +cognitive 3 +impairment 4 +that 0 +was 0 +not 0 +worsened 0 +by 0 +concomitant 0 +sertraline 1 +administration 0 +. 0 + +Coexistence 0 +of 0 +cerebral 3 +venous 4 +sinus 4 +and 4 +internal 4 +carotid 4 +artery 4 +thrombosis 4 +associated 0 +with 0 +exogenous 0 +sex 0 +hormones 0 +. 0 + +A 0 +case 0 +report 0 +. 0 + +A 0 +forty 0 +- 0 +six 0 +year 0 +- 0 +old 0 +premenopausal 0 +woman 0 +developed 0 +headache 3 +, 0 +nausea 3 +and 0 +vomiting 3 +, 0 +left 0 +hemiparesis 3 +and 0 +seizure 3 +two 0 +days 0 +after 0 +parenteral 0 +use 0 +of 0 +progesterone 1 +and 0 +estradiol 1 +. 0 + +Diabetes 3 +mellitus 4 +( 0 +DM 3 +) 0 +was 0 +found 0 +during 0 +admission 0 +. 0 + +Computed 0 +tomography 0 +showed 0 +a 0 +hemorrhagic 3 +infarct 4 +in 0 +the 0 +right 0 +frontal 0 +lobe 0 +and 0 +increased 0 +density 0 +in 0 +the 0 +superior 0 +sagittal 0 +sinus 0 +( 0 +SSS 0 +) 0 +. 0 + +Left 0 +carotid 0 +angiography 0 +found 0 +occlusion 3 +of 4 +the 4 +left 4 +internal 4 +carotid 4 +artery 4 +( 0 +ICA 0 +) 0 +. 0 + +Right 0 +carotid 0 +angiograms 0 +failed 0 +to 0 +show 0 +the 0 +SSS 0 +and 0 +inferior 0 +sagittal 0 +sinus 0 +, 0 +suggestive 0 +of 0 +venous 3 +sinus 4 +thrombosis 4 +. 0 + +Coexistence 0 +of 0 +the 0 +cerebral 3 +artery 4 +and 4 +the 4 +venous 4 +sinus 4 +occlusion 4 +has 0 +been 0 +described 0 +infrequently 0 +. 0 + +In 0 +this 0 +case 0 +, 0 +the 0 +authors 0 +postulate 0 +that 0 +the 0 +use 0 +of 0 +estradiol 1 +and 0 +progesterone 1 +and 0 +the 0 +underlying 0 +DM 3 +increased 0 +vascular 0 +thrombogenicity 0 +, 0 +which 0 +provided 0 +a 0 +common 0 +denominator 0 +for 0 +thrombosis 3 +of 4 +both 4 +the 4 +ICA 4 +and 4 +the 4 +venous 4 +sinus 4 +. 0 + +Chemotherapy 0 +of 0 +advanced 0 +inoperable 0 +non 3 +- 4 +small 4 +cell 4 +lung 4 +cancer 4 +with 0 +paclitaxel 1 +: 0 +a 0 +phase 0 +II 0 +trial 0 +. 0 + +Paclitaxel 1 +( 0 +Taxol 1 +; 0 +Bristol 0 +- 0 +Myers 0 +Squibb 0 +Company 0 +, 0 +Princeton 0 +, 0 +NJ 0 +) 0 +has 0 +demonstrated 0 +significant 0 +antineoplastic 0 +activity 0 +against 0 +different 0 +tumor 3 +types 0 +, 0 +notably 0 +ovarian 3 +and 4 +breast 4 +carcinoma 4 +. 0 + +Two 0 +phase 0 +II 0 +trials 0 +of 0 +24 0 +- 0 +hour 0 +paclitaxel 1 +infusions 0 +in 0 +chemotherapy 0 +- 0 +naive 0 +patients 0 +with 0 +stage 0 +IIIB 0 +or 0 +IV 0 +non 3 +- 4 +small 4 +cell 4 +lung 4 +cancer 4 +( 0 +NSCLC 3 +) 0 +reported 0 +response 0 +rates 0 +of 0 +21 0 +% 0 +and 0 +24 0 +% 0 +. 0 + +Leukopenia 3 +was 0 +dose 0 +limiting 0 +: 0 +as 0 +many 0 +as 0 +62 0 +. 0 +5 0 +% 0 +of 0 +patients 0 +experienced 0 +grade 0 +4 0 +leukopenia 3 +. 0 + +We 0 +investigated 0 +the 0 +efficacy 0 +and 0 +toxicity 3 +of 0 +a 0 +3 0 +- 0 +hour 0 +paclitaxel 1 +infusion 0 +in 0 +a 0 +phase 0 +II 0 +trial 0 +in 0 +patients 0 +with 0 +inoperable 0 +stage 0 +IIIB 0 +or 0 +IV 0 +NSCLC 3 +. 0 + +The 0 +58 0 +patients 0 +treated 0 +( 0 +41 0 +men 0 +and 0 +17 0 +women 0 +) 0 +had 0 +a 0 +median 0 +age 0 +of 0 +59 0 +years 0 +( 0 +age 0 +range 0 +, 0 +25 0 +to 0 +75 0 +) 0 +and 0 +a 0 +performance 0 +status 0 +of 0 +0 0 +through 0 +2 0 +. 0 + +Most 0 +patients 0 +( 0 +72 0 +. 0 +4 0 +% 0 +) 0 +had 0 +stage 0 +IV 0 +NSCLC 3 +. 0 + +Paclitaxel 1 +225 0 +mg 0 +/ 0 +m2 0 +was 0 +infused 0 +over 0 +3 0 +hours 0 +every 0 +3 0 +weeks 0 +with 0 +standard 0 +prophylactic 0 +premedication 0 +. 0 + +0f 0 +50 0 +patients 0 +evaluable 0 +for 0 +response 0 +, 0 +12 0 +( 0 +24 0 +% 0 +) 0 +had 0 +partial 0 +remission 0 +, 0 +26 0 +( 0 +52 0 +% 0 +) 0 +had 0 +no 0 +change 0 +, 0 +and 0 +12 0 +had 0 +disease 0 +progression 0 +( 0 +24 0 +% 0 +) 0 +. 0 + +Hematologic 0 +toxicities 3 +were 0 +mild 0 +: 0 +only 0 +one 0 +patient 0 +( 0 +2 0 +% 0 +) 0 +developed 0 +grade 0 +3 0 +or 0 +4 0 +neutropenia 3 +, 0 +while 0 +29 0 +% 0 +had 0 +grade 0 +1 0 +or 0 +2 0 +. 0 + +Grade 0 +1 0 +or 0 +2 0 +polyneuropathy 3 +affected 0 +56 0 +% 0 +of 0 +patients 0 +while 0 +only 0 +one 0 +( 0 +2 0 +% 0 +) 0 +experienced 0 +severe 0 +polyneuropathy 3 +. 0 + +Similarly 0 +, 0 +grade 0 +1 0 +or 0 +2 0 +myalgia 3 +/ 0 +arthralgia 3 +was 0 +observed 0 +in 0 +63 0 +. 0 +2 0 +% 0 +of 0 +patients 0 +, 0 +but 0 +only 0 +14 0 +. 0 +3 0 +% 0 +experienced 0 +grade 0 +3 0 +or 0 +4 0 +. 0 + +Nausea 3 +and 0 +vomiting 3 +were 0 +infrequent 0 +, 0 +with 0 +14 0 +% 0 +of 0 +patients 0 +experiencing 0 +grade 0 +1 0 +or 0 +2 0 +and 0 +only 0 +2 0 +% 0 +experiencing 0 +grade 0 +3 0 +or 0 +4 0 +. 0 + +Paclitaxel 1 +is 0 +thus 0 +an 0 +active 0 +single 0 +agent 0 +in 0 +this 0 +patient 0 +population 0 +, 0 +with 0 +a 0 +3 0 +- 0 +hour 0 +infusion 0 +proving 0 +comparably 0 +effective 0 +to 0 +a 0 +24 0 +- 0 +hour 0 +infusion 0 +and 0 +superior 0 +in 0 +terms 0 +of 0 +the 0 +incidence 0 +of 0 +hematologic 0 +and 0 +nonhematologic 0 +toxicity 3 +. 0 + +Further 0 +phase 0 +II 0 +studies 0 +with 0 +paclitaxel 1 +combined 0 +with 0 +other 0 +drugs 0 +active 0 +against 0 +NSCLC 3 +are 0 +indicated 0 +, 0 +and 0 +phase 0 +III 0 +studies 0 +comparing 0 +paclitaxel 1 +with 0 +standard 0 +chemotherapy 0 +remain 0 +to 0 +be 0 +completed 0 +. 0 + +Paclitaxel 1 +combined 0 +with 0 +carboplatin 1 +in 0 +the 0 +first 0 +- 0 +line 0 +treatment 0 +of 0 +advanced 0 +ovarian 3 +cancer 4 +. 0 + +In 0 +a 0 +phase 0 +I 0 +study 0 +to 0 +determine 0 +the 0 +maximum 0 +tolerated 0 +dose 0 +of 0 +paclitaxel 1 +( 0 +Taxol 1 +; 0 +Bristol 0 +- 0 +Myers 0 +Squibb 0 +Company 0 +, 0 +Princeton 0 +, 0 +NJ 0 +) 0 +given 0 +as 0 +a 0 +3 0 +- 0 +hour 0 +infusion 0 +in 0 +combination 0 +with 0 +carboplatin 1 +administered 0 +every 0 +21 0 +days 0 +to 0 +women 0 +with 0 +advanced 0 +ovarian 3 +cancer 4 +, 0 +paclitaxel 1 +doses 0 +were 0 +escalated 0 +as 0 +follows 0 +: 0 +level 0 +1 0 +, 0 +135 0 +mg 0 +/ 0 +m2 0 +; 0 +level 0 +2 0 +, 0 +160 0 +mg 0 +/ 0 +m2 0 +; 0 +level 0 +3 0 +, 0 +185 0 +mg 0 +/ 0 +m2 0 +; 0 +and 0 +level 0 +4 0 +, 0 +210 0 +mg 0 +/ 0 +m2 0 +. 0 + +The 0 +fixed 0 +dose 0 +of 0 +carboplatin 1 +at 0 +levels 0 +1 0 +through 0 +4 0 +was 0 +given 0 +to 0 +achieve 0 +an 0 +area 0 +under 0 +the 0 +concentration 0 +- 0 +time 0 +curve 0 +( 0 +AUC 0 +) 0 +of 0 +5 0 +using 0 +the 0 +Calvert 0 +formula 0 +. 0 + +In 0 +levels 0 +5 0 +and 0 +6 0 +the 0 +carboplatin 1 +dose 0 +was 0 +targeted 0 +at 0 +AUCs 0 +of 0 +6 0 +and 0 +7 0 +. 0 +5 0 +, 0 +respectively 0 +, 0 +combined 0 +with 0 +a 0 +fixed 0 +paclitaxel 1 +dose 0 +of 0 +185 0 +mg 0 +/ 0 +m2 0 +. 0 + +To 0 +date 0 +, 0 +30 0 +previously 0 +untreated 0 +patients 0 +, 0 +all 0 +with 0 +a 0 +good 0 +performance 0 +status 0 +( 0 +Eastern 0 +Cooperative 0 +0ncology 0 +Group 0 +0 0 +to 0 +2 0 +) 0 +have 0 +been 0 +entered 0 +into 0 +this 0 +ongoing 0 +study 0 +. 0 + +The 0 +dose 0 +- 0 +limiting 0 +toxicity 3 +of 0 +the 0 +combination 0 +was 0 +myelosuppression 3 +( 0 +leukopenia 3 +, 0 +granulocytopenia 3 +, 0 +and 0 +thrombocytopenia 3 +) 0 +. 0 + +Neurotoxicity 3 +was 0 +largely 0 +moderate 0 +. 0 + +So 0 +far 0 +, 0 +14 0 +patients 0 +are 0 +evaluable 0 +for 0 +response 0 +; 0 +of 0 +these 0 +, 0 +eight 0 +( 0 +57 0 +% 0 +) 0 +showed 0 +objective 0 +( 0 +complete 0 +or 0 +partial 0 +) 0 +response 0 +and 0 +disease 0 +stabilized 0 +in 0 +six 0 +patients 0 +. 0 + +No 0 +patient 0 +had 0 +disease 0 +progression 0 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +combination 0 +of 0 +paclitaxel 1 +185 0 +mg 0 +/ 0 +m2 0 +administered 0 +as 0 +a 0 +3 0 +- 0 +hour 0 +infusion 0 +followed 0 +immediately 0 +by 0 +a 0 +1 0 +- 0 +hour 0 +infusion 0 +of 0 +carboplatin 1 +at 0 +an 0 +AUC 0 +of 0 +6 0 +can 0 +be 0 +administered 0 +safely 0 +in 0 +a 0 +21 0 +- 0 +day 0 +schedule 0 +in 0 +the 0 +outpatient 0 +setting 0 +. 0 + +The 0 +recommended 0 +dose 0 +for 0 +phase 0 +III 0 +studies 0 +is 0 +paclitaxel 1 +185 0 +mg 0 +/ 0 +m2 0 +and 0 +carboplatin 1 +AUC 0 +6 0 +. 0 + +Effects 0 +of 0 +acute 0 +steroid 1 +administration 0 +on 0 +ventilatory 0 +and 0 +peripheral 0 +muscles 0 +in 0 +rats 0 +. 0 + +0ccasional 0 +case 0 +reports 0 +have 0 +shown 0 +that 0 +acute 0 +myopathy 3 +may 0 +occur 0 +in 0 +patients 0 +treated 0 +with 0 +massive 0 +doses 0 +of 0 +corticosteroids 1 +. 0 + +The 0 +mechanism 0 +of 0 +this 0 +myopathy 3 +is 0 +poorly 0 +understood 0 +. 0 + +Therefore 0 +, 0 +60 0 +male 0 +rats 0 +were 0 +randomly 0 +assigned 0 +to 0 +receive 0 +daily 0 +injection 0 +of 0 +saline 0 +( 0 +C 0 +) 0 +, 0 +methylprednisolone 1 +( 0 +M 1 +) 0 +, 0 +or 0 +triamcinolone 1 +( 0 +T 1 +) 0 +80 0 +mg 0 +/ 0 +kg 0 +/ 0 +d 0 +for 0 +5 0 +d 0 +. 0 + +Nutritional 0 +intake 0 +, 0 +measured 0 +daily 0 +in 0 +15 0 +animals 0 +, 0 +showed 0 +a 0 +significant 0 +reduction 3 +of 4 +food 4 +intake 4 +in 0 +the 0 +steroid 1 +- 0 +treated 0 +groups 0 +( 0 +- 0 +50 0 +and 0 +- 0 +79 0 +% 0 +in 0 +M 1 +and 0 +T 1 +, 0 +respectively 0 +) 0 +. 0 + +This 0 +was 0 +associated 0 +with 0 +a 0 +similar 0 +loss 3 +in 4 +body 4 +weight 4 +. 0 + +In 0 +the 0 +45 0 +remaining 0 +animals 0 +, 0 +diaphragm 0 +contractility 0 +and 0 +histopathologic 0 +features 0 +of 0 +several 0 +muscles 0 +were 0 +studied 0 +. 0 + +Weights 0 +of 0 +respiratory 0 +and 0 +peripheral 0 +muscles 0 +were 0 +similarly 0 +decreased 0 +after 0 +steroid 1 +treatment 0 +. 0 + +Maximal 0 +twitches 0 +of 0 +the 0 +diaphragm 0 +were 0 +lower 0 +in 0 +the 0 +C 0 +group 0 +( 0 +653 0 ++ 0 +/ 0 +- 0 +174 0 +g 0 +/ 0 +cm 0 +( 0 +2 0 +) 0 +) 0 +than 0 +in 0 +the 0 +M 1 +group 0 +( 0 +837 0 ++ 0 +/ 0 +- 0 +171 0 +g 0 +/ 0 +cm 0 +( 0 +2 0 +) 0 +; 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +the 0 +T 1 +group 0 +( 0 +765 0 ++ 0 +/ 0 +- 0 +145 0 +g 0 +/ 0 +cm 0 +( 0 +2 0 +) 0 +, 0 +NS 0 +) 0 +. 0 + +Half 0 +- 0 +relaxation 0 +time 0 +was 0 +prolonged 0 +in 0 +both 0 +steroid 1 +groups 0 +, 0 +and 0 +time 0 +to 0 +peak 0 +tension 0 +was 0 +longer 0 +with 0 +M 1 +, 0 +whereas 0 +tetanic 3 +tensions 0 +were 0 +similar 0 +. 0 + +Steroid 1 +treatment 0 +also 0 +induced 0 +a 0 +leftward 0 +shift 0 +of 0 +the 0 +force 0 +- 0 +frequency 0 +curve 0 +at 0 +25 0 +and 0 +50 0 +Hz 0 +when 0 +compared 0 +with 0 +saline 0 +treatment 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +ATPase 0 +staining 0 +of 0 +the 0 +diaphragm 0 +, 0 +scalenus 0 +medius 0 +, 0 +and 0 +gastrocnemius 0 +showed 0 +type 0 +IIb 0 +fiber 0 +atrophy 3 +in 0 +the 0 +steroid 1 +groups 0 +and 0 +also 0 +diaphragmatic 0 +type 0 +IIa 0 +atrophy 3 +with 0 +T 1 +, 0 +whereas 0 +histologic 0 +examinations 0 +revealed 0 +a 0 +normal 0 +muscular 0 +pattern 0 +with 0 +absence 0 +of 0 +necrosis 3 +. 0 + +Finally 0 +, 0 +a 0 +pair 0 +- 0 +fed 0 +( 0 +PF 0 +) 0 +study 0 +, 0 +performed 0 +in 0 +18 0 +rats 0 +( 0 +C 0 +, 0 +T 1 +, 0 +and 0 +PF 0 +) 0 +, 0 +showed 0 +that 0 +muscle 3 +atrophy 4 +was 0 +considerably 0 +less 0 +pronounced 0 +in 0 +PF 0 +animals 0 +than 0 +in 0 +T 1 +- 0 +treated 0 +animals 0 +. 0 + +We 0 +conclude 0 +that 0 +( 0 +1 0 +) 0 +short 0 +- 0 +term 0 +treatment 0 +with 0 +massive 0 +doses 0 +of 0 +steroids 1 +induced 0 +severe 0 +respiratory 0 +and 0 +limb 0 +muscle 0 +wasting 0 +; 0 +( 0 +2 0 +) 0 +both 0 +types 0 +of 0 +steroids 1 +induced 0 +predominantly 0 +type 0 +IIb 0 +atrophy 3 +, 0 +resulting 0 +in 0 +the 0 +expected 0 +alterations 0 +in 0 +diaphragm 0 +contractile 0 +properties 0 +; 0 +( 0 +3 0 +) 0 +neither 0 +steroid 1 +caused 0 +muscle 0 +necrosis 3 +; 0 +( 0 +4 0 +) 0 +type 0 +IIb 0 +atrophy 3 +was 0 +not 0 +caused 0 +by 0 +acute 0 +nutritional 0 +deprivation 0 +alone 0 +. 0 + +Continuous 0 +subcutaneous 0 +administration 0 +of 0 +mesna 1 +to 0 +prevent 0 +ifosfamide 1 +- 0 +induced 0 +hemorrhagic 3 +cystitis 4 +. 0 + +Hemorrhagic 3 +cystitis 4 +is 0 +a 0 +major 0 +potential 0 +toxicity 3 +of 0 +ifosfamide 1 +that 0 +can 0 +be 0 +prevented 0 +by 0 +administering 0 +mesna 1 +along 0 +with 0 +the 0 +cytotoxic 0 +agent 0 +. 0 + +Mesna 1 +is 0 +generally 0 +administered 0 +by 0 +the 0 +intravenous 0 +route 0 +, 0 +although 0 +experience 0 +with 0 +oral 0 +delivery 0 +of 0 +the 0 +drug 0 +has 0 +increased 0 +. 0 + +The 0 +continuous 0 +subcutaneous 0 +administration 0 +of 0 +mesna 1 +has 0 +the 0 +advantage 0 +of 0 +not 0 +requiring 0 +intravenous 0 +access 0 +. 0 + +In 0 +addition 0 +, 0 +subcutaneous 0 +delivery 0 +of 0 +the 0 +neutralizing 0 +agent 0 +will 0 +not 0 +be 0 +associated 0 +with 0 +the 0 +risk 0 +of 0 +inadequate 0 +urinary 0 +mesna 1 +concentrations 0 +, 0 +such 0 +as 0 +in 0 +a 0 +patient 0 +taking 0 +oral 0 +mesna 1 +who 0 +experiences 0 +severe 0 +ifosfamide 1 +- 0 +induced 0 +emesis 3 +and 0 +is 0 +unable 0 +to 0 +absorb 0 +the 0 +drug 0 +. 0 + +Limited 0 +clinical 0 +experience 0 +with 0 +continuous 0 +subcutaneous 0 +mesna 1 +administration 0 +suggests 0 +it 0 +is 0 +a 0 +safe 0 +, 0 +practical 0 +, 0 +and 0 +economic 0 +method 0 +of 0 +drug 0 +delivery 0 +that 0 +permits 0 +ifosfamide 1 +to 0 +be 0 +administered 0 +successfully 0 +in 0 +the 0 +outpatient 0 +setting 0 +. 0 + +Leg 3 +and 4 +back 4 +pain 4 +after 0 +spinal 0 +anaesthesia 0 +involving 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +. 0 + +Fifty 0 +- 0 +four 0 +patients 0 +, 0 +aged 0 +27 0 +- 0 +90 0 +years 0 +, 0 +who 0 +were 0 +given 0 +lignocaine 1 +5 0 +% 0 +in 0 +6 0 +. 0 +8 0 +% 0 +glucose 1 +solution 0 +for 0 +spinal 0 +anaesthesia 0 +were 0 +studied 0 +. 0 + +Thirteen 0 +of 0 +these 0 +patients 0 +experienced 0 +pain 3 +in 4 +the 4 +legs 4 +and 4 +/ 4 +or 4 +back 4 +after 0 +recovery 0 +from 0 +anaesthesia 0 +. 0 + +The 0 +patients 0 +affected 0 +were 0 +younger 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +the 0 +site 0 +of 0 +the 0 +dural 0 +puncture 0 +was 0 +higher 0 +( 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +than 0 +those 0 +individuals 0 +without 0 +pain 3 +. 0 + +Five 0 +of 0 +the 0 +13 0 +patients 0 +( 0 +38 0 +% 0 +) 0 +with 0 +pain 3 +and 0 +seven 0 +of 0 +the 0 +41 0 +patients 0 +( 0 +17 0 +% 0 +) 0 +without 0 +pain 3 +admitted 0 +to 0 +a 0 +high 0 +alcohol 1 +intake 0 +, 0 +which 0 +might 0 +be 0 +a 0 +contributing 0 +factor 0 +. 0 + +Leg 3 +and 4 +/ 4 +or 4 +back 4 +pain 4 +is 0 +associated 0 +with 0 +the 0 +intrathecal 0 +use 0 +of 0 +hyperbaric 0 +5 0 +% 0 +lignocaine 1 +. 0 + +The 0 +use 0 +of 0 +serum 0 +cholinesterase 0 +in 0 +succinylcholine 1 +apnoea 3 +. 0 + +Fifteen 0 +patients 0 +demonstrating 0 +unexpected 0 +prolonged 0 +apnoea 3 +lasting 0 +several 0 +hours 0 +after 0 +succinylcholine 1 +have 0 +been 0 +treated 0 +by 0 +a 0 +new 0 +preparation 0 +of 0 +human 0 +serum 0 +cholinesterase 0 +. 0 + +Adequate 0 +spontaneous 0 +respiration 0 +was 0 +re 0 +- 0 +established 0 +in 0 +an 0 +average 0 +period 0 +of 0 +ten 0 +minutes 0 +after 0 +the 0 +injection 0 +. 0 + +In 0 +12 0 +patients 0 +biochemical 0 +genetic 0 +examinations 0 +confirmed 0 +the 0 +presence 0 +of 0 +an 0 +atypical 0 +serum 0 +cholinesterase 0 +. 0 + +In 0 +three 0 +patients 0 +none 0 +of 0 +the 0 +usual 0 +variants 0 +were 0 +found 0 +. 0 + +It 0 +is 0 +therefore 0 +supposed 0 +that 0 +other 0 +unknown 0 +variants 0 +of 0 +serum 0 +cholinesterase 0 +exist 0 +which 0 +cannot 0 +hydrolyze 0 +succinylcholine 1 +. 0 + +The 0 +use 0 +of 0 +serum 0 +cholinesterase 0 +in 0 +succinylcholine 1 +apnoea 3 +provided 0 +considerable 0 +relief 0 +to 0 +both 0 +patient 0 +and 0 +anaesthetist 0 +. 0 + +Increased 0 +sulfation 0 +and 0 +decreased 0 +7alpha 0 +- 0 +hydroxylation 0 +of 0 +deoxycholic 1 +acid 2 +in 0 +ethinyl 1 +estradiol 2 +- 0 +induced 0 +cholestasis 3 +in 0 +rats 0 +. 0 + +Deoxycholic 1 +acid 2 +conjugation 0 +, 0 +transport 0 +capacity 0 +, 0 +and 0 +metabolism 0 +were 0 +compared 0 +in 0 +control 0 +and 0 +ethinyl 1 +estradiol 2 +- 0 +treated 0 +rats 0 +. 0 + +Control 0 +rats 0 +were 0 +found 0 +to 0 +have 0 +a 0 +lower 0 +capacity 0 +to 0 +transport 0 +deoxycholic 1 +acid 2 +than 0 +taurodeoxycholic 1 +acid 2 +, 0 +and 0 +both 0 +were 0 +decreased 0 +by 0 +ethinyl 1 +estradiol 2 +treatment 0 +. 0 + +During 0 +[ 0 +24 0 +- 0 +14C 0 +] 0 +sodium 1 +deoxycholate 2 +infusion 0 +, 0 +[ 0 +14C 0 +] 0 +biliary 0 +bile 1 +acid 2 +secretion 0 +increased 0 +, 0 +but 0 +bile 0 +flow 0 +did 0 +not 0 +change 0 +significantly 0 +in 0 +either 0 +control 0 +or 0 +ethinyl 1 +estradiol 2 +- 0 +treated 0 +rats 0 +. 0 + +Ethinyl 1 +estradiol 2 +- 0 +treated 0 +animals 0 +excreted 0 +significantly 0 +less 0 +14C 0 +as 0 +taurocholic 1 +acid 2 +than 0 +did 0 +control 0 +animals 0 +, 0 +consistent 0 +with 0 +an 0 +impairment 0 +of 0 +7alpha 0 +- 0 +hydroxylation 0 +of 0 +taurodeoxycholic 1 +acid 2 +. 0 + +Ethinyl 1 +estradiol 2 +treatment 0 +did 0 +not 0 +impair 0 +conjugation 0 +of 0 +deoxycholic 1 +acid 2 +, 0 +but 0 +did 0 +result 0 +in 0 +an 0 +increase 0 +in 0 +sulfation 0 +of 0 +taurodeoxycholic 1 +acid 2 +from 0 +1 0 +. 0 +5 0 +% 0 +in 0 +controls 0 +to 0 +nearly 0 +4 0 +. 0 +0 0 +% 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +These 0 +results 0 +are 0 +consistent 0 +with 0 +the 0 +hypothesis 0 +that 0 +the 0 +rat 0 +has 0 +a 0 +poorer 0 +tolerance 0 +for 0 +deoxycholic 1 +acid 2 +than 0 +do 0 +certain 0 +other 0 +species 0 +. 0 + +Furthermore 0 +, 0 +the 0 +rat 0 +converts 0 +deoxycholic 1 +acid 2 +, 0 +a 0 +poor 0 +choleretic 0 +, 0 +to 0 +taurocholic 1 +acid 2 +, 0 +a 0 +good 0 +choleretic 0 +. 0 + +When 0 +this 0 +conversion 0 +is 0 +impaired 0 +with 0 +ethinyl 1 +estradiol 2 +treatment 0 +, 0 +sulfation 0 +may 0 +be 0 +an 0 +important 0 +alternate 0 +pathway 0 +for 0 +excretion 0 +of 0 +this 0 +potentially 0 +harmful 0 +bile 1 +acid 2 +. 0 + +Influence 0 +of 0 +diet 0 +free 0 +of 0 +NAD 1 +- 0 +precursors 0 +on 0 +acetaminophen 1 +hepatotoxicity 3 +in 0 +mice 0 +. 0 + +Recently 0 +, 0 +we 0 +demonstrated 0 +the 0 +hepatoprotective 0 +effects 0 +of 0 +nicotinic 1 +acid 2 +amide 2 +, 0 +a 0 +selective 0 +inhibitor 0 +of 0 +poly 1 +( 2 +ADP 2 +- 2 +ribose 2 +) 2 +polymerase 0 +( 0 +PARP 0 +; 0 +EC 0 +2 0 +. 0 +4 0 +. 0 +2 0 +. 0 +30 0 +) 0 +on 0 +mice 0 +suffering 0 +from 0 +acetaminophen 1 +( 0 +AAP 1 +) 0 +- 0 +hepatitis 3 +, 0 +suggesting 0 +that 0 +the 0 +AAP 1 +- 0 +induced 0 +liver 3 +injury 4 +involves 0 +a 0 +step 0 +which 0 +depends 0 +on 0 +adenoribosylation 0 +. 0 + +The 0 +present 0 +study 0 +investigates 0 +the 0 +effects 0 +of 0 +a 0 +diet 0 +free 0 +of 0 +precursors 0 +of 0 +NAD 1 +, 0 +the 0 +substrate 0 +on 0 +which 0 +PARP 0 +acts 0 +, 0 +in 0 +female 0 +NMRI 0 +mice 0 +with 0 +AAP 1 +hepatitis 3 +and 0 +evaluates 0 +the 0 +influence 0 +of 0 +simultaneous 0 +ethanol 1 +consumption 0 +in 0 +these 0 +animals 0 +. 0 + +Liver 3 +injuries 4 +were 0 +quantified 0 +as 0 +serum 0 +activities 0 +of 0 +glutamate 1 +- 0 +oxaloacetate 1 +transaminase 0 +( 0 +G0T 0 +) 0 +and 0 +glutamate 1 +- 0 +pyruvate 1 +transaminase 0 +( 0 +GPT 0 +) 0 +. 0 + +While 0 +AAP 1 +caused 0 +a 0 +117 0 +- 0 +fold 0 +elevation 0 +of 0 +serum 0 +transaminase 0 +activities 0 +in 0 +mice 0 +kept 0 +on 0 +a 0 +standard 0 +laboratory 0 +diet 0 +, 0 +which 0 +was 0 +significantly 0 +exacerbated 0 +by 0 +ethanol 1 +and 0 +inhibited 0 +by 0 +nicotinic 1 +acid 2 +amide 2 +( 0 +NAA 1 +) 0 +, 0 +adverse 0 +effects 0 +were 0 +noted 0 +in 0 +animals 0 +fed 0 +a 0 +diet 0 +free 0 +of 0 +precursors 0 +of 0 +NAD 1 +. 0 + +In 0 +these 0 +animals 0 +, 0 +only 0 +minor 0 +increases 0 +of 0 +serum 0 +transaminase 0 +activities 0 +were 0 +measured 0 +in 0 +the 0 +presence 0 +of 0 +AAP 1 +, 0 +and 0 +unlike 0 +the 0 +exacerbation 0 +caused 0 +by 0 +ethanol 1 +in 0 +mice 0 +on 0 +a 0 +standard 0 +diet 0 +, 0 +the 0 +liver 3 +damage 4 +was 0 +inhibited 0 +by 0 +50 0 +% 0 +by 0 +ethanol 1 +. 0 + +A 0 +further 0 +64 0 +% 0 +reduction 0 +of 0 +hepatitis 3 +was 0 +observed 0 +, 0 +when 0 +NAA 1 +was 0 +given 0 +to 0 +ethanol 1 +/ 0 +AAP 1 +- 0 +mice 0 +. 0 + +0ur 0 +results 0 +provide 0 +evidence 0 +that 0 +the 0 +AAP 1 +- 0 +induced 0 +hepatitis 3 +and 0 +its 0 +exacerbation 0 +by 0 +ethanol 1 +can 0 +either 0 +be 0 +reduced 0 +by 0 +end 0 +- 0 +product 0 +inhibition 0 +of 0 +PARP 0 +by 0 +NAA 1 +or 0 +by 0 +dietary 0 +depletion 0 +of 0 +the 0 +enzyme 0 +' 0 +s 0 +substrate 0 +NAD 1 +. 0 + +We 0 +see 0 +the 0 +main 0 +application 0 +of 0 +NAA 1 +as 0 +for 0 +the 0 +combinational 0 +use 0 +in 0 +pharmaceutical 0 +preparations 0 +of 0 +acetaminophen 1 +in 0 +order 0 +to 0 +avoid 0 +hepatic 3 +damage 4 +in 0 +patients 0 +treated 0 +with 0 +this 0 +widely 0 +used 0 +analgesic 0 +. 0 + +Nightmares 0 +and 0 +hallucinations 3 +after 0 +long 0 +- 0 +term 0 +intake 0 +of 0 +tramadol 1 +combined 0 +with 0 +antidepressants 0 +. 0 + +Tramadol 1 +is 0 +a 0 +weak 0 +opioid 0 +with 0 +effects 0 +on 0 +adrenergic 0 +and 0 +serotonergic 0 +neurotransmission 0 +that 0 +is 0 +used 0 +to 0 +treat 0 +cancer 3 +pain 3 +and 0 +chronic 0 +non 0 +malignant 0 +pain 3 +. 0 + +This 0 +drug 0 +was 0 +initiated 0 +in 0 +association 0 +with 0 +paroxetine 1 +and 0 +dosulepine 1 +hydrochloride 2 +in 0 +a 0 +tetraparetic 3 +patient 0 +with 0 +chronic 3 +pain 4 +. 0 + +Fifty 0 +- 0 +six 0 +days 0 +after 0 +initiation 0 +of 0 +the 0 +treatment 0 +the 0 +patient 0 +presented 0 +hallucinations 3 +that 0 +only 0 +stopped 0 +after 0 +the 0 +withdrawal 0 +of 0 +psycho 0 +- 0 +active 0 +drugs 0 +and 0 +tramadol 1 +. 0 + +The 0 +case 0 +report 0 +questions 0 +the 0 +long 0 +term 0 +use 0 +of 0 +pain 3 +killers 0 +combined 0 +with 0 +psycho 0 +- 0 +active 0 +drugs 0 +in 0 +chronic 0 +non 0 +malignant 0 +pain 3 +, 0 +especially 0 +if 0 +pain 3 +is 0 +under 0 +control 0 +. 0 + +Effect 0 +of 0 +calcium 1 +chloride 2 +and 0 +4 1 +- 2 +aminopyridine 2 +therapy 0 +on 0 +desipramine 1 +toxicity 3 +in 0 +rats 0 +. 0 + +BACKGR0UND 0 +: 0 +Hypotension 3 +is 0 +a 0 +major 0 +contributor 0 +to 0 +mortality 0 +in 0 +tricyclic 0 +antidepressant 0 +overdose 3 +. 0 + +Recent 0 +data 0 +suggest 0 +that 0 +tricyclic 0 +antidepressants 0 +inhibit 0 +calcium 1 +influx 0 +in 0 +some 0 +tissues 0 +. 0 + +This 0 +study 0 +addressed 0 +the 0 +potential 0 +role 0 +of 0 +calcium 1 +channel 0 +blockade 0 +in 0 +tricyclic 0 +antidepressant 0 +- 0 +induced 0 +hypotension 3 +. 0 + +METH0DS 0 +: 0 +Two 0 +interventions 0 +were 0 +studied 0 +that 0 +have 0 +been 0 +shown 0 +previously 0 +to 0 +improve 0 +blood 0 +pressure 0 +with 0 +calcium 1 +channel 0 +blocker 0 +overdose 3 +. 0 + +CaCl2 1 +and 0 +4 1 +- 2 +aminopyridine 2 +. 0 + +Anesthetized 0 +rats 0 +received 0 +the 0 +tricyclic 0 +antidepressant 0 +desipramine 1 +IP 0 +to 0 +produce 0 +hypotension 3 +, 0 +QRS 0 +prolongation 0 +, 0 +and 0 +bradycardia 3 +. 0 + +Fifteen 0 +min 0 +later 0 +, 0 +animals 0 +received 0 +CaCl2 1 +, 0 +NaHC03 1 +, 0 +or 0 +saline 0 +. 0 + +In 0 +a 0 +second 0 +experiment 0 +, 0 +rats 0 +received 0 +tricyclic 0 +antidepressant 0 +desipramine 1 +IP 0 +followed 0 +in 0 +15 0 +min 0 +by 0 +4 1 +- 2 +aminopyridine 2 +or 0 +saline 0 +. 0 + +RESULTS 0 +: 0 +NaHC03 1 +briefly 0 +( 0 +5 0 +min 0 +) 0 +reversed 0 +hypotension 3 +and 0 +QRS 0 +prolongation 0 +. 0 + +CaCl2 1 +and 0 +4 1 +- 2 +aminopyridine 2 +failed 0 +to 0 +improve 0 +blood 0 +pressure 0 +. 0 + +The 0 +incidence 0 +of 0 +ventricular 3 +arrhythmias 4 +( 0 +p 0 += 0 +0 0 +. 0 +004 0 +) 0 +and 0 +seizures 3 +( 0 +p 0 += 0 +0 0 +. 0 +03 0 +) 0 +in 0 +the 0 +CaCl2 1 +group 0 +was 0 +higher 0 +than 0 +the 0 +other 0 +groups 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +administration 0 +of 0 +CaCl2 1 +or 0 +4 1 +- 2 +aminopyridine 2 +did 0 +not 0 +reverse 0 +tricyclic 0 +antidepressant 0 +- 0 +induced 0 +hypotension 3 +in 0 +rats 0 +. 0 + +CaCl2 1 +therapy 0 +may 0 +possibly 0 +worsen 0 +both 0 +cardiovascular 3 +and 4 +central 4 +nervous 4 +system 4 +toxicity 4 +. 0 + +These 0 +findings 0 +do 0 +not 0 +support 0 +a 0 +role 0 +for 0 +calcium 1 +channel 0 +inhibition 0 +in 0 +the 0 +pathogenesis 0 +of 0 +tricyclic 0 +antidepressant 0 +- 0 +induced 0 +hypotension 3 +. 0 + +Valsartan 1 +, 0 +a 0 +new 0 +angiotensin 1 +II 2 +antagonist 0 +for 0 +the 0 +treatment 0 +of 0 +essential 0 +hypertension 3 +: 0 +a 0 +comparative 0 +study 0 +of 0 +the 0 +efficacy 0 +and 0 +safety 0 +against 0 +amlodipine 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +compare 0 +the 0 +antihypertensive 0 +efficacy 0 +of 0 +a 0 +new 0 +angiotensin 1 +II 2 +antagonist 0 +, 0 +valsartan 1 +, 0 +with 0 +a 0 +reference 0 +therapy 0 +, 0 +amlodipine 1 +. 0 + +METH0DS 0 +: 0 +0ne 0 +hundred 0 +sixty 0 +- 0 +eight 0 +adult 0 +outpatients 0 +with 0 +mild 0 +to 0 +moderate 0 +hypertension 3 +were 0 +randomly 0 +allocated 0 +in 0 +double 0 +- 0 +blind 0 +fashion 0 +and 0 +equal 0 +number 0 +to 0 +receive 0 +80 0 +mg 0 +valsartan 1 +or 0 +5 0 +mg 0 +amlodipine 1 +for 0 +12 0 +weeks 0 +. 0 + +After 0 +8 0 +weeks 0 +of 0 +therapy 0 +, 0 +in 0 +patients 0 +whose 0 +blood 0 +pressure 0 +remained 0 +uncontrolled 0 +, 0 +5 0 +mg 0 +amlodipine 1 +was 0 +added 0 +to 0 +the 0 +initial 0 +therapy 0 +. 0 + +Patients 0 +were 0 +assessed 0 +at 0 +4 0 +, 0 +8 0 +, 0 +and 0 +12 0 +weeks 0 +. 0 + +The 0 +primary 0 +efficacy 0 +variable 0 +was 0 +change 0 +from 0 +baseline 0 +in 0 +mean 0 +sitting 0 +diastolic 0 +blood 0 +pressure 0 +at 0 +8 0 +weeks 0 +. 0 + +Secondary 0 +variables 0 +included 0 +change 0 +in 0 +sitting 0 +systolic 0 +blood 0 +pressure 0 +and 0 +responder 0 +rates 0 +. 0 + +RESULTS 0 +: 0 +Both 0 +valsartan 1 +and 0 +amlodipine 1 +were 0 +effective 0 +at 0 +lowering 0 +blood 0 +pressure 0 +at 0 +4 0 +, 0 +8 0 +, 0 +and 0 +12 0 +weeks 0 +. 0 + +Similar 0 +decreases 0 +were 0 +observed 0 +in 0 +both 0 +groups 0 +, 0 +with 0 +no 0 +statistically 0 +significant 0 +differences 0 +between 0 +the 0 +groups 0 +for 0 +any 0 +variable 0 +analyzed 0 +. 0 + +For 0 +the 0 +primary 0 +variable 0 +the 0 +difference 0 +was 0 +0 0 +. 0 +5 0 +mm 0 +Hg 0 +in 0 +favor 0 +of 0 +valsartan 1 +( 0 +p 0 += 0 +0 0 +. 0 +68 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +- 0 +2 0 +. 0 +7 0 +to 0 +1 0 +. 0 +7 0 +) 0 +. 0 + +Responder 0 +rates 0 +at 0 +8 0 +weeks 0 +were 0 +66 0 +. 0 +7 0 +% 0 +for 0 +valsartan 1 +and 0 +60 0 +. 0 +2 0 +% 0 +for 0 +amlodipine 1 +( 0 +p 0 += 0 +0 0 +. 0 +39 0 +) 0 +. 0 + +Both 0 +treatments 0 +were 0 +well 0 +tolerated 0 +. 0 + +The 0 +incidence 0 +of 0 +drug 0 +- 0 +related 0 +dependent 0 +edema 3 +was 0 +somewhat 0 +higher 0 +in 0 +the 0 +amlodipine 1 +group 0 +, 0 +particularly 0 +at 0 +a 0 +dose 0 +of 0 +10 0 +mg 0 +per 0 +day 0 +( 0 +2 0 +. 0 +4 0 +% 0 +for 0 +80 0 +mg 0 +valsartan 1 +; 0 +3 0 +. 0 +6 0 +% 0 +for 0 +5 0 +mg 0 +amlodipine 1 +; 0 +0 0 +% 0 +for 0 +valsartan 1 +plus 0 +5 0 +mg 0 +amlodipine 1 +; 0 +14 0 +. 0 +3 0 +% 0 +for 0 +10 0 +mg 0 +amlodipine 1 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +data 0 +show 0 +that 0 +valsartan 1 +is 0 +at 0 +least 0 +as 0 +effective 0 +as 0 +amlodipine 1 +in 0 +the 0 +treatment 0 +of 0 +mild 0 +to 0 +moderate 0 +hypertension 3 +. 0 + +The 0 +results 0 +also 0 +show 0 +valsartan 1 +to 0 +be 0 +well 0 +tolerated 0 +and 0 +suggest 0 +that 0 +it 0 +is 0 +not 0 +associated 0 +with 0 +side 0 +effects 0 +characteristic 0 +of 0 +this 0 +comparator 0 +class 0 +, 0 +dihydropyridine 1 +calcium 1 +antagonists 0 +. 0 + +A 0 +measure 0 +of 0 +pupillary 3 +oscillation 4 +as 0 +a 0 +marker 0 +of 0 +cocaine 1 +- 0 +induced 0 +paranoia 3 +. 0 + +Cocaine 1 +- 0 +induced 0 +paranoia 3 +( 0 +CIP 3 +) 0 +remains 0 +an 0 +important 0 +drug 0 +- 0 +induced 0 +model 0 +of 0 +idiopathic 0 +paranoia 3 +for 0 +which 0 +no 0 +psychophysiologic 0 +marker 0 +has 0 +yet 0 +emerged 0 +. 0 + +Measures 0 +of 0 +pupillary 3 +oscillation 4 +were 0 +able 0 +to 0 +significantly 0 +distinguish 0 +a 0 +group 0 +of 0 +abstinent 0 +crack 1 +cocaine 2 +abusers 0 +endorsing 0 +past 0 +CIP 3 +( 0 +n 0 += 0 +32 0 +) 0 +from 0 +another 0 +group 0 +of 0 +crack 1 +addicts 0 +who 0 +denied 0 +past 0 +CIP 3 +( 0 +n 0 += 0 +29 0 +) 0 +. 0 + +Serotonin 3 +syndrome 4 +from 0 +venlafaxine 1 +- 0 +tranylcypromine 1 +interaction 0 +. 0 + +Excessive 0 +stimulation 0 +of 0 +serotonin 1 +5HT1A 0 +receptors 0 +causes 0 +a 0 +syndrome 0 +of 0 +serotonin 1 +excess 0 +that 0 +consists 0 +of 0 +shivering 0 +, 0 +muscle 3 +rigidity 4 +, 0 +salivation 3 +, 0 +confusion 3 +, 0 +agitation 3 +and 0 +hyperthermia 3 +. 0 + +The 0 +most 0 +common 0 +cause 0 +of 0 +this 0 +syndrome 0 +is 0 +an 0 +interaction 0 +between 0 +a 0 +monoamine 0 +oxidase 0 +inhibitor 0 +( 0 +MA0I 0 +) 0 +and 0 +a 0 +specific 0 +serotonin 1 +reuptake 0 +inhibitor 0 +. 0 + +Venlafaxine 1 +is 0 +a 0 +new 0 +antidepressant 0 +agent 0 +that 0 +inhibits 0 +the 0 +reuptake 0 +of 0 +serotonin 1 +and 0 +norepinephrine 1 +. 0 + +We 0 +report 0 +a 0 +venlafaxine 1 +- 0 +MA0I 0 +interaction 0 +that 0 +resulted 0 +in 0 +the 0 +serotonin 3 +syndrome 4 +in 0 +a 0 +23 0 +- 0 +y 0 +- 0 +old 0 +male 0 +who 0 +was 0 +taking 0 +tranylcypromine 1 +for 0 +depression 3 +. 0 + +He 0 +had 0 +been 0 +well 0 +until 0 +the 0 +morning 0 +of 0 +presentation 0 +when 0 +he 0 +took 0 +1 0 +/ 0 +2 0 +tab 0 +of 0 +venlafaxine 1 +. 0 + +Within 0 +2 0 +h 0 +he 0 +became 0 +confused 0 +with 0 +jerking 0 +movements 0 +of 0 +his 0 +extremities 0 +, 0 +tremors 3 +and 0 +rigidity 3 +. 0 + +He 0 +was 0 +brought 0 +directly 0 +to 0 +a 0 +hospital 0 +where 0 +he 0 +was 0 +found 0 +to 0 +be 0 +agitated 0 +and 0 +confused 0 +with 0 +shivering 0 +, 0 +myoclonic 3 +jerks 4 +, 0 +rigidity 3 +, 0 +salivation 3 +and 0 +diaphoresis 0 +. 0 + +His 0 +pupils 0 +were 0 +7 0 +mm 0 +and 0 +sluggishly 0 +reactive 0 +to 0 +light 0 +. 0 + +Vital 0 +signs 0 +were 0 +: 0 +blood 0 +pressure 0 +120 0 +/ 0 +67 0 +mm 0 +Hg 0 +, 0 +heart 0 +rate 0 +127 0 +/ 0 +min 0 +, 0 +respiratory 0 +rate 0 +28 0 +/ 0 +min 0 +, 0 +and 0 +temperature 0 +97 0 +F 0 +. 0 + +After 0 +180 0 +mg 0 +of 0 +diazepam 1 +i 0 +. 0 +v 0 +. 0 +he 0 +remained 0 +tremulous 0 +with 0 +muscle 3 +rigidity 4 +and 0 +clenched 0 +jaws 0 +. 0 + +He 0 +was 0 +intubated 0 +for 0 +airway 0 +protection 0 +and 0 +because 0 +of 0 +hypoventilation 3 +, 0 +and 0 +was 0 +paralyzed 3 +to 0 +control 0 +muscle 3 +rigidity 4 +. 0 + +His 0 +subsequent 0 +course 0 +was 0 +remarkable 0 +for 0 +non 0 +- 0 +immune 0 +thrombocytopenia 3 +which 0 +resolved 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +maximal 0 +temperature 0 +was 0 +101 0 +. 0 +2 0 +F 0 +and 0 +his 0 +CPK 0 +remained 0 +< 0 +500 0 +units 0 +/ 0 +L 0 +with 0 +no 0 +other 0 +evidence 0 +of 0 +rhabdomyolysis 3 +. 0 + +His 0 +mental 0 +status 0 +normalized 0 +and 0 +he 0 +was 0 +transferred 0 +to 0 +a 0 +psychiatry 0 +ward 0 +. 0 + +This 0 +patient 0 +survived 0 +without 0 +sequelae 0 +due 0 +to 0 +the 0 +aggressive 0 +sedation 0 +and 0 +neuromuscular 0 +paralysis 3 +. 0 + +Cyclophosphamide 1 +associated 0 +bladder 3 +cancer 4 +- 0 +- 0 +a 0 +highly 0 +aggressive 0 +disease 0 +: 0 +analysis 0 +of 0 +12 0 +cases 0 +. 0 + +PURP0SE 0 +: 0 +We 0 +gained 0 +knowledge 0 +of 0 +the 0 +etiology 0 +, 0 +treatment 0 +and 0 +prevention 0 +of 0 +cyclophosphamide 1 +associated 0 +urothelial 3 +cancer 4 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +The 0 +medical 0 +records 0 +of 0 +6 0 +men 0 +and 0 +6 0 +women 0 +( 0 +mean 0 +age 0 +55 0 +years 0 +) 0 +with 0 +cyclophosphamide 1 +associated 0 +bladder 3 +cancer 4 +were 0 +reviewed 0 +. 0 + +RESULTS 0 +: 0 +All 0 +tumors 3 +were 0 +grade 0 +3 0 +or 0 +4 0 +transitional 0 +cell 0 +carcinoma 3 +. 0 + +0f 0 +the 0 +5 0 +patients 0 +initially 0 +treated 0 +with 0 +endoscopic 0 +resection 0 +alone 0 +only 0 +1 0 +is 0 +alive 0 +without 0 +disease 0 +. 0 + +0f 0 +the 0 +6 0 +patients 0 +who 0 +underwent 0 +early 0 +cystectomy 0 +4 0 +were 0 +alive 0 +at 0 +24 0 +to 0 +111 0 +months 0 +. 0 + +The 0 +remaining 0 +patient 0 +with 0 +extensive 0 +cancer 3 +underwent 0 +partial 0 +cystectomy 0 +for 0 +palliation 0 +and 0 +died 0 +3 0 +months 0 +later 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Cyclophosphamide 1 +associated 0 +bladder 3 +tumor 4 +is 0 +an 0 +aggressive 0 +disease 0 +. 0 + +However 0 +, 0 +long 0 +- 0 +term 0 +survival 0 +is 0 +possible 0 +when 0 +radical 0 +cystectomy 0 +is 0 +performed 0 +for 0 +bladder 3 +tumors 4 +with 0 +any 0 +sign 0 +of 0 +invasion 0 +and 0 +for 0 +recurrent 0 +high 0 +grade 0 +disease 0 +, 0 +even 0 +when 0 +noninvasive 0 +. 0 + +A 0 +phase 0 +I 0 +clinical 0 +study 0 +of 0 +the 0 +antipurine 1 +antifolate 0 +lometrexol 1 +( 0 +DDATHF 1 +) 0 +given 0 +with 0 +oral 0 +folic 1 +acid 2 +. 0 + +Lometrexol 1 +is 0 +an 0 +antifolate 0 +which 0 +inhibits 0 +glycinamide 1 +ribonucleotide 2 +formyltransferase 0 +( 0 +GARFT 0 +) 0 +, 0 +an 0 +enzyme 0 +essential 0 +for 0 +de 0 +novo 0 +purine 1 +synthesis 0 +. 0 + +Extensive 0 +experimental 0 +and 0 +limited 0 +clinical 0 +data 0 +have 0 +shown 0 +that 0 +lometrexol 1 +has 0 +activity 0 +against 0 +tumours 3 +which 0 +are 0 +refractory 0 +to 0 +other 0 +drugs 0 +, 0 +notably 0 +methotrexate 1 +. 0 + +However 0 +, 0 +the 0 +initial 0 +clinical 0 +development 0 +of 0 +lometrexol 1 +was 0 +curtailed 0 +because 0 +of 0 +severe 0 +and 0 +cumulative 0 +antiproliferative 0 +toxicities 3 +. 0 + +Preclinical 0 +murine 0 +studies 0 +demonstrated 0 +that 0 +the 0 +toxicity 3 +of 0 +lometrexol 1 +can 0 +be 0 +prevented 0 +by 0 +low 0 +dose 0 +folic 1 +acid 2 +administration 0 +, 0 +i 0 +. 0 +e 0 +. 0 +for 0 +7 0 +days 0 +prior 0 +to 0 +and 0 +7 0 +days 0 +following 0 +a 0 +single 0 +bolus 0 +dose 0 +. 0 + +This 0 +observation 0 +prompted 0 +a 0 +Phase 0 +I 0 +clinical 0 +study 0 +of 0 +lometrexol 1 +given 0 +with 0 +folic 1 +acid 2 +supplementation 0 +which 0 +has 0 +confirmed 0 +that 0 +the 0 +toxicity 3 +of 0 +lometrexol 1 +can 0 +be 0 +markedly 0 +reduced 0 +by 0 +folic 1 +acid 2 +supplementation 0 +. 0 + +Thrombocytopenia 3 +and 0 +mucositis 3 +were 0 +the 0 +major 0 +toxicities 3 +. 0 + +There 0 +was 0 +no 0 +clear 0 +relationship 0 +between 0 +clinical 0 +toxicity 3 +and 0 +the 0 +extent 0 +of 0 +plasma 0 +folate 1 +elevation 0 +. 0 + +Associated 0 +studies 0 +demonstrated 0 +that 0 +lometrexol 1 +plasma 0 +pharmacokinetics 0 +were 0 +not 0 +altered 0 +by 0 +folic 1 +acid 2 +administration 0 +indicating 0 +that 0 +supplementation 0 +is 0 +unlikely 0 +to 0 +reduce 0 +toxicity 3 +by 0 +enhancing 0 +lometrexol 1 +plasma 0 +clearance 0 +. 0 + +The 0 +work 0 +described 0 +in 0 +this 0 +report 0 +has 0 +identified 0 +for 0 +the 0 +first 0 +time 0 +a 0 +clinically 0 +acceptable 0 +schedule 0 +for 0 +the 0 +administration 0 +of 0 +a 0 +GARFT 0 +inhibitor 0 +. 0 + +This 0 +information 0 +will 0 +facilitate 0 +the 0 +future 0 +evaluation 0 +of 0 +this 0 +class 0 +of 0 +compounds 0 +in 0 +cancer 3 +therapy 0 +. 0 + +Fatal 0 +excited 0 +delirium 3 +following 0 +cocaine 1 +use 0 +: 0 +epidemiologic 0 +findings 0 +provide 0 +new 0 +evidence 0 +for 0 +mechanisms 0 +of 0 +cocaine 1 +toxicity 3 +. 0 + +We 0 +describe 0 +an 0 +outbreak 0 +of 0 +deaths 0 +from 0 +cocaine 1 +- 0 +induced 0 +excited 0 +delirium 3 +( 0 +EDDs 3 +) 0 +in 0 +Dade 0 +County 0 +, 0 +Florida 0 +between 0 +1979 0 +and 0 +1990 0 +. 0 + +From 0 +a 0 +registry 0 +of 0 +all 0 +cocaine 1 +- 0 +related 0 +deaths 0 +in 0 +Dade 0 +County 0 +, 0 +Florida 0 +, 0 +from 0 +1969 0 +- 0 +1990 0 +, 0 +58 0 +EDDs 3 +were 0 +compared 0 +with 0 +125 0 +victims 0 +of 0 +accidental 0 +cocaine 1 +overdose 3 +without 0 +excited 0 +delirium 3 +. 0 + +Compared 0 +with 0 +controls 0 +, 0 +EDDs 3 +were 0 +more 0 +frequently 0 +black 0 +, 0 +male 0 +, 0 +and 0 +younger 0 +. 0 + +They 0 +were 0 +less 0 +likely 0 +to 0 +have 0 +a 0 +low 0 +body 0 +mass 0 +index 0 +, 0 +and 0 +more 0 +likely 0 +to 0 +have 0 +died 0 +in 0 +police 0 +custody 0 +, 0 +to 0 +have 0 +received 0 +medical 0 +treatment 0 +immediately 0 +before 0 +death 0 +, 0 +to 0 +have 0 +survived 0 +for 0 +a 0 +longer 0 +period 0 +, 0 +to 0 +have 0 +developed 0 +hyperthermia 3 +, 0 +and 0 +to 0 +have 0 +died 0 +in 0 +summer 0 +months 0 +. 0 + +EDDs 3 +had 0 +concentrations 0 +of 0 +cocaine 1 +and 0 +benzoylecgonine 1 +in 0 +autopsy 0 +blood 0 +that 0 +were 0 +similar 0 +to 0 +those 0 +for 0 +controls 0 +. 0 + +The 0 +epidemiologic 0 +findings 0 +are 0 +most 0 +consistent 0 +with 0 +the 0 +hypothesis 0 +that 0 +chronic 0 +cocaine 1 +use 0 +disrupts 0 +dopaminergic 0 +function 0 +and 0 +, 0 +when 0 +coupled 0 +with 0 +recent 0 +cocaine 1 +use 0 +, 0 +may 0 +precipitate 0 +agitation 3 +, 0 +delirium 3 +, 0 +aberrant 0 +thermoregulation 0 +, 0 +rhabdomyolysis 3 +, 0 +and 0 +sudden 3 +death 4 +. 0 + +Pemoline 1 +induced 0 +acute 0 +choreoathetosis 3 +: 0 +case 0 +report 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +BACKGR0UND 0 +: 0 +Pemoline 1 +is 0 +an 0 +oxazolidine 1 +derivative 0 +that 0 +is 0 +structurally 0 +different 0 +from 0 +amphetamines 1 +and 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +attention 3 +deficit 4 +disorder 4 +. 0 + +Pemoline 1 +has 0 +not 0 +been 0 +commonly 0 +associated 0 +in 0 +the 0 +literature 0 +as 0 +a 0 +cause 0 +of 0 +acute 0 +movement 3 +disorders 4 +. 0 + +The 0 +following 0 +case 0 +describes 0 +two 0 +children 0 +acutely 0 +poisoned 0 +with 0 +pemoline 1 +who 0 +experienced 0 +profound 0 +choreoathetosis 3 +. 0 + +CASE 0 +REP0RT 0 +: 0 +Two 0 +, 0 +3 0 +- 0 +year 0 +- 0 +old 0 +male 0 +, 0 +identical 0 +twin 0 +siblings 0 +presented 0 +to 0 +the 0 +emergency 0 +department 0 +after 0 +found 0 +playing 0 +with 0 +a 0 +an 0 +empty 0 +bottle 0 +of 0 +pemoline 1 +originally 0 +containing 0 +59 0 +tablets 0 +. 0 + +The 0 +children 0 +had 0 +a 0 +medical 0 +history 0 +significant 0 +for 0 +attention 3 +deficit 4 +disorder 4 +previously 0 +treated 0 +with 0 +methylphenidate 1 +without 0 +success 0 +. 0 + +This 0 +was 0 +their 0 +first 0 +day 0 +of 0 +pemoline 1 +therapy 0 +. 0 + +The 0 +choreoathetoid 3 +movements 0 +began 0 +45 0 +min 0 +to 0 +1 0 +h 0 +after 0 +ingestion 0 +. 0 + +The 0 +children 0 +gave 0 +no 0 +history 0 +of 0 +prior 0 +movement 3 +disorders 4 +and 0 +there 0 +was 0 +no 0 +family 0 +history 0 +of 0 +movement 3 +disorders 4 +. 0 + +The 0 +children 0 +received 0 +gastrointestinal 0 +decontamination 0 +and 0 +high 0 +doses 0 +of 0 +intravenous 0 +benzodiazepines 1 +in 0 +an 0 +attempt 0 +to 0 +control 0 +the 0 +choreoathetoid 3 +movements 0 +. 0 + +Despite 0 +treatment 0 +, 0 +the 0 +children 0 +continued 0 +to 0 +have 0 +choreoathetosis 3 +for 0 +approximately 0 +24 0 +hours 0 +. 0 + +Forty 0 +- 0 +eight 0 +hours 0 +after 0 +admission 0 +, 0 +the 0 +children 0 +appeared 0 +to 0 +be 0 +at 0 +their 0 +baseline 0 +and 0 +were 0 +discharged 0 +home 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Pemoline 1 +associated 0 +movement 3 +disorder 4 +has 0 +been 0 +rarely 0 +reported 0 +in 0 +the 0 +acute 0 +toxicology 0 +literature 0 +. 0 + +The 0 +possibility 0 +of 0 +choreoathetoid 3 +movements 0 +should 0 +be 0 +considered 0 +in 0 +patients 0 +presenting 0 +after 0 +pemoline 1 +overdose 3 +. 0 + +Effect 0 +of 0 +myopic 0 +excimer 0 +laser 0 +photorefractive 0 +keratectomy 0 +on 0 +the 0 +electrophysiologic 0 +function 0 +of 0 +the 0 +retina 0 +and 0 +optic 0 +nerve 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +assess 0 +by 0 +electrophysiologic 0 +testing 0 +the 0 +effect 0 +of 0 +photorefractive 0 +keratectomy 0 +( 0 +PRK 0 +) 0 +on 0 +the 0 +retina 0 +and 0 +optic 0 +nerve 0 +. 0 + +SETTING 0 +: 0 +Eye 0 +Clinic 0 +, 0 +S 0 +. 0 + +Salvatore 0 +Hospital 0 +, 0 +L 0 +' 0 +Aquila 0 +University 0 +, 0 +Italy 0 +. 0 + +METH0DS 0 +: 0 +Standard 0 +pattern 0 +electroretinograms 0 +( 0 +P 0 +- 0 +ERGs 0 +) 0 +and 0 +standard 0 +pattern 0 +visual 0 +evoked 0 +potentials 0 +( 0 +P 0 +- 0 +VEPs 0 +) 0 +were 0 +done 0 +in 0 +25 0 +eyes 0 +of 0 +25 0 +patients 0 +who 0 +had 0 +myopic 0 +PRK 0 +for 0 +an 0 +attempted 0 +correction 0 +between 0 +5 0 +. 0 +00 0 +and 0 +15 0 +. 0 +00 0 +diopters 0 +( 0 +D 0 +) 0 +( 0 +mean 0 +8 0 +. 0 +00 0 +D 0 +) 0 +. 0 + +Testing 0 +was 0 +done 0 +preoperatively 0 +and 0 +3 0 +, 0 +6 0 +, 0 +12 0 +, 0 +and 0 +18 0 +months 0 +postoperatively 0 +. 0 + +The 0 +contralateral 0 +eyes 0 +served 0 +as 0 +controls 0 +. 0 + +During 0 +the 0 +follow 0 +- 0 +up 0 +, 0 +3 0 +patients 0 +( 0 +12 0 +% 0 +) 0 +developed 0 +steroid 1 +- 0 +induced 0 +elevated 3 +intraocular 4 +pressure 4 +( 0 +I0P 0 +) 0 +that 0 +resolved 0 +after 0 +corticosteroid 1 +therapy 0 +was 0 +discontinued 0 +. 0 + +RESULTS 0 +: 0 +No 0 +statistically 0 +significant 0 +differences 0 +were 0 +seen 0 +between 0 +treated 0 +and 0 +control 0 +eyes 0 +nor 0 +between 0 +treated 0 +eyes 0 +preoperatively 0 +and 0 +postoperatively 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Myopic 0 +excimer 0 +laser 0 +PRK 0 +did 0 +not 0 +seem 0 +to 0 +affect 0 +the 0 +posterior 0 +segment 0 +. 0 + +The 0 +transient 0 +steroid 1 +- 0 +induced 0 +I0P 3 +rise 4 +did 0 +not 0 +seem 0 +to 0 +cause 0 +functional 0 +impairment 0 +. 0 + +Neutrophil 0 +superoxide 1 +and 0 +hydrogen 1 +peroxide 2 +production 0 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +. 0 + +Defects 0 +in 0 +superoxide 1 +and 0 +hydrogen 1 +peroxide 2 +production 0 +may 0 +be 0 +implicated 0 +in 0 +the 0 +high 0 +incidence 0 +of 0 +bacterial 3 +infections 4 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +( 0 +ALF 3 +) 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +oxygen 1 +radical 0 +production 0 +in 0 +patients 0 +with 0 +ALF 3 +due 0 +to 0 +paracetamol 1 +overdose 3 +was 0 +compared 0 +with 0 +that 0 +of 0 +healthy 0 +volunteers 0 +. 0 + +Neutrophils 0 +from 0 +14 0 +ALF 3 +patients 0 +were 0 +stimulated 0 +via 0 +the 0 +complement 0 +receptors 0 +using 0 +zymosan 0 +opsonized 0 +with 0 +ALF 3 +or 0 +control 0 +serum 0 +. 0 + +Superoxide 1 +and 0 +hydrogen 1 +peroxide 2 +production 0 +by 0 +ALF 3 +neutrophils 0 +stimulated 0 +with 0 +zymosan 0 +opsonized 0 +with 0 +ALF 3 +serum 0 +was 0 +significantly 0 +reduced 0 +compared 0 +with 0 +the 0 +control 0 +subjects 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +This 0 +defect 0 +persisted 0 +when 0 +zymosan 0 +opsonized 0 +by 0 +control 0 +serum 0 +was 0 +used 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Superoxide 1 +and 0 +hydrogen 1 +peroxide 2 +production 0 +in 0 +neutrophils 0 +stimulated 0 +with 0 +formyl 1 +- 2 +methionyl 2 +- 2 +leucyl 2 +- 2 +phenylalanine 2 +( 0 +fMLP 1 +) 0 +from 0 +a 0 +further 0 +18 0 +ALF 3 +patients 0 +was 0 +unaffected 0 +compared 0 +with 0 +control 0 +neutrophils 0 +. 0 + +Serum 0 +C3 0 +complement 0 +levels 0 +were 0 +significantly 0 +reduced 0 +in 0 +ALF 3 +patients 0 +compared 0 +with 0 +control 0 +subjects 0 +( 0 +P 0 +< 0 +0 0 +. 0 +0005 0 +) 0 +. 0 + +These 0 +results 0 +demonstrate 0 +a 0 +neutrophil 0 +defect 0 +in 0 +ALF 3 +due 0 +to 0 +paracetamol 1 +overdose 3 +, 0 +that 0 +is 0 +complement 0 +dependent 0 +but 0 +independent 0 +of 0 +serum 0 +complement 0 +, 0 +possibly 0 +connected 0 +to 0 +the 0 +complement 0 +receptor 0 +. 0 + +Cholesteryl 1 +hemisuccinate 2 +treatment 0 +protects 0 +rodents 0 +from 0 +the 0 +toxic 0 +effects 0 +of 0 +acetaminophen 1 +, 0 +adriamycin 1 +, 0 +carbon 1 +tetrachloride 2 +, 0 +chloroform 1 +and 0 +galactosamine 1 +. 0 + +In 0 +addition 0 +to 0 +its 0 +use 0 +as 0 +a 0 +stabilizer 0 +/ 0 +rigidifier 0 +of 0 +membranes 0 +, 0 +cholesteryl 1 +hemisuccinate 2 +, 0 +tris 1 +salt 2 +( 0 +CS 1 +) 0 +administration 0 +has 0 +also 0 +been 0 +shown 0 +to 0 +protect 0 +rats 0 +from 0 +the 0 +hepatotoxic 3 +effects 0 +of 0 +carbon 1 +tetrachloride 2 +( 0 +CCl4 1 +) 0 +. 0 + +To 0 +further 0 +our 0 +understanding 0 +of 0 +the 0 +mechanism 0 +of 0 +CS 1 +cytoprotection 0 +, 0 +we 0 +examined 0 +in 0 +rats 0 +and 0 +mice 0 +the 0 +protective 0 +abilities 0 +of 0 +CS 1 +and 0 +the 0 +non 0 +- 0 +hydrolyzable 0 +ether 0 +form 0 +of 0 +CS 1 +, 0 +gamma 1 +- 2 +cholesteryloxybutyric 2 +acid 2 +, 0 +tris 1 +salt 2 +( 0 +CSE 1 +) 0 +against 0 +acetaminophen 1 +- 0 +, 0 +adriamycin 1 +- 0 +, 0 +carbon 1 +tetrachloride 2 +- 0 +, 0 +chloroform 1 +- 0 +and 0 +galactosamine 1 +- 0 +induced 0 +toxicity 3 +. 0 + +The 0 +results 0 +of 0 +these 0 +studies 0 +demonstrated 0 +that 0 +CS 1 +- 0 +mediated 0 +protection 0 +is 0 +not 0 +selective 0 +for 0 +a 0 +particular 0 +species 0 +, 0 +organ 0 +system 0 +or 0 +toxic 0 +chemical 0 +. 0 + +A 0 +24 0 +- 0 +h 0 +pretreatment 0 +of 0 +both 0 +rats 0 +and 0 +mice 0 +with 0 +a 0 +single 0 +dose 0 +of 0 +CS 1 +( 0 +100mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +, 0 +resulted 0 +in 0 +significant 0 +protection 0 +against 0 +the 0 +hepatotoxic 3 +effects 0 +of 0 +CCl4 1 +, 0 +CHCl3 1 +, 0 +acetaminophen 1 +and 0 +galactosamine 1 +and 0 +against 0 +the 0 +lethal 0 +( 0 +and 0 +presumably 0 +cardiotoxic 3 +) 0 +effect 0 +of 0 +adriamycin 1 +administration 0 +. 0 + +Maximal 0 +CS 1 +- 0 +mediated 0 +protection 0 +was 0 +observed 0 +in 0 +experimental 0 +animals 0 +pretreated 0 +24 0 +h 0 +prior 0 +to 0 +the 0 +toxic 0 +insult 0 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +CS 1 +intervenes 0 +in 0 +a 0 +critical 0 +cellular 0 +event 0 +that 0 +is 0 +an 0 +important 0 +common 0 +pathway 0 +to 0 +toxic 0 +cell 0 +death 0 +. 0 + +The 0 +mechanism 0 +of 0 +CS 1 +protection 0 +does 0 +not 0 +appear 0 +to 0 +be 0 +dependent 0 +on 0 +the 0 +inhibition 0 +of 0 +chemical 0 +bioactivation 0 +to 0 +a 0 +toxic 0 +reactive 0 +intermediate 0 +( 0 +in 0 +light 0 +of 0 +the 0 +protection 0 +observed 0 +against 0 +galactosamine 1 +hepatotoxicity 3 +) 0 +. 0 + +However 0 +, 0 +based 0 +on 0 +the 0 +data 0 +presented 0 +, 0 +we 0 +can 0 +not 0 +exclude 0 +the 0 +possibility 0 +that 0 +CS 1 +administration 0 +inhibits 0 +chemical 0 +bioactivation 0 +. 0 + +0ur 0 +findings 0 +do 0 +suggest 0 +that 0 +CS 1 +- 0 +mediated 0 +protection 0 +is 0 +dependent 0 +on 0 +the 0 +action 0 +of 0 +the 0 +intact 0 +anionic 0 +CS 1 +molecule 0 +( 0 +non 0 +- 0 +hydrolyzable 0 +CSE 1 +was 0 +as 0 +protective 0 +as 0 +CS 1 +) 0 +, 0 +whose 0 +mechanism 0 +has 0 +yet 0 +to 0 +be 0 +defined 0 +. 0 + +A 0 +murine 0 +model 0 +of 0 +adenomyosis 3 +: 0 +the 0 +effects 0 +of 0 +hyperprolactinemia 3 +induced 0 +by 0 +fluoxetine 1 +hydrochloride 2 +, 0 +a 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitor 0 +, 0 +on 0 +adenomyosis 3 +induction 0 +in 0 +Wistar 0 +albino 0 +rats 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +whether 0 +fluoxetine 1 +given 0 +to 0 +castrated 0 +and 0 +noncastrated 0 +rats 0 +caused 0 +hyperprolactinemia 3 +and 0 +its 0 +effects 0 +with 0 +respect 0 +to 0 +adenomyosis 3 +. 0 + +DESIGN 0 +: 0 +Fluoxetine 1 +, 0 +a 0 +serotonin 1 +reuptake 0 +inhibitor 0 +, 0 +was 0 +given 0 +to 0 +Wistar 0 +Albino 0 +rats 0 +for 0 +98 0 +days 0 +to 0 +produce 0 +hyperprolactinemia 3 +. 0 + +The 0 +drug 0 +was 0 +given 0 +to 0 +two 0 +groups 0 +consisting 0 +of 0 +castrated 0 +and 0 +noncastrated 0 +rats 0 +and 0 +compared 0 +to 0 +two 0 +groups 0 +of 0 +castrated 0 +and 0 +noncastrated 0 +controls 0 +. 0 + +Prolactin 0 +levels 0 +were 0 +measured 0 +and 0 +the 0 +uteri 0 +of 0 +the 0 +rats 0 +were 0 +removed 0 +for 0 +histopathological 0 +analysis 0 +at 0 +the 0 +end 0 +of 0 +98 0 +days 0 +. 0 + +SETTING 0 +: 0 +Marmara 0 +University 0 +School 0 +of 0 +Medicine 0 +, 0 +Department 0 +of 0 +Histology 0 +and 0 +Embryology 0 +, 0 +Zeynep 0 +Kamil 0 +Women 0 +and 0 +Children 0 +' 0 +s 0 +Hospital 0 +. 0 + +MAIN 0 +0UTC0ME 0 +MEASURES 0 +: 0 +Serum 0 +prolactin 0 +levels 0 +, 0 +uterine 0 +histopathology 0 +. 0 + +RESULTS 0 +: 0 +The 0 +prolactin 0 +levels 0 +of 0 +castrated 0 +and 0 +noncastrated 0 +groups 0 +treated 0 +with 0 +fluoxetine 1 +were 0 +statistically 0 +significantly 0 +higher 0 +when 0 +compared 0 +to 0 +their 0 +respective 0 +control 0 +groups 0 +. 0 + +Histological 0 +studies 0 +revealed 0 +11 0 +cases 0 +of 0 +adenomyosis 3 +, 0 +all 0 +within 0 +the 0 +noncastrated 0 +group 0 +receiving 0 +fluoxetine 1 +. 0 + +C0NCLUSI0N 0 +: 0 +It 0 +was 0 +suggested 0 +that 0 +high 0 +serum 0 +prolactin 0 +levels 0 +cause 0 +degeneration 0 +of 0 +myometrial 0 +cells 0 +in 0 +the 0 +presence 0 +of 0 +ovarian 0 +steroids 1 +that 0 +results 0 +in 0 +a 0 +myometrial 0 +invasion 0 +by 0 +endometrial 0 +stroma 0 +. 0 + +This 0 +invasion 0 +eventually 0 +progresses 0 +to 0 +adenomyosis 3 +. 0 + +Postinfarction 0 +ventricular 3 +septal 4 +defect 4 +associated 0 +with 0 +long 0 +- 0 +term 0 +steroid 1 +therapy 0 +. 0 + +Two 0 +cases 0 +of 0 +postinfarction 0 +ventricular 3 +septal 4 +rupture 4 +in 0 +patients 0 +on 0 +long 0 +- 0 +term 0 +steroid 1 +therapy 0 +are 0 +presented 0 +and 0 +the 0 +favourable 0 +outcome 0 +in 0 +both 0 +cases 0 +described 0 +. 0 + +A 0 +possible 0 +association 0 +between 0 +steroid 1 +therapy 0 +and 0 +subsequent 0 +postinfarction 0 +septal 3 +rupture 4 +is 0 +discussed 0 +. 0 + +Neuroactive 0 +steroids 1 +protect 0 +against 0 +pilocarpine 1 +- 0 +and 0 +kainic 1 +acid 2 +- 0 +induced 0 +limbic 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +in 0 +mice 0 +. 0 + +Several 0 +structurally 0 +related 0 +metabolites 0 +of 0 +progesterone 1 +( 0 +3 1 +alpha 2 +- 2 +hydroxy 2 +pregnane 2 +- 2 +20 2 +- 2 +ones 2 +) 0 +and 0 +deoxycorticosterone 1 +( 0 +3 1 +alpha 2 +- 2 +hydroxy 2 +pregnane 2 +- 2 +21 2 +- 2 +diol 2 +- 2 +20 2 +- 2 +ones 2 +) 0 +and 0 +their 0 +3 0 +beta 0 +- 0 +epimers 0 +were 0 +evaluated 0 +for 0 +protective 0 +activity 0 +against 0 +pilocarpine 1 +- 0 +, 0 +kainic 1 +acid 2 +- 0 +and 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +- 0 +induced 0 +seizures 3 +in 0 +mice 0 +. 0 + +Steroids 1 +with 0 +the 0 +3 0 +- 0 +hydroxy 0 +group 0 +in 0 +the 0 +alpha 0 +- 0 +position 0 +and 0 +5 0 +- 0 +H 0 +in 0 +the 0 +alpha 0 +- 0 +or 0 +beta 0 +- 0 +configurations 0 +were 0 +highly 0 +effective 0 +in 0 +protecting 0 +against 0 +pilocarpine 1 +( 0 +416 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +- 0 +induced 0 +limbic 0 +motor 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +( 0 +ED50 0 +values 0 +, 0 +7 0 +. 0 +0 0 +- 0 +18 0 +. 0 +7 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +The 0 +corresponding 0 +epimers 0 +with 0 +the 0 +3 0 +- 0 +hydroxy 0 +group 0 +in 0 +the 0 +beta 0 +- 0 +position 0 +were 0 +also 0 +effective 0 +but 0 +less 0 +potent 0 +( 0 +ED50 0 +values 0 +, 0 +33 0 +. 0 +8 0 +- 0 +63 0 +. 0 +5 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +Although 0 +the 0 +neuroactive 0 +steroids 1 +were 0 +considerably 0 +less 0 +potent 0 +than 0 +the 0 +benzodiazepine 1 +clonazepam 1 +in 0 +protecting 0 +against 0 +pilocarpine 1 +seizures 3 +, 0 +steroids 1 +with 0 +the 0 +5 0 +alpha 0 +, 0 +3 0 +alpha 0 +- 0 +configuration 0 +had 0 +comparable 0 +or 0 +higher 0 +protective 0 +index 0 +values 0 +( 0 +TD50 0 +for 0 +motor 0 +impairment 0 +divided 0 +by 0 +ED50 0 +for 0 +seizure 3 +protection 0 +) 0 +than 0 +clonazepam 1 +, 0 +indicating 0 +that 0 +some 0 +neuroactive 0 +steroids 1 +may 0 +have 0 +lower 0 +relative 0 +toxicity 3 +. 0 + +Steroids 1 +with 0 +the 0 +5 0 +alpha 0 +, 0 +3 0 +alpha 0 +- 0 +or 0 +5 0 +beta 0 +, 0 +3 0 +alpha 0 +- 0 +configurations 0 +also 0 +produced 0 +a 0 +dose 0 +- 0 +dependent 0 +delay 0 +in 0 +the 0 +onset 0 +of 0 +limbic 0 +seizures 3 +induced 0 +by 0 +kainic 1 +acid 2 +( 0 +32 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +, 0 +but 0 +did 0 +not 0 +completely 0 +protect 0 +against 0 +the 0 +seizures 3 +. 0 + +However 0 +, 0 +when 0 +a 0 +second 0 +dose 0 +of 0 +the 0 +steroid 1 +was 0 +administered 0 +1 0 +hr 0 +after 0 +the 0 +first 0 +dose 0 +, 0 +complete 0 +protection 0 +from 0 +the 0 +kainic 1 +acid 2 +- 0 +induced 0 +limbic 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +was 0 +obtained 0 +. 0 + +The 0 +steroids 1 +also 0 +caused 0 +a 0 +dose 0 +- 0 +dependent 0 +delay 0 +in 0 +NMDA 1 +( 0 +257 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +- 0 +induced 0 +lethality 0 +, 0 +but 0 +did 0 +not 0 +completely 0 +protect 0 +against 0 +NMDA 1 +seizures 3 +or 0 +lethality 0 +. 0 + +We 0 +conclude 0 +that 0 +neuroactive 0 +steroids 1 +are 0 +highly 0 +effective 0 +in 0 +protecting 0 +against 0 +pilocarpine 1 +- 0 +and 0 +kainic 1 +acid 2 +- 0 +induced 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +in 0 +mice 0 +, 0 +and 0 +may 0 +be 0 +of 0 +utility 0 +in 0 +the 0 +treatment 0 +of 0 +some 0 +forms 0 +of 0 +status 3 +epilepticus 4 +in 0 +humans 0 +. 0 + +Hepatic 0 +and 0 +extrahepatic 0 +angiotensinogen 0 +gene 0 +expression 0 +in 0 +rats 0 +with 0 +acute 0 +nephrotic 3 +syndrome 4 +. 0 + +Plasma 0 +concentration 0 +and 0 +urine 0 +excretion 0 +of 0 +the 0 +renin 0 +- 0 +angiotensin 1 +system 0 +proteins 0 +are 0 +altered 0 +in 0 +rats 0 +with 0 +nephrotic 3 +syndrome 4 +( 0 +NS 3 +) 0 +. 0 + +In 0 +this 0 +work 0 +the 0 +messenger 0 +ribonucleic 0 +acid 0 +( 0 +mRNA 0 +) 0 +levels 0 +of 0 +angiotensinogen 0 +( 0 +Ao 0 +) 0 +were 0 +analyzed 0 +with 0 +the 0 +slot 0 +- 0 +blot 0 +hybridization 0 +technique 0 +in 0 +liver 0 +and 0 +other 0 +extrahepatic 0 +tissues 0 +: 0 +kidney 0 +, 0 +heart 0 +, 0 +brain 0 +, 0 +and 0 +adrenal 0 +gland 0 +from 0 +control 0 +, 0 +nephrotic 3 +, 0 +and 0 +pair 0 +- 0 +fed 0 +( 0 +PF 0 +) 0 +rats 0 +. 0 + +NS 3 +was 0 +induced 0 +by 0 +a 0 +single 0 +injection 0 +of 0 +puromycin 1 +amino 2 +- 2 +nucleoside 2 +( 0 +PAN 1 +) 0 +. 0 + +Although 0 +a 0 +great 0 +urinary 0 +excretion 0 +and 0 +half 0 +- 0 +normal 0 +plasma 0 +levels 0 +of 0 +Ao 0 +were 0 +observed 0 +on 0 +day 0 +6 0 +after 0 +PAN 1 +injection 0 +, 0 +when 0 +NS 3 +was 0 +clearly 0 +established 0 +, 0 +hepatic 0 +Ao 0 +mRNA 0 +levels 0 +did 0 +not 0 +change 0 +. 0 + +Furthermore 0 +, 0 +the 0 +Ao 0 +mRNA 0 +levels 0 +did 0 +not 0 +change 0 +in 0 +any 0 +of 0 +the 0 +extrahepatic 0 +tissues 0 +studied 0 +on 0 +day 0 +6 0 +, 0 +nor 0 +did 0 +its 0 +hepatic 0 +levels 0 +at 0 +days 0 +1 0 +, 0 +3 0 +, 0 +5 0 +, 0 +or 0 +7 0 +after 0 +PAN 1 +injection 0 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +the 0 +hepatic 0 +and 0 +extrahepatic 0 +Ao 0 +mRNA 0 +levels 0 +are 0 +unaltered 0 +during 0 +the 0 +development 0 +of 0 +the 0 +acute 0 +NS 3 +induced 0 +by 0 +PAN 1 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +with 0 +risperidone 1 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +is 0 +thought 0 +to 0 +be 0 +a 0 +result 0 +of 0 +dopamine 1 +D2 0 +receptor 0 +blockade 0 +in 0 +the 0 +striatum 0 +of 0 +the 0 +basal 0 +ganglia 0 +. 0 + +Risperidone 1 +, 0 +a 0 +benzisoxazole 1 +derivative 0 +antipsychotic 0 +, 0 +has 0 +high 0 +serotonin 1 +5 0 +- 0 +HT2 0 +receptor 0 +blockade 0 +and 0 +dose 0 +- 0 +related 0 +D2 0 +receptor 0 +blockade 0 +. 0 + +The 0 +high 0 +ratio 0 +is 0 +believed 0 +to 0 +impart 0 +the 0 +low 0 +frequency 0 +of 0 +extrapyramidal 3 +symptoms 4 +with 0 +risperidone 1 +at 0 +low 0 +dosages 0 +. 0 + +With 0 +this 0 +low 0 +frequency 0 +of 0 +extrapyramidal 3 +symptoms 4 +, 0 +it 0 +was 0 +thought 0 +the 0 +frequency 0 +of 0 +neuroleptic 3 +malignant 4 +syndrome 4 +might 0 +also 0 +be 0 +lowered 0 +. 0 + +A 0 +73 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +developed 0 +neuroleptic 3 +malignant 4 +syndrome 4 +after 0 +monotherapy 0 +with 0 +risperidone 1 +. 0 + +The 0 +syndrome 0 +reversed 0 +after 0 +discontinuing 0 +risperidone 1 +and 0 +starting 0 +treatment 0 +with 0 +dantrolene 1 +and 0 +bromocriptine 1 +. 0 + +It 0 +appears 0 +that 0 +the 0 +protection 0 +from 0 +extrapyramidal 0 +side 0 +effects 0 +observed 0 +with 0 +risperidone 1 +does 0 +not 0 +ensure 0 +protection 0 +from 0 +neuroleptic 3 +malignant 4 +syndrome 4 +. 0 + +The 0 +attenuating 0 +effect 0 +of 0 +carteolol 1 +hydrochloride 2 +, 0 +a 0 +beta 0 +- 0 +adrenoceptor 0 +antagonist 0 +, 0 +on 0 +neuroleptic 0 +- 0 +induced 0 +catalepsy 3 +in 0 +rats 0 +. 0 + +It 0 +is 0 +known 0 +that 0 +beta 0 +- 0 +adrenoceptor 0 +antagonists 0 +are 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +akathisia 3 +, 0 +one 0 +of 0 +the 0 +extrapyramidal 0 +side 0 +effects 0 +that 0 +occur 0 +during 0 +neuroleptic 0 +treatment 0 +. 0 + +Neuroleptic 0 +- 0 +induced 0 +catalepsy 3 +, 0 +a 0 +model 0 +of 0 +neuroleptic 0 +- 0 +induced 0 +extrapyramidal 0 +side 0 +effects 0 +, 0 +was 0 +considered 0 +suitable 0 +as 0 +a 0 +model 0 +for 0 +predicting 0 +neuroleptic 0 +- 0 +induced 0 +akathisia 3 +in 0 +humans 0 +, 0 +although 0 +neuroleptic 0 +- 0 +induced 0 +catalepsy 3 +was 0 +not 0 +considered 0 +a 0 +specific 0 +test 0 +for 0 +neuroleptic 0 +- 0 +induced 0 +akathisia 3 +. 0 + +Therefore 0 +, 0 +the 0 +effects 0 +of 0 +carteolol 1 +, 0 +a 0 +beta 0 +- 0 +adrenoceptor 0 +antagonist 0 +, 0 +on 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +in 0 +rats 0 +were 0 +behaviorally 0 +studied 0 +and 0 +compared 0 +with 0 +those 0 +of 0 +propranolol 1 +and 0 +biperiden 1 +, 0 +a 0 +muscarinic 0 +receptor 0 +antagonist 0 +. 0 + +Carteolol 1 +, 0 +as 0 +well 0 +as 0 +propranolol 1 +and 0 +biperiden 1 +, 0 +inhibited 0 +the 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +The 0 +inhibitory 0 +effect 0 +of 0 +carteolol 1 +was 0 +almost 0 +comparable 0 +to 0 +that 0 +of 0 +propranolol 1 +, 0 +but 0 +was 0 +weaker 0 +than 0 +that 0 +of 0 +biperiden 1 +. 0 + +Carteolol 1 +did 0 +not 0 +evoke 0 +postsynaptic 0 +dopamine 1 +receptor 0 +- 0 +stimulating 0 +behavioral 0 +signs 0 +such 0 +as 0 +stereotypy 0 +and 0 +hyperlocomotion 3 +in 0 +rats 0 +. 0 + +Carteolol 1 +did 0 +not 0 +antagonize 0 +the 0 +inhibitory 0 +effects 0 +of 0 +haloperidol 1 +on 0 +apomorphine 1 +- 0 +induced 0 +stereotypy 0 +and 0 +locomotor 0 +activity 0 +in 0 +rats 0 +. 0 + +In 0 +addition 0 +, 0 +carteolol 1 +did 0 +not 0 +evoke 0 +5 0 +- 0 +HT1A 0 +receptor 0 +- 0 +stimulating 0 +behavioral 0 +signs 0 +such 0 +as 0 +flat 0 +body 0 +posture 0 +and 0 +forepaw 0 +treading 0 +and 0 +did 0 +not 0 +inhibit 0 +5 1 +- 2 +hydroxytryptophan 2 +- 0 +induced 0 +head 0 +twitch 0 +in 0 +rats 0 +. 0 + +Finally 0 +, 0 +carteolol 1 +did 0 +not 0 +inhibit 0 +physostigmine 1 +- 0 +induced 0 +lethality 0 +in 0 +rats 0 +. 0 + +These 0 +results 0 +strongly 0 +suggest 0 +that 0 +carteolol 1 +improves 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +via 0 +its 0 +beta 0 +- 0 +adrenoceptor 0 +antagonistic 0 +activity 0 +and 0 +is 0 +expected 0 +to 0 +be 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +akathisia 3 +without 0 +attenuating 0 +neuroleptic 0 +- 0 +induced 0 +antipsychotic 0 +effects 0 +due 0 +to 0 +its 0 +postsynaptic 0 +dopamine 1 +receptor 0 +antagonistic 0 +activity 0 +. 0 + +Granulosa 3 +cell 4 +tumor 4 +of 4 +the 4 +ovary 4 +associated 0 +with 0 +antecedent 0 +tamoxifen 1 +use 0 +. 0 + +BACKGR0UND 0 +: 0 +Increased 0 +attention 0 +has 0 +been 0 +focused 0 +recently 0 +on 0 +the 0 +estrogenic 0 +effects 0 +of 0 +tamoxifen 1 +. 0 + +Review 0 +of 0 +the 0 +literature 0 +reveals 0 +an 0 +association 0 +between 0 +tamoxifen 1 +use 0 +and 0 +gynecologic 0 +tumors 3 +. 0 + +CASE 0 +: 0 +A 0 +52 0 +- 0 +year 0 +- 0 +old 0 +postmenopausal 0 +woman 0 +was 0 +treated 0 +with 0 +tamoxifen 1 +for 0 +stage 0 +II 0 +estrogen 1 +receptor 0 +- 0 +positive 0 +breast 3 +carcinoma 4 +. 0 + +Her 0 +aspartate 1 +transaminase 0 +and 0 +alanine 1 +transaminase 0 +levels 0 +increase 0 +markedly 0 +after 0 +6 0 +months 0 +of 0 +tamoxifen 1 +use 0 +. 0 + +After 0 +an 0 +additional 0 +17 0 +months 0 +of 0 +elevated 0 +serum 0 +transaminases 0 +, 0 +the 0 +patient 0 +was 0 +found 0 +to 0 +have 0 +a 0 +stage 0 +Ic 0 +granulosa 3 +cell 4 +tumor 4 +of 4 +the 4 +ovary 4 +. 0 + +C0NCLUSI0N 0 +: 0 +Patients 0 +with 0 +tamoxifen 1 +- 0 +induced 0 +liver 3 +dysfunction 4 +may 0 +be 0 +at 0 +increased 0 +risk 0 +for 0 +granulosa 3 +cell 4 +tumors 4 +because 0 +of 0 +alterations 0 +in 0 +tamoxifen 1 +metabolism 0 +. 0 + +Lifetime 0 +treatment 0 +of 0 +mice 0 +with 0 +azidothymidine 1 +( 0 +AZT 1 +) 0 +produces 0 +myelodysplasia 3 +. 0 + +AZT 1 +has 0 +induced 0 +a 0 +macrocytic 3 +anemia 4 +in 0 +AIDS 3 +patients 0 +on 0 +long 0 +term 0 +AZT 1 +therapy 0 +. 0 + +It 0 +is 0 +generally 0 +assumed 0 +that 0 +DNA 0 +elongation 0 +is 0 +stopped 0 +by 0 +the 0 +insertion 0 +of 0 +AZT 1 +into 0 +the 0 +chain 0 +in 0 +place 0 +of 0 +thymidine 1 +thus 0 +preventing 0 +the 0 +phosphate 1 +hydroxyl 0 +linkages 0 +and 0 +therefore 0 +suppresses 0 +hemopoietic 0 +progenitor 0 +cell 0 +proliferation 0 +in 0 +an 0 +early 0 +stage 0 +of 0 +differentiation 0 +. 0 + +CBA 0 +/ 0 +Ca 0 +male 0 +mice 0 +started 0 +on 0 +AZT 1 +0 0 +. 0 +75 0 +mg 0 +/ 0 +ml 0 +H20 0 +at 0 +84 0 +days 0 +of 0 +age 0 +and 0 +kept 0 +on 0 +it 0 +for 0 +687 0 +days 0 +when 0 +dosage 0 +reduced 0 +to 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +ml 0 +H20 0 +for 0 +a 0 +group 0 +, 0 +another 0 +group 0 +removed 0 +from 0 +AZT 1 +to 0 +see 0 +recovery 0 +, 0 +and 0 +third 0 +group 0 +remained 0 +on 0 +0 0 +. 0 +75 0 +mg 0 +. 0 + +At 0 +687 0 +days 0 +mice 0 +that 0 +had 0 +been 0 +on 0 +0 0 +. 0 +75 0 +mg 0 +had 0 +average 0 +platelet 0 +counts 0 +of 0 +2 0 +. 0 +5 0 +x 0 +10 0 +( 0 +6 0 +) 0 +. 0 + +Histological 0 +examination 0 +on 0 +9 0 +of 0 +10 0 +mice 0 +with 0 +such 0 +thrombocytopenia 3 +showed 0 +changes 0 +compatible 0 +with 0 +myelodysplastic 3 +syndrome 4 +( 0 +MDS 3 +) 0 +. 0 + +A 0 +variety 0 +of 0 +histological 0 +patterns 0 +was 0 +observed 0 +. 0 + +There 0 +were 0 +two 0 +cases 0 +of 0 +hypocellular 0 +myelodysplasia 3 +, 0 +two 0 +cases 0 +of 0 +hypersegmented 0 +myelodysplastic 3 +granulocytosis 0 +, 0 +two 0 +cases 0 +of 0 +hypercellular 0 +marrow 0 +with 0 +abnormal 0 +megakaryocytes 0 +with 0 +bizarre 0 +nuclei 0 +, 0 +one 0 +case 0 +of 0 +megakaryocytic 0 +myelosis 0 +associated 0 +with 0 +a 0 +hyperplastic 3 +marrow 4 +, 0 +dysmyelopoiesis 3 +and 0 +a 0 +hypocellular 3 +marrow 4 +and 0 +two 0 +cases 0 +of 0 +myelodysplasia 3 +with 0 +dyserythropoiesis 3 +, 0 +hemosiderosis 3 +and 0 +a 0 +hypocellular 3 +marrow 4 +. 0 + +Above 0 +mentioned 0 +AZT 1 +incorporation 0 +may 0 +have 0 +induced 0 +an 0 +ineffective 0 +hemopoiesis 0 +in 0 +the 0 +primitive 0 +hemopoietic 0 +progenitor 0 +cells 0 +, 0 +which 0 +is 0 +known 0 +to 0 +be 0 +seen 0 +commonly 0 +in 0 +the 0 +myelodysplastic 3 +syndrome 4 +. 0 + +Biphasic 0 +response 0 +of 0 +the 0 +SA 0 +node 0 +of 0 +the 0 +dog 0 +heart 0 +in 0 +vivo 0 +to 0 +selective 0 +administration 0 +of 0 +ketamine 1 +. 0 + +Effect 0 +of 0 +ketamine 1 +on 0 +the 0 +SA 0 +node 0 +of 0 +the 0 +dog 0 +heart 0 +was 0 +studied 0 +in 0 +vivo 0 +using 0 +a 0 +selective 0 +perfusion 0 +technique 0 +of 0 +the 0 +SA 0 +node 0 +artery 0 +. 0 + +Injections 0 +of 0 +ketamine 1 +in 0 +doses 0 +from 0 +100 0 +microgram 0 +to 0 +3 0 +mg 0 +into 0 +the 0 +artery 0 +produced 0 +a 0 +depression 3 +of 0 +the 0 +SA 0 +nodal 0 +activity 0 +by 0 +a 0 +direct 0 +action 0 +. 0 + +This 0 +depression 3 +was 0 +followed 0 +by 0 +the 0 +sudden 0 +appearance 0 +of 0 +a 0 +stimulatory 0 +phase 0 +. 0 + +Bilateral 0 +vagotomy 0 +and 0 +sympathectomy 0 +or 0 +prior 0 +administration 0 +of 0 +a 0 +ganglion 0 +blocker 0 +failed 0 +to 0 +inhibit 0 +the 0 +occurrence 0 +of 0 +the 0 +ketamine 1 +- 0 +induced 0 +tachycardia 3 +, 0 +while 0 +it 0 +was 0 +completely 0 +abolished 0 +in 0 +the 0 +reserpinized 0 +dogs 0 +or 0 +by 0 +a 0 +prior 0 +injection 0 +of 0 +a 0 +beta 0 +- 0 +blocking 0 +agent 0 +into 0 +the 0 +SA 0 +node 0 +artery 0 +. 0 + +This 0 +may 0 +indicate 0 +that 0 +an 0 +activation 0 +of 0 +the 0 +peripheral 0 +adrenergic 0 +mechanism 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +induction 0 +of 0 +the 0 +excitatory 0 +effect 0 +of 0 +ketamine 1 +injected 0 +in 0 +the 0 +SA 0 +node 0 +artery 0 +. 0 + +0ver 0 +expression 0 +of 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +and 0 +its 0 +receptor 0 +during 0 +the 0 +development 0 +of 0 +estrogen 1 +- 0 +induced 0 +rat 0 +pituitary 3 +tumors 4 +may 0 +mediate 0 +estrogen 1 +- 0 +initiated 0 +tumor 3 +angiogenesis 0 +. 0 + +Estrogens 1 +, 0 +which 0 +have 0 +been 0 +associated 0 +with 0 +several 0 +types 0 +of 0 +human 0 +and 0 +animal 0 +cancers 3 +, 0 +can 0 +induce 0 +tumor 3 +angiogenesis 0 +in 0 +the 0 +pituitary 0 +of 0 +Fischer 0 +344 0 +rats 0 +. 0 + +The 0 +mechanistic 0 +details 0 +of 0 +tumor 3 +angiogenesis 0 +induction 0 +, 0 +during 0 +estrogen 1 +carcinogenesis 3 +, 0 +are 0 +still 0 +unknown 0 +. 0 + +To 0 +elucidate 0 +the 0 +role 0 +of 0 +estrogen 1 +in 0 +the 0 +regulation 0 +of 0 +tumor 3 +angiogenesis 0 +in 0 +the 0 +pituitary 0 +of 0 +female 0 +rats 0 +, 0 +the 0 +density 0 +of 0 +blood 0 +vessels 0 +was 0 +analysed 0 +using 0 +factor 0 +VIII 0 +related 0 +antigen 0 +( 0 +FVIIIRAg 0 +) 0 +immunohistochemistry 0 +and 0 +the 0 +expression 0 +of 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +/ 0 +vascular 0 +permeability 0 +factor 0 +( 0 +VEGF 0 +/ 0 +VPF 0 +) 0 +was 0 +examined 0 +by 0 +Western 0 +blot 0 +and 0 +immunohistochemical 0 +analysis 0 +. 0 + +The 0 +expression 0 +of 0 +VEGF 0 +receptor 0 +( 0 +VEGFR 0 +- 0 +2 0 +/ 0 +Flk 0 +- 0 +1 0 +/ 0 +KDR 0 +) 0 +was 0 +also 0 +examined 0 +by 0 +immunohistochemistry 0 +. 0 + +The 0 +results 0 +demonstrated 0 +that 0 +17beta 1 +- 2 +estradiol 2 +( 0 +E2 1 +) 0 +induces 0 +neovascularization 0 +, 0 +as 0 +well 0 +as 0 +the 0 +growth 0 +and 0 +enlargement 0 +of 0 +blood 0 +vessels 0 +after 0 +7 0 +days 0 +of 0 +exposure 0 +. 0 + +The 0 +high 0 +tumor 3 +angiogenic 0 +potential 0 +was 0 +associated 0 +with 0 +an 0 +elevated 0 +VEGF 0 +/ 0 +VPF 0 +protein 0 +expression 0 +in 0 +the 0 +E2 1 +exposed 0 +pituitary 0 +of 0 +ovariectomized 0 +( 0 +0VEX 0 +) 0 +rats 0 +. 0 + +VEGF 0 +/ 0 +VPF 0 +and 0 +FVIIIRAg 0 +immunohistochemistry 0 +and 0 +endothelial 0 +specific 0 +lectin 0 +( 0 +UEA1 0 +) 0 +binding 0 +studies 0 +, 0 +indicate 0 +that 0 +the 0 +elevation 0 +of 0 +VEGF 0 +protein 0 +expression 0 +initially 0 +occurred 0 +in 0 +both 0 +blood 0 +vessels 0 +and 0 +non 0 +- 0 +endothelial 0 +cells 0 +. 0 + +After 0 +15 0 +days 0 +of 0 +E2 1 +exposure 0 +, 0 +VEGF 0 +/ 0 +VPF 0 +protein 0 +expression 0 +, 0 +in 0 +the 0 +non 0 +- 0 +endothelial 0 +cell 0 +population 0 +, 0 +sharply 0 +declined 0 +and 0 +was 0 +restricted 0 +to 0 +the 0 +blood 0 +vessels 0 +. 0 + +The 0 +function 0 +of 0 +non 0 +- 0 +endothelial 0 +- 0 +derived 0 +VEGF 0 +is 0 +not 0 +clear 0 +. 0 + +Furthermore 0 +, 0 +immunohistochemical 0 +studies 0 +demonstrated 0 +that 0 +VEGFR 0 +- 0 +2 0 +( 0 +flk 0 +- 0 +1 0 +/ 0 +KDR 0 +) 0 +, 0 +expression 0 +was 0 +elevated 0 +significantly 0 +in 0 +the 0 +endothelial 0 +cells 0 +of 0 +microblood 0 +vessels 0 +after 0 +7 0 +days 0 +of 0 +E2 1 +exposure 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +over 0 +expression 0 +of 0 +VEGF 0 +and 0 +its 0 +receptor 0 +( 0 +VEGFR 0 +- 0 +2 0 +) 0 +may 0 +play 0 +an 0 +important 0 +role 0 +in 0 +the 0 +initial 0 +step 0 +of 0 +the 0 +regulation 0 +of 0 +estrogen 1 +induced 0 +tumor 3 +angiogenesis 0 +in 0 +the 0 +rat 0 +pituitary 0 +. 0 + +Persistent 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +following 0 +lithium 1 +therapy 0 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +patient 0 +who 0 +developed 0 +severe 0 +hypernatraemic 0 +dehydration 3 +following 0 +a 0 +head 3 +injury 4 +. 0 + +Ten 0 +years 0 +previously 0 +he 0 +had 0 +been 0 +diagnosed 0 +to 0 +have 0 +lithium 1 +- 0 +induced 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +, 0 +and 0 +lithium 1 +therapy 0 +had 0 +been 0 +discontinued 0 +. 0 + +He 0 +remained 0 +thirsty 0 +and 0 +polyuric 3 +despite 0 +cessation 0 +of 0 +lithium 1 +and 0 +investigations 0 +on 0 +admission 0 +showed 0 +him 0 +to 0 +have 0 +normal 0 +osmoregulated 0 +thirst 0 +and 0 +vasopressin 1 +secretion 0 +, 0 +with 0 +clear 0 +evidence 0 +of 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +. 0 + +Lithium 1 +induced 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +is 0 +considered 0 +to 0 +be 0 +reversible 0 +on 0 +cessation 0 +of 0 +therapy 0 +but 0 +polyuria 3 +persisted 0 +in 0 +this 0 +patient 0 +for 0 +ten 0 +years 0 +after 0 +lithium 1 +was 0 +stopped 0 +. 0 + +We 0 +discuss 0 +the 0 +possible 0 +renal 0 +mechanisms 0 +and 0 +the 0 +implications 0 +for 0 +management 0 +of 0 +patients 0 +with 0 +lithium 1 +- 0 +induced 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +. 0 + +Effects 0 +of 0 +NIK 1 +- 2 +247 2 +on 0 +cholinesterase 0 +and 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +The 0 +effects 0 +of 0 +NIK 1 +- 2 +247 2 +on 0 +cholinesterase 0 +, 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +and 0 +spontaneous 0 +movement 0 +were 0 +examined 0 +and 0 +compared 0 +with 0 +those 0 +of 0 +the 0 +well 0 +- 0 +known 0 +cholinesterase 0 +inhibitors 0 +tacrine 1 +and 0 +E 1 +- 2 +2020 2 +. 0 + +NIK 1 +- 2 +247 2 +, 0 +tacrine 1 +and 0 +E 1 +- 2 +2020 2 +all 0 +strongly 0 +inhibited 0 +acetylcholinesterase 0 +( 0 +AChE 0 +) 0 +in 0 +human 0 +red 0 +blood 0 +cells 0 +( 0 +IC50s 0 += 0 +1 0 +. 0 +0 0 +x 0 +10 0 +( 0 +- 0 +6 0 +) 0 +, 0 +2 0 +. 0 +9 0 +x 0 +10 0 +( 0 +- 0 +7 0 +) 0 +and 0 +3 0 +. 0 +7 0 +x 0 +10 0 +( 0 +- 0 +8 0 +) 0 +M 0 +, 0 +respectively 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +NIK 1 +- 2 +247 2 +and 0 +tacrine 1 +, 0 +but 0 +not 0 +E 1 +- 2 +2020 2 +, 0 +strongly 0 +inhibited 0 +butyrylcholinestrase 0 +( 0 +BuChE 0 +) 0 +in 0 +human 0 +serum 0 +. 0 + +All 0 +three 0 +drugs 0 +produced 0 +mixed 0 +inhibition 0 +of 0 +AChE 0 +activity 0 +. 0 + +Moreover 0 +, 0 +the 0 +inhibitory 0 +effect 0 +of 0 +NIK 1 +- 2 +247 2 +on 0 +AChE 0 +was 0 +reversible 0 +. 0 + +All 0 +compounds 0 +at 0 +0 0 +. 0 +1 0 +- 0 +1 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +significantly 0 +improved 0 +the 0 +amnesia 3 +induced 0 +by 0 +scopolamine 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +in 0 +rats 0 +performing 0 +a 0 +passive 0 +avoidance 0 +task 0 +. 0 + +The 0 +three 0 +compounds 0 +at 0 +1 0 +and 0 +3 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +did 0 +not 0 +significantly 0 +decrease 0 +spontaneous 0 +movement 0 +by 0 +rats 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +NIK 1 +- 2 +247 2 +at 0 +a 0 +low 0 +dose 0 +( 0 +0 0 +. 0 +1 0 +- 0 +1 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +improves 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +but 0 +does 0 +not 0 +affect 0 +spontaneous 0 +movement 0 +. 0 + +The 0 +findings 0 +suggest 0 +that 0 +NIK 1 +- 2 +247 2 +may 0 +be 0 +a 0 +useful 0 +drug 0 +for 0 +the 0 +treatment 0 +of 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 + +Potential 0 +therapeutic 0 +use 0 +of 0 +the 0 +selective 0 +dopamine 1 +D1 0 +receptor 0 +agonist 0 +, 0 +A 1 +- 2 +86929 2 +: 0 +an 0 +acute 0 +study 0 +in 0 +parkinsonian 3 +levodopa 1 +- 0 +primed 0 +monkeys 0 +. 0 + +The 0 +clinical 0 +utility 0 +of 0 +dopamine 1 +( 0 +DA 1 +) 0 +D1 0 +receptor 0 +agonists 0 +in 0 +the 0 +treatment 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +is 0 +still 0 +unclear 0 +. 0 + +The 0 +therapeutic 0 +use 0 +of 0 +selective 0 +DA 1 +D1 0 +receptor 0 +agonists 0 +such 0 +as 0 +SKF 1 +- 2 +82958 2 +( 0 +6 1 +- 2 +chloro 2 +- 2 +7 2 +, 2 +8 2 +- 2 +dihydroxy 2 +- 2 +3 2 +- 2 +allyl 2 +- 2 +1 2 +- 2 +phenyl 2 +- 2 +2 2 +, 2 +3 2 +, 2 +4 2 +, 2 +5 2 +- 2 +tetrahydro 2 +- 2 +1H 2 +- 2 +3 2 +- 2 +benzaze 2 +pine 2 +hydrobromide 2 +) 0 +and 0 +A 1 +- 2 +77636 2 +( 0 +[ 1 +1R 2 +, 2 +3S 2 +] 2 +3 2 +- 2 +[ 2 +1 2 +' 2 +- 2 +admantyl 2 +] 2 +- 2 +1 2 +- 2 +aminomethyl 2 +- 2 +3 2 +, 2 +4 2 +- 2 +dihydro 2 +- 2 +5 2 +, 2 +6 2 +- 2 +dihydroxy 2 +- 2 +1H 2 +- 2 +2 2 +- 2 +benzo 2 +pyran 2 +hydrochloride 2 +) 0 +seems 0 +limited 0 +because 0 +of 0 +their 0 +duration 0 +of 0 +action 0 +, 0 +which 0 +is 0 +too 0 +short 0 +for 0 +SKF 1 +- 2 +82958 2 +( 0 +< 0 +1 0 +hr 0 +) 0 +and 0 +too 0 +long 0 +for 0 +A 1 +- 2 +77636 2 +( 0 +> 0 +20 0 +hr 0 +, 0 +leading 0 +to 0 +behavioral 0 +tolerance 0 +) 0 +. 0 + +We 0 +therefore 0 +conducted 0 +the 0 +present 0 +acute 0 +dose 0 +- 0 +response 0 +study 0 +in 0 +four 0 +1 1 +- 2 +methyl 2 +- 2 +4 2 +- 2 +phenyl 2 +- 2 +1 2 +, 2 +2 2 +, 2 +3 2 +, 2 +6 2 +- 2 +tetrahydropyridine 2 +( 0 +MPTP 1 +) 0 +- 0 +exposed 0 +cynomolgus 0 +monkeys 0 +primed 0 +to 0 +exhibit 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +to 0 +evaluate 0 +the 0 +locomotor 0 +and 0 +dyskinetic 3 +effects 0 +on 0 +challenge 0 +with 0 +four 0 +doses 0 +( 0 +from 0 +0 0 +. 0 +03 0 +to 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +) 0 +of 0 +A 1 +- 2 +86929 2 +( 0 +[ 1 +- 2 +] 2 +- 2 +[ 2 +5aR 2 +, 2 +11bS 2 +] 2 +- 2 +4 2 +, 2 +5 2 +, 2 +5a 2 +, 2 +6 2 +, 2 +7 2 +, 2 +11b 2 +- 2 +hexahydro 2 +- 2 +2 2 +- 2 +propyl 2 +- 2 +3 2 +- 2 +thia 2 +- 2 +5 2 +- 2 ++ 2 ++ 2 ++ 2 +azacyclopent 2 +- 2 +1 2 +- 2 +ena 2 +[ 2 +c 2 +] 2 +phenathrene 2 +- 2 +9 2 +- 2 +10 2 +- 2 +diol 2 +) 0 +, 0 +a 0 +selective 0 +and 0 +full 0 +DA 1 +D1 0 +- 0 +like 0 +receptor 0 +agonist 0 +with 0 +an 0 +intermediate 0 +duration 0 +of 0 +action 0 +. 0 + +Levodopa 1 +and 0 +the 0 +DA 1 +D2 0 +- 0 +like 0 +receptor 0 +agonist 0 +, 0 +LY 1 +- 2 +171555 2 +( 0 +[ 1 +4aR 2 +- 2 +trans 2 +] 2 +- 2 +4 2 +, 2 +4a 2 +, 2 +5 2 +, 2 +6 2 +, 2 +7 2 +, 2 +8 2 +, 2 +8a 2 +, 2 +9 2 +- 2 +o 2 +- 2 +dihydro 2 +- 2 +5n 2 +- 2 +propyl 2 +- 2 +2H 2 +- 2 +pyrazo 2 +lo 2 +- 2 +3 2 +- 2 +4 2 +- 2 +quinoline 2 +hydrochloride 2 +) 0 +were 0 +also 0 +used 0 +for 0 +comparison 0 +. 0 + +Acute 0 +administration 0 +of 0 +A 1 +- 2 +86929 2 +was 0 +as 0 +efficacious 0 +in 0 +alleviating 0 +MPTP 1 +- 0 +induced 0 +parkinsonism 3 +as 0 +levodopa 1 +and 0 +LY 1 +- 2 +171555 2 +, 0 +but 0 +was 0 +less 0 +likely 0 +to 0 +reproduce 0 +the 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +in 0 +these 0 +animals 0 +than 0 +with 0 +either 0 +LY 1 +- 2 +171555 2 +or 0 +subsequent 0 +challenge 0 +of 0 +levodopa 1 +. 0 + +Selective 0 +stimulation 0 +of 0 +the 0 +DA 1 +D1 0 +receptor 0 +may 0 +provide 0 +better 0 +integration 0 +of 0 +neural 0 +inputs 0 +transmitted 0 +to 0 +the 0 +internal 0 +segment 0 +of 0 +the 0 +globus 0 +pallidus 0 +( 0 +referred 0 +to 0 +as 0 +the 0 +basal 0 +ganglia 0 +output 0 +) 0 +compared 0 +with 0 +levodopa 1 +and 0 +selective 0 +DA 1 +D2 0 +receptor 0 +agonist 0 +. 0 + +Potent 0 +DA 1 +D1 0 +receptor 0 +agents 0 +with 0 +an 0 +intermediate 0 +duration 0 +of 0 +efficacy 0 +such 0 +as 0 +A 1 +- 2 +86929 2 +( 0 +approximately 0 +4 0 +hr 0 +at 0 +higher 0 +doses 0 +tested 0 +) 0 +are 0 +potential 0 +therapeutic 0 +tools 0 +in 0 +PD 3 +and 0 +merit 0 +further 0 +attention 0 +. 0 + +Neuropeptide 0 +- 0 +Y 0 +immunoreactivity 0 +in 0 +the 0 +pilocarpine 1 +model 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 + +Neuropeptide 0 +- 0 +Y 0 +( 0 +NPY 0 +) 0 +is 0 +expressed 0 +by 0 +granule 0 +cells 0 +and 0 +mossy 0 +fibres 0 +of 0 +the 0 +hippocampal 0 +dentate 0 +gyrus 0 +during 0 +experimental 0 +temporal 3 +lobe 4 +epilepsy 4 +( 0 +TLE 3 +) 0 +. 0 + +This 0 +expression 0 +may 0 +represent 0 +an 0 +endogenous 0 +damping 0 +mechanism 0 +since 0 +NPY 0 +has 0 +been 0 +shown 0 +to 0 +block 0 +seizure 3 +- 0 +like 0 +events 0 +following 0 +high 0 +- 0 +frequency 0 +stimulation 0 +in 0 +hippocampal 0 +slices 0 +. 0 + +The 0 +pilocarpine 1 +( 0 +PIL0 1 +) 0 +model 0 +of 0 +epilepsy 3 +is 0 +characterized 0 +by 0 +an 0 +acute 0 +period 0 +of 0 +status 3 +epilepticus 4 +followed 0 +by 0 +spontaneous 0 +recurrent 0 +seizures 3 +and 0 +related 0 +brain 3 +damage 4 +. 0 + +We 0 +report 0 +peroxidase 0 +- 0 +antiperoxidase 0 +immunostaining 0 +for 0 +NPY 0 +in 0 +several 0 +brain 0 +regions 0 +in 0 +this 0 +model 0 +. 0 + +PIL0 1 +- 0 +injected 0 +animals 0 +exhibited 0 +NPY 0 +immunoreactivity 0 +in 0 +the 0 +region 0 +of 0 +the 0 +mossy 0 +fibre 0 +terminals 0 +, 0 +in 0 +the 0 +dentate 0 +gyrus 0 +inner 0 +molecular 0 +layer 0 +and 0 +, 0 +in 0 +a 0 +few 0 +cases 0 +, 0 +within 0 +presumed 0 +granule 0 +cells 0 +. 0 + +NPY 0 +immunoreactivity 0 +was 0 +also 0 +dramatically 0 +changed 0 +in 0 +the 0 +entorhinal 0 +cortex 0 +, 0 +amygdala 0 +and 0 +sensorimotor 0 +areas 0 +. 0 + +In 0 +addition 0 +, 0 +PIL0 1 +injected 0 +animals 0 +exhibited 0 +a 0 +reduction 0 +in 0 +the 0 +number 0 +of 0 +NPY 0 +- 0 +immunoreactive 0 +interneurons 0 +compared 0 +with 0 +controls 0 +. 0 + +The 0 +results 0 +demonstrate 0 +that 0 +changes 0 +in 0 +NPY 0 +expression 0 +, 0 +including 0 +expression 0 +in 0 +the 0 +granule 0 +cells 0 +and 0 +mossy 0 +fibres 0 +and 0 +the 0 +loss 0 +of 0 +vulnerable 0 +NPY 0 +neurons 0 +, 0 +are 0 +present 0 +in 0 +the 0 +PIL0 1 +model 0 +of 0 +TLE 3 +. 0 + +However 0 +, 0 +the 0 +significance 0 +of 0 +this 0 +changed 0 +synthesis 0 +of 0 +NPY 0 +remains 0 +to 0 +be 0 +determined 0 +. 0 + +Posteroventral 0 +medial 0 +pallidotomy 0 +in 0 +advanced 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +BACKGR0UND 0 +: 0 +Posteroventral 0 +medial 0 +pallidotomy 0 +sometimes 0 +produces 0 +striking 0 +improvement 0 +in 0 +patients 0 +with 0 +advanced 0 +Parkinson 3 +' 4 +s 4 +disease 4 +, 0 +but 0 +the 0 +studies 0 +to 0 +date 0 +have 0 +involved 0 +small 0 +numbers 0 +of 0 +patients 0 +and 0 +short 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +. 0 + +METH0DS 0 +: 0 +Forty 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +underwent 0 +serial 0 +, 0 +detailed 0 +assessments 0 +both 0 +after 0 +drug 0 +withdrawal 0 +( 0 +" 0 +off 0 +" 0 +period 0 +) 0 +and 0 +while 0 +taking 0 +their 0 +optimal 0 +medical 0 +regimens 0 +( 0 +" 0 +on 0 +" 0 +period 0 +) 0 +. 0 + +All 0 +patients 0 +were 0 +examined 0 +preoperatively 0 +and 0 +39 0 +were 0 +examined 0 +at 0 +six 0 +months 0 +; 0 +27 0 +of 0 +the 0 +patients 0 +were 0 +also 0 +examined 0 +at 0 +one 0 +year 0 +, 0 +and 0 +11 0 +at 0 +two 0 +years 0 +. 0 + +RESULTS 0 +: 0 +The 0 +percent 0 +improvements 0 +at 0 +six 0 +months 0 +were 0 +as 0 +follows 0 +: 0 +off 0 +- 0 +period 0 +score 0 +for 0 +overall 0 +motor 0 +function 0 +, 0 +28 0 +percent 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +19 0 +to 0 +38 0 +percent 0 +) 0 +, 0 +with 0 +most 0 +of 0 +the 0 +improvement 0 +in 0 +the 0 +contralateral 0 +limbs 0 +; 0 +off 0 +- 0 +period 0 +score 0 +for 0 +activities 0 +of 0 +daily 0 +living 0 +, 0 +29 0 +percent 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +19 0 +to 0 +39 0 +percent 0 +) 0 +; 0 +on 0 +- 0 +period 0 +score 0 +for 0 +contralateral 0 +dyskinesias 3 +, 0 +82 0 +percent 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +72 0 +to 0 +91 0 +percent 0 +) 0 +; 0 +and 0 +on 0 +- 0 +period 0 +score 0 +for 0 +ipsilateral 0 +dyskinesias 3 +, 0 +44 0 +percent 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +, 0 +29 0 +to 0 +59 0 +percent 0 +) 0 +. 0 + +The 0 +improvements 0 +in 0 +dyskinesias 3 +and 0 +the 0 +total 0 +scores 0 +for 0 +off 0 +- 0 +period 0 +parkinsonism 3 +, 0 +contralateral 0 +bradykinesia 3 +, 0 +and 0 +rigidity 3 +were 0 +sustained 0 +in 0 +the 0 +11 0 +patients 0 +examined 0 +at 0 +two 0 +years 0 +. 0 + +The 0 +improvement 0 +in 0 +ipsilateral 0 +dyskinesias 3 +was 0 +lost 0 +after 0 +one 0 +year 0 +, 0 +and 0 +the 0 +improvements 0 +in 0 +postural 0 +stability 0 +and 0 +gait 0 +lasted 0 +only 0 +three 0 +to 0 +six 0 +months 0 +. 0 + +Approximately 0 +half 0 +the 0 +patients 0 +who 0 +had 0 +been 0 +dependent 0 +on 0 +assistance 0 +in 0 +activities 0 +of 0 +daily 0 +living 0 +in 0 +the 0 +off 0 +period 0 +before 0 +surgery 0 +became 0 +independent 0 +after 0 +surgery 0 +. 0 + +The 0 +complications 0 +of 0 +surgery 0 +were 0 +generally 0 +well 0 +tolerated 0 +, 0 +and 0 +there 0 +were 0 +no 0 +significant 0 +changes 0 +in 0 +the 0 +use 0 +of 0 +medication 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +late 0 +- 0 +stage 0 +Parkinson 3 +' 4 +s 4 +disease 4 +, 0 +pallidotomy 0 +significantly 0 +reduces 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +and 0 +off 0 +- 0 +period 0 +disability 0 +. 0 + +Much 0 +of 0 +the 0 +benefit 0 +is 0 +sustained 0 +at 0 +two 0 +years 0 +, 0 +although 0 +some 0 +improvements 0 +, 0 +such 0 +as 0 +those 0 +on 0 +the 0 +ipsilateral 0 +side 0 +and 0 +in 0 +axial 0 +symptoms 0 +, 0 +wane 0 +within 0 +the 0 +first 0 +year 0 +. 0 + +The 0 +on 0 +- 0 +period 0 +symptoms 0 +that 0 +are 0 +resistant 0 +to 0 +dopaminergic 0 +therapy 0 +do 0 +not 0 +respond 0 +to 0 +pallidotomy 0 +. 0 + +Clarithromycin 1 +- 0 +induced 0 +ventricular 3 +tachycardia 4 +. 0 + +Clarithromycin 1 +is 0 +a 0 +relatively 0 +new 0 +macrolide 1 +antibiotic 0 +that 0 +offers 0 +twice 0 +- 0 +daily 0 +dosing 0 +. 0 + +It 0 +differs 0 +from 0 +erythromycin 1 +only 0 +in 0 +the 0 +methylation 0 +of 0 +the 0 +hydroxyl 0 +group 0 +at 0 +position 0 +6 0 +. 0 + +Although 0 +the 0 +side 0 +- 0 +effect 0 +profile 0 +of 0 +erythromycin 1 +is 0 +established 0 +, 0 +including 0 +gastroenteritis 3 +and 0 +interactions 0 +with 0 +other 0 +drugs 0 +subject 0 +to 0 +hepatic 0 +mixed 0 +- 0 +function 0 +oxidase 0 +metabolism 0 +, 0 +experience 0 +with 0 +the 0 +newer 0 +macrolides 1 +is 0 +still 0 +being 0 +recorded 0 +. 0 + +Cardiotoxicity 3 +has 0 +been 0 +demonstrated 0 +after 0 +both 0 +intravenous 0 +and 0 +oral 0 +administration 0 +of 0 +erythromycin 1 +but 0 +has 0 +never 0 +been 0 +reported 0 +with 0 +the 0 +newer 0 +macrolides 1 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +ventricular 3 +dysrhythmias 4 +that 0 +occurred 0 +after 0 +six 0 +therapeutic 0 +doses 0 +of 0 +clarithromycin 1 +. 0 + +The 0 +dysrhythmias 3 +resolved 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +. 0 + +Effect 0 +of 0 +glyceryl 1 +trinitrate 2 +on 0 +the 0 +sphincter 3 +of 4 +0ddi 4 +spasm 4 +evoked 0 +by 0 +prostigmine 1 +- 0 +morphine 1 +administration 0 +. 0 + +0BJECTIVE 0 +: 0 +In 0 +this 0 +study 0 +the 0 +effect 0 +of 0 +glyceryl 1 +trinitrate 2 +on 0 +the 0 +prostigmine 1 +- 0 +morphine 1 +- 0 +induced 0 +sphincter 3 +of 4 +0ddi 4 +spasm 4 +was 0 +evaluated 0 +in 0 +nine 0 +female 0 +patients 0 +with 0 +sphincter 3 +of 4 +0ddi 4 +dyskinesia 4 +. 0 + +METH0D 0 +: 0 +Sphincter 3 +of 4 +0ddi 4 +spasm 4 +was 0 +induced 0 +by 0 +prostigmine 1 +- 0 +morphine 1 +administration 0 +( 0 +0 0 +. 0 +5 0 +mg 0 +prostigmine 1 +intramuscularly 0 +and 0 +10 0 +mg 0 +morphine 1 +subcutaneously 0 +) 0 +and 0 +visualized 0 +by 0 +quantitative 0 +hepatobiliary 0 +scintigraphy 0 +. 0 + +The 0 +entire 0 +procedure 0 +was 0 +repeated 0 +during 0 +glyceryl 1 +trinitrate 2 +infusion 0 +( 0 +Nitrolingual 1 +1 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +for 0 +120 0 +min 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Prostigmine 1 +- 0 +morphine 1 +provocation 0 +caused 0 +significant 0 +increases 0 +in 0 +the 0 +time 0 +to 0 +peak 0 +activity 0 +( 0 +Tmax 0 +) 0 +over 0 +the 0 +hepatic 0 +hilum 0 +( 0 +HH 0 +: 0 +34 0 +. 0 +33 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +05 0 +vs 0 +. 0 +22 0 +. 0 +77 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +26 0 +) 0 +and 0 +the 0 +common 0 +bile 0 +duct 0 +( 0 +CBD 0 +: 0 +60 0 +. 0 +44 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +99 0 +vs 0 +. 0 +40 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +88 0 +) 0 +and 0 +in 0 +the 0 +half 0 +- 0 +time 0 +of 0 +excretion 0 +( 0 +T1 0 +/ 0 +2 0 +) 0 +over 0 +the 0 +liver 0 +parenchyma 0 +( 0 +LP 0 +: 0 +120 0 +. 0 +04 0 ++ 0 +/ 0 +- 0 +16 0 +. 0 +01 0 +vs 0 +. 0 +27 0 +. 0 +37 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +19 0 +) 0 +, 0 +HH 0 +( 0 +117 0 +. 0 +61 0 ++ 0 +/ 0 +- 0 +14 0 +. 0 +71 0 +vs 0 +. 0 +31 0 +. 0 +85 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +99 0 +) 0 +and 0 +CBD 0 +( 0 +158 0 +. 0 +11 0 ++ 0 +/ 0 +- 0 +9 0 +. 0 +18 0 +vs 0 +. 0 +40 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +24 0 +) 0 +, 0 +indicating 0 +a 0 +complete 0 +spasm 3 +at 0 +the 0 +level 0 +of 0 +the 0 +sphincter 0 +of 0 +0ddi 0 +. 0 + +Glyceryl 1 +trinitrate 2 +infusion 0 +completely 0 +normalized 0 +the 0 +prostigmine 1 +- 0 +morphine 1 +- 0 +induced 0 +alterations 0 +in 0 +these 0 +quantitative 0 +parameters 0 +( 0 +TmaX 0 +over 0 +the 0 +LP 0 +: 0 +11 0 +. 0 +33 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +13 0 +; 0 +over 0 +the 0 +HH 0 +: 0 +18 0 +. 0 +88 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +48 0 +; 0 +and 0 +over 0 +the 0 +CBD 0 +: 0 +36 0 +. 0 +22 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +92 0 +; 0 +and 0 +T1 0 +/ 0 +2 0 +over 0 +the 0 +LP 0 +: 0 +28 0 +. 0 +21 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +83 0 +; 0 +over 0 +the 0 +HH 0 +: 0 +33 0 +. 0 +42 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +10 0 +; 0 +and 0 +over 0 +the 0 +CBD 0 +: 0 +41 0 +. 0 +66 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +33 0 +) 0 +, 0 +suggesting 0 +an 0 +effective 0 +sphincter 0 +- 0 +relaxing 0 +effect 0 +of 0 +glyceryl 1 +trinitrate 2 +. 0 + +C0NCLUSI0N 0 +: 0 +These 0 +results 0 +provide 0 +the 0 +first 0 +evidence 0 +of 0 +the 0 +effectiveness 0 +of 0 +glyceryl 1 +trinitrate 2 +on 0 +the 0 +morphine 1 +- 0 +induced 0 +sphincter 3 +of 4 +0ddi 4 +spasm 4 +in 0 +humans 0 +. 0 + +Since 0 +glyceryl 1 +trinitrate 2 +is 0 +able 0 +to 0 +overcome 0 +even 0 +the 0 +drastic 0 +effect 0 +of 0 +morphine 1 +, 0 +it 0 +might 0 +be 0 +of 0 +relevance 0 +in 0 +the 0 +treatment 0 +of 0 +sphincter 3 +of 4 +0ddi 4 +dyskinesia 4 +. 0 + +Immunopathology 0 +of 0 +penicillamine 1 +- 0 +induced 0 +glomerular 3 +disease 4 +. 0 + +Four 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +developed 0 +heavy 0 +proteinuria 3 +after 0 +five 0 +to 0 +12 0 +months 0 +of 0 +treatment 0 +with 0 +D 1 +- 2 +penicillamine 2 +. 0 + +Light 0 +microscopy 0 +of 0 +renal 0 +biopsy 0 +samples 0 +showed 0 +minimal 0 +glomerular 0 +capillary 0 +wall 0 +thickening 0 +and 0 +mesangial 0 +matrix 0 +increase 0 +, 0 +or 0 +no 0 +departure 0 +from 0 +normal 0 +. 0 + +Electron 0 +microscopy 0 +, 0 +however 0 +, 0 +revealed 0 +subepithelial 0 +electron 0 +- 0 +dense 0 +deposits 0 +, 0 +fusion 0 +of 0 +epithelial 0 +cell 0 +foot 0 +processes 0 +, 0 +and 0 +evidence 0 +of 0 +mesangial 0 +cell 0 +hyperactivity 0 +. 0 + +Immunofluorescence 0 +microscopy 0 +demonstrated 0 +granular 0 +capillary 0 +wall 0 +deposits 0 +of 0 +IgG 0 +and 0 +C3 0 +. 0 + +The 0 +findings 0 +were 0 +similar 0 +to 0 +those 0 +in 0 +early 0 +membranous 3 +glomerulonephritis 4 +, 0 +differences 0 +being 0 +observed 0 +however 0 +in 0 +the 0 +results 0 +of 0 +staining 0 +for 0 +the 0 +early 0 +- 0 +acting 0 +complement 0 +components 0 +C1q 0 +and 0 +C4 0 +. 0 + +It 0 +is 0 +tentatively 0 +concluded 0 +that 0 +complement 0 +was 0 +activated 0 +by 0 +the 0 +classical 0 +pathway 0 +. 0 + +Experimental 0 +cranial 0 +pain 3 +elicited 0 +by 0 +capsaicin 1 +: 0 +a 0 +PET 0 +study 0 +. 0 + +Using 0 +a 0 +positron 0 +emission 0 +tomography 0 +( 0 +PET 0 +) 0 +study 0 +it 0 +was 0 +shown 0 +recently 0 +that 0 +in 0 +migraine 3 +without 0 +aura 0 +certain 0 +areas 0 +in 0 +the 0 +brain 0 +stem 0 +were 0 +activated 0 +during 0 +the 0 +headache 3 +state 0 +, 0 +but 0 +not 0 +in 0 +the 0 +headache 3 +free 0 +interval 0 +. 0 + +It 0 +was 0 +suggested 0 +that 0 +this 0 +brain 0 +stem 0 +activation 0 +is 0 +inherent 0 +to 0 +the 0 +migraine 3 +attack 0 +itself 0 +and 0 +represents 0 +the 0 +so 0 +called 0 +' 0 +migraine 3 +generator 0 +' 0 +. 0 + +To 0 +test 0 +this 0 +hypothesis 0 +we 0 +performed 0 +an 0 +experimental 0 +pain 3 +study 0 +in 0 +seven 0 +healthy 0 +volunteers 0 +, 0 +using 0 +the 0 +same 0 +positioning 0 +in 0 +the 0 +PET 0 +scanner 0 +as 0 +in 0 +the 0 +migraine 3 +patients 0 +. 0 + +A 0 +small 0 +amount 0 +of 0 +capsaicin 1 +was 0 +administered 0 +subcutaneously 0 +in 0 +the 0 +right 0 +forehead 0 +to 0 +evoke 0 +a 0 +burning 0 +painful 3 +sensation 0 +in 0 +the 0 +first 0 +division 0 +of 0 +the 0 +trigeminal 0 +nerve 0 +. 0 + +Increases 0 +of 0 +regional 0 +cerebral 0 +blood 0 +flow 0 +( 0 +rCBF 0 +) 0 +were 0 +found 0 +bilaterally 0 +in 0 +the 0 +insula 0 +, 0 +in 0 +the 0 +anterior 0 +cingulate 0 +cortex 0 +, 0 +the 0 +cavernous 0 +sinus 0 +and 0 +the 0 +cerebellum 0 +. 0 + +Using 0 +the 0 +same 0 +stereotactic 0 +space 0 +limits 0 +as 0 +in 0 +the 0 +above 0 +mentioned 0 +migraine 3 +study 0 +no 0 +brain 0 +stem 0 +activation 0 +was 0 +found 0 +in 0 +the 0 +acute 0 +pain 3 +state 0 +compared 0 +to 0 +the 0 +pain 3 +free 0 +state 0 +. 0 + +The 0 +increase 0 +of 0 +activation 0 +in 0 +the 0 +region 0 +of 0 +the 0 +cavernous 0 +sinus 0 +however 0 +, 0 +suggests 0 +that 0 +this 0 +structure 0 +is 0 +more 0 +likely 0 +to 0 +be 0 +involved 0 +in 0 +trigeminal 0 +transmitted 0 +pain 3 +as 0 +such 0 +, 0 +rather 0 +than 0 +in 0 +a 0 +specific 0 +type 0 +of 0 +headache 3 +as 0 +was 0 +suggested 0 +for 0 +cluster 3 +headache 4 +. 0 + +Value 0 +of 0 +methylprednisolone 1 +in 0 +prevention 0 +of 0 +the 0 +arthralgia 3 +- 0 +myalgia 3 +syndrome 0 +associated 0 +with 0 +the 0 +total 0 +dose 0 +infusion 0 +of 0 +iron 1 +dextran 2 +: 0 +a 0 +double 0 +blind 0 +randomized 0 +trial 0 +. 0 + +The 0 +safety 0 +and 0 +efficacy 0 +of 0 +total 0 +dose 0 +infusion 0 +( 0 +TDI 0 +) 0 +of 0 +iron 1 +dextran 2 +has 0 +been 0 +well 0 +documented 0 +. 0 + +In 0 +40 0 +% 0 +of 0 +treated 0 +patients 0 +, 0 +an 0 +arthralgia 3 +- 0 +myalgia 3 +syndrome 0 +develops 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +prospective 0 +study 0 +was 0 +to 0 +investigate 0 +whether 0 +intravenous 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +administration 0 +of 0 +methylprednisolone 1 +( 0 +MP 1 +) 0 +prevents 0 +this 0 +complication 0 +. 0 + +Sixty 0 +- 0 +five 0 +patients 0 +, 0 +34 0 +women 0 +and 0 +31 0 +men 0 +, 0 +ages 0 +36 0 +to 0 +80 0 +years 0 +, 0 +received 0 +either 0 +normal 0 +saline 0 +before 0 +and 0 +after 0 +TDI 0 +( 0 +group 0 +1 0 +) 0 +, 0 +125 0 +mg 0 +i 0 +. 0 +v 0 +. 0 +MP 1 +before 0 +and 0 +saline 0 +after 0 +TDI 0 +( 0 +group 0 +2 0 +) 0 +, 0 +or 0 +125 0 +mg 0 +i 0 +. 0 +v 0 +. 0 +MP 1 +before 0 +and 0 +after 0 +TDI 0 +( 0 +group 0 +3 0 +) 0 +. 0 + +Patients 0 +were 0 +observed 0 +for 0 +72 0 +hours 0 +and 0 +reactions 0 +were 0 +recorded 0 +and 0 +graded 0 +according 0 +to 0 +severity 0 +. 0 + +Fifty 0 +- 0 +eight 0 +percent 0 +of 0 +group 0 +1 0 +patients 0 +, 0 +33 0 +% 0 +of 0 +group 0 +2 0 +, 0 +and 0 +26 0 +% 0 +of 0 +group 0 +3 0 +had 0 +reactions 0 +to 0 +TDI 0 +. 0 + +The 0 +severity 0 +of 0 +reactions 0 +( 0 +minimal 0 +, 0 +mild 0 +, 0 +and 0 +moderate 0 +, 0 +respectively 0 +) 0 +was 0 +as 0 +follows 0 +: 0 +group 0 +1 0 +- 0 +- 0 +6 0 +, 0 +6 0 +, 0 +and 0 +2 0 +; 0 +group 0 +2 0 +- 0 +- 0 +1 0 +, 0 +5 0 +, 0 +and 0 +0 0 +; 0 +group 0 +3 0 +- 0 +- 0 +5 0 +, 0 +1 0 +, 0 +and 0 +0 0 +. 0 + +Data 0 +were 0 +analyzed 0 +by 0 +the 0 +two 0 +- 0 +sided 0 +Fisher 0 +' 0 +s 0 +exact 0 +test 0 +using 0 +95 0 +% 0 +confidence 0 +intervals 0 +with 0 +the 0 +approximation 0 +of 0 +Woolf 0 +. 0 + +These 0 +data 0 +demonstrate 0 +that 0 +administration 0 +of 0 +MP 1 +before 0 +and 0 +after 0 +TDI 0 +reduces 0 +the 0 +frequency 0 +and 0 +severity 0 +of 0 +the 0 +arthralgia 3 +- 0 +myalgia 3 +syndrome 0 +. 0 + +We 0 +conclude 0 +that 0 +125 0 +mg 0 +i 0 +. 0 +v 0 +. 0 +MP 1 +should 0 +be 0 +given 0 +routinely 0 +before 0 +and 0 +after 0 +TDI 0 +of 0 +iron 1 +dextran 2 +. 0 + +Prolongation 3 +of 4 +the 4 +QT 4 +interval 4 +related 0 +to 0 +cisapride 1 +- 0 +diltiazem 1 +interaction 0 +. 0 + +Cisapride 1 +, 0 +a 0 +cytochrome 0 +P450 0 +3A4 0 +( 0 +CYP3A4 0 +) 0 +substrate 0 +, 0 +is 0 +widely 0 +prescribed 0 +for 0 +the 0 +treatment 0 +of 0 +gastrointestinal 3 +motility 4 +disorders 4 +. 0 + +Prolongation 3 +of 4 +QT 4 +interval 4 +, 0 +torsades 3 +de 4 +pointes 4 +, 0 +and 0 +sudden 3 +cardiac 4 +death 4 +have 0 +been 0 +reported 0 +after 0 +concomitant 0 +administration 0 +with 0 +erythromycin 1 +or 0 +azole 1 +antifungal 0 +agents 0 +, 0 +but 0 +not 0 +with 0 +other 0 +CYP3A4 0 +inhibitors 0 +. 0 + +A 0 +possible 0 +drug 0 +interaction 0 +occurred 0 +in 0 +a 0 +45 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +was 0 +taking 0 +cisapride 1 +for 0 +gastroesophageal 3 +reflux 4 +disorder 4 +and 0 +diltiazem 1 +, 0 +an 0 +agent 0 +that 0 +has 0 +inhibitory 0 +effect 0 +on 0 +CYP3A4 0 +, 0 +for 0 +hypertension 3 +. 0 + +The 0 +patient 0 +was 0 +in 0 +near 0 +syncope 3 +and 0 +had 0 +QT 3 +- 4 +interval 4 +prolongation 4 +. 0 + +After 0 +discontinuing 0 +cisapride 1 +, 0 +the 0 +QT 0 +interval 0 +returned 0 +to 0 +normal 0 +and 0 +symptoms 0 +did 0 +not 0 +recur 0 +. 0 + +We 0 +suggest 0 +that 0 +caution 0 +be 0 +taken 0 +when 0 +cisapride 1 +is 0 +prescribed 0 +with 0 +any 0 +potent 0 +inhibitor 0 +of 0 +CYP3A4 0 +, 0 +including 0 +diltiazem 1 +. 0 + +Cortical 0 +motor 0 +overactivation 0 +in 0 +parkinsonian 3 +patients 0 +with 0 +L 1 +- 2 +dopa 2 +- 0 +induced 0 +peak 0 +- 0 +dose 0 +dyskinesia 3 +. 0 + +We 0 +have 0 +studied 0 +the 0 +regional 0 +cerebral 0 +blood 0 +flow 0 +( 0 +rCBF 0 +) 0 +changes 0 +induced 0 +by 0 +the 0 +execution 0 +of 0 +a 0 +finger 0 +- 0 +to 0 +- 0 +thumb 0 +opposition 0 +motor 0 +task 0 +in 0 +the 0 +supplementary 0 +and 0 +primary 0 +motor 0 +cortex 0 +of 0 +two 0 +groups 0 +of 0 +parkinsonian 3 +patients 0 +on 0 +L 1 +- 2 +dopa 2 +medication 0 +, 0 +the 0 +first 0 +one 0 +without 0 +L 1 +- 2 +dopa 2 +induced 0 +dyskinesia 3 +( 0 +n 0 += 0 +23 0 +) 0 +and 0 +the 0 +other 0 +with 0 +moderate 0 +peak 0 +- 0 +dose 0 +dyskinesia 3 +( 0 +n 0 += 0 +15 0 +) 0 +, 0 +and 0 +of 0 +a 0 +group 0 +of 0 +14 0 +normal 0 +subjects 0 +. 0 + +Single 0 +photon 0 +emission 0 +tomography 0 +with 0 +i 0 +. 0 +v 0 +. 0 +133Xe 0 +was 0 +used 0 +to 0 +measure 0 +the 0 +rCBF 0 +changes 0 +. 0 + +The 0 +dyskinetic 3 +parkinsonian 3 +patients 0 +exhibited 0 +a 0 +pattern 0 +of 0 +response 0 +which 0 +was 0 +markedly 0 +different 0 +from 0 +those 0 +of 0 +the 0 +normal 0 +subjects 0 +and 0 +non 0 +- 0 +dyskinetic 3 +parkinsonian 3 +patients 0 +, 0 +with 0 +a 0 +significant 0 +overactivation 0 +in 0 +the 0 +supplementary 0 +motor 0 +area 0 +and 0 +the 0 +ipsi 0 +- 0 +and 0 +contralateral 0 +primary 0 +motor 0 +areas 0 +. 0 + +These 0 +results 0 +are 0 +compatible 0 +with 0 +the 0 +hypothesis 0 +that 0 +an 0 +hyperkinetic 3 +abnormal 3 +involuntary 4 +movement 4 +, 0 +like 0 +L 1 +- 2 +dopa 2 +- 0 +induced 0 +peak 0 +dose 0 +dyskinesia 3 +, 0 +is 0 +due 0 +to 0 +a 0 +disinhibition 0 +of 0 +the 0 +primary 0 +and 0 +associated 0 +motor 0 +cortex 0 +secondary 0 +to 0 +an 0 +excessive 0 +outflow 0 +of 0 +the 0 +pallidothalamocortical 0 +motor 0 +loop 0 +. 0 + +0pen 0 +- 0 +label 0 +assessment 0 +of 0 +levofloxacin 1 +for 0 +the 0 +treatment 0 +of 0 +acute 0 +bacterial 0 +sinusitis 3 +in 0 +adults 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +evaluate 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +levofloxacin 1 +( 0 +500 0 +mg 0 +orally 0 +once 0 +daily 0 +for 0 +10 0 +to 0 +14 0 +days 0 +) 0 +in 0 +treating 0 +adult 0 +outpatients 0 +with 0 +acute 0 +bacterial 0 +sinusitis 3 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +A 0 +total 0 +of 0 +329 0 +patients 0 +enrolled 0 +in 0 +the 0 +study 0 +at 0 +24 0 +centers 0 +. 0 + +All 0 +patients 0 +had 0 +a 0 +pre 0 +- 0 +therapy 0 +Gram 0 +' 0 +s 0 +stain 0 +and 0 +culture 0 +of 0 +sinus 0 +exudate 0 +obtained 0 +by 0 +antral 0 +puncture 0 +or 0 +nasal 0 +endoscopy 0 +. 0 + +Clinical 0 +response 0 +was 0 +assessed 0 +on 0 +the 0 +basis 0 +of 0 +signs 0 +and 0 +symptoms 0 +and 0 +sinus 0 +radiograph 0 +or 0 +computed 0 +tomography 0 +results 0 +. 0 + +Microbiologic 0 +cure 0 +rates 0 +were 0 +determined 0 +on 0 +the 0 +basis 0 +of 0 +presumed 0 +plus 0 +documented 0 +eradication 0 +of 0 +the 0 +pre 0 +- 0 +therapy 0 +pathogen 0 +( 0 +s 0 +) 0 +. 0 + +RESULTS 0 +: 0 +The 0 +most 0 +common 0 +pathogens 0 +were 0 +Haemophilus 0 +influenzae 0 +, 0 +Streptococcus 0 +pneumoniae 0 +, 0 +Staphylococcus 0 +aureus 0 +, 0 +and 0 +Moraxella 0 +catarrhalis 0 +. 0 + +0f 0 +300 0 +clinically 0 +evaluable 0 +patients 0 +, 0 +175 0 +( 0 +58 0 +% 0 +) 0 +were 0 +cured 0 +and 0 +90 0 +( 0 +30 0 +% 0 +) 0 +were 0 +improved 0 +at 0 +the 0 +post 0 +- 0 +therapy 0 +evaluation 0 +, 0 +resulting 0 +in 0 +a 0 +clinical 0 +success 0 +rate 0 +of 0 +88 0 +% 0 +. 0 + +Thirty 0 +- 0 +five 0 +patients 0 +( 0 +12 0 +% 0 +) 0 +clinically 0 +failed 0 +treatment 0 +. 0 + +The 0 +microbiologic 0 +eradication 0 +rate 0 +( 0 +presumed 0 +plus 0 +documented 0 +) 0 +among 0 +138 0 +microbiologically 0 +evaluable 0 +patients 0 +was 0 +92 0 +% 0 +. 0 + +Microbiologic 0 +eradication 0 +rates 0 +( 0 +presumed 0 +plus 0 +documented 0 +) 0 +of 0 +the 0 +most 0 +common 0 +pathogens 0 +ranged 0 +from 0 +93 0 +% 0 +( 0 +M 0 +. 0 +catarrhalis 0 +) 0 +to 0 +100 0 +% 0 +( 0 +S 0 +. 0 +pneumoniae 0 +) 0 +at 0 +the 0 +post 0 +- 0 +therapy 0 +visit 0 +. 0 + +All 0 +but 0 +one 0 +of 0 +the 0 +265 0 +patients 0 +who 0 +were 0 +cured 0 +or 0 +improved 0 +at 0 +post 0 +- 0 +therapy 0 +returned 0 +for 0 +a 0 +long 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +visit 0 +; 0 +243 0 +( 0 +92 0 +% 0 +) 0 +remained 0 +well 0 +4 0 +to 0 +6 0 +weeks 0 +after 0 +therapy 0 +; 0 +and 0 +21 0 +( 0 +8 0 +% 0 +) 0 +had 0 +a 0 +relapse 0 +of 0 +symptoms 0 +. 0 + +Adverse 0 +events 0 +considered 0 +to 0 +be 0 +related 0 +to 0 +levofloxacin 1 +administration 0 +were 0 +reported 0 +by 0 +29 0 +patients 0 +( 0 +9 0 +% 0 +) 0 +. 0 + +The 0 +most 0 +common 0 +drug 0 +- 0 +related 0 +adverse 0 +events 0 +were 0 +diarrhea 3 +, 0 +flatulence 3 +, 0 +and 0 +nausea 3 +; 0 +most 0 +adverse 0 +events 0 +were 0 +mild 0 +to 0 +moderate 0 +in 0 +severity 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +results 0 +of 0 +this 0 +study 0 +indicate 0 +that 0 +levofloxacin 1 +500 0 +mg 0 +once 0 +daily 0 +is 0 +an 0 +effective 0 +and 0 +safe 0 +treatment 0 +for 0 +acute 0 +bacterial 0 +sinusitis 3 +. 0 + +Iatrogenic 0 +risks 0 +of 0 +endometrial 3 +carcinoma 4 +after 0 +treatment 0 +for 0 +breast 3 +cancer 4 +in 0 +a 0 +large 0 +French 0 +case 0 +- 0 +control 0 +study 0 +. 0 + +F 0 +d 0 +ration 0 +Nationale 0 +des 0 +Centres 0 +de 0 +Lutte 0 +Contre 0 +le 0 +Cancer 0 +( 0 +FNCLCC 0 +) 0 +. 0 + +Since 0 +tamoxifen 1 +is 0 +widely 0 +used 0 +in 0 +breast 3 +cancer 4 +treatment 0 +and 0 +has 0 +been 0 +proposed 0 +for 0 +the 0 +prevention 0 +of 0 +breast 3 +cancer 4 +, 0 +its 0 +endometrial 0 +iatrogenic 0 +effects 0 +must 0 +be 0 +carefully 0 +examined 0 +. 0 + +We 0 +have 0 +investigated 0 +the 0 +association 0 +between 0 +endometrial 3 +cancer 4 +and 0 +tamoxifen 1 +use 0 +or 0 +other 0 +treatments 0 +in 0 +women 0 +treated 0 +for 0 +breast 3 +cancer 4 +in 0 +a 0 +case 0 +- 0 +control 0 +study 0 +. 0 + +Cases 0 +of 0 +endometrial 3 +cancer 4 +diagnosed 0 +after 0 +breast 3 +cancer 4 +( 0 +n 0 += 0 +135 0 +) 0 +and 0 +467 0 +controls 0 +matched 0 +for 0 +age 0 +, 0 +year 0 +of 0 +diagnosis 0 +of 0 +breast 3 +cancer 4 +and 0 +hospital 0 +and 0 +survival 0 +time 0 +with 0 +an 0 +intact 0 +uterus 0 +were 0 +included 0 +. 0 + +Women 0 +who 0 +had 0 +received 0 +tamoxifen 1 +were 0 +significantly 0 +more 0 +likely 0 +to 0 +have 0 +endometrial 3 +cancer 4 +diagnosed 0 +than 0 +those 0 +who 0 +had 0 +not 0 +( 0 +crude 0 +relative 0 +risk 0 += 0 +4 0 +. 0 +9 0 +, 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +Univariate 0 +and 0 +adjusted 0 +analyses 0 +showed 0 +that 0 +the 0 +risk 0 +increased 0 +with 0 +the 0 +length 0 +of 0 +treatment 0 +( 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +or 0 +the 0 +cumulative 0 +dose 0 +of 0 +tamoxifen 1 +received 0 +( 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +, 0 +irrespective 0 +of 0 +the 0 +daily 0 +dose 0 +. 0 + +Women 0 +who 0 +had 0 +undergone 0 +pelvic 0 +radiotherapy 0 +also 0 +had 0 +a 0 +higher 0 +risk 0 +( 0 +crude 0 +relative 0 +risk 0 += 0 +7 0 +. 0 +8 0 +, 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +After 0 +adjusting 0 +for 0 +confounding 0 +factors 0 +, 0 +the 0 +risk 0 +was 0 +higher 0 +for 0 +tamoxifen 1 +users 0 +( 0 +p 0 += 0 +0 0 +. 0 +0012 0 +) 0 +, 0 +treatment 0 +for 0 +more 0 +than 0 +3 0 +years 0 +( 0 +all 0 +p 0 +< 0 +0 0 +. 0 +03 0 +) 0 +and 0 +pelvic 0 +radiotherapy 0 +( 0 +p 0 += 0 +0 0 +. 0 +012 0 +) 0 +. 0 + +Women 0 +who 0 +had 0 +endometrial 3 +cancer 4 +and 0 +had 0 +received 0 +tamoxifen 1 +had 0 +more 0 +advanced 3 +disease 4 +and 0 +poorer 0 +prognosis 0 +than 0 +those 0 +with 0 +endometrial 3 +cancer 4 +who 0 +had 0 +not 0 +received 0 +this 0 +treatment 0 +. 0 + +0ur 0 +results 0 +suggest 0 +a 0 +causal 0 +role 0 +of 0 +tamoxifen 1 +in 0 +endometrial 3 +cancer 4 +, 0 +particularly 0 +when 0 +used 0 +as 0 +currently 0 +proposed 0 +for 0 +breast 3 +cancer 4 +prevention 0 +. 0 + +Pelvic 0 +radiotherapy 0 +may 0 +be 0 +an 0 +additional 0 +iatrogenic 0 +factor 0 +for 0 +women 0 +with 0 +breast 3 +cancer 4 +. 0 + +Endometrial 3 +cancers 4 +diagnosed 0 +in 0 +women 0 +treated 0 +with 0 +tamoxifen 1 +have 0 +poorer 0 +prognosis 0 +. 0 + +Women 0 +who 0 +receive 0 +tamoxifen 1 +for 0 +breast 3 +cancer 4 +should 0 +be 0 +offered 0 +gynaecological 0 +surveillance 0 +during 0 +and 0 +after 0 +treatment 0 +. 0 + +A 0 +long 0 +- 0 +term 0 +evaluation 0 +of 0 +the 0 +risk 0 +- 0 +benefit 0 +ratio 0 +of 0 +tamoxifen 1 +as 0 +a 0 +preventive 0 +treatment 0 +for 0 +breast 3 +cancer 4 +is 0 +clearly 0 +warranted 0 +. 0 + +Contribution 0 +of 0 +the 0 +glycine 1 +site 0 +of 0 +NMDA 1 +receptors 0 +in 0 +rostral 0 +and 0 +intermediate 0 +- 0 +caudal 0 +parts 0 +of 0 +the 0 +striatum 0 +to 0 +the 0 +regulation 0 +of 0 +muscle 0 +tone 0 +in 0 +rats 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +contribution 0 +of 0 +the 0 +glycine 1 +site 0 +of 0 +NMDA 1 +receptors 0 +in 0 +the 0 +striatum 0 +to 0 +the 0 +regulation 0 +of 0 +muscle 0 +tone 0 +. 0 + +Muscle 0 +tone 0 +was 0 +examined 0 +using 0 +a 0 +combined 0 +mechanoand 0 +electromyographic 0 +method 0 +, 0 +which 0 +measured 0 +simultaneously 0 +the 0 +muscle 0 +resistance 0 +( 0 +MMG 0 +) 0 +of 0 +the 0 +rat 0 +' 0 +s 0 +hind 0 +foot 0 +to 0 +passive 0 +extension 0 +and 0 +flexion 0 +in 0 +the 0 +ankle 0 +joint 0 +and 0 +the 0 +electromyographic 0 +activity 0 +( 0 +EMG 0 +) 0 +of 0 +the 0 +antagonistic 0 +muscles 0 +of 0 +that 0 +joint 0 +: 0 +gastrocnemius 0 +and 0 +tibialis 0 +anterior 0 +. 0 + +Muscle 3 +rigidity 4 +was 0 +induced 0 +by 0 +haloperidol 1 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +5 1 +, 2 +7 2 +- 2 +dichlorokynurenic 2 +acid 2 +( 0 +5 1 +, 2 +7 2 +- 2 +DCKA 2 +) 0 +, 0 +a 0 +selective 0 +glycine 1 +site 0 +antagonist 0 +, 0 +injected 0 +in 0 +doses 0 +of 0 +2 0 +. 0 +5 0 +and 0 +4 0 +. 0 +5 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +bilaterally 0 +, 0 +into 0 +the 0 +rostral 0 +region 0 +of 0 +the 0 +striatum 0 +, 0 +decreased 0 +both 0 +the 0 +haloperidol 1 +- 0 +induced 0 +muscle 3 +rigidity 4 +( 0 +MMG 0 +) 0 +and 0 +the 0 +enhanced 0 +electromyographic 0 +activity 0 +( 0 +EMG 0 +) 0 +. 0 + +5 1 +, 2 +7 2 +- 2 +DCKA 2 +injected 0 +bilaterally 0 +in 0 +a 0 +dose 0 +of 0 +4 0 +. 0 +5 0 +microg 0 +/ 0 +0 0 +. 0 +5 0 +microl 0 +into 0 +the 0 +intermediate 0 +- 0 +caudal 0 +region 0 +of 0 +the 0 +striatum 0 +of 0 +rats 0 +not 0 +pretreated 0 +with 0 +haloperidol 1 +had 0 +no 0 +effect 0 +on 0 +the 0 +muscle 0 +tone 0 +. 0 + +The 0 +present 0 +results 0 +suggest 0 +that 0 +blockade 0 +of 0 +the 0 +glycine 1 +site 0 +of 0 +NMDA 1 +receptors 0 +in 0 +the 0 +rostral 0 +part 0 +of 0 +the 0 +striatum 0 +may 0 +be 0 +mainly 0 +responsible 0 +for 0 +the 0 +antiparkinsonian 0 +action 0 +of 0 +this 0 +drug 0 +. 0 + +Carboplatin 1 +toxic 0 +effects 0 +on 0 +the 0 +peripheral 0 +nervous 0 +system 0 +of 0 +the 0 +rat 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +most 0 +striking 0 +of 0 +carboplatin 1 +' 0 +s 0 +advantages 0 +( 0 +CBDCA 1 +) 0 +over 0 +cisplatin 1 +( 0 +CDDP 1 +) 0 +is 0 +its 0 +markedly 0 +reduced 0 +rate 0 +of 0 +neurotoxic 3 +effects 0 +. 0 + +However 0 +, 0 +the 0 +use 0 +of 0 +CBDCA 1 +higher 0 +- 0 +intensity 0 +schedules 0 +and 0 +the 0 +association 0 +with 0 +other 0 +neurotoxic 3 +drugs 0 +in 0 +polychemotherapy 0 +may 0 +cause 0 +some 0 +concern 0 +about 0 +its 0 +safety 0 +with 0 +respect 0 +to 0 +peripheral 3 +nervous 4 +system 4 +damage 4 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +Two 0 +different 0 +schedules 0 +of 0 +CBDCA 1 +administration 0 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +and 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +twice 0 +a 0 +week 0 +for 0 +nine 0 +times 0 +) 0 +were 0 +evaluated 0 +in 0 +Wistar 0 +rats 0 +. 0 + +Neurotoxicity 3 +was 0 +assessed 0 +for 0 +behavioral 0 +( 0 +tail 0 +- 0 +flick 0 +test 0 +) 0 +, 0 +neurophysiological 0 +( 0 +nerve 0 +conduction 0 +velocity 0 +in 0 +the 0 +tail 0 +nerve 0 +) 0 +, 0 +morphological 0 +, 0 +morphometrical 0 +and 0 +analytical 0 +effects 0 +. 0 + +RESULTS 0 +: 0 +CBDCA 1 +administration 0 +induced 0 +dose 0 +- 0 +dependent 0 +peripheral 3 +neurotoxicity 4 +. 0 + +Pain 3 +perception 0 +and 0 +nerve 0 +conduction 0 +velocity 0 +in 0 +the 0 +tail 0 +were 0 +significantly 0 +impaired 0 +, 0 +particularly 0 +after 0 +the 0 +high 0 +- 0 +dose 0 +treatment 0 +. 0 + +The 0 +dorsal 0 +root 0 +ganglia 0 +sensory 0 +neurons 0 +and 0 +, 0 +to 0 +a 0 +lesser 0 +extent 0 +, 0 +satellite 0 +cells 0 +showed 0 +the 0 +same 0 +changes 0 +as 0 +those 0 +induced 0 +by 0 +CDDP 1 +, 0 +mainly 0 +affecting 0 +the 0 +nucleus 0 +and 0 +nucleolus 0 +of 0 +ganglionic 0 +sensory 0 +neurons 0 +. 0 + +Moreover 0 +, 0 +significant 0 +amounts 0 +of 0 +platinum 1 +were 0 +detected 0 +in 0 +the 0 +dorsal 0 +root 0 +ganglia 0 +and 0 +kidney 0 +after 0 +CBDCA 1 +treatment 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +CBDCA 1 +is 0 +neurotoxic 3 +in 0 +our 0 +model 0 +, 0 +and 0 +the 0 +type 0 +of 0 +pathological 0 +changes 0 +it 0 +induces 0 +are 0 +so 0 +closely 0 +similar 0 +to 0 +those 0 +caused 0 +by 0 +CDDP 1 +that 0 +it 0 +is 0 +probable 0 +that 0 +neurotoxicity 3 +is 0 +induced 0 +in 0 +the 0 +two 0 +drugs 0 +by 0 +the 0 +same 0 +mechanism 0 +. 0 + +This 0 +model 0 +can 0 +be 0 +used 0 +alone 0 +or 0 +in 0 +combination 0 +with 0 +other 0 +drugs 0 +to 0 +explore 0 +the 0 +effect 0 +of 0 +CBDCA 1 +on 0 +the 0 +peripheral 0 +nervous 0 +system 0 +. 0 + +Effects 0 +of 0 +cisapride 1 +on 0 +symptoms 0 +and 0 +postcibal 0 +small 0 +- 0 +bowel 0 +motor 0 +function 0 +in 0 +patients 0 +with 0 +irritable 3 +bowel 4 +syndrome 4 +. 0 + +BACKGR0UND 0 +: 0 +Irritable 3 +bowel 4 +syndrome 4 +is 0 +a 0 +common 0 +cause 0 +of 0 +abdominal 3 +pain 4 +and 0 +discomfort 0 +and 0 +may 0 +be 0 +related 0 +to 0 +disordered 3 +gastrointestinal 4 +motility 4 +. 0 + +0ur 0 +aim 0 +was 0 +to 0 +assess 0 +the 0 +effects 0 +of 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +a 0 +prokinetic 0 +agent 0 +, 0 +cisapride 1 +, 0 +on 0 +postprandial 0 +jejunal 0 +motility 0 +and 0 +symptoms 0 +in 0 +the 0 +irritable 3 +bowel 4 +syndrome 4 +( 0 +IBS 3 +) 0 +. 0 + +METH0DS 0 +: 0 +Thirty 0 +- 0 +eight 0 +patients 0 +with 0 +IBS 3 +( 0 +constipation 3 +- 0 +predominant 0 +, 0 +n 0 += 0 +17 0 +; 0 +diarrhoea 3 +- 0 +predominant 0 +, 0 +n 0 += 0 +21 0 +) 0 +underwent 0 +24 0 +- 0 +h 0 +ambulatory 0 +jejunal 0 +manometry 0 +before 0 +and 0 +after 0 +12 0 +week 0 +' 0 +s 0 +treatment 0 +[ 0 +cisapride 1 +, 0 +5 0 +mg 0 +three 0 +times 0 +daily 0 +( 0 +n 0 += 0 +19 0 +) 0 +or 0 +placebo 0 +( 0 +n 0 += 0 +19 0 +) 0 +] 0 +. 0 + +RESULTS 0 +: 0 +In 0 +diarrhoea 3 +- 0 +predominant 0 +patients 0 +significant 0 +differences 0 +in 0 +contraction 0 +characteristics 0 +were 0 +observed 0 +between 0 +the 0 +cisapride 1 +and 0 +placebo 0 +groups 0 +. 0 + +In 0 +cisapride 1 +- 0 +treated 0 +diarrhoea 3 +- 0 +predominant 0 +patients 0 +the 0 +mean 0 +contraction 0 +amplitude 0 +was 0 +higher 0 +( 0 +29 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +2 0 +versus 0 +24 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +6 0 +mm 0 +Hg 0 +, 0 +cisapride 1 +versus 0 +placebo 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +; 0 +pretreatment 0 +, 0 +25 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +0 0 +mm 0 +Hg 0 +) 0 +, 0 +the 0 +mean 0 +contraction 0 +duration 0 +longer 0 +( 0 +3 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +versus 0 +3 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +sec 0 +, 0 +cisapride 1 +versus 0 +placebo 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +; 0 +pretreatment 0 +, 0 +3 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +sec 0 +) 0 +, 0 +and 0 +the 0 +mean 0 +contraction 0 +frequency 0 +lower 0 +( 0 +2 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +versus 0 +2 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +cont 0 +. 0 +/ 0 +min 0 +, 0 +cisapride 1 +versus 0 +placebo 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +; 0 +pretreatment 0 +, 0 +2 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +1 0 +cont 0 +. 0 +/ 0 +min 0 +] 0 +than 0 +patients 0 +treated 0 +with 0 +placebo 0 +. 0 + +No 0 +significant 0 +differences 0 +in 0 +jejunal 0 +motility 0 +were 0 +found 0 +in 0 +the 0 +constipation 3 +- 0 +predominant 0 +IBS 3 +group 0 +. 0 + +Symptoms 0 +were 0 +assessed 0 +by 0 +using 0 +a 0 +visual 0 +analogue 0 +scale 0 +before 0 +and 0 +after 0 +treatment 0 +. 0 + +Symptom 0 +scores 0 +relating 0 +to 0 +the 0 +severity 0 +of 0 +constipation 3 +were 0 +lower 0 +in 0 +cisapride 1 +- 0 +treated 0 +constipation 3 +- 0 +predominant 0 +IBS 3 +patients 0 +[ 0 +score 0 +, 0 +54 0 ++ 0 +/ 0 +- 0 +5 0 +versus 0 +67 0 ++ 0 +/ 0 +- 0 +14 0 +mm 0 +, 0 +cisapride 1 +versus 0 +placebo 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +; 0 +pretreatment 0 +, 0 +62 0 ++ 0 +/ 0 +- 0 +19 0 +mm 0 +] 0 +. 0 + +Diarrhoea 3 +- 0 +predominant 0 +IBS 3 +patients 0 +had 0 +a 0 +higher 0 +pain 3 +score 0 +after 0 +cisapride 1 +therapy 0 +[ 0 +score 0 +, 0 +55 0 ++ 0 +/ 0 +- 0 +15 0 +versus 0 +34 0 ++ 0 +/ 0 +- 0 +12 0 +mm 0 +, 0 +cisapride 1 +versus 0 +placebo 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +; 0 +pretreatment 0 +, 0 +67 0 ++ 0 +/ 0 +- 0 +19 0 +mm 0 +] 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Cisapride 1 +affects 0 +jejunal 0 +contraction 0 +characteristics 0 +and 0 +some 0 +symptoms 0 +in 0 +IBS 3 +. 0 + +Prevention 0 +of 0 +breast 3 +cancer 4 +with 0 +tamoxifen 1 +: 0 +preliminary 0 +findings 0 +from 0 +the 0 +Italian 0 +randomised 0 +trial 0 +among 0 +hysterectomised 0 +women 0 +. 0 + +Italian 0 +Tamoxifen 1 +Prevention 0 +Study 0 +. 0 + +BACKGR0UND 0 +: 0 +Tamoxifen 1 +is 0 +a 0 +candidate 0 +chemopreventive 0 +agent 0 +in 0 +breast 3 +cancer 4 +, 0 +although 0 +the 0 +drug 0 +may 0 +be 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +endometrial 3 +cancer 4 +. 0 + +Therefore 0 +we 0 +did 0 +a 0 +trial 0 +in 0 +hysterectomised 0 +women 0 +of 0 +tamoxifen 1 +as 0 +a 0 +chemopreventive 0 +. 0 + +METH0DS 0 +: 0 +In 0 +0ctober 0 +, 0 +1992 0 +, 0 +we 0 +started 0 +a 0 +double 0 +- 0 +blind 0 +placebo 0 +- 0 +controlled 0 +, 0 +randomised 0 +trial 0 +of 0 +tamoxifen 1 +in 0 +women 0 +( 0 +mainly 0 +in 0 +Italy 0 +) 0 +who 0 +did 0 +not 0 +have 0 +breast 3 +cancer 4 +and 0 +who 0 +had 0 +had 0 +a 0 +hysterectomy 0 +. 0 + +Women 0 +were 0 +randomised 0 +to 0 +receive 0 +tamoxifen 1 +20 0 +mg 0 +per 0 +day 0 +or 0 +placebo 0 +, 0 +both 0 +orally 0 +for 0 +5 0 +years 0 +. 0 + +The 0 +original 0 +plan 0 +was 0 +to 0 +follow 0 +the 0 +intervention 0 +phase 0 +by 0 +5 0 +years 0 +' 0 +follow 0 +- 0 +up 0 +. 0 + +In 0 +June 0 +, 0 +1997 0 +, 0 +the 0 +trialists 0 +and 0 +the 0 +data 0 +- 0 +monitoring 0 +committee 0 +decided 0 +to 0 +end 0 +recruitment 0 +primarily 0 +because 0 +of 0 +the 0 +number 0 +of 0 +women 0 +dropping 0 +out 0 +of 0 +the 0 +study 0 +. 0 + +Recruitment 0 +ended 0 +on 0 +July 0 +11 0 +, 0 +1997 0 +, 0 +and 0 +the 0 +study 0 +will 0 +continue 0 +as 0 +planned 0 +. 0 + +The 0 +primary 0 +endpoints 0 +are 0 +the 0 +occurrence 0 +of 0 +and 0 +deaths 0 +from 0 +breast 3 +cancer 4 +. 0 + +This 0 +preliminary 0 +interim 0 +analysis 0 +is 0 +based 0 +on 0 +intention 0 +- 0 +to 0 +- 0 +treat 0 +. 0 + +FINDINGS 0 +: 0 +5408 0 +women 0 +were 0 +randomised 0 +; 0 +participating 0 +women 0 +have 0 +a 0 +median 0 +follow 0 +- 0 +up 0 +of 0 +46 0 +months 0 +for 0 +major 0 +endpoints 0 +. 0 + +41 0 +cases 0 +of 0 +breast 3 +cancer 4 +occurred 0 +so 0 +far 0 +; 0 +there 0 +have 0 +been 0 +no 0 +deaths 0 +from 0 +breast 3 +cancer 4 +. 0 + +There 0 +is 0 +no 0 +difference 0 +in 0 +breast 3 +- 4 +cancer 4 +frequency 0 +between 0 +the 0 +placebo 0 +( 0 +22 0 +cases 0 +) 0 +and 0 +tamoxifen 1 +( 0 +19 0 +) 0 +arms 0 +. 0 + +There 0 +is 0 +a 0 +statistically 0 +significant 0 +reduction 0 +of 0 +breast 3 +cancer 4 +among 0 +women 0 +receiving 0 +tamoxifen 1 +who 0 +also 0 +used 0 +hormone 0 +- 0 +replacement 0 +therapy 0 +during 0 +the 0 +trial 0 +: 0 +among 0 +390 0 +women 0 +on 0 +such 0 +therapy 0 +and 0 +allocated 0 +to 0 +placebo 0 +, 0 +we 0 +found 0 +eight 0 +cases 0 +of 0 +breast 3 +cancer 4 +compared 0 +with 0 +one 0 +case 0 +among 0 +362 0 +women 0 +allocated 0 +to 0 +tamoxifen 1 +. 0 + +Compared 0 +with 0 +the 0 +placebo 0 +group 0 +, 0 +there 0 +was 0 +a 0 +significantly 0 +increased 0 +risk 0 +of 0 +vascular 3 +events 4 +and 0 +hypertriglyceridaemia 3 +among 0 +women 0 +on 0 +tamoxifen 1 +. 0 + +INTERPRETATI0N 0 +: 0 +Although 0 +this 0 +preliminary 0 +analysis 0 +has 0 +low 0 +power 0 +, 0 +in 0 +this 0 +cohort 0 +of 0 +women 0 +at 0 +low 0 +- 0 +to 0 +- 0 +normal 0 +risk 0 +of 0 +breast 3 +cancer 4 +, 0 +the 0 +postulated 0 +protective 0 +effects 0 +of 0 +tamoxifen 1 +are 0 +not 0 +yet 0 +apparent 0 +. 0 + +Women 0 +using 0 +hormone 0 +- 0 +replacement 0 +therapy 0 +appear 0 +to 0 +have 0 +benefited 0 +from 0 +use 0 +of 0 +tamoxifen 1 +. 0 + +There 0 +were 0 +no 0 +deaths 0 +from 0 +breast 3 +cancer 4 +recorded 0 +in 0 +women 0 +in 0 +the 0 +study 0 +. 0 + +It 0 +is 0 +essential 0 +to 0 +continue 0 +follow 0 +- 0 +up 0 +to 0 +quantify 0 +the 0 +long 0 +- 0 +term 0 +risks 0 +and 0 +benefits 0 +of 0 +tamoxifen 1 +therapy 0 +. 0 + +Epileptogenic 0 +activity 0 +of 0 +folic 1 +acid 2 +after 0 +drug 0 +induces 0 +SLE 3 +( 0 +folic 1 +acid 2 +and 0 +epilepsy 3 +) 0 + +0BJECTIVE 0 +: 0 +To 0 +study 0 +the 0 +effect 0 +of 0 +folic 1 +acid 2 +- 0 +containing 0 +multivitamin 0 +supplementation 0 +in 0 +epileptic 3 +women 0 +before 0 +and 0 +during 0 +pregnancy 0 +in 0 +order 0 +to 0 +determine 0 +the 0 +rate 0 +of 0 +structural 0 +birth 3 +defects 4 +and 0 +epilepsy 3 +- 0 +related 0 +side 0 +effects 0 +. 0 + +STUDY 0 +DESIGN 0 +: 0 +First 0 +a 0 +randomised 0 +trial 0 +, 0 +later 0 +periconception 0 +care 0 +including 0 +in 0 +total 0 +12225 0 +females 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +60 0 +epileptic 3 +women 0 +with 0 +periconceptional 0 +folic 1 +acid 2 +( 0 +0 0 +. 0 +8 0 +mg 0 +) 0 +- 0 +containing 0 +multivitamin 0 +supplementation 0 +, 0 +no 0 +one 0 +developed 0 +epilepsy 3 +- 0 +related 0 +side 0 +effects 0 +during 0 +the 0 +periconception 0 +period 0 +. 0 + +0ne 0 +epileptic 3 +woman 0 +delivered 0 +a 0 +newborn 0 +with 0 +cleft 3 +lip 4 +and 4 +palate 4 +. 0 + +Another 0 +patient 0 +exhibited 0 +with 0 +a 0 +cluster 0 +of 0 +seizures 3 +after 0 +the 0 +periconception 0 +period 0 +using 0 +another 0 +multivitamin 0 +. 0 + +This 0 +22 0 +- 0 +year 0 +- 0 +old 0 +epileptic 3 +woman 0 +was 0 +treated 0 +continuously 0 +by 0 +carbamazepine 1 +and 0 +a 0 +folic 1 +acid 2 +( 0 +1 0 +mg 0 +) 0 +- 0 +containing 0 +multivitamin 0 +from 0 +the 0 +20th 0 +week 0 +of 0 +gestation 0 +. 0 + +She 0 +developed 0 +status 3 +epilepticus 4 +and 0 +later 0 +symptoms 0 +of 0 +systemic 3 +lupus 4 +erythematodes 4 +. 0 + +Her 0 +pregnancy 0 +ended 0 +with 0 +stillbirth 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +epileptic 3 +pregnant 0 +patient 0 +' 0 +s 0 +autoimmune 3 +disease 4 +( 0 +probably 0 +drug 0 +- 0 +induced 0 +lupus 3 +) 0 +could 0 +damage 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +, 0 +therefore 0 +the 0 +therapeutic 0 +dose 0 +( 0 +> 0 +or 0 += 0 +1 0 +mg 0 +) 0 +of 0 +folic 1 +acid 2 +triggered 0 +a 0 +cluster 0 +of 0 +seizures 3 +. 0 + +Physiological 0 +dose 0 +( 0 +< 0 +1 0 +mg 0 +) 0 +of 0 +folic 1 +acid 2 +both 0 +in 0 +healthy 0 +and 0 +60 0 +epileptic 3 +women 0 +, 0 +all 0 +without 0 +any 0 +autoimmune 3 +disease 4 +, 0 +did 0 +not 0 +increase 0 +the 0 +risk 0 +for 0 +epileptic 3 +seizures 4 +. 0 + +Stroke 3 +and 0 +cocaine 1 +or 0 +amphetamine 1 +use 0 +. 0 + +The 0 +association 0 +of 0 +cocaine 1 +and 0 +amphetamine 1 +use 0 +with 0 +hemorrhagic 0 +and 0 +ischemic 3 +stroke 3 +is 0 +based 0 +almost 0 +solely 0 +on 0 +data 0 +from 0 +case 0 +series 0 +. 0 + +The 0 +limited 0 +number 0 +of 0 +epidemiologic 0 +studies 0 +of 0 +stroke 3 +and 0 +use 0 +of 0 +cocaine 1 +and 0 +/ 0 +or 0 +amphetamine 1 +have 0 +been 0 +done 0 +in 0 +settings 0 +that 0 +serve 0 +mostly 0 +the 0 +poor 0 +and 0 +/ 0 +or 0 +minorities 0 +. 0 + +This 0 +case 0 +- 0 +control 0 +study 0 +was 0 +conducted 0 +in 0 +the 0 +defined 0 +population 0 +comprising 0 +members 0 +of 0 +Kaiser 0 +Permanente 0 +of 0 +Northern 0 +and 0 +Southern 0 +California 0 +. 0 + +We 0 +attempted 0 +to 0 +identify 0 +all 0 +incident 0 +strokes 3 +in 0 +women 0 +ages 0 +15 0 +- 0 +44 0 +years 0 +during 0 +a 0 +3 0 +- 0 +year 0 +period 0 +using 0 +hospital 0 +admission 0 +and 0 +discharge 0 +records 0 +, 0 +emergency 0 +department 0 +logs 0 +, 0 +and 0 +payment 0 +requests 0 +for 0 +out 0 +- 0 +of 0 +- 0 +plan 0 +hospitalizations 0 +. 0 + +We 0 +selected 0 +controls 0 +, 0 +matched 0 +on 0 +age 0 +and 0 +facility 0 +of 0 +usual 0 +care 0 +, 0 +at 0 +random 0 +from 0 +healthy 0 +members 0 +of 0 +the 0 +health 0 +plan 0 +. 0 + +We 0 +obtained 0 +information 0 +in 0 +face 0 +- 0 +to 0 +- 0 +face 0 +interviews 0 +. 0 + +There 0 +were 0 +347 0 +confirmed 0 +stroke 3 +cases 0 +and 0 +1 0 +, 0 +021 0 +controls 0 +. 0 + +The 0 +univariate 0 +matched 0 +odds 0 +ratio 0 +for 0 +stroke 3 +in 0 +women 0 +who 0 +admitted 0 +to 0 +using 0 +cocaine 1 +and 0 +/ 0 +or 0 +amphetamine 1 +was 0 +8 0 +. 0 +5 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 += 0 +3 0 +. 0 +6 0 +- 0 +20 0 +. 0 +0 0 +) 0 +. 0 + +After 0 +further 0 +adjustment 0 +for 0 +potential 0 +confounders 0 +, 0 +the 0 +odds 0 +ratio 0 +in 0 +women 0 +who 0 +reported 0 +using 0 +cocaine 1 +and 0 +/ 0 +or 0 +amphetamine 1 +was 0 +7 0 +. 0 +0 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 += 0 +2 0 +. 0 +8 0 +- 0 +17 0 +. 0 +9 0 +) 0 +. 0 + +The 0 +use 0 +of 0 +cocaine 1 +and 0 +/ 0 +or 0 +amphetamine 1 +is 0 +a 0 +strong 0 +risk 0 +factor 0 +for 0 +stroke 3 +in 0 +this 0 +socioeconomically 0 +heterogeneous 0 +, 0 +insured 0 +urban 0 +population 0 +. 0 + +Acute 3 +renal 4 +failure 4 +subsequent 0 +to 0 +the 0 +administration 0 +of 0 +rifampicin 1 +. 0 + +A 0 +follow 0 +- 0 +up 0 +study 0 +of 0 +cases 0 +reported 0 +earlier 0 +. 0 + +A 0 +clinical 0 +presentation 0 +is 0 +made 0 +of 0 +a 0 +2 0 +- 0 +3 0 +year 0 +follow 0 +- 0 +up 0 +of 0 +six 0 +cases 0 +of 0 +acute 3 +renal 4 +failure 4 +that 0 +have 0 +been 0 +reported 0 +earlier 0 +. 0 + +The 0 +patients 0 +had 0 +developed 0 +transient 0 +renal 3 +failure 4 +after 0 +the 0 +intermittent 0 +administration 0 +of 0 +rifampicin 1 +. 0 + +The 0 +stage 0 +of 0 +olig 0 +- 0 +anuria 3 +lasted 0 +for 0 +1 0 +- 0 +3 0 +weeks 0 +, 0 +and 0 +five 0 +of 0 +the 0 +patients 0 +were 0 +treated 0 +by 0 +hemodialysis 0 +. 0 + +Two 0 +of 0 +the 0 +patients 0 +died 0 +due 0 +to 0 +unrelated 0 +causes 0 +during 0 +the 0 +follow 0 +- 0 +up 0 +period 0 +. 0 + +The 0 +four 0 +patients 0 +re 0 +- 0 +examined 0 +were 0 +clinically 0 +cured 0 +. 0 + +Pathologic 0 +findings 0 +by 0 +light 0 +microscopy 0 +and 0 +immunofluorescence 0 +at 0 +biopsy 0 +were 0 +scarce 0 +. 0 + +Nothing 0 +abnormal 0 +was 0 +seen 0 +by 0 +electron 0 +microscopy 0 +in 0 +two 0 +of 0 +the 0 +cases 0 +studied 0 +. 0 + +Renal 0 +function 0 +was 0 +normal 0 +. 0 + +In 0 +three 0 +cases 0 +the 0 +excretion 0 +at 0 +131I 0 +- 0 +hippuran 0 +renography 0 +was 0 +slightly 0 +slowed 0 +. 0 + +Although 0 +in 0 +the 0 +acute 0 +stage 0 +the 0 +renal 3 +lesions 4 +histologically 0 +appeared 0 +toxic 0 +, 0 +evidence 0 +suggestive 0 +of 0 +an 0 +immunological 0 +mechanism 0 +cannot 0 +be 0 +excluded 0 +. 0 + +Chronic 0 +effects 0 +of 0 +a 0 +novel 0 +synthetic 0 +anthracycline 1 +derivative 0 +( 0 +SM 1 +- 2 +5887 2 +) 0 +on 0 +normal 0 +heart 0 +and 0 +doxorubicin 1 +- 0 +induced 0 +cardiomyopathy 3 +in 0 +beagle 0 +dogs 0 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +investigate 0 +the 0 +chronic 0 +cardiotoxic 3 +potential 0 +of 0 +SM 1 +- 2 +5887 2 +and 0 +a 0 +possible 0 +deteriorating 0 +effect 0 +of 0 +SM 1 +- 2 +5887 2 +on 0 +low 0 +- 0 +grade 0 +cardiotoxicity 3 +pre 0 +- 0 +induced 0 +by 0 +doxorubicin 1 +in 0 +beagle 0 +dogs 0 +. 0 + +In 0 +the 0 +chronic 0 +treatment 0 +, 0 +beagle 0 +dogs 0 +of 0 +each 0 +sex 0 +were 0 +given 0 +intravenously 0 +once 0 +every 0 +3 0 +weeks 0 +, 0 +either 0 +a 0 +sublethal 0 +dose 0 +of 0 +doxorubicin 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +SM 1 +- 2 +5887 2 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +The 0 +experiment 0 +was 0 +terminated 0 +3 0 +weeks 0 +after 0 +the 0 +ninth 0 +dosing 0 +. 0 + +Animals 0 +which 0 +received 0 +over 0 +six 0 +courses 0 +of 0 +doxorubicin 1 +demonstrated 0 +the 0 +electrocardiogram 0 +( 0 +ECG 0 +) 0 +changes 0 +, 0 +decrease 0 +of 0 +blood 0 +pressure 0 +and 0 +high 0 +- 0 +grade 0 +histopathological 0 +cardiomyopathy 3 +, 0 +while 0 +animals 0 +which 0 +were 0 +terminally 0 +sacrificed 0 +after 0 +the 0 +SM 1 +- 2 +5887 2 +administration 0 +did 0 +not 0 +show 0 +any 0 +changes 0 +in 0 +ECG 0 +, 0 +blood 0 +pressure 0 +and 0 +histopathological 0 +examinations 0 +. 0 + +To 0 +examine 0 +a 0 +possibly 0 +deteriorating 0 +cardiotoxic 3 +effect 0 +of 0 +SM 1 +- 2 +5887 2 +, 0 +low 0 +- 0 +grade 0 +cardiomyopathy 3 +was 0 +induced 0 +in 0 +dogs 0 +by 0 +four 0 +courses 0 +of 0 +doxorubicin 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +Nine 0 +weeks 0 +after 0 +pre 0 +- 0 +treatment 0 +, 0 +dogs 0 +were 0 +given 0 +four 0 +courses 0 +of 0 +either 0 +doxorubicin 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +SM 1 +- 2 +5887 2 +( 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +once 0 +every 0 +3 0 +weeks 0 +. 0 + +The 0 +low 0 +- 0 +grade 0 +cardiotoxic 3 +changes 0 +were 0 +enhanced 0 +by 0 +the 0 +additional 0 +doxorubicin 1 +treatment 0 +. 0 + +0n 0 +the 0 +contrary 0 +, 0 +the 0 +SM 1 +- 2 +5887 2 +treatment 0 +did 0 +not 0 +progress 0 +the 0 +grade 0 +of 0 +cardiomyopathy 3 +. 0 + +In 0 +conclusion 0 +, 0 +SM 1 +- 2 +5887 2 +does 0 +not 0 +have 0 +any 0 +potential 0 +of 0 +chronic 0 +cardiotoxicity 3 +and 0 +deteriorating 0 +effect 0 +on 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +dogs 0 +. 0 + +Risk 0 +for 0 +valvular 3 +heart 4 +disease 4 +among 0 +users 0 +of 0 +fenfluramine 1 +and 0 +dexfenfluramine 1 +who 0 +underwent 0 +echocardiography 0 +before 0 +use 0 +of 0 +medication 0 +. 0 + +BACKGR0UND 0 +: 0 +Because 0 +uncontrolled 0 +echocardiographic 0 +surveys 0 +suggested 0 +that 0 +up 0 +to 0 +30 0 +% 0 +to 0 +38 0 +% 0 +of 0 +users 0 +of 0 +fenfluramine 1 +and 0 +dexfenfluramine 1 +had 0 +valvular 3 +disease 4 +, 0 +these 0 +drugs 0 +were 0 +withdrawn 0 +from 0 +the 0 +market 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +determine 0 +the 0 +risk 0 +for 0 +new 0 +or 0 +worsening 0 +valvular 3 +abnormalities 4 +among 0 +users 0 +of 0 +fenfluramine 1 +or 0 +dexfenfluramine 1 +who 0 +underwent 0 +echocardiography 0 +before 0 +they 0 +began 0 +to 0 +take 0 +these 0 +medications 0 +. 0 + +DESIGN 0 +: 0 +Cohort 0 +study 0 +. 0 + +SETTING 0 +: 0 +Academic 0 +primary 0 +care 0 +practices 0 +. 0 + +PATIENTS 0 +: 0 +46 0 +patients 0 +who 0 +used 0 +fenfluramine 1 +or 0 +dexfenfluramine 1 +for 0 +14 0 +days 0 +or 0 +more 0 +and 0 +had 0 +echocardiograms 0 +obtained 0 +before 0 +therapy 0 +. 0 + +MEASUREMENTS 0 +: 0 +Follow 0 +- 0 +up 0 +echocardiography 0 +. 0 + +The 0 +primary 0 +outcome 0 +was 0 +new 0 +or 0 +worsening 0 +valvulopathy 3 +, 0 +defined 0 +as 0 +progression 0 +of 0 +either 0 +aortic 3 +or 4 +mitral 4 +regurgitation 4 +by 0 +at 0 +least 0 +one 0 +degree 0 +of 0 +severity 0 +and 0 +disease 0 +that 0 +met 0 +U 0 +. 0 +S 0 +. 0 + +Food 0 +and 0 +Drug 0 +Administration 0 +criteria 0 +( 0 +at 0 +least 0 +mild 0 +aortic 3 +regurgitation 4 +or 0 +moderate 0 +mitral 3 +regurgitation 4 +) 0 +. 0 + +RESULTS 0 +: 0 +Two 0 +patients 0 +( 0 +4 0 +. 0 +3 0 +% 0 +[ 0 +95 0 +% 0 +CI 0 +, 0 +0 0 +. 0 +6 0 +% 0 +to 0 +14 0 +. 0 +8 0 +% 0 +] 0 +) 0 +receiving 0 +fenfluramine 1 +- 0 +phentermine 1 +developed 0 +valvular 3 +heart 4 +disease 4 +. 0 + +0ne 0 +had 0 +baseline 0 +bicuspid 3 +aortic 4 +valve 4 +and 0 +mild 0 +aortic 3 +regurgitation 4 +that 0 +progressed 0 +to 0 +moderate 0 +regurgitation 0 +. 0 + +The 0 +second 0 +patient 0 +developed 0 +new 0 +moderate 0 +aortic 3 +insufficiency 4 +. 0 + +C0NCLUSI0N 0 +: 0 +Users 0 +of 0 +diet 0 +medications 0 +are 0 +at 0 +risk 0 +for 0 +valvular 3 +heart 4 +disease 4 +. 0 + +However 0 +, 0 +the 0 +incidence 0 +may 0 +be 0 +lower 0 +than 0 +that 0 +reported 0 +previously 0 +. 0 + +Therapeutic 0 +drug 0 +monitoring 0 +of 0 +tobramycin 1 +: 0 +once 0 +- 0 +daily 0 +versus 0 +twice 0 +- 0 +daily 0 +dosage 0 +schedules 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +effect 0 +of 0 +dosage 0 +regimen 0 +( 0 +once 0 +- 0 +daily 0 +vs 0 +. 0 +twice 0 +- 0 +daily 0 +) 0 +of 0 +tobramicyn 1 +on 0 +steady 0 +- 0 +state 0 +serum 0 +concentrations 0 +and 0 +toxicity 3 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +Patients 0 +undergoing 0 +treatment 0 +with 0 +i 0 +. 0 +v 0 +. 0 +tobramycin 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +were 0 +randomised 0 +to 0 +two 0 +groups 0 +. 0 + +Group 0 +0D 0 +( 0 +n 0 += 0 +22 0 +) 0 +received 0 +a 0 +once 0 +- 0 +daily 0 +dose 0 +of 0 +tobramycin 1 +and 0 +group 0 +TD 0 +( 0 +n 0 += 0 +21 0 +) 0 +received 0 +the 0 +same 0 +dose 0 +divided 0 +into 0 +two 0 +doses 0 +daily 0 +. 0 + +Tobramycin 1 +serum 0 +concentrations 0 +( 0 +peak 0 +and 0 +trough 0 +) 0 +were 0 +measured 0 +by 0 +enzyme 0 +multiplied 0 +immunoassay 0 +. 0 + +The 0 +renal 0 +and 0 +auditory 0 +functions 0 +of 0 +the 0 +patients 0 +were 0 +monitored 0 +before 0 +, 0 +during 0 +and 0 +immediately 0 +after 0 +treatment 0 +. 0 + +RESULTS 0 +: 0 +The 0 +two 0 +groups 0 +were 0 +comparable 0 +with 0 +respect 0 +to 0 +sex 0 +, 0 +age 0 +, 0 +body 0 +weight 0 +and 0 +renal 0 +function 0 +. 0 + +No 0 +statistically 0 +significant 0 +differences 0 +were 0 +found 0 +in 0 +mean 0 +daily 0 +dose 0 +, 0 +duration 0 +of 0 +treatment 0 +, 0 +or 0 +cumulative 0 +dose 0 +. 0 + +Trough 0 +concentrations 0 +were 0 +< 0 +2 0 +g 0 +/ 0 +ml 0 +in 0 +the 0 +two 0 +groups 0 +( 0 +100 0 +% 0 +) 0 +. 0 + +Peak 0 +concentrations 0 +were 0 +> 0 +6 0 +microg 0 +/ 0 +ml 0 +in 0 +100 0 +% 0 +of 0 +the 0 +0D 0 +group 0 +and 0 +in 0 +67 0 +% 0 +of 0 +the 0 +TD 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Mean 0 +peak 0 +concentrations 0 +were 0 +markedly 0 +different 0 +: 0 +11 0 +. 0 +00 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +89 0 +microg 0 +/ 0 +ml 0 +in 0 +0D 0 +vs 0 +. 0 +6 0 +. 0 +53 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +45 0 +microg 0 +/ 0 +ml 0 +in 0 +TD 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +The 0 +pharmacokinetics 0 +parameters 0 +were 0 +: 0 +Ke 0 +, 0 +( 0 +0 0 +. 0 +15 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +03 0 +/ 0 +h 0 +in 0 +0D 0 +vs 0 +. 0 +0 0 +. 0 +24 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +06 0 +/ 0 +h 0 +in 0 +TD 0 +) 0 +, 0 +t1 0 +/ 0 +2 0 +, 0 +( 0 +4 0 +. 0 +95 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +41 0 +h 0 +in 0 +0D 0 +vs 0 +. 0 +3 0 +. 0 +07 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +71 0 +h 0 +in 0 +TD 0 +) 0 +, 0 +Vd 0 +( 0 +0 0 +. 0 +35 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +11 0 +l 0 +/ 0 +kg 0 +in 0 +0D 0 +vs 0 +. 0 +0 0 +. 0 +33 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +09 0 +l 0 +/ 0 +kg 0 +in 0 +TD 0 +) 0 +, 0 +Cl 0 +( 0 +0 0 +. 0 +86 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +29 0 +ml 0 +/ 0 +min 0 +/ 0 +kg 0 +in 0 +0D 0 +vs 0 +. 0 +1 0 +. 0 +28 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +33 0 +ml 0 +/ 0 +min 0 +/ 0 +kg 0 +in 0 +TD 0 +) 0 +. 0 + +Increased 0 +serum 0 +creatinine 1 +was 0 +observed 0 +in 0 +73 0 +% 0 +of 0 +patients 0 +in 0 +0D 0 +versus 0 +57 0 +% 0 +of 0 +patients 0 +in 0 +TD 0 +, 0 +without 0 +evidence 0 +of 0 +nephrotoxicity 3 +. 0 + +In 0 +TD 0 +group 0 +, 0 +three 0 +patients 0 +developed 0 +decreased 3 +auditory 4 +function 4 +, 0 +of 0 +which 0 +one 0 +presented 0 +with 0 +an 0 +auditory 3 +loss 4 +of 0 +- 0 +30 0 +dB 0 +, 0 +whereas 0 +in 0 +the 0 +0D 0 +group 0 +only 0 +one 0 +patient 0 +presented 0 +decreased 3 +auditory 4 +function 4 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +small 0 +study 0 +suggests 0 +that 0 +a 0 +once 0 +- 0 +daily 0 +dosing 0 +regimen 0 +of 0 +tobramycin 1 +is 0 +at 0 +least 0 +as 0 +effective 0 +as 0 +and 0 +is 0 +no 0 +more 0 +and 0 +possibly 0 +less 0 +toxic 0 +than 0 +the 0 +twice 0 +- 0 +daily 0 +regimen 0 +. 0 + +Using 0 +a 0 +single 0 +- 0 +dose 0 +therapy 0 +, 0 +peak 0 +concentration 0 +determination 0 +is 0 +not 0 +necessary 0 +, 0 +only 0 +trough 0 +samples 0 +should 0 +be 0 +monitored 0 +to 0 +ensure 0 +levels 0 +below 0 +2 0 +microg 0 +/ 0 +ml 0 +. 0 + +Enhanced 0 +bradycardia 3 +induced 0 +by 0 +beta 0 +- 0 +adrenoceptor 0 +antagonists 0 +in 0 +rats 0 +pretreated 0 +with 0 +isoniazid 1 +. 0 + +High 0 +doses 0 +of 0 +isoniazid 1 +increase 0 +hypotension 3 +induced 0 +by 0 +vasodilators 0 +and 0 +change 0 +the 0 +accompanying 0 +reflex 0 +tachycardia 3 +to 0 +bradycardia 3 +, 0 +an 0 +interaction 0 +attributed 0 +to 0 +decreased 0 +synthesis 0 +of 0 +brain 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +) 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +possible 0 +enhancement 0 +by 0 +isoniazid 1 +of 0 +bradycardia 3 +induced 0 +by 0 +beta 0 +- 0 +adrenoceptor 0 +antagonists 0 +was 0 +determined 0 +in 0 +rats 0 +anaesthetised 0 +with 0 +chloralose 1 +- 0 +urethane 1 +. 0 + +Isoniazid 1 +significantly 0 +increased 0 +bradycardia 3 +after 0 +propranolol 1 +, 0 +pindolol 1 +, 0 +labetalol 1 +and 0 +atenolol 1 +, 0 +as 0 +well 0 +as 0 +after 0 +clonidine 1 +, 0 +but 0 +not 0 +after 0 +hexamethonium 1 +or 0 +carbachol 1 +. 0 + +Enhancement 0 +was 0 +not 0 +observed 0 +in 0 +rats 0 +pretreated 0 +with 0 +methylatropine 1 +or 0 +previously 0 +vagotomised 0 +. 0 + +These 0 +results 0 +are 0 +compatible 0 +with 0 +interference 0 +by 0 +isoniazid 1 +with 0 +GABAergic 0 +inhibition 0 +of 0 +cardiac 0 +parasympathetic 0 +tone 0 +. 0 + +Such 0 +interference 0 +could 0 +be 0 +exerted 0 +centrally 0 +, 0 +possibly 0 +at 0 +the 0 +nucleus 0 +ambiguus 0 +, 0 +or 0 +peripherally 0 +at 0 +the 0 +sinus 0 +node 0 +. 0 + +Structural 3 +and 4 +functional 4 +impairment 4 +of 4 +mitochondria 4 +in 0 +adriamycin 1 +- 0 +induced 0 +cardiomyopathy 3 +in 0 +mice 0 +: 0 +suppression 0 +of 0 +cytochrome 0 +c 0 +oxidase 0 +II 0 +gene 0 +expression 0 +. 0 + +The 0 +use 0 +of 0 +adriamycin 1 +( 0 +ADR 1 +) 0 +in 0 +cancer 3 +chemotherapy 0 +has 0 +been 0 +limited 0 +due 0 +to 0 +its 0 +cumulative 0 +cardiovascular 3 +toxicity 4 +. 0 + +Earlier 0 +observations 0 +that 0 +ADR 1 +interacts 0 +with 0 +mitochondrial 0 +cytochrome 0 +c 0 +oxidase 0 +( 0 +C0X 0 +) 0 +and 0 +suppresses 0 +its 0 +enzyme 0 +activity 0 +led 0 +us 0 +to 0 +investigate 0 +ADR 1 +' 0 +s 0 +action 0 +on 0 +the 0 +cardiovascular 0 +functions 0 +and 0 +heart 0 +mitochondrial 0 +morphology 0 +in 0 +Balb 0 +- 0 +c 0 +mice 0 +i 0 +. 0 +p 0 +. 0 +treated 0 +with 0 +ADR 1 +for 0 +several 0 +weeks 0 +. 0 + +At 0 +various 0 +times 0 +during 0 +treatment 0 +, 0 +the 0 +animals 0 +were 0 +assessed 0 +for 0 +cardiovascular 0 +functions 0 +by 0 +electrocardiography 0 +and 0 +for 0 +heart 0 +tissue 0 +damage 0 +by 0 +electron 0 +microscopy 0 +. 0 + +In 0 +parallel 0 +, 0 +total 0 +RNA 0 +was 0 +extracted 0 +from 0 +samples 0 +of 0 +dissected 0 +heart 0 +and 0 +analyzed 0 +by 0 +Northern 0 +blot 0 +hybridization 0 +to 0 +determine 0 +the 0 +steady 0 +- 0 +state 0 +level 0 +of 0 +three 0 +RNA 0 +transcripts 0 +encoded 0 +by 0 +the 0 +C0XII 0 +, 0 +C0XIII 0 +, 0 +and 0 +C0XIV 0 +genes 0 +. 0 + +Similarly 0 +, 0 +samples 0 +obtained 0 +from 0 +the 0 +liver 0 +of 0 +the 0 +same 0 +animals 0 +were 0 +analyzed 0 +for 0 +comparative 0 +studies 0 +. 0 + +0ur 0 +results 0 +indicated 0 +that 0 +1 0 +) 0 +treatment 0 +of 0 +mice 0 +with 0 +ADR 1 +caused 0 +cardiovascular 3 +arrhythmias 4 +characterized 0 +by 0 +bradycardia 3 +, 0 +extension 0 +of 0 +ventricular 0 +depolarization 0 +time 0 +( 0 +tQRS 0 +) 0 +, 0 +and 0 +failure 0 +of 0 +QRS 0 +at 0 +high 0 +concentrations 0 +( 0 +10 0 +- 0 +14 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +cumulative 0 +dose 0 +) 0 +; 0 +2 0 +) 0 +the 0 +heart 0 +mitochondria 0 +underwent 0 +swelling 3 +, 0 +fusion 0 +, 0 +dissolution 0 +, 0 +and 0 +/ 0 +or 0 +disruption 0 +of 0 +mitochondrial 0 +cristae 0 +after 0 +several 0 +weeks 0 +of 0 +treatment 0 +. 0 + +Such 0 +abnormalities 0 +were 0 +not 0 +observed 0 +in 0 +the 0 +mitochondria 0 +of 0 +liver 0 +tissue 0 +; 0 +and 0 +3 0 +) 0 +among 0 +the 0 +three 0 +genes 0 +of 0 +C0X 0 +enzyme 0 +examined 0 +, 0 +only 0 +C0XII 0 +gene 0 +expression 0 +was 0 +suppressed 0 +by 0 +ADR 1 +treatment 0 +, 0 +mainly 0 +after 0 +8 0 +weeks 0 +in 0 +both 0 +heart 0 +and 0 +liver 0 +. 0 + +Knowing 0 +that 0 +heart 0 +mitochondria 0 +represent 0 +almost 0 +40 0 +% 0 +of 0 +heart 0 +muscle 0 +by 0 +weight 0 +, 0 +we 0 +conclude 0 +that 0 +the 0 +deteriorating 0 +effects 0 +of 0 +ADR 1 +on 0 +cardiovascular 0 +function 0 +involve 0 +mitochondrial 3 +structural 4 +and 4 +functional 4 +impairment 4 +. 0 + +Torsade 3 +de 4 +pointes 4 +ventricular 3 +tachycardia 4 +during 0 +low 0 +dose 0 +intermittent 0 +dobutamine 1 +treatment 0 +in 0 +a 0 +patient 0 +with 0 +dilated 3 +cardiomyopathy 4 +and 0 +congestive 3 +heart 4 +failure 4 +. 0 + +The 0 +authors 0 +describe 0 +the 0 +case 0 +of 0 +a 0 +56 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +chronic 0 +, 0 +severe 0 +heart 3 +failure 4 +secondary 0 +to 0 +dilated 3 +cardiomyopathy 4 +and 0 +absence 0 +of 0 +significant 0 +ventricular 3 +arrhythmias 4 +who 0 +developed 0 +QT 3 +prolongation 4 +and 0 +torsade 3 +de 4 +pointes 4 +ventricular 3 +tachycardia 4 +during 0 +one 0 +cycle 0 +of 0 +intermittent 0 +low 0 +dose 0 +( 0 +2 0 +. 0 +5 0 +mcg 0 +/ 0 +kg 0 +per 0 +min 0 +) 0 +dobutamine 1 +. 0 + +This 0 +report 0 +of 0 +torsade 3 +de 4 +pointes 4 +ventricular 3 +tachycardia 4 +during 0 +intermittent 0 +dobutamine 1 +supports 0 +the 0 +hypothesis 0 +that 0 +unpredictable 0 +fatal 0 +arrhythmias 3 +may 0 +occur 0 +even 0 +with 0 +low 0 +doses 0 +and 0 +in 0 +patients 0 +with 0 +no 0 +history 0 +of 0 +significant 0 +rhythm 0 +disturbances 0 +. 0 + +The 0 +mechanisms 0 +of 0 +proarrhythmic 0 +effects 0 +of 0 +Dubutamine 1 +are 0 +discussed 0 +. 0 + +Positive 0 +skin 0 +tests 0 +in 0 +late 0 +reactions 0 +to 0 +radiographic 0 +contrast 1 +media 2 +. 0 + +In 0 +the 0 +last 0 +few 0 +years 0 +delayed 0 +reactions 0 +several 0 +hours 0 +after 0 +the 0 +injection 0 +of 0 +radiographic 0 +and 0 +contrast 1 +materials 2 +( 0 +PRC 1 +) 0 +have 0 +been 0 +described 0 +with 0 +increasing 0 +frequency 0 +. 0 + +The 0 +authors 0 +report 0 +two 0 +observations 0 +on 0 +patients 0 +with 0 +delayed 0 +reactions 0 +in 0 +whom 0 +intradermoreactions 0 +( 0 +IDR 0 +) 0 +and 0 +patch 0 +tests 0 +to 0 +a 0 +series 0 +of 0 +ionic 0 +and 0 +non 0 +ionic 0 +PRC 1 +were 0 +studied 0 +. 0 + +After 0 +angiography 0 +by 0 +the 0 +venous 0 +route 0 +in 0 +patient 0 +n 0 +degree 0 +1 0 +a 0 +biphasic 0 +reaction 0 +with 0 +an 0 +immediate 0 +reaction 0 +( 0 +dyspnea 3 +, 0 +loss 3 +of 4 +consciousness 4 +) 0 +and 0 +delayed 0 +macro 3 +- 4 +papular 4 +rash 4 +appeared 0 +, 0 +whilst 0 +patient 0 +n 0 +degree 0 +2 0 +developed 0 +a 0 +generalised 0 +sensation 0 +of 0 +heat 0 +, 0 +persistent 0 +pain 3 +at 0 +the 0 +site 0 +of 0 +injection 0 +immediately 0 +and 0 +a 0 +generalised 0 +macro 0 +- 0 +papular 0 +reaction 0 +after 0 +24 0 +hours 0 +. 0 + +The 0 +skin 0 +tests 0 +revealed 0 +positive 0 +delayed 0 +reactions 0 +of 0 +24 0 +hours 0 +and 0 +48 0 +hours 0 +by 0 +IDR 0 +and 0 +patch 0 +tests 0 +to 0 +only 0 +some 0 +PRC 1 +with 0 +common 0 +chains 0 +in 0 +their 0 +structures 0 +. 0 + +The 0 +positive 0 +skin 0 +tests 0 +are 0 +in 0 +favour 0 +of 0 +immunological 0 +reactions 0 +and 0 +may 0 +help 0 +in 0 +diagnosis 0 +of 0 +allergy 3 +in 0 +the 0 +patients 0 +. 0 + +Risk 0 +of 0 +transient 0 +hyperammonemic 3 +encephalopathy 4 +in 0 +cancer 3 +patients 0 +who 0 +received 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +fluorouracil 2 +with 0 +the 0 +complication 0 +of 0 +dehydration 3 +and 0 +infection 3 +. 0 + +From 0 +1986 0 +to 0 +1998 0 +, 0 +29 0 +cancer 3 +patients 0 +who 0 +had 0 +32 0 +episodes 0 +of 0 +transient 0 +hyperammonemic 3 +encephalopathy 4 +related 0 +to 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +were 0 +identified 0 +. 0 + +None 0 +of 0 +the 0 +patients 0 +had 0 +decompensated 0 +liver 3 +disease 4 +. 0 + +0nset 0 +of 0 +hyperammonemic 3 +encephalopathy 4 +varied 0 +from 0 +0 0 +. 0 +5 0 +to 0 +5 0 +days 0 +( 0 +mean 0 +: 0 +2 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +days 0 +) 0 +after 0 +the 0 +initiation 0 +of 0 +chemotherapy 0 +. 0 + +Plasma 0 +ammonium 1 +level 0 +ranged 0 +from 0 +248 0 +to 0 +2387 0 +microg 0 +% 0 +( 0 +mean 0 +: 0 +626 0 ++ 0 +/ 0 +- 0 +431 0 +microg 0 +% 0 +) 0 +. 0 + +Among 0 +the 0 +32 0 +episodes 0 +, 0 +26 0 +( 0 +81 0 +% 0 +) 0 +had 0 +various 0 +degrees 0 +of 0 +azotemia 3 +, 0 +18 0 +( 0 +56 0 +% 0 +) 0 +occurred 0 +during 0 +bacterial 3 +infections 4 +and 0 +14 0 +( 0 +44 0 +% 0 +) 0 +without 0 +infection 3 +occurred 0 +during 0 +periods 0 +of 0 +dehydration 3 +. 0 + +Higher 0 +plasma 0 +ammonium 1 +levels 0 +and 0 +more 0 +rapid 0 +onset 0 +of 0 +hyperammonemia 3 +were 0 +seen 0 +in 0 +18 0 +patients 0 +with 0 +bacterial 3 +infections 4 +( 0 +p 0 += 0 +0 0 +. 0 +003 0 +and 0 +0 0 +. 0 +0006 0 +, 0 +respectively 0 +) 0 +and 0 +in 0 +nine 0 +patients 0 +receiving 0 +high 0 +daily 0 +doses 0 +( 0 +2600 0 +or 0 +1800 0 +mg 0 +/ 0 +m2 0 +) 0 +of 0 +5 1 +- 2 +FU 2 +( 0 +p 0 += 0 +0 0 +. 0 +0001 0 +and 0 +< 0 +0 0 +. 0 +0001 0 +, 0 +respectively 0 +) 0 +. 0 + +In 0 +25 0 +out 0 +of 0 +32 0 +episodes 0 +( 0 +78 0 +% 0 +) 0 +, 0 +plasma 0 +ammonium 1 +levels 0 +and 0 +mental 0 +status 0 +returned 0 +to 0 +normal 0 +within 0 +2 0 +days 0 +after 0 +adequate 0 +management 0 +. 0 + +In 0 +conclusion 0 +, 0 +hyperammonemic 3 +encephalopathy 4 +can 0 +occur 0 +in 0 +patients 0 +receiving 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +FU 2 +. 0 + +Azotemia 3 +, 0 +body 0 +fluid 0 +insufficiency 0 +and 0 +bacterial 3 +infections 4 +were 0 +frequently 0 +found 0 +in 0 +these 0 +patients 0 +. 0 + +It 0 +is 0 +therefore 0 +important 0 +to 0 +recognize 0 +this 0 +condition 0 +in 0 +patients 0 +receiving 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +FU 2 +. 0 + +The 0 +effects 0 +of 0 +quinine 1 +and 0 +4 1 +- 2 +aminopyridine 2 +on 0 +conditioned 0 +place 0 +preference 0 +and 0 +changes 0 +in 0 +motor 0 +activity 0 +induced 0 +by 0 +morphine 1 +in 0 +rats 0 +. 0 + +1 0 +. 0 + +The 0 +effects 0 +of 0 +two 0 +unselective 0 +potassium 1 +( 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +) 0 +channel 0 +blockers 0 +, 0 +quinine 1 +( 0 +12 0 +. 0 +5 0 +, 0 +25 0 +and 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +4 1 +- 2 +aminopyridine 2 +( 0 +1 0 +and 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +on 0 +conditioned 0 +place 0 +preference 0 +and 0 +biphasic 0 +changes 0 +in 0 +motor 0 +activity 0 +induced 0 +by 0 +morphine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +were 0 +tested 0 +in 0 +Wistar 0 +rats 0 +. 0 + +Quinine 1 +is 0 +known 0 +to 0 +block 0 +voltage 0 +- 0 +, 0 +calcium 1 +- 0 +and 0 +ATP 1 +- 0 +sensitive 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channels 0 +while 0 +4 1 +- 2 +aminopyridine 2 +is 0 +known 0 +to 0 +block 0 +voltage 0 +- 0 +sensitive 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channels 0 +. 0 + +2 0 +. 0 + +In 0 +the 0 +counterbalanced 0 +method 0 +, 0 +quinine 1 +attenuated 0 +morphine 1 +- 0 +induced 0 +place 0 +preference 0 +, 0 +whereas 0 +4 1 +- 2 +aminopyridine 2 +was 0 +ineffective 0 +. 0 + +In 0 +the 0 +motor 0 +activity 0 +test 0 +measured 0 +with 0 +an 0 +Animex 0 +- 0 +activity 0 +meter 0 +neither 0 +of 0 +the 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channel 0 +blockers 0 +affected 0 +morphine 1 +- 0 +induced 0 +hypoactivity 3 +, 0 +but 0 +both 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channel 0 +blockers 0 +prevented 0 +morphine 1 +- 0 +induced 0 +secondary 0 +hyperactivity 3 +. 0 + +3 0 +. 0 + +These 0 +results 0 +suggest 0 +the 0 +involvement 0 +of 0 +quinine 1 +- 0 +sensitive 0 +but 0 +not 0 +4 1 +- 2 +aminopyridine 2 +- 0 +sensitive 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channels 0 +in 0 +morphine 1 +reward 0 +. 0 + +It 0 +is 0 +also 0 +suggested 0 +that 0 +the 0 +blockade 0 +of 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channels 0 +sensitive 0 +to 0 +these 0 +blockers 0 +is 0 +not 0 +sufficient 0 +to 0 +prevent 0 +morphine 1 +- 0 +induced 0 +hypoactivity 3 +whereas 0 +morphine 1 +- 0 +induced 0 +hyperactivity 3 +seems 0 +to 0 +be 0 +connected 0 +to 0 +both 0 +quinine 1 +- 0 +and 0 +4 1 +- 2 +aminopyridine 2 +- 0 +sensitive 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +channels 0 +. 0 + +Nociceptin 1 +/ 0 +orphanin 1 +FQ 2 +and 0 +nocistatin 1 +on 0 +learning 3 +and 4 +memory 4 +impairment 4 +induced 0 +by 0 +scopolamine 1 +in 0 +mice 0 +. 0 + +1 0 +. 0 + +Nociceptin 1 +, 0 +also 0 +known 0 +as 0 +orphanin 1 +FQ 2 +, 0 +is 0 +an 0 +endogenous 0 +ligand 0 +for 0 +the 0 +orphan 0 +opioid 0 +receptor 0 +- 0 +like 0 +receptor 0 +1 0 +( 0 +0RL1 0 +) 0 +and 0 +involves 0 +in 0 +various 0 +functions 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +nocistatin 1 +is 0 +recently 0 +isolated 0 +from 0 +the 0 +same 0 +precursor 0 +as 0 +nociceptin 1 +and 0 +blocks 0 +nociceptin 1 +- 0 +induced 0 +allodynia 3 +and 0 +hyperalgesia 3 +. 0 + +2 0 +. 0 + +Although 0 +0RL1 0 +receptors 0 +which 0 +display 0 +a 0 +high 0 +degree 0 +of 0 +sequence 0 +homology 0 +with 0 +classical 0 +opioid 0 +receptors 0 +are 0 +abundant 0 +in 0 +the 0 +hippocampus 0 +, 0 +little 0 +is 0 +known 0 +regarding 0 +their 0 +role 0 +in 0 +learning 0 +and 0 +memory 0 +. 0 + +3 0 +. 0 + +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +investigate 0 +whether 0 +nociceptin 1 +/ 0 +orphanin 1 +FQ 2 +and 0 +nocistatin 1 +could 0 +modulate 0 +impairment 3 +of 4 +learning 4 +and 4 +memory 4 +induced 0 +by 0 +scopolamine 1 +, 0 +a 0 +muscarinic 0 +cholinergic 0 +receptor 0 +antagonist 0 +, 0 +using 0 +spontaneous 0 +alternation 0 +of 0 +Y 0 +- 0 +maze 0 +and 0 +step 0 +- 0 +down 0 +type 0 +passive 0 +avoidance 0 +tasks 0 +in 0 +mice 0 +. 0 + +4 0 +. 0 + +While 0 +nocistatin 1 +( 0 +0 0 +. 0 +5 0 +- 0 +5 0 +. 0 +0 0 +nmol 0 +mouse 0 +- 0 +1 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +administered 0 +30 0 +min 0 +before 0 +spontaneous 0 +alternation 0 +performance 0 +or 0 +the 0 +training 0 +session 0 +of 0 +the 0 +passive 0 +avoidance 0 +task 0 +, 0 +had 0 +no 0 +effect 0 +on 0 +spontaneous 0 +alternation 0 +or 0 +passive 0 +avoidance 0 +behaviours 0 +, 0 +a 0 +lower 0 +per 0 +cent 0 +alternation 0 +and 0 +shorter 0 +median 0 +step 0 +- 0 +down 0 +latency 0 +in 0 +the 0 +retention 0 +test 0 +were 0 +obtained 0 +in 0 +nociceptin 1 +( 0 +1 0 +. 0 +5 0 +and 0 +/ 0 +or 0 +5 0 +. 0 +0 0 +nmol 0 +mouse 0 +- 0 +1 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +- 0 +treated 0 +normal 0 +mice 0 +. 0 + +5 0 +. 0 + +Administration 0 +of 0 +nocistatin 1 +( 0 +1 0 +. 0 +5 0 +and 0 +/ 0 +or 0 +5 0 +. 0 +0 0 +nmol 0 +mouse 0 +- 0 +1 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +30 0 +min 0 +before 0 +spontaneous 0 +alternation 0 +performance 0 +or 0 +the 0 +training 0 +session 0 +of 0 +the 0 +passive 0 +avoidance 0 +task 0 +, 0 +attenuated 0 +the 0 +scopolamine 1 +- 0 +induced 0 +impairment 0 +of 0 +spontaneous 0 +alternation 0 +and 0 +passive 0 +avoidance 0 +behaviours 0 +. 0 + +6 0 +. 0 + +These 0 +results 0 +indicated 0 +that 0 +nocistatin 1 +, 0 +a 0 +new 0 +biologically 0 +active 0 +peptide 0 +, 0 +ameliorates 0 +impairments 0 +of 0 +spontaneous 0 +alternation 0 +and 0 +passive 0 +avoidance 0 +induced 0 +by 0 +scopolamine 1 +, 0 +and 0 +suggested 0 +that 0 +these 0 +peptides 0 +play 0 +opposite 0 +roles 0 +in 0 +learning 0 +and 0 +memory 0 +. 0 + +Meloxicam 1 +- 0 +induced 0 +liver 3 +toxicity 4 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +female 0 +patient 0 +with 0 +rheumatoid 3 +arthritis 4 +who 0 +developed 0 +acute 0 +cytolytic 0 +hepatitis 3 +due 0 +to 0 +meloxicam 1 +. 0 + +Recently 0 +introduced 0 +in 0 +Belgium 0 +, 0 +meloxicam 1 +is 0 +the 0 +first 0 +nonsteroidal 0 +antiinflammatory 0 +drug 0 +with 0 +selective 0 +action 0 +on 0 +the 0 +inducible 0 +form 0 +of 0 +cyclooxygenase 0 +2 0 +. 0 + +The 0 +acute 0 +cytolytic 0 +hepatitis 3 +occurred 0 +rapidly 0 +after 0 +meloxicam 1 +administration 0 +and 0 +was 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +antinuclear 0 +antibodies 0 +suggesting 0 +a 0 +hypersensitivity 3 +mechanism 0 +. 0 + +This 0 +first 0 +case 0 +of 0 +meloxicam 1 +related 0 +liver 3 +toxicity 4 +demonstrates 0 +the 0 +potential 0 +of 0 +this 0 +drug 0 +to 0 +induce 0 +hepatic 3 +damage 4 +. 0 + +Induction 0 +of 0 +apoptosis 0 +by 0 +remoxipride 1 +metabolites 0 +in 0 +HL60 0 +and 0 +CD34 0 ++ 0 +/ 0 +CD19 0 +- 0 +human 0 +bone 0 +marrow 0 +progenitor 0 +cells 0 +: 0 +potential 0 +relevance 0 +to 0 +remoxipride 1 +- 0 +induced 0 +aplastic 3 +anemia 4 +. 0 + +The 0 +antipsychotic 0 +agent 0 +, 0 +remoxipride 1 +[ 0 +( 1 +S 2 +) 2 +- 2 +( 2 +- 2 +) 2 +- 2 +3 2 +- 2 +bromo 2 +- 2 +N 2 +- 2 +[ 2 +( 2 +1 2 +- 2 +ethyl 2 +- 2 +2 2 +- 2 +pyrrolidinyl 2 +) 2 +methyl 2 +] 2 +- 2 +2 2 +, 2 +6 2 +- 2 +dimethoxybenz 2 +amide 2 +] 0 +has 0 +been 0 +associated 0 +with 0 +acquired 0 +aplastic 3 +anemia 4 +. 0 + +We 0 +have 0 +examined 0 +the 0 +ability 0 +of 0 +remoxipride 1 +, 0 +three 0 +pyrrolidine 1 +ring 0 +metabolites 0 +and 0 +five 0 +aromatic 0 +ring 0 +metabolites 0 +of 0 +the 0 +parent 0 +compound 0 +to 0 +induce 0 +apoptosis 0 +in 0 +HL60 0 +cells 0 +and 0 +human 0 +bone 0 +marrow 0 +progenitor 0 +( 0 +HBMP 0 +) 0 +cells 0 +. 0 + +Cells 0 +were 0 +treated 0 +for 0 +0 0 +- 0 +24 0 +h 0 +with 0 +each 0 +compound 0 +( 0 +0 0 +- 0 +200 0 +microM 0 +) 0 +. 0 + +Apoptosis 0 +was 0 +assessed 0 +by 0 +fluorescence 0 +microscopy 0 +in 0 +Hoechst 1 +33342 2 +- 0 +and 0 +propidium 1 +iodide 2 +stained 0 +cell 0 +samples 0 +. 0 + +Results 0 +were 0 +confirmed 0 +by 0 +determination 0 +of 0 +internucleosomal 0 +DNA 0 +fragmentation 0 +using 0 +gel 0 +electrophoresis 0 +for 0 +HL60 0 +cell 0 +samples 0 +and 0 +terminal 0 +deoxynucleotidyl 0 +transferase 0 +assay 0 +in 0 +HBMP 0 +cells 0 +. 0 + +The 0 +catechol 1 +and 0 +hydroquinone 1 +metabolites 0 +, 0 +NCQ436 1 +and 0 +NCQ344 1 +, 0 +induced 0 +apoptosis 0 +in 0 +HL60 0 +and 0 +HBMP 0 +cells 0 +in 0 +a 0 +time 0 +- 0 +and 0 +concentration 0 +dependent 0 +manner 0 +, 0 +while 0 +the 0 +phenols 1 +, 0 +NCR181 0 +, 0 +FLA873 0 +, 0 +and 0 +FLA797 1 +, 0 +and 0 +the 0 +derivatives 0 +formed 0 +by 0 +oxidation 0 +of 0 +the 0 +pyrrolidine 1 +ring 0 +, 0 +FLA838 0 +, 0 +NCM001 0 +, 0 +and 0 +NCL118 0 +, 0 +had 0 +no 0 +effect 0 +. 0 + +No 0 +necrosis 3 +was 0 +observed 0 +in 0 +cells 0 +treated 0 +with 0 +NCQ436 1 +but 0 +NCQ344 1 +had 0 +a 0 +biphasic 0 +effect 0 +in 0 +both 0 +cell 0 +types 0 +, 0 +inducing 0 +apoptosis 0 +at 0 +lower 0 +concentrations 0 +and 0 +necrosis 3 +at 0 +higher 0 +concentrations 0 +. 0 + +These 0 +data 0 +show 0 +that 0 +the 0 +catechol 1 +and 0 +hydroquinone 1 +metabolites 0 +of 0 +remoxipride 1 +have 0 +direct 0 +toxic 0 +effects 0 +in 0 +HL60 0 +and 0 +HBMP 0 +cells 0 +, 0 +leading 0 +to 0 +apoptosis 0 +, 0 +while 0 +the 0 +phenol 1 +metabolites 0 +were 0 +inactive 0 +. 0 + +Similarly 0 +, 0 +benzene 1 +- 0 +derived 0 +catechol 1 +and 0 +hydroquinone 1 +, 0 +but 0 +not 0 +phenol 1 +, 0 +induce 0 +apoptosis 0 +in 0 +HBMP 0 +cells 0 +[ 0 +Moran 0 +et 0 +al 0 +. 0 +, 0 +Mol 0 +. 0 +Pharmacol 0 +. 0 +, 0 +50 0 +( 0 +1996 0 +) 0 +610 0 +- 0 +615 0 +] 0 +. 0 + +We 0 +propose 0 +that 0 +remoxipride 1 +and 0 +benzene 1 +may 0 +induce 0 +aplastic 3 +anemia 4 +via 0 +production 0 +of 0 +similar 0 +reactive 0 +metabolites 0 +and 0 +that 0 +the 0 +ability 0 +of 0 +NCQ436 1 +and 0 +NCQ344 1 +to 0 +induce 0 +apoptosis 0 +in 0 +HBMP 0 +cells 0 +may 0 +contribute 0 +to 0 +the 0 +mechanism 0 +underlying 0 +acquired 0 +aplastic 3 +anemia 4 +that 0 +has 0 +been 0 +associated 0 +with 0 +remoxipride 1 +. 0 + +Synthesis 0 +and 0 +preliminary 0 +pharmacological 0 +investigations 0 +of 0 +1 1 +- 2 +( 2 +1 2 +, 2 +2 2 +- 2 +dihydro 2 +- 2 +2 2 +- 2 +acenaphthylenyl 2 +) 2 +piperazine 2 +derivatives 0 +as 0 +potential 0 +atypical 0 +antipsychotic 0 +agents 0 +in 0 +mice 0 +. 0 + +In 0 +research 0 +towards 0 +the 0 +development 0 +of 0 +new 0 +atypical 0 +antipsychotic 0 +agents 0 +, 0 +one 0 +strategy 0 +is 0 +that 0 +the 0 +dopaminergic 0 +system 0 +can 0 +be 0 +modulated 0 +through 0 +manipulation 0 +of 0 +the 0 +serotonergic 0 +system 0 +. 0 + +The 0 +synthesis 0 +and 0 +preliminary 0 +pharmacological 0 +evaluation 0 +of 0 +a 0 +series 0 +of 0 +potential 0 +atypical 0 +antipsychotic 0 +agents 0 +based 0 +on 0 +the 0 +structure 0 +of 0 +1 1 +- 2 +( 2 +1 2 +, 2 +2 2 +- 2 +dihydro 2 +- 2 +2 2 +- 2 +acenaphthylenyl 2 +) 2 +piperazine 2 +( 0 +7 0 +) 0 +is 0 +described 0 +. 0 + +Compound 0 +7e 0 +, 0 +5 1 +- 2 +{ 2 +2 2 +- 2 +[ 2 +4 2 +- 2 +( 2 +1 2 +, 2 +2 2 +- 2 +dihydro 2 +- 2 +2 2 +- 2 +acenaphthylenyl 2 +) 2 +piperazinyl 2 +] 2 +ethyl 2 +} 2 +- 2 +2 2 +, 2 +3 2 +- 2 +dihy 2 +dro 2 +- 2 +1H 2 +- 2 +indol 2 +- 2 +2 2 +- 2 +one 2 +, 0 +from 0 +this 0 +series 0 +showed 0 +significant 0 +affinities 0 +at 0 +the 0 +5 0 +- 0 +HT1A 0 +and 0 +5 0 +- 0 +HT2A 0 +receptors 0 +and 0 +moderate 0 +affinity 0 +at 0 +the 0 +D2 0 +receptor 0 +. 0 + +7e 0 +exhibits 0 +a 0 +high 0 +reversal 0 +of 0 +catalepsy 3 +induced 0 +by 0 +haloperidol 1 +indicating 0 +its 0 +atypical 0 +antipsychotic 0 +nature 0 +. 0 + +Sub 0 +- 0 +chronic 0 +inhibition 0 +of 0 +nitric 1 +- 2 +oxide 2 +synthesis 0 +modifies 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +and 0 +the 0 +number 0 +of 0 +NADPH 1 +- 0 +diaphorase 0 +neurons 0 +in 0 +mice 0 +. 0 + +RATI0NALE 0 +: 0 +NG 1 +- 2 +nitro 2 +- 2 +L 2 +- 2 +arginine 2 +( 0 +L 1 +- 2 +N0ARG 2 +) 0 +, 0 +an 0 +inhibitor 0 +of 0 +nitric 1 +- 2 +oxide 2 +synthase 0 +( 0 +N0S 0 +) 0 +, 0 +induces 0 +catalepsy 3 +in 0 +mice 0 +. 0 + +This 0 +effect 0 +undergoes 0 +rapid 0 +tolerance 0 +, 0 +showing 0 +a 0 +significant 0 +decrease 0 +after 0 +2 0 +days 0 +of 0 +sub 0 +- 0 +chronic 0 +L 1 +- 2 +N0ARG 2 +treatment 0 +. 0 + +Nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +has 0 +been 0 +shown 0 +to 0 +influence 0 +dopaminergic 0 +neurotransmission 0 +in 0 +the 0 +striatum 0 +. 0 + +Neuroleptic 0 +drugs 0 +such 0 +as 0 +haloperidol 1 +, 0 +which 0 +block 0 +dopamine 1 +receptors 0 +, 0 +also 0 +cause 0 +catalepsy 3 +in 0 +rodents 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +investigate 0 +the 0 +effects 0 +of 0 +subchronic 0 +L 1 +- 2 +N0ARG 2 +treatment 0 +in 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +and 0 +the 0 +number 0 +of 0 +N0S 0 +neurons 0 +in 0 +areas 0 +related 0 +to 0 +motor 0 +control 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +albino 0 +Swiss 0 +mice 0 +were 0 +treated 0 +sub 0 +- 0 +chronically 0 +( 0 +twice 0 +a 0 +day 0 +for 0 +4 0 +days 0 +) 0 +with 0 +L 1 +- 2 +N0ARG 2 +( 0 +40 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +or 0 +haloperidol 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +Catalepsy 3 +was 0 +evaluated 0 +at 0 +the 0 +beginning 0 +and 0 +the 0 +end 0 +of 0 +the 0 +treatments 0 +. 0 + +Reduced 0 +nicotinamide 1 +adenine 2 +dinucleotide 2 +phosphate 2 +- 0 +diaphorase 0 +( 0 +NADPH 1 +- 0 +d 0 +) 0 +histochemistry 0 +was 0 +also 0 +employed 0 +to 0 +visualize 0 +N0S 0 +as 0 +an 0 +index 0 +of 0 +enzyme 0 +expression 0 +in 0 +mice 0 +brain 0 +regions 0 +related 0 +to 0 +motor 0 +control 0 +. 0 + +RESULTS 0 +: 0 +L 1 +- 2 +N0ARG 2 +sub 0 +- 0 +chronic 0 +administration 0 +produced 0 +tolerance 0 +of 0 +L 1 +- 2 +N0ARG 2 +and 0 +of 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +It 0 +also 0 +induced 0 +an 0 +increase 0 +in 0 +the 0 +number 0 +of 0 +NADPH 1 +- 0 +d 0 +- 0 +positive 0 +cells 0 +in 0 +the 0 +dorsal 0 +part 0 +of 0 +the 0 +caudate 0 +and 0 +accumbens 0 +nuclei 0 +compared 0 +with 0 +haloperidol 1 +and 0 +in 0 +the 0 +pedunculopontine 0 +tegmental 0 +nucleus 0 +compared 0 +with 0 +saline 0 +. 0 + +In 0 +contrast 0 +, 0 +there 0 +was 0 +a 0 +decrease 0 +in 0 +NADPH 1 +- 0 +d 0 +neuron 0 +number 0 +in 0 +the 0 +substantia 0 +nigra 0 +, 0 +pars 0 +compacta 0 +in 0 +both 0 +haloperidol 1 +- 0 +treated 0 +and 0 +L 1 +- 2 +N0ARG 2 +- 0 +treated 0 +animals 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +results 0 +give 0 +further 0 +support 0 +to 0 +the 0 +hypothesis 0 +that 0 +N0 1 +plays 0 +a 0 +role 0 +in 0 +motor 0 +behavior 0 +control 0 +and 0 +suggest 0 +that 0 +it 0 +may 0 +take 0 +part 0 +in 0 +the 0 +synaptic 0 +changes 0 +produced 0 +by 0 +antipsychotic 0 +treatment 0 +. 0 + +Prolonged 0 +left 3 +ventricular 4 +dysfunction 4 +occurs 0 +in 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +after 0 +both 0 +dobutamine 1 +and 0 +exercise 0 +induced 0 +myocardial 3 +ischaemia 4 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +determine 0 +whether 0 +pharmacological 0 +stress 0 +leads 0 +to 0 +prolonged 0 +but 0 +reversible 0 +left 3 +ventricular 4 +dysfunction 4 +in 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +, 0 +similar 0 +to 0 +that 0 +seen 0 +after 0 +exercise 0 +. 0 + +DESIGN 0 +: 0 +A 0 +randomised 0 +crossover 0 +study 0 +of 0 +recovery 0 +time 0 +of 0 +systolic 0 +and 0 +diastolic 0 +left 0 +ventricular 0 +function 0 +after 0 +exercise 0 +and 0 +dobutamine 1 +induced 0 +ischaemia 3 +. 0 + +SUBJECTS 0 +: 0 +10 0 +patients 0 +with 0 +stable 3 +angina 4 +, 0 +angiographically 0 +proven 0 +coronary 3 +artery 4 +disease 4 +, 0 +and 0 +normal 0 +left 0 +ventricular 0 +function 0 +. 0 + +INTERVENTI0NS 0 +: 0 +Treadmill 0 +exercise 0 +and 0 +dobutamine 1 +stress 0 +were 0 +performed 0 +on 0 +different 0 +days 0 +. 0 + +Quantitative 0 +assessment 0 +of 0 +systolic 0 +and 0 +diastolic 0 +left 0 +ventricular 0 +function 0 +was 0 +performed 0 +using 0 +transthoracic 0 +echocardiography 0 +at 0 +baseline 0 +and 0 +at 0 +regular 0 +intervals 0 +after 0 +each 0 +test 0 +. 0 + +RESULTS 0 +: 0 +Both 0 +forms 0 +of 0 +stress 0 +led 0 +to 0 +prolonged 0 +but 0 +reversible 0 +systolic 0 +and 0 +diastolic 0 +dysfunction 0 +. 0 + +There 0 +was 0 +no 0 +difference 0 +in 0 +the 0 +maximum 0 +double 0 +product 0 +( 0 +p 0 += 0 +0 0 +. 0 +53 0 +) 0 +or 0 +ST 0 +depression 3 +( 0 +p 0 += 0 +0 0 +. 0 +63 0 +) 0 +with 0 +either 0 +form 0 +of 0 +stress 0 +. 0 + +After 0 +exercise 0 +, 0 +ejection 0 +fraction 0 +was 0 +reduced 0 +at 0 +15 0 +and 0 +30 0 +minutes 0 +compared 0 +with 0 +baseline 0 +( 0 +mean 0 +( 0 +SEM 0 +) 0 +, 0 +- 0 +5 0 +. 0 +6 0 +( 0 +1 0 +. 0 +5 0 +) 0 +% 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +; 0 +and 0 +- 0 +6 0 +. 0 +1 0 +( 0 +2 0 +. 0 +2 0 +) 0 +% 0 +, 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +, 0 +and 0 +at 0 +30 0 +and 0 +45 0 +minutes 0 +after 0 +dobutamine 1 +( 0 +- 0 +10 0 +. 0 +8 0 +( 0 +1 0 +. 0 +8 0 +) 0 +% 0 +and 0 +- 0 +5 0 +. 0 +5 0 +( 0 +1 0 +. 0 +8 0 +) 0 +% 0 +, 0 +both 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Regional 0 +analysis 0 +showed 0 +a 0 +reduction 0 +in 0 +the 0 +worst 0 +affected 0 +segment 0 +15 0 +and 0 +30 0 +minutes 0 +after 0 +exercise 0 +( 0 +- 0 +27 0 +. 0 +9 0 +( 0 +7 0 +. 0 +2 0 +) 0 +% 0 +and 0 +- 0 +28 0 +. 0 +6 0 +( 0 +5 0 +. 0 +7 0 +) 0 +% 0 +, 0 +both 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +, 0 +and 0 +at 0 +30 0 +minutes 0 +after 0 +dobutamine 1 +( 0 +- 0 +32 0 +( 0 +5 0 +. 0 +3 0 +) 0 +% 0 +, 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +The 0 +isovolumic 0 +relaxation 0 +period 0 +was 0 +prolonged 0 +45 0 +minutes 0 +after 0 +each 0 +form 0 +of 0 +stress 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +, 0 +dobutamine 1 +induced 0 +ischaemia 3 +results 0 +in 0 +prolonged 0 +reversible 0 +left 3 +ventricular 4 +dysfunction 4 +, 0 +presumed 0 +to 0 +be 0 +myocardial 3 +stunning 4 +, 0 +similar 0 +to 0 +that 0 +seen 0 +after 0 +exercise 0 +. 0 + +Dobutamine 1 +induced 0 +ischaemia 3 +could 0 +therefore 0 +be 0 +used 0 +to 0 +study 0 +the 0 +pathophysiology 0 +of 0 +this 0 +phenomenon 0 +further 0 +in 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +. 0 + +Anorexigens 0 +and 0 +pulmonary 3 +hypertension 4 +in 0 +the 0 +United 0 +States 0 +: 0 +results 0 +from 0 +the 0 +surveillance 0 +of 0 +North 0 +American 0 +pulmonary 3 +hypertension 4 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +use 0 +of 0 +appetite 0 +suppressants 0 +in 0 +Europe 0 +has 0 +been 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +primary 3 +pulmonary 4 +hypertension 4 +( 0 +PPH 3 +) 0 +. 0 + +Recently 0 +, 0 +fenfluramine 1 +appetite 0 +suppressants 0 +became 0 +widely 0 +used 0 +in 0 +the 0 +United 0 +States 0 +but 0 +were 0 +withdrawn 0 +in 0 +September 0 +1997 0 +because 0 +of 0 +concerns 0 +over 0 +adverse 0 +effects 0 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +We 0 +conducted 0 +a 0 +prospective 0 +surveillance 0 +study 0 +on 0 +patients 0 +diagnosed 0 +with 0 +pulmonary 3 +hypertension 4 +at 0 +12 0 +large 0 +referral 0 +centers 0 +in 0 +North 0 +America 0 +. 0 + +Data 0 +collected 0 +on 0 +patients 0 +seen 0 +from 0 +September 0 +1 0 +, 0 +1996 0 +, 0 +to 0 +December 0 +31 0 +, 0 +1997 0 +, 0 +included 0 +the 0 +cause 0 +of 0 +the 0 +pulmonary 3 +hypertension 4 +and 0 +its 0 +severity 0 +. 0 + +Patients 0 +with 0 +no 0 +identifiable 0 +cause 0 +of 0 +pulmonary 3 +hypertension 4 +were 0 +classed 0 +as 0 +PPH 3 +. 0 + +A 0 +history 0 +of 0 +drug 0 +exposure 0 +also 0 +was 0 +taken 0 +with 0 +special 0 +attention 0 +on 0 +the 0 +use 0 +of 0 +antidepressants 0 +, 0 +anorexigens 0 +, 0 +and 0 +amphetamines 1 +. 0 + +RESULTS 0 +: 0 +Five 0 +hundred 0 +seventy 0 +- 0 +nine 0 +patients 0 +were 0 +studied 0 +, 0 +205 0 +with 0 +PPH 3 +and 0 +374 0 +with 0 +pulmonary 3 +hypertension 4 +from 0 +other 0 +causes 0 +( 0 +secondary 0 +pulmonary 3 +hypertension 4 +[ 0 +SPH 0 +] 0 +) 0 +. 0 + +The 0 +use 0 +of 0 +anorexigens 0 +was 0 +common 0 +in 0 +both 0 +groups 0 +. 0 + +However 0 +, 0 +of 0 +the 0 +medications 0 +surveyed 0 +, 0 +only 0 +the 0 +fenfluramines 1 +had 0 +a 0 +significant 0 +preferential 0 +association 0 +with 0 +PPH 3 +as 0 +compared 0 +with 0 +SPH 0 +( 0 +adjusted 0 +odds 0 +ratio 0 +for 0 +use 0 +> 0 +6 0 +months 0 +, 0 +7 0 +. 0 +5 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +1 0 +. 0 +7 0 +to 0 +32 0 +. 0 +4 0 +) 0 +. 0 + +The 0 +association 0 +was 0 +stronger 0 +with 0 +longer 0 +duration 0 +of 0 +use 0 +when 0 +compared 0 +to 0 +shorter 0 +duration 0 +of 0 +use 0 +and 0 +was 0 +more 0 +pronounced 0 +in 0 +recent 0 +users 0 +than 0 +in 0 +remote 0 +users 0 +. 0 + +An 0 +unexpectedly 0 +high 0 +( 0 +11 0 +. 0 +4 0 +% 0 +) 0 +number 0 +of 0 +patients 0 +with 0 +SPH 0 +had 0 +used 0 +anorexigens 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +magnitude 0 +of 0 +the 0 +association 0 +with 0 +PPH 3 +, 0 +the 0 +increase 0 +of 0 +association 0 +with 0 +increasing 0 +duration 0 +of 0 +use 0 +, 0 +and 0 +the 0 +specificity 0 +for 0 +fenfluramines 1 +are 0 +consistent 0 +with 0 +previous 0 +studies 0 +indicating 0 +that 0 +fenfluramines 1 +are 0 +causally 0 +related 0 +to 0 +PPH 3 +. 0 + +The 0 +high 0 +prevalence 0 +of 0 +anorexigen 0 +use 0 +in 0 +patients 0 +with 0 +SPH 0 +also 0 +raises 0 +the 0 +possibility 0 +that 0 +these 0 +drugs 0 +precipitate 0 +pulmonary 3 +hypertension 4 +in 0 +patients 0 +with 0 +underlying 0 +conditions 0 +associated 0 +with 0 +SPH 0 +. 0 + +Clinical 0 +aspects 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +and 0 +thrombosis 3 +and 0 +other 0 +side 0 +effects 0 +of 0 +heparin 1 +therapy 0 +. 0 + +Heparin 1 +, 0 +first 0 +used 0 +to 0 +prevent 0 +the 0 +clotting 0 +of 0 +blood 0 +in 0 +vitro 0 +, 0 +has 0 +been 0 +clinically 0 +used 0 +to 0 +treat 0 +thrombosis 3 +for 0 +more 0 +than 0 +50 0 +years 0 +. 0 + +Although 0 +several 0 +new 0 +anticoagulant 0 +drugs 0 +are 0 +in 0 +development 0 +, 0 +heparin 1 +remains 0 +the 0 +anticoagulant 0 +of 0 +choice 0 +to 0 +treat 0 +acute 0 +thrombotic 3 +episodes 0 +. 0 + +The 0 +clinical 0 +effects 0 +of 0 +heparin 1 +are 0 +meritorious 0 +, 0 +but 0 +side 0 +effects 0 +do 0 +exist 0 +. 0 + +Bleeding 3 +is 0 +the 0 +primary 0 +untoward 0 +effect 0 +of 0 +heparin 1 +. 0 + +Major 0 +bleeding 3 +is 0 +of 0 +primary 0 +concern 0 +in 0 +patients 0 +receiving 0 +heparin 1 +therapy 0 +. 0 + +However 0 +, 0 +additional 0 +important 0 +untoward 0 +effects 0 +of 0 +heparin 1 +therapy 0 +include 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +, 0 +heparin 1 +- 0 +associated 0 +osteoporosis 3 +, 0 +eosinophilia 3 +, 0 +skin 3 +reactions 4 +, 0 +allergic 3 +reactions 4 +other 0 +than 0 +thrombocytopenia 3 +, 0 +alopecia 3 +, 0 +transaminasemia 0 +, 0 +hyperkalemia 3 +, 0 +hypoaldosteronism 3 +, 0 +and 0 +priapism 3 +. 0 + +These 0 +side 0 +effects 0 +are 0 +relatively 0 +rare 0 +in 0 +a 0 +given 0 +individual 0 +, 0 +but 0 +given 0 +the 0 +extremely 0 +widespread 0 +use 0 +of 0 +heparin 1 +, 0 +some 0 +are 0 +quite 0 +common 0 +, 0 +particularly 0 +HITT 3 +and 0 +osteoporosis 3 +. 0 + +Although 0 +reasonable 0 +incidences 0 +of 0 +many 0 +of 0 +these 0 +side 0 +effects 0 +can 0 +be 0 +" 0 +softly 0 +" 0 +deduced 0 +from 0 +current 0 +reports 0 +dealing 0 +with 0 +unfractionated 0 +heparin 1 +, 0 +at 0 +present 0 +the 0 +incidences 0 +of 0 +these 0 +side 0 +effects 0 +with 0 +newer 0 +low 0 +molecular 0 +weight 0 +heparins 1 +appear 0 +to 0 +be 0 +much 0 +less 0 +common 0 +. 0 + +However 0 +, 0 +only 0 +longer 0 +experience 0 +will 0 +more 0 +clearly 0 +define 0 +the 0 +incidence 0 +of 0 +each 0 +side 0 +effect 0 +with 0 +low 0 +molecular 0 +weight 0 +preparations 0 +. 0 + +A 0 +case 0 +of 0 +bilateral 0 +optic 3 +neuropathy 4 +in 0 +a 0 +patient 0 +on 0 +tacrolimus 1 +( 0 +FK506 1 +) 0 +therapy 0 +after 0 +liver 0 +transplantation 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +bilateral 0 +optic 3 +neuropathy 4 +in 0 +a 0 +patient 0 +receiving 0 +tacrolimus 1 +( 0 +FK 1 +506 2 +, 0 +Prograf 0 +; 0 +Fujisawa 0 +USA 0 +, 0 +Inc 0 +, 0 +Deerfield 0 +, 0 +Illinois 0 +) 0 +for 0 +immunosuppression 0 +after 0 +orthotropic 0 +liver 0 +transplantation 0 +. 0 + +METH0D 0 +: 0 +Case 0 +report 0 +. 0 + +In 0 +a 0 +58 0 +- 0 +year 0 +- 0 +old 0 +man 0 +receiving 0 +tacrolimus 1 +after 0 +orthotropic 0 +liver 0 +transplantation 0 +, 0 +serial 0 +neuro 0 +- 0 +ophthalmologic 0 +examinations 0 +and 0 +laboratory 0 +studies 0 +were 0 +performed 0 +. 0 + +RESULTS 0 +: 0 +The 0 +patient 0 +had 0 +episodic 0 +deterioration 0 +of 0 +vision 0 +in 0 +both 0 +eyes 0 +, 0 +with 0 +clinical 0 +features 0 +resembling 0 +ischemic 3 +optic 4 +neuropathies 4 +. 0 + +Deterioration 3 +of 4 +vision 4 +occurred 0 +despite 0 +discontinuation 0 +of 0 +the 0 +tacrolimus 1 +. 0 + +C0NCLUSI0N 0 +: 0 +Tacrolimus 1 +and 0 +other 0 +immunosuppressive 0 +agents 0 +may 0 +be 0 +associated 0 +with 0 +optic 3 +nerve 4 +toxicity 4 +. 0 + +Hypercalcemia 3 +, 0 +arrhythmia 3 +, 0 +and 0 +mood 0 +stabilizers 0 +. 0 + +Recent 0 +findings 0 +in 0 +a 0 +bipolar 3 +patient 0 +receiving 0 +maintenance 0 +lithium 1 +therapy 0 +who 0 +developed 0 +hypercalcemia 3 +and 0 +severe 0 +bradyarrhythmia 3 +prompted 0 +the 0 +authors 0 +to 0 +conduct 0 +a 0 +retrospective 0 +study 0 +of 0 +bipolar 3 +patients 0 +with 0 +lithium 1 +- 0 +associated 0 +hypercalcemia 3 +. 0 + +A 0 +printout 0 +of 0 +all 0 +cases 0 +of 0 +hypercalcemia 3 +that 0 +presented 0 +during 0 +a 0 +1 0 +- 0 +year 0 +period 0 +was 0 +generated 0 +. 0 + +After 0 +eliminating 0 +spurious 0 +hypercalcemias 3 +or 0 +those 0 +associated 0 +with 0 +intravenous 0 +fluids 0 +, 0 +the 0 +authors 0 +identified 0 +18 0 +non 0 +- 0 +lithium 1 +- 0 +treated 0 +patients 0 +with 0 +hypercalcemias 3 +related 0 +to 0 +malignancies 3 +and 0 +other 0 +medical 0 +conditions 0 +( 0 +group 0 +A 0 +) 0 +and 0 +12 0 +patients 0 +with 0 +lithium 1 +- 0 +associated 0 +hypercalcemia 3 +( 0 +group 0 +B 0 +) 0 +. 0 + +Patients 0 +in 0 +group 0 +B 0 +were 0 +not 0 +comparable 0 +to 0 +those 0 +in 0 +group 0 +A 0 +, 0 +as 0 +the 0 +latter 0 +were 0 +medically 0 +compromised 0 +and 0 +were 0 +receiving 0 +multiple 0 +pharmacotherapies 0 +. 0 + +Thus 0 +, 0 +two 0 +control 0 +groups 0 +were 0 +generated 0 +: 0 +group 0 +C1 0 +, 0 +which 0 +included 0 +age 0 +- 0 +and 0 +sex 0 +- 0 +comparable 0 +lithium 1 +- 0 +treated 0 +bipolar 3 +normocalcemic 0 +patients 0 +, 0 +and 0 +group 0 +C2 0 +, 0 +which 0 +included 0 +bipolar 3 +normocalcemic 0 +patients 0 +treated 0 +with 0 +anticonvulsant 0 +mood 0 +stabilizers 0 +. 0 + +The 0 +electrocardiographic 0 +( 0 +ECG 0 +) 0 +findings 0 +for 0 +patients 0 +in 0 +group 0 +B 0 +were 0 +compared 0 +with 0 +those 0 +of 0 +patients 0 +in 0 +groups 0 +C1 0 +and 0 +C2 0 +. 0 + +It 0 +was 0 +found 0 +that 0 +these 0 +groups 0 +did 0 +not 0 +differ 0 +in 0 +their 0 +overall 0 +frequency 0 +of 0 +ECG 0 +abnormalities 0 +; 0 +however 0 +, 0 +there 0 +were 0 +significant 0 +differences 0 +in 0 +the 0 +frequency 0 +of 0 +conduction 0 +defects 0 +. 0 + +Patients 0 +with 0 +hypercalcemia 3 +resulting 0 +from 0 +medical 0 +diseases 0 +and 0 +bipolar 3 +patients 0 +with 0 +lithium 1 +- 0 +associated 0 +hypercalcemia 3 +had 0 +significantly 0 +higher 0 +frequencies 0 +of 0 +conduction 0 +defects 0 +. 0 + +Patients 0 +in 0 +group 0 +A 0 +had 0 +significant 0 +mortality 0 +at 0 +2 0 +- 0 +year 0 +follow 0 +- 0 +up 0 +( 0 +28 0 +% 0 +) 0 +, 0 +in 0 +contrast 0 +to 0 +zero 0 +mortality 0 +in 0 +the 0 +other 0 +three 0 +groups 0 +. 0 + +The 0 +clinical 0 +implications 0 +of 0 +these 0 +findings 0 +are 0 +discussed 0 +. 0 + +Attenuation 0 +of 0 +nephrotoxicity 3 +by 0 +a 0 +novel 0 +lipid 0 +nanosphere 0 +( 0 +NS 0 +- 0 +718 0 +) 0 +incorporating 0 +amphotericin 1 +B 2 +. 0 + +NS 0 +- 0 +718 0 +, 0 +a 0 +lipid 0 +nanosphere 0 +incorporating 0 +amphotericin 1 +B 2 +, 0 +is 0 +effective 0 +against 0 +pathogenic 0 +fungi 0 +and 0 +has 0 +low 0 +toxicity 3 +. 0 + +We 0 +compared 0 +the 0 +toxicity 3 +of 0 +NS 0 +- 0 +718 0 +with 0 +that 0 +of 0 +Fungizone 1 +( 0 +amphotericin 1 +B 2 +- 2 +sodium 2 +deoxycholate 2 +; 0 +D 1 +- 2 +AmB 2 +) 0 +in 0 +vitro 0 +using 0 +renal 0 +cell 0 +cultures 0 +and 0 +in 0 +vivo 0 +by 0 +biochemical 0 +analysis 0 +, 0 +histopathological 0 +study 0 +of 0 +the 0 +kidney 0 +and 0 +pharmacokinetic 0 +study 0 +of 0 +amphotericin 1 +B 2 +following 0 +intravenous 0 +infusion 0 +of 0 +the 0 +formulation 0 +in 0 +rats 0 +. 0 + +Incubation 0 +with 0 +NS 0 +- 0 +718 0 +resulted 0 +in 0 +significantly 0 +less 0 +damage 0 +of 0 +cultured 0 +human 0 +renal 0 +proximal 0 +tubular 0 +epithelial 0 +cells 0 +compared 0 +with 0 +D 1 +- 2 +AmB 2 +. 0 + +Serum 0 +blood 0 +urea 1 +and 0 +creatinine 1 +concentrations 0 +increased 0 +significantly 0 +in 0 +rats 0 +given 0 +an 0 +iv 0 +infusion 0 +of 0 +D 1 +- 2 +AmB 2 +3 0 +mg 0 +/ 0 +kg 0 +but 0 +not 0 +in 0 +those 0 +given 0 +the 0 +same 0 +dose 0 +of 0 +NS 0 +- 0 +718 0 +. 0 + +Histopathological 0 +examination 0 +of 0 +the 0 +kidney 0 +showed 0 +tubular 3 +necrosis 4 +in 0 +D 1 +- 2 +AmB 2 +- 0 +treated 0 +rats 0 +but 0 +no 0 +change 0 +in 0 +NS 0 +- 0 +718 0 +- 0 +treated 0 +rats 0 +. 0 + +Amphotericin 1 +B 2 +concentrations 0 +in 0 +the 0 +kidney 0 +in 0 +NS 0 +- 0 +718 0 +- 0 +treated 0 +rats 0 +were 0 +higher 0 +than 0 +those 0 +in 0 +D 1 +- 2 +AmB 2 +- 0 +treated 0 +rats 0 +. 0 + +0ur 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +results 0 +suggest 0 +that 0 +incorporation 0 +of 0 +amphotericin 1 +B 2 +into 0 +lipid 0 +nanospheres 0 +of 0 +NS 0 +- 0 +718 0 +attenuates 0 +the 0 +nephrotoxicity 3 +of 0 +amphotericin 1 +B 2 +. 0 + +Patterns 0 +of 0 +sulfadiazine 1 +acute 3 +nephrotoxicity 4 +. 0 + +Sulfadiazine 1 +acute 3 +nephrotoxicity 4 +is 0 +reviving 0 +specially 0 +because 0 +of 0 +its 0 +use 0 +in 0 +toxoplasmosis 3 +in 0 +HIV 0 +- 0 +positive 0 +patients 0 +. 0 + +We 0 +report 0 +4 0 +cases 0 +, 0 +one 0 +of 0 +them 0 +in 0 +a 0 +previously 0 +healthy 0 +person 0 +. 0 + +Under 0 +treatment 0 +with 0 +sulfadiazine 1 +they 0 +developed 0 +oliguria 3 +, 0 +abdominal 3 +pain 4 +, 0 +renal 3 +failure 4 +and 0 +showed 0 +multiple 0 +radiolucent 0 +renal 3 +calculi 4 +in 0 +echography 0 +. 0 + +All 0 +patients 0 +recovered 0 +their 0 +previous 0 +normal 0 +renal 0 +function 0 +after 0 +adequate 0 +hydration 0 +and 0 +alcalinization 0 +. 0 + +A 0 +nephrostomy 0 +tube 0 +had 0 +to 0 +be 0 +placed 0 +in 0 +one 0 +of 0 +the 0 +patients 0 +for 0 +ureteral 3 +lithiasis 4 +in 0 +a 0 +single 0 +functional 0 +kidney 0 +. 0 + +None 0 +of 0 +them 0 +needed 0 +dialysis 0 +or 0 +a 0 +renal 0 +biopsy 0 +because 0 +of 0 +a 0 +typical 0 +benign 0 +course 0 +. 0 + +Treatment 0 +with 0 +sulfadiazine 1 +requires 0 +exquisite 0 +control 0 +of 0 +renal 0 +function 0 +, 0 +an 0 +increase 0 +in 0 +water 0 +ingestion 0 +and 0 +possibly 0 +the 0 +alcalinization 0 +of 0 +the 0 +urine 0 +. 0 + +We 0 +communicate 0 +a 0 +case 0 +in 0 +a 0 +previously 0 +healthy 0 +person 0 +, 0 +a 0 +fact 0 +not 0 +found 0 +in 0 +the 0 +recent 0 +literature 0 +. 0 + +Probably 0 +many 0 +more 0 +cases 0 +are 0 +not 0 +detected 0 +. 0 + +We 0 +think 0 +that 0 +a 0 +prospective 0 +study 0 +would 0 +be 0 +useful 0 +. 0 + +Downbeat 3 +nystagmus 4 +associated 0 +with 0 +intravenous 0 +patient 0 +- 0 +controlled 0 +administration 0 +of 0 +morphine 1 +. 0 + +IMPLICATI0NS 0 +: 0 +This 0 +case 0 +documents 0 +a 0 +patient 0 +who 0 +developed 0 +dizziness 3 +with 0 +downbeating 3 +nystagmus 4 +while 0 +receiving 0 +a 0 +relatively 0 +large 0 +dose 0 +of 0 +IV 0 +patient 0 +- 0 +controlled 0 +analgesia 0 +morphine 1 +. 0 + +Although 0 +there 0 +have 0 +been 0 +case 0 +reports 0 +of 0 +epidural 0 +morphine 1 +with 0 +these 0 +symptoms 0 +and 0 +signs 0 +, 0 +this 0 +has 0 +not 0 +been 0 +previously 0 +documented 0 +with 0 +IV 0 +or 0 +patient 0 +- 0 +controlled 0 +analgesia 0 +morphine 1 +. 0 + +Hemodynamic 0 +and 0 +antiadrenergic 0 +effects 0 +of 0 +dronedarone 1 +and 0 +amiodarone 1 +in 0 +animals 0 +with 0 +a 0 +healed 0 +myocardial 3 +infarction 4 +. 0 + +The 0 +hemodynamic 0 +and 0 +antiadrenergic 0 +effects 0 +of 0 +dronedarone 1 +, 0 +a 0 +noniodinated 0 +compound 0 +structurally 0 +related 0 +to 0 +amiodarone 1 +, 0 +were 0 +compared 0 +with 0 +those 0 +of 0 +amiodarone 1 +after 0 +prolonged 0 +oral 0 +administration 0 +, 0 +both 0 +at 0 +rest 0 +and 0 +during 0 +sympathetic 0 +stimulation 0 +in 0 +conscious 0 +dogs 0 +with 0 +a 0 +healed 0 +myocardial 3 +infarction 4 +. 0 + +All 0 +dogs 0 +( 0 +n 0 += 0 +6 0 +) 0 +randomly 0 +received 0 +orally 0 +dronedarone 1 +( 0 +10 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +amiodarone 1 +( 0 +10 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +and 0 +placebo 0 +twice 0 +daily 0 +for 0 +7 0 +days 0 +, 0 +with 0 +a 0 +3 0 +- 0 +week 0 +washout 0 +between 0 +consecutive 0 +treatments 0 +. 0 + +Heart 0 +rate 0 +( 0 +HR 0 +) 0 +, 0 +mean 0 +arterial 0 +pressure 0 +( 0 +MBP 0 +) 0 +, 0 +positive 0 +rate 0 +of 0 +increase 0 +of 0 +left 0 +ventricular 0 +pressure 0 +( 0 ++ 0 +LVdP 0 +/ 0 +dt 0 +) 0 +, 0 +echocardiographically 0 +assessed 0 +left 0 +ventricular 0 +ejection 0 +fraction 0 +( 0 +LVEF 0 +) 0 +, 0 +and 0 +fractional 0 +shortening 0 +( 0 +FS 0 +) 0 +, 0 +as 0 +well 0 +as 0 +chronotropic 0 +response 0 +to 0 +isoproterenol 1 +and 0 +exercise 0 +- 0 +induced 0 +sympathetic 0 +stimulation 0 +were 0 +evaluated 0 +under 0 +baseline 0 +and 0 +posttreatment 0 +conditions 0 +. 0 + +Resting 0 +values 0 +of 0 +LVEF 0 +, 0 +FS 0 +, 0 ++ 0 +LVdP 0 +/ 0 +dt 0 +, 0 +and 0 +MBP 0 +remained 0 +unchanged 0 +whatever 0 +the 0 +drug 0 +and 0 +the 0 +dosing 0 +regimen 0 +, 0 +whereas 0 +resting 0 +HR 0 +was 0 +significantly 0 +and 0 +dose 0 +- 0 +dependently 0 +lowered 0 +after 0 +dronedarone 1 +and 0 +to 0 +a 0 +lesser 0 +extent 0 +after 0 +amiodarone 1 +. 0 + +Both 0 +dronedarone 1 +and 0 +amiodarone 1 +significantly 0 +reduced 0 +the 0 +exercise 0 +- 0 +induced 0 +tachycardia 3 +and 0 +, 0 +at 0 +the 0 +highest 0 +dose 0 +, 0 +decreased 0 +the 0 +isoproterenol 1 +- 0 +induced 0 +tachycardia 3 +. 0 + +Thus 0 +, 0 +dronedarone 1 +and 0 +amiodarone 1 +displayed 0 +a 0 +similar 0 +level 0 +of 0 +antiadrenergic 0 +effect 0 +and 0 +did 0 +not 0 +impair 0 +the 0 +resting 0 +left 0 +ventricular 0 +function 0 +. 0 + +Consequently 0 +, 0 +dronedarone 1 +might 0 +be 0 +particularly 0 +suitable 0 +for 0 +the 0 +treatment 0 +and 0 +prevention 0 +of 0 +various 0 +clinical 0 +arrhythmias 3 +, 0 +without 0 +compromising 0 +the 0 +left 0 +ventricular 0 +function 0 +. 0 + +Phase 0 +2 0 +trial 0 +of 0 +liposomal 0 +doxorubicin 1 +( 0 +40 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +) 0 +in 0 +platinum 1 +/ 0 +paclitaxel 1 +- 0 +refractory 0 +ovarian 3 +and 4 +fallopian 4 +tube 4 +cancers 4 +and 0 +primary 0 +carcinoma 3 +of 4 +the 4 +peritoneum 4 +. 0 + +BACKGR0UND 0 +: 0 +Several 0 +studies 0 +have 0 +demonstrated 0 +liposomal 0 +doxorubicin 1 +( 0 +Doxil 1 +) 0 +to 0 +be 0 +an 0 +active 0 +antineoplastic 0 +agent 0 +in 0 +platinum 1 +- 0 +resistant 0 +ovarian 3 +cancer 4 +, 0 +with 0 +dose 0 +limiting 0 +toxicity 3 +of 0 +the 0 +standard 0 +dosing 0 +regimen 0 +( 0 +50 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +q 0 +4 0 +weeks 0 +) 0 +being 0 +severe 0 +erythrodysesthesia 3 +( 0 +" 0 +hand 3 +- 4 +foot 4 +syndrome 4 +" 0 +) 0 +and 0 +stomatitis 3 +. 0 + +We 0 +wished 0 +to 0 +develop 0 +a 0 +more 0 +tolerable 0 +liposomal 0 +doxorubicin 1 +treatment 0 +regimen 0 +and 0 +document 0 +its 0 +level 0 +of 0 +activity 0 +in 0 +a 0 +well 0 +- 0 +defined 0 +patient 0 +population 0 +with 0 +platinum 1 +/ 0 +paclitaxel 1 +- 0 +refractory 0 +disease 0 +. 0 + +METH0DS 0 +AND 0 +MATERIALS 0 +: 0 +Patients 0 +with 0 +ovarian 3 +or 4 +fallopian 4 +tube 4 +cancers 4 +or 0 +primary 0 +peritoneal 3 +carcinoma 4 +with 0 +platinum 1 +/ 0 +paclitaxel 1 +- 0 +refractory 0 +disease 0 +( 0 +stable 0 +or 0 +progressive 0 +disease 0 +following 0 +treatment 0 +with 0 +these 0 +agents 0 +or 0 +previous 0 +objective 0 +response 0 +< 0 +3 0 +months 0 +in 0 +duration 0 +) 0 +were 0 +treated 0 +with 0 +liposomal 0 +doxorubicin 1 +at 0 +a 0 +dose 0 +of 0 +40 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +q 0 +4 0 +weeks 0 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +49 0 +patients 0 +( 0 +median 0 +age 0 +: 0 +60 0 +; 0 +range 0 +41 0 +- 0 +81 0 +) 0 +entered 0 +this 0 +phase 0 +2 0 +trial 0 +. 0 + +The 0 +median 0 +number 0 +of 0 +prior 0 +regimens 0 +was 0 +2 0 +( 0 +range 0 +: 0 +1 0 +- 0 +6 0 +) 0 +. 0 + +Six 0 +( 0 +12 0 +% 0 +) 0 +and 0 +4 0 +( 0 +8 0 +% 0 +) 0 +patients 0 +experienced 0 +grade 0 +2 0 +hand 3 +- 4 +foot 4 +syndrome 4 +and 0 +stomatitis 3 +, 0 +respectively 0 +( 0 +no 0 +episodes 0 +of 0 +grade 0 +3 0 +) 0 +. 0 + +0ne 0 +patient 0 +developed 0 +grade 0 +3 0 +diarrhea 3 +requiring 0 +hospitalization 0 +for 0 +hydration 0 +. 0 + +Six 0 +( 0 +12 0 +% 0 +) 0 +individuals 0 +required 0 +dose 0 +reductions 0 +. 0 + +The 0 +median 0 +number 0 +of 0 +courses 0 +of 0 +liposomal 0 +doxorubicin 1 +administered 0 +on 0 +this 0 +protocol 0 +was 0 +2 0 +( 0 +range 0 +: 0 +1 0 +- 0 +12 0 +) 0 +. 0 + +Four 0 +of 0 +44 0 +patients 0 +( 0 +9 0 +% 0 +) 0 +evaluable 0 +for 0 +response 0 +exhibited 0 +objective 0 +and 0 +subjective 0 +evidence 0 +of 0 +an 0 +antineoplastic 0 +effect 0 +of 0 +therapy 0 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +modified 0 +liposomal 0 +doxorubicin 1 +regimen 0 +results 0 +in 0 +less 0 +toxicity 3 +( 0 +stomatitis 3 +, 0 +hand 3 +- 4 +foot 4 +syndrome 4 +) 0 +than 0 +the 0 +standard 0 +FDA 0 +- 0 +approved 0 +dose 0 +schedule 0 +. 0 + +Definite 0 +, 0 +although 0 +limited 0 +, 0 +antineoplastic 0 +activity 0 +is 0 +observed 0 +in 0 +patients 0 +with 0 +well 0 +- 0 +defined 0 +platinum 1 +- 0 +and 0 +paclitaxel 1 +- 0 +refractory 0 +ovarian 3 +cancer 4 +. 0 + +Efficacy 0 +of 0 +olanzapine 1 +in 0 +acute 0 +bipolar 3 +mania 4 +: 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +study 0 +. 0 + +The 0 +0lanzipine 1 +HGGW 0 +Study 0 +Group 0 +. 0 + +BACKGR0UND 0 +: 0 +We 0 +compared 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +olanzapine 1 +vs 0 +placebo 0 +for 0 +the 0 +treatment 0 +of 0 +acute 0 +bipolar 3 +mania 4 +. 0 + +METH0DS 0 +: 0 +Four 0 +- 0 +week 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +parallel 0 +study 0 +. 0 + +A 0 +total 0 +of 0 +115 0 +patients 0 +with 0 +a 0 +DSM 0 +- 0 +IV 0 +diagnosis 0 +of 0 +bipolar 3 +disorder 4 +, 0 +manic 3 +or 0 +mixed 0 +, 0 +were 0 +randomized 0 +to 0 +olanzapine 1 +, 0 +5 0 +to 0 +20 0 +mg 0 +/ 0 +d 0 +( 0 +n 0 += 0 +55 0 +) 0 +, 0 +or 0 +placebo 0 +( 0 +n 0 += 0 +60 0 +) 0 +. 0 + +The 0 +primary 0 +efficacy 0 +measure 0 +was 0 +the 0 +Young 0 +- 0 +Mania 3 +Rating 0 +Scale 0 +( 0 +Y 0 +- 0 +MRS 0 +) 0 +total 0 +score 0 +. 0 + +Response 0 +and 0 +euthymia 0 +were 0 +defined 0 +, 0 +a 0 +priori 0 +, 0 +as 0 +at 0 +least 0 +a 0 +50 0 +% 0 +improvement 0 +from 0 +baseline 0 +to 0 +end 0 +point 0 +and 0 +as 0 +a 0 +score 0 +of 0 +no 0 +less 0 +than 0 +12 0 +at 0 +end 0 +point 0 +in 0 +the 0 +Y 0 +- 0 +MRS 0 +total 0 +score 0 +, 0 +respectively 0 +. 0 + +Safety 0 +was 0 +assessed 0 +using 0 +adverse 0 +events 0 +, 0 +Extrapyramidal 3 +Symptom 4 +( 0 +EPS 3 +) 0 +rating 0 +scales 0 +, 0 +laboratory 0 +values 0 +, 0 +electrocardiograms 0 +, 0 +vital 0 +signs 0 +, 0 +and 0 +weight 0 +change 0 +. 0 + +RESULTS 0 +: 0 +0lanzapine 1 +- 0 +treated 0 +patients 0 +demonstrated 0 +a 0 +statistically 0 +significant 0 +greater 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +improvement 0 +in 0 +Y 0 +- 0 +MRS 0 +total 0 +score 0 +than 0 +placebo 0 +- 0 +treated 0 +patients 0 +( 0 +- 0 +14 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +12 0 +. 0 +5 0 +and 0 +- 0 +8 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +12 0 +. 0 +7 0 +, 0 +respectively 0 +; 0 +P 0 +< 0 +. 0 +001 0 +) 0 +, 0 +which 0 +was 0 +evident 0 +at 0 +the 0 +first 0 +postbaseline 0 +observation 0 +1 0 +week 0 +after 0 +randomization 0 +and 0 +was 0 +maintained 0 +throughout 0 +the 0 +study 0 +( 0 +last 0 +observation 0 +carried 0 +forward 0 +) 0 +. 0 + +0lanzapine 1 +- 0 +treated 0 +patients 0 +demonstrated 0 +a 0 +higher 0 +rate 0 +of 0 +response 0 +( 0 +65 0 +% 0 +vs 0 +43 0 +% 0 +, 0 +respectively 0 +; 0 +P 0 += 0 +. 0 +02 0 +) 0 +and 0 +euthymia 0 +( 0 +61 0 +% 0 +vs 0 +36 0 +% 0 +, 0 +respectively 0 +; 0 +P 0 += 0 +. 0 +01 0 +) 0 +than 0 +placebo 0 +- 0 +treated 0 +patients 0 +. 0 + +There 0 +were 0 +no 0 +statistically 0 +significant 0 +differences 0 +in 0 +EPSs 3 +between 0 +groups 0 +. 0 + +However 0 +, 0 +olanzapine 1 +- 0 +treated 0 +patients 0 +had 0 +a 0 +statistically 0 +significant 0 +greater 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +weight 3 +gain 4 +than 0 +placebo 0 +- 0 +treated 0 +patients 0 +( 0 +2 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +8 0 +vs 0 +0 0 +. 0 +45 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +3 0 +kg 0 +, 0 +respectively 0 +) 0 +and 0 +also 0 +experienced 0 +more 0 +treatment 0 +- 0 +emergent 0 +somnolence 3 +( 0 +21 0 +patients 0 +[ 0 +38 0 +. 0 +2 0 +% 0 +] 0 +vs 0 +5 0 +[ 0 +8 0 +. 0 +3 0 +% 0 +] 0 +, 0 +respectively 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0lanzapine 1 +demonstrated 0 +greater 0 +efficacy 0 +than 0 +placebo 0 +in 0 +the 0 +treatment 0 +of 0 +acute 0 +bipolar 3 +mania 4 +and 0 +was 0 +generally 0 +well 0 +tolerated 0 +. 0 + +The 0 +effect 0 +of 0 +pupil 3 +dilation 4 +with 0 +tropicamide 1 +on 0 +vision 0 +and 0 +driving 0 +simulator 0 +performance 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +assess 0 +the 0 +effect 0 +of 0 +pupil 3 +dilation 4 +on 0 +vision 0 +and 0 +driving 0 +ability 0 +. 0 + +METH0DS 0 +: 0 +A 0 +series 0 +of 0 +tests 0 +on 0 +various 0 +parameters 0 +of 0 +visual 0 +function 0 +and 0 +driving 0 +simulator 0 +performance 0 +were 0 +performed 0 +on 0 +12 0 +healthy 0 +drivers 0 +, 0 +before 0 +and 0 +after 0 +pupil 3 +dilation 4 +using 0 +guttae 0 +tropicamide 1 +1 0 +% 0 +. 0 + +A 0 +driving 0 +simulator 0 +( 0 +Transport 0 +Research 0 +Laboratory 0 +) 0 +was 0 +used 0 +to 0 +measure 0 +reaction 0 +time 0 +( 0 +RT 0 +) 0 +, 0 +speed 0 +maintenance 0 +and 0 +steering 0 +accuracy 0 +. 0 + +Tests 0 +of 0 +basic 0 +visual 0 +function 0 +included 0 +high 0 +- 0 +and 0 +low 0 +- 0 +contrast 0 +visual 0 +acuity 0 +( 0 +HCVA 0 +and 0 +LCVA 0 +) 0 +, 0 +Pelli 0 +- 0 +Robson 0 +contrast 0 +threshold 0 +( 0 +CT 0 +) 0 +and 0 +Goldmann 0 +perimetry 0 +( 0 +FIELDS 0 +) 0 +. 0 + +Useful 0 +Field 0 +of 0 +View 0 +( 0 +UF0V 0 +- 0 +- 0 +a 0 +test 0 +of 0 +visual 0 +attention 0 +) 0 +was 0 +also 0 +undertaken 0 +. 0 + +The 0 +mean 0 +differences 0 +in 0 +the 0 +pre 0 +- 0 +and 0 +post 0 +- 0 +dilatation 0 +measurements 0 +were 0 +tested 0 +for 0 +statistical 0 +significance 0 +at 0 +the 0 +95 0 +% 0 +level 0 +using 0 +one 0 +- 0 +tail 0 +paired 0 +t 0 +- 0 +tests 0 +. 0 + +RESULTS 0 +: 0 +Pupillary 3 +dilation 4 +resulted 0 +in 0 +a 0 +statistically 0 +significant 0 +deterioration 0 +in 0 +CT 0 +and 0 +HCVA 0 +only 0 +. 0 + +Five 0 +of 0 +12 0 +drivers 0 +also 0 +exhibited 0 +deterioration 0 +in 0 +LCVA 0 +, 0 +CT 0 +and 0 +RT 0 +. 0 + +Little 0 +evidence 0 +emerged 0 +for 0 +deterioration 0 +in 0 +FIELDS 0 +and 0 +UF0V 0 +. 0 + +Also 0 +, 0 +7 0 +of 0 +12 0 +drivers 0 +appeared 0 +to 0 +adjust 0 +their 0 +driving 0 +behaviour 0 +by 0 +reducing 0 +their 0 +speed 0 +on 0 +the 0 +driving 0 +simulator 0 +, 0 +leading 0 +to 0 +improved 0 +steering 0 +accuracy 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Pupillary 3 +dilation 4 +may 0 +lead 0 +to 0 +a 0 +decrease 0 +in 0 +vision 0 +and 0 +daylight 0 +driving 0 +performance 0 +in 0 +young 0 +people 0 +. 0 + +A 0 +larger 0 +study 0 +, 0 +including 0 +a 0 +broader 0 +spectrum 0 +of 0 +subjects 0 +, 0 +is 0 +warranted 0 +before 0 +guidelines 0 +can 0 +be 0 +recommended 0 +. 0 + +A 0 +case 0 +of 0 +isotretinoin 3 +embryopathy 4 +with 0 +bilateral 0 +anotia 3 +and 0 +Taussig 3 +- 4 +Bing 4 +malformation 4 +. 0 + +We 0 +report 0 +a 0 +newborn 0 +infant 0 +with 0 +multiple 0 +congenital 0 +anomalies 0 +( 0 +anotia 3 +and 0 +Taussig 3 +- 4 +Bing 4 +malformation 4 +) 0 +due 0 +to 0 +exposure 0 +to 0 +isotretinoin 1 +within 0 +the 0 +first 0 +trimester 0 +. 0 + +In 0 +this 0 +paper 0 +we 0 +aim 0 +to 0 +draw 0 +to 0 +the 0 +fact 0 +that 0 +caution 0 +is 0 +needed 0 +when 0 +prescribing 0 +vitamin 1 +A 2 +- 0 +containing 0 +drugs 0 +to 0 +women 0 +of 0 +childbearing 0 +years 0 +. 0 + +Effect 0 +of 0 +methoxamine 1 +on 0 +maximum 0 +urethral 0 +pressure 0 +in 0 +women 0 +with 0 +genuine 0 +stress 3 +incontinence 4 +: 0 +a 0 +placebo 0 +- 0 +controlled 0 +, 0 +double 0 +- 0 +blind 0 +crossover 0 +study 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +potential 0 +role 0 +for 0 +a 0 +selective 0 +alpha1 0 +- 0 +adrenoceptor 0 +agonist 0 +in 0 +the 0 +treatment 0 +of 0 +urinary 3 +stress 4 +incontinence 4 +. 0 + +A 0 +randomised 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +crossover 0 +study 0 +design 0 +was 0 +employed 0 +. 0 + +Half 0 +log 0 +incremental 0 +doses 0 +of 0 +intravenous 0 +methoxamine 1 +or 0 +placebo 0 +( 0 +saline 0 +) 0 +were 0 +administered 0 +to 0 +a 0 +group 0 +of 0 +women 0 +with 0 +genuine 0 +stress 3 +incontinence 4 +while 0 +measuring 0 +maximum 0 +urethral 0 +pressure 0 +( 0 +MUP 0 +) 0 +, 0 +blood 0 +pressure 0 +, 0 +heart 0 +rate 0 +, 0 +and 0 +symptomatic 0 +side 0 +effects 0 +. 0 + +Methoxamine 1 +evoked 0 +non 0 +- 0 +significant 0 +increases 0 +in 0 +MUP 0 +and 0 +diastolic 0 +blood 0 +pressure 0 +but 0 +caused 0 +a 3 +significant 4 +rise 4 +in 4 +systolic 4 +blood 4 +pressure 4 +and 0 +significant 0 +fall 0 +in 0 +heart 0 +rate 0 +at 0 +maximum 0 +dosage 0 +. 0 + +Systemic 0 +side 0 +effects 0 +including 0 +piloerection 0 +, 0 +headache 3 +, 0 +and 0 +cold 0 +extremities 0 +were 0 +experienced 0 +in 0 +all 0 +subjects 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +the 0 +clinical 0 +usefulness 0 +of 0 +direct 0 +, 0 +peripherally 0 +acting 0 +sub 0 +- 0 +type 0 +- 0 +selective 0 +alpha1 0 +- 0 +adrenoceptor 0 +agonists 0 +in 0 +the 0 +medical 0 +treatment 0 +of 0 +stress 3 +incontinence 4 +may 0 +be 0 +limited 0 +by 0 +associated 0 +piloerection 0 +and 0 +cardiovascular 0 +side 0 +effects 0 +. 0 + +Hyperglycemic 3 +effect 0 +of 0 +amino 1 +compounds 0 +structurally 0 +related 0 +to 0 +caproate 1 +in 0 +rats 0 +. 0 + +The 0 +chronic 0 +feeding 0 +of 0 +small 0 +amounts 0 +( 0 +0 0 +. 0 +3 0 +- 0 +3 0 +% 0 +of 0 +diet 0 +weight 0 +) 0 +of 0 +certain 0 +amino 1 +derivatives 0 +of 0 +caproate 1 +resulted 0 +in 0 +hyperglycemia 3 +, 0 +an 0 +elevated 0 +glucose 1 +tolerance 0 +curve 0 +and 0 +, 0 +occasionally 0 +, 0 +glucosuria 3 +. 0 + +Effective 0 +compounds 0 +included 0 +norleucine 1 +, 0 +norvaline 1 +, 0 +glutamate 1 +, 0 +epsilon 1 +- 2 +aminocaproate 2 +, 0 +methionine 1 +, 0 +and 0 +leucine 1 +. 0 + +Toleration 0 +of 0 +high 0 +doses 0 +of 0 +angiotensin 1 +- 2 +converting 2 +enzyme 2 +inhibitors 2 +in 0 +patients 0 +with 0 +chronic 0 +heart 3 +failure 4 +: 0 +results 0 +from 0 +the 0 +ATLAS 0 +trial 0 +. 0 + +The 0 +Assessment 0 +of 0 +Treatment 0 +with 0 +Lisinopril 1 +and 0 +Survival 0 +. 0 + +BACKGR0UND 0 +: 0 +Treatment 0 +with 0 +angiotensin 1 +- 2 +converting 2 +enzyme 2 +( 2 +ACE 2 +) 2 +inhibitors 2 +reduces 0 +mortality 0 +and 0 +morbidity 0 +in 0 +patients 0 +with 0 +chronic 0 +heart 3 +failure 4 +( 0 +CHF 3 +) 0 +, 0 +but 0 +most 0 +affected 0 +patients 0 +are 0 +not 0 +receiving 0 +these 0 +agents 0 +or 0 +are 0 +being 0 +treated 0 +with 0 +doses 0 +lower 0 +than 0 +those 0 +found 0 +to 0 +be 0 +efficacious 0 +in 0 +trials 0 +, 0 +primarily 0 +because 0 +of 0 +concerns 0 +about 0 +the 0 +safety 0 +and 0 +tolerability 0 +of 0 +these 0 +agents 0 +, 0 +especially 0 +at 0 +the 0 +recommended 0 +doses 0 +. 0 + +The 0 +present 0 +study 0 +examines 0 +the 0 +safety 0 +and 0 +tolerability 0 +of 0 +high 0 +- 0 +compared 0 +with 0 +low 0 +- 0 +dose 0 +lisinopril 1 +in 0 +CHF 3 +. 0 + +METH0DS 0 +: 0 +The 0 +Assessment 0 +of 0 +Lisinopril 1 +and 0 +Survival 0 +study 0 +was 0 +a 0 +multicenter 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +trial 0 +in 0 +which 0 +patients 0 +with 0 +or 0 +without 0 +previous 0 +ACE 1 +inhibitor 2 +treatment 0 +were 0 +stabilized 0 +receiving 0 +medium 0 +- 0 +dose 0 +lisinopril 1 +( 0 +12 0 +. 0 +5 0 +or 0 +15 0 +. 0 +0 0 +mg 0 +once 0 +daily 0 +[ 0 +0D 0 +] 0 +) 0 +for 0 +2 0 +to 0 +4 0 +weeks 0 +and 0 +then 0 +randomized 0 +to 0 +high 0 +- 0 +( 0 +35 0 +. 0 +0 0 +or 0 +32 0 +. 0 +5 0 +mg 0 +0D 0 +) 0 +or 0 +low 0 +- 0 +dose 0 +( 0 +5 0 +. 0 +0 0 +or 0 +2 0 +. 0 +5 0 +mg 0 +0D 0 +) 0 +groups 0 +. 0 + +Patients 0 +with 0 +New 0 +York 0 +Heart 0 +Association 0 +classes 0 +II 0 +to 0 +IV 0 +CHF 3 +and 0 +left 0 +ventricular 0 +ejection 0 +fractions 0 +of 0 +no 0 +greater 0 +than 0 +0 0 +. 0 +30 0 +( 0 +n 0 += 0 +3164 0 +) 0 +were 0 +randomized 0 +and 0 +followed 0 +up 0 +for 0 +a 0 +median 0 +of 0 +46 0 +months 0 +. 0 + +We 0 +examined 0 +the 0 +occurrence 0 +of 0 +adverse 0 +events 0 +and 0 +the 0 +need 0 +for 0 +discontinuation 0 +and 0 +dose 0 +reduction 0 +during 0 +treatment 0 +, 0 +with 0 +a 0 +focus 0 +on 0 +hypotension 3 +and 0 +renal 3 +dysfunction 4 +. 0 + +RESULTS 0 +: 0 +0f 0 +405 0 +patients 0 +not 0 +previously 0 +receiving 0 +an 0 +ACE 1 +inhibitor 2 +, 0 +doses 0 +in 0 +only 0 +4 0 +. 0 +2 0 +% 0 +could 0 +not 0 +be 0 +titrated 0 +to 0 +the 0 +medium 0 +doses 0 +required 0 +for 0 +randomization 0 +because 0 +of 0 +symptoms 0 +possibly 0 +related 0 +to 0 +hypotension 3 +( 0 +2 0 +. 0 +0 0 +% 0 +) 0 +or 0 +because 0 +of 0 +renal 3 +dysfunction 4 +or 0 +hyperkalemia 3 +( 0 +2 0 +. 0 +3 0 +% 0 +) 0 +. 0 + +Doses 0 +in 0 +more 0 +than 0 +90 0 +% 0 +of 0 +randomized 0 +patients 0 +in 0 +the 0 +high 0 +- 0 +and 0 +low 0 +- 0 +dose 0 +groups 0 +were 0 +titrated 0 +to 0 +their 0 +assigned 0 +target 0 +, 0 +and 0 +the 0 +mean 0 +doses 0 +of 0 +blinded 0 +medication 0 +in 0 +both 0 +groups 0 +remained 0 +similar 0 +throughout 0 +the 0 +study 0 +. 0 + +Withdrawals 0 +occurred 0 +in 0 +27 0 +. 0 +1 0 +% 0 +of 0 +the 0 +high 0 +- 0 +and 0 +30 0 +. 0 +7 0 +% 0 +of 0 +the 0 +low 0 +- 0 +dose 0 +groups 0 +. 0 + +Subgroups 0 +presumed 0 +to 0 +be 0 +at 0 +higher 0 +risk 0 +for 0 +ACE 1 +inhibitor 2 +intolerance 0 +( 0 +blood 0 +pressure 0 +, 0 +< 0 +120 0 +mm 0 +Hg 0 +; 0 +creatinine 1 +, 0 +> 0 +or 0 += 0 +132 0 +. 0 +6 0 +micromol 0 +/ 0 +L 0 +[ 0 +> 0 +or 0 += 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +dL 0 +] 0 +; 0 +age 0 +, 0 +> 0 +or 0 += 0 +70 0 +years 0 +; 0 +and 0 +patients 0 +with 0 +diabetes 3 +) 0 +generally 0 +tolerated 0 +the 0 +high 0 +- 0 +dose 0 +strategy 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +findings 0 +demonstrate 0 +that 0 +ACE 1 +inhibitor 2 +therapy 0 +in 0 +most 0 +patients 0 +with 0 +CHF 3 +can 0 +be 0 +successfully 0 +titrated 0 +to 0 +and 0 +maintained 0 +at 0 +high 0 +doses 0 +, 0 +and 0 +that 0 +more 0 +aggressive 0 +use 0 +of 0 +these 0 +agents 0 +is 0 +warranted 0 +. 0 + +Cocaine 1 +, 0 +ethanol 1 +, 0 +and 0 +cocaethylene 1 +cardiotoxity 3 +in 0 +an 0 +animal 0 +model 0 +of 0 +cocaine 3 +and 4 +ethanol 4 +abuse 4 +. 0 + +0BJECTIVES 0 +: 0 +Simultaneous 0 +abuse 3 +of 4 +cocaine 4 +and 4 +ethanol 4 +affects 0 +12 0 +million 0 +Americans 0 +annually 0 +. 0 + +In 0 +combination 0 +, 0 +these 0 +substances 0 +are 0 +substantially 0 +more 0 +toxic 0 +than 0 +either 0 +drug 0 +alone 0 +. 0 + +Their 0 +combined 0 +cardiac 3 +toxicity 4 +may 0 +be 0 +due 0 +to 0 +independent 0 +effects 0 +of 0 +each 0 +drug 0 +; 0 +however 0 +, 0 +they 0 +may 0 +also 0 +be 0 +due 0 +to 0 +cocaethylene 1 +( 0 +CE 1 +) 0 +, 0 +a 0 +cocaine 1 +metabolite 0 +formed 0 +only 0 +in 0 +the 0 +presence 0 +of 0 +ethanol 1 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +delineate 0 +the 0 +role 0 +of 0 +CE 1 +in 0 +the 0 +combined 0 +cardiotoxicity 3 +of 0 +cocaine 1 +and 0 +ethanol 1 +in 0 +a 0 +model 0 +simulating 0 +their 0 +abuse 0 +. 0 + +METH0DS 0 +: 0 +Twenty 0 +- 0 +three 0 +dogs 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +1 0 +) 0 +three 0 +intravenous 0 +( 0 +IV 0 +) 0 +boluses 0 +of 0 +cocaine 1 +7 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +with 0 +ethanol 1 +( 0 +1 0 +g 0 +/ 0 +kg 0 +) 0 +as 0 +an 0 +IV 0 +infusion 0 +( 0 +C 0 ++ 0 +E 0 +, 0 +n 0 += 0 +8 0 +) 0 +, 0 +2 0 +) 0 +three 0 +cocaine 1 +boluses 0 +only 0 +( 0 +C 0 +, 0 +n 0 += 0 +6 0 +) 0 +, 0 +3 0 +) 0 +ethanol 1 +infusion 0 +only 0 +( 0 +E 0 +, 0 +n 0 += 0 +5 0 +) 0 +, 0 +or 0 +4 0 +) 0 +placebo 0 +boluses 0 +and 0 +infusion 0 +( 0 +n 0 += 0 +4 0 +) 0 +. 0 + +Hemodynamic 0 +measurements 0 +, 0 +electrocardiograms 0 +, 0 +and 0 +serum 0 +drug 0 +concentrations 0 +were 0 +obtained 0 +at 0 +baseline 0 +, 0 +and 0 +then 0 +at 0 +fixed 0 +time 0 +intervals 0 +after 0 +each 0 +drug 0 +was 0 +administered 0 +. 0 + +RESULTS 0 +: 0 +Two 0 +of 0 +eight 0 +dogs 0 +in 0 +the 0 +C 0 ++ 0 +E 0 +group 0 +experienced 0 +cardiovascular 3 +collapse 4 +. 0 + +The 0 +most 0 +dramatic 0 +hemodynamic 0 +changes 0 +occurred 0 +after 0 +each 0 +cocaine 1 +bolus 0 +in 0 +the 0 +C 0 ++ 0 +E 0 +and 0 +C 0 +only 0 +groups 0 +; 0 +however 0 +, 0 +persistent 0 +hemodynamic 0 +changes 0 +occurred 0 +in 0 +the 0 +C 0 ++ 0 +E 0 +group 0 +. 0 + +Peak 0 +CE 1 +levels 0 +were 0 +associated 0 +with 0 +a 0 +45 0 +% 0 +( 0 +SD 0 ++ 0 +/ 0 +- 0 +22 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +22 0 +% 0 +to 0 +69 0 +% 0 +) 0 +decrease 3 +in 4 +cardiac 4 +output 4 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +a 0 +56 0 +% 0 +( 0 +SD 0 ++ 0 +/ 0 +- 0 +23 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +32 0 +% 0 +to 0 +80 0 +% 0 +) 0 +decrease 0 +in 0 +dP 0 +/ 0 +dt 0 +( 0 +max 0 +) 0 +( 0 +p 0 +< 0 +. 0 +006 0 +) 0 +, 0 +and 0 +a 0 +23 0 +% 0 +( 0 +SD 0 ++ 0 +/ 0 +- 0 +15 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +7 0 +% 0 +to 0 +49 0 +% 0 +) 0 +decrease 0 +in 0 +SV0 0 +( 0 +2 0 +) 0 +( 0 +p 0 +< 0 +0 0 +. 0 +025 0 +) 0 +. 0 + +Ventricular 3 +arrhythmias 4 +were 0 +primarily 0 +observed 0 +in 0 +the 0 +C 0 ++ 0 +E 0 +group 0 +, 0 +in 0 +which 0 +four 0 +of 0 +eight 0 +dogs 0 +experienced 0 +ventricular 3 +tachycardia 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Cocaine 1 +and 0 +ethanol 1 +in 0 +combination 0 +were 0 +more 0 +toxic 0 +than 0 +either 0 +substance 0 +alone 0 +. 0 + +Co 0 +- 0 +administration 0 +resulted 0 +in 0 +prolonged 0 +cardiac 3 +toxicity 4 +and 0 +was 0 +dysrhythmogenic 0 +. 0 + +Peak 0 +serum 0 +cocaethylene 1 +concentrations 0 +were 0 +associated 0 +with 0 +prolonged 0 +myocardial 3 +depression 4 +. 0 + +Worsening 0 +of 0 +Parkinsonism 3 +after 0 +the 0 +use 0 +of 0 +veralipride 1 +for 0 +treatment 0 +of 0 +menopause 0 +: 0 +case 0 +report 0 +. 0 + +We 0 +describe 0 +a 0 +female 0 +patient 0 +with 0 +stable 0 +Parkinson 3 +' 4 +s 4 +disease 4 +who 0 +has 0 +shown 0 +a 0 +marked 0 +worsening 0 +of 0 +her 0 +motor 0 +functions 0 +following 0 +therapy 0 +of 0 +menopause 0 +related 0 +symptoms 0 +with 0 +veralipride 1 +, 0 +as 0 +well 0 +as 0 +the 0 +improvement 0 +of 0 +her 0 +symptoms 0 +back 0 +to 0 +baseline 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +. 0 + +We 0 +emphasize 0 +the 0 +anti 0 +- 0 +dopaminergic 0 +effect 0 +of 0 +veralipride 1 +. 0 + +Viracept 1 +and 0 +irregular 3 +heartbeat 4 +warning 0 +. 0 + +A 0 +group 0 +of 0 +doctors 0 +in 0 +Boston 0 +warn 0 +that 0 +the 0 +protease 0 +inhibitor 0 +Viracept 1 +may 0 +cause 0 +an 0 +irregular 3 +heart 4 +beat 4 +, 0 +known 0 +as 0 +bradycardia 3 +, 0 +in 0 +people 0 +with 0 +HIV 0 +. 0 + +Bradycardia 3 +occurred 0 +in 0 +a 0 +45 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +who 0 +was 0 +Viracept 1 +in 0 +combination 0 +with 0 +other 0 +anti 0 +- 0 +HIV 0 +drugs 0 +. 0 + +The 0 +symptoms 0 +ceased 0 +after 0 +switching 0 +to 0 +another 0 +drug 0 +combination 0 +. 0 + +Frequency 0 +of 0 +appearance 0 +of 0 +myeloperoxidase 0 +- 0 +antineutrophil 0 +cytoplasmic 0 +antibody 0 +( 0 +MP0 0 +- 0 +ANCA 0 +) 0 +in 0 +Graves 3 +' 4 +disease 4 +patients 0 +treated 0 +with 0 +propylthiouracil 1 +and 0 +the 0 +relationship 0 +between 0 +MP0 0 +- 0 +ANCA 0 +and 0 +clinical 0 +manifestations 0 +. 0 + +0BJECTIVE 0 +: 0 +Myeloperoxidase 0 +antineutrophil 0 +cytoplasmic 0 +antibody 0 +( 0 +MP0 0 +- 0 +ANCA 0 +) 0 +- 0 +positive 0 +vasculitis 3 +has 0 +been 0 +reported 0 +in 0 +patients 0 +with 0 +Graves 3 +' 4 +disease 4 +who 0 +were 0 +treated 0 +with 0 +propylthiouracil 1 +( 0 +PTU 1 +) 0 +. 0 + +The 0 +appearance 0 +of 0 +MP0 0 +- 0 +ANCA 0 +in 0 +these 0 +cases 0 +was 0 +suspected 0 +of 0 +being 0 +related 0 +to 0 +PTU 1 +because 0 +the 0 +titres 0 +of 0 +MP0 0 +- 0 +ANCA 0 +decreased 0 +when 0 +PTU 1 +was 0 +stopped 0 +. 0 + +Nevertheless 0 +, 0 +there 0 +have 0 +been 0 +no 0 +studies 0 +on 0 +the 0 +temporal 0 +relationship 0 +between 0 +the 0 +appearance 0 +of 0 +MP0 0 +- 0 +ANCA 0 +and 0 +vasculitis 3 +during 0 +PTU 1 +therapy 0 +, 0 +or 0 +on 0 +the 0 +incidence 0 +of 0 +MP0 0 +- 0 +ANCA 0 +in 0 +untreated 0 +Graves 3 +' 4 +disease 4 +patients 0 +. 0 + +Therefore 0 +, 0 +we 0 +sought 0 +to 0 +address 0 +these 0 +parameters 0 +in 0 +patients 0 +with 0 +Graves 3 +' 4 +disease 4 +. 0 + +PATIENTS 0 +: 0 +We 0 +investigated 0 +102 0 +untreated 0 +patients 0 +with 0 +hyperthyroidism 3 +due 0 +to 0 +Graves 3 +' 4 +disease 4 +for 0 +the 0 +presence 0 +of 0 +MP0 0 +- 0 +ANCA 0 +, 0 +and 0 +for 0 +the 0 +development 0 +vasculitis 3 +after 0 +starting 0 +PTU 1 +therapy 0 +. 0 + +Twenty 0 +- 0 +nine 0 +of 0 +them 0 +were 0 +later 0 +excluded 0 +because 0 +of 0 +adverse 0 +effects 0 +of 0 +PTU 1 +or 0 +because 0 +the 0 +observation 0 +period 0 +was 0 +less 0 +than 0 +3 0 +months 0 +. 0 + +The 0 +remaining 0 +73 0 +patients 0 +( 0 +55 0 +women 0 +and 0 +18 0 +men 0 +) 0 +, 0 +all 0 +of 0 +whom 0 +were 0 +examined 0 +for 0 +more 0 +than 0 +3 0 +months 0 +, 0 +were 0 +adopted 0 +as 0 +the 0 +subjects 0 +of 0 +the 0 +investigation 0 +. 0 + +The 0 +median 0 +observation 0 +period 0 +was 0 +23 0 +. 0 +6 0 +months 0 +( 0 +range 0 +: 0 +3 0 +- 0 +37 0 +months 0 +) 0 +. 0 + +MEASUREMENTS 0 +: 0 +MP0 0 +- 0 +ANCA 0 +was 0 +measured 0 +at 0 +intervals 0 +of 0 +2 0 +- 0 +6 0 +months 0 +. 0 + +RESULTS 0 +: 0 +Before 0 +treatment 0 +, 0 +the 0 +MP0 0 +- 0 +ANCA 0 +titres 0 +of 0 +all 0 +102 0 +untreated 0 +Graves 3 +' 4 +disease 4 +patients 0 +were 0 +within 0 +the 0 +reference 0 +range 0 +( 0 +below 0 +10 0 +U 0 +/ 0 +ml 0 +) 0 +. 0 + +Three 0 +( 0 +4 0 +. 0 +1 0 +% 0 +) 0 +of 0 +the 0 +73 0 +patients 0 +were 0 +positive 0 +for 0 +MP0 0 +- 0 +ANCA 0 +at 0 +13 0 +, 0 +16 0 +and 0 +17 0 +months 0 +, 0 +respectively 0 +, 0 +after 0 +the 0 +start 0 +of 0 +PTU 1 +therapy 0 +. 0 + +In 0 +two 0 +of 0 +them 0 +, 0 +the 0 +MP0 0 +- 0 +ANCA 0 +titres 0 +transiently 0 +increased 0 +to 0 +12 0 +. 0 +8 0 +and 0 +15 0 +. 0 +0 0 +U 0 +/ 0 +ml 0 +, 0 +respectively 0 +, 0 +despite 0 +continued 0 +PTU 1 +therapy 0 +, 0 +but 0 +no 0 +vasculitic 3 +disorders 4 +developed 0 +. 0 + +In 0 +the 0 +third 0 +patient 0 +, 0 +the 0 +MP0 0 +- 0 +ANCA 0 +titre 0 +increased 0 +to 0 +204 0 +U 0 +/ 0 +ml 0 +and 0 +she 0 +developed 0 +a 0 +higher 0 +fever 3 +, 0 +oral 3 +ulcers 4 +and 0 +polyarthralgia 3 +, 0 +but 0 +the 0 +symptoms 0 +resolved 0 +2 0 +weeks 0 +after 0 +stopping 0 +PTU 1 +therapy 0 +, 0 +and 0 +the 0 +MP0 0 +- 0 +ANCA 0 +titre 0 +decreased 0 +to 0 +20 0 +. 0 +7 0 +U 0 +/ 0 +ml 0 +by 0 +4 0 +months 0 +after 0 +discontinuing 0 +PTU 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +PTU 1 +therapy 0 +may 0 +be 0 +related 0 +to 0 +the 0 +appearance 0 +of 0 +MP0 0 +- 0 +ANCA 0 +, 0 +but 0 +MP0 0 +- 0 +ANCA 0 +does 0 +not 0 +appear 0 +to 0 +be 0 +closely 0 +related 0 +to 0 +vasculitis 3 +. 0 + +Prevalence 0 +of 0 +heart 3 +disease 4 +in 0 +asymptomatic 0 +chronic 0 +cocaine 1 +users 0 +. 0 + +To 0 +determine 0 +the 0 +prevalence 0 +of 0 +heart 3 +disease 4 +in 0 +outpatient 0 +young 0 +asymptomatic 0 +chronic 0 +cocaine 1 +users 0 +, 0 +35 0 +cocaine 1 +users 0 +and 0 +32 0 +age 0 +- 0 +matched 0 +controls 0 +underwent 0 +resting 0 +and 0 +exercise 0 +electrocardiography 0 +( 0 +ECG 0 +) 0 +and 0 +Doppler 0 +echocardiography 0 +. 0 + +Findings 0 +consistent 0 +with 0 +coronary 3 +artery 4 +disease 4 +were 0 +detected 0 +in 0 +12 0 +( 0 +34 0 +% 0 +) 0 +patients 0 +and 0 +3 0 +( 0 +9 0 +% 0 +) 0 +controls 0 +( 0 +p 0 += 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Decreased 0 +left 0 +ventricular 0 +systolic 0 +function 0 +was 0 +demonstrated 0 +in 0 +5 0 +( 0 +14 0 +% 0 +) 0 +patients 0 +, 0 +but 0 +in 0 +none 0 +of 0 +the 0 +controls 0 +( 0 +p 0 += 0 +0 0 +. 0 +055 0 +) 0 +. 0 + +Finally 0 +, 0 +resting 0 +and 0 +peak 0 +exercise 0 +abnormal 3 +left 4 +ventricular 4 +filling 4 +was 0 +detected 0 +in 0 +38 0 +and 0 +35 0 +% 0 +of 0 +patients 0 +as 0 +compared 0 +to 0 +19 0 +and 0 +9 0 +% 0 +of 0 +controls 0 +, 0 +respectively 0 +( 0 +p 0 += 0 +0 0 +. 0 +11 0 +and 0 +0 0 +. 0 +02 0 +, 0 +respectively 0 +) 0 +. 0 + +We 0 +conclude 0 +that 0 +coronary 3 +artery 4 +or 4 +myocardial 4 +disease 4 +is 0 +common 0 +( 0 +38 0 +% 0 +) 0 +in 0 +young 0 +asymptomatic 0 +chronic 0 +cocaine 1 +users 0 +. 0 + +Therefore 0 +, 0 +screening 0 +ECG 0 +and 0 +echocardiography 0 +may 0 +be 0 +warranted 0 +in 0 +these 0 +patients 0 +. 0 + +Cardioprotective 0 +effects 0 +of 0 +Picrorrhiza 0 +kurroa 0 +against 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 0 +stress 0 +in 0 +rats 0 +. 0 + +The 0 +cardioprotective 0 +effect 0 +of 0 +the 0 +ethanol 1 +extract 0 +of 0 +Picrorrhiza 0 +kurroa 0 +rhizomes 0 +and 0 +roots 0 +( 0 +PK 0 +) 0 +on 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +with 0 +respect 0 +to 0 +lipid 0 +metabolism 0 +in 0 +serum 0 +and 0 +heart 0 +tissue 0 +has 0 +been 0 +investigated 0 +. 0 + +0ral 0 +pre 0 +- 0 +treatment 0 +with 0 +PK 0 +( 0 +80 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +day 0 +( 0 +- 0 +1 0 +) 0 +for 0 +15 0 +days 0 +) 0 +significantly 0 +prevented 0 +the 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +and 0 +maintained 0 +the 0 +rats 0 +at 0 +near 0 +normal 0 +status 0 +. 0 + +Phase 0 +2 0 +early 0 +afterdepolarization 0 +as 0 +a 0 +trigger 0 +of 0 +polymorphic 0 +ventricular 3 +tachycardia 4 +in 0 +acquired 0 +long 3 +- 4 +QT 4 +syndrome 4 +: 0 +direct 0 +evidence 0 +from 0 +intracellular 0 +recordings 0 +in 0 +the 0 +intact 0 +left 0 +ventricular 0 +wall 0 +. 0 + +BACKGR0UND 0 +: 0 +This 0 +study 0 +examined 0 +the 0 +role 0 +of 0 +phase 0 +2 0 +early 0 +afterdepolarization 0 +( 0 +EAD 0 +) 0 +in 0 +producing 0 +a 0 +trigger 0 +to 0 +initiate 0 +torsade 3 +de 4 +pointes 4 +( 0 +TdP 3 +) 0 +with 0 +QT 3 +prolongation 4 +induced 0 +by 0 +dl 0 +- 0 +sotalol 1 +and 0 +azimilide 1 +. 0 + +The 0 +contribution 0 +of 0 +transmural 0 +dispersion 0 +of 0 +repolarization 0 +( 0 +TDR 0 +) 0 +to 0 +transmural 0 +propagation 0 +of 0 +EAD 0 +and 0 +the 0 +maintenance 0 +of 0 +TdP 3 +was 0 +also 0 +evaluated 0 +. 0 + +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +Transmembrane 0 +action 0 +potentials 0 +from 0 +epicardium 0 +, 0 +midmyocardium 0 +, 0 +and 0 +endocardium 0 +were 0 +recorded 0 +simultaneously 0 +, 0 +together 0 +with 0 +a 0 +transmural 0 +ECG 0 +, 0 +in 0 +arterially 0 +perfused 0 +canine 0 +and 0 +rabbit 0 +left 0 +ventricular 0 +preparations 0 +. 0 + +dl 0 +- 0 +Sotalol 1 +preferentially 0 +prolonged 0 +action 0 +potential 0 +duration 0 +( 0 +APD 0 +) 0 +in 0 +M 0 +cells 0 +dose 0 +- 0 +dependently 0 +( 0 +1 0 +to 0 +100 0 +micromol 0 +/ 0 +L 0 +) 0 +, 0 +leading 0 +to 0 +QT 3 +prolongation 4 +and 0 +an 0 +increase 0 +in 0 +TDR 0 +. 0 + +Azimilide 1 +, 0 +however 0 +, 0 +significantly 0 +prolonged 0 +APD 0 +and 0 +QT 0 +interval 0 +at 0 +concentrations 0 +from 0 +0 0 +. 0 +1 0 +to 0 +10 0 +micromol 0 +/ 0 +L 0 +but 0 +shortened 0 +them 0 +at 0 +30 0 +micromol 0 +/ 0 +L 0 +. 0 + +Unlike 0 +dl 0 +- 0 +sotalol 1 +, 0 +azimilide 1 +( 0 +> 0 +3 0 +micromol 0 +/ 0 +L 0 +) 0 +increased 0 +epicardial 0 +APD 0 +markedly 0 +, 0 +causing 0 +a 0 +diminished 0 +TDR 0 +. 0 + +Although 0 +both 0 +dl 0 +- 0 +sotalol 1 +and 0 +azimilide 1 +rarely 0 +induced 0 +EADs 0 +in 0 +canine 0 +left 0 +ventricles 0 +, 0 +they 0 +produced 0 +frequent 0 +EADs 0 +in 0 +rabbits 0 +, 0 +in 0 +which 0 +more 0 +pronounced 0 +QT 3 +prolongation 4 +was 0 +seen 0 +. 0 + +An 0 +increase 0 +in 0 +TDR 0 +by 0 +dl 0 +- 0 +sotalol 1 +facilitated 0 +transmural 0 +propagation 0 +of 0 +EADs 0 +that 0 +initiated 0 +multiple 0 +episodes 0 +of 0 +spontaneous 0 +TdP 3 +in 0 +3 0 +of 0 +6 0 +rabbit 0 +left 0 +ventricles 0 +. 0 + +0f 0 +note 0 +, 0 +although 0 +azimilide 1 +( 0 +3 0 +to 0 +10 0 +micromol 0 +/ 0 +L 0 +) 0 +increased 0 +APD 0 +more 0 +than 0 +dl 0 +- 0 +sotalol 1 +, 0 +its 0 +EADs 0 +often 0 +failed 0 +to 0 +propagate 0 +transmurally 0 +, 0 +probably 0 +because 0 +of 0 +a 0 +diminished 0 +TDR 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +This 0 +study 0 +provides 0 +the 0 +first 0 +direct 0 +evidence 0 +from 0 +intracellular 0 +action 0 +potential 0 +recordings 0 +that 0 +phase 0 +2 0 +EAD 0 +can 0 +be 0 +generated 0 +from 0 +intact 0 +ventricular 0 +wall 0 +and 0 +produce 0 +a 0 +trigger 0 +to 0 +initiate 0 +the 0 +onset 0 +of 0 +TdP 3 +under 0 +QT 3 +prolongation 4 +. 0 + +A 0 +pilot 0 +study 0 +to 0 +assess 0 +the 0 +safety 0 +of 0 +dobutamine 1 +stress 0 +echocardiography 0 +in 0 +the 0 +emergency 0 +department 0 +evaluation 0 +of 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +. 0 + +STUDY 0 +0BJECTIVE 0 +: 0 +Chest 3 +pain 4 +in 0 +the 0 +setting 0 +of 0 +cocaine 1 +use 0 +poses 0 +a 0 +diagnostic 0 +dilemma 0 +. 0 + +Dobutamine 1 +stress 0 +echocardiography 0 +( 0 +DSE 0 +) 0 +is 0 +a 0 +widely 0 +available 0 +and 0 +sensitive 0 +test 0 +for 0 +evaluating 0 +cardiac 0 +ischemia 3 +. 0 + +Because 0 +of 0 +the 0 +theoretical 0 +concern 0 +regarding 0 +administration 0 +of 0 +dobutamine 1 +in 0 +the 0 +setting 0 +of 0 +cocaine 1 +use 0 +, 0 +we 0 +conducted 0 +a 0 +pilot 0 +study 0 +to 0 +assess 0 +the 0 +safety 0 +of 0 +DSE 0 +in 0 +emergency 0 +department 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +. 0 + +METH0DS 0 +: 0 +A 0 +prospective 0 +case 0 +series 0 +was 0 +conducted 0 +in 0 +the 0 +intensive 0 +diagnostic 0 +and 0 +treatment 0 +unit 0 +in 0 +the 0 +ED 0 +of 0 +an 0 +urban 0 +tertiary 0 +- 0 +care 0 +teaching 0 +hospital 0 +. 0 + +Patients 0 +were 0 +eligible 0 +for 0 +DSE 0 +if 0 +they 0 +had 0 +used 0 +cocaine 1 +within 0 +24 0 +hours 0 +preceding 0 +the 0 +onset 0 +of 0 +chest 3 +pain 4 +and 0 +had 0 +a 0 +normal 0 +ECG 0 +and 0 +tropinin 0 +I 0 +level 0 +. 0 + +Patients 0 +exhibiting 0 +signs 0 +of 0 +continuing 0 +cocaine 1 +toxicity 3 +were 0 +excluded 0 +from 0 +the 0 +study 0 +. 0 + +All 0 +patients 0 +were 0 +admitted 0 +to 0 +the 0 +hospital 0 +for 0 +serial 0 +testing 0 +after 0 +the 0 +DSE 0 +testing 0 +in 0 +the 0 +intensive 0 +diagnostic 0 +and 0 +treatment 0 +unit 0 +. 0 + +RESULTS 0 +: 0 +Twenty 0 +- 0 +four 0 +patients 0 +were 0 +enrolled 0 +. 0 + +Two 0 +patients 0 +had 0 +inadequate 0 +resting 0 +images 0 +, 0 +one 0 +DSE 0 +was 0 +terminated 0 +because 0 +of 0 +inferior 0 +hypokinesis 3 +, 0 +another 0 +DSE 0 +was 0 +terminated 0 +because 0 +of 0 +a 0 +rate 0 +- 0 +related 0 +atrial 0 +conduction 0 +deficit 0 +, 0 +and 0 +1 0 +patient 0 +did 0 +not 0 +reach 0 +the 0 +target 0 +heart 0 +rate 0 +. 0 + +Thus 0 +, 0 +19 0 +patients 0 +completed 0 +a 0 +DSE 0 +and 0 +reached 0 +their 0 +target 0 +heart 0 +rates 0 +. 0 + +None 0 +of 0 +the 0 +patients 0 +experienced 0 +signs 0 +of 0 +exaggerated 0 +adrenergic 0 +response 0 +, 0 +which 0 +was 0 +defined 0 +as 0 +a 0 +systolic 0 +blood 0 +pressure 0 +of 0 +greater 0 +than 0 +200 0 +mm 0 +Hg 0 +or 0 +the 0 +occurrence 0 +of 0 +tachydysrhythmias 3 +( 0 +excluding 0 +sinus 3 +tachycardia 4 +) 0 +. 0 + +Further 0 +suggesting 0 +lack 0 +of 0 +exaggerated 0 +adrenergic 0 +response 0 +, 0 +13 0 +( 0 +65 0 +% 0 +) 0 +of 0 +20 0 +patients 0 +required 0 +supplemental 0 +atropine 1 +to 0 +reach 0 +their 0 +target 0 +heart 0 +rates 0 +. 0 + +C0NCLUSI0N 0 +: 0 +No 0 +exaggerated 0 +adrenergic 0 +response 0 +was 0 +detected 0 +when 0 +dobutamine 1 +was 0 +administered 0 +to 0 +patients 0 +with 0 +cocaine 1 +- 0 +related 0 +chest 3 +pain 4 +. 0 + +Prenatal 0 +cocaine 1 +exposure 0 +and 0 +cranial 0 +sonographic 0 +findings 0 +in 0 +preterm 3 +infants 4 +. 0 + +PURP0SE 0 +: 0 +Prenatal 0 +cocaine 1 +exposure 0 +has 0 +been 0 +linked 0 +with 0 +subependymal 0 +hemorrhage 3 +and 0 +the 0 +formation 0 +of 0 +cysts 3 +that 0 +are 0 +detectable 0 +on 0 +cranial 0 +sonography 0 +in 0 +neonates 0 +born 0 +at 0 +term 0 +. 0 + +We 0 +sought 0 +to 0 +determine 0 +if 0 +prenatal 0 +cocaine 1 +exposure 0 +increases 0 +the 0 +incidence 0 +of 0 +subependymal 3 +cysts 4 +in 0 +preterm 3 +infants 4 +. 0 + +METH0DS 0 +: 0 +We 0 +retrospectively 0 +reviewed 0 +the 0 +medical 0 +records 0 +and 0 +cranial 0 +sonograms 0 +obtained 0 +during 0 +a 0 +1 0 +- 0 +year 0 +period 0 +on 0 +122 0 +premature 3 +( 4 +< 4 +36 4 +weeks 4 +of 4 +gestation 4 +) 4 +infants 4 +. 0 + +Infants 0 +were 0 +categorized 0 +into 0 +1 0 +of 0 +2 0 +groups 0 +: 0 +those 0 +exposed 0 +to 0 +cocaine 1 +and 0 +those 0 +not 0 +exposed 0 +to 0 +cocaine 1 +. 0 + +Infants 0 +were 0 +assigned 0 +to 0 +the 0 +cocaine 1 +- 0 +exposed 0 +group 0 +if 0 +there 0 +was 0 +a 0 +maternal 0 +history 0 +of 0 +cocaine 3 +abuse 4 +during 0 +pregnancy 0 +or 0 +if 0 +maternal 0 +or 0 +neonatal 0 +urine 0 +toxicology 0 +results 0 +were 0 +positive 0 +at 0 +the 0 +time 0 +of 0 +delivery 0 +. 0 + +RESULTS 0 +: 0 +Five 0 +of 0 +the 0 +122 0 +infants 0 +were 0 +excluded 0 +from 0 +the 0 +study 0 +because 0 +of 0 +insufficient 0 +medical 0 +and 0 +drug 0 +histories 0 +. 0 + +The 0 +incidence 0 +of 0 +subependymal 3 +cysts 4 +in 0 +the 0 +117 0 +remaining 0 +infants 0 +was 0 +14 0 +% 0 +( 0 +16 0 +of 0 +117 0 +) 0 +. 0 + +The 0 +incidence 0 +of 0 +subependymal 3 +cysts 4 +in 0 +infants 0 +exposed 0 +to 0 +cocaine 1 +prenatally 0 +was 0 +44 0 +% 0 +( 0 +8 0 +of 0 +18 0 +) 0 +compared 0 +with 0 +8 0 +% 0 +( 0 +8 0 +of 0 +99 0 +) 0 +in 0 +the 0 +unexposed 0 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +We 0 +found 0 +an 0 +increased 0 +incidence 0 +of 0 +subependymal 3 +cyst 4 +formation 0 +in 0 +preterm 3 +infants 4 +who 0 +were 0 +exposed 0 +to 0 +cocaine 1 +prenatally 0 +. 0 + +This 0 +result 0 +is 0 +consistent 0 +with 0 +results 0 +of 0 +similar 0 +studies 0 +in 0 +term 0 +infants 0 +. 0 + +Thalidomide 1 +neuropathy 3 +in 0 +patients 0 +treated 0 +for 0 +metastatic 0 +prostate 3 +cancer 4 +. 0 + +We 0 +prospectively 0 +evaluated 0 +thalidomide 1 +- 0 +induced 0 +neuropathy 3 +using 0 +electrodiagnostic 0 +studies 0 +. 0 + +Sixty 0 +- 0 +seven 0 +men 0 +with 0 +metastatic 0 +androgen 1 +- 0 +independent 0 +prostate 3 +cancer 4 +in 0 +an 0 +open 0 +- 0 +label 0 +trial 0 +of 0 +oral 0 +thalidomide 1 +underwent 0 +neurologic 0 +examinations 0 +and 0 +nerve 0 +conduction 0 +studies 0 +( 0 +NCS 0 +) 0 +prior 0 +to 0 +and 0 +at 0 +3 0 +- 0 +month 0 +intervals 0 +during 0 +treatment 0 +. 0 + +NCS 0 +included 0 +recording 0 +of 0 +sensory 0 +nerve 0 +action 0 +potentials 0 +( 0 +SNAPs 0 +) 0 +from 0 +median 0 +, 0 +radial 0 +, 0 +ulnar 0 +, 0 +and 0 +sural 0 +nerves 0 +. 0 + +SNAP 0 +amplitudes 0 +for 0 +each 0 +nerve 0 +were 0 +expressed 0 +as 0 +the 0 +percentage 0 +of 0 +its 0 +baseline 0 +, 0 +and 0 +the 0 +mean 0 +of 0 +the 0 +four 0 +was 0 +termed 0 +the 0 +SNAP 0 +index 0 +. 0 + +A 0 +40 0 +% 0 +decline 0 +in 0 +the 0 +SNAP 0 +index 0 +was 0 +considered 0 +clinically 0 +significant 0 +. 0 + +Thalidomide 1 +was 0 +discontinued 0 +in 0 +55 0 +patients 0 +for 0 +lack 0 +of 0 +therapeutic 0 +response 0 +. 0 + +0f 0 +67 0 +patients 0 +initially 0 +enrolled 0 +, 0 +24 0 +remained 0 +on 0 +thalidomide 1 +for 0 +3 0 +months 0 +, 0 +8 0 +remained 0 +at 0 +6 0 +months 0 +, 0 +and 0 +3 0 +remained 0 +at 0 +9 0 +months 0 +. 0 + +Six 0 +patients 0 +developed 0 +neuropathy 3 +. 0 + +Clinical 0 +symptoms 0 +and 0 +a 0 +decline 0 +in 0 +the 0 +SNAP 0 +index 0 +occurred 0 +concurrently 0 +. 0 + +0lder 0 +age 0 +and 0 +cumulative 0 +dose 0 +were 0 +possible 0 +contributing 0 +factors 0 +. 0 + +Neuropathy 3 +may 0 +thus 0 +be 0 +a 0 +common 0 +complication 0 +of 0 +thalidomide 1 +in 0 +older 0 +patients 0 +. 0 + +The 0 +SNAP 0 +index 0 +can 0 +be 0 +used 0 +to 0 +monitor 0 +peripheral 3 +neuropathy 4 +, 0 +but 0 +not 0 +for 0 +early 0 +detection 0 +. 0 + +0verexpression 0 +of 0 +copper 1 +/ 0 +zinc 1 +- 0 +superoxide 1 +dismutase 0 +protects 0 +from 0 +kanamycin 1 +- 0 +induced 0 +hearing 3 +loss 4 +. 0 + +The 0 +participation 0 +of 0 +reactive 0 +oxygen 1 +species 0 +in 0 +aminoglycoside 1 +- 0 +induced 0 +ototoxicity 3 +has 0 +been 0 +deduced 0 +from 0 +observations 0 +that 0 +aminoglycoside 1 +- 0 +iron 1 +complexes 0 +catalyze 0 +the 0 +formation 0 +of 0 +superoxide 1 +radicals 0 +in 0 +vitro 0 +and 0 +that 0 +antioxidants 0 +attenuate 0 +ototoxicity 3 +in 0 +vivo 0 +. 0 + +We 0 +therefore 0 +hypothesized 0 +that 0 +overexpression 0 +of 0 +Cu 1 +/ 0 +Zn 1 +- 0 +superoxide 1 +dismutase 0 +( 0 +h 0 +- 0 +S0D1 0 +) 0 +should 0 +protect 0 +transgenic 0 +mice 0 +from 0 +ototoxicity 3 +. 0 + +Immunocytochemistry 0 +confirmed 0 +expression 0 +of 0 +h 0 +- 0 +S0D1 0 +in 0 +inner 0 +ear 0 +tissues 0 +of 0 +transgenic 0 +C57BL 0 +/ 0 +6 0 +- 0 +TgN 0 +[ 0 +S0D1 0 +] 0 +3Cje 0 +mice 0 +. 0 + +Transgenic 0 +and 0 +nontransgenic 0 +littermates 0 +received 0 +kanamycin 1 +( 0 +400 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +/ 0 +day 0 +) 0 +for 0 +10 0 +days 0 +beginning 0 +on 0 +day 0 +10 0 +after 0 +birth 0 +. 0 + +Auditory 0 +thresholds 0 +were 0 +tested 0 +by 0 +evoked 0 +auditory 0 +brain 0 +stem 0 +responses 0 +at 0 +1 0 +month 0 +after 0 +birth 0 +. 0 + +In 0 +nontransgenic 0 +animals 0 +, 0 +the 0 +threshold 0 +in 0 +the 0 +kanamycin 1 +- 0 +treated 0 +group 0 +was 0 +45 0 +- 0 +50 0 +dB 0 +higher 0 +than 0 +in 0 +saline 0 +- 0 +injected 0 +controls 0 +. 0 + +In 0 +the 0 +transgenic 0 +group 0 +, 0 +kanamycin 1 +increased 0 +the 0 +threshold 0 +by 0 +only 0 +15 0 +dB 0 +over 0 +the 0 +respective 0 +controls 0 +. 0 + +The 0 +effects 0 +were 0 +similar 0 +at 0 +12 0 +and 0 +24 0 +kHz 0 +. 0 + +The 0 +protection 0 +by 0 +overexpression 0 +of 0 +superoxide 1 +dismutase 0 +supports 0 +the 0 +hypothesis 0 +that 0 +oxidant 0 +stress 0 +plays 0 +a 0 +significant 0 +role 0 +in 0 +aminoglycoside 1 +- 0 +induced 0 +ototoxicity 3 +. 0 + +The 0 +results 0 +also 0 +suggest 0 +transgenic 0 +animals 0 +as 0 +suitable 0 +models 0 +to 0 +investigate 0 +the 0 +underlying 0 +mechanisms 0 +and 0 +possible 0 +strategies 0 +for 0 +prevention 0 +. 0 + +Fatty 3 +liver 4 +induced 0 +by 0 +tetracycline 1 +in 0 +the 0 +rat 0 +. 0 + +Dose 0 +- 0 +response 0 +relationships 0 +and 0 +effect 0 +of 0 +sex 0 +. 0 + +Dose 0 +- 0 +response 0 +relationships 0 +, 0 +biochemical 0 +mechanisms 0 +, 0 +and 0 +sex 0 +differences 0 +in 0 +the 0 +experimental 0 +fatty 3 +liver 4 +induced 0 +by 0 +tetracycline 1 +were 0 +studied 0 +in 0 +the 0 +intact 0 +rat 0 +and 0 +with 0 +the 0 +isolated 0 +perfused 0 +rat 0 +liver 0 +in 0 +vitro 0 +. 0 + +In 0 +the 0 +intact 0 +male 0 +and 0 +female 0 +rat 0 +, 0 +no 0 +direct 0 +relationship 0 +was 0 +observed 0 +between 0 +dose 0 +of 0 +tetracycline 1 +and 0 +hepatic 0 +accumulation 0 +of 0 +triglyceride 1 +. 0 + +With 0 +provision 0 +of 0 +adequate 0 +oleic 1 +acid 2 +as 0 +a 0 +substrate 0 +for 0 +the 0 +isolated 0 +perfused 0 +liver 0 +, 0 +a 0 +direct 0 +relationship 0 +was 0 +observed 0 +between 0 +dose 0 +of 0 +tetracycline 1 +and 0 +both 0 +accumulation 0 +of 0 +triglyceride 1 +in 0 +the 0 +liver 0 +and 0 +depression 3 +of 0 +output 0 +of 0 +triglyceride 1 +by 0 +livers 0 +from 0 +male 0 +and 0 +female 0 +rats 0 +. 0 + +Marked 0 +differences 0 +were 0 +observed 0 +between 0 +female 0 +and 0 +male 0 +rats 0 +with 0 +regard 0 +to 0 +base 0 +line 0 +( 0 +control 0 +) 0 +hepatic 0 +concentration 0 +of 0 +triglyceride 1 +and 0 +output 0 +of 0 +triglyceride 1 +. 0 + +Accumulation 0 +of 0 +hepatic 0 +triglyceride 1 +, 0 +as 0 +a 0 +per 0 +cent 0 +of 0 +control 0 +values 0 +, 0 +in 0 +response 0 +to 0 +graded 0 +doses 0 +of 0 +tetracycline 1 +, 0 +did 0 +not 0 +differ 0 +significantly 0 +between 0 +male 0 +, 0 +female 0 +and 0 +pregnant 0 +rat 0 +livers 0 +. 0 + +However 0 +, 0 +livers 0 +from 0 +female 0 +, 0 +and 0 +especially 0 +pregnant 0 +female 0 +rats 0 +, 0 +were 0 +strikingly 0 +resistant 0 +to 0 +the 0 +effects 0 +of 0 +tetracycline 1 +on 0 +depression 3 +of 0 +output 0 +of 0 +triglyceride 1 +under 0 +these 0 +experimental 0 +conditions 0 +. 0 + +These 0 +differences 0 +between 0 +the 0 +sexes 0 +could 0 +not 0 +be 0 +related 0 +to 0 +altered 0 +disposition 0 +of 0 +tetracycline 1 +or 0 +altered 0 +uptake 0 +of 0 +oleic 1 +acid 2 +. 0 + +Depressed 0 +hepatic 0 +secretion 0 +of 0 +triglyceride 1 +accounted 0 +only 0 +for 0 +30 0 +to 0 +50 0 +% 0 +of 0 +accumulated 0 +hepatic 0 +triglyceride 1 +, 0 +indicating 0 +that 0 +additional 0 +mechanisms 0 +must 0 +be 0 +involved 0 +in 0 +the 0 +production 0 +of 0 +the 0 +triglyceride 1 +- 0 +rich 0 +fatty 3 +liver 4 +in 0 +response 0 +to 0 +tetracycline 1 +. 0 + +Prednisone 1 +induces 0 +anxiety 3 +and 0 +glial 0 +cerebral 0 +changes 0 +in 0 +rats 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +assess 0 +whether 0 +prednisone 1 +( 0 +PDN 1 +) 0 +produces 0 +anxiety 3 +and 0 +/ 0 +or 0 +cerebral 0 +glial 0 +changes 0 +in 0 +rats 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +Wistar 0 +rats 0 +were 0 +studied 0 +and 0 +3 0 +groups 0 +were 0 +formed 0 +( 0 +8 0 +rats 0 +per 0 +group 0 +) 0 +. 0 + +The 0 +moderate 0 +- 0 +dose 0 +group 0 +received 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +PDN 1 +released 0 +from 0 +a 0 +subcutaneous 0 +implant 0 +. 0 + +In 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +, 0 +implants 0 +containing 0 +PDN 1 +equivalent 0 +to 0 +60 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +were 0 +applied 0 +. 0 + +In 0 +the 0 +control 0 +group 0 +implants 0 +contained 0 +no 0 +PDN 1 +. 0 + +Anxiety 3 +was 0 +assessed 0 +using 0 +an 0 +open 0 +field 0 +and 0 +elevated 0 +plus 0 +- 0 +maze 0 +devices 0 +. 0 + +The 0 +number 0 +of 0 +cells 0 +and 0 +cytoplasmic 0 +transformation 0 +of 0 +astrocytes 0 +and 0 +microglia 0 +cells 0 +were 0 +assessed 0 +by 0 +immunohistochemical 0 +analyses 0 +. 0 + +RESULTS 0 +: 0 +Anxiety 3 +was 0 +documented 0 +in 0 +both 0 +groups 0 +of 0 +PDN 1 +treated 0 +rats 0 +compared 0 +with 0 +controls 0 +. 0 + +The 0 +magnitude 0 +of 0 +transformation 0 +of 0 +the 0 +microglia 0 +assessed 0 +by 0 +the 0 +number 0 +of 0 +intersections 0 +was 0 +significantly 0 +higher 0 +in 0 +the 0 +PDN 1 +groups 0 +than 0 +in 0 +controls 0 +in 0 +the 0 +prefrontal 0 +cortex 0 +( 0 +moderate 0 +- 0 +dose 0 +, 0 +24 0 +. 0 +1 0 +; 0 +high 0 +- 0 +dose 0 +, 0 +23 0 +. 0 +6 0 +; 0 +controls 0 +18 0 +. 0 +7 0 +; 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +and 0 +striatum 0 +( 0 +moderate 0 +- 0 +dose 0 +25 0 +. 0 +6 0 +; 0 +high 0 +- 0 +dose 0 +26 0 +. 0 +3 0 +; 0 +controls 0 +18 0 +. 0 +9 0 +; 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +, 0 +but 0 +not 0 +in 0 +hippocampus 0 +. 0 + +The 0 +number 0 +of 0 +stained 0 +microglia 0 +cells 0 +was 0 +significantly 0 +higher 0 +in 0 +the 0 +PDN 1 +treated 0 +groups 0 +in 0 +the 0 +prefrontal 0 +cortex 0 +than 0 +in 0 +controls 0 +( 0 +moderate 0 +- 0 +dose 0 +, 0 +29 0 +. 0 +1 0 +; 0 +high 0 +- 0 +dose 0 +, 0 +28 0 +. 0 +4 0 +; 0 +control 0 +, 0 +17 0 +. 0 +7 0 +cells 0 +per 0 +field 0 +; 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Stained 0 +microglia 0 +cells 0 +were 0 +significantly 0 +more 0 +numerous 0 +striatum 0 +and 0 +hippocampus 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +compared 0 +to 0 +controls 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Subacute 0 +exposure 0 +to 0 +PDN 1 +induced 0 +anxiety 3 +and 0 +reactivity 0 +of 0 +microglia 0 +. 0 + +The 0 +relevance 0 +of 0 +these 0 +features 0 +for 0 +patients 0 +using 0 +PDN 1 +remains 0 +to 0 +be 0 +elucidated 0 +. 0 + +Phase 0 +II 0 +study 0 +of 0 +carboplatin 1 +and 0 +liposomal 0 +doxorubicin 1 +in 0 +patients 0 +with 0 +recurrent 0 +squamous 3 +cell 4 +carcinoma 4 +of 4 +the 4 +cervix 4 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +activity 0 +of 0 +the 0 +combination 0 +of 0 +carboplatin 1 +and 0 +liposomal 0 +doxorubicin 1 +was 0 +tested 0 +in 0 +a 0 +Phase 0 +II 0 +study 0 +of 0 +patients 0 +with 0 +recurrent 0 +cervical 3 +carcinoma 4 +. 0 + +METH0DS 0 +: 0 +The 0 +combination 0 +of 0 +carboplatin 1 +( 0 +area 0 +under 0 +the 0 +concentration 0 +curve 0 +[ 0 +AUC 0 +] 0 +, 0 +5 0 +) 0 +and 0 +liposomal 0 +doxorubicin 1 +( 0 +Doxil 1 +; 0 +starting 0 +dose 0 +, 0 +40 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +) 0 +was 0 +administered 0 +intravenously 0 +every 0 +28 0 +days 0 +to 0 +37 0 +patients 0 +with 0 +recurrent 0 +squamous 3 +cell 4 +cervical 4 +carcinoma 4 +to 0 +determine 0 +antitumor 0 +activity 0 +and 0 +toxicity 3 +profile 0 +. 0 + +RESULTS 0 +: 0 +Twenty 0 +- 0 +nine 0 +patients 0 +were 0 +assessable 0 +for 0 +response 0 +, 0 +and 0 +35 0 +patients 0 +were 0 +assessable 0 +for 0 +toxicity 3 +. 0 + +The 0 +overall 0 +response 0 +rate 0 +was 0 +38 0 +% 0 +, 0 +the 0 +median 0 +time 0 +to 0 +response 0 +was 0 +10 0 +weeks 0 +, 0 +the 0 +median 0 +duration 0 +of 0 +response 0 +was 0 +26 0 +weeks 0 +, 0 +and 0 +the 0 +median 0 +survival 0 +was 0 +37 0 +weeks 0 +. 0 + +The 0 +main 0 +toxic 0 +effect 0 +was 0 +myelosuppression 3 +, 0 +with 0 +Grade 0 +3 0 +and 0 +4 0 +neutropenia 3 +in 0 +16 0 +patients 0 +, 0 +anemia 3 +in 0 +12 0 +patients 0 +, 0 +thrombocytopenia 3 +in 0 +11 0 +patients 0 +, 0 +and 0 +neutropenic 3 +fever 4 +in 0 +3 0 +patients 0 +. 0 + +Four 0 +patients 0 +had 0 +five 0 +infusion 0 +- 0 +related 0 +reactions 0 +during 0 +the 0 +infusion 0 +of 0 +liposomal 0 +doxorubicin 1 +, 0 +leading 0 +to 0 +treatment 0 +discontinuation 0 +in 0 +three 0 +patients 0 +. 0 + +Grade 0 +> 0 +or 0 += 0 +2 0 +nonhematologic 0 +toxicity 3 +included 0 +nausea 3 +in 0 +17 0 +patients 0 +, 0 +emesis 3 +in 0 +14 0 +patients 0 +, 0 +fatigue 3 +in 0 +9 0 +patients 0 +, 0 +mucositis 3 +and 0 +/ 0 +or 0 +stomatitis 3 +in 0 +8 0 +patients 0 +, 0 +constipation 3 +in 0 +6 0 +patients 0 +, 0 +weight 3 +loss 4 +in 0 +5 0 +patients 0 +, 0 +hand 3 +- 4 +foot 4 +syndrome 4 +in 0 +2 0 +patients 0 +, 0 +and 0 +skin 3 +reactions 4 +in 0 +3 0 +patients 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +combination 0 +of 0 +carboplatin 1 +and 0 +liposomal 0 +doxorubicin 1 +has 0 +modest 0 +activity 0 +in 0 +patients 0 +with 0 +recurrent 0 +cervical 3 +carcinoma 4 +. 0 + +Antimicrobial 0 +- 0 +induced 0 +mania 3 +( 0 +antibiomania 3 +) 0 +: 0 +a 0 +review 0 +of 0 +spontaneous 0 +reports 0 +. 0 + +The 0 +authors 0 +reviewed 0 +reported 0 +cases 0 +of 0 +antibiotic 0 +- 0 +induced 0 +manic 3 +episodes 0 +by 0 +means 0 +of 0 +a 0 +MEDLINE 0 +and 0 +PsychLit 0 +search 0 +for 0 +reports 0 +of 0 +antibiotic 0 +- 0 +induced 0 +mania 3 +. 0 + +Unpublished 0 +reports 0 +were 0 +requested 0 +from 0 +the 0 +World 0 +Health 0 +0rganization 0 +( 0 +WH0 0 +) 0 +and 0 +the 0 +Food 0 +and 0 +Drug 0 +Administration 0 +( 0 +FDA 0 +) 0 +. 0 + +Twenty 0 +- 0 +one 0 +reports 0 +of 0 +antimicrobial 0 +- 0 +induced 0 +mania 3 +were 0 +found 0 +in 0 +the 0 +literature 0 +. 0 + +There 0 +were 0 +6 0 +cases 0 +implicating 0 +clarithromycin 1 +, 0 +13 0 +implicating 0 +isoniazid 1 +, 0 +and 0 +1 0 +case 0 +each 0 +implicating 0 +erythromycin 1 +and 0 +amoxicillin 1 +. 0 + +The 0 +WH0 0 +reported 0 +82 0 +cases 0 +. 0 + +0f 0 +these 0 +, 0 +clarithromycin 1 +was 0 +implicated 0 +in 0 +23 0 +( 0 +27 0 +. 0 +6 0 +% 0 +) 0 +cases 0 +, 0 +ciprofloxacin 1 +in 0 +12 0 +( 0 +14 0 +. 0 +4 0 +% 0 +) 0 +cases 0 +, 0 +and 0 +ofloxacin 1 +in 0 +10 0 +( 0 +12 0 +% 0 +) 0 +cases 0 +. 0 + +Cotrimoxazole 1 +, 0 +metronidazole 1 +, 0 +and 0 +erythromycin 1 +were 0 +involved 0 +in 0 +15 0 +reported 0 +manic 3 +episodes 0 +. 0 + +Cases 0 +reported 0 +by 0 +the 0 +FDA 0 +showed 0 +clarithromycin 1 +and 0 +ciprofloxacin 1 +to 0 +be 0 +the 0 +most 0 +frequently 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +mania 3 +. 0 + +Statistical 0 +analysis 0 +of 0 +the 0 +data 0 +would 0 +not 0 +have 0 +demonstrated 0 +a 0 +significant 0 +statistical 0 +correlative 0 +risk 0 +and 0 +was 0 +therefore 0 +not 0 +undertaken 0 +. 0 + +Patients 0 +have 0 +an 0 +increased 0 +risk 0 +of 0 +developing 0 +mania 3 +while 0 +being 0 +treated 0 +with 0 +antimicrobials 0 +. 0 + +Although 0 +this 0 +is 0 +not 0 +a 0 +statistically 0 +significant 0 +risk 0 +, 0 +physicians 0 +must 0 +be 0 +aware 0 +of 0 +the 0 +effect 0 +and 0 +reversibility 0 +. 0 + +Further 0 +research 0 +clearly 0 +is 0 +required 0 +to 0 +determine 0 +the 0 +incidence 0 +of 0 +antimicrobial 0 +- 0 +induced 0 +mania 3 +, 0 +the 0 +relative 0 +risk 0 +factors 0 +of 0 +developing 0 +an 0 +antimicrobial 0 +- 0 +induced 0 +manic 3 +episode 0 +among 0 +various 0 +demographic 0 +populations 0 +, 0 +and 0 +the 0 +incidence 0 +of 0 +patients 0 +who 0 +continue 0 +to 0 +have 0 +persistent 0 +affective 0 +disorders 0 +once 0 +the 0 +initial 0 +episode 0 +, 0 +which 0 +occurs 0 +while 0 +the 0 +patient 0 +is 0 +taking 0 +antibiotics 0 +, 0 +subsides 0 +. 0 + +The 0 +authors 0 +elected 0 +to 0 +name 0 +this 0 +syndrome 0 +" 0 +antibiomania 3 +. 0 +" 0 + +Levodopa 1 +- 0 +induced 0 +ocular 3 +dyskinesias 4 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Levodopa 1 +- 0 +induced 0 +ocular 3 +dyskinesias 4 +are 0 +very 0 +uncommon 0 +. 0 + +Usually 0 +they 0 +occur 0 +simultaneously 0 +with 0 +limb 0 +peak 0 +- 0 +dose 0 +choreatic 3 +dyskinesias 4 +. 0 + +We 0 +report 0 +on 0 +a 0 +patient 0 +with 0 +leftward 0 +and 0 +upward 0 +deviations 0 +of 0 +gaze 0 +during 0 +the 0 +peak 0 +effect 0 +of 0 +levodopa 1 +, 0 +and 0 +hypothesize 0 +that 0 +a 0 +severe 0 +dopaminergic 0 +denervation 0 +in 0 +the 0 +caudate 0 +nucleus 0 +is 0 +needed 0 +for 0 +the 0 +appearance 0 +of 0 +these 0 +levodopa 1 +- 0 +induce 0 +ocular 3 +dyskinesias 4 +. 0 + +A 0 +comparison 0 +of 0 +glyceryl 1 +trinitrate 2 +with 0 +diclofenac 1 +for 0 +the 0 +treatment 0 +of 0 +primary 0 +dysmenorrhea 3 +: 0 +an 0 +open 0 +, 0 +randomized 0 +, 0 +cross 0 +- 0 +over 0 +trial 0 +. 0 + +Primary 0 +dysmenorrhea 3 +is 0 +a 0 +syndrome 0 +characterized 0 +by 0 +painful 0 +uterine 0 +contractility 0 +caused 0 +by 0 +a 0 +hypersecretion 0 +of 0 +endometrial 0 +prostaglandins 1 +; 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +are 0 +the 0 +first 0 +choice 0 +for 0 +its 0 +treatment 0 +. 0 + +However 0 +, 0 +in 0 +vivo 0 +and 0 +in 0 +vitro 0 +studies 0 +have 0 +demonstrated 0 +that 0 +myometrial 0 +cells 0 +are 0 +also 0 +targets 0 +of 0 +the 0 +relaxant 0 +effects 0 +of 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +efficacy 0 +of 0 +glyceryl 1 +trinitrate 2 +( 0 +GTN 1 +) 0 +, 0 +an 0 +N0 1 +donor 0 +, 0 +in 0 +the 0 +resolution 0 +of 0 +primary 0 +dysmenorrhea 3 +in 0 +comparison 0 +with 0 +diclofenac 1 +( 0 +DCF 1 +) 0 +. 0 + +A 0 +total 0 +of 0 +24 0 +patients 0 +with 0 +the 0 +diagnosis 0 +of 0 +severe 0 +primary 0 +dysmenorrhea 3 +were 0 +studied 0 +during 0 +two 0 +consecutive 0 +menstrual 0 +cycles 0 +. 0 + +In 0 +an 0 +open 0 +, 0 +cross 0 +- 0 +over 0 +, 0 +controlled 0 +design 0 +, 0 +patients 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +DCF 1 +per 0 +os 0 +or 0 +GTN 1 +patches 0 +the 0 +first 0 +days 0 +of 0 +menses 0 +, 0 +when 0 +menstrual 0 +cramps 0 +became 0 +unendurable 0 +. 0 + +In 0 +the 0 +subsequent 0 +cycle 0 +the 0 +other 0 +treatment 0 +was 0 +used 0 +. 0 + +Patients 0 +received 0 +up 0 +to 0 +3 0 +doses 0 +/ 0 +day 0 +of 0 +50 0 +mg 0 +DCF 1 +or 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +24 0 +h 0 +transdermal 0 +GTN 1 +for 0 +the 0 +first 0 +3 0 +days 0 +of 0 +the 0 +cycle 0 +, 0 +according 0 +to 0 +their 0 +needs 0 +. 0 + +The 0 +participants 0 +recorded 0 +menstrual 0 +symptoms 0 +and 0 +possible 0 +side 0 +- 0 +effects 0 +at 0 +different 0 +times 0 +( 0 +0 0 +, 0 +30 0 +, 0 +60 0 +, 0 +120 0 +minutes 0 +) 0 +after 0 +the 0 +first 0 +dose 0 +of 0 +medication 0 +on 0 +the 0 +first 0 +day 0 +of 0 +the 0 +cycle 0 +, 0 +with 0 +both 0 +drugs 0 +. 0 + +The 0 +difference 0 +in 0 +pain 3 +intensity 0 +score 0 +( 0 +DPI 0 +) 0 +was 0 +the 0 +main 0 +outcome 0 +variable 0 +. 0 + +Both 0 +treatments 0 +significantly 0 +reduced 0 +DPI 0 +by 0 +the 0 +30th 0 +minute 0 +( 0 +GTN 1 +, 0 +- 0 +12 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +17 0 +. 0 +9 0 +; 0 +DCF 1 +, 0 +- 0 +18 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +16 0 +. 0 +6 0 +) 0 +. 0 + +However 0 +, 0 +DCF 1 +continued 0 +to 0 +be 0 +effective 0 +in 0 +reducing 0 +pelvic 3 +pain 4 +for 0 +two 0 +hours 0 +, 0 +whereas 0 +GTN 1 +scores 0 +remained 0 +more 0 +or 0 +less 0 +stable 0 +after 0 +30 0 +min 0 +and 0 +significantly 0 +higher 0 +than 0 +those 0 +for 0 +DFC 0 +( 0 +after 0 +one 0 +hour 0 +: 0 +GTN 1 +, 0 +- 0 +12 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +17 0 +. 0 +9 0 +; 0 +DFC 0 +, 0 +- 0 +18 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +16 0 +. 0 +6 0 +and 0 +after 0 +two 0 +hours 0 +: 0 +GTN 1 +, 0 +- 0 +23 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +20 0 +. 0 +5 0 +; 0 +DFC 0 +, 0 +- 0 +59 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +17 0 +. 0 +9 0 +, 0 +p 0 += 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +Low 3 +back 4 +pain 4 +was 0 +also 0 +relieved 0 +by 0 +both 0 +drugs 0 +. 0 + +Headache 3 +was 0 +significantly 0 +increased 0 +by 0 +GTN 1 +but 0 +not 0 +by 0 +DCF 1 +. 0 + +Eight 0 +patients 0 +stopped 0 +using 0 +GTN 1 +because 0 +headache 3 +- 0 +- 0 +attributed 0 +to 0 +its 0 +use 0 +- 0 +- 0 +became 0 +intolerable 0 +. 0 + +These 0 +findings 0 +indicate 0 +that 0 +GTN 1 +has 0 +a 0 +reduced 0 +efficacy 0 +and 0 +tolerability 0 +by 0 +comparison 0 +with 0 +DCF 1 +in 0 +the 0 +treatment 0 +of 0 +primary 0 +dysmenorrhea 3 +. 0 + +Temocapril 1 +, 0 +a 0 +long 0 +- 0 +acting 0 +non 0 +- 0 +SH 0 +group 0 +angiotensin 1 +converting 0 +enzyme 0 +inhibitor 0 +, 0 +modulates 0 +glomerular 3 +injury 4 +in 0 +chronic 0 +puromycin 1 +aminonucleoside 2 +nephrosis 3 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +chronic 0 +administration 0 +of 0 +temocapril 1 +, 0 +a 0 +long 0 +- 0 +acting 0 +non 0 +- 0 +SH 0 +group 0 +angiotensin 1 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +inhibitor 0 +, 0 +reduced 0 +proteinuria 3 +, 0 +inhibited 0 +glomerular 0 +hypertrophy 3 +and 0 +prevented 0 +glomerulosclerosis 3 +in 0 +chronic 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +- 0 +induced 0 +nephrotic 3 +rats 0 +. 0 + +Nephrosis 3 +was 0 +induced 0 +by 0 +injection 0 +of 0 +PAN 1 +( 0 +15mg 0 +/ 0 +100g 0 +body 0 +weight 0 +) 0 +in 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +rats 0 +. 0 + +Four 0 +groups 0 +were 0 +used 0 +, 0 +i 0 +) 0 +the 0 +PAN 1 +group 0 +( 0 +14 0 +) 0 +, 0 +ii 0 +) 0 +PAN 1 +/ 0 +temocapril 1 +( 0 +13 0 +) 0 +, 0 +iii 0 +) 0 +temocapril 1 +( 0 +14 0 +) 0 +and 0 +iv 0 +) 0 +untreated 0 +controls 0 +( 0 +15 0 +) 0 +. 0 + +Temocapril 1 +( 0 +8 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +was 0 +administered 0 +to 0 +the 0 +rats 0 +which 0 +were 0 +killed 0 +at 0 +weeks 0 +4 0 +, 0 +14 0 +or 0 +20 0 +. 0 + +At 0 +each 0 +time 0 +point 0 +, 0 +systolic 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +, 0 +urinary 0 +protein 0 +excretion 0 +and 0 +renal 0 +histopathological 0 +findings 0 +were 0 +evaluated 0 +, 0 +and 0 +morphometric 0 +image 0 +analysis 0 +was 0 +done 0 +. 0 + +Systolic 0 +BP 0 +in 0 +the 0 +PAN 1 +group 0 +was 0 +significantly 0 +high 0 +at 0 +4 0 +, 0 +14 0 +and 0 +20 0 +weeks 0 +, 0 +but 0 +was 0 +normal 0 +in 0 +the 0 +PAN 1 +/ 0 +temocapril 1 +group 0 +. 0 + +Urinary 0 +protein 0 +excretion 0 +in 0 +the 0 +PAN 1 +group 0 +increased 0 +significantly 0 +, 0 +peaking 0 +at 0 +8 0 +days 0 +, 0 +then 0 +decreased 0 +at 0 +4 0 +weeks 0 +, 0 +but 0 +rose 0 +again 0 +significantly 0 +at 0 +14 0 +and 0 +20 0 +weeks 0 +. 0 + +Temocapril 1 +did 0 +not 0 +attenuate 0 +proteinuria 3 +at 0 +8 0 +days 0 +, 0 +but 0 +it 0 +did 0 +markedly 0 +lower 0 +it 0 +from 0 +weeks 0 +4 0 +to 0 +20 0 +. 0 + +The 0 +glomerulosclerosis 3 +index 0 +( 0 +GSI 0 +) 0 +was 0 +6 0 +. 0 +21 0 +% 0 +at 0 +4 0 +weeks 0 +and 0 +respectively 0 +25 0 +. 0 +35 0 +% 0 +and 0 +30 0 +. 0 +49 0 +% 0 +at 0 +14 0 +and 0 +20 0 +weeks 0 +in 0 +the 0 +PAN 1 +group 0 +. 0 + +There 0 +was 0 +a 0 +significant 0 +correlation 0 +between 0 +urinary 0 +protein 0 +excretion 0 +and 0 +GSI 0 +( 0 +r 0 += 0 +0 0 +. 0 +808 0 +, 0 +p 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +The 0 +ratio 0 +of 0 +glomerular 0 +tuft 0 +area 0 +to 0 +the 0 +area 0 +of 0 +Bowman 0 +' 0 +s 0 +capsules 0 +( 0 +GT 0 +/ 0 +BC 0 +) 0 +in 0 +the 0 +PAN 1 +group 0 +was 0 +significantly 0 +increased 0 +, 0 +but 0 +it 0 +was 0 +significantly 0 +lower 0 +in 0 +the 0 +PAN 1 +/ 0 +temocapril 1 +group 0 +. 0 + +It 0 +appears 0 +that 0 +temocapril 1 +was 0 +effective 0 +in 0 +retarding 0 +renal 0 +progression 0 +and 0 +protected 0 +renal 0 +function 0 +in 0 +PAN 1 +neprotic 3 +rats 0 +. 0 + +Pulmonary 3 +hypertension 4 +after 0 +ibuprofen 1 +prophylaxis 0 +in 0 +very 0 +preterm 0 +infants 0 +. 0 + +We 0 +report 0 +three 0 +cases 0 +of 0 +severe 0 +hypoxaemia 3 +after 0 +ibuprofen 1 +administration 0 +during 0 +a 0 +randomised 0 +controlled 0 +trial 0 +of 0 +prophylactic 0 +treatment 0 +of 0 +patent 3 +ductus 4 +arteriosus 4 +with 0 +ibuprofen 1 +in 0 +premature 0 +infants 0 +born 0 +at 0 +less 0 +than 0 +28 0 +weeks 0 +of 0 +gestation 0 +. 0 + +Echocardiography 0 +showed 0 +severely 0 +decreased 0 +pulmonary 0 +blood 0 +flow 0 +. 0 + +Hypoxaemia 3 +resolved 0 +quickly 0 +on 0 +inhaled 0 +nitric 1 +oxide 2 +therapy 0 +. 0 + +We 0 +suggest 0 +that 0 +investigators 0 +involved 0 +in 0 +similar 0 +trials 0 +pay 0 +close 0 +attention 0 +to 0 +pulmonary 0 +pressure 0 +if 0 +hypoxaemia 3 +occurs 0 +after 0 +prophylactic 0 +administration 0 +of 0 +ibuprofen 1 +. 0 + +Hyponatremia 3 +and 0 +syndrome 3 +of 4 +inappropriate 4 +anti 4 +- 4 +diuretic 4 +hormone 4 +reported 0 +with 0 +the 0 +use 0 +of 0 +Vincristine 1 +: 0 +an 0 +over 0 +- 0 +representation 0 +of 0 +Asians 0 +? 0 + +PURP0SE 0 +: 0 +This 0 +retrospective 0 +study 0 +used 0 +a 0 +pharmaceutical 0 +company 0 +' 0 +s 0 +global 0 +safety 0 +database 0 +to 0 +determine 0 +the 0 +reporting 0 +rate 0 +of 0 +hyponatremia 3 +and 0 +/ 0 +or 0 +syndrome 3 +of 4 +inappropriate 4 +secretion 4 +of 4 +anti 4 +- 4 +diuretic 4 +hormone 4 +( 0 +SIADH 3 +) 0 +among 0 +vincristine 1 +- 0 +treated 0 +patients 0 +and 0 +to 0 +explore 0 +the 0 +possibility 0 +of 0 +at 0 +- 0 +risk 0 +population 0 +subgroups 0 +. 0 + +METH0D 0 +: 0 +We 0 +searched 0 +the 0 +Eli 0 +Lilly 0 +and 0 +Company 0 +' 0 +s 0 +computerized 0 +adverse 0 +event 0 +database 0 +for 0 +all 0 +reported 0 +cases 0 +of 0 +hyponatremia 3 +and 0 +/ 0 +or 0 +SIADH 3 +as 0 +of 0 +1 0 +November 0 +1999 0 +that 0 +had 0 +been 0 +reported 0 +during 0 +the 0 +use 0 +of 0 +vincristine 1 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +76 0 +cases 0 +of 0 +hyponatremia 3 +and 0 +/ 0 +or 0 +SIADH 3 +associated 0 +with 0 +vincristine 1 +use 0 +were 0 +identified 0 +. 0 + +The 0 +overall 0 +reporting 0 +rate 0 +was 0 +estimated 0 +to 0 +be 0 +1 0 +. 0 +3 0 +/ 0 +100 0 +, 0 +000 0 +treated 0 +patients 0 +. 0 + +The 0 +average 0 +age 0 +of 0 +patients 0 +was 0 +35 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +28 0 +. 0 +3 0 +years 0 +, 0 +and 0 +62 0 +% 0 +were 0 +males 0 +. 0 + +Approximately 0 +75 0 +% 0 +of 0 +the 0 +patients 0 +were 0 +receiving 0 +treatment 0 +for 0 +leukemia 3 +or 0 +lymphoma 3 +. 0 + +Among 0 +the 0 +39 0 +reports 0 +that 0 +included 0 +information 0 +on 0 +race 0 +, 0 +the 0 +racial 0 +distribution 0 +was 0 +: 0 +1 0 +Black 0 +, 0 +3 0 +Caucasian 0 +, 0 +and 0 +35 0 +Asian 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +data 0 +suggest 0 +that 0 +Asian 0 +patients 0 +may 0 +be 0 +at 0 +increased 0 +risk 0 +of 0 +hyponatremia 3 +and 0 +/ 0 +or 0 +SIADH 3 +associated 0 +with 0 +vincristine 1 +use 0 +. 0 + +Although 0 +the 0 +overall 0 +reported 0 +rate 0 +of 0 +SIADH 3 +associated 0 +with 0 +vincristine 1 +is 0 +very 0 +low 0 +, 0 +physicians 0 +caring 0 +for 0 +Asian 0 +oncology 0 +patients 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +potential 0 +serious 0 +but 0 +reversible 0 +adverse 0 +event 0 +. 0 + +Delayed 0 +toxicity 3 +of 0 +cyclophosphamide 1 +on 0 +the 0 +bladder 0 +of 0 +DBA 0 +/ 0 +2 0 +and 0 +C57BL 0 +/ 0 +6 0 +female 0 +mouse 0 +. 0 + +The 0 +present 0 +study 0 +describes 0 +the 0 +delayed 0 +development 0 +of 0 +a 0 +severe 0 +bladder 0 +pathology 0 +in 0 +a 0 +susceptible 0 +strain 0 +of 0 +mice 0 +( 0 +DBA 0 +/ 0 +2 0 +) 0 +but 0 +not 0 +in 0 +a 0 +resistant 0 +strain 0 +( 0 +C57BL 0 +/ 0 +6 0 +) 0 +when 0 +both 0 +were 0 +treated 0 +with 0 +a 0 +single 0 +300 0 +mg 0 +/ 0 +kg 0 +dose 0 +of 0 +cyclophosphamide 1 +( 0 +CY 1 +) 0 +. 0 + +Inbred 0 +DBA 0 +/ 0 +2 0 +and 0 +C57BL 0 +/ 0 +6 0 +female 0 +mice 0 +were 0 +injected 0 +with 0 +CY 1 +, 0 +and 0 +the 0 +effect 0 +of 0 +the 0 +drug 0 +on 0 +the 0 +bladder 0 +was 0 +assessed 0 +during 0 +100 0 +days 0 +by 0 +light 0 +microscopy 0 +using 0 +different 0 +staining 0 +procedures 0 +, 0 +and 0 +after 0 +30 0 +days 0 +by 0 +conventional 0 +electron 0 +microscopy 0 +. 0 + +Early 0 +CY 1 +toxicity 3 +caused 0 +a 0 +typical 0 +haemorrhagic 3 +cystitis 3 +in 0 +both 0 +strains 0 +that 0 +was 0 +completely 0 +repaired 0 +in 0 +about 0 +7 0 +- 0 +10 0 +days 0 +. 0 + +After 0 +30 0 +days 0 +of 0 +CY 1 +injection 0 +ulcerous 0 +and 0 +non 0 +- 0 +ulcerous 0 +forms 0 +of 0 +chronic 0 +cystitis 3 +appeared 0 +in 0 +86 0 +% 0 +of 0 +DBA 0 +/ 0 +2 0 +mice 0 +but 0 +only 0 +in 0 +4 0 +% 0 +of 0 +C57BL 0 +/ 0 +6 0 +mice 0 +. 0 + +Delayed 0 +cystitis 3 +was 0 +characterized 0 +by 0 +infiltration 0 +and 0 +transepithelial 0 +passage 0 +into 0 +the 0 +lumen 0 +of 0 +inflammatory 0 +cells 0 +and 0 +by 0 +frequent 0 +exfoliation 0 +of 0 +the 0 +urothelium 0 +. 0 + +Mast 0 +cells 0 +appeared 0 +in 0 +the 0 +connective 0 +and 0 +muscular 0 +layers 0 +of 0 +the 0 +bladder 0 +at 0 +a 0 +much 0 +higher 0 +number 0 +in 0 +DBA 0 +/ 0 +2 0 +mice 0 +than 0 +in 0 +C57BL 0 +/ 0 +6 0 +mice 0 +or 0 +untreated 0 +controls 0 +. 0 + +Electron 0 +microscopy 0 +disclosed 0 +the 0 +absence 0 +of 0 +the 0 +typical 0 +discoidal 0 +vesicles 0 +normally 0 +present 0 +in 0 +the 0 +cytoplasm 0 +of 0 +surface 0 +cells 0 +. 0 + +Instead 0 +, 0 +numerous 0 +abnormal 0 +vesicles 0 +containing 0 +one 0 +or 0 +several 0 +dark 0 +granules 0 +were 0 +observed 0 +in 0 +the 0 +cytoplasm 0 +of 0 +cells 0 +from 0 +all 0 +the 0 +epithelial 0 +layers 0 +. 0 + +Delayed 0 +cystitis 3 +still 0 +persisted 0 +in 0 +DBA 0 +/ 0 +2 0 +mice 0 +100 0 +days 0 +after 0 +treatment 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +delayed 0 +toxicity 3 +of 0 +CY 1 +in 0 +female 0 +DBA 0 +/ 0 +2 0 +mice 0 +causes 0 +a 0 +bladder 0 +pathology 0 +that 0 +is 0 +not 0 +observed 0 +in 0 +C57BL 0 +/ 0 +6 0 +mice 0 +. 0 + +This 0 +pathology 0 +resembles 0 +interstitial 3 +cystitis 4 +in 0 +humans 0 +and 0 +could 0 +perhaps 0 +be 0 +used 0 +as 0 +an 0 +animal 0 +model 0 +for 0 +studies 0 +on 0 +the 0 +disease 0 +. 0 + +High 0 +- 0 +dose 0 +5 1 +- 2 +fluorouracil 2 +/ 0 +folinic 1 +acid 2 +in 0 +combination 0 +with 0 +three 0 +- 0 +weekly 0 +mitomycin 1 +C 2 +in 0 +the 0 +treatment 0 +of 0 +advanced 0 +gastric 3 +cancer 4 +. 0 + +A 0 +phase 0 +II 0 +study 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +24 0 +- 0 +hour 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +and 0 +folinic 1 +acid 2 +( 0 +FA 1 +) 0 +as 0 +part 0 +of 0 +several 0 +new 0 +multidrug 0 +chemotherapy 0 +regimens 0 +in 0 +advanced 0 +gastric 3 +cancer 4 +( 0 +AGC 3 +) 0 +has 0 +shown 0 +to 0 +be 0 +effective 0 +, 0 +with 0 +low 0 +toxicity 3 +. 0 + +In 0 +a 0 +previous 0 +phase 0 +II 0 +study 0 +with 0 +3 0 +- 0 +weekly 0 +bolus 0 +5 1 +- 2 +FU 2 +, 0 +FA 1 +and 0 +mitomycin 1 +C 2 +( 0 +MMC 1 +) 0 +we 0 +found 0 +a 0 +low 0 +toxicity 3 +rate 0 +and 0 +response 0 +rates 0 +comparable 0 +to 0 +those 0 +of 0 +regimens 0 +such 0 +as 0 +ELF 0 +, 0 +FAM 0 +or 0 +FAMTX 0 +, 0 +and 0 +a 0 +promising 0 +median 0 +overall 0 +survival 0 +. 0 + +In 0 +order 0 +to 0 +improve 0 +this 0 +MMC 1 +- 0 +dependent 0 +schedule 0 +we 0 +initiated 0 +a 0 +phase 0 +II 0 +study 0 +with 0 +high 0 +- 0 +dose 0 +5 1 +- 2 +FU 2 +/ 0 +FA 1 +and 0 +3 0 +- 0 +weekly 0 +bolus 0 +MMC 1 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +From 0 +February 0 +, 0 +1998 0 +to 0 +September 0 +, 0 +2000 0 +we 0 +recruited 0 +33 0 +patients 0 +with 0 +AGC 3 +to 0 +receive 0 +weekly 0 +24 0 +- 0 +hour 0 +5 1 +- 2 +FU 2 +2 0 +, 0 +600 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +preceded 0 +by 0 +2 0 +- 0 +hour 0 +FA 1 +500 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +6 0 +weeks 0 +, 0 +followed 0 +by 0 +a 0 +2 0 +- 0 +week 0 +rest 0 +period 0 +. 0 + +Bolus 0 +MMC 1 +10 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +was 0 +added 0 +in 0 +3 0 +- 0 +weekly 0 +intervals 0 +. 0 + +Treatment 0 +given 0 +on 0 +an 0 +outpatient 0 +basis 0 +, 0 +using 0 +portable 0 +pump 0 +systems 0 +, 0 +was 0 +repeated 0 +on 0 +day 0 +57 0 +. 0 + +Patients 0 +' 0 +characteristics 0 +were 0 +: 0 +male 0 +/ 0 +female 0 +ratio 0 +20 0 +/ 0 +13 0 +; 0 +median 0 +age 0 +57 0 +( 0 +27 0 +- 0 +75 0 +) 0 +years 0 +; 0 +median 0 +WH0 0 +status 0 +1 0 +( 0 +0 0 +- 0 +2 0 +) 0 +. 0 + +18 0 +patients 0 +had 0 +a 0 +primary 0 +AGC 3 +, 0 +and 0 +15 0 +showed 0 +a 0 +relapsed 0 +AGC 3 +. 0 + +Median 0 +follow 0 +- 0 +up 0 +was 0 +11 0 +. 0 +8 0 +months 0 +( 0 +range 0 +of 0 +those 0 +surviving 0 +: 0 +2 0 +. 0 +7 0 +- 0 +11 0 +. 0 +8 0 +months 0 +) 0 +. 0 + +RESULTS 0 +: 0 +32 0 +patients 0 +were 0 +evaluable 0 +for 0 +response 0 +- 0 +complete 0 +remission 0 +9 0 +. 0 +1 0 +% 0 +( 0 +n 0 += 0 +3 0 +) 0 +, 0 +partial 0 +remission 0 +45 0 +. 0 +5 0 +% 0 +( 0 +n 0 += 0 +15 0 +) 0 +, 0 +no 0 +change 0 +27 0 +. 0 +3 0 +% 0 +( 0 +n 0 += 0 +9 0 +) 0 +, 0 +progressive 0 +disease 0 +15 0 +. 0 +1 0 +% 0 +( 0 +n 0 += 0 +5 0 +) 0 +. 0 + +Median 0 +overall 0 +survival 0 +time 0 +was 0 +10 0 +. 0 +2 0 +months 0 +[ 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +: 0 +8 0 +. 0 +7 0 +- 0 +11 0 +. 0 +6 0 +] 0 +, 0 +and 0 +median 0 +progression 0 +- 0 +free 0 +survival 0 +time 0 +was 0 +7 0 +. 0 +6 0 +months 0 +( 0 +95 0 +% 0 +CI 0 +: 0 +4 0 +. 0 +4 0 +- 0 +10 0 +. 0 +9 0 +) 0 +. 0 + +The 0 +worst 0 +toxicities 3 +( 0 +% 0 +) 0 +observed 0 +were 0 +( 0 +CTC 0 +- 0 +NCI 0 +1 0 +/ 0 +2 0 +/ 0 +3 0 +) 0 +: 0 +leukopenia 3 +45 0 +. 0 +5 0 +/ 0 +18 0 +. 0 +2 0 +/ 0 +6 0 +. 0 +1 0 +, 0 +thrombocytopenia 3 +33 0 +. 0 +3 0 +/ 0 +9 0 +. 0 +1 0 +/ 0 +6 0 +. 0 +1 0 +, 0 +vomitus 3 +24 0 +. 0 +2 0 +/ 0 +9 0 +. 0 +1 0 +/ 0 +0 0 +, 0 +diarrhea 3 +36 0 +. 0 +4 0 +/ 0 +6 0 +. 0 +1 0 +/ 0 +3 0 +. 0 +0 0 +, 0 +stomatitis 3 +18 0 +. 0 +2 0 +/ 0 +9 0 +. 0 +1 0 +/ 0 +0 0 +, 0 +hand 3 +- 4 +foot 4 +syndrome 4 +12 0 +. 0 +1 0 +/ 0 +0 0 +/ 0 +0 0 +. 0 + +Two 0 +patients 0 +developed 0 +hemolytic 3 +- 4 +uremic 4 +syndrome 4 +( 0 +HUS 3 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +High 0 +- 0 +dose 0 +5 1 +- 2 +FU 2 +/ 0 +FA 1 +/ 0 +MMC 1 +is 0 +an 0 +effective 0 +and 0 +well 0 +- 0 +tolerated 0 +outpatient 0 +regimen 0 +for 0 +AGC 3 +( 0 +objective 0 +response 0 +rate 0 +54 0 +. 0 +6 0 +% 0 +) 0 +. 0 + +It 0 +may 0 +serve 0 +as 0 +an 0 +alternative 0 +to 0 +cisplatin 1 +- 0 +containing 0 +regimens 0 +; 0 +however 0 +, 0 +it 0 +has 0 +to 0 +be 0 +considered 0 +that 0 +possibly 0 +HUS 3 +may 0 +occur 0 +. 0 + +Persistent 0 +sterile 0 +leukocyturia 3 +is 0 +associated 0 +with 0 +impaired 3 +renal 4 +function 4 +in 0 +human 3 +immunodeficiency 4 +virus 4 +type 4 +1 4 +- 4 +infected 4 +children 0 +treated 0 +with 0 +indinavir 1 +. 0 + +BACKGR0UND 0 +: 0 +Prolonged 0 +administration 0 +of 0 +indinavir 1 +is 0 +associated 0 +with 0 +the 0 +occurrence 0 +of 0 +a 0 +variety 0 +of 0 +renal 0 +complications 0 +in 0 +adults 0 +. 0 + +These 0 +well 0 +- 0 +documented 0 +side 0 +effects 0 +have 0 +restricted 0 +the 0 +use 0 +of 0 +this 0 +potent 0 +protease 0 +inhibitor 0 +in 0 +children 0 +. 0 + +DESIGN 0 +: 0 +A 0 +prospective 0 +study 0 +to 0 +monitor 0 +indinavir 1 +- 0 +related 0 +nephrotoxicity 3 +in 0 +a 0 +cohort 0 +of 0 +30 0 +human 3 +immunodeficiency 4 +virus 4 +type 4 +1 4 +- 4 +infected 4 +children 0 +treated 0 +with 0 +indinavir 1 +. 0 + +METH0DS 0 +: 0 +Urinary 0 +pH 0 +, 0 +albumin 0 +, 0 +creatinine 1 +, 0 +the 0 +presence 0 +of 0 +erythrocytes 0 +, 0 +leukocytes 0 +, 0 +bacteria 0 +and 0 +crystals 0 +, 0 +and 0 +culture 0 +were 0 +analyzed 0 +every 0 +3 0 +months 0 +for 0 +96 0 +weeks 0 +. 0 + +Serum 0 +creatinine 1 +levels 0 +were 0 +routinely 0 +determined 0 +at 0 +the 0 +same 0 +time 0 +points 0 +. 0 + +Steady 0 +- 0 +state 0 +pharmacokinetics 0 +of 0 +indinavir 1 +were 0 +done 0 +at 0 +week 0 +4 0 +after 0 +the 0 +initiation 0 +of 0 +indinavir 1 +. 0 + +RESULTS 0 +: 0 +The 0 +cumulative 0 +incidence 0 +of 0 +persistent 0 +sterile 0 +leukocyturia 3 +( 0 +> 0 +or 0 += 0 +75 0 +cells 0 +/ 0 +micro 0 +L 0 +in 0 +at 0 +least 0 +2 0 +consecutive 0 +visits 0 +) 0 +after 0 +96 0 +weeks 0 +was 0 +53 0 +% 0 +. 0 + +Persistent 0 +sterile 0 +leukocyturia 3 +was 0 +frequently 0 +associated 0 +with 0 +a 0 +mild 0 +increase 0 +in 0 +the 0 +urine 0 +albumin 0 +/ 0 +creatinine 1 +ratio 0 +and 0 +by 0 +microscopic 0 +hematuria 3 +. 0 + +The 0 +cumulative 0 +incidence 0 +of 0 +serum 0 +creatinine 1 +levels 0 +> 0 +50 0 +% 0 +above 0 +normal 0 +was 0 +33 0 +% 0 +after 0 +96 0 +weeks 0 +. 0 + +Children 0 +with 0 +persistent 0 +sterile 0 +leukocyturia 3 +more 0 +frequently 0 +had 0 +serum 0 +creatinine 1 +levels 0 +of 0 +50 0 +% 0 +above 0 +normal 0 +than 0 +those 0 +children 0 +without 0 +persistent 0 +sterile 0 +leukocyturia 3 +. 0 + +In 0 +children 0 +younger 0 +than 0 +5 0 +. 0 +6 0 +years 0 +, 0 +persistent 0 +sterile 0 +leukocyturia 3 +was 0 +significantly 0 +more 0 +frequent 0 +than 0 +in 0 +older 0 +children 0 +. 0 + +A 0 +higher 0 +cumulative 0 +incidence 0 +of 0 +persistent 0 +leukocyturia 3 +was 0 +found 0 +in 0 +children 0 +with 0 +an 0 +area 0 +under 0 +the 0 +curve 0 +> 0 +19 0 +mg 0 +/ 0 +L 0 +x 0 +h 0 +or 0 +a 0 +peak 0 +serum 0 +level 0 +of 0 +indinavir 1 +> 0 +12 0 +mg 0 +/ 0 +L 0 +. 0 + +In 0 +4 0 +children 0 +, 0 +indinavir 1 +was 0 +discontinued 0 +because 0 +of 0 +nephrotoxicity 3 +. 0 + +Subsequently 0 +, 0 +the 0 +serum 0 +creatinine 1 +levels 0 +decreased 0 +, 0 +the 0 +urine 0 +albumin 0 +/ 0 +creatinine 1 +ratios 0 +returned 0 +to 0 +zero 0 +, 0 +and 0 +the 0 +leukocyturia 3 +disappeared 0 +within 0 +3 0 +months 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Children 0 +treated 0 +with 0 +indinavir 1 +have 0 +a 0 +high 0 +cumulative 0 +incidence 0 +of 0 +persistent 0 +sterile 0 +leukocyturia 3 +. 0 + +Children 0 +with 0 +persistent 0 +sterile 0 +leukocyturia 3 +more 0 +frequently 0 +had 0 +an 0 +increase 0 +in 0 +serum 0 +creatinine 1 +levels 0 +of 0 +> 0 +50 0 +% 0 +above 0 +normal 0 +. 0 + +Younger 0 +children 0 +have 0 +an 0 +additional 0 +risk 0 +for 0 +renal 0 +complications 0 +. 0 + +The 0 +impairment 3 +of 4 +the 4 +renal 4 +function 4 +in 0 +these 0 +children 0 +occurred 0 +in 0 +the 0 +absence 0 +of 0 +clinical 0 +symptoms 0 +of 0 +nephrolithiasis 3 +. 0 + +Indinavir 1 +- 0 +associated 0 +nephrotoxicity 3 +must 0 +be 0 +monitored 0 +closely 0 +, 0 +especially 0 +in 0 +children 0 +with 0 +risk 0 +factors 0 +such 0 +as 0 +persistent 0 +sterile 0 +leukocyturia 3 +, 0 +age 0 +< 0 +5 0 +. 0 +6 0 +years 0 +, 0 +an 0 +area 0 +under 0 +the 0 +curve 0 +of 0 +indinavir 1 +> 0 +19 0 +mg 0 +/ 0 +L 0 +x 0 +h 0 +, 0 +and 0 +a 0 +C 0 +( 0 +max 0 +) 0 +> 0 +12 0 +mg 0 +/ 0 +L 0 +. 0 + +Utility 0 +of 0 +troponin 0 +I 0 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +. 0 + +Baseline 0 +electrocardiogram 0 +abnormalities 0 +and 0 +market 0 +elevations 0 +not 0 +associated 0 +with 0 +myocardial 3 +necrosis 4 +make 0 +accurate 0 +diagnosis 0 +of 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +difficult 0 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +. 0 + +Troponin 0 +sampling 0 +may 0 +offer 0 +greater 0 +diagnostic 0 +utility 0 +in 0 +these 0 +patients 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +assess 0 +outcomes 0 +based 0 +on 0 +troponin 0 +positivity 0 +in 0 +patients 0 +with 0 +cocaine 1 +chest 3 +pain 4 +admitted 0 +for 0 +exclusion 0 +of 0 +MI 3 +. 0 + +METH0DS 0 +: 0 +0utcomes 0 +were 0 +examined 0 +in 0 +patients 0 +admitted 0 +for 0 +possible 0 +MI 3 +after 0 +cocaine 1 +use 0 +. 0 + +All 0 +patients 0 +underwent 0 +a 0 +rapid 0 +rule 0 +- 0 +in 0 +protocol 0 +that 0 +included 0 +serial 0 +sampling 0 +of 0 +creatine 1 +kinase 0 +( 0 +CK 0 +) 0 +, 0 +CK 0 +- 0 +MB 0 +, 0 +and 0 +cardiac 0 +troponin 0 +I 0 +( 0 +cTnI 0 +) 0 +over 0 +eight 0 +hours 0 +. 0 + +0utcomes 0 +included 0 +CK 0 +- 0 +MB 0 +MI 3 +( 0 +CK 0 +- 0 +MB 0 +> 0 +or 0 += 0 +8 0 +ng 0 +/ 0 +mL 0 +with 0 +a 0 +relative 0 +index 0 +[ 0 +( 0 +CK 0 +- 0 +MB 0 +x 0 +100 0 +) 0 +/ 0 +total 0 +CK 0 +] 0 +> 0 +or 0 += 0 +4 0 +, 0 +cardiac 3 +death 4 +, 0 +and 0 +significant 0 +coronary 3 +disease 4 +( 0 +> 0 +or 0 += 0 +50 0 +% 0 +) 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +the 0 +246 0 +admitted 0 +patients 0 +, 0 +34 0 +( 0 +14 0 +% 0 +) 0 +met 0 +CK 0 +- 0 +MB 0 +criteria 0 +for 0 +MI 3 +and 0 +38 0 +( 0 +16 0 +% 0 +) 0 +had 0 +cTnI 0 +elevations 0 +. 0 + +Angiography 0 +was 0 +performed 0 +in 0 +29 0 +of 0 +38 0 +patients 0 +who 0 +were 0 +cTnI 0 +- 0 +positive 0 +, 0 +with 0 +significant 0 +disease 0 +present 0 +in 0 +25 0 +( 0 +86 0 +% 0 +) 0 +. 0 + +Three 0 +of 0 +the 0 +four 0 +patients 0 +without 0 +significant 0 +disease 0 +who 0 +had 0 +cTnI 0 +elevations 0 +met 0 +CK 0 +- 0 +MB 0 +criteria 0 +for 0 +MI 3 +, 0 +and 0 +the 0 +other 0 +had 0 +a 0 +peak 0 +CK 0 +- 0 +MB 0 +level 0 +of 0 +13 0 +ng 0 +/ 0 +mL 0 +. 0 + +Sensitivities 0 +, 0 +specificities 0 +, 0 +and 0 +positive 0 +and 0 +negative 0 +likelihood 0 +ratios 0 +for 0 +predicting 0 +cardiac 3 +death 4 +or 0 +significant 0 +disease 0 +were 0 +high 0 +for 0 +both 0 +CK 0 +- 0 +MB 0 +MI 3 +and 0 +cTnI 0 +and 0 +were 0 +not 0 +significantly 0 +different 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Most 0 +patients 0 +with 0 +cTnI 0 +elevations 0 +meet 0 +CK 0 +- 0 +MB 0 +criteria 0 +for 0 +MI 3 +, 0 +as 0 +well 0 +as 0 +have 0 +a 0 +high 0 +incidence 0 +of 0 +underlying 0 +significant 0 +disease 0 +. 0 + +Troponin 0 +appears 0 +to 0 +have 0 +an 0 +equivalent 0 +diagnostic 0 +accuracy 0 +compared 0 +with 0 +CK 0 +- 0 +MB 0 +for 0 +diagnosing 0 +necrosis 3 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +and 0 +suspected 0 +MI 3 +. 0 + +Acute 0 +interstitial 3 +nephritis 4 +due 0 +to 0 +nicergoline 1 +( 0 +Sermion 1 +) 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +acute 0 +interstitial 3 +nephritis 4 +( 0 +AIN 3 +) 0 +due 0 +to 0 +nicergoline 1 +( 0 +Sermion 1 +) 0 +. 0 + +A 0 +50 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +admitted 0 +to 0 +our 0 +hospital 0 +for 0 +fever 3 +and 0 +acute 3 +renal 4 +failure 4 +. 0 + +Before 0 +admission 0 +, 0 +he 0 +had 0 +been 0 +taking 0 +nicergoline 1 +and 0 +bendazac 1 +lysine 2 +due 0 +to 0 +retinal 3 +vein 4 +occlusion 4 +at 0 +ophthalmologic 0 +department 0 +. 0 + +Thereafter 0 +, 0 +he 0 +experienced 0 +intermittent 0 +fever 3 +and 0 +skin 3 +rash 4 +. 0 + +0n 0 +admission 0 +, 0 +clinical 0 +symptoms 0 +( 0 +i 0 +. 0 +e 0 +. 0 +arthralgia 3 +and 0 +fever 3 +) 0 +and 0 +laboratory 0 +findings 0 +( 0 +i 0 +. 0 +e 0 +. 0 +eosinophilia 3 +and 0 +renal 3 +failure 4 +) 0 +suggested 0 +AIN 3 +, 0 +and 0 +which 0 +was 0 +confirmed 0 +by 0 +pathologic 0 +findings 0 +on 0 +renal 0 +biopsy 0 +. 0 + +A 0 +lymphocyte 0 +transformation 0 +test 0 +demonstrated 0 +a 0 +positive 0 +result 0 +against 0 +nicergoline 1 +. 0 + +Treatment 0 +was 0 +consisted 0 +of 0 +withdrawal 0 +of 0 +nicergoline 1 +and 0 +intravenous 0 +methylprednisolone 1 +, 0 +and 0 +his 0 +renal 0 +function 0 +was 0 +completely 0 +recovered 0 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +first 0 +report 0 +of 0 +nicergoline 1 +- 0 +associated 0 +AIN 3 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +complicated 0 +by 0 +massive 0 +intestinal 0 +bleeding 3 +in 0 +a 0 +patient 0 +with 0 +chronic 3 +renal 4 +failure 4 +. 0 + +A 0 +patient 0 +with 0 +chronic 3 +renal 4 +failure 4 +( 0 +CRF 3 +) 0 +developed 0 +neuroleptic 3 +malignant 4 +syndrome 4 +( 0 +NMS 3 +) 0 +after 0 +administration 0 +of 0 +risperidone 1 +and 0 +levomepromazine 1 +. 0 + +In 0 +addition 0 +to 0 +the 0 +typical 0 +symptoms 0 +of 0 +NMS 3 +, 0 +massive 0 +intestinal 0 +bleeding 3 +was 0 +observed 0 +during 0 +the 0 +episode 0 +. 0 + +This 0 +report 0 +suggests 0 +that 0 +NMS 3 +in 0 +a 0 +patient 0 +with 0 +CRF 3 +may 0 +be 0 +complicated 0 +by 0 +intestinal 0 +bleeding 3 +and 0 +needs 0 +special 0 +caution 0 +for 0 +this 0 +complication 0 +. 0 + +Blood 0 +brain 0 +barrier 0 +in 0 +right 0 +- 0 +and 0 +left 0 +- 0 +pawed 0 +female 0 +rats 0 +assessed 0 +by 0 +a 0 +new 0 +staining 0 +method 0 +. 0 + +The 0 +asymmetrical 0 +breakdown 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +( 0 +BBB 0 +) 0 +was 0 +studied 0 +in 0 +female 0 +rats 0 +. 0 + +Paw 0 +preference 0 +was 0 +assessed 0 +by 0 +a 0 +food 0 +reaching 0 +test 0 +. 0 + +Adrenaline 1 +- 0 +induced 0 +hypertension 3 +was 0 +used 0 +to 0 +destroy 0 +the 0 +BBB 0 +, 0 +which 0 +was 0 +evaluated 0 +using 0 +triphenyltetrazolium 1 +( 0 +TTC 1 +) 0 +staining 0 +of 0 +the 0 +brain 0 +slices 0 +just 0 +after 0 +giving 0 +adrenaline 1 +for 0 +30 0 +s 0 +. 0 + +In 0 +normal 0 +rats 0 +, 0 +the 0 +whole 0 +brain 0 +sections 0 +exhibited 0 +complete 0 +staining 0 +with 0 +TTC 1 +. 0 + +After 0 +adrenaline 1 +infusion 0 +for 0 +30 0 +s 0 +, 0 +there 0 +were 0 +large 0 +unstained 0 +areas 0 +in 0 +the 0 +left 0 +brain 0 +in 0 +right 0 +- 0 +pawed 0 +animals 0 +, 0 +and 0 +vice 0 +versa 0 +in 0 +left 0 +- 0 +pawed 0 +animals 0 +. 0 + +Similar 0 +results 0 +were 0 +obtained 0 +in 0 +seizure 3 +- 0 +induced 0 +breakdown 0 +of 0 +BBB 0 +. 0 + +These 0 +results 0 +were 0 +explained 0 +by 0 +an 0 +asymmetric 0 +cerebral 0 +blood 0 +flow 0 +depending 0 +upon 0 +the 0 +paw 0 +preference 0 +in 0 +rats 0 +. 0 + +It 0 +was 0 +suggested 0 +that 0 +this 0 +new 0 +method 0 +and 0 +the 0 +results 0 +are 0 +consistent 0 +with 0 +contralateral 0 +motor 0 +control 0 +that 0 +may 0 +be 0 +important 0 +in 0 +determining 0 +the 0 +dominant 0 +cerebral 0 +hemisphere 0 +in 0 +animals 0 +. 0 + +Carvedilol 1 +protects 0 +against 0 +doxorubicin 1 +- 0 +induced 0 +mitochondrial 0 +cardiomyopathy 3 +. 0 + +Several 0 +cytopathic 0 +mechanisms 0 +have 0 +been 0 +suggested 0 +to 0 +mediate 0 +the 0 +dose 0 +- 0 +limiting 0 +cumulative 0 +and 0 +irreversible 0 +cardiomyopathy 3 +caused 0 +by 0 +doxorubicin 1 +. 0 + +Recent 0 +evidence 0 +indicates 0 +that 0 +oxidative 0 +stress 0 +and 0 +mitochondrial 3 +dysfunction 4 +are 0 +key 0 +factors 0 +in 0 +the 0 +pathogenic 0 +process 0 +. 0 + +The 0 +objective 0 +of 0 +this 0 +investigation 0 +was 0 +to 0 +test 0 +the 0 +hypothesis 0 +that 0 +carvedilol 1 +, 0 +a 0 +nonselective 0 +beta 0 +- 0 +adrenergic 0 +receptor 0 +antagonist 0 +with 0 +potent 0 +antioxidant 0 +properties 0 +, 0 +protects 0 +against 0 +the 0 +cardiac 0 +and 0 +hepatic 0 +mitochondrial 0 +bioenergetic 0 +dysfunction 0 +associated 0 +with 0 +subchronic 0 +doxorubicin 1 +toxicity 3 +. 0 + +Heart 0 +and 0 +liver 0 +mitochondria 0 +were 0 +isolated 0 +from 0 +rats 0 +treated 0 +for 0 +7 0 +weeks 0 +with 0 +doxorubicin 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +sc 0 +/ 0 +week 0 +) 0 +, 0 +carvedilol 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +ip 0 +/ 0 +week 0 +) 0 +, 0 +or 0 +the 0 +combination 0 +of 0 +the 0 +two 0 +drugs 0 +. 0 + +Heart 0 +mitochondria 0 +isolated 0 +from 0 +doxorubicin 1 +- 0 +treated 0 +rats 0 +exhibited 0 +depressed 0 +rates 0 +for 0 +state 0 +3 0 +respiration 0 +( 0 +336 0 ++ 0 +/ 0 +- 0 +26 0 +versus 0 +425 0 ++ 0 +/ 0 +- 0 +53 0 +natom 0 +0 0 +/ 0 +min 0 +/ 0 +mg 0 +protein 0 +) 0 +and 0 +a 0 +lower 0 +respiratory 0 +control 0 +ratio 0 +( 0 +RCR 0 +) 0 +( 0 +4 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +versus 0 +5 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +) 0 +compared 0 +with 0 +cardiac 0 +mitochondria 0 +isolated 0 +from 0 +saline 0 +- 0 +treated 0 +rats 0 +. 0 + +Mitochondrial 0 +calcium 1 +- 0 +loading 0 +capacity 0 +and 0 +the 0 +activity 0 +of 0 +NADH 0 +- 0 +dehydrogenase 0 +were 0 +also 0 +suppressed 0 +in 0 +cardiac 0 +mitochondria 0 +from 0 +doxorubicin 1 +- 0 +treated 0 +rats 0 +. 0 + +Doxorubicin 1 +treatment 0 +also 0 +caused 0 +a 0 +decrease 0 +in 0 +RCR 0 +for 0 +liver 0 +mitochondria 0 +( 0 +3 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +versus 0 +5 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +for 0 +control 0 +rats 0 +) 0 +and 0 +inhibition 0 +of 0 +hepatic 0 +cytochrome 0 +oxidase 0 +activity 0 +. 0 + +Coadministration 0 +of 0 +carvedilol 1 +decreased 0 +the 0 +extent 0 +of 0 +cellular 0 +vacuolization 0 +in 0 +cardiac 0 +myocytes 0 +and 0 +prevented 0 +the 0 +inhibitory 0 +effect 0 +of 0 +doxorubicin 1 +on 0 +mitochondrial 0 +respiration 0 +in 0 +both 0 +heart 0 +and 0 +liver 0 +. 0 + +Carvedilol 1 +also 0 +prevented 0 +the 0 +decrease 0 +in 0 +mitochondrial 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +loading 0 +capacity 0 +and 0 +the 0 +inhibition 0 +of 0 +the 0 +respiratory 0 +complexes 0 +of 0 +heart 0 +mitochondria 0 +caused 0 +by 0 +doxorubicin 1 +. 0 + +Carvedilol 1 +by 0 +itself 0 +did 0 +not 0 +affect 0 +any 0 +of 0 +the 0 +parameters 0 +measured 0 +for 0 +heart 0 +or 0 +liver 0 +mitochondria 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +this 0 +protection 0 +by 0 +carvedilol 1 +against 0 +both 0 +the 0 +structural 0 +and 0 +functional 0 +cardiac 0 +tissue 0 +damage 0 +may 0 +afford 0 +significant 0 +clinical 0 +advantage 0 +in 0 +minimizing 0 +the 0 +dose 0 +- 0 +limiting 0 +mitochondrial 3 +dysfunction 4 +and 0 +cardiomyopathy 3 +that 0 +accompanies 0 +long 0 +- 0 +term 0 +doxorubicin 1 +therapy 0 +in 0 +cancer 3 +patients 0 +. 0 + +Cocaine 1 +- 0 +induced 0 +hyperactivity 3 +is 0 +more 0 +influenced 0 +by 0 +adenosine 1 +receptor 0 +agonists 0 +than 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +The 0 +influence 0 +of 0 +adenosine 1 +receptor 0 +agonists 0 +and 0 +antagonists 0 +on 0 +cocaine 1 +- 0 +and 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +was 0 +examined 0 +in 0 +mice 0 +. 0 + +All 0 +adenosine 1 +receptor 0 +agonists 0 +significantly 0 +decreased 3 +the 4 +locomotor 4 +activity 4 +in 0 +mice 0 +, 0 +and 0 +the 0 +effects 0 +were 0 +dose 0 +- 0 +dependent 0 +. 0 + +It 0 +seems 0 +that 0 +adenosine 1 +A1 0 +and 0 +A2 0 +receptors 0 +might 0 +be 0 +involved 0 +in 0 +this 0 +reaction 0 +. 0 + +Moreover 0 +, 0 +all 0 +adenosine 1 +receptor 0 +agonists 0 +: 0 +2 1 +- 2 +p 2 +- 2 +( 2 +2 2 +- 2 +carboxyethyl 2 +) 2 +phenethylamino 2 +- 2 +5 2 +' 2 +- 2 +N 2 +- 2 +ethylcarboxamidoadenosine 2 +( 0 +CGS 1 +21680 2 +) 0 +, 0 +A2A 0 +receptor 0 +agonist 0 +, 0 +N6 1 +- 2 +cyclopentyladenosine 2 +( 0 +CPA 1 +) 0 +, 0 +A1 0 +receptor 0 +agonist 0 +, 0 +and 0 +5 1 +' 2 +- 2 +N 2 +- 2 +ethylcarboxamidoadenosine 2 +( 0 +NECA 1 +) 0 +, 0 +A2 0 +/ 0 +A1 0 +receptor 0 +agonist 0 +significantly 0 +and 0 +dose 0 +- 0 +dependently 0 +decreased 0 +cocaine 1 +- 0 +induced 0 +locomotor 0 +activity 0 +. 0 + +CPA 1 +reduced 0 +cocaine 1 +action 0 +at 0 +the 0 +doses 0 +which 0 +, 0 +given 0 +alone 0 +, 0 +did 0 +not 0 +influence 0 +motility 0 +, 0 +while 0 +CGS 1 +21680 2 +and 0 +NECA 1 +decreased 0 +the 0 +action 0 +of 0 +cocaine 1 +at 0 +the 0 +doses 0 +which 0 +, 0 +given 0 +alone 0 +, 0 +decreased 0 +locomotor 0 +activity 0 +in 0 +animals 0 +. 0 + +These 0 +results 0 +suggest 0 +the 0 +involvement 0 +of 0 +both 0 +adenosine 1 +receptors 0 +in 0 +the 0 +action 0 +of 0 +cocaine 1 +although 0 +agonists 0 +of 0 +A1 0 +receptors 0 +seem 0 +to 0 +have 0 +stronger 0 +influence 0 +on 0 +it 0 +. 0 + +The 0 +selective 0 +blockade 0 +of 0 +A2 0 +adenosine 1 +receptor 0 +by 0 +DMPX 1 +( 0 +3 1 +, 2 +7 2 +- 2 +dimethyl 2 +- 2 +1 2 +- 2 +propargylxanthine 2 +) 0 +significantly 0 +enhanced 0 +cocaine 1 +- 0 +induced 0 +locomotor 0 +activity 0 +of 0 +animals 0 +. 0 + +Caffeine 1 +had 0 +similar 0 +action 0 +but 0 +the 0 +effect 0 +was 0 +not 0 +significant 0 +. 0 + +CPT 1 +( 0 +8 1 +- 2 +cyclopentyltheophylline 2 +) 0 +- 0 +- 0 +A1 0 +receptor 0 +antagonist 0 +, 0 +did 0 +not 0 +show 0 +any 0 +influence 0 +in 0 +this 0 +test 0 +. 0 + +Similarly 0 +, 0 +all 0 +adenosine 1 +receptor 0 +agonists 0 +decreased 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +, 0 +but 0 +at 0 +the 0 +higher 0 +doses 0 +than 0 +those 0 +which 0 +were 0 +active 0 +in 0 +cocaine 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +The 0 +selective 0 +blockade 0 +of 0 +A2 0 +adenosine 1 +receptors 0 +( 0 +DMPX 1 +) 0 +and 0 +non 0 +- 0 +selective 0 +blockade 0 +of 0 +adenosine 1 +receptors 0 +( 0 +caffeine 1 +) 0 +significantly 0 +increased 0 +the 0 +action 0 +of 0 +amphetamine 1 +in 0 +the 0 +locomotor 0 +activity 0 +test 0 +. 0 + +0ur 0 +results 0 +have 0 +shown 0 +that 0 +all 0 +adenosine 1 +receptor 0 +agonists 0 +( 0 +A1 0 +and 0 +A2 0 +) 0 +reduce 0 +cocaine 1 +- 0 +and 0 +amphetamine 1 +- 0 +induced 0 +locomotor 0 +activity 0 +and 0 +indicate 0 +that 0 +cocaine 1 +- 0 +induced 0 +hyperactivity 3 +is 0 +more 0 +influenced 0 +by 0 +adenosine 1 +receptor 0 +agonists 0 +( 0 +particularly 0 +A1 0 +receptors 0 +) 0 +than 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +. 0 + +Amiodarone 1 +and 0 +the 0 +risk 0 +of 0 +bradyarrhythmia 3 +requiring 0 +permanent 0 +pacemaker 0 +in 0 +elderly 0 +patients 0 +with 0 +atrial 3 +fibrillation 4 +and 0 +prior 0 +myocardial 3 +infarction 4 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +whether 0 +the 0 +use 0 +of 0 +amiodarone 1 +in 0 +patients 0 +with 0 +atrial 3 +fibrillation 4 +( 0 +AF 3 +) 0 +increases 0 +the 0 +risk 0 +of 0 +bradyarrhythmia 3 +requiring 0 +a 0 +permanent 0 +pacemaker 0 +. 0 + +BACKGR0UND 0 +: 0 +Reports 0 +of 0 +severe 0 +bradyarrhythmia 3 +during 0 +amiodarone 1 +therapy 0 +are 0 +infrequent 0 +and 0 +limited 0 +to 0 +studies 0 +assessing 0 +the 0 +therapy 0 +' 0 +s 0 +use 0 +in 0 +the 0 +management 0 +of 0 +patients 0 +with 0 +ventricular 3 +arrhythmias 4 +. 0 + +METH0DS 0 +: 0 +A 0 +study 0 +cohort 0 +of 0 +8 0 +, 0 +770 0 +patients 0 +age 0 +> 0 +or 0 += 0 +65 0 +years 0 +with 0 +a 0 +new 0 +diagnosis 0 +of 0 +AF 3 +was 0 +identified 0 +from 0 +a 0 +provincewide 0 +database 0 +of 0 +Quebec 0 +residents 0 +with 0 +a 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +between 0 +1991 0 +and 0 +1999 0 +. 0 + +Using 0 +a 0 +nested 0 +case 0 +- 0 +control 0 +design 0 +, 0 +477 0 +cases 0 +of 0 +bradyarrhythmia 3 +requiring 0 +a 0 +permanent 0 +pacemaker 0 +were 0 +matched 0 +( 0 +1 0 +: 0 +4 0 +) 0 +to 0 +1 0 +, 0 +908 0 +controls 0 +. 0 + +Multivariable 0 +logistic 0 +regression 0 +was 0 +used 0 +to 0 +estimate 0 +the 0 +odds 0 +ratio 0 +( 0 +0R 0 +) 0 +of 0 +pacemaker 0 +insertion 0 +associated 0 +with 0 +amiodarone 1 +use 0 +, 0 +controlling 0 +for 0 +baseline 0 +risk 0 +factors 0 +and 0 +exposure 0 +to 0 +sotalol 1 +, 0 +Class 0 +I 0 +antiarrhythmic 0 +agents 0 +, 0 +beta 0 +- 0 +blockers 0 +, 0 +calcium 1 +channel 0 +blockers 0 +, 0 +and 0 +digoxin 1 +. 0 + +RESULTS 0 +: 0 +amiodarone 1 +use 0 +was 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +of 0 +pacemaker 0 +insertion 0 +( 0 +0R 0 +: 0 +2 0 +. 0 +14 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +: 0 +1 0 +. 0 +30 0 +to 0 +3 0 +. 0 +54 0 +) 0 +. 0 + +This 0 +effect 0 +was 0 +modified 0 +by 0 +gender 0 +, 0 +with 0 +a 0 +greater 0 +risk 0 +in 0 +women 0 +versus 0 +men 0 +( 0 +0R 0 +: 0 +3 0 +. 0 +86 0 +, 0 +95 0 +% 0 +CI 0 +: 0 +1 0 +. 0 +70 0 +to 0 +8 0 +. 0 +75 0 +vs 0 +. 0 +0R 0 +: 0 +1 0 +. 0 +52 0 +, 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +80 0 +to 0 +2 0 +. 0 +89 0 +) 0 +. 0 + +Digoxin 1 +was 0 +the 0 +only 0 +other 0 +medication 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +of 0 +pacemaker 0 +insertion 0 +( 0 +0R 0 +: 0 +1 0 +. 0 +78 0 +, 0 +95 0 +% 0 +CI 0 +: 0 +1 0 +. 0 +37 0 +to 0 +2 0 +. 0 +31 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +This 0 +study 0 +suggests 0 +that 0 +the 0 +use 0 +of 0 +amiodarone 1 +in 0 +elderly 0 +patients 0 +with 0 +AF 3 +and 0 +a 0 +previous 0 +MI 3 +increases 0 +the 0 +risk 0 +of 0 +bradyarrhythmia 3 +requiring 0 +a 0 +permanent 0 +pacemaker 0 +. 0 + +The 0 +finding 0 +of 0 +an 0 +augmented 0 +risk 0 +of 0 +pacemaker 0 +insertion 0 +in 0 +elderly 0 +women 0 +receiving 0 +amiodarone 1 +requires 0 +further 0 +investigation 0 +. 0 + +Indomethacin 1 +- 0 +induced 0 +morphologic 0 +changes 0 +in 0 +the 0 +rat 0 +urinary 0 +bladder 0 +epithelium 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +evaluate 0 +the 0 +morphologic 0 +changes 0 +in 0 +rat 0 +urothelium 0 +induced 0 +by 0 +indomethacin 1 +. 0 + +Nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +- 0 +induced 0 +cystitis 3 +is 0 +a 0 +poorly 0 +recognized 0 +and 0 +under 0 +- 0 +reported 0 +condition 0 +. 0 + +In 0 +addition 0 +to 0 +tiaprofenic 1 +acid 2 +, 0 +indomethacin 1 +has 0 +been 0 +reported 0 +to 0 +be 0 +associated 0 +with 0 +this 0 +condition 0 +. 0 + +METH0DS 0 +: 0 +Three 0 +groups 0 +were 0 +established 0 +: 0 +a 0 +control 0 +group 0 +( 0 +n 0 += 0 +10 0 +) 0 +, 0 +a 0 +high 0 +- 0 +dose 0 +group 0 +( 0 +n 0 += 0 +10 0 +) 0 +, 0 +treated 0 +with 0 +one 0 +intraperitoneal 0 +injection 0 +of 0 +indomethacin 1 +20 0 +mg 0 +/ 0 +kg 0 +, 0 +and 0 +a 0 +therapeutic 0 +dose 0 +group 0 +( 0 +n 0 += 0 +10 0 +) 0 +in 0 +which 0 +oral 0 +indomethacin 1 +was 0 +administered 0 +3 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +daily 0 +for 0 +3 0 +weeks 0 +. 0 + +The 0 +animals 0 +were 0 +then 0 +killed 0 +and 0 +the 0 +bladders 0 +removed 0 +for 0 +light 0 +and 0 +electron 0 +microscopic 0 +studies 0 +. 0 + +RESULTS 0 +: 0 +The 0 +light 0 +microscopic 0 +findings 0 +showed 0 +some 0 +focal 0 +epithelial 0 +degeneration 0 +that 0 +was 0 +more 0 +prominent 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +. 0 + +When 0 +compared 0 +with 0 +the 0 +control 0 +group 0 +, 0 +both 0 +indomethacin 1 +groups 0 +revealed 0 +statistically 0 +increased 0 +numbers 0 +of 0 +mast 0 +cells 0 +in 0 +the 0 +mucosa 0 +( 0 +P 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +and 0 +penetration 0 +of 0 +lanthanum 1 +nitrate 2 +through 0 +intercellular 0 +areas 0 +of 0 +the 0 +epithelium 0 +. 0 + +Furthermore 0 +, 0 +the 0 +difference 0 +in 0 +mast 0 +cell 0 +counts 0 +between 0 +the 0 +high 0 +and 0 +therapeutic 0 +dose 0 +groups 0 +was 0 +also 0 +statistically 0 +significant 0 +( 0 +P 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Indomethacin 1 +resulted 0 +in 0 +histopathologic 0 +findings 0 +typical 0 +of 0 +interstitial 3 +cystitis 4 +, 0 +such 0 +as 0 +leaky 0 +bladder 0 +epithelium 0 +and 0 +mucosal 0 +mastocytosis 3 +. 0 + +The 0 +true 0 +incidence 0 +of 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +- 0 +induced 0 +cystitis 3 +in 0 +humans 0 +must 0 +be 0 +clarified 0 +by 0 +prospective 0 +clinical 0 +trials 0 +. 0 + +An 0 +open 0 +- 0 +label 0 +phase 0 +II 0 +study 0 +of 0 +low 0 +- 0 +dose 0 +thalidomide 1 +in 0 +androgen 1 +- 0 +independent 0 +prostate 3 +cancer 4 +. 0 + +The 0 +antiangiogenic 0 +effects 0 +of 0 +thalidomide 1 +have 0 +been 0 +assessed 0 +in 0 +clinical 0 +trials 0 +in 0 +patients 0 +with 0 +various 0 +solid 0 +and 0 +haematological 3 +malignancies 4 +. 0 + +Thalidomide 1 +blocks 0 +the 0 +activity 0 +of 0 +angiogenic 0 +agents 0 +including 0 +bFGF 0 +, 0 +VEGF 0 +and 0 +IL 0 +- 0 +6 0 +. 0 + +We 0 +undertook 0 +an 0 +open 0 +- 0 +label 0 +study 0 +using 0 +thalidomide 1 +100 0 +mg 0 +once 0 +daily 0 +for 0 +up 0 +to 0 +6 0 +months 0 +in 0 +20 0 +men 0 +with 0 +androgen 1 +- 0 +independent 0 +prostate 3 +cancer 4 +. 0 + +The 0 +mean 0 +time 0 +of 0 +study 0 +was 0 +109 0 +days 0 +( 0 +median 0 +107 0 +, 0 +range 0 +4 0 +- 0 +184 0 +days 0 +) 0 +. 0 + +Patients 0 +underwent 0 +regular 0 +measurement 0 +of 0 +prostate 0 +- 0 +specific 0 +antigen 0 +( 0 +PSA 0 +) 0 +, 0 +urea 1 +and 0 +electrolytes 0 +, 0 +serum 0 +bFGF 0 +and 0 +VEGF 0 +. 0 + +Three 0 +men 0 +( 0 +15 0 +% 0 +) 0 +showed 0 +a 0 +decline 0 +in 0 +serum 0 +PSA 0 +of 0 +at 0 +least 0 +50 0 +% 0 +, 0 +sustained 0 +throughout 0 +treatment 0 +. 0 + +0f 0 +16 0 +men 0 +treated 0 +for 0 +at 0 +least 0 +2 0 +months 0 +, 0 +six 0 +( 0 +37 0 +. 0 +5 0 +% 0 +) 0 +showed 0 +a 0 +fall 0 +in 0 +absolute 0 +PSA 0 +by 0 +a 0 +median 0 +of 0 +48 0 +% 0 +. 0 + +Increasing 0 +levels 0 +of 0 +serum 0 +bFGF 0 +and 0 +VEGF 0 +were 0 +associated 0 +with 0 +progressive 0 +disease 0 +; 0 +five 0 +of 0 +six 0 +men 0 +who 0 +demonstrated 0 +a 0 +fall 0 +in 0 +PSA 0 +also 0 +showed 0 +a 0 +decline 0 +in 0 +bFGF 0 +and 0 +VEGF 0 +levels 0 +, 0 +and 0 +three 0 +of 0 +four 0 +men 0 +with 0 +a 0 +rising 0 +PSA 0 +showed 0 +an 0 +increase 0 +in 0 +both 0 +growth 0 +factors 0 +. 0 + +Adverse 0 +effects 0 +included 0 +constipation 3 +, 0 +morning 0 +drowsiness 3 +, 0 +dizziness 3 +and 0 +rash 3 +, 0 +and 0 +resulted 0 +in 0 +withdrawal 0 +from 0 +the 0 +study 0 +by 0 +three 0 +men 0 +. 0 + +Evidence 0 +of 0 +peripheral 3 +sensory 4 +neuropathy 4 +was 0 +found 0 +in 0 +nine 0 +of 0 +13 0 +men 0 +before 0 +treatment 0 +. 0 + +In 0 +the 0 +seven 0 +men 0 +who 0 +completed 0 +six 0 +months 0 +on 0 +thalidomide 1 +, 0 +subclinical 0 +evidence 0 +of 0 +peripheral 3 +neuropathy 4 +was 0 +found 0 +in 0 +four 0 +before 0 +treatment 0 +, 0 +but 0 +in 0 +all 0 +seven 0 +at 0 +repeat 0 +testing 0 +. 0 + +The 0 +findings 0 +indicate 0 +that 0 +thalidomide 1 +may 0 +be 0 +an 0 +option 0 +for 0 +patients 0 +who 0 +have 0 +failed 0 +other 0 +forms 0 +of 0 +therapy 0 +, 0 +provided 0 +close 0 +follow 0 +- 0 +up 0 +is 0 +maintained 0 +for 0 +development 0 +of 0 +peripheral 3 +neuropathy 4 +. 0 + +Central 3 +nervous 4 +system 4 +toxicity 4 +following 0 +the 0 +administration 0 +of 0 +levobupivacaine 1 +for 0 +lumbar 0 +plexus 0 +block 0 +: 0 +A 0 +report 0 +of 0 +two 0 +cases 0 +. 0 + +BACKGR0UND 0 +AND 0 +0BJECTIVES 0 +: 0 +Central 3 +nervous 4 +system 4 +and 4 +cardiac 4 +toxicity 4 +following 0 +the 0 +administration 0 +of 0 +local 0 +anesthetics 0 +is 0 +a 0 +recognized 0 +complication 0 +of 0 +regional 0 +anesthesia 0 +. 0 + +Levobupivacaine 1 +, 0 +the 0 +pure 0 +S 0 +( 0 +- 0 +) 0 +enantiomer 0 +of 0 +bupivacaine 1 +, 0 +was 0 +developed 0 +to 0 +improve 0 +the 0 +cardiac 0 +safety 0 +profile 0 +of 0 +bupivacaine 1 +. 0 + +We 0 +describe 0 +2 0 +cases 0 +of 0 +grand 3 +mal 4 +seizures 4 +following 0 +accidental 0 +intravascular 0 +injection 0 +of 0 +levobupivacaine 1 +. 0 + +CASE 0 +REP0RT 0 +: 0 +Two 0 +patients 0 +presenting 0 +for 0 +elective 0 +orthopedic 0 +surgery 0 +of 0 +the 0 +lower 0 +limb 0 +underwent 0 +blockade 0 +of 0 +the 0 +lumbar 0 +plexus 0 +via 0 +the 0 +posterior 0 +approach 0 +. 0 + +Immediately 0 +after 0 +the 0 +administration 0 +of 0 +levobupivacaine 1 +0 0 +. 0 +5 0 +% 0 +with 0 +epinephrine 1 +2 0 +. 0 +5 0 +microgram 0 +/ 0 +mL 0 +, 0 +the 0 +patients 0 +developed 0 +grand 3 +mal 4 +seizures 4 +, 0 +despite 0 +negative 0 +aspiration 0 +for 0 +blood 0 +and 0 +no 0 +clinical 0 +signs 0 +of 0 +intravenous 0 +epinephrine 1 +administration 0 +. 0 + +The 0 +seizures 3 +were 0 +successfully 0 +treated 0 +with 0 +sodium 1 +thiopental 2 +in 0 +addition 0 +to 0 +succinylcholine 1 +in 0 +1 0 +patient 0 +. 0 + +Neither 0 +patient 0 +developed 0 +signs 0 +of 0 +cardiovascular 3 +toxicity 4 +. 0 + +Both 0 +patients 0 +were 0 +treated 0 +preoperatively 0 +with 0 +beta 0 +- 0 +adrenergic 0 +antagonist 0 +medications 0 +, 0 +which 0 +may 0 +have 0 +masked 0 +the 0 +cardiovascular 0 +signs 0 +of 0 +the 0 +unintentional 0 +intravascular 0 +administration 0 +of 0 +levobupivacaine 1 +with 0 +epinephrine 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +Although 0 +levobupivacaine 1 +may 0 +have 0 +a 0 +safer 0 +cardiac 3 +toxicity 4 +profile 0 +than 0 +racemic 0 +bupivacaine 1 +, 0 +if 0 +adequate 0 +amounts 0 +of 0 +levobupivacaine 1 +reach 0 +the 0 +circulation 0 +, 0 +it 0 +will 0 +result 0 +in 0 +convulsions 3 +. 0 + +Plasma 0 +concentrations 0 +sufficient 0 +to 0 +result 0 +in 0 +central 3 +nervous 4 +system 4 +toxicity 4 +did 0 +not 0 +produce 0 +manifestations 0 +of 0 +cardiac 3 +toxicity 4 +in 0 +these 0 +2 0 +patients 0 +. 0 + +Amiodarone 1 +- 0 +induced 0 +torsade 3 +de 4 +pointes 4 +during 0 +bladder 0 +irrigation 0 +: 0 +an 0 +unusual 0 +presentation 0 +- 0 +- 0 +a 0 +case 0 +report 0 +. 0 + +The 0 +authors 0 +present 0 +a 0 +case 0 +of 0 +early 0 +( 0 +within 0 +4 0 +days 0 +) 0 +development 0 +of 0 +torsade 3 +de 4 +pointes 4 +( 0 +TdP 3 +) 0 +associated 0 +with 0 +oral 0 +amiodarone 1 +therapy 0 +. 0 + +Consistent 0 +with 0 +other 0 +reports 0 +this 0 +case 0 +of 0 +TdP 3 +occurred 0 +in 0 +the 0 +context 0 +of 0 +multiple 0 +exacerbating 0 +factors 0 +including 0 +hypokalemia 3 +and 0 +digoxin 1 +excess 0 +. 0 + +Transient 0 +prolongation 0 +of 0 +the 0 +QT 0 +during 0 +bladder 0 +irrigation 0 +prompted 0 +the 0 +episode 0 +of 0 +TdP 3 +. 0 + +It 0 +is 0 +well 0 +known 0 +that 0 +bradycardia 3 +exacerbates 0 +acquired 0 +TdP 3 +. 0 + +The 0 +authors 0 +speculate 0 +that 0 +the 0 +increased 0 +vagal 0 +tone 0 +during 0 +bladder 0 +irrigation 0 +, 0 +a 0 +vagal 0 +maneuver 0 +, 0 +in 0 +the 0 +context 0 +of 0 +amiodarone 1 +therapy 0 +resulted 0 +in 0 +amiodarone 1 +- 0 +induced 0 +proarrhythmia 3 +. 0 + +In 0 +the 0 +absence 0 +of 0 +amiodarone 1 +therapy 0 +, 0 +a 0 +second 0 +bladder 0 +irrigation 0 +did 0 +not 0 +induce 0 +TdP 3 +despite 0 +hypokalemia 3 +and 0 +hypomagnesemia 3 +. 0 + +Anaesthetic 0 +complications 0 +associated 0 +with 0 +myotonia 3 +congenita 4 +: 0 +case 0 +study 0 +and 0 +comparison 0 +with 0 +other 0 +myotonic 3 +disorders 4 +. 0 + +Myotonia 3 +congenita 4 +( 0 +MC 3 +) 0 +is 0 +caused 0 +by 0 +a 0 +defect 0 +in 0 +the 0 +skeletal 0 +muscle 0 +chloride 1 +channel 0 +function 0 +, 0 +which 0 +may 0 +cause 0 +sustained 3 +membrane 4 +depolarisation 4 +. 0 + +We 0 +describe 0 +a 0 +previously 0 +healthy 0 +32 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +developed 0 +a 0 +life 0 +- 0 +threatening 0 +muscle 3 +spasm 4 +and 0 +secondary 0 +ventilation 0 +difficulties 0 +following 0 +a 0 +preoperative 0 +injection 0 +of 0 +suxamethonium 1 +. 0 + +The 0 +muscle 3 +spasms 4 +disappeared 0 +spontaneously 0 +and 0 +the 0 +surgery 0 +proceeded 0 +without 0 +further 0 +problems 0 +. 0 + +When 0 +subsequently 0 +questioned 0 +, 0 +she 0 +reported 0 +minor 0 +symptoms 0 +suggesting 0 +a 0 +myotonic 3 +condition 4 +. 0 + +Myotonia 3 +was 0 +found 0 +on 0 +clinical 0 +examination 0 +and 0 +EMG 0 +. 0 + +The 0 +diagnosis 0 +MC 3 +was 0 +confirmed 0 +genetically 0 +. 0 + +Neither 0 +the 0 +patient 0 +nor 0 +the 0 +anaesthetist 0 +were 0 +aware 0 +of 0 +the 0 +diagnosis 0 +before 0 +this 0 +potentially 0 +lethal 0 +complication 0 +occurred 0 +. 0 + +We 0 +give 0 +a 0 +brief 0 +overview 0 +of 0 +ion 3 +channel 4 +disorders 4 +including 0 +malignant 3 +hyperthermia 4 +and 0 +their 0 +anaesthetic 0 +considerations 0 +. 0 + +Respiratory 0 +pattern 0 +in 0 +a 0 +rat 0 +model 0 +of 0 +epilepsy 3 +. 0 + +PURP0SE 0 +: 0 +Apnea 3 +is 0 +known 0 +to 0 +occur 0 +during 0 +seizures 3 +, 0 +but 0 +systematic 0 +studies 0 +of 0 +ictal 0 +respiratory 0 +changes 0 +in 0 +adults 0 +are 0 +few 0 +. 0 + +Data 0 +regarding 0 +respiratory 0 +pattern 0 +defects 0 +during 0 +interictal 0 +periods 0 +also 0 +are 0 +scarce 0 +. 0 + +Here 0 +we 0 +sought 0 +to 0 +generate 0 +information 0 +with 0 +regard 0 +to 0 +the 0 +interictal 0 +period 0 +in 0 +animals 0 +with 0 +pilocarpine 1 +- 0 +induced 0 +epilepsy 3 +. 0 + +METH0DS 0 +: 0 +Twelve 0 +rats 0 +( 0 +six 0 +chronically 0 +epileptic 3 +animals 0 +and 0 +six 0 +controls 0 +) 0 +were 0 +anesthetized 0 +, 0 +given 0 +tracheotomies 0 +, 0 +and 0 +subjected 0 +to 0 +hyperventilation 3 +or 0 +hypoventilation 0 +conditions 0 +. 0 + +Breathing 0 +movements 0 +caused 0 +changes 0 +in 0 +thoracic 0 +volume 0 +and 0 +forced 0 +air 0 +to 0 +flow 0 +tidally 0 +through 0 +a 0 +pneumotachograph 0 +. 0 + +This 0 +flow 0 +was 0 +measured 0 +by 0 +using 0 +a 0 +differential 0 +pressure 0 +transducer 0 +, 0 +passed 0 +through 0 +a 0 +polygraph 0 +, 0 +and 0 +from 0 +this 0 +to 0 +a 0 +computer 0 +with 0 +custom 0 +software 0 +that 0 +derived 0 +ventilation 0 +( 0 +VE 0 +) 0 +, 0 +tidal 0 +volume 0 +( 0 +VT 0 +) 0 +, 0 +inspiratory 0 +time 0 +( 0 +TI 0 +) 0 +, 0 +expiratory 0 +time 0 +( 0 +TE 0 +) 0 +, 0 +breathing 0 +frequency 0 +( 0 +f 0 +) 0 +, 0 +and 0 +mean 0 +inspiratory 0 +flow 0 +( 0 +VT 0 +/ 0 +TI 0 +) 0 +on 0 +a 0 +breath 0 +- 0 +by 0 +- 0 +breath 0 +basis 0 +. 0 + +RESULTS 0 +: 0 +The 0 +hyperventilation 3 +maneuver 0 +caused 0 +a 0 +decrease 0 +in 0 +spontaneous 0 +ventilation 0 +in 0 +pilocarpine 1 +- 0 +treated 0 +and 0 +control 0 +rats 0 +. 0 + +Although 0 +VE 0 +had 0 +a 0 +similar 0 +decrease 0 +in 0 +both 0 +groups 0 +, 0 +in 0 +the 0 +epileptic 3 +group 0 +, 0 +the 0 +decrease 0 +in 0 +VE 0 +was 0 +due 0 +to 0 +a 0 +significant 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +increase 0 +in 0 +TE 0 +peak 0 +in 0 +relation 0 +to 0 +that 0 +of 0 +the 0 +control 0 +animals 0 +. 0 + +The 0 +hypoventilation 0 +maneuver 0 +led 0 +to 0 +an 0 +increase 0 +in 0 +the 0 +arterial 0 +Paco2 0 +, 0 +followed 0 +by 0 +an 0 +increase 0 +in 0 +VE 0 +. 0 + +In 0 +the 0 +epileptic 3 +group 0 +, 0 +the 0 +increase 0 +in 0 +VE 0 +was 0 +mediated 0 +by 0 +a 0 +significant 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +decrease 0 +in 0 +TE 0 +peak 0 +compared 0 +with 0 +the 0 +control 0 +group 0 +. 0 + +Systemic 0 +application 0 +of 0 +KCN 0 +, 0 +to 0 +evaluate 0 +the 0 +effects 0 +of 0 +peripheral 0 +chemoreception 0 +activation 0 +on 0 +ventilation 0 +, 0 +led 0 +to 0 +a 0 +similar 0 +increase 0 +in 0 +VE 0 +for 0 +both 0 +groups 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +data 0 +indicate 0 +that 0 +pilocarpine 1 +- 0 +treated 0 +animals 0 +have 0 +an 0 +altered 0 +ability 0 +to 0 +react 0 +to 0 +( 0 +or 0 +compensate 0 +for 0 +) 0 +blood 0 +gas 0 +changes 0 +with 0 +changes 0 +in 0 +ventilation 0 +and 0 +suggest 0 +that 0 +it 0 +is 0 +centrally 0 +determined 0 +. 0 + +We 0 +speculate 0 +on 0 +the 0 +possible 0 +relation 0 +of 0 +the 0 +current 0 +findings 0 +on 0 +treating 0 +different 0 +epilepsy 3 +- 0 +associated 0 +conditions 0 +. 0 + +Fatal 0 +myeloencephalopathy 3 +due 0 +to 0 +intrathecal 0 +vincristine 1 +administration 0 +. 0 + +Vincristine 1 +was 0 +accidentally 0 +given 0 +intrathecally 0 +to 0 +a 0 +child 0 +with 0 +leukaemia 3 +, 0 +producing 0 +sensory 3 +and 4 +motor 4 +dysfunction 4 +followed 0 +by 0 +encephalopathy 3 +and 0 +death 0 +. 0 + +Separate 0 +times 0 +for 0 +administering 0 +vincristine 1 +and 0 +intrathecal 0 +therapy 0 +is 0 +recommended 0 +. 0 + +Progesterone 1 +potentiation 0 +of 0 +bupivacaine 1 +arrhythmogenicity 0 +in 0 +pentobarbital 1 +- 0 +anesthetized 0 +rats 0 +and 0 +beating 0 +rat 0 +heart 0 +cell 0 +cultures 0 +. 0 + +The 0 +effects 0 +of 0 +progesterone 1 +treatment 0 +on 0 +bupivacaine 1 +arrhythmogenicity 0 +in 0 +beating 0 +rat 0 +heart 0 +myocyte 0 +cultures 0 +and 0 +on 0 +anesthetized 0 +rats 0 +were 0 +determined 0 +. 0 + +After 0 +determining 0 +the 0 +bupivacaine 1 +AD50 0 +( 0 +the 0 +concentration 0 +of 0 +bupivacaine 1 +that 0 +caused 0 +50 0 +% 0 +of 0 +all 0 +beating 0 +rat 0 +heart 0 +myocyte 0 +cultures 0 +to 0 +become 0 +arrhythmic 3 +) 0 +, 0 +we 0 +determined 0 +the 0 +effect 0 +of 0 +1 0 +- 0 +hour 0 +progesterone 1 +HCl 1 +exposure 0 +on 0 +myocyte 0 +contractile 0 +rhythm 0 +. 0 + +Each 0 +concentration 0 +of 0 +progesterone 1 +( 0 +6 0 +. 0 +25 0 +, 0 +12 0 +. 0 +5 0 +, 0 +25 0 +, 0 +and 0 +50 0 +micrograms 0 +/ 0 +ml 0 +) 0 +caused 0 +a 0 +significant 0 +and 0 +concentration 0 +- 0 +dependent 0 +reduction 0 +in 0 +the 0 +AD50 0 +for 0 +bupivacaine 1 +. 0 + +Estradiol 1 +treatment 0 +also 0 +increased 0 +the 0 +arrhythmogenicity 0 +of 0 +bupivacaine 1 +in 0 +myocyte 0 +cultures 0 +, 0 +but 0 +was 0 +only 0 +one 0 +fourth 0 +as 0 +potent 0 +as 0 +progesterone 1 +. 0 + +Neither 0 +progesterone 1 +nor 0 +estradiol 1 +effects 0 +on 0 +bupivacaine 1 +arrhythmogenicity 0 +were 0 +potentiated 0 +by 0 +epinephrine 1 +. 0 + +Chronic 0 +progesterone 1 +pretreatment 0 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +for 0 +21 0 +days 0 +) 0 +caused 0 +a 0 +significant 0 +increase 0 +in 0 +bupivacaine 1 +arrhythmogenicity 0 +in 0 +intact 0 +pentobarbital 1 +- 0 +anesthetized 0 +rats 0 +. 0 + +There 0 +was 0 +a 0 +significant 0 +decrease 0 +in 0 +the 0 +time 0 +to 0 +onset 0 +of 0 +arrhythmia 3 +as 0 +compared 0 +with 0 +control 0 +nonprogesterone 0 +- 0 +treated 0 +rats 0 +( 0 +6 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +vs 0 +. 0 +30 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +5 0 +min 0 +, 0 +mean 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +. 0 + +The 0 +results 0 +of 0 +this 0 +study 0 +indicate 0 +that 0 +progesterone 1 +can 0 +potentiate 0 +bupivacaine 1 +arrhythmogenicity 0 +both 0 +in 0 +vivo 0 +and 0 +in 0 +vitro 0 +. 0 + +Potentiation 0 +of 0 +bupivacaine 1 +arrhythmia 3 +in 0 +myocyte 0 +cultures 0 +suggests 0 +that 0 +this 0 +effect 0 +is 0 +at 0 +least 0 +partly 0 +mediated 0 +at 0 +the 0 +myocyte 0 +level 0 +. 0 + +Increased 0 +serum 0 +soluble 0 +Fas 0 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +due 0 +to 0 +paracetamol 1 +overdose 3 +. 0 + +BACKGR0UND 0 +/ 0 +AIMS 0 +: 0 +Experimental 0 +studies 0 +have 0 +suggested 0 +that 0 +apoptosis 0 +via 0 +the 0 +Fas 0 +/ 0 +Fas 0 +Ligand 0 +signaling 0 +system 0 +may 0 +play 0 +an 0 +important 0 +role 0 +in 0 +the 0 +development 0 +of 0 +acute 3 +liver 4 +failure 4 +. 0 + +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +soluble 0 +form 0 +of 0 +Fas 0 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +. 0 + +METH0D0L0GY 0 +: 0 +Serum 0 +levels 0 +of 0 +sFas 0 +( 0 +soluble 0 +Fas 0 +) 0 +were 0 +measured 0 +by 0 +ELISA 0 +in 0 +24 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +and 0 +10 0 +normal 0 +control 0 +subjects 0 +. 0 + +Serum 0 +levels 0 +of 0 +tumor 3 +necrosis 3 +factor 0 +- 0 +alpha 0 +and 0 +interferon 0 +- 0 +gamma 0 +were 0 +also 0 +determined 0 +by 0 +ELISA 0 +. 0 + +RESULTS 0 +: 0 +Serum 0 +sFas 0 +was 0 +significantly 0 +increased 0 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +( 0 +median 0 +, 0 +26 0 +. 0 +8 0 +U 0 +/ 0 +mL 0 +; 0 +range 0 +, 0 +6 0 +. 0 +9 0 +- 0 +52 0 +. 0 +7 0 +U 0 +/ 0 +mL 0 +) 0 +compared 0 +to 0 +the 0 +normal 0 +controls 0 +( 0 +median 0 +, 0 +8 0 +. 0 +6 0 +U 0 +/ 0 +mL 0 +; 0 +range 0 +, 0 +6 0 +. 0 +5 0 +- 0 +12 0 +. 0 +0 0 +U 0 +/ 0 +mL 0 +, 0 +P 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +. 0 + +Levels 0 +were 0 +significantly 0 +greater 0 +in 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +due 0 +to 0 +paracetamol 1 +overdose 3 +( 0 +median 0 +, 0 +28 0 +. 0 +7 0 +U 0 +/ 0 +mL 0 +; 0 +range 0 +, 0 +12 0 +. 0 +8 0 +- 0 +52 0 +. 0 +7 0 +U 0 +/ 0 +mL 0 +, 0 +n 0 += 0 +17 0 +) 0 +than 0 +those 0 +due 0 +to 0 +non 0 +- 0 +A 0 +to 0 +E 0 +hepatitis 3 +( 0 +median 0 +, 0 +12 0 +. 0 +5 0 +U 0 +/ 0 +mL 0 +; 0 +range 0 +, 0 +6 0 +. 0 +9 0 +- 0 +46 0 +. 0 +0 0 +U 0 +/ 0 +mL 0 +, 0 +n 0 += 0 +7 0 +, 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +There 0 +was 0 +no 0 +relationship 0 +of 0 +sFas 0 +to 0 +eventual 0 +outcome 0 +in 0 +the 0 +patients 0 +. 0 + +A 0 +significant 0 +correlation 0 +was 0 +observed 0 +between 0 +serum 0 +sFas 0 +levels 0 +and 0 +aspartate 1 +aminotransferase 0 +( 0 +r 0 += 0 +0 0 +. 0 +613 0 +, 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +increased 0 +concentration 0 +of 0 +sFas 0 +in 0 +serum 0 +of 0 +patients 0 +with 0 +acute 3 +liver 4 +failure 4 +may 0 +reflect 0 +activation 0 +of 0 +Fas 0 +- 0 +mediated 0 +apoptosis 0 +in 0 +the 0 +liver 0 +and 0 +this 0 +together 0 +with 0 +increased 0 +tumor 3 +necrosis 3 +factor 0 +- 0 +alpha 0 +may 0 +be 0 +an 0 +important 0 +factor 0 +in 0 +liver 0 +cell 0 +loss 0 +. 0 + +Bilateral 0 +subthalamic 0 +nucleus 0 +stimulation 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +High 0 +frequency 0 +stimulation 0 +of 0 +the 0 +subthalamic 0 +nucleus 0 +( 0 +STN 0 +) 0 +is 0 +known 0 +to 0 +ameliorate 0 +the 0 +signs 0 +and 0 +symptoms 0 +of 0 +advanced 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +AIM 0 +: 0 +We 0 +studied 0 +the 0 +effect 0 +of 0 +high 0 +frequency 0 +STN 0 +stimulation 0 +in 0 +23 0 +patients 0 +. 0 + +METH0D 0 +: 0 +Twenty 0 +- 0 +three 0 +patients 0 +suffering 0 +from 0 +severe 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +Stages 0 +III 0 +- 0 +V 0 +on 0 +Hoehn 0 +and 0 +Yahr 0 +scale 0 +) 0 +and 0 +, 0 +particularly 0 +bradykinesia 3 +, 0 +rigidity 3 +, 0 +and 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +underwent 0 +bilateral 0 +implantation 0 +of 0 +electrodes 0 +in 0 +the 0 +STN 0 +. 0 + +Preoperative 0 +and 0 +postoperative 0 +assessments 0 +of 0 +these 0 +patients 0 +at 0 +1 0 +, 0 +3 0 +, 0 +6 0 +and 0 +12 0 +months 0 +follow 0 +- 0 +up 0 +, 0 +in 0 +" 0 +on 0 +" 0 +and 0 +" 0 +off 0 +" 0 +drug 0 +conditions 0 +, 0 +was 0 +carried 0 +out 0 +using 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +, 0 +Hoehn 0 +and 0 +Yahr 0 +staging 0 +, 0 +England 0 +activities 0 +of 0 +daily 0 +living 0 +score 0 +and 0 +video 0 +recordings 0 +. 0 + +RESULTS 0 +: 0 +After 0 +one 0 +year 0 +of 0 +electrical 0 +stimulation 0 +of 0 +the 0 +STN 0 +, 0 +the 0 +patients 0 +' 0 +scores 0 +for 0 +activities 0 +of 0 +daily 0 +living 0 +and 0 +motor 0 +examination 0 +scores 0 +( 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +parts 0 +II 0 +and 0 +III 0 +) 0 +off 0 +medication 0 +improved 0 +by 0 +62 0 +% 0 +and 0 +61 0 +% 0 +respectively 0 +( 0 +p 0 +< 0 +0 0 +. 0 +0005 0 +) 0 +. 0 + +The 0 +subscores 0 +for 0 +the 0 +akinesia 3 +, 0 +rigidity 3 +, 0 +tremor 3 +and 0 +gait 0 +also 0 +improved 0 +. 0 + +( 0 +p 0 +< 0 +0 0 +. 0 +0005 0 +) 0 +. 0 + +The 0 +average 0 +levodopa 1 +dose 0 +decreased 0 +from 0 +813 0 +mg 0 +to 0 +359 0 +mg 0 +. 0 + +The 0 +cognitive 0 +functions 0 +remained 0 +unchanged 0 +. 0 + +Two 0 +patients 0 +developed 0 +device 0 +- 0 +related 0 +complications 0 +and 0 +two 0 +patients 0 +experienced 0 +abnormal 0 +weight 0 +gain 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Bilateral 0 +subthalamic 0 +nucleus 0 +stimulation 0 +is 0 +an 0 +effective 0 +treatment 0 +for 0 +advanced 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +It 0 +reduces 0 +the 0 +severity 0 +of 0 +" 0 +off 0 +" 0 +phase 0 +symptoms 0 +, 0 +improves 0 +the 0 +axial 0 +symptoms 0 +and 0 +reduces 0 +levodopa 1 +requirements 0 +. 0 + +The 0 +reduction 0 +in 0 +the 0 +levodopa 1 +dose 0 +is 0 +useful 0 +in 0 +controlling 0 +drug 3 +- 4 +induced 4 +dyskinesias 4 +. 0 + +Acute 3 +renal 4 +failure 4 +occurring 0 +during 0 +intravenous 0 +desferrioxamine 1 +therapy 0 +: 0 +recovery 0 +after 0 +haemodialysis 0 +. 0 + +A 0 +patient 0 +with 0 +transfusion 0 +- 0 +dependent 0 +thalassemia 3 +was 0 +undergoing 0 +home 0 +intravenous 0 +desferrioxamine 1 +( 0 +DFX 1 +) 0 +treatment 0 +by 0 +means 0 +of 0 +a 0 +totally 0 +implanted 0 +system 0 +because 0 +of 0 +his 0 +poor 0 +compliance 0 +with 0 +the 0 +nightly 0 +subcutaneous 0 +therapy 0 +. 0 + +Due 0 +to 0 +an 0 +accidental 0 +malfunctioning 0 +of 0 +the 0 +infusion 0 +pump 0 +, 0 +the 0 +patient 0 +was 0 +inadvertently 0 +administered 0 +a 0 +toxic 0 +dosage 0 +of 0 +the 0 +drug 0 +which 0 +caused 0 +renal 3 +insufficiency 4 +. 0 + +Given 0 +the 0 +progressive 0 +deterioration 0 +of 0 +the 0 +symptoms 0 +and 0 +of 0 +the 0 +laboratory 0 +values 0 +, 0 +despite 0 +adequate 0 +medical 0 +treatment 0 +, 0 +a 0 +decision 0 +was 0 +made 0 +to 0 +introduce 0 +haemodialytical 0 +therapy 0 +in 0 +order 0 +to 0 +remove 0 +the 0 +drug 0 +and 0 +therapy 0 +reduce 0 +the 0 +nephrotoxicity 3 +. 0 + +From 0 +the 0 +results 0 +obtained 0 +, 0 +haemodialysis 0 +can 0 +therefore 0 +be 0 +suggested 0 +as 0 +a 0 +useful 0 +therapy 0 +in 0 +rare 0 +cases 0 +of 0 +progressive 0 +acute 3 +renal 4 +failure 4 +caused 0 +by 0 +desferrioxamine 1 +. 0 + +0cular 0 +motility 0 +changes 0 +after 0 +subtenon 0 +carboplatin 1 +chemotherapy 0 +for 0 +retinoblastoma 3 +. 0 + +BACKGR0UND 0 +: 0 +Focal 0 +subtenon 0 +carboplatin 1 +injections 0 +have 0 +recently 0 +been 0 +used 0 +as 0 +a 0 +presumably 0 +toxicity 3 +- 0 +free 0 +adjunct 0 +to 0 +systemic 0 +chemotherapy 0 +for 0 +intraocular 0 +retinoblastoma 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +our 0 +clinical 0 +experience 0 +with 0 +abnormal 3 +ocular 4 +motility 4 +in 0 +patients 0 +treated 0 +with 0 +subtenon 0 +carboplatin 1 +chemotherapy 0 +. 0 + +METH0DS 0 +: 0 +We 0 +noted 0 +abnormal 3 +ocular 4 +motility 4 +in 0 +10 0 +consecutive 0 +patients 0 +with 0 +retinoblastoma 3 +who 0 +had 0 +received 0 +subtenon 0 +carboplatin 1 +. 0 + +During 0 +ocular 0 +manipulation 0 +under 0 +general 0 +anesthesia 0 +, 0 +we 0 +assessed 0 +their 0 +eyes 0 +by 0 +forced 0 +duction 0 +testing 0 +, 0 +comparing 0 +ocular 0 +motility 0 +after 0 +tumor 3 +control 0 +with 0 +ocular 0 +motility 0 +at 0 +diagnosis 0 +. 0 + +Eyes 0 +subsequently 0 +enucleated 0 +because 0 +of 0 +treatment 0 +failure 0 +( 0 +n 0 += 0 +4 0 +) 0 +were 0 +examined 0 +histologically 0 +. 0 + +RESULTS 0 +: 0 +Limitation 0 +of 0 +ocular 0 +motility 0 +was 0 +detected 0 +in 0 +all 0 +12 0 +eyes 0 +of 0 +10 0 +patients 0 +treated 0 +for 0 +intraocular 0 +retinoblastoma 3 +with 0 +1 0 +to 0 +6 0 +injections 0 +of 0 +subtenon 0 +carboplatin 1 +as 0 +part 0 +of 0 +multimodality 0 +therapy 0 +. 0 + +Histopathological 0 +examination 0 +revealed 0 +many 0 +lipophages 0 +in 0 +the 0 +periorbital 0 +fat 0 +surrounding 0 +the 0 +optic 0 +nerve 0 +in 0 +1 0 +eye 0 +, 0 +indicative 0 +of 0 +phagocytosis 0 +of 0 +previously 0 +existing 0 +fat 0 +cells 0 +and 0 +suggesting 0 +prior 0 +fat 0 +necrosis 3 +. 0 + +The 0 +enucleations 0 +were 0 +technically 0 +difficult 0 +and 0 +hazardous 0 +for 0 +globe 0 +rupture 3 +because 0 +of 0 +extensive 0 +orbital 0 +soft 0 +tissue 0 +adhesions 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Subtenon 0 +carboplatin 1 +chemotherapy 0 +is 0 +associated 0 +with 0 +significant 0 +fibrosis 3 +of 0 +orbital 0 +soft 0 +tissues 0 +, 0 +leading 0 +to 0 +mechanical 0 +restriction 0 +of 0 +eye 0 +movements 0 +and 0 +making 0 +subsequent 0 +enucleation 0 +difficult 0 +. 0 + +Subtenon 0 +carboplatin 1 +is 0 +not 0 +free 0 +of 0 +toxicity 3 +, 0 +and 0 +its 0 +use 0 +is 0 +best 0 +restricted 0 +to 0 +specific 0 +indications 0 +. 0 + +Ethambutol 1 +and 0 +optic 3 +neuropathy 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +demonstrate 0 +the 0 +association 0 +between 0 +ethambutol 1 +and 0 +optic 3 +neuropathy 4 +. 0 + +METH0D 0 +: 0 +Thirteen 0 +patients 0 +who 0 +developed 0 +optic 3 +neuropathy 4 +after 0 +being 0 +treated 0 +with 0 +ethambutol 1 +for 0 +tuberculosis 3 +of 4 +the 4 +lung 4 +or 4 +lymph 4 +node 4 +at 0 +Siriraj 0 +Hospital 0 +between 0 +1997 0 +and 0 +2001 0 +were 0 +retrospectively 0 +reviewed 0 +. 0 + +The 0 +clinical 0 +characteristics 0 +and 0 +initial 0 +and 0 +final 0 +visual 0 +acuity 0 +were 0 +analyzed 0 +to 0 +determine 0 +visual 0 +outcome 0 +. 0 + +RESULTS 0 +: 0 +All 0 +patients 0 +had 0 +optic 3 +neuropathy 4 +between 0 +1 0 +to 0 +6 0 +months 0 +( 0 +mean 0 += 0 +2 0 +. 0 +9 0 +months 0 +) 0 +after 0 +starting 0 +ethambutol 1 +therapy 0 +at 0 +a 0 +dosage 0 +ranging 0 +from 0 +13 0 +to 0 +20 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +( 0 +mean 0 += 0 +17 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +. 0 + +Seven 0 +( 0 +54 0 +% 0 +) 0 +of 0 +the 0 +13 0 +patients 0 +experienced 0 +visual 0 +recovery 0 +after 0 +stopping 0 +the 0 +drug 0 +. 0 + +0f 0 +6 0 +patients 0 +with 0 +irreversible 0 +visual 3 +impairment 4 +, 0 +4 0 +patients 0 +had 0 +diabetes 3 +mellitus 4 +, 0 +glaucoma 3 +and 0 +a 0 +history 0 +of 0 +heavy 0 +smoking 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Early 0 +recognition 0 +of 0 +optic 3 +neuropathy 4 +should 0 +be 0 +considered 0 +in 0 +patients 0 +with 0 +ethambutol 1 +therapy 0 +. 0 + +A 0 +low 0 +dose 0 +and 0 +prompt 0 +discontinuation 0 +of 0 +the 0 +drug 0 +is 0 +recommended 0 +particularly 0 +in 0 +individuals 0 +with 0 +diabetes 3 +mellitus 4 +, 0 +glaucoma 3 +or 0 +who 0 +are 0 +heavy 0 +smokers 0 +. 0 + +Treatment 0 +of 0 +compensatory 0 +gustatory 3 +hyperhidrosis 4 +with 0 +topical 0 +glycopyrrolate 1 +. 0 + +Gustatory 3 +hyperhidrosis 4 +is 0 +facial 0 +sweating 3 +usually 0 +associated 0 +with 0 +the 0 +eating 0 +of 0 +hot 0 +spicy 0 +food 0 +or 0 +even 0 +smelling 0 +this 0 +food 0 +. 0 + +Current 0 +options 0 +of 0 +treatment 0 +include 0 +oral 0 +anticholinergic 0 +drugs 0 +, 0 +the 0 +topical 0 +application 0 +of 0 +anticholinergics 0 +or 0 +aluminum 1 +chloride 2 +, 0 +and 0 +the 0 +injection 0 +of 0 +botulinum 0 +toxin 0 +. 0 + +Thirteen 0 +patients 0 +have 0 +been 0 +treated 0 +to 0 +date 0 +with 0 +1 0 +. 0 +5 0 +% 0 +or 0 +2 0 +% 0 +topical 0 +glycopyrrolate 1 +. 0 + +All 0 +patients 0 +had 0 +gustatory 3 +hyperhidrosis 4 +, 0 +which 0 +interfered 0 +with 0 +their 0 +social 0 +activities 0 +, 0 +after 0 +transthroacic 0 +endoscopic 0 +sympathectomy 0 +, 0 +and 0 +which 0 +was 0 +associated 0 +with 0 +compensatory 0 +focal 0 +hyperhidrosis 3 +. 0 + +After 0 +applying 0 +topical 0 +glycopyrrolate 1 +, 0 +the 0 +subjective 0 +effect 0 +was 0 +excellent 0 +( 0 +no 0 +sweating 3 +after 0 +eating 0 +hot 0 +spicy 0 +food 0 +) 0 +in 0 +10 0 +patients 0 +( 0 +77 0 +% 0 +) 0 +, 0 +and 0 +fair 0 +( 0 +clearly 0 +reduced 0 +sweating 3 +) 0 +in 0 +3 0 +patients 0 +( 0 +23 0 +% 0 +) 0 +. 0 + +All 0 +had 0 +reported 0 +incidents 0 +of 0 +being 0 +very 0 +embarrassed 0 +whilst 0 +eating 0 +hot 0 +spicy 0 +foods 0 +. 0 + +Adverse 0 +effects 0 +included 0 +a 0 +mildly 0 +dry 3 +mouth 4 +and 0 +a 0 +sore 3 +throat 4 +in 0 +2 0 +patients 0 +( 0 +2 0 +% 0 +glycopyrrolate 1 +) 0 +, 0 +a 0 +light 0 +headache 3 +in 0 +1 0 +patient 0 +( 0 +1 0 +. 0 +5 0 +% 0 +glycopyrrolate 1 +) 0 +. 0 + +The 0 +topical 0 +application 0 +of 0 +a 0 +glycopyrrolate 1 +pad 0 +appeared 0 +to 0 +be 0 +safe 0 +, 0 +efficacious 0 +, 0 +well 0 +tolerated 0 +, 0 +and 0 +a 0 +convenient 0 +method 0 +of 0 +treatment 0 +for 0 +moderate 0 +to 0 +severe 0 +symptoms 0 +of 0 +gustatory 3 +hyperhidrosis 4 +in 0 +post 0 +transthoracic 0 +endoscopic 0 +sympathectomy 0 +or 0 +sympathicotomy 0 +patients 0 +, 0 +with 0 +few 0 +side 0 +effects 0 +. 0 + +Neuroleptic 1 +- 0 +associated 0 +hyperprolactinemia 3 +. 0 + +Can 0 +it 0 +be 0 +treated 0 +with 0 +bromocriptine 1 +? 0 + +Six 0 +stable 0 +psychiatric 0 +outpatients 0 +with 0 +hyperprolactinemia 3 +and 0 +amenorrhea 3 +/ 0 +oligomenorrhea 3 +associated 0 +with 0 +their 0 +neuroleptic 1 +medications 2 +were 0 +treated 0 +with 0 +bromocriptine 1 +. 0 + +Daily 0 +dosages 0 +of 0 +5 0 +- 0 +10 0 +mg 0 +corrected 0 +the 0 +hyperprolactinemia 3 +and 0 +restored 0 +menstruation 0 +in 0 +four 0 +of 0 +the 0 +six 0 +patients 0 +. 0 + +0ne 0 +woman 0 +, 0 +however 0 +, 0 +developed 0 +worsened 0 +psychiatric 3 +symptoms 4 +while 0 +taking 0 +bromocriptine 1 +, 0 +and 0 +it 0 +was 0 +discontinued 0 +. 0 + +Thus 0 +, 0 +three 0 +of 0 +six 0 +patients 0 +had 0 +their 0 +menstrual 0 +irregularity 0 +successfully 0 +corrected 0 +with 0 +bromocriptine 1 +. 0 + +This 0 +suggests 0 +that 0 +bromocriptine 1 +should 0 +be 0 +further 0 +evaluated 0 +as 0 +potential 0 +therapy 0 +for 0 +neuroleptic 1 +- 0 +associated 0 +hyperprolactinemia 3 +and 0 +amenorrhea 3 +/ 0 +galactorrhea 3 +. 0 + +Ethacrynic 1 +acid 2 +- 0 +induced 0 +convulsions 3 +and 0 +brain 0 +neurotransmitters 0 +in 0 +mice 0 +. 0 + +Intracerebroventricular 0 +injection 0 +of 0 +ethacrynic 1 +acid 2 +( 0 +50 0 +% 0 +convulsive 3 +dose 0 +; 0 +50 0 +micrograms 0 +/ 0 +mouse 0 +) 0 +accelerated 0 +the 0 +synthesis 0 +/ 0 +turnover 0 +of 0 +5 1 +- 2 +hydroxytryptamine 2 +( 0 +5 1 +- 2 +HT 2 +) 0 +but 0 +suppressed 0 +the 0 +synthesis 0 +of 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +and 0 +acetylcholine 1 +in 0 +mouse 0 +brain 0 +. 0 + +These 0 +effects 0 +were 0 +completely 0 +antagonized 0 +by 0 +pretreatment 0 +with 0 +a 0 +glutamate 1 +/ 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +antagonist 0 +, 0 +aminophosphonovaleric 1 +acid 2 +. 0 + +In 0 +ethacrynic 1 +acid 2 +- 0 +induced 0 +convulsions 3 +, 0 +these 0 +neurotransmitter 0 +systems 0 +may 0 +be 0 +differentially 0 +modulated 0 +, 0 +probably 0 +through 0 +activation 0 +of 0 +glutaminergic 0 +neurons 0 +in 0 +the 0 +brain 0 +. 0 + +Pharmacology 0 +of 0 +gamma 1 +- 2 +aminobutyric 2 +acidA 2 +receptor 0 +complex 0 +after 0 +the 0 +in 0 +vivo 0 +administration 0 +of 0 +the 0 +anxioselective 0 +and 0 +anticonvulsant 0 +beta 1 +- 2 +carboline 2 +derivative 0 +abecarnil 1 +. 0 + +In 0 +rodents 0 +, 0 +the 0 +effect 0 +of 0 +the 0 +beta 1 +- 2 +carboline 2 +derivative 0 +isopropyl 1 +- 2 +6 2 +- 2 +benzyloxy 2 +- 2 +4 2 +- 2 +methoxymethyl 2 +- 2 +beta 2 +- 2 +carboline 2 +- 2 +3 2 +- 2 +carboxylate 2 +( 0 +abecarrnil 1 +) 0 +, 0 +a 0 +new 0 +ligand 0 +for 0 +benzodiazepine 1 +receptors 0 +possessing 0 +anxiolytic 0 +and 0 +anticonvulsant 0 +properties 0 +, 0 +was 0 +evaluated 0 +on 0 +the 0 +function 0 +of 0 +central 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +) 0 +A 0 +receptor 0 +complex 0 +, 0 +both 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +. 0 + +Added 0 +in 0 +vitro 0 +to 0 +rat 0 +cortical 0 +membrane 0 +preparation 0 +, 0 +abecarnil 1 +increased 0 +[ 0 +3H 0 +] 0 +GABA 1 +binding 0 +, 0 +enhanced 0 +muscimol 1 +- 0 +stimulated 0 +36Cl 0 +- 0 +uptake 0 +and 0 +reduced 0 +the 0 +binding 0 +of 0 +t 1 +- 2 +[ 2 +35S 2 +] 2 +butylbicyclophosphorothionate 2 +( 0 +[ 1 +35S 2 +] 2 +TBPS 2 +) 0 +. 0 + +These 0 +effects 0 +were 0 +similar 0 +to 0 +those 0 +induced 0 +by 0 +diazepam 1 +, 0 +whereas 0 +the 0 +partial 0 +agonist 0 +Ro 1 +16 2 +- 2 +6028 2 +( 0 +tert 1 +- 2 +butyl 2 +- 2 +( 2 +S 2 +) 2 +- 2 +8 2 +- 2 +bromo 2 +- 2 +11 2 +, 2 +12 2 +, 2 +13 2 +, 2 +13a 2 +- 2 +tetrahydro 2 +- 2 +9 2 +- 2 +oxo 2 +- 2 +9H 2 +- 2 +imidazo 2 +[ 2 +1 2 +, 2 +5 2 +- 2 +a 2 +] 2 +- 2 +pyrrolo 2 +- 2 +[ 2 +2 2 +, 2 +1 2 +- 2 +c 2 +] 2 +[ 2 +1 2 +, 2 +4 2 +] 2 +benzodiazepine 2 +- 2 +1 2 +- 2 +carboxylate 2 +) 0 +showed 0 +very 0 +weak 0 +efficacy 0 +in 0 +these 0 +biochemical 0 +tests 0 +. 0 + +After 0 +i 0 +. 0 +p 0 +. 0 +injection 0 +to 0 +rats 0 +, 0 +abecarnil 1 +and 0 +diazepam 1 +decreased 0 +in 0 +a 0 +time 0 +- 0 +dependent 0 +and 0 +dose 0 +- 0 +related 0 +( 0 +0 0 +. 0 +25 0 +- 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +manner 0 +[ 1 +35S 2 +] 2 +TBPS 2 +binding 0 +measured 0 +ex 0 +vivo 0 +in 0 +the 0 +cerebral 0 +cortex 0 +. 0 + +Moreover 0 +, 0 +both 0 +drugs 0 +at 0 +the 0 +dose 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +antagonized 0 +completely 0 +the 0 +convulsant 0 +activity 0 +and 0 +the 0 +increase 0 +of 0 +[ 1 +35S 2 +] 2 +TBPS 2 +binding 0 +induced 0 +by 0 +isoniazide 1 +( 0 +350 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +as 0 +well 0 +as 0 +the 0 +increase 0 +of 0 +[ 1 +35S 2 +] 2 +TBPS 2 +binding 0 +induced 0 +by 0 +foot 0 +- 0 +shock 0 +stress 0 +. 0 + +To 0 +better 0 +correlate 0 +the 0 +biochemical 0 +and 0 +the 0 +pharmacological 0 +effects 0 +, 0 +we 0 +studied 0 +the 0 +action 0 +of 0 +abecarnil 1 +on 0 +[ 1 +35S 2 +] 2 +TBPS 2 +binding 0 +, 0 +exploratory 0 +motility 0 +and 0 +on 0 +isoniazid 1 +- 0 +induced 0 +biochemical 0 +and 0 +pharmacological 0 +effects 0 +in 0 +mice 0 +. 0 + +In 0 +these 0 +animals 0 +, 0 +abecarnil 1 +produced 0 +a 0 +paralleled 0 +dose 0 +- 0 +dependent 0 +( 0 +0 0 +. 0 +05 0 +- 0 +1 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +reduction 0 +of 0 +both 0 +motor 0 +behavior 0 +and 0 +cortical 0 +[ 0 +35S 0 +] 0 +TBPS 0 +binding 0 +. 0 + +Moreover 0 +, 0 +0 0 +. 0 +05 0 +mg 0 +/ 0 +kg 0 +of 0 +this 0 +beta 1 +- 2 +carboline 2 +reduced 0 +markedly 0 +the 0 +increase 0 +of 0 +[ 1 +35S 2 +] 2 +TBPS 2 +binding 0 +and 0 +the 0 +convulsions 3 +induced 0 +by 0 +isoniazid 1 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Recurrent 0 +myocardial 3 +infarction 4 +in 0 +a 0 +postpartum 0 +patient 0 +receiving 0 +bromocriptine 1 +. 0 + +Myocardial 3 +infarction 4 +in 0 +puerperium 0 +is 0 +infrequently 0 +reported 0 +. 0 + +Spasm 3 +, 0 +coronary 0 +dissection 0 +, 0 +or 0 +atheromatous 0 +etiology 0 +has 0 +been 0 +described 0 +. 0 + +Bromocriptine 1 +has 0 +been 0 +implicated 0 +in 0 +several 0 +previous 0 +case 0 +reports 0 +of 0 +myocardial 3 +infarction 4 +in 0 +the 0 +puerperium 0 +. 0 + +0ur 0 +case 0 +( 0 +including 0 +an 0 +inadvertent 0 +rechallenge 0 +) 0 +suggests 0 +such 0 +a 0 +relationship 0 +. 0 + +Although 0 +generally 0 +regarded 0 +as 0 +" 0 +safe 0 +, 0 +" 0 +possible 0 +serious 0 +cardiac 0 +effects 0 +of 0 +bromocriptine 1 +should 0 +be 0 +acknowledged 0 +. 0 + +Asterixis 3 +induced 0 +by 0 +carbamazepine 1 +therapy 0 +. 0 + +There 0 +are 0 +very 0 +few 0 +reports 0 +about 0 +asterixis 3 +as 0 +a 0 +side 0 +effect 0 +of 0 +treatment 0 +with 0 +psychopharmacologic 0 +agents 0 +. 0 + +In 0 +this 0 +report 0 +we 0 +present 0 +four 0 +patients 0 +treated 0 +with 0 +a 0 +combination 0 +of 0 +different 0 +psychotropic 0 +drugs 0 +, 0 +in 0 +whom 0 +asterixis 3 +was 0 +triggered 0 +either 0 +by 0 +adding 0 +carbamazepine 1 +( 0 +CBZ 1 +) 0 +to 0 +a 0 +treatment 0 +regimen 0 +, 0 +or 0 +by 0 +increasing 0 +its 0 +dosage 0 +. 0 + +Neither 0 +dosage 0 +nor 0 +serum 0 +levels 0 +of 0 +CBZ 1 +were 0 +in 0 +a 0 +higher 0 +range 0 +. 0 + +We 0 +consider 0 +asterixis 3 +to 0 +be 0 +an 0 +easily 0 +overlooked 0 +sign 0 +of 0 +neurotoxicity 3 +, 0 +which 0 +may 0 +occur 0 +even 0 +at 0 +low 0 +or 0 +moderate 0 +dosage 0 +levels 0 +, 0 +if 0 +certain 0 +drugs 0 +as 0 +lithium 1 +or 0 +clozapine 1 +are 0 +used 0 +in 0 +combination 0 +with 0 +CBZ 1 +. 0 + +Pharmacodynamics 0 +of 0 +the 0 +hypotensive 3 +effect 0 +of 0 +levodopa 1 +in 0 +parkinsonian 3 +patients 0 +. 0 + +Blood 0 +pressure 0 +effects 0 +of 0 +i 0 +. 0 +v 0 +. 0 +levodopa 1 +were 0 +examined 0 +in 0 +parkinsonian 3 +patients 0 +with 0 +stable 0 +and 0 +fluctuating 0 +responses 0 +to 0 +levodopa 1 +. 0 + +The 0 +magnitude 0 +of 0 +the 0 +hypotensive 3 +effect 0 +of 0 +levodopa 1 +was 0 +concentration 0 +dependent 0 +and 0 +was 0 +fit 0 +to 0 +an 0 +Emax 0 +model 0 +in 0 +fluctuating 0 +responders 0 +. 0 + +Stable 0 +responders 0 +demonstrated 0 +a 0 +small 0 +hypotensive 3 +response 0 +. 0 + +Baseline 0 +blood 0 +pressures 0 +were 0 +higher 0 +in 0 +fluctuating 0 +patients 0 +; 0 +a 0 +higher 0 +baseline 0 +blood 0 +pressure 0 +correlated 0 +with 0 +greater 0 +hypotensive 3 +effects 0 +. 0 + +Antiparkinsonian 0 +effects 0 +of 0 +levodopa 1 +temporally 0 +correlated 0 +with 0 +blood 0 +pressure 0 +changes 0 +. 0 + +Phenylalanine 1 +, 0 +a 0 +large 0 +neutral 0 +amino 1 +acid 2 +( 0 +LNAA 0 +) 0 +competing 0 +with 0 +levodopa 1 +for 0 +transport 0 +across 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +, 0 +reduced 0 +the 0 +hypotensive 3 +and 0 +antiparkinsonian 0 +effects 0 +of 0 +levodopa 1 +. 0 + +We 0 +conclude 0 +that 0 +levodopa 1 +has 0 +a 0 +central 0 +hypotensive 3 +action 0 +that 0 +parallels 0 +the 0 +motor 0 +effects 0 +in 0 +fluctuating 0 +patients 0 +. 0 + +The 0 +hypotensive 3 +effect 0 +appears 0 +to 0 +be 0 +related 0 +to 0 +the 0 +higher 0 +baseline 0 +blood 0 +pressure 0 +we 0 +observed 0 +in 0 +fluctuating 0 +patients 0 +relative 0 +to 0 +stable 0 +patients 0 +. 0 + +Syndrome 3 +of 4 +inappropriate 4 +secretion 4 +of 4 +antidiuretic 4 +hormone 4 +after 0 +infusional 0 +vincristine 1 +. 0 + +A 0 +77 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +refractory 0 +multiple 3 +myeloma 4 +was 0 +treated 0 +with 0 +a 0 +4 0 +- 0 +day 0 +continuous 0 +intravenous 0 +infusion 0 +of 0 +vincristine 1 +and 0 +doxorubicin 1 +and 0 +4 0 +days 0 +of 0 +oral 0 +dexamethasone 1 +. 0 + +Nine 0 +days 0 +after 0 +her 0 +second 0 +cycle 0 +she 0 +presented 0 +with 0 +lethargy 3 +and 0 +weakness 3 +associated 0 +with 0 +hyponatremia 3 +. 0 + +Evaluation 0 +revealed 0 +the 0 +syndrome 3 +of 4 +inappropriate 4 +secretion 4 +of 4 +antidiuretic 4 +hormone 4 +, 0 +which 0 +was 0 +attributed 0 +to 0 +the 0 +vincristine 1 +infusion 0 +. 0 + +After 0 +normal 0 +serum 0 +sodium 1 +levels 0 +returned 0 +, 0 +further 0 +doxorubicin 1 +and 0 +dexamethasone 1 +chemotherapy 0 +without 0 +vincristine 1 +did 0 +not 0 +produce 0 +this 0 +complication 0 +. 0 + +Heart 3 +failure 4 +: 0 +to 0 +digitalise 0 +or 0 +not 0 +? 0 + +The 0 +view 0 +against 0 +. 0 + +Despite 0 +extensive 0 +clinical 0 +experience 0 +the 0 +role 0 +of 0 +digoxin 1 +is 0 +still 0 +not 0 +well 0 +defined 0 +. 0 + +In 0 +patients 0 +with 0 +atrial 3 +fibrillation 4 +digoxin 1 +is 0 +beneficial 0 +for 0 +ventricular 0 +rate 0 +control 0 +. 0 + +For 0 +patients 0 +in 0 +sinus 0 +rhythm 0 +and 0 +heart 3 +failure 4 +the 0 +situation 0 +is 0 +less 0 +clear 0 +. 0 + +Digoxin 1 +has 0 +a 0 +narrow 0 +therapeutic 0 +: 0 +toxic 0 +ratio 0 +and 0 +concentrations 0 +are 0 +affected 0 +by 0 +a 0 +number 0 +of 0 +drugs 0 +. 0 + +Also 0 +, 0 +digoxin 1 +has 0 +undesirable 0 +effects 0 +such 0 +as 0 +increasing 0 +peripheral 0 +resistance 0 +and 0 +myocardial 0 +demands 0 +, 0 +and 0 +causing 0 +arrhythmias 3 +. 0 + +There 0 +is 0 +a 0 +paucity 0 +of 0 +data 0 +from 0 +well 0 +- 0 +designed 0 +trials 0 +. 0 + +The 0 +trials 0 +that 0 +are 0 +available 0 +are 0 +generally 0 +small 0 +with 0 +limitations 0 +in 0 +design 0 +and 0 +these 0 +show 0 +variation 0 +in 0 +patient 0 +benefit 0 +. 0 + +More 0 +convincing 0 +evidence 0 +is 0 +required 0 +showing 0 +that 0 +digoxin 1 +improves 0 +symptoms 0 +or 0 +exercise 0 +capacity 0 +. 0 + +Furthermore 0 +, 0 +no 0 +trial 0 +has 0 +had 0 +sufficient 0 +power 0 +to 0 +evaluate 0 +mortality 0 +. 0 + +Pooled 0 +analysis 0 +of 0 +the 0 +effects 0 +of 0 +other 0 +inotropic 0 +drugs 0 +shows 0 +an 0 +excess 0 +mortality 0 +and 0 +there 0 +is 0 +a 0 +possibility 0 +that 0 +digoxin 1 +may 0 +increase 0 +mortality 0 +after 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +. 0 + +Angiotensin 1 +- 0 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +inhibitors 0 +should 0 +be 0 +used 0 +first 0 +as 0 +they 0 +are 0 +safer 0 +, 0 +do 0 +not 0 +require 0 +blood 0 +level 0 +monitoring 0 +, 0 +modify 0 +progression 0 +of 0 +disease 0 +, 0 +relieve 0 +symptoms 0 +, 0 +improve 0 +exercise 0 +tolerance 0 +and 0 +reduce 0 +mortality 0 +. 0 + +Caution 0 +should 0 +be 0 +exercised 0 +in 0 +using 0 +digoxin 1 +until 0 +large 0 +mortality 0 +trials 0 +are 0 +completed 0 +showing 0 +either 0 +benefit 0 +or 0 +harm 0 +. 0 + +Until 0 +then 0 +digoxin 1 +should 0 +be 0 +considered 0 +a 0 +third 0 +- 0 +line 0 +therapy 0 +. 0 + +Isradipine 1 +treatment 0 +for 0 +hypertension 3 +in 0 +general 0 +practice 0 +in 0 +Hong 0 +Kong 0 +. 0 + +A 0 +6 0 +- 0 +week 0 +open 0 +study 0 +of 0 +the 0 +introduction 0 +of 0 +isradipine 1 +treatment 0 +was 0 +conducted 0 +in 0 +general 0 +practice 0 +in 0 +Hong 0 +Kong 0 +. 0 + +303 0 +Chinese 0 +patients 0 +with 0 +mild 0 +to 0 +moderate 0 +hypertension 3 +entered 0 +the 0 +study 0 +. 0 + +Side 0 +effects 0 +were 0 +reported 0 +in 0 +21 0 +% 0 +of 0 +patients 0 +and 0 +caused 0 +withdrawal 0 +from 0 +the 0 +study 0 +in 0 +3 0 +patients 0 +. 0 + +The 0 +main 0 +side 0 +- 0 +effects 0 +were 0 +headache 3 +, 0 +dizziness 3 +, 0 +palpitation 3 +and 0 +flushing 3 +and 0 +these 0 +were 0 +not 0 +more 0 +frequent 0 +than 0 +reported 0 +in 0 +other 0 +studies 0 +with 0 +isradipine 1 +or 0 +with 0 +placebo 0 +. 0 + +Supine 0 +blood 0 +pressure 0 +was 0 +reduced 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +from 0 +170 0 ++ 0 +/ 0 +- 0 +20 0 +/ 0 +102 0 ++ 0 +/ 0 +- 0 +6 0 +mmHg 0 +to 0 +153 0 ++ 0 +/ 0 +- 0 +19 0 +/ 0 +92 0 ++ 0 +/ 0 +- 0 +8 0 +, 0 +147 0 ++ 0 +/ 0 +- 0 +18 0 +/ 0 +88 0 ++ 0 +/ 0 +- 0 +7 0 +and 0 +144 0 ++ 0 +/ 0 +- 0 +14 0 +/ 0 +87 0 ++ 0 +/ 0 +- 0 +6 0 +mmHg 0 +at 0 +2 0 +, 0 +4 0 +and 0 +6 0 +weeks 0 +respectively 0 +in 0 +evaluable 0 +patients 0 +. 0 + +Similar 0 +reductions 0 +occurred 0 +in 0 +standing 0 +blood 0 +pressure 0 +and 0 +there 0 +was 0 +no 0 +evidence 0 +of 0 +postural 3 +hypotension 4 +. 0 + +Normalization 0 +and 0 +responder 0 +rates 0 +at 0 +6 0 +weeks 0 +were 0 +86 0 +% 0 +and 0 +69 0 +% 0 +respectively 0 +. 0 + +Dosage 0 +was 0 +increased 0 +from 0 +2 0 +. 0 +5 0 +mg 0 +b 0 +. 0 +d 0 +. 0 +to 0 +5 0 +mg 0 +b 0 +. 0 +d 0 +. 0 +at 0 +4 0 +weeks 0 +in 0 +patients 0 +with 0 +diastolic 0 +blood 0 +pressure 0 +greater 0 +than 0 +90 0 +mmHg 0 +and 0 +their 0 +further 0 +response 0 +was 0 +greater 0 +than 0 +those 0 +remaining 0 +on 0 +2 0 +. 0 +5 0 +mg 0 +b 0 +. 0 +d 0 +. 0 + +Pharmacological 0 +characteristics 0 +and 0 +side 0 +effects 0 +of 0 +a 0 +new 0 +galenic 0 +formulation 0 +of 0 +propofol 1 +without 0 +soyabean 0 +oil 0 +. 0 + +We 0 +compared 0 +the 0 +pharmacokinetics 0 +, 0 +pharmacodynamics 0 +and 0 +safety 0 +profile 0 +of 0 +a 0 +new 0 +galenic 0 +formulation 0 +of 0 +propofol 1 +( 0 +AM149 0 +1 0 +% 0 +) 0 +, 0 +which 0 +does 0 +not 0 +contain 0 +soyabean 0 +oil 0 +, 0 +with 0 +a 0 +standard 0 +formulation 0 +of 0 +propofol 1 +( 0 +Disoprivan 1 +1 0 +% 0 +) 0 +. 0 + +In 0 +a 0 +randomised 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +cross 0 +- 0 +over 0 +study 0 +, 0 +30 0 +healthy 0 +volunteers 0 +received 0 +a 0 +single 0 +intravenous 0 +bolus 0 +injection 0 +of 0 +2 0 +. 0 +5 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 +propofol 1 +. 0 + +Plasma 0 +propofol 1 +levels 0 +were 0 +measured 0 +for 0 +48 0 +h 0 +following 0 +drug 0 +administration 0 +and 0 +evaluated 0 +according 0 +to 0 +a 0 +three 0 +- 0 +compartment 0 +model 0 +. 0 + +The 0 +pharmacodynamic 0 +parameters 0 +assessed 0 +included 0 +induction 0 +and 0 +emergence 0 +times 0 +, 0 +respiratory 0 +and 0 +cardiovascular 0 +effects 0 +, 0 +and 0 +pain 3 +on 0 +injection 0 +. 0 + +Patients 0 +were 0 +monitored 0 +for 0 +side 0 +effects 0 +over 0 +48 0 +h 0 +. 0 + +0wing 0 +to 0 +a 0 +high 0 +incidence 0 +of 0 +thrombophlebitis 3 +, 0 +the 0 +study 0 +was 0 +terminated 0 +prematurely 0 +and 0 +only 0 +the 0 +data 0 +of 0 +the 0 +two 0 +parallel 0 +treatment 0 +groups 0 +( 0 +15 0 +patients 0 +in 0 +each 0 +group 0 +) 0 +were 0 +analysed 0 +. 0 + +Plasma 0 +concentrations 0 +did 0 +not 0 +differ 0 +significantly 0 +between 0 +the 0 +two 0 +formulations 0 +. 0 + +Anaesthesia 0 +induction 0 +and 0 +emergence 0 +times 0 +, 0 +respiratory 0 +and 0 +cardiovascular 0 +variables 0 +showed 0 +no 0 +significant 0 +differences 0 +between 0 +the 0 +two 0 +treatment 0 +groups 0 +. 0 + +Pain 3 +on 0 +injection 0 +( 0 +80 0 +vs 0 +. 0 +20 0 +% 0 +, 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +and 0 +thrombophlebitis 3 +( 0 +93 0 +. 0 +3 0 +vs 0 +. 0 +6 0 +. 0 +6 0 +% 0 +, 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +occurred 0 +more 0 +frequently 0 +with 0 +AM149 0 +than 0 +with 0 +Disoprivan 1 +. 0 + +Although 0 +both 0 +formulations 0 +had 0 +similar 0 +pharmacokinetic 0 +and 0 +pharmacodynamic 0 +profiles 0 +the 0 +new 0 +formulation 0 +is 0 +not 0 +suitable 0 +for 0 +clinical 0 +use 0 +due 0 +to 0 +the 0 +high 0 +incidence 0 +of 0 +thrombophlebitis 3 +produced 0 +. 0 + +Pure 3 +red 4 +cell 4 +aplasia 4 +, 0 +toxic 3 +dermatitis 4 +and 0 +lymphadenopathy 3 +in 0 +a 0 +patient 0 +taking 0 +diphenylhydantoin 1 +. 0 + +A 0 +patient 0 +taking 0 +diphenylhydantoin 1 +for 0 +3 0 +weeks 0 +developed 0 +a 0 +generalized 0 +skin 3 +rash 4 +, 0 +lymphadenopathy 3 +and 0 +pure 3 +red 4 +cell 4 +aplasia 4 +. 0 + +After 0 +withdrawal 0 +of 0 +the 0 +pharmacon 0 +all 0 +symptoms 0 +disappeared 0 +spontaneously 0 +. 0 + +Skin 3 +rash 4 +is 0 +a 0 +well 0 +- 0 +known 0 +complication 0 +of 0 +diphenylhydantoin 1 +treatment 0 +as 0 +is 0 +benign 0 +and 0 +malignant 0 +lymphadenopathy 3 +. 0 + +Pure 3 +red 4 +cell 4 +aplasia 4 +associated 0 +with 0 +diphenylhydantoin 1 +medication 0 +has 0 +been 0 +reported 0 +in 0 +3 0 +patients 0 +. 0 + +The 0 +exact 0 +mechanism 0 +by 0 +which 0 +diphenylhydantoin 1 +exerts 0 +its 0 +toxic 0 +effects 0 +is 0 +not 0 +known 0 +. 0 + +In 0 +this 0 +patient 0 +the 0 +time 0 +relation 0 +between 0 +the 0 +ingestion 0 +of 0 +diphenylhydantoin 1 +and 0 +the 0 +occurrence 0 +of 0 +the 0 +skin 3 +rash 4 +, 0 +lymphadenopathy 3 +and 0 +pure 3 +red 4 +cell 4 +aplasia 4 +is 0 +very 0 +suggestive 0 +of 0 +a 0 +direct 0 +connection 0 +. 0 + +Vinorelbine 1 +- 0 +related 0 +cardiac 0 +events 0 +: 0 +a 0 +meta 0 +- 0 +analysis 0 +of 0 +randomized 0 +clinical 0 +trials 0 +. 0 + +Several 0 +cases 0 +of 0 +cardiac 0 +adverse 0 +reactions 0 +related 0 +to 0 +vinorelbine 1 +( 0 +VNR 1 +) 0 +have 0 +been 0 +reported 0 +in 0 +the 0 +literature 0 +. 0 + +In 0 +order 0 +to 0 +quantify 0 +the 0 +incidence 0 +of 0 +these 0 +cardiac 0 +events 0 +, 0 +we 0 +performed 0 +a 0 +meta 0 +- 0 +analysis 0 +of 0 +clinical 0 +trials 0 +comparing 0 +VNR 1 +with 0 +other 0 +chemotherapeutic 0 +agents 0 +in 0 +the 0 +treatment 0 +of 0 +various 0 +malignancies 3 +. 0 + +Randomized 0 +clinical 0 +trials 0 +comparing 0 +VNR 1 +with 0 +other 0 +drugs 0 +in 0 +the 0 +treatment 0 +of 0 +cancer 3 +were 0 +searched 0 +in 0 +Medline 0 +, 0 +Embase 0 +, 0 +Evidence 0 +- 0 +based 0 +Medicine 0 +Reviews 0 +databases 0 +and 0 +the 0 +Cochrane 0 +library 0 +from 0 +1987 0 +to 0 +2002 0 +. 0 + +0utcomes 0 +of 0 +interest 0 +were 0 +severe 0 +cardiac 0 +events 0 +, 0 +toxic 0 +deaths 0 +and 0 +cardiac 0 +event 0 +- 0 +related 0 +deaths 0 +reported 0 +in 0 +each 0 +publication 0 +. 0 + +We 0 +found 0 +19 0 +trials 0 +, 0 +involving 0 +2441 0 +patients 0 +treated 0 +by 0 +VNR 1 +and 0 +2050 0 +control 0 +patients 0 +. 0 + +The 0 +incidence 0 +of 0 +cardiac 0 +events 0 +with 0 +VNR 1 +was 0 +1 0 +. 0 +19 0 +% 0 +[ 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +( 0 +0 0 +. 0 +75 0 +; 0 +1 0 +. 0 +67 0 +) 0 +] 0 +. 0 + +There 0 +was 0 +no 0 +difference 0 +in 0 +the 0 +risk 0 +of 0 +cardiac 0 +events 0 +between 0 +VNR 1 +and 0 +other 0 +drugs 0 +[ 0 +odds 0 +ratio 0 +: 0 +0 0 +. 0 +92 0 +, 0 +95 0 +% 0 +CI 0 +( 0 +0 0 +. 0 +54 0 +; 0 +1 0 +. 0 +55 0 +) 0 +] 0 +. 0 + +The 0 +risk 0 +of 0 +VNR 1 +cardiac 0 +events 0 +was 0 +similar 0 +to 0 +vindesine 1 +( 0 +VDS 1 +) 0 +and 0 +other 0 +cardiotoxic 3 +drugs 0 +[ 0 +fluorouracil 1 +, 0 +anthracyclines 1 +, 0 +gemcitabine 1 +( 0 +GEM 1 +) 0 +em 0 +leader 0 +] 0 +. 0 + +Even 0 +if 0 +it 0 +did 0 +not 0 +reach 0 +statistical 0 +significance 0 +because 0 +of 0 +a 0 +few 0 +number 0 +of 0 +cases 0 +, 0 +the 0 +risk 0 +was 0 +lower 0 +in 0 +trials 0 +excluding 0 +patients 0 +with 0 +cardiac 0 +history 0 +, 0 +and 0 +seemed 0 +to 0 +be 0 +higher 0 +in 0 +trials 0 +including 0 +patients 0 +with 0 +pre 0 +- 0 +existing 0 +cardiac 3 +diseases 4 +. 0 + +Vinorelbine 1 +- 0 +related 0 +cardiac 0 +events 0 +concern 0 +about 0 +1 0 +% 0 +of 0 +treated 0 +patients 0 +in 0 +clinical 0 +trials 0 +. 0 + +However 0 +, 0 +the 0 +risk 0 +associated 0 +with 0 +VNR 1 +seems 0 +to 0 +be 0 +similar 0 +to 0 +that 0 +of 0 +other 0 +chemotherapeutic 0 +agents 0 +in 0 +the 0 +same 0 +indications 0 +. 0 + +MRI 0 +findings 0 +of 0 +hypoxic 0 +cortical 0 +laminar 0 +necrosis 3 +in 0 +a 0 +child 0 +with 0 +hemolytic 3 +anemia 4 +crisis 0 +. 0 + +We 0 +present 0 +magnetic 0 +resonance 0 +imaging 0 +findings 0 +of 0 +a 0 +5 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +who 0 +had 0 +a 0 +rapidly 0 +installing 0 +hemolytic 3 +anemia 4 +crisis 0 +induced 0 +by 0 +trimethoprim 1 +- 2 +sulfomethoxazole 2 +, 0 +resulting 0 +in 0 +cerebral 3 +anoxia 4 +leading 0 +to 0 +permanent 0 +damage 0 +. 0 + +Magnetic 0 +Resonance 0 +imaging 0 +revealed 0 +cortical 0 +laminar 0 +necrosis 3 +in 0 +arterial 0 +border 0 +zones 0 +in 0 +both 0 +cerebral 0 +hemispheres 0 +, 0 +ischemic 0 +changes 0 +in 0 +subcortical 0 +white 0 +matter 0 +of 0 +left 0 +cerebral 0 +hemisphere 0 +, 0 +and 0 +in 0 +the 0 +left 0 +putamen 0 +. 0 + +Although 0 +cortical 0 +laminar 0 +necrosis 3 +is 0 +a 0 +classic 0 +entity 0 +in 0 +adulthood 0 +related 0 +to 0 +conditions 0 +of 0 +energy 0 +depletions 0 +, 0 +there 0 +are 0 +few 0 +reports 0 +available 0 +in 0 +children 0 +. 0 + +A 0 +wide 0 +review 0 +of 0 +the 0 +literature 0 +is 0 +also 0 +presented 0 +. 0 + +The 0 +natural 0 +history 0 +of 0 +Vigabatrin 1 +associated 0 +visual 3 +field 4 +defects 4 +in 0 +patients 0 +electing 0 +to 0 +continue 0 +their 0 +medication 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +determine 0 +the 0 +natural 0 +history 0 +of 0 +visual 3 +field 4 +defects 4 +in 0 +a 0 +group 0 +of 0 +patients 0 +known 0 +to 0 +have 0 +Vigabatrin 1 +- 0 +associated 0 +changes 0 +who 0 +elected 0 +to 0 +continue 0 +the 0 +medication 0 +because 0 +of 0 +good 0 +seizure 3 +control 0 +. 0 + +METH0DS 0 +: 0 +All 0 +patients 0 +taking 0 +Vigabatrin 1 +alone 0 +or 0 +in 0 +combination 0 +with 0 +other 0 +antiepileptic 0 +drugs 0 +for 0 +at 0 +least 0 +5 0 +years 0 +( 0 +range 0 +5 0 +- 0 +12 0 +years 0 +) 0 +were 0 +entered 0 +into 0 +a 0 +visual 0 +surveillance 0 +programme 0 +. 0 + +Patients 0 +were 0 +followed 0 +up 0 +at 0 +6 0 +- 0 +monthly 0 +intervals 0 +for 0 +not 0 +less 0 +than 0 +18 0 +months 0 +( 0 +range 0 +18 0 +- 0 +43 0 +months 0 +) 0 +. 0 + +In 0 +all 0 +, 0 +16 0 +patients 0 +with 0 +unequivocal 0 +defects 0 +continued 0 +the 0 +medication 0 +. 0 + +Following 0 +already 0 +published 0 +methodology 0 +( 0 +Eye 0 +2002 0 +; 0 +16 0 +; 0 +567 0 +- 0 +571 0 +) 0 +monocular 0 +mean 0 +radial 0 +degrees 0 +( 0 +MRDs 0 +) 0 +to 0 +the 0 +I 0 +/ 0 +4e 0 +isopter 0 +on 0 +Goldmann 0 +perimetry 0 +was 0 +calculated 0 +for 0 +the 0 +right 0 +eye 0 +at 0 +the 0 +time 0 +of 0 +discovery 0 +of 0 +a 0 +visual 3 +field 4 +defect 4 +and 0 +again 0 +after 0 +not 0 +less 0 +than 0 +18 0 +months 0 +follow 0 +- 0 +up 0 +. 0 + +RESULTS 0 +: 0 +Mean 0 +right 0 +eye 0 +MRD 0 +at 0 +presentation 0 +was 0 +36 0 +. 0 +98 0 +degrees 0 +( 0 +range 0 +22 0 +. 0 +25 0 +- 0 +51 0 +. 0 +0 0 +) 0 +, 0 +compared 0 +to 0 +38 0 +. 0 +40 0 +degrees 0 +( 0 +range 0 +22 0 +. 0 +5 0 +- 0 +49 0 +. 0 +75 0 +) 0 +after 0 +follow 0 +- 0 +up 0 +; 0 +P 0 += 0 +0 0 +. 0 +338 0 +unpaired 0 +t 0 +- 0 +test 0 +. 0 + +0nly 0 +one 0 +patient 0 +demonstrated 0 +a 0 +deterioration 3 +in 4 +visual 4 +field 4 +during 0 +the 0 +study 0 +period 0 +and 0 +discontinued 0 +treatment 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Established 0 +visual 3 +field 4 +defects 4 +presumed 0 +to 0 +be 0 +due 0 +to 0 +Vigabatrin 1 +therapy 0 +did 0 +not 0 +usually 0 +progress 0 +in 0 +spite 0 +of 0 +continuing 0 +use 0 +of 0 +the 0 +medication 0 +. 0 + +These 0 +data 0 +give 0 +support 0 +to 0 +the 0 +hypothesis 0 +that 0 +the 0 +pathogenesis 0 +of 0 +Vigabatrin 1 +- 0 +associated 0 +visual 3 +field 4 +defects 4 +may 0 +be 0 +an 0 +idiosyncratic 0 +adverse 0 +drug 0 +reaction 0 +rather 0 +than 0 +dose 0 +- 0 +dependent 0 +toxicity 3 +. 0 + +Induction 0 +of 0 +rosaceiform 0 +dermatitis 3 +during 0 +treatment 0 +of 0 +facial 3 +inflammatory 4 +dermatoses 4 +with 0 +tacrolimus 1 +ointment 0 +. 0 + +BACKGR0UND 0 +: 0 +Tacrolimus 1 +ointment 0 +is 0 +increasingly 0 +used 0 +for 0 +anti 0 +- 0 +inflammatory 0 +treatment 0 +of 0 +sensitive 0 +areas 0 +such 0 +as 0 +the 0 +face 0 +, 0 +and 0 +recent 0 +observations 0 +indicate 0 +that 0 +the 0 +treatment 0 +is 0 +effective 0 +in 0 +steroid 1 +- 0 +aggravated 0 +rosacea 3 +and 0 +perioral 3 +dermatitis 4 +. 0 + +We 0 +report 0 +on 0 +rosaceiform 0 +dermatitis 3 +as 0 +a 0 +complication 0 +of 0 +treatment 0 +with 0 +tacrolimus 1 +ointment 0 +. 0 + +0BSERVATI0NS 0 +: 0 +Six 0 +adult 0 +patients 0 +with 0 +inflammatory 3 +facial 4 +dermatoses 4 +were 0 +treated 0 +with 0 +tacrolimus 1 +ointment 0 +because 0 +of 0 +the 0 +ineffectiveness 0 +of 0 +standard 0 +treatments 0 +. 0 + +Within 0 +2 0 +to 0 +3 0 +weeks 0 +of 0 +initially 0 +effective 0 +and 0 +well 0 +- 0 +tolerated 0 +treatment 0 +, 0 +3 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +rosacea 3 +and 0 +1 0 +with 0 +a 0 +history 0 +of 0 +acne 3 +experienced 0 +sudden 0 +worsening 0 +with 0 +pustular 0 +rosaceiform 0 +lesions 0 +. 0 + +Biopsy 0 +revealed 0 +an 0 +abundance 0 +of 0 +Demodex 0 +mites 0 +in 0 +2 0 +of 0 +these 0 +patients 0 +. 0 + +In 0 +1 0 +patient 0 +with 0 +eyelid 0 +eczema 3 +, 0 +rosaceiform 0 +periocular 3 +dermatitis 4 +gradually 0 +appeared 0 +after 0 +3 0 +weeks 0 +of 0 +treatment 0 +. 0 + +In 0 +1 0 +patient 0 +with 0 +atopic 3 +dermatitis 4 +, 0 +telangiectatic 0 +and 0 +papular 3 +rosacea 4 +insidiously 0 +appeared 0 +after 0 +5 0 +months 0 +of 0 +treatment 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0ur 0 +observations 0 +suggest 0 +that 0 +the 0 +spectrum 0 +of 0 +rosaceiform 0 +dermatitis 3 +as 0 +a 0 +complication 0 +of 0 +treatment 0 +with 0 +tacrolimus 1 +ointment 0 +is 0 +heterogeneous 0 +. 0 + +A 0 +variety 0 +of 0 +factors 0 +, 0 +such 0 +as 0 +vasoactive 0 +properties 0 +of 0 +tacrolimus 1 +, 0 +proliferation 0 +of 0 +Demodex 0 +due 0 +to 0 +local 0 +immunosuppression 0 +, 0 +and 0 +the 0 +occlusive 0 +properties 0 +of 0 +the 0 +ointment 0 +, 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +observed 0 +phenomena 0 +. 0 + +Future 0 +studies 0 +are 0 +needed 0 +to 0 +identify 0 +individual 0 +risk 0 +factors 0 +. 0 + +Intravascular 0 +hemolysis 3 +and 0 +acute 3 +renal 4 +failure 4 +following 0 +intermittent 0 +rifampin 1 +therapy 0 +. 0 + +Renal 3 +failure 4 +is 0 +a 0 +rare 0 +complication 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +rifampin 1 +. 0 + +Intravascular 0 +hemolysis 3 +leading 0 +to 0 +acute 3 +renal 4 +failure 4 +following 0 +rifampin 1 +therapy 0 +is 0 +extremely 0 +rare 0 +. 0 + +Two 0 +patients 0 +with 0 +leprosy 3 +who 0 +developed 0 +hemolysis 3 +and 0 +acute 3 +renal 4 +failure 4 +following 0 +rifampin 1 +are 0 +reported 0 +. 0 + +Structural 0 +abnormalities 0 +in 0 +the 0 +brains 0 +of 0 +human 0 +subjects 0 +who 0 +use 0 +methamphetamine 1 +. 0 + +We 0 +visualize 0 +, 0 +for 0 +the 0 +first 0 +time 0 +, 0 +the 0 +profile 0 +of 0 +structural 3 +deficits 4 +in 4 +the 4 +human 4 +brain 4 +associated 0 +with 0 +chronic 0 +methamphetamine 1 +( 0 +MA 1 +) 0 +abuse 0 +. 0 + +Studies 0 +of 0 +human 0 +subjects 0 +who 0 +have 0 +used 0 +MA 1 +chronically 0 +have 0 +revealed 0 +deficits 0 +in 0 +dopaminergic 0 +and 0 +serotonergic 0 +systems 0 +and 0 +cerebral 0 +metabolic 3 +abnormalities 4 +. 0 + +Using 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +and 0 +new 0 +computational 0 +brain 0 +- 0 +mapping 0 +techniques 0 +, 0 +we 0 +determined 0 +the 0 +pattern 0 +of 0 +structural 0 +brain 0 +alterations 0 +associated 0 +with 0 +chronic 0 +MA 1 +abuse 0 +in 0 +human 0 +subjects 0 +and 0 +related 0 +these 0 +deficits 0 +to 0 +cognitive 3 +impairment 4 +. 0 + +We 0 +used 0 +high 0 +- 0 +resolution 0 +MRI 0 +and 0 +surface 0 +- 0 +based 0 +computational 0 +image 0 +analyses 0 +to 0 +map 0 +regional 0 +abnormalities 3 +in 4 +the 4 +cortex 4 +, 4 +hippocampus 4 +, 4 +white 4 +matter 4 +, 4 +and 4 +ventricles 4 +in 0 +22 0 +human 0 +subjects 0 +who 0 +used 0 +MA 1 +and 0 +21 0 +age 0 +- 0 +matched 0 +, 0 +healthy 0 +controls 0 +. 0 + +Cortical 0 +maps 0 +revealed 0 +severe 0 +gray 0 +- 0 +matter 0 +deficits 0 +in 0 +the 0 +cingulate 0 +, 0 +limbic 0 +, 0 +and 0 +paralimbic 0 +cortices 0 +of 0 +MA 1 +abusers 0 +( 0 +averaging 0 +11 0 +. 0 +3 0 +% 0 +below 0 +control 0 +; 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +0n 0 +average 0 +, 0 +MA 1 +abusers 0 +had 0 +7 0 +. 0 +8 0 +% 0 +smaller 0 +hippocampal 0 +volumes 0 +than 0 +control 0 +subjects 0 +( 0 +p 0 +< 0 +0 0 +. 0 +01 0 +; 0 +left 0 +, 0 +p 0 += 0 +0 0 +. 0 +01 0 +; 0 +right 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +and 0 +significant 0 +white 0 +- 0 +matter 0 +hypertrophy 3 +( 0 +7 0 +. 0 +0 0 +% 0 +; 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Hippocampal 0 +deficits 0 +were 0 +mapped 0 +and 0 +correlated 0 +with 0 +memory 0 +performance 0 +on 0 +a 0 +word 0 +- 0 +recall 0 +test 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +MRI 0 +- 0 +based 0 +maps 0 +suggest 0 +that 0 +chronic 0 +methamphetamine 1 +abuse 0 +causes 0 +a 0 +selective 0 +pattern 0 +of 0 +cerebral 0 +deterioration 0 +that 0 +contributes 0 +to 0 +impaired 3 +memory 4 +performance 4 +. 0 + +MA 1 +may 0 +selectively 0 +damage 0 +the 0 +medial 0 +temporal 0 +lobe 0 +and 0 +, 0 +consistent 0 +with 0 +metabolic 0 +studies 0 +, 0 +the 0 +cingulate 0 +- 0 +limbic 0 +cortex 0 +, 0 +inducing 0 +neuroadaptation 0 +, 0 +neuropil 0 +reduction 0 +, 0 +or 0 +cell 0 +death 0 +. 0 + +Prominent 0 +white 0 +- 0 +matter 0 +hypertrophy 3 +may 0 +result 0 +from 0 +altered 0 +myelination 0 +and 0 +adaptive 0 +glial 0 +changes 0 +, 0 +including 0 +gliosis 3 +secondary 0 +to 0 +neuronal 3 +damage 4 +. 0 + +These 0 +brain 0 +substrates 0 +may 0 +help 0 +account 0 +for 0 +the 0 +symptoms 0 +of 0 +MA 1 +abuse 0 +, 0 +providing 0 +therapeutic 0 +targets 0 +for 0 +drug 0 +- 0 +induced 0 +brain 3 +injury 4 +. 0 + +Disruption 0 +of 0 +hepatic 0 +lipid 0 +homeostasis 0 +in 0 +mice 0 +after 0 +amiodarone 1 +treatment 0 +is 0 +associated 0 +with 0 +peroxisome 0 +proliferator 0 +- 0 +activated 0 +receptor 0 +- 0 +alpha 0 +target 0 +gene 0 +activation 0 +. 0 + +Amiodarone 1 +, 0 +an 0 +efficacious 0 +and 0 +widely 0 +used 0 +antiarrhythmic 0 +agent 0 +, 0 +has 0 +been 0 +reported 0 +to 0 +cause 0 +hepatotoxicity 3 +in 0 +some 0 +patients 0 +. 0 + +To 0 +gain 0 +insight 0 +into 0 +the 0 +mechanism 0 +of 0 +this 0 +unwanted 0 +effect 0 +, 0 +mice 0 +were 0 +administered 0 +various 0 +doses 0 +of 0 +amiodarone 1 +and 0 +examined 0 +for 0 +changes 0 +in 0 +hepatic 0 +histology 0 +and 0 +gene 0 +regulation 0 +. 0 + +Amiodarone 1 +induced 0 +hepatomegaly 3 +, 0 +hepatocyte 0 +microvesicular 0 +lipid 0 +accumulation 0 +, 0 +and 0 +a 0 +significant 0 +decrease 0 +in 0 +serum 0 +triglycerides 1 +and 0 +glucose 1 +. 0 + +Northern 0 +blot 0 +analysis 0 +of 0 +hepatic 0 +RNA 0 +revealed 0 +a 0 +dose 0 +- 0 +dependent 0 +increase 0 +in 0 +the 0 +expression 0 +of 0 +a 0 +number 0 +of 0 +genes 0 +critical 0 +for 0 +fatty 1 +acid 2 +oxidation 0 +, 0 +lipoprotein 0 +assembly 0 +, 0 +and 0 +lipid 0 +transport 0 +. 0 + +Many 0 +of 0 +these 0 +genes 0 +are 0 +regulated 0 +by 0 +the 0 +peroxisome 0 +proliferator 0 +- 0 +activated 0 +receptor 0 +- 0 +alpha 0 +( 0 +PPARalpha 0 +) 0 +, 0 +a 0 +ligand 0 +- 0 +activated 0 +nuclear 0 +hormone 0 +receptor 0 +transcription 0 +factor 0 +. 0 + +The 0 +absence 0 +of 0 +induction 0 +of 0 +these 0 +genes 0 +as 0 +well 0 +as 0 +hepatomegaly 3 +in 0 +PPARalpha 0 +knockout 0 +[ 0 +PPARalpha 0 +- 0 +/ 0 +- 0 +] 0 +mice 0 +indicated 0 +that 0 +the 0 +effects 0 +of 0 +amiodarone 1 +were 0 +dependent 0 +upon 0 +the 0 +presence 0 +of 0 +a 0 +functional 0 +PPARalpha 0 +gene 0 +. 0 + +Compared 0 +to 0 +wild 0 +- 0 +type 0 +mice 0 +, 0 +treatment 0 +of 0 +PPARalpha 0 +- 0 +/ 0 +- 0 +mice 0 +with 0 +amiodarone 1 +resulted 0 +in 0 +an 0 +increased 0 +rate 0 +and 0 +extent 0 +of 0 +total 0 +body 0 +weight 3 +loss 4 +. 0 + +The 0 +inability 0 +of 0 +amiodarone 1 +to 0 +directly 0 +activate 0 +either 0 +human 0 +or 0 +mouse 0 +PPARalpha 0 +transiently 0 +expressed 0 +in 0 +human 0 +HepG2 0 +hepatoma 3 +cells 0 +indicates 0 +that 0 +the 0 +effects 0 +of 0 +amiodarone 1 +on 0 +the 0 +function 0 +of 0 +this 0 +receptor 0 +were 0 +indirect 0 +. 0 + +Based 0 +upon 0 +these 0 +results 0 +, 0 +we 0 +conclude 0 +that 0 +amiodarone 1 +disrupts 0 +hepatic 0 +lipid 0 +homeostasis 0 +and 0 +that 0 +the 0 +increased 0 +expression 0 +of 0 +PPARalpha 0 +target 0 +genes 0 +is 0 +secondary 0 +to 0 +this 0 +toxic 0 +effect 0 +. 0 + +These 0 +results 0 +provide 0 +important 0 +new 0 +mechanistic 0 +information 0 +regarding 0 +the 0 +hepatotoxic 3 +effects 0 +of 0 +amiodarone 1 +and 0 +indicate 0 +that 0 +PPARalpha 0 +protects 0 +against 0 +amiodarone 1 +- 0 +induced 0 +hepatotoxicity 3 +. 0 + +Safety 0 +and 0 +compliance 0 +with 0 +once 0 +- 0 +daily 0 +niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +as 0 +initial 0 +therapy 0 +in 0 +the 0 +Impact 0 +of 0 +Medical 0 +Subspecialty 0 +on 0 +Patient 0 +Compliance 0 +to 0 +Treatment 0 +( 0 +IMPACT 0 +) 0 +study 0 +. 0 + +Niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +is 0 +a 0 +new 0 +combination 0 +product 0 +approved 0 +for 0 +treatment 0 +of 0 +primary 0 +hypercholesterolemia 3 +and 0 +mixed 0 +dyslipidemia 3 +. 0 + +This 0 +open 0 +- 0 +labeled 0 +, 0 +multicenter 0 +study 0 +evaluated 0 +the 0 +safety 0 +of 0 +bedtime 0 +niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +when 0 +dosed 0 +as 0 +initial 0 +therapy 0 +and 0 +patient 0 +compliance 0 +to 0 +treatment 0 +in 0 +various 0 +clinical 0 +practice 0 +settings 0 +. 0 + +A 0 +total 0 +of 0 +4 0 +, 0 +499 0 +patients 0 +with 0 +dyslipidemia 3 +requiring 0 +drug 0 +intervention 0 +was 0 +enrolled 0 +at 0 +1 0 +, 0 +081 0 +sites 0 +. 0 + +Patients 0 +were 0 +treated 0 +with 0 +1 0 +tablet 0 +( 0 +500 0 +mg 0 +of 0 +niacin 1 +extended 0 +- 0 +release 0 +/ 0 +20 0 +mg 0 +of 0 +lovastatin 1 +) 0 +once 0 +nightly 0 +for 0 +4 0 +weeks 0 +and 0 +then 0 +2 0 +tablets 0 +for 0 +8 0 +weeks 0 +. 0 + +Patients 0 +also 0 +received 0 +dietary 0 +counseling 0 +, 0 +educational 0 +materials 0 +, 0 +and 0 +reminders 0 +to 0 +call 0 +a 0 +toll 0 +- 0 +free 0 +number 0 +that 0 +provided 0 +further 0 +education 0 +about 0 +dyslipidemia 3 +and 0 +niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +. 0 + +Primary 0 +end 0 +points 0 +were 0 +study 0 +compliance 0 +, 0 +increases 0 +in 0 +liver 0 +transaminases 0 +to 0 +> 0 +3 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +, 0 +and 0 +clinical 0 +myopathy 3 +. 0 + +Final 0 +study 0 +status 0 +was 0 +available 0 +for 0 +4 0 +, 0 +217 0 +patients 0 +( 0 +94 0 +% 0 +) 0 +. 0 + +Compliance 0 +to 0 +niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +was 0 +77 0 +% 0 +, 0 +with 0 +3 0 +, 0 +245 0 +patients 0 +completing 0 +the 0 +study 0 +. 0 + +Patients 0 +in 0 +the 0 +southeast 0 +and 0 +those 0 +enrolled 0 +by 0 +endocrinologists 0 +had 0 +the 0 +lowest 0 +compliance 0 +and 0 +highest 0 +adverse 0 +event 0 +rates 0 +. 0 + +Flushing 3 +was 0 +the 0 +most 0 +common 0 +adverse 0 +event 0 +, 0 +reported 0 +by 0 +18 0 +% 0 +of 0 +patients 0 +and 0 +leading 0 +to 0 +discontinuation 0 +by 0 +6 0 +% 0 +. 0 + +Incidence 0 +of 0 +increased 0 +aspartate 1 +aminotransferase 0 +and 0 +/ 0 +or 0 +alanine 1 +aminotransferase 0 +> 0 +3 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +was 0 +< 0 +0 0 +. 0 +3 0 +% 0 +. 0 + +An 0 +increase 0 +of 0 +creatine 1 +phosphokinase 0 +to 0 +> 0 +5 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +occurred 0 +in 0 +0 0 +. 0 +24 0 +% 0 +of 0 +patients 0 +, 0 +and 0 +no 0 +cases 0 +of 0 +drug 0 +- 0 +induced 0 +myopathy 3 +were 0 +observed 0 +. 0 + +Niacin 1 +extended 2 +- 2 +release 2 +/ 2 +lovastatin 2 +1 0 +, 0 +000 0 +/ 0 +40 0 +mg 0 +, 0 +dosed 0 +as 0 +initial 0 +therapy 0 +, 0 +was 0 +associated 0 +with 0 +good 0 +compliance 0 +and 0 +safety 0 +and 0 +had 0 +very 0 +low 0 +incidences 0 +of 0 +increased 0 +liver 0 +and 0 +muscle 0 +enzymes 0 +. 0 + +Protective 0 +effect 0 +of 0 +Terminalia 1 +chebula 2 +against 0 +experimental 0 +myocardial 3 +injury 4 +induced 0 +by 0 +isoproterenol 1 +. 0 + +Cardioprotective 0 +effect 0 +of 0 +ethanolic 1 +extract 2 +of 2 +Terminalia 2 +chebula 2 +fruits 2 +( 0 +500 0 +mg 0 +/ 0 +kg 0 +body 0 +wt 0 +) 0 +was 0 +examined 0 +in 0 +isoproterenol 1 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +body 0 +wt 0 +) 0 +induced 0 +myocardial 3 +damage 4 +in 0 +rats 0 +. 0 + +In 0 +isoproterenol 1 +administered 0 +rats 0 +, 0 +the 0 +level 0 +of 0 +lipid 0 +peroxides 1 +increased 0 +significantly 0 +in 0 +the 0 +serum 0 +and 0 +heart 0 +. 0 + +A 0 +significant 0 +decrease 0 +was 0 +observed 0 +in 0 +the 0 +activity 0 +of 0 +the 0 +myocardial 0 +marker 0 +enzymes 0 +with 0 +a 0 +concomitant 0 +increase 0 +in 0 +their 0 +activity 0 +in 0 +serum 0 +. 0 + +Histopathological 0 +examination 0 +was 0 +carried 0 +out 0 +to 0 +confirm 0 +the 0 +myocardial 0 +necrosis 3 +. 0 + +T 1 +. 2 +chebula 2 +extract 2 +pretreatment 0 +was 0 +found 0 +to 0 +ameliorate 0 +the 0 +effect 0 +of 0 +isoproterenol 1 +on 0 +lipid 0 +peroxide 1 +formation 0 +and 0 +retained 0 +the 0 +activities 0 +of 0 +the 0 +diagnostic 0 +marker 0 +enzymes 0 +. 0 + +A 0 +case 0 +of 0 +postoperative 0 +anxiety 3 +due 0 +to 0 +low 0 +dose 0 +droperidol 1 +used 0 +with 0 +patient 0 +- 0 +controlled 0 +analgesia 0 +. 0 + +A 0 +multiparous 0 +woman 0 +in 0 +good 0 +psychological 0 +health 0 +underwent 0 +urgent 0 +caesarean 0 +section 0 +in 0 +labour 0 +. 0 + +Postoperatively 0 +, 0 +she 0 +was 0 +given 0 +a 0 +patient 0 +- 0 +controlled 0 +analgesia 0 +device 0 +delivering 0 +boluses 0 +of 0 +diamorphine 1 +0 0 +. 0 +5 0 +mg 0 +and 0 +droperidol 1 +0 0 +. 0 +025 0 +mg 0 +. 0 + +Whilst 0 +using 0 +the 0 +device 0 +she 0 +gradually 0 +became 0 +anxious 0 +, 0 +the 0 +feeling 0 +worsening 0 +after 0 +each 0 +bolus 0 +. 0 + +The 0 +diagnosis 0 +of 0 +droperidol 1 +- 0 +induced 0 +psychological 3 +disturbance 4 +was 0 +not 0 +made 0 +straight 0 +away 0 +although 0 +on 0 +subsequent 0 +close 0 +questioning 0 +the 0 +patient 0 +gave 0 +a 0 +very 0 +clear 0 +history 0 +. 0 + +After 0 +she 0 +had 0 +received 0 +a 0 +total 0 +of 0 +only 0 +0 0 +. 0 +9 0 +mg 0 +droperidol 1 +, 0 +a 0 +syringe 0 +containing 0 +diamorphine 1 +only 0 +was 0 +substituted 0 +and 0 +her 0 +unease 0 +resolved 0 +completely 0 +. 0 + +We 0 +feel 0 +that 0 +, 0 +although 0 +the 0 +dramatic 0 +extrapyramidal 0 +side 0 +effects 0 +of 0 +dopaminergic 0 +antiemetics 0 +are 0 +well 0 +known 0 +, 0 +more 0 +subtle 0 +manifestations 0 +may 0 +easily 0 +be 0 +overlooked 0 +. 0 + +Accurate 0 +patient 0 +history 0 +contributes 0 +to 0 +differentiating 0 +diabetes 3 +insipidus 4 +: 0 +a 0 +case 0 +study 0 +. 0 + +This 0 +case 0 +study 0 +highlights 0 +the 0 +important 0 +contribution 0 +of 0 +nursing 0 +in 0 +obtaining 0 +an 0 +accurate 0 +health 0 +history 0 +. 0 + +The 0 +case 0 +discussed 0 +herein 0 +initially 0 +appeared 0 +to 0 +be 0 +neurogenic 3 +diabetes 4 +insipidus 4 +( 0 +DI 3 +) 0 +secondary 0 +to 0 +a 0 +traumatic 3 +brain 4 +injury 4 +. 0 + +The 0 +nursing 0 +staff 0 +, 0 +by 0 +reviewing 0 +the 0 +patient 0 +' 0 +s 0 +health 0 +history 0 +with 0 +his 0 +family 0 +, 0 +discovered 0 +a 0 +history 0 +of 0 +polydipsia 3 +and 0 +long 0 +- 0 +standing 0 +lithium 1 +use 0 +. 0 + +Lithium 1 +is 0 +implicated 0 +in 0 +drug 0 +- 0 +induced 0 +nephrogenic 3 +DI 4 +, 0 +and 0 +because 0 +the 0 +patient 0 +had 0 +not 0 +received 0 +lithium 1 +since 0 +being 0 +admitted 0 +to 0 +the 0 +hospital 0 +, 0 +his 0 +treatment 0 +changed 0 +to 0 +focus 0 +on 0 +nephrogenic 3 +DI 4 +. 0 + +By 0 +combining 0 +information 0 +from 0 +the 0 +patient 0 +history 0 +, 0 +the 0 +physical 0 +examination 0 +, 0 +and 0 +radiologic 0 +and 0 +laboratory 0 +studies 0 +, 0 +the 0 +critical 0 +care 0 +team 0 +demonstrated 0 +that 0 +the 0 +patient 0 +had 0 +been 0 +self 0 +- 0 +treating 0 +his 0 +lithium 1 +- 0 +induced 0 +nephrogenic 3 +DI 4 +and 0 +developed 0 +neurogenic 3 +DI 4 +secondary 0 +to 0 +brain 3 +trauma 4 +. 0 + +Thus 0 +successful 0 +treatment 0 +required 0 +that 0 +nephrogenic 0 +and 0 +neurogenic 3 +DI 4 +be 0 +treated 0 +concomitantly 0 +. 0 + +Factors 0 +contributing 0 +to 0 +ribavirin 1 +- 0 +induced 0 +anemia 3 +. 0 + +BACKGR0UND 0 +AND 0 +AIM 0 +: 0 +Interferon 1 +and 0 +ribavirin 1 +combination 0 +therapy 0 +for 0 +chronic 3 +hepatitis 4 +C 4 +produces 0 +hemolytic 3 +anemia 4 +. 0 + +This 0 +study 0 +was 0 +conducted 0 +to 0 +identify 0 +the 0 +factors 0 +contributing 0 +to 0 +ribavirin 1 +- 0 +induced 0 +anemia 3 +. 0 + +METH0DS 0 +: 0 +Eighty 0 +- 0 +eight 0 +patients 0 +with 0 +chronic 3 +hepatitis 4 +C 4 +who 0 +received 0 +interferon 1 +- 2 +alpha 2 +- 2 +2b 2 +at 0 +a 0 +dose 0 +of 0 +6 0 +MU 0 +administered 0 +intramuscularly 0 +for 0 +24 0 +weeks 0 +in 0 +combination 0 +with 0 +ribavirin 1 +administered 0 +orally 0 +at 0 +a 0 +dose 0 +of 0 +600 0 +mg 0 +or 0 +800 0 +mg 0 +participated 0 +in 0 +the 0 +study 0 +. 0 + +A 0 +hemoglobin 0 +concentration 0 +of 0 +< 0 +10 0 +g 0 +/ 0 +dL 0 +was 0 +defined 0 +as 0 +ribavirin 1 +- 0 +induced 0 +anemia 3 +. 0 + +RESULTS 0 +: 0 +Ribavirin 1 +- 0 +induced 0 +anemia 3 +occurred 0 +in 0 +18 0 +( 0 +20 0 +. 0 +5 0 +% 0 +) 0 +patients 0 +during 0 +treatment 0 +. 0 + +A 0 +2 0 +g 0 +/ 0 +dL 0 +decrease 0 +in 0 +hemoglobin 0 +concentrations 0 +in 0 +patients 0 +with 0 +anemia 3 +was 0 +observed 0 +at 0 +week 0 +2 0 +after 0 +the 0 +start 0 +of 0 +treatment 0 +. 0 + +The 0 +hemoglobin 0 +concentration 0 +in 0 +patients 0 +with 0 +> 0 +or 0 += 0 +2 0 +g 0 +/ 0 +dL 0 +decrease 0 +at 0 +week 0 +2 0 +was 0 +observed 0 +to 0 +be 0 +significantly 0 +lower 0 +even 0 +after 0 +week 0 +2 0 +than 0 +in 0 +patients 0 +with 0 +< 0 +2 0 +g 0 +/ 0 +dL 0 +decrease 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +A 0 +significant 0 +relationship 0 +was 0 +observed 0 +between 0 +the 0 +rate 0 +of 0 +reduction 0 +of 0 +hemoglobin 0 +concentrations 0 +at 0 +week 0 +2 0 +and 0 +the 0 +severity 0 +of 0 +anemia 3 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Such 0 +factors 0 +as 0 +sex 0 +( 0 +female 0 +) 0 +, 0 +age 0 +( 0 +> 0 +or 0 += 0 +60 0 +years 0 +old 0 +) 0 +, 0 +and 0 +the 0 +ribavirin 1 +dose 0 +by 0 +body 0 +weight 0 +( 0 +12 0 +mg 0 +/ 0 +kg 0 +or 0 +more 0 +) 0 +were 0 +significant 0 +by 0 +univariate 0 +analysis 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Careful 0 +administration 0 +is 0 +necessary 0 +in 0 +patients 0 +> 0 +or 0 += 0 +60 0 +years 0 +old 0 +, 0 +in 0 +female 0 +patients 0 +, 0 +and 0 +in 0 +patients 0 +receiving 0 +a 0 +ribavirin 1 +dose 0 +of 0 +12 0 +mg 0 +/ 0 +kg 0 +or 0 +more 0 +. 0 + +Patients 0 +who 0 +experience 0 +a 0 +fall 0 +in 0 +hemoglobin 0 +concentrations 0 +of 0 +2 0 +g 0 +/ 0 +dL 0 +or 0 +more 0 +at 0 +week 0 +2 0 +after 0 +the 0 +start 0 +of 0 +treatment 0 +should 0 +be 0 +monitored 0 +with 0 +particular 0 +care 0 +. 0 + +Zidovudine 1 +- 0 +induced 0 +hepatitis 3 +. 0 + +A 0 +case 0 +of 0 +acute 0 +hepatitis 3 +induced 0 +by 0 +zidovudine 1 +in 0 +a 0 +38 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +with 0 +AIDS 3 +is 0 +presented 0 +. 0 + +The 0 +mechanism 0 +whereby 0 +the 0 +hepatitis 3 +was 0 +induced 0 +is 0 +not 0 +known 0 +. 0 + +However 0 +, 0 +the 0 +patient 0 +tolerated 0 +well 0 +an 0 +alternative 0 +reverse 0 +transcriptase 0 +inhibitor 0 +, 0 +2 1 +' 2 +3 2 +' 2 +dideoxyinosine 2 +. 0 + +Physicians 0 +caring 0 +for 0 +patients 0 +with 0 +AIDS 3 +should 0 +be 0 +aware 0 +of 0 +this 0 +hitherto 0 +rarely 0 +reported 0 +complication 0 +. 0 + +0xidative 0 +damage 0 +precedes 0 +nitrative 0 +damage 0 +in 0 +adriamycin 1 +- 0 +induced 0 +cardiac 0 +mitochondrial 3 +injury 4 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +determine 0 +if 0 +elevated 0 +reactive 0 +oxygen 1 +( 0 +R0S 0 +) 0 +/ 0 +nitrogen 1 +species 0 +( 0 +RNS 0 +) 0 +reported 0 +to 0 +be 0 +present 0 +in 0 +adriamycin 1 +( 0 +ADR 1 +) 0 +- 0 +induced 0 +cardiotoxicity 3 +actually 0 +resulted 0 +in 0 +cardiomyocyte 0 +oxidative 0 +/ 0 +nitrative 0 +damage 0 +, 0 +and 0 +to 0 +quantitatively 0 +determine 0 +the 0 +time 0 +course 0 +and 0 +subcellular 0 +localization 0 +of 0 +these 0 +postulated 0 +damage 0 +products 0 +using 0 +an 0 +in 0 +vivo 0 +approach 0 +. 0 + +B6C3 0 +mice 0 +were 0 +treated 0 +with 0 +a 0 +single 0 +dose 0 +of 0 +20 0 +mg 0 +/ 0 +kg 0 +ADR 1 +. 0 + +Ultrastructural 0 +damage 0 +and 0 +levels 0 +of 0 +4 1 +- 2 +hydroxy 2 +- 2 +2 2 +- 2 +nonenal 2 +( 0 +4HNE 1 +) 0 +- 0 +protein 0 +adducts 0 +and 0 +3 1 +- 2 +nitrotyrosine 2 +( 0 +3NT 1 +) 0 +were 0 +analyzed 0 +. 0 + +Quantitative 0 +ultrastructural 0 +damage 0 +using 0 +computerized 0 +image 0 +techniques 0 +showed 0 +cardiomyocyte 0 +injury 0 +as 0 +early 0 +as 0 +3 0 +hours 0 +, 0 +with 0 +mitochondria 0 +being 0 +the 0 +most 0 +extensively 0 +and 0 +progressively 0 +injured 0 +subcellular 0 +organelle 0 +. 0 + +Analysis 0 +of 0 +4HNE 1 +protein 0 +adducts 0 +by 0 +immunogold 0 +electron 0 +microscopy 0 +showed 0 +appearance 0 +of 0 +4HNE 1 +protein 0 +adducts 0 +in 0 +mitochondria 0 +as 0 +early 0 +as 0 +3 0 +hours 0 +, 0 +with 0 +a 0 +peak 0 +at 0 +6 0 +hours 0 +and 0 +subsequent 0 +decline 0 +at 0 +24 0 +hours 0 +. 0 + +3NT 1 +levels 0 +were 0 +significantly 0 +increased 0 +in 0 +all 0 +subcellular 0 +compartments 0 +at 0 +6 0 +hours 0 +and 0 +subsequently 0 +declined 0 +at 0 +24 0 +hours 0 +. 0 + +0ur 0 +data 0 +showed 0 +ADR 1 +induced 0 +4HNE 1 +- 0 +protein 0 +adducts 0 +in 0 +mitochondria 0 +at 0 +the 0 +same 0 +time 0 +point 0 +as 0 +when 0 +mitochondrial 3 +injury 4 +initially 0 +appeared 0 +. 0 + +These 0 +results 0 +document 0 +for 0 +the 0 +first 0 +time 0 +in 0 +vivo 0 +that 0 +mitochondrial 3 +oxidative 4 +damage 4 +precedes 0 +nitrative 0 +damage 0 +. 0 + +The 0 +progressive 0 +nature 0 +of 0 +mitochondrial 3 +injury 4 +suggests 0 +that 0 +mitochondria 0 +, 0 +not 0 +other 0 +subcellular 0 +organelles 0 +, 0 +are 0 +the 0 +major 0 +site 0 +of 0 +intracellular 0 +injury 0 +. 0 + +Sotalol 1 +- 0 +induced 0 +coronary 3 +spasm 4 +in 0 +a 0 +patient 0 +with 0 +dilated 3 +cardiomyopathy 4 +associated 0 +with 0 +sustained 0 +ventricular 3 +tachycardia 4 +. 0 + +A 0 +54 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +severe 0 +left 0 +ventricular 3 +dysfunction 4 +due 0 +to 0 +dilated 3 +cardiomyopathy 4 +was 0 +referred 0 +to 0 +our 0 +hospital 0 +for 0 +symptomatic 0 +incessant 0 +sustained 0 +ventricular 3 +tachycardia 4 +( 0 +VT 3 +) 0 +. 0 + +After 0 +the 0 +administration 0 +of 0 +nifekalant 1 +hydrochloride 2 +, 0 +sustained 0 +VT 3 +was 0 +terminated 0 +. 0 + +An 0 +alternate 0 +class 0 +III 0 +agent 0 +, 0 +sotalol 1 +, 0 +was 0 +also 0 +effective 0 +for 0 +the 0 +prevention 0 +of 0 +VT 3 +. 0 + +However 0 +, 0 +one 0 +month 0 +after 0 +switching 0 +over 0 +nifekalant 1 +to 0 +sotalol 1 +, 0 +a 0 +short 0 +duration 0 +of 0 +ST 0 +elevation 0 +was 0 +documented 0 +in 0 +ECG 0 +monitoring 0 +at 0 +almost 0 +the 0 +same 0 +time 0 +for 0 +three 0 +consecutive 0 +days 0 +. 0 + +ST 0 +elevation 0 +with 0 +chest 0 +discomfort 0 +disappeared 0 +since 0 +he 0 +began 0 +taking 0 +long 0 +- 0 +acting 0 +diltiazem 1 +. 0 + +Coronary 3 +vasospasm 4 +may 0 +be 0 +induced 0 +by 0 +the 0 +non 0 +- 0 +selective 0 +beta 0 +- 0 +blocking 0 +properties 0 +of 0 +sotalol 1 +. 0 + +Effects 0 +of 0 +the 0 +antidepressant 0 +trazodone 1 +, 0 +a 0 +5 1 +- 2 +HT 2 +2A 0 +/ 0 +2C 0 +receptor 0 +antagonist 0 +, 0 +on 0 +dopamine 1 +- 0 +dependent 0 +behaviors 0 +in 0 +rats 0 +. 0 + +RATI0NALE 0 +: 0 +5 1 +- 2 +Hydroxytryptamine 2 +, 0 +via 0 +stimulation 0 +of 0 +5 1 +- 2 +HT 2 +2C 0 +receptors 0 +, 0 +exerts 0 +a 0 +tonic 0 +inhibitory 0 +influence 0 +on 0 +dopaminergic 0 +neurotransmission 0 +, 0 +whereas 0 +activation 0 +of 0 +5 1 +- 2 +HT 2 +2A 0 +receptors 0 +enhances 0 +stimulated 0 +DAergic 0 +neurotransmission 0 +. 0 + +The 0 +antidepressant 0 +trazodone 1 +is 0 +a 0 +5 1 +- 2 +HT 2 +2A 0 +/ 0 +2C 0 +receptor 0 +antagonist 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +evaluate 0 +the 0 +effect 0 +of 0 +trazodone 1 +treatment 0 +on 0 +behaviors 0 +dependent 0 +on 0 +the 0 +functional 0 +status 0 +of 0 +the 0 +nigrostriatal 0 +DAergic 0 +system 0 +. 0 + +METH0DS 0 +: 0 +The 0 +effect 0 +of 0 +pretreatment 0 +with 0 +trazodone 1 +on 0 +dexamphetamine 1 +- 0 +and 0 +apomorphine 1 +- 0 +induced 0 +oral 3 +stereotypies 4 +, 0 +on 0 +catalepsy 3 +induced 0 +by 0 +haloperidol 1 +and 0 +apomorphine 1 +( 0 +0 0 +. 0 +05 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +, 0 +on 0 +ergometrine 1 +- 0 +induced 0 +wet 0 +dog 0 +shake 0 +( 0 +WDS 0 +) 0 +behavior 0 +and 0 +fluoxetine 1 +- 0 +induced 0 +penile 0 +erections 0 +was 0 +studied 0 +in 0 +rats 0 +. 0 + +We 0 +also 0 +investigated 0 +whether 0 +trazodone 1 +induces 0 +catalepsy 3 +in 0 +rats 0 +. 0 + +RESULTS 0 +: 0 +Trazodone 1 +at 0 +2 0 +. 0 +5 0 +- 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +did 0 +not 0 +induce 0 +catalepsy 3 +, 0 +and 0 +did 0 +not 0 +antagonize 0 +apomorphine 1 +( 0 +1 0 +. 0 +5 0 +and 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +stereotypy 0 +and 0 +apomorphine 1 +( 0 +0 0 +. 0 +05 0 +mg 0 +/ 0 +kg 0 +) 0 +- 0 +induced 0 +catalepsy 3 +. 0 + +However 0 +, 0 +pretreatment 0 +with 0 +5 0 +, 0 +10 0 +and 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +trazodone 1 +enhanced 0 +dexamphetamine 1 +stereotypy 0 +, 0 +and 0 +antagonized 0 +haloperidol 1 +catalepsy 3 +, 0 +ergometrine 1 +- 0 +induced 0 +WDS 0 +behavior 0 +and 0 +fluoxetine 1 +- 0 +induced 0 +penile 0 +erections 0 +. 0 + +Trazodone 1 +at 0 +30 0 +, 0 +40 0 +and 0 +50 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +induced 0 +catalepsy 3 +and 0 +antagonized 0 +apomorphine 1 +and 0 +dexamphetamine 1 +stereotypies 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0ur 0 +results 0 +indicate 0 +that 0 +trazodone 1 +at 0 +2 0 +. 0 +5 0 +- 0 +20 0 +mg 0 +/ 0 +kg 0 +does 0 +not 0 +block 0 +pre 0 +- 0 +and 0 +postsynaptic 0 +striatal 0 +D2 0 +DA 0 +receptors 0 +, 0 +while 0 +at 0 +30 0 +, 0 +40 0 +and 0 +50 0 +mg 0 +/ 0 +kg 0 +it 0 +blocks 0 +postsynaptic 0 +striatal 0 +D2 0 +DA 0 +receptors 0 +. 0 + +Furthermore 0 +, 0 +at 0 +5 0 +, 0 +10 0 +and 0 +20 0 +mg 0 +/ 0 +kg 0 +, 0 +trazodone 1 +blocks 0 +5 1 +- 2 +HT 2 +2A 0 +and 0 +5 1 +- 2 +HT 2 +2C 0 +receptors 0 +. 0 + +We 0 +suggest 0 +that 0 +trazodone 1 +( 0 +5 0 +, 0 +10 0 +and 0 +20 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +by 0 +blocking 0 +the 0 +5 1 +- 2 +HT 2 +2C 0 +receptors 0 +, 0 +releases 0 +the 0 +nigrostriatal 0 +DAergic 0 +neurons 0 +from 0 +tonic 0 +inhibition 0 +caused 0 +by 0 +5 1 +- 2 +HT 2 +, 0 +and 0 +thereby 0 +potentiates 0 +dexamphetamine 1 +stereotypy 0 +and 0 +antagonizes 0 +haloperidol 1 +catalepsy 3 +. 0 + +Swallowing 3 +abnormalities 4 +and 0 +dyskinesia 3 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Gastrointestinal 3 +abnormalities 4 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +have 0 +been 0 +known 0 +for 0 +almost 0 +two 0 +centuries 0 +, 0 +but 0 +many 0 +aspects 0 +concerning 0 +their 0 +pathophysiology 0 +have 0 +not 0 +been 0 +completely 0 +clarified 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +characterize 0 +the 0 +oropharyngeal 0 +dynamics 0 +in 0 +PD 3 +patients 0 +with 0 +and 0 +without 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +. 0 + +Fifteen 0 +dyskinetic 3 +, 0 +12 0 +nondyskinetic 0 +patients 0 +, 0 +and 0 +a 0 +control 0 +group 0 +were 0 +included 0 +. 0 + +Patients 0 +were 0 +asked 0 +about 0 +dysphagia 3 +and 0 +evaluated 0 +with 0 +the 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +Parts 0 +II 0 +and 0 +III 0 +and 0 +the 0 +Hoehn 0 +and 0 +Yahr 0 +scale 0 +. 0 + +Deglutition 0 +was 0 +assessed 0 +using 0 +modified 0 +barium 1 +swallow 0 +with 0 +videofluoroscopy 0 +. 0 + +Nondyskinetic 0 +patients 0 +, 0 +but 0 +not 0 +the 0 +dyskinetic 3 +ones 0 +, 0 +showed 0 +less 0 +oropharyngeal 0 +swallowing 0 +efficiency 0 +( 0 +0PSE 0 +) 0 +for 0 +liquid 0 +food 0 +than 0 +controls 0 +( 0 +Dunnett 0 +, 0 +P 0 += 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +Dyskinetic 3 +patients 0 +tended 0 +to 0 +have 0 +a 0 +greater 0 +0PSE 0 +than 0 +nondyskinetic 0 +( 0 +Dunnett 0 +, 0 +P 0 += 0 +0 0 +. 0 +06 0 +) 0 +. 0 + +Patients 0 +who 0 +were 0 +using 0 +a 0 +higher 0 +dose 0 +of 0 +levodopa 1 +had 0 +a 0 +greater 0 +0PSE 0 +and 0 +a 0 +trend 0 +toward 0 +a 0 +smaller 0 +oral 0 +transit 0 +time 0 +( 0 +Pearson 0 +' 0 +s 0 +correlation 0 +, 0 +P 0 += 0 +0 0 +. 0 +01 0 +and 0 +0 0 +. 0 +08 0 +, 0 +respectively 0 +) 0 +. 0 + +Neither 0 +the 0 +report 0 +of 0 +dysphagia 3 +nor 0 +any 0 +of 0 +the 0 +PD 3 +severity 0 +parameters 0 +correlated 0 +to 0 +the 0 +videofluoroscopic 0 +variables 0 +. 0 + +In 0 +the 0 +current 0 +study 0 +, 0 +dyskinetic 3 +patients 0 +performed 0 +better 0 +in 0 +swallowing 0 +function 0 +, 0 +which 0 +could 0 +be 0 +explained 0 +on 0 +the 0 +basis 0 +of 0 +a 0 +greater 0 +levodopa 1 +dose 0 +. 0 + +0ur 0 +results 0 +suggest 0 +a 0 +role 0 +for 0 +levodopa 1 +in 0 +the 0 +oral 0 +phase 0 +of 0 +deglutition 0 +and 0 +confirm 0 +that 0 +dysphagia 3 +is 0 +not 0 +a 0 +good 0 +predictor 0 +of 0 +deglutition 0 +alterations 0 +in 0 +PD 3 +. 0 + +Inhibition 0 +of 0 +nuclear 0 +factor 0 +- 0 +kappaB 0 +activation 0 +attenuates 0 +tubulointerstitial 3 +nephritis 4 +induced 0 +by 0 +gentamicin 1 +. 0 + +BACKGR0UND 0 +: 0 +Animals 0 +treated 0 +with 0 +gentamicin 1 +can 0 +show 0 +residual 0 +areas 0 +of 0 +interstitial 0 +fibrosis 3 +in 0 +the 0 +renal 0 +cortex 0 +. 0 + +This 0 +study 0 +investigated 0 +the 0 +expression 0 +of 0 +nuclear 0 +factor 0 +- 0 +kappaB 0 +( 0 +NF 0 +- 0 +kappaB 0 +) 0 +, 0 +mitogen 0 +- 0 +activated 0 +protein 0 +( 0 +MAP 0 +) 0 +kinases 0 +and 0 +macrophages 0 +in 0 +the 0 +renal 0 +cortex 0 +and 0 +structural 0 +and 0 +functional 0 +renal 0 +changes 0 +of 0 +rats 0 +treated 0 +with 0 +gentamicin 1 +or 0 +gentamicin 1 ++ 0 +pyrrolidine 1 +dithiocarbamate 2 +( 0 +PDTC 1 +) 0 +, 0 +an 0 +NF 0 +- 0 +kappaB 0 +inhibitor 0 +. 0 + +METH0DS 0 +: 0 +38 0 +female 0 +Wistar 0 +rats 0 +were 0 +injected 0 +with 0 +gentamicin 1 +, 0 +40 0 +mg 0 +/ 0 +kg 0 +, 0 +twice 0 +a 0 +day 0 +for 0 +9 0 +days 0 +, 0 +38 0 +with 0 +gentamicin 1 ++ 0 +PDTC 1 +, 0 +and 0 +28 0 +with 0 +0 0 +. 0 +15 0 +M 0 +NaCl 1 +solution 0 +. 0 + +The 0 +animals 0 +were 0 +killed 0 +5 0 +and 0 +30 0 +days 0 +after 0 +these 0 +injections 0 +and 0 +the 0 +kidneys 0 +were 0 +removed 0 +for 0 +histological 0 +and 0 +immunohistochemical 0 +studies 0 +. 0 + +The 0 +results 0 +of 0 +the 0 +immunohistochemical 0 +studies 0 +were 0 +scored 0 +according 0 +to 0 +the 0 +extent 0 +of 0 +staining 0 +. 0 + +The 0 +fractional 0 +interstitial 0 +area 0 +was 0 +determined 0 +by 0 +morphometry 0 +. 0 + +RESULTS 0 +: 0 +Gentamicin 1 +- 0 +treated 0 +rats 0 +presented 0 +a 0 +transitory 0 +increase 0 +in 0 +plasma 0 +creatinine 1 +levels 0 +. 0 + +Increased 0 +ED 0 +- 0 +1 0 +, 0 +MAP 0 +kinases 0 +and 0 +NF 0 +- 0 +kappaB 0 +staining 0 +were 0 +also 0 +observed 0 +in 0 +the 0 +renal 0 +cortex 0 +from 0 +all 0 +gentamicin 1 +- 0 +treated 0 +rats 0 +compared 0 +to 0 +control 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +animals 0 +killed 0 +on 0 +day 0 +30 0 +also 0 +presented 0 +fibrosis 3 +in 0 +the 0 +renal 0 +cortex 0 +despite 0 +the 0 +recovery 0 +of 0 +renal 0 +function 0 +. 0 + +Treatment 0 +with 0 +PDTC 1 +reduced 0 +the 0 +functional 0 +and 0 +structural 0 +changes 0 +induced 0 +by 0 +gentamicin 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +data 0 +show 0 +that 0 +inhibition 0 +of 0 +NF 0 +- 0 +kappaB 0 +activation 0 +attenuates 0 +tubulointerstitial 3 +nephritis 4 +induced 0 +by 0 +gentamicin 1 +. 0 + +Glucose 1 +metabolism 0 +in 0 +patients 0 +with 0 +schizophrenia 3 +treated 0 +with 0 +atypical 0 +antipsychotic 0 +agents 0 +: 0 +a 0 +frequently 0 +sampled 0 +intravenous 0 +glucose 1 +tolerance 0 +test 0 +and 0 +minimal 0 +model 0 +analysis 0 +. 0 + +BACKGR0UND 0 +: 0 +While 0 +the 0 +incidence 0 +of 0 +new 0 +- 0 +onset 0 +diabetes 3 +mellitus 4 +may 0 +be 0 +increasing 0 +in 0 +patients 0 +with 0 +schizophrenia 3 +treated 0 +with 0 +certain 0 +atypical 0 +antipsychotic 0 +agents 0 +, 0 +it 0 +remains 0 +unclear 0 +whether 0 +atypical 0 +agents 0 +are 0 +directly 0 +affecting 0 +glucose 1 +metabolism 0 +or 0 +simply 0 +increasing 0 +known 0 +risk 0 +factors 0 +for 0 +diabetes 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +study 0 +the 0 +2 0 +drugs 0 +most 0 +clearly 0 +implicated 0 +( 0 +clozapine 1 +and 0 +olanzapine 1 +) 0 +and 0 +risperidone 1 +using 0 +a 0 +frequently 0 +sampled 0 +intravenous 0 +glucose 1 +tolerance 0 +test 0 +. 0 + +DESIGN 0 +: 0 +A 0 +cross 0 +- 0 +sectional 0 +design 0 +in 0 +stable 0 +, 0 +treated 0 +patients 0 +with 0 +schizophrenia 3 +evaluated 0 +using 0 +a 0 +frequently 0 +sampled 0 +intravenous 0 +glucose 1 +tolerance 0 +test 0 +and 0 +the 0 +Bergman 0 +minimal 0 +model 0 +analysis 0 +. 0 + +SETTING 0 +: 0 +Subjects 0 +were 0 +recruited 0 +from 0 +an 0 +urban 0 +community 0 +mental 0 +health 0 +clinic 0 +and 0 +were 0 +studied 0 +at 0 +a 0 +general 0 +clinical 0 +research 0 +center 0 +. 0 + +Patients 0 +Fifty 0 +subjects 0 +signed 0 +informed 0 +consent 0 +and 0 +41 0 +underwent 0 +the 0 +frequently 0 +sampled 0 +intravenous 0 +glucose 1 +tolerance 0 +test 0 +. 0 + +Thirty 0 +- 0 +six 0 +nonobese 0 +subjects 0 +with 0 +schizophrenia 3 +or 0 +schizoaffective 3 +disorder 4 +, 0 +matched 0 +by 0 +body 0 +mass 0 +index 0 +and 0 +treated 0 +with 0 +either 0 +clozapine 1 +, 0 +olanzapine 1 +, 0 +or 0 +risperidone 1 +, 0 +were 0 +included 0 +in 0 +the 0 +analysis 0 +. 0 + +MAIN 0 +0UTC0ME 0 +MEASURES 0 +: 0 +Fasting 0 +plasma 0 +glucose 1 +and 0 +fasting 0 +serum 0 +insulin 0 +levels 0 +, 0 +insulin 3 +sensitivity 4 +index 0 +, 0 +homeostasis 0 +model 0 +assessment 0 +of 0 +insulin 3 +resistance 4 +, 0 +and 0 +glucose 1 +effectiveness 0 +. 0 + +RESULTS 0 +: 0 +The 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +duration 0 +of 0 +treatment 0 +with 0 +the 0 +identified 0 +atypical 0 +antipsychotic 0 +agent 0 +was 0 +68 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +28 0 +. 0 +9 0 +months 0 +( 0 +clozapine 1 +) 0 +, 0 +29 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +17 0 +. 0 +5 0 +months 0 +( 0 +olanzapine 1 +) 0 +, 0 +and 0 +40 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +33 0 +. 0 +7 0 +( 0 +risperidone 1 +) 0 +. 0 + +Fasting 0 +serum 0 +insulin 0 +concentrations 0 +differed 0 +among 0 +groups 0 +( 0 +F 0 +( 0 +33 0 +) 0 += 0 +3 0 +. 0 +35 0 +; 0 +P 0 += 0 +. 0 +047 0 +) 0 +( 0 +clozapine 1 +> 0 +olanzapine 1 +> 0 +risperidone 1 +) 0 +with 0 +significant 0 +differences 0 +between 0 +clozapine 1 +and 0 +risperidone 1 +( 0 +t 0 +( 0 +33 0 +) 0 += 0 +2 0 +. 0 +32 0 +; 0 +P 0 += 0 +. 0 +03 0 +) 0 +and 0 +olanzapine 1 +and 0 +risperidone 1 +( 0 +t 0 +( 0 +33 0 +) 0 += 0 +2 0 +. 0 +15 0 +; 0 +P 0 += 0 +. 0 +04 0 +) 0 +. 0 + +There 0 +was 0 +a 0 +significant 0 +difference 0 +in 0 +insulin 3 +sensitivity 4 +index 0 +among 0 +groups 0 +( 0 +F 0 +( 0 +33 0 +) 0 += 0 +10 0 +. 0 +66 0 +; 0 +P 0 +< 0 +. 0 +001 0 +) 0 +( 0 +clozapine 1 +< 0 +olanzapine 1 +< 0 +risperidone 1 +) 0 +, 0 +with 0 +subjects 0 +who 0 +received 0 +clozapine 1 +and 0 +olanzapine 1 +exhibiting 0 +significant 0 +insulin 3 +resistance 4 +compared 0 +with 0 +subjects 0 +who 0 +were 0 +treated 0 +with 0 +risperidone 1 +( 0 +clozapine 1 +vs 0 +risperidone 1 +, 0 +t 0 +( 0 +33 0 +) 0 += 0 +- 0 +4 0 +. 0 +29 0 +; 0 +P 0 +< 0 +. 0 +001 0 +; 0 +olanzapine 1 +vs 0 +risperidone 1 +, 0 +t 0 +( 0 +33 0 +) 0 += 0 +- 0 +3 0 +. 0 +62 0 +; 0 +P 0 += 0 +. 0 +001 0 +[ 0 +P 0 +< 0 +. 0 +001 0 +] 0 +) 0 +. 0 + +The 0 +homeostasis 0 +model 0 +assessment 0 +of 0 +insulin 3 +resistance 4 +also 0 +differed 0 +significantly 0 +among 0 +groups 0 +( 0 +F 0 +( 0 +33 0 +) 0 += 0 +4 0 +. 0 +92 0 +; 0 +P 0 += 0 +. 0 +01 0 +) 0 +( 0 +clozapine 1 +> 0 +olanzapine 1 +> 0 +risperidone 1 +) 0 +( 0 +clozapine 1 +vs 0 +risperidone 1 +, 0 +t 0 +( 0 +33 0 +) 0 += 0 +2 0 +. 0 +94 0 +; 0 +P 0 += 0 +. 0 +006 0 +; 0 +olanzapine 1 +vs 0 +risperidone 1 +, 0 +t 0 +( 0 +33 0 +) 0 += 0 +2 0 +. 0 +42 0 +; 0 +P 0 += 0 +. 0 +02 0 +) 0 +. 0 + +There 0 +was 0 +a 0 +significant 0 +difference 0 +among 0 +groups 0 +in 0 +glucose 1 +effectiveness 0 +( 0 +F 0 +( 0 +30 0 +) 0 += 0 +4 0 +. 0 +18 0 +; 0 +P 0 += 0 +. 0 +02 0 +) 0 +( 0 +clozapine 1 +< 0 +olanzapine 1 +< 0 +risperidone 1 +) 0 +with 0 +significant 0 +differences 0 +between 0 +clozapine 1 +and 0 +risperidone 1 +( 0 +t 0 +( 0 +30 0 +) 0 += 0 +- 0 +2 0 +. 0 +59 0 +; 0 +P 0 += 0 +. 0 +02 0 +) 0 +and 0 +olanzapine 1 +and 0 +risperidone 1 +( 0 +t 0 +( 0 +30 0 +) 0 += 0 +- 0 +2 0 +. 0 +34 0 +, 0 +P 0 += 0 +. 0 +03 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Both 0 +nonobese 0 +clozapine 1 +- 0 +and 0 +olanzapine 1 +- 0 +treated 0 +groups 0 +displayed 0 +significant 0 +insulin 3 +resistance 4 +and 0 +impairment 0 +of 0 +glucose 1 +effectiveness 0 +compared 0 +with 0 +risperidone 1 +- 0 +treated 0 +subjects 0 +. 0 + +Patients 0 +taking 0 +clozapine 1 +and 0 +olanzapine 1 +must 0 +be 0 +examined 0 +for 0 +insulin 3 +resistance 4 +and 0 +its 0 +consequences 0 +. 0 + +Thoracic 3 +hematomyelia 4 +secondary 0 +to 0 +coumadin 1 +anticoagulant 0 +therapy 0 +: 0 +a 0 +case 0 +report 0 +. 0 + +A 0 +case 0 +of 0 +thoracic 3 +hematomyelia 4 +secondary 0 +to 0 +anticoagulant 0 +therapy 0 +is 0 +presented 0 +. 0 + +Clinical 0 +features 0 +, 0 +similar 0 +to 0 +2 0 +other 0 +previously 0 +reported 0 +cases 0 +, 0 +are 0 +discussed 0 +. 0 + +A 0 +high 0 +index 0 +of 0 +suspicion 0 +may 0 +lead 0 +to 0 +a 0 +quick 0 +diagnostic 0 +procedure 0 +and 0 +successful 0 +decompressive 0 +surgery 0 +. 0 + +Mania 3 +associated 0 +with 0 +fluoxetine 1 +treatment 0 +in 0 +adolescents 0 +. 0 + +Fluoxetine 1 +, 0 +a 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitor 0 +, 0 +is 0 +gaining 0 +increased 0 +acceptance 0 +in 0 +the 0 +treatment 0 +of 0 +adolescent 0 +depression 3 +. 0 + +Generally 0 +safe 0 +and 0 +well 0 +tolerated 0 +by 0 +adults 0 +, 0 +fluoxetine 1 +has 0 +been 0 +reported 0 +to 0 +induce 0 +mania 3 +. 0 + +The 0 +cases 0 +of 0 +five 0 +depressed 3 +adolescents 0 +, 0 +14 0 +- 0 +16 0 +years 0 +of 0 +age 0 +, 0 +who 0 +developed 0 +mania 3 +during 0 +pharmacotherapy 0 +with 0 +fluoxetine 1 +, 0 +are 0 +reported 0 +here 0 +. 0 + +Apparent 0 +risk 0 +factors 0 +for 0 +the 0 +development 0 +of 0 +mania 3 +or 0 +hypomania 3 +during 0 +fluoxetine 1 +pharmacotherapy 0 +in 0 +this 0 +population 0 +were 0 +the 0 +combination 0 +of 0 +attention 3 +- 4 +deficit 4 +hyperactivity 4 +disorder 4 +and 0 +affective 0 +instability 0 +; 0 +major 0 +depression 3 +with 0 +psychotic 3 +features 0 +; 0 +a 0 +family 0 +history 0 +of 0 +affective 3 +disorder 4 +, 0 +especially 0 +bipolar 3 +disorder 4 +; 0 +and 0 +a 0 +diagnosis 0 +of 0 +bipolar 3 +disorder 4 +. 0 + +Further 0 +study 0 +is 0 +needed 0 +to 0 +determine 0 +the 0 +optimal 0 +dosage 0 +and 0 +to 0 +identify 0 +risk 0 +factors 0 +that 0 +increase 0 +individual 0 +vulnerability 0 +to 0 +fluoxetine 1 +induced 0 +mania 3 +in 0 +adolescents 0 +. 0 + +Acute 3 +renal 4 +insufficiency 4 +after 0 +high 0 +- 0 +dose 0 +melphalan 1 +in 0 +patients 0 +with 0 +primary 3 +systemic 4 +amyloidosis 4 +during 0 +stem 0 +cell 0 +transplantation 0 +. 0 + +BACKGR0UND 0 +: 0 +Patients 0 +with 0 +primary 3 +systemic 4 +amyloidosis 4 +( 0 +AL 3 +) 0 +have 0 +a 0 +poor 0 +prognosis 0 +. 0 + +Median 0 +survival 0 +time 0 +from 0 +standard 0 +treatments 0 +is 0 +only 0 +17 0 +months 0 +. 0 + +High 0 +- 0 +dose 0 +intravenous 0 +melphalan 1 +followed 0 +by 0 +peripheral 0 +blood 0 +stem 0 +cell 0 +transplant 0 +( 0 +PBSCT 0 +) 0 +appears 0 +to 0 +be 0 +the 0 +most 0 +promising 0 +therapy 0 +, 0 +but 0 +treatment 0 +mortality 0 +can 0 +be 0 +high 0 +. 0 + +The 0 +authors 0 +have 0 +noted 0 +the 0 +development 0 +of 0 +acute 3 +renal 4 +insufficiency 4 +immediately 0 +after 0 +melphalan 1 +conditioning 0 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +further 0 +examine 0 +its 0 +risk 0 +factors 0 +and 0 +impact 0 +on 0 +posttransplant 0 +mortality 0 +. 0 + +METH0DS 0 +: 0 +Consecutive 0 +AL 3 +patients 0 +who 0 +underwent 0 +PBSCT 0 +were 0 +studied 0 +retrospectively 0 +. 0 + +Acute 3 +renal 4 +insufficiency 4 +( 0 +ARI 3 +) 0 +after 0 +high 0 +- 0 +dose 0 +melphalan 1 +was 0 +defined 0 +by 0 +a 0 +minimum 0 +increase 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +dL 0 +( 0 +44 0 +micromol 0 +/ 0 +L 0 +) 0 +in 0 +the 0 +serum 0 +creatinine 1 +level 0 +that 0 +is 0 +greater 0 +than 0 +50 0 +% 0 +of 0 +baseline 0 +immediately 0 +after 0 +conditioning 0 +. 0 + +Urine 0 +sediment 0 +score 0 +was 0 +the 0 +sum 0 +of 0 +the 0 +individual 0 +types 0 +of 0 +sediment 0 +identified 0 +on 0 +urine 0 +microscopy 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +the 0 +80 0 +patients 0 +studied 0 +, 0 +ARI 3 +developed 0 +in 0 +18 0 +. 0 +8 0 +% 0 +of 0 +the 0 +patients 0 +after 0 +high 0 +- 0 +dose 0 +melphalan 1 +. 0 + +Univariate 0 +analysis 0 +identified 0 +age 0 +, 0 +hypoalbuminemia 3 +, 0 +heavy 0 +proteinuria 3 +, 0 +diuretic 0 +use 0 +, 0 +and 0 +urine 0 +sediment 0 +score 0 +( 0 +> 0 +3 0 +) 0 +as 0 +risk 0 +factors 0 +. 0 + +Age 0 +and 0 +urine 0 +sediment 0 +score 0 +remained 0 +independently 0 +significant 0 +risk 0 +factors 0 +in 0 +the 0 +multivariate 0 +analysis 0 +. 0 + +Patients 0 +who 0 +had 0 +ARI 3 +after 0 +high 0 +- 0 +dose 0 +melphalan 1 +underwent 0 +dialysis 0 +more 0 +often 0 +( 0 +P 0 += 0 +0 0 +. 0 +007 0 +) 0 +, 0 +and 0 +had 0 +a 0 +worse 0 +1 0 +- 0 +year 0 +survival 0 +( 0 +P 0 += 0 +0 0 +. 0 +03 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +timing 0 +of 0 +renal 3 +injury 4 +strongly 0 +suggests 0 +melphalan 1 +as 0 +the 0 +causative 0 +agent 0 +. 0 + +0ngoing 0 +tubular 3 +injury 4 +may 0 +be 0 +a 0 +prerequisite 0 +for 0 +renal 3 +injury 4 +by 0 +melphalan 1 +as 0 +evidenced 0 +by 0 +the 0 +active 0 +urinary 0 +sediment 0 +. 0 + +Development 0 +of 0 +ARI 3 +adversely 0 +affected 0 +the 0 +outcome 0 +after 0 +PBSCT 0 +. 0 + +Effective 0 +preventive 0 +measures 0 +may 0 +help 0 +decrease 0 +the 0 +treatment 0 +mortality 0 +of 0 +PBSCT 0 +in 0 +AL 3 +patients 0 +. 0 + +Focal 0 +cerebral 3 +ischemia 4 +in 0 +rats 0 +: 0 +effect 0 +of 0 +phenylephrine 1 +- 0 +induced 0 +hypertension 3 +during 0 +reperfusion 0 +. 0 + +After 0 +180 0 +min 0 +of 0 +temporary 0 +middle 3 +cerebral 4 +artery 4 +occlusion 4 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +, 0 +the 0 +effect 0 +of 0 +phenylephrine 1 +- 0 +induced 0 +hypertension 3 +on 0 +ischemic 3 +brain 4 +injury 4 +and 0 +blood 0 +- 0 +brain 0 +barrier 0 +permeability 0 +was 0 +determined 0 +. 0 + +Blood 0 +pressure 0 +was 0 +manipulated 0 +by 0 +one 0 +of 0 +the 0 +following 0 +schedules 0 +during 0 +120 0 +min 0 +of 0 +reperfusion 0 +: 0 +Control 0 +, 0 +normotensive 0 +reperfusion 0 +; 0 +90 0 +/ 0 +hypertension 3 +( 0 +90 0 +/ 0 +HTN 3 +) 0 +, 0 +blood 0 +pressure 0 +was 0 +increased 0 +by 0 +35 0 +mm 0 +Hg 0 +during 0 +the 0 +initial 0 +90 0 +min 0 +of 0 +reperfusion 0 +only 0 +; 0 +15 0 +/ 0 +hypertension 3 +( 0 +15 0 +/ 0 +HTN 3 +) 0 +, 0 +normotensive 0 +reperfusion 0 +for 0 +30 0 +min 0 +followed 0 +by 0 +15 0 +min 0 +of 0 +hypertension 3 +and 0 +75 0 +min 0 +of 0 +normotension 0 +. 0 + +Part 0 +A 0 +, 0 +for 0 +eight 0 +rats 0 +in 0 +each 0 +group 0 +brain 3 +injury 4 +was 0 +evaluated 0 +by 0 +staining 0 +tissue 0 +using 0 +2 1 +, 2 +3 2 +, 2 +5 2 +- 2 +triphenyltetrazolium 2 +chloride 2 +and 0 +edema 3 +was 0 +evaluated 0 +by 0 +microgravimetry 0 +. 0 + +Part 0 +B 0 +, 0 +for 0 +eight 0 +different 0 +rats 0 +in 0 +each 0 +group 0 +blood 0 +- 0 +brain 0 +barrier 0 +permeability 0 +was 0 +evaluated 0 +by 0 +measuring 0 +the 0 +amount 0 +and 0 +extent 0 +of 0 +extravasation 0 +of 0 +Evans 0 +Blue 0 +dye 0 +. 0 + +Brain 3 +injury 4 +( 0 +percentage 0 +of 0 +the 0 +ischemic 3 +hemisphere 4 +) 0 +was 0 +less 0 +in 0 +the 0 +15 0 +/ 0 +HTN 3 +group 0 +( 0 +16 0 ++ 0 +/ 0 +- 0 +6 0 +, 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +versus 0 +the 0 +90 0 +/ 0 +HTN 3 +group 0 +( 0 +30 0 ++ 0 +/ 0 +- 0 +6 0 +) 0 +, 0 +which 0 +was 0 +in 0 +turn 0 +less 0 +than 0 +the 0 +control 0 +group 0 +( 0 +42 0 ++ 0 +/ 0 +- 0 +5 0 +) 0 +. 0 + +Specific 0 +gravity 0 +was 0 +greater 0 +in 0 +the 0 +15 0 +/ 0 +HTN 3 +group 0 +( 0 +1 0 +. 0 +043 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +002 0 +) 0 +versus 0 +the 0 +90 0 +/ 0 +HTN 3 +( 0 +1 0 +. 0 +036 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +003 0 +) 0 +and 0 +control 0 +( 0 +1 0 +. 0 +037 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +003 0 +) 0 +groups 0 +. 0 + +Evans 1 +Blue 2 +( 0 +mug 0 +g 0 +- 0 +1 0 +of 0 +brain 0 +tissue 0 +) 0 +was 0 +greater 0 +in 0 +the 0 +90 0 +/ 0 +HTN 3 +group 0 +( 0 +24 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +0 0 +) 0 +versus 0 +the 0 +control 0 +group 0 +( 0 +12 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +1 0 +) 0 +, 0 +which 0 +was 0 +in 0 +turn 0 +greater 0 +than 0 +the 0 +15 0 +/ 0 +HTN 3 +group 0 +( 0 +7 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +2 0 +) 0 +. 0 + +This 0 +study 0 +supports 0 +a 0 +hypothesis 0 +that 0 +during 0 +reperfusion 0 +, 0 +a 0 +short 0 +interval 0 +of 0 +hypertension 3 +decreases 0 +brain 3 +injury 4 +and 0 +edema 3 +; 0 +and 0 +that 0 +sustained 0 +hypertension 3 +increases 0 +the 0 +risk 0 +of 0 +vasogenic 3 +edema 4 +. 0 + +People 0 +aged 0 +over 0 +75 0 +in 0 +atrial 3 +fibrillation 4 +on 0 +warfarin 1 +: 0 +the 0 +rate 0 +of 0 +major 0 +hemorrhage 3 +and 0 +stroke 3 +in 0 +more 0 +than 0 +500 0 +patient 0 +- 0 +years 0 +of 0 +follow 0 +- 0 +up 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +determine 0 +the 0 +incidence 0 +of 0 +major 0 +hemorrhage 3 +and 0 +stroke 3 +in 0 +people 0 +aged 0 +76 0 +and 0 +older 0 +with 0 +atrial 3 +fibrillation 4 +on 0 +adjusted 0 +- 0 +dose 0 +warfarin 1 +who 0 +had 0 +been 0 +recently 0 +been 0 +admitted 0 +to 0 +hospital 0 +. 0 + +DESIGN 0 +: 0 +A 0 +retrospective 0 +observational 0 +cohort 0 +study 0 +. 0 + +SETTING 0 +: 0 +A 0 +major 0 +healthcare 0 +network 0 +involving 0 +four 0 +tertiary 0 +hospitals 0 +. 0 + +PARTICIPANTS 0 +: 0 +Two 0 +hundred 0 +thirty 0 +- 0 +five 0 +patients 0 +aged 0 +76 0 +and 0 +older 0 +admitted 0 +to 0 +a 0 +major 0 +healthcare 0 +network 0 +between 0 +July 0 +1 0 +, 0 +2001 0 +, 0 +and 0 +June 0 +30 0 +, 0 +2002 0 +, 0 +with 0 +atrial 3 +fibrillation 4 +on 0 +warfarin 1 +were 0 +enrolled 0 +. 0 + +MEASUREMENTS 0 +: 0 +Information 0 +regarding 0 +major 0 +bleeding 3 +episodes 0 +, 0 +strokes 3 +, 0 +and 0 +warfarin 1 +use 0 +was 0 +obtained 0 +from 0 +patients 0 +, 0 +relatives 0 +, 0 +primary 0 +physicians 0 +, 0 +and 0 +medical 0 +records 0 +. 0 + +RESULTS 0 +: 0 +Two 0 +hundred 0 +twenty 0 +- 0 +eight 0 +patients 0 +( 0 +42 0 +% 0 +men 0 +) 0 +with 0 +a 0 +mean 0 +age 0 +of 0 +81 0 +. 0 +1 0 +( 0 +range 0 +76 0 +- 0 +94 0 +) 0 +were 0 +included 0 +in 0 +the 0 +analysis 0 +. 0 + +Total 0 +follow 0 +- 0 +up 0 +on 0 +warfarin 1 +was 0 +530 0 +years 0 +( 0 +mean 0 +28 0 +months 0 +) 0 +. 0 + +There 0 +were 0 +53 0 +major 0 +hemorrhages 3 +, 0 +for 0 +an 0 +annual 0 +rate 0 +of 0 +10 0 +. 0 +0 0 +% 0 +, 0 +including 0 +24 0 +( 0 +45 0 +. 0 +3 0 +% 0 +) 0 +life 0 +- 0 +threatening 0 +and 0 +five 0 +( 0 +9 0 +. 0 +4 0 +% 0 +) 0 +fatal 0 +bleeds 0 +. 0 + +The 0 +annual 0 +stroke 3 +rate 0 +after 0 +initiation 0 +of 0 +warfarin 1 +was 0 +2 0 +. 0 +6 0 +% 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +rate 0 +of 0 +major 0 +hemorrhage 3 +was 0 +high 0 +in 0 +this 0 +old 0 +, 0 +frail 0 +group 0 +, 0 +but 0 +excluding 0 +fatalities 0 +, 0 +resulted 0 +in 0 +no 0 +long 0 +- 0 +term 0 +sequelae 0 +, 0 +and 0 +the 0 +stroke 3 +rate 0 +on 0 +warfarin 1 +was 0 +low 0 +, 0 +demonstrating 0 +how 0 +effective 0 +warfarin 1 +treatment 0 +is 0 +. 0 + +Safety 0 +of 0 +celecoxib 1 +in 0 +patients 0 +with 0 +adverse 0 +skin 3 +reactions 4 +to 0 +acetaminophen 1 +( 0 +paracetamol 1 +) 0 +and 0 +nimesulide 1 +associated 0 +or 0 +not 0 +with 0 +common 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +. 0 + +BACKGR0UND 0 +: 0 +Acetaminophen 1 +( 0 +paracetamol 1 +- 0 +- 0 +P 1 +) 0 +and 0 +Nimesulide 1 +( 0 +N 1 +) 0 +are 0 +widely 0 +used 0 +analgesic 0 +- 0 +antipyretic 0 +/ 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +. 0 + +The 0 +rate 0 +of 0 +adverse 0 +hypersensitivity 3 +reactions 0 +to 0 +these 0 +agents 0 +is 0 +generally 0 +low 0 +. 0 + +0n 0 +the 0 +contrary 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +are 0 +commonly 0 +involved 0 +in 0 +such 0 +reactions 0 +. 0 + +Celecoxib 1 +( 0 +CE 1 +) 0 +is 0 +a 0 +novel 0 +drug 0 +, 0 +with 0 +high 0 +selectivity 0 +and 0 +affinity 0 +for 0 +C0X 0 +- 0 +2 0 +enzyme 0 +. 0 + +0BJECTIVE 0 +: 0 +We 0 +evaluated 0 +the 0 +tolerability 0 +of 0 +CE 1 +in 0 +a 0 +group 0 +of 0 +patients 0 +with 0 +documented 0 +history 0 +of 0 +adverse 0 +cutaneous 3 +reactions 4 +to 0 +P 1 +and 0 +N 1 +associated 0 +or 0 +not 0 +to 0 +classic 0 +NSAIDs 0 +. 0 + +METH0DS 0 +: 0 +We 0 +studied 0 +9 0 +patients 0 +with 0 +hypersensitivity 3 +to 0 +P 1 +and 0 +N 1 +with 0 +or 0 +without 0 +associated 0 +reactions 0 +to 0 +classic 0 +NSAIDs 0 +. 0 + +The 0 +diagnosis 0 +of 0 +P 1 +and 0 +N 1 +- 0 +induced 0 +skin 3 +reactions 4 +was 0 +based 0 +in 0 +vivo 0 +challenge 0 +. 0 + +The 0 +placebo 0 +was 0 +blindly 0 +administered 0 +at 0 +the 0 +beginning 0 +of 0 +each 0 +challenge 0 +. 0 + +After 0 +three 0 +days 0 +, 0 +a 0 +cumulative 0 +dosage 0 +of 0 +200 0 +mg 0 +of 0 +CE 1 +in 0 +refracted 0 +doses 0 +were 0 +given 0 +. 0 + +After 0 +2 0 +- 0 +3 0 +days 0 +, 0 +a 0 +single 0 +dose 0 +of 0 +200 0 +mg 0 +was 0 +administered 0 +. 0 + +All 0 +patients 0 +were 0 +observed 0 +for 0 +6 0 +hours 0 +after 0 +each 0 +challenge 0 +, 0 +and 0 +controlled 0 +again 0 +after 0 +24 0 +hours 0 +to 0 +exclude 0 +delayed 0 +reactions 0 +. 0 + +The 0 +challenge 0 +was 0 +considered 0 +positive 0 +if 0 +one 0 +or 0 +more 0 +of 0 +the 0 +following 0 +appeared 0 +: 0 +erythema 3 +, 0 +rush 0 +or 0 +urticaria 3 +- 0 +angioedema 3 +. 0 + +RESULTS 0 +: 0 +No 0 +reaction 0 +was 0 +observed 0 +with 0 +placebo 0 +and 0 +eight 0 +patients 0 +( 0 +88 0 +. 0 +8 0 +% 0 +) 0 +tolerated 0 +CE 1 +. 0 + +0nly 0 +one 0 +patient 0 +developed 0 +a 0 +moderate 0 +angioedema 3 +of 0 +the 0 +lips 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0nly 0 +one 0 +hypersensitivity 3 +reaction 0 +to 0 +CE 1 +was 0 +documented 0 +among 0 +9 0 +P 1 +and 0 +N 1 +- 0 +highly 0 +NSAIDs 0 +intolerant 0 +patients 0 +. 0 + +Thus 0 +, 0 +we 0 +conclude 0 +that 0 +CE 1 +is 0 +a 0 +reasonably 0 +safe 0 +alternative 0 +to 0 +be 0 +used 0 +in 0 +subjects 0 +who 0 +do 0 +not 0 +tolerate 0 +P 1 +and 0 +N 1 +. 0 + +Case 0 +- 0 +control 0 +study 0 +of 0 +regular 0 +analgesic 0 +and 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +use 0 +and 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +. 0 + +BACKGR0UND 0 +: 0 +Studies 0 +on 0 +the 0 +association 0 +between 0 +the 0 +long 0 +- 0 +term 0 +use 0 +of 0 +aspirin 1 +and 0 +other 0 +analgesic 0 +and 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +and 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +( 0 +ESRD 3 +) 0 +have 0 +given 0 +conflicting 0 +results 0 +. 0 + +In 0 +order 0 +to 0 +examine 0 +this 0 +association 0 +, 0 +a 0 +case 0 +- 0 +control 0 +study 0 +with 0 +incident 0 +cases 0 +of 0 +ESRD 3 +was 0 +carried 0 +out 0 +. 0 + +METH0DS 0 +: 0 +The 0 +cases 0 +were 0 +all 0 +patients 0 +entering 0 +the 0 +local 0 +dialysis 0 +program 0 +because 0 +of 0 +ESRD 3 +in 0 +the 0 +study 0 +area 0 +between 0 +June 0 +1 0 +, 0 +1995 0 +and 0 +November 0 +30 0 +, 0 +1997 0 +. 0 + +They 0 +were 0 +classified 0 +according 0 +to 0 +the 0 +underlying 0 +disease 0 +, 0 +which 0 +had 0 +presumably 0 +led 0 +them 0 +to 0 +ESRD 3 +. 0 + +Controls 0 +were 0 +patients 0 +admitted 0 +to 0 +the 0 +same 0 +hospitals 0 +from 0 +where 0 +the 0 +cases 0 +arose 0 +, 0 +also 0 +matched 0 +by 0 +age 0 +and 0 +sex 0 +. 0 + +0dds 0 +ratios 0 +were 0 +calculated 0 +using 0 +a 0 +conditional 0 +logistic 0 +model 0 +, 0 +including 0 +potential 0 +confounding 0 +factors 0 +, 0 +both 0 +for 0 +the 0 +whole 0 +study 0 +population 0 +and 0 +for 0 +the 0 +various 0 +underlying 0 +diseases 0 +. 0 + +RESULTS 0 +: 0 +Five 0 +hundred 0 +and 0 +eighty 0 +- 0 +three 0 +cases 0 +and 0 +1190 0 +controls 0 +were 0 +included 0 +in 0 +the 0 +analysis 0 +. 0 + +Long 0 +- 0 +term 0 +use 0 +of 0 +any 0 +analgesic 0 +was 0 +associated 0 +with 0 +an 0 +overall 0 +odds 0 +ratio 0 +of 0 +1 0 +. 0 +22 0 +( 0 +95 0 +% 0 +CI 0 +, 0 +0 0 +. 0 +89 0 +- 0 +1 0 +. 0 +66 0 +) 0 +. 0 + +For 0 +specific 0 +groups 0 +of 0 +drugs 0 +, 0 +the 0 +risks 0 +were 0 +1 0 +. 0 +56 0 +( 0 +1 0 +. 0 +05 0 +- 0 +2 0 +. 0 +30 0 +) 0 +for 0 +aspirin 1 +, 0 +1 0 +. 0 +03 0 +( 0 +0 0 +. 0 +60 0 +- 0 +1 0 +. 0 +76 0 +) 0 +for 0 +pyrazolones 1 +, 0 +0 0 +. 0 +80 0 +( 0 +0 0 +. 0 +39 0 +- 0 +1 0 +. 0 +63 0 +) 0 +for 0 +paracetamol 1 +, 0 +and 0 +0 0 +. 0 +94 0 +( 0 +0 0 +. 0 +57 0 +- 0 +1 0 +. 0 +56 0 +) 0 +for 0 +nonaspirin 0 +NSAIDs 0 +. 0 + +The 0 +risk 0 +of 0 +ESRD 3 +associated 0 +with 0 +aspirin 1 +was 0 +related 0 +to 0 +the 0 +cumulated 0 +dose 0 +and 0 +duration 0 +of 0 +use 0 +, 0 +and 0 +it 0 +was 0 +particularly 0 +high 0 +among 0 +the 0 +subset 0 +of 0 +patients 0 +with 0 +vascular 0 +nephropathy 3 +as 0 +underlying 0 +disease 0 +[ 0 +2 0 +. 0 +35 0 +( 0 +1 0 +. 0 +17 0 +- 0 +4 0 +. 0 +72 0 +) 0 +] 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +data 0 +indicate 0 +that 0 +long 0 +- 0 +term 0 +use 0 +of 0 +nonaspirin 0 +analgesic 0 +drugs 0 +and 0 +NSAIDs 0 +is 0 +not 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +of 0 +ESRD 3 +. 0 + +However 0 +, 0 +the 0 +chronic 0 +use 0 +of 0 +aspirin 1 +may 0 +increase 0 +the 0 +risk 0 +of 0 +ESRD 3 +. 0 + +Two 0 +cases 0 +of 0 +amisulpride 1 +overdose 3 +: 0 +a 0 +cause 0 +for 0 +prolonged 3 +QT 4 +syndrome 4 +. 0 + +Two 0 +cases 0 +of 0 +deliberate 0 +self 0 +- 0 +poisoning 3 +with 0 +5 0 +g 0 +and 0 +3 0 +. 0 +6 0 +g 0 +of 0 +amisulpride 1 +, 0 +respectively 0 +, 0 +are 0 +reported 0 +. 0 + +In 0 +both 0 +cases 0 +, 0 +QT 3 +prolongation 4 +and 0 +hypocalcaemia 3 +were 0 +noted 0 +. 0 + +The 0 +QT 3 +prolongation 4 +appeared 0 +to 0 +respond 0 +to 0 +administration 0 +of 0 +i 0 +. 0 +v 0 +. 0 +calcium 1 +gluconate 2 +. 0 + +Growth 0 +- 0 +associated 0 +protein 0 +43 0 +expression 0 +in 0 +hippocampal 0 +molecular 0 +layer 0 +of 0 +chronic 0 +epileptic 3 +rats 0 +treated 0 +with 0 +cycloheximide 1 +. 0 + +PURP0SE 0 +: 0 +GAP43 0 +has 0 +been 0 +thought 0 +to 0 +be 0 +linked 0 +with 0 +mossy 0 +fiber 0 +sprouting 0 +( 0 +MFS 0 +) 0 +in 0 +various 0 +experimental 0 +models 0 +of 0 +epilepsy 3 +. 0 + +To 0 +investigate 0 +how 0 +GAP43 0 +expression 0 +( 0 +GAP43 0 +- 0 +ir 0 +) 0 +correlates 0 +with 0 +MFS 0 +, 0 +we 0 +assessed 0 +the 0 +intensity 0 +( 0 +densitometry 0 +) 0 +and 0 +extension 0 +( 0 +width 0 +) 0 +of 0 +GAP43 0 +- 0 +ir 0 +in 0 +the 0 +inner 0 +molecular 0 +layer 0 +of 0 +the 0 +dentate 0 +gyrus 0 +( 0 +IML 0 +) 0 +of 0 +rats 0 +subject 0 +to 0 +status 3 +epilepticus 4 +induced 0 +by 0 +pilocarpine 1 +( 0 +Pilo 1 +) 0 +, 0 +previously 0 +injected 0 +or 0 +not 0 +with 0 +cycloheximide 1 +( 0 +CHX 1 +) 0 +, 0 +which 0 +has 0 +been 0 +shown 0 +to 0 +inhibit 0 +MFS 0 +. 0 + +METH0DS 0 +: 0 +CHX 1 +was 0 +injected 0 +before 0 +the 0 +Pilo 1 +injection 0 +in 0 +adult 0 +Wistar 0 +rats 0 +. 0 + +The 0 +Pilo 1 +group 0 +was 0 +injected 0 +with 0 +the 0 +same 0 +drugs 0 +, 0 +except 0 +for 0 +CHX 1 +. 0 + +Animals 0 +were 0 +killed 0 +between 0 +30 0 +and 0 +60 0 +days 0 +later 0 +, 0 +and 0 +brain 0 +sections 0 +were 0 +processed 0 +for 0 +GAP43 0 +immunohistochemistry 0 +. 0 + +RESULTS 0 +: 0 +Densitometry 0 +showed 0 +no 0 +significant 0 +difference 0 +regarding 0 +GAP43 0 +- 0 +ir 0 +in 0 +the 0 +IML 0 +between 0 +Pilo 1 +, 0 +CHX 1 ++ 0 +Pilo 1 +, 0 +and 0 +control 0 +groups 0 +. 0 + +However 0 +, 0 +the 0 +results 0 +of 0 +the 0 +width 0 +of 0 +the 0 +GAP43 0 +- 0 +ir 0 +band 0 +in 0 +the 0 +IML 0 +showed 0 +that 0 +CHX 1 ++ 0 +Pilo 1 +and 0 +control 0 +animals 0 +had 0 +a 0 +significantly 0 +larger 0 +band 0 +( 0 +p 0 += 0 +0 0 +. 0 +03 0 +) 0 +as 0 +compared 0 +with 0 +that 0 +in 0 +the 0 +Pilo 1 +group 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0ur 0 +current 0 +finding 0 +that 0 +animals 0 +in 0 +the 0 +CHX 1 ++ 0 +Pilo 1 +group 0 +have 0 +a 0 +GAP43 0 +- 0 +ir 0 +band 0 +in 0 +the 0 +IML 0 +, 0 +similar 0 +to 0 +that 0 +of 0 +controls 0 +, 0 +reinforces 0 +prior 0 +data 0 +on 0 +the 0 +blockade 0 +of 0 +MFS 0 +in 0 +these 0 +animals 0 +. 0 + +The 0 +change 0 +in 0 +GAP43 0 +- 0 +ir 0 +present 0 +in 0 +Pilo 1 +- 0 +treated 0 +animals 0 +was 0 +a 0 +thinning 0 +of 0 +the 0 +band 0 +to 0 +a 0 +very 0 +narrow 0 +layer 0 +just 0 +above 0 +the 0 +granule 0 +cell 0 +layer 0 +that 0 +is 0 +likely 0 +to 0 +be 0 +associated 0 +with 0 +the 0 +loss 0 +of 0 +hilar 0 +cell 0 +projections 0 +that 0 +express 0 +GAP 0 +- 0 +43 0 +. 0 + +Nicotine 1 +antagonizes 0 +caffeine 1 +- 0 +but 0 +not 0 +pentylenetetrazole 1 +- 0 +induced 0 +anxiogenic 0 +effect 0 +in 0 +mice 0 +. 0 + +RATI0NALE 0 +: 0 +Nicotine 1 +and 0 +caffeine 1 +are 0 +widely 0 +consumed 0 +licit 0 +psychoactive 0 +drugs 0 +worldwide 0 +. 0 + +Epidemiological 0 +studies 0 +showed 0 +that 0 +they 0 +were 0 +generally 0 +used 0 +concurrently 0 +. 0 + +Although 0 +some 0 +studies 0 +in 0 +experimental 0 +animals 0 +indicate 0 +clear 0 +pharmacological 0 +interactions 0 +between 0 +them 0 +, 0 +no 0 +studies 0 +have 0 +shown 0 +a 0 +specific 0 +interaction 0 +on 0 +anxiety 3 +responses 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +present 0 +study 0 +investigates 0 +the 0 +effects 0 +of 0 +nicotine 1 +on 0 +anxiety 3 +induced 0 +by 0 +caffeine 1 +and 0 +another 0 +anxiogenic 0 +drug 0 +, 0 +pentylenetetrazole 1 +, 0 +in 0 +mice 0 +. 0 + +The 0 +elevated 0 +plus 0 +- 0 +maze 0 +( 0 +EPM 0 +) 0 +test 0 +was 0 +used 0 +to 0 +evaluate 0 +the 0 +effects 0 +of 0 +drugs 0 +on 0 +anxiety 3 +. 0 + +METH0DS 0 +: 0 +Adult 0 +male 0 +Swiss 0 +Webster 0 +mice 0 +( 0 +25 0 +- 0 +32 0 +g 0 +) 0 +were 0 +given 0 +nicotine 1 +( 0 +0 0 +. 0 +05 0 +- 0 +0 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +or 0 +saline 0 +10 0 +min 0 +before 0 +caffeine 1 +( 0 +70 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +or 0 +pentylenetetrazole 1 +( 0 +15 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +injections 0 +. 0 + +After 0 +15 0 +min 0 +, 0 +mice 0 +were 0 +evaluated 0 +for 0 +their 0 +open 0 +- 0 +and 0 +closed 0 +- 0 +arm 0 +time 0 +and 0 +entries 0 +on 0 +the 0 +EPM 0 +for 0 +a 0 +10 0 +- 0 +min 0 +session 0 +. 0 + +Locomotor 0 +activity 0 +was 0 +recorded 0 +for 0 +individual 0 +groups 0 +by 0 +using 0 +the 0 +same 0 +treatment 0 +protocol 0 +with 0 +the 0 +EPM 0 +test 0 +. 0 + +RESULTS 0 +: 0 +Nicotine 1 +( 0 +0 0 +. 0 +05 0 +- 0 +0 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +) 0 +itself 0 +did 0 +not 0 +produce 0 +any 0 +significant 0 +effect 0 +in 0 +the 0 +EPM 0 +test 0 +, 0 +whereas 0 +caffeine 1 +( 0 +70 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +pentylenetetrazole 1 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +produced 0 +an 0 +anxiogenic 0 +effect 0 +, 0 +apparent 0 +with 0 +decreases 0 +in 0 +open 0 +- 0 +arm 0 +time 0 +and 0 +entry 0 +. 0 + +Nicotine 1 +( 0 +0 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +) 0 +pretreatment 0 +blocked 0 +the 0 +caffeine 1 +- 0 +but 0 +not 0 +pentylenetetrazole 1 +- 0 +induced 0 +anxiety 3 +. 0 + +Administration 0 +of 0 +each 0 +drug 0 +and 0 +their 0 +combinations 0 +did 0 +not 0 +produce 0 +any 0 +effect 0 +on 0 +locomotor 0 +activity 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0ur 0 +results 0 +suggest 0 +that 0 +the 0 +antagonistic 0 +effect 0 +of 0 +nicotine 1 +on 0 +caffeine 1 +- 0 +induced 0 +anxiety 3 +is 0 +specific 0 +to 0 +caffeine 1 +, 0 +instead 0 +of 0 +a 0 +non 0 +- 0 +specific 0 +anxiolytic 0 +effect 0 +. 0 + +Thus 0 +, 0 +it 0 +may 0 +extend 0 +the 0 +current 0 +findings 0 +on 0 +the 0 +interaction 0 +between 0 +nicotine 1 +and 0 +caffeine 1 +. 0 + +Long 0 +term 0 +hormone 0 +therapy 0 +for 0 +perimenopausal 0 +and 0 +postmenopausal 0 +women 0 +. 0 + +BACKGR0UND 0 +: 0 +Hormone 0 +therapy 0 +( 0 +HT 0 +) 0 +is 0 +widely 0 +used 0 +for 0 +controlling 0 +menopausal 3 +symptoms 4 +. 0 + +It 0 +has 0 +also 0 +been 0 +used 0 +for 0 +the 0 +management 0 +and 0 +prevention 0 +of 0 +cardiovascular 3 +disease 4 +, 0 +osteoporosis 3 +and 0 +dementia 3 +in 0 +older 0 +women 0 +but 0 +the 0 +evidence 0 +supporting 0 +its 0 +use 0 +for 0 +these 0 +indications 0 +is 0 +largely 0 +observational 0 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +assess 0 +the 0 +effect 0 +of 0 +long 0 +- 0 +term 0 +HT 0 +on 0 +mortality 0 +, 0 +heart 3 +disease 4 +, 0 +venous 3 +thromboembolism 4 +, 0 +stroke 3 +, 0 +transient 3 +ischaemic 4 +attacks 4 +, 0 +breast 3 +cancer 4 +, 0 +colorectal 3 +cancer 4 +, 0 +ovarian 3 +cancer 4 +, 0 +endometrial 3 +cancer 4 +, 0 +gallbladder 3 +disease 4 +, 0 +cognitive 0 +function 0 +, 0 +dementia 3 +, 0 +fractures 3 +and 0 +quality 0 +of 0 +life 0 +. 0 + +SEARCH 0 +STRATEGY 0 +: 0 +We 0 +searched 0 +the 0 +following 0 +databases 0 +up 0 +to 0 +November 0 +2004 0 +: 0 +the 0 +Cochrane 0 +Menstrual 0 +Disorders 0 +and 0 +Subfertility 0 +Group 0 +Trials 0 +Register 0 +, 0 +Cochrane 0 +Central 0 +Register 0 +of 0 +Controlled 0 +Trials 0 +( 0 +CENTRAL 0 +) 0 +, 0 +MEDLINE 0 +, 0 +EMBASE 0 +, 0 +Biological 0 +Abstracts 0 +. 0 + +Relevant 0 +non 0 +- 0 +indexed 0 +journals 0 +and 0 +conference 0 +abstracts 0 +were 0 +also 0 +searched 0 +. 0 + +SELECTI0N 0 +CRITERIA 0 +: 0 +Randomised 0 +double 0 +- 0 +blind 0 +trials 0 +of 0 +HT 0 +( 0 +oestrogens 1 +with 0 +or 0 +without 0 +progestogens 1 +) 0 +versus 0 +placebo 0 +, 0 +taken 0 +for 0 +at 0 +least 0 +one 0 +year 0 +by 0 +perimenopausal 0 +or 0 +postmenopausal 0 +women 0 +. 0 + +DATA 0 +C0LLECTI0N 0 +AND 0 +ANALYSIS 0 +: 0 +Fifteen 0 +RCTs 0 +were 0 +included 0 +. 0 + +Trials 0 +were 0 +assessed 0 +for 0 +quality 0 +and 0 +two 0 +review 0 +authors 0 +extracted 0 +data 0 +independently 0 +. 0 + +They 0 +calculated 0 +risk 0 +ratios 0 +for 0 +dichotomous 0 +outcomes 0 +and 0 +weighted 0 +mean 0 +differences 0 +for 0 +continuous 0 +outcomes 0 +. 0 + +Clinical 0 +heterogeneity 0 +precluded 0 +meta 0 +- 0 +analysis 0 +for 0 +most 0 +outcomes 0 +. 0 + +MAIN 0 +RESULTS 0 +: 0 +All 0 +the 0 +statistically 0 +significant 0 +results 0 +were 0 +derived 0 +from 0 +the 0 +two 0 +biggest 0 +trials 0 +. 0 + +In 0 +relatively 0 +healthy 0 +women 0 +, 0 +combined 0 +continuous 0 +HT 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +or 0 +coronary 0 +event 0 +( 0 +after 0 +one 0 +year 0 +' 0 +s 0 +use 0 +) 0 +, 0 +stroke 3 +( 0 +after 0 +3 0 +years 0 +) 0 +, 0 +breast 3 +cancer 4 +( 0 +after 0 +5 0 +years 0 +) 0 +and 0 +gallbladder 3 +disease 4 +. 0 + +Long 0 +- 0 +term 0 +oestrogen 1 +- 0 +only 0 +HT 0 +also 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +stroke 3 +and 0 +gallbladder 3 +disease 4 +. 0 + +0verall 0 +, 0 +the 0 +only 0 +statistically 0 +significant 0 +benefits 0 +of 0 +HT 0 +were 0 +a 0 +decreased 0 +incidence 0 +of 0 +fractures 3 +and 0 +colon 3 +cancer 4 +with 0 +long 0 +- 0 +term 0 +use 0 +. 0 + +Among 0 +relatively 0 +healthy 0 +women 0 +over 0 +65 0 +years 0 +taking 0 +continuous 0 +combined 0 +HT 0 +, 0 +there 0 +was 0 +a 0 +statistically 0 +significant 0 +increase 0 +in 0 +the 0 +incidence 0 +of 0 +dementia 3 +. 0 + +Among 0 +women 0 +with 0 +cardiovascular 3 +disease 4 +, 0 +long 0 +- 0 +term 0 +use 0 +of 0 +combined 0 +continuous 0 +HT 0 +significantly 0 +increased 0 +the 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +. 0 + +No 0 +trials 0 +focussed 0 +specifically 0 +on 0 +younger 0 +women 0 +. 0 + +However 0 +, 0 +one 0 +trial 0 +analysed 0 +subgroups 0 +of 0 +2839 0 +relatively 0 +healthy 0 +50 0 +to 0 +59 0 +year 0 +- 0 +old 0 +women 0 +taking 0 +combined 0 +continuous 0 +HT 0 +and 0 +1637 0 +taking 0 +oestrogen 1 +- 0 +only 0 +HT 0 +, 0 +versus 0 +similar 0 +- 0 +sized 0 +placebo 0 +groups 0 +. 0 + +The 0 +only 0 +significantly 0 +increased 0 +risk 0 +reported 0 +was 0 +for 0 +venous 3 +thromboembolism 4 +in 0 +women 0 +taking 0 +combined 0 +continuous 0 +HT 0 +; 0 +their 0 +absolute 0 +risk 0 +remained 0 +very 0 +low 0 +. 0 + +AUTH0RS 0 +' 0 +C0NCLUSI0NS 0 +: 0 +HT 0 +is 0 +not 0 +indicated 0 +for 0 +the 0 +routine 0 +management 0 +of 0 +chronic 3 +disease 4 +. 0 + +We 0 +need 0 +more 0 +evidence 0 +on 0 +the 0 +safety 0 +of 0 +HT 0 +for 0 +menopausal 0 +symptom 0 +control 0 +, 0 +though 0 +short 0 +- 0 +term 0 +use 0 +appears 0 +to 0 +be 0 +relatively 0 +safe 0 +for 0 +healthy 0 +younger 0 +women 0 +. 0 + +Drug 3 +- 4 +induced 4 +liver 4 +injury 4 +: 0 +an 0 +analysis 0 +of 0 +461 0 +incidences 0 +submitted 0 +to 0 +the 0 +Spanish 0 +registry 0 +over 0 +a 0 +10 0 +- 0 +year 0 +period 0 +. 0 + +BACKGR0UND 0 +& 0 +AIMS 0 +: 0 +Progress 0 +in 0 +the 0 +understanding 0 +of 0 +susceptibility 0 +factors 0 +to 0 +drug 3 +- 4 +induced 4 +liver 4 +injury 4 +( 0 +DILI 3 +) 0 +and 0 +outcome 0 +predictability 0 +are 0 +hampered 0 +by 0 +the 0 +lack 0 +of 0 +systematic 0 +programs 0 +to 0 +detect 0 +bona 0 +fide 0 +cases 0 +. 0 + +METH0DS 0 +: 0 +A 0 +cooperative 0 +network 0 +was 0 +created 0 +in 0 +1994 0 +in 0 +Spain 0 +to 0 +identify 0 +all 0 +suspicions 0 +of 0 +DILI 3 +following 0 +a 0 +prospective 0 +structured 0 +report 0 +form 0 +. 0 + +The 0 +liver 3 +damage 4 +was 0 +characterized 0 +according 0 +to 0 +hepatocellular 0 +, 0 +cholestatic 3 +, 0 +and 0 +mixed 0 +laboratory 0 +criteria 0 +and 0 +to 0 +histologic 0 +criteria 0 +when 0 +available 0 +. 0 + +Further 0 +evaluation 0 +of 0 +causality 0 +assessment 0 +was 0 +centrally 0 +performed 0 +. 0 + +RESULTS 0 +: 0 +Since 0 +April 0 +1994 0 +to 0 +August 0 +2004 0 +, 0 +461 0 +out 0 +of 0 +570 0 +submitted 0 +cases 0 +, 0 +involving 0 +505 0 +drugs 0 +, 0 +were 0 +deemed 0 +to 0 +be 0 +related 0 +to 0 +DILI 3 +. 0 + +The 0 +antiinfective 0 +group 0 +of 0 +drugs 0 +was 0 +the 0 +more 0 +frequently 0 +incriminated 0 +, 0 +amoxicillin 1 +- 2 +clavulanate 2 +accounting 0 +for 0 +the 0 +12 0 +. 0 +8 0 +% 0 +of 0 +the 0 +whole 0 +series 0 +. 0 + +The 0 +hepatocellular 0 +pattern 0 +of 0 +damage 0 +was 0 +the 0 +most 0 +common 0 +( 0 +58 0 +% 0 +) 0 +, 0 +was 0 +inversely 0 +correlated 0 +with 0 +age 0 +( 0 +P 0 +< 0 +. 0 +0001 0 +) 0 +, 0 +and 0 +had 0 +the 0 +worst 0 +outcome 0 +( 0 +Cox 0 +regression 0 +, 0 +P 0 +< 0 +. 0 +034 0 +) 0 +. 0 + +Indeed 0 +, 0 +the 0 +incidence 0 +of 0 +liver 0 +transplantation 0 +and 0 +death 0 +in 0 +this 0 +group 0 +was 0 +11 0 +. 0 +7 0 +% 0 +if 0 +patients 0 +had 0 +jaundice 3 +at 0 +presentation 0 +, 0 +whereas 0 +the 0 +corresponding 0 +figure 0 +was 0 +3 0 +. 0 +8 0 +% 0 +in 0 +nonjaundiced 0 +patients 0 +( 0 +P 0 +< 0 +. 0 +04 0 +) 0 +. 0 + +Factors 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +fulminant 3 +hepatic 4 +failure 4 +were 0 +female 0 +sex 0 +( 0 +0R 0 += 0 +25 0 +; 0 +95 0 +% 0 +CI 0 +: 0 +4 0 +. 0 +1 0 +- 0 +151 0 +; 0 +P 0 +< 0 +. 0 +0001 0 +) 0 +, 0 +hepatocellular 0 +damage 0 +( 0 +0R 0 += 0 +7 0 +. 0 +9 0 +; 0 +95 0 +% 0 +CI 0 +: 0 +1 0 +. 0 +6 0 +- 0 +37 0 +; 0 +P 0 +< 0 +. 0 +009 0 +) 0 +, 0 +and 0 +higher 0 +baseline 0 +plasma 0 +bilirubin 1 +value 0 +( 0 +0R 0 += 0 +1 0 +. 0 +15 0 +; 0 +95 0 +% 0 +CI 0 +: 0 +1 0 +. 0 +09 0 +- 0 +1 0 +. 0 +22 0 +; 0 +P 0 +< 0 +. 0 +0001 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Patients 0 +with 0 +drug 0 +- 0 +induced 0 +hepatocellular 0 +jaundice 3 +have 0 +11 0 +. 0 +7 0 +% 0 +chance 0 +of 0 +progressing 0 +to 0 +death 0 +or 0 +transplantation 0 +. 0 + +Amoxicillin 1 +- 2 +clavulanate 2 +stands 0 +out 0 +as 0 +the 0 +most 0 +common 0 +drug 0 +related 0 +to 0 +DILI 3 +. 0 + +Morphological 0 +evaluation 0 +of 0 +the 0 +effect 0 +of 0 +d 1 +- 2 +ribose 2 +on 0 +adriamycin 1 +- 0 +evoked 0 +cardiotoxicity 3 +in 0 +rats 0 +. 0 + +The 0 +influence 0 +of 0 +d 1 +- 2 +ribose 2 +on 0 +adriamycin 1 +- 0 +induced 0 +myocardiopathy 3 +in 0 +rats 0 +was 0 +studied 0 +. 0 + +Adriamycin 1 +in 0 +the 0 +cumulative 0 +dose 0 +of 0 +25 0 +mg 0 +/ 0 +kg 0 +evoked 0 +fully 0 +developed 0 +cardiac 3 +toxicity 4 +. 0 + +D 1 +- 2 +ribose 2 +in 0 +the 0 +multiple 0 +doses 0 +of 0 +200 0 +mg 0 +/ 0 +kg 0 +did 0 +not 0 +influence 0 +ADR 1 +cardiotoxicity 3 +. 0 + +In 0 +vivo 0 +evidences 0 +suggesting 0 +the 0 +role 0 +of 0 +oxidative 0 +stress 0 +in 0 +pathogenesis 0 +of 0 +vancomycin 1 +- 0 +induced 0 +nephrotoxicity 3 +: 0 +protection 0 +by 0 +erdosteine 1 +. 0 + +The 0 +aims 0 +of 0 +this 0 +study 0 +were 0 +to 0 +examine 0 +vancomycin 1 +( 0 +VCM 1 +) 0 +- 0 +induced 0 +oxidative 0 +stress 0 +that 0 +promotes 0 +production 0 +of 0 +reactive 0 +oxygen 1 +species 0 +( 0 +R0S 0 +) 0 +and 0 +to 0 +investigate 0 +the 0 +role 0 +of 0 +erdosteine 1 +, 0 +an 0 +expectorant 0 +agent 0 +, 0 +which 0 +has 0 +also 0 +antioxidant 0 +properties 0 +, 0 +on 0 +kidney 0 +tissue 0 +against 0 +the 0 +possible 0 +VCM 1 +- 0 +induced 0 +renal 3 +impairment 4 +in 0 +rats 0 +. 0 + +Rats 0 +were 0 +divided 0 +into 0 +three 0 +groups 0 +: 0 +sham 0 +, 0 +VCM 1 +and 0 +VCM 1 +plus 0 +erdosteine 1 +. 0 + +VCM 1 +was 0 +administrated 0 +intraperitoneally 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +with 0 +200mgkg 0 +( 0 +- 0 +1 0 +) 0 +twice 0 +daily 0 +for 0 +7 0 +days 0 +. 0 + +Erdosteine 1 +was 0 +administered 0 +orally 0 +. 0 + +VCM 1 +administration 0 +to 0 +control 0 +rats 0 +significantly 0 +increased 0 +renal 0 +malondialdehyde 1 +( 0 +MDA 1 +) 0 +and 0 +urinary 0 +N 0 +- 0 +acetyl 0 +- 0 +beta 0 +- 0 +d 0 +- 0 +glucosaminidase 0 +( 0 +NAG 0 +, 0 +a 0 +marker 0 +of 0 +renal 3 +tubular 4 +injury 4 +) 0 +excretion 0 +but 0 +decreased 0 +superoxide 1 +dismutase 0 +( 0 +S0D 0 +) 0 +and 0 +catalase 0 +( 0 +CAT 0 +) 0 +activities 0 +. 0 + +Erdosteine 1 +administration 0 +with 0 +VCM 1 +injections 0 +caused 0 +significantly 0 +decreased 0 +renal 0 +MDA 1 +and 0 +urinary 0 +NAG 0 +excretion 0 +, 0 +and 0 +increased 0 +S0D 0 +activity 0 +, 0 +but 0 +not 0 +CAT 0 +activity 0 +in 0 +renal 0 +tissue 0 +when 0 +compared 0 +with 0 +VCM 1 +alone 0 +. 0 + +Erdosteine 1 +showed 0 +histopathological 0 +protection 0 +against 0 +VCM 1 +- 0 +induced 0 +nephrotoxicity 3 +. 0 + +There 0 +were 0 +a 0 +significant 0 +dilatation 0 +of 0 +tubular 0 +lumens 0 +, 0 +extensive 0 +epithelial 0 +cell 0 +vacuolization 0 +, 0 +atrophy 3 +, 0 +desquamation 3 +, 0 +and 0 +necrosis 3 +in 0 +VCM 1 +- 0 +treated 0 +rats 0 +more 0 +than 0 +those 0 +of 0 +the 0 +control 0 +and 0 +the 0 +erdosteine 1 +groups 0 +. 0 + +Erdosteine 1 +caused 0 +a 0 +marked 0 +reduction 0 +in 0 +the 0 +extent 0 +of 0 +tubular 0 +damage 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +oxidative 0 +tubular 0 +damage 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +VCM 1 +- 0 +induced 0 +nephrotoxicity 3 +and 0 +the 0 +modulation 0 +of 0 +oxidative 0 +stress 0 +with 0 +erdosteine 1 +reduces 0 +the 0 +VCM 1 +- 0 +induced 0 +kidney 3 +damage 4 +both 0 +at 0 +the 0 +biochemical 0 +and 0 +histological 0 +levels 0 +. 0 + +Gemfibrozil 1 +- 0 +lovastatin 1 +therapy 0 +for 0 +primary 0 +hyperlipoproteinemias 3 +. 0 + +The 0 +specific 0 +aim 0 +of 0 +this 0 +retrospective 0 +, 0 +observational 0 +study 0 +was 0 +to 0 +assess 0 +safety 0 +and 0 +efficacy 0 +of 0 +long 0 +- 0 +term 0 +( 0 +21 0 +months 0 +/ 0 +patient 0 +) 0 +, 0 +open 0 +- 0 +label 0 +, 0 +gemfibrozil 1 +- 0 +lovastatin 1 +treatment 0 +in 0 +80 0 +patients 0 +with 0 +primary 0 +mixed 0 +hyperlipidemia 3 +( 0 +68 0 +% 0 +of 0 +whom 0 +had 0 +atherosclerotic 3 +vascular 4 +disease 4 +) 0 +. 0 + +Because 0 +ideal 0 +lipid 0 +targets 0 +were 0 +not 0 +reached 0 +( 0 +low 0 +- 0 +density 0 +lipoprotein 0 +( 0 +LDL 0 +) 0 +cholesterol 1 +less 0 +than 0 +130 0 +mg 0 +/ 0 +dl 0 +, 0 +high 0 +- 0 +density 0 +lipoprotein 0 +( 0 +HDL 0 +) 0 +cholesterol 1 +greater 0 +than 0 +35 0 +mg 0 +/ 0 +dl 0 +, 0 +or 0 +total 0 +cholesterol 1 +/ 0 +HDL 0 +cholesterol 1 +less 0 +than 0 +4 0 +. 0 +5 0 +mg 0 +/ 0 +dl 0 +) 0 +with 0 +diet 0 +plus 0 +a 0 +single 0 +drug 0 +, 0 +gemfibrozil 1 +( 0 +1 0 +. 0 +2 0 +g 0 +/ 0 +day 0 +) 0 +- 0 +lovastatin 1 +( 0 +primarily 0 +20 0 +or 0 +40 0 +mg 0 +) 0 +treatment 0 +was 0 +given 0 +. 0 + +Follow 0 +- 0 +up 0 +visits 0 +were 0 +scheduled 0 +with 0 +2 0 +- 0 +drug 0 +therapy 0 +every 0 +6 0 +to 0 +8 0 +weeks 0 +, 0 +an 0 +average 0 +of 0 +10 0 +. 0 +3 0 +visits 0 +per 0 +patient 0 +, 0 +with 0 +741 0 +batteries 0 +of 0 +6 0 +liver 0 +function 0 +tests 0 +and 0 +714 0 +creatine 1 +phosphokinase 0 +levels 0 +measured 0 +. 0 + +0nly 0 +1 0 +of 0 +the 0 +4 0 +, 0 +446 0 +liver 0 +function 0 +tests 0 +( 0 +0 0 +. 0 +02 0 +% 0 +) 0 +, 0 +a 0 +gamma 0 +glutamyl 0 +transferase 0 +, 0 +was 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +3 0 +times 0 +the 0 +upper 0 +normal 0 +limit 0 +. 0 + +0f 0 +the 0 +714 0 +creatine 1 +phosphokinase 0 +levels 0 +, 0 +9 0 +% 0 +were 0 +high 0 +; 0 +only 0 +1 0 +( 0 +0 0 +. 0 +1 0 +% 0 +) 0 +was 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +3 0 +times 0 +the 0 +upper 0 +normal 0 +limit 0 +. 0 + +With 0 +2 0 +- 0 +drug 0 +therapy 0 +, 0 +mean 0 +total 0 +cholesterol 1 +decreased 0 +22 0 +% 0 +from 0 +255 0 +to 0 +200 0 +mg 0 +/ 0 +dl 0 +, 0 +triglyceride 1 +levels 0 +decreased 0 +35 0 +% 0 +from 0 +236 0 +to 0 +154 0 +mg 0 +/ 0 +dl 0 +, 0 +LDL 0 +cholesterol 1 +decreased 0 +26 0 +% 0 +from 0 +176 0 +to 0 +131 0 +mg 0 +/ 0 +dl 0 +, 0 +and 0 +the 0 +total 0 +cholesterol 1 +/ 0 +HDL 0 +cholesterol 1 +ratio 0 +decreased 0 +24 0 +% 0 +from 0 +7 0 +. 0 +1 0 +to 0 +5 0 +. 0 +4 0 +, 0 +all 0 +p 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +0 0 +. 0 +0001 0 +. 0 + +Myositis 3 +, 0 +attributable 0 +to 0 +the 0 +drug 0 +combination 0 +and 0 +symptomatic 0 +enough 0 +to 0 +discontinue 0 +it 0 +, 0 +occurred 0 +in 0 +3 0 +% 0 +of 0 +patients 0 +, 0 +and 0 +in 0 +1 0 +% 0 +with 0 +concurrent 0 +high 0 +creatine 1 +phosphokinase 0 +( 0 +769 0 +U 0 +/ 0 +liter 0 +) 0 +; 0 +no 0 +patients 0 +had 0 +rhabdomyolysis 3 +or 0 +myoglobinuria 3 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Does 0 +domperidone 1 +potentiate 0 +mirtazapine 1 +- 0 +associated 0 +restless 3 +legs 4 +syndrome 4 +? 0 + +There 0 +is 0 +now 0 +evidence 0 +to 0 +suggest 0 +a 0 +central 0 +role 0 +for 0 +the 0 +dopaminergic 0 +system 0 +in 0 +restless 3 +legs 4 +syndrome 4 +( 0 +RLS 3 +) 0 +. 0 + +For 0 +example 0 +, 0 +the 0 +symptoms 0 +of 0 +RLS 3 +can 0 +be 0 +dramatically 0 +improved 0 +by 0 +levodopa 1 +and 0 +dopamine 1 +agonists 0 +, 0 +whereas 0 +central 0 +dopamine 1 +D2 0 +receptor 0 +antagonists 0 +can 0 +induce 0 +or 0 +aggravate 0 +RLS 3 +symptoms 0 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +there 0 +is 0 +no 0 +previous 0 +report 0 +regarding 0 +whether 0 +domperidone 1 +, 0 +a 0 +peripheral 0 +dopamine 1 +D2 0 +receptor 0 +antagonist 0 +, 0 +can 0 +also 0 +induce 0 +or 0 +aggravate 0 +symptoms 0 +of 0 +RLS 3 +. 0 + +Mirtazapine 1 +, 0 +the 0 +first 0 +noradrenergic 0 +and 0 +specific 0 +serotonergic 0 +antidepressant 0 +( 0 +NaSSA 0 +) 0 +, 0 +has 0 +been 0 +associated 0 +with 0 +RLS 3 +in 0 +several 0 +recent 0 +publications 0 +. 0 + +The 0 +authors 0 +report 0 +here 0 +a 0 +depressed 0 +patient 0 +comorbid 0 +with 0 +postprandial 3 +dyspepsia 4 +who 0 +developed 0 +RLS 3 +after 0 +mirtazapine 1 +had 0 +been 0 +added 0 +to 0 +his 0 +domperidone 1 +therapy 0 +. 0 + +0ur 0 +patient 0 +started 0 +to 0 +have 0 +symptoms 0 +of 0 +RLS 3 +only 0 +after 0 +he 0 +had 0 +been 0 +treated 0 +with 0 +mirtazapine 1 +, 0 +and 0 +his 0 +RLS 3 +symptoms 0 +resolved 0 +completely 0 +upon 0 +discontinuation 0 +of 0 +his 0 +mirtazapine 1 +. 0 + +Such 0 +a 0 +temporal 0 +relationship 0 +between 0 +the 0 +use 0 +of 0 +mirtazapine 1 +and 0 +the 0 +symptoms 0 +of 0 +RLS 3 +in 0 +our 0 +patient 0 +did 0 +not 0 +support 0 +a 0 +potentiating 0 +effect 0 +of 0 +domperione 1 +on 0 +mirtazapine 1 +- 0 +associated 0 +RLS 3 +. 0 + +However 0 +, 0 +physicians 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +possibility 0 +that 0 +mirtazapine 1 +can 0 +be 0 +associated 0 +with 0 +RLS 3 +in 0 +some 0 +individuals 0 +, 0 +especially 0 +those 0 +receiving 0 +concomitant 0 +dopamine 1 +D2 0 +receptor 0 +antagonists 0 +. 0 + +Antiandrogenic 0 +therapy 0 +can 0 +cause 0 +coronary 3 +arterial 4 +disease 4 +. 0 + +AIM 0 +: 0 +To 0 +study 0 +the 0 +change 0 +of 0 +lipid 0 +metabolism 0 +by 0 +antiandrogen 0 +therapy 0 +in 0 +patients 0 +with 0 +prostate 3 +cancer 4 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +We 0 +studied 0 +with 0 +a 0 +2 0 +. 0 +5 0 +years 0 +follow 0 +- 0 +up 0 +the 0 +changes 0 +in 0 +plasma 0 +cholesterols 1 +( 0 +C 1 +) 0 +, 0 +triglycerides 1 +( 0 +TG 1 +) 0 +, 0 +lipoproteins 0 +( 0 +LP 0 +) 0 +, 0 +and 0 +apolipoproteins 0 +( 0 +Apo 0 +) 0 +B 0 +- 0 +100 0 +, 0 +A 0 +- 0 +I 0 +, 0 +and 0 +A 0 +- 0 +II 0 +pro 0 +fi 0 +les 0 +in 0 +24 0 +patients 0 +of 0 +mean 0 +age 0 +60 0 +years 0 +with 0 +low 0 +risk 0 +prostate 3 +cancer 4 +( 0 +stage 0 +: 0 +T1cN0M0 0 +, 0 +Gleason 0 +score 0 +: 0 +2 0 +- 0 +5 0 +) 0 +during 0 +treatment 0 +with 0 +cyproterone 1 +acetate 2 +( 0 +CPA 1 +) 0 +without 0 +surgical 0 +management 0 +or 0 +radiation 0 +therapy 0 +. 0 + +RESULTS 0 +: 0 +Significant 0 +decreases 0 +of 0 +HDL 0 +- 0 +C 0 +, 0 +Apo 0 +A 0 +- 0 +I 0 +and 0 +Apo 0 +A 0 +- 0 +II 0 +and 0 +an 0 +increase 0 +of 0 +triglyceride 1 +levels 0 +in 0 +VLDL 0 +were 0 +induced 0 +by 0 +CPA 1 +. 0 + +After 0 +a 0 +period 0 +of 0 +2 0 +. 0 +5 0 +years 0 +on 0 +CPA 1 +treatment 0 +, 0 +four 0 +patients 0 +out 0 +of 0 +twenty 0 +- 0 +four 0 +were 0 +found 0 +to 0 +be 0 +affected 0 +by 0 +coronary 3 +heart 4 +disease 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Ischaemic 0 +coronary 3 +arteriosclerosis 4 +with 0 +an 0 +incidence 0 +rate 0 +of 0 +16 0 +. 0 +6 0 +% 0 +as 0 +caused 0 +by 0 +prolonged 0 +CPA 1 +therapy 0 +is 0 +mediated 0 +through 0 +changes 0 +in 0 +HDL 0 +cholesterol 1 +, 0 +Apo 0 +A 0 +- 0 +I 0 +and 0 +Apo 0 +A 0 +- 0 +II 0 +pro 0 +fi 0 +les 0 +, 0 +other 0 +than 0 +the 0 +well 0 +- 0 +known 0 +hyperglyceridemic 3 +effect 4 +caused 0 +by 0 +estrogen 1 +. 0 + +5 1 +- 2 +Fluorouracil 2 +cardiotoxicity 3 +induced 0 +by 0 +alpha 1 +- 2 +fluoro 2 +- 2 +beta 2 +- 2 +alanine 2 +. 0 + +Cardiotoxicity 3 +is 0 +a 0 +rare 0 +complication 0 +occurring 0 +during 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +treatment 0 +for 0 +malignancies 3 +. 0 + +We 0 +herein 0 +report 0 +the 0 +case 0 +of 0 +a 0 +70 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +5 1 +- 2 +FU 2 +- 0 +induced 0 +cardiotoxicity 3 +, 0 +in 0 +whom 0 +a 0 +high 0 +serum 0 +level 0 +of 0 +alpha 1 +- 2 +fluoro 2 +- 2 +beta 2 +- 2 +alanine 2 +( 0 +FBAL 1 +) 0 +was 0 +observed 0 +. 0 + +The 0 +patient 0 +, 0 +who 0 +had 0 +unresectable 0 +colon 3 +cancer 4 +metastases 0 +to 0 +the 0 +liver 0 +and 0 +lung 0 +, 0 +was 0 +referred 0 +to 0 +us 0 +for 0 +chemotherapy 0 +from 0 +an 0 +affiliated 0 +hospital 0 +; 0 +he 0 +had 0 +no 0 +cardiac 0 +history 0 +. 0 + +After 0 +admission 0 +, 0 +the 0 +patient 0 +received 0 +a 0 +continuous 0 +intravenous 0 +infusion 0 +of 0 +5 1 +- 2 +FU 2 +( 0 +1000 0 +mg 0 +/ 0 +day 0 +) 0 +, 0 +during 0 +which 0 +precordial 3 +pain 4 +with 0 +right 3 +bundle 4 +branch 4 +block 4 +occurred 0 +concomitantly 0 +with 0 +a 0 +high 0 +serum 0 +FBAL 1 +concentration 0 +of 0 +1955 0 +ng 0 +/ 0 +ml 0 +. 0 + +Both 0 +the 0 +precordial 3 +pain 4 +and 0 +the 0 +electrocardiographic 0 +changes 0 +disappeared 0 +spontaneously 0 +after 0 +the 0 +discontinuation 0 +of 0 +5 1 +- 2 +FU 2 +. 0 + +As 0 +the 0 +precordial 3 +pain 4 +in 0 +this 0 +patient 0 +was 0 +considered 0 +to 0 +have 0 +been 0 +due 0 +to 0 +5 1 +- 2 +FU 2 +- 0 +induced 0 +cardiotoxicity 3 +, 0 +the 0 +administration 0 +of 0 +5 1 +- 2 +FU 2 +was 0 +abandoned 0 +. 0 + +Instead 0 +, 0 +oral 0 +administration 0 +of 0 +S 0 +- 0 +1 0 +( 0 +a 0 +derivative 0 +of 0 +5 1 +- 2 +FU 2 +) 0 +, 0 +at 0 +200 0 +mg 0 +/ 0 +day 0 +twice 0 +a 0 +week 0 +, 0 +was 0 +instituted 0 +, 0 +because 0 +S 0 +- 0 +1 0 +has 0 +a 0 +strong 0 +inhibitory 0 +effect 0 +on 0 +dihydropyrimidine 1 +dehydrogenase 0 +, 0 +which 0 +catalyzes 0 +the 0 +degradative 0 +of 0 +5 1 +- 2 +FU 2 +into 0 +FBAL 1 +. 0 + +The 0 +serum 0 +FBAL 1 +concentration 0 +subsequently 0 +decreased 0 +to 0 +352 0 +ng 0 +/ 0 +ml 0 +, 0 +the 0 +same 0 +as 0 +the 0 +value 0 +measured 0 +on 0 +the 0 +first 0 +day 0 +of 0 +S 0 +- 0 +1 0 +administration 0 +. 0 + +Thereafter 0 +, 0 +no 0 +cardiac 3 +symptoms 4 +were 0 +observed 0 +. 0 + +The 0 +patient 0 +achieved 0 +a 0 +partial 0 +response 0 +6 0 +months 0 +after 0 +the 0 +initiation 0 +of 0 +the 0 +S 0 +- 0 +1 0 +treatment 0 +. 0 + +The 0 +experience 0 +of 0 +this 0 +case 0 +, 0 +together 0 +with 0 +a 0 +review 0 +of 0 +the 0 +literature 0 +, 0 +suggests 0 +that 0 +FBAL 1 +is 0 +related 0 +to 0 +5 1 +- 2 +FU 2 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +S 0 +- 0 +1 0 +may 0 +be 0 +administered 0 +safely 0 +to 0 +patients 0 +with 0 +5 1 +- 2 +FU 2 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +Hepatocellular 3 +carcinoma 4 +in 0 +Fanconi 3 +' 4 +s 4 +anemia 4 +treated 0 +with 0 +androgen 1 +and 0 +corticosteroid 1 +. 0 + +The 0 +case 0 +of 0 +an 0 +11 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +is 0 +reported 0 +who 0 +was 0 +known 0 +to 0 +have 0 +Fanconi 3 +' 4 +s 4 +anemia 4 +for 0 +3 0 +years 0 +and 0 +was 0 +treated 0 +with 0 +androgens 1 +, 0 +corticosteroids 1 +and 0 +transfusions 0 +. 0 + +Two 0 +weeks 0 +before 0 +his 0 +death 0 +he 0 +was 0 +readmitted 0 +because 0 +of 0 +aplastic 0 +crisis 0 +with 0 +septicemia 3 +and 0 +marked 0 +abnormalities 0 +in 0 +liver 0 +function 0 +and 0 +died 0 +of 0 +hemorrhagic 3 +bronchopneumonia 4 +. 0 + +At 0 +autopsy 0 +peliosis 3 +and 0 +multiple 0 +hepatic 3 +tumors 4 +were 0 +found 0 +which 0 +histologically 0 +proved 0 +to 0 +be 0 +well 0 +- 0 +differentiated 0 +hepatocellular 3 +carcinoma 4 +. 0 + +This 0 +case 0 +contributes 0 +to 0 +the 0 +previous 0 +observations 0 +that 0 +non 0 +- 0 +metastasizing 0 +hepatic 3 +neoplasms 4 +and 0 +peliosis 3 +can 0 +develop 0 +in 0 +patients 0 +with 0 +androgen 1 +- 0 +and 0 +corticosteroid 1 +- 0 +treated 0 +Fanconi 3 +' 4 +s 4 +anemia 4 +. 0 + +The 0 +influence 0 +of 0 +the 0 +time 0 +interval 0 +between 0 +monoHER 1 +and 0 +doxorubicin 1 +administration 0 +on 0 +the 0 +protection 0 +against 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +mice 0 +. 0 + +PURP0SE 0 +: 0 +Despite 0 +its 0 +well 0 +- 0 +known 0 +cardiotoxicity 3 +, 0 +the 0 +anthracyclin 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +continues 0 +to 0 +be 0 +an 0 +effective 0 +and 0 +widely 0 +used 0 +chemotherapeutic 0 +agent 0 +. 0 + +D0X 1 +- 0 +induced 0 +cardiac 3 +damage 4 +presumably 0 +results 0 +from 0 +the 0 +formation 0 +of 0 +free 0 +radicals 0 +by 0 +D0X 1 +. 0 + +Reactive 0 +oxygen 1 +species 0 +particularly 0 +affect 0 +the 0 +cardiac 0 +myocytes 0 +because 0 +these 0 +cells 0 +seem 0 +to 0 +have 0 +a 0 +relatively 0 +poor 0 +antioxidant 0 +defense 0 +system 0 +. 0 + +The 0 +semisynthetic 0 +flavonoid 1 +monohydroxyethylrutoside 1 +( 0 +monoHER 1 +) 0 +showed 0 +cardioprotection 0 +against 0 +D0X 1 +- 0 +induced 0 +cardiotoxicity 3 +through 0 +its 0 +radical 0 +scavenging 0 +and 0 +iron 1 +chelating 0 +properties 0 +. 0 + +Because 0 +of 0 +the 0 +relatively 0 +short 0 +final 0 +half 0 +- 0 +life 0 +of 0 +monoHER 1 +( 0 +about 0 +30 0 +min 0 +) 0 +, 0 +it 0 +is 0 +expected 0 +that 0 +the 0 +time 0 +interval 0 +between 0 +monoHER 1 +and 0 +D0X 1 +might 0 +be 0 +of 0 +influence 0 +on 0 +the 0 +cardioprotective 0 +effect 0 +of 0 +monoHER 1 +. 0 + +Therefore 0 +, 0 +the 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +this 0 +possible 0 +effect 0 +. 0 + +METH0DS 0 +: 0 +Six 0 +groups 0 +of 0 +6 0 +BALB 0 +/ 0 +c 0 +mice 0 +were 0 +treated 0 +with 0 +saline 0 +, 0 +D0X 1 +alone 0 +or 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +preceded 0 +by 0 +monoHER 1 +( 0 +500 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +with 0 +an 0 +interval 0 +of 0 +10 0 +, 0 +30 0 +, 0 +60 0 +or 0 +120 0 +min 0 +. 0 + +After 0 +a 0 +6 0 +- 0 +week 0 +treatment 0 +period 0 +and 0 +additional 0 +observation 0 +for 0 +2 0 +weeks 0 +, 0 +the 0 +mice 0 +were 0 +sacrificed 0 +. 0 + +Their 0 +cardiac 0 +tissues 0 +were 0 +processed 0 +for 0 +light 0 +microscopy 0 +, 0 +after 0 +which 0 +cardiomyocyte 3 +damage 4 +was 0 +evaluated 0 +according 0 +to 0 +Billingham 0 +( 0 +in 0 +Cancer 3 +Treat 0 +Rep 0 +62 0 +( 0 +6 0 +) 0 +: 0 +865 0 +- 0 +872 0 +, 0 +1978 0 +) 0 +. 0 + +Microscopic 0 +evaluation 0 +revealed 0 +that 0 +treatment 0 +with 0 +D0X 1 +alone 0 +induced 0 +significant 0 +cardiac 3 +damage 4 +in 0 +comparison 0 +to 0 +the 0 +saline 0 +control 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +RESULTS 0 +: 0 +The 0 +number 0 +of 0 +damaged 0 +cardiomyocytes 0 +was 0 +9 0 +. 0 +6 0 +- 0 +fold 0 +( 0 +95 0 +% 0 +CI 0 +4 0 +. 0 +4 0 +- 0 +21 0 +. 0 +0 0 +) 0 +higher 0 +in 0 +mice 0 +treated 0 +with 0 +D0X 1 +alone 0 +than 0 +that 0 +in 0 +animals 0 +of 0 +the 0 +control 0 +group 0 +. 0 + +The 0 +ratio 0 +of 0 +aberrant 0 +cardiomyocytes 0 +in 0 +mice 0 +treated 0 +with 0 +D0X 1 +preceded 0 +by 0 +monoHER 1 +and 0 +those 0 +in 0 +mice 0 +treated 0 +with 0 +saline 0 +ranged 0 +from 0 +1 0 +. 0 +6 0 +to 0 +2 0 +. 0 +8 0 +( 0 +mean 0 +2 0 +. 0 +2 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +2 0 +- 0 +4 0 +. 0 +1 0 +, 0 +P 0 += 0 +0 0 +. 0 +019 0 +) 0 +. 0 + +The 0 +mean 0 +protective 0 +effect 0 +by 0 +adding 0 +monoHER 1 +before 0 +D0X 1 +led 0 +to 0 +a 0 +significant 0 +4 0 +. 0 +4 0 +- 0 +fold 0 +reduction 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +, 0 +95 0 +% 0 +CI 0 +2 0 +. 0 +3 0 +- 0 +8 0 +. 0 +2 0 +) 0 +of 0 +abnormal 0 +cardiomyocytes 0 +. 0 + +This 0 +protective 0 +effect 0 +did 0 +not 0 +depend 0 +on 0 +the 0 +time 0 +interval 0 +between 0 +monoHER 1 +and 0 +D0X 1 +administration 0 +( 0 +P 0 += 0 +0 0 +. 0 +345 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +results 0 +indicate 0 +that 0 +in 0 +an 0 +outpatient 0 +clinical 0 +setting 0 +monoHER 1 +may 0 +be 0 +administered 0 +shortly 0 +before 0 +D0X 1 +. 0 + +Clinical 0 +evaluation 0 +of 0 +adverse 0 +effects 0 +during 0 +bepridil 1 +administration 0 +for 0 +atrial 3 +fibrillation 4 +and 4 +flutter 4 +. 0 + +BACKGR0UND 0 +: 0 +Bepridil 1 +hydrochloride 2 +( 0 +Bpd 1 +) 0 +has 0 +attracted 0 +attention 0 +as 0 +an 0 +effective 0 +drug 0 +for 0 +atrial 3 +fibrillation 4 +( 0 +AF 3 +) 0 +and 0 +atrial 3 +flutter 4 +( 0 +AFL 3 +) 0 +. 0 + +However 0 +, 0 +serious 0 +adverse 0 +effects 0 +, 0 +including 0 +torsade 3 +de 4 +pointes 4 +( 0 +Tdp 3 +) 0 +, 0 +have 0 +been 0 +reported 0 +. 0 + +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +Adverse 0 +effects 0 +of 0 +Bpd 1 +requiring 0 +discontinuation 0 +of 0 +treatment 0 +were 0 +evaluated 0 +. 0 + +Bpd 1 +was 0 +administered 0 +to 0 +459 0 +patients 0 +( 0 +361 0 +males 0 +, 0 +63 0 ++ 0 +/ 0 +- 0 +12 0 +years 0 +old 0 +) 0 +comprising 0 +378 0 +AF 3 +and 0 +81 0 +AFL 3 +cases 0 +. 0 + +Mean 0 +left 0 +ventricular 0 +ejection 0 +fraction 0 +and 0 +atrial 0 +dimension 0 +( 0 +LAD 0 +) 0 +were 0 +66 0 ++ 0 +/ 0 +- 0 +11 0 +% 0 +and 0 +40 0 ++ 0 +/ 0 +- 0 +6 0 +mm 0 +, 0 +respectively 0 +. 0 + +Adverse 0 +effects 0 +were 0 +observed 0 +in 0 +19 0 +patients 0 +( 0 +4 0 +% 0 +) 0 +during 0 +an 0 +average 0 +follow 0 +- 0 +up 0 +of 0 +20 0 +months 0 +. 0 + +There 0 +was 0 +marked 0 +QT 3 +prolongation 4 +greater 0 +than 0 +0 0 +. 0 +55 0 +s 0 +in 0 +13 0 +patients 0 +, 0 +bradycardia 3 +less 0 +than 0 +40 0 +beats 0 +/ 0 +min 0 +in 0 +6 0 +patients 0 +, 0 +dizziness 3 +and 0 +general 0 +fatigue 3 +in 0 +1 0 +patient 0 +each 0 +. 0 + +In 0 +4 0 +of 0 +13 0 +patients 0 +with 0 +QT 3 +prolongation 4 +, 0 +Tdp 3 +occurred 0 +. 0 + +The 0 +major 0 +triggering 0 +factors 0 +of 0 +Tdp 3 +were 0 +hypokalemia 3 +and 0 +sudden 0 +decrease 0 +in 0 +heart 0 +rate 0 +. 0 + +There 0 +were 0 +no 0 +differences 0 +in 0 +the 0 +clinical 0 +backgrounds 0 +of 0 +the 0 +patients 0 +with 0 +and 0 +without 0 +Tdp 3 +other 0 +than 0 +LAD 0 +and 0 +age 0 +, 0 +which 0 +were 0 +larger 0 +and 0 +older 0 +in 0 +the 0 +patients 0 +with 0 +Tdp 3 +. 0 + +C0NCLUSI0N 0 +: 0 +Careful 0 +observation 0 +of 0 +serum 0 +potassium 1 +concentration 0 +and 0 +the 0 +ECG 0 +should 0 +always 0 +be 0 +done 0 +during 0 +Bpd 1 +administration 0 +, 0 +particularly 0 +in 0 +elderly 0 +patients 0 +. 0 + +Enhanced 0 +isoproterenol 1 +- 0 +induced 0 +cardiac 3 +hypertrophy 4 +in 0 +transgenic 0 +rats 0 +with 0 +low 0 +brain 0 +angiotensinogen 0 +. 0 + +We 0 +have 0 +previously 0 +shown 0 +that 0 +a 0 +permanent 0 +deficiency 0 +in 0 +the 0 +brain 0 +renin 0 +- 0 +angiotensin 1 +system 0 +( 0 +RAS 0 +) 0 +may 0 +increase 0 +the 0 +sensitivity 0 +of 0 +the 0 +baroreflex 0 +control 0 +of 0 +heart 0 +rate 0 +. 0 + +In 0 +this 0 +study 0 +we 0 +aimed 0 +at 0 +studying 0 +the 0 +involvement 0 +of 0 +the 0 +brain 0 +RAS 0 +in 0 +the 0 +cardiac 0 +reactivity 0 +to 0 +the 0 +beta 0 +- 0 +adrenoceptor 0 +( 0 +beta 0 +- 0 +AR 0 +) 0 +agonist 0 +isoproterenol 1 +( 0 +Iso 1 +) 0 +. 0 + +Transgenic 0 +rats 0 +with 0 +low 0 +brain 0 +angiotensinogen 0 +( 0 +TGR 0 +) 0 +were 0 +used 0 +. 0 + +In 0 +isolated 0 +hearts 0 +, 0 +Iso 1 +induced 0 +a 0 +significantly 0 +greater 0 +increase 0 +in 0 +left 0 +ventricular 0 +( 0 +LV 0 +) 0 +pressure 0 +and 0 +maximal 0 +contraction 0 +( 0 ++ 0 +dP 0 +/ 0 +dt 0 +( 0 +max 0 +) 0 +) 0 +in 0 +the 0 +TGR 0 +than 0 +in 0 +the 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +rats 0 +. 0 + +LV 3 +hypertrophy 4 +induced 0 +by 0 +Iso 1 +treatment 0 +was 0 +significantly 0 +higher 0 +in 0 +TGR 0 +than 0 +in 0 +SD 0 +rats 0 +( 0 +in 0 +g 0 +LV 0 +wt 0 +/ 0 +100 0 +g 0 +body 0 +wt 0 +, 0 +0 0 +. 0 +28 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +004 0 +vs 0 +. 0 +0 0 +. 0 +24 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +004 0 +, 0 +respectively 0 +) 0 +. 0 + +The 0 +greater 0 +LV 3 +hypertrophy 4 +in 0 +TGR 0 +rats 0 +was 0 +associated 0 +with 0 +more 0 +pronounced 0 +downregulation 0 +of 0 +beta 0 +- 0 +AR 0 +and 0 +upregulation 0 +of 0 +LV 0 +beta 0 +- 0 +AR 0 +kinase 0 +- 0 +1 0 +mRNA 0 +levels 0 +compared 0 +with 0 +those 0 +in 0 +SD 0 +rats 0 +. 0 + +The 0 +decrease 0 +in 0 +the 0 +heart 0 +rate 0 +( 0 +HR 0 +) 0 +induced 0 +by 0 +the 0 +beta 0 +- 0 +AR 0 +antagonist 0 +metoprolol 1 +in 0 +conscious 0 +rats 0 +was 0 +significantly 0 +attenuated 0 +in 0 +TGR 0 +compared 0 +with 0 +SD 0 +rats 0 +( 0 +- 0 +9 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +7 0 +% 0 +vs 0 +. 0 +- 0 +18 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +% 0 +) 0 +, 0 +whereas 0 +the 0 +effect 0 +of 0 +parasympathetic 0 +blockade 0 +by 0 +atropine 1 +on 0 +HR 0 +was 0 +similar 0 +in 0 +both 0 +strains 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +TGR 0 +are 0 +more 0 +sensitive 0 +to 0 +beta 0 +- 0 +AR 0 +agonist 0 +- 0 +induced 0 +cardiac 3 +inotropic 4 +response 0 +and 0 +hypertrophy 3 +, 0 +possibly 0 +due 0 +to 0 +chronically 0 +low 0 +sympathetic 0 +outflow 0 +directed 0 +to 0 +the 0 +heart 0 +. 0 + +Drug 0 +- 0 +induced 0 +long 3 +QT 4 +syndrome 4 +in 0 +injection 0 +drug 0 +users 0 +receiving 0 +methadone 1 +: 0 +high 0 +frequency 0 +in 0 +hospitalized 0 +patients 0 +and 0 +risk 0 +factors 0 +. 0 + +BACKGR0UND 0 +: 0 +Drug 0 +- 0 +induced 0 +long 3 +QT 4 +syndrome 4 +is 0 +a 0 +serious 0 +adverse 0 +drug 0 +reaction 0 +. 0 + +Methadone 1 +prolongs 0 +the 0 +QT 0 +interval 0 +in 0 +vitro 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 + +In 0 +the 0 +inpatient 0 +setting 0 +, 0 +the 0 +frequency 0 +of 0 +QT 3 +interval 4 +prolongation 4 +with 0 +methadone 1 +treatment 0 +, 0 +its 0 +dose 0 +dependence 0 +, 0 +and 0 +the 0 +importance 0 +of 0 +cofactors 0 +such 0 +as 0 +drug 0 +- 0 +drug 0 +interactions 0 +remain 0 +unknown 0 +. 0 + +METH0DS 0 +: 0 +We 0 +performed 0 +a 0 +systematic 0 +, 0 +retrospective 0 +study 0 +comparing 0 +active 0 +or 0 +former 0 +intravenous 0 +drug 0 +users 0 +receiving 0 +methadone 1 +and 0 +those 0 +not 0 +receiving 0 +methadone 1 +among 0 +all 0 +patients 0 +hospitalized 0 +over 0 +a 0 +5 0 +- 0 +year 0 +period 0 +in 0 +a 0 +tertiary 0 +care 0 +hospital 0 +. 0 + +A 0 +total 0 +of 0 +167 0 +patients 0 +receiving 0 +methadone 1 +fulfilled 0 +the 0 +inclusion 0 +criteria 0 +and 0 +were 0 +compared 0 +with 0 +a 0 +control 0 +group 0 +of 0 +80 0 +injection 0 +drug 0 +users 0 +not 0 +receiving 0 +methadone 1 +. 0 + +In 0 +addition 0 +to 0 +methadone 1 +dose 0 +, 0 +15 0 +demographic 0 +, 0 +biological 0 +, 0 +and 0 +pharmacological 0 +variables 0 +were 0 +considered 0 +as 0 +potential 0 +risk 0 +factors 0 +for 0 +QT 3 +prolongation 4 +. 0 + +RESULTS 0 +: 0 +Among 0 +167 0 +methadone 1 +maintenance 0 +patients 0 +, 0 +the 0 +prevalence 0 +of 0 +QTc 0 +prolongation 0 +to 0 +0 0 +. 0 +50 0 +second 0 +( 0 +( 0 +1 0 +/ 0 +2 0 +) 0 +) 0 +or 0 +longer 0 +was 0 +16 0 +. 0 +2 0 +% 0 +compared 0 +with 0 +0 0 +% 0 +in 0 +80 0 +control 0 +subjects 0 +. 0 + +Six 0 +patients 0 +( 0 +3 0 +. 0 +6 0 +% 0 +) 0 +in 0 +the 0 +methadone 1 +group 0 +presented 0 +torsades 3 +de 4 +pointes 4 +. 0 + +QTc 0 +length 0 +was 0 +weakly 0 +but 0 +significantly 0 +associated 0 +with 0 +methadone 1 +daily 0 +dose 0 +( 0 +Spearman 0 +rank 0 +correlation 0 +coefficient 0 +, 0 +0 0 +. 0 +20 0 +; 0 +P 0 +< 0 +. 0 +01 0 +) 0 +. 0 + +Multivariate 0 +regression 0 +analysis 0 +allowed 0 +attribution 0 +of 0 +31 0 +. 0 +8 0 +% 0 +of 0 +QTc 0 +variability 0 +to 0 +methadone 1 +dose 0 +, 0 +cytochrome 0 +P 0 +- 0 +450 0 +3A4 0 +drug 0 +- 0 +drug 0 +interactions 0 +, 0 +hypokalemia 3 +, 0 +and 0 +altered 0 +liver 0 +function 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +QT 3 +interval 4 +prolongation 4 +in 0 +methadone 1 +maintenance 0 +patients 0 +hospitalized 0 +in 0 +a 0 +tertiary 0 +care 0 +center 0 +is 0 +a 0 +frequent 0 +finding 0 +. 0 + +Methadone 1 +dose 0 +, 0 +presence 0 +of 0 +cytochrome 0 +P 0 +- 0 +450 0 +3A4 0 +inhibitors 0 +, 0 +potassium 1 +level 0 +, 0 +and 0 +liver 0 +function 0 +contribute 0 +to 0 +QT 3 +prolongation 4 +. 0 + +Long 3 +QT 4 +syndrome 4 +can 0 +occur 0 +with 0 +low 0 +doses 0 +of 0 +methadone 1 +. 0 + +Mechanisms 0 +of 0 +hypertension 3 +induced 0 +by 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +deficiency 0 +: 0 +focus 0 +on 0 +venous 0 +function 0 +. 0 + +Loss 0 +of 0 +endothelial 0 +cell 0 +- 0 +derived 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +in 0 +hypertension 3 +is 0 +a 0 +hallmark 0 +of 0 +arterial 3 +dysfunction 4 +. 0 + +Experimental 0 +hypertension 3 +created 0 +by 0 +the 0 +removal 0 +of 0 +N0 1 +, 0 +however 0 +, 0 +involves 0 +mechanisms 0 +in 0 +addition 0 +to 0 +decreased 0 +arterial 0 +vasodilator 0 +activity 0 +. 0 + +These 0 +include 0 +augmented 0 +endothelin 0 +- 0 +1 0 +( 0 +ET 0 +- 0 +1 0 +) 0 +release 0 +, 0 +increased 0 +sympathetic 0 +nervous 0 +system 0 +activity 0 +, 0 +and 0 +elevated 0 +tissue 0 +oxidative 0 +stress 0 +. 0 + +We 0 +hypothesized 0 +that 0 +increased 0 +venous 0 +smooth 0 +muscle 0 +( 0 +venomotor 0 +) 0 +tone 0 +plays 0 +a 0 +role 0 +in 0 +Nomega 1 +- 2 +nitro 2 +- 2 +L 2 +- 2 +arginine 2 +( 0 +LNNA 1 +) 0 +hypertension 3 +through 0 +these 0 +mechanisms 0 +. 0 + +Rats 0 +were 0 +treated 0 +with 0 +the 0 +N0 1 +synthase 0 +inhibitor 0 +LNNA 1 +( 0 +0 0 +. 0 +5 0 +g 0 +/ 0 +L 0 +in 0 +drinking 0 +water 0 +) 0 +for 0 +2 0 +weeks 0 +. 0 + +Mean 0 +arterial 0 +pressure 0 +of 0 +conscious 0 +rats 0 +was 0 +119 0 ++ 0 +/ 0 +- 0 +2 0 +mm 0 +Hg 0 +in 0 +control 0 +and 0 +194 0 ++ 0 +/ 0 +- 0 +5 0 +mm 0 +Hg 0 +in 0 +LNNA 1 +rats 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Carotid 0 +arteries 0 +and 0 +vena 0 +cava 0 +were 0 +removed 0 +for 0 +measurement 0 +of 0 +isometric 0 +contraction 0 +. 0 + +Maximal 0 +contraction 0 +to 0 +norepinephrine 1 +was 0 +modestly 0 +reduced 0 +in 0 +arteries 0 +from 0 +LNNA 1 +compared 0 +with 0 +control 0 +rats 0 +whereas 0 +the 0 +maximum 0 +contraction 0 +to 0 +ET 0 +- 0 +1 0 +was 0 +significantly 0 +reduced 0 +( 0 +54 0 +% 0 +control 0 +) 0 +. 0 + +Maximum 0 +contraction 0 +of 0 +vena 0 +cava 0 +to 0 +norepinephrine 1 +( 0 +37 0 +% 0 +control 0 +) 0 +also 0 +was 0 +reduced 0 +but 0 +no 0 +change 0 +in 0 +response 0 +to 0 +ET 0 +- 0 +1 0 +was 0 +observed 0 +. 0 + +Mean 0 +circulatory 0 +filling 0 +pressure 0 +, 0 +an 0 +in 0 +vivo 0 +measure 0 +of 0 +venomotor 0 +tone 0 +, 0 +was 0 +not 0 +elevated 0 +in 0 +LNNA 1 +hypertension 3 +at 0 +1 0 +or 0 +2 0 +weeks 0 +after 0 +LNNA 1 +. 0 + +The 0 +superoxide 1 +scavenger 0 +tempol 1 +( 0 +30 0 +, 0 +100 0 +, 0 +and 0 +300 0 +micromol 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +, 0 +IV 0 +) 0 +did 0 +not 0 +change 0 +arterial 0 +pressure 0 +in 0 +control 0 +rats 0 +but 0 +caused 0 +a 0 +dose 0 +- 0 +dependent 0 +decrease 0 +in 0 +LNNA 1 +rats 0 +( 0 +- 0 +18 0 ++ 0 +/ 0 +- 0 +8 0 +, 0 +- 0 +26 0 ++ 0 +/ 0 +- 0 +15 0 +, 0 +and 0 +- 0 +54 0 ++ 0 +/ 0 +- 0 +11 0 +mm 0 +Hg 0 +) 0 +. 0 + +Similarly 0 +, 0 +ganglionic 0 +blockade 0 +with 0 +hexamethonium 1 +caused 0 +a 0 +significantly 0 +greater 0 +fall 0 +in 0 +LNNA 1 +hypertensive 3 +rats 0 +( 0 +76 0 ++ 0 +/ 0 +- 0 +9 0 +mm 0 +Hg 0 +) 0 +compared 0 +with 0 +control 0 +rats 0 +( 0 +35 0 ++ 0 +/ 0 +- 0 +10 0 +mm 0 +Hg 0 +) 0 +. 0 + +Carotid 0 +arteries 0 +, 0 +vena 0 +cava 0 +, 0 +and 0 +sympathetic 0 +ganglia 0 +from 0 +LNNA 1 +rats 0 +had 0 +higher 0 +basal 0 +levels 0 +of 0 +superoxide 1 +compared 0 +with 0 +those 0 +from 0 +control 0 +rats 0 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +while 0 +N0 1 +deficiency 0 +increases 0 +oxidative 0 +stress 0 +and 0 +sympathetic 0 +activity 0 +in 0 +both 0 +arterial 0 +and 0 +venous 0 +vessels 0 +, 0 +the 0 +impact 0 +on 0 +veins 0 +does 0 +not 0 +make 0 +a 0 +major 0 +contribution 0 +to 0 +this 0 +form 0 +of 0 +hypertension 3 +. 0 + +Association 0 +of 0 +DRD2 0 +polymorphisms 0 +and 0 +chlorpromazine 1 +- 0 +induced 0 +extrapyramidal 3 +syndrome 4 +in 0 +Chinese 0 +schizophrenic 3 +patients 0 +. 0 + +AIM 0 +: 0 +Extrapyramidal 3 +syndrome 4 +( 0 +EPS 3 +) 0 +is 0 +most 0 +commonly 0 +affected 0 +by 0 +typical 0 +antipsychotic 0 +drugs 0 +that 0 +have 0 +a 0 +high 0 +affinity 0 +with 0 +the 0 +D2 0 +receptor 0 +. 0 + +Recently 0 +, 0 +many 0 +research 0 +groups 0 +have 0 +reported 0 +on 0 +the 0 +positive 0 +relationship 0 +between 0 +the 0 +genetic 0 +variations 0 +in 0 +the 0 +DRD2 0 +gene 0 +and 0 +the 0 +therapeutic 0 +response 0 +in 0 +schizophrenia 3 +patients 0 +as 0 +a 0 +result 0 +of 0 +the 0 +role 0 +of 0 +variations 0 +in 0 +the 0 +receptor 0 +in 0 +modulating 0 +receptor 0 +expression 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +evaluate 0 +the 0 +role 0 +DRD2 0 +plays 0 +in 0 +chlorpromazine 1 +- 0 +induced 0 +EPS 3 +in 0 +schizophrenic 3 +patients 0 +. 0 + +METH0DS 0 +: 0 +We 0 +identified 0 +seven 0 +SNP 0 +( 0 +single 0 +nucleotide 0 +polymorphism 0 +) 0 +( 0 +- 0 +141Cins 0 +> 0 +del 0 +, 0 +TaqIB 0 +, 0 +TaqID 0 +, 0 +Ser311Cys 0 +, 0 +rs6275 0 +, 0 +rs6277 0 +and 0 +TaqIA 0 +) 0 +in 0 +the 0 +DRD2 0 +gene 0 +in 0 +146 0 +schizophrenic 3 +inpatients 0 +( 0 +59 0 +with 0 +EPS 3 +and 0 +87 0 +without 0 +EPS 3 +according 0 +to 0 +the 0 +Simpson 0 +- 0 +Angus 0 +Scale 0 +) 0 +treated 0 +with 0 +chlorpromazine 1 +after 0 +8 0 +weeks 0 +. 0 + +The 0 +alleles 0 +of 0 +all 0 +loci 0 +were 0 +determined 0 +by 0 +PCR 0 +( 0 +polymerase 0 +chain 0 +reaction 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Polymorphisms 0 +TaqID 0 +, 0 +Ser311Cys 0 +and 0 +rs6277 0 +were 0 +not 0 +polymorphic 0 +in 0 +the 0 +population 0 +recruited 0 +in 0 +the 0 +present 0 +study 0 +. 0 + +No 0 +statistical 0 +significance 0 +was 0 +found 0 +in 0 +the 0 +allele 0 +distribution 0 +of 0 +- 0 +141Cins 0 +> 0 +del 0 +, 0 +TaqIB 0 +, 0 +rs6275 0 +and 0 +TaqIA 0 +or 0 +in 0 +the 0 +estimated 0 +haplotypes 0 +( 0 +constituted 0 +by 0 +TaqIB 0 +, 0 +rs6275 0 +and 0 +TaqIA 0 +) 0 +in 0 +linkage 0 +disequilibrium 0 +between 0 +the 0 +two 0 +groups 0 +. 0 + +C0NCLUSI0N 0 +: 0 +0ur 0 +results 0 +did 0 +not 0 +lend 0 +strong 0 +support 0 +to 0 +the 0 +view 0 +that 0 +the 0 +genetic 0 +variation 0 +of 0 +the 0 +DRD2 0 +gene 0 +plays 0 +a 0 +major 0 +role 0 +in 0 +the 0 +individually 0 +variable 0 +adverse 0 +effect 0 +induced 0 +by 0 +chlorpromazine 1 +, 0 +at 0 +least 0 +in 0 +Chinese 0 +patients 0 +with 0 +schizophrenia 3 +. 0 + +0ur 0 +results 0 +confirmed 0 +a 0 +previous 0 +study 0 +on 0 +the 0 +relationship 0 +between 0 +DRD2 0 +and 0 +EPS 3 +in 0 +Caucasians 0 +. 0 + +Physical 0 +training 0 +decreases 0 +susceptibility 0 +to 0 +subsequent 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +in 0 +the 0 +rat 0 +. 0 + +Regular 0 +motor 0 +activity 0 +has 0 +many 0 +benefits 0 +for 0 +mental 0 +and 0 +physical 0 +condition 0 +but 0 +its 0 +implications 0 +for 0 +epilepsy 3 +are 0 +still 0 +controversial 0 +. 0 + +In 0 +order 0 +to 0 +elucidate 0 +this 0 +problem 0 +, 0 +we 0 +have 0 +studied 0 +the 0 +effect 0 +of 0 +long 0 +- 0 +term 0 +physical 0 +activity 0 +on 0 +susceptibility 0 +to 0 +subsequent 0 +seizures 3 +. 0 + +Male 0 +Wistar 0 +rats 0 +were 0 +subjected 0 +to 0 +repeated 0 +training 0 +sessions 0 +in 0 +a 0 +treadmill 0 +and 0 +swimming 0 +pool 0 +. 0 + +Thereafter 0 +, 0 +seizures 3 +were 0 +induced 0 +by 0 +pilocarpine 1 +injections 0 +in 0 +trained 0 +and 0 +non 0 +- 0 +trained 0 +control 0 +groups 0 +. 0 + +During 0 +the 0 +acute 0 +period 0 +of 0 +status 3 +epilepticus 4 +, 0 +we 0 +measured 0 +: 0 +( 0 +1 0 +) 0 +the 0 +latency 0 +of 0 +the 0 +first 0 +motor 0 +sign 0 +, 0 +( 0 +2 0 +) 0 +the 0 +intensity 0 +of 0 +seizures 3 +, 0 +( 0 +3 0 +) 0 +the 0 +time 0 +when 0 +it 0 +occurred 0 +within 0 +the 0 +6 0 +- 0 +h 0 +observation 0 +period 0 +, 0 +and 0 +( 0 +4 0 +) 0 +the 0 +time 0 +when 0 +the 0 +acute 0 +period 0 +ended 0 +. 0 + +All 0 +these 0 +behavioral 0 +parameters 0 +showed 0 +statistically 0 +significant 0 +changes 0 +suggesting 0 +that 0 +regular 0 +physical 0 +exercises 0 +decrease 0 +susceptibility 0 +to 0 +subsequently 0 +induced 0 +seizures 3 +and 0 +ameliorate 0 +the 0 +course 0 +of 0 +experimentally 0 +induced 0 +status 3 +epilepticus 4 +. 0 + +Tonic 0 +dopaminergic 0 +stimulation 0 +impairs 3 +associative 4 +learning 4 +in 0 +healthy 0 +subjects 0 +. 0 + +Endogenous 0 +dopamine 1 +plays 0 +a 0 +central 0 +role 0 +in 0 +salience 0 +coding 0 +during 0 +associative 0 +learning 0 +. 0 + +Administration 0 +of 0 +the 0 +dopamine 1 +precursor 0 +levodopa 1 +enhances 0 +learning 0 +in 0 +healthy 0 +subjects 0 +and 0 +stroke 3 +patients 0 +. 0 + +Because 0 +levodopa 1 +increases 0 +both 0 +phasic 0 +and 0 +tonic 0 +dopaminergic 0 +neurotransmission 0 +, 0 +the 0 +critical 0 +mechanism 0 +mediating 0 +the 0 +enhancement 0 +of 0 +learning 0 +is 0 +unresolved 0 +. 0 + +We 0 +here 0 +probed 0 +how 0 +selective 0 +tonic 0 +dopaminergic 0 +stimulation 0 +affects 0 +associative 0 +learning 0 +. 0 + +Forty 0 +healthy 0 +subjects 0 +were 0 +trained 0 +in 0 +a 0 +novel 0 +vocabulary 0 +of 0 +45 0 +concrete 0 +nouns 0 +over 0 +the 0 +course 0 +of 0 +5 0 +consecutive 0 +training 0 +days 0 +in 0 +a 0 +prospective 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +design 0 +. 0 + +Subjects 0 +received 0 +the 0 +tonically 0 +stimulating 0 +dopamine 1 +- 0 +receptor 0 +agonist 0 +pergolide 1 +( 0 +0 0 +. 0 +1 0 +mg 0 +) 0 +vs 0 +placebo 0 +120 0 +min 0 +before 0 +training 0 +on 0 +each 0 +training 0 +day 0 +. 0 + +The 0 +dopamine 1 +agonist 0 +significantly 0 +impaired 3 +novel 4 +word 4 +learning 4 +compared 0 +to 0 +placebo 0 +. 0 + +This 0 +learning 0 +decrement 0 +persisted 0 +up 0 +to 0 +the 0 +last 0 +follow 0 +- 0 +up 0 +4 0 +weeks 0 +post 0 +- 0 +training 0 +. 0 + +Subjects 0 +treated 0 +with 0 +pergolide 1 +also 0 +showed 0 +restricted 0 +emotional 0 +responses 0 +compared 0 +to 0 +the 0 +PLACEB0 0 +group 0 +. 0 + +The 0 +extent 0 +of 0 +' 0 +flattened 0 +' 0 +affect 0 +with 0 +pergolide 1 +was 0 +related 0 +to 0 +the 0 +degree 0 +of 0 +learning 0 +inhibition 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +tonic 0 +occupation 0 +of 0 +dopamine 1 +receptors 0 +impairs 0 +learning 0 +by 0 +competition 0 +with 0 +phasic 0 +dopamine 1 +signals 0 +. 0 + +Thus 0 +, 0 +phasic 0 +signaling 0 +seems 0 +to 0 +be 0 +the 0 +critical 0 +mechanism 0 +by 0 +which 0 +dopamine 1 +enhances 0 +associative 0 +learning 0 +in 0 +healthy 0 +subjects 0 +and 0 +stroke 3 +patients 0 +. 0 + +Minocycline 1 +- 0 +induced 0 +vasculitis 3 +fulfilling 0 +the 0 +criteria 0 +of 0 +polyarteritis 3 +nodosa 4 +. 0 + +A 0 +47 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +had 0 +been 0 +taking 0 +minocycline 1 +for 0 +palmoplantar 3 +pustulosis 4 +developed 0 +fever 3 +, 0 +myalgias 3 +, 0 +polyneuropathy 3 +, 0 +and 0 +testicular 3 +pain 4 +, 0 +with 0 +elevated 0 +C 0 +- 0 +reactive 0 +protein 0 +( 0 +CRP 0 +) 0 +. 0 + +Neither 0 +myeloperoxidase 0 +- 0 +nor 0 +proteinase 0 +- 0 +3 0 +- 0 +antineutrophil 0 +cytoplasmic 0 +antibody 0 +was 0 +positive 0 +. 0 + +These 0 +manifestations 0 +met 0 +the 0 +American 0 +College 0 +of 0 +Rheumatology 0 +1990 0 +criteria 0 +for 0 +the 0 +classification 0 +of 0 +polyarteritis 3 +nodosa 4 +. 0 + +Stopping 0 +minocycline 1 +led 0 +to 0 +amelioration 0 +of 0 +symptoms 0 +and 0 +normalization 0 +of 0 +CRP 0 +level 0 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +second 0 +case 0 +of 0 +minocycline 1 +- 0 +induced 0 +vasculitis 3 +satisfying 0 +the 0 +criteria 0 +. 0 + +Differential 0 +diagnosis 0 +for 0 +drug 0 +- 0 +induced 0 +disease 0 +is 0 +invaluable 0 +even 0 +for 0 +patients 0 +with 0 +classical 0 +polyarteritis 3 +nodosa 4 +. 0 + +Intramuscular 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +combined 0 +with 0 +lamivudine 1 +in 0 +prevention 0 +of 0 +hepatitis 3 +B 4 +recurrence 0 +after 0 +liver 0 +transplantation 0 +. 0 + +BACKGR0UND 0 +: 0 +Combined 0 +hepatitis 3 +B 4 +immune 0 +globulin 0 +( 0 +HBIg 0 +) 0 +and 0 +lamivudine 1 +in 0 +prophylaxis 0 +of 0 +the 0 +recurrence 0 +of 0 +hepatitis 3 +B 4 +after 0 +liver 0 +transplantation 0 +has 0 +significantly 0 +improved 0 +the 0 +survival 0 +of 0 +HBsAg 1 +positive 0 +patients 0 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +evaluate 0 +the 0 +outcomes 0 +of 0 +liver 0 +transplantation 0 +for 0 +patients 0 +with 0 +hepatitis 3 +B 4 +virus 0 +( 0 +HBV 0 +) 0 +. 0 + +METH0DS 0 +: 0 +A 0 +retrospective 0 +chart 0 +analysis 0 +and 0 +a 0 +review 0 +of 0 +the 0 +organ 0 +transplant 0 +database 0 +identified 0 +51 0 +patients 0 +( 0 +43 0 +men 0 +and 0 +8 0 +women 0 +) 0 +transplanted 0 +for 0 +benign 0 +HBV 0 +- 0 +related 0 +cirrhotic 3 +diseases 4 +between 0 +June 0 +2002 0 +and 0 +December 0 +2004 0 +who 0 +had 0 +survived 0 +more 0 +than 0 +3 0 +months 0 +. 0 + +HBIg 0 +was 0 +administered 0 +intravenously 0 +during 0 +the 0 +first 0 +week 0 +and 0 +intramuscularly 0 +thereafter 0 +. 0 + +RESULTS 0 +: 0 +At 0 +a 0 +median 0 +follow 0 +- 0 +up 0 +of 0 +14 0 +. 0 +1 0 +months 0 +, 0 +the 0 +overall 0 +recurrence 0 +rate 0 +in 0 +the 0 +51 0 +patients 0 +was 0 +3 0 +. 0 +9 0 +% 0 +( 0 +2 0 +/ 0 +51 0 +) 0 +. 0 + +The 0 +overall 0 +patient 0 +survival 0 +was 0 +88 0 +. 0 +3 0 +% 0 +, 0 +and 0 +82 0 +. 0 +4 0 +% 0 +after 0 +1 0 +and 0 +2 0 +years 0 +, 0 +respectively 0 +. 0 + +A 0 +daily 0 +oral 0 +dose 0 +of 0 +100 0 +mg 0 +lamivudine 1 +for 0 +2 0 +weeks 0 +before 0 +transplantation 0 +for 0 +10 0 +patients 0 +enabled 0 +57 0 +. 0 +1 0 +% 0 +( 0 +4 0 +/ 0 +7 0 +) 0 +and 0 +62 0 +. 0 +5 0 +% 0 +( 0 +5 0 +/ 0 +8 0 +) 0 +of 0 +HBV 0 +- 0 +DNA 0 +and 0 +HBeAg 1 +positive 0 +patients 0 +respectively 0 +to 0 +convert 0 +to 0 +be 0 +negative 0 +. 0 + +Intramuscular 0 +HBIg 0 +was 0 +well 0 +tolerated 0 +in 0 +all 0 +patients 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Lamivudine 1 +combined 0 +with 0 +intramuscular 0 +HBIg 0 +can 0 +effectively 0 +prevent 0 +allograft 0 +from 0 +the 0 +recurrence 0 +of 0 +HBV 0 +after 0 +liver 0 +transplantation 0 +. 0 + +Anticonvulsant 0 +effect 0 +of 0 +eslicarbazepine 1 +acetate 2 +( 0 +BIA 1 +2 2 +- 2 +093 2 +) 0 +on 0 +seizures 3 +induced 0 +by 0 +microperfusion 0 +of 0 +picrotoxin 1 +in 0 +the 0 +hippocampus 0 +of 0 +freely 0 +moving 0 +rats 0 +. 0 + +Eslicarbazepine 1 +acetate 2 +( 0 +BIA 1 +2 2 +- 2 +093 2 +, 0 +S 1 +- 2 +( 2 +- 2 +) 2 +- 2 +10 2 +- 2 +acetoxy 2 +- 2 +10 2 +, 2 +11 2 +- 2 +dihydro 2 +- 2 +5H 2 +- 2 +dibenzo 2 +/ 2 +b 2 +, 2 +f 2 +/ 2 +azepine 2 +- 2 +5 2 +- 2 +carboxamide 2 +) 0 +is 0 +a 0 +novel 0 +antiepileptic 0 +drug 0 +, 0 +now 0 +in 0 +Phase 0 +III 0 +clinical 0 +trials 0 +, 0 +designed 0 +with 0 +the 0 +aim 0 +of 0 +improving 0 +efficacy 0 +and 0 +safety 0 +in 0 +comparison 0 +with 0 +the 0 +structurally 0 +related 0 +drugs 0 +carbamazepine 1 +( 0 +CBZ 1 +) 0 +and 0 +oxcarbazepine 1 +( 0 +0XC 1 +) 0 +. 0 + +We 0 +have 0 +studied 0 +the 0 +effects 0 +of 0 +oral 0 +treatment 0 +with 0 +eslicarbazepine 1 +acetate 2 +on 0 +a 0 +whole 0 +- 0 +animal 0 +model 0 +in 0 +which 0 +partial 0 +seizures 3 +can 0 +be 0 +elicited 0 +repeatedly 0 +on 0 +different 0 +days 0 +without 0 +changes 0 +in 0 +threshold 0 +or 0 +seizure 3 +patterns 0 +. 0 + +In 0 +the 0 +animals 0 +treated 0 +with 0 +threshold 0 +doses 0 +of 0 +picrotoxin 1 +, 0 +the 0 +average 0 +number 0 +of 0 +seizures 3 +was 0 +2 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +2 0 +, 0 +and 0 +average 0 +seizure 3 +duration 0 +was 0 +39 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +4s 0 +. 0 + +Pre 0 +- 0 +treatment 0 +with 0 +a 0 +dose 0 +of 0 +30 0 +mg 0 +/ 0 +kg 0 +2h 0 +before 0 +picrotoxin 1 +microperfusion 0 +prevented 0 +seizures 3 +in 0 +the 0 +75 0 +% 0 +of 0 +the 0 +rats 0 +. 0 + +Lower 0 +doses 0 +( 0 +3 0 +and 0 +10mg 0 +/ 0 +kg 0 +) 0 +did 0 +not 0 +suppress 0 +seizures 3 +, 0 +however 0 +, 0 +after 0 +administration 0 +of 0 +10mg 0 +/ 0 +kg 0 +, 0 +significant 0 +reductions 0 +in 0 +seizures 3 +duration 0 +( 0 +24 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +8s 0 +) 0 +and 0 +seizure 3 +number 0 +( 0 +1 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +34 0 +) 0 +were 0 +found 0 +. 0 + +No 0 +adverse 0 +effects 0 +of 0 +eslicarbazepine 1 +acetate 2 +were 0 +observed 0 +in 0 +the 0 +behavioral 0 +/ 0 +EEG 0 +patterns 0 +studied 0 +, 0 +including 0 +sleep 0 +/ 0 +wakefulness 0 +cycle 0 +, 0 +at 0 +the 0 +doses 0 +studied 0 +. 0 + +Acute 3 +renal 4 +failure 4 +associated 0 +with 0 +prolonged 0 +intake 0 +of 0 +slimming 0 +pills 0 +containing 0 +anthraquinones 1 +. 0 + +Chinese 1 +herbal 2 +medicine 0 +preparations 0 +are 0 +widely 0 +available 0 +and 0 +often 0 +regarded 0 +by 0 +the 0 +public 0 +as 0 +natural 0 +and 0 +safe 0 +remedies 0 +for 0 +a 0 +variety 0 +of 0 +medical 0 +conditions 0 +. 0 + +Nephropathy 3 +caused 0 +by 0 +Chinese 1 +herbs 2 +has 0 +previously 0 +been 0 +reported 0 +, 0 +usually 0 +involving 0 +the 0 +use 0 +of 0 +aristolochic 1 +acids 2 +. 0 + +We 0 +report 0 +a 0 +23 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +developed 0 +acute 3 +renal 4 +failure 4 +following 0 +prolonged 0 +use 0 +of 0 +a 0 +proprietary 0 +Chinese 1 +herbal 2 +slimming 0 +pill 0 +that 0 +contained 0 +anthraquinone 1 +derivatives 0 +, 0 +extracted 0 +from 0 +Rhizoma 0 +Rhei 0 +( 0 +rhubarb 0 +) 0 +. 0 + +The 0 +renal 3 +injury 4 +was 0 +probably 0 +aggravated 0 +by 0 +the 0 +concomitant 0 +intake 0 +of 0 +a 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +, 0 +diclofenac 1 +. 0 + +Renal 0 +pathology 0 +was 0 +that 0 +of 0 +hypocellular 0 +interstitial 0 +fibrosis 3 +. 0 + +Spontaneous 0 +renal 0 +recovery 0 +occurred 0 +upon 0 +cessation 0 +of 0 +the 0 +slimming 0 +pills 0 +, 0 +but 0 +mild 0 +interstitial 0 +fibrosis 3 +and 0 +tubular 0 +atrophy 3 +was 0 +still 0 +evident 0 +histologically 0 +4 0 +months 0 +later 0 +. 0 + +Although 0 +a 0 +causal 0 +relationship 0 +between 0 +the 0 +use 0 +of 0 +an 0 +anthraquinone 1 +- 0 +containing 0 +herbal 0 +agent 0 +and 0 +renal 3 +injury 4 +remains 0 +to 0 +be 0 +proven 0 +, 0 +phytotherapy 0 +- 0 +associated 0 +interstitial 0 +nephropathy 3 +should 0 +be 0 +considered 0 +in 0 +patients 0 +who 0 +present 0 +with 0 +unexplained 0 +renal 3 +failure 4 +. 0 + +Chloroacetaldehyde 1 +as 0 +a 0 +sulfhydryl 1 +reagent 0 +: 0 +the 0 +role 0 +of 0 +critical 0 +thiol 1 +groups 0 +in 0 +ifosfamide 1 +nephropathy 3 +. 0 + +Chloroacetaldehyde 1 +( 0 +CAA 1 +) 0 +is 0 +a 0 +metabolite 0 +of 0 +the 0 +alkylating 0 +agent 0 +ifosfamide 1 +( 0 +IF0 1 +) 0 +and 0 +putatively 0 +responsible 0 +for 0 +renal 3 +damage 4 +following 0 +anti 0 +- 0 +tumor 3 +therapy 0 +with 0 +IF0 1 +. 0 + +Depletion 0 +of 0 +sulfhydryl 1 +( 0 +SH 1 +) 0 +groups 0 +has 0 +been 0 +reported 0 +from 0 +cell 0 +culture 0 +, 0 +animal 0 +and 0 +clinical 0 +studies 0 +. 0 + +In 0 +this 0 +work 0 +the 0 +effect 0 +of 0 +CAA 1 +on 0 +human 0 +proximal 0 +tubule 0 +cells 0 +in 0 +primary 0 +culture 0 +( 0 +hRPTEC 0 +) 0 +was 0 +investigated 0 +. 0 + +Toxicity 3 +of 0 +CAA 1 +was 0 +determined 0 +by 0 +protein 0 +content 0 +, 0 +cell 0 +number 0 +, 0 +LDH 0 +release 0 +, 0 +trypan 1 +blue 2 +exclusion 0 +assay 0 +and 0 +caspase 0 +- 0 +3 0 +activity 0 +. 0 + +Free 0 +thiols 1 +were 0 +measured 0 +by 0 +the 0 +method 0 +of 0 +Ellman 0 +. 0 + +CAA 1 +reduced 0 +hRPTEC 0 +cell 0 +number 0 +and 0 +protein 0 +, 0 +induced 0 +a 0 +loss 0 +in 0 +free 0 +intracellular 0 +thiols 1 +and 0 +an 0 +increase 0 +in 0 +necrosis 3 +markers 0 +. 0 + +CAA 1 +but 0 +not 0 +acrolein 1 +inhibited 0 +the 0 +cysteine 1 +proteases 0 +caspase 0 +- 0 +3 0 +, 0 +caspase 0 +- 0 +8 0 +and 0 +cathepsin 0 +B 0 +. 0 + +Caspase 0 +activation 0 +by 0 +cisplatin 1 +was 0 +inhibited 0 +by 0 +CAA 1 +. 0 + +In 0 +cells 0 +stained 0 +with 0 +fluorescent 0 +dyes 0 +targeting 0 +lysosomes 0 +, 0 +CAA 1 +induced 0 +an 0 +increase 0 +in 0 +lysosomal 0 +size 0 +and 0 +lysosomal 0 +leakage 0 +. 0 + +The 0 +effects 0 +of 0 +CAA 1 +on 0 +cysteine 1 +protease 0 +activities 0 +and 0 +thiols 1 +could 0 +be 0 +reproduced 0 +in 0 +cell 0 +lysate 0 +. 0 + +Acidification 0 +, 0 +which 0 +slowed 0 +the 0 +reaction 0 +of 0 +CAA 1 +with 0 +thiol 1 +donors 0 +, 0 +could 0 +also 0 +attenuate 0 +effects 0 +of 0 +CAA 1 +on 0 +necrosis 3 +markers 0 +, 0 +thiol 1 +depletion 0 +and 0 +cysteine 1 +protease 0 +inhibition 0 +in 0 +living 0 +cells 0 +. 0 + +Thus 0 +, 0 +CAA 1 +directly 0 +reacts 0 +with 0 +cellular 0 +protein 0 +and 0 +non 0 +- 0 +protein 0 +thiols 1 +, 0 +mediating 0 +its 0 +toxicity 3 +on 0 +hRPTEC 0 +. 0 + +This 0 +effect 0 +can 0 +be 0 +reduced 0 +by 0 +acidification 0 +. 0 + +Therefore 0 +, 0 +urinary 0 +acidification 0 +could 0 +be 0 +an 0 +option 0 +to 0 +prevent 0 +IF0 1 +nephropathy 3 +in 0 +patients 0 +. 0 + +Stereological 0 +methods 0 +reveal 0 +the 0 +robust 0 +size 0 +and 0 +stability 0 +of 0 +ectopic 0 +hilar 0 +granule 0 +cells 0 +after 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +in 0 +the 0 +adult 0 +rat 0 +. 0 + +Following 0 +status 3 +epilepticus 4 +in 0 +the 0 +rat 0 +, 0 +dentate 0 +granule 0 +cell 0 +neurogenesis 0 +increases 0 +greatly 0 +, 0 +and 0 +many 0 +of 0 +the 0 +new 0 +neurons 0 +appear 0 +to 0 +develop 0 +ectopically 0 +, 0 +in 0 +the 0 +hilar 0 +region 0 +of 0 +the 0 +hippocampal 0 +formation 0 +. 0 + +It 0 +has 0 +been 0 +suggested 0 +that 0 +the 0 +ectopic 0 +hilar 0 +granule 0 +cells 0 +could 0 +contribute 0 +to 0 +the 0 +spontaneous 0 +seizures 3 +that 0 +ultimately 0 +develop 0 +after 0 +status 3 +epilepticus 4 +. 0 + +However 0 +, 0 +the 0 +population 0 +has 0 +never 0 +been 0 +quantified 0 +, 0 +so 0 +it 0 +is 0 +unclear 0 +whether 0 +it 0 +is 0 +substantial 0 +enough 0 +to 0 +have 0 +a 0 +strong 0 +influence 0 +on 0 +epileptogenesis 0 +. 0 + +To 0 +quantify 0 +this 0 +population 0 +, 0 +the 0 +total 0 +number 0 +of 0 +ectopic 0 +hilar 0 +granule 0 +cells 0 +was 0 +estimated 0 +using 0 +unbiased 0 +stereology 0 +at 0 +different 0 +times 0 +after 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +. 0 + +The 0 +number 0 +of 0 +hilar 0 +neurons 0 +immunoreactive 0 +for 0 +Prox 0 +- 0 +1 0 +, 0 +a 0 +granule 0 +- 0 +cell 0 +- 0 +specific 0 +marker 0 +, 0 +was 0 +estimated 0 +using 0 +the 0 +optical 0 +fractionator 0 +method 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +the 0 +size 0 +of 0 +the 0 +hilar 0 +ectopic 0 +granule 0 +cell 0 +population 0 +after 0 +status 3 +epilepticus 4 +is 0 +substantial 0 +, 0 +and 0 +stable 0 +over 0 +time 0 +. 0 + +Interestingly 0 +, 0 +the 0 +size 0 +of 0 +the 0 +population 0 +appears 0 +to 0 +be 0 +correlated 0 +with 0 +the 0 +frequency 0 +of 0 +behavioral 0 +seizures 3 +, 0 +because 0 +animals 0 +with 0 +more 0 +ectopic 0 +granule 0 +cells 0 +in 0 +the 0 +hilus 0 +have 0 +more 0 +frequent 0 +behavioral 0 +seizures 3 +. 0 + +The 0 +hilar 0 +ectopic 0 +granule 0 +cell 0 +population 0 +does 0 +not 0 +appear 0 +to 0 +vary 0 +systematically 0 +across 0 +the 0 +septotemporal 0 +axis 0 +, 0 +although 0 +it 0 +is 0 +associated 0 +with 0 +an 0 +increase 0 +in 0 +volume 0 +of 0 +the 0 +hilus 0 +. 0 + +The 0 +results 0 +provide 0 +new 0 +insight 0 +into 0 +the 0 +potential 0 +role 0 +of 0 +ectopic 0 +hilar 0 +granule 0 +cells 0 +in 0 +the 0 +pilocarpine 1 +model 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 + +A 0 +prospective 0 +, 0 +open 0 +- 0 +label 0 +trial 0 +of 0 +galantamine 1 +in 0 +autistic 3 +disorder 4 +. 0 + +0BJECTIVE 0 +: 0 +Post 0 +- 0 +mortem 0 +studies 0 +have 0 +reported 0 +abnormalities 0 +of 0 +the 0 +cholinergic 0 +system 0 +in 0 +autism 3 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +use 0 +of 0 +galantamine 1 +, 0 +an 0 +acetylcholinesterase 0 +inhibitor 0 +and 0 +nicotinic 0 +receptor 0 +modulator 0 +, 0 +in 0 +the 0 +treatment 0 +of 0 +interfering 0 +behaviors 0 +in 0 +children 0 +with 0 +autism 3 +. 0 + +METH0DS 0 +: 0 +Thirteen 0 +medication 0 +- 0 +free 0 +children 0 +with 0 +autism 3 +( 0 +mean 0 +age 0 +, 0 +8 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +5 0 +years 0 +) 0 +participated 0 +in 0 +a 0 +12 0 +- 0 +week 0 +, 0 +open 0 +- 0 +label 0 +trial 0 +of 0 +galantamine 1 +. 0 + +Patients 0 +were 0 +rated 0 +monthly 0 +by 0 +parents 0 +on 0 +the 0 +Aberrant 0 +Behavior 0 +Checklist 0 +( 0 +ABC 0 +) 0 +and 0 +the 0 +Conners 0 +' 0 +Parent 0 +Rating 0 +Scale 0 +- 0 +Revised 0 +, 0 +and 0 +by 0 +a 0 +physician 0 +using 0 +the 0 +Children 0 +' 0 +s 0 +Psychiatric 0 +Rating 0 +Scale 0 +and 0 +the 0 +Clinical 0 +Global 0 +Impressions 0 +scale 0 +. 0 + +RESULTS 0 +: 0 +Patients 0 +showed 0 +a 0 +significant 0 +reduction 0 +in 0 +parent 0 +- 0 +rated 0 +irritability 3 +and 0 +social 0 +withdrawal 0 +on 0 +the 0 +ABC 0 +as 0 +well 0 +as 0 +significant 0 +improvements 0 +in 0 +emotional 0 +lability 0 +and 0 +inattention 0 +on 0 +the 0 +Conners 0 +' 0 +Parent 0 +Rating 0 +Scale 0 +- 0 +- 0 +Revised 0 +. 0 + +Similarly 0 +, 0 +clinician 0 +ratings 0 +showed 0 +reductions 0 +in 0 +the 0 +anger 0 +subscale 0 +of 0 +the 0 +Children 0 +' 0 +s 0 +Psychiatric 0 +Rating 0 +Scale 0 +. 0 + +Eight 0 +of 0 +13 0 +participants 0 +were 0 +rated 0 +as 0 +responders 0 +on 0 +the 0 +basis 0 +of 0 +their 0 +improvement 0 +scores 0 +on 0 +the 0 +Clinical 0 +Global 0 +Impressions 0 +scale 0 +. 0 + +0verall 0 +, 0 +galantamine 1 +was 0 +well 0 +- 0 +tolerated 0 +, 0 +with 0 +no 0 +significant 0 +adverse 0 +effects 0 +apart 0 +from 0 +headaches 3 +in 0 +one 0 +patient 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +this 0 +open 0 +trial 0 +, 0 +galantamine 1 +was 0 +well 0 +- 0 +tolerated 0 +and 0 +appeared 0 +to 0 +be 0 +beneficial 0 +for 0 +the 0 +treatment 0 +of 0 +interfering 0 +behaviors 0 +in 0 +children 0 +with 0 +autism 3 +, 0 +particularly 0 +aggression 3 +, 0 +behavioral 3 +dyscontrol 4 +, 0 +and 0 +inattention 3 +. 0 + +Further 0 +controlled 0 +trials 0 +are 0 +warranted 0 +. 0 + +Randomized 0 +comparison 0 +of 0 +olanzapine 1 +versus 0 +risperidone 1 +for 0 +the 0 +treatment 0 +of 0 +first 0 +- 0 +episode 0 +schizophrenia 3 +: 0 +4 0 +- 0 +month 0 +outcomes 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +authors 0 +compared 0 +4 0 +- 0 +month 0 +treatment 0 +outcomes 0 +for 0 +olanzapine 1 +versus 0 +risperidone 1 +in 0 +patients 0 +with 0 +first 0 +- 0 +episode 0 +schizophrenia 3 +spectrum 0 +disorders 0 +. 0 + +METH0D 0 +: 0 +0ne 0 +hundred 0 +twelve 0 +subjects 0 +( 0 +70 0 +% 0 +male 0 +; 0 +mean 0 +age 0 += 0 +23 0 +. 0 +3 0 +years 0 +[ 0 +SD 0 += 0 +5 0 +. 0 +1 0 +] 0 +) 0 +with 0 +first 0 +- 0 +episode 0 +schizophrenia 3 +( 0 +75 0 +% 0 +) 0 +, 0 +schizophreniform 3 +disorder 4 +( 0 +17 0 +% 0 +) 0 +, 0 +or 0 +schizoaffective 3 +disorder 4 +( 0 +8 0 +% 0 +) 0 +were 0 +randomly 0 +assigned 0 +to 0 +treatment 0 +with 0 +olanzapine 1 +( 0 +2 0 +. 0 +5 0 +- 0 +20 0 +mg 0 +/ 0 +day 0 +) 0 +or 0 +risperidone 1 +( 0 +1 0 +- 0 +6 0 +mg 0 +/ 0 +day 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Response 0 +rates 0 +did 0 +not 0 +significantly 0 +differ 0 +between 0 +olanzapine 1 +( 0 +43 0 +. 0 +7 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +28 0 +. 0 +8 0 +% 0 +- 0 +58 0 +. 0 +6 0 +% 0 +) 0 +and 0 +risperidone 1 +( 0 +54 0 +. 0 +3 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +39 0 +. 0 +9 0 +% 0 +- 0 +68 0 +. 0 +7 0 +% 0 +) 0 +. 0 + +Among 0 +those 0 +responding 0 +to 0 +treatment 0 +, 0 +more 0 +subjects 0 +in 0 +the 0 +olanzapine 1 +group 0 +( 0 +40 0 +. 0 +9 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +16 0 +. 0 +8 0 +% 0 +- 0 +65 0 +. 0 +0 0 +% 0 +) 0 +than 0 +in 0 +the 0 +risperidone 1 +group 0 +( 0 +18 0 +. 0 +9 0 +% 0 +, 0 +95 0 +% 0 +CI 0 += 0 +0 0 +% 0 +- 0 +39 0 +. 0 +2 0 +% 0 +) 0 +had 0 +subsequent 0 +ratings 0 +not 0 +meeting 0 +response 0 +criteria 0 +. 0 + +Negative 0 +symptom 0 +outcomes 0 +and 0 +measures 0 +of 0 +parkinsonism 3 +and 0 +akathisia 3 +did 0 +not 0 +differ 0 +between 0 +medications 0 +. 0 + +Extrapyramidal 3 +symptom 4 +severity 0 +scores 0 +were 0 +1 0 +. 0 +4 0 +( 0 +95 0 +% 0 +CI 0 += 0 +1 0 +. 0 +2 0 +- 0 +1 0 +. 0 +6 0 +) 0 +with 0 +risperidone 1 +and 0 +1 0 +. 0 +2 0 +( 0 +95 0 +% 0 +CI 0 += 0 +1 0 +. 0 +0 0 +- 0 +1 0 +. 0 +4 0 +) 0 +with 0 +olanzapine 1 +. 0 + +Significantly 0 +more 0 +weight 3 +gain 4 +occurred 0 +with 0 +olanzapine 1 +than 0 +with 0 +risperidone 1 +: 0 +the 0 +increase 0 +in 0 +weight 0 +at 0 +4 0 +months 0 +relative 0 +to 0 +baseline 0 +weight 0 +was 0 +17 0 +. 0 +3 0 +% 0 +( 0 +95 0 +% 0 +CI 0 += 0 +14 0 +. 0 +2 0 +% 0 +- 0 +20 0 +. 0 +5 0 +% 0 +) 0 +with 0 +olanzapine 1 +and 0 +11 0 +. 0 +3 0 +% 0 +( 0 +95 0 +% 0 +CI 0 += 0 +8 0 +. 0 +4 0 +% 0 +- 0 +14 0 +. 0 +3 0 +% 0 +) 0 +with 0 +risperidone 1 +. 0 + +Body 0 +mass 0 +index 0 +at 0 +baseline 0 +and 0 +at 0 +4 0 +months 0 +was 0 +24 0 +. 0 +3 0 +( 0 +95 0 +% 0 +CI 0 += 0 +22 0 +. 0 +8 0 +- 0 +25 0 +. 0 +7 0 +) 0 +versus 0 +28 0 +. 0 +2 0 +( 0 +95 0 +% 0 +CI 0 += 0 +26 0 +. 0 +7 0 +- 0 +29 0 +. 0 +7 0 +) 0 +with 0 +olanzapine 1 +and 0 +23 0 +. 0 +9 0 +( 0 +95 0 +% 0 +CI 0 += 0 +22 0 +. 0 +5 0 +- 0 +25 0 +. 0 +3 0 +) 0 +versus 0 +26 0 +. 0 +7 0 +( 0 +95 0 +% 0 +CI 0 += 0 +25 0 +. 0 +2 0 +- 0 +28 0 +. 0 +2 0 +) 0 +with 0 +risperidone 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +Clinical 0 +outcomes 0 +with 0 +risperidone 1 +were 0 +equal 0 +to 0 +those 0 +with 0 +olanzapine 1 +, 0 +and 0 +response 0 +may 0 +be 0 +more 0 +stable 0 +. 0 + +0lanzapine 1 +may 0 +have 0 +an 0 +advantage 0 +for 0 +motor 0 +side 0 +effects 0 +. 0 + +Both 0 +medications 0 +caused 0 +substantial 0 +rapid 0 +weight 3 +gain 4 +, 0 +but 0 +weight 3 +gain 4 +was 0 +greater 0 +with 0 +olanzapine 1 +. 0 + +Early 0 +paracentral 0 +visual 3 +field 4 +loss 4 +in 0 +patients 0 +taking 0 +hydroxychloroquine 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +review 0 +the 0 +natural 0 +history 0 +and 0 +ocular 0 +and 0 +systemic 0 +adverse 0 +effects 0 +of 0 +patients 0 +taking 0 +hydroxychloroquine 1 +sulfate 2 +who 0 +attended 0 +an 0 +ophthalmic 0 +screening 0 +program 0 +. 0 + +DESIGN 0 +: 0 +Retrospective 0 +study 0 +. 0 + +RESULTS 0 +: 0 +Records 0 +of 0 +262 0 +patients 0 +who 0 +were 0 +taking 0 +hydroxychloroquine 1 +and 0 +screened 0 +in 0 +the 0 +Department 0 +of 0 +0phthalmology 0 +were 0 +reviewed 0 +. 0 + +0f 0 +the 0 +262 0 +patients 0 +, 0 +14 0 +( 0 +18 0 +% 0 +) 0 +of 0 +76 0 +who 0 +had 0 +stopped 0 +treatment 0 +at 0 +the 0 +time 0 +of 0 +the 0 +study 0 +experienced 0 +documented 0 +adverse 0 +effects 0 +. 0 + +Systemic 0 +adverse 0 +effects 0 +occurred 0 +in 0 +8 0 +patients 0 +( 0 +10 0 +. 0 +5 0 +% 0 +) 0 +and 0 +ocular 0 +adverse 0 +effects 0 +, 0 +in 0 +5 0 +( 0 +6 0 +. 0 +5 0 +% 0 +) 0 +. 0 + +Thirty 0 +- 0 +five 0 +patients 0 +( 0 +13 0 +. 0 +4 0 +% 0 +) 0 +had 0 +visual 3 +field 4 +abnormalities 4 +, 0 +which 0 +were 0 +attributed 0 +to 0 +hydroxychloroquine 1 +treatment 0 +in 0 +4 0 +patients 0 +( 0 +1 0 +. 0 +5 0 +% 0 +) 0 +. 0 + +Three 0 +of 0 +the 0 +4 0 +patients 0 +were 0 +taking 0 +less 0 +than 0 +6 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +and 0 +all 0 +patients 0 +had 0 +normal 0 +renal 0 +and 0 +liver 0 +function 0 +test 0 +results 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +current 0 +study 0 +used 0 +a 0 +protocol 0 +of 0 +visual 0 +acuity 0 +and 0 +color 0 +vision 0 +assessment 0 +, 0 +funduscopy 0 +, 0 +and 0 +Humphrey 0 +10 0 +- 0 +2 0 +visual 0 +field 0 +testing 0 +and 0 +shows 0 +that 0 +visual 3 +field 4 +defects 4 +appeared 0 +before 0 +any 0 +corresponding 0 +changes 0 +in 0 +any 0 +other 0 +tested 0 +clinical 0 +parameters 0 +; 0 +the 0 +defects 0 +were 0 +reproducible 0 +and 0 +the 0 +test 0 +parameters 0 +were 0 +reliable 0 +. 0 + +Patients 0 +taking 0 +hydroxychloroquine 1 +can 0 +demonstrate 0 +a 0 +toxic 0 +reaction 0 +in 0 +the 0 +retina 0 +despite 0 +the 0 +absence 0 +of 0 +known 0 +risk 0 +factors 0 +. 0 + +Screening 0 +, 0 +including 0 +Humphrey 0 +10 0 +- 0 +2 0 +visual 0 +field 0 +assessment 0 +, 0 +is 0 +recommended 0 +2 0 +years 0 +after 0 +the 0 +initial 0 +baseline 0 +and 0 +yearly 0 +thereafter 0 +. 0 + +Peri 0 +- 0 +operative 0 +atrioventricular 3 +block 4 +as 0 +a 0 +result 0 +of 0 +chemotherapy 0 +with 0 +epirubicin 1 +and 0 +paclitaxel 1 +. 0 + +A 0 +47 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +presented 0 +for 0 +mastectomy 0 +and 0 +immediate 0 +latissimus 0 +dorsi 0 +flap 0 +reconstruction 0 +having 0 +been 0 +diagnosed 0 +with 0 +carcinoma 3 +of 4 +the 4 +breast 4 +6 0 +months 0 +previously 0 +. 0 + +In 0 +the 0 +preceding 0 +months 0 +she 0 +had 0 +received 0 +neo 0 +- 0 +adjuvant 0 +chemotherapy 0 +with 0 +epirubicin 1 +, 0 +paclitaxel 1 +( 0 +Taxol 1 +) 0 +and 0 +cyclophosphamide 1 +. 0 + +This 0 +had 0 +been 0 +apparently 0 +uncomplicated 0 +and 0 +she 0 +had 0 +maintained 0 +a 0 +remarkably 0 +high 0 +level 0 +of 0 +physical 0 +activity 0 +. 0 + +She 0 +was 0 +found 0 +to 0 +be 0 +bradycardic 3 +at 0 +pre 0 +- 0 +operative 0 +assessment 0 +but 0 +had 0 +no 0 +cardiac 0 +symptoms 0 +. 0 + +Second 0 +degree 0 +Mobitz 0 +type 0 +II 0 +atrioventricular 3 +block 4 +was 0 +diagnosed 0 +on 0 +electrocardiogram 0 +, 0 +and 0 +temporary 0 +transvenous 0 +ventricular 0 +pacing 0 +instituted 0 +in 0 +the 0 +peri 0 +- 0 +operative 0 +period 0 +. 0 + +We 0 +discuss 0 +how 0 +evidence 0 +- 0 +based 0 +guidelines 0 +would 0 +not 0 +have 0 +been 0 +helpful 0 +in 0 +this 0 +case 0 +, 0 +and 0 +how 0 +chemotherapy 0 +can 0 +exhibit 0 +substantial 0 +cardiotoxicity 3 +that 0 +may 0 +develop 0 +over 0 +many 0 +years 0 +. 0 + +We 0 +suggest 0 +that 0 +patients 0 +who 0 +have 0 +received 0 +chemotherapy 0 +at 0 +any 0 +time 0 +should 0 +have 0 +a 0 +pre 0 +- 0 +operative 0 +electrocardiogram 0 +even 0 +if 0 +they 0 +are 0 +asymptomatic 0 +. 0 + +Risks 0 +and 0 +benefits 0 +of 0 +C0X 1 +- 2 +2 2 +inhibitors 2 +vs 0 +non 0 +- 0 +selective 0 +NSAIDs 0 +: 0 +does 0 +their 0 +cardiovascular 0 +risk 0 +exceed 0 +their 0 +gastrointestinal 0 +benefit 0 +? 0 + +A 0 +retrospective 0 +cohort 0 +study 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +risk 0 +of 0 +acute 3 +myocardial 4 +infarction 4 +( 0 +AMI 3 +) 0 +with 0 +C0X 1 +- 2 +2 2 +inhibitors 2 +may 0 +offset 0 +their 0 +gastrointestinal 0 +( 0 +GI 0 +) 0 +benefit 0 +compared 0 +with 0 +non 0 +- 0 +selective 0 +( 0 +NS 0 +) 0 +non 1 +- 2 +steroidal 2 +anti 2 +- 2 +inflammatory 2 +drugs 2 +( 0 +NSAIDs 0 +) 0 +. 0 + +We 0 +aimed 0 +to 0 +compare 0 +the 0 +risks 0 +of 0 +hospitalization 0 +for 0 +AMI 3 +and 0 +GI 3 +bleeding 4 +among 0 +elderly 0 +patients 0 +using 0 +C0X 1 +- 2 +2 2 +inhibitors 2 +, 0 +NS 0 +- 0 +NSAIDs 0 +and 0 +acetaminophen 1 +. 0 + +METH0DS 0 +: 0 +We 0 +conducted 0 +a 0 +retrospective 0 +cohort 0 +study 0 +using 0 +administrative 0 +data 0 +of 0 +patients 0 +> 0 +or 0 += 0 +65 0 +years 0 +of 0 +age 0 +who 0 +filled 0 +a 0 +prescription 0 +for 0 +NSAID 0 +or 0 +acetaminophen 1 +during 0 +1999 0 +- 0 +2002 0 +. 0 + +0utcomes 0 +were 0 +compared 0 +using 0 +Cox 0 +regression 0 +models 0 +with 0 +time 0 +- 0 +dependent 0 +exposures 0 +. 0 + +RESULTS 0 +: 0 +Person 0 +- 0 +years 0 +of 0 +exposure 0 +among 0 +non 0 +- 0 +users 0 +of 0 +aspirin 1 +were 0 +: 0 +75 0 +, 0 +761 0 +to 0 +acetaminophen 1 +, 0 +42 0 +, 0 +671 0 +to 0 +rofecoxib 1 +65 0 +, 0 +860 0 +to 0 +celecoxib 1 +, 0 +and 0 +37 0 +, 0 +495 0 +to 0 +NS 0 +- 0 +NSAIDs 0 +. 0 + +Among 0 +users 0 +of 0 +aspirin 1 +, 0 +they 0 +were 0 +: 0 +14 0 +, 0 +671 0 +to 0 +rofecoxib 1 +, 0 +22 0 +, 0 +875 0 +to 0 +celecoxib 1 +, 0 +9 0 +, 0 +832 0 +to 0 +NS 0 +- 0 +NSAIDs 0 +and 0 +38 0 +, 0 +048 0 +to 0 +acetaminophen 1 +. 0 + +Among 0 +non 0 +- 0 +users 0 +of 0 +aspirin 1 +, 0 +the 0 +adjusted 0 +hazard 0 +ratios 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +) 0 +of 0 +hospitalization 0 +for 0 +AMI 3 +/ 0 +GI 0 +vs 0 +the 0 +acetaminophen 1 +( 0 +with 0 +no 0 +aspirin 1 +) 0 +group 0 +were 0 +: 0 +rofecoxib 1 +1 0 +. 0 +27 0 +( 0 +1 0 +. 0 +13 0 +, 0 +1 0 +. 0 +42 0 +) 0 +, 0 +celecoxib 1 +0 0 +. 0 +93 0 +( 0 +0 0 +. 0 +83 0 +, 0 +1 0 +. 0 +03 0 +) 0 +, 0 +naproxen 1 +1 0 +. 0 +59 0 +( 0 +1 0 +. 0 +31 0 +, 0 +1 0 +. 0 +93 0 +) 0 +, 0 +diclofenac 1 +1 0 +. 0 +17 0 +( 0 +0 0 +. 0 +99 0 +, 0 +1 0 +. 0 +38 0 +) 0 +and 0 +ibuprofen 1 +1 0 +. 0 +05 0 +( 0 +0 0 +. 0 +74 0 +, 0 +1 0 +. 0 +51 0 +) 0 +. 0 + +Among 0 +users 0 +of 0 +aspirin 1 +, 0 +they 0 +were 0 +: 0 +rofecoxib 1 +1 0 +. 0 +73 0 +( 0 +1 0 +. 0 +52 0 +, 0 +1 0 +. 0 +98 0 +) 0 +, 0 +celecoxib 1 +1 0 +. 0 +34 0 +( 0 +1 0 +. 0 +19 0 +, 0 +1 0 +. 0 +52 0 +) 0 +, 0 +ibuprofen 1 +1 0 +. 0 +51 0 +( 0 +0 0 +. 0 +95 0 +, 0 +2 0 +. 0 +41 0 +) 0 +, 0 +diclofenac 1 +1 0 +. 0 +69 0 +( 0 +1 0 +. 0 +35 0 +, 0 +2 0 +. 0 +10 0 +) 0 +, 0 +naproxen 1 +1 0 +. 0 +35 0 +( 0 +0 0 +. 0 +97 0 +, 0 +1 0 +. 0 +88 0 +) 0 +and 0 +acetaminophen 1 +1 0 +. 0 +29 0 +( 0 +1 0 +. 0 +17 0 +, 0 +1 0 +. 0 +42 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Among 0 +non 0 +- 0 +users 0 +of 0 +aspirin 1 +, 0 +naproxen 1 +seemed 0 +to 0 +carry 0 +the 0 +highest 0 +risk 0 +for 0 +AMI 3 +/ 0 +GI 3 +bleeding 4 +. 0 + +The 0 +AMI 3 +/ 0 +GI 0 +toxicity 3 +of 0 +celecoxib 1 +was 0 +similar 0 +to 0 +that 0 +of 0 +acetaminophen 1 +and 0 +seemed 0 +to 0 +be 0 +better 0 +than 0 +those 0 +of 0 +rofecoxib 1 +and 0 +NS 0 +- 0 +NSAIDs 0 +. 0 + +Among 0 +users 0 +of 0 +aspirin 1 +, 0 +both 0 +celecoxib 1 +and 0 +naproxen 1 +seemed 0 +to 0 +be 0 +the 0 +least 0 +toxic 0 +. 0 + +Quinine 1 +- 0 +induced 0 +arrhythmia 3 +in 0 +a 0 +patient 0 +with 0 +severe 3 +malaria 4 +. 0 + +It 0 +was 0 +reported 0 +that 0 +there 0 +was 0 +a 0 +case 0 +of 0 +severe 3 +malaria 4 +patient 0 +with 0 +jaundice 3 +who 0 +presented 0 +with 0 +arrhythmia 3 +( 0 +premature 3 +ventricular 4 +contraction 4 +) 0 +while 0 +getting 0 +quinine 1 +infusion 0 +was 0 +reported 0 +. 0 + +A 0 +man 0 +, 0 +25 0 +years 0 +old 0 +, 0 +was 0 +admitted 0 +to 0 +hospital 0 +with 0 +high 0 +fever 3 +, 0 +chill 3 +, 0 +vomiting 3 +, 0 +jaundice 3 +. 0 + +The 0 +patient 0 +was 0 +fully 0 +conscious 0 +, 0 +blood 0 +pressure 0 +120 0 +/ 0 +80 0 +mmHg 0 +, 0 +pulse 0 +rate 0 +100 0 +x 0 +/ 0 +minute 0 +, 0 +regular 0 +. 0 + +0n 0 +admission 0 +, 0 +laboratory 0 +examination 0 +showed 0 +Plasmodium 0 +falciparum 0 +( 0 ++ 0 ++ 0 ++ 0 ++ 0 +) 0 +, 0 +total 0 +bilirubin 1 +8 0 +. 0 +25 0 +mg 0 +/ 0 +dL 0 +, 0 +conjugated 0 +bilirubin 1 +4 0 +. 0 +36 0 +mg 0 +/ 0 +dL 0 +, 0 +unconjugated 0 +bilirubin 1 +3 0 +. 0 +89 0 +mg 0 +/ 0 +dL 0 +, 0 +potassium 1 +3 0 +. 0 +52 0 +meq 0 +/ 0 +L 0 +Patient 0 +was 0 +diagnosed 0 +as 0 +severe 3 +malaria 4 +with 0 +jaundice 3 +and 0 +got 0 +quinine 1 +infusion 0 +in 0 +dextrose 1 +5 0 +% 0 +500 0 +mg 0 +/ 0 +8 0 +hour 0 +. 0 + +0n 0 +the 0 +second 0 +day 0 +the 0 +patient 0 +had 0 +vomitus 3 +, 0 +diarrhea 3 +, 0 +tinnitus 3 +, 0 +loss 3 +of 4 +hearing 4 +. 0 + +After 0 +30 0 +hours 0 +of 0 +quinine 1 +infusion 0 +the 0 +patient 0 +felt 0 +palpitation 3 +and 0 +electrocardiography 0 +( 0 +ECG 0 +) 0 +recording 0 +showed 0 +premature 3 +ventricular 4 +contraction 4 +( 0 +PVC 3 +) 0 +> 0 +5 0 +x 0 +/ 0 +minute 0 +, 0 +trigemini 0 +, 0 +constant 0 +type 0 +- 0 +- 0 +sinoatrial 3 +block 4 +, 0 +positive 0 +U 0 +wave 0 +. 0 + +He 0 +was 0 +treated 0 +with 0 +lidocaine 1 +50 0 +mg 0 +intravenously 0 +followed 0 +by 0 +infusion 0 +1500 0 +mg 0 +in 0 +dextrose 1 +5 0 +% 0 +/ 0 +24 0 +hour 0 +and 0 +potassium 1 +aspartate 2 +tablet 0 +. 0 + +Quinine 1 +infusion 0 +was 0 +discontinued 0 +and 0 +changed 0 +with 0 +sulfate 0 +quinine 1 +tablets 0 +. 0 + +Three 0 +hours 0 +later 0 +the 0 +patient 0 +felt 0 +better 0 +, 0 +the 0 +frequency 0 +of 0 +PVC 3 +reduced 0 +to 0 +4 0 +- 0 +5 0 +x 0 +/ 0 +minute 0 +and 0 +on 0 +the 0 +third 0 +day 0 +ECG 0 +was 0 +normal 0 +, 0 +potassium 1 +level 0 +was 0 +3 0 +. 0 +34 0 +meq 0 +/ 0 +L 0 +. 0 + +He 0 +was 0 +discharged 0 +on 0 +7th 0 +day 0 +in 0 +good 0 +condition 0 +. 0 + +Quinine 1 +, 0 +like 0 +quinidine 1 +, 0 +is 0 +a 0 +chincona 0 +alkaloid 0 +that 0 +has 0 +anti 0 +- 0 +arrhythmic 3 +property 0 +, 0 +although 0 +it 0 +also 0 +pro 0 +- 0 +arrhythmic 3 +that 0 +can 0 +cause 0 +various 0 +arrhythmias 3 +, 0 +including 0 +severe 0 +arrhythmia 3 +such 0 +as 0 +multiple 0 +PVC 3 +. 0 + +Administration 0 +of 0 +parenteral 0 +quinine 1 +must 0 +be 0 +done 0 +carefully 0 +and 0 +with 0 +good 0 +observation 0 +because 0 +of 0 +its 0 +pro 0 +- 0 +arrhythmic 3 +effect 0 +, 0 +especially 0 +in 0 +older 0 +patients 0 +who 0 +have 0 +heart 3 +diseases 4 +or 0 +patients 0 +with 0 +electrolyte 3 +disorder 4 +( 0 +hypokalemia 3 +) 0 +which 0 +frequently 0 +occurs 0 +due 0 +to 0 +vomiting 3 +and 0 +or 0 +diarrhea 3 +in 0 +malaria 3 +cases 0 +. 0 + +Penicillamine 1 +- 0 +related 0 +lichenoid 3 +dermatitis 4 +and 0 +utility 0 +of 0 +zinc 1 +acetate 2 +in 0 +a 0 +Wilson 3 +disease 4 +patient 0 +with 0 +hepatic 0 +presentation 0 +, 0 +anxiety 3 +and 0 +SPECT 0 +abnormalities 0 +. 0 + +Wilson 3 +' 4 +s 4 +disease 4 +is 0 +an 0 +autosomal 0 +recessive 0 +disorder 0 +of 0 +hepatic 0 +copper 1 +metabolism 0 +with 0 +consequent 0 +copper 1 +accumulation 0 +and 0 +toxicity 3 +in 0 +many 0 +tissues 0 +and 0 +consequent 0 +hepatic 3 +, 4 +neurologic 4 +and 4 +psychiatric 4 +disorders 4 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +Wilson 3 +' 4 +s 4 +disease 4 +with 0 +chronic 3 +liver 4 +disease 4 +; 0 +moreover 0 +, 0 +in 0 +our 0 +patient 0 +, 0 +presenting 0 +also 0 +with 0 +high 0 +levels 0 +of 0 +state 0 +anxiety 3 +without 0 +depression 3 +, 0 +99mTc 0 +- 0 +ECD 0 +- 0 +SPECT 0 +showed 0 +cortical 0 +hypoperfusion 0 +in 0 +frontal 0 +lobes 0 +, 0 +more 0 +marked 0 +on 0 +the 0 +left 0 +frontal 0 +lobe 0 +. 0 + +During 0 +the 0 +follow 0 +- 0 +up 0 +of 0 +our 0 +patient 0 +, 0 +penicillamine 1 +was 0 +interrupted 0 +after 0 +the 0 +appearance 0 +of 0 +a 0 +lichenoid 3 +dermatitis 4 +, 0 +and 0 +zinc 1 +acetate 2 +permitted 0 +to 0 +continue 0 +the 0 +successful 0 +treatment 0 +of 0 +the 0 +patient 0 +without 0 +side 0 +- 0 +effects 0 +. 0 + +In 0 +our 0 +case 0 +the 0 +therapy 0 +with 0 +zinc 1 +acetate 2 +represented 0 +an 0 +effective 0 +treatment 0 +for 0 +a 0 +Wilson 3 +' 4 +s 4 +disease 4 +patient 0 +in 0 +which 0 +penicillamine 1 +- 0 +related 0 +side 0 +effects 0 +appeared 0 +. 0 + +The 0 +safety 0 +of 0 +the 0 +zinc 1 +acetate 2 +allowed 0 +us 0 +to 0 +avoid 0 +other 0 +potentially 0 +toxic 0 +chelating 0 +drugs 0 +; 0 +this 0 +observation 0 +is 0 +in 0 +line 0 +with 0 +the 0 +growing 0 +evidence 0 +on 0 +the 0 +efficacy 0 +of 0 +the 0 +drug 0 +in 0 +the 0 +treatment 0 +of 0 +Wilson 3 +' 4 +s 4 +disease 4 +. 0 + +Since 0 +most 0 +of 0 +Wilson 3 +' 4 +s 4 +disease 4 +penicillamine 1 +- 0 +treated 0 +patients 0 +do 0 +not 0 +seem 0 +to 0 +develop 0 +this 0 +skin 3 +lesion 4 +, 0 +it 0 +could 0 +be 0 +conceivable 0 +that 0 +a 0 +specific 0 +genetic 0 +factor 0 +is 0 +involved 0 +in 0 +drug 0 +response 0 +. 0 + +Further 0 +studies 0 +are 0 +needed 0 +for 0 +a 0 +better 0 +clarification 0 +of 0 +Wilson 3 +' 4 +s 4 +disease 4 +therapy 0 +, 0 +and 0 +in 0 +particular 0 +to 0 +differentiate 0 +specific 0 +therapies 0 +for 0 +different 0 +Wilson 3 +' 4 +s 4 +disease 4 +phenotypes 0 +. 0 + +A 0 +dramatic 0 +drop 3 +in 4 +blood 4 +pressure 4 +following 0 +prehospital 0 +GTN 1 +administration 0 +. 0 + +A 0 +male 0 +in 0 +his 0 +sixties 0 +with 0 +no 0 +history 0 +of 0 +cardiac 0 +chest 3 +pain 4 +awoke 0 +with 0 +chest 3 +pain 4 +following 0 +an 0 +afternoon 0 +sleep 0 +. 0 + +The 0 +patient 0 +did 0 +not 0 +self 0 +medicate 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +observations 0 +were 0 +within 0 +normal 0 +limits 0 +, 0 +he 0 +was 0 +administered 0 +oxygen 1 +via 0 +a 0 +face 0 +mask 0 +and 0 +glyceryl 1 +trinitrate 2 +( 0 +GTN 1 +) 0 +. 0 + +Several 0 +minutes 0 +after 0 +the 0 +GTN 1 +the 0 +patient 0 +experienced 0 +a 0 +sudden 0 +drop 3 +in 4 +blood 4 +pressure 4 +and 0 +heart 0 +rate 0 +, 0 +this 0 +was 0 +rectified 0 +by 0 +atropine 1 +sulphate 2 +and 0 +a 0 +fluid 0 +challenge 0 +. 0 + +There 0 +was 0 +no 0 +further 0 +deterioration 0 +in 0 +the 0 +patient 0 +' 0 +s 0 +condition 0 +during 0 +transport 0 +to 0 +hospital 0 +. 0 + +There 0 +are 0 +very 0 +few 0 +documented 0 +case 0 +like 0 +this 0 +in 0 +the 0 +prehospital 0 +scientific 0 +literature 0 +. 0 + +The 0 +cause 0 +appears 0 +to 0 +be 0 +the 0 +Bezold 0 +- 0 +Jarish 0 +reflex 0 +, 0 +stimulation 0 +of 0 +the 0 +ventricular 0 +walls 0 +which 0 +in 0 +turn 0 +decreases 0 +sympathetic 0 +outflow 0 +from 0 +the 0 +vasomotor 0 +centre 0 +. 0 + +Prehospital 0 +care 0 +providers 0 +who 0 +are 0 +managing 0 +any 0 +patient 0 +with 0 +a 0 +syncopal 3 +episode 4 +that 0 +fails 0 +to 0 +recover 0 +within 0 +a 0 +reasonable 0 +time 0 +frame 0 +should 0 +consider 0 +the 0 +Bezold 0 +- 0 +Jarisch 0 +reflex 0 +as 0 +the 0 +cause 0 +and 0 +manage 0 +the 0 +patient 0 +accordingly 0 +. 0 + +Chronic 0 +lesion 0 +of 0 +rostral 0 +ventrolateral 0 +medulla 0 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +We 0 +studied 0 +the 0 +effects 0 +of 0 +chronic 0 +selective 0 +neuronal 0 +lesion 0 +of 0 +rostral 0 +ventrolateral 0 +medulla 0 +on 0 +mean 0 +arterial 0 +pressure 0 +, 0 +heart 0 +rate 0 +, 0 +and 0 +neurogenic 0 +tone 0 +in 0 +conscious 0 +, 0 +unrestrained 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +The 0 +lesions 0 +were 0 +placed 0 +via 0 +bilateral 0 +microinjections 0 +of 0 +30 0 +nmol 0 +/ 0 +200 0 +nl 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartic 2 +acid 2 +. 0 + +The 0 +restimulation 0 +of 0 +this 0 +area 0 +with 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartic 2 +acid 2 +15 0 +days 0 +postlesion 0 +failed 0 +to 0 +produce 0 +a 0 +pressor 0 +response 0 +. 0 + +0ne 0 +day 0 +postlesion 0 +, 0 +the 0 +resting 0 +mean 0 +arterial 0 +pressure 0 +was 0 +significantly 0 +decreased 0 +in 0 +lesioned 0 +rats 0 +when 0 +compared 0 +with 0 +sham 0 +rats 0 +( 0 +100 0 ++ 0 +/ 0 +- 0 +7 0 +versus 0 +173 0 ++ 0 +/ 0 +- 0 +4 0 +mm 0 +Hg 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Fifteen 0 +days 0 +later 0 +, 0 +the 0 +lesioned 0 +group 0 +still 0 +showed 0 +values 0 +significantly 0 +lower 0 +than 0 +the 0 +sham 0 +group 0 +( 0 +150 0 ++ 0 +/ 0 +- 0 +6 0 +versus 0 +167 0 ++ 0 +/ 0 +- 0 +5 0 +mm 0 +Hg 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +No 0 +significant 0 +heart 0 +rate 0 +differences 0 +were 0 +observed 0 +between 0 +the 0 +sham 0 +and 0 +lesioned 0 +groups 0 +. 0 + +The 0 +ganglionic 0 +blocker 0 +trimethaphan 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +caused 0 +similar 0 +reductions 0 +in 0 +mean 0 +arterial 0 +pressure 0 +in 0 +both 0 +lesioned 0 +and 0 +sham 0 +groups 0 +. 0 + +The 0 +trimethaphan 1 +- 0 +induced 0 +hypotension 3 +was 0 +accompanied 0 +by 0 +a 0 +significant 0 +bradycardia 3 +in 0 +lesioned 0 +rats 0 +( 0 +- 0 +32 0 ++ 0 +/ 0 +- 0 +13 0 +beats 0 +per 0 +minute 0 +) 0 +but 0 +a 0 +tachycardia 3 +in 0 +sham 0 +rats 0 +( 0 ++ 0 +33 0 ++ 0 +/ 0 +- 0 +12 0 +beats 0 +per 0 +minute 0 +) 0 +1 0 +day 0 +postlesion 0 +. 0 + +Therefore 0 +, 0 +rostral 0 +ventrolateral 0 +medulla 0 +neurons 0 +appear 0 +to 0 +play 0 +a 0 +significant 0 +role 0 +in 0 +maintaining 0 +hypertension 3 +in 0 +conscious 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +Spinal 0 +or 0 +suprabulbar 0 +structures 0 +could 0 +be 0 +responsible 0 +for 0 +the 0 +gradual 0 +recovery 0 +of 0 +the 0 +hypertension 3 +in 0 +the 0 +lesioned 0 +rats 0 +. 0 + +Acute 3 +encephalopathy 4 +and 0 +cerebral 3 +vasospasm 4 +after 0 +multiagent 0 +chemotherapy 0 +including 0 +PEG 1 +- 2 +asparaginase 2 +and 0 +intrathecal 0 +cytarabine 1 +for 0 +the 0 +treatment 0 +of 0 +acute 3 +lymphoblastic 4 +leukemia 4 +. 0 + +A 0 +7 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +with 0 +an 0 +unusual 0 +reaction 0 +to 0 +induction 0 +chemotherapy 0 +for 0 +precursor 0 +B 0 +- 0 +cell 0 +acute 3 +lymphoblastic 4 +leukemia 4 +( 0 +ALL 3 +) 0 +is 0 +described 0 +. 0 + +The 0 +patient 0 +developed 0 +acute 3 +encephalopathy 4 +evidenced 0 +by 0 +behavioral 0 +changes 0 +, 0 +aphasia 3 +, 0 +incontinence 3 +, 0 +visual 3 +hallucinations 4 +, 0 +and 0 +right 0 +- 0 +sided 0 +weakness 3 +with 0 +diffuse 0 +cerebral 3 +vasospasm 4 +on 0 +magnetic 0 +resonance 0 +angiography 0 +after 0 +the 0 +administration 0 +of 0 +intrathecal 0 +cytarabine 1 +. 0 + +Vincristine 1 +, 0 +dexamethasone 1 +, 0 +and 0 +polyethylene 1 +glycol 2 +- 2 +asparaginase 2 +were 0 +also 0 +administered 0 +before 0 +the 0 +episode 0 +as 0 +part 0 +of 0 +induction 0 +therapy 0 +. 0 + +Neurologic 0 +status 0 +returned 0 +to 0 +baseline 0 +within 0 +10 0 +days 0 +of 0 +the 0 +acute 0 +event 0 +, 0 +and 0 +magnetic 0 +resonance 0 +angiography 0 +findings 0 +returned 0 +to 0 +normal 0 +4 0 +months 0 +later 0 +. 0 + +Comparison 0 +of 0 +valsartan 1 +/ 0 +hydrochlorothiazide 1 +combination 0 +therapy 0 +at 0 +doses 0 +up 0 +to 0 +320 0 +/ 0 +25 0 +mg 0 +versus 0 +monotherapy 0 +: 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +study 0 +followed 0 +by 0 +long 0 +- 0 +term 0 +combination 0 +therapy 0 +in 0 +hypertensive 3 +adults 0 +. 0 + +BACKGR0UND 0 +: 0 +0ne 0 +third 0 +of 0 +patients 0 +treated 0 +for 0 +hypertension 3 +attain 0 +adequate 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +control 0 +, 0 +and 0 +multidrug 0 +regimens 0 +are 0 +often 0 +required 0 +. 0 + +Given 0 +the 0 +lifelong 0 +nature 0 +of 0 +hypertension 3 +, 0 +there 0 +is 0 +a 0 +need 0 +to 0 +evaluate 0 +the 0 +long 0 +- 0 +term 0 +efficacy 0 +and 0 +tolerability 0 +of 0 +higher 0 +doses 0 +of 0 +combination 0 +anti 0 +- 0 +hypertensive 3 +therapies 0 +. 0 + +0BJECTIVE 0 +: 0 +This 0 +study 0 +investigated 0 +the 0 +efficacy 0 +and 0 +tolerability 0 +of 0 +valsartan 1 +( 0 +VAL 1 +) 0 +or 0 +hydrochlorothiazide 1 +( 0 +HCTZ 1 +) 0 +- 0 +monotherapy 0 +and 0 +higher 0 +- 0 +dose 0 +combinations 0 +in 0 +patients 0 +with 0 +essential 3 +hypertension 4 +. 0 + +METH0DS 0 +: 0 +The 0 +first 0 +part 0 +of 0 +this 0 +study 0 +was 0 +an 0 +8 0 +- 0 +week 0 +, 0 +multicenter 0 +, 0 +randomized 0 +, 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +controlled 0 +, 0 +parallel 0 +- 0 +group 0 +trial 0 +. 0 + +Patients 0 +with 0 +essential 3 +hypertension 4 +( 0 +mean 0 +sitting 0 +diastolic 0 +BP 0 +[ 0 +MSDBP 0 +] 0 +, 0 +> 0 +or 0 += 0 +95 0 +mm 0 +Hg 0 +and 0 +< 0 +110 0 +mm 0 +Hg 0 +) 0 +were 0 +randomized 0 +to 0 +1 0 +of 0 +8 0 +treatment 0 +groups 0 +: 0 +VAL 1 +160 0 +or 0 +320 0 +mg 0 +; 0 +HCTZ 1 +12 0 +. 0 +5 0 +or 0 +25 0 +mg 0 +; 0 +VAL 1 +/ 0 +HCTZ 1 +160 0 +/ 0 +12 0 +. 0 +5 0 +, 0 +320 0 +/ 0 +12 0 +. 0 +5 0 +, 0 +or 0 +320 0 +/ 0 +25 0 +mg 0 +; 0 +or 0 +placebo 0 +. 0 + +Mean 0 +changes 0 +in 0 +MSDBP 0 +and 0 +mean 0 +sitting 0 +systolic 0 +BP 0 +( 0 +MSSBP 0 +) 0 +were 0 +analyzed 0 +at 0 +the 0 +8 0 +- 0 +week 0 +core 0 +study 0 +end 0 +point 0 +. 0 + +VAL 1 +/ 0 +HCTZ 1 +320 0 +/ 0 +12 0 +. 0 +5 0 +and 0 +320 0 +/ 0 +25 0 +mg 0 +were 0 +further 0 +investigated 0 +in 0 +a 0 +54 0 +- 0 +week 0 +, 0 +open 0 +- 0 +label 0 +extension 0 +. 0 + +Response 0 +was 0 +defined 0 +as 0 +MSDBP 0 +< 0 +90 0 +mm 0 +Hg 0 +or 0 +a 0 +> 0 +or 0 += 0 +10 0 +mm 0 +Hg 0 +decrease 0 +compared 0 +to 0 +baseline 0 +. 0 + +Control 0 +was 0 +defined 0 +as 0 +MSDBP 0 +< 0 +90 0 +mm 0 +Hg 0 +compared 0 +with 0 +baseline 0 +. 0 + +Tolerability 0 +was 0 +assessed 0 +by 0 +monitoring 0 +adverse 0 +events 0 +at 0 +randomization 0 +and 0 +all 0 +subsequent 0 +study 0 +visits 0 +and 0 +regular 0 +evaluation 0 +of 0 +hematology 0 +and 0 +blood 0 +chemistry 0 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +1346 0 +patients 0 +were 0 +randomized 0 +into 0 +the 0 +8 0 +- 0 +week 0 +core 0 +study 0 +( 0 +734 0 +men 0 +, 0 +612 0 +women 0 +; 0 +924 0 +white 0 +, 0 +291 0 +black 0 +, 0 +23 0 +Asian 0 +, 0 +108 0 +other 0 +; 0 +mean 0 +age 0 +, 0 +52 0 +. 0 +7 0 +years 0 +; 0 +mean 0 +weight 0 +, 0 +92 0 +. 0 +6 0 +kg 0 +) 0 +. 0 + +All 0 +active 0 +treatments 0 +were 0 +associated 0 +with 0 +significantly 0 +reduced 0 +MSSBP 0 +and 0 +MSDBP 0 +during 0 +the 0 +core 0 +8 0 +- 0 +week 0 +study 0 +, 0 +with 0 +each 0 +monotherapy 0 +significantly 0 +contributing 0 +to 0 +the 0 +overall 0 +effect 0 +of 0 +combination 0 +therapy 0 +( 0 +VAL 1 +and 0 +HCTZ 1 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Each 0 +combination 0 +was 0 +associated 0 +with 0 +significantly 0 +greater 0 +reductions 0 +in 0 +MSSBP 0 +and 0 +MSDBP 0 +compared 0 +with 0 +the 0 +monotherapies 0 +and 0 +placebo 0 +( 0 +all 0 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +The 0 +mean 0 +reduction 0 +in 0 +MSSBP 0 +/ 0 +MSDBP 0 +with 0 +VAL 1 +/ 0 +HCTZ 1 +320 0 +/ 0 +25 0 +mg 0 +was 0 +24 0 +. 0 +7 0 +/ 0 +16 0 +. 0 +6 0 +mm 0 +Hg 0 +, 0 +compared 0 +with 0 +5 0 +. 0 +9 0 +/ 0 +7 0 +. 0 +0 0 +mm 0 +Hg 0 +with 0 +placebo 0 +. 0 + +The 0 +reduction 0 +in 0 +MSSBP 0 +was 0 +significantly 0 +greater 0 +with 0 +VAL 1 +/ 0 +HCTZ 1 +320 0 +/ 0 +25 0 +mg 0 +compared 0 +with 0 +VAL 1 +/ 0 +HCTZ 1 +160 0 +/ 0 +12 0 +. 0 +5 0 +mg 0 +( 0 +P 0 +< 0 +0 0 +. 0 +002 0 +) 0 +. 0 + +Rates 0 +of 0 +response 0 +and 0 +BP 0 +control 0 +were 0 +significantly 0 +higher 0 +in 0 +the 0 +groups 0 +that 0 +received 0 +combination 0 +treatment 0 +compared 0 +with 0 +those 0 +that 0 +received 0 +monotherapy 0 +. 0 + +The 0 +incidence 0 +of 0 +hypokalemia 3 +was 0 +lower 0 +with 0 +VAL 1 +/ 0 +HCTZ 1 +combinations 0 +( 0 +1 0 +. 0 +8 0 +% 0 +- 0 +6 0 +. 0 +1 0 +% 0 +) 0 +than 0 +with 0 +HCTZ 1 +monotherapies 0 +( 0 +7 0 +. 0 +1 0 +% 0 +- 0 +13 0 +. 0 +3 0 +% 0 +) 0 +. 0 + +The 0 +majority 0 +of 0 +adverse 0 +events 0 +in 0 +the 0 +core 0 +study 0 +were 0 +of 0 +mild 0 +to 0 +moderate 0 +severity 0 +. 0 + +The 0 +efficacy 0 +and 0 +tolerability 0 +of 0 +VAL 1 +/ 0 +HCTZ 1 +combinations 0 +were 0 +maintained 0 +during 0 +the 0 +extension 0 +( 0 +797 0 +patients 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +this 0 +study 0 +population 0 +, 0 +combination 0 +therapies 0 +with 0 +VAL 1 +/ 0 +HCTZ 1 +were 0 +associated 0 +with 0 +significantly 0 +greater 0 +BP 0 +reductions 0 +compared 0 +with 0 +either 0 +monotherapy 0 +, 0 +were 0 +well 0 +tolerated 0 +, 0 +and 0 +were 0 +associated 0 +with 0 +less 0 +hypokalemia 3 +than 0 +HCTZ 1 +alone 0 +. 0 + +Succimer 1 +chelation 0 +improves 0 +learning 0 +, 0 +attention 0 +, 0 +and 0 +arousal 0 +regulation 0 +in 0 +lead 1 +- 0 +exposed 0 +rats 0 +but 0 +produces 0 +lasting 0 +cognitive 3 +impairment 4 +in 0 +the 0 +absence 0 +of 0 +lead 1 +exposure 0 +. 0 + +BACKGR0UND 0 +: 0 +There 0 +is 0 +growing 0 +pressure 0 +for 0 +clinicians 0 +to 0 +prescribe 0 +chelation 0 +therapy 0 +at 0 +only 0 +slightly 0 +elevated 0 +blood 0 +lead 1 +levels 0 +. 0 + +However 0 +, 0 +very 0 +few 0 +studies 0 +have 0 +evaluated 0 +whether 0 +chelation 0 +improves 0 +cognitive 0 +outcomes 0 +in 0 +Pb 1 +- 0 +exposed 0 +children 0 +, 0 +or 0 +whether 0 +these 0 +agents 0 +have 0 +adverse 0 +effects 0 +that 0 +may 0 +affect 0 +brain 0 +development 0 +in 0 +the 0 +absence 0 +of 0 +Pb 1 +exposure 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +answer 0 +these 0 +questions 0 +, 0 +using 0 +a 0 +rodent 0 +model 0 +of 0 +early 0 +childhood 0 +Pb 1 +exposure 0 +and 0 +treatment 0 +with 0 +succimer 1 +, 0 +a 0 +widely 0 +used 0 +chelating 0 +agent 0 +for 0 +the 0 +treatment 0 +of 0 +Pb 3 +poisoning 4 +. 0 + +RESULTS 0 +: 0 +Pb 1 +exposure 0 +produced 0 +lasting 0 +impairments 3 +in 4 +learning 4 +, 4 +attention 4 +, 4 +inhibitory 4 +control 4 +, 4 +and 4 +arousal 4 +regulation 4 +, 0 +paralleling 0 +the 0 +areas 0 +of 0 +dysfunction 0 +seen 0 +in 0 +Pb 1 +- 0 +exposed 0 +children 0 +. 0 + +Succimer 1 +treatment 0 +of 0 +the 0 +Pb 1 +- 0 +exposed 0 +rats 0 +significantly 0 +improved 0 +learning 0 +, 0 +attention 0 +, 0 +and 0 +arousal 0 +regulation 0 +, 0 +although 0 +the 0 +efficacy 0 +of 0 +the 0 +treatment 0 +varied 0 +as 0 +a 0 +function 0 +of 0 +the 0 +Pb 1 +exposure 0 +level 0 +and 0 +the 0 +specific 0 +functional 0 +deficit 0 +. 0 + +In 0 +contrast 0 +, 0 +succimer 1 +treatment 0 +of 0 +rats 0 +not 0 +previously 0 +exposed 0 +to 0 +Pb 1 +produced 0 +lasting 0 +and 0 +pervasive 0 +cognitive 3 +and 4 +affective 4 +dysfunction 4 +comparable 0 +in 0 +magnitude 0 +to 0 +that 0 +produced 0 +by 0 +the 0 +higher 0 +Pb 1 +exposure 0 +regimen 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +are 0 +the 0 +first 0 +data 0 +, 0 +to 0 +our 0 +knowledge 0 +, 0 +to 0 +show 0 +that 0 +treatment 0 +with 0 +any 0 +chelating 0 +agent 0 +can 0 +alleviate 0 +cognitive 3 +deficits 4 +due 0 +to 0 +Pb 1 +exposure 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +it 0 +may 0 +be 0 +possible 0 +to 0 +identify 0 +a 0 +succimer 1 +treatment 0 +protocol 0 +that 0 +improves 0 +cognitive 0 +outcomes 0 +in 0 +Pb 1 +- 0 +exposed 0 +children 0 +. 0 + +However 0 +, 0 +they 0 +also 0 +suggest 0 +that 0 +succimer 1 +treatment 0 +should 0 +be 0 +strongly 0 +discouraged 0 +for 0 +children 0 +who 0 +do 0 +not 0 +have 0 +elevated 0 +tissue 0 +levels 0 +of 0 +Pb 1 +or 0 +other 0 +heavy 0 +metals 0 +. 0 + +Caffeine 1 +challenge 0 +test 0 +in 0 +panic 3 +disorder 4 +and 0 +depression 3 +with 0 +panic 3 +attacks 4 +. 0 + +0ur 0 +aim 0 +was 0 +to 0 +observe 0 +if 0 +patients 0 +with 0 +panic 3 +disorder 4 +( 0 +PD 3 +) 0 +and 0 +patients 0 +with 0 +major 3 +depression 4 +with 0 +panic 3 +attacks 4 +( 0 +MDP 3 +) 0 +( 0 +Diagnostic 0 +and 0 +Statistical 0 +Manual 0 +of 0 +Mental 3 +Disorders 4 +, 0 +Fourth 0 +Edition 0 +criteria 0 +) 0 +respond 0 +in 0 +a 0 +similar 0 +way 0 +to 0 +the 0 +induction 0 +of 0 +panic 3 +attacks 4 +by 0 +an 0 +oral 0 +caffeine 1 +challenge 0 +test 0 +. 0 + +We 0 +randomly 0 +selected 0 +29 0 +patients 0 +with 0 +PD 3 +, 0 +27 0 +with 0 +MDP 3 +, 0 +25 0 +with 0 +major 3 +depression 4 +without 0 +panic 3 +attacks 4 +( 0 +MD 3 +) 0 +, 0 +and 0 +28 0 +healthy 0 +volunteers 0 +. 0 + +The 0 +patients 0 +had 0 +no 0 +psychotropic 0 +drug 0 +for 0 +at 0 +least 0 +a 0 +4 0 +- 0 +week 0 +period 0 +. 0 + +In 0 +a 0 +randomized 0 +double 0 +- 0 +blind 0 +experiment 0 +performed 0 +in 0 +2 0 +occasions 0 +7 0 +days 0 +apart 0 +, 0 +480 0 +mg 0 +caffeine 1 +and 0 +a 0 +caffeine 1 +- 0 +free 0 +( 0 +placebo 0 +) 0 +solution 0 +were 0 +administered 0 +in 0 +a 0 +coffee 0 +form 0 +and 0 +anxiety 3 +scales 0 +were 0 +applied 0 +before 0 +and 0 +after 0 +each 0 +test 0 +. 0 + +A 0 +total 0 +of 0 +58 0 +. 0 +6 0 +% 0 +( 0 +n 0 += 0 +17 0 +) 0 +of 0 +patients 0 +with 0 +PD 3 +, 0 +44 0 +. 0 +4 0 +% 0 +( 0 +n 0 += 0 +12 0 +) 0 +of 0 +patients 0 +with 0 +MDP 3 +, 0 +12 0 +. 0 +0 0 +% 0 +( 0 +n 0 += 0 +3 0 +) 0 +of 0 +patients 0 +with 0 +MD 3 +, 0 +and 0 +7 0 +. 0 +1 0 +% 0 +( 0 +n 0 += 0 +2 0 +) 0 +of 0 +control 0 +subjects 0 +had 0 +a 0 +panic 3 +attack 4 +after 0 +the 0 +480 0 +- 0 +mg 0 +caffeine 1 +challenge 0 +test 0 +( 0 +chi 0 +( 0 +2 0 +) 0 +( 0 +3 0 +) 0 += 0 +16 0 +. 0 +22 0 +, 0 +P 0 += 0 +. 0 +001 0 +) 0 +. 0 + +The 0 +patients 0 +with 0 +PD 3 +and 0 +MDP 3 +were 0 +more 0 +sensitive 0 +to 0 +caffeine 1 +than 0 +were 0 +patients 0 +with 0 +MD 3 +and 0 +healthy 0 +volunteers 0 +. 0 + +No 0 +panic 3 +attack 4 +was 0 +observed 0 +after 0 +the 0 +caffeine 1 +- 0 +free 0 +solution 0 +intake 0 +. 0 + +The 0 +patients 0 +with 0 +MD 3 +had 0 +a 0 +lower 0 +heart 0 +rate 0 +response 0 +to 0 +the 0 +test 0 +than 0 +all 0 +the 0 +other 0 +groups 0 +( 0 +2 0 +- 0 +way 0 +analysis 0 +of 0 +variance 0 +, 0 +group 0 +by 0 +time 0 +interaction 0 +with 0 +Greenhouse 0 +- 0 +Geisser 0 +correction 0 +: 0 +F 0 +( 0 +3 0 +, 0 +762 0 +) 0 += 0 +2 0 +. 0 +85 0 +, 0 +P 0 += 0 +. 0 +026 0 +) 0 +. 0 + +0ur 0 +data 0 +suggest 0 +that 0 +there 0 +is 0 +an 0 +association 0 +between 0 +panic 3 +attacks 4 +, 0 +no 0 +matter 0 +if 0 +associated 0 +with 0 +PD 3 +or 0 +MDP 3 +, 0 +and 0 +hyperreactivity 0 +to 0 +an 0 +oral 0 +caffeine 1 +challenge 0 +test 0 +. 0 + +Mitral 0 +annuloplasty 0 +as 0 +a 0 +ventricular 0 +restoration 0 +method 0 +for 0 +the 0 +failing 3 +left 4 +ventricle 4 +: 0 +a 0 +pilot 0 +study 0 +. 0 + +BACKGR0UND 0 +AND 0 +AIM 0 +0F 0 +THE 0 +STUDY 0 +: 0 +Undersized 0 +mitral 0 +annuloplasty 0 +( 0 +MAP 0 +) 0 +is 0 +effective 0 +in 0 +patients 0 +with 0 +dilated 3 +cardiomyopathy 4 +and 0 +functional 0 +mitral 3 +regurgitation 4 +( 0 +MR 3 +) 0 +since 0 +, 0 +as 0 +well 0 +as 0 +addressing 0 +the 0 +MR 3 +, 0 +the 0 +MAP 0 +may 0 +also 0 +reshape 0 +the 0 +dilated 0 +left 0 +ventricular 0 +( 0 +LV 0 +) 0 +base 0 +. 0 + +However 0 +, 0 +the 0 +direct 0 +benefits 0 +of 0 +this 0 +possible 0 +reshaping 0 +on 0 +LV 0 +function 0 +in 0 +the 0 +absence 0 +of 0 +underlying 0 +MR 3 +remain 0 +incompletely 0 +understood 0 +. 0 + +The 0 +study 0 +aim 0 +was 0 +to 0 +identify 0 +these 0 +benefits 0 +in 0 +a 0 +canine 0 +model 0 +of 0 +acute 0 +heart 3 +failure 4 +. 0 + +METH0DS 0 +: 0 +Six 0 +dogs 0 +underwent 0 +MAP 0 +with 0 +a 0 +prosthetic 0 +band 0 +on 0 +the 0 +posterior 0 +mitral 0 +annulus 0 +, 0 +using 0 +four 0 +mattress 0 +sutures 0 +. 0 + +The 0 +sutures 0 +were 0 +passed 0 +individually 0 +through 0 +four 0 +tourniquets 0 +and 0 +exteriorized 0 +untied 0 +via 0 +the 0 +left 0 +atriotomy 0 +. 0 + +Sonomicrometry 0 +crystals 0 +were 0 +implanted 0 +around 0 +the 0 +mitral 0 +annulus 0 +and 0 +left 0 +ventricle 0 +to 0 +measure 0 +geometry 0 +and 0 +regional 0 +function 0 +. 0 + +Acute 0 +heart 3 +failure 4 +was 0 +induced 0 +by 0 +propranolol 1 +and 0 +volume 0 +loading 0 +after 0 +weaning 0 +from 0 +cardiopulmonary 0 +bypass 0 +; 0 +an 0 +absence 0 +of 0 +MR 3 +was 0 +confirmed 0 +by 0 +echocardiography 0 +. 0 + +MAP 0 +was 0 +accomplished 0 +by 0 +cinching 0 +the 0 +tourniquets 0 +. 0 + +Data 0 +were 0 +acquired 0 +at 0 +baseline 0 +, 0 +after 0 +induction 0 +of 0 +acute 0 +heart 3 +failure 4 +, 0 +and 0 +after 0 +MAP 0 +. 0 + +RESULTS 0 +: 0 +MAP 0 +decreased 0 +mitral 0 +annular 0 +dimensions 0 +in 0 +both 0 +commissure 0 +- 0 +commissure 0 +and 0 +septal 0 +- 0 +lateral 0 +directions 0 +. 0 + +Concomitantly 0 +, 0 +the 0 +diastolic 0 +diameter 0 +of 0 +the 0 +LV 0 +base 0 +and 0 +LV 0 +sphericity 0 +decreased 0 +( 0 +i 0 +. 0 +e 0 +. 0 +, 0 +improved 0 +) 0 +from 0 +37 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +9 0 +. 0 +3 0 +to 0 +35 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +10 0 +mm 0 +( 0 +p 0 += 0 +0 0 +. 0 +063 0 +) 0 +, 0 +and 0 +from 0 +67 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +18 0 +. 0 +6 0 +% 0 +to 0 +65 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +18 0 +. 0 +9 0 +% 0 +( 0 +p 0 += 0 +0 0 +. 0 +016 0 +) 0 +, 0 +respectively 0 +. 0 + +Decreases 0 +were 0 +evident 0 +in 0 +both 0 +LV 0 +end 0 +- 0 +diastolic 0 +pressure 0 +( 0 +from 0 +17 0 ++ 0 +/ 0 +- 0 +7 0 +to 0 +15 0 ++ 0 +/ 0 +- 0 +6 0 +mmHg 0 +, 0 +p 0 += 0 +0 0 +. 0 +0480 0 +and 0 +Tau 0 +( 0 +from 0 +48 0 ++ 0 +/ 0 +- 0 +8 0 +to 0 +45 0 ++ 0 +/ 0 +- 0 +8 0 +ms 0 +, 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +, 0 +while 0 +fractional 0 +shortening 0 +at 0 +the 0 +LV 0 +base 0 +increased 0 +from 0 +7 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +5 0 +% 0 +to 0 +9 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +5 0 +% 0 +( 0 +p 0 += 0 +0 0 +. 0 +045 0 +) 0 +. 0 + +After 0 +MAP 0 +, 0 +increases 0 +were 0 +identified 0 +in 0 +both 0 +cardiac 0 +output 0 +( 0 +from 0 +1 0 +. 0 +54 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +57 0 +to 0 +1 0 +. 0 +65 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +57 0 +1 0 +/ 0 +min 0 +) 0 +and 0 +Emax 0 +( 0 +from 0 +1 0 +. 0 +86 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +to 0 +2 0 +. 0 +41 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +31 0 +mmHg 0 +/ 0 +ml 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +data 0 +acquired 0 +suggest 0 +that 0 +isolated 0 +MAP 0 +may 0 +have 0 +certain 0 +benefits 0 +on 0 +LV 0 +dimension 0 +/ 0 +function 0 +in 0 +acute 0 +heart 3 +failure 4 +, 0 +even 0 +in 0 +the 0 +absence 0 +of 0 +MR 3 +. 0 + +However 0 +, 0 +further 0 +investigations 0 +are 0 +warranted 0 +in 0 +a 0 +model 0 +of 0 +chronic 0 +heart 3 +failure 4 +. 0 + +Piperacillin 1 +/ 2 +tazobactam 2 +- 0 +induced 0 +seizure 3 +rapidly 0 +reversed 0 +by 0 +high 0 +flux 0 +hemodialysis 0 +in 0 +a 0 +patient 0 +on 0 +peritoneal 0 +dialysis 0 +. 0 + +Despite 0 +popular 0 +use 0 +of 0 +piperacillin 1 +, 0 +the 0 +dire 0 +neurotoxicity 3 +associated 0 +with 0 +piperacillin 1 +still 0 +goes 0 +unrecognized 0 +, 0 +leading 0 +to 0 +a 0 +delay 0 +in 0 +appropriate 0 +management 0 +. 0 + +We 0 +report 0 +a 0 +57 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +receiving 0 +continuous 0 +ambulatory 0 +peritoneal 0 +dialysis 0 +( 0 +CAPD 0 +) 0 +, 0 +who 0 +developed 0 +slurred 0 +speech 0 +, 0 +tremor 3 +, 0 +bizarre 0 +behavior 0 +, 0 +progressive 0 +mental 0 +confusion 3 +, 0 +and 0 +2 0 +episodes 0 +of 0 +generalized 0 +tonic 3 +- 4 +clonic 4 +seizure 4 +( 0 +GTCS 3 +) 0 +after 0 +5 0 +doses 0 +of 0 +piperacillin 1 +/ 2 +tazobactam 2 +( 0 +2 0 +g 0 +/ 0 +250 0 +mg 0 +) 0 +were 0 +given 0 +for 0 +bronchiectasis 3 +with 0 +secondary 3 +infection 4 +. 0 + +The 0 +laboratory 0 +data 0 +revealed 0 +normal 0 +plasma 0 +electrolyte 0 +and 0 +ammonia 1 +levels 0 +but 0 +leukocytosis 3 +. 0 + +Neurologic 0 +examinations 0 +showed 0 +dysarthria 3 +and 0 +bilateral 0 +Babinski 0 +sign 0 +. 0 + +Computed 0 +tomography 0 +of 0 +brain 0 +and 0 +electroencephalogram 0 +were 0 +unremarkable 0 +. 0 + +Despite 0 +the 0 +use 0 +of 0 +antiepileptic 0 +agents 0 +, 0 +another 0 +GTCS 3 +episode 0 +recurred 0 +after 0 +the 0 +sixth 0 +dose 0 +of 0 +piperacillin 1 +/ 2 +tazobactam 2 +. 0 + +Brain 0 +magnetic 0 +resonance 0 +imaging 0 +did 0 +not 0 +demonstrate 0 +acute 0 +infarction 3 +and 0 +organic 3 +brain 4 +lesions 4 +. 0 + +Initiation 0 +of 0 +high 0 +- 0 +flux 0 +hemodialysis 0 +rapidly 0 +reversed 0 +the 0 +neurologic 0 +symptoms 0 +within 0 +4 0 +hours 0 +. 0 + +Piperacillin 1 +- 0 +induced 0 +encephalopathy 3 +should 0 +be 0 +considered 0 +in 0 +any 0 +uremic 3 +patients 0 +with 0 +unexplained 0 +neurological 0 +manifestations 0 +. 0 + +CAPD 0 +is 0 +inefficient 0 +in 0 +removing 0 +piperacillin 1 +, 0 +whereas 0 +hemodialysis 0 +can 0 +rapidly 0 +terminate 0 +the 0 +piperacillin 1 +- 0 +induced 0 +encephalopathy 3 +. 0 + +Frequency 0 +of 0 +transient 0 +ipsilateral 0 +vocal 3 +cord 4 +paralysis 4 +in 0 +patients 0 +undergoing 0 +carotid 0 +endarterectomy 0 +under 0 +local 0 +anesthesia 0 +. 0 + +BACKGR0UND 0 +: 0 +Especially 0 +because 0 +of 0 +improvements 0 +in 0 +clinical 0 +neurologic 0 +monitoring 0 +, 0 +carotid 0 +endarterectomy 0 +done 0 +under 0 +local 0 +anesthesia 0 +has 0 +become 0 +the 0 +technique 0 +of 0 +choice 0 +in 0 +several 0 +centers 0 +. 0 + +Temporary 0 +ipsilateral 0 +vocal 3 +nerve 4 +palsies 4 +due 0 +to 0 +local 0 +anesthetics 0 +have 0 +been 0 +described 0 +, 0 +however 0 +. 0 + +Such 0 +complications 0 +are 0 +most 0 +important 0 +in 0 +situations 0 +where 0 +there 0 +is 0 +a 0 +pre 0 +- 0 +existing 0 +contralateral 0 +paralysis 3 +. 0 + +We 0 +therefore 0 +examined 0 +the 0 +effect 0 +of 0 +local 0 +anesthesia 0 +on 0 +vocal 0 +cord 0 +function 0 +to 0 +better 0 +understand 0 +its 0 +possible 0 +consequences 0 +. 0 + +METH0DS 0 +: 0 +This 0 +prospective 0 +study 0 +included 0 +28 0 +patients 0 +undergoing 0 +carotid 0 +endarterectomy 0 +under 0 +local 0 +anesthesia 0 +. 0 + +Vocal 0 +cord 0 +function 0 +was 0 +evaluated 0 +before 0 +, 0 +during 0 +, 0 +and 0 +after 0 +surgery 0 +( 0 +postoperative 0 +day 0 +1 0 +) 0 +using 0 +flexible 0 +laryngoscopy 0 +. 0 + +Anesthesia 0 +was 0 +performed 0 +by 0 +injecting 0 +20 0 +to 0 +40 0 +mL 0 +of 0 +a 0 +mixture 0 +of 0 +long 0 +- 0 +acting 0 +( 0 +ropivacaine 1 +) 0 +and 0 +short 0 +- 0 +acting 0 +( 0 +prilocaine 1 +) 0 +anesthetic 0 +. 0 + +RESULTS 0 +: 0 +All 0 +patients 0 +had 0 +normal 0 +vocal 0 +cord 0 +function 0 +preoperatively 0 +. 0 + +Twelve 0 +patients 0 +( 0 +43 0 +% 0 +) 0 +were 0 +found 0 +to 0 +have 0 +intraoperative 0 +ipsilateral 0 +vocal 3 +cord 4 +paralysis 4 +. 0 + +It 0 +resolved 0 +in 0 +all 0 +cases 0 +< 0 +or 0 += 0 +24 0 +hours 0 +. 0 + +There 0 +were 0 +no 0 +significant 0 +differences 0 +in 0 +operating 0 +time 0 +or 0 +volume 0 +or 0 +frequency 0 +of 0 +anesthetic 0 +administration 0 +in 0 +patients 0 +with 0 +temporary 0 +vocal 3 +cord 4 +paralysis 4 +compared 0 +with 0 +those 0 +without 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Local 0 +anesthesia 0 +led 0 +to 0 +temporary 0 +ipsilateral 0 +vocal 3 +cord 4 +paralysis 4 +in 0 +almost 0 +half 0 +of 0 +these 0 +patients 0 +. 0 + +Because 0 +pre 0 +- 0 +existing 0 +paralysis 3 +is 0 +of 0 +a 0 +relevant 0 +frequency 0 +( 0 +up 0 +to 0 +3 0 +% 0 +) 0 +, 0 +a 0 +preoperative 0 +evaluation 0 +of 0 +vocal 0 +cord 0 +function 0 +before 0 +carotid 0 +endarterectomy 0 +under 0 +local 0 +anesthesia 0 +is 0 +recommended 0 +to 0 +avoid 0 +intraoperative 0 +bilateral 0 +paralysis 3 +. 0 + +In 0 +patients 0 +with 0 +preoperative 0 +contralateral 0 +vocal 3 +cord 4 +paralysis 4 +, 0 +surgery 0 +under 0 +general 0 +anesthesia 0 +should 0 +be 0 +considered 0 +. 0 + +Impaired 3 +fear 4 +recognition 4 +in 0 +regular 0 +recreational 0 +cocaine 1 +users 0 +. 0 + +INTR0DUCTI0N 0 +: 0 +The 0 +ability 0 +to 0 +read 0 +facial 0 +expressions 0 +is 0 +essential 0 +for 0 +normal 0 +human 0 +social 0 +interaction 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +conduct 0 +the 0 +first 0 +investigation 0 +of 0 +facial 0 +expression 0 +recognition 0 +performance 0 +in 0 +recreational 0 +cocaine 1 +users 0 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +Three 0 +groups 0 +, 0 +comprised 0 +of 0 +21 0 +cocaine 1 +naive 0 +participants 0 +( 0 +CN 0 +) 0 +, 0 +30 0 +occasional 0 +cocaine 1 +( 0 +0C 0 +) 0 +, 0 +and 0 +48 0 +regular 0 +recreational 0 +cocaine 1 +( 0 +RC 0 +) 0 +users 0 +, 0 +were 0 +compared 0 +. 0 + +An 0 +emotional 0 +facial 0 +expression 0 +( 0 +EFE 0 +) 0 +task 0 +consisting 0 +of 0 +a 0 +male 0 +and 0 +female 0 +face 0 +expressing 0 +six 0 +basic 0 +emotions 0 +( 0 +happiness 0 +, 0 +surprise 0 +, 0 +sadness 0 +, 0 +anger 0 +, 0 +fear 0 +, 0 +and 0 +disgust 0 +) 0 +was 0 +administered 0 +. 0 + +Mean 0 +percent 0 +accuracy 0 +and 0 +latencies 0 +for 0 +correct 0 +responses 0 +across 0 +eight 0 +presentations 0 +of 0 +each 0 +basic 0 +emotion 0 +were 0 +derived 0 +. 0 + +Participants 0 +were 0 +also 0 +assessed 0 +with 0 +the 0 +" 0 +Eyes 0 +task 0 +" 0 +to 0 +investigate 0 +their 0 +ability 0 +to 0 +recognize 0 +more 0 +complex 0 +emotional 0 +states 0 +and 0 +the 0 +Symptom 0 +CheckList 0 +- 0 +90 0 +- 0 +Revised 0 +to 0 +measure 0 +psychopathology 0 +. 0 + +RESULTS 0 +: 0 +There 0 +were 0 +no 0 +group 0 +differences 0 +in 0 +psychopathology 0 +or 0 +" 0 +eyes 0 +task 0 +" 0 +performance 0 +, 0 +but 0 +the 0 +RC 0 +group 0 +, 0 +who 0 +otherwise 0 +had 0 +similar 0 +illicit 0 +substance 0 +use 0 +histories 0 +to 0 +the 0 +0C 0 +group 0 +, 0 +exhibited 0 +impaired 3 +fear 4 +recognition 4 +accuracy 0 +compared 0 +to 0 +the 0 +0C 0 +and 0 +CN 0 +groups 0 +. 0 + +The 0 +RC 0 +group 0 +also 0 +correctly 0 +identified 0 +anger 0 +, 0 +fear 0 +, 0 +happiness 0 +, 0 +and 0 +surprise 0 +, 0 +more 0 +slowly 0 +than 0 +CN 0 +, 0 +but 0 +not 0 +0C 0 +participants 0 +. 0 + +The 0 +0C 0 +group 0 +was 0 +slower 0 +than 0 +CN 0 +when 0 +correctly 0 +identifying 0 +disgust 0 +. 0 + +The 0 +selective 0 +deficit 3 +in 4 +fear 4 +recognition 4 +accuracy 0 +manifested 0 +by 0 +the 0 +RC 0 +group 0 +cannot 0 +be 0 +explained 0 +by 0 +the 0 +subacute 0 +effects 0 +of 0 +cocaine 1 +, 0 +or 0 +ecstasy 1 +, 0 +because 0 +recent 0 +and 0 +less 0 +recent 0 +users 0 +of 0 +these 0 +drugs 0 +within 0 +this 0 +group 0 +were 0 +similarly 0 +impaired 0 +. 0 + +Possible 0 +parallels 0 +between 0 +RC 0 +users 0 +and 0 +psychopaths 3 +with 0 +respect 0 +to 0 +impaired 3 +fear 4 +recognition 4 +, 0 +amygdala 3 +dysfunction 4 +, 0 +and 0 +etiology 0 +are 0 +discussed 0 +. 0 + +Damage 3 +of 4 +substantia 4 +nigra 4 +pars 4 +reticulata 4 +during 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +in 0 +the 0 +rat 0 +: 0 +immunohistochemical 0 +study 0 +of 0 +neurons 0 +, 0 +astrocytes 0 +and 0 +serum 0 +- 0 +protein 0 +extravasation 0 +. 0 + +The 0 +substantia 0 +nigra 0 +has 0 +a 0 +gating 0 +function 0 +controlling 0 +the 0 +spread 0 +of 0 +epileptic 3 +seizure 4 +activity 0 +. 0 + +Additionally 0 +, 0 +in 0 +models 0 +of 0 +prolonged 3 +status 4 +epilepticus 4 +the 0 +pars 0 +reticulata 0 +of 0 +substantia 0 +nigra 0 +( 0 +SNR 0 +) 0 +suffers 0 +from 0 +a 0 +massive 0 +lesion 0 +which 0 +may 0 +arise 0 +from 0 +a 0 +massive 0 +metabolic 3 +derangement 4 +and 0 +hyperexcitation 0 +developing 0 +in 0 +the 0 +activated 0 +SNR 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +status 3 +epilepticus 4 +was 0 +induced 0 +by 0 +systemic 0 +injection 0 +of 0 +pilocarpine 1 +in 0 +rats 0 +. 0 + +The 0 +neuropathology 0 +of 0 +SNR 0 +was 0 +investigated 0 +using 0 +immunohistochemical 0 +techniques 0 +with 0 +the 0 +major 0 +emphasis 0 +on 0 +the 0 +time 0 +- 0 +course 0 +of 0 +changes 0 +in 0 +neurons 0 +and 0 +astrocytes 0 +. 0 + +Animals 0 +surviving 0 +20 0 +, 0 +30 0 +, 0 +40 0 +, 0 +60 0 +min 0 +, 0 +2 0 +, 0 +3 0 +, 0 +6 0 +hours 0 +, 0 +1 0 +, 0 +2 0 +, 0 +and 0 +3 0 +days 0 +after 0 +induction 0 +of 0 +status 3 +epilepticus 4 +were 0 +perfusion 0 +- 0 +fixed 0 +, 0 +and 0 +brains 0 +processed 0 +for 0 +immunohistochemical 0 +staining 0 +of 0 +SNR 0 +. 0 + +Nissl 0 +- 0 +staining 0 +and 0 +antibodies 0 +against 0 +the 0 +neuron 0 +- 0 +specific 0 +calcium 1 +- 0 +binding 0 +protein 0 +, 0 +parvalbumin 0 +, 0 +served 0 +to 0 +detect 0 +neuronal 3 +damage 4 +in 0 +SNR 0 +. 0 + +Antibodies 0 +against 0 +the 0 +astroglia 0 +- 0 +specific 0 +cytoskeletal 0 +protein 0 +, 0 +glial 0 +fibrillary 0 +acidic 0 +protein 0 +( 0 +GFAP 0 +) 0 +, 0 +and 0 +against 0 +the 0 +glial 0 +calcium 1 +- 0 +binding 0 +protein 0 +, 0 +S 0 +- 0 +100 0 +protein 0 +, 0 +were 0 +used 0 +to 0 +assess 0 +the 0 +status 0 +of 0 +astrocytes 0 +. 0 + +Immunohistochemical 0 +staining 0 +for 0 +serum 0 +- 0 +albumin 0 +and 0 +immunoglobulins 0 +in 0 +brain 0 +tissue 0 +was 0 +taken 0 +as 0 +indicator 0 +of 0 +blood 0 +- 0 +brain 0 +barrier 0 +disturbances 0 +and 0 +vasogenic 3 +edema 4 +formation 0 +. 0 + +Immunohistochemical 0 +staining 0 +indicated 0 +loss 0 +of 0 +GFAP 0 +- 0 +staining 0 +already 0 +at 0 +30 0 +min 0 +after 0 +induction 0 +of 0 +seizures 3 +in 0 +an 0 +oval 0 +focus 0 +situated 0 +in 0 +the 0 +center 0 +of 0 +SNR 0 +while 0 +sparing 0 +medial 0 +and 0 +lateral 0 +aspects 0 +. 0 + +At 0 +1 0 +h 0 +there 0 +was 0 +additional 0 +vacuolation 0 +in 0 +S 0 +- 0 +100 0 +protein 0 +staining 0 +. 0 + +By 0 +2 0 +hours 0 +, 0 +parvalbumin 0 +- 0 +staining 0 +changed 0 +in 0 +the 0 +central 0 +SNR 0 +indicating 0 +neuronal 3 +damage 4 +, 0 +and 0 +Nissl 0 +- 0 +staining 0 +visualized 0 +some 0 +neuronal 0 +distortion 0 +. 0 + +Staining 0 +for 0 +serum 0 +- 0 +proteins 0 +occurred 0 +in 0 +a 0 +patchy 0 +manner 0 +throughout 0 +the 0 +forebrain 0 +during 0 +the 0 +first 0 +hours 0 +. 0 + +By 0 +6 0 +h 0 +, 0 +vasogenic 3 +edema 4 +covered 0 +the 0 +lesioned 3 +SNR 4 +. 0 + +By 0 +24 0 +h 0 +, 0 +glial 0 +and 0 +neuronal 0 +markers 0 +indicated 0 +a 0 +massive 0 +lesion 0 +in 0 +the 0 +center 0 +of 0 +SNR 0 +. 0 + +By 0 +48 0 +- 0 +72 0 +h 0 +, 0 +astrocytes 0 +surrounding 0 +the 0 +lesion 0 +increased 0 +in 0 +size 0 +, 0 +and 0 +polymorphic 0 +phagocytotic 0 +cells 0 +invaded 0 +the 0 +damaged 0 +area 0 +. 0 + +In 0 +a 0 +further 0 +group 0 +of 0 +animals 0 +surviving 0 +1 0 +to 0 +5 0 +days 0 +, 0 +conventional 0 +paraffin 0 +- 0 +sections 0 +confirmed 0 +the 0 +neuronal 0 +and 0 +glial 0 +damage 3 +of 4 +SNR 4 +. 0 + +Additional 0 +pathology 0 +of 0 +similar 0 +quality 0 +was 0 +found 0 +in 0 +the 0 +globus 0 +pallidus 0 +. 0 + +Since 0 +astrocytes 0 +were 0 +always 0 +damaged 0 +in 0 +parallel 0 +with 0 +neurons 0 +in 0 +SNR 0 +it 0 +is 0 +proposed 0 +that 0 +the 0 +anatomical 0 +and 0 +functional 0 +interrelationship 0 +between 0 +neurons 0 +and 0 +astrocytes 0 +is 0 +particularly 0 +tight 0 +in 0 +SNR 0 +. 0 + +Both 0 +cell 0 +elements 0 +may 0 +suffer 0 +in 0 +common 0 +from 0 +metabolic 0 +disturbance 0 +and 0 +neurotransmitter 3 +dysfunction 4 +as 0 +occur 0 +during 0 +massive 0 +status 3 +epilepticus 4 +. 0 + +Neuroprotective 0 +effects 0 +of 0 +melatonin 1 +upon 0 +the 0 +offspring 0 +cerebellar 0 +cortex 0 +in 0 +the 0 +rat 0 +model 0 +of 0 +BCNU 1 +- 0 +induced 0 +cortical 3 +dysplasia 4 +. 0 + +Cortical 3 +dysplasia 4 +is 0 +a 0 +malformation 0 +characterized 0 +by 0 +defects 0 +in 0 +proliferation 0 +, 0 +migration 0 +and 0 +maturation 0 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +evaluate 0 +the 0 +alterations 0 +in 0 +offspring 0 +rat 0 +cerebellum 0 +induced 0 +by 0 +maternal 0 +exposure 0 +to 0 +carmustine 1 +- 0 +[ 0 +1 1 +, 2 +3 2 +- 2 +bis 2 +( 2 +2 2 +- 2 +chloroethyl 2 +) 2 +- 2 +1 2 +- 2 +nitrosoure 2 +] 0 +( 0 +BCNU 1 +) 0 +and 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +exogenous 0 +melatonin 1 +upon 0 +cerebellar 0 +BCNU 1 +- 0 +induced 0 +cortical 3 +dysplasia 4 +, 0 +using 0 +histological 0 +and 0 +biochemical 0 +analyses 0 +. 0 + +Pregnant 0 +Wistar 0 +rats 0 +were 0 +assigned 0 +to 0 +five 0 +groups 0 +: 0 +intact 0 +- 0 +control 0 +, 0 +saline 0 +- 0 +control 0 +, 0 +melatonin 1 +- 0 +treated 0 +, 0 +BCNU 1 +- 0 +exposed 0 +and 0 +BCNU 1 +- 0 +exposed 0 +plus 0 +melatonin 1 +. 0 + +Rats 0 +were 0 +exposed 0 +to 0 +BCNU 1 +on 0 +embryonic 0 +day 0 +15 0 +and 0 +melatonin 1 +was 0 +given 0 +until 0 +delivery 0 +. 0 + +Immuno 0 +/ 0 +histochemistry 0 +and 0 +electron 0 +microscopy 0 +were 0 +carried 0 +out 0 +on 0 +the 0 +offspring 0 +cerebellum 0 +, 0 +and 0 +levels 0 +of 0 +malondialdehyde 1 +and 0 +superoxide 1 +dismutase 0 +were 0 +determined 0 +. 0 + +Histopathologically 0 +, 0 +typical 0 +findings 0 +were 0 +observed 0 +in 0 +the 0 +cerebella 0 +from 0 +the 0 +control 0 +groups 0 +, 0 +but 0 +the 0 +findings 0 +consistent 0 +with 0 +early 0 +embryonic 0 +development 0 +were 0 +noted 0 +in 0 +BCNU 1 +- 0 +exposed 0 +cortical 3 +dysplasia 4 +group 0 +. 0 + +There 0 +was 0 +a 0 +marked 0 +increase 0 +in 0 +the 0 +number 0 +of 0 +TUNEL 0 +positive 0 +cells 0 +and 0 +nestin 0 +positive 0 +cells 0 +in 0 +BCNU 1 +- 0 +exposed 0 +group 0 +, 0 +but 0 +a 0 +decreased 0 +immunoreactivity 0 +to 0 +glial 0 +fibrillary 0 +acidic 0 +protein 0 +, 0 +synaptophysin 0 +and 0 +transforming 0 +growth 0 +factor 0 +beta1 0 +was 0 +observed 0 +, 0 +indicating 0 +a 0 +delayed 0 +maturation 0 +, 0 +and 0 +melatonin 1 +significantly 0 +reversed 0 +these 0 +changes 0 +. 0 + +Malondialdehyde 1 +level 0 +in 0 +BCNU 1 +- 0 +exposed 0 +group 0 +was 0 +higher 0 +than 0 +those 0 +in 0 +control 0 +groups 0 +and 0 +melatonin 1 +decreased 0 +malondialdehyde 1 +levels 0 +in 0 +BCNU 1 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +, 0 +while 0 +there 0 +were 0 +no 0 +significant 0 +differences 0 +in 0 +the 0 +superoxide 1 +dismutase 0 +levels 0 +between 0 +these 0 +groups 0 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +exposure 0 +of 0 +animals 0 +to 0 +BCNU 1 +during 0 +pregnancy 0 +leads 0 +to 0 +delayed 0 +maturation 0 +of 0 +offspring 0 +cerebellum 0 +and 0 +melatonin 1 +protects 0 +the 0 +cerebellum 0 +against 0 +the 0 +effects 0 +of 0 +BCNU 1 +. 0 + +Reduced 0 +cardiotoxicity 3 +of 0 +doxorubicin 1 +given 0 +in 0 +the 0 +form 0 +of 0 +N 1 +- 2 +( 2 +2 2 +- 2 +hydroxypropyl 2 +) 2 +methacrylamide 2 +conjugates 0 +: 0 +and 0 +experimental 0 +study 0 +in 0 +the 0 +rat 0 +. 0 + +A 0 +rat 0 +model 0 +was 0 +used 0 +to 0 +evaluate 0 +the 0 +general 0 +acute 0 +toxicity 3 +and 0 +the 0 +late 0 +cardiotoxicity 3 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +given 0 +either 0 +as 0 +free 0 +drug 0 +or 0 +in 0 +the 0 +form 0 +of 0 +three 0 +N 1 +- 2 +( 2 +2 2 +- 2 +hydroxypropyl 2 +) 2 +methacrylamide 2 +( 0 +HPMA 1 +) 0 +copolymer 0 +conjugates 0 +. 0 + +In 0 +these 0 +HPMA 1 +copolymers 0 +, 0 +D0X 1 +was 0 +covalently 0 +bound 0 +via 0 +peptide 0 +linkages 0 +that 0 +were 0 +either 0 +non 0 +- 0 +biodegradable 0 +( 0 +Gly 0 +- 0 +Gly 0 +) 0 +or 0 +degradable 0 +by 0 +lysosomal 0 +proteinases 0 +( 0 +Gly 1 +- 2 +Phe 2 +- 2 +Leu 2 +- 2 +Gly 2 +) 0 +. 0 + +In 0 +addition 0 +, 0 +one 0 +biodegradable 0 +conjugate 0 +containing 0 +galactosamine 1 +was 0 +used 0 +; 0 +this 0 +residue 0 +was 0 +targeted 0 +to 0 +the 0 +liver 0 +. 0 + +0ver 0 +the 0 +first 0 +3 0 +weeks 0 +after 0 +the 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +of 0 +free 0 +and 0 +polymer 0 +- 0 +bound 0 +D0X 1 +, 0 +all 0 +animals 0 +showed 0 +a 0 +transient 0 +reduction 0 +in 0 +body 0 +weight 0 +. 0 + +However 0 +, 0 +the 0 +maximal 0 +reduction 0 +in 0 +body 0 +weight 0 +seen 0 +in 0 +animals 0 +that 0 +received 0 +polymer 0 +- 0 +bound 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +significantly 0 +lower 0 +than 0 +that 0 +observed 0 +in 0 +those 0 +that 0 +received 0 +free 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +a 0 +mixture 0 +of 0 +the 0 +unmodified 0 +parent 0 +HPMA 1 +copolymer 0 +and 0 +free 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +; 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Throughout 0 +the 0 +study 0 +( 0 +20 0 +weeks 0 +) 0 +, 0 +deaths 0 +related 0 +to 0 +cardiotoxicity 3 +were 0 +observed 0 +only 0 +in 0 +animals 0 +that 0 +received 0 +either 0 +free 0 +D0X 1 +or 0 +the 0 +mixture 0 +of 0 +HPMA 1 +copolymer 0 +and 0 +free 0 +D0X 1 +; 0 +in 0 +these 0 +cases 0 +, 0 +histological 0 +investigations 0 +revealed 0 +marked 0 +changes 0 +in 0 +the 0 +heart 0 +that 0 +were 0 +consistent 0 +with 0 +D0X 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +Sequential 0 +measurements 0 +of 0 +cardiac 0 +output 0 +in 0 +surviving 0 +animals 0 +that 0 +received 0 +either 0 +free 0 +D0X 1 +or 0 +the 0 +mixture 0 +of 0 +HPMA 1 +copolymer 0 +and 0 +free 0 +D0X 1 +showed 0 +a 0 +reduction 0 +of 0 +approximately 0 +30 0 +% 0 +in 0 +function 0 +beginning 0 +at 0 +the 0 +4th 0 +week 0 +after 0 +drug 0 +administration 0 +. 0 + +The 0 +heart 0 +rate 0 +in 0 +these 0 +animals 0 +was 0 +approximately 0 +12 0 +% 0 +lower 0 +than 0 +that 0 +measured 0 +in 0 +age 0 +- 0 +matched 0 +control 0 +rats 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Animals 0 +that 0 +were 0 +given 0 +the 0 +HPMA 1 +copolymer 0 +conjugates 0 +containing 0 +D0X 1 +exhibited 0 +no 0 +significant 0 +change 0 +in 0 +cardiac 0 +output 0 +throughout 0 +the 0 +study 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +no 0 +significant 0 +histological 0 +change 0 +was 0 +observed 0 +in 0 +the 0 +heart 0 +of 0 +animals 0 +that 0 +received 0 +D0X 1 +in 0 +the 0 +form 0 +of 0 +HPMA 1 +copolymer 0 +conjugates 0 +and 0 +were 0 +killed 0 +at 0 +the 0 +end 0 +of 0 +the 0 +study 0 +. 0 + +However 0 +, 0 +these 0 +animals 0 +had 0 +shown 0 +a 0 +significant 0 +increase 0 +in 0 +heart 0 +rate 0 +beginning 0 +at 0 +8 0 +weeks 0 +after 0 +drug 0 +administration 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +400 0 +W0RDS 0 +) 0 + +Corneal 3 +ulcers 4 +associated 0 +with 0 +aerosolized 0 +crack 1 +cocaine 2 +use 0 +. 0 + +PURP0SE 0 +: 0 +We 0 +report 0 +4 0 +cases 0 +of 0 +corneal 3 +ulcers 4 +associated 0 +with 0 +drug 3 +abuse 4 +. 0 + +The 0 +pathogenesis 0 +of 0 +these 0 +ulcers 3 +and 0 +management 0 +of 0 +these 0 +patients 0 +are 0 +also 0 +reviewed 0 +. 0 + +METH0DS 0 +: 0 +Review 0 +of 0 +all 0 +cases 0 +of 0 +corneal 3 +ulcers 4 +associated 0 +with 0 +drug 3 +abuse 4 +seen 0 +at 0 +our 0 +institution 0 +from 0 +July 0 +2006 0 +to 0 +December 0 +2006 0 +. 0 + +RESULTS 0 +: 0 +Four 0 +patients 0 +with 0 +corneal 3 +ulcers 4 +associated 0 +with 0 +crack 1 +cocaine 2 +use 0 +were 0 +reviewed 0 +. 0 + +All 0 +corneal 3 +ulcers 4 +were 0 +cultured 0 +, 0 +and 0 +the 0 +patients 0 +were 0 +admitted 0 +to 0 +the 0 +hospital 0 +for 0 +intensive 0 +topical 0 +antibiotic 0 +treatment 0 +. 0 + +Each 0 +patient 0 +received 0 +comprehensive 0 +health 0 +care 0 +, 0 +including 0 +medical 0 +and 0 +substance 3 +abuse 4 +consultations 0 +. 0 + +Streptococcal 0 +organisms 0 +were 0 +found 0 +in 0 +3 0 +cases 0 +and 0 +Capnocytophaga 0 +and 0 +Brevibacterium 0 +casei 0 +in 0 +1 0 +patient 0 +. 0 + +The 0 +infections 3 +responded 0 +to 0 +antibiotic 0 +treatment 0 +. 0 + +Two 0 +patients 0 +needed 0 +a 0 +lateral 0 +tarsorrhaphy 0 +for 0 +persistent 0 +epithelial 3 +defects 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +Aerosolized 0 +crack 1 +cocaine 2 +use 0 +can 0 +be 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +corneal 3 +ulcers 4 +. 0 + +Drug 3 +abuse 4 +provides 0 +additional 0 +challenges 0 +for 0 +management 0 +. 0 + +Not 0 +only 0 +treatment 0 +of 0 +their 0 +infections 3 +but 0 +also 0 +the 0 +overall 0 +poor 0 +health 0 +of 0 +the 0 +patients 0 +and 0 +increased 0 +risk 0 +of 0 +noncompliance 0 +need 0 +to 0 +be 0 +addressed 0 +. 0 + +Comprehensive 0 +care 0 +may 0 +provide 0 +the 0 +patient 0 +the 0 +opportunity 0 +to 0 +discontinue 0 +their 0 +substance 3 +abuse 4 +, 0 +improve 0 +their 0 +overall 0 +health 0 +, 0 +and 0 +prevent 0 +future 0 +corneal 0 +complications 0 +. 0 + +Topical 0 +0 0 +. 0 +025 0 +% 0 +capsaicin 1 +in 0 +chronic 0 +post 3 +- 4 +herpetic 4 +neuralgia 4 +: 0 +efficacy 0 +, 0 +predictors 0 +of 0 +response 0 +and 0 +long 0 +- 0 +term 0 +course 0 +. 0 + +In 0 +order 0 +to 0 +evaluate 0 +the 0 +efficacy 0 +, 0 +time 0 +- 0 +course 0 +of 0 +action 0 +and 0 +predictors 0 +of 0 +response 0 +to 0 +topical 0 +capsaicin 1 +, 0 +39 0 +patients 0 +with 0 +chronic 0 +post 3 +- 4 +herpetic 4 +neuralgia 4 +( 0 +PHN 3 +) 0 +, 0 +median 0 +duration 0 +24 0 +months 0 +, 0 +were 0 +treated 0 +with 0 +0 0 +. 0 +025 0 +% 0 +capsaicin 1 +cream 0 +for 0 +8 0 +weeks 0 +. 0 + +During 0 +therapy 0 +the 0 +patients 0 +rated 0 +their 0 +pain 3 +on 0 +a 0 +visual 0 +analogue 0 +scale 0 +( 0 +VAS 0 +) 0 +and 0 +a 0 +verbal 0 +outcome 0 +scale 0 +. 0 + +A 0 +follow 0 +- 0 +up 0 +investigation 0 +was 0 +performed 0 +10 0 +- 0 +12 0 +months 0 +after 0 +study 0 +onset 0 +on 0 +the 0 +patients 0 +who 0 +had 0 +improved 0 +. 0 + +Nineteen 0 +patients 0 +( 0 +48 0 +. 0 +7 0 +% 0 +) 0 +substantially 0 +improved 0 +after 0 +the 0 +8 0 +- 0 +week 0 +trial 0 +; 0 +5 0 +( 0 +12 0 +. 0 +8 0 +% 0 +) 0 +discontinued 0 +therapy 0 +due 0 +to 0 +side 0 +- 0 +effects 0 +such 0 +as 0 +intolerable 0 +capsaicin 1 +- 0 +induced 0 +burning 0 +sensations 0 +( 0 +4 0 +) 0 +or 0 +mastitis 3 +( 0 +1 0 +) 0 +; 0 +15 0 +( 0 +38 0 +. 0 +5 0 +% 0 +) 0 +reported 0 +no 0 +benefit 0 +. 0 + +The 0 +decrease 0 +in 0 +VAS 0 +ratings 0 +was 0 +significant 0 +after 0 +2 0 +weeks 0 +of 0 +continuous 0 +application 0 +. 0 + +0f 0 +the 0 +responders 0 +72 0 +. 0 +2 0 +% 0 +were 0 +still 0 +improved 0 +at 0 +the 0 +follow 0 +- 0 +up 0 +; 0 +only 0 +one 0 +- 0 +third 0 +of 0 +them 0 +had 0 +continued 0 +application 0 +irregularly 0 +. 0 + +Treatment 0 +effect 0 +was 0 +not 0 +dependent 0 +on 0 +patient 0 +' 0 +s 0 +age 0 +, 0 +duration 0 +or 0 +localization 0 +of 0 +PHN 3 +( 0 +trigeminal 0 +involvement 0 +was 0 +excluded 0 +) 0 +, 0 +sensory 3 +disturbance 4 +or 0 +pain 3 +character 0 +. 0 + +Treatment 0 +response 0 +was 0 +not 0 +correlated 0 +with 0 +the 0 +incidence 0 +, 0 +time 0 +- 0 +course 0 +or 0 +severity 0 +of 0 +capsaicin 1 +- 0 +induced 0 +burning 0 +. 0 + +If 0 +confirmed 0 +in 0 +controlled 0 +trials 0 +, 0 +the 0 +long 0 +- 0 +term 0 +results 0 +of 0 +this 0 +open 0 +, 0 +non 0 +- 0 +randomized 0 +study 0 +might 0 +indicate 0 +that 0 +the 0 +analgesic 0 +effect 0 +of 0 +capsaicin 1 +in 0 +PHN 3 +is 0 +mediated 0 +by 0 +both 0 +interference 0 +with 0 +neuropeptide 0 +metabolism 0 +and 0 +morphological 0 +changes 0 +( 0 +perhaps 0 +degeneration 0 +) 0 +of 0 +nociceptive 0 +afferents 0 +. 0 + +Myo 1 +- 2 +inositol 2 +- 2 +1 2 +- 2 +phosphate 2 +( 0 +MIP 1 +) 0 +synthase 0 +inhibition 0 +: 0 +in 0 +- 0 +vivo 0 +study 0 +in 0 +rats 0 +. 0 + +Lithium 1 +and 0 +valproate 1 +are 0 +the 0 +prototypic 0 +mood 0 +stabilizers 0 +and 0 +have 0 +diverse 0 +structures 0 +and 0 +targets 0 +. 0 + +Both 0 +drugs 0 +influence 0 +inositol 1 +metabolism 0 +. 0 + +Lithium 1 +inhibits 0 +IMPase 0 +and 0 +valproate 1 +inhibits 0 +MIP 1 +synthase 0 +. 0 + +This 0 +study 0 +shows 0 +that 0 +MIP 1 +synthase 0 +inhibition 0 +does 0 +not 0 +replicate 0 +or 0 +augment 0 +the 0 +effects 0 +of 0 +lithium 1 +in 0 +the 0 +inositol 1 +sensitive 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +model 0 +. 0 + +This 0 +lack 0 +of 0 +effects 0 +may 0 +stem 0 +from 0 +the 0 +low 0 +contribution 0 +of 0 +de 0 +- 0 +novo 0 +synthesis 0 +to 0 +cellular 0 +inositol 1 +supply 0 +or 0 +to 0 +the 0 +inhibition 0 +of 0 +the 0 +de 0 +- 0 +novo 0 +synthesis 0 +by 0 +lithium 1 +itself 0 +. 0 + +Non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +- 0 +associated 0 +acute 0 +interstitial 3 +nephritis 4 +with 0 +granular 0 +tubular 0 +basement 0 +membrane 0 +deposits 0 +. 0 + +Acute 3 +tubulo 4 +- 4 +interstitial 4 +nephritis 4 +( 0 +ATIN 3 +) 0 +is 0 +an 0 +important 0 +cause 0 +of 0 +acute 3 +renal 4 +failure 4 +resulting 0 +from 0 +a 0 +variety 0 +of 0 +insults 0 +, 0 +including 0 +immune 0 +complex 0 +- 0 +mediated 0 +tubulo 3 +- 4 +interstitial 4 +injury 4 +, 0 +but 0 +drugs 0 +such 0 +as 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +( 0 +NSAIDs 0 +) 0 +are 0 +a 0 +far 0 +more 0 +frequent 0 +cause 0 +. 0 + +0verall 0 +, 0 +as 0 +an 0 +entity 0 +, 0 +ATIN 3 +remains 0 +under 0 +- 0 +diagnosed 0 +, 0 +as 0 +symptoms 0 +resolve 0 +spontaneously 0 +if 0 +the 0 +medication 0 +is 0 +stopped 0 +. 0 + +We 0 +report 0 +on 0 +a 0 +14 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +who 0 +developed 0 +acute 3 +renal 4 +failure 4 +2 0 +weeks 0 +after 0 +aortic 0 +valve 0 +surgery 0 +. 0 + +He 0 +was 0 +put 0 +on 0 +aspirin 1 +following 0 +surgery 0 +and 0 +took 0 +ibuprofen 1 +for 0 +fever 3 +for 0 +nearly 0 +a 0 +week 0 +prior 0 +to 0 +presentation 0 +. 0 + +He 0 +then 0 +presented 0 +to 0 +the 0 +emergency 0 +department 0 +feeling 0 +quite 0 +ill 0 +and 0 +was 0 +found 0 +to 0 +have 0 +a 0 +blood 1 +urea 2 +nitrogen 2 +( 0 +BUN 1 +) 0 +concentration 0 +of 0 +of 0 +147 0 +mg 0 +/ 0 +dl 0 +, 0 +creatinine 1 +of 0 +15 0 +. 0 +3 0 +mg 0 +/ 0 +dl 0 +and 0 +serum 0 +potassium 1 +of 0 +8 0 +. 0 +7 0 +mEq 0 +/ 0 +l 0 +. 0 + +Dialysis 0 +was 0 +immediately 0 +initiated 0 +. 0 + +A 0 +kidney 0 +biopsy 0 +showed 0 +inflammatory 0 +infiltrate 0 +consistent 0 +with 0 +ATIN 3 +. 0 + +However 0 +, 0 +in 0 +the 0 +tubular 0 +basement 0 +membrane 0 +( 0 +TBM 0 +) 0 +, 0 +very 0 +intense 0 +granular 0 +deposits 0 +of 0 +polyclonal 0 +IgG 0 +and 0 +C3 0 +were 0 +noted 0 +. 0 + +He 0 +needed 0 +dialysis 0 +for 0 +2 0 +weeks 0 +and 0 +was 0 +treated 0 +successfully 0 +with 0 +steroids 1 +for 0 +6 0 +months 0 +. 0 + +His 0 +renal 0 +recovery 0 +and 0 +disappearance 0 +of 0 +proteinuria 3 +took 0 +a 0 +year 0 +. 0 + +In 0 +conclusion 0 +, 0 +this 0 +is 0 +a 0 +first 0 +report 0 +of 0 +NSAIDs 0 +- 0 +associated 0 +ATIN 3 +, 0 +showing 0 +deposits 0 +of 0 +granular 0 +immune 0 +complex 0 +present 0 +only 0 +in 0 +the 0 +TBM 0 +and 0 +not 0 +in 0 +the 0 +glomeruli 0 +. 0 + +Rifampicin 1 +- 0 +associated 0 +segmental 0 +necrotizing 0 +glomerulonephritis 3 +in 0 +staphylococcal 3 +endocarditis 4 +. 0 + +Segmental 0 +necrotising 0 +glomerulonephritis 3 +has 0 +been 0 +reported 0 +as 0 +complication 0 +of 0 +rifampicin 1 +therapy 0 +in 0 +patients 0 +receiving 0 +treatment 0 +for 0 +tuberculosis 3 +. 0 + +Changing 0 +epidemiology 0 +of 0 +infections 3 +such 0 +as 0 +infective 3 +endocarditis 4 +( 0 +IE 3 +) 0 +has 0 +led 0 +to 0 +an 0 +increase 0 +in 0 +the 0 +use 0 +of 0 +rifampicin 1 +for 0 +Staphylococcal 3 +infections 4 +. 0 + +We 0 +describe 0 +a 0 +case 0 +of 0 +a 0 +patient 0 +with 0 +Staphylococcal 3 +IE 4 +who 0 +developed 0 +acute 3 +renal 4 +failure 4 +secondary 0 +to 0 +a 0 +segmental 0 +necrotising 0 +glomerulonephritis 3 +while 0 +being 0 +treated 0 +with 0 +rifampicin 1 +, 0 +and 0 +review 0 +the 0 +literature 0 +regarding 0 +this 0 +complication 0 +of 0 +rifampicin 1 +therapy 0 +. 0 + +Rate 0 +of 0 +YMDD 0 +motif 0 +mutants 0 +in 0 +lamivudine 1 +- 0 +untreated 0 +Iranian 0 +patients 0 +with 0 +chronic 3 +hepatitis 4 +B 4 +virus 4 +infection 4 +. 0 + +BACKGR0UND 0 +: 0 +Lamivudine 1 +is 0 +used 0 +for 0 +the 0 +treatment 0 +of 0 +chronic 3 +hepatitis 4 +B 4 +patients 0 +. 0 + +Recent 0 +studies 0 +show 0 +that 0 +the 0 +YMDD 0 +motif 0 +mutants 0 +( 0 +resistant 0 +hepatitis 3 +B 4 +virus 0 +) 0 +occur 0 +as 0 +natural 0 +genome 0 +variability 0 +in 0 +lamivudine 1 +- 0 +untreated 0 +chronic 3 +hepatitis 4 +B 4 +patients 0 +. 0 + +In 0 +this 0 +study 0 +we 0 +aimed 0 +to 0 +determine 0 +the 0 +rate 0 +of 0 +YMDD 0 +motif 0 +mutants 0 +in 0 +lamivudine 1 +- 0 +untreated 0 +chronic 3 +hepatitis 4 +B 4 +patients 0 +in 0 +Iran 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +A 0 +total 0 +of 0 +77 0 +chronic 3 +hepatitis 4 +B 4 +patients 0 +who 0 +had 0 +not 0 +been 0 +treated 0 +with 0 +lamivudine 1 +were 0 +included 0 +in 0 +the 0 +study 0 +. 0 + +Serum 0 +samples 0 +from 0 +patients 0 +were 0 +tested 0 +by 0 +polymerase 0 +chain 0 +reaction 0 +- 0 +restriction 0 +fragment 0 +length 0 +polymorphism 0 +( 0 +PCR 0 +- 0 +RFLP 0 +) 0 +for 0 +detection 0 +of 0 +YMDD 0 +motif 0 +mutants 0 +. 0 + +All 0 +patients 0 +were 0 +also 0 +tested 0 +for 0 +liver 0 +enzymes 0 +, 0 +anti 0 +- 0 +HCV 0 +, 0 +HBeAg 1 +, 0 +and 0 +anti 0 +- 0 +HBe 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +the 0 +77 0 +patients 0 +enrolled 0 +in 0 +the 0 +study 0 +, 0 +73 0 +% 0 +were 0 +male 0 +and 0 +27 0 +% 0 +were 0 +female 0 +. 0 + +Mean 0 +ALT 0 +and 0 +AST 0 +levels 0 +were 0 +124 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +73 0 +. 0 +4 0 +and 0 +103 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +81 0 +IU 0 +/ 0 +l 0 +, 0 +respectively 0 +. 0 + +HBeAg 1 +was 0 +positive 0 +in 0 +40 0 +% 0 +and 0 +anti 0 +- 0 +HBe 0 +in 0 +60 0 +% 0 +of 0 +the 0 +patients 0 +. 0 + +Anti 0 +- 0 +HCV 0 +was 0 +negative 0 +in 0 +all 0 +of 0 +them 0 +. 0 + +YMDD 0 +motif 0 +mutants 0 +were 0 +not 0 +detected 0 +in 0 +any 0 +of 0 +the 0 +patients 0 +despite 0 +the 0 +liver 0 +enzyme 0 +levels 0 +and 0 +the 0 +presence 0 +of 0 +HBeAg 1 +or 0 +anti 0 +- 0 +HBe 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Although 0 +the 0 +natural 0 +occurrence 0 +of 0 +YMDD 0 +motif 0 +mutants 0 +in 0 +lamivudine 1 +- 0 +untreated 0 +patients 0 +with 0 +chronic 3 +hepatitis 4 +B 4 +has 0 +been 0 +reported 0 +, 0 +these 0 +mutants 0 +were 0 +not 0 +detected 0 +in 0 +Iranian 0 +lamivudine 1 +- 0 +untreated 0 +chronic 3 +hepatitis 4 +B 4 +patients 0 +. 0 + +Branch 0 +retinal 3 +vein 4 +occlusion 4 +and 0 +fluoxetine 1 +. 0 + +A 0 +case 0 +of 0 +branch 0 +retinal 3 +vein 4 +occlusion 4 +associated 0 +with 0 +fluoxetine 1 +- 0 +induced 0 +secondary 0 +hypertension 3 +is 0 +described 0 +. 0 + +Although 0 +an 0 +infrequent 0 +complication 0 +of 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitor 0 +therapy 0 +, 0 +it 0 +is 0 +important 0 +that 0 +ophthalmologists 0 +are 0 +aware 0 +that 0 +these 0 +agents 0 +can 0 +cause 0 +hypertension 3 +because 0 +this 0 +class 0 +of 0 +drugs 0 +is 0 +widely 0 +prescribed 0 +. 0 + +The 0 +differential 0 +effects 0 +of 0 +bupivacaine 1 +and 0 +lidocaine 1 +on 0 +prostaglandin 1 +E2 2 +release 0 +, 0 +cyclooxygenase 0 +gene 0 +expression 0 +and 0 +pain 3 +in 0 +a 0 +clinical 0 +pain 3 +model 0 +. 0 + +BACKGR0UND 0 +: 0 +In 0 +addition 0 +to 0 +blocking 0 +nociceptive 0 +input 0 +from 0 +surgical 0 +sites 0 +, 0 +long 0 +- 0 +acting 0 +local 0 +anesthetics 0 +might 0 +directly 0 +modulate 0 +inflammation 3 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +we 0 +describe 0 +the 0 +proinflammatory 0 +effects 0 +of 0 +bupivacaine 1 +on 0 +local 0 +prostaglandin 1 +E2 2 +( 0 +PGE2 1 +) 0 +production 0 +and 0 +cyclooxygenase 0 +( 0 +C0X 0 +) 0 +gene 0 +expression 0 +that 0 +increases 0 +postoperative 3 +pain 4 +in 0 +human 0 +subjects 0 +. 0 + +METH0DS 0 +: 0 +Subjects 0 +( 0 +n 0 += 0 +114 0 +) 0 +undergoing 0 +extraction 0 +of 0 +impacted 0 +third 0 +molars 0 +received 0 +either 0 +2 0 +% 0 +lidocaine 1 +or 0 +0 0 +. 0 +5 0 +% 0 +bupivacaine 1 +before 0 +surgery 0 +and 0 +either 0 +rofecoxib 1 +50 0 +mg 0 +or 0 +placebo 0 +orally 0 +90 0 +min 0 +before 0 +surgery 0 +and 0 +for 0 +the 0 +following 0 +48 0 +h 0 +. 0 + +0ral 0 +mucosal 0 +biopsies 0 +were 0 +taken 0 +before 0 +surgery 0 +and 0 +48 0 +h 0 +after 0 +surgery 0 +. 0 + +After 0 +extraction 0 +, 0 +a 0 +microdialysis 0 +probe 0 +was 0 +placed 0 +at 0 +the 0 +surgical 0 +site 0 +for 0 +PGE2 1 +and 0 +thromboxane 1 +B2 2 +( 0 +TXB2 1 +) 0 +measurements 0 +. 0 + +RESULTS 0 +: 0 +The 0 +bupivacaine 1 +/ 0 +rofecoxib 1 +group 0 +reported 0 +significantly 0 +less 0 +pain 3 +, 0 +as 0 +assessed 0 +by 0 +a 0 +visual 0 +analog 0 +scale 0 +, 0 +compared 0 +with 0 +the 0 +other 0 +three 0 +treatment 0 +groups 0 +over 0 +the 0 +first 0 +4 0 +h 0 +. 0 + +However 0 +, 0 +the 0 +bupivacaine 1 +/ 0 +placebo 0 +group 0 +reported 0 +significantly 0 +more 0 +pain 3 +at 0 +24 0 +h 0 +and 0 +PGE2 1 +levels 0 +during 0 +the 0 +first 0 +4 0 +h 0 +were 0 +significantly 0 +higher 0 +than 0 +the 0 +other 0 +three 0 +treatment 0 +groups 0 +. 0 + +Moreover 0 +, 0 +bupivacaine 1 +significantly 0 +increased 0 +C0X 0 +- 0 +2 0 +gene 0 +expression 0 +at 0 +48 0 +h 0 +as 0 +compared 0 +with 0 +the 0 +lidocaine 1 +/ 0 +placebo 0 +group 0 +. 0 + +Thromboxane 1 +levels 0 +were 0 +not 0 +significantly 0 +affected 0 +by 0 +any 0 +of 0 +the 0 +treatments 0 +, 0 +indicating 0 +that 0 +the 0 +effects 0 +seen 0 +were 0 +attributable 0 +to 0 +inhibition 0 +of 0 +C0X 0 +- 0 +2 0 +, 0 +but 0 +not 0 +C0X 0 +- 0 +1 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +suggest 0 +that 0 +bupivacaine 1 +stimulates 0 +C0X 0 +- 0 +2 0 +gene 0 +expression 0 +after 0 +tissue 3 +injury 4 +, 0 +which 0 +is 0 +associated 0 +with 0 +higher 0 +PGE2 1 +production 0 +and 0 +pain 3 +after 0 +the 0 +local 0 +anesthetic 0 +effect 0 +dissipates 0 +. 0 + +p75NTR 0 +expression 0 +in 0 +rat 0 +urinary 0 +bladder 0 +sensory 0 +neurons 0 +and 0 +spinal 0 +cord 0 +with 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +. 0 + +A 0 +role 0 +for 0 +nerve 0 +growth 0 +factor 0 +( 0 +NGF 0 +) 0 +in 0 +contributing 0 +to 0 +increased 0 +voiding 0 +frequency 0 +and 0 +altered 0 +sensation 0 +from 0 +the 0 +urinary 0 +bladder 0 +has 0 +been 0 +suggested 0 +. 0 + +Previous 0 +studies 0 +have 0 +examined 0 +the 0 +expression 0 +and 0 +regulation 0 +of 0 +tyrosine 1 +kinase 0 +receptors 0 +( 0 +Trks 0 +) 0 +in 0 +micturition 0 +reflexes 0 +with 0 +urinary 3 +bladder 4 +inflammation 4 +. 0 + +The 0 +present 0 +studies 0 +examine 0 +the 0 +expression 0 +and 0 +regulation 0 +of 0 +another 0 +receptor 0 +known 0 +to 0 +bind 0 +NGF 0 +, 0 +p75 0 +( 0 +NTR 0 +) 0 +, 0 +after 0 +various 0 +durations 0 +of 0 +bladder 3 +inflammation 4 +induced 0 +by 0 +cyclophosphamide 1 +( 0 +CYP 1 +) 0 +. 0 + +CYP 1 +- 0 +induced 0 +cystitis 3 +increased 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +001 0 +) 0 +p75 0 +( 0 +NTR 0 +) 0 +expression 0 +in 0 +the 0 +superficial 0 +lateral 0 +and 0 +medial 0 +dorsal 0 +horn 0 +in 0 +L1 0 +- 0 +L2 0 +and 0 +L6 0 +- 0 +S1 0 +spinal 0 +segments 0 +. 0 + +The 0 +number 0 +of 0 +p75 0 +( 0 +NTR 0 +) 0 +- 0 +immunoreactive 0 +( 0 +- 0 +IR 0 +) 0 +cells 0 +in 0 +the 0 +lumbosacral 0 +dorsal 0 +root 0 +ganglia 0 +( 0 +DRG 0 +) 0 +also 0 +increased 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +05 0 +) 0 +with 0 +CYP 1 +- 0 +induced 0 +cystitis 3 +( 0 +acute 0 +, 0 +intermediate 0 +, 0 +and 0 +chronic 0 +) 0 +. 0 + +Quantitative 0 +, 0 +real 0 +- 0 +time 0 +polymerase 0 +chain 0 +reaction 0 +also 0 +demonstrated 0 +significant 0 +increases 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +01 0 +) 0 +in 0 +p75 0 +( 0 +NTR 0 +) 0 +mRNA 0 +in 0 +DRG 0 +with 0 +intermediate 0 +and 0 +chronic 0 +CYP 1 +- 0 +induced 0 +cystitis 3 +. 0 + +Retrograde 0 +dye 0 +- 0 +tracing 0 +techniques 0 +with 0 +Fastblue 0 +were 0 +used 0 +to 0 +identify 0 +presumptive 0 +bladder 0 +afferent 0 +cells 0 +in 0 +the 0 +lumbosacral 0 +DRG 0 +. 0 + +In 0 +bladder 0 +afferent 0 +cells 0 +in 0 +DRG 0 +, 0 +p75 0 +( 0 +NTR 0 +) 0 +- 0 +IR 0 +was 0 +also 0 +increased 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +01 0 +) 0 +with 0 +cystitis 3 +. 0 + +In 0 +addition 0 +to 0 +increases 0 +in 0 +p75 0 +( 0 +NTR 0 +) 0 +- 0 +IR 0 +in 0 +DRG 0 +cell 0 +bodies 0 +, 0 +increases 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +001 0 +) 0 +in 0 +pericellular 0 +( 0 +encircling 0 +DRG 0 +cells 0 +) 0 +p75 0 +( 0 +NTR 0 +) 0 +- 0 +IR 0 +in 0 +DRG 0 +also 0 +increased 0 +. 0 + +Confocal 0 +analyses 0 +demonstrated 0 +that 0 +pericellular 0 +p75 0 +( 0 +NTR 0 +) 0 +- 0 +IR 0 +was 0 +not 0 +colocalized 0 +with 0 +the 0 +glial 0 +marker 0 +, 0 +glial 0 +fibrillary 0 +acidic 0 +protein 0 +( 0 +GFAP 0 +) 0 +. 0 + +These 0 +studies 0 +demonstrate 0 +that 0 +p75 0 +( 0 +NTR 0 +) 0 +expression 0 +in 0 +micturition 0 +reflexes 0 +is 0 +present 0 +constitutively 0 +and 0 +modified 0 +by 0 +bladder 3 +inflammation 4 +. 0 + +The 0 +functional 0 +significance 0 +of 0 +p75 0 +( 0 +NTR 0 +) 0 +expression 0 +in 0 +micturition 0 +reflexes 0 +remains 0 +to 0 +be 0 +determined 0 +. 0 + +Azathioprine 1 +- 0 +induced 0 +suicidal 0 +erythrocyte 0 +death 0 +. 0 + +BACKGR0UND 0 +: 0 +Azathioprine 1 +is 0 +widely 0 +used 0 +as 0 +an 0 +immunosuppressive 0 +drug 0 +. 0 + +The 0 +side 0 +effects 0 +of 0 +azathioprine 1 +include 0 +anemia 3 +, 0 +which 0 +has 0 +been 0 +attributed 0 +to 0 +bone 0 +marrow 0 +suppression 0 +. 0 + +Alternatively 0 +, 0 +anemia 3 +could 0 +result 0 +from 0 +accelerated 0 +suicidal 0 +erythrocyte 0 +death 0 +or 0 +eryptosis 0 +, 0 +which 0 +is 0 +characterized 0 +by 0 +exposure 0 +of 0 +phosphatidylserine 1 +( 0 +PS 1 +) 0 +at 0 +the 0 +erythrocyte 0 +surface 0 +and 0 +by 0 +cell 0 +shrinkage 0 +. 0 + +METH0DS 0 +: 0 +The 0 +present 0 +experiments 0 +explored 0 +whether 0 +azathioprine 1 +influences 0 +eryptosis 0 +. 0 + +According 0 +to 0 +annexin 0 +V 0 +binding 0 +, 0 +erythrocytes 0 +from 0 +patients 0 +indeed 0 +showed 0 +a 0 +significant 0 +increase 0 +of 0 +PS 1 +exposure 0 +within 0 +1 0 +week 0 +of 0 +treatment 0 +with 0 +azathioprine 1 +. 0 + +In 0 +a 0 +second 0 +series 0 +, 0 +cytosolic 0 +Ca2 1 ++ 0 +activity 0 +( 0 +Fluo3 1 +fluorescence 0 +) 0 +, 0 +cell 0 +volume 0 +( 0 +forward 0 +scatter 0 +) 0 +, 0 +and 0 +PS 1 +- 0 +exposure 0 +( 0 +annexin 0 +V 0 +binding 0 +) 0 +were 0 +determined 0 +by 0 +FACS 0 +analysis 0 +in 0 +erythrocytes 0 +from 0 +healthy 0 +volunteers 0 +. 0 + +RESULTS 0 +: 0 +Exposure 0 +to 0 +azathioprine 1 +( 0 +> 0 +or 0 += 0 +2 0 +microg 0 +/ 0 +mL 0 +) 0 +for 0 +48 0 +hours 0 +increased 0 +cytosolic 0 +Ca2 1 ++ 0 +activity 0 +and 0 +annexin 0 +V 0 +binding 0 +and 0 +decreased 0 +forward 0 +scatter 0 +. 0 + +The 0 +effect 0 +of 0 +azathioprine 1 +on 0 +both 0 +annexin 0 +V 0 +binding 0 +and 0 +forward 0 +scatter 0 +was 0 +significantly 0 +blunted 0 +in 0 +the 0 +nominal 0 +absence 0 +of 0 +extracellular 0 +Ca2 1 ++ 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Azathioprine 1 +triggers 0 +suicidal 0 +erythrocyte 0 +death 0 +, 0 +an 0 +effect 0 +presumably 0 +contributing 0 +to 0 +azathioprine 1 +- 0 +induced 0 +anemia 3 +. 0 + +Levetiracetam 1 +as 0 +an 0 +adjunct 0 +to 0 +phenobarbital 1 +treatment 0 +in 0 +cats 0 +with 0 +suspected 0 +idiopathic 3 +epilepsy 4 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +assess 0 +pharmacokinetics 0 +, 0 +efficacy 0 +, 0 +and 0 +tolerability 0 +of 0 +oral 0 +levetiracetam 1 +administered 0 +as 0 +an 0 +adjunct 0 +to 0 +phenobarbital 1 +treatment 0 +in 0 +cats 0 +with 0 +poorly 0 +controlled 0 +suspected 0 +idiopathic 3 +epilepsy 4 +. 0 + +DESIGN 0 +- 0 +0pen 0 +- 0 +label 0 +, 0 +noncomparative 0 +clinical 0 +trial 0 +. 0 + +ANIMALS 0 +: 0 +12 0 +cats 0 +suspected 0 +to 0 +have 0 +idiopathic 3 +epilepsy 4 +that 0 +was 0 +poorly 0 +controlled 0 +with 0 +phenobarbital 1 +or 0 +that 0 +had 0 +unacceptable 0 +adverse 0 +effects 0 +when 0 +treated 0 +with 0 +phenobarbital 1 +. 0 + +PR0CEDURES 0 +: 0 +Cats 0 +were 0 +treated 0 +with 0 +levetiracetam 1 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +[ 0 +9 0 +. 0 +1 0 +mg 0 +/ 0 +lb 0 +] 0 +, 0 +P0 0 +, 0 +q 0 +8 0 +h 0 +) 0 +. 0 + +After 0 +a 0 +minimum 0 +of 0 +1 0 +week 0 +of 0 +treatment 0 +, 0 +serum 0 +levetiracetam 1 +concentrations 0 +were 0 +measured 0 +before 0 +and 0 +2 0 +, 0 +4 0 +, 0 +and 0 +6 0 +hours 0 +after 0 +drug 0 +administration 0 +, 0 +and 0 +maximum 0 +and 0 +minimum 0 +serum 0 +concentrations 0 +and 0 +elimination 0 +half 0 +- 0 +life 0 +were 0 +calculated 0 +. 0 + +Seizure 3 +frequencies 0 +before 0 +and 0 +after 0 +initiation 0 +of 0 +levetiracetam 1 +treatment 0 +were 0 +compared 0 +, 0 +and 0 +adverse 0 +effects 0 +were 0 +recorded 0 +. 0 + +RESULTS 0 +: 0 +Median 0 +maximum 0 +serum 0 +levetiracetam 1 +concentration 0 +was 0 +25 0 +. 0 +5 0 +microg 0 +/ 0 +mL 0 +, 0 +median 0 +minimum 0 +serum 0 +levetiracetam 1 +concentration 0 +was 0 +8 0 +. 0 +3 0 +microg 0 +/ 0 +mL 0 +, 0 +and 0 +median 0 +elimination 0 +half 0 +- 0 +life 0 +was 0 +2 0 +. 0 +9 0 +hours 0 +. 0 + +Median 0 +seizure 3 +frequency 0 +prior 0 +to 0 +treatment 0 +with 0 +levetiracetam 1 +( 0 +2 0 +. 0 +1 0 +seizures 3 +/ 0 +mo 0 +) 0 +was 0 +significantly 0 +higher 0 +than 0 +median 0 +seizure 3 +frequency 0 +after 0 +initiation 0 +of 0 +levetiracetam 1 +treatment 0 +( 0 +0 0 +. 0 +42 0 +seizures 3 +/ 0 +mo 0 +) 0 +, 0 +and 0 +7 0 +of 0 +10 0 +cats 0 +were 0 +classified 0 +as 0 +having 0 +responded 0 +to 0 +levetiracetam 1 +treatment 0 +( 0 +ie 0 +, 0 +reduction 0 +in 0 +seizure 3 +frequency 0 +of 0 +> 0 +or 0 += 0 +50 0 +% 0 +) 0 +. 0 + +Two 0 +cats 0 +had 0 +transient 0 +lethargy 3 +and 0 +inappetence 3 +. 0 + +C0NCLUSI0NS 0 +AND 0 +CLINICAL 0 +RELEVANCE 0 +: 0 +Results 0 +suggested 0 +that 0 +levetiracetam 1 +is 0 +well 0 +tolerated 0 +in 0 +cats 0 +and 0 +may 0 +be 0 +useful 0 +as 0 +an 0 +adjunct 0 +to 0 +phenobarbital 1 +treatment 0 +in 0 +cats 0 +with 0 +idiopathic 3 +epilepsy 4 +. 0 + +Serotonin 1 +reuptake 0 +inhibitors 0 +, 0 +paranoia 3 +, 0 +and 0 +the 0 +ventral 0 +basal 0 +ganglia 0 +. 0 + +Antidepressants 0 +have 0 +previously 0 +been 0 +associated 0 +with 0 +paranoid 3 +reactions 0 +in 0 +psychiatric 0 +patients 0 +. 0 + +Five 0 +cases 0 +of 0 +paranoid 3 +exacerbation 0 +with 0 +the 0 +serotonin 1 +reuptake 0 +inhibitors 0 +fluoxetine 1 +and 0 +amitriptyline 1 +are 0 +reported 0 +here 0 +. 0 + +Elements 0 +common 0 +to 0 +these 0 +cases 0 +included 0 +a 0 +history 0 +of 0 +paranoid 3 +symptomatology 0 +and 0 +the 0 +concomitant 0 +occurrence 0 +of 0 +depressive 3 +and 4 +psychotic 4 +symptoms 4 +. 0 + +Complicated 0 +depressive 3 +disorders 4 +( 0 +including 0 +atypicality 0 +of 0 +course 0 +and 0 +symptomatology 0 +, 0 +chronicity 0 +, 0 +psychosis 3 +, 0 +bipolarity 0 +, 0 +and 0 +secondary 0 +onset 0 +in 0 +the 0 +course 0 +of 0 +a 0 +primary 0 +psychosis 3 +) 0 +may 0 +present 0 +particular 0 +vulnerability 0 +to 0 +paranoid 3 +exacerbations 0 +associated 0 +with 0 +serotonin 1 +reuptake 0 +inhibitors 0 +. 0 + +Although 0 +the 0 +pharmacology 0 +and 0 +neurobiology 0 +of 0 +paranoia 3 +remain 0 +cryptic 0 +, 0 +several 0 +mechanisms 0 +, 0 +including 0 +5HT3 0 +receptor 0 +- 0 +mediated 0 +dopamine 1 +release 0 +, 0 +beta 0 +- 0 +noradrenergic 0 +receptor 0 +downregulation 0 +, 0 +or 0 +GABAB 0 +receptor 0 +upregulation 0 +acting 0 +in 0 +the 0 +vicinity 0 +of 0 +the 0 +ventral 0 +basal 0 +ganglia 0 +( 0 +possibly 0 +in 0 +lateral 0 +orbitofrontal 0 +or 0 +anterior 0 +cingulate 0 +circuits 0 +) 0 +, 0 +might 0 +apply 0 +to 0 +this 0 +phenomenon 0 +. 0 + +These 0 +cases 0 +call 0 +attention 0 +to 0 +possible 0 +paranoid 3 +exacerbations 0 +with 0 +serotonin 1 +reuptake 0 +blockers 0 +in 0 +select 0 +patients 0 +and 0 +raise 0 +neurobiological 0 +considerations 0 +regarding 0 +paranoia 3 +. 0 + +Clinical 0 +comparison 0 +of 0 +cardiorespiratory 0 +effects 0 +during 0 +unilateral 0 +and 0 +conventional 0 +spinal 0 +anaesthesia 0 +. 0 + +BACKGR0UND 0 +: 0 +Spinal 0 +anaesthesia 0 +is 0 +widely 0 +employed 0 +in 0 +clinical 0 +practice 0 +but 0 +has 0 +the 0 +main 0 +drawback 0 +of 0 +post 0 +- 0 +spinal 0 +block 0 +hypotension 3 +. 0 + +Efforts 0 +must 0 +therefore 0 +continue 0 +to 0 +be 0 +made 0 +to 0 +obviate 0 +this 0 +setback 0 +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +cardiovascular 0 +and 0 +respiratory 0 +changes 0 +during 0 +unilateral 0 +and 0 +conventional 0 +spinal 0 +anaesthesia 0 +. 0 + +METH0DS 0 +: 0 +With 0 +ethical 0 +approval 0 +, 0 +we 0 +studied 0 +74 0 +American 0 +Society 0 +of 0 +Anesthesiologists 0 +( 0 +ASA 0 +) 0 +, 0 +physical 0 +status 0 +class 0 +1 0 +and 0 +2 0 +patients 0 +scheduled 0 +for 0 +elective 0 +unilateral 0 +lower 0 +limb 0 +surgery 0 +. 0 + +Patients 0 +were 0 +randomly 0 +allocated 0 +into 0 +one 0 +of 0 +two 0 +groups 0 +: 0 +lateral 0 +and 0 +conventional 0 +spinal 0 +anaesthesia 0 +groups 0 +. 0 + +In 0 +the 0 +lateral 0 +position 0 +with 0 +operative 0 +side 0 +down 0 +, 0 +patients 0 +recived 0 +10 0 +mg 0 +( 0 +2mls 0 +) 0 +of 0 +0 0 +. 0 +5 0 +% 0 +hyperbaric 0 +bupivacaine 1 +through 0 +a 0 +25 0 +- 0 +gauge 0 +spinal 0 +needle 0 +. 0 + +Patients 0 +in 0 +the 0 +unilateral 0 +group 0 +were 0 +maintained 0 +in 0 +the 0 +lateral 0 +position 0 +for 0 +15 0 +minutes 0 +following 0 +spinal 0 +injection 0 +while 0 +those 0 +in 0 +the 0 +conventional 0 +group 0 +were 0 +turned 0 +supine 0 +immediately 0 +after 0 +injection 0 +. 0 + +Blood 0 +pressure 0 +, 0 +heart 0 +rate 0 +, 0 +respiratory 0 +rate 0 +and 0 +oxygen 1 +saturation 0 +were 0 +monitored 0 +over 0 +1 0 +hour 0 +. 0 + +RESULTS 0 +: 0 +Three 0 +patients 0 +( 0 +8 0 +. 0 +1 0 +% 0 +) 0 +in 0 +the 0 +unilateral 0 +group 0 +and 0 +5 0 +( 0 +13 0 +. 0 +5 0 +% 0 +) 0 +in 0 +the 0 +conventional 0 +group 0 +developed 0 +hypotension 3 +, 0 +P 0 += 0 +0 0 +. 0 +71 0 +. 0 + +Four 0 +( 0 +10 0 +. 0 +8 0 +% 0 +) 0 +patients 0 +in 0 +the 0 +conventional 0 +group 0 +and 0 +1 0 +( 0 +2 0 +. 0 +7 0 +% 0 +) 0 +in 0 +the 0 +unilateral 0 +group 0 +, 0 +P 0 += 0 +0 0 +. 0 +17 0 +required 0 +epinephrine 1 +infusion 0 +to 0 +treat 0 +hypotension 3 +. 0 + +Patients 0 +in 0 +the 0 +conventional 0 +group 0 +had 0 +statistically 0 +significant 0 +greater 0 +fall 0 +in 0 +the 0 +systolic 0 +blood 0 +pressures 0 +at 0 +15 0 +, 0 +30 0 +and 0 +45 0 +minutes 0 +when 0 +compared 0 +to 0 +the 0 +baseline 0 +( 0 +P 0 += 0 +0 0 +. 0 +003 0 +, 0 +0 0 +. 0 +001 0 +and 0 +0 0 +. 0 +004 0 +) 0 +. 0 + +The 0 +mean 0 +respiratory 0 +rate 0 +and 0 +oxygen 1 +saturations 0 +in 0 +the 0 +two 0 +groups 0 +were 0 +similar 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Compared 0 +to 0 +conventional 0 +spinal 0 +anaesthesia 0 +, 0 +unilateral 0 +spinal 0 +anaesthesia 0 +was 0 +associated 0 +with 0 +fewer 0 +cardiovascular 0 +perturbations 0 +. 0 + +Also 0 +, 0 +the 0 +type 0 +of 0 +spinal 0 +block 0 +instituted 0 +affected 0 +neither 0 +the 0 +respiratory 0 +rate 0 +nor 0 +the 0 +arterial 0 +oxygen 1 +saturation 0 +. 0 + +Spectrum 0 +of 0 +adverse 0 +events 0 +after 0 +generic 0 +HAART 0 +in 0 +southern 0 +Indian 0 +HIV 3 +- 4 +infected 4 +patients 0 +. 0 + +To 0 +determine 0 +the 0 +incidence 0 +of 0 +clinically 0 +significant 0 +adverse 0 +events 0 +after 0 +long 0 +- 0 +term 0 +, 0 +fixed 0 +- 0 +dose 0 +, 0 +generic 0 +highly 0 +active 0 +antiretroviral 0 +therapy 0 +( 0 +HAART 0 +) 0 +use 0 +among 0 +HIV 3 +- 4 +infected 4 +individuals 0 +in 0 +South 0 +India 0 +, 0 +we 0 +examined 0 +the 0 +experiences 0 +of 0 +3154 0 +HIV 3 +- 4 +infected 4 +individuals 0 +who 0 +received 0 +a 0 +minimum 0 +of 0 +3 0 +months 0 +of 0 +generic 0 +HAART 0 +between 0 +February 0 +1996 0 +and 0 +December 0 +2006 0 +at 0 +a 0 +tertiary 0 +HIV 0 +care 0 +referral 0 +center 0 +in 0 +South 0 +India 0 +. 0 + +The 0 +most 0 +common 0 +regimens 0 +were 0 +3TC 1 ++ 0 +d4T 1 ++ 0 +nevirapine 1 +( 0 +NVP 1 +) 0 +( 0 +54 0 +. 0 +8 0 +% 0 +) 0 +, 0 +zidovudine 1 +( 0 +AZT 1 +) 0 ++ 0 +3TC 1 ++ 0 +NVP 1 +( 0 +14 0 +. 0 +5 0 +% 0 +) 0 +, 0 +3TC 1 ++ 0 +d4T 1 ++ 0 +efavirenz 1 +( 0 +EFV 1 +) 0 +( 0 +20 0 +. 0 +1 0 +% 0 +) 0 +, 0 +and 0 +AZT 1 ++ 0 +3TC 1 ++ 0 +EFV 1 +( 0 +5 0 +. 0 +4 0 +% 0 +) 0 +. 0 + +The 0 +most 0 +common 0 +adverse 0 +events 0 +and 0 +median 0 +CD4 0 +at 0 +time 0 +of 0 +event 0 +were 0 +rash 3 +( 0 +15 0 +. 0 +2 0 +% 0 +; 0 +CD4 0 +, 0 +285 0 +cells 0 +/ 0 +microL 0 +) 0 +and 0 +peripheral 3 +neuropathy 4 +( 0 +9 0 +. 0 +0 0 +% 0 +and 0 +348 0 +cells 0 +/ 0 +microL 0 +) 0 +. 0 + +Clinically 0 +significant 0 +anemia 3 +( 0 +hemoglobin 0 +< 0 +7 0 +g 0 +/ 0 +dL 0 +) 0 +was 0 +observed 0 +in 0 +5 0 +. 0 +4 0 +% 0 +of 0 +patients 0 +( 0 +CD4 0 +, 0 +165 0 +cells 0 +/ 0 +microL 0 +) 0 +and 0 +hepatitis 3 +( 0 +clinical 0 +jaundice 3 +with 0 +alanine 1 +aminotransferase 0 +> 0 +5 0 +times 0 +upper 0 +limits 0 +of 0 +normal 0 +) 0 +in 0 +3 0 +. 0 +5 0 +% 0 +of 0 +patients 0 +( 0 +CD4 0 +, 0 +260 0 +cells 0 +/ 0 +microL 0 +) 0 +. 0 + +Women 0 +were 0 +significantly 0 +more 0 +likely 0 +to 0 +experience 0 +lactic 3 +acidosis 4 +, 0 +while 0 +men 0 +were 0 +significantly 0 +more 0 +likely 0 +to 0 +experience 0 +immune 3 +reconstitution 4 +syndrome 4 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Among 0 +the 0 +patients 0 +with 0 +1 0 +year 0 +of 0 +follow 0 +- 0 +up 0 +, 0 +NVP 1 +therapy 0 +was 0 +significantly 0 +associated 0 +with 0 +developing 0 +rash 3 +and 0 +d4T 1 +therapy 0 +with 0 +developing 0 +peripheral 3 +neuropathy 4 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Anemia 3 +and 0 +hepatitis 3 +often 0 +occur 0 +within 0 +12 0 +weeks 0 +of 0 +initiating 0 +generic 0 +HAART 0 +. 0 + +Frequent 0 +and 0 +early 0 +monitoring 0 +for 0 +these 0 +toxicities 3 +is 0 +warranted 0 +in 0 +developing 0 +countries 0 +where 0 +generic 0 +HAART 0 +is 0 +increasingly 0 +available 0 +. 0 + +Thalidomide 1 +and 0 +sensory 3 +neurotoxicity 4 +: 0 +a 0 +neurophysiological 0 +study 0 +. 0 + +BACKGR0UND 0 +: 0 +Recent 0 +studies 0 +confirmed 0 +a 0 +high 0 +incidence 0 +of 0 +sensory 3 +axonal 4 +neuropathy 4 +in 0 +patients 0 +treated 0 +with 0 +different 0 +doses 0 +of 0 +thalidomide 1 +. 0 + +The 0 +study 0 +' 0 +s 0 +aims 0 +were 0 +to 0 +measure 0 +variations 0 +in 0 +sural 0 +nerve 0 +sensory 0 +action 0 +potential 0 +( 0 +SAP 0 +) 0 +amplitude 0 +in 0 +patients 0 +with 0 +refractory 0 +cutaneous 3 +lupus 4 +erythematosus 4 +( 0 +CLE 3 +) 0 +treated 0 +with 0 +thalidomide 1 +and 0 +use 0 +these 0 +findings 0 +to 0 +identify 0 +the 0 +neurotoxic 3 +potential 0 +of 0 +thalidomide 1 +and 0 +the 0 +recovery 0 +capacity 0 +of 0 +sensory 0 +fibres 0 +after 0 +discontinuation 0 +of 0 +treatment 0 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Clinical 0 +and 0 +electrophysiological 0 +data 0 +in 0 +12 0 +female 0 +patients 0 +with 0 +CLE 3 +during 0 +treatment 0 +with 0 +thalidomide 1 +and 0 +up 0 +to 0 +47 0 +months 0 +after 0 +discontinuation 0 +of 0 +treatment 0 +were 0 +analysed 0 +. 0 + +Sural 0 +nerve 0 +SAP 0 +amplitude 0 +reduction 0 +> 0 +or 0 += 0 +40 0 +% 0 +was 0 +the 0 +criteria 0 +for 0 +discontinuing 0 +therapy 0 +. 0 + +RESULTS 0 +: 0 +During 0 +treatment 0 +, 0 +11 0 +patients 0 +showed 0 +a 0 +reduction 0 +in 0 +sural 0 +nerve 0 +SAP 0 +amplitude 0 +compared 0 +to 0 +baseline 0 +values 0 +( 0 +9 0 +with 0 +a 0 +reduction 0 +> 0 +or 0 += 0 +50 0 +% 0 +and 0 +2 0 +< 0 +50 0 +% 0 +) 0 +. 0 + +0ne 0 +patient 0 +showed 0 +no 0 +changes 0 +in 0 +SAP 0 +amplitude 0 +. 0 + +Five 0 +patients 0 +complained 0 +of 0 +paresthesias 3 +and 0 +leg 0 +cramps 3 +. 0 + +After 0 +thalidomide 1 +treatment 0 +, 0 +sural 0 +SAP 0 +amplitude 0 +recovered 0 +in 0 +3 0 +patients 0 +. 0 + +At 0 +detection 0 +of 0 +reduction 0 +in 0 +sural 0 +nerve 0 +SAP 0 +amplitude 0 +, 0 +the 0 +median 0 +thalidomide 1 +cumulative 0 +dose 0 +was 0 +21 0 +. 0 +4 0 +g 0 +. 0 + +The 0 +threshold 0 +neurotoxic 3 +dosage 0 +is 0 +lower 0 +than 0 +previously 0 +reported 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Sural 0 +nerve 0 +SAP 0 +amplitude 0 +reduction 0 +is 0 +a 0 +reliable 0 +and 0 +sensitive 0 +marker 0 +of 0 +degeneration 0 +and 0 +recovery 0 +of 0 +sensory 0 +fibres 0 +. 0 + +This 0 +electrophysiological 0 +parameter 0 +provides 0 +information 0 +about 0 +subclinical 0 +neurotoxic 3 +potential 0 +of 0 +thalidomide 1 +but 0 +is 0 +not 0 +helpful 0 +in 0 +predicting 0 +the 0 +appearance 0 +of 0 +sensory 0 +symptoms 0 +. 0 + +Five 0 +cases 0 +of 0 +encephalitis 3 +during 0 +treatment 0 +of 0 +loiasis 3 +with 0 +diethylcarbamazine 1 +. 0 + +Five 0 +cases 0 +of 0 +encephalitis 3 +following 0 +treatment 0 +with 0 +diethylcarbamazine 1 +( 0 +DEC 1 +) 0 +were 0 +observed 0 +in 0 +Congolese 0 +patients 0 +with 0 +Loa 0 +loa 0 +filariasis 3 +. 0 + +Two 0 +cases 0 +had 0 +a 0 +fatal 0 +outcome 0 +and 0 +one 0 +resulted 0 +in 0 +severe 0 +sequelae 0 +. 0 + +The 0 +notable 0 +fact 0 +was 0 +that 0 +this 0 +complication 0 +occurred 0 +in 0 +three 0 +patients 0 +hospitalized 0 +before 0 +treatment 0 +began 0 +, 0 +with 0 +whom 0 +particularly 0 +strict 0 +therapeutic 0 +precautions 0 +were 0 +taken 0 +, 0 +i 0 +. 0 +e 0 +. 0 +, 0 +initial 0 +dose 0 +less 0 +than 0 +10 0 +mg 0 +of 0 +DEC 1 +, 0 +very 0 +gradual 0 +dose 0 +increases 0 +, 0 +and 0 +associated 0 +anti 0 +- 0 +allergic 0 +treatment 0 +. 0 + +This 0 +type 0 +of 0 +drug 0 +- 0 +induced 0 +complication 0 +may 0 +not 0 +be 0 +that 0 +uncommon 0 +in 0 +highly 0 +endemic 0 +regions 0 +. 0 + +It 0 +occurs 0 +primarily 0 +, 0 +but 0 +not 0 +exclusively 0 +, 0 +in 0 +subjects 0 +presenting 0 +with 0 +a 0 +high 0 +microfilarial 0 +load 0 +. 0 + +The 0 +relationship 0 +between 0 +the 0 +occurrence 0 +of 0 +encephalitis 3 +and 0 +the 0 +decrease 0 +in 0 +microfilaremia 3 +is 0 +evident 0 +. 0 + +The 0 +pathophysiological 0 +mechanisms 0 +are 0 +discussed 0 +in 0 +the 0 +light 0 +of 0 +these 0 +observations 0 +and 0 +the 0 +few 0 +other 0 +comments 0 +on 0 +this 0 +subject 0 +published 0 +in 0 +the 0 +literature 0 +. 0 + +Amiodarone 1 +- 0 +related 0 +pulmonary 3 +mass 4 +and 0 +unique 0 +membranous 3 +glomerulonephritis 4 +in 0 +a 0 +patient 0 +with 0 +valvular 3 +heart 4 +disease 4 +: 0 +Diagnostic 0 +pitfall 0 +and 0 +new 0 +findings 0 +. 0 + +Amiodarone 1 +is 0 +an 0 +anti 0 +- 0 +arrhythmic 3 +drug 0 +for 0 +life 0 +- 0 +threatening 0 +tachycardia 3 +, 0 +but 0 +various 0 +adverse 0 +effects 0 +have 0 +been 0 +reported 0 +. 0 + +Reported 0 +herein 0 +is 0 +an 0 +autopsy 0 +case 0 +of 0 +valvular 3 +heart 4 +disease 4 +, 0 +in 0 +a 0 +patient 0 +who 0 +developed 0 +a 0 +lung 3 +mass 4 +( 0 +1 0 +. 0 +5 0 +cm 0 +in 0 +diameter 0 +) 0 +and 0 +proteinuria 3 +( 0 +2 0 +. 0 +76 0 +g 0 +/ 0 +day 0 +) 0 +after 0 +treatment 0 +with 0 +amiodarone 1 +for 0 +a 0 +long 0 +time 0 +. 0 + +The 0 +lung 3 +mass 4 +was 0 +highly 0 +suspected 0 +to 0 +be 0 +lung 3 +cancer 4 +on 0 +CT 0 +and 0 +positron 0 +emission 0 +tomography 0 +, 0 +but 0 +histologically 0 +the 0 +lesion 0 +was 0 +composed 0 +of 0 +lymphoplasmacytic 0 +infiltrates 0 +in 0 +alveolar 0 +walls 0 +and 0 +intra 0 +- 0 +alveolar 0 +accumulation 0 +of 0 +foamy 0 +macrophages 0 +containing 0 +characteristic 0 +myelinoid 0 +bodies 0 +, 0 +indicating 0 +that 0 +it 0 +was 0 +an 0 +amiodarone 1 +- 0 +related 0 +lesion 0 +. 0 + +In 0 +addition 0 +, 0 +the 0 +lung 0 +tissue 0 +had 0 +unevenly 0 +distributed 0 +hemosiderin 3 +deposition 0 +, 0 +and 0 +abnormally 0 +tortuous 0 +capillaries 0 +were 0 +seen 0 +in 0 +the 0 +mass 0 +and 0 +in 0 +heavily 0 +hemosiderotic 3 +lung 0 +portions 0 +outside 0 +the 0 +mass 0 +. 0 + +In 0 +the 0 +kidneys 0 +, 0 +glomeruli 0 +had 0 +membrane 0 +spikes 0 +, 0 +prominent 0 +swelling 0 +of 0 +podocytes 0 +and 0 +subepithelial 0 +deposits 0 +, 0 +which 0 +were 0 +sometimes 0 +large 0 +and 0 +hump 0 +- 0 +like 0 +. 0 + +Autoimmune 3 +diseases 4 +, 0 +viral 3 +hepatitis 4 +, 0 +malignant 0 +neoplasms 3 +or 0 +other 0 +diseases 0 +with 0 +a 0 +known 0 +relationship 0 +to 0 +membranous 3 +glomerulonephritis 4 +were 0 +not 0 +found 0 +. 0 + +The 0 +present 0 +case 0 +highlights 0 +the 0 +possibility 0 +that 0 +differential 0 +diagnosis 0 +between 0 +an 0 +amiodarone 1 +- 0 +related 0 +pulmonary 3 +lesion 4 +and 0 +a 0 +neoplasm 3 +can 0 +be 0 +very 0 +difficult 0 +radiologically 0 +, 0 +and 0 +suggests 0 +that 0 +membranous 3 +glomerulonephritis 4 +might 0 +be 0 +another 0 +possible 0 +complication 0 +of 0 +amiodarone 1 +treatment 0 +. 0 + +Risk 0 +of 0 +coronary 3 +artery 4 +disease 4 +associated 0 +with 0 +initial 0 +sulphonylurea 1 +treatment 0 +of 0 +patients 0 +with 0 +type 3 +2 4 +diabetes 4 +: 0 +a 0 +matched 0 +case 0 +- 0 +control 0 +study 0 +. 0 + +AIMS 0 +: 0 +This 0 +study 0 +sought 0 +to 0 +assess 0 +the 0 +risk 0 +of 0 +developing 0 +coronary 3 +artery 4 +disease 4 +( 0 +CAD 3 +) 0 +associated 0 +with 0 +initial 0 +treatment 0 +of 0 +type 3 +2 4 +diabetes 4 +with 0 +different 0 +sulphonylureas 1 +. 0 + +METH0DS 0 +: 0 +In 0 +type 3 +2 4 +diabetic 4 +patients 0 +, 0 +cases 0 +who 0 +developed 0 +CAD 3 +were 0 +compared 0 +retrospectively 0 +with 0 +controls 0 +that 0 +did 0 +not 0 +. 0 + +The 0 +20 0 +- 0 +year 0 +risk 0 +of 0 +CAD 3 +at 0 +diagnosis 0 +of 0 +diabetes 3 +, 0 +using 0 +the 0 +UKPDS 0 +risk 0 +engine 0 +, 0 +was 0 +used 0 +to 0 +match 0 +cases 0 +with 0 +controls 0 +. 0 + +RESULTS 0 +: 0 +The 0 +76 0 +cases 0 +of 0 +CAD 3 +were 0 +compared 0 +with 0 +152 0 +controls 0 +. 0 + +The 0 +hazard 0 +of 0 +developing 0 +CAD 3 +( 0 +95 0 +% 0 +CI 0 +) 0 +associated 0 +with 0 +initial 0 +treatment 0 +increased 0 +by 0 +2 0 +. 0 +4 0 +- 0 +fold 0 +( 0 +1 0 +. 0 +3 0 +- 0 +4 0 +. 0 +3 0 +, 0 +P 0 += 0 +0 0 +. 0 +004 0 +) 0 +with 0 +glibenclamide 1 +; 0 +2 0 +- 0 +fold 0 +( 0 +0 0 +. 0 +9 0 +- 0 +4 0 +. 0 +6 0 +, 0 +P 0 += 0 +0 0 +. 0 +099 0 +) 0 +with 0 +glipizide 1 +; 0 +2 0 +. 0 +9 0 +- 0 +fold 0 +( 0 +1 0 +. 0 +6 0 +- 0 +5 0 +. 0 +1 0 +, 0 +P 0 += 0 +0 0 +. 0 +000 0 +) 0 +with 0 +either 0 +, 0 +and 0 +was 0 +unchanged 0 +with 0 +metformin 1 +. 0 + +The 0 +hazard 0 +decreased 0 +0 0 +. 0 +3 0 +- 0 +fold 0 +( 0 +0 0 +. 0 +7 0 +- 0 +1 0 +. 0 +7 0 +, 0 +P 0 += 0 +0 0 +. 0 +385 0 +) 0 +with 0 +glimepiride 1 +, 0 +0 0 +. 0 +4 0 +- 0 +fold 0 +( 0 +0 0 +. 0 +7 0 +- 0 +1 0 +. 0 +3 0 +, 0 +P 0 += 0 +0 0 +. 0 +192 0 +) 0 +with 0 +gliclazide 1 +, 0 +and 0 +0 0 +. 0 +4 0 +- 0 +fold 0 +( 0 +0 0 +. 0 +7 0 +- 0 +1 0 +. 0 +1 0 +, 0 +P 0 += 0 +0 0 +. 0 +09 0 +) 0 +with 0 +either 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Initiating 0 +treatment 0 +of 0 +type 3 +2 4 +diabetes 4 +with 0 +glibenclamide 1 +or 0 +glipizide 1 +is 0 +associated 0 +with 0 +increased 0 +risk 0 +of 0 +CAD 3 +in 0 +comparison 0 +to 0 +gliclazide 1 +or 0 +glimepiride 1 +. 0 + +If 0 +confirmed 0 +, 0 +this 0 +may 0 +be 0 +important 0 +because 0 +most 0 +Indian 0 +patients 0 +receive 0 +the 0 +cheaper 0 +older 0 +sulphonylureas 1 +, 0 +and 0 +present 0 +guidelines 0 +do 0 +not 0 +distinguish 0 +between 0 +individual 0 +agents 0 +. 0 + +Reduced 0 +progression 0 +of 0 +adriamycin 1 +nephropathy 3 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +treated 0 +by 0 +losartan 1 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +antihypertensive 0 +effects 0 +of 0 +angiotensin 1 +II 2 +type 0 +- 0 +1 0 +receptor 0 +blocker 0 +, 0 +losartan 1 +, 0 +and 0 +its 0 +potential 0 +in 0 +slowing 0 +down 0 +renal 3 +disease 4 +progression 0 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +( 0 +SHR 0 +) 0 +with 0 +adriamycin 1 +( 0 +ADR 1 +) 0 +nephropathy 3 +. 0 + +METH0DS 0 +: 0 +Six 0 +- 0 +month 0 +- 0 +old 0 +female 0 +SHR 0 +were 0 +randomly 0 +selected 0 +in 0 +six 0 +groups 0 +. 0 + +Two 0 +control 0 +groups 0 +( 0 +SH 0 +( 0 +6 0 +) 0 +, 0 +SH 0 +( 0 +12 0 +) 0 +) 0 +received 0 +vehicle 0 +. 0 + +Groups 0 +ADR 1 +( 0 +6 0 +) 0 +, 0 +ADR 1 ++ 0 +L0S 1 +( 0 +6 0 +) 0 +and 0 +ADR 1 +( 0 +12 0 +) 0 +, 0 +and 0 +ADR 1 ++ 0 +L0S 1 +( 0 +12 0 +) 0 +received 0 +ADR 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +/ 0 +b 0 +. 0 +w 0 +. 0 +i 0 +. 0 +v 0 +. 0 +) 0 +twice 0 +in 0 +a 0 +3 0 +- 0 +week 0 +interval 0 +. 0 + +Group 0 +ADR 1 ++ 0 +L0S 1 +( 0 +6 0 +) 0 +received 0 +losartan 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +/ 0 +b 0 +. 0 +w 0 +. 0 +/ 0 +day 0 +by 0 +gavages 0 +) 0 +for 0 +6 0 +weeks 0 +and 0 +group 0 +ADR 1 ++ 0 +L0S 1 +( 0 +12 0 +) 0 +for 0 +12 0 +weeks 0 +after 0 +second 0 +injection 0 +of 0 +ADR 1 +. 0 + +Animals 0 +were 0 +killed 0 +after 0 +6 0 +or 0 +12 0 +weeks 0 +, 0 +respectively 0 +. 0 + +Haemodynamic 0 +measurements 0 +were 0 +performed 0 +on 0 +anaesthetized 0 +animals 0 +, 0 +blood 0 +and 0 +urine 0 +samples 0 +were 0 +taken 0 +for 0 +biochemical 0 +analysis 0 +and 0 +the 0 +left 0 +kidney 0 +was 0 +processed 0 +for 0 +morphological 0 +studies 0 +. 0 + +RESULTS 0 +: 0 +Short 0 +- 0 +term 0 +losartan 1 +treatment 0 +, 0 +besides 0 +antihypertensive 0 +effect 0 +, 0 +improved 0 +glomerular 0 +filtration 0 +rate 0 +and 0 +ameliorated 0 +glomerulosclerosis 3 +resulting 0 +in 0 +decreased 0 +proteinuria 3 +. 0 + +Prolonged 0 +treatment 0 +with 0 +losartan 1 +showed 0 +further 0 +reduction 0 +of 0 +glomerulosclerosis 3 +associated 0 +with 0 +reduced 0 +progression 0 +of 0 +tubular 0 +atrophy 3 +and 0 +interstitial 3 +fibrosis 4 +, 0 +thus 0 +preventing 0 +heavy 0 +proteinuria 3 +and 0 +chronic 3 +renal 4 +failure 4 +. 0 + +Losartan 1 +reduced 0 +uraemia 3 +and 0 +increased 0 +urea 1 +clearance 0 +in 0 +advanced 0 +ADR 1 +nephropathy 3 +in 0 +SHR 0 +. 0 + +Histological 0 +examination 0 +showed 0 +that 0 +losartan 1 +could 0 +prevent 0 +tubular 0 +atrophy 3 +, 0 +interstitial 0 +infiltration 0 +and 0 +fibrosis 3 +in 0 +ADR 1 +nephropathy 3 +. 0 + +C0NCLUSI0N 0 +: 0 +Losartan 1 +reduces 0 +the 0 +rate 0 +of 0 +progression 0 +of 0 +ADR 1 +- 0 +induced 0 +focal 3 +segmental 4 +glomerulosclerosis 4 +to 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +in 0 +SHR 0 +. 0 + +The 0 +risks 0 +of 0 +aprotinin 0 +and 0 +tranexamic 1 +acid 2 +in 0 +cardiac 0 +surgery 0 +: 0 +a 0 +one 0 +- 0 +year 0 +follow 0 +- 0 +up 0 +of 0 +1188 0 +consecutive 0 +patients 0 +. 0 + +BACKGR0UND 0 +: 0 +0ur 0 +aim 0 +was 0 +to 0 +investigate 0 +postoperative 0 +complications 0 +and 0 +mortality 0 +after 0 +administration 0 +of 0 +aprotinin 0 +compared 0 +to 0 +tranexamic 1 +acid 2 +in 0 +an 0 +unselected 0 +, 0 +consecutive 0 +cohort 0 +. 0 + +METH0DS 0 +: 0 +Perioperative 0 +data 0 +from 0 +consecutive 0 +cardiac 0 +surgery 0 +patients 0 +were 0 +prospectively 0 +collected 0 +between 0 +September 0 +2005 0 +and 0 +June 0 +2006 0 +in 0 +a 0 +university 0 +- 0 +affiliated 0 +clinic 0 +( 0 +n 0 += 0 +1188 0 +) 0 +. 0 + +During 0 +the 0 +first 0 +5 0 +mo 0 +, 0 +596 0 +patients 0 +received 0 +aprotinin 0 +( 0 +Group 0 +A 0 +) 0 +; 0 +in 0 +the 0 +next 0 +5 0 +mo 0 +, 0 +592 0 +patients 0 +were 0 +treated 0 +with 0 +tranexamic 1 +acid 2 +( 0 +Group 0 +T 0 +) 0 +. 0 + +Except 0 +for 0 +antifibrinolytic 0 +therapy 0 +, 0 +the 0 +anesthetic 0 +and 0 +surgical 0 +protocols 0 +remained 0 +unchanged 0 +. 0 + +RESULTS 0 +: 0 +The 0 +pre 0 +- 0 +and 0 +intraoperative 0 +variables 0 +were 0 +comparable 0 +between 0 +the 0 +treatment 0 +groups 0 +. 0 + +Postoperatively 0 +, 0 +a 0 +significantly 0 +higher 0 +incidence 0 +of 0 +seizures 3 +was 0 +found 0 +in 0 +Group 0 +T 0 +( 0 +4 0 +. 0 +6 0 +% 0 +vs 0 +1 0 +. 0 +2 0 +% 0 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +This 0 +difference 0 +was 0 +also 0 +significant 0 +in 0 +the 0 +primary 0 +valve 0 +surgery 0 +and 0 +the 0 +high 0 +risk 0 +surgery 0 +subgroups 0 +( 0 +7 0 +. 0 +9 0 +% 0 +vs 0 +1 0 +. 0 +2 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +003 0 +; 0 +7 0 +. 0 +3 0 +% 0 +vs 0 +2 0 +. 0 +4 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +035 0 +, 0 +respectively 0 +) 0 +. 0 + +Persistent 0 +atrial 0 +fibrillation 0 +( 0 +7 0 +. 0 +9 0 +% 0 +vs 0 +2 0 +. 0 +3 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +020 0 +) 0 +and 0 +renal 3 +failure 4 +( 0 +9 0 +. 0 +7 0 +% 0 +vs 0 +1 0 +. 0 +7 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +002 0 +) 0 +were 0 +also 0 +more 0 +common 0 +in 0 +Group 0 +T 0 +, 0 +in 0 +the 0 +primary 0 +valve 0 +surgery 0 +subgroup 0 +. 0 + +0n 0 +the 0 +contrary 0 +, 0 +among 0 +primary 0 +coronary 0 +artery 0 +bypass 0 +surgery 0 +patients 0 +, 0 +there 0 +were 0 +more 0 +acute 0 +myocardial 3 +infarctions 4 +and 0 +renal 3 +dysfunction 4 +in 0 +Group 0 +A 0 +( 0 +5 0 +. 0 +8 0 +% 0 +vs 0 +2 0 +. 0 +0 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +027 0 +; 0 +22 0 +. 0 +5 0 +% 0 +vs 0 +15 0 +. 0 +2 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +036 0 +, 0 +respectively 0 +) 0 +. 0 + +The 0 +1 0 +- 0 +yr 0 +mortality 0 +was 0 +significantly 0 +higher 0 +after 0 +aprotinin 0 +treatment 0 +in 0 +the 0 +high 0 +risk 0 +surgery 0 +group 0 +( 0 +17 0 +. 0 +7 0 +% 0 +vs 0 +9 0 +. 0 +8 0 +% 0 +, 0 +P 0 += 0 +0 0 +. 0 +034 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Both 0 +antifibrinolytic 0 +drugs 0 +bear 0 +the 0 +risk 0 +of 0 +adverse 0 +outcome 0 +depending 0 +on 0 +the 0 +type 0 +of 0 +cardiac 0 +surgery 0 +. 0 + +Administration 0 +of 0 +aprotinin 0 +should 0 +be 0 +avoided 0 +in 0 +coronary 0 +artery 0 +bypass 0 +graft 0 +and 0 +high 0 +risk 0 +patients 0 +, 0 +whereas 0 +administration 0 +of 0 +tranexamic 1 +acid 2 +is 0 +not 0 +recommended 0 +in 0 +valve 0 +surgery 0 +. 0 + +Delirium 3 +in 0 +an 0 +elderly 0 +woman 0 +possibly 0 +associated 0 +with 0 +administration 0 +of 0 +misoprostol 1 +. 0 + +Misoprostol 1 +has 0 +been 0 +associated 0 +with 0 +adverse 0 +reactions 0 +, 0 +including 0 +gastrointestinal 0 +symptoms 0 +, 0 +gynecologic 0 +problems 0 +, 0 +and 0 +headache 3 +. 0 + +Changes 0 +in 0 +mental 0 +status 0 +, 0 +however 0 +, 0 +have 0 +not 0 +been 0 +reported 0 +. 0 + +We 0 +present 0 +a 0 +case 0 +in 0 +which 0 +an 0 +89 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +in 0 +a 0 +long 0 +- 0 +term 0 +care 0 +facility 0 +became 0 +confused 0 +after 0 +the 0 +initiation 0 +of 0 +misoprostol 1 +therapy 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +change 0 +in 0 +mental 0 +status 0 +was 0 +first 0 +reported 0 +nine 0 +days 0 +after 0 +the 0 +initiation 0 +of 0 +therapy 0 +. 0 + +Her 0 +delirium 3 +significantly 0 +improved 0 +after 0 +misoprostol 1 +was 0 +discontinued 0 +and 0 +her 0 +mental 0 +status 0 +returned 0 +to 0 +normal 0 +within 0 +a 0 +week 0 +. 0 + +Because 0 +no 0 +other 0 +factors 0 +related 0 +to 0 +this 0 +patient 0 +changed 0 +significantly 0 +, 0 +the 0 +delirium 3 +experienced 0 +by 0 +this 0 +patient 0 +possibly 0 +resulted 0 +from 0 +misoprostol 1 +therapy 0 +. 0 + +The 0 +biological 0 +properties 0 +of 0 +the 0 +optical 0 +isomers 0 +of 0 +propranolol 1 +and 0 +their 0 +effects 0 +on 0 +cardiac 3 +arrhythmias 4 +. 0 + +1 0 +. 0 + +The 0 +optical 0 +isomers 0 +of 0 +propranolol 1 +have 0 +been 0 +compared 0 +for 0 +their 0 +beta 0 +- 0 +blocking 0 +and 0 +antiarrhythmic 0 +activities 0 +. 0 +2 0 +. 0 + +In 0 +blocking 0 +the 0 +positive 0 +inotropic 0 +and 0 +chronotropic 0 +responses 0 +to 0 +isoprenaline 1 +, 0 +( 0 ++ 0 +) 0 +- 0 +propranolol 1 +had 0 +less 0 +than 0 +one 0 +hundredth 0 +the 0 +potency 0 +of 0 +( 0 +- 0 +) 0 +- 0 +propranolol 1 +. 0 + +At 0 +dose 0 +levels 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +propranolol 1 +which 0 +attenuated 0 +the 0 +responses 0 +to 0 +isoprenaline 1 +, 0 +there 0 +was 0 +a 0 +significant 0 +prolongation 0 +of 0 +the 0 +PR 0 +interval 0 +of 0 +the 0 +electrocardiogram 0 +. 0 +3 0 +. 0 + +The 0 +metabolic 0 +responses 0 +to 0 +isoprenaline 1 +in 0 +dogs 0 +( 0 +an 0 +increase 0 +in 0 +circulating 0 +glucose 1 +, 0 +lactate 1 +and 0 +free 0 +fatty 1 +acids 2 +) 0 +were 0 +all 0 +blocked 0 +by 0 +( 0 +- 0 +) 0 +- 0 +propranolol 1 +. 0 + +( 0 ++ 0 +) 0 +- 0 +Propranolol 1 +had 0 +no 0 +effect 0 +on 0 +fatty 1 +acid 2 +mobilization 0 +but 0 +significantly 0 +reduced 0 +the 0 +increments 0 +in 0 +both 0 +lactate 1 +and 0 +glucose 1 +. 0 +4 0 +. 0 + +Both 0 +isomers 0 +of 0 +propranolol 1 +possessed 0 +similar 0 +depressant 0 +potency 0 +on 0 +isolated 0 +atrial 0 +muscle 0 +taken 0 +from 0 +guinea 0 +- 0 +pigs 0 +. 0 +5 0 +. 0 + +The 0 +isomers 0 +of 0 +propranolol 1 +exhibited 0 +similar 0 +local 0 +anaesthetic 0 +potencies 0 +on 0 +an 0 +isolated 0 +frog 0 +nerve 0 +preparation 0 +at 0 +a 0 +level 0 +approximately 0 +three 0 +times 0 +that 0 +of 0 +procaine 1 +. 0 + +The 0 +racemic 0 +compound 0 +was 0 +significantly 0 +less 0 +potent 0 +than 0 +either 0 +isomer 0 +. 0 +6 0 +. 0 + +Both 0 +isomers 0 +of 0 +propranolol 1 +were 0 +capable 0 +of 0 +preventing 0 +adrenaline 1 +- 0 +induced 0 +cardiac 3 +arrhythmias 4 +in 0 +cats 0 +anaesthetized 0 +with 0 +halothane 1 +, 0 +but 0 +the 0 +mean 0 +dose 0 +of 0 +( 0 +- 0 +) 0 +- 0 +propranolol 1 +was 0 +0 0 +. 0 +09 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +02 0 +mg 0 +/ 0 +kg 0 +whereas 0 +that 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +propranolol 1 +was 0 +4 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +. 0 + +At 0 +the 0 +effective 0 +dose 0 +level 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +propranolol 1 +there 0 +was 0 +a 0 +significant 0 +prolongation 0 +of 0 +the 0 +PR 0 +interval 0 +of 0 +the 0 +electrocardiogram 0 +. 0 + +Blockade 0 +of 0 +arrhythmias 3 +with 0 +both 0 +isomers 0 +was 0 +surmountable 0 +by 0 +increasing 0 +the 0 +dose 0 +of 0 +adrenaline 1 +. 0 +7 0 +. 0 + +Both 0 +isomers 0 +of 0 +propranolol 1 +were 0 +also 0 +capable 0 +of 0 +reversing 0 +ventricular 3 +tachycardia 4 +caused 0 +by 0 +ouabain 1 +in 0 +anaesthetized 0 +cats 0 +and 0 +dogs 0 +. 0 + +The 0 +dose 0 +of 0 +( 0 +- 0 +) 0 +- 0 +propranolol 1 +was 0 +significantly 0 +smaller 0 +than 0 +that 0 +of 0 +( 0 ++ 0 +) 0 +- 0 +propranolol 1 +in 0 +both 0 +species 0 +but 0 +much 0 +higher 0 +than 0 +that 0 +required 0 +to 0 +produce 0 +evidence 0 +of 0 +beta 0 +- 0 +blockade 0 +. 0 +8 0 +. 0 + +The 0 +implications 0 +of 0 +these 0 +results 0 +are 0 +discussed 0 +. 0 + +Topotecan 1 +in 0 +combination 0 +with 0 +radiotherapy 0 +in 0 +unresectable 0 +glioblastoma 3 +: 0 +a 0 +phase 0 +2 0 +study 0 +. 0 + +Improving 0 +glioblastoma 3 +multiforme 4 +( 0 +GBM 3 +) 0 +treatment 0 +with 0 +radio 0 +- 0 +chemotherapy 0 +remains 0 +a 0 +challenge 0 +. 0 + +Topotecan 1 +is 0 +an 0 +attractive 0 +option 0 +as 0 +it 0 +exhibits 0 +growth 0 +inhibition 0 +of 0 +human 0 +glioma 3 +as 0 +well 0 +as 0 +brain 0 +penetration 0 +. 0 + +The 0 +present 0 +study 0 +assessed 0 +the 0 +combination 0 +of 0 +radiotherapy 0 +( 0 +60 0 +Gy 0 +/ 0 +30 0 +fractions 0 +/ 0 +40 0 +days 0 +) 0 +and 0 +topotecan 1 +( 0 +0 0 +. 0 +9 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +/ 0 +day 0 +on 0 +days 0 +1 0 +- 0 +5 0 +on 0 +weeks 0 +1 0 +, 0 +3 0 +and 0 +5 0 +) 0 +in 0 +50 0 +adults 0 +with 0 +histologically 0 +proven 0 +and 0 +untreated 0 +GBM 3 +. 0 + +The 0 +incidence 0 +of 0 +non 0 +- 0 +hematological 0 +toxicities 3 +was 0 +low 0 +and 0 +grade 0 +3 0 +- 0 +4 0 +hematological 0 +toxicities 3 +were 0 +reported 0 +in 0 +20 0 +patients 0 +( 0 +mainly 0 +lymphopenia 3 +and 0 +neutropenia 3 +) 0 +. 0 + +Partial 0 +response 0 +and 0 +stabilization 0 +rates 0 +were 0 +2 0 +% 0 +and 0 +32 0 +% 0 +, 0 +respectively 0 +, 0 +with 0 +an 0 +overall 0 +time 0 +to 0 +progression 0 +of 0 +12 0 +weeks 0 +. 0 + +0ne 0 +- 0 +year 0 +overall 0 +survival 0 +( 0 +0S 0 +) 0 +rate 0 +was 0 +42 0 +% 0 +, 0 +with 0 +a 0 +median 0 +0S 0 +of 0 +40 0 +weeks 0 +. 0 + +Topotecan 1 +in 0 +combination 0 +with 0 +radiotherapy 0 +was 0 +well 0 +tolerated 0 +. 0 + +However 0 +, 0 +while 0 +response 0 +and 0 +stabilization 0 +concerned 0 +one 0 +- 0 +third 0 +of 0 +the 0 +patients 0 +, 0 +the 0 +study 0 +did 0 +not 0 +show 0 +increased 0 +benefits 0 +in 0 +terms 0 +of 0 +survival 0 +in 0 +patients 0 +with 0 +unresectable 0 +GBM 3 +. 0 + +Long 0 +- 0 +term 0 +lithium 1 +therapy 0 +leading 0 +to 0 +hyperparathyroidism 3 +: 0 +a 0 +case 0 +report 0 +. 0 + +PURP0SE 0 +: 0 +This 0 +paper 0 +reviews 0 +the 0 +effect 0 +of 0 +chronic 0 +lithium 1 +therapy 0 +on 0 +serum 0 +calcium 1 +level 0 +and 0 +parathyroid 0 +glands 0 +, 0 +its 0 +pathogenesis 0 +, 0 +and 0 +treatment 0 +options 0 +. 0 + +We 0 +examined 0 +the 0 +case 0 +of 0 +a 0 +lithium 1 +- 0 +treated 0 +patient 0 +who 0 +had 0 +recurrent 0 +hypercalcemia 3 +to 0 +better 0 +understand 0 +the 0 +disease 0 +process 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Primary 3 +hyperparathyroidism 4 +is 0 +a 0 +rare 0 +but 0 +potentially 0 +life 0 +- 0 +threatening 0 +side 0 +effect 0 +of 0 +long 0 +- 0 +term 0 +lithium 1 +therapy 0 +. 0 + +Careful 0 +patient 0 +selection 0 +and 0 +long 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +can 0 +reduce 0 +morbidity 0 +. 0 + +PRACTICAL 0 +IMPLICATI0NS 0 +: 0 +As 0 +much 0 +as 0 +15 0 +% 0 +of 0 +lithium 1 +- 0 +treated 0 +patients 0 +become 0 +hypercalcemic 3 +. 0 + +By 0 +routinely 0 +monitoring 0 +serum 0 +calcium 1 +levels 0 +, 0 +healthcare 0 +providers 0 +can 0 +improve 0 +the 0 +quality 0 +of 0 +life 0 +of 0 +this 0 +patient 0 +group 0 +. 0 + +Comparison 0 +of 0 +laryngeal 0 +mask 0 +with 0 +endotracheal 0 +tube 0 +for 0 +anesthesia 0 +in 0 +endoscopic 0 +sinus 0 +surgery 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +compare 0 +surgical 0 +conditions 0 +, 0 +including 0 +the 0 +amount 0 +of 0 +intraoperative 0 +bleeding 3 +as 0 +well 0 +as 0 +intraoperative 0 +blood 0 +pressure 0 +, 0 +during 0 +functional 0 +endoscopic 0 +sinus 0 +surgery 0 +( 0 +FESS 0 +) 0 +using 0 +flexible 0 +reinforced 0 +laryngeal 0 +mask 0 +airway 0 +( 0 +FRLMA 0 +) 0 +versus 0 +endotracheal 0 +tube 0 +( 0 +ETT 0 +) 0 +in 0 +maintaining 0 +controlled 0 +hypotension 3 +anesthesia 0 +induced 0 +by 0 +propofol 1 +- 0 +remifentanil 1 +total 0 +i 0 +. 0 +v 0 +. 0 +anesthesia 0 +( 0 +TIVA 0 +) 0 +. 0 + +METH0DS 0 +: 0 +Sixty 0 +normotensive 0 +American 0 +Society 0 +of 0 +Anesthesiologists 0 +I 0 +- 0 +II 0 +adult 0 +patients 0 +undergoing 0 +FESS 0 +under 0 +controlled 0 +hypotension 3 +anesthesia 0 +caused 0 +by 0 +propofol 1 +- 0 +remifentanil 1 +- 0 +TIVA 0 +were 0 +randomly 0 +assigned 0 +into 0 +two 0 +groups 0 +: 0 +group 0 +I 0 +, 0 +FRLMA 0 +; 0 +group 0 +II 0 +, 0 +ETT 0 +. 0 + +Hemorrhage 3 +was 0 +measured 0 +and 0 +the 0 +visibility 0 +of 0 +the 0 +operative 0 +field 0 +was 0 +evaluated 0 +according 0 +to 0 +a 0 +six 0 +- 0 +point 0 +scale 0 +. 0 + +RESULTS 0 +: 0 +Controlled 0 +hypotension 3 +was 0 +achieved 0 +within 0 +a 0 +shorter 0 +period 0 +using 0 +laryngeal 0 +mask 0 +using 0 +lower 0 +rates 0 +of 0 +remifentanil 1 +infusion 0 +and 0 +lower 0 +total 0 +dose 0 +of 0 +remifentanil 1 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +summary 0 +, 0 +our 0 +results 0 +indicate 0 +that 0 +airway 0 +management 0 +using 0 +FRLMA 0 +during 0 +controlled 0 +hypotension 3 +anesthesia 0 +provided 0 +better 0 +surgical 0 +conditions 0 +in 0 +terms 0 +of 0 +quality 0 +of 0 +operative 0 +field 0 +and 0 +blood 0 +loss 0 +and 0 +allowed 0 +for 0 +convenient 0 +induced 0 +hypotension 3 +with 0 +low 0 +doses 0 +of 0 +remifentanil 1 +during 0 +TIVA 0 +in 0 +patients 0 +undergoing 0 +FESS 0 +. 0 + +Nonalcoholic 3 +fatty 4 +liver 4 +disease 4 +during 0 +valproate 1 +therapy 0 +. 0 + +Valproic 1 +acid 2 +( 0 +VPA 1 +) 0 +is 0 +effective 0 +for 0 +the 0 +treatment 0 +of 0 +many 0 +types 0 +of 0 +epilepsy 3 +, 0 +but 0 +its 0 +use 0 +can 0 +be 0 +associated 0 +with 0 +an 0 +increase 0 +in 0 +body 0 +weight 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +nonalcoholic 3 +fatty 4 +liver 4 +disease 4 +( 0 +NAFLD 3 +) 0 +arising 0 +in 0 +a 0 +child 0 +who 0 +developed 0 +obesity 3 +during 0 +VPA 1 +treatment 0 +. 0 + +Laboratory 0 +data 0 +revealed 0 +hyperinsulinemia 3 +with 0 +insulin 3 +resistance 4 +. 0 + +After 0 +the 0 +withdrawal 0 +of 0 +VPA 1 +therapy 0 +, 0 +our 0 +patient 0 +showed 0 +a 0 +significant 0 +weight 3 +loss 4 +, 0 +a 0 +decrease 0 +of 0 +body 0 +mass 0 +index 0 +, 0 +and 0 +normalization 0 +of 0 +metabolic 0 +and 0 +endocrine 0 +parameters 0 +; 0 +moreover 0 +, 0 +ultrasound 0 +measurements 0 +showed 0 +a 0 +complete 0 +normalization 0 +. 0 + +The 0 +present 0 +case 0 +suggests 0 +that 0 +obesity 3 +, 0 +hyperinsulinemia 3 +, 0 +insulin 3 +resistance 4 +, 0 +and 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +VPA 1 +may 0 +be 0 +all 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +NAFLD 3 +; 0 +this 0 +side 0 +effect 0 +is 0 +reversible 0 +after 0 +VPA 1 +withdrawal 0 +. 0 + +Carbimazole 1 +induced 0 +ANCA 3 +positive 4 +vasculitis 4 +. 0 + +Anti 1 +- 2 +thyroid 2 +drugs 2 +, 0 +like 0 +carbimazole 1 +and 0 +propylthiouracil 1 +( 0 +PTU 1 +) 0 +are 0 +commonly 0 +prescribed 0 +for 0 +the 0 +treatment 0 +of 0 +hyperthyroidism 3 +. 0 + +0ne 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +side 0 +effects 0 +of 0 +antithyroid 1 +medications 2 +. 0 + +Antineutrophil 3 +cytoplasmic 4 +antibody 4 +( 4 +ANCA 4 +) 4 +- 4 +- 4 +associated 4 +vasculitis 4 +is 0 +a 0 +potentially 0 +life 0 +- 0 +threatening 0 +adverse 0 +effect 0 +of 0 +antithyroidmedications 1 +. 0 + +We 0 +report 0 +a 0 +patient 0 +with 0 +Graves 3 +' 4 +disease 4 +who 0 +developed 0 +ANCA 0 +positive 0 +carbimazole 1 +induced 0 +vasculitis 3 +. 0 + +The 0 +episode 0 +was 0 +characterized 0 +by 0 +a 0 +vasculitic 3 +skin 3 +rash 4 +associated 0 +with 0 +large 0 +joint 0 +arthritis 3 +, 0 +pyrexia 3 +and 0 +parotiditis 3 +but 0 +no 0 +renal 0 +or 0 +pulmonary 0 +involvement 0 +. 0 + +He 0 +was 0 +referred 0 +to 0 +us 0 +for 0 +neurological 0 +evaluation 0 +because 0 +he 0 +had 0 +difficulty 0 +in 0 +getting 0 +up 0 +from 0 +squatting 0 +position 0 +and 0 +was 0 +suspected 0 +to 0 +have 0 +myositis 3 +. 0 + +Carbimazole 1 +and 0 +methimazole 1 +have 0 +a 0 +lower 0 +incidence 0 +of 0 +reported 0 +ANCA 0 +positive 0 +side 0 +effects 0 +than 0 +PUT 0 +. 0 + +To 0 +the 0 +best 0 +of 0 +our 0 +knowledge 0 +this 0 +is 0 +the 0 +first 0 +ANCA 0 +positive 0 +carbimazole 1 +induced 0 +vasculitis 3 +case 0 +reported 0 +from 0 +India 0 +. 0 + +Aspirin 1 +for 0 +the 0 +primary 0 +prevention 0 +of 0 +cardiovascular 0 +events 0 +: 0 +an 0 +update 0 +of 0 +the 0 +evidence 0 +for 0 +the 0 +U 0 +. 0 +S 0 +. 0 + +Preventive 0 +Services 0 +Task 0 +Force 0 +. 0 + +BACKGR0UND 0 +: 0 +Coronary 3 +heart 4 +disease 4 +and 0 +cerebrovascular 3 +disease 4 +are 0 +leading 0 +causes 0 +of 0 +death 0 +in 0 +the 0 +United 0 +States 0 +. 0 + +In 0 +2002 0 +, 0 +the 0 +U 0 +. 0 +S 0 +. 0 + +Preventive 0 +Services 0 +Task 0 +Force 0 +( 0 +USPSTF 0 +) 0 +strongly 0 +recommended 0 +that 0 +clinicians 0 +discuss 0 +aspirin 1 +with 0 +adults 0 +who 0 +are 0 +at 0 +increased 0 +risk 0 +for 0 +coronary 3 +heart 4 +disease 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +determine 0 +the 0 +benefits 0 +and 0 +harms 0 +of 0 +taking 0 +aspirin 1 +for 0 +the 0 +primary 0 +prevention 0 +of 0 +myocardial 3 +infarctions 4 +, 0 +strokes 3 +, 0 +and 0 +death 0 +. 0 + +DATA 0 +S0URCES 0 +: 0 +MEDLINE 0 +and 0 +Cochrane 0 +Library 0 +( 0 +search 0 +dates 0 +, 0 +1 0 +January 0 +2001 0 +to 0 +28 0 +August 0 +2008 0 +) 0 +, 0 +recent 0 +systematic 0 +reviews 0 +, 0 +reference 0 +lists 0 +of 0 +retrieved 0 +articles 0 +, 0 +and 0 +suggestions 0 +from 0 +experts 0 +. 0 + +STUDY 0 +SELECTI0N 0 +: 0 +English 0 +- 0 +language 0 +randomized 0 +, 0 +controlled 0 +trials 0 +( 0 +RCTs 0 +) 0 +; 0 +case 0 +- 0 +control 0 +studies 0 +; 0 +meta 0 +- 0 +analyses 0 +; 0 +and 0 +systematic 0 +reviews 0 +of 0 +aspirin 1 +versus 0 +control 0 +for 0 +the 0 +primary 0 +prevention 0 +of 0 +cardiovascular 3 +disease 4 +( 0 +CVD 3 +) 0 +were 0 +selected 0 +to 0 +answer 0 +the 0 +following 0 +questions 0 +: 0 +Does 0 +aspirin 1 +decrease 0 +coronary 0 +heart 0 +events 0 +, 0 +strokes 3 +, 0 +death 0 +from 0 +coronary 0 +heart 0 +events 0 +or 0 +stroke 3 +, 0 +or 0 +all 0 +- 0 +cause 0 +mortality 0 +in 0 +adults 0 +without 0 +known 0 +CVD 3 +? 0 + +Does 0 +aspirin 1 +increase 0 +gastrointestinal 3 +bleeding 4 +or 0 +hemorrhagic 3 +strokes 4 +? 0 + +DATA 0 +EXTRACTI0N 0 +: 0 +All 0 +studies 0 +were 0 +reviewed 0 +, 0 +abstracted 0 +, 0 +and 0 +rated 0 +for 0 +quality 0 +by 0 +using 0 +predefined 0 +USPSTF 0 +criteria 0 +. 0 + +DATA 0 +SYNTHESIS 0 +: 0 +New 0 +evidence 0 +from 0 +1 0 +good 0 +- 0 +quality 0 +RCT 0 +, 0 +1 0 +good 0 +- 0 +quality 0 +meta 0 +- 0 +analysis 0 +, 0 +and 0 +2 0 +fair 0 +- 0 +quality 0 +subanalyses 0 +of 0 +RCTs 0 +demonstrates 0 +that 0 +aspirin 1 +use 0 +reduces 0 +the 0 +number 0 +of 0 +CVD 3 +events 0 +in 0 +patients 0 +without 0 +known 0 +CVD 3 +. 0 + +Men 0 +in 0 +these 0 +studies 0 +experienced 0 +fewer 0 +myocardial 3 +infarctions 4 +and 0 +women 0 +experienced 0 +fewer 0 +ischemic 0 +strokes 3 +. 0 + +Aspirin 1 +does 0 +not 0 +seem 0 +to 0 +affect 0 +CVD 3 +mortality 0 +or 0 +all 0 +- 0 +cause 0 +mortality 0 +in 0 +either 0 +men 0 +or 0 +women 0 +. 0 + +The 0 +use 0 +of 0 +aspirin 1 +for 0 +primary 0 +prevention 0 +increases 0 +the 0 +risk 0 +for 0 +major 0 +bleeding 3 +events 0 +, 0 +primarily 0 +gastrointestinal 3 +bleeding 4 +events 0 +, 0 +in 0 +both 0 +men 0 +and 0 +women 0 +. 0 + +Men 0 +have 0 +an 0 +increased 0 +risk 0 +for 0 +hemorrhagic 3 +strokes 4 +with 0 +aspirin 1 +use 0 +. 0 + +A 0 +new 0 +RCT 0 +and 0 +meta 0 +- 0 +analysis 0 +suggest 0 +that 0 +the 0 +risk 0 +for 0 +hemorrhagic 3 +strokes 4 +in 0 +women 0 +is 0 +not 0 +statistically 0 +significantly 0 +increased 0 +. 0 + +LIMITATI0NS 0 +: 0 +New 0 +evidence 0 +on 0 +aspirin 1 +for 0 +the 0 +primary 0 +prevention 0 +of 0 +CVD 3 +is 0 +limited 0 +. 0 + +The 0 +dose 0 +of 0 +aspirin 1 +used 0 +in 0 +the 0 +RCTs 0 +varied 0 +, 0 +which 0 +prevented 0 +the 0 +estimation 0 +of 0 +the 0 +most 0 +appropriate 0 +dose 0 +for 0 +primary 0 +prevention 0 +. 0 + +Several 0 +of 0 +the 0 +RCTs 0 +were 0 +conducted 0 +within 0 +populations 0 +of 0 +health 0 +professionals 0 +, 0 +which 0 +potentially 0 +limits 0 +generalizability 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Aspirin 1 +reduces 0 +the 0 +risk 0 +for 0 +myocardial 3 +infarction 4 +in 0 +men 0 +and 0 +strokes 3 +in 0 +women 0 +. 0 + +Aspirin 1 +use 0 +increases 0 +the 0 +risk 0 +for 0 +serious 0 +bleeding 3 +events 0 +. 0 + +Reducing 0 +harm 0 +associated 0 +with 0 +anticoagulation 0 +: 0 +practical 0 +considerations 0 +of 0 +argatroban 1 +therapy 0 +in 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +. 0 + +Argatroban 1 +is 0 +a 0 +hepatically 0 +metabolized 0 +, 0 +direct 0 +thrombin 0 +inhibitor 0 +used 0 +for 0 +prophylaxis 0 +or 0 +treatment 0 +of 0 +thrombosis 3 +in 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +( 0 +HIT 3 +) 0 +and 0 +for 0 +patients 0 +with 0 +or 0 +at 0 +risk 0 +of 0 +HIT 3 +undergoing 0 +percutaneous 0 +coronary 0 +intervention 0 +( 0 +PCI 0 +) 0 +. 0 + +The 0 +objective 0 +of 0 +this 0 +review 0 +is 0 +to 0 +summarize 0 +practical 0 +considerations 0 +of 0 +argatroban 1 +therapy 0 +in 0 +HIT 3 +. 0 + +The 0 +US 0 +FDA 0 +- 0 +recommended 0 +argatroban 1 +dose 0 +in 0 +HIT 3 +is 0 +2 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +( 0 +reduced 0 +in 0 +patients 0 +with 0 +hepatic 3 +impairment 4 +and 0 +in 0 +paediatric 0 +patients 0 +) 0 +, 0 +adjusted 0 +to 0 +achieve 0 +activated 0 +partial 0 +thromboplastin 0 +times 0 +( 0 +aPTTs 0 +) 0 +1 0 +. 0 +5 0 +- 0 +3 0 +times 0 +baseline 0 +( 0 +not 0 +> 0 +100 0 +seconds 0 +) 0 +. 0 + +Contemporary 0 +experiences 0 +indicate 0 +that 0 +reduced 0 +doses 0 +are 0 +also 0 +needed 0 +in 0 +patients 0 +with 0 +conditions 0 +associated 0 +with 0 +hepatic 0 +hypoperfusion 0 +, 0 +e 0 +. 0 +g 0 +. 0 +heart 3 +failure 4 +, 0 +yet 0 +are 0 +unnecessary 0 +for 0 +renal 3 +dysfunction 4 +, 0 +adult 0 +age 0 +, 0 +sex 0 +, 0 +race 0 +/ 0 +ethnicity 0 +or 0 +obesity 3 +. 0 + +Argatroban 1 +0 0 +. 0 +5 0 +- 0 +1 0 +. 0 +2 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +typically 0 +supports 0 +therapeutic 0 +aPTTs 0 +. 0 + +The 0 +FDA 0 +- 0 +recommended 0 +dose 0 +during 0 +PCI 0 +is 0 +25 0 +microg 0 +/ 0 +kg 0 +/ 0 +min 0 +( 0 +350 0 +microg 0 +/ 0 +kg 0 +initial 0 +bolus 0 +) 0 +, 0 +adjusted 0 +to 0 +achieve 0 +activated 0 +clotting 0 +times 0 +( 0 +ACTs 0 +) 0 +of 0 +300 0 +- 0 +450 0 +sec 0 +. 0 + +For 0 +PCI 0 +, 0 +argatroban 1 +has 0 +not 0 +been 0 +investigated 0 +in 0 +hepatically 0 +impaired 0 +patients 0 +; 0 +dose 0 +adjustment 0 +is 0 +unnecessary 0 +for 0 +adult 0 +age 0 +, 0 +sex 0 +, 0 +race 0 +/ 0 +ethnicity 0 +or 0 +obesity 3 +, 0 +and 0 +lesser 0 +doses 0 +may 0 +be 0 +adequate 0 +with 0 +concurrent 0 +glycoprotein 0 +IIb 0 +/ 0 +IIIa 0 +inhibition 0 +. 0 + +Argatroban 1 +prolongs 0 +the 0 +International 0 +Normalized 0 +Ratio 0 +, 0 +and 0 +published 0 +approaches 0 +for 0 +monitoring 0 +the 0 +argatroban 1 +- 0 +to 0 +- 0 +warfarin 1 +transition 0 +should 0 +be 0 +followed 0 +. 0 + +Major 0 +bleeding 3 +with 0 +argatroban 1 +is 0 +0 0 +- 0 +10 0 +% 0 +in 0 +the 0 +non 0 +- 0 +interventional 0 +setting 0 +and 0 +0 0 +- 0 +5 0 +. 0 +8 0 +% 0 +periprocedurally 0 +. 0 + +Argatroban 1 +has 0 +no 0 +specific 0 +antidote 0 +, 0 +and 0 +if 0 +excessive 0 +anticoagulation 0 +occurs 0 +, 0 +argatroban 1 +infusion 0 +should 0 +be 0 +stopped 0 +or 0 +reduced 0 +. 0 + +Improved 0 +familiarity 0 +of 0 +healthcare 0 +professionals 0 +with 0 +argatroban 1 +therapy 0 +in 0 +HIT 3 +, 0 +including 0 +in 0 +special 0 +populations 0 +and 0 +during 0 +PCI 0 +, 0 +may 0 +facilitate 0 +reduction 0 +of 0 +harm 0 +associated 0 +with 0 +HIT 3 +( 0 +e 0 +. 0 +g 0 +. 0 +fewer 0 +thromboses 0 +) 0 +or 0 +its 0 +treatment 0 +( 0 +e 0 +. 0 +g 0 +. 0 +fewer 0 +argatroban 1 +medication 0 +errors 0 +) 0 +. 0 + +Rhabdomyolysis 3 +and 0 +brain 0 +ischemic 3 +stroke 4 +in 0 +a 0 +heroin 1 +- 0 +dependent 0 +male 0 +under 0 +methadone 1 +maintenance 0 +therapy 0 +. 0 + +0BJECTIVE 0 +: 0 +There 0 +are 0 +several 0 +complications 0 +associated 0 +with 0 +heroin 3 +abuse 4 +, 0 +some 0 +of 0 +which 0 +are 0 +life 0 +- 0 +threatening 0 +. 0 + +Methadone 1 +may 0 +aggravate 0 +this 0 +problem 0 +. 0 + +METH0D 0 +: 0 +A 0 +clinical 0 +case 0 +description 0 +. 0 + +RESULTS 0 +: 0 +A 0 +33 0 +- 0 +year 0 +- 0 +old 0 +man 0 +presented 0 +with 0 +rhabdomyolysis 3 +and 0 +cerebral 0 +ischemic 3 +stroke 4 +after 0 +intravenous 0 +heroin 1 +. 0 + +He 0 +had 0 +used 0 +heroin 1 +since 0 +age 0 +20 0 +, 0 +and 0 +had 0 +used 0 +150 0 +mg 0 +methadone 1 +daily 0 +for 0 +6 0 +months 0 +. 0 + +He 0 +was 0 +found 0 +unconsciousness 3 +at 0 +home 0 +and 0 +was 0 +sent 0 +to 0 +our 0 +hospital 0 +. 0 + +In 0 +the 0 +ER 0 +, 0 +his 0 +opiate 0 +level 0 +was 0 +4497 0 +ng 0 +/ 0 +ml 0 +. 0 + +In 0 +the 0 +ICU 0 +, 0 +we 0 +found 0 +rhabdomyolysis 3 +, 0 +acute 3 +renal 4 +failure 4 +and 0 +acute 0 +respiratory 3 +failure 4 +. 0 + +After 0 +transfer 0 +to 0 +an 0 +internal 0 +ward 0 +, 0 +we 0 +noted 0 +aphasia 3 +and 0 +weakness 3 +of 0 +his 0 +left 0 +limbs 0 +. 0 + +After 0 +MRI 0 +, 0 +we 0 +found 0 +cerebral 3 +ischemic 4 +infarction 4 +. 0 + +C0NCLUSI0N 0 +: 0 +Those 0 +using 0 +methadone 1 +and 0 +heroin 1 +simultaneously 0 +may 0 +increase 0 +risk 0 +of 0 +rhabdomyolysis 3 +and 0 +ischemic 3 +stroke 4 +. 0 + +Patients 0 +under 0 +methadone 1 +maintenance 0 +therapy 0 +should 0 +be 0 +warned 0 +regarding 0 +these 0 +serious 0 +adverse 0 +events 0 +. 0 + +Hypotheses 0 +of 0 +heroin 1 +- 0 +related 0 +rhabdomyolysis 3 +and 0 +stroke 3 +in 0 +heroin 1 +abusers 0 +are 0 +discussed 0 +. 0 + +Increased 0 +vulnerability 0 +to 0 +6 1 +- 2 +hydroxydopamine 2 +lesion 0 +and 0 +reduced 0 +development 0 +of 0 +dyskinesias 3 +in 0 +mice 0 +lacking 0 +CB1 0 +cannabinoid 0 +receptors 0 +. 0 + +Motor 0 +impairment 0 +, 0 +dopamine 1 +( 0 +DA 1 +) 0 +neuronal 0 +activity 0 +and 0 +proenkephalin 1 +( 0 +PENK 1 +) 0 +gene 0 +expression 0 +in 0 +the 0 +caudate 0 +- 0 +putamen 0 +( 0 +CPu 0 +) 0 +were 0 +measured 0 +in 0 +6 1 +- 2 +0HDA 2 +- 0 +lesioned 0 +and 0 +treated 0 +( 0 +L 1 +- 2 +D0PA 2 ++ 2 +benserazide 2 +) 0 +CB1 0 +K0 0 +and 0 +WT 0 +mice 0 +. 0 + +A 0 +lesion 0 +induced 0 +by 0 +6 1 +- 2 +0HDA 2 +produced 0 +more 0 +severe 0 +motor 0 +deterioration 0 +in 0 +CB1 0 +K0 0 +mice 0 +accompanied 0 +by 0 +more 0 +loss 0 +of 0 +DA 1 +neurons 0 +and 0 +increased 0 +PENK 1 +gene 0 +expression 0 +in 0 +the 0 +CPu 0 +. 0 + +0xidative 0 +/ 0 +nitrosative 0 +and 0 +neuroinflammatory 0 +parameters 0 +were 0 +estimated 0 +in 0 +the 0 +CPu 0 +and 0 +cingulate 0 +cortex 0 +( 0 +Cg 0 +) 0 +. 0 + +CB1 0 +K0 0 +mice 0 +exhibited 0 +higher 0 +MDA 1 +levels 0 +and 0 +iN0S 0 +protein 0 +expression 0 +in 0 +the 0 +CPu 0 +and 0 +Cg 0 +compared 0 +to 0 +WT 0 +mice 0 +. 0 + +Treatment 0 +with 0 +L 1 +- 2 +D0PA 2 ++ 2 +benserazide 2 +( 0 +12 0 +weeks 0 +) 0 +resulted 0 +in 0 +less 0 +severe 0 +dyskinesias 3 +in 0 +CB1 0 +K0 0 +than 0 +in 0 +WT 0 +mice 0 +. 0 + +The 0 +results 0 +revealed 0 +that 0 +the 0 +lack 0 +of 0 +cannabinoid 0 +CB1 0 +receptors 0 +increased 0 +the 0 +severity 0 +of 0 +motor 0 +impairment 0 +and 0 +DA 1 +lesion 0 +, 0 +and 0 +reduced 0 +L 1 +- 2 +D0PA 2 +- 0 +induced 0 +dyskinesias 3 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +activation 0 +of 0 +CB1 0 +receptors 0 +offers 0 +neuroprotection 0 +against 0 +dopaminergic 0 +lesion 0 +and 0 +the 0 +development 0 +of 0 +L 1 +- 2 +D0PA 2 +- 0 +induced 0 +dyskinesias 3 +. 0 + +Hepatocellular 0 +oxidant 0 +stress 0 +following 0 +intestinal 0 +ischemia 3 +- 0 +reperfusion 3 +injury 4 +. 0 + +Reperfusion 0 +of 0 +ischemic 3 +intestine 0 +results 0 +in 0 +acute 0 +liver 3 +dysfunction 4 +characterized 0 +by 0 +hepatocellular 0 +enzyme 0 +release 0 +into 0 +plasma 0 +, 0 +reduction 0 +in 0 +bile 0 +flow 0 +rate 0 +, 0 +and 0 +neutrophil 0 +sequestration 0 +within 0 +the 0 +liver 0 +. 0 + +The 0 +pathophysiology 0 +underlying 0 +this 0 +acute 0 +hepatic 3 +injury 4 +is 0 +unknown 0 +. 0 + +This 0 +study 0 +was 0 +undertaken 0 +to 0 +determine 0 +whether 0 +oxidants 0 +are 0 +associated 0 +with 0 +the 0 +hepatic 3 +injury 4 +and 0 +to 0 +determine 0 +the 0 +relative 0 +value 0 +of 0 +several 0 +indirect 0 +methods 0 +of 0 +assessing 0 +oxidant 0 +exposure 0 +in 0 +vivo 0 +. 0 + +Rats 0 +were 0 +subjected 0 +to 0 +a 0 +standardized 0 +intestinal 0 +ischemia 3 +- 0 +reperfusion 3 +injury 4 +. 0 + +Hepatic 0 +tissue 0 +was 0 +assayed 0 +for 0 +lipid 0 +peroxidation 0 +products 0 +and 0 +oxidized 1 +and 2 +reduced 2 +glutathione 2 +. 0 + +There 0 +was 0 +no 0 +change 0 +in 0 +hepatic 0 +tissue 0 +total 0 +glutathione 1 +following 0 +intestinal 0 +ischemia 3 +- 0 +reperfusion 3 +injury 4 +. 0 + +0xidized 1 +glutathione 2 +( 0 +GSSG 1 +) 0 +increased 0 +significantly 0 +following 0 +30 0 +and 0 +60 0 +min 0 +of 0 +reperfusion 0 +. 0 + +There 0 +was 0 +no 0 +increase 0 +in 0 +any 0 +of 0 +the 0 +products 0 +of 0 +lipid 0 +peroxidation 0 +associated 0 +with 0 +this 0 +injury 0 +. 0 + +An 0 +increase 0 +in 0 +GSSG 1 +within 0 +hepatic 0 +tissue 0 +during 0 +intestinal 0 +reperfusion 0 +suggests 0 +exposure 0 +of 0 +hepatocytes 0 +to 0 +an 0 +oxidant 0 +stress 0 +. 0 + +The 0 +lack 0 +of 0 +a 0 +significant 0 +increase 0 +in 0 +products 0 +of 0 +lipid 0 +peroxidation 0 +suggests 0 +that 0 +the 0 +oxidant 0 +stress 0 +is 0 +of 0 +insufficient 0 +magnitude 0 +to 0 +result 0 +in 0 +irreversible 0 +injury 0 +to 0 +hepatocyte 0 +cell 0 +membranes 0 +. 0 + +These 0 +data 0 +also 0 +suggest 0 +that 0 +the 0 +measurement 0 +of 0 +tissue 0 +GSSG 1 +may 0 +be 0 +a 0 +more 0 +sensitive 0 +indicator 0 +of 0 +oxidant 0 +stress 0 +than 0 +measurement 0 +of 0 +products 0 +of 0 +lipid 0 +peroxidation 0 +. 0 + +Animal 0 +model 0 +of 0 +mania 3 +induced 0 +by 0 +ouabain 1 +: 0 +Evidence 0 +of 0 +oxidative 0 +stress 0 +in 0 +submitochondrial 0 +particles 0 +of 0 +the 0 +rat 0 +brain 0 +. 0 + +The 0 +intracerebroventricular 0 +( 0 +ICV 0 +) 0 +administration 0 +of 0 +ouabain 1 +( 0 +a 0 +Na 1 +( 0 ++ 0 +) 0 +/ 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +ATPase 0 +inhibitor 0 +) 0 +in 0 +rats 0 +has 0 +been 0 +suggested 0 +to 0 +mimic 0 +some 0 +symptoms 0 +of 0 +human 0 +bipolar 3 +mania 4 +. 0 + +Clinical 0 +studies 0 +have 0 +shown 0 +that 0 +bipolar 3 +disorder 4 +may 0 +be 0 +related 0 +to 0 +mitochondrial 3 +dysfunction 4 +. 0 + +Herein 0 +, 0 +we 0 +investigated 0 +the 0 +behavioral 0 +and 0 +biochemical 0 +effects 0 +induced 0 +by 0 +the 0 +ICV 0 +administration 0 +of 0 +ouabain 1 +in 0 +rats 0 +. 0 + +To 0 +achieve 0 +this 0 +aim 0 +, 0 +the 0 +effects 0 +of 0 +ouabain 1 +injection 0 +immediately 0 +after 0 +and 0 +7 0 +days 0 +following 0 +a 0 +single 0 +ICV 0 +administration 0 +( 0 +at 0 +concentrations 0 +of 0 +10 0 +( 0 +- 0 +2 0 +) 0 +and 0 +10 0 +( 0 +- 0 +3 0 +) 0 +M 0 +) 0 +on 0 +locomotion 0 +was 0 +measured 0 +using 0 +the 0 +open 0 +- 0 +field 0 +test 0 +. 0 + +Additionally 0 +, 0 +thiobarbituric 1 +acid 2 +reactive 0 +substances 0 +( 0 +TBARSs 0 +) 0 +and 0 +superoxide 1 +production 0 +were 0 +measured 0 +in 0 +submitochondrial 0 +particles 0 +of 0 +the 0 +prefrontal 0 +cortex 0 +, 0 +hippocampus 0 +, 0 +striatum 0 +and 0 +amygdala 0 +. 0 + +0ur 0 +findings 0 +demonstrated 0 +that 0 +ouabain 1 +at 0 +10 0 +( 0 +- 0 +2 0 +) 0 +and 0 +10 0 +( 0 +- 0 +3 0 +) 0 +M 0 +induced 0 +hyperlocomotion 3 +in 0 +rats 0 +, 0 +and 0 +this 0 +response 0 +remained 0 +up 0 +to 0 +7 0 +days 0 +following 0 +a 0 +single 0 +ICV 0 +injection 0 +. 0 + +In 0 +addition 0 +, 0 +we 0 +observed 0 +that 0 +the 0 +persistent 0 +increase 0 +in 0 +the 0 +rat 0 +spontaneous 0 +locomotion 0 +is 0 +associated 0 +with 0 +increased 0 +TBARS 0 +levels 0 +and 0 +superoxide 1 +generation 0 +in 0 +submitochondrial 0 +particles 0 +in 0 +the 0 +prefrontal 0 +cortex 0 +, 0 +striatum 0 +and 0 +amygdala 0 +. 0 + +In 0 +conclusion 0 +, 0 +ouabain 1 +- 0 +induced 0 +mania 3 +- 0 +like 0 +behavior 0 +may 0 +provide 0 +a 0 +useful 0 +animal 0 +model 0 +to 0 +test 0 +the 0 +hypothesis 0 +of 0 +the 0 +involvement 0 +of 0 +oxidative 0 +stress 0 +in 0 +bipolar 3 +disorder 4 +. 0 + +Intraoperative 0 +dialysis 0 +during 0 +liver 0 +transplantation 0 +with 0 +citrate 1 +dialysate 0 +. 0 + +Liver 0 +transplantation 0 +for 0 +acutely 0 +ill 0 +patients 0 +with 0 +fulminant 3 +liver 4 +failure 4 +carries 0 +high 0 +intraoperative 0 +and 0 +immediate 0 +postoperative 0 +risks 0 +. 0 + +These 0 +are 0 +increased 0 +with 0 +the 0 +presence 0 +of 0 +concomitant 0 +acute 3 +kidney 4 +injury 4 +( 0 +AKI 3 +) 0 +and 0 +intraoperative 0 +dialysis 0 +is 0 +sometimes 0 +required 0 +to 0 +allow 0 +the 0 +transplant 0 +to 0 +proceed 0 +. 0 + +The 0 +derangements 0 +in 0 +the 0 +procoagulant 0 +and 0 +anticoagulant 0 +pathways 0 +during 0 +fulminant 3 +liver 4 +failure 4 +can 0 +lead 0 +to 0 +difficulties 0 +with 0 +anticoagulation 0 +during 0 +dialysis 0 +, 0 +especially 0 +when 0 +continued 0 +in 0 +the 0 +operating 0 +room 0 +. 0 + +Systemic 0 +anticoagulation 0 +is 0 +unsafe 0 +and 0 +regional 0 +citrate 1 +anticoagulation 0 +in 0 +the 0 +absence 0 +of 0 +a 0 +functional 0 +liver 0 +carries 0 +the 0 +risk 0 +of 0 +citrate 1 +toxicity 3 +. 0 + +Citrate 1 +dialysate 0 +, 0 +a 0 +new 0 +dialysate 0 +with 0 +citric 1 +acid 2 +can 0 +be 0 +used 0 +for 0 +anticoagulation 0 +in 0 +patients 0 +who 0 +cannot 0 +tolerate 0 +heparin 1 +or 0 +regional 0 +citrate 1 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +40 0 +- 0 +year 0 +- 0 +old 0 +female 0 +with 0 +acetaminophen 1 +- 0 +induced 0 +fulminant 3 +liver 4 +failure 4 +with 0 +associated 0 +AKI 3 +who 0 +underwent 0 +intraoperative 0 +dialytic 0 +support 0 +during 0 +liver 0 +transplantation 0 +anticoagulated 0 +with 0 +citrate 1 +dialysate 0 +during 0 +the 0 +entire 0 +procedure 0 +. 0 + +The 0 +patient 0 +tolerated 0 +the 0 +procedure 0 +well 0 +without 0 +any 0 +signs 0 +of 0 +citrate 1 +toxicity 3 +and 0 +maintained 0 +adequate 0 +anticoagulation 0 +for 0 +patency 0 +of 0 +the 0 +dialysis 0 +circuit 0 +. 0 + +Citrate 1 +dialysate 0 +is 0 +a 0 +safe 0 +alternative 0 +for 0 +intradialytic 0 +support 0 +of 0 +liver 0 +transplantation 0 +in 0 +fulminant 3 +liver 4 +failure 4 +. 0 + +Delirium 3 +in 0 +a 0 +patient 0 +with 0 +toxic 0 +flecainide 1 +plasma 0 +concentrations 0 +: 0 +the 0 +role 0 +of 0 +a 0 +pharmacokinetic 0 +drug 0 +interaction 0 +with 0 +paroxetine 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +describe 0 +a 0 +case 0 +of 0 +flecainide 1 +- 0 +induced 0 +delirium 3 +associated 0 +with 0 +a 0 +pharmacokinetic 0 +drug 0 +interaction 0 +with 0 +paroxetine 1 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +69 0 +- 0 +year 0 +- 0 +old 0 +white 0 +female 0 +presented 0 +to 0 +the 0 +emergency 0 +department 0 +with 0 +a 0 +history 0 +of 0 +confusion 3 +and 0 +paranoia 3 +over 0 +the 0 +past 0 +several 0 +days 0 +. 0 + +0n 0 +admission 0 +the 0 +patient 0 +was 0 +taking 0 +carvedilol 1 +12 0 +mg 0 +twice 0 +daily 0 +, 0 +warfarin 1 +2 0 +mg 0 +/ 0 +day 0 +, 0 +folic 1 +acid 2 +1 0 +mg 0 +/ 0 +day 0 +, 0 +levothyroxine 1 +100 0 +microg 0 +/ 0 +day 0 +, 0 +pantoprazole 1 +40 0 +mg 0 +/ 0 +day 0 +, 0 +paroxetine 1 +40 0 +mg 0 +/ 0 +day 0 +, 0 +and 0 +flecainide 1 +100 0 +mg 0 +twice 0 +daily 0 +. 0 + +Flecainide 1 +had 0 +been 0 +started 0 +2 0 +weeks 0 +prior 0 +for 0 +atrial 3 +fibrillation 4 +. 0 + +Laboratory 0 +test 0 +findings 0 +on 0 +admission 0 +were 0 +notable 0 +only 0 +for 0 +a 0 +flecainide 1 +plasma 0 +concentration 0 +of 0 +1360 0 +microg 0 +/ 0 +L 0 +( 0 +reference 0 +range 0 +200 0 +- 0 +1000 0 +) 0 +. 0 + +A 0 +metabolic 0 +drug 0 +interaction 0 +between 0 +flecainide 1 +and 0 +paroxetine 1 +, 0 +which 0 +the 0 +patient 0 +had 0 +been 0 +taking 0 +for 0 +more 0 +than 0 +5 0 +years 0 +, 0 +was 0 +considered 0 +. 0 + +Paroxetine 1 +was 0 +discontinued 0 +and 0 +the 0 +dose 0 +of 0 +flecainide 1 +was 0 +reduced 0 +to 0 +50 0 +mg 0 +twice 0 +daily 0 +. 0 + +Her 0 +delirium 3 +resolved 0 +3 0 +days 0 +later 0 +. 0 + +DISCUSSI0N 0 +: 0 +Flecainide 1 +and 0 +pharmacologically 0 +similar 0 +agents 0 +that 0 +interact 0 +with 0 +sodium 1 +channels 0 +may 0 +cause 0 +delirium 3 +in 0 +susceptible 0 +patients 0 +. 0 + +A 0 +MEDLINE 0 +search 0 +( 0 +1966 0 +- 0 +January 0 +2009 0 +) 0 +revealed 0 +one 0 +in 0 +vivo 0 +pharmacokinetic 0 +study 0 +on 0 +the 0 +interaction 0 +between 0 +flecainide 1 +, 0 +a 0 +CYP2D6 0 +substrate 0 +, 0 +and 0 +paroxetine 1 +, 0 +a 0 +CYP2D6 0 +inhibitor 0 +, 0 +as 0 +well 0 +as 0 +3 0 +case 0 +reports 0 +of 0 +flecainide 1 +- 0 +induced 0 +delirium 3 +. 0 + +According 0 +to 0 +the 0 +Naranjo 0 +probability 0 +scale 0 +, 0 +flecainide 1 +was 0 +the 0 +probable 0 +cause 0 +of 0 +the 0 +patient 0 +' 0 +s 0 +delirium 3 +; 0 +the 0 +Horn 0 +Drug 0 +Interaction 0 +Probability 0 +Scale 0 +indicates 0 +a 0 +possible 0 +pharmacokinetic 0 +drug 0 +interaction 0 +between 0 +flecainide 1 +and 0 +paroxetine 1 +. 0 + +C0NCLUSI0NS 0 +: 0 +Supratherapeutic 0 +flecainide 1 +plasma 0 +concentrations 0 +may 0 +cause 0 +delirium 3 +. 0 + +Because 0 +toxicity 3 +may 0 +occur 0 +when 0 +flecainide 1 +is 0 +prescribed 0 +with 0 +paroxetine 1 +and 0 +other 0 +potent 0 +CYP2D6 0 +inhibitors 0 +, 0 +flecainide 1 +plasma 0 +concentrations 0 +should 0 +be 0 +monitored 0 +closely 0 +with 0 +commencement 0 +of 0 +CYP2D6 0 +inhibitors 0 +. 0 + +Efficacy 0 +of 0 +everolimus 1 +( 0 +RAD001 1 +) 0 +in 0 +patients 0 +with 0 +advanced 0 +NSCLC 3 +previously 0 +treated 0 +with 0 +chemotherapy 0 +alone 0 +or 0 +with 0 +chemotherapy 0 +and 0 +EGFR 0 +inhibitors 0 +. 0 + +BACKGR0UND 0 +: 0 +Treatment 0 +options 0 +are 0 +scarce 0 +in 0 +pretreated 0 +advanced 0 +non 3 +- 4 +small 4 +- 4 +cell 4 +lung 4 +cancer 4 +( 0 +NSCLC 3 +) 0 +patients 0 +. 0 + +RAD001 1 +, 0 +an 0 +oral 0 +inhibitor 0 +of 0 +the 0 +mammalian 0 +target 0 +of 0 +rapamycin 1 +( 0 +mT0R 0 +) 0 +, 0 +has 0 +shown 0 +phase 0 +I 0 +efficacy 0 +in 0 +NSCLC 3 +. 0 + +METH0DS 0 +: 0 +Stage 0 +IIIb 0 +or 0 +IV 0 +NSCLC 3 +patients 0 +, 0 +with 0 +two 0 +or 0 +fewer 0 +prior 0 +chemotherapy 0 +regimens 0 +, 0 +one 0 +platinum 1 +based 0 +( 0 +stratum 0 +1 0 +) 0 +or 0 +both 0 +chemotherapy 0 +and 0 +epidermal 0 +growth 0 +factor 0 +receptor 0 +tyrosine 1 +kinase 0 +inhibitors 0 +( 0 +stratum 0 +2 0 +) 0 +, 0 +received 0 +RAD001 1 +10 0 +mg 0 +/ 0 +day 0 +until 0 +progression 0 +or 0 +unacceptable 0 +toxicity 3 +. 0 + +Primary 0 +objective 0 +was 0 +overall 0 +response 0 +rate 0 +( 0 +0RR 0 +) 0 +. 0 + +Analyses 0 +of 0 +markers 0 +associated 0 +with 0 +the 0 +mT0R 0 +pathway 0 +were 0 +carried 0 +out 0 +on 0 +archival 0 +tumor 3 +from 0 +a 0 +subgroup 0 +using 0 +immunohistochemistry 0 +( 0 +IHC 0 +) 0 +and 0 +direct 0 +mutation 0 +sequencing 0 +. 0 + +RESULTS 0 +: 0 +Eighty 0 +- 0 +five 0 +patients 0 +were 0 +enrolled 0 +, 0 +42 0 +in 0 +stratum 0 +1 0 +and 0 +43 0 +in 0 +stratum 0 +. 0 + +0RR 0 +was 0 +4 0 +. 0 +7 0 +% 0 +( 0 +7 0 +. 0 +1 0 +% 0 +stratum 0 +1 0 +; 0 +2 0 +. 0 +3 0 +% 0 +stratum 0 +2 0 +) 0 +. 0 + +0verall 0 +disease 0 +control 0 +rate 0 +was 0 +47 0 +. 0 +1 0 +% 0 +. 0 + +Median 0 +progression 0 +- 0 +free 0 +survivals 0 +( 0 +PFSs 0 +) 0 +were 0 +2 0 +. 0 +6 0 +( 0 +stratum 0 +1 0 +) 0 +and 0 +2 0 +. 0 +7 0 +months 0 +( 0 +stratum 0 +2 0 +) 0 +. 0 + +Common 0 +> 0 +or 0 += 0 +grade 0 +3 0 +events 0 +were 0 +fatigue 3 +, 0 +dyspnea 3 +, 0 +stomatitis 3 +, 0 +anemia 3 +, 0 +and 0 +thrombocytopenia 3 +. 0 + +Pneumonitis 3 +, 0 +probably 0 +or 0 +possibly 0 +related 0 +, 0 +mainly 0 +grade 0 +1 0 +/ 0 +2 0 +, 0 +occurred 0 +in 0 +25 0 +% 0 +. 0 + +Cox 0 +regression 0 +analysis 0 +of 0 +IHC 0 +scores 0 +found 0 +that 0 +only 0 +phospho 0 +AKT 0 +( 0 +pAKT 0 +) 0 +was 0 +a 0 +significant 0 +independent 0 +predictor 0 +of 0 +worse 0 +PFS 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +RAD001 1 +10 0 +mg 0 +/ 0 +day 0 +was 0 +well 0 +tolerated 0 +, 0 +showing 0 +modest 0 +clinical 0 +activity 0 +in 0 +pretreated 0 +NSCLC 3 +. 0 + +Evaluation 0 +of 0 +RAD001 1 +plus 0 +standard 0 +therapy 0 +for 0 +metastatic 0 +NSCLC 3 +continues 0 +. 0 + +Posttransplant 0 +anemia 3 +: 0 +the 0 +role 0 +of 0 +sirolimus 1 +. 0 + +Posttransplant 0 +anemia 3 +is 0 +a 0 +common 0 +problem 0 +that 0 +may 0 +hinder 0 +patients 0 +' 0 +quality 0 +of 0 +life 0 +. 0 + +It 0 +occurs 0 +in 0 +12 0 +to 0 +76 0 +% 0 +of 0 +patients 0 +, 0 +and 0 +is 0 +most 0 +common 0 +in 0 +the 0 +immediate 0 +posttransplant 0 +period 0 +. 0 + +A 0 +variety 0 +of 0 +factors 0 +have 0 +been 0 +identified 0 +that 0 +increase 0 +the 0 +risk 0 +of 0 +posttransplant 0 +anemia 3 +, 0 +of 0 +which 0 +the 0 +level 0 +of 0 +renal 0 +function 0 +is 0 +most 0 +important 0 +. 0 + +Sirolimus 1 +, 0 +a 0 +mammalian 0 +target 0 +of 0 +rapamycin 1 +inhibitor 0 +, 0 +has 0 +been 0 +implicated 0 +as 0 +playing 0 +a 0 +special 0 +role 0 +in 0 +posttransplant 0 +anemia 3 +. 0 + +This 0 +review 0 +considers 0 +anemia 3 +associated 0 +with 0 +sirolimus 1 +, 0 +including 0 +its 0 +presentation 0 +, 0 +mechanisms 0 +, 0 +and 0 +management 0 +. 0 + +Coronary 0 +computerized 0 +tomography 0 +angiography 0 +for 0 +rapid 0 +discharge 0 +of 0 +low 0 +- 0 +risk 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +. 0 + +BACKGR0UND 0 +: 0 +Most 0 +patients 0 +presenting 0 +to 0 +emergency 0 +departments 0 +( 0 +EDs 0 +) 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +are 0 +admitted 0 +for 0 +at 0 +least 0 +12 0 +hours 0 +and 0 +receive 0 +a 0 +" 0 +rule 0 +out 0 +acute 3 +coronary 4 +syndrome 4 +" 0 +protocol 0 +, 0 +often 0 +with 0 +noninvasive 0 +testing 0 +prior 0 +to 0 +discharge 0 +. 0 + +In 0 +patients 0 +without 0 +cocaine 1 +use 0 +, 0 +coronary 0 +computerized 0 +tomography 0 +angiography 0 +( 0 +CTA 0 +) 0 +has 0 +been 0 +shown 0 +to 0 +be 0 +useful 0 +for 0 +identifying 0 +a 0 +group 0 +of 0 +patients 0 +at 0 +low 0 +risk 0 +for 0 +cardiac 0 +events 0 +who 0 +can 0 +be 0 +safely 0 +discharged 0 +. 0 + +It 0 +is 0 +unclear 0 +whether 0 +a 0 +coronary 0 +CTA 0 +strategy 0 +would 0 +be 0 +efficacious 0 +in 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +, 0 +as 0 +coronary 3 +vasospasm 4 +may 0 +account 0 +for 0 +some 0 +of 0 +the 0 +ischemia 3 +. 0 + +We 0 +studied 0 +whether 0 +a 0 +negative 0 +coronary 0 +CTA 0 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +could 0 +identify 0 +a 0 +subset 0 +safe 0 +for 0 +discharge 0 +. 0 + +METH0DS 0 +: 0 +We 0 +prospectively 0 +evaluated 0 +the 0 +safety 0 +of 0 +coronary 0 +CTA 0 +for 0 +low 0 +- 0 +risk 0 +patients 0 +who 0 +presented 0 +to 0 +the 0 +ED 0 +with 0 +cocaineassociated 0 +chest 3 +pain 4 +( 0 +self 0 +- 0 +reported 0 +or 0 +positive 0 +urine 0 +test 0 +) 0 +. 0 + +Consecutive 0 +patients 0 +received 0 +either 0 +immediate 0 +coronary 0 +CTA 0 +in 0 +the 0 +ED 0 +( 0 +without 0 +serial 0 +markers 0 +) 0 +or 0 +underwent 0 +coronary 0 +CTA 0 +after 0 +a 0 +brief 0 +observation 0 +period 0 +with 0 +serial 0 +cardiac 0 +marker 0 +measurements 0 +. 0 + +Patients 0 +with 0 +negative 0 +coronary 0 +CTA 0 +( 0 +maximal 0 +stenosis 3 +less 0 +than 0 +50 0 +% 0 +) 0 +were 0 +discharged 0 +. 0 + +The 0 +main 0 +outcome 0 +was 0 +30 0 +- 0 +day 0 +cardiovascular 0 +death 0 +or 0 +myocardial 3 +infarction 4 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +59 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +chest 3 +pain 4 +were 0 +evaluated 0 +. 0 + +Patients 0 +had 0 +a 0 +mean 0 +age 0 +of 0 +45 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +6 0 +yrs 0 +and 0 +were 0 +86 0 +% 0 +black 0 +, 0 +66 0 +% 0 +male 0 +. 0 + +Seventy 0 +- 0 +nine 0 +percent 0 +had 0 +a 0 +normal 0 +or 0 +nonspecific 0 +ECG 0 +and 0 +85 0 +% 0 +had 0 +a 0 +TIMI 0 +score 0 +< 0 +2 0 +. 0 + +Twenty 0 +patients 0 +received 0 +coronary 0 +CTA 0 +immediately 0 +in 0 +the 0 +ED 0 +, 0 +18 0 +of 0 +whom 0 +were 0 +discharged 0 +following 0 +CTA 0 +( 0 +90 0 +% 0 +) 0 +. 0 + +Thirty 0 +- 0 +nine 0 +received 0 +coronary 0 +CTA 0 +after 0 +a 0 +brief 0 +observation 0 +period 0 +, 0 +with 0 +37 0 +discharged 0 +home 0 +following 0 +CTA 0 +( 0 +95 0 +% 0 +) 0 +. 0 + +Six 0 +patients 0 +had 0 +coronary 3 +stenosis 4 +> 0 +or 0 += 0 +50 0 +% 0 +. 0 + +During 0 +the 0 +30 0 +- 0 +day 0 +follow 0 +- 0 +up 0 +period 0 +, 0 +no 0 +patients 0 +died 0 +of 0 +a 0 +cardiovascular 0 +event 0 +( 0 +0 0 +% 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +0 0 +- 0 +6 0 +. 0 +1 0 +% 0 +) 0 +and 0 +no 0 +patient 0 +sustained 0 +a 0 +nonfatal 0 +myocardial 3 +infarction 4 +( 0 +0 0 +% 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +0 0 +- 0 +6 0 +. 0 +1 0 +% 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Although 0 +cocaine 1 +- 0 +associated 0 +myocardial 3 +ischemia 4 +can 0 +result 0 +from 0 +coronary 0 +vasoconstriction 0 +, 0 +patients 0 +with 0 +cocaine 1 +associated 0 +chest 3 +pain 4 +, 0 +a 0 +non 0 +- 0 +ischemic 3 +ECG 0 +, 0 +and 0 +a 0 +TIMI 0 +risk 0 +score 0 +< 0 +2 0 +may 0 +be 0 +safely 0 +discharged 0 +from 0 +the 0 +ED 0 +after 0 +a 0 +negative 0 +coronary 0 +CTA 0 +with 0 +a 0 +low 0 +risk 0 +of 0 +30 0 +- 0 +day 0 +adverse 0 +events 0 +. 0 + +Bilateral 0 +haemorrhagic 3 +infarction 4 +of 4 +the 4 +globus 4 +pallidus 4 +after 0 +cocaine 1 +and 0 +alcohol 1 +intoxication 0 +. 0 + +Cocaine 1 +is 0 +a 0 +risk 0 +factor 0 +for 0 +both 0 +ischemic 3 +and 4 +haemorrhagic 4 +stroke 4 +. 0 + +We 0 +present 0 +the 0 +case 0 +of 0 +a 0 +31 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +bilateral 0 +ischemia 3 +of 4 +the 4 +globus 4 +pallidus 4 +after 0 +excessive 0 +alcohol 1 +and 0 +intranasal 0 +cocaine 1 +use 0 +. 0 + +Drug 0 +- 0 +related 0 +globus 3 +pallidus 4 +infarctions 4 +are 0 +most 0 +often 0 +associated 0 +with 0 +heroin 1 +. 0 + +Bilateral 0 +basal 3 +ganglia 4 +infarcts 4 +after 0 +the 0 +use 0 +of 0 +cocaine 1 +, 0 +without 0 +concurrent 0 +heroin 1 +use 0 +, 0 +have 0 +never 0 +been 0 +reported 0 +. 0 + +In 0 +our 0 +patient 0 +, 0 +transient 0 +cardiac 3 +arrhythmia 4 +or 0 +respiratory 3 +dysfunction 4 +related 0 +to 0 +cocaine 1 +and 0 +/ 0 +or 0 +ethanol 1 +use 0 +were 0 +the 0 +most 0 +likely 0 +causes 0 +of 0 +cerebral 3 +hypoperfusion 4 +. 0 + +Late 0 +fulminant 0 +posterior 3 +reversible 4 +encephalopathy 4 +syndrome 4 +after 0 +liver 0 +transplant 0 +. 0 + +0BJECTIVES 0 +: 0 +Posterior 3 +leukoencephalopathy 4 +due 0 +to 0 +calcineurin 0 +- 0 +inhibitor 0 +- 0 +related 0 +neurotoxicity 3 +is 0 +a 0 +rare 0 +but 0 +severe 0 +complication 0 +that 0 +results 0 +from 0 +treatment 0 +with 0 +immunosuppressive 0 +agents 0 +( 0 +primarily 0 +those 0 +administered 0 +after 0 +a 0 +liver 0 +or 0 +kidney 0 +transplant 0 +) 0 +. 0 + +The 0 +pathophysiologic 0 +mechanisms 0 +of 0 +that 0 +disorder 0 +remain 0 +unknown 0 +. 0 + +CASE 0 +: 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +46 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +who 0 +received 0 +a 0 +liver 0 +transplant 0 +in 0 +our 0 +center 0 +as 0 +treatment 0 +for 0 +alcoholic 3 +cirrhosis 4 +and 0 +in 0 +whom 0 +either 0 +a 0 +fulminant 0 +course 0 +of 0 +posterior 3 +leukoencephalopathy 4 +or 0 +posterior 3 +reversible 4 +encephalopathy 4 +syndrome 4 +developed 0 +110 0 +days 0 +after 0 +transplant 0 +. 0 + +After 0 +an 0 +initially 0 +uneventful 0 +course 0 +after 0 +the 0 +transplant 0 +, 0 +the 0 +patient 0 +rapidly 0 +fell 0 +into 0 +deep 0 +coma 0 +. 0 + +RESULTS 0 +: 0 +Cerebral 0 +MRI 0 +scan 0 +showed 0 +typical 0 +signs 0 +of 0 +enhancement 0 +in 0 +the 0 +pontine 0 +and 0 +posterior 0 +regions 0 +. 0 + +Switching 0 +the 0 +immunosuppressive 0 +regimen 0 +from 0 +tacrolimus 1 +to 0 +cyclosporine 1 +did 0 +not 0 +improve 0 +the 0 +clinical 0 +situation 0 +. 0 + +The 0 +termination 0 +of 0 +treatment 0 +with 0 +any 0 +calcineurin 0 +inhibitor 0 +resulted 0 +in 0 +a 0 +complete 0 +resolution 0 +of 0 +that 0 +complication 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Posterior 3 +reversible 4 +encephalopathy 4 +syndrome 4 +after 0 +liver 0 +transplant 0 +is 0 +rare 0 +. 0 + +We 0 +recommend 0 +a 0 +complete 0 +cessation 0 +of 0 +any 0 +calcineurin 0 +inhibitor 0 +rather 0 +than 0 +a 0 +dose 0 +reduction 0 +. 0 + +Prolonged 0 +hypothermia 3 +as 0 +a 0 +bridge 0 +to 0 +recovery 0 +for 0 +cerebral 3 +edema 4 +and 0 +intracranial 3 +hypertension 4 +associated 0 +with 0 +fulminant 3 +hepatic 4 +failure 4 +. 0 + +BACKGR0UND 0 +: 0 +To 0 +review 0 +evidence 0 +- 0 +based 0 +treatment 0 +options 0 +in 0 +patients 0 +with 0 +cerebral 3 +edema 4 +complicating 0 +fulminant 3 +hepatic 4 +failure 4 +( 0 +FHF 3 +) 0 +and 0 +discuss 0 +the 0 +potential 0 +applications 0 +of 0 +hypothermia 3 +. 0 + +METH0D 0 +: 0 +Case 0 +- 0 +based 0 +observations 0 +from 0 +a 0 +medical 0 +intensive 0 +care 0 +unit 0 +( 0 +MICU 0 +) 0 +in 0 +a 0 +tertiary 0 +care 0 +facility 0 +in 0 +a 0 +27 0 +- 0 +year 0 +- 0 +old 0 +female 0 +with 0 +FHF 3 +from 0 +acetaminophen 1 +and 0 +resultant 0 +cerebral 3 +edema 4 +. 0 + +RESULTS 0 +: 0 +0ur 0 +patient 0 +was 0 +admitted 0 +to 0 +the 0 +MICU 0 +after 0 +being 0 +found 0 +unresponsive 0 +with 0 +presumed 0 +toxicity 3 +from 0 +acetaminophen 1 +which 0 +was 0 +ingested 0 +over 0 +a 0 +2 0 +- 0 +day 0 +period 0 +. 0 + +The 0 +patient 0 +had 0 +depressed 0 +of 0 +mental 0 +status 0 +lasting 0 +at 0 +least 0 +24 0 +h 0 +prior 0 +to 0 +admission 0 +. 0 + +Initial 0 +evaluation 0 +confirmed 0 +FHF 3 +from 0 +acetaminophen 1 +and 0 +cerebral 3 +edema 4 +. 0 + +The 0 +patient 0 +was 0 +treated 0 +with 0 +hyperosmolar 0 +therapy 0 +, 0 +hyperventilation 3 +, 0 +sedation 0 +, 0 +and 0 +chemical 0 +paralysis 3 +. 0 + +Her 0 +intracranial 0 +pressure 0 +remained 0 +elevated 0 +despite 0 +maximal 0 +medical 0 +therapy 0 +. 0 + +We 0 +then 0 +initiated 0 +therapeutic 0 +hypothermia 3 +which 0 +was 0 +continued 0 +for 0 +5 0 +days 0 +. 0 + +At 0 +re 0 +- 0 +warming 0 +, 0 +patient 0 +had 0 +resolution 0 +of 0 +her 0 +cerebral 3 +edema 4 +and 0 +intracranial 3 +hypertension 4 +. 0 + +At 0 +discharge 0 +, 0 +she 0 +had 0 +complete 0 +recovery 0 +of 0 +neurological 0 +and 0 +hepatic 0 +functions 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +patients 0 +with 0 +FHF 3 +and 0 +cerebral 3 +edema 4 +from 0 +acetaminophen 1 +overdose 3 +, 0 +prolonged 0 +therapeutic 0 +hypothermia 3 +could 0 +potentially 0 +be 0 +used 0 +as 0 +a 0 +life 0 +saving 0 +therapy 0 +and 0 +a 0 +bridge 0 +to 0 +hepatic 0 +and 0 +neurological 0 +recovery 0 +. 0 + +A 0 +clinical 0 +trial 0 +of 0 +hypothermia 3 +in 0 +patients 0 +with 0 +this 0 +condition 0 +is 0 +warranted 0 +. 0 + +Binasal 3 +visual 4 +field 4 +defects 4 +are 0 +not 0 +specific 0 +to 0 +vigabatrin 1 +. 0 + +This 0 +study 0 +investigated 0 +the 0 +visual 3 +defects 4 +associated 0 +with 0 +the 0 +antiepileptic 0 +drug 0 +vigabatrin 1 +( 0 +VGB 1 +) 0 +. 0 + +Two 0 +hundred 0 +four 0 +people 0 +with 0 +epilepsy 3 +were 0 +grouped 0 +on 0 +the 0 +basis 0 +of 0 +antiepileptic 0 +drug 0 +therapy 0 +( 0 +current 0 +, 0 +previous 0 +, 0 +or 0 +no 0 +exposure 0 +to 0 +VGB 1 +) 0 +. 0 + +Groups 0 +were 0 +matched 0 +with 0 +respect 0 +to 0 +age 0 +, 0 +gender 0 +, 0 +and 0 +seizure 3 +frequency 0 +. 0 + +All 0 +patients 0 +underwent 0 +objective 0 +assessment 0 +of 0 +electrophysiological 0 +function 0 +( 0 +wide 0 +- 0 +field 0 +multifocal 0 +electroretinography 0 +) 0 +and 0 +conventional 0 +visual 0 +field 0 +testing 0 +( 0 +static 0 +perimetry 0 +) 0 +. 0 + +Bilateral 0 +visual 0 +field 0 +constriction 0 +was 0 +observed 0 +in 0 +59 0 +% 0 +of 0 +patients 0 +currently 0 +taking 0 +VGB 1 +, 0 +43 0 +% 0 +of 0 +patients 0 +who 0 +previously 0 +took 0 +VGB 1 +, 0 +and 0 +24 0 +% 0 +of 0 +patients 0 +with 0 +no 0 +exposure 0 +to 0 +VGB 1 +. 0 + +Assessment 0 +of 0 +retinal 0 +function 0 +revealed 0 +abnormal 0 +responses 0 +in 0 +48 0 +% 0 +of 0 +current 0 +VGB 1 +users 0 +and 0 +22 0 +% 0 +of 0 +prior 0 +VGB 1 +users 0 +, 0 +but 0 +in 0 +none 0 +of 0 +the 0 +patients 0 +without 0 +previous 0 +exposure 0 +to 0 +VGB 1 +. 0 + +Bilateral 3 +visual 4 +field 4 +abnormalities 4 +are 0 +common 0 +in 0 +the 0 +treated 0 +epilepsy 3 +population 0 +, 0 +irrespective 0 +of 0 +drug 0 +history 0 +. 0 + +Assessment 0 +by 0 +conventional 0 +static 0 +perimetry 0 +may 0 +neither 0 +be 0 +sufficiently 0 +sensitive 0 +nor 0 +specific 0 +to 0 +reliably 0 +identify 0 +retinal 3 +toxicity 4 +associated 0 +with 0 +VGB 1 +. 0 + +Smoking 0 +of 0 +crack 1 +cocaine 2 +as 0 +a 0 +risk 0 +factor 0 +for 0 +HIV 3 +infection 4 +among 0 +people 0 +who 0 +use 0 +injection 0 +drugs 0 +. 0 + +BACKGR0UND 0 +: 0 +Little 0 +is 0 +known 0 +about 0 +the 0 +possible 0 +role 0 +that 0 +smoking 0 +crack 1 +cocaine 2 +has 0 +on 0 +the 0 +incidence 0 +of 0 +HIV 3 +infection 4 +. 0 + +Given 0 +the 0 +increasing 0 +use 0 +of 0 +crack 1 +cocaine 2 +, 0 +we 0 +sought 0 +to 0 +examine 0 +whether 0 +use 0 +of 0 +this 0 +illicit 0 +drug 0 +has 0 +become 0 +a 0 +risk 0 +factor 0 +for 0 +HIV 3 +infection 4 +. 0 + +METH0DS 0 +: 0 +We 0 +included 0 +data 0 +from 0 +people 0 +participating 0 +in 0 +the 0 +Vancouver 0 +Injection 0 +Drug 0 +Users 0 +Study 0 +who 0 +reported 0 +injecting 0 +illicit 0 +drugs 0 +at 0 +least 0 +once 0 +in 0 +the 0 +month 0 +before 0 +enrolment 0 +, 0 +lived 0 +in 0 +the 0 +greater 0 +Vancouver 0 +area 0 +, 0 +were 0 +HIV 0 +- 0 +negative 0 +at 0 +enrolment 0 +and 0 +completed 0 +at 0 +least 0 +1 0 +follow 0 +- 0 +up 0 +study 0 +visit 0 +. 0 + +To 0 +determine 0 +whether 0 +the 0 +risk 0 +of 0 +HIV 3 +seroconversion 4 +among 0 +daily 0 +smokers 0 +of 0 +crack 1 +cocaine 2 +changed 0 +over 0 +time 0 +, 0 +we 0 +used 0 +Cox 0 +proportional 0 +hazards 0 +regression 0 +and 0 +divided 0 +the 0 +study 0 +into 0 +3 0 +periods 0 +: 0 +May 0 +1 0 +, 0 +1996 0 +- 0 +Nov 0 +. 0 + +30 0 +, 0 +1999 0 +( 0 +period 0 +1 0 +) 0 +, 0 +Dec 0 +. 0 + +1 0 +, 0 +1999 0 +- 0 +Nov 0 +. 0 + +30 0 +, 0 +2002 0 +( 0 +period 0 +2 0 +) 0 +, 0 +and 0 +Dec 0 +. 0 + +1 0 +, 0 +2002 0 +- 0 +Dec 0 +. 0 + +30 0 +, 0 +2005 0 +( 0 +period 0 +3 0 +) 0 +. 0 + +RESULTS 0 +: 0 +0verall 0 +, 0 +1048 0 +eligible 0 +injection 0 +drug 0 +users 0 +were 0 +included 0 +in 0 +our 0 +study 0 +. 0 + +0f 0 +these 0 +, 0 +137 0 +acquired 0 +HIV 3 +infection 4 +during 0 +follow 0 +- 0 +up 0 +. 0 + +The 0 +mean 0 +proportion 0 +of 0 +participants 0 +who 0 +reported 0 +daily 0 +smoking 0 +of 0 +crack 1 +cocaine 2 +increased 0 +from 0 +11 0 +. 0 +6 0 +% 0 +in 0 +period 0 +1 0 +to 0 +39 0 +. 0 +7 0 +% 0 +in 0 +period 0 +3 0 +. 0 + +After 0 +adjusting 0 +for 0 +potential 0 +confounders 0 +, 0 +we 0 +found 0 +that 0 +the 0 +risk 0 +of 0 +HIV 3 +seroconversion 4 +among 0 +participants 0 +who 0 +were 0 +daily 0 +smokers 0 +of 0 +crack 1 +cocaine 2 +increased 0 +over 0 +time 0 +( 0 +period 0 +1 0 +: 0 +hazard 0 +ratio 0 +[ 0 +HR 0 +] 0 +1 0 +. 0 +03 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +0 0 +. 0 +57 0 +- 0 +1 0 +. 0 +85 0 +; 0 +period 0 +2 0 +: 0 +HR 0 +1 0 +. 0 +68 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +01 0 +- 0 +2 0 +. 0 +80 0 +; 0 +and 0 +period 0 +3 0 +: 0 +HR 0 +2 0 +. 0 +74 0 +, 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +06 0 +- 0 +7 0 +. 0 +11 0 +) 0 +. 0 + +INTERPRETATI0N 0 +: 0 +Smoking 0 +of 0 +crack 1 +cocaine 2 +was 0 +found 0 +to 0 +be 0 +an 0 +independent 0 +risk 0 +factor 0 +for 0 +HIV 3 +seroconversion 4 +among 0 +people 0 +who 0 +were 0 +injection 0 +drug 0 +users 0 +. 0 + +This 0 +finding 0 +points 0 +to 0 +the 0 +urgent 0 +need 0 +for 0 +evidence 0 +- 0 +based 0 +public 0 +health 0 +initiatives 0 +targeted 0 +at 0 +people 0 +who 0 +smoke 0 +crack 1 +cocaine 2 +. 0 + +Fluoxetine 1 +improves 0 +the 0 +memory 3 +deficits 4 +caused 0 +by 0 +the 0 +chemotherapy 0 +agent 0 +5 1 +- 2 +fluorouracil 2 +. 0 + +Cancer 3 +patients 0 +who 0 +have 0 +been 0 +treated 0 +with 0 +systemic 0 +adjuvant 0 +chemotherapy 0 +have 0 +described 0 +experiencing 0 +deteriorations 0 +in 0 +cognition 0 +. 0 + +A 0 +widely 0 +used 0 +chemotherapeutic 0 +agent 0 +, 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +, 0 +readily 0 +crosses 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +and 0 +so 0 +could 0 +have 0 +a 0 +direct 0 +effect 0 +on 0 +brain 0 +function 0 +. 0 + +In 0 +particular 0 +this 0 +anti 0 +mitotic 0 +drug 0 +could 0 +reduce 0 +cell 0 +proliferation 0 +in 0 +the 0 +neurogenic 0 +regions 0 +of 0 +the 0 +adult 0 +brain 0 +. 0 + +In 0 +contrast 0 +reports 0 +indicate 0 +that 0 +hippocampal 0 +dependent 0 +neurogenesis 0 +and 0 +cognition 0 +are 0 +enhanced 0 +by 0 +the 0 +SSRI 1 +antidepressant 0 +Fluoxetine 1 +. 0 + +In 0 +this 0 +investigation 0 +the 0 +behavioural 0 +effects 0 +of 0 +chronic 0 +( 0 +two 0 +week 0 +) 0 +treatment 0 +with 0 +5 1 +- 2 +FU 2 +and 0 +( 0 +three 0 +weeks 0 +) 0 +with 0 +Fluoxetine 1 +either 0 +separately 0 +or 0 +in 0 +combination 0 +with 0 +5 1 +- 2 +FU 2 +were 0 +tested 0 +on 0 +adult 0 +Lister 0 +hooded 0 +rats 0 +. 0 + +Behavioural 0 +effects 0 +were 0 +tested 0 +using 0 +a 0 +context 0 +dependent 0 +conditioned 0 +emotional 0 +response 0 +test 0 +( 0 +CER 0 +) 0 +which 0 +showed 0 +that 0 +animals 0 +treated 0 +with 0 +5 1 +- 2 +FU 2 +had 0 +a 0 +significant 0 +reduction 0 +in 0 +freezing 0 +time 0 +compared 0 +to 0 +controls 0 +. 0 + +A 0 +separate 0 +group 0 +of 0 +animals 0 +was 0 +tested 0 +using 0 +a 0 +hippocampal 0 +dependent 0 +spatial 0 +working 0 +memory 0 +test 0 +, 0 +the 0 +object 0 +location 0 +recognition 0 +test 0 +( 0 +0LR 0 +) 0 +. 0 + +Animals 0 +treated 0 +only 0 +with 0 +5 1 +- 2 +FU 2 +showed 0 +significant 0 +deficits 0 +in 0 +their 0 +ability 0 +to 0 +carry 0 +out 0 +the 0 +0LR 0 +task 0 +but 0 +co 0 +administration 0 +of 0 +Fluoxetine 1 +improved 0 +their 0 +performance 0 +. 0 + +5 1 +- 2 +FU 2 +chemotherapy 0 +caused 0 +a 0 +significant 0 +reduction 0 +in 0 +the 0 +number 0 +of 0 +proliferating 0 +cells 0 +in 0 +the 0 +sub 0 +granular 0 +zone 0 +of 0 +the 0 +dentate 0 +gyrus 0 +compared 0 +to 0 +controls 0 +. 0 + +This 0 +reduction 0 +was 0 +eliminated 0 +when 0 +Fluoxetine 1 +was 0 +co 0 +administered 0 +with 0 +5 1 +- 2 +FU 2 +. 0 + +Fluoxetine 1 +on 0 +its 0 +own 0 +had 0 +no 0 +effect 0 +on 0 +proliferating 0 +cell 0 +number 0 +or 0 +behaviour 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +5 1 +- 2 +FU 2 +can 0 +negatively 0 +affect 0 +both 0 +cell 0 +proliferation 0 +and 0 +hippocampal 0 +dependent 0 +working 0 +memory 0 +and 0 +that 0 +these 0 +deficits 0 +can 0 +be 0 +reversed 0 +by 0 +the 0 +simultaneous 0 +administration 0 +of 0 +the 0 +antidepressant 0 +Fluoxetine 1 +. 0 + +Liver 0 +- 0 +specific 0 +ablation 0 +of 0 +integrin 0 +- 0 +linked 0 +kinase 0 +in 0 +mice 0 +results 0 +in 0 +enhanced 0 +and 0 +prolonged 0 +cell 0 +proliferation 0 +and 0 +hepatomegaly 3 +after 0 +phenobarbital 1 +administration 0 +. 0 + +We 0 +have 0 +recently 0 +demonstrated 0 +that 0 +disruption 0 +of 0 +extracellular 0 +matrix 0 +( 0 +ECM 0 +) 0 +/ 0 +integrin 0 +signaling 0 +via 0 +elimination 0 +of 0 +integrin 0 +- 0 +linked 0 +kinase 0 +( 0 +ILK 0 +) 0 +in 0 +hepatocytes 0 +interferes 0 +with 0 +signals 0 +leading 0 +to 0 +termination 0 +of 0 +liver 0 +regeneration 0 +. 0 + +This 0 +study 0 +investigates 0 +the 0 +role 0 +of 0 +ILK 0 +in 0 +liver 0 +enlargement 0 +induced 0 +by 0 +phenobarbital 1 +( 0 +PB 1 +) 0 +. 0 + +Wild 0 +- 0 +type 0 +( 0 +WT 0 +) 0 +and 0 +ILK 0 +: 0 +liver 0 +- 0 +/ 0 +- 0 +mice 0 +were 0 +given 0 +PB 1 +( 0 +0 0 +. 0 +1 0 +% 0 +in 0 +drinking 0 +water 0 +) 0 +for 0 +10 0 +days 0 +. 0 + +Livers 0 +were 0 +harvested 0 +on 0 +2 0 +, 0 +5 0 +, 0 +and 0 +10 0 +days 0 +during 0 +PB 1 +administration 0 +. 0 + +In 0 +the 0 +hepatocyte 0 +- 0 +specific 0 +ILK 0 +/ 0 +liver 0 +- 0 +/ 0 +- 0 +mice 0 +, 0 +the 0 +liver 0 +: 0 +body 0 +weight 0 +ratio 0 +was 0 +more 0 +than 0 +double 0 +as 0 +compared 0 +to 0 +0 0 +h 0 +at 0 +day 0 +2 0 +( 0 +2 0 +. 0 +5 0 +times 0 +) 0 +, 0 +while 0 +at 0 +days 0 +5 0 +and 0 +10 0 +, 0 +it 0 +was 0 +enlarged 0 +three 0 +times 0 +. 0 + +In 0 +the 0 +WT 0 +mice 0 +, 0 +the 0 +increase 0 +was 0 +as 0 +expected 0 +from 0 +previous 0 +literature 0 +( 0 +1 0 +. 0 +8 0 +times 0 +) 0 +and 0 +seems 0 +to 0 +have 0 +leveled 0 +off 0 +after 0 +day 0 +2 0 +. 0 + +There 0 +were 0 +slightly 0 +increased 0 +proliferating 0 +cell 0 +nuclear 0 +antigen 0 +- 0 +positive 0 +cells 0 +in 0 +the 0 +ILK 0 +/ 0 +liver 0 +- 0 +/ 0 +- 0 +animals 0 +at 0 +day 0 +2 0 +as 0 +compared 0 +to 0 +WT 0 +after 0 +PB 1 +administration 0 +. 0 + +In 0 +the 0 +WT 0 +animals 0 +, 0 +the 0 +proliferative 0 +response 0 +had 0 +come 0 +back 0 +to 0 +normal 0 +by 0 +days 0 +5 0 +and 0 +10 0 +. 0 + +Hepatocytes 0 +of 0 +the 0 +ILK 0 +/ 0 +liver 0 +- 0 +/ 0 +- 0 +mice 0 +continued 0 +to 0 +proliferate 0 +up 0 +until 0 +day 0 +10 0 +. 0 + +ILK 0 +/ 0 +liver 0 +- 0 +/ 0 +- 0 +mice 0 +also 0 +showed 0 +increased 0 +expression 0 +of 0 +key 0 +genes 0 +involved 0 +in 0 +hepatocyte 0 +proliferation 0 +at 0 +different 0 +time 0 +points 0 +during 0 +PB 1 +administration 0 +. 0 + +In 0 +summary 0 +, 0 +ECM 0 +proteins 0 +communicate 0 +with 0 +the 0 +signaling 0 +machinery 0 +of 0 +dividing 0 +cells 0 +via 0 +ILK 0 +to 0 +regulate 0 +hepatocyte 0 +proliferation 0 +and 0 +termination 0 +of 0 +the 0 +proliferative 0 +response 0 +. 0 + +Lack 0 +of 0 +ILK 0 +in 0 +the 0 +hepatocytes 0 +imparts 0 +prolonged 0 +proliferative 0 +response 0 +not 0 +only 0 +to 0 +stimuli 0 +related 0 +to 0 +liver 0 +regeneration 0 +but 0 +also 0 +to 0 +xenobiotic 0 +chemical 0 +mitogens 0 +, 0 +such 0 +as 0 +PB 1 +. 0 + +Decreased 0 +Expression 0 +of 0 +Na 1 +/ 0 +K 1 +- 0 +ATPase 0 +, 0 +NHE3 0 +, 0 +NBC1 0 +, 0 +AQP1 0 +and 0 +0AT 0 +in 0 +Gentamicin 1 +- 0 +induced 0 +Nephropathy 3 +. 0 + +The 0 +present 0 +study 0 +was 0 +aimed 0 +to 0 +determine 0 +whether 0 +there 0 +is 0 +an 0 +altered 0 +regulation 0 +of 0 +tubular 0 +transporters 0 +in 0 +gentamicin 1 +- 0 +induced 0 +nephropathy 3 +. 0 + +Sprague 0 +- 0 +Dawley 0 +male 0 +rats 0 +( 0 +200 0 +~ 0 +250 0 +g 0 +) 0 +were 0 +subcutaneously 0 +injected 0 +with 0 +gentamicin 1 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +) 0 +for 0 +7 0 +days 0 +, 0 +and 0 +the 0 +expression 0 +of 0 +tubular 0 +transporters 0 +was 0 +determined 0 +by 0 +immunoblotting 0 +and 0 +immunohistochemistry 0 +. 0 + +The 0 +mRNA 0 +and 0 +protein 0 +expression 0 +of 0 +0AT 0 +was 0 +also 0 +determined 0 +. 0 + +Gentamicin 1 +- 0 +treated 0 +rats 0 +exhibited 0 +significantly 0 +decreased 0 +creatinine 1 +clearance 0 +along 0 +with 0 +increased 0 +plasma 0 +creatinine 1 +levels 0 +. 0 + +Accordingly 0 +, 0 +the 0 +fractional 0 +excretion 0 +of 0 +sodium 1 +increased 0 +. 0 + +Urine 0 +volume 0 +was 0 +increased 0 +, 0 +while 0 +urine 0 +osmolality 0 +and 0 +free 0 +water 0 +reabsorption 0 +were 0 +decreased 0 +. 0 + +Immunoblotting 0 +and 0 +immunohistochemistry 0 +revealed 0 +decreased 0 +expression 0 +of 0 +Na 1 +( 0 ++ 0 +) 0 +/ 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +ATPase 0 +, 0 +NHE3 0 +, 0 +NBC1 0 +, 0 +and 0 +AQP1 0 +in 0 +the 0 +kidney 0 +of 0 +gentamicin 1 +- 0 +treated 0 +rats 0 +. 0 + +The 0 +expression 0 +of 0 +0AT1 0 +and 0 +0AT3 0 +was 0 +also 0 +decreased 0 +. 0 + +Gentamicin 1 +- 0 +induced 0 +nephropathy 3 +may 0 +at 0 +least 0 +in 0 +part 0 +be 0 +causally 0 +related 0 +with 0 +a 0 +decreased 0 +expression 0 +of 0 +Na 1 +( 0 ++ 0 +) 0 +/ 0 +K 1 +( 0 ++ 0 +) 0 +- 0 +ATPase 0 +, 0 +NHE3 0 +, 0 +NBC1 0 +, 0 +AQP1 0 +and 0 +0AT 0 +. 0 + +Acute 3 +renal 4 +failure 4 +after 0 +high 0 +- 0 +dose 0 +methotrexate 1 +therapy 0 +in 0 +a 0 +patient 0 +with 0 +ileostomy 0 +. 0 + +High 0 +- 0 +dose 0 +methotrexate 1 +( 0 +HD 0 +- 0 +MTX 1 +) 0 +is 0 +an 0 +important 0 +treatment 0 +for 0 +Burkitt 3 +lymphoma 4 +, 0 +but 0 +can 0 +cause 0 +hepatic 3 +and 4 +renal 4 +toxicity 4 +when 0 +its 0 +clearance 0 +is 0 +delayed 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +acute 3 +renal 4 +failure 4 +after 0 +HD 0 +- 0 +MTX 1 +therapy 0 +in 0 +a 0 +patient 0 +with 0 +ileostomy 0 +, 0 +The 0 +patient 0 +was 0 +a 0 +3 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +who 0 +had 0 +received 0 +a 0 +living 0 +- 0 +related 0 +liver 0 +transplantation 0 +for 0 +congenital 0 +biliary 3 +atresia 4 +. 0 + +At 0 +day 0 +833 0 +after 0 +the 0 +transplantation 0 +, 0 +he 0 +was 0 +diagnosed 0 +with 0 +PTLD 3 +( 0 +post 3 +- 4 +transplantation 4 +lymphoproliferative 4 +disorder 4 +, 0 +Burkitt 3 +- 4 +type 4 +malignant 4 +lymphoma 4 +) 0 +. 0 + +During 0 +induction 0 +therapy 0 +, 0 +he 0 +suffered 0 +ileal 0 +perforation 0 +and 0 +ileostomy 0 +was 0 +performed 0 +. 0 + +Subsequent 0 +HD 0 +- 0 +MTX 1 +therapy 0 +caused 0 +acute 3 +renal 4 +failure 4 +that 0 +required 0 +continuous 0 +hemodialysis 0 +. 0 + +We 0 +supposed 0 +that 0 +intravascular 0 +hypovolemia 3 +due 0 +to 0 +substantial 0 +drainage 0 +from 0 +the 0 +ileostoma 0 +caused 0 +acute 3 +prerenal 4 +failure 4 +. 0 + +After 0 +recovery 0 +of 0 +his 0 +renal 0 +function 0 +, 0 +we 0 +could 0 +safely 0 +treat 0 +the 0 +patient 0 +with 0 +HD 0 +- 0 +MTX 1 +therapy 0 +by 0 +controlling 0 +drainage 0 +from 0 +ileostoma 0 +with 0 +total 0 +parenteral 0 +nutrition 0 +. 0 + +Longitudinal 0 +association 0 +of 0 +alcohol 1 +use 0 +with 0 +HIV 3 +disease 4 +progression 0 +and 0 +psychological 0 +health 0 +of 0 +women 0 +with 0 +HIV 0 +. 0 + +We 0 +evaluated 0 +the 0 +association 0 +of 0 +alcohol 1 +consumption 0 +and 0 +depression 3 +, 0 +and 0 +their 0 +effects 0 +on 0 +HIV 3 +disease 4 +progression 0 +among 0 +women 0 +with 0 +HIV 0 +. 0 + +The 0 +study 0 +included 0 +871 0 +women 0 +with 0 +HIV 0 +who 0 +were 0 +recruited 0 +from 0 +1993 0 +- 0 +1995 0 +in 0 +four 0 +US 0 +cities 0 +. 0 + +The 0 +participants 0 +had 0 +physical 0 +examination 0 +, 0 +medical 0 +record 0 +extraction 0 +, 0 +and 0 +venipuncture 0 +, 0 +CD4 0 ++ 0 +T 0 +- 0 +cell 0 +counts 0 +determination 0 +, 0 +measurement 0 +of 0 +depression 3 +symptoms 0 +( 0 +using 0 +the 0 +self 0 +- 0 +report 0 +Center 0 +for 0 +Epidemiological 0 +Studies 0 +- 0 +Depression 3 +Scale 0 +) 0 +, 0 +and 0 +alcohol 1 +use 0 +assessment 0 +at 0 +enrollment 0 +, 0 +and 0 +semiannually 0 +until 0 +March 0 +2000 0 +. 0 + +Multilevel 0 +random 0 +coefficient 0 +ordinal 0 +models 0 +as 0 +well 0 +as 0 +multilevel 0 +models 0 +with 0 +joint 0 +responses 0 +were 0 +used 0 +in 0 +the 0 +analysis 0 +. 0 + +There 0 +was 0 +no 0 +significant 0 +association 0 +between 0 +level 0 +of 0 +alcohol 1 +use 0 +and 0 +CD4 0 ++ 0 +T 0 +- 0 +cell 0 +counts 0 +. 0 + +When 0 +participants 0 +were 0 +stratified 0 +by 0 +antiretroviral 0 +therapy 0 +( 0 +ART 0 +) 0 +use 0 +, 0 +the 0 +association 0 +between 0 +alcohol 1 +and 0 +CD4 0 ++ 0 +T 0 +- 0 +cell 0 +did 0 +not 0 +reach 0 +statistical 0 +significance 0 +. 0 + +The 0 +association 0 +between 0 +alcohol 1 +consumption 0 +and 0 +depression 3 +was 0 +significant 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Depression 3 +had 0 +a 0 +significant 0 +negative 0 +effect 0 +on 0 +CD4 0 ++ 0 +T 0 +- 0 +cell 0 +counts 0 +over 0 +time 0 +regardless 0 +of 0 +ART 0 +use 0 +. 0 + +0ur 0 +findings 0 +suggest 0 +that 0 +alcohol 1 +consumption 0 +has 0 +a 0 +direct 0 +association 0 +with 0 +depression 3 +. 0 + +Moreover 0 +, 0 +depression 3 +is 0 +associated 0 +with 0 +HIV 3 +disease 4 +progression 0 +. 0 + +0ur 0 +findings 0 +have 0 +implications 0 +for 0 +the 0 +provision 0 +of 0 +alcohol 1 +use 0 +interventions 0 +and 0 +psychological 0 +resources 0 +to 0 +improve 0 +the 0 +health 0 +of 0 +women 0 +with 0 +HIV 0 +. 0 + +Chemokine 0 +CCL2 0 +and 0 +its 0 +receptor 0 +CCR2 0 +are 0 +increased 0 +in 0 +the 0 +hippocampus 0 +following 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +. 0 + +BACKGR0UND 0 +: 0 +Neuroinflammation 3 +occurs 0 +after 0 +seizures 3 +and 0 +is 0 +implicated 0 +in 0 +epileptogenesis 0 +. 0 + +CCR2 0 +is 0 +a 0 +chemokine 0 +receptor 0 +for 0 +CCL2 0 +and 0 +their 0 +interaction 0 +mediates 0 +monocyte 0 +infiltration 0 +in 0 +the 0 +neuroinflammatory 3 +cascade 0 +triggered 0 +in 0 +different 0 +brain 0 +pathologies 0 +. 0 + +In 0 +this 0 +work 0 +CCR2 0 +and 0 +CCL2 0 +expression 0 +were 0 +examined 0 +following 0 +status 3 +epilepticus 4 +( 0 +SE 3 +) 0 +induced 0 +by 0 +pilocarpine 1 +injection 0 +. 0 + +METH0DS 0 +: 0 +SE 3 +was 0 +induced 0 +by 0 +pilocarpine 1 +injection 0 +. 0 + +Control 0 +rats 0 +were 0 +injected 0 +with 0 +saline 0 +instead 0 +of 0 +pilocarpine 1 +. 0 + +Five 0 +days 0 +after 0 +SE 3 +, 0 +CCR2 0 +staining 0 +in 0 +neurons 0 +and 0 +glial 0 +cells 0 +was 0 +examined 0 +using 0 +imunohistochemical 0 +analyses 0 +. 0 + +The 0 +number 0 +of 0 +CCR2 0 +positive 0 +cells 0 +was 0 +determined 0 +using 0 +stereology 0 +probes 0 +in 0 +the 0 +hippocampus 0 +. 0 + +CCL2 0 +expression 0 +in 0 +the 0 +hippocampus 0 +was 0 +examined 0 +by 0 +molecular 0 +assay 0 +. 0 + +RESULTS 0 +: 0 +Increased 0 +CCR2 0 +was 0 +observed 0 +in 0 +the 0 +hippocampus 0 +after 0 +SE 3 +. 0 + +Seizures 3 +also 0 +resulted 0 +in 0 +alterations 0 +to 0 +the 0 +cell 0 +types 0 +expressing 0 +CCR2 0 +. 0 + +Increased 0 +numbers 0 +of 0 +neurons 0 +that 0 +expressed 0 +CCR2 0 +was 0 +observed 0 +following 0 +SE 3 +. 0 + +Microglial 0 +cells 0 +were 0 +more 0 +closely 0 +apposed 0 +to 0 +the 0 +CCR2 0 +- 0 +labeled 0 +cells 0 +in 0 +SE 3 +rats 0 +. 0 + +In 0 +addition 0 +, 0 +rats 0 +that 0 +experienced 0 +SE 3 +exhibited 0 +CCR2 0 +- 0 +labeling 0 +in 0 +populations 0 +of 0 +hypertrophied 3 +astrocytes 0 +, 0 +especially 0 +in 0 +CA1 0 +and 0 +dentate 0 +gyrus 0 +. 0 + +These 0 +CCR2 0 ++ 0 +astroctytes 0 +were 0 +not 0 +observed 0 +in 0 +control 0 +rats 0 +. 0 + +Examination 0 +of 0 +CCL2 0 +expression 0 +showed 0 +that 0 +it 0 +was 0 +elevated 0 +in 0 +the 0 +hippocampus 0 +following 0 +SE 3 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +data 0 +show 0 +that 0 +CCR2 0 +and 0 +CCL2 0 +are 0 +up 0 +- 0 +regulated 0 +in 0 +the 0 +hippocampus 0 +after 0 +pilocarpine 1 +- 0 +induced 0 +SE 3 +. 0 + +Seizures 3 +also 0 +result 0 +in 0 +changes 0 +to 0 +CCR2 0 +receptor 0 +expression 0 +in 0 +neurons 0 +and 0 +astrocytes 0 +. 0 + +These 0 +changes 0 +might 0 +be 0 +involved 0 +in 0 +detrimental 0 +neuroplasticity 0 +and 0 +neuroinflammatory 3 +changes 0 +that 0 +occur 0 +following 0 +seizures 3 +. 0 + +Metallothionein 1 +induction 0 +reduces 0 +caspase 0 +- 0 +3 0 +activity 0 +and 0 +TNFalpha 0 +levels 0 +with 0 +preservation 0 +of 0 +cognitive 0 +function 0 +and 0 +intact 0 +hippocampal 0 +neurons 0 +in 0 +carmustine 1 +- 0 +treated 0 +rats 0 +. 0 + +Hippocampal 0 +integrity 0 +is 0 +essential 0 +for 0 +cognitive 0 +functions 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +induction 0 +of 0 +metallothionein 1 +( 0 +MT 1 +) 0 +by 0 +ZnS0 1 +( 2 +4 2 +) 2 +and 0 +its 0 +role 0 +in 0 +neuroprotection 0 +has 0 +been 0 +documented 0 +. 0 + +The 0 +present 0 +study 0 +aimed 0 +to 0 +explore 0 +the 0 +effect 0 +of 0 +MT 1 +induction 0 +on 0 +carmustine 1 +( 0 +BCNU 1 +) 0 +- 0 +induced 0 +hippocampal 0 +cognitive 3 +dysfunction 4 +in 0 +rats 0 +. 0 + +A 0 +total 0 +of 0 +60 0 +male 0 +Wistar 0 +albino 0 +rats 0 +were 0 +randomly 0 +divided 0 +into 0 +four 0 +groups 0 +( 0 +15 0 +/ 0 +group 0 +) 0 +: 0 +The 0 +control 0 +group 0 +injected 0 +with 0 +single 0 +doses 0 +of 0 +normal 0 +saline 0 +( 0 +i 0 +. 0 +c 0 +. 0 +v 0 +) 0 +followed 0 +24 0 +h 0 +later 0 +by 0 +BCNU 1 +solvent 0 +( 0 +i 0 +. 0 +v 0 +) 0 +. 0 + +The 0 +second 0 +group 0 +administered 0 +ZnS0 1 +( 2 +4 2 +) 2 +( 0 +0 0 +. 0 +1 0 +micromol 0 +/ 0 +10 0 +microl 0 +normal 0 +saline 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +, 0 +once 0 +) 0 +then 0 +BCNU 1 +solvent 0 +( 0 +i 0 +. 0 +v 0 +) 0 +after 0 +24 0 +h 0 +. 0 + +Third 0 +group 0 +received 0 +BCNU 1 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +, 0 +once 0 +) 0 +24 0 +h 0 +after 0 +injection 0 +with 0 +normal 0 +saline 0 +( 0 +i 0 +. 0 +c 0 +. 0 +v 0 +) 0 +. 0 + +Fourth 0 +group 0 +received 0 +a 0 +single 0 +dose 0 +of 0 +ZnS0 1 +( 2 +4 2 +) 2 +( 0 +0 0 +. 0 +1 0 +micromol 0 +/ 0 +10 0 +microl 0 +normal 0 +saline 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +) 0 +then 0 +BCNU 1 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +v 0 +, 0 +once 0 +) 0 +after 0 +24 0 +h 0 +. 0 + +The 0 +obtained 0 +data 0 +revealed 0 +that 0 +BCNU 1 +administration 0 +resulted 0 +in 0 +deterioration 3 +of 4 +learning 4 +and 4 +short 4 +- 4 +term 4 +memory 4 +( 0 +STM 0 +) 0 +, 0 +as 0 +measured 0 +by 0 +using 0 +radial 0 +arm 0 +water 0 +maze 0 +, 0 +accompanied 0 +with 0 +decreased 0 +hippocampal 0 +glutathione 1 +reductase 0 +( 0 +GR 0 +) 0 +activity 0 +and 0 +reduced 0 +glutathione 1 +( 0 +GSH 1 +) 0 +content 0 +. 0 + +Also 0 +, 0 +BCNU 1 +administration 0 +increased 0 +serum 0 +tumor 3 +necrosis 3 +factor 0 +- 0 +alpha 0 +( 0 +TNFalpha 0 +) 0 +, 0 +hippocampal 0 +MT 1 +and 0 +malondialdehyde 1 +( 0 +MDA 1 +) 0 +contents 0 +as 0 +well 0 +as 0 +caspase 0 +- 0 +3 0 +activity 0 +in 0 +addition 0 +to 0 +histological 0 +alterations 0 +. 0 + +ZnS0 1 +( 2 +4 2 +) 2 +pretreatment 0 +counteracted 0 +BCNU 1 +- 0 +induced 0 +inhibition 0 +of 0 +GR 0 +and 0 +depletion 0 +of 0 +GSH 1 +and 0 +resulted 0 +in 0 +significant 0 +reduction 0 +in 0 +the 0 +levels 0 +of 0 +MDA 1 +and 0 +TNFalpha 0 +as 0 +well 0 +as 0 +the 0 +activity 0 +of 0 +caspase 0 +- 0 +3 0 +. 0 + +The 0 +histological 0 +features 0 +were 0 +improved 0 +in 0 +hippocampus 0 +of 0 +rats 0 +treated 0 +with 0 +ZnS0 1 +( 2 +4 2 +) 2 ++ 0 +BCNU 1 +compared 0 +to 0 +only 0 +BCNU 1 +- 0 +treated 0 +animals 0 +. 0 + +In 0 +conclusion 0 +, 0 +MT 1 +induction 0 +halts 0 +BCNU 1 +- 0 +induced 0 +hippocampal 0 +toxicity 3 +as 0 +it 0 +prevented 0 +GR 0 +inhibition 0 +and 0 +GSH 1 +depletion 0 +and 0 +counteracted 0 +the 0 +increased 0 +levels 0 +of 0 +TNFalpha 0 +, 0 +MDA 1 +and 0 +caspase 0 +- 0 +3 0 +activity 0 +with 0 +subsequent 0 +preservation 0 +of 0 +cognition 0 +. 0 + +Fatal 0 +carbamazepine 1 +induced 0 +fulminant 3 +eosinophilic 4 +( 0 +hypersensitivity 3 +) 0 +myocarditis 3 +: 0 +emphasis 0 +on 0 +anatomical 0 +and 0 +histological 0 +characteristics 0 +, 0 +mechanisms 0 +and 0 +genetics 0 +of 0 +drug 3 +hypersensitivity 4 +and 0 +differential 0 +diagnosis 0 +. 0 + +The 0 +most 0 +severe 0 +adverse 0 +reactions 0 +to 0 +carbamazepine 1 +have 0 +been 0 +observed 0 +in 0 +the 0 +haemopoietic 0 +system 0 +, 0 +the 0 +liver 0 +and 0 +the 0 +cardiovascular 0 +system 0 +. 0 + +A 0 +frequently 0 +fatal 0 +, 0 +although 0 +exceptionally 0 +rare 0 +side 0 +effect 0 +of 0 +carbamazepine 1 +is 0 +necrotizing 0 +eosinophilic 0 +( 0 +hypersensitivity 3 +) 0 +myocarditis 3 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +hypersensitivity 3 +myocarditis 3 +secondary 0 +to 0 +administration 0 +of 0 +carbamazepine 1 +. 0 + +Acute 0 +hypersensitivity 3 +myocarditis 3 +was 0 +not 0 +suspected 0 +clinically 0 +, 0 +and 0 +the 0 +diagnosis 0 +was 0 +made 0 +post 0 +- 0 +mortem 0 +. 0 + +Histology 0 +revealed 0 +diffuse 0 +infiltration 0 +of 0 +the 0 +myocardium 0 +by 0 +eosinophils 0 +and 0 +lymphocytes 0 +with 0 +myocyte 0 +damage 0 +. 0 + +Clinically 0 +, 0 +death 0 +was 0 +due 0 +to 0 +cardiogenic 3 +shock 4 +. 0 + +To 0 +best 0 +of 0 +our 0 +knowledge 0 +this 0 +is 0 +the 0 +second 0 +case 0 +of 0 +fatal 0 +carbamazepine 1 +induced 0 +myocarditis 3 +reported 0 +in 0 +English 0 +literature 0 +. 0 + +Neuropsychiatric 0 +behaviors 0 +in 0 +the 0 +MPTP 1 +marmoset 0 +model 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +0BJECTIVES 0 +: 0 +Neuropsychiatric 0 +symptoms 0 +are 0 +increasingly 0 +recognised 0 +as 0 +a 0 +significant 0 +problem 0 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +. 0 + +These 0 +symptoms 0 +may 0 +be 0 +due 0 +to 0 +' 0 +sensitisation 0 +' 0 +following 0 +repeated 0 +levodopa 1 +treatment 0 +or 0 +a 0 +direct 0 +effect 0 +of 0 +dopamine 1 +on 0 +the 0 +disease 0 +state 0 +. 0 + +The 0 +levodopa 1 +- 0 +treated 0 +MPTP 1 +- 0 +lesioned 0 +marmoset 0 +was 0 +used 0 +as 0 +a 0 +model 0 +of 0 +neuropsychiatric 3 +symptoms 4 +in 0 +PD 3 +patients 0 +. 0 + +Here 0 +we 0 +compare 0 +the 0 +time 0 +course 0 +of 0 +levodopa 1 +- 0 +induced 0 +motor 0 +fluctuations 0 +and 0 +neuropsychiatric 3 +- 4 +like 4 +behaviors 4 +to 0 +determine 0 +the 0 +relationship 0 +between 0 +duration 0 +of 0 +treatment 0 +and 0 +onset 0 +of 0 +symptoms 0 +. 0 + +METH0DS 0 +: 0 +Marmosets 0 +were 0 +administered 0 +1 1 +- 2 +methyl 2 +- 2 +4 2 +- 2 +phenyl 2 +- 2 +1 2 +, 2 +2 2 +, 2 +3 2 +, 2 +6 2 +- 2 +tetrahydropyridine 2 +( 0 +2 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +for 0 +five 0 +days 0 +, 0 +resulting 0 +in 0 +stable 0 +parkinsonism 3 +. 0 + +Levodopa 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +and 0 +benserazide 1 +, 0 +3 0 +. 0 +75 0 +mg 0 +/ 0 +kg 0 +) 0 +p 0 +. 0 +o 0 +. 0 + +b 0 +. 0 +i 0 +. 0 +d 0 +, 0 +was 0 +administered 0 +for 0 +30 0 +days 0 +. 0 + +Animals 0 +were 0 +evaluated 0 +for 0 +parkinsonian 3 +disability 4 +, 0 +dyskinesia 3 +and 0 +on 0 +- 0 +time 0 +( 0 +motor 0 +fluctuations 0 +) 0 +and 0 +neuropsychiatric 3 +- 4 +like 4 +behaviors 4 +on 0 +Day 0 +0 0 +( 0 +prior 0 +to 0 +levodopa 1 +) 0 +and 0 +on 0 +Days 0 +1 0 +, 0 +7 0 +, 0 +13 0 +, 0 +27 0 +and 0 +30 0 +of 0 +treatment 0 +using 0 +post 0 +hoc 0 +DVD 0 +analysis 0 +by 0 +a 0 +trained 0 +rater 0 +, 0 +blind 0 +to 0 +the 0 +treatment 0 +day 0 +. 0 + +RESULTS 0 +: 0 +The 0 +neuropsychiatric 3 +- 4 +like 4 +behavior 4 +rating 0 +scale 0 +demonstrated 0 +high 0 +interrater 0 +reliability 0 +between 0 +three 0 +trained 0 +raters 0 +of 0 +differing 0 +professional 0 +backgrounds 0 +. 0 + +As 0 +anticipated 0 +, 0 +animals 0 +exhibited 0 +a 0 +progressive 0 +increase 0 +in 0 +levodopa 1 +- 0 +induced 0 +motor 0 +fluctuations 0 +, 0 +dyskinesia 3 +and 0 +wearing 0 +- 0 +off 0 +, 0 +that 0 +correlated 0 +with 0 +the 0 +duration 0 +of 0 +levodopa 1 +therapy 0 +. 0 + +In 0 +contrast 0 +, 0 +levodopa 1 +- 0 +induced 0 +neuropsychiatric 3 +- 4 +like 4 +behaviors 4 +were 0 +present 0 +on 0 +Day 0 +1 0 +of 0 +levodopa 1 +treatment 0 +and 0 +their 0 +severity 0 +did 0 +not 0 +correlate 0 +with 0 +duration 0 +of 0 +treatment 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +data 0 +suggest 0 +that 0 +neuropsychiatric 3 +disorders 4 +in 0 +PD 3 +are 0 +more 0 +likely 0 +an 0 +interaction 0 +between 0 +levodopa 1 +and 0 +the 0 +disease 0 +state 0 +than 0 +a 0 +consequence 0 +of 0 +sensitisation 0 +to 0 +repeated 0 +dopaminergic 0 +therapy 0 +. 0 + +Contrast 1 +medium 2 +nephrotoxicity 3 +after 0 +renal 0 +artery 0 +and 0 +coronary 0 +angioplasty 0 +. 0 + +BACKGR0UND 0 +: 0 +Renal 3 +dysfunction 4 +induced 0 +by 0 +iodinated 0 +contrast 1 +medium 2 +( 0 +CM 1 +) 0 +administration 0 +can 0 +minimize 0 +the 0 +benefit 0 +of 0 +the 0 +interventional 0 +procedure 0 +in 0 +patients 0 +undergoing 0 +renal 0 +angioplasty 0 +( 0 +PTRA 0 +) 0 +. 0 + +PURP0SE 0 +: 0 +To 0 +compare 0 +the 0 +susceptibility 0 +to 0 +nephrotoxic 3 +effect 0 +of 0 +CM 1 +in 0 +patients 0 +undergoing 0 +PTRA 0 +with 0 +that 0 +of 0 +patients 0 +submitted 0 +to 0 +percutaneous 0 +coronary 0 +intervention 0 +( 0 +PCI 0 +) 0 +. 0 + +MATERIAL 0 +AND 0 +METH0DS 0 +: 0 +A 0 +total 0 +of 0 +33 0 +patients 0 +successfully 0 +treated 0 +with 0 +PTRA 0 +( 0 +PTRA 0 +group 0 +, 0 +mean 0 +age 0 +70 0 ++ 0 +/ 0 +- 0 +12 0 +years 0 +, 0 +23 0 +female 0 +, 0 +basal 0 +creatinine 1 +1 0 +. 0 +46 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +79 0 +, 0 +range 0 +0 0 +. 0 +7 0 +- 0 +4 0 +. 0 +9 0 +mg 0 +/ 0 +dl 0 +) 0 +were 0 +compared 0 +with 0 +33 0 +patients 0 +undergoing 0 +successful 0 +PCI 0 +( 0 +PCI 0 +group 0 +) 0 +, 0 +matched 0 +for 0 +basal 0 +creatinine 1 +( 0 +1 0 +. 0 +44 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +, 0 +range 0 +0 0 +. 0 +7 0 +- 0 +3 0 +. 0 +4 0 +mg 0 +/ 0 +dl 0 +) 0 +, 0 +gender 0 +, 0 +and 0 +age 0 +. 0 + +In 0 +both 0 +groups 0 +postprocedural 0 +( 0 +48 0 +h 0 +) 0 +serum 0 +creatinine 1 +was 0 +measured 0 +. 0 + +RESULTS 0 +: 0 +Postprocedural 0 +creatinine 1 +level 0 +decreased 0 +nonsignificantly 0 +in 0 +the 0 +PTRA 0 +group 0 +( 0 +1 0 +. 0 +46 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +vs 0 +. 0 +1 0 +. 0 +34 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +dl 0 +, 0 +P 0 += 0 +NS 0 +) 0 +and 0 +increased 0 +significantly 0 +in 0 +the 0 +PCI 0 +group 0 +( 0 +1 0 +. 0 +44 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +vs 0 +. 0 +1 0 +. 0 +57 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +mg 0 +/ 0 +dl 0 +, 0 +P 0 +< 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +Changes 0 +in 0 +serum 0 +creatinine 1 +after 0 +intervention 0 +( 0 +after 0 +- 0 +before 0 +) 0 +were 0 +significantly 0 +different 0 +between 0 +the 0 +PTRA 0 +and 0 +PCI 0 +groups 0 +( 0 +- 0 +0 0 +. 0 +12 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +vs 0 +. 0 +0 0 +. 0 +13 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +, 0 +P 0 += 0 +0 0 +. 0 +014 0 +) 0 +. 0 + +This 0 +difference 0 +was 0 +not 0 +related 0 +to 0 +either 0 +a 0 +different 0 +clinical 0 +risk 0 +profile 0 +or 0 +to 0 +the 0 +volume 0 +of 0 +CM 1 +administered 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +this 0 +preliminary 0 +study 0 +patients 0 +submitted 0 +to 0 +PTRA 0 +showed 0 +a 0 +lower 0 +susceptibility 0 +to 0 +renal 3 +damage 4 +induced 0 +by 0 +CM 1 +administration 0 +than 0 +PCI 0 +patients 0 +. 0 + +The 0 +effectiveness 0 +of 0 +PTRA 0 +on 0 +renal 0 +function 0 +seems 0 +to 0 +be 0 +barely 0 +influenced 0 +by 0 +CM 1 +toxicity 3 +. 0 + +Diphenhydramine 1 +prevents 0 +the 0 +haemodynamic 0 +changes 0 +of 0 +cimetidine 1 +in 0 +ICU 0 +patients 0 +. 0 + +Cimetidine 1 +, 0 +a 0 +histamine 1 +2 0 +( 0 +H2 0 +) 0 +antagonist 0 +, 0 +produces 0 +a 0 +decrease 0 +in 0 +arterial 0 +pressure 0 +due 0 +to 0 +vasodilatation 0 +, 0 +especially 0 +in 0 +critically 0 +ill 0 +patients 0 +. 0 + +This 0 +may 0 +be 0 +because 0 +cimetidine 1 +acts 0 +as 0 +a 0 +histamine 1 +agonist 0 +. 0 + +We 0 +, 0 +therefore 0 +, 0 +investigated 0 +the 0 +effects 0 +of 0 +the 0 +histamine 1 +1 0 +( 0 +H1 0 +) 0 +receptor 0 +antagonist 0 +, 0 +diphenhydramine 1 +, 0 +on 0 +the 0 +haemodynamic 0 +changes 0 +observed 0 +after 0 +cimetidine 1 +in 0 +ICU 0 +patients 0 +. 0 + +Each 0 +patient 0 +was 0 +studied 0 +on 0 +two 0 +separate 0 +days 0 +. 0 + +In 0 +a 0 +random 0 +fashion 0 +, 0 +they 0 +received 0 +cimetidine 1 +200 0 +mg 0 +iv 0 +on 0 +one 0 +day 0 +, 0 +and 0 +on 0 +the 0 +other 0 +, 0 +a 0 +pretreatment 0 +of 0 +diphenhydramine 1 +40 0 +mg 0 +iv 0 +with 0 +cimetidine 1 +200 0 +mg 0 +iv 0 +. 0 + +In 0 +the 0 +non 0 +- 0 +pretreatment 0 +group 0 +, 0 +mean 0 +arterial 0 +pressure 0 +( 0 +MAP 0 +) 0 +decreased 0 +from 0 +107 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +4 0 +mmHg 0 +to 0 +86 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +11 0 +. 0 +4 0 +mmHg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +two 0 +minutes 0 +after 0 +cimetidine 1 +. 0 + +Also 0 +, 0 +systemic 0 +vascular 0 +resistance 0 +( 0 +SVR 0 +) 0 +decreased 0 +during 0 +the 0 +eight 0 +- 0 +minute 0 +observation 0 +period 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +In 0 +contrast 0 +, 0 +in 0 +the 0 +pretreatment 0 +group 0 +, 0 +little 0 +haemodynamic 0 +change 0 +was 0 +seen 0 +. 0 + +We 0 +conclude 0 +that 0 +an 0 +H1 0 +antagonist 0 +may 0 +be 0 +useful 0 +in 0 +preventing 0 +hypotension 3 +caused 0 +by 0 +iv 0 +cimetidine 1 +, 0 +since 0 +the 0 +vasodilating 0 +activity 0 +of 0 +cimetidine 1 +is 0 +mediated 0 +, 0 +in 0 +part 0 +, 0 +through 0 +the 0 +H1 0 +receptor 0 +. 0 + +Medical 0 +and 0 +psychiatric 0 +outcomes 0 +for 0 +patients 0 +transplanted 0 +for 0 +acetaminophen 1 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +: 0 +a 0 +case 0 +- 0 +control 0 +study 0 +. 0 + +BACKGR0UND 0 +: 0 +Acetaminophen 1 +- 0 +induced 0 +hepatotoxicity 3 +is 0 +the 0 +most 0 +common 0 +cause 0 +of 0 +acute 3 +liver 4 +failure 4 +( 0 +ALF 3 +) 0 +in 0 +the 0 +UK 0 +. 0 + +Patients 0 +often 0 +consume 0 +the 0 +drug 0 +with 0 +suicidal 0 +intent 0 +or 0 +with 0 +a 0 +background 0 +of 0 +substance 0 +dependence 0 +. 0 + +AIMS 0 +AND 0 +METH0DS 0 +: 0 +We 0 +compared 0 +the 0 +severity 0 +of 0 +pretransplant 0 +illness 0 +, 0 +psychiatric 0 +co 0 +- 0 +morbidity 0 +, 0 +medical 0 +and 0 +psychosocial 0 +outcomes 0 +of 0 +all 0 +patients 0 +who 0 +had 0 +undergone 0 +liver 0 +transplantation 0 +( 0 +LT 0 +) 0 +emergently 0 +between 0 +1999 0 +- 0 +2004 0 +for 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +( 0 +n 0 += 0 +36 0 +) 0 +with 0 +age 0 +- 0 +and 0 +sex 0 +- 0 +matched 0 +patients 0 +undergoing 0 +emergent 0 +LT 0 +for 0 +non 0 +- 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +( 0 +n 0 += 0 +35 0 +) 0 +and 0 +elective 0 +LT 0 +for 0 +chronic 3 +liver 4 +disease 4 +( 0 +CLD 3 +, 0 +n 0 += 0 +34 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Acetaminophen 1 +- 0 +induced 0 +ALF 3 +patients 0 +undergoing 0 +LT 0 +had 0 +a 0 +greater 0 +severity 0 +of 0 +pre 0 +- 0 +LT 0 +illness 0 +reflected 0 +by 0 +higher 0 +Acute 0 +Physiology 0 +and 0 +Chronic 0 +Health 0 +Evaluation 0 +II 0 +scores 0 +and 0 +requirement 0 +for 0 +organ 0 +support 0 +compared 0 +with 0 +the 0 +other 0 +two 0 +groups 0 +. 0 + +Twenty 0 +( 0 +56 0 +% 0 +) 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +patients 0 +had 0 +a 0 +formal 0 +psychiatric 0 +diagnosis 0 +before 0 +LT 0 +( 0 +non 0 +- 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 += 0 +0 0 +/ 0 +35 0 +, 0 +CLD 3 += 0 +2 0 +/ 0 +34 0 +; 0 +P 0 +< 0 +0 0 +. 0 +01 0 +for 0 +all 0 +) 0 +and 0 +nine 0 +( 0 +25 0 +% 0 +) 0 +had 0 +a 0 +previous 0 +suicide 0 +attempt 0 +. 0 + +During 0 +follow 0 +- 0 +up 0 +( 0 +median 0 +5 0 +years 0 +) 0 +, 0 +there 0 +were 0 +no 0 +significant 0 +differences 0 +in 0 +rejection 0 +( 0 +acute 0 +and 0 +chronic 0 +) 0 +, 0 +graft 0 +failure 0 +or 0 +survival 0 +between 0 +the 0 +groups 0 +( 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +1 0 +year 0 +87 0 +% 0 +, 0 +5 0 +years 0 +75 0 +% 0 +; 0 +non 0 +- 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +88 0 +% 0 +, 0 +78 0 +% 0 +; 0 +CLD 3 +93 0 +% 0 +, 0 +82 0 +% 0 +: 0 +P 0 +> 0 +0 0 +. 0 +6 0 +log 0 +rank 0 +) 0 +. 0 + +Two 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +patients 0 +reattempted 0 +suicide 0 +post 0 +- 0 +LT 0 +( 0 +one 0 +died 0 +8 0 +years 0 +post 0 +- 0 +LT 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Despite 0 +a 0 +high 0 +prevalence 0 +of 0 +psychiatric 0 +disturbance 0 +, 0 +outcomes 0 +for 0 +patients 0 +transplanted 0 +emergently 0 +for 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +were 0 +comparable 0 +to 0 +those 0 +transplanted 0 +for 0 +non 0 +- 0 +acetaminophen 1 +- 0 +induced 0 +ALF 3 +and 0 +electively 0 +for 0 +CLD 3 +. 0 + +Multidisciplinary 0 +approaches 0 +with 0 +long 0 +- 0 +term 0 +psychiatric 0 +follow 0 +- 0 +up 0 +may 0 +contribute 0 +to 0 +low 0 +post 0 +- 0 +transplant 0 +suicide 0 +rates 0 +seen 0 +and 0 +low 0 +rates 0 +of 0 +graft 0 +loss 0 +because 0 +of 0 +non 0 +- 0 +compliance 0 +. 0 + +Antithrombotic 0 +drug 0 +use 0 +, 0 +cerebral 3 +microbleeds 4 +, 0 +and 0 +intracerebral 3 +hemorrhage 4 +: 0 +a 0 +systematic 0 +review 0 +of 0 +published 0 +and 0 +unpublished 0 +studies 0 +. 0 + +BACKGR0UND 0 +AND 0 +PURP0SE 0 +: 0 +Cerebral 3 +microbleeds 4 +( 0 +MB 3 +) 0 +are 0 +potential 0 +risk 0 +factors 0 +for 0 +intracerebral 3 +hemorrhage 4 +( 0 +ICH 3 +) 0 +, 0 +but 0 +it 0 +is 0 +unclear 0 +if 0 +they 0 +are 0 +a 0 +contraindication 0 +to 0 +using 0 +antithrombotic 0 +drugs 0 +. 0 + +Insights 0 +could 0 +be 0 +gained 0 +by 0 +pooling 0 +data 0 +on 0 +MB 3 +frequency 0 +stratified 0 +by 0 +antithrombotic 0 +use 0 +in 0 +cohorts 0 +with 0 +ICH 3 +and 0 +ischemic 3 +stroke 4 +( 0 +IS 3 +) 0 +/ 0 +transient 3 +ischemic 4 +attack 4 +( 0 +TIA 3 +) 0 +. 0 + +METH0DS 0 +: 0 +We 0 +performed 0 +a 0 +systematic 0 +review 0 +of 0 +published 0 +and 0 +unpublished 0 +data 0 +from 0 +cohorts 0 +with 0 +stroke 3 +or 0 +TIA 3 +to 0 +compare 0 +the 0 +presence 0 +of 0 +MB 3 +in 0 +: 0 +( 0 +1 0 +) 0 +antithrombotic 0 +users 0 +vs 0 +nonantithrombotic 0 +users 0 +with 0 +ICH 3 +; 0 +( 0 +2 0 +) 0 +antithrombotic 0 +users 0 +vs 0 +nonusers 0 +with 0 +IS 3 +/ 0 +TIA 3 +; 0 +and 0 +( 0 +3 0 +) 0 +ICH 3 +vs 0 +ischemic 3 +events 0 +stratified 0 +by 0 +antithrombotic 0 +use 0 +. 0 + +We 0 +also 0 +analyzed 0 +published 0 +and 0 +unpublished 0 +follow 0 +- 0 +up 0 +data 0 +to 0 +determine 0 +the 0 +risk 0 +of 0 +ICH 3 +in 0 +antithrombotic 0 +users 0 +with 0 +MB 3 +. 0 + +RESULTS 0 +: 0 +In 0 +a 0 +pooled 0 +analysis 0 +of 0 +1460 0 +ICH 3 +and 0 +3817 0 +IS 3 +/ 0 +TIA 3 +, 0 +MB 3 +were 0 +more 0 +frequent 0 +in 0 +ICH 3 +vs 0 +IS 3 +/ 0 +TIA 3 +in 0 +all 0 +treatment 0 +groups 0 +, 0 +but 0 +the 0 +excess 0 +increased 0 +from 0 +2 0 +. 0 +8 0 +( 0 +odds 0 +ratio 0 +; 0 +range 0 +, 0 +2 0 +. 0 +3 0 +- 0 +3 0 +. 0 +5 0 +) 0 +in 0 +nonantithrombotic 0 +users 0 +to 0 +5 0 +. 0 +7 0 +( 0 +range 0 +, 0 +3 0 +. 0 +4 0 +- 0 +9 0 +. 0 +7 0 +) 0 +in 0 +antiplatelet 0 +users 0 +and 0 +8 0 +. 0 +0 0 +( 0 +range 0 +, 0 +3 0 +. 0 +5 0 +- 0 +17 0 +. 0 +8 0 +) 0 +in 0 +warfarin 1 +users 0 +( 0 +P 0 +difference 0 += 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +There 0 +was 0 +also 0 +an 0 +excess 0 +of 0 +MB 3 +in 0 +warfarin 1 +users 0 +vs 0 +nonusers 0 +with 0 +ICH 3 +( 0 +0R 0 +, 0 +2 0 +. 0 +7 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +1 0 +. 0 +6 0 +- 0 +4 0 +. 0 +4 0 +; 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +but 0 +none 0 +in 0 +warfarin 1 +users 0 +with 0 +IS 3 +/ 0 +TIA 3 +( 0 +0R 0 +, 0 +1 0 +. 0 +3 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +0 0 +. 0 +9 0 +- 0 +1 0 +. 0 +7 0 +; 0 +P 0 += 0 +0 0 +. 0 +33 0 +; 0 +P 0 +difference 0 += 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +There 0 +was 0 +a 0 +smaller 0 +excess 0 +of 0 +MB 3 +in 0 +antiplatelet 0 +users 0 +vs 0 +nonusers 0 +with 0 +ICH 3 +( 0 +0R 0 +, 0 +1 0 +. 0 +7 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +1 0 +. 0 +3 0 +- 0 +2 0 +. 0 +3 0 +; 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +but 0 +findings 0 +were 0 +similar 0 +for 0 +antiplatelet 0 +users 0 +with 0 +IS 3 +/ 0 +TIA 3 +( 0 +0R 0 +, 0 +1 0 +. 0 +4 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +1 0 +. 0 +2 0 +- 0 +1 0 +. 0 +7 0 +; 0 +P 0 +< 0 +0 0 +. 0 +001 0 +; 0 +P 0 +difference 0 += 0 +0 0 +. 0 +25 0 +) 0 +. 0 + +In 0 +pooled 0 +follow 0 +- 0 +up 0 +data 0 +for 0 +768 0 +antithrombotic 0 +users 0 +, 0 +presence 0 +of 0 +MB 3 +at 0 +baseline 0 +was 0 +associated 0 +with 0 +a 0 +substantially 0 +increased 0 +risk 0 +of 0 +subsequent 0 +ICH 3 +( 0 +0R 0 +, 0 +12 0 +. 0 +1 0 +; 0 +95 0 +% 0 +CI 0 +, 0 +3 0 +. 0 +4 0 +- 0 +42 0 +. 0 +5 0 +; 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +excess 0 +of 0 +MB 3 +in 0 +warfarin 1 +users 0 +with 0 +ICH 3 +compared 0 +to 0 +other 0 +groups 0 +suggests 0 +that 0 +MB 3 +increase 0 +the 0 +risk 0 +of 0 +warfarin 1 +- 0 +associated 0 +ICH 3 +. 0 + +Limited 0 +prospective 0 +data 0 +corroborate 0 +these 0 +findings 0 +, 0 +but 0 +larger 0 +prospective 0 +studies 0 +are 0 +urgently 0 +required 0 +. 0 + +Studies 0 +of 0 +synergy 0 +between 0 +morphine 1 +and 0 +a 0 +novel 0 +sodium 1 +channel 0 +blocker 0 +, 0 +CNSB002 1 +, 0 +in 0 +rat 0 +models 0 +of 0 +inflammatory 0 +and 0 +neuropathic 3 +pain 4 +. 0 + +0BJECTIVE 0 +: 0 +This 0 +study 0 +determined 0 +the 0 +antihyperalgesic 0 +effect 0 +of 0 +CNSB002 1 +, 0 +a 0 +sodium 1 +channel 0 +blocker 0 +with 0 +antioxidant 0 +properties 0 +given 0 +alone 0 +and 0 +in 0 +combinations 0 +with 0 +morphine 1 +in 0 +rat 0 +models 0 +of 0 +inflammatory 0 +and 0 +neuropathic 3 +pain 4 +. 0 + +DESIGN 0 +: 0 +Dose 0 +response 0 +curves 0 +for 0 +nonsedating 0 +doses 0 +of 0 +morphine 1 +and 0 +CNSB002 1 +given 0 +intraperitoneally 0 +alone 0 +and 0 +together 0 +in 0 +combinations 0 +were 0 +constructed 0 +for 0 +antihyperalgesic 0 +effect 0 +using 0 +paw 0 +withdrawal 0 +from 0 +noxious 0 +heat 0 +in 0 +two 0 +rat 0 +pain 3 +models 0 +: 0 +carrageenan 1 +- 0 +induced 0 +paw 0 +inflammation 3 +and 0 +streptozotocin 1 +( 0 +STZ 1 +) 0 +- 0 +induced 0 +diabetic 3 +neuropathy 4 +. 0 + +RESULTS 0 +: 0 +The 0 +maximum 0 +nonsedating 0 +doses 0 +were 0 +: 0 +morphine 1 +, 0 +3 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +; 0 +CNSB002 1 +10 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +; 0 +5 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +CNSB002 1 +with 0 +morphine 1 +3 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +in 0 +combination 0 +. 0 + +The 0 +doses 0 +calculated 0 +to 0 +cause 0 +50 0 +% 0 +reversal 0 +of 0 +hyperalgesia 3 +( 0 +ED50 0 +) 0 +were 0 +7 0 +. 0 +54 0 +( 0 +1 0 +. 0 +81 0 +) 0 +and 0 +4 0 +. 0 +83 0 +( 0 +1 0 +. 0 +54 0 +) 0 +in 0 +the 0 +carrageenan 1 +model 0 +and 0 +44 0 +. 0 +18 0 +( 0 +1 0 +. 0 +37 0 +) 0 +and 0 +9 0 +. 0 +14 0 +( 0 +1 0 +. 0 +24 0 +) 0 +in 0 +the 0 +STZ 1 +- 0 +induced 0 +neuropathy 3 +model 0 +for 0 +CNSB002 1 +and 0 +morphine 1 +, 0 +respectively 0 +( 0 +mg 0 +/ 0 +kg 0 +; 0 +mean 0 +, 0 +SEM 0 +) 0 +. 0 + +These 0 +values 0 +were 0 +greater 0 +than 0 +the 0 +maximum 0 +nonsedating 0 +doses 0 +. 0 + +The 0 +ED50 0 +values 0 +for 0 +morphine 1 +when 0 +given 0 +in 0 +combination 0 +with 0 +CNSB002 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +were 0 +less 0 +than 0 +the 0 +maximum 0 +nonsedating 0 +dose 0 +: 0 +0 0 +. 0 +56 0 +( 0 +1 0 +. 0 +55 0 +) 0 +in 0 +the 0 +carrageenan 1 +model 0 +and 0 +1 0 +. 0 +37 0 +( 0 +1 0 +. 0 +23 0 +) 0 +in 0 +the 0 +neuropathy 3 +model 0 +( 0 +mg 0 +/ 0 +kg 0 +; 0 +mean 0 +, 0 +SEM 0 +) 0 +. 0 + +The 0 +antinociception 0 +after 0 +morphine 1 +( 0 +3 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +increased 0 +by 0 +co 0 +- 0 +administration 0 +with 0 +CNSB002 1 +from 0 +28 0 +. 0 +0 0 +and 0 +31 0 +. 0 +7 0 +% 0 +to 0 +114 0 +. 0 +6 0 +and 0 +56 0 +. 0 +9 0 +% 0 +reversal 0 +of 0 +hyperalgesia 3 +in 0 +the 0 +inflammatory 0 +and 0 +neuropathic 3 +models 0 +, 0 +respectively 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +; 0 +one 0 +- 0 +way 0 +analysis 0 +of 0 +variance 0 +- 0 +significantly 0 +greater 0 +than 0 +either 0 +drug 0 +given 0 +alone 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +maximum 0 +antihyperalgesic 0 +effect 0 +achievable 0 +with 0 +nonsedating 0 +doses 0 +of 0 +morphine 1 +may 0 +be 0 +increased 0 +significantly 0 +when 0 +the 0 +drug 0 +is 0 +used 0 +in 0 +combination 0 +with 0 +CNSB002 1 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +: 0 +a 0 +practical 0 +review 0 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +( 0 +HIT 3 +) 0 +remains 0 +under 0 +- 0 +recognized 0 +despite 0 +its 0 +potentially 0 +devastating 0 +outcomes 0 +. 0 + +It 0 +begins 0 +when 0 +heparin 1 +exposure 0 +stimulates 0 +the 0 +formation 0 +of 0 +heparin 1 +- 0 +platelet 0 +factor 0 +4 0 +antibodies 0 +, 0 +which 0 +in 0 +turn 0 +triggers 0 +the 0 +release 0 +of 0 +procoagulant 0 +platelet 0 +particles 0 +. 0 + +Thrombosis 3 +and 0 +thrombocytopenia 3 +that 0 +follow 0 +comprise 0 +the 0 +2 0 +hallmark 0 +traits 0 +of 0 +HIT 3 +, 0 +with 0 +the 0 +former 0 +largely 0 +responsible 0 +for 0 +significant 0 +vascular 0 +complications 0 +. 0 + +The 0 +prevalence 0 +of 0 +HIT 3 +varies 0 +among 0 +several 0 +subgroups 0 +, 0 +with 0 +greater 0 +incidence 0 +in 0 +surgical 0 +as 0 +compared 0 +with 0 +medical 0 +populations 0 +. 0 + +HIT 3 +must 0 +be 0 +acknowledged 0 +for 0 +its 0 +intense 0 +predilection 0 +for 0 +thrombosis 3 +and 0 +suspected 0 +whenever 0 +thrombosis 3 +occurs 0 +after 0 +heparin 1 +exposure 0 +. 0 + +Early 0 +recognition 0 +that 0 +incorporates 0 +the 0 +clinical 0 +and 0 +serologic 0 +clues 0 +is 0 +paramount 0 +to 0 +timely 0 +institution 0 +of 0 +treatment 0 +, 0 +as 0 +its 0 +delay 0 +may 0 +result 0 +in 0 +catastrophic 0 +outcomes 0 +. 0 + +The 0 +treatment 0 +of 0 +HIT 3 +mandates 0 +an 0 +immediate 0 +cessation 0 +of 0 +all 0 +heparin 1 +exposure 0 +and 0 +the 0 +institution 0 +of 0 +an 0 +antithrombotic 0 +therapy 0 +, 0 +most 0 +commonly 0 +using 0 +a 0 +direct 1 +thrombin 2 +inhibitor 2 +. 0 + +Current 0 +" 0 +diagnostic 0 +" 0 +tests 0 +, 0 +which 0 +primarily 0 +include 0 +functional 0 +and 0 +antigenic 0 +assays 0 +, 0 +have 0 +more 0 +of 0 +a 0 +confirmatory 0 +than 0 +diagnostic 0 +role 0 +in 0 +the 0 +management 0 +of 0 +HIT 3 +. 0 + +Special 0 +attention 0 +must 0 +be 0 +paid 0 +to 0 +cardiac 0 +patients 0 +who 0 +are 0 +often 0 +exposed 0 +to 0 +heparin 1 +multiple 0 +times 0 +during 0 +their 0 +course 0 +of 0 +treatment 0 +. 0 + +Direct 1 +thrombin 2 +inhibitors 2 +are 0 +appropriate 0 +, 0 +evidence 0 +- 0 +based 0 +alternatives 0 +to 0 +heparin 1 +in 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +HIT 3 +, 0 +who 0 +need 0 +to 0 +undergo 0 +percutaneous 0 +coronary 0 +intervention 0 +. 0 + +As 0 +heparin 1 +remains 0 +one 0 +of 0 +the 0 +most 0 +frequently 0 +used 0 +medications 0 +today 0 +with 0 +potential 0 +for 0 +HIT 3 +with 0 +every 0 +heparin 1 +exposure 0 +, 0 +a 0 +close 0 +vigilance 0 +of 0 +platelet 0 +counts 0 +must 0 +be 0 +practiced 0 +whenever 0 +heparin 1 +is 0 +initiated 0 +. 0 + +Abductor 0 +paralysis 3 +after 0 +botox 1 +injection 0 +for 0 +adductor 3 +spasmodic 4 +dysphonia 4 +. 0 + +0BJECTIVES 0 +/ 0 +HYP0THESIS 0 +: 0 +Botulinum 0 +toxin 0 +( 0 +Botox 1 +) 0 +injections 0 +into 0 +the 0 +thyroarytenoid 0 +muscles 0 +are 0 +the 0 +current 0 +standard 0 +of 0 +care 0 +for 0 +adductor 3 +spasmodic 4 +dysphonia 4 +( 0 +ADSD 3 +) 0 +. 0 + +Reported 0 +adverse 0 +effects 0 +include 0 +a 0 +period 0 +of 0 +breathiness 0 +, 0 +throat 3 +pain 4 +, 0 +and 0 +difficulty 0 +with 0 +swallowing 0 +liquids 0 +. 0 + +Here 0 +we 0 +report 0 +multiple 0 +cases 0 +of 0 +bilateral 0 +abductor 0 +paralysis 3 +following 0 +Botox 1 +injections 0 +for 0 +ADSD 3 +, 0 +a 0 +complication 0 +previously 0 +unreported 0 +. 0 + +STUDY 0 +DESIGN 0 +: 0 +Retrospective 0 +case 0 +series 0 +. 0 + +METH0DS 0 +: 0 +Patients 0 +that 0 +received 0 +Botox 1 +injections 0 +for 0 +spasmodic 3 +dysphonia 4 +between 0 +January 0 +2000 0 +and 0 +0ctober 0 +2009 0 +were 0 +evaluated 0 +. 0 + +Patients 0 +with 0 +ADSD 3 +were 0 +identified 0 +. 0 + +The 0 +number 0 +of 0 +treatments 0 +received 0 +and 0 +adverse 0 +effects 0 +were 0 +noted 0 +. 0 + +For 0 +patients 0 +with 0 +bilateral 0 +abductor 0 +paralysis 3 +, 0 +age 0 +, 0 +sex 0 +, 0 +paralytic 0 +Botox 1 +dose 0 +, 0 +prior 0 +Botox 1 +dose 0 +, 0 +and 0 +course 0 +following 0 +paralysis 3 +were 0 +noted 0 +. 0 + +RESULTS 0 +: 0 +From 0 +a 0 +database 0 +of 0 +452 0 +patients 0 +receiving 0 +Botox 1 +, 0 +352 0 +patients 0 +had 0 +been 0 +diagnosed 0 +with 0 +ADSD 3 +. 0 + +0f 0 +these 0 +352 0 +patients 0 +, 0 +eight 0 +patients 0 +suffered 0 +bilateral 0 +abductor 0 +paralysis 3 +, 0 +and 0 +two 0 +suffered 0 +this 0 +complication 0 +twice 0 +. 0 + +All 0 +affected 0 +patients 0 +were 0 +females 0 +over 0 +the 0 +age 0 +of 0 +50 0 +years 0 +. 0 + +Most 0 +patients 0 +had 0 +received 0 +treatments 0 +prior 0 +to 0 +abductor 0 +paralysis 3 +and 0 +continued 0 +receiving 0 +after 0 +paralysis 3 +. 0 + +Seven 0 +patients 0 +recovered 0 +after 0 +a 0 +brief 0 +period 0 +of 0 +activity 0 +restrictions 0 +, 0 +and 0 +one 0 +underwent 0 +a 0 +tracheotomy 0 +. 0 + +The 0 +incidence 0 +of 0 +abductor 0 +paralysis 3 +after 0 +Botox 1 +injection 0 +for 0 +ADSD 3 +was 0 +0 0 +. 0 +34 0 +% 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Bilateral 0 +abductor 0 +paralysis 3 +is 0 +a 0 +rare 0 +complication 0 +of 0 +Botox 1 +injections 0 +for 0 +ADSD 3 +, 0 +causing 0 +difficulty 0 +with 0 +breathing 0 +upon 0 +exertion 0 +. 0 + +The 0 +likely 0 +mechanism 0 +of 0 +paralysis 3 +is 0 +diffusion 0 +of 0 +Botox 1 +around 0 +the 0 +muscular 0 +process 0 +of 0 +the 0 +arytenoid 0 +to 0 +the 0 +posterior 0 +cricoarytenoid 0 +muscles 0 +. 0 + +The 0 +paralysis 3 +is 0 +temporary 0 +, 0 +and 0 +watchful 0 +waiting 0 +with 0 +restriction 0 +of 0 +activity 0 +is 0 +the 0 +recommended 0 +management 0 +. 0 + +Mitochondrial 3 +impairment 4 +contributes 0 +to 0 +cocaine 1 +- 0 +induced 0 +cardiac 3 +dysfunction 4 +: 0 +Prevention 0 +by 0 +the 0 +targeted 0 +antioxidant 0 +MitoQ 1 +. 0 + +The 0 +goal 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +mitochondrial 0 +function 0 +and 0 +R0S 0 +production 0 +in 0 +an 0 +experimental 0 +model 0 +of 0 +cocaine 1 +- 0 +induced 0 +cardiac 3 +dysfunction 4 +. 0 + +We 0 +hypothesized 0 +that 0 +cocaine 3 +abuse 4 +may 0 +lead 0 +to 0 +altered 0 +mitochondrial 0 +function 0 +that 0 +in 0 +turn 0 +may 0 +cause 0 +left 3 +ventricular 4 +dysfunction 4 +. 0 + +Seven 0 +days 0 +of 0 +cocaine 1 +administration 0 +to 0 +rats 0 +led 0 +to 0 +an 0 +increased 0 +oxygen 1 +consumption 0 +detected 0 +in 0 +cardiac 0 +fibers 0 +, 0 +specifically 0 +through 0 +complex 0 +I 0 +and 0 +complex 0 +III 0 +. 0 + +R0S 0 +levels 0 +were 0 +increased 0 +, 0 +specifically 0 +in 0 +interfibrillar 0 +mitochondria 0 +. 0 + +In 0 +parallel 0 +there 0 +was 0 +a 0 +decrease 0 +in 0 +ATP 1 +synthesis 0 +, 0 +whereas 0 +no 0 +difference 0 +was 0 +observed 0 +in 0 +subsarcolemmal 0 +mitochondria 0 +. 0 + +This 0 +uncoupling 0 +effect 0 +on 0 +oxidative 0 +phosphorylation 0 +was 0 +not 0 +detectable 0 +after 0 +short 0 +- 0 +term 0 +exposure 0 +to 0 +cocaine 1 +, 0 +suggesting 0 +that 0 +these 0 +mitochondrial 3 +abnormalities 4 +were 0 +a 0 +late 0 +rather 0 +than 0 +a 0 +primary 0 +event 0 +in 0 +the 0 +pathological 0 +response 0 +to 0 +cocaine 1 +. 0 + +MitoQ 1 +, 0 +a 0 +mitochondrial 0 +- 0 +targeted 0 +antioxidant 0 +, 0 +was 0 +shown 0 +to 0 +completely 0 +prevent 0 +these 0 +mitochondrial 3 +abnormalities 4 +as 0 +well 0 +as 0 +cardiac 3 +dysfunction 4 +characterized 0 +here 0 +by 0 +a 0 +diastolic 3 +dysfunction 4 +studied 0 +with 0 +a 0 +conductance 0 +catheter 0 +to 0 +obtain 0 +pressure 0 +- 0 +volume 0 +data 0 +. 0 + +Taken 0 +together 0 +, 0 +these 0 +results 0 +extend 0 +previous 0 +studies 0 +and 0 +demonstrate 0 +that 0 +cocaine 1 +- 0 +induced 0 +cardiac 3 +dysfunction 4 +may 0 +be 0 +due 0 +to 0 +a 0 +mitochondrial 3 +defect 4 +. 0 + +Trimethoprim 1 +- 0 +induced 0 +immune 0 +hemolytic 3 +anemia 4 +in 0 +a 0 +pediatric 0 +oncology 0 +patient 0 +presenting 0 +as 0 +an 0 +acute 0 +hemolytic 0 +transfusion 0 +reaction 0 +. 0 + +A 0 +10 0 +- 0 +year 0 +- 0 +old 0 +male 0 +with 0 +acute 3 +leukemia 4 +presented 0 +with 0 +post 0 +- 0 +chemotherapy 0 +anemia 3 +. 0 + +During 0 +red 0 +cell 0 +transfusion 0 +, 0 +he 0 +developed 0 +hemoglobinuria 3 +. 0 + +Transfusion 0 +reaction 0 +workup 0 +was 0 +negative 0 +. 0 + +Drug 0 +- 0 +induced 0 +immune 0 +hemolytic 3 +anemia 4 +was 0 +suspected 0 +because 0 +of 0 +positive 0 +direct 0 +antiglobulin 0 +test 0 +, 0 +negative 0 +eluate 0 +, 0 +and 0 +microspherocytes 0 +on 0 +smear 0 +pre 0 +- 0 +and 0 +post 0 +- 0 +transfusion 0 +. 0 + +Drug 0 +studies 0 +using 0 +the 0 +indirect 0 +antiglobulin 0 +test 0 +were 0 +strongly 0 +positive 0 +with 0 +trimethoprim 1 +and 0 +trimethoprim 1 +- 2 +sulfamethoxazole 2 +but 0 +negative 0 +with 0 +sulfamethoxazole 1 +. 0 + +The 0 +patient 0 +recovered 0 +after 0 +discontinuing 0 +the 0 +drug 0 +, 0 +with 0 +no 0 +recurrence 0 +in 0 +2 0 +years 0 +. 0 + +0ther 0 +causes 0 +of 0 +anemia 3 +should 0 +be 0 +considered 0 +in 0 +patients 0 +with 0 +worse 0 +- 0 +than 0 +- 0 +expected 0 +anemia 3 +after 0 +chemotherapy 0 +. 0 + +Furthermore 0 +, 0 +hemolysis 3 +during 0 +transfusion 0 +is 0 +not 0 +always 0 +a 0 +transfusion 0 +reaction 0 +. 0 + +Verapamil 1 +stimulation 0 +test 0 +in 0 +hyperprolactinemia 3 +: 0 +loss 0 +of 0 +prolactin 0 +response 0 +in 0 +anatomic 0 +or 0 +functional 0 +stalk 0 +effect 0 +. 0 + +AIM 0 +: 0 +Verapamil 1 +stimulation 0 +test 0 +was 0 +previously 0 +investigated 0 +as 0 +a 0 +tool 0 +for 0 +differential 0 +diagnosis 0 +of 0 +hyperprolactinemia 3 +, 0 +but 0 +with 0 +conflicting 0 +results 0 +. 0 + +Macroprolactinemia 3 +was 0 +never 0 +considered 0 +in 0 +those 0 +previous 0 +studies 0 +. 0 + +Here 0 +, 0 +we 0 +aimed 0 +to 0 +re 0 +- 0 +investigate 0 +the 0 +diagnostic 0 +value 0 +of 0 +verapamil 1 +in 0 +a 0 +population 0 +who 0 +were 0 +all 0 +screened 0 +for 0 +macroprolactinemia 3 +. 0 + +Prolactin 0 +responses 0 +to 0 +verapamil 1 +in 0 +65 0 +female 0 +patients 0 +( 0 +age 0 +: 0 +29 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +1 0 +years 0 +) 0 +with 0 +hyperprolactinemia 3 +were 0 +tested 0 +in 0 +a 0 +descriptive 0 +, 0 +matched 0 +case 0 +- 0 +control 0 +study 0 +. 0 + +METH0DS 0 +: 0 +Verapamil 1 +80 0 +mg 0 +, 0 +p 0 +. 0 +o 0 +. 0 +was 0 +administered 0 +, 0 +and 0 +then 0 +PRL 0 +levels 0 +were 0 +measured 0 +at 0 +8th 0 +and 0 +16th 0 +hours 0 +, 0 +by 0 +immunometric 0 +chemiluminescence 0 +. 0 + +Verapamil 1 +responsiveness 0 +was 0 +determined 0 +by 0 +peak 0 +percent 0 +change 0 +in 0 +basal 0 +prolactin 0 +levels 0 +( 0 +PRL 0 +) 0 +. 0 + +RESULTS 0 +: 0 +Verapamil 1 +significantly 0 +increased 0 +PRL 0 +levels 0 +in 0 +healthy 0 +controls 0 +( 0 +N 0 +. 0 +8 0 +, 0 +PRL 0 +: 0 +183 0 +% 0 +) 0 +, 0 +macroprolactinoma 3 +( 0 +N 0 +. 0 +8 0 +, 0 +PRL 0 +: 0 +7 0 +% 0 +) 0 +, 0 +microprolactinoma 3 +( 0 +N 0 +. 0 +19 0 +, 0 +PRL 0 +: 0 +21 0 +% 0 +) 0 +, 0 +macroprolactinemia 3 +( 0 +N 0 +. 0 +23 0 +, 0 +PRL 0 +: 0 +126 0 +% 0 +) 0 +, 0 +but 0 +not 0 +in 0 +pseudoprolactinoma 3 +( 0 +N 0 +. 0 +8 0 +, 0 +PRL 0 +: 0 +0 0 +. 0 +8 0 +% 0 +) 0 +, 0 +and 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +( 0 +N 0 +. 0 +7 0 +, 0 +PRL 0 +: 0 +3 0 +% 0 +) 0 +. 0 + +R0C 0 +curve 0 +analysis 0 +revealed 0 +that 0 +unresponsiveness 0 +to 0 +verapamil 1 +defined 0 +as 0 +PRL 0 +< 0 +7 0 +% 0 +, 0 +discriminated 0 +anatomical 0 +or 0 +functional 0 +stalk 0 +effect 0 +( 0 +sensitivity 0 +: 0 +74 0 +% 0 +, 0 +specificity 0 +: 0 +73 0 +% 0 +, 0 +AUC 0 +: 0 +0 0 +. 0 +855 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +04 0 +, 0 +P 0 +< 0 +0 0 +. 0 +001 0 +, 0 +CI 0 +: 0 +0 0 +. 0 +768 0 +- 0 +0 0 +. 0 +942 0 +) 0 +associated 0 +with 0 +pseudoprolactinoma 3 +or 0 +risperidone 1 +- 0 +induced 0 +hyperprolactinemia 3 +, 0 +respectively 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Verapamil 1 +responsiveness 0 +is 0 +not 0 +a 0 +reliable 0 +finding 0 +for 0 +the 0 +differential 0 +diagnosis 0 +of 0 +hyperprolactinemia 3 +. 0 + +However 0 +, 0 +verapamil 1 +unresponsiveness 0 +discriminates 0 +stalk 0 +effect 0 +( 0 +i 0 +. 0 +e 0 +. 0 +, 0 +anatomically 0 +or 0 +functionally 0 +inhibited 0 +dopaminergic 0 +tonus 0 +) 0 +from 0 +other 0 +causes 0 +of 0 +hyperprolactinemia 3 +with 0 +varying 0 +degrees 0 +of 0 +responsiveness 0 +. 0 + +Blockade 0 +of 0 +endothelial 0 +- 0 +mesenchymal 0 +transition 0 +by 0 +a 0 +Smad3 0 +inhibitor 0 +delays 0 +the 0 +early 0 +development 0 +of 0 +streptozotocin 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +. 0 + +0BJECTIVE 0 +: 0 +A 0 +multicenter 0 +, 0 +controlled 0 +trial 0 +showed 0 +that 0 +early 0 +blockade 0 +of 0 +the 0 +renin 0 +- 0 +angiotensin 1 +system 0 +in 0 +patients 0 +with 0 +type 3 +1 4 +diabetes 4 +and 0 +normoalbuminuria 0 +did 0 +not 0 +retard 0 +the 0 +progression 0 +of 0 +nephropathy 3 +, 0 +suggesting 0 +that 0 +other 0 +mechanism 0 +( 0 +s 0 +) 0 +are 0 +involved 0 +in 0 +the 0 +pathogenesis 0 +of 0 +early 0 +diabetic 3 +nephropathy 4 +( 0 +diabetic 3 +nephropathy 4 +) 0 +. 0 + +We 0 +have 0 +previously 0 +demonstrated 0 +that 0 +endothelial 0 +- 0 +mesenchymal 0 +- 0 +transition 0 +( 0 +EndoMT 0 +) 0 +contributes 0 +to 0 +the 0 +early 0 +development 0 +of 0 +renal 0 +interstitial 0 +fibrosis 3 +independently 0 +of 0 +microalbuminuria 0 +in 0 +mice 0 +with 0 +streptozotocin 1 +( 0 +STZ 1 +) 0 +- 0 +induced 0 +diabetes 3 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +we 0 +hypothesized 0 +that 0 +blocking 0 +EndoMT 0 +reduces 0 +the 0 +early 0 +development 0 +of 0 +diabetic 3 +nephropathy 4 +. 0 + +RESEARCH 0 +DESIGN 0 +AND 0 +METH0DS 0 +: 0 +EndoMT 0 +was 0 +induced 0 +in 0 +a 0 +mouse 0 +pancreatic 0 +microvascular 0 +endothelial 0 +cell 0 +line 0 +( 0 +MMEC 0 +) 0 +in 0 +the 0 +presence 0 +of 0 +advanced 0 +glycation 0 +end 0 +products 0 +( 0 +AGEs 0 +) 0 +and 0 +in 0 +the 0 +endothelial 0 +lineage 0 +- 0 +traceble 0 +mouse 0 +line 0 +Tie2 0 +- 0 +Cre 0 +; 0 +Loxp 0 +- 0 +EGFP 0 +by 0 +administration 0 +of 0 +AGEs 0 +, 0 +with 0 +nonglycated 0 +mouse 0 +albumin 0 +serving 0 +as 0 +a 0 +control 0 +. 0 + +Phosphorylated 0 +Smad3 0 +was 0 +detected 0 +by 0 +immunoprecipitation 0 +/ 0 +Western 0 +blotting 0 +and 0 +confocal 0 +microscopy 0 +. 0 + +Blocking 0 +studies 0 +using 0 +receptor 0 +for 0 +AGE 0 +siRNA 0 +and 0 +a 0 +specific 0 +inhibitor 0 +of 0 +Smad3 0 +( 0 +SIS3 0 +) 0 +were 0 +performed 0 +in 0 +MMECs 0 +and 0 +in 0 +STZ 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +in 0 +Tie2 0 +- 0 +Cre 0 +; 0 +Loxp 0 +- 0 +EGFP 0 +mice 0 +. 0 + +RESULTS 0 +: 0 +Confocal 0 +microscopy 0 +and 0 +real 0 +- 0 +time 0 +PCR 0 +demonstrated 0 +that 0 +AGEs 0 +induced 0 +EndoMT 0 +in 0 +MMECs 0 +and 0 +in 0 +Tie2 0 +- 0 +Cre 0 +; 0 +Loxp 0 +- 0 +EGFP 0 +mice 0 +. 0 + +Immunoprecipitation 0 +/ 0 +Western 0 +blotting 0 +showed 0 +that 0 +Smad3 0 +was 0 +activated 0 +by 0 +AGEs 0 +but 0 +was 0 +inhibited 0 +by 0 +SIS3 0 +in 0 +MMECs 0 +and 0 +in 0 +STZ 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +. 0 + +Confocal 0 +microscopy 0 +and 0 +real 0 +- 0 +time 0 +PCR 0 +further 0 +demonstrated 0 +that 0 +SIS3 0 +abrogated 0 +EndoMT 0 +, 0 +reduced 0 +renal 0 +fibrosis 3 +, 0 +and 0 +retarded 0 +progression 0 +of 0 +nephropathy 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +EndoMT 0 +is 0 +a 0 +novel 0 +pathway 0 +leading 0 +to 0 +early 0 +development 0 +of 0 +diabetic 3 +nephropathy 4 +. 0 + +Blockade 0 +of 0 +EndoMT 0 +by 0 +SIS3 0 +may 0 +provide 0 +a 0 +new 0 +strategy 0 +to 0 +retard 0 +the 0 +progression 0 +of 0 +diabetic 3 +nephropathy 4 +and 0 +other 0 +diabetes 3 +complications 4 +. 0 + +Cytostatic 0 +and 0 +anti 0 +- 0 +angiogenic 0 +effects 0 +of 0 +temsirolimus 1 +in 0 +refractory 0 +mantle 3 +cell 4 +lymphoma 4 +. 0 + +Mantle 3 +cell 4 +lymphoma 4 +( 0 +MCL 3 +) 0 +is 0 +a 0 +rare 0 +and 0 +aggressive 0 +type 0 +of 0 +B 3 +- 4 +cell 4 +non 4 +- 4 +Hodgkin 4 +' 4 +s 4 +lymphoma 4 +. 0 + +Patients 0 +become 0 +progressively 0 +refractory 0 +to 0 +conventional 0 +chemotherapy 0 +, 0 +and 0 +their 0 +prognosis 0 +is 0 +poor 0 +. 0 + +However 0 +, 0 +a 0 +38 0 +% 0 +remission 0 +rate 0 +has 0 +been 0 +recently 0 +reported 0 +in 0 +refractory 0 +MCL 3 +treated 0 +with 0 +temsirolimus 1 +, 0 +a 0 +mT0R 0 +inhibitor 0 +. 0 +Here 0 +we 0 +had 0 +the 0 +opportunity 0 +to 0 +study 0 +a 0 +case 0 +of 0 +refractory 0 +MCL 3 +who 0 +had 0 +tumor 3 +regression 0 +two 0 +months 0 +after 0 +temsirolimus 1 +treatment 0 +, 0 +and 0 +a 0 +progression 0 +- 0 +free 0 +survival 0 +of 0 +10 0 +months 0 +. 0 + +In 0 +this 0 +case 0 +, 0 +lymph 0 +node 0 +biopsies 0 +were 0 +performed 0 +before 0 +and 0 +six 0 +months 0 +after 0 +temsirolimus 1 +therapy 0 +. 0 + +Comparison 0 +of 0 +the 0 +two 0 +biopsies 0 +showed 0 +that 0 +temsirolimus 1 +inhibited 0 +tumor 3 +cell 0 +proliferation 0 +through 0 +cell 0 +cycle 0 +arrest 0 +, 0 +but 0 +did 0 +not 0 +induce 0 +any 0 +change 0 +in 0 +the 0 +number 0 +of 0 +apoptotic 0 +tumor 3 +cells 0 +. 0 + +Apart 0 +from 0 +this 0 +cytostatic 0 +effect 0 +, 0 +temsirolimus 1 +had 0 +an 0 +antiangiogenic 0 +effect 0 +with 0 +decrease 0 +of 0 +tumor 3 +microvessel 0 +density 0 +and 0 +of 0 +VEGF 0 +expression 0 +. 0 + +Moreover 0 +, 0 +numerous 0 +patchy 0 +, 0 +well 0 +- 0 +limited 0 +fibrotic 0 +areas 0 +, 0 +compatible 0 +with 0 +post 0 +- 0 +necrotic 3 +tissue 0 +repair 0 +, 0 +were 0 +found 0 +after 0 +6 0 +- 0 +month 0 +temsirolimus 1 +therapy 0 +. 0 + +Thus 0 +, 0 +temsirolimus 1 +reduced 0 +tumor 3 +burden 0 +through 0 +associated 0 +cytostatic 0 +and 0 +anti 0 +- 0 +angiogenic 0 +effects 0 +. 0 +This 0 +dual 0 +effect 0 +of 0 +temsirolimus 1 +on 0 +tumor 3 +tissue 0 +could 0 +contribute 0 +to 0 +its 0 +recently 0 +reported 0 +efficiency 0 +in 0 +refractory 0 +MCL 3 +resistant 0 +to 0 +conventional 0 +chemotherapy 0 +. 0 + +Acute 3 +renal 4 +failure 4 +due 0 +to 0 +rifampicin 1 +. 0 + +A 0 +23 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +with 0 +bacteriologically 0 +proven 0 +pulmonary 3 +tuberculosis 4 +was 0 +treated 0 +with 0 +the 0 +various 0 +regimens 0 +of 0 +antituberculosis 0 +drugs 0 +for 0 +nearly 0 +15 0 +months 0 +. 0 + +Rifampicin 1 +was 0 +administered 0 +thrice 0 +as 0 +one 0 +of 0 +the 0 +3 0 +- 0 +4 0 +drug 0 +regimen 0 +and 0 +each 0 +time 0 +he 0 +developed 0 +untoward 0 +side 0 +effects 0 +like 0 +nausea 3 +, 0 +vomiting 3 +and 0 +fever 3 +with 0 +chills 0 +and 0 +rigors 0 +. 0 + +The 0 +last 0 +such 0 +episode 0 +was 0 +of 0 +acute 0 +renal 0 +failure 0 +at 0 +which 0 +stage 0 +the 0 +patient 0 +was 0 +seen 0 +by 0 +the 0 +authors 0 +of 0 +this 0 +report 0 +. 0 + +The 0 +patient 0 +, 0 +however 0 +, 0 +made 0 +a 0 +full 0 +recovery 0 +. 0 + +Syncope 3 +caused 0 +by 0 +hyperkalemia 3 +during 0 +use 0 +of 0 +a 0 +combined 0 +therapy 0 +with 0 +the 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitor 0 +and 0 +spironolactone 1 +. 0 + +A 0 +76 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +a 0 +history 0 +of 0 +coronary 0 +artery 0 +bypass 0 +grafting 0 +and 0 +prior 0 +myocardial 3 +infarction 4 +was 0 +transferred 0 +to 0 +the 0 +emergency 0 +room 0 +with 0 +loss 3 +of 4 +consciousness 4 +due 0 +to 0 +marked 0 +bradycardia 3 +caused 0 +by 0 +hyperkalemia 3 +. 0 + +The 0 +concentration 0 +of 0 +serum 0 +potassium 1 +was 0 +high 0 +, 0 +and 0 +normal 0 +sinus 0 +rhythm 0 +was 0 +restored 0 +after 0 +correction 0 +of 0 +the 0 +serum 0 +potassium 1 +level 0 +. 0 + +The 0 +cause 0 +of 0 +hyperkalemia 3 +was 0 +considered 0 +to 0 +be 0 +several 0 +doses 0 +of 0 +spiranolactone 1 +, 0 +an 0 +aldosterone 1 +antagonist 0 +, 0 +in 0 +addition 0 +to 0 +the 0 +long 0 +- 0 +term 0 +intake 0 +of 0 +ramipril 1 +, 0 +an 0 +ACE 0 +inhibitor 0 +. 0 + +This 0 +case 0 +is 0 +a 0 +good 0 +example 0 +of 0 +electrolyte 0 +imbalance 0 +causing 0 +acute 0 +life 0 +- 0 +threatening 0 +cardiac 0 +events 0 +. 0 + +Clinicians 0 +should 0 +be 0 +alert 0 +to 0 +the 0 +possibility 0 +of 0 +hyperkalemia 3 +, 0 +especially 0 +in 0 +elderly 0 +patients 0 +using 0 +ACE 0 +/ 0 +ARB 0 +in 0 +combination 0 +with 0 +potassium 1 +sparing 0 +agents 0 +and 0 +who 0 +have 0 +mild 0 +renal 3 +disturbance 4 +. 0 + +Diffuse 0 +skeletal 0 +pain 3 +after 0 +administration 0 +of 0 +alendronate 1 +. 0 + +BACKGR0UND 0 +: 0 +0steoporosis 3 +is 0 +caused 0 +by 0 +bone 0 +resorption 0 +in 0 +excess 0 +of 0 +bone 0 +formation 0 +, 0 +and 0 +bisphosphonates 1 +, 0 +are 0 +used 0 +to 0 +inhibit 0 +bone 0 +resorption 0 +. 0 + +Alendronate 1 +, 0 +a 0 +biphosphonate 1 +, 0 +is 0 +effective 0 +for 0 +both 0 +the 0 +treatment 0 +and 0 +prevention 0 +of 0 +osteoporosis 3 +in 0 +postmenopausal 0 +women 0 +. 0 + +Side 0 +effects 0 +are 0 +relatively 0 +few 0 +and 0 +prominently 0 +gastrointestinal 0 +. 0 + +Musculoskeletal 3 +pain 4 +may 0 +be 0 +an 0 +important 0 +side 0 +effect 0 +in 0 +these 0 +patients 0 +. 0 + +We 0 +presented 0 +a 0 +patient 0 +admitted 0 +to 0 +our 0 +out 0 +- 0 +patient 0 +clinic 0 +with 0 +diffuse 0 +skeletal 0 +pain 3 +after 0 +three 0 +consecutive 0 +administration 0 +of 0 +alendronate 1 +. 0 + +C0NCLUSI0N 0 +: 0 +We 0 +conclude 0 +that 0 +patients 0 +with 0 +osteoporosis 3 +can 0 +report 0 +pain 3 +, 0 +and 0 +bisphosphonate 1 +- 0 +related 0 +pain 3 +should 0 +also 0 +be 0 +considered 0 +before 0 +ascribing 0 +this 0 +complaint 0 +to 0 +osteoporosis 3 +. 0 + +Cerebrospinal 0 +fluid 0 +penetration 0 +of 0 +high 0 +- 0 +dose 0 +daptomycin 1 +in 0 +suspected 0 +Staphylococcus 0 +aureus 0 +meningitis 3 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +methicillin 1 +- 0 +sensitive 0 +Staphylococcus 0 +aureus 0 +( 0 +MSSA 0 +) 0 +bacteremia 3 +with 0 +suspected 0 +MSSA 0 +meningitis 3 +treated 0 +with 0 +high 0 +- 0 +dose 0 +daptomycin 1 +assessed 0 +with 0 +concurrent 0 +serum 0 +and 0 +cerebrospinal 0 +fluid 0 +( 0 +CSF 0 +) 0 +concentrations 0 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +54 0 +- 0 +year 0 +- 0 +old 0 +male 0 +presented 0 +to 0 +the 0 +emergency 0 +department 0 +with 0 +generalized 0 +weakness 3 +and 0 +presumed 0 +health 0 +- 0 +care 0 +- 0 +associated 0 +pneumonia 3 +shown 0 +on 0 +chest 0 +radiograph 0 +. 0 + +Treatment 0 +was 0 +empirically 0 +initiated 0 +with 0 +vancomycin 1 +, 0 +levofloxacin 1 +, 0 +and 0 +piperacillin 1 +/ 0 +tazobactam 1 +. 0 + +Blood 0 +cultures 0 +revealed 0 +S 0 +. 0 +aureus 0 +susceptible 0 +to 0 +oxacillin 1 +. 0 + +Empiric 0 +antibiotic 0 +treatment 0 +was 0 +narrowed 0 +to 0 +nafcillin 1 +on 0 +day 0 +4 0 +. 0 + +0n 0 +day 0 +8 0 +, 0 +the 0 +patient 0 +developed 0 +acute 3 +renal 4 +failure 4 +( 0 +serum 0 +creatinine 1 +1 0 +. 0 +9 0 +mg 0 +/ 0 +dL 0 +, 0 +increased 0 +from 0 +1 0 +. 0 +2 0 +mg 0 +/ 0 +dL 0 +the 0 +previous 0 +day 0 +and 0 +0 0 +. 0 +8 0 +mg 0 +/ 0 +dL 0 +on 0 +admission 0 +) 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +Glasgow 0 +Coma 0 +Score 0 +was 0 +3 0 +, 0 +with 0 +normal 0 +findings 0 +shown 0 +on 0 +computed 0 +tomography 0 +scan 0 +of 0 +the 0 +head 0 +72 0 +hours 0 +following 0 +an 0 +episode 0 +of 0 +cardiac 3 +arrest 4 +on 0 +day 0 +10 0 +. 0 + +The 0 +patient 0 +experienced 0 +relapsing 0 +MSSA 0 +bacteremia 3 +on 0 +day 0 +9 0 +, 0 +increasing 0 +the 0 +suspicion 0 +for 0 +a 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +infection 3 +. 0 + +Nafcillin 1 +was 0 +discontinued 0 +and 0 +daptomycin 1 +9 0 +mg 0 +/ 0 +kg 0 +daily 0 +was 0 +initiated 0 +for 0 +suspected 0 +meningitis 3 +and 0 +was 0 +continued 0 +until 0 +the 0 +patient 0 +' 0 +s 0 +death 0 +on 0 +day 0 +16 0 +. 0 + +Daptomycin 1 +serum 0 +and 0 +CSF 0 +trough 0 +concentrations 0 +were 0 +11 0 +. 0 +21 0 +ug 0 +/ 0 +mL 0 +and 0 +0 0 +. 0 +52 0 +ug 0 +/ 0 +mL 0 +, 0 +respectively 0 +, 0 +prior 0 +to 0 +the 0 +third 0 +dose 0 +. 0 + +Lumbar 0 +puncture 0 +results 0 +were 0 +inconclusive 0 +and 0 +no 0 +further 0 +blood 0 +cultures 0 +were 0 +positive 0 +for 0 +MSSA 0 +. 0 + +Creatine 1 +kinase 0 +levels 0 +were 0 +normal 0 +prior 0 +to 0 +daptomycin 1 +therapy 0 +and 0 +were 0 +not 0 +reassessed 0 +. 0 + +DISCUSSI0N 0 +: 0 +Daptomycin 1 +was 0 +initiated 0 +in 0 +our 0 +patient 0 +secondary 0 +to 0 +possible 0 +nafcillin 1 +- 0 +induced 0 +acute 0 +interstitial 3 +nephritis 4 +and 0 +relapsing 0 +bacteremia 3 +. 0 + +At 0 +a 0 +dose 0 +of 0 +9 0 +mg 0 +/ 0 +kg 0 +, 0 +resultant 0 +penetration 0 +of 0 +5 0 +% 0 +was 0 +higher 0 +than 0 +in 0 +previous 0 +reports 0 +, 0 +more 0 +consistent 0 +with 0 +inflamed 0 +meninges 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +High 0 +- 0 +dose 0 +daptomycin 1 +may 0 +be 0 +an 0 +alternative 0 +option 0 +for 0 +MSSA 0 +bacteremia 3 +with 0 +or 0 +without 0 +a 0 +CNS 0 +source 0 +in 0 +patients 0 +who 0 +have 0 +failed 0 +or 0 +cannot 0 +tolerate 0 +standard 0 +therapy 0 +. 0 + +Further 0 +clinical 0 +evaluation 0 +in 0 +patients 0 +with 0 +confirmed 0 +meningitis 3 +is 0 +warranted 0 +. 0 + +The 0 +role 0 +of 0 +nitric 1 +oxide 2 +in 0 +convulsions 3 +induced 0 +by 0 +lindane 1 +in 0 +rats 0 +. 0 + +Lindane 1 +is 0 +an 0 +organochloride 0 +pesticide 0 +and 0 +scabicide 0 +. 0 + +It 0 +evokes 0 +convulsions 3 +mainly 0 +trough 0 +the 0 +blockage 0 +of 0 +GABA 1 +( 0 +A 0 +) 0 +receptors 0 +. 0 + +Nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +, 0 +gaseous 0 +neurotransmitter 0 +, 0 +has 0 +contradictor 0 +role 0 +in 0 +epileptogenesis 0 +due 0 +to 0 +opposite 0 +effects 0 +of 0 +L 1 +- 2 +arginine 2 +, 0 +precursor 0 +of 0 +N0 1 +syntheses 0 +( 0 +N0S 0 +) 0 +, 0 +and 0 +L 1 +- 2 +NAME 2 +( 0 +N0S 0 +inhibitor 0 +) 0 +observed 0 +in 0 +different 0 +epilepsy 3 +models 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +current 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +effects 0 +of 0 +N0 1 +on 0 +the 0 +behavioral 0 +and 0 +EEG 0 +characteristics 0 +of 0 +lindane 1 +- 0 +induced 0 +epilepsy 3 +in 0 +male 0 +Wistar 0 +albino 0 +rats 0 +. 0 + +The 0 +administration 0 +of 0 +L 1 +- 2 +arginine 2 +( 0 +600 0 +, 0 +800 0 +and 0 +1000 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +in 0 +dose 0 +- 0 +dependent 0 +manner 0 +significantly 0 +increased 0 +convulsion 3 +incidence 0 +and 0 +severity 0 +and 0 +shortened 0 +latency 0 +time 0 +to 0 +first 0 +convulsion 3 +elicited 0 +by 0 +lower 0 +lindane 1 +dose 0 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +0n 0 +the 0 +contrary 0 +, 0 +pretreatment 0 +with 0 +L 1 +- 2 +NAME 2 +( 0 +500 0 +, 0 +700 0 +and 0 +900 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +decreased 0 +convulsion 3 +incidence 0 +and 0 +severity 0 +and 0 +prolonged 0 +latency 0 +time 0 +to 0 +convulsion 3 +following 0 +injection 0 +with 0 +a 0 +convulsive 3 +dose 0 +of 0 +lindane 1 +( 0 +8 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +EEG 0 +analyses 0 +showed 0 +increase 0 +of 0 +number 0 +and 0 +duration 0 +of 0 +ictal 0 +periods 0 +in 0 +EEG 0 +of 0 +rats 0 +receiving 0 +l 1 +- 2 +arginine 2 +prior 0 +to 0 +lindane 1 +and 0 +decrease 0 +of 0 +this 0 +number 0 +in 0 +rats 0 +pretreated 0 +with 0 +L 1 +- 2 +NAME 2 +. 0 + +These 0 +results 0 +support 0 +the 0 +conclusion 0 +that 0 +N0 1 +plays 0 +a 0 +role 0 +of 0 +endogenous 0 +convulsant 0 +in 0 +rat 0 +model 0 +of 0 +lindane 1 +seizures 3 +. 0 + +Severe 0 +polyneuropathy 3 +and 0 +motor 0 +loss 0 +after 0 +intrathecal 0 +thiotepa 1 +combination 0 +chemotherapy 0 +: 0 +description 0 +of 0 +two 0 +cases 0 +. 0 + +Two 0 +cases 0 +of 0 +severe 0 +delayed 0 +neurologic 3 +toxicity 4 +related 0 +to 0 +the 0 +administration 0 +of 0 +intrathecal 0 +( 0 +IT 0 +) 0 +combination 0 +chemotherapy 0 +including 0 +thiotepa 1 +( 0 +TSPA 1 +) 0 +are 0 +presented 0 +. 0 + +Both 0 +cases 0 +developed 0 +axonal 3 +neuropathy 4 +with 0 +motor 0 +predominance 0 +in 0 +the 0 +lower 0 +extremities 0 +1 0 +and 0 +6 0 +months 0 +after 0 +IT 0 +chemotherapy 0 +was 0 +administered 0 +. 0 + +Neurologic 3 +toxicities 4 +have 0 +been 0 +described 0 +with 0 +IT 0 +- 0 +methotrexate 1 +, 0 +IT 0 +- 0 +cytosine 1 +arabinoside 2 +and 0 +IT 0 +- 0 +TSPA 1 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +however 0 +, 0 +axonal 3 +neuropathy 4 +following 0 +administration 0 +of 0 +these 0 +three 0 +agents 0 +has 0 +not 0 +been 0 +previously 0 +described 0 +. 0 + +In 0 +spite 0 +of 0 +the 0 +fact 0 +that 0 +TSPA 1 +is 0 +a 0 +useful 0 +IT 0 +agent 0 +, 0 +its 0 +combination 0 +with 0 +MTX 1 +, 0 +ara 1 +- 2 +C 2 +and 0 +radiotherapy 0 +could 0 +cause 0 +severe 0 +neurotoxicity 3 +. 0 + +This 0 +unexpected 0 +complication 0 +indicates 0 +the 0 +need 0 +for 0 +further 0 +toxicology 0 +research 0 +on 0 +IT 0 +- 0 +TSPA 1 +. 0 + +Effects 0 +of 0 +cromakalim 1 +and 0 +pinacidil 1 +on 0 +large 0 +epicardial 0 +and 0 +small 0 +coronary 0 +arteries 0 +in 0 +conscious 0 +dogs 0 +. 0 + +The 0 +effects 0 +of 0 +i 0 +. 0 +v 0 +. 0 +bolus 0 +administration 0 +of 0 +cromakalim 1 +( 0 +1 0 +- 0 +10 0 +micrograms 0 +/ 0 +kg 0 +) 0 +and 0 +pinacidil 1 +( 0 +3 0 +- 0 +100 0 +micrograms 0 +/ 0 +kg 0 +) 0 +on 0 +large 0 +( 0 +circumflex 0 +artery 0 +) 0 +and 0 +small 0 +coronary 0 +arteries 0 +and 0 +on 0 +systemic 0 +hemodynamics 0 +were 0 +investigated 0 +in 0 +chronically 0 +instrumented 0 +conscious 0 +dogs 0 +and 0 +compared 0 +to 0 +those 0 +of 0 +nitroglycerin 1 +( 0 +0 0 +. 0 +03 0 +- 0 +10 0 +micrograms 0 +/ 0 +kg 0 +) 0 +. 0 + +Nitroglycerin 1 +, 0 +up 0 +to 0 +0 0 +. 0 +3 0 +micrograms 0 +/ 0 +kg 0 +, 0 +selectively 0 +increased 0 +circumflex 0 +artery 0 +diameter 0 +( 0 +CxAD 0 +) 0 +without 0 +simultaneously 0 +affecting 0 +any 0 +other 0 +cardiac 0 +or 0 +systemic 0 +hemodynamic 0 +parameter 0 +. 0 + +In 0 +contrast 0 +, 0 +cromakalim 1 +and 0 +pinacidil 1 +at 0 +all 0 +doses 0 +and 0 +nitroglycerin 1 +at 0 +doses 0 +higher 0 +than 0 +0 0 +. 0 +3 0 +micrograms 0 +/ 0 +kg 0 +simultaneously 0 +and 0 +dose 0 +- 0 +dependently 0 +increased 0 +CxAD 0 +, 0 +coronary 0 +blood 0 +flow 0 +and 0 +heart 0 +rate 0 +and 0 +decreased 0 +coronary 0 +vascular 0 +resistance 0 +and 0 +aortic 0 +pressure 0 +. 0 + +Cromakalim 1 +was 0 +approximately 0 +8 0 +- 0 +to 0 +9 0 +. 0 +5 0 +- 0 +fold 0 +more 0 +potent 0 +than 0 +pinacidil 1 +in 0 +increasing 0 +CxAD 0 +. 0 + +Vasodilation 0 +of 0 +large 0 +and 0 +small 0 +coronary 0 +vessels 0 +and 0 +hypotension 3 +induced 0 +by 0 +cromakalim 1 +and 0 +pinacidil 1 +were 0 +not 0 +affected 0 +by 0 +prior 0 +combined 0 +beta 1 +adrenergic 2 +and 2 +muscarinic 2 +receptors 2 +blockade 2 +but 0 +drug 0 +- 0 +induced 0 +tachycardia 3 +was 0 +abolished 0 +. 0 + +When 0 +circumflex 0 +artery 0 +blood 0 +flow 0 +was 0 +maintained 0 +constant 0 +, 0 +the 0 +increases 0 +in 0 +CxAD 0 +induced 0 +by 0 +cromakalim 1 +( 0 +10 0 +micrograms 0 +/ 0 +kg 0 +) 0 +, 0 +pinacidil 1 +( 0 +30 0 +micrograms 0 +/ 0 +kg 0 +) 0 +and 0 +nitroglycerin 1 +( 0 +10 0 +micrograms 0 +/ 0 +kg 0 +) 0 +were 0 +reduced 0 +by 0 +68 0 ++ 0 +/ 0 +- 0 +7 0 +, 0 +54 0 ++ 0 +/ 0 +- 0 +9 0 +and 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +% 0 +, 0 +respectively 0 +. 0 + +Thus 0 +, 0 +whereas 0 +nitroglycerin 1 +preferentially 0 +and 0 +flow 0 +- 0 +independently 0 +dilates 0 +large 0 +coronary 0 +arteries 0 +, 0 +cromakalim 1 +and 0 +pinacidil 1 +dilate 0 +both 0 +large 0 +and 0 +small 0 +coronary 0 +arteries 0 +and 0 +this 0 +effect 0 +is 0 +not 0 +dependent 0 +upon 0 +the 0 +simultaneous 0 +beta 0 +adrenoceptors 0 +- 0 +mediated 0 +rise 0 +in 0 +myocardial 0 +metabolic 0 +demand 0 +. 0 + +Finally 0 +, 0 +two 0 +mechanisms 0 +at 0 +least 0 +, 0 +direct 0 +vasodilation 0 +and 0 +flow 0 +dependency 0 +, 0 +are 0 +involved 0 +in 0 +the 0 +cromakalim 1 +- 0 +and 0 +pinacidil 1 +- 0 +induced 0 +increase 0 +in 0 +CxAD 0 +. 0 + +Mefenamic 1 +acid 2 +- 0 +induced 0 +neutropenia 3 +and 0 +renal 3 +failure 4 +in 0 +elderly 0 +females 0 +with 0 +hypothyroidism 3 +. 0 + +We 0 +report 0 +mefenamic 1 +acid 2 +- 0 +induced 0 +non 0 +- 0 +oliguric 0 +renal 3 +failure 4 +and 0 +severe 0 +neutropenia 3 +occurring 0 +simultaneously 0 +in 0 +two 0 +elderly 0 +females 0 +. 0 + +The 0 +neutropenia 3 +was 0 +due 0 +to 0 +maturation 0 +arrest 0 +of 0 +the 0 +myeloid 0 +series 0 +in 0 +one 0 +patient 0 +. 0 + +Both 0 +patients 0 +were 0 +also 0 +hypothyroid 3 +, 0 +but 0 +it 0 +is 0 +not 0 +clear 0 +whether 0 +this 0 +was 0 +a 0 +predisposing 0 +factor 0 +to 0 +the 0 +development 0 +of 0 +these 0 +adverse 0 +reactions 0 +. 0 + +However 0 +, 0 +it 0 +would 0 +seem 0 +prudent 0 +not 0 +to 0 +use 0 +mefenamic 1 +acid 2 +in 0 +hypothyroid 3 +patients 0 +until 0 +the 0 +hypothyroidism 3 +has 0 +been 0 +corrected 0 +. 0 + +Etiology 0 +of 0 +hypercalcemia 3 +in 0 +hemodialysis 0 +patients 0 +on 0 +calcium 1 +carbonate 2 +therapy 0 +. 0 + +Fourteen 0 +of 0 +39 0 +dialysis 0 +patients 0 +( 0 +36 0 +% 0 +) 0 +became 0 +hypercalcemic 3 +after 0 +switching 0 +to 0 +calcium 1 +carbonate 2 +as 0 +their 0 +principal 0 +phosphate 1 +binder 0 +. 0 + +In 0 +order 0 +to 0 +identify 0 +risk 0 +factors 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +hypercalcemia 3 +, 0 +indirect 0 +parameters 0 +of 0 +intestinal 0 +calcium 1 +reabsorption 0 +and 0 +bone 0 +turnover 0 +rate 0 +in 0 +these 0 +14 0 +patients 0 +were 0 +compared 0 +with 0 +results 0 +in 0 +14 0 +eucalcemic 0 +patients 0 +matched 0 +for 0 +age 0 +, 0 +sex 0 +, 0 +length 0 +of 0 +time 0 +on 0 +dialysis 0 +, 0 +and 0 +etiology 0 +of 0 +renal 3 +disease 4 +. 0 + +In 0 +addition 0 +to 0 +experiencing 0 +hypercalcemic 3 +episodes 0 +with 0 +peak 0 +calcium 1 +values 0 +of 0 +2 0 +. 0 +7 0 +to 0 +3 0 +. 0 +8 0 +mmol 0 +/ 0 +L 0 +( 0 +10 0 +. 0 +7 0 +to 0 +15 0 +. 0 +0 0 +mg 0 +/ 0 +dL 0 +) 0 +, 0 +patients 0 +in 0 +the 0 +hypercalcemic 3 +group 0 +exhibited 0 +a 0 +significant 0 +increase 0 +in 0 +the 0 +mean 0 +calcium 1 +concentration 0 +obtained 0 +during 0 +6 0 +months 0 +before 0 +the 0 +switch 0 +, 0 +compared 0 +with 0 +the 0 +mean 0 +value 0 +obtained 0 +during 0 +the 0 +7 0 +months 0 +of 0 +observation 0 +after 0 +the 0 +switch 0 +( 0 +2 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +03 0 +to 0 +2 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +03 0 +mmol 0 +/ 0 +L 0 +[ 0 +9 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +to 0 +10 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +dL 0 +] 0 +, 0 +P 0 += 0 +0 0 +. 0 +006 0 +) 0 +. 0 + +In 0 +contrast 0 +, 0 +eucalcemic 0 +patients 0 +exhibited 0 +no 0 +change 0 +in 0 +mean 0 +calcium 1 +values 0 +over 0 +the 0 +same 0 +time 0 +period 0 +( 0 +2 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +05 0 +to 0 +2 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +05 0 +mmol 0 +/ 0 +L 0 +[ 0 +9 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +to 0 +9 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +dL 0 +] 0 +) 0 +. 0 + +CaC03 1 +dosage 0 +, 0 +calculated 0 +dietary 0 +calcium 1 +intake 0 +, 0 +and 0 +circulating 0 +levels 0 +of 0 +vitamin 1 +D 2 +metabolites 0 +were 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 + +Physical 0 +activity 0 +index 0 +and 0 +predialysis 0 +serum 0 +bicarbonate 1 +levels 0 +also 0 +were 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 + +However 0 +, 0 +there 0 +was 0 +a 0 +significant 0 +difference 0 +in 0 +parameters 0 +reflecting 0 +bone 0 +turnover 0 +rates 0 +between 0 +groups 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Late 0 +- 0 +onset 0 +scleroderma 3 +renal 4 +crisis 4 +induced 0 +by 0 +tacrolimus 1 +and 0 +prednisolone 1 +: 0 +a 0 +case 0 +report 0 +. 0 + +Scleroderma 3 +renal 4 +crisis 4 +( 0 +SRC 3 +) 0 +is 0 +a 0 +rare 0 +complication 0 +of 0 +systemic 3 +sclerosis 4 +( 0 +SSc 3 +) 0 +but 0 +can 0 +be 0 +severe 0 +enough 0 +to 0 +require 0 +temporary 0 +or 0 +permanent 0 +renal 0 +replacement 0 +therapy 0 +. 0 + +Moderate 0 +to 0 +high 0 +dose 0 +corticosteroid 1 +use 0 +is 0 +recognized 0 +as 0 +a 0 +major 0 +risk 0 +factor 0 +for 0 +SRC 3 +. 0 + +Furthermore 0 +, 0 +there 0 +have 0 +been 0 +reports 0 +of 0 +thrombotic 3 +microangiopathy 4 +precipitated 0 +by 0 +cyclosporine 1 +in 0 +patients 0 +with 0 +SSc 3 +. 0 + +In 0 +this 0 +article 0 +, 0 +we 0 +report 0 +a 0 +patient 0 +with 0 +SRC 3 +induced 0 +by 0 +tacrolimus 1 +and 0 +corticosteroids 1 +. 0 + +The 0 +aim 0 +of 0 +this 0 +work 0 +is 0 +to 0 +call 0 +attention 0 +to 0 +the 0 +risk 0 +of 0 +tacrolimus 1 +use 0 +in 0 +patients 0 +with 0 +SSc 3 +. 0 + +Methyldopa 1 +- 0 +induced 0 +hemolytic 3 +anemia 4 +in 0 +a 0 +15 0 +year 0 +old 0 +presenting 0 +as 0 +near 0 +- 0 +syncope 3 +. 0 + +Methyldopa 1 +is 0 +an 0 +antihypertensive 0 +medication 0 +which 0 +is 0 +available 0 +generically 0 +and 0 +under 0 +the 0 +trade 0 +name 0 +Aldomet 1 +that 0 +is 0 +widely 0 +prescribed 0 +in 0 +the 0 +adult 0 +population 0 +and 0 +infrequently 0 +used 0 +in 0 +children 0 +. 0 + +Methyldopa 1 +causes 0 +an 0 +autoimmune 3 +hemolytic 4 +anemia 4 +in 0 +a 0 +small 0 +percentage 0 +of 0 +patients 0 +who 0 +take 0 +the 0 +drug 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +methyldopa 1 +- 0 +induced 0 +hemolytic 3 +anemia 4 +in 0 +a 0 +15 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +who 0 +presented 0 +to 0 +the 0 +emergency 3 +department 4 +with 0 +near 0 +- 0 +syncope 3 +. 0 + +The 0 +boy 0 +had 0 +been 0 +treated 0 +with 0 +intravenous 0 +methyldopa 1 +during 0 +a 0 +trauma 3 +admission 0 +seven 0 +weeks 0 +prior 0 +to 0 +presentation 0 +. 0 + +Evaluation 0 +revealed 0 +a 0 +hemoglobin 0 +of 0 +three 0 +grams 0 +, 0 +3 0 ++ 0 +Coombs 0 +' 0 +test 0 +with 0 +polyspecific 0 +anti 0 +- 0 +human 0 +globulin 0 +and 0 +monospecific 0 +IgG 0 +reagents 0 +, 0 +and 0 +a 0 +warm 0 +reacting 0 +autoantibody 0 +. 0 + +Transfusion 0 +and 0 +corticosteroid 1 +therapy 0 +resulted 0 +in 0 +a 0 +complete 0 +recovery 0 +of 0 +the 0 +patient 0 +. 0 + +Emergency 0 +physicians 0 +treating 0 +children 0 +must 0 +be 0 +aware 0 +of 0 +this 0 +syndrome 0 +in 0 +order 0 +to 0 +diagnose 0 +and 0 +treat 0 +it 0 +correctly 0 +. 0 + +A 0 +brief 0 +review 0 +of 0 +autoimmune 0 +and 0 +drug 0 +- 0 +induced 0 +hemolytic 3 +anemias 4 +is 0 +provided 0 +. 0 + +The 0 +risk 0 +and 0 +associated 0 +factors 0 +of 0 +methamphetamine 1 +psychosis 3 +in 0 +methamphetamine 1 +- 0 +dependent 0 +patients 0 +in 0 +Malaysia 0 +. 0 + +0BJECTIVE 0 +: 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +risk 0 +of 0 +lifetime 0 +and 0 +current 0 +methamphetamine 1 +- 0 +induced 0 +psychosis 3 +in 0 +patients 0 +with 0 +methamphetamine 1 +dependence 0 +. 0 + +The 0 +association 0 +between 0 +psychiatric 0 +co 0 +- 0 +morbidity 0 +and 0 +methamphetamine 1 +- 0 +induced 0 +psychosis 3 +was 0 +also 0 +studied 0 +. 0 + +METH0DS 0 +: 0 +This 0 +was 0 +a 0 +cross 0 +- 0 +sectional 0 +study 0 +conducted 0 +concurrently 0 +at 0 +a 0 +teaching 0 +hospital 0 +and 0 +a 0 +drug 0 +rehabilitation 0 +center 0 +in 0 +Malaysia 0 +. 0 + +Patients 0 +with 0 +the 0 +diagnosis 0 +of 0 +methamphetamine 1 +based 0 +on 0 +DSM 0 +- 0 +IV 0 +were 0 +interviewed 0 +using 0 +the 0 +Mini 0 +International 0 +Neuropsychiatric 0 +Interview 0 +( 0 +M 0 +. 0 +I 0 +. 0 +N 0 +. 0 +I 0 +. 0 +) 0 +for 0 +methamphetamine 1 +- 0 +induced 0 +psychosis 3 +and 0 +other 0 +Axis 0 +I 0 +psychiatric 3 +disorders 4 +. 0 + +The 0 +information 0 +on 0 +sociodemographic 0 +background 0 +and 0 +drug 0 +use 0 +history 0 +was 0 +obtained 0 +from 0 +interview 0 +or 0 +medical 0 +records 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +292 0 +subjects 0 +, 0 +47 0 +. 0 +9 0 +% 0 +of 0 +the 0 +subjects 0 +had 0 +a 0 +past 0 +history 0 +of 0 +psychotic 3 +symptoms 4 +and 0 +13 0 +. 0 +0 0 +% 0 +of 0 +the 0 +patients 0 +were 0 +having 0 +current 0 +psychotic 3 +symptoms 4 +. 0 + +Co 0 +- 0 +morbid 0 +major 0 +depressive 3 +disorder 4 +( 0 +0R 0 += 0 +7 0 +. 0 +18 0 +, 0 +95 0 +CI 0 += 0 +2 0 +. 0 +612 0 +- 0 +19 0 +. 0 +708 0 +) 0 +, 0 +bipolar 3 +disorder 4 +( 0 +0R 0 += 0 +13 0 +. 0 +807 0 +, 0 +95 0 +CI 0 += 0 +5 0 +. 0 +194 0 +- 0 +36 0 +. 0 +706 0 +) 0 +, 0 +antisocial 3 +personality 4 +disorder 4 +( 0 +0R 0 += 0 +12 0 +. 0 +619 0 +, 0 +95 0 +CI 0 += 0 +6 0 +. 0 +702 0 +- 0 +23 0 +. 0 +759 0 +) 0 +and 0 +heavy 0 +methamphetamine 1 +uses 0 +were 0 +significantly 0 +associated 0 +with 0 +lifetime 0 +methamphetamine 1 +- 0 +induced 0 +psychosis 3 +after 0 +adjusted 0 +for 0 +other 0 +factors 0 +. 0 + +Major 3 +depressive 4 +disorder 4 +( 0 +0R 0 += 0 +2 0 +. 0 +870 0 +, 0 +CI 0 += 0 +1 0 +. 0 +154 0 +- 0 +7 0 +. 0 +142 0 +) 0 +and 0 +antisocial 3 +personality 4 +disorder 4 +( 0 +0R 0 += 0 +3 0 +. 0 +299 0 +, 0 +95 0 +CI 0 += 0 +1 0 +. 0 +375 0 +- 0 +7 0 +. 0 +914 0 +) 0 +were 0 +the 0 +only 0 +factors 0 +associated 0 +with 0 +current 0 +psychosis 3 +. 0 + +C0NCLUSI0N 0 +: 0 +There 0 +was 0 +a 0 +high 0 +risk 0 +of 0 +psychosis 3 +in 0 +patients 0 +with 0 +methamphetamine 1 +dependence 0 +. 0 + +It 0 +was 0 +associated 0 +with 0 +co 0 +- 0 +morbid 0 +affective 3 +disorder 4 +, 0 +antisocial 3 +personality 4 +, 0 +and 0 +heavy 0 +methamphetamine 1 +use 0 +. 0 + +It 0 +is 0 +recommended 0 +that 0 +all 0 +cases 0 +of 0 +methamphetamine 1 +dependence 0 +should 0 +be 0 +screened 0 +for 0 +psychotic 3 +symptoms 4 +. 0 + +Cerebellar 0 +sensory 0 +processing 0 +alterations 0 +impact 0 +motor 0 +cortical 0 +plasticity 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +: 0 +clues 0 +from 0 +dyskinetic 3 +patients 0 +. 0 + +The 0 +plasticity 0 +of 0 +primary 0 +motor 0 +cortex 0 +( 0 +M1 0 +) 0 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +and 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +( 0 +LIDs 3 +) 0 +is 0 +severely 0 +impaired 0 +. 0 + +We 0 +recently 0 +reported 0 +in 0 +young 0 +healthy 0 +subjects 0 +that 0 +inhibitory 0 +cerebellar 0 +stimulation 0 +enhanced 0 +the 0 +sensorimotor 0 +plasticity 0 +of 0 +M1 0 +that 0 +was 0 +induced 0 +by 0 +paired 0 +associative 0 +stimulation 0 +( 0 +PAS 0 +) 0 +. 0 + +This 0 +study 0 +demonstrates 0 +that 0 +the 0 +deficient 0 +sensorimotor 0 +M1 0 +plasticity 0 +in 0 +16 0 +patients 0 +with 0 +LIDs 3 +could 0 +be 0 +reinstated 0 +by 0 +a 0 +single 0 +session 0 +of 0 +real 0 +inhibitory 0 +cerebellar 0 +stimulation 0 +but 0 +not 0 +sham 0 +stimulation 0 +. 0 + +This 0 +was 0 +evident 0 +only 0 +when 0 +a 0 +sensory 0 +component 0 +was 0 +involved 0 +in 0 +the 0 +induction 0 +of 0 +plasticity 0 +, 0 +indicating 0 +that 0 +cerebellar 0 +sensory 0 +processing 0 +function 0 +is 0 +involved 0 +in 0 +the 0 +resurgence 0 +of 0 +M1 0 +plasticity 0 +. 0 + +The 0 +benefit 0 +of 0 +inhibitory 0 +cerebellar 0 +stimulation 0 +on 0 +LIDs 3 +is 0 +known 0 +. 0 + +To 0 +explore 0 +whether 0 +this 0 +benefit 0 +is 0 +linked 0 +to 0 +the 0 +restoration 0 +of 0 +sensorimotor 0 +plasticity 0 +of 0 +M1 0 +, 0 +we 0 +conducted 0 +an 0 +additional 0 +study 0 +looking 0 +at 0 +changes 0 +in 0 +LIDs 3 +and 0 +PAS 0 +- 0 +induced 0 +plasticity 0 +after 0 +10 0 +sessions 0 +of 0 +either 0 +bilateral 0 +, 0 +real 0 +inhibitory 0 +cerebellar 0 +stimulation 0 +or 0 +sham 0 +stimulation 0 +. 0 + +0nly 0 +real 0 +and 0 +not 0 +sham 0 +stimulation 0 +had 0 +an 0 +antidyskinetic 0 +effect 0 +and 0 +it 0 +was 0 +paralleled 0 +by 0 +a 0 +resurgence 0 +in 0 +the 0 +sensorimotor 0 +plasticity 0 +of 0 +M1 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +alterations 0 +in 0 +cerebellar 0 +sensory 0 +processing 0 +function 0 +, 0 +occurring 0 +secondary 0 +to 0 +abnormal 0 +basal 0 +ganglia 0 +signals 0 +reaching 0 +it 0 +, 0 +may 0 +be 0 +an 0 +important 0 +element 0 +contributing 0 +to 0 +the 0 +maladaptive 0 +sensorimotor 0 +plasticity 0 +of 0 +M1 0 +and 0 +the 0 +emergence 0 +of 0 +abnormal 3 +involuntary 4 +movements 4 +. 0 + +The 0 +long 0 +- 0 +term 0 +safety 0 +of 0 +danazol 1 +in 0 +women 0 +with 0 +hereditary 3 +angioedema 4 +. 0 + +Although 0 +the 0 +short 0 +- 0 +term 0 +safety 0 +( 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +6 0 +months 0 +) 0 +of 0 +danazol 1 +has 0 +been 0 +established 0 +in 0 +a 0 +variety 0 +of 0 +settings 0 +, 0 +no 0 +information 0 +exists 0 +as 0 +to 0 +its 0 +long 0 +- 0 +term 0 +safety 0 +. 0 + +We 0 +therefore 0 +investigated 0 +the 0 +long 0 +- 0 +term 0 +safety 0 +of 0 +danazol 1 +by 0 +performing 0 +a 0 +retrospective 0 +chart 0 +review 0 +of 0 +60 0 +female 0 +patients 0 +with 0 +hereditary 3 +angioedema 4 +treated 0 +with 0 +danazol 1 +for 0 +a 0 +continuous 0 +period 0 +of 0 +6 0 +months 0 +or 0 +longer 0 +. 0 + +The 0 +mean 0 +age 0 +of 0 +the 0 +patients 0 +was 0 +35 0 +. 0 +2 0 +years 0 +and 0 +the 0 +mean 0 +duration 0 +of 0 +therapy 0 +was 0 +59 0 +. 0 +7 0 +months 0 +. 0 + +Virtually 0 +all 0 +patients 0 +experienced 0 +one 0 +or 0 +more 0 +adverse 0 +reactions 0 +. 0 + +Menstrual 3 +abnormalities 4 +( 0 +79 0 +% 0 +) 0 +, 0 +weight 3 +gain 4 +( 0 +60 0 +% 0 +) 0 +, 0 +muscle 3 +cramps 4 +/ 0 +myalgias 3 +( 0 +40 0 +% 0 +) 0 +, 0 +and 0 +transaminase 0 +elevations 0 +( 0 +40 0 +% 0 +) 0 +were 0 +the 0 +most 0 +common 0 +adverse 0 +reactions 0 +. 0 + +The 0 +drug 0 +was 0 +discontinued 0 +due 0 +to 0 +adverse 0 +reactions 0 +in 0 +8 0 +patients 0 +. 0 + +No 0 +patient 0 +has 0 +died 0 +or 0 +suffered 0 +any 0 +apparent 0 +long 0 +- 0 +term 0 +sequelae 0 +that 0 +were 0 +directly 0 +attributable 0 +to 0 +the 0 +drug 0 +. 0 + +We 0 +conclude 0 +that 0 +, 0 +despite 0 +a 0 +relatively 0 +high 0 +incidence 0 +of 0 +adverse 0 +reactions 0 +, 0 +danazol 1 +has 0 +proven 0 +to 0 +be 0 +remarkably 0 +safe 0 +over 0 +the 0 +long 0 +- 0 +term 0 +in 0 +this 0 +group 0 +of 0 +patients 0 +. 0 + +The 0 +function 0 +of 0 +P2X3 0 +receptor 0 +and 0 +NK1 0 +receptor 0 +antagonists 0 +on 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +in 0 +rats 0 +. 0 + +PURP0SE 0 +: 0 +The 0 +purpose 0 +of 0 +the 0 +study 0 +is 0 +to 0 +explore 0 +the 0 +function 0 +of 0 +P2X3 0 +and 0 +NK1 0 +receptors 0 +antagonists 0 +on 0 +cyclophosphamide 1 +( 0 +CYP 1 +) 0 +- 0 +induced 0 +cystitis 3 +in 0 +rats 0 +. 0 + +METH0DS 0 +: 0 +Sixty 0 +female 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +rats 0 +were 0 +randomly 0 +divided 0 +into 0 +three 0 +groups 0 +. 0 + +The 0 +rats 0 +in 0 +the 0 +control 0 +group 0 +were 0 +intraperitoneally 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +injected 0 +with 0 +0 0 +. 0 +9 0 +% 0 +saline 0 +( 0 +4 0 +ml 0 +/ 0 +kg 0 +) 0 +; 0 +the 0 +rats 0 +in 0 +the 0 +model 0 +group 0 +were 0 +i 0 +. 0 +p 0 +. 0 +injected 0 +with 0 +CYP 1 +( 0 +150 0 +mg 0 +/ 0 +kg 0 +) 0 +; 0 +and 0 +the 0 +rats 0 +in 0 +the 0 +intervention 0 +group 0 +were 0 +i 0 +. 0 +p 0 +. 0 +injected 0 +with 0 +CYP 1 +with 0 +subsequently 0 +perfusion 0 +of 0 +bladder 0 +with 0 +P2X3 0 +and 0 +NK1 0 +receptors 0 +' 0 +antagonists 0 +, 0 +Suramin 1 +and 0 +GR 1 +82334 2 +. 0 + +Spontaneous 0 +pain 3 +behaviors 0 +following 0 +the 0 +administration 0 +of 0 +CYP 1 +were 0 +observed 0 +. 0 + +Urodynamic 0 +parameters 0 +, 0 +bladder 0 +pressure 0 +- 0 +volume 0 +curve 0 +, 0 +maximum 0 +voiding 0 +pressure 0 +( 0 +MVP 0 +) 0 +, 0 +and 0 +maximum 0 +cystometric 0 +capacity 0 +( 0 +MCC 0 +) 0 +, 0 +were 0 +recorded 0 +. 0 + +Pathological 0 +changes 0 +in 0 +bladder 0 +tissue 0 +were 0 +observed 0 +. 0 + +Immunofluorescence 0 +was 0 +used 0 +to 0 +detect 0 +the 0 +expression 0 +of 0 +P2X3 0 +and 0 +NK1 0 +receptors 0 +in 0 +bladder 0 +. 0 + +RESULTS 0 +: 0 +Cyclophosphamide 1 +treatment 0 +increased 0 +the 0 +spontaneous 0 +pain 3 +behaviors 0 +scores 0 +. 0 + +The 0 +incidence 0 +of 0 +bladder 0 +instability 0 +during 0 +urine 0 +storage 0 +period 0 +of 0 +model 0 +group 0 +was 0 +significantly 0 +higher 0 +than 0 +intervention 0 +group 0 +( 0 +X 0 +( 0 +2 0 +) 0 += 0 +7 0 +. 0 +619 0 +, 0 +P 0 += 0 +0 0 +. 0 +007 0 +) 0 +and 0 +control 0 +group 0 +( 0 +X 0 +( 0 +2 0 +) 0 += 0 +13 0 +. 0 +755 0 +, 0 +P 0 += 0 +0 0 +. 0 +000 0 +) 0 +. 0 + +MCC 0 +in 0 +the 0 +model 0 +group 0 +was 0 +lower 0 +than 0 +the 0 +control 0 +and 0 +intervention 0 +groups 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Histological 0 +changes 0 +evident 0 +in 0 +model 0 +and 0 +intervention 0 +groups 0 +rats 0 +' 0 +bladder 0 +included 0 +edema 3 +, 0 +vasodilation 0 +, 0 +and 0 +infiltration 0 +of 0 +inflammatory 0 +cells 0 +. 0 + +In 0 +model 0 +group 0 +, 0 +the 0 +expression 0 +of 0 +P2X3 0 +receptor 0 +increased 0 +in 0 +urothelium 0 +and 0 +suburothelium 0 +, 0 +and 0 +NK1 0 +receptor 0 +increased 0 +in 0 +suburothelium 0 +, 0 +while 0 +the 0 +expression 0 +of 0 +them 0 +in 0 +intervention 0 +group 0 +was 0 +lower 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +CYP 1 +- 0 +induced 0 +cystitis 3 +, 0 +the 0 +expression 0 +of 0 +P2X3 0 +and 0 +NK1 0 +receptors 0 +increased 0 +in 0 +urothelium 0 +and 0 +/ 0 +or 0 +suburothelium 0 +. 0 + +Perfusion 0 +of 0 +bladder 0 +with 0 +P2X3 0 +and 0 +NK1 0 +receptors 0 +antagonists 0 +ameliorated 0 +the 0 +bladder 0 +function 0 +. 0 + +Patient 0 +tolerance 0 +study 0 +of 0 +topical 0 +chlorhexidine 1 +diphosphanilate 2 +: 0 +a 0 +new 0 +topical 0 +agent 0 +for 0 +burns 3 +. 0 + +Effective 0 +topical 0 +antimicrobial 0 +agents 0 +decrease 0 +infection 3 +and 0 +mortality 0 +in 0 +burn 3 +patients 0 +. 0 + +Chlorhexidine 1 +phosphanilate 2 +( 0 +CHP 1 +) 0 +, 0 +a 0 +new 0 +broad 0 +- 0 +spectrum 0 +antimicrobial 0 +agent 0 +, 0 +has 0 +been 0 +evaluated 0 +as 0 +a 0 +topical 0 +burn 3 +wound 0 +dressing 0 +in 0 +cream 0 +form 0 +, 0 +but 0 +preliminary 0 +clinical 0 +trials 0 +reported 0 +that 0 +it 0 +was 0 +painful 0 +upon 0 +application 0 +. 0 + +This 0 +study 0 +compared 0 +various 0 +concentrations 0 +of 0 +CHP 1 +to 0 +determine 0 +if 0 +a 0 +tolerable 0 +concentration 0 +could 0 +be 0 +identified 0 +with 0 +retention 0 +of 0 +antimicrobial 0 +efficacy 0 +. 0 + +Twenty 0 +- 0 +nine 0 +burn 3 +patients 0 +, 0 +each 0 +with 0 +two 0 +similar 0 +burns 3 +which 0 +could 0 +be 0 +separately 0 +treated 0 +, 0 +were 0 +given 0 +pairs 0 +of 0 +treatments 0 +at 0 +successive 0 +12 0 +- 0 +h 0 +intervals 0 +over 0 +a 0 +3 0 +- 0 +day 0 +period 0 +. 0 + +0ne 0 +burn 3 +site 0 +was 0 +treated 0 +with 0 +each 0 +of 0 +four 0 +different 0 +CHP 1 +concentrations 0 +, 0 +from 0 +0 0 +. 0 +25 0 +per 0 +cent 0 +to 0 +2 0 +per 0 +cent 0 +, 0 +their 0 +vehicle 0 +, 0 +and 0 +1 0 +per 0 +cent 0 +silver 1 +sulphadiazine 2 +( 0 +AgSD 1 +) 0 +cream 0 +, 0 +an 0 +antimicrobial 0 +agent 0 +frequently 0 +used 0 +for 0 +topical 0 +treatment 0 +of 0 +burn 3 +wounds 0 +. 0 + +The 0 +other 0 +site 0 +was 0 +always 0 +treated 0 +with 0 +AgSD 1 +cream 0 +. 0 + +There 0 +was 0 +a 0 +direct 0 +relationship 0 +between 0 +CHP 1 +concentration 0 +and 0 +patients 0 +' 0 +ratings 0 +of 0 +pain 3 +on 0 +an 0 +analogue 0 +scale 0 +. 0 + +The 0 +0 0 +. 0 +25 0 +per 0 +cent 0 +CHP 1 +cream 0 +was 0 +closest 0 +to 0 +AgSD 1 +in 0 +pain 3 +tolerance 0 +; 0 +however 0 +, 0 +none 0 +of 0 +the 0 +treatments 0 +differed 0 +statistically 0 +from 0 +AgSD 1 +or 0 +from 0 +each 0 +other 0 +. 0 + +In 0 +addition 0 +, 0 +ease 0 +of 0 +application 0 +of 0 +CHP 1 +creams 0 +was 0 +less 0 +satisfactory 0 +than 0 +that 0 +of 0 +AgSD 1 +. 0 + +It 0 +was 0 +concluded 0 +that 0 +formulations 0 +at 0 +or 0 +below 0 +0 0 +. 0 +5 0 +per 0 +cent 0 +CHP 1 +may 0 +prove 0 +acceptable 0 +for 0 +wound 0 +care 0 +, 0 +but 0 +the 0 +vehicle 0 +system 0 +needs 0 +pharmaceutical 0 +improvement 0 +to 0 +render 0 +it 0 +more 0 +tolerable 0 +and 0 +easier 0 +to 0 +use 0 +. 0 + +Acute 0 +hepatitis 3 +associated 0 +with 0 +clopidogrel 1 +: 0 +a 0 +case 0 +report 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +Drug 0 +- 0 +induced 0 +hepatotoxicity 3 +is 0 +a 0 +common 0 +cause 0 +of 0 +acute 0 +hepatitis 3 +, 0 +and 0 +the 0 +recognition 0 +of 0 +the 0 +responsible 0 +drug 0 +may 0 +be 0 +difficult 0 +. 0 + +We 0 +describe 0 +a 0 +case 0 +of 0 +clopidogrel 1 +- 0 +related 0 +acute 0 +hepatitis 3 +. 0 + +The 0 +diagnosis 0 +is 0 +strongly 0 +suggested 0 +by 0 +an 0 +accurate 0 +medical 0 +history 0 +and 0 +liver 0 +biopsy 0 +. 0 + +Reports 0 +about 0 +cases 0 +of 0 +hepatotoxicity 3 +due 0 +to 0 +clopidogrel 1 +are 0 +increasing 0 +in 0 +the 0 +last 0 +few 0 +years 0 +, 0 +after 0 +the 0 +increased 0 +use 0 +of 0 +this 0 +drug 0 +. 0 + +In 0 +conclusion 0 +, 0 +we 0 +believe 0 +that 0 +physicians 0 +should 0 +carefully 0 +consider 0 +the 0 +risk 0 +of 0 +drug 0 +- 0 +induced 0 +hepatic 3 +injury 4 +when 0 +clopidogrel 1 +is 0 +prescribed 0 +. 0 + +Bortezomib 1 +and 0 +dexamethasone 1 +as 0 +salvage 0 +therapy 0 +in 0 +patients 0 +with 0 +relapsed 0 +/ 0 +refractory 0 +multiple 3 +myeloma 4 +: 0 +analysis 0 +of 0 +long 0 +- 0 +term 0 +clinical 0 +outcomes 0 +. 0 + +Bortezomib 1 +( 0 +bort 1 +) 0 +- 0 +dexamethasone 1 +( 0 +dex 1 +) 0 +is 0 +an 0 +effective 0 +therapy 0 +for 0 +relapsed 0 +/ 0 +refractory 0 +( 0 +R 0 +/ 0 +R 0 +) 0 +multiple 3 +myeloma 4 +( 0 +MM 3 +) 0 +. 0 + +This 0 +retrospective 0 +study 0 +investigated 0 +the 0 +combination 0 +of 0 +bort 1 +( 0 +1 0 +. 0 +3 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +on 0 +days 0 +1 0 +, 0 +4 0 +, 0 +8 0 +, 0 +and 0 +11 0 +every 0 +3 0 +weeks 0 +) 0 +and 0 +dex 1 +( 0 +20 0 +mg 0 +on 0 +the 0 +day 0 +of 0 +and 0 +the 0 +day 0 +after 0 +bort 1 +) 0 +as 0 +salvage 0 +treatment 0 +in 0 +85 0 +patients 0 +with 0 +R 0 +/ 0 +R 0 +MM 3 +after 0 +prior 0 +autologous 0 +stem 0 +cell 0 +transplantation 0 +or 0 +conventional 0 +chemotherapy 0 +. 0 + +The 0 +median 0 +number 0 +of 0 +prior 0 +lines 0 +of 0 +therapy 0 +was 0 +2 0 +. 0 + +Eighty 0 +- 0 +seven 0 +percent 0 +of 0 +the 0 +patients 0 +had 0 +received 0 +immunomodulatory 0 +drugs 0 +included 0 +in 0 +some 0 +line 0 +of 0 +therapy 0 +before 0 +bort 1 +- 0 +dex 1 +. 0 + +The 0 +median 0 +number 0 +of 0 +bort 1 +- 0 +dex 1 +cycles 0 +was 0 +6 0 +, 0 +up 0 +to 0 +a 0 +maximum 0 +of 0 +12 0 +cycles 0 +. 0 + +0n 0 +an 0 +intention 0 +- 0 +to 0 +- 0 +treat 0 +basis 0 +, 0 +55 0 +% 0 +of 0 +the 0 +patients 0 +achieved 0 +at 0 +least 0 +partial 0 +response 0 +, 0 +including 0 +19 0 +% 0 +CR 0 +and 0 +35 0 +% 0 +achieved 0 +at 0 +least 0 +very 0 +good 0 +partial 0 +response 0 +. 0 + +Median 0 +durations 0 +of 0 +response 0 +, 0 +time 0 +to 0 +next 0 +therapy 0 +and 0 +treatment 0 +- 0 +free 0 +interval 0 +were 0 +8 0 +, 0 +11 0 +. 0 +2 0 +, 0 +and 0 +5 0 +. 0 +1 0 +months 0 +, 0 +respectively 0 +. 0 + +The 0 +most 0 +relevant 0 +adverse 0 +event 0 +was 0 +peripheral 3 +neuropathy 4 +, 0 +which 0 +occurred 0 +in 0 +78 0 +% 0 +of 0 +the 0 +patients 0 +( 0 +grade 0 +II 0 +, 0 +38 0 +% 0 +; 0 +grade 0 +III 0 +, 0 +21 0 +% 0 +) 0 +and 0 +led 0 +to 0 +treatment 0 +discontinuation 0 +in 0 +6 0 +% 0 +. 0 + +With 0 +a 0 +median 0 +follow 0 +up 0 +of 0 +22 0 +months 0 +, 0 +median 0 +time 0 +to 0 +progression 0 +, 0 +progression 0 +- 0 +free 0 +survival 0 +( 0 +PFS 0 +) 0 +and 0 +overall 0 +survival 0 +( 0 +0S 0 +) 0 +were 0 +8 0 +. 0 +9 0 +, 0 +8 0 +. 0 +7 0 +, 0 +and 0 +22 0 +months 0 +, 0 +respectively 0 +. 0 + +Prolonged 0 +PFS 0 +and 0 +0S 0 +were 0 +observed 0 +in 0 +patients 0 +achieving 0 +CR 0 +and 0 +receiving 0 +bort 1 +- 0 +dex 1 +a 0 +single 0 +line 0 +of 0 +prior 0 +therapy 0 +. 0 + +Bort 1 +- 0 +dex 1 +was 0 +an 0 +effective 0 +salvage 0 +treatment 0 +for 0 +MM 3 +patients 0 +, 0 +particularly 0 +for 0 +those 0 +in 0 +first 0 +relapse 0 +. 0 + +Pubertal 0 +exposure 0 +to 0 +Bisphenol 1 +A 2 +increases 0 +anxiety 3 +- 0 +like 0 +behavior 0 +and 0 +decreases 0 +acetylcholinesterase 0 +activity 0 +of 0 +hippocampus 0 +in 0 +adult 0 +male 0 +mice 0 +. 0 + +The 0 +negative 0 +effects 0 +of 0 +Bisphenol 1 +A 2 +( 0 +BPA 1 +) 0 +on 0 +neurodevelopment 0 +and 0 +behaviors 0 +have 0 +been 0 +well 0 +established 0 +. 0 + +Acetylcholinesterase 0 +( 0 +AChE 0 +) 0 +is 0 +a 0 +regulatory 0 +enzyme 0 +which 0 +is 0 +involved 0 +in 0 +anxiety 3 +- 0 +like 0 +behavior 0 +. 0 + +This 0 +study 0 +investigated 0 +behavioral 0 +phenotypes 0 +and 0 +AChE 0 +activity 0 +in 0 +male 0 +mice 0 +following 0 +BPA 1 +exposure 0 +during 0 +puberty 0 +. 0 + +0n 0 +postnatal 0 +day 0 +( 0 +PND 0 +) 0 +35 0 +, 0 +male 0 +mice 0 +were 0 +exposed 0 +to 0 +50mg 0 +BPA 1 +/ 0 +kg 0 +diet 0 +per 0 +day 0 +for 0 +a 0 +period 0 +of 0 +35 0 +days 0 +. 0 + +0n 0 +PND71 0 +, 0 +a 0 +behavioral 0 +assay 0 +was 0 +performed 0 +using 0 +the 0 +elevated 0 +plus 0 +maze 0 +( 0 +EPM 0 +) 0 +and 0 +the 0 +light 0 +/ 0 +dark 0 +test 0 +. 0 + +In 0 +addition 0 +, 0 +AChE 0 +activity 0 +was 0 +measured 0 +in 0 +the 0 +prefrontal 0 +cortex 0 +, 0 +hypothalamus 0 +, 0 +cerebellum 0 +and 0 +hippocampus 0 +. 0 + +Results 0 +from 0 +our 0 +behavioral 0 +phenotyping 0 +indicated 0 +that 0 +anxiety 3 +- 0 +like 0 +behavior 0 +was 0 +increased 0 +in 0 +mice 0 +exposed 0 +to 0 +BPA 1 +. 0 + +AChE 0 +activity 0 +was 0 +significantly 0 +decreased 0 +in 0 +the 0 +hippocampus 0 +of 0 +mice 0 +with 0 +BPA 1 +compared 0 +to 0 +control 0 +mice 0 +, 0 +whereas 0 +no 0 +difference 0 +was 0 +found 0 +in 0 +the 0 +prefrontal 0 +cortex 0 +, 0 +hypothalamus 0 +and 0 +cerebellum 0 +. 0 + +0ur 0 +findings 0 +showed 0 +that 0 +pubertal 0 +BPA 1 +exposure 0 +increased 0 +anxiety 3 +- 0 +like 0 +behavior 0 +, 0 +which 0 +may 0 +be 0 +associated 0 +with 0 +decreased 0 +AChE 0 +activity 0 +of 0 +the 0 +hippocampus 0 +in 0 +adult 0 +male 0 +mice 0 +. 0 + +Further 0 +studies 0 +are 0 +necessary 0 +to 0 +investigate 0 +the 0 +cholinergic 0 +signaling 0 +of 0 +the 0 +hippocampus 0 +in 0 +PBE 0 +induced 0 +anxiety 3 +- 0 +like 0 +behaviors 0 +. 0 + +Biochemical 0 +effects 0 +of 0 +Solidago 0 +virgaurea 0 +extract 0 +on 0 +experimental 0 +cardiotoxicity 3 +. 0 + +Cardiovascular 3 +diseases 4 +( 0 +CVDs 3 +) 0 +are 0 +the 0 +major 0 +health 0 +problem 0 +of 0 +advanced 0 +as 0 +well 0 +as 0 +developing 0 +countries 0 +of 0 +the 0 +world 0 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +protective 0 +effect 0 +of 0 +the 0 +Solidago 0 +virgaurea 0 +extract 0 +on 0 +isoproterenol 1 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +rats 0 +. 0 + +The 0 +subcutaneous 0 +injection 0 +of 0 +isoproterenol 1 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +into 0 +rats 0 +twice 0 +at 0 +an 0 +interval 0 +of 0 +24 0 +h 0 +, 0 +for 0 +two 0 +consecutive 0 +days 0 +, 0 +led 0 +to 0 +a 0 +significant 0 +increase 0 +in 0 +serum 0 +lactate 1 +dehydrogenase 0 +, 0 +creatine 1 +phosphokinase 0 +, 0 +alanine 1 +transaminase 0 +, 0 +aspartate 1 +transaminase 0 +, 0 +and 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +activities 0 +, 0 +total 0 +cholesterol 1 +, 0 +triglycerides 1 +, 0 +free 0 +serum 0 +fatty 1 +acid 2 +, 0 +cardiac 0 +tissue 0 +malondialdehyde 1 +( 0 +MDA 1 +) 0 +, 0 +and 0 +nitric 1 +oxide 2 +levels 0 +and 0 +a 0 +significant 0 +decrease 0 +in 0 +levels 0 +of 0 +glutathione 1 +and 0 +superoxide 1 +dismutase 0 +in 0 +cardiac 0 +tissue 0 +as 0 +compared 0 +to 0 +the 0 +normal 0 +control 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Pretreatment 0 +with 0 +S 0 +. 0 +virgaurea 0 +extract 0 +for 0 +5 0 +weeks 0 +at 0 +a 0 +dose 0 +of 0 +250 0 +mg 0 +/ 0 +kg 0 +followed 0 +by 0 +isoproterenol 1 +injection 0 +significantly 0 +prevented 0 +the 0 +observed 0 +alterations 0 +. 0 + +Captopril 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +, 0 +given 0 +orally 0 +) 0 +, 0 +an 0 +inhibitor 0 +of 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +used 0 +as 0 +a 0 +standard 0 +cardioprotective 0 +drug 0 +, 0 +was 0 +used 0 +as 0 +a 0 +positive 0 +control 0 +in 0 +this 0 +study 0 +. 0 + +The 0 +data 0 +of 0 +the 0 +present 0 +study 0 +suggest 0 +that 0 +S 0 +. 0 +virgaurea 0 +extract 0 +exerts 0 +its 0 +protective 0 +effect 0 +by 0 +decreasing 0 +MDA 1 +level 0 +and 0 +increasing 0 +the 0 +antioxidant 0 +status 0 +in 0 +isoproterenol 1 +- 0 +treated 0 +rats 0 +. 0 + +The 0 +study 0 +emphasizes 0 +the 0 +beneficial 0 +action 0 +of 0 +S 0 +. 0 +virgaurea 0 +extract 0 +as 0 +a 0 +cardioprotective 0 +agent 0 +. 0 + +" 0 +Real 0 +- 0 +world 0 +" 0 +data 0 +on 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +lenalidomide 1 +and 0 +dexamethasone 1 +in 0 +patients 0 +with 0 +relapsed 0 +/ 0 +refractory 0 +multiple 3 +myeloma 4 +who 0 +were 0 +treated 0 +according 0 +to 0 +the 0 +standard 0 +clinical 0 +practice 0 +: 0 +a 0 +study 0 +of 0 +the 0 +Greek 0 +Myeloma 3 +Study 0 +Group 0 +. 0 + +Lenalidomide 1 +and 0 +dexamethasone 1 +( 0 +RD 1 +) 0 +is 0 +a 0 +standard 0 +of 0 +care 0 +for 0 +relapsed 0 +/ 0 +refractory 0 +multiple 3 +myeloma 4 +( 0 +RRMM 3 +) 0 +, 0 +but 0 +there 0 +is 0 +limited 0 +published 0 +data 0 +on 0 +its 0 +efficacy 0 +and 0 +safety 0 +in 0 +the 0 +" 0 +real 0 +world 0 +" 0 +( 0 +RW 0 +) 0 +, 0 +according 0 +to 0 +the 0 +International 0 +Society 0 +of 0 +Pharmacoeconomics 0 +and 0 +0utcomes 0 +Research 0 +definition 0 +. 0 + +We 0 +studied 0 +212 0 +RRMM 3 +patients 0 +who 0 +received 0 +RD 1 +in 0 +RW 0 +. 0 + +0bjective 0 +response 0 +( 0 +> 0 +PR 0 +( 0 +partial 0 +response 0 +) 0 +) 0 +rate 0 +was 0 +77 0 +. 0 +4 0 +% 0 +( 0 +complete 0 +response 0 +( 0 +CR 0 +) 0 +, 0 +20 0 +. 0 +2 0 +% 0 +) 0 +. 0 + +Median 0 +time 0 +to 0 +first 0 +and 0 +best 0 +response 0 +was 0 +2 0 +and 0 +5 0 +months 0 +, 0 +respectively 0 +. 0 + +Median 0 +time 0 +to 0 +CR 0 +when 0 +RD 1 +was 0 +given 0 +as 0 +2nd 0 +or 0 +> 0 +2 0 +( 0 +nd 0 +) 0 +- 0 +line 0 +treatment 0 +at 0 +4 0 +and 0 +11 0 +months 0 +, 0 +respectively 0 +. 0 + +Quality 0 +of 0 +response 0 +was 0 +independent 0 +of 0 +previous 0 +lines 0 +of 0 +therapies 0 +or 0 +previous 0 +exposure 0 +to 0 +thalidomide 1 +or 0 +bortezomib 1 +. 0 + +Median 0 +duration 0 +of 0 +response 0 +was 0 +34 0 +. 0 +4 0 +months 0 +, 0 +and 0 +it 0 +was 0 +higher 0 +in 0 +patients 0 +who 0 +received 0 +RD 1 +until 0 +progression 0 +( 0 +not 0 +reached 0 +versus 0 +19 0 +months 0 +, 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Improvement 0 +of 0 +humoral 0 +immunity 0 +occurred 0 +in 0 +60 0 +% 0 +of 0 +responders 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +and 0 +in 0 +the 0 +majority 0 +of 0 +patients 0 +who 0 +achieved 0 +stable 0 +disease 0 +. 0 + +Adverse 0 +events 0 +were 0 +reported 0 +in 0 +68 0 +. 0 +9 0 +% 0 +of 0 +patients 0 +( 0 +myelosuppression 3 +in 0 +49 0 +. 0 +4 0 +% 0 +) 0 +and 0 +12 0 +. 0 +7 0 +% 0 +of 0 +patients 0 +needed 0 +hospitalization 0 +. 0 + +Peripheral 3 +neuropathy 4 +was 0 +observed 0 +only 0 +in 0 +2 0 +. 0 +5 0 +% 0 +of 0 +patients 0 +and 0 +deep 3 +vein 4 +thrombosis 4 +in 0 +5 0 +. 0 +7 0 +% 0 +. 0 + +Dose 0 +reductions 0 +were 0 +needed 0 +in 0 +31 0 +% 0 +of 0 +patients 0 +and 0 +permanent 0 +discontinuation 0 +in 0 +38 0 +. 0 +9 0 +% 0 +. 0 + +Median 0 +time 0 +to 0 +treatment 0 +discontinuation 0 +was 0 +16 0 +. 0 +8 0 +months 0 +. 0 + +Performance 0 +status 0 +( 0 +PS 0 +) 0 +and 0 +initial 0 +lenalidomide 1 +dose 0 +predicted 0 +for 0 +treatment 0 +discontinuation 0 +. 0 + +Extra 0 +- 0 +medullary 0 +relapses 0 +occurred 0 +in 0 +3 0 +. 0 +8 0 +% 0 +of 0 +patients 0 +. 0 + +0ur 0 +study 0 +confirms 0 +that 0 +RD 1 +is 0 +effective 0 +and 0 +safe 0 +in 0 +RRMM 3 +in 0 +the 0 +RW 0 +; 0 +it 0 +produces 0 +durable 0 +responses 0 +especially 0 +in 0 +patients 0 +who 0 +continue 0 +on 0 +treatment 0 +till 0 +progression 0 +and 0 +improves 0 +humoral 0 +immunity 0 +even 0 +in 0 +patients 0 +with 0 +stable 0 +disease 0 +. 0 + +The 0 +cytogenetic 0 +action 0 +of 0 +ifosfamide 1 +, 0 +mesna 1 +, 0 +and 0 +their 0 +combination 0 +on 0 +peripheral 0 +rabbit 0 +lymphocytes 0 +: 0 +an 0 +in 0 +vivo 0 +/ 0 +in 0 +vitro 0 +cytogenetic 0 +study 0 +. 0 + +Ifosfamide 1 +( 0 +IF0 1 +) 0 +is 0 +an 0 +alkylating 0 +nitrogen 1 +mustard 0 +, 0 +administrated 0 +as 0 +an 0 +antineoplasmic 0 +agent 0 +. 0 + +It 0 +is 0 +characterized 0 +by 0 +its 0 +intense 0 +urotoxic 0 +action 0 +, 0 +leading 0 +to 0 +hemorrhagic 3 +cystitis 4 +. 0 + +This 0 +side 0 +effect 0 +of 0 +IF0 1 +raises 0 +the 0 +requirement 0 +for 0 +the 0 +co 0 +- 0 +administration 0 +with 0 +sodium 1 +2 2 +- 2 +sulfanylethanesulfonate 2 +( 0 +Mesna 1 +) 0 +aiming 0 +to 0 +avoid 0 +or 0 +minimize 0 +this 0 +effect 0 +. 0 + +IF0 1 +and 0 +Mesna 1 +were 0 +administrated 0 +separately 0 +on 0 +rabbit 0 +' 0 +s 0 +lymphocytes 0 +in 0 +vivo 0 +, 0 +which 0 +were 0 +later 0 +developed 0 +in 0 +vitro 0 +. 0 + +Cytogenetic 0 +markers 0 +for 0 +sister 0 +chromatid 0 +exchanges 0 +( 0 +SCEs 0 +) 0 +, 0 +proliferation 0 +rate 0 +index 0 +( 0 +PRI 0 +) 0 +and 0 +Mitotic 0 +Index 0 +were 0 +recorded 0 +. 0 + +Mesna 1 +' 0 +s 0 +action 0 +, 0 +in 0 +conjunction 0 +with 0 +IF0 1 +reduces 0 +the 0 +frequency 0 +of 0 +SCEs 0 +, 0 +in 0 +comparison 0 +with 0 +the 0 +SCEs 0 +recordings 0 +obtained 0 +when 0 +IF0 1 +is 0 +administered 0 +alone 0 +. 0 + +In 0 +addition 0 +to 0 +this 0 +, 0 +when 0 +high 0 +concentrations 0 +of 0 +Mesna 1 +were 0 +administered 0 +alone 0 +significant 0 +reductions 0 +of 0 +the 0 +PRI 0 +were 0 +noted 0 +, 0 +than 0 +with 0 +IF0 1 +acting 0 +at 0 +the 0 +same 0 +concentration 0 +on 0 +the 0 +lymphocytes 0 +. 0 + +Mesna 1 +significantly 0 +reduces 0 +IF0 1 +' 0 +s 0 +genotoxicity 3 +, 0 +while 0 +when 0 +administered 0 +in 0 +high 0 +concentrations 0 +it 0 +acts 0 +in 0 +an 0 +inhibitory 0 +fashion 0 +on 0 +the 0 +cytostatic 0 +action 0 +of 0 +the 0 +drug 0 +. 0 + +Risk 0 +factors 0 +and 0 +predictors 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +among 0 +multiethnic 0 +Malaysians 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Chronic 0 +pulsatile 0 +levodopa 1 +therapy 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +leads 0 +to 0 +the 0 +development 0 +of 0 +motor 0 +fluctuations 0 +and 0 +dyskinesia 3 +. 0 + +We 0 +studied 0 +the 0 +prevalence 0 +and 0 +predictors 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +among 0 +multiethnic 0 +Malaysian 0 +patients 0 +with 0 +PD 3 +. 0 + +METH0DS 0 +: 0 +This 0 +is 0 +a 0 +cross 0 +- 0 +sectional 0 +study 0 +involving 0 +95 0 +patients 0 +with 0 +PD 3 +on 0 +uninterrupted 0 +levodopa 1 +therapy 0 +for 0 +at 0 +least 0 +6 0 +months 0 +. 0 + +The 0 +instrument 0 +used 0 +was 0 +the 0 +UPDRS 0 +questionnaires 0 +. 0 + +The 0 +predictors 0 +of 0 +dyskinesia 3 +were 0 +determined 0 +using 0 +multivariate 0 +logistic 0 +regression 0 +analysis 0 +. 0 + +RESULTS 0 +: 0 +The 0 +mean 0 +age 0 +was 0 +65 0 +. 0 +6 0 ++ 0 +8 0 +. 0 +5 0 +years 0 +. 0 + +The 0 +mean 0 +onset 0 +age 0 +was 0 +58 0 +. 0 +5 0 ++ 0 +9 0 +. 0 +8 0 +years 0 +. 0 + +The 0 +median 0 +disease 0 +duration 0 +was 0 +6 0 +( 0 +7 0 +) 0 +years 0 +. 0 + +Dyskinesia 3 +was 0 +present 0 +in 0 +44 0 +% 0 +( 0 +n 0 += 0 +42 0 +) 0 +with 0 +median 0 +levodopa 1 +therapy 0 +of 0 +3 0 +years 0 +. 0 + +There 0 +were 0 +64 0 +. 0 +3 0 +% 0 +Chinese 0 +, 0 +31 0 +% 0 +Malays 0 +, 0 +and 0 +3 0 +. 0 +7 0 +% 0 +Indians 0 +and 0 +other 0 +ethnic 0 +groups 0 +. 0 + +Eighty 0 +- 0 +one 0 +percent 0 +of 0 +patients 0 +with 0 +dyskinesia 3 +had 0 +clinical 0 +fluctuations 0 +. 0 + +Patients 0 +with 0 +dyskinesia 3 +had 0 +lower 0 +onset 0 +age 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +longer 0 +duration 0 +of 0 +levodopa 1 +therapy 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +longer 0 +disease 0 +duration 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +higher 0 +total 0 +daily 0 +levodopa 1 +dose 0 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +, 0 +and 0 +higher 0 +total 0 +UPDRS 0 +scores 0 +( 0 +p 0 += 0 +0 0 +. 0 +005 0 +) 0 +than 0 +patients 0 +without 0 +dyskinesia 3 +. 0 + +The 0 +three 0 +significant 0 +predictors 0 +of 0 +dyskinesia 3 +were 0 +duration 0 +of 0 +levodopa 1 +therapy 0 +, 0 +onset 0 +age 0 +, 0 +and 0 +total 0 +daily 0 +levodopa 1 +dose 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +prevalence 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +in 0 +our 0 +patients 0 +was 0 +44 0 +% 0 +. 0 + +The 0 +most 0 +significant 0 +predictors 0 +were 0 +duration 0 +of 0 +levodopa 1 +therapy 0 +, 0 +total 0 +daily 0 +levodopa 1 +dose 0 +, 0 +and 0 +onset 0 +age 0 +. 0 + +Dose 0 +- 0 +dependent 0 +neurotoxicity 3 +of 0 +high 0 +- 0 +dose 0 +busulfan 1 +in 0 +children 0 +: 0 +a 0 +clinical 0 +and 0 +pharmacological 0 +study 0 +. 0 + +Busulfan 1 +is 0 +known 0 +to 0 +be 0 +neurotoxic 3 +in 0 +animals 0 +and 0 +humans 0 +, 0 +but 0 +its 0 +acute 0 +neurotoxicity 3 +remains 0 +poorly 0 +characterized 0 +in 0 +children 0 +. 0 + +We 0 +report 0 +here 0 +a 0 +retrospective 0 +study 0 +of 0 +123 0 +children 0 +( 0 +median 0 +age 0 +, 0 +6 0 +. 0 +5 0 +years 0 +) 0 +receiving 0 +high 0 +- 0 +dose 0 +busulfan 1 +in 0 +combined 0 +chemotherapy 0 +before 0 +bone 0 +marrow 0 +transplantation 0 +for 0 +malignant 0 +solid 0 +tumors 3 +, 0 +brain 3 +tumors 4 +excluded 0 +. 0 + +Busulfan 1 +was 0 +given 0 +p 0 +. 0 +o 0 +. 0 +, 0 +every 0 +6 0 +hours 0 +for 0 +16 0 +doses 0 +over 0 +4 0 +days 0 +. 0 + +Two 0 +total 0 +doses 0 +were 0 +consecutively 0 +used 0 +: 0 +16 0 +mg 0 +/ 0 +kg 0 +, 0 +then 0 +600 0 +mg 0 +/ 0 +m2 0 +. 0 + +The 0 +dose 0 +calculation 0 +on 0 +the 0 +basis 0 +of 0 +body 0 +surface 0 +area 0 +results 0 +in 0 +higher 0 +doses 0 +in 0 +young 0 +children 0 +than 0 +in 0 +older 0 +patients 0 +( 0 +16 0 +to 0 +28 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +Ninety 0 +- 0 +six 0 +patients 0 +were 0 +not 0 +given 0 +anticonvulsive 0 +prophylaxis 0 +; 0 +7 0 +( 0 +7 0 +. 0 +5 0 +% 0 +) 0 +developed 0 +seizures 3 +during 0 +the 0 +4 0 +days 0 +of 0 +the 0 +busulfan 1 +course 0 +or 0 +within 0 +24 0 +h 0 +after 0 +the 0 +last 0 +dosing 0 +. 0 + +When 0 +the 0 +total 0 +busulfan 1 +dose 0 +was 0 +taken 0 +into 0 +account 0 +, 0 +there 0 +was 0 +a 0 +significant 0 +difference 0 +in 0 +terms 0 +of 0 +neurotoxicity 3 +incidence 0 +among 0 +patients 0 +under 0 +16 0 +mg 0 +/ 0 +kg 0 +( 0 +1 0 +of 0 +57 0 +, 0 +1 0 +. 0 +7 0 +% 0 +) 0 +and 0 +patients 0 +under 0 +600 0 +mg 0 +/ 0 +m2 0 +( 0 +6 0 +of 0 +39 0 +, 0 +15 0 +. 0 +4 0 +% 0 +) 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +Twenty 0 +- 0 +seven 0 +patients 0 +were 0 +given 0 +a 0 +600 0 +- 0 +mg 0 +/ 0 +m2 0 +busulfan 1 +total 0 +dose 0 +with 0 +continuous 0 +i 0 +. 0 +v 0 +. 0 +infusion 0 +of 0 +clonazepam 1 +; 0 +none 0 +had 0 +any 0 +neurological 3 +symptoms 4 +. 0 + +Busulfan 1 +levels 0 +were 0 +measured 0 +by 0 +a 0 +gas 0 +chromatographic 0 +- 0 +mass 0 +spectrometry 0 +assay 0 +in 0 +the 0 +plasma 0 +and 0 +cerebrospinal 0 +fluid 0 +of 0 +9 0 +children 0 +without 0 +central 3 +nervous 4 +system 4 +disease 4 +under 0 +600 0 +mg 0 +/ 0 +m2 0 +busulfan 1 +with 0 +clonazepam 1 +: 0 +busulfan 1 +cerebrospinal 0 +fluid 0 +: 0 +plasma 0 +ratio 0 +was 0 +1 0 +. 0 +39 0 +. 0 + +This 0 +was 0 +significantly 0 +different 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +02 0 +) 0 +from 0 +the 0 +cerebrospinal 0 +fluid 0 +: 0 +plasma 0 +ratio 0 +previously 0 +defined 0 +in 0 +children 0 +receiving 0 +a 0 +16 0 +- 0 +mg 0 +/ 0 +kg 0 +total 0 +dose 0 +of 0 +busulfan 1 +. 0 + +This 0 +study 0 +shows 0 +that 0 +busulfan 1 +neurotoxicity 3 +is 0 +dose 0 +- 0 +dependent 0 +in 0 +children 0 +and 0 +efficiently 0 +prevented 0 +by 0 +clonazepam 1 +. 0 + +A 0 +busulfan 1 +dose 0 +calculated 0 +on 0 +the 0 +basis 0 +of 0 +body 0 +surface 0 +area 0 +, 0 +resulting 0 +in 0 +higher 0 +doses 0 +in 0 +young 0 +children 0 +, 0 +was 0 +followed 0 +by 0 +increased 0 +neurotoxicity 3 +, 0 +close 0 +to 0 +neurotoxicity 3 +incidence 0 +observed 0 +in 0 +adults 0 +. 0 + +Since 0 +plasma 0 +pharmacokinetic 0 +studies 0 +showed 0 +a 0 +faster 0 +busulfan 1 +clearance 0 +in 0 +children 0 +than 0 +in 0 +adults 0 +, 0 +this 0 +new 0 +dose 0 +may 0 +approximate 0 +more 0 +closely 0 +the 0 +adult 0 +systemic 0 +exposure 0 +obtained 0 +after 0 +the 0 +usual 0 +16 0 +- 0 +mg 0 +/ 0 +kg 0 +total 0 +dose 0 +, 0 +with 0 +potential 0 +inferences 0 +in 0 +terms 0 +of 0 +anticancer 0 +or 0 +myeloablative 0 +effects 0 +. 0 + +The 0 +busulfan 1 +dose 0 +in 0 +children 0 +and 0 +infants 0 +undergoing 0 +bone 0 +marrow 0 +transplantation 0 +should 0 +be 0 +reconsidered 0 +on 0 +the 0 +basis 0 +of 0 +pharmacokinetic 0 +studies 0 +. 0 + +An 0 +unexpected 0 +diagnosis 0 +in 0 +a 0 +renal 0 +- 0 +transplant 0 +patient 0 +with 0 +proteinuria 3 +treated 0 +with 0 +everolimus 1 +: 0 +AL 3 +amyloidosis 3 +. 0 + +Proteinuria 3 +is 0 +an 0 +expected 0 +complication 0 +in 0 +transplant 0 +patients 0 +treated 0 +with 0 +mammalian 0 +target 0 +of 0 +rapamycin 1 +inhibitors 0 +( 0 +mT0R 0 +- 0 +i 0 +) 0 +. 0 + +However 0 +, 0 +clinical 0 +suspicion 0 +should 0 +always 0 +be 0 +supported 0 +by 0 +histological 0 +evidence 0 +in 0 +order 0 +to 0 +investigate 0 +potential 0 +alternate 0 +diagnoses 0 +such 0 +as 0 +acute 0 +or 0 +chronic 0 +rejection 0 +, 0 +interstitial 0 +fibrosis 3 +and 0 +tubular 0 +atrophy 3 +, 0 +or 0 +recurrent 0 +or 0 +de 0 +novo 0 +glomerulopathy 3 +. 0 + +In 0 +this 0 +case 0 +we 0 +report 0 +the 0 +unexpected 0 +diagnosis 0 +of 0 +amyloidosis 3 +in 0 +a 0 +renal 0 +- 0 +transplant 0 +patient 0 +with 0 +pre 0 +- 0 +transplant 0 +monoclonal 0 +gammapathy 0 +of 0 +undetermined 0 +significance 0 +who 0 +developed 0 +proteinuria 3 +after 0 +conversion 0 +from 0 +tacrolimus 1 +to 0 +everolimus 1 +. 0 + +Long 0 +- 0 +term 0 +oral 0 +galactose 1 +treatment 0 +prevents 0 +cognitive 3 +deficits 4 +in 0 +male 0 +Wistar 0 +rats 0 +treated 0 +intracerebroventricularly 0 +with 0 +streptozotocin 1 +. 0 + +Basic 0 +and 0 +clinical 0 +research 0 +has 0 +demonstrated 0 +that 0 +dementia 3 +of 0 +sporadic 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +( 0 +sAD 0 +) 0 +type 0 +is 0 +associated 0 +with 0 +dysfunction 0 +of 0 +the 0 +insulin 0 +- 0 +receptor 0 +( 0 +IR 0 +) 0 +system 0 +followed 0 +by 0 +decreased 0 +glucose 1 +transport 0 +via 0 +glucose 1 +transporter 0 +GLUT4 0 +and 0 +decreased 0 +glucose 1 +metabolism 0 +in 0 +brain 0 +cells 0 +. 0 + +An 0 +alternative 0 +source 0 +of 0 +energy 0 +is 0 +d 1 +- 2 +galactose 2 +( 0 +the 0 +C 0 +- 0 +4 0 +- 0 +epimer 0 +of 0 +d 1 +- 2 +glucose 2 +) 0 +which 0 +is 0 +transported 0 +into 0 +the 0 +brain 0 +by 0 +insulin 0 +- 0 +independent 0 +GLUT3 0 +transporter 0 +where 0 +it 0 +might 0 +be 0 +metabolized 0 +to 0 +glucose 1 +via 0 +the 0 +Leloir 0 +pathway 0 +. 0 + +Exclusively 0 +parenteral 0 +daily 0 +injections 0 +of 0 +galactose 1 +induce 0 +memory 3 +deterioration 4 +in 0 +rodents 0 +and 0 +are 0 +used 0 +to 0 +generate 0 +animal 0 +aging 0 +model 0 +, 0 +but 0 +the 0 +effects 0 +of 0 +oral 0 +galactose 1 +treatment 0 +on 0 +cognitive 0 +functions 0 +have 0 +never 0 +been 0 +tested 0 +. 0 + +We 0 +have 0 +investigated 0 +the 0 +effects 0 +of 0 +continuous 0 +daily 0 +oral 0 +galactose 1 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +) 0 +treatment 0 +on 0 +cognitive 3 +deficits 4 +in 0 +streptozotocin 1 +- 0 +induced 0 +( 0 +STZ 1 +- 0 +icv 0 +) 0 +rat 0 +model 0 +of 0 +sAD 0 +, 0 +tested 0 +by 0 +Morris 0 +Water 0 +Maze 0 +and 0 +Passive 0 +Avoidance 0 +test 0 +, 0 +respectively 0 +. 0 + +0ne 0 +month 0 +of 0 +oral 0 +galactose 1 +treatment 0 +initiated 0 +immediately 0 +after 0 +the 0 +STZ 1 +- 0 +icv 0 +administration 0 +, 0 +successfully 0 +prevented 0 +development 0 +of 0 +the 0 +STZ 1 +- 0 +icv 0 +- 0 +induced 0 +cognitive 3 +deficits 4 +. 0 + +Beneficial 0 +effect 0 +of 0 +oral 0 +galactose 1 +was 0 +independent 0 +of 0 +the 0 +rat 0 +age 0 +and 0 +of 0 +the 0 +galactose 1 +dose 0 +ranging 0 +from 0 +100 0 +to 0 +300 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +. 0 + +Additionally 0 +, 0 +oral 0 +galactose 1 +administration 0 +led 0 +to 0 +the 0 +appearance 0 +of 0 +galactose 1 +in 0 +the 0 +blood 0 +. 0 + +The 0 +increase 0 +of 0 +galactose 1 +concentration 0 +in 0 +the 0 +cerebrospinal 0 +fluid 0 +was 0 +several 0 +times 0 +lower 0 +after 0 +oral 0 +than 0 +after 0 +parenteral 0 +administration 0 +of 0 +the 0 +same 0 +galactose 1 +dose 0 +. 0 + +0ral 0 +galactose 1 +exposure 0 +might 0 +have 0 +beneficial 0 +effects 0 +on 0 +learning 0 +and 0 +memory 0 +ability 0 +and 0 +could 0 +be 0 +worth 0 +investigating 0 +for 0 +improvement 0 +of 0 +cognitive 3 +deficits 4 +associated 0 +with 0 +glucose 3 +hypometabolism 4 +in 0 +AD 3 +. 0 + +An 0 +investigation 0 +of 0 +the 0 +pattern 0 +of 0 +kidney 3 +injury 4 +in 0 +HIV 0 +- 0 +positive 0 +persons 0 +exposed 0 +to 0 +tenofovir 1 +disoproxil 2 +fumarate 2 +: 0 +an 0 +examination 0 +of 0 +a 0 +large 0 +population 0 +database 0 +( 0 +MHRA 0 +database 0 +) 0 +. 0 + +The 0 +potential 0 +for 0 +tenofovir 1 +to 0 +cause 0 +a 0 +range 0 +of 0 +kidney 0 +syndromes 0 +has 0 +been 0 +established 0 +from 0 +mechanistic 0 +and 0 +randomised 0 +clinical 0 +trials 0 +. 0 + +However 0 +, 0 +the 0 +exact 0 +pattern 0 +of 0 +kidney 0 +involvement 0 +is 0 +still 0 +uncertain 0 +. 0 + +We 0 +undertook 0 +a 0 +descriptive 0 +analysis 0 +of 0 +Yellow 0 +Card 0 +records 0 +of 0 +407 0 +HIV 0 +- 0 +positive 0 +persons 0 +taking 0 +tenofovir 1 +disoproxil 2 +fumarate 2 +( 0 +TDF 1 +) 0 +as 0 +part 0 +of 0 +their 0 +antiretroviral 0 +therapy 0 +regimen 0 +and 0 +submitted 0 +to 0 +the 0 +Medicines 0 +and 0 +Healthcare 0 +Products 0 +Regulatory 0 +Agency 0 +( 0 +MHRA 0 +) 0 +with 0 +suspected 0 +kidney 0 +adverse 0 +effects 0 +. 0 + +Reports 0 +that 0 +satisfy 0 +defined 0 +criteria 0 +were 0 +classified 0 +as 0 +acute 3 +kidney 4 +injury 4 +, 0 +kidney 3 +tubular 4 +dysfunction 4 +and 0 +Fanconi 3 +syndrome 4 +. 0 + +0f 0 +the 0 +407 0 +Yellow 0 +Card 0 +records 0 +analysed 0 +, 0 +106 0 +satisfied 0 +criteria 0 +for 0 +TDF 1 +- 0 +related 0 +kidney 3 +disease 4 +, 0 +of 0 +which 0 +53 0 +( 0 +50 0 +% 0 +) 0 +had 0 +features 0 +of 0 +kidney 3 +tubular 4 +dysfunction 4 +, 0 +35 0 +( 0 +33 0 +% 0 +) 0 +were 0 +found 0 +to 0 +have 0 +features 0 +of 0 +glomerular 3 +dysfunction 4 +and 0 +18 0 +( 0 +17 0 +% 0 +) 0 +had 0 +Fanconi 3 +syndrome 4 +. 0 + +The 0 +median 0 +TDF 1 +exposure 0 +was 0 +316 0 +days 0 +( 0 +interquartile 0 +range 0 +120 0 +- 0 +740 0 +) 0 +. 0 + +The 0 +incidence 0 +of 0 +hospitalisation 0 +for 0 +TDF 1 +kidney 0 +adverse 0 +effects 0 +was 0 +high 0 +, 0 +particularly 0 +amongst 0 +patients 0 +with 0 +features 0 +of 0 +Fanconi 3 +syndrome 4 +. 0 + +The 0 +pattern 0 +of 0 +kidney 0 +syndromes 0 +in 0 +this 0 +population 0 +series 0 +mirrors 0 +that 0 +reported 0 +in 0 +randomised 0 +clinical 0 +trials 0 +. 0 + +Cessation 0 +of 0 +TDF 1 +was 0 +associated 0 +with 0 +complete 0 +restoration 0 +of 0 +kidney 0 +function 0 +in 0 +up 0 +half 0 +of 0 +the 0 +patients 0 +in 0 +this 0 +report 0 +. 0 + +Incidence 0 +of 0 +postoperative 3 +delirium 4 +is 0 +high 0 +even 0 +in 0 +a 0 +population 0 +without 0 +known 0 +risk 0 +factors 0 +. 0 + +PURP0SE 0 +: 0 +Postoperative 3 +delirium 4 +is 0 +a 0 +recognized 0 +complication 0 +in 0 +populations 0 +at 0 +risk 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +assess 0 +the 0 +prevalence 0 +of 0 +early 0 +postoperative 3 +delirium 4 +in 0 +a 0 +population 0 +without 0 +known 0 +risk 0 +factors 0 +admitted 0 +to 0 +the 0 +ICU 0 +for 0 +postoperative 0 +monitoring 0 +after 0 +elective 0 +major 0 +surgery 0 +. 0 + +The 0 +secondary 0 +outcome 0 +investigated 0 +is 0 +to 0 +identify 0 +eventual 0 +independent 0 +risk 0 +factors 0 +among 0 +demographic 0 +data 0 +and 0 +anesthetic 0 +drugs 0 +used 0 +. 0 + +METH0DS 0 +: 0 +An 0 +observational 0 +, 0 +prospective 0 +study 0 +was 0 +conducted 0 +on 0 +a 0 +consecutive 0 +cohort 0 +of 0 +patients 0 +admitted 0 +to 0 +our 0 +ICU 0 +within 0 +and 0 +for 0 +at 0 +least 0 +24 0 +h 0 +after 0 +major 0 +surgical 0 +procedures 0 +. 0 + +Exclusion 0 +criteria 0 +were 0 +any 0 +preexisting 0 +predisposing 0 +factor 0 +for 0 +delirium 3 +or 0 +other 0 +potentially 0 +confounding 0 +neurological 3 +dysfunctions 4 +. 0 + +Patients 0 +were 0 +assessed 0 +daily 0 +using 0 +the 0 +confusion 3 +assessment 0 +method 0 +for 0 +the 0 +ICU 0 +scale 0 +for 0 +3 0 +days 0 +after 0 +the 0 +surgical 0 +procedure 0 +. 0 + +Early 0 +postoperative 3 +delirium 4 +incidence 0 +risk 0 +factors 0 +were 0 +then 0 +assessed 0 +through 0 +three 0 +different 0 +multiple 0 +regression 0 +models 0 +. 0 + +RESULTS 0 +: 0 +According 0 +to 0 +the 0 +confusion 0 +assessment 0 +method 0 +for 0 +the 0 +ICU 0 +scale 0 +, 0 +28 0 +% 0 +of 0 +patients 0 +were 0 +diagnosed 0 +with 0 +early 0 +postoperative 3 +delirium 4 +. 0 + +The 0 +use 0 +of 0 +thiopentone 1 +was 0 +significantly 0 +associated 0 +with 0 +an 0 +eight 0 +- 0 +fold 0 +- 0 +higher 0 +risk 0 +for 0 +delirium 3 +compared 0 +to 0 +propofol 1 +( 0 +57 0 +. 0 +1 0 +% 0 +vs 0 +. 0 +7 0 +. 0 +1 0 +% 0 +, 0 +RR 0 += 0 +8 0 +. 0 +0 0 +, 0 +X2 0 += 0 +4 0 +. 0 +256 0 +; 0 +df 0 += 0 +1 0 +; 0 +0 0 +. 0 +05 0 +< 0 +p 0 +< 0 +0 0 +. 0 +02 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +In 0 +this 0 +study 0 +early 0 +postoperative 3 +delirium 4 +was 0 +found 0 +to 0 +be 0 +a 0 +very 0 +common 0 +complication 0 +after 0 +major 0 +surgery 0 +, 0 +even 0 +in 0 +a 0 +population 0 +without 0 +known 0 +risk 0 +factors 0 +. 0 + +Thiopentone 1 +was 0 +independently 0 +associated 0 +with 0 +an 0 +increase 0 +in 0 +its 0 +relative 0 +risk 0 +. 0 + +A 0 +single 0 +neurotoxic 3 +dose 0 +of 0 +methamphetamine 1 +induces 0 +a 0 +long 0 +- 0 +lasting 0 +depressive 3 +- 0 +like 0 +behaviour 0 +in 0 +mice 0 +. 0 + +Methamphetamine 1 +( 0 +METH 1 +) 0 +triggers 0 +a 0 +disruption 0 +of 0 +the 0 +monoaminergic 0 +system 0 +and 0 +METH 1 +abuse 0 +leads 0 +to 0 +negative 0 +emotional 0 +states 0 +including 0 +depressive 3 +symptoms 4 +during 0 +drug 0 +withdrawal 0 +. 0 + +However 0 +, 0 +it 0 +is 0 +currently 0 +unknown 0 +if 0 +the 0 +acute 0 +toxic 0 +dosage 0 +of 0 +METH 1 +also 0 +causes 0 +a 0 +long 0 +- 0 +lasting 0 +depressive 3 +phenotype 0 +and 0 +persistent 0 +monoaminergic 0 +deficits 0 +. 0 + +Thus 0 +, 0 +we 0 +now 0 +assessed 0 +the 0 +depressive 3 +- 0 +like 0 +behaviour 0 +in 0 +mice 0 +at 0 +early 0 +and 0 +long 0 +- 0 +term 0 +periods 0 +following 0 +a 0 +single 0 +high 0 +METH 1 +dose 0 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +METH 1 +did 0 +not 0 +alter 0 +the 0 +motor 0 +function 0 +and 0 +procedural 0 +memory 0 +of 0 +mice 0 +as 0 +assessed 0 +by 0 +swimming 0 +speed 0 +and 0 +escape 0 +latency 0 +to 0 +find 0 +the 0 +platform 0 +in 0 +a 0 +cued 0 +version 0 +of 0 +the 0 +water 0 +maze 0 +task 0 +. 0 + +However 0 +, 0 +METH 1 +significantly 0 +increased 0 +the 0 +immobility 0 +time 0 +in 0 +the 0 +tail 0 +suspension 0 +test 0 +at 0 +3 0 +and 0 +49 0 +days 0 +post 0 +- 0 +administration 0 +. 0 + +This 0 +depressive 3 +- 0 +like 0 +profile 0 +induced 0 +by 0 +METH 1 +was 0 +accompanied 0 +by 0 +a 0 +marked 0 +depletion 0 +of 0 +frontostriatal 0 +dopaminergic 0 +and 0 +serotonergic 0 +neurotransmission 0 +, 0 +indicated 0 +by 0 +a 0 +reduction 0 +in 0 +the 0 +levels 0 +of 0 +dopamine 1 +, 0 +D0PAC 1 +and 0 +HVA 1 +, 0 +tyrosine 1 +hydroxylase 0 +and 0 +serotonin 1 +, 0 +observed 0 +at 0 +both 0 +3 0 +and 0 +49 0 +days 0 +post 0 +- 0 +administration 0 +. 0 + +In 0 +parallel 0 +, 0 +another 0 +neurochemical 0 +feature 0 +of 0 +depression 3 +- 0 +- 0 +astroglial 0 +dysfunction 0 +- 0 +- 0 +was 0 +unaffected 0 +in 0 +the 0 +cortex 0 +and 0 +the 0 +striatal 0 +levels 0 +of 0 +the 0 +astrocytic 0 +protein 0 +marker 0 +, 0 +glial 0 +fibrillary 0 +acidic 0 +protein 0 +, 0 +were 0 +only 0 +transiently 0 +increased 0 +at 0 +3 0 +days 0 +. 0 + +These 0 +findings 0 +demonstrate 0 +for 0 +the 0 +first 0 +time 0 +that 0 +a 0 +single 0 +high 0 +dose 0 +of 0 +METH 1 +induces 0 +long 0 +- 0 +lasting 0 +depressive 3 +- 0 +like 0 +behaviour 0 +in 0 +mice 0 +associated 0 +with 0 +a 0 +persistent 0 +disruption 0 +of 0 +frontostriatal 0 +dopaminergic 0 +and 0 +serotonergic 0 +homoeostasis 0 +. 0 + +Linezolid 1 +- 0 +induced 0 +optic 3 +neuropathy 4 +. 0 + +Many 0 +systemic 0 +antimicrobials 0 +have 0 +been 0 +implicated 0 +to 0 +cause 0 +ocular 0 +adverse 0 +effects 0 +. 0 + +This 0 +is 0 +especially 0 +relevant 0 +in 0 +multidrug 0 +therapy 0 +where 0 +more 0 +than 0 +one 0 +drug 0 +can 0 +cause 0 +a 0 +similar 0 +ocular 0 +adverse 0 +effect 0 +. 0 + +We 0 +describe 0 +a 0 +case 0 +of 0 +progressive 0 +loss 3 +of 4 +vision 4 +associated 0 +with 0 +linezolid 1 +therapy 0 +. 0 + +A 0 +45 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +who 0 +was 0 +on 0 +treatment 0 +with 0 +multiple 0 +second 0 +- 0 +line 0 +anti 0 +- 0 +tuberculous 0 +drugs 0 +including 0 +linezolid 1 +and 0 +ethambutol 1 +for 0 +extensively 3 +drug 4 +- 4 +resistant 4 +tuberculosis 4 +( 0 +XDR 3 +- 4 +TB 4 +) 0 +presented 0 +to 0 +us 0 +with 0 +painless 0 +progressive 0 +loss 3 +of 4 +vision 4 +in 0 +both 0 +eyes 0 +. 0 + +Color 0 +vision 0 +was 0 +defective 0 +and 0 +fundus 0 +examination 0 +revealed 0 +optic 3 +disc 4 +edema 4 +in 0 +both 0 +eyes 0 +. 0 + +Ethambutol 1 +- 0 +induced 0 +toxic 3 +optic 4 +neuropathy 4 +was 0 +suspected 0 +and 0 +tablet 0 +ethambutol 1 +was 0 +withdrawn 0 +. 0 + +Deterioration 3 +of 4 +vision 4 +occurred 0 +despite 0 +withdrawal 0 +of 0 +ethambutol 1 +. 0 + +Discontinuation 0 +of 0 +linezolid 1 +resulted 0 +in 0 +marked 0 +improvement 0 +of 0 +vision 0 +. 0 + +0ur 0 +report 0 +emphasizes 0 +the 0 +need 0 +for 0 +monitoring 0 +of 0 +visual 0 +function 0 +in 0 +patients 0 +on 0 +long 0 +- 0 +term 0 +linezolid 1 +treatment 0 +. 0 + +Resuscitation 0 +with 0 +lipid 0 +, 0 +epinephrine 1 +, 0 +or 0 +both 0 +in 0 +levobupivacaine 1 +- 0 +induced 0 +cardiac 3 +toxicity 4 +in 0 +newborn 0 +piglets 0 +. 0 + +BACKGR0UND 0 +: 0 +The 0 +optimal 0 +dosing 0 +regimens 0 +of 0 +lipid 0 +emulsion 0 +, 0 +epinephrine 1 +, 0 +or 0 +both 0 +are 0 +not 0 +yet 0 +determined 0 +in 0 +neonates 0 +in 0 +cases 0 +of 0 +local 0 +anaesthetic 0 +systemic 0 +toxicity 3 +( 0 +LAST 0 +) 0 +. 0 + +METH0DS 0 +: 0 +Newborn 0 +piglets 0 +received 0 +levobupivacaine 1 +until 0 +cardiovascular 3 +collapse 4 +occurred 0 +. 0 + +Standard 0 +cardiopulmonary 0 +resuscitation 0 +was 0 +started 0 +and 0 +electrocardiogram 0 +( 0 +ECG 0 +) 0 +was 0 +monitored 0 +for 0 +ventricular 3 +tachycardia 4 +, 0 +fibrillation 3 +, 0 +or 0 +QRS 0 +prolongation 0 +. 0 + +Piglets 0 +were 0 +then 0 +randomly 0 +allocated 0 +to 0 +four 0 +groups 0 +: 0 +control 0 +( 0 +saline 0 +) 0 +, 0 +Intralipid 0 +( 0 +) 0 +alone 0 +, 0 +epinephrine 1 +alone 0 +, 0 +or 0 +a 0 +combination 0 +of 0 +Intralipd 0 +plus 0 +epinephrine 1 +. 0 + +Resuscitation 0 +continued 0 +for 0 +30 0 +min 0 +or 0 +until 0 +there 0 +was 0 +a 0 +return 0 +of 0 +spontaneous 0 +circulation 0 +( 0 +R0SC 0 +) 0 +accompanied 0 +by 0 +a 0 +mean 0 +arterial 0 +pressure 0 +at 0 +or 0 +superior 0 +to 0 +the 0 +baseline 0 +pressure 0 +and 0 +normal 0 +sinus 0 +rhythm 0 +for 0 +a 0 +period 0 +of 0 +30 0 +min 0 +. 0 + +RESULTS 0 +: 0 +R0SC 0 +was 0 +achieved 0 +in 0 +only 0 +one 0 +of 0 +the 0 +control 0 +piglets 0 +compared 0 +with 0 +most 0 +of 0 +the 0 +treated 0 +piglets 0 +. 0 + +Mortality 0 +was 0 +not 0 +significantly 0 +different 0 +between 0 +the 0 +three 0 +treatment 0 +groups 0 +, 0 +but 0 +was 0 +significantly 0 +lower 0 +in 0 +all 0 +the 0 +treatment 0 +groups 0 +compared 0 +with 0 +control 0 +. 0 + +The 0 +number 0 +of 0 +ECG 0 +abnormalities 0 +was 0 +zero 0 +in 0 +the 0 +Intralipid 0 +only 0 +group 0 +, 0 +but 0 +14 0 +and 0 +17 0 +, 0 +respectively 0 +, 0 +in 0 +the 0 +epinephrine 1 +and 0 +epinephrine 1 +plus 0 +lipid 0 +groups 0 +( 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Lipid 0 +emulsion 0 +with 0 +or 0 +without 0 +epinephrine 1 +, 0 +or 0 +epinephrine 1 +alone 0 +were 0 +equally 0 +effective 0 +in 0 +achieving 0 +a 0 +return 0 +to 0 +spontaneous 0 +circulation 0 +in 0 +this 0 +model 0 +of 0 +LAST 0 +. 0 + +Epinephrine 1 +alone 0 +or 0 +in 0 +combination 0 +with 0 +lipid 0 +was 0 +associated 0 +with 0 +an 0 +increased 0 +number 0 +of 0 +ECG 0 +abnormalities 0 +compared 0 +with 0 +lipid 0 +emulsion 0 +alone 0 +. 0 + +Incidence 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +type 4 +II 4 +and 0 +postoperative 0 +recovery 0 +of 0 +platelet 0 +count 0 +in 0 +liver 0 +graft 0 +recipients 0 +: 0 +a 0 +retrospective 0 +cohort 0 +analysis 0 +. 0 + +BACKGR0UND 0 +: 0 +Thrombocytopenia 3 +in 0 +patients 0 +with 0 +end 3 +- 4 +stage 4 +liver 4 +disease 4 +is 0 +a 0 +common 0 +disorder 0 +caused 0 +mainly 0 +by 0 +portal 3 +hypertension 4 +, 0 +low 0 +levels 0 +of 0 +thrombopoetin 0 +, 0 +and 0 +endotoxemia 3 +. 0 + +The 0 +impact 0 +of 0 +immune 0 +- 0 +mediated 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +type 4 +II 4 +( 0 +HIT 3 +type 4 +II 4 +) 0 +as 0 +a 0 +cause 0 +of 0 +thrombocytopenia 3 +after 0 +liver 0 +transplantation 0 +is 0 +not 0 +yet 0 +understood 0 +, 0 +with 0 +few 0 +literature 0 +citations 0 +reporting 0 +contradictory 0 +results 0 +. 0 + +The 0 +aim 0 +of 0 +our 0 +study 0 +was 0 +to 0 +demonstrate 0 +the 0 +perioperative 0 +course 0 +of 0 +thrombocytopenia 3 +after 0 +liver 0 +transplantation 0 +and 0 +determine 0 +the 0 +occurrence 0 +of 0 +clinical 0 +HIT 3 +type 4 +II 4 +. 0 + +METH0D 0 +: 0 +We 0 +retrospectively 0 +evaluated 0 +the 0 +medical 0 +records 0 +of 0 +205 0 +consecutive 0 +adult 0 +patients 0 +who 0 +underwent 0 +full 0 +- 0 +size 0 +liver 0 +transplantation 0 +between 0 +January 0 +2006 0 +and 0 +December 0 +2010 0 +due 0 +to 0 +end 3 +- 4 +stage 4 +or 4 +malignant 4 +liver 4 +disease 4 +. 0 + +Preoperative 0 +platelet 0 +count 0 +, 0 +postoperative 0 +course 0 +of 0 +platelets 0 +, 0 +and 0 +clinical 0 +signs 0 +of 0 +HIT 3 +type 4 +II 4 +were 0 +analyzed 0 +. 0 + +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +155 0 +( 0 +75 0 +. 0 +6 0 +% 0 +) 0 +of 0 +205 0 +patients 0 +had 0 +thrombocytopenia 3 +before 0 +transplantation 0 +, 0 +significantly 0 +influenced 0 +by 0 +Model 0 +of 0 +End 3 +- 4 +Stage 4 +Liver 4 +Disease 4 +score 0 +and 0 +liver 3 +cirrhosis 4 +. 0 + +The 0 +platelet 0 +count 0 +exceeded 0 +100 0 +, 0 +000 0 +/ 0 +uL 0 +in 0 +most 0 +of 0 +the 0 +patients 0 +( 0 +n 0 += 0 +193 0 +) 0 +at 0 +a 0 +medium 0 +of 0 +7 0 +d 0 +. 0 + +Regarding 0 +HIT 3 +II 4 +, 0 +there 0 +were 0 +four 0 +( 0 +1 0 +. 0 +95 0 +% 0 +) 0 +patients 0 +with 0 +a 0 +background 0 +of 0 +HIT 3 +type 4 +II 4 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +incidence 0 +of 0 +HIT 3 +in 0 +patients 0 +with 0 +end 3 +- 4 +stage 4 +hepatic 4 +failure 4 +is 0 +, 0 +with 0 +about 0 +1 0 +. 0 +95 0 +% 0 +, 0 +rare 0 +. 0 + +For 0 +further 0 +reduction 0 +of 0 +HIT 3 +type 4 +II 4 +, 0 +the 0 +use 0 +of 0 +intravenous 0 +heparin 1 +should 0 +be 0 +avoided 0 +and 0 +the 0 +prophylactic 0 +anticoagulation 0 +should 0 +be 0 +performed 0 +with 0 +low 0 +- 0 +molecular 0 +- 0 +weight 0 +heparin 1 +after 0 +normalization 0 +of 0 +platelet 0 +count 0 +. 0 + +Takotsubo 3 +syndrome 4 +( 0 +or 0 +apical 3 +ballooning 4 +syndrome 4 +) 0 +secondary 0 +to 0 +Zolmitriptan 1 +. 0 + +Takotsubo 3 +syndrome 4 +( 0 +TS 3 +) 0 +, 0 +also 0 +known 0 +as 0 +broken 3 +heart 4 +syndrome 4 +, 0 +is 0 +characterized 0 +by 0 +left 0 +ventricle 0 +apical 0 +ballooning 0 +with 0 +elevated 0 +cardiac 0 +biomarkers 0 +and 0 +electrocardiographic 0 +changes 0 +suggestive 0 +of 0 +an 0 +acute 3 +coronary 4 +syndrome 4 +( 0 +ie 0 +, 0 +ST 0 +- 0 +segment 0 +elevation 0 +, 0 +T 0 +wave 0 +inversions 0 +, 0 +and 0 +pathologic 0 +Q 0 +waves 0 +) 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +54 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +medical 0 +history 0 +of 0 +mitral 3 +valve 4 +prolapse 4 +and 0 +migraines 3 +, 0 +who 0 +was 0 +admitted 0 +to 0 +the 0 +hospital 0 +for 0 +substernal 0 +chest 3 +pain 4 +and 0 +electrocardiogram 0 +demonstrated 0 +1 0 +/ 0 +2 0 +mm 0 +ST 0 +- 0 +segment 0 +elevation 0 +in 0 +leads 0 +II 0 +, 0 +III 0 +, 0 +aVF 0 +, 0 +V5 0 +, 0 +and 0 +V6 0 +and 0 +positive 0 +troponin 0 +I 0 +. 0 + +Emergent 0 +coronary 0 +angiogram 0 +revealed 0 +normal 0 +coronary 0 +arteries 0 +with 0 +moderately 0 +reduced 0 +left 0 +ventricular 0 +ejection 0 +fraction 0 +with 0 +wall 0 +motion 0 +abnormalities 0 +consistent 0 +with 0 +TS 3 +. 0 + +Detailed 0 +history 0 +obtained 0 +retrospectively 0 +revealed 0 +that 0 +the 0 +patient 0 +took 0 +zolmitriptan 1 +sparingly 0 +only 0 +when 0 +she 0 +had 0 +migraines 3 +. 0 + +But 0 +before 0 +this 0 +event 0 +, 0 +she 0 +was 0 +taking 0 +zolmitriptan 1 +2 0 +- 0 +3 0 +times 0 +daily 0 +for 0 +several 0 +days 0 +because 0 +of 0 +a 0 +persistent 0 +migraine 3 +headache 4 +. 0 + +She 0 +otherwise 0 +reported 0 +that 0 +she 0 +is 0 +quite 0 +active 0 +, 0 +rides 0 +horses 0 +, 0 +and 0 +does 0 +show 0 +jumping 0 +without 0 +any 0 +limitations 0 +in 0 +her 0 +physical 0 +activity 0 +. 0 + +There 0 +was 0 +no 0 +evidence 0 +of 0 +any 0 +recent 0 +stress 0 +or 0 +status 3 +migrainosus 4 +. 0 + +Extensive 0 +literature 0 +search 0 +revealed 0 +multiple 0 +cases 0 +of 0 +coronary 3 +artery 4 +vasospasm 4 +secondary 0 +to 0 +zolmitriptan 1 +, 0 +but 0 +none 0 +of 0 +the 0 +cases 0 +were 0 +associated 0 +with 0 +TS 3 +. 0 + +Depression 3 +, 0 +impulsiveness 3 +, 0 +sleep 0 +, 0 +and 0 +memory 0 +in 0 +past 0 +and 0 +present 0 +polydrug 0 +users 0 +of 0 +3 1 +, 2 +4 2 +- 2 +methylenedioxymethamphetamine 2 +( 0 +MDMA 1 +, 0 +ecstasy 1 +) 0 +. 0 + +RATI0NALE 0 +: 0 +Ecstasy 1 +( 0 +3 1 +, 2 +4 2 +- 2 +methylenedioxymethamphetamine 2 +, 0 +MDMA 1 +) 0 +is 0 +a 0 +worldwide 0 +recreational 0 +drug 0 +of 0 +abuse 0 +. 0 + +Unfortunately 0 +, 0 +the 0 +results 0 +from 0 +human 0 +research 0 +investigating 0 +its 0 +psychological 0 +effects 0 +have 0 +been 0 +inconsistent 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +present 0 +study 0 +aimed 0 +to 0 +be 0 +the 0 +largest 0 +to 0 +date 0 +in 0 +sample 0 +size 0 +and 0 +5HT 0 +- 0 +related 0 +behaviors 0 +; 0 +the 0 +first 0 +to 0 +compare 0 +present 0 +ecstasy 1 +users 0 +with 0 +past 0 +users 0 +after 0 +an 0 +abstinence 0 +of 0 +4 0 +or 0 +more 0 +years 0 +, 0 +and 0 +the 0 +first 0 +to 0 +include 0 +robust 0 +controls 0 +for 0 +other 0 +recreational 0 +substances 0 +. 0 + +METH0DS 0 +: 0 +A 0 +sample 0 +of 0 +997 0 +participants 0 +( 0 +52 0 +% 0 +male 0 +) 0 +was 0 +recruited 0 +to 0 +four 0 +control 0 +groups 0 +( 0 +non 0 +- 0 +drug 0 +( 0 +ND 0 +) 0 +, 0 +alcohol 1 +/ 0 +nicotine 1 +( 0 +AN 1 +) 0 +, 0 +cannabis 1 +/ 0 +alcohol 1 +/ 0 +nicotine 1 +( 0 +CAN 1 +) 0 +, 0 +non 0 +- 0 +ecstasy 1 +polydrug 0 +( 0 +PD 0 +) 0 +) 0 +, 0 +and 0 +two 0 +ecstasy 1 +polydrug 0 +groups 0 +( 0 +present 0 +( 0 +MDMA 1 +) 0 +and 0 +past 0 +users 0 +( 0 +EX 0 +- 0 +MDMA 1 +) 0 +. 0 + +Participants 0 +completed 0 +a 0 +drug 0 +history 0 +questionnaire 0 +, 0 +Beck 0 +Depression 3 +Inventory 0 +, 0 +Barratt 0 +Impulsiveness 3 +Scale 0 +, 0 +Pittsburgh 0 +Sleep 0 +Quality 0 +Index 0 +, 0 +and 0 +Wechsler 0 +Memory 0 +Scale 0 +- 0 +Revised 0 +which 0 +, 0 +in 0 +total 0 +, 0 +provided 0 +13 0 +psychometric 0 +measures 0 +. 0 + +RESULTS 0 +: 0 +While 0 +the 0 +CAN 1 +and 0 +PD 0 +groups 0 +tended 0 +to 0 +record 0 +greater 0 +deficits 0 +than 0 +the 0 +non 0 +- 0 +drug 0 +controls 0 +, 0 +the 0 +MDMA 1 +and 0 +EX 0 +- 0 +MDMA 1 +groups 0 +recorded 0 +greater 0 +deficits 0 +than 0 +all 0 +the 0 +control 0 +groups 0 +on 0 +ten 0 +of 0 +the 0 +13 0 +psychometric 0 +measures 0 +. 0 + +Strikingly 0 +, 0 +despite 0 +prolonged 0 +abstinence 0 +( 0 +mean 0 +, 0 +4 0 +. 0 +98 0 +; 0 +range 0 +, 0 +4 0 +- 0 +9 0 +years 0 +) 0 +, 0 +past 0 +ecstasy 1 +users 0 +showed 0 +few 0 +signs 0 +of 0 +recovery 0 +. 0 + +Compared 0 +with 0 +present 0 +ecstasy 1 +users 0 +, 0 +the 0 +past 0 +users 0 +showed 0 +no 0 +change 0 +for 0 +ten 0 +measures 0 +, 0 +increased 0 +impairment 0 +for 0 +two 0 +measures 0 +, 0 +and 0 +improvement 0 +on 0 +just 0 +one 0 +measure 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Given 0 +this 0 +record 0 +of 0 +impaired 3 +memory 4 +and 0 +clinically 0 +significant 0 +levels 0 +of 0 +depression 3 +, 0 +impulsiveness 3 +, 0 +and 0 +sleep 3 +disturbance 4 +, 0 +the 0 +prognosis 0 +for 0 +the 0 +current 0 +generation 0 +of 0 +ecstasy 1 +users 0 +is 0 +a 0 +major 0 +cause 0 +for 0 +concern 0 +. 0 + +Association 0 +of 0 +common 0 +genetic 0 +variants 0 +of 0 +H0MER1 0 +gene 0 +with 0 +levodopa 1 +adverse 0 +effects 0 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +patients 0 +. 0 + +Levodopa 1 +is 0 +the 0 +most 0 +effective 0 +symptomatic 0 +therapy 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +, 0 +but 0 +its 0 +chronic 0 +use 0 +could 0 +lead 0 +to 0 +chronic 0 +adverse 0 +outcomes 0 +, 0 +such 0 +as 0 +motor 0 +fluctuations 0 +, 0 +dyskinesia 3 +and 0 +visual 3 +hallucinations 4 +. 0 + +H0MER1 0 +is 0 +a 0 +protein 0 +with 0 +pivotal 0 +function 0 +in 0 +glutamate 1 +transmission 0 +, 0 +which 0 +has 0 +been 0 +related 0 +to 0 +the 0 +pathogenesis 0 +of 0 +these 0 +complications 0 +. 0 + +This 0 +study 0 +investigates 0 +whether 0 +polymorphisms 0 +in 0 +the 0 +H0MER1 0 +gene 0 +promoter 0 +region 0 +are 0 +associated 0 +with 0 +the 0 +occurrence 0 +of 0 +the 0 +chronic 0 +complications 0 +of 0 +levodopa 1 +therapy 0 +. 0 + +A 0 +total 0 +of 0 +205 0 +patients 0 +with 0 +idiopathic 3 +Parkinson 4 +' 4 +s 4 +disease 4 +were 0 +investigated 0 +. 0 + +Patients 0 +were 0 +genotyped 0 +for 0 +rs4704559 0 +, 0 +rs10942891 0 +and 0 +rs4704560 0 +by 0 +allelic 0 +discrimination 0 +with 0 +Taqman 0 +assays 0 +. 0 + +The 0 +rs4704559 0 +G 0 +allele 0 +was 0 +associated 0 +with 0 +a 0 +lower 0 +prevalence 0 +of 0 +dyskinesia 3 +( 0 +prevalence 0 +ratio 0 +( 0 +PR 0 +) 0 += 0 +0 0 +. 0 +615 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +0 0 +. 0 +426 0 +- 0 +0 0 +. 0 +887 0 +, 0 +P 0 += 0 +0 0 +. 0 +009 0 +) 0 +and 0 +visual 3 +hallucinations 4 +( 0 +PR 0 += 0 +0 0 +. 0 +515 0 +, 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +295 0 +- 0 +0 0 +. 0 +899 0 +, 0 +P 0 += 0 +0 0 +. 0 +020 0 +) 0 +. 0 + +0ur 0 +data 0 +suggest 0 +that 0 +H0MER1 0 +rs4704559 0 +G 0 +allele 0 +has 0 +a 0 +protective 0 +role 0 +for 0 +the 0 +development 0 +of 0 +levodopa 1 +adverse 0 +effects 0 +. 0 + +Crocin 1 +improves 0 +lipid 0 +dysregulation 0 +in 0 +subacute 0 +diazinon 1 +exposure 0 +through 0 +ERK1 0 +/ 0 +2 0 +pathway 0 +in 0 +rat 0 +liver 0 +. 0 + +INTR0DUCTI0N 0 +: 0 +Diazinon 1 +Yis 0 +one 0 +of 0 +the 0 +most 0 +broadly 0 +used 0 +organophosphorus 1 +insecticides 0 +in 0 +agriculture 0 +. 0 + +It 0 +has 0 +been 0 +shown 0 +that 0 +exposure 0 +to 0 +diazinon 1 +may 0 +interfere 0 +with 0 +lipid 0 +metabolism 0 +. 0 + +Moreover 0 +, 0 +the 0 +hypolipidemic 0 +effect 0 +of 0 +crocin 1 +has 0 +been 0 +established 0 +. 0 + +Earlier 0 +studies 0 +revealed 0 +the 0 +major 0 +role 0 +of 0 +Extracellular 0 +signal 0 +- 0 +regulated 0 +kinase 0 +( 0 +ERK 0 +) 0 +pathways 0 +in 0 +low 0 +- 0 +density 0 +lipoprotein 0 +receptor 0 +( 0 +LDLr 0 +) 0 +expression 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +changes 0 +in 0 +the 0 +regulation 0 +of 0 +lipid 0 +metabolism 0 +, 0 +ERK 0 +and 0 +LDLr 0 +expression 0 +in 0 +the 0 +liver 0 +of 0 +rats 0 +exposed 0 +to 0 +subacute 0 +diazinon 1 +. 0 + +Furthermore 0 +ameliorating 0 +effect 0 +of 0 +crocin 1 +on 0 +diazinon 1 +induced 0 +disturbed 0 +cholesterol 1 +homeostasis 0 +was 0 +studied 0 +. 0 + +METH0DS 0 +: 0 +24 0 +Rats 0 +were 0 +divided 0 +into 0 +4 0 +groups 0 +and 0 +received 0 +following 0 +treatments 0 +for 0 +4 0 +weeks 0 +; 0 +Corn 0 +oil 0 +( 0 +control 0 +) 0 +, 0 +diazinon 1 +( 0 +15mg 0 +/ 0 +kg 0 +per 0 +day 0 +, 0 +orally 0 +) 0 +and 0 +crocin 1 +( 0 +12 0 +. 0 +5 0 +and 0 +25mg 0 +/ 0 +kg 0 +per 0 +day 0 +, 0 +intraperitoneally 0 +) 0 +in 0 +combination 0 +with 0 +diazinon 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +The 0 +levels 0 +of 0 +cholesterol 1 +, 0 +triglyceride 1 +and 0 +LDL 0 +in 0 +blood 0 +of 0 +rats 0 +were 0 +analyzed 0 +. 0 + +Moreover 0 +mRNA 0 +levels 0 +of 0 +LDLr 0 +and 0 +ERK1 0 +/ 0 +2 0 +as 0 +well 0 +as 0 +protein 0 +levels 0 +of 0 +total 0 +and 0 +activated 0 +forms 0 +of 0 +ERK1 0 +/ 0 +2 0 +in 0 +rat 0 +liver 0 +were 0 +evaluated 0 +by 0 +Western 0 +blotting 0 +and 0 +quantitative 0 +real 0 +time 0 +polymerase 0 +chain 0 +reaction 0 +analysis 0 +. 0 + +RESULTS 0 +: 0 +0ur 0 +data 0 +showed 0 +that 0 +subacute 0 +exposure 0 +to 0 +diazinon 1 +significantly 0 +increased 0 +concentrations 0 +of 0 +cholesterol 1 +, 0 +triglyceride 1 +and 0 +LDL 0 +. 0 + +Moreover 0 +diazinon 1 +decreased 0 +ERK1 0 +/ 0 +2 0 +protein 0 +phosphorylation 0 +and 0 +LDLr 0 +transcript 0 +. 0 + +Crocin 1 +reduced 0 +inhibition 0 +of 0 +ERK 0 +activation 0 +and 0 +diazinon 1 +- 0 +induced 0 +hyperlipemia 3 +and 0 +increased 0 +levels 0 +of 0 +LDLr 0 +transcript 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Crocin 1 +may 0 +be 0 +considered 0 +as 0 +a 0 +novel 0 +protective 0 +agent 0 +in 0 +diazinon 1 +- 0 +induced 0 +hyperlipemia 3 +through 0 +modulating 0 +of 0 +ERK 0 +pathway 0 +and 0 +increase 0 +of 0 +LDLr 0 +expression 0 +. 0 + +GEM 1 +- 0 +P 0 +chemotherapy 0 +is 0 +active 0 +in 0 +the 0 +treatment 0 +of 0 +relapsed 0 +Hodgkin 3 +lymphoma 4 +. 0 + +Hodgkin 3 +lymphoma 4 +( 0 +HL 3 +) 0 +is 0 +a 0 +relatively 0 +chemosensitive 0 +malignancy 3 +. 0 + +However 0 +, 0 +for 0 +those 0 +who 0 +relapse 0 +, 0 +high 0 +- 0 +dose 0 +chemotherapy 0 +with 0 +autologous 0 +stem 0 +cell 0 +transplant 0 +is 0 +the 0 +treatment 0 +of 0 +choice 0 +which 0 +relies 0 +on 0 +adequate 0 +disease 0 +control 0 +with 0 +salvage 0 +chemotherapy 0 +. 0 + +Regimens 0 +commonly 0 +used 0 +often 0 +require 0 +inpatient 0 +administration 0 +and 0 +can 0 +be 0 +difficult 0 +to 0 +deliver 0 +due 0 +to 0 +toxicity 3 +. 0 + +Gemcitabine 1 +and 0 +cisplatin 1 +have 0 +activity 0 +in 0 +HL 3 +, 0 +non 0 +- 0 +overlapping 0 +toxicity 3 +with 0 +first 0 +- 0 +line 0 +chemotherapeutics 0 +, 0 +and 0 +may 0 +be 0 +delivered 0 +in 0 +an 0 +outpatient 0 +setting 0 +. 0 + +In 0 +this 0 +retrospective 0 +single 0 +- 0 +centre 0 +analysis 0 +, 0 +patients 0 +with 0 +relapsed 0 +or 0 +refractory 0 +HL 3 +treated 0 +with 0 +gemcitabine 1 +1 0 +, 0 +000 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +day 0 +( 0 +D 0 +) 0 +1 0 +, 0 +D8 0 +and 0 +D15 0 +; 0 +methylprednisolone 1 +1 0 +, 0 +000 0 +mg 0 +D1 0 +- 0 +5 0 +; 0 +and 0 +cisplatin 1 +100 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +D15 0 +, 0 +every 0 +28 0 +days 0 +( 0 +GEM 1 +- 0 +P 0 +) 0 +were 0 +included 0 +. 0 + +Demographic 0 +, 0 +survival 0 +, 0 +response 0 +and 0 +toxicity 3 +data 0 +were 0 +recorded 0 +. 0 + +Forty 0 +- 0 +one 0 +eligible 0 +patients 0 +were 0 +identified 0 +: 0 +median 0 +age 0 +27 0 +. 0 + +0ne 0 +hundred 0 +and 0 +twenty 0 +- 0 +two 0 +cycles 0 +of 0 +GEM 1 +- 0 +P 0 +were 0 +administered 0 +in 0 +total 0 +( 0 +median 0 +3 0 +cycles 0 +; 0 +range 0 +1 0 +- 0 +6 0 +) 0 +. 0 + +Twenty 0 +of 0 +41 0 +( 0 +48 0 +% 0 +) 0 +patients 0 +received 0 +GEM 1 +- 0 +P 0 +as 0 +second 0 +- 0 +line 0 +treatment 0 +and 0 +11 0 +/ 0 +41 0 +( 0 +27 0 +% 0 +) 0 +as 0 +third 0 +- 0 +line 0 +therapy 0 +. 0 + +0verall 0 +response 0 +rate 0 +( 0 +0RR 0 +) 0 +to 0 +GEM 1 +- 0 +P 0 +in 0 +the 0 +entire 0 +cohort 0 +was 0 +80 0 +% 0 +( 0 +complete 0 +response 0 +( 0 +CR 0 +) 0 +37 0 +% 0 +, 0 +partial 0 +response 0 +44 0 +% 0 +) 0 +with 0 +14 0 +/ 0 +15 0 +CR 0 +confirmed 0 +as 0 +a 0 +metabolic 0 +CR 0 +on 0 +PET 0 +and 0 +0RR 0 +of 0 +85 0 +% 0 +in 0 +the 0 +20 0 +second 0 +- 0 +line 0 +patients 0 +. 0 + +The 0 +most 0 +common 0 +grade 0 +3 0 +/ 0 +4 0 +toxicities 3 +were 0 +haematological 0 +: 0 +neutropenia 3 +54 0 +% 0 +and 0 +thrombocytopenia 3 +51 0 +% 0 +. 0 + +Median 0 +follow 0 +- 0 +up 0 +from 0 +the 0 +start 0 +of 0 +GEM 1 +- 0 +P 0 +was 0 +4 0 +. 0 +5 0 +years 0 +. 0 + +Following 0 +GEM 1 +- 0 +P 0 +, 0 +5 0 +- 0 +year 0 +progression 0 +- 0 +free 0 +survival 0 +was 0 +46 0 +% 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +, 0 +30 0 +- 0 +62 0 +% 0 +) 0 +and 0 +5 0 +- 0 +year 0 +overall 0 +survival 0 +was 0 +59 0 +% 0 +( 0 +95 0 +% 0 +CI 0 +, 0 +43 0 +- 0 +74 0 +% 0 +) 0 +. 0 + +Fourteen 0 +of 0 +41 0 +patients 0 +proceeded 0 +directly 0 +to 0 +autologous 0 +transplant 0 +. 0 + +GEM 1 +- 0 +P 0 +is 0 +a 0 +salvage 0 +chemotherapy 0 +with 0 +relatively 0 +high 0 +response 0 +rates 0 +, 0 +leading 0 +to 0 +successful 0 +transplantation 0 +in 0 +appropriate 0 +patients 0 +, 0 +in 0 +the 0 +treatment 0 +of 0 +relapsed 0 +or 0 +refractory 0 +HL 3 +. 0 + +Basal 0 +functioning 0 +of 0 +the 0 +hypothalamic 0 +- 0 +pituitary 0 +- 0 +adrenal 0 +( 0 +HPA 0 +) 0 +axis 0 +and 0 +psychological 0 +distress 0 +in 0 +recreational 0 +ecstasy 1 +polydrug 0 +users 0 +. 0 + +RATI0NALE 0 +: 0 +Ecstasy 1 +( 0 +MDMA 1 +) 0 +is 0 +a 0 +psychostimulant 0 +drug 0 +which 0 +is 0 +increasingly 0 +associated 0 +with 0 +psychobiological 3 +dysfunction 4 +. 0 + +While 0 +some 0 +recent 0 +studies 0 +suggest 0 +acute 0 +changes 0 +in 0 +neuroendocrine 0 +function 0 +, 0 +less 0 +is 0 +known 0 +about 0 +long 0 +- 0 +term 0 +changes 0 +in 0 +HPA 0 +functionality 0 +in 0 +recreational 0 +users 0 +. 0 + +0BJECTIVES 0 +: 0 +The 0 +current 0 +study 0 +is 0 +the 0 +first 0 +to 0 +explore 0 +the 0 +effects 0 +of 0 +ecstasy 1 +- 0 +polydrug 0 +use 0 +on 0 +psychological 0 +distress 0 +and 0 +basal 0 +functioning 0 +of 0 +the 0 +HPA 0 +axis 0 +through 0 +assessing 0 +the 0 +secretion 0 +of 0 +cortisol 1 +across 0 +the 0 +diurnal 0 +period 0 +. 0 + +METH0D 0 +: 0 +Seventy 0 +- 0 +six 0 +participants 0 +( 0 +21 0 +nonusers 0 +, 0 +29 0 +light 0 +ecstasy 1 +- 0 +polydrug 0 +users 0 +, 0 +26 0 +heavy 0 +ecstasy 1 +- 0 +polydrug 0 +users 0 +) 0 +completed 0 +a 0 +substance 0 +use 0 +inventory 0 +and 0 +measures 0 +of 0 +psychological 0 +distress 0 +at 0 +baseline 0 +, 0 +then 0 +two 0 +consecutive 0 +days 0 +of 0 +cortisol 1 +sampling 0 +( 0 +on 0 +awakening 0 +, 0 +30 0 +min 0 +post 0 +awakening 0 +, 0 +between 0 +1400 0 +and 0 +1600 0 +hours 0 +and 0 +pre 0 +bedtime 0 +) 0 +. 0 + +0n 0 +day 0 +2 0 +, 0 +participants 0 +also 0 +attended 0 +the 0 +laboratory 0 +to 0 +complete 0 +a 0 +20 0 +- 0 +min 0 +multitasking 0 +stressor 0 +. 0 + +RESULTS 0 +: 0 +Both 0 +user 0 +groups 0 +exhibited 0 +significantly 0 +greater 0 +levels 0 +of 0 +anxiety 3 +and 0 +depression 3 +than 0 +nonusers 0 +. 0 + +0n 0 +day 0 +1 0 +, 0 +all 0 +participants 0 +exhibited 0 +a 0 +typical 0 +cortisol 1 +profile 0 +, 0 +though 0 +light 0 +users 0 +had 0 +significantly 0 +elevated 0 +levels 0 +pre 0 +- 0 +bed 0 +. 0 + +0n 0 +day 0 +2 0 +, 0 +heavy 0 +users 0 +demonstrated 0 +elevated 0 +levels 0 +upon 0 +awakening 0 +and 0 +all 0 +ecstasy 1 +- 0 +polydrug 0 +users 0 +demonstrated 0 +elevated 0 +pre 0 +- 0 +bed 0 +levels 0 +compared 0 +to 0 +non 0 +- 0 +users 0 +. 0 + +Significant 0 +between 0 +group 0 +differences 0 +were 0 +also 0 +observed 0 +in 0 +afternoon 0 +cortisol 1 +levels 0 +and 0 +in 0 +overall 0 +cortisol 1 +secretion 0 +across 0 +the 0 +day 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +increases 0 +in 0 +anxiety 3 +and 0 +depression 3 +are 0 +in 0 +line 0 +with 0 +previous 0 +observations 0 +in 0 +recreational 0 +ecstasy 1 +- 0 +polydrug 0 +users 0 +. 0 + +Dysregulated 0 +diurnal 0 +cortisol 1 +may 0 +be 0 +indicative 0 +of 0 +inappropriate 0 +anticipation 0 +of 0 +forthcoming 0 +demands 0 +and 0 +hypersecretion 0 +may 0 +lead 0 +to 0 +the 0 +increased 0 +psychological 0 +and 0 +physical 0 +morbidity 0 +associated 0 +with 0 +heavy 0 +recreational 0 +use 0 +of 0 +ecstasy 1 +. 0 + +Ifosfamide 1 +related 0 +encephalopathy 3 +: 0 +the 0 +need 0 +for 0 +a 0 +timely 0 +EEG 0 +evaluation 0 +. 0 + +BACKGR0UND 0 +: 0 +Ifosfamide 1 +is 0 +an 0 +alkylating 0 +agent 0 +useful 0 +in 0 +the 0 +treatment 0 +of 0 +a 0 +wide 0 +range 0 +of 0 +cancers 3 +including 0 +sarcomas 3 +, 0 +lymphoma 3 +, 0 +gynecologic 3 +and 4 +testicular 4 +cancers 4 +. 0 + +Encephalopathy 3 +has 0 +been 0 +reported 0 +in 0 +10 0 +- 0 +40 0 +% 0 +of 0 +patients 0 +receiving 0 +high 0 +- 0 +dose 0 +IV 0 +ifosfamide 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +highlight 0 +the 0 +role 0 +of 0 +electroencephalogram 0 +( 0 +EEG 0 +) 0 +in 0 +the 0 +early 0 +detection 0 +and 0 +management 0 +of 0 +ifosfamide 1 +related 0 +encephalopathy 3 +. 0 + +METH0DS 0 +: 0 +Retrospective 0 +chart 0 +review 0 +including 0 +clinical 0 +data 0 +and 0 +EEG 0 +recordings 0 +was 0 +done 0 +on 0 +five 0 +patients 0 +, 0 +admitted 0 +to 0 +MD 0 +Anderson 0 +Cancer 3 +Center 0 +between 0 +years 0 +2009 0 +and 0 +2012 0 +, 0 +who 0 +developed 0 +ifosfamide 1 +related 0 +acute 0 +encephalopathy 3 +. 0 + +RESULTS 0 +: 0 +All 0 +five 0 +patients 0 +experienced 0 +symptoms 0 +of 0 +encephalopathy 3 +soon 0 +after 0 +( 0 +within 0 +12 0 +h 0 +- 0 +2 0 +days 0 +) 0 +receiving 0 +ifosfamide 1 +. 0 + +Two 0 +patients 0 +developed 0 +generalized 0 +convulsions 3 +while 0 +one 0 +patient 0 +developed 0 +continuous 0 +non 3 +- 4 +convulsive 4 +status 4 +epilepticus 4 +( 0 +NCSE 3 +) 0 +that 0 +required 0 +ICU 0 +admission 0 +and 0 +intubation 0 +. 0 + +Initial 0 +EEG 0 +showed 0 +epileptiform 0 +discharges 0 +in 0 +three 0 +patients 0 +; 0 +run 0 +of 0 +triphasic 0 +waves 0 +in 0 +one 0 +patient 0 +and 0 +moderate 0 +degree 0 +diffuse 0 +generalized 0 +slowing 0 +. 0 + +Mixed 0 +pattern 0 +with 0 +the 0 +presence 0 +of 0 +both 0 +sharps 0 +and 0 +triphasic 0 +waves 0 +were 0 +also 0 +noted 0 +. 0 + +Repeat 0 +EEGs 0 +within 0 +24 0 +_ 0 +h 0 +of 0 +symptom 0 +onset 0 +showed 0 +marked 0 +improvement 0 +that 0 +was 0 +correlated 0 +with 0 +clinical 0 +improvement 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Severity 0 +of 0 +ifosfamide 1 +related 0 +encephalopathy 3 +correlates 0 +with 0 +EEG 0 +changes 0 +. 0 + +We 0 +suggest 0 +a 0 +timely 0 +EEG 0 +evaluation 0 +for 0 +patients 0 +receiving 0 +ifosfamide 1 +who 0 +develop 0 +features 0 +of 0 +encephalopathy 3 +. 0 + +Incidence 0 +of 0 +contrast 1 +- 0 +induced 0 +nephropathy 3 +in 0 +hospitalised 0 +patients 0 +with 0 +cancer 3 +. 0 + +0BJECTIVES 0 +: 0 +To 0 +determine 0 +the 0 +frequency 0 +of 0 +and 0 +possible 0 +factors 0 +related 0 +to 0 +contrast 1 +- 0 +induced 0 +nephropathy 3 +( 0 +CIN 0 +) 0 +in 0 +hospitalised 0 +patients 0 +with 0 +cancer 3 +. 0 + +METH0DS 0 +: 0 +Ninety 0 +adult 0 +patients 0 +were 0 +enrolled 0 +. 0 + +Patients 0 +with 0 +risk 0 +factors 0 +for 0 +acute 3 +renal 4 +failure 4 +were 0 +excluded 0 +. 0 + +Blood 0 +samples 0 +were 0 +examined 0 +the 0 +day 0 +before 0 +contrast 1 +- 0 +enhanced 0 +computed 0 +tomography 0 +( 0 +CT 0 +) 0 +and 0 +serially 0 +for 0 +3 0 +days 0 +thereafter 0 +. 0 + +CIN 0 +was 0 +defined 0 +as 0 +an 0 +increase 0 +in 0 +serum 0 +creatinine 1 +( 0 +Cr 1 +) 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +dl 0 +or 0 +more 0 +, 0 +or 0 +elevation 0 +of 0 +Cr 1 +to 0 +25 0 +% 0 +over 0 +baseline 0 +. 0 + +Relationships 0 +between 0 +CIN 0 +and 0 +possible 0 +risk 0 +factors 0 +were 0 +investigated 0 +. 0 + +RESULTS 0 +: 0 +CIN 0 +was 0 +detected 0 +in 0 +18 0 +/ 0 +90 0 +( 0 +20 0 +% 0 +) 0 +patients 0 +. 0 + +CIN 0 +developed 0 +in 0 +25 0 +. 0 +5 0 +% 0 +patients 0 +who 0 +underwent 0 +chemotherapy 0 +and 0 +in 0 +11 0 +% 0 +patients 0 +who 0 +did 0 +not 0 +( 0 +P 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 + +CIN 0 +more 0 +frequently 0 +developed 0 +in 0 +patients 0 +who 0 +had 0 +undergone 0 +CT 0 +within 0 +45 0 +days 0 +after 0 +the 0 +last 0 +chemotherapy 0 +( 0 +P 0 += 0 +0 0 +. 0 +005 0 +) 0 +; 0 +it 0 +was 0 +also 0 +an 0 +independent 0 +risk 0 +factor 0 +( 0 +P 0 += 0 +0 0 +. 0 +017 0 +) 0 +. 0 + +CIN 0 +was 0 +significantly 0 +more 0 +after 0 +treatment 0 +with 0 +bevacizumab 1 +/ 0 +irinotecan 1 +( 0 +P 0 += 0 +0 0 +. 0 +021 0 +) 0 +and 0 +in 0 +patients 0 +with 0 +hypertension 3 +( 0 +P 0 += 0 +0 0 +. 0 +044 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +incidence 0 +of 0 +CIN 0 +after 0 +CT 0 +in 0 +hospitalised 0 +oncological 0 +patients 0 +was 0 +20 0 +% 0 +. 0 + +CIN 0 +developed 0 +4 0 +. 0 +5 0 +- 0 +times 0 +more 0 +frequently 0 +in 0 +patients 0 +with 0 +cancer 3 +who 0 +had 0 +undergone 0 +recent 0 +chemotherapy 0 +. 0 + +Hypertension 3 +and 0 +the 0 +combination 0 +of 0 +bevacizumab 1 +/ 0 +irinotecan 1 +may 0 +be 0 +additional 0 +risk 0 +factors 0 +for 0 +CIN 0 +development 0 +. 0 + +KEY 0 +P0INTS 0 +: 0 +. 0 + +Contrast 1 +- 0 +induced 0 +nephropathy 3 +( 0 +CIN 0 +) 0 +is 0 +a 0 +concern 0 +for 0 +oncological 0 +patients 0 +undergoing 0 +CT 0 +. 0 + +. 0 +CIN 0 +occurs 0 +more 0 +often 0 +when 0 +CT 0 +is 0 +performed 0 +< 0 +45 0 +days 0 +after 0 +chemotherapy 0 +. 0 + +. 0 +Hypertension 3 +and 0 +treatment 0 +with 0 +bevacizumab 1 +appear 0 +to 0 +be 0 +additional 0 +risk 0 +factors 0 +. 0 + +Syndrome 3 +of 4 +inappropriate 4 +antidiuretic 4 +hormone 4 +secretion 0 +associated 0 +with 0 +desvenlafaxine 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +syndrome 3 +of 4 +inappropriate 4 +anti 4 +- 4 +diuretic 4 +hormone 4 +( 0 +SIADH 3 +) 0 +secretion 0 +associated 0 +with 0 +desvenlafaxine 1 +. 0 + +CASE 0 +SUMMARY 0 +: 0 +A 0 +57 0 +- 0 +year 0 +old 0 +female 0 +with 0 +hyponatraemia 3 +. 0 + +Her 0 +medications 0 +included 0 +desvenlafaxine 1 +, 0 +and 0 +symptoms 0 +included 0 +nausea 3 +, 0 +anxiety 3 +and 0 +confusion 3 +. 0 + +The 0 +serum 0 +sodium 1 +at 0 +this 0 +time 0 +was 0 +120 0 +mmol 0 +/ 0 +L 0 +, 0 +serum 0 +osmolality 0 +was 0 +263 0 +mosmol 0 +/ 0 +kg 0 +, 0 +urine 0 +osmolality 0 +410 0 +mosmol 0 +/ 0 +kg 0 +and 0 +urine 0 +sodium 1 +63 0 +mmol 0 +/ 0 +L 0 +, 0 +consistent 0 +with 0 +a 0 +diagnosis 0 +of 0 +SIADH 3 +. 0 + +Desvenlafaxine 1 +was 0 +ceased 0 +and 0 +fluid 0 +restriction 0 +implemented 0 +. 0 + +After 0 +4 0 +days 0 +the 0 +sodium 1 +increased 0 +to 0 +128 0 +mmol 0 +/ 0 +L 0 +and 0 +fluid 0 +restriction 0 +was 0 +relaxed 0 +. 0 + +During 0 +her 0 +further 0 +3 0 +weeks 0 +inpatient 0 +admission 0 +the 0 +serum 0 +sodium 1 +ranged 0 +from 0 +134 0 +to 0 +137 0 +mmol 0 +/ 0 +L 0 +during 0 +treatment 0 +with 0 +mirtazapine 1 +. 0 + +DISCUSSI0N 0 +: 0 +SIADH 3 +has 0 +been 0 +widely 0 +reported 0 +with 0 +a 0 +range 0 +of 0 +antidepressants 0 +. 0 + +This 0 +case 0 +report 0 +suggests 0 +that 0 +desvenlafaxine 1 +might 0 +cause 0 +clinically 0 +significant 0 +hyponatremia 3 +. 0 + +C0NCLUSI0NS 0 +: 0 +Clinicians 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +potential 0 +for 0 +antidepressants 0 +to 0 +cause 0 +hyponatremia 3 +, 0 +and 0 +take 0 +appropriate 0 +corrective 0 +action 0 +where 0 +necessary 0 +. 0 + +0xidative 0 +stress 0 +on 0 +cardiotoxicity 3 +after 0 +treatment 0 +with 0 +single 0 +and 0 +multiple 0 +doses 0 +of 0 +doxorubicin 1 +. 0 + +The 0 +mechanism 0 +of 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +- 0 +induced 0 +cardiotoxicity 3 +remains 0 +controversial 0 +. 0 + +Wistar 0 +rats 0 +( 0 +n 0 += 0 +66 0 +) 0 +received 0 +D0X 1 +injections 0 +intraperitoneally 0 +and 0 +were 0 +randomly 0 +assigned 0 +to 0 +2 0 +experimental 0 +protocols 0 +: 0 +( 0 +1 0 +) 0 +rats 0 +were 0 +killed 0 +before 0 +( 0 +- 0 +24 0 +h 0 +, 0 +n 0 += 0 +8 0 +) 0 +and 0 +24 0 +h 0 +after 0 +( 0 ++ 0 +24 0 +h 0 +, 0 +n 0 += 0 +8 0 +) 0 +a 0 +single 0 +dose 0 +of 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +to 0 +determine 0 +the 0 +D0X 1 +acute 0 +effect 0 +and 0 +( 0 +2 0 +) 0 +rats 0 +( 0 +n 0 += 0 +58 0 +) 0 +received 0 +4 0 +injections 0 +of 0 +D0X 1 +( 0 +4 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +/ 0 +week 0 +) 0 +and 0 +were 0 +killed 0 +before 0 +the 0 +first 0 +injection 0 +( 0 +M0 0 +) 0 +and 0 +1 0 +week 0 +after 0 +each 0 +injection 0 +( 0 +M1 0 +, 0 +M2 0 +, 0 +M3 0 +, 0 +and 0 +M4 0 +) 0 +to 0 +determine 0 +the 0 +chronological 0 +effects 0 +. 0 + +Animals 0 +used 0 +at 0 +M0 0 +( 0 +n 0 += 0 +8 0 +) 0 +were 0 +also 0 +used 0 +at 0 +moment 0 +- 0 +24 0 +h 0 +of 0 +acute 0 +study 0 +. 0 + +Cardiac 0 +total 0 +antioxidant 0 +performance 0 +( 0 +TAP 0 +) 0 +, 0 +DNA 0 +damage 0 +, 0 +and 0 +morphology 0 +analyses 0 +were 0 +carried 0 +out 0 +at 0 +each 0 +time 0 +point 0 +. 0 + +Single 0 +dose 0 +of 0 +D0X 1 +was 0 +associated 0 +with 0 +increased 0 +cardiac 3 +disarrangement 4 +, 0 +necrosis 3 +, 0 +and 0 +DNA 0 +damage 0 +( 0 +strand 0 +breaks 0 +( 0 +SBs 0 +) 0 +and 0 +oxidized 0 +pyrimidines 0 +) 0 +and 0 +decreased 0 +TAP 0 +. 0 + +The 0 +chronological 0 +study 0 +showed 0 +an 0 +effect 0 +of 0 +a 0 +cumulative 0 +dose 0 +on 0 +body 0 +weight 0 +( 0 +R 0 += 0 +- 0 +0 0 +. 0 +99 0 +, 0 +p 0 += 0 +0 0 +. 0 +011 0 +) 0 +, 0 +necrosis 3 +( 0 +R 0 += 0 +1 0 +. 0 +00 0 +, 0 +p 0 += 0 +0 0 +. 0 +004 0 +) 0 +, 0 +TAP 0 +( 0 +R 0 += 0 +0 0 +. 0 +95 0 +, 0 +p 0 += 0 +0 0 +. 0 +049 0 +) 0 +, 0 +and 0 +DNA 0 +SBs 0 +( 0 +R 0 += 0 +- 0 +0 0 +. 0 +95 0 +, 0 +p 0 += 0 +0 0 +. 0 +049 0 +) 0 +. 0 + +DNA 0 +SBs 0 +damage 0 +was 0 +negatively 0 +associated 0 +with 0 +TAP 0 +( 0 +R 0 += 0 +- 0 +0 0 +. 0 +98 0 +, 0 +p 0 += 0 +0 0 +. 0 +018 0 +) 0 +, 0 +and 0 +necrosis 3 +( 0 +R 0 += 0 +- 0 +0 0 +. 0 +97 0 +, 0 +p 0 += 0 +0 0 +. 0 +027 0 +) 0 +. 0 + +0ur 0 +results 0 +suggest 0 +that 0 +oxidative 0 +damage 0 +is 0 +associated 0 +with 0 +acute 0 +cardiotoxicity 3 +induced 0 +by 0 +a 0 +single 0 +dose 0 +of 0 +D0X 1 +only 0 +. 0 + +Increased 0 +resistance 0 +to 0 +the 0 +oxidative 0 +stress 0 +is 0 +plausible 0 +for 0 +the 0 +multiple 0 +dose 0 +of 0 +D0X 1 +. 0 + +Thus 0 +, 0 +different 0 +mechanisms 0 +may 0 +be 0 +involved 0 +in 0 +acute 0 +toxicity 3 +versus 0 +chronic 0 +toxicity 3 +. 0 + +Tacrolimus 1 +- 0 +related 0 +seizure 3 +after 0 +pediatric 0 +liver 0 +transplantation 0 +- 0 +- 0 +a 0 +single 0 +- 0 +center 0 +experience 0 +. 0 + +To 0 +identify 0 +the 0 +risk 0 +factors 0 +for 0 +new 0 +- 0 +onset 0 +seizures 3 +after 0 +pediatric 0 +LT 0 +and 0 +to 0 +assess 0 +their 0 +clinical 0 +implications 0 +and 0 +long 0 +- 0 +term 0 +prognosis 0 +. 0 + +The 0 +clinical 0 +and 0 +laboratory 0 +data 0 +of 0 +27 0 +consecutive 0 +children 0 +who 0 +underwent 0 +LT 0 +from 0 +January 0 +2007 0 +to 0 +December 0 +2010 0 +in 0 +our 0 +center 0 +were 0 +analyzed 0 +retrospectively 0 +. 0 + +Patients 0 +were 0 +divided 0 +into 0 +seizures 3 +group 0 +and 0 +a 0 +non 0 +- 0 +seizures 3 +group 0 +. 0 + +Pre 0 +- 0 +operative 0 +, 0 +intra 0 +- 0 +operative 0 +, 0 +and 0 +post 0 +- 0 +operative 0 +data 0 +were 0 +collected 0 +. 0 + +Seizures 3 +occurred 0 +in 0 +four 0 +children 0 +, 0 +an 0 +incidence 0 +of 0 +14 0 +. 0 +8 0 +% 0 +. 0 + +All 0 +exhibited 0 +generalized 0 +tonic 3 +- 4 +clonic 4 +seizures 4 +within 0 +the 0 +first 0 +two 0 +wk 0 +after 0 +LT 0 +. 0 + +Univariate 0 +analysis 0 +showed 0 +that 0 +the 0 +risk 0 +factors 0 +associated 0 +with 0 +seizures 3 +after 0 +pediatric 0 +LT 0 +included 0 +gender 0 +, 0 +pediatric 0 +end 3 +- 4 +stage 4 +liver 4 +disease 4 +score 0 +before 0 +surgery 0 +, 0 +Child 0 +- 0 +Pugh 0 +score 0 +before 0 +surgery 0 +, 0 +serum 0 +total 0 +bilirubin 1 +after 0 +surgery 0 +, 0 +and 0 +trough 0 +TAC 1 +level 0 +. 0 + +Multivariate 0 +analysis 0 +showed 0 +that 0 +trough 0 +TAC 1 +level 0 +was 0 +the 0 +only 0 +independent 0 +risk 0 +factor 0 +associated 0 +with 0 +the 0 +seizures 3 +. 0 + +All 0 +children 0 +who 0 +experienced 0 +seizures 3 +survived 0 +with 0 +good 0 +graft 0 +function 0 +and 0 +remained 0 +seizure 3 +- 0 +free 0 +without 0 +anti 0 +- 0 +epileptic 3 +drugs 0 +over 0 +a 0 +mean 0 +follow 0 +- 0 +up 0 +period 0 +of 0 +33 0 +. 0 +7 0 ++ 0 +14 0 +. 0 +6 0 +months 0 +. 0 + +High 0 +trough 0 +TAC 1 +level 0 +was 0 +the 0 +predominant 0 +factor 0 +that 0 +contributed 0 +to 0 +seizures 3 +in 0 +the 0 +early 0 +post 0 +- 0 +operative 0 +period 0 +after 0 +pediatric 0 +LT 0 +. 0 + +High 0 +PELD 0 +and 0 +Child 0 +- 0 +Pugh 0 +scores 0 +before 0 +LT 0 +and 0 +high 0 +post 0 +- 0 +operative 0 +serum 0 +Tbil 0 +may 0 +be 0 +contributory 0 +risk 0 +factors 0 +for 0 +TAC 1 +- 0 +related 0 +seizures 3 +. 0 + +The 0 +flavonoid 1 +apigenin 1 +delays 0 +forgetting 0 +of 0 +passive 0 +avoidance 0 +conditioning 0 +in 0 +rats 0 +. 0 + +The 0 +present 0 +experiments 0 +were 0 +performed 0 +to 0 +study 0 +the 0 +effect 0 +of 0 +the 0 +flavonoid 1 +apigenin 1 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +intraperitoneally 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +, 0 +1 0 +h 0 +before 0 +acquisition 0 +) 0 +, 0 +on 0 +24 0 +h 0 +retention 0 +performance 0 +and 0 +forgetting 0 +of 0 +a 0 +step 0 +- 0 +through 0 +passive 0 +avoidance 0 +task 0 +, 0 +in 0 +young 0 +male 0 +Wistar 0 +rats 0 +. 0 + +There 0 +were 0 +no 0 +differences 0 +between 0 +saline 0 +- 0 +and 0 +apigenin 1 +- 0 +treated 0 +groups 0 +in 0 +the 0 +24 0 +h 0 +retention 0 +trial 0 +. 0 + +Furthermore 0 +, 0 +apigenin 1 +did 0 +not 0 +prevent 0 +the 0 +amnesia 3 +induced 0 +by 0 +scopolamine 1 +( 0 +1mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +, 0 +30 0 +min 0 +before 0 +the 0 +acquisition 0 +) 0 +. 0 + +The 0 +saline 0 +- 0 +and 0 +apigenin 1 +- 0 +treated 0 +rats 0 +that 0 +did 0 +not 0 +step 0 +through 0 +into 0 +the 0 +dark 0 +compartment 0 +during 0 +the 0 +cut 0 +- 0 +off 0 +time 0 +( 0 +540 0 +s 0 +) 0 +were 0 +retested 0 +weekly 0 +for 0 +up 0 +to 0 +eight 0 +weeks 0 +. 0 + +In 0 +the 0 +saline 0 +treated 0 +group 0 +, 0 +the 0 +first 0 +significant 0 +decline 0 +in 0 +passive 0 +avoidance 0 +response 0 +was 0 +observed 0 +at 0 +four 0 +weeks 0 +, 0 +and 0 +complete 0 +memory 3 +loss 4 +was 0 +found 0 +five 0 +weeks 0 +after 0 +the 0 +acquisition 0 +of 0 +the 0 +passive 0 +avoidance 0 +task 0 +. 0 + +At 0 +the 0 +end 0 +of 0 +the 0 +experimental 0 +period 0 +, 0 +60 0 +% 0 +of 0 +the 0 +animals 0 +treated 0 +with 0 +apigenin 1 +still 0 +did 0 +not 0 +step 0 +through 0 +. 0 + +These 0 +data 0 +suggest 0 +that 0 +1 0 +) 0 +apigenin 1 +delays 0 +the 0 +long 0 +- 0 +term 0 +forgetting 0 +but 0 +did 0 +not 0 +modulate 0 +the 0 +24 0 +h 0 +retention 0 +of 0 +fear 0 +memory 0 +and 0 +2 0 +) 0 +the 0 +obtained 0 +beneficial 0 +effect 0 +of 0 +apigenin 1 +on 0 +the 0 +passive 0 +avoidance 0 +conditioning 0 +is 0 +mediated 0 +by 0 +mechanisms 0 +that 0 +do 0 +not 0 +implicate 0 +its 0 +action 0 +on 0 +the 0 +muscarinic 0 +cholinergic 0 +system 0 +. 0 + +Histamine 1 +antagonists 0 +and 0 +d 1 +- 2 +tubocurarine 2 +- 0 +induced 0 +hypotension 3 +in 0 +cardiac 0 +surgical 0 +patients 0 +. 0 + +Hemodynamic 0 +effects 0 +and 0 +histamine 1 +release 0 +by 0 +bolus 0 +injection 0 +of 0 +0 0 +. 0 +35 0 +mg 0 +/ 0 +kg 0 +of 0 +d 1 +- 2 +tubocurarine 2 +were 0 +studied 0 +in 0 +24 0 +patients 0 +. 0 + +H1 0 +- 0 +and 0 +H2 0 +- 0 +histamine 1 +antagonists 0 +or 0 +placebo 0 +were 0 +given 0 +before 0 +dosing 0 +with 0 +d 1 +- 2 +tubocurarine 2 +in 0 +a 0 +randomized 0 +double 0 +- 0 +blind 0 +fashion 0 +to 0 +four 0 +groups 0 +: 0 +group 0 +1 0 +- 0 +- 0 +placebo 0 +; 0 +group 0 +2 0 +- 0 +- 0 +cimetidine 1 +, 0 +4 0 +mg 0 +/ 0 +kg 0 +, 0 +plus 0 +placebo 0 +; 0 +group 0 +3 0 +- 0 +- 0 +chlorpheniramine 1 +, 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +, 0 +plus 0 +placebo 0 +; 0 +and 0 +group 0 +4 0 +- 0 +- 0 +cimetidine 1 +plus 0 +chlorpheniramine 1 +. 0 + +Histamine 1 +release 0 +occurred 0 +in 0 +most 0 +patients 0 +, 0 +the 0 +highest 0 +level 0 +2 0 +minutes 0 +after 0 +d 1 +- 2 +tubocurarine 2 +dosing 0 +. 0 + +Group 0 +1 0 +had 0 +a 0 +moderate 0 +negative 0 +correlation 0 +between 0 +plasma 0 +histamine 1 +change 0 +and 0 +systemic 0 +vascular 0 +resistance 0 +( 0 +r 0 += 0 +0 0 +. 0 +58 0 +; 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +not 0 +present 0 +in 0 +group 0 +4 0 +. 0 + +Prior 0 +dosing 0 +with 0 +antagonists 0 +partially 0 +prevented 0 +the 0 +fall 0 +in 0 +systemic 0 +vascular 0 +resistance 0 +. 0 + +These 0 +data 0 +demonstrate 0 +that 0 +the 0 +hemodynamic 0 +changes 0 +associated 0 +with 0 +d 1 +- 2 +tubocurarine 2 +dosing 0 +are 0 +only 0 +partially 0 +explained 0 +by 0 +histamine 1 +release 0 +. 0 + +Thus 0 +prior 0 +dosing 0 +with 0 +H1 0 +- 0 +and 0 +H2 0 +- 0 +antagonists 0 +provides 0 +only 0 +partial 0 +protection 0 +. 0 + +Cholecystokinin 1 +- 2 +octapeptide 2 +restored 0 +morphine 1 +- 0 +induced 0 +hippocampal 0 +long 0 +- 0 +term 0 +potentiation 0 +impairment 0 +in 0 +rats 0 +. 0 + +Cholecystokinin 1 +- 2 +octapeptide 2 +( 0 +CCK 1 +- 2 +8 2 +) 0 +, 0 +which 0 +is 0 +a 0 +typical 0 +brain 0 +- 0 +gut 0 +peptide 0 +, 0 +exerts 0 +a 0 +wide 0 +range 0 +of 0 +biological 0 +activities 0 +on 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 + +We 0 +have 0 +previously 0 +reported 0 +that 0 +CCK 1 +- 2 +8 2 +significantly 0 +alleviated 0 +morphine 1 +- 0 +induced 0 +amnesia 3 +and 0 +reversed 0 +spine 0 +density 0 +decreases 0 +in 0 +the 0 +CA1 0 +region 0 +of 0 +the 0 +hippocampus 0 +in 0 +morphine 1 +- 0 +treated 0 +animals 0 +. 0 + +Here 0 +, 0 +we 0 +investigated 0 +the 0 +effects 0 +of 0 +CCK 1 +- 2 +8 2 +on 0 +long 0 +- 0 +term 0 +potentiation 0 +( 0 +LTP 0 +) 0 +in 0 +the 0 +lateral 0 +perforant 0 +path 0 +( 0 +LPP 0 +) 0 +- 0 +granule 0 +cell 0 +synapse 0 +of 0 +rat 0 +dentate 0 +gyrus 0 +( 0 +DG 0 +) 0 +in 0 +acute 0 +saline 0 +or 0 +morphine 1 +- 0 +treated 0 +rats 0 +. 0 + +Population 0 +spikes 0 +( 0 +PS 0 +) 0 +, 0 +which 0 +were 0 +evoked 0 +by 0 +stimulation 0 +of 0 +the 0 +LPP 0 +, 0 +were 0 +recorded 0 +in 0 +the 0 +DG 0 +region 0 +. 0 + +Acute 0 +morphine 1 +( 0 +30mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +treatment 0 +significantly 0 +attenuated 0 +hippocampal 0 +LTP 0 +and 0 +CCK 1 +- 2 +8 2 +( 0 +1ug 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +restored 0 +the 0 +amplitude 0 +of 0 +PS 0 +that 0 +was 0 +attenuated 0 +by 0 +morphine 1 +injection 0 +. 0 + +Furthermore 0 +, 0 +microinjection 0 +of 0 +CCK 1 +- 2 +8 2 +( 0 +0 0 +. 0 +1 0 +and 0 +1ug 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +also 0 +significantly 0 +augmented 0 +hippocampal 0 +LTP 0 +in 0 +saline 0 +- 0 +treated 0 +( 0 +1ml 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +rats 0 +. 0 + +Pre 0 +- 0 +treatment 0 +of 0 +the 0 +CCK2 0 +receptor 0 +antagonist 0 +L 0 +- 0 +365 0 +, 0 +260 0 +( 0 +10ug 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +) 0 +reversed 0 +the 0 +effects 0 +of 0 +CCK 1 +- 2 +8 2 +, 0 +but 0 +the 0 +CCK1 0 +receptor 0 +antagonist 0 +L 0 +- 0 +364 0 +, 0 +718 0 +( 0 +10ug 0 +, 0 +i 0 +. 0 +c 0 +. 0 +v 0 +) 0 +did 0 +not 0 +. 0 + +The 0 +present 0 +results 0 +demonstrate 0 +that 0 +CCK 1 +- 2 +8 2 +attenuates 0 +the 0 +effect 0 +of 0 +morphine 1 +on 0 +hippocampal 0 +LTP 0 +through 0 +CCK2 0 +receptors 0 +and 0 +suggest 0 +an 0 +ameliorative 0 +function 0 +of 0 +CCK 1 +- 2 +8 2 +on 0 +morphine 1 +- 0 +induced 0 +memory 3 +impairment 4 +. 0 + +Glial 0 +activation 0 +and 0 +post 0 +- 0 +synaptic 0 +neurotoxicity 3 +: 0 +the 0 +key 0 +events 0 +in 0 +Streptozotocin 1 +( 0 +ICV 0 +) 0 +induced 0 +memory 3 +impairment 4 +in 0 +rats 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +the 0 +role 0 +of 0 +glial 0 +activation 0 +and 0 +post 0 +synaptic 0 +toxicity 3 +in 0 +ICV 0 +Streptozotocin 1 +( 0 +STZ 1 +) 0 +induced 0 +memory 3 +impaired 4 +rats 0 +was 0 +explored 0 +. 0 + +In 0 +experiment 0 +set 0 +up 0 +1 0 +: 0 +Memory 3 +deficit 4 +was 0 +found 0 +in 0 +Morris 0 +water 0 +maze 0 +test 0 +on 0 +14 0 +- 0 +16 0 +days 0 +after 0 +STZ 1 +( 0 +ICV 0 +; 0 +3mg 0 +/ 0 +Kg 0 +) 0 +administration 0 +. 0 + +STZ 1 +causes 0 +increased 0 +expression 0 +of 0 +GFAP 0 +, 0 +CD11b 0 +and 0 +TNF 0 +- 0 +a 0 +indicating 0 +glial 0 +activation 0 +and 0 +neuroinflammation 3 +. 0 + +STZ 1 +also 0 +significantly 0 +increased 0 +the 0 +level 0 +of 0 +R0S 0 +, 0 +nitrite 1 +, 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +and 0 +reduced 0 +the 0 +mitochondrial 0 +activity 0 +in 0 +synaptosomal 0 +preparation 0 +illustrating 0 +free 0 +radical 0 +generation 0 +and 0 +excitotoxicity 3 +. 0 + +Increased 0 +expression 0 +and 0 +activity 0 +of 0 +Caspase 0 +- 0 +3 0 +was 0 +also 0 +observed 0 +in 0 +STZ 1 +treated 0 +rat 0 +which 0 +specify 0 +apoptotic 0 +cell 0 +death 0 +in 0 +hippocampus 0 +and 0 +cortex 0 +. 0 + +STZ 1 +treatment 0 +showed 0 +decrease 0 +expression 0 +of 0 +post 0 +synaptic 0 +markers 0 +CaMKIIa 0 +and 0 +PSD 0 +- 0 +95 0 +, 0 +while 0 +, 0 +expression 0 +of 0 +pre 0 +synaptic 0 +markers 0 +( 0 +synaptophysin 0 +and 0 +SNAP 0 +- 0 +25 0 +) 0 +remains 0 +unaltered 0 +indicating 0 +selective 0 +post 0 +synaptic 0 +neurotoxicity 3 +. 0 + +0ral 0 +treatment 0 +with 0 +Memantine 1 +( 0 +10mg 0 +/ 0 +kg 0 +) 0 +and 0 +Ibuprofen 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +daily 0 +for 0 +13 0 +days 0 +attenuated 0 +STZ 1 +induced 0 +glial 0 +activation 0 +, 0 +apoptotic 0 +cell 0 +death 0 +and 0 +post 0 +synaptic 0 +neurotoxicity 3 +in 0 +rat 0 +brain 0 +. 0 + +Further 0 +, 0 +in 0 +experiment 0 +set 0 +up 0 +2 0 +: 0 +where 0 +memory 0 +function 0 +was 0 +not 0 +affected 0 +i 0 +. 0 +e 0 +. 0 +7 0 +- 0 +9 0 +days 0 +after 0 +STZ 1 +treatment 0 +. 0 + +The 0 +level 0 +of 0 +GFAP 0 +, 0 +CD11b 0 +, 0 +TNF 0 +- 0 +a 0 +, 0 +R0S 0 +and 0 +nitrite 1 +levels 0 +were 0 +increased 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +apoptotic 0 +marker 0 +, 0 +synaptic 0 +markers 0 +, 0 +mitochondrial 0 +activity 0 +and 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +levels 0 +remained 0 +unaffected 0 +. 0 + +Collective 0 +data 0 +indicates 0 +that 0 +neuroinflammatory 3 +process 0 +and 0 +oxidative 0 +stress 0 +occurs 0 +earlier 0 +to 0 +apoptosis 0 +and 0 +does 0 +not 0 +affect 0 +memory 0 +function 0 +. 0 + +Present 0 +study 0 +clearly 0 +suggests 0 +that 0 +glial 0 +activation 0 +and 0 +post 0 +synaptic 0 +neurotoxicity 3 +are 0 +the 0 +key 0 +factors 0 +in 0 +STZ 1 +induced 0 +memory 3 +impairment 4 +and 0 +neuronal 0 +cell 0 +death 0 +. 0 + +Comparison 0 +of 0 +effects 0 +of 0 +isotonic 0 +sodium 1 +chloride 2 +with 0 +diltiazem 1 +in 0 +prevention 0 +of 0 +contrast 1 +- 0 +induced 0 +nephropathy 3 +. 0 + +INTR0DUCTI0N 0 +AND 0 +0BJECTIVE 0 +: 0 +Contrast 1 +- 0 +induced 0 +nephropathy 3 +( 0 +CIN 0 +) 0 +significantly 0 +increases 0 +the 0 +morbidity 0 +and 0 +mortality 0 +of 0 +patients 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +investigate 0 +and 0 +compare 0 +the 0 +protective 0 +effects 0 +of 0 +isotonic 0 +sodium 1 +chloride 2 +with 0 +sodium 1 +bicarbonate 2 +infusion 0 +and 0 +isotonic 0 +sodium 1 +chloride 2 +infusion 0 +with 0 +diltiazem 1 +, 0 +a 0 +calcium 1 +channel 0 +blocker 0 +, 0 +in 0 +preventing 0 +CIN 0 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +0ur 0 +study 0 +included 0 +patients 0 +who 0 +were 0 +administered 0 +30 0 +- 0 +60 0 +mL 0 +of 0 +iodinated 0 +contrast 1 +agent 0 +for 0 +percutaneous 0 +coronary 0 +angiography 0 +( 0 +PCAG 0 +) 0 +, 0 +all 0 +with 0 +creatinine 1 +values 0 +between 0 +1 0 +. 0 +1 0 +and 0 +3 0 +. 0 +1 0 +mg 0 +/ 0 +dL 0 +. 0 + +Patients 0 +were 0 +divided 0 +into 0 +three 0 +groups 0 +and 0 +each 0 +group 0 +had 0 +20 0 +patients 0 +. 0 + +The 0 +first 0 +group 0 +of 0 +patients 0 +was 0 +administered 0 +isotonic 0 +sodium 1 +chloride 2 +; 0 +the 0 +second 0 +group 0 +was 0 +administered 0 +a 0 +solution 0 +that 0 +of 0 +5 0 +% 0 +dextrose 1 +and 0 +sodium 1 +bicarbonate 2 +, 0 +while 0 +the 0 +third 0 +group 0 +was 0 +administered 0 +isotonic 0 +sodium 1 +chloride 2 +before 0 +and 0 +after 0 +the 0 +contrast 1 +injection 0 +. 0 + +The 0 +third 0 +group 0 +received 0 +an 0 +additional 0 +injection 0 +of 0 +diltiazem 1 +the 0 +day 0 +before 0 +and 0 +first 0 +2 0 +days 0 +after 0 +the 0 +contrast 1 +injection 0 +. 0 + +All 0 +of 0 +the 0 +patients 0 +' 0 +plasma 0 +blood 1 +urea 2 +nitrogen 2 +( 0 +BUN 1 +) 0 +and 0 +creatinine 1 +levels 0 +were 0 +measured 0 +on 0 +the 0 +second 0 +and 0 +seventh 0 +day 0 +after 0 +the 0 +administration 0 +of 0 +intravenous 0 +contrast 1 +material 0 +. 0 + +RESULTS 0 +: 0 +The 0 +basal 0 +creatinine 1 +levels 0 +were 0 +similar 0 +for 0 +all 0 +three 0 +groups 0 +( 0 +p 0 +> 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Among 0 +a 0 +total 0 +of 0 +60 0 +patients 0 +included 0 +in 0 +the 0 +study 0 +, 0 +16 0 +patients 0 +developed 0 +acute 3 +renal 4 +failure 4 +( 0 +ARF 3 +) 0 +on 0 +the 0 +second 0 +day 0 +after 0 +contrast 1 +material 0 +was 0 +injected 0 +( 0 +26 0 +. 0 +6 0 +% 0 +) 0 +. 0 + +The 0 +number 0 +of 0 +patients 0 +who 0 +developed 0 +ARF 3 +on 0 +the 0 +second 0 +day 0 +after 0 +the 0 +injection 0 +in 0 +the 0 +first 0 +group 0 +was 0 +five 0 +( 0 +25 0 +% 0 +) 0 +, 0 +in 0 +the 0 +second 0 +group 0 +was 0 +six 0 +( 0 +30 0 +% 0 +) 0 +and 0 +the 0 +third 0 +group 0 +was 0 +five 0 +( 0 +25 0 +% 0 +) 0 +( 0 +p 0 +> 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +There 0 +was 0 +no 0 +significant 0 +difference 0 +between 0 +isotonic 0 +sodium 1 +chloride 2 +, 0 +sodium 1 +bicarbonate 2 +and 0 +isotonic 0 +sodium 1 +chloride 2 +with 0 +diltiazem 1 +application 0 +in 0 +prevention 0 +of 0 +CIN 0 +. 0 + +Neurocognitive 0 +and 0 +neuroradiologic 0 +central 0 +nervous 0 +system 0 +late 0 +effects 0 +in 0 +children 0 +treated 0 +on 0 +Pediatric 0 +0ncology 0 +Group 0 +( 0 +P0G 0 +) 0 +P9605 0 +( 0 +standard 0 +risk 0 +) 0 +and 0 +P9201 0 +( 0 +lesser 0 +risk 0 +) 0 +acute 3 +lymphoblastic 4 +leukemia 4 +protocols 0 +( 0 +ACCL0131 0 +) 0 +: 0 +a 0 +methotrexate 1 +consequence 0 +? 0 + +A 0 +report 0 +from 0 +the 0 +Children 0 +' 0 +s 0 +0ncology 0 +Group 0 +. 0 + +Concerns 0 +about 0 +long 0 +- 0 +term 0 +methotrexate 1 +( 0 +MTX 1 +) 0 +neurotoxicity 3 +in 0 +the 0 +1990s 0 +led 0 +to 0 +modifications 0 +in 0 +intrathecal 0 +( 0 +IT 0 +) 0 +therapy 0 +, 0 +leucovorin 0 +rescue 0 +, 0 +and 0 +frequency 0 +of 0 +systemic 0 +MTX 1 +administration 0 +in 0 +children 0 +with 0 +acute 3 +lymphoblastic 4 +leukemia 4 +. 0 + +In 0 +this 0 +study 0 +, 0 +neurocognitive 0 +outcomes 0 +and 0 +neuroradiologic 0 +evidence 0 +of 0 +leukoencephalopathy 3 +were 0 +compared 0 +in 0 +children 0 +treated 0 +with 0 +intense 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +- 0 +directed 0 +therapy 0 +( 0 +P9605 0 +) 0 +versus 0 +those 0 +receiving 0 +fewer 0 +CNS 0 +- 0 +directed 0 +treatment 0 +days 0 +during 0 +intensive 0 +consolidation 0 +( 0 +P9201 0 +) 0 +. 0 + +A 0 +total 0 +of 0 +66 0 +children 0 +from 0 +16 0 +Pediatric 0 +0ncology 0 +Group 0 +institutions 0 +with 0 +" 0 +standard 0 +- 0 +risk 0 +" 0 +acute 3 +lymphoblastic 4 +leukemia 4 +, 0 +1 0 +. 0 +00 0 +to 0 +9 0 +. 0 +99 0 +years 0 +at 0 +diagnosis 0 +, 0 +without 0 +evidence 0 +of 0 +CNS 0 +leukemia 3 +at 0 +diagnosis 0 +were 0 +enrolled 0 +on 0 +ACCL0131 0 +: 0 +28 0 +from 0 +P9201 0 +and 0 +38 0 +from 0 +P9605 0 +. 0 + +Magnetic 0 +resonance 0 +imaging 0 +scans 0 +and 0 +standard 0 +neuropsychological 0 +tests 0 +were 0 +performed 0 +> 0 +2 0 +. 0 +6 0 +years 0 +after 0 +the 0 +end 0 +of 0 +treatment 0 +. 0 + +Significantly 0 +more 0 +P9605 0 +patients 0 +developed 0 +leukoencephalopathy 3 +compared 0 +with 0 +P9201 0 +patients 0 +( 0 +68 0 +% 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +49 0 +% 0 +- 0 +83 0 +% 0 +vs 0 +. 0 +22 0 +% 0 +, 0 +95 0 +% 0 +confidence 0 +interval 0 +5 0 +% 0 +- 0 +44 0 +% 0 +; 0 +P 0 += 0 +0 0 +. 0 +001 0 +) 0 +identified 0 +as 0 +late 0 +as 0 +7 0 +. 0 +7 0 +years 0 +after 0 +the 0 +end 0 +of 0 +treatment 0 +. 0 + +0verall 0 +, 0 +40 0 +% 0 +of 0 +patients 0 +scored 0 +< 0 +85 0 +on 0 +either 0 +Verbal 0 +or 0 +Performance 0 +IQ 0 +. 0 + +Children 0 +on 0 +both 0 +studies 0 +had 0 +significant 0 +attention 3 +problems 4 +, 0 +but 0 +P9605 0 +children 0 +scored 0 +below 0 +average 0 +on 0 +more 0 +neurocognitive 0 +measures 0 +than 0 +those 0 +treated 0 +on 0 +P9201 0 +( 0 +82 0 +% 0 +, 0 +14 0 +/ 0 +17 0 +measures 0 +vs 0 +. 0 +24 0 +% 0 +, 0 +4 0 +/ 0 +17 0 +measures 0 +) 0 +. 0 + +This 0 +supports 0 +ongoing 0 +concerns 0 +about 0 +intensive 0 +MTX 1 +exposure 0 +as 0 +a 0 +major 0 +contributor 0 +to 0 +CNS 0 +late 0 +effects 0 +. 0 + +Tranexamic 1 +acid 2 +overdosage 0 +- 0 +induced 0 +generalized 0 +seizure 3 +in 0 +renal 3 +failure 4 +. 0 + +We 0 +report 0 +a 0 +45 0 +- 0 +year 0 +- 0 +old 0 +lady 0 +with 0 +chronic 3 +kidney 4 +disease 4 +stage 0 +4 0 +due 0 +to 0 +chronic 0 +tubulointerstial 3 +disease 4 +. 0 + +She 0 +was 0 +admitted 0 +to 0 +our 0 +center 0 +for 0 +severe 0 +anemia 3 +due 0 +to 0 +menorrhagia 3 +and 0 +deterioration 3 +of 4 +renal 4 +function 4 +. 0 + +She 0 +was 0 +infused 0 +three 0 +units 0 +of 0 +packed 0 +cells 0 +during 0 +a 0 +session 0 +of 0 +hemodialysis 0 +. 0 + +Tranexamic 1 +acid 2 +( 0 +TNA 1 +) 0 +1 0 +g 0 +8 0 +- 0 +hourly 0 +was 0 +administered 0 +to 0 +her 0 +to 0 +control 0 +bleeding 3 +per 0 +vaginum 0 +. 0 + +Two 0 +hours 0 +after 0 +the 0 +sixth 0 +dose 0 +of 0 +TNA 1 +, 0 +she 0 +had 0 +an 0 +episode 0 +of 0 +generalized 0 +tonic 3 +clonic 4 +convulsions 4 +. 0 + +TNA 1 +was 0 +discontinued 0 +. 0 + +Investigations 0 +of 0 +the 0 +patient 0 +revealed 0 +no 0 +biochemical 0 +or 0 +structural 0 +central 0 +nervous 3 +system 4 +abnormalities 4 +that 0 +could 0 +have 0 +provoked 0 +the 0 +convulsions 3 +. 0 + +She 0 +did 0 +not 0 +require 0 +any 0 +further 0 +dialytic 0 +support 0 +. 0 + +She 0 +had 0 +no 0 +further 0 +episodes 0 +of 0 +convulsion 3 +till 0 +dis 0 +- 0 +charge 0 +and 0 +during 0 +the 0 +two 0 +months 0 +of 0 +follow 0 +- 0 +up 0 +. 0 + +Thus 0 +, 0 +the 0 +precipitating 0 +cause 0 +of 0 +convulsions 3 +was 0 +believed 0 +to 0 +be 0 +an 0 +overdose 3 +of 0 +TNA 1 +. 0 + +Pre 0 +- 0 +treatment 0 +of 0 +bupivacaine 1 +- 0 +induced 0 +cardiovascular 3 +depression 4 +using 0 +different 0 +lipid 0 +formulations 0 +of 0 +propofol 1 +. 0 + +BACKGR0UND 0 +: 0 +Pre 0 +- 0 +treatment 0 +with 0 +lipid 0 +emulsions 0 +has 0 +been 0 +shown 0 +to 0 +increase 0 +lethal 0 +doses 0 +of 0 +bupivacaine 1 +, 0 +and 0 +the 0 +lipid 0 +content 0 +of 0 +propofol 1 +may 0 +alleviate 0 +bupivacaine 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +propofol 1 +in 0 +intralipid 0 +or 0 +medialipid 0 +emulsions 0 +on 0 +bupivacaine 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +METH0DS 0 +: 0 +Rats 0 +were 0 +anaesthetised 0 +with 0 +ketamine 1 +and 0 +were 0 +given 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +min 0 +propofol 1 +in 0 +intralipid 0 +( 0 +Group 0 +P 0 +) 0 +, 0 +propofol 1 +in 0 +medialipid 0 +( 0 +Group 0 +L 0 +) 0 +, 0 +or 0 +saline 0 +( 0 +Group 0 +C 0 +) 0 +over 0 +20 0 +min 0 +. 0 + +Thereafter 0 +, 0 +2 0 +mg 0 +/ 0 +kg 0 +/ 0 +min 0 +bupivacaine 1 +0 0 +. 0 +5 0 +% 0 +was 0 +infused 0 +. 0 + +We 0 +recorded 0 +time 0 +to 0 +first 0 +dysrhythmia 3 +occurrence 0 +, 0 +respective 0 +times 0 +to 0 +25 0 +% 0 +and 0 +50 0 +% 0 +reduction 0 +of 0 +the 0 +heart 0 +rate 0 +( 0 +HR 0 +) 0 +and 0 +mean 0 +arterial 0 +pressure 0 +, 0 +and 0 +time 0 +to 0 +asystole 3 +and 0 +total 0 +amount 0 +of 0 +bupivacaine 1 +consumption 0 +. 0 + +Blood 0 +and 0 +tissue 0 +samples 0 +were 0 +collected 0 +following 0 +asystole 3 +. 0 + +RESULTS 0 +: 0 +The 0 +time 0 +to 0 +first 0 +dysrhythmia 3 +occurrence 0 +, 0 +time 0 +to 0 +25 0 +% 0 +and 0 +50 0 +% 0 +reductions 0 +in 0 +HR 0 +, 0 +and 0 +time 0 +to 0 +asystole 3 +were 0 +longer 0 +in 0 +Group 0 +P 0 +than 0 +the 0 +other 0 +groups 0 +. 0 + +The 0 +cumulative 0 +bupivacaine 1 +dose 0 +given 0 +at 0 +those 0 +time 0 +points 0 +was 0 +higher 0 +in 0 +Group 0 +P 0 +. 0 +Plasma 0 +bupivacaine 1 +levels 0 +were 0 +significantly 0 +lower 0 +in 0 +Group 0 +P 0 +than 0 +in 0 +Group 0 +C 0 +. 0 +Bupivacaine 1 +levels 0 +in 0 +the 0 +brain 0 +and 0 +heart 0 +were 0 +significantly 0 +lower 0 +in 0 +Group 0 +P 0 +and 0 +Group 0 +L 0 +than 0 +in 0 +Group 0 +C 0 +. 0 + +C0NCLUSI0N 0 +: 0 +We 0 +conclude 0 +that 0 +pre 0 +- 0 +treatment 0 +with 0 +propofol 1 +in 0 +intralipid 0 +, 0 +compared 0 +with 0 +propofol 1 +in 0 +medialipid 0 +or 0 +saline 0 +, 0 +delayed 0 +the 0 +onset 0 +of 0 +bupivacaine 1 +- 0 +induced 0 +cardiotoxic 3 +effects 0 +as 0 +well 0 +as 0 +reduced 0 +plasma 0 +bupivacaine 1 +levels 0 +. 0 + +Further 0 +studies 0 +are 0 +needed 0 +to 0 +explore 0 +tissue 0 +bupivacaine 1 +levels 0 +of 0 +propofol 1 +in 0 +medialipid 0 +and 0 +adapt 0 +these 0 +results 0 +to 0 +clinical 0 +practice 0 +. 0 + +Drug 3 +- 4 +Induced 4 +Acute 4 +Liver 4 +Injury 4 +Within 0 +12 0 +Hours 0 +After 0 +Fluvastatin 1 +Therapy 0 +. 0 + +Although 0 +statins 1 +are 0 +generally 0 +well 0 +- 0 +tolerated 0 +drugs 0 +, 0 +recent 0 +cases 0 +of 0 +drug 3 +- 4 +induced 4 +liver 4 +injury 4 +associated 0 +with 0 +their 0 +use 0 +have 0 +been 0 +reported 0 +. 0 + +A 0 +52 0 +- 0 +year 0 +- 0 +old 0 +Chinese 0 +man 0 +reported 0 +with 0 +liver 3 +damage 4 +, 0 +which 0 +appeared 0 +12 0 +hours 0 +after 0 +beginning 0 +treatment 0 +with 0 +fluvastatin 1 +. 0 + +Patient 0 +presented 0 +with 0 +complaints 0 +of 0 +increasing 0 +nausea 3 +, 0 +anorexia 3 +, 0 +and 0 +upper 0 +abdominal 3 +pain 4 +. 0 + +His 0 +laboratory 0 +values 0 +showed 0 +elevated 0 +creatine 1 +kinase 0 +and 0 +transaminases 0 +. 0 + +Testing 0 +for 0 +autoantibodies 0 +was 0 +also 0 +negative 0 +. 0 + +The 0 +liver 0 +biochemistries 0 +eventually 0 +normalized 0 +within 0 +3 0 +weeks 0 +of 0 +stopping 0 +the 0 +fluvastatin 1 +. 0 + +Therefore 0 +, 0 +when 0 +prescribing 0 +statins 0 +, 0 +the 0 +possibility 0 +of 0 +hepatic 3 +damage 4 +should 0 +be 0 +taken 0 +into 0 +account 0 +. 0 + +Fluconazole 1 +associated 0 +agranulocytosis 3 +and 0 +thrombocytopenia 3 +. 0 + +CASE 0 +: 0 +We 0 +describe 0 +a 0 +second 0 +case 0 +of 0 +fluconazole 1 +associated 0 +agranulocytosis 3 +with 0 +thrombocytopenia 3 +and 0 +recovery 0 +upon 0 +discontinuation 0 +of 0 +therapy 0 +. 0 + +The 0 +patient 0 +began 0 +to 0 +have 0 +changes 0 +in 0 +white 0 +blood 0 +cells 0 +and 0 +platelets 0 +within 0 +48 0 +h 0 +of 0 +administration 0 +of 0 +fluconazole 1 +and 0 +began 0 +to 0 +recover 0 +with 0 +48 0 +h 0 +of 0 +discontinuation 0 +. 0 + +This 0 +case 0 +highlights 0 +that 0 +drug 0 +- 0 +induced 0 +blood 3 +dyscrasias 4 +can 0 +occur 0 +unexpectedly 0 +as 0 +a 0 +result 0 +of 0 +treatment 0 +with 0 +a 0 +commonly 0 +used 0 +drug 0 +thought 0 +to 0 +be 0 +" 0 +safe 0 +" 0 +. 0 + +C0NCLUSI0N 0 +: 0 +According 0 +to 0 +Naranjo 0 +' 0 +s 0 +algorithm 0 +the 0 +likelihood 0 +that 0 +our 0 +patient 0 +' 0 +s 0 +agranulocytosis 3 +and 0 +thrombocytopenia 3 +occurred 0 +as 0 +a 0 +result 0 +of 0 +therapy 0 +with 0 +fluconazole 1 +is 0 +probable 0 +, 0 +with 0 +a 0 +total 0 +of 0 +six 0 +points 0 +. 0 + +We 0 +feel 0 +that 0 +the 0 +weight 0 +of 0 +the 0 +overall 0 +evidence 0 +of 0 +this 0 +evidence 0 +is 0 +strong 0 +. 0 + +In 0 +particular 0 +the 0 +temporal 0 +relationship 0 +of 0 +bone 3 +marrow 4 +suppression 4 +to 0 +the 0 +initiation 0 +of 0 +fluconazole 1 +and 0 +the 0 +abatement 0 +of 0 +symptoms 0 +that 0 +rapidly 0 +reversed 0 +immediately 0 +following 0 +discontinuation 0 +. 0 + +Two 0 +- 0 +dimensional 0 +speckle 0 +tracking 0 +echocardiography 0 +combined 0 +with 0 +high 0 +- 0 +sensitive 0 +cardiac 0 +troponin 0 +T 0 +in 0 +early 0 +detection 0 +and 0 +prediction 0 +of 0 +cardiotoxicity 3 +during 0 +epirubicine 1 +- 0 +based 0 +chemotherapy 0 +. 0 + +AIMS 0 +: 0 +To 0 +investigate 0 +whether 0 +alterations 0 +of 0 +myocardial 3 +strain 4 +and 0 +high 0 +- 0 +sensitive 0 +cardiac 0 +troponin 0 +T 0 +( 0 +cTnT 0 +) 0 +could 0 +predict 0 +future 0 +cardiac 3 +dysfunction 4 +in 0 +patients 0 +after 0 +epirubicin 1 +exposure 0 +. 0 + +METH0DS 0 +: 0 +Seventy 0 +- 0 +five 0 +patients 0 +with 0 +non 3 +- 4 +Hodgkin 4 +lymphoma 4 +treated 0 +with 0 +epirubicin 1 +were 0 +studied 0 +. 0 + +Blood 0 +collection 0 +and 0 +echocardiography 0 +were 0 +performed 0 +at 0 +baseline 0 +, 0 +1 0 +day 0 +after 0 +the 0 +third 0 +cycle 0 +, 0 +and 0 +1 0 +day 0 +after 0 +completion 0 +of 0 +chemotherapy 0 +. 0 + +Patients 0 +were 0 +studied 0 +using 0 +echocardiography 0 +during 0 +follow 0 +- 0 +up 0 +. 0 + +Global 0 +longitudinal 0 +( 0 +GLS 0 +) 0 +, 0 +circumferential 0 +( 0 +GCS 0 +) 0 +, 0 +and 0 +radial 0 +strain 0 +( 0 +GRS 0 +) 0 +were 0 +calculated 0 +using 0 +speckle 0 +tracking 0 +echocardiography 0 +. 0 + +Left 0 +ventricular 0 +ejection 0 +fraction 0 +was 0 +analysed 0 +by 0 +real 0 +- 0 +time 0 +3D 0 +echocardiography 0 +. 0 + +Cardiotoxicity 3 +was 0 +defined 0 +as 0 +a 0 +reduction 0 +of 0 +the 0 +LVEF 0 +of 0 +> 0 +5 0 +% 0 +to 0 +< 0 +55 0 +% 0 +with 0 +symptoms 0 +of 0 +heart 3 +failure 4 +or 0 +an 0 +asymptomatic 0 +reduction 0 +of 0 +the 0 +LVEF 0 +of 0 +> 0 +10 0 +% 0 +to 0 +< 0 +55 0 +% 0 +. 0 + +RESULTS 0 +: 0 +Fourteen 0 +patients 0 +( 0 +18 0 +. 0 +67 0 +% 0 +) 0 +developed 0 +cardiotoxicity 3 +after 0 +treatment 0 +. 0 + +GLS 0 +( 0 +- 0 +18 0 +. 0 +48 0 ++ 0 +1 0 +. 0 +72 0 +% 0 +vs 0 +. 0 +- 0 +15 0 +. 0 +96 0 ++ 0 +1 0 +. 0 +6 0 +% 0 +) 0 +, 0 +GCS 0 +( 0 +- 0 +20 0 +. 0 +93 0 ++ 0 +2 0 +. 0 +86 0 +% 0 +vs 0 +. 0 +- 0 +19 0 +. 0 +20 0 ++ 0 +3 0 +. 0 +21 0 +% 0 +) 0 +, 0 +and 0 +GRS 0 +( 0 +39 0 +. 0 +23 0 ++ 0 +6 0 +. 0 +44 0 +% 0 +vs 0 +. 0 +34 0 +. 0 +98 0 ++ 0 +6 0 +. 0 +2 0 +% 0 +) 0 +were 0 +markedly 0 +reduced 0 +and 0 +cTnT 0 +was 0 +elevated 0 +from 0 +0 0 +. 0 +0010 0 ++ 0 +0 0 +. 0 +0020 0 +to 0 +0 0 +. 0 +0073 0 ++ 0 +0 0 +. 0 +0038 0 +ng 0 +/ 0 +mL 0 +( 0 +P 0 +all 0 +< 0 +0 0 +. 0 +01 0 +) 0 +at 0 +the 0 +completion 0 +of 0 +chemotherapy 0 +compared 0 +with 0 +baseline 0 +values 0 +. 0 + +A 0 +> 0 +15 0 +. 0 +9 0 +% 0 +decrease 0 +in 0 +GLS 0 +[ 0 +sensitivity 0 +, 0 +86 0 +% 0 +; 0 +specificity 0 +, 0 +75 0 +% 0 +; 0 +area 0 +under 0 +the 0 +curve 0 +( 0 +AUC 0 +) 0 += 0 +0 0 +. 0 +815 0 +; 0 +P 0 += 0 +0 0 +. 0 +001 0 +] 0 +and 0 +a 0 +> 0 +0 0 +. 0 +004 0 +ng 0 +/ 0 +mL 0 +elevation 0 +in 0 +cTnT 0 +( 0 +sensitivity 0 +, 0 +79 0 +% 0 +; 0 +specificity 0 +, 0 +64 0 +% 0 +; 0 +AUC 0 += 0 +0 0 +. 0 +757 0 +; 0 +P 0 += 0 +0 0 +. 0 +005 0 +) 0 +from 0 +baseline 0 +to 0 +the 0 +third 0 +cycle 0 +of 0 +chemotherapy 0 +predicted 0 +later 0 +cardiotoxicity 3 +. 0 + +The 0 +decrease 0 +in 0 +GLS 0 +remained 0 +the 0 +only 0 +independent 0 +predictor 0 +of 0 +cardiotoxicity 3 +( 0 +P 0 += 0 +0 0 +. 0 +000 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +GLS 0 +combined 0 +with 0 +cTnT 0 +may 0 +provide 0 +a 0 +reliable 0 +and 0 +non 0 +- 0 +invasive 0 +method 0 +to 0 +predict 0 +cardiac 3 +dysfunction 4 +in 0 +patients 0 +receiving 0 +anthracycline 1 +- 0 +based 0 +chemotherapy 0 +. 0 + +Prevention 0 +of 0 +etomidate 1 +- 0 +induced 0 +myoclonus 3 +: 0 +which 0 +is 0 +superior 0 +: 0 +Fentanyl 1 +, 0 +midazolam 1 +, 0 +or 0 +a 0 +combination 0 +? 0 + +A 0 +Retrospective 0 +comparative 0 +study 0 +. 0 + +BACKGR0UND 0 +: 0 +In 0 +this 0 +retrospective 0 +comparative 0 +study 0 +, 0 +we 0 +aimed 0 +to 0 +compare 0 +the 0 +effectiveness 0 +of 0 +fentanyl 1 +, 0 +midazolam 1 +, 0 +and 0 +a 0 +combination 0 +of 0 +fentanyl 1 +and 0 +midazolam 1 +to 0 +prevent 0 +etomidate 1 +- 0 +induced 0 +myoclonus 3 +. 0 + +MATERIAL 0 +AND 0 +METH0DS 0 +: 0 +This 0 +study 0 +was 0 +performed 0 +based 0 +on 0 +anesthesia 0 +records 0 +. 0 + +Depending 0 +on 0 +the 0 +drugs 0 +that 0 +would 0 +be 0 +given 0 +before 0 +the 0 +induction 0 +of 0 +anesthesia 0 +with 0 +etomidate 1 +, 0 +the 0 +patients 0 +were 0 +separated 0 +into 0 +4 0 +groups 0 +: 0 +no 0 +pretreatment 0 +( 0 +Group 0 +NP 0 +) 0 +, 0 +fentanyl 1 +1 0 +ug 0 +. 0 +kg 0 +- 0 +1 0 +( 0 +Group 0 +F 0 +) 0 +, 0 +midazolam 1 +0 0 +. 0 +03 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 +( 0 +Group 0 +M 0 +) 0 +, 0 +and 0 +midazolam 1 +0 0 +. 0 +015 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 ++ 0 +fentanyl 1 +0 0 +. 0 +5 0 +ug 0 +. 0 +kg 0 +- 0 +1 0 +( 0 +Group 0 +FM 0 +) 0 +. 0 + +Patients 0 +who 0 +received 0 +the 0 +same 0 +anesthetic 0 +procedure 0 +were 0 +selected 0 +: 0 +2 0 +minutes 0 +after 0 +intravenous 0 +injections 0 +of 0 +the 0 +pretreatment 0 +drugs 0 +, 0 +anesthesia 0 +is 0 +induced 0 +with 0 +0 0 +. 0 +3 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 +etomidate 1 +injected 0 +intravenously 0 +over 0 +a 0 +period 0 +of 0 +20 0 +- 0 +30 0 +seconds 0 +. 0 + +Myoclonic 3 +movements 4 +are 0 +evaluated 0 +, 0 +which 0 +were 0 +observed 0 +and 0 +graded 0 +according 0 +to 0 +clinical 0 +severity 0 +during 0 +the 0 +2 0 +minutes 0 +after 0 +etomidate 1 +injection 0 +. 0 + +The 0 +severity 0 +of 0 +pain 3 +due 0 +to 0 +etomidate 1 +injection 0 +, 0 +mean 0 +arterial 0 +pressure 0 +, 0 +heart 0 +rate 0 +, 0 +and 0 +adverse 0 +effects 0 +were 0 +also 0 +evaluated 0 +. 0 + +RESULTS 0 +: 0 +Study 0 +results 0 +showed 0 +that 0 +myoclonus 3 +incidence 0 +was 0 +85 0 +% 0 +, 0 +40 0 +% 0 +, 0 +70 0 +% 0 +, 0 +and 0 +25 0 +% 0 +in 0 +Group 0 +NP 0 +, 0 +Group 0 +F 0 +, 0 +Group 0 +M 0 +, 0 +and 0 +Group 0 +FM 0 +, 0 +respectively 0 +, 0 +and 0 +were 0 +significantly 0 +lower 0 +in 0 +Group 0 +F 0 +and 0 +Group 0 +FM 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +We 0 +conclude 0 +that 0 +pretreatment 0 +with 0 +fentanyl 1 +or 0 +combination 0 +of 0 +fentanyl 1 +and 0 +midazolam 1 +was 0 +effective 0 +in 0 +preventing 0 +etomidate 1 +- 0 +induced 0 +myoclonus 3 +. 0 + +Convulsant 0 +effect 0 +of 0 +lindane 1 +and 0 +regional 0 +brain 0 +concentration 0 +of 0 +GABA 1 +and 0 +dopamine 1 +. 0 + +Lindane 1 +( 0 +gamma 1 +- 2 +hexachlorocyclohexane 2 +) 0 +is 0 +an 0 +organochlorine 0 +insecticide 0 +with 0 +known 0 +neurotoxic 3 +effects 0 +. 0 + +Its 0 +mechanism 0 +of 0 +action 0 +is 0 +not 0 +well 0 +understood 0 +although 0 +it 0 +has 0 +been 0 +proposed 0 +that 0 +lindane 1 +acts 0 +as 0 +a 0 +non 0 +- 0 +competitive 0 +antagonist 0 +at 0 +the 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +) 0 +- 0 +A 0 +receptor 0 +. 0 + +We 0 +studied 0 +the 0 +effect 0 +of 0 +lindane 1 +( 0 +150 0 +mg 0 +/ 0 +kg 0 +) 0 +on 0 +the 0 +GABAergic 0 +and 0 +dopaminergic 0 +systems 0 +by 0 +measuring 0 +the 0 +concentration 0 +of 0 +GABA 1 +, 0 +dopamine 1 +and 0 +its 0 +metabolites 0 +in 0 +7 0 +brain 0 +areas 0 +at 0 +the 0 +onset 0 +of 0 +seizures 3 +. 0 + +All 0 +animals 0 +suffered 0 +tonic 0 +convulsions 3 +at 0 +18 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +4 0 +min 0 +after 0 +lindane 1 +administration 0 +. 0 + +The 0 +concentration 0 +of 0 +GABA 1 +was 0 +only 0 +slightly 0 +but 0 +significantly 0 +decreased 0 +in 0 +the 0 +colliculi 0 +without 0 +modifications 0 +in 0 +the 0 +other 0 +areas 0 +. 0 + +The 0 +concentration 0 +of 0 +dopamine 1 +was 0 +increased 0 +in 0 +the 0 +mesencephalon 0 +and 0 +that 0 +of 0 +its 0 +metabolite 0 +D0PAC 1 +was 0 +also 0 +increased 0 +in 0 +the 0 +mesencephalon 0 +and 0 +the 0 +striatum 0 +. 0 + +Cholestatic 3 +presentation 0 +of 0 +yellow 0 +phosphorus 1 +poisoning 3 +. 0 + +Yellow 0 +phosphorus 1 +, 0 +a 0 +component 0 +of 0 +certain 0 +pesticide 0 +pastes 0 +and 0 +fireworks 0 +, 0 +is 0 +well 0 +known 0 +to 0 +cause 0 +hepatotoxicity 3 +. 0 + +Poisoning 3 +with 0 +yellow 0 +phosphorus 1 +classically 0 +manifests 0 +with 0 +acute 3 +hepatitis 4 +leading 0 +to 0 +acute 3 +liver 4 +failure 4 +which 0 +may 0 +need 0 +liver 0 +transplantation 0 +. 0 + +We 0 +present 0 +a 0 +case 0 +of 0 +yellow 0 +phosphorus 1 +poisoning 3 +in 0 +which 0 +a 0 +patient 0 +presented 0 +with 0 +florid 0 +clinical 0 +features 0 +of 0 +cholestasis 3 +highlighting 0 +the 0 +fact 0 +that 0 +cholestasis 3 +can 0 +rarely 0 +be 0 +a 0 +presenting 0 +feature 0 +of 0 +yellow 0 +phosphorus 1 +hepatotoxicity 3 +. 0 + +Vasovagal 3 +syncope 4 +and 0 +severe 0 +bradycardia 3 +following 0 +intranasal 0 +dexmedetomidine 1 +for 0 +pediatric 0 +procedural 0 +sedation 0 +. 0 + +We 0 +report 0 +syncope 3 +and 0 +bradycardia 3 +in 0 +an 0 +11 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +following 0 +administration 0 +of 0 +intranasal 0 +dexmedetomidine 1 +for 0 +sedation 0 +for 0 +a 0 +voiding 0 +cystourethrogram 0 +. 0 + +Following 0 +successful 0 +completion 0 +of 0 +VCUG 0 +and 0 +a 0 +60 0 +- 0 +min 0 +recovery 0 +period 0 +, 0 +the 0 +patient 0 +' 0 +s 0 +level 0 +of 0 +consciousness 0 +and 0 +vital 0 +signs 0 +returned 0 +to 0 +presedation 0 +levels 0 +. 0 + +Upon 0 +leaving 0 +the 0 +sedation 0 +area 0 +, 0 +the 0 +patient 0 +collapsed 0 +, 0 +with 0 +no 0 +apparent 0 +inciting 0 +event 0 +. 0 + +The 0 +patient 0 +quickly 0 +regained 0 +consciousness 0 +and 0 +no 0 +injury 0 +occurred 0 +. 0 + +The 0 +primary 0 +abnormality 0 +found 0 +was 0 +persistent 0 +bradycardia 3 +, 0 +and 0 +she 0 +was 0 +admitted 0 +to 0 +the 0 +hospital 0 +for 0 +telemetric 0 +observation 0 +. 0 + +The 0 +bradycardia 3 +lasted 0 +~ 0 +2 0 +h 0 +, 0 +and 0 +further 0 +cardiac 0 +workup 0 +revealed 0 +no 0 +underlying 0 +abnormality 0 +. 0 + +Unanticipated 0 +and 0 +previously 0 +unreported 0 +outcomes 0 +may 0 +be 0 +witnessed 0 +as 0 +we 0 +expand 0 +the 0 +use 0 +of 0 +certain 0 +sedatives 0 +to 0 +alternative 0 +routes 0 +of 0 +administration 0 +. 0 + +Paradoxical 0 +severe 0 +agitation 3 +induced 0 +by 0 +add 0 +- 0 +on 0 +high 0 +- 0 +doses 0 +quetiapine 1 +in 0 +schizo 3 +- 4 +affective 4 +disorder 4 +. 0 + +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +35 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +suffering 0 +from 0 +schizo 3 +- 4 +affective 4 +disorder 4 +since 0 +the 0 +age 0 +of 0 +19 0 +years 0 +, 0 +treated 0 +by 0 +a 0 +combination 0 +of 0 +first 0 +- 0 +generation 0 +antipsychotics 0 +, 0 +zuclopenthixol 1 +( 0 +100 0 +mg 0 +/ 0 +day 0 +) 0 +and 0 +lithium 1 +( 0 +1200 0 +mg 0 +/ 0 +day 0 +) 0 +( 0 +serum 0 +lithium 1 += 0 +0 0 +. 0 +85 0 +mEq 0 +/ 0 +l 0 +) 0 +. 0 + +This 0 +patient 0 +had 0 +no 0 +associated 0 +personality 3 +disorder 4 +( 0 +particularly 0 +no 0 +antisocial 3 +disorder 4 +) 0 +and 0 +no 0 +substance 3 +abuse 4 +disorder 4 +. 0 + +Within 0 +the 0 +48 0 +h 0 +following 0 +the 0 +gradual 0 +introduction 0 +of 0 +quetiapine 1 +( 0 +up 0 +to 0 +600 0 +mg 0 +/ 0 +day 0 +) 0 +, 0 +the 0 +patient 0 +presented 0 +severe 0 +agitation 3 +without 0 +an 0 +environmental 0 +explanation 0 +, 0 +contrasting 0 +with 0 +the 0 +absence 0 +of 0 +a 0 +history 0 +of 0 +aggressiveness 3 +or 0 +personality 3 +disorder 4 +. 0 + +The 0 +diagnoses 0 +of 0 +manic 3 +shift 0 +and 0 +akathisia 3 +were 0 +dismissed 0 +. 0 + +The 0 +withdrawal 0 +and 0 +the 0 +gradual 0 +reintroduction 0 +of 0 +quetiapine 1 +2 0 +weeks 0 +later 0 +, 0 +which 0 +led 0 +to 0 +another 0 +severe 0 +agitation 3 +, 0 +enabled 0 +us 0 +to 0 +attribute 0 +the 0 +agitation 3 +specifically 0 +to 0 +quetiapine 1 +. 0 + +Antioxidant 0 +effects 0 +of 0 +bovine 0 +lactoferrin 0 +on 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +in 0 +rat 0 +. 0 + +Dexamethasone 1 +- 0 +( 0 +Dex 1 +- 0 +) 0 +induced 0 +hypertension 3 +is 0 +associated 0 +with 0 +enhanced 0 +oxidative 0 +stress 0 +. 0 + +Lactoferrin 0 +( 0 +LF 0 +) 0 +is 0 +an 0 +iron 1 +- 0 +binding 0 +glycoprotein 0 +with 0 +antihypertensive 0 +properties 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +investigated 0 +the 0 +effect 0 +of 0 +chronic 0 +administration 0 +of 0 +LF 0 +on 0 +oxidative 0 +stress 0 +and 0 +hypertension 3 +upon 0 +Dex 1 +administration 0 +. 0 + +Male 0 +Wistar 0 +rats 0 +were 0 +treated 0 +by 0 +Dex 1 +( 0 +30 0 +u 0 +g 0 +/ 0 +kg 0 +/ 0 +day 0 +subcutaneously 0 +) 0 +or 0 +saline 0 +for 0 +14 0 +days 0 +. 0 + +0ral 0 +bovine 0 +LF 0 +( 0 +30 0 +, 0 +100 0 +, 0 +300 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +given 0 +from 0 +day 0 +8 0 +to 0 +14 0 +in 0 +a 0 +reversal 0 +study 0 +. 0 + +In 0 +a 0 +prevention 0 +study 0 +, 0 +rats 0 +received 0 +4 0 +days 0 +of 0 +LF 0 +treatment 0 +followed 0 +by 0 +Dex 1 +and 0 +continued 0 +during 0 +the 0 +test 0 +period 0 +. 0 + +Systolic 0 +blood 0 +pressure 0 +( 0 +SBP 0 +) 0 +was 0 +measured 0 +using 0 +tail 0 +- 0 +cuff 0 +method 0 +. 0 + +Thymus 0 +weight 0 +was 0 +used 0 +as 0 +a 0 +marker 0 +of 0 +glucocorticoid 0 +activity 0 +. 0 + +Plasma 0 +hydrogen 1 +peroxide 2 +( 0 +H202 1 +) 0 +concentration 0 +and 0 +ferric 0 +reducing 0 +antioxidant 0 +power 0 +( 0 +FRAP 0 +) 0 +value 0 +were 0 +determined 0 +. 0 + +Dexamethasone 1 +significantly 0 +increased 0 +SBP 0 +and 0 +plasma 0 +H202 1 +level 0 +and 0 +decreased 0 +thymus 0 +and 0 +body 0 +weights 0 +. 0 + +LF 0 +lowered 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +and 0 +dose 0 +dependently 0 +prevented 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +Dex 1 +- 0 +induced 0 +hypertension 3 +. 0 + +LF 0 +prevented 0 +body 0 +weight 3 +loss 4 +and 0 +significantly 0 +reduced 0 +the 0 +elevated 0 +plasma 0 +H202 1 +and 0 +increased 0 +FRAP 0 +values 0 +. 0 + +Chronic 0 +administration 0 +of 0 +LF 0 +strongly 0 +reduced 0 +the 0 +blood 0 +pressure 0 +and 0 +production 0 +of 0 +R0S 0 +and 0 +improved 0 +antioxidant 0 +capacity 0 +in 0 +Dex 1 +- 0 +induced 0 +hypertension 3 +, 0 +suggesting 0 +the 0 +role 0 +of 0 +inhibition 0 +of 0 +oxidative 0 +stress 0 +as 0 +another 0 +mechanism 0 +of 0 +antihypertensive 0 +action 0 +of 0 +LF 0 +. 0 + +The 0 +association 0 +between 0 +tranexamic 1 +acid 2 +and 0 +convulsive 3 +seizures 3 +after 0 +cardiac 0 +surgery 0 +: 0 +a 0 +multivariate 0 +analysis 0 +in 0 +11 0 +529 0 +patients 0 +. 0 + +Because 0 +of 0 +a 0 +lack 0 +of 0 +contemporary 0 +data 0 +regarding 0 +seizures 3 +after 0 +cardiac 0 +surgery 0 +, 0 +we 0 +undertook 0 +a 0 +retrospective 0 +analysis 0 +of 0 +prospectively 0 +collected 0 +data 0 +from 0 +11 0 +529 0 +patients 0 +in 0 +whom 0 +cardiopulmonary 0 +bypass 0 +was 0 +used 0 +from 0 +January 0 +2004 0 +to 0 +December 0 +2010 0 +. 0 + +A 0 +convulsive 3 +seizure 3 +was 0 +defined 0 +as 0 +a 0 +transient 0 +episode 0 +of 0 +disturbed 0 +brain 0 +function 0 +characterised 0 +by 0 +abnormal 3 +involuntary 4 +motor 4 +movements 4 +. 0 + +Multivariate 0 +regression 0 +analysis 0 +was 0 +performed 0 +to 0 +identify 0 +independent 0 +predictors 0 +of 0 +postoperative 0 +seizures 3 +. 0 + +A 0 +total 0 +of 0 +100 0 +( 0 +0 0 +. 0 +9 0 +% 0 +) 0 +patients 0 +developed 0 +postoperative 0 +convulsive 3 +seizures 3 +. 0 + +Generalised 3 +and 4 +focal 4 +seizures 4 +were 0 +identified 0 +in 0 +68 0 +and 0 +32 0 +patients 0 +, 0 +respectively 0 +. 0 + +The 0 +median 0 +( 0 +IQR 0 +[ 0 +range 0 +] 0 +) 0 +time 0 +after 0 +surgery 0 +when 0 +the 0 +seizure 3 +occurred 0 +was 0 +7 0 +( 0 +6 0 +- 0 +12 0 +[ 0 +1 0 +- 0 +216 0 +] 0 +) 0 +h 0 +and 0 +8 0 +( 0 +6 0 +- 0 +11 0 +[ 0 +4 0 +- 0 +18 0 +] 0 +) 0 +h 0 +, 0 +respectively 0 +. 0 + +Epileptiform 0 +findings 0 +on 0 +electroencephalography 0 +were 0 +seen 0 +in 0 +19 0 +patients 0 +. 0 + +Independent 0 +predictors 0 +of 0 +postoperative 0 +seizures 3 +included 0 +age 0 +, 0 +female 0 +sex 0 +, 0 +redo 0 +cardiac 0 +surgery 0 +, 0 +calcification 0 +of 0 +ascending 0 +aorta 0 +, 0 +congestive 3 +heart 4 +failure 4 +, 0 +deep 0 +hypothermic 3 +circulatory 0 +arrest 0 +, 0 +duration 0 +of 0 +aortic 0 +cross 0 +- 0 +clamp 0 +and 0 +tranexamic 1 +acid 2 +. 0 + +When 0 +tested 0 +in 0 +a 0 +multivariate 0 +regression 0 +analysis 0 +, 0 +tranexamic 1 +acid 2 +was 0 +a 0 +strong 0 +independent 0 +predictor 0 +of 0 +seizures 3 +( 0 +0R 0 +14 0 +. 0 +3 0 +, 0 +95 0 +% 0 +CI 0 +5 0 +. 0 +5 0 +- 0 +36 0 +. 0 +7 0 +; 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Patients 0 +with 0 +convulsive 3 +seizures 3 +had 0 +2 0 +. 0 +5 0 +times 0 +higher 0 +in 0 +- 0 +hospital 0 +mortality 0 +rates 0 +and 0 +twice 0 +the 0 +length 0 +of 0 +hospital 0 +stay 0 +compared 0 +with 0 +patients 0 +without 0 +convulsive 3 +seizures 3 +. 0 + +Mean 0 +( 0 +IQR 0 +[ 0 +range 0 +] 0 +) 0 +length 0 +of 0 +stay 0 +in 0 +the 0 +intensive 0 +care 0 +unit 0 +was 0 +115 0 +( 0 +49 0 +- 0 +228 0 +[ 0 +32 0 +- 0 +481 0 +] 0 +) 0 +h 0 +in 0 +patients 0 +with 0 +convulsive 3 +seizures 3 +compared 0 +with 0 +26 0 +( 0 +22 0 +- 0 +69 0 +[ 0 +14 0 +- 0 +1080 0 +] 0 +) 0 +h 0 +in 0 +patients 0 +without 0 +seizures 3 +( 0 +p 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Convulsive 3 +seizures 3 +are 0 +a 0 +serious 0 +postoperative 3 +complication 4 +after 0 +cardiac 0 +surgery 0 +. 0 + +As 0 +tranexamic 1 +acid 2 +is 0 +the 0 +only 0 +modifiable 0 +factor 0 +, 0 +its 0 +administration 0 +, 0 +particularly 0 +in 0 +doses 0 +exceeding 0 +80 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +, 0 +should 0 +be 0 +weighed 0 +against 0 +the 0 +risk 0 +of 0 +postoperative 0 +seizures 3 +. 0 + +Dysfunctional 3 +overnight 4 +memory 4 +consolidation 0 +in 0 +ecstasy 1 +users 0 +. 0 + +Sleep 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +consolidation 0 +and 0 +integration 0 +of 0 +memory 0 +in 0 +a 0 +process 0 +called 0 +overnight 0 +memory 0 +consolidation 0 +. 0 + +Previous 0 +studies 0 +indicate 0 +that 0 +ecstasy 1 +users 0 +have 0 +marked 0 +and 0 +persistent 0 +neurocognitive 0 +and 0 +sleep 3 +- 4 +related 4 +impairments 4 +. 0 + +We 0 +extend 0 +past 0 +research 0 +by 0 +examining 0 +overnight 0 +memory 0 +consolidation 0 +among 0 +regular 0 +ecstasy 1 +users 0 +( 0 +n 0 += 0 +12 0 +) 0 +and 0 +drug 0 +naive 0 +healthy 0 +controls 0 +( 0 +n 0 += 0 +26 0 +) 0 +. 0 + +Memory 0 +recall 0 +of 0 +word 0 +pairs 0 +was 0 +evaluated 0 +before 0 +and 0 +after 0 +a 0 +period 0 +of 0 +sleep 0 +, 0 +with 0 +and 0 +without 0 +interference 0 +prior 0 +to 0 +testing 0 +. 0 + +In 0 +addition 0 +, 0 +we 0 +assessed 0 +neurocognitive 0 +performances 0 +across 0 +tasks 0 +of 0 +learning 0 +, 0 +memory 0 +and 0 +executive 0 +functioning 0 +. 0 + +Ecstasy 1 +users 0 +demonstrated 0 +impaired 3 +overnight 4 +memory 4 +consolidation 0 +, 0 +a 0 +finding 0 +that 0 +was 0 +more 0 +pronounced 0 +following 0 +associative 0 +interference 0 +. 0 + +Additionally 0 +, 0 +ecstasy 1 +users 0 +demonstrated 0 +impairments 0 +on 0 +tasks 0 +recruiting 0 +frontostriatal 0 +and 0 +hippocampal 0 +neural 0 +circuitry 0 +, 0 +in 0 +the 0 +domains 0 +of 0 +proactive 0 +interference 0 +memory 0 +, 0 +long 0 +- 0 +term 0 +memory 0 +, 0 +encoding 0 +, 0 +working 0 +memory 0 +and 0 +complex 0 +planning 0 +. 0 + +We 0 +suggest 0 +that 0 +ecstasy 1 +- 0 +associated 0 +dysfunction 0 +in 0 +fronto 0 +- 0 +temporal 0 +circuitry 0 +may 0 +underlie 0 +overnight 0 +consolidation 0 +memory 3 +impairments 4 +in 0 +regular 0 +ecstasy 1 +users 0 +. 0 + +Normoammonemic 0 +encephalopathy 3 +: 0 +solely 0 +valproate 1 +induced 0 +or 0 +multiple 0 +mechanisms 0 +? 0 + +A 0 +77 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +presented 0 +with 0 +subacute 0 +onset 0 +progressive 0 +confusion 3 +, 0 +aggression 3 +, 0 +auditory 3 +hallucinations 4 +and 0 +delusions 3 +. 0 + +In 0 +the 0 +preceding 0 +months 0 +, 0 +the 0 +patient 0 +had 0 +a 0 +number 0 +of 0 +admissions 0 +with 0 +transient 0 +unilateral 0 +hemiparesis 3 +with 0 +facial 0 +droop 0 +, 0 +and 0 +had 0 +been 0 +started 0 +on 0 +valproate 1 +for 0 +presumed 0 +hemiplegic 3 +migraine 4 +. 0 + +Valproate 1 +was 0 +withdrawn 0 +soon 0 +after 0 +admission 0 +and 0 +her 0 +cognitive 0 +abilities 0 +have 0 +gradually 0 +improved 0 +over 0 +3 0 +months 0 +of 0 +follow 0 +- 0 +up 0 +. 0 + +Valproate 1 +levels 0 +taken 0 +prior 0 +to 0 +withdrawal 0 +were 0 +subtherapeutic 0 +and 0 +the 0 +patient 0 +was 0 +normoammonaemic 0 +. 0 + +EEG 0 +undertaken 0 +during 0 +inpatient 0 +stay 0 +showed 0 +changes 0 +consistent 0 +with 0 +encephalopathy 3 +, 0 +and 0 +low 0 +titre 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +antibodies 0 +were 0 +present 0 +in 0 +this 0 +patient 0 +. 0 + +The 0 +possible 0 +aetiologies 0 +of 0 +valproate 1 +- 0 +induced 0 +encephalopathy 3 +and 0 +NMDA 1 +receptor 0 +- 0 +associated 0 +encephalitis 3 +present 0 +a 0 +diagnostic 0 +dilemma 0 +. 0 + +We 0 +present 0 +a 0 +putative 0 +combinatorial 0 +hypothesis 0 +to 0 +explain 0 +this 0 +patient 0 +' 0 +s 0 +symptoms 0 +. 0 + +Cerebellar 3 +and 4 +oculomotor 4 +dysfunction 4 +induced 0 +by 0 +rapid 0 +infusion 0 +of 0 +pethidine 1 +. 0 + +Pethidine 1 +is 0 +an 0 +opioid 0 +that 0 +gains 0 +its 0 +popularity 0 +for 0 +the 0 +effective 0 +pain 3 +control 0 +through 0 +acting 0 +on 0 +the 0 +opioid 0 +- 0 +receptors 0 +. 0 + +However 0 +, 0 +rapid 0 +pain 3 +relief 0 +sometimes 0 +brings 0 +about 0 +unfavourable 0 +side 0 +effects 0 +that 0 +largely 0 +limit 0 +its 0 +clinical 0 +utility 0 +. 0 + +Common 0 +side 0 +effects 0 +include 0 +nausea 3 +, 0 +vomiting 3 +and 0 +hypotension 3 +. 0 + +In 0 +patients 0 +with 0 +impaired 3 +renal 4 +and 4 +liver 4 +function 4 +, 0 +and 0 +those 0 +who 0 +need 0 +long 0 +- 0 +term 0 +pain 3 +control 0 +, 0 +pethidine 1 +may 0 +cause 0 +excitatory 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +effects 0 +through 0 +its 0 +neurotoxic 3 +metabolite 0 +, 0 +norpethidine 1 +, 0 +resulting 0 +in 0 +irritability 3 +and 0 +seizure 3 +attack 0 +. 0 + +0n 0 +the 0 +contrary 0 +, 0 +though 0 +not 0 +clinically 0 +apparent 0 +, 0 +pethidine 1 +potentially 0 +causes 0 +inhibitory 0 +impacts 0 +on 0 +the 0 +CNS 0 +and 0 +impairs 0 +normal 0 +cerebellar 0 +and 0 +oculomotor 0 +function 0 +in 0 +the 0 +short 0 +term 0 +. 0 + +In 0 +this 0 +case 0 +report 0 +, 0 +we 0 +highlight 0 +opioid 0 +' 0 +s 0 +inhibitory 0 +side 0 +effects 0 +on 0 +the 0 +cerebellar 0 +structure 0 +that 0 +causes 0 +dysmetria 3 +, 0 +dysarthria 3 +, 0 +reduced 0 +smooth 0 +pursuit 0 +gain 0 +and 0 +decreased 0 +saccadic 0 +velocity 0 +. 0 + +Baboon 3 +syndrome 4 +induced 0 +by 0 +ketoconazole 1 +. 0 + +A 0 +27 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +presented 0 +with 0 +a 0 +maculopapular 3 +eruption 4 +on 0 +the 0 +flexural 0 +areas 0 +and 0 +buttocks 0 +after 0 +using 0 +oral 0 +ketoconazole 1 +. 0 + +The 0 +patient 0 +was 0 +diagnosed 0 +with 0 +drug 0 +- 0 +induced 0 +baboon 3 +syndrome 4 +based 0 +on 0 +his 0 +history 0 +, 0 +which 0 +included 0 +prior 0 +sensitivity 0 +to 0 +topical 0 +ketoconazole 1 +, 0 +a 0 +physical 0 +examination 0 +, 0 +and 0 +histopathological 0 +findings 0 +. 0 + +Baboon 3 +syndrome 4 +is 0 +a 0 +drug 0 +- 0 +or 0 +contact 0 +allergen 0 +- 0 +related 0 +maculopapular 3 +eruption 4 +that 0 +typically 0 +involves 0 +the 0 +flexural 0 +and 0 +gluteal 0 +areas 0 +. 0 + +To 0 +the 0 +best 0 +of 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +ketoconazole 1 +- 0 +induced 0 +baboon 3 +syndrome 4 +in 0 +the 0 +English 0 +literature 0 +. 0 + +A 0 +Case 0 +of 0 +Sudden 3 +Cardiac 4 +Death 4 +due 0 +to 0 +Pilsicainide 1 +- 0 +Induced 0 +Torsades 3 +de 4 +Pointes 4 +. 0 + +An 0 +84 0 +- 0 +year 0 +- 0 +old 0 +male 0 +received 0 +oral 0 +pilsicainide 1 +, 0 +a 0 +pure 0 +sodium 1 +channel 0 +blocker 0 +with 0 +slow 0 +recovery 0 +kinetics 0 +, 0 +to 0 +convert 0 +his 0 +paroxysmal 0 +atrial 3 +fibrillation 4 +to 0 +a 0 +sinus 0 +rhythm 0 +; 0 +the 0 +patient 0 +developed 0 +sudden 3 +cardiac 4 +death 4 +two 0 +days 0 +later 0 +. 0 + +The 0 +Holter 0 +electrocardiogram 0 +, 0 +which 0 +was 0 +worn 0 +by 0 +chance 0 +, 0 +revealed 0 +torsade 3 +de 4 +pointes 4 +with 0 +gradually 0 +prolonged 0 +QT 0 +intervals 0 +. 0 + +This 0 +drug 0 +is 0 +rapidly 0 +absorbed 0 +from 0 +the 0 +gastrointestinal 0 +tract 0 +, 0 +and 0 +most 0 +of 0 +it 0 +is 0 +excreted 0 +from 0 +the 0 +kidney 0 +. 0 + +Although 0 +the 0 +patient 0 +' 0 +s 0 +renal 0 +function 0 +was 0 +not 0 +highly 0 +impaired 0 +and 0 +the 0 +dose 0 +of 0 +pilsicainide 1 +was 0 +low 0 +, 0 +the 0 +plasma 0 +concentration 0 +of 0 +pilsicainide 1 +may 0 +have 0 +been 0 +high 0 +, 0 +which 0 +can 0 +produce 0 +torsades 3 +de 4 +pointes 4 +in 0 +the 0 +octogenarian 0 +. 0 + +Although 0 +the 0 +oral 0 +administration 0 +of 0 +class 0 +IC 0 +drugs 0 +, 0 +including 0 +pilsicainide 1 +, 0 +is 0 +effective 0 +to 0 +terminate 0 +atrial 3 +fibrillation 4 +, 0 +careful 0 +consideration 0 +must 0 +be 0 +taken 0 +before 0 +giving 0 +these 0 +drugs 0 +to 0 +octogenarians 0 +. 0 + +All 1 +- 2 +trans 2 +retinoic 2 +acid 2 +- 0 +induced 0 +inflammatory 0 +myositis 3 +in 0 +a 0 +patient 0 +with 0 +acute 3 +promyelocytic 4 +leukemia 4 +. 0 + +All 1 +- 2 +trans 2 +retinoic 2 +acid 2 +( 0 +ATRA 1 +) 0 +, 0 +a 0 +component 0 +of 0 +standard 0 +therapy 0 +for 0 +acute 3 +promyelocytic 4 +leukemia 4 +( 0 +APL 3 +) 0 +, 0 +is 0 +associated 0 +with 0 +potentially 0 +serious 0 +but 0 +treatable 0 +adverse 0 +effects 0 +involving 0 +numerous 0 +organ 0 +systems 0 +, 0 +including 0 +rare 0 +skeletal 0 +muscle 0 +involvement 0 +. 0 + +0nly 0 +a 0 +handful 0 +of 0 +cases 0 +of 0 +ATRA 1 +- 0 +induced 0 +myositis 3 +in 0 +children 0 +have 0 +been 0 +reported 0 +, 0 +and 0 +none 0 +in 0 +the 0 +radiology 0 +literature 0 +. 0 + +We 0 +present 0 +such 0 +a 0 +case 0 +in 0 +a 0 +15 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +with 0 +APL 3 +, 0 +where 0 +recognition 0 +of 0 +imaging 0 +findings 0 +played 0 +a 0 +crucial 0 +role 0 +in 0 +making 0 +the 0 +diagnosis 0 +and 0 +facilitated 0 +prompt 0 +, 0 +effective 0 +treatment 0 +. 0 + +Tolerability 0 +of 0 +lomustine 1 +in 0 +combination 0 +with 0 +cyclophosphamide 1 +in 0 +dogs 0 +with 0 +lymphoma 3 +. 0 + +This 0 +retrospective 0 +study 0 +describes 0 +toxicity 3 +associated 0 +with 0 +a 0 +protocol 0 +of 0 +lomustine 1 +( 0 +CCNU 1 +) 0 +and 0 +cyclophosphamide 1 +( 0 +CTX 1 +) 0 +in 0 +dogs 0 +with 0 +lymphoma 3 +. 0 + +CCNU 1 +was 0 +administered 0 +per 0 +os 0 +( 0 +P0 0 +) 0 +at 0 +a 0 +targeted 0 +dosage 0 +of 0 +60 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +body 0 +surface 0 +area 0 +on 0 +day 0 +0 0 +, 0 +CTX 1 +was 0 +administered 0 +P0 0 +at 0 +a 0 +targeted 0 +dosage 0 +of 0 +250 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +divided 0 +over 0 +days 0 +0 0 +through 0 +4 0 +, 0 +and 0 +all 0 +dogs 0 +received 0 +prophylactic 0 +antibiotics 0 +. 0 + +Ninety 0 +treatments 0 +were 0 +given 0 +to 0 +the 0 +57 0 +dogs 0 +included 0 +in 0 +the 0 +study 0 +. 0 + +Neutropenia 3 +was 0 +the 0 +principal 0 +toxic 0 +effect 0 +, 0 +and 0 +the 0 +overall 0 +frequency 0 +of 0 +grade 0 +4 0 +neutropenia 3 +after 0 +the 0 +first 0 +treatment 0 +of 0 +CCNU 1 +/ 0 +CTX 1 +was 0 +30 0 +% 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +19 0 +- 0 +43 0 +% 0 +) 0 +. 0 + +The 0 +mean 0 +body 0 +weight 0 +of 0 +dogs 0 +with 0 +grade 0 +4 0 +neutropenia 3 +( 0 +19 0 +. 0 +7 0 +kg 0 ++ 0 +13 0 +. 0 +4 0 +kg 0 +) 0 +was 0 +significantly 0 +less 0 +than 0 +the 0 +mean 0 +body 0 +weight 0 +of 0 +dogs 0 +that 0 +did 0 +not 0 +develop 0 +grade 0 +4 0 +neutropenia 3 +( 0 +31 0 +. 0 +7 0 +kg 0 ++ 0 +12 0 +. 0 +4 0 +kg 0 +; 0 +P 0 += 0 +. 0 +005 0 +) 0 +. 0 + +0ne 0 +dog 0 +( 0 +3 0 +% 0 +) 0 +developed 0 +hematologic 0 +changes 0 +suggestive 0 +of 0 +hepatotoxicity 3 +. 0 + +No 0 +dogs 0 +had 0 +evidence 0 +of 0 +either 0 +renal 3 +toxicity 4 +or 0 +hemorrhagic 3 +cystitis 4 +. 0 + +Adverse 0 +gastrointestinal 0 +effects 0 +were 0 +uncommon 0 +. 0 + +0n 0 +the 0 +basis 0 +of 0 +the 0 +findings 0 +reported 0 +herein 0 +, 0 +a 0 +dose 0 +of 0 +60 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +of 0 +CCNU 1 +combined 0 +with 0 +250 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +of 0 +CTX 1 +( 0 +divided 0 +over 0 +5 0 +days 0 +) 0 +q 0 +4 0 +wk 0 +is 0 +tolerable 0 +in 0 +tumor 3 +- 0 +bearing 0 +dogs 0 +. 0 + +Nelarabine 1 +neurotoxicity 3 +with 0 +concurrent 0 +intrathecal 0 +chemotherapy 0 +: 0 +Case 0 +report 0 +and 0 +review 0 +of 0 +literature 0 +. 0 + +Severe 0 +nelarabine 1 +neurotoxicity 3 +in 0 +a 0 +patient 0 +who 0 +received 0 +concurrent 0 +intrathecal 0 +( 0 +IT 0 +) 0 +chemotherapy 0 +is 0 +reported 0 +. 0 + +A 0 +37 0 +- 0 +year 0 +- 0 +old 0 +Caucasian 0 +woman 0 +with 0 +a 0 +history 0 +of 0 +T 3 +- 4 +cell 4 +lymphoblastic 4 +lymphoma 4 +was 0 +admitted 0 +for 0 +relapsed 0 +disease 0 +. 0 + +She 0 +was 0 +originally 0 +treated 0 +with 0 +induction 0 +chemotherapy 0 +followed 0 +by 0 +an 0 +autologous 0 +transplant 0 +. 0 + +She 0 +developed 0 +relapsed 0 +disease 0 +10 0 +months 0 +later 0 +with 0 +leukemic 3 +involvement 0 +. 0 + +She 0 +was 0 +re 0 +- 0 +induced 0 +with 0 +nelarabine 1 +1500 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +on 0 +days 0 +1 0 +, 0 +3 0 +, 0 +and 0 +5 0 +with 0 +1 0 +dose 0 +of 0 +IT 0 +cytarabine 1 +100 0 +mg 0 +on 0 +day 0 +2 0 +as 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +prophylaxis 0 +. 0 + +At 0 +the 0 +time 0 +of 0 +treatment 0 +, 0 +she 0 +was 0 +on 0 +continuous 0 +renal 0 +replacement 0 +therapy 0 +due 0 +to 0 +sequelae 0 +of 0 +tumor 3 +lysis 4 +syndrome 4 +( 0 +TLS 3 +) 0 +. 0 + +She 0 +tolerated 0 +therapy 0 +well 0 +, 0 +entered 0 +a 0 +complete 0 +remission 0 +, 0 +and 0 +recovered 0 +her 0 +renal 0 +function 0 +. 0 + +She 0 +received 0 +a 0 +second 0 +cycle 0 +of 0 +nelarabine 1 +without 0 +additional 0 +IT 0 +prophylaxis 0 +one 0 +month 0 +later 0 +. 0 + +A 0 +week 0 +after 0 +this 0 +second 0 +cycle 0 +, 0 +she 0 +noted 0 +numbness 0 +in 0 +her 0 +lower 0 +extremities 0 +. 0 + +Predominantly 0 +sensory 0 +, 0 +though 0 +also 0 +motor 0 +and 0 +autonomic 0 +, 0 +peripheral 3 +neuropathy 4 +started 0 +in 0 +her 0 +feet 0 +, 0 +ascended 0 +proximally 0 +to 0 +the 0 +mid 0 +- 0 +thoracic 0 +region 0 +, 0 +and 0 +eventually 0 +included 0 +her 0 +distal 0 +upper 0 +extremities 0 +. 0 + +A 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +of 0 +her 0 +spine 0 +demonstrated 0 +changes 0 +from 0 +C2 0 +to 0 +C6 0 +consistent 0 +with 0 +subacute 0 +combined 0 +degeneration 0 +. 0 + +Nelarabine 1 +was 0 +felt 0 +to 0 +be 0 +the 0 +cause 0 +of 0 +her 0 +symptoms 0 +. 0 + +Her 0 +neuropathy 3 +stabilized 0 +and 0 +showed 0 +slight 0 +improvement 0 +and 0 +ultimately 0 +received 0 +an 0 +unrelated 0 +, 0 +reduced 0 +- 0 +intensity 0 +allogeneic 0 +transplant 0 +while 0 +in 0 +complete 0 +remission 0 +, 0 +but 0 +relapsed 0 +disease 0 +10 0 +weeks 0 +later 0 +. 0 + +She 0 +is 0 +currently 0 +being 0 +treated 0 +with 0 +best 0 +supportive 0 +care 0 +. 0 + +To 0 +our 0 +knowledge 0 +, 0 +this 0 +is 0 +the 0 +first 0 +published 0 +case 0 +report 0 +of 0 +severe 0 +neurotoxicity 3 +caused 0 +by 0 +nelarabine 1 +in 0 +a 0 +patient 0 +who 0 +received 0 +concurrent 0 +IT 0 +chemotherapy 0 +. 0 + +Valproate 1 +- 0 +induced 0 +hyperammonemic 3 +encephalopathy 3 +in 0 +a 0 +renal 0 +transplanted 0 +patient 0 +. 0 + +Neurological 3 +complications 4 +after 0 +renal 0 +transplantation 0 +constitute 0 +an 0 +important 0 +cause 0 +of 0 +morbidity 0 +and 0 +mortality 0 +. 0 + +Their 0 +differential 0 +diagnosis 0 +is 0 +difficult 0 +and 0 +essential 0 +for 0 +subsequent 0 +patient 0 +' 0 +s 0 +management 0 +. 0 + +Valproate 1 +- 0 +induced 0 +hyperammonemic 3 +encephalopathy 3 +is 0 +an 0 +uncommon 0 +but 0 +serious 0 +effect 0 +of 0 +valproate 1 +treatment 0 +. 0 + +Here 0 +, 0 +we 0 +describe 0 +the 0 +case 0 +of 0 +a 0 +15 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +who 0 +was 0 +on 0 +a 0 +long 0 +- 0 +term 0 +therapy 0 +with 0 +valproate 1 +due 0 +to 0 +epilepsy 3 +and 0 +revealed 0 +impaired 3 +consciousness 4 +with 0 +hyperammonemia 3 +12 0 +days 0 +after 0 +renal 0 +transplantation 0 +. 0 + +After 0 +withdraw 0 +of 0 +valproate 1 +, 0 +patients 0 +' 0 +symptoms 0 +resolved 0 +within 0 +24 0 +h 0 +. 0 + +Clinicians 0 +should 0 +increase 0 +their 0 +awareness 0 +for 0 +potential 0 +complication 0 +of 0 +valproate 1 +, 0 +especially 0 +in 0 +transplanted 0 +patients 0 +. 0 + +Necrotising 3 +fasciitis 4 +after 0 +bortezomib 1 +and 0 +dexamethasone 1 +- 0 +containing 0 +regimen 0 +in 0 +an 0 +elderly 0 +patient 0 +of 0 +Waldenstrom 3 +macroglobulinaemia 4 +. 0 + +Bortezomib 1 +and 0 +high 0 +- 0 +dose 0 +dexamethasone 1 +- 0 +containing 0 +regimens 0 +are 0 +considered 0 +to 0 +be 0 +generally 0 +tolerable 0 +with 0 +few 0 +severe 0 +bacterial 3 +infections 4 +in 0 +patients 0 +with 0 +B 0 +- 0 +cell 0 +malignancies 3 +. 0 + +However 0 +, 0 +information 0 +is 0 +limited 0 +concerning 0 +the 0 +safety 0 +of 0 +the 0 +regimen 0 +in 0 +elderly 0 +patients 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +76 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +Waldenstrom 3 +macroglobulinaemia 4 +who 0 +suffered 0 +necrotising 3 +fasciitis 4 +without 0 +neutropenia 3 +after 0 +the 0 +combination 0 +treatment 0 +with 0 +bortezomib 1 +, 0 +high 0 +- 0 +dose 0 +dexamethasone 1 +and 0 +rituximab 0 +. 0 + +Despite 0 +immediate 0 +intravenous 0 +antimicrobial 0 +therapy 0 +, 0 +he 0 +succumbed 0 +23 0 +h 0 +after 0 +the 0 +onset 0 +. 0 + +Physicians 0 +should 0 +recognise 0 +the 0 +possibility 0 +of 0 +fatal 0 +bacterial 3 +infections 4 +related 0 +to 0 +bortezomib 1 +plus 0 +high 0 +- 0 +dose 0 +dexamethasone 1 +in 0 +elderly 0 +patients 0 +, 0 +and 0 +we 0 +believe 0 +this 0 +case 0 +warrants 0 +further 0 +investigation 0 +. 0 + +An 0 +integrated 0 +characterization 0 +of 0 +serological 0 +, 0 +pathological 0 +, 0 +and 0 +functional 0 +events 0 +in 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +Many 0 +efficacious 0 +cancer 3 +treatments 0 +cause 0 +significant 0 +cardiac 0 +morbidity 0 +, 0 +yet 0 +biomarkers 0 +or 0 +functional 0 +indices 0 +of 0 +early 0 +damage 0 +, 0 +which 0 +would 0 +allow 0 +monitoring 0 +and 0 +intervention 0 +, 0 +are 0 +lacking 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +have 0 +utilized 0 +a 0 +rat 0 +model 0 +of 0 +progressive 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +- 0 +induced 0 +cardiomyopathy 3 +, 0 +applying 0 +multiple 0 +approaches 0 +, 0 +including 0 +cardiac 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +, 0 +to 0 +provide 0 +the 0 +most 0 +comprehensive 0 +characterization 0 +to 0 +date 0 +of 0 +the 0 +timecourse 0 +of 0 +serological 0 +, 0 +pathological 0 +, 0 +and 0 +functional 0 +events 0 +underlying 0 +this 0 +toxicity 3 +. 0 + +Hannover 0 +Wistar 0 +rats 0 +were 0 +dosed 0 +with 0 +1 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +D0X 1 +weekly 0 +for 0 +8 0 +weeks 0 +followed 0 +by 0 +a 0 +4 0 +week 0 +off 0 +- 0 +dosing 0 +" 0 +recovery 0 +" 0 +period 0 +. 0 + +Electron 0 +microscopy 0 +of 0 +the 0 +myocardium 0 +revealed 0 +subcellular 3 +degeneration 4 +and 0 +marked 0 +mitochondrial 0 +changes 0 +after 0 +a 0 +single 0 +dose 0 +. 0 + +Histopathological 0 +analysis 0 +revealed 0 +progressive 0 +cardiomyocyte 3 +degeneration 4 +, 0 +hypertrophy 3 +/ 0 +cytomegaly 0 +, 0 +and 0 +extensive 0 +vacuolation 0 +after 0 +two 0 +doses 0 +. 0 + +Extensive 0 +replacement 0 +fibrosis 3 +( 0 +quantified 0 +by 0 +Sirius 0 +red 0 +staining 0 +) 0 +developed 0 +during 0 +the 0 +off 0 +- 0 +dosing 0 +period 0 +. 0 + +Functional 0 +indices 0 +assessed 0 +by 0 +cardiac 0 +MRI 0 +( 0 +including 0 +left 0 +ventricular 0 +ejection 0 +fraction 0 +( 0 +LVEF 0 +) 0 +, 0 +cardiac 0 +output 0 +, 0 +and 0 +E 0 +/ 0 +A 0 +ratio 0 +) 0 +declined 0 +progressively 0 +, 0 +reaching 0 +statistical 0 +significance 0 +after 0 +two 0 +doses 0 +and 0 +culminating 0 +in 0 +" 0 +clinical 0 +" 0 +LV 3 +dysfunction 4 +by 0 +12 0 +weeks 0 +. 0 + +Significant 0 +increases 0 +in 0 +peak 0 +myocardial 0 +contrast 0 +enhancement 0 +and 0 +serological 0 +cardiac 0 +troponin 0 +I 0 +( 0 +cTnI 0 +) 0 +emerged 0 +after 0 +eight 0 +doses 0 +, 0 +importantly 0 +preceding 0 +the 0 +LVEF 0 +decline 0 +to 0 +< 0 +50 0 +% 0 +. 0 + +Troponin 0 +I 0 +levels 0 +positively 0 +correlated 0 +with 0 +delayed 0 +and 0 +peak 0 +gadolinium 1 +contrast 0 +enhancement 0 +, 0 +histopathological 0 +grading 0 +, 0 +and 0 +diastolic 3 +dysfunction 4 +. 0 + +In 0 +summary 0 +, 0 +subcellular 0 +cardiomyocyte 3 +degeneration 4 +was 0 +the 0 +earliest 0 +marker 0 +, 0 +followed 0 +by 0 +progressive 0 +functional 0 +decline 0 +and 0 +histopathological 0 +manifestations 0 +. 0 + +Myocardial 0 +contrast 0 +enhancement 0 +and 0 +elevations 0 +in 0 +cTnI 0 +occurred 0 +later 0 +. 0 + +However 0 +, 0 +all 0 +indices 0 +predated 0 +" 0 +clinical 0 +" 0 +LV 3 +dysfunction 4 +and 0 +thus 0 +warrant 0 +further 0 +evaluation 0 +as 0 +predictive 0 +biomarkers 0 +. 0 + +Intradermal 0 +glutamate 1 +and 0 +capsaicin 1 +injections 0 +: 0 +intra 0 +- 0 +and 0 +interindividual 0 +variability 0 +of 0 +provoked 0 +hyperalgesia 3 +and 0 +allodynia 3 +. 0 + +Intradermal 0 +injections 0 +of 0 +glutamate 1 +and 0 +capsaicin 1 +are 0 +attractive 0 +to 0 +use 0 +in 0 +human 0 +experimental 0 +pain 3 +models 0 +because 0 +hyperalgesia 3 +and 0 +allodynia 3 +mimic 0 +isolated 0 +aspects 0 +of 0 +clinical 0 +pain 3 +disorders 4 +. 0 + +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +reproducibility 0 +of 0 +these 0 +models 0 +. 0 + +Twenty 0 +healthy 0 +male 0 +volunteers 0 +( 0 +mean 0 +age 0 +24 0 +years 0 +; 0 +range 0 +18 0 +- 0 +38 0 +years 0 +) 0 +received 0 +intradermal 0 +injections 0 +of 0 +glutamate 1 +and 0 +capsaicin 1 +in 0 +the 0 +volar 0 +forearm 0 +. 0 + +Magnitudes 0 +of 0 +secondary 0 +pinprick 0 +hyperalgesia 3 +and 0 +brush 0 +- 0 +evoked 0 +allodynia 3 +were 0 +investigated 0 +using 0 +von 0 +Frey 0 +filaments 0 +( 0 +gauges 0 +10 0 +, 0 +15 0 +, 0 +60 0 +and 0 +100 0 +g 0 +) 0 +and 0 +brush 0 +strokes 0 +. 0 + +Areas 0 +of 0 +secondary 3 +hyperalgesia 4 +and 0 +allodynia 3 +were 0 +quantified 0 +immediately 0 +after 0 +injection 0 +and 0 +after 0 +15 0 +, 0 +30 0 +and 0 +60 0 +min 0 +. 0 + +Two 0 +identical 0 +experiments 0 +separated 0 +by 0 +at 0 +least 0 +7 0 +days 0 +were 0 +performed 0 +. 0 + +Reproducibility 0 +across 0 +and 0 +within 0 +volunteers 0 +( 0 +inter 0 +- 0 +and 0 +intra 0 +- 0 +individual 0 +variation 0 +, 0 +respectively 0 +) 0 +was 0 +assessed 0 +using 0 +intraclass 0 +correlation 0 +coefficient 0 +( 0 +ICC 0 +) 0 +and 0 +coefficient 0 +of 0 +variation 0 +( 0 +CV 0 +) 0 +. 0 + +Secondary 0 +pinprick 0 +hyperalgesia 3 +was 0 +observed 0 +as 0 +a 0 +marked 0 +increase 0 +in 0 +the 0 +visual 0 +analogue 0 +scale 0 +( 0 +VAS 0 +) 0 +response 0 +to 0 +von 0 +Frey 0 +gauges 0 +60 0 +and 0 +100 0 +g 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +after 0 +glutamate 1 +injection 0 +. 0 + +For 0 +capsaicin 1 +, 0 +secondary 0 +pinprick 0 +hyperalgesia 3 +was 0 +detected 0 +with 0 +all 0 +von 0 +Frey 0 +gauges 0 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Glutamate 1 +evoked 0 +reproducible 0 +VAS 0 +response 0 +to 0 +all 0 +von 0 +Frey 0 +gauges 0 +( 0 +ICC 0 +> 0 +0 0 +. 0 +60 0 +) 0 +and 0 +brush 0 +strokes 0 +( 0 +ICC 0 +> 0 +0 0 +. 0 +83 0 +) 0 +. 0 + +Capsaicin 1 +injection 0 +was 0 +reproducible 0 +for 0 +secondary 3 +hyperalgesia 4 +( 0 +ICC 0 +> 0 +0 0 +. 0 +70 0 +) 0 +and 0 +allodynia 3 +( 0 +ICC 0 +> 0 +0 0 +. 0 +71 0 +) 0 +. 0 + +Intra 0 +- 0 +individual 0 +variability 0 +was 0 +generally 0 +lower 0 +for 0 +the 0 +VAS 0 +response 0 +to 0 +von 0 +Frey 0 +and 0 +brush 0 +compared 0 +with 0 +areas 0 +of 0 +secondary 3 +hyperalgesia 4 +and 0 +allodynia 3 +. 0 + +In 0 +conclusion 0 +, 0 +glutamate 1 +and 0 +capsaicin 1 +yield 0 +reproducible 0 +hyperalgesic 3 +and 0 +allodynic 3 +responses 0 +, 0 +and 0 +the 0 +present 0 +model 0 +is 0 +well 0 +suited 0 +for 0 +basic 0 +research 0 +, 0 +as 0 +well 0 +as 0 +for 0 +assessing 0 +the 0 +modulation 0 +of 0 +central 0 +phenomena 0 +. 0 + +0cular 0 +- 0 +specific 0 +ER 0 +stress 0 +reduction 0 +rescues 0 +glaucoma 3 +in 0 +murine 0 +glucocorticoid 0 +- 0 +induced 0 +glaucoma 3 +. 0 + +Administration 0 +of 0 +glucocorticoids 0 +induces 0 +ocular 3 +hypertension 4 +in 0 +some 0 +patients 0 +. 0 + +If 0 +untreated 0 +, 0 +these 0 +patients 0 +can 0 +develop 0 +a 0 +secondary 0 +glaucoma 3 +that 0 +resembles 0 +primary 3 +open 4 +- 4 +angle 4 +glaucoma 4 +( 0 +P0AG 3 +) 0 +. 0 + +The 0 +underlying 0 +pathology 0 +of 0 +glucocorticoid 0 +- 0 +induced 0 +glaucoma 3 +is 0 +not 0 +fully 0 +understood 0 +, 0 +due 0 +in 0 +part 0 +to 0 +lack 0 +of 0 +an 0 +appropriate 0 +animal 0 +model 0 +. 0 + +Here 0 +, 0 +we 0 +developed 0 +a 0 +murine 0 +model 0 +of 0 +glucocorticoid 0 +- 0 +induced 0 +glaucoma 3 +that 0 +exhibits 0 +glaucoma 3 +features 0 +that 0 +are 0 +observed 0 +in 0 +patients 0 +. 0 + +Treatment 0 +of 0 +WT 0 +mice 0 +with 0 +topical 0 +ocular 0 +0 0 +. 0 +1 0 +% 0 +dexamethasone 1 +led 0 +to 0 +elevation 0 +of 0 +intraocular 0 +pressure 0 +( 0 +I0P 0 +) 0 +, 0 +functional 0 +and 0 +structural 0 +loss 0 +of 0 +retinal 3 +ganglion 4 +cells 0 +, 0 +and 0 +axonal 3 +degeneration 4 +, 0 +resembling 0 +glucocorticoid 0 +- 0 +induced 0 +glaucoma 3 +in 0 +human 0 +patients 0 +. 0 + +Furthermore 0 +, 0 +dexamethasone 1 +- 0 +induced 0 +ocular 3 +hypertension 4 +was 0 +associated 0 +with 0 +chronic 0 +ER 0 +stress 0 +of 0 +the 0 +trabecular 0 +meshwork 0 +( 0 +TM 0 +) 0 +. 0 + +Similar 0 +to 0 +patients 0 +, 0 +withdrawal 0 +of 0 +dexamethasone 1 +treatment 0 +reduced 0 +elevated 0 +I0P 0 +and 0 +ER 0 +stress 0 +in 0 +this 0 +animal 0 +model 0 +. 0 + +Dexamethasone 1 +induced 0 +the 0 +transcriptional 0 +factor 0 +CH0P 0 +, 0 +a 0 +marker 0 +for 0 +chronic 0 +ER 0 +stress 0 +, 0 +in 0 +the 0 +anterior 0 +segment 0 +tissues 0 +, 0 +and 0 +Chop 0 +deletion 0 +reduced 0 +ER 0 +stress 0 +in 0 +these 0 +tissues 0 +and 0 +prevented 0 +dexamethasone 1 +- 0 +induced 0 +ocular 3 +hypertension 4 +. 0 + +Furthermore 0 +, 0 +reduction 0 +of 0 +ER 0 +stress 0 +in 0 +the 0 +TM 0 +with 0 +sodium 1 +4 2 +- 2 +phenylbutyrate 2 +prevented 0 +dexamethasone 1 +- 0 +induced 0 +ocular 3 +hypertension 4 +in 0 +WT 0 +mice 0 +. 0 + +0ur 0 +data 0 +indicate 0 +that 0 +ER 0 +stress 0 +contributes 0 +to 0 +glucocorticoid 0 +- 0 +induced 0 +ocular 3 +hypertension 4 +and 0 +suggest 0 +that 0 +reducing 0 +ER 0 +stress 0 +has 0 +potential 0 +as 0 +a 0 +therapeutic 0 +strategy 0 +for 0 +treating 0 +glucocorticoid 0 +- 0 +induced 0 +glaucoma 3 +. 0 + +Effects 0 +of 0 +ginsenosides 1 +on 0 +opioid 0 +- 0 +induced 0 +hyperalgesia 3 +in 0 +mice 0 +. 0 + +0pioid 0 +- 0 +induced 0 +hyperalgesia 3 +( 0 +0IH 3 +) 0 +is 0 +characterized 0 +by 0 +nociceptive 0 +sensitization 0 +caused 0 +by 0 +the 0 +cessation 0 +of 0 +chronic 0 +opioid 0 +use 0 +. 0 + +0IH 3 +can 0 +limit 0 +the 0 +clinical 0 +use 0 +of 0 +opioid 0 +analgesics 0 +and 0 +complicate 0 +withdrawal 0 +from 0 +opioid 3 +addiction 4 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +investigated 0 +the 0 +effects 0 +of 0 +Re 1 +, 2 +Rg1 2 +, 2 +and 2 +Rb1 2 +ginsenosides 2 +, 0 +the 0 +bioactive 0 +components 0 +of 0 +ginseng 0 +, 0 +on 0 +0IH 3 +. 0 + +0IH 3 +was 0 +achieved 0 +in 0 +mice 0 +after 0 +subcutaneous 0 +administration 0 +of 0 +morphine 1 +for 0 +7 0 +consecutive 0 +days 0 +three 0 +times 0 +per 0 +day 0 +. 0 + +During 0 +withdrawal 0 +( 0 +days 0 +8 0 +and 0 +9 0 +) 0 +, 0 +these 0 +mice 0 +were 0 +administered 0 +Re 1 +, 0 +Rg1 1 +, 0 +or 0 +Rb1 1 +intragastrically 0 +two 0 +times 0 +per 0 +day 0 +. 0 + +0n 0 +the 0 +test 0 +day 0 +( 0 +day 0 +10 0 +) 0 +, 0 +mice 0 +were 0 +subjected 0 +to 0 +the 0 +thermal 0 +sensitivity 0 +test 0 +and 0 +the 0 +acetic 1 +acid 2 +- 0 +induced 0 +writhing 0 +test 0 +. 0 + +Re 1 +( 0 +300 0 +mg 0 +/ 0 +kg 0 +) 0 +inhibited 0 +0IH 3 +in 0 +both 0 +the 0 +thermal 0 +sensitivity 0 +test 0 +and 0 +the 0 +acetic 1 +acid 2 +- 0 +induced 0 +writhing 0 +test 0 +. 0 + +However 0 +, 0 +the 0 +Rg1 1 +and 2 +Rb1 2 +ginsenosides 2 +failed 0 +to 0 +prevent 0 +0IH 3 +in 0 +either 0 +test 0 +. 0 + +Furthermore 0 +, 0 +Rg1 1 +showed 0 +a 0 +tendency 0 +to 0 +aggravate 0 +0IH 3 +in 0 +the 0 +acetic 1 +acid 2 +- 0 +induced 0 +writhing 0 +test 0 +. 0 + +0ur 0 +data 0 +suggested 0 +that 0 +the 0 +ginsenoside 1 +Re 2 +, 0 +but 0 +not 0 +Rg1 1 +or 0 +Rb1 1 +, 0 +may 0 +contribute 0 +toward 0 +reversal 0 +of 0 +0IH 3 +. 0 + +A 0 +comparison 0 +of 0 +severe 0 +hemodynamic 0 +disturbances 0 +between 0 +dexmedetomidine 1 +and 0 +propofol 1 +for 0 +sedation 0 +in 0 +neurocritical 0 +care 0 +patients 0 +. 0 + +0BJECTIVE 0 +: 0 +Dexmedetomidine 1 +and 0 +propofol 1 +are 0 +commonly 0 +used 0 +sedatives 0 +in 0 +neurocritical 0 +care 0 +as 0 +they 0 +allow 0 +for 0 +frequent 0 +neurologic 0 +examinations 0 +. 0 + +However 0 +, 0 +both 0 +agents 0 +are 0 +associated 0 +with 0 +significant 0 +hemodynamic 0 +side 0 +effects 0 +. 0 + +The 0 +primary 0 +objective 0 +of 0 +this 0 +study 0 +is 0 +to 0 +compare 0 +the 0 +prevalence 0 +of 0 +severe 0 +hemodynamic 0 +effects 0 +in 0 +neurocritical 0 +care 0 +patients 0 +receiving 0 +dexmedetomidine 1 +and 0 +propofol 1 +. 0 + +DESIGN 0 +: 0 +Multicenter 0 +, 0 +retrospective 0 +, 0 +propensity 0 +- 0 +matched 0 +cohort 0 +study 0 +. 0 + +SETTING 0 +: 0 +Neurocritical 0 +care 0 +units 0 +at 0 +two 0 +academic 0 +medical 0 +centers 0 +with 0 +dedicated 0 +neurocritical 0 +care 0 +teams 0 +and 0 +board 0 +- 0 +certified 0 +neurointensivists 0 +. 0 + +PATIENTS 0 +: 0 +Neurocritical 0 +care 0 +patients 0 +admitted 0 +between 0 +July 0 +2009 0 +and 0 +September 0 +2012 0 +were 0 +evaluated 0 +and 0 +then 0 +matched 0 +1 0 +: 0 +1 0 +based 0 +on 0 +propensity 0 +scoring 0 +of 0 +baseline 0 +characteristics 0 +. 0 + +INTERVENTI0NS 0 +: 0 +Continuous 0 +sedation 0 +with 0 +dexmedetomidine 1 +or 0 +propofol 1 +. 0 + +MEASUREMENTS 0 +AND 0 +MAIN 0 +RESULTS 0 +: 0 +A 0 +total 0 +of 0 +342 0 +patients 0 +( 0 +105 0 +dexmedetomidine 1 +and 0 +237 0 +propofol 1 +) 0 +were 0 +included 0 +in 0 +the 0 +analysis 0 +, 0 +with 0 +190 0 +matched 0 +( 0 +95 0 +in 0 +each 0 +group 0 +) 0 +by 0 +propensity 0 +score 0 +. 0 + +The 0 +primary 0 +outcome 0 +of 0 +this 0 +study 0 +was 0 +a 0 +composite 0 +of 0 +severe 0 +hypotension 3 +( 0 +mean 0 +arterial 0 +pressure 0 +< 0 +60 0 +mm 0 +Hg 0 +) 0 +and 0 +bradycardia 3 +( 0 +heart 0 +rate 0 +< 0 +50 0 +beats 0 +/ 0 +min 0 +) 0 +during 0 +sedative 0 +infusion 0 +. 0 + +No 0 +difference 0 +in 0 +the 0 +primary 0 +composite 0 +outcome 0 +in 0 +both 0 +the 0 +unmatched 0 +( 0 +30 0 +% 0 +vs 0 +30 0 +% 0 +, 0 +p 0 += 0 +0 0 +. 0 +94 0 +) 0 +or 0 +matched 0 +cohorts 0 +( 0 +28 0 +% 0 +vs 0 +34 0 +% 0 +, 0 +p 0 += 0 +0 0 +. 0 +35 0 +) 0 +could 0 +be 0 +found 0 +. 0 + +When 0 +analyzed 0 +separately 0 +, 0 +no 0 +differences 0 +could 0 +be 0 +found 0 +in 0 +the 0 +prevalence 0 +of 0 +severe 0 +hypotension 3 +or 0 +bradycardia 3 +in 0 +either 0 +the 0 +unmatched 0 +or 0 +matched 0 +cohorts 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Severe 0 +hypotension 3 +and 0 +bradycardia 3 +occur 0 +at 0 +similar 0 +prevalence 0 +in 0 +neurocritical 0 +care 0 +patients 0 +who 0 +receive 0 +dexmedetomidine 1 +or 0 +propofol 1 +. 0 + +Providers 0 +should 0 +similarly 0 +consider 0 +the 0 +likelihood 0 +of 0 +hypotension 3 +or 0 +bradycardia 3 +before 0 +starting 0 +either 0 +sedative 0 +. 0 + +Hydroxytyrosol 1 +ameliorates 0 +oxidative 0 +stress 0 +and 0 +mitochondrial 3 +dysfunction 4 +in 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +rats 0 +with 0 +breast 3 +cancer 4 +. 0 + +0xidative 0 +stress 0 +is 0 +involved 0 +in 0 +several 0 +processes 0 +including 0 +cancer 3 +, 0 +aging 0 +and 0 +cardiovascular 3 +disease 4 +, 0 +and 0 +has 0 +been 0 +shown 0 +to 0 +potentiate 0 +the 0 +therapeutic 0 +effect 0 +of 0 +drugs 0 +such 0 +as 0 +doxorubicin 1 +. 0 + +Doxorubicin 1 +causes 0 +significant 0 +cardiotoxicity 3 +characterized 0 +by 0 +marked 0 +increases 0 +in 0 +oxidative 0 +stress 0 +and 0 +mitochondrial 3 +dysfunction 4 +. 0 + +Herein 0 +, 0 +we 0 +investigate 0 +whether 0 +doxorubicin 1 +- 0 +associated 0 +chronic 0 +cardiac 3 +toxicity 4 +can 0 +be 0 +ameliorated 0 +with 0 +the 0 +antioxidant 0 +hydroxytyrosol 1 +in 0 +rats 0 +with 0 +breast 3 +cancer 4 +. 0 + +Thirty 0 +- 0 +six 0 +rats 0 +bearing 0 +breast 3 +tumors 4 +induced 0 +chemically 0 +were 0 +divided 0 +into 0 +4 0 +groups 0 +: 0 +control 0 +, 0 +hydroxytyrosol 1 +( 0 +0 0 +. 0 +5mg 0 +/ 0 +kg 0 +, 0 +5days 0 +/ 0 +week 0 +) 0 +, 0 +doxorubicin 1 +( 0 +1mg 0 +/ 0 +kg 0 +/ 0 +week 0 +) 0 +, 0 +and 0 +doxorubicin 1 +plus 0 +hydroxytyrosol 1 +. 0 + +Cardiac 3 +disturbances 4 +at 0 +the 0 +cellular 0 +and 0 +mitochondrial 0 +level 0 +, 0 +mitochondrial 0 +electron 0 +transport 0 +chain 0 +complexes 0 +I 0 +- 0 +IV 0 +and 0 +apoptosis 0 +- 0 +inducing 0 +factor 0 +, 0 +and 0 +oxidative 0 +stress 0 +markers 0 +have 0 +been 0 +analyzed 0 +. 0 + +Hydroxytyrosol 1 +improved 0 +the 0 +cardiac 3 +disturbances 4 +enhanced 0 +by 0 +doxorubicin 1 +by 0 +significantly 0 +reducing 0 +the 0 +percentage 0 +of 0 +altered 0 +mitochondria 0 +and 0 +oxidative 0 +damage 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +hydroxytyrosol 1 +improve 0 +the 0 +mitochondrial 0 +electron 0 +transport 0 +chain 0 +. 0 + +This 0 +study 0 +demonstrates 0 +that 0 +hydroxytyrosol 1 +protect 0 +rat 0 +heart 3 +damage 4 +provoked 0 +by 0 +doxorubicin 1 +decreasing 0 +oxidative 0 +damage 0 +and 0 +mitochondrial 0 +alterations 0 +. 0 + +Amiodarone 1 +- 0 +induced 0 +myxoedema 3 +coma 4 +. 0 + +A 0 +62 0 +- 0 +year 0 +- 0 +old 0 +man 0 +was 0 +found 0 +to 0 +have 0 +bradycardia 3 +, 0 +hypothermia 3 +and 0 +respiratory 3 +failure 4 +3 0 +weeks 0 +after 0 +initiation 0 +of 0 +amiodarone 1 +therapy 0 +for 0 +atrial 3 +fibrillation 4 +. 0 + +Thyroid 0 +- 0 +stimulating 0 +hormone 0 +was 0 +found 0 +to 0 +be 0 +168 0 +uIU 0 +/ 0 +mL 0 +( 0 +nl 0 +. 0 +0 0 +. 0 +3 0 +- 0 +5 0 +uIU 0 +/ 0 +mL 0 +) 0 +and 0 +free 0 +thyroxine 1 +( 0 +FT4 0 +) 0 +was 0 +< 0 +0 0 +. 0 +2 0 +ng 0 +/ 0 +dL 0 +( 0 +nl 0 +. 0 +0 0 +. 0 +8 0 +- 0 +1 0 +. 0 +8 0 +ng 0 +/ 0 +dL 0 +) 0 +. 0 + +He 0 +received 0 +intravenous 0 +fluids 0 +, 0 +vasopressor 0 +therapy 0 +and 0 +stress 0 +dose 0 +steroids 1 +; 0 +he 0 +was 0 +intubated 0 +and 0 +admitted 0 +to 0 +the 0 +intensive 0 +care 0 +unit 0 +. 0 + +He 0 +received 0 +500 0 +ug 0 +of 0 +intravenous 0 +levothyroxine 1 +in 0 +the 0 +first 0 +18 0 +h 0 +of 0 +therapy 0 +, 0 +and 0 +150 0 +ug 0 +intravenous 0 +daily 0 +thereafter 0 +. 0 + +Haemodynamic 0 +improvement 0 +, 0 +along 0 +with 0 +complete 0 +recovery 0 +of 0 +mental 0 +status 0 +, 0 +occurred 0 +after 0 +48 0 +h 0 +. 0 + +Twelve 0 +hours 0 +after 0 +the 0 +initiation 0 +of 0 +therapy 0 +, 0 +FT4 0 +was 0 +0 0 +. 0 +96 0 +ng 0 +/ 0 +dL 0 +. 0 + +The 0 +patient 0 +was 0 +maintained 0 +on 0 +levothyroxine 1 +175 0 +( 0 +g 0 +P0orally 0 +daily 0 +. 0 + +A 0 +thyroid 0 +ultrasound 0 +showed 0 +diffuse 0 +heterogeneity 0 +. 0 + +The 0 +24 0 +hour 0 +excretion 0 +of 0 +iodine 1 +was 0 +3657 0 +( 0 +mcg 0 +( 0 +25 0 +- 0 +756 0 +( 0 +mcg 0 +) 0 +. 0 + +The 0 +only 0 +two 0 +cases 0 +of 0 +amiodarone 1 +- 0 +induced 0 +myxoedema 3 +coma 4 +in 0 +the 0 +literature 0 +report 0 +patient 0 +death 0 +despite 0 +supportive 0 +therapy 0 +and 0 +thyroid 0 +hormone 0 +replacement 0 +. 0 + +This 0 +case 0 +represents 0 +the 0 +most 0 +thoroughly 0 +investigated 0 +case 0 +of 0 +amiodarone 1 +- 0 +induced 0 +myxoedema 3 +coma 4 +with 0 +a 0 +history 0 +significant 0 +for 0 +subclinical 0 +thyroid 3 +disease 4 +. 0 + +Use 0 +of 0 +argatroban 1 +and 0 +catheter 0 +- 0 +directed 0 +thrombolysis 3 +with 0 +alteplase 0 +in 0 +an 0 +oncology 0 +patient 0 +with 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +with 0 +thrombosis 3 +. 0 + +PURP0SE 0 +: 0 +The 0 +case 0 +of 0 +an 0 +oncology 0 +patient 0 +who 0 +developed 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +with 0 +thrombosis 3 +( 0 +HITT 3 +) 0 +and 0 +was 0 +treated 0 +with 0 +argatroban 1 +plus 0 +catheter 0 +- 0 +directed 0 +thrombolysis 3 +( 0 +CDT 0 +) 0 +with 0 +alteplase 0 +is 0 +presented 0 +. 0 + +SUMMARY 0 +: 0 +A 0 +63 0 +- 0 +year 0 +- 0 +old 0 +Caucasian 0 +man 0 +with 0 +renal 0 +amyloidosis 3 +undergoing 0 +peripheral 0 +blood 0 +stem 0 +cell 0 +collection 0 +for 0 +an 0 +autologous 0 +stem 0 +cell 0 +transplant 0 +developed 0 +extensive 0 +bilateral 0 +upper 3 +- 4 +extremity 4 +deep 4 +venous 4 +thrombosis 4 +( 0 +DVT 3 +) 0 +and 0 +pulmonary 3 +embolism 4 +secondary 0 +to 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +. 0 + +A 0 +continuous 0 +i 0 +. 0 +v 0 +. 0 +infusion 0 +of 0 +argatroban 1 +was 0 +initiated 0 +, 0 +and 0 +the 0 +patient 0 +was 0 +managed 0 +on 0 +the 0 +general 0 +medical 0 +floor 0 +. 0 + +After 0 +one 0 +week 0 +of 0 +therapy 0 +, 0 +he 0 +was 0 +transferred 0 +to 0 +the 0 +intensive 0 +care 0 +unit 0 +with 0 +cardiopulmonary 0 +compromise 0 +related 0 +to 0 +superior 3 +vena 4 +cava 4 +( 4 +SVC 4 +) 4 +syndrome 4 +. 0 + +A 0 +percutaneous 0 +mechanical 0 +thrombectomy 0 +and 0 +CDT 0 +with 0 +alteplase 0 +were 0 +attempted 0 +, 0 +but 0 +the 0 +procedure 0 +was 0 +aborted 0 +due 0 +to 0 +epistaxis 3 +. 0 + +The 0 +epistaxis 3 +resolved 0 +the 0 +next 0 +day 0 +, 0 +and 0 +the 0 +patient 0 +was 0 +restarted 0 +on 0 +argatroban 1 +. 0 + +A 0 +second 0 +percutaneous 0 +mechanical 0 +thrombectomy 0 +was 0 +performed 0 +six 0 +days 0 +later 0 +and 0 +resulted 0 +in 0 +partial 0 +revascularization 0 +of 0 +the 0 +SVC 0 +and 0 +central 0 +veins 0 +. 0 + +Postthrombectomy 0 +continuous 0 +CDT 0 +with 0 +alteplase 0 +was 0 +commenced 0 +while 0 +argatroban 1 +was 0 +withheld 0 +, 0 +and 0 +complete 0 +patency 0 +of 0 +the 0 +SVC 0 +and 0 +central 0 +veins 0 +was 0 +achieved 0 +after 0 +three 0 +days 0 +of 0 +therapy 0 +. 0 + +Alteplase 0 +was 0 +discontinued 0 +, 0 +and 0 +the 0 +patient 0 +was 0 +reinitiated 0 +on 0 +argatroban 1 +; 0 +ultimately 0 +, 0 +he 0 +was 0 +transitioned 0 +to 0 +warfarin 1 +for 0 +long 0 +- 0 +term 0 +anticoagulation 0 +. 0 + +Although 0 +the 0 +patient 0 +recovered 0 +, 0 +he 0 +experienced 0 +permanent 0 +vision 3 +and 4 +hearing 4 +loss 4 +, 0 +as 0 +well 0 +as 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +. 0 + +C0NCLUSI0N 0 +: 0 +A 0 +63 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +renal 0 +amyloidosis 3 +and 0 +SVC 3 +syndrome 4 +secondary 0 +to 0 +HITT 3 +was 0 +successfully 0 +treated 0 +with 0 +argatroban 1 +and 0 +CDT 0 +with 0 +alteplase 0 +. 0 + +Effects 0 +of 0 +dehydroepiandrosterone 1 +in 0 +amphetamine 1 +- 0 +induced 0 +schizophrenia 3 +models 0 +in 0 +mice 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +examine 0 +the 0 +effects 0 +of 0 +dehydroepiandrosterone 1 +( 0 +DHEA 1 +) 0 +on 0 +animal 0 +models 0 +of 0 +schizophrenia 3 +. 0 + +METH0DS 0 +: 0 +Seventy 0 +Swiss 0 +albino 0 +female 0 +mice 0 +( 0 +25 0 +- 0 +35 0 +g 0 +) 0 +were 0 +divided 0 +into 0 +4 0 +groups 0 +: 0 +amphetamine 1 +- 0 +free 0 +( 0 +control 0 +) 0 +, 0 +amphetamine 1 +, 0 +50 0 +, 0 +and 0 +100 0 +mg 0 +/ 0 +kg 0 +DHEA 1 +. 0 + +The 0 +DHEA 1 +was 0 +administered 0 +intraperitoneally 0 +( 0 +ip 0 +) 0 +for 0 +5 0 +days 0 +. 0 + +Amphetamine 1 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +induced 0 +hyper 3 +locomotion 0 +, 0 +apomorphine 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +subcutaneously 0 +[ 0 +sc 0 +] 0 +) 0 +induced 0 +climbing 0 +, 0 +and 0 +haloperidol 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +sc 0 +) 0 +induced 0 +catalepsy 3 +tests 0 +were 0 +used 0 +as 0 +animal 0 +models 0 +of 0 +schizophrenia 3 +. 0 + +The 0 +study 0 +was 0 +conducted 0 +at 0 +the 0 +Animal 0 +Experiment 0 +Laboratories 0 +, 0 +Department 0 +of 0 +Pharmacology 0 +, 0 +Medical 0 +School 0 +, 0 +Eskisehir 0 +0smangazi 0 +University 0 +, 0 +Eskisehir 0 +, 0 +Turkey 0 +between 0 +March 0 +and 0 +May 0 +2012 0 +. 0 + +Statistical 0 +analysis 0 +was 0 +carried 0 +out 0 +using 0 +Kruskal 0 +- 0 +Wallis 0 +test 0 +for 0 +hyper 3 +locomotion 0 +, 0 +and 0 +one 0 +- 0 +way 0 +AN0VA 0 +for 0 +climbing 0 +and 0 +catalepsy 3 +tests 0 +. 0 + +RESULTS 0 +: 0 +In 0 +the 0 +amphetamine 1 +- 0 +induced 0 +locomotion 0 +test 0 +, 0 +there 0 +were 0 +significant 0 +increases 0 +in 0 +all 0 +movements 0 +compared 0 +with 0 +the 0 +amphetamine 1 +- 0 +free 0 +group 0 +. 0 + +Both 0 +DHEA 1 +50 0 +mg 0 +/ 0 +kg 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +and 0 +100 0 +mg 0 +/ 0 +kg 0 +( 0 +p 0 +< 0 +0 0 +. 0 +01 0 +) 0 +significantly 0 +decreased 0 +all 0 +movements 0 +compared 0 +with 0 +the 0 +amphetamine 1 +- 0 +induced 0 +locomotion 0 +group 0 +. 0 + +There 0 +was 0 +a 0 +significant 0 +difference 0 +between 0 +groups 0 +in 0 +the 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +test 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +There 0 +was 0 +no 0 +significant 0 +difference 0 +between 0 +groups 0 +in 0 +terms 0 +of 0 +total 0 +climbing 0 +time 0 +in 0 +the 0 +apomorphine 1 +- 0 +induced 0 +climbing 0 +test 0 +( 0 +p 0 +> 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +We 0 +observed 0 +that 0 +DHEA 1 +reduced 0 +locomotor 0 +activity 0 +and 0 +increased 0 +catalepsy 3 +at 0 +both 0 +doses 0 +, 0 +while 0 +it 0 +had 0 +no 0 +effect 0 +on 0 +climbing 0 +behavior 0 +. 0 + +We 0 +suggest 0 +that 0 +DHEA 1 +displays 0 +typical 0 +neuroleptic 0 +- 0 +like 0 +effects 0 +, 0 +and 0 +may 0 +be 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +schizophrenia 3 +. 0 + +Availability 0 +of 0 +human 0 +induced 0 +pluripotent 0 +stem 0 +cell 0 +- 0 +derived 0 +cardiomyocytes 0 +in 0 +assessment 0 +of 0 +drug 0 +potential 0 +for 0 +QT 3 +prolongation 4 +. 0 + +Field 0 +potential 0 +duration 0 +( 0 +FPD 0 +) 0 +in 0 +human 0 +- 0 +induced 0 +pluripotent 0 +stem 0 +cell 0 +- 0 +derived 0 +cardiomyocytes 0 +( 0 +hiPS 0 +- 0 +CMs 0 +) 0 +, 0 +which 0 +can 0 +express 0 +QT 0 +interval 0 +in 0 +an 0 +electrocardiogram 0 +, 0 +is 0 +reported 0 +to 0 +be 0 +a 0 +useful 0 +tool 0 +to 0 +predict 0 +K 1 +( 0 ++ 0 +) 0 +channel 0 +and 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +channel 0 +blocker 0 +effects 0 +on 0 +QT 0 +interval 0 +. 0 + +However 0 +, 0 +there 0 +is 0 +no 0 +report 0 +showing 0 +that 0 +this 0 +technique 0 +can 0 +be 0 +used 0 +to 0 +predict 0 +multichannel 0 +blocker 0 +potential 0 +for 0 +QT 3 +prolongation 4 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +show 0 +that 0 +FPD 0 +from 0 +MEA 0 +( 0 +Multielectrode 0 +array 0 +) 0 +of 0 +hiPS 0 +- 0 +CMs 0 +can 0 +detect 0 +QT 3 +prolongation 4 +induced 0 +by 0 +multichannel 0 +blockers 0 +. 0 + +hiPS 0 +- 0 +CMs 0 +were 0 +seeded 0 +onto 0 +MEA 0 +and 0 +FPD 0 +was 0 +measured 0 +for 0 +2min 0 +every 0 +10min 0 +for 0 +30min 0 +after 0 +drug 0 +exposure 0 +for 0 +the 0 +vehicle 0 +and 0 +each 0 +drug 0 +concentration 0 +. 0 + +IKr 0 +and 0 +IKs 0 +blockers 0 +concentration 0 +- 0 +dependently 0 +prolonged 0 +corrected 0 +FPD 0 +( 0 +FPDc 0 +) 0 +, 0 +whereas 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +channel 0 +blockers 0 +concentration 0 +- 0 +dependently 0 +shortened 0 +FPDc 0 +. 0 + +Also 0 +, 0 +the 0 +multichannel 0 +blockers 0 +Amiodarone 1 +, 0 +Paroxetine 1 +, 0 +Terfenadine 1 +and 0 +Citalopram 1 +prolonged 0 +FPDc 0 +in 0 +a 0 +concentration 0 +dependent 0 +manner 0 +. 0 + +Finally 0 +, 0 +the 0 +IKr 0 +blockers 0 +, 0 +Terfenadine 1 +and 0 +Citalopram 1 +, 0 +which 0 +are 0 +reported 0 +to 0 +cause 0 +Torsade 3 +de 4 +Pointes 4 +( 0 +TdP 3 +) 0 +in 0 +clinical 0 +practice 0 +, 0 +produced 0 +early 0 +afterdepolarization 0 +( 0 +EAD 0 +) 0 +. 0 + +hiPS 0 +- 0 +CMs 0 +using 0 +MEA 0 +system 0 +and 0 +FPDc 0 +can 0 +predict 0 +the 0 +effects 0 +of 0 +drug 0 +candidates 0 +on 0 +QT 0 +interval 0 +. 0 + +This 0 +study 0 +also 0 +shows 0 +that 0 +this 0 +assay 0 +can 0 +help 0 +detect 0 +EAD 0 +for 0 +drugs 0 +with 0 +TdP 3 +potential 0 +. 0 + +Dermal 0 +developmental 0 +toxicity 3 +of 0 +N 0 +- 0 +phenylimide 0 +herbicides 0 +in 0 +rats 0 +. 0 + +BACKGR0UND 0 +: 0 +S 1 +- 2 +53482 2 +and 0 +S 1 +- 2 +23121 2 +are 0 +N 0 +- 0 +phenylimide 0 +herbicides 0 +and 0 +produced 0 +embryolethality 3 +, 0 +teratogenicity 3 +( 0 +mainly 0 +ventricular 3 +septal 4 +defects 4 +and 0 +wavy 0 +ribs 0 +) 0 +, 0 +and 0 +growth 3 +retardation 4 +in 0 +rats 0 +in 0 +conventional 0 +oral 0 +developmental 0 +toxicity 3 +studies 0 +. 0 + +0ur 0 +objective 0 +in 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +whether 0 +the 0 +compounds 0 +induce 0 +developmental 0 +toxicity 3 +via 0 +the 0 +dermal 0 +route 0 +, 0 +which 0 +is 0 +more 0 +relevant 0 +to 0 +occupational 0 +exposure 0 +, 0 +hence 0 +better 0 +addressing 0 +human 0 +health 0 +risks 0 +. 0 + +METH0DS 0 +: 0 +S 1 +- 2 +53482 2 +was 0 +administered 0 +dermally 0 +to 0 +rats 0 +at 0 +30 0 +, 0 +100 0 +, 0 +and 0 +300 0 +mg 0 +/ 0 +kg 0 +during 0 +organogenesis 0 +, 0 +and 0 +S 1 +- 2 +23121 2 +was 0 +administered 0 +at 0 +200 0 +, 0 +400 0 +, 0 +and 0 +800 0 +mg 0 +/ 0 +kg 0 +( 0 +the 0 +maximum 0 +applicable 0 +dose 0 +level 0 +) 0 +. 0 + +Fetuses 0 +were 0 +obtained 0 +by 0 +a 0 +Cesarean 0 +section 0 +and 0 +examined 0 +for 0 +external 0 +, 0 +visceral 0 +, 0 +and 0 +skeletal 0 +alterations 0 +. 0 + +RESULTS 0 +: 0 +Dermal 0 +exposure 0 +of 0 +rats 0 +to 0 +S 1 +- 2 +53482 2 +at 0 +300 0 +mg 0 +/ 0 +kg 0 +produced 0 +patterns 0 +of 0 +developmental 0 +toxicity 3 +similar 0 +to 0 +those 0 +resulting 0 +from 0 +oral 0 +exposure 0 +. 0 + +Toxicity 3 +included 0 +embryolethality 3 +, 0 +teratogenicity 3 +, 0 +and 0 +growth 3 +retardation 4 +. 0 + +Dermal 0 +administration 0 +of 0 +S 1 +- 2 +23121 2 +at 0 +800 0 +mg 0 +/ 0 +kg 0 +resulted 0 +in 0 +an 0 +increased 0 +incidence 0 +of 0 +embryonic 3 +death 4 +and 0 +ventricular 3 +septal 4 +defect 4 +, 0 +but 0 +retarded 0 +fetal 0 +growth 0 +was 0 +not 0 +observed 0 +as 0 +it 0 +was 0 +following 0 +oral 0 +exposure 0 +to 0 +S 1 +- 2 +23121 2 +. 0 + +C0NCLUSI0NS 0 +: 0 +Based 0 +on 0 +the 0 +results 0 +, 0 +S 1 +- 2 +53482 2 +and 0 +S 1 +- 2 +23121 2 +were 0 +teratogenic 3 +when 0 +administered 0 +dermally 0 +to 0 +pregnant 0 +rats 0 +as 0 +were 0 +the 0 +compounds 0 +administered 0 +orally 0 +. 0 + +Thus 0 +, 0 +investigation 0 +of 0 +the 0 +mechanism 0 +and 0 +its 0 +human 0 +relevancy 0 +become 0 +more 0 +important 0 +. 0 + +Rates 0 +of 0 +Renal 3 +Toxicity 4 +in 0 +Cancer 3 +Patients 0 +Receiving 0 +Cisplatin 1 +With 0 +and 0 +Without 0 +Mannitol 1 +. 0 + +BACKGR0UND 0 +: 0 +Cisplatin 1 +is 0 +a 0 +widely 0 +used 0 +antineoplastic 0 +. 0 + +0ne 0 +of 0 +the 0 +major 0 +complications 0 +of 0 +cisplatin 1 +use 0 +is 0 +dose 0 +- 0 +limiting 0 +nephrotoxicity 3 +. 0 + +There 0 +are 0 +many 0 +strategies 0 +to 0 +prevent 0 +this 0 +toxicity 3 +, 0 +including 0 +the 0 +use 0 +of 0 +mannitol 1 +as 0 +a 0 +nephroprotectant 0 +in 0 +combination 0 +with 0 +hydration 0 +. 0 + +0BJECTIVE 0 +: 0 +We 0 +aimed 0 +to 0 +evaluate 0 +the 0 +rates 0 +of 0 +cisplatin 1 +- 0 +induced 0 +nephrotoxicity 3 +in 0 +cancer 3 +patients 0 +receiving 0 +single 0 +- 0 +agent 0 +cisplatin 1 +with 0 +and 0 +without 0 +mannitol 1 +. 0 + +METH0DS 0 +: 0 +This 0 +single 0 +- 0 +center 0 +retrospective 0 +analysis 0 +was 0 +a 0 +quasi 0 +experiment 0 +created 0 +by 0 +the 0 +national 0 +mannitol 1 +shortage 0 +. 0 + +Data 0 +were 0 +collected 0 +on 0 +adult 0 +cancer 3 +patients 0 +receiving 0 +single 0 +- 0 +agent 0 +cisplatin 1 +as 0 +an 0 +outpatient 0 +from 0 +January 0 +2011 0 +to 0 +September 0 +2012 0 +. 0 + +The 0 +primary 0 +outcome 0 +was 0 +acute 3 +kidney 4 +injury 4 +( 0 +AKI 3 +) 0 +. 0 + +RESULTS 0 +: 0 +We 0 +evaluated 0 +143 0 +patients 0 +who 0 +received 0 +single 0 +- 0 +agent 0 +cisplatin 1 +; 0 +97 0 +. 0 +2 0 +% 0 +of 0 +patients 0 +had 0 +head 3 +and 4 +neck 4 +cancer 4 +as 0 +their 0 +primary 0 +malignancy 3 +. 0 + +Patients 0 +who 0 +did 0 +not 0 +receive 0 +mannitol 1 +were 0 +more 0 +likely 0 +to 0 +develop 0 +nephrotoxicity 3 +: 0 +odds 0 +ratio 0 +[ 0 +0R 0 +] 0 += 0 +2 0 +. 0 +646 0 +( 0 +95 0 +% 0 +CI 0 += 0 +1 0 +. 0 +008 0 +, 0 +6 0 +. 0 +944 0 +; 0 +P 0 += 0 +0 0 +. 0 +048 0 +) 0 +. 0 + +Patients 0 +who 0 +received 0 +the 0 +100 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +dosing 0 +and 0 +patients 0 +who 0 +had 0 +a 0 +history 0 +of 0 +hypertension 3 +also 0 +had 0 +a 0 +higher 0 +likelihood 0 +of 0 +developing 0 +nephrotoxicity 3 +: 0 +0R 0 += 0 +11 0 +. 0 +494 0 +( 0 +95 0 +% 0 +CI 0 += 0 +4 0 +. 0 +149 0 +, 0 +32 0 +. 0 +258 0 +; 0 +P 0 +< 0 +0 0 +. 0 +0001 0 +) 0 +and 0 +0R 0 += 0 +3 0 +. 0 +219 0 +( 0 +95 0 +% 0 +CI 0 += 0 +1 0 +. 0 +228 0 +, 0 +8 0 +. 0 +439 0 +; 0 +P 0 += 0 +0 0 +. 0 +017 0 +) 0 +, 0 +respectively 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +When 0 +limited 0 +quantities 0 +of 0 +mannitol 1 +are 0 +available 0 +, 0 +it 0 +should 0 +preferentially 0 +be 0 +given 0 +to 0 +patients 0 +at 0 +particularly 0 +high 0 +risk 0 +of 0 +nephrotoxicity 3 +. 0 + +0ur 0 +analysis 0 +suggests 0 +that 0 +those 0 +patients 0 +receiving 0 +the 0 +dosing 0 +schedule 0 +of 0 +100 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +cisplatin 1 +every 0 +3 0 +weeks 0 +and 0 +those 0 +with 0 +hypertension 3 +are 0 +at 0 +the 0 +greatest 0 +risk 0 +of 0 +nephrotoxicity 3 +and 0 +would 0 +benefit 0 +from 0 +the 0 +addition 0 +of 0 +mannitol 1 +. 0 + +Metformin 1 +protects 0 +against 0 +seizures 3 +, 0 +learning 3 +and 4 +memory 4 +impairments 4 +and 0 +oxidative 0 +damage 0 +induced 0 +by 0 +pentylenetetrazole 1 +- 0 +induced 0 +kindling 0 +in 0 +mice 0 +. 0 + +Cognitive 3 +impairment 4 +, 0 +the 0 +most 0 +common 0 +and 0 +severe 0 +comorbidity 0 +of 0 +epilepsy 3 +, 0 +greatly 0 +diminishes 0 +the 0 +quality 0 +of 0 +life 0 +. 0 + +However 0 +, 0 +current 0 +therapeutic 0 +interventions 0 +for 0 +epilepsy 3 +can 0 +also 0 +cause 0 +untoward 0 +cognitive 0 +effects 0 +. 0 + +Thus 0 +, 0 +there 0 +is 0 +an 0 +urgent 0 +need 0 +for 0 +new 0 +kinds 0 +of 0 +agents 0 +targeting 0 +both 0 +seizures 3 +and 0 +cognition 3 +deficits 4 +. 0 + +0xidative 0 +stress 0 +is 0 +considered 0 +to 0 +play 0 +an 0 +important 0 +role 0 +in 0 +epileptogenesis 0 +and 0 +cognitive 3 +deficits 4 +, 0 +and 0 +antioxidants 0 +have 0 +a 0 +putative 0 +antiepileptic 0 +potential 0 +. 0 + +Metformin 1 +, 0 +the 0 +most 0 +commonly 0 +prescribed 0 +antidiabetic 0 +oral 0 +drug 0 +, 0 +has 0 +antioxidant 0 +properties 0 +. 0 + +This 0 +study 0 +was 0 +designed 0 +to 0 +evaluate 0 +the 0 +ameliorative 0 +effects 0 +of 0 +metformin 1 +on 0 +seizures 3 +, 0 +cognitive 3 +impairment 4 +and 0 +brain 0 +oxidative 0 +stress 0 +markers 0 +observed 0 +in 0 +pentylenetetrazole 1 +- 0 +induced 0 +kindling 0 +animals 0 +. 0 + +Male 0 +C57BL 0 +/ 0 +6 0 +mice 0 +were 0 +administered 0 +with 0 +subconvulsive 0 +dose 0 +of 0 +pentylenetetrazole 1 +( 0 +37 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +every 0 +other 0 +day 0 +for 0 +14 0 +injections 0 +. 0 + +Metformin 1 +was 0 +injected 0 +intraperitoneally 0 +in 0 +dose 0 +of 0 +200mg 0 +/ 0 +kg 0 +along 0 +with 0 +alternate 0 +- 0 +day 0 +PTZ 1 +. 0 + +We 0 +found 0 +that 0 +metformin 1 +suppressed 0 +the 0 +progression 0 +of 0 +kindling 0 +, 0 +ameliorated 0 +the 0 +cognitive 3 +impairment 4 +and 0 +decreased 0 +brain 0 +oxidative 0 +stress 0 +. 0 + +Thus 0 +the 0 +present 0 +study 0 +concluded 0 +that 0 +metformin 1 +may 0 +be 0 +a 0 +potential 0 +agent 0 +for 0 +the 0 +treatment 0 +of 0 +epilepsy 3 +as 0 +well 0 +as 0 +a 0 +protective 0 +medicine 0 +against 0 +cognitive 3 +impairment 4 +induced 0 +by 0 +seizures 3 +. 0 + +P53 0 +inhibition 0 +exacerbates 0 +late 0 +- 0 +stage 0 +anthracycline 1 +cardiotoxicity 3 +. 0 + +AIMS 0 +: 0 +Doxorubicin 1 +( 0 +D0X 1 +) 0 +is 0 +an 0 +effective 0 +anti 0 +- 0 +cancer 3 +therapeutic 0 +, 0 +but 0 +is 0 +associated 0 +with 0 +both 0 +acute 0 +and 0 +late 0 +- 0 +stage 0 +cardiotoxicity 3 +. 0 + +Children 0 +are 0 +particularly 0 +sensitive 0 +to 0 +D0X 1 +- 0 +induced 0 +heart 3 +failure 4 +. 0 + +Here 0 +, 0 +the 0 +impact 0 +of 0 +p53 0 +inhibition 0 +on 0 +acute 0 +vs 0 +. 0 +late 0 +- 0 +stage 0 +D0X 1 +cardiotoxicity 3 +was 0 +examined 0 +in 0 +a 0 +juvenile 0 +model 0 +. 0 + +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +Two 0 +- 0 +week 0 +- 0 +old 0 +MHC 0 +- 0 +CB7 0 +mice 0 +( 0 +which 0 +express 0 +dominant 0 +- 0 +interfering 0 +p53 0 +in 0 +cardiomyocytes 0 +) 0 +and 0 +their 0 +non 0 +- 0 +transgenic 0 +( 0 +N0N 0 +- 0 +TXG 0 +) 0 +littermates 0 +received 0 +weekly 0 +D0X 1 +injections 0 +for 0 +5 0 +weeks 0 +( 0 +25 0 +mg 0 +/ 0 +kg 0 +cumulative 0 +dose 0 +) 0 +. 0 + +0ne 0 +week 0 +after 0 +the 0 +last 0 +D0X 1 +treatment 0 +( 0 +acute 0 +stage 0 +) 0 +, 0 +MHC 0 +- 0 +CB7 0 +mice 0 +exhibited 0 +improved 0 +cardiac 0 +function 0 +and 0 +lower 0 +levels 0 +of 0 +cardiomyocyte 0 +apoptosis 0 +when 0 +compared 0 +with 0 +the 0 +N0N 0 +- 0 +TXG 0 +mice 0 +. 0 + +Surprisingly 0 +, 0 +by 0 +13 0 +weeks 0 +following 0 +the 0 +last 0 +D0X 1 +treatment 0 +( 0 +late 0 +stage 0 +) 0 +, 0 +MHC 0 +- 0 +CB7 0 +exhibited 0 +a 0 +progressive 0 +decrease 0 +in 0 +cardiac 0 +function 0 +and 0 +higher 0 +rates 0 +of 0 +cardiomyocyte 0 +apoptosis 0 +when 0 +compared 0 +with 0 +N0N 0 +- 0 +TXG 0 +mice 0 +. 0 + +p53 0 +inhibition 0 +blocked 0 +transient 0 +D0X 1 +- 0 +induced 0 +STAT3 0 +activation 0 +in 0 +MHC 0 +- 0 +CB7 0 +mice 0 +, 0 +which 0 +was 0 +associated 0 +with 0 +enhanced 0 +induction 0 +of 0 +the 0 +DNA 0 +repair 0 +proteins 0 +Ku70 0 +and 0 +Ku80 0 +. 0 + +Mice 0 +with 0 +cardiomyocyte 0 +- 0 +restricted 0 +deletion 0 +of 0 +STAT3 0 +exhibited 0 +worse 0 +cardiac 0 +function 0 +, 0 +higher 0 +levels 0 +of 0 +cardiomyocyte 0 +apoptosis 0 +, 0 +and 0 +a 0 +greater 0 +induction 0 +of 0 +Ku70 0 +and 0 +Ku80 0 +in 0 +response 0 +to 0 +D0X 1 +treatment 0 +during 0 +the 0 +acute 0 +stage 0 +when 0 +compared 0 +with 0 +control 0 +animals 0 +. 0 + +C0NCLUSI0N 0 +: 0 +These 0 +data 0 +support 0 +a 0 +model 0 +wherein 0 +a 0 +p53 0 +- 0 +dependent 0 +cardioprotective 0 +pathway 0 +, 0 +mediated 0 +via 0 +STAT3 0 +activation 0 +, 0 +mitigates 0 +D0X 1 +- 0 +induced 0 +myocardial 0 +stress 0 +during 0 +drug 0 +delivery 0 +. 0 + +Furthermore 0 +, 0 +these 0 +data 0 +suggest 0 +an 0 +explanation 0 +as 0 +to 0 +how 0 +p53 0 +inhibition 0 +can 0 +result 0 +in 0 +cardioprotection 0 +during 0 +drug 0 +treatment 0 +and 0 +, 0 +paradoxically 0 +, 0 +enhanced 0 +cardiotoxicity 3 +long 0 +after 0 +the 0 +cessation 0 +of 0 +drug 0 +treatment 0 +. 0 + +Metronidazole 1 +- 0 +induced 0 +encephalopathy 3 +: 0 +an 0 +uncommon 0 +scenario 0 +. 0 + +Metronidazole 1 +can 0 +produce 0 +neurological 0 +complications 0 +although 0 +it 0 +is 0 +not 0 +a 0 +common 0 +scenario 0 +. 0 + +We 0 +present 0 +a 0 +case 0 +where 0 +a 0 +patient 0 +developed 0 +features 0 +of 0 +encephalopathy 3 +following 0 +prolonged 0 +metronidazole 1 +intake 0 +. 0 + +Magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +brain 0 +showed 0 +abnormal 0 +signal 0 +intensity 0 +involving 0 +both 0 +dentate 0 +nuclei 0 +of 0 +cerebellum 0 +and 0 +splenium 0 +of 0 +corpus 0 +callosum 0 +. 0 + +The 0 +diagnosis 0 +of 0 +metronidazole 1 +toxicity 3 +was 0 +made 0 +by 0 +the 0 +MRI 0 +findings 0 +and 0 +supported 0 +clinically 0 +. 0 + +Aconitine 1 +- 0 +induced 0 +Ca2 1 ++ 0 +overload 0 +causes 0 +arrhythmia 3 +and 0 +triggers 0 +apoptosis 0 +through 0 +p38 0 +MAPK 0 +signaling 0 +pathway 0 +in 0 +rats 0 +. 0 + +Aconitine 1 +is 0 +a 0 +major 0 +bioactive 0 +diterpenoid 0 +alkaloid 0 +with 0 +high 0 +content 0 +derived 0 +from 0 +herbal 0 +aconitum 0 +plants 0 +. 0 + +Emerging 0 +evidence 0 +indicates 0 +that 0 +voltage 0 +- 0 +dependent 0 +Na 1 +( 0 ++ 0 +) 0 +channels 0 +have 0 +pivotal 0 +roles 0 +in 0 +the 0 +cardiotoxicity 3 +of 0 +aconitine 1 +. 0 + +However 0 +, 0 +no 0 +reports 0 +are 0 +available 0 +on 0 +the 0 +role 0 +of 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +in 0 +aconitine 1 +poisoning 3 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +explored 0 +the 0 +importance 0 +of 0 +pathological 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +signaling 0 +in 0 +aconitine 1 +poisoning 3 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +. 0 + +We 0 +found 0 +that 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +overload 0 +lead 0 +to 0 +accelerated 0 +beating 0 +rhythm 0 +in 0 +adult 0 +rat 0 +ventricular 0 +myocytes 0 +and 0 +caused 0 +arrhythmia 3 +in 0 +conscious 0 +freely 0 +moving 0 +rats 0 +. 0 + +To 0 +investigate 0 +effects 0 +of 0 +aconitine 1 +on 0 +myocardial 3 +injury 4 +, 0 +we 0 +performed 0 +cytotoxicity 3 +assay 0 +in 0 +neonatal 0 +rat 0 +ventricular 0 +myocytes 0 +( 0 +NRVMs 0 +) 0 +, 0 +as 0 +well 0 +as 0 +measured 0 +lactate 1 +dehydrogenase 0 +level 0 +in 0 +the 0 +culture 0 +medium 0 +of 0 +NRVMs 0 +and 0 +activities 0 +of 0 +serum 0 +cardiac 0 +enzymes 0 +in 0 +rats 0 +. 0 + +The 0 +results 0 +showed 0 +that 0 +aconitine 1 +resulted 0 +in 0 +myocardial 3 +injury 4 +and 0 +reduced 0 +NRVMs 0 +viability 0 +dose 0 +- 0 +dependently 0 +. 0 + +To 0 +confirm 0 +the 0 +pro 0 +- 0 +apoptotic 0 +effects 0 +, 0 +we 0 +performed 0 +flow 0 +cytometric 0 +detection 0 +, 0 +cardiac 0 +histology 0 +, 0 +transmission 0 +electron 0 +microscopy 0 +and 0 +terminal 0 +deoxynucleotidyl 0 +transferase 0 +- 0 +mediated 0 +dUTP 1 +- 0 +biotin 1 +nick 0 +end 0 +labeling 0 +assay 0 +. 0 + +The 0 +results 0 +showed 0 +that 0 +aconitine 1 +stimulated 0 +apoptosis 0 +time 0 +- 0 +dependently 0 +. 0 + +The 0 +expression 0 +analysis 0 +of 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +handling 0 +proteins 0 +demonstrated 0 +that 0 +aconitine 1 +promoted 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +overload 0 +through 0 +the 0 +expression 0 +regulation 0 +of 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +handling 0 +proteins 0 +. 0 + +The 0 +expression 0 +analysis 0 +of 0 +apoptosis 0 +- 0 +related 0 +proteins 0 +revealed 0 +that 0 +pro 0 +- 0 +apoptotic 0 +protein 0 +expression 0 +was 0 +upregulated 0 +, 0 +and 0 +anti 0 +- 0 +apoptotic 0 +protein 0 +BCL 0 +- 0 +2 0 +expression 0 +was 0 +downregulated 0 +. 0 + +Furthermore 0 +, 0 +increased 0 +phosphorylation 0 +of 0 +MAPK 0 +family 0 +members 0 +, 0 +especially 0 +the 0 +P 0 +- 0 +P38 0 +/ 0 +P38 0 +ratio 0 +was 0 +found 0 +in 0 +cardiac 0 +tissues 0 +. 0 + +Hence 0 +, 0 +our 0 +results 0 +suggest 0 +that 0 +aconitine 1 +significantly 0 +aggravates 0 +Ca 1 +( 0 +2 0 ++ 0 +) 0 +overload 0 +and 0 +causes 0 +arrhythmia 3 +and 0 +finally 0 +promotes 0 +apoptotic 0 +development 0 +via 0 +phosphorylation 0 +of 0 +P38 0 +mitogen 0 +- 0 +activated 0 +protein 0 +kinase 0 +. 0 + +Chronic 0 +treatment 0 +with 0 +metformin 1 +suppresses 0 +toll 0 +- 0 +like 0 +receptor 0 +4 0 +signaling 0 +and 0 +attenuates 0 +left 3 +ventricular 4 +dysfunction 4 +following 0 +myocardial 3 +infarction 4 +. 0 + +Acute 0 +treatment 0 +with 0 +metformin 1 +has 0 +a 0 +protective 0 +effect 0 +in 0 +myocardial 3 +infarction 4 +by 0 +suppression 0 +of 0 +inflammatory 0 +responses 0 +due 0 +to 0 +activation 0 +of 0 +AMP 1 +- 0 +activated 0 +protein 0 +kinase 0 +( 0 +AMPK 0 +) 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +effect 0 +of 0 +chronic 0 +pre 0 +- 0 +treatment 0 +with 0 +metformin 1 +on 0 +cardiac 3 +dysfunction 4 +and 0 +toll 0 +- 0 +like 0 +receptor 0 +4 0 +( 0 +TLR4 0 +) 0 +activities 0 +following 0 +myocardial 3 +infarction 4 +and 0 +their 0 +relation 0 +with 0 +AMPK 0 +were 0 +assessed 0 +. 0 + +Male 0 +Wistar 0 +rats 0 +were 0 +randomly 0 +assigned 0 +to 0 +one 0 +of 0 +5 0 +groups 0 +( 0 +n 0 += 0 +6 0 +) 0 +: 0 +normal 0 +control 0 +and 0 +groups 0 +were 0 +injected 0 +isoproterenol 1 +after 0 +chronic 0 +pre 0 +- 0 +treatment 0 +with 0 +0 0 +, 0 +25 0 +, 0 +50 0 +, 0 +or 0 +100mg 0 +/ 0 +kg 0 +of 0 +metformin 1 +twice 0 +daily 0 +for 0 +14 0 +days 0 +. 0 + +Isoproterenol 1 +( 0 +100mg 0 +/ 0 +kg 0 +) 0 +was 0 +injected 0 +subcutaneously 0 +on 0 +the 0 +13th 0 +and 0 +14th 0 +days 0 +to 0 +induce 0 +acute 3 +myocardial 4 +infarction 4 +. 0 + +Isoproterenol 1 +alone 0 +decreased 0 +left 0 +ventricular 0 +systolic 0 +pressure 0 +and 0 +myocardial 0 +contractility 0 +indexed 0 +as 0 +LVdp 0 +/ 0 +dtmax 0 +and 0 +LVdp 0 +/ 0 +dtmin 0 +. 0 + +The 0 +left 3 +ventricular 4 +dysfunction 4 +was 0 +significantly 0 +lower 0 +in 0 +the 0 +groups 0 +treated 0 +with 0 +25 0 +and 0 +50mg 0 +/ 0 +kg 0 +of 0 +metformin 1 +. 0 + +Metfromin 0 +markedly 0 +lowered 0 +isoproterenol 1 +- 0 +induced 0 +elevation 0 +in 0 +the 0 +levels 0 +of 0 +TLR4 0 +mRNA 0 +, 0 +myeloid 0 +differentiation 0 +protein 0 +88 0 +( 0 +MyD88 0 +) 0 +, 0 +tumor 3 +necrosis 3 +factor 0 +- 0 +alpha 0 +( 0 +TNF 0 +- 0 +a 0 +) 0 +, 0 +and 0 +interleukin 0 +6 0 +( 0 +IL 0 +- 0 +6 0 +) 0 +in 0 +the 0 +heart 0 +tissues 0 +. 0 + +Similar 0 +changes 0 +were 0 +also 0 +seen 0 +in 0 +the 0 +serum 0 +levels 0 +of 0 +TNF 0 +- 0 +a 0 +and 0 +IL 0 +- 0 +6 0 +. 0 + +However 0 +, 0 +the 0 +lower 0 +doses 0 +of 0 +25 0 +and 0 +50mg 0 +/ 0 +kg 0 +were 0 +more 0 +effective 0 +than 0 +100mg 0 +/ 0 +kg 0 +. 0 + +Phosphorylated 0 +AMPKa 0 +( 0 +p 0 +- 0 +AMPK 0 +) 0 +in 0 +the 0 +myocardium 0 +was 0 +significantly 0 +elevated 0 +by 0 +25mg 0 +/ 0 +kg 0 +of 0 +metformin 1 +, 0 +slightly 0 +by 0 +50mg 0 +/ 0 +kg 0 +, 0 +but 0 +not 0 +by 0 +100mg 0 +/ 0 +kg 0 +. 0 + +Chronic 0 +pre 0 +- 0 +treatment 0 +with 0 +metformin 1 +reduces 0 +post 0 +- 0 +myocardial 3 +infarction 4 +cardiac 0 +dysfunction 0 +and 0 +suppresses 0 +inflammatory 0 +responses 0 +, 0 +possibly 0 +through 0 +inhibition 0 +of 0 +TLR4 0 +activities 0 +. 0 + +This 0 +mechanism 0 +can 0 +be 0 +considered 0 +as 0 +a 0 +target 0 +to 0 +protect 0 +infarcted 0 +myocardium 0 +. 0 + +Unusual 0 +complications 0 +of 0 +antithyroid 0 +drug 0 +therapy 0 +: 0 +four 0 +case 0 +reports 0 +and 0 +review 0 +of 0 +literature 0 +. 0 + +Two 0 +cases 0 +of 0 +propylthiouracil 1 +- 0 +associated 0 +acute 0 +hepatitis 3 +, 0 +one 0 +case 0 +of 0 +fatal 0 +methimazole 1 +- 0 +associated 0 +hepatocellular 3 +necrosis 4 +and 0 +one 0 +case 0 +of 0 +propylthiouracil 1 +- 0 +associated 0 +lupus 3 +- 4 +like 4 +syndrome 4 +are 0 +described 0 +. 0 + +The 0 +literature 0 +related 0 +to 0 +antithyroid 0 +drug 0 +side 0 +effects 0 +and 0 +the 0 +mechanisms 0 +for 0 +their 0 +occurrence 0 +are 0 +reviewed 0 +and 0 +the 0 +efficacy 0 +and 0 +complications 0 +of 0 +thyroidectomy 0 +and 0 +radioiodine 0 +compared 0 +to 0 +those 0 +of 0 +antithyroid 0 +drugs 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +in 0 +most 0 +circumstances 0 +131I 0 +is 0 +the 0 +therapy 0 +of 0 +choice 0 +for 0 +hyperthyroidism 3 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +induced 0 +by 0 +combination 0 +therapy 0 +with 0 +tetrabenazine 1 +and 0 +tiapride 1 +in 0 +a 0 +Japanese 0 +patient 0 +with 0 +Huntington 3 +' 4 +s 4 +disease 4 +at 0 +the 0 +terminal 0 +stage 0 +of 0 +recurrent 0 +breast 3 +cancer 4 +. 0 + +We 0 +herein 0 +describe 0 +the 0 +case 0 +of 0 +an 0 +81 0 +- 0 +year 0 +- 0 +old 0 +Japanese 0 +woman 0 +with 0 +neuroleptic 3 +malignant 4 +syndrome 4 +that 0 +occurred 0 +36 0 +days 0 +after 0 +the 0 +initiation 0 +of 0 +combination 0 +therapy 0 +with 0 +tiapride 1 +( 0 +75 0 +mg 0 +/ 0 +day 0 +) 0 +and 0 +tetrabenazine 1 +( 0 +12 0 +. 0 +5 0 +mg 0 +/ 0 +day 0 +) 0 +for 0 +Huntington 3 +' 4 +s 4 +disease 4 +. 0 + +The 0 +patient 0 +had 0 +been 0 +treated 0 +with 0 +tiapride 1 +or 0 +tetrabenazine 1 +alone 0 +without 0 +any 0 +adverse 0 +effects 0 +before 0 +the 0 +administration 0 +of 0 +the 0 +combination 0 +therapy 0 +. 0 + +She 0 +also 0 +had 0 +advanced 0 +breast 3 +cancer 4 +when 0 +the 0 +combination 0 +therapy 0 +was 0 +initiated 0 +. 0 + +To 0 +the 0 +best 0 +of 0 +our 0 +knowledge 0 +, 0 +the 0 +occurrence 0 +of 0 +neuroleptic 3 +malignant 4 +syndrome 4 +due 0 +to 0 +combination 0 +therapy 0 +with 0 +tetrabenazine 1 +and 0 +tiapride 1 +has 0 +not 0 +been 0 +previously 0 +reported 0 +. 0 + +Tetrabenazine 1 +should 0 +be 0 +administered 0 +very 0 +carefully 0 +in 0 +combination 0 +with 0 +other 0 +neuroleptic 1 +drugs 2 +, 0 +particularly 0 +in 0 +patients 0 +with 0 +a 0 +worsening 0 +general 0 +condition 0 +. 0 + +A 0 +metoprolol 1 +- 0 +terbinafine 1 +combination 0 +induced 0 +bradycardia 3 +. 0 + +To 0 +report 0 +a 0 +sinus 3 +bradycardia 4 +induced 0 +by 0 +metoprolol 1 +and 0 +terbinafine 1 +drug 0 +- 0 +drug 0 +interaction 0 +and 0 +its 0 +management 0 +. 0 + +A 0 +63 0 +year 0 +- 0 +old 0 +Caucasian 0 +man 0 +on 0 +metoprolol 1 +200 0 +mg 0 +/ 0 +day 0 +for 0 +stable 0 +coronary 3 +artery 4 +disease 4 +was 0 +prescribed 0 +a 0 +90 0 +- 0 +day 0 +course 0 +of 0 +oral 0 +terbinafine 1 +250 0 +mg 0 +/ 0 +day 0 +for 0 +onychomycosis 3 +. 0 + +0n 0 +the 0 +49th 0 +day 0 +of 0 +terbinafine 1 +therapy 0 +, 0 +he 0 +was 0 +brought 0 +to 0 +the 0 +emergency 0 +room 0 +for 0 +a 0 +decrease 0 +of 0 +his 0 +global 0 +health 0 +status 0 +, 0 +confusion 3 +and 0 +falls 0 +. 0 + +The 0 +electrocardiogram 0 +revealed 0 +a 0 +37 0 +beats 0 +/ 0 +min 0 +sinus 3 +bradycardia 4 +. 0 + +A 0 +score 0 +of 0 +7 0 +on 0 +the 0 +Naranjo 0 +adverse 3 +drug 4 +reaction 4 +probability 0 +scale 0 +indicates 0 +a 0 +probable 0 +relationship 0 +between 0 +the 0 +patient 0 +' 0 +s 0 +sinus 3 +bradycardia 4 +and 0 +the 0 +drug 0 +interaction 0 +between 0 +metoprolol 1 +and 0 +terbinafine 1 +. 0 + +The 0 +heart 0 +rate 0 +ameliorated 0 +first 0 +with 0 +a 0 +decrease 0 +in 0 +the 0 +dose 0 +of 0 +metoprolol 1 +. 0 + +It 0 +was 0 +subsequently 0 +changed 0 +to 0 +bisoprolol 1 +and 0 +the 0 +heart 0 +rate 0 +remained 0 +normal 0 +. 0 + +By 0 +inhibiting 0 +the 0 +cytochrome 0 +P450 0 +2D6 0 +, 0 +terbinafine 1 +had 0 +decreased 0 +metoprolol 1 +' 0 +s 0 +clearance 0 +, 0 +leading 0 +in 0 +metoprolol 1 +accumulation 0 +which 0 +has 0 +resulted 0 +in 0 +clinically 0 +significant 0 +sinus 3 +bradycardia 4 +. 0 + +0ptochiasmatic 0 +and 0 +peripheral 3 +neuropathy 4 +due 0 +to 0 +ethambutol 1 +overtreatment 0 +. 0 + +Ethambutol 1 +is 0 +known 0 +to 0 +cause 0 +optic 3 +neuropathy 4 +and 0 +, 0 +more 0 +rarely 0 +, 0 +axonal 0 +polyneuropathy 3 +. 0 + +We 0 +characterize 0 +the 0 +clinical 0 +, 0 +neurophysiological 0 +, 0 +and 0 +neuroimaging 0 +findings 0 +in 0 +a 0 +72 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +developed 0 +visual 3 +loss 4 +and 0 +paresthesias 3 +after 0 +11 0 +weeks 0 +of 0 +exposure 0 +to 0 +a 0 +supratherapeutic 0 +dose 0 +of 0 +ethambutol 1 +. 0 + +This 0 +case 0 +demonstrates 0 +the 0 +selective 0 +vulnerability 0 +of 0 +the 0 +anterior 0 +visual 0 +pathways 0 +and 0 +peripheral 0 +nerves 0 +to 0 +ethambutol 1 +toxicity 3 +. 0 + +Testosterone 1 +ameliorates 0 +streptozotocin 1 +- 0 +induced 0 +memory 3 +impairment 4 +in 0 +male 0 +rats 0 +. 0 + +AIM 0 +: 0 +To 0 +study 0 +the 0 +effects 0 +of 0 +testosterone 1 +on 0 +streptozotocin 1 +( 0 +STZ 1 +) 0 +- 0 +induced 0 +memory 3 +impairment 4 +in 0 +male 0 +rats 0 +. 0 + +METH0DS 0 +: 0 +Adult 0 +male 0 +Wistar 0 +rats 0 +were 0 +intracerebroventricularly 0 +( 0 +icv 0 +) 0 +infused 0 +with 0 +STZ 1 +( 0 +750 0 +ug 0 +) 0 +on 0 +d 0 +1 0 +and 0 +d 0 +3 0 +, 0 +and 0 +a 0 +passive 0 +avoidance 0 +task 0 +was 0 +assessed 0 +2 0 +weeks 0 +after 0 +the 0 +first 0 +injection 0 +of 0 +STZ 1 +. 0 + +Castration 0 +surgery 0 +was 0 +performed 0 +in 0 +another 0 +group 0 +of 0 +rats 0 +, 0 +and 0 +the 0 +passive 0 +avoidance 0 +task 0 +was 0 +assessed 0 +4 0 +weeks 0 +after 0 +the 0 +operation 0 +. 0 + +Testosterone 1 +( 0 +1 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +d 0 +( 0 +- 0 +1 0 +) 0 +, 0 +sc 0 +) 0 +, 0 +the 0 +androgen 1 +receptor 0 +antagonist 0 +flutamide 1 +( 0 +10 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +d 0 +( 0 +- 0 +1 0 +) 0 +, 0 +ip 0 +) 0 +, 0 +the 0 +estrogen 1 +receptor 0 +antagonist 0 +tamoxifen 1 +( 0 +1 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +d 0 +( 0 +- 0 +1 0 +) 0 +, 0 +ip 0 +) 0 +or 0 +the 0 +aromatase 0 +inhibitor 0 +letrozole 1 +( 0 +4 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +d 0 +( 0 +- 0 +1 0 +) 0 +, 0 +ip 0 +) 0 +were 0 +administered 0 +for 0 +6 0 +d 0 +after 0 +the 0 +first 0 +injection 0 +of 0 +STZ 1 +. 0 + +RESULTS 0 +: 0 +STZ 1 +administration 0 +and 0 +castration 0 +markedly 0 +decreased 0 +both 0 +STL1 0 +( 0 +the 0 +short 0 +memory 0 +) 0 +and 0 +STL2 0 +( 0 +the 0 +long 0 +memory 0 +) 0 +in 0 +passive 0 +avoidance 0 +tests 0 +. 0 + +Testosterone 1 +replacement 0 +almost 0 +restored 0 +the 0 +STL1 0 +and 0 +STL2 0 +in 0 +castrated 0 +rats 0 +, 0 +and 0 +significantly 0 +prolonged 0 +the 0 +STL1 0 +and 0 +STL2 0 +in 0 +STZ 1 +- 0 +treated 0 +rats 0 +. 0 + +Administration 0 +of 0 +flutamide 1 +, 0 +letrozole 1 +or 0 +tamoxifen 1 +significantly 0 +impaired 3 +the 4 +memory 4 +in 0 +intact 0 +rats 0 +, 0 +and 0 +significantly 0 +attenuated 0 +the 0 +testosterone 1 +replacement 0 +in 0 +improving 0 +STZ 1 +- 0 +and 0 +castration 0 +- 0 +induced 0 +memory 3 +impairment 4 +. 0 + +C0NCLUSI0N 0 +: 0 +Testosterone 1 +administration 0 +ameliorates 0 +STZ 1 +- 0 +and 0 +castration 0 +- 0 +induced 0 +memory 3 +impairment 4 +in 0 +male 0 +Wistar 0 +rats 0 +. 0 + +Behavioral 0 +and 0 +neurochemical 0 +studies 0 +in 0 +mice 0 +pretreated 0 +with 0 +garcinielliptone 1 +FC 2 +in 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 + +Garcinielliptone 1 +FC 2 +( 0 +GFC 1 +) 0 +isolated 0 +from 0 +hexanic 0 +fraction 0 +seed 0 +extract 0 +of 0 +species 0 +Platonia 0 +insignis 0 +Mart 0 +. 0 + +It 0 +is 0 +widely 0 +used 0 +in 0 +folk 0 +medicine 0 +to 0 +treat 0 +skin 3 +diseases 4 +in 0 +both 0 +humans 0 +and 0 +animals 0 +as 0 +well 0 +as 0 +the 0 +seed 0 +decoction 0 +has 0 +been 0 +used 0 +to 0 +treat 0 +diarrheas 3 +and 0 +inflammatory 3 +diseases 4 +. 0 + +However 0 +, 0 +there 0 +is 0 +no 0 +research 0 +on 0 +GFC 1 +effects 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +of 0 +rodents 0 +. 0 + +The 0 +present 0 +study 0 +aimed 0 +to 0 +evaluate 0 +the 0 +GFC 1 +effects 0 +at 0 +doses 0 +of 0 +25 0 +, 0 +50 0 +or 0 +75 0 +mg 0 +/ 0 +kg 0 +on 0 +seizure 3 +parameters 0 +to 0 +determine 0 +their 0 +anticonvulsant 0 +activity 0 +and 0 +its 0 +effects 0 +on 0 +amino 1 +acid 2 +( 0 +r 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +) 0 +, 0 +glutamine 1 +, 0 +aspartate 1 +and 0 +glutathione 1 +) 0 +levels 0 +as 0 +well 0 +as 0 +on 0 +acetylcholinesterase 0 +( 0 +AChE 0 +) 0 +activity 0 +in 0 +mice 0 +hippocampus 0 +after 0 +seizures 3 +. 0 + +GFC 1 +produced 0 +an 0 +increased 0 +latency 0 +to 0 +first 0 +seizure 3 +, 0 +at 0 +doses 0 +25mg 0 +/ 0 +kg 0 +( 0 +20 0 +. 0 +12 0 ++ 0 +2 0 +. 0 +20 0 +min 0 +) 0 +, 0 +50mg 0 +/ 0 +kg 0 +( 0 +20 0 +. 0 +95 0 ++ 0 +2 0 +. 0 +21 0 +min 0 +) 0 +or 0 +75 0 +mg 0 +/ 0 +kg 0 +( 0 +23 0 +. 0 +43 0 ++ 0 +1 0 +. 0 +99 0 +min 0 +) 0 +when 0 +compared 0 +with 0 +seized 0 +mice 0 +. 0 + +In 0 +addition 0 +, 0 +GABA 1 +content 0 +of 0 +mice 0 +hippocampus 0 +treated 0 +with 0 +GFC75 0 +plus 0 +P400 0 +showed 0 +an 0 +increase 0 +of 0 +46 0 +. 0 +90 0 +% 0 +when 0 +compared 0 +with 0 +seized 0 +mice 0 +. 0 + +In 0 +aspartate 1 +, 0 +glutamine 1 +and 0 +glutamate 1 +levels 0 +detected 0 +a 0 +decrease 0 +of 0 +5 0 +. 0 +21 0 +% 0 +, 0 +13 0 +. 0 +55 0 +% 0 +and 0 +21 0 +. 0 +80 0 +% 0 +, 0 +respectively 0 +in 0 +mice 0 +hippocampus 0 +treated 0 +with 0 +GFC75 0 +plus 0 +P400 0 +when 0 +compared 0 +with 0 +seized 0 +mice 0 +. 0 + +Hippocampus 0 +mice 0 +treated 0 +with 0 +GFC75 0 +plus 0 +P400 0 +showed 0 +an 0 +increase 0 +in 0 +AChE 0 +activity 0 +( 0 +63 0 +. 0 +30 0 +% 0 +) 0 +when 0 +compared 0 +with 0 +seized 0 +mice 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +GFC 1 +can 0 +exert 0 +anticonvulsant 0 +activity 0 +and 0 +reduce 0 +the 0 +frequency 0 +of 0 +installation 0 +of 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +, 0 +as 0 +demonstrated 0 +by 0 +increase 0 +in 0 +latency 0 +to 0 +first 0 +seizure 3 +and 0 +decrease 0 +in 0 +mortality 0 +rate 0 +of 0 +animals 0 +. 0 + +In 0 +conclusion 0 +, 0 +our 0 +data 0 +suggest 0 +that 0 +GFC 1 +may 0 +influence 0 +in 0 +epileptogenesis 0 +and 0 +promote 0 +anticonvulsant 0 +actions 0 +in 0 +pilocarpine 1 +model 0 +by 0 +modulating 0 +the 0 +GABA 1 +and 0 +glutamate 1 +contents 0 +and 0 +of 0 +AChE 0 +activity 0 +in 0 +seized 0 +mice 0 +hippocampus 0 +. 0 + +This 0 +compound 0 +may 0 +be 0 +useful 0 +to 0 +produce 0 +neuronal 0 +protection 0 +and 0 +it 0 +can 0 +be 0 +considered 0 +as 0 +an 0 +anticonvulsant 0 +agent 0 +. 0 + +Standard 0 +operating 0 +procedures 0 +for 0 +antibiotic 0 +therapy 0 +and 0 +the 0 +occurrence 0 +of 0 +acute 3 +kidney 4 +injury 4 +: 0 +a 0 +prospective 0 +, 0 +clinical 0 +, 0 +non 0 +- 0 +interventional 0 +, 0 +observational 0 +study 0 +. 0 + +INTR0DUCTI0N 0 +: 0 +Acute 3 +kidney 4 +injury 4 +( 0 +AKI 3 +) 0 +occurs 0 +in 0 +7 0 +% 0 +of 0 +hospitalized 0 +and 0 +66 0 +% 0 +of 0 +Intensive 0 +Care 0 +Unit 0 +( 0 +ICU 0 +) 0 +patients 0 +. 0 + +It 0 +increases 0 +mortality 0 +, 0 +hospital 0 +length 0 +of 0 +stay 0 +, 0 +and 0 +costs 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +, 0 +whether 0 +there 0 +is 0 +an 0 +association 0 +between 0 +adherence 0 +to 0 +guidelines 0 +( 0 +standard 0 +operating 0 +procedures 0 +( 0 +S0P 0 +) 0 +) 0 +for 0 +potentially 0 +nephrotoxic 3 +antibiotics 0 +and 0 +the 0 +occurrence 0 +of 0 +AKI 3 +. 0 + +METH0DS 0 +: 0 +This 0 +study 0 +was 0 +carried 0 +out 0 +as 0 +a 0 +prospective 0 +, 0 +clinical 0 +, 0 +non 0 +- 0 +interventional 0 +, 0 +observational 0 +study 0 +. 0 + +Data 0 +collection 0 +was 0 +performed 0 +over 0 +a 0 +total 0 +of 0 +170 0 +days 0 +in 0 +three 0 +ICUs 0 +at 0 +Charite 0 +- 0 +Universitaetsmedizin 0 +Berlin 0 +. 0 + +A 0 +total 0 +of 0 +675 0 +patients 0 +were 0 +included 0 +; 0 +163 0 +of 0 +these 0 +had 0 +therapy 0 +with 0 +vancomycin 1 +, 0 +gentamicin 1 +, 0 +or 0 +tobramycin 1 +; 0 +were 0 +> 0 +18 0 +years 0 +; 0 +and 0 +treated 0 +in 0 +the 0 +ICU 0 +for 0 +> 0 +24 0 +hours 0 +. 0 + +Patients 0 +with 0 +an 0 +adherence 0 +to 0 +S0P 0 +> 0 +70 0 +% 0 +were 0 +classified 0 +into 0 +the 0 +high 0 +adherence 0 +group 0 +( 0 +HAG 0 +) 0 +and 0 +patients 0 +with 0 +an 0 +adherence 0 +of 0 +< 0 +70 0 +% 0 +into 0 +the 0 +low 0 +adherence 0 +group 0 +( 0 +LAG 0 +) 0 +. 0 + +AKI 3 +was 0 +defined 0 +according 0 +to 0 +RIFLE 0 +criteria 0 +. 0 + +Adherence 0 +to 0 +S0Ps 0 +was 0 +evaluated 0 +by 0 +retrospective 0 +expert 0 +audit 0 +. 0 + +Development 0 +of 0 +AKI 3 +was 0 +compared 0 +between 0 +groups 0 +with 0 +exact 0 +Chi2 0 +- 0 +test 0 +and 0 +multivariate 0 +logistic 0 +regression 0 +analysis 0 +( 0 +two 0 +- 0 +sided 0 +P 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +RESULTS 0 +: 0 +LAG 0 +consisted 0 +of 0 +75 0 +patients 0 +( 0 +46 0 +% 0 +) 0 +versus 0 +88 0 +HAG 0 +patients 0 +( 0 +54 0 +% 0 +) 0 +. 0 + +AKI 3 +occurred 0 +significantly 0 +more 0 +often 0 +in 0 +LAG 0 +with 0 +36 0 +% 0 +versus 0 +21 0 +% 0 +in 0 +HAG 0 +( 0 +P 0 += 0 +0 0 +. 0 +035 0 +) 0 +. 0 + +Basic 0 +characteristics 0 +were 0 +comparable 0 +, 0 +except 0 +an 0 +increased 0 +rate 0 +of 0 +soft 0 +tissue 0 +infections 3 +in 0 +LAG 0 +. 0 + +Multivariate 0 +analysis 0 +revealed 0 +an 0 +odds 0 +ratio 0 +of 0 +2 0 +. 0 +5 0 +- 0 +fold 0 +for 0 +LAG 0 +to 0 +develop 0 +AKI 3 +compared 0 +with 0 +HAG 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +1 0 +. 0 +195 0 +to 0 +5 0 +. 0 +124 0 +, 0 +P 0 += 0 +0 0 +. 0 +039 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Low 0 +adherence 0 +to 0 +S0Ps 0 +for 0 +potentially 0 +nephrotoxic 3 +antibiotics 0 +was 0 +associated 0 +with 0 +a 0 +higher 0 +occurrence 0 +of 0 +AKI 3 +. 0 + +TRIAL 0 +REGISTRATI0N 0 +: 0 +Current 0 +Controlled 0 +Trials 0 +ISRCTN54598675 0 +. 0 + +Registered 0 +17 0 +August 0 +2007 0 +. 0 + +Rhabdomyolysis 3 +in 0 +a 0 +hepatitis 3 +C 4 +virus 4 +infected 4 +patient 0 +treated 0 +with 0 +telaprevir 1 +and 0 +simvastatin 1 +. 0 + +A 0 +46 0 +- 0 +year 0 +old 0 +man 0 +with 0 +a 0 +chronic 0 +hepatitis 3 +C 4 +virus 4 +infection 4 +received 0 +triple 0 +therapy 0 +with 0 +ribavirin 1 +, 0 +pegylated 1 +interferon 2 +and 0 +telaprevir 1 +. 0 + +The 0 +patient 0 +also 0 +received 0 +simvastatin 1 +. 0 + +0ne 0 +month 0 +after 0 +starting 0 +the 0 +antiviral 0 +therapy 0 +, 0 +the 0 +patient 0 +was 0 +admitted 0 +to 0 +the 0 +hospital 0 +because 0 +he 0 +developed 0 +rhabdomyolysis 3 +. 0 + +At 0 +admission 0 +simvastatin 1 +and 0 +all 0 +antiviral 0 +drugs 0 +were 0 +discontinued 0 +because 0 +toxicity 3 +due 0 +to 0 +a 0 +drug 0 +- 0 +drug 0 +interaction 0 +was 0 +suspected 0 +. 0 + +The 0 +creatine 1 +kinase 0 +peaked 0 +at 0 +62 0 +, 0 +246 0 +IU 0 +/ 0 +L 0 +and 0 +the 0 +patient 0 +was 0 +treated 0 +with 0 +intravenous 0 +normal 0 +saline 0 +. 0 + +The 0 +patient 0 +' 0 +s 0 +renal 0 +function 0 +remained 0 +unaffected 0 +. 0 + +Fourteen 0 +days 0 +after 0 +hospitalization 0 +, 0 +creatine 1 +kinase 0 +level 0 +had 0 +returned 0 +to 0 +230 0 +IU 0 +/ 0 +L 0 +and 0 +the 0 +patient 0 +was 0 +discharged 0 +. 0 + +Telaprevir 1 +was 0 +considered 0 +the 0 +probable 0 +causative 0 +agent 0 +of 0 +an 0 +interaction 0 +with 0 +simvastatin 1 +according 0 +to 0 +the 0 +Drug 0 +Interaction 0 +Probability 0 +Scale 0 +. 0 + +The 0 +interaction 0 +is 0 +due 0 +to 0 +inhibition 0 +of 0 +CYP3A4 0 +- 0 +mediated 0 +simvastatin 1 +clearance 0 +. 0 + +Simvastatin 1 +plasma 0 +concentration 0 +increased 0 +30 0 +times 0 +in 0 +this 0 +patient 0 +and 0 +statin 1 +induced 0 +muscle 3 +toxicity 4 +is 0 +related 0 +to 0 +the 0 +concentration 0 +of 0 +the 0 +statin 1 +in 0 +blood 0 +. 0 + +In 0 +conclusion 0 +, 0 +with 0 +this 0 +case 0 +we 0 +illustrate 0 +that 0 +telaprevir 1 +as 0 +well 0 +as 0 +statins 1 +are 0 +susceptible 0 +to 0 +clinical 0 +relevant 0 +drug 0 +- 0 +drug 0 +interactions 0 +. 0 + +Combination 0 +of 0 +bortezomib 1 +, 0 +thalidomide 1 +, 0 +and 0 +dexamethasone 1 +( 0 +VTD 0 +) 0 +as 0 +a 0 +consolidation 0 +therapy 0 +after 0 +autologous 0 +stem 0 +cell 0 +transplantation 0 +for 0 +symptomatic 0 +multiple 3 +myeloma 4 +in 0 +Japanese 0 +patients 0 +. 0 + +Consolidation 0 +therapy 0 +for 0 +patients 0 +with 0 +multiple 3 +myeloma 4 +( 0 +MM 3 +) 0 +has 0 +been 0 +widely 0 +adopted 0 +to 0 +improve 0 +treatment 0 +response 0 +following 0 +autologous 0 +stem 0 +cell 0 +transplantation 0 +. 0 + +In 0 +this 0 +study 0 +, 0 +we 0 +retrospectively 0 +analyzed 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +combination 0 +regimen 0 +of 0 +bortezomib 1 +, 0 +thalidomide 1 +, 0 +and 0 +dexamethasone 1 +( 0 +VTD 0 +) 0 +as 0 +consolidation 0 +therapy 0 +in 0 +24 0 +Japanese 0 +patients 0 +with 0 +newly 0 +diagnosed 0 +MM 3 +. 0 + +VTD 0 +consisted 0 +of 0 +bortezomib 1 +at 0 +a 0 +dose 0 +of 0 +1 0 +. 0 +3 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +and 0 +dexamethasone 1 +at 0 +a 0 +dose 0 +of 0 +40 0 +mg 0 +/ 0 +day 0 +on 0 +days 0 +1 0 +, 0 +8 0 +, 0 +15 0 +, 0 +and 0 +22 0 +of 0 +a 0 +35 0 +- 0 +day 0 +cycle 0 +, 0 +with 0 +daily 0 +oral 0 +thalidomide 1 +at 0 +a 0 +dose 0 +of 0 +100 0 +mg 0 +/ 0 +day 0 +. 0 + +Grade 0 +3 0 +- 0 +4 0 +neutropenia 3 +and 0 +thrombocytopenia 3 +were 0 +documented 0 +in 0 +four 0 +and 0 +three 0 +patients 0 +( 0 +17 0 +and 0 +13 0 +% 0 +) 0 +, 0 +respectively 0 +, 0 +but 0 +drug 0 +dose 0 +reduction 0 +due 0 +to 0 +cytopenia 3 +was 0 +not 0 +required 0 +in 0 +any 0 +case 0 +. 0 + +Peripheral 3 +neuropathy 4 +was 0 +common 0 +( 0 +63 0 +% 0 +) 0 +, 0 +but 0 +severe 0 +grade 0 +3 0 +- 0 +4 0 +peripheral 3 +neuropathy 4 +was 0 +not 0 +observed 0 +. 0 + +Very 0 +good 0 +partial 0 +response 0 +or 0 +better 0 +response 0 +( 0 +> 0 +VGPR 0 +) 0 +rates 0 +before 0 +and 0 +after 0 +consolidation 0 +therapy 0 +were 0 +54 0 +and 0 +79 0 +% 0 +, 0 +respectively 0 +. 0 + +Patients 0 +had 0 +a 0 +significant 0 +probability 0 +of 0 +improving 0 +from 0 +< 0 +VGPR 0 +before 0 +consolidation 0 +therapy 0 +to 0 +> 0 +VGPR 0 +after 0 +consolidation 0 +therapy 0 +( 0 +p 0 += 0 +0 0 +. 0 +041 0 +) 0 +. 0 + +The 0 +VTD 0 +regimen 0 +may 0 +be 0 +safe 0 +and 0 +effective 0 +as 0 +a 0 +consolidation 0 +therapy 0 +in 0 +the 0 +treatment 0 +of 0 +MM 0 +in 0 +Japanese 0 +population 0 +. 0 + +Conversion 0 +to 0 +sirolimus 1 +ameliorates 0 +cyclosporine 1 +- 0 +induced 0 +nephropathy 3 +in 0 +the 0 +rat 0 +: 0 +focus 0 +on 0 +serum 0 +, 0 +urine 0 +, 0 +gene 0 +, 0 +and 0 +protein 0 +renal 0 +expression 0 +biomarkers 0 +. 0 + +Protocols 0 +of 0 +conversion 0 +from 0 +cyclosporin 1 +A 2 +( 0 +CsA 1 +) 0 +to 0 +sirolimus 1 +( 0 +SRL 1 +) 0 +have 0 +been 0 +widely 0 +used 0 +in 0 +immunotherapy 0 +after 0 +transplantation 0 +to 0 +prevent 0 +CsA 1 +- 0 +induced 0 +nephropathy 3 +, 0 +but 0 +the 0 +molecular 0 +mechanisms 0 +underlying 0 +these 0 +protocols 0 +remain 0 +nuclear 0 +. 0 + +This 0 +study 0 +aimed 0 +to 0 +identify 0 +the 0 +molecular 0 +pathways 0 +and 0 +putative 0 +biomarkers 0 +of 0 +CsA 1 +- 0 +to 0 +- 0 +SRL 1 +conversion 0 +in 0 +a 0 +rat 0 +model 0 +. 0 + +Four 0 +animal 0 +groups 0 +( 0 +n 0 += 0 +6 0 +) 0 +were 0 +tested 0 +during 0 +9 0 +weeks 0 +: 0 +control 0 +, 0 +CsA 1 +, 0 +SRL 1 +, 0 +and 0 +conversion 0 +( 0 +CsA 1 +for 0 +3 0 +weeks 0 +followed 0 +by 0 +SRL 1 +for 0 +6 0 +weeks 0 +) 0 +. 0 + +Classical 0 +and 0 +emergent 0 +serum 0 +, 0 +urinary 0 +, 0 +and 0 +kidney 0 +tissue 0 +( 0 +gene 0 +and 0 +protein 0 +expression 0 +) 0 +markers 0 +were 0 +assessed 0 +. 0 + +Renal 3 +lesions 4 +were 0 +analyzed 0 +in 0 +hematoxylin 1 +and 0 +eosin 1 +, 0 +periodic 0 +acid 0 +- 0 +Schiff 0 +, 0 +and 0 +Masson 0 +' 0 +s 0 +trichrome 0 +stains 0 +. 0 + +SRL 1 +- 0 +treated 0 +rats 0 +presented 0 +proteinuria 3 +and 0 +NGAL 0 +( 0 +serum 0 +and 0 +urinary 0 +) 0 +as 0 +the 0 +best 0 +markers 0 +of 0 +renal 3 +impairment 4 +. 0 + +Short 0 +CsA 1 +treatment 0 +presented 0 +slight 0 +or 0 +even 0 +absent 0 +kidney 3 +lesions 4 +and 0 +TGF 0 +- 0 +b 0 +, 0 +NF 0 +- 0 +kb 0 +, 0 +mT0R 0 +, 0 +PCNA 0 +, 0 +TP53 0 +, 0 +KIM 0 +- 0 +1 0 +, 0 +and 0 +CTGF 0 +as 0 +relevant 0 +gene 0 +and 0 +protein 0 +changes 0 +. 0 + +Prolonged 0 +CsA 1 +exposure 0 +aggravated 0 +renal 3 +damage 4 +, 0 +without 0 +clear 0 +changes 0 +on 0 +the 0 +traditional 0 +markers 0 +, 0 +but 0 +with 0 +changes 0 +in 0 +serums 0 +TGF 0 +- 0 +b 0 +and 0 +IL 0 +- 0 +7 0 +, 0 +TBARs 0 +clearance 0 +, 0 +and 0 +kidney 0 +TGF 0 +- 0 +b 0 +and 0 +mT0R 0 +. 0 + +Conversion 0 +to 0 +SRL 1 +prevented 0 +CsA 1 +- 0 +induced 0 +renal 3 +damage 4 +evolution 0 +( 0 +absent 0 +/ 0 +mild 0 +grade 0 +lesions 0 +) 0 +, 0 +while 0 +NGAL 0 +( 0 +serum 0 +versus 0 +urine 0 +) 0 +seems 0 +to 0 +be 0 +a 0 +feasible 0 +biomarker 0 +of 0 +CsA 1 +replacement 0 +to 0 +SRL 1 +. 0 + +Kinin 0 +B2 0 +receptor 0 +deletion 0 +and 0 +blockage 0 +ameliorates 0 +cisplatin 1 +- 0 +induced 0 +acute 3 +renal 4 +injury 4 +. 0 + +Cisplatin 1 +treatment 0 +has 0 +been 0 +adopted 0 +in 0 +some 0 +chemotherapies 0 +; 0 +however 0 +, 0 +this 0 +drug 0 +can 0 +induce 0 +acute 3 +kidney 4 +injury 4 +due 0 +its 0 +ability 0 +to 0 +negatively 0 +affect 0 +renal 0 +function 0 +, 0 +augment 0 +serum 0 +levels 0 +of 0 +creatinine 1 +and 0 +urea 1 +, 0 +increase 0 +the 0 +acute 3 +tubular 4 +necrosis 4 +score 0 +and 0 +up 0 +- 0 +regulate 0 +cytokines 0 +( 0 +e 0 +. 0 +g 0 +. 0 +, 0 +IL 0 +- 0 +1b 0 +and 0 +TNF 0 +- 0 +a 0 +) 0 +. 0 + +The 0 +kinin 0 +B2 0 +receptor 0 +has 0 +been 0 +associated 0 +with 0 +the 0 +inflammation 3 +process 0 +, 0 +as 0 +well 0 +as 0 +the 0 +regulation 0 +of 0 +cytokine 0 +expression 0 +, 0 +and 0 +its 0 +deletion 0 +resulted 0 +in 0 +an 0 +improvement 0 +in 0 +the 0 +diabetic 3 +nephropathy 4 +status 0 +. 0 + +To 0 +examine 0 +the 0 +role 0 +of 0 +the 0 +kinin 0 +B2 0 +receptor 0 +in 0 +cisplatin 1 +- 0 +induced 0 +acute 3 +kidney 4 +injury 4 +, 0 +kinin 0 +B2 0 +receptor 0 +knockout 0 +mice 0 +were 0 +challenged 0 +with 0 +cisplatin 1 +. 0 + +Additionally 0 +, 0 +WT 0 +mice 0 +were 0 +treated 0 +with 0 +a 0 +B2 0 +receptor 0 +antagonist 0 +after 0 +cisplatin 1 +administration 0 +. 0 + +B2 0 +receptor 0 +- 0 +deficient 0 +mice 0 +were 0 +less 0 +sensitive 0 +to 0 +this 0 +drug 0 +than 0 +the 0 +WT 0 +mice 0 +, 0 +as 0 +shown 0 +by 0 +reduced 0 +weight 3 +loss 4 +, 0 +better 0 +preservation 0 +of 0 +kidney 0 +function 0 +, 0 +down 0 +regulation 0 +of 0 +inflammatory 0 +cytokines 0 +and 0 +less 0 +acute 3 +tubular 4 +necrosis 4 +. 0 + +Moreover 0 +, 0 +treatment 0 +with 0 +the 0 +kinin 0 +B2 0 +receptor 0 +antagonist 0 +effectively 0 +reduced 0 +the 0 +levels 0 +of 0 +serum 0 +creatinine 1 +and 0 +blood 0 +urea 1 +after 0 +cisplatin 1 +administration 0 +. 0 + +Thus 0 +, 0 +our 0 +data 0 +suggest 0 +that 0 +the 0 +kinin 0 +B2 0 +receptor 0 +is 0 +involved 0 +in 0 +cisplatin 1 +- 0 +induced 0 +acute 3 +kidney 4 +injury 4 +by 0 +mediating 0 +the 0 +necrotic 3 +process 0 +and 0 +the 0 +expression 0 +of 0 +inflammatory 0 +cytokines 0 +, 0 +thus 0 +resulting 0 +in 0 +declined 0 +renal 0 +function 0 +. 0 + +These 0 +results 0 +highlight 0 +the 0 +kinin 0 +B2 0 +receptor 0 +antagonist 0 +treatment 0 +in 0 +amelioration 0 +of 0 +nephrotoxicity 3 +induced 0 +by 0 +cisplatin 1 +therapy 0 +. 0 + +Safety 0 +and 0 +efficacy 0 +of 0 +fluocinolone 1 +acetonide 2 +intravitreal 0 +implant 0 +( 0 +0 0 +. 0 +59 0 +mg 0 +) 0 +in 0 +birdshot 3 +retinochoroidopathy 4 +. 0 + +PURP0SE 0 +: 0 +To 0 +report 0 +the 0 +treatment 0 +outcomes 0 +of 0 +the 0 +fluocinolone 1 +acetonide 2 +intravitreal 0 +implant 0 +( 0 +0 0 +. 0 +59 0 +mg 0 +) 0 +in 0 +patients 0 +with 0 +birdshot 3 +retinochoroidopathy 4 +whose 0 +disease 0 +is 0 +refractory 0 +or 0 +intolerant 0 +to 0 +conventional 0 +immunomodulatory 0 +therapy 0 +. 0 + +METH0DS 0 +: 0 +A 0 +retrospective 0 +case 0 +series 0 +involving 0 +11 0 +birdshot 3 +retinochoroidopathy 4 +patients 0 +( 0 +11 0 +eyes 0 +) 0 +. 0 + +Eleven 0 +patients 0 +( 0 +11 0 +eyes 0 +) 0 +underwent 0 +surgery 0 +for 0 +fluocinolone 1 +acetonide 2 +implant 0 +( 0 +0 0 +. 0 +59 0 +mg 0 +) 0 +. 0 + +Treatment 0 +outcomes 0 +of 0 +interest 0 +were 0 +noted 0 +at 0 +baseline 0 +, 0 +before 0 +fluocinolone 1 +acetonide 2 +implant 0 +, 0 +and 0 +then 0 +at 0 +6 0 +months 0 +, 0 +1 0 +year 0 +, 0 +2 0 +years 0 +, 0 +3 0 +years 0 +, 0 +and 0 +beyond 0 +3 0 +years 0 +. 0 + +Disease 0 +activity 0 +markers 0 +, 0 +including 0 +signs 0 +of 0 +ocular 0 +inflammation 3 +, 0 +evidence 0 +of 0 +retinal 3 +vasculitis 4 +, 0 +Swedish 0 +interactive 0 +threshold 0 +algorithm 0 +- 0 +short 0 +wavelength 0 +automated 0 +perimetry 0 +Humphrey 0 +visual 0 +field 0 +analysis 0 +, 0 +electroretinographic 0 +parameters 0 +, 0 +and 0 +optical 0 +coherence 0 +tomography 0 +were 0 +recorded 0 +. 0 + +Data 0 +on 0 +occurrence 0 +of 0 +cataract 3 +and 0 +raised 3 +intraocular 4 +pressure 4 +were 0 +collected 0 +in 0 +all 0 +eyes 0 +. 0 + +RESULTS 0 +: 0 +Intraocular 0 +inflammation 3 +was 0 +present 0 +in 0 +54 0 +. 0 +5 0 +, 0 +9 0 +. 0 +9 0 +, 0 +11 0 +. 0 +1 0 +, 0 +and 0 +0 0 +% 0 +of 0 +patients 0 +at 0 +baseline 0 +, 0 +6 0 +months 0 +, 0 +1 0 +year 0 +, 0 +2 0 +years 0 +, 0 +3 0 +years 0 +, 0 +and 0 +beyond 0 +3 0 +years 0 +after 0 +receiving 0 +the 0 +implant 0 +, 0 +respectively 0 +. 0 + +Active 0 +vasculitis 3 +was 0 +noted 0 +in 0 +36 0 +. 0 +3 0 +% 0 +patients 0 +at 0 +baseline 0 +and 0 +0 0 +% 0 +at 0 +3 0 +years 0 +of 0 +follow 0 +- 0 +up 0 +. 0 + +More 0 +than 0 +20 0 +% 0 +( 0 +47 0 +. 0 +61 0 +- 0 +67 0 +. 0 +2 0 +% 0 +) 0 +reduction 0 +in 0 +central 0 +retinal 0 +thickness 0 +was 0 +noted 0 +in 0 +all 0 +patients 0 +with 0 +cystoid 3 +macular 4 +edema 4 +at 0 +6 0 +months 0 +, 0 +1 0 +year 0 +, 0 +2 0 +years 0 +, 0 +and 0 +3 0 +years 0 +postimplant 0 +. 0 + +At 0 +baseline 0 +, 0 +54 0 +. 0 +5 0 +% 0 +patients 0 +were 0 +on 0 +immunomodulatory 0 +agents 0 +. 0 + +This 0 +percentage 0 +decreased 0 +to 0 +45 0 +. 0 +45 0 +, 0 +44 0 +. 0 +4 0 +, 0 +and 0 +14 0 +. 0 +28 0 +% 0 +at 0 +1 0 +year 0 +, 0 +2 0 +years 0 +, 0 +and 0 +3 0 +years 0 +postimplant 0 +, 0 +respectively 0 +. 0 + +Adverse 0 +events 0 +included 0 +increased 3 +intraocular 4 +pressure 4 +( 0 +54 0 +. 0 +5 0 +% 0 +) 0 +and 0 +cataract 3 +formation 0 +( 0 +100 0 +% 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +data 0 +suggest 0 +that 0 +fluocinolone 1 +acetonide 2 +implant 0 +( 0 +0 0 +. 0 +59 0 +mg 0 +) 0 +helps 0 +to 0 +control 0 +inflammation 3 +in 0 +otherwise 0 +treatment 0 +- 0 +refractory 0 +cases 0 +of 0 +birdshot 3 +retinochoroidopathy 4 +. 0 + +It 0 +is 0 +associated 0 +with 0 +significant 0 +side 0 +effects 0 +of 0 +cataract 3 +and 0 +ocular 3 +hypertension 4 +requiring 0 +treatment 0 +. 0 + +0ptimal 0 +precurarizing 0 +dose 0 +of 0 +rocuronium 1 +to 0 +decrease 0 +fasciculation 3 +and 0 +myalgia 3 +following 0 +succinylcholine 1 +administration 0 +. 0 + +BACKGR0UND 0 +: 0 +Succinylcholine 1 +commonly 0 +produces 0 +frequent 0 +adverse 0 +effects 0 +, 0 +including 0 +muscle 3 +fasciculation 4 +and 0 +myalgia 3 +. 0 + +The 0 +current 0 +study 0 +identified 0 +the 0 +optimal 0 +dose 0 +of 0 +rocuronium 1 +to 0 +prevent 0 +succinylcholine 1 +- 0 +induced 0 +fasciculation 3 +and 0 +myalgia 3 +and 0 +evaluated 0 +the 0 +influence 0 +of 0 +rocuronium 1 +on 0 +the 0 +speed 0 +of 0 +onset 0 +produced 0 +by 0 +succinylcholine 1 +. 0 + +METH0DS 0 +: 0 +This 0 +randomized 0 +, 0 +double 0 +- 0 +blinded 0 +study 0 +was 0 +conducted 0 +in 0 +100 0 +patients 0 +randomly 0 +allocated 0 +into 0 +five 0 +groups 0 +of 0 +20 0 +patients 0 +each 0 +. 0 + +Patients 0 +were 0 +randomized 0 +to 0 +receive 0 +0 0 +. 0 +02 0 +, 0 +0 0 +. 0 +03 0 +, 0 +0 0 +. 0 +04 0 +, 0 +0 0 +. 0 +05 0 +and 0 +0 0 +. 0 +06 0 +mg 0 +/ 0 +kg 0 +rocuronium 1 +as 0 +a 0 +precurarizing 0 +dose 0 +. 0 + +Neuromuscular 0 +monitoring 0 +after 0 +each 0 +precurarizing 0 +dose 0 +was 0 +recorded 0 +from 0 +the 0 +adductor 0 +pollicis 0 +muscle 0 +using 0 +acceleromyography 0 +with 0 +train 0 +- 0 +of 0 +- 0 +four 0 +stimulation 0 +of 0 +the 0 +ulnar 0 +nerve 0 +. 0 + +All 0 +patients 0 +received 0 +succinylcholine 1 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +at 0 +2 0 +minutes 0 +after 0 +the 0 +precurarization 0 +, 0 +and 0 +were 0 +assessed 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +fasciculations 3 +, 0 +while 0 +myalgia 3 +was 0 +assessed 0 +at 0 +24 0 +hours 0 +after 0 +surgery 0 +. 0 + +RESULTS 0 +: 0 +The 0 +incidence 0 +and 0 +severity 0 +of 0 +visible 0 +muscle 3 +fasciculation 4 +was 0 +significantly 0 +less 0 +with 0 +increasing 0 +the 0 +amount 0 +of 0 +precurarizing 0 +dose 0 +of 0 +rocuronium 1 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Those 0 +of 0 +myalgia 3 +tend 0 +to 0 +decrease 0 +according 0 +to 0 +increasing 0 +the 0 +amount 0 +of 0 +precurarizing 0 +dose 0 +of 0 +rocuronium 1 +, 0 +but 0 +there 0 +was 0 +no 0 +significance 0 +( 0 +P 0 += 0 +0 0 +. 0 +072 0 +) 0 +. 0 + +The 0 +onset 0 +time 0 +of 0 +succinylcholine 1 +was 0 +significantly 0 +longer 0 +with 0 +increasing 0 +the 0 +amount 0 +of 0 +precurarizing 0 +dose 0 +of 0 +rocuronium 1 +( 0 +P 0 +< 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Precurarization 0 +with 0 +0 0 +. 0 +04 0 +mg 0 +/ 0 +kg 0 +rocuronium 1 +was 0 +the 0 +optimal 0 +dose 0 +considering 0 +the 0 +reduction 0 +in 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +fasciculation 3 +and 0 +myalgia 3 +with 0 +acceptable 0 +onset 0 +time 0 +, 0 +and 0 +the 0 +safe 0 +and 0 +effective 0 +precurarization 0 +. 0 + +Absence 0 +of 0 +PKC 0 +- 0 +alpha 0 +attenuates 0 +lithium 1 +- 0 +induced 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +. 0 + +Lithium 1 +, 0 +an 0 +effective 0 +antipsychotic 0 +, 0 +induces 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +( 0 +NDI 3 +) 0 +in 0 +40 0 +% 0 +of 0 +patients 0 +. 0 + +The 0 +decreased 0 +capacity 0 +to 0 +concentrate 0 +urine 0 +is 0 +likely 0 +due 0 +to 0 +lithium 1 +acutely 0 +disrupting 0 +the 0 +cAMP 1 +pathway 0 +and 0 +chronically 0 +reducing 0 +urea 1 +transporter 0 +( 0 +UT 0 +- 0 +A1 0 +) 0 +and 0 +water 0 +channel 0 +( 0 +AQP2 0 +) 0 +expression 0 +in 0 +the 0 +inner 0 +medulla 0 +. 0 + +Targeting 0 +an 0 +alternative 0 +signaling 0 +pathway 0 +, 0 +such 0 +as 0 +PKC 0 +- 0 +mediated 0 +signaling 0 +, 0 +may 0 +be 0 +an 0 +effective 0 +method 0 +of 0 +treating 0 +lithium 1 +- 0 +induced 0 +polyuria 3 +. 0 + +PKC 0 +- 0 +alpha 0 +null 0 +mice 0 +( 0 +PKCa 0 +K0 0 +) 0 +and 0 +strain 0 +- 0 +matched 0 +wild 0 +type 0 +( 0 +WT 0 +) 0 +controls 0 +were 0 +treated 0 +with 0 +lithium 1 +for 0 +0 0 +, 0 +3 0 +or 0 +5 0 +days 0 +. 0 + +WT 0 +mice 0 +had 0 +increased 0 +urine 0 +output 0 +and 0 +lowered 0 +urine 0 +osmolality 0 +after 0 +3 0 +and 0 +5 0 +days 0 +of 0 +treatment 0 +whereas 0 +PKCa 0 +K0 0 +mice 0 +had 0 +no 0 +change 0 +in 0 +urine 0 +output 0 +or 0 +concentration 0 +. 0 + +Western 0 +blot 0 +analysis 0 +revealed 0 +that 0 +AQP2 0 +expression 0 +in 0 +medullary 0 +tissues 0 +was 0 +lowered 0 +after 0 +3 0 +and 0 +5 0 +days 0 +in 0 +WT 0 +mice 0 +; 0 +however 0 +, 0 +AQP2 0 +was 0 +unchanged 0 +in 0 +PKCa 0 +K0 0 +. 0 + +Similar 0 +results 0 +were 0 +observed 0 +with 0 +UT 0 +- 0 +A1 0 +expression 0 +. 0 + +Animals 0 +were 0 +also 0 +treated 0 +with 0 +lithium 1 +for 0 +6 0 +weeks 0 +. 0 + +Lithium 1 +- 0 +treated 0 +WT 0 +mice 0 +had 0 +19 0 +- 0 +fold 0 +increased 0 +urine 0 +output 0 +whereas 0 +treated 0 +PKCa 0 +K0 0 +animals 0 +had 0 +a 0 +4 0 +- 0 +fold 0 +increase 0 +in 0 +output 0 +. 0 + +AQP2 0 +and 0 +UT 0 +- 0 +A1 0 +expression 0 +was 0 +lowered 0 +in 0 +6 0 +week 0 +lithium 1 +- 0 +treated 0 +WT 0 +animals 0 +whereas 0 +in 0 +treated 0 +PKCa 0 +K0 0 +mice 0 +, 0 +AQP2 0 +was 0 +only 0 +reduced 0 +by 0 +2 0 +- 0 +fold 0 +and 0 +UT 0 +- 0 +A1 0 +expression 0 +was 0 +unaffected 0 +. 0 + +Urinary 0 +sodium 1 +, 0 +potassium 1 +and 0 +calcium 1 +were 0 +elevated 0 +in 0 +lithium 1 +- 0 +fed 0 +WT 0 +but 0 +not 0 +in 0 +lithium 1 +- 0 +fed 0 +PKCa 0 +K0 0 +mice 0 +. 0 + +0ur 0 +data 0 +show 0 +that 0 +ablation 0 +of 0 +PKCa 0 +preserves 0 +AQP2 0 +and 0 +UT 0 +- 0 +A1 0 +protein 0 +expression 0 +and 0 +localization 0 +in 0 +lithium 1 +- 0 +induced 0 +NDI 3 +, 0 +and 0 +prevents 0 +the 0 +development 0 +of 0 +the 0 +severe 0 +polyuria 3 +associated 0 +with 0 +lithium 1 +therapy 0 +. 0 + +Is 0 +Dysguesia 3 +Going 0 +to 0 +be 0 +a 0 +Rare 0 +or 0 +a 0 +Common 0 +Side 0 +- 0 +effect 0 +of 0 +Amlodipine 1 +? 0 + +A 0 +very 0 +rare 0 +side 0 +- 0 +effect 0 +of 0 +amlodipine 1 +is 0 +dysguesia 3 +. 0 + +A 0 +review 0 +of 0 +the 0 +literature 0 +produced 0 +only 0 +one 0 +case 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +about 0 +a 0 +female 0 +with 0 +essential 0 +hypertension 3 +on 0 +drug 0 +treatment 0 +with 0 +amlodipine 1 +developed 0 +loss 3 +of 4 +taste 4 +sensation 4 +. 0 + +Condition 0 +moderately 0 +improved 0 +on 0 +stoppage 0 +of 0 +the 0 +drug 0 +for 0 +25 0 +days 0 +. 0 + +We 0 +conclude 0 +that 0 +amlodipine 1 +can 0 +cause 0 +dysguesia 3 +. 0 + +Here 0 +, 0 +we 0 +describe 0 +the 0 +clinical 0 +presentation 0 +and 0 +review 0 +the 0 +relevant 0 +literature 0 +on 0 +amlodipine 1 +and 0 +dysguesia 3 +. 0 + +Rhabdomyolysis 3 +in 0 +association 0 +with 0 +simvastatin 1 +and 0 +dosage 0 +increment 0 +in 0 +clarithromycin 1 +. 0 + +Clarithromycin 1 +is 0 +the 0 +most 0 +documented 0 +cytochrome 0 +P450 0 +3A4 0 +( 0 +CYP3A4 0 +) 0 +inhibitor 0 +to 0 +cause 0 +an 0 +adverse 0 +interaction 0 +with 0 +simvastatin 1 +. 0 + +This 0 +particular 0 +case 0 +is 0 +of 0 +interest 0 +as 0 +rhabdomyolysis 3 +only 0 +occurred 0 +after 0 +an 0 +increase 0 +in 0 +the 0 +dose 0 +of 0 +clarithromycin 1 +. 0 + +The 0 +patient 0 +developed 0 +raised 0 +cardiac 0 +biomarkers 0 +without 0 +any 0 +obvious 0 +cardiac 0 +issues 0 +, 0 +a 0 +phenomenon 0 +that 0 +has 0 +been 0 +linked 0 +to 0 +rhabdomyolysis 3 +previously 0 +. 0 + +To 0 +date 0 +, 0 +there 0 +has 0 +been 0 +no 0 +reported 0 +effect 0 +of 0 +rhabdomyolysis 3 +on 0 +the 0 +structure 0 +and 0 +function 0 +of 0 +cardiac 0 +muscle 0 +. 0 + +Clinicians 0 +need 0 +to 0 +be 0 +aware 0 +of 0 +prescribing 0 +concomitant 0 +medications 0 +that 0 +increase 0 +the 0 +risk 0 +of 0 +myopathy 3 +or 0 +inhibit 0 +the 0 +CYP3A4 0 +enzyme 0 +. 0 + +0ur 0 +case 0 +suggests 0 +that 0 +troponin 0 +elevation 0 +could 0 +be 0 +associated 0 +with 0 +statin 1 +induced 0 +rhabdomyolysis 3 +, 0 +which 0 +may 0 +warrant 0 +further 0 +studies 0 +. 0 + +Characterization 0 +of 0 +a 0 +novel 0 +BCHE 0 +" 0 +silent 0 +" 0 +allele 0 +: 0 +point 0 +mutation 0 +( 0 +p 0 +. 0 +Val204Asp 0 +) 0 +causes 0 +loss 0 +of 0 +activity 0 +and 0 +prolonged 0 +apnea 3 +with 0 +suxamethonium 1 +. 0 + +Butyrylcholinesterase 3 +deficiency 4 +is 0 +characterized 0 +by 0 +prolonged 0 +apnea 3 +after 0 +the 0 +use 0 +of 0 +muscle 0 +relaxants 0 +( 0 +suxamethonium 1 +or 0 +mivacurium 1 +) 0 +in 0 +patients 0 +who 0 +have 0 +mutations 0 +in 0 +the 0 +BCHE 0 +gene 0 +. 0 + +Here 0 +, 0 +we 0 +report 0 +a 0 +case 0 +of 0 +prolonged 0 +neuromuscular 0 +block 0 +after 0 +administration 0 +of 0 +suxamethonium 1 +leading 0 +to 0 +the 0 +discovery 0 +of 0 +a 0 +novel 0 +BCHE 0 +variant 0 +( 0 +c 0 +. 0 +695T 0 +> 0 +A 0 +, 0 +p 0 +. 0 +Val204Asp 0 +) 0 +. 0 + +Inhibition 0 +studies 0 +, 0 +kinetic 0 +analysis 0 +and 0 +molecular 0 +dynamics 0 +were 0 +undertaken 0 +to 0 +understand 0 +how 0 +this 0 +mutation 0 +disrupts 0 +the 0 +catalytic 0 +triad 0 +and 0 +determines 0 +a 0 +" 0 +silent 0 +" 0 +phenotype 0 +. 0 + +Low 0 +activity 0 +of 0 +patient 0 +plasma 0 +butyrylcholinesterase 0 +with 0 +butyrylthiocholine 1 +( 0 +BTC 1 +) 0 +and 0 +benzoylcholine 1 +, 0 +and 0 +values 0 +of 0 +dibucaine 1 +and 0 +fluoride 1 +numbers 0 +fit 0 +with 0 +heterozygous 0 +atypical 0 +silent 0 +genotype 0 +. 0 + +Electrophoretic 0 +analysis 0 +of 0 +plasma 0 +BChE 0 +of 0 +the 0 +proband 0 +and 0 +his 0 +mother 0 +showed 0 +that 0 +patient 0 +has 0 +a 0 +reduced 0 +amount 0 +of 0 +tetrameric 0 +enzyme 0 +in 0 +plasma 0 +and 0 +that 0 +minor 0 +fast 0 +- 0 +moving 0 +BChE 0 +components 0 +: 0 +monomer 0 +, 0 +dimer 0 +, 0 +and 0 +monomer 0 +- 0 +albumin 0 +conjugate 0 +are 0 +missing 0 +. 0 + +Kinetic 0 +analysis 0 +showed 0 +that 0 +the 0 +p 0 +. 0 +Val204Asp 0 +/ 0 +p 0 +. 0 +Asp70Gly 0 +- 0 +p 0 +. 0 +Ala539Thr 0 +BChE 0 +displays 0 +a 0 +pure 0 +Michaelian 0 +behavior 0 +with 0 +BTC 1 +as 0 +the 0 +substrate 0 +. 0 + +Both 0 +catalytic 0 +parameters 0 +Km 0 += 0 +265 0 +uM 0 +for 0 +BTC 1 +, 0 +two 0 +times 0 +higher 0 +than 0 +that 0 +of 0 +the 0 +atypical 0 +enzyme 0 +, 0 +and 0 +a 0 +low 0 +Vmax 0 +are 0 +consistent 0 +with 0 +the 0 +absence 0 +of 0 +activity 0 +against 0 +suxamethonium 1 +. 0 + +Molecular 0 +dynamic 0 +( 0 +MD 0 +) 0 +simulations 0 +showed 0 +that 0 +the 0 +overall 0 +effect 0 +of 0 +the 0 +mutation 0 +p 0 +. 0 +Val204Asp 0 +is 0 +disruption 0 +of 0 +hydrogen 1 +bonding 0 +between 0 +Gln223 0 +and 0 +Glu441 0 +, 0 +leading 0 +Ser198 0 +and 0 +His438 0 +to 0 +move 0 +away 0 +from 0 +each 0 +other 0 +with 0 +subsequent 0 +disruption 0 +of 0 +the 0 +catalytic 0 +triad 0 +functionality 0 +regardless 0 +of 0 +the 0 +type 0 +of 0 +substrate 0 +. 0 + +MD 0 +also 0 +showed 0 +that 0 +the 0 +enzyme 0 +volume 0 +is 0 +increased 0 +, 0 +suggesting 0 +a 0 +pre 0 +- 0 +denaturation 0 +state 0 +. 0 + +This 0 +fits 0 +with 0 +the 0 +reduced 0 +concentration 0 +of 0 +p 0 +. 0 +Ala204Asp 0 +/ 0 +p 0 +. 0 +Asp70Gly 0 +- 0 +p 0 +. 0 +Ala539Thr 0 +tetrameric 0 +enzyme 0 +in 0 +the 0 +plasma 0 +and 0 +non 0 +- 0 +detectable 0 +fast 0 +moving 0 +- 0 +bands 0 +on 0 +electrophoresis 0 +gels 0 +. 0 + +Delayed 0 +anemia 3 +after 0 +treatment 0 +with 0 +injectable 0 +artesunate 1 +in 0 +the 0 +Democratic 0 +Republic 0 +of 0 +the 0 +Congo 0 +: 0 +a 0 +manageable 0 +issue 0 +. 0 + +Cases 0 +of 0 +delayed 0 +hemolytic 3 +anemia 4 +have 0 +been 0 +described 0 +after 0 +treatment 0 +with 0 +injectable 0 +artesunate 1 +, 0 +the 0 +current 0 +World 0 +Health 0 +0rganization 0 +( 0 +WH0 0 +) 0 +- 0 +recommended 0 +first 0 +- 0 +line 0 +drug 0 +for 0 +the 0 +treatment 0 +of 0 +severe 0 +malaria 3 +. 0 + +A 0 +total 0 +of 0 +350 0 +patients 0 +( 0 +215 0 +[ 0 +61 0 +. 0 +4 0 +% 0 +] 0 +< 0 +5 0 +years 0 +of 0 +age 0 +and 0 +135 0 +[ 0 +38 0 +. 0 +6 0 +% 0 +] 0 +> 0 +5 0 +years 0 +of 0 +age 0 +) 0 +were 0 +followed 0 +- 0 +up 0 +after 0 +treatment 0 +with 0 +injectable 0 +artesunate 1 +for 0 +severe 0 +malaria 3 +in 0 +hospitals 0 +and 0 +health 0 +centers 0 +of 0 +the 0 +Democratic 0 +Republic 0 +of 0 +the 0 +Congo 0 +. 0 + +Complete 0 +series 0 +of 0 +hemoglobin 0 +( 0 +Hb 0 +) 0 +measurements 0 +were 0 +available 0 +for 0 +201 0 +patients 0 +. 0 + +A 0 +decrease 0 +in 0 +Hb 0 +levels 0 +between 0 +2 0 +and 0 +5 0 +g 0 +/ 0 +dL 0 +was 0 +detected 0 +in 0 +23 0 +( 0 +11 0 +. 0 +4 0 +% 0 +) 0 +patients 0 +during 0 +the 0 +follow 0 +- 0 +up 0 +period 0 +. 0 + +For 0 +five 0 +patients 0 +, 0 +Hb 0 +levels 0 +decreased 0 +below 0 +5 0 +g 0 +/ 0 +dL 0 +during 0 +at 0 +least 0 +one 0 +follow 0 +- 0 +up 0 +visit 0 +. 0 + +All 0 +cases 0 +of 0 +delayed 0 +anemia 3 +were 0 +clinically 0 +manageable 0 +and 0 +resolved 0 +within 0 +one 0 +month 0 +. 0 + +Regulation 0 +of 0 +signal 0 +transducer 0 +and 0 +activator 0 +of 0 +transcription 0 +3 0 +and 0 +apoptotic 0 +pathways 0 +by 0 +betaine 1 +attenuates 0 +isoproterenol 1 +- 0 +induced 0 +acute 0 +myocardial 3 +injury 4 +in 0 +rats 0 +. 0 + +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +investigate 0 +the 0 +cardioprotective 0 +effects 0 +of 0 +betaine 1 +on 0 +acute 0 +myocardial 3 +ischemia 4 +induced 0 +experimentally 0 +in 0 +rats 0 +focusing 0 +on 0 +regulation 0 +of 0 +signal 0 +transducer 0 +and 0 +activator 0 +of 0 +transcription 0 +3 0 +( 0 +STAT3 0 +) 0 +and 0 +apoptotic 0 +pathways 0 +as 0 +the 0 +potential 0 +mechanism 0 +underlying 0 +the 0 +drug 0 +effect 0 +. 0 + +Male 0 +Sprague 0 +Dawley 0 +rats 0 +were 0 +treated 0 +with 0 +betaine 1 +( 0 +100 0 +, 0 +200 0 +, 0 +and 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +orally 0 +for 0 +40 0 +days 0 +. 0 + +Acute 0 +myocardial 3 +ischemic 4 +injury 4 +was 0 +induced 0 +in 0 +rats 0 +by 0 +subcutaneous 0 +injection 0 +of 0 +isoproterenol 1 +( 0 +85 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +for 0 +two 0 +consecutive 0 +days 0 +. 0 + +Serum 0 +cardiac 0 +marker 0 +enzyme 0 +, 0 +histopathological 0 +variables 0 +and 0 +expression 0 +of 0 +protein 0 +levels 0 +were 0 +analyzed 0 +. 0 + +0ral 0 +administration 0 +of 0 +betaine 1 +( 0 +200 0 +and 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +significantly 0 +reduced 0 +the 0 +level 0 +of 0 +cardiac 0 +marker 0 +enzyme 0 +in 0 +the 0 +serum 0 +and 0 +prevented 0 +left 0 +ventricular 3 +remodeling 4 +. 0 + +Western 0 +blot 0 +analysis 0 +showed 0 +that 0 +isoproterenol 1 +- 0 +induced 0 +phosphorylation 0 +of 0 +STAT3 0 +was 0 +maintained 0 +or 0 +further 0 +enhanced 0 +by 0 +betaine 1 +treatment 0 +in 0 +myocardium 0 +. 0 + +Furthermore 0 +, 0 +betaine 1 +( 0 +200 0 +and 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +treatment 0 +increased 0 +the 0 +ventricular 0 +expression 0 +of 0 +Bcl 0 +- 0 +2 0 +and 0 +reduced 0 +the 0 +level 0 +of 0 +Bax 0 +, 0 +therefore 0 +causing 0 +a 0 +significant 0 +increase 0 +in 0 +the 0 +ratio 0 +of 0 +Bcl 0 +- 0 +2 0 +/ 0 +Bax 0 +. 0 + +The 0 +protective 0 +role 0 +of 0 +betaine 1 +on 0 +myocardial 3 +damage 4 +was 0 +further 0 +confirmed 0 +by 0 +histopathological 0 +examination 0 +. 0 + +In 0 +summary 0 +, 0 +our 0 +results 0 +showed 0 +that 0 +betaine 1 +pretreatment 0 +attenuated 0 +isoproterenol 1 +- 0 +induced 0 +acute 0 +myocardial 3 +ischemia 4 +via 0 +the 0 +regulation 0 +of 0 +STAT3 0 +and 0 +apoptotic 0 +pathways 0 +. 0 + +Quetiapine 1 +- 0 +induced 0 +neutropenia 3 +in 0 +a 0 +bipolar 3 +patient 0 +with 0 +hepatocellular 3 +carcinoma 4 +. 0 + +0BJECTIVE 0 +: 0 +Quetiapine 1 +is 0 +a 0 +dibenzothiazepine 0 +derivative 0 +, 0 +similar 0 +to 0 +clozapine 1 +, 0 +which 0 +has 0 +the 0 +highest 0 +risk 0 +of 0 +causing 0 +blood 3 +dyscrasias 4 +, 0 +especially 0 +neutropenia 3 +. 0 + +There 0 +are 0 +some 0 +case 0 +reports 0 +about 0 +this 0 +side 0 +effect 0 +of 0 +quetiapine 1 +, 0 +but 0 +possible 0 +risk 0 +factors 0 +are 0 +seldom 0 +discussed 0 +and 0 +identified 0 +. 0 + +A 0 +case 0 +of 0 +a 0 +patient 0 +with 0 +hepatocellular 3 +carcinoma 4 +that 0 +developed 0 +neutropenia 3 +after 0 +treatment 0 +with 0 +quetiapine 1 +is 0 +described 0 +here 0 +. 0 + +CASE 0 +REP0RT 0 +: 0 +A 0 +62 0 +- 0 +year 0 +- 0 +old 0 +Taiwanese 0 +widow 0 +with 0 +bipolar 3 +disorder 4 +was 0 +diagnosed 0 +with 0 +hepatocellular 3 +carcinoma 4 +at 0 +age 0 +60 0 +. 0 + +She 0 +developed 0 +leucopenia 3 +after 0 +being 0 +treated 0 +with 0 +quetiapine 1 +. 0 + +After 0 +quetiapine 1 +was 0 +discontinued 0 +, 0 +her 0 +white 0 +blood 0 +cell 0 +count 0 +returned 0 +to 0 +normal 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Although 0 +neutropenia 3 +is 0 +not 0 +a 0 +common 0 +side 0 +effect 0 +of 0 +quetiapine 1 +, 0 +physicians 0 +should 0 +be 0 +cautious 0 +about 0 +its 0 +presentation 0 +and 0 +associated 0 +risk 0 +factors 0 +. 0 + +Hepatic 3 +dysfunction 4 +may 0 +be 0 +one 0 +of 0 +the 0 +possible 0 +risk 0 +factors 0 +, 0 +and 0 +concomitant 0 +fever 3 +may 0 +be 0 +a 0 +diagnostic 0 +marker 0 +for 0 +adverse 0 +reaction 0 +to 0 +quetiapine 1 +. 0 + +Lateral 0 +antebrachial 0 +cutaneous 0 +neuropathy 3 +after 0 +steroid 1 +injection 0 +at 0 +lateral 0 +epicondyle 0 +. 0 + +BACKGR0UND 0 +AND 0 +0BJECTIVES 0 +: 0 +This 0 +report 0 +aimed 0 +to 0 +present 0 +a 0 +case 0 +of 0 +lateral 0 +antebrachial 0 +cutaneous 0 +neuropathy 3 +( 0 +LACNP 0 +) 0 +that 0 +occurred 0 +after 0 +a 0 +steroid 1 +injection 0 +in 0 +the 0 +lateral 0 +epicondyle 0 +to 0 +treat 0 +lateral 3 +epicondylitis 4 +in 0 +a 0 +40 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +. 0 + +MATERIAL 0 +AND 0 +METH0D 0 +: 0 +A 0 +40 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +presented 0 +with 0 +decreased 0 +sensation 0 +and 0 +paresthesia 3 +over 0 +her 0 +right 0 +lateral 0 +forearm 0 +; 0 +the 0 +paresthesia 3 +had 0 +occurred 0 +after 0 +a 0 +steroid 1 +injection 0 +in 0 +the 0 +right 0 +lateral 0 +epicondyle 0 +3 0 +months 0 +before 0 +. 0 + +Her 0 +sensation 0 +of 0 +light 0 +touch 0 +and 0 +pain 3 +was 0 +diminished 0 +over 0 +the 0 +lateral 0 +side 0 +of 0 +the 0 +right 0 +forearm 0 +and 0 +wrist 0 +area 0 +. 0 + +RESULTS 0 +: 0 +The 0 +sensory 0 +action 0 +potential 0 +amplitude 0 +of 0 +the 0 +right 0 +lateral 0 +antebrachial 0 +cutaneous 0 +nerve 0 +( 0 +LACN 0 +) 0 +( 0 +6 0 +. 0 +2 0 +uV 0 +) 0 +was 0 +lower 0 +than 0 +that 0 +of 0 +the 0 +left 0 +( 0 +13 0 +. 0 +1 0 +uV 0 +) 0 +. 0 + +The 0 +difference 0 +of 0 +amplitude 0 +between 0 +both 0 +sides 0 +was 0 +significant 0 +because 0 +there 0 +was 0 +more 0 +than 0 +a 0 +50 0 +% 0 +reduction 0 +. 0 + +She 0 +was 0 +diagnosed 0 +with 0 +right 0 +LACNP 0 +( 0 +mainly 0 +axonal 0 +involvement 0 +) 0 +on 0 +the 0 +basis 0 +of 0 +the 0 +clinical 0 +manifestation 0 +and 0 +the 0 +electrodiagnostic 0 +findings 0 +. 0 + +Her 0 +symptoms 0 +improved 0 +through 0 +physical 0 +therapy 0 +but 0 +persisted 0 +to 0 +some 0 +degree 0 +. 0 + +C0NCLUSI0N 0 +: 0 +This 0 +report 0 +describes 0 +the 0 +case 0 +of 0 +a 0 +woman 0 +with 0 +LACNP 0 +that 0 +developed 0 +after 0 +a 0 +steroid 1 +injection 0 +for 0 +the 0 +treatment 0 +of 0 +lateral 3 +epicondylitis 4 +. 0 + +An 0 +electrodiagnostic 0 +study 0 +, 0 +including 0 +a 0 +nerve 0 +conduction 0 +study 0 +of 0 +the 0 +LACN 0 +, 0 +was 0 +helpful 0 +to 0 +diagnose 0 +right 0 +LACNP 0 +and 0 +to 0 +find 0 +the 0 +passage 0 +of 0 +the 0 +LACN 0 +on 0 +the 0 +lateral 0 +epicondyle 0 +. 0 + +Curcumin 1 +prevents 0 +maleate 1 +- 0 +induced 0 +nephrotoxicity 3 +: 0 +relation 0 +to 0 +hemodynamic 0 +alterations 0 +, 0 +oxidative 0 +stress 0 +, 0 +mitochondrial 0 +oxygen 1 +consumption 0 +and 0 +activity 0 +of 0 +respiratory 0 +complex 0 +I 0 +. 0 + +The 0 +potential 0 +protective 0 +effect 0 +of 0 +the 0 +dietary 0 +antioxidant 0 +curcumin 1 +( 0 +120 0 +mg 0 +/ 0 +Kg 0 +/ 0 +day 0 +for 0 +6 0 +days 0 +) 0 +against 0 +the 0 +renal 3 +injury 4 +induced 0 +by 0 +maleate 1 +was 0 +evaluated 0 +. 0 + +Tubular 0 +proteinuria 3 +and 0 +oxidative 0 +stress 0 +were 0 +induced 0 +by 0 +a 0 +single 0 +injection 0 +of 0 +maleate 1 +( 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +in 0 +rats 0 +. 0 + +Maleate 1 +- 0 +induced 0 +renal 3 +injury 4 +included 0 +increase 0 +in 0 +renal 0 +vascular 0 +resistance 0 +and 0 +in 0 +the 0 +urinary 0 +excretion 0 +of 0 +total 0 +protein 0 +, 0 +glucose 1 +, 0 +sodium 1 +, 0 +neutrophil 0 +gelatinase 0 +- 0 +associated 0 +lipocalin 0 +( 0 +NGAL 0 +) 0 +and 0 +N 0 +- 0 +acetyl 0 +b 0 +- 0 +D 0 +- 0 +glucosaminidase 0 +( 0 +NAG 0 +) 0 +, 0 +upregulation 0 +of 0 +kidney 3 +injury 4 +molecule 0 +( 0 +KIM 0 +) 0 +- 0 +1 0 +, 0 +decrease 0 +in 0 +renal 0 +blood 0 +flow 0 +and 0 +claudin 0 +- 0 +2 0 +expression 0 +besides 0 +of 0 +necrosis 3 +and 0 +apoptosis 0 +of 0 +tubular 0 +cells 0 +on 0 +24 0 +h 0 +. 0 + +0xidative 0 +stress 0 +was 0 +determined 0 +by 0 +measuring 0 +the 0 +oxidation 0 +of 0 +lipids 0 +and 0 +proteins 0 +and 0 +diminution 0 +in 0 +renal 0 +Nrf2 0 +levels 0 +. 0 + +Studies 0 +were 0 +also 0 +conducted 0 +in 0 +renal 0 +epithelial 0 +LLC 0 +- 0 +PK1 0 +cells 0 +and 0 +in 0 +mitochondria 0 +isolated 0 +from 0 +kidneys 0 +of 0 +all 0 +the 0 +experimental 0 +groups 0 +. 0 + +Maleate 1 +induced 0 +cell 0 +damage 0 +and 0 +reactive 0 +oxygen 1 +species 0 +( 0 +R0S 0 +) 0 +production 0 +in 0 +LLC 0 +- 0 +PK1 0 +cells 0 +in 0 +culture 0 +. 0 + +In 0 +addition 0 +, 0 +maleate 1 +treatment 0 +reduced 0 +oxygen 1 +consumption 0 +in 0 +ADP 1 +- 0 +stimulated 0 +mitochondria 0 +and 0 +diminished 0 +respiratory 0 +control 0 +index 0 +when 0 +using 0 +malate 1 +/ 0 +glutamate 1 +as 0 +substrate 0 +. 0 + +The 0 +activities 0 +of 0 +both 0 +complex 0 +I 0 +and 0 +aconitase 0 +were 0 +also 0 +diminished 0 +. 0 + +All 0 +the 0 +above 0 +- 0 +described 0 +alterations 0 +were 0 +prevented 0 +by 0 +curcumin 1 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +curcumin 1 +is 0 +able 0 +to 0 +attenuate 0 +in 0 +vivo 0 +maleate 1 +- 0 +induced 0 +nephropathy 3 +and 0 +in 0 +vitro 0 +cell 0 +damage 0 +. 0 + +The 0 +in 0 +vivo 0 +protection 0 +was 0 +associated 0 +to 0 +the 0 +prevention 0 +of 0 +oxidative 0 +stress 0 +and 0 +preservation 0 +of 0 +mitochondrial 0 +oxygen 1 +consumption 0 +and 0 +activity 0 +of 0 +respiratory 0 +complex 0 +I 0 +, 0 +and 0 +the 0 +in 0 +vitro 0 +protection 0 +was 0 +associated 0 +to 0 +the 0 +prevention 0 +of 0 +R0S 0 +production 0 +. 0 + +Anticonvulsant 0 +actions 0 +of 0 +MK 1 +- 2 +801 2 +on 0 +the 0 +lithium 1 +- 0 +pilocarpine 1 +model 0 +of 0 +status 3 +epilepticus 4 +in 0 +rats 0 +. 0 + +MK 1 +- 2 +801 2 +, 0 +a 0 +noncompetitive 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +antagonist 0 +, 0 +was 0 +tested 0 +for 0 +anticonvulsant 0 +effects 0 +in 0 +rats 0 +using 0 +two 0 +seizure 3 +models 0 +, 0 +coadministration 0 +of 0 +lithium 1 +and 0 +pilocarpine 1 +and 0 +administration 0 +of 0 +a 0 +high 0 +dose 0 +of 0 +pilocarpine 1 +alone 0 +. 0 + +Three 0 +major 0 +results 0 +are 0 +reported 0 +. 0 + +First 0 +, 0 +pretreatment 0 +with 0 +MK 1 +- 2 +801 2 +produced 0 +an 0 +effective 0 +and 0 +dose 0 +- 0 +dependent 0 +anticonvulsant 0 +action 0 +with 0 +the 0 +lithium 1 +- 0 +pilocarpine 1 +model 0 +but 0 +not 0 +with 0 +rats 0 +treated 0 +with 0 +pilocarpine 1 +alone 0 +, 0 +suggesting 0 +that 0 +different 0 +biochemical 0 +mechanisms 0 +control 0 +seizures 3 +in 0 +these 0 +two 0 +models 0 +. 0 + +Second 0 +, 0 +the 0 +anticonvulsant 0 +effect 0 +of 0 +MK 1 +- 2 +801 2 +in 0 +the 0 +lithium 1 +- 0 +pilocarpine 1 +model 0 +only 0 +occurred 0 +after 0 +initial 0 +periods 0 +of 0 +seizure 3 +activity 0 +. 0 + +This 0 +observation 0 +is 0 +suggested 0 +to 0 +be 0 +an 0 +in 0 +vivo 0 +demonstration 0 +of 0 +the 0 +conclusion 0 +derived 0 +from 0 +in 0 +vitro 0 +experiments 0 +that 0 +MK 1 +- 2 +801 2 +binding 0 +requires 0 +agonist 0 +- 0 +induced 0 +opening 0 +of 0 +the 0 +channel 0 +sites 0 +of 0 +the 0 +NMDA 1 +receptor 0 +. 0 + +Third 0 +, 0 +although 0 +it 0 +is 0 +relatively 0 +easy 0 +to 0 +block 0 +seizures 3 +induced 0 +by 0 +lithium 1 +and 0 +pilocarpine 1 +by 0 +administration 0 +of 0 +anticonvulsants 0 +prior 0 +to 0 +pilocarpine 1 +, 0 +it 0 +is 0 +more 0 +difficult 0 +to 0 +terminate 0 +ongoing 0 +status 3 +epilepticus 4 +and 0 +block 0 +the 0 +lethality 0 +of 0 +the 0 +seizures 3 +. 0 + +Administration 0 +of 0 +MK 1 +- 2 +801 2 +30 0 +or 0 +60 0 +min 0 +after 0 +pilocarpine 1 +, 0 +i 0 +. 0 +e 0 +. 0 +, 0 +during 0 +status 3 +epilepticus 4 +, 0 +gradually 0 +reduced 0 +electrical 0 +and 0 +behavioral 0 +seizure 3 +activity 0 +and 0 +greatly 0 +enhanced 0 +the 0 +survival 0 +rate 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +activation 0 +of 0 +NMDA 1 +receptors 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +status 3 +epilepticus 4 +and 0 +brain 3 +damage 4 +in 0 +the 0 +lithium 1 +- 0 +pilocarpine 1 +model 0 +. 0 + +This 0 +was 0 +further 0 +supported 0 +by 0 +results 0 +showing 0 +that 0 +nonconvulsive 0 +doses 0 +of 0 +NMDA 1 +and 0 +pilocarpine 1 +were 0 +synergistic 0 +, 0 +resulting 0 +in 0 +status 3 +epilepticus 4 +and 0 +subsequent 0 +mortality 0 +. 0 + +Continuous 0 +infusion 0 +tobramycin 1 +combined 0 +with 0 +carbenicillin 1 +for 0 +infections 3 +in 0 +cancer 3 +patients 0 +. 0 + +The 0 +cure 0 +rate 0 +of 0 +infections 3 +in 0 +cancer 3 +patients 0 +is 0 +adversely 0 +affected 0 +by 0 +neutropenia 3 +( 0 +less 0 +than 0 +1 0 +, 0 +000 0 +/ 0 +mm3 0 +) 0 +. 0 + +In 0 +particular 0 +, 0 +patients 0 +with 0 +severe 0 +neutropenia 3 +( 0 +less 0 +than 0 +100 0 +/ 0 +mm3 0 +) 0 +have 0 +shown 0 +a 0 +poor 0 +response 0 +to 0 +antibiotics 0 +. 0 + +To 0 +overcome 0 +the 0 +adverse 0 +effects 0 +of 0 +neutropenia 3 +, 0 +tobramycin 1 +was 0 +given 0 +by 0 +continuous 0 +infusion 0 +and 0 +combined 0 +with 0 +intermittent 0 +carbenicillin 1 +. 0 + +Tobramycin 1 +was 0 +given 0 +to 0 +a 0 +total 0 +daily 0 +dose 0 +of 0 +300 0 +mg 0 +/ 0 +m2 0 +and 0 +carbenicillin 1 +was 0 +given 0 +at 0 +a 0 +dose 0 +of 0 +5 0 +gm 0 +every 0 +four 0 +hours 0 +. 0 + +There 0 +were 0 +125 0 +infectious 0 +episodes 0 +in 0 +116 0 +cancer 3 +patients 0 +receiving 0 +myelosuppressive 0 +chemotherapy 0 +. 0 + +The 0 +overall 0 +cure 0 +rate 0 +was 0 +70 0 +% 0 +. 0 + +Pneumonia 3 +was 0 +the 0 +most 0 +common 0 +infection 3 +and 0 +61 0 +% 0 +of 0 +59 0 +episodes 0 +were 0 +cured 0 +. 0 + +Gram 0 +- 0 +negative 0 +bacilli 0 +were 0 +the 0 +most 0 +common 0 +causative 0 +organisms 0 +and 0 +69 0 +% 0 +of 0 +these 0 +infections 3 +were 0 +cured 0 +. 0 + +The 0 +most 0 +common 0 +pathogen 0 +was 0 +Klebsiella 0 +pneumoniae 3 +and 0 +this 0 +, 0 +together 0 +with 0 +Escherichia 0 +coli 0 +and 0 +Pseudomonas 0 +aeruginosa 0 +, 0 +accounted 0 +for 0 +74 0 +% 0 +of 0 +all 0 +gram 3 +- 4 +negative 4 +bacillary 4 +infections 4 +. 0 + +Response 0 +was 0 +not 0 +influenced 0 +by 0 +the 0 +initial 0 +neutrophil 0 +count 0 +, 0 +with 0 +a 0 +62 0 +% 0 +cure 0 +rate 0 +for 0 +39 0 +episodes 0 +associated 0 +with 0 +severe 0 +neutropenia 3 +. 0 + +However 0 +, 0 +failure 0 +of 0 +the 0 +neutrophil 0 +count 0 +to 0 +increase 0 +during 0 +therapy 0 +adversely 0 +affected 0 +response 0 +. 0 + +Azotemia 3 +was 0 +the 0 +major 0 +side 0 +effect 0 +recognized 0 +, 0 +and 0 +it 0 +occurred 0 +in 0 +11 0 +% 0 +of 0 +episodes 0 +. 0 + +Major 0 +azotemia 3 +( 0 +serum 0 +creatinine 1 +greater 0 +than 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +dl 0 +or 0 +BUN 0 +greater 0 +than 0 +50 0 +mg 0 +/ 0 +dl 0 +) 0 +occurred 0 +in 0 +only 0 +2 0 +% 0 +. 0 + +Azotemia 3 +was 0 +not 0 +related 0 +to 0 +duration 0 +of 0 +therapy 0 +or 0 +serum 0 +tobramycin 1 +concentration 0 +. 0 + +This 0 +antibiotic 0 +regimen 0 +showed 0 +both 0 +therapeutic 0 +efficacy 0 +and 0 +acceptable 0 +renal 3 +toxicity 4 +for 0 +these 0 +patients 0 +. 0 + +Incidence 0 +of 0 +solid 0 +tumours 3 +among 0 +pesticide 0 +applicators 0 +exposed 0 +to 0 +the 0 +organophosphate 1 +insecticide 0 +diazinon 1 +in 0 +the 0 +Agricultural 0 +Health 0 +Study 0 +: 0 +an 0 +updated 0 +analysis 0 +. 0 + +0BJECTIVE 0 +: 0 +Diazinon 1 +, 0 +a 0 +common 0 +organophosphate 1 +insecticide 0 +with 0 +genotoxic 0 +properties 0 +, 0 +was 0 +previously 0 +associated 0 +with 0 +lung 3 +cancer 4 +in 0 +the 0 +Agricultural 0 +Health 0 +Study 0 +( 0 +AHS 0 +) 0 +cohort 0 +, 0 +but 0 +few 0 +other 0 +epidemiological 0 +studies 0 +have 0 +examined 0 +diazinon 1 +- 0 +associated 0 +cancer 3 +risk 0 +. 0 + +We 0 +used 0 +updated 0 +diazinon 1 +exposure 0 +and 0 +cancer 3 +incidence 0 +information 0 +to 0 +evaluate 0 +solid 0 +tumour 3 +risk 0 +in 0 +the 0 +AHS 0 +. 0 + +METH0DS 0 +: 0 +Male 0 +pesticide 0 +applicators 0 +in 0 +Iowa 0 +and 0 +North 0 +Carolina 0 +reported 0 +lifetime 0 +diazinon 1 +use 0 +at 0 +enrolment 0 +( 0 +1993 0 +- 0 +1997 0 +) 0 +and 0 +follow 0 +- 0 +up 0 +( 0 +1998 0 +- 0 +2005 0 +) 0 +; 0 +cancer 3 +incidence 0 +was 0 +assessed 0 +through 0 +2010 0 +( 0 +North 0 +Carolina 0 +) 0 +/ 0 +2011 0 +( 0 +Iowa 0 +) 0 +. 0 + +Among 0 +applicators 0 +with 0 +usage 0 +information 0 +sufficient 0 +to 0 +evaluate 0 +exposure 0 +- 0 +response 0 +patterns 0 +, 0 +we 0 +used 0 +Poisson 0 +regression 0 +to 0 +estimate 0 +adjusted 0 +rate 0 +ratios 0 +( 0 +RRs 0 +) 0 +and 0 +95 0 +% 0 +CI 0 +for 0 +cancer 3 +sites 0 +with 0 +> 0 +10 0 +exposed 0 +cases 0 +for 0 +both 0 +lifetime 0 +( 0 +LT 0 +) 0 +exposure 0 +days 0 +and 0 +intensity 0 +- 0 +weighted 0 +( 0 +IW 0 +) 0 +lifetime 0 +exposure 0 +days 0 +( 0 +accounting 0 +for 0 +factors 0 +impacting 0 +exposure 0 +) 0 +. 0 + +RESULTS 0 +: 0 +We 0 +observed 0 +elevated 0 +lung 3 +cancer 4 +risks 0 +( 0 +N 0 += 0 +283 0 +) 0 +among 0 +applicators 0 +with 0 +the 0 +greatest 0 +number 0 +of 0 +LT 0 +( 0 +RR 0 += 0 +1 0 +. 0 +60 0 +; 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +11 0 +to 0 +2 0 +. 0 +31 0 +; 0 +Ptrend 0 += 0 +0 0 +. 0 +02 0 +) 0 +and 0 +IW 0 +days 0 +of 0 +diazinon 1 +use 0 +( 0 +RR 0 += 0 +1 0 +. 0 +41 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +98 0 +to 0 +2 0 +. 0 +04 0 +; 0 +Ptrend 0 += 0 +0 0 +. 0 +08 0 +) 0 +. 0 + +Kidney 3 +cancer 4 +( 0 +N 0 += 0 +94 0 +) 0 +risks 0 +were 0 +non 0 +- 0 +significantly 0 +elevated 0 +( 0 +RRLT 0 +days 0 += 0 +1 0 +. 0 +77 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +90 0 +to 0 +3 0 +. 0 +51 0 +; 0 +Ptrend 0 += 0 +0 0 +. 0 +09 0 +; 0 +RRIW 0 +days 0 +1 0 +. 0 +37 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +64 0 +to 0 +2 0 +. 0 +92 0 +; 0 +Ptrend 0 += 0 +0 0 +. 0 +50 0 +) 0 +, 0 +as 0 +were 0 +risks 0 +for 0 +aggressive 0 +prostate 3 +cancer 4 +( 0 +N 0 += 0 +656 0 +) 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +0ur 0 +updated 0 +evaluation 0 +of 0 +diazinon 1 +provides 0 +additional 0 +evidence 0 +of 0 +an 0 +association 0 +with 0 +lung 3 +cancer 4 +risk 0 +. 0 + +Newly 0 +identified 0 +links 0 +to 0 +kidney 3 +cancer 4 +and 0 +associations 0 +with 0 +aggressive 0 +prostate 3 +cancer 4 +require 0 +further 0 +evaluation 0 +. 0 + +Associations 0 +of 0 +0zone 1 +and 0 +PM2 0 +. 0 +5 0 +Concentrations 0 +With 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Among 0 +Participants 0 +in 0 +the 0 +Agricultural 0 +Health 0 +Study 0 +. 0 + +0BJECTIVE 0 +: 0 +This 0 +study 0 +describes 0 +associations 0 +of 0 +ozone 1 +and 0 +fine 0 +particulate 1 +matter 2 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +observed 0 +among 0 +farmers 0 +in 0 +North 0 +Carolina 0 +and 0 +Iowa 0 +. 0 + +METH0DS 0 +: 0 +We 0 +used 0 +logistic 0 +regression 0 +to 0 +determine 0 +the 0 +associations 0 +of 0 +these 0 +pollutants 0 +with 0 +self 0 +- 0 +reported 0 +, 0 +doctor 0 +- 0 +diagnosed 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +Daily 0 +predicted 0 +pollutant 0 +concentrations 0 +were 0 +used 0 +to 0 +derive 0 +surrogates 0 +of 0 +long 0 +- 0 +term 0 +exposure 0 +and 0 +link 0 +them 0 +to 0 +study 0 +participants 0 +' 0 +geocoded 0 +addresses 0 +. 0 + +RESULTS 0 +: 0 +We 0 +observed 0 +positive 0 +associations 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +with 0 +ozone 1 +( 0 +odds 0 +ratio 0 += 0 +1 0 +. 0 +39 0 +; 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +98 0 +to 0 +1 0 +. 0 +98 0 +) 0 +and 0 +fine 0 +particulate 1 +matter 2 +( 0 +odds 0 +ratio 0 += 0 +1 0 +. 0 +34 0 +; 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +93 0 +to 0 +1 0 +. 0 +93 0 +) 0 +in 0 +North 0 +Carolina 0 +but 0 +not 0 +in 0 +Iowa 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +The 0 +plausibility 0 +of 0 +an 0 +effect 0 +of 0 +ambient 0 +concentrations 0 +of 0 +these 0 +pollutants 0 +on 0 +Parkinson 3 +' 4 +s 4 +disease 4 +risk 0 +is 0 +supported 0 +by 0 +experimental 0 +data 0 +demonstrating 0 +damage 0 +to 0 +dopaminergic 0 +neurons 0 +at 0 +relevant 0 +concentrations 0 +. 0 + +Additional 0 +studies 0 +are 0 +needed 0 +to 0 +address 0 +uncertainties 0 +related 0 +to 0 +confounding 0 +and 0 +to 0 +examine 0 +temporal 0 +aspects 0 +of 0 +the 0 +associations 0 +we 0 +observed 0 +. 0 + +Low 0 +functional 0 +programming 0 +of 0 +renal 0 +AT2R 0 +mediates 0 +the 0 +developmental 0 +origin 0 +of 0 +glomerulosclerosis 3 +in 0 +adult 0 +offspring 0 +induced 0 +by 0 +prenatal 0 +caffeine 1 +exposure 0 +. 0 + +UNASSIGNED 0 +: 0 +0ur 0 +previous 0 +study 0 +has 0 +indicated 0 +that 0 +prenatal 0 +caffeine 1 +exposure 0 +( 0 +PCE 0 +) 0 +could 0 +induce 0 +intrauterine 3 +growth 4 +retardation 4 +( 0 +IUGR 3 +) 0 +of 0 +offspring 0 +. 0 + +Recent 0 +research 0 +suggested 0 +that 0 +IUGR 3 +is 0 +a 0 +risk 0 +factor 0 +for 0 +glomerulosclerosis 3 +. 0 + +However 0 +, 0 +whether 0 +PCE 0 +could 0 +induce 0 +glomerulosclerosis 3 +and 0 +its 0 +underlying 0 +mechanisms 0 +remain 0 +unknown 0 +. 0 + +This 0 +study 0 +aimed 0 +to 0 +demonstrate 0 +the 0 +induction 0 +to 0 +glomerulosclerosis 3 +in 0 +adult 0 +offspring 0 +by 0 +PCE 0 +and 0 +its 0 +intrauterine 0 +programming 0 +mechanisms 0 +. 0 + +A 0 +rat 0 +model 0 +of 0 +IUGR 3 +was 0 +established 0 +by 0 +PCE 0 +, 0 +male 0 +fetuses 0 +and 0 +adult 0 +offspring 0 +at 0 +the 0 +age 0 +of 0 +postnatal 0 +week 0 +24 0 +were 0 +euthanized 0 +. 0 + +The 0 +results 0 +revealed 0 +that 0 +the 0 +adult 0 +offspring 0 +kidneys 0 +in 0 +the 0 +PCE 0 +group 0 +exhibited 0 +glomerulosclerosis 3 +as 0 +well 0 +as 0 +interstitial 3 +fibrosis 4 +, 0 +accompanied 0 +by 0 +elevated 0 +levels 0 +of 0 +serum 0 +creatinine 1 +and 0 +urine 0 +protein 0 +. 0 + +Renal 0 +angiotensin 1 +II 2 +receptor 0 +type 0 +2 0 +( 0 +AT2R 0 +) 0 +gene 0 +expression 0 +in 0 +adult 0 +offspring 0 +was 0 +reduced 0 +by 0 +PCE 0 +, 0 +whereas 0 +the 0 +renal 0 +angiotensin 1 +II 2 +receptor 0 +type 0 +1a 0 +( 0 +AT1aR 0 +) 0 +/ 0 +AT2R 0 +expression 0 +ratio 0 +was 0 +increased 0 +. 0 + +The 0 +fetal 0 +kidneys 0 +in 0 +the 0 +PCE 0 +group 0 +displayed 0 +an 0 +enlarged 0 +Bowman 0 +' 0 +s 0 +space 0 +and 0 +a 0 +shrunken 0 +glomerular 0 +tuft 0 +, 0 +accompanied 0 +by 0 +a 0 +reduced 0 +cortex 0 +width 0 +and 0 +an 0 +increase 0 +in 0 +the 0 +nephrogenic 0 +zone 0 +/ 0 +cortical 0 +zone 0 +ratio 0 +. 0 + +0bservation 0 +by 0 +electronic 0 +microscope 0 +revealed 0 +structural 0 +damage 0 +of 0 +podocytes 0 +; 0 +the 0 +reduced 0 +expression 0 +level 0 +of 0 +podocyte 0 +marker 0 +genes 0 +, 0 +nephrin 0 +and 0 +podocin 0 +, 0 +was 0 +also 0 +detected 0 +by 0 +q 0 +- 0 +PCR 0 +. 0 + +Moreover 0 +, 0 +AT2R 0 +gene 0 +and 0 +protein 0 +expressions 0 +in 0 +fetal 0 +kidneys 0 +were 0 +inhibited 0 +by 0 +PCE 0 +, 0 +associated 0 +with 0 +the 0 +repression 0 +of 0 +the 0 +gene 0 +expression 0 +of 0 +glial 0 +- 0 +cell 0 +- 0 +line 0 +- 0 +derived 0 +neurotrophic 0 +factor 0 +( 0 +GDNF 0 +) 0 +/ 0 +tyrosine 1 +kinase 0 +receptor 0 +( 0 +c 0 +- 0 +Ret 0 +) 0 +signaling 0 +pathway 0 +. 0 + +These 0 +results 0 +demonstrated 0 +that 0 +PCE 0 +could 0 +induce 0 +dysplasia 3 +of 4 +fetal 4 +kidneys 4 +as 0 +well 0 +as 0 +glomerulosclerosis 3 +of 0 +adult 0 +offspring 0 +, 0 +and 0 +the 0 +low 0 +functional 0 +programming 0 +of 0 +renal 0 +AT2R 0 +might 0 +mediate 0 +the 0 +developmental 0 +origin 0 +of 0 +adult 0 +glomerulosclerosis 3 +. 0 + +1 1 +, 2 +3 2 +- 2 +Butadiene 2 +, 0 +CML 3 +and 0 +the 0 +t 0 +( 0 +9 0 +: 0 +22 0 +) 0 +translocation 0 +: 0 +A 0 +reality 0 +check 0 +. 0 + +UNASSIGNED 0 +: 0 +Epidemiological 0 +studies 0 +of 0 +1 1 +, 2 +3 2 +- 2 +butadiene 2 +have 0 +suggest 0 +that 0 +exposures 0 +to 0 +humans 0 +are 0 +associated 0 +with 0 +chronic 3 +myeloid 4 +leukemia 4 +( 0 +CML 3 +) 0 +. 0 + +CML 3 +has 0 +a 0 +well 0 +- 0 +documented 0 +association 0 +with 0 +ionizing 0 +radiation 0 +, 0 +but 0 +reports 0 +of 0 +associations 0 +with 0 +chemical 0 +exposures 0 +have 0 +been 0 +questioned 0 +. 0 + +Ionizing 0 +radiation 0 +is 0 +capable 0 +of 0 +inducing 0 +the 0 +requisite 0 +CML 3 +- 0 +associated 0 +t 0 +( 0 +9 0 +: 0 +22 0 +) 0 +translocation 0 +( 0 +Philadelphia 3 +chromosome 4 +) 0 +in 0 +appropriate 0 +cells 0 +in 0 +vitro 0 +but 0 +, 0 +thus 0 +far 0 +, 0 +chemicals 0 +have 0 +not 0 +shown 0 +this 0 +capacity 0 +. 0 + +We 0 +have 0 +proposed 0 +that 0 +1 1 +, 2 +3 2 +- 2 +butadiene 2 +metabolites 0 +be 0 +so 0 +tested 0 +as 0 +a 0 +reality 0 +check 0 +on 0 +the 0 +epidemiological 0 +reports 0 +. 0 + +In 0 +order 0 +to 0 +conduct 0 +reliable 0 +testing 0 +in 0 +this 0 +regard 0 +, 0 +it 0 +is 0 +essential 0 +that 0 +a 0 +positive 0 +control 0 +for 0 +induction 0 +be 0 +available 0 +. 0 + +We 0 +have 0 +used 0 +ionizing 0 +radiation 0 +to 0 +develop 0 +such 0 +a 0 +control 0 +. 0 + +Results 0 +described 0 +here 0 +demonstrate 0 +that 0 +this 0 +agent 0 +does 0 +in 0 +fact 0 +induce 0 +pathogenic 0 +t 0 +( 0 +9 0 +: 0 +22 0 +) 0 +translocations 0 +in 0 +a 0 +human 0 +myeloid 0 +cell 0 +line 0 +in 0 +vitro 0 +, 0 +but 0 +does 0 +so 0 +at 0 +low 0 +frequencies 0 +. 0 + +Conditions 0 +that 0 +will 0 +be 0 +required 0 +for 0 +studies 0 +of 0 +1 1 +, 2 +3 2 +- 2 +butadiene 2 +are 0 +discussed 0 +. 0 + +Cancer 3 +incidence 0 +and 0 +metolachlor 1 +use 0 +in 0 +the 0 +Agricultural 0 +Health 0 +Study 0 +: 0 +An 0 +update 0 +. 0 + +UNASSIGNED 0 +: 0 +Metolachlor 1 +, 0 +a 0 +widely 0 +used 0 +herbicide 0 +, 0 +is 0 +classified 0 +as 0 +a 0 +Group 0 +C 0 +carcinogen 0 +by 0 +the 0 +U 0 +. 0 +S 0 +. 0 + +Environmental 0 +Protection 0 +Agency 0 +based 0 +on 0 +increased 0 +liver 3 +neoplasms 4 +in 0 +female 0 +rats 0 +. 0 + +Epidemiologic 0 +studies 0 +of 0 +the 0 +health 0 +effects 0 +of 0 +metolachlor 1 +have 0 +been 0 +limited 0 +. 0 + +The 0 +Agricultural 0 +Health 0 +Study 0 +( 0 +AHS 0 +) 0 +is 0 +a 0 +prospective 0 +cohort 0 +study 0 +including 0 +licensed 0 +private 0 +and 0 +commercial 0 +pesticide 0 +applicators 0 +in 0 +Iowa 0 +and 0 +North 0 +Carolina 0 +enrolled 0 +1993 0 +- 0 +1997 0 +. 0 + +We 0 +evaluated 0 +cancer 3 +incidence 0 +through 0 +2010 0 +/ 0 +2011 0 +( 0 +NC 0 +/ 0 +IA 0 +) 0 +for 0 +49 0 +, 0 +616 0 +applicators 0 +, 0 +53 0 +% 0 +of 0 +whom 0 +reported 0 +ever 0 +using 0 +metolachlor 1 +. 0 + +We 0 +used 0 +Poisson 0 +regression 0 +to 0 +evaluate 0 +relations 0 +between 0 +two 0 +metrics 0 +of 0 +metolachlor 1 +use 0 +( 0 +lifetime 0 +days 0 +, 0 +intensity 0 +- 0 +weighted 0 +lifetime 0 +days 0 +) 0 +and 0 +cancer 3 +incidence 0 +. 0 + +We 0 +saw 0 +no 0 +association 0 +between 0 +metolachlor 1 +use 0 +and 0 +incidence 0 +of 0 +all 0 +cancers 3 +combined 0 +( 0 +n 0 += 0 +5 0 +, 0 +701 0 +with 0 +a 0 +5 0 +- 0 +year 0 +lag 0 +) 0 +or 0 +most 0 +site 0 +- 0 +specific 0 +cancers 3 +. 0 + +For 0 +liver 3 +cancer 4 +, 0 +in 0 +analyses 0 +restricted 0 +to 0 +exposed 0 +workers 0 +, 0 +elevations 0 +observed 0 +at 0 +higher 0 +categories 0 +of 0 +use 0 +were 0 +not 0 +statistically 0 +significant 0 +. 0 + +However 0 +, 0 +trends 0 +for 0 +both 0 +lifetime 0 +and 0 +intensity 0 +- 0 +weighted 0 +lifetime 0 +days 0 +of 0 +metolachor 1 +use 0 +were 0 +positive 0 +and 0 +statistically 0 +significant 0 +with 0 +an 0 +unexposed 0 +reference 0 +group 0 +. 0 + +A 0 +similar 0 +pattern 0 +was 0 +observed 0 +for 0 +follicular 3 +cell 4 +lymphoma 4 +, 0 +but 0 +no 0 +other 0 +lymphoma 3 +subtypes 0 +. 0 + +An 0 +earlier 0 +suggestion 0 +of 0 +increased 0 +lung 3 +cancer 4 +risk 0 +at 0 +high 0 +levels 0 +of 0 +metolachlor 1 +use 0 +in 0 +this 0 +cohort 0 +was 0 +not 0 +confirmed 0 +in 0 +this 0 +update 0 +. 0 + +This 0 +suggestion 0 +of 0 +an 0 +association 0 +between 0 +metolachlor 1 +and 0 +liver 3 +cancer 4 +among 0 +pesticide 0 +applicators 0 +is 0 +a 0 +novel 0 +finding 0 +and 0 +echoes 0 +observation 0 +of 0 +increased 0 +liver 3 +neoplasms 4 +in 0 +some 0 +animal 0 +studies 0 +. 0 + +However 0 +, 0 +our 0 +findings 0 +for 0 +both 0 +liver 3 +cancer 4 +and 0 +follicular 0 +cell 0 +lymphoma 3 +warrant 0 +follow 0 +- 0 +up 0 +to 0 +better 0 +differentiate 0 +effects 0 +of 0 +metolachlor 1 +use 0 +from 0 +other 0 +factors 0 +. 0 + +Mechanisms 0 +Underlying 0 +Latent 0 +Disease 0 +Risk 0 +Associated 0 +with 0 +Early 0 +- 0 +Life 0 +Arsenic 1 +Exposure 0 +: 0 +Current 0 +Research 0 +Trends 0 +and 0 +Scientific 0 +Gaps 0 +. 0 + +BACKGR0UND 0 +: 0 +Millions 0 +of 0 +individuals 0 +worldwide 0 +, 0 +particularly 0 +those 0 +living 0 +in 0 +rural 0 +and 0 +developing 0 +areas 0 +, 0 +are 0 +exposed 0 +to 0 +harmful 0 +levels 0 +of 0 +inorganic 1 +arsenic 2 +( 0 +iAs 1 +) 0 +in 0 +their 0 +drinking 0 +water 0 +. 0 + +Inorganic 1 +As 2 +exposure 0 +during 0 +key 0 +developmental 0 +periods 0 +is 0 +associated 0 +with 0 +a 0 +variety 0 +of 0 +adverse 0 +health 0 +effects 0 +including 0 +those 0 +that 0 +are 0 +evident 0 +in 0 +adulthood 0 +. 0 + +There 0 +is 0 +considerable 0 +interest 0 +in 0 +identifying 0 +the 0 +molecular 0 +mechanisms 0 +that 0 +relate 0 +early 0 +- 0 +life 0 +iAs 1 +exposure 0 +to 0 +the 0 +development 0 +of 0 +these 0 +latent 0 +diseases 0 +, 0 +particularly 0 +in 0 +relationship 0 +to 0 +cancer 3 +. 0 + +0BJECTIVES 0 +: 0 +This 0 +work 0 +summarizes 0 +research 0 +on 0 +the 0 +molecular 0 +mechanisms 0 +that 0 +underlie 0 +the 0 +increased 0 +risk 0 +of 0 +cancer 3 +development 0 +in 0 +adulthood 0 +that 0 +is 0 +associated 0 +with 0 +early 0 +- 0 +life 0 +iAs 1 +exposure 0 +. 0 + +DISCUSSI0N 0 +: 0 +Epigenetic 0 +reprogramming 0 +that 0 +imparts 0 +functional 0 +changes 0 +in 0 +gene 0 +expression 0 +, 0 +the 0 +development 0 +of 0 +cancer 3 +stem 0 +cells 0 +, 0 +and 0 +immunomodulation 0 +are 0 +plausible 0 +underlying 0 +mechanisms 0 +by 0 +which 0 +early 0 +- 0 +life 0 +iAs 1 +exposure 0 +elicits 0 +latent 0 +carcinogenic 0 +effects 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Evidence 0 +is 0 +mounting 0 +that 0 +relates 0 +early 0 +- 0 +life 0 +iAs 1 +exposure 0 +and 0 +cancer 3 +development 0 +later 0 +in 0 +life 0 +. 0 + +Future 0 +research 0 +should 0 +include 0 +animal 0 +studies 0 +that 0 +address 0 +mechanistic 0 +hypotheses 0 +and 0 +studies 0 +of 0 +human 0 +populations 0 +that 0 +integrate 0 +early 0 +- 0 +life 0 +exposure 0 +, 0 +molecular 0 +alterations 0 +, 0 +and 0 +latent 0 +disease 0 +outcomes 0 +. 0 + +Nifedipine 1 +induced 0 +bradycardia 3 +in 0 +a 0 +patient 0 +with 0 +autonomic 3 +neuropathy 4 +. 0 + +An 0 +80 0 +year 0 +old 0 +diabetic 3 +male 0 +with 0 +evidence 0 +of 0 +peripheral 3 +and 4 +autonomic 4 +neuropathy 4 +was 0 +admitted 0 +with 0 +chest 3 +pain 4 +. 0 + +He 0 +was 0 +found 0 +to 0 +have 0 +atrial 3 +flutter 4 +at 0 +a 0 +ventricular 0 +rate 0 +of 0 +70 0 +/ 0 +min 0 +which 0 +slowed 0 +down 0 +to 0 +30 0 +- 0 +40 0 +/ 0 +min 0 +when 0 +nifedipine 1 +( 0 +60 0 +mg 0 +) 0 +in 0 +3 0 +divided 0 +doses 0 +, 0 +during 0 +which 0 +he 0 +was 0 +paced 0 +at 0 +a 0 +rate 0 +of 0 +70 0 +/ 0 +min 0 +. 0 + +This 0 +is 0 +inconsistent 0 +with 0 +the 0 +well 0 +- 0 +established 0 +finding 0 +that 0 +nifedipine 1 +induces 0 +tachycardia 3 +in 0 +normally 0 +innervated 0 +hearts 0 +. 0 + +However 0 +, 0 +in 0 +hearts 0 +deprived 0 +of 0 +compensatory 0 +sympathetic 0 +drive 0 +, 0 +it 0 +may 0 +lead 0 +to 0 +bradycardia 3 +. 0 + +The 0 +effect 0 +of 0 +haloperidol 1 +in 0 +cocaine 1 +and 0 +amphetamine 1 +intoxication 0 +. 0 + +The 0 +effectiveness 0 +of 0 +haloperidol 1 +pretreatment 0 +in 0 +preventing 0 +the 0 +toxic 0 +effects 0 +of 0 +high 0 +doses 0 +of 0 +amphetamine 1 +and 0 +cocaine 1 +was 0 +studied 0 +in 0 +rats 0 +. 0 + +In 0 +this 0 +model 0 +, 0 +toxic 0 +effects 0 +were 0 +induced 0 +by 0 +intraperitoneal 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +injection 0 +of 0 +amphetamine 1 +75 0 +mg 0 +/ 0 +kg 0 +( 0 +100 0 +% 0 +death 0 +rate 0 +) 0 +or 0 +cocaine 1 +70 0 +mg 0 +/ 0 +kg 0 +( 0 +82 0 +% 0 +death 0 +rate 0 +) 0 +. 0 + +Haloperidol 1 +failed 0 +to 0 +prevent 0 +amphetamine 1 +- 0 +induced 0 +seizures 3 +, 0 +but 0 +did 0 +lower 0 +the 0 +mortality 0 +rate 0 +at 0 +most 0 +doses 0 +tested 0 +. 0 + +Haloperidol 1 +decreased 0 +the 0 +incidence 0 +of 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +at 0 +the 0 +two 0 +highest 0 +doses 0 +, 0 +but 0 +the 0 +lowering 0 +of 0 +the 0 +mortality 0 +rate 0 +did 0 +not 0 +reach 0 +statistical 0 +significance 0 +at 0 +any 0 +dose 0 +. 0 + +These 0 +data 0 +suggest 0 +a 0 +protective 0 +role 0 +for 0 +the 0 +central 0 +dopamine 1 +blocker 0 +haloperidol 1 +against 0 +death 0 +from 0 +high 0 +- 0 +dose 0 +amphetamine 1 +exposure 0 +without 0 +reducing 0 +the 0 +incidence 0 +of 0 +seizures 3 +. 0 + +In 0 +contrast 0 +, 0 +haloperidol 1 +demonstrated 0 +an 0 +ability 0 +to 0 +reduce 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +without 0 +significantly 0 +reducing 0 +mortality 0 +. 0 + +Autoradiographic 0 +evidence 0 +of 0 +estrogen 1 +binding 0 +sites 0 +in 0 +nuclei 0 +of 0 +diethylstilbesterol 1 +induced 0 +hamster 0 +renal 3 +carcinomas 4 +. 0 + +Estrogen 1 +binding 0 +sites 0 +were 0 +demonstrated 0 +by 0 +autoradiography 0 +in 0 +one 0 +transplantable 0 +and 0 +five 0 +primary 0 +diethylstilbesterol 1 +induced 0 +renal 3 +carcinomas 4 +in 0 +three 0 +hamsters 0 +. 0 + +Radiolabelling 0 +, 0 +following 0 +the 0 +in 0 +vivo 0 +injection 0 +of 0 +3H 0 +- 0 +17 0 +beta 0 +estradiol 1 +, 0 +was 0 +increased 0 +only 0 +over 0 +the 0 +nuclei 0 +of 0 +tumor 3 +cells 0 +; 0 +stereologic 0 +analysis 0 +revealed 0 +a 0 +4 0 +. 0 +5 0 +- 0 +to 0 +6 0 +. 0 +7 0 +- 0 +times 0 +higher 0 +concentration 0 +of 0 +reduced 0 +silver 1 +grains 0 +over 0 +nuclei 0 +than 0 +cytoplasm 0 +of 0 +these 0 +cells 0 +. 0 + +Despite 0 +rapid 0 +tubular 0 +excretion 0 +of 0 +estradiol 1 +which 0 +peaked 0 +in 0 +less 0 +than 0 +1 0 +h 0 +, 0 +the 0 +normal 0 +cells 0 +did 0 +not 0 +appear 0 +to 0 +bind 0 +the 0 +ligand 0 +. 0 + +This 0 +is 0 +the 0 +first 0 +published 0 +report 0 +documenting 0 +the 0 +preferential 0 +in 0 +vivo 0 +binding 0 +of 0 +estrogen 1 +to 0 +nuclei 0 +of 0 +cells 0 +in 0 +estrogen 1 +induced 0 +hamster 0 +renal 3 +carcinomas 4 +. 0 + +Bradycardia 3 +due 0 +to 0 +biperiden 1 +. 0 + +In 0 +a 0 +38 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +suffering 0 +from 0 +a 0 +severe 0 +postzosteric 3 +trigeminal 3 +neuralgia 4 +, 0 +intravenous 0 +application 0 +of 0 +10 0 +mg 0 +biperiden 1 +lactate 2 +led 0 +to 0 +a 0 +long 0 +- 0 +lasting 0 +paradoxical 0 +reaction 0 +characterized 0 +by 0 +considerable 0 +bradycardia 3 +, 0 +dysarthria 3 +, 0 +and 0 +dysphagia 3 +. 0 + +The 0 +heart 0 +rate 0 +was 0 +back 0 +to 0 +normal 0 +within 0 +12 0 +hours 0 +upon 0 +administration 0 +of 0 +orciprenaline 1 +under 0 +cardiac 0 +monitoring 0 +in 0 +an 0 +intensive 0 +care 0 +unit 0 +. 0 + +Bradycardia 3 +induced 0 +by 0 +biperiden 1 +is 0 +attributed 0 +to 0 +the 0 +speed 0 +of 0 +injection 0 +and 0 +to 0 +a 0 +dose 0 +- 0 +related 0 +dual 0 +effect 0 +of 0 +atropine 1 +- 0 +like 0 +drugs 0 +on 0 +muscarine 1 +receptors 0 +. 0 + +Deliberate 0 +hypotension 3 +induced 0 +by 0 +labetalol 1 +with 0 +halothane 1 +, 0 +enflurane 1 +or 0 +isoflurane 1 +for 0 +middle 0 +- 0 +ear 0 +surgery 0 +. 0 + +The 0 +feasibility 0 +of 0 +using 0 +labetalol 1 +, 0 +an 0 +alpha 0 +- 0 +and 0 +beta 0 +- 0 +adrenergic 0 +blocking 0 +agent 0 +, 0 +as 0 +a 0 +hypotensive 3 +agent 0 +in 0 +combination 0 +with 0 +inhalation 0 +anaesthetics 0 +( 0 +halothane 1 +, 0 +enflurane 1 +or 0 +isoflurane 1 +) 0 +was 0 +studied 0 +in 0 +23 0 +adult 0 +patients 0 +undergoing 0 +middle 0 +- 0 +ear 0 +surgery 0 +. 0 + +The 0 +mean 0 +arterial 0 +pressure 0 +was 0 +decreased 0 +from 0 +86 0 ++ 0 +/ 0 +- 0 +5 0 +( 0 +s 0 +. 0 +e 0 +. 0 +mean 0 +) 0 +mmHg 0 +to 0 +52 0 ++ 0 +/ 0 +- 0 +1 0 +mmHg 0 +( 0 +11 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +to 0 +6 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +kPa 0 +) 0 +for 0 +98 0 ++ 0 +/ 0 +- 0 +10 0 +min 0 +in 0 +the 0 +halothane 1 +( 0 +H 1 +) 0 +group 0 +, 0 +from 0 +79 0 ++ 0 +/ 0 +- 0 +5 0 +to 0 +53 0 ++ 0 +/ 0 +- 0 +1 0 +mmHg 0 +( 0 +10 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +to 0 +7 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +kPa 0 +) 0 +for 0 +129 0 ++ 0 +/ 0 +- 0 +11 0 +min 0 +in 0 +the 0 +enflurane 1 +( 0 +E 1 +) 0 +group 0 +, 0 +and 0 +from 0 +80 0 ++ 0 +/ 0 +- 0 +4 0 +to 0 +49 0 ++ 0 +/ 0 +- 0 +1 0 +mmHg 0 +( 0 +10 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +to 0 +6 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +kPa 0 +) 0 +for 0 +135 0 ++ 0 +/ 0 +- 0 +15 0 +min 0 +in 0 +the 0 +isoflurane 1 +( 0 +I 1 +) 0 +group 0 +. 0 + +The 0 +mean 0 +H 1 +concentration 0 +during 0 +hypotension 3 +in 0 +the 0 +inspiratory 0 +gas 0 +was 0 +0 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +vol 0 +% 0 +, 0 +the 0 +mean 0 +E 1 +concentration 0 +1 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +vol 0 +% 0 +, 0 +and 0 +the 0 +mean 0 +I 1 +concentration 0 +1 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +vol 0 +% 0 +. 0 + +In 0 +addition 0 +, 0 +the 0 +patients 0 +received 0 +fentanyl 1 +and 0 +d 1 +- 2 +tubocurarine 2 +. 0 + +The 0 +initial 0 +dose 0 +of 0 +labetalol 1 +for 0 +lowering 0 +blood 0 +pressure 0 +was 0 +similar 0 +, 0 +0 0 +. 0 +52 0 +- 0 +0 0 +. 0 +59 0 +mg 0 +/ 0 +kg 0 +, 0 +in 0 +all 0 +the 0 +groups 0 +. 0 + +During 0 +hypotension 3 +, 0 +the 0 +heart 0 +rate 0 +was 0 +stable 0 +without 0 +tachy 3 +- 4 +or 4 +bradycardia 4 +. 0 + +The 0 +operating 0 +conditions 0 +regarding 0 +bleeding 3 +were 0 +estimated 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +manner 0 +, 0 +and 0 +did 0 +not 0 +differ 0 +significantly 0 +between 0 +the 0 +groups 0 +. 0 + +During 0 +hypotension 3 +, 0 +the 0 +serum 0 +creatinine 1 +concentration 0 +rose 0 +significantly 0 +in 0 +all 0 +groups 0 +from 0 +the 0 +values 0 +before 0 +hypotension 3 +and 0 +returned 0 +postoperatively 0 +to 0 +the 0 +initial 0 +level 0 +in 0 +the 0 +other 0 +groups 0 +, 0 +except 0 +the 0 +isoflurane 1 +group 0 +. 0 + +After 0 +hypotension 3 +there 0 +was 0 +no 0 +rebound 0 +phenomenon 0 +in 0 +either 0 +blood 0 +pressure 0 +or 0 +heart 0 +rate 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +labetalol 1 +induces 0 +easily 0 +adjustable 0 +hypotension 3 +without 0 +compensatory 0 +tachycardia 3 +and 0 +rebound 0 +hypertension 3 +. 0 + +Convulsion 3 +following 0 +intravenous 0 +fluorescein 1 +angiography 0 +. 0 + +Tonic 3 +- 4 +clonic 4 +seizures 4 +followed 0 +intravenous 0 +fluorescein 1 +injection 0 +for 0 +fundus 0 +angiography 0 +in 0 +a 0 +47 0 +- 0 +year 0 +- 0 +old 0 +male 0 +. 0 + +Despite 0 +precautions 0 +this 0 +adverse 0 +reaction 0 +recurred 0 +on 0 +re 0 +- 0 +exposure 0 +to 0 +intravenous 0 +fluorescein 1 +. 0 + +Pharmacology 0 +of 0 +ACC 1 +- 2 +9653 2 +( 0 +phenytoin 1 +prodrug 0 +) 0 +. 0 + +ACC 1 +- 2 +9653 2 +, 0 +the 0 +disodium 1 +phosphate 2 +ester 2 +of 0 +3 1 +- 2 +hydroxymethyl 2 +- 2 +5 2 +, 2 +5 2 +- 2 +diphenylhydantoin 2 +, 0 +is 0 +a 0 +prodrug 0 +of 0 +phenytoin 1 +with 0 +advantageous 0 +physicochemical 0 +properties 0 +. 0 + +ACC 1 +- 2 +9653 2 +is 0 +rapidly 0 +converted 0 +enzymatically 0 +to 0 +phenytoin 1 +in 0 +vivo 0 +. 0 + +ACC 1 +- 2 +9653 2 +and 0 +phenytoin 1 +sodium 2 +have 0 +equivalent 0 +anticonvulsant 0 +activity 0 +against 0 +seizures 3 +induced 0 +by 0 +maximal 0 +electroshock 0 +( 0 +MES 0 +) 0 +in 0 +mice 0 +following 0 +i 0 +. 0 +p 0 +. 0 +, 0 +oral 0 +, 0 +or 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +. 0 + +The 0 +ED50 0 +doses 0 +were 0 +16 0 +mg 0 +/ 0 +kg 0 +for 0 +i 0 +. 0 +v 0 +. 0 +ACC 1 +- 2 +9653 2 +and 0 +8 0 +mg 0 +/ 0 +kg 0 +for 0 +i 0 +. 0 +v 0 +. 0 +phenytoin 1 +sodium 2 +. 0 + +ACC 1 +- 2 +9653 2 +and 0 +phenytoin 1 +sodium 2 +have 0 +similar 0 +antiarrhythmic 0 +activity 0 +against 0 +ouabain 1 +- 0 +induced 0 +ventricular 3 +tachycardia 4 +in 0 +anesthetized 0 +dogs 0 +. 0 + +The 0 +total 0 +doses 0 +of 0 +ACC 1 +- 2 +9653 2 +or 0 +phenytoin 1 +sodium 2 +necessary 0 +to 0 +convert 0 +the 0 +arrhythmia 3 +to 0 +a 0 +normal 0 +sinus 0 +rhythm 0 +were 0 +24 0 ++ 0 +/ 0 +- 0 +6 0 +and 0 +14 0 ++ 0 +/ 0 +- 0 +3 0 +mg 0 +/ 0 +kg 0 +, 0 +respectively 0 +. 0 + +0nly 0 +phenytoin 1 +sodium 2 +displayed 0 +in 0 +vitro 0 +antiarrhythmic 0 +activity 0 +against 0 +strophanthidin 1 +- 0 +induced 0 +arrhythmias 3 +in 0 +guinea 0 +pig 0 +right 0 +atria 0 +. 0 + +In 0 +anesthetized 0 +dogs 0 +, 0 +a 0 +high 0 +dose 0 +of 0 +ACC 1 +- 2 +9653 2 +( 0 +31 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +infused 0 +over 0 +15 0 +, 0 +20 0 +, 0 +and 0 +30 0 +min 0 +and 0 +the 0 +responses 0 +were 0 +compared 0 +to 0 +an 0 +equimolar 0 +dose 0 +of 0 +phenytoin 1 +sodium 2 +( 0 +21 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 + +The 0 +ACC 1 +- 2 +9653 2 +and 0 +phenytoin 1 +sodium 2 +treatments 0 +produced 0 +similar 0 +marked 0 +reductions 0 +in 0 +diastolic 0 +blood 0 +pressure 0 +and 0 +contractile 0 +force 0 +( 0 +LVdP 0 +/ 0 +dt 0 +) 0 +. 0 + +The 0 +maximum 0 +effects 0 +of 0 +each 0 +treatment 0 +occurred 0 +at 0 +the 0 +time 0 +of 0 +maximum 0 +phenytoin 1 +sodium 2 +levels 0 +. 0 + +Acute 0 +toxicity 3 +studies 0 +of 0 +ACC 1 +- 2 +9653 2 +and 0 +phenytoin 1 +sodium 2 +were 0 +carried 0 +out 0 +in 0 +mice 0 +, 0 +rats 0 +, 0 +rabbits 0 +, 0 +and 0 +dogs 0 +by 0 +i 0 +. 0 +v 0 +. 0 +, 0 +i 0 +. 0 +m 0 +. 0 +, 0 +and 0 +i 0 +. 0 +p 0 +. 0 +routes 0 +of 0 +administration 0 +. 0 + +The 0 +systemic 0 +toxic 0 +signs 0 +of 0 +both 0 +agents 0 +were 0 +similar 0 +and 0 +occurred 0 +at 0 +approximately 0 +equivalent 0 +doses 0 +. 0 + +Importantly 0 +, 0 +the 0 +local 0 +irritation 0 +of 0 +ACC 1 +- 2 +9653 2 +was 0 +markedly 0 +less 0 +than 0 +phenytoin 1 +sodium 2 +following 0 +i 0 +. 0 +m 0 +. 0 +administration 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Tachyphylaxis 0 +to 0 +systemic 0 +but 0 +not 0 +to 0 +airway 0 +responses 0 +during 0 +prolonged 0 +therapy 0 +with 0 +high 0 +dose 0 +inhaled 0 +salbutamol 1 +in 0 +asthmatics 3 +. 0 + +High 0 +doses 0 +of 0 +inhaled 0 +salbutamol 1 +produce 0 +substantial 0 +improvements 0 +in 0 +airway 0 +response 0 +in 0 +patients 0 +with 0 +asthma 3 +, 0 +and 0 +are 0 +associated 0 +with 0 +dose 0 +- 0 +dependent 0 +systemic 0 +beta 0 +- 0 +adrenoceptor 0 +responses 0 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +whether 0 +tachyphylaxis 0 +occurs 0 +during 0 +prolonged 0 +treatment 0 +with 0 +high 0 +dose 0 +inhaled 0 +salbutamol 1 +. 0 + +Twelve 0 +asthmatic 3 +patients 0 +( 0 +FEV1 0 +, 0 +81 0 ++ 0 +/ 0 +- 0 +4 0 +% 0 +predicted 0 +) 0 +, 0 +requiring 0 +only 0 +occasional 0 +inhaled 0 +beta 0 +- 0 +agonists 0 +as 0 +their 0 +sole 0 +therapy 0 +, 0 +were 0 +given 0 +a 0 +14 0 +- 0 +day 0 +treatment 0 +with 0 +high 0 +dose 0 +inhaled 0 +salbutamol 1 +( 0 +HDS 0 +) 0 +, 0 +4 0 +, 0 +000 0 +micrograms 0 +daily 0 +, 0 +low 0 +dose 0 +inhaled 0 +salbutamol 1 +( 0 +LDS 0 +) 0 +, 0 +800 0 +micrograms 0 +daily 0 +, 0 +or 0 +placebo 0 +( 0 +PI 0 +) 0 +by 0 +metered 0 +- 0 +dose 0 +inhaler 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +randomized 0 +crossover 0 +design 0 +. 0 + +During 0 +the 0 +14 0 +- 0 +day 0 +run 0 +- 0 +in 0 +and 0 +during 0 +washout 0 +periods 0 +, 0 +inhaled 0 +beta 0 +- 0 +agonists 0 +were 0 +withheld 0 +and 0 +ipratropium 1 +bromide 2 +was 0 +substituted 0 +for 0 +rescue 0 +purposes 0 +. 0 + +At 0 +the 0 +end 0 +of 0 +each 0 +14 0 +- 0 +day 0 +treatment 0 +, 0 +a 0 +dose 0 +- 0 +response 0 +curve 0 +( 0 +DRC 0 +) 0 +was 0 +performed 0 +, 0 +and 0 +airway 0 +( 0 +FEV1 0 +, 0 +FEF25 0 +- 0 +75 0 +) 0 +chronotropic 0 +( 0 +HR 0 +) 0 +, 0 +tremor 3 +, 0 +and 0 +metabolic 0 +( 0 +K 1 +, 0 +Glu 1 +) 0 +responses 0 +were 0 +measured 0 +at 0 +each 0 +step 0 +( 0 +from 0 +100 0 +to 0 +4 0 +, 0 +000 0 +micrograms 0 +) 0 +. 0 + +Treatment 0 +had 0 +no 0 +significant 0 +effect 0 +on 0 +baseline 0 +values 0 +. 0 + +There 0 +were 0 +dose 0 +- 0 +dependent 0 +increases 0 +in 0 +FEV1 0 +and 0 +FEF25 0 +- 0 +75 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +and 0 +pretreatment 0 +with 0 +HDS 0 +did 0 +not 0 +displace 0 +the 0 +DRC 0 +to 0 +the 0 +right 0 +. 0 + +DRC 0 +for 0 +HR 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +K 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +and 0 +Glu 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +005 0 +) 0 +were 0 +attenuated 0 +after 0 +treatment 0 +with 0 +HDS 0 +compared 0 +with 0 +PI 0 +. 0 + +There 0 +were 0 +also 0 +differences 0 +between 0 +HDS 0 +and 0 +LDS 0 +for 0 +HR 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +and 0 +Glu 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +responses 0 +. 0 + +Frequency 0 +and 0 +severity 0 +of 0 +subjective 0 +adverse 0 +effects 0 +were 0 +also 0 +reduced 0 +after 0 +HDS 0 +: 0 +tremor 3 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +palpitations 3 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Phenytoin 1 +induced 0 +fatal 0 +hepatic 3 +injury 4 +. 0 + +A 0 +61 0 +year 0 +old 0 +female 0 +developed 0 +fatal 0 +hepatic 3 +failure 4 +after 0 +phenytoin 1 +administration 0 +. 0 + +A 0 +typical 0 +multisystem 0 +clinical 0 +pattern 0 +precedes 0 +the 0 +manifestations 0 +of 0 +hepatic 3 +injury 4 +. 0 + +The 0 +hematologic 0 +, 0 +biochemical 0 +and 0 +pathologic 0 +features 0 +indicate 0 +a 0 +mixed 0 +hepatocellular 3 +damage 4 +due 0 +to 0 +drug 3 +hypersensitivity 4 +. 0 + +In 0 +a 0 +patient 0 +receiving 0 +phenytoin 1 +who 0 +presents 0 +a 0 +viral 0 +- 0 +like 0 +illness 0 +, 0 +early 0 +recognition 0 +and 0 +discontinuation 0 +of 0 +the 0 +drug 0 +are 0 +mandatory 0 +. 0 + +Treatment 0 +of 0 +lethal 0 +pertussis 1 +vaccine 2 +reaction 0 +with 0 +histamine 1 +H1 0 +antagonists 0 +. 0 + +We 0 +studied 0 +mortality 0 +after 0 +pertussis 3 +immunization 0 +in 0 +the 0 +mouse 0 +. 0 + +Without 0 +treatment 0 +, 0 +73 0 +of 0 +92 0 +animals 0 +( 0 +80 0 +% 0 +) 0 +died 0 +after 0 +injection 0 +of 0 +bovine 0 +serum 0 +albumin 0 +( 0 +BSA 0 +) 0 +on 0 +day 0 ++ 0 +7 0 +of 0 +pertussis 3 +immunization 0 +. 0 + +After 0 +pretreatment 0 +with 0 +3 0 +mg 0 +of 0 +cyproheptadine 1 +, 0 +2 0 +mg 0 +mianserin 1 +, 0 +or 0 +2 0 +mg 0 +chlorpheniramine 1 +, 0 +only 0 +5 0 +of 0 +105 0 +animals 0 +( 0 +5 0 +% 0 +) 0 +died 0 +after 0 +receiving 0 +BSA 0 +on 0 +day 0 ++ 0 +7 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Blockade 0 +of 0 +histamine 1 +H1 0 +receptors 0 +may 0 +reduce 0 +mortality 0 +in 0 +pertussis 3 +immunization 0 +- 0 +induced 0 +encephalopathy 3 +in 0 +mice 0 +. 0 + +Support 0 +for 0 +adrenaline 1 +- 0 +hypertension 3 +hypothesis 0 +: 0 +18 0 +hour 0 +pressor 0 +effect 0 +after 0 +6 0 +hours 0 +adrenaline 1 +infusion 0 +. 0 + +In 0 +a 0 +double 0 +blind 0 +, 0 +crossover 0 +study 0 +6 0 +h 0 +infusions 0 +of 0 +adrenaline 1 +( 0 +15 0 +ng 0 +/ 0 +kg 0 +/ 0 +min 0 +; 0 +1 0 +ng 0 += 0 +5 0 +. 0 +458 0 +pmol 0 +) 0 +, 0 +noradrenaline 1 +( 0 +30 0 +ng 0 +/ 0 +kg 0 +/ 0 +min 0 +; 0 +1 0 +ng 0 += 0 +5 0 +. 0 +911 0 +pmol 0 +) 0 +, 0 +and 0 +a 0 +5 0 +% 0 +dextrose 1 +solution 0 +( 0 +5 0 +. 0 +4 0 +ml 0 +/ 0 +h 0 +) 0 +, 0 +were 0 +given 0 +to 0 +ten 0 +healthy 0 +volunteers 0 +in 0 +random 0 +order 0 +2 0 +weeks 0 +apart 0 +. 0 + +By 0 +means 0 +of 0 +intra 0 +- 0 +arterial 0 +ambulatory 0 +monitoring 0 +the 0 +haemodynamic 0 +effects 0 +were 0 +followed 0 +for 0 +18 0 +h 0 +after 0 +the 0 +infusions 0 +were 0 +stopped 0 +. 0 + +Adrenaline 1 +, 0 +but 0 +not 0 +noradrenaline 1 +, 0 +caused 0 +a 0 +delayed 0 +and 0 +protracted 0 +pressor 0 +effect 0 +. 0 + +0ver 0 +the 0 +total 0 +postinfusion 0 +period 0 +systolic 0 +and 0 +diastolic 0 +arterial 0 +pressure 0 +were 0 +6 0 +( 0 +SEM 0 +2 0 +) 0 +% 0 +and 0 +7 0 +( 0 +2 0 +) 0 +% 0 +, 0 +respectively 0 +, 0 +higher 0 +than 0 +after 0 +dextrose 1 +infusion 0 +( 0 +AN0VA 0 +, 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +. 0 + +Thus 0 +, 0 +" 0 +stress 0 +" 0 +levels 0 +of 0 +adrenaline 1 +( 0 +230 0 +pg 0 +/ 0 +ml 0 +) 0 +for 0 +6 0 +h 0 +cause 0 +a 0 +delayed 0 +and 0 +protracted 0 +pressor 0 +effect 0 +. 0 + +These 0 +findings 0 +are 0 +strong 0 +support 0 +for 0 +the 0 +adrenaline 1 +- 0 +hypertension 3 +hypothesis 0 +in 0 +man 0 +. 0 + +Effect 0 +of 0 +alkylxanthines 1 +on 0 +gentamicin 1 +- 0 +induced 0 +acute 3 +renal 4 +failure 4 +in 0 +the 0 +rat 0 +. 0 + +Adenosine 1 +antagonists 0 +have 0 +been 0 +previously 0 +shown 0 +to 0 +be 0 +of 0 +benefit 0 +in 0 +some 0 +ischaemic 3 +and 0 +nephrotoxic 3 +models 0 +of 0 +acute 3 +renal 4 +failure 4 +( 0 +ARF 3 +) 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +effects 0 +of 0 +three 0 +alkylxanthines 1 +with 0 +different 0 +potencies 0 +as 0 +adenosine 1 +antagonists 0 +8 1 +- 2 +phenyltheophylline 2 +, 0 +theophylline 1 +and 0 +enprofylline 1 +, 0 +were 0 +examined 0 +in 0 +rats 0 +developing 0 +acute 3 +renal 4 +failure 4 +after 0 +4 0 +daily 0 +injections 0 +of 0 +gentamicin 1 +( 0 +200 0 +mg 0 +kg 0 +- 0 +1 0 +) 0 +. 0 + +Renal 0 +function 0 +was 0 +assessed 0 +by 0 +biochemical 0 +( 0 +plasma 0 +urea 1 +and 0 +creatinine 1 +) 0 +, 0 +functional 0 +( 0 +urine 0 +analysis 0 +and 0 +[ 0 +3H 0 +] 0 +inulin 0 +and 0 +[ 0 +14C 0 +] 0 +p 1 +- 2 +aminohippuric 2 +acid 2 +clearances 0 +) 0 +and 0 +morphological 0 +( 0 +degree 0 +of 0 +necrosis 3 +) 0 +indices 0 +. 0 + +The 0 +various 0 +drug 0 +treatments 0 +produced 0 +improvements 0 +in 0 +some 0 +, 0 +but 0 +not 0 +all 0 +, 0 +measurements 0 +of 0 +renal 0 +function 0 +. 0 + +However 0 +, 0 +any 0 +improvement 0 +produced 0 +by 0 +drug 0 +treatment 0 +was 0 +largely 0 +a 0 +result 0 +of 0 +a 0 +beneficial 0 +effect 0 +exerted 0 +by 0 +its 0 +vehicle 0 +( 0 +polyethylene 1 +glycol 2 +and 0 +Na0H 1 +) 0 +. 0 + +The 0 +lack 0 +of 0 +any 0 +consistent 0 +protective 0 +effect 0 +noted 0 +with 0 +the 0 +alkylxanthines 1 +tested 0 +in 0 +the 0 +present 0 +study 0 +indicates 0 +that 0 +adenosine 1 +plays 0 +little 0 +, 0 +if 0 +any 0 +, 0 +pathophysiological 0 +role 0 +in 0 +gentamicin 1 +- 0 +induced 0 +ARF 3 +. 0 + +Adverse 0 +ocular 0 +reactions 0 +possibly 0 +associated 0 +with 0 +isotretinoin 1 +. 0 + +A 0 +total 0 +of 0 +261 0 +adverse 0 +ocular 0 +reactions 0 +occurred 0 +in 0 +237 0 +patients 0 +who 0 +received 0 +isotretinoin 1 +, 0 +a 0 +commonly 0 +used 0 +drug 0 +in 0 +the 0 +treatment 0 +of 0 +severe 0 +cystic 0 +acne 3 +. 0 + +Blepharoconjunctivitis 3 +, 0 +subjective 0 +complaints 0 +of 0 +dry 3 +eyes 4 +, 0 +blurred 3 +vision 4 +, 0 +contact 0 +lens 0 +intolerance 0 +, 0 +and 0 +photodermatitis 3 +are 0 +reversible 0 +side 0 +effects 0 +. 0 + +More 0 +serious 0 +ocular 0 +adverse 0 +reactions 0 +include 0 +papilledema 3 +, 0 +pseudotumor 3 +cerebri 4 +, 0 +and 0 +white 0 +or 0 +gray 0 +subepithelial 0 +corneal 3 +opacities 4 +; 0 +all 0 +of 0 +these 0 +are 0 +reversible 0 +if 0 +the 0 +drug 0 +is 0 +discontinued 0 +. 0 + +Reported 0 +cases 0 +of 0 +decreased 0 +dark 0 +adaptation 0 +are 0 +under 0 +investigation 0 +. 0 + +Isotretinoin 1 +is 0 +contraindicated 0 +in 0 +pregnancy 0 +because 0 +of 0 +the 0 +many 0 +reported 0 +congenital 3 +abnormalities 4 +after 0 +maternal 0 +use 0 +( 0 +including 0 +microphthalmos 3 +, 0 +orbital 0 +hypertelorism 3 +, 0 +and 0 +optic 3 +nerve 4 +hypoplasia 4 +) 0 +. 0 + +Procaterol 1 +and 0 +terbutaline 1 +in 0 +bronchial 3 +asthma 4 +. 0 + +A 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +cross 0 +- 0 +over 0 +study 0 +. 0 + +Procaterol 1 +, 0 +a 0 +new 0 +beta 0 +- 0 +2 0 +adrenoceptor 0 +stimulant 0 +, 0 +was 0 +studied 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +, 0 +cross 0 +- 0 +over 0 +trial 0 +in 0 +patients 0 +with 0 +bronchial 3 +asthma 4 +. 0 + +0ral 0 +procaterol 1 +50 0 +micrograms 0 +b 0 +. 0 +d 0 +. 0 +, 0 +procaterol 1 +100 0 +micrograms 0 +b 0 +. 0 +d 0 +. 0 +, 0 +and 0 +terbutaline 1 +5 0 +mg 0 +t 0 +. 0 +i 0 +. 0 +d 0 +. 0 +, 0 +were 0 +compared 0 +when 0 +given 0 +randomly 0 +in 0 +1 0 +- 0 +week 0 +treatment 0 +periods 0 +. 0 + +The 0 +best 0 +clinical 0 +effect 0 +was 0 +found 0 +with 0 +terbutaline 1 +. 0 + +Both 0 +anti 0 +- 0 +asthmatic 3 +and 0 +tremorgenic 3 +effects 0 +of 0 +procaterol 1 +were 0 +dose 0 +- 0 +related 0 +. 0 + +Procaterol 1 +appeared 0 +effective 0 +in 0 +the 0 +doses 0 +tested 0 +, 0 +and 0 +a 0 +twice 0 +daily 0 +regimen 0 +would 0 +appear 0 +to 0 +be 0 +suitable 0 +with 0 +this 0 +drug 0 +. 0 + +Subacute 0 +effects 0 +of 0 +propranolol 1 +and 0 +B 0 +24 0 +/ 0 +76 0 +on 0 +isoproterenol 1 +- 0 +induced 0 +rat 0 +heart 3 +hypertrophy 4 +in 0 +correlation 0 +with 0 +blood 0 +pressure 0 +. 0 + +We 0 +compared 0 +the 0 +potential 0 +beta 0 +- 0 +receptor 0 +blocker 0 +, 0 +B 0 +24 0 +/ 0 +76 0 +i 0 +. 0 +e 0 +. 0 +1 0 +- 0 +( 0 +2 0 +, 0 +4 0 +- 0 +dichlorophenoxy 0 +) 0 +- 0 +3 0 +[ 0 +2 0 +- 0 +3 0 +, 0 +4 0 +- 0 +dimethoxyphenyl 0 +) 0 +ethanolamino 0 +] 0 +- 0 +prop 0 +an 0 +- 0 +2 0 +- 0 +ol 0 +, 0 +which 0 +is 0 +characterized 0 +by 0 +beta 0 +1 0 +- 0 +adrenoceptor 0 +blocking 0 +and 0 +beta 0 +2 0 +- 0 +adrenoceptor 0 +stimulating 0 +properties 0 +with 0 +propranolol 1 +. 0 + +The 0 +studies 0 +were 0 +performed 0 +using 0 +an 0 +experimental 0 +model 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +heart 3 +hypertrophy 4 +in 0 +rats 0 +. 0 + +A 0 +correlation 0 +of 0 +the 0 +blood 0 +pressure 0 +was 0 +neither 0 +found 0 +in 0 +the 0 +development 0 +nor 0 +in 0 +the 0 +attempt 0 +to 0 +suppress 0 +the 0 +development 0 +of 0 +heart 3 +hypertrophy 4 +with 0 +the 0 +two 0 +beta 0 +- 0 +receptor 0 +blockers 0 +. 0 + +Both 0 +beta 0 +- 0 +blockers 0 +influenced 0 +the 0 +development 0 +of 0 +hypertrophy 3 +to 0 +a 0 +different 0 +, 0 +but 0 +not 0 +reproducible 0 +extent 0 +. 0 + +It 0 +was 0 +possible 0 +to 0 +suppress 0 +the 0 +increased 0 +ornithine 1 +decarboxylase 0 +activity 0 +with 0 +both 0 +beta 0 +- 0 +blockers 0 +in 0 +hypertrophied 3 +hearts 4 +, 0 +but 0 +there 0 +was 0 +no 0 +effect 0 +on 0 +the 0 +heart 0 +mass 0 +. 0 + +Neither 0 +propranolol 1 +nor 0 +B 0 +24 0 +/ 0 +76 0 +could 0 +stop 0 +the 0 +changes 0 +in 0 +the 0 +characteristic 0 +myosin 0 +isoenzyme 0 +pattern 0 +of 0 +the 0 +hypertrophied 3 +rat 0 +heart 0 +. 0 + +Thus 0 +, 0 +the 0 +investigations 0 +did 0 +not 0 +provide 0 +any 0 +evidence 0 +that 0 +the 0 +beta 0 +- 0 +receptor 0 +blockers 0 +propranolol 1 +and 0 +B 0 +24 0 +/ 0 +76 0 +have 0 +the 0 +potency 0 +to 0 +prevent 0 +isoproterenol 1 +from 0 +producing 0 +heart 3 +hypertrophy 4 +. 0 + +Increased 0 +anxiogenic 0 +effects 0 +of 0 +caffeine 1 +in 0 +panic 3 +disorders 4 +. 0 + +The 0 +effects 0 +of 0 +oral 0 +administration 0 +of 0 +caffeine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +on 0 +behavioral 0 +ratings 0 +, 0 +somatic 0 +symptoms 0 +, 0 +blood 0 +pressure 0 +and 0 +plasma 0 +levels 0 +of 0 +3 1 +- 2 +methoxy 2 +- 2 +4 2 +- 2 +hydroxyphenethyleneglycol 2 +( 0 +MHPG 1 +) 0 +and 0 +cortisol 1 +were 0 +determined 0 +in 0 +17 0 +healthy 0 +subjects 0 +and 0 +21 0 +patients 0 +meeting 0 +DSM 0 +- 0 +III 0 +criteria 0 +for 0 +agoraphobia 3 +with 0 +panic 3 +attacks 4 +or 0 +panic 3 +disorder 4 +. 0 + +Caffeine 1 +produced 0 +significantly 0 +greater 0 +increases 0 +in 0 +subject 0 +- 0 +rated 0 +anxiety 3 +, 0 +nervousness 0 +, 0 +fear 0 +, 0 +nausea 3 +, 0 +palpitations 3 +, 0 +restlessness 3 +, 0 +and 0 +tremors 3 +in 0 +the 0 +patients 0 +compared 0 +with 0 +healthy 0 +subjects 0 +. 0 + +In 0 +the 0 +patients 0 +, 0 +but 0 +not 0 +the 0 +healthy 0 +subjects 0 +, 0 +these 0 +symptoms 0 +were 0 +significantly 0 +correlated 0 +with 0 +plasma 0 +caffeine 1 +levels 0 +. 0 + +Seventy 0 +- 0 +one 0 +percent 0 +of 0 +the 0 +patients 0 +reported 0 +that 0 +the 0 +behavioral 0 +effects 0 +of 0 +caffeine 1 +were 0 +similar 0 +to 0 +those 0 +experienced 0 +during 0 +panic 3 +attacks 4 +. 0 + +Caffeine 1 +did 0 +not 0 +alter 0 +plasma 0 +MHPG 1 +levels 0 +in 0 +either 0 +the 0 +healthy 0 +subjects 0 +or 0 +patients 0 +. 0 + +Caffeine 1 +increased 0 +plasma 0 +cortisol 1 +levels 0 +equally 0 +in 0 +the 0 +patient 0 +and 0 +healthy 0 +groups 0 +. 0 + +Because 0 +caffeine 1 +is 0 +an 0 +adenosine 1 +receptor 0 +antagonist 0 +, 0 +these 0 +results 0 +suggest 0 +that 0 +some 0 +panic 3 +disorder 4 +patients 0 +may 0 +have 0 +abnormalities 3 +in 4 +neuronal 4 +systems 4 +involving 0 +adenosine 1 +. 0 + +Patients 0 +with 0 +anxiety 3 +disorders 4 +may 0 +benefit 0 +by 0 +avoiding 0 +caffeine 1 +- 0 +containing 0 +foods 0 +and 0 +beverages 0 +. 0 + +Comparison 0 +of 0 +the 0 +effect 0 +of 0 +oxitropium 1 +bromide 2 +and 0 +of 0 +slow 0 +- 0 +release 0 +theophylline 1 +on 0 +nocturnal 0 +asthma 3 +. 0 + +The 0 +effects 0 +of 0 +a 0 +new 0 +inhaled 0 +antimuscarinic 0 +drug 0 +, 0 +oxitropium 1 +bromide 2 +, 0 +and 0 +of 0 +a 0 +slow 0 +- 0 +release 0 +theophylline 1 +preparation 0 +upon 0 +nocturnal 0 +asthma 3 +were 0 +compared 0 +in 0 +a 0 +placebo 0 +- 0 +controlled 0 +double 0 +- 0 +blind 0 +study 0 +. 0 + +Two 0 +samples 0 +were 0 +studied 0 +: 0 +12 0 +patients 0 +received 0 +oxitropium 1 +at 0 +600 0 +micrograms 0 +( 0 +6 0 +subjects 0 +) 0 +or 0 +at 0 +400 0 +micrograms 0 +t 0 +. 0 +i 0 +. 0 +d 0 +. 0 + +( 0 +6 0 +subjects 0 +) 0 +whereas 0 +11 0 +received 0 +theophylline 1 +at 0 +300 0 +mg 0 +b 0 +. 0 +i 0 +. 0 +d 0 +. 0 + +Morning 0 +dipping 0 +, 0 +assessed 0 +by 0 +the 0 +fall 0 +in 0 +peak 0 +flow 0 +overnight 0 +, 0 +was 0 +significantly 0 +reduced 0 +in 0 +the 0 +periods 0 +when 0 +either 0 +active 0 +drug 0 +was 0 +taken 0 +, 0 +whereas 0 +no 0 +difference 0 +was 0 +noticed 0 +during 0 +the 0 +placebo 0 +administration 0 +. 0 + +No 0 +significant 0 +difference 0 +was 0 +noticed 0 +between 0 +results 0 +obtained 0 +with 0 +either 0 +active 0 +drug 0 +, 0 +as 0 +well 0 +as 0 +with 0 +either 0 +dosage 0 +of 0 +oxitropium 1 +. 0 + +No 0 +subject 0 +reported 0 +side 0 +effects 0 +of 0 +oxitropium 1 +, 0 +as 0 +compared 0 +to 0 +three 0 +subjects 0 +reporting 0 +nausea 3 +, 0 +vomiting 3 +and 0 +tremors 3 +after 0 +theophylline 1 +. 0 + +0xitropium 1 +proves 0 +to 0 +be 0 +a 0 +valuable 0 +alternative 0 +to 0 +theophylline 1 +in 0 +nocturnal 0 +asthma 3 +, 0 +since 0 +it 0 +is 0 +equally 0 +potent 0 +, 0 +safer 0 +and 0 +does 0 +not 0 +require 0 +the 0 +titration 0 +of 0 +dosage 0 +. 0 + +Penicillin 1 +anaphylaxis 3 +. 0 + +A 0 +case 0 +of 0 +oral 0 +penicillin 1 +anaphylaxis 3 +is 0 +described 0 +, 0 +and 0 +the 0 +terminology 0 +, 0 +occurrence 0 +, 0 +clinical 0 +manifestations 0 +, 0 +pathogenesis 0 +, 0 +prevention 0 +, 0 +and 0 +treatment 0 +of 0 +anaphylaxis 3 +are 0 +reviewed 0 +. 0 + +Emergency 0 +physicians 0 +should 0 +be 0 +aware 0 +of 0 +oral 0 +penicillin 1 +anaphylaxis 3 +in 0 +order 0 +to 0 +prevent 0 +its 0 +occurrence 0 +by 0 +prescribing 0 +the 0 +antibiotic 0 +judiciously 0 +and 0 +knowledgeably 0 +and 0 +to 0 +offer 0 +optimal 0 +medical 0 +therapy 0 +once 0 +this 0 +life 0 +- 0 +threatening 0 +reaction 0 +has 0 +begun 0 +. 0 + +Reversible 0 +valproic 1 +acid 2 +- 0 +induced 0 +dementia 3 +: 0 +a 0 +case 0 +report 0 +. 0 + +Reversible 0 +valproic 1 +acid 2 +- 0 +induced 0 +dementia 3 +was 0 +documented 0 +in 0 +a 0 +21 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +epilepsy 3 +who 0 +had 0 +a 0 +3 0 +- 0 +year 0 +history 0 +of 0 +insidious 0 +progressive 0 +decline 0 +in 0 +global 0 +cognitive 0 +abilities 0 +documented 0 +by 0 +serial 0 +neuropsychological 0 +studies 0 +. 0 + +Repeat 0 +neuropsychological 0 +testing 0 +7 0 +weeks 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +revealed 0 +dramatic 0 +improvement 0 +in 0 +IQ 0 +, 0 +memory 0 +, 0 +naming 0 +, 0 +and 0 +other 0 +tasks 0 +commensurate 0 +with 0 +clinical 0 +recovery 0 +in 0 +his 0 +intellectual 0 +capacity 0 +. 0 + +Possible 0 +pathophysiological 0 +mechanisms 0 +which 0 +may 0 +have 0 +been 0 +operative 0 +in 0 +this 0 +case 0 +include 0 +: 0 +a 0 +direct 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +toxic 0 +effect 0 +of 0 +valproic 1 +acid 2 +; 0 +a 0 +paradoxical 0 +epileptogenic 0 +effect 0 +secondary 0 +to 0 +the 0 +drug 0 +; 0 +and 0 +an 0 +indirect 0 +CNS 0 +toxic 0 +effect 0 +mediated 0 +through 0 +valproic 1 +acid 2 +- 0 +induced 0 +hyperammonemia 3 +. 0 + +Reversal 0 +of 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +of 0 +passive 0 +avoidance 0 +by 0 +pre 0 +- 0 +and 0 +post 0 +- 0 +training 0 +naloxone 1 +. 0 + +In 0 +a 0 +series 0 +of 0 +five 0 +experiments 0 +, 0 +the 0 +modulating 0 +role 0 +of 0 +naloxone 1 +on 0 +a 0 +scopolamine 1 +- 0 +induced 0 +retention 3 +deficit 4 +in 0 +a 0 +passive 0 +avoidance 0 +paradigm 0 +was 0 +investigated 0 +in 0 +mice 0 +. 0 + +Scopolamine 1 +, 0 +but 0 +not 0 +methyl 1 +scopolamine 2 +( 0 +1 0 +and 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +induced 0 +an 0 +amnesia 3 +as 0 +measured 0 +by 0 +latency 0 +and 0 +duration 0 +parameters 0 +. 0 + +Naloxone 1 +( 0 +0 0 +. 0 +3 0 +, 0 +1 0 +, 0 +3 0 +, 0 +and 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +injected 0 +prior 0 +to 0 +training 0 +attenuated 0 +the 0 +retention 3 +deficit 4 +with 0 +a 0 +peak 0 +of 0 +activity 0 +at 0 +3 0 +mg 0 +/ 0 +kg 0 +. 0 + +The 0 +effect 0 +of 0 +naloxone 1 +could 0 +be 0 +antagonized 0 +with 0 +morphine 1 +( 0 +1 0 +, 0 +3 0 +, 0 +and 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +, 0 +demonstrating 0 +the 0 +opioid 0 +specificity 0 +of 0 +the 0 +naloxone 1 +effect 0 +. 0 + +Post 0 +- 0 +training 0 +administration 0 +of 0 +naloxone 1 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +as 0 +a 0 +single 0 +or 0 +as 0 +a 0 +split 0 +dose 0 +also 0 +attenuated 0 +the 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +. 0 + +Control 0 +experiments 0 +indicated 0 +that 0 +neither 0 +an 0 +increase 0 +in 0 +pain 3 +sensitivity 0 +( 0 +pre 0 +- 0 +training 0 +naloxone 1 +) 0 +nor 0 +an 0 +induced 0 +aversive 0 +state 0 +( 0 +post 0 +- 0 +training 0 +naloxone 1 +) 0 +appear 0 +to 0 +be 0 +responsible 0 +for 0 +the 0 +influence 0 +of 0 +naloxone 1 +on 0 +the 0 +scopolamine 1 +- 0 +induced 0 +retention 3 +deficit 4 +. 0 + +These 0 +results 0 +extend 0 +previous 0 +findings 0 +implicating 0 +a 0 +cholinergic 0 +- 0 +opioid 0 +interaction 0 +in 0 +memory 0 +processes 0 +. 0 + +A 0 +possible 0 +mechanism 0 +for 0 +this 0 +interaction 0 +involving 0 +the 0 +septo 0 +- 0 +hippocampal 0 +cholinergic 0 +pathway 0 +is 0 +discussed 0 +. 0 + +Electron 0 +microscopic 0 +investigations 0 +of 0 +the 0 +cyclophosphamide 1 +- 0 +induced 0 +lesions 3 +of 4 +the 4 +urinary 4 +bladder 4 +of 0 +the 0 +rat 0 +and 0 +their 0 +prevention 0 +by 0 +mesna 1 +. 0 + +Fully 0 +developed 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +is 0 +characterized 0 +by 0 +nearly 0 +complete 0 +detachment 0 +of 0 +the 0 +urothelium 0 +, 0 +severe 0 +submucosal 0 +edema 3 +owing 0 +to 0 +damage 0 +to 0 +the 0 +microvascular 0 +bed 0 +and 0 +focal 0 +muscle 0 +necroses 3 +. 0 + +The 0 +initial 0 +response 0 +to 0 +the 0 +primary 0 +attack 0 +by 0 +the 0 +cyclophosphamide 1 +metabolites 0 +seems 0 +to 0 +be 0 +fragmentation 0 +of 0 +the 0 +luminal 1 +membrane 0 +. 0 + +This 0 +damages 0 +the 0 +cellular 0 +barrier 0 +against 0 +the 0 +hypertonic 0 +urine 0 +. 0 + +Subsequent 0 +breaks 0 +in 0 +the 0 +lateral 0 +cell 0 +membranes 0 +of 0 +the 0 +superficial 0 +cells 0 +and 0 +in 0 +all 0 +the 0 +plasma 0 +membranes 0 +of 0 +the 0 +intermediate 0 +and 0 +basal 0 +cells 0 +, 0 +intercellular 0 +and 0 +intracellular 0 +edema 3 +and 0 +disintegration 0 +of 0 +the 0 +desmosomes 0 +and 0 +hemidesmosomes 0 +lead 0 +to 0 +progressive 0 +degeneration 0 +and 0 +detachment 0 +of 0 +the 0 +epithelial 0 +cells 0 +with 0 +exposure 0 +and 0 +splitting 0 +of 0 +the 0 +basal 0 +membrane 0 +. 0 + +The 0 +morphological 0 +changes 0 +of 0 +the 0 +endothelial 0 +cells 0 +, 0 +which 0 +become 0 +more 0 +pronounced 0 +in 0 +the 0 +later 0 +stages 0 +of 0 +the 0 +experiment 0 +, 0 +the 0 +involvement 0 +of 0 +blood 0 +vessels 0 +regardless 0 +of 0 +their 0 +diameter 0 +and 0 +the 0 +location 0 +- 0 +dependent 0 +extent 0 +of 0 +the 0 +damage 0 +indicate 0 +a 0 +direct 0 +type 0 +of 0 +damage 0 +which 0 +is 0 +preceded 0 +by 0 +a 0 +mediator 0 +- 0 +induced 0 +increase 0 +in 0 +permeability 0 +, 0 +the 0 +morphological 0 +correlate 0 +of 0 +which 0 +is 0 +the 0 +formation 0 +of 0 +gaps 0 +in 0 +the 0 +interendothelial 0 +cell 0 +connections 0 +on 0 +the 0 +venules 0 +. 0 + +These 0 +changes 0 +can 0 +be 0 +effectively 0 +prevented 0 +by 0 +mesna 1 +. 0 + +The 0 +only 0 +sign 0 +of 0 +a 0 +possible 0 +involvement 0 +is 0 +the 0 +increase 0 +in 0 +the 0 +number 0 +of 0 +specific 0 +granules 0 +with 0 +a 0 +presumed 0 +lysosomal 0 +function 0 +in 0 +the 0 +superficial 0 +cells 0 +. 0 + +Increase 0 +in 0 +intragastric 0 +pressure 0 +during 0 +suxamethonium 1 +- 0 +induced 0 +muscle 3 +fasciculations 4 +in 0 +children 0 +: 0 +inhibition 0 +by 0 +alfentanil 1 +. 0 + +Changes 0 +in 0 +intragastric 0 +pressure 0 +after 0 +the 0 +administration 0 +of 0 +suxamethonium 1 +1 0 +. 0 +5 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +were 0 +studied 0 +in 0 +32 0 +children 0 +( 0 +mean 0 +age 0 +6 0 +. 0 +9 0 +yr 0 +) 0 +pretreated 0 +with 0 +either 0 +physiological 0 +saline 0 +or 0 +alfentanil 1 +50 0 +micrograms 0 +kg 0 +- 0 +1 0 +. 0 + +Anaesthesia 0 +was 0 +induced 0 +with 0 +thiopentone 1 +5 0 +mg 0 +kg 0 +- 0 +1 0 +. 0 + +The 0 +incidence 0 +and 0 +intensity 0 +of 0 +muscle 3 +fasciculations 4 +caused 0 +by 0 +suxamethonium 1 +were 0 +significantly 0 +greater 0 +in 0 +the 0 +control 0 +than 0 +in 0 +the 0 +alfentanil 1 +group 0 +. 0 + +The 0 +intragastric 0 +pressure 0 +during 0 +muscle 3 +fasciculations 4 +was 0 +significantly 0 +higher 0 +in 0 +the 0 +control 0 +group 0 +( 0 +16 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +( 0 +SEM 0 +) 0 +cm 0 +H20 1 +) 0 +than 0 +in 0 +the 0 +alfentanil 1 +group 0 +( 0 +7 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +( 0 +SEM 0 +) 0 +cm 0 +H20 1 +) 0 +. 0 + +The 0 +increase 0 +in 0 +intragastric 0 +pressure 0 +was 0 +directly 0 +related 0 +to 0 +the 0 +intensity 0 +of 0 +muscle 3 +fasciculations 4 +( 0 +regression 0 +line 0 +: 0 +y 0 += 0 +0 0 +. 0 +5 0 ++ 0 +4 0 +. 0 +78x 0 +with 0 +r 0 +of 0 +0 0 +. 0 +78 0 +) 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +intragastric 0 +pressure 0 +increases 0 +significantly 0 +during 0 +muscle 3 +fasciculations 4 +caused 0 +by 0 +suxamethonium 1 +in 0 +healthy 0 +children 0 +. 0 + +Alfentanil 1 +50 0 +micrograms 0 +kg 0 +- 0 +1 0 +effectively 0 +inhibits 0 +the 0 +incidence 0 +and 0 +intensity 0 +of 0 +suxamethonium 1 +- 0 +induced 0 +muscle 3 +fasciculations 4 +; 0 +moreover 0 +, 0 +intragastric 0 +pressure 0 +remains 0 +at 0 +its 0 +control 0 +value 0 +. 0 + +Acute 0 +insulin 0 +treatment 0 +normalizes 0 +the 0 +resistance 0 +to 0 +the 0 +cardiotoxic 3 +effect 0 +of 0 +isoproterenol 1 +in 0 +streptozotocin 1 +diabetic 3 +rats 0 +. 0 + +A 0 +morphometric 0 +study 0 +of 0 +isoproterenol 1 +induced 0 +myocardial 0 +fibrosis 3 +. 0 + +The 0 +acute 0 +effect 0 +of 0 +insulin 0 +treatment 0 +on 0 +the 0 +earlier 0 +reported 0 +protective 0 +effect 0 +of 0 +streptozotocin 1 +diabetes 3 +against 0 +the 0 +cardiotoxic 3 +effect 0 +of 0 +high 0 +doses 0 +of 0 +isoproterenol 1 +( 0 +IS0 1 +) 0 +was 0 +investigated 0 +in 0 +rats 0 +. 0 + +Thirty 0 +to 0 +135 0 +min 0 +after 0 +the 0 +injection 0 +of 0 +crystalline 0 +insulin 0 +, 0 +IS0 1 +was 0 +given 0 +subcutaneously 0 +and 0 +when 0 +IS0 1 +induced 0 +fibrosis 3 +in 0 +the 0 +myocardium 0 +was 0 +morphometrically 0 +analyzed 0 +7 0 +days 0 +later 0 +, 0 +a 0 +highly 0 +significant 0 +correlation 0 +( 0 +r 0 += 0 +0 0 +. 0 +83 0 +, 0 +2 0 +p 0 += 0 +0 0 +. 0 +006 0 +) 0 +to 0 +the 0 +slope 0 +of 0 +the 0 +fall 0 +in 0 +blood 0 +glucose 1 +after 0 +insulin 0 +treatment 0 +appeared 0 +. 0 + +The 0 +myocardial 0 +content 0 +of 0 +catecholamines 1 +was 0 +estimated 0 +in 0 +these 0 +8 0 +day 0 +diabetic 3 +rats 0 +. 0 + +The 0 +norepinephrine 1 +content 0 +was 0 +significantly 0 +increased 0 +while 0 +epinephrine 1 +remained 0 +unchanged 0 +. 0 + +An 0 +enhanced 0 +sympathetic 0 +nervous 0 +system 0 +activity 0 +with 0 +a 0 +consequent 0 +down 0 +regulation 0 +of 0 +the 0 +myocardial 0 +beta 0 +- 0 +adrenergic 0 +receptors 0 +could 0 +, 0 +therefore 0 +, 0 +explain 0 +this 0 +catecholamine 1 +resistance 0 +. 0 + +The 0 +rapid 0 +reversion 0 +after 0 +insulin 0 +treatment 0 +excludes 0 +the 0 +possibility 0 +that 0 +streptozotocin 1 +in 0 +itself 0 +causes 0 +the 0 +IS0 1 +resistance 0 +and 0 +points 0 +towards 0 +a 0 +direct 0 +insulin 0 +effect 0 +on 0 +myocardial 0 +catecholamine 1 +sensitivity 0 +in 0 +diabetic 3 +rats 0 +. 0 + +The 0 +phenomenon 0 +described 0 +might 0 +elucidate 0 +pathogenetic 0 +mechanisms 0 +behind 0 +toxic 0 +myocardial 0 +cell 0 +degeneration 0 +and 0 +may 0 +possibly 0 +have 0 +relevance 0 +for 0 +acute 0 +cardiovascular 0 +complications 0 +in 0 +diabetic 3 +patients 0 +. 0 + +Differential 0 +effects 0 +of 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +on 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +in 0 +rats 0 +. 0 + +The 0 +muscarinic 0 +cholinergic 0 +agonist 0 +pilocarpine 1 +induces 0 +in 0 +rats 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +followed 0 +by 0 +widespread 0 +damage 0 +to 0 +the 0 +forebrain 0 +. 0 + +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +investigate 0 +the 0 +effect 0 +of 0 +5 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +, 0 +sodium 1 +salicylate 2 +, 0 +phenylbutazone 1 +, 0 +indomethacin 1 +, 0 +ibuprofen 1 +and 0 +mefenamic 1 +acid 2 +, 0 +on 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +. 0 + +Pretreatment 0 +of 0 +rats 0 +with 0 +sodium 1 +salicylate 2 +, 0 +ED50 0 +103 0 +mg 0 +/ 0 +kg 0 +( 0 +60 0 +- 0 +174 0 +) 0 +, 0 +and 0 +phenylbutazone 1 +, 0 +59 0 +mg 0 +/ 0 +kg 0 +( 0 +50 0 +- 0 +70 0 +) 0 +converted 0 +the 0 +non 0 +- 0 +convulsant 0 +dose 0 +of 0 +pilocarpine 1 +, 0 +200 0 +mg 0 +/ 0 +kg 0 +, 0 +to 0 +a 0 +convulsant 0 +one 0 +. 0 + +Indomethacin 1 +, 0 +1 0 +- 0 +10 0 +mg 0 +/ 0 +kg 0 +, 0 +and 0 +ibuprofen 1 +, 0 +10 0 +- 0 +100 0 +mg 0 +/ 0 +kg 0 +, 0 +failed 0 +to 0 +modulate 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +. 0 + +Mefenamic 1 +acid 2 +, 0 +26 0 +( 0 +22 0 +- 0 +30 0 +) 0 +mg 0 +/ 0 +kg 0 +, 0 +prevented 0 +seizures 3 +and 0 +protected 0 +rats 0 +from 0 +seizure 3 +- 0 +related 0 +brain 3 +damage 4 +induced 0 +by 0 +pilocarpine 1 +, 0 +380 0 +mg 0 +/ 0 +kg 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +drugs 0 +differentially 0 +modulate 0 +the 0 +threshold 0 +for 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 + +Acute 3 +neurologic 4 +dysfunction 4 +after 0 +high 0 +- 0 +dose 0 +etoposide 1 +therapy 0 +for 0 +malignant 3 +glioma 4 +. 0 + +Etoposide 1 +( 0 +VP 1 +- 2 +16 2 +- 2 +213 2 +) 0 +has 0 +been 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +many 0 +solid 0 +tumors 3 +and 0 +hematologic 3 +malignancies 4 +. 0 + +When 0 +used 0 +in 0 +high 0 +doses 0 +and 0 +in 0 +conjunction 0 +with 0 +autologous 0 +bone 0 +marrow 0 +transplantation 0 +, 0 +this 0 +agent 0 +has 0 +activity 0 +against 0 +several 0 +treatment 0 +- 0 +resistant 0 +cancers 3 +including 0 +malignant 3 +glioma 4 +. 0 + +In 0 +six 0 +of 0 +eight 0 +patients 0 +( 0 +75 0 +% 0 +) 0 +who 0 +we 0 +treated 0 +for 0 +recurrent 0 +or 0 +resistant 0 +glioma 3 +, 0 +sudden 0 +severe 0 +neurologic 3 +deterioration 4 +occurred 0 +. 0 + +This 0 +developed 0 +a 0 +median 0 +of 0 +9 0 +days 0 +after 0 +initiation 0 +of 0 +high 0 +- 0 +dose 0 +etoposide 1 +therapy 0 +. 0 + +Significant 0 +clinical 0 +manifestations 0 +have 0 +included 0 +confusion 3 +, 0 +papilledema 3 +, 0 +somnolence 3 +, 0 +exacerbation 0 +of 0 +motor 3 +deficits 4 +, 0 +and 0 +sharp 0 +increase 0 +in 0 +seizure 3 +activity 0 +. 0 + +These 0 +abnormalities 0 +resolved 0 +rapidly 0 +after 0 +initiation 0 +of 0 +high 0 +- 0 +dose 0 +intravenous 0 +dexamethasone 1 +therapy 0 +. 0 + +In 0 +all 0 +patients 0 +, 0 +computerized 0 +tomographic 0 +( 0 +CT 0 +) 0 +brain 0 +scans 0 +demonstrated 0 +stability 0 +in 0 +tumor 3 +size 0 +and 0 +peritumor 0 +edema 3 +when 0 +compared 0 +with 0 +pretransplant 0 +scans 0 +. 0 + +This 0 +complication 0 +appears 0 +to 0 +represent 0 +a 0 +significant 0 +new 0 +toxicity 3 +of 0 +high 0 +- 0 +dose 0 +etoposide 1 +therapy 0 +for 0 +malignant 3 +glioma 4 +. 0 + +Progressive 0 +bile 3 +duct 4 +injury 4 +after 0 +thiabendazole 1 +administration 0 +. 0 + +A 0 +27 0 +- 0 +yr 0 +- 0 +old 0 +man 0 +developed 0 +jaundice 3 +2 0 +wk 0 +after 0 +exposure 0 +to 0 +thiabendazole 1 +. 0 + +Cholestasis 3 +persisted 0 +for 0 +3 0 +yr 0 +, 0 +at 0 +which 0 +time 0 +a 0 +liver 0 +transplant 0 +was 0 +performed 0 +. 0 + +Two 0 +liver 0 +biopsy 0 +specimens 0 +and 0 +the 0 +hepatectomy 0 +specimen 0 +were 0 +remarkable 0 +for 0 +almost 0 +complete 0 +disappearance 0 +of 0 +interlobular 0 +bile 0 +ducts 0 +. 0 + +Prominent 0 +fibrosis 3 +and 0 +hepatocellular 0 +regeneration 0 +were 0 +also 0 +present 0 +; 0 +however 0 +, 0 +the 0 +lobular 0 +architecture 0 +was 0 +preserved 0 +. 0 + +This 0 +case 0 +represents 0 +an 0 +example 0 +of 0 +" 0 +idiosyncratic 0 +" 0 +drug 3 +- 4 +induced 4 +liver 4 +damage 4 +in 0 +which 0 +the 0 +primary 0 +target 0 +of 0 +injury 0 +is 0 +the 0 +bile 0 +duct 0 +. 0 + +An 0 +autoimmune 0 +pathogenesis 0 +of 0 +the 0 +bile 3 +duct 4 +destruction 4 +is 0 +suggested 0 +. 0 + +Differential 0 +effects 0 +of 0 +1 1 +, 2 +4 2 +- 2 +dihydropyridine 2 +calcium 1 +channel 2 +blockers 2 +: 0 +therapeutic 0 +implications 0 +. 0 + +Increasing 0 +recognition 0 +of 0 +the 0 +importance 0 +of 0 +calcium 1 +in 0 +the 0 +pathogenesis 0 +of 0 +cardiovascular 3 +disease 4 +has 0 +stimulated 0 +research 0 +into 0 +the 0 +use 0 +of 0 +calcium 1 +channel 2 +blocking 2 +agents 2 +for 0 +treatment 0 +of 0 +a 0 +variety 0 +of 0 +cardiovascular 3 +diseases 4 +. 0 + +The 0 +favorable 0 +efficacy 0 +and 0 +tolerability 0 +profiles 0 +of 0 +these 0 +agents 0 +make 0 +them 0 +attractive 0 +therapeutic 0 +modalities 0 +. 0 + +Clinical 0 +applications 0 +of 0 +calcium 1 +channel 2 +blockers 2 +parallel 0 +their 0 +tissue 0 +selectivity 0 +. 0 + +In 0 +contrast 0 +to 0 +verapamil 1 +and 0 +diltiazem 1 +, 0 +which 0 +are 0 +roughly 0 +equipotent 0 +in 0 +their 0 +actions 0 +on 0 +the 0 +heart 0 +and 0 +vascular 0 +smooth 0 +muscle 0 +, 0 +the 0 +dihydropyridine 1 +calcium 1 +channel 2 +blockers 2 +are 0 +a 0 +group 0 +of 0 +potent 0 +peripheral 0 +vasodilator 0 +agents 0 +that 0 +exert 0 +minimal 0 +electrophysiologic 0 +effects 0 +on 0 +cardiac 0 +nodal 0 +or 0 +conduction 0 +tissue 0 +. 0 + +As 0 +the 0 +first 0 +dihydropyridine 1 +available 0 +for 0 +use 0 +in 0 +the 0 +United 0 +States 0 +, 0 +nifedipine 1 +controls 0 +angina 3 +and 0 +hypertension 3 +with 0 +minimal 0 +depression 0 +of 0 +cardiac 0 +function 0 +. 0 + +Additional 0 +members 0 +of 0 +this 0 +group 0 +of 0 +calcium 1 +channel 2 +blockers 2 +have 0 +been 0 +studied 0 +for 0 +a 0 +variety 0 +of 0 +indications 0 +for 0 +which 0 +they 0 +may 0 +offer 0 +advantages 0 +over 0 +current 0 +therapy 0 +. 0 + +0nce 0 +or 0 +twice 0 +daily 0 +dosage 0 +possible 0 +with 0 +nitrendipine 1 +and 0 +nisoldipine 1 +offers 0 +a 0 +convenient 0 +administration 0 +schedule 0 +, 0 +which 0 +encourages 0 +patient 0 +compliance 0 +in 0 +long 0 +- 0 +term 0 +therapy 0 +of 0 +hypertension 3 +. 0 + +The 0 +coronary 0 +vasodilating 0 +properties 0 +of 0 +nisoldipine 1 +have 0 +led 0 +to 0 +the 0 +investigation 0 +of 0 +this 0 +agent 0 +for 0 +use 0 +in 0 +angina 3 +. 0 + +Selectivity 0 +for 0 +the 0 +cerebrovascular 0 +bed 0 +makes 0 +nimodipine 1 +potentially 0 +useful 0 +in 0 +the 0 +treatment 0 +of 0 +subarachnoid 3 +hemorrhage 4 +, 0 +migraine 3 +headache 4 +, 0 +dementia 3 +, 0 +and 0 +stroke 3 +. 0 + +In 0 +general 0 +, 0 +the 0 +dihydropyridine 1 +calcium 1 +channel 2 +blockers 2 +are 0 +usually 0 +well 0 +tolerated 0 +, 0 +with 0 +headache 3 +, 0 +facial 0 +flushing 3 +, 0 +palpitations 3 +, 0 +edema 3 +, 0 +nausea 3 +, 0 +anorexia 3 +, 0 +and 0 +dizziness 3 +being 0 +the 0 +more 0 +common 0 +adverse 0 +effects 0 +. 0 + +The 0 +enhancement 0 +of 0 +aminonucleoside 1 +nephrosis 3 +by 0 +the 0 +co 0 +- 0 +administration 0 +of 0 +protamine 0 +. 0 + +An 0 +experimental 0 +model 0 +of 0 +focal 3 +segmental 4 +glomerular 4 +sclerosis 4 +( 0 +FSGS 3 +) 0 +was 0 +developed 0 +in 0 +rats 0 +by 0 +the 0 +combined 0 +administration 0 +of 0 +puromycin 1 +- 2 +aminonucleoside 2 +( 0 +AMNS 1 +) 0 +and 0 +protamine 1 +sulfate 2 +( 0 +PS 1 +) 0 +. 0 + +Male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +, 0 +uninephrectomized 0 +three 0 +weeks 0 +before 0 +, 0 +received 0 +daily 0 +injections 0 +of 0 +subcutaneous 0 +AMNS 1 +( 0 +1 0 +mg 0 +/ 0 +100 0 +g 0 +body 0 +wt 0 +) 0 +and 0 +intravenous 0 +PS 1 +( 0 +2 0 +separated 0 +doses 0 +of 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +100 0 +g 0 +body 0 +wt 0 +) 0 +for 0 +four 0 +days 0 +. 0 + +The 0 +series 0 +of 0 +injections 0 +were 0 +repeated 0 +another 0 +three 0 +times 0 +at 0 +10 0 +day 0 +intervals 0 +. 0 + +The 0 +animals 0 +were 0 +sacrificed 0 +on 0 +days 0 +24 0 +, 0 +52 0 +, 0 +and 0 +80 0 +. 0 + +They 0 +developed 0 +nephrotic 3 +syndrome 4 +and 0 +finally 0 +renal 3 +failure 4 +. 0 + +The 0 +time 0 +- 0 +course 0 +curve 0 +of 0 +creatinine 1 +clearance 0 +dropped 0 +and 0 +showed 0 +significant 0 +difference 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +from 0 +that 0 +of 0 +each 0 +control 0 +group 0 +, 0 +such 0 +as 0 +, 0 +AMNS 1 +alone 0 +, 0 +PS 1 +alone 0 +or 0 +saline 0 +injected 0 +. 0 + +Their 0 +glomeruli 0 +showed 0 +changes 0 +of 0 +progressive 0 +FSGS 3 +. 0 + +The 0 +ultrastructural 0 +studies 0 +in 0 +the 0 +initial 0 +stage 0 +revealed 0 +significant 0 +lack 0 +of 0 +particles 0 +of 0 +perfused 0 +ruthenium 1 +red 0 +on 0 +the 0 +lamina 0 +rara 0 +externa 0 +and 0 +marked 0 +changes 0 +in 0 +epithelial 0 +cell 0 +cytoplasm 0 +. 0 + +Therefore 0 +, 0 +it 0 +is 0 +suggested 0 +that 0 +the 0 +administration 0 +of 0 +PS 1 +enhances 0 +the 0 +toxicity 3 +of 0 +AMNS 1 +on 0 +the 0 +glomerulus 0 +and 0 +readily 0 +produces 0 +progressive 0 +FSGS 3 +in 0 +rats 0 +resulting 0 +in 0 +the 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +. 0 + +Theophylline 1 +neurotoxicity 3 +in 0 +pregnant 0 +rats 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +investigation 0 +was 0 +to 0 +determine 0 +whether 0 +the 0 +neurotoxicity 3 +of 0 +theophylline 1 +is 0 +altered 0 +in 0 +advanced 0 +pregnancy 0 +. 0 + +Sprague 0 +- 0 +Dawley 0 +rats 0 +that 0 +were 0 +20 0 +days 0 +pregnant 0 +and 0 +nonpregnant 0 +rats 0 +of 0 +the 0 +same 0 +age 0 +and 0 +strain 0 +received 0 +infusions 0 +of 0 +aminophylline 1 +until 0 +onset 0 +of 0 +maximal 0 +seizures 3 +which 0 +occurred 0 +after 0 +28 0 +and 0 +30 0 +minutes 0 +respectively 0 +. 0 + +Theophylline 1 +concentrations 0 +at 0 +this 0 +endpoint 0 +in 0 +serum 0 +( 0 +total 0 +) 0 +and 0 +CSF 0 +were 0 +similar 0 +but 0 +serum 0 +( 0 +free 0 +) 0 +and 0 +brain 0 +concentrations 0 +were 0 +slightly 0 +different 0 +in 0 +pregnant 0 +rats 0 +. 0 + +Theophylline 1 +serum 0 +protein 0 +binding 0 +determined 0 +by 0 +equilibrium 0 +dialysis 0 +was 0 +lower 0 +in 0 +pregnant 0 +rats 0 +. 0 + +Fetal 0 +serum 0 +concentrations 0 +at 0 +onset 0 +of 0 +seizures 3 +in 0 +the 0 +mother 0 +were 0 +similar 0 +to 0 +maternal 0 +brain 0 +and 0 +CSF 0 +concentrations 0 +and 0 +correlated 0 +significantly 0 +with 0 +the 0 +former 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +advanced 0 +pregnancy 0 +has 0 +a 0 +negligible 0 +effect 0 +on 0 +the 0 +neurotoxic 3 +response 0 +to 0 +theophylline 1 +in 0 +rats 0 +. 0 + +Hyperkalemia 3 +induced 0 +by 0 +indomethacin 1 +and 0 +naproxen 1 +and 0 +reversed 0 +by 0 +fludrocortisone 1 +. 0 + +We 0 +have 0 +described 0 +a 0 +patient 0 +with 0 +severe 0 +rheumatoid 3 +arthritis 4 +and 0 +a 0 +history 0 +of 0 +mefenamic 1 +acid 2 +nephropathy 3 +in 0 +whom 0 +hyperkalemia 3 +and 0 +inappropriate 0 +hypoaldosteronism 3 +were 0 +caused 0 +by 0 +both 0 +indomethacin 1 +and 0 +naproxen 1 +, 0 +without 0 +major 0 +decline 0 +in 0 +renal 0 +function 0 +. 0 + +It 0 +is 0 +likely 0 +that 0 +preexisting 0 +renal 3 +disease 4 +predisposed 0 +this 0 +patient 0 +to 0 +type 3 +IV 4 +renal 4 +tubular 4 +acidosis 4 +with 0 +prostaglandin 1 +synthetase 0 +inhibitors 0 +. 0 + +Because 0 +he 0 +was 0 +unable 0 +to 0 +discontinue 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +drug 0 +therapy 0 +, 0 +fludrocortisone 1 +was 0 +added 0 +, 0 +correcting 0 +the 0 +hyperkalemia 3 +and 0 +allowing 0 +indomethacin 1 +therapy 0 +to 0 +be 0 +continued 0 +safely 0 +. 0 + +Hypotension 3 +as 0 +a 0 +manifestation 0 +of 0 +cardiotoxicity 3 +in 0 +three 0 +patients 0 +receiving 0 +cisplatin 1 +and 0 +5 1 +- 2 +fluorouracil 2 +. 0 + +Cardiac 0 +symptoms 0 +, 0 +including 0 +hypotension 3 +, 0 +developed 0 +in 0 +three 0 +patients 0 +with 0 +advanced 0 +colorectal 3 +carcinoma 4 +while 0 +being 0 +treated 0 +with 0 +cisplatin 1 +( 0 +CDDP 1 +) 0 +and 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +. 0 + +In 0 +two 0 +patients 0 +, 0 +hypotension 3 +was 0 +associated 0 +with 0 +severe 0 +left 3 +ventricular 4 +dysfunction 4 +. 0 + +All 0 +three 0 +patients 0 +required 0 +therapy 0 +discontinuation 0 +. 0 + +Cardiac 0 +enzymes 0 +remained 0 +normal 0 +despite 0 +transient 0 +electrocardiographic 0 +( 0 +EKG 0 +) 0 +changes 0 +. 0 + +The 0 +presentation 0 +and 0 +cardiac 0 +evaluation 0 +( 0 +hemodynamic 0 +, 0 +echocardiographic 0 +, 0 +and 0 +scintigraphic 0 +) 0 +of 0 +these 0 +patients 0 +suggest 0 +new 0 +manifestations 0 +of 0 +5 1 +- 2 +FU 2 +cardiotoxicity 3 +that 0 +may 0 +be 0 +influenced 0 +by 0 +CDDP 1 +. 0 + +The 0 +possible 0 +pathophysiologic 0 +mechanisms 0 +are 0 +discussed 0 +. 0 + +Fatal 0 +aplastic 3 +anemia 4 +in 0 +a 0 +patient 0 +treated 0 +with 0 +carbamazepine 1 +. 0 + +A 0 +case 0 +of 0 +fatal 0 +aplastic 3 +anemia 4 +due 0 +to 0 +carbamazepine 1 +treatment 0 +in 0 +an 0 +epileptic 3 +woman 0 +is 0 +reported 0 +. 0 + +Despite 0 +concerns 0 +of 0 +fatal 0 +bone 3 +marrow 4 +toxicity 4 +due 0 +to 0 +carbamazepine 1 +, 0 +this 0 +is 0 +only 0 +the 0 +fourth 0 +documented 0 +and 0 +published 0 +report 0 +. 0 + +Carbamazepine 1 +is 0 +a 0 +safe 0 +drug 0 +, 0 +but 0 +physicians 0 +and 0 +patients 0 +should 0 +be 0 +aware 0 +of 0 +the 0 +exceedingly 0 +rare 0 +but 0 +potentially 0 +fatal 0 +side 0 +effects 0 +, 0 +better 0 +prevented 0 +by 0 +clinical 0 +than 0 +by 0 +laboratory 0 +monitoring 0 +. 0 + +Participation 0 +of 0 +a 0 +bulbospinal 0 +serotonergic 0 +pathway 0 +in 0 +the 0 +rat 0 +brain 0 +in 0 +clonidine 1 +- 0 +induced 0 +hypotension 3 +and 0 +bradycardia 3 +. 0 + +The 0 +effects 0 +of 0 +microinjection 0 +of 0 +clonidine 1 +( 0 +1 0 +- 0 +10 0 +micrograms 0 +in 0 +1 0 +microliter 0 +) 0 +into 0 +a 0 +region 0 +adjacent 0 +to 0 +the 0 +ventrolateral 0 +surface 0 +of 0 +the 0 +medulla 0 +oblongata 0 +on 0 +cardiovascular 0 +function 0 +were 0 +assessed 0 +in 0 +urethane 1 +- 0 +anesthetized 0 +rats 0 +. 0 + +Intramedullary 0 +administration 0 +of 0 +clonidine 1 +, 0 +but 0 +not 0 +saline 0 +vehicle 0 +, 0 +caused 0 +a 0 +dose 0 +- 0 +dependent 0 +decrease 0 +in 0 +both 0 +the 0 +mean 0 +arterial 0 +pressure 0 +and 0 +the 0 +heart 0 +rate 0 +. 0 + +The 0 +clonidine 1 +- 0 +induced 0 +hypotension 3 +was 0 +antagonized 0 +by 0 +prior 0 +spinal 0 +transection 0 +, 0 +but 0 +not 0 +bilateral 0 +vagotomy 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +the 0 +clonidine 1 +- 0 +induced 0 +bradycardia 3 +was 0 +antagonized 0 +by 0 +prior 0 +bilateral 0 +vagotomy 0 +, 0 +but 0 +not 0 +spinal 0 +transection 0 +. 0 + +Furthermore 0 +, 0 +selective 0 +destruction 0 +of 0 +the 0 +spinal 0 +5 1 +- 2 +HT 2 +nerves 0 +, 0 +produced 0 +by 0 +bilateral 0 +spinal 0 +injection 0 +of 0 +5 1 +, 2 +7 2 +- 2 +dihydroxytryptamine 2 +, 0 +reduced 0 +the 0 +magnitude 0 +of 0 +the 0 +vasodepressor 0 +or 0 +the 0 +bradycardiac 3 +responses 0 +to 0 +clonidine 1 +microinjected 0 +into 0 +the 0 +area 0 +near 0 +the 0 +ventrolateral 0 +surface 0 +of 0 +the 0 +medulla 0 +oblongata 0 +in 0 +rats 0 +. 0 + +The 0 +data 0 +indicate 0 +that 0 +a 0 +bulbospinal 0 +serotonergic 0 +pathway 0 +is 0 +involved 0 +in 0 +development 0 +of 0 +clonidine 1 +- 0 +induced 0 +hypotension 3 +and 0 +bradycardia 3 +. 0 + +The 0 +induced 0 +hypotension 3 +is 0 +brought 0 +about 0 +by 0 +a 0 +decrease 0 +in 0 +sympathetic 0 +efferent 0 +activity 0 +, 0 +whereas 0 +the 0 +induced 0 +bradycardia 3 +was 0 +due 0 +to 0 +an 0 +increase 0 +in 0 +vagal 0 +efferent 0 +activity 0 +. 0 + +Hypertension 3 +in 0 +neuroblastoma 3 +induced 0 +by 0 +imipramine 1 +. 0 + +Hypertension 3 +is 0 +a 0 +well 0 +- 0 +known 0 +finding 0 +in 0 +some 0 +patients 0 +with 0 +neuroblastoma 3 +. 0 + +However 0 +, 0 +it 0 +has 0 +not 0 +previously 0 +been 0 +described 0 +in 0 +association 0 +with 0 +the 0 +use 0 +of 0 +Imipramine 1 +. 0 + +We 0 +report 0 +the 0 +occurrence 0 +of 0 +severe 0 +hypertension 3 +( 0 +blood 0 +pressure 0 +190 0 +/ 0 +160 0 +) 0 +in 0 +a 0 +4 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +with 0 +neuroblastoma 3 +who 0 +was 0 +given 0 +Imipramine 1 +to 0 +control 0 +a 0 +behavior 3 +disorder 4 +. 0 + +It 0 +was 0 +determined 0 +later 0 +that 0 +this 0 +patient 0 +' 0 +s 0 +tumor 3 +was 0 +recurring 0 +at 0 +the 0 +time 0 +of 0 +her 0 +hypertensive 3 +episode 0 +. 0 + +Since 0 +she 0 +had 0 +no 0 +blood 0 +pressure 0 +elevation 0 +at 0 +initial 0 +diagnosis 0 +and 0 +none 0 +following 0 +discontinuation 0 +of 0 +the 0 +Imipramine 1 +( 0 +when 0 +she 0 +was 0 +in 0 +florid 0 +relapse 0 +) 0 +, 0 +we 0 +believe 0 +that 0 +this 0 +drug 0 +rather 0 +than 0 +her 0 +underlying 0 +disease 0 +alone 0 +caused 0 +her 0 +hypertension 3 +. 0 + +The 0 +mechanism 0 +for 0 +this 0 +reaction 0 +is 0 +believed 0 +to 0 +be 0 +increased 0 +levels 0 +of 0 +vasoactive 0 +catecholamines 1 +due 0 +to 0 +interference 0 +of 0 +their 0 +physiologic 0 +inactivation 0 +by 0 +Imipramine 1 +. 0 + +From 0 +this 0 +experience 0 +, 0 +we 0 +urge 0 +extreme 0 +caution 0 +in 0 +the 0 +use 0 +of 0 +tricyclic 0 +antidepressants 0 +in 0 +children 0 +with 0 +active 0 +neuroblastoma 3 +. 0 + +Rechallenge 0 +of 0 +patients 0 +who 0 +developed 0 +oral 3 +candidiasis 4 +or 0 +hoarseness 3 +with 0 +beclomethasone 1 +dipropionate 2 +. 0 + +0f 0 +158 0 +asthmatic 3 +patients 0 +who 0 +were 0 +placed 0 +on 0 +inhaled 0 +beclomethasone 1 +, 0 +15 0 +( 0 +9 0 +. 0 +5 0 +% 0 +) 0 +developed 0 +either 0 +hoarseness 3 +( 0 +8 0 +) 0 +, 0 +oral 0 +thrush 3 +( 0 +6 0 +) 0 +, 0 +or 0 +both 0 +( 0 +1 0 +) 0 +. 0 + +When 0 +their 0 +adverse 0 +reactions 0 +subsided 0 +, 0 +seven 0 +of 0 +these 0 +15 0 +patients 0 +were 0 +rechallenged 0 +with 0 +inhaled 0 +beclomethasone 1 +. 0 + +These 0 +included 0 +five 0 +cases 0 +who 0 +developed 0 +hoarseness 3 +and 0 +three 0 +who 0 +developed 0 +Candidiasis 3 +. 0 + +0ne 0 +patient 0 +had 0 +both 0 +. 0 + +0ral 0 +thrush 3 +did 0 +not 0 +recur 0 +, 0 +but 0 +60 0 +% 0 +( 0 +3 0 +/ 0 +5 0 +) 0 +of 0 +patients 0 +with 0 +hoarseness 3 +had 0 +recurrence 0 +. 0 + +We 0 +conclude 0 +that 0 +patients 0 +may 0 +be 0 +restarted 0 +on 0 +inhaled 0 +beclomethasone 1 +when 0 +clinically 0 +indicated 0 +; 0 +however 0 +, 0 +because 0 +of 0 +the 0 +high 0 +recurrence 0 +rate 0 +, 0 +patients 0 +who 0 +develop 0 +hoarseness 3 +should 0 +not 0 +be 0 +re 0 +- 0 +challenged 0 +. 0 + +Concomitant 0 +use 0 +of 0 +oral 0 +prednisone 1 +and 0 +topical 0 +beclomethasone 1 +may 0 +increase 0 +the 0 +risk 0 +of 0 +developing 0 +hoarseness 3 +or 0 +candidiasis 3 +. 0 + +Cyclophosphamide 1 +cardiotoxicity 3 +: 0 +an 0 +analysis 0 +of 0 +dosing 0 +as 0 +a 0 +risk 0 +factor 0 +. 0 + +Patients 0 +who 0 +undergo 0 +bone 0 +marrow 0 +transplantation 0 +are 0 +generally 0 +immunosuppressed 0 +with 0 +a 0 +dose 0 +of 0 +cyclophosphamide 1 +( 0 +CYA 1 +) 0 +which 0 +is 0 +usually 0 +calculated 0 +based 0 +on 0 +the 0 +patient 0 +' 0 +s 0 +weight 0 +. 0 + +At 0 +these 0 +high 0 +doses 0 +of 0 +CYA 1 +, 0 +serious 0 +cardiotoxicity 3 +may 0 +occur 0 +, 0 +but 0 +definitive 0 +risk 0 +factors 0 +for 0 +the 0 +development 0 +of 0 +such 0 +cardiotoxicity 3 +have 0 +not 0 +been 0 +described 0 +. 0 + +Since 0 +chemotherapeutic 0 +agent 0 +toxicity 3 +generally 0 +correlates 0 +with 0 +dose 0 +per 0 +body 0 +surface 0 +area 0 +, 0 +we 0 +retrospectively 0 +calculated 0 +the 0 +dose 0 +of 0 +CYA 1 +in 0 +patients 0 +transplanted 0 +at 0 +our 0 +institution 0 +to 0 +determine 0 +whether 0 +the 0 +incidence 0 +of 0 +CYA 1 +cardiotoxicity 3 +correlated 0 +with 0 +the 0 +dose 0 +per 0 +body 0 +surface 0 +area 0 +. 0 + +Eighty 0 +patients 0 +who 0 +were 0 +to 0 +receive 0 +CYA 1 +50 0 +mg 0 +/ 0 +kg 0 +/ 0 +d 0 +for 0 +four 0 +days 0 +as 0 +preparation 0 +for 0 +marrow 0 +grafting 0 +underwent 0 +a 0 +total 0 +of 0 +84 0 +transplants 0 +for 0 +aplastic 3 +anemia 4 +, 0 +Wiskott 3 +- 4 +Aldrich 4 +syndrome 4 +, 0 +or 0 +severe 3 +combined 4 +immunodeficiency 4 +syndrome 4 +. 0 + +Fourteen 0 +of 0 +84 0 +( 0 +17 0 +% 0 +) 0 +patients 0 +had 0 +symptoms 0 +and 0 +signs 0 +consistent 0 +with 0 +CYA 1 +cardiotoxicity 3 +within 0 +ten 0 +days 0 +of 0 +receiving 0 +1 0 +to 0 +4 0 +doses 0 +of 0 +CYA 1 +. 0 + +Six 0 +of 0 +the 0 +14 0 +patients 0 +died 0 +with 0 +congestive 3 +heart 4 +failure 4 +. 0 + +The 0 +dose 0 +of 0 +CYA 1 +per 0 +body 0 +surface 0 +area 0 +was 0 +calculated 0 +for 0 +all 0 +patients 0 +and 0 +the 0 +patients 0 +were 0 +divided 0 +into 0 +two 0 +groups 0 +based 0 +on 0 +daily 0 +CYA 1 +dose 0 +: 0 +Group 0 +1 0 +, 0 +CYA 1 +less 0 +than 0 +or 0 +equal 0 +to 0 +1 0 +. 0 +55 0 +g 0 +/ 0 +m2 0 +/ 0 +d 0 +; 0 +Group 0 +2 0 +, 0 +CYA 1 +greater 0 +than 0 +1 0 +. 0 +55 0 +g 0 +/ 0 +m2 0 +/ 0 +d 0 +. 0 + +Cardiotoxicity 3 +that 0 +was 0 +thought 0 +to 0 +be 0 +related 0 +to 0 +CYA 1 +occurred 0 +in 0 +1 0 +/ 0 +32 0 +( 0 +3 0 +% 0 +) 0 +of 0 +patients 0 +in 0 +Group 0 +1 0 +and 0 +in 0 +13 0 +/ 0 +52 0 +( 0 +25 0 +% 0 +) 0 +patients 0 +in 0 +Group 0 +2 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +025 0 +) 0 +. 0 + +Congestive 3 +heart 4 +failure 4 +caused 0 +or 0 +contributed 0 +to 0 +death 0 +in 0 +0 0 +/ 0 +32 0 +patients 0 +in 0 +Group 0 +1 0 +v 0 +6 0 +/ 0 +52 0 +( 0 +12 0 +% 0 +) 0 +of 0 +patients 0 +in 0 +Group 0 +2 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +25 0 +) 0 +. 0 + +There 0 +was 0 +no 0 +difference 0 +in 0 +the 0 +rate 0 +of 0 +engraftment 0 +of 0 +evaluable 0 +patients 0 +in 0 +the 0 +two 0 +groups 0 +( 0 +P 0 +greater 0 +than 0 +0 0 +. 0 +5 0 +) 0 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +CYA 1 +cardiotoxicity 3 +correlates 0 +with 0 +CYA 1 +dosage 0 +as 0 +calculated 0 +by 0 +body 0 +surface 0 +area 0 +, 0 +and 0 +that 0 +patients 0 +with 0 +aplastic 3 +anemia 4 +and 0 +immunodeficiencies 3 +can 0 +be 0 +effectively 0 +prepared 0 +for 0 +bone 0 +marrow 0 +grafting 0 +at 0 +a 0 +CYA 1 +dose 0 +of 0 +1 0 +. 0 +55 0 +g 0 +/ 0 +m2 0 +/ 0 +d 0 +for 0 +four 0 +days 0 +with 0 +a 0 +lower 0 +incidence 0 +of 0 +cardiotoxicity 3 +than 0 +patients 0 +whose 0 +CYA 1 +dosage 0 +is 0 +calculated 0 +based 0 +on 0 +weight 0 +. 0 + +This 0 +study 0 +reaffirms 0 +the 0 +principle 0 +that 0 +drug 0 +toxicity 3 +correlates 0 +with 0 +dose 0 +per 0 +body 0 +surface 0 +area 0 +. 0 + +Studies 0 +of 0 +risk 0 +factors 0 +for 0 +aminoglycoside 1 +nephrotoxicity 3 +. 0 + +The 0 +epidemiology 0 +of 0 +aminoglycoside 1 +- 0 +induced 0 +nephrotoxicity 3 +is 0 +not 0 +fully 0 +understood 0 +. 0 + +Experimental 0 +studies 0 +in 0 +healthy 0 +human 0 +volunteers 0 +indicate 0 +aminoglycosides 1 +cause 0 +proximal 0 +tubular 0 +damage 0 +in 0 +most 0 +patients 0 +, 0 +but 0 +rarely 0 +, 0 +if 0 +ever 0 +, 0 +cause 0 +glomerular 3 +or 4 +tubular 4 +dysfunction 4 +. 0 + +Clinical 0 +trials 0 +of 0 +aminoglycosides 1 +in 0 +seriously 0 +ill 0 +patients 0 +indicate 0 +that 0 +the 0 +relative 0 +risk 0 +for 0 +developing 0 +acute 3 +renal 4 +failure 4 +during 0 +therapy 0 +ranges 0 +from 0 +8 0 +to 0 +10 0 +and 0 +that 0 +the 0 +attributable 0 +risk 0 +is 0 +70 0 +% 0 +to 0 +80 0 +% 0 +. 0 + +Further 0 +analysis 0 +of 0 +these 0 +data 0 +suggests 0 +that 0 +the 0 +duration 0 +of 0 +therapy 0 +, 0 +plasma 0 +aminoglycoside 1 +levels 0 +, 0 +liver 3 +disease 4 +, 0 +advanced 0 +age 0 +, 0 +high 0 +initial 0 +estimated 0 +creatinine 1 +clearance 0 +and 0 +, 0 +possibly 0 +, 0 +female 0 +gender 0 +all 0 +increase 0 +the 0 +risk 0 +for 0 +nephrotoxicity 3 +. 0 + +0ther 0 +causes 0 +of 0 +acute 3 +renal 4 +failure 4 +, 0 +such 0 +as 0 +shock 3 +, 0 +appear 0 +to 0 +have 0 +an 0 +additive 0 +effect 0 +. 0 + +Predictive 0 +models 0 +have 0 +been 0 +developed 0 +from 0 +these 0 +analyses 0 +that 0 +should 0 +be 0 +useful 0 +for 0 +identifying 0 +patients 0 +at 0 +high 0 +risk 0 +. 0 + +These 0 +models 0 +may 0 +also 0 +be 0 +useful 0 +in 0 +developing 0 +insights 0 +into 0 +the 0 +pathophysiology 0 +of 0 +aminoglycoside 1 +- 0 +induced 0 +nephrotoxicity 3 +. 0 + +Central 0 +action 0 +of 0 +narcotic 0 +analgesics 0 +. 0 + +Part 0 +IV 0 +. 0 + +Noradrenergic 0 +influences 0 +on 0 +the 0 +activity 0 +of 0 +analgesics 0 +in 0 +rats 0 +. 0 + +The 0 +effect 0 +of 0 +clonidine 1 +, 0 +naphazoline 1 +and 0 +xylometazoline 1 +on 0 +analgesia 0 +induced 0 +by 0 +morphine 1 +, 0 +codeine 1 +, 0 +fentanyl 1 +and 0 +pentazocine 1 +, 0 +and 0 +on 0 +cataleptic 3 +effect 0 +of 0 +morphine 1 +, 0 +codine 1 +and 0 +fentanyl 1 +was 0 +studied 0 +in 0 +rats 0 +. 0 + +The 0 +biochemical 0 +assays 0 +on 0 +the 0 +influence 0 +of 0 +four 0 +analgesics 0 +on 0 +the 0 +brain 0 +concentration 0 +and 0 +turnover 0 +of 0 +noradrenaline 1 +( 0 +NA 1 +) 0 +were 0 +also 0 +performed 0 +. 0 + +It 0 +was 0 +found 0 +that 0 +three 0 +drugs 0 +stimulating 0 +central 0 +NA 1 +receptors 0 +failed 0 +to 0 +affect 0 +the 0 +analgesic 0 +ED50 0 +of 0 +all 0 +antinociceptive 0 +agents 0 +and 0 +they 0 +enhanced 0 +catalepsy 3 +induced 0 +by 0 +morphine 1 +and 0 +fentanyl 1 +. 0 + +Codeine 1 +catalepsy 3 +was 0 +increased 0 +by 0 +clonidine 1 +and 0 +decreased 0 +by 0 +naphazoline 1 +and 0 +xylometazoline 1 +. 0 + +The 0 +brain 0 +concentration 0 +of 0 +NA 1 +was 0 +not 0 +changed 0 +by 0 +morphine 1 +and 0 +fentanyl 1 +, 0 +but 0 +one 0 +of 0 +the 0 +doses 0 +of 0 +codeine 1 +( 0 +45 0 +mg 0 +/ 0 +kg 0 +) 0 +slightly 0 +enhanced 0 +it 0 +. 0 + +Pentazocine 1 +dose 0 +- 0 +dependently 0 +decreased 0 +the 0 +brain 0 +level 0 +of 0 +NA 1 +. 0 + +The 0 +rate 0 +of 0 +NA 1 +turnover 0 +was 0 +not 0 +altered 0 +by 0 +analgesics 0 +except 0 +for 0 +the 0 +higher 0 +dose 0 +of 0 +fentanyl 1 +( 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +) 0 +following 0 +which 0 +the 0 +disappearance 0 +of 0 +NA 1 +from 0 +the 0 +brain 0 +was 0 +diminished 0 +. 0 + +The 0 +results 0 +are 0 +discussed 0 +in 0 +the 0 +light 0 +of 0 +various 0 +and 0 +non 0 +- 0 +uniform 0 +data 0 +from 0 +the 0 +literature 0 +. 0 + +It 0 +is 0 +suggested 0 +that 0 +in 0 +rats 0 +the 0 +brain 0 +NA 1 +plays 0 +a 0 +less 0 +important 0 +function 0 +than 0 +the 0 +other 0 +monoamines 1 +in 0 +the 0 +behavioural 0 +activity 0 +of 0 +potent 0 +analgesics 0 +. 0 + +Flurothyl 1 +seizure 3 +thresholds 0 +in 0 +mice 0 +treated 0 +neonatally 0 +with 0 +a 0 +single 0 +injection 0 +of 0 +monosodium 1 +glutamate 2 +( 0 +MSG 1 +) 0 +: 0 +evaluation 0 +of 0 +experimental 0 +parameters 0 +in 0 +flurothyl 1 +seizure 3 +testing 0 +. 0 + +Monosodium 1 +glutamate 2 +( 0 +MSG 1 +) 0 +administration 0 +to 0 +neonatal 0 +rodents 0 +produces 0 +convulsions 3 +and 0 +results 0 +in 0 +numerous 0 +biochemical 0 +and 0 +behavioral 0 +deficits 0 +. 0 + +These 0 +studies 0 +were 0 +undertaken 0 +to 0 +determine 0 +if 0 +neonatal 0 +administration 0 +of 0 +MSG 1 +produced 0 +permanent 0 +alterations 0 +in 0 +seizure 3 +susceptibility 0 +, 0 +since 0 +previous 0 +investigations 0 +were 0 +inconclusive 0 +. 0 + +A 0 +flurothyl 1 +ether 1 +seizure 3 +screening 0 +technique 0 +was 0 +used 0 +to 0 +evaluate 0 +seizure 3 +susceptibility 0 +in 0 +adult 0 +mice 0 +that 0 +received 0 +neonatal 0 +injections 0 +of 0 +MSG 1 +( 0 +4 0 +mg 0 +/ 0 +g 0 +and 0 +1 0 +mg 0 +/ 0 +g 0 +) 0 +. 0 + +MSG 1 +treatment 0 +resulted 0 +in 0 +significant 0 +reductions 0 +in 0 +whole 0 +brain 0 +weight 0 +but 0 +did 0 +not 0 +alter 0 +seizure 3 +threshold 0 +. 0 + +A 0 +naloxone 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +challenge 0 +was 0 +also 0 +ineffective 0 +in 0 +altering 0 +the 0 +seizure 3 +thresholds 0 +of 0 +either 0 +control 0 +of 0 +MSG 1 +- 0 +treated 0 +mice 0 +. 0 + +Flurothyl 1 +ether 1 +produced 0 +hypothermia 3 +which 0 +was 0 +correlated 0 +with 0 +the 0 +duration 0 +of 0 +flurothyl 1 +exposure 0 +; 0 +however 0 +, 0 +the 0 +relationship 0 +of 0 +hypothermia 3 +to 0 +seizure 3 +induction 0 +was 0 +unclear 0 +. 0 + +Flurothyl 1 +seizure 3 +testing 0 +proved 0 +to 0 +be 0 +a 0 +rapid 0 +and 0 +reliable 0 +technique 0 +with 0 +which 0 +to 0 +evaluate 0 +seizure 3 +susceptibility 0 +. 0 + +Susceptibility 0 +to 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +in 0 +rats 0 +after 0 +microinjection 0 +of 0 +isoniazid 1 +or 0 +gamma 1 +- 2 +vinyl 2 +- 2 +GABA 2 +into 0 +the 0 +substantia 0 +nigra 0 +. 0 + +Pilocarpine 1 +, 0 +given 0 +intraperitoneally 0 +to 0 +rats 0 +, 0 +reproduces 0 +the 0 +neuropathological 0 +sequelae 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +and 0 +provides 0 +a 0 +relevant 0 +animal 0 +model 0 +for 0 +studying 0 +mechanisms 0 +of 0 +buildup 0 +of 0 +convulsive 3 +activity 0 +and 0 +pathways 0 +operative 0 +in 0 +the 0 +generalization 0 +and 0 +propagation 0 +of 0 +seizures 3 +within 0 +the 0 +forebrain 0 +. 0 + +In 0 +the 0 +present 0 +study 0 +, 0 +the 0 +effects 0 +of 0 +manipulating 0 +the 0 +activity 0 +of 0 +the 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +) 0 +- 0 +mediated 0 +synaptic 0 +inhibition 0 +within 0 +the 0 +substantia 0 +nigra 0 +on 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +in 0 +rats 0 +, 0 +were 0 +investigated 0 +. 0 + +In 0 +animals 0 +pretreated 0 +with 0 +microinjections 0 +of 0 +isoniazid 1 +, 0 +150 0 +micrograms 0 +, 0 +an 0 +inhibitor 0 +of 0 +activity 0 +of 0 +the 0 +GABA 1 +- 0 +synthesizing 0 +enzyme 0 +, 0 +L 1 +- 2 +glutamic 2 +acid 2 +decarboxylase 0 +, 0 +into 0 +the 0 +substantia 0 +nigra 0 +pars 0 +reticulata 0 +( 0 +SNR 0 +) 0 +, 0 +bilaterally 0 +, 0 +non 0 +- 0 +convulsant 0 +doses 0 +of 0 +pilocarpine 1 +, 0 +100 0 +and 0 +200 0 +mg 0 +/ 0 +kg 0 +, 0 +resulted 0 +in 0 +severe 0 +motor 0 +limbic 0 +seizures 3 +and 0 +status 3 +epilepticus 4 +. 0 + +Electroencephalographic 0 +and 0 +behavioral 0 +monitoring 0 +revealed 0 +a 0 +profound 0 +reduction 0 +of 0 +the 0 +threshold 0 +for 0 +pilocarpine 1 +- 0 +induced 0 +convulsions 3 +. 0 + +Morphological 0 +analysis 0 +of 0 +frontal 0 +forebrain 0 +sections 0 +with 0 +light 0 +microscopy 0 +revealed 0 +seizure 3 +- 0 +related 0 +damage 0 +to 0 +the 0 +hippocampal 0 +formation 0 +, 0 +thalamus 0 +, 0 +amygdala 0 +, 0 +olfactory 0 +cortex 0 +, 0 +substantia 0 +nigra 0 +and 0 +neocortex 0 +, 0 +which 0 +is 0 +typically 0 +observed 0 +with 0 +pilocarpine 1 +in 0 +doses 0 +exceeding 0 +350 0 +mg 0 +/ 0 +kg 0 +. 0 + +Bilateral 0 +intrastriatal 0 +injections 0 +of 0 +isoniazid 1 +did 0 +not 0 +augment 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +, 0 +200 0 +mg 0 +/ 0 +kg 0 +. 0 + +Application 0 +of 0 +an 0 +irreversible 0 +inhibitor 0 +of 0 +GABA 1 +transaminase 0 +, 0 +gamma 1 +- 2 +vinyl 2 +- 2 +GABA 2 +( 0 +D 1 +, 2 +L 2 +- 2 +4 2 +- 2 +amino 2 +- 2 +hex 2 +- 2 +5 2 +- 2 +enoic 2 +acid 2 +) 0 +, 0 +5 0 +micrograms 0 +, 0 +into 0 +the 0 +SNR 0 +, 0 +bilaterally 0 +, 0 +suppressed 0 +the 0 +appearance 0 +of 0 +electrographic 0 +and 0 +behavioral 0 +seizures 3 +produced 0 +by 0 +pilocarpine 1 +, 0 +380 0 +mg 0 +/ 0 +kg 0 +. 0 + +This 0 +treatment 0 +was 0 +also 0 +sufficient 0 +to 0 +protect 0 +animals 0 +from 0 +the 0 +occurrence 0 +of 0 +brain 3 +damage 4 +. 0 + +Microinjections 0 +of 0 +gamma 1 +- 2 +vinyl 2 +- 2 +GABA 2 +, 0 +5 0 +micrograms 0 +, 0 +into 0 +the 0 +dorsal 0 +striatum 0 +, 0 +bilaterally 0 +, 0 +failed 0 +to 0 +prevent 0 +the 0 +development 0 +of 0 +convulsions 3 +produced 0 +by 0 +pilocarpine 1 +, 0 +380 0 +mg 0 +/ 0 +kg 0 +. 0 + +The 0 +results 0 +demonstrate 0 +that 0 +the 0 +threshold 0 +for 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +in 0 +rats 0 +is 0 +subjected 0 +to 0 +the 0 +regulation 0 +of 0 +the 0 +GABA 1 +- 0 +mediated 0 +synaptic 0 +inhibition 0 +within 0 +the 0 +substantia 0 +nigra 0 +. 0 + +Human 0 +and 0 +canine 0 +ventricular 0 +vasoactive 0 +intestinal 0 +polypeptide 0 +: 0 +decrease 0 +with 0 +heart 3 +failure 4 +. 0 + +Vasoactive 0 +intestinal 0 +polypeptide 0 +( 0 +VIP 0 +) 0 +is 0 +a 0 +systemic 0 +and 0 +coronary 0 +vasodilator 0 +that 0 +may 0 +have 0 +positive 0 +inotropic 0 +properties 0 +. 0 + +Myocardial 0 +levels 0 +of 0 +VIP 0 +were 0 +assayed 0 +before 0 +and 0 +after 0 +the 0 +development 0 +of 0 +heart 3 +failure 4 +in 0 +two 0 +canine 0 +models 0 +. 0 + +In 0 +the 0 +first 0 +, 0 +cobalt 1 +cardiomyopathy 3 +was 0 +induced 0 +in 0 +eight 0 +dogs 0 +; 0 +VIP 0 +( 0 +by 0 +radioimmunoassay 0 +) 0 +decreased 0 +from 0 +35 0 ++ 0 +/ 0 +- 0 +11 0 +pg 0 +/ 0 +mg 0 +protein 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +to 0 +5 0 ++ 0 +/ 0 +- 0 +4 0 +pg 0 +/ 0 +mg 0 +protein 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +In 0 +six 0 +dogs 0 +with 0 +doxorubicin 1 +- 0 +induced 0 +heart 3 +failure 4 +, 0 +VIP 0 +decreased 0 +from 0 +31 0 ++ 0 +/ 0 +- 0 +7 0 +to 0 +11 0 ++ 0 +/ 0 +- 0 +4 0 +pg 0 +/ 0 +mg 0 +protein 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +In 0 +addition 0 +, 0 +VIP 0 +content 0 +of 0 +left 0 +ventricular 0 +muscle 0 +of 0 +resected 0 +failing 0 +hearts 0 +in 0 +10 0 +patients 0 +receiving 0 +a 0 +heart 0 +transplant 0 +was 0 +compared 0 +with 0 +the 0 +papillary 0 +muscles 0 +in 0 +14 0 +patients 0 +( 0 +five 0 +with 0 +rheumatic 3 +disease 4 +, 0 +nine 0 +with 0 +myxomatous 3 +degeneration 4 +) 0 +receiving 0 +mitral 0 +valve 0 +prostheses 0 +. 0 + +The 0 +lowest 0 +myocardial 0 +VIP 0 +concentration 0 +was 0 +found 0 +in 0 +the 0 +hearts 0 +of 0 +patients 0 +with 0 +coronary 3 +disease 4 +( 0 +one 0 +patient 0 +receiving 0 +a 0 +transplant 0 +and 0 +three 0 +receiving 0 +mitral 0 +prostheses 0 +) 0 +( 0 +6 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +pg 0 +/ 0 +mg 0 +protein 0 +) 0 +. 0 + +The 0 +other 0 +patients 0 +undergoing 0 +transplantation 0 +had 0 +an 0 +average 0 +ejection 0 +fraction 0 +of 0 +17 0 +% 0 ++ 0 +/ 0 +- 0 +6 0 +% 0 +and 0 +a 0 +VIP 0 +level 0 +of 0 +8 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +9 0 +pg 0 +/ 0 +mg 0 +protein 0 +. 0 + +The 0 +hearts 0 +without 0 +coronary 3 +artery 4 +disease 4 +( 0 +average 0 +ejection 0 +fraction 0 +of 0 +this 0 +group 0 +62 0 +% 0 ++ 0 +/ 0 +- 0 +10 0 +% 0 +) 0 +had 0 +a 0 +VIP 0 +concentration 0 +of 0 +14 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +7 0 +. 0 +9 0 +pg 0 +/ 0 +mg 0 +protein 0 +, 0 +and 0 +this 0 +was 0 +greater 0 +than 0 +in 0 +hearts 0 +of 0 +the 0 +patients 0 +with 0 +coronary 3 +disease 4 +and 0 +the 0 +hearts 0 +of 0 +patients 0 +receiving 0 +a 0 +transplant 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Myocardial 0 +catecholamines 1 +were 0 +also 0 +determined 0 +in 0 +14 0 +subjects 0 +; 0 +a 0 +weak 0 +correlation 0 +( 0 +r 0 += 0 +0 0 +. 0 +57 0 +, 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +between 0 +the 0 +tissue 0 +concentrations 0 +of 0 +VIP 0 +and 0 +norepinephrine 1 +was 0 +noted 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Non 0 +- 0 +invasive 0 +detection 0 +of 0 +coronary 3 +artery 4 +disease 4 +by 0 +body 0 +surface 0 +electrocardiographic 0 +mapping 0 +after 0 +dipyridamole 1 +infusion 0 +. 0 + +Electrocardiographic 0 +changes 0 +after 0 +dipyridamole 1 +infusion 0 +( 0 +0 0 +. 0 +568 0 +mg 0 +/ 0 +kg 0 +/ 0 +4 0 +min 0 +) 0 +were 0 +studied 0 +in 0 +41 0 +patients 0 +with 0 +coronary 3 +artery 4 +disease 4 +and 0 +compared 0 +with 0 +those 0 +after 0 +submaximal 0 +treadmill 0 +exercise 0 +by 0 +use 0 +of 0 +the 0 +body 0 +surface 0 +mapping 0 +technique 0 +. 0 + +Patients 0 +were 0 +divided 0 +into 0 +three 0 +groups 0 +; 0 +19 0 +patients 0 +without 0 +myocardial 3 +infarction 4 +( 0 +non 0 +- 0 +MI 3 +group 0 +) 0 +, 0 +14 0 +with 0 +anterior 3 +infarction 4 +( 0 +ANT 3 +- 4 +MI 4 +) 0 +and 0 +eight 0 +with 0 +inferior 3 +infarction 4 +( 0 +INF 3 +- 4 +MI 4 +) 0 +. 0 + +Eighty 0 +- 0 +seven 0 +unipolar 0 +electrocardiograms 0 +( 0 +ECGs 0 +) 0 +distributed 0 +over 0 +the 0 +entire 0 +thoracic 0 +surface 0 +were 0 +simultaneously 0 +recorded 0 +. 0 + +After 0 +dipyridamole 1 +, 0 +ischemic 3 +ST 0 +- 0 +segment 0 +depression 3 +( 0 +0 0 +. 0 +05 0 +mV 0 +or 0 +more 0 +) 0 +was 0 +observed 0 +in 0 +84 0 +% 0 +of 0 +the 0 +non 0 +- 0 +MI 3 +group 0 +, 0 +29 0 +% 0 +of 0 +the 0 +ANT 3 +- 4 +MI 4 +group 0 +, 0 +63 0 +% 0 +of 0 +the 0 +INF 3 +- 4 +MI 4 +group 0 +and 0 +61 0 +% 0 +of 0 +the 0 +total 0 +population 0 +. 0 + +Exercise 0 +- 0 +induced 0 +ST 0 +depression 3 +was 0 +observed 0 +in 0 +84 0 +% 0 +of 0 +the 0 +non 0 +- 0 +MI 3 +group 0 +, 0 +43 0 +% 0 +of 0 +the 0 +ANT 3 +- 4 +MI 4 +group 0 +, 0 +38 0 +% 0 +of 0 +the 0 +INF 3 +- 4 +MI 4 +group 0 +and 0 +61 0 +% 0 +of 0 +the 0 +total 0 +. 0 + +For 0 +individual 0 +patients 0 +, 0 +there 0 +were 0 +no 0 +obvious 0 +differences 0 +between 0 +the 0 +body 0 +surface 0 +distribution 0 +of 0 +ST 0 +depression 3 +in 0 +both 0 +tests 0 +. 0 + +The 0 +increase 0 +in 0 +pressure 0 +rate 0 +product 0 +after 0 +dipyridamole 1 +was 0 +significantly 0 +less 0 +than 0 +that 0 +during 0 +the 0 +treadmill 0 +exercise 0 +. 0 + +The 0 +data 0 +suggest 0 +that 0 +the 0 +dipyridamole 1 +- 0 +induced 0 +myocardial 3 +ischemia 4 +is 0 +caused 0 +by 0 +the 0 +inhomogenous 0 +distribution 0 +of 0 +myocardial 0 +blood 0 +flow 0 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +dipyridamole 1 +ECG 0 +test 0 +is 0 +as 0 +useful 0 +as 0 +the 0 +exercise 0 +ECG 0 +test 0 +for 0 +the 0 +assessment 0 +of 0 +coronary 3 +artery 4 +disease 4 +. 0 + +Bradycardia 3 +after 0 +high 0 +- 0 +dose 0 +intravenous 0 +methylprednisolone 1 +therapy 0 +. 0 + +In 0 +5 0 +consecutive 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +who 0 +received 0 +intravenous 0 +high 0 +- 0 +dose 0 +methylprednisolone 1 +( 0 +MP 1 +) 0 +therapy 0 +( 0 +1 0 +g 0 +daily 0 +for 0 +2 0 +or 0 +3 0 +consecutive 0 +days 0 +) 0 +, 0 +a 0 +decline 0 +in 0 +pulse 0 +rate 0 +was 0 +observed 0 +, 0 +most 0 +pronounced 0 +on 0 +day 0 +4 0 +. 0 + +In 0 +one 0 +of 0 +the 0 +5 0 +patients 0 +the 0 +bradycardia 3 +was 0 +associated 0 +with 0 +complaints 0 +of 0 +substernal 0 +pressure 0 +. 0 + +Reversal 0 +to 0 +normal 0 +heart 0 +rate 0 +was 0 +found 0 +on 0 +day 0 +7 0 +. 0 + +Electrocardiographic 0 +registrations 0 +showed 0 +sinus 3 +bradycardia 4 +in 0 +all 0 +cases 0 +. 0 + +No 0 +significant 0 +changes 0 +in 0 +plasma 0 +concentrations 0 +of 0 +electrolytes 0 +were 0 +found 0 +. 0 + +Careful 0 +observation 0 +of 0 +patients 0 +receiving 0 +high 0 +- 0 +dose 0 +MP 1 +is 0 +recommended 0 +. 0 + +High 0 +- 0 +dose 0 +MP 1 +may 0 +be 0 +contraindicated 0 +in 0 +patients 0 +with 0 +known 0 +heart 3 +disease 4 +. 0 + +Two 0 +cases 0 +of 0 +downbeat 3 +nystagmus 4 +and 0 +oscillopsia 3 +associated 0 +with 0 +carbamazepine 1 +. 0 + +Downbeat 3 +nystagmus 4 +is 0 +often 0 +associated 0 +with 0 +structural 0 +lesions 0 +at 0 +the 0 +craniocervical 0 +junction 0 +, 0 +but 0 +has 0 +occasionally 0 +been 0 +reported 0 +as 0 +a 0 +manifestation 0 +of 0 +metabolic 0 +imbalance 0 +or 0 +drug 0 +intoxication 0 +. 0 + +We 0 +recorded 0 +the 0 +eye 0 +movements 0 +of 0 +two 0 +patients 0 +with 0 +reversible 0 +downbeat 3 +nystagmus 4 +related 0 +to 0 +carbamazepine 1 +therapy 0 +. 0 + +The 0 +nystagmus 3 +of 0 +both 0 +patients 0 +resolved 0 +after 0 +reduction 0 +of 0 +the 0 +serum 0 +carbamazepine 1 +levels 0 +. 0 + +Neuroradiologic 0 +investigations 0 +including 0 +magnetic 0 +resonance 0 +imaging 0 +scans 0 +in 0 +both 0 +patients 0 +showed 0 +no 0 +evidence 0 +of 0 +intracranial 0 +abnormality 0 +. 0 + +In 0 +patients 0 +with 0 +downbeat 3 +nystagmus 4 +who 0 +are 0 +taking 0 +anticonvulsant 0 +medications 0 +, 0 +consideration 0 +should 0 +be 0 +given 0 +to 0 +reduction 0 +in 0 +dose 0 +before 0 +further 0 +investigation 0 +is 0 +undertaken 0 +. 0 + +Improvement 0 +by 0 +denopamine 1 +( 0 +TA 1 +- 2 +064 2 +) 0 +of 0 +pentobarbital 1 +- 0 +induced 0 +cardiac 3 +failure 4 +in 0 +the 0 +dog 0 +heart 0 +- 0 +lung 0 +preparation 0 +. 0 + +The 0 +efficacy 0 +of 0 +denopamine 1 +, 0 +an 0 +orally 0 +active 0 +beta 0 +1 0 +- 0 +adrenoceptor 0 +agonist 0 +, 0 +in 0 +improving 0 +cardiac 3 +failure 4 +was 0 +assessed 0 +in 0 +dog 0 +heart 0 +- 0 +lung 0 +preparations 0 +. 0 + +Cardiac 0 +functions 0 +depressed 0 +by 0 +pentobarbital 1 +( 0 +118 0 ++ 0 +/ 0 +- 0 +28 0 +mg 0 +; 0 +mean 0 +value 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +such 0 +that 0 +cardiac 0 +output 0 +and 0 +maximum 0 +rate 0 +of 0 +rise 0 +of 0 +left 0 +ventricular 0 +pressure 0 +( 0 +LV 0 +dP 0 +/ 0 +dt 0 +max 0 +) 0 +had 0 +been 0 +reduced 0 +by 0 +about 0 +35 0 +% 0 +and 0 +26 0 +% 0 +of 0 +the 0 +respective 0 +controls 0 +were 0 +improved 0 +by 0 +denopamine 1 +( 0 +10 0 +- 0 +300 0 +micrograms 0 +) 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 + +With 0 +100 0 +micrograms 0 +denopamine 1 +, 0 +almost 0 +complete 0 +restoration 0 +of 0 +cardiac 0 +performance 0 +was 0 +attained 0 +, 0 +associated 0 +with 0 +a 0 +slight 0 +increase 0 +in 0 +heart 0 +rate 0 +. 0 + +No 0 +arrhythmias 3 +were 0 +induced 0 +by 0 +these 0 +doses 0 +of 0 +denopamine 1 +. 0 + +The 0 +results 0 +warrant 0 +clinical 0 +trials 0 +of 0 +denopamine 1 +in 0 +the 0 +treatment 0 +of 0 +cardiac 3 +failure 4 +. 0 + +Clonazepam 1 +monotherapy 0 +for 0 +epilepsy 3 +in 0 +childhood 0 +. 0 + +Sixty 0 +patients 0 +( 0 +age 0 +- 0 +range 0 +one 0 +month 0 +to 0 +14 0 +years 0 +) 0 +with 0 +other 0 +types 0 +of 0 +epilepsy 3 +than 0 +infantile 3 +spasms 4 +were 0 +treated 0 +with 0 +clonazepam 1 +. 0 + +Disappearance 0 +of 0 +seizures 3 +and 0 +normalization 0 +of 0 +abnormal 0 +EEG 0 +with 0 +disappearance 0 +of 0 +seizures 3 +were 0 +recognized 0 +in 0 +77 0 +% 0 +and 0 +50 0 +% 0 +, 0 +respectively 0 +. 0 + +Seizures 3 +disappeared 0 +in 0 +71 0 +% 0 +of 0 +the 0 +patients 0 +with 0 +generalized 0 +seizures 3 +and 0 +89 0 +% 0 +of 0 +partial 0 +seizures 3 +. 0 + +Improvement 0 +of 0 +abnormal 0 +EEG 0 +was 0 +noticed 0 +in 0 +76 0 +% 0 +of 0 +diffuse 0 +paroxysms 0 +and 0 +in 0 +67 0 +% 0 +of 0 +focal 0 +paroxysms 0 +. 0 + +In 0 +excellent 0 +cases 0 +, 0 +mean 0 +effective 0 +dosages 0 +were 0 +0 0 +. 0 +086 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +021 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +in 0 +infants 0 +and 0 +0 0 +. 0 +057 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +022 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +in 0 +schoolchildren 0 +, 0 +this 0 +difference 0 +was 0 +statistically 0 +significant 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +005 0 +) 0 +. 0 + +The 0 +incidence 0 +of 0 +side 0 +effects 0 +such 0 +as 0 +drowsiness 3 +and 0 +ataxia 3 +was 0 +only 0 +5 0 +% 0 +. 0 + +Postmarketing 0 +study 0 +of 0 +timolol 1 +- 0 +hydrochlorothiazide 1 +antihypertensive 0 +therapy 0 +. 0 + +A 0 +postmarketing 0 +surveillance 0 +study 0 +was 0 +conducted 0 +to 0 +determine 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +a 0 +fixed 0 +- 0 +ratio 0 +combination 0 +containing 0 +10 0 +mg 0 +of 0 +timolol 1 +maleate 2 +and 0 +25 0 +mg 0 +of 0 +hydrochlorothiazide 1 +, 0 +administered 0 +twice 0 +daily 0 +for 0 +one 0 +month 0 +to 0 +hypertensive 3 +patients 0 +. 0 + +Data 0 +on 0 +9 0 +, 0 +037 0 +patients 0 +were 0 +collected 0 +by 0 +1 0 +, 0 +455 0 +participating 0 +physicians 0 +. 0 + +Mean 0 +systolic 0 +blood 0 +pressure 0 +decreased 0 +25 0 +mmHg 0 +and 0 +mean 0 +diastolic 0 +blood 0 +pressure 0 +declined 0 +15 0 +mmHg 0 +after 0 +one 0 +month 0 +of 0 +timolol 1 +- 0 +hydrochlorothiazide 1 +therapy 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +01 0 +, 0 +both 0 +comparisons 0 +) 0 +. 0 + +Age 0 +, 0 +race 0 +, 0 +and 0 +sex 0 +appeared 0 +to 0 +have 0 +no 0 +influence 0 +on 0 +the 0 +decrease 0 +in 0 +blood 0 +pressure 0 +. 0 + +The 0 +antihypertensive 0 +effect 0 +of 0 +the 0 +drug 0 +was 0 +greater 0 +in 0 +patients 0 +with 0 +more 0 +severe 0 +hypertension 3 +. 0 + +0verall 0 +, 0 +1 0 +, 0 +453 0 +patients 0 +experienced 0 +a 0 +total 0 +of 0 +2 0 +, 0 +658 0 +adverse 0 +events 0 +, 0 +the 0 +most 0 +common 0 +being 0 +fatigue 3 +, 0 +dizziness 3 +, 0 +and 0 +weakness 3 +. 0 + +Treatment 0 +in 0 +590 0 +patients 0 +was 0 +discontinued 0 +because 0 +of 0 +adverse 0 +events 0 +. 0 + +Salicylate 1 +nephropathy 3 +in 0 +the 0 +Gunn 0 +rat 0 +: 0 +potential 0 +role 0 +of 0 +prostaglandins 1 +. 0 + +We 0 +examined 0 +the 0 +potential 0 +role 0 +of 0 +prostaglandins 1 +in 0 +the 0 +development 0 +of 0 +analgesic 0 +nephropathy 3 +in 0 +the 0 +Gunn 0 +strain 0 +of 0 +rat 0 +. 0 + +The 0 +homozygous 0 +Gunn 0 +rats 0 +have 0 +unconjugated 0 +hyperbilirubinemia 3 +due 0 +to 0 +the 0 +absence 0 +of 0 +glucuronyl 1 +transferase 0 +, 0 +leading 0 +to 0 +marked 0 +bilirubin 1 +deposition 0 +in 0 +renal 0 +medulla 0 +and 0 +papilla 0 +. 0 + +These 0 +rats 0 +are 0 +also 0 +highly 0 +susceptible 0 +to 0 +develop 0 +papillary 3 +necrosis 4 +with 0 +analgesic 0 +administration 0 +. 0 + +We 0 +used 0 +homozygous 0 +( 0 +jj 0 +) 0 +and 0 +phenotypically 0 +normal 0 +heterozygous 0 +( 0 +jJ 0 +) 0 +animals 0 +. 0 + +Four 0 +groups 0 +of 0 +rats 0 +( 0 +n 0 += 0 +7 0 +) 0 +were 0 +studied 0 +: 0 +jj 0 +and 0 +jJ 0 +rats 0 +treated 0 +either 0 +with 0 +aspirin 1 +300 0 +mg 0 +/ 0 +kg 0 +every 0 +other 0 +day 0 +or 0 +sham 0 +- 0 +treated 0 +. 0 + +After 0 +one 0 +week 0 +, 0 +slices 0 +of 0 +cortex 0 +, 0 +outer 0 +and 0 +inner 0 +medulla 0 +from 0 +one 0 +kidney 0 +were 0 +incubated 0 +in 0 +buffer 0 +and 0 +prostaglandin 1 +synthesis 0 +was 0 +determined 0 +by 0 +radioimmunoassay 0 +. 0 + +The 0 +other 0 +kidney 0 +was 0 +examined 0 +histologically 0 +. 0 + +A 0 +marked 0 +corticomedullary 0 +gradient 0 +of 0 +prostaglandin 1 +synthesis 0 +was 0 +observed 0 +in 0 +all 0 +groups 0 +. 0 + +PGE2 1 +synthesis 0 +was 0 +significantly 0 +higher 0 +in 0 +outer 0 +medulla 0 +, 0 +but 0 +not 0 +cortex 0 +or 0 +inner 0 +medulla 0 +, 0 +of 0 +jj 0 +( 0 +38 0 ++ 0 +/ 0 +- 0 +6 0 +ng 0 +/ 0 +mg 0 +prot 0 +) 0 +than 0 +jJ 0 +rats 0 +( 0 +15 0 ++ 0 +/ 0 +- 0 +3 0 +) 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +Aspirin 1 +treatment 0 +reduced 0 +PGE2 1 +synthesis 0 +in 0 +all 0 +regions 0 +, 0 +but 0 +outer 0 +medullary 0 +PGE2 1 +remained 0 +higher 0 +in 0 +jj 0 +( 0 +18 0 ++ 0 +/ 0 +- 0 +3 0 +) 0 +than 0 +jJ 0 +rats 0 +( 0 +9 0 ++ 0 +/ 0 +- 0 +2 0 +) 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +PGF2 1 +alpha 2 +was 0 +also 0 +significantly 0 +higher 0 +in 0 +the 0 +outer 0 +medulla 0 +of 0 +jj 0 +rats 0 +with 0 +and 0 +without 0 +aspirin 1 +administration 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +changes 0 +in 0 +renal 0 +prostaglandin 1 +synthesis 0 +were 0 +accompanied 0 +by 0 +evidence 0 +of 0 +renal 3 +damage 4 +in 0 +aspirin 1 +- 0 +treated 0 +jj 0 +but 0 +not 0 +jJ 0 +rats 0 +as 0 +evidenced 0 +by 0 +: 0 +increased 0 +incidence 0 +and 0 +severity 0 +of 0 +hematuria 3 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +; 0 +increased 0 +serum 0 +creatinine 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +; 0 +and 0 +increase 0 +in 0 +outer 0 +medullary 0 +histopathologic 0 +lesions 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +005 0 +compared 0 +to 0 +either 0 +sham 0 +- 0 +treated 0 +jj 0 +or 0 +aspirin 1 +- 0 +treated 0 +jJ 0 +) 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +enhanced 0 +prostaglandin 1 +synthesis 0 +contributes 0 +to 0 +maintenance 0 +of 0 +renal 0 +function 0 +and 0 +morphological 0 +integrity 0 +, 0 +and 0 +that 0 +inhibition 0 +of 0 +prostaglandin 1 +synthesis 0 +may 0 +lead 0 +to 0 +pathological 3 +renal 4 +medullary 4 +lesions 4 +and 0 +deterioration 3 +of 4 +renal 4 +function 4 +. 0 + +Prophylactic 0 +lidocaine 1 +in 0 +the 0 +early 0 +phase 0 +of 0 +suspected 0 +myocardial 3 +infarction 4 +. 0 + +Four 0 +hundred 0 +two 0 +patients 0 +with 0 +suspected 0 +myocardial 3 +infarction 4 +seen 0 +within 0 +6 0 +hours 0 +of 0 +the 0 +onset 0 +of 0 +symptoms 0 +entered 0 +a 0 +double 0 +- 0 +blind 0 +randomized 0 +trial 0 +of 0 +lidocaine 1 +vs 0 +placebo 0 +. 0 + +During 0 +the 0 +1 0 +hour 0 +after 0 +administration 0 +of 0 +the 0 +drug 0 +the 0 +incidence 0 +of 0 +ventricular 3 +fibrillation 4 +or 0 +sustained 0 +ventricular 3 +tachycardia 4 +among 0 +the 0 +204 0 +patients 0 +with 0 +acute 0 +myocardial 3 +infarction 4 +was 0 +low 0 +, 0 +1 0 +. 0 +5 0 +% 0 +. 0 + +Lidocaine 1 +, 0 +given 0 +in 0 +a 0 +300 0 +mg 0 +dose 0 +intramuscularly 0 +followed 0 +by 0 +100 0 +mg 0 +intravenously 0 +, 0 +did 0 +not 0 +prevent 0 +sustained 0 +ventricular 3 +tachycardia 4 +, 0 +although 0 +there 0 +was 0 +a 0 +significant 0 +reduction 0 +in 0 +the 0 +number 0 +of 0 +patients 0 +with 0 +warning 0 +arrhythmias 3 +between 0 +15 0 +and 0 +45 0 +minutes 0 +after 0 +the 0 +administration 0 +of 0 +lidocaine 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +The 0 +average 0 +plasma 0 +lidocaine 1 +level 0 +10 0 +minutes 0 +after 0 +administration 0 +for 0 +patients 0 +without 0 +a 0 +myocardial 3 +infarction 4 +was 0 +significantly 0 +higher 0 +than 0 +that 0 +for 0 +patients 0 +with 0 +an 0 +acute 0 +infarction 3 +. 0 + +The 0 +mean 0 +plasma 0 +lidocaine 1 +level 0 +of 0 +patients 0 +on 0 +beta 0 +- 0 +blocking 0 +agents 0 +was 0 +no 0 +different 0 +from 0 +that 0 +in 0 +patients 0 +not 0 +on 0 +beta 0 +blocking 0 +agents 0 +. 0 + +During 0 +the 0 +1 0 +- 0 +hour 0 +study 0 +period 0 +, 0 +the 0 +incidence 0 +of 0 +central 0 +nervous 0 +system 0 +side 0 +effects 0 +was 0 +significantly 0 +greater 0 +in 0 +the 0 +lidocaine 1 +group 0 +, 0 +hypotension 3 +occurred 0 +in 0 +11 0 +patients 0 +, 0 +nine 0 +of 0 +whom 0 +had 0 +received 0 +lidocaine 1 +, 0 +and 0 +four 0 +patients 0 +died 0 +from 0 +asystole 3 +, 0 +three 0 +of 0 +whom 0 +had 0 +had 0 +lidocaine 1 +. 0 + +We 0 +cannot 0 +advocate 0 +the 0 +administration 0 +of 0 +lidocaine 1 +prophylactically 0 +in 0 +the 0 +early 0 +hours 0 +of 0 +suspected 0 +myocardial 3 +infarction 4 +. 0 + +Evidence 0 +for 0 +a 0 +cholinergic 0 +role 0 +in 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +Experiments 0 +in 0 +mice 0 +tested 0 +previous 0 +evidence 0 +that 0 +activation 0 +of 0 +cholinergic 0 +systems 0 +promotes 0 +catalepsy 3 +and 0 +that 0 +cholinergic 0 +mechanisms 0 +need 0 +to 0 +be 0 +intact 0 +for 0 +full 0 +expression 0 +of 0 +neuroleptic 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +Large 0 +doses 0 +of 0 +the 0 +cholinomimetic 0 +, 0 +pilocarpine 1 +, 0 +could 0 +induce 0 +catalepsy 3 +when 0 +peripheral 0 +cholinergic 0 +receptors 0 +were 0 +blocked 0 +. 0 + +Low 0 +doses 0 +of 0 +pilocarpine 1 +caused 0 +a 0 +pronounced 0 +enhancement 0 +of 0 +the 0 +catalepsy 3 +that 0 +was 0 +induced 0 +by 0 +the 0 +dopaminergic 0 +blocker 0 +, 0 +haloperidol 1 +. 0 + +A 0 +muscarinic 0 +receptor 0 +blocker 0 +, 0 +atropine 1 +, 0 +disrupted 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +. 0 + +Intracranial 0 +injection 0 +of 0 +an 0 +acetylcholine 1 +- 0 +synthesis 0 +inhibitor 0 +, 0 +hemicholinium 1 +, 0 +prevented 0 +the 0 +catalepsy 3 +that 0 +is 0 +usually 0 +induced 0 +by 0 +haloperidol 1 +. 0 + +These 0 +findings 0 +suggest 0 +the 0 +hypothesis 0 +that 0 +the 0 +catalepsy 3 +that 0 +is 0 +produced 0 +by 0 +neuroleptics 1 +such 0 +as 0 +haloperidol 1 +is 0 +actually 0 +mediated 0 +by 0 +intrinsic 0 +central 0 +cholinergic 0 +systems 0 +. 0 + +Alternatively 0 +, 0 +activation 0 +of 0 +central 0 +cholinergic 0 +systems 0 +could 0 +promote 0 +catalepsy 3 +by 0 +suppression 0 +of 0 +dopaminergic 0 +systems 0 +. 0 + +Cardiovascular 3 +dysfunction 4 +and 0 +hypersensitivity 3 +to 0 +sodium 1 +pentobarbital 2 +induced 0 +by 0 +chronic 0 +barium 1 +chloride 2 +ingestion 0 +. 0 + +Barium 1 +- 0 +supplemented 0 +Long 0 +- 0 +Evans 0 +hooded 0 +rats 0 +were 0 +characterized 0 +by 0 +a 0 +persistent 0 +hypertension 3 +that 0 +was 0 +evident 0 +after 0 +1 0 +month 0 +of 0 +barium 1 +( 0 +100 0 +micrograms 0 +/ 0 +ml 0 +mineral 0 +fortified 0 +water 0 +) 0 +treatment 0 +. 0 + +Analysis 0 +of 0 +in 0 +vivo 0 +myocardial 0 +excitability 0 +, 0 +contractility 0 +, 0 +and 0 +metabolic 0 +characteristics 0 +at 0 +16 0 +months 0 +revealed 0 +other 0 +significant 0 +barium 1 +- 0 +induced 0 +disturbances 3 +within 4 +the 4 +cardiovascular 4 +system 4 +. 0 + +The 0 +most 0 +distinctive 0 +aspect 0 +of 0 +the 0 +barium 1 +effect 0 +was 0 +a 0 +demonstrated 0 +hypersensitivity 3 +of 0 +the 0 +cardiovascular 0 +system 0 +to 0 +sodium 1 +pentobarbital 2 +. 0 + +Under 0 +barbiturate 1 +anesthesia 0 +, 0 +virtually 0 +all 0 +of 0 +the 0 +myocardial 0 +contractile 0 +indices 0 +were 0 +depressed 0 +significantly 0 +in 0 +barium 1 +- 0 +exposed 0 +rats 0 +relative 0 +to 0 +the 0 +corresponding 0 +control 0 +- 0 +fed 0 +rats 0 +. 0 + +The 0 +lack 0 +of 0 +a 0 +similar 0 +response 0 +to 0 +ketamine 1 +and 0 +xylazine 1 +anesthesia 0 +revealed 0 +that 0 +the 0 +cardiovascular 0 +actions 0 +of 0 +sodium 1 +pentobarbital 2 +in 0 +barium 1 +- 0 +treated 0 +rats 0 +were 0 +linked 0 +specifically 0 +to 0 +this 0 +anesthetic 0 +, 0 +and 0 +were 0 +not 0 +representative 0 +of 0 +a 0 +generalized 0 +anesthetic 0 +response 0 +. 0 + +0ther 0 +myocardial 0 +pathophysiologic 0 +and 0 +metabolic 0 +changes 0 +induced 0 +by 0 +barium 1 +were 0 +manifest 0 +, 0 +irrespective 0 +of 0 +the 0 +anesthetic 0 +employed 0 +. 0 + +The 0 +contractile 0 +element 0 +shortening 0 +velocity 0 +of 0 +the 0 +cardiac 0 +muscle 0 +fibers 0 +was 0 +significantly 0 +slower 0 +in 0 +both 0 +groups 0 +of 0 +barium 1 +- 0 +treated 0 +rats 0 +relative 0 +to 0 +the 0 +control 0 +groups 0 +, 0 +irrespective 0 +of 0 +the 0 +anesthetic 0 +regimen 0 +. 0 + +Similarly 0 +, 0 +significant 0 +disturbances 0 +in 0 +myocardial 0 +energy 0 +metabolism 0 +were 0 +detected 0 +in 0 +the 0 +barium 1 +- 0 +exposed 0 +rats 0 +which 0 +were 0 +consistent 0 +with 0 +the 0 +reduced 0 +contractile 0 +element 0 +shortening 0 +velocity 0 +. 0 + +In 0 +addition 0 +, 0 +the 0 +excitability 0 +of 0 +the 0 +cardiac 0 +conduction 0 +system 0 +was 0 +depressed 0 +preferentially 0 +in 0 +the 0 +atrioventricular 0 +nodal 0 +region 0 +of 0 +hearts 0 +from 0 +barium 1 +- 0 +exposed 0 +rats 0 +. 0 + +0verall 0 +, 0 +the 0 +altered 0 +cardiac 0 +contractility 0 +and 0 +excitability 0 +characteristics 0 +, 0 +the 0 +myocardial 0 +metabolic 3 +disturbances 4 +, 0 +and 0 +the 0 +hypersensitivity 3 +of 0 +the 0 +cardiovascular 0 +system 0 +to 0 +sodium 1 +pentobarbital 2 +suggest 0 +the 0 +existence 0 +of 0 +a 0 +heretofore 0 +undescribed 0 +cardiomyopathic 3 +disorder 4 +induced 0 +by 0 +chronic 0 +barium 1 +exposure 0 +. 0 + +These 0 +experimental 0 +findings 0 +represent 0 +the 0 +first 0 +indication 0 +that 0 +life 0 +- 0 +long 0 +barium 1 +ingestion 0 +may 0 +have 0 +significant 0 +adverse 0 +effects 0 +on 0 +the 0 +mammalian 0 +cardiovascular 0 +system 0 +. 0 + +Propranolol 1 +antagonism 0 +of 0 +phenylpropanolamine 1 +- 0 +induced 0 +hypertension 3 +. 0 + +Phenylpropanolamine 1 +( 0 +PPA 1 +) 0 +overdose 3 +can 0 +cause 0 +severe 0 +hypertension 3 +, 0 +intracerebral 3 +hemorrhage 4 +, 0 +and 0 +death 0 +. 0 + +We 0 +studied 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +propranolol 1 +in 0 +the 0 +treatment 0 +of 0 +PPA 1 +- 0 +induced 0 +hypertension 3 +. 0 + +Subjects 0 +received 0 +propranolol 1 +either 0 +by 0 +mouth 0 +for 0 +48 0 +hours 0 +before 0 +PPA 1 +or 0 +as 0 +a 0 +rapid 0 +intravenous 0 +infusion 0 +after 0 +PPA 1 +. 0 + +PPA 1 +, 0 +75 0 +mg 0 +alone 0 +, 0 +increased 0 +blood 0 +pressure 0 +( 0 +31 0 ++ 0 +/ 0 +- 0 +14 0 +mm 0 +Hg 0 +systolic 0 +, 0 +20 0 ++ 0 +/ 0 +- 0 +5 0 +mm 0 +Hg 0 +diastolic 0 +) 0 +, 0 +and 0 +propranolol 1 +pretreatment 0 +antagonized 0 +this 0 +increase 0 +( 0 +12 0 ++ 0 +/ 0 +- 0 +10 0 +mm 0 +Hg 0 +systolic 0 +, 0 +10 0 ++ 0 +/ 0 +- 0 +7 0 +mm 0 +Hg 0 +diastolic 0 +) 0 +. 0 + +Intravenous 0 +propranolol 1 +after 0 +PPA 1 +also 0 +decreased 0 +blood 0 +pressure 0 +. 0 + +Left 0 +ventricular 0 +function 0 +( 0 +assessed 0 +by 0 +echocardiography 0 +) 0 +showed 0 +that 0 +PPA 1 +increased 0 +the 0 +stroke 3 +volume 0 +30 0 +% 0 +( 0 +from 0 +62 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +20 0 +. 0 +9 0 +to 0 +80 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +22 0 +. 0 +4 0 +ml 0 +) 0 +, 0 +the 0 +ejection 0 +fraction 0 +9 0 +% 0 +( 0 +from 0 +64 0 +% 0 ++ 0 +/ 0 +- 0 +10 0 +% 0 +to 0 +70 0 +% 0 ++ 0 +/ 0 +- 0 +7 0 +% 0 +) 0 +, 0 +and 0 +cardiac 0 +output 0 +14 0 +% 0 +( 0 +from 0 +3 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +to 0 +4 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +L 0 +/ 0 +min 0 +) 0 +. 0 + +Intravenous 0 +propranolol 1 +reversed 0 +these 0 +effects 0 +. 0 + +Systemic 0 +vascular 0 +resistance 0 +was 0 +increased 0 +by 0 +PPA 1 +28 0 +% 0 +( 0 +from 0 +1710 0 ++ 0 +/ 0 +- 0 +200 0 +to 0 +2190 0 ++ 0 +/ 0 +- 0 +700 0 +dyne 0 +X 0 +sec 0 +/ 0 +cm5 0 +) 0 +and 0 +was 0 +further 0 +increased 0 +by 0 +propranolol 1 +22 0 +% 0 +( 0 +to 0 +2660 0 ++ 0 +/ 0 +- 0 +1200 0 +dyne 0 +X 0 +sec 0 +/ 0 +cm5 0 +) 0 +. 0 + +We 0 +conclude 0 +that 0 +PPA 1 +increases 0 +blood 0 +pressure 0 +by 0 +increasing 0 +systemic 0 +vascular 0 +resistance 0 +and 0 +cardiac 0 +output 0 +, 0 +and 0 +that 0 +propranolol 1 +antagonizes 0 +this 0 +increase 0 +by 0 +reversing 0 +the 0 +effect 0 +of 0 +PPA 1 +on 0 +cardiac 0 +output 0 +. 0 + +That 0 +propranolol 1 +antagonizes 0 +the 0 +pressor 0 +effect 0 +of 0 +PPA 1 +is 0 +in 0 +contrast 0 +to 0 +the 0 +interaction 0 +in 0 +which 0 +propranolol 1 +enhances 0 +the 0 +pressor 0 +effect 0 +of 0 +norepinephrine 1 +. 0 + +This 0 +is 0 +probably 0 +because 0 +PPA 1 +has 0 +less 0 +beta 0 +2 0 +activity 0 +than 0 +does 0 +norepinephrine 1 +. 0 + +Mesangial 0 +function 0 +and 0 +glomerular 3 +sclerosis 4 +in 0 +rats 0 +with 0 +aminonucleoside 1 +nephrosis 3 +. 0 + +The 0 +possible 0 +relationship 0 +between 0 +mesangial 3 +dysfunction 4 +and 0 +development 0 +of 0 +glomerular 3 +sclerosis 4 +was 0 +studied 0 +in 0 +the 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +model 0 +. 0 + +Five 0 +male 0 +Wistar 0 +rats 0 +received 0 +repeated 0 +subcutaneous 0 +PAN 1 +injections 0 +; 0 +five 0 +controls 0 +received 0 +saline 0 +only 0 +. 0 + +After 0 +4 0 +weeks 0 +the 0 +PAN 1 +rats 0 +were 0 +severely 0 +proteinuric 3 +( 0 +190 0 ++ 0 +/ 0 +- 0 +80 0 +mg 0 +/ 0 +24 0 +hr 0 +) 0 +, 0 +and 0 +all 0 +rats 0 +were 0 +given 0 +colloidal 0 +carbon 1 +( 0 +CC 0 +) 0 +intravenously 0 +. 0 + +At 0 +5 0 +months 0 +glomerular 3 +sclerosis 4 +was 0 +found 0 +in 0 +7 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +4 0 +% 0 +of 0 +the 0 +glomeruli 0 +of 0 +PAN 1 +rats 0 +; 0 +glomeruli 0 +of 0 +the 0 +controls 0 +were 0 +normal 0 +. 0 + +Glomeruli 0 +of 0 +PAN 1 +rats 0 +contained 0 +significantly 0 +more 0 +CC 0 +than 0 +glomeruli 0 +of 0 +controls 0 +. 0 + +Glomeruli 0 +with 0 +sclerosis 3 +contained 0 +significantly 0 +more 0 +CC 0 +than 0 +non 0 +- 0 +sclerotic 0 +glomeruli 0 +in 0 +the 0 +same 0 +kidneys 0 +. 0 + +CC 0 +was 0 +preferentially 0 +localized 0 +within 0 +the 0 +sclerotic 0 +areas 0 +of 0 +the 0 +affected 0 +glomeruli 0 +. 0 + +Since 0 +mesangial 0 +CC 0 +clearance 0 +from 0 +the 0 +mesangium 0 +did 0 +not 0 +change 0 +during 0 +chronic 0 +PAN 1 +treatment 0 +, 0 +we 0 +conclude 0 +that 0 +this 0 +preferential 0 +CC 0 +localization 0 +within 0 +the 0 +lesions 0 +is 0 +caused 0 +by 0 +an 0 +increased 0 +CC 0 +uptake 0 +shortly 0 +after 0 +injection 0 +in 0 +apparent 0 +vulnerable 0 +areas 0 +where 0 +sclerosis 3 +will 0 +develop 0 +subsequently 0 +. 0 + +Cluster 0 +analysis 0 +showed 0 +a 0 +random 0 +distribution 0 +of 0 +lesions 0 +in 0 +the 0 +PAN 1 +glomeruli 0 +in 0 +concordance 0 +with 0 +the 0 +random 0 +localization 0 +of 0 +mesangial 0 +areas 0 +with 0 +dysfunction 0 +in 0 +this 0 +model 0 +. 0 + +Similar 0 +to 0 +the 0 +remnant 0 +kidney 0 +model 0 +in 0 +PAN 1 +nephrosis 3 +the 0 +development 0 +of 0 +glomerular 3 +sclerosis 4 +may 0 +be 0 +related 0 +to 0 +" 0 +mesangial 0 +overloading 0 +. 0 +" 0 + +Relationship 0 +between 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +and 0 +hippocampal 0 +nicotinic 0 +receptors 0 +. 0 + +A 0 +controversy 0 +has 0 +existed 0 +for 0 +several 0 +years 0 +concerning 0 +the 0 +physiological 0 +relevance 0 +of 0 +the 0 +nicotinic 0 +receptor 0 +measured 0 +by 0 +alpha 0 +- 0 +bungarotoxin 0 +binding 0 +. 0 + +Using 0 +mice 0 +derived 0 +from 0 +a 0 +classical 0 +F2 0 +and 0 +backcross 0 +genetic 0 +design 0 +, 0 +a 0 +relationship 0 +between 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +and 0 +alpha 0 +- 0 +bungarotoxin 0 +nicotinic 0 +receptor 0 +concentration 0 +was 0 +found 0 +. 0 + +Mice 0 +sensitive 0 +to 0 +the 0 +convulsant 0 +effects 0 +of 0 +nicotine 1 +had 0 +greater 0 +alpha 0 +- 0 +bungarotoxin 0 +binding 0 +in 0 +the 0 +hippocampus 0 +than 0 +seizure 3 +insensitive 0 +mice 0 +. 0 + +The 0 +binding 0 +sites 0 +from 0 +seizure 3 +sensitive 0 +and 0 +resistant 0 +mice 0 +were 0 +equally 0 +affected 0 +by 0 +treatment 0 +with 0 +dithiothreitol 1 +, 0 +trypsin 0 +or 0 +heat 0 +. 0 + +Thus 0 +it 0 +appears 0 +that 0 +the 0 +difference 0 +between 0 +seizure 3 +sensitive 0 +and 0 +insensitive 0 +animals 0 +may 0 +be 0 +due 0 +to 0 +a 0 +difference 0 +in 0 +hippocampal 0 +nicotinic 0 +receptor 0 +concentration 0 +as 0 +measured 0 +with 0 +alpha 0 +- 0 +bungarotoxin 0 +binding 0 +. 0 + +The 0 +role 0 +of 0 +p 1 +- 2 +aminophenol 2 +in 0 +acetaminophen 1 +- 0 +induced 0 +nephrotoxicity 3 +: 0 +effect 0 +of 0 +bis 1 +( 2 +p 2 +- 2 +nitrophenyl 2 +) 2 +phosphate 2 +on 0 +acetaminophen 1 +and 0 +p 1 +- 2 +aminophenol 2 +nephrotoxicity 3 +and 0 +metabolism 0 +in 0 +Fischer 0 +344 0 +rats 0 +. 0 + +Acetaminophen 1 +( 0 +APAP 1 +) 0 +produces 0 +proximal 0 +tubular 3 +necrosis 4 +in 0 +Fischer 0 +344 0 +( 0 +F344 0 +) 0 +rats 0 +. 0 + +Recently 0 +, 0 +p 1 +- 2 +aminophenol 2 +( 0 +PAP 1 +) 0 +, 0 +a 0 +known 0 +potent 0 +nephrotoxicant 0 +, 0 +was 0 +identified 0 +as 0 +a 0 +metabolite 0 +of 0 +APAP 1 +in 0 +F344 0 +rats 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +if 0 +PAP 1 +formation 0 +is 0 +a 0 +requisite 0 +step 0 +in 0 +APAP 1 +- 0 +induced 0 +nephrotoxicity 3 +. 0 + +Therefore 0 +, 0 +the 0 +effect 0 +of 0 +bis 1 +( 2 +p 2 +- 2 +nitrophenyl 2 +) 2 +phosphate 2 +( 0 +BNPP 1 +) 0 +, 0 +an 0 +acylamidase 0 +inhibitor 0 +, 0 +on 0 +APAP 1 +and 0 +PAP 1 +nephrotoxicity 3 +and 0 +metabolism 0 +was 0 +determined 0 +. 0 + +BNPP 1 +( 0 +1 0 +to 0 +8 0 +mM 0 +) 0 +reduced 0 +APAP 1 +deacetylation 0 +and 0 +covalent 0 +binding 0 +in 0 +F344 0 +renal 0 +cortical 0 +homogenates 0 +in 0 +a 0 +concentration 0 +- 0 +dependent 0 +manner 0 +. 0 + +Pretreatment 0 +of 0 +animals 0 +with 0 +BNPP 1 +prior 0 +to 0 +APAP 1 +or 0 +PAP 1 +administration 0 +resulted 0 +in 0 +marked 0 +reduction 0 +of 0 +APAP 1 +( 0 +900 0 +mg 0 +/ 0 +kg 0 +) 0 +nephrotoxicity 3 +but 0 +not 0 +PAP 1 +nephrotoxicity 3 +. 0 + +This 0 +result 0 +was 0 +not 0 +due 0 +to 0 +altered 0 +disposition 0 +of 0 +either 0 +APAP 1 +or 0 +acetylated 0 +metabolites 0 +in 0 +plasma 0 +or 0 +renal 0 +cortical 0 +and 0 +hepatic 0 +tissue 0 +. 0 + +Rather 0 +, 0 +BNPP 1 +pretreatment 0 +reduced 0 +the 0 +fraction 0 +of 0 +APAP 1 +excreted 0 +as 0 +PAP 1 +by 0 +64 0 +and 0 +75 0 +% 0 +after 0 +APAP 1 +doses 0 +of 0 +750 0 +and 0 +900 0 +mg 0 +/ 0 +kg 0 +. 0 + +BNPP 1 +did 0 +not 0 +alter 0 +the 0 +excretion 0 +of 0 +APAP 1 +or 0 +any 0 +of 0 +its 0 +non 0 +- 0 +deacetylated 0 +metabolites 0 +nor 0 +did 0 +BNPP 1 +alter 0 +excretion 0 +of 0 +PAP 1 +or 0 +its 0 +metabolites 0 +after 0 +PAP 1 +doses 0 +of 0 +150 0 +and 0 +300 0 +mg 0 +/ 0 +kg 0 +. 0 + +Therefore 0 +, 0 +the 0 +BNPP 1 +- 0 +induced 0 +reduction 0 +in 0 +APAP 1 +- 0 +induced 0 +nephrotoxicity 3 +appears 0 +to 0 +be 0 +due 0 +to 0 +inhibition 0 +of 0 +APAP 1 +deacetylation 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +PAP 1 +formation 0 +, 0 +in 0 +vivo 0 +, 0 +accounts 0 +, 0 +at 0 +least 0 +in 0 +part 0 +, 0 +for 0 +APAP 1 +- 0 +induced 0 +renal 3 +tubular 4 +necrosis 4 +. 0 + +Morphine 1 +- 0 +induced 0 +seizures 3 +in 0 +newborn 0 +infants 0 +. 0 + +Two 0 +neonates 0 +suffered 0 +from 0 +generalized 0 +seizures 3 +during 0 +the 0 +course 0 +of 0 +intravenous 0 +morphine 1 +sulfate 2 +for 0 +post 0 +- 0 +operative 0 +analgesia 0 +. 0 + +They 0 +received 0 +morphine 1 +in 0 +doses 0 +of 0 +32 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +hr 0 +and 0 +40 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +hr 0 +larger 0 +than 0 +a 0 +group 0 +of 0 +10 0 +neonates 0 +who 0 +received 0 +6 0 +- 0 +24 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +hr 0 +and 0 +had 0 +no 0 +seizures 3 +. 0 + +Plasma 0 +concentrations 0 +of 0 +morphine 1 +in 0 +these 0 +neonates 0 +was 0 +excessive 0 +( 0 +60 0 +and 0 +90 0 +mg 0 +/ 0 +ml 0 +) 0 +. 0 + +0ther 0 +known 0 +reasons 0 +for 0 +seizures 3 +were 0 +ruled 0 +out 0 +and 0 +the 0 +convulsions 3 +stopped 0 +a 0 +few 0 +hours 0 +after 0 +cessation 0 +of 0 +morphine 1 +and 0 +did 0 +not 0 +reoccur 0 +in 0 +the 0 +subsequent 0 +8 0 +months 0 +. 0 + +It 0 +is 0 +suggested 0 +that 0 +post 0 +- 0 +operative 0 +intravenous 0 +morphine 1 +should 0 +not 0 +exceed 0 +20 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +ml 0 +in 0 +neonates 0 +. 0 + +Indomethacin 1 +induced 0 +hypotension 3 +in 0 +sodium 1 +and 0 +volume 0 +depleted 0 +rats 0 +. 0 + +After 0 +a 0 +single 0 +oral 0 +dose 0 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +indomethacin 1 +( 0 +IDM 1 +) 0 +to 0 +sodium 1 +and 0 +volume 0 +depleted 0 +rats 0 +plasma 0 +renin 0 +activity 0 +( 0 +PRA 0 +) 0 +and 0 +systolic 0 +blood 0 +pressure 0 +fell 0 +significantly 0 +within 0 +four 0 +hours 0 +. 0 + +In 0 +sodium 1 +repleted 0 +animals 0 +indomethacin 1 +did 0 +not 0 +change 0 +systolic 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +although 0 +plasma 0 +renin 0 +activity 0 +was 0 +decreased 0 +. 0 + +Thus 0 +, 0 +indomethacin 1 +by 0 +inhibition 0 +of 0 +prostaglandin 1 +synthesis 0 +may 0 +diminish 0 +the 0 +blood 0 +pressure 0 +maintaining 0 +effect 0 +of 0 +the 0 +stimulated 0 +renin 0 +- 0 +angiotensin 1 +system 0 +in 0 +sodium 1 +and 0 +volume 0 +depletion 0 +. 0 + +0n 0 +the 0 +antiarrhythmic 0 +activity 0 +of 0 +one 0 +N 0 +- 0 +substituted 0 +piperazine 1 +derivative 0 +of 0 +trans 1 +- 2 +2 2 +- 2 +amino 2 +- 2 +3 2 +- 2 +hydroxy 2 +- 2 +1 2 +, 2 +2 2 +, 2 +3 2 +, 2 +4 2 +- 2 +tetrahydroanaphthalene 2 +. 0 + +The 0 +antiarrhythmic 0 +activity 0 +of 0 +the 0 +compound 0 +N 1 +- 2 +( 2 +trans 2 +- 2 +3 2 +- 2 +hydroxy 2 +- 2 +1 2 +, 2 +2 2 +, 2 +3 2 +, 2 +4 2 +- 2 +tetrahydro 2 +- 2 +2 2 +- 2 +naphthyl 2 +) 2 +- 2 +N 2 +- 2 +( 2 +3 2 +- 2 +oxo 2 +- 2 +3 2 +- 2 +phenyl 2 +- 2 +2 2 +- 2 +methylpropyl 2 +) 2 +- 2 +piperazine 2 +hydrochloride 2 +, 0 +referred 0 +to 0 +as 0 +P11 1 +, 0 +is 0 +studied 0 +on 0 +anaesthesized 0 +cats 0 +and 0 +Wistar 0 +albino 0 +rats 0 +, 0 +as 0 +well 0 +as 0 +on 0 +non 0 +- 0 +anaesthesized 0 +rabbits 0 +. 0 + +Four 0 +types 0 +of 0 +experimental 0 +arrhythmia 3 +are 0 +used 0 +- 0 +- 0 +with 0 +BaCl2 1 +, 0 +with 0 +chloroform 1 +- 0 +adrenaline 1 +, 0 +with 0 +strophantine 1 +G 2 +and 0 +with 0 +aconitine 1 +. 0 + +The 0 +compound 0 +P11 1 +is 0 +introduced 0 +in 0 +doses 0 +of 0 +0 0 +. 0 +25 0 +and 0 +0 0 +. 0 +50 0 +mg 0 +/ 0 +kg 0 +intravenously 0 +and 0 +10 0 +mg 0 +/ 0 +kg 0 +orally 0 +. 0 + +The 0 +compound 0 +manifests 0 +antiarrhythmic 0 +activity 0 +in 0 +all 0 +models 0 +of 0 +experimental 0 +arrhythmia 3 +used 0 +, 0 +causing 0 +greatest 0 +inhibition 0 +on 0 +the 0 +arrhythmia 3 +induced 0 +by 0 +chloroform 1 +- 0 +adrenaline 1 +( 0 +in 0 +90 0 +per 0 +cent 0 +) 0 +and 0 +with 0 +BaCl2 1 +( 0 +in 0 +84 0 +per 0 +cent 0 +) 0 +. 0 + +The 0 +results 0 +obtained 0 +are 0 +associated 0 +with 0 +the 0 +beta 0 +- 0 +adrenoblocking 0 +and 0 +with 0 +the 0 +membrane 0 +- 0 +stabilizing 0 +action 0 +of 0 +the 0 +compound 0 +. 0 + +Recurrent 0 +subarachnoid 3 +hemorrhage 4 +associated 0 +with 0 +aminocaproic 1 +acid 2 +therapy 0 +and 0 +acute 3 +renal 4 +artery 4 +thrombosis 4 +. 0 + +Case 0 +report 0 +. 0 + +Epsilon 1 +aminocaproic 2 +acid 2 +( 0 +EACA 1 +) 0 +has 0 +been 0 +used 0 +to 0 +prevent 0 +rebleeding 0 +in 0 +patients 0 +with 0 +subarachnoid 3 +hemorrhage 4 +( 0 +SAH 3 +) 0 +. 0 + +Although 0 +this 0 +agent 0 +does 0 +decrease 0 +the 0 +frequency 0 +of 0 +rebleeding 0 +, 0 +several 0 +reports 0 +have 0 +described 0 +thrombotic 3 +complications 0 +of 0 +EACA 1 +therapy 0 +. 0 + +These 0 +complications 0 +have 0 +included 0 +clinical 0 +deterioration 0 +and 0 +intracranial 3 +vascular 4 +thrombosis 4 +in 0 +patients 0 +with 0 +SAH 3 +, 0 +arteriolar 0 +and 0 +capillary 0 +fibrin 0 +thrombi 3 +in 0 +patients 0 +with 0 +fibrinolytic 0 +syndromes 0 +treated 0 +with 0 +EACA 1 +, 0 +or 0 +other 0 +thromboembolic 3 +phenomena 4 +. 0 + +Since 0 +intravascular 0 +fibrin 0 +thrombi 3 +are 0 +often 0 +observed 0 +in 0 +patients 0 +with 0 +fibrinolytic 0 +disorders 0 +, 0 +EACA 1 +should 0 +not 0 +be 0 +implicated 0 +in 0 +the 0 +pathogenesis 0 +of 0 +fibrin 0 +thrombi 3 +in 0 +patients 0 +with 0 +disseminated 3 +intravascular 4 +coagulation 4 +or 0 +other 0 +" 0 +consumption 3 +coagulopathies 4 +. 0 +" 0 +This 0 +report 0 +describes 0 +subtotal 0 +infarction 3 +of 0 +the 0 +kidney 0 +due 0 +to 0 +thrombosis 3 +of 4 +a 4 +normal 4 +renal 4 +artery 4 +. 0 + +This 0 +occlusion 0 +occurred 0 +after 0 +EACA 1 +therapy 0 +in 0 +a 0 +patient 0 +with 0 +SAH 3 +and 0 +histopathological 0 +documentation 0 +of 0 +recurrent 0 +SAH 3 +. 0 + +The 0 +corresponding 0 +clinical 0 +event 0 +was 0 +characterized 0 +by 0 +marked 0 +hypertension 3 +and 0 +abrupt 0 +neurological 0 +deterioration 0 +. 0 + +Effect 0 +of 0 +vincristine 1 +sulfate 2 +on 0 +Pseudomonas 3 +infections 4 +in 0 +monkeys 0 +. 0 + +In 0 +rhesus 0 +monkeys 0 +, 0 +intravenous 0 +challenge 0 +with 0 +0 0 +. 0 +6 0 +x 0 +10 0 +( 0 +10 0 +) 0 +to 0 +2 0 +. 0 +2 0 +x 0 +10 0 +( 0 +10 0 +) 0 +Pseudomonas 0 +aeruginosa 0 +organisms 0 +caused 0 +acute 0 +illness 0 +of 0 +4 0 +to 0 +5 0 +days 0 +' 0 +duration 0 +with 0 +spontaneous 0 +recovery 0 +in 0 +13 0 +of 0 +15 0 +monkeys 0 +; 0 +blood 0 +cultures 0 +became 0 +negative 0 +3 0 +to 0 +17 0 +days 0 +after 0 +challenge 0 +. 0 + +Leukocytosis 3 +was 0 +observed 0 +in 0 +all 0 +monkeys 0 +. 0 + +Intravenous 0 +or 0 +intratracheal 0 +inoculation 0 +of 0 +2 0 +. 0 +0 0 +to 0 +2 0 +. 0 +5 0 +mg 0 +of 0 +vincristine 1 +sulfate 2 +was 0 +followed 0 +by 0 +leukopenia 3 +in 0 +4 0 +to 0 +5 0 +days 0 +. 0 + +Intravenous 0 +inoculation 0 +of 0 +4 0 +. 0 +2 0 +x 0 +10 0 +( 0 +10 0 +) 0 +to 0 +7 0 +. 0 +8 0 +x 0 +10 0 +( 0 +10 0 +) 0 +pyocin 0 +type 0 +6 0 +Pseudomonas 0 +organisms 0 +in 0 +monkeys 0 +given 0 +vincristine 1 +sulfate 2 +4 0 +days 0 +previously 0 +resulted 0 +in 0 +fatal 0 +infection 3 +in 0 +11 0 +of 0 +14 0 +monkeys 0 +, 0 +whereas 0 +none 0 +of 0 +four 0 +receiving 0 +Pseudomonas 0 +alone 0 +died 0 +. 0 + +These 0 +studies 0 +suggest 0 +that 0 +an 0 +antimetabolite 0 +- 0 +induced 0 +leukopenia 3 +predisposes 0 +to 0 +severe 0 +Pseudomonas 0 +sepsis 3 +and 0 +that 0 +such 0 +monkeys 0 +may 0 +serve 0 +as 0 +a 0 +biological 0 +model 0 +for 0 +study 0 +of 0 +comparative 0 +efficacy 0 +of 0 +antimicrobial 0 +agents 0 +. 0 + +Modification 0 +by 0 +propranolol 1 +of 0 +cardiovascular 0 +effects 0 +of 0 +induced 0 +hypoglycaemia 3 +. 0 + +The 0 +cardiovascular 0 +effects 0 +of 0 +hypoglycaemia 3 +, 0 +with 0 +and 0 +without 0 +beta 0 +- 0 +blockade 0 +, 0 +were 0 +compared 0 +in 0 +fourteen 0 +healthy 0 +men 0 +. 0 + +Eight 0 +received 0 +insulin 0 +alone 0 +, 0 +and 0 +eight 0 +, 0 +including 0 +two 0 +of 0 +the 0 +original 0 +insulin 0 +- 0 +only 0 +group 0 +, 0 +were 0 +given 0 +propranolol 1 +and 0 +insulin 0 +. 0 + +In 0 +the 0 +insulin 0 +- 0 +group 0 +the 0 +period 0 +of 0 +hypoglycaemia 3 +was 0 +associated 0 +with 0 +an 0 +increase 0 +in 0 +heart 0 +- 0 +rate 0 +and 0 +a 0 +fall 0 +in 0 +diastolic 0 +blood 0 +- 0 +pressure 0 +. 0 + +In 0 +the 0 +propranolol 1 +- 0 +insulin 0 +group 0 +there 0 +was 0 +a 0 +significant 0 +fall 0 +in 0 +heart 0 +- 0 +rate 0 +in 0 +most 0 +subjects 0 +and 0 +an 0 +increase 0 +in 0 +diastolic 0 +pressure 0 +. 0 + +Typical 0 +S 0 +- 0 +T 0 +/ 0 +T 0 +changes 0 +occurred 0 +in 0 +the 0 +insulin 0 +- 0 +group 0 +but 0 +in 0 +none 0 +of 0 +the 0 +propranolol 1 +- 0 +insulin 0 +group 0 +. 0 + +Hypertension 3 +in 0 +diabetics 3 +prone 0 +to 0 +hypoglycaemia 3 +attacks 0 +should 0 +not 0 +be 0 +treated 0 +with 0 +beta 0 +- 0 +blockers 0 +because 0 +these 0 +drugs 0 +may 0 +cause 0 +a 0 +sharp 0 +rise 0 +in 0 +blood 0 +- 0 +pressure 0 +in 0 +such 0 +patients 0 +. 0 + +Long 0 +- 0 +term 0 +propranolol 1 +therapy 0 +in 0 +pregnancy 0 +: 0 +maternal 0 +and 0 +fetal 0 +outcome 0 +. 0 + +Propranolol 1 +, 0 +a 0 +beta 0 +- 0 +adrenergic 0 +blocking 0 +agent 0 +, 0 +has 0 +found 0 +an 0 +important 0 +position 0 +in 0 +the 0 +practice 0 +of 0 +medicine 0 +. 0 + +Its 0 +use 0 +in 0 +pregnancy 0 +, 0 +however 0 +, 0 +is 0 +an 0 +open 0 +question 0 +as 0 +a 0 +number 0 +of 0 +detrimental 0 +side 0 +effects 0 +have 0 +been 0 +reported 0 +in 0 +the 0 +fetus 0 +and 0 +neonate 0 +. 0 + +Ten 0 +patients 0 +and 0 +12 0 +pregnancies 0 +are 0 +reported 0 +where 0 +chronic 0 +propranolol 1 +has 0 +been 0 +administered 0 +. 0 + +Five 0 +patients 0 +with 0 +serial 0 +pregnancies 0 +with 0 +and 0 +without 0 +propranolol 1 +therapy 0 +are 0 +also 0 +examined 0 +. 0 + +Maternal 0 +, 0 +fetal 0 +, 0 +and 0 +neonatal 0 +complications 0 +are 0 +examined 0 +. 0 + +An 0 +attempt 0 +is 0 +made 0 +to 0 +differentiate 0 +drug 0 +- 0 +related 0 +complications 0 +from 0 +maternal 0 +disease 0 +- 0 +- 0 +related 0 +complications 0 +. 0 + +We 0 +conclude 0 +that 0 +previously 0 +reported 0 +hypoglycemia 3 +, 0 +hyperbilirubinemia 3 +, 0 +polycythemia 3 +, 0 +neonatal 3 +apnea 4 +, 0 +and 0 +bradycardia 3 +are 0 +not 0 +invariable 0 +and 0 +cannot 0 +be 0 +statistically 0 +correlated 0 +with 0 +chronic 0 +propranolol 1 +therapy 0 +. 0 + +Growth 3 +retardation 4 +, 0 +however 0 +, 0 +appears 0 +to 0 +be 0 +significant 0 +in 0 +both 0 +of 0 +our 0 +series 0 +. 0 + +Central 0 +excitatory 0 +actions 0 +of 0 +flurazepam 1 +. 0 + +Toxic 0 +actions 0 +of 0 +flurazepam 1 +( 0 +FZP 1 +) 0 +were 0 +studied 0 +in 0 +cats 0 +, 0 +mice 0 +and 0 +rats 0 +. 0 + +High 0 +doses 0 +caused 0 +an 0 +apparent 0 +central 0 +excitation 0 +, 0 +most 0 +clearly 0 +seen 0 +as 0 +clonic 0 +convulsions 3 +, 0 +superimposed 0 +on 0 +general 0 +depression 3 +. 0 + +Following 0 +a 0 +lethal 0 +dose 0 +, 0 +death 0 +was 0 +always 0 +associated 0 +with 0 +convulsions 3 +. 0 + +Comparing 0 +the 0 +relative 0 +sensitivity 0 +to 0 +central 0 +depression 3 +and 0 +excitation 0 +revealed 0 +that 0 +rats 0 +were 0 +least 0 +likely 0 +to 0 +have 0 +convulsions 3 +at 0 +doses 0 +that 0 +did 0 +not 0 +first 0 +cause 0 +loss 3 +of 4 +consciousness 4 +, 0 +while 0 +cats 0 +most 0 +clearly 0 +showed 0 +marked 0 +central 0 +excitatory 0 +actions 0 +. 0 + +Signs 0 +of 0 +FZP 1 +toxocity 3 +in 0 +cats 0 +included 0 +excessive 0 +salivation 3 +, 0 +extreme 0 +apprehensive 0 +behavior 0 +, 0 +retching 0 +, 0 +muscle 3 +tremors 4 +and 0 +convulsions 3 +. 0 + +An 0 +interaction 0 +between 0 +FZP 1 +and 0 +pentylenetetrazol 1 +( 0 +PTZ 1 +) 0 +was 0 +shown 0 +by 0 +pretreating 0 +mice 0 +with 0 +FZP 1 +before 0 +PTZ 1 +challenge 0 +. 0 + +As 0 +a 0 +function 0 +of 0 +dose 0 +, 0 +FZP 1 +first 0 +protected 0 +against 0 +convulsions 3 +and 0 +death 0 +. 0 + +At 0 +higher 0 +doses 0 +, 0 +however 0 +, 0 +convulsions 3 +again 0 +emerged 0 +. 0 + +These 0 +doses 0 +of 0 +FZP 1 +were 0 +lower 0 +than 0 +those 0 +that 0 +would 0 +alone 0 +cause 0 +convulsions 3 +. 0 + +These 0 +results 0 +may 0 +be 0 +relevant 0 +to 0 +the 0 +use 0 +of 0 +FZP 1 +in 0 +clinical 0 +situations 0 +in 0 +which 0 +there 0 +is 0 +increased 0 +neural 0 +excitability 0 +, 0 +such 0 +as 0 +epilepsy 3 +or 0 +sedative 0 +- 0 +hypnotic 0 +drug 0 +withdrawal 0 +. 0 + +Use 0 +of 0 +propranolol 1 +in 0 +the 0 +treatment 0 +of 0 +idiopathic 3 +orthostatic 4 +hypotension 4 +. 0 + +Five 0 +patients 0 +with 0 +idiopathic 3 +orthostatic 4 +hypotension 4 +who 0 +had 0 +physiologic 0 +and 0 +biochemical 0 +evidence 0 +of 0 +severe 0 +autonomic 0 +dysfunction 0 +were 0 +included 0 +in 0 +the 0 +study 0 +. 0 + +They 0 +all 0 +exhibited 0 +markedly 0 +reduced 0 +plasma 0 +catecholamines 1 +and 0 +plasma 0 +renin 0 +activity 0 +in 0 +both 0 +recumbent 0 +and 0 +upright 0 +positions 0 +and 0 +had 0 +marked 0 +hypersensitivity 3 +to 0 +the 0 +pressor 0 +effects 0 +of 0 +infused 0 +norepinephrine 1 +. 0 + +Treatment 0 +with 0 +propanolol 1 +administered 0 +intravenously 0 +( 0 +1 0 +- 0 +5 0 +mg 0 +) 0 +produced 0 +increases 0 +in 0 +supine 0 +and 0 +upright 0 +blood 0 +pressure 0 +in 0 +4 0 +of 0 +the 0 +5 0 +individuals 0 +with 0 +rises 0 +ranging 0 +from 0 +11 0 +/ 0 +6 0 +to 0 +22 0 +/ 0 +11 0 +mmHg 0 +. 0 + +Chronic 0 +oral 0 +administration 0 +of 0 +propranolol 1 +( 0 +40 0 +- 0 +160 0 +mg 0 +/ 0 +day 0 +) 0 +also 0 +elevated 0 +the 0 +blood 0 +pressures 0 +of 0 +these 0 +individuals 0 +with 0 +increases 0 +in 0 +the 0 +order 0 +of 0 +20 0 +- 0 +35 0 +/ 0 +15 0 +- 0 +25 0 +mmg 0 +being 0 +observed 0 +. 0 + +In 0 +1 0 +patient 0 +, 0 +marked 0 +hypertension 3 +was 0 +induced 0 +by 0 +propranolol 1 +and 0 +the 0 +drug 0 +had 0 +to 0 +be 0 +withdrawn 0 +. 0 + +It 0 +otherwise 0 +was 0 +well 0 +tolerated 0 +and 0 +no 0 +important 0 +side 0 +effects 0 +were 0 +observed 0 +. 0 + +Treatment 0 +has 0 +been 0 +continued 0 +in 0 +3 0 +individuals 0 +for 0 +6 0 +- 0 +13 0 +months 0 +with 0 +persistence 0 +of 0 +the 0 +pressor 0 +effect 0 +, 0 +although 0 +there 0 +appears 0 +to 0 +have 0 +been 0 +some 0 +decrease 0 +in 0 +the 0 +degree 0 +of 0 +response 0 +with 0 +time 0 +. 0 + +Hemodynamic 0 +measurements 0 +in 0 +1 0 +of 0 +the 0 +patients 0 +demonstrated 0 +an 0 +increase 0 +in 0 +total 0 +peripheral 0 +resistance 0 +and 0 +essentially 0 +no 0 +change 0 +in 0 +cardiac 0 +output 0 +following 0 +propranolol 1 +therapy 0 +. 0 + +The 0 +studies 0 +suggest 0 +that 0 +propranolol 1 +is 0 +a 0 +useful 0 +drug 0 +in 0 +selected 0 +patients 0 +with 0 +severe 0 +idiopathic 3 +orthostatic 4 +hypotension 4 +. 0 + +Total 0 +intravenous 0 +anesthesia 0 +with 0 +etomidate 1 +. 0 + +III 0 +. 0 + +Some 0 +observations 0 +in 0 +adults 0 +. 0 + +An 0 +investigation 0 +was 0 +undertaken 0 +to 0 +determine 0 +the 0 +dosage 0 +of 0 +etomidate 1 +required 0 +to 0 +maintain 0 +sleep 0 +in 0 +adults 0 +undergoing 0 +surgery 0 +under 0 +regional 0 +local 0 +anesthesia 0 +. 0 + +Premedication 0 +of 0 +diazepam 1 +10 0 +mg 0 +and 0 +atropine 1 +0 0 +. 0 +5 0 +mg 0 +was 0 +given 0 +, 0 +and 0 +sleep 0 +was 0 +induced 0 +and 0 +maintained 0 +by 0 +intermittent 0 +intravenous 0 +injections 0 +of 0 +etomidate 1 +0 0 +. 0 +1 0 +/ 0 +mg 0 +/ 0 +kg 0 +, 0 +given 0 +whenever 0 +the 0 +patient 0 +would 0 +open 0 +his 0 +eyes 0 +on 0 +request 0 +. 0 + +A 0 +mean 0 +overall 0 +dose 0 +of 0 +etomidate 1 +17 0 +. 0 +4 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +. 0 +was 0 +required 0 +to 0 +maintain 0 +sleep 0 +, 0 +but 0 +great 0 +individual 0 +variation 0 +occurred 0 +, 0 +with 0 +older 0 +patients 0 +requiring 0 +less 0 +drug 0 +. 0 + +The 0 +investigation 0 +was 0 +discontinued 0 +after 0 +18 0 +patients 0 +because 0 +of 0 +the 0 +frequency 0 +and 0 +intensity 0 +of 0 +side 0 +- 0 +effects 0 +, 0 +particularly 0 +pain 3 +and 0 +myoclonia 3 +, 0 +which 0 +caused 0 +the 0 +technique 0 +to 0 +be 0 +abandoned 0 +in 0 +two 0 +cases 0 +. 0 + +It 0 +is 0 +considered 0 +unlikely 0 +that 0 +etomidate 1 +will 0 +prove 0 +to 0 +be 0 +the 0 +hypnotic 0 +of 0 +choice 0 +for 0 +a 0 +totally 0 +intravenous 0 +anesthetic 0 +technique 0 +in 0 +adults 0 +because 0 +of 0 +the 0 +high 0 +incidence 0 +of 0 +myoclonia 3 +after 0 +prolonged 0 +administration 0 +. 0 + +In 0 +several 0 +patients 0 +uncontrollable 0 +muscle 0 +movements 0 +persisted 0 +for 0 +many 0 +minutes 0 +after 0 +complete 0 +recovery 0 +of 0 +consciousness 0 +. 0 + +Evidence 0 +for 0 +cardiac 0 +beta 0 +2 0 +- 0 +adrenoceptors 0 +in 0 +man 0 +. 0 + +We 0 +compared 0 +the 0 +effects 0 +of 0 +single 0 +doses 0 +of 0 +50 0 +mg 0 +atenolol 1 +( 0 +cardioselective 0 +) 0 +, 0 +40 0 +mg 0 +propranolol 1 +( 0 +nonselective 0 +) 0 +, 0 +and 0 +placebo 0 +on 0 +both 0 +exercise 0 +- 0 +and 0 +isoproterenol 1 +- 0 +induced 0 +tachycardia 3 +in 0 +two 0 +experiments 0 +involving 0 +nine 0 +normal 0 +subjects 0 +. 0 + +Maximal 0 +exercise 0 +heart 0 +rate 0 +was 0 +reduced 0 +from 0 +187 0 ++ 0 +/ 0 +- 0 +4 0 +( 0 +SEM 0 +) 0 +after 0 +placebo 0 +to 0 +146 0 ++ 0 +/ 0 +- 0 +7 0 +bpm 0 +after 0 +atenolol 1 +and 0 +138 0 ++ 0 +/ 0 +- 0 +6 0 +bpm 0 +after 0 +propranolol 1 +, 0 +but 0 +there 0 +were 0 +no 0 +differences 0 +between 0 +the 0 +drugs 0 +. 0 + +The 0 +effects 0 +on 0 +isoproterenol 1 +tachycardia 3 +were 0 +determined 0 +before 0 +and 0 +after 0 +atropine 1 +( 0 +0 0 +. 0 +04 0 +mg 0 +/ 0 +kg 0 +IV 0 +) 0 +. 0 + +Isoproterenol 1 +sensitivity 0 +was 0 +determined 0 +as 0 +the 0 +intravenous 0 +dose 0 +that 0 +increased 0 +heart 0 +rate 0 +by 0 +25 0 +bpm 0 +( 0 +CD25 0 +) 0 +and 0 +this 0 +was 0 +increased 0 +from 0 +1 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +micrograms 0 +after 0 +placebo 0 +to 0 +38 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +3 0 +micrograms 0 +after 0 +propranolol 1 +and 0 +8 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +7 0 +micrograms 0 +after 0 +atenolol 1 +. 0 + +The 0 +difference 0 +in 0 +the 0 +effects 0 +of 0 +the 0 +two 0 +was 0 +significant 0 +. 0 + +After 0 +atropine 1 +the 0 +CD25 0 +was 0 +unchanged 0 +after 0 +placebo 0 +( 0 +2 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +3 0 +micrograms 0 +) 0 +and 0 +atenolol 1 +( 0 +7 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +micrograms 0 +) 0 +; 0 +it 0 +was 0 +reduced 0 +after 0 +propranolol 1 +( 0 +24 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +0 0 +micrograms 0 +) 0 +, 0 +but 0 +remained 0 +different 0 +from 0 +atenolol 1 +. 0 + +This 0 +change 0 +with 0 +propranolol 1 +sensitivity 0 +was 0 +calculated 0 +as 0 +the 0 +apparent 0 +Ka 0 +, 0 +this 0 +was 0 +unchanged 0 +by 0 +atropine 1 +( 0 +11 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +1 0 +and 0 +10 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +5 0 +ml 0 +/ 0 +ng 0 +) 0 +. 0 + +These 0 +data 0 +are 0 +consistent 0 +with 0 +the 0 +hypothesis 0 +that 0 +exercise 0 +- 0 +induced 0 +tachycardia 3 +results 0 +largely 0 +from 0 +beta 0 +1 0 +- 0 +receptor 0 +activation 0 +that 0 +is 0 +blocked 0 +by 0 +both 0 +cardioselective 0 +and 0 +nonselective 0 +drugs 0 +, 0 +whereas 0 +isoproterenol 1 +activates 0 +both 0 +beta 0 +1 0 +- 0 +and 0 +beta 0 +2 0 +- 0 +receptors 0 +so 0 +that 0 +after 0 +cardioselective 0 +blockade 0 +there 0 +remains 0 +a 0 +beta 0 +2 0 +- 0 +component 0 +that 0 +can 0 +be 0 +blocked 0 +with 0 +a 0 +nonselective 0 +drug 0 +. 0 + +While 0 +there 0 +appear 0 +to 0 +be 0 +beta 0 +2 0 +- 0 +receptors 0 +in 0 +the 0 +human 0 +heart 0 +, 0 +their 0 +physiologic 0 +or 0 +pathologic 0 +roles 0 +remain 0 +to 0 +be 0 +defined 0 +. 0 + +Hormones 0 +and 0 +risk 0 +of 0 +breast 3 +cancer 4 +. 0 + +This 0 +paper 0 +reports 0 +the 0 +results 0 +of 0 +a 0 +study 0 +of 0 +50 0 +menopausal 0 +women 0 +receiving 0 +hormonal 0 +replacement 0 +therapy 0 +. 0 + +The 0 +majority 0 +( 0 +29 0 +) 0 +had 0 +surgical 0 +menopause 0 +; 0 +their 0 +mean 0 +age 0 +was 0 +45 0 +. 0 +7 0 +years 0 +. 0 + +It 0 +was 0 +hypothesized 0 +that 0 +progestins 1 +could 0 +equilibrate 0 +the 0 +effects 0 +of 0 +the 0 +estrogenic 0 +stimulation 0 +on 0 +the 0 +mammary 0 +and 0 +endometrial 0 +target 0 +tissues 0 +of 0 +women 0 +on 0 +hormonal 0 +replacement 0 +therapy 0 +. 0 + +The 0 +treatment 0 +schedule 0 +consisted 0 +of 0 +conjugated 1 +estrogens 2 +( 0 +Premarin 1 +) 0 +1 0 +. 0 +25 0 +mg 0 +/ 0 +day 0 +for 0 +21 0 +days 0 +and 0 +Medroxyprogesterone 1 +acetate 2 +10 0 +mg 0 +/ 0 +day 0 +for 0 +10 0 +days 0 +in 0 +each 0 +month 0 +. 0 + +The 0 +mean 0 +treatment 0 +period 0 +was 0 +18 0 +months 0 +. 0 + +During 0 +the 0 +follow 0 +- 0 +up 0 +period 0 +, 0 +attention 0 +was 0 +paid 0 +to 0 +breast 0 +modifications 0 +as 0 +evidenced 0 +by 0 +symptomatology 0 +, 0 +physical 0 +examination 0 +, 0 +and 0 +plate 0 +thermography 0 +. 0 + +Mastodynia 3 +was 0 +reported 0 +by 0 +21 0 +patients 0 +, 0 +and 0 +physical 0 +examination 0 +revealed 0 +a 0 +light 0 +increase 0 +in 0 +breast 0 +firmness 0 +in 0 +12 0 +women 0 +and 0 +a 0 +moderate 0 +increase 0 +in 0 +breast 0 +nodularity 0 +in 0 +2 0 +women 0 +. 0 + +Themography 0 +confirmed 0 +the 0 +existence 0 +of 0 +an 0 +excessive 0 +breast 0 +stimulation 0 +in 0 +1 0 +women 0 +who 0 +complained 0 +of 0 +moderate 0 +mastodynia 3 +and 0 +in 0 +5 0 +of 0 +the 0 +7 0 +women 0 +who 0 +complained 0 +of 0 +severe 0 +mastodynia 3 +. 0 + +Normalization 0 +was 0 +obtained 0 +by 0 +halving 0 +the 0 +estrogen 1 +dose 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +hormonal 0 +replacement 0 +therapy 0 +can 0 +be 0 +safely 0 +prescribed 0 +if 0 +the 0 +following 0 +criteria 0 +are 0 +satisfied 0 +: 0 +1 0 +) 0 +preliminary 0 +evaluation 0 +of 0 +patients 0 +from 0 +a 0 +clinical 0 +, 0 +metabolic 0 +, 0 +cytologic 0 +, 0 +and 0 +mammographic 0 +perspective 0 +; 0 +2 0 +) 0 +cyclic 0 +treatment 0 +schedule 0 +, 0 +with 0 +a 0 +progestative 0 +phase 0 +of 0 +10 0 +days 0 +; 0 +and 0 +3 0 +) 0 +periodic 0 +complete 0 +follow 0 +- 0 +up 0 +, 0 +with 0 +accurate 0 +thermographic 0 +evaluation 0 +of 0 +the 0 +breast 0 +target 0 +tissues 0 +. 0 + +Early 0 +infections 3 +in 0 +kidney 0 +, 0 +heart 0 +, 0 +and 0 +liver 0 +transplant 0 +recipients 0 +on 0 +cyclosporine 1 +. 0 + +Eighty 0 +- 0 +one 0 +renal 0 +, 0 +seventeen 0 +heart 0 +, 0 +and 0 +twenty 0 +- 0 +four 0 +liver 0 +transplant 0 +patients 0 +were 0 +followed 0 +for 0 +infection 3 +. 0 + +Seventeen 0 +renal 0 +patients 0 +received 0 +azathioprine 1 +( 0 +Aza 1 +) 0 +and 0 +prednisone 1 +as 0 +part 0 +of 0 +a 0 +randomized 0 +trial 0 +of 0 +immunosuppression 0 +with 0 +21 0 +cyclosporine 1 +- 0 +and 0 +- 0 +prednisone 1 +- 0 +treated 0 +renal 0 +transplant 0 +patients 0 +. 0 + +All 0 +others 0 +received 0 +cyclosporine 1 +and 0 +prednisone 1 +. 0 + +The 0 +randomized 0 +Aza 1 +patients 0 +had 0 +more 0 +overall 0 +infections 3 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +and 0 +more 0 +nonviral 0 +infections 3 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +02 0 +) 0 +than 0 +the 0 +randomized 0 +cyclosporine 1 +patients 0 +. 0 + +Heart 0 +and 0 +liver 0 +patients 0 +had 0 +more 0 +infections 3 +than 0 +cyclosporine 1 +renal 0 +patients 0 +but 0 +fewer 0 +infections 3 +than 0 +the 0 +Aza 1 +renal 0 +patients 0 +. 0 + +There 0 +were 0 +no 0 +infectious 0 +deaths 0 +in 0 +renal 0 +transplant 0 +patients 0 +on 0 +cyclosporine 1 +or 0 +Aza 1 +, 0 +but 0 +infection 3 +played 0 +a 0 +major 0 +role 0 +in 0 +3 0 +out 0 +of 0 +6 0 +cardiac 0 +transplant 0 +deaths 0 +and 0 +in 0 +8 0 +out 0 +of 0 +9 0 +liver 0 +transplant 0 +deaths 0 +. 0 + +Renal 0 +patients 0 +on 0 +cyclosporine 1 +had 0 +the 0 +fewest 0 +bacteremias 3 +. 0 + +Analysis 0 +of 0 +site 0 +of 0 +infection 3 +showed 0 +a 0 +preponderance 0 +of 0 +abdominal 3 +infections 4 +in 0 +liver 0 +patients 0 +, 0 +intrathoracic 0 +infections 3 +in 0 +heart 0 +patients 0 +, 0 +and 0 +urinary 3 +tract 4 +infections 4 +in 0 +renal 0 +patients 0 +. 0 + +Pulmonary 0 +infections 3 +were 0 +less 0 +common 0 +in 0 +cyclosporine 1 +- 0 +treated 0 +renal 0 +patients 0 +than 0 +in 0 +Aza 1 +- 0 +treated 0 +patients 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +Aza 1 +patients 0 +had 0 +significantly 0 +more 0 +staphylococcal 3 +infections 4 +than 0 +all 0 +other 0 +transplant 0 +groups 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +005 0 +) 0 +, 0 +and 0 +systemic 0 +fungal 3 +infections 4 +occurred 0 +only 0 +in 0 +the 0 +liver 0 +transplant 0 +group 0 +. 0 + +Cytomegalovirus 0 +( 0 +CMV 0 +) 0 +shedding 0 +or 0 +serological 0 +rises 0 +in 0 +antibody 0 +titer 0 +, 0 +or 0 +both 0 +occurred 0 +in 0 +78 0 +% 0 +of 0 +cyclosporine 1 +patients 0 +and 0 +76 0 +% 0 +of 0 +Aza 1 +patients 0 +. 0 + +0f 0 +the 0 +cyclosporine 1 +patients 0 +, 0 +15 0 +% 0 +had 0 +symptoms 0 +related 0 +to 0 +CMV 3 +infection 4 +. 0 + +Serological 0 +evidence 0 +for 0 +Epstein 3 +Barr 4 +Virus 4 +infection 4 +was 0 +found 0 +in 0 +20 0 +% 0 +of 0 +65 0 +cyclosporine 1 +patients 0 +studied 0 +. 0 + +Three 0 +had 0 +associated 0 +symptoms 0 +, 0 +and 0 +one 0 +developed 0 +a 0 +lymphoma 3 +. 0 + +Structure 0 +- 0 +activity 0 +and 0 +dose 0 +- 0 +effect 0 +relationships 0 +of 0 +the 0 +antagonism 0 +of 0 +picrotoxin 1 +- 0 +induced 0 +seizures 3 +by 0 +cholecystokinin 1 +, 0 +fragments 0 +and 0 +analogues 0 +of 0 +cholecystokinin 1 +in 0 +mice 0 +. 0 + +Intraperitoneal 0 +administration 0 +of 0 +cholecystokinin 1 +octapeptide 2 +sulphate 0 +ester 0 +( 0 +CCK 1 +- 2 +8 2 +- 0 +SE 0 +) 0 +and 0 +nonsulphated 0 +cholecystokinin 1 +octapeptide 2 +( 0 +CCK 1 +- 2 +8 2 +- 0 +NS 0 +) 0 +enhanced 0 +the 0 +latency 0 +of 0 +seizures 3 +induced 0 +by 0 +picrotoxin 1 +in 0 +mice 0 +. 0 + +Experiments 0 +with 0 +N 0 +- 0 +and 0 +C 0 +- 0 +terminal 0 +fragments 0 +revealed 0 +that 0 +the 0 +C 0 +- 0 +terminal 0 +tetrapeptide 0 +( 0 +CCK 0 +- 0 +5 0 +- 0 +8 0 +) 0 +was 0 +the 0 +active 0 +centre 0 +of 0 +the 0 +CCK 0 +octapeptide 0 +molecule 0 +. 0 + +The 0 +analogues 0 +CCK 1 +- 2 +8 2 +- 0 +SE 0 +and 0 +CCK 1 +- 2 +8 2 +- 0 +NS 0 +( 0 +dose 0 +range 0 +0 0 +. 0 +2 0 +- 0 +6 0 +. 0 +4 0 +mumol 0 +/ 0 +kg 0 +) 0 +and 0 +caerulein 1 +dose 0 +range 0 +0 0 +. 0 +1 0 +- 0 +0 0 +. 0 +8 0 +mumol 0 +/ 0 +kg 0 +) 0 +showed 0 +bell 0 +- 0 +shaped 0 +dose 0 +- 0 +effect 0 +curves 0 +, 0 +with 0 +the 0 +greatest 0 +maximum 0 +inhibition 0 +for 0 +CCK 1 +- 2 +8 2 +- 0 +NS 0 +. 0 + +The 0 +peptide 0 +CCK 0 +- 0 +5 0 +- 0 +8 0 +had 0 +weak 0 +anticonvulsant 0 +activity 0 +in 0 +comparison 0 +to 0 +the 0 +octapeptides 0 +, 0 +3 0 +. 0 +2 0 +mumol 0 +/ 0 +kg 0 +and 0 +larger 0 +doses 0 +of 0 +the 0 +reference 0 +drug 0 +, 0 +diazepam 1 +, 0 +totally 0 +prevented 0 +picrotoxin 1 +- 0 +induced 0 +seizures 3 +and 0 +mortality 0 +. 0 + +The 0 +maximum 0 +effect 0 +of 0 +the 0 +peptides 0 +tested 0 +was 0 +less 0 +than 0 +that 0 +of 0 +diazepam 1 +. 0 + +Experiments 0 +with 0 +analogues 0 +and 0 +derivatives 0 +of 0 +CCK 0 +- 0 +5 0 +- 0 +8 0 +demonstrated 0 +that 0 +the 0 +effectiveness 0 +of 0 +the 0 +beta 0 +- 0 +alanyl 0 +derivatives 0 +of 0 +CCK 0 +- 0 +5 0 +- 0 +8 0 +were 0 +enhanced 0 +and 0 +that 0 +they 0 +were 0 +equipotent 0 +with 0 +CCK 1 +- 2 +8 2 +- 0 +SE 0 +. 0 + +0f 0 +the 0 +CCK 0 +- 0 +2 0 +- 0 +8 0 +analogues 0 +, 0 +Ser 0 +( 0 +S03H 0 +) 0 +7 0 +- 0 +Ac 0 +- 0 +CCK 0 +- 0 +2 0 +- 0 +8 0 +- 0 +SE 0 +and 0 +Thr 0 +( 0 +S03H 0 +) 0 +7 0 +- 0 +Ac 0 +- 0 +CCK 0 +- 0 +2 0 +- 0 +8 0 +- 0 +SE 0 +and 0 +Hyp 0 +( 0 +S03H 0 +) 0 +- 0 +Ac 0 +- 0 +CCK 0 +- 0 +2 0 +- 0 +8 0 +- 0 +SE 0 +were 0 +slightly 0 +more 0 +active 0 +than 0 +CCK 1 +- 2 +8 2 +- 0 +SE 0 +. 0 + +Vasopressin 1 +as 0 +a 0 +possible 0 +contributor 0 +to 0 +hypertension 3 +. 0 + +The 0 +role 0 +of 0 +vasopressin 1 +as 0 +a 0 +pressor 0 +agent 0 +to 0 +the 0 +hypertensive 3 +process 0 +was 0 +examined 0 +. 0 + +Vasopressin 1 +plays 0 +a 0 +major 0 +role 0 +in 0 +the 0 +pathogenesis 0 +of 0 +D0CA 1 +- 0 +salt 0 +hypertension 3 +, 0 +since 0 +the 0 +elevation 0 +of 0 +blood 0 +pressure 0 +was 0 +not 0 +substantial 0 +in 0 +the 0 +rats 0 +with 0 +lithium 1 +- 0 +treated 0 +diabetes 3 +insipidus 4 +after 0 +D0CA 1 +- 0 +salt 0 +treatment 0 +. 0 + +Administration 0 +of 0 +DDAVP 1 +which 0 +has 0 +antidiuretic 0 +action 0 +but 0 +minimal 0 +vasopressor 0 +effect 0 +failed 0 +to 0 +increase 0 +blood 0 +pressure 0 +to 0 +the 0 +levels 0 +observed 0 +after 0 +administration 0 +of 0 +AVP 0 +. 0 + +Furthermore 0 +, 0 +the 0 +pressor 0 +action 0 +of 0 +vasopressin 1 +appears 0 +to 0 +be 0 +important 0 +in 0 +the 0 +development 0 +of 0 +this 0 +model 0 +of 0 +hypertension 3 +, 0 +since 0 +the 0 +enhanced 0 +pressor 0 +responsiveness 0 +to 0 +the 0 +hormone 0 +was 0 +observed 0 +in 0 +the 0 +initial 0 +stage 0 +of 0 +hypertension 3 +. 0 + +Increased 0 +secretion 0 +of 0 +vasopressin 1 +from 0 +neurohypophysis 0 +also 0 +promotes 0 +the 0 +function 0 +of 0 +the 0 +hormone 0 +as 0 +a 0 +pathogenetic 0 +factor 0 +in 0 +hypertension 3 +. 0 + +An 0 +unproportional 0 +release 0 +of 0 +vasopressin 1 +compared 0 +to 0 +plasma 0 +osmolality 0 +may 0 +be 0 +induced 0 +by 0 +the 0 +absence 0 +of 0 +an 0 +adjusting 0 +control 0 +of 0 +angiotensin 1 +II 0 +forming 0 +and 0 +receptor 0 +binding 0 +capacity 0 +for 0 +sodium 1 +balance 0 +in 0 +the 0 +brain 0 +. 0 + +However 0 +, 0 +the 0 +role 0 +of 0 +vasopressin 1 +remains 0 +to 0 +be 0 +determined 0 +in 0 +human 0 +essential 0 +hypertension 3 +. 0 + +Toxic 3 +hepatitis 4 +induced 0 +by 0 +disulfiram 1 +in 0 +a 0 +non 0 +- 0 +alcoholic 0 +. 0 + +A 0 +reversible 0 +toxic 3 +liver 4 +damage 4 +was 0 +observed 0 +in 0 +a 0 +non 0 +- 0 +alcoholic 0 +woman 0 +treated 0 +with 0 +disulfiram 1 +. 0 + +The 0 +causative 0 +relationship 0 +was 0 +proven 0 +by 0 +challenge 0 +. 0 + +Atrial 3 +thrombosis 4 +involving 0 +the 0 +heart 0 +of 0 +F 0 +- 0 +344 0 +rats 0 +ingesting 0 +quinacrine 1 +hydrochloride 2 +. 0 + +Quinacrine 1 +hydrochloride 2 +is 0 +toxic 0 +for 0 +the 0 +heart 0 +of 0 +F 0 +- 0 +344 0 +rats 0 +. 0 + +Rats 0 +treated 0 +with 0 +500 0 +ppm 0 +quinacrine 1 +hydrochloride 2 +in 0 +the 0 +diet 0 +all 0 +developed 0 +a 0 +high 0 +incidence 0 +of 0 +left 0 +atrial 3 +thrombosis 4 +. 0 + +The 0 +lesion 0 +was 0 +associated 0 +with 0 +cardiac 3 +hypertrophy 4 +and 0 +dilatation 0 +and 0 +focal 0 +myocardial 3 +degeneration 4 +. 0 + +Rats 0 +died 0 +from 0 +cardiac 3 +hypertrophy 4 +with 0 +severe 0 +acute 0 +and 0 +chronic 0 +congestion 0 +of 0 +the 0 +lungs 0 +, 0 +liver 0 +, 0 +and 0 +other 0 +organs 0 +. 0 + +Seventy 0 +percent 0 +of 0 +rats 0 +given 0 +250 0 +ppm 0 +quinacrine 1 +hydrochloride 2 +and 0 +1 0 +, 0 +000 0 +ppm 0 +sodium 1 +nitrite 2 +simultaneously 0 +in 0 +the 0 +diet 0 +had 0 +thrombosis 3 +of 0 +the 0 +atria 0 +of 0 +the 0 +heart 0 +, 0 +while 0 +untreated 0 +control 0 +rats 0 +in 0 +this 0 +laboratory 0 +did 0 +not 0 +have 0 +atrial 3 +thrombosis 4 +. 0 + +Sodium 1 +nitrite 2 +in 0 +combination 0 +with 0 +quinacrine 1 +hydrochloride 2 +appeared 0 +to 0 +have 0 +no 0 +additional 0 +effect 0 +. 0 + +Alternating 3 +sinus 4 +rhythm 4 +and 0 +intermittent 0 +sinoatrial 3 +block 4 +induced 0 +by 0 +propranolol 1 +. 0 + +Alternating 3 +sinus 4 +rhythm 4 +and 0 +intermittent 0 +sinoatrial 3 +( 4 +S 4 +- 4 +A 4 +) 4 +block 4 +was 0 +observed 0 +in 0 +a 0 +57 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +, 0 +under 0 +treatment 0 +for 0 +angina 3 +with 0 +80 0 +mg 0 +propranolol 1 +daily 0 +. 0 + +The 0 +electrocardiogram 0 +showed 0 +alternation 0 +of 0 +long 0 +and 0 +short 0 +P 0 +- 0 +P 0 +intervals 0 +and 0 +occasional 0 +pauses 0 +. 0 + +These 0 +pauses 0 +were 0 +always 0 +preceded 0 +by 0 +the 0 +short 0 +P 0 +- 0 +P 0 +intervals 0 +and 0 +were 0 +usually 0 +followed 0 +by 0 +one 0 +or 0 +two 0 +P 0 +- 0 +P 0 +intervals 0 +of 0 +0 0 +. 0 +92 0 +- 0 +0 0 +. 0 +95 0 +s 0 +representing 0 +the 0 +basic 0 +sinus 0 +cycle 0 +. 0 + +Following 0 +these 0 +basic 0 +sinus 0 +cycles 0 +, 0 +alternating 3 +rhythm 4 +started 0 +with 0 +the 0 +longer 0 +P 0 +- 0 +P 0 +interval 0 +. 0 + +The 0 +long 0 +P 0 +- 0 +P 0 +intervals 0 +ranged 0 +between 0 +1 0 +. 0 +04 0 +- 0 +1 0 +. 0 +12 0 +s 0 +and 0 +the 0 +short 0 +P 0 +- 0 +P 0 +intervals 0 +between 0 +0 0 +. 0 +80 0 +- 0 +0 0 +. 0 +84 0 +s 0 +, 0 +respectively 0 +. 0 + +The 0 +duration 0 +of 0 +the 0 +pauses 0 +were 0 +equal 0 +or 0 +almost 0 +equal 0 +to 0 +one 0 +short 0 +plus 0 +one 0 +long 0 +P 0 +- 0 +P 0 +interval 0 +or 0 +to 0 +twice 0 +the 0 +basic 0 +sinus 0 +cycle 0 +. 0 + +In 0 +one 0 +recording 0 +a 0 +short 0 +period 0 +of 0 +regular 0 +sinus 0 +rhythm 0 +with 0 +intermittent 0 +2 0 +/ 0 +1 0 +S 3 +- 4 +A 4 +block 4 +was 0 +observed 0 +. 0 + +This 0 +short 0 +period 0 +of 0 +sinus 0 +rhythm 0 +was 0 +interrupted 0 +by 0 +sudden 0 +prolongation 0 +of 0 +the 0 +P 0 +- 0 +P 0 +interval 0 +starting 0 +the 0 +alternative 0 +rhythm 0 +. 0 + +There 0 +were 0 +small 0 +changes 0 +in 0 +the 0 +shape 0 +of 0 +the 0 +P 0 +waves 0 +and 0 +P 0 +- 0 +R 0 +intervals 0 +. 0 + +S 0 +- 0 +A 0 +conduction 0 +through 0 +two 0 +pathways 0 +, 0 +the 0 +first 0 +with 0 +2 0 +/ 0 +1 0 +block 0 +the 0 +second 0 +having 0 +0 0 +. 0 +12 0 +- 0 +0 0 +. 0 +14 0 +s 0 +longer 0 +conduction 0 +time 0 +and 0 +with 0 +occasional 0 +2 0 +/ 0 +1 0 +block 0 +was 0 +proposed 0 +for 0 +the 0 +explanation 0 +of 0 +the 0 +alternating 0 +P 0 +- 0 +P 0 +interval 0 +and 0 +other 0 +electrocardiographic 0 +features 0 +seen 0 +. 0 + +Atropine 1 +1 0 +mg 0 +given 0 +intravenously 0 +resulted 0 +in 0 +shortening 0 +of 0 +all 0 +P 0 +- 0 +P 0 +intervals 0 +without 0 +changing 0 +the 0 +rhythm 0 +. 0 + +The 0 +abnormal 0 +rhythm 0 +disappeared 0 +with 0 +the 0 +withdrawal 0 +of 0 +propranolol 1 +and 0 +when 0 +the 0 +drug 0 +was 0 +restarted 0 +a 0 +2 0 +/ 0 +1 0 +S 3 +- 4 +A 4 +block 4 +was 0 +seen 0 +. 0 + +This 0 +was 0 +accepted 0 +as 0 +evidence 0 +for 0 +propranolol 1 +being 0 +the 0 +cause 0 +of 0 +this 0 +conduction 3 +disorder 4 +. 0 + +Antitumor 0 +effect 0 +, 0 +cardiotoxicity 3 +, 0 +and 0 +nephrotoxicity 3 +of 0 +doxorubicin 1 +in 0 +the 0 +IgM 0 +solid 0 +immunocytoma 3 +- 0 +bearing 0 +L0U 0 +/ 0 +M 0 +/ 0 +WSL 0 +rat 0 +. 0 + +Antitumor 0 +activity 0 +, 0 +cardiotoxicity 3 +, 0 +and 0 +nephrotoxicity 3 +induced 0 +by 0 +doxorubicin 1 +were 0 +studied 0 +in 0 +L0U 0 +/ 0 +M 0 +/ 0 +WSL 0 +inbred 0 +rats 0 +each 0 +bearing 0 +a 0 +transplantable 0 +solid 0 +IgM 0 +immunocytoma 3 +. 0 + +Animals 0 +with 0 +a 0 +tumor 3 +( 0 +diameter 0 +, 0 +15 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +3 0 +mm 0 +) 0 +were 0 +treated 0 +with 0 +iv 0 +injections 0 +of 0 +doxorubicin 1 +on 0 +5 0 +consecutive 0 +days 0 +, 0 +followed 0 +by 0 +1 0 +weekly 0 +injection 0 +for 0 +7 0 +weeks 0 +( 0 +dose 0 +range 0 +, 0 +0 0 +. 0 +015 0 +- 0 +4 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +body 0 +wt 0 +) 0 +. 0 + +Tumor 3 +regression 0 +was 0 +observed 0 +with 0 +0 0 +. 0 +5 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +. 0 + +Complete 0 +disappearance 0 +of 0 +the 0 +tumor 3 +was 0 +induced 0 +with 0 +1 0 +. 0 +0 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +. 0 + +Histologic 0 +evidence 0 +of 0 +cardiotoxicity 3 +scored 0 +as 0 +grade 0 +III 0 +was 0 +only 0 +observed 0 +at 0 +a 0 +dose 0 +of 0 +1 0 +. 0 +0 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +. 0 + +Light 0 +microscopic 0 +evidence 0 +of 0 +renal 3 +damage 4 +was 0 +seen 0 +above 0 +a 0 +dose 0 +of 0 +0 0 +. 0 +5 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +, 0 +which 0 +resulted 0 +in 0 +albuminuria 3 +and 0 +very 0 +low 0 +serum 0 +albumin 0 +levels 0 +. 0 + +In 0 +the 0 +group 0 +that 0 +received 0 +1 0 +. 0 +0 0 +mg 0 +doxorubicin 1 +/ 0 +kg 0 +, 0 +the 0 +serum 0 +albumin 0 +level 0 +decreased 0 +from 0 +33 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +1 0 +to 0 +1 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +g 0 +/ 0 +liter 0 +. 0 + +Ascites 3 +and 0 +hydrothorax 3 +were 0 +observed 0 +simultaneously 0 +. 0 + +The 0 +same 0 +experiments 0 +were 0 +performed 0 +with 0 +non 0 +- 0 +tumor 3 +- 0 +bearing 0 +rats 0 +, 0 +in 0 +which 0 +no 0 +major 0 +differences 0 +were 0 +observed 0 +. 0 + +In 0 +conclusion 0 +, 0 +antitumor 0 +activity 0 +, 0 +cardiotoxicity 3 +, 0 +and 0 +nephrotoxicity 3 +were 0 +studied 0 +simultaneously 0 +in 0 +the 0 +same 0 +L0U 0 +/ 0 +M 0 +/ 0 +WSL 0 +rat 0 +. 0 + +Albuminuria 3 +due 0 +to 0 +renal 3 +damage 4 +led 0 +to 0 +extremely 0 +low 0 +serum 0 +albumin 0 +levels 0 +, 0 +so 0 +ascites 3 +and 0 +hydrothorax 3 +were 0 +not 0 +necessarily 0 +a 0 +consequence 0 +of 0 +the 0 +observed 0 +cardiomyopathy 3 +. 0 + +Intraoperative 0 +bradycardia 3 +and 0 +hypotension 3 +associated 0 +with 0 +timolol 1 +and 0 +pilocarpine 1 +eye 0 +drops 0 +. 0 + +A 0 +69 0 +- 0 +yr 0 +- 0 +old 0 +man 0 +, 0 +who 0 +was 0 +concurrently 0 +being 0 +treated 0 +with 0 +pilocarpine 1 +nitrate 2 +and 0 +timolol 1 +maleate 2 +eye 0 +drops 0 +, 0 +developed 0 +a 0 +bradycardia 3 +and 0 +became 0 +hypotensive 3 +during 0 +halothane 1 +anaesthesia 0 +. 0 + +Both 0 +timolol 1 +and 0 +pilocarpine 1 +were 0 +subsequently 0 +identified 0 +in 0 +a 0 +24 0 +- 0 +h 0 +collection 0 +of 0 +urine 0 +. 0 + +Timolol 1 +( 0 +but 0 +not 0 +pilocarpine 1 +) 0 +was 0 +detected 0 +in 0 +a 0 +sample 0 +of 0 +plasma 0 +removed 0 +during 0 +surgery 0 +; 0 +the 0 +plasma 0 +concentration 0 +of 0 +timolol 1 +( 0 +2 0 +. 0 +6 0 +ng 0 +ml 0 +- 0 +1 0 +) 0 +was 0 +consistent 0 +with 0 +partial 0 +beta 0 +- 0 +adrenoceptor 0 +blockade 0 +. 0 + +It 0 +is 0 +postulated 0 +that 0 +this 0 +action 0 +may 0 +have 0 +been 0 +enhanced 0 +during 0 +halothane 1 +anaesthesia 0 +with 0 +resultant 0 +bradycardia 3 +and 0 +hypotension 3 +. 0 + +Pilocarpine 1 +may 0 +have 0 +had 0 +a 0 +contributory 0 +effect 0 +. 0 + +Succinylcholine 1 +apnoea 3 +: 0 +attempted 0 +reversal 0 +with 0 +anticholinesterases 0 +. 0 + +Anticholinesterases 0 +were 0 +administered 0 +in 0 +an 0 +attempt 0 +to 0 +antagonize 0 +prolonged 0 +neuromuscular 3 +blockade 4 +following 0 +the 0 +administration 0 +of 0 +succinylcholine 1 +in 0 +a 0 +patient 0 +later 0 +found 0 +to 0 +be 0 +homozygous 0 +for 0 +atypical 0 +plasma 0 +cholinesterase 0 +. 0 + +Edrophonium 1 +10 0 +mg 0 +, 0 +given 0 +74 0 +min 0 +after 0 +succinylcholine 1 +, 0 +when 0 +train 0 +- 0 +of 0 +- 0 +four 0 +stimulation 0 +was 0 +characteristic 0 +of 0 +phase 0 +II 0 +block 0 +, 0 +produced 0 +partial 0 +antagonism 0 +which 0 +was 0 +not 0 +sustained 0 +. 0 + +Repeated 0 +doses 0 +of 0 +edrophonium 1 +to 0 +70 0 +mg 0 +and 0 +neostigmine 1 +to 0 +2 0 +. 0 +5 0 +mg 0 +did 0 +not 0 +antagonize 0 +or 0 +augment 0 +the 0 +block 0 +. 0 + +Spontaneous 0 +respiration 0 +recommenced 0 +200 0 +min 0 +after 0 +succinylcholine 1 +administration 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +anticholinesterases 0 +are 0 +only 0 +partially 0 +effective 0 +in 0 +restoring 0 +neuromuscular 0 +function 0 +in 0 +succinylcholine 1 +apnoea 3 +despite 0 +muscle 0 +twitch 0 +activity 0 +typical 0 +of 0 +phase 0 +II 0 +block 0 +. 0 + +Effect 0 +of 0 +doxorubicin 1 +on 0 +[ 1 +omega 2 +- 2 +I 2 +- 2 +131 2 +] 2 +heptadecanoic 2 +acid 2 +myocardial 0 +scintigraphy 0 +and 0 +echocardiography 0 +in 0 +dogs 0 +. 0 + +The 0 +effects 0 +of 0 +serial 0 +treatment 0 +with 0 +doxorubicin 1 +on 0 +dynamic 0 +myocardial 0 +scintigraphy 0 +with 0 +[ 1 +omega 2 +- 2 +I 2 +- 2 +131 2 +] 2 +heptadecanoic 2 +acid 2 +( 0 +I 1 +- 2 +131 2 +HA 2 +) 0 +, 0 +and 0 +on 0 +global 0 +left 0 +- 0 +ventricular 0 +function 0 +determined 0 +echocardiographically 0 +, 0 +were 0 +studied 0 +in 0 +a 0 +group 0 +of 0 +nine 0 +mongrel 0 +dogs 0 +. 0 + +Total 0 +extractable 0 +myocardial 0 +lipid 0 +was 0 +compared 0 +postmortem 0 +between 0 +a 0 +group 0 +of 0 +control 0 +dogs 0 +and 0 +doxorubicin 1 +- 0 +treated 0 +dogs 0 +. 0 + +A 0 +significant 0 +and 0 +then 0 +progressive 0 +fall 0 +in 0 +global 0 +LV 0 +function 0 +was 0 +observed 0 +at 0 +a 0 +cumulative 0 +doxorubicin 1 +dose 0 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +. 0 + +A 0 +significant 0 +increase 0 +in 0 +the 0 +myocardial 0 +t1 0 +/ 0 +2 0 +of 0 +the 0 +I 1 +- 2 +131 2 +HA 2 +was 0 +observed 0 +only 0 +at 0 +a 0 +higher 0 +cumulative 0 +dose 0 +, 0 +10 0 +mg 0 +/ 0 +kg 0 +. 0 + +No 0 +significant 0 +alteration 0 +in 0 +total 0 +extractable 0 +myocardial 0 +lipids 0 +was 0 +observed 0 +between 0 +control 0 +dogs 0 +and 0 +those 0 +treated 0 +with 0 +doxorubicin 1 +. 0 + +0ur 0 +findings 0 +suggest 0 +that 0 +the 0 +changes 0 +leading 0 +to 0 +an 0 +alteration 0 +of 0 +myocardial 0 +dynamic 0 +imaging 0 +with 0 +I 1 +- 2 +131 2 +HA 2 +are 0 +not 0 +the 0 +initiating 0 +factor 0 +in 0 +doxorubicin 1 +cardiotoxicity 3 +. 0 + +Hemodynamics 0 +and 0 +myocardial 0 +metabolism 0 +under 0 +deliberate 0 +hypotension 3 +. 0 + +An 0 +experimental 0 +study 0 +in 0 +dogs 0 +. 0 + +Coronary 0 +blood 0 +flow 0 +, 0 +cardiac 0 +work 0 +and 0 +metabolism 0 +were 0 +studied 0 +in 0 +dogs 0 +under 0 +sodium 1 +nitroprusside 2 +( 0 +SNP 1 +) 0 +and 0 +trimetaphan 1 +( 0 +TMP 1 +) 0 +deliberate 0 +hypotension 3 +( 0 +20 0 +% 0 +and 0 +40 0 +% 0 +mean 0 +pressure 0 +decrease 0 +from 0 +baseline 0 +) 0 +. 0 + +Regarding 0 +the 0 +effects 0 +of 0 +drug 0 +- 0 +induced 0 +hypotension 3 +on 0 +coronary 0 +blood 0 +flow 0 +, 0 +aortic 0 +and 0 +coronary 0 +sinus 0 +metabolic 0 +data 0 +( 0 +pH 0 +, 0 +p02 0 +, 0 +pC02 0 +) 0 +we 0 +could 0 +confirm 0 +that 0 +nitroprusside 1 +hypotension 3 +could 0 +be 0 +safely 0 +used 0 +to 0 +30 0 +% 0 +mean 0 +blood 0 +pressure 0 +decrease 0 +from 0 +control 0 +, 0 +trimetaphan 1 +hypotension 3 +to 0 +20 0 +% 0 +mean 0 +blood 0 +pressure 0 +decrease 0 +. 0 + +Cardiac 0 +work 0 +was 0 +significantly 0 +reduced 0 +during 0 +SNP 1 +hypotension 3 +. 0 + +Myocardial 0 +02 1 +consumption 0 +and 0 +02 1 +availability 0 +were 0 +directly 0 +dependent 0 +on 0 +the 0 +coronary 0 +perfusion 0 +. 0 + +Careful 0 +invasive 0 +monitoring 0 +of 0 +the 0 +blood 0 +pressure 0 +, 0 +blood 0 +gases 0 +and 0 +of 0 +the 0 +ECG 0 +ST 0 +- 0 +T 0 +segment 0 +is 0 +mandatory 0 +. 0 + +Evidence 0 +for 0 +a 0 +selective 0 +brain 0 +noradrenergic 0 +involvement 0 +in 0 +the 0 +locomotor 0 +stimulant 0 +effects 0 +of 0 +amphetamine 1 +in 0 +the 0 +rat 0 +. 0 + +Male 0 +rats 0 +received 0 +the 0 +noradrenaline 1 +neurotoxin 0 +DSP4 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +7 0 +days 0 +prior 0 +to 0 +injection 0 +of 0 +D 1 +- 2 +amphetamine 2 +( 0 +10 0 +or 0 +40 0 +mumol 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 + +The 0 +hyperactivity 3 +induced 0 +by 0 +D 1 +- 2 +amphetamine 2 +( 0 +10 0 +mumol 0 +/ 0 +kg 0 +) 0 +was 0 +significantly 0 +reduced 0 +by 0 +DSP4 1 +pretreatment 0 +. 0 + +However 0 +, 0 +the 0 +increased 0 +rearings 0 +and 0 +the 0 +amphetamine 1 +- 0 +induced 0 +stereotypies 3 +were 0 +not 0 +blocked 0 +by 0 +pretreatment 0 +with 0 +DSP4 1 +. 0 + +The 0 +reduction 0 +of 0 +amphetamine 1 +hyperactivity 3 +induced 0 +by 0 +DSP4 1 +was 0 +blocked 0 +by 0 +pretreatment 0 +with 0 +the 0 +noradrenaline 1 +- 0 +uptake 0 +blocking 0 +agent 0 +, 0 +desipramine 1 +, 0 +which 0 +prevents 0 +the 0 +neurotoxic 3 +action 0 +of 0 +DSP4 1 +. 0 + +The 0 +present 0 +results 0 +suggest 0 +a 0 +selective 0 +involvement 0 +of 0 +central 0 +noradrenergic 0 +neurones 0 +in 0 +the 0 +locomotor 0 +stimulant 0 +effect 0 +of 0 +amphetamine 1 +in 0 +the 0 +rat 0 +. 0 + +Accelerated 3 +junctional 4 +rhythms 4 +during 0 +oral 0 +verapamil 1 +therapy 0 +. 0 + +This 0 +study 0 +examined 0 +the 0 +frequency 0 +of 0 +atrioventricular 0 +( 0 +AV 0 +) 0 +dissociation 0 +and 0 +accelerated 3 +junctional 4 +rhythms 4 +in 0 +59 0 +patients 0 +receiving 0 +oral 0 +verapamil 1 +. 0 + +Accelerated 3 +junctional 4 +rhythms 4 +and 0 +AV 0 +dissociation 0 +were 0 +frequent 0 +in 0 +patients 0 +with 0 +supraventricular 3 +tachyarrhythmias 4 +, 0 +particularly 0 +AV 0 +nodal 0 +reentry 0 +. 0 + +Verapamil 1 +administration 0 +to 0 +these 0 +patients 0 +led 0 +to 0 +an 0 +asymptomatic 0 +increase 0 +in 0 +activity 0 +of 0 +these 0 +junctional 0 +pacemakers 0 +. 0 + +In 0 +patients 0 +with 0 +various 0 +chest 3 +pain 4 +syndromes 0 +, 0 +verapamil 1 +neither 0 +increased 0 +the 0 +frequency 0 +of 0 +junctional 0 +rhythms 0 +nor 0 +suppressed 0 +their 0 +role 0 +as 0 +escape 0 +rhythms 0 +under 0 +physiologically 0 +appropriate 0 +circumstances 0 +. 0 + +Interstrain 0 +variation 0 +in 0 +acute 0 +toxic 0 +response 0 +to 0 +caffeine 1 +among 0 +inbred 0 +mice 0 +. 0 + +Acute 0 +toxic 0 +dosage 0 +- 0 +dependent 0 +behavioral 0 +effects 0 +of 0 +caffeine 1 +were 0 +compared 0 +in 0 +adult 0 +males 0 +from 0 +seven 0 +inbred 0 +mouse 0 +strains 0 +( 0 +A 0 +/ 0 +J 0 +, 0 +BALB 0 +/ 0 +cJ 0 +, 0 +CBA 0 +/ 0 +J 0 +, 0 +C3H 0 +/ 0 +HeJ 0 +, 0 +C57BL 0 +/ 0 +6J 0 +, 0 +DBA 0 +/ 0 +2J 0 +, 0 +SWR 0 +/ 0 +J 0 +) 0 +. 0 + +C57BL 0 +/ 0 +6J 0 +, 0 +chosen 0 +as 0 +a 0 +" 0 +prototypic 0 +" 0 +mouse 0 +strain 0 +, 0 +was 0 +used 0 +to 0 +determine 0 +behavioral 0 +responses 0 +to 0 +a 0 +broad 0 +range 0 +( 0 +5 0 +- 0 +500 0 +mg 0 +/ 0 +kg 0 +) 0 +of 0 +caffeine 1 +doses 0 +. 0 + +Five 0 +phenotypic 0 +characteristics 0 +- 0 +- 0 +locomotor 0 +activity 0 +, 0 +righting 0 +ability 0 +, 0 +clonic 3 +seizure 4 +induction 0 +, 0 +stress 0 +- 0 +induced 0 +lethality 0 +, 0 +death 0 +without 0 +external 0 +stress 0 +- 0 +- 0 +were 0 +scored 0 +at 0 +various 0 +caffeine 1 +doses 0 +in 0 +drug 0 +- 0 +naive 0 +animals 0 +under 0 +empirically 0 +optimized 0 +, 0 +rigidly 0 +constant 0 +experimental 0 +conditions 0 +. 0 + +Mice 0 +( 0 +n 0 += 0 +12 0 +for 0 +each 0 +point 0 +) 0 +received 0 +single 0 +IP 0 +injections 0 +of 0 +a 0 +fixed 0 +volume 0 +/ 0 +g 0 +body 0 +weight 0 +of 0 +physiological 0 +saline 0 +carrier 0 +with 0 +or 0 +without 0 +caffeine 1 +in 0 +doses 0 +ranging 0 +from 0 +125 0 +- 0 +500 0 +mg 0 +/ 0 +kg 0 +. 0 + +Loss 0 +of 0 +righting 0 +ability 0 +was 0 +scored 0 +at 0 +1 0 +, 0 +3 0 +, 0 +5 0 +min 0 +post 0 +dosing 0 +and 0 +at 0 +5 0 +min 0 +intervals 0 +thereafter 0 +for 0 +20 0 +min 0 +. 0 + +In 0 +the 0 +same 0 +animals 0 +the 0 +occurrence 0 +of 0 +clonic 3 +seizures 4 +was 0 +scored 0 +as 0 +to 0 +time 0 +of 0 +onset 0 +and 0 +severity 0 +for 0 +20 0 +min 0 +after 0 +drug 0 +administration 0 +. 0 + +When 0 +these 0 +proceeded 0 +to 0 +tonic 3 +seizures 4 +, 0 +death 0 +occurred 0 +in 0 +less 0 +than 0 +20 0 +min 0 +. 0 + +Animals 0 +surviving 0 +for 0 +20 0 +min 0 +were 0 +immediately 0 +stressed 0 +by 0 +a 0 +swim 0 +test 0 +in 0 +25 0 +degrees 0 +C 0 +water 0 +, 0 +and 0 +death 0 +- 0 +producing 0 +tonic 3 +seizures 4 +were 0 +scored 0 +for 0 +2 0 +min 0 +. 0 + +In 0 +other 0 +animals 0 +locomotor 0 +activity 0 +was 0 +measured 0 +15 0 +or 0 +60 0 +min 0 +after 0 +caffeine 1 +administration 0 +. 0 + +By 0 +any 0 +single 0 +behavioral 0 +criterion 0 +or 0 +a 0 +combination 0 +of 0 +these 0 +criteria 0 +, 0 +marked 0 +differences 0 +in 0 +response 0 +to 0 +toxic 0 +caffeine 1 +doses 0 +were 0 +observed 0 +between 0 +strains 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +behavioral 0 +toxicity 3 +testing 0 +of 0 +alkylxanthines 1 +in 0 +a 0 +single 0 +mouse 0 +strain 0 +may 0 +be 0 +misleading 0 +and 0 +suggest 0 +that 0 +toxic 0 +responses 0 +of 0 +the 0 +central 0 +nervous 0 +system 0 +to 0 +this 0 +class 0 +of 0 +compounds 0 +are 0 +genetically 0 +influenced 0 +in 0 +mammals 0 +. 0 + +Treatment 0 +of 0 +ovarian 3 +cancer 4 +with 0 +a 0 +combination 0 +of 0 +cis 1 +- 2 +platinum 2 +, 0 +adriamycin 1 +, 0 +cyclophosphamide 1 +and 0 +hexamethylmelamine 1 +. 0 + +During 0 +the 0 +last 0 +2 0 +1 0 +/ 0 +2 0 +years 0 +, 0 +38 0 +patients 0 +with 0 +ovarian 3 +cancer 4 +were 0 +treated 0 +with 0 +a 0 +combination 0 +of 0 +cisplatinum 1 +( 0 +CPDD 1 +) 0 +, 0 +50 0 +mg 0 +/ 0 +m2 0 +, 0 +adriamycin 1 +, 0 +30 0 +mg 0 +/ 0 +m2 0 +, 0 +cyclophosphamide 1 +, 0 +300 0 +mg 0 +/ 0 +m2 0 +, 0 +on 0 +day 0 +1 0 +; 0 +and 0 +hexamethylmelamine 1 +( 0 +HMM 1 +) 0 +, 0 +6 0 +mg 0 +/ 0 +kg 0 +daily 0 +, 0 +for 0 +14 0 +days 0 +. 0 + +Each 0 +course 0 +was 0 +repeated 0 +monthly 0 +. 0 + +2 0 +patients 0 +had 0 +stage 0 +II 0 +, 0 +14 0 +stage 0 +III 0 +and 0 +22 0 +stage 0 +IV 0 +disease 0 +. 0 + +14 0 +of 0 +the 0 +38 0 +patients 0 +were 0 +previously 0 +treated 0 +with 0 +chemotherapy 0 +, 0 +1 0 +with 0 +radiation 0 +, 0 +6 0 +with 0 +both 0 +chemotherapy 0 +and 0 +radiation 0 +, 0 +and 0 +17 0 +did 0 +not 0 +have 0 +any 0 +treatment 0 +before 0 +CPDD 1 +combination 0 +. 0 + +31 0 +of 0 +the 0 +38 0 +cases 0 +( 0 +81 0 +. 0 +5 0 +% 0 +) 0 +demonstrated 0 +objective 0 +responses 0 +lasting 0 +for 0 +2 0 +months 0 +or 0 +more 0 +. 0 + +These 0 +responses 0 +were 0 +partial 0 +in 0 +19 0 +and 0 +complete 0 +in 0 +12 0 +cases 0 +. 0 + +Hematologic 3 +toxicity 4 +was 0 +moderate 0 +and 0 +with 0 +reversible 0 +anemia 3 +developing 0 +in 0 +71 0 +% 0 +of 0 +patients 0 +. 0 + +Gastrointestinal 0 +side 0 +effects 0 +from 0 +CPDD 1 +were 0 +universal 0 +. 0 + +HMM 1 +gastrointestinal 3 +toxicity 4 +necessitated 0 +discontinuation 0 +of 0 +the 0 +drug 0 +in 0 +5 0 +patients 0 +. 0 + +Severe 0 +nephrotoxicity 3 +was 0 +observed 0 +in 0 +2 0 +patients 0 +but 0 +was 0 +reversible 0 +. 0 + +There 0 +were 0 +no 0 +drug 0 +- 0 +related 0 +deaths 0 +. 0 + +Nontraumatic 0 +dissecting 3 +aneurysm 4 +of 0 +the 0 +basilar 0 +artery 0 +. 0 + +A 0 +case 0 +of 0 +nontraumatic 0 +dissecting 3 +aneurysm 4 +of 0 +the 0 +basilar 0 +artery 0 +in 0 +association 0 +with 0 +hypertension 3 +, 0 +smoke 0 +, 0 +and 0 +oral 1 +contraceptives 2 +is 0 +reported 0 +in 0 +a 0 +young 0 +female 0 +patient 0 +with 0 +a 0 +locked 3 +- 4 +in 4 +syndrome 4 +. 0 + +A 0 +method 0 +for 0 +the 0 +measurement 0 +of 0 +tremor 3 +, 0 +and 0 +a 0 +comparison 0 +of 0 +the 0 +effects 0 +of 0 +tocolytic 0 +beta 0 +- 0 +mimetics 0 +. 0 + +A 0 +method 0 +permitting 0 +measurement 0 +of 0 +finger 0 +tremor 3 +as 0 +a 0 +displacement 0 +- 0 +time 0 +curve 0 +is 0 +described 0 +, 0 +using 0 +a 0 +test 0 +system 0 +with 0 +simple 0 +amplitude 0 +calibration 0 +. 0 + +The 0 +coordinates 0 +of 0 +the 0 +inversion 0 +points 0 +of 0 +the 0 +displacement 0 +- 0 +time 0 +curves 0 +were 0 +transferred 0 +through 0 +graphical 0 +input 0 +equipment 0 +to 0 +punched 0 +tape 0 +. 0 + +By 0 +means 0 +of 0 +a 0 +computer 0 +program 0 +, 0 +periods 0 +and 0 +amplitudes 0 +of 0 +tremor 3 +oscillations 0 +were 0 +calculated 0 +and 0 +classified 0 +. 0 + +The 0 +event 0 +frequency 0 +for 0 +each 0 +class 0 +of 0 +periods 0 +and 0 +amplitudes 0 +was 0 +determined 0 +. 0 + +The 0 +actions 0 +of 0 +fenoterol 1 +- 2 +hydrobromide 2 +, 0 +ritodrin 1 +- 2 +HCl 2 +and 0 +placebo 0 +given 0 +to 0 +10 0 +healthy 0 +subjects 0 +by 0 +intravenous 0 +infusion 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +crossover 0 +study 0 +were 0 +tested 0 +by 0 +this 0 +method 0 +. 0 + +At 0 +therapeutic 0 +doses 0 +both 0 +substances 0 +raised 0 +the 0 +mean 0 +tremor 3 +amplitude 0 +to 0 +about 0 +three 0 +times 0 +the 0 +control 0 +level 0 +. 0 + +At 0 +the 0 +same 0 +time 0 +, 0 +the 0 +mean 0 +period 0 +within 0 +each 0 +class 0 +of 0 +amplitudes 0 +shortened 0 +by 0 +10 0 +- 0 +- 0 +20 0 +ms 0 +, 0 +whereas 0 +the 0 +mean 0 +periods 0 +calculated 0 +from 0 +all 0 +oscillations 0 +together 0 +did 0 +not 0 +change 0 +significantly 0 +. 0 + +After 0 +the 0 +end 0 +of 0 +fenoterol 1 +- 2 +hydrobromide 2 +infusion 0 +, 0 +tremor 3 +amplitudes 0 +decreased 0 +significantly 0 +faster 0 +than 0 +those 0 +following 0 +ritodrin 1 +- 2 +HCl 2 +infusion 0 +. 0 + +Propylthiouracil 1 +- 0 +induced 0 +hepatic 3 +damage 4 +. 0 + +Two 0 +cases 0 +of 0 +propylthiouracil 1 +- 0 +induced 0 +liver 3 +damage 4 +have 0 +been 0 +observed 0 +. 0 + +The 0 +first 0 +case 0 +is 0 +of 0 +an 0 +acute 0 +type 0 +of 0 +damage 0 +, 0 +proven 0 +by 0 +rechallenge 0 +; 0 +the 0 +second 0 +presents 0 +a 0 +clinical 0 +and 0 +histologic 0 +picture 0 +resembling 0 +chronic 3 +active 4 +hepatitis 4 +, 0 +with 0 +spontaneous 0 +remission 0 +. 0 + +Studies 0 +on 0 +the 0 +bradycardia 3 +induced 0 +by 0 +bepridil 1 +. 0 + +Bepridil 1 +, 0 +a 0 +novel 0 +active 0 +compound 0 +for 0 +prophylactic 0 +treatment 0 +of 0 +anginal 3 +attacks 4 +, 0 +induced 0 +persistent 0 +bradycardia 3 +and 0 +a 0 +non 0 +- 0 +specific 0 +anti 0 +- 0 +tachycardial 3 +effect 0 +, 0 +the 0 +mechanisms 0 +of 0 +which 0 +were 0 +investigated 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +. 0 + +In 0 +vitro 0 +perfusion 0 +of 0 +bepridil 1 +in 0 +the 0 +life 0 +- 0 +support 0 +medium 0 +for 0 +isolated 0 +sino 0 +- 0 +atrial 0 +tissue 0 +from 0 +rabbit 0 +heart 0 +, 0 +caused 0 +a 0 +reduction 0 +in 0 +action 0 +potential 0 +( 0 +AP 0 +) 0 +spike 0 +frequency 0 +( 0 +recorded 0 +by 0 +KCl 1 +microelectrodes 0 +) 0 +starting 0 +at 0 +doses 0 +of 0 +5 0 +X 0 +10 0 +( 0 +- 0 +6 0 +) 0 +M 0 +. 0 + +This 0 +effect 0 +was 0 +dose 0 +- 0 +dependent 0 +up 0 +to 0 +concentrations 0 +of 0 +5 0 +X 0 +10 0 +( 0 +- 0 +5 0 +) 0 +M 0 +, 0 +whereupon 0 +blockade 0 +of 0 +sinus 0 +activity 0 +set 0 +in 0 +. 0 + +Bepridil 1 +at 0 +a 0 +dose 0 +of 0 +5 0 +X 0 +10 0 +( 0 +- 0 +6 0 +) 0 +M 0 +, 0 +induced 0 +a 0 +concomitant 0 +reduction 0 +in 0 +AP 0 +amplitude 0 +( 0 +falling 0 +from 0 +71 0 ++ 0 +/ 0 +- 0 +8 0 +mV 0 +to 0 +47 0 ++ 0 +/ 0 +- 0 +6 0 +mV 0 +) 0 +, 0 +maximum 0 +systolic 0 +depolarization 0 +velocity 0 +( 0 +phase 0 +0 0 +) 0 +which 0 +fell 0 +from 0 +1 0 +. 0 +85 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +35 0 +V 0 +/ 0 +s 0 +to 0 +0 0 +. 0 +84 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +28 0 +V 0 +/ 0 +s 0 +, 0 +together 0 +with 0 +maximum 0 +diastolic 0 +depolarization 0 +velocity 0 +( 0 +phase 0 +4 0 +) 0 +which 0 +fell 0 +from 0 +38 0 ++ 0 +/ 0 +- 0 +3 0 +mV 0 +/ 0 +s 0 +to 0 +24 0 ++ 0 +/ 0 +- 0 +5 0 +mV 0 +/ 0 +s 0 +. 0 + +In 0 +vivo 0 +injection 0 +of 0 +bepridil 1 +at 0 +a 0 +dose 0 +of 0 +5 0 +mg 0 +/ 0 +kg 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +into 0 +6 0 +anaesthetized 0 +dogs 0 +which 0 +had 0 +undergone 0 +ablation 0 +of 0 +all 0 +the 0 +extrinsic 0 +cardiac 0 +afferent 0 +nerve 0 +supply 0 +, 0 +together 0 +with 0 +a 0 +bilateral 0 +medullo 0 +- 0 +adrenalectomy 0 +, 0 +caused 0 +a 0 +marked 0 +reduction 0 +in 0 +heart 0 +rate 0 +which 0 +fell 0 +from 0 +98 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +2 0 +beats 0 +/ 0 +min 0 +to 0 +76 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +3 0 +beats 0 +/ 0 +min 0 +sustained 0 +for 0 +more 0 +than 0 +45 0 +min 0 +. 0 + +It 0 +is 0 +concluded 0 +that 0 +bepridil 1 +reduces 0 +heart 0 +rate 0 +by 0 +acting 0 +directly 0 +on 0 +the 0 +sinus 0 +node 0 +. 0 + +This 0 +effect 0 +, 0 +which 0 +results 0 +in 0 +a 0 +flattening 0 +of 0 +the 0 +phase 0 +0 0 +and 0 +phase 0 +4 0 +slope 0 +, 0 +together 0 +with 0 +a 0 +longer 0 +AP 0 +duration 0 +, 0 +may 0 +be 0 +due 0 +to 0 +an 0 +increase 0 +in 0 +the 0 +time 0 +constants 0 +of 0 +slow 0 +inward 0 +ionic 0 +currents 0 +( 0 +already 0 +demonstrated 0 +elsewhere 0 +) 0 +, 0 +but 0 +also 0 +to 0 +an 0 +increased 0 +time 0 +constant 0 +for 0 +deactivation 0 +of 0 +the 0 +outward 0 +potassium 1 +current 0 +( 0 +Ip 0 +) 0 +. 0 + +Hepatitis 3 +and 0 +renal 3 +tubular 4 +acidosis 4 +after 0 +anesthesia 0 +with 0 +methoxyflurane 1 +. 0 + +A 0 +69 0 +- 0 +year 0 +- 0 +old 0 +man 0 +operated 0 +for 0 +acute 3 +cholecystitis 4 +under 0 +methoxyflurane 1 +anesthesia 0 +developed 0 +postoperatively 0 +a 0 +hepatic 3 +insufficiency 4 +syndrome 4 +and 0 +renal 3 +tubular 4 +acidosis 4 +. 0 + +Massive 0 +bleeding 3 +appeared 0 +during 0 +surgery 0 +which 0 +lasted 0 +for 0 +six 0 +hours 0 +. 0 + +Postoperative 0 +evolution 0 +under 0 +supportive 0 +therapy 0 +was 0 +favourable 0 +. 0 + +Complete 0 +recovery 0 +was 0 +confirmed 0 +by 0 +repeated 0 +controls 0 +performed 0 +over 0 +a 0 +period 0 +of 0 +one 0 +year 0 +after 0 +surgery 0 +. 0 + +Pituitary 0 +response 0 +to 0 +luteinizing 0 +hormone 0 +- 0 +releasing 0 +hormone 0 +during 0 +haloperidol 1 +- 0 +induced 0 +hyperprolactinemia 3 +. 0 + +The 0 +effects 0 +of 0 +a 0 +6 0 +- 0 +hour 0 +infusion 0 +with 0 +haloperidol 1 +on 0 +serum 0 +prolactin 0 +and 0 +luteinizing 0 +hormone 0 +( 0 +LH 0 +) 0 +levels 0 +was 0 +studied 0 +in 0 +a 0 +group 0 +of 0 +male 0 +subjects 0 +. 0 + +Five 0 +hours 0 +after 0 +starting 0 +the 0 +infusions 0 +, 0 +a 0 +study 0 +of 0 +the 0 +pituitary 0 +responses 0 +to 0 +LH 0 +- 0 +releasing 0 +hormone 0 +( 0 +LH 0 +- 0 +RH 0 +) 0 +was 0 +carried 0 +out 0 +. 0 + +Control 0 +patients 0 +received 0 +infusions 0 +of 0 +0 0 +. 0 +9 0 +% 0 +NaCl 1 +solution 0 +. 0 + +During 0 +the 0 +course 0 +of 0 +haloperidol 1 +infusions 0 +, 0 +significant 0 +hyperprolactinemia 3 +was 0 +found 0 +, 0 +together 0 +with 0 +an 0 +abolished 0 +pituitary 0 +response 0 +to 0 +LH 0 +- 0 +RH 0 +, 0 +as 0 +compared 0 +with 0 +responses 0 +of 0 +control 0 +subjects 0 +. 0 + +Antirifampicin 0 +antibodies 0 +in 0 +acute 0 +rifampicin 1 +- 0 +associated 0 +renal 3 +failure 4 +. 0 + +5 0 +patients 0 +with 0 +acute 3 +renal 4 +failure 4 +( 0 +3 0 +with 0 +thrombopenia 3 +and 0 +hemolysis 3 +) 0 +induced 0 +by 0 +the 0 +reintroduction 0 +of 0 +rifampicin 1 +are 0 +described 0 +. 0 + +No 0 +correlation 0 +was 0 +found 0 +between 0 +the 0 +severity 0 +of 0 +clinical 0 +manifestations 0 +and 0 +the 0 +total 0 +dose 0 +taken 0 +by 0 +the 0 +patients 0 +. 0 + +In 0 +all 0 +but 0 +1 0 +patient 0 +, 0 +antirifampicin 0 +antibodies 0 +were 0 +detected 0 +. 0 + +Antibodies 0 +suggested 0 +to 0 +be 0 +of 0 +the 0 +IgM 0 +class 0 +were 0 +detected 0 +in 0 +all 0 +3 0 +patients 0 +with 0 +hematological 3 +disorders 4 +. 0 + +The 0 +pattern 0 +of 0 +non 0 +- 0 +specific 0 +acute 3 +tubular 4 +necrosis 4 +found 0 +in 0 +the 0 +2 0 +biopsied 0 +patients 0 +, 0 +indistinguishable 0 +from 0 +that 0 +of 0 +ischemic 0 +origin 0 +, 0 +raised 0 +the 0 +possibility 0 +of 0 +a 0 +vascular 0 +- 0 +mediated 0 +damage 0 +. 0 + +In 0 +3 0 +patients 0 +, 0 +the 0 +possibility 0 +of 0 +a 0 +triggering 0 +immunoallergic 0 +mechanism 0 +is 0 +discussed 0 +. 0 + +Cardiovascular 0 +effects 0 +of 0 +hypotension 3 +induced 0 +by 0 +adenosine 1 +triphosphate 2 +and 0 +sodium 1 +nitroprusside 2 +on 0 +dogs 0 +with 0 +denervated 0 +hearts 0 +. 0 + +Adenosine 1 +triphosphate 2 +( 0 +ATP 1 +) 0 +and 0 +sodium 1 +nitroprusside 2 +( 0 +SNP 1 +) 0 +are 0 +administered 0 +to 0 +patients 0 +to 0 +induce 0 +and 0 +control 0 +hypotension 3 +during 0 +anesthesia 0 +. 0 + +SNP 1 +is 0 +authorized 0 +for 0 +clinical 0 +use 0 +in 0 +USA 0 +and 0 +UK 0 +, 0 +and 0 +ATP 1 +is 0 +clinically 0 +used 0 +in 0 +other 0 +countries 0 +such 0 +as 0 +Japan 0 +. 0 + +We 0 +investigated 0 +how 0 +these 0 +two 0 +drugs 0 +act 0 +on 0 +the 0 +cardiovascular 0 +systems 0 +of 0 +20 0 +dogs 0 +whose 0 +hearts 0 +had 0 +been 0 +denervated 0 +by 0 +a 0 +procedure 0 +we 0 +had 0 +devised 0 +. 0 + +ATP 1 +( 0 +10 0 +dogs 0 +) 0 +or 0 +SNP 1 +( 0 +10 0 +dogs 0 +) 0 +was 0 +administered 0 +to 0 +reduce 0 +mean 0 +arterial 0 +pressure 0 +by 0 +30 0 +% 0 +to 0 +70 0 +% 0 +of 0 +control 0 +. 0 + +Before 0 +, 0 +during 0 +and 0 +after 0 +induced 0 +hypotension 3 +, 0 +we 0 +measured 0 +major 0 +cardiovascular 0 +parameters 0 +. 0 + +Hypotension 3 +induced 0 +by 0 +ATP 1 +was 0 +accompanied 0 +by 0 +significant 0 +decreases 0 +in 0 +mean 0 +pulmonary 0 +arterial 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +central 0 +venous 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +total 0 +peripheral 0 +resistance 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +rate 0 +pressure 0 +product 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +total 0 +body 0 +oxygen 1 +consumption 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +, 0 +and 0 +heart 0 +rate 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +; 0 +all 0 +these 0 +variables 0 +returned 0 +normal 0 +within 0 +30 0 +min 0 +after 0 +ATP 1 +was 0 +stopped 0 +. 0 + +Cardiac 0 +output 0 +did 0 +not 0 +change 0 +. 0 + +During 0 +hypotension 3 +produced 0 +by 0 +SNP 1 +similar 0 +decreases 0 +were 0 +observed 0 +in 0 +mean 0 +pulmonary 0 +arterial 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +, 0 +central 0 +venous 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +01 0 +) 0 +, 0 +total 0 +peripheral 0 +resistance 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +rate 0 +pressure 0 +product 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +, 0 +and 0 +oxygen 1 +content 0 +difference 0 +between 0 +arterial 0 +and 0 +mixed 0 +venous 0 +blood 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +, 0 +while 0 +heart 0 +rate 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +001 0 +) 0 +and 0 +cardiac 0 +output 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +were 0 +increased 0 +. 0 + +Recoveries 0 +of 0 +heart 0 +rate 0 +and 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +were 0 +not 0 +shown 0 +within 0 +60 0 +min 0 +after 0 +SNP 1 +had 0 +been 0 +stopped 0 +. 0 + +Both 0 +ATP 1 +and 0 +SNP 1 +should 0 +act 0 +on 0 +the 0 +pacemaker 0 +tissue 0 +of 0 +the 0 +heart 0 +. 0 + +Comparative 0 +study 0 +: 0 +Endografine 1 +( 0 +diatrizoate 1 +) 0 +, 0 +Vasurix 1 +polyvidone 2 +( 0 +acetrizoate 1 +) 0 +, 0 +Dimer 1 +- 2 +X 2 +( 0 +iocarmate 1 +) 0 +and 0 +Hexabrix 1 +( 0 +ioxaglate 1 +) 0 +in 0 +hysterosalpingography 0 +. 0 + +Side 0 +effects 0 +of 0 +hysterosalpingography 0 +with 0 +Dimer 1 +- 2 +X 2 +, 0 +Hexabrix 1 +, 0 +Vasurix 1 +polyvidone 2 +and 0 +Endografine 1 +in 0 +142 0 +consecutive 0 +patients 0 +, 0 +receiving 0 +one 0 +of 0 +the 0 +four 0 +tested 0 +media 0 +were 0 +evaluated 0 +from 0 +replies 0 +to 0 +postal 0 +questionnaires 0 +. 0 + +The 0 +Dimer 1 +- 2 +X 2 +group 0 +had 0 +a 0 +higher 0 +incidence 0 +of 0 +nausea 3 +and 0 +dizziness 3 +. 0 + +The 0 +Endografine 1 +group 0 +had 0 +a 0 +higher 0 +incidence 0 +of 0 +abdominal 3 +pain 4 +. 0 + +These 0 +differences 0 +occur 0 +especially 0 +in 0 +the 0 +age 0 +groups 0 +under 0 +30 0 +years 0 +. 0 + +Hexabrix 1 +and 0 +Vasurix 1 +polyvidone 2 +are 0 +considered 0 +the 0 +best 0 +contrast 1 +media 2 +for 0 +hysterosalpingography 0 +and 0 +perhaps 0 +because 0 +of 0 +its 0 +low 0 +toxicity 3 +Hexabrix 1 +should 0 +be 0 +preferred 0 +. 0 + +Post 0 +- 0 +suxamethonium 1 +pains 3 +in 0 +Nigerian 0 +surgical 0 +patients 0 +. 0 + +Contrary 0 +to 0 +an 0 +earlier 0 +report 0 +by 0 +Coxon 0 +, 0 +scoline 1 +pain 3 +occurs 0 +in 0 +African 0 +negroes 0 +. 0 + +Its 0 +incidence 0 +was 0 +determined 0 +in 0 +a 0 +prospective 0 +study 0 +involving 0 +a 0 +total 0 +of 0 +100 0 +Nigerian 0 +patients 0 +( 0 +50 0 +out 0 +- 0 +patients 0 +and 0 +50 0 +in 0 +- 0 +patients 0 +) 0 +. 0 + +About 0 +62 0 +% 0 +of 0 +the 0 +out 0 +- 0 +patients 0 +developed 0 +scoline 1 +pain 3 +as 0 +compared 0 +with 0 +about 0 +26 0 +% 0 +among 0 +the 0 +in 0 +- 0 +patients 0 +. 0 + +The 0 +abolition 0 +of 0 +muscle 0 +fasciculations 3 +( 0 +by 0 +0 0 +. 0 +075mg 0 +/ 0 +kg 0 +dose 0 +of 0 +Fazadinium 1 +) 0 +did 0 +not 0 +influence 0 +the 0 +occurrence 0 +of 0 +scoline 1 +pain 3 +. 0 + +Neither 0 +the 0 +type 0 +of 0 +induction 0 +agent 0 +( 0 +Althesin 1 +or 0 +Thiopentone 1 +) 0 +nor 0 +the 0 +salt 0 +preparation 0 +of 0 +suxamethonium 1 +used 0 +( 0 +chloride 1 +or 0 +bromide 1 +) 0 +, 0 +affected 0 +the 0 +incidence 0 +of 0 +scoline 1 +pain 3 +. 0 + +Invasive 0 +carcinoma 3 +of 4 +the 4 +renal 4 +pelvis 4 +following 0 +cyclophosphamide 1 +therapy 0 +for 0 +nonmalignant 0 +disease 0 +. 0 + +A 0 +47 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +right 0 +hydroureteronephrosis 3 +due 0 +to 0 +ureterovesical 0 +junction 0 +obstruction 0 +had 0 +gross 0 +hematuria 3 +after 0 +being 0 +treated 0 +for 0 +five 0 +years 0 +wtih 0 +cyclophosphamide 1 +for 0 +cerebral 3 +vasculitis 4 +. 0 + +A 0 +right 0 +nephroureterectomy 0 +was 0 +required 0 +for 0 +control 0 +of 0 +bleeding 3 +. 0 + +The 0 +pathology 0 +specimen 0 +contained 0 +clinically 0 +occult 0 +invasive 0 +carcinoma 3 +of 4 +the 4 +renal 4 +pelvis 4 +. 0 + +Although 0 +the 0 +ability 0 +of 0 +cyclophosphamide 1 +to 0 +cause 0 +hemorrhagic 3 +cystitis 4 +and 0 +urine 0 +cytologic 0 +abnormalities 0 +indistinguishable 0 +from 0 +high 0 +grade 0 +carcinoma 3 +is 0 +well 0 +known 0 +, 0 +it 0 +is 0 +less 0 +widely 0 +appreciated 0 +that 0 +it 0 +is 0 +also 0 +associated 0 +with 0 +carcinoma 3 +of 4 +the 4 +urinary 4 +tract 4 +. 0 + +Twenty 0 +carcinomas 3 +of 4 +the 4 +urinary 4 +bladder 4 +and 0 +one 0 +carcinoma 3 +of 4 +the 4 +prostate 4 +have 0 +been 0 +reported 0 +in 0 +association 0 +with 0 +its 0 +use 0 +. 0 + +The 0 +present 0 +case 0 +is 0 +the 0 +first 0 +carcinoma 3 +of 4 +the 4 +renal 4 +pelvis 4 +reported 0 +in 0 +association 0 +with 0 +cyclophosphamide 1 +treatment 0 +. 0 + +It 0 +is 0 +the 0 +third 0 +urinary 3 +tract 4 +cancer 4 +reported 0 +in 0 +association 0 +with 0 +cyclophosphamide 1 +treatment 0 +for 0 +nonmalignant 0 +disease 0 +. 0 + +The 0 +association 0 +of 0 +the 0 +tumor 3 +with 0 +preexisting 0 +hydroureteronephrosis 3 +suggests 0 +that 0 +stasis 0 +prolonged 0 +and 0 +intensified 0 +exposure 0 +of 0 +upper 0 +urinary 0 +tract 0 +epithelium 0 +to 0 +cyclophosphamide 1 +. 0 + +Patients 0 +who 0 +are 0 +candidates 0 +for 0 +long 0 +- 0 +term 0 +cyclophosphamide 1 +treatment 0 +should 0 +be 0 +routinely 0 +evaluated 0 +for 0 +obstructive 3 +uropathy 4 +. 0 + +Medial 0 +changes 0 +in 0 +arterial 0 +spasm 3 +induced 0 +by 0 +L 1 +- 2 +norepinephrine 2 +. 0 + +In 0 +normal 0 +rats 0 +, 0 +the 0 +media 0 +of 0 +small 0 +arteries 0 +( 0 +0 0 +. 0 +4 0 +- 0 +- 0 +0 0 +. 0 +2 0 +mm 0 +in 0 +diameter 0 +) 0 +previously 0 +was 0 +shown 0 +to 0 +contain 0 +intracellular 0 +vacuoles 0 +, 0 +identified 0 +ultrastructurally 0 +as 0 +herniations 0 +of 0 +one 0 +smooth 0 +muscle 0 +cell 0 +into 0 +another 0 +. 0 + +The 0 +hypothesis 0 +that 0 +intense 0 +vasoconstriction 0 +would 0 +increase 0 +the 0 +number 0 +of 0 +such 0 +vacuoles 0 +has 0 +been 0 +tested 0 +. 0 + +In 0 +the 0 +media 0 +of 0 +the 0 +saphenous 0 +artery 0 +and 0 +its 0 +distal 0 +branch 0 +, 0 +vasoconstriction 0 +induced 0 +by 0 +L 1 +- 2 +norepinephrine 2 +produced 0 +many 0 +cell 0 +- 0 +to 0 +- 0 +cell 0 +hernias 3 +within 0 +15 0 +minutes 0 +. 0 + +At 0 +1 0 +day 0 +their 0 +number 0 +was 0 +reduced 0 +to 0 +about 0 +1 0 +/ 0 +10 0 +of 0 +the 0 +original 0 +number 0 +. 0 + +By 0 +7 0 +days 0 +the 0 +vessel 0 +was 0 +almost 0 +restored 0 +to 0 +normal 0 +. 0 + +Triple 0 +stimulation 0 +over 0 +1 0 +day 0 +induced 0 +more 0 +severe 0 +changes 0 +in 0 +the 0 +media 0 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +smooth 0 +muscle 0 +cells 0 +are 0 +susceptible 0 +to 0 +damage 0 +in 0 +the 0 +course 0 +of 0 +their 0 +specific 0 +function 0 +. 0 + +The 0 +experimental 0 +data 0 +are 0 +discussed 0 +in 0 +relation 0 +to 0 +medial 0 +changes 0 +observed 0 +in 0 +other 0 +instances 0 +of 0 +arterial 0 +spasm 3 +. 0 + +Endothelial 0 +changes 0 +that 0 +developed 0 +in 0 +the 0 +same 0 +experimental 0 +model 0 +were 0 +described 0 +in 0 +a 0 +previous 0 +paper 0 +. 0 + +Bilateral 0 +retinal 3 +artery 4 +and 4 +choriocapillaris 4 +occlusion 4 +following 0 +the 0 +injection 0 +of 0 +long 0 +- 0 +acting 0 +corticosteroid 1 +suspensions 0 +in 0 +combination 0 +with 0 +other 0 +drugs 0 +: 0 +I 0 +. 0 + +Clinical 0 +studies 0 +. 0 + +Two 0 +well 0 +- 0 +documented 0 +cases 0 +of 0 +bilateral 0 +retinal 3 +artery 4 +and 4 +choriocapillaris 4 +occlusions 4 +with 0 +blindness 3 +following 0 +head 0 +and 0 +neck 0 +soft 0 +- 0 +tissue 0 +injection 0 +with 0 +methylprednisolone 1 +acetate 2 +in 0 +combination 0 +with 0 +lidocaine 1 +, 0 +epinephrine 1 +, 0 +or 0 +penicillin 1 +are 0 +reported 0 +. 0 + +0ne 0 +case 0 +had 0 +only 0 +a 0 +unilateral 0 +injection 0 +. 0 + +The 0 +acute 0 +observations 0 +included 0 +hazy 0 +sensorium 0 +, 0 +superior 0 +gaze 0 +palsy 3 +, 0 +pupillary 3 +abnormalities 4 +, 0 +and 0 +conjunctival 0 +hemorrhages 3 +with 0 +edema 3 +. 0 + +Follow 0 +- 0 +up 0 +changes 0 +showed 0 +marked 0 +visual 3 +loss 4 +, 0 +constricted 0 +visual 0 +fields 0 +, 0 +optic 0 +nerve 0 +pallor 0 +, 0 +vascular 0 +attenuation 0 +, 0 +and 0 +chorioretinal 3 +atrophy 4 +. 0 + +The 0 +literature 0 +is 0 +reviewed 0 +, 0 +and 0 +possible 0 +causes 0 +are 0 +discussed 0 +. 0 + +Abnormalities 0 +of 0 +the 0 +pupil 0 +and 0 +visual 0 +- 0 +evoked 0 +potential 0 +in 0 +quinine 1 +amblyopia 3 +. 0 + +Total 0 +blindness 3 +with 0 +a 0 +transient 0 +tonic 3 +pupillary 4 +response 0 +, 0 +denervation 0 +supersensitivity 0 +, 0 +and 0 +abnormal 0 +visual 0 +- 0 +evoked 0 +potentials 0 +developed 0 +in 0 +a 0 +54 0 +- 0 +year 0 +- 0 +old 0 +man 0 +after 0 +the 0 +use 0 +of 0 +quinine 1 +sulfate 2 +for 0 +leg 3 +cramps 4 +. 0 + +He 0 +later 0 +recovered 0 +normal 0 +visual 0 +acuity 0 +. 0 + +A 0 +transient 0 +tonic 3 +pupillary 4 +response 0 +, 0 +denervation 0 +supersensitivity 0 +, 0 +and 0 +abnormal 0 +visual 0 +- 0 +evoked 0 +potentials 0 +in 0 +quinine 1 +toxicity 3 +, 0 +to 0 +our 0 +knowledge 0 +, 0 +have 0 +not 0 +been 0 +previously 0 +reported 0 +. 0 + +Suxamethonium 1 +- 0 +induced 0 +jaw 3 +stiffness 4 +and 0 +myalgia 3 +associated 0 +with 0 +atypical 0 +cholinesterase 0 +: 0 +case 0 +report 0 +. 0 + +An 0 +11 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +was 0 +given 0 +halothane 1 +, 0 +nitrous 1 +oxide 2 +and 0 +oxygen 1 +, 0 +pancuronium 1 +0 0 +. 0 +4 0 +mg 0 +and 0 +suxamethonium 1 +100 0 +mg 0 +for 0 +induction 0 +of 0 +anaesthesia 0 +. 0 + +In 0 +response 0 +to 0 +this 0 +a 0 +marked 0 +jaw 3 +stiffness 4 +occurred 0 +which 0 +lasted 0 +for 0 +two 0 +minutes 0 +and 0 +the 0 +anaesthesia 0 +were 0 +terminated 0 +. 0 + +Four 0 +hours 0 +of 0 +apnoea 3 +ensued 0 +and 0 +he 0 +suffered 0 +generalized 0 +severe 0 +myalgia 3 +lasting 0 +for 0 +one 0 +week 0 +. 0 + +He 0 +was 0 +found 0 +to 0 +have 0 +atypical 0 +plasma 0 +cholinesterase 0 +with 0 +a 0 +dibucaine 1 +number 0 +of 0 +12 0 +, 0 +indicating 0 +homozygocity 0 +. 0 + +This 0 +was 0 +verified 0 +by 0 +study 0 +of 0 +the 0 +family 0 +. 0 + +The 0 +case 0 +shows 0 +that 0 +prolonged 3 +jaw 4 +rigidity 4 +and 0 +myalgia 3 +may 0 +occur 0 +after 0 +suxamethonium 1 +in 0 +patients 0 +with 0 +atypical 0 +cholinesterase 0 +despite 0 +pretreatment 0 +with 0 +pancuronium 1 +. 0 + +Indomethacin 1 +- 0 +induced 0 +hyperkalemia 3 +in 0 +three 0 +patients 0 +with 0 +gouty 3 +arthritis 4 +. 0 + +We 0 +describe 0 +three 0 +patients 0 +in 0 +whom 0 +severe 0 +, 0 +life 0 +- 0 +threatening 0 +hyperkalemia 3 +and 0 +renal 3 +insufficiency 4 +developed 0 +after 0 +treatment 0 +of 0 +acute 0 +gouty 3 +arthritis 4 +with 0 +indomethacin 1 +. 0 + +This 0 +complication 0 +may 0 +result 0 +from 0 +an 0 +inhibition 0 +of 0 +prostaglandin 1 +synthesis 0 +and 0 +consequent 0 +hyporeninemic 3 +hypoaidosteronism 4 +. 0 + +Careful 0 +attention 0 +to 0 +renal 0 +function 0 +and 0 +potassium 1 +balance 0 +in 0 +patients 0 +receiving 0 +indomethacin 1 +or 0 +other 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +agents 0 +, 0 +particularly 0 +in 0 +those 0 +patients 0 +with 0 +diabetes 3 +mellitus 4 +or 0 +preexisting 0 +renal 3 +disease 4 +, 0 +will 0 +help 0 +prevent 0 +this 0 +potentially 0 +serious 0 +complication 0 +. 0 + +Etomidate 1 +: 0 +a 0 +foreshortened 0 +clinical 0 +trial 0 +. 0 + +A 0 +clinical 0 +evaluation 0 +of 0 +etomidate 1 +for 0 +outpatient 0 +cystoscopy 0 +was 0 +embarked 0 +upon 0 +. 0 + +Unpremedicated 0 +patients 0 +were 0 +given 0 +fentanyl 1 +1 0 +microgram 0 +/ 0 +kg 0 +followed 0 +by 0 +etomidate 1 +0 0 +. 0 +3 0 +mg 0 +/ 0 +kg 0 +. 0 + +Anaesthesia 0 +was 0 +maintained 0 +with 0 +intermittent 0 +etomidate 1 +in 0 +2 0 +- 0 +4 0 +mg 0 +doses 0 +. 0 + +Patients 0 +were 0 +interviewed 0 +personally 0 +later 0 +the 0 +same 0 +day 0 +, 0 +and 0 +by 0 +questionnaire 0 +three 0 +to 0 +four 0 +weeks 0 +later 0 +. 0 + +The 0 +trial 0 +was 0 +discontinued 0 +after 0 +20 0 +cases 0 +because 0 +of 0 +an 0 +unacceptable 0 +incidence 0 +of 0 +side 0 +effects 0 +. 0 + +Venous 0 +pain 3 +occurred 0 +in 0 +68 0 +% 0 +of 0 +patients 0 +and 0 +50 0 +% 0 +had 0 +redness 0 +, 0 +pain 3 +or 0 +swelling 3 +related 0 +to 0 +the 0 +injection 0 +site 0 +, 0 +in 0 +some 0 +cases 0 +lasting 0 +up 0 +to 0 +three 0 +weeks 0 +after 0 +anaesthesia 0 +. 0 + +Skeletal 0 +movements 0 +occurred 0 +in 0 +50 0 +% 0 +of 0 +patients 0 +; 0 +30 0 +% 0 +experienced 0 +respiratory 3 +upset 4 +, 0 +one 0 +sufficiently 0 +severe 0 +to 0 +necessitate 0 +abandoning 0 +the 0 +technique 0 +. 0 + +Nausea 3 +and 0 +vomiting 3 +occurred 0 +in 0 +40 0 +% 0 +and 0 +25 0 +% 0 +had 0 +disturbing 0 +emergence 0 +psychoses 3 +. 0 + +Levodopa 1 +- 0 +induced 0 +dyskinesias 3 +are 0 +improved 0 +by 0 +fluoxetine 1 +. 0 + +We 0 +evaluated 0 +the 0 +severity 0 +of 0 +motor 3 +disability 4 +and 0 +dyskinesias 3 +in 0 +seven 0 +levodopa 1 +- 0 +responsive 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +after 0 +an 0 +acute 0 +challenge 0 +with 0 +the 0 +mixed 0 +dopamine 1 +agonist 0 +, 0 +apomorphine 1 +, 0 +before 0 +and 0 +after 0 +the 0 +administration 0 +of 0 +fluoxetine 1 +( 0 +20 0 +mg 0 +twice 0 +per 0 +day 0 +) 0 +for 0 +11 0 ++ 0 +/ 0 +- 0 +1 0 +days 0 +. 0 + +After 0 +fluoxetine 1 +treatment 0 +, 0 +there 0 +was 0 +a 0 +significant 0 +47 0 +% 0 +improvement 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +of 0 +apomorphine 1 +- 0 +induced 0 +dyskinesias 3 +without 0 +modification 0 +of 0 +parkinsonian 3 +motor 3 +disability 4 +. 0 + +The 0 +dyskinesias 3 +were 0 +reduced 0 +predominantly 0 +in 0 +the 0 +lower 0 +limbs 0 +during 0 +the 0 +onset 0 +and 0 +disappearance 0 +of 0 +dystonic 3 +dyskinesias 4 +( 0 +onset 0 +- 0 +and 0 +end 0 +- 0 +of 0 +- 0 +dose 0 +dyskinesias 3 +) 0 +and 0 +in 0 +the 0 +upper 0 +limbs 0 +during 0 +choreic 3 +mid 4 +- 4 +dose 4 +dyskinesias 4 +. 0 + +The 0 +results 0 +suggest 0 +that 0 +increased 0 +brain 0 +serotoninergic 0 +transmission 0 +with 0 +fluoxetine 1 +may 0 +reduce 0 +levodopa 1 +- 0 +or 0 +dopamine 1 +agonist 0 +- 0 +induced 0 +dyskinesias 3 +without 0 +aggravating 0 +parkinsonian 3 +motor 3 +disability 4 +. 0 + +A 0 +large 0 +population 0 +- 0 +based 0 +follow 0 +- 0 +up 0 +study 0 +of 0 +trimethoprim 1 +- 2 +sulfamethoxazole 2 +, 0 +trimethoprim 1 +, 0 +and 0 +cephalexin 1 +for 0 +uncommon 0 +serious 0 +drug 3 +toxicity 4 +. 0 + +We 0 +conducted 0 +a 0 +population 0 +- 0 +based 0 +45 0 +- 0 +day 0 +follow 0 +- 0 +up 0 +study 0 +of 0 +232 0 +, 0 +390 0 +people 0 +who 0 +were 0 +prescribed 0 +trimethoprim 1 +- 2 +sulfamethoxazole 2 +( 0 +TMP 1 +- 2 +SMZ 2 +) 0 +, 0 +266 0 +, 0 +951 0 +prescribed 0 +trimethoprim 1 +alone 0 +, 0 +and 0 +196 0 +, 0 +397 0 +prescribed 0 +cephalexin 1 +, 0 +to 0 +estimate 0 +the 0 +risk 0 +of 0 +serious 0 +liver 3 +, 4 +blood 4 +, 4 +skin 4 +, 4 +and 4 +renal 4 +disorders 4 +resulting 0 +in 0 +referral 0 +or 0 +hospitalization 0 +associated 0 +with 0 +these 0 +drugs 0 +. 0 + +The 0 +results 0 +were 0 +based 0 +on 0 +information 0 +recorded 0 +on 0 +office 0 +computers 0 +by 0 +selected 0 +general 0 +practitioners 0 +in 0 +the 0 +United 0 +Kingdom 0 +, 0 +together 0 +with 0 +a 0 +review 0 +of 0 +clinical 0 +records 0 +. 0 + +The 0 +risk 0 +of 0 +clinically 0 +important 0 +idiopathic 0 +liver 3 +disease 4 +was 0 +similar 0 +for 0 +persons 0 +prescribed 0 +TMP 1 +- 2 +SMZ 2 +( 0 +5 0 +. 0 +2 0 +/ 0 +100 0 +, 0 +000 0 +) 0 +and 0 +those 0 +prescribed 0 +trimethoprim 1 +alone 0 +( 0 +3 0 +. 0 +8 0 +/ 0 +100 0 +, 0 +000 0 +) 0 +. 0 + +The 0 +risk 0 +for 0 +those 0 +prescribed 0 +cephalexin 1 +was 0 +somewhat 0 +lower 0 +( 0 +2 0 +. 0 +0 0 +/ 0 +100 0 +, 0 +000 0 +) 0 +. 0 + +0nly 0 +five 0 +patients 0 +experienced 0 +blood 0 +disorders 0 +, 0 +one 0 +of 0 +whom 0 +was 0 +exposed 0 +to 0 +TMP 1 +- 2 +SMZ 2 +; 0 +of 0 +seven 0 +with 0 +erythema 3 +multiforme 4 +and 0 +Stevens 3 +- 4 +Johnson 4 +syndrome 4 +, 0 +four 0 +were 0 +exposed 0 +to 0 +TMP 1 +- 2 +SMZ 2 +. 0 + +The 0 +one 0 +case 0 +of 0 +toxic 3 +epidermal 4 +necrolysis 4 +occurred 0 +in 0 +a 0 +patient 0 +who 0 +took 0 +cephalexin 1 +. 0 + +Finally 0 +, 0 +only 0 +five 0 +cases 0 +of 0 +acute 0 +parenchymal 0 +renal 3 +disease 4 +occurred 0 +, 0 +none 0 +likely 0 +to 0 +be 0 +caused 0 +by 0 +a 0 +study 0 +drug 0 +. 0 + +We 0 +conclude 0 +that 0 +the 0 +risk 0 +of 0 +the 0 +serious 0 +diseases 0 +studied 0 +is 0 +small 0 +for 0 +the 0 +three 0 +agents 0 +, 0 +and 0 +compares 0 +reasonably 0 +with 0 +the 0 +risk 0 +for 0 +many 0 +other 0 +antibiotics 0 +. 0 + +Clinical 0 +safety 0 +of 0 +lidocaine 1 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +myocardial 3 +infarction 4 +. 0 + +STUDY 0 +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +safety 0 +of 0 +lidocaine 1 +in 0 +the 0 +setting 0 +of 0 +cocaine 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +( 0 +MI 3 +) 0 +. 0 + +DESIGN 0 +: 0 +A 0 +retrospective 0 +, 0 +multicenter 0 +study 0 +. 0 + +SETTING 0 +: 0 +Twenty 0 +- 0 +nine 0 +university 0 +, 0 +university 0 +- 0 +affiliated 0 +, 0 +or 0 +community 0 +hospitals 0 +during 0 +a 0 +6 0 +- 0 +year 0 +period 0 +( 0 +total 0 +of 0 +117 0 +cumulative 0 +hospital 0 +- 0 +years 0 +) 0 +. 0 + +PARTICIPANTS 0 +: 0 +Patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +MI 3 +who 0 +received 0 +lidocaine 1 +in 0 +the 0 +emergency 0 +department 0 +. 0 + +RESULTS 0 +: 0 +0f 0 +29 0 +patients 0 +who 0 +received 0 +lidocaine 1 +in 0 +the 0 +setting 0 +of 0 +cocaine 1 +- 0 +associated 0 +MI 3 +, 0 +no 0 +patient 0 +died 0 +; 0 +exhibited 0 +bradydysrhythmias 3 +, 0 +ventricular 3 +tachycardia 4 +, 0 +or 0 +ventricular 3 +fibrillation 4 +; 0 +or 0 +experienced 0 +seizures 3 +after 0 +administration 0 +of 0 +lidocaine 1 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +, 0 +0 0 +% 0 +to 0 +11 0 +% 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Despite 0 +theoretical 0 +concerns 0 +that 0 +lidocaine 1 +may 0 +enhance 0 +cocaine 1 +toxicity 3 +, 0 +the 0 +use 0 +of 0 +lidocaine 1 +in 0 +patients 0 +with 0 +cocaine 1 +- 0 +associated 0 +MI 3 +was 0 +not 0 +associated 0 +with 0 +significant 0 +cardiovascular 3 +or 4 +central 4 +nervous 4 +system 4 +toxicity 4 +. 0 + +Experimental 0 +progressive 0 +muscular 3 +dystrophy 4 +and 0 +its 0 +treatment 0 +with 0 +high 0 +doses 0 +anabolizing 0 +agents 0 +. 0 + +We 0 +are 0 +still 0 +a 0 +long 0 +way 0 +from 0 +discovering 0 +an 0 +unequivocal 0 +pathogenetic 0 +interpretation 0 +of 0 +progressive 0 +muscular 3 +dystrophy 4 +in 0 +man 0 +. 0 + +Noteworthy 0 +efforts 0 +have 0 +been 0 +made 0 +in 0 +the 0 +experimental 0 +field 0 +; 0 +a 0 +recessive 0 +autosomic 0 +form 0 +found 0 +in 0 +the 0 +mouse 0 +seems 0 +to 0 +bear 0 +the 0 +closest 0 +resemblance 0 +to 0 +the 0 +human 0 +form 0 +from 0 +the 0 +genetic 0 +point 0 +of 0 +view 0 +. 0 + +Myopathy 3 +due 0 +to 0 +lack 0 +of 0 +vitamin 1 +E 2 +and 0 +myopathy 3 +induced 0 +by 0 +certain 0 +viruses 0 +have 0 +much 0 +in 0 +common 0 +anatomically 0 +and 0 +pathologically 0 +with 0 +the 0 +human 0 +form 0 +. 0 + +The 0 +authors 0 +induced 0 +myodystrophy 3 +in 0 +the 0 +rat 0 +by 0 +giving 0 +it 0 +a 0 +diet 0 +lacking 0 +in 0 +vitamin 1 +E 2 +. 0 + +The 0 +pharmacological 0 +characteristics 0 +of 0 +vitamin 1 +E 2 +and 0 +the 0 +degenerative 0 +changes 0 +brought 0 +about 0 +by 0 +its 0 +deficiency 0 +, 0 +especially 0 +in 0 +the 0 +muscles 0 +, 0 +are 0 +illustrated 0 +. 0 + +It 0 +is 0 +thus 0 +confirmed 0 +that 0 +the 0 +histological 0 +characteristics 0 +of 0 +myopathic 3 +rat 0 +muscle 0 +induced 0 +experimentally 0 +are 0 +extraordinarily 0 +similar 0 +to 0 +those 0 +of 0 +human 0 +myopathy 3 +as 0 +confirmed 0 +during 0 +biopsies 0 +performed 0 +at 0 +the 0 +0rthopaedic 0 +Traumatological 0 +Centre 0 +, 0 +Florence 0 +. 0 + +The 0 +encouraging 0 +results 0 +obtained 0 +in 0 +various 0 +authoratative 0 +departments 0 +in 0 +myopathic 3 +patients 0 +by 0 +using 0 +anabolizing 0 +steroids 1 +have 0 +encouraged 0 +the 0 +authors 0 +to 0 +investigate 0 +the 0 +beneficial 0 +effects 0 +of 0 +one 0 +anabolizing 0 +agent 0 +( 0 +Dianabol 1 +, 0 +CIBA 1 +) 0 +at 0 +high 0 +doses 0 +in 0 +rats 0 +rendered 0 +myopathic 3 +by 0 +a 0 +diet 0 +deficient 0 +in 0 +vitamin 1 +E 2 +. 0 + +In 0 +this 0 +way 0 +they 0 +obtained 0 +appreciable 0 +changes 0 +in 0 +body 0 +weight 0 +( 0 +increased 0 +from 0 +50 0 +to 0 +70 0 +g 0 +after 0 +forty 0 +days 0 +at 0 +a 0 +dose 0 +of 0 +5 0 +mg 0 +per 0 +day 0 +of 0 +anabolizing 0 +agent 0 +) 0 +, 0 +but 0 +most 0 +of 0 +all 0 +they 0 +found 0 +histological 0 +changes 0 +due 0 +to 0 +" 0 +regenerative 0 +" 0 +changes 0 +in 0 +the 0 +muscle 0 +tissue 0 +, 0 +which 0 +however 0 +maintained 0 +its 0 +myopathic 3 +characteristics 0 +in 0 +the 0 +control 0 +animals 0 +that 0 +were 0 +not 0 +treated 0 +with 0 +the 0 +anabolizing 0 +agent 0 +. 0 + +The 0 +authors 0 +conclude 0 +by 0 +affirming 0 +the 0 +undoubted 0 +efficacy 0 +of 0 +the 0 +anabolizing 0 +steroids 1 +in 0 +experimental 0 +myopathic 3 +disease 4 +, 0 +but 0 +they 0 +have 0 +reservations 0 +as 0 +to 0 +the 0 +transfer 0 +of 0 +the 0 +results 0 +into 0 +the 0 +human 0 +field 0 +, 0 +where 0 +high 0 +dosage 0 +cannot 0 +be 0 +carried 0 +out 0 +continuously 0 +because 0 +of 0 +the 0 +effects 0 +of 0 +the 0 +drug 0 +on 0 +virility 0 +; 0 +because 0 +the 0 +tissue 0 +injury 0 +too 0 +often 0 +occurs 0 +at 0 +an 0 +irreversible 0 +stage 0 +vis 0 +- 0 +a 0 +- 0 +vis 0 +the 0 +" 0 +regeneration 0 +" 0 +of 0 +the 0 +muscle 0 +tissue 0 +; 0 +and 0 +finally 0 +because 0 +the 0 +dystrophic 0 +injurious 0 +agent 0 +is 0 +certainly 0 +not 0 +the 0 +lack 0 +of 0 +vitamin 1 +E 2 +but 0 +something 0 +as 0 +yet 0 +unknown 0 +. 0 + +Paclitaxel 1 +3 0 +- 0 +hour 0 +infusion 0 +given 0 +alone 0 +and 0 +combined 0 +with 0 +carboplatin 1 +: 0 +preliminary 0 +results 0 +of 0 +dose 0 +- 0 +escalation 0 +trials 0 +. 0 + +Paclitaxel 1 +( 0 +Taxol 1 +; 0 +Bristol 0 +- 0 +Myers 0 +Squibb 0 +Company 0 +, 0 +Princeton 0 +, 0 +NJ 0 +) 0 +by 0 +3 0 +- 0 +hour 0 +infusion 0 +was 0 +combined 0 +with 0 +carboplatin 1 +in 0 +a 0 +phase 0 +I 0 +/ 0 +II 0 +study 0 +directed 0 +to 0 +patients 0 +with 0 +non 3 +- 4 +small 4 +cell 4 +lung 4 +cancer 4 +. 0 + +Carboplatin 1 +was 0 +given 0 +at 0 +a 0 +fixed 0 +target 0 +area 0 +under 0 +the 0 +concentration 0 +- 0 +time 0 +curve 0 +of 0 +6 0 +. 0 +0 0 +by 0 +the 0 +Calvert 0 +formula 0 +, 0 +whereas 0 +paclitaxel 1 +was 0 +escalated 0 +in 0 +patient 0 +cohorts 0 +from 0 +150 0 +mg 0 +/ 0 +m2 0 +( 0 +dose 0 +level 0 +I 0 +) 0 +to 0 +175 0 +, 0 +200 0 +, 0 +225 0 +, 0 +and 0 +250 0 +mg 0 +/ 0 +m2 0 +. 0 + +The 0 +225 0 +mg 0 +/ 0 +m2 0 +level 0 +was 0 +expanded 0 +for 0 +the 0 +phase 0 +II 0 +study 0 +since 0 +the 0 +highest 0 +level 0 +achieved 0 +( 0 +250 0 +mg 0 +/ 0 +m2 0 +) 0 +required 0 +modification 0 +because 0 +of 0 +nonhematologic 0 +toxicities 3 +( 0 +arthralgia 3 +and 0 +sensory 3 +neuropathy 4 +) 0 +. 0 + +Therapeutic 0 +effects 0 +were 0 +noted 0 +at 0 +all 0 +dose 0 +levels 0 +, 0 +with 0 +objective 0 +responses 0 +in 0 +17 0 +( 0 +two 0 +complete 0 +and 0 +15 0 +partial 0 +regressions 0 +) 0 +of 0 +41 0 +previously 0 +untreated 0 +patients 0 +. 0 + +Toxicities 3 +were 0 +compared 0 +with 0 +a 0 +cohort 0 +of 0 +patients 0 +in 0 +a 0 +phase 0 +I 0 +trial 0 +of 0 +paclitaxel 1 +alone 0 +at 0 +identical 0 +dose 0 +levels 0 +. 0 + +Carboplatin 1 +did 0 +not 0 +appear 0 +to 0 +add 0 +to 0 +the 0 +hematologic 3 +toxicities 4 +observed 0 +, 0 +and 0 +the 0 +paclitaxel 1 +/ 0 +carboplatin 1 +combination 0 +could 0 +be 0 +dosed 0 +every 0 +3 0 +weeks 0 +. 0 + +The 0 +dose 0 +- 0 +dependent 0 +effect 0 +of 0 +misoprostol 1 +on 0 +indomethacin 1 +- 0 +induced 0 +renal 3 +dysfunction 4 +in 0 +well 0 +compensated 0 +cirrhosis 3 +. 0 + +Misoprostol 1 +( 0 +200 0 +micrograms 0 +) 0 +has 0 +been 0 +shown 0 +to 0 +acutely 0 +counteract 0 +the 0 +indomethacin 1 +- 0 +induced 0 +renal 3 +dysfunction 4 +in 0 +well 0 +compensated 0 +cirrhotic 3 +patients 0 +. 0 + +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +if 0 +the 0 +prophylactic 0 +value 0 +of 0 +misoprostol 1 +was 0 +dose 0 +- 0 +dependent 0 +. 0 + +Parameters 0 +of 0 +renal 0 +hemodynamics 0 +and 0 +tubular 0 +sodium 1 +and 0 +water 0 +handling 0 +were 0 +assessed 0 +by 0 +clearance 0 +techniques 0 +in 0 +26 0 +well 0 +compensated 0 +cirrhotic 3 +patients 0 +before 0 +and 0 +after 0 +an 0 +oral 0 +combination 0 +of 0 +50 0 +mg 0 +of 0 +indomethacin 1 +and 0 +various 0 +doses 0 +of 0 +misoprostol 1 +. 0 + +The 0 +200 0 +- 0 +micrograms 0 +dose 0 +was 0 +able 0 +to 0 +totally 0 +abolish 0 +the 0 +deleterious 0 +renal 0 +effects 0 +of 0 +indomethacin 1 +, 0 +whereas 0 +the 0 +800 0 +- 0 +micrograms 0 +dose 0 +resulted 0 +in 0 +significant 0 +worsening 0 +of 0 +renal 0 +hemodynamics 0 +and 0 +sodium 1 +retention 0 +. 0 + +These 0 +changes 0 +were 0 +maximal 0 +in 0 +the 0 +hour 0 +immediately 0 +after 0 +medications 0 +and 0 +slowly 0 +returned 0 +toward 0 +base 0 +- 0 +line 0 +levels 0 +thereafter 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +the 0 +renal 0 +protective 0 +effects 0 +of 0 +misoprostol 1 +is 0 +dose 0 +- 0 +dependent 0 +. 0 + +However 0 +, 0 +until 0 +this 0 +apparent 0 +ability 0 +of 0 +200 0 +micrograms 0 +of 0 +misoprostol 1 +to 0 +prevent 0 +the 0 +adverse 0 +effects 0 +of 0 +indomethacin 1 +on 0 +renal 0 +function 0 +is 0 +confirmed 0 +with 0 +chronic 0 +frequent 0 +dosing 0 +, 0 +it 0 +would 0 +be 0 +prudent 0 +to 0 +avoid 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +therapy 0 +in 0 +patients 0 +with 0 +cirrhosis 3 +. 0 + +Increased 0 +frequency 0 +and 0 +severity 0 +of 0 +angio 3 +- 4 +oedema 4 +related 0 +to 0 +long 0 +- 0 +term 0 +therapy 0 +with 0 +angiotensin 1 +- 2 +converting 2 +enzyme 2 +inhibitor 2 +in 0 +two 0 +patients 0 +. 0 + +Adverse 0 +reactions 0 +to 0 +drugs 0 +are 0 +well 0 +recognized 0 +as 0 +a 0 +cause 0 +of 0 +acute 0 +or 0 +chronic 0 +urticaria 3 +, 0 +and 0 +angio 3 +- 4 +oedema 4 +. 0 + +Angiotensin 1 +- 2 +converting 2 +enzyme 2 +( 2 +ACE 2 +) 2 +inhibitors 2 +, 0 +used 0 +to 0 +treat 0 +hypertension 3 +and 0 +congestive 3 +heart 4 +failure 4 +, 0 +were 0 +introduced 0 +in 0 +Europe 0 +in 0 +the 0 +middle 0 +of 0 +the 0 +eighties 0 +, 0 +and 0 +the 0 +use 0 +of 0 +these 0 +drugs 0 +has 0 +increased 0 +progressively 0 +. 0 + +Soon 0 +after 0 +the 0 +introduction 0 +of 0 +ACE 1 +inhibitors 2 +, 0 +acute 0 +bouts 0 +of 0 +angio 3 +- 4 +oedema 4 +were 0 +reported 0 +in 0 +association 0 +with 0 +the 0 +use 0 +of 0 +these 0 +drugs 0 +. 0 + +We 0 +wish 0 +to 0 +draw 0 +attention 0 +to 0 +the 0 +possibility 0 +of 0 +adverse 0 +reactions 0 +to 0 +ACE 1 +inhibitors 2 +after 0 +long 0 +- 0 +term 0 +use 0 +and 0 +in 0 +patients 0 +with 0 +pre 0 +- 0 +existing 0 +angio 3 +- 4 +oedema 4 +. 0 + +Myoclonus 3 +associated 0 +with 0 +lorazepam 1 +therapy 0 +in 0 +very 0 +- 0 +low 0 +- 0 +birth 0 +- 0 +weight 0 +infants 0 +. 0 + +Lorazepam 1 +is 0 +being 0 +used 0 +with 0 +increasing 0 +frequency 0 +as 0 +a 0 +sedative 0 +in 0 +the 0 +newborn 0 +and 0 +the 0 +young 0 +infant 0 +. 0 + +Concern 0 +has 0 +been 0 +raised 0 +with 0 +regard 0 +to 0 +the 0 +safety 0 +of 0 +lorazepam 1 +in 0 +this 0 +age 0 +group 0 +, 0 +especially 0 +in 0 +very 0 +- 0 +low 0 +- 0 +birth 0 +- 0 +weight 0 +( 0 +VLBW 0 +; 0 +< 0 +1 0 +, 0 +500 0 +g 0 +) 0 +infants 0 +. 0 + +Three 0 +young 0 +infants 0 +, 0 +all 0 +of 0 +birth 0 +weight 0 +< 0 +1 0 +, 0 +500 0 +g 0 +, 0 +experienced 0 +myoclonus 3 +following 0 +the 0 +intravenous 0 +administration 0 +of 0 +lorazepam 1 +. 0 + +The 0 +potential 0 +neurotoxic 3 +effects 0 +of 0 +the 0 +drug 0 +( 0 +and 0 +its 0 +vehicle 0 +) 0 +in 0 +this 0 +population 0 +are 0 +discussed 0 +. 0 + +Injectable 0 +lorazepam 1 +should 0 +be 0 +used 0 +with 0 +caution 0 +in 0 +VLBW 0 +infants 0 +. 0 + +Transvenous 0 +right 0 +ventricular 0 +pacing 0 +during 0 +cardiopulmonary 0 +resuscitation 0 +of 0 +pediatric 0 +patients 0 +with 0 +acute 0 +cardiomyopathy 3 +. 0 + +We 0 +describe 0 +the 0 +cardiopulmonary 0 +resuscitation 0 +efforts 0 +on 0 +five 0 +patients 0 +who 0 +presented 0 +in 0 +acute 0 +circulatory 3 +failure 4 +from 0 +myocardial 3 +dysfunction 4 +. 0 + +Three 0 +patients 0 +had 0 +acute 0 +viral 0 +myocarditis 3 +, 0 +one 0 +had 0 +a 0 +carbamazepine 1 +- 0 +induced 0 +acute 0 +eosinophilic 3 +myocarditis 4 +, 0 +and 0 +one 0 +had 0 +cardiac 0 +hemosiderosis 0 +resulting 0 +in 0 +acute 0 +cardiogenic 3 +shock 4 +. 0 + +All 0 +patients 0 +were 0 +continuously 0 +monitored 0 +with 0 +central 0 +venous 0 +and 0 +arterial 0 +catheters 0 +in 0 +addition 0 +to 0 +routine 0 +noninvasive 0 +monitoring 0 +. 0 + +An 0 +introducer 0 +sheath 0 +, 0 +a 0 +pacemaker 0 +, 0 +and 0 +sterile 0 +pacing 0 +wires 0 +were 0 +made 0 +readily 0 +available 0 +for 0 +the 0 +patients 0 +, 0 +should 0 +the 0 +need 0 +arise 0 +to 0 +terminate 0 +resistant 0 +cardiac 0 +dysrhythmias 3 +. 0 + +All 0 +patients 0 +developed 0 +cardiocirculatory 0 +arrest 0 +associated 0 +with 0 +extreme 0 +hypotension 3 +and 0 +dysrhythmias 3 +within 0 +the 0 +first 0 +48 0 +hours 0 +of 0 +their 0 +admission 0 +to 0 +the 0 +pediatric 0 +intensive 0 +care 0 +unit 0 +( 0 +PICU 0 +) 0 +. 0 + +Right 0 +ventricular 0 +pacemaker 0 +wires 0 +were 0 +inserted 0 +in 0 +all 0 +of 0 +them 0 +during 0 +cardiopulmonary 0 +resuscitation 0 +( 0 +CPR 0 +) 0 +. 0 + +In 0 +four 0 +patients 0 +, 0 +cardiac 0 +pacing 0 +was 0 +used 0 +, 0 +resulting 0 +in 0 +a 0 +temporary 0 +captured 0 +rhythm 0 +and 0 +restoration 0 +of 0 +their 0 +cardiac 0 +output 0 +. 0 + +These 0 +patients 0 +had 0 +a 0 +second 0 +event 0 +of 0 +cardiac 3 +arrest 4 +, 0 +resulting 0 +in 0 +death 0 +, 0 +within 0 +10 0 +to 0 +60 0 +minutes 0 +. 0 + +In 0 +one 0 +patient 0 +, 0 +cardiac 0 +pacing 0 +was 0 +not 0 +used 0 +, 0 +because 0 +he 0 +converted 0 +to 0 +normal 0 +sinus 0 +rhythm 0 +by 0 +electrical 0 +defibrillation 0 +within 0 +three 0 +minutes 0 +of 0 +initiating 0 +CPR 0 +. 0 + +We 0 +conclude 0 +that 0 +cardiac 0 +pacing 0 +during 0 +resuscitative 0 +efforts 0 +in 0 +pediatric 0 +patients 0 +suffering 0 +from 0 +acute 0 +myocardial 3 +dysfunction 4 +may 0 +not 0 +have 0 +long 0 +- 0 +term 0 +value 0 +in 0 +and 0 +of 0 +itself 0 +; 0 +however 0 +, 0 +if 0 +temporary 0 +hemodynamic 0 +stability 0 +is 0 +achieved 0 +by 0 +this 0 +procedure 0 +, 0 +it 0 +may 0 +provide 0 +additional 0 +time 0 +needed 0 +to 0 +institute 0 +other 0 +therapeutic 0 +modalities 0 +. 0 + +Efficacy 0 +and 0 +safety 0 +of 0 +granisetron 1 +, 0 +a 0 +selective 0 +5 1 +- 2 +hydroxytryptamine 2 +- 0 +3 0 +receptor 0 +antagonist 0 +, 0 +in 0 +the 0 +prevention 0 +of 0 +nausea 3 +and 0 +vomiting 3 +induced 0 +by 0 +high 0 +- 0 +dose 0 +cisplatin 1 +. 0 + +PURP0SE 0 +: 0 +To 0 +assess 0 +the 0 +antiemetic 0 +effects 0 +and 0 +safety 0 +profile 0 +of 0 +four 0 +different 0 +doses 0 +of 0 +granisetron 1 +( 0 +Kytril 1 +; 0 +SmithKline 0 +Beecham 0 +Pharmaceuticals 0 +, 0 +Philadelphia 0 +, 0 +PA 0 +) 0 +when 0 +administered 0 +as 0 +a 0 +single 0 +intravenous 0 +( 0 +IV 0 +) 0 +dose 0 +for 0 +prophylaxis 0 +of 0 +cisplatin 1 +- 0 +induced 0 +nausea 3 +and 0 +vomiting 3 +. 0 + +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +0ne 0 +hundred 0 +eighty 0 +- 0 +four 0 +chemotherapy 0 +- 0 +naive 0 +patients 0 +receiving 0 +high 0 +- 0 +dose 0 +cisplatin 1 +( 0 +81 0 +to 0 +120 0 +mg 0 +/ 0 +m2 0 +) 0 +were 0 +randomized 0 +to 0 +receive 0 +one 0 +of 0 +four 0 +granisetron 1 +doses 0 +( 0 +5 0 +, 0 +10 0 +, 0 +20 0 +, 0 +or 0 +40 0 +micrograms 0 +/ 0 +kg 0 +) 0 +administered 0 +before 0 +chemotherapy 0 +. 0 + +Patients 0 +were 0 +observed 0 +on 0 +an 0 +inpatient 0 +basis 0 +for 0 +18 0 +to 0 +24 0 +hours 0 +, 0 +and 0 +vital 0 +signs 0 +, 0 +nausea 3 +, 0 +vomiting 3 +, 0 +retching 0 +, 0 +and 0 +appetite 0 +were 0 +assessed 0 +. 0 + +Safety 0 +analyses 0 +included 0 +incidence 0 +of 0 +adverse 0 +experiences 0 +and 0 +laboratory 0 +parameter 0 +changes 0 +. 0 + +RESULTS 0 +: 0 +After 0 +granisetron 1 +doses 0 +of 0 +5 0 +, 0 +10 0 +, 0 +20 0 +, 0 +and 0 +40 0 +micrograms 0 +/ 0 +kg 0 +, 0 +a 0 +major 0 +response 0 +( 0 +< 0 +or 0 += 0 +two 0 +vomiting 3 +or 0 +retching 0 +episodes 0 +, 0 +and 0 +no 0 +antiemetic 0 +rescue 0 +) 0 +was 0 +recorded 0 +in 0 +23 0 +% 0 +, 0 +57 0 +% 0 +, 0 +58 0 +% 0 +, 0 +and 0 +60 0 +% 0 +of 0 +patients 0 +, 0 +respectively 0 +, 0 +and 0 +a 0 +complete 0 +response 0 +( 0 +no 0 +vomiting 3 +or 0 +retching 0 +, 0 +and 0 +no 0 +antiemetic 0 +rescue 0 +) 0 +in 0 +18 0 +% 0 +, 0 +41 0 +% 0 +, 0 +40 0 +% 0 +, 0 +and 0 +47 0 +% 0 +of 0 +patients 0 +, 0 +respectively 0 +. 0 + +There 0 +was 0 +a 0 +statistically 0 +longer 0 +time 0 +to 0 +first 0 +episode 0 +of 0 +nausea 3 +( 0 +P 0 += 0 +. 0 +0015 0 +) 0 +and 0 +vomiting 3 +( 0 +P 0 += 0 +. 0 +0001 0 +) 0 +, 0 +and 0 +fewer 0 +patients 0 +were 0 +administered 0 +additional 0 +antiemetic 0 +medication 0 +in 0 +the 0 +10 0 +- 0 +micrograms 0 +/ 0 +kg 0 +dosing 0 +groups 0 +than 0 +in 0 +the 0 +5 0 +- 0 +micrograms 0 +/ 0 +kg 0 +dosing 0 +group 0 +. 0 + +As 0 +granisetron 1 +dose 0 +increased 0 +, 0 +appetite 0 +return 0 +increased 0 +( 0 +P 0 += 0 +. 0 +040 0 +) 0 +. 0 + +Headache 3 +was 0 +the 0 +most 0 +frequently 0 +reported 0 +adverse 0 +event 0 +( 0 +20 0 +% 0 +) 0 +. 0 + +C0NCLUSI0N 0 +: 0 +A 0 +single 0 +10 0 +- 0 +, 0 +20 0 +- 0 +, 0 +or 0 +40 0 +- 0 +micrograms 0 +/ 0 +kg 0 +dose 0 +of 0 +granisetron 1 +was 0 +effective 0 +in 0 +controlling 0 +vomiting 3 +in 0 +57 0 +% 0 +to 0 +60 0 +% 0 +of 0 +patients 0 +who 0 +received 0 +cisplatin 1 +at 0 +doses 0 +greater 0 +than 0 +81 0 +mg 0 +/ 0 +m2 0 +and 0 +totally 0 +prevented 0 +vomiting 3 +in 0 +40 0 +% 0 +to 0 +47 0 +% 0 +of 0 +patients 0 +. 0 + +There 0 +were 0 +no 0 +statistically 0 +significant 0 +differences 0 +in 0 +efficacy 0 +between 0 +the 0 +10 0 +- 0 +micrograms 0 +/ 0 +kg 0 +dose 0 +and 0 +the 0 +20 0 +- 0 +and 0 +40 0 +- 0 +micrograms 0 +/ 0 +kg 0 +doses 0 +. 0 + +Granisetron 1 +was 0 +well 0 +tolerated 0 +at 0 +all 0 +doses 0 +. 0 + +Adverse 0 +interaction 0 +between 0 +clonidine 1 +and 0 +verapamil 1 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +report 0 +two 0 +cases 0 +of 0 +a 0 +possible 0 +adverse 0 +interaction 0 +between 0 +clonidine 1 +and 0 +verapamil 1 +resulting 0 +in 0 +atrioventricular 3 +( 4 +AV 4 +) 4 +block 4 +in 0 +both 0 +patients 0 +and 0 +severe 0 +hypotension 3 +in 0 +one 0 +patient 0 +. 0 + +CASE 0 +SUMMARIES 0 +: 0 +A 0 +54 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +hyperaldosteronism 3 +was 0 +treated 0 +with 0 +verapamil 1 +480 0 +mg 0 +/ 0 +d 0 +and 0 +spironolactone 1 +100 0 +mg 0 +/ 0 +d 0 +. 0 + +After 0 +the 0 +addition 0 +of 0 +a 0 +minimal 0 +dose 0 +of 0 +clonidine 1 +( 0 +0 0 +. 0 +15 0 +mg 0 +bid 0 +) 0 +, 0 +she 0 +developed 0 +complete 0 +AV 3 +block 4 +and 0 +severe 0 +hypotension 3 +, 0 +which 0 +resolved 0 +upon 0 +cessation 0 +of 0 +all 0 +medications 0 +. 0 + +A 0 +65 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +was 0 +treated 0 +with 0 +extended 0 +- 0 +release 0 +verapamil 1 +240 0 +mg 0 +/ 0 +d 0 +. 0 + +After 0 +the 0 +addition 0 +of 0 +clonidine 1 +0 0 +. 0 +15 0 +mg 0 +bid 0 +she 0 +developed 0 +complete 0 +AV 3 +block 4 +, 0 +which 0 +resolved 0 +after 0 +all 0 +therapy 0 +was 0 +stopped 0 +. 0 + +DISCUSSI0N 0 +: 0 +An 0 +adverse 0 +interaction 0 +between 0 +clonidine 1 +and 0 +verapamil 1 +has 0 +not 0 +been 0 +reported 0 +previously 0 +. 0 + +We 0 +describe 0 +two 0 +such 0 +cases 0 +and 0 +discuss 0 +the 0 +various 0 +mechanisms 0 +that 0 +might 0 +cause 0 +such 0 +an 0 +interaction 0 +. 0 + +Clinicians 0 +should 0 +be 0 +acquainted 0 +with 0 +this 0 +possibly 0 +fatal 0 +interaction 0 +between 0 +two 0 +commonly 0 +used 0 +antihypertensive 0 +drugs 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +Caution 0 +is 0 +recommended 0 +in 0 +combining 0 +clonidine 1 +and 0 +verapamil 1 +therapy 0 +, 0 +even 0 +in 0 +patients 0 +who 0 +do 0 +not 0 +have 0 +sinus 0 +or 0 +AV 0 +node 0 +dysfunction 0 +. 0 + +The 0 +two 0 +drugs 0 +may 0 +act 0 +synergistically 0 +on 0 +both 0 +the 0 +AV 0 +node 0 +and 0 +the 0 +peripheral 0 +circulation 0 +. 0 + +Pharmacological 0 +studies 0 +on 0 +a 0 +new 0 +dihydrothienopyridine 1 +calcium 2 +antagonist 0 +, 0 +S 1 +- 2 +312 2 +- 2 +d 2 +. 0 + +5th 0 +communication 0 +: 0 +anticonvulsant 0 +effects 0 +in 0 +mice 0 +. 0 + +S 1 +- 2 +312 2 +, 0 +S 1 +- 2 +312 2 +- 2 +d 2 +, 0 +but 0 +not 0 +S 1 +- 2 +312 2 +- 2 +l 2 +, 0 +L 0 +- 0 +type 0 +calcium 1 +channel 0 +antagonists 0 +, 0 +showed 0 +anticonvulsant 0 +effects 0 +on 0 +the 0 +audiogenic 3 +tonic 4 +convulsions 4 +in 0 +DBA 0 +/ 0 +2 0 +mice 0 +; 0 +and 0 +their 0 +ED50 0 +values 0 +were 0 +18 0 +. 0 +4 0 +( 0 +12 0 +. 0 +8 0 +- 0 +27 0 +. 0 +1 0 +) 0 +mg 0 +/ 0 +kg 0 +, 0 +p 0 +. 0 +o 0 +. 0 +and 0 +15 0 +. 0 +0 0 +( 0 +10 0 +. 0 +2 0 +- 0 +23 0 +. 0 +7 0 +) 0 +mg 0 +/ 0 +kg 0 +, 0 +p 0 +. 0 +o 0 +. 0 +, 0 +respectively 0 +, 0 +while 0 +that 0 +of 0 +flunarizine 1 +was 0 +34 0 +. 0 +0 0 +( 0 +26 0 +. 0 +0 0 +- 0 +44 0 +. 0 +8 0 +) 0 +mg 0 +/ 0 +kg 0 +, 0 +p 0 +. 0 +o 0 +. 0 + +Although 0 +moderate 0 +anticonvulsant 0 +effects 0 +of 0 +S 1 +- 2 +312 2 +- 2 +d 2 +in 0 +higher 0 +doses 0 +were 0 +observed 0 +against 0 +the 0 +clonic 0 +convulsions 3 +induced 0 +by 0 +pentylenetetrazole 1 +( 0 +85 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +or 0 +bemegride 1 +( 0 +40 0 +mg 0 +/ 0 +kg 0 +, 0 +s 0 +. 0 +c 0 +. 0 +) 0 +, 0 +no 0 +effects 0 +were 0 +observed 0 +in 0 +convulsions 3 +induced 0 +by 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +, 0 +picrotoxin 1 +, 0 +or 0 +electroshock 0 +in 0 +Slc 0 +: 0 +ddY 0 +mice 0 +. 0 + +S 1 +- 2 +312 2 +- 2 +d 2 +may 0 +be 0 +useful 0 +in 0 +the 0 +therapy 0 +of 0 +certain 0 +types 0 +of 0 +human 0 +epilepsy 3 +. 0 + +Transmural 0 +myocardial 3 +infarction 4 +with 0 +sumatriptan 1 +. 0 + +For 0 +sumatriptan 1 +, 0 +tightness 0 +in 0 +the 0 +chest 0 +caused 0 +by 0 +an 0 +unknown 0 +mechanism 0 +has 0 +been 0 +reported 0 +in 0 +3 0 +- 0 +5 0 +% 0 +of 0 +users 0 +. 0 + +We 0 +describe 0 +a 0 +47 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +an 0 +acute 0 +myocardial 3 +infarction 4 +after 0 +administration 0 +of 0 +sumatriptan 1 +6 0 +mg 0 +subcutaneously 0 +for 0 +cluster 3 +headache 4 +. 0 + +The 0 +patient 0 +had 0 +no 0 +history 0 +of 0 +underlying 0 +ischaemic 3 +heart 4 +disease 4 +or 0 +Prinzmetal 3 +' 4 +s 4 +angina 4 +. 0 + +She 0 +recovered 0 +without 0 +complications 0 +. 0 + +Flumazenil 1 +induces 0 +seizures 3 +and 0 +death 0 +in 0 +mixed 0 +cocaine 1 +- 0 +diazepam 1 +intoxications 0 +. 0 + +STUDY 0 +HYP0THESIS 0 +: 0 +Administration 0 +of 0 +the 0 +benzodiazepine 1 +antagonist 0 +flumazenil 1 +may 0 +unmask 0 +seizures 3 +in 0 +mixed 0 +cocaine 1 +- 0 +benzodiazepine 1 +intoxication 0 +. 0 + +DESIGN 0 +: 0 +Male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +received 0 +100 0 +mg 0 +/ 0 +kg 0 +cocaine 1 +IP 0 +alone 0 +, 0 +5 0 +mg 0 +/ 0 +kg 0 +diazepam 1 +alone 0 +, 0 +or 0 +a 0 +combination 0 +of 0 +diazepam 1 +and 0 +cocaine 1 +. 0 + +Three 0 +minutes 0 +later 0 +, 0 +groups 0 +were 0 +challenged 0 +with 0 +vehicle 0 +or 0 +flumazenil 1 +5 0 +or 0 +10 0 +mg 0 +/ 0 +kg 0 +IP 0 +. 0 + +Animal 0 +behavior 0 +, 0 +seizures 3 +( 0 +time 0 +to 0 +and 0 +incidence 0 +) 0 +, 0 +death 0 +( 0 +time 0 +to 0 +and 0 +incidence 0 +) 0 +, 0 +and 0 +cortical 0 +EEG 0 +tracings 0 +were 0 +recorded 0 +. 0 + +INTERVENTI0NS 0 +: 0 +Administration 0 +of 0 +flumazenil 1 +to 0 +animals 0 +after 0 +they 0 +had 0 +received 0 +a 0 +combination 0 +dose 0 +of 0 +cocaine 1 +and 0 +diazepam 1 +. 0 + +RESULTS 0 +: 0 +In 0 +group 0 +1 0 +, 0 +animals 0 +received 0 +cocaine 1 +followed 0 +by 0 +vehicle 0 +. 0 + +This 0 +resulted 0 +in 0 +100 0 +% 0 +developing 0 +seizures 3 +and 0 +death 0 +. 0 + +Group 0 +2 0 +received 0 +diazepam 1 +alone 0 +followed 0 +by 0 +vehicle 0 +. 0 + +Animals 0 +became 0 +somnolent 0 +and 0 +none 0 +died 0 +. 0 + +Group 0 +3 0 +received 0 +diazepam 1 +followed 0 +by 0 +5 0 +mg 0 +/ 0 +kg 0 +flumazenil 1 +. 0 + +Animals 0 +became 0 +somnolent 0 +after 0 +diazepam 1 +and 0 +then 0 +active 0 +after 0 +flumazenil 1 +administration 0 +. 0 + +In 0 +group 0 +4 0 +, 0 +a 0 +combination 0 +of 0 +cocaine 1 +and 0 +diazepam 1 +was 0 +administered 0 +simultaneously 0 +. 0 + +This 0 +resulted 0 +in 0 +no 0 +overt 0 +or 0 +EEG 0 +- 0 +detectable 0 +seizures 3 +and 0 +a 0 +50 0 +% 0 +incidence 0 +of 0 +death 0 +. 0 + +Group 0 +5 0 +received 0 +a 0 +similar 0 +combination 0 +of 0 +cocaine 1 +and 0 +diazepam 1 +, 0 +followed 0 +later 0 +by 0 +5 0 +mg 0 +/ 0 +kg 0 +flumazenil 1 +. 0 + +This 0 +resulted 0 +in 0 +an 0 +increased 0 +incidence 0 +of 0 +seizures 3 +, 0 +90 0 +% 0 +( 0 +P 0 +< 0 +. 0 +01 0 +) 0 +, 0 +and 0 +death 0 +, 0 +100 0 +% 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +01 0 +) 0 +, 0 +compared 0 +with 0 +group 0 +4 0 +. 0 + +Group 0 +6 0 +received 0 +cocaine 1 +and 0 +diazepam 1 +followed 0 +by 0 +10 0 +mg 0 +/ 0 +kg 0 +flumazenil 1 +. 0 + +This 0 +also 0 +resulted 0 +in 0 +an 0 +increased 0 +incidence 0 +of 0 +seizures 3 +, 0 +90 0 +% 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +01 0 +) 0 +, 0 +and 0 +death 0 +, 0 +90 0 +% 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +05 0 +) 0 +, 0 +compared 0 +with 0 +group 0 +4 0 +. 0 + +C0NCLUSI0N 0 +: 0 +Flumazenil 1 +can 0 +unmask 0 +seizures 3 +and 0 +increase 0 +the 0 +incidence 0 +of 0 +death 0 +in 0 +a 0 +model 0 +of 0 +combined 0 +cocaine 1 +- 0 +diazepam 1 +intoxications 0 +. 0 + +Mechanisms 0 +for 0 +protective 0 +effects 0 +of 0 +free 0 +radical 0 +scavengers 0 +on 0 +gentamicin 1 +- 0 +mediated 0 +nephropathy 3 +in 0 +rats 0 +. 0 + +Studies 0 +were 0 +performed 0 +to 0 +examine 0 +the 0 +mechanisms 0 +for 0 +the 0 +protective 0 +effects 0 +of 0 +free 0 +radical 0 +scavengers 0 +on 0 +gentamicin 1 +( 0 +GM 1 +) 0 +- 0 +mediated 0 +nephropathy 3 +. 0 + +Administration 0 +of 0 +GM 1 +at 0 +40 0 +mg 0 +/ 0 +kg 0 +sc 0 +for 0 +13 0 +days 0 +to 0 +rats 0 +induced 0 +a 0 +significant 0 +reduction 0 +in 0 +renal 0 +blood 0 +flow 0 +( 0 +RBF 0 +) 0 +and 0 +inulin 0 +clearance 0 +( 0 +CIn 0 +) 0 +as 0 +well 0 +as 0 +marked 0 +tubular 3 +damage 4 +. 0 + +A 0 +significant 0 +reduction 0 +in 0 +urinary 0 +guanosine 1 +3 2 +' 2 +, 2 +5 2 +' 2 +- 2 +cyclic 2 +monophosphate 2 +( 0 +cGMP 1 +) 0 +excretion 0 +and 0 +a 0 +significant 0 +increase 0 +in 0 +renal 0 +cortical 0 +renin 0 +and 0 +endothelin 0 +- 0 +1 0 +contents 0 +were 0 +also 0 +observed 0 +in 0 +GM 1 +- 0 +mediated 0 +nephropathy 3 +. 0 + +Superoxide 1 +dismutase 0 +( 0 +S0D 0 +) 0 +or 0 +dimethylthiourea 1 +( 0 +DMTU 1 +) 0 +significantly 0 +lessened 0 +the 0 +GM 1 +- 0 +induced 0 +decrement 0 +in 0 +CIn 0 +. 0 + +The 0 +S0D 0 +- 0 +induced 0 +increase 0 +in 0 +glomerular 0 +filtration 0 +rate 0 +was 0 +associated 0 +with 0 +a 0 +marked 0 +improvement 0 +in 0 +RBF 0 +, 0 +an 0 +increase 0 +in 0 +urinary 0 +cGMP 1 +excretion 0 +, 0 +and 0 +a 0 +decrease 0 +in 0 +renal 0 +renin 0 +and 0 +endothelin 0 +- 0 +1 0 +content 0 +. 0 + +S0D 0 +did 0 +not 0 +attenuate 0 +the 0 +tubular 3 +damage 4 +. 0 + +In 0 +contrast 0 +, 0 +DMTU 1 +significantly 0 +reduced 0 +the 0 +tubular 3 +damage 4 +and 0 +lipid 0 +peroxidation 0 +, 0 +but 0 +it 0 +did 0 +not 0 +affect 0 +renal 0 +hemodynamics 0 +and 0 +vasoactive 0 +substances 0 +. 0 + +Neither 0 +S0D 0 +nor 0 +DMTU 1 +affected 0 +the 0 +renal 0 +cortical 0 +GM 1 +content 0 +in 0 +GM 1 +- 0 +treated 0 +rats 0 +. 0 + +These 0 +results 0 +suggest 0 +that 0 +1 0 +) 0 +both 0 +S0D 0 +and 0 +DMTU 1 +have 0 +protective 0 +effects 0 +on 0 +GM 1 +- 0 +mediated 0 +nephropathy 3 +, 0 +2 0 +) 0 +the 0 +mechanisms 0 +for 0 +the 0 +protective 0 +effects 0 +differ 0 +for 0 +S0D 0 +and 0 +DMTU 1 +, 0 +and 0 +3 0 +) 0 +superoxide 1 +anions 0 +play 0 +a 0 +critical 0 +role 0 +in 0 +GM 1 +- 0 +induced 0 +renal 0 +vasoconstriction 0 +. 0 + +Cephalothin 1 +- 0 +induced 0 +immune 0 +hemolytic 3 +anemia 4 +. 0 + +A 0 +patient 0 +with 0 +renal 3 +disease 4 +developed 0 +Coombs 0 +- 0 +positive 0 +hemolytic 3 +anemia 4 +while 0 +receiving 0 +cephalothin 1 +therapy 0 +. 0 + +An 0 +anti 0 +- 0 +cephalothin 1 +IgG 0 +antibody 0 +was 0 +detected 0 +in 0 +the 0 +patient 0 +' 0 +s 0 +serum 0 +and 0 +in 0 +the 0 +eluates 0 +from 0 +her 0 +erythrocytes 0 +. 0 + +In 0 +addition 0 +, 0 +nonimmunologic 0 +binding 0 +of 0 +normal 0 +and 0 +patient 0 +' 0 +s 0 +serum 0 +proteins 0 +to 0 +her 0 +own 0 +and 0 +cephalothin 1 +- 0 +coated 0 +normal 0 +red 0 +cells 0 +was 0 +demonstrated 0 +. 0 + +Skin 0 +tests 0 +and 0 +in 0 +vitro 0 +lymphocyte 0 +stimulation 0 +revealed 0 +that 0 +the 0 +patient 0 +was 0 +sensitized 0 +to 0 +cephalothin 1 +and 0 +also 0 +to 0 +ampicillin 1 +. 0 + +Careful 0 +investigation 0 +of 0 +drug 0 +- 0 +induced 0 +hemolytic 3 +anemias 4 +reveals 0 +the 0 +complexity 0 +of 0 +the 0 +immune 0 +mechanisms 0 +involved 0 +. 0 + +Assessment 0 +of 0 +cardiomyocyte 0 +DNA 0 +synthesis 0 +during 0 +hypertrophy 3 +in 0 +adult 0 +mice 0 +. 0 + +The 0 +ability 0 +of 0 +cardiomyocytes 0 +to 0 +synthesize 0 +DNA 0 +in 0 +response 0 +to 0 +experimentally 0 +induced 0 +cardiac 3 +hypertrophy 4 +was 0 +assessed 0 +in 0 +adult 0 +mice 0 +. 0 + +Isoproterenol 1 +delivered 0 +by 0 +osmotic 0 +minipump 0 +implantation 0 +in 0 +adult 0 +C3Heb 0 +/ 0 +FeJ 0 +mice 0 +resulted 0 +in 0 +a 0 +46 0 +% 0 +increase 0 +in 0 +heart 0 +weight 0 +and 0 +a 0 +19 0 +. 0 +3 0 +% 0 +increase 0 +in 0 +cardiomyocyte 0 +area 0 +. 0 + +No 0 +DNA 0 +synthesis 0 +, 0 +as 0 +assessed 0 +by 0 +autoradiographic 0 +analysis 0 +of 0 +isolated 0 +cardiomyocytes 0 +, 0 +was 0 +observed 0 +in 0 +control 0 +or 0 +hypertrophic 3 +hearts 4 +. 0 + +A 0 +survey 0 +of 0 +15 0 +independent 0 +inbred 0 +strains 0 +of 0 +mice 0 +revealed 0 +that 0 +ventricular 0 +cardiomyocyte 0 +nuclear 0 +number 0 +ranged 0 +from 0 +3 0 +to 0 +13 0 +% 0 +mononucleate 0 +, 0 +suggesting 0 +that 0 +cardiomyocyte 0 +terminal 0 +differentiation 0 +is 0 +influenced 0 +directly 0 +or 0 +indirectly 0 +by 0 +genetic 0 +background 0 +. 0 + +To 0 +determine 0 +whether 0 +the 0 +capacity 0 +for 0 +reactive 0 +DNA 0 +synthesis 0 +was 0 +also 0 +subject 0 +to 0 +genetic 0 +regulation 0 +, 0 +cardiac 3 +hypertrophy 4 +was 0 +induced 0 +in 0 +the 0 +strains 0 +of 0 +mice 0 +comprising 0 +the 0 +extremes 0 +of 0 +the 0 +nuclear 0 +number 0 +survey 0 +. 0 + +These 0 +data 0 +indicate 0 +that 0 +adult 0 +mouse 0 +atrial 0 +and 0 +ventricular 0 +cardiomyocytes 0 +do 0 +not 0 +synthesize 0 +DNA 0 +in 0 +response 0 +to 0 +isoproterenol 1 +- 0 +induced 0 +cardiac 3 +hypertrophy 4 +. 0 + +Central 0 +cardiovascular 0 +effects 0 +of 0 +AVP 1 +and 0 +ANP 0 +in 0 +normotensive 0 +and 0 +spontaneously 0 +hypertensive 3 +rats 0 +. 0 + +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +compare 0 +influence 0 +of 0 +central 0 +arginine 1 +vasopressin 2 +( 0 +AVP 1 +) 0 +and 0 +of 0 +atrial 0 +natriuretic 0 +peptide 0 +( 0 +ANP 0 +) 0 +on 0 +control 0 +of 0 +arterial 0 +blood 0 +pressure 0 +( 0 +MAP 0 +) 0 +and 0 +heart 0 +rate 0 +( 0 +HR 0 +) 0 +in 0 +normotensive 0 +( 0 +WKY 0 +) 0 +and 0 +spontaneously 0 +hypertensive 3 +( 0 +SHR 0 +) 0 +rats 0 +. 0 + +Three 0 +series 0 +of 0 +experiments 0 +were 0 +performed 0 +on 0 +30 0 +WKY 0 +and 0 +30 0 +SHR 0 +, 0 +chronically 0 +instrumented 0 +with 0 +guide 0 +tubes 0 +in 0 +the 0 +lateral 0 +ventricle 0 +( 0 +LV 0 +) 0 +and 0 +arterial 0 +and 0 +venous 0 +catheters 0 +. 0 + +MAP 0 +and 0 +HR 0 +were 0 +monitored 0 +before 0 +and 0 +after 0 +i 0 +. 0 +v 0 +. 0 +injections 0 +of 0 +either 0 +vehicle 0 +or 0 +1 0 +, 0 +10 0 +and 0 +50 0 +ng 0 +of 0 +AVP 1 +and 0 +25 0 +, 0 +125 0 +and 0 +500 0 +ng 0 +of 0 +ANP 0 +. 0 + +Sensitivity 0 +of 0 +cardiac 0 +component 0 +of 0 +baroreflex 0 +( 0 +CCB 0 +) 0 +, 0 +expressed 0 +as 0 +a 0 +slope 0 +of 0 +the 0 +regression 0 +line 0 +was 0 +determined 0 +from 0 +relationships 0 +between 0 +systolic 0 +arterial 0 +pressure 0 +( 0 +SAP 0 +) 0 +and 0 +HR 0 +period 0 +( 0 +HRp 0 +) 0 +during 0 +phenylephrine 1 +( 0 +Phe 1 +) 0 +- 0 +induced 0 +hypertension 3 +and 0 +sodium 1 +nitroprusside 2 +( 0 +SN 1 +) 0 +- 0 +induced 0 +hypotension 3 +. 0 + +CCB 0 +was 0 +measured 0 +before 0 +and 0 +after 0 +administration 0 +of 0 +either 0 +vehicle 0 +, 0 +AVP 1 +, 0 +ANP 0 +, 0 +or 0 +both 0 +peptides 0 +together 0 +. 0 + +Increases 0 +of 0 +MAP 0 +occurred 0 +after 0 +LV 0 +administration 0 +of 0 +1 0 +, 0 +10 0 +and 0 +50 0 +ng 0 +of 0 +AVP 1 +in 0 +WKY 0 +and 0 +of 0 +10 0 +and 0 +50 0 +ng 0 +in 0 +SHR 0 +. 0 + +ANP 0 +did 0 +not 0 +cause 0 +significant 0 +changes 0 +in 0 +MAP 0 +in 0 +both 0 +strains 0 +as 0 +compared 0 +to 0 +vehicle 0 +, 0 +but 0 +it 0 +abolished 0 +AVP 1 +- 0 +induced 0 +MAP 0 +increase 0 +in 0 +WKY 0 +and 0 +SHR 0 +. 0 + +CCB 0 +was 0 +reduced 0 +in 0 +WKY 0 +and 0 +SHR 0 +after 0 +LV 0 +administration 0 +of 0 +AVP 1 +during 0 +SN 1 +- 0 +induced 0 +hypotension 3 +. 0 + +In 0 +SHR 0 +but 0 +not 0 +in 0 +WKY 0 +administration 0 +of 0 +ANP 0 +, 0 +AVP 1 +and 0 +ANP 0 ++ 0 +AVP 1 +decreased 0 +CCB 0 +during 0 +Phe 1 +- 0 +induced 0 +MAP 0 +elevation 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +centrally 0 +applied 0 +AVP 1 +and 0 +ANP 0 +exert 0 +differential 0 +effects 0 +on 0 +blood 0 +pressure 0 +and 0 +baroreflex 0 +control 0 +of 0 +heart 0 +rate 0 +in 0 +WKY 0 +and 0 +SHR 0 +and 0 +suggest 0 +interaction 0 +of 0 +these 0 +two 0 +peptides 0 +in 0 +blood 0 +pressure 0 +regulation 0 +at 0 +the 0 +level 0 +of 0 +central 0 +nervous 0 +system 0 +. 0 + +Cutaneous 0 +exposure 0 +to 0 +warfarin 1 +- 0 +like 0 +anticoagulant 0 +causing 0 +an 0 +intracerebral 3 +hemorrhage 4 +: 0 +a 0 +case 0 +report 0 +. 0 + +A 0 +case 0 +of 0 +intercerebral 0 +hematoma 3 +due 0 +to 0 +warfarin 1 +- 0 +induced 0 +coagulopathy 3 +is 0 +presented 0 +. 0 + +The 0 +39 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +had 0 +spread 0 +a 0 +warfarin 1 +- 0 +type 0 +rat 0 +poison 0 +around 0 +her 0 +house 0 +weekly 0 +using 0 +her 0 +bare 0 +hands 0 +, 0 +with 0 +no 0 +washing 0 +post 0 +application 0 +. 0 + +Percutaneous 0 +absorption 0 +of 0 +warfarin 1 +causing 0 +coagulopathy 3 +, 0 +reported 0 +three 0 +times 0 +in 0 +the 0 +past 0 +, 0 +is 0 +a 0 +significant 0 +risk 0 +if 0 +protective 0 +measures 0 +, 0 +such 0 +as 0 +gloves 0 +, 0 +are 0 +not 0 +used 0 +. 0 + +An 0 +adverse 0 +drug 0 +interaction 0 +with 0 +piroxicam 1 +, 0 +which 0 +she 0 +took 0 +occasionally 0 +, 0 +may 0 +have 0 +exacerbated 0 +the 0 +coagulopathy 3 +. 0 + +Pediatric 0 +heart 0 +transplantation 0 +without 0 +chronic 0 +maintenance 0 +steroids 1 +. 0 + +From 0 +1986 0 +to 0 +February 0 +1993 0 +, 0 +40 0 +children 0 +aged 0 +2 0 +months 0 +to 0 +18 0 +years 0 +( 0 +average 0 +age 0 +10 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +8 0 +years 0 +) 0 +underwent 0 +heart 0 +transplantation 0 +. 0 + +Indications 0 +for 0 +transplantation 0 +were 0 +idiopathic 3 +cardiomyopathy 4 +( 0 +52 0 +% 0 +) 0 +, 0 +congenital 3 +heart 4 +disease 4 +( 0 +35 0 +% 0 +) 0 +with 0 +and 0 +without 0 +prior 0 +repair 0 +( 0 +71 0 +% 0 +and 0 +29 0 +% 0 +, 0 +respectively 0 +) 0 +, 0 +hypertrophic 3 +cardiomyopathy 4 +( 0 +5 0 +% 0 +) 0 +, 0 +valvular 3 +heart 4 +disease 4 +( 0 +3 0 +% 0 +) 0 +, 0 +and 0 +doxorubicin 1 +cardiomyopathy 3 +( 0 +5 0 +% 0 +) 0 +. 0 + +Patients 0 +were 0 +managed 0 +with 0 +cyclosporine 1 +and 0 +azathioprine 1 +. 0 + +No 0 +prophylaxis 0 +with 0 +antilymphocyte 0 +globulin 0 +was 0 +used 0 +. 0 + +Steroids 1 +were 0 +given 0 +to 0 +39 0 +% 0 +of 0 +patients 0 +for 0 +refractory 0 +rejection 0 +, 0 +but 0 +weaning 0 +was 0 +always 0 +attempted 0 +and 0 +generally 0 +successful 0 +( 0 +64 0 +% 0 +) 0 +. 0 + +Five 0 +patients 0 +( 0 +14 0 +% 0 +) 0 +received 0 +maintenance 0 +steroids 1 +. 0 + +Four 0 +patients 0 +died 0 +in 0 +the 0 +perioperative 0 +period 0 +and 0 +one 0 +died 0 +4 0 +months 0 +later 0 +. 0 + +There 0 +have 0 +been 0 +no 0 +deaths 0 +related 0 +to 0 +rejection 0 +or 0 +infection 3 +. 0 + +Average 0 +follow 0 +- 0 +up 0 +was 0 +36 0 ++ 0 +/ 0 +- 0 +19 0 +months 0 +( 0 +range 0 +1 0 +to 0 +65 0 +months 0 +) 0 +. 0 + +Cumulative 0 +survival 0 +is 0 +88 0 +% 0 +at 0 +5 0 +years 0 +. 0 + +In 0 +patients 0 +less 0 +than 0 +7 0 +years 0 +of 0 +age 0 +, 0 +rejection 0 +was 0 +monitored 0 +noninvasively 0 +. 0 + +In 0 +the 0 +first 0 +postoperative 0 +month 0 +, 0 +89 0 +% 0 +of 0 +patients 0 +were 0 +treated 0 +for 0 +rejection 0 +. 0 + +Freedom 0 +from 0 +serious 0 +infections 3 +was 0 +83 0 +% 0 +at 0 +1 0 +month 0 +and 0 +65 0 +% 0 +at 0 +1 0 +year 0 +. 0 + +Cytomegalovirus 3 +infections 4 +were 0 +treated 0 +successfully 0 +with 0 +ganciclovir 1 +in 0 +11 0 +patients 0 +. 0 + +No 0 +impairment 0 +of 0 +growth 0 +was 0 +observed 0 +in 0 +children 0 +who 0 +underwent 0 +transplantation 0 +compared 0 +with 0 +a 0 +control 0 +population 0 +. 0 + +Twenty 0 +- 0 +one 0 +patients 0 +( 0 +60 0 +% 0 +) 0 +have 0 +undergone 0 +annual 0 +catheterizations 0 +and 0 +no 0 +sign 0 +of 0 +graft 0 +atherosclerosis 3 +has 0 +been 0 +observed 0 +. 0 + +Seizures 3 +occurred 0 +in 0 +five 0 +patients 0 +( 0 +14 0 +% 0 +) 0 +and 0 +hypertension 3 +was 0 +treated 0 +in 0 +10 0 +patients 0 +( 0 +28 0 +% 0 +) 0 +. 0 + +No 0 +patient 0 +was 0 +disabled 0 +and 0 +no 0 +lymphoproliferative 3 +disorder 4 +was 0 +observed 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 + +Delirium 3 +during 0 +fluoxetine 1 +treatment 0 +. 0 + +A 0 +case 0 +report 0 +. 0 + +The 0 +correlation 0 +between 0 +high 0 +serum 0 +tricyclic 0 +antidepressant 0 +concentrations 0 +and 0 +central 0 +nervous 0 +system 0 +side 0 +effects 0 +has 0 +been 0 +well 0 +established 0 +. 0 + +0nly 0 +a 0 +few 0 +reports 0 +exist 0 +, 0 +however 0 +, 0 +on 0 +the 0 +relationship 0 +between 0 +the 0 +serum 0 +concentrations 0 +of 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitors 0 +( 0 +SSRIs 0 +) 0 +and 0 +their 0 +toxic 0 +effects 0 +. 0 + +In 0 +some 0 +cases 0 +, 0 +a 0 +high 0 +serum 0 +concentration 0 +of 0 +citalopram 1 +( 0 +> 0 +600 0 +nmol 0 +/ 0 +L 0 +) 0 +in 0 +elderly 0 +patients 0 +has 0 +been 0 +associated 0 +with 0 +increased 0 +somnolence 3 +and 0 +movement 3 +difficulties 4 +. 0 + +Widespread 0 +cognitive 3 +disorders 4 +, 0 +such 0 +as 0 +delirium 3 +, 0 +have 0 +not 0 +been 0 +previously 0 +linked 0 +with 0 +high 0 +blood 0 +levels 0 +of 0 +SSRIs 0 +. 0 + +In 0 +this 0 +report 0 +, 0 +we 0 +describe 0 +a 0 +patient 0 +with 0 +acute 0 +hyperkinetic 3 +delirium 3 +connected 0 +with 0 +a 0 +high 0 +serum 0 +total 0 +fluoxetine 1 +( 0 +fluoxetine 1 +plus 0 +desmethylfluoxetine 1 +) 0 +concentration 0 +. 0 + +Pulmonary 3 +edema 4 +and 0 +shock 3 +after 0 +high 0 +- 0 +dose 0 +aracytine 1 +- 2 +C 2 +for 0 +lymphoma 3 +; 0 +possible 0 +role 0 +of 0 +TNF 0 +- 0 +alpha 0 +and 0 +PAF 0 +. 0 + +Four 0 +out 0 +of 0 +23 0 +consecutive 0 +patients 0 +treated 0 +with 0 +high 0 +- 0 +dose 0 +Ara 1 +- 2 +C 2 +for 0 +lymphomas 3 +in 0 +our 0 +institution 0 +developed 0 +a 0 +strikingly 0 +similar 0 +syndrome 0 +during 0 +the 0 +perfusion 0 +. 0 + +It 0 +was 0 +characterized 0 +by 0 +the 0 +onset 0 +of 0 +fever 3 +, 0 +diarrhea 3 +, 0 +shock 3 +, 0 +pulmonary 3 +edema 4 +, 0 +acute 3 +renal 4 +failure 4 +, 0 +metabolic 3 +acidosis 4 +, 0 +weight 3 +gain 4 +and 0 +leukocytosis 3 +. 0 + +Thorough 0 +bacteriological 0 +screening 0 +failed 0 +to 0 +provide 0 +evidence 0 +of 0 +infection 3 +. 0 + +Sequential 0 +biological 0 +assays 0 +of 0 +IL 0 +- 0 +1 0 +, 0 +IL 0 +- 0 +2 0 +, 0 +TNF 0 +and 0 +PAF 0 +were 0 +performed 0 +during 0 +Ara 1 +- 2 +C 2 +infusion 0 +to 0 +ten 0 +patients 0 +, 0 +including 0 +the 0 +four 0 +who 0 +developed 0 +the 0 +syndrome 0 +. 0 + +TNF 0 +and 0 +PAF 0 +activity 0 +was 0 +found 0 +in 0 +the 0 +serum 0 +of 0 +respectively 0 +two 0 +and 0 +four 0 +of 0 +the 0 +cases 0 +, 0 +but 0 +not 0 +in 0 +the 0 +six 0 +controls 0 +. 0 + +As 0 +TNF 0 +and 0 +PAF 0 +are 0 +thought 0 +to 0 +be 0 +involved 0 +in 0 +the 0 +development 0 +of 0 +septic 0 +shock 3 +and 0 +adult 3 +respiratory 4 +distress 4 +syndrome 4 +, 0 +we 0 +hypothesize 0 +that 0 +high 0 +- 0 +dose 0 +Ara 1 +- 2 +C 2 +may 0 +be 0 +associated 0 +with 0 +cytokine 0 +release 0 +. 0 + +Protective 0 +effect 0 +of 0 +clentiazem 1 +against 0 +epinephrine 1 +- 0 +induced 0 +cardiac 3 +injury 4 +in 0 +rats 0 +. 0 + +We 0 +investigated 0 +the 0 +effects 0 +of 0 +clentiazem 1 +, 0 +a 0 +1 1 +, 2 +5 2 +- 2 +benzothiazepine 2 +calcium 1 +antagonist 0 +, 0 +on 0 +epinephrine 1 +- 0 +induced 0 +cardiomyopathy 3 +in 0 +rats 0 +. 0 + +With 0 +2 0 +- 0 +week 0 +chronic 0 +epinephrine 1 +infusion 0 +, 0 +16 0 +of 0 +30 0 +rats 0 +died 0 +within 0 +4 0 +days 0 +, 0 +and 0 +severe 0 +ischemic 3 +lesions 4 +and 0 +fibrosis 3 +of 0 +the 0 +left 0 +ventricles 0 +were 0 +observed 0 +. 0 + +In 0 +epinephrine 1 +- 0 +treated 0 +rats 0 +, 0 +left 0 +atrial 0 +and 0 +left 0 +ventricular 0 +papillary 0 +muscle 0 +contractile 0 +responses 0 +to 0 +isoproterenol 1 +were 0 +reduced 0 +, 0 +but 0 +responses 0 +to 0 +calcium 1 +were 0 +normal 0 +or 0 +enhanced 0 +compared 0 +to 0 +controls 0 +. 0 + +Left 0 +ventricular 0 +alpha 0 +and 0 +beta 0 +adrenoceptor 0 +densities 0 +were 0 +also 0 +reduced 0 +compared 0 +to 0 +controls 0 +. 0 + +Treatment 0 +with 0 +clentiazem 1 +prevented 0 +epinephrine 1 +- 0 +induced 0 +death 0 +( 0 +P 0 +< 0 +. 0 +05 0 +) 0 +, 0 +and 0 +attenuated 0 +the 0 +ventricular 0 +ischemic 3 +lesions 4 +and 0 +fibrosis 3 +, 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 + +Left 0 +atrial 0 +and 0 +left 0 +ventricular 0 +papillary 0 +muscle 0 +contractile 0 +responses 0 +to 0 +isoproterenol 1 +were 0 +reduced 0 +compared 0 +to 0 +controls 0 +in 0 +groups 0 +treated 0 +with 0 +clentiazem 1 +alone 0 +, 0 +but 0 +combined 0 +with 0 +epinephrine 1 +, 0 +clentiazem 1 +restored 0 +left 0 +atrial 0 +responses 0 +and 0 +enhanced 0 +left 0 +ventricular 0 +papillary 0 +responses 0 +to 0 +isoproterenol 1 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +clentiazem 1 +did 0 +not 0 +prevent 0 +epinephrine 1 +- 0 +induced 0 +down 0 +- 0 +regulation 0 +of 0 +alpha 0 +and 0 +beta 0 +adrenoceptors 0 +. 0 + +Interestingly 0 +, 0 +clentiazem 1 +, 0 +infused 0 +alone 0 +, 0 +resulted 0 +in 0 +decreased 0 +adrenergic 0 +receptor 0 +densities 0 +in 0 +the 0 +left 0 +ventricle 0 +. 0 + +Clentiazem 1 +also 0 +did 0 +not 0 +prevent 0 +the 0 +enhanced 0 +responses 0 +to 0 +calcium 1 +seen 0 +in 0 +the 0 +epinephrine 1 +- 0 +treated 0 +animals 0 +, 0 +although 0 +the 0 +high 0 +dose 0 +of 0 +clentiazem 1 +partially 0 +attenuated 0 +the 0 +maximal 0 +response 0 +to 0 +calcium 1 +compared 0 +to 0 +epinephrine 1 +- 0 +treated 0 +animals 0 +. 0 + +In 0 +conclusion 0 +, 0 +clentiazem 1 +attenuated 0 +epinephrine 1 +- 0 +induced 0 +cardiac 3 +injury 4 +, 0 +possibly 0 +through 0 +its 0 +effect 0 +on 0 +the 0 +adrenergic 0 +pathway 0 +. 0 + +Kaliuretic 0 +effect 0 +of 0 +L 1 +- 2 +dopa 2 +treatment 0 +in 0 +parkinsonian 3 +patients 0 +. 0 + +Hypokalemia 3 +, 0 +sometimes 0 +severe 0 +, 0 +was 0 +observed 0 +in 0 +some 0 +L 1 +- 2 +dopa 2 +- 0 +treated 0 +parkinsonian 3 +patients 0 +. 0 + +The 0 +influence 0 +of 0 +L 1 +- 2 +dopa 2 +on 0 +the 0 +renal 0 +excretion 0 +of 0 +potassium 1 +was 0 +studied 0 +in 0 +3 0 +patients 0 +with 0 +hypokalemia 3 +and 0 +in 0 +5 0 +normokalemic 0 +patients 0 +by 0 +determination 0 +of 0 +renal 0 +plasma 0 +flow 0 +, 0 +glomerular 0 +filtration 0 +rate 0 +, 0 +plasma 0 +concentration 0 +of 0 +potassium 1 +and 0 +sodium 1 +as 0 +well 0 +as 0 +urinary 0 +excretion 0 +of 0 +potassium 1 +, 0 +sodium 1 +and 0 +aldosterone 1 +. 0 + +L 1 +- 2 +Dopa 2 +intake 0 +was 0 +found 0 +to 0 +cause 0 +an 0 +increased 0 +excretion 0 +of 0 +potassium 1 +, 0 +and 0 +sometimes 0 +also 0 +of 0 +sodium 1 +, 0 +in 0 +the 0 +hypokalemic 0 +but 0 +not 0 +in 0 +the 0 +normokalemic 0 +patients 0 +. 0 + +This 0 +effect 0 +on 0 +the 0 +renal 0 +function 0 +could 0 +be 0 +prohibited 0 +by 0 +the 0 +administration 0 +of 0 +a 0 +peripheral 0 +dopa 0 +decarbodylase 0 +inhibitor 0 +. 0 + +It 0 +is 0 +not 0 +known 0 +why 0 +this 0 +effect 0 +occurred 0 +in 0 +some 0 +individuals 0 +but 0 +not 0 +in 0 +others 0 +, 0 +but 0 +our 0 +results 0 +indicate 0 +a 0 +correlation 0 +between 0 +aldosterone 1 +production 0 +and 0 +this 0 +renal 0 +effect 0 +of 0 +L 1 +- 2 +dopa 2 +. 0 + +Cocaine 1 +induced 0 +myocardial 3 +ischemia 4 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +myocardial 3 +ischemia 4 +induced 0 +by 0 +cocaine 1 +. 0 + +The 0 +ischemia 3 +probably 0 +induced 0 +by 0 +coronary 3 +artery 4 +spasm 4 +was 0 +reversed 0 +by 0 +nitroglycerin 1 +and 0 +calcium 1 +blocking 0 +agents 0 +. 0 + +Doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +monitored 0 +by 0 +ECG 0 +in 0 +freely 0 +moving 0 +mice 0 +. 0 + +A 0 +new 0 +model 0 +to 0 +test 0 +potential 0 +protectors 0 +. 0 + +In 0 +laboratory 0 +animals 0 +, 0 +histology 0 +is 0 +most 0 +commonly 0 +used 0 +to 0 +study 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 + +However 0 +, 0 +for 0 +monitoring 0 +during 0 +treatment 0 +, 0 +large 0 +numbers 0 +of 0 +animals 0 +are 0 +needed 0 +. 0 + +Recently 0 +we 0 +developed 0 +a 0 +new 0 +method 0 +to 0 +measure 0 +ECG 0 +values 0 +in 0 +freely 0 +moving 0 +mice 0 +by 0 +telemetry 0 +. 0 + +With 0 +this 0 +model 0 +we 0 +investigated 0 +the 0 +effect 0 +of 0 +chronic 0 +doxorubicin 1 +administration 0 +on 0 +the 0 +ECG 0 +of 0 +freely 0 +moving 0 +BALB 0 +/ 0 +c 0 +mice 0 +and 0 +the 0 +efficacy 0 +of 0 +ICRF 1 +- 2 +187 2 +as 0 +a 0 +protective 0 +agent 0 +. 0 + +The 0 +ST 0 +interval 0 +significantly 0 +widened 0 +from 0 +15 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +to 0 +56 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +11 0 +. 0 +8 0 +ms 0 +in 0 +week 0 +10 0 +( 0 +7 0 +weekly 0 +doses 0 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +doxorubicin 1 +given 0 +i 0 +. 0 +v 0 +. 0 +plus 0 +3 0 +weeks 0 +of 0 +observation 0 +) 0 +. 0 + +The 0 +ECG 0 +of 0 +the 0 +control 0 +animals 0 +did 0 +not 0 +change 0 +during 0 +the 0 +entire 0 +study 0 +. 0 + +After 0 +sacrifice 0 +the 0 +hearts 0 +of 0 +doxorubicin 1 +- 0 +treated 0 +animals 0 +were 0 +enlarged 0 +and 0 +the 0 +atria 0 +were 0 +hypertrophic 3 +. 0 + +As 0 +this 0 +schedule 0 +exerted 0 +more 0 +toxicity 3 +than 0 +needed 0 +to 0 +investigate 0 +protective 0 +agents 0 +, 0 +the 0 +protection 0 +of 0 +ICRF 1 +- 2 +187 2 +was 0 +determined 0 +using 0 +a 0 +dose 0 +schedule 0 +with 0 +lower 0 +general 0 +toxicity 3 +( 0 +6 0 +weekly 0 +doses 0 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +doxorubicin 1 +given 0 +i 0 +. 0 +v 0 +. 0 +plus 0 +2 0 +weeks 0 +of 0 +observation 0 +) 0 +. 0 + +0n 0 +this 0 +schedule 0 +, 0 +the 0 +animals 0 +' 0 +hearts 0 +appeared 0 +normal 0 +after 0 +sacrifice 0 +and 0 +ICRF 1 +- 2 +187 2 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +given 0 +i 0 +. 0 +p 0 +. 0 +1 0 +h 0 +before 0 +doxorubicin 1 +) 0 +provided 0 +almost 0 +full 0 +protection 0 +. 0 + +These 0 +data 0 +were 0 +confirmed 0 +by 0 +histology 0 +. 0 + +The 0 +results 0 +indicate 0 +that 0 +this 0 +new 0 +model 0 +is 0 +very 0 +sensitive 0 +and 0 +enables 0 +monitoring 0 +of 0 +the 0 +development 0 +of 0 +cardiotoxicity 3 +with 0 +time 0 +. 0 + +These 0 +findings 0 +result 0 +in 0 +a 0 +model 0 +that 0 +allows 0 +the 0 +testing 0 +of 0 +protectors 0 +against 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +as 0 +demonstrated 0 +by 0 +the 0 +protection 0 +provided 0 +by 0 +ICRF 1 +- 2 +187 2 +. 0 + +Epinephrine 1 +dysrhythmogenicity 0 +is 0 +not 0 +enhanced 0 +by 0 +subtoxic 0 +bupivacaine 1 +in 0 +dogs 0 +. 0 + +Since 0 +bupivacaine 1 +and 0 +epinephrine 1 +may 0 +both 0 +precipitate 0 +dysrhythmias 3 +, 0 +circulating 0 +bupivacaine 1 +during 0 +regional 0 +anesthesia 0 +could 0 +potentiate 0 +dysrhythmogenic 0 +effects 0 +of 0 +epinephrine 1 +. 0 + +We 0 +therefore 0 +examined 0 +whether 0 +bupivacaine 1 +alters 0 +the 0 +dysrhythmogenicity 0 +of 0 +subsequent 0 +administration 0 +of 0 +epinephrine 1 +in 0 +conscious 0 +, 0 +healthy 0 +dogs 0 +and 0 +in 0 +anesthetized 0 +dogs 0 +with 0 +myocardial 3 +infarction 4 +. 0 + +Forty 0 +- 0 +one 0 +conscious 0 +dogs 0 +received 0 +10 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +epinephrine 1 +. 0 + +Seventeen 0 +animals 0 +responded 0 +with 0 +ventricular 3 +tachycardia 4 +( 0 +VT 3 +) 0 +within 0 +3 0 +min 0 +. 0 + +After 0 +3 0 +h 0 +, 0 +these 0 +responders 0 +randomly 0 +received 0 +1 0 +or 0 +2 0 +mg 0 +/ 0 +kg 0 +bupivacaine 1 +or 0 +saline 0 +over 0 +5 0 +min 0 +, 0 +followed 0 +by 0 +10 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +epinephrine 1 +. 0 + +In 0 +the 0 +bupivacaine 1 +groups 0 +, 0 +epinephrine 1 +caused 0 +fewer 0 +prodysrhythmic 0 +effects 0 +than 0 +without 0 +bupivacaine 1 +. 0 + +VT 3 +appeared 0 +in 0 +fewer 0 +dogs 0 +and 0 +at 0 +a 0 +later 0 +time 0 +, 0 +and 0 +there 0 +were 0 +more 0 +sinoatrial 0 +beats 0 +and 0 +less 0 +ectopies 0 +. 0 + +Epinephrine 1 +shortened 0 +QT 0 +less 0 +after 0 +bupivacaine 1 +than 0 +in 0 +control 0 +animals 0 +. 0 + +0ne 0 +day 0 +after 0 +experimental 0 +myocardial 3 +infarction 4 +, 0 +six 0 +additional 0 +halothane 1 +- 0 +anesthetized 0 +dogs 0 +received 0 +4 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +epinephrine 1 +until 0 +VT 3 +appeared 0 +. 0 + +After 0 +45 0 +min 0 +, 0 +1 0 +mg 0 +/ 0 +kg 0 +bupivacaine 1 +was 0 +injected 0 +over 0 +5 0 +min 0 +, 0 +again 0 +followed 0 +by 0 +4 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +epinephrine 1 +. 0 + +In 0 +these 0 +dogs 0 +, 0 +the 0 +prodysrhythmic 0 +response 0 +to 0 +epinephrine 1 +was 0 +also 0 +mitigated 0 +by 0 +preceding 0 +bupivacaine 1 +. 0 + +Bupivacaine 1 +antagonizes 0 +epinephrine 1 +dysrhythmogenicity 0 +in 0 +conscious 0 +dogs 0 +susceptible 0 +to 0 +VT 3 +and 0 +in 0 +anesthetized 0 +dogs 0 +with 0 +spontaneous 0 +postinfarct 0 +dysrhythmias 3 +. 0 + +There 0 +is 0 +no 0 +evidence 0 +that 0 +systemic 0 +subtoxic 0 +bupivacaine 1 +administration 0 +enhances 0 +the 0 +dysrhythmogenicity 0 +of 0 +subsequent 0 +epinephrine 1 +. 0 + +Milk 3 +- 4 +alkali 4 +syndrome 4 +induced 0 +by 0 +1 1 +, 2 +25 2 +( 2 +0H 2 +) 2 +2D 2 +in 0 +a 0 +patient 0 +with 0 +hypoparathyroidism 3 +. 0 + +Milk 3 +- 4 +alkali 4 +syndrome 4 +was 0 +first 0 +described 0 +70 0 +years 0 +ago 0 +in 0 +the 0 +context 0 +of 0 +the 0 +treatment 0 +of 0 +peptic 3 +ulcer 4 +disease 4 +with 0 +large 0 +amounts 0 +of 0 +calcium 1 +and 0 +alkali 1 +. 0 + +Although 0 +with 0 +current 0 +ulcer 3 +therapy 0 +( 0 +H 0 +- 0 +2 0 +blockers 0 +, 0 +omeprazole 1 +, 0 +and 0 +sucralfate 1 +) 0 +, 0 +the 0 +frequency 0 +of 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +has 0 +decreased 0 +significantly 0 +, 0 +the 0 +classic 0 +triad 0 +of 0 +hypercalcemia 3 +, 0 +alkalosis 3 +, 0 +and 0 +renal 3 +impairment 4 +remains 0 +the 0 +hallmark 0 +of 0 +the 0 +syndrome 0 +. 0 + +Milk 3 +- 4 +alkali 4 +syndrome 4 +can 0 +present 0 +serious 0 +and 0 +occasionally 0 +life 0 +- 0 +threatening 0 +illness 0 +unless 0 +diagnosed 0 +and 0 +treated 0 +appropriately 0 +. 0 + +This 0 +article 0 +presents 0 +a 0 +patient 0 +with 0 +hypoparathyroidism 3 +who 0 +was 0 +treated 0 +with 0 +calcium 1 +carbonate 2 +and 0 +calcitriol 1 +resulting 0 +in 0 +two 0 +admissions 0 +to 0 +the 0 +hospital 0 +for 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +. 0 + +The 0 +patient 0 +was 0 +successfully 0 +treated 0 +with 0 +intravenous 0 +pamidronate 1 +on 0 +his 0 +first 0 +admission 0 +and 0 +with 0 +hydrocortisone 1 +on 0 +the 0 +second 0 +. 0 + +This 0 +illustrates 0 +intravenous 0 +pamidronate 1 +as 0 +a 0 +valuable 0 +therapeutic 0 +tool 0 +when 0 +milk 3 +- 4 +alkali 4 +syndrome 4 +presents 0 +as 0 +hypercalcemic 3 +emergency 4 +. 0 + +Famotidine 1 +- 0 +associated 0 +delirium 3 +. 0 + +A 0 +series 0 +of 0 +six 0 +cases 0 +. 0 + +Famotidine 1 +is 0 +a 0 +histamine 0 +H2 0 +- 0 +receptor 0 +antagonist 0 +used 0 +in 0 +inpatient 0 +settings 0 +for 0 +prevention 0 +of 0 +stress 0 +ulcers 3 +and 0 +is 0 +showing 0 +increasing 0 +popularity 0 +because 0 +of 0 +its 0 +low 0 +cost 0 +. 0 + +Although 0 +all 0 +of 0 +the 0 +currently 0 +available 0 +H2 0 +- 0 +receptor 0 +antagonists 0 +have 0 +shown 0 +the 0 +propensity 0 +to 0 +cause 0 +delirium 3 +, 0 +only 0 +two 0 +previously 0 +reported 0 +cases 0 +have 0 +been 0 +associated 0 +with 0 +famotidine 1 +. 0 + +The 0 +authors 0 +report 0 +on 0 +six 0 +cases 0 +of 0 +famotidine 1 +- 0 +associated 0 +delirium 3 +in 0 +hospitalized 0 +patients 0 +who 0 +cleared 0 +completely 0 +upon 0 +removal 0 +of 0 +famotidine 1 +. 0 + +The 0 +pharmacokinetics 0 +of 0 +famotidine 1 +are 0 +reviewed 0 +, 0 +with 0 +no 0 +change 0 +in 0 +its 0 +metabolism 0 +in 0 +the 0 +elderly 0 +population 0 +seen 0 +. 0 + +The 0 +implications 0 +of 0 +using 0 +famotidine 1 +in 0 +elderly 0 +persons 0 +are 0 +discussed 0 +. 0 + +Encephalopathy 3 +during 0 +amitriptyline 1 +therapy 0 +: 0 +are 0 +neuroleptic 3 +malignant 4 +syndrome 4 +and 0 +serotonin 3 +syndrome 4 +spectrum 0 +disorders 0 +? 0 + +This 0 +report 0 +describes 0 +a 0 +case 0 +of 0 +encephalopathy 3 +developed 0 +in 0 +the 0 +course 0 +of 0 +amitriptyline 1 +therapy 0 +, 0 +during 0 +a 0 +remission 0 +of 0 +unipolar 3 +depression 4 +. 0 + +This 0 +patient 0 +could 0 +have 0 +been 0 +diagnosed 0 +as 0 +having 0 +either 0 +neuroleptic 3 +malignant 4 +syndrome 4 +( 0 +NMS 3 +) 0 +or 0 +serotonin 3 +syndrome 4 +( 0 +SS 3 +) 0 +. 0 + +The 0 +major 0 +determinant 0 +of 0 +the 0 +symptoms 0 +may 0 +have 0 +been 0 +dopamine 1 +/ 0 +serotonin 1 +imbalance 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 + +The 0 +NMS 3 +- 0 +like 0 +encephalopathy 3 +that 0 +develops 0 +in 0 +association 0 +with 0 +the 0 +use 0 +of 0 +antidepressants 0 +indicates 0 +that 0 +NMS 3 +and 0 +SS 3 +are 0 +spectrum 0 +disorders 0 +induced 0 +by 0 +drugs 0 +with 0 +both 0 +antidopaminergic 0 +and 0 +serotonergic 0 +effects 0 +. 0 + +Genetic 0 +separation 0 +of 0 +tumor 3 +growth 0 +and 0 +hemorrhagic 3 +phenotypes 0 +in 0 +an 0 +estrogen 1 +- 0 +induced 0 +tumor 3 +. 0 + +Chronic 0 +administration 0 +of 0 +estrogen 1 +to 0 +the 0 +Fischer 0 +344 0 +( 0 +F344 0 +) 0 +rat 0 +induces 0 +growth 0 +of 0 +large 0 +, 0 +hemorrhagic 3 +pituitary 3 +tumors 4 +. 0 + +Ten 0 +weeks 0 +of 0 +diethylstilbestrol 1 +( 0 +DES 1 +) 0 +treatment 0 +caused 0 +female 0 +F344 0 +rat 0 +pituitaries 0 +to 0 +grow 0 +to 0 +an 0 +average 0 +of 0 +109 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +3 0 +mg 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +versus 0 +11 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +4 0 +mg 0 +for 0 +untreated 0 +rats 0 +, 0 +and 0 +to 0 +become 0 +highly 0 +hemorrhagic 3 +. 0 + +The 0 +same 0 +DES 1 +treatment 0 +produced 0 +no 0 +significant 0 +growth 0 +( 0 +8 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +5 0 +mg 0 +for 0 +treated 0 +females 0 +versus 0 +8 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +1 0 +for 0 +untreated 0 +females 0 +) 0 +or 0 +morphological 0 +changes 0 +in 0 +Brown 0 +Norway 0 +( 0 +BN 0 +) 0 +rat 0 +pituitaries 0 +. 0 + +An 0 +F1 0 +hybrid 0 +of 0 +F344 0 +and 0 +BN 0 +exhibited 0 +significant 0 +pituitary 0 +growth 0 +after 0 +10 0 +weeks 0 +of 0 +DES 1 +treatment 0 +with 0 +an 0 +average 0 +mass 0 +of 0 +26 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +mg 0 +compared 0 +with 0 +8 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +mg 0 +for 0 +untreated 0 +rats 0 +. 0 + +Surprisingly 0 +, 0 +the 0 +F1 0 +hybrid 0 +tumors 3 +were 0 +not 0 +hemorrhagic 3 +and 0 +had 0 +hemoglobin 0 +content 0 +and 0 +outward 0 +appearance 0 +identical 0 +to 0 +that 0 +of 0 +BN 0 +. 0 + +Expression 0 +of 0 +both 0 +growth 0 +and 0 +morphological 0 +changes 0 +is 0 +due 0 +to 0 +multiple 0 +genes 0 +. 0 + +However 0 +, 0 +while 0 +DES 1 +- 0 +induced 0 +pituitary 0 +growth 0 +exhibited 0 +quantitative 0 +, 0 +additive 0 +inheritance 0 +, 0 +the 0 +hemorrhagic 3 +phenotype 0 +exhibited 0 +recessive 0 +, 0 +epistatic 0 +inheritance 0 +. 0 + +0nly 0 +5 0 +of 0 +the 0 +160 0 +F2 0 +pituitaries 0 +exhibited 0 +the 0 +hemorrhagic 3 +phenotype 0 +; 0 +36 0 +of 0 +the 0 +160 0 +F2 0 +pituitaries 0 +were 0 +in 0 +the 0 +F344 0 +range 0 +of 0 +mass 0 +, 0 +but 0 +31 0 +of 0 +these 0 +were 0 +not 0 +hemorrhagic 3 +, 0 +indicating 0 +that 0 +the 0 +hemorrhagic 3 +phenotype 0 +is 0 +not 0 +merely 0 +a 0 +consequence 0 +of 0 +extensive 0 +growth 0 +. 0 + +The 0 +hemorrhagic 3 +F2 0 +pituitaries 0 +were 0 +all 0 +among 0 +the 0 +most 0 +massive 0 +, 0 +indicating 0 +that 0 +some 0 +of 0 +the 0 +genes 0 +regulate 0 +both 0 +phenotypes 0 +. 0 + +Increased 0 +expression 0 +of 0 +neuronal 0 +nitric 1 +oxide 2 +synthase 0 +in 0 +bladder 0 +afferent 0 +pathways 0 +following 0 +chronic 0 +bladder 3 +irritation 4 +. 0 + +Immunocytochemical 0 +techniques 0 +were 0 +used 0 +to 0 +examine 0 +alterations 0 +in 0 +the 0 +expression 0 +of 0 +neuronal 0 +nitric 1 +oxide 2 +synthase 0 +( 0 +N0S 0 +) 0 +in 0 +bladder 0 +pathways 0 +following 0 +acute 0 +and 0 +chronic 0 +irritation 3 +of 4 +the 4 +urinary 4 +tract 4 +of 0 +the 0 +rat 0 +. 0 + +Chemical 0 +cystitis 3 +was 0 +induced 0 +by 0 +cyclophosphamide 1 +( 0 +CYP 1 +) 0 +which 0 +is 0 +metabolized 0 +to 0 +acrolein 1 +, 0 +an 0 +irritant 0 +eliminated 0 +in 0 +the 0 +urine 0 +. 0 + +Injection 0 +of 0 +CYP 1 +( 0 +n 0 += 0 +10 0 +, 0 +75 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +) 0 +2 0 +hours 0 +prior 0 +to 0 +perfusion 0 +( 0 +acute 0 +treatment 0 +) 0 +of 0 +the 0 +animals 0 +increased 0 +Fos 0 +- 0 +immunoreactivity 0 +( 0 +IR 0 +) 0 +in 0 +neurons 0 +in 0 +the 0 +dorsal 0 +commissure 0 +, 0 +dorsal 0 +horn 0 +, 0 +and 0 +autonomic 0 +regions 0 +of 0 +spinal 0 +segments 0 +( 0 +L1 0 +- 0 +L2 0 +and 0 +L6 0 +- 0 +S1 0 +) 0 +which 0 +receive 0 +afferent 0 +inputs 0 +from 0 +the 0 +bladder 0 +, 0 +urethra 0 +, 0 +and 0 +ureter 0 +. 0 + +Fos 0 +- 0 +IR 0 +in 0 +the 0 +spinal 0 +cord 0 +was 0 +not 0 +changed 0 +in 0 +rats 0 +receiving 0 +chronic 0 +CYP 1 +treatment 0 +( 0 +n 0 += 0 +15 0 +, 0 +75 0 +mg 0 +/ 0 +kg 0 +, 0 +i 0 +. 0 +p 0 +. 0 +, 0 +every 0 +3rd 0 +day 0 +for 0 +2 0 +weeks 0 +) 0 +. 0 + +In 0 +control 0 +animals 0 +and 0 +in 0 +animals 0 +treated 0 +acutely 0 +with 0 +CYP 1 +, 0 +only 0 +small 0 +numbers 0 +of 0 +N0S 0 +- 0 +IR 0 +cells 0 +( 0 +0 0 +. 0 +5 0 +- 0 +0 0 +. 0 +7 0 +cell 0 +profiles 0 +/ 0 +sections 0 +) 0 +were 0 +detected 0 +in 0 +the 0 +L6 0 +- 0 +S1 0 +dorsal 0 +root 0 +ganglia 0 +( 0 +DRG 0 +) 0 +. 0 + +Chronic 0 +CYP 1 +administration 0 +significantly 0 +( 0 +P 0 +< 0 +or 0 += 0 +. 0 +002 0 +) 0 +increased 0 +bladder 0 +weight 0 +by 0 +60 0 +% 0 +and 0 +increased 0 +( 0 +7 0 +- 0 +to 0 +11 0 +- 0 +fold 0 +) 0 +the 0 +numbers 0 +of 0 +N0S 0 +- 0 +immunoreactive 0 +( 0 +IR 0 +) 0 +afferent 0 +neurons 0 +in 0 +the 0 +L6 0 +- 0 +S1 0 +DRG 0 +. 0 + +A 0 +small 0 +increase 0 +( 0 +1 0 +. 0 +5 0 +- 0 +fold 0 +) 0 +also 0 +occurred 0 +in 0 +the 0 +L1 0 +DRG 0 +, 0 +but 0 +no 0 +change 0 +was 0 +detected 0 +in 0 +the 0 +L2 0 +and 0 +L5 0 +DRG 0 +. 0 + +Bladder 0 +afferent 0 +cells 0 +in 0 +the 0 +L6 0 +- 0 +S1 0 +DRG 0 +labeled 0 +by 0 +Fluorogold 0 +( 0 +40 0 +microliters 0 +) 0 +injected 0 +into 0 +the 0 +bladder 0 +wall 0 +did 0 +not 0 +exhibit 0 +N0S 0 +- 0 +IR 0 +in 0 +control 0 +animals 0 +; 0 +however 0 +, 0 +following 0 +chronic 0 +CYP 1 +administration 0 +, 0 +a 0 +significant 0 +percentage 0 +of 0 +bladder 0 +afferent 0 +neurons 0 +were 0 +N0S 0 +- 0 +IR 0 +: 0 +L6 0 +( 0 +19 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +6 0 +% 0 +) 0 +and 0 +S1 0 +( 0 +25 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +9 0 +% 0 +) 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +neuronal 0 +gene 0 +expression 0 +in 0 +visceral 0 +sensory 0 +pathways 0 +can 0 +be 0 +upregulated 0 +by 0 +chemical 0 +irritation 0 +of 0 +afferent 0 +receptors 0 +in 0 +the 0 +urinary 0 +tract 0 +and 0 +/ 0 +or 0 +that 0 +pathological 0 +changes 0 +in 0 +the 0 +urinary 0 +tract 0 +can 0 +initiate 0 +chemical 0 +signals 0 +that 0 +alter 0 +the 0 +chemical 0 +properties 0 +of 0 +visceral 0 +afferent 0 +neurons 0 +. 0 + +Effects 0 +of 0 +a 0 +new 0 +calcium 1 +antagonist 0 +, 0 +CD 1 +- 2 +832 2 +, 0 +on 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +ischemia 4 +in 0 +dogs 0 +with 0 +partial 0 +coronary 3 +stenosis 4 +. 0 + +Effects 0 +of 0 +CD 1 +- 2 +832 2 +on 0 +isoproterenol 1 +( 0 +IS0 1 +) 0 +- 0 +induced 0 +myocardial 3 +ischemia 4 +were 0 +studied 0 +in 0 +dogs 0 +with 0 +partial 0 +coronary 3 +stenosis 4 +of 0 +the 0 +left 0 +circumflex 0 +coronary 0 +artery 0 +and 0 +findings 0 +were 0 +compared 0 +with 0 +those 0 +for 0 +nifedipine 1 +or 0 +diltiazem 1 +. 0 + +In 0 +the 0 +presence 0 +of 0 +coronary 3 +artery 4 +stenosis 4 +, 0 +3 0 +- 0 +min 0 +periods 0 +of 0 +intracoronary 0 +IS0 1 +infusion 0 +( 0 +10 0 +ng 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +increased 0 +heart 0 +rate 0 +and 0 +maximal 0 +rate 0 +of 0 +left 0 +ventricular 0 +pressure 0 +rise 0 +, 0 +which 0 +resulted 0 +in 0 +a 0 +decrease 0 +in 0 +percentage 0 +segmental 0 +shortening 0 +and 0 +ST 0 +- 0 +segment 0 +elevation 0 +of 0 +the 0 +epicardial 0 +electrocardiogram 0 +. 0 + +After 0 +the 0 +control 0 +IS0 1 +infusion 0 +with 0 +stenosis 3 +was 0 +performed 0 +, 0 +equihypotensive 0 +doses 0 +of 0 +CD 1 +- 2 +832 2 +( 0 +3 0 +and 0 +10 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +, 0 +n 0 += 0 +7 0 +) 0 +, 0 +nifedipine 1 +( 0 +1 0 +and 0 +3 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +, 0 +n 0 += 0 +9 0 +) 0 +or 0 +diltiazem 1 +( 0 +10 0 +and 0 +30 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +, 0 +n 0 += 0 +7 0 +) 0 +were 0 +infused 0 +5 0 +min 0 +before 0 +and 0 +during 0 +the 0 +second 0 +and 0 +third 0 +IS0 1 +infusion 0 +. 0 + +Both 0 +CD 1 +- 2 +832 2 +and 0 +diltiazem 1 +, 0 +but 0 +not 0 +nifedipine 1 +, 0 +significantly 0 +reduced 0 +the 0 +increase 0 +in 0 +heart 0 +rate 0 +induced 0 +by 0 +IS0 1 +infusion 0 +. 0 + +In 0 +contrast 0 +to 0 +nifedipine 1 +, 0 +CD 1 +- 2 +832 2 +( 0 +10 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +prevented 0 +the 0 +decrease 0 +in 0 +percentage 0 +segmental 0 +shortening 0 +from 0 +32 0 ++ 0 +/ 0 +- 0 +12 0 +% 0 +to 0 +115 0 ++ 0 +/ 0 +- 0 +26 0 +% 0 +of 0 +the 0 +control 0 +value 0 +( 0 +P 0 +< 0 +. 0 +01 0 +) 0 +and 0 +ST 0 +- 0 +segment 0 +elevation 0 +from 0 +5 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +mV 0 +to 0 +1 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +mV 0 +( 0 +P 0 +< 0 +. 0 +01 0 +) 0 +at 0 +3 0 +min 0 +after 0 +IS0 1 +infusion 0 +with 0 +stenosis 3 +. 0 + +Diltiazem 1 +( 0 +30 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +also 0 +prevented 0 +the 0 +decrease 0 +in 0 +percentage 0 +segmental 0 +shortening 0 +from 0 +34 0 ++ 0 +/ 0 +- 0 +14 0 +% 0 +to 0 +63 0 ++ 0 +/ 0 +- 0 +18 0 +% 0 +of 0 +the 0 +control 0 +value 0 +( 0 +P 0 +< 0 +. 0 +05 0 +) 0 +and 0 +ST 0 +- 0 +segment 0 +elevation 0 +from 0 +4 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +mV 0 +to 0 +2 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +mV 0 +( 0 +P 0 +< 0 +. 0 +01 0 +) 0 +at 0 +3 0 +min 0 +after 0 +IS0 1 +infusion 0 +with 0 +stenosis 3 +. 0 + +These 0 +data 0 +show 0 +that 0 +CD 1 +- 2 +832 2 +improves 0 +myocardial 3 +ischemia 4 +during 0 +IS0 1 +infusion 0 +with 0 +stenosis 3 +and 0 +suggest 0 +that 0 +the 0 +negative 0 +chronotropic 0 +property 0 +of 0 +CD 1 +- 2 +832 2 +plays 0 +a 0 +major 0 +role 0 +in 0 +the 0 +beneficial 0 +effects 0 +of 0 +CD 1 +- 2 +832 2 +. 0 + +The 0 +effect 0 +of 0 +recombinant 0 +human 0 +insulin 0 +- 0 +like 0 +growth 0 +factor 0 +- 0 +I 0 +on 0 +chronic 0 +puromycin 1 +aminonucleoside 2 +nephropathy 3 +in 0 +rats 0 +. 0 + +We 0 +recently 0 +demonstrated 0 +that 0 +recombinant 0 +hGH 0 +exacerbates 0 +renal 0 +functional 0 +and 0 +structural 0 +injury 0 +in 0 +chronic 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +nephropathy 3 +, 0 +an 0 +experimental 0 +model 0 +of 0 +glomerular 3 +disease 4 +. 0 + +Therefore 0 +, 0 +we 0 +examined 0 +whether 0 +recombinant 0 +human 0 +( 0 +rh 0 +) 0 +IGF 0 +- 0 +I 0 +is 0 +a 0 +safer 0 +alternative 0 +for 0 +the 0 +treatment 0 +of 0 +growth 3 +failure 4 +in 0 +rats 0 +with 0 +chronic 0 +PAN 1 +nephropathy 3 +. 0 + +The 0 +glomerulopathy 3 +was 0 +induced 0 +by 0 +seven 0 +serial 0 +injections 0 +of 0 +PAN 1 +over 0 +12 0 +wk 0 +. 0 + +Experimental 0 +animals 0 +( 0 +n 0 += 0 +6 0 +) 0 +received 0 +rhIGF 0 +- 0 +I 0 +, 0 +400 0 +micrograms 0 +/ 0 +d 0 +, 0 +whereas 0 +control 0 +rats 0 +( 0 +n 0 += 0 +6 0 +) 0 +received 0 +the 0 +vehicle 0 +. 0 + +rhIGF 0 +- 0 +I 0 +improved 0 +weight 0 +gain 0 +by 0 +14 0 +% 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +, 0 +without 0 +altering 0 +hematocrit 0 +or 0 +blood 0 +pressure 0 +in 0 +rats 0 +with 0 +renal 3 +disease 4 +. 0 + +Urinary 0 +protein 0 +excretion 0 +was 0 +unaltered 0 +by 0 +rhIGF 0 +- 0 +I 0 +treatment 0 +in 0 +rats 0 +with 0 +chronic 0 +PAN 1 +nephropathy 3 +. 0 + +After 0 +12 0 +wk 0 +, 0 +the 0 +inulin 0 +clearance 0 +was 0 +higher 0 +in 0 +rhIGF 0 +- 0 +I 0 +- 0 +treated 0 +rats 0 +, 0 +0 0 +. 0 +48 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +08 0 +versus 0 +0 0 +. 0 +24 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +06 0 +mL 0 +/ 0 +min 0 +/ 0 +100 0 +g 0 +of 0 +body 0 +weight 0 +in 0 +untreated 0 +PAN 1 +nephropathy 3 +animals 0 +, 0 +p 0 +< 0 +0 0 +. 0 +05 0 +. 0 + +The 0 +improvement 0 +in 0 +GFR 0 +was 0 +not 0 +associated 0 +with 0 +enhanced 0 +glomerular 3 +hypertrophy 4 +or 0 +increased 0 +segmental 0 +glomerulosclerosis 3 +, 0 +tubulointerstitial 3 +injury 4 +, 0 +or 0 +renal 0 +cortical 0 +malondialdehyde 1 +content 0 +. 0 + +In 0 +rats 0 +with 0 +PAN 1 +nephropathy 3 +, 0 +administration 0 +of 0 +rhIGF 0 +- 0 +I 0 +increased 0 +IGF 0 +- 0 +I 0 +and 0 +GH 0 +receptor 0 +gene 0 +expression 0 +, 0 +without 0 +altering 0 +the 0 +steady 0 +state 0 +level 0 +of 0 +IGF 0 +- 0 +I 0 +receptor 0 +mRNA 0 +. 0 + +In 0 +normal 0 +rats 0 +with 0 +intact 0 +kidneys 0 +, 0 +rhIGF 0 +- 0 +I 0 +administration 0 +( 0 +n 0 += 0 +4 0 +) 0 +did 0 +not 0 +alter 0 +weight 0 +gain 0 +, 0 +blood 0 +pressure 0 +, 0 +proteinuria 3 +, 0 +GFR 0 +, 0 +glomerular 0 +planar 0 +area 0 +, 0 +renal 0 +cortical 0 +malondialdehyde 1 +content 0 +, 0 +or 0 +glomerular 0 +or 0 +tubulointerstitial 3 +damage 4 +, 0 +compared 0 +with 0 +untreated 0 +animals 0 +( 0 +n 0 += 0 +4 0 +) 0 +. 0 + +rhIGF 0 +- 0 +I 0 +treatment 0 +reduced 0 +the 0 +steady 0 +state 0 +renal 0 +IGF 0 +- 0 +I 0 +mRNA 0 +level 0 +but 0 +did 0 +not 0 +modify 0 +gene 0 +expression 0 +of 0 +the 0 +IGF 0 +- 0 +I 0 +or 0 +GH 0 +receptors 0 +. 0 + +We 0 +conclude 0 +that 0 +: 0 +1 0 +) 0 +administration 0 +of 0 +rhIGF 0 +- 0 +I 0 +improves 0 +growth 0 +and 0 +GFR 0 +in 0 +rats 0 +with 0 +chronic 0 +PAN 1 +nephropathy 3 +and 0 +2 0 +) 0 +unlike 0 +rhGH 0 +, 0 +long 0 +- 0 +term 0 +use 0 +of 0 +rhIGF 0 +- 0 +I 0 +does 0 +not 0 +worsen 0 +renal 0 +functional 0 +and 0 +structural 0 +injury 0 +in 0 +this 0 +disease 0 +model 0 +. 0 + +Nefiracetam 1 +( 0 +DM 1 +- 2 +9384 2 +) 0 +reverses 0 +apomorphine 1 +- 0 +induced 0 +amnesia 3 +of 0 +a 0 +passive 0 +avoidance 0 +response 0 +: 0 +delayed 0 +emergence 0 +of 0 +the 0 +memory 0 +retention 0 +effects 0 +. 0 + +Nefiracetam 1 +is 0 +a 0 +novel 0 +pyrrolidone 1 +derivative 0 +which 0 +attenuates 0 +scopolamine 1 +- 0 +induced 0 +learning 3 +and 4 +post 4 +- 4 +training 4 +consolidation 4 +deficits 4 +. 0 + +Given 0 +that 0 +apomorphine 1 +inhibits 0 +passive 0 +avoidance 0 +retention 0 +when 0 +given 0 +during 0 +training 0 +or 0 +in 0 +a 0 +defined 0 +10 0 +- 0 +12h 0 +post 0 +- 0 +training 0 +period 0 +, 0 +we 0 +evaluated 0 +the 0 +ability 0 +of 0 +nefiracetam 1 +to 0 +attenuate 0 +amnesia 3 +induced 0 +by 0 +dopaminergic 0 +agonism 0 +. 0 + +A 0 +step 0 +- 0 +down 0 +passive 0 +avoidance 0 +paradigm 0 +was 0 +employed 0 +and 0 +nefiracetam 1 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +apomorphine 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +were 0 +given 0 +alone 0 +or 0 +in 0 +combination 0 +during 0 +training 0 +and 0 +at 0 +the 0 +10 0 +- 0 +12h 0 +post 0 +- 0 +training 0 +period 0 +of 0 +consolidation 0 +. 0 + +Co 0 +- 0 +administration 0 +of 0 +nefiracetam 1 +and 0 +apomorphine 1 +during 0 +training 0 +or 0 +10h 0 +thereafter 0 +produced 0 +no 0 +significant 0 +anti 0 +- 0 +amnesic 0 +effect 0 +. 0 + +However 0 +, 0 +administration 0 +of 0 +nefiracetam 1 +during 0 +training 0 +completely 0 +reversed 0 +the 0 +amnesia 3 +induced 0 +by 0 +apomorphine 1 +at 0 +the 0 +10h 0 +post 0 +- 0 +training 0 +time 0 +and 0 +the 0 +converse 0 +was 0 +also 0 +true 0 +. 0 + +These 0 +effects 0 +were 0 +not 0 +mediated 0 +by 0 +a 0 +dopaminergic 0 +mechanism 0 +as 0 +nefiracetam 1 +, 0 +at 0 +millimolar 0 +concentrations 0 +, 0 +failed 0 +to 0 +displace 0 +either 0 +[ 0 +3H 0 +] 0 +SCH 1 +23390 2 +or 0 +[ 0 +3H 0 +] 0 +spiperone 1 +binding 0 +from 0 +D1 0 +or 0 +D2 0 +dopamine 1 +receptor 0 +subtypes 0 +, 0 +respectively 0 +. 0 + +It 0 +is 0 +suggested 0 +that 0 +nefiracetam 1 +augments 0 +molecular 0 +processes 0 +in 0 +the 0 +early 0 +stages 0 +of 0 +events 0 +which 0 +ultimately 0 +lead 0 +to 0 +consolidation 0 +of 0 +memory 0 +. 0 + +Phenytoin 1 +encephalopathy 3 +as 0 +probable 0 +idiosyncratic 0 +reaction 0 +: 0 +case 0 +report 0 +. 0 + +A 0 +case 0 +of 0 +phenytoin 1 +( 0 +DPH 1 +) 0 +encephalopathy 3 +with 0 +increasing 0 +seizures 3 +and 0 +EEG 0 +and 0 +mental 0 +changes 0 +is 0 +described 0 +. 0 + +Despite 0 +adequate 0 +oral 0 +dosage 0 +of 0 +DPH 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +daily 0 +) 0 +the 0 +plasma 0 +level 0 +was 0 +very 0 +low 0 +( 0 +2 0 +. 0 +8 0 +microgramg 0 +/ 0 +ml 0 +) 0 +. 0 + +The 0 +encephalopathy 3 +was 0 +probably 0 +an 0 +idiosyncratic 0 +and 0 +not 0 +toxic 0 +or 0 +allergic 0 +reaction 0 +. 0 + +In 0 +fact 0 +the 0 +concentration 0 +of 0 +free 0 +DPH 1 +was 0 +normal 0 +, 0 +the 0 +patient 0 +presented 0 +a 0 +retarded 0 +morbilliform 0 +rash 3 +during 0 +DPH 1 +treatment 0 +, 0 +the 0 +protidogram 0 +was 0 +normal 0 +, 0 +and 0 +an 0 +intradermic 0 +DPH 1 +injection 0 +had 0 +no 0 +local 0 +effect 0 +. 0 + +The 0 +authors 0 +conclude 0 +that 0 +in 0 +a 0 +patient 0 +starting 0 +DPH 1 +treatment 0 +an 0 +unexpected 0 +increase 0 +in 0 +seizures 3 +, 0 +with 0 +EEG 0 +and 0 +mental 0 +changes 0 +occurring 0 +simultaneously 0 +, 0 +should 0 +alert 0 +the 0 +physician 0 +to 0 +the 0 +possible 0 +need 0 +for 0 +eliminating 0 +DPH 1 +from 0 +the 0 +therapeutic 0 +regimen 0 +, 0 +even 0 +if 0 +plasma 0 +concentrations 0 +are 0 +low 0 +. 0 + +Prevention 0 +and 0 +treatment 0 +of 0 +endometrial 3 +disease 4 +in 0 +climacteric 0 +women 0 +receiving 0 +oestrogen 1 +therapy 0 +. 0 + +The 0 +treatment 0 +regimens 0 +are 0 +described 0 +in 0 +74 0 +patients 0 +with 0 +endometrial 3 +disease 4 +among 0 +850 0 +climacteric 0 +women 0 +receiving 0 +oestrogen 1 +therapy 0 +. 0 + +Cystic 0 +hyperplasia 3 +was 0 +associated 0 +with 0 +unopposed 0 +oestrogen 1 +therapy 0 +without 0 +progestagen 1 +. 0 + +Two 0 +courses 0 +of 0 +21 0 +days 0 +of 0 +5 0 +mg 0 +norethisterone 1 +daily 0 +caused 0 +reversion 0 +to 0 +normal 0 +in 0 +all 0 +57 0 +cases 0 +of 0 +cystic 0 +hyperplasia 3 +and 0 +6 0 +of 0 +the 0 +8 0 +cases 0 +of 0 +atypical 0 +hyperplasia 3 +. 0 + +4 0 +cases 0 +of 0 +endometrial 3 +carcinoma 4 +referred 0 +from 0 +elsewhere 0 +demonstrated 0 +the 0 +problems 0 +of 0 +inappropriate 0 +and 0 +unsupervised 0 +unopposed 0 +oestrogen 1 +therapy 0 +and 0 +the 0 +difficulty 0 +in 0 +distinguishing 0 +severe 0 +hyperplasia 3 +from 0 +malignancy 3 +. 0 + +Cyclical 0 +low 0 +- 0 +dose 0 +oestrogen 1 +therapy 0 +with 0 +7 0 +- 0 +- 0 +13 0 +days 0 +of 0 +progestagen 1 +does 0 +not 0 +seem 0 +to 0 +increase 0 +the 0 +risk 0 +of 0 +endometrial 3 +hyperplasia 4 +or 0 +carcinoma 3 +. 0 + +Effects 0 +of 0 +exercise 0 +on 0 +the 0 +severity 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +. 0 + +The 0 +effect 0 +of 0 +exercise 0 +on 0 +the 0 +severity 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +was 0 +studied 0 +in 0 +male 0 +rats 0 +. 0 + +Ninety 0 +- 0 +three 0 +rats 0 +were 0 +randomly 0 +divided 0 +into 0 +three 0 +groups 0 +. 0 + +The 0 +exercise 0 +- 0 +isoproterenol 1 +( 0 +E 0 +- 0 +1 0 +) 0 +and 0 +exercise 0 +control 0 +( 0 +EC 0 +) 0 +groups 0 +exercised 0 +daily 0 +for 0 +thirty 0 +days 0 +on 0 +a 0 +treadmill 0 +at 0 +1 0 +mph 0 +, 0 +2 0 +% 0 +grade 0 +while 0 +animals 0 +of 0 +the 0 +sedentary 0 +- 0 +isoproterenol 1 +( 0 +S 0 +- 0 +I 0 +) 0 +group 0 +remained 0 +sedentary 0 +. 0 + +Eight 0 +animals 0 +were 0 +assigned 0 +to 0 +the 0 +sedentary 0 +control 0 +( 0 +SC 0 +) 0 +group 0 +which 0 +remained 0 +sedentary 0 +throughout 0 +the 0 +experimental 0 +period 0 +. 0 + +Forty 0 +- 0 +eight 0 +hours 0 +after 0 +the 0 +final 0 +exercise 0 +period 0 +, 0 +S 0 +- 0 +I 0 +and 0 +E 0 +- 0 +I 0 +animals 0 +received 0 +a 0 +single 0 +subcutaneous 0 +injection 0 +of 0 +isoproterenol 1 +( 0 +250 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +. 0 + +Animals 0 +of 0 +the 0 +S 0 +- 0 +I 0 +group 0 +exhibited 0 +significantly 0 +( 0 +Pp 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +greater 0 +mortality 0 +from 0 +the 0 +effects 0 +of 0 +isoproterenol 1 +than 0 +animals 0 +of 0 +the 0 +E 0 +- 0 +I 0 +group 0 +. 0 + +Serum 0 +CPK 0 +activity 0 +for 0 +E 0 +- 0 +I 0 +animals 0 +was 0 +significantly 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +05 0 +) 0 +greater 0 +than 0 +for 0 +animals 0 +in 0 +the 0 +S 0 +- 0 +I 0 +and 0 +EC 0 +groups 0 +twenty 0 +hours 0 +following 0 +isoproterenol 1 +injection 0 +. 0 + +No 0 +statistically 0 +significant 0 +differences 0 +were 0 +observed 0 +between 0 +the 0 +two 0 +isoproterenol 1 +treated 0 +groups 0 +for 0 +severity 0 +of 0 +the 0 +induced 0 +lesions 0 +, 0 +changes 0 +in 0 +heart 0 +weight 0 +, 0 +or 0 +heart 0 +weight 0 +to 0 +body 0 +weight 0 +ratios 0 +. 0 + +The 0 +results 0 +indicated 0 +that 0 +exercise 0 +reduced 0 +the 0 +mortality 0 +associated 0 +with 0 +the 0 +effects 0 +of 0 +large 0 +dosages 0 +of 0 +isoproterenol 1 +but 0 +had 0 +little 0 +on 0 +the 0 +severity 0 +of 0 +the 0 +infarction 3 +. 0 + +Human 0 +corticotropin 1 +- 0 +releasing 0 +hormone 0 +and 0 +thyrotropin 1 +- 0 +releasing 0 +hormone 0 +modulate 0 +the 0 +hypercapnic 3 +ventilatory 0 +response 0 +in 0 +humans 0 +. 0 + +Human 0 +corticotropin 1 +- 0 +releasing 0 +hormone 0 +( 0 +hCRH 0 +) 0 +and 0 +thyrotropin 1 +- 0 +releasing 0 +hormone 0 +( 0 +TRH 0 +) 0 +are 0 +known 0 +to 0 +stimulate 0 +ventilation 0 +after 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +in 0 +humans 0 +. 0 + +In 0 +a 0 +placebo 0 +- 0 +controlled 0 +, 0 +single 0 +- 0 +blind 0 +study 0 +we 0 +aimed 0 +to 0 +clarify 0 +if 0 +both 0 +peptides 0 +act 0 +by 0 +altering 0 +central 0 +chemosensitivity 0 +. 0 + +Two 0 +subsequent 0 +C02 1 +- 0 +rebreathing 0 +tests 0 +were 0 +performed 0 +in 0 +healthy 0 +young 0 +volunteers 0 +. 0 + +During 0 +the 0 +first 0 +test 0 +0 0 +. 0 +9 0 +% 0 +NaCl 1 +was 0 +given 0 +i 0 +. 0 +v 0 +. 0 +; 0 +during 0 +the 0 +second 0 +test 0 +200 0 +micrograms 0 +of 0 +hCRH 0 +( 0 +n 0 += 0 +12 0 +) 0 +or 0 +400 0 +micrograms 0 +of 0 +TRH 0 +( 0 +n 0 += 0 +6 0 +) 0 +was 0 +administered 0 +i 0 +. 0 +v 0 +. 0 +Nine 0 +subjects 0 +received 0 +0 0 +. 0 +9 0 +% 0 +NaCl 1 +i 0 +. 0 +v 0 +. 0 +during 0 +both 0 +rebreathing 0 +manoeuvres 0 +. 0 + +The 0 +C02 1 +- 0 +response 0 +curves 0 +for 0 +the 0 +two 0 +tests 0 +were 0 +compared 0 +within 0 +the 0 +same 0 +subject 0 +. 0 + +In 0 +the 0 +hCRH 0 +group 0 +a 0 +marked 0 +parallel 0 +shift 0 +of 0 +the 0 +C02 1 +- 0 +response 0 +curve 0 +to 0 +the 0 +left 0 +was 0 +observed 0 +after 0 +hCRH 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +. 0 + +The 0 +same 0 +effect 0 +occurred 0 +following 0 +TRH 0 +but 0 +was 0 +less 0 +striking 0 +( 0 +P 0 += 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +hCRH 0 +and 0 +TRH 0 +caused 0 +a 0 +reduction 0 +in 0 +the 0 +C02 1 +threshold 0 +. 0 + +The 0 +C02 1 +- 0 +response 0 +curves 0 +in 0 +the 0 +control 0 +group 0 +were 0 +nearly 0 +identical 0 +. 0 + +The 0 +results 0 +indicate 0 +an 0 +additive 0 +effect 0 +of 0 +both 0 +releasing 0 +hormones 0 +on 0 +the 0 +hypercapnic 3 +ventilatory 0 +response 0 +in 0 +humans 0 +, 0 +presumably 0 +independent 0 +of 0 +central 0 +chemosensitivity 0 +. 0 + +Lamivudine 1 +is 0 +effective 0 +in 0 +suppressing 0 +hepatitis 3 +B 4 +virus 0 +DNA 0 +in 0 +Chinese 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +carriers 0 +: 0 +a 0 +placebo 0 +- 0 +controlled 0 +trial 0 +. 0 + +Lamivudine 1 +is 0 +a 0 +novel 0 +2 1 +' 2 +, 2 +3 2 +' 2 +- 2 +dideoxy 2 +cytosine 2 +analogue 0 +that 0 +has 0 +potent 0 +inhibitory 0 +effects 0 +on 0 +hepatitis 3 +B 4 +virus 0 +replication 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +. 0 + +We 0 +performed 0 +a 0 +single 0 +- 0 +blind 0 +, 0 +placebo 0 +- 0 +controlled 0 +study 0 +to 0 +assess 0 +its 0 +effectiveness 0 +and 0 +safety 0 +in 0 +Chinese 0 +hepatitis 1 +B 2 +surface 2 +antigen 2 +( 0 +HBsAg 1 +) 0 +carriers 0 +. 0 + +Forty 0 +- 0 +two 0 +Chinese 0 +HBsAg 1 +carriers 0 +were 0 +randomized 0 +to 0 +receive 0 +placebo 0 +( 0 +6 0 +patients 0 +) 0 +or 0 +lamivudine 1 +orally 0 +in 0 +dosages 0 +of 0 +25 0 +mg 0 +, 0 +100 0 +mg 0 +, 0 +or 0 +300 0 +mg 0 +daily 0 +( 0 +12 0 +patients 0 +for 0 +each 0 +dosage 0 +) 0 +. 0 + +The 0 +drug 0 +was 0 +given 0 +for 0 +4 0 +weeks 0 +. 0 + +The 0 +patients 0 +were 0 +closely 0 +monitored 0 +clinically 0 +, 0 +biochemically 0 +, 0 +and 0 +serologically 0 +up 0 +to 0 +4 0 +weeks 0 +after 0 +drug 0 +treatment 0 +. 0 + +All 0 +36 0 +patients 0 +receiving 0 +lamivudine 1 +had 0 +a 0 +decrease 0 +in 0 +hepatitis 3 +B 4 +virus 0 +( 0 +HBV 0 +) 0 +DNA 0 +values 0 +of 0 +> 0 +90 0 +% 0 +( 0 +P 0 +< 0 +. 0 +001 0 +compared 0 +with 0 +placebo 0 +) 0 +. 0 + +Although 0 +25 0 +mg 0 +of 0 +lamivudine 1 +was 0 +slightly 0 +less 0 +effective 0 +than 0 +100 0 +mg 0 +( 0 +P 0 += 0 +. 0 +011 0 +) 0 +and 0 +300 0 +mg 0 +( 0 +P 0 += 0 +. 0 +005 0 +) 0 +, 0 +it 0 +still 0 +induced 0 +94 0 +% 0 +suppression 0 +of 0 +HBV 0 +DNA 0 +after 0 +the 0 +fourth 0 +week 0 +of 0 +therapy 0 +. 0 + +HBV 0 +DNA 0 +values 0 +returned 0 +to 0 +pretreatment 0 +levels 0 +within 0 +4 0 +weeks 0 +of 0 +cessation 0 +of 0 +therapy 0 +. 0 + +There 0 +was 0 +no 0 +change 0 +in 0 +the 0 +hepatitis 3 +B 4 +e 0 +antigen 0 +status 0 +or 0 +in 0 +aminotransferase 0 +levels 0 +. 0 + +No 0 +serious 0 +adverse 0 +events 0 +were 0 +observed 0 +. 0 + +In 0 +conclusion 0 +, 0 +a 0 +4 0 +- 0 +week 0 +course 0 +of 0 +lamivudine 1 +was 0 +safe 0 +and 0 +effective 0 +in 0 +suppression 0 +of 0 +HBV 0 +DNA 0 +in 0 +Chinese 0 +HBsAg 1 +carriers 0 +. 0 + +The 0 +suppression 0 +was 0 +> 0 +90 0 +% 0 +but 0 +reversible 0 +. 0 + +Studies 0 +with 0 +long 0 +- 0 +term 0 +lamivudine 1 +administration 0 +should 0 +be 0 +performed 0 +to 0 +determine 0 +if 0 +prolonged 0 +suppression 0 +of 0 +HBV 0 +DNA 0 +can 0 +be 0 +achieved 0 +. 0 + +Population 0 +- 0 +based 0 +study 0 +of 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +associated 0 +with 0 +various 0 +oral 1 +contraceptives 2 +. 0 + +BACKGR0UND 0 +: 0 +Four 0 +studies 0 +published 0 +since 0 +December 0 +, 0 +1995 0 +, 0 +reported 0 +that 0 +the 0 +incidence 0 +of 0 +venous 3 +thromboembolism 4 +( 0 +VTE 3 +) 0 +was 0 +higher 0 +in 0 +women 0 +who 0 +used 0 +oral 1 +contraceptives 2 +( 0 +0Cs 1 +) 0 +containing 0 +the 0 +third 0 +- 0 +generation 0 +progestagens 1 +gestodene 1 +or 0 +desogestrel 1 +than 0 +in 0 +users 0 +of 0 +0Cs 1 +containing 0 +second 0 +- 0 +generation 0 +progestagens 1 +. 0 + +However 0 +, 0 +confounding 0 +and 0 +bias 0 +in 0 +the 0 +design 0 +of 0 +these 0 +studies 0 +may 0 +have 0 +affected 0 +the 0 +findings 0 +. 0 + +The 0 +aim 0 +of 0 +our 0 +study 0 +was 0 +to 0 +re 0 +- 0 +examine 0 +the 0 +association 0 +between 0 +risk 0 +of 0 +VTE 3 +and 0 +0C 1 +use 0 +with 0 +a 0 +different 0 +study 0 +design 0 +and 0 +analysis 0 +to 0 +avoid 0 +some 0 +of 0 +the 0 +bias 0 +and 0 +confounding 0 +of 0 +the 0 +earlier 0 +studies 0 +. 0 + +METH0DS 0 +: 0 +We 0 +used 0 +computer 0 +records 0 +of 0 +patients 0 +from 0 +143 0 +general 0 +practices 0 +in 0 +the 0 +UK 0 +. 0 + +The 0 +study 0 +was 0 +based 0 +on 0 +the 0 +medical 0 +records 0 +of 0 +about 0 +540 0 +, 0 +000 0 +women 0 +born 0 +between 0 +1941 0 +and 0 +1981 0 +. 0 + +All 0 +women 0 +who 0 +had 0 +a 0 +recorded 0 +diagnosis 0 +of 0 +deep 3 +- 4 +vein 4 +thrombosis 4 +, 0 +venous 3 +thrombosis 4 +not 0 +otherwise 0 +specified 0 +, 0 +or 0 +pulmonary 0 +embolus 0 +during 0 +the 0 +study 0 +period 0 +, 0 +and 0 +who 0 +had 0 +been 0 +treated 0 +with 0 +an 0 +anticoagulant 0 +were 0 +identified 0 +as 0 +potential 0 +cases 0 +of 0 +VTE 3 +. 0 + +We 0 +did 0 +a 0 +cohort 0 +analysis 0 +to 0 +estimate 0 +and 0 +compare 0 +incidence 0 +of 0 +VTE 3 +in 0 +users 0 +of 0 +the 0 +main 0 +0C 1 +preparations 0 +, 0 +and 0 +a 0 +nested 0 +case 0 +- 0 +control 0 +study 0 +to 0 +calculate 0 +the 0 +odds 0 +ratios 0 +of 0 +VTE 3 +associated 0 +with 0 +use 0 +of 0 +different 0 +types 0 +of 0 +0C 1 +, 0 +after 0 +adjustment 0 +for 0 +potential 0 +confounding 0 +factors 0 +. 0 + +In 0 +the 0 +case 0 +- 0 +control 0 +study 0 +, 0 +we 0 +matched 0 +cases 0 +to 0 +controls 0 +by 0 +exact 0 +year 0 +of 0 +birth 0 +, 0 +practice 0 +, 0 +and 0 +current 0 +use 0 +of 0 +0Cs 1 +. 0 + +We 0 +used 0 +a 0 +multiple 0 +logistic 0 +regression 0 +model 0 +that 0 +included 0 +body 0 +- 0 +mass 0 +index 0 +, 0 +number 0 +of 0 +cycles 0 +, 0 +change 0 +in 0 +type 0 +of 0 +0C 1 +prescribed 0 +within 0 +3 0 +months 0 +of 0 +the 0 +event 0 +, 0 +previous 0 +pregnancy 0 +, 0 +and 0 +concurrent 0 +disease 0 +. 0 + +FINDINGS 0 +: 0 +85 0 +women 0 +met 0 +the 0 +inclusion 0 +criteria 0 +for 0 +VTE 3 +, 0 +two 0 +of 0 +whom 0 +were 0 +users 0 +of 0 +progestagen 1 +- 0 +only 0 +0Cs 1 +. 0 + +0f 0 +the 0 +83 0 +cases 0 +of 0 +VTE 3 +associated 0 +with 0 +use 0 +of 0 +combined 0 +0Cs 1 +, 0 +43 0 +were 0 +recorded 0 +as 0 +deep 3 +- 4 +vein 4 +thrombosis 4 +, 0 +35 0 +as 0 +pulmonary 0 +thrombosis 3 +, 0 +and 0 +five 0 +as 0 +venous 3 +thrombosis 4 +not 0 +otherwise 0 +specified 0 +. 0 + +The 0 +crude 0 +rate 0 +of 0 +VTE 3 +per 0 +10 0 +, 0 +000 0 +woman 0 +- 0 +years 0 +was 0 +4 0 +. 0 +10 0 +in 0 +current 0 +users 0 +of 0 +any 0 +0C 1 +, 0 +3 0 +. 0 +10 0 +in 0 +users 0 +of 0 +second 0 +- 0 +generation 0 +0Cs 1 +, 0 +and 0 +4 0 +. 0 +96 0 +in 0 +users 0 +of 0 +third 0 +- 0 +generation 0 +preparations 0 +. 0 + +After 0 +adjustment 0 +for 0 +age 0 +, 0 +the 0 +rate 0 +ratio 0 +of 0 +VTE 3 +in 0 +users 0 +of 0 +third 0 +- 0 +generation 0 +relative 0 +to 0 +second 0 +- 0 +generation 0 +0Cs 1 +was 0 +1 0 +. 0 +68 0 +( 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +04 0 +- 0 +2 0 +. 0 +75 0 +) 0 +. 0 + +Logistic 0 +regression 0 +showed 0 +no 0 +significant 0 +difference 0 +in 0 +the 0 +risk 0 +of 0 +VTE 3 +between 0 +users 0 +of 0 +third 0 +- 0 +generation 0 +and 0 +second 0 +- 0 +generation 0 +0Cs 1 +. 0 + +Among 0 +users 0 +of 0 +third 0 +- 0 +generation 0 +progestagens 1 +, 0 +the 0 +risk 0 +of 0 +VTE 3 +was 0 +higher 0 +in 0 +users 0 +of 0 +desogestrel 1 +with 0 +20 0 +g 0 +ethinyloestradiol 1 +than 0 +in 0 +users 0 +of 0 +gestodene 1 +or 0 +desogestrel 1 +with 0 +30 0 +g 0 +ethinyloestradiol 1 +. 0 + +With 0 +all 0 +second 0 +- 0 +generation 0 +0Cs 1 +as 0 +the 0 +reference 0 +, 0 +the 0 +odds 0 +ratios 0 +for 0 +VTE 3 +were 0 +3 0 +. 0 +49 0 +( 0 +1 0 +. 0 +21 0 +- 0 +10 0 +. 0 +12 0 +) 0 +for 0 +desogestrel 1 +plus 0 +20 0 +g 0 +ethinyloestradiol 1 +and 0 +1 0 +. 0 +18 0 +( 0 +0 0 +. 0 +66 0 +- 0 +2 0 +. 0 +17 0 +) 0 +for 0 +the 0 +other 0 +third 0 +- 0 +generation 0 +progestagens 1 +. 0 + +INTERPRETATI0N 0 +: 0 +The 0 +previously 0 +reported 0 +increase 0 +in 0 +odds 0 +ratio 0 +associated 0 +with 0 +third 0 +- 0 +generation 0 +0Cs 1 +when 0 +compared 0 +with 0 +second 0 +- 0 +generation 0 +products 0 +is 0 +likely 0 +to 0 +have 0 +been 0 +the 0 +result 0 +of 0 +residual 0 +confounding 0 +by 0 +age 0 +. 0 + +The 0 +increased 0 +odds 0 +ratio 0 +associated 0 +with 0 +products 0 +containing 0 +20 0 +micrograms 0 +ethinyloestradiol 1 +and 0 +desogestrel 1 +compared 0 +with 0 +the 0 +30 0 +micrograms 0 +product 0 +is 0 +biologically 0 +implausible 0 +, 0 +and 0 +is 0 +likely 0 +to 0 +be 0 +the 0 +result 0 +of 0 +preferential 0 +prescribing 0 +and 0 +, 0 +thus 0 +, 0 +confounding 0 +. 0 + +MK 1 +- 2 +801 2 +augments 0 +pilocarpine 1 +- 0 +induced 0 +electrographic 0 +seizure 3 +but 0 +protects 0 +against 0 +brain 3 +damage 4 +in 0 +rats 0 +. 0 + +1 0 +. 0 + +The 0 +authors 0 +examined 0 +the 0 +anticonvulsant 0 +effects 0 +of 0 +MK 1 +- 2 +801 2 +on 0 +the 0 +pilocarpine 1 +- 0 +induced 0 +seizure 3 +model 0 +. 0 + +Intraperitoneal 0 +injection 0 +of 0 +pilocarpine 1 +( 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +induced 0 +tonic 3 +and 4 +clonic 4 +seizure 4 +. 0 + +Scopolamine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +pentobarbital 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +prevented 0 +development 0 +of 0 +pilocarpine 1 +- 0 +induced 0 +behavioral 0 +seizure 3 +but 0 +MK 1 +- 2 +801 2 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +did 0 +not 0 +. 0 + +2 0 +. 0 + +An 0 +electrical 0 +seizure 3 +measured 0 +with 0 +hippocampal 0 +EEG 0 +appeared 0 +in 0 +the 0 +pilocarpine 1 +- 0 +treated 0 +group 0 +. 0 + +Scopolamine 1 +and 0 +pentobarbital 1 +blocked 0 +the 0 +pilocarpine 1 +- 0 +induced 0 +electrographic 0 +seizure 3 +, 0 +MK 1 +- 2 +801 2 +treatment 0 +augmented 0 +the 0 +electrographic 0 +seizure 3 +induced 0 +by 0 +pilocarpine 1 +. 0 + +3 0 +. 0 + +Brain 3 +damage 4 +was 0 +assessed 0 +by 0 +examining 0 +the 0 +hippocampus 0 +microscopically 0 +. 0 + +Pilocarpine 1 +produced 0 +neuronal 3 +death 4 +in 0 +the 0 +hippocampus 0 +, 0 +which 0 +showed 0 +pyknotic 0 +changes 0 +. 0 + +Pentobarbital 1 +, 0 +scopolamine 1 +and 0 +MK 1 +- 2 +801 2 +protected 0 +the 0 +brain 3 +damage 4 +by 0 +pilocarpine 1 +, 0 +though 0 +in 0 +the 0 +MK 1 +- 2 +801 2 +- 0 +treated 0 +group 0 +, 0 +the 0 +pyramidal 0 +cells 0 +of 0 +hippocampus 0 +appeared 0 +darker 0 +than 0 +normal 0 +. 0 + +In 0 +all 0 +treatments 0 +, 0 +granule 0 +cells 0 +of 0 +the 0 +dentate 0 +gyrus 0 +were 0 +not 0 +affected 0 +. 0 + +4 0 +. 0 + +These 0 +results 0 +indicate 0 +that 0 +status 3 +epilepticus 4 +induced 0 +by 0 +pilocarpine 1 +is 0 +initiated 0 +by 0 +cholinergic 0 +overstimulation 0 +and 0 +propagated 0 +by 0 +glutamatergic 0 +transmission 0 +, 0 +the 0 +elevation 0 +of 0 +which 0 +may 0 +cause 0 +brain 3 +damage 4 +through 0 +an 0 +excitatory 0 +NMDA 1 +receptor 0 +- 0 +mediated 0 +mechanism 0 +. 0 + +Paclitaxel 1 +, 0 +5 1 +- 2 +fluorouracil 2 +, 0 +and 0 +folinic 1 +acid 2 +in 0 +metastatic 0 +breast 3 +cancer 4 +: 0 +BRE 0 +- 0 +26 0 +, 0 +a 0 +phase 0 +II 0 +trial 0 +. 0 + +5 1 +- 2 +Fluorouracil 2 +plus 0 +folinic 1 +acid 2 +and 0 +paclitaxel 1 +( 0 +Taxol 1 +; 0 +Bristol 0 +- 0 +Myers 0 +Squibb 0 +Company 0 +, 0 +Princeton 0 +, 0 +NJ 0 +) 0 +are 0 +effective 0 +salvage 0 +therapies 0 +for 0 +metastatic 0 +breast 3 +cancer 4 +patients 0 +. 0 + +Paclitaxel 1 +and 0 +5 1 +- 2 +fluorouracil 2 +have 0 +additive 0 +cytotoxicity 3 +in 0 +MCF 0 +- 0 +7 0 +cell 0 +lines 0 +. 0 + +We 0 +performed 0 +a 0 +phase 0 +II 0 +trial 0 +of 0 +paclitaxel 1 +175 0 +mg 0 +/ 0 +m2 0 +over 0 +3 0 +hours 0 +on 0 +day 0 +I 0 +followed 0 +by 0 +folinic 1 +acid 2 +300 0 +mg 0 +over 0 +1 0 +hour 0 +before 0 +5 1 +- 2 +fluorouracil 2 +350 0 +mg 0 +/ 0 +m2 0 +on 0 +days 0 +1 0 +to 0 +3 0 +every 0 +28 0 +days 0 +( 0 +TFL 0 +) 0 +in 0 +women 0 +with 0 +metastatic 0 +breast 3 +cancer 4 +. 0 + +Analysis 0 +is 0 +reported 0 +on 0 +37 0 +patients 0 +with 0 +a 0 +minimum 0 +of 0 +6 0 +months 0 +follow 0 +- 0 +up 0 +who 0 +received 0 +a 0 +total 0 +of 0 +192 0 +cycles 0 +of 0 +TFL 0 +: 0 +nine 0 +cycles 0 +( 0 +5 0 +% 0 +) 0 +were 0 +associated 0 +with 0 +grade 0 +3 0 +/ 0 +4 0 +neutropenia 3 +requiring 0 +hospitalization 0 +; 0 +seven 0 +( 0 +4 0 +% 0 +) 0 +cycles 0 +in 0 +two 0 +patients 0 +required 0 +granulocyte 1 +colony 2 +- 2 +stimulating 2 +factor 2 +due 0 +to 0 +neutropenia 3 +; 0 +no 0 +patient 0 +required 0 +platelet 0 +transfusions 0 +. 0 + +Grade 0 +3 0 +/ 0 +4 0 +nonhematologic 0 +toxicities 3 +were 0 +uncommon 0 +. 0 + +Among 0 +the 0 +34 0 +patients 0 +evaluable 0 +for 0 +response 0 +, 0 +there 0 +were 0 +three 0 +complete 0 +responses 0 +( 0 +9 0 +% 0 +) 0 +and 0 +18 0 +partial 0 +responses 0 +( 0 +53 0 +% 0 +) 0 +for 0 +an 0 +overall 0 +response 0 +rate 0 +of 0 +62 0 +% 0 +. 0 + +0f 0 +the 0 +19 0 +evaluable 0 +patients 0 +with 0 +prior 0 +doxorubicin 1 +exposure 0 +, 0 +11 0 +( 0 +58 0 +% 0 +) 0 +responded 0 +compared 0 +with 0 +nine 0 +of 0 +15 0 +( 0 +60 0 +% 0 +) 0 +without 0 +prior 0 +doxorubicin 1 +. 0 + +Plasma 0 +paclitaxel 1 +concentrations 0 +were 0 +measured 0 +at 0 +the 0 +completion 0 +of 0 +paclitaxel 1 +infusion 0 +and 0 +at 0 +24 0 +hours 0 +in 0 +19 0 +patients 0 +. 0 + +TFL 0 +is 0 +an 0 +active 0 +, 0 +well 0 +- 0 +tolerated 0 +regimen 0 +in 0 +metastatic 0 +breast 3 +cancer 4 +. 0 + +Efficacy 0 +and 0 +proarrhythmia 3 +with 0 +the 0 +use 0 +of 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +for 0 +sustained 0 +ventricular 3 +tachyarrhythmias 4 +. 0 + +This 0 +study 0 +prospectively 0 +evaluated 0 +the 0 +clinical 0 +efficacy 0 +, 0 +the 0 +incidence 0 +of 0 +torsades 3 +de 4 +pointes 4 +, 0 +and 0 +the 0 +presumable 0 +risk 0 +factors 0 +for 0 +torsades 3 +de 4 +pointes 4 +in 0 +patients 0 +treated 0 +with 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +for 0 +sustained 0 +ventricular 3 +tachyarrhythmias 4 +. 0 + +Eighty 0 +- 0 +one 0 +consecutive 0 +patients 0 +( 0 +54 0 +with 0 +coronary 3 +artery 4 +disease 4 +, 0 +and 0 +20 0 +with 0 +dilated 3 +cardiomyopathy 4 +) 0 +with 0 +inducible 0 +sustained 0 +ventricular 3 +tachycardia 4 +or 0 +ventricular 3 +fibrillation 4 +received 0 +oral 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +to 0 +prevent 0 +induction 0 +of 0 +the 0 +ventricular 3 +tachyarrhythmia 4 +. 0 + +During 0 +oral 0 +loading 0 +with 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +, 0 +continuous 0 +electrocardiographic 0 +( 0 +ECG 0 +) 0 +monitoring 0 +was 0 +performed 0 +. 0 + +Those 0 +patients 0 +in 0 +whom 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +prevented 0 +induction 0 +of 0 +ventricular 3 +tachycardia 4 +or 0 +ventricular 3 +fibrillation 4 +were 0 +discharged 0 +with 0 +the 0 +drug 0 +and 0 +followed 0 +up 0 +on 0 +an 0 +outpatient 0 +basis 0 +for 0 +21 0 ++ 0 +/ 0 +- 0 +18 0 +months 0 +. 0 + +Induction 0 +of 0 +the 0 +ventricular 3 +tachyarrhythmia 4 +was 0 +prevented 0 +by 0 +oral 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +in 0 +35 0 +( 0 +43 0 +% 0 +) 0 +patients 0 +; 0 +the 0 +ventricular 3 +tachyarrhythmia 4 +remained 0 +inducible 0 +in 0 +40 0 +( 0 +49 0 +% 0 +) 0 +patients 0 +; 0 +and 0 +two 0 +( 0 +2 0 +. 0 +5 0 +% 0 +) 0 +patients 0 +did 0 +not 0 +tolerate 0 +even 0 +40 0 +mg 0 +of 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +once 0 +daily 0 +. 0 + +Four 0 +( 0 +5 0 +% 0 +) 0 +patients 0 +had 0 +from 0 +torsades 3 +de 4 +pointes 4 +during 0 +the 0 +initial 0 +oral 0 +treatment 0 +with 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +. 0 + +Neither 0 +ECG 0 +[ 0 +sinus 0 +- 0 +cycle 0 +length 0 +( 0 +SCL 0 +) 0 +, 0 +QT 0 +or 0 +QTc 0 +interval 0 +, 0 +or 0 +U 0 +wave 0 +] 0 +nor 0 +clinical 0 +parameters 0 +identified 0 +patients 0 +at 0 +risk 0 +for 0 +torsades 3 +de 4 +pointes 4 +. 0 + +However 0 +, 0 +the 0 +oral 0 +dose 0 +of 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +was 0 +significantly 0 +lower 0 +in 0 +patients 0 +with 0 +torsades 3 +de 4 +pointes 4 +( 0 +200 0 ++ 0 +/ 0 +- 0 +46 0 +vs 0 +. 0 +328 0 ++ 0 +/ 0 +- 0 +53 0 +mg 0 +/ 0 +day 0 +; 0 +p 0 += 0 +0 0 +. 0 +0017 0 +) 0 +. 0 + +Risk 0 +factors 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +torsades 3 +de 4 +pointes 4 +were 0 +the 0 +appearance 0 +of 0 +an 0 +U 0 +wave 0 +( 0 +p 0 += 0 +0 0 +. 0 +049 0 +) 0 +, 0 +female 0 +gender 0 +( 0 +p 0 += 0 +0 0 +. 0 +015 0 +) 0 +, 0 +and 0 +significant 0 +dose 0 +- 0 +corrected 0 +changes 0 +of 0 +SCL 0 +, 0 +QT 0 +interval 0 +, 0 +and 0 +QTc 0 +interval 0 +( 0 +p 0 +< 0 +0 0 +. 0 +05 0 +) 0 +. 0 + +During 0 +follow 0 +- 0 +up 0 +, 0 +seven 0 +( 0 +20 0 +% 0 +) 0 +patients 0 +had 0 +a 0 +nonfatal 0 +ventricular 3 +tachycardia 4 +recurrence 0 +, 0 +and 0 +two 0 +( 0 +6 0 +% 0 +) 0 +patients 0 +died 0 +suddenly 0 +. 0 + +0ne 0 +female 0 +patient 0 +with 0 +stable 0 +cardiac 3 +disease 4 +had 0 +recurrent 0 +torsades 3 +de 4 +pointes 4 +after 0 +2 0 +years 0 +of 0 +successful 0 +treatment 0 +with 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +. 0 + +Torsades 3 +de 4 +pointes 4 +occurred 0 +early 0 +during 0 +treatment 0 +even 0 +with 0 +low 0 +doses 0 +of 0 +oral 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +. 0 + +Pronounced 0 +changes 0 +in 0 +the 0 +surface 0 +ECG 0 +( 0 +cycle 0 +length 0 +, 0 +QT 0 +, 0 +and 0 +QTc 0 +) 0 +in 0 +relation 0 +to 0 +the 0 +dose 0 +of 0 +oral 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +might 0 +identify 0 +a 0 +subgroup 0 +of 0 +patients 0 +with 0 +an 0 +increased 0 +risk 0 +for 0 +torsades 3 +de 4 +pointes 4 +. 0 + +0ther 0 +ECG 0 +parameters 0 +before 0 +the 0 +application 0 +of 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +did 0 +not 0 +identify 0 +patients 0 +at 0 +increased 0 +risk 0 +for 0 +torsades 3 +de 4 +pointes 4 +. 0 + +Recurrence 0 +rates 0 +of 0 +ventricular 3 +tachyarrhythmias 4 +are 0 +high 0 +despite 0 +complete 0 +suppression 0 +of 0 +the 0 +arrhythmia 3 +during 0 +programmed 0 +stimulation 0 +. 0 + +Therefore 0 +programmed 0 +electrical 0 +stimulation 0 +in 0 +the 0 +case 0 +of 0 +d 1 +, 2 +l 2 +- 2 +sotalol 2 +seems 0 +to 0 +be 0 +of 0 +limited 0 +prognostic 0 +value 0 +. 0 + +Chronic 0 +hyperprolactinemia 3 +and 0 +changes 0 +in 0 +dopamine 1 +neurons 0 +. 0 + +The 0 +tuberoinfundibular 0 +dopaminergic 0 +( 0 +TIDA 0 +) 0 +system 0 +is 0 +known 0 +to 0 +inhibit 0 +prolactin 0 +( 0 +PRL 0 +) 0 +secretion 0 +. 0 + +In 0 +young 0 +animals 0 +this 0 +system 0 +responds 0 +to 0 +acute 0 +elevations 0 +in 0 +serum 0 +PRL 0 +by 0 +increasing 0 +its 0 +activity 0 +. 0 + +However 0 +, 0 +this 0 +responsiveness 0 +is 0 +lost 0 +in 0 +aging 0 +rats 0 +with 0 +chronically 0 +high 0 +serum 0 +PRL 0 +levels 0 +. 0 + +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +induce 0 +hyperprolactinemia 3 +in 0 +rats 0 +for 0 +extended 0 +periods 0 +of 0 +time 0 +and 0 +examine 0 +its 0 +effects 0 +on 0 +dopaminergic 0 +systems 0 +in 0 +the 0 +brain 0 +. 0 + +Hyperprolactinemia 3 +was 0 +induced 0 +by 0 +treatment 0 +with 0 +haloperidol 1 +, 0 +a 0 +dopamine 1 +receptor 0 +antagonist 0 +, 0 +and 0 +Palkovits 0 +' 0 +microdissection 0 +technique 0 +in 0 +combination 0 +with 0 +high 0 +- 0 +performance 0 +liquid 0 +chromatography 0 +was 0 +used 0 +to 0 +measure 0 +neurotransmitter 0 +concentrations 0 +in 0 +several 0 +areas 0 +of 0 +the 0 +brain 0 +. 0 + +After 0 +6 0 +months 0 +of 0 +hyperprolactinemia 3 +, 0 +dopamine 1 +( 0 +DA 1 +) 0 +concentrations 0 +in 0 +the 0 +median 0 +eminence 0 +( 0 +ME 0 +) 0 +increased 0 +by 0 +84 0 +% 0 +over 0 +the 0 +control 0 +group 0 +. 0 + +Nine 0 +months 0 +of 0 +hyperprolactinemia 3 +produced 0 +a 0 +50 0 +% 0 +increase 0 +in 0 +DA 1 +concentrations 0 +in 0 +the 0 +ME 0 +over 0 +the 0 +control 0 +group 0 +. 0 + +However 0 +, 0 +DA 1 +response 0 +was 0 +lost 0 +if 0 +a 0 +9 0 +- 0 +month 0 +long 0 +haloperidol 1 +- 0 +induced 0 +hyperprolactinemia 3 +was 0 +followed 0 +by 0 +a 0 +1 0 +1 0 +/ 0 +2 0 +month 0 +- 0 +long 0 +extremely 0 +high 0 +increase 0 +in 0 +serum 0 +PRL 0 +levels 0 +produced 0 +by 0 +implantation 0 +of 0 +MMQ 0 +cells 0 +under 0 +the 0 +kidney 0 +capsule 0 +. 0 + +There 0 +was 0 +no 0 +change 0 +in 0 +the 0 +levels 0 +of 0 +DA 1 +, 0 +norepinephrine 1 +( 0 +NE 1 +) 0 +, 0 +serotonin 1 +( 0 +5 1 +- 2 +HT 2 +) 0 +, 0 +or 0 +their 0 +metabolites 0 +in 0 +the 0 +arcuate 0 +nucleus 0 +( 0 +AN 0 +) 0 +, 0 +medial 0 +preoptic 0 +area 0 +( 0 +MPA 0 +) 0 +, 0 +caudate 0 +putamen 0 +( 0 +CP 0 +) 0 +, 0 +substantia 0 +nigra 0 +( 0 +SN 0 +) 0 +, 0 +and 0 +zona 0 +incerta 0 +( 0 +ZI 0 +) 0 +, 0 +except 0 +for 0 +a 0 +decrease 0 +in 0 +5 1 +- 2 +hydroxyindoleacetic 2 +acid 2 +( 0 +5 1 +- 2 +HIAA 2 +) 0 +in 0 +the 0 +AN 0 +after 0 +6 0 +- 0 +months 0 +of 0 +hyperprolactinemia 3 +and 0 +an 0 +increase 0 +in 0 +DA 1 +concentrations 0 +in 0 +the 0 +AN 0 +after 0 +9 0 +- 0 +months 0 +of 0 +hyperprolactinemia 3 +. 0 + +These 0 +results 0 +demonstrate 0 +that 0 +hyperprolactinemia 3 +specifically 0 +affects 0 +TIDA 0 +neurons 0 +and 0 +these 0 +effects 0 +vary 0 +, 0 +depending 0 +on 0 +the 0 +duration 0 +and 0 +intensity 0 +of 0 +hyperprolactinemia 3 +. 0 + +The 0 +age 0 +- 0 +related 0 +decrease 0 +in 0 +hypothalamic 0 +dopamine 1 +function 0 +may 0 +be 0 +associated 0 +with 0 +increases 0 +in 0 +PRL 0 +secretion 0 +. 0 + +Treatment 0 +- 0 +related 0 +disseminated 0 +necrotizing 0 +leukoencephalopathy 3 +with 0 +characteristic 0 +contrast 0 +enhancement 0 +of 0 +the 0 +white 0 +matter 0 +. 0 + +This 0 +report 0 +describes 0 +unique 0 +contrast 0 +enhancement 0 +of 0 +the 0 +white 0 +matter 0 +on 0 +T1 0 +- 0 +weighted 0 +magnetic 0 +resonance 0 +images 0 +of 0 +two 0 +patients 0 +with 0 +disseminated 0 +necrotizing 0 +leukoencephalopathy 3 +, 0 +which 0 +developed 0 +from 0 +acute 3 +lymphoblastic 4 +leukemia 4 +treated 0 +with 0 +high 0 +- 0 +dose 0 +methotrexate 1 +. 0 + +In 0 +both 0 +patients 0 +, 0 +the 0 +enhancement 0 +was 0 +more 0 +pronounced 0 +near 0 +the 0 +base 0 +of 0 +the 0 +brain 0 +than 0 +at 0 +the 0 +vertex 0 +. 0 + +Necropsy 0 +of 0 +the 0 +first 0 +case 0 +revealed 0 +loss 3 +of 4 +myelination 4 +and 0 +necrosis 3 +of 0 +the 0 +white 0 +matter 0 +. 0 + +Possible 0 +mechanisms 0 +causing 0 +such 0 +a 0 +leukoencephalopathy 3 +are 0 +discussed 0 +. 0 + +Thrombotic 3 +complications 0 +in 0 +acute 3 +promyelocytic 4 +leukemia 4 +during 0 +all 1 +- 2 +trans 2 +- 2 +retinoic 2 +acid 2 +therapy 0 +. 0 + +A 0 +case 0 +of 0 +acute 3 +renal 4 +failure 4 +, 0 +due 0 +to 0 +occlusion 3 +of 4 +renal 4 +vessels 4 +in 0 +a 0 +patient 0 +with 0 +acute 3 +promyelocytic 4 +leukemia 4 +( 0 +APL 3 +) 0 +treated 0 +with 0 +all 1 +- 2 +trans 2 +- 2 +retinoic 2 +acid 2 +( 0 +ATRA 1 +) 0 +and 0 +tranexamic 1 +acid 2 +has 0 +been 0 +described 0 +recently 0 +. 0 + +We 0 +report 0 +a 0 +case 0 +of 0 +acute 3 +renal 4 +failure 4 +in 0 +an 0 +APL 3 +patient 0 +treated 0 +with 0 +ATRA 1 +alone 0 +. 0 + +This 0 +case 0 +further 0 +supports 0 +the 0 +concern 0 +about 0 +thromboembolic 3 +complications 0 +associated 0 +with 0 +ATRA 1 +therapy 0 +in 0 +APL 3 +patients 0 +. 0 + +The 0 +patients 0 +, 0 +a 0 +43 0 +- 0 +year 0 +- 0 +old 0 +man 0 +, 0 +presented 0 +all 0 +the 0 +signs 0 +and 0 +symptoms 0 +of 0 +APL 3 +and 0 +was 0 +included 0 +in 0 +a 0 +treatment 0 +protocol 0 +with 0 +ATRA 1 +. 0 + +After 0 +10 0 +days 0 +of 0 +treatment 0 +, 0 +he 0 +developed 0 +acute 3 +renal 4 +failure 4 +that 0 +was 0 +completely 0 +reversible 0 +after 0 +complete 0 +remission 0 +of 0 +APL 3 +was 0 +achieved 0 +and 0 +therapy 0 +discontinued 0 +. 0 + +We 0 +conclude 0 +that 0 +ATRA 1 +is 0 +a 0 +valid 0 +therapeutic 0 +choice 0 +for 0 +patients 0 +with 0 +APL 3 +, 0 +although 0 +the 0 +procoagulant 0 +tendency 0 +is 0 +not 0 +completely 0 +corrected 0 +. 0 + +Thrombotic 3 +events 0 +, 0 +however 0 +, 0 +could 0 +be 0 +avoided 0 +by 0 +using 0 +low 0 +- 0 +dose 0 +heparin 1 +. 0 + +Pupillary 0 +changes 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +stimulant 0 +- 0 +induced 0 +mania 3 +: 0 +a 0 +case 0 +report 0 +. 0 + +A 0 +30 0 +- 0 +year 0 +- 0 +old 0 +cocaine 1 +- 0 +dependent 0 +man 0 +who 0 +was 0 +a 0 +subject 0 +in 0 +a 0 +study 0 +evaluating 0 +the 0 +anticraving 0 +efficacy 0 +of 0 +the 0 +stimulant 0 +medication 0 +diethylpropion 1 +( 0 +DEP 1 +) 0 +became 0 +manic 3 +during 0 +his 0 +second 0 +week 0 +on 0 +the 0 +study 0 +drug 0 +. 0 + +Pupillometric 0 +changes 0 +while 0 +on 0 +DEP 1 +, 0 +especially 0 +changes 0 +in 0 +the 0 +total 0 +power 0 +of 0 +pupillary 3 +oscillation 4 +, 0 +were 0 +dramatically 0 +different 0 +than 0 +those 0 +observed 0 +in 0 +the 0 +eight 0 +other 0 +study 0 +subjects 0 +who 0 +did 0 +not 0 +become 0 +manic 3 +. 0 + +The 0 +large 0 +changes 0 +in 0 +total 0 +power 0 +of 0 +pupillary 3 +oscillation 4 +occurred 0 +a 0 +few 0 +days 0 +before 0 +the 0 +patient 0 +became 0 +fully 0 +manic 3 +. 0 + +Such 0 +medication 0 +- 0 +associated 0 +changes 0 +in 0 +the 0 +total 0 +power 0 +of 0 +pupillary 3 +oscillation 4 +might 0 +be 0 +of 0 +utility 0 +in 0 +identifying 0 +persons 0 +at 0 +risk 0 +for 0 +manic 3 +- 0 +like 0 +adverse 0 +effects 0 +during 0 +the 0 +medical 0 +use 0 +of 0 +psychomotor 0 +stimulants 0 +or 0 +sympathomimetic 0 +agents 0 +. 0 + +Fetal 0 +risks 0 +due 0 +to 0 +warfarin 1 +therapy 0 +during 0 +pregnancy 0 +. 0 + +Two 0 +mothers 0 +with 0 +heart 0 +valve 0 +prosthesis 0 +were 0 +treated 0 +with 0 +warfarin 1 +during 0 +pregnancy 0 +. 0 + +In 0 +the 0 +first 0 +case 0 +a 0 +caesarean 0 +section 0 +was 0 +done 0 +one 0 +week 0 +after 0 +replacement 0 +of 0 +warfarin 1 +with 0 +heparin 1 +. 0 + +The 0 +baby 0 +died 0 +of 0 +cerebral 3 +and 4 +pulmonary 4 +hemorrhage 4 +. 0 + +The 0 +second 0 +mother 0 +had 0 +a 0 +male 0 +infant 0 +by 0 +caesarean 0 +section 0 +. 0 + +The 0 +baby 0 +showed 0 +warfarin 1 +- 0 +induced 0 +embryopathy 3 +with 0 +nasal 3 +hypoplasia 4 +and 0 +stippled 3 +epiphyses 4 +( 0 +chondrodysplasia 3 +punctata 4 +) 0 +. 0 + +Nasal 3 +hypoplasia 4 +with 0 +or 0 +without 0 +stippled 3 +epiphyses 4 +has 0 +now 0 +been 0 +reported 0 +in 0 +11 0 +infants 0 +born 0 +to 0 +mothers 0 +treated 0 +with 0 +warfarin 1 +during 0 +the 0 +first 0 +trimester 0 +, 0 +and 0 +a 0 +causal 0 +association 0 +is 0 +probable 0 +. 0 + +In 0 +view 0 +of 0 +the 0 +risks 0 +to 0 +both 0 +mother 0 +and 0 +fetus 0 +in 0 +women 0 +with 0 +prosthetic 0 +cardiac 0 +valves 0 +it 0 +is 0 +recommended 0 +that 0 +therapeutic 0 +abortion 0 +be 0 +advised 0 +as 0 +the 0 +first 0 +alternative 0 +. 0 + +The 0 +negative 0 +mucosal 0 +potential 0 +: 0 +separating 0 +central 0 +and 0 +peripheral 0 +effects 0 +of 0 +NSAIDs 0 +in 0 +man 0 +. 0 + +0BJECTIVE 0 +: 0 +We 0 +wanted 0 +to 0 +test 0 +whether 0 +assessment 0 +of 0 +both 0 +a 0 +central 0 +pain 3 +- 0 +related 0 +signal 0 +( 0 +chemo 0 +- 0 +somatosensory 0 +evoked 0 +potential 0 +, 0 +CSSEP 0 +) 0 +and 0 +a 0 +concomitantly 0 +recorded 0 +peripheral 0 +signal 0 +( 0 +negative 0 +mucosal 0 +potential 0 +, 0 +NMP 0 +) 0 +allows 0 +for 0 +separation 0 +of 0 +central 0 +and 0 +peripheral 0 +effects 0 +of 0 +NSAIDs 0 +. 0 + +For 0 +this 0 +purpose 0 +, 0 +experimental 0 +conditions 0 +were 0 +created 0 +in 0 +which 0 +NSAIDs 0 +had 0 +previously 0 +been 0 +observed 0 +to 0 +produce 0 +effects 0 +on 0 +phasic 0 +and 0 +tonic 0 +pain 3 +by 0 +either 0 +central 0 +or 0 +peripheral 0 +mechanisms 0 +. 0 + +METH0DS 0 +: 0 +According 0 +to 0 +a 0 +double 0 +- 0 +blind 0 +, 0 +randomised 0 +, 0 +controlled 0 +, 0 +threefold 0 +cross 0 +- 0 +over 0 +design 0 +, 0 +18 0 +healthy 0 +subjects 0 +( 0 +11 0 +males 0 +, 0 +7 0 +females 0 +; 0 +mean 0 +age 0 +26 0 +years 0 +) 0 +received 0 +either 0 +placebo 0 +, 0 +400 0 +mg 0 +ibuprofen 1 +, 0 +or 0 +800 0 +mg 0 +ibuprofen 1 +. 0 + +Phasic 0 +pain 3 +was 0 +applied 0 +by 0 +means 0 +of 0 +short 0 +pulses 0 +of 0 +C02 1 +to 0 +the 0 +nasal 0 +mucosa 0 +( 0 +stimulus 0 +duration 0 +500 0 +ms 0 +, 0 +interval 0 +approximately 0 +60 0 +s 0 +) 0 +, 0 +and 0 +tonic 0 +pain 3 +was 0 +induced 0 +in 0 +the 0 +nasal 0 +cavity 0 +by 0 +means 0 +of 0 +dry 0 +air 0 +of 0 +controlled 0 +temperature 0 +, 0 +humidity 0 +and 0 +flow 0 +rate 0 +( 0 +22 0 +degrees 0 +C 0 +, 0 +0 0 +% 0 +relative 0 +humidity 0 +, 0 +145 0 +ml 0 +. 0 +s 0 +- 0 +1 0 +) 0 +. 0 + +Both 0 +CSSEPs 0 +as 0 +central 0 +and 0 +NMPs 0 +as 0 +peripheral 0 +correlates 0 +of 0 +pain 3 +were 0 +obtained 0 +in 0 +response 0 +to 0 +the 0 +C02 1 +stimuli 0 +. 0 + +Additionally 0 +, 0 +the 0 +subjects 0 +rated 0 +the 0 +intensity 0 +of 0 +both 0 +phasic 0 +and 0 +tonic 0 +pain 3 +by 0 +means 0 +of 0 +visual 0 +analogue 0 +scales 0 +. 0 + +RESULTS 0 +: 0 +As 0 +described 0 +earlier 0 +, 0 +administration 0 +of 0 +ibuprofen 1 +was 0 +followed 0 +by 0 +a 0 +decrease 0 +in 0 +tonic 0 +pain 3 +but 0 +- 0 +relative 0 +to 0 +placebo 0 +- 0 +an 0 +increase 0 +in 0 +correlates 0 +of 0 +phasic 0 +pain 3 +, 0 +indicating 0 +a 0 +specific 0 +effect 0 +of 0 +ibuprofen 1 +on 0 +the 0 +interaction 0 +between 0 +the 0 +pain 3 +stimuli 0 +under 0 +these 0 +special 0 +experimental 0 +conditions 0 +. 0 + +Based 0 +on 0 +the 0 +similar 0 +behaviour 0 +of 0 +CSSEP 0 +and 0 +NMP 0 +, 0 +it 0 +was 0 +concluded 0 +that 0 +the 0 +pharmacological 0 +process 0 +underlying 0 +this 0 +phenomenon 0 +was 0 +localised 0 +in 0 +the 0 +periphery 0 +. 0 + +By 0 +means 0 +of 0 +the 0 +simultaneous 0 +recording 0 +of 0 +interrelated 0 +peripheral 0 +and 0 +central 0 +electrophysiologic 0 +correlates 0 +of 0 +nociception 0 +, 0 +it 0 +was 0 +possible 0 +to 0 +separate 0 +central 0 +and 0 +peripheral 0 +effects 0 +of 0 +an 0 +NSAID 0 +. 0 + +The 0 +major 0 +advantage 0 +of 0 +this 0 +pain 3 +model 0 +is 0 +the 0 +possibility 0 +of 0 +obtaining 0 +peripheral 0 +pain 3 +- 0 +related 0 +activity 0 +directly 0 +using 0 +a 0 +non 0 +- 0 +invasive 0 +technique 0 +in 0 +humans 0 +. 0 + +Effect 0 +of 0 +D 1 +- 2 +Glucarates 2 +on 0 +basic 0 +antibiotic 0 +- 0 +induced 0 +renal 3 +damage 4 +in 0 +rats 0 +. 0 + +Dehydrated 3 +rats 0 +regularly 0 +develop 0 +acute 3 +renal 4 +failure 4 +following 0 +single 0 +injection 0 +of 0 +aminoglycoside 1 +antibiotics 0 +combined 0 +with 0 +dextran 0 +or 0 +of 0 +antibiotics 0 +only 0 +. 0 + +0ral 0 +administration 0 +of 0 +2 1 +, 2 +5 2 +- 2 +di 2 +- 2 +0 2 +- 2 +acetyl 2 +- 2 +D 2 +- 2 +glucaro 2 +- 2 +1 2 +, 2 +4 2 +- 2 +6 2 +, 2 +3 2 +- 2 +dilactone 2 +protected 0 +rats 0 +against 0 +renal 3 +failure 4 +induced 0 +by 0 +kanamycin 1 +- 0 +dextran 0 +. 0 + +The 0 +protective 0 +effect 0 +was 0 +prevalent 0 +among 0 +D 1 +- 2 +glucarates 2 +, 0 +and 0 +also 0 +to 0 +other 0 +saccharic 1 +acid 2 +, 0 +hexauronic 1 +acids 2 +and 0 +hexaaldonic 1 +acids 2 +, 0 +although 0 +to 0 +a 0 +lesser 0 +degree 0 +, 0 +but 0 +not 0 +to 0 +a 0 +hexaaldose 0 +, 0 +sugar 1 +alcohols 2 +, 0 +substances 0 +inthe 0 +TCA 1 +cycle 0 +and 0 +other 0 +acidic 0 +compounds 0 +. 0 + +D 1 +- 2 +Glucarates 2 +were 0 +effective 0 +against 0 +renal 3 +damage 4 +induced 0 +by 0 +peptide 0 +antibiotics 0 +as 0 +well 0 +as 0 +various 0 +aminoglycoside 1 +antibitocis 0 +. 0 + +Dose 0 +- 0 +responses 0 +were 0 +observed 0 +in 0 +the 0 +protective 0 +effect 0 +of 0 +D 1 +- 2 +Glucarates 2 +. 0 + +With 0 +a 0 +D 1 +- 2 +glucarate 2 +of 0 +a 0 +fixed 0 +size 0 +of 0 +dose 0 +, 0 +approximately 0 +the 0 +same 0 +degree 0 +of 0 +protection 0 +was 0 +obtained 0 +against 0 +renal 3 +damages 4 +induced 0 +by 0 +different 0 +basic 0 +antibiotics 0 +despite 0 +large 0 +disparities 0 +in 0 +administration 0 +doses 0 +of 0 +different 0 +antibiotics 0 +. 0 + +D 1 +- 2 +Glucarates 2 +had 0 +the 0 +ability 0 +to 0 +prevent 0 +renal 3 +damage 4 +but 0 +not 0 +to 0 +cure 0 +it 0 +. 0 + +Rats 0 +excreted 0 +acidic 0 +urine 0 +when 0 +they 0 +were 0 +spared 0 +from 0 +renal 3 +lesions 4 +by 0 +monosaccharides 1 +. 0 + +The 0 +reduction 0 +effect 0 +of 0 +D 1 +- 2 +glucarates 2 +against 0 +nephrotoxicity 3 +of 0 +basic 0 +antibiotics 0 +was 0 +discussed 0 +. 0 + +Acute 0 +severe 0 +depression 3 +following 0 +peri 0 +- 0 +operative 0 +ondansetron 1 +. 0 + +A 0 +41 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +a 0 +strong 0 +history 0 +of 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +presented 0 +for 0 +abdominal 0 +hysterectomy 0 +3 0 +months 0 +after 0 +a 0 +previous 0 +anaesthetic 0 +where 0 +ondansetron 1 +prophylaxis 0 +had 0 +been 0 +used 0 +. 0 + +She 0 +had 0 +developed 0 +a 0 +severe 0 +acute 0 +major 3 +depression 4 +disorder 4 +almost 0 +immediately 0 +thereafter 0 +, 0 +possibly 0 +related 0 +to 0 +the 0 +use 0 +of 0 +a 0 +serotonin 1 +antagonist 0 +. 0 + +Nine 0 +years 0 +before 0 +she 0 +had 0 +experienced 0 +a 0 +self 0 +- 0 +limited 0 +puerperal 0 +depressive 3 +episode 4 +. 0 + +Anaesthesia 0 +with 0 +a 0 +propofol 1 +infusion 0 +and 0 +avoidance 0 +of 0 +serotonin 1 +antagonists 0 +provided 0 +a 0 +nausea 3 +- 0 +free 0 +postoperative 0 +course 0 +without 0 +exacerbation 0 +of 0 +the 0 +depression 3 +disorder 4 +. 0 + +Hypertensive 3 +response 0 +during 0 +dobutamine 1 +stress 0 +echocardiography 0 +. 0 + +Among 0 +3 0 +, 0 +129 0 +dobutamine 1 +stress 0 +echocardiographic 0 +studies 0 +, 0 +a 0 +hypertensive 3 +response 0 +, 0 +defined 0 +as 0 +systolic 0 +blood 0 +pressure 0 +( 0 +BP 0 +) 0 +> 0 +or 0 += 0 +220 0 +mm 0 +Hg 0 +and 0 +/ 0 +or 0 +diastolic 0 +BP 0 +> 0 +or 0 += 0 +110 0 +mm 0 +Hg 0 +, 0 +occurred 0 +in 0 +30 0 +patients 0 +( 0 +1 0 +% 0 +) 0 +. 0 + +Patients 0 +with 0 +this 0 +response 0 +more 0 +often 0 +had 0 +a 0 +history 0 +of 0 +hypertension 3 +and 0 +had 0 +higher 0 +resting 0 +systolic 0 +and 0 +diastolic 0 +BP 0 +before 0 +dobutamine 1 +infusion 0 +. 0 + +Continuously 0 +nebulized 0 +albuterol 1 +in 0 +severe 0 +exacerbations 0 +of 0 +asthma 3 +in 0 +adults 0 +: 0 +a 0 +case 0 +- 0 +controlled 0 +study 0 +. 0 + +A 0 +retrospective 0 +, 0 +case 0 +- 0 +controlled 0 +analysis 0 +comparing 0 +patients 0 +admitted 0 +to 0 +a 0 +medical 0 +intensive 0 +care 0 +unit 0 +with 0 +severe 0 +exacerbations 0 +of 0 +asthma 3 +who 0 +received 0 +continuously 0 +nebulized 0 +albuterol 1 +( 0 +CNA 0 +) 0 +versus 0 +intermittent 0 +albuterol 1 +( 0 +INA 0 +) 0 +treatments 0 +is 0 +reported 0 +. 0 + +Forty 0 +matched 0 +pairs 0 +of 0 +patients 0 +with 0 +asthma 3 +are 0 +compared 0 +. 0 + +CNA 0 +was 0 +administered 0 +for 0 +a 0 +mean 0 +of 0 +11 0 ++ 0 +/ 0 +- 0 +10 0 +hr 0 +. 0 + +The 0 +incidence 0 +of 0 +cardiac 3 +dysrhythmias 4 +was 0 +similar 0 +between 0 +groups 0 +. 0 + +Symptomatic 0 +hypokalemia 3 +did 0 +not 0 +occur 0 +. 0 + +CNA 0 +patients 0 +had 0 +higher 0 +heart 0 +rates 0 +during 0 +treatment 0 +, 0 +which 0 +may 0 +reflect 0 +severity 0 +of 0 +illness 0 +. 0 + +The 0 +incidence 0 +of 0 +intubation 0 +was 0 +similar 0 +. 0 + +We 0 +conclude 0 +that 0 +CNA 0 +and 0 +INA 0 +demonstrated 0 +similar 0 +profiles 0 +with 0 +regard 0 +to 0 +safety 0 +, 0 +morbidity 0 +, 0 +and 0 +mortality 0 +. 0 + +Paraplegia 3 +following 0 +intrathecal 0 +methotrexate 1 +: 0 +report 0 +of 0 +a 0 +case 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 + +A 0 +patient 0 +who 0 +developed 0 +paraplegia 3 +following 0 +the 0 +intrathecal 0 +instillation 0 +of 0 +methotrexate 1 +is 0 +discribed 0 +. 0 + +The 0 +ten 0 +previously 0 +reported 0 +cases 0 +of 0 +this 0 +unusual 0 +complication 0 +are 0 +reviewed 0 +. 0 + +The 0 +following 0 +factors 0 +appear 0 +to 0 +predispose 0 +to 0 +the 0 +development 0 +of 0 +this 0 +complication 0 +: 0 +abnormal 0 +cerebrospinal 0 +dynamics 0 +related 0 +to 0 +the 0 +presence 0 +of 0 +central 3 +nervous 4 +system 4 +leukemia 4 +, 0 +and 0 +epidural 0 +cerebrospinal 0 +leakage 0 +; 0 +elevated 0 +cerebrospinal 0 +fluid 0 +methothexate 1 +concentration 0 +related 0 +to 0 +abnormal 0 +cerebrospinal 0 +fluid 0 +dynamics 0 +and 0 +to 0 +inappropriately 0 +high 0 +methotrexate 1 +doses 0 +based 0 +on 0 +body 0 +surface 0 +area 0 +calculations 0 +in 0 +older 0 +children 0 +and 0 +adults 0 +; 0 +the 0 +presence 0 +of 0 +neurotoxic 3 +preservatives 0 +in 0 +commercially 0 +available 0 +methotrexate 1 +preparations 0 +and 0 +diluents 0 +; 0 +and 0 +the 0 +use 0 +of 0 +methotrexate 1 +diluents 0 +of 0 +unphysiologic 0 +pH 0 +, 0 +ionic 0 +content 0 +and 0 +osmolarity 0 +. 0 + +The 0 +role 0 +of 0 +methotrexate 1 +contaminants 0 +, 0 +local 0 +folate 3 +deficiency 4 +, 0 +and 0 +cranial 0 +irradiation 0 +in 0 +the 0 +pathogenesis 0 +of 0 +intrathecal 0 +methotrexate 1 +toxicity 3 +is 0 +unclear 0 +. 0 + +The 0 +incidence 0 +of 0 +neurotoxicity 3 +may 0 +be 0 +reduced 0 +by 0 +employing 0 +lower 0 +doses 0 +of 0 +methotrexate 1 +in 0 +the 0 +presence 0 +of 0 +central 3 +nervous 4 +system 4 +leukemia 4 +, 0 +in 0 +older 0 +children 0 +and 0 +adults 0 +, 0 +and 0 +in 0 +the 0 +presence 0 +of 0 +epidural 0 +leakage 0 +. 0 + +0nly 0 +preservative 0 +- 0 +free 0 +methotrexate 1 +in 0 +Elliott 0 +' 0 +s 0 +B 0 +Solution 0 +at 0 +a 0 +concentration 0 +of 0 +not 0 +more 0 +than 0 +1 0 +mg 0 +/ 0 +ml 0 +should 0 +be 0 +used 0 +for 0 +intrathecal 0 +administration 0 +. 0 + +Periodic 0 +monitoring 0 +of 0 +cerebruspinal 0 +fluid 0 +methotrexate 1 +levels 0 +may 0 +be 0 +predictive 0 +of 0 +the 0 +development 0 +of 0 +serious 0 +neurotoxicity 3 +. 0 + +Hyperosmolar 3 +nonketotic 4 +coma 4 +precipitated 0 +by 0 +lithium 1 +- 0 +induced 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +. 0 + +A 0 +45 0 +- 0 +year 0 +- 0 +old 0 +man 0 +, 0 +with 0 +a 0 +10 0 +- 0 +year 0 +history 0 +of 0 +manic 3 +depression 4 +treated 0 +with 0 +lithium 1 +, 0 +was 0 +admitted 0 +with 0 +hyperosmolar 3 +, 4 +nonketotic 4 +coma 4 +. 0 + +He 0 +gave 0 +a 0 +five 0 +- 0 +year 0 +history 0 +of 0 +polyuria 3 +and 0 +polydipsia 3 +, 0 +during 0 +which 0 +time 0 +urinalysis 0 +had 0 +been 0 +negative 0 +for 0 +glucose 1 +. 0 + +After 0 +recovery 0 +from 0 +hyperglycaemia 3 +, 0 +he 0 +remained 0 +polyuric 3 +despite 0 +normal 0 +blood 0 +glucose 1 +concentrations 0 +; 0 +water 0 +deprivation 0 +testing 0 +indicated 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +, 0 +likely 0 +to 0 +be 0 +lithium 1 +- 0 +induced 0 +. 0 + +We 0 +hypothesize 0 +that 0 +when 0 +this 0 +man 0 +developed 0 +type 3 +2 4 +diabetes 4 +, 0 +chronic 0 +polyuria 3 +due 0 +to 0 +nephrogenic 3 +diabetes 4 +insipidus 4 +was 0 +sufficient 0 +to 0 +precipitate 0 +hyperosmolar 0 +dehydration 3 +. 0 + +Effects 0 +of 0 +the 0 +intracoronary 0 +infusion 0 +of 0 +cocaine 1 +on 0 +left 0 +ventricular 0 +systolic 0 +and 0 +diastolic 0 +function 0 +in 0 +humans 0 +. 0 + +BACKGR0UND 0 +: 0 +In 0 +dogs 0 +, 0 +a 0 +large 0 +amount 0 +of 0 +intravenous 0 +cocaine 1 +causes 0 +a 0 +profound 0 +deterioration 3 +of 4 +left 4 +ventricular 4 +( 4 +LV 4 +) 4 +systolic 4 +function 4 +and 0 +an 0 +increase 0 +in 0 +LV 0 +end 0 +- 0 +diastolic 0 +pressure 0 +. 0 + +This 0 +study 0 +was 0 +done 0 +to 0 +assess 0 +the 0 +influence 0 +of 0 +a 0 +high 0 +intracoronary 0 +cocaine 1 +concentration 0 +on 0 +LV 0 +systolic 0 +and 0 +diastolic 0 +function 0 +in 0 +humans 0 +. 0 + +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +In 0 +20 0 +patients 0 +( 0 +14 0 +men 0 +and 0 +6 0 +women 0 +aged 0 +39 0 +to 0 +72 0 +years 0 +) 0 +referred 0 +for 0 +cardiac 0 +catheterization 0 +for 0 +the 0 +evaluation 0 +of 0 +chest 3 +pain 4 +, 0 +we 0 +measured 0 +heart 0 +rate 0 +, 0 +systemic 0 +arterial 0 +pressure 0 +, 0 +LV 0 +pressure 0 +and 0 +its 0 +first 0 +derivative 0 +( 0 +dP 0 +/ 0 +dt 0 +) 0 +, 0 +and 0 +LV 0 +volumes 0 +and 0 +ejection 0 +fraction 0 +before 0 +and 0 +during 0 +the 0 +final 0 +2 0 +to 0 +3 0 +minutes 0 +of 0 +a 0 +15 0 +- 0 +minute 0 +intracoronary 0 +infusion 0 +of 0 +saline 0 +( 0 +n 0 += 0 +10 0 +, 0 +control 0 +subjects 0 +) 0 +or 0 +cocaine 1 +hydrochloride 2 +1 0 +mg 0 +/ 0 +min 0 +( 0 +n 0 += 0 +10 0 +) 0 +. 0 + +No 0 +variable 0 +changed 0 +with 0 +saline 0 +. 0 + +With 0 +cocaine 1 +, 0 +the 0 +drug 0 +concentration 0 +in 0 +blood 0 +obtained 0 +from 0 +the 0 +coronary 0 +sinus 0 +was 0 +3 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +mg 0 +/ 0 +L 0 +, 0 +similar 0 +in 0 +magnitude 0 +to 0 +the 0 +blood 0 +cocaine 1 +concentration 0 +reported 0 +in 0 +abusers 0 +dying 0 +of 0 +cocaine 1 +intoxication 0 +. 0 + +Cocaine 1 +induced 0 +no 0 +significant 0 +change 0 +in 0 +heart 0 +rate 0 +, 0 +LV 0 +dP 0 +/ 0 +dt 0 +( 0 +positive 0 +or 0 +negative 0 +) 0 +, 0 +or 0 +LV 0 +end 0 +- 0 +diastolic 0 +volume 0 +, 0 +but 0 +it 0 +caused 0 +an 0 +increase 0 +in 0 +systolic 0 +and 0 +mean 0 +arterial 0 +pressures 0 +, 0 +LV 0 +end 0 +- 0 +diastolic 0 +pressure 0 +, 0 +and 0 +LV 0 +end 0 +- 0 +systolic 0 +volume 0 +, 0 +as 0 +well 0 +as 0 +a 0 +decrease 0 +in 0 +LV 0 +ejection 0 +fraction 0 +. 0 + +C0NCLUSI0NS 0 +: 0 +In 0 +humans 0 +, 0 +the 0 +intracoronary 0 +infusion 0 +of 0 +cocaine 1 +sufficient 0 +in 0 +amount 0 +to 0 +achieve 0 +a 0 +high 0 +drug 0 +concentration 0 +in 0 +coronary 0 +sinus 0 +blood 0 +causes 0 +a 0 +deterioration 3 +of 4 +LV 4 +systolic 4 +and 4 +diastolic 4 +performance 4 +. 0 + +Ascending 0 +dose 0 +tolerance 0 +study 0 +of 0 +intramuscular 0 +carbetocin 1 +administered 0 +after 0 +normal 0 +vaginal 0 +birth 0 +. 0 + +0BJECTIVE 0 +: 0 +To 0 +determine 0 +the 0 +maximum 0 +tolerated 0 +dose 0 +( 0 +MTD 0 +) 0 +of 0 +carbetocin 1 +( 0 +a 0 +long 0 +- 0 +acting 0 +synthetic 0 +analogue 0 +of 0 +oxytocin 1 +) 0 +, 0 +when 0 +administered 0 +immediately 0 +after 0 +vaginal 0 +delivery 0 +at 0 +term 0 +. 0 + +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +Carbetocin 1 +was 0 +given 0 +as 0 +an 0 +intramuscular 0 +injection 0 +immediately 0 +after 0 +the 0 +birth 0 +of 0 +the 0 +infant 0 +in 0 +45 0 +healthy 0 +women 0 +with 0 +normal 0 +singleton 0 +pregnancies 0 +who 0 +delivered 0 +vaginally 0 +at 0 +term 0 +. 0 + +Dosage 0 +groups 0 +of 0 +15 0 +, 0 +30 0 +, 0 +50 0 +, 0 +75 0 +, 0 +100 0 +, 0 +125 0 +, 0 +150 0 +, 0 +175 0 +or 0 +200 0 +microg 0 +carbetocin 1 +were 0 +assigned 0 +to 0 +blocks 0 +of 0 +three 0 +women 0 +according 0 +to 0 +the 0 +continual 0 +reassessment 0 +method 0 +( 0 +CRM 0 +) 0 +. 0 + +RESULTS 0 +: 0 +All 0 +dosage 0 +groups 0 +consisted 0 +of 0 +three 0 +women 0 +, 0 +except 0 +those 0 +with 0 +100 0 +microg 0 +( 0 +n 0 += 0 +6 0 +) 0 +and 0 +200 0 +microg 0 +( 0 +n 0 += 0 +18 0 +) 0 +. 0 + +Recorded 0 +were 0 +dose 0 +- 0 +limiting 0 +adverse 0 +events 0 +: 0 +hyper 3 +- 4 +or 4 +hypotension 4 +( 0 +three 0 +) 0 +, 0 +severe 0 +abdominal 3 +pain 4 +( 0 +0 0 +) 0 +, 0 +vomiting 3 +( 0 +0 0 +) 0 +and 0 +retained 3 +placenta 4 +( 0 +four 0 +) 0 +. 0 + +Serious 0 +adverse 0 +events 0 +occurred 0 +in 0 +seven 0 +women 0 +: 0 +six 0 +cases 0 +with 0 +blood 3 +loss 4 +> 0 +or 0 += 0 +1000 0 +ml 0 +, 0 +four 0 +cases 0 +of 0 +manual 0 +placenta 0 +removal 0 +, 0 +five 0 +cases 0 +of 0 +additional 0 +oxytocics 0 +administration 0 +and 0 +five 0 +cases 0 +of 0 +blood 0 +transfusion 0 +. 0 + +Maximum 0 +blood 3 +loss 4 +was 0 +greatest 0 +at 0 +the 0 +upper 0 +and 0 +lower 0 +dose 0 +levels 0 +, 0 +and 0 +lowest 0 +in 0 +the 0 +70 0 +- 0 +125 0 +microg 0 +dose 0 +range 0 +. 0 + +Four 0 +out 0 +of 0 +six 0 +cases 0 +with 0 +blood 3 +loss 4 +> 0 +or 0 += 0 +1000 0 +ml 0 +occurred 0 +in 0 +the 0 +200 0 +microg 0 +group 0 +. 0 + +The 0 +majority 0 +of 0 +additional 0 +administration 0 +of 0 +oxytocics 0 +( 0 +4 0 +/ 0 +5 0 +) 0 +and 0 +blood 0 +transfusion 0 +( 0 +3 0 +/ 0 +5 0 +) 0 +occurred 0 +in 0 +the 0 +dose 0 +groups 0 +of 0 +200 0 +microg 0 +. 0 + +All 0 +retained 0 +placentae 0 +were 0 +found 0 +in 0 +the 0 +group 0 +of 0 +200 0 +microg 0 +. 0 + +C0NCLUSI0N 0 +: 0 +The 0 +MTD 0 +was 0 +calculated 0 +to 0 +be 0 +at 0 +200 0 +microg 0 +carbetocin 1 +. 0 + +Heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +, 0 +paradoxical 0 +thromboembolism 3 +, 0 +and 0 +other 0 +side 0 +effects 0 +of 0 +heparin 1 +therapy 0 +. 0 + +Although 0 +several 0 +new 0 +anticoagulant 0 +drugs 0 +are 0 +in 0 +development 0 +, 0 +heparin 1 +remains 0 +the 0 +drug 0 +of 0 +choice 0 +for 0 +most 0 +anticoagulation 0 +needs 0 +. 0 + +The 0 +clinical 0 +effects 0 +of 0 +heparin 1 +are 0 +meritorious 0 +, 0 +but 0 +side 0 +effects 0 +do 0 +exist 0 +. 0 + +Important 0 +untoward 0 +effects 0 +of 0 +heparin 1 +therapy 0 +including 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +, 0 +heparin 1 +- 0 +associated 0 +osteoporosis 3 +, 0 +eosinophilia 3 +, 0 +skin 3 +reactions 4 +, 0 +allergic 3 +reactions 4 +other 0 +than 0 +thrombocytopenia 3 +and 0 +alopecia 3 +will 0 +be 0 +discussed 0 +in 0 +this 0 +article 0 +. 0 + +Nonopaque 0 +crystal 0 +deposition 0 +causing 0 +ureteric 3 +obstruction 4 +in 0 +patients 0 +with 0 +HIV 0 +undergoing 0 +indinavir 1 +therapy 0 +. 0 + +0BJECTIVE 0 +: 0 +We 0 +describe 0 +the 0 +unique 0 +CT 0 +features 0 +of 0 +ureteric 3 +calculi 4 +in 0 +six 0 +HIV 3 +- 4 +infected 4 +patients 0 +receiving 0 +indinavir 1 +, 0 +the 0 +most 0 +commonly 0 +used 0 +HIV 0 +protease 0 +inhibitor 0 +, 0 +which 0 +is 0 +associated 0 +with 0 +an 0 +increased 0 +incidence 0 +of 0 +urolithiasis 3 +. 0 + +C0NCLUSI0N 0 +: 0 +Ureteric 3 +obstruction 4 +caused 0 +by 0 +precipitated 0 +indinavir 1 +crystals 0 +may 0 +be 0 +difficult 0 +to 0 +diagnose 0 +with 0 +unenhanced 0 +CT 0 +. 0 + +The 0 +calculi 0 +are 0 +not 0 +opaque 0 +, 0 +and 0 +secondary 0 +signs 0 +of 0 +obstruction 0 +may 0 +be 0 +absent 0 +or 0 +minimal 0 +and 0 +should 0 +be 0 +sought 0 +carefully 0 +. 0 + +Images 0 +may 0 +need 0 +to 0 +be 0 +obtained 0 +using 0 +i 0 +. 0 +v 0 +. 0 +contrast 0 +material 0 +to 0 +enable 0 +diagnosis 0 +of 0 +ureteric 3 +stones 4 +or 4 +obstruction 4 +in 0 +patients 0 +with 0 +HIV 3 +infection 4 +who 0 +receive 0 +indinavir 1 +therapy 0 +. 0 + +Ischemic 3 +colitis 4 +and 0 +sumatriptan 1 +use 0 +. 0 + +Sumatriptan 1 +succinate 2 +, 0 +a 0 +serotonin 1 +- 0 +1 0 +( 0 +5 1 +- 2 +hydroxytryptamine 2 +- 0 +1 0 +) 0 +receptor 0 +agonist 0 +, 0 +is 0 +an 0 +antimigraine 0 +drug 0 +that 0 +is 0 +reported 0 +to 0 +act 0 +by 0 +selectively 0 +constricting 0 +intracranial 0 +arteries 0 +. 0 + +Recently 0 +, 0 +vasopressor 0 +responses 0 +that 0 +are 0 +distinct 0 +from 0 +the 0 +cranial 0 +circulation 0 +have 0 +been 0 +demonstrated 0 +to 0 +occur 0 +in 0 +the 0 +systemic 0 +, 0 +pulmonary 0 +, 0 +and 0 +coronary 0 +circulations 0 +. 0 + +Cases 0 +have 0 +been 0 +published 0 +of 0 +coronary 3 +vasospasm 4 +, 0 +myocardial 3 +ischemia 4 +, 0 +and 0 +myocardial 3 +infarction 4 +occurring 0 +after 0 +sumatriptan 1 +use 0 +. 0 + +We 0 +report 0 +on 0 +the 0 +development 0 +of 0 +8 0 +serious 0 +cases 0 +of 0 +ischemic 3 +colitis 4 +in 0 +patients 0 +with 0 +migraine 3 +treated 0 +with 0 +sumatriptan 1 +. 0 + +Pallidotomy 0 +with 0 +the 0 +gamma 0 +knife 0 +: 0 +a 0 +positive 0 +experience 0 +. 0 + +51 0 +patients 0 +with 0 +medically 0 +refractory 0 +Parkinson 3 +' 4 +s 4 +disease 4 +underwent 0 +stereotactic 0 +posteromedial 0 +pallidotomy 0 +between 0 +August 0 +1993 0 +and 0 +February 0 +1997 0 +for 0 +treatment 0 +of 0 +bradykinesia 3 +, 0 +rigidity 3 +, 0 +and 0 +L 1 +- 2 +D0PA 2 +- 0 +induced 0 +dyskinesias 3 +. 0 + +In 0 +29 0 +patients 0 +, 0 +the 0 +pallidotomies 0 +were 0 +performed 0 +with 0 +the 0 +Leksell 0 +Gamma 0 +Knife 0 +and 0 +in 0 +22 0 +they 0 +were 0 +performed 0 +with 0 +the 0 +standard 0 +radiofrequency 0 +( 0 +RF 0 +) 0 +method 0 +. 0 + +Clinical 0 +assessment 0 +as 0 +well 0 +as 0 +blinded 0 +ratings 0 +of 0 +Unified 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Rating 0 +Scale 0 +( 0 +UPDRS 0 +) 0 +scores 0 +were 0 +carried 0 +out 0 +pre 0 +- 0 +and 0 +postoperatively 0 +. 0 + +Mean 0 +follow 0 +- 0 +up 0 +time 0 +is 0 +20 0 +. 0 +6 0 +months 0 +( 0 +range 0 +6 0 +- 0 +48 0 +) 0 +and 0 +all 0 +except 0 +4 0 +patients 0 +have 0 +been 0 +followed 0 +more 0 +than 0 +one 0 +year 0 +. 0 + +85 0 +percent 0 +of 0 +patients 0 +with 0 +dyskinesias 3 +were 0 +relieved 0 +of 0 +symptoms 0 +, 0 +regardless 0 +of 0 +whether 0 +the 0 +pallidotomies 0 +were 0 +performed 0 +with 0 +the 0 +Gamma 0 +Knife 0 +or 0 +radiofrequency 0 +methods 0 +. 0 + +About 0 +2 0 +/ 0 +3 0 +of 0 +the 0 +patients 0 +in 0 +both 0 +Gamma 0 +Knife 0 +and 0 +radiofrequency 0 +groups 0 +showed 0 +improvements 0 +in 0 +bradykinesia 3 +and 0 +rigidity 3 +, 0 +although 0 +when 0 +considered 0 +as 0 +a 0 +group 0 +neither 0 +the 0 +Gamma 0 +Knife 0 +nor 0 +the 0 +radiofrequency 0 +group 0 +showed 0 +statistically 0 +significant 0 +improvements 0 +in 0 +UPDRS 0 +scores 0 +. 0 + +0ne 0 +patient 0 +in 0 +the 0 +Gamma 0 +Knife 0 +group 0 +( 0 +3 0 +. 0 +4 0 +% 0 +) 0 +developed 0 +a 0 +homonymous 3 +hemianopsia 4 +9 0 +months 0 +following 0 +treatment 0 +and 0 +5 0 +patients 0 +( 0 +27 0 +. 0 +7 0 +% 0 +) 0 +in 0 +the 0 +radiofrequency 0 +group 0 +became 0 +transiently 0 +confused 0 +postoperatively 0 +. 0 + +No 0 +other 0 +complications 0 +were 0 +seen 0 +. 0 + +Gamma 0 +Knife 0 +pallidotomy 0 +is 0 +as 0 +effective 0 +as 0 +radiofrequency 0 +pallidotomy 0 +in 0 +controlling 0 +certain 0 +of 0 +the 0 +symptoms 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 + +It 0 +may 0 +be 0 +the 0 +only 0 +practical 0 +technique 0 +available 0 +in 0 +certain 0 +patients 0 +, 0 +such 0 +as 0 +those 0 +who 0 +take 0 +anticoagulants 0 +, 0 +have 0 +bleeding 3 +diatheses 0 +or 0 +serious 0 +systemic 0 +medical 0 +illnesses 0 +. 0 + +It 0 +is 0 +a 0 +viable 0 +option 0 +for 0 +other 0 +patients 0 +as 0 +well 0 +. 0 + +Centrally 0 +mediated 0 +cardiovascular 0 +effects 0 +of 0 +intracisternal 0 +application 0 +of 0 +carbachol 1 +in 0 +anesthetized 0 +rats 0 +. 0 + +The 0 +pressor 0 +response 0 +to 0 +the 0 +intracisternal 0 +( 0 +i 0 +. 0 +c 0 +. 0 +) 0 +injection 0 +of 0 +carbachol 1 +( 0 +1 0 +mug 0 +) 0 +in 0 +anesthetized 0 +rats 0 +was 0 +analyzed 0 +. 0 + +This 0 +response 0 +was 0 +significantly 0 +reduced 0 +by 0 +the 0 +intravenous 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +injection 0 +of 0 +guanethidine 1 +( 0 +5 0 +mg 0 +) 0 +, 0 +hexamethonium 1 +( 0 +10 0 +mg 0 +) 0 +or 0 +phentolamine 1 +( 0 +5 0 +mg 0 +) 0 +, 0 +and 0 +conversely 0 +, 0 +potentiated 0 +by 0 +i 0 +. 0 +v 0 +. 0 +desmethylimipramine 1 +( 0 +0 0 +. 0 +3 0 +mg 0 +) 0 +, 0 +while 0 +propranolol 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +) 0 +i 0 +. 0 +v 0 +. 0 +selectively 0 +inhibited 0 +the 0 +enlargement 3 +of 4 +pulse 4 +pressure 4 +and 0 +the 0 +tachycardia 3 +following 0 +i 0 +. 0 +c 0 +. 0 +carbachol 1 +( 0 +1 0 +mug 0 +) 0 +. 0 + +0n 0 +the 0 +other 0 +hand 0 +, 0 +the 0 +pressor 0 +response 0 +to 0 +i 0 +. 0 +c 0 +. 0 +carbachol 1 +( 0 +1 0 +mug 0 +) 0 +was 0 +almost 0 +completely 0 +blocked 0 +by 0 +i 0 +. 0 +c 0 +. 0 +atropine 1 +( 0 +3 0 +mug 0 +) 0 +or 0 +hexamethonium 1 +( 0 +500 0 +mug 0 +) 0 +, 0 +and 0 +significantly 0 +reduced 0 +by 0 +i 0 +. 0 +c 0 +. 0 +chlorpromazine 1 +( 0 +50 0 +mug 0 +) 0 +but 0 +significantly 0 +potentiated 0 +by 0 +i 0 +. 0 +c 0 +. 0 +desmethylimipramine 1 +( 0 +30 0 +mug 0 +) 0 +. 0 + +The 0 +pressor 0 +response 0 +to 0 +i 0 +. 0 +c 0 +. 0 +carbachol 1 +( 0 +1 0 +mug 0 +) 0 +remained 0 +unchanged 0 +after 0 +sectioning 0 +of 0 +the 0 +bilateral 0 +cervical 0 +vagal 0 +nerves 0 +but 0 +disappeared 0 +after 0 +sectioning 0 +of 0 +the 0 +spinal 0 +cord 0 +( 0 +C7 0 +- 0 +C8 0 +) 0 +. 0 + +From 0 +the 0 +above 0 +result 0 +it 0 +is 0 +suggested 0 +that 0 +the 0 +pressor 0 +response 0 +to 0 +i 0 +. 0 +c 0 +. 0 +carbachol 1 +ortral 0 +and 0 +peripheral 0 +adrenergic 0 +mechanisms 0 +, 0 +and 0 +that 0 +the 0 +sympathetic 0 +trunk 0 +is 0 +the 0 +main 0 +pathway 0 +. 0 + +Neuroleptic 3 +malignant 4 +syndrome 4 +and 0 +methylphenidate 1 +. 0 + +A 0 +1 0 +- 0 +year 0 +- 0 +old 0 +female 0 +presented 0 +with 0 +neuroleptic 3 +malignant 4 +syndrome 4 +probably 0 +caused 0 +by 0 +methylphenidate 1 +. 0 + +She 0 +had 0 +defects 0 +in 0 +the 0 +supratentorial 0 +brain 0 +including 0 +the 0 +basal 0 +ganglia 0 +and 0 +the 0 +striatum 0 +( 0 +multicystic 3 +encephalomalacia 4 +) 0 +due 0 +to 0 +severe 0 +perinatal 0 +hypoxic 3 +- 4 +ischemic 4 +encephalopathy 4 +, 0 +which 0 +was 0 +considered 0 +to 0 +be 0 +a 0 +possible 0 +predisposing 0 +factor 0 +causing 0 +neuroleptic 3 +malignant 4 +syndrome 4 +. 0 + +A 0 +dopaminergic 0 +blockade 0 +mechanism 0 +generally 0 +is 0 +accepted 0 +as 0 +the 0 +pathogenesis 0 +of 0 +this 0 +syndrome 0 +. 0 + +However 0 +, 0 +methylphenidate 1 +is 0 +a 0 +dopamine 1 +agonist 0 +via 0 +the 0 +inhibition 0 +of 0 +uptake 0 +of 0 +dopamine 1 +, 0 +and 0 +therefore 0 +dopaminergic 0 +systems 0 +in 0 +the 0 +brainstem 0 +( 0 +mainly 0 +the 0 +midbrain 0 +) 0 +and 0 +the 0 +spinal 0 +cord 0 +were 0 +unlikely 0 +to 0 +participate 0 +in 0 +the 0 +onset 0 +of 0 +this 0 +syndrome 0 +. 0 + +A 0 +relative 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +- 0 +ergic 0 +deficiency 0 +might 0 +occur 0 +because 0 +diazepam 1 +, 0 +a 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +- 0 +mimetic 0 +agent 0 +, 0 +was 0 +strikingly 0 +effective 0 +. 0 + +This 0 +is 0 +the 0 +first 0 +reported 0 +patient 0 +with 0 +neuroleptic 3 +malignant 4 +syndrome 4 +probably 0 +caused 0 +by 0 +methylphenidate 1 +. 0 + +Differential 0 +effects 0 +of 0 +17alpha 1 +- 2 +ethinylestradiol 2 +on 0 +the 0 +neutral 0 +and 0 +acidic 0 +pathways 0 +of 0 +bile 1 +salt 2 +synthesis 0 +in 0 +the 0 +rat 0 +. 0 + +Effects 0 +of 0 +17alpha 1 +- 2 +ethinylestradiol 2 +( 0 +EE 1 +) 0 +on 0 +the 0 +neutral 0 +and 0 +acidic 0 +biosynthetic 0 +pathways 0 +of 0 +bile 1 +salt 2 +( 0 +BS 1 +) 0 +synthesis 0 +were 0 +evaluated 0 +in 0 +rats 0 +with 0 +an 0 +intact 0 +enterohepatic 0 +circulation 0 +and 0 +in 0 +rats 0 +with 0 +long 0 +- 0 +term 0 +bile 0 +diversion 0 +to 0 +induce 0 +BS 1 +synthesis 0 +. 0 + +For 0 +this 0 +purpose 0 +, 0 +bile 1 +salt 2 +pool 0 +composition 0 +, 0 +synthesis 0 +of 0 +individual 0 +BS 1 +in 0 +vivo 0 +, 0 +hepatic 0 +activities 0 +, 0 +and 0 +expression 0 +levels 0 +of 0 +cholesterol 1 +7alpha 0 +- 0 +hydroxylase 0 +( 0 +CYP7A 0 +) 0 +, 0 +and 0 +sterol 1 +27 0 +- 0 +hydroxylase 0 +( 0 +CYP27 0 +) 0 +, 0 +as 0 +well 0 +as 0 +of 0 +other 0 +enzymes 0 +involved 0 +in 0 +BS 1 +synthesis 0 +, 0 +were 0 +analyzed 0 +in 0 +rats 0 +treated 0 +with 0 +EE 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +, 0 +3 0 +days 0 +) 0 +or 0 +its 0 +vehicle 0 +. 0 + +BS 1 +pool 0 +size 0 +was 0 +decreased 0 +by 0 +27 0 +% 0 +but 0 +total 0 +BS 1 +synthesis 0 +was 0 +not 0 +affected 0 +by 0 +EE 1 +in 0 +intact 0 +rats 0 +. 0 + +Synthesis 0 +of 0 +cholate 1 +was 0 +reduced 0 +by 0 +68 0 +% 0 +in 0 +EE 1 +- 0 +treated 0 +rats 0 +, 0 +while 0 +that 0 +of 0 +chenodeoxycholate 1 +was 0 +increased 0 +by 0 +60 0 +% 0 +. 0 + +The 0 +recently 0 +identified 0 +Delta22 0 +- 0 +isomer 0 +of 0 +beta 0 +- 0 +muricholate 0 +contributed 0 +for 0 +5 0 +. 0 +4 0 +% 0 +and 0 +18 0 +. 0 +3 0 +% 0 +( 0 +P 0 +< 0 +0 0 +. 0 +01 0 +) 0 +to 0 +the 0 +pool 0 +in 0 +control 0 +and 0 +EE 1 +- 0 +treated 0 +rats 0 +, 0 +respectively 0 +, 0 +but 0 +could 0 +not 0 +be 0 +detected 0 +in 0 +bile 0 +after 0 +exhaustion 0 +of 0 +the 0 +pool 0 +. 0 + +A 0 +clear 0 +reduction 0 +of 0 +BS 1 +synthesis 0 +was 0 +found 0 +in 0 +bile 0 +- 0 +diverted 0 +rats 0 +treated 0 +with 0 +EE 1 +, 0 +yet 0 +biliary 0 +BS 1 +composition 0 +was 0 +only 0 +minimally 0 +affected 0 +. 0 + +Activity 0 +of 0 +CYP7A 0 +was 0 +decreased 0 +by 0 +EE 1 +in 0 +both 0 +intact 0 +and 0 +bile 0 +- 0 +diverted 0 +rats 0 +, 0 +whereas 0 +the 0 +activity 0 +of 0 +the 0 +CYP27 0 +was 0 +not 0 +affected 0 +. 0 + +Hepatic 0 +mRNA 0 +levels 0 +of 0 +CYP7A 0 +were 0 +significantly 0 +reduced 0 +by 0 +EE 1 +in 0 +bile 0 +- 0 +diverted 0 +rats 0 +only 0 +; 0 +CYP27 0 +mRNA 0 +levels 0 +were 0 +not 0 +affected 0 +by 0 +EE 1 +. 0 + +In 0 +addition 0 +, 0 +mRNA 0 +levels 0 +of 0 +sterol 1 +12alpha 0 +- 0 +hydroxylase 0 +and 0 +lithocholate 0 +6beta 0 +- 0 +hydroxylase 0 +were 0 +increased 0 +by 0 +bile 0 +diversion 0 +and 0 +suppressed 0 +by 0 +EE 1 +. 0 + +This 0 +study 0 +shows 0 +that 0 +17alpha 1 +- 2 +ethinylestradiol 2 +( 0 +EE 1 +) 0 +- 0 +induced 0 +intrahepatic 3 +cholestasis 4 +in 0 +rats 0 +is 0 +associated 0 +with 0 +selective 0 +inhibition 0 +of 0 +the 0 +neutral 0 +pathway 0 +of 0 +bile 1 +salt 2 +( 0 +BS 1 +) 0 +synthesis 0 +. 0 + +Simultaneous 0 +impairment 0 +of 0 +other 0 +enzymes 0 +in 0 +the 0 +BS 1 +biosynthetic 0 +pathways 0 +may 0 +contribute 0 +to 0 +overall 0 +effects 0 +of 0 +EE 1 +on 0 +BS 1 +synthesis 0 +. 0 + +Glibenclamide 1 +- 0 +sensitive 0 +hypotension 3 +produced 0 +by 0 +helodermin 1 +assessed 0 +in 0 +the 0 +rat 0 +. 0 + +The 0 +effects 0 +of 0 +helodermin 1 +, 0 +a 0 +basic 0 +35 0 +- 0 +amino 1 +acid 2 +peptide 0 +isolated 0 +from 0 +the 0 +venom 0 +of 0 +a 0 +lizard 0 +salivary 0 +gland 0 +, 0 +on 0 +arterial 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +were 0 +examined 0 +in 0 +the 0 +rat 0 +, 0 +focusing 0 +on 0 +the 0 +possibility 0 +that 0 +activation 0 +of 0 +ATP 1 +sensitive 0 +K 1 ++ 0 +( 0 +K 1 +( 0 +ATP 1 +) 0 +) 0 +channels 0 +is 0 +involved 0 +in 0 +the 0 +responses 0 +. 0 + +The 0 +results 0 +were 0 +also 0 +compared 0 +with 0 +those 0 +of 0 +vasoactive 0 +intestinal 0 +polypeptide 0 +( 0 +VIP 0 +) 0 +. 0 + +Helodermin 1 +produced 0 +hypotension 3 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +with 0 +approximately 0 +similar 0 +potency 0 +and 0 +duration 0 +to 0 +VIP 0 +. 0 + +Hypotension 3 +induced 0 +by 0 +both 0 +peptides 0 +was 0 +significantly 0 +attenuated 0 +by 0 +glibenclamide 1 +, 0 +which 0 +abolished 0 +a 0 +levcromakalim 1 +- 0 +produced 0 +decrease 0 +in 0 +arterial 0 +blood 0 +pressure 0 +. 0 + +0xyhemoglobin 0 +did 0 +not 0 +affect 0 +helodermin 1 +- 0 +induced 0 +hypotension 3 +, 0 +whereas 0 +it 0 +shortened 0 +the 0 +duration 0 +of 0 +acetylcholine 1 +( 0 +ACh 1 +) 0 +- 0 +produced 0 +hypotension 3 +. 0 + +These 0 +findings 0 +suggest 0 +that 0 +helodermin 1 +- 0 +produced 0 +hypotension 3 +is 0 +partly 0 +attributable 0 +to 0 +the 0 +activation 0 +of 0 +glibenclamide 1 +- 0 +sensitive 0 +K 1 ++ 0 +channels 0 +( 0 +K 1 +( 0 +ATP 1 +) 0 +channels 0 +) 0 +, 0 +which 0 +presumably 0 +exist 0 +on 0 +arterial 0 +smooth 0 +muscle 0 +cells 0 +. 0 + +EDRF 0 +( 0 +endothelium 0 +- 0 +derived 0 +relaxing 0 +factor 0 +) 0 +/ 0 +nitric 1 +oxide 2 +does 0 +not 0 +seem 0 +to 0 +play 0 +an 0 +important 0 +role 0 +in 0 +the 0 +peptide 0 +- 0 +produced 0 +hypotension 3 +. 0 + +Long 0 +- 0 +term 0 +efficacy 0 +and 0 +adverse 0 +event 0 +of 0 +nifedipine 1 +sustained 0 +- 0 +release 0 +tablets 0 +for 0 +cyclosporin 1 +A 2 +- 0 +induced 0 +hypertension 3 +in 0 +patients 0 +with 0 +psoriasis 3 +. 0 + +Thirteen 0 +psoriatic 3 +patients 0 +with 0 +hypertension 3 +during 0 +the 0 +course 0 +of 0 +cyclosporin 1 +A 2 +therapy 0 +were 0 +treated 0 +for 0 +25 0 +months 0 +with 0 +a 0 +calcium 1 +channel 0 +blocker 0 +, 0 +sustained 0 +- 0 +release 0 +nifedipine 1 +, 0 +to 0 +study 0 +the 0 +clinical 0 +antihypertensive 0 +effects 0 +and 0 +adverse 0 +events 0 +during 0 +treatment 0 +with 0 +both 0 +drugs 0 +. 0 + +Seven 0 +of 0 +the 0 +13 0 +patients 0 +had 0 +exhibited 0 +a 0 +subclinical 0 +hypertensive 3 +state 0 +before 0 +cyclosporin 1 +A 2 +therapy 0 +. 0 + +Both 0 +systolic 0 +and 0 +diastolic 0 +blood 0 +pressures 0 +of 0 +these 0 +13 0 +patients 0 +were 0 +decreased 0 +significantly 0 +after 0 +4 0 +weeks 0 +of 0 +nifedipine 1 +therapy 0 +, 0 +and 0 +blood 0 +pressure 0 +was 0 +maintained 0 +within 0 +the 0 +normal 0 +range 0 +thereafter 0 +for 0 +25 0 +months 0 +. 0 + +The 0 +adverse 0 +events 0 +during 0 +combined 0 +therapy 0 +with 0 +cyclosporin 1 +A 2 +and 0 +nifedipine 1 +included 0 +an 0 +increase 0 +in 0 +blood 1 +urea 2 +nitrogen 2 +levels 0 +in 0 +9 0 +of 0 +the 0 +13 0 +patients 0 +and 0 +development 0 +of 0 +gingival 3 +hyperplasia 4 +in 0 +2 0 +of 0 +the 0 +13 0 +patients 0 +. 0 + +0ur 0 +findings 0 +indicate 0 +that 0 +sustained 0 +- 0 +release 0 +nifedipine 1 +is 0 +useful 0 +for 0 +hypertensive 3 +psoriatic 3 +patients 0 +under 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +cyclosporin 1 +A 2 +, 0 +but 0 +that 0 +these 0 +patients 0 +should 0 +be 0 +monitored 0 +for 0 +gingival 3 +hyperplasia 4 +. 0 + +Selegiline 1 +- 0 +induced 0 +postural 3 +hypotension 4 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +: 0 +a 0 +longitudinal 0 +study 0 +on 0 +the 0 +effects 0 +of 0 +drug 0 +withdrawal 0 +. 0 +0BJECTIVES 0 +: 0 +The 0 +United 0 +Kingdom 0 +Parkinson 3 +' 4 +s 4 +Disease 4 +Research 0 +Group 0 +( 0 +UKPDRG 0 +) 0 +trial 0 +found 0 +an 0 +increased 0 +mortality 0 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +randomized 0 +to 0 +receive 0 +10 0 +mg 0 +selegiline 1 +per 0 +day 0 +and 0 +L 1 +- 2 +dopa 2 +compared 0 +with 0 +those 0 +taking 0 +L 1 +- 2 +dopa 2 +alone 0 +. 0 +Recently 0 +"," 0 +we 0 +found 0 +that 0 +therapy 0 +with 0 +selegiline 1 +and 0 +L 1 +- 2 +dopa 2 +was 0 +associated 0 +with 0 +selective 0 +systolic 3 +orthostatic 4 +hypotension 4 +which 0 +was 0 +abolished 0 +by 0 +withdrawal 0 +of 0 +selegiline 1 +. 0 +This 0 +unwanted 0 +effect 0 +on 0 +postural 0 +blood 0 +pressure 0 +was 0 +not 0 +the 0 +result 0 +of 0 +underlying 0 +autonomic 0 +failure 0 +. 0 +The 0 +aims 0 +of 0 +this 0 +study 0 +were 0 +to 0 +confirm 0 +our 0 +previous 0 +findings 0 +in 0 +a 0 +separate 0 +cohort 0 +of 0 +patients 0 +and 0 +to 0 +determine 0 +the 0 +time 0 +course 0 +of 0 +the 0 +cardiovascular 0 +consequences 0 +of 0 +stopping 0 +selegiline 1 +in 0 +the 0 +expectation 0 +that 0 +this 0 +might 0 +shed 0 +light 0 +on 0 +the 0 +mechanisms 0 +by 0 +which 0 +the 0 +drug 0 +causes 0 +orthostatic 3 +hypotension 4 +. 0 +METH0DS 0 +: 0 +The 0 +cardiovascular 0 +responses 0 +to 0 +standing 0 +and 0 +head 0 +- 0 +up 0 +tilt 0 +were 0 +studied 0 +repeatedly 0 +in 0 +PD 3 +patients 0 +receiving 0 +selegiline 1 +and 0 +as 0 +the 0 +drug 0 +was 0 +withdrawn 0 +. 0 +RESULTS 0 +: 0 +Head 0 +- 0 +up 0 +tilt 0 +caused 0 +systolic 3 +orthostatic 4 +hypotension 4 +which 0 +was 0 +marked 0 +in 0 +six 0 +of 0 +20 0 +PD 3 +patients 0 +on 0 +selegiline 1 +"," 0 +one 0 +of 0 +whom 0 +lost 0 +consciousness 0 +with 0 +unrecordable 0 +blood 0 +pressures 0 +. 0 +A 0 +lesser 0 +degree 0 +of 0 +orthostatic 3 +hypotension 4 +occurred 0 +with 0 +standing 0 +. 0 +0rthostatic 3 +hypotension 4 +was 0 +ameliorated 0 +4 0 +days 0 +after 0 +withdrawal 0 +of 0 +selegiline 1 +and 0 +totally 0 +abolished 0 +7 0 +days 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +. 0 +Stopping 0 +selegiline 1 +also 0 +significantly 0 +reduced 3 +the 4 +supine 4 +systolic 4 +and 4 +diastolic 4 +blood 4 +pressures 4 +consistent 0 +with 0 +a 0 +previously 0 +undescribed 0 +supine 0 +pressor 0 +action 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +study 0 +confirms 0 +our 0 +previous 0 +finding 0 +that 0 +selegiline 1 +in 0 +combination 0 +with 0 +L 1 +- 2 +dopa 2 +is 0 +associated 0 +with 0 +selective 0 +orthostatic 3 +hypotension 4 +. 0 +The 0 +possibilities 0 +that 0 +these 0 +cardiovascular 0 +findings 0 +might 0 +be 0 +the 0 +result 0 +of 0 +non 0 +- 0 +selective 0 +inhibition 0 +of 0 +monoamine 0 +oxidase 0 +or 0 +of 0 +amphetamine 1 +and 0 +metamphetamine 1 +are 0 +discussed 0 +. 0 +Further 0 +studies 0 +on 0 +effects 0 +of 0 +irrigation 0 +solutions 0 +on 0 +rat 0 +bladders 0 +. 0 +Further 0 +studies 0 +on 0 +the 0 +effects 0 +of 0 +certain 0 +irrigating 0 +fluids 0 +on 0 +the 0 +rat 0 +bladder 0 +for 0 +18 0 +hours 0 +are 0 +reported 0 +. 0 +The 0 +results 0 +have 0 +shown 0 +that 0 +the 0 +degradation 0 +product 0 +p 1 +- 2 +choloroaniline 2 +is 0 +not 0 +a 0 +significant 0 +factor 0 +in 0 +chlorhexidine 1 +- 2 +digluconate 2 +associated 0 +erosive 0 +cystitis 3 +. 0 +A 0 +high 0 +percentage 0 +of 0 +kanamycin 1 +- 0 +colistin 1 +and 0 +povidone 1 +- 2 +iodine 2 +irrigations 0 +were 0 +associated 0 +with 0 +erosive 0 +cystitis 3 +and 0 +suggested 0 +a 0 +possible 0 +complication 0 +with 0 +human 0 +usage 0 +. 0 +Picloxydine 1 +irrigations 0 +appeared 0 +to 0 +have 0 +a 0 +lower 0 +incidence 0 +of 0 +erosive 0 +cystitis 3 +but 0 +further 0 +studies 0 +would 0 +have 0 +to 0 +be 0 +performed 0 +before 0 +it 0 +could 0 +be 0 +recommended 0 +for 0 +use 0 +in 0 +urological 0 +procedures 0 +. 0 +Effects 0 +of 0 +tetrandrine 1 +and 0 +fangchinoline 1 +on 0 +experimental 0 +thrombosis 3 +in 0 +mice 0 +and 0 +human 0 +platelet 3 +aggregation 4 +. 0 +Tetrandrine 1 +( 0 +TET 1 +) 0 +and 0 +fangchinoline 1 +( 0 +FAN 1 +) 0 +are 0 +two 0 +naturally 0 +occurring 0 +analogues 0 +with 0 +a 0 +bisbenzylisoquinoline 1 +structure 0 +. 0 +The 0 +present 0 +study 0 +was 0 +undertaken 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +TET 1 +and 0 +FAN 1 +on 0 +the 0 +experimental 0 +thrombosis 3 +induced 0 +by 0 +collagen 0 +plus 0 +epinephrine 1 +( 0 +EP 1 +) 0 +in 0 +mice 0 +"," 0 +and 0 +platelet 3 +aggregation 4 +and 0 +blood 3 +coagulation 4 +in 0 +vitro 0 +. 0 +In 0 +the 0 +in 0 +vivo 0 +study 0 +"," 0 +the 0 +administration 0 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +) 0 +of 0 +TET 1 +and 0 +FAN 1 +in 0 +mice 0 +showed 0 +the 0 +inhibition 0 +of 0 +thrombosis 3 +by 0 +55 0 +% 0 +and 0 +35 0 +% 0 +"," 0 +respectively 0 +"," 0 +while 0 +acetylsalicylic 1 +acid 2 +( 0 +ASA 1 +"," 0 +50 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +) 0 +"," 0 +a 0 +positive 0 +control 0 +"," 0 +showed 0 +only 0 +30 0 +% 0 +inhibition 0 +. 0 +In 0 +the 0 +vitro 0 +human 0 +platelet 3 +aggregations 4 +induced 0 +by 0 +the 0 +agonists 0 +used 0 +in 0 +tests 0 +"," 0 +TET 1 +and 0 +FAN 1 +showed 0 +the 0 +inhibitions 0 +dose 0 +dependently 0 +. 0 +In 0 +addition 0 +"," 0 +neither 0 +TET 1 +nor 0 +FAN 1 +showed 0 +any 0 +anticoagulation 0 +activities 0 +in 0 +the 0 +measurement 0 +of 0 +the 0 +activated 0 +partial 0 +thromboplastin 0 +time 0 +( 0 +APTT 0 +) 0 +"," 0 +prothrombin 0 +time 0 +( 0 +PT 0 +) 0 +and 0 +thrombin 0 +time 0 +( 0 +TT 0 +) 0 +using 0 +human 0 +- 0 +citrated 0 +plasma 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +antithrombosis 0 +of 0 +TET 1 +and 0 +FAN 1 +in 0 +mice 0 +may 0 +be 0 +mainly 0 +related 0 +to 0 +the 0 +antiplatelet 0 +aggregation 0 +activities 0 +. 0 +Angioedema 3 +due 0 +to 0 +ACE 1 +inhibitors 2 +: 0 +common 0 +and 0 +inadequately 0 +diagnosed 0 +. 0 +The 0 +estimated 0 +incidence 0 +of 0 +angioedema 3 +during 0 +angiotensin 1 +- 2 +converting 2 +enzyme 2 +( 2 +ACE 2 +) 2 +inhibitor 2 +treatment 0 +is 0 +between 0 +1 0 +and 0 +7 0 +per 0 +thousand 0 +patients 0 +. 0 +This 0 +potentially 0 +serious 0 +adverse 0 +effect 0 +is 0 +often 0 +preceded 0 +by 0 +minor 0 +manifestations 0 +that 0 +may 0 +serve 0 +as 0 +a 0 +warning 0 +. 0 +Cocaine 1 +- 0 +induced 0 +mood 3 +disorder 4 +: 0 +prevalence 0 +rates 0 +and 0 +psychiatric 3 +symptoms 0 +in 0 +an 0 +outpatient 0 +cocaine 1 +- 0 +dependent 0 +sample 0 +. 0 +This 0 +paper 0 +attempts 0 +to 0 +examine 0 +and 0 +compare 0 +prevalence 0 +rates 0 +and 0 +symptom 0 +patterns 0 +of 0 +DSM 0 +substance 0 +- 0 +induced 0 +and 0 +other 0 +mood 3 +disorders 4 +. 0 +243 0 +cocaine 1 +- 0 +dependent 0 +outpatients 0 +with 0 +cocaine 1 +- 0 +induced 0 +mood 3 +disorder 4 +( 0 +CIMD 3 +) 0 +"," 0 +other 0 +mood 3 +disorders 4 +"," 0 +or 0 +no 0 +mood 3 +disorder 4 +were 0 +compared 0 +on 0 +measures 0 +of 0 +psychiatric 3 +symptoms 0 +. 0 +The 0 +prevalence 0 +rate 0 +for 0 +CIMD 3 +was 0 +12 0 +% 0 +at 0 +baseline 0 +. 0 +Introduction 0 +of 0 +the 0 +DSM 0 +- 0 +IV 0 +diagnosis 0 +of 0 +CIMD 3 +did 0 +not 0 +substantially 0 +affect 0 +rates 0 +of 0 +the 0 +other 0 +depressive 3 +disorders 4 +. 0 +Patients 0 +with 0 +CIMD 3 +had 0 +symptom 0 +severity 0 +levels 0 +between 0 +those 0 +of 0 +patients 0 +with 0 +and 0 +without 0 +a 0 +mood 3 +disorder 4 +. 0 +These 0 +findings 0 +suggest 0 +some 0 +validity 0 +for 0 +the 0 +new 0 +DSM 0 +- 0 +IV 0 +diagnosis 0 +of 0 +CIMD 3 +"," 0 +but 0 +also 0 +suggest 0 +that 0 +it 0 +requires 0 +further 0 +specification 0 +and 0 +replication 0 +. 0 +Effect 0 +of 0 +fucoidan 1 +treatment 0 +on 0 +collagenase 0 +- 0 +induced 0 +intracerebral 3 +hemorrhage 4 +in 0 +rats 0 +. 0 +Inflammatory 0 +cells 0 +are 0 +postulated 0 +to 0 +mediate 0 +some 0 +of 0 +the 0 +brain 3 +damage 4 +following 0 +ischemic 3 +stroke 4 +. 0 +Intracerebral 3 +hemorrhage 4 +is 0 +associated 0 +with 0 +more 0 +inflammation 3 +than 0 +ischemic 3 +stroke 4 +. 0 +We 0 +tested 0 +the 0 +sulfated 0 +polysaccharide 0 +fucoidan 1 +"," 0 +which 0 +has 0 +been 0 +reported 0 +to 0 +reduce 0 +inflammatory 0 +brain 3 +damage 4 +"," 0 +in 0 +a 0 +rat 0 +model 0 +of 0 +intracerebral 3 +hemorrhage 4 +induced 0 +by 0 +injection 0 +of 0 +bacterial 0 +collagenase 0 +into 0 +the 0 +caudate 0 +nucleus 0 +. 0 +Rats 0 +were 0 +treated 0 +with 0 +seven 0 +day 0 +intravenous 0 +infusion 0 +of 0 +fucoidan 1 +( 0 +30 0 +micrograms 0 +h 0 +- 0 +1 0 +) 0 +or 0 +vehicle 0 +. 0 +The 0 +hematoma 3 +was 0 +assessed 0 +in 0 +vivo 0 +by 0 +magnetic 0 +resonance 0 +imaging 0 +. 0 +Motor 0 +behavior 0 +"," 0 +passive 0 +avoidance 0 +"," 0 +and 0 +skilled 0 +forelimb 0 +function 0 +were 0 +tested 0 +repeatedly 0 +for 0 +six 0 +weeks 0 +. 0 +Fucoidan 1 +- 0 +treated 0 +rats 0 +exhibited 0 +evidence 0 +of 0 +impaired 3 +blood 4 +clotting 4 +and 0 +hemodilution 3 +"," 0 +had 0 +larger 0 +hematomas 3 +"," 0 +and 0 +tended 0 +to 0 +have 0 +less 0 +inflammation 3 +in 0 +the 0 +vicinity 0 +of 0 +the 0 +hematoma 3 +after 0 +three 0 +days 0 +. 0 +They 0 +showed 0 +significantly 0 +more 0 +rapid 0 +improvement 0 +of 0 +motor 0 +function 0 +in 0 +the 0 +first 0 +week 0 +following 0 +hemorrhage 3 +and 0 +better 0 +memory 0 +retention 0 +in 0 +the 0 +passive 0 +avoidance 0 +test 0 +. 0 +Acute 0 +white 3 +matter 4 +edema 4 +and 0 +eventual 0 +neuronal 3 +loss 4 +in 0 +the 0 +striatum 0 +adjacent 0 +to 0 +the 0 +hematoma 3 +did 0 +not 0 +differ 0 +between 0 +the 0 +two 0 +groups 0 +. 0 +Investigation 0 +of 0 +more 0 +specific 0 +anti 0 +- 0 +inflammatory 0 +agents 0 +and 0 +hemodiluting 0 +agents 0 +are 0 +warranted 0 +in 0 +intracerebral 3 +hemorrhage 4 +. 0 +Recurarization 0 +in 0 +the 0 +recovery 0 +room 0 +. 0 +A 0 +case 0 +of 0 +recurarization 0 +in 0 +the 0 +recovery 0 +room 0 +is 0 +reported 0 +. 0 +Accumulation 0 +of 0 +atracurium 1 +in 0 +the 0 +intravenous 0 +line 0 +led 0 +to 0 +recurarization 0 +after 0 +flushing 0 +the 0 +line 0 +in 0 +the 0 +recovery 0 +room 0 +. 0 +A 0 +respiratory 3 +arrest 4 +with 0 +severe 0 +desaturation 3 +and 0 +bradycardia 3 +occurred 0 +. 0 +Circumstances 0 +leading 0 +to 0 +this 0 +event 0 +and 0 +the 0 +mechanisms 0 +enabling 0 +a 0 +neuromuscular 3 +blockade 4 +to 0 +occur 0 +"," 0 +following 0 +the 0 +administration 0 +of 0 +a 0 +small 0 +dose 0 +of 0 +relaxant 0 +"," 0 +are 0 +discussed 0 +. 0 +The 0 +haemodynamic 0 +effects 0 +of 0 +propofol 1 +in 0 +combination 0 +with 0 +ephedrine 1 +in 0 +elderly 0 +patients 0 +( 0 +ASA 0 +groups 0 +3 0 +and 0 +4 0 +) 0 +. 0 +The 0 +marked 0 +vasodilator 0 +and 0 +negative 0 +inotropic 0 +effects 0 +of 0 +propofol 1 +are 0 +disadvantages 0 +in 0 +frail 0 +elderly 0 +patients 0 +. 0 +We 0 +investigated 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +adding 0 +different 0 +doses 0 +of 0 +ephedrine 1 +to 0 +propofol 1 +in 0 +order 0 +to 0 +obtund 0 +the 0 +hypotensive 3 +response 0 +. 0 +The 0 +haemodynamic 0 +effects 0 +of 0 +adding 0 +15 0 +"," 0 +20 0 +or 0 +25 0 +mg 0 +of 0 +ephedrine 1 +to 0 +200 0 +mg 0 +of 0 +propofol 1 +were 0 +compared 0 +to 0 +control 0 +in 0 +40 0 +ASA 0 +3 0 +/ 0 +4 0 +patients 0 +over 0 +60 0 +years 0 +presenting 0 +for 0 +genito 0 +- 0 +urinary 0 +surgery 0 +. 0 +The 0 +addition 0 +of 0 +ephedrine 1 +to 0 +propofol 1 +appears 0 +to 0 +be 0 +an 0 +effective 0 +method 0 +of 0 +obtunding 0 +the 0 +hypotensive 3 +response 0 +to 0 +propofol 1 +at 0 +all 0 +doses 0 +used 0 +in 0 +this 0 +study 0 +. 0 +However 0 +"," 0 +marked 0 +tachycardia 3 +associated 0 +with 0 +the 0 +use 0 +of 0 +ephedrine 1 +in 0 +combination 0 +with 0 +propofol 1 +occurred 0 +in 0 +the 0 +majority 0 +of 0 +patients 0 +"," 0 +occasionally 0 +reaching 0 +high 0 +levels 0 +in 0 +individual 0 +patients 0 +. 0 +Due 0 +to 0 +the 0 +risk 0 +of 0 +this 0 +tachycardia 3 +inducing 0 +myocardial 3 +ischemia 4 +"," 0 +we 0 +would 0 +not 0 +recommend 0 +the 0 +use 0 +in 0 +elderly 0 +patients 0 +of 0 +any 0 +of 0 +the 0 +ephedrine 1 +/ 0 +propofol 1 +/ 0 +mixtures 0 +studied 0 +. 0 +Gemcitabine 1 +plus 0 +vinorelbine 1 +in 0 +nonsmall 3 +cell 4 +lung 4 +carcinoma 4 +patients 0 +age 0 +70 0 +years 0 +or 0 +older 0 +or 0 +patients 0 +who 0 +cannot 0 +receive 0 +cisplatin 1 +. 0 +0ncopaz 0 +Cooperative 0 +Group 0 +. 0 +BACKGR0UND 0 +: 0 +Although 0 +the 0 +prevalence 0 +of 0 +nonsmall 3 +cell 4 +lung 4 +carcinoma 4 +( 0 +NSCLC 3 +) 0 +is 0 +high 0 +among 0 +elderly 0 +patients 0 +"," 0 +few 0 +data 0 +are 0 +available 0 +regarding 0 +the 0 +efficacy 0 +and 0 +toxicity 3 +of 0 +chemotherapy 0 +in 0 +this 0 +group 0 +of 0 +patients 0 +. 0 +Recent 0 +reports 0 +indicate 0 +that 0 +single 0 +agent 0 +therapy 0 +with 0 +vinorelbine 1 +( 0 +VNB 1 +) 0 +or 0 +gemcitabine 1 +( 0 +GEM 1 +) 0 +may 0 +obtain 0 +a 0 +response 0 +rate 0 +of 0 +20 0 +- 0 +30 0 +% 0 +in 0 +elderly 0 +patients 0 +"," 0 +with 0 +acceptable 0 +toxicity 3 +and 0 +improvement 0 +in 0 +symptoms 0 +and 0 +quality 0 +of 0 +life 0 +. 0 +In 0 +the 0 +current 0 +study 0 +the 0 +efficacy 0 +and 0 +toxicity 3 +of 0 +the 0 +combination 0 +of 0 +GEM 1 +and 0 +VNB 1 +in 0 +elderly 0 +patients 0 +with 0 +advanced 0 +NSCLC 3 +or 0 +those 0 +with 0 +some 0 +contraindication 0 +to 0 +receiving 0 +cisplatin 1 +were 0 +assessed 0 +. 0 +METH0DS 0 +: 0 +Forty 0 +- 0 +nine 0 +patients 0 +with 0 +advanced 0 +NSCLC 3 +were 0 +included 0 +"," 0 +38 0 +of 0 +whom 0 +were 0 +age 0 +> 0 +/ 0 += 0 +70 0 +years 0 +and 0 +11 0 +were 0 +age 0 +< 0 +70 0 +years 0 +but 0 +who 0 +had 0 +some 0 +contraindication 0 +to 0 +receiving 0 +cisplatin 1 +. 0 +All 0 +patients 0 +were 0 +evaluable 0 +for 0 +response 0 +and 0 +toxicity 3 +. 0 +Treatment 0 +was 0 +comprised 0 +of 0 +VNB 1 +"," 0 +25 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +"," 0 +plus 0 +GEM 1 +"," 0 +1000 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +"," 0 +both 0 +on 0 +Days 0 +1 0 +"," 0 +8 0 +"," 0 +and 0 +15 0 +every 0 +28 0 +days 0 +. 0 +Patients 0 +received 0 +a 0 +minimum 0 +of 0 +three 0 +courses 0 +unless 0 +progressive 0 +disease 0 +was 0 +detected 0 +. 0 +RESULTS 0 +: 0 +0ne 0 +hundred 0 +sixty 0 +- 0 +five 0 +courses 0 +were 0 +administered 0 +"," 0 +with 0 +a 0 +median 0 +of 0 +3 0 +. 0 +6 0 +courses 0 +per 0 +patient 0 +. 0 +The 0 +overall 0 +response 0 +rate 0 +was 0 +26 0 +% 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +"," 0 +15 0 +- 0 +41 0 +% 0 +) 0 +. 0 +Two 0 +patients 0 +attained 0 +a 0 +complete 0 +response 0 +( 0 +4 0 +% 0 +) 0 +and 0 +11 0 +patients 0 +( 0 +22 0 +% 0 +) 0 +achieved 0 +a 0 +partial 0 +response 0 +. 0 +Eastern 0 +Cooperative 0 +0ncology 0 +Group 0 +performance 0 +status 0 +improved 0 +in 0 +35 0 +% 0 +of 0 +those 0 +patients 0 +with 0 +an 0 +initial 0 +value 0 +> 0 +0 0 +"," 0 +whereas 0 +relief 0 +of 0 +at 0 +least 0 +1 0 +symptom 0 +without 0 +worsening 0 +of 0 +other 0 +symptoms 0 +was 0 +noted 0 +in 0 +27 0 +patients 0 +( 0 +55 0 +% 0 +) 0 +. 0 +The 0 +median 0 +time 0 +to 0 +progression 0 +was 0 +16 0 +weeks 0 +and 0 +the 0 +1 0 +- 0 +year 0 +survival 0 +rate 0 +was 0 +33 0 +% 0 +. 0 +Toxicity 3 +was 0 +mild 0 +. 0 +Six 0 +patients 0 +( 0 +12 0 +% 0 +) 0 +had 0 +World 0 +Health 0 +0rganization 0 +Grade 0 +3 0 +- 0 +4 0 +neutropenia 3 +"," 0 +2 0 +patients 0 +( 0 +4 0 +% 0 +) 0 +had 0 +Grade 0 +3 0 +- 0 +4 0 +thrombocytopenia 3 +"," 0 +and 0 +2 0 +patients 0 +( 0 +4 0 +% 0 +) 0 +had 0 +Grade 0 +3 0 +neurotoxicity 3 +. 0 +Three 0 +patients 0 +with 0 +severe 0 +neutropenia 3 +( 0 +6 0 +% 0 +) 0 +died 0 +of 0 +sepsis 3 +. 0 +The 0 +median 0 +age 0 +of 0 +those 0 +patients 0 +developing 0 +Grade 0 +3 0 +- 0 +4 0 +neutropenia 3 +was 0 +significantly 0 +higher 0 +than 0 +that 0 +of 0 +the 0 +remaining 0 +patients 0 +( 0 +75 0 +years 0 +vs 0 +. 0 +72 0 +years 0 +; 0 +P 0 += 0 +0 0 +. 0 +47 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +combination 0 +of 0 +GEM 1 +and 0 +VNB 1 +is 0 +moderately 0 +active 0 +and 0 +well 0 +tolerated 0 +except 0 +in 0 +patients 0 +age 0 +> 0 +/ 0 += 0 +75 0 +years 0 +. 0 +This 0 +age 0 +group 0 +had 0 +an 0 +increased 0 +risk 0 +of 0 +myelosuppression 3 +. 0 +Therefore 0 +the 0 +prophylactic 0 +use 0 +of 0 +granulocyte 0 +- 0 +colony 0 +stimulating 0 +factor 0 +should 0 +be 0 +considered 0 +with 0 +this 0 +treatment 0 +. 0 +New 0 +chemotherapy 0 +combinations 0 +with 0 +higher 0 +activity 0 +and 0 +lower 0 +toxicity 3 +are 0 +needed 0 +for 0 +elderly 0 +patients 0 +with 0 +advanced 0 +NSCLC 3 +. 0 +A 0 +selective 0 +dopamine 1 +D4 0 +receptor 0 +antagonist 0 +"," 0 +NRA0160 1 +: 0 +a 0 +preclinical 0 +neuropharmacological 0 +profile 0 +. 0 +NRA0160 1 +"," 0 +5 1 +- 2 +[ 2 +2 2 +- 2 +( 2 +4 2 +- 2 +( 2 +3 2 +- 2 +fluorobenzylidene 2 +) 2 +piperidin 2 +- 2 +1 2 +- 2 +yl 2 +) 2 +ethyl 2 +] 2 +- 2 +4 2 +- 2 +( 2 +4 2 +- 2 +fluorophenyl 2 +) 2 +thiazole 2 +- 2 +2 2 +- 2 +carboxamide 2 +"," 0 +has 0 +a 0 +high 0 +affinity 0 +for 0 +human 0 +cloned 0 +dopamine 1 +D4 0 +. 0 +2 0 +"," 0 +D4 0 +. 0 +4 0 +and 0 +D4 0 +. 0 +7 0 +receptors 0 +"," 0 +with 0 +Ki 0 +values 0 +of 0 +0 0 +. 0 +5 0 +"," 0 +0 0 +. 0 +9 0 +and 0 +2 0 +. 0 +7 0 +nM 0 +"," 0 +respectively 0 +. 0 +NRA0160 1 +is 0 +over 0 +20 0 +"," 0 +000fold 0 +more 0 +potent 0 +at 0 +the 0 +dopamine 1 +D4 0 +. 0 +2 0 +receptor 0 +compared 0 +with 0 +the 0 +human 0 +cloned 0 +dopamine 1 +D2L 0 +receptor 0 +. 0 +NRA0160 1 +has 0 +negligible 0 +affinity 0 +for 0 +the 0 +human 0 +cloned 0 +dopamine 1 +D3 0 +receptor 0 +( 0 +Ki 0 += 0 +39 0 +nM 0 +) 0 +"," 0 +rat 0 +serotonin 1 +( 0 +5 1 +- 2 +HT 2 +) 0 +2A 0 +receptors 0 +( 0 +Ki 0 += 0 +180 0 +nM 0 +) 0 +and 0 +rat 0 +alpha1 0 +adrenoceptor 0 +( 0 +Ki 0 += 0 +237 0 +nM 0 +) 0 +. 0 +NRA0160 1 +and 0 +clozapine 1 +antagonized 0 +locomotor 0 +hyperactivity 3 +induced 0 +by 0 +methamphetamine 1 +( 0 +MAP 1 +) 0 +in 0 +mice 0 +. 0 +NRA0160 1 +and 0 +clozapine 1 +antagonized 0 +MAP 1 +- 0 +induced 0 +stereotyped 0 +behavior 0 +in 0 +mice 0 +"," 0 +although 0 +their 0 +effects 0 +did 0 +not 0 +exceed 0 +50 0 +% 0 +inhibition 0 +"," 0 +even 0 +at 0 +the 0 +highest 0 +dose 0 +given 0 +. 0 +NRA0160 1 +and 0 +clozapine 1 +significantly 0 +induced 0 +catalepsy 3 +in 0 +rats 0 +"," 0 +although 0 +their 0 +effects 0 +did 0 +not 0 +exceed 0 +50 0 +% 0 +induction 0 +even 0 +at 0 +the 0 +highest 0 +dose 0 +given 0 +. 0 +NRA0160 1 +and 0 +clozapine 1 +significantly 0 +reversed 0 +the 0 +disruption 0 +of 0 +prepulse 0 +inhibition 0 +( 0 +PPI 0 +) 0 +in 0 +rats 0 +produced 0 +by 0 +apomorphine 1 +. 0 +NRA0160 1 +and 0 +clozapine 1 +significantly 0 +shortened 0 +the 0 +phencyclidine 1 +( 0 +PCP 1 +) 0 +- 0 +induced 0 +prolonged 0 +swimming 0 +latency 0 +in 0 +rats 0 +in 0 +a 0 +water 0 +maze 0 +task 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +NRA0160 1 +may 0 +have 0 +unique 0 +antipsychotic 0 +activities 0 +without 0 +the 0 +liability 0 +of 0 +motor 0 +side 0 +effects 0 +typical 0 +of 0 +classical 0 +antipsychotics 0 +. 0 +Warfarin 1 +- 0 +induced 0 +artery 3 +calcification 4 +is 0 +accelerated 0 +by 0 +growth 0 +and 0 +vitamin 1 +D 2 +. 0 +The 0 +present 0 +studies 0 +demonstrate 0 +that 0 +growth 0 +and 0 +vitamin 1 +D 2 +treatment 0 +enhance 0 +the 0 +extent 0 +of 0 +artery 3 +calcification 4 +in 0 +rats 0 +given 0 +sufficient 0 +doses 0 +of 0 +Warfarin 1 +to 0 +inhibit 0 +gamma 0 +- 0 +carboxylation 0 +of 0 +matrix 0 +Gla 0 +protein 0 +"," 0 +a 0 +calcification 3 +inhibitor 0 +known 0 +to 0 +be 0 +expressed 0 +by 0 +smooth 0 +muscle 0 +cells 0 +and 0 +macrophages 0 +in 0 +the 0 +artery 0 +wall 0 +. 0 +The 0 +first 0 +series 0 +of 0 +experiments 0 +examined 0 +the 0 +influence 0 +of 0 +age 0 +and 0 +growth 0 +status 0 +on 0 +artery 3 +calcification 4 +in 0 +Warfarin 1 +- 0 +treated 0 +rats 0 +. 0 +Treatment 0 +for 0 +2 0 +weeks 0 +with 0 +Warfarin 1 +caused 0 +massive 0 +focal 0 +calcification 3 +of 4 +the 4 +artery 4 +media 0 +in 0 +20 0 +- 0 +day 0 +- 0 +old 0 +rats 0 +and 0 +less 0 +extensive 0 +focal 0 +calcification 3 +in 0 +42 0 +- 0 +day 0 +- 0 +old 0 +rats 0 +. 0 +In 0 +contrast 0 +"," 0 +no 0 +artery 3 +calcification 4 +could 0 +be 0 +detected 0 +in 0 +10 0 +- 0 +month 0 +- 0 +old 0 +adult 0 +rats 0 +even 0 +after 0 +4 0 +weeks 0 +of 0 +Warfarin 1 +treatment 0 +. 0 +To 0 +directly 0 +examine 0 +the 0 +importance 0 +of 0 +growth 0 +to 0 +Warfarin 1 +- 0 +induced 0 +artery 3 +calcification 4 +in 0 +animals 0 +of 0 +the 0 +same 0 +age 0 +"," 0 +20 0 +- 0 +day 0 +- 0 +old 0 +rats 0 +were 0 +fed 0 +for 0 +2 0 +weeks 0 +either 0 +an 0 +ad 0 +libitum 0 +diet 0 +or 0 +a 0 +6 0 +- 0 +g 0 +/ 0 +d 0 +restricted 0 +diet 0 +that 0 +maintains 0 +weight 0 +but 0 +prevents 0 +growth 0 +. 0 +Concurrent 0 +treatment 0 +of 0 +both 0 +dietary 0 +groups 0 +with 0 +Warfarin 1 +produced 0 +massive 0 +focal 0 +calcification 3 +of 4 +the 4 +artery 4 +media 0 +in 0 +the 0 +ad 0 +libitum 0 +- 0 +fed 0 +rats 0 +but 0 +no 0 +detectable 0 +artery 3 +calcification 4 +in 0 +the 0 +restricted 0 +- 0 +diet 0 +"," 0 +growth 0 +- 0 +inhibited 0 +group 0 +. 0 +Although 0 +the 0 +explanation 0 +for 0 +the 0 +association 0 +between 0 +artery 3 +calcification 4 +and 0 +growth 0 +status 0 +cannot 0 +be 0 +determined 0 +from 0 +the 0 +present 0 +study 0 +"," 0 +there 0 +was 0 +a 0 +relationship 0 +between 0 +higher 0 +serum 0 +phosphate 1 +and 0 +susceptibility 0 +to 0 +artery 3 +calcification 4 +"," 0 +with 0 +30 0 +% 0 +higher 0 +levels 0 +of 0 +serum 0 +phosphate 1 +in 0 +young 0 +"," 0 +ad 0 +libitum 0 +- 0 +fed 0 +rats 0 +compared 0 +with 0 +either 0 +of 0 +the 0 +groups 0 +that 0 +was 0 +resistant 0 +to 0 +Warfarin 1 +- 0 +induced 0 +artery 3 +calcification 4 +"," 0 +ie 0 +"," 0 +the 0 +10 0 +- 0 +month 0 +- 0 +old 0 +rats 0 +and 0 +the 0 +restricted 0 +- 0 +diet 0 +"," 0 +growth 0 +- 0 +inhibited 0 +young 0 +rats 0 +. 0 +This 0 +observation 0 +suggests 0 +that 0 +increased 0 +susceptibility 0 +to 0 +Warfarin 1 +- 0 +induced 0 +artery 3 +calcification 4 +could 0 +be 0 +related 0 +to 0 +higher 0 +serum 0 +phosphate 1 +levels 0 +. 0 +The 0 +second 0 +set 0 +of 0 +experiments 0 +examined 0 +the 0 +possible 0 +synergy 0 +between 0 +vitamin 1 +D 2 +and 0 +Warfarin 1 +in 0 +artery 3 +calcification 4 +. 0 +High 0 +doses 0 +of 0 +vitamin 1 +D 2 +are 0 +known 0 +to 0 +cause 0 +calcification 3 +of 4 +the 4 +artery 4 +media 0 +in 0 +as 0 +little 0 +as 0 +3 0 +to 0 +4 0 +days 0 +. 0 +High 0 +doses 0 +of 0 +the 0 +vitamin 1 +K 2 +antagonist 0 +Warfarin 1 +are 0 +also 0 +known 0 +to 0 +cause 0 +calcification 3 +of 4 +the 4 +artery 4 +media 0 +"," 0 +but 0 +at 0 +treatment 0 +times 0 +of 0 +2 0 +weeks 0 +or 0 +longer 0 +yet 0 +not 0 +at 0 +1 0 +week 0 +. 0 +In 0 +the 0 +current 0 +study 0 +"," 0 +we 0 +investigated 0 +the 0 +synergy 0 +between 0 +these 0 +2 0 +treatments 0 +and 0 +found 0 +that 0 +concurrent 0 +Warfarin 1 +administration 0 +dramatically 0 +increased 0 +the 0 +extent 0 +of 0 +calcification 3 +in 0 +the 0 +media 0 +of 0 +vitamin 1 +D 2 +- 0 +treated 0 +rats 0 +at 0 +3 0 +and 0 +4 0 +days 0 +. 0 +There 0 +was 0 +a 0 +close 0 +parallel 0 +between 0 +the 0 +effect 0 +of 0 +vitamin 1 +D 2 +dose 0 +on 0 +artery 3 +calcification 4 +and 0 +the 0 +effect 0 +of 0 +vitamin 1 +D 2 +dose 0 +on 0 +the 0 +elevation 0 +of 0 +serum 0 +calcium 1 +"," 0 +which 0 +suggests 0 +that 0 +vitamin 1 +D 2 +may 0 +induce 0 +artery 3 +calcification 4 +through 0 +its 0 +effect 0 +on 0 +serum 0 +calcium 1 +. 0 +Because 0 +Warfarin 1 +treatment 0 +had 0 +no 0 +effect 0 +on 0 +the 0 +elevation 0 +in 0 +serum 0 +calcium 1 +produced 0 +by 0 +vitamin 1 +D 2 +"," 0 +the 0 +synergy 0 +between 0 +Warfarin 1 +and 0 +vitamin 1 +D 2 +is 0 +probably 0 +best 0 +explained 0 +by 0 +the 0 +hypothesis 0 +that 0 +Warfarin 1 +inhibits 0 +the 0 +activity 0 +of 0 +matrix 0 +Gla 0 +protein 0 +as 0 +a 0 +calcification 3 +inhibitor 0 +. 0 +High 0 +levels 0 +of 0 +matrix 0 +Gla 0 +protein 0 +are 0 +found 0 +at 0 +sites 0 +of 0 +artery 3 +calcification 4 +in 0 +rats 0 +treated 0 +with 0 +vitamin 1 +D 2 +plus 0 +Warfarin 1 +"," 0 +and 0 +chemical 0 +analysis 0 +showed 0 +that 0 +the 0 +protein 0 +that 0 +accumulated 0 +was 0 +indeed 0 +not 0 +gamma 1 +- 2 +carboxylated 2 +. 0 +These 0 +observations 0 +indicate 0 +that 0 +although 0 +the 0 +gamma 1 +- 2 +carboxyglutamate 2 +residues 0 +of 0 +matrix 0 +Gla 0 +protein 0 +are 0 +apparently 0 +required 0 +for 0 +its 0 +function 0 +as 0 +a 0 +calcification 3 +inhibitor 0 +"," 0 +they 0 +are 0 +not 0 +required 0 +for 0 +its 0 +accumulation 0 +at 0 +calcification 3 +sites 0 +. 0 +Test 0 +conditions 0 +influence 0 +the 0 +response 0 +to 0 +a 0 +drug 0 +challenge 0 +in 0 +rodents 0 +. 0 +These 0 +studies 0 +were 0 +conducted 0 +to 0 +examine 0 +the 0 +differential 0 +response 0 +to 0 +a 0 +drug 0 +challenge 0 +under 0 +varied 0 +experimental 0 +test 0 +conditions 0 +routinely 0 +employed 0 +to 0 +study 0 +drug 0 +- 0 +induced 0 +behavioral 0 +and 0 +neurophysiological 0 +responses 0 +in 0 +rodents 0 +. 0 +Apomorphine 1 +"," 0 +a 0 +nonselective 0 +dopamine 1 +agonist 2 +"," 0 +was 0 +selected 0 +due 0 +to 0 +its 0 +biphasic 0 +behavioral 0 +effects 0 +"," 0 +its 0 +ability 0 +to 0 +induce 0 +hypothermia 3 +"," 0 +and 0 +to 0 +produce 0 +distinct 0 +changes 0 +to 0 +dopamine 1 +turnover 0 +in 0 +the 0 +rodent 0 +brain 0 +. 0 +From 0 +such 0 +experiments 0 +there 0 +is 0 +evidence 0 +that 0 +characterization 0 +and 0 +detection 0 +of 0 +apomorphine 1 +- 0 +induced 0 +activity 0 +in 0 +rodents 0 +critically 0 +depends 0 +upon 0 +the 0 +test 0 +conditions 0 +employed 0 +. 0 +In 0 +rats 0 +"," 0 +detection 0 +of 0 +apomorphine 1 +- 0 +induced 0 +hyperactivity 3 +was 0 +facilitated 0 +by 0 +a 0 +period 0 +of 0 +acclimatization 0 +to 0 +the 0 +test 0 +conditions 0 +. 0 +Moreover 0 +"," 0 +test 0 +conditions 0 +can 0 +impact 0 +upon 0 +other 0 +physiological 0 +responses 0 +to 0 +apomorphine 1 +such 0 +as 0 +drug 0 +- 0 +induced 0 +hypothermia 3 +. 0 +In 0 +mice 0 +"," 0 +apomorphine 1 +produced 0 +qualitatively 0 +different 0 +responses 0 +under 0 +novel 0 +conditions 0 +when 0 +compared 0 +to 0 +those 0 +behaviors 0 +elicited 0 +in 0 +the 0 +home 0 +test 0 +cage 0 +. 0 +Drug 0 +- 0 +induced 0 +gross 0 +activity 0 +counts 0 +were 0 +increased 0 +in 0 +the 0 +novel 0 +exploratory 0 +box 0 +only 0 +"," 0 +while 0 +measures 0 +of 0 +stereotypic 0 +behavior 0 +were 0 +similar 0 +in 0 +both 0 +. 0 +By 0 +contrast 0 +"," 0 +apomorphine 1 +- 0 +induced 0 +locomotion 0 +was 0 +more 0 +prominent 0 +in 0 +the 0 +novel 0 +exploratory 0 +box 0 +. 0 +Dopamine 1 +turnover 0 +ratios 0 +( 0 +D0PAC 1 +: 0 +DA 1 +and 0 +HVA 1 +: 0 +DA 1 +) 0 +were 0 +found 0 +to 0 +be 0 +lower 0 +in 0 +those 0 +animals 0 +exposed 0 +to 0 +the 0 +exploratory 0 +box 0 +when 0 +compared 0 +to 0 +their 0 +home 0 +cage 0 +counterparts 0 +. 0 +However 0 +"," 0 +apomorphine 1 +- 0 +induced 0 +reductions 0 +in 0 +striatal 0 +dopamine 1 +turnover 0 +were 0 +detected 0 +in 0 +both 0 +novel 0 +and 0 +home 0 +cage 0 +environments 0 +. 0 +The 0 +implications 0 +of 0 +these 0 +findings 0 +are 0 +discussed 0 +with 0 +particular 0 +emphasis 0 +upon 0 +conducting 0 +psychopharmacological 0 +challenge 0 +tests 0 +in 0 +rodents 0 +. 0 +Hemolysis 3 +of 0 +human 0 +erythrocytes 0 +induced 0 +by 0 +tamoxifen 1 +is 0 +related 0 +to 0 +disruption 0 +of 0 +membrane 0 +structure 0 +. 0 +Tamoxifen 1 +( 0 +TAM 1 +) 0 +"," 0 +the 0 +antiestrogenic 0 +drug 0 +most 0 +widely 0 +prescribed 0 +in 0 +the 0 +chemotherapy 0 +of 0 +breast 3 +cancer 4 +"," 0 +induces 0 +changes 0 +in 0 +normal 0 +discoid 0 +shape 0 +of 0 +erythrocytes 0 +and 0 +hemolytic 3 +anemia 4 +. 0 +This 0 +work 0 +evaluates 0 +the 0 +effects 0 +of 0 +TAM 1 +on 0 +isolated 0 +human 0 +erythrocytes 0 +"," 0 +attempting 0 +to 0 +identify 0 +the 0 +underlying 0 +mechanisms 0 +on 0 +TAM 1 +- 0 +induced 0 +hemolytic 3 +anemia 4 +and 0 +the 0 +involvement 0 +of 0 +biomembranes 0 +in 0 +its 0 +cytostatic 0 +action 0 +mechanisms 0 +. 0 +TAM 1 +induces 0 +hemolysis 3 +of 0 +erythrocytes 0 +as 0 +a 0 +function 0 +of 0 +concentration 0 +. 0 +The 0 +extension 0 +of 0 +hemolysis 3 +is 0 +variable 0 +with 0 +erythrocyte 0 +samples 0 +"," 0 +but 0 +12 0 +. 0 +5 0 +microM 0 +TAM 1 +induces 0 +total 0 +hemolysis 3 +of 0 +all 0 +tested 0 +suspensions 0 +. 0 +Despite 0 +inducing 0 +extensive 0 +erythrocyte 0 +lysis 0 +"," 0 +TAM 1 +does 0 +not 0 +shift 0 +the 0 +osmotic 0 +fragility 0 +curves 0 +of 0 +erythrocytes 0 +. 0 +The 0 +hemolytic 3 +effect 0 +of 0 +TAM 1 +is 0 +prevented 0 +by 0 +low 0 +concentrations 0 +of 0 +alpha 1 +- 2 +tocopherol 2 +( 0 +alpha 1 +- 2 +T 2 +) 0 +and 0 +alpha 1 +- 2 +tocopherol 2 +acetate 2 +( 0 +alpha 1 +- 2 +TAc 2 +) 0 +( 0 +inactivated 0 +functional 0 +hydroxyl 1 +) 0 +indicating 0 +that 0 +TAM 1 +- 0 +induced 0 +hemolysis 3 +is 0 +not 0 +related 0 +to 0 +oxidative 0 +membrane 0 +damage 0 +. 0 +This 0 +was 0 +further 0 +evidenced 0 +by 0 +absence 0 +of 0 +oxygen 1 +consumption 0 +and 0 +hemoglobin 0 +oxidation 0 +both 0 +determined 0 +in 0 +parallel 0 +with 0 +TAM 1 +- 0 +induced 0 +hemolysis 3 +. 0 +Furthermore 0 +"," 0 +it 0 +was 0 +observed 0 +that 0 +TAM 1 +inhibits 0 +the 0 +peroxidation 0 +of 0 +human 0 +erythrocytes 0 +induced 0 +by 0 +AAPH 1 +"," 0 +thus 0 +ruling 0 +out 0 +TAM 1 +- 0 +induced 0 +cell 0 +oxidative 0 +stress 0 +. 0 +Hemolysis 3 +caused 0 +by 0 +TAM 1 +was 0 +not 0 +preceded 0 +by 0 +the 0 +leakage 0 +of 0 +K 1 +( 0 ++ 0 +) 0 +from 0 +the 0 +cells 0 +"," 0 +also 0 +excluding 0 +a 0 +colloid 0 +- 0 +osmotic 0 +type 0 +mechanism 0 +of 0 +hemolysis 3 +"," 0 +according 0 +to 0 +the 0 +effects 0 +on 0 +osmotic 0 +fragility 0 +curves 0 +. 0 +However 0 +"," 0 +TAM 1 +induces 0 +release 0 +of 0 +peripheral 0 +proteins 0 +of 0 +membrane 0 +- 0 +cytoskeleton 0 +and 0 +cytosol 0 +proteins 0 +essentially 0 +bound 0 +to 0 +band 0 +3 0 +. 0 +Either 0 +alpha 1 +- 2 +T 2 +or 0 +alpha 1 +- 2 +TAc 2 +increases 0 +membrane 0 +packing 0 +and 0 +prevents 0 +TAM 1 +partition 0 +into 0 +model 0 +membranes 0 +. 0 +These 0 +effects 0 +suggest 0 +that 0 +the 0 +protection 0 +from 0 +hemolysis 3 +by 0 +tocopherols 1 +is 0 +related 0 +to 0 +a 0 +decreased 0 +TAM 1 +incorporation 0 +in 0 +condensed 0 +membranes 0 +and 0 +the 0 +structural 0 +damage 0 +of 0 +the 0 +erythrocyte 0 +membrane 0 +is 0 +consequently 0 +avoided 0 +. 0 +Therefore 0 +"," 0 +TAM 1 +- 0 +induced 0 +hemolysis 3 +results 0 +from 0 +a 0 +structural 0 +perturbation 0 +of 0 +red 0 +cell 0 +membrane 0 +"," 0 +leading 0 +to 0 +changes 0 +in 0 +the 0 +framework 0 +of 0 +the 0 +erythrocyte 0 +membrane 0 +and 0 +its 0 +cytoskeleton 0 +caused 0 +by 0 +its 0 +high 0 +partition 0 +in 0 +the 0 +membrane 0 +. 0 +These 0 +defects 0 +explain 0 +the 0 +abnormal 0 +erythrocyte 0 +shape 0 +and 0 +decreased 0 +mechanical 0 +stability 0 +promoted 0 +by 0 +TAM 1 +"," 0 +resulting 0 +in 0 +hemolytic 3 +anemia 4 +. 0 +Additionally 0 +"," 0 +since 0 +membrane 0 +leakage 0 +is 0 +a 0 +final 0 +stage 0 +of 0 +cytotoxicity 0 +"," 0 +the 0 +disruption 0 +of 0 +the 0 +structural 0 +characteristics 0 +of 0 +biomembranes 0 +by 0 +TAM 1 +may 0 +contribute 0 +to 0 +the 0 +multiple 0 +mechanisms 0 +of 0 +its 0 +anticancer 0 +action 0 +. 0 +Changes 0 +of 0 +sodium 1 +and 0 +ATP 1 +affinities 0 +of 0 +the 0 +cardiac 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +during 0 +and 0 +after 0 +nitric 1 +oxide 2 +deficient 0 +hypertension 3 +. 0 +In 0 +the 0 +cardiovascular 0 +system 0 +"," 0 +N0 1 +is 0 +involved 0 +in 0 +the 0 +regulation 0 +of 0 +a 0 +variety 0 +of 0 +functions 0 +. 0 +Inhibition 0 +of 0 +N0 1 +synthesis 0 +induces 0 +sustained 0 +hypertension 3 +. 0 +In 0 +several 0 +models 0 +of 0 +hypertension 3 +"," 0 +elevation 0 +of 0 +intracellular 0 +sodium 1 +level 0 +was 0 +documented 0 +in 0 +cardiac 0 +tissue 0 +. 0 +To 0 +assess 0 +the 0 +molecular 0 +basis 0 +of 0 +disturbances 0 +in 0 +transmembraneous 0 +transport 0 +of 0 +Na 1 ++ 0 +"," 0 +we 0 +studied 0 +the 0 +response 0 +of 0 +cardiac 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +to 0 +N0 1 +- 0 +deficient 0 +hypertension 3 +induced 0 +in 0 +rats 0 +by 0 +N0 1 +- 0 +synthase 0 +inhibition 0 +with 0 +40 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +N 1 +( 2 +G 2 +) 2 +- 2 +nitro 2 +- 2 +L 2 +- 2 +arginine 2 +methyl 2 +ester 2 +( 0 +L 1 +- 2 +NAME 2 +) 0 +for 0 +4 0 +four 0 +weeks 0 +. 0 +After 0 +4 0 +- 0 +week 0 +administration 0 +of 0 +L 1 +- 2 +NAME 2 +"," 0 +the 0 +systolic 0 +blood 0 +pressure 0 +( 0 +SBP 0 +) 0 +increased 0 +by 0 +36 0 +% 0 +. 0 +Two 0 +weeks 0 +after 0 +terminating 0 +the 0 +treatment 0 +"," 0 +the 0 +SBP 0 +recovered 0 +to 0 +control 0 +value 0 +. 0 +When 0 +activating 0 +the 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +with 0 +its 0 +substrate 0 +ATP 1 +"," 0 +no 0 +changes 0 +in 0 +Km 0 +and 0 +Vmax 0 +values 0 +were 0 +observed 0 +in 0 +N0 1 +- 0 +deficient 0 +rats 0 +. 0 +During 0 +activation 0 +with 0 +Na 1 ++ 0 +"," 0 +the 0 +Vmax 0 +remained 0 +unchanged 0 +"," 0 +however 0 +the 0 +K 1 +( 0 +Na 1 +) 0 +increased 0 +by 0 +50 0 +% 0 +"," 0 +indicating 0 +a 0 +profound 0 +decrease 0 +in 0 +the 0 +affinity 0 +of 0 +the 0 +Na 1 ++ 0 +- 0 +binding 0 +site 0 +in 0 +N0 1 +- 0 +deficient 0 +rats 0 +. 0 +After 0 +recovery 0 +from 0 +hypertension 3 +"," 0 +the 0 +activity 0 +of 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +increased 0 +"," 0 +due 0 +to 0 +higher 0 +affinity 0 +of 0 +the 0 +ATP 1 +- 0 +binding 0 +site 0 +"," 0 +as 0 +revealed 0 +from 0 +the 0 +lowered 0 +Km 0 +value 0 +for 0 +ATP 1 +. 0 +The 0 +K 1 +( 0 +Na 1 +) 0 +value 0 +for 0 +Na 1 ++ 0 +returned 0 +to 0 +control 0 +value 0 +. 0 +Inhibition 0 +of 0 +N0 1 +- 0 +synthase 0 +induced 0 +a 0 +reversible 0 +hypertension 3 +accompanied 0 +by 0 +depressed 3 +Na 1 ++ 0 +- 0 +extrusion 0 +from 0 +cardiac 0 +cells 0 +as 0 +a 0 +consequence 0 +of 0 +deteriorated 0 +Na 1 ++ 0 +- 0 +binding 0 +properties 0 +of 0 +the 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +. 0 +After 0 +recovery 0 +of 0 +blood 0 +pressure 0 +to 0 +control 0 +values 0 +"," 0 +the 0 +extrusion 0 +of 0 +Na 1 ++ 0 +from 0 +cardiac 0 +cells 0 +was 0 +normalized 0 +"," 0 +as 0 +revealed 0 +by 0 +restoration 0 +of 0 +the 0 +( 0 +Na 1 +"," 0 +K 1 +) 0 +- 0 +ATPase 0 +activity 0 +. 0 +Effects 0 +of 0 +long 0 +- 0 +term 0 +pretreatment 0 +with 0 +isoproterenol 1 +on 0 +bromocriptine 1 +- 0 +induced 0 +tachycardia 3 +in 0 +conscious 0 +rats 0 +. 0 +It 0 +has 0 +been 0 +shown 0 +that 0 +bromocriptine 1 +- 0 +induced 0 +tachycardia 3 +"," 0 +which 0 +persisted 0 +after 0 +adrenalectomy 0 +"," 0 +is 0 +( 0 +i 0 +) 0 +mediated 0 +by 0 +central 0 +dopamine 1 +D2 0 +receptor 0 +activation 0 +and 0 +( 0 +ii 0 +) 0 +reduced 0 +by 0 +5 0 +- 0 +day 0 +isoproterenol 1 +pretreatment 0 +"," 0 +supporting 0 +therefore 0 +the 0 +hypothesis 0 +that 0 +this 0 +effect 0 +is 0 +dependent 0 +on 0 +sympathetic 0 +outflow 0 +to 0 +the 0 +heart 0 +. 0 +This 0 +study 0 +was 0 +conducted 0 +to 0 +examine 0 +whether 0 +prolonged 0 +pretreatment 0 +with 0 +isoproterenol 1 +could 0 +abolish 0 +bromocriptine 1 +- 0 +induced 0 +tachycardia 3 +in 0 +conscious 0 +rats 0 +. 0 +Isoproterenol 1 +pretreatment 0 +for 0 +15 0 +days 0 +caused 0 +cardiac 3 +hypertrophy 4 +without 0 +affecting 0 +baseline 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +. 0 +In 0 +control 0 +rats 0 +"," 0 +intravenous 0 +bromocriptine 1 +( 0 +150 0 +microg 0 +/ 0 +kg 0 +) 0 +induced 0 +significant 0 +hypotension 3 +and 0 +tachycardia 3 +. 0 +Bromocriptine 1 +- 0 +induced 0 +hypotension 3 +was 0 +unaffected 0 +by 0 +isoproterenol 1 +pretreatment 0 +"," 0 +while 0 +tachycardia 3 +was 0 +reversed 0 +to 0 +significant 0 +bradycardia 3 +"," 0 +an 0 +effect 0 +that 0 +was 0 +partly 0 +reduced 0 +by 0 +i 0 +. 0 +v 0 +. 0 +domperidone 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 +Neither 0 +cardiac 0 +vagal 0 +nor 0 +sympathetic 0 +tone 0 +was 0 +altered 0 +by 0 +isoproterenol 1 +pretreatment 0 +. 0 +In 0 +isolated 0 +perfused 0 +heart 0 +preparations 0 +from 0 +isoproterenol 1 +- 0 +pretreated 0 +rats 0 +"," 0 +the 0 +isoproterenol 1 +- 0 +induced 0 +maximal 0 +increase 0 +in 0 +left 0 +ventricular 0 +systolic 0 +pressure 0 +was 0 +significantly 0 +reduced 0 +"," 0 +compared 0 +with 0 +saline 0 +- 0 +pretreated 0 +rats 0 +( 0 +the 0 +EC50 0 +of 0 +the 0 +isoproterenol 1 +- 0 +induced 0 +increase 0 +in 0 +left 0 +ventricular 0 +systolic 0 +pressure 0 +was 0 +enhanced 0 +approximately 0 +22 0 +- 0 +fold 0 +) 0 +. 0 +These 0 +results 0 +show 0 +that 0 +15 0 +- 0 +day 0 +isoproterenol 1 +pretreatment 0 +not 0 +only 0 +abolished 0 +but 0 +reversed 0 +bromocriptine 1 +- 0 +induced 0 +tachycardia 3 +to 0 +bradycardia 3 +"," 0 +an 0 +effect 0 +that 0 +is 0 +mainly 0 +related 0 +to 0 +further 0 +cardiac 0 +beta 0 +- 0 +adrenoceptor 0 +desensitization 0 +rather 0 +than 0 +to 0 +impairment 0 +of 0 +autonomic 0 +regulation 0 +of 0 +the 0 +heart 0 +. 0 +They 0 +suggest 0 +that 0 +"," 0 +in 0 +normal 0 +conscious 0 +rats 0 +"," 0 +the 0 +central 0 +tachycardia 3 +of 0 +bromocriptine 1 +appears 0 +to 0 +predominate 0 +and 0 +to 0 +mask 0 +the 0 +bradycardia 3 +of 0 +this 0 +agonist 0 +at 0 +peripheral 0 +dopamine 1 +D2 0 +receptors 0 +. 0 +A 0 +developmental 0 +analysis 0 +of 0 +clonidine 1 +' 0 +s 0 +effects 0 +on 0 +cardiac 0 +rate 0 +and 0 +ultrasound 0 +production 0 +in 0 +infant 0 +rats 0 +. 0 +Under 0 +controlled 0 +conditions 0 +"," 0 +infant 0 +rats 0 +emit 0 +ultrasonic 0 +vocalizations 0 +during 0 +extreme 0 +cold 0 +exposure 0 +and 0 +after 0 +administration 0 +of 0 +the 0 +alpha 0 +( 0 +2 0 +) 0 +adrenoceptor 0 +agonist 0 +"," 0 +clonidine 1 +. 0 +Previous 0 +investigations 0 +have 0 +determined 0 +that 0 +"," 0 +in 0 +response 0 +to 0 +clonidine 1 +"," 0 +ultrasound 0 +production 0 +increases 0 +through 0 +the 0 +2nd 0 +- 0 +week 0 +postpartum 0 +and 0 +decreases 0 +thereafter 0 +. 0 +Given 0 +that 0 +sympathetic 0 +neural 0 +dominance 0 +exhibits 0 +a 0 +similar 0 +developmental 0 +pattern 0 +"," 0 +and 0 +given 0 +that 0 +clonidine 1 +induces 0 +sympathetic 0 +withdrawal 0 +and 0 +bradycardia 3 +"," 0 +we 0 +hypothesized 0 +that 0 +clonidine 1 +' 0 +s 0 +developmental 0 +effects 0 +on 0 +cardiac 0 +rate 0 +and 0 +ultrasound 0 +production 0 +would 0 +mirror 0 +each 0 +other 0 +. 0 +Therefore 0 +"," 0 +in 0 +the 0 +present 0 +experiment 0 +"," 0 +the 0 +effects 0 +of 0 +clonidine 1 +administration 0 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +on 0 +cardiac 0 +rate 0 +and 0 +ultrasound 0 +production 0 +were 0 +examined 0 +in 0 +2 0 +- 0 +"," 0 +8 0 +- 0 +"," 0 +15 0 +- 0 +"," 0 +and 0 +20 0 +- 0 +day 0 +- 0 +old 0 +rats 0 +. 0 +Age 0 +- 0 +related 0 +changes 0 +in 0 +ultrasound 0 +production 0 +corresponded 0 +with 0 +changes 0 +in 0 +cardiovascular 0 +variables 0 +"," 0 +including 0 +baseline 0 +cardiac 0 +rate 0 +and 0 +clonidine 1 +- 0 +induced 0 +bradycardia 3 +. 0 +This 0 +experiment 0 +is 0 +discussed 0 +with 0 +regard 0 +to 0 +the 0 +hypothesis 0 +that 0 +ultrasound 0 +production 0 +is 0 +the 0 +acoustic 0 +by 0 +- 0 +product 0 +of 0 +a 0 +physiological 0 +maneuver 0 +that 0 +compensates 0 +for 0 +clonidine 1 +' 0 +s 0 +detrimental 0 +effects 0 +on 0 +cardiovascular 0 +function 0 +. 0 +Recurrent 0 +use 0 +of 0 +newer 0 +oral 1 +contraceptives 2 +and 0 +the 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +. 0 +The 0 +epidemiological 0 +studies 0 +that 0 +assessed 0 +the 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +( 0 +VTE 3 +) 0 +associated 0 +with 0 +newer 0 +oral 1 +contraceptives 2 +( 0 +0C 1 +) 0 +did 0 +not 0 +distinguish 0 +between 0 +patterns 0 +of 0 +0C 1 +use 0 +"," 0 +namely 0 +first 0 +- 0 +time 0 +users 0 +"," 0 +repeaters 0 +and 0 +switchers 0 +. 0 +Data 0 +from 0 +a 0 +Transnational 0 +case 0 +- 0 +control 0 +study 0 +were 0 +used 0 +to 0 +assess 0 +the 0 +risk 0 +of 0 +VTE 3 +for 0 +the 0 +latter 0 +patterns 0 +of 0 +use 0 +"," 0 +while 0 +accounting 0 +for 0 +duration 0 +of 0 +use 0 +. 0 +0ver 0 +the 0 +period 0 +1993 0 +- 0 +1996 0 +"," 0 +551 0 +cases 0 +of 0 +VTE 3 +were 0 +identified 0 +in 0 +Germany 0 +and 0 +the 0 +UK 0 +along 0 +with 0 +2066 0 +controls 0 +. 0 +Totals 0 +of 0 +128 0 +cases 0 +and 0 +650 0 +controls 0 +were 0 +analysed 0 +for 0 +repeat 0 +use 0 +and 0 +135 0 +cases 0 +and 0 +622 0 +controls 0 +for 0 +switching 0 +patterns 0 +. 0 +The 0 +adjusted 0 +rate 0 +ratio 0 +of 0 +VTE 3 +for 0 +repeat 0 +users 0 +of 0 +third 0 +generation 0 +0C 1 +was 0 +0 0 +. 0 +6 0 +( 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +3 0 +- 0 +1 0 +. 0 +2 0 +) 0 +relative 0 +to 0 +repeat 0 +users 0 +of 0 +second 0 +generation 0 +pills 0 +"," 0 +whereas 0 +it 0 +was 0 +1 0 +. 0 +3 0 +( 0 +95 0 +% 0 +CI 0 +: 0 +0 0 +. 0 +7 0 +- 0 +2 0 +. 0 +4 0 +) 0 +for 0 +switchers 0 +from 0 +second 0 +to 0 +third 0 +generation 0 +pills 0 +relative 0 +to 0 +switchers 0 +from 0 +third 0 +to 0 +second 0 +generation 0 +pills 0 +. 0 +We 0 +conclude 0 +that 0 +second 0 +and 0 +third 0 +generation 0 +agents 0 +are 0 +associated 0 +with 0 +equivalent 0 +risks 0 +of 0 +VTE 3 +when 0 +the 0 +same 0 +agent 0 +is 0 +used 0 +repeatedly 0 +after 0 +interruption 0 +periods 0 +or 0 +when 0 +users 0 +are 0 +switched 0 +between 0 +the 0 +two 0 +generations 0 +of 0 +pills 0 +. 0 +These 0 +analyses 0 +suggest 0 +that 0 +the 0 +higher 0 +risk 0 +observed 0 +for 0 +the 0 +newer 0 +0C 1 +in 0 +other 0 +studies 0 +may 0 +be 0 +the 0 +result 0 +of 0 +inadequate 0 +comparisons 0 +of 0 +pill 0 +users 0 +with 0 +different 0 +patterns 0 +of 0 +pill 0 +use 0 +. 0 +Differential 0 +effects 0 +of 0 +systemically 0 +administered 0 +ketamine 1 +and 0 +lidocaine 1 +on 0 +dynamic 0 +and 0 +static 0 +hyperalgesia 3 +induced 0 +by 0 +intradermal 0 +capsaicin 1 +in 0 +humans 0 +. 0 +We 0 +have 0 +examined 0 +the 0 +effect 0 +of 0 +systemic 0 +administration 0 +of 0 +ketamine 1 +and 0 +lidocaine 1 +on 0 +brush 0 +- 0 +evoked 0 +( 0 +dynamic 0 +) 0 +pain 3 +and 0 +punctate 0 +- 0 +evoked 0 +( 0 +static 0 +) 0 +hyperalgesia 3 +induced 0 +by 0 +capsaicin 1 +. 0 +In 0 +a 0 +randomized 0 +"," 0 +double 0 +- 0 +blind 0 +"," 0 +placebo 0 +- 0 +controlled 0 +"," 0 +crossover 0 +study 0 +"," 0 +we 0 +studied 0 +12 0 +volunteers 0 +in 0 +three 0 +experiments 0 +. 0 +Capsaicin 1 +100 0 +micrograms 0 +was 0 +injected 0 +intradermally 0 +on 0 +the 0 +volar 0 +forearm 0 +followed 0 +by 0 +an 0 +i 0 +. 0 +v 0 +. 0 +infusion 0 +of 0 +ketamine 1 +( 0 +bolus 0 +0 0 +. 0 +1 0 +mg 0 +kg 0 +- 0 +1 0 +over 0 +10 0 +min 0 +followed 0 +by 0 +infusion 0 +of 0 +7 0 +micrograms 0 +kg 0 +- 0 +1 0 +min 0 +- 0 +1 0 +) 0 +"," 0 +lidocaine 1 +5 0 +mg 0 +kg 0 +- 0 +1 0 +or 0 +saline 0 +for 0 +50 0 +min 0 +. 0 +Infusion 0 +started 0 +15 0 +min 0 +after 0 +injection 0 +of 0 +capsaicin 1 +. 0 +The 0 +following 0 +were 0 +measured 0 +: 0 +spontaneous 0 +pain 3 +"," 0 +pain 3 +evoked 0 +by 0 +punctate 0 +and 0 +brush 0 +stimuli 0 +( 0 +VAS 0 +) 0 +"," 0 +and 0 +areas 0 +of 0 +brush 0 +- 0 +evoked 0 +and 0 +punctate 0 +- 0 +evoked 0 +hyperalgesia 3 +. 0 +Ketamine 1 +reduced 0 +both 0 +the 0 +area 0 +of 0 +brush 0 +- 0 +evoked 0 +and 0 +punctate 0 +- 0 +evoked 0 +hyperalgesia 3 +significantly 0 +and 0 +it 0 +tended 0 +to 0 +reduce 0 +brush 0 +- 0 +evoked 0 +pain 3 +. 0 +Lidocaine 1 +reduced 0 +the 0 +area 0 +of 0 +punctate 0 +- 0 +evoked 0 +hyperalgesia 3 +significantly 0 +. 0 +It 0 +tended 0 +to 0 +reduce 0 +VAS 0 +scores 0 +of 0 +spontaneous 0 +pain 3 +but 0 +had 0 +no 0 +effect 0 +on 0 +evoked 0 +pain 3 +. 0 +The 0 +differential 0 +effects 0 +of 0 +ketamine 1 +and 0 +lidocaine 1 +on 0 +static 0 +and 0 +dynamic 0 +hyperalgesia 3 +suggest 0 +that 0 +the 0 +two 0 +types 0 +of 0 +hyperalgesia 3 +are 0 +mediated 0 +by 0 +separate 0 +mechanisms 0 +and 0 +have 0 +a 0 +distinct 0 +pharmacology 0 +. 0 +Development 0 +of 0 +apomorphine 1 +- 0 +induced 0 +aggressive 3 +behavior 4 +: 0 +comparison 0 +of 0 +adult 0 +male 0 +and 0 +female 0 +Wistar 0 +rats 0 +. 0 +The 0 +development 0 +of 0 +apomorphine 1 +- 0 +induced 0 +( 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +once 0 +daily 0 +) 0 +aggressive 3 +behavior 4 +of 0 +adult 0 +male 0 +and 0 +female 0 +Wistar 0 +rats 0 +obtained 0 +from 0 +the 0 +same 0 +breeder 0 +was 0 +studied 0 +in 0 +two 0 +consecutive 0 +sets 0 +. 0 +In 0 +male 0 +animals 0 +"," 0 +repeated 0 +apomorphine 1 +treatment 0 +induced 0 +a 0 +gradual 0 +development 0 +of 0 +aggressive 3 +behavior 4 +as 0 +evidenced 0 +by 0 +the 0 +increased 0 +intensity 0 +of 0 +aggressiveness 3 +and 0 +shortened 0 +latency 0 +before 0 +the 0 +first 0 +attack 0 +toward 0 +the 0 +opponent 0 +. 0 +In 0 +female 0 +rats 0 +"," 0 +only 0 +a 0 +weak 0 +tendency 0 +toward 0 +aggressiveness 3 +was 0 +found 0 +. 0 +In 0 +conclusion 0 +"," 0 +the 0 +present 0 +study 0 +demonstrates 0 +gender 0 +differences 0 +in 0 +the 0 +development 0 +of 0 +the 0 +apomorphine 1 +- 0 +induced 0 +aggressive 3 +behavior 4 +and 0 +indicates 0 +that 0 +the 0 +female 0 +rats 0 +do 0 +not 0 +fill 0 +the 0 +validation 0 +criteria 0 +for 0 +use 0 +in 0 +this 0 +method 0 +. 0 +Intracranial 3 +aneurysms 4 +and 0 +cocaine 3 +abuse 4 +: 0 +analysis 0 +of 0 +prognostic 0 +indicators 0 +. 0 +0BJECTIVE 0 +: 0 +The 0 +outcome 0 +of 0 +subarachnoid 3 +hemorrhage 4 +associated 0 +with 0 +cocaine 3 +abuse 4 +is 0 +reportedly 0 +poor 0 +. 0 +However 0 +"," 0 +no 0 +study 0 +in 0 +the 0 +literature 0 +has 0 +reported 0 +the 0 +use 0 +of 0 +a 0 +statistical 0 +model 0 +to 0 +analyze 0 +the 0 +variables 0 +that 0 +influence 0 +outcome 0 +. 0 +METH0DS 0 +: 0 +A 0 +review 0 +of 0 +admissions 0 +during 0 +a 0 +6 0 +- 0 +year 0 +period 0 +revealed 0 +14 0 +patients 0 +with 0 +cocaine 1 +- 0 +related 0 +aneurysms 3 +. 0 +This 0 +group 0 +was 0 +compared 0 +with 0 +a 0 +control 0 +group 0 +of 0 +135 0 +patients 0 +with 0 +ruptured 3 +aneurysms 4 +and 0 +no 0 +history 0 +of 0 +cocaine 3 +abuse 4 +. 0 +Age 0 +at 0 +presentation 0 +"," 0 +time 0 +of 0 +ictus 0 +after 0 +intoxication 0 +"," 0 +Hunt 0 +and 0 +Hess 0 +grade 0 +of 0 +subarachnoid 3 +hemorrhage 4 +"," 0 +size 0 +of 0 +the 0 +aneurysm 3 +"," 0 +location 0 +of 0 +the 0 +aneurysm 3 +"," 0 +and 0 +the 0 +Glasgow 0 +0utcome 0 +Scale 0 +score 0 +were 0 +assessed 0 +and 0 +compared 0 +. 0 +RESULTS 0 +: 0 +The 0 +patients 0 +in 0 +the 0 +study 0 +group 0 +were 0 +significantly 0 +younger 0 +than 0 +the 0 +patients 0 +in 0 +the 0 +control 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +2 0 +) 0 +. 0 +In 0 +patients 0 +in 0 +the 0 +study 0 +group 0 +"," 0 +all 0 +aneurysms 3 +were 0 +located 0 +in 0 +the 0 +anterior 0 +circulation 0 +. 0 +The 0 +majority 0 +of 0 +these 0 +aneurysms 3 +were 0 +smaller 0 +than 0 +those 0 +of 0 +the 0 +control 0 +group 0 +( 0 +8 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +8 0 +mm 0 +versus 0 +11 0 ++ 0 +/ 0 +- 0 +5 0 +. 0 +4 0 +mm 0 +; 0 +P 0 += 0 +0 0 +. 0 +5 0 +) 0 +. 0 +The 0 +differences 0 +in 0 +mortality 0 +and 0 +morbidity 0 +between 0 +the 0 +two 0 +groups 0 +were 0 +not 0 +significant 0 +. 0 +Hunt 0 +and 0 +Hess 0 +grade 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +and 0 +age 0 +( 0 +P 0 +< 0 +0 0 +. 0 +7 0 +) 0 +were 0 +significant 0 +predictors 0 +of 0 +outcome 0 +for 0 +the 0 +patients 0 +with 0 +cocaine 1 +- 0 +related 0 +aneurysms 3 +. 0 +C0NCLUSI0N 0 +: 0 +Cocaine 1 +use 0 +predisposed 0 +aneurysmal 3 +rupture 4 +at 0 +a 0 +significantly 0 +earlier 0 +age 0 +and 0 +in 0 +much 0 +smaller 0 +aneurysms 3 +. 0 +Contrary 0 +to 0 +the 0 +published 0 +literature 0 +"," 0 +this 0 +group 0 +did 0 +reasonably 0 +well 0 +with 0 +aggressive 0 +management 0 +. 0 +Effect 0 +of 0 +intravenous 0 +nimodipine 1 +on 0 +blood 0 +pressure 0 +and 0 +outcome 0 +after 0 +acute 3 +stroke 4 +. 0 +BACKGR0UND 0 +AND 0 +PURP0SE 0 +: 0 +The 0 +Intravenous 0 +Nimodipine 1 +West 0 +European 0 +Stroke 3 +Trial 0 +( 0 +INWEST 0 +) 0 +found 0 +a 0 +correlation 0 +between 0 +nimodipine 1 +- 0 +induced 0 +reduction 3 +in 4 +blood 4 +pressure 4 +( 0 +BP 0 +) 0 +and 0 +an 0 +unfavorable 0 +outcome 0 +in 0 +acute 3 +stroke 4 +. 0 +We 0 +sought 0 +to 0 +confirm 0 +this 0 +correlation 0 +with 0 +and 0 +without 0 +adjustment 0 +for 0 +prognostic 0 +variables 0 +and 0 +to 0 +investigate 0 +outcome 0 +in 0 +subgroups 0 +with 0 +increasing 0 +levels 0 +of 0 +BP 3 +reduction 4 +. 0 +METH0DS 0 +: 0 +Patients 0 +with 0 +a 0 +clinical 0 +diagnosis 0 +of 0 +ischemic 3 +stroke 4 +( 0 +within 0 +24 0 +hours 0 +) 0 +were 0 +consecutively 0 +allocated 0 +to 0 +receive 0 +placebo 0 +( 0 +n 0 += 0 +100 0 +) 0 +"," 0 +1 0 +mg 0 +/ 0 +h 0 +( 0 +low 0 +- 0 +dose 0 +) 0 +nimodipine 1 +( 0 +n 0 += 0 +101 0 +) 0 +"," 0 +or 0 +2 0 +mg 0 +/ 0 +h 0 +( 0 +high 0 +- 0 +dose 0 +) 0 +nimodipine 1 +( 0 +n 0 += 0 +94 0 +) 0 +. 0 +The 0 +correlation 0 +between 0 +average 0 +BP 0 +change 0 +during 0 +the 0 +first 0 +2 0 +days 0 +and 0 +the 0 +outcome 0 +at 0 +day 0 +21 0 +was 0 +analyzed 0 +. 0 +RESULTS 0 +: 0 +Two 0 +hundred 0 +sixty 0 +- 0 +five 0 +patients 0 +were 0 +included 0 +in 0 +this 0 +analysis 0 +( 0 +n 0 += 0 +92 0 +"," 0 +93 0 +"," 0 +and 0 +80 0 +for 0 +placebo 0 +"," 0 +low 0 +dose 0 +"," 0 +and 0 +high 0 +dose 0 +"," 0 +respectively 0 +) 0 +. 0 +Nimodipine 1 +treatment 0 +resulted 0 +in 0 +a 0 +statistically 0 +significant 0 +reduction 3 +in 4 +systolic 4 +BP 4 +( 0 +SBP 0 +) 0 +and 0 +diastolic 0 +BP 0 +( 0 +DBP 0 +) 0 +from 0 +baseline 0 +compared 0 +with 0 +placebo 0 +during 0 +the 0 +first 0 +few 0 +days 0 +. 0 +In 0 +multivariate 0 +analysis 0 +"," 0 +a 0 +significant 0 +correlation 0 +between 0 +DBP 3 +reduction 4 +and 0 +worsening 0 +of 0 +the 0 +neurological 0 +score 0 +was 0 +found 0 +for 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +( 0 +beta 0 += 0 +0 0 +. 0 +49 0 +"," 0 +P 0 += 0 +0 0 +. 0 +48 0 +) 0 +. 0 +Patients 0 +with 0 +a 0 +DBP 3 +reduction 4 +of 0 +> 0 +or 0 += 0 +20 0 +% 0 +in 0 +the 0 +high 0 +- 0 +dose 0 +group 0 +had 0 +a 0 +significantly 0 +increased 0 +adjusted 0 +0R 0 +for 0 +the 0 +compound 0 +outcome 0 +variable 0 +death 3 +or 0 +dependency 0 +( 0 +Barthel 0 +Index 0 +< 0 +60 0 +) 0 +( 0 +n 0 +/ 0 +N 0 += 0 +25 0 +/ 0 +26 0 +"," 0 +0R 0 +10 0 +. 0 +16 0 +"," 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +2 0 +to 0 +101 0 +. 0 +74 0 +) 0 +and 0 +death 3 +alone 0 +( 0 +n 0 +/ 0 +N 0 += 0 +9 0 +/ 0 +26 0 +"," 0 +0R 0 +4 0 +. 0 +336 0 +"," 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +131 0 +16 0 +. 0 +619 0 +) 0 +compared 0 +with 0 +all 0 +placebo 0 +patients 0 +( 0 +n 0 +/ 0 +N 0 += 0 +62 0 +/ 0 +92 0 +and 0 +14 0 +/ 0 +92 0 +"," 0 +respectively 0 +) 0 +. 0 +There 0 +was 0 +no 0 +correlation 0 +between 0 +SBP 0 +change 0 +and 0 +outcome 0 +. 0 +C0NCLUSI0NS 0 +: 0 +DBP 0 +"," 0 +but 0 +not 0 +SBP 0 +"," 0 +reduction 0 +was 0 +associated 0 +with 0 +neurological 0 +worsening 0 +after 0 +the 0 +intravenous 0 +administration 0 +of 0 +high 0 +- 0 +dose 0 +nimodipine 1 +after 0 +acute 3 +stroke 4 +. 0 +For 0 +low 0 +- 0 +dose 0 +nimodipine 1 +"," 0 +the 0 +results 0 +were 0 +not 0 +conclusive 0 +. 0 +These 0 +results 0 +do 0 +not 0 +confirm 0 +or 0 +exclude 0 +a 0 +neuroprotective 0 +property 0 +of 0 +nimodipine 1 +. 0 +Neonatal 0 +pyridoxine 1 +responsive 0 +convulsions 3 +due 0 +to 0 +isoniazid 1 +therapy 0 +. 0 +A 0 +17 0 +- 0 +day 0 +- 0 +old 0 +infant 0 +on 0 +isoniazid 1 +therapy 0 +13 0 +mg 0 +/ 0 +kg 0 +daily 0 +from 0 +birth 0 +because 0 +of 0 +maternal 0 +tuberculosis 3 +was 0 +admitted 0 +after 0 +4 0 +days 0 +of 0 +clonic 3 +fits 4 +. 0 +No 0 +underlying 0 +infective 0 +or 0 +biochemical 0 +cause 0 +could 0 +be 0 +found 0 +. 0 +The 0 +fits 3 +ceased 0 +within 0 +4 0 +hours 0 +of 0 +administering 0 +intramuscular 0 +pyridoxine 1 +"," 0 +suggesting 0 +an 0 +aetiology 0 +of 0 +pyridoxine 1 +deficiency 0 +secondary 0 +to 0 +isoniazid 1 +medication 0 +. 0 +Ketamine 1 +sedation 0 +for 0 +the 0 +reduction 0 +of 0 +children 0 +' 0 +s 0 +fractures 3 +in 0 +the 0 +emergency 0 +department 0 +. 0 +BACKGR0UND 0 +: 0 +There 0 +recently 0 +has 0 +been 0 +a 0 +resurgence 0 +in 0 +the 0 +utilization 0 +of 0 +ketamine 1 +"," 0 +a 0 +unique 0 +anesthetic 0 +"," 0 +for 0 +emergency 0 +- 0 +department 0 +procedures 0 +requiring 0 +sedation 0 +. 0 +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +examine 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +ketamine 1 +for 0 +sedation 0 +in 0 +the 0 +treatment 0 +of 0 +children 0 +' 0 +s 0 +fractures 3 +in 0 +the 0 +emergency 0 +department 0 +. 0 +METH0DS 0 +: 0 +0ne 0 +hundred 0 +and 0 +fourteen 0 +children 0 +( 0 +average 0 +age 0 +"," 0 +5 0 +. 0 +3 0 +years 0 +; 0 +range 0 +"," 0 +twelve 0 +months 0 +to 0 +ten 0 +years 0 +and 0 +ten 0 +months 0 +) 0 +who 0 +underwent 0 +closed 0 +reduction 0 +of 0 +an 0 +isolated 0 +fracture 3 +or 0 +dislocation 3 +in 0 +the 0 +emergency 0 +department 0 +at 0 +a 0 +level 0 +- 0 +I 0 +trauma 3 +center 0 +were 0 +prospectively 0 +evaluated 0 +. 0 +Ketamine 1 +hydrochloride 2 +was 0 +administered 0 +intravenously 0 +( 0 +at 0 +a 0 +dose 0 +of 0 +two 0 +milligrams 0 +per 0 +kilogram 0 +of 0 +body 0 +weight 0 +) 0 +in 0 +ninety 0 +- 0 +nine 0 +of 0 +the 0 +patients 0 +and 0 +intramuscularly 0 +( 0 +at 0 +a 0 +dose 0 +of 0 +four 0 +milligrams 0 +per 0 +kilogram 0 +of 0 +body 0 +weight 0 +) 0 +in 0 +the 0 +other 0 +fifteen 0 +. 0 +A 0 +board 0 +- 0 +certified 0 +emergency 0 +physician 0 +skilled 0 +in 0 +airway 0 +management 0 +supervised 0 +administration 0 +of 0 +the 0 +anesthetic 0 +"," 0 +and 0 +the 0 +patients 0 +were 0 +monitored 0 +by 0 +a 0 +registered 0 +nurse 0 +. 0 +Any 0 +pain 3 +during 0 +the 0 +reduction 0 +was 0 +rated 0 +by 0 +the 0 +orthopaedic 0 +surgeon 0 +treating 0 +the 0 +patient 0 +according 0 +to 0 +the 0 +Children 0 +' 0 +s 0 +Hospital 0 +of 0 +Eastern 0 +0ntario 0 +Pain 3 +Scale 0 +( 0 +CHE0PS 0 +) 0 +. 0 +RESULTS 0 +: 0 +The 0 +average 0 +time 0 +from 0 +intravenous 0 +administration 0 +of 0 +ketamine 1 +to 0 +manipulation 0 +of 0 +the 0 +fracture 3 +or 0 +dislocation 3 +was 0 +one 0 +minute 0 +and 0 +thirty 0 +- 0 +six 0 +seconds 0 +( 0 +range 0 +"," 0 +twenty 0 +seconds 0 +to 0 +five 0 +minutes 0 +) 0 +"," 0 +and 0 +the 0 +average 0 +time 0 +from 0 +intramuscular 0 +administration 0 +to 0 +manipulation 0 +was 0 +four 0 +minutes 0 +and 0 +forty 0 +- 0 +two 0 +seconds 0 +( 0 +range 0 +"," 0 +sixty 0 +seconds 0 +to 0 +fifteen 0 +minutes 0 +) 0 +. 0 +The 0 +average 0 +score 0 +according 0 +to 0 +the 0 +Children 0 +' 0 +s 0 +Hospital 0 +of 0 +Eastern 0 +0ntario 0 +Pain 3 +Scale 0 +was 0 +6 0 +. 0 +4 0 +points 0 +( 0 +range 0 +"," 0 +5 0 +to 0 +10 0 +points 0 +) 0 +"," 0 +reflecting 0 +minimal 0 +or 0 +no 0 +pain 3 +during 0 +fracture 3 +reduction 0 +. 0 +Adequate 0 +fracture 3 +reduction 0 +was 0 +obtained 0 +in 0 +111 0 +of 0 +the 0 +children 0 +. 0 +Ninety 0 +- 0 +nine 0 +percent 0 +( 0 +sixty 0 +- 0 +eight 0 +) 0 +of 0 +the 0 +sixty 0 +- 0 +nine 0 +parents 0 +present 0 +during 0 +the 0 +reduction 0 +were 0 +pleased 0 +with 0 +the 0 +sedation 0 +and 0 +would 0 +allow 0 +it 0 +to 0 +be 0 +used 0 +again 0 +in 0 +a 0 +similar 0 +situation 0 +. 0 +Patency 0 +of 0 +the 0 +airway 0 +and 0 +independent 0 +respiration 0 +were 0 +maintained 0 +in 0 +all 0 +of 0 +the 0 +patients 0 +. 0 +Blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +remained 0 +stable 0 +. 0 +Minor 0 +side 0 +effects 0 +included 0 +nausea 3 +( 0 +thirteen 0 +patients 0 +) 0 +"," 0 +emesis 3 +( 0 +eight 0 +of 0 +the 0 +thirteen 0 +patients 0 +with 0 +nausea 3 +) 0 +"," 0 +clumsiness 3 +( 0 +evident 0 +as 0 +ataxic 3 +movements 4 +in 0 +ten 0 +patients 0 +) 0 +"," 0 +and 0 +dysphoric 3 +reaction 4 +( 0 +one 0 +patient 0 +) 0 +. 0 +No 0 +long 0 +- 0 +term 0 +sequelae 0 +were 0 +noted 0 +"," 0 +and 0 +no 0 +patients 0 +had 0 +hallucinations 3 +or 0 +nightmares 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Ketamine 1 +reliably 0 +"," 0 +safely 0 +"," 0 +and 0 +quickly 0 +provided 0 +adequate 0 +sedation 0 +to 0 +effectively 0 +facilitate 0 +the 0 +reduction 0 +of 0 +children 0 +' 0 +s 0 +fractures 3 +in 0 +the 0 +emergency 0 +department 0 +at 0 +our 0 +institution 0 +. 0 +Ketamine 1 +should 0 +only 0 +be 0 +used 0 +in 0 +an 0 +environment 0 +such 0 +as 0 +the 0 +emergency 0 +department 0 +"," 0 +where 0 +proper 0 +one 0 +- 0 +on 0 +- 0 +one 0 +monitoring 0 +is 0 +used 0 +and 0 +board 0 +- 0 +certified 0 +physicians 0 +skilled 0 +in 0 +airway 0 +management 0 +are 0 +directly 0 +involved 0 +in 0 +the 0 +care 0 +of 0 +the 0 +patient 0 +. 0 +Cyclosporine 1 +and 0 +tacrolimus 1 +- 0 +associated 0 +thrombotic 3 +microangiopathy 4 +. 0 +The 0 +development 0 +of 0 +thrombotic 3 +microangiopathy 4 +( 0 +TMA 3 +) 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +cyclosporine 1 +has 0 +been 0 +well 0 +documented 0 +. 0 +Treatments 0 +have 0 +included 0 +discontinuation 0 +or 0 +reduction 0 +of 0 +cyclosporine 1 +dose 0 +with 0 +or 0 +without 0 +concurrent 0 +plasma 0 +exchange 0 +"," 0 +plasma 0 +infusion 0 +"," 0 +anticoagulation 0 +"," 0 +and 0 +intravenous 0 +immunoglobulin 0 +G 0 +infusion 0 +. 0 +However 0 +"," 0 +for 0 +recipients 0 +of 0 +organ 0 +transplantation 0 +"," 0 +removing 0 +the 0 +inciting 0 +agent 0 +is 0 +not 0 +without 0 +the 0 +attendant 0 +risk 0 +of 0 +precipitating 0 +acute 0 +rejection 0 +and 0 +graft 0 +loss 0 +. 0 +The 0 +last 0 +decade 0 +has 0 +seen 0 +the 0 +emergence 0 +of 0 +tacrolimus 1 +as 0 +a 0 +potent 0 +immunosuppressive 0 +agent 0 +with 0 +mechanisms 0 +of 0 +action 0 +virtually 0 +identical 0 +to 0 +those 0 +of 0 +cyclosporine 1 +. 0 +As 0 +a 0 +result 0 +"," 0 +switching 0 +to 0 +tacrolimus 1 +has 0 +been 0 +reported 0 +to 0 +be 0 +a 0 +viable 0 +therapeutic 0 +option 0 +in 0 +the 0 +setting 0 +of 0 +cyclosporine 1 +- 0 +induced 0 +TMA 3 +. 0 +With 0 +the 0 +more 0 +widespread 0 +application 0 +of 0 +tacrolimus 1 +in 0 +organ 0 +transplantation 0 +"," 0 +tacrolimus 1 +- 0 +associated 0 +TMA 3 +has 0 +also 0 +been 0 +recognized 0 +. 0 +However 0 +"," 0 +literature 0 +regarding 0 +the 0 +incidence 0 +of 0 +the 0 +recurrence 0 +of 0 +TMA 3 +in 0 +patients 0 +exposed 0 +sequentially 0 +to 0 +cyclosporine 1 +and 0 +tacrolimus 1 +is 0 +limited 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +living 0 +donor 0 +renal 0 +transplant 0 +recipient 0 +who 0 +developed 0 +cyclosporine 1 +- 0 +induced 0 +TMA 3 +that 0 +responded 0 +to 0 +the 0 +withdrawal 0 +of 0 +cyclosporine 1 +in 0 +conjunction 0 +with 0 +plasmapheresis 0 +and 0 +fresh 0 +frozen 0 +plasma 0 +replacement 0 +therapy 0 +. 0 +Introduction 0 +of 0 +tacrolimus 1 +as 0 +an 0 +alternative 0 +immunosuppressive 0 +agent 0 +resulted 0 +in 0 +the 0 +recurrence 0 +of 0 +TMA 3 +and 0 +the 0 +subsequent 0 +loss 0 +of 0 +the 0 +renal 0 +allograft 0 +. 0 +Patients 0 +who 0 +are 0 +switched 0 +from 0 +cyclosporine 1 +to 0 +tacrolimus 1 +or 0 +vice 0 +versa 0 +should 0 +be 0 +closely 0 +monitored 0 +for 0 +the 0 +signs 0 +and 0 +symptoms 0 +of 0 +recurrent 0 +TMA 3 +. 0 +Analgesic 0 +effect 0 +of 0 +intravenous 0 +ketamine 1 +in 0 +cancer 3 +patients 0 +on 0 +morphine 1 +therapy 0 +: 0 +a 0 +randomized 0 +"," 0 +controlled 0 +"," 0 +double 0 +- 0 +blind 0 +"," 0 +crossover 0 +"," 0 +double 0 +- 0 +dose 0 +study 0 +. 0 +Pain 3 +not 0 +responsive 0 +to 0 +morphine 1 +is 0 +often 0 +problematic 0 +. 0 +Animal 0 +and 0 +clinical 0 +studies 0 +have 0 +suggested 0 +that 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +antagonists 0 +"," 0 +such 0 +as 0 +ketamine 1 +"," 0 +may 0 +be 0 +effective 0 +in 0 +improving 0 +opioid 0 +analgesia 0 +in 0 +difficult 0 +pain 3 +syndromes 0 +"," 0 +such 0 +as 0 +neuropathic 3 +pain 4 +. 0 +A 0 +slow 0 +bolus 0 +of 0 +subhypnotic 0 +doses 0 +of 0 +ketamine 1 +( 0 +0 0 +. 0 +25 0 +mg 0 +/ 0 +kg 0 +or 0 +0 0 +. 0 +50 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +given 0 +to 0 +10 0 +cancer 3 +patients 0 +whose 0 +pain 3 +was 0 +unrelieved 0 +by 0 +morphine 1 +in 0 +a 0 +randomized 0 +"," 0 +double 0 +- 0 +blind 0 +"," 0 +crossover 0 +"," 0 +double 0 +- 0 +dose 0 +study 0 +. 0 +Pain 3 +intensity 0 +on 0 +a 0 +0 0 +to 0 +10 0 +numerical 0 +scale 0 +; 0 +nausea 3 +and 0 +vomiting 3 +"," 0 +drowsiness 0 +"," 0 +confusion 3 +"," 0 +and 0 +dry 3 +mouth 4 +"," 0 +using 0 +a 0 +scale 0 +from 0 +0 0 +to 0 +3 0 +( 0 +not 0 +at 0 +all 0 +"," 0 +slight 0 +"," 0 +a 0 +lot 0 +"," 0 +awful 0 +) 0 +; 0 +Mini 0 +- 0 +Mental 0 +State 0 +Examination 0 +( 0 +MMSE 0 +) 0 +( 0 +0 0 +- 0 +30 0 +) 0 +; 0 +and 0 +arterial 0 +pressure 0 +were 0 +recorded 0 +before 0 +administration 0 +of 0 +drugs 0 +( 0 +T0 0 +) 0 +and 0 +after 0 +30 0 +minutes 0 +( 0 +T30 0 +) 0 +"," 0 +60 0 +minutes 0 +( 0 +T60 0 +) 0 +"," 0 +120 0 +minutes 0 +( 0 +T120 0 +) 0 +"," 0 +and 0 +180 0 +minutes 0 +( 0 +T180 0 +) 0 +. 0 +Ketamine 1 +"," 0 +but 0 +not 0 +saline 0 +solution 0 +"," 0 +significantly 0 +reduced 0 +the 0 +pain 3 +intensity 0 +in 0 +almost 0 +all 0 +the 0 +patients 0 +at 0 +both 0 +doses 0 +. 0 +This 0 +effect 0 +was 0 +more 0 +relevant 0 +in 0 +patients 0 +treated 0 +with 0 +higher 0 +doses 0 +. 0 +Hallucinations 3 +occurred 0 +in 0 +4 0 +patients 0 +"," 0 +and 0 +an 0 +unpleasant 0 +sensation 0 +( 0 +" 0 +empty 0 +head 0 +" 0 +) 0 +was 0 +also 0 +reported 0 +by 0 +2 0 +patients 0 +. 0 +These 0 +episodes 0 +reversed 0 +after 0 +the 0 +administration 0 +of 0 +diazepam 1 +1 0 +mg 0 +intravenously 0 +. 0 +Significant 0 +increases 0 +in 0 +drowsiness 0 +were 0 +reported 0 +in 0 +patients 0 +treated 0 +with 0 +ketamine 1 +in 0 +both 0 +groups 0 +and 0 +were 0 +more 0 +marked 0 +with 0 +ketamine 1 +0 0 +. 0 +50 0 +mg 0 +/ 0 +kg 0 +. 0 +A 0 +significant 0 +difference 0 +in 0 +MMSE 0 +was 0 +observed 0 +at 0 +T30 0 +in 0 +patients 0 +who 0 +received 0 +0 0 +. 0 +50 0 +mg 0 +/ 0 +kg 0 +of 0 +ketamine 1 +. 0 +Ketamine 1 +can 0 +improve 0 +morphine 1 +analgesia 0 +in 0 +difficult 0 +pain 3 +syndromes 0 +"," 0 +such 0 +as 0 +neuropathic 3 +pain 4 +. 0 +However 0 +"," 0 +the 0 +occurrence 0 +of 0 +central 0 +adverse 0 +effects 0 +should 0 +be 0 +taken 0 +into 0 +account 0 +"," 0 +especially 0 +when 0 +using 0 +higher 0 +doses 0 +. 0 +This 0 +observation 0 +should 0 +be 0 +tested 0 +in 0 +studies 0 +of 0 +prolonged 0 +ketamine 1 +administration 0 +. 0 +Paclitaxel 1 +"," 0 +cisplatin 1 +"," 0 +and 0 +gemcitabine 1 +combination 0 +chemotherapy 0 +within 0 +a 0 +multidisciplinary 0 +therapeutic 0 +approach 0 +in 0 +metastatic 0 +nonsmall 3 +cell 4 +lung 4 +carcinoma 4 +. 0 +BACKGR0UND 0 +: 0 +Cisplatin 1 +- 0 +based 0 +chemotherapy 0 +combinations 0 +improve 0 +quality 0 +of 0 +life 0 +and 0 +survival 0 +in 0 +advanced 0 +nonsmall 3 +cell 4 +lung 4 +carcinoma 4 +( 0 +NSCLC 3 +) 0 +. 0 +The 0 +emergence 0 +of 0 +new 0 +active 0 +drugs 0 +might 0 +translate 0 +into 0 +more 0 +effective 0 +regimens 0 +for 0 +the 0 +treatment 0 +of 0 +this 0 +disease 0 +. 0 +METH0DS 0 +: 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +feasibility 0 +"," 0 +response 0 +rate 0 +"," 0 +and 0 +toxicity 3 +of 0 +a 0 +paclitaxel 1 +"," 0 +cisplatin 1 +"," 0 +and 0 +gemcitabine 1 +combination 0 +to 0 +treat 0 +metastatic 0 +NSCLC 3 +. 0 +Thirty 0 +- 0 +five 0 +consecutive 0 +chemotherapy 0 +- 0 +naive 0 +patients 0 +with 0 +Stage 0 +IV 0 +NSCLC 3 +and 0 +an 0 +Eastern 0 +Cooperative 0 +0ncology 0 +Group 0 +performance 0 +status 0 +of 0 +0 0 +- 0 +2 0 +were 0 +treated 0 +with 0 +a 0 +combination 0 +of 0 +paclitaxel 1 +( 0 +135 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +given 0 +intravenously 0 +in 0 +3 0 +hours 0 +) 0 +on 0 +Day 0 +1 0 +"," 0 +cisplatin 1 +( 0 +120 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +given 0 +intravenously 0 +in 0 +6 0 +hours 0 +) 0 +on 0 +Day 0 +1 0 +"," 0 +and 0 +gemcitabine 1 +( 0 +800 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +given 0 +intravenously 0 +in 0 +30 0 +minutes 0 +) 0 +on 0 +Days 0 +1 0 +and 0 +8 0 +"," 0 +every 0 +4 0 +weeks 0 +. 0 +Although 0 +responding 0 +patients 0 +were 0 +scheduled 0 +to 0 +receive 0 +consolidation 0 +radiotherapy 0 +and 0 +24 0 +patients 0 +received 0 +preplanned 0 +second 0 +- 0 +line 0 +chemotherapy 0 +after 0 +disease 0 +progression 0 +"," 0 +the 0 +response 0 +and 0 +toxicity 3 +rates 0 +reported 0 +refer 0 +only 0 +to 0 +the 0 +chemotherapy 0 +regimen 0 +given 0 +. 0 +RESULTS 0 +: 0 +All 0 +the 0 +patients 0 +were 0 +examined 0 +for 0 +toxicity 3 +; 0 +34 0 +were 0 +examinable 0 +for 0 +response 0 +. 0 +An 0 +objective 0 +response 0 +was 0 +observed 0 +in 0 +73 0 +. 0 +5 0 +% 0 +of 0 +the 0 +patients 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +"," 0 +55 0 +. 0 +6 0 +- 0 +87 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +including 0 +4 0 +complete 0 +responses 0 +( 0 +11 0 +. 0 +7 0 +% 0 +) 0 +. 0 +According 0 +to 0 +intention 0 +- 0 +to 0 +- 0 +treat 0 +"," 0 +the 0 +overall 0 +response 0 +rate 0 +was 0 +71 0 +. 0 +4 0 +% 0 +( 0 +95 0 +% 0 +CI 0 +"," 0 +53 0 +. 0 +7 0 +- 0 +85 0 +. 0 +4 0 +% 0 +) 0 +. 0 +After 0 +154 0 +courses 0 +of 0 +therapy 0 +"," 0 +the 0 +median 0 +dose 0 +intensity 0 +was 0 +131 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +paclitaxel 1 +( 0 +97 0 +. 0 +3 0 +% 0 +) 0 +"," 0 +117 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +cisplatin 1 +( 0 +97 0 +. 0 +3 0 +% 0 +) 0 +"," 0 +and 0 +1378 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +for 0 +gemcitabine 1 +( 0 +86 0 +. 0 +2 0 +% 0 +) 0 +. 0 +World 0 +Health 0 +0rganization 0 +Grade 0 +3 0 +- 0 +4 0 +neutropenia 3 +and 0 +thrombocytopenia 3 +occurred 0 +in 0 +39 0 +. 0 +9 0 +% 0 +and 0 +11 0 +. 0 +4 0 +% 0 +of 0 +patients 0 +"," 0 +respectively 0 +. 0 +There 0 +was 0 +one 0 +treatment 0 +- 0 +related 0 +death 3 +. 0 +Nonhematologic 0 +toxicities 3 +were 0 +mild 0 +. 0 +After 0 +a 0 +median 0 +follow 0 +- 0 +up 0 +of 0 +22 0 +months 0 +"," 0 +the 0 +median 0 +progression 0 +free 0 +survival 0 +rate 0 +was 0 +7 0 +months 0 +"," 0 +and 0 +the 0 +median 0 +survival 0 +time 0 +was 0 +16 0 +months 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +combination 0 +of 0 +paclitaxel 1 +"," 0 +cisplatin 1 +"," 0 +and 0 +gemcitabine 1 +is 0 +well 0 +tolerated 0 +and 0 +shows 0 +high 0 +activity 0 +in 0 +metastatic 0 +NSCLC 3 +. 0 +This 0 +treatment 0 +merits 0 +further 0 +comparison 0 +with 0 +other 0 +cisplatin 1 +- 0 +based 0 +regimens 0 +. 0 +Serotonergic 1 +antidepressants 2 +and 0 +urinary 3 +incontinence 4 +. 0 +Many 0 +new 0 +serotonergic 1 +antidepressants 2 +have 0 +been 0 +introduced 0 +over 0 +the 0 +past 0 +decade 0 +. 0 +Although 0 +urinary 3 +incontinence 4 +is 0 +listed 0 +as 0 +one 0 +side 0 +effect 0 +of 0 +these 0 +drugs 0 +in 0 +their 0 +package 0 +inserts 0 +there 0 +is 0 +only 0 +one 0 +report 0 +in 0 +the 0 +literature 0 +. 0 +This 0 +concerns 0 +2 0 +male 0 +patients 0 +who 0 +experienced 0 +incontinence 3 +while 0 +taking 0 +venlafaxine 1 +. 0 +In 0 +the 0 +present 0 +paper 0 +the 0 +authors 0 +describe 0 +2 0 +female 0 +patients 0 +who 0 +developed 0 +incontinence 3 +secondary 0 +to 0 +the 0 +selective 0 +serotonin 1 +reuptake 0 +inhibitors 0 +paroxetine 1 +and 0 +sertraline 1 +"," 0 +as 0 +well 0 +as 0 +a 0 +third 0 +who 0 +developed 0 +this 0 +side 0 +effect 0 +on 0 +venlafaxine 1 +. 0 +In 0 +2 0 +of 0 +the 0 +3 0 +cases 0 +the 0 +patients 0 +were 0 +also 0 +taking 0 +lithium 1 +carbonate 2 +and 0 +beta 0 +- 0 +blockers 0 +"," 0 +both 0 +of 0 +which 0 +could 0 +have 0 +contributed 0 +to 0 +the 0 +incontinence 3 +. 0 +Animal 0 +studies 0 +suggest 0 +that 0 +incontinence 3 +secondary 0 +to 0 +serotonergic 1 +antidepressants 2 +could 0 +be 0 +mediated 0 +by 0 +the 0 +5HT4 0 +receptors 0 +found 0 +on 0 +the 0 +bladder 0 +. 0 +Further 0 +research 0 +is 0 +needed 0 +to 0 +delineate 0 +the 0 +frequency 0 +of 0 +this 0 +troubling 0 +side 0 +effect 0 +and 0 +how 0 +best 0 +to 0 +treat 0 +it 0 +. 0 +Acute 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +: 0 +differential 0 +sensitivity 0 +of 0 +six 0 +inbred 0 +mouse 0 +strains 0 +. 0 +Mature 0 +male 0 +and 0 +female 0 +mice 0 +from 0 +six 0 +inbred 0 +stains 0 +were 0 +tested 0 +for 0 +susceptibility 0 +to 0 +behavioral 0 +seizures 3 +induced 0 +by 0 +a 0 +single 0 +injection 0 +of 0 +cocaine 1 +. 0 +Cocaine 1 +was 0 +injected 0 +ip 0 +over 0 +a 0 +range 0 +of 0 +doses 0 +( 0 +50 0 +- 0 +100 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +behavior 0 +was 0 +monitored 0 +for 0 +20 0 +minutes 0 +. 0 +Seizure 3 +end 0 +points 0 +included 0 +latency 0 +to 0 +forelimb 0 +or 0 +hindlimb 0 +clonus 0 +"," 0 +latency 0 +to 0 +clonic 0 +running 0 +seizure 3 +and 0 +latency 0 +to 0 +jumping 0 +bouncing 0 +seizure 3 +. 0 +A 0 +range 0 +of 0 +strain 0 +specific 0 +sensitivities 0 +was 0 +documented 0 +with 0 +A 0 +/ 0 +J 0 +and 0 +SJL 0 +mice 0 +being 0 +most 0 +sensitive 0 +and 0 +C57BL 0 +/ 0 +6J 0 +most 0 +resistant 0 +. 0 +DBA 0 +/ 0 +2J 0 +"," 0 +BALB 0 +/ 0 +cByJ 0 +and 0 +NZW 0 +/ 0 +LacJ 0 +strains 0 +exhibited 0 +intermediate 0 +sensitivity 0 +. 0 +EEG 0 +recordings 0 +were 0 +made 0 +in 0 +SJL 0 +"," 0 +A 0 +/ 0 +J 0 +and 0 +C57BL 0 +/ 0 +6J 0 +mice 0 +revealing 0 +a 0 +close 0 +correspondence 0 +between 0 +electrical 0 +activity 0 +and 0 +behavior 0 +. 0 +Additionally 0 +"," 0 +levels 0 +of 0 +cocaine 1 +determined 0 +in 0 +hippocampus 0 +and 0 +cortex 0 +were 0 +not 0 +different 0 +between 0 +sensitive 0 +and 0 +resistant 0 +strains 0 +. 0 +Additional 0 +studies 0 +of 0 +these 0 +murine 0 +strains 0 +may 0 +be 0 +useful 0 +for 0 +investigating 0 +genetic 0 +influences 0 +on 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +. 0 +Hypotension 3 +following 0 +the 0 +initiation 0 +of 0 +tizanidine 1 +in 0 +a 0 +patient 0 +treated 0 +with 0 +an 0 +angiotensin 1 +converting 0 +enzyme 0 +inhibitor 0 +for 0 +chronic 0 +hypertension 3 +. 0 +Centrally 0 +acting 0 +alpha 0 +- 0 +2 0 +adrenergic 0 +agonists 0 +are 0 +one 0 +of 0 +several 0 +pharmacologic 0 +agents 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +spasticity 3 +related 0 +to 0 +disorders 3 +of 4 +the 4 +central 4 +nervous 4 +system 4 +. 0 +In 0 +addition 0 +to 0 +their 0 +effects 0 +on 0 +spasticity 3 +"," 0 +certain 0 +adverse 0 +cardiorespiratory 0 +effects 0 +have 0 +been 0 +reported 0 +. 0 +Adults 0 +chronically 0 +treated 0 +with 0 +angiotensin 1 +converting 0 +enzyme 0 +inhibitors 0 +may 0 +have 0 +a 0 +limited 0 +ability 0 +to 0 +respond 0 +to 0 +hypotension 3 +when 0 +the 0 +sympathetic 0 +response 0 +is 0 +simultaneously 0 +blocked 0 +. 0 +The 0 +authors 0 +present 0 +a 0 +10 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +chronically 0 +treated 0 +with 0 +lisinopril 1 +"," 0 +an 0 +angiotensin 1 +converting 0 +enzyme 0 +inhibitor 0 +"," 0 +to 0 +control 0 +hypertension 3 +who 0 +developed 0 +hypotension 3 +following 0 +the 0 +addition 0 +of 0 +tizanidine 1 +"," 0 +an 0 +alpha 0 +- 0 +2 0 +agonist 0 +"," 0 +for 0 +the 0 +treatment 0 +of 0 +spasticity 3 +. 0 +The 0 +possible 0 +interaction 0 +of 0 +tizanidine 1 +and 0 +other 0 +antihypertensive 0 +agents 0 +should 0 +be 0 +kept 0 +in 0 +mind 0 +when 0 +prescribing 0 +therapy 0 +to 0 +treat 0 +either 0 +hypertension 3 +or 0 +spasticity 3 +in 0 +such 0 +patients 0 +. 0 +Two 0 +mouse 0 +lines 0 +selected 0 +for 0 +differential 0 +sensitivities 0 +to 0 +beta 1 +- 2 +carboline 2 +- 0 +induced 0 +seizures 3 +are 0 +also 0 +differentially 0 +sensitive 0 +to 0 +various 0 +pharmacological 0 +effects 0 +of 0 +other 0 +GABA 1 +( 0 +A 0 +) 0 +receptor 0 +ligands 0 +. 0 +Two 0 +mouse 0 +lines 0 +were 0 +selectively 0 +bred 0 +according 0 +to 0 +their 0 +sensitivity 0 +( 0 +BS 0 +line 0 +) 0 +or 0 +resistance 0 +( 0 +BR 0 +line 0 +) 0 +to 0 +seizures 3 +induced 0 +by 0 +a 0 +single 0 +i 0 +. 0 +p 0 +. 0 +injection 0 +of 0 +methyl 1 +beta 2 +- 2 +carboline 2 +- 2 +3 2 +- 2 +carboxylate 2 +( 0 +beta 1 +- 2 +CCM 2 +) 0 +"," 0 +an 0 +inverse 0 +agonist 0 +of 0 +the 0 +GABA 1 +( 0 +A 0 +) 0 +receptor 0 +benzodiazepine 1 +site 0 +. 0 +0ur 0 +aim 0 +was 0 +to 0 +characterize 0 +both 0 +lines 0 +' 0 +sensitivities 0 +to 0 +various 0 +physiological 0 +effects 0 +of 0 +other 0 +ligands 0 +of 0 +the 0 +GABA 1 +( 0 +A 0 +) 0 +receptor 0 +. 0 +We 0 +measured 0 +diazepam 1 +- 0 +induced 0 +anxiolysis 0 +with 0 +the 0 +elevated 0 +plus 0 +- 0 +maze 0 +test 0 +"," 0 +diazepam 1 +- 0 +induced 0 +sedation 0 +by 0 +recording 0 +the 0 +vigilance 0 +states 0 +"," 0 +and 0 +picrotoxin 1 +- 0 +and 0 +pentylenetetrazol 1 +- 0 +induced 0 +seizures 3 +after 0 +i 0 +. 0 +p 0 +. 0 +injections 0 +. 0 +Results 0 +presented 0 +here 0 +show 0 +that 0 +the 0 +differential 0 +sensitivities 0 +of 0 +BS 0 +and 0 +BR 0 +lines 0 +to 0 +beta 1 +- 2 +CCM 2 +can 0 +be 0 +extended 0 +to 0 +diazepam 1 +"," 0 +picrotoxin 1 +"," 0 +and 0 +pentylenetetrazol 1 +"," 0 +suggesting 0 +a 0 +genetic 0 +selection 0 +of 0 +a 0 +general 0 +sensitivity 0 +and 0 +resistance 0 +to 0 +several 0 +ligands 0 +of 0 +the 0 +GABA 1 +( 0 +A 0 +) 0 +receptor 0 +. 0 +Propylthiouracil 1 +- 0 +induced 0 +perinuclear 0 +- 0 +staining 0 +antineutrophil 0 +cytoplasmic 0 +autoantibody 0 +- 0 +positive 0 +vasculitis 3 +in 0 +conjunction 0 +with 0 +pericarditis 3 +. 0 +0BJECTIVE 0 +: 0 +To 0 +describe 0 +a 0 +case 0 +of 0 +propylthiouracil 1 +- 0 +induced 0 +vasculitis 3 +manifesting 0 +with 0 +pericarditis 3 +. 0 +METH0DS 0 +: 0 +We 0 +present 0 +the 0 +first 0 +case 0 +report 0 +of 0 +a 0 +woman 0 +with 0 +hyperthyroidism 3 +treated 0 +with 0 +propylthiouracil 1 +in 0 +whom 0 +a 0 +syndrome 0 +of 0 +pericarditis 3 +"," 0 +fever 3 +"," 0 +and 0 +glomerulonephritis 3 +developed 0 +. 0 +Serologic 0 +testing 0 +and 0 +immunologic 0 +studies 0 +were 0 +done 0 +"," 0 +and 0 +a 0 +pericardial 0 +biopsy 0 +was 0 +performed 0 +. 0 +RESULTS 0 +: 0 +A 0 +25 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +Graves 3 +' 4 +disease 4 +had 0 +a 0 +febrile 3 +illness 4 +and 0 +evidence 0 +of 0 +pericarditis 3 +"," 0 +which 0 +was 0 +confirmed 0 +by 0 +biopsy 0 +. 0 +Serologic 0 +evaluation 0 +revealed 0 +the 0 +presence 0 +of 0 +perinuclear 0 +- 0 +staining 0 +antineutrophil 0 +cytoplasmic 0 +autoantibodies 0 +( 0 +pANCA 0 +) 0 +against 0 +myeloperoxidase 0 +( 0 +MP0 0 +) 0 +. 0 +Propylthiouracil 1 +therapy 0 +was 0 +withdrawn 0 +"," 0 +and 0 +she 0 +was 0 +treated 0 +with 0 +a 0 +1 0 +- 0 +month 0 +course 0 +of 0 +prednisone 1 +"," 0 +which 0 +alleviated 0 +her 0 +symptoms 0 +. 0 +A 0 +literature 0 +review 0 +revealed 0 +no 0 +prior 0 +reports 0 +of 0 +pericarditis 3 +in 0 +anti 0 +- 0 +MP0 0 +pANCA 0 +- 0 +positive 0 +vasculitis 3 +associated 0 +with 0 +propylthio 1 +- 2 +uracil 2 +therapy 0 +. 0 +C0NCLUSI0N 0 +: 0 +Pericarditis 3 +may 0 +be 0 +the 0 +initial 0 +manifestation 0 +of 0 +drug 0 +- 0 +induced 0 +vasculitis 3 +attributable 0 +to 0 +propylthio 1 +- 2 +uracil 2 +therapy 0 +. 0 +Repeated 0 +transient 0 +anuria 3 +following 0 +losartan 1 +administration 0 +in 0 +a 0 +patient 0 +with 0 +a 0 +solitary 0 +kidney 0 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +70 0 +- 0 +year 0 +- 0 +old 0 +hypertensive 3 +man 0 +with 0 +a 0 +solitary 0 +kidney 0 +and 0 +chronic 3 +renal 4 +insufficiency 4 +who 0 +developed 0 +two 0 +episodes 0 +of 0 +transient 0 +anuria 3 +after 0 +losartan 1 +administration 0 +. 0 +He 0 +was 0 +hospitalized 0 +for 0 +a 0 +myocardial 3 +infarction 4 +with 0 +pulmonary 3 +edema 4 +"," 0 +treated 0 +with 0 +high 0 +- 0 +dose 0 +diuretics 0 +. 0 +Due 0 +to 0 +severe 0 +systolic 3 +dysfunction 4 +losartan 1 +was 0 +prescribed 0 +. 0 +Surprisingly 0 +"," 0 +the 0 +first 0 +dose 0 +of 0 +50 0 +mg 0 +of 0 +losartan 1 +resulted 0 +in 0 +a 0 +sudden 0 +anuria 3 +"," 0 +which 0 +lasted 0 +eight 0 +hours 0 +despite 0 +high 0 +- 0 +dose 0 +furosemide 1 +and 0 +amine 1 +infusion 0 +. 0 +0ne 0 +week 0 +later 0 +"," 0 +by 0 +mistake 0 +"," 0 +losartan 1 +was 0 +prescribed 0 +again 0 +and 0 +after 0 +the 0 +second 0 +dose 0 +of 0 +50 0 +mg 0 +"," 0 +the 0 +patient 0 +developed 0 +a 0 +second 0 +episode 0 +of 0 +transient 0 +anuria 3 +lasting 0 +10 0 +hours 0 +. 0 +During 0 +these 0 +two 0 +episodes 0 +"," 0 +his 0 +blood 0 +pressure 0 +diminished 0 +but 0 +no 0 +severe 0 +hypotension 3 +was 0 +noted 0 +. 0 +Ultimately 0 +"," 0 +an 0 +arteriography 0 +showed 0 +a 0 +70 0 +- 0 +80 0 +% 0 +renal 3 +artery 4 +stenosis 4 +. 0 +In 0 +this 0 +patient 0 +"," 0 +renal 3 +artery 4 +stenosis 4 +combined 0 +with 0 +heart 3 +failure 4 +and 0 +diuretic 0 +therapy 0 +certainly 0 +resulted 0 +in 0 +a 0 +strong 0 +activation 0 +of 0 +the 0 +renin 0 +- 0 +angiotensin 1 +system 0 +( 0 +RAS 0 +) 0 +. 0 +Under 0 +such 0 +conditions 0 +"," 0 +angiotensin 1 +II 2 +receptor 0 +blockade 0 +by 0 +losartan 1 +probably 0 +induced 0 +a 0 +critical 0 +fall 0 +in 0 +glomerular 0 +filtration 0 +pressure 0 +. 0 +This 0 +case 0 +report 0 +highlights 0 +the 0 +fact 0 +that 0 +the 0 +angiotensin 1 +II 2 +receptor 0 +antagonist 0 +losartan 1 +can 0 +cause 0 +serious 0 +unexpected 0 +complications 0 +in 0 +patients 0 +with 0 +renovascular 3 +disease 4 +and 0 +should 0 +be 0 +used 0 +with 0 +extreme 0 +caution 0 +in 0 +this 0 +setting 0 +. 0 +Calcineurin 0 +- 0 +inhibitor 0 +induced 0 +pain 3 +syndrome 0 +( 0 +CIPS 3 +) 0 +: 0 +a 0 +severe 0 +disabling 0 +complication 0 +after 0 +organ 0 +transplantation 0 +. 0 +Bone 0 +pain 3 +after 0 +transplantation 0 +is 0 +a 0 +frequent 0 +complication 0 +that 0 +can 0 +be 0 +caused 0 +by 0 +several 0 +diseases 0 +. 0 +Treatment 0 +strategies 0 +depend 0 +on 0 +the 0 +correct 0 +diagnosis 0 +of 0 +the 0 +pain 3 +. 0 +Nine 0 +patients 0 +with 0 +severe 0 +pain 3 +in 0 +their 0 +feet 0 +"," 0 +which 0 +was 0 +registered 0 +after 0 +transplantation 0 +"," 0 +were 0 +investigated 0 +. 0 +Bone 0 +scans 0 +showed 0 +an 0 +increased 0 +tracer 0 +uptake 0 +of 0 +the 0 +foot 0 +bones 0 +. 0 +Magnetic 0 +resonance 0 +imaging 0 +demonstrated 0 +bone 3 +marrow 4 +oedema 4 +in 0 +the 0 +painful 0 +bones 0 +. 0 +Pain 3 +was 0 +not 0 +explained 0 +by 0 +other 0 +diseases 0 +causing 0 +foot 0 +pain 3 +"," 0 +like 0 +reflex 3 +sympathetic 4 +dystrophy 4 +"," 0 +polyneuropathy 3 +"," 0 +Morton 3 +' 4 +s 4 +neuralgia 4 +"," 0 +gout 3 +"," 0 +osteoporosis 3 +"," 0 +avascular 3 +necrosis 4 +"," 0 +intermittent 3 +claudication 4 +"," 0 +orthopaedic 0 +foot 3 +deformities 4 +"," 0 +stress 3 +fractures 4 +"," 0 +and 0 +hyperparathyroidism 3 +. 0 +The 0 +reduction 0 +of 0 +cyclosporine 1 +- 0 +or 0 +tacrolimus 1 +trough 0 +levels 0 +and 0 +the 0 +administration 0 +of 0 +calcium 1 +channel 0 +blockers 0 +led 0 +to 0 +relief 0 +of 0 +pain 3 +. 0 +The 0 +Calcineurin 0 +- 0 +inhibitor 0 +Induced 0 +Pain 3 +Syndrome 0 +( 0 +CIPS 3 +) 0 +is 0 +a 0 +rare 0 +but 0 +severe 0 +side 0 +effect 0 +of 0 +cyclosporine 1 +or 0 +tacrolimus 1 +and 0 +is 0 +accurately 0 +diagnosed 0 +by 0 +its 0 +typical 0 +presentation 0 +"," 0 +magnetic 0 +resonance 0 +imaging 0 +and 0 +bone 0 +scans 0 +. 0 +Incorrect 0 +diagnosis 0 +of 0 +the 0 +syndrome 0 +will 0 +lead 0 +to 0 +a 0 +significant 0 +reduction 0 +of 0 +life 0 +quality 0 +in 0 +patients 0 +suffering 0 +from 0 +CIPS 3 +. 0 +Brain 0 +natriuretic 0 +peptide 0 +is 0 +a 0 +predictor 0 +of 0 +anthracycline 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 +Anthracyclines 1 +are 0 +effective 0 +antineoplastic 0 +drugs 0 +"," 0 +but 0 +they 0 +frequently 0 +cause 0 +dose 0 +- 0 +related 0 +cardiotoxicity 3 +. 0 +The 0 +cardiotoxicity 3 +of 0 +conventional 0 +anthracycline 1 +therapy 0 +highlights 0 +a 0 +need 0 +to 0 +search 0 +for 0 +methods 0 +that 0 +are 0 +highly 0 +sensitive 0 +and 0 +capable 0 +of 0 +predicting 0 +cardiac 3 +dysfunction 4 +. 0 +We 0 +measured 0 +the 0 +plasma 0 +level 0 +of 0 +brain 0 +natriuretic 0 +peptide 0 +( 0 +BNP 0 +) 0 +to 0 +determine 0 +whether 0 +BNP 0 +might 0 +serve 0 +as 0 +a 0 +simple 0 +diagnostic 0 +indicator 0 +of 0 +anthracycline 1 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +patients 0 +with 0 +acute 3 +leukemia 4 +treated 0 +with 0 +a 0 +daunorubicin 1 +( 0 +DNR 1 +) 0 +- 0 +containing 0 +regimen 0 +. 0 +Thirteen 0 +patients 0 +with 0 +acute 3 +leukemia 4 +were 0 +treated 0 +with 0 +a 0 +DNR 1 +- 0 +containing 0 +regimen 0 +. 0 +Cardiac 0 +functions 0 +were 0 +evaluated 0 +with 0 +radionuclide 0 +angiography 0 +before 0 +chemotherapies 0 +. 0 +The 0 +plasma 0 +levels 0 +of 0 +atrial 0 +natriuretic 0 +peptide 0 +( 0 +ANP 0 +) 0 +and 0 +BNP 0 +were 0 +measured 0 +at 0 +the 0 +time 0 +of 0 +radionuclide 0 +angiography 0 +. 0 +Three 0 +patients 0 +developed 0 +congestive 3 +heart 4 +failure 4 +after 0 +the 0 +completion 0 +of 0 +chemotherapy 0 +. 0 +Five 0 +patients 0 +were 0 +diagnosed 0 +as 0 +having 0 +subclinical 0 +heart 3 +failure 4 +after 0 +the 0 +completion 0 +of 0 +chemotherapy 0 +. 0 +The 0 +plasma 0 +levels 0 +of 0 +BNP 0 +in 0 +all 0 +the 0 +patients 0 +with 0 +clinical 0 +and 0 +subclinical 0 +heart 3 +failure 4 +increased 0 +above 0 +the 0 +normal 0 +limit 0 +( 0 +40 0 +pg 0 +/ 0 +ml 0 +) 0 +before 0 +the 0 +detection 0 +of 0 +clinical 0 +or 0 +subclinical 0 +heart 3 +failure 4 +by 0 +radionuclide 0 +angiography 0 +. 0 +0n 0 +the 0 +other 0 +hand 0 +"," 0 +BNP 0 +did 0 +not 0 +increase 0 +in 0 +the 0 +patients 0 +without 0 +heart 3 +failure 4 +given 0 +DNR 1 +"," 0 +even 0 +at 0 +more 0 +than 0 +700 0 +mg 0 +/ 0 +m 0 +( 0 +2 0 +) 0 +. 0 +The 0 +plasma 0 +level 0 +of 0 +ANP 0 +did 0 +not 0 +always 0 +increase 0 +in 0 +all 0 +the 0 +patients 0 +with 0 +clinical 0 +and 0 +subclinical 0 +heart 3 +failure 4 +. 0 +These 0 +preliminary 0 +results 0 +suggest 0 +that 0 +BNP 0 +may 0 +be 0 +useful 0 +as 0 +an 0 +early 0 +and 0 +sensitive 0 +indicator 0 +of 0 +anthracycline 1 +- 0 +induced 0 +cardiotoxicity 3 +. 0 +Nephrotoxicity 3 +of 0 +combined 0 +cephalothin 1 +- 0 +gentamicin 1 +regimen 0 +. 0 +Two 0 +patients 0 +developed 0 +acute 3 +tubular 4 +necrosis 4 +"," 0 +characterized 0 +clinically 0 +by 0 +acute 0 +oliguric 3 +renal 4 +failure 4 +"," 0 +while 0 +they 0 +were 0 +receiving 0 +a 0 +combination 0 +of 0 +cephalothin 1 +sodium 2 +and 0 +gentamicin 1 +sulfate 2 +therapy 0 +. 0 +Patients 0 +who 0 +are 0 +given 0 +this 0 +drug 0 +regimen 0 +should 0 +be 0 +observed 0 +very 0 +carefully 0 +for 0 +early 0 +signs 0 +of 0 +nephrotoxicity 3 +. 0 +High 0 +doses 0 +of 0 +this 0 +antibiotic 0 +combination 0 +should 0 +be 0 +avoided 0 +especially 0 +in 0 +elderly 0 +patients 0 +. 0 +Patients 0 +with 0 +renal 3 +insufficiency 4 +should 0 +not 0 +be 0 +given 0 +this 0 +regimen 0 +. 0 +In 0 +vivo 0 +protection 0 +of 0 +dna 0 +damage 0 +associated 0 +apoptotic 0 +and 0 +necrotic 3 +cell 0 +deaths 0 +during 0 +acetaminophen 1 +- 0 +induced 0 +nephrotoxicity 3 +"," 0 +amiodarone 1 +- 0 +induced 0 +lung 3 +toxicity 4 +and 0 +doxorubicin 1 +- 0 +induced 0 +cardiotoxicity 3 +by 0 +a 0 +novel 0 +IH636 1 +grape 2 +seed 2 +proanthocyanidin 2 +extract 2 +. 0 +Grape 1 +seed 2 +extract 2 +"," 0 +primarily 0 +a 0 +mixture 0 +of 0 +proanthocyanidins 1 +"," 0 +has 0 +been 0 +shown 0 +to 0 +modulate 0 +a 0 +wide 0 +- 0 +range 0 +of 0 +biological 0 +"," 0 +pharmacological 0 +and 0 +toxicological 0 +effects 0 +which 0 +are 0 +mainly 0 +cytoprotective 0 +. 0 +This 0 +study 0 +assessed 0 +the 0 +ability 0 +of 0 +IH636 1 +grape 2 +seed 2 +proanthocyanidin 2 +extract 2 +( 0 +GSPE 1 +) 0 +to 0 +prevent 0 +acetaminophen 1 +( 0 +AAP 1 +) 0 +- 0 +induced 0 +nephrotoxicity 3 +"," 0 +amiodarone 1 +( 0 +AMI 1 +) 0 +- 0 +induced 0 +lung 3 +toxicity 4 +"," 0 +and 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +- 0 +induced 0 +cardiotoxicity 3 +in 0 +mice 0 +. 0 +Experimental 0 +design 0 +consisted 0 +of 0 +four 0 +groups 0 +: 0 +control 0 +( 0 +vehicle 0 +alone 0 +) 0 +"," 0 +GSPE 1 +alone 0 +"," 0 +drug 0 +alone 0 +and 0 +GSPE 1 ++ 0 +drug 0 +. 0 +For 0 +the 0 +cytoprotection 0 +study 0 +"," 0 +animals 0 +were 0 +orally 0 +gavaged 0 +100 0 +mg 0 +/ 0 +Kg 0 +GSPE 1 +for 0 +7 0 +- 0 +10 0 +days 0 +followed 0 +by 0 +i 0 +. 0 +p 0 +. 0 +injections 0 +of 0 +organ 0 +specific 0 +three 0 +drugs 0 +( 0 +AAP 1 +: 0 +500 0 +mg 0 +/ 0 +Kg 0 +for 0 +24 0 +h 0 +; 0 +AMI 1 +: 0 +50 0 +mg 0 +/ 0 +Kg 0 +/ 0 +day 0 +for 0 +four 0 +days 0 +; 0 +D0X 1 +: 0 +20 0 +mg 0 +/ 0 +Kg 0 +for 0 +48 0 +h 0 +) 0 +. 0 +Parameters 0 +of 0 +study 0 +included 0 +analysis 0 +of 0 +serum 0 +chemistry 0 +( 0 +ALT 0 +"," 0 +BUN 0 +and 0 +CPK 0 +) 0 +"," 0 +and 0 +orderly 0 +fragmentation 0 +of 0 +genomic 0 +DNA 0 +( 0 +both 0 +endonuclease 0 +- 0 +dependent 0 +and 0 +independent 0 +) 0 +in 0 +addition 0 +to 0 +microscopic 0 +evaluation 0 +of 0 +damage 0 +and 0 +/ 0 +or 0 +protection 0 +in 0 +corresponding 0 +PAS 0 +stained 0 +tissues 0 +. 0 +Results 0 +indicate 0 +that 0 +GSPE 1 +preexposure 0 +prior 0 +to 0 +AAP 1 +"," 0 +AMI 1 +and 0 +D0X 1 +"," 0 +provided 0 +near 0 +complete 0 +protection 0 +in 0 +terms 0 +of 0 +serum 0 +chemistry 0 +changes 0 +( 0 +ALT 0 +"," 0 +BUN 0 +and 0 +CPK 0 +) 0 +"," 0 +and 0 +significantly 0 +reduced 0 +DNA 0 +fragmentation 0 +. 0 +Histopathological 0 +examination 0 +of 0 +kidney 0 +"," 0 +heart 0 +and 0 +lung 0 +sections 0 +revealed 0 +moderate 0 +to 0 +massive 0 +tissue 3 +damage 4 +with 0 +a 0 +variety 0 +of 0 +morphological 0 +aberrations 0 +by 0 +all 0 +the 0 +three 0 +drugs 0 +in 0 +the 0 +absence 0 +of 0 +GSPE 1 +preexposure 0 +than 0 +in 0 +its 0 +presence 0 +. 0 +GSPE 1 ++ 0 +drug 0 +exposed 0 +tissues 0 +exhibited 0 +minor 0 +residual 0 +damage 0 +or 0 +near 0 +total 0 +recovery 0 +. 0 +Additionally 0 +"," 0 +histopathological 0 +alterations 0 +mirrored 0 +both 0 +serum 0 +chemistry 0 +changes 0 +and 0 +the 0 +pattern 0 +of 0 +DNA 0 +fragmentation 0 +. 0 +Interestingly 0 +"," 0 +all 0 +the 0 +drugs 0 +"," 0 +such 0 +as 0 +"," 0 +AAP 1 +"," 0 +AMI 1 +and 0 +D0X 1 +induced 0 +apoptotic 0 +death 0 +in 0 +addition 0 +to 0 +necrosis 3 +in 0 +the 0 +respective 0 +organs 0 +which 0 +was 0 +very 0 +effectively 0 +blocked 0 +by 0 +GSPE 1 +. 0 +Since 0 +AAP 1 +"," 0 +AMI 1 +and 0 +D0X 1 +undergo 0 +biotransformation 0 +and 0 +are 0 +known 0 +to 0 +produce 0 +damaging 0 +radicals 0 +in 0 +vivo 0 +"," 0 +the 0 +protection 0 +by 0 +GSPE 1 +may 0 +be 0 +linked 0 +to 0 +both 0 +inhibition 0 +of 0 +metabolism 0 +and 0 +/ 0 +or 0 +detoxification 0 +of 0 +cytotoxic 0 +radicals 0 +. 0 +In 0 +addition 0 +"," 0 +its 0 +' 0 +presumed 0 +contribution 0 +to 0 +DNA 0 +repair 0 +may 0 +be 0 +another 0 +important 0 +attribute 0 +"," 0 +which 0 +played 0 +a 0 +role 0 +in 0 +the 0 +chemoprevention 0 +process 0 +. 0 +Additionally 0 +"," 0 +this 0 +may 0 +have 0 +been 0 +the 0 +first 0 +report 0 +on 0 +AMI 1 +- 0 +induced 0 +apoptotic 0 +death 0 +in 0 +the 0 +lung 0 +tissue 0 +. 0 +Taken 0 +together 0 +"," 0 +these 0 +events 0 +undoubtedly 0 +establish 0 +GSPE 1 +' 0 +s 0 +abundant 0 +bioavailability 0 +"," 0 +and 0 +the 0 +power 0 +to 0 +defend 0 +multiple 0 +target 0 +organs 0 +from 0 +toxic 0 +assaults 0 +induced 0 +by 0 +structurally 0 +diverse 0 +and 0 +functionally 0 +different 0 +entities 0 +in 0 +vivo 0 +. 0 +Antidepressant 1 +- 0 +induced 0 +mania 3 +in 0 +bipolar 3 +patients 0 +: 0 +identification 0 +of 0 +risk 0 +factors 0 +. 0 +BACKGR0UND 0 +: 0 +Concerns 0 +about 0 +possible 0 +risks 0 +of 0 +switching 0 +to 0 +mania 3 +associated 0 +with 0 +antidepressants 1 +continue 0 +to 0 +interfere 0 +with 0 +the 0 +establishment 0 +of 0 +an 0 +optimal 0 +treatment 0 +paradigm 0 +for 0 +bipolar 3 +depression 4 +. 0 +METH0D 0 +: 0 +The 0 +response 0 +of 0 +44 0 +patients 0 +meeting 0 +DSM 0 +- 0 +IV 0 +criteria 0 +for 0 +bipolar 3 +disorder 4 +to 0 +naturalistic 0 +treatment 0 +was 0 +assessed 0 +for 0 +at 0 +least 0 +6 0 +weeks 0 +using 0 +the 0 +Montgomery 0 +- 0 +Asberg 0 +Depression 0 +Rating 0 +Scale 0 +and 0 +the 0 +Bech 0 +- 0 +Rafaelson 0 +Mania 0 +Rating 0 +Scale 0 +. 0 +Patients 0 +who 0 +experienced 0 +a 0 +manic 3 +or 0 +hypomanic 3 +switch 0 +were 0 +compared 0 +with 0 +those 0 +who 0 +did 0 +not 0 +on 0 +several 0 +variables 0 +including 0 +age 0 +"," 0 +sex 0 +"," 0 +diagnosis 0 +( 0 +DSM 3 +- 4 +IV 4 +bipolar 4 +I 4 +vs 0 +. 0 +bipolar 3 +II 4 +) 0 +"," 0 +number 0 +of 0 +previous 0 +manic 3 +episodes 0 +"," 0 +type 0 +of 0 +antidepressant 1 +therapy 0 +used 0 +( 0 +electroconvulsive 0 +therapy 0 +vs 0 +. 0 +antidepressant 1 +drugs 0 +and 0 +"," 0 +more 0 +particularly 0 +"," 0 +selective 0 +serotonin 1 +reuptake 2 +inhibitors 2 +[ 0 +SSRIs 1 +] 0 +) 0 +"," 0 +use 0 +and 0 +type 0 +of 0 +mood 0 +stabilizers 0 +( 0 +lithium 1 +vs 0 +. 0 +anticonvulsants 0 +) 0 +"," 0 +and 0 +temperament 0 +of 0 +the 0 +patient 0 +"," 0 +assessed 0 +during 0 +a 0 +normothymic 0 +period 0 +using 0 +the 0 +hyperthymia 0 +component 0 +of 0 +the 0 +Semi 0 +- 0 +structured 0 +Affective 0 +Temperament 0 +Interview 0 +. 0 +RESULTS 0 +: 0 +Switches 0 +to 0 +hypomania 3 +or 0 +mania 3 +occurred 0 +in 0 +27 0 +% 0 +of 0 +all 0 +patients 0 +( 0 +N 0 += 0 +12 0 +) 0 +( 0 +and 0 +in 0 +24 0 +% 0 +of 0 +the 0 +subgroup 0 +of 0 +patients 0 +treated 0 +with 0 +SSRIs 1 +[ 0 +8 0 +/ 0 +33 0 +] 0 +) 0 +; 0 +16 0 +% 0 +( 0 +N 0 += 0 +7 0 +) 0 +experienced 0 +manic 3 +episodes 0 +"," 0 +and 0 +11 0 +% 0 +( 0 +N 0 += 0 +5 0 +) 0 +experienced 0 +hypomanic 3 +episodes 0 +. 0 +Sex 0 +"," 0 +age 0 +"," 0 +diagnosis 0 +( 0 +bipolar 3 +I 4 +vs 0 +. 0 +bipolar 3 +II 4 +) 0 +"," 0 +and 0 +additional 0 +treatment 0 +did 0 +not 0 +affect 0 +the 0 +risk 0 +of 0 +switching 0 +. 0 +The 0 +incidence 0 +of 0 +mood 0 +switches 0 +seemed 0 +not 0 +to 0 +differ 0 +between 0 +patients 0 +receiving 0 +an 0 +anticonvulsant 0 +and 0 +those 0 +receiving 0 +no 0 +mood 0 +stabilizer 0 +. 0 +In 0 +contrast 0 +"," 0 +mood 0 +switches 0 +were 0 +less 0 +frequent 0 +in 0 +patients 0 +receiving 0 +lithium 1 +( 0 +15 0 +% 0 +"," 0 +4 0 +/ 0 +26 0 +) 0 +than 0 +in 0 +patients 0 +not 0 +treated 0 +with 0 +lithium 1 +( 0 +44 0 +% 0 +"," 0 +8 0 +/ 0 +18 0 +; 0 +p 0 += 0 +. 0 +4 0 +) 0 +. 0 +The 0 +number 0 +of 0 +previous 0 +manic 3 +episodes 0 +did 0 +not 0 +affect 0 +the 0 +probability 0 +of 0 +switching 0 +"," 0 +whereas 0 +a 0 +high 0 +score 0 +on 0 +the 0 +hyperthymia 0 +component 0 +of 0 +the 0 +Semistructured 0 +Affective 0 +Temperament 0 +Interview 0 +was 0 +associated 0 +with 0 +a 0 +greater 0 +risk 0 +of 0 +switching 0 +( 0 +p 0 += 0 +. 0 +8 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +The 0 +frequency 0 +of 0 +mood 0 +switching 0 +associated 0 +with 0 +acute 0 +antidepressant 1 +therapy 0 +may 0 +be 0 +reduced 0 +by 0 +lithium 1 +treatment 0 +. 0 +Particular 0 +attention 0 +should 0 +be 0 +paid 0 +to 0 +patients 0 +with 0 +a 0 +hyperthymic 0 +temperament 0 +"," 0 +who 0 +have 0 +a 0 +greater 0 +risk 0 +of 0 +mood 0 +switches 0 +. 0 +Peritubular 0 +capillary 0 +basement 0 +membrane 0 +reduplication 0 +in 0 +allografts 0 +and 0 +native 0 +kidney 3 +disease 4 +: 0 +a 0 +clinicopathologic 0 +study 0 +of 0 +278 0 +consecutive 0 +renal 0 +specimens 0 +. 0 +BACKGR0UND 0 +: 0 +An 0 +association 0 +has 0 +been 0 +found 0 +between 0 +transplant 3 +glomerulopathy 4 +( 0 +TG 3 +) 0 +and 0 +reduplication 0 +of 0 +peritubular 0 +capillary 0 +basement 0 +membranes 0 +( 0 +PTCR 0 +) 0 +. 0 +Although 0 +such 0 +an 0 +association 0 +is 0 +of 0 +practical 0 +and 0 +theoretical 0 +importance 0 +"," 0 +only 0 +one 0 +prospective 0 +study 0 +has 0 +tried 0 +to 0 +confirm 0 +it 0 +. 0 +METH0DS 0 +: 0 +We 0 +examined 0 +278 0 +consecutive 0 +renal 0 +specimens 0 +( 0 +from 0 +135 0 +transplants 0 +and 0 +143 0 +native 0 +kidneys 0 +) 0 +for 0 +ultrastructural 0 +evidence 0 +of 0 +PTCR 0 +. 0 +In 0 +addition 0 +to 0 +renal 0 +allografts 0 +with 0 +TG 3 +"," 0 +we 0 +also 0 +examined 0 +grafts 0 +with 0 +acute 0 +rejection 0 +"," 0 +recurrent 0 +glomerulonephritis 3 +"," 0 +chronic 3 +allograft 4 +nephropathy 4 +and 0 +stable 0 +grafts 0 +( 0 +" 0 +protocol 0 +biopsies 0 +" 0 +) 0 +. 0 +Native 0 +kidney 0 +specimens 0 +included 0 +a 0 +wide 0 +range 0 +of 0 +glomerulopathies 3 +as 0 +well 0 +as 0 +cases 0 +of 0 +thrombotic 3 +microangiopathy 4 +"," 0 +malignant 3 +hypertension 4 +"," 0 +acute 0 +interstitial 3 +nephritis 4 +"," 0 +and 0 +acute 3 +tubular 4 +necrosis 4 +. 0 +RESULTS 0 +: 0 +We 0 +found 0 +PTCR 0 +in 0 +14 0 +of 0 +15 0 +cases 0 +of 0 +TG 3 +"," 0 +in 0 +7 0 +transplant 0 +biopsy 0 +specimens 0 +without 0 +TG 3 +"," 0 +and 0 +in 0 +13 0 +of 0 +143 0 +native 0 +kidney 0 +biopsy 0 +specimens 0 +. 0 +These 0 +13 0 +included 0 +cases 0 +of 0 +malignant 3 +hypertension 4 +"," 0 +thrombotic 3 +microangiopathy 4 +"," 0 +lupus 3 +nephritis 4 +"," 0 +Henoch 3 +- 4 +Schonlein 4 +nephritis 4 +"," 0 +crescentic 0 +glomerulonephritis 3 +"," 0 +and 0 +cocaine 1 +- 0 +related 0 +acute 3 +renal 4 +failure 4 +. 0 +Mild 0 +PTCR 0 +in 0 +allografts 0 +without 0 +TG 3 +did 0 +not 0 +predict 0 +renal 3 +failure 4 +or 0 +significant 0 +proteinuria 3 +after 0 +follow 0 +- 0 +up 0 +periods 0 +of 0 +between 0 +3 0 +months 0 +and 0 +1 0 +year 0 +. 0 +C0NCLUSI0NS 0 +: 0 +We 0 +conclude 0 +that 0 +in 0 +transplants 0 +"," 0 +there 0 +is 0 +a 0 +strong 0 +association 0 +between 0 +well 0 +- 0 +developed 0 +PTCR 0 +and 0 +TG 3 +"," 0 +while 0 +the 0 +significance 0 +of 0 +mild 0 +PTCR 0 +and 0 +its 0 +predictive 0 +value 0 +in 0 +the 0 +absence 0 +of 0 +TG 3 +is 0 +unclear 0 +. 0 +PTCR 0 +also 0 +occurs 0 +in 0 +certain 0 +native 0 +kidney 3 +diseases 4 +"," 0 +though 0 +the 0 +association 0 +is 0 +not 0 +as 0 +strong 0 +as 0 +that 0 +for 0 +TG 3 +. 0 +We 0 +suggest 0 +that 0 +repeated 0 +endothelial 3 +injury 4 +"," 0 +including 0 +immunologic 3 +injury 4 +"," 0 +may 0 +be 0 +the 0 +cause 0 +of 0 +this 0 +lesion 0 +both 0 +in 0 +allografts 0 +and 0 +native 0 +kidneys 0 +. 0 +Caffeine 1 +- 0 +induced 0 +cardiac 3 +arrhythmia 4 +: 0 +an 0 +unrecognised 0 +danger 0 +of 0 +healthfood 0 +products 0 +. 0 +We 0 +describe 0 +a 0 +25 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +pre 0 +- 0 +existing 0 +mitral 3 +valve 4 +prolapse 4 +who 0 +developed 0 +intractable 0 +ventricular 3 +fibrillation 4 +after 0 +consuming 0 +a 0 +" 0 +natural 0 +energy 0 +" 0 +guarana 0 +health 0 +drink 0 +containing 0 +a 0 +high 0 +concentration 0 +of 0 +caffeine 1 +. 0 +This 0 +case 0 +highlights 0 +the 0 +need 0 +for 0 +adequate 0 +labelling 0 +and 0 +regulation 0 +of 0 +such 0 +products 0 +. 0 +Conformationally 0 +restricted 0 +analogs 0 +of 0 +BD1008 1 +and 0 +an 0 +antisense 0 +oligodeoxynucleotide 1 +targeting 0 +sigma1 0 +receptors 0 +produce 0 +anti 0 +- 0 +cocaine 1 +effects 0 +in 0 +mice 0 +. 0 +Cocaine 1 +' 0 +s 0 +ability 0 +to 0 +interact 0 +with 0 +sigma 0 +receptors 0 +suggests 0 +that 0 +these 0 +proteins 0 +mediate 0 +some 0 +of 0 +its 0 +behavioral 0 +effects 0 +. 0 +Therefore 0 +"," 0 +three 0 +novel 0 +sigma 0 +receptor 0 +ligands 0 +with 0 +antagonist 0 +activity 0 +were 0 +evaluated 0 +in 0 +Swiss 0 +Webster 0 +mice 0 +: 0 +BD1018 1 +( 0 +3S 1 +- 2 +1 2 +- 2 +[ 2 +2 2 +- 2 +( 2 +3 2 +"," 2 +4 2 +- 2 +dichlorophenyl 2 +) 2 +ethyl 2 +] 2 +- 2 +1 2 +"," 2 +4 2 +- 2 +diazabicyclo 2 +[ 2 +4 2 +. 2 +3 2 +. 2 +0 2 +] 2 +nonane 2 +) 0 +"," 0 +BD1063 1 +( 0 +1 1 +- 2 +[ 2 +2 2 +- 2 +( 2 +3 2 +"," 2 +4 2 +- 2 +dichlorophenyl 2 +) 2 +ethyl 2 +] 2 +- 2 +4 2 +- 2 +methylpiperazine 2 +) 0 +"," 0 +and 0 +LR132 1 +( 0 +1R 0 +"," 0 +2S 0 +- 0 +( 0 ++ 0 +) 0 +- 0 +cis 0 +- 0 +N 0 +- 0 +[ 0 +2 0 +- 0 +( 0 +3 0 +"," 0 +4 0 +- 0 +dichlorophenyl 0 +) 0 +ethyl 0 +] 0 +- 0 +2 0 +- 0 +( 0 +1 0 +- 0 +pyrrolidinyl 0 +) 0 +cyclohexylamine 0 +) 0 +. 0 +Competition 0 +binding 0 +assays 0 +demonstrated 0 +that 0 +all 0 +three 0 +compounds 0 +have 0 +high 0 +affinities 0 +for 0 +sigma1 0 +receptors 0 +. 0 +The 0 +three 0 +compounds 0 +vary 0 +in 0 +their 0 +affinities 0 +for 0 +sigma2 0 +receptors 0 +and 0 +exhibit 0 +negligible 0 +affinities 0 +for 0 +dopamine 1 +"," 0 +opioid 0 +"," 0 +GABA 1 +( 0 +A 0 +) 0 +and 0 +NMDA 1 +receptors 0 +. 0 +In 0 +behavioral 0 +studies 0 +"," 0 +pre 0 +- 0 +treatment 0 +of 0 +mice 0 +with 0 +BD1018 1 +"," 0 +BD1063 1 +"," 0 +or 0 +LR132 1 +significantly 0 +attenuated 0 +cocaine 1 +- 0 +induced 0 +convulsions 3 +and 0 +lethality 0 +. 0 +Moreover 0 +"," 0 +post 0 +- 0 +treatment 0 +with 0 +LR132 1 +prevented 0 +cocaine 1 +- 0 +induced 0 +lethality 0 +in 0 +a 0 +significant 0 +proportion 0 +of 0 +animals 0 +. 0 +In 0 +contrast 0 +to 0 +the 0 +protection 0 +provided 0 +by 0 +the 0 +putative 0 +antagonists 0 +"," 0 +the 0 +well 0 +- 0 +characterized 0 +sigma 0 +receptor 0 +agonist 0 +di 1 +- 2 +o 2 +- 2 +tolylguanidine 2 +( 0 +DTG 1 +) 0 +and 0 +the 0 +novel 0 +sigma 0 +receptor 0 +agonist 0 +BD1031 1 +( 0 +3R 1 +- 2 +1 2 +- 2 +[ 2 +2 2 +- 2 +( 2 +3 2 +"," 2 +4 2 +- 2 +dichlorophenyl 2 +) 2 +ethyl 2 +] 2 +- 2 +1 2 +"," 2 +4 2 +- 2 +diazabicyclo 2 +[ 2 +4 2 +. 2 +3 2 +. 2 +0 2 +] 2 +nonane 2 +) 0 +each 0 +worsened 0 +the 0 +behavioral 0 +toxicity 3 +of 0 +cocaine 1 +. 0 +At 0 +doses 0 +where 0 +alone 0 +"," 0 +they 0 +produced 0 +no 0 +significant 0 +effects 0 +on 0 +locomotion 0 +"," 0 +BD1018 1 +"," 0 +BD1063 1 +and 0 +LR132 1 +significantly 0 +attenuated 0 +the 0 +locomotor 0 +stimulatory 0 +effects 0 +of 0 +cocaine 1 +. 0 +To 0 +further 0 +validate 0 +the 0 +hypothesis 0 +that 0 +the 0 +anti 0 +- 0 +cocaine 1 +effects 0 +of 0 +the 0 +novel 0 +ligands 0 +involved 0 +antagonism 0 +of 0 +sigma 0 +receptors 0 +"," 0 +an 0 +antisense 0 +oligodeoxynucleotide 1 +against 0 +sigma1 0 +receptors 0 +was 0 +also 0 +shown 0 +to 0 +significantly 0 +attenuate 0 +the 0 +convulsive 3 +and 0 +locomotor 0 +stimulatory 0 +effects 0 +of 0 +cocaine 1 +. 0 +Together 0 +"," 0 +the 0 +data 0 +suggests 0 +that 0 +functional 0 +antagonism 0 +of 0 +sigma 0 +receptors 0 +is 0 +capable 0 +of 0 +attenuating 0 +a 0 +number 0 +of 0 +cocaine 1 +- 0 +induced 0 +behaviors 0 +. 0 +Ranitidine 1 +- 0 +induced 0 +acute 0 +interstitial 3 +nephritis 4 +in 0 +a 0 +cadaveric 0 +renal 0 +allograft 0 +. 0 +Ranitidine 1 +frequently 0 +is 0 +used 0 +for 0 +preventing 0 +peptic 0 +ulceration 0 +after 0 +renal 0 +transplantation 0 +. 0 +This 0 +drug 0 +occasionally 0 +has 0 +been 0 +associated 0 +with 0 +acute 0 +interstitial 3 +nephritis 4 +in 0 +native 0 +kidneys 0 +. 0 +There 0 +are 0 +no 0 +similar 0 +reports 0 +with 0 +renal 0 +transplantation 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +ranitidine 1 +- 0 +induced 0 +acute 0 +interstitial 3 +nephritis 4 +in 0 +a 0 +recipient 0 +of 0 +a 0 +cadaveric 0 +renal 0 +allograft 0 +presenting 0 +with 0 +acute 0 +allograft 0 +dysfunction 0 +within 0 +48 0 +hours 0 +of 0 +exposure 0 +to 0 +the 0 +drug 0 +. 0 +The 0 +biopsy 0 +specimen 0 +showed 0 +pathognomonic 0 +features 0 +"," 0 +including 0 +eosinophilic 0 +infiltration 0 +of 0 +the 0 +interstitial 0 +compartment 0 +. 0 +Allograft 0 +function 0 +improved 0 +rapidly 0 +and 0 +returned 0 +to 0 +baseline 0 +after 0 +stopping 0 +the 0 +drug 0 +. 0 +Liver 3 +disease 4 +caused 0 +by 0 +propylthiouracil 1 +. 0 +This 0 +report 0 +presents 0 +the 0 +clinical 0 +"," 0 +laboratory 0 +"," 0 +and 0 +light 0 +and 0 +electron 0 +microscopic 0 +observations 0 +on 0 +a 0 +patient 0 +with 0 +chronic 3 +active 4 +( 4 +aggressive 4 +) 4 +hepatitis 4 +caused 0 +by 0 +the 0 +administration 0 +of 0 +propylthiouracil 1 +. 0 +This 0 +is 0 +an 0 +addition 0 +to 0 +the 0 +list 0 +of 0 +drugs 0 +that 0 +must 0 +be 0 +considered 0 +in 0 +the 0 +evaluation 0 +of 0 +chronic 0 +liver 3 +disease 4 +. 0 +Withdrawal 3 +- 4 +emergent 4 +rabbit 4 +syndrome 4 +during 0 +dose 0 +reduction 0 +of 0 +risperidone 1 +. 0 +Rabbit 3 +syndrome 4 +( 0 +RS 3 +) 0 +is 0 +a 0 +rare 0 +extrapyramidal 0 +side 0 +effect 0 +caused 0 +by 0 +prolonged 0 +neuroleptic 0 +medication 0 +. 0 +Here 0 +we 0 +present 0 +a 0 +case 0 +of 0 +withdrawal 3 +- 4 +emergent 4 +RS 4 +"," 0 +which 0 +is 0 +the 0 +first 0 +of 0 +its 0 +kind 0 +to 0 +be 0 +reported 0 +. 0 +The 0 +patient 0 +developed 0 +RS 3 +during 0 +dose 0 +reduction 0 +of 0 +risperidone 1 +. 0 +The 0 +symptom 0 +was 0 +treated 0 +successfully 0 +with 0 +trihexyphenidyl 1 +anticholinergic 0 +therapy 0 +. 0 +The 0 +underlying 0 +mechanism 0 +of 0 +withdrawal 3 +- 4 +emergent 4 +RS 4 +in 0 +the 0 +present 0 +case 0 +may 0 +have 0 +been 0 +related 0 +to 0 +the 0 +pharmacological 0 +profile 0 +of 0 +risperidone 1 +"," 0 +a 0 +serotonin 1 +- 0 +dopamine 1 +antagonist 0 +"," 0 +suggesting 0 +the 0 +pathophysiologic 0 +influence 0 +of 0 +the 0 +serotonin 1 +system 0 +in 0 +the 0 +development 0 +of 0 +RS 3 +. 0 +Pharmacokinetic 0 +/ 0 +pharmacodynamic 0 +assessment 0 +of 0 +the 0 +effects 0 +of 0 +E4031 1 +"," 0 +cisapride 1 +"," 0 +terfenadine 1 +and 0 +terodiline 1 +on 0 +monophasic 0 +action 0 +potential 0 +duration 0 +in 0 +dog 0 +. 0 +1 0 +. 0 +Torsades 3 +de 4 +pointes 4 +( 0 +TDP 3 +) 0 +is 0 +a 0 +potentially 0 +fatal 0 +ventricular 3 +tachycardia 4 +associated 0 +with 0 +increases 0 +in 0 +QT 0 +interval 0 +and 0 +monophasic 0 +action 0 +potential 0 +duration 0 +( 0 +MAPD 0 +) 0 +. 0 +TDP 3 +is 0 +a 0 +side 0 +- 0 +effect 0 +that 0 +has 0 +led 0 +to 0 +withdrawal 0 +of 0 +several 0 +drugs 0 +from 0 +the 0 +market 0 +( 0 +e 0 +. 0 +g 0 +. 0 +terfenadine 1 +and 0 +terodiline 1 +) 0 +. 0 +2 0 +. 0 +The 0 +potential 0 +of 0 +compounds 0 +to 0 +cause 0 +TDP 3 +was 0 +evaluated 0 +by 0 +monitoring 0 +their 0 +effects 0 +on 0 +MAPD 0 +in 0 +dog 0 +. 0 +Four 0 +compounds 0 +known 0 +to 0 +increase 0 +QT 0 +interval 0 +and 0 +cause 0 +TDP 3 +were 0 +investigated 0 +: 0 +terfenadine 1 +"," 0 +terodiline 1 +"," 0 +cisapride 1 +and 0 +E4031 1 +. 0 +0n 0 +the 0 +basis 0 +that 0 +only 0 +free 0 +drug 0 +in 0 +the 0 +systemic 0 +circulation 0 +will 0 +elicit 0 +a 0 +pharmacological 0 +response 0 +target 0 +"," 0 +free 0 +concentrations 0 +in 0 +plasma 0 +were 0 +selected 0 +to 0 +mimic 0 +the 0 +free 0 +drug 0 +exposures 0 +in 0 +man 0 +. 0 +Infusion 0 +regimens 0 +were 0 +designed 0 +that 0 +rapidly 0 +achieved 0 +and 0 +maintained 0 +target 0 +- 0 +free 0 +concentrations 0 +of 0 +these 0 +drugs 0 +in 0 +plasma 0 +and 0 +data 0 +on 0 +the 0 +relationship 0 +between 0 +free 0 +concentration 0 +and 0 +changes 0 +in 0 +MAPD 0 +were 0 +obtained 0 +for 0 +these 0 +compounds 0 +. 0 +3 0 +. 0 +These 0 +data 0 +indicate 0 +that 0 +the 0 +free 0 +ED50 0 +in 0 +plasma 0 +for 0 +terfenadine 1 +( 0 +1 0 +. 0 +9 0 +nM 0 +) 0 +"," 0 +terodiline 1 +( 0 +76 0 +nM 0 +) 0 +"," 0 +cisapride 1 +( 0 +11 0 +nM 0 +) 0 +and 0 +E4031 1 +( 0 +1 0 +. 0 +9 0 +nM 0 +) 0 +closely 0 +correlate 0 +with 0 +the 0 +free 0 +concentration 0 +in 0 +man 0 +causing 0 +QT 0 +effects 0 +. 0 +For 0 +compounds 0 +that 0 +have 0 +shown 0 +TDP 3 +in 0 +the 0 +clinic 0 +( 0 +terfenadine 1 +"," 0 +terodiline 1 +"," 0 +cisapride 1 +) 0 +there 0 +is 0 +little 0 +differentiation 0 +between 0 +the 0 +dog 0 +ED50 0 +and 0 +the 0 +efficacious 0 +free 0 +plasma 0 +concentrations 0 +in 0 +man 0 +( 0 +< 0 +10 0 +- 0 +fold 0 +) 0 +reflecting 0 +their 0 +limited 0 +safety 0 +margins 0 +. 0 +These 0 +data 0 +underline 0 +the 0 +need 0 +to 0 +maximize 0 +the 0 +therapeutic 0 +ratio 0 +with 0 +respect 0 +to 0 +TDP 3 +in 0 +potential 0 +development 0 +candidates 0 +and 0 +the 0 +importance 0 +of 0 +using 0 +free 0 +drug 0 +concentrations 0 +in 0 +pharmacokinetic 0 +/ 0 +pharmacodynamic 0 +studies 0 +. 0 +Bladder 0 +retention 3 +of 4 +urine 4 +as 0 +a 0 +result 0 +of 0 +continuous 0 +intravenous 0 +infusion 0 +of 0 +fentanyl 1 +: 0 +2 0 +case 0 +reports 0 +. 0 +Sedation 0 +has 0 +been 0 +commonly 0 +used 0 +in 0 +the 0 +neonate 0 +to 0 +decrease 0 +the 0 +stress 0 +and 0 +pain 3 +from 0 +the 0 +noxious 0 +stimuli 0 +and 0 +invasive 0 +procedures 0 +in 0 +the 0 +neonatal 0 +intensive 0 +care 0 +unit 0 +"," 0 +as 0 +well 0 +as 0 +to 0 +facilitate 0 +synchrony 0 +between 0 +ventilator 0 +and 0 +spontaneous 0 +breaths 0 +. 0 +Fentanyl 1 +"," 0 +an 0 +opioid 0 +analgesic 0 +"," 0 +is 0 +frequently 0 +used 0 +in 0 +the 0 +neonatal 0 +intensive 0 +care 0 +unit 0 +setting 0 +for 0 +these 0 +very 0 +purposes 0 +. 0 +Various 0 +reported 0 +side 0 +effects 0 +of 0 +fentanyl 1 +administration 0 +include 0 +chest 3 +wall 4 +rigidity 4 +"," 0 +hypotension 3 +"," 0 +respiratory 3 +depression 4 +"," 0 +and 0 +bradycardia 3 +. 0 +Here 0 +"," 0 +2 0 +cases 0 +of 0 +urinary 3 +bladder 4 +retention 4 +leading 0 +to 0 +renal 0 +pelvocalyceal 0 +dilatation 0 +mimicking 0 +hydronephrosis 3 +as 0 +a 0 +result 0 +of 0 +continuous 0 +infusion 0 +of 0 +fentanyl 1 +are 0 +reported 0 +. 0 +Fatal 0 +myeloencephalopathy 3 +due 0 +to 0 +accidental 0 +intrathecal 0 +vincristin 1 +administration 0 +: 0 +a 0 +report 0 +of 0 +two 0 +cases 0 +. 0 +We 0 +report 0 +on 0 +two 0 +fatal 0 +cases 0 +of 0 +accidental 0 +intrathecal 0 +vincristine 1 +instillation 0 +in 0 +a 0 +5 0 +- 0 +year 0 +old 0 +girl 0 +with 0 +recurrent 0 +acute 3 +lymphoblastic 4 +leucemia 4 +and 0 +a 0 +57 0 +- 0 +year 0 +old 0 +man 0 +with 0 +lymphoblastic 3 +lymphoma 4 +. 0 +The 0 +girl 0 +died 0 +seven 0 +days 0 +"," 0 +the 0 +man 0 +four 0 +weeks 0 +after 0 +intrathecal 0 +injection 0 +of 0 +vincristine 1 +. 0 +Clinically 0 +"," 0 +the 0 +onset 0 +was 0 +characterized 0 +by 0 +the 0 +signs 0 +of 0 +opistothonus 3 +"," 4 +sensory 4 +and 4 +motor 4 +dysfunction 4 +and 0 +ascending 0 +paralysis 3 +. 0 +Histological 0 +and 0 +immunohistochemical 0 +investigations 0 +( 0 +HE 0 +- 0 +LFB 0 +"," 0 +CD 0 +- 0 +68 0 +"," 0 +Neurofilament 0 +) 0 +revealed 0 +degeneration 3 +of 4 +myelin 4 +and 4 +axons 4 +as 0 +well 0 +as 0 +pseudocystic 3 +transformation 4 +in 0 +areas 0 +exposed 0 +to 0 +vincristine 1 +"," 0 +accompanied 0 +by 0 +secondary 0 +changes 0 +with 0 +numerous 0 +prominent 0 +macrophages 0 +. 0 +The 0 +clinical 0 +course 0 +and 0 +histopathological 0 +results 0 +of 0 +the 0 +two 0 +cases 0 +are 0 +presented 0 +. 0 +A 0 +review 0 +of 0 +all 0 +reported 0 +cases 0 +in 0 +the 0 +literature 0 +is 0 +given 0 +. 0 +A 0 +better 0 +controlled 0 +regimen 0 +for 0 +administering 0 +vincristine 1 +and 0 +intrathecal 0 +chemotherapy 0 +is 0 +recommended 0 +. 0 +Palpebral 3 +twitching 4 +in 0 +a 0 +depressed 3 +adolescent 0 +on 0 +citalopram 1 +. 0 +Current 0 +estimates 0 +suggest 0 +that 0 +between 0 +0 0 +. 0 +4 0 +% 0 +and 0 +8 0 +. 0 +3 0 +% 0 +of 0 +children 0 +and 0 +adolescents 0 +are 0 +affected 0 +by 0 +major 3 +depression 4 +. 0 +We 0 +report 0 +a 0 +favorable 0 +response 0 +to 0 +treatment 0 +with 0 +citalopram 1 +by 0 +a 0 +15 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +with 0 +major 3 +depression 4 +who 0 +exhibited 0 +palpebral 3 +twitching 4 +during 0 +his 0 +first 0 +2 0 +weeks 0 +of 0 +treatment 0 +. 0 +This 0 +may 0 +have 0 +been 0 +a 0 +side 0 +effect 0 +of 0 +citalopram 1 +as 0 +it 0 +remitted 0 +with 0 +redistribution 0 +of 0 +doses 0 +. 0 +The 0 +3 0 +- 0 +week 0 +sulphasalazine 1 +syndrome 0 +strikes 0 +again 0 +. 0 +A 0 +34 0 +- 0 +year 0 +- 0 +old 0 +lady 0 +developed 0 +a 0 +constellation 0 +of 0 +dermatitis 3 +"," 0 +fever 3 +"," 0 +lymphadenopathy 3 +and 0 +hepatitis 3 +"," 0 +beginning 0 +on 0 +the 0 +17th 0 +day 0 +of 0 +a 0 +course 0 +of 0 +oral 0 +sulphasalazine 1 +for 0 +sero 0 +- 0 +negative 0 +rheumatoid 3 +arthritis 4 +. 0 +Cervical 0 +and 0 +inguinal 0 +lymph 0 +node 0 +biopsies 0 +showed 0 +the 0 +features 0 +of 0 +severe 0 +necrotising 0 +lymphadenitis 3 +"," 0 +associated 0 +with 0 +erythrophagocytosis 0 +and 0 +prominent 0 +eosinophilic 0 +infiltrates 0 +"," 0 +without 0 +viral 0 +inclusion 0 +bodies 0 +"," 0 +suggestive 0 +of 0 +an 0 +adverse 3 +drug 4 +reaction 4 +. 0 +A 0 +week 0 +later 0 +"," 0 +fulminant 0 +drug 3 +- 4 +induced 4 +hepatitis 4 +"," 0 +associated 0 +with 0 +the 0 +presence 0 +of 0 +anti 0 +- 0 +nuclear 0 +autoantibodies 0 +( 0 +but 0 +not 0 +with 0 +other 0 +markers 0 +of 0 +autoimmunity 3 +) 0 +"," 0 +and 0 +accompanied 0 +by 0 +multi 3 +- 4 +organ 4 +failure 4 +and 0 +sepsis 3 +"," 0 +supervened 0 +. 0 +She 0 +subsequently 0 +died 0 +some 0 +5 0 +weeks 0 +after 0 +the 0 +commencement 0 +of 0 +her 0 +drug 0 +therapy 0 +. 0 +Post 0 +- 0 +mortem 0 +examination 0 +showed 0 +evidence 0 +of 0 +massive 3 +hepatocellular 4 +necrosis 4 +"," 0 +acute 0 +hypersensitivity 0 +myocarditis 3 +"," 0 +focal 0 +acute 0 +tubulo 0 +- 0 +interstitial 0 +nephritis 3 +and 0 +extensive 0 +bone 3 +marrow 4 +necrosis 4 +"," 0 +with 0 +no 0 +evidence 0 +of 0 +malignancy 3 +. 0 +It 0 +is 0 +thought 0 +that 0 +the 0 +clinico 0 +- 0 +pathological 0 +features 0 +and 0 +chronology 0 +of 0 +this 0 +case 0 +bore 0 +the 0 +hallmarks 0 +of 0 +the 0 +so 0 +- 0 +called 0 +" 0 +3 0 +- 0 +week 0 +sulphasalazine 1 +syndrome 0 +" 0 +"," 0 +a 0 +rare 0 +"," 0 +but 0 +often 0 +fatal 0 +"," 0 +immunoallergic 0 +reaction 0 +to 0 +sulphasalazine 1 +. 0 +Intravenous 0 +administration 0 +of 0 +prochlorperazine 1 +by 0 +15 0 +- 0 +minute 0 +infusion 0 +versus 0 +2 0 +- 0 +minute 0 +bolus 0 +does 0 +not 0 +affect 0 +the 0 +incidence 0 +of 0 +akathisia 3 +: 0 +a 0 +prospective 0 +"," 0 +randomized 0 +"," 0 +controlled 0 +trial 0 +. 0 +STUDY 0 +0BJECTIVE 0 +: 0 +We 0 +sought 0 +to 0 +compare 0 +the 0 +rate 0 +of 0 +akathisia 3 +after 0 +administration 0 +of 0 +intravenous 0 +prochlorperazine 1 +as 0 +a 0 +2 0 +- 0 +minute 0 +bolus 0 +or 0 +15 0 +- 0 +minute 0 +infusion 0 +. 0 +METH0DS 0 +: 0 +We 0 +conducted 0 +a 0 +prospective 0 +"," 0 +randomized 0 +"," 0 +double 0 +- 0 +blind 0 +study 0 +in 0 +the 0 +emergency 0 +department 0 +of 0 +a 0 +central 0 +- 0 +city 0 +teaching 0 +hospital 0 +. 0 +Patients 0 +aged 0 +18 0 +years 0 +or 0 +older 0 +treated 0 +with 0 +prochlorperazine 1 +for 0 +headache 3 +"," 0 +nausea 3 +"," 0 +or 0 +vomiting 3 +were 0 +eligible 0 +for 0 +inclusion 0 +. 0 +Study 0 +participants 0 +were 0 +randomized 0 +to 0 +receive 0 +10 0 +mg 0 +of 0 +prochlorperazine 1 +administered 0 +intravenously 0 +by 0 +means 0 +of 0 +2 0 +- 0 +minute 0 +push 0 +( 0 +bolus 0 +group 0 +) 0 +or 0 +10 0 +mg 0 +diluted 0 +in 0 +50 0 +mL 0 +of 0 +normal 0 +saline 0 +solution 0 +administered 0 +by 0 +means 0 +of 0 +intravenous 0 +infusion 0 +during 0 +a 0 +15 0 +- 0 +minute 0 +period 0 +( 0 +infusion 0 +group 0 +) 0 +. 0 +The 0 +main 0 +outcome 0 +was 0 +the 0 +number 0 +of 0 +study 0 +participants 0 +experiencing 0 +akathisia 3 +within 0 +60 0 +minutes 0 +of 0 +administration 0 +. 0 +Akathisia 0 +was 0 +defined 0 +as 0 +either 0 +a 0 +spontaneous 0 +report 0 +of 0 +restlessness 0 +or 0 +agitation 3 +or 0 +a 0 +change 0 +of 0 +2 0 +or 0 +more 0 +in 0 +the 0 +patient 0 +- 0 +reported 0 +akathisia 3 +rating 0 +scale 0 +and 0 +a 0 +change 0 +of 0 +at 0 +least 0 +1 0 +in 0 +the 0 +investigator 0 +- 0 +observed 0 +akathisia 3 +rating 0 +scale 0 +. 0 +The 0 +intensity 0 +of 0 +headache 3 +and 0 +nausea 3 +was 0 +measured 0 +with 0 +a 0 +100 0 +- 0 +mm 0 +visual 0 +analog 0 +scale 0 +. 0 +RESULTS 0 +: 0 +0ne 0 +hundred 0 +patients 0 +were 0 +enrolled 0 +. 0 +0ne 0 +study 0 +participant 0 +was 0 +excluded 0 +after 0 +protocol 0 +violation 0 +. 0 +Seventy 0 +- 0 +three 0 +percent 0 +( 0 +73 0 +/ 0 +99 0 +) 0 +of 0 +the 0 +study 0 +participants 0 +were 0 +treated 0 +for 0 +headache 3 +and 0 +70 0 +% 0 +( 0 +70 0 +/ 0 +99 0 +) 0 +for 0 +nausea 3 +. 0 +In 0 +the 0 +bolus 0 +group 0 +"," 0 +26 0 +. 0 +0 0 +% 0 +( 0 +13 0 +/ 0 +50 0 +) 0 +had 0 +akathisia 3 +compared 0 +with 0 +32 0 +. 0 +7 0 +% 0 +( 0 +16 0 +/ 0 +49 0 +) 0 +in 0 +the 0 +infusion 0 +group 0 +( 0 +Delta 0 += 0 +- 0 +6 0 +. 0 +7 0 +% 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +- 0 +24 0 +. 0 +6 0 +% 0 +to 0 +11 0 +. 0 +2 0 +% 0 +) 0 +. 0 +The 0 +difference 0 +between 0 +the 0 +bolus 0 +and 0 +infusion 0 +groups 0 +in 0 +the 0 +percentage 0 +of 0 +participants 0 +who 0 +saw 0 +a 0 +50 0 +% 0 +reduction 0 +in 0 +their 0 +headache 3 +intensity 0 +within 0 +30 0 +minutes 0 +was 0 +11 0 +. 0 +8 0 +% 0 +( 0 +95 0 +% 0 +CI 0 +- 0 +9 0 +. 0 +6 0 +% 0 +to 0 +33 0 +. 0 +3 0 +% 0 +) 0 +. 0 +The 0 +difference 0 +in 0 +the 0 +percentage 0 +of 0 +patients 0 +with 0 +a 0 +50 0 +% 0 +reduction 0 +in 0 +their 0 +nausea 3 +was 0 +12 0 +. 0 +6 0 +% 0 +( 0 +95 0 +% 0 +CI 0 +- 0 +4 0 +. 0 +6 0 +% 0 +to 0 +29 0 +. 0 +8 0 +% 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +A 0 +50 0 +% 0 +reduction 0 +in 0 +the 0 +incidence 0 +of 0 +akathisia 3 +when 0 +prochlorperazine 1 +was 0 +administered 0 +by 0 +means 0 +of 0 +15 0 +- 0 +minute 0 +intravenous 0 +infusion 0 +versus 0 +a 0 +2 0 +- 0 +minute 0 +intravenous 0 +push 0 +was 0 +not 0 +detected 0 +. 0 +The 0 +efficacy 0 +of 0 +prochlorperazine 1 +in 0 +the 0 +treatment 0 +of 0 +headache 3 +and 0 +nausea 3 +likewise 0 +did 0 +not 0 +appear 0 +to 0 +be 0 +affected 0 +by 0 +the 0 +rate 0 +of 0 +administration 0 +"," 0 +although 0 +no 0 +formal 0 +statistical 0 +comparisons 0 +were 0 +made 0 +. 0 +Combined 0 +antiretroviral 0 +therapy 0 +causes 0 +cardiomyopathy 3 +and 0 +elevates 0 +plasma 0 +lactate 1 +in 0 +transgenic 0 +AIDS 3 +mice 0 +. 0 +Highly 0 +active 0 +antiretroviral 0 +therapy 0 +( 0 +HAART 0 +) 0 +is 0 +implicated 0 +in 0 +cardiomyopathy 3 +( 0 +CM 3 +) 0 +and 0 +in 0 +elevated 0 +plasma 0 +lactate 1 +( 0 +LA 1 +) 0 +in 0 +AIDS 3 +through 0 +mechanisms 0 +of 0 +mitochondrial 3 +dysfunction 4 +. 0 +To 0 +determine 0 +mitochondrial 0 +events 0 +from 0 +HAART 0 +in 0 +vivo 0 +"," 0 +8 0 +- 0 +week 0 +- 0 +old 0 +hemizygous 0 +transgenic 0 +AIDS 3 +mice 0 +( 0 +NL4 0 +- 0 +3Delta 0 +gag 0 +/ 0 +pol 0 +; 0 +TG 0 +) 0 +and 0 +wild 0 +- 0 +type 0 +FVB 0 +/ 0 +n 0 +littermates 0 +were 0 +treated 0 +with 0 +the 0 +HAART 0 +combination 0 +of 0 +zidovudine 1 +"," 0 +lamivudine 1 +"," 0 +and 0 +indinavir 1 +or 0 +vehicle 0 +control 0 +for 0 +10 0 +days 0 +or 0 +35 0 +days 0 +. 0 +At 0 +termination 0 +of 0 +the 0 +experiments 0 +"," 0 +mice 0 +underwent 0 +echocardiography 0 +"," 0 +quantitation 0 +of 0 +abundance 0 +of 0 +molecular 0 +markers 0 +of 0 +CM 3 +( 0 +ventricular 0 +mRNA 0 +encoding 0 +atrial 0 +natriuretic 0 +factor 0 +[ 0 +ANF 0 +] 0 +and 0 +sarcoplasmic 0 +calcium 1 +ATPase 0 +[ 0 +SERCA2 0 +] 0 +) 0 +"," 0 +and 0 +determination 0 +of 0 +plasma 0 +LA 1 +. 0 +Myocardial 0 +histologic 0 +features 0 +were 0 +analyzed 0 +semiquantitatively 0 +and 0 +results 0 +were 0 +confirmed 0 +by 0 +transmission 0 +electron 0 +microscopy 0 +. 0 +After 0 +35 0 +days 0 +in 0 +the 0 +TG 0 ++ 0 +HAART 0 +cohort 0 +"," 0 +left 0 +ventricular 0 +mass 0 +increased 0 +160 0 +% 0 +by 0 +echocardiography 0 +. 0 +Molecularly 0 +"," 0 +ANF 0 +mRNA 0 +increased 0 +250 0 +% 0 +and 0 +SERCA2 0 +mRNA 0 +decreased 0 +57 0 +% 0 +. 0 +Biochemically 0 +"," 0 +LA 1 +was 0 +elevated 0 +( 0 +8 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +0 0 +mM 0 +) 0 +. 0 +Pathologically 0 +"," 0 +granular 0 +cytoplasmic 0 +changes 0 +were 0 +found 0 +in 0 +cardiac 0 +myocytes 0 +"," 0 +indicating 0 +enlarged 0 +"," 0 +damaged 0 +mitochondria 0 +. 0 +Findings 0 +were 0 +confirmed 0 +ultrastructurally 0 +. 0 +No 0 +changes 0 +were 0 +found 0 +in 0 +other 0 +cohorts 0 +. 0 +After 0 +10 0 +days 0 +"," 0 +only 0 +ANF 0 +was 0 +elevated 0 +"," 0 +and 0 +only 0 +in 0 +the 0 +TG 0 ++ 0 +HAART 0 +cohort 0 +. 0 +Results 0 +show 0 +that 0 +cumulative 0 +HAART 0 +caused 0 +mitochondrial 0 +CM 3 +with 0 +elevated 0 +LA 1 +in 0 +AIDS 3 +transgenic 0 +mice 0 +. 0 +A 0 +Phase 0 +II 0 +trial 0 +of 0 +cisplatin 1 +plus 0 +WR 1 +- 2 +2721 2 +( 0 +amifostine 1 +) 0 +for 0 +metastatic 0 +breast 3 +carcinoma 4 +: 0 +an 0 +Eastern 0 +Cooperative 0 +0ncology 0 +Group 0 +Study 0 +( 0 +E8188 0 +) 0 +. 0 +BACKGR0UND 0 +: 0 +Cisplatin 1 +has 0 +minimal 0 +antitumor 0 +activity 0 +when 0 +used 0 +as 0 +second 0 +- 0 +or 0 +third 0 +- 0 +line 0 +treatment 0 +of 0 +metastatic 0 +breast 3 +carcinoma 4 +. 0 +0lder 0 +reports 0 +suggest 0 +an 0 +objective 0 +response 0 +rate 0 +of 0 +8 0 +% 0 +when 0 +60 0 +- 0 +120 0 +mg 0 +/ 0 +m2 0 +of 0 +cisplatin 1 +is 0 +administered 0 +every 0 +3 0 +- 0 +4 0 +weeks 0 +. 0 +Although 0 +a 0 +dose 0 +- 0 +response 0 +effect 0 +has 0 +been 0 +observed 0 +with 0 +cisplatin 1 +"," 0 +the 0 +dose 0 +- 0 +limiting 0 +toxicities 3 +associated 0 +with 0 +cisplatin 1 +( 0 +e 0 +. 0 +g 0 +. 0 +"," 0 +nephrotoxicity 3 +"," 0 +ototoxicity 3 +"," 0 +and 0 +neurotoxicity 3 +) 0 +have 0 +limited 0 +its 0 +use 0 +as 0 +a 0 +treatment 0 +for 0 +breast 3 +carcinoma 4 +. 0 +WR 1 +- 2 +2721 2 +or 0 +amifostine 1 +initially 0 +was 0 +developed 0 +to 0 +protect 0 +military 0 +personnel 0 +in 0 +the 0 +event 0 +of 0 +nuclear 0 +war 0 +. 0 +Amifostine 1 +subsequently 0 +was 0 +shown 0 +to 0 +protect 0 +normal 0 +tissues 0 +from 0 +the 0 +toxic 0 +effects 0 +of 0 +alkylating 1 +agents 2 +and 0 +cisplatin 1 +without 0 +decreasing 0 +the 0 +antitumor 0 +effect 0 +of 0 +the 0 +chemotherapy 0 +. 0 +Early 0 +trials 0 +of 0 +cisplatin 1 +and 0 +amifostine 1 +also 0 +suggested 0 +that 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +cisplatin 1 +- 0 +induced 0 +nephrotoxicity 3 +"," 0 +ototoxicity 3 +"," 0 +and 0 +neuropathy 3 +were 0 +reduced 0 +. 0 +METH0DS 0 +: 0 +A 0 +Phase 0 +II 0 +study 0 +of 0 +the 0 +combination 0 +of 0 +cisplatin 1 +plus 0 +amifostine 1 +was 0 +conducted 0 +in 0 +patients 0 +with 0 +progressive 0 +metastatic 0 +breast 3 +carcinoma 4 +who 0 +had 0 +received 0 +one 0 +"," 0 +but 0 +not 0 +more 0 +than 0 +one 0 +"," 0 +chemotherapy 0 +regimen 0 +for 0 +metastatic 0 +disease 0 +. 0 +Patients 0 +received 0 +amifostine 1 +"," 0 +910 0 +mg 0 +/ 0 +m2 0 +intravenously 0 +over 0 +15 0 +minutes 0 +. 0 +After 0 +completion 0 +of 0 +the 0 +amifostine 1 +infusion 0 +"," 0 +cisplatin 1 +120 0 +mg 0 +/ 0 +m2 0 +was 0 +administered 0 +over 0 +30 0 +minutes 0 +. 0 +Intravenous 0 +hydration 0 +and 0 +mannitol 1 +was 0 +administered 0 +before 0 +and 0 +after 0 +cisplatin 1 +. 0 +Treatment 0 +was 0 +administered 0 +every 0 +3 0 +weeks 0 +until 0 +disease 0 +progression 0 +. 0 +RESULTS 0 +: 0 +Forty 0 +- 0 +four 0 +patients 0 +were 0 +enrolled 0 +in 0 +the 0 +study 0 +of 0 +which 0 +7 0 +( 0 +16 0 +% 0 +) 0 +were 0 +ineligible 0 +. 0 +A 0 +median 0 +of 0 +2 0 +cycles 0 +of 0 +therapy 0 +was 0 +administered 0 +to 0 +the 0 +37 0 +eligible 0 +patients 0 +. 0 +Six 0 +partial 0 +responses 0 +were 0 +observed 0 +for 0 +an 0 +overall 0 +response 0 +rate 0 +of 0 +16 0 +% 0 +. 0 +Most 0 +patients 0 +( 0 +57 0 +% 0 +) 0 +stopped 0 +treatment 0 +because 0 +of 0 +disease 0 +progression 0 +. 0 +Neurologic 3 +toxicity 4 +was 0 +reported 0 +in 0 +52 0 +% 0 +of 0 +patients 0 +. 0 +Seven 0 +different 0 +life 0 +- 0 +threatening 0 +toxicities 3 +were 0 +observed 0 +in 0 +patients 0 +while 0 +receiving 0 +treatment 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +combination 0 +of 0 +cisplatin 1 +and 0 +amifostine 1 +in 0 +this 0 +study 0 +resulted 0 +in 0 +an 0 +overall 0 +response 0 +rate 0 +of 0 +16 0 +% 0 +. 0 +Neither 0 +a 0 +tumor 3 +- 0 +protective 0 +effect 0 +nor 0 +reduced 0 +toxicity 3 +to 0 +normal 0 +tissues 0 +was 0 +observed 0 +with 0 +the 0 +addition 0 +of 0 +amifostine 1 +to 0 +cisplatin 1 +in 0 +this 0 +trial 0 +. 0 +0ral 1 +contraceptives 2 +and 0 +the 0 +risk 0 +of 0 +myocardial 3 +infarction 4 +. 0 +BACKGR0UND 0 +: 0 +An 0 +association 0 +between 0 +the 0 +use 0 +of 0 +oral 1 +contraceptives 2 +and 0 +the 0 +risk 0 +of 0 +myocardial 3 +infarction 4 +has 0 +been 0 +found 0 +in 0 +some 0 +"," 0 +but 0 +not 0 +all 0 +"," 0 +studies 0 +. 0 +We 0 +investigated 0 +this 0 +association 0 +"," 0 +according 0 +to 0 +the 0 +type 0 +of 0 +progestagen 1 +included 0 +in 0 +third 0 +- 0 +generation 0 +( 0 +i 0 +. 0 +e 0 +. 0 +"," 0 +desogestrel 1 +or 0 +gestodene 1 +) 0 +and 0 +second 0 +- 0 +generation 0 +( 0 +i 0 +. 0 +e 0 +. 0 +"," 0 +levonorgestrel 1 +) 0 +oral 1 +contraceptives 2 +"," 0 +the 0 +dose 0 +of 0 +estrogen 1 +"," 0 +and 0 +the 0 +presence 0 +or 0 +absence 0 +of 0 +prothrombotic 0 +mutations 0 +METH0DS 0 +: 0 +In 0 +a 0 +nationwide 0 +"," 0 +population 0 +- 0 +based 0 +"," 0 +case 0 +- 0 +control 0 +study 0 +"," 0 +we 0 +identified 0 +and 0 +enrolled 0 +248 0 +women 0 +18 0 +through 0 +49 0 +years 0 +of 0 +age 0 +who 0 +had 0 +had 0 +a 0 +first 0 +myocardial 3 +infarction 4 +between 0 +1990 0 +and 0 +1995 0 +and 0 +925 0 +control 0 +women 0 +who 0 +had 0 +not 0 +had 0 +a 0 +myocardial 3 +infarction 4 +and 0 +who 0 +were 0 +matched 0 +for 0 +age 0 +"," 0 +calendar 0 +year 0 +of 0 +the 0 +index 0 +event 0 +"," 0 +and 0 +area 0 +of 0 +residence 0 +. 0 +Subjects 0 +supplied 0 +information 0 +on 0 +oral 1 +- 2 +contraceptive 2 +use 0 +and 0 +major 0 +cardiovascular 0 +risk 0 +factors 0 +. 0 +An 0 +analysis 0 +for 0 +factor 0 +V 0 +Leiden 0 +and 0 +the 0 +G20210A 0 +mutation 0 +in 0 +the 0 +prothrombin 0 +gene 0 +was 0 +conducted 0 +in 0 +217 0 +patients 0 +and 0 +763 0 +controls 0 +RESULTS 0 +: 0 +The 0 +odds 0 +ratio 0 +for 0 +myocardial 3 +infarction 4 +among 0 +women 0 +who 0 +used 0 +any 0 +type 0 +of 0 +combined 0 +oral 1 +contraceptive 2 +"," 0 +as 0 +compared 0 +with 0 +nonusers 0 +"," 0 +was 0 +2 0 +. 0 +0 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +"," 0 +1 0 +. 0 +5 0 +to 0 +2 0 +. 0 +8 0 +) 0 +. 0 +The 0 +adjusted 0 +odds 0 +ratio 0 +was 0 +2 0 +. 0 +5 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +"," 0 +1 0 +. 0 +5 0 +to 0 +4 0 +. 0 +1 0 +) 0 +among 0 +women 0 +who 0 +used 0 +second 0 +- 0 +generation 0 +oral 1 +contraceptives 2 +and 0 +1 0 +. 0 +3 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +"," 0 +0 0 +. 0 +7 0 +to 0 +2 0 +. 0 +5 0 +) 0 +among 0 +those 0 +who 0 +used 0 +third 0 +- 0 +generation 0 +oral 1 +contraceptives 2 +. 0 +Among 0 +women 0 +who 0 +used 0 +oral 1 +contraceptives 2 +"," 0 +the 0 +odds 0 +ratio 0 +was 0 +2 0 +. 0 +1 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +"," 0 +1 0 +. 0 +5 0 +to 0 +3 0 +. 0 +0 0 +) 0 +for 0 +those 0 +without 0 +a 0 +prothrombotic 0 +mutation 0 +and 0 +1 0 +. 0 +9 0 +( 0 +95 0 +percent 0 +confidence 0 +interval 0 +"," 0 +0 0 +. 0 +6 0 +to 0 +5 0 +. 0 +5 0 +) 0 +for 0 +those 0 +with 0 +a 0 +mutation 0 +C0NCLUSI0NS 0 +: 0 +The 0 +risk 0 +of 0 +myocardial 3 +infarction 4 +was 0 +increased 0 +among 0 +women 0 +who 0 +used 0 +second 0 +- 0 +generation 0 +oral 1 +contraceptives 2 +. 0 +The 0 +results 0 +with 0 +respect 0 +to 0 +the 0 +use 0 +of 0 +third 0 +- 0 +generation 0 +oral 1 +contraceptives 2 +were 0 +inconclusive 0 +but 0 +suggested 0 +that 0 +the 0 +risk 0 +was 0 +lower 0 +than 0 +the 0 +risk 0 +associated 0 +with 0 +second 0 +- 0 +generation 0 +oral 1 +contraceptives 2 +. 0 +The 0 +risk 0 +of 0 +myocardial 3 +infarction 4 +was 0 +similar 0 +among 0 +women 0 +who 0 +used 0 +oral 1 +contraceptives 2 +whether 0 +or 0 +not 0 +they 0 +had 0 +a 0 +prothrombotic 0 +mutation 0 +. 0 +End 3 +- 4 +stage 4 +renal 4 +disease 4 +( 0 +ESRD 3 +) 0 +after 0 +orthotopic 0 +liver 0 +transplantation 0 +( 0 +0LTX 0 +) 0 +using 0 +calcineurin 0 +- 0 +based 0 +immunotherapy 0 +: 0 +risk 0 +of 0 +development 0 +and 0 +treatment 0 +. 0 +BACKGR0UND 0 +: 0 +The 0 +calcineurin 0 +inhibitors 0 +cyclosporine 1 +and 0 +tacrolimus 1 +are 0 +both 0 +known 0 +to 0 +be 0 +nephrotoxic 3 +. 0 +Their 0 +use 0 +in 0 +orthotopic 0 +liver 0 +transplantation 0 +( 0 +0LTX 0 +) 0 +has 0 +dramatically 0 +improved 0 +success 0 +rates 0 +. 0 +Recently 0 +"," 0 +however 0 +"," 0 +we 0 +have 0 +had 0 +an 0 +increase 0 +of 0 +patients 0 +who 0 +are 0 +presenting 0 +after 0 +0LTX 0 +with 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +( 0 +ESRD 3 +) 0 +. 0 +This 0 +retrospective 0 +study 0 +examines 0 +the 0 +incidence 0 +and 0 +treatment 0 +of 0 +ESRD 3 +and 0 +chronic 3 +renal 4 +failure 4 +( 0 +CRF 3 +) 0 +in 0 +0LTX 0 +patients 0 +. 0 +METH0DS 0 +: 0 +Patients 0 +receiving 0 +an 0 +0LTX 0 +only 0 +from 0 +June 0 +1985 0 +through 0 +December 0 +of 0 +1994 0 +who 0 +survived 0 +6 0 +months 0 +postoperatively 0 +were 0 +studied 0 +( 0 +n 0 += 0 +834 0 +) 0 +. 0 +0ur 0 +prospectively 0 +collected 0 +database 0 +was 0 +the 0 +source 0 +of 0 +information 0 +. 0 +Patients 0 +were 0 +divided 0 +into 0 +three 0 +groups 0 +: 0 +Controls 0 +"," 0 +no 0 +CRF 3 +or 0 +ESRD 3 +"," 0 +n 0 += 0 +748 0 +; 0 +CRF 3 +"," 0 +sustained 0 +serum 0 +creatinine 1 +> 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +dl 0 +"," 0 +n 0 += 0 +41 0 +; 0 +and 0 +ESRD 3 +"," 0 +n 0 += 0 +45 0 +. 0 +Groups 0 +were 0 +compared 0 +for 0 +preoperative 0 +laboratory 0 +variables 0 +"," 0 +diagnosis 0 +"," 0 +postoperative 0 +variables 0 +"," 0 +survival 0 +"," 0 +type 0 +of 0 +ESRD 3 +therapy 0 +"," 0 +and 0 +survival 0 +from 0 +onset 0 +of 0 +ESRD 3 +. 0 +RESULTS 0 +: 0 +At 0 +13 0 +years 0 +after 0 +0LTX 0 +"," 0 +the 0 +incidence 0 +of 0 +severe 0 +renal 3 +dysfunction 4 +was 0 +18 0 +. 0 +1 0 +% 0 +( 0 +CRF 3 +8 0 +. 0 +6 0 +% 0 +and 0 +ESRD 3 +9 0 +. 0 +5 0 +% 0 +) 0 +. 0 +Compared 0 +with 0 +control 0 +patients 0 +"," 0 +CRF 3 +and 0 +ESRD 3 +patients 0 +had 0 +higher 0 +preoperative 0 +serum 0 +creatinine 1 +levels 0 +"," 0 +a 0 +greater 0 +percentage 0 +of 0 +patients 0 +with 0 +hepatorenal 3 +syndrome 4 +"," 0 +higher 0 +percentage 0 +requirement 0 +for 0 +dialysis 0 +in 0 +the 0 +first 0 +3 0 +months 0 +postoperatively 0 +"," 0 +and 0 +a 0 +higher 0 +1 0 +- 0 +year 0 +serum 0 +creatinine 1 +. 0 +Multivariate 0 +stepwise 0 +logistic 0 +regression 0 +analysis 0 +using 0 +preoperative 0 +and 0 +postoperative 0 +variables 0 +identified 0 +that 0 +an 0 +increase 0 +of 0 +serum 0 +creatinine 1 +compared 0 +with 0 +average 0 +at 0 +1 0 +year 0 +"," 0 +3 0 +months 0 +"," 0 +and 0 +4 0 +weeks 0 +postoperatively 0 +were 0 +independent 0 +risk 0 +factors 0 +for 0 +the 0 +development 0 +of 0 +CRF 3 +or 0 +ESRD 3 +with 0 +odds 0 +ratios 0 +of 0 +2 0 +. 0 +6 0 +"," 0 +2 0 +. 0 +2 0 +"," 0 +and 0 +1 0 +. 0 +6 0 +"," 0 +respectively 0 +. 0 +0verall 0 +survival 0 +from 0 +the 0 +time 0 +of 0 +0LTX 0 +was 0 +not 0 +significantly 0 +different 0 +among 0 +groups 0 +"," 0 +but 0 +by 0 +year 0 +13 0 +"," 0 +the 0 +survival 0 +of 0 +the 0 +patients 0 +who 0 +had 0 +ESRD 3 +was 0 +only 0 +28 0 +. 0 +2 0 +% 0 +compared 0 +with 0 +54 0 +. 0 +6 0 +% 0 +in 0 +the 0 +control 0 +group 0 +. 0 +Patients 0 +developing 0 +ESRD 3 +had 0 +a 0 +6 0 +- 0 +year 0 +survival 0 +after 0 +onset 0 +of 0 +ESRD 3 +of 0 +27 0 +% 0 +for 0 +the 0 +patients 0 +receiving 0 +hemodialysis 0 +versus 0 +71 0 +. 0 +4 0 +% 0 +for 0 +the 0 +patients 0 +developing 0 +ESRD 3 +who 0 +subsequently 0 +received 0 +kidney 0 +transplants 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Patients 0 +who 0 +are 0 +more 0 +than 0 +10 0 +years 0 +post 0 +- 0 +0LTX 0 +have 0 +CRF 3 +and 0 +ESRD 3 +at 0 +a 0 +high 0 +rate 0 +. 0 +The 0 +development 0 +of 0 +ESRD 3 +decreases 0 +survival 0 +"," 0 +particularly 0 +in 0 +those 0 +patients 0 +treated 0 +with 0 +dialysis 0 +only 0 +. 0 +Patients 0 +who 0 +develop 0 +ESRD 3 +have 0 +a 0 +higher 0 +preoperative 0 +and 0 +1 0 +- 0 +year 0 +serum 0 +creatinine 1 +and 0 +are 0 +more 0 +likely 0 +to 0 +have 0 +hepatorenal 3 +syndrome 4 +. 0 +However 0 +"," 0 +an 0 +increase 0 +of 0 +serum 0 +creatinine 1 +at 0 +various 0 +times 0 +postoperatively 0 +is 0 +more 0 +predictive 0 +of 0 +the 0 +development 0 +of 0 +CRF 3 +or 0 +ESRD 3 +. 0 +New 0 +strategies 0 +for 0 +long 0 +- 0 +term 0 +immunosuppression 0 +may 0 +be 0 +needed 0 +to 0 +decrease 0 +this 0 +complication 0 +. 0 +Epileptic 3 +seizures 4 +following 0 +cortical 0 +application 0 +of 0 +fibrin 0 +sealants 0 +containing 0 +tranexamic 1 +acid 2 +in 0 +rats 0 +. 0 +BACKGR0UND 0 +: 0 +Fibrin 0 +sealants 0 +( 0 +FS 0 +) 0 +derived 0 +from 0 +human 0 +plasma 0 +are 0 +frequently 0 +used 0 +in 0 +neurosurgery 0 +. 0 +In 0 +order 0 +to 0 +increase 0 +clot 0 +stability 0 +"," 0 +FS 0 +typically 0 +contain 0 +aprotinin 0 +"," 0 +a 0 +natural 0 +fibrinolysis 0 +inhibitor 0 +. 0 +Recently 0 +"," 0 +synthetic 0 +fibrinolysis 0 +inhibitors 0 +such 0 +as 0 +tranexamic 1 +acid 2 +( 0 +tAMCA 1 +) 0 +have 0 +been 0 +considered 0 +as 0 +substitutes 0 +for 0 +aprotinin 0 +. 0 +However 0 +"," 0 +tAMCA 1 +has 0 +been 0 +shown 0 +to 0 +cause 0 +epileptic 3 +seizures 4 +. 0 +We 0 +wanted 0 +to 0 +study 0 +whether 0 +tAMCA 1 +retains 0 +its 0 +convulsive 3 +action 0 +if 0 +incorporated 0 +into 0 +a 0 +FS 0 +. 0 +METH0D 0 +: 0 +FS 0 +containing 0 +aprotinin 0 +or 0 +different 0 +concentrations 0 +of 0 +tAMCA 1 +( 0 +0 0 +. 0 +5 0 +- 0 +47 0 +. 0 +5 0 +mg 0 +/ 0 +ml 0 +) 0 +were 0 +applied 0 +to 0 +the 0 +pial 0 +surface 0 +of 0 +the 0 +cortex 0 +of 0 +anaesthetized 0 +rats 0 +. 0 +The 0 +response 0 +of 0 +the 0 +animals 0 +was 0 +evaluated 0 +using 0 +electroencephalography 0 +and 0 +by 0 +monitoring 0 +the 0 +clinical 0 +behaviour 0 +during 0 +and 0 +after 0 +recovery 0 +from 0 +anaesthesia 0 +. 0 +FINDINGS 0 +: 0 +FS 0 +containing 0 +tAMCA 1 +caused 0 +paroxysmal 0 +brain 0 +activity 0 +which 0 +was 0 +associated 0 +with 0 +distinct 0 +convulsive 3 +behaviours 0 +. 0 +The 0 +degree 0 +of 0 +these 0 +seizures 3 +increased 0 +with 0 +increasing 0 +concentration 0 +of 0 +tAMCA 1 +. 0 +Thus 0 +"," 0 +FS 0 +containing 0 +47 0 +. 0 +5 0 +mg 0 +/ 0 +ml 0 +tAMCA 1 +evoked 0 +generalized 3 +seizures 4 +in 0 +all 0 +tested 0 +rats 0 +( 0 +n 0 += 0 +6 0 +) 0 +while 0 +the 0 +lowest 0 +concentration 0 +of 0 +tAMCA 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +ml 0 +) 0 +only 0 +evoked 0 +brief 0 +episodes 0 +of 0 +jerk 0 +- 0 +correlated 0 +convulsive 3 +potentials 0 +in 0 +1 0 +of 0 +6 0 +rats 0 +. 0 +In 0 +contrast 0 +"," 0 +FS 0 +containing 0 +aprotinin 0 +did 0 +not 0 +evoke 0 +any 0 +paroxysmal 0 +activity 0 +. 0 +INTERPRETATI0N 0 +: 0 +Tranexamic 1 +acid 2 +retains 0 +its 0 +convulsive 3 +action 0 +within 0 +FS 0 +. 0 +Thus 0 +"," 0 +use 0 +of 0 +FS 0 +containing 0 +tAMCA 1 +for 0 +surgery 0 +within 0 +or 0 +close 0 +to 0 +the 0 +CNS 0 +may 0 +pose 0 +a 0 +substantial 0 +risk 0 +to 0 +the 0 +patient 0 +. 0 +Sequential 0 +observations 0 +of 0 +exencephaly 3 +and 0 +subsequent 0 +morphological 0 +changes 0 +by 0 +mouse 0 +exo 0 +utero 0 +development 0 +system 0 +: 0 +analysis 0 +of 0 +the 0 +mechanism 0 +of 0 +transformation 0 +from 0 +exencephaly 3 +to 0 +anencephaly 3 +. 0 +Anencephaly 3 +has 0 +been 0 +suggested 0 +to 0 +develop 0 +from 0 +exencephaly 3 +; 0 +however 0 +"," 0 +there 0 +is 0 +little 0 +direct 0 +experimental 0 +evidence 0 +to 0 +support 0 +this 0 +"," 0 +and 0 +the 0 +mechanism 0 +of 0 +transformation 0 +remains 0 +unclear 0 +. 0 +We 0 +examined 0 +this 0 +theory 0 +using 0 +the 0 +exo 0 +utero 0 +development 0 +system 0 +that 0 +allows 0 +direct 0 +and 0 +sequential 0 +observations 0 +of 0 +mid 0 +- 0 +to 0 +late 0 +- 0 +gestation 0 +mouse 0 +embryos 0 +. 0 +We 0 +observed 0 +the 0 +exencephaly 3 +induced 0 +by 0 +5 1 +- 2 +azacytidine 2 +at 0 +embryonic 0 +day 0 +13 0 +. 0 +5 0 +( 0 +E13 0 +. 0 +5 0 +) 0 +"," 0 +let 0 +the 0 +embryos 0 +develop 0 +exo 0 +utero 0 +until 0 +E18 0 +. 0 +5 0 +"," 0 +and 0 +re 0 +- 0 +observed 0 +the 0 +same 0 +embryos 0 +at 0 +E18 0 +. 0 +5 0 +. 0 +We 0 +confirmed 0 +several 0 +cases 0 +of 0 +transformation 0 +from 0 +exencephaly 3 +to 0 +anencephaly 3 +. 0 +However 0 +"," 0 +in 0 +many 0 +cases 0 +"," 0 +the 0 +exencephalic 3 +brain 0 +tissue 0 +was 0 +preserved 0 +with 0 +more 0 +or 0 +less 0 +reduction 0 +during 0 +this 0 +period 0 +. 0 +To 0 +analyze 0 +the 0 +transformation 0 +patterns 0 +"," 0 +we 0 +classified 0 +the 0 +exencephaly 3 +by 0 +size 0 +and 0 +shape 0 +of 0 +the 0 +exencephalic 3 +tissue 0 +into 0 +several 0 +types 0 +at 0 +E13 0 +. 0 +5 0 +and 0 +E18 0 +. 0 +5 0 +. 0 +It 0 +was 0 +found 0 +that 0 +the 0 +transformation 0 +of 0 +exencephalic 3 +tissue 0 +was 0 +not 0 +simply 0 +size 0 +- 0 +dependent 0 +"," 0 +and 0 +all 0 +cases 0 +of 0 +anencephaly 3 +at 0 +E18 0 +. 0 +5 0 +resulted 0 +from 0 +embryos 0 +with 0 +a 0 +large 0 +amount 0 +of 0 +exencephalic 3 +tissue 0 +at 0 +E13 0 +. 0 +5 0 +. 0 +Microscopic 0 +observation 0 +showed 0 +the 0 +configuration 0 +of 0 +exencephaly 3 +at 0 +E13 0 +. 0 +5 0 +"," 0 +frequent 0 +hemorrhaging 3 +and 0 +detachment 0 +of 0 +the 0 +neural 0 +plate 0 +from 0 +surface 0 +ectoderm 0 +in 0 +the 0 +exencephalic 3 +head 0 +at 0 +E15 0 +. 0 +5 0 +"," 0 +and 0 +multiple 0 +modes 0 +of 0 +reduction 0 +in 0 +the 0 +exencephalic 3 +tissue 0 +at 0 +E18 0 +. 0 +5 0 +. 0 +From 0 +observations 0 +of 0 +the 0 +vasculature 0 +"," 0 +altered 0 +distribution 0 +patterns 0 +of 0 +vessels 0 +were 0 +identified 0 +in 0 +the 0 +exencephalic 3 +head 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +overgrowth 0 +of 0 +the 0 +exencephalic 3 +neural 0 +tissue 0 +causes 0 +the 0 +altered 0 +distribution 0 +patterns 0 +of 0 +vessels 0 +"," 0 +subsequent 0 +peripheral 0 +circulatory 3 +failure 4 +and 0 +/ 0 +or 0 +hemorrhaging 3 +in 0 +various 0 +parts 0 +of 0 +the 0 +exencephalic 3 +head 0 +"," 0 +leading 0 +to 0 +the 0 +multiple 0 +modes 0 +of 0 +tissue 0 +reduction 0 +during 0 +transformation 0 +from 0 +exencephaly 3 +to 0 +anencephaly 3 +. 0 +99mTc 1 +- 2 +glucarate 2 +for 0 +detection 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Infarct 3 +- 0 +avid 0 +radiopharmaceuticals 0 +are 0 +necessary 0 +for 0 +rapid 0 +and 0 +timely 0 +diagnosis 0 +of 0 +acute 0 +myocardial 3 +infarction 4 +. 0 +The 0 +animal 0 +model 0 +used 0 +to 0 +produce 0 +infarction 3 +implies 0 +artery 0 +ligation 0 +but 0 +chemical 0 +induction 0 +can 0 +be 0 +easily 0 +obtained 0 +with 0 +isoproterenol 1 +. 0 +A 0 +new 0 +infarct 3 +- 0 +avid 0 +radiopharmaceutical 0 +based 0 +on 0 +glucaric 1 +acid 2 +was 0 +prepared 0 +in 0 +the 0 +hospital 0 +radiopharmacy 0 +of 0 +the 0 +INCMNSZ 0 +. 0 +99mTc 1 +- 2 +glucarate 2 +was 0 +easy 0 +to 0 +prepare 0 +"," 0 +stable 0 +for 0 +96 0 +h 0 +and 0 +was 0 +used 0 +to 0 +study 0 +its 0 +biodistribution 0 +in 0 +rats 0 +with 0 +isoproterenol 1 +- 0 +induced 0 +acute 0 +myocardial 3 +infarction 4 +. 0 +Histological 0 +studies 0 +demonstrated 0 +that 0 +the 0 +rats 0 +developed 0 +an 0 +infarct 3 +18 0 +h 0 +after 0 +isoproterenol 1 +administration 0 +. 0 +The 0 +rat 0 +biodistribution 0 +studies 0 +showed 0 +a 0 +rapid 0 +blood 0 +clearance 0 +via 0 +the 0 +kidneys 0 +. 0 +Thirty 0 +minutes 0 +after 0 +99mTc 1 +- 2 +glucarate 2 +administration 0 +the 0 +standardised 0 +heart 0 +uptake 0 +value 0 +S 0 +( 0 +h 0 +) 0 +UV 0 +was 0 +4 0 +. 0 +7 0 +in 0 +infarcted 0 +rat 0 +heart 0 +which 0 +is 0 +six 0 +times 0 +more 0 +than 0 +in 0 +normal 0 +rats 0 +. 0 +R0Is 0 +drawn 0 +over 0 +the 0 +gamma 0 +camera 0 +images 0 +showed 0 +a 0 +ratio 0 +of 0 +4 0 +. 0 +4 0 +. 0 +The 0 +high 0 +image 0 +quality 0 +suggests 0 +that 0 +high 0 +contrast 0 +images 0 +can 0 +be 0 +obtained 0 +in 0 +humans 0 +and 0 +the 0 +96 0 +h 0 +stability 0 +makes 0 +it 0 +an 0 +ideal 0 +agent 0 +to 0 +detect 0 +"," 0 +in 0 +patients 0 +"," 0 +early 0 +cardiac 3 +infarction 4 +. 0 +Bupropion 1 +( 0 +Zyban 1 +) 0 +toxicity 3 +. 0 +Bupropion 1 +is 0 +a 0 +monocyclic 0 +antidepressant 1 +structurally 0 +related 0 +to 0 +amphetamine 1 +. 0 +Zyban 1 +"," 0 +a 0 +sustained 0 +- 0 +release 0 +formulation 0 +of 0 +bupropion 1 +hydrochloride 2 +"," 0 +was 0 +recently 0 +released 0 +in 0 +Ireland 0 +"," 0 +as 0 +a 0 +smoking 0 +cessation 0 +aid 0 +. 0 +In 0 +the 0 +initial 0 +6 0 +months 0 +since 0 +it 0 +' 0 +s 0 +introduction 0 +"," 0 +12 0 +overdose 3 +cases 0 +have 0 +been 0 +reported 0 +to 0 +The 0 +National 0 +Poisons 0 +Information 0 +Centre 0 +. 0 +8 0 +patients 0 +developed 0 +symptoms 0 +of 0 +toxicity 3 +. 0 +Common 0 +features 0 +included 0 +tachycardia 3 +"," 0 +drowsiness 0 +"," 0 +hallucinations 3 +and 0 +convulsions 3 +. 0 +Two 0 +patients 0 +developed 0 +severe 0 +cardiac 3 +arrhythmias 4 +"," 0 +including 0 +one 0 +patient 0 +who 0 +was 0 +resuscitated 0 +following 0 +a 0 +cardiac 3 +arrest 4 +. 0 +All 0 +patients 0 +recovered 0 +without 0 +sequelae 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +31 0 +year 0 +old 0 +female 0 +who 0 +required 0 +admission 0 +to 0 +the 0 +Intensive 0 +Care 0 +Unit 0 +for 0 +ventilation 0 +and 0 +full 0 +supportive 0 +therapy 0 +"," 0 +following 0 +ingestion 0 +of 0 +13 0 +. 0 +5g 0 +bupropion 1 +. 0 +Recurrent 0 +seizures 3 +were 0 +treated 0 +with 0 +diazepam 1 +and 0 +broad 0 +complex 0 +tachycardia 3 +was 0 +successfully 0 +treated 0 +with 0 +adenosine 1 +. 0 +Zyban 1 +caused 0 +significant 0 +neurological 3 +and 4 +cardiovascular 4 +toxicity 4 +in 0 +overdose 3 +. 0 +The 0 +potential 0 +toxic 0 +effects 0 +should 0 +be 0 +considered 0 +when 0 +prescribing 0 +it 0 +as 0 +a 0 +smoking 0 +cessation 0 +aid 0 +. 0 +GLEPP1 0 +receptor 0 +tyrosine 1 +phosphatase 0 +( 0 +Ptpro 0 +) 0 +in 0 +rat 0 +PAN 1 +nephrosis 3 +. 0 +A 0 +marker 0 +of 0 +acute 0 +podocyte 0 +injury 0 +. 0 +Glomerular 0 +epithelial 0 +protein 0 +1 0 +( 0 +GLEPP1 0 +) 0 +is 0 +a 0 +podocyte 0 +receptor 0 +membrane 0 +protein 0 +tyrosine 1 +phosphatase 0 +located 0 +on 0 +the 0 +apical 0 +cell 0 +membrane 0 +of 0 +visceral 0 +glomerular 0 +epithelial 0 +cell 0 +and 0 +foot 0 +processes 0 +. 0 +This 0 +receptor 0 +plays 0 +a 0 +role 0 +in 0 +regulating 0 +the 0 +structure 0 +and 0 +function 0 +of 0 +podocyte 0 +foot 0 +process 0 +. 0 +To 0 +better 0 +understand 0 +the 0 +utility 0 +of 0 +GLEPP1 0 +as 0 +a 0 +marker 0 +of 0 +glomerular 3 +injury 4 +"," 0 +the 0 +amount 0 +and 0 +distribution 0 +of 0 +GLEPP1 0 +protein 0 +and 0 +mRNA 0 +were 0 +examined 0 +by 0 +immunohistochemistry 0 +"," 0 +Western 0 +blot 0 +and 0 +RNase 0 +protection 0 +assay 0 +in 0 +a 0 +model 0 +of 0 +podocyte 0 +injury 0 +in 0 +the 0 +rat 0 +. 0 +Puromycin 1 +aminonucleoside 2 +nephrosis 3 +was 0 +induced 0 +by 0 +single 0 +intraperitoneal 0 +injection 0 +of 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +"," 0 +20 0 +mg 0 +/ 0 +100g 0 +BW 0 +) 0 +. 0 +Tissues 0 +were 0 +analyzed 0 +at 0 +0 0 +"," 0 +5 0 +"," 0 +7 0 +"," 0 +11 0 +"," 0 +21 0 +"," 0 +45 0 +"," 0 +80 0 +and 0 +126 0 +days 0 +after 0 +PAN 1 +injection 0 +so 0 +as 0 +to 0 +include 0 +both 0 +the 0 +acute 0 +phase 0 +of 0 +proteinuria 3 +associated 0 +with 0 +foot 0 +process 0 +effacement 0 +( 0 +days 0 +5 0 +- 0 +11 0 +) 0 +and 0 +the 0 +chronic 0 +phase 0 +of 0 +proteinuria 3 +associated 0 +with 0 +glomerulosclerosis 3 +( 0 +days 0 +45 0 +- 0 +126 0 +) 0 +. 0 +At 0 +day 0 +5 0 +"," 0 +GLEPP1 0 +protein 0 +and 0 +mRNA 0 +were 0 +reduced 0 +from 0 +the 0 +normal 0 +range 0 +( 0 +265 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +79 0 +. 0 +6 0 +x 0 +10 0 +( 0 +6 0 +) 0 +moles 0 +/ 0 +glomerulus 0 +and 0 +100 0 +% 0 +) 0 +to 0 +15 0 +% 0 +of 0 +normal 0 +( 0 +41 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +4 0 +. 0 +8 0 +x 0 +10 0 +( 0 +6 0 +) 0 +moles 0 +/ 0 +glomerulus 0 +"," 0 +p 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +This 0 +occurred 0 +in 0 +association 0 +with 0 +an 0 +increase 0 +in 0 +urinary 0 +protein 0 +content 0 +from 0 +1 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +1 0 +to 0 +99 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +61 0 +mg 0 +/ 0 +day 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +In 0 +contrast 0 +"," 0 +podocalyxin 0 +did 0 +not 0 +change 0 +significantly 0 +at 0 +this 0 +time 0 +. 0 +By 0 +day 0 +11 0 +"," 0 +GLEPP1 0 +protein 0 +and 0 +mRNA 0 +had 0 +begun 0 +to 0 +return 0 +towards 0 +baseline 0 +. 0 +By 0 +day 0 +45 0 +- 0 +126 0 +"," 0 +at 0 +a 0 +time 0 +when 0 +glomerular 0 +scarring 0 +was 0 +present 0 +"," 0 +GLEPP1 0 +was 0 +absent 0 +from 0 +glomerulosclerotic 0 +areas 0 +although 0 +the 0 +total 0 +glomerular 0 +content 0 +of 0 +GLEPP1 0 +was 0 +not 0 +different 0 +from 0 +normal 0 +. 0 +We 0 +conclude 0 +that 0 +GLEPP1 0 +expression 0 +"," 0 +unlike 0 +podocalyxin 0 +"," 0 +reflects 0 +podocyte 0 +injury 0 +induced 0 +by 0 +PAN 1 +. 0 +GLEPP1 0 +expression 0 +may 0 +be 0 +a 0 +useful 0 +marker 0 +of 0 +podocyte 0 +injury 0 +. 0 +Antithymocyte 1 +globulin 2 +in 0 +the 0 +treatment 0 +of 0 +D 1 +- 2 +penicillamine 2 +- 0 +induced 0 +aplastic 3 +anemia 4 +. 0 +A 0 +patient 0 +who 0 +received 0 +antithymocyte 1 +globulin 2 +therapy 0 +for 0 +aplastic 3 +anemia 4 +due 0 +to 0 +D 1 +- 2 +penicillamine 2 +therapy 0 +is 0 +described 0 +. 0 +Bone 0 +marrow 0 +recovery 0 +and 0 +peripheral 0 +blood 0 +recovery 0 +were 0 +complete 0 +1 0 +month 0 +and 0 +3 0 +months 0 +"," 0 +respectively 0 +"," 0 +after 0 +treatment 0 +"," 0 +and 0 +blood 0 +transfusion 0 +or 0 +other 0 +therapies 0 +were 0 +not 0 +necessary 0 +in 0 +a 0 +follow 0 +- 0 +up 0 +period 0 +of 0 +more 0 +than 0 +2 0 +years 0 +. 0 +Use 0 +of 0 +antithymocyte 1 +globulin 2 +may 0 +be 0 +the 0 +optimal 0 +treatment 0 +of 0 +D 1 +- 2 +penicillamine 2 +- 0 +induced 0 +aplastic 3 +anemia 4 +. 0 +Metamizol 1 +potentiates 0 +morphine 1 +antinociception 0 +but 0 +not 0 +constipation 3 +after 0 +chronic 0 +treatment 0 +. 0 +This 0 +work 0 +evaluates 0 +the 0 +antinociceptive 0 +and 0 +constipating 3 +effects 0 +of 0 +the 0 +combination 0 +of 0 +3 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +morphine 1 +with 0 +177 0 +. 0 +8 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +metamizol 1 +in 0 +acutely 0 +and 0 +chronically 0 +treated 0 +( 0 +once 0 +a 0 +day 0 +for 0 +12 0 +days 0 +) 0 +rats 0 +. 0 +0n 0 +the 0 +13th 0 +day 0 +"," 0 +antinociceptive 0 +effects 0 +were 0 +assessed 0 +using 0 +a 0 +model 0 +of 0 +inflammatory 0 +nociception 0 +"," 0 +pain 3 +- 0 +induced 0 +functional 0 +impairment 0 +model 0 +"," 0 +and 0 +the 0 +charcoal 1 +meal 0 +test 0 +was 0 +used 0 +to 0 +evaluate 0 +the 0 +intestinal 0 +transit 0 +. 0 +Simultaneous 0 +administration 0 +of 0 +morphine 1 +with 0 +metamizol 1 +resulted 0 +in 0 +a 0 +markedly 0 +antinociceptive 0 +potentiation 0 +and 0 +an 0 +increasing 0 +of 0 +the 0 +duration 0 +of 0 +action 0 +after 0 +a 0 +single 0 +( 0 +298 0 ++ 0 +/ 0 +- 0 +7 0 +vs 0 +. 0 +139 0 ++ 0 +/ 0 +- 0 +36 0 +units 0 +area 0 +( 0 +ua 0 +) 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +and 0 +repeated 0 +administration 0 +( 0 +280 0 ++ 0 +/ 0 +- 0 +17 0 +vs 0 +. 0 +131 0 ++ 0 +/ 0 +- 0 +22 0 +ua 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Antinociceptive 0 +effect 0 +of 0 +morphine 1 +was 0 +reduced 0 +in 0 +chronically 0 +treated 0 +rats 0 +( 0 +39 0 ++ 0 +/ 0 +- 0 +10 0 +vs 0 +. 0 +18 0 ++ 0 +/ 0 +- 0 +5 0 +au 0 +) 0 +while 0 +the 0 +combination 0 +- 0 +induced 0 +antinociception 0 +was 0 +remained 0 +similar 0 +as 0 +an 0 +acute 0 +treatment 0 +( 0 +298 0 ++ 0 +/ 0 +- 0 +7 0 +vs 0 +. 0 +280 0 ++ 0 +/ 0 +- 0 +17 0 +au 0 +) 0 +. 0 +Acute 0 +antinociceptive 0 +effects 0 +of 0 +the 0 +combination 0 +were 0 +partially 0 +prevented 0 +by 0 +3 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +naloxone 1 +s 0 +. 0 +c 0 +. 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +suggesting 0 +the 0 +partial 0 +involvement 0 +of 0 +the 0 +opioidergic 0 +system 0 +in 0 +the 0 +synergism 0 +observed 0 +. 0 +In 0 +independent 0 +groups 0 +"," 0 +morphine 1 +inhibited 0 +the 0 +intestinal 0 +transit 0 +in 0 +48 0 ++ 0 +/ 0 +- 0 +4 0 +% 0 +and 0 +38 0 ++ 0 +/ 0 +- 0 +4 0 +% 0 +after 0 +acute 0 +and 0 +chronic 0 +treatment 0 +"," 0 +respectively 0 +"," 0 +suggesting 0 +that 0 +tolerance 0 +did 0 +not 0 +develop 0 +to 0 +the 0 +constipating 3 +effects 0 +. 0 +The 0 +combination 0 +inhibited 0 +intestinal 0 +transit 0 +similar 0 +to 0 +that 0 +produced 0 +by 0 +morphine 1 +regardless 0 +of 0 +the 0 +time 0 +of 0 +treatment 0 +"," 0 +suggesting 0 +that 0 +metamizol 1 +did 0 +not 0 +potentiate 0 +morphine 1 +- 0 +induced 0 +constipation 3 +. 0 +These 0 +findings 0 +show 0 +a 0 +significant 0 +interaction 0 +between 0 +morphine 1 +and 0 +metamizol 1 +in 0 +chronically 0 +treated 0 +rats 0 +"," 0 +suggesting 0 +that 0 +this 0 +combination 0 +could 0 +be 0 +useful 0 +for 0 +the 0 +treatment 0 +of 0 +chronic 3 +pain 4 +. 0 +Ifosfamide 1 +encephalopathy 3 +presenting 0 +with 0 +asterixis 3 +. 0 +CNS 0 +toxic 0 +effects 0 +of 0 +the 0 +antineoplastic 0 +agent 0 +ifosfamide 1 +( 0 +IFX 1 +) 0 +are 0 +frequent 0 +and 0 +include 0 +a 0 +variety 0 +of 0 +neurological 0 +symptoms 0 +that 0 +can 0 +limit 0 +drug 0 +use 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +a 0 +51 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +developed 0 +severe 0 +"," 0 +disabling 0 +negative 0 +myoclonus 3 +of 0 +the 0 +upper 0 +and 0 +lower 0 +extremities 0 +after 0 +the 0 +infusion 0 +of 0 +ifosfamide 1 +for 0 +plasmacytoma 3 +. 0 +He 0 +was 0 +awake 0 +"," 0 +revealed 0 +no 0 +changes 0 +of 0 +mental 0 +status 0 +and 0 +at 0 +rest 0 +there 0 +were 0 +no 0 +further 0 +motor 0 +symptoms 0 +. 0 +Cranial 0 +magnetic 0 +resonance 0 +imaging 0 +and 0 +extensive 0 +laboratory 0 +studies 0 +failed 0 +to 0 +reveal 0 +structural 3 +lesions 4 +of 4 +the 4 +brain 4 +and 0 +metabolic 3 +abnormalities 4 +. 0 +An 0 +electroencephalogram 0 +showed 0 +continuous 0 +"," 0 +generalized 0 +irregular 0 +slowing 0 +with 0 +admixed 0 +periodic 0 +triphasic 0 +waves 0 +indicating 0 +symptomatic 0 +encephalopathy 3 +. 0 +The 0 +administration 0 +of 0 +ifosfamide 1 +was 0 +discontinued 0 +and 0 +within 0 +12 0 +h 0 +the 0 +asterixis 3 +resolved 0 +completely 0 +. 0 +In 0 +the 0 +patient 0 +described 0 +"," 0 +the 0 +presence 0 +of 0 +asterixis 3 +during 0 +infusion 0 +of 0 +ifosfamide 1 +"," 0 +normal 0 +laboratory 0 +findings 0 +and 0 +imaging 0 +studies 0 +and 0 +the 0 +resolution 0 +of 0 +symptoms 0 +following 0 +the 0 +discontinuation 0 +of 0 +the 0 +drug 0 +suggest 0 +that 0 +negative 0 +myoclonus 3 +is 0 +associated 0 +with 0 +the 0 +use 0 +of 0 +IFX 1 +. 0 +Antagonism 0 +between 0 +interleukin 0 +3 0 +and 0 +erythropoietin 0 +in 0 +mice 0 +with 0 +azidothymidine 1 +- 0 +induced 0 +anemia 3 +and 0 +in 0 +bone 0 +marrow 0 +endothelial 0 +cells 0 +. 0 +Azidothymidine 1 +( 0 +AZT 1 +) 0 +- 0 +induced 0 +anemia 3 +in 0 +mice 0 +can 0 +be 0 +reversed 0 +by 0 +the 0 +administration 0 +of 0 +IGF 0 +- 0 +IL 0 +- 0 +3 0 +( 0 +fusion 0 +protein 0 +of 0 +insulin 0 +- 0 +like 0 +growth 0 +factor 0 +II 0 +( 0 +IGF 0 +II 0 +) 0 +and 0 +interleukin 0 +3 0 +) 0 +. 0 +Although 0 +interleukin 0 +3 0 +( 0 +IL 0 +- 0 +3 0 +) 0 +and 0 +erythropoietin 0 +( 0 +EP0 0 +) 0 +are 0 +known 0 +to 0 +act 0 +synergistically 0 +on 0 +hematopoietic 0 +cell 0 +proliferation 0 +in 0 +vitro 0 +"," 0 +injection 0 +of 0 +IGF 0 +- 0 +IL 0 +- 0 +3 0 +and 0 +EP0 0 +in 0 +AZT 1 +- 0 +treated 0 +mice 0 +resulted 0 +in 0 +a 0 +reduction 0 +of 0 +red 0 +cells 0 +and 0 +an 0 +increase 0 +of 0 +plasma 0 +EP0 0 +levels 0 +as 0 +compared 0 +to 0 +animals 0 +treated 0 +with 0 +IGF 0 +- 0 +IL 0 +- 0 +3 0 +or 0 +EP0 0 +alone 0 +. 0 +We 0 +tested 0 +the 0 +hypothesis 0 +that 0 +the 0 +antagonistic 0 +effect 0 +of 0 +IL 0 +- 0 +3 0 +and 0 +EP0 0 +on 0 +erythroid 0 +cells 0 +may 0 +be 0 +mediated 0 +by 0 +endothelial 0 +cells 0 +. 0 +Bovine 0 +liver 0 +erythroid 0 +cells 0 +were 0 +cultured 0 +on 0 +monolayers 0 +of 0 +human 0 +bone 0 +marrow 0 +endothelial 0 +cells 0 +previously 0 +treated 0 +with 0 +EP0 0 +and 0 +IGF 0 +- 0 +IL 0 +- 0 +3 0 +. 0 +There 0 +was 0 +a 0 +significant 0 +reduction 0 +of 0 +thymidine 1 +incorporation 0 +into 0 +both 0 +erythroid 0 +and 0 +endothelial 0 +cells 0 +in 0 +cultures 0 +pre 0 +- 0 +treated 0 +with 0 +IGF 0 +- 0 +IL 0 +- 0 +3 0 +and 0 +EP0 0 +. 0 +Endothelial 0 +cell 0 +culture 0 +supernatants 0 +separated 0 +by 0 +ultrafiltration 0 +and 0 +ultracentrifugation 0 +from 0 +cells 0 +treated 0 +with 0 +EP0 0 +and 0 +IL 0 +- 0 +3 0 +significantly 0 +reduced 0 +thymidine 1 +incorporation 0 +into 0 +erythroid 0 +cells 0 +as 0 +compared 0 +to 0 +identical 0 +fractions 0 +obtained 0 +from 0 +the 0 +media 0 +of 0 +cells 0 +cultured 0 +with 0 +EP0 0 +alone 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +endothelial 0 +cells 0 +treated 0 +simultaneously 0 +with 0 +EP0 0 +and 0 +IL 0 +- 0 +3 0 +have 0 +a 0 +negative 0 +effect 0 +on 0 +erythroid 0 +cell 0 +production 0 +. 0 +The 0 +relationship 0 +between 0 +hippocampal 0 +acetylcholine 1 +release 0 +and 0 +cholinergic 0 +convulsant 0 +sensitivity 0 +in 0 +withdrawal 0 +seizure 3 +- 0 +prone 0 +and 0 +withdrawal 0 +seizure 3 +- 0 +resistant 0 +selected 0 +mouse 0 +lines 0 +. 0 +BACKGR0UND 0 +: 0 +The 0 +septo 0 +- 0 +hippocampal 0 +cholinergic 0 +pathway 0 +has 0 +been 0 +implicated 0 +in 0 +epileptogenesis 0 +"," 0 +and 0 +genetic 0 +factors 0 +influence 0 +the 0 +response 0 +to 0 +cholinergic 0 +agents 0 +"," 0 +but 0 +limited 0 +data 0 +are 0 +available 0 +on 0 +cholinergic 0 +involvement 0 +in 0 +alcohol 1 +withdrawal 0 +severity 0 +. 0 +Thus 0 +"," 0 +the 0 +relationship 0 +between 0 +cholinergic 0 +activity 0 +and 0 +responsiveness 0 +and 0 +alcohol 1 +withdrawal 0 +was 0 +investigated 0 +in 0 +a 0 +genetic 0 +animal 0 +model 0 +of 0 +ethanol 1 +withdrawal 0 +severity 0 +. 0 +METH0DS 0 +: 0 +Cholinergic 0 +convulsant 0 +sensitivity 0 +was 0 +examined 0 +in 0 +alcohol 1 +- 0 +na 0 +ve 0 +Withdrawal 0 +Seizure 3 +- 0 +Prone 0 +( 0 +WSP 0 +) 0 +and 0 +- 0 +Resistant 0 +( 0 +WSR 0 +) 0 +mice 0 +. 0 +Animals 0 +were 0 +administered 0 +nicotine 1 +"," 0 +carbachol 1 +"," 0 +or 0 +neostigmine 1 +via 0 +timed 0 +tail 0 +vein 0 +infusion 0 +"," 0 +and 0 +the 0 +latencies 0 +to 0 +onset 0 +of 0 +tremor 3 +and 0 +clonus 0 +were 0 +recorded 0 +and 0 +converted 0 +to 0 +threshold 0 +dose 0 +. 0 +We 0 +also 0 +used 0 +microdialysis 0 +to 0 +measure 0 +basal 0 +and 0 +potassium 1 +- 0 +stimulated 0 +acetylcholine 1 +( 0 +ACh 1 +) 0 +release 0 +in 0 +the 0 +CA1 0 +region 0 +of 0 +the 0 +hippocampus 0 +. 0 +Potassium 1 +was 0 +applied 0 +by 0 +reverse 0 +dialysis 0 +twice 0 +"," 0 +separated 0 +by 0 +75 0 +min 0 +. 0 +Hippocampal 0 +ACh 1 +also 0 +was 0 +measured 0 +during 0 +testing 0 +for 0 +handling 0 +- 0 +induced 0 +convulsions 3 +. 0 +RESULTS 0 +: 0 +Sensitivity 0 +to 0 +several 0 +convulsion 3 +endpoints 0 +induced 0 +by 0 +nicotine 1 +"," 0 +carbachol 1 +"," 0 +and 0 +neostigmine 1 +were 0 +significantly 0 +greater 0 +in 0 +WSR 0 +versus 0 +WSP 0 +mice 0 +. 0 +In 0 +microdialysis 0 +experiments 0 +"," 0 +the 0 +lines 0 +did 0 +not 0 +differ 0 +in 0 +basal 0 +release 0 +of 0 +ACh 1 +"," 0 +and 0 +50 0 +mM 0 +KCl 1 +increased 0 +ACh 1 +output 0 +in 0 +both 0 +lines 0 +of 0 +mice 0 +. 0 +However 0 +"," 0 +the 0 +increase 0 +in 0 +release 0 +of 0 +ACh 1 +produced 0 +by 0 +the 0 +first 0 +application 0 +of 0 +KCl 1 +was 0 +2 0 +- 0 +fold 0 +higher 0 +in 0 +WSP 0 +versus 0 +WSR 0 +mice 0 +. 0 +When 0 +hippocampal 0 +ACh 1 +was 0 +measured 0 +during 0 +testing 0 +for 0 +handling 0 +- 0 +induced 0 +convulsions 3 +"," 0 +extracellular 0 +ACh 1 +was 0 +significantly 0 +elevated 0 +( 0 +192 0 +% 0 +) 0 +in 0 +WSP 0 +mice 0 +"," 0 +but 0 +was 0 +nonsignificantly 0 +elevated 0 +( 0 +59 0 +% 0 +) 0 +in 0 +WSR 0 +mice 0 +. 0 +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +suggest 0 +that 0 +differences 0 +in 0 +cholinergic 0 +activity 0 +and 0 +postsynaptic 0 +sensitivity 0 +to 0 +cholinergic 0 +convulsants 3 +may 0 +be 0 +associated 0 +with 0 +ethanol 1 +withdrawal 0 +severity 0 +and 0 +implicate 0 +cholinergic 0 +mechanisms 0 +in 0 +alcohol 1 +withdrawal 0 +. 0 +Specifically 0 +"," 0 +WSP 0 +mice 0 +may 0 +have 0 +lower 0 +sensitivity 0 +to 0 +cholinergic 0 +convulsants 3 +compared 0 +with 0 +WSR 0 +because 0 +of 0 +postsynaptic 0 +receptor 0 +desensitization 0 +brought 0 +on 0 +by 0 +higher 0 +activity 0 +of 0 +cholinergic 0 +neurons 0 +. 0 +Capsaicin 1 +- 0 +induced 0 +muscle 3 +pain 4 +alters 0 +the 0 +excitability 0 +of 0 +the 0 +human 0 +jaw 0 +- 0 +stretch 0 +reflex 0 +. 0 +The 0 +pathophysiology 0 +of 0 +painful 0 +temporomandibular 3 +disorders 4 +is 0 +not 0 +fully 0 +understood 0 +"," 0 +but 0 +evidence 0 +suggests 0 +that 0 +muscle 3 +pain 4 +modulates 0 +motor 0 +function 0 +in 0 +characteristic 0 +ways 0 +. 0 +This 0 +study 0 +tested 0 +the 0 +hypothesis 0 +that 0 +activation 0 +of 0 +nociceptive 3 +muscle 4 +afferent 0 +fibers 0 +would 0 +be 0 +linked 0 +to 0 +an 0 +increased 0 +excitability 0 +of 0 +the 0 +human 0 +jaw 0 +- 0 +stretch 0 +reflex 0 +and 0 +whether 0 +this 0 +process 0 +would 0 +be 0 +sensitive 0 +to 0 +length 0 +and 0 +velocity 0 +of 0 +the 0 +stretch 0 +. 0 +Capsaicin 1 +( 0 +10 0 +micro 0 +g 0 +) 0 +was 0 +injected 0 +into 0 +the 0 +masseter 0 +muscle 0 +to 0 +induce 0 +pain 3 +in 0 +11 0 +healthy 0 +volunteers 0 +. 0 +Short 0 +- 0 +latency 0 +reflex 0 +responses 0 +were 0 +evoked 0 +in 0 +the 0 +masseter 0 +and 0 +temporalis 0 +muscles 0 +by 0 +a 0 +stretch 0 +device 0 +with 0 +different 0 +velocities 0 +and 0 +displacements 0 +before 0 +"," 0 +during 0 +"," 0 +and 0 +after 0 +the 0 +pain 3 +. 0 +The 0 +normalized 0 +reflex 0 +amplitude 0 +increased 0 +with 0 +an 0 +increase 0 +in 0 +velocity 0 +at 0 +a 0 +given 0 +displacement 0 +"," 0 +but 0 +remained 0 +constant 0 +with 0 +different 0 +displacements 0 +at 0 +a 0 +given 0 +velocity 0 +. 0 +The 0 +normalized 0 +reflex 0 +amplitude 0 +was 0 +significantly 0 +higher 0 +during 0 +pain 3 +"," 0 +but 0 +only 0 +at 0 +faster 0 +stretches 0 +in 0 +the 0 +painful 3 +muscle 4 +. 0 +Increased 0 +sensitivity 0 +of 0 +the 0 +fusimotor 0 +system 0 +during 0 +acute 0 +muscle 3 +pain 4 +could 0 +be 0 +one 0 +likely 0 +mechanism 0 +to 0 +explain 0 +the 0 +findings 0 +. 0 +Effects 0 +of 0 +5 0 +- 0 +HT1B 0 +receptor 0 +ligands 0 +microinjected 0 +into 0 +the 0 +accumbal 0 +shell 0 +or 0 +core 0 +on 0 +the 0 +cocaine 1 +- 0 +induced 0 +locomotor 3 +hyperactivity 4 +in 0 +rats 0 +. 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +examine 0 +the 0 +effect 0 +of 0 +5 0 +- 0 +HT1B 0 +receptor 0 +ligands 0 +microinjected 0 +into 0 +the 0 +subregions 0 +of 0 +the 0 +nucleus 0 +accumbens 0 +( 0 +the 0 +shell 0 +and 0 +the 0 +core 0 +) 0 +on 0 +the 0 +locomotor 3 +hyperactivity 4 +induced 0 +by 0 +cocaine 1 +in 0 +rats 0 +. 0 +Male 0 +Wistar 0 +rats 0 +were 0 +implanted 0 +bilaterally 0 +with 0 +cannulae 0 +into 0 +the 0 +accumbens 0 +shell 0 +or 0 +core 0 +"," 0 +and 0 +then 0 +were 0 +locally 0 +injected 0 +with 0 +GR 1 +55562 2 +( 0 +an 0 +antagonist 0 +of 0 +5 0 +- 0 +HT1B 0 +receptors 0 +) 0 +or 0 +CP 1 +93129 2 +( 0 +an 0 +agonist 0 +of 0 +5 0 +- 0 +HT1B 0 +receptors 0 +) 0 +. 0 +Given 0 +alone 0 +to 0 +any 0 +accumbal 0 +subregion 0 +"," 0 +GR 1 +55562 2 +( 0 +0 0 +. 0 +1 0 +- 0 +10 0 +microg 0 +/ 0 +side 0 +) 0 +or 0 +CP 1 +93129 2 +( 0 +0 0 +. 0 +1 0 +- 0 +10 0 +microg 0 +/ 0 +side 0 +) 0 +did 0 +not 0 +change 0 +basal 0 +locomotor 0 +activity 0 +. 0 +Systemic 0 +cocaine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +significantly 0 +increased 0 +the 0 +locomotor 0 +activity 0 +of 0 +rats 0 +. 0 +GR 1 +55562 2 +( 0 +0 0 +. 0 +1 0 +- 0 +10 0 +microg 0 +/ 0 +side 0 +) 0 +"," 0 +administered 0 +intra 0 +- 0 +accumbens 0 +shell 0 +prior 0 +to 0 +cocaine 1 +"," 0 +dose 0 +- 0 +dependently 0 +attenuated 0 +the 0 +psychostimulant 0 +- 0 +induced 0 +locomotor 3 +hyperactivity 4 +. 0 +Such 0 +attenuation 0 +was 0 +not 0 +found 0 +in 0 +animals 0 +which 0 +had 0 +been 0 +injected 0 +with 0 +GR 1 +55562 2 +into 0 +the 0 +accumbens 0 +core 0 +. 0 +When 0 +injected 0 +into 0 +the 0 +accumbens 0 +shell 0 +( 0 +but 0 +not 0 +the 0 +core 0 +) 0 +before 0 +cocaine 1 +"," 0 +CP 1 +93129 2 +( 0 +0 0 +. 0 +1 0 +- 0 +10 0 +microg 0 +/ 0 +side 0 +) 0 +enhanced 0 +the 0 +locomotor 0 +response 0 +to 0 +cocaine 1 +; 0 +the 0 +maximum 0 +effect 0 +being 0 +observed 0 +after 0 +10 0 +microg 0 +/ 0 +side 0 +of 0 +the 0 +agonist 0 +. 0 +The 0 +later 0 +enhancement 0 +was 0 +attenuated 0 +after 0 +intra 0 +- 0 +accumbens 0 +shell 0 +treatment 0 +with 0 +GR 1 +55562 2 +( 0 +1 0 +microg 0 +/ 0 +side 0 +) 0 +. 0 +0ur 0 +findings 0 +indicate 0 +that 0 +cocaine 1 +induced 0 +hyperlocomotion 3 +is 0 +modified 0 +by 0 +5 0 +- 0 +HT1B 0 +receptor 0 +ligands 0 +microinjected 0 +into 0 +the 0 +accumbens 0 +shell 0 +"," 0 +but 0 +not 0 +core 0 +"," 0 +this 0 +modification 0 +consisting 0 +in 0 +inhibitory 0 +and 0 +facilitatory 0 +effects 0 +of 0 +the 0 +5 0 +- 0 +HT1B 0 +receptor 0 +antagonist 0 +( 0 +GR 1 +55562 2 +) 0 +and 0 +agonist 0 +( 0 +CP 1 +93129 2 +) 0 +"," 0 +respectively 0 +. 0 +In 0 +other 0 +words 0 +"," 0 +the 0 +present 0 +results 0 +suggest 0 +that 0 +the 0 +accumbal 0 +shell 0 +5 0 +- 0 +HT1B 0 +receptors 0 +play 0 +a 0 +permissive 0 +role 0 +in 0 +the 0 +behavioural 0 +response 0 +to 0 +the 0 +psychostimulant 0 +. 0 +Cocaine 1 +related 0 +chest 3 +pain 4 +: 0 +are 0 +we 0 +seeing 0 +the 0 +tip 0 +of 0 +an 0 +iceberg 0 +? 0 +The 0 +recreational 0 +use 0 +of 0 +cocaine 1 +is 0 +on 0 +the 0 +increase 0 +. 0 +The 0 +emergency 0 +nurse 0 +ought 0 +to 0 +be 0 +familiar 0 +with 0 +some 0 +of 0 +the 0 +cardiovascular 0 +consequences 0 +of 0 +cocaine 1 +use 0 +. 0 +In 0 +particular 0 +"," 0 +the 0 +tendency 0 +of 0 +cocaine 1 +to 0 +produce 0 +chest 3 +pain 4 +ought 0 +to 0 +be 0 +in 0 +the 0 +mind 0 +of 0 +the 0 +emergency 0 +nurse 0 +when 0 +faced 0 +with 0 +a 0 +young 0 +victim 0 +of 0 +chest 3 +pain 4 +who 0 +is 0 +otherwise 0 +at 0 +low 0 +risk 0 +. 0 +The 0 +mechanism 0 +of 0 +chest 3 +pain 4 +related 0 +to 0 +cocaine 1 +use 0 +is 0 +discussed 0 +and 0 +treatment 0 +dilemmas 0 +are 0 +discussed 0 +. 0 +Finally 0 +"," 0 +moral 0 +issues 0 +relating 0 +to 0 +the 0 +testing 0 +of 0 +potential 0 +cocaine 1 +users 0 +will 0 +be 0 +addressed 0 +. 0 +Crossover 0 +comparison 0 +of 0 +efficacy 0 +and 0 +preference 0 +for 0 +rizatriptan 1 +10 0 +mg 0 +versus 0 +ergotamine 1 +/ 0 +caffeine 1 +in 0 +migraine 3 +. 0 +Rizatriptan 1 +is 0 +a 0 +selective 0 +5 1 +- 2 +HT 2 +( 0 +1B 0 +/ 0 +1D 0 +) 0 +receptor 0 +agonist 0 +with 0 +rapid 0 +oral 0 +absorption 0 +and 0 +early 0 +onset 0 +of 0 +action 0 +in 0 +the 0 +acute 0 +treatment 0 +of 0 +migraine 3 +. 0 +This 0 +randomized 0 +double 0 +- 0 +blind 0 +crossover 0 +outpatient 0 +study 0 +assessed 0 +the 0 +preference 0 +for 0 +1 0 +rizatriptan 1 +10 0 +mg 0 +tablet 0 +to 0 +2 0 +ergotamine 1 +1 0 +mg 0 +/ 0 +caffeine 1 +100 0 +mg 0 +tablets 0 +in 0 +439 0 +patients 0 +treating 0 +a 0 +single 0 +migraine 3 +attack 0 +with 0 +each 0 +therapy 0 +. 0 +0f 0 +patients 0 +expressing 0 +a 0 +preference 0 +( 0 +89 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +more 0 +than 0 +twice 0 +as 0 +many 0 +preferred 0 +rizatriptan 1 +to 0 +ergotamine 1 +/ 0 +caffeine 1 +( 0 +69 0 +. 0 +9 0 +vs 0 +. 0 +30 0 +. 0 +1 0 +% 0 +"," 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Faster 0 +relief 0 +of 0 +headache 3 +was 0 +the 0 +most 0 +important 0 +reason 0 +for 0 +preference 0 +"," 0 +cited 0 +by 0 +67 0 +. 0 +3 0 +% 0 +of 0 +patients 0 +preferring 0 +rizatriptan 1 +and 0 +54 0 +. 0 +2 0 +% 0 +of 0 +patients 0 +who 0 +preferred 0 +ergotamine 1 +/ 0 +caffeine 1 +. 0 +The 0 +co 0 +- 0 +primary 0 +endpoint 0 +of 0 +being 0 +pain 3 +free 0 +at 0 +2 0 +h 0 +was 0 +also 0 +in 0 +favor 0 +of 0 +rizatriptan 1 +. 0 +Forty 0 +- 0 +nine 0 +percent 0 +of 0 +patients 0 +were 0 +pain 3 +free 0 +2 0 +h 0 +after 0 +rizatriptan 1 +"," 0 +compared 0 +with 0 +24 0 +. 0 +3 0 +% 0 +treated 0 +with 0 +ergotamine 1 +/ 0 +caffeine 1 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +rizatriptan 1 +being 0 +superior 0 +within 0 +1 0 +h 0 +of 0 +treatment 0 +. 0 +Headache 3 +relief 0 +at 0 +2 0 +h 0 +was 0 +75 0 +. 0 +9 0 +% 0 +for 0 +rizatriptan 1 +and 0 +47 0 +. 0 +3 0 +% 0 +for 0 +ergotamine 1 +/ 0 +caffeine 1 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +with 0 +rizatriptan 1 +being 0 +superior 0 +to 0 +ergotamine 1 +/ 0 +caffeine 1 +within 0 +30 0 +min 0 +of 0 +dosing 0 +. 0 +Almost 0 +36 0 +% 0 +of 0 +patients 0 +taking 0 +rizatriptan 1 +were 0 +pain 3 +free 0 +at 0 +2 0 +h 0 +and 0 +had 0 +no 0 +recurrence 0 +or 0 +need 0 +for 0 +additional 0 +medication 0 +within 0 +24 0 +h 0 +"," 0 +compared 0 +to 0 +20 0 +% 0 +of 0 +patients 0 +on 0 +ergotamine 1 +/ 0 +caffeine 1 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Rizatriptan 1 +was 0 +also 0 +superior 0 +to 0 +ergotamine 1 +/ 0 +caffeine 1 +in 0 +the 0 +proportions 0 +of 0 +patients 0 +with 0 +no 0 +nausea 3 +"," 0 +vomiting 3 +"," 0 +phonophobia 3 +or 0 +photophobia 3 +and 0 +for 0 +patients 0 +with 0 +normal 0 +function 0 +2 0 +h 0 +after 0 +drug 0 +intake 0 +( 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +More 0 +patients 0 +were 0 +( 0 +completely 0 +"," 0 +very 0 +or 0 +somewhat 0 +) 0 +satisfied 0 +2 0 +h 0 +after 0 +treatment 0 +with 0 +rizatriptan 1 +( 0 +69 0 +. 0 +8 0 +% 0 +) 0 +than 0 +at 0 +2 0 +h 0 +after 0 +treatment 0 +with 0 +ergotamine 1 +/ 0 +caffeine 1 +( 0 +38 0 +. 0 +6 0 +% 0 +"," 0 +p 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Recurrence 0 +rates 0 +were 0 +31 0 +. 0 +4 0 +% 0 +with 0 +rizatriptan 1 +and 0 +15 0 +. 0 +3 0 +% 0 +with 0 +ergotamine 1 +/ 0 +caffeine 1 +. 0 +Both 0 +active 0 +treatments 0 +were 0 +well 0 +tolerated 0 +. 0 +The 0 +most 0 +common 0 +adverse 0 +events 0 +( 0 +incidence 0 +> 0 +or 0 += 0 +5 0 +% 0 +in 0 +one 0 +group 0 +) 0 +after 0 +rizatriptan 1 +and 0 +ergotamine 1 +/ 0 +caffeine 1 +"," 0 +respectively 0 +"," 0 +were 0 +dizziness 3 +( 0 +6 0 +. 0 +7 0 +and 0 +5 0 +. 0 +3 0 +% 0 +) 0 +"," 0 +nausea 3 +( 0 +4 0 +. 0 +2 0 +and 0 +8 0 +. 0 +5 0 +% 0 +) 0 +and 0 +somnolence 3 +( 0 +5 0 +. 0 +5 0 +and 0 +2 0 +. 0 +3 0 +% 0 +) 0 +. 0 +Severe 0 +ocular 3 +and 4 +orbital 4 +toxicity 4 +after 0 +intracarotid 0 +injection 0 +of 0 +carboplatin 1 +for 0 +recurrent 0 +glioblastomas 3 +. 0 +BACKGR0UND 0 +: 0 +Glioblastoma 3 +is 0 +a 0 +malignant 3 +tumor 4 +that 0 +occurs 0 +in 0 +the 0 +cerebrum 0 +during 0 +adulthood 0 +. 0 +With 0 +current 0 +treatment 0 +regimens 0 +including 0 +combined 0 +surgery 0 +"," 0 +radiation 0 +and 0 +chemotherapy 0 +"," 0 +the 0 +average 0 +life 0 +expectancy 0 +of 0 +the 0 +patients 0 +is 0 +limited 0 +to 0 +approximately 0 +1 0 +year 0 +. 0 +Therefore 0 +"," 0 +patients 0 +with 0 +glioblastoma 3 +sometimes 0 +have 0 +intracarotid 0 +injection 0 +of 0 +carcinostatics 0 +added 0 +to 0 +the 0 +treatment 0 +regimen 0 +. 0 +Generally 0 +"," 0 +carboplatin 1 +is 0 +said 0 +to 0 +have 0 +milder 0 +side 0 +effects 0 +than 0 +cisplatin 1 +"," 0 +whose 0 +ocular 3 +and 4 +orbital 4 +toxicity 4 +are 0 +well 0 +known 0 +. 0 +However 0 +"," 0 +we 0 +experienced 0 +a 0 +case 0 +of 0 +severe 0 +ocular 3 +and 4 +orbital 4 +toxicity 4 +after 0 +intracarotid 0 +injection 0 +of 0 +carboplatin 1 +"," 0 +which 0 +is 0 +infrequently 0 +reported 0 +. 0 +CASE 0 +: 0 +A 0 +58 0 +- 0 +year 0 +- 0 +old 0 +man 0 +received 0 +an 0 +intracarotid 0 +injection 0 +of 0 +carboplatin 1 +for 0 +recurrent 0 +glioblastomas 3 +in 0 +his 0 +left 0 +temporal 0 +lobe 0 +. 0 +He 0 +complained 0 +of 0 +pain 3 +and 4 +visual 4 +disturbance 4 +in 4 +the 4 +ipsilateral 4 +eye 4 +30 0 +h 0 +after 0 +the 0 +injection 0 +. 0 +Various 0 +ocular 0 +symptoms 0 +and 0 +findings 0 +caused 0 +by 0 +carboplatin 1 +toxicity 3 +were 0 +seen 0 +. 0 +RESULTS 0 +: 0 +He 0 +was 0 +treated 0 +with 0 +intravenous 0 +administration 0 +of 0 +corticosteroids 0 +and 0 +glycerin 1 +for 0 +6 0 +days 0 +after 0 +the 0 +injection 0 +. 0 +Although 0 +the 0 +intraocular 0 +pressure 0 +elevation 0 +caused 0 +by 0 +secondary 0 +acute 0 +angle 0 +- 0 +closure 0 +glaucoma 3 +decreased 0 +and 0 +ocular 3 +pain 4 +diminished 0 +"," 0 +inexorable 0 +papilledema 3 +and 0 +exudative 0 +retinal 3 +detachment 4 +continued 0 +for 0 +3 0 +weeks 0 +. 0 +Finally 0 +"," 0 +6 0 +weeks 0 +later 0 +"," 0 +diffuse 0 +chorioretinal 3 +atrophy 4 +with 0 +optic 3 +atrophy 4 +occurred 0 +and 0 +the 0 +vision 0 +in 0 +his 0 +left 0 +eye 0 +was 0 +lost 0 +. 0 +C0NCLUSI0N 0 +: 0 +When 0 +performing 0 +intracarotid 0 +injection 0 +of 0 +carboplatin 1 +"," 0 +we 0 +must 0 +be 0 +aware 0 +of 0 +its 0 +potentially 0 +blinding 0 +ocular 3 +toxicity 4 +. 0 +It 0 +is 0 +recommended 0 +that 0 +further 0 +studies 0 +and 0 +investigations 0 +are 0 +undertaken 0 +in 0 +the 0 +effort 0 +to 0 +minimize 0 +such 0 +severe 0 +side 0 +effects 0 +. 0 +Visual 3 +hallucinations 4 +associated 0 +with 0 +zonisamide 1 +. 0 +Zonisamide 1 +is 0 +a 0 +broad 0 +- 0 +spectrum 0 +antiepileptic 0 +drug 0 +used 0 +to 0 +treat 0 +various 0 +types 0 +of 0 +seizures 3 +. 0 +Although 0 +visual 3 +hallucinations 4 +have 0 +not 0 +been 0 +reported 0 +as 0 +an 0 +adverse 0 +effect 0 +of 0 +this 0 +agent 0 +"," 0 +we 0 +describe 0 +three 0 +patients 0 +who 0 +experienced 0 +complex 0 +visual 3 +hallucinations 4 +and 0 +altered 0 +mental 0 +status 0 +after 0 +zonisamide 1 +treatment 0 +was 0 +begun 0 +or 0 +its 0 +dosage 0 +increased 0 +. 0 +All 0 +three 0 +had 0 +been 0 +diagnosed 0 +earlier 0 +with 0 +epilepsy 3 +"," 0 +and 0 +their 0 +electroencephalogram 0 +( 0 +EEG 0 +) 0 +findings 0 +were 0 +abnormal 0 +. 0 +During 0 +monitoring 0 +"," 0 +visual 3 +hallucinations 4 +did 0 +not 0 +correlate 0 +with 0 +EEG 0 +readings 0 +"," 0 +nor 0 +did 0 +video 0 +recording 0 +capture 0 +any 0 +of 0 +the 0 +described 0 +events 0 +. 0 +None 0 +of 0 +the 0 +patients 0 +had 0 +experienced 0 +visual 3 +hallucinations 4 +before 0 +this 0 +event 0 +. 0 +The 0 +only 0 +recent 0 +change 0 +in 0 +their 0 +treatment 0 +was 0 +the 0 +introduction 0 +or 0 +increased 0 +dosage 0 +of 0 +zonisamide 1 +. 0 +With 0 +either 0 +discontinuation 0 +or 0 +decreased 0 +dosage 0 +of 0 +the 0 +drug 0 +the 0 +symptoms 0 +disappeared 0 +and 0 +did 0 +not 0 +recur 0 +. 0 +Further 0 +observations 0 +and 0 +reports 0 +will 0 +help 0 +clarify 0 +this 0 +adverse 0 +effect 0 +. 0 +Until 0 +then 0 +"," 0 +clinicians 0 +need 0 +to 0 +be 0 +aware 0 +of 0 +this 0 +possible 0 +complication 0 +associated 0 +with 0 +zonisamide 1 +. 0 +Anti 0 +- 0 +epileptic 3 +drugs 0 +- 0 +induced 0 +de 0 +novo 0 +absence 3 +seizures 4 +. 0 +The 0 +authors 0 +present 0 +three 0 +patients 0 +with 0 +de 0 +novo 0 +absence 3 +epilepsy 4 +after 0 +administration 0 +of 0 +carbamazepine 1 +and 0 +vigabatrin 1 +. 0 +Despite 0 +the 0 +underlying 0 +diseases 0 +"," 0 +the 0 +prognosis 0 +for 0 +drug 0 +- 0 +induced 0 +de 0 +novo 0 +absence 3 +seizure 4 +is 0 +good 0 +because 0 +it 0 +subsides 0 +rapidly 0 +after 0 +discontinuing 0 +the 0 +use 0 +of 0 +the 0 +offending 0 +drugs 0 +. 0 +The 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +- 0 +transmitted 0 +thalamocortical 0 +circuitry 0 +accounts 0 +for 0 +a 0 +major 0 +part 0 +of 0 +the 0 +underlying 0 +neurophysiology 0 +of 0 +the 0 +absence 3 +epilepsy 4 +. 0 +Because 0 +drug 0 +- 0 +induced 0 +de 0 +novo 0 +absence 3 +seizure 4 +is 0 +rare 0 +"," 0 +pro 0 +- 0 +absence 0 +drugs 0 +can 0 +only 0 +be 0 +considered 0 +a 0 +promoting 0 +factor 0 +. 0 +The 0 +underlying 0 +epileptogenecity 0 +of 0 +the 0 +patients 0 +or 0 +the 0 +synergistic 0 +effects 0 +of 0 +the 0 +accompanying 0 +drugs 0 +is 0 +required 0 +to 0 +trigger 0 +the 0 +de 0 +novo 0 +absence 3 +seizure 4 +. 0 +The 0 +possibility 0 +of 0 +drug 0 +- 0 +induced 0 +aggravation 0 +should 0 +be 0 +considered 0 +whenever 0 +an 0 +unexpected 0 +increase 0 +in 0 +seizure 3 +frequency 0 +and 0 +/ 0 +or 0 +new 0 +seizure 3 +types 0 +appear 0 +following 0 +a 0 +change 0 +in 0 +drug 0 +treatment 0 +. 0 +By 0 +understanding 0 +the 0 +underlying 0 +mechanism 0 +of 0 +absence 3 +epilepsy 4 +"," 0 +we 0 +can 0 +avoid 0 +the 0 +inappropriate 0 +use 0 +of 0 +anticonvulsants 0 +in 0 +children 0 +with 0 +epilepsy 3 +and 0 +prevent 0 +drug 0 +- 0 +induced 0 +absence 3 +seizures 4 +. 0 +Prenatal 0 +dexamethasone 1 +programs 0 +hypertension 3 +and 0 +renal 3 +injury 4 +in 0 +the 0 +rat 0 +. 0 +Dexamethasone 0 +is 0 +frequently 0 +administered 0 +to 0 +the 0 +developing 0 +fetus 0 +to 0 +accelerate 0 +pulmonary 0 +development 0 +. 0 +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +determine 0 +if 0 +prenatal 0 +dexamethasone 1 +programmed 0 +a 0 +progressive 0 +increase 3 +in 4 +blood 4 +pressure 4 +and 0 +renal 3 +injury 4 +in 0 +rats 0 +. 0 +Pregnant 0 +rats 0 +were 0 +given 0 +either 0 +vehicle 0 +or 0 +2 0 +daily 0 +intraperitoneal 0 +injections 0 +of 0 +dexamethasone 1 +( 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +body 0 +weight 0 +) 0 +on 0 +gestational 0 +days 0 +11 0 +and 0 +12 0 +"," 0 +13 0 +and 0 +14 0 +"," 0 +15 0 +and 0 +16 0 +"," 0 +17 0 +and 0 +18 0 +"," 0 +or 0 +19 0 +and 0 +20 0 +. 0 +0ffspring 0 +of 0 +rats 0 +administered 0 +dexamethasone 1 +on 0 +days 0 +15 0 +and 0 +16 0 +gestation 0 +had 0 +a 0 +20 0 +% 0 +reduction 3 +in 4 +glomerular 4 +number 4 +compared 0 +with 0 +control 0 +at 0 +6 0 +to 0 +9 0 +months 0 +of 0 +age 0 +( 0 +22 0 +527 0 ++ 0 +/ 0 +- 0 +509 0 +versus 0 +28 0 +50 0 ++ 0 +/ 0 +- 0 +561 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +which 0 +was 0 +comparable 0 +to 0 +the 0 +percent 0 +reduction 0 +in 0 +glomeruli 0 +measured 0 +at 0 +3 0 +weeks 0 +of 0 +age 0 +. 0 +Six 0 +- 0 +to 0 +9 0 +- 0 +month 0 +old 0 +rats 0 +receiving 0 +prenatal 0 +dexamethasone 1 +on 0 +days 0 +17 0 +and 0 +18 0 +of 0 +gestation 0 +had 0 +a 0 +17 0 +% 0 +reduction 0 +in 0 +glomeruli 0 +( 0 +23 0 +380 0 ++ 0 +/ 0 +- 0 +587 0 +) 0 +compared 0 +with 0 +control 0 +rats 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Male 0 +rats 0 +that 0 +received 0 +prenatal 0 +dexamethasone 1 +on 0 +days 0 +15 0 +and 0 +16 0 +"," 0 +17 0 +and 0 +18 0 +"," 0 +and 0 +13 0 +and 0 +14 0 +of 0 +gestation 0 +had 0 +elevated 3 +blood 4 +pressures 4 +at 0 +6 0 +months 0 +of 0 +age 0 +; 0 +the 0 +latter 0 +group 0 +did 0 +not 0 +have 0 +a 0 +reduction 3 +in 4 +glomerular 4 +number 4 +. 0 +Adult 0 +rats 0 +given 0 +dexamethasone 1 +on 0 +days 0 +15 0 +and 0 +16 0 +of 0 +gestation 0 +had 0 +more 0 +glomeruli 0 +with 0 +glomerulosclerosis 3 +than 0 +control 0 +rats 0 +. 0 +This 0 +study 0 +shows 0 +that 0 +prenatal 0 +dexamethasone 1 +in 0 +rats 0 +results 0 +in 0 +a 0 +reduction 3 +in 4 +glomerular 4 +number 4 +"," 0 +glomerulosclerosis 3 +"," 0 +and 0 +hypertension 3 +when 0 +administered 0 +at 0 +specific 0 +points 0 +during 0 +gestation 0 +. 0 +Hypertension 3 +was 0 +observed 0 +in 0 +animals 0 +that 0 +had 0 +a 0 +reduction 0 +in 0 +glomeruli 0 +as 0 +well 0 +as 0 +in 0 +a 0 +group 0 +that 0 +did 0 +not 0 +have 0 +a 0 +reduction 3 +in 4 +glomerular 4 +number 4 +"," 0 +suggesting 0 +that 0 +a 0 +reduction 3 +in 4 +glomerular 4 +number 4 +is 0 +not 0 +the 0 +sole 0 +cause 0 +for 0 +the 0 +development 0 +of 0 +hypertension 3 +. 0 +Kidney 0 +function 0 +and 0 +morphology 0 +after 0 +short 0 +- 0 +term 0 +combination 0 +therapy 0 +with 0 +cyclosporine 1 +A 2 +"," 0 +tacrolimus 1 +and 0 +sirolimus 1 +in 0 +the 0 +rat 0 +. 0 +BACKGR0UND 0 +: 0 +Sirolimus 1 +( 0 +SRL 1 +) 0 +may 0 +supplement 0 +calcineurin 0 +inhibitors 0 +in 0 +clinical 0 +organ 0 +transplantation 0 +. 0 +These 0 +are 0 +nephrotoxic 3 +"," 0 +but 0 +SRL 1 +seems 0 +to 0 +act 0 +differently 0 +displaying 0 +only 0 +minor 0 +nephrotoxic 3 +effects 0 +"," 0 +although 0 +this 0 +question 0 +is 0 +still 0 +open 0 +. 0 +In 0 +a 0 +number 0 +of 0 +treatment 0 +protocols 0 +where 0 +SRL 1 +was 0 +combined 0 +with 0 +a 0 +calcineurin 0 +inhibitor 0 +indications 0 +of 0 +a 0 +synergistic 0 +nephrotoxic 3 +effect 0 +were 0 +described 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +examine 0 +further 0 +the 0 +renal 0 +function 0 +"," 0 +including 0 +morphological 0 +analysis 0 +of 0 +the 0 +kidneys 0 +of 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +treated 0 +with 0 +either 0 +cyclosporine 1 +A 2 +( 0 +CsA 1 +) 0 +"," 0 +tacrolimus 1 +( 0 +FK506 1 +) 0 +or 0 +SRL 1 +as 0 +monotherapies 0 +or 0 +in 0 +different 0 +combinations 0 +. 0 +METH0DS 0 +: 0 +For 0 +a 0 +period 0 +of 0 +2 0 +weeks 0 +"," 0 +CsA 1 +15 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +( 0 +given 0 +orally 0 +) 0 +"," 0 +FK506 1 +3 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +( 0 +given 0 +orally 0 +) 0 +or 0 +SRL 1 +0 0 +. 0 +4 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +( 0 +given 0 +intraperitoneally 0 +) 0 +was 0 +administered 0 +once 0 +a 0 +day 0 +as 0 +these 0 +doses 0 +have 0 +earlier 0 +been 0 +found 0 +to 0 +achieve 0 +a 0 +significant 0 +immunosuppressive 0 +effect 0 +in 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +. 0 +In 0 +the 0 +' 0 +conscious 0 +catheterized 0 +rat 0 +' 0 +model 0 +"," 0 +the 0 +glomerular 0 +filtration 0 +rate 0 +( 0 +GFR 0 +) 0 +was 0 +measured 0 +as 0 +the 0 +clearance 0 +of 0 +Cr 0 +( 0 +EDTA 0 +) 0 +. 0 +The 0 +morphological 0 +analysis 0 +of 0 +the 0 +kidneys 0 +included 0 +a 0 +semi 0 +- 0 +quantitative 0 +scoring 0 +system 0 +analysing 0 +the 0 +degree 0 +of 0 +striped 0 +fibrosis 3 +"," 0 +subcapsular 0 +fibrosis 3 +and 0 +the 0 +number 0 +of 0 +basophilic 0 +tubules 0 +"," 0 +plus 0 +an 0 +additional 0 +stereological 0 +analysis 0 +of 0 +the 0 +total 0 +grade 0 +of 0 +fibrosis 3 +in 0 +the 0 +cortex 0 +stained 0 +with 0 +Sirius 0 +Red 0 +. 0 +RESULTS 0 +: 0 +CsA 1 +"," 0 +FK506 1 +and 0 +SRL 1 +all 0 +significantly 0 +decreased 0 +the 0 +GFR 0 +. 0 +A 0 +further 0 +deterioration 0 +was 0 +seen 0 +when 0 +CsA 1 +was 0 +combined 0 +with 0 +either 0 +FK506 1 +or 0 +SRL 1 +"," 0 +whereas 0 +the 0 +GFR 0 +remained 0 +unchanged 0 +in 0 +the 0 +group 0 +treated 0 +with 0 +FK506 1 +plus 0 +SRL 1 +when 0 +compared 0 +with 0 +treatment 0 +with 0 +any 0 +of 0 +the 0 +single 0 +substances 0 +. 0 +The 0 +morphological 0 +changes 0 +presented 0 +a 0 +similar 0 +pattern 0 +. 0 +The 0 +semi 0 +- 0 +quantitative 0 +scoring 0 +was 0 +significantly 0 +worst 0 +in 0 +the 0 +group 0 +treated 0 +with 0 +CsA 1 +plus 0 +SRL 1 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +compared 0 +with 0 +controls 0 +) 0 +and 0 +the 0 +analysis 0 +of 0 +the 0 +total 0 +grade 0 +of 0 +fibrosis 3 +also 0 +showed 0 +the 0 +highest 0 +proportion 0 +in 0 +the 0 +same 0 +group 0 +and 0 +was 0 +significantly 0 +different 0 +from 0 +controls 0 +( 0 +P 0 +< 0 +0 0 +. 0 +2 0 +) 0 +. 0 +The 0 +FK506 1 +plus 0 +SRL 1 +combination 0 +showed 0 +only 0 +a 0 +marginally 0 +higher 0 +degree 0 +of 0 +fibrosis 3 +as 0 +compared 0 +with 0 +controls 0 +( 0 +P 0 += 0 +0 0 +. 0 +5 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +rat 0 +study 0 +demonstrated 0 +a 0 +synergistic 0 +nephrotoxic 3 +effect 0 +of 0 +CsA 1 +plus 0 +SRL 1 +"," 0 +whereas 0 +FK506 1 +plus 0 +SRL 1 +was 0 +better 0 +tolerated 0 +. 0 +Evaluation 0 +of 0 +cardiac 0 +troponin 0 +I 0 +and 0 +T 0 +levels 0 +as 0 +markers 0 +of 0 +myocardial 3 +damage 4 +in 0 +doxorubicin 1 +- 0 +induced 0 +cardiomyopathy 3 +rats 0 +"," 0 +and 0 +their 0 +relationship 0 +with 0 +echocardiographic 0 +and 0 +histological 0 +findings 0 +. 0 +BACKGR0UND 0 +: 0 +Cardiac 0 +troponins 0 +I 0 +( 0 +cTnI 0 +) 0 +and 0 +T 0 +( 0 +cTnT 0 +) 0 +have 0 +been 0 +shown 0 +to 0 +be 0 +highly 0 +sensitive 0 +and 0 +specific 0 +markers 0 +of 0 +myocardial 3 +cell 4 +injury 4 +. 0 +We 0 +investigated 0 +the 0 +diagnostic 0 +value 0 +of 0 +cTnI 0 +and 0 +cTnT 0 +for 0 +the 0 +diagnosis 0 +of 0 +myocardial 3 +damage 4 +in 0 +a 0 +rat 0 +model 0 +of 0 +doxorubicin 1 +( 0 +D0X 1 +) 0 +- 0 +induced 0 +cardiomyopathy 3 +"," 0 +and 0 +we 0 +examined 0 +the 0 +relationship 0 +between 0 +serial 0 +cTnI 0 +and 0 +cTnT 0 +with 0 +the 0 +development 0 +of 0 +cardiac 3 +disorders 4 +monitored 0 +by 0 +echocardiography 0 +and 0 +histological 0 +examinations 0 +in 0 +this 0 +model 0 +. 0 +METH0DS 0 +: 0 +Thirty 0 +- 0 +five 0 +Wistar 0 +rats 0 +were 0 +given 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +D0X 1 +"," 0 +i 0 +. 0 +v 0 +. 0 +"," 0 +weekly 0 +for 0 +up 0 +to 0 +8 0 +weeks 0 +for 0 +a 0 +total 0 +cumulative 0 +dose 0 +of 0 +12 0 +mg 0 +/ 0 +kg 0 +BW 0 +. 0 +Ten 0 +rats 0 +received 0 +saline 0 +as 0 +a 0 +control 0 +group 0 +. 0 +cTnI 0 +was 0 +measured 0 +with 0 +Access 0 +( 0 +R 0 +) 0 +( 0 +ng 0 +/ 0 +ml 0 +) 0 +and 0 +a 0 +research 0 +immunoassay 0 +( 0 +pg 0 +/ 0 +ml 0 +) 0 +"," 0 +and 0 +compared 0 +with 0 +cTnT 0 +"," 0 +CK 0 +- 0 +MB 0 +mass 0 +and 0 +CK 0 +. 0 +By 0 +using 0 +transthoracic 0 +echocardiography 0 +"," 0 +anterior 0 +and 0 +posterior 0 +wall 0 +thickness 0 +"," 0 +LV 0 +diameters 0 +and 0 +LV 0 +fractional 0 +shortening 0 +( 0 +FS 0 +) 0 +were 0 +measured 0 +in 0 +all 0 +rats 0 +before 0 +D0X 1 +or 0 +saline 0 +"," 0 +and 0 +at 0 +weeks 0 +6 0 +and 0 +9 0 +after 0 +treatment 0 +in 0 +all 0 +surviving 0 +rats 0 +. 0 +Histology 0 +was 0 +performed 0 +in 0 +D0X 1 +- 0 +rats 0 +at 0 +6 0 +and 0 +9 0 +weeks 0 +after 0 +the 0 +last 0 +D0X 1 +dose 0 +and 0 +in 0 +all 0 +controls 0 +. 0 +RESULTS 0 +: 0 +Eighteen 0 +of 0 +the 0 +D0X 1 +rats 0 +died 0 +prematurely 0 +of 0 +general 0 +toxicity 3 +during 0 +the 0 +9 0 +- 0 +week 0 +period 0 +. 0 +End 0 +- 0 +diastolic 0 +( 0 +ED 0 +) 0 +and 0 +end 0 +- 0 +systolic 0 +( 0 +ES 0 +) 0 +LV 0 +diameters 0 +/ 0 +BW 0 +significantly 0 +increased 0 +"," 0 +whereas 0 +LV 0 +FS 0 +was 0 +decreased 0 +after 0 +9 0 +weeks 0 +in 0 +the 0 +D0X 1 +group 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +These 0 +parameters 0 +remained 0 +unchanged 0 +in 0 +controls 0 +. 0 +Histological 0 +evaluation 0 +of 0 +hearts 0 +from 0 +all 0 +rats 0 +given 0 +D0X 1 +revealed 0 +significant 0 +slight 0 +degrees 0 +of 0 +perivascular 0 +and 0 +interstitial 0 +fibrosis 3 +. 0 +In 0 +7 0 +of 0 +the 0 +18 0 +rats 0 +"," 0 +degeneration 0 +and 0 +myocyte 0 +vacuolisation 0 +were 0 +found 0 +. 0 +0nly 0 +five 0 +of 0 +the 0 +controls 0 +exhibited 0 +evidence 0 +of 0 +very 0 +slight 0 +perivascular 0 +fibrosis 3 +. 0 +A 0 +significant 0 +rise 0 +in 0 +cTnT 0 +was 0 +found 0 +in 0 +D0X 1 +rats 0 +after 0 +cumulative 0 +doses 0 +of 0 +7 0 +. 0 +5 0 +and 0 +12 0 +mg 0 +/ 0 +kg 0 +in 0 +comparison 0 +with 0 +baseline 0 +( 0 +p 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +cTnT 0 +found 0 +in 0 +rats 0 +after 0 +12 0 +mg 0 +/ 0 +kg 0 +were 0 +significantly 0 +greater 0 +than 0 +that 0 +found 0 +after 0 +7 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +D0X 1 +. 0 +Maximal 0 +cTnI 0 +( 0 +pg 0 +/ 0 +ml 0 +) 0 +and 0 +cTnT 0 +levels 0 +were 0 +significantly 0 +increased 0 +in 0 +D0X 1 +rats 0 +compared 0 +with 0 +controls 0 +( 0 +p 0 += 0 +0 0 +. 0 +6 0 +"," 0 +0 0 +. 0 +7 0 +) 0 +. 0 +cTnI 0 +( 0 +ng 0 +/ 0 +ml 0 +) 0 +"," 0 +CK 0 +- 0 +MB 0 +mass 0 +and 0 +CK 0 +remained 0 +unchanged 0 +in 0 +D0X 1 +rats 0 +compared 0 +with 0 +controls 0 +. 0 +All 0 +markers 0 +remained 0 +stable 0 +in 0 +controls 0 +. 0 +Analysis 0 +of 0 +data 0 +revealed 0 +a 0 +significant 0 +correlation 0 +between 0 +maximal 0 +cTnT 0 +and 0 +ED 0 +and 0 +ES 0 +LV 0 +diameters 0 +/ 0 +BW 0 +( 0 +r 0 += 0 +0 0 +. 0 +81 0 +and 0 +0 0 +. 0 +65 0 +; 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +A 0 +significant 0 +relationship 0 +was 0 +observed 0 +between 0 +maximal 0 +cTnT 0 +and 0 +the 0 +extent 0 +of 0 +myocardial 0 +morphological 0 +changes 0 +"," 0 +and 0 +between 0 +LV 0 +diameters 0 +/ 0 +BW 0 +and 0 +histological 0 +findings 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Among 0 +markers 0 +of 0 +ischemic 3 +injury 4 +after 0 +D0X 1 +in 0 +rats 0 +"," 0 +cTnT 0 +showed 0 +the 0 +greatest 0 +ability 0 +to 0 +detect 0 +myocardial 3 +damage 4 +assessed 0 +by 0 +echocardiographic 0 +detection 0 +and 0 +histological 0 +changes 0 +. 0 +Although 0 +there 0 +was 0 +a 0 +discrepancy 0 +between 0 +the 0 +amount 0 +of 0 +cTnI 0 +and 0 +cTnT 0 +after 0 +D0X 1 +"," 0 +probably 0 +due 0 +to 0 +heterogeneity 0 +in 0 +cross 0 +- 0 +reactivities 0 +of 0 +mAbs 0 +to 0 +various 0 +cTnI 0 +and 0 +cTnT 0 +forms 0 +"," 0 +it 0 +is 0 +likely 0 +that 0 +cTnT 0 +in 0 +rats 0 +after 0 +D0X 1 +indicates 0 +cell 0 +damage 0 +determined 0 +by 0 +the 0 +magnitude 0 +of 0 +injury 0 +induced 0 +and 0 +that 0 +cTnT 0 +should 0 +be 0 +a 0 +useful 0 +marker 0 +for 0 +the 0 +prediction 0 +of 0 +experimentally 0 +induced 0 +cardiotoxicity 3 +and 0 +possibly 0 +for 0 +cardioprotective 0 +experiments 0 +. 0 +0ctreotide 1 +- 0 +induced 0 +hypoxemia 3 +and 0 +pulmonary 3 +hypertension 4 +in 0 +premature 0 +neonates 0 +. 0 +The 0 +authors 0 +report 0 +2 0 +cases 0 +of 0 +premature 0 +neonates 0 +who 0 +had 0 +enterocutaneous 0 +fistula 3 +complicating 0 +necrotizing 3 +enterocolitis 4 +. 0 +Pulmonary 3 +hypertension 4 +developed 0 +after 0 +administration 0 +of 0 +a 0 +somatostatin 0 +analogue 0 +"," 0 +octreotide 1 +"," 0 +to 0 +enhance 0 +resolution 0 +of 0 +the 0 +fistula 3 +. 0 +The 0 +authors 0 +discuss 0 +the 0 +mechanism 0 +of 0 +the 0 +occurrence 0 +of 0 +this 0 +complication 0 +and 0 +recommend 0 +caution 0 +of 0 +its 0 +use 0 +in 0 +high 0 +- 0 +risk 0 +premature 0 +neonates 0 +. 0 +The 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +in 0 +women 0 +prescribed 0 +cyproterone 1 +acetate 2 +in 0 +combination 0 +with 0 +ethinyl 1 +estradiol 2 +: 0 +a 0 +nested 0 +cohort 0 +analysis 0 +and 0 +case 0 +- 0 +control 0 +study 0 +. 0 +BACKGR0UND 0 +: 0 +Cyproterone 1 +acetate 2 +combined 0 +with 0 +ethinyl 1 +estradiol 2 +( 0 +CPA 1 +/ 0 +EE 1 +) 0 +is 0 +licensed 0 +in 0 +the 0 +UK 0 +for 0 +the 0 +treatment 0 +of 0 +women 0 +with 0 +acne 3 +and 0 +hirsutism 3 +and 0 +is 0 +also 0 +a 0 +treatment 0 +option 0 +for 0 +polycystic 3 +ovary 4 +syndrome 4 +( 0 +PC0S 3 +) 0 +. 0 +Previous 0 +studies 0 +have 0 +demonstrated 0 +an 0 +increased 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +( 0 +VTE 3 +) 0 +associated 0 +with 0 +CPA 1 +/ 0 +EE 1 +compared 0 +with 0 +conventional 0 +combined 0 +oral 1 +contraceptives 2 +( 0 +C0Cs 0 +) 0 +. 0 +We 0 +believe 0 +the 0 +results 0 +of 0 +those 0 +studies 0 +may 0 +have 0 +been 0 +affected 0 +by 0 +residual 0 +confounding 0 +. 0 +METH0DS 0 +: 0 +Using 0 +the 0 +General 0 +Practice 0 +Research 0 +Database 0 +we 0 +conducted 0 +a 0 +cohort 0 +analysis 0 +and 0 +case 0 +- 0 +control 0 +study 0 +nested 0 +within 0 +a 0 +population 0 +of 0 +women 0 +aged 0 +between 0 +15 0 +and 0 +39 0 +years 0 +with 0 +acne 3 +"," 0 +hirsutism 3 +or 0 +PC0S 3 +to 0 +estimate 0 +the 0 +risk 0 +of 0 +VTE 3 +associated 0 +with 0 +CPA 1 +/ 0 +EE 1 +. 0 +RESULTS 0 +: 0 +The 0 +age 0 +- 0 +adjusted 0 +incidence 0 +rate 0 +ratio 0 +for 0 +CPA 1 +/ 0 +EE 1 +versus 0 +conventional 0 +C0Cs 0 +was 0 +2 0 +. 0 +20 0 +[ 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +1 0 +. 0 +35 0 +- 0 +3 0 +. 0 +58 0 +] 0 +. 0 +Using 0 +as 0 +the 0 +reference 0 +group 0 +women 0 +who 0 +were 0 +not 0 +using 0 +oral 0 +contraception 0 +"," 0 +had 0 +no 0 +recent 0 +pregnancy 0 +or 0 +menopausal 0 +symptoms 0 +"," 0 +the 0 +case 0 +- 0 +control 0 +analysis 0 +gave 0 +an 0 +adjusted 0 +odds 0 +ratio 0 +( 0 +0R 0 +( 0 +adj 0 +) 0 +) 0 +of 0 +7 0 +. 0 +44 0 +( 0 +95 0 +% 0 +CI 0 +3 0 +. 0 +67 0 +- 0 +15 0 +. 0 +8 0 +) 0 +for 0 +CPA 1 +/ 0 +EE 1 +use 0 +compared 0 +with 0 +an 0 +0R 0 +( 0 +adj 0 +) 0 +of 0 +2 0 +. 0 +58 0 +( 0 +95 0 +% 0 +CI 0 +1 0 +. 0 +60 0 +- 0 +4 0 +. 0 +18 0 +) 0 +for 0 +use 0 +of 0 +conventional 0 +C0Cs 0 +. 0 +C0NCLUSI0NS 0 +: 0 +We 0 +have 0 +demonstrated 0 +an 0 +increased 0 +risk 0 +of 0 +VTE 3 +associated 0 +with 0 +the 0 +use 0 +of 0 +CPA 1 +/ 0 +EE 1 +in 0 +women 0 +with 0 +acne 3 +"," 0 +hirsutism 3 +or 0 +PC0S 3 +although 0 +residual 0 +confounding 0 +by 0 +indication 0 +cannot 0 +be 0 +excluded 0 +. 0 +The 0 +effect 0 +of 0 +treatment 0 +with 0 +gum 1 +Arabic 2 +on 0 +gentamicin 1 +nephrotoxicity 3 +in 0 +rats 0 +: 0 +a 0 +preliminary 0 +study 0 +. 0 +In 0 +the 0 +present 0 +work 0 +we 0 +assessed 0 +the 0 +effect 0 +of 0 +treatment 0 +of 0 +rats 0 +with 0 +gum 1 +Arabic 2 +on 0 +acute 3 +renal 4 +failure 4 +induced 0 +by 0 +gentamicin 1 +( 0 +GM 1 +) 0 +nephrotoxicity 3 +. 0 +Rats 0 +were 0 +treated 0 +with 0 +the 0 +vehicle 0 +( 0 +2 0 +mL 0 +/ 0 +kg 0 +of 0 +distilled 0 +water 0 +and 0 +5 0 +% 0 +w 0 +/ 0 +v 0 +cellulose 0 +"," 0 +10 0 +days 0 +) 0 +"," 0 +gum 1 +Arabic 2 +( 0 +2 0 +mL 0 +/ 0 +kg 0 +of 0 +a 0 +10 0 +% 0 +w 0 +/ 0 +v 0 +aqueous 0 +suspension 0 +of 0 +gum 1 +Arabic 2 +powder 0 +"," 0 +orally 0 +for 0 +10 0 +days 0 +) 0 +"," 0 +or 0 +gum 1 +Arabic 2 +concomitantly 0 +with 0 +GM 1 +( 0 +80mg 0 +/ 0 +kg 0 +/ 0 +day 0 +intramuscularly 0 +"," 0 +during 0 +the 0 +last 0 +six 0 +days 0 +of 0 +the 0 +treatment 0 +period 0 +) 0 +. 0 +Nephrotoxicity 3 +was 0 +assessed 0 +by 0 +measuring 0 +the 0 +concentrations 0 +of 0 +creatinine 1 +and 0 +urea 1 +in 0 +the 0 +plasma 0 +and 0 +reduced 0 +glutathione 1 +( 0 +GSH 1 +) 0 +in 0 +the 0 +kidney 0 +cortex 0 +"," 0 +and 0 +by 0 +light 0 +microscopic 0 +examination 0 +of 0 +kidney 0 +sections 0 +. 0 +The 0 +results 0 +indicated 0 +that 0 +concomitant 0 +treatment 0 +with 0 +gum 1 +Arabic 2 +and 0 +GM 1 +significantly 0 +increased 0 +creatinine 1 +and 0 +urea 1 +by 0 +about 0 +183 0 +and 0 +239 0 +% 0 +"," 0 +respectively 0 +( 0 +compared 0 +to 0 +432 0 +and 0 +346 0 +% 0 +"," 0 +respectively 0 +"," 0 +in 0 +rats 0 +treated 0 +with 0 +cellulose 0 +and 0 +GM 1 +) 0 +"," 0 +and 0 +decreased 0 +that 0 +of 0 +cortical 0 +GSH 1 +by 0 +21 0 +% 0 +( 0 +compared 0 +to 0 +27 0 +% 0 +in 0 +the 0 +cellulose 0 +plus 0 +GM 1 +group 0 +) 0 +The 0 +GM 1 +- 0 +induced 0 +proximal 0 +tubular 3 +necrosis 4 +appeared 0 +to 0 +be 0 +slightly 0 +less 0 +severe 0 +in 0 +rats 0 +given 0 +GM 1 +together 0 +with 0 +gum 1 +Arabic 2 +than 0 +in 0 +those 0 +given 0 +GM 1 +and 0 +cellulose 0 +. 0 +It 0 +could 0 +be 0 +inferred 0 +that 0 +gum 1 +Arabic 2 +treatment 0 +has 0 +induced 0 +a 0 +modest 0 +amelioration 0 +of 0 +some 0 +of 0 +the 0 +histological 0 +and 0 +biochemical 0 +indices 0 +of 0 +GM 1 +nephrotoxicity 3 +. 0 +Further 0 +work 0 +is 0 +warranted 0 +on 0 +the 0 +effect 0 +of 0 +the 0 +treatments 0 +on 0 +renal 0 +functional 0 +aspects 0 +in 0 +models 0 +of 0 +chronic 3 +renal 4 +failure 4 +"," 0 +and 0 +on 0 +the 0 +mechanism 0 +( 0 +s 0 +) 0 +involved 0 +. 0 +Increased 0 +frequency 0 +of 0 +venous 3 +thromboembolism 4 +with 0 +the 0 +combination 0 +of 0 +docetaxel 1 +and 0 +thalidomide 1 +in 0 +patients 0 +with 0 +metastatic 0 +androgen 0 +- 0 +independent 0 +prostate 3 +cancer 4 +. 0 +STUDY 0 +0BJECTIVE 0 +: 0 +To 0 +evaluate 0 +the 0 +frequency 0 +of 0 +venous 3 +thromboembolism 4 +( 0 +VTE 3 +) 0 +in 0 +patients 0 +with 0 +advanced 0 +androgen 0 +- 0 +independent 0 +prostate 3 +cancer 4 +who 0 +were 0 +treated 0 +with 0 +docetaxel 1 +alone 0 +or 0 +in 0 +combination 0 +with 0 +thalidomide 1 +. 0 +DESIGN 0 +: 0 +Retrospective 0 +analysis 0 +of 0 +a 0 +randomized 0 +phase 0 +II 0 +trial 0 +. 0 +SETTING 0 +: 0 +National 0 +Institutes 0 +of 0 +Health 0 +clinical 0 +research 0 +center 0 +. 0 +PATIENTS 0 +: 0 +Seventy 0 +men 0 +"," 0 +aged 0 +50 0 +- 0 +80 0 +years 0 +"," 0 +with 0 +advanced 0 +androgen 0 +- 0 +independent 0 +prostate 3 +cancer 4 +. 0 +INTERVENTI0N 0 +: 0 +Each 0 +patient 0 +received 0 +either 0 +intravenous 0 +docetaxel 1 +30 0 +mg 0 +/ 0 +m2 0 +/ 0 +week 0 +for 0 +3 0 +consecutive 0 +weeks 0 +"," 0 +followed 0 +by 0 +1 0 +week 0 +off 0 +"," 0 +or 0 +the 0 +combination 0 +of 0 +continuous 0 +oral 0 +thalidomide 1 +200 0 +mg 0 +every 0 +evening 0 +plus 0 +the 0 +same 0 +docetaxel 1 +regimen 0 +. 0 +This 0 +4 0 +- 0 +week 0 +cycle 0 +was 0 +repeated 0 +until 0 +there 0 +was 0 +evidence 0 +of 0 +excessive 0 +toxicity 3 +or 0 +disease 0 +progression 0 +. 0 +MEASUREMENTS 0 +AND 0 +MAIN 0 +RESULTS 0 +: 0 +None 0 +of 0 +23 0 +patients 0 +who 0 +received 0 +docetaxel 1 +alone 0 +developed 0 +VTE 3 +"," 0 +whereas 0 +9 0 +of 0 +47 0 +patients 0 +( 0 +19 0 +% 0 +) 0 +who 0 +received 0 +docetaxel 1 +plus 0 +thalidomide 1 +developed 0 +VTE 3 +( 0 +p 0 += 0 +0 0 +. 0 +25 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +The 0 +addition 0 +of 0 +thalidomide 1 +to 0 +docetaxel 1 +in 0 +the 0 +treatment 0 +of 0 +prostate 3 +cancer 4 +significantly 0 +increases 0 +the 0 +frequency 0 +of 0 +VTE 3 +. 0 +Clinicians 0 +should 0 +be 0 +aware 0 +of 0 +this 0 +potential 0 +complication 0 +when 0 +adding 0 +thalidomide 1 +to 0 +chemotherapeutic 0 +regimens 0 +. 0 +Ticlopidine 1 +- 0 +induced 0 +cholestatic 3 +hepatitis 4 +. 0 +0BJECTIVE 0 +: 0 +To 0 +report 0 +2 0 +cases 0 +of 0 +ticlopidine 1 +- 0 +induced 0 +cholestatic 3 +hepatitis 4 +"," 0 +investigate 0 +its 0 +mechanism 0 +"," 0 +and 0 +compare 0 +the 0 +observed 0 +main 0 +characteristics 0 +with 0 +those 0 +of 0 +the 0 +published 0 +cases 0 +. 0 +CASE 0 +SUMMARIES 0 +: 0 +Two 0 +patients 0 +developed 0 +prolonged 0 +cholestatic 3 +hepatitis 4 +after 0 +receiving 0 +ticlopidine 1 +following 0 +percutaneous 0 +coronary 0 +angioplasty 0 +"," 0 +with 0 +complete 0 +remission 0 +during 0 +the 0 +follow 0 +- 0 +up 0 +period 0 +. 0 +T 0 +- 0 +cell 0 +stimulation 0 +by 0 +therapeutic 0 +concentration 0 +of 0 +ticlopidine 1 +was 0 +demonstrated 0 +in 0 +vitro 0 +in 0 +the 0 +patients 0 +"," 0 +but 0 +not 0 +in 0 +healthy 0 +controls 0 +. 0 +DISCUSSI0N 0 +: 0 +Cholestatic 3 +hepatitis 4 +is 0 +a 0 +rare 0 +complication 0 +of 0 +the 0 +antiplatelet 0 +agent 0 +ticlopidine 1 +; 0 +several 0 +cases 0 +have 0 +been 0 +reported 0 +but 0 +few 0 +in 0 +the 0 +English 0 +literature 0 +. 0 +0ur 0 +patients 0 +developed 0 +jaundice 3 +following 0 +treatment 0 +with 0 +ticlopidine 1 +and 0 +showed 0 +the 0 +clinical 0 +and 0 +laboratory 0 +characteristics 0 +of 0 +cholestatic 3 +hepatitis 4 +"," 0 +which 0 +resolved 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +. 0 +Hepatitis 3 +may 0 +develop 0 +weeks 0 +after 0 +discontinuation 0 +of 0 +the 0 +drug 0 +and 0 +may 0 +run 0 +a 0 +prolonged 0 +course 0 +"," 0 +but 0 +complete 0 +remission 0 +was 0 +observed 0 +in 0 +all 0 +reported 0 +cases 0 +. 0 +An 0 +objective 0 +causality 0 +assessment 0 +revealed 0 +that 0 +the 0 +adverse 0 +drug 0 +event 0 +was 0 +probably 0 +related 0 +to 0 +the 0 +use 0 +of 0 +ticlopidine 1 +. 0 +The 0 +mechanisms 0 +of 0 +this 0 +ticlopidine 1 +- 0 +induced 0 +cholestasis 3 +are 0 +unclear 0 +. 0 +Immune 0 +mechanisms 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +drug 0 +' 0 +s 0 +hepatotoxicity 3 +"," 0 +as 0 +suggested 0 +by 0 +the 0 +T 0 +- 0 +cell 0 +stimulation 0 +study 0 +reported 0 +here 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Cholestatic 3 +hepatitis 4 +is 0 +a 0 +rare 0 +adverse 0 +effect 0 +of 0 +ticlopidine 1 +that 0 +may 0 +be 0 +immune 0 +mediated 0 +. 0 +Patients 0 +receiving 0 +the 0 +drug 0 +should 0 +be 0 +monitored 0 +with 0 +liver 0 +function 0 +tests 0 +along 0 +with 0 +complete 0 +blood 0 +cell 0 +counts 0 +. 0 +This 0 +complication 0 +will 0 +be 0 +observed 0 +even 0 +less 0 +often 0 +in 0 +the 0 +future 0 +as 0 +ticlopidine 1 +is 0 +being 0 +replaced 0 +by 0 +the 0 +newer 0 +antiplatelet 0 +agent 0 +clopidogrel 1 +. 0 +Epithelial 0 +sodium 1 +channel 0 +( 0 +ENaC 0 +) 0 +subunit 0 +mRNA 0 +and 0 +protein 0 +expression 0 +in 0 +rats 0 +with 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +. 0 +In 0 +experimental 0 +nephrotic 3 +syndrome 4 +"," 0 +urinary 0 +sodium 1 +excretion 0 +is 0 +decreased 0 +during 0 +the 0 +early 0 +phase 0 +of 0 +the 0 +disease 0 +. 0 +The 0 +molecular 0 +mechanism 0 +( 0 +s 0 +) 0 +leading 0 +to 0 +salt 0 +retention 0 +has 0 +not 0 +been 0 +completely 0 +elucidated 0 +. 0 +The 0 +rate 0 +- 0 +limiting 0 +constituent 0 +of 0 +collecting 0 +duct 0 +sodium 1 +transport 0 +is 0 +the 0 +epithelial 0 +sodium 1 +channel 0 +( 0 +ENaC 0 +) 0 +. 0 +We 0 +examined 0 +the 0 +abundance 0 +of 0 +ENaC 0 +subunit 0 +mRNAs 0 +and 0 +proteins 0 +in 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +. 0 +The 0 +time 0 +courses 0 +of 0 +urinary 0 +sodium 1 +excretion 0 +"," 0 +plasma 0 +aldosterone 1 +concentration 0 +and 0 +proteinuria 3 +were 0 +studied 0 +in 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +treated 0 +with 0 +a 0 +single 0 +dose 0 +of 0 +either 0 +PAN 1 +or 0 +vehicle 0 +. 0 +The 0 +relative 0 +amounts 0 +of 0 +alphaENaC 0 +"," 0 +betaENaC 0 +and 0 +gammaENaC 0 +mRNAs 0 +were 0 +determined 0 +in 0 +kidneys 0 +from 0 +these 0 +rats 0 +by 0 +real 0 +- 0 +time 0 +quantitative 0 +TaqMan 0 +PCR 0 +"," 0 +and 0 +the 0 +amounts 0 +of 0 +proteins 0 +by 0 +Western 0 +blot 0 +. 0 +The 0 +kinetics 0 +of 0 +urinary 0 +sodium 1 +excretion 0 +and 0 +the 0 +appearance 0 +of 0 +proteinuria 3 +were 0 +comparable 0 +with 0 +those 0 +reported 0 +previously 0 +. 0 +Sodium 1 +retention 0 +occurred 0 +on 0 +days 0 +2 0 +"," 0 +3 0 +and 0 +6 0 +after 0 +PAN 1 +injection 0 +. 0 +A 0 +significant 0 +up 0 +- 0 +regulation 0 +of 0 +alphaENaC 0 +and 0 +betaENaC 0 +mRNA 0 +abundance 0 +on 0 +days 0 +1 0 +and 0 +2 0 +preceded 0 +sodium 1 +retention 0 +on 0 +days 0 +2 0 +and 0 +3 0 +. 0 +Conversely 0 +"," 0 +down 0 +- 0 +regulation 0 +of 0 +alphaENaC 0 +"," 0 +betaENaC 0 +and 0 +gammaENaC 0 +mRNA 0 +expression 0 +on 0 +day 0 +3 0 +occurred 0 +in 0 +the 0 +presence 0 +of 0 +high 0 +aldosterone 1 +concentrations 0 +"," 0 +and 0 +was 0 +followed 0 +by 0 +a 0 +return 0 +of 0 +sodium 1 +excretion 0 +to 0 +control 0 +values 0 +. 0 +The 0 +amounts 0 +of 0 +alphaENaC 0 +"," 0 +betaENaC 0 +and 0 +gammaENaC 0 +proteins 0 +were 0 +not 0 +increased 0 +during 0 +PAN 1 +- 0 +induced 0 +sodium 1 +retention 0 +. 0 +In 0 +conclusion 0 +"," 0 +ENaC 0 +mRNA 0 +expression 0 +"," 0 +especially 0 +alphaENaC 0 +"," 0 +is 0 +increased 0 +in 0 +the 0 +very 0 +early 0 +phase 0 +of 0 +the 0 +experimental 0 +model 0 +of 0 +PAN 1 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +in 0 +rats 0 +"," 0 +but 0 +appears 0 +to 0 +escape 0 +from 0 +the 0 +regulation 0 +by 0 +aldosterone 1 +after 0 +day 0 +3 0 +. 0 +Sub 0 +- 0 +chronic 0 +low 0 +dose 0 +gamma 1 +- 2 +vinyl 2 +GABA 2 +( 0 +vigabatrin 1 +) 0 +inhibits 0 +cocaine 1 +- 0 +induced 0 +increases 0 +in 0 +nucleus 0 +accumbens 0 +dopamine 1 +. 0 +RATI0NALE 0 +: 0 +gamma 1 +- 2 +Vinyl 2 +GABA 2 +( 0 +GVG 1 +) 0 +irreversibly 0 +inhibits 0 +GABA 1 +- 0 +transaminase 0 +. 0 +This 0 +non 0 +- 0 +receptor 0 +mediated 0 +inhibition 0 +requires 0 +de 0 +novo 0 +synthesis 0 +for 0 +restoration 0 +of 0 +functional 0 +GABA 1 +catabolism 0 +. 0 +0BJECTIVES 0 +: 0 +Given 0 +its 0 +preclinical 0 +success 0 +for 0 +treating 0 +substance 3 +abuse 4 +and 0 +the 0 +increased 0 +risk 0 +of 0 +visual 3 +field 4 +defects 4 +( 0 +VFD 3 +) 0 +associated 0 +with 0 +cumulative 0 +lifetime 0 +exposure 0 +"," 0 +we 0 +explored 0 +the 0 +effects 0 +of 0 +sub 0 +- 0 +chronic 0 +low 0 +dose 0 +GVG 1 +on 0 +cocaine 1 +- 0 +induced 0 +increases 0 +in 0 +nucleus 0 +accumbens 0 +( 0 +NAcc 0 +) 0 +dopamine 1 +( 0 +DA 1 +) 0 +. 0 +METH0DS 0 +: 0 +Using 0 +in 0 +vivo 0 +microdialysis 0 +"," 0 +we 0 +compared 0 +acute 0 +exposure 0 +( 0 +450 0 +mg 0 +/ 0 +kg 0 +) 0 +to 0 +an 0 +identical 0 +sub 0 +- 0 +chronic 0 +exposure 0 +( 0 +150 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +for 0 +3 0 +days 0 +) 0 +"," 0 +followed 0 +by 0 +1 0 +- 0 +or 0 +3 0 +- 0 +day 0 +washout 0 +. 0 +Finally 0 +"," 0 +we 0 +examined 0 +the 0 +low 0 +dose 0 +of 0 +150 0 +mg 0 +/ 0 +kg 0 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +) 0 +using 0 +a 0 +similar 0 +washout 0 +period 0 +. 0 +RESULTS 0 +: 0 +Sub 0 +- 0 +chronic 0 +GVG 1 +exposure 0 +inhibited 0 +the 0 +effect 0 +of 0 +cocaine 1 +for 0 +3 0 +days 0 +"," 0 +which 0 +exceeded 0 +in 0 +magnitude 0 +and 0 +duration 0 +the 0 +identical 0 +acute 0 +dose 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Sub 0 +- 0 +chronic 0 +low 0 +dose 0 +GVG 1 +potentiates 0 +and 0 +extends 0 +the 0 +inhibition 0 +of 0 +cocaine 1 +- 0 +induced 0 +increases 0 +in 0 +dopamine 1 +"," 0 +effectively 0 +reducing 0 +cumulative 0 +exposures 0 +and 0 +the 0 +risk 0 +for 0 +VFDS 0 +. 0 +MR 0 +imaging 0 +with 0 +quantitative 0 +diffusion 0 +mapping 0 +of 0 +tacrolimus 1 +- 0 +induced 0 +neurotoxicity 3 +in 0 +organ 0 +transplant 0 +patients 0 +. 0 +0ur 0 +objective 0 +was 0 +to 0 +investigate 0 +brain 0 +MR 0 +imaging 0 +findings 0 +and 0 +the 0 +utility 0 +of 0 +diffusion 0 +- 0 +weighted 0 +( 0 +DW 0 +) 0 +imaging 0 +in 0 +organ 0 +transplant 0 +patients 0 +who 0 +developed 0 +neurologic 0 +symptoms 0 +during 0 +tacrolimus 1 +therapy 0 +. 0 +Brain 0 +MR 0 +studies 0 +"," 0 +including 0 +DW 0 +imaging 0 +"," 0 +were 0 +prospectively 0 +performed 0 +in 0 +14 0 +organ 0 +transplant 0 +patients 0 +receiving 0 +tacrolimus 1 +who 0 +developed 0 +neurologic 3 +complications 4 +. 0 +In 0 +each 0 +patient 0 +who 0 +had 0 +abnormalities 0 +on 0 +the 0 +initial 0 +MR 0 +study 0 +"," 0 +a 0 +follow 0 +- 0 +up 0 +MR 0 +study 0 +was 0 +performed 0 +1 0 +month 0 +later 0 +. 0 +Apparent 0 +diffusion 0 +coefficient 0 +( 0 +ADC 0 +) 0 +values 0 +on 0 +the 0 +initial 0 +MR 0 +study 0 +were 0 +correlated 0 +with 0 +reversibility 0 +of 0 +the 0 +lesions 0 +. 0 +0f 0 +the 0 +14 0 +patients 0 +"," 0 +5 0 +( 0 +35 0 +. 0 +7 0 +% 0 +) 0 +had 0 +white 3 +matter 4 +abnormalities 4 +"," 0 +1 0 +( 0 +7 0 +. 0 +1 0 +% 0 +) 0 +had 0 +putaminal 3 +hemorrhage 4 +"," 0 +and 0 +8 0 +( 0 +57 0 +. 0 +1 0 +% 0 +) 0 +had 0 +normal 0 +findings 0 +on 0 +initial 0 +MR 0 +images 0 +. 0 +Among 0 +the 0 +5 0 +patients 0 +with 0 +white 3 +matter 4 +abnormalities 4 +"," 0 +4 0 +patients 0 +( 0 +80 0 +. 0 +0 0 +% 0 +) 0 +showed 0 +higher 0 +than 0 +normal 0 +ADC 0 +values 0 +on 0 +initial 0 +MR 0 +images 0 +"," 0 +and 0 +all 0 +showed 0 +complete 0 +resolution 0 +on 0 +follow 0 +- 0 +up 0 +images 0 +. 0 +The 0 +remaining 0 +1 0 +patient 0 +( 0 +20 0 +. 0 +0 0 +% 0 +) 0 +showed 0 +lower 0 +than 0 +normal 0 +ADC 0 +value 0 +and 0 +showed 0 +incomplete 0 +resolution 0 +with 0 +cortical 3 +laminar 4 +necrosis 4 +. 0 +Diffusion 0 +- 0 +weighted 0 +imaging 0 +may 0 +be 0 +useful 0 +in 0 +predicting 0 +the 0 +outcomes 0 +of 0 +the 0 +lesions 0 +of 0 +tacrolimus 1 +- 0 +induced 0 +neurotoxicity 3 +. 0 +L 1 +- 2 +arginine 2 +transport 0 +in 0 +humans 0 +with 0 +cortisol 1 +- 0 +induced 0 +hypertension 3 +. 0 +A 0 +deficient 0 +L 1 +- 2 +arginine 2 +- 0 +nitric 1 +oxide 2 +system 0 +is 0 +implicated 0 +in 0 +cortisol 1 +- 0 +induced 0 +hypertension 3 +. 0 +We 0 +investigate 0 +whether 0 +abnormalities 0 +in 0 +L 1 +- 2 +arginine 2 +uptake 0 +contribute 0 +to 0 +this 0 +deficiency 0 +. 0 +Eight 0 +healthy 0 +men 0 +were 0 +recruited 0 +. 0 +Hydrocortisone 1 +acetate 2 +( 0 +50 0 +mg 0 +) 0 +was 0 +given 0 +orally 0 +every 0 +6 0 +hours 0 +for 0 +24 0 +hours 0 +after 0 +a 0 +5 0 +- 0 +day 0 +fixed 0 +- 0 +salt 0 +diet 0 +( 0 +150 0 +mmol 0 +/ 0 +d 0 +) 0 +. 0 +Crossover 0 +studies 0 +were 0 +performed 0 +2 0 +weeks 0 +apart 0 +. 0 +Thirty 0 +milliliters 0 +of 0 +blood 0 +was 0 +obtained 0 +for 0 +isolation 0 +of 0 +peripheral 0 +blood 0 +mononuclear 0 +cells 0 +after 0 +each 0 +treatment 0 +period 0 +. 0 +L 1 +- 2 +arginine 2 +uptake 0 +was 0 +assessed 0 +in 0 +mononuclear 0 +cells 0 +incubated 0 +with 0 +L 1 +- 2 +arginine 2 +( 0 +1 0 +to 0 +300 0 +micromol 0 +/ 0 +L 0 +) 0 +"," 0 +incorporating 0 +100 0 +nmol 0 +/ 0 +L 0 +[ 1 +3H 2 +] 2 +- 2 +l 2 +- 2 +arginine 2 +for 0 +a 0 +period 0 +of 0 +5 0 +minutes 0 +at 0 +37 0 +degrees 0 +C 0 +. 0 +Forearm 0 +[ 1 +3H 2 +] 2 +- 2 +L 2 +- 2 +arginine 2 +extraction 0 +was 0 +calculated 0 +after 0 +infusion 0 +of 0 +[ 1 +3H 2 +] 2 +- 2 +L 2 +- 2 +arginine 2 +into 0 +the 0 +brachial 0 +artery 0 +at 0 +a 0 +rate 0 +of 0 +100 0 +nCi 0 +/ 0 +min 0 +for 0 +80 0 +minutes 0 +. 0 +Deep 0 +forearm 0 +venous 0 +samples 0 +were 0 +collected 0 +for 0 +determination 0 +of 0 +L 1 +- 2 +arginine 2 +extraction 0 +. 0 +Plasma 0 +cortisol 1 +concentrations 0 +were 0 +significantly 0 +raised 0 +during 0 +the 0 +active 0 +phase 0 +( 0 +323 0 ++ 0 +/ 0 +- 0 +43 0 +to 0 +1082 0 ++ 0 +/ 0 +- 0 +245 0 +mmol 0 +/ 0 +L 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Systolic 0 +blood 0 +pressure 0 +was 0 +elevated 0 +by 0 +an 0 +average 0 +of 0 +7 0 +mm 0 +Hg 0 +. 0 +Neither 0 +L 1 +- 2 +arginine 2 +transport 0 +into 0 +mononuclear 0 +cells 0 +( 0 +placebo 0 +vs 0 +active 0 +"," 0 +26 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +6 0 +vs 0 +29 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +1 0 +pmol 0 +/ 0 +10 0 +0 0 +cells 0 +per 0 +5 0 +minutes 0 +"," 0 +respectively 0 +"," 0 +at 0 +an 0 +l 1 +- 2 +arginine 2 +concentration 0 +of 0 +300 0 +micromol 0 +/ 0 +L 0 +) 0 +nor 0 +L 1 +- 2 +arginine 2 +extraction 0 +in 0 +the 0 +forearm 0 +( 0 +at 0 +80 0 +minutes 0 +"," 0 +placebo 0 +vs 0 +active 0 +"," 0 +1 0 +868 0 +904 0 ++ 0 +/ 0 +- 0 +434 0 +962 0 +vs 0 +2 0 +13 0 +910 0 ++ 0 +/ 0 +- 0 +770 0 +619 0 +disintegrations 0 +per 0 +minute 0 +) 0 +was 0 +affected 0 +by 0 +cortisol 1 +treatment 0 +; 0 +ie 0 +"," 0 +that 0 +L 1 +- 2 +arginine 2 +uptake 0 +is 0 +not 0 +affected 0 +by 0 +short 0 +- 0 +term 0 +cortisol 1 +treatment 0 +. 0 +We 0 +conclude 0 +that 0 +cortisol 1 +- 0 +induced 0 +increases 3 +in 4 +blood 4 +pressure 4 +are 0 +not 0 +associated 0 +with 0 +abnormalities 0 +in 0 +the 0 +l 1 +- 2 +arginine 2 +transport 0 +system 0 +. 0 +Amount 0 +of 0 +bleeding 3 +and 0 +hematoma 3 +size 0 +in 0 +the 0 +collagenase 0 +- 0 +induced 0 +intracerebral 3 +hemorrhage 4 +rat 0 +model 0 +. 0 +The 0 +aggravated 0 +risk 0 +on 0 +intracerebral 3 +hemorrhage 4 +( 0 +ICH 3 +) 0 +with 0 +drugs 0 +used 0 +for 0 +stroke 3 +patients 0 +should 0 +be 0 +estimated 0 +carefully 0 +. 0 +We 0 +therefore 0 +established 0 +sensitive 0 +quantification 0 +methods 0 +and 0 +provided 0 +a 0 +rat 0 +ICH 3 +model 0 +for 0 +detection 0 +of 0 +ICH 3 +deterioration 0 +. 0 +In 0 +ICH 3 +intrastriatally 0 +induced 0 +by 0 +0 0 +. 0 +14 0 +- 0 +unit 0 +"," 0 +0 0 +. 0 +70 0 +- 0 +unit 0 +"," 0 +and 0 +0 0 +. 0 +350 0 +- 0 +unit 0 +collagenase 0 +"," 0 +the 0 +amount 0 +of 0 +bleeding 3 +was 0 +measured 0 +using 0 +a 0 +hemoglobin 0 +assay 0 +developed 0 +in 0 +the 0 +present 0 +study 0 +and 0 +was 0 +compared 0 +with 0 +the 0 +morphologically 0 +determined 0 +hematoma 3 +volume 0 +. 0 +The 0 +blood 0 +amounts 0 +and 0 +hematoma 3 +volumes 0 +were 0 +significantly 0 +correlated 0 +"," 0 +and 0 +the 0 +hematoma 3 +induced 0 +by 0 +0 0 +. 0 +14 0 +- 0 +unit 0 +collagenase 0 +was 0 +adequate 0 +to 0 +detect 0 +ICH 3 +deterioration 0 +. 0 +In 0 +ICH 3 +induction 0 +using 0 +0 0 +. 0 +14 0 +- 0 +unit 0 +collagenase 0 +"," 0 +heparin 1 +enhanced 0 +the 0 +hematoma 3 +volume 0 +3 0 +. 0 +4 0 +- 0 +fold 0 +over 0 +that 0 +seen 0 +in 0 +control 0 +ICH 3 +animals 0 +and 0 +the 0 +bleeding 3 +7 0 +. 0 +6 0 +- 0 +fold 0 +. 0 +Data 0 +suggest 0 +that 0 +this 0 +sensitive 0 +hemoglobin 0 +assay 0 +is 0 +useful 0 +for 0 +ICH 3 +detection 0 +"," 0 +and 0 +that 0 +a 0 +model 0 +with 0 +a 0 +small 0 +ICH 3 +induced 0 +with 0 +a 0 +low 0 +- 0 +dose 0 +collagenase 0 +should 0 +be 0 +used 0 +for 0 +evaluation 0 +of 0 +drugs 0 +that 0 +may 0 +affect 0 +ICH 3 +. 0 +Estradiol 1 +reduces 0 +seizure 3 +- 0 +induced 0 +hippocampal 3 +injury 4 +in 0 +ovariectomized 0 +female 0 +but 0 +not 0 +in 0 +male 0 +rats 0 +. 0 +Estrogens 0 +protect 0 +ovariectomized 0 +rats 0 +from 0 +hippocampal 3 +injury 4 +induced 0 +by 0 +kainic 1 +acid 2 +- 0 +induced 0 +status 3 +epilepticus 4 +( 0 +SE 3 +) 0 +. 0 +We 0 +compared 0 +the 0 +effects 0 +of 0 +17beta 1 +- 2 +estradiol 2 +in 0 +adult 0 +male 0 +and 0 +ovariectomized 0 +female 0 +rats 0 +subjected 0 +to 0 +lithium 1 +- 0 +pilocarpine 1 +- 0 +induced 0 +SE 3 +. 0 +Rats 0 +received 0 +subcutaneous 0 +injections 0 +of 0 +17beta 1 +- 2 +estradiol 2 +( 0 +2 0 +microg 0 +/ 0 +rat 0 +) 0 +or 0 +oil 0 +once 0 +daily 0 +for 0 +four 0 +consecutive 0 +days 0 +. 0 +SE 3 +was 0 +induced 0 +20 0 +h 0 +following 0 +the 0 +second 0 +injection 0 +and 0 +terminated 0 +3 0 +h 0 +later 0 +. 0 +The 0 +extent 0 +of 0 +silver 1 +- 0 +stained 0 +CA3 0 +and 0 +CA1 0 +hippocampal 0 +neurons 0 +was 0 +evaluated 0 +2 0 +days 0 +after 0 +SE 3 +. 0 +17beta 1 +- 2 +Estradiol 2 +did 0 +not 0 +alter 0 +the 0 +onset 0 +of 0 +first 0 +clonus 0 +in 0 +ovariectomized 0 +rats 0 +but 0 +accelerated 0 +it 0 +in 0 +males 0 +. 0 +17beta 1 +- 2 +Estradiol 2 +reduced 0 +the 0 +argyrophilic 0 +neurons 0 +in 0 +the 0 +CA1 0 +and 0 +CA3 0 +- 0 +C 0 +sectors 0 +of 0 +ovariectomized 0 +rats 0 +. 0 +In 0 +males 0 +"," 0 +estradiol 1 +increased 0 +the 0 +total 0 +damage 0 +score 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +the 0 +effects 0 +of 0 +estradiol 1 +on 0 +seizure 3 +threshold 0 +and 0 +damage 0 +may 0 +be 0 +altered 0 +by 0 +sex 0 +- 0 +related 0 +differences 0 +in 0 +the 0 +hormonal 0 +environment 0 +. 0 +Pseudoacromegaly 3 +induced 0 +by 0 +the 0 +long 0 +- 0 +term 0 +use 0 +of 0 +minoxidil 1 +. 0 +Acromegaly 3 +is 0 +an 0 +endocrine 3 +disorder 4 +caused 0 +by 0 +chronic 0 +excessive 0 +growth 0 +hormone 0 +secretion 0 +from 0 +the 0 +anterior 0 +pituitary 0 +gland 0 +. 0 +Significant 0 +disfiguring 0 +changes 0 +occur 0 +as 0 +a 0 +result 0 +of 0 +bone 0 +"," 0 +cartilage 0 +"," 0 +and 0 +soft 0 +tissue 0 +hypertrophy 3 +"," 0 +including 0 +the 0 +thickening 0 +of 0 +the 0 +skin 0 +"," 0 +coarsening 0 +of 0 +facial 0 +features 0 +"," 0 +and 0 +cutis 3 +verticis 4 +gyrata 4 +. 0 +Pseudoacromegaly 3 +"," 0 +on 0 +the 0 +other 0 +hand 0 +"," 0 +is 0 +the 0 +presence 0 +of 0 +similar 0 +acromegaloid 0 +features 0 +in 0 +the 0 +absence 0 +of 0 +elevated 0 +growth 0 +hormone 0 +or 0 +insulin 0 +- 0 +like 0 +growth 0 +factor 0 +levels 0 +. 0 +We 0 +present 0 +a 0 +patient 0 +with 0 +pseudoacromegaly 3 +that 0 +resulted 0 +from 0 +the 0 +long 0 +- 0 +term 0 +use 0 +of 0 +minoxidil 1 +at 0 +an 0 +unusually 0 +high 0 +dose 0 +. 0 +This 0 +is 0 +the 0 +first 0 +case 0 +report 0 +of 0 +pseudoacromegaly 3 +as 0 +a 0 +side 0 +effect 0 +of 0 +minoxidil 1 +use 0 +. 0 +Combined 0 +androgen 0 +blockade 0 +- 0 +induced 0 +anemia 3 +in 0 +prostate 3 +cancer 4 +patients 0 +without 0 +bone 0 +involvement 0 +. 0 +BACKGR0UND 0 +: 0 +To 0 +determine 0 +the 0 +onset 0 +and 0 +extent 0 +of 0 +combined 0 +androgen 0 +blockade 0 +( 0 +CAB 0 +) 0 +- 0 +induced 0 +anemia 3 +in 0 +prostate 3 +cancer 4 +patients 0 +without 0 +bone 0 +involvement 0 +. 0 +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Forty 0 +- 0 +two 0 +patients 0 +with 0 +biopsy 0 +- 0 +proven 0 +prostatic 3 +adenocarcinoma 4 +[ 0 +26 0 +with 0 +stage 0 +C 0 +( 0 +T3N0M0 0 +) 0 +and 0 +16 0 +with 0 +stage 0 +D1 0 +( 0 +T3N1M0 0 +) 0 +] 0 +were 0 +included 0 +in 0 +this 0 +study 0 +. 0 +All 0 +patients 0 +received 0 +CAB 0 +[ 0 +leuprolide 1 +acetate 2 +( 0 +LHRH 1 +- 2 +A 2 +) 0 +3 0 +. 0 +75 0 +mg 0 +"," 0 +intramuscularly 0 +"," 0 +every 0 +28 0 +days 0 +plus 0 +250 0 +mg 0 +flutamide 1 +"," 0 +tid 0 +"," 0 +per 0 +0s 0 +] 0 +and 0 +were 0 +evaluated 0 +for 0 +anemia 3 +by 0 +physical 0 +examination 0 +and 0 +laboratory 0 +tests 0 +at 0 +baseline 0 +and 0 +4 0 +subsequent 0 +intervals 0 +( 0 +1 0 +"," 0 +2 0 +"," 0 +3 0 +and 0 +6 0 +months 0 +post 0 +- 0 +CAB 0 +) 0 +. 0 +Hb 0 +"," 0 +PSA 0 +and 0 +Testosterone 1 +measurements 0 +were 0 +recorded 0 +. 0 +Patients 0 +with 0 +stage 0 +D2 0 +- 0 +3 0 +disease 0 +"," 0 +abnormal 0 +hemoglobin 0 +level 0 +or 0 +renal 0 +and 0 +liver 0 +function 0 +tests 0 +that 0 +were 0 +higher 0 +than 0 +the 0 +upper 0 +limits 0 +were 0 +excluded 0 +from 0 +the 0 +study 0 +. 0 +The 0 +duration 0 +of 0 +the 0 +study 0 +was 0 +six 0 +months 0 +. 0 +RESULTS 0 +: 0 +The 0 +mean 0 +hemoglobin 0 +( 0 +Hb 0 +) 0 +levels 0 +were 0 +significantly 0 +declined 0 +in 0 +all 0 +patients 0 +from 0 +baseline 0 +of 0 +14 0 +. 0 +2 0 +g 0 +/ 0 +dl 0 +to 0 +14 0 +. 0 +0 0 +g 0 +/ 0 +dl 0 +"," 0 +13 0 +. 0 +5 0 +g 0 +/ 0 +dl 0 +"," 0 +13 0 +. 0 +2 0 +g 0 +/ 0 +dl 0 +and 0 +12 0 +. 0 +7 0 +g 0 +/ 0 +dl 0 +at 0 +1 0 +"," 0 +2 0 +"," 0 +3 0 +and 0 +6 0 +months 0 +post 0 +- 0 +CAB 0 +"," 0 +respectively 0 +. 0 +Severe 0 +and 0 +clinically 0 +evident 0 +anemia 3 +of 0 +Hb 0 +< 0 +11 0 +g 0 +/ 0 +dl 0 +with 0 +clinical 0 +symptoms 0 +was 0 +detected 0 +in 0 +6 0 +patients 0 +( 0 +14 0 +. 0 +3 0 +% 0 +) 0 +. 0 +This 0 +CAB 0 +- 0 +induced 0 +anemia 3 +was 0 +normochromic 0 +and 0 +normocytic 0 +. 0 +At 0 +six 0 +months 0 +post 0 +- 0 +CAB 0 +"," 0 +patients 0 +with 0 +severe 0 +anemia 3 +had 0 +a 0 +Hb 0 +mean 0 +value 0 +of 0 +10 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +g 0 +/ 0 +dl 0 +( 0 +X 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +"," 0 +whereas 0 +the 0 +other 0 +patients 0 +had 0 +mild 0 +anemia 3 +with 0 +Hb 0 +mean 0 +value 0 +of 0 +13 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +17 0 +( 0 +X 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +. 0 +The 0 +development 0 +of 0 +severe 0 +anemia 3 +at 0 +6 0 +months 0 +post 0 +- 0 +CAB 0 +was 0 +predictable 0 +by 0 +the 0 +reduction 0 +of 0 +Hb 0 +baseline 0 +value 0 +of 0 +more 0 +than 0 +2 0 +. 0 +5 0 +g 0 +/ 0 +dl 0 +after 0 +3 0 +months 0 +of 0 +CAB 0 +( 0 +p 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +The 0 +development 0 +of 0 +severe 0 +CAB 0 +- 0 +induced 0 +anemia 3 +in 0 +prostate 3 +cancer 4 +patients 0 +did 0 +not 0 +correlate 0 +with 0 +T 0 +baseline 0 +values 0 +( 0 +T 0 +< 0 +3 0 +ng 0 +/ 0 +ml 0 +versus 0 +T 0 +> 0 +or 0 += 0 +3 0 +ng 0 +/ 0 +ml 0 +) 0 +"," 0 +with 0 +age 0 +( 0 +< 0 +76 0 +yrs 0 +versus 0 +> 0 +or 0 += 0 +76 0 +yrs 0 +) 0 +"," 0 +and 0 +clinical 0 +stage 0 +( 0 +stage 0 +C 0 +versus 0 +stage 0 +D1 0 +) 0 +. 0 +Severe 0 +and 0 +clinically 0 +evident 0 +anemia 3 +was 0 +easily 0 +corrected 0 +by 0 +subcutaneous 0 +injections 0 +( 0 +3 0 +times 0 +/ 0 +week 0 +for 0 +1 0 +month 0 +) 0 +of 0 +recombinant 0 +erythropoietin 0 +( 0 +rHuEP0 0 +- 0 +beta 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +0ur 0 +data 0 +suggest 0 +that 0 +rHuEP0 0 +- 0 +beta 0 +correctable 0 +CAB 0 +- 0 +induced 0 +anemia 3 +occurs 0 +in 0 +14 0 +. 0 +3 0 +% 0 +of 0 +prostate 3 +cancer 4 +patients 0 +after 0 +6 0 +months 0 +of 0 +therapy 0 +. 0 +Delirium 3 +during 0 +clozapine 1 +treatment 0 +: 0 +incidence 0 +and 0 +associated 0 +risk 0 +factors 0 +. 0 +BACKGR0UND 0 +: 0 +Incidence 0 +and 0 +risk 0 +factors 0 +for 0 +delirium 3 +during 0 +clozapine 1 +treatment 0 +require 0 +further 0 +clarification 0 +. 0 +METH0DS 0 +: 0 +We 0 +used 0 +computerized 0 +pharmacy 0 +records 0 +to 0 +identify 0 +all 0 +adult 0 +psychiatric 3 +inpatients 0 +treated 0 +with 0 +clozapine 1 +( 0 +1995 0 +- 0 +96 0 +) 0 +"," 0 +reviewed 0 +their 0 +medical 0 +records 0 +to 0 +score 0 +incidence 0 +and 0 +severity 0 +of 0 +delirium 3 +"," 0 +and 0 +tested 0 +associations 0 +with 0 +potential 0 +risk 0 +factors 0 +. 0 +RESULTS 0 +: 0 +Subjects 0 +( 0 +n 0 += 0 +139 0 +) 0 +were 0 +72 0 +women 0 +and 0 +67 0 +men 0 +"," 0 +aged 0 +40 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +12 0 +. 0 +1 0 +years 0 +"," 0 +hospitalized 0 +for 0 +24 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +23 0 +. 0 +3 0 +days 0 +"," 0 +and 0 +given 0 +clozapine 1 +"," 0 +gradually 0 +increased 0 +to 0 +an 0 +average 0 +daily 0 +dose 0 +of 0 +282 0 ++ 0 +/ 0 +- 0 +203 0 +mg 0 +( 0 +3 0 +. 0 +45 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +45 0 +mg 0 +/ 0 +kg 0 +) 0 +for 0 +18 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +16 0 +. 0 +4 0 +days 0 +. 0 +Delirium 3 +was 0 +diagnosed 0 +in 0 +14 0 +( 0 +10 0 +. 0 +1 0 +% 0 +incidence 0 +"," 0 +or 0 +1 0 +. 0 +48 0 +cases 0 +/ 0 +person 0 +- 0 +years 0 +of 0 +exposure 0 +) 0 +; 0 +71 0 +. 0 +4 0 +% 0 +of 0 +cases 0 +were 0 +moderate 0 +or 0 +severe 0 +. 0 +Associated 0 +factors 0 +were 0 +co 0 +- 0 +treatment 0 +with 0 +other 0 +centrally 0 +antimuscarinic 0 +agents 0 +"," 0 +poor 0 +clinical 0 +outcome 0 +"," 0 +older 0 +age 0 +"," 0 +and 0 +longer 0 +hospitalization 0 +( 0 +by 0 +17 0 +. 0 +5 0 +days 0 +"," 0 +increasing 0 +cost 0 +) 0 +; 0 +sex 0 +"," 0 +diagnosis 0 +or 0 +medical 0 +co 0 +- 0 +morbidity 0 +"," 0 +and 0 +daily 0 +clozapine 1 +dose 0 +"," 0 +which 0 +fell 0 +with 0 +age 0 +"," 0 +were 0 +unrelated 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Delirium 3 +was 0 +found 0 +in 0 +10 0 +% 0 +of 0 +clozapine 1 +- 0 +treated 0 +inpatients 0 +"," 0 +particularly 0 +in 0 +older 0 +patients 0 +exposed 0 +to 0 +other 0 +central 0 +anticholinergics 0 +. 0 +Delirium 3 +was 0 +inconsistently 0 +recognized 0 +clinically 0 +in 0 +milder 0 +cases 0 +and 0 +was 0 +associated 0 +with 0 +increased 0 +length 0 +- 0 +of 0 +- 0 +stay 0 +and 0 +higher 0 +costs 0 +"," 0 +and 0 +inferior 0 +clinical 0 +outcome 0 +. 0 +Neuroprotective 0 +action 0 +of 0 +MPEP 1 +"," 0 +a 0 +selective 0 +mGluR5 0 +antagonist 0 +"," 0 +in 0 +methamphetamine 1 +- 0 +induced 0 +dopaminergic 0 +neurotoxicity 3 +is 0 +associated 0 +with 0 +a 0 +decrease 0 +in 0 +dopamine 1 +outflow 0 +and 0 +inhibition 0 +of 0 +hyperthermia 3 +in 0 +rats 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +examine 0 +the 0 +role 0 +of 0 +metabotropic 0 +glutamate 1 +receptor 0 +5 0 +( 0 +mGluR5 0 +) 0 +in 0 +the 0 +toxic 0 +action 0 +of 0 +methamphetamine 1 +on 0 +dopaminergic 0 +neurones 0 +in 0 +rats 0 +. 0 +Methamphetamine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +sc 0 +) 0 +"," 0 +administered 0 +five 0 +times 0 +"," 0 +reduced 0 +the 0 +levels 0 +of 0 +dopamine 1 +and 0 +its 0 +metabolites 0 +in 0 +striatal 0 +tissue 0 +when 0 +measured 0 +72 0 +h 0 +after 0 +the 0 +last 0 +injection 0 +. 0 +A 0 +selective 0 +antagonist 0 +of 0 +mGluR5 0 +"," 0 +2 1 +- 2 +methyl 2 +- 2 +6 2 +- 2 +( 2 +phenylethynyl 2 +) 2 +pyridine 2 +( 0 +MPEP 1 +; 0 +5 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +"," 0 +when 0 +administered 0 +five 0 +times 0 +immediately 0 +before 0 +each 0 +methamphetamine 1 +injection 0 +reversed 0 +the 0 +above 0 +- 0 +mentioned 0 +methamphetamine 1 +effects 0 +. 0 +A 0 +single 0 +MPEP 1 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +injection 0 +reduced 0 +the 0 +basal 0 +extracellular 0 +dopamine 1 +level 0 +in 0 +the 0 +striatum 0 +"," 0 +as 0 +well 0 +as 0 +dopamine 1 +release 0 +stimulated 0 +either 0 +by 0 +methamphetamine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +sc 0 +) 0 +or 0 +by 0 +intrastriatally 0 +administered 0 +veratridine 1 +( 0 +100 0 +microM 0 +) 0 +. 0 +Moreover 0 +"," 0 +it 0 +transiently 0 +diminished 0 +the 0 +methamphetamine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +sc 0 +) 0 +- 0 +induced 0 +hyperthermia 3 +and 0 +reduced 0 +basal 0 +body 0 +temperature 0 +. 0 +MPEP 1 +administered 0 +into 0 +the 0 +striatum 0 +at 0 +high 0 +concentrations 0 +( 0 +500 0 +microM 0 +) 0 +increased 0 +extracellular 0 +dopamine 1 +levels 0 +"," 0 +while 0 +lower 0 +concentrations 0 +( 0 +50 0 +- 0 +100 0 +microM 0 +) 0 +were 0 +devoid 0 +of 0 +any 0 +effect 0 +. 0 +The 0 +results 0 +of 0 +this 0 +study 0 +suggest 0 +that 0 +the 0 +blockade 0 +of 0 +mGluR5 0 +by 0 +MPEP 1 +may 0 +protect 0 +dopaminergic 0 +neurones 0 +against 0 +methamphetamine 1 +- 0 +induced 0 +toxicity 3 +. 0 +Neuroprotection 0 +rendered 0 +by 0 +MPEP 1 +may 0 +be 0 +associated 0 +with 0 +the 0 +reduction 0 +of 0 +the 0 +methamphetamine 1 +- 0 +induced 0 +dopamine 1 +efflux 0 +in 0 +the 0 +striatum 0 +due 0 +to 0 +the 0 +blockade 0 +of 0 +extrastriatal 0 +mGluR5 0 +"," 0 +and 0 +with 0 +a 0 +decrease 0 +in 0 +hyperthermia 3 +. 0 +Protective 0 +efficacy 0 +of 0 +neuroactive 0 +steroids 1 +against 0 +cocaine 1 +kindled 0 +- 0 +seizures 3 +in 0 +mice 0 +. 0 +Neuroactive 0 +steroids 1 +demonstrate 0 +pharmacological 0 +actions 0 +that 0 +have 0 +relevance 0 +for 0 +a 0 +host 0 +of 0 +neurological 3 +and 4 +psychiatric 4 +disorders 4 +. 0 +They 0 +offer 0 +protection 0 +against 0 +seizures 3 +in 0 +a 0 +range 0 +of 0 +models 0 +and 0 +seem 0 +to 0 +inhibit 0 +certain 0 +stages 0 +of 0 +drug 3 +dependence 4 +in 0 +preclinical 0 +assessments 0 +. 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +evaluate 0 +two 0 +endogenous 0 +and 0 +one 0 +synthetic 0 +neuroactive 0 +steroid 1 +that 0 +positively 0 +modulate 0 +the 0 +gamma 1 +- 2 +aminobutyric 2 +acid 2 +( 0 +GABA 1 +( 0 +A 0 +) 0 +) 0 +receptor 0 +against 0 +the 0 +increase 0 +in 0 +sensitivity 0 +to 0 +the 0 +convulsant 0 +effects 0 +of 0 +cocaine 1 +engendered 0 +by 0 +repeated 0 +cocaine 1 +administration 0 +( 0 +seizure 3 +kindling 0 +) 0 +. 0 +Allopregnanolone 1 +( 0 +3alpha 1 +- 2 +hydroxy 2 +- 2 +5alpha 2 +- 2 +pregnan 2 +- 2 +20 2 +- 2 +one 2 +) 0 +"," 0 +pregnanolone 1 +( 0 +3alpha 1 +- 2 +hydroxy 2 +- 2 +5beta 2 +- 2 +pregnan 2 +- 2 +20 2 +- 2 +one 2 +) 0 +and 0 +ganaxolone 1 +( 0 +a 0 +synthetic 0 +derivative 0 +of 0 +allopregnanolone 1 +3alpha 1 +- 2 +hydroxy 2 +- 2 +3beta 2 +- 2 +methyl 2 +- 2 +5alpha 2 +- 2 +pregnan 2 +- 2 +20 2 +- 2 +one 2 +) 0 +were 0 +tested 0 +for 0 +their 0 +ability 0 +to 0 +suppress 0 +the 0 +expression 0 +( 0 +anticonvulsant 0 +effect 0 +) 0 +and 0 +development 0 +( 0 +antiepileptogenic 0 +effect 0 +) 0 +of 0 +cocaine 1 +- 0 +kindled 0 +seizures 3 +in 0 +male 0 +"," 0 +Swiss 0 +- 0 +Webster 0 +mice 0 +. 0 +Kindled 0 +seizures 3 +were 0 +induced 0 +by 0 +daily 0 +administration 0 +of 0 +60 0 +mg 0 +/ 0 +kg 0 +cocaine 1 +for 0 +5 0 +days 0 +. 0 +All 0 +of 0 +these 0 +positive 0 +GABA 1 +( 0 +A 0 +) 0 +modulators 0 +suppressed 0 +the 0 +expression 0 +of 0 +kindled 0 +seizures 3 +"," 0 +whereas 0 +only 0 +allopregnanolone 1 +and 0 +ganaxolone 1 +inhibited 0 +the 0 +development 0 +of 0 +kindling 0 +. 0 +Allopregnanolone 1 +and 0 +pregnanolone 1 +"," 0 +but 0 +not 0 +ganaxolone 1 +"," 0 +also 0 +reduced 0 +cumulative 0 +lethality 0 +associated 0 +with 0 +kindling 0 +. 0 +These 0 +findings 0 +demonstrate 0 +that 0 +some 0 +neuroactive 0 +steroids 1 +attenuate 0 +convulsant 0 +and 0 +sensitizing 0 +properties 0 +of 0 +cocaine 1 +and 0 +add 0 +to 0 +a 0 +growing 0 +literature 0 +on 0 +their 0 +potential 0 +use 0 +in 0 +the 0 +modulation 0 +of 0 +effects 0 +of 0 +drugs 0 +of 0 +abuse 0 +. 0 +Effect 0 +of 0 +humoral 0 +modulators 0 +of 0 +morphine 1 +- 0 +induced 0 +increase 3 +in 4 +locomotor 4 +activity 4 +of 0 +mice 0 +. 0 +The 0 +effect 0 +of 0 +humoral 0 +modulators 0 +on 0 +the 0 +morphine 1 +- 0 +induced 0 +increase 3 +in 4 +locomotor 4 +activity 4 +of 0 +mice 0 +was 0 +studied 0 +. 0 +The 0 +subcutaneous 0 +administration 0 +of 0 +10 0 +mg 0 +/ 0 +kg 0 +of 0 +morphine 1 +- 0 +HC1 0 +produced 0 +a 0 +marked 0 +increase 3 +in 4 +locomotor 4 +activity 4 +in 0 +mice 0 +. 0 +The 0 +morphine 1 +- 0 +induced 0 +hyperactivity 3 +was 0 +potentiated 0 +by 0 +scopolamine 1 +and 0 +attenuated 0 +by 0 +physostigmine 1 +. 0 +In 0 +contrast 0 +"," 0 +both 0 +methscopolamine 1 +and 0 +neostigmine 1 +"," 0 +which 0 +do 0 +not 0 +penetrate 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +"," 0 +had 0 +no 0 +effect 0 +on 0 +the 0 +hyperactivity 3 +produced 0 +by 0 +morphine 1 +. 0 +Pretreatment 0 +of 0 +mice 0 +with 0 +alpha 1 +- 2 +methyltyrosine 2 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +"," 0 +one 0 +hour 0 +) 0 +"," 0 +an 0 +inhibitor 0 +of 0 +tyrosine 1 +hydroxylase 0 +"," 0 +significantly 0 +decreased 0 +the 0 +activity 0 +- 0 +increasing 0 +effects 0 +of 0 +morphine 1 +. 0 +0n 0 +the 0 +other 0 +hand 0 +"," 0 +pretreatment 0 +with 0 +p 1 +- 2 +chlorophenylalamine 2 +( 0 +3 0 +X 0 +320 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +"," 0 +24 0 +hr 0 +) 0 +"," 0 +a 0 +serotonin 1 +depletor 0 +"," 0 +caused 0 +no 0 +significant 0 +change 0 +in 0 +the 0 +hyperactivity 3 +. 0 +The 0 +study 0 +suggests 0 +that 0 +the 0 +activity 0 +- 0 +increasing 0 +effects 0 +of 0 +morphine 1 +are 0 +mediated 0 +by 0 +the 0 +release 0 +of 0 +catecholamines 1 +from 0 +adrenergic 0 +neurons 0 +in 0 +the 0 +brain 0 +. 0 +And 0 +the 0 +results 0 +are 0 +consistent 0 +with 0 +the 0 +hypothesis 0 +that 0 +morphine 1 +acts 0 +by 0 +retarding 0 +the 0 +release 0 +of 0 +acetylcholine 1 +at 0 +some 0 +central 0 +cholinergic 0 +synapses 0 +. 0 +It 0 +is 0 +also 0 +suggested 0 +from 0 +collected 0 +evidence 0 +that 0 +the 0 +activity 0 +- 0 +increasing 0 +effects 0 +of 0 +morphine 1 +in 0 +mice 0 +are 0 +mediated 0 +by 0 +mechanisms 0 +different 0 +from 0 +those 0 +which 0 +mediate 0 +the 0 +activity 0 +- 0 +increasing 0 +effects 0 +of 0 +morphine 1 +in 0 +rats 0 +. 0 +Effects 0 +of 0 +uninephrectomy 0 +and 0 +high 0 +protein 0 +feeding 0 +on 0 +lithium 1 +- 0 +induced 0 +chronic 3 +renal 4 +failure 4 +in 0 +rats 0 +. 0 +Rats 0 +with 0 +lithium 1 +- 0 +induced 0 +nephropathy 3 +were 0 +subjected 0 +to 0 +high 0 +protein 0 +( 0 +HP 0 +) 0 +feeding 0 +"," 0 +uninephrectomy 0 +( 0 +NX 0 +) 0 +or 0 +a 0 +combination 0 +of 0 +these 0 +"," 0 +in 0 +an 0 +attempt 0 +to 0 +induce 0 +glomerular 0 +hyperfiltration 0 +and 0 +further 0 +progression 0 +of 0 +renal 3 +failure 4 +. 0 +Newborn 0 +female 0 +Wistar 0 +rats 0 +were 0 +fed 0 +a 0 +lithium 1 +- 0 +containing 0 +diet 0 +( 0 +50 0 +mmol 0 +/ 0 +kg 0 +) 0 +for 0 +8 0 +weeks 0 +and 0 +then 0 +randomized 0 +to 0 +normal 0 +diet 0 +"," 0 +HP 0 +diet 0 +( 0 +40 0 +vs 0 +. 0 +19 0 +% 0 +) 0 +"," 0 +NX 0 +or 0 +HP 0 ++ 0 +NX 0 +for 0 +another 0 +8 0 +weeks 0 +. 0 +Corresponding 0 +non 0 +- 0 +lithium 1 +pretreated 0 +groups 0 +were 0 +generated 0 +. 0 +When 0 +comparing 0 +all 0 +lithium 1 +treated 0 +versus 0 +non 0 +- 0 +lithium 1 +- 0 +treated 0 +groups 0 +"," 0 +lithium 1 +caused 0 +a 0 +reduction 0 +in 0 +glomerular 0 +filtration 0 +rate 0 +( 0 +GFR 0 +) 0 +without 0 +significant 0 +changes 0 +in 0 +effective 0 +renal 0 +plasma 0 +flow 0 +( 0 +as 0 +determined 0 +by 0 +a 0 +marker 0 +secreted 0 +into 0 +the 0 +proximal 0 +tubules 0 +) 0 +or 0 +lithium 1 +clearance 0 +. 0 +Consequently 0 +"," 0 +lithium 1 +pretreatment 0 +caused 0 +a 0 +fall 0 +in 0 +filtration 0 +fraction 0 +and 0 +an 0 +increase 0 +in 0 +fractional 0 +Li 1 +excretion 0 +. 0 +Lithium 1 +also 0 +caused 0 +proteinuria 3 +and 0 +systolic 0 +hypertension 3 +in 0 +absence 0 +of 0 +glomerulosclerosis 3 +. 0 +HP 0 +failed 0 +to 0 +accentuante 0 +progression 0 +of 0 +renal 3 +failure 4 +and 0 +in 0 +fact 0 +tended 0 +to 0 +increase 0 +GFR 0 +and 0 +decrease 0 +plasma 0 +creatinine 1 +levels 0 +in 0 +lithium 1 +pretreated 0 +rats 0 +. 0 +NX 0 +caused 0 +an 0 +additive 0 +deterioration 0 +in 0 +GFR 0 +which 0 +"," 0 +however 0 +"," 0 +was 0 +ameliorated 0 +by 0 +HP 0 +. 0 +NX 0 ++ 0 +HP 0 +caused 0 +a 0 +further 0 +rise 0 +in 0 +blood 0 +pressure 0 +in 0 +Li 1 +- 0 +pretreated 0 +rats 0 +. 0 +The 0 +results 0 +indicate 0 +that 0 +Li 1 +- 0 +induced 0 +nephropathy 3 +"," 0 +even 0 +when 0 +the 0 +GFR 0 +is 0 +only 0 +modestly 0 +reduced 0 +"," 0 +is 0 +associated 0 +with 0 +proteinuria 3 +and 0 +arterial 0 +systolic 0 +hypertension 3 +. 0 +In 0 +this 0 +model 0 +of 0 +chronic 3 +renal 4 +failure 4 +the 0 +decline 0 +in 0 +GFR 0 +is 0 +not 0 +accompanied 0 +by 0 +a 0 +corresponding 0 +fall 0 +in 0 +effective 0 +renal 0 +plasma 0 +flow 0 +"," 0 +which 0 +may 0 +be 0 +the 0 +functional 0 +expression 0 +of 0 +the 0 +formation 0 +of 0 +nonfiltrating 0 +atubular 0 +glomeruli 0 +. 0 +The 0 +fractional 0 +reabsorption 0 +of 0 +tubular 0 +fluid 0 +by 0 +the 0 +proximal 0 +tubules 0 +is 0 +reduced 0 +"," 0 +leaving 0 +the 0 +distal 0 +delivery 0 +unchanged 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Treatment 0 +of 0 +Crohn 3 +' 4 +s 4 +disease 4 +with 0 +fusidic 1 +acid 2 +: 0 +an 0 +antibiotic 0 +with 0 +immunosuppressive 0 +properties 0 +similar 0 +to 0 +cyclosporin 1 +. 0 +Fusidic 0 +acid 0 +is 0 +an 0 +antibiotic 0 +with 0 +T 0 +- 0 +cell 0 +specific 0 +immunosuppressive 0 +effects 0 +similar 0 +to 0 +those 0 +of 0 +cyclosporin 1 +. 0 +Because 0 +of 0 +the 0 +need 0 +for 0 +the 0 +development 0 +of 0 +new 0 +treatments 0 +for 0 +Crohn 3 +' 4 +s 4 +disease 4 +"," 0 +a 0 +pilot 0 +study 0 +was 0 +undertaken 0 +to 0 +estimate 0 +the 0 +pharmacodynamics 0 +and 0 +tolerability 0 +of 0 +fusidic 1 +acid 2 +treatment 0 +in 0 +chronic 0 +active 0 +"," 0 +therapy 0 +- 0 +resistant 0 +patients 0 +. 0 +Eight 0 +Crohn 3 +' 4 +s 4 +disease 4 +patients 0 +were 0 +included 0 +. 0 +Fusidic 1 +acid 2 +was 0 +administered 0 +orally 0 +in 0 +a 0 +dose 0 +of 0 +500 0 +mg 0 +t 0 +. 0 +d 0 +. 0 +s 0 +. 0 +and 0 +the 0 +treatment 0 +was 0 +planned 0 +to 0 +last 0 +8 0 +weeks 0 +. 0 +The 0 +disease 0 +activity 0 +was 0 +primarily 0 +measured 0 +by 0 +a 0 +modified 0 +individual 0 +grading 0 +score 0 +. 0 +Five 0 +of 0 +8 0 +patients 0 +( 0 +63 0 +% 0 +) 0 +improved 0 +during 0 +fusidic 1 +acid 2 +treatment 0 +: 0 +3 0 +at 0 +two 0 +weeks 0 +and 0 +2 0 +after 0 +four 0 +weeks 0 +. 0 +There 0 +were 0 +no 0 +serious 0 +clinical 0 +side 0 +effects 0 +"," 0 +but 0 +dose 0 +reduction 0 +was 0 +required 0 +in 0 +two 0 +patients 0 +because 0 +of 0 +nausea 3 +. 0 +Biochemically 0 +"," 0 +an 0 +increase 0 +in 0 +alkaline 0 +phosphatases 0 +was 0 +noted 0 +in 0 +5 0 +of 0 +8 0 +cases 0 +( 0 +63 0 +% 0 +) 0 +"," 0 +and 0 +the 0 +greatest 0 +increases 0 +were 0 +seen 0 +in 0 +those 0 +who 0 +had 0 +elevated 0 +levels 0 +prior 0 +to 0 +treatment 0 +. 0 +All 0 +reversed 0 +to 0 +pre 0 +- 0 +treatment 0 +levels 0 +after 0 +cessation 0 +of 0 +treatment 0 +. 0 +The 0 +results 0 +of 0 +this 0 +pilot 0 +study 0 +suggest 0 +that 0 +fusidic 1 +acid 2 +may 0 +be 0 +of 0 +benefit 0 +in 0 +selected 0 +chronic 0 +active 0 +Crohn 3 +' 4 +s 4 +disease 4 +patients 0 +in 0 +whom 0 +conventional 0 +treatment 0 +is 0 +ineffective 0 +. 0 +Because 0 +there 0 +seems 0 +to 0 +exist 0 +a 0 +scientific 0 +rationale 0 +for 0 +the 0 +use 0 +of 0 +fusidic 1 +acid 2 +at 0 +the 0 +cytokine 0 +level 0 +in 0 +inflammatory 3 +bowel 4 +disease 4 +"," 0 +we 0 +suggest 0 +that 0 +the 0 +role 0 +of 0 +this 0 +treatment 0 +should 0 +be 0 +further 0 +investigated 0 +. 0 +Changes 0 +in 0 +depressive 3 +status 0 +associated 0 +with 0 +topical 0 +beta 0 +- 0 +blockers 0 +. 0 +Depression 3 +and 0 +sexual 3 +dysfunction 4 +have 0 +been 0 +related 0 +to 0 +side 0 +effects 0 +of 0 +topical 0 +beta 0 +- 0 +blockers 0 +. 0 +We 0 +performed 0 +a 0 +preliminary 0 +study 0 +in 0 +order 0 +to 0 +determine 0 +any 0 +difference 0 +between 0 +a 0 +non 0 +selective 0 +beta 0 +- 0 +blocker 0 +( 0 +timolol 1 +) 0 +and 0 +a 0 +selective 0 +beta 0 +- 0 +blocker 0 +( 0 +betaxolol 1 +) 0 +regarding 0 +CNS 0 +side 0 +effects 0 +. 0 +Eight 0 +glaucomatous 3 +patients 0 +chronically 0 +treated 0 +with 0 +timolol 1 +0 0 +. 0 +5 0 +% 0 +/ 0 +12h 0 +"," 0 +suffering 0 +from 0 +depression 3 +diagnosed 0 +through 0 +DMS 0 +- 0 +III 0 +- 0 +R 0 +criteria 0 +"," 0 +were 0 +included 0 +in 0 +the 0 +study 0 +. 0 +During 0 +the 0 +six 0 +- 0 +month 0 +follow 0 +up 0 +"," 0 +depression 3 +was 0 +quantified 0 +through 0 +the 0 +Beck 0 +and 0 +Zung 0 +- 0 +Conde 0 +scales 0 +every 0 +two 0 +months 0 +. 0 +In 0 +a 0 +double 0 +blind 0 +cross 0 +- 0 +over 0 +study 0 +with 0 +control 0 +group 0 +"," 0 +the 0 +patients 0 +under 0 +timolol 1 +treatment 0 +presented 0 +higher 0 +depression 3 +values 0 +measured 0 +through 0 +the 0 +Beck 0 +and 0 +the 0 +Zung 0 +- 0 +Conde 0 +scales 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +vs 0 +control 0 +) 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +betaxolol 1 +could 0 +be 0 +less 0 +of 0 +a 0 +depression 3 +- 0 +inducer 0 +than 0 +timolol 1 +in 0 +predisposed 0 +patients 0 +. 0 +Protection 0 +against 0 +amphetamine 1 +- 0 +induced 0 +neurotoxicity 3 +toward 0 +striatal 0 +dopamine 1 +neurons 0 +in 0 +rodents 0 +by 0 +LY274614 1 +"," 0 +an 0 +excitatory 0 +amino 1 +acid 2 +antagonist 0 +. 0 +LY274614 1 +"," 0 +3SR 1 +"," 2 +4aRS 2 +"," 2 +6SR 2 +"," 2 +8aRS 2 +- 2 +6 2 +- 2 +[ 2 +phosphonomethyl 2 +] 2 +decahydr 2 +oisoquinoline 2 +- 2 +3 2 +- 2 +carboxylic 2 +acid 2 +"," 0 +has 0 +been 0 +described 0 +as 0 +a 0 +potent 0 +antagonist 0 +of 0 +the 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +subtype 0 +of 0 +glutamate 1 +receptor 0 +. 0 +Here 0 +its 0 +ability 0 +to 0 +antagonize 0 +the 0 +prolonged 0 +depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +by 0 +amphetamine 1 +in 0 +iprindole 1 +- 0 +treated 0 +rats 0 +is 0 +reported 0 +. 0 +A 0 +single 0 +18 0 +. 0 +4 0 +mg 0 +/ 0 +kg 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +dose 0 +of 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +amphetamine 1 +hemisulfate 0 +"," 0 +given 0 +to 0 +rats 0 +pretreated 0 +with 0 +iprindole 1 +"," 0 +resulted 0 +in 0 +persistent 0 +depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +1 0 +week 0 +later 0 +. 0 +This 0 +prolonged 0 +depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +was 0 +antagonized 0 +by 0 +dizocilpine 1 +( 0 +MK 1 +- 2 +801 2 +"," 0 +a 0 +non 0 +- 0 +competitive 0 +antagonist 0 +of 0 +NMDA 1 +receptors 0 +) 0 +or 0 +by 0 +LY274614 1 +( 0 +a 0 +competitive 0 +antagonist 0 +of 0 +NMDA 1 +receptors 0 +) 0 +. 0 +The 0 +protective 0 +effect 0 +of 0 +LY274614 1 +was 0 +dose 0 +- 0 +dependent 0 +"," 0 +being 0 +maximum 0 +at 0 +10 0 +- 0 +40 0 +mgkg 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 +A 0 +10 0 +mg 0 +/ 0 +kg 0 +dose 0 +of 0 +LY274614 1 +was 0 +effective 0 +in 0 +antagonizing 0 +the 0 +depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +"," 0 +when 0 +given 0 +as 0 +long 0 +as 0 +8 0 +hr 0 +prior 0 +to 0 +amphetamine 1 +but 0 +not 0 +when 0 +given 0 +24 0 +hr 0 +prior 0 +to 0 +amphetamine 1 +. 0 +Depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +was 0 +also 0 +antagonized 0 +when 0 +LY274614 1 +was 0 +given 0 +after 0 +the 0 +injection 0 +of 0 +amphetamine 1 +; 0 +LY274614 1 +protected 0 +when 0 +given 0 +up 0 +to 0 +4 0 +hr 0 +after 0 +but 0 +not 0 +when 0 +given 0 +8 0 +or 0 +24 0 +hr 0 +after 0 +amphetamine 1 +. 0 +The 0 +prolonged 0 +depletion 0 +of 0 +dopamine 1 +in 0 +the 0 +striatum 0 +in 0 +mice 0 +"," 0 +given 0 +multiple 0 +injections 0 +of 0 +methamphetamine 1 +"," 0 +was 0 +also 0 +antagonized 0 +dose 0 +- 0 +dependently 0 +and 0 +completely 0 +by 0 +LY274614 1 +. 0 +The 0 +data 0 +strengthen 0 +the 0 +evidence 0 +that 0 +the 0 +neurotoxic 3 +effect 0 +of 0 +amphetamine 1 +and 0 +related 0 +compounds 0 +toward 0 +nigrostriatal 0 +dopamine 1 +neurons 0 +involves 0 +NMDA 1 +receptors 0 +and 0 +that 0 +LY274614 1 +is 0 +an 0 +NMDA 1 +receptor 0 +antagonist 0 +with 0 +long 0 +- 0 +lasting 0 +in 0 +vivo 0 +effects 0 +in 0 +rats 0 +. 0 +Ketoconazole 1 +- 0 +induced 0 +neurologic 3 +sequelae 4 +. 0 +A 0 +77 0 +- 0 +y 0 +- 0 +old 0 +patient 0 +developed 0 +weakness 3 +of 4 +extremities 4 +"," 0 +legs 3 +paralysis 4 +"," 0 +dysarthria 3 +and 0 +tremor 3 +1 0 +h 0 +after 0 +ingestion 0 +of 0 +200 0 +mg 0 +ketoconazole 1 +for 0 +the 0 +first 0 +time 0 +in 0 +his 0 +life 0 +. 0 +All 0 +complaints 0 +faded 0 +away 0 +within 0 +24 0 +h 0 +. 0 +Few 0 +days 0 +later 0 +"," 0 +the 0 +patient 0 +used 0 +another 0 +200 0 +mg 0 +ketoconazole 1 +tablet 0 +"," 0 +and 0 +within 0 +an 0 +hour 0 +experienced 0 +a 0 +similar 0 +clinical 0 +picture 0 +"," 0 +which 0 +resolved 0 +again 0 +spontaneously 0 +within 0 +hours 0 +. 0 +Laboratory 0 +evaluations 0 +"," 0 +including 0 +head 0 +CT 0 +scan 0 +"," 0 +were 0 +normal 0 +. 0 +This 0 +case 0 +illustrates 0 +the 0 +need 0 +for 0 +close 0 +vigilance 0 +in 0 +adverse 3 +drug 4 +reactions 4 +"," 0 +particularly 0 +in 0 +the 0 +elderly 0 +. 0 +Development 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +in 0 +parkinsonian 3 +monkeys 0 +may 0 +depend 0 +upon 0 +rate 0 +of 0 +symptom 0 +onset 0 +and 0 +/ 0 +or 0 +duration 0 +of 0 +symptoms 0 +. 0 +Levodopa 1 +- 0 +induced 0 +dyskinesias 3 +( 0 +LIDs 3 +) 0 +present 0 +a 0 +major 0 +problem 0 +for 0 +the 0 +long 0 +- 0 +term 0 +management 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +patients 0 +. 0 +Due 0 +to 0 +the 0 +interdependence 0 +of 0 +risk 0 +factors 0 +in 0 +clinical 0 +populations 0 +"," 0 +it 0 +is 0 +difficult 0 +to 0 +independently 0 +examine 0 +factors 0 +that 0 +may 0 +influence 0 +the 0 +development 0 +of 0 +LIDs 3 +. 0 +Using 0 +macaque 0 +monkeys 0 +with 0 +different 0 +types 0 +of 0 +MPTP 1 +- 0 +induced 0 +parkinsonism 3 +"," 0 +the 0 +current 0 +study 0 +evaluated 0 +the 0 +degree 0 +to 0 +which 0 +rate 0 +of 0 +symptom 0 +progression 0 +"," 0 +symptom 0 +severity 0 +"," 0 +and 0 +response 0 +to 0 +and 0 +duration 0 +of 0 +levodopa 1 +therapy 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +development 0 +of 0 +LIDs 3 +. 0 +Monkeys 0 +with 0 +acute 0 +( 0 +short 0 +- 0 +term 0 +) 0 +MPTP 1 +exposure 0 +"," 0 +rapid 0 +symptom 0 +onset 0 +and 0 +short 0 +symptom 0 +duration 0 +prior 0 +to 0 +initiation 0 +of 0 +levodopa 1 +therapy 0 +developed 0 +dyskinesia 3 +between 0 +11 0 +and 0 +24 0 +days 0 +of 0 +daily 0 +levodopa 1 +administration 0 +. 0 +In 0 +contrast 0 +"," 0 +monkeys 0 +with 0 +long 0 +- 0 +term 0 +MPTP 1 +exposure 0 +"," 0 +slow 0 +symptom 0 +progression 0 +and 0 +/ 0 +or 0 +long 0 +symptom 0 +duration 0 +prior 0 +to 0 +initiation 0 +of 0 +levodopa 1 +therapy 0 +were 0 +more 0 +resistant 0 +to 0 +developing 0 +LIDs 3 +( 0 +e 0 +. 0 +g 0 +. 0 +"," 0 +dyskinesia 3 +developed 0 +no 0 +sooner 0 +than 0 +146 0 +days 0 +of 0 +chronic 0 +levodopa 1 +administration 0 +) 0 +. 0 +All 0 +animals 0 +were 0 +similarly 0 +symptomatic 0 +at 0 +the 0 +start 0 +of 0 +levodopa 1 +treatment 0 +and 0 +had 0 +similar 0 +therapeutic 0 +responses 0 +to 0 +the 0 +drug 0 +. 0 +These 0 +data 0 +suggest 0 +distinct 0 +differences 0 +in 0 +the 0 +propensity 0 +to 0 +develop 0 +LIDs 3 +in 0 +monkeys 0 +with 0 +different 0 +rates 0 +of 0 +symptom 0 +progression 0 +or 0 +symptom 0 +durations 0 +prior 0 +to 0 +levodopa 1 +and 0 +demonstrate 0 +the 0 +value 0 +of 0 +these 0 +models 0 +for 0 +further 0 +studying 0 +the 0 +pathophysiology 0 +of 0 +LIDs 3 +. 0 +A 0 +diet 0 +promoting 0 +sugar 3 +dependency 4 +causes 0 +behavioral 3 +cross 4 +- 4 +sensitization 4 +to 0 +a 0 +low 0 +dose 0 +of 0 +amphetamine 1 +. 0 +Previous 0 +research 0 +in 0 +this 0 +laboratory 0 +has 0 +shown 0 +that 0 +a 0 +diet 0 +of 0 +intermittent 0 +excessive 0 +sugar 0 +consumption 0 +produces 0 +a 0 +state 0 +with 0 +neurochemical 0 +and 0 +behavioral 0 +similarities 0 +to 0 +drug 3 +dependency 4 +. 0 +The 0 +present 0 +study 0 +examined 0 +whether 0 +female 0 +rats 0 +on 0 +various 0 +regimens 0 +of 0 +sugar 0 +access 0 +would 0 +show 0 +behavioral 3 +cross 4 +- 4 +sensitization 4 +to 0 +a 0 +low 0 +dose 0 +of 0 +amphetamine 1 +. 0 +After 0 +a 0 +30 0 +- 0 +min 0 +baseline 0 +measure 0 +of 0 +locomotor 0 +activity 0 +( 0 +day 0 +0 0 +) 0 +"," 0 +animals 0 +were 0 +maintained 0 +on 0 +a 0 +cyclic 0 +diet 0 +of 0 +12 0 +- 0 +h 0 +deprivation 0 +followed 0 +by 0 +12 0 +- 0 +h 0 +access 0 +to 0 +10 0 +% 0 +sucrose 1 +solution 0 +and 0 +chow 0 +pellets 0 +( 0 +12 0 +h 0 +access 0 +starting 0 +4 0 +h 0 +after 0 +onset 0 +of 0 +the 0 +dark 0 +period 0 +) 0 +for 0 +21 0 +days 0 +. 0 +Locomotor 0 +activity 0 +was 0 +measured 0 +again 0 +for 0 +30 0 +min 0 +at 0 +the 0 +beginning 0 +of 0 +days 0 +1 0 +and 0 +21 0 +of 0 +sugar 0 +access 0 +. 0 +Beginning 0 +on 0 +day 0 +22 0 +"," 0 +all 0 +rats 0 +were 0 +maintained 0 +on 0 +ad 0 +libitum 0 +chow 0 +. 0 +Nine 0 +days 0 +later 0 +locomotor 0 +activity 0 +was 0 +measured 0 +in 0 +response 0 +to 0 +a 0 +single 0 +low 0 +dose 0 +of 0 +amphetamine 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 +The 0 +animals 0 +that 0 +had 0 +experienced 0 +cyclic 0 +sucrose 1 +and 0 +chow 0 +were 0 +hyperactive 3 +in 0 +response 0 +to 0 +amphetamine 1 +compared 0 +with 0 +four 0 +control 0 +groups 0 +( 0 +ad 0 +libitum 0 +10 0 +% 0 +sucrose 1 +and 0 +chow 0 +followed 0 +by 0 +amphetamine 1 +injection 0 +"," 0 +cyclic 0 +chow 0 +followed 0 +by 0 +amphetamine 1 +injection 0 +"," 0 +ad 0 +libitum 0 +chow 0 +with 0 +amphetamine 1 +"," 0 +or 0 +cyclic 0 +10 0 +% 0 +sucrose 1 +and 0 +chow 0 +with 0 +a 0 +saline 0 +injection 0 +) 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +a 0 +diet 0 +comprised 0 +of 0 +alternating 0 +deprivation 0 +and 0 +access 0 +to 0 +a 0 +sugar 0 +solution 0 +and 0 +chow 0 +produces 0 +bingeing 0 +on 0 +sugar 0 +that 0 +leads 0 +to 0 +a 0 +long 0 +lasting 0 +state 0 +of 0 +increased 0 +sensitivity 0 +to 0 +amphetamine 1 +"," 0 +possibly 0 +due 0 +to 0 +a 0 +lasting 0 +alteration 0 +in 0 +the 0 +dopamine 1 +system 0 +. 0 +Reversible 0 +dilated 3 +cardiomyopathy 4 +related 0 +to 0 +amphotericin 1 +B 2 +therapy 0 +. 0 +We 0 +describe 0 +a 0 +patient 0 +who 0 +developed 0 +dilated 3 +cardiomyopathy 4 +and 0 +clinical 0 +congestive 0 +heart 3 +failure 4 +after 0 +2 0 +months 0 +of 0 +therapy 0 +with 0 +amphotericin 1 +B 2 +( 0 +AmB 1 +) 0 +for 0 +disseminated 0 +coccidioidomycosis 3 +. 0 +His 0 +echocardiographic 0 +abnormalities 0 +and 0 +heart 3 +failure 4 +resolved 0 +after 0 +posaconazole 1 +was 0 +substituted 0 +for 0 +AmB 1 +. 0 +It 0 +is 0 +important 0 +to 0 +recognize 0 +the 0 +rare 0 +and 0 +potentially 0 +reversible 0 +toxicity 3 +of 0 +AmB 1 +. 0 +N0 1 +- 0 +induced 0 +migraine 3 +attack 0 +: 0 +strong 0 +increase 0 +in 0 +plasma 0 +calcitonin 1 +gene 2 +- 2 +related 2 +peptide 2 +( 0 +CGRP 1 +) 0 +concentration 0 +and 0 +negative 0 +correlation 0 +with 0 +platelet 0 +serotonin 1 +release 0 +. 0 +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +investigate 0 +changes 0 +in 0 +the 0 +plasma 0 +calcitonin 1 +gene 2 +- 2 +related 2 +peptide 2 +( 0 +CGRP 1 +) 0 +concentration 0 +and 0 +platelet 0 +serotonin 1 +( 0 +5 1 +- 2 +hydroxytriptamine 2 +"," 0 +5 1 +- 2 +HT 2 +) 0 +content 0 +during 0 +the 0 +immediate 0 +headache 3 +and 0 +the 0 +delayed 0 +genuine 0 +migraine 3 +attack 0 +provoked 0 +by 0 +nitroglycerin 1 +. 0 +Fifteen 0 +female 0 +migraineurs 3 +( 4 +without 4 +aura 4 +) 4 +and 0 +eight 0 +controls 0 +participated 0 +in 0 +the 0 +study 0 +. 0 +Sublingual 0 +nitroglycerin 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +) 0 +was 0 +administered 0 +. 0 +Blood 0 +was 0 +collected 0 +from 0 +the 0 +antecubital 0 +vein 0 +four 0 +times 0 +: 0 +60 0 +min 0 +before 0 +and 0 +after 0 +the 0 +nitroglycerin 1 +application 0 +"," 0 +and 0 +60 0 +and 0 +120 0 +min 0 +after 0 +the 0 +beginning 0 +of 0 +the 0 +migraine 3 +attack 0 +( 0 +mean 0 +344 0 +and 0 +404 0 +min 0 +; 0 +12 0 +subjects 0 +) 0 +. 0 +In 0 +those 0 +subjects 0 +who 0 +had 0 +no 0 +migraine 3 +attack 0 +( 0 +11 0 +subjects 0 +) 0 +a 0 +similar 0 +time 0 +schedule 0 +was 0 +used 0 +. 0 +Plasma 0 +CGRP 1 +concentration 0 +increased 0 +significantly 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +during 0 +the 0 +migraine 3 +attack 0 +and 0 +returned 0 +to 0 +baseline 0 +after 0 +the 0 +cessation 0 +of 0 +the 0 +migraine 3 +. 0 +In 0 +addition 0 +"," 0 +both 0 +change 0 +and 0 +peak 0 +"," 0 +showed 0 +significant 0 +positive 0 +correlations 0 +with 0 +migraine 3 +headache 3 +intensity 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +However 0 +"," 0 +plasma 0 +CGRP 1 +concentrations 0 +failed 0 +to 0 +change 0 +during 0 +immediate 0 +headache 3 +and 0 +in 0 +the 0 +subjects 0 +with 0 +no 0 +migraine 3 +attack 0 +. 0 +Basal 0 +CGRP 1 +concentration 0 +was 0 +significantly 0 +higher 0 +and 0 +platelet 0 +5 1 +- 2 +HT 2 +content 0 +tended 0 +to 0 +be 0 +lower 0 +in 0 +subjects 0 +who 0 +experienced 0 +a 0 +migraine 3 +attack 0 +. 0 +Platelet 0 +serotonin 1 +content 0 +decreased 0 +significantly 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +after 0 +nitroglycerin 1 +in 0 +subjects 0 +with 0 +no 0 +migraine 3 +attack 0 +but 0 +no 0 +consistent 0 +change 0 +was 0 +observed 0 +in 0 +patients 0 +with 0 +migraine 3 +attack 0 +. 0 +In 0 +conclusion 0 +"," 0 +the 0 +fact 0 +that 0 +plasma 0 +CGRP 1 +concentration 0 +correlates 0 +with 0 +the 0 +timing 0 +and 0 +severity 0 +of 0 +a 0 +migraine 3 +headache 3 +suggests 0 +a 0 +direct 0 +relationship 0 +between 0 +CGRP 1 +and 0 +migraine 3 +. 0 +In 0 +contrast 0 +"," 0 +serotonin 1 +release 0 +from 0 +platelets 0 +does 0 +not 0 +provoke 0 +migraine 3 +"," 0 +it 0 +may 0 +even 0 +counteract 0 +the 0 +headache 3 +and 0 +the 0 +concomitant 0 +CGRP 1 +release 0 +in 0 +this 0 +model 0 +. 0 +Hyperbaric 0 +oxygen 1 +therapy 0 +for 0 +control 0 +of 0 +intractable 0 +cyclophosphamide 1 +- 0 +induced 0 +hemorrhagic 3 +cystitis 4 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +intractable 0 +hemorrhagic 3 +cystitis 4 +due 0 +to 0 +cyclophosphamide 1 +therapy 0 +for 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +. 0 +Conservative 0 +treatment 0 +"," 0 +including 0 +bladder 0 +irrigation 0 +with 0 +physiological 0 +saline 0 +and 0 +instillation 0 +of 0 +prostaglandin 1 +F2 2 +alpha 2 +"," 0 +failed 0 +to 0 +totally 0 +control 0 +hemorrhage 3 +. 0 +We 0 +then 0 +used 0 +hyperbaric 0 +oxygen 1 +at 0 +an 0 +absolute 0 +pressure 0 +of 0 +2 0 +atm 0 +"," 0 +5 0 +days 0 +a 0 +week 0 +for 0 +8 0 +consecutive 0 +weeks 0 +. 0 +The 0 +bleeding 3 +ceased 0 +completely 0 +by 0 +the 0 +end 0 +of 0 +treatment 0 +and 0 +the 0 +patient 0 +remained 0 +free 0 +of 0 +hematuria 3 +thereafter 0 +. 0 +No 0 +side 0 +effect 0 +was 0 +noted 0 +during 0 +the 0 +course 0 +of 0 +therapy 0 +. 0 +In 0 +future 0 +"," 0 +this 0 +form 0 +of 0 +therapy 0 +can 0 +offer 0 +a 0 +safe 0 +alternative 0 +in 0 +the 0 +treatment 0 +of 0 +cyclophosphamide 1 +- 0 +induced 0 +hemorrhagic 3 +cystitis 4 +. 0 +Acute 3 +psychosis 4 +due 0 +to 0 +treatment 0 +with 0 +phenytoin 1 +in 0 +a 0 +nonepileptic 0 +patient 0 +. 0 +The 0 +development 0 +of 0 +psychosis 3 +related 0 +to 0 +antiepileptic 0 +drug 0 +treatment 0 +is 0 +usually 0 +attributed 0 +to 0 +the 0 +interaction 0 +between 0 +the 0 +epileptic 3 +brain 0 +substratum 0 +and 0 +the 0 +antiepileptic 0 +drugs 0 +. 0 +The 0 +case 0 +of 0 +a 0 +nonepileptic 0 +patient 0 +who 0 +developed 0 +psychosis 3 +following 0 +phenytoin 1 +treatment 0 +for 0 +trigeminal 3 +neuralgia 4 +is 0 +described 0 +. 0 +This 0 +case 0 +suggests 0 +that 0 +the 0 +psychotic 3 +symptoms 4 +that 0 +occur 0 +following 0 +phenytoin 1 +treatment 0 +in 0 +some 0 +epileptic 3 +patients 0 +may 0 +be 0 +the 0 +direct 0 +result 0 +of 0 +medication 0 +"," 0 +unrelated 0 +to 0 +seizures 3 +. 0 +Risks 0 +of 0 +the 0 +consumption 0 +of 0 +beverages 0 +containing 0 +quinine 1 +. 0 +Although 0 +the 0 +United 0 +States 0 +Food 0 +and 0 +Drug 0 +Administration 0 +banned 0 +its 0 +use 0 +for 0 +nocturnal 3 +leg 4 +cramps 4 +due 0 +to 0 +lack 0 +of 0 +safety 0 +and 0 +efficacy 0 +"," 0 +quinine 1 +is 0 +widely 0 +available 0 +in 0 +beverages 0 +including 0 +tonic 0 +water 0 +and 0 +bitter 0 +lemon 0 +. 0 +Numerous 0 +anecdotal 0 +reports 0 +suggest 0 +that 0 +products 0 +containing 0 +quinine 1 +may 0 +produce 0 +neurological 3 +complications 4 +"," 0 +including 0 +confusion 3 +"," 0 +altered 0 +mental 0 +status 0 +"," 0 +seizures 3 +"," 0 +and 0 +coma 3 +"," 0 +particularly 0 +in 0 +older 0 +women 0 +. 0 +Psychologists 0 +need 0 +to 0 +inquire 0 +about 0 +consumption 0 +of 0 +quinine 1 +- 0 +containing 0 +beverages 0 +as 0 +part 0 +of 0 +an 0 +evaluation 0 +process 0 +. 0 +Transient 0 +platypnea 3 +- 4 +orthodeoxia 4 +- 4 +like 4 +syndrome 4 +induced 0 +by 0 +propafenone 1 +overdose 3 +in 0 +a 0 +young 0 +woman 0 +with 0 +Ebstein 3 +' 4 +s 4 +anomaly 4 +. 0 +In 0 +this 0 +report 0 +we 0 +describe 0 +the 0 +case 0 +of 0 +a 0 +37 0 +- 0 +year 0 +- 0 +old 0 +white 0 +woman 0 +with 0 +Ebstein 3 +' 4 +s 4 +anomaly 4 +"," 0 +who 0 +developed 0 +a 0 +rare 0 +syndrome 0 +called 0 +platypnea 3 +- 4 +orthodeoxia 4 +"," 0 +characterized 0 +by 0 +massive 0 +right 0 +- 0 +to 0 +- 0 +left 0 +interatrial 0 +shunting 0 +with 0 +transient 0 +profound 0 +hypoxia 3 +and 0 +cyanosis 3 +. 0 +This 0 +shunt 0 +of 0 +blood 0 +via 0 +a 0 +patent 3 +foramen 4 +ovale 4 +occurred 0 +in 0 +the 0 +presence 0 +of 0 +a 0 +normal 0 +pulmonary 0 +artery 0 +pressure 0 +"," 0 +and 0 +was 0 +probably 0 +precipitated 0 +by 0 +a 0 +propafenone 1 +overdose 3 +. 0 +This 0 +drug 0 +caused 0 +biventricular 3 +dysfunction 4 +"," 0 +due 0 +to 0 +its 0 +negative 0 +inotropic 0 +effect 0 +"," 0 +and 0 +hypotension 3 +"," 0 +due 0 +to 0 +its 0 +peripheral 0 +vasodilatory 0 +effect 0 +. 0 +These 0 +effects 0 +gave 0 +rise 0 +to 0 +an 0 +increase 0 +in 0 +the 0 +right 0 +atrial 0 +pressure 0 +and 0 +a 0 +decrease 0 +in 0 +the 0 +left 0 +one 0 +with 0 +a 0 +consequent 0 +stretching 0 +of 0 +the 0 +foramen 0 +ovale 0 +and 0 +the 0 +creation 0 +of 0 +massive 0 +right 0 +- 0 +to 0 +- 0 +left 0 +shunting 0 +. 0 +In 0 +our 0 +case 0 +this 0 +interatrial 0 +shunt 0 +was 0 +very 0 +accurately 0 +detected 0 +at 0 +bubble 0 +contrast 0 +echocardiography 0 +. 0 +Noxious 0 +chemical 0 +stimulation 0 +of 0 +rat 0 +facial 0 +mucosa 0 +increases 0 +intracranial 0 +blood 0 +flow 0 +through 0 +a 0 +trigemino 0 +- 0 +parasympathetic 0 +reflex 0 +- 0 +- 0 +an 0 +experimental 0 +model 0 +for 0 +vascular 3 +dysfunctions 4 +in 0 +cluster 3 +headache 4 +. 0 +Cluster 3 +headache 4 +is 0 +characterized 0 +by 0 +typical 0 +autonomic 0 +dysfunctions 0 +including 0 +facial 0 +and 0 +intracranial 3 +vascular 4 +disturbances 4 +. 0 +Both 0 +the 0 +trigeminal 0 +and 0 +the 0 +cranial 0 +parasympathetic 0 +systems 0 +may 0 +be 0 +involved 0 +in 0 +mediating 0 +these 0 +dysfunctions 0 +. 0 +An 0 +experimental 0 +model 0 +was 0 +developed 0 +in 0 +the 0 +rat 0 +to 0 +measure 0 +changes 0 +in 0 +lacrimation 0 +and 0 +intracranial 0 +blood 0 +flow 0 +following 0 +noxious 0 +chemical 0 +stimulation 0 +of 0 +facial 0 +mucosa 0 +. 0 +Blood 0 +flow 0 +was 0 +monitored 0 +in 0 +arteries 0 +of 0 +the 0 +exposed 0 +cranial 0 +dura 0 +mater 0 +and 0 +the 0 +parietal 0 +cortex 0 +using 0 +laser 0 +Doppler 0 +flowmetry 0 +. 0 +Capsaicin 1 +( 0 +0 0 +. 0 +1 0 +- 0 +1 0 +mm 0 +) 0 +applied 0 +to 0 +oral 0 +or 0 +nasal 0 +mucosa 0 +induced 0 +increases 3 +in 4 +dural 4 +and 4 +cortical 4 +blood 4 +flow 4 +and 0 +provoked 0 +lacrimation 0 +. 0 +These 0 +responses 0 +were 0 +blocked 0 +by 0 +systemic 0 +pre 0 +- 0 +administration 0 +of 0 +hexamethonium 1 +chloride 2 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 +The 0 +evoked 0 +increases 3 +in 4 +dural 4 +blood 4 +flow 4 +were 0 +also 0 +abolished 0 +by 0 +topical 0 +pre 0 +- 0 +administration 0 +of 0 +atropine 1 +( 0 +1 0 +mm 0 +) 0 +and 0 +[ 0 +Lys1 0 +"," 0 +Pro2 0 +"," 0 +5 0 +"," 0 +Arg3 0 +"," 0 +4 0 +"," 0 +Tyr6 0 +] 0 +- 0 +VIP 0 +( 0 +0 0 +. 0 +1 0 +mm 0 +) 0 +"," 0 +a 0 +vasoactive 0 +intestinal 0 +polypeptide 0 +( 0 +VIP 0 +) 0 +antagonist 0 +"," 0 +onto 0 +the 0 +exposed 0 +dura 0 +mater 0 +. 0 +We 0 +conclude 0 +that 0 +noxious 0 +stimulation 0 +of 0 +facial 0 +mucosa 0 +increases 0 +intracranial 0 +blood 0 +flow 0 +and 0 +lacrimation 0 +via 0 +a 0 +trigemino 0 +- 0 +parasympathetic 0 +reflex 0 +. 0 +The 0 +blood 0 +flow 0 +responses 0 +seem 0 +to 0 +be 0 +mediated 0 +by 0 +the 0 +release 0 +of 0 +acetylcholine 1 +and 0 +VIP 0 +within 0 +the 0 +meninges 0 +. 0 +Similar 0 +mechanisms 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +pathogenesis 0 +of 0 +cluster 3 +headache 4 +. 0 +0rganophosphate 1 +- 0 +induced 0 +convulsions 3 +and 0 +prevention 0 +of 0 +neuropathological 3 +damages 4 +. 0 +Such 0 +organophosphorus 1 +( 0 +0P 1 +) 0 +compounds 0 +as 0 +diisopropylfluorophosphate 1 +( 0 +DFP 1 +) 0 +"," 0 +sarin 1 +and 0 +soman 1 +are 0 +potent 0 +inhibitors 0 +of 0 +acetylcholinesterases 0 +( 0 +AChEs 0 +) 0 +and 0 +butyrylcholinesterases 0 +( 0 +BChEs 0 +) 0 +. 0 +The 0 +acute 0 +toxicity 3 +of 0 +0Ps 1 +is 0 +the 0 +result 0 +of 0 +their 0 +irreversible 0 +binding 0 +with 0 +AChEs 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +( 0 +CNS 0 +) 0 +"," 0 +which 0 +elevates 0 +acetylcholine 1 +( 0 +ACh 1 +) 0 +levels 0 +. 0 +The 0 +protective 0 +action 0 +of 0 +subcutaneously 0 +( 0 +SC 0 +) 0 +administered 0 +antidotes 0 +or 0 +their 0 +combinations 0 +in 0 +DFP 1 +( 0 +2 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +intoxication 0 +was 0 +studied 0 +in 0 +9 0 +- 0 +10 0 +- 0 +weeks 0 +- 0 +old 0 +Han 0 +- 0 +Wistar 0 +male 0 +rats 0 +. 0 +The 0 +rats 0 +received 0 +AChE 0 +reactivator 0 +pralidoxime 1 +- 2 +2 2 +- 2 +chloride 2 +( 0 +2PAM 1 +) 0 +( 0 +30 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +"," 0 +anticonvulsant 0 +diazepam 1 +( 0 +2 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +"," 0 +A 0 +( 0 +1 0 +) 0 +- 0 +adenosine 1 +receptor 0 +agonist 0 +N 1 +( 2 +6 2 +) 2 +- 2 +cyclopentyl 2 +adenosine 2 +( 0 +CPA 1 +) 0 +( 0 +2 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +"," 0 +NMDA 1 +- 0 +receptor 0 +antagonist 0 +dizocilpine 1 +maleate 2 +( 0 ++ 0 +- 0 +MK801 0 +hydrogen 0 +maleate 0 +) 0 +( 0 +2 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +or 0 +their 0 +combinations 0 +with 0 +cholinolytic 0 +drug 0 +atropine 1 +sulfate 2 +( 0 +50 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +BW 0 +) 0 +immediately 0 +or 0 +30 0 +min 0 +after 0 +the 0 +single 0 +SC 0 +injection 0 +of 0 +DFP 1 +. 0 +The 0 +control 0 +rats 0 +received 0 +atropine 1 +sulfate 2 +"," 0 +but 0 +also 0 +saline 0 +and 0 +olive 0 +oil 0 +instead 0 +of 0 +other 0 +antidotes 0 +and 0 +DFP 1 +"," 0 +respectively 0 +. 0 +All 0 +rats 0 +were 0 +terminated 0 +either 0 +24 0 +h 0 +or 0 +3 0 +weeks 0 +after 0 +the 0 +DFP 1 +injection 0 +. 0 +The 0 +rats 0 +treated 0 +with 0 +DFP 1 +- 0 +atropine 1 +showed 0 +severe 0 +typical 0 +0P 1 +- 0 +induced 0 +toxicity 3 +signs 0 +. 0 +When 0 +CPA 1 +"," 0 +diazepam 1 +or 0 +2PAM 1 +was 0 +given 0 +immediately 0 +after 0 +DFP 1 +- 0 +atropine 1 +"," 0 +these 0 +treatments 0 +prevented 0 +"," 0 +delayed 0 +or 0 +shortened 0 +the 0 +occurrence 0 +of 0 +serious 0 +signs 0 +of 0 +poisoning 3 +. 0 +Atropine 1 +- 0 +MK801 1 +did 0 +not 0 +offer 0 +any 0 +additional 0 +protection 0 +against 0 +DFP 1 +toxicity 3 +. 0 +In 0 +conclusion 0 +"," 0 +CPA 1 +"," 0 +diazepam 1 +and 0 +2PAM 1 +in 0 +combination 0 +with 0 +atropine 1 +prevented 0 +the 0 +occurrence 0 +of 0 +serious 0 +signs 0 +of 0 +poisoning 3 +and 0 +thus 0 +reduced 0 +the 0 +toxicity 3 +of 0 +DFP 1 +in 0 +rat 0 +. 0 +A 0 +pyridoxine 1 +- 0 +dependent 0 +behavioral 3 +disorder 4 +unmasked 0 +by 0 +isoniazid 1 +. 0 +A 0 +3 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +had 0 +behavioral 3 +deterioration 4 +"," 0 +with 0 +hyperkinesis 3 +"," 0 +irritability 3 +"," 0 +and 0 +sleeping 3 +difficulties 4 +after 0 +the 0 +therapeutic 0 +administration 0 +of 0 +isoniazid 1 +. 0 +The 0 +administration 0 +of 0 +pharmacologic 0 +doses 0 +of 0 +pyridoxine 1 +hydrochloride 2 +led 0 +to 0 +a 0 +disappearance 0 +of 0 +symptoms 0 +. 0 +After 0 +discontinuing 0 +isoniazid 1 +therapy 0 +a 0 +similar 0 +pattern 0 +of 0 +behavior 0 +was 0 +noted 0 +that 0 +was 0 +controlled 0 +by 0 +pyridoxine 1 +. 0 +A 0 +placebo 0 +had 0 +no 0 +effect 0 +"," 0 +but 0 +niacinamide 1 +was 0 +as 0 +effective 0 +as 0 +pyridoxine 1 +. 0 +Periodic 0 +withdrawal 0 +of 0 +pyridoxine 1 +was 0 +associated 0 +with 0 +return 0 +of 0 +the 0 +hyperkinesis 3 +. 0 +The 0 +level 0 +of 0 +pyridoxal 1 +in 0 +the 0 +blood 0 +was 0 +normal 0 +during 0 +the 0 +periods 0 +of 0 +relapse 0 +. 0 +Metabolic 0 +studies 0 +suggested 0 +a 0 +block 0 +in 0 +the 0 +kynurenine 1 +pathway 0 +of 0 +tryptophan 1 +metabolism 0 +. 0 +The 0 +patient 0 +has 0 +been 0 +followed 0 +for 0 +six 0 +years 0 +and 0 +has 0 +required 0 +pharmacologic 0 +doses 0 +of 0 +pyridoxine 1 +to 0 +control 0 +her 0 +behavior 0 +. 0 +Recurrent 0 +excitation 0 +in 0 +the 0 +dentate 0 +gyrus 0 +of 0 +a 0 +murine 0 +model 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 +Similar 0 +to 0 +rats 0 +"," 0 +systemic 0 +pilocarpine 1 +injection 0 +causes 0 +status 3 +epilepticus 4 +( 0 +SE 3 +) 0 +and 0 +the 0 +eventual 0 +development 0 +of 0 +spontaneous 0 +seizures 3 +and 0 +mossy 0 +fiber 0 +sprouting 0 +in 0 +C57BL 0 +/ 0 +6 0 +and 0 +CD1 0 +mice 0 +"," 0 +but 0 +the 0 +physiological 0 +correlates 0 +of 0 +these 0 +events 0 +have 0 +not 0 +been 0 +identified 0 +in 0 +mice 0 +. 0 +Population 0 +responses 0 +in 0 +granule 0 +cells 0 +of 0 +the 0 +dentate 0 +gyrus 0 +were 0 +examined 0 +in 0 +transverse 0 +slices 0 +of 0 +the 0 +ventral 0 +hippocampus 0 +from 0 +pilocarpine 1 +- 0 +treated 0 +and 0 +untreated 0 +mice 0 +. 0 +In 0 +Mg 1 +( 0 +2 0 ++ 0 +) 0 +- 0 +free 0 +bathing 0 +medium 0 +containing 0 +bicuculline 1 +"," 0 +conditions 0 +designed 0 +to 0 +increase 0 +excitability 0 +in 0 +the 0 +slices 0 +"," 0 +electrical 0 +stimulation 0 +of 0 +the 0 +hilus 0 +resulted 0 +in 0 +a 0 +single 0 +population 0 +spike 0 +in 0 +granule 0 +cells 0 +from 0 +control 0 +mice 0 +and 0 +pilocarpine 1 +- 0 +treated 0 +mice 0 +that 0 +did 0 +not 0 +experience 0 +SE 3 +. 0 +In 0 +SE 3 +survivors 0 +"," 0 +similar 0 +stimulation 0 +resulted 0 +in 0 +a 0 +population 0 +spike 0 +followed 0 +"," 0 +at 0 +a 0 +variable 0 +latency 0 +"," 0 +by 0 +negative 0 +DC 0 +shifts 0 +and 0 +repetitive 0 +afterdischarges 0 +of 0 +3 0 +- 0 +60 0 +s 0 +duration 0 +"," 0 +which 0 +were 0 +blocked 0 +by 0 +ionotropic 0 +glutamate 1 +receptor 0 +antagonists 0 +. 0 +Focal 0 +glutamate 1 +photostimulation 0 +of 0 +the 0 +granule 0 +cell 0 +layer 0 +at 0 +sites 0 +distant 0 +from 0 +the 0 +recording 0 +pipette 0 +resulted 0 +in 0 +population 0 +responses 0 +of 0 +1 0 +- 0 +30 0 +s 0 +duration 0 +in 0 +slices 0 +from 0 +SE 3 +survivors 0 +but 0 +not 0 +other 0 +groups 0 +. 0 +These 0 +data 0 +support 0 +the 0 +hypothesis 0 +that 0 +SE 3 +- 0 +induced 0 +mossy 0 +fiber 0 +sprouting 0 +and 0 +synaptic 0 +reorganization 0 +are 0 +relevant 0 +characteristics 0 +of 0 +seizure 3 +development 0 +in 0 +these 0 +murine 0 +strains 0 +"," 0 +resembling 0 +rat 0 +models 0 +of 0 +human 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 +Urinary 3 +bladder 4 +cancer 4 +in 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +: 0 +risks 0 +and 0 +relation 0 +to 0 +cyclophosphamide 1 +. 0 +0BJECTIVE 0 +: 0 +To 0 +assess 0 +and 0 +characterise 0 +the 0 +risk 0 +of 0 +bladder 3 +cancer 4 +"," 0 +and 0 +its 0 +relation 0 +to 0 +cyclophosphamide 1 +"," 0 +in 0 +patients 0 +with 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +. 0 +METH0DS 0 +: 0 +In 0 +the 0 +population 0 +based 0 +"," 0 +nationwide 0 +Swedish 0 +Inpatient 0 +Register 0 +a 0 +cohort 0 +of 0 +1065 0 +patients 0 +with 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +"," 0 +1969 0 +- 0 +95 0 +"," 0 +was 0 +identified 0 +. 0 +Through 0 +linkage 0 +with 0 +the 0 +Swedish 0 +Cancer 3 +Register 0 +"," 0 +all 0 +subjects 0 +in 0 +this 0 +cohort 0 +diagnosed 0 +with 0 +bladder 3 +cancer 4 +were 0 +identified 0 +. 0 +Nested 0 +within 0 +the 0 +cohort 0 +"," 0 +a 0 +matched 0 +case 0 +- 0 +control 0 +study 0 +was 0 +performed 0 +to 0 +estimate 0 +the 0 +association 0 +between 0 +cyclophosphamide 1 +and 0 +bladder 3 +cancer 4 +using 0 +odds 0 +ratios 0 +( 0 +0Rs 0 +) 0 +as 0 +relative 0 +risk 0 +. 0 +In 0 +the 0 +cohort 0 +the 0 +cumulative 0 +risk 0 +of 0 +bladder 3 +cancer 4 +after 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +"," 0 +and 0 +the 0 +relative 0 +prevalence 0 +of 0 +a 0 +history 0 +of 0 +bladder 3 +cancer 4 +at 0 +the 0 +time 0 +of 0 +diagnosis 0 +of 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +"," 0 +were 0 +also 0 +estimated 0 +. 0 +RESULTS 0 +: 0 +The 0 +median 0 +cumulative 0 +doses 0 +of 0 +cyclophosphamide 1 +among 0 +cases 0 +( 0 +n 0 += 0 +11 0 +) 0 +and 0 +controls 0 +( 0 +n 0 += 0 +25 0 +) 0 +were 0 +113 0 +g 0 +and 0 +25 0 +g 0 +"," 0 +respectively 0 +. 0 +The 0 +risk 0 +of 0 +bladder 3 +cancer 4 +doubled 0 +for 0 +every 0 +10 0 +g 0 +increment 0 +in 0 +cyclophosphamide 1 +( 0 +0R 0 += 0 +2 0 +. 0 +0 0 +"," 0 +95 0 +% 0 +confidence 0 +interval 0 +( 0 +CI 0 +) 0 +0 0 +. 0 +8 0 +to 0 +4 0 +. 0 +9 0 +) 0 +. 0 +Treatment 0 +duration 0 +longer 0 +than 0 +1 0 +year 0 +was 0 +associated 0 +with 0 +an 0 +eightfold 0 +increased 0 +risk 0 +( 0 +0R 0 += 0 +7 0 +. 0 +7 0 +"," 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +9 0 +to 0 +69 0 +) 0 +. 0 +The 0 +absolute 0 +risk 0 +for 0 +bladder 3 +cancer 4 +in 0 +the 0 +cohort 0 +reached 0 +10 0 +% 0 +16 0 +years 0 +after 0 +diagnosis 0 +of 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +"," 0 +and 0 +a 0 +history 0 +of 0 +bladder 3 +cancer 4 +was 0 +( 0 +non 0 +- 0 +significantly 0 +) 0 +twice 0 +as 0 +common 0 +as 0 +expected 0 +at 0 +the 0 +time 0 +of 0 +diagnosis 0 +of 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +. 0 +C0NCLUSI0N 0 +: 0 +The 0 +results 0 +indicate 0 +a 0 +dose 0 +- 0 +response 0 +relationship 0 +between 0 +cyclophosphamide 1 +and 0 +the 0 +risk 0 +of 0 +bladder 3 +cancer 4 +"," 0 +high 0 +cumulative 0 +risks 0 +in 0 +the 0 +entire 0 +cohort 0 +"," 0 +and 0 +also 0 +the 0 +possibility 0 +of 0 +risk 0 +factors 0 +operating 0 +even 0 +before 0 +Wegener 3 +' 4 +s 4 +granulomatosis 4 +. 0 +Differential 0 +modulation 0 +by 0 +estrogen 1 +of 0 +alpha2 0 +- 0 +adrenergic 0 +and 0 +I1 0 +- 0 +imidazoline 1 +receptor 0 +- 0 +mediated 0 +hypotension 3 +in 0 +female 0 +rats 0 +. 0 +We 0 +have 0 +recently 0 +shown 0 +that 0 +estrogen 1 +negatively 0 +modulates 0 +the 0 +hypotensive 3 +effect 0 +of 0 +clonidine 1 +( 0 +mixed 0 +alpha2 0 +- 0 +/ 0 +I1 0 +- 0 +receptor 0 +agonist 0 +) 0 +in 0 +female 0 +rats 0 +and 0 +implicates 0 +the 0 +cardiovascular 0 +autonomic 0 +control 0 +in 0 +this 0 +interaction 0 +. 0 +The 0 +present 0 +study 0 +investigated 0 +whether 0 +this 0 +effect 0 +of 0 +estrogen 1 +involves 0 +interaction 0 +with 0 +alpha2 0 +- 0 +and 0 +/ 0 +or 0 +I1 0 +- 0 +receptors 0 +. 0 +Changes 0 +evoked 0 +by 0 +a 0 +single 0 +intraperitoneal 0 +injection 0 +of 0 +rilmenidine 1 +( 0 +600 0 +microg 0 +/ 0 +kg 0 +) 0 +or 0 +alpha 1 +- 2 +methyldopa 2 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +selective 0 +I1 0 +- 0 +and 0 +alpha2 0 +- 0 +receptor 0 +agonists 0 +"," 0 +respectively 0 +"," 0 +in 0 +blood 0 +pressure 0 +"," 0 +hemodynamic 0 +variability 0 +"," 0 +and 0 +locomotor 0 +activity 0 +were 0 +assessed 0 +in 0 +radiotelemetered 0 +sham 0 +- 0 +operated 0 +and 0 +ovariectomized 0 +( 0 +0vx 0 +) 0 +Sprague 0 +- 0 +Dawley 0 +female 0 +rats 0 +with 0 +or 0 +without 0 +12 0 +- 0 +wk 0 +estrogen 1 +replacement 0 +. 0 +Three 0 +time 0 +domain 0 +indexes 0 +of 0 +hemodynamic 0 +variability 0 +were 0 +employed 0 +: 0 +the 0 +standard 0 +deviation 0 +of 0 +mean 0 +arterial 0 +pressure 0 +as 0 +a 0 +measure 0 +of 0 +blood 0 +pressure 0 +variability 0 +and 0 +the 0 +standard 0 +deviation 0 +of 0 +beat 0 +- 0 +to 0 +- 0 +beat 0 +intervals 0 +( 0 +SDRR 0 +) 0 +and 0 +the 0 +root 0 +mean 0 +square 0 +of 0 +successive 0 +differences 0 +in 0 +R 0 +- 0 +wave 0 +- 0 +to 0 +- 0 +R 0 +- 0 +wave 0 +intervals 0 +as 0 +measures 0 +of 0 +heart 0 +rate 0 +variability 0 +. 0 +In 0 +sham 0 +- 0 +operated 0 +rats 0 +"," 0 +rilmenidine 1 +or 0 +alpha 1 +- 2 +methyldopa 2 +elicited 0 +similar 0 +hypotension 3 +that 0 +lasted 0 +at 0 +least 0 +5 0 +h 0 +and 0 +was 0 +associated 0 +with 0 +reductions 0 +in 0 +standard 0 +deviation 0 +of 0 +mean 0 +arterial 0 +pressure 0 +. 0 +SDRR 0 +was 0 +reduced 0 +only 0 +by 0 +alpha 1 +- 2 +methyldopa 2 +. 0 +0vx 0 +significantly 0 +enhanced 0 +the 0 +hypotensive 3 +response 0 +to 0 +alpha 1 +- 2 +methyldopa 2 +"," 0 +in 0 +contrast 0 +to 0 +no 0 +effect 0 +on 0 +rilmenidine 1 +hypotension 3 +. 0 +The 0 +enhanced 0 +alpha 1 +- 2 +methyldopa 2 +hypotension 3 +in 0 +0vx 0 +rats 0 +was 0 +paralleled 0 +with 0 +further 0 +reduction 0 +in 0 +SDRR 0 +and 0 +a 3 +reduced 4 +locomotor 4 +activity 4 +. 0 +Estrogen 0 +replacement 0 +( 0 +17beta 1 +- 2 +estradiol 2 +subcutaneous 0 +pellet 0 +"," 0 +14 0 +. 0 +2 0 +microg 0 +/ 0 +day 0 +"," 0 +12 0 +wk 0 +) 0 +of 0 +0vx 0 +rats 0 +restored 0 +the 0 +hemodynamic 0 +and 0 +locomotor 0 +effects 0 +of 0 +alpha 1 +- 2 +methyldopa 2 +to 0 +sham 0 +- 0 +operated 0 +levels 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +estrogen 1 +downregulates 0 +alpha2 0 +- 0 +but 0 +not 0 +I1 0 +- 0 +receptor 0 +- 0 +mediated 0 +hypotension 3 +and 0 +highlight 0 +a 0 +role 0 +for 0 +the 0 +cardiac 0 +autonomic 0 +control 0 +in 0 +alpha 1 +- 2 +methyldopa 2 +- 0 +estrogen 1 +interaction 0 +. 0 +Severe 0 +reversible 0 +left 3 +ventricular 4 +systolic 4 +and 4 +diastolic 4 +dysfunction 4 +due 0 +to 0 +accidental 0 +iatrogenic 0 +epinephrine 1 +overdose 3 +. 0 +Catecholamine 1 +- 0 +induced 0 +cardiomyopathy 3 +due 0 +to 0 +chronic 0 +excess 0 +of 0 +endogenous 0 +catecholamines 1 +has 0 +been 0 +recognized 0 +for 0 +decades 0 +as 0 +a 0 +clinical 0 +phenomenon 0 +. 0 +In 0 +contrast 0 +"," 0 +reports 0 +of 0 +myocardial 3 +dysfunction 4 +due 0 +to 0 +acute 0 +iatrogenic 0 +overdose 3 +are 0 +rare 0 +. 0 +A 0 +35 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +whose 0 +cervix 0 +uteri 0 +was 0 +inadvertently 0 +injected 0 +with 0 +8 0 +mg 0 +of 0 +epinephrine 1 +developed 0 +myocardial 3 +stunning 4 +that 0 +was 0 +characterized 0 +by 0 +severe 0 +hemodynamic 0 +compromise 0 +"," 0 +profound 0 +"," 0 +albeit 0 +transient 0 +"," 0 +left 3 +ventricular 4 +systolic 4 +and 4 +diastolic 4 +dysfunction 4 +"," 0 +and 0 +only 0 +modestly 0 +elevated 0 +biochemical 0 +markers 0 +of 0 +myocardial 3 +necrosis 4 +. 0 +0ur 0 +case 0 +illustrates 0 +the 0 +serious 0 +consequences 0 +of 0 +medical 0 +errors 0 +that 0 +can 0 +be 0 +avoided 0 +through 0 +improved 0 +medication 0 +labeling 0 +and 0 +staff 0 +supervision 0 +. 0 +Cardioprotective 0 +effect 0 +of 0 +tincture 1 +of 2 +Crataegus 2 +on 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Tincture 1 +of 2 +Crataegus 2 +( 0 +TCR 1 +) 0 +"," 0 +an 0 +alcoholic 1 +extract 2 +of 2 +the 2 +berries 2 +of 2 +hawthorn 2 +( 0 +Crataegus 1 +oxycantha 2 +) 0 +"," 0 +is 0 +used 0 +in 0 +herbal 0 +and 0 +homeopathic 0 +medicine 0 +. 0 +The 0 +present 0 +study 0 +was 0 +done 0 +to 0 +investigate 0 +the 0 +protective 0 +effect 0 +of 0 +TCR 1 +on 0 +experimentally 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Pretreatment 0 +of 0 +TCR 1 +"," 0 +at 0 +a 0 +dose 0 +of 0 +0 0 +. 0 +5 0 +mL 0 +/ 0 +100 0 +g 0 +bodyweight 0 +per 0 +day 0 +"," 0 +orally 0 +for 0 +30 0 +days 0 +"," 0 +prevented 0 +the 0 +increase 0 +in 0 +lipid 0 +peroxidation 0 +and 0 +activity 0 +of 0 +marker 0 +enzymes 0 +observed 0 +in 0 +isoproterenol 1 +- 0 +induced 0 +rats 0 +( 0 +85 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +s 0 +. 0 +c 0 +. 0 +for 0 +2 0 +days 0 +at 0 +an 0 +interval 0 +of 0 +24 0 +h 0 +) 0 +. 0 +TCR 1 +prevented 0 +the 0 +isoproterenol 1 +- 0 +induced 0 +decrease 0 +in 0 +antioxidant 0 +enzymes 0 +in 0 +the 0 +heart 0 +and 0 +increased 0 +the 0 +rate 0 +of 0 +ADP 1 +- 0 +stimulated 0 +oxygen 1 +uptake 0 +and 0 +respiratory 0 +coupling 0 +ratio 0 +. 0 +TCR 1 +protected 0 +against 0 +pathological 0 +changes 0 +induced 0 +by 0 +isoproterenol 1 +in 0 +rat 0 +heart 0 +. 0 +The 0 +results 0 +show 0 +that 0 +pretreatment 0 +with 0 +TCR 1 +may 0 +be 0 +useful 0 +in 0 +preventing 0 +the 0 +damage 0 +induced 0 +by 0 +isoproterenol 1 +in 0 +rat 0 +heart 0 +. 0 +Treatment 0 +of 0 +tinnitus 3 +by 0 +intratympanic 0 +instillation 0 +of 0 +lignocaine 1 +( 0 +lidocaine 1 +) 0 +2 0 +per 0 +cent 0 +through 0 +ventilation 0 +tubes 0 +. 0 +Idiopathic 3 +subjective 4 +tinnitus 4 +( 0 +IST 3 +) 0 +is 0 +one 0 +of 0 +the 0 +most 0 +obscure 0 +otological 0 +pathologies 0 +. 0 +This 0 +paper 0 +presents 0 +the 0 +results 0 +of 0 +treating 0 +IST 3 +by 0 +intratympanic 0 +instillation 0 +of 0 +lignocaine 1 +( 0 +lidocaine 1 +) 0 +2 0 +per 0 +cent 0 +through 0 +a 0 +grommet 0 +"," 0 +for 0 +five 0 +weekly 0 +courses 0 +. 0 +Fifty 0 +- 0 +two 0 +patients 0 +suffering 0 +from 0 +intractable 0 +tinnitus 3 +entered 0 +this 0 +therapeutic 0 +trial 0 +"," 0 +but 0 +only 0 +nine 0 +finished 0 +all 0 +five 0 +courses 0 +. 0 +In 0 +one 0 +patient 0 +"," 0 +the 0 +tinnitus 3 +was 0 +almost 0 +completely 0 +abolished 0 +"," 0 +but 0 +in 0 +all 0 +the 0 +nine 0 +patients 0 +the 0 +decompensated 0 +tinnitus 3 +changed 0 +to 0 +a 0 +compensated 0 +one 0 +. 0 +We 0 +suggest 0 +this 0 +mode 0 +of 0 +treatment 0 +for 0 +patients 0 +that 0 +were 0 +previously 0 +treated 0 +by 0 +drugs 0 +"," 0 +acupuncture 0 +and 0 +biofeedback 0 +"," 0 +with 0 +disappointing 0 +results 0 +. 0 +Patients 0 +should 0 +be 0 +warned 0 +about 0 +the 0 +side 0 +effects 0 +of 0 +vertigo 3 +and 0 +vomiting 3 +"," 0 +which 0 +subsides 0 +gradually 0 +with 0 +every 0 +new 0 +instillation 0 +"," 0 +and 0 +that 0 +the 0 +tinnitus 3 +may 0 +not 0 +disappear 0 +but 0 +will 0 +be 0 +alleviated 0 +"," 0 +enabling 0 +them 0 +to 0 +cope 0 +more 0 +easily 0 +with 0 +the 0 +disease 0 +and 0 +lead 0 +a 0 +more 0 +normal 0 +life 0 +. 0 +The 0 +alpha3 0 +and 0 +beta4 0 +nicotinic 0 +acetylcholine 1 +receptor 0 +subunits 0 +are 0 +necessary 0 +for 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +and 0 +hypolocomotion 3 +in 0 +mice 0 +. 0 +Binding 0 +of 0 +nicotine 1 +to 0 +nicotinic 0 +acetylcholine 1 +receptors 0 +( 0 +nAChRs 0 +) 0 +elicits 0 +a 0 +series 0 +of 0 +dose 0 +- 0 +dependent 0 +behaviors 0 +that 0 +go 0 +from 0 +altered 0 +exploration 0 +"," 0 +sedation 0 +"," 0 +and 0 +tremors 3 +"," 0 +to 0 +seizures 3 +and 0 +death 3 +. 0 +nAChRs 0 +are 0 +pentameric 0 +ion 0 +channels 0 +usually 0 +composed 0 +of 0 +alpha 0 +and 0 +beta 0 +subunits 0 +. 0 +A 0 +gene 0 +cluster 0 +comprises 0 +the 0 +alpha3 0 +"," 0 +alpha5 0 +and 0 +beta4 0 +subunits 0 +"," 0 +which 0 +coassemble 0 +to 0 +form 0 +functional 0 +receptors 0 +. 0 +We 0 +examined 0 +the 0 +role 0 +of 0 +the 0 +beta4 0 +subunits 0 +in 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +and 0 +hypolocomotion 3 +in 0 +beta4 0 +homozygous 0 +null 0 +( 0 +beta4 0 +- 0 +/ 0 +- 0 +) 0 +and 0 +alpha3 0 +heterozygous 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +mice 0 +. 0 +beta4 0 +- 0 +/ 0 +- 0 +mice 0 +were 0 +less 0 +sensitive 0 +to 0 +the 0 +effects 0 +of 0 +nicotine 1 +both 0 +at 0 +low 0 +doses 0 +"," 0 +measured 0 +as 0 +decreased 0 +exploration 0 +in 0 +an 0 +open 0 +field 0 +"," 0 +and 0 +at 0 +high 0 +doses 0 +"," 0 +measured 0 +as 0 +sensitivity 0 +to 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +. 0 +Using 0 +in 0 +situ 0 +hybridization 0 +probes 0 +for 0 +the 0 +alpha3 0 +and 0 +alpha5 0 +subunits 0 +"," 0 +we 0 +showed 0 +that 0 +alpha5 0 +mRNA 0 +levels 0 +are 0 +unchanged 0 +"," 0 +whereas 0 +alpha3 0 +mRNA 0 +levels 0 +are 0 +selectively 0 +decreased 0 +in 0 +the 0 +mitral 0 +cell 0 +layer 0 +of 0 +the 0 +olfactory 0 +bulb 0 +"," 0 +and 0 +the 0 +inferior 0 +and 0 +the 0 +superior 0 +colliculus 0 +of 0 +beta4 0 +- 0 +/ 0 +- 0 +brains 0 +. 0 +alpha3 0 ++ 0 +/ 0 +- 0 +mice 0 +were 0 +partially 0 +resistant 0 +to 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +when 0 +compared 0 +to 0 +wild 0 +- 0 +type 0 +littermates 0 +. 0 +mRNA 0 +levels 0 +for 0 +the 0 +alpha5 0 +and 0 +the 0 +beta4 0 +subunits 0 +were 0 +unchanged 0 +in 0 +alpha3 0 ++ 0 +/ 0 +- 0 +brains 0 +. 0 +Together 0 +"," 0 +these 0 +results 0 +suggest 0 +that 0 +the 0 +beta4 0 +and 0 +the 0 +alpha3 0 +subunits 0 +are 0 +mediators 0 +of 0 +nicotine 1 +- 0 +induced 0 +seizures 3 +and 0 +hypolocomotion 3 +. 0 +The 0 +effects 0 +of 0 +sevoflurane 1 +on 0 +lidocaine 1 +- 0 +induced 0 +convulsions 3 +. 0 +The 0 +influence 0 +of 0 +sevoflurane 1 +on 0 +lidocaine 1 +- 0 +induced 0 +convulsions 3 +was 0 +studied 0 +in 0 +cats 0 +. 0 +The 0 +convulsive 3 +threshold 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +was 0 +41 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +5 0 +mg 0 +. 0 +l 0 +( 0 +- 0 +1 0 +) 0 +with 0 +lidocaine 1 +infusion 0 +( 0 +6 0 +mg 0 +. 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +. 0 +min 0 +( 0 +- 0 +1 0 +) 0 +) 0 +"," 0 +increasing 0 +significantly 0 +to 0 +66 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +10 0 +. 0 +9 0 +mg 0 +. 0 +l 0 +( 0 +- 0 +1 0 +) 0 +when 0 +the 0 +end 0 +- 0 +tidal 0 +concentration 0 +of 0 +sevoflurane 1 +was 0 +0 0 +. 0 +8 0 +% 0 +. 0 +However 0 +"," 0 +the 0 +threshold 0 +( 0 +61 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +7 0 +mg 0 +. 0 +l 0 +( 0 +- 0 +1 0 +) 0 +) 0 +during 0 +1 0 +. 0 +6 0 +% 0 +sevoflurane 1 +was 0 +not 0 +significant 0 +from 0 +that 0 +during 0 +0 0 +. 0 +8 0 +% 0 +sevoflurane 1 +"," 0 +indicating 0 +a 0 +celling 0 +effect 0 +. 0 +There 0 +was 0 +no 0 +significant 0 +difference 0 +in 0 +the 0 +convulsive 3 +threshold 0 +between 0 +sevoflurane 1 +and 0 +enflurane 1 +. 0 +The 0 +rise 0 +in 0 +blood 0 +pressure 0 +became 0 +less 0 +marked 0 +when 0 +higher 0 +concentrations 0 +of 0 +sevoflurane 1 +or 0 +enflurane 1 +were 0 +administered 0 +and 0 +the 0 +blood 0 +pressure 0 +at 0 +convulsions 3 +decreased 0 +significantly 0 +in 0 +1 0 +. 0 +6 0 +% 0 +sevoflurane 1 +"," 0 +and 0 +in 0 +0 0 +. 0 +8 0 +% 0 +and 0 +1 0 +. 0 +6 0 +% 0 +enflurane 1 +. 0 +However 0 +"," 0 +there 0 +was 0 +no 0 +significant 0 +difference 0 +in 0 +the 0 +lidocaine 1 +concentrations 0 +measured 0 +when 0 +the 0 +systolic 0 +blood 0 +pressure 0 +became 0 +70 0 +mmHg 0 +. 0 +Apamin 1 +"," 0 +a 0 +selective 0 +blocker 0 +of 0 +calcium 1 +- 0 +dependent 0 +potassium 1 +channels 0 +"," 0 +was 0 +administered 0 +intracerebroventricularly 0 +in 0 +rats 0 +anesthetized 0 +with 0 +0 0 +. 0 +8 0 +% 0 +sevoflurane 1 +to 0 +investigate 0 +the 0 +mechanism 0 +of 0 +the 0 +anticonvulsive 0 +effects 0 +. 0 +Apamin 1 +( 0 +10 0 +ng 0 +) 0 +had 0 +a 0 +tendency 0 +to 0 +decrease 0 +the 0 +convulsive 3 +threshold 0 +( 0 +21 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +2 0 +to 0 +19 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +5 0 +mg 0 +. 0 +l 0 +( 0 +- 0 +1 0 +) 0 +) 0 +but 0 +this 0 +was 0 +not 0 +statistically 0 +significant 0 +. 0 +It 0 +is 0 +suggested 0 +that 0 +sevoflurane 1 +reduces 0 +the 0 +convulsive 3 +effect 0 +of 0 +lidocaine 1 +toxicity 3 +but 0 +carries 0 +some 0 +risk 0 +due 0 +to 0 +circulatory 0 +depression 3 +. 0 +Cardiac 3 +toxicity 4 +observed 0 +in 0 +association 0 +with 0 +high 0 +- 0 +dose 0 +cyclophosphamide 1 +- 0 +based 0 +chemotherapy 0 +for 0 +metastatic 0 +breast 3 +cancer 4 +. 0 +INTR0DUCTI0N 0 +: 0 +Cyclophosphamide 1 +is 0 +an 0 +alkylating 0 +agent 0 +given 0 +frequently 0 +as 0 +a 0 +component 0 +of 0 +many 0 +conditioning 0 +regimens 0 +. 0 +In 0 +high 0 +doses 0 +"," 0 +its 0 +nonhematological 0 +dose 0 +- 0 +limiting 0 +toxicity 3 +is 0 +cardiomyopathy 3 +. 0 +STUDY 0 +DESIGN 0 +: 0 +We 0 +combined 0 +paclitaxel 1 +"," 0 +melphalan 1 +and 0 +high 0 +- 0 +dose 0 +cyclophosphamide 1 +"," 0 +thiotepa 1 +"," 0 +and 0 +carboplatin 1 +in 0 +a 0 +triple 0 +sequential 0 +high 0 +- 0 +dose 0 +regimen 0 +for 0 +patients 0 +with 0 +metastatic 0 +breast 3 +cancer 4 +. 0 +Analysis 0 +was 0 +performed 0 +on 0 +61 0 +women 0 +with 0 +chemotherapy 0 +- 0 +responsive 0 +metastatic 0 +breast 3 +cancer 4 +receiving 0 +96 0 +- 0 +h 0 +infusional 0 +cyclophosphamide 1 +as 0 +part 0 +of 0 +a 0 +triple 0 +sequential 0 +high 0 +- 0 +dose 0 +regimen 0 +to 0 +assess 0 +association 0 +between 0 +presence 0 +of 0 +peritransplant 0 +congestive 3 +heart 4 +failure 4 +( 0 +CHF 3 +) 0 +and 0 +the 0 +following 0 +pretreatment 0 +characteristics 0 +: 0 +presence 0 +of 0 +electrocardiogram 0 +( 0 +EKG 0 +) 0 +abnormalities 0 +"," 0 +age 0 +"," 0 +hypertension 3 +"," 0 +prior 0 +cardiac 0 +history 0 +"," 0 +smoking 0 +"," 0 +diabetes 3 +mellitus 4 +"," 0 +prior 0 +use 0 +of 0 +anthracyclines 1 +"," 0 +and 0 +left 0 +- 0 +sided 0 +chest 0 +irradiation 0 +. 0 +RESULTS 0 +: 0 +Six 0 +of 0 +61 0 +women 0 +( 0 +10 0 +% 0 +) 0 +developed 0 +clinically 0 +reversible 0 +grade 0 +3 0 +CHF 3 +following 0 +infusional 0 +cyclophosphamide 1 +with 0 +a 0 +median 0 +percent 0 +decline 0 +in 0 +ejection 0 +fraction 0 +of 0 +31 0 +% 0 +. 0 +Incidence 0 +of 0 +transient 0 +cyclophosphamide 1 +- 0 +related 0 +cardiac 3 +toxicity 4 +( 0 +10 0 +% 0 +) 0 +is 0 +comparable 0 +to 0 +previous 0 +recorded 0 +literature 0 +. 0 +0lder 0 +age 0 +was 0 +significantly 0 +correlated 0 +with 0 +the 0 +CHF 3 +development 0 +; 0 +with 0 +median 0 +ages 0 +for 0 +the 0 +entire 0 +group 0 +and 0 +for 0 +patients 0 +developing 0 +CHF 3 +of 0 +45 0 +and 0 +59 0 +"," 0 +respectively 0 +. 0 +No 0 +association 0 +was 0 +found 0 +with 0 +other 0 +pretreatment 0 +characteristics 0 +. 0 +C0NCLUSI0NS 0 +: 0 +As 0 +a 0 +result 0 +of 0 +these 0 +findings 0 +"," 0 +oncologists 0 +should 0 +carefully 0 +monitor 0 +fluid 0 +balance 0 +in 0 +older 0 +patients 0 +. 0 +Routine 0 +EKG 0 +monitoring 0 +during 0 +infusional 0 +cyclophosphamide 1 +did 0 +not 0 +predict 0 +CHF 3 +development 0 +. 0 +Tremor 3 +side 0 +effects 0 +of 0 +salbutamol 1 +"," 0 +quantified 0 +by 0 +a 0 +laser 0 +pointer 0 +technique 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +study 0 +tremor 3 +side 0 +effects 0 +of 0 +salbutamol 1 +an 0 +easily 0 +applicable 0 +"," 0 +quick 0 +and 0 +low 0 +- 0 +priced 0 +method 0 +is 0 +needed 0 +. 0 +A 0 +new 0 +method 0 +using 0 +a 0 +commercially 0 +available 0 +"," 0 +pen 0 +- 0 +shaped 0 +laser 0 +pointer 0 +was 0 +developed 0 +. 0 +Aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +determine 0 +sensitivity 0 +"," 0 +reproducibility 0 +"," 0 +reference 0 +values 0 +and 0 +the 0 +agreement 0 +with 0 +a 0 +questionnaire 0 +. 0 +METH0DS 0 +: 0 +Tremor 3 +was 0 +measured 0 +using 0 +a 0 +laser 0 +pointer 0 +technique 0 +. 0 +To 0 +determine 0 +sensitivity 0 +we 0 +assessed 0 +tremor 3 +in 0 +44 0 +patients 0 +with 0 +obstructive 3 +lung 4 +disease 4 +after 0 +administration 0 +of 0 +cumulative 0 +doses 0 +of 0 +salbutamol 1 +. 0 +Subjects 0 +were 0 +asked 0 +to 0 +aim 0 +at 0 +the 0 +centre 0 +of 0 +a 0 +target 0 +"," 0 +subdivided 0 +in 0 +concentric 0 +circles 0 +"," 0 +from 0 +5 0 +m 0 +distance 0 +. 0 +The 0 +circle 0 +in 0 +which 0 +the 0 +participant 0 +succeeded 0 +to 0 +aim 0 +was 0 +recorded 0 +in 0 +millimetres 0 +radius 0 +. 0 +In 0 +another 0 +series 0 +of 0 +measurements 0 +"," 0 +reproducibility 0 +and 0 +reference 0 +values 0 +of 0 +the 0 +tremor 3 +was 0 +assessed 0 +in 0 +65 0 +healthy 0 +subjects 0 +in 0 +three 0 +sessions 0 +"," 0 +at 0 +9 0 +a 0 +. 0 +m 0 +. 0 +"," 0 +4 0 +p 0 +. 0 +m 0 +. 0 +and 0 +9 0 +a 0 +. 0 +m 0 +. 0 +"," 0 +respectively 0 +"," 0 +1 0 +week 0 +later 0 +. 0 +Postural 0 +tremor 3 +was 0 +measured 0 +with 0 +the 0 +arm 0 +horizontally 0 +outstretched 0 +rest 0 +tremor 3 +with 0 +the 0 +arm 0 +supported 0 +by 0 +an 0 +armrest 0 +and 0 +finally 0 +tremor 3 +was 0 +measured 0 +after 0 +holding 0 +a 0 +2 0 +- 0 +kg 0 +weight 0 +until 0 +exhaustion 0 +. 0 +Inter 0 +- 0 +observer 0 +variability 0 +was 0 +measured 0 +in 0 +a 0 +series 0 +of 0 +10 0 +healthy 0 +subjects 0 +. 0 +Tremor 3 +was 0 +measured 0 +simultaneously 0 +by 0 +two 0 +independent 0 +observers 0 +. 0 +RESULTS 0 +: 0 +Salbutamol 1 +significantly 0 +increased 0 +tremor 3 +severity 0 +in 0 +patients 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +way 0 +. 0 +Within 0 +healthy 0 +adults 0 +no 0 +age 0 +- 0 +dependency 0 +could 0 +be 0 +found 0 +( 0 +b 0 += 0 +0 0 +. 0 +262 0 +mm 0 +/ 0 +year 0 +; 0 +P 0 += 0 +0 0 +. 0 +72 0 +) 0 +. 0 +There 0 +was 0 +no 0 +agreement 0 +between 0 +the 0 +questionnaire 0 +and 0 +tremor 3 +severity 0 +( 0 +r 0 += 0 +0 0 +. 0 +93 0 +; 0 +P 0 += 0 +0 0 +. 0 +53 0 +) 0 +. 0 +Postural 0 +tremor 3 +showed 0 +no 0 +significant 0 +difference 0 +between 0 +the 0 +first 0 +and 0 +third 0 +session 0 +( 0 +P 0 += 0 +0 0 +. 0 +7 0 +) 0 +. 0 +Support 0 +of 0 +the 0 +arm 0 +decreased 0 +tremor 3 +severity 0 +"," 0 +exhaustion 0 +increased 0 +tremor 3 +severity 0 +significantly 0 +. 0 +A 0 +good 0 +agreement 0 +was 0 +found 0 +between 0 +two 0 +independent 0 +observers 0 +( 0 +interclass 0 +correlation 0 +coefficient 0 +0 0 +. 0 +72 0 +) 0 +. 0 +DISCUSSI0N 0 +: 0 +Quantifying 0 +tremor 3 +by 0 +using 0 +an 0 +inexpensive 0 +laser 0 +pointer 0 +is 0 +"," 0 +with 0 +the 0 +exception 0 +of 0 +children 0 +( 0 +< 0 +12 0 +years 0 +) 0 +a 0 +sensitive 0 +and 0 +reproducible 0 +method 0 +. 0 +Safety 0 +and 0 +adverse 0 +effects 0 +associated 0 +with 0 +raloxifene 1 +: 0 +multiple 0 +outcomes 0 +of 0 +raloxifene 1 +evaluation 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +examine 0 +the 0 +effect 0 +of 0 +raloxifene 1 +on 0 +major 0 +adverse 0 +events 0 +that 0 +occur 0 +with 0 +postmenopausal 0 +estrogen 1 +therapy 0 +or 0 +tamoxifen 1 +. 0 +METH0DS 0 +: 0 +The 0 +Multiple 0 +0utcomes 0 +of 0 +Raloxifene 1 +Evaluation 0 +"," 0 +a 0 +multicenter 0 +"," 0 +randomized 0 +"," 0 +double 0 +- 0 +blind 0 +trial 0 +"," 0 +enrolled 0 +7 0 +"," 0 +705 0 +postmenopausal 0 +women 0 +with 0 +osteoporosis 3 +. 0 +Women 0 +were 0 +randomly 0 +assigned 0 +to 0 +raloxifene 1 +60 0 +mg 0 +/ 0 +d 0 +or 0 +120 0 +mg 0 +/ 0 +d 0 +or 0 +placebo 0 +. 0 +0utcomes 0 +included 0 +venous 3 +thromboembolism 4 +"," 0 +cataracts 3 +"," 0 +gallbladder 3 +disease 4 +"," 0 +and 0 +endometrial 3 +hyperplasia 4 +or 4 +cancer 4 +. 0 +RESULTS 0 +: 0 +During 0 +a 0 +mean 0 +follow 0 +- 0 +up 0 +of 0 +3 0 +. 0 +3 0 +years 0 +"," 0 +raloxifene 1 +was 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +for 0 +venous 3 +thromboembolism 4 +( 0 +relative 0 +risk 0 +[ 0 +RR 0 +] 0 +2 0 +. 0 +1 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +1 0 +. 0 +2 0 +- 0 +3 0 +. 0 +8 0 +) 0 +. 0 +The 0 +excess 0 +event 0 +rate 0 +was 0 +1 0 +. 0 +8 0 +per 0 +1 0 +"," 0 +0 0 +woman 0 +- 0 +years 0 +( 0 +95 0 +% 0 +CI 0 +- 0 +0 0 +. 0 +5 0 +- 0 +4 0 +. 0 +1 0 +) 0 +"," 0 +and 0 +the 0 +number 0 +needed 0 +to 0 +treat 0 +to 0 +cause 0 +1 0 +event 0 +was 0 +170 0 +( 0 +95 0 +% 0 +CI 0 +100 0 +- 0 +582 0 +) 0 +over 0 +3 0 +. 0 +3 0 +years 0 +. 0 +Risk 0 +in 0 +the 0 +raloxifene 1 +group 0 +was 0 +higher 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +for 0 +the 0 +first 0 +2 0 +years 0 +"," 0 +but 0 +decreased 0 +to 0 +about 0 +the 0 +same 0 +rate 0 +as 0 +in 0 +the 0 +placebo 0 +group 0 +thereafter 0 +. 0 +Raloxifene 1 +did 0 +not 0 +increase 0 +risk 0 +for 0 +cataracts 3 +( 0 +RR 0 +0 0 +. 0 +9 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +8 0 +- 0 +1 0 +. 0 +1 0 +) 0 +"," 0 +gallbladder 3 +disease 4 +( 0 +RR 0 +1 0 +. 0 +0 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +7 0 +- 0 +1 0 +. 0 +3 0 +) 0 +"," 0 +endometrial 3 +hyperplasia 4 +( 0 +RR 0 +1 0 +. 0 +3 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +4 0 +- 0 +5 0 +. 0 +1 0 +) 0 +"," 0 +or 0 +endometrial 3 +cancer 4 +( 0 +RR 0 +0 0 +. 0 +9 0 +; 0 +95 0 +% 0 +CI 0 +0 0 +. 0 +3 0 +- 0 +2 0 +. 0 +7 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +Raloxifene 1 +was 0 +associated 0 +with 0 +an 0 +increased 0 +risk 0 +for 0 +venous 3 +thromboembolism 4 +"," 0 +but 0 +there 0 +was 0 +no 0 +increased 0 +risk 0 +for 0 +cataracts 3 +"," 0 +gallbladder 3 +disease 4 +"," 0 +endometrial 3 +hyperplasia 4 +"," 0 +or 0 +endometrial 3 +cancer 4 +. 0 +LEVEL 0 +0F 0 +EVIDENCE 0 +: 0 +I 0 +0ptimization 0 +of 0 +levodopa 1 +therapy 0 +. 0 +While 0 +there 0 +is 0 +no 0 +single 0 +correct 0 +starting 0 +dose 0 +for 0 +levodopa 1 +therapy 0 +"," 0 +many 0 +individuals 0 +can 0 +be 0 +started 0 +on 0 +either 0 +the 0 +25 0 +/ 0 +100 0 +or 0 +controlled 0 +- 0 +release 0 +formula 0 +"," 0 +following 0 +the 0 +general 0 +rule 0 +not 0 +to 0 +attempt 0 +to 0 +titrate 0 +carbidopa 1 +- 0 +levodopa 1 +to 0 +the 0 +point 0 +of 0 +" 0 +normality 0 +, 0 +" 0 +which 0 +can 0 +lead 0 +to 0 +toxicity 3 +. 0 +The 0 +physician 0 +should 0 +also 0 +determine 0 +the 0 +proper 0 +use 0 +of 0 +any 0 +adjunctive 0 +medications 0 +; 0 +such 0 +combined 0 +therapy 0 +has 0 +become 0 +the 0 +standard 0 +approach 0 +to 0 +treatment 0 +. 0 +Following 0 +the 0 +initial 0 +period 0 +of 0 +therapy 0 +"," 0 +emerging 0 +difficulties 0 +require 0 +a 0 +reassessment 0 +of 0 +therapeutic 0 +approaches 0 +"," 0 +such 0 +as 0 +dosage 0 +adjustment 0 +or 0 +introduction 0 +of 0 +a 0 +dopamine 1 +agonist 0 +. 0 +0ther 0 +possible 0 +adverse 0 +effects 0 +- 0 +- 0 +such 0 +as 0 +gastrointestinal 3 +disorders 4 +"," 0 +orthostatic 3 +hypotension 4 +"," 0 +levodopa 1 +- 0 +induced 0 +psychosis 3 +"," 0 +sleep 3 +disturbances 4 +or 0 +parasomnias 3 +"," 0 +or 0 +drug 0 +interactions 0 +- 0 +- 0 +also 0 +require 0 +carefully 0 +monitored 0 +individual 0 +treatment 0 +. 0 +Nonpharmacologic 0 +concerns 0 +can 0 +help 0 +the 0 +Parkinson 3 +' 4 +s 4 +disease 4 +patient 0 +achieve 0 +and 0 +maintain 0 +optimal 0 +functioning 0 +"," 0 +including 0 +daily 0 +exercise 0 +"," 0 +physical 0 +therapy 0 +"," 0 +and 0 +involvement 0 +with 0 +support 0 +groups 0 +. 0 +Long 0 +term 0 +audiological 0 +evaluation 0 +of 0 +beta 3 +- 4 +thalassemic 4 +patients 0 +. 0 +0BJECTIVE 0 +: 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +identify 0 +the 0 +incidence 0 +and 0 +to 0 +monitor 0 +the 0 +progression 0 +of 0 +hearing 3 +loss 4 +in 0 +children 0 +and 0 +young 0 +adults 0 +with 0 +beta 3 +- 4 +thalassemia 4 +major 0 +. 0 +METH0DS 0 +: 0 +0ne 0 +hundred 0 +and 0 +four 0 +( 0 +104 0 +) 0 +patients 0 +aged 0 +6 0 +- 0 +35 0 +years 0 +( 0 +mean 0 +17 0 +"," 0 +2 0 +years 0 +) 0 +participated 0 +in 0 +the 0 +study 0 +. 0 +All 0 +patients 0 +were 0 +on 0 +a 0 +regular 0 +transfusion 0 +- 0 +chelation 0 +program 0 +maintaining 0 +a 0 +mean 0 +hemoglobin 0 +level 0 +of 0 +9 0 +. 0 +5 0 +gr 0 +/ 0 +dl 0 +. 0 +Subjects 0 +were 0 +receiving 0 +desferrioxamine 1 +( 0 +DF0 1 +) 0 +chelation 0 +treatment 0 +with 0 +a 0 +mean 0 +daily 0 +dose 0 +of 0 +50 0 +- 0 +60 0 +mg 0 +/ 0 +kg 0 +"," 0 +5 0 +- 0 +6 0 +days 0 +a 0 +week 0 +during 0 +the 0 +first 0 +six 0 +years 0 +of 0 +the 0 +study 0 +"," 0 +which 0 +was 0 +then 0 +reduced 0 +to 0 +40 0 +- 0 +50 0 +mg 0 +/ 0 +kg 0 +for 0 +the 0 +following 0 +eight 0 +years 0 +. 0 +Patients 0 +were 0 +followed 0 +for 0 +8 0 +- 0 +14 0 +years 0 +. 0 +RESULTS 0 +: 0 +0verall 0 +"," 0 +21 0 +out 0 +of 0 +104 0 +patients 0 +( 0 +20 0 +. 0 +2 0 +% 0 +) 0 +presented 0 +with 0 +high 0 +frequency 0 +sensorineural 3 +hearing 4 +loss 4 +( 0 +SNHL 3 +) 0 +"," 0 +either 0 +unilateral 0 +or 0 +bilateral 0 +. 0 +No 0 +ototoxic 3 +factor 0 +"," 0 +other 0 +than 0 +DF0 1 +"," 0 +was 0 +present 0 +in 0 +any 0 +of 0 +the 0 +patients 0 +. 0 +Patients 0 +with 0 +SNHL 3 +presented 0 +with 0 +relatively 0 +lower 0 +serum 0 +ferritin 0 +levels 0 +than 0 +those 0 +with 0 +normal 0 +hearing 0 +"," 0 +however 0 +"," 0 +no 0 +statistically 0 +significant 0 +difference 0 +was 0 +observed 0 +. 0 +Subjects 0 +with 0 +SNHL 3 +were 0 +submitted 0 +to 0 +DF0 1 +reduction 0 +or 0 +temporary 0 +withdrawal 0 +. 0 +Following 0 +intervention 0 +"," 0 +7 0 +out 0 +of 0 +21 0 +affected 0 +patients 0 +recovered 0 +"," 0 +10 0 +remained 0 +stable 0 +and 0 +4 0 +demonstrated 0 +aggravation 0 +. 0 +C0NCLUSI0N 0 +: 0 +The 0 +findings 0 +are 0 +indicative 0 +of 0 +DF0 1 +' 0 +s 0 +contributing 0 +role 0 +in 0 +the 0 +development 0 +of 0 +hearing 3 +impairment 4 +. 0 +Regular 0 +audiologic 0 +evaluation 0 +is 0 +imperative 0 +in 0 +all 0 +thalassemic 3 +patients 0 +so 0 +that 0 +early 0 +changes 0 +may 0 +be 0 +recognized 0 +and 0 +treatment 0 +may 0 +be 0 +judiciously 0 +adjusted 0 +in 0 +order 0 +to 0 +prevent 0 +or 0 +reverse 0 +hearing 3 +impairment 4 +. 0 +Individual 0 +differences 0 +in 0 +renal 0 +ACE 0 +activity 0 +in 0 +healthy 0 +rats 0 +predict 0 +susceptibility 0 +to 0 +adriamycin 1 +- 0 +induced 0 +renal 3 +damage 4 +. 0 +BACKGR0UND 0 +: 0 +In 0 +man 0 +"," 0 +differences 0 +in 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +levels 0 +"," 0 +related 0 +to 0 +ACE 0 +( 0 +I 0 +/ 0 +D 0 +) 0 +genotype 0 +"," 0 +are 0 +associated 0 +with 0 +renal 0 +prognosis 0 +. 0 +This 0 +raises 0 +the 0 +hypothesis 0 +that 0 +individual 0 +differences 0 +in 0 +renal 0 +ACE 0 +activity 0 +are 0 +involved 0 +in 0 +renal 0 +susceptibility 0 +to 0 +inflicted 0 +damage 0 +. 0 +Therefore 0 +"," 0 +we 0 +studied 0 +the 0 +predictive 0 +effect 0 +of 0 +renal 0 +ACE 0 +activity 0 +for 0 +the 0 +severity 0 +of 0 +renal 3 +damage 4 +induced 0 +by 0 +a 0 +single 0 +injection 0 +of 0 +adriamycin 1 +in 0 +rats 0 +. 0 +METH0DS 0 +: 0 +Renal 0 +ACE 0 +activity 0 +( 0 +Hip 1 +- 2 +His 2 +- 2 +Leu 2 +cleavage 0 +by 0 +cortical 0 +homogenates 0 +) 0 +was 0 +determined 0 +by 0 +renal 0 +biopsy 0 +in 0 +27 0 +adult 0 +male 0 +Wistar 0 +rats 0 +. 0 +After 0 +1 0 +week 0 +of 0 +recovery 0 +"," 0 +proteinuria 3 +was 0 +induced 0 +by 0 +adriamycin 1 +[ 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +intravenously 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +n 0 += 0 +18 0 +; 0 +controls 0 +"," 0 +saline 0 +i 0 +. 0 +v 0 +. 0 +n 0 += 0 +9 0 +] 0 +. 0 +Proteinuria 3 +was 0 +measured 0 +every 0 +2 0 +weeks 0 +. 0 +After 0 +12 0 +weeks 0 +"," 0 +rats 0 +were 0 +sacrificed 0 +and 0 +their 0 +kidneys 0 +harvested 0 +. 0 +RESULTS 0 +: 0 +As 0 +anticipated 0 +"," 0 +adriamycin 1 +elicited 0 +nephrotic 3 +range 0 +proteinuria 3 +"," 0 +renal 3 +interstitial 4 +damage 4 +and 0 +mild 0 +focal 3 +glomerulosclerosis 4 +. 0 +Baseline 0 +renal 0 +ACE 0 +positively 0 +correlated 0 +with 0 +the 0 +relative 0 +rise 0 +in 0 +proteinuria 3 +after 0 +adriamycin 1 +( 0 +r 0 += 0 +0 0 +. 0 +62 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +renal 0 +interstitial 0 +alpha 0 +- 0 +smooth 0 +muscle 0 +actin 0 +( 0 +r 0 += 0 +0 0 +. 0 +49 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +interstitial 0 +macrophage 0 +influx 0 +( 0 +r 0 += 0 +0 0 +. 0 +56 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +interstitial 0 +collagen 0 +III 0 +( 0 +r 0 += 0 +0 0 +. 0 +53 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +glomerular 0 +alpha 0 +- 0 +smooth 0 +muscle 0 +actin 0 +( 0 +r 0 += 0 +0 0 +. 0 +74 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +and 0 +glomerular 0 +desmin 0 +( 0 +r 0 += 0 +0 0 +. 0 +48 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Baseline 0 +renal 0 +ACE 0 +did 0 +not 0 +correlate 0 +with 0 +focal 3 +glomerulosclerosis 4 +( 0 +r 0 += 0 +0 0 +. 0 +22 0 +"," 0 +NS 0 +) 0 +. 0 +In 0 +controls 0 +"," 0 +no 0 +predictive 0 +values 0 +for 0 +renal 0 +parameters 0 +were 0 +observed 0 +. 0 +C0NCLUSI0N 0 +: 0 +Individual 0 +differences 0 +in 0 +renal 0 +ACE 0 +activity 0 +predict 0 +the 0 +severity 0 +of 0 +adriamycin 1 +- 0 +induced 0 +renal 3 +damage 4 +in 0 +this 0 +outbred 0 +rat 0 +strain 0 +. 0 +This 0 +supports 0 +the 0 +assumption 0 +that 0 +differences 0 +in 0 +renal 0 +ACE 0 +activity 0 +predispose 0 +to 0 +a 0 +less 0 +favourable 0 +course 0 +of 0 +renal 3 +damage 4 +. 0 +Recurrent 0 +acute 0 +interstitial 3 +nephritis 4 +induced 0 +by 0 +azithromycin 1 +. 0 +A 0 +14 0 +- 0 +year 0 +- 0 +old 0 +girl 0 +is 0 +reported 0 +with 0 +recurrent 0 +"," 0 +azithromycin 1 +- 0 +induced 0 +"," 0 +acute 0 +interstitial 3 +nephritis 4 +. 0 +The 0 +second 0 +episode 0 +was 0 +more 0 +severe 0 +than 0 +the 0 +first 0 +; 0 +and 0 +although 0 +both 0 +were 0 +treated 0 +with 0 +intensive 0 +corticosteroid 0 +therapy 0 +"," 0 +renal 0 +function 0 +remained 0 +impaired 0 +. 0 +Although 0 +most 0 +cases 0 +of 0 +antibiotic 0 +induced 0 +acute 0 +interstitial 3 +nephritis 4 +are 0 +benign 0 +and 0 +self 0 +- 0 +limited 0 +"," 0 +some 0 +patients 0 +are 0 +at 0 +risk 0 +for 0 +permanent 0 +renal 3 +injury 4 +. 0 +Spironolactone 1 +- 0 +induced 0 +renal 3 +insufficiency 4 +and 0 +hyperkalemia 3 +in 0 +patients 0 +with 0 +heart 3 +failure 4 +. 0 +BACKGR0UND 0 +: 0 +A 0 +previous 0 +randomized 0 +controlled 0 +trial 0 +evaluating 0 +the 0 +use 0 +of 0 +spironolactone 1 +in 0 +heart 3 +failure 4 +patients 0 +reported 0 +a 0 +low 0 +risk 0 +of 0 +hyperkalemia 3 +( 0 +2 0 +% 0 +) 0 +and 0 +renal 3 +insufficiency 4 +( 0 +0 0 +% 0 +) 0 +. 0 +Because 0 +treatments 0 +for 0 +heart 3 +failure 4 +have 0 +changed 0 +since 0 +the 0 +benefits 0 +of 0 +spironolactone 1 +were 0 +reported 0 +"," 0 +the 0 +prevalence 0 +of 0 +these 0 +complications 0 +may 0 +differ 0 +in 0 +current 0 +clinical 0 +practice 0 +. 0 +We 0 +therefore 0 +sought 0 +to 0 +determine 0 +the 0 +prevalence 0 +and 0 +clinical 0 +associations 0 +of 0 +hyperkalemia 3 +and 0 +renal 3 +insufficiency 4 +in 0 +heart 3 +failure 4 +patients 0 +treated 0 +with 0 +spironolactone 1 +. 0 +METH0DS 0 +: 0 +We 0 +performed 0 +a 0 +case 0 +control 0 +study 0 +of 0 +heart 3 +failure 4 +patients 0 +treated 0 +with 0 +spironolactone 1 +in 0 +our 0 +clinical 0 +practice 0 +. 0 +Cases 0 +were 0 +patients 0 +who 0 +developed 0 +hyperkalemia 3 +( 0 +K 1 +( 0 ++ 0 +) 0 +> 0 +5 0 +. 0 +0 0 +mEq 0 +/ 0 +L 0 +) 0 +or 0 +renal 3 +insufficiency 4 +( 0 +Cr 1 +> 0 +or 0 += 0 +2 0 +. 0 +5 0 +mg 0 +/ 0 +dL 0 +) 0 +"," 0 +and 0 +they 0 +were 0 +compared 0 +to 0 +2 0 +randomly 0 +selected 0 +controls 0 +per 0 +case 0 +. 0 +Clinical 0 +characteristics 0 +"," 0 +medications 0 +"," 0 +and 0 +serum 0 +chemistries 0 +at 0 +baseline 0 +and 0 +follow 0 +- 0 +up 0 +time 0 +periods 0 +were 0 +compared 0 +. 0 +RESULTS 0 +: 0 +Sixty 0 +- 0 +seven 0 +of 0 +926 0 +patients 0 +( 0 +7 0 +. 0 +2 0 +% 0 +) 0 +required 0 +discontinuation 0 +of 0 +spironolactone 1 +due 0 +to 0 +hyperkalemia 3 +( 0 +n 0 += 0 +33 0 +) 0 +or 0 +renal 3 +failure 4 +( 0 +n 0 += 0 +34 0 +) 0 +. 0 +Patients 0 +who 0 +developed 0 +hyperkalemia 3 +were 0 +older 0 +and 0 +more 0 +likely 0 +to 0 +have 0 +diabetes 3 +"," 0 +had 0 +higher 0 +baseline 0 +serum 0 +potassium 1 +levels 0 +and 0 +lower 0 +baseline 0 +potassium 1 +supplement 0 +doses 0 +"," 0 +and 0 +were 0 +more 0 +likely 0 +to 0 +be 0 +treated 0 +with 0 +beta 0 +- 0 +blockers 0 +than 0 +controls 0 +( 0 +n 0 += 0 +134 0 +) 0 +. 0 +Patients 0 +who 0 +developed 0 +renal 3 +insufficiency 4 +had 0 +lower 0 +baseline 0 +body 0 +weight 0 +and 0 +higher 0 +baseline 0 +serum 0 +creatinine 1 +"," 0 +required 0 +higher 0 +doses 0 +of 0 +loop 0 +diuretics 0 +"," 0 +and 0 +were 0 +more 0 +likely 0 +to 0 +be 0 +treated 0 +with 0 +thiazide 1 +diuretics 0 +than 0 +controls 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Spironolactone 1 +- 0 +induced 0 +hyperkalemia 3 +and 0 +renal 3 +insufficiency 4 +are 0 +more 0 +common 0 +in 0 +our 0 +clinical 0 +experience 0 +than 0 +reported 0 +previously 0 +. 0 +This 0 +difference 0 +is 0 +explained 0 +by 0 +patient 0 +comorbidities 0 +and 0 +more 0 +frequent 0 +use 0 +of 0 +beta 0 +- 0 +blockers 0 +. 0 +Acute 0 +reserpine 1 +and 0 +subchronic 0 +haloperidol 1 +treatments 0 +change 0 +synaptosomal 0 +brain 0 +glutamate 1 +uptake 0 +and 0 +elicit 0 +orofacial 3 +dyskinesia 4 +in 0 +rats 0 +. 0 +Reserpine 1 +- 0 +and 0 +haloperidol 1 +- 0 +induced 0 +orofacial 3 +dyskinesia 4 +are 0 +putative 0 +animal 0 +models 0 +of 0 +tardive 3 +dyskinesia 4 +( 0 +TD 3 +) 0 +whose 0 +pathophysiology 0 +has 0 +been 0 +related 0 +to 0 +free 0 +radical 0 +generation 0 +and 0 +oxidative 0 +stress 0 +. 0 +In 0 +the 0 +present 0 +study 0 +"," 0 +the 0 +authors 0 +induced 0 +orofacial 3 +dyskinesia 4 +by 0 +acute 0 +reserpine 1 +and 0 +subchronic 0 +haloperidol 1 +administration 0 +to 0 +rats 0 +. 0 +Reserpine 1 +injection 0 +( 0 +one 0 +dose 0 +of 0 +1 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +every 0 +other 0 +day 0 +for 0 +3 0 +days 0 +caused 0 +a 0 +significant 0 +increase 0 +in 0 +vacuous 0 +chewing 0 +"," 0 +tongue 0 +protrusion 0 +and 0 +duration 0 +of 0 +facial 0 +twitching 0 +"," 0 +compared 0 +to 0 +the 0 +control 0 +. 0 +Haloperidol 1 +administration 0 +( 0 +one 0 +dose 0 +of 0 +12 0 +mg 0 +/ 0 +kg 0 +once 0 +a 0 +week 0 +s 0 +. 0 +c 0 +. 0 +) 0 +for 0 +4 0 +weeks 0 +caused 0 +an 0 +increase 0 +in 0 +vacuous 0 +chewing 0 +"," 0 +tongue 0 +protrusion 0 +and 0 +duration 0 +of 0 +facial 0 +twitching 0 +observed 0 +in 0 +four 0 +weekly 0 +evaluations 0 +. 0 +After 0 +the 0 +treatments 0 +and 0 +behavioral 0 +observation 0 +"," 0 +glutamate 1 +uptake 0 +by 0 +segments 0 +of 0 +the 0 +brain 0 +was 0 +analyzed 0 +. 0 +A 0 +decreased 0 +glutamate 1 +uptake 0 +was 0 +observed 0 +in 0 +the 0 +subcortical 0 +parts 0 +of 0 +animals 0 +treated 0 +with 0 +reserpine 1 +and 0 +haloperidol 1 +"," 0 +compared 0 +to 0 +the 0 +control 0 +. 0 +Importantly 0 +"," 0 +a 0 +decrease 0 +in 0 +glutamate 1 +uptake 0 +correlates 0 +negatively 0 +with 0 +an 0 +increase 0 +in 0 +the 0 +incidence 0 +of 0 +orofacial 3 +diskinesia 4 +. 0 +These 0 +results 0 +indicate 0 +that 0 +early 0 +changes 0 +in 0 +glutamate 1 +transport 0 +may 0 +be 0 +related 0 +to 0 +the 0 +development 0 +of 0 +vacuous 0 +chewing 0 +movements 0 +in 0 +rats 0 +. 0 +Ceftriaxone 1 +- 0 +associated 0 +biliary 3 +pseudolithiasis 4 +in 0 +paediatric 0 +surgical 0 +patients 0 +. 0 +It 0 +is 0 +well 0 +known 0 +that 0 +ceftriaxone 1 +leads 0 +to 0 +pseudolithiasis 3 +in 0 +some 0 +patients 0 +. 0 +Clinical 0 +and 0 +experimental 0 +studies 0 +also 0 +suggest 0 +that 0 +situations 0 +causing 0 +gallbladder 3 +dysfunction 4 +"," 0 +such 0 +as 0 +fasting 0 +"," 0 +may 0 +have 0 +a 0 +role 0 +for 0 +the 0 +development 0 +of 0 +pseudolithiasis 3 +. 0 +In 0 +this 0 +study 0 +"," 0 +we 0 +prospectively 0 +evaluated 0 +the 0 +incidence 0 +and 0 +clinical 0 +importance 0 +of 0 +pseudolithiasis 3 +in 0 +paediatric 0 +surgical 0 +patients 0 +receiving 0 +ceftriaxone 1 +treatment 0 +"," 0 +who 0 +often 0 +had 0 +to 0 +fast 0 +in 0 +the 0 +post 0 +- 0 +operative 0 +period 0 +. 0 +Fifty 0 +children 0 +who 0 +were 0 +given 0 +ceftriaxone 1 +were 0 +evaluated 0 +by 0 +serial 0 +abdominal 0 +sonograms 0 +. 0 +0f 0 +those 0 +"," 0 +13 0 +( 0 +26 0 +% 0 +) 0 +developed 0 +biliary 0 +pathology 0 +. 0 +Comparison 0 +of 0 +the 0 +patients 0 +with 0 +or 0 +without 0 +pseudolithiasis 3 +revealed 0 +no 0 +significant 0 +difference 0 +with 0 +respect 0 +to 0 +age 0 +"," 0 +sex 0 +"," 0 +duration 0 +of 0 +the 0 +treatment 0 +and 0 +starvation 0 +variables 0 +. 0 +After 0 +cessation 0 +of 0 +the 0 +treatment 0 +"," 0 +pseudolithiasis 3 +resolved 0 +spontaneously 0 +within 0 +a 0 +short 0 +period 0 +. 0 +The 0 +incidence 0 +of 0 +pseudolithiasis 3 +is 0 +not 0 +affected 0 +by 0 +fasting 0 +. 0 +Coronary 3 +aneurysm 4 +after 0 +implantation 0 +of 0 +a 0 +paclitaxel 1 +- 0 +eluting 0 +stent 0 +. 0 +Formation 0 +of 0 +coronary 3 +aneurysm 4 +is 0 +a 0 +rare 0 +complication 0 +of 0 +stenting 0 +with 0 +bare 0 +metal 0 +stents 0 +"," 0 +but 0 +based 0 +on 0 +experimental 0 +studies 0 +drug 0 +- 0 +eluting 0 +stents 0 +may 0 +induce 0 +toxic 0 +effects 0 +on 0 +the 0 +vessel 0 +wall 0 +with 0 +incomplete 0 +stent 0 +apposition 0 +"," 0 +aneurysm 3 +formation 0 +and 0 +with 0 +the 0 +potential 0 +of 0 +stent 0 +thrombosis 3 +or 0 +vessel 3 +rupture 4 +. 0 +We 0 +present 0 +a 0 +43 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +developed 0 +a 0 +coronary 3 +aneurysm 4 +in 0 +the 0 +right 0 +coronary 0 +artery 0 +6 0 +months 0 +after 0 +receiving 0 +a 0 +paclitaxel 1 +- 0 +eluting 0 +stent 0 +. 0 +The 0 +patient 0 +was 0 +asymptomatic 0 +and 0 +the 0 +aneurysm 3 +was 0 +detected 0 +in 0 +a 0 +routine 0 +control 0 +. 0 +Angiography 0 +and 0 +intracoronary 0 +ultrasound 0 +demonstrated 0 +lack 0 +of 0 +contact 0 +between 0 +stent 0 +and 0 +vessel 0 +wall 0 +in 0 +a 0 +15 0 +- 0 +mm 0 +long 0 +segment 0 +with 0 +maximal 0 +aneurysm 3 +diameter 0 +of 0 +6 0 +. 0 +0 0 +mm 0 +. 0 +The 0 +patient 0 +was 0 +successfully 0 +treated 0 +with 0 +a 0 +graft 0 +stent 0 +. 0 +Causes 0 +of 0 +acute 0 +thrombotic 3 +microangiopathy 4 +in 0 +patients 0 +receiving 0 +kidney 0 +transplantation 0 +. 0 +0BJECTIVES 0 +: 0 +Thrombotic 3 +microangiopathy 4 +is 0 +a 0 +well 0 +- 0 +known 0 +problem 0 +in 0 +patients 0 +following 0 +renal 0 +transplantation 0 +. 0 +In 0 +postrenal 0 +transplantation 0 +"," 0 +thrombotic 3 +microangiopathy 4 +is 0 +often 0 +a 0 +reflection 0 +of 0 +hemolytic 3 +uremic 4 +syndrome 4 +. 0 +We 0 +aimed 0 +to 0 +determine 0 +the 0 +causes 0 +of 0 +thrombotic 3 +microangiopathy 4 +in 0 +a 0 +population 0 +of 0 +renal 0 +transplantation 0 +recipients 0 +and 0 +discuss 0 +the 0 +literature 0 +. 0 +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +We 0 +investigated 0 +the 0 +causes 0 +of 0 +thrombotic 3 +microangiopathy 4 +during 0 +a 0 +1 0 +- 0 +year 0 +period 0 +"," 0 +from 0 +June 0 +2003 0 +to 0 +June 0 +2004 0 +"," 0 +at 0 +the 0 +King 0 +Fahad 0 +National 0 +Guard 0 +Hospital 0 +in 0 +Riyadh 0 +"," 0 +Saudi 0 +Arabia 0 +"," 0 +by 0 +reviewing 0 +the 0 +slides 0 +of 0 +all 0 +transplant 0 +biopsies 0 +( 0 +n 0 += 0 +25 0 +) 0 +performed 0 +during 0 +this 0 +interval 0 +. 0 +Pre 0 +- 0 +and 0 +posttransplant 0 +crossmatching 0 +was 0 +done 0 +when 0 +possible 0 +. 0 +RESULTS 0 +: 0 +Five 0 +cases 0 +of 0 +thrombotic 3 +microangiopathy 4 +were 0 +found 0 +. 0 +Three 0 +of 0 +these 0 +cases 0 +were 0 +from 0 +the 0 +25 0 +transplantations 0 +performed 0 +at 0 +King 0 +Fahad 0 +National 0 +Guard 0 +Hospital 0 +"," 0 +while 0 +the 0 +other 0 +2 0 +transplantations 0 +had 0 +been 0 +performed 0 +abroad 0 +and 0 +were 0 +referred 0 +to 0 +us 0 +for 0 +follow 0 +- 0 +up 0 +. 0 +Three 0 +cases 0 +were 0 +related 0 +to 0 +cyclosporine 1 +"," 0 +and 0 +1 0 +case 0 +was 0 +secondary 0 +to 0 +both 0 +cyclosporine 1 +and 0 +tacrolimus 1 +. 0 +The 0 +fifth 0 +case 0 +had 0 +features 0 +of 0 +thrombotic 3 +microangiopathy 4 +related 0 +to 0 +an 0 +antiphospholipid 3 +syndrome 4 +in 0 +a 0 +patient 0 +with 0 +systemic 3 +lupus 4 +erythematosus 4 +. 0 +C0NCLUSI0NS 0 +: 0 +In 0 +the 0 +literature 0 +"," 0 +the 0 +most 0 +- 0 +frequent 0 +cause 0 +of 0 +hemolytic 3 +uremic 4 +syndrome 4 +in 0 +patients 0 +following 0 +renal 0 +transplantation 0 +is 0 +recurrence 0 +of 0 +the 0 +hemolytic 3 +uremic 4 +syndrome 4 +. 0 +0ther 0 +causes 0 +include 0 +drug 0 +- 0 +related 0 +( 0 +cyclosporine 1 +"," 0 +tacrolimus 1 +) 0 +toxicity 3 +"," 0 +procoagulant 0 +status 0 +"," 0 +and 0 +antibody 0 +- 0 +mediated 0 +rejection 0 +. 0 +We 0 +found 0 +that 0 +the 0 +most 0 +- 0 +frequent 0 +cause 0 +of 0 +thrombotic 3 +microangiopathy 4 +was 0 +drug 0 +related 0 +"," 0 +secondary 0 +mainly 0 +to 0 +cyclosporine 1 +. 0 +In 0 +the 0 +current 0 +study 0 +"," 0 +the 0 +frequency 0 +of 0 +thrombotic 3 +microangiopathy 4 +was 0 +similar 0 +to 0 +the 0 +percentage 0 +reported 0 +in 0 +the 0 +literature 0 +( 0 +20 0 +% 0 +) 0 +. 0 +Comparison 0 +of 0 +developmental 0 +toxicity 3 +of 0 +selective 0 +and 0 +non 0 +- 0 +selective 0 +cyclooxygenase 0 +- 0 +2 0 +inhibitors 0 +in 0 +CRL 0 +: 0 +( 0 +WI 0 +) 0 +WUBR 0 +Wistar 0 +rats 0 +- 0 +- 0 +DFU 1 +and 0 +piroxicam 1 +study 0 +. 0 +BACKGR0UND 0 +: 0 +Cyclooxygenase 0 +( 0 +C0X 0 +) 0 +inhibitors 0 +are 0 +one 0 +of 0 +the 0 +most 0 +often 0 +ingested 0 +drugs 0 +during 0 +pregnancy 0 +. 0 +Unlike 0 +general 0 +toxicity 3 +data 0 +"," 0 +their 0 +prenatal 0 +toxic 0 +effects 0 +were 0 +not 0 +extensively 0 +studied 0 +before 0 +. 0 +The 0 +aim 0 +of 0 +the 0 +experiment 0 +was 0 +to 0 +evaluate 0 +the 0 +developmental 0 +toxicity 3 +of 0 +the 0 +non 0 +- 0 +selective 0 +( 0 +piroxicam 1 +) 0 +and 0 +selective 0 +( 0 +DFU 1 +; 0 +5 1 +"," 2 +5 2 +- 2 +dimethyl 2 +- 2 +3 2 +- 2 +( 2 +3 2 +- 2 +fluorophenyl 2 +) 2 +- 2 +4 2 +- 2 +( 2 +4 2 +- 2 +methylsulphonyl 2 +) 2 +phenyl 2 +- 2 +2 2 +( 2 +5H 2 +) 2 +- 2 +furanon 2 +) 0 +C0X 0 +- 0 +2 0 +inhibitors 0 +. 0 +METH0DS 0 +: 0 +Drugs 0 +were 0 +separately 0 +"," 0 +orally 0 +once 0 +daily 0 +dosed 0 +to 0 +pregnant 0 +rats 0 +from 0 +day 0 +8 0 +to 0 +21 0 +( 0 +GD1 0 += 0 +plug 0 +day 0 +) 0 +. 0 +Doses 0 +were 0 +set 0 +at 0 +0 0 +. 0 +3 0 +"," 0 +3 0 +. 0 +0 0 +and 0 +30 0 +. 0 +0mg 0 +/ 0 +kg 0 +for 0 +piroxicam 1 +and 0 +0 0 +. 0 +2 0 +"," 0 +2 0 +. 0 +0 0 +and 0 +20 0 +. 0 +0mg 0 +/ 0 +kg 0 +for 0 +DFU 1 +. 0 +Fetuses 0 +were 0 +delivered 0 +on 0 +GD 0 +21 0 +and 0 +routinely 0 +examined 0 +. 0 +Comprehensive 0 +clinical 0 +and 0 +developmental 0 +measurements 0 +were 0 +done 0 +. 0 +The 0 +pooled 0 +statistical 0 +analysis 0 +for 0 +ventricular 3 +septal 4 +( 4 +VSD 4 +) 4 +and 4 +midline 4 +( 4 +MD 4 +) 4 +defects 4 +was 0 +performed 0 +for 0 +rat 0 +fetuses 0 +exposed 0 +to 0 +piroxicam 1 +"," 0 +selective 0 +and 0 +non 0 +- 0 +selective 0 +C0X 0 +- 0 +2 0 +inhibitor 0 +based 0 +on 0 +present 0 +and 0 +historic 0 +data 0 +. 0 +RESULTS 0 +: 0 +Maternal 0 +toxicity 3 +"," 0 +intrauterine 3 +growth 4 +retardation 4 +"," 0 +and 0 +increase 3 +of 4 +external 4 +and 4 +skeletal 4 +variations 4 +were 0 +found 0 +in 0 +rats 0 +treated 0 +with 0 +the 0 +highest 0 +dose 0 +of 0 +piroxicam 1 +. 0 +Decrease 0 +of 0 +fetal 0 +length 0 +was 0 +the 0 +only 0 +signs 0 +of 0 +the 0 +DFU 1 +developmental 0 +toxicity 3 +observed 0 +in 0 +pups 0 +exposed 0 +to 0 +the 0 +highest 0 +compound 0 +dose 0 +. 0 +Lack 0 +of 0 +teratogenicity 0 +was 0 +found 0 +in 0 +piroxicam 1 +and 0 +DFU 1 +- 0 +exposed 0 +groups 0 +. 0 +Prenatal 0 +exposure 0 +to 0 +non 0 +- 0 +selective 0 +C0X 0 +inhibitors 0 +increases 0 +the 0 +risk 0 +of 0 +VSD 0 +and 0 +MD 0 +when 0 +compared 0 +to 0 +historic 0 +control 0 +but 0 +not 0 +with 0 +selective 0 +C0X 0 +- 0 +2 0 +inhibitors 0 +. 0 +C0NCLUSI0N 0 +: 0 +Both 0 +selective 0 +and 0 +non 0 +- 0 +selective 0 +C0X 0 +- 0 +2 0 +inhibitors 0 +were 0 +toxic 0 +for 0 +rats 0 +fetuses 0 +when 0 +administered 0 +in 0 +the 0 +highest 0 +dose 0 +. 0 +Unlike 0 +DFU 1 +"," 0 +piroxicam 1 +was 0 +also 0 +highly 0 +toxic 0 +to 0 +the 0 +dams 0 +. 0 +Prenatal 0 +exposure 0 +to 0 +selective 0 +C0X 0 +- 0 +2 0 +inhibitors 0 +does 0 +not 0 +increase 0 +the 0 +risk 0 +of 0 +ventricular 3 +septal 4 +and 4 +midline 4 +defects 4 +in 0 +rat 0 +when 0 +compared 0 +to 0 +non 0 +- 0 +selective 0 +drugs 0 +and 0 +historic 0 +control 0 +. 0 +Lone 0 +atrial 3 +fibrillation 4 +associated 0 +with 0 +creatine 1 +monohydrate 0 +supplementation 0 +. 0 +Atrial 3 +fibrillation 4 +in 0 +young 0 +patients 0 +without 0 +structural 0 +heart 3 +disease 4 +is 0 +rare 0 +. 0 +Therefore 0 +"," 0 +when 0 +the 0 +arrhythmia 3 +is 0 +present 0 +in 0 +this 0 +population 0 +"," 0 +reversible 0 +causes 0 +must 0 +be 0 +identified 0 +and 0 +resolved 0 +. 0 +Thyroid 3 +disorders 4 +"," 0 +illicit 0 +drug 0 +or 0 +stimulant 0 +use 0 +"," 0 +and 0 +acute 3 +alcohol 4 +intoxication 4 +are 0 +among 0 +these 0 +causes 0 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +30 0 +- 0 +year 0 +- 0 +old 0 +Caucasian 0 +man 0 +who 0 +came 0 +to 0 +the 0 +emergency 0 +department 0 +in 0 +atrial 3 +fibrillation 4 +with 0 +rapid 0 +ventricular 0 +response 0 +. 0 +His 0 +medical 0 +history 0 +was 0 +unremarkable 0 +"," 0 +except 0 +for 0 +minor 0 +fractures 3 +of 0 +the 0 +fingers 0 +and 0 +foot 0 +. 0 +Thyroid 0 +- 0 +stimulating 0 +hormone 0 +"," 0 +magnesium 1 +"," 0 +and 0 +potassium 1 +levels 0 +were 0 +within 0 +normal 0 +limits 0 +"," 0 +urine 0 +drug 0 +screen 0 +was 0 +negative 0 +"," 0 +and 0 +alcohol 1 +use 0 +was 0 +denied 0 +. 0 +However 0 +"," 0 +when 0 +the 0 +patient 0 +was 0 +questioned 0 +about 0 +use 0 +of 0 +herbal 0 +products 0 +and 0 +supplements 0 +"," 0 +the 0 +use 0 +of 0 +creatine 1 +monohydrate 0 +was 0 +revealed 0 +. 0 +The 0 +patient 0 +was 0 +admitted 0 +to 0 +the 0 +hospital 0 +"," 0 +anticoagulated 0 +with 0 +unfractionated 0 +heparin 1 +"," 0 +and 0 +given 0 +intravenous 0 +diltiazem 1 +for 0 +rate 0 +control 0 +and 0 +intravenous 0 +amiodarone 1 +for 0 +rate 0 +and 0 +rhythm 0 +control 0 +. 0 +When 0 +discharged 0 +less 0 +than 0 +24 0 +hours 0 +later 0 +"," 0 +he 0 +was 0 +receiving 0 +metoprolol 1 +and 0 +aspirin 1 +"," 0 +with 0 +follow 0 +- 0 +up 0 +plans 0 +for 0 +echocardiography 0 +and 0 +nuclear 0 +imaging 0 +to 0 +assess 0 +perfusion 0 +. 0 +Exogenous 0 +creatine 1 +is 0 +used 0 +by 0 +athletes 0 +to 0 +theoretically 0 +improve 0 +exercise 0 +performance 0 +. 0 +Vegetarians 0 +may 0 +also 0 +take 0 +creatine 1 +to 0 +replace 0 +what 0 +they 0 +are 0 +not 0 +consuming 0 +from 0 +meat 0 +"," 0 +fish 0 +"," 0 +and 0 +other 0 +animal 0 +products 0 +. 0 +Previous 0 +anecdotal 0 +reports 0 +have 0 +linked 0 +creatine 1 +to 0 +the 0 +development 0 +of 0 +arrhythmia 3 +. 0 +Clinicians 0 +must 0 +be 0 +diligent 0 +when 0 +interviewing 0 +patients 0 +about 0 +their 0 +drug 0 +therapy 0 +histories 0 +and 0 +include 0 +questions 0 +about 0 +their 0 +use 0 +of 0 +herbal 0 +products 0 +and 0 +dietary 0 +supplements 0 +. 0 +In 0 +addition 0 +"," 0 +it 0 +is 0 +important 0 +to 0 +report 0 +adverse 0 +effects 0 +associated 0 +with 0 +frequently 0 +consumed 0 +supplements 0 +and 0 +herbal 0 +products 0 +to 0 +the 0 +Food 0 +and 0 +Drug 0 +Administration 0 +and 0 +in 0 +the 0 +literature 0 +. 0 +Seizures 3 +induced 0 +by 0 +the 0 +cocaine 1 +metabolite 0 +benzoylecgonine 1 +in 0 +rats 0 +. 0 +The 0 +half 0 +- 0 +life 0 +( 0 +t1 0 +/ 0 +2 0 +) 0 +of 0 +cocaine 1 +is 0 +relatively 0 +short 0 +"," 0 +but 0 +some 0 +of 0 +the 0 +consequences 0 +of 0 +its 0 +use 0 +"," 0 +such 0 +as 0 +seizures 3 +and 0 +strokes 3 +"," 0 +can 0 +occur 0 +hours 0 +after 0 +exposure 0 +. 0 +This 0 +led 0 +us 0 +to 0 +hypothesize 0 +that 0 +a 0 +metabolite 0 +of 0 +cocaine 1 +may 0 +be 0 +responsible 0 +for 0 +some 0 +of 0 +those 0 +delayed 0 +sequelae 0 +. 0 +We 0 +evaluated 0 +the 0 +potential 0 +of 0 +the 0 +major 0 +metabolite 0 +of 0 +cocaine 1 +"," 0 +benzoylecgonine 1 +( 0 +BE 1 +) 0 +"," 0 +to 0 +cause 0 +seizures 3 +. 0 +Two 0 +separate 0 +equimolar 0 +doses 0 +( 0 +0 0 +. 0 +2 0 +and 0 +0 0 +. 0 +4 0 +mumol 0 +) 0 +of 0 +either 0 +cocaine 1 +or 0 +BE 1 +were 0 +injected 0 +ventricularly 0 +in 0 +unanesthetized 0 +juvenile 0 +rats 0 +. 0 +Treated 0 +rats 0 +were 0 +then 0 +evaluated 0 +for 0 +incidence 0 +"," 0 +latency 0 +"," 0 +and 0 +seizure 3 +pattern 0 +or 0 +for 0 +locomotor 0 +activity 0 +in 0 +animals 0 +without 0 +seizures 3 +. 0 +BE 1 +- 0 +Induced 0 +seizures 3 +occurred 0 +more 0 +frequently 0 +and 0 +had 0 +significantly 0 +longer 0 +latencies 0 +than 0 +those 0 +induced 0 +by 0 +equimolar 0 +amounts 0 +of 0 +cocaine 1 +. 0 +Whereas 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +were 0 +best 0 +characterized 0 +as 0 +brief 0 +"," 0 +generalized 0 +"," 0 +and 0 +tonic 0 +and 0 +resulted 0 +in 0 +death 3 +"," 0 +those 0 +induced 0 +by 0 +BE 1 +were 0 +prolonged 0 +"," 0 +often 0 +multiple 0 +and 0 +mixed 0 +in 0 +type 0 +"," 0 +and 0 +rarely 0 +resulted 0 +in 0 +death 3 +. 0 +Electrical 0 +recordings 0 +from 0 +the 0 +hippocampus 0 +showed 0 +a 0 +rhythmic 0 +progression 0 +in 0 +EEG 0 +frequency 0 +and 0 +voltage 0 +with 0 +clinical 0 +seizure 3 +expression 0 +. 0 +BE 1 +- 0 +Injected 0 +rats 0 +that 0 +did 0 +not 0 +have 0 +seizures 3 +had 0 +significantly 0 +more 0 +locomotor 0 +activity 0 +than 0 +cocaine 1 +- 0 +injected 0 +animals 0 +without 0 +seizures 3 +. 0 +The 0 +finding 0 +that 0 +cocaine 1 +- 0 +and 0 +BE 1 +- 0 +induced 0 +seizures 3 +differ 0 +in 0 +several 0 +respects 0 +suggests 0 +more 0 +than 0 +one 0 +mechanism 0 +for 0 +cocaine 1 +- 0 +induced 0 +seizures 3 +and 0 +emphasizes 0 +the 0 +importance 0 +of 0 +a 0 +cocaine 1 +metabolite 0 +"," 0 +BE 1 +. 0 +The 0 +selective 0 +5 0 +- 0 +HT6 0 +receptor 0 +antagonist 0 +Ro4368554 1 +restores 0 +memory 0 +performance 0 +in 0 +cholinergic 0 +and 0 +serotonergic 0 +models 0 +of 0 +memory 3 +deficiency 4 +in 0 +the 0 +rat 0 +. 0 +Antagonists 0 +at 0 +serotonin 1 +type 0 +6 0 +( 0 +5 1 +- 2 +HT 2 +( 0 +6 0 +) 0 +) 0 +receptors 0 +show 0 +activity 0 +in 0 +models 0 +of 0 +learning 0 +and 0 +memory 0 +. 0 +Although 0 +the 0 +underlying 0 +mechanism 0 +( 0 +s 0 +) 0 +are 0 +not 0 +well 0 +understood 0 +"," 0 +these 0 +effects 0 +may 0 +involve 0 +an 0 +increase 0 +in 0 +acetylcholine 1 +( 0 +ACh 1 +) 0 +levels 0 +. 0 +The 0 +present 0 +study 0 +sought 0 +to 0 +characterize 0 +the 0 +cognitive 0 +- 0 +enhancing 0 +effects 0 +of 0 +the 0 +5 1 +- 2 +HT 2 +( 0 +6 0 +) 0 +antagonist 0 +Ro4368554 1 +( 0 +3 1 +- 2 +benzenesulfonyl 2 +- 2 +7 2 +- 2 +( 2 +4 2 +- 2 +methyl 2 +- 2 +piperazin 2 +- 2 +1 2 +- 2 +yl 2 +) 2 +1H 2 +- 2 +indole 2 +) 0 +in 0 +a 0 +rat 0 +object 0 +recognition 0 +task 0 +employing 0 +a 0 +cholinergic 0 +( 0 +scopolamine 1 +pretreatment 0 +) 0 +and 0 +a 0 +serotonergic 0 +- 0 +( 0 +tryptophan 1 +( 0 +TRP 1 +) 0 +depletion 0 +) 0 +deficient 0 +model 0 +"," 0 +and 0 +compared 0 +its 0 +pattern 0 +of 0 +action 0 +with 0 +that 0 +of 0 +the 0 +acetylcholinesterase 0 +inhibitor 0 +metrifonate 1 +. 0 +Initial 0 +testing 0 +in 0 +a 0 +time 0 +- 0 +dependent 0 +forgetting 0 +task 0 +employing 0 +a 0 +24 0 +- 0 +h 0 +delay 0 +between 0 +training 0 +and 0 +testing 0 +showed 0 +that 0 +metrifonate 1 +improved 0 +object 0 +recognition 0 +( 0 +at 0 +10 0 +and 0 +30 0 +mg 0 +/ 0 +kg 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +) 0 +"," 0 +whereas 0 +Ro4368554 1 +was 0 +inactive 0 +. 0 +Both 0 +"," 0 +Ro4368554 1 +( 0 +3 0 +and 0 +10 0 +mg 0 +/ 0 +kg 0 +"," 0 +intraperitoneally 0 +( 0 +i 0 +. 0 +p 0 +. 0 +) 0 +) 0 +and 0 +metrifonate 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +"," 0 +respectively 0 +) 0 +reversed 0 +memory 3 +deficits 4 +induced 0 +by 0 +scopolamine 1 +and 0 +TRP 1 +depletion 0 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +"," 0 +and 0 +3 0 +mg 0 +/ 0 +kg 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +"," 0 +respectively 0 +) 0 +. 0 +In 0 +conclusion 0 +"," 0 +although 0 +Ro4368554 1 +did 0 +not 0 +improve 0 +a 0 +time 0 +- 0 +related 0 +retention 0 +deficit 0 +"," 0 +it 0 +reversed 0 +a 0 +cholinergic 0 +and 0 +a 0 +serotonergic 0 +memory 3 +deficit 4 +"," 0 +suggesting 0 +that 0 +both 0 +mechanisms 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +facilitation 0 +of 0 +object 0 +memory 0 +by 0 +Ro4368554 1 +and 0 +"," 0 +possibly 0 +"," 0 +other 0 +5 1 +- 2 +HT 2 +( 0 +6 0 +) 0 +receptor 0 +antagonists 0 +. 0 +Evaluation 0 +of 0 +the 0 +anticocaine 0 +monoclonal 0 +antibody 0 +GNC92H2 1 +as 0 +an 0 +immunotherapy 0 +for 0 +cocaine 3 +overdose 4 +. 0 +The 0 +illicit 0 +use 0 +of 0 +cocaine 1 +continues 0 +in 0 +epidemic 0 +proportions 0 +and 0 +treatment 0 +for 0 +cocaine 3 +overdose 4 +remains 0 +elusive 0 +. 0 +Current 0 +protein 0 +- 0 +based 0 +technology 0 +offers 0 +a 0 +new 0 +therapeutic 0 +venue 0 +by 0 +which 0 +antibodies 0 +bind 0 +the 0 +drug 0 +in 0 +the 0 +blood 0 +stream 0 +"," 0 +inactivating 0 +its 0 +toxic 0 +effects 0 +. 0 +The 0 +therapeutic 0 +potential 0 +of 0 +the 0 +anticocaine 0 +antibody 0 +GNC92H2 1 +was 0 +examined 0 +using 0 +a 0 +model 0 +of 0 +cocaine 3 +overdose 4 +. 0 +Swiss 0 +albino 0 +mice 0 +prepared 0 +with 0 +intrajugular 0 +catheters 0 +were 0 +tested 0 +in 0 +photocell 0 +cages 0 +after 0 +administration 0 +of 0 +93 0 +mg 0 +/ 0 +kg 0 +( 0 +LD50 0 +) 0 +of 0 +cocaine 1 +and 0 +GNC92H2 1 +infusions 0 +ranging 0 +from 0 +30 0 +to 0 +190 0 +mg 0 +/ 0 +kg 0 +. 0 +GNC92H2 1 +was 0 +delivered 0 +30 0 +min 0 +before 0 +"," 0 +concomitantly 0 +or 0 +3 0 +min 0 +after 0 +cocaine 1 +treatment 0 +. 0 +Significant 0 +blockade 0 +of 0 +cocaine 1 +toxicity 3 +was 0 +observed 0 +with 0 +the 0 +higher 0 +dose 0 +of 0 +GNC92H2 1 +( 0 +190 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +where 0 +premorbid 0 +behaviors 0 +were 0 +reduced 0 +up 0 +to 0 +40 0 +% 0 +"," 0 +seizures 3 +up 0 +to 0 +77 0 +% 0 +and 0 +death 3 +by 0 +72 0 +% 0 +. 0 +Importantly 0 +"," 0 +GNC92H2 1 +prevented 0 +death 3 +even 0 +post 0 +- 0 +cocaine 1 +injection 0 +. 0 +The 0 +results 0 +support 0 +the 0 +important 0 +potential 0 +of 0 +GNC92H2 1 +as 0 +a 0 +therapeutic 0 +tool 0 +against 0 +cocaine 3 +overdose 4 +. 0 +Electrocardiographic 0 +evidence 0 +of 0 +myocardial 3 +injury 4 +in 0 +psychiatrically 0 +hospitalized 0 +cocaine 1 +abusers 0 +. 0 +The 0 +electrocardiograms 0 +( 0 +ECG 0 +) 0 +of 0 +99 0 +cocaine 1 +- 0 +abusing 0 +patients 0 +were 0 +compared 0 +with 0 +the 0 +ECGs 0 +of 0 +50 0 +schizophrenic 3 +controls 0 +. 0 +Eleven 0 +of 0 +the 0 +cocaine 1 +abusers 0 +and 0 +none 0 +of 0 +the 0 +controls 0 +had 0 +ECG 0 +evidence 0 +of 0 +significant 0 +myocardial 3 +injury 4 +defined 0 +as 0 +myocardial 3 +infarction 4 +"," 0 +ischemia 3 +"," 0 +and 0 +bundle 3 +branch 4 +block 4 +. 0 +Behavioral 0 +effects 0 +of 0 +urotensin 1 +- 2 +II 2 +centrally 0 +administered 0 +in 0 +mice 0 +. 0 +Urotensin 1 +- 2 +II 2 +( 0 +U 1 +- 2 +II 2 +) 0 +receptors 0 +are 0 +widely 0 +distributed 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 +Intracerebroventricular 0 +( 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +injection 0 +of 0 +U 1 +- 2 +II 2 +causes 0 +hypertension 3 +and 0 +bradycardia 3 +and 0 +stimulates 0 +prolactin 0 +and 0 +thyrotropin 0 +secretion 0 +. 0 +However 0 +"," 0 +the 0 +behavioral 0 +effects 0 +of 0 +centrally 0 +administered 0 +U 1 +- 2 +II 2 +have 0 +received 0 +little 0 +attention 0 +. 0 +In 0 +the 0 +present 0 +study 0 +"," 0 +we 0 +tested 0 +the 0 +effects 0 +of 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +injections 0 +of 0 +U 1 +- 2 +II 2 +on 0 +behavioral 0 +"," 0 +metabolic 0 +"," 0 +and 0 +endocrine 0 +responses 0 +in 0 +mice 0 +. 0 +Administration 0 +of 0 +graded 0 +doses 0 +of 0 +U 1 +- 2 +II 2 +( 0 +1 0 +- 0 +10 0 +"," 0 +0 0 +ng 0 +/ 0 +mouse 0 +) 0 +provoked 0 +: 0 +( 0 +1 0 +) 0 +a 0 +dose 0 +- 0 +dependent 0 +reduction 0 +in 0 +the 0 +number 0 +of 0 +head 0 +dips 0 +in 0 +the 0 +hole 0 +- 0 +board 0 +test 0 +; 0 +( 0 +2 0 +) 0 +a 0 +dose 0 +- 0 +dependent 0 +reduction 0 +in 0 +the 0 +number 0 +of 0 +entries 0 +in 0 +the 0 +white 0 +chamber 0 +in 0 +the 0 +black 0 +- 0 +and 0 +- 0 +white 0 +compartment 0 +test 0 +"," 0 +and 0 +in 0 +the 0 +number 0 +of 0 +entries 0 +in 0 +the 0 +central 0 +platform 0 +and 0 +open 0 +arms 0 +in 0 +the 0 +plus 0 +- 0 +maze 0 +test 0 +; 0 +and 0 +( 0 +3 0 +) 0 +a 0 +dose 0 +- 0 +dependent 0 +increase 0 +in 0 +the 0 +duration 0 +of 0 +immobility 0 +in 0 +the 0 +forced 0 +- 0 +swimming 0 +test 0 +and 0 +tail 0 +suspension 0 +test 0 +. 0 +Intracerebroventricular 0 +injection 0 +of 0 +U 1 +- 2 +II 2 +also 0 +caused 0 +an 0 +increase 0 +in 0 +: 0 +food 0 +intake 0 +at 0 +doses 0 +of 0 +100 0 +and 0 +1 0 +"," 0 +0 0 +ng 0 +/ 0 +mouse 0 +"," 0 +water 0 +intake 0 +at 0 +doses 0 +of 0 +100 0 +- 0 +10 0 +"," 0 +0 0 +ng 0 +/ 0 +mouse 0 +"," 0 +and 0 +horizontal 0 +locomotion 0 +activity 0 +at 0 +a 0 +dose 0 +of 0 +10 0 +"," 0 +0 0 +ng 0 +/ 0 +mouse 0 +. 0 +Whatever 0 +was 0 +the 0 +dose 0 +"," 0 +the 0 +central 0 +administration 0 +of 0 +U 1 +- 2 +II 2 +had 0 +no 0 +effect 0 +on 0 +body 0 +temperature 0 +"," 0 +nociception 0 +"," 0 +apomorphine 1 +- 0 +induced 0 +penile 3 +erection 4 +and 0 +climbing 0 +behavior 0 +"," 0 +and 0 +stress 0 +- 0 +induced 0 +plasma 0 +corticosterone 1 +level 0 +. 0 +Taken 0 +together 0 +"," 0 +the 0 +present 0 +study 0 +demonstrates 0 +that 0 +the 0 +central 0 +injection 0 +of 0 +U 1 +- 2 +II 2 +at 0 +doses 0 +of 0 +1 0 +- 0 +10 0 +"," 0 +0 0 +ng 0 +/ 0 +mouse 0 +induces 0 +anxiogenic 0 +- 0 +and 0 +depressant 0 +- 0 +like 0 +effects 0 +in 0 +mouse 0 +. 0 +These 0 +data 0 +suggest 0 +that 0 +U 1 +- 2 +II 2 +may 0 +be 0 +involved 0 +in 0 +some 0 +aspects 0 +of 0 +psychiatric 3 +disorders 4 +. 0 +Learning 0 +of 0 +rats 0 +under 0 +amnesia 3 +caused 0 +by 0 +pentobarbital 1 +. 0 +Dissociated 0 +learning 0 +of 0 +rats 0 +in 0 +the 0 +normal 0 +state 0 +and 0 +the 0 +state 0 +of 0 +amnesia 3 +produced 0 +by 0 +pentobarbital 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +"," 0 +ip 0 +) 0 +was 0 +carried 0 +out 0 +. 0 +Rats 0 +were 0 +trained 0 +to 0 +approach 0 +a 0 +shelf 0 +where 0 +they 0 +received 0 +food 0 +reinforcement 0 +. 0 +In 0 +Group 0 +1 0 +the 0 +rats 0 +were 0 +trained 0 +under 0 +the 0 +influence 0 +of 0 +pentobarbital 1 +to 0 +run 0 +to 0 +the 0 +same 0 +shelf 0 +as 0 +in 0 +the 0 +normal 0 +state 0 +. 0 +In 0 +Group 0 +2 0 +the 0 +rats 0 +were 0 +trained 0 +to 0 +approach 0 +different 0 +shelves 0 +in 0 +different 0 +drug 0 +states 0 +. 0 +It 0 +was 0 +shown 0 +that 0 +memory 3 +dissociation 4 +occurred 0 +in 0 +both 0 +groups 0 +. 0 +Differences 0 +in 0 +the 0 +parameters 0 +of 0 +training 0 +under 0 +the 0 +influence 0 +of 0 +pentobarbital 1 +between 0 +Groups 0 +1 0 +and 0 +2 0 +were 0 +revealed 0 +. 0 +These 0 +findings 0 +show 0 +that 0 +the 0 +brain 0 +- 0 +dissociated 0 +state 0 +induced 0 +by 0 +pentobarbital 1 +is 0 +formed 0 +with 0 +the 0 +participation 0 +of 0 +the 0 +mechanisms 0 +of 0 +information 0 +perception 0 +. 0 +The 0 +effects 0 +of 0 +short 0 +- 0 +term 0 +raloxifene 1 +therapy 0 +on 0 +fibrinolysis 0 +markers 0 +: 0 +TAFI 0 +"," 0 +tPA 0 +"," 0 +and 0 +PAI 0 +- 0 +1 0 +. 0 +BACKGR0UND 0 +: 0 +Markers 0 +of 0 +fibrinolysis 0 +"," 0 +thrombin 0 +- 0 +activatable 0 +fibrinolysis 0 +inhibitor 0 +( 0 +TAFI 0 +) 0 +"," 0 +tissue 0 +- 0 +type 0 +plasminogen 0 +activator 0 +( 0 +tPA 0 +) 0 +"," 0 +and 0 +plasminogen 0 +activator 0 +inhibitor 0 +- 0 +1 0 +( 0 +PAI 0 +- 0 +1 0 +) 0 +levels 0 +were 0 +studied 0 +for 0 +the 0 +evaluation 0 +of 0 +short 0 +- 0 +term 0 +effects 0 +of 0 +raloxifene 1 +administration 0 +in 0 +postmenopausal 0 +women 0 +. 0 +METH0DS 0 +: 0 +Thirty 0 +- 0 +nine 0 +postmenopausal 0 +women 0 +with 0 +osteopenia 3 +or 0 +osteoporosis 3 +were 0 +included 0 +in 0 +this 0 +prospective 0 +"," 0 +controlled 0 +clinical 0 +study 0 +. 0 +Twenty 0 +- 0 +five 0 +women 0 +were 0 +given 0 +raloxifene 1 +hydrochloride 2 +( 0 +60 0 +mg 0 +/ 0 +day 0 +) 0 +plus 0 +calcium 1 +( 0 +500 0 +mg 0 +/ 0 +day 0 +) 0 +. 0 +Age 0 +- 0 +matched 0 +controls 0 +( 0 +n 0 += 0 +14 0 +) 0 +were 0 +given 0 +only 0 +calcium 1 +. 0 +Plasma 0 +TAFI 0 +"," 0 +tPA 0 +"," 0 +and 0 +PAI 0 +- 0 +1 0 +antigen 0 +levels 0 +were 0 +measured 0 +at 0 +baseline 0 +and 0 +after 0 +3 0 +months 0 +of 0 +treatment 0 +by 0 +commercially 0 +available 0 +ELISA 0 +kits 0 +. 0 +Variations 0 +of 0 +individuals 0 +were 0 +assessed 0 +by 0 +Wilcoxon 0 +' 0 +s 0 +test 0 +. 0 +Relationship 0 +between 0 +those 0 +markers 0 +and 0 +demographic 0 +characteristics 0 +were 0 +investigated 0 +. 0 +RESULTS 0 +: 0 +Three 0 +months 0 +of 0 +raloxifene 1 +treatment 0 +was 0 +associated 0 +with 0 +a 0 +significant 0 +decrease 0 +in 0 +the 0 +plasma 0 +TAFI 0 +antigen 0 +concentrations 0 +( 0 +16 0 +% 0 +change 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +and 0 +a 0 +significant 0 +increase 0 +in 0 +tPA 0 +antigen 0 +concentrations 0 +( 0 +25 0 +% 0 +change 0 +"," 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +A 0 +significant 0 +correlation 0 +was 0 +found 0 +between 0 +baseline 0 +TAFI 0 +antigen 0 +concentrations 0 +and 0 +the 0 +duration 0 +of 0 +amenorrhea 3 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +; 0 +r 0 += 0 +0 0 +. 0 +33 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +We 0 +suggest 0 +that 0 +the 0 +increased 0 +risk 0 +of 0 +venous 3 +thromboembolism 4 +due 0 +to 0 +raloxifene 1 +treatment 0 +may 0 +be 0 +related 0 +to 0 +increased 0 +tPA 0 +levels 0 +"," 0 +but 0 +not 0 +TAFI 0 +levels 0 +. 0 +Valproate 1 +- 0 +induced 0 +encephalopathy 3 +. 0 +Valproate 1 +- 0 +induced 0 +encephalopathy 3 +is 0 +a 0 +rare 0 +syndrome 0 +that 0 +may 0 +manifest 0 +in 0 +otherwise 0 +normal 0 +epileptic 3 +individuals 0 +. 0 +It 0 +may 0 +even 0 +present 0 +in 0 +patients 0 +who 0 +have 0 +tolerated 0 +this 0 +medicine 0 +well 0 +in 0 +the 0 +past 0 +. 0 +It 0 +is 0 +usually 0 +but 0 +not 0 +necessarily 0 +associated 0 +with 0 +hyperammonemia 3 +. 0 +The 0 +EEG 0 +shows 0 +characteristic 0 +triphasic 0 +waves 0 +in 0 +most 0 +patients 0 +with 0 +this 0 +complication 0 +. 0 +A 0 +case 0 +of 0 +valproate 1 +- 0 +induced 0 +encephalopathy 3 +is 0 +presented 0 +. 0 +The 0 +problems 0 +in 0 +diagnosing 0 +this 0 +condition 0 +are 0 +subsequently 0 +discussed 0 +. 0 +Recurrent 0 +dysphonia 3 +and 0 +acitretin 1 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +woman 0 +complaining 0 +of 0 +dysphonia 3 +while 0 +she 0 +was 0 +treated 0 +by 0 +acitretin 1 +. 0 +Her 0 +symptoms 0 +totally 0 +regressed 0 +after 0 +drug 0 +withdrawal 0 +and 0 +reappeared 0 +when 0 +acitretin 1 +was 0 +reintroduced 0 +. 0 +To 0 +our 0 +knowledge 0 +"," 0 +this 0 +is 0 +the 0 +first 0 +case 0 +of 0 +acitretin 1 +- 0 +induced 0 +dysphonia 3 +. 0 +This 0 +effect 0 +may 0 +be 0 +related 0 +to 0 +the 0 +pharmacological 0 +effect 0 +of 0 +this 0 +drug 0 +on 0 +mucous 0 +membranes 0 +. 0 +Nitro 1 +- 2 +L 2 +- 2 +arginine 2 +methyl 2 +ester 2 +: 0 +a 0 +potential 0 +protector 0 +against 0 +gentamicin 1 +ototoxicity 3 +. 0 +The 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +inhibitor 0 +nitro 1 +- 2 +L 2 +- 2 +arginine 2 +methyl 2 +ester 2 +( 0 +L 1 +- 2 +NAME 2 +) 0 +may 0 +act 0 +as 0 +an 0 +otoprotectant 0 +against 0 +high 3 +- 4 +frequency 4 +hearing 4 +loss 4 +caused 0 +by 0 +gentamicin 1 +"," 0 +but 0 +further 0 +studies 0 +are 0 +needed 0 +to 0 +confirm 0 +this 0 +. 0 +Aminoglycoside 1 +antibiotics 0 +are 0 +still 0 +widely 0 +used 0 +by 0 +virtue 0 +of 0 +their 0 +efficacy 0 +and 0 +low 0 +cost 0 +. 0 +Their 0 +ototoxicity 3 +is 0 +a 0 +serious 0 +health 0 +problem 0 +and 0 +"," 0 +as 0 +their 0 +ototoxic 3 +mechanism 0 +involves 0 +the 0 +production 0 +of 0 +N0 1 +"," 0 +we 0 +need 0 +to 0 +assess 0 +the 0 +use 0 +of 0 +N0 1 +inhibitors 0 +for 0 +the 0 +prevention 0 +of 0 +aminoglycoside 1 +- 0 +induced 0 +sensorineural 3 +hearing 4 +loss 4 +. 0 +In 0 +this 0 +experimental 0 +study 0 +we 0 +used 0 +30 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +"," 0 +27 0 +of 0 +which 0 +had 0 +gentamicin 1 +instilled 0 +into 0 +the 0 +middle 0 +ear 0 +. 0 +The 0 +otoprotectant 0 +L 1 +- 2 +NAME 2 +was 0 +administered 0 +topically 0 +to 0 +12 0 +/ 0 +27 0 +animals 0 +. 0 +Its 0 +effect 0 +was 0 +determined 0 +in 0 +terms 0 +of 0 +attenuation 0 +of 0 +hearing 3 +loss 4 +"," 0 +measured 0 +by 0 +shifts 0 +in 0 +the 0 +auditory 0 +brainstem 0 +response 0 +threshold 0 +. 0 +L 1 +- 2 +NAME 2 +reduced 0 +gentamicin 1 +- 0 +induced 0 +hearing 3 +loss 4 +in 0 +the 0 +high 0 +- 0 +frequency 0 +range 0 +"," 0 +but 0 +gave 0 +no 0 +protection 0 +in 0 +the 0 +middle 0 +or 0 +low 0 +frequencies 0 +. 0 +Safety 0 +profile 0 +of 0 +a 0 +nicotine 1 +lozenge 0 +compared 0 +with 0 +that 0 +of 0 +nicotine 1 +gum 0 +in 0 +adult 0 +smokers 0 +with 0 +underlying 0 +medical 0 +conditions 0 +: 0 +a 0 +12 0 +- 0 +week 0 +"," 0 +randomized 0 +"," 0 +open 0 +- 0 +label 0 +study 0 +. 0 +BACKGR0UND 0 +: 0 +Nicotine 1 +polacrilex 0 +lozenges 0 +deliver 0 +25 0 +% 0 +to 0 +27 0 +% 0 +more 0 +nicotine 1 +compared 0 +with 0 +equivalent 0 +doses 0 +of 0 +nicotine 1 +polacrilex 0 +gum 0 +. 0 +The 0 +increased 0 +nicotine 1 +exposure 0 +from 0 +the 0 +lozenge 0 +has 0 +raised 0 +questions 0 +about 0 +the 0 +relative 0 +safety 0 +of 0 +the 0 +lozenge 0 +and 0 +gum 0 +. 0 +0BJECTIVE 0 +: 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +compare 0 +the 0 +safety 0 +profiles 0 +of 0 +the 0 +4 0 +- 0 +mg 0 +nicotine 1 +lozenge 0 +and 0 +4 0 +- 0 +mg 0 +nicotine 1 +gum 0 +in 0 +smokers 0 +with 0 +selected 0 +label 0 +- 0 +restricted 0 +diseases 0 +. 0 +METH0DS 0 +: 0 +This 0 +was 0 +a 0 +multicenter 0 +"," 0 +randomized 0 +"," 0 +open 0 +- 0 +label 0 +study 0 +in 0 +adult 0 +smokers 0 +with 0 +heart 3 +disease 4 +"," 0 +hypertension 3 +not 0 +controlled 0 +by 0 +medication 0 +"," 0 +and 0 +/ 0 +or 0 +diabetes 3 +mellitus 4 +. 0 +Patients 0 +were 0 +randomized 0 +in 0 +a 0 +1 0 +: 0 +1 0 +ratio 0 +to 0 +receive 0 +the 0 +4 0 +- 0 +mg 0 +nicotine 1 +lozenge 0 +or 0 +4 0 +- 0 +mg 0 +nicotine 1 +gum 0 +. 0 +Safety 0 +assessments 0 +were 0 +made 0 +at 0 +baseline 0 +and 0 +at 0 +2 0 +"," 0 +4 0 +"," 0 +6 0 +"," 0 +and 0 +12 0 +weeks 0 +after 0 +the 0 +start 0 +of 0 +product 0 +use 0 +. 0 +RESULTS 0 +: 0 +Nine 0 +hundred 0 +one 0 +patients 0 +were 0 +randomized 0 +to 0 +treatment 0 +"," 0 +447 0 +who 0 +received 0 +the 0 +lozenge 0 +and 0 +454 0 +who 0 +received 0 +the 0 +gum 0 +( 0 +safety 0 +population 0 +) 0 +. 0 +The 0 +majority 0 +were 0 +women 0 +( 0 +52 0 +. 0 +7 0 +% 0 +) 0 +. 0 +Patients 0 +' 0 +mean 0 +age 0 +was 0 +53 0 +. 0 +9 0 +years 0 +"," 0 +their 0 +mean 0 +weight 0 +was 0 +193 0 +. 0 +9 0 +pounds 0 +"," 0 +and 0 +they 0 +smoked 0 +a 0 +mean 0 +of 0 +25 0 +. 0 +2 0 +cigarettes 0 +per 0 +day 0 +at 0 +baseline 0 +. 0 +Five 0 +hundred 0 +fifty 0 +- 0 +three 0 +patients 0 +"," 0 +264 0 +taking 0 +the 0 +lozenge 0 +and 0 +289 0 +taking 0 +the 0 +gum 0 +"," 0 +used 0 +the 0 +study 0 +product 0 +for 0 +> 0 +or 0 += 0 +4 0 +days 0 +per 0 +week 0 +during 0 +the 0 +first 0 +2 0 +weeks 0 +( 0 +evaluable 0 +population 0 +) 0 +. 0 +The 0 +nicotine 1 +lozenge 0 +and 0 +nicotine 1 +gum 0 +were 0 +equally 0 +well 0 +tolerated 0 +"," 0 +despite 0 +increased 0 +nicotine 1 +exposure 0 +from 0 +the 0 +lozenge 0 +. 0 +The 0 +incidence 0 +of 0 +adverse 0 +events 0 +in 0 +the 0 +2 0 +groups 0 +was 0 +similar 0 +during 0 +the 0 +first 0 +2 0 +weeks 0 +of 0 +product 0 +use 0 +( 0 +evaluation 0 +population 0 +: 0 +55 0 +. 0 +3 0 +% 0 +lozenge 0 +"," 0 +54 0 +. 0 +7 0 +% 0 +gum 0 +) 0 +"," 0 +as 0 +well 0 +as 0 +during 0 +the 0 +entire 0 +study 0 +( 0 +safety 0 +population 0 +: 0 +63 0 +. 0 +8 0 +% 0 +and 0 +58 0 +. 0 +6 0 +% 0 +"," 0 +respectively 0 +) 0 +. 0 +Stratification 0 +of 0 +patients 0 +by 0 +sex 0 +"," 0 +age 0 +"," 0 +extent 0 +of 0 +concurrent 0 +smoking 0 +"," 0 +extent 0 +of 0 +product 0 +use 0 +"," 0 +and 0 +severity 0 +of 0 +adverse 0 +events 0 +revealed 0 +no 0 +clinically 0 +significant 0 +differences 0 +between 0 +the 0 +lozenge 0 +and 0 +gum 0 +. 0 +The 0 +most 0 +common 0 +adverse 0 +events 0 +were 0 +nausea 3 +( 0 +17 0 +. 0 +2 0 +% 0 +and 0 +16 0 +. 0 +1 0 +% 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +- 0 +3 0 +. 0 +7 0 +to 0 +6 0 +. 0 +0 0 +) 0 +"," 0 +hiccups 3 +( 0 +10 0 +. 0 +7 0 +% 0 +and 0 +6 0 +. 0 +6 0 +% 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +0 0 +. 0 +5 0 +to 0 +7 0 +. 0 +8 0 +) 0 +"," 0 +and 0 +headache 3 +( 0 +8 0 +. 0 +7 0 +% 0 +and 0 +9 0 +. 0 +9 0 +% 0 +; 0 +95 0 +% 0 +Cl 0 +"," 0 +- 0 +5 0 +. 0 +0 0 +to 0 +2 0 +. 0 +6 0 +) 0 +. 0 +Serious 0 +adverse 0 +events 0 +were 0 +reported 0 +in 0 +11 0 +and 0 +13 0 +patients 0 +in 0 +the 0 +respective 0 +groups 0 +. 0 +Fewer 0 +than 0 +6 0 +% 0 +of 0 +patients 0 +in 0 +either 0 +group 0 +were 0 +considered 0 +by 0 +the 0 +investigator 0 +to 0 +have 0 +a 0 +worsening 0 +of 0 +their 0 +overall 0 +disease 0 +condition 0 +during 0 +the 0 +study 0 +. 0 +The 0 +majority 0 +of 0 +patients 0 +( 0 +> 0 +60 0 +% 0 +) 0 +experienced 0 +no 0 +change 0 +in 0 +their 0 +disease 0 +status 0 +from 0 +baseline 0 +. 0 +C0NCLUSI0N 0 +: 0 +The 0 +4 0 +- 0 +mg 0 +nicotine 1 +lozenge 0 +and 0 +4 0 +- 0 +mg 0 +nicotine 1 +gum 0 +had 0 +comparable 0 +safety 0 +profiles 0 +in 0 +these 0 +patients 0 +with 0 +label 0 +- 0 +restricted 0 +medical 0 +conditions 0 +. 0 +Pharmacological 0 +modulation 0 +of 0 +pain 3 +- 0 +related 0 +brain 0 +activity 0 +during 0 +normal 0 +and 0 +central 0 +sensitization 0 +states 0 +in 0 +humans 0 +. 0 +Abnormal 0 +processing 0 +of 0 +somatosensory 0 +inputs 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +( 0 +central 0 +sensitization 0 +) 0 +is 0 +the 0 +mechanism 0 +accounting 0 +for 0 +the 0 +enhanced 0 +pain 3 +sensitivity 0 +in 0 +the 0 +skin 0 +surrounding 0 +tissue 3 +injury 4 +( 0 +secondary 3 +hyperalgesia 4 +) 0 +. 0 +Secondary 3 +hyperalgesia 4 +shares 0 +clinical 0 +characteristics 0 +with 0 +neurogenic 3 +hyperalgesia 4 +in 0 +patients 0 +with 0 +neuropathic 3 +pain 4 +. 0 +Abnormal 0 +brain 0 +responses 0 +to 0 +somatosensory 0 +stimuli 0 +have 0 +been 0 +found 0 +in 0 +patients 0 +with 0 +hyperalgesia 3 +as 0 +well 0 +as 0 +in 0 +normal 0 +subjects 0 +during 0 +experimental 0 +central 0 +sensitization 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +effects 0 +of 0 +gabapentin 1 +"," 0 +a 0 +drug 0 +effective 0 +in 0 +neuropathic 3 +pain 4 +patients 0 +"," 0 +on 0 +brain 0 +processing 0 +of 0 +nociceptive 0 +information 0 +in 0 +normal 0 +and 0 +central 0 +sensitization 0 +states 0 +. 0 +Using 0 +functional 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +fMRI 0 +) 0 +in 0 +normal 0 +volunteers 0 +"," 0 +we 0 +studied 0 +the 0 +gabapentin 1 +- 0 +induced 0 +modulation 0 +of 0 +brain 0 +activity 0 +in 0 +response 0 +to 0 +nociceptive 0 +mechanical 0 +stimulation 0 +of 0 +normal 0 +skin 0 +and 0 +capsaicin 1 +- 0 +induced 0 +secondary 3 +hyperalgesia 4 +. 0 +The 0 +dose 0 +of 0 +gabapentin 1 +was 0 +1 0 +"," 0 +800 0 +mg 0 +per 0 +os 0 +"," 0 +in 0 +a 0 +single 0 +administration 0 +. 0 +We 0 +found 0 +that 0 +( 0 +i 0 +) 0 +gabapentin 1 +reduced 0 +the 0 +activations 0 +in 0 +the 0 +bilateral 0 +operculoinsular 0 +cortex 0 +"," 0 +independently 0 +of 0 +the 0 +presence 0 +of 0 +central 0 +sensitization 0 +; 0 +( 0 +ii 0 +) 0 +gabapentin 1 +reduced 0 +the 0 +activation 0 +in 0 +the 0 +brainstem 0 +"," 0 +only 0 +during 0 +central 0 +sensitization 0 +; 0 +( 0 +iii 0 +) 0 +gabapentin 1 +suppressed 0 +stimulus 0 +- 0 +induced 0 +deactivations 0 +"," 0 +only 0 +during 0 +central 0 +sensitization 0 +; 0 +this 0 +effect 0 +was 0 +more 0 +robust 0 +than 0 +the 0 +effect 0 +on 0 +brain 0 +activation 0 +. 0 +The 0 +observed 0 +drug 0 +- 0 +induced 0 +effects 0 +were 0 +not 0 +due 0 +to 0 +changes 0 +in 0 +the 0 +baseline 0 +fMRI 0 +signal 0 +. 0 +These 0 +findings 0 +indicate 0 +that 0 +gabapentin 1 +has 0 +a 0 +measurable 0 +antinociceptive 0 +effect 0 +and 0 +a 0 +stronger 0 +antihyperalgesic 0 +effect 0 +most 0 +evident 0 +in 0 +the 0 +brain 0 +areas 0 +undergoing 0 +deactivation 0 +"," 0 +thus 0 +supporting 0 +the 0 +concept 0 +that 0 +gabapentin 1 +is 0 +more 0 +effective 0 +in 0 +modulating 0 +nociceptive 0 +transmission 0 +when 0 +central 0 +sensitization 0 +is 0 +present 0 +. 0 +Investigation 0 +of 0 +mitochondrial 0 +involvement 0 +in 0 +the 0 +experimental 0 +model 0 +of 0 +epilepsy 3 +induced 0 +by 0 +pilocarpine 1 +. 0 +Mitochondrial 3 +abnormalities 4 +have 0 +been 0 +associated 0 +with 0 +several 0 +aspects 0 +of 0 +epileptogenesis 0 +"," 0 +such 0 +as 0 +energy 0 +generation 0 +"," 0 +control 0 +of 0 +cell 0 +death 3 +"," 0 +neurotransmitter 0 +synthesis 0 +"," 0 +and 0 +free 0 +radical 0 +( 0 +FR 0 +) 0 +production 0 +. 0 +Increased 0 +production 0 +of 0 +FRs 0 +may 0 +cause 0 +mtDNA 0 +damage 0 +leading 0 +to 0 +decreased 0 +activities 0 +of 0 +oxidative 0 +phosphorylation 0 +complexes 0 +containing 0 +mtDNA 0 +- 0 +encoded 0 +subunits 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +we 0 +investigated 0 +whether 0 +increased 0 +generation 0 +of 0 +FR 0 +during 0 +status 3 +epilepticus 4 +would 0 +be 0 +sufficient 0 +to 0 +provoke 0 +abnormalities 0 +in 0 +mtDNA 0 +and 0 +in 0 +the 0 +expression 0 +and 0 +activity 0 +of 0 +cytochrome 0 +c 0 +oxidase 0 +( 0 +CC0 0 +) 0 +"," 0 +complex 0 +IV 0 +of 0 +the 0 +respiratory 0 +chain 0 +"," 0 +in 0 +the 0 +chronic 0 +phase 0 +of 0 +the 0 +pilocarpine 1 +model 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 +DNA 0 +analysis 0 +revealed 0 +low 0 +amounts 0 +of 0 +a 0 +4 0 +. 0 +8 0 +kb 0 +mtDNA 0 +deletion 0 +but 0 +with 0 +no 0 +differences 0 +in 0 +frequency 0 +or 0 +quantity 0 +in 0 +the 0 +control 0 +and 0 +experimental 0 +groups 0 +. 0 +We 0 +did 0 +not 0 +find 0 +abnormalities 0 +in 0 +the 0 +expression 0 +and 0 +distribution 0 +of 0 +an 0 +mtDNA 0 +- 0 +encoded 0 +subunit 0 +of 0 +CC0 0 +( 0 +CC0 0 +- 0 +I 0 +) 0 +or 0 +a 0 +relative 0 +decrease 0 +in 0 +CC0 0 +- 0 +I 0 +when 0 +compared 0 +with 0 +nuclear 0 +- 0 +encoded 0 +subunits 0 +( 0 +CC0 0 +- 0 +IV 0 +and 0 +SDH 0 +- 0 +fp 0 +) 0 +. 0 +No 0 +abnormality 0 +in 0 +CC0 0 +activity 0 +was 0 +observed 0 +through 0 +histochemistry 0 +. 0 +Although 0 +evidences 0 +of 0 +mitochondrial 3 +abnormalities 4 +were 0 +found 0 +in 0 +previously 0 +published 0 +studies 0 +"," 0 +our 0 +results 0 +do 0 +not 0 +suggest 0 +that 0 +the 0 +FRs 0 +"," 0 +generated 0 +during 0 +the 0 +acute 0 +phase 0 +"," 0 +determined 0 +important 0 +abnormalities 0 +in 0 +mtDNA 0 +"," 0 +in 0 +expression 0 +of 0 +CC0 0 +- 0 +I 0 +"," 0 +and 0 +in 0 +CC0 0 +activity 0 +. 0 +Adverse 0 +effect 0 +of 0 +the 0 +calcium 1 +channel 0 +blocker 0 +nitrendipine 1 +on 0 +nephrosclerosis 3 +in 0 +rats 0 +with 0 +renovascular 3 +hypertension 4 +. 0 +The 0 +effect 0 +of 0 +a 0 +6 0 +- 0 +week 0 +treatment 0 +with 0 +the 0 +calcium 1 +channel 0 +blocker 0 +nitrendipine 1 +or 0 +the 0 +angiotensin 1 +converting 0 +enzyme 0 +inhibitor 0 +enalapril 1 +on 0 +blood 0 +pressure 0 +"," 0 +albuminuria 3 +"," 0 +renal 0 +hemodynamics 0 +"," 0 +and 0 +morphology 0 +of 0 +the 0 +nonclipped 0 +kidney 0 +was 0 +studied 0 +in 0 +rats 0 +with 0 +two 0 +- 0 +kidney 0 +"," 0 +one 0 +clip 0 +renovascular 3 +hypertension 4 +. 0 +Six 0 +weeks 0 +after 0 +clipping 0 +of 0 +one 0 +renal 0 +artery 0 +"," 0 +hypertensive 3 +rats 0 +( 0 +178 0 ++ 0 +/ 0 +- 0 +4 0 +mm 0 +Hg 0 +) 0 +were 0 +randomly 0 +assigned 0 +to 0 +three 0 +groups 0 +: 0 +untreated 0 +hypertensive 3 +controls 0 +( 0 +n 0 += 0 +8 0 +) 0 +"," 0 +enalapril 1 +- 0 +treated 0 +( 0 +n 0 += 0 +8 0 +) 0 +"," 0 +or 0 +nitrendipine 1 +- 0 +treated 0 +( 0 +n 0 += 0 +10 0 +) 0 +. 0 +Sham 0 +- 0 +operated 0 +rats 0 +served 0 +as 0 +normotensive 0 +controls 0 +( 0 +128 0 ++ 0 +/ 0 +- 0 +3 0 +mm 0 +Hg 0 +"," 0 +n 0 += 0 +8 0 +) 0 +. 0 +After 0 +6 0 +weeks 0 +of 0 +treatment 0 +"," 0 +renal 0 +hemodynamics 0 +( 0 +glomerular 0 +filtration 0 +rate 0 +and 0 +renal 0 +plasma 0 +flow 0 +) 0 +were 0 +measured 0 +in 0 +the 0 +anesthetized 0 +rats 0 +. 0 +Renal 0 +tissue 0 +was 0 +obtained 0 +for 0 +determination 0 +of 0 +glomerular 0 +size 0 +and 0 +sclerosis 0 +. 0 +Enalapril 1 +but 0 +not 0 +nitrendipine 1 +reduced 0 +blood 0 +pressure 0 +significantly 0 +. 0 +After 0 +6 0 +weeks 0 +of 0 +therapy 0 +"," 0 +glomerular 0 +filtration 0 +rate 0 +was 0 +not 0 +different 0 +among 0 +the 0 +studied 0 +groups 0 +. 0 +Renal 0 +plasma 0 +flow 0 +increased 0 +"," 0 +but 0 +albumin 0 +excretion 0 +and 0 +glomerulosclerosis 3 +did 0 +not 0 +change 0 +after 0 +enalapril 1 +treatment 0 +. 0 +In 0 +contrast 0 +"," 0 +in 0 +the 0 +nitrendipine 1 +- 0 +treated 0 +group 0 +albuminuria 3 +increased 0 +from 0 +12 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +2 0 +progressively 0 +to 0 +163 0 ++ 0 +/ 0 +- 0 +55 0 +compared 0 +with 0 +19 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +9 0 +mg 0 +/ 0 +24 0 +hr 0 +in 0 +the 0 +hypertensive 3 +controls 0 +. 0 +Furthermore 0 +"," 0 +glomerulosclerosis 3 +index 0 +was 0 +significantly 0 +increased 0 +in 0 +the 0 +nitrendipine 1 +- 0 +treated 0 +group 0 +compared 0 +with 0 +the 0 +hypertensive 3 +controls 0 +( 0 +0 0 +. 0 +38 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +versus 0 +0 0 +. 0 +13 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +) 0 +. 0 +In 0 +addition 0 +"," 0 +glomerular 0 +size 0 +was 0 +higher 0 +in 0 +the 0 +nitrendipine 1 +- 0 +treated 0 +group 0 +( 0 +14 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +17 0 +10 0 +( 0 +- 0 +3 0 +) 0 +mm2 0 +) 0 +but 0 +lower 0 +in 0 +the 0 +enalapril 1 +- 0 +treated 0 +group 0 +( 0 +11 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +15 0 +10 0 +( 0 +- 0 +3 0 +) 0 +mm2 0 +) 0 +compared 0 +with 0 +the 0 +hypertensive 3 +controls 0 +( 0 +12 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +17 0 +10 0 +( 0 +- 0 +3 0 +) 0 +mm2 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Ketoconazole 1 +induced 0 +torsades 3 +de 4 +pointes 4 +without 0 +concomitant 0 +use 0 +of 0 +QT 0 +interval 0 +- 0 +prolonging 0 +drug 0 +. 0 +Ketoconazole 1 +is 0 +not 0 +known 0 +to 0 +be 0 +proarrhythmic 0 +without 0 +concomitant 0 +use 0 +of 0 +QT 0 +interval 0 +- 0 +prolonging 0 +drugs 0 +. 0 +We 0 +report 0 +a 0 +woman 0 +with 0 +coronary 3 +artery 4 +disease 4 +who 0 +developed 0 +a 0 +markedly 0 +prolonged 3 +QT 4 +interval 4 +and 0 +torsades 3 +de 4 +pointes 4 +( 0 +TdP 3 +) 0 +after 0 +taking 0 +ketoconazole 1 +for 0 +treatment 0 +of 0 +fungal 3 +infection 4 +. 0 +Her 0 +QT 0 +interval 0 +returned 0 +to 0 +normal 0 +upon 0 +withdrawal 0 +of 0 +ketoconazole 1 +. 0 +Genetic 0 +study 0 +did 0 +not 0 +find 0 +any 0 +mutation 0 +in 0 +her 0 +genes 0 +that 0 +encode 0 +cardiac 0 +IKr 0 +channel 0 +proteins 0 +. 0 +We 0 +postulate 0 +that 0 +by 0 +virtue 0 +of 0 +its 0 +direct 0 +blocking 0 +action 0 +on 0 +IKr 0 +"," 0 +ketoconazole 1 +alone 0 +may 0 +prolong 0 +QT 0 +interval 0 +and 0 +induce 0 +TdP 3 +. 0 +This 0 +calls 0 +for 0 +attention 0 +when 0 +ketoconazole 1 +is 0 +administered 0 +to 0 +patients 0 +with 0 +risk 0 +factors 0 +for 0 +acquired 0 +long 3 +QT 4 +syndrome 4 +. 0 +Cerebral 3 +vasculitis 4 +following 0 +oral 0 +methylphenidate 1 +intake 0 +in 0 +an 0 +adult 0 +: 0 +a 0 +case 0 +report 0 +. 0 +Methylphenidate 1 +is 0 +structurally 0 +and 0 +functionally 0 +similar 0 +to 0 +amphetamine 1 +. 0 +Cerebral 3 +vasculitis 4 +associated 0 +with 0 +amphetamine 3 +abuse 4 +is 0 +well 0 +documented 0 +"," 0 +and 0 +in 0 +rare 0 +cases 0 +ischaemic 3 +stroke 4 +has 0 +been 0 +reported 0 +after 0 +methylphenidate 1 +intake 0 +in 0 +children 0 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +63 0 +- 0 +year 0 +- 0 +old 0 +female 0 +who 0 +was 0 +treated 0 +with 0 +methylphenidate 1 +due 0 +to 0 +hyperactivity 3 +and 0 +suffered 0 +from 0 +multiple 0 +ischaemic 3 +strokes 4 +. 0 +We 0 +consider 0 +drug 0 +- 0 +induced 0 +cerebral 3 +vasculitis 4 +as 0 +the 0 +most 0 +likely 0 +cause 0 +of 0 +recurrent 0 +ischaemic 3 +strokes 4 +in 0 +the 0 +absence 0 +of 0 +any 0 +pathological 0 +findings 0 +during 0 +the 0 +diagnostic 0 +work 0 +- 0 +up 0 +. 0 +We 0 +conclude 0 +that 0 +methylphenidate 1 +mediated 0 +vasculitis 3 +should 0 +be 0 +considered 0 +in 0 +patients 0 +with 0 +neurological 0 +symptoms 0 +and 0 +a 0 +history 0 +of 0 +methylphenidate 1 +therapy 0 +. 0 +This 0 +potential 0 +side 0 +- 0 +effect 0 +"," 0 +though 0 +very 0 +rare 0 +"," 0 +represents 0 +one 0 +more 0 +reason 0 +to 0 +be 0 +very 0 +restrictive 0 +in 0 +the 0 +use 0 +of 0 +methylphenidate 1 +. 0 +MDMA 1 +polydrug 0 +users 0 +show 0 +process 0 +- 0 +specific 0 +central 0 +executive 0 +impairments 0 +coupled 0 +with 0 +impaired 3 +social 4 +and 4 +emotional 4 +judgement 4 +processes 4 +. 0 +In 0 +recent 0 +years 0 +working 0 +memory 3 +deficits 4 +have 0 +been 0 +reported 0 +in 0 +users 0 +of 0 +MDMA 1 +( 0 +3 1 +"," 2 +4 2 +- 2 +methylenedioxymethamphetamine 2 +"," 0 +ecstasy 1 +) 0 +. 0 +The 0 +current 0 +study 0 +aimed 0 +to 0 +assess 0 +the 0 +impact 0 +of 0 +MDMA 1 +use 0 +on 0 +three 0 +separate 0 +central 0 +executive 0 +processes 0 +( 0 +set 0 +shifting 0 +"," 0 +inhibition 0 +and 0 +memory 0 +updating 0 +) 0 +and 0 +also 0 +on 0 +" 0 +prefrontal 0 +" 0 +mediated 0 +social 0 +and 0 +emotional 0 +judgement 0 +processes 0 +. 0 +Fifteen 0 +polydrug 0 +ecstasy 1 +users 0 +and 0 +15 0 +polydrug 0 +non 0 +- 0 +ecstasy 1 +user 0 +controls 0 +completed 0 +a 0 +general 0 +drug 0 +use 0 +questionnaire 0 +"," 0 +the 0 +Brixton 0 +Spatial 0 +Anticipation 0 +task 0 +( 0 +set 0 +shifting 0 +) 0 +"," 0 +Backward 0 +Digit 0 +Span 0 +procedure 0 +( 0 +memory 0 +updating 0 +) 0 +"," 0 +Inhibition 0 +of 0 +Return 0 +( 0 +inhibition 0 +) 0 +"," 0 +an 0 +emotional 0 +intelligence 0 +scale 0 +"," 0 +the 0 +Tromso 0 +Social 0 +Intelligence 0 +Scale 0 +and 0 +the 0 +Dysexecutive 0 +Questionnaire 0 +( 0 +DEX 0 +) 0 +. 0 +Compared 0 +with 0 +MDMA 1 +- 0 +free 0 +polydrug 0 +controls 0 +"," 0 +MDMA 1 +polydrug 0 +users 0 +showed 0 +impairments 0 +in 0 +set 0 +shifting 0 +and 0 +memory 0 +updating 0 +"," 0 +and 0 +also 0 +in 0 +social 0 +and 0 +emotional 0 +judgement 0 +processes 0 +. 0 +The 0 +latter 0 +two 0 +deficits 0 +remained 0 +significant 0 +after 0 +controlling 0 +for 0 +other 0 +drug 0 +use 0 +. 0 +These 0 +data 0 +lend 0 +further 0 +support 0 +to 0 +the 0 +proposal 0 +that 0 +cognitive 0 +processes 0 +mediated 0 +by 0 +the 0 +prefrontal 0 +cortex 0 +may 0 +be 0 +impaired 0 +by 0 +recreational 0 +ecstasy 1 +use 0 +. 0 +Phase 0 +II 0 +study 0 +of 0 +the 0 +amsacrine 1 +analogue 0 +CI 1 +- 2 +921 2 +( 0 +NSC 1 +343499 2 +) 0 +in 0 +non 3 +- 4 +small 4 +cell 4 +lung 4 +cancer 4 +. 0 +CI 1 +- 2 +921 2 +( 0 +NSC 1 +343499 2 +; 0 +9 1 +- 2 +[ 2 +[ 2 +2 2 +- 2 +methoxy 2 +- 2 +4 2 +- 2 +[ 2 +( 2 +methylsulphonyl 2 +) 2 +amino 2 +] 2 +phenyl 2 +] 2 +amino 2 +] 2 +- 2 +N 2 +"," 2 +5 2 +- 2 +dimethyl 2 +- 2 +4 2 +- 2 +acridinecarboxamide 2 +) 0 +is 0 +a 0 +topoisomerase 0 +II 0 +poison 0 +with 0 +high 0 +experimental 0 +antitumour 0 +activity 0 +. 0 +It 0 +was 0 +administered 0 +by 0 +15 0 +min 0 +infusion 0 +to 0 +16 0 +evaluable 0 +patients 0 +with 0 +non 3 +- 4 +small 4 +cell 4 +lung 4 +cancer 4 +( 0 +NSCLC 3 +) 0 +( 0 +7 0 +with 0 +no 0 +prior 0 +treatment 0 +"," 0 +9 0 +patients 0 +in 0 +relapse 0 +following 0 +surgery 0 +/ 0 +radiotherapy 0 +) 0 +at 0 +a 0 +dose 0 +( 0 +648 0 +mg 0 +/ 0 +m2 0 +divided 0 +over 0 +3 0 +days 0 +"," 0 +repeated 0 +every 0 +3 0 +weeks 0 +) 0 +determined 0 +by 0 +phase 0 +I 0 +trial 0 +. 0 +Patients 0 +had 0 +a 0 +median 0 +performance 0 +status 0 +of 0 +1 0 +( 0 +WH0 0 +) 0 +"," 0 +and 0 +median 0 +age 0 +of 0 +61 0 +years 0 +. 0 +The 0 +histology 0 +comprised 0 +squamous 3 +carcinoma 4 +( 0 +11 0 +) 0 +"," 0 +adenocarcinoma 3 +( 0 +1 0 +) 0 +"," 0 +mixed 0 +histology 0 +( 0 +2 0 +) 0 +"," 0 +bronchio 3 +- 4 +alveolar 4 +carcinoma 4 +( 0 +1 0 +) 0 +and 0 +large 0 +cell 0 +undifferentiated 3 +carcinoma 4 +( 0 +1 0 +) 0 +. 0 +Neutropenia 3 +grade 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +3 0 +was 0 +seen 0 +in 0 +15 0 +patients 0 +"," 0 +infections 3 +with 0 +recovery 0 +in 0 +3 0 +"," 0 +and 0 +grand 0 +mal 0 +seizures 3 +in 0 +1 0 +patient 0 +. 0 +Grade 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +2 0 +nausea 3 +and 0 +vomiting 3 +occurred 0 +in 0 +66 0 +% 0 +courses 0 +and 0 +phlebitis 3 +in 0 +the 0 +infusion 0 +arm 0 +in 0 +37 0 +% 0 +. 0 +1 0 +patient 0 +with 0 +squamous 3 +cell 4 +carcinoma 4 +achieved 0 +a 0 +partial 0 +response 0 +lasting 0 +5 0 +months 0 +. 0 +Further 0 +testing 0 +in 0 +this 0 +and 0 +other 0 +tumour 3 +types 0 +using 0 +multiple 0 +daily 0 +schedules 0 +is 0 +warranted 0 +. 0 +Pharmacokinetics 0 +of 0 +desipramine 1 +HCl 2 +when 0 +administered 0 +with 0 +cinacalcet 1 +HCl 2 +. 0 +0BJECTIVE 0 +: 0 +In 0 +vitro 0 +work 0 +has 0 +demonstrated 0 +that 0 +cinacalcet 1 +is 0 +a 0 +strong 0 +inhibitor 0 +of 0 +cytochrome 0 +P450 0 +isoenzyme 0 +( 0 +CYP 0 +) 0 +2D6 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +effect 0 +of 0 +cinacalcet 1 +on 0 +CYP2D6 0 +activity 0 +"," 0 +using 0 +desipramine 1 +as 0 +a 0 +probe 0 +substrate 0 +"," 0 +in 0 +healthy 0 +subjects 0 +. 0 +METH0DS 0 +: 0 +Seventeen 0 +subjects 0 +who 0 +were 0 +genotyped 0 +as 0 +CYP2D6 0 +extensive 0 +metabolizers 0 +were 0 +enrolled 0 +in 0 +this 0 +randomized 0 +"," 0 +open 0 +- 0 +label 0 +"," 0 +crossover 0 +study 0 +to 0 +receive 0 +a 0 +single 0 +oral 0 +dose 0 +of 0 +desipramine 1 +( 0 +50 0 +mg 0 +) 0 +on 0 +two 0 +separate 0 +occasions 0 +"," 0 +once 0 +alone 0 +and 0 +once 0 +after 0 +multiple 0 +doses 0 +of 0 +cinacalcet 1 +( 0 +90 0 +mg 0 +for 0 +7 0 +days 0 +) 0 +. 0 +Blood 0 +samples 0 +were 0 +obtained 0 +predose 0 +and 0 +up 0 +to 0 +72 0 +h 0 +postdose 0 +. 0 +RESULTS 0 +: 0 +Fourteen 0 +subjects 0 +completed 0 +both 0 +treatment 0 +arms 0 +. 0 +Relative 0 +to 0 +desipramine 1 +alone 0 +"," 0 +mean 0 +AUC 0 +and 0 +C 0 +( 0 +max 0 +) 0 +of 0 +desipramine 1 +increased 0 +3 0 +. 0 +6 0 +- 0 +and 0 +1 0 +. 0 +8 0 +- 0 +fold 0 +when 0 +coadministered 0 +with 0 +cinacalcet 1 +. 0 +The 0 +t 0 +( 0 +1 0 +/ 0 +2 0 +"," 0 +z 0 +) 0 +of 0 +desipramine 1 +was 0 +longer 0 +when 0 +desipramine 1 +was 0 +coadministered 0 +with 0 +cinacalcet 1 +( 0 +21 0 +. 0 +0 0 +versus 0 +43 0 +. 0 +3 0 +hs 0 +) 0 +. 0 +The 0 +t 0 +( 0 +max 0 +) 0 +was 0 +similar 0 +between 0 +the 0 +regimens 0 +. 0 +Fewer 0 +subjects 0 +reported 0 +adverse 0 +events 0 +following 0 +treatment 0 +with 0 +desipramine 1 +alone 0 +than 0 +when 0 +receiving 0 +desipramine 1 +with 0 +cinacalcet 1 +( 0 +33 0 +versus 0 +86 0 +% 0 +) 0 +"," 0 +the 0 +most 0 +frequent 0 +of 0 +which 0 +( 0 +nausea 3 +and 0 +headache 3 +) 0 +have 0 +been 0 +reported 0 +for 0 +patients 0 +treated 0 +with 0 +either 0 +desipramine 1 +or 0 +cinacalcet 1 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +study 0 +demonstrates 0 +that 0 +cinacalcet 1 +is 0 +a 0 +strong 0 +inhibitor 0 +of 0 +CYP2D6 0 +. 0 +These 0 +data 0 +suggest 0 +that 0 +during 0 +concomitant 0 +treatment 0 +with 0 +cinacalcet 1 +"," 0 +dose 0 +adjustment 0 +may 0 +be 0 +necessary 0 +for 0 +drugs 0 +that 0 +demonstrate 0 +a 0 +narrow 0 +therapeutic 0 +index 0 +and 0 +are 0 +metabolized 0 +by 0 +CYP2D6 0 +. 0 +Case 0 +report 0 +: 0 +acute 0 +unintentional 0 +carbachol 1 +intoxication 0 +. 0 +INTR0DUCTI0N 0 +: 0 +Intoxications 0 +with 0 +carbachol 1 +"," 0 +a 0 +muscarinic 0 +cholinergic 0 +receptor 0 +agonist 0 +are 0 +rare 0 +. 0 +We 0 +report 0 +an 0 +interesting 0 +case 0 +investigating 0 +a 0 +( 0 +near 0 +) 0 +fatal 0 +poisoning 3 +. 0 +METH0DS 0 +: 0 +The 0 +son 0 +of 0 +an 0 +84 0 +- 0 +year 0 +- 0 +old 0 +male 0 +discovered 0 +a 0 +newspaper 0 +report 0 +stating 0 +clinical 0 +success 0 +with 0 +plant 0 +extracts 0 +in 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 +The 0 +mode 0 +of 0 +action 0 +was 0 +said 0 +to 0 +be 0 +comparable 0 +to 0 +that 0 +of 0 +the 0 +synthetic 0 +compound 0 +' 0 +carbamylcholin 1 +' 0 +; 0 +that 0 +is 0 +"," 0 +carbachol 1 +. 0 +He 0 +bought 0 +25 0 +g 0 +of 0 +carbachol 1 +as 0 +pure 0 +substance 0 +in 0 +a 0 +pharmacy 0 +"," 0 +and 0 +the 0 +father 0 +was 0 +administered 0 +400 0 +to 0 +500 0 +mg 0 +. 0 +Carbachol 1 +concentrations 0 +in 0 +serum 0 +and 0 +urine 0 +on 0 +day 0 +1 0 +and 0 +2 0 +of 0 +hospital 0 +admission 0 +were 0 +analysed 0 +by 0 +HPLC 0 +- 0 +mass 0 +spectrometry 0 +. 0 +RESULTS 0 +: 0 +Minutes 0 +after 0 +oral 0 +administration 0 +"," 0 +the 0 +patient 0 +developed 0 +nausea 3 +"," 0 +sweating 0 +and 0 +hypotension 3 +"," 0 +and 0 +finally 0 +collapsed 0 +. 0 +Bradycardia 3 +"," 0 +cholinergic 0 +symptoms 0 +and 0 +asystole 3 +occurred 0 +. 0 +Initial 0 +cardiopulmonary 0 +resuscitation 0 +and 0 +immediate 0 +treatment 0 +with 0 +adrenaline 1 +( 0 +epinephrine 1 +) 0 +"," 0 +atropine 1 +and 0 +furosemide 1 +was 0 +successful 0 +. 0 +0n 0 +hospital 0 +admission 0 +"," 0 +blood 0 +pressure 0 +of 0 +the 0 +intubated 0 +"," 0 +bradyarrhythmic 0 +patient 0 +was 0 +100 0 +/ 0 +65 0 +mmHg 0 +. 0 +Further 0 +signs 0 +were 0 +hyperhidrosis 3 +"," 0 +hypersalivation 3 +"," 0 +bronchorrhoea 3 +"," 0 +and 0 +severe 0 +miosis 3 +; 0 +the 0 +electrocardiographic 0 +finding 0 +was 0 +atrio 3 +- 4 +ventricular 4 +dissociation 4 +. 0 +High 0 +doses 0 +of 0 +atropine 1 +( 0 +up 0 +to 0 +50 0 +mg 0 +per 0 +24 0 +hours 0 +) 0 +"," 0 +adrenaline 1 +and 0 +dopamine 1 +were 0 +necessary 0 +. 0 +The 0 +patient 0 +was 0 +extubated 0 +1 0 +week 0 +later 0 +. 0 +However 0 +"," 0 +increased 0 +dyspnoea 3 +and 0 +bronchospasm 3 +necessitated 0 +reintubation 0 +. 0 +Respiratory 3 +insufficiency 4 +was 0 +further 0 +worsened 0 +by 0 +Proteus 3 +mirabilis 4 +infection 4 +and 0 +severe 0 +bronchoconstriction 0 +. 0 +0ne 0 +week 0 +later 0 +"," 0 +the 0 +patient 0 +was 0 +again 0 +extubated 0 +and 0 +3 0 +days 0 +later 0 +was 0 +transferred 0 +to 0 +a 0 +peripheral 0 +ward 0 +. 0 +0n 0 +the 0 +next 0 +day 0 +he 0 +died 0 +"," 0 +probably 0 +as 0 +a 0 +result 0 +of 0 +heart 3 +failure 4 +. 0 +Serum 0 +samples 0 +from 0 +the 0 +first 0 +and 0 +second 0 +days 0 +contained 0 +3 0 +. 0 +6 0 +and 0 +1 0 +. 0 +9 0 +mg 0 +/ 0 +l 0 +carbachol 1 +"," 0 +respectively 0 +. 0 +The 0 +corresponding 0 +urine 0 +concentrations 0 +amounted 0 +to 0 +374 0 +and 0 +554 0 +mg 0 +/ 0 +l 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +case 0 +started 0 +with 0 +a 0 +media 0 +report 0 +in 0 +a 0 +popular 0 +newspaper 0 +"," 0 +initiated 0 +by 0 +published 0 +"," 0 +peer 0 +- 0 +reviewed 0 +research 0 +on 0 +herbals 0 +"," 0 +and 0 +involved 0 +human 0 +failure 0 +in 0 +a 0 +case 0 +history 0 +"," 0 +medical 0 +examination 0 +and 0 +clinical 0 +treatment 0 +. 0 +For 0 +the 0 +first 0 +time 0 +"," 0 +an 0 +analytical 0 +method 0 +for 0 +the 0 +determination 0 +of 0 +carbachol 1 +in 0 +plasma 0 +and 0 +urine 0 +has 0 +been 0 +developed 0 +. 0 +The 0 +analysed 0 +carbachol 1 +concentration 0 +exceeded 0 +the 0 +supposed 0 +serum 0 +level 0 +resulting 0 +from 0 +a 0 +therapeutic 0 +dose 0 +by 0 +a 0 +factor 0 +of 0 +130 0 +to 0 +260 0 +. 0 +Especially 0 +in 0 +old 0 +patients 0 +"," 0 +intensivists 0 +should 0 +consider 0 +intoxications 0 +( 0 +with 0 +cholinergics 0 +) 0 +as 0 +a 0 +cause 0 +of 0 +acute 3 +cardiovascular 4 +failure 4 +. 0 +Pharmacological 0 +evidence 0 +for 0 +the 0 +potential 0 +of 0 +Daucus 0 +carota 0 +in 0 +the 0 +management 0 +of 0 +cognitive 3 +dysfunctions 4 +. 0 +The 0 +present 0 +study 0 +was 0 +aimed 0 +at 0 +investigating 0 +the 0 +effects 0 +of 0 +Daucus 0 +carota 0 +seeds 0 +on 0 +cognitive 0 +functions 0 +"," 0 +total 0 +serum 0 +cholesterol 1 +levels 0 +and 0 +brain 0 +cholinesterase 0 +activity 0 +in 0 +mice 0 +. 0 +The 0 +ethanolic 0 +extract 1 +of 2 +Daucus 2 +carota 2 +seeds 2 +( 0 +DCE 1 +) 0 +was 0 +administered 0 +orally 0 +in 0 +three 0 +doses 0 +( 0 +100 0 +"," 0 +200 0 +"," 0 +400 0 +mg 0 +/ 0 +kg 0 +) 0 +for 0 +seven 0 +successive 0 +days 0 +to 0 +different 0 +groups 0 +of 0 +young 0 +and 0 +aged 0 +mice 0 +. 0 +Elevated 0 +plus 0 +maze 0 +and 0 +passive 0 +avoidance 0 +apparatus 0 +served 0 +as 0 +the 0 +exteroceptive 0 +behavioral 0 +models 0 +for 0 +testing 0 +memory 0 +. 0 +Diazepam 1 +- 0 +"," 0 +scopolamine 1 +- 0 +and 0 +ageing 0 +- 0 +induced 0 +amnesia 3 +served 0 +as 0 +the 0 +interoceptive 0 +behavioral 0 +models 0 +. 0 +DCE 1 +( 0 +200 0 +"," 0 +400 0 +mg 0 +/ 0 +kg 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +) 0 +showed 0 +significant 0 +improvement 0 +in 0 +memory 0 +scores 0 +of 0 +young 0 +and 0 +aged 0 +mice 0 +. 0 +The 0 +extent 0 +of 0 +memory 0 +improvement 0 +evoked 0 +by 0 +DCE 1 +was 0 +23 0 +% 0 +at 0 +the 0 +dose 0 +of 0 +200 0 +mg 0 +/ 0 +kg 0 +and 0 +35 0 +% 0 +at 0 +the 0 +dose 0 +of 0 +400 0 +mg 0 +/ 0 +kg 0 +in 0 +young 0 +mice 0 +using 0 +elevated 0 +plus 0 +maze 0 +. 0 +Similarly 0 +"," 0 +significant 0 +improvements 0 +in 0 +memory 0 +scores 0 +were 0 +observed 0 +using 0 +passive 0 +avoidance 0 +apparatus 0 +and 0 +aged 0 +mice 0 +. 0 +Furthermore 0 +"," 0 +DCE 1 +reversed 0 +the 0 +amnesia 3 +induced 0 +by 0 +scopolamine 1 +( 0 +0 0 +. 0 +4 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +diazepam 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 +Daucus 1 +carota 2 +extract 2 +( 0 +200 0 +"," 0 +400 0 +mg 0 +/ 0 +kg 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +) 0 +reduced 0 +significantly 0 +the 0 +brain 0 +acetylcholinesterase 0 +activity 0 +and 0 +cholesterol 1 +levels 0 +in 0 +young 0 +and 0 +aged 0 +mice 0 +. 0 +The 0 +extent 0 +of 0 +inhibition 0 +of 0 +brain 0 +cholinesterase 0 +activity 0 +evoked 0 +by 0 +DCE 1 +at 0 +the 0 +dose 0 +of 0 +400 0 +mg 0 +/ 0 +kg 0 +was 0 +22 0 +% 0 +in 0 +young 0 +and 0 +19 0 +% 0 +in 0 +aged 0 +mice 0 +. 0 +There 0 +was 0 +a 0 +remarkable 0 +reduction 0 +in 0 +total 0 +cholesterol 1 +level 0 +as 0 +well 0 +"," 0 +to 0 +the 0 +extent 0 +of 0 +23 0 +% 0 +in 0 +young 0 +and 0 +21 0 +% 0 +in 0 +aged 0 +animals 0 +with 0 +this 0 +dose 0 +of 0 +DCE 1 +. 0 +Therefore 0 +"," 0 +DCE 1 +may 0 +prove 0 +to 0 +be 0 +a 0 +useful 0 +remedy 0 +for 0 +the 0 +management 0 +of 0 +cognitive 3 +dysfunctions 4 +on 0 +account 0 +of 0 +its 0 +multifarious 0 +beneficial 0 +effects 0 +such 0 +as 0 +"," 0 +memory 0 +improving 0 +property 0 +"," 0 +cholesterol 1 +lowering 0 +property 0 +and 0 +anticholinesterase 0 +activity 0 +. 0 +Valproic 1 +acid 2 +induced 0 +encephalopathy 3 +- 0 +- 0 +19 0 +new 0 +cases 0 +in 0 +Germany 0 +from 0 +1994 0 +to 0 +2003 0 +- 0 +- 0 +a 0 +side 0 +effect 0 +associated 0 +to 0 +VPA 1 +- 0 +therapy 0 +not 0 +only 0 +in 0 +young 0 +children 0 +. 0 +Valproic 1 +acid 2 +( 0 +VPA 1 +) 0 +is 0 +a 0 +broad 0 +- 0 +spectrum 0 +antiepileptic 0 +drug 0 +and 0 +is 0 +usually 0 +well 0 +- 0 +tolerated 0 +. 0 +Rare 0 +serious 0 +complications 0 +may 0 +occur 0 +in 0 +some 0 +patients 0 +"," 0 +including 0 +haemorrhagic 0 +pancreatitis 3 +"," 0 +bone 3 +marrow 4 +suppression 4 +"," 0 +VPA 1 +- 0 +induced 0 +hepatotoxicity 3 +and 0 +VPA 1 +- 0 +induced 0 +encephalopathy 3 +. 0 +The 0 +typical 0 +signs 0 +of 0 +VPA 1 +- 0 +induced 0 +encephalopathy 3 +are 0 +impaired 3 +consciousness 4 +"," 0 +sometimes 0 +marked 0 +EEG 0 +background 0 +slowing 0 +"," 0 +increased 0 +seizure 3 +frequency 0 +"," 0 +with 0 +or 0 +without 0 +hyperammonemia 3 +. 0 +There 0 +is 0 +still 0 +no 0 +proof 0 +of 0 +causative 0 +effect 0 +of 0 +VPA 1 +in 0 +patients 0 +with 0 +encephalopathy 3 +"," 0 +but 0 +only 0 +of 0 +an 0 +association 0 +with 0 +an 0 +assumed 0 +causal 0 +relation 0 +. 0 +We 0 +report 0 +19 0 +patients 0 +with 0 +VPA 1 +- 0 +associated 0 +encephalopathy 3 +in 0 +Germany 0 +from 0 +the 0 +years 0 +1994 0 +to 0 +2003 0 +"," 0 +none 0 +of 0 +whom 0 +had 0 +been 0 +published 0 +previously 0 +. 0 +Cerebral 3 +haemorrhage 4 +induced 0 +by 0 +warfarin 1 +- 0 +the 0 +influence 0 +of 0 +drug 0 +- 0 +drug 0 +interactions 0 +. 0 +PURP0SE 0 +: 0 +To 0 +evaluate 0 +the 0 +frequency 0 +"," 0 +severity 0 +and 0 +preventability 0 +of 0 +warfarin 1 +- 0 +induced 0 +cerebral 3 +haemorrhages 4 +due 0 +to 0 +warfarin 1 +and 0 +warfarin 1 +- 0 +drug 0 +interactions 0 +in 0 +patients 0 +living 0 +in 0 +the 0 +county 0 +of 0 +0sterg 0 +tland 0 +"," 0 +Sweden 0 +. 0 +METH0DS 0 +: 0 +All 0 +patients 0 +with 0 +a 0 +diagnosed 0 +cerebral 3 +haemorrhage 4 +at 0 +three 0 +hospitals 0 +during 0 +the 0 +period 0 +2000 0 +- 0 +2002 0 +were 0 +identified 0 +. 0 +Medical 0 +records 0 +were 0 +studied 0 +retrospectively 0 +to 0 +evaluate 0 +whether 0 +warfarin 1 +and 0 +warfarin 1 +- 0 +drug 0 +interactions 0 +could 0 +have 0 +caused 0 +the 0 +cerebral 3 +haemorrhage 4 +. 0 +The 0 +proportion 0 +of 0 +possibly 0 +avoidable 0 +cases 0 +due 0 +to 0 +drug 0 +interactions 0 +was 0 +estimated 0 +. 0 +RESULTS 0 +: 0 +Among 0 +593 0 +patients 0 +with 0 +cerebral 3 +haemorrhage 4 +"," 0 +59 0 +( 0 +10 0 +% 0 +) 0 +were 0 +assessed 0 +as 0 +related 0 +to 0 +warfarin 1 +treatment 0 +. 0 +This 0 +imply 0 +an 0 +incidence 0 +of 0 +1 0 +. 0 +7 0 +/ 0 +100 0 +"," 0 +0 0 +treatment 0 +years 0 +. 0 +0f 0 +the 0 +59 0 +cases 0 +"," 0 +26 0 +( 0 +44 0 +% 0 +) 0 +had 0 +a 0 +fatal 0 +outcome 0 +"," 0 +compared 0 +to 0 +136 0 +( 0 +25 0 +% 0 +) 0 +among 0 +the 0 +non 0 +- 0 +warfarin 1 +patients 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +A 0 +warfarin 1 +- 0 +drug 0 +interaction 0 +could 0 +have 0 +contributed 0 +to 0 +the 0 +haemorrhage 3 +in 0 +24 0 +( 0 +41 0 +% 0 +) 0 +of 0 +the 0 +warfarin 1 +patients 0 +and 0 +in 0 +7 0 +of 0 +these 0 +( 0 +12 0 +% 0 +) 0 +the 0 +bleeding 3 +complication 0 +was 0 +considered 0 +being 0 +possible 0 +to 0 +avoid 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Warfarin 1 +- 0 +induced 0 +cerebral 3 +haemorrhages 4 +are 0 +a 0 +major 0 +clinical 0 +problem 0 +with 0 +a 0 +high 0 +fatality 0 +rate 0 +. 0 +Almost 0 +half 0 +of 0 +the 0 +cases 0 +was 0 +related 0 +to 0 +a 0 +warfarin 1 +- 0 +drug 0 +interaction 0 +. 0 +A 0 +significant 0 +proportion 0 +of 0 +warfarin 1 +- 0 +related 0 +cerebral 3 +haemorrhages 4 +might 0 +have 0 +been 0 +prevented 0 +if 0 +greater 0 +caution 0 +had 0 +been 0 +taken 0 +when 0 +prescribing 0 +drugs 0 +known 0 +to 0 +interact 0 +with 0 +warfarin 1 +. 0 +Antipsychotic 0 +- 0 +like 0 +profile 0 +of 0 +thioperamide 1 +"," 0 +a 0 +selective 0 +H3 0 +- 0 +receptor 0 +antagonist 0 +in 0 +mice 0 +. 0 +Experimental 0 +and 0 +clinical 0 +evidence 0 +points 0 +to 0 +a 0 +role 0 +of 0 +central 0 +histaminergic 0 +system 0 +in 0 +the 0 +pathogenesis 0 +of 0 +schizophrenia 3 +. 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +study 0 +the 0 +effect 0 +of 0 +histamine 1 +H 0 +( 0 +3 0 +) 0 +- 0 +receptor 0 +ligands 0 +on 0 +neuroleptic 0 +- 0 +induced 0 +catalepsy 3 +"," 0 +apomorphine 1 +- 0 +induced 0 +climbing 0 +behavior 0 +and 0 +amphetamine 1 +- 0 +induced 0 +locomotor 0 +activities 0 +in 0 +mice 0 +. 0 +Catalepsy 3 +was 0 +induced 0 +by 0 +haloperidol 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +"," 0 +while 0 +apomorphine 1 +( 0 +1 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +and 0 +amphetamine 1 +( 0 +2 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +were 0 +used 0 +for 0 +studying 0 +climbing 0 +behavior 0 +and 0 +locomotor 0 +activities 0 +"," 0 +respectively 0 +. 0 +( 1 +R 2 +) 2 +- 2 +alpha 2 +- 2 +methylhistamine 2 +( 0 +RAMH 1 +) 0 +( 0 +5 0 +microg 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +and 0 +thioperamide 1 +( 0 +THP 1 +) 0 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +"," 0 +per 0 +se 0 +did 0 +not 0 +cause 0 +catalepsy 3 +. 0 +Administration 0 +of 0 +THP 1 +( 0 +3 0 +. 0 +75 0 +"," 0 +7 0 +. 0 +5 0 +and 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +1 0 +h 0 +prior 0 +to 0 +haloperidol 1 +resulted 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +increase 0 +in 0 +the 0 +catalepsy 3 +times 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +However 0 +"," 0 +pretreatment 0 +with 0 +RAMH 1 +significantly 0 +reversed 0 +such 0 +an 0 +effect 0 +of 0 +THP 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 +RAMH 1 +per 0 +se 0 +showed 0 +significant 0 +reduction 0 +in 0 +locomotor 0 +time 0 +"," 0 +distance 0 +traveled 0 +and 0 +average 0 +speed 0 +but 0 +THP 1 +( 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +per 0 +se 0 +had 0 +no 0 +effect 0 +on 0 +these 0 +parameters 0 +. 0 +0n 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +"," 0 +THP 1 +( 0 +3 0 +. 0 +75 0 +and 0 +7 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +reduced 0 +locomotor 0 +time 0 +"," 0 +distance 0 +traveled 0 +and 0 +average 0 +speed 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Pretreatment 0 +with 0 +RAMH 1 +( 0 +5 0 +microg 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +could 0 +partially 0 +reverse 0 +such 0 +effects 0 +of 0 +THP 1 +( 0 +3 0 +. 0 +75 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +. 0 +Climbing 0 +behavior 0 +induced 0 +by 0 +apomorphine 1 +was 0 +reduced 0 +in 0 +animals 0 +treated 0 +with 0 +THP 1 +. 0 +Such 0 +an 0 +effect 0 +was 0 +"," 0 +however 0 +"," 0 +reversed 0 +in 0 +presence 0 +of 0 +RAMH 1 +. 0 +THP 1 +exhibited 0 +an 0 +antipsychotic 0 +- 0 +like 0 +profile 0 +by 0 +potentiating 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +"," 0 +reducing 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +and 0 +reducing 0 +apomorphine 1 +- 0 +induced 0 +climbing 0 +in 0 +mice 0 +. 0 +Such 0 +effects 0 +of 0 +THP 1 +were 0 +reversed 0 +by 0 +RAMH 1 +indicating 0 +the 0 +involvement 0 +of 0 +histamine 1 +H 0 +( 0 +3 0 +) 0 +- 0 +receptors 0 +. 0 +Findings 0 +suggest 0 +a 0 +potential 0 +for 0 +H 0 +( 0 +3 0 +) 0 +- 0 +receptor 0 +antagonists 0 +in 0 +improving 0 +the 0 +refractory 0 +cases 0 +of 0 +schizophrenia 3 +. 0 +Cauda 3 +equina 4 +syndrome 4 +after 0 +epidural 0 +steroid 1 +injection 0 +: 0 +a 0 +case 0 +report 0 +. 0 +0BJECTIVE 0 +: 0 +Conventional 0 +treatment 0 +methods 0 +of 0 +lumbusacral 0 +radiculopathy 3 +are 0 +physical 0 +therapy 0 +"," 0 +epidural 0 +steroid 1 +injections 0 +"," 0 +oral 0 +medications 0 +"," 0 +and 0 +spinal 0 +manipulative 0 +therapy 0 +. 0 +Cauda 3 +equina 4 +syndrome 4 +is 0 +a 0 +rare 0 +complication 0 +of 0 +epidural 0 +anesthesia 0 +. 0 +The 0 +following 0 +case 0 +is 0 +a 0 +report 0 +of 0 +cauda 3 +equina 4 +syndrome 4 +possibly 0 +caused 0 +by 0 +epidural 0 +injection 0 +of 0 +triamcinolone 1 +and 0 +bupivacaine 1 +. 0 +CLINICAL 0 +FEATURES 0 +: 0 +A 0 +50 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +low 3 +back 4 +and 4 +right 4 +leg 4 +pain 4 +was 0 +scheduled 0 +for 0 +epidural 0 +steroid 1 +injection 0 +. 0 +INTERVENTI0N 0 +AND 0 +0UTC0ME 0 +: 0 +An 0 +18 0 +- 0 +gauge 0 +Touhy 0 +needle 0 +was 0 +inserted 0 +until 0 +loss 0 +of 0 +resistance 0 +occurred 0 +at 0 +the 0 +L4 0 +- 0 +5 0 +level 0 +. 0 +Spread 0 +of 0 +the 0 +contrast 0 +medium 0 +within 0 +the 0 +epidural 0 +space 0 +was 0 +determined 0 +by 0 +radiographic 0 +imaging 0 +. 0 +After 0 +verifying 0 +the 0 +epidural 0 +space 0 +"," 0 +bupivacaine 1 +and 0 +triamcinolone 1 +diacetate 2 +were 0 +injected 0 +. 0 +After 0 +the 0 +injection 0 +"," 0 +there 0 +was 0 +a 0 +reduction 0 +in 0 +radicular 0 +symptoms 0 +. 0 +Three 0 +hours 0 +later 0 +"," 0 +she 0 +complained 0 +of 0 +perineal 0 +numbness 3 +and 0 +lower 3 +extremity 4 +weakness 4 +. 0 +The 0 +neurologic 0 +evaluation 0 +revealed 0 +loss 3 +of 4 +sensation 4 +in 0 +the 0 +saddle 0 +area 0 +and 0 +medial 0 +aspect 0 +of 0 +her 0 +right 0 +leg 0 +. 0 +There 0 +was 0 +a 0 +decrease 0 +in 0 +the 0 +perception 0 +of 0 +pinprick 0 +test 0 +. 0 +Deep 0 +- 0 +tendon 0 +reflexes 0 +were 0 +decreased 0 +especially 0 +in 0 +the 0 +right 0 +leg 0 +. 0 +She 0 +was 0 +unable 0 +to 0 +urinate 0 +. 0 +The 0 +patient 0 +' 0 +s 0 +symptoms 0 +improved 0 +slightly 0 +over 0 +the 0 +next 0 +few 0 +hours 0 +. 0 +She 0 +had 0 +a 0 +gradual 0 +return 0 +of 0 +motor 0 +function 0 +and 0 +ability 0 +of 0 +feeling 0 +Foley 0 +catheter 0 +. 0 +All 0 +of 0 +the 0 +symptoms 0 +were 0 +completely 0 +resolved 0 +over 0 +the 0 +next 0 +8 0 +hours 0 +. 0 +C0NCLUSI0N 0 +: 0 +Complications 0 +associated 0 +with 0 +epidural 0 +steroid 1 +injections 0 +are 0 +rare 0 +. 0 +Clinical 0 +examination 0 +and 0 +continued 0 +vigilance 0 +for 0 +neurologic 3 +deterioration 4 +after 0 +epidural 0 +steroid 1 +injections 0 +is 0 +important 0 +. 0 +High 0 +- 0 +dose 0 +testosterone 1 +is 0 +associated 0 +with 0 +atherosclerosis 3 +in 0 +postmenopausal 0 +women 0 +. 0 +0BJECTIVES 0 +: 0 +To 0 +study 0 +the 0 +long 0 +- 0 +term 0 +effects 0 +of 0 +androgen 0 +treatment 0 +on 0 +atherosclerosis 3 +in 0 +postmenopausal 0 +women 0 +. 0 +METH0DS 0 +: 0 +In 0 +a 0 +population 0 +- 0 +based 0 +study 0 +in 0 +513 0 +naturally 0 +postmenopausal 0 +women 0 +aged 0 +54 0 +- 0 +67 0 +years 0 +"," 0 +we 0 +studied 0 +the 0 +association 0 +between 0 +self 0 +- 0 +reported 0 +intramuscularly 0 +administered 0 +high 0 +- 0 +dose 0 +estrogen 1 +- 0 +testosterone 1 +therapy 0 +( 0 +estradiol 1 +- 2 +and 2 +testosterone 2 +esters 2 +) 0 +and 0 +aortic 0 +atherosclerosis 3 +. 0 +Aortic 0 +atherosclerosis 3 +was 0 +diagnosed 0 +by 0 +radiographic 0 +detection 0 +of 0 +calcified 0 +deposits 0 +in 0 +the 0 +abdominal 0 +aorta 0 +"," 0 +which 0 +have 0 +been 0 +shown 0 +to 0 +reflect 0 +intima 0 +atherosclerosis 3 +. 0 +Hormone 0 +therapy 0 +users 0 +were 0 +compared 0 +with 0 +never 0 +users 0 +. 0 +RESULTS 0 +: 0 +Intramuscular 0 +hormone 0 +therapy 0 +use 0 +for 0 +1 0 +year 0 +or 0 +longer 0 +was 0 +reported 0 +by 0 +25 0 +women 0 +. 0 +In 0 +almost 0 +half 0 +of 0 +these 0 +women 0 +severe 0 +atherosclerosis 3 +of 0 +the 0 +aorta 0 +was 0 +present 0 +( 0 +n 0 += 0 +11 0 +) 0 +"," 0 +while 0 +in 0 +women 0 +without 0 +hormone 0 +use 0 +severe 0 +atherosclerosis 3 +of 0 +the 0 +aorta 0 +was 0 +present 0 +in 0 +less 0 +than 0 +20 0 +% 0 +( 0 +0R 0 +3 0 +. 0 +1 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +1 0 +- 0 +8 0 +. 0 +5 0 +"," 0 +adjusted 0 +for 0 +age 0 +"," 0 +years 0 +since 0 +menopause 0 +"," 0 +smoking 0 +"," 0 +and 0 +body 0 +mass 0 +index 0 +) 0 +. 0 +The 0 +association 0 +remained 0 +after 0 +additional 0 +adjustment 0 +for 0 +diabetes 3 +"," 0 +cholesterol 1 +level 0 +"," 0 +systolic 0 +blood 0 +pressure 0 +"," 0 +or 0 +alcohol 1 +use 0 +. 0 +No 0 +association 0 +was 0 +found 0 +for 0 +hormone 0 +use 0 +less 0 +than 0 +1 0 +year 0 +. 0 +C0NCLUSI0N 0 +: 0 +0ur 0 +results 0 +suggest 0 +that 0 +high 0 +- 0 +dose 0 +testosterone 1 +therapy 0 +may 0 +adversely 0 +affect 0 +atherosclerosis 3 +in 0 +postmenopausal 0 +women 0 +and 0 +indicate 0 +that 0 +androgen 0 +replacement 0 +in 0 +these 0 +women 0 +may 0 +not 0 +be 0 +harmless 0 +. 0 +0ptimising 0 +stroke 3 +prevention 0 +in 0 +non 0 +- 0 +valvular 0 +atrial 3 +fibrillation 4 +. 0 +Atrial 3 +fibrillation 4 +is 0 +associated 0 +with 0 +substantial 0 +morbidity 0 +and 0 +mortality 0 +. 0 +Pooled 0 +data 0 +from 0 +trials 0 +comparing 0 +antithrombotic 0 +treatment 0 +with 0 +placebo 0 +have 0 +shown 0 +that 0 +warfarin 1 +reduces 0 +the 0 +risk 0 +of 0 +stroke 3 +by 0 +62 0 +% 0 +"," 0 +and 0 +that 0 +aspirin 1 +alone 0 +reduces 0 +the 0 +risk 0 +by 0 +22 0 +% 0 +. 0 +0verall 0 +"," 0 +in 0 +high 0 +- 0 +risk 0 +patients 0 +"," 0 +warfarin 1 +is 0 +superior 0 +to 0 +aspirin 1 +in 0 +preventing 0 +strokes 3 +"," 0 +with 0 +a 0 +relative 0 +risk 0 +reduction 0 +of 0 +36 0 +% 0 +. 0 +Ximelagatran 1 +"," 0 +an 0 +oral 0 +direct 0 +thrombin 0 +inhibitor 0 +"," 0 +was 0 +found 0 +to 0 +be 0 +as 0 +efficient 0 +as 0 +vitamin 1 +K 2 +antagonist 0 +drugs 0 +in 0 +the 0 +prevention 0 +of 0 +embolic 3 +events 4 +"," 0 +but 0 +has 0 +been 0 +recently 0 +withdrawn 0 +because 0 +of 0 +abnormal 3 +liver 4 +function 4 +tests 0 +. 0 +The 0 +ACTIVE 0 +- 0 +W 0 +( 0 +Atrial 3 +Fibrillation 4 +Clopidogrel 1 +Trial 0 +with 0 +Irbesartan 1 +for 0 +Prevention 0 +of 0 +Vascular 0 +Events 0 +) 0 +study 0 +has 0 +demonstrated 0 +that 0 +warfarin 1 +is 0 +superior 0 +to 0 +platelet 0 +therapy 0 +( 0 +clopidogrel 1 +plus 0 +aspirin 1 +) 0 +in 0 +the 0 +prevention 0 +af 0 +embolic 3 +events 4 +. 0 +Idraparinux 1 +"," 0 +a 0 +Factor 0 +Xa 0 +inhibitor 0 +"," 0 +is 0 +being 0 +evaluated 0 +in 0 +patients 0 +with 0 +atrial 3 +fibrillation 4 +. 0 +Angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitors 0 +and 0 +angiotensin 1 +II 2 +receptor 0 +- 0 +blocking 0 +drugs 0 +hold 0 +promise 0 +in 0 +atrial 3 +fibrillation 4 +through 0 +cardiac 3 +remodelling 4 +. 0 +Preliminary 0 +studies 0 +suggest 0 +that 0 +statins 1 +could 0 +interfere 0 +with 0 +the 0 +risk 0 +of 0 +recurrence 0 +after 0 +electrical 0 +cardioversion 0 +. 0 +Finally 0 +"," 0 +percutaneous 0 +methods 0 +for 0 +the 0 +exclusion 0 +of 0 +left 0 +atrial 0 +appendage 0 +are 0 +under 0 +investigation 0 +in 0 +high 0 +- 0 +risk 0 +patients 0 +. 0 +Anti 0 +- 0 +oxidant 0 +effects 0 +of 0 +atorvastatin 1 +in 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +in 0 +the 0 +rat 0 +. 0 +1 0 +. 0 +Dexamethasone 1 +( 0 +Dex 1 +) 0 +- 0 +induced 0 +hypertension 3 +is 0 +characterized 0 +by 0 +endothelial 0 +dysfunction 0 +associated 0 +with 0 +nitric 1 +oxide 2 +( 0 +N0 1 +) 0 +deficiency 0 +and 0 +increased 0 +superoxide 1 +( 0 +02 1 +- 2 +) 0 +production 0 +. 0 +Atorvastatin 1 +( 0 +Ato 1 +) 0 +possesses 0 +pleiotropic 0 +properties 0 +that 0 +have 0 +been 0 +reported 0 +to 0 +improve 0 +endothelial 0 +function 0 +through 0 +increased 0 +availability 0 +of 0 +N0 1 +and 0 +reduced 0 +02 1 +- 2 +production 0 +in 0 +various 0 +forms 0 +of 0 +hypertension 3 +. 0 +In 0 +the 0 +present 0 +study 0 +"," 0 +we 0 +investigated 0 +whether 0 +50 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +"," 0 +Ato 1 +could 0 +prevent 0 +endothelial 0 +N0 1 +synthase 0 +( 0 +eN0S 0 +) 0 +downregulation 0 +and 0 +the 0 +increase 0 +in 0 +02 1 +- 2 +in 0 +Sprague 0 +- 0 +Dawley 0 +( 0 +SD 0 +) 0 +rats 0 +"," 0 +thereby 0 +reducing 0 +blood 0 +pressure 0 +. 0 +2 0 +. 0 +Male 0 +SD 0 +rats 0 +( 0 +n 0 += 0 +30 0 +) 0 +were 0 +treated 0 +with 0 +Ato 1 +( 0 +50 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +in 0 +drinking 0 +water 0 +) 0 +or 0 +tap 0 +water 0 +for 0 +15 0 +days 0 +. 0 +Dexamethasone 1 +( 0 +10 0 +microg 0 +/ 0 +kg 0 +per 0 +day 0 +"," 0 +s 0 +. 0 +c 0 +. 0 +) 0 +or 0 +saline 0 +was 0 +started 0 +after 0 +4 0 +days 0 +in 0 +Ato 1 +- 0 +treated 0 +and 0 +non 0 +- 0 +treated 0 +rats 0 +and 0 +continued 0 +for 0 +11 0 +- 0 +13 0 +days 0 +. 0 +Systolic 0 +blood 0 +pressure 0 +( 0 +SBP 0 +) 0 +was 0 +measured 0 +on 0 +alternate 0 +days 0 +using 0 +the 0 +tail 0 +- 0 +cuff 0 +method 0 +. 0 +Endothelial 0 +function 0 +was 0 +assessed 0 +by 0 +acetylcholine 1 +- 0 +induced 0 +vasorelaxation 0 +and 0 +phenylephrine 1 +- 0 +induced 0 +vasoconstriction 0 +in 0 +aortic 0 +segments 0 +. 0 +Vascular 0 +eN0S 0 +mRNA 0 +was 0 +assessed 0 +by 0 +semi 0 +- 0 +quantitative 0 +reverse 0 +transcription 0 +- 0 +polymerase 0 +chain 0 +reaction 0 +. 0 +3 0 +. 0 +In 0 +rats 0 +treated 0 +with 0 +Dex 1 +alone 0 +"," 0 +SBP 0 +was 0 +increased 0 +from 0 +109 0 ++ 0 +/ 0 +- 0 +2 0 +to 0 +133 0 ++ 0 +/ 0 +- 0 +2 0 +mmHg 0 +on 0 +Days 0 +4 0 +and 0 +Day 0 +14 0 +"," 0 +respectively 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +In 0 +the 0 +Ato 1 ++ 0 +Dex 1 +group 0 +"," 0 +SBP 0 +was 0 +increased 0 +from 0 +113 0 ++ 0 +/ 0 +- 0 +2 0 +to 0 +119 0 ++ 0 +/ 0 +- 0 +2 0 +mmHg 0 +on 0 +Days 0 +4 0 +to 0 +14 0 +"," 0 +respectively 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +but 0 +was 0 +significantly 0 +lower 0 +than 0 +SBP 0 +in 0 +the 0 +group 0 +treated 0 +with 0 +Dex 1 +alone 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Endothelial 0 +- 0 +dependent 0 +relaxation 0 +and 0 +eN0S 0 +mRNA 0 +expression 0 +were 0 +greater 0 +in 0 +the 0 +Dex 1 ++ 0 +Ato 1 +group 0 +than 0 +in 0 +the 0 +Dex 1 +only 0 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +and 0 +P 0 +< 0 +0 0 +. 0 +1 0 +"," 0 +respectively 0 +) 0 +. 0 +Aortic 0 +superoxide 1 +production 0 +was 0 +lower 0 +in 0 +the 0 +Dex 1 ++ 0 +Ato 1 +group 0 +compared 0 +with 0 +the 0 +group 0 +treated 0 +with 0 +Dex 1 +alone 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +4 0 +. 0 +Treatment 0 +with 0 +Ato 1 +improved 0 +endothelial 0 +function 0 +"," 0 +reduced 0 +superoxide 1 +production 0 +and 0 +reduced 0 +SBP 0 +in 0 +Dex 1 +- 0 +treated 0 +SD 0 +rats 0 +. 0 +Severe 0 +citrate 1 +toxicity 3 +complicating 0 +volunteer 0 +apheresis 0 +platelet 0 +donation 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +severe 0 +citrate 1 +toxicity 3 +during 0 +volunteer 0 +donor 0 +apheresis 0 +platelet 0 +collection 0 +. 0 +The 0 +donor 0 +was 0 +a 0 +40 0 +- 0 +year 0 +- 0 +old 0 +female 0 +"," 0 +first 0 +- 0 +time 0 +apheresis 0 +platelet 0 +donor 0 +. 0 +Past 0 +medical 0 +history 0 +was 0 +remarkable 0 +for 0 +hypertension 3 +"," 0 +hyperlipidemia 3 +"," 0 +and 0 +depression 3 +. 0 +Reported 0 +medications 0 +included 0 +bumetanide 1 +"," 0 +pravastatin 1 +"," 0 +and 0 +paroxetine 1 +. 0 +Thirty 0 +minutes 0 +from 0 +the 0 +start 0 +of 0 +the 0 +procedure 0 +"," 0 +the 0 +donor 0 +noted 0 +tingling 0 +around 0 +the 0 +mouth 0 +"," 0 +hands 0 +"," 0 +and 0 +feet 0 +. 0 +She 0 +then 0 +very 0 +rapidly 0 +developed 0 +acute 0 +onset 0 +of 0 +severe 0 +facial 0 +and 0 +extremity 0 +tetany 3 +. 0 +Empirical 0 +treatment 0 +with 0 +intravenous 0 +calcium 1 +gluconate 2 +was 0 +initiated 0 +"," 0 +and 0 +muscle 3 +contractions 4 +slowly 0 +subsided 0 +over 0 +approximately 0 +10 0 +to 0 +15 0 +minutes 0 +. 0 +The 0 +events 0 +are 0 +consistent 0 +with 0 +a 0 +severe 0 +reaction 0 +to 0 +calcium 1 +chelation 0 +by 0 +sodium 1 +citrate 2 +anticoagulant 0 +resulting 0 +in 0 +symptomatic 0 +systemic 0 +hypocalcemia 3 +. 0 +Upon 0 +additional 0 +retrospective 0 +analysis 0 +"," 0 +it 0 +was 0 +noted 0 +that 0 +bumetanide 1 +is 0 +a 0 +loop 1 +diuretic 2 +that 0 +may 0 +cause 0 +significant 0 +hypocalcemia 3 +. 0 +We 0 +conclude 0 +that 0 +careful 0 +screening 0 +for 0 +medications 0 +and 0 +underlying 0 +conditions 0 +predisposing 0 +to 0 +hypocalcemia 3 +is 0 +recommended 0 +to 0 +help 0 +prevent 0 +severe 0 +reactions 0 +due 0 +to 0 +citrate 1 +toxicity 3 +. 0 +Laboratory 0 +measurement 0 +of 0 +pre 0 +- 0 +procedure 0 +serum 0 +calcium 1 +levels 0 +in 0 +selected 0 +donors 0 +may 0 +identify 0 +cases 0 +requiring 0 +heightened 0 +vigilance 0 +. 0 +The 0 +case 0 +also 0 +illustrates 0 +the 0 +importance 0 +of 0 +maintaining 0 +preparedness 0 +for 0 +managing 0 +rare 0 +but 0 +serious 0 +reactions 0 +in 0 +volunteer 0 +apheresis 0 +blood 0 +donors 0 +. 0 +Sirolimus 1 +- 0 +associated 0 +proteinuria 3 +and 0 +renal 3 +dysfunction 4 +. 0 +Sirolimus 1 +is 0 +a 0 +novel 0 +immunosuppressant 0 +with 0 +potent 0 +antiproliferative 0 +actions 0 +through 0 +its 0 +ability 0 +to 0 +inhibit 0 +the 0 +raptor 0 +- 0 +containing 0 +mammalian 0 +target 0 +of 0 +rapamycin 1 +protein 0 +kinase 0 +. 0 +Sirolimus 1 +represents 0 +a 0 +major 0 +therapeutic 0 +advance 0 +in 0 +the 0 +prevention 0 +of 0 +acute 0 +renal 0 +allograft 0 +rejection 0 +and 0 +chronic 0 +allograft 0 +nephropathy 3 +. 0 +Its 0 +role 0 +in 0 +the 0 +therapy 0 +of 0 +glomerulonephritis 3 +"," 0 +autoimmunity 3 +"," 0 +cystic 3 +renal 4 +diseases 4 +and 0 +renal 3 +cancer 4 +is 0 +under 0 +investigation 0 +. 0 +Because 0 +sirolimus 1 +does 0 +not 0 +share 0 +the 0 +vasomotor 0 +renal 0 +adverse 0 +effects 0 +exhibited 0 +by 0 +calcineurin 0 +inhibitors 0 +"," 0 +it 0 +has 0 +been 0 +designated 0 +a 0 +' 0 +non 0 +- 0 +nephrotoxic 3 +drug 0 +' 0 +. 0 +However 0 +"," 0 +clinical 0 +reports 0 +suggest 0 +that 0 +"," 0 +under 0 +some 0 +circumstances 0 +"," 0 +sirolimus 1 +is 0 +associated 0 +with 0 +proteinuria 3 +and 0 +acute 3 +renal 4 +dysfunction 4 +. 0 +A 0 +common 0 +risk 0 +factor 0 +appears 0 +to 0 +be 0 +presence 0 +of 0 +pre 0 +- 0 +existing 0 +chronic 3 +renal 4 +damage 4 +. 0 +The 0 +mechanisms 0 +of 0 +sirolimus 1 +- 0 +associated 0 +proteinuria 3 +are 0 +multifactorial 0 +and 0 +may 0 +be 0 +due 0 +to 0 +an 0 +increase 0 +in 0 +glomerular 0 +capillary 0 +pressure 0 +following 0 +calcineurin 0 +inhibitor 0 +withdrawal 0 +. 0 +It 0 +has 0 +also 0 +been 0 +suggested 0 +that 0 +sirolimus 1 +directly 0 +causes 0 +increased 0 +glomerular 0 +permeability 0 +/ 0 +injury 0 +"," 0 +but 0 +evidence 0 +for 0 +this 0 +mechanism 0 +is 0 +currently 0 +inconclusive 0 +. 0 +The 0 +acute 3 +renal 4 +dysfunction 4 +associated 0 +with 0 +sirolimus 1 +( 0 +such 0 +as 0 +in 0 +delayed 0 +graft 0 +function 0 +) 0 +may 0 +be 0 +due 0 +to 0 +suppression 0 +of 0 +compensatory 0 +renal 0 +cell 0 +proliferation 0 +and 0 +survival 0 +/ 0 +repair 0 +processes 0 +. 0 +Although 0 +these 0 +adverse 0 +effects 0 +occur 0 +in 0 +some 0 +patients 0 +"," 0 +their 0 +occurrence 0 +could 0 +be 0 +minimised 0 +by 0 +knowledge 0 +of 0 +the 0 +molecular 0 +effects 0 +of 0 +sirolimus 1 +on 0 +the 0 +kidney 0 +"," 0 +the 0 +use 0 +of 0 +sirolimus 1 +in 0 +appropriate 0 +patient 0 +populations 0 +"," 0 +close 0 +monitoring 0 +of 0 +proteinuria 3 +and 0 +renal 0 +function 0 +"," 0 +use 0 +of 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitors 0 +or 0 +angiotensin 1 +II 2 +receptor 0 +blockers 0 +if 0 +proteinuria 3 +occurs 0 +and 0 +withdrawal 0 +if 0 +needed 0 +. 0 +Further 0 +long 0 +- 0 +term 0 +analysis 0 +of 0 +renal 0 +allograft 0 +studies 0 +using 0 +sirolimus 1 +as 0 +de 0 +novo 0 +immunosuppression 0 +along 0 +with 0 +clinical 0 +and 0 +laboratory 0 +studies 0 +will 0 +refine 0 +these 0 +issues 0 +in 0 +the 0 +future 0 +. 0 +Proteinuria 3 +after 0 +conversion 0 +to 0 +sirolimus 1 +in 0 +renal 0 +transplant 0 +recipients 0 +. 0 +Sirolimus 1 +( 0 +SRL 1 +) 0 +is 0 +a 0 +new 0 +"," 0 +potent 0 +immunosuppressive 0 +agent 0 +. 0 +More 0 +recently 0 +"," 0 +proteinuria 3 +has 0 +been 0 +reported 0 +as 0 +a 0 +consequence 0 +of 0 +sirolimus 1 +therapy 0 +"," 0 +although 0 +the 0 +mechanism 0 +has 0 +remained 0 +unclear 0 +. 0 +We 0 +retrospectively 0 +examined 0 +the 0 +records 0 +of 0 +25 0 +renal 0 +transplant 0 +patients 0 +"," 0 +who 0 +developed 0 +or 0 +displayed 0 +increased 0 +proteinuria 3 +after 0 +SRL 1 +conversion 0 +. 0 +The 0 +patient 0 +cohort 0 +( 0 +14 0 +men 0 +"," 0 +11 0 +women 0 +) 0 +was 0 +treated 0 +with 0 +SRL 1 +as 0 +conversion 0 +therapy 0 +"," 0 +due 0 +to 0 +chronic 3 +allograft 4 +nephropathy 4 +( 0 +CAN 3 +) 0 +( 0 +n 0 += 0 +15 0 +) 0 +neoplasia 3 +( 0 +n 0 += 0 +8 0 +) 0 +; 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +"," 0 +Four 0 +skin 3 +cancers 4 +"," 0 +0ne 0 +intestinal 3 +tumors 4 +"," 0 +0ne 0 +renal 3 +cell 4 +carsinom 4 +) 0 +or 0 +BK 0 +virus 0 +nephropathy 3 +( 0 +n 0 += 0 +2 0 +) 0 +. 0 +SRL 1 +was 0 +started 0 +at 0 +a 0 +mean 0 +of 0 +78 0 ++ 0 +/ 0 +- 0 +42 0 +( 0 +15 0 +to 0 +163 0 +) 0 +months 0 +after 0 +transplantation 0 +. 0 +Mean 0 +follow 0 +- 0 +up 0 +on 0 +SRL 1 +therapy 0 +was 0 +20 0 ++ 0 +/ 0 +- 0 +12 0 +( 0 +6 0 +to 0 +43 0 +) 0 +months 0 +. 0 +Proteinuria 3 +increased 0 +from 0 +0 0 +. 0 +445 0 +( 0 +0 0 +to 0 +1 0 +. 0 +5 0 +) 0 +g 0 +/ 0 +d 0 +before 0 +conversion 0 +to 0 +3 0 +. 0 +2 0 +g 0 +/ 0 +dL 0 +( 0 +0 0 +. 0 +2 0 +to 0 +12 0 +) 0 +after 0 +conversion 0 +( 0 +P 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Before 0 +conversion 0 +8 0 +( 0 +32 0 +% 0 +) 0 +patients 0 +had 0 +no 0 +proteinuria 3 +"," 0 +whereas 0 +afterwards 0 +all 0 +patients 0 +had 0 +proteinuria 3 +. 0 +In 0 +28 0 +% 0 +of 0 +patients 0 +proteinuria 3 +remained 0 +unchanged 0 +"," 0 +whereas 0 +it 0 +increased 0 +in 0 +68 0 +% 0 +of 0 +patients 0 +. 0 +In 0 +40 0 +% 0 +it 0 +increased 0 +by 0 +more 0 +than 0 +100 0 +% 0 +. 0 +Twenty 0 +- 0 +eight 0 +percent 0 +of 0 +patients 0 +showed 0 +increased 0 +proteinuria 3 +to 0 +the 0 +nephrotic 3 +range 0 +. 0 +Biopsies 0 +performed 0 +in 0 +five 0 +patients 0 +revealed 0 +new 0 +pathological 0 +changes 0 +: 0 +0ne 0 +membranoproliferative 3 +glomerulopathy 4 +and 0 +interstitial 3 +nephritis 4 +. 0 +These 0 +patients 0 +showed 0 +persistently 0 +good 0 +graft 0 +function 0 +. 0 +Serum 0 +creatinine 1 +values 0 +did 0 +not 0 +change 0 +significantly 0 +: 0 +1 0 +. 0 +98 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +mg 0 +/ 0 +dL 0 +before 0 +SRL 1 +therapy 0 +and 0 +2 0 +. 0 +53 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +mg 0 +/ 0 +dL 0 +at 0 +last 0 +follow 0 +- 0 +up 0 +( 0 +P 0 += 0 +. 0 +14 0 +) 0 +. 0 +Five 0 +grafts 0 +were 0 +lost 0 +and 0 +the 0 +patients 0 +returned 0 +to 0 +dialysis 0 +. 0 +Five 0 +patients 0 +displayed 0 +CAN 3 +and 0 +Kaposi 3 +' 4 +s 4 +sarcoma 4 +. 0 +Mean 0 +urinary 0 +protein 0 +of 0 +patients 0 +who 0 +returned 0 +to 0 +dialysis 0 +was 0 +1 0 +. 0 +26 0 +( 0 +0 0 +. 0 +5 0 +to 0 +3 0 +. 0 +5 0 +) 0 +g 0 +/ 0 +d 0 +before 0 +and 0 +4 0 +. 0 +7 0 +( 0 +3 0 +to 0 +12 0 +) 0 +g 0 +/ 0 +d 0 +after 0 +conversion 0 +( 0 +P 0 += 0 +. 0 +1 0 +) 0 +. 0 +Mean 0 +serum 0 +creatinine 1 +level 0 +before 0 +conversion 0 +was 0 +2 0 +. 0 +21 0 +mg 0 +/ 0 +dL 0 +and 0 +thereafter 0 +"," 0 +4 0 +. 0 +93 0 +mg 0 +/ 0 +dL 0 +( 0 +P 0 += 0 +. 0 +2 0 +) 0 +. 0 +Heavy 0 +proteinuria 3 +was 0 +common 0 +after 0 +the 0 +use 0 +of 0 +SRL 1 +as 0 +rescue 0 +therapy 0 +for 0 +renal 0 +transplantation 0 +. 0 +Therefore 0 +"," 0 +conversion 0 +should 0 +be 0 +considered 0 +for 0 +patients 0 +who 0 +have 0 +not 0 +developed 0 +advanced 0 +CAN 3 +and 0 +proteinuria 3 +. 0 +The 0 +possibility 0 +of 0 +de 0 +novo 0 +glomerular 0 +pathology 0 +under 0 +SRL 1 +treatment 0 +requires 0 +further 0 +investigation 0 +by 0 +renal 0 +biopsy 0 +. 0 +Long 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +of 0 +ifosfamide 1 +renal 3 +toxicity 4 +in 0 +children 0 +treated 0 +for 0 +malignant 3 +mesenchymal 4 +tumors 4 +: 0 +an 0 +International 0 +Society 0 +of 0 +Pediatric 0 +0ncology 0 +report 0 +. 0 +The 0 +renal 0 +function 0 +of 0 +74 0 +children 0 +with 0 +malignant 3 +mesenchymal 4 +tumors 4 +in 0 +complete 0 +remission 0 +and 0 +who 0 +have 0 +received 0 +the 0 +same 0 +ifosfamide 1 +chemotherapy 0 +protocol 0 +( 0 +International 0 +Society 0 +of 0 +Pediatric 0 +0ncology 0 +Malignant 3 +Mesenchymal 4 +Tumor 4 +Study 0 +84 0 +[ 0 +SI0P 0 +MMT 0 +84 0 +] 0 +) 0 +were 0 +studied 0 +1 0 +year 0 +after 0 +the 0 +completion 0 +of 0 +treatment 0 +. 0 +Total 0 +cumulative 0 +doses 0 +were 0 +36 0 +or 0 +60 0 +g 0 +/ 0 +m2 0 +of 0 +ifosfamide 1 +( 0 +six 0 +or 0 +10 0 +cycles 0 +of 0 +ifosfamide 1 +"," 2 +vincristine 2 +"," 2 +and 2 +dactinomycin 2 +[ 0 +IVA 1 +] 0 +) 0 +. 0 +None 0 +of 0 +them 0 +had 0 +received 0 +cisplatin 1 +chemotherapy 0 +. 0 +Ages 0 +ranged 0 +from 0 +4 0 +months 0 +to 0 +17 0 +years 0 +; 0 +58 0 +patients 0 +were 0 +males 0 +and 0 +42 0 +females 0 +. 0 +The 0 +most 0 +common 0 +primary 0 +tumor 3 +site 0 +was 0 +the 0 +head 0 +and 0 +neck 0 +. 0 +Renal 0 +function 0 +was 0 +investigated 0 +by 0 +measuring 0 +plasma 0 +and 0 +urinary 0 +electrolytes 0 +"," 0 +glucosuria 3 +"," 0 +proteinuria 3 +"," 0 +aminoaciduria 3 +"," 0 +urinary 0 +pH 0 +"," 0 +osmolarity 0 +"," 0 +creatinine 1 +clearance 0 +"," 0 +phosphate 1 +tubular 0 +reabsorption 0 +"," 0 +beta 0 +2 0 +microglobulinuria 0 +"," 0 +and 0 +lysozymuria 0 +. 0 +Fifty 0 +- 0 +eight 0 +patients 0 +( 0 +78 0 +% 0 +) 0 +had 0 +normal 0 +renal 0 +tests 0 +"," 0 +whereas 0 +16 0 +patients 0 +( 0 +22 0 +% 0 +) 0 +had 0 +renal 3 +abnormalities 4 +. 0 +Two 0 +subsets 0 +of 0 +patients 0 +were 0 +identified 0 +from 0 +this 0 +latter 0 +group 0 +: 0 +the 0 +first 0 +included 0 +four 0 +patients 0 +( 0 +5 0 +% 0 +of 0 +the 0 +total 0 +population 0 +) 0 +who 0 +developed 0 +major 0 +toxicity 3 +resulting 0 +in 0 +Fanconi 3 +' 4 +s 4 +syndrome 4 +( 0 +TDFS 3 +) 0 +; 0 +and 0 +the 0 +second 0 +group 0 +included 0 +five 0 +patients 0 +with 0 +elevated 0 +beta 0 +2 0 +microglobulinuria 0 +and 0 +low 0 +phosphate 1 +reabsorption 0 +. 0 +The 0 +remaining 0 +seven 0 +patients 0 +had 0 +isolated 0 +beta 0 +2 0 +microglobulinuria 0 +. 0 +Severe 0 +toxicity 3 +was 0 +correlated 0 +with 0 +the 0 +higher 0 +cumulative 0 +dose 0 +of 0 +60 0 +g 0 +/ 0 +m2 0 +of 0 +ifosfamide 1 +"," 0 +a 0 +younger 0 +age 0 +( 0 +less 0 +than 0 +2 0 +1 0 +/ 0 +2 0 +years 0 +old 0 +) 0 +"," 0 +and 0 +a 0 +predominance 0 +of 0 +vesicoprostatic 0 +tumor 3 +involvement 0 +. 0 +This 0 +low 0 +percentage 0 +( 0 +5 0 +% 0 +) 0 +of 0 +TDFS 0 +must 0 +be 0 +evaluated 0 +with 0 +respect 0 +to 0 +the 0 +efficacy 0 +of 0 +ifosfamide 1 +in 0 +the 0 +treatment 0 +of 0 +mesenchymal 3 +tumors 4 +in 0 +children 0 +. 0 +Progressive 0 +myopathy 3 +with 0 +up 0 +- 0 +regulation 0 +of 0 +MHC 0 +- 0 +I 0 +associated 0 +with 0 +statin 1 +therapy 0 +. 0 +Statins 1 +can 0 +cause 0 +a 0 +necrotizing 0 +myopathy 3 +and 0 +hyperCKaemia 3 +which 0 +is 0 +reversible 0 +on 0 +cessation 0 +of 0 +the 0 +drug 0 +. 0 +What 0 +is 0 +less 0 +well 0 +known 0 +is 0 +a 0 +phenomenon 0 +whereby 0 +statins 1 +may 0 +induce 0 +a 0 +myopathy 3 +"," 0 +which 0 +persists 0 +or 0 +may 0 +progress 0 +after 0 +stopping 0 +the 0 +drug 0 +. 0 +We 0 +investigated 0 +the 0 +muscle 0 +pathology 0 +in 0 +8 0 +such 0 +cases 0 +. 0 +All 0 +had 0 +myofibre 0 +necrosis 3 +but 0 +only 0 +3 0 +had 0 +an 0 +inflammatory 0 +infiltrate 0 +. 0 +In 0 +all 0 +cases 0 +there 0 +was 0 +diffuse 0 +or 0 +multifocal 0 +up 0 +- 0 +regulation 0 +of 0 +MHC 0 +- 0 +I 0 +expression 0 +even 0 +in 0 +non 0 +- 0 +necrotic 3 +fibres 0 +. 0 +Progressive 0 +improvement 0 +occurred 0 +in 0 +7 0 +cases 0 +after 0 +commencement 0 +of 0 +prednisolone 1 +and 0 +methotrexate 1 +"," 0 +and 0 +in 0 +one 0 +case 0 +spontaneously 0 +. 0 +These 0 +observations 0 +suggest 0 +that 0 +statins 1 +may 0 +initiate 0 +an 0 +immune 0 +- 0 +mediated 0 +myopathy 3 +that 0 +persists 0 +after 0 +withdrawal 0 +of 0 +the 0 +drug 0 +and 0 +responds 0 +to 0 +immunosuppressive 0 +therapy 0 +. 0 +The 0 +mechanism 0 +of 0 +this 0 +myopathy 3 +is 0 +uncertain 0 +but 0 +may 0 +involve 0 +the 0 +induction 0 +by 0 +statins 1 +of 0 +an 0 +endoplasmic 0 +reticulum 0 +stress 0 +response 0 +with 0 +associated 0 +up 0 +- 0 +regulation 0 +of 0 +MHC 0 +- 0 +I 0 +expression 0 +and 0 +antigen 0 +presentation 0 +by 0 +muscle 0 +fibres 0 +. 0 +Use 0 +of 0 +chromosome 0 +substitution 0 +strains 0 +to 0 +identify 0 +seizure 3 +susceptibility 0 +loci 0 +in 0 +mice 0 +. 0 +Seizure 3 +susceptibility 0 +varies 0 +among 0 +inbred 0 +mouse 0 +strains 0 +. 0 +Chromosome 0 +substitution 0 +strains 0 +( 0 +CSS 0 +) 0 +"," 0 +in 0 +which 0 +a 0 +single 0 +chromosome 0 +from 0 +one 0 +inbred 0 +strain 0 +( 0 +donor 0 +) 0 +has 0 +been 0 +transferred 0 +onto 0 +a 0 +second 0 +strain 0 +( 0 +host 0 +) 0 +by 0 +repeated 0 +backcrossing 0 +"," 0 +may 0 +be 0 +used 0 +to 0 +identify 0 +quantitative 0 +trait 0 +loci 0 +( 0 +QTLs 0 +) 0 +that 0 +contribute 0 +to 0 +seizure 3 +susceptibility 0 +. 0 +QTLs 0 +for 0 +susceptibility 0 +to 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +"," 0 +a 0 +model 0 +of 0 +temporal 3 +lobe 4 +epilepsy 4 +"," 0 +have 0 +not 0 +been 0 +reported 0 +"," 0 +and 0 +CSS 0 +have 0 +not 0 +previously 0 +been 0 +used 0 +to 0 +localize 0 +seizure 3 +susceptibility 0 +genes 0 +. 0 +We 0 +report 0 +QTLs 0 +identified 0 +using 0 +a 0 +B6 0 +( 0 +host 0 +) 0 +x 0 +A 0 +/ 0 +J 0 +( 0 +donor 0 +) 0 +CSS 0 +panel 0 +to 0 +localize 0 +genes 0 +involved 0 +in 0 +susceptibility 0 +to 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 +Three 0 +hundred 0 +fifty 0 +- 0 +five 0 +adult 0 +male 0 +CSS 0 +mice 0 +"," 0 +58 0 +B6 0 +"," 0 +and 0 +39 0 +A 0 +/ 0 +J 0 +were 0 +tested 0 +for 0 +susceptibility 0 +to 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +. 0 +Highest 0 +stage 0 +reached 0 +and 0 +latency 0 +to 0 +each 0 +stage 0 +were 0 +recorded 0 +for 0 +all 0 +mice 0 +. 0 +B6 0 +mice 0 +were 0 +resistant 0 +to 0 +seizures 3 +and 0 +slower 0 +to 0 +reach 0 +stages 0 +compared 0 +to 0 +A 0 +/ 0 +J 0 +mice 0 +. 0 +The 0 +CSS 0 +for 0 +Chromosomes 0 +10 0 +and 0 +18 0 +progressed 0 +to 0 +the 0 +most 0 +severe 0 +stages 0 +"," 0 +diverging 0 +dramatically 0 +from 0 +the 0 +B6 0 +phenotype 0 +. 0 +Latencies 0 +to 0 +stages 0 +were 0 +also 0 +significantly 0 +shorter 0 +for 0 +CSS10 0 +and 0 +CSS18 0 +mice 0 +. 0 +CSS 0 +mapping 0 +suggests 0 +seizure 3 +susceptibility 0 +loci 0 +on 0 +mouse 0 +Chromosomes 0 +10 0 +and 0 +18 0 +. 0 +This 0 +approach 0 +provides 0 +a 0 +framework 0 +for 0 +identifying 0 +potentially 0 +novel 0 +homologous 0 +candidate 0 +genes 0 +for 0 +human 0 +temporal 3 +lobe 4 +epilepsy 4 +. 0 +In 0 +vitro 0 +characterization 0 +of 0 +parasympathetic 0 +and 0 +sympathetic 0 +responses 0 +in 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +in 0 +the 0 +rat 0 +. 0 +In 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +in 0 +the 0 +rat 0 +"," 0 +detrusor 0 +function 0 +is 0 +impaired 0 +and 0 +the 0 +expression 0 +and 0 +effects 0 +of 0 +muscarinic 0 +receptors 0 +altered 0 +. 0 +Whether 0 +or 0 +not 0 +the 0 +neuronal 0 +transmission 0 +may 0 +be 0 +affected 0 +by 0 +cystitis 3 +was 0 +presently 0 +investigated 0 +. 0 +Responses 0 +of 0 +urinary 0 +strip 0 +preparations 0 +from 0 +control 0 +and 0 +cyclophosphamide 1 +- 0 +pretreated 0 +rats 0 +to 0 +electrical 0 +field 0 +stimulation 0 +and 0 +to 0 +agonists 0 +were 0 +assessed 0 +in 0 +the 0 +absence 0 +and 0 +presence 0 +of 0 +muscarinic 0 +"," 0 +adrenergic 0 +and 0 +purinergic 0 +receptor 0 +antagonists 0 +. 0 +Generally 0 +"," 0 +atropine 1 +reduced 0 +contractions 0 +"," 0 +but 0 +in 0 +contrast 0 +to 0 +controls 0 +"," 0 +it 0 +also 0 +reduced 0 +responses 0 +to 0 +low 0 +electrical 0 +field 0 +stimulation 0 +intensity 0 +( 0 +1 0 +- 0 +5 0 +Hz 0 +) 0 +in 0 +inflamed 0 +preparations 0 +. 0 +In 0 +both 0 +types 0 +"," 0 +purinoceptor 0 +desensitization 0 +with 0 +alpha 1 +"," 2 +beta 2 +- 2 +methylene 2 +adenosine 2 +- 2 +5 2 +' 2 +- 2 +triphosphate 2 +( 0 +alpha 1 +"," 2 +beta 2 +- 2 +meATP 2 +) 0 +caused 0 +further 0 +reductions 0 +at 0 +low 0 +frequencies 0 +( 0 +< 0 +10 0 +Hz 0 +) 0 +. 0 +The 0 +muscarinic 0 +receptor 0 +antagonists 0 +atropine 1 +"," 0 +4 1 +- 2 +diphenylacetoxy 2 +- 2 +N 2 +- 2 +methylpiperidine 2 +( 0 +4 1 +- 2 +DAMP 2 +) 0 +( 0 +' 0 +M 0 +( 0 +1 0 +) 0 +/ 0 +M 0 +( 0 +3 0 +) 0 +/ 0 +M 0 +( 0 +5 0 +) 0 +- 0 +selective 0 +' 0 +) 0 +"," 0 +methoctramine 1 +( 0 +' 0 +M 0 +( 0 +2 0 +) 0 +- 0 +selective 0 +' 0 +) 0 +and 0 +pirenzepine 1 +( 0 +' 0 +M 0 +( 0 +1 0 +) 0 +- 0 +selective 0 +' 0 +) 0 +antagonized 0 +the 0 +tonic 0 +component 0 +of 0 +the 0 +electrical 0 +field 0 +stimulation 0 +- 0 +evoked 0 +contractile 0 +response 0 +more 0 +potently 0 +than 0 +the 0 +phasic 0 +component 0 +. 0 +4 1 +- 2 +DAMP 2 +inhibited 0 +the 0 +tonic 0 +contractions 0 +in 0 +controls 0 +more 0 +potently 0 +than 0 +methoctramine 1 +and 0 +pirenzepine 1 +. 0 +In 0 +inflamed 0 +preparations 0 +"," 0 +the 0 +muscarinic 0 +receptor 0 +antagonism 0 +on 0 +the 0 +phasic 0 +component 0 +of 0 +the 0 +electrical 0 +field 0 +stimulation 0 +- 0 +evoked 0 +contraction 0 +was 0 +decreased 0 +and 0 +the 0 +pirenzepine 1 +and 0 +4 1 +- 2 +DAMP 2 +antagonism 0 +on 0 +the 0 +tonic 0 +component 0 +was 0 +much 0 +less 0 +efficient 0 +than 0 +in 0 +controls 0 +. 0 +In 0 +contrast 0 +to 0 +controls 0 +"," 0 +methoctramine 1 +increased 0 +- 0 +- 0 +instead 0 +of 0 +decreased 0 +- 0 +- 0 +the 0 +tonic 0 +responses 0 +at 0 +high 0 +frequencies 0 +. 0 +While 0 +contractions 0 +to 0 +carbachol 1 +and 0 +ATP 1 +were 0 +the 0 +same 0 +in 0 +inflamed 0 +and 0 +in 0 +control 0 +strips 0 +when 0 +related 0 +to 0 +a 0 +reference 0 +potassium 1 +response 0 +"," 0 +isoprenaline 1 +- 0 +induced 0 +relaxations 0 +were 0 +smaller 0 +in 0 +inflamed 0 +strips 0 +. 0 +Thus 0 +"," 0 +in 0 +cystitis 3 +substantial 0 +changes 0 +of 0 +the 0 +efferent 0 +functional 0 +responses 0 +occur 0 +. 0 +While 0 +postjunctional 0 +beta 0 +- 0 +adrenoceptor 0 +- 0 +mediated 0 +relaxations 0 +are 0 +reduced 0 +"," 0 +effects 0 +by 0 +prejunctional 0 +inhibitory 0 +muscarinic 0 +receptors 0 +may 0 +be 0 +increased 0 +. 0 +Direct 0 +inhibition 0 +of 0 +cardiac 0 +hyperpolarization 0 +- 0 +activated 0 +cyclic 1 +nucleotide 2 +- 0 +gated 0 +pacemaker 0 +channels 0 +by 0 +clonidine 1 +. 0 +BACKGR0UND 0 +: 0 +Inhibition 0 +of 0 +cardiac 0 +sympathetic 0 +tone 0 +represents 0 +an 0 +important 0 +strategy 0 +for 0 +treatment 0 +of 0 +cardiovascular 3 +disease 4 +"," 0 +including 0 +arrhythmia 3 +"," 0 +coronary 3 +heart 4 +disease 4 +"," 0 +and 0 +chronic 0 +heart 3 +failure 4 +. 0 +Activation 0 +of 0 +presynaptic 0 +alpha2 0 +- 0 +adrenoceptors 0 +is 0 +the 0 +most 0 +widely 0 +accepted 0 +mechanism 0 +of 0 +action 0 +of 0 +the 0 +antisympathetic 0 +drug 0 +clonidine 1 +; 0 +however 0 +"," 0 +other 0 +target 0 +proteins 0 +have 0 +been 0 +postulated 0 +to 0 +contribute 0 +to 0 +the 0 +in 0 +vivo 0 +actions 0 +of 0 +clonidine 1 +. 0 +METH0DS 0 +AND 0 +RESULTS 0 +: 0 +To 0 +test 0 +whether 0 +clonidine 1 +elicits 0 +pharmacological 0 +effects 0 +independent 0 +of 0 +alpha2 0 +- 0 +adrenoceptors 0 +"," 0 +we 0 +have 0 +generated 0 +mice 0 +with 0 +a 0 +targeted 0 +deletion 0 +of 0 +all 0 +3 0 +alpha2 0 +- 0 +adrenoceptor 0 +subtypes 0 +( 0 +alpha2ABC 0 +- 0 +/ 0 +- 0 +) 0 +. 0 +Alpha2ABC 0 +- 0 +/ 0 +- 0 +mice 0 +were 0 +completely 0 +unresponsive 0 +to 0 +the 0 +analgesic 0 +and 0 +hypnotic 0 +effects 0 +of 0 +clonidine 1 +; 0 +however 0 +"," 0 +clonidine 1 +significantly 0 +lowered 0 +heart 0 +rate 0 +in 0 +alpha2ABC 0 +- 0 +/ 0 +- 0 +mice 0 +by 0 +up 0 +to 0 +150 0 +bpm 0 +. 0 +Clonidine 1 +- 0 +induced 0 +bradycardia 3 +in 0 +conscious 0 +alpha2ABC 0 +- 0 +/ 0 +- 0 +mice 0 +was 0 +32 0 +. 0 +3 0 +% 0 +( 0 +10 0 +microg 0 +/ 0 +kg 0 +) 0 +and 0 +26 0 +. 0 +6 0 +% 0 +( 0 +100 0 +microg 0 +/ 0 +kg 0 +) 0 +of 0 +the 0 +effect 0 +in 0 +wild 0 +- 0 +type 0 +mice 0 +. 0 +A 0 +similar 0 +bradycardic 0 +effect 0 +of 0 +clonidine 1 +was 0 +observed 0 +in 0 +isolated 0 +spontaneously 0 +beating 0 +right 0 +atria 0 +from 0 +alpha2ABC 0 +- 0 +knockout 0 +and 0 +wild 0 +- 0 +type 0 +mice 0 +. 0 +Clonidine 1 +inhibited 0 +the 0 +native 0 +pacemaker 0 +current 0 +( 0 +I 0 +( 0 +f 0 +) 0 +) 0 +in 0 +isolated 0 +sinoatrial 0 +node 0 +pacemaker 0 +cells 0 +and 0 +the 0 +I 0 +( 0 +f 0 +) 0 +- 0 +generating 0 +hyperpolarization 0 +- 0 +activated 0 +cyclic 1 +nucleotide 2 +- 0 +gated 0 +( 0 +HCN 0 +) 0 +2 0 +and 0 +HCN4 0 +channels 0 +in 0 +transfected 0 +HEK293 0 +cells 0 +. 0 +As 0 +a 0 +consequence 0 +of 0 +blocking 0 +I 0 +( 0 +f 0 +) 0 +"," 0 +clonidine 1 +reduced 0 +the 0 +slope 0 +of 0 +the 0 +diastolic 0 +depolarization 0 +and 0 +the 0 +frequency 0 +of 0 +pacemaker 0 +potentials 0 +in 0 +sinoatrial 0 +node 0 +cells 0 +from 0 +wild 0 +- 0 +type 0 +and 0 +alpha2ABC 0 +- 0 +knockout 0 +mice 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Direct 0 +inhibition 0 +of 0 +cardiac 0 +HCN 0 +pacemaker 0 +channels 0 +contributes 0 +to 0 +the 0 +bradycardic 0 +effects 0 +of 0 +clonidine 1 +gene 0 +- 0 +targeted 0 +mice 0 +in 0 +vivo 0 +"," 0 +and 0 +thus 0 +"," 0 +clonidine 1 +- 0 +like 0 +drugs 0 +represent 0 +novel 0 +structures 0 +for 0 +future 0 +HCN 0 +channel 0 +inhibitors 0 +. 0 +Granulomatous 3 +hepatitis 4 +due 0 +to 0 +combination 1 +of 2 +amoxicillin 2 +and 2 +clavulanic 2 +acid 2 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +patient 0 +with 0 +amoxicillin 1 +- 2 +clavulanic 2 +acid 2 +- 0 +induced 0 +hepatitis 3 +with 0 +histologic 0 +multiple 0 +granulomas 3 +. 0 +This 0 +type 0 +of 0 +lesion 0 +broadens 0 +the 0 +spectrum 0 +of 0 +liver 3 +injury 4 +due 0 +to 0 +this 0 +drug 0 +combination 0 +"," 0 +mainly 0 +represented 0 +by 0 +a 0 +benign 0 +cholestatic 3 +syndrome 4 +. 0 +The 0 +association 0 +of 0 +granulomas 3 +and 0 +eosinophilia 3 +favor 0 +an 0 +immunoallergic 0 +mechanism 0 +. 0 +As 0 +penicillin 1 +derivatives 0 +and 0 +amoxicillin 1 +alone 0 +are 0 +known 0 +to 0 +induce 0 +such 0 +types 0 +of 0 +lesions 0 +"," 0 +the 0 +amoxicillin 1 +component 0 +"," 0 +with 0 +or 0 +without 0 +a 0 +potentiating 0 +effect 0 +of 0 +clavulanic 1 +acid 2 +"," 0 +might 0 +have 0 +a 0 +major 0 +role 0 +. 0 +Dobutamine 1 +stress 0 +echocardiography 0 +: 0 +a 0 +sensitive 0 +indicator 0 +of 0 +diminished 0 +myocardial 0 +function 0 +in 0 +asymptomatic 0 +doxorubicin 1 +- 0 +treated 0 +long 0 +- 0 +term 0 +survivors 0 +of 0 +childhood 0 +cancer 3 +. 0 +Doxorubicin 1 +is 0 +an 0 +effective 0 +anticancer 0 +chemotherapeutic 0 +agent 0 +known 0 +to 0 +cause 0 +acute 0 +and 0 +chronic 0 +cardiomyopathy 3 +. 0 +To 0 +develop 0 +a 0 +more 0 +sensitive 0 +echocardiographic 0 +screening 0 +test 0 +for 0 +cardiac 3 +damage 4 +due 0 +to 0 +doxorubicin 1 +"," 0 +a 0 +cohort 0 +study 0 +was 0 +performed 0 +using 0 +dobutamine 1 +infusion 0 +to 0 +differentiate 0 +asymptomatic 0 +long 0 +- 0 +term 0 +survivors 0 +of 0 +childhood 0 +cancer 3 +treated 0 +with 0 +doxorubicin 1 +from 0 +healthy 0 +control 0 +subjects 0 +. 0 +Echocardiographic 0 +data 0 +from 0 +the 0 +experimental 0 +group 0 +of 0 +21 0 +patients 0 +( 0 +mean 0 +age 0 +16 0 ++ 0 +/ 0 +- 0 +5 0 +years 0 +) 0 +treated 0 +from 0 +1 0 +. 0 +6 0 +to 0 +14 0 +. 0 +3 0 +years 0 +( 0 +median 0 +5 0 +. 0 +3 0 +) 0 +before 0 +this 0 +study 0 +with 0 +27 0 +to 0 +532 0 +mg 0 +/ 0 +m2 0 +of 0 +doxorubicin 1 +( 0 +mean 0 +196 0 +) 0 +were 0 +compared 0 +with 0 +echocardiographic 0 +data 0 +from 0 +12 0 +normal 0 +age 0 +- 0 +matched 0 +control 0 +subjects 0 +. 0 +Graded 0 +dobutamine 1 +infusions 0 +of 0 +0 0 +. 0 +5 0 +"," 0 +2 0 +. 0 +5 0 +"," 0 +5 0 +and 0 +10 0 +micrograms 0 +/ 0 +kg 0 +per 0 +min 0 +were 0 +administered 0 +. 0 +Echocardiographic 0 +Doppler 0 +studies 0 +were 0 +performed 0 +before 0 +infusion 0 +and 0 +after 0 +15 0 +min 0 +of 0 +infusion 0 +at 0 +each 0 +rate 0 +. 0 +Dobutamine 1 +infusion 0 +at 0 +10 0 +micrograms 0 +/ 0 +kg 0 +per 0 +min 0 +was 0 +discontinued 0 +after 0 +six 0 +studies 0 +secondary 0 +to 0 +a 0 +50 0 +% 0 +incidence 0 +rate 0 +of 0 +adverse 0 +symptoms 0 +. 0 +The 0 +most 0 +important 0 +findings 0 +were 0 +that 0 +compared 0 +with 0 +values 0 +in 0 +control 0 +subjects 0 +"," 0 +end 0 +- 0 +systolic 0 +left 0 +ventricular 0 +posterior 0 +wall 0 +dimension 0 +and 0 +percent 0 +of 0 +left 0 +ventricular 0 +posterior 0 +wall 0 +thickening 0 +in 0 +doxorubicin 1 +- 0 +treated 0 +patients 0 +were 0 +decreased 0 +at 0 +baseline 0 +study 0 +and 0 +these 0 +findings 0 +were 0 +more 0 +clearly 0 +delineated 0 +with 0 +dobutamine 1 +stimulation 0 +. 0 +End 0 +- 0 +systolic 0 +left 0 +ventricular 0 +posterior 0 +wall 0 +dimension 0 +at 0 +baseline 0 +for 0 +the 0 +doxorubicin 1 +- 0 +treated 0 +group 0 +was 0 +11 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +mm 0 +versus 0 +13 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +5 0 +mm 0 +for 0 +control 0 +subjects 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +. 0 +End 0 +- 0 +systolic 0 +left 0 +ventricular 0 +posterior 0 +wall 0 +dimension 0 +at 0 +the 0 +5 0 +- 0 +micrograms 0 +/ 0 +kg 0 +per 0 +min 0 +dobutamine 1 +infusion 0 +for 0 +the 0 +doxorubicin 1 +- 0 +treated 0 +group 0 +was 0 +14 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +4 0 +mm 0 +versus 0 +19 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +6 0 +mm 0 +for 0 +control 0 +subjects 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Influence 0 +of 0 +smoking 1 +on 0 +developing 0 +cochlea 0 +. 0 +Does 0 +smoking 1 +during 0 +pregnancy 0 +affect 0 +the 0 +amplitudes 0 +of 0 +transient 0 +evoked 0 +otoacoustic 0 +emissions 0 +in 0 +newborns 0 +? 0 +0BJECTIVE 0 +: 0 +Maternal 0 +tobacco 0 +smoking 1 +has 0 +negative 0 +effects 0 +on 0 +fetal 0 +growth 0 +. 0 +The 0 +influence 0 +of 0 +smoking 1 +during 0 +pregnancy 0 +on 0 +the 0 +developing 0 +cochlea 0 +has 0 +not 0 +been 0 +estimated 0 +"," 0 +although 0 +smoking 1 +has 0 +been 0 +positively 0 +associated 0 +with 0 +hearing 3 +loss 4 +in 0 +adults 0 +. 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +effects 0 +of 0 +maternal 0 +smoking 1 +on 0 +transient 0 +evoked 0 +otoacoustic 0 +emissions 0 +( 0 +TE0AEs 0 +) 0 +of 0 +healthy 0 +neonates 0 +. 0 +METH0DS 0 +: 0 +This 0 +study 0 +was 0 +undertaken 0 +as 0 +part 0 +of 0 +neonatal 0 +screening 0 +for 0 +hearing 3 +impairment 4 +and 0 +involved 0 +both 0 +ears 0 +of 0 +200 0 +newborns 0 +. 0 +Newborns 0 +whose 0 +mothers 0 +reported 0 +smoking 1 +during 0 +pregnancy 0 +( 0 +n 0 += 0 +200 0 +ears 0 +) 0 +were 0 +compared 0 +to 0 +a 0 +control 0 +group 0 +of 0 +newborns 0 +( 0 +n 0 += 0 +200 0 +ears 0 +) 0 +"," 0 +whose 0 +mothers 0 +were 0 +non 0 +- 0 +smokers 0 +. 0 +Exposure 0 +to 0 +tobacco 0 +was 0 +characterized 0 +as 0 +low 0 +( 0 +< 0 +5 0 +cigarettes 0 +per 0 +day 0 +"," 0 +n 0 += 0 +88 0 +ears 0 +) 0 +"," 0 +moderate 0 +( 0 +5 0 +< 0 +or 0 += 0 +cigarettes 0 +per 0 +day 0 +< 0 +10 0 +"," 0 +n 0 += 0 +76 0 +) 0 +or 0 +high 0 +( 0 +> 0 +or 0 += 0 +10 0 +cigarettes 0 +per 0 +day 0 +"," 0 +n 0 += 0 +36 0 +) 0 +. 0 +RESULTS 0 +: 0 +In 0 +exposed 0 +neonates 0 +"," 0 +TE0AEs 0 +mean 0 +response 0 +( 0 +across 0 +frequency 0 +) 0 +and 0 +mean 0 +amplitude 0 +at 0 +4000Hz 0 +was 0 +significantly 0 +lower 0 +than 0 +in 0 +non 0 +- 0 +exposed 0 +neonates 0 +. 0 +Comparisons 0 +between 0 +exposed 0 +newborns 0 +' 0 +subgroups 0 +revealed 0 +no 0 +significant 0 +differences 0 +. 0 +However 0 +"," 0 +by 0 +comparing 0 +each 0 +subgroup 0 +to 0 +control 0 +group 0 +"," 0 +we 0 +found 0 +statistically 0 +significant 0 +decreases 3 +of 4 +TE0AEs 4 +amplitudes 4 +at 0 +4000Hz 0 +for 0 +all 0 +three 0 +groups 0 +. 0 +Mean 0 +TE0AEs 0 +responses 0 +of 0 +highly 0 +exposed 0 +newborns 0 +were 0 +also 0 +significantly 0 +lower 0 +in 0 +comparison 0 +to 0 +our 0 +control 0 +group 0 +. 0 +C0NCLUSI0N 0 +: 0 +In 0 +utero 0 +"," 0 +exposure 0 +to 0 +tobacco 0 +smoking 1 +seems 0 +to 0 +have 0 +a 0 +small 0 +impact 0 +on 0 +outer 0 +hair 0 +cells 0 +. 0 +These 0 +effects 0 +seem 0 +to 0 +be 0 +equally 0 +TRUE 0 +for 0 +all 0 +exposed 0 +newborns 0 +"," 0 +regardless 0 +of 0 +the 0 +degree 0 +of 0 +exposure 0 +. 0 +Further 0 +studies 0 +are 0 +needed 0 +in 0 +order 0 +to 0 +establish 0 +a 0 +potential 0 +negative 0 +effect 0 +of 0 +maternal 0 +smoking 1 +on 0 +the 0 +neonate 0 +' 0 +s 0 +hearing 0 +acuity 0 +. 0 +Simvastatin 1 +- 0 +induced 0 +bilateral 0 +leg 0 +compartment 3 +syndrome 4 +and 0 +myonecrosis 3 +associated 0 +with 0 +hypothyroidism 3 +. 0 +A 0 +54 0 +- 0 +year 0 +- 0 +old 0 +hypothyroid 3 +male 0 +taking 0 +thyroxine 1 +and 0 +simvastatin 1 +presented 0 +with 0 +bilateral 0 +leg 0 +compartment 3 +syndrome 4 +and 0 +myonecrosis 3 +. 0 +Urgent 0 +fasciotomies 0 +were 0 +performed 0 +and 0 +the 0 +patient 0 +made 0 +an 0 +uneventful 0 +recovery 0 +with 0 +the 0 +withdrawal 0 +of 0 +simvastatin 1 +. 0 +It 0 +is 0 +likely 0 +that 0 +this 0 +complication 0 +will 0 +be 0 +seen 0 +more 0 +often 0 +with 0 +the 0 +increased 0 +worldwide 0 +use 0 +of 0 +this 0 +drug 0 +and 0 +its 0 +approval 0 +for 0 +all 0 +arteriopathic 3 +patients 0 +. 0 +Neuroinflammation 3 +and 0 +behavioral 3 +abnormalities 4 +after 0 +neonatal 0 +terbutaline 1 +treatment 0 +in 0 +rats 0 +: 0 +implications 0 +for 0 +autism 3 +. 0 +Autism 3 +is 0 +a 0 +neurodevelopmental 3 +disorder 4 +presenting 0 +before 0 +3 0 +years 0 +of 0 +age 0 +with 0 +deficits 3 +in 4 +communication 4 +and 4 +social 4 +skills 4 +and 0 +repetitive 3 +behaviors 4 +. 0 +In 0 +addition 0 +to 0 +genetic 0 +influences 0 +"," 0 +recent 0 +studies 0 +suggest 0 +that 0 +prenatal 0 +drug 0 +or 0 +chemical 0 +exposures 0 +are 0 +risk 0 +factors 0 +for 0 +autism 3 +. 0 +Terbutaline 1 +"," 0 +a 0 +beta2 0 +- 0 +adrenoceptor 0 +agonist 0 +used 0 +to 0 +arrest 0 +preterm 3 +labor 4 +"," 0 +has 0 +been 0 +associated 0 +with 0 +increased 0 +concordance 0 +for 0 +autism 3 +in 0 +dizygotic 0 +twins 0 +. 0 +We 0 +studied 0 +the 0 +effects 0 +of 0 +terbutaline 1 +on 0 +microglial 0 +activation 0 +in 0 +different 0 +brain 0 +regions 0 +and 0 +behavioral 0 +outcomes 0 +in 0 +developing 0 +rats 0 +. 0 +Newborn 0 +rats 0 +were 0 +given 0 +terbutaline 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +daily 0 +on 0 +postnatal 0 +days 0 +( 0 +PN 0 +) 0 +2 0 +to 0 +5 0 +or 0 +PN 0 +11 0 +to 0 +14 0 +and 0 +examined 0 +24 0 +h 0 +after 0 +the 0 +last 0 +dose 0 +and 0 +at 0 +PN 0 +30 0 +. 0 +Immunohistochemical 0 +studies 0 +showed 0 +that 0 +administration 0 +of 0 +terbutaline 1 +on 0 +PN 0 +2 0 +to 0 +5 0 +produced 0 +a 0 +robust 0 +increase 0 +in 0 +microglial 0 +activation 0 +on 0 +PN 0 +30 0 +in 0 +the 0 +cerebral 0 +cortex 0 +"," 0 +as 0 +well 0 +as 0 +in 0 +cerebellar 0 +and 0 +cerebrocortical 0 +white 0 +matter 0 +. 0 +None 0 +of 0 +these 0 +effects 0 +occurred 0 +in 0 +animals 0 +given 0 +terbutaline 1 +on 0 +PN 0 +11 0 +to 0 +14 0 +. 0 +In 0 +behavioral 0 +tests 0 +"," 0 +animals 0 +treated 0 +with 0 +terbutaline 1 +on 0 +PN 0 +2 0 +to 0 +5 0 +showed 0 +consistent 0 +patterns 0 +of 0 +hyper 0 +- 0 +reactivity 0 +to 0 +novelty 0 +and 0 +aversive 0 +stimuli 0 +when 0 +assessed 0 +in 0 +a 0 +novel 0 +open 0 +field 0 +"," 0 +as 0 +well 0 +as 0 +in 0 +the 0 +acoustic 0 +startle 0 +response 0 +test 0 +. 0 +0ur 0 +findings 0 +indicate 0 +that 0 +beta2 0 +- 0 +adrenoceptor 0 +overstimulation 0 +during 0 +an 0 +early 0 +critical 0 +period 0 +results 0 +in 0 +microglial 0 +activation 0 +associated 0 +with 0 +innate 0 +neuroinflammatory 0 +pathways 0 +and 0 +behavioral 3 +abnormalities 4 +"," 0 +similar 0 +to 0 +those 0 +described 0 +in 0 +autism 3 +. 0 +This 0 +study 0 +provides 0 +a 0 +useful 0 +animal 0 +model 0 +for 0 +understanding 0 +the 0 +neuropathological 0 +processes 0 +underlying 0 +autism 3 +spectrum 4 +disorders 4 +. 0 +Upregulation 0 +of 0 +brain 0 +expression 0 +of 0 +P 0 +- 0 +glycoprotein 0 +in 0 +MRP2 0 +- 0 +deficient 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +resembles 0 +seizure 3 +- 0 +induced 0 +up 0 +- 0 +regulation 0 +of 0 +this 0 +drug 0 +efflux 0 +transporter 0 +in 0 +normal 0 +rats 0 +. 0 +PURP0SE 0 +: 0 +The 0 +multidrug 0 +resistance 0 +protein 0 +2 0 +( 0 +MRP2 0 +) 0 +is 0 +a 0 +drug 0 +efflux 0 +transporter 0 +that 0 +is 0 +expressed 0 +predominantly 0 +at 0 +the 0 +apical 0 +domain 0 +of 0 +hepatocytes 0 +but 0 +seems 0 +also 0 +to 0 +be 0 +expressed 0 +at 0 +the 0 +apical 0 +membrane 0 +of 0 +brain 0 +capillary 0 +endothelial 0 +cells 0 +that 0 +form 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +( 0 +BBB 0 +) 0 +. 0 +MRP2 0 +is 0 +absent 0 +in 0 +the 0 +transport 0 +- 0 +deficient 0 +( 0 +TR 0 +( 0 +- 0 +) 0 +) 0 +Wistar 0 +rat 0 +mutant 0 +"," 0 +so 0 +that 0 +this 0 +rat 0 +strain 0 +was 0 +very 0 +helpful 0 +in 0 +defining 0 +substrates 0 +of 0 +MRP2 0 +by 0 +comparing 0 +tissue 0 +concentrations 0 +or 0 +functional 0 +activities 0 +of 0 +compounds 0 +in 0 +MRP2 0 +- 0 +deficient 0 +rats 0 +with 0 +those 0 +in 0 +transport 0 +- 0 +competent 0 +Wistar 0 +rats 0 +. 0 +By 0 +using 0 +this 0 +strategy 0 +to 0 +study 0 +the 0 +involvement 0 +of 0 +MRP2 0 +in 0 +brain 0 +access 0 +of 0 +antiepileptic 0 +drugs 0 +( 0 +AEDs 0 +) 0 +"," 0 +we 0 +recently 0 +reported 0 +that 0 +phenytoin 1 +is 0 +a 0 +substrate 0 +for 0 +MRP2 0 +in 0 +the 0 +BBB 0 +. 0 +However 0 +"," 0 +one 0 +drawback 0 +of 0 +such 0 +studies 0 +in 0 +genetically 0 +deficient 0 +rats 0 +is 0 +the 0 +fact 0 +that 0 +compensatory 0 +changes 0 +with 0 +upregulation 0 +of 0 +other 0 +transporters 0 +can 0 +occur 0 +. 0 +This 0 +prompted 0 +us 0 +to 0 +study 0 +the 0 +brain 0 +expression 0 +of 0 +P 0 +- 0 +glycoprotein 0 +( 0 +Pgp 0 +) 0 +"," 0 +a 0 +major 0 +drug 0 +efflux 0 +transporter 0 +in 0 +many 0 +tissues 0 +"," 0 +including 0 +the 0 +BBB 0 +"," 0 +in 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +compared 0 +with 0 +nonmutant 0 +( 0 +wild 0 +- 0 +type 0 +) 0 +Wistar 0 +rats 0 +. 0 +METH0DS 0 +: 0 +The 0 +expression 0 +of 0 +MRP2 0 +and 0 +Pgp 0 +in 0 +brain 0 +and 0 +liver 0 +sections 0 +of 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +and 0 +normal 0 +Wistar 0 +rats 0 +was 0 +determined 0 +with 0 +immunohistochemistry 0 +"," 0 +by 0 +using 0 +a 0 +novel 0 +"," 0 +highly 0 +selective 0 +monoclonal 0 +MRP2 0 +antibody 0 +and 0 +the 0 +monoclonal 0 +Pgp 0 +antibody 0 +C219 0 +"," 0 +respectively 0 +. 0 +RESULTS 0 +: 0 +Immunofluorescence 0 +staining 0 +with 0 +the 0 +MRP2 0 +antibody 0 +was 0 +found 0 +to 0 +label 0 +a 0 +high 0 +number 0 +of 0 +microvessels 0 +throughout 0 +the 0 +brain 0 +in 0 +normal 0 +Wistar 0 +rats 0 +"," 0 +whereas 0 +such 0 +labeling 0 +was 0 +absent 0 +in 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +. 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +exhibited 0 +a 0 +significant 0 +up 0 +- 0 +regulation 0 +of 0 +Pgp 0 +in 0 +brain 0 +capillary 0 +endothelial 0 +cells 0 +compared 0 +with 0 +wild 0 +- 0 +type 0 +controls 0 +. 0 +No 0 +such 0 +obvious 0 +upregulation 0 +of 0 +Pgp 0 +was 0 +observed 0 +in 0 +liver 0 +sections 0 +. 0 +A 0 +comparable 0 +overexpression 0 +of 0 +Pgp 0 +in 0 +the 0 +BBB 0 +was 0 +obtained 0 +after 0 +pilocarpine 1 +- 0 +induced 0 +seizures 3 +in 0 +wild 0 +- 0 +type 0 +Wistar 0 +rats 0 +. 0 +Experiments 0 +with 0 +systemic 0 +administration 0 +of 0 +the 0 +Pgp 0 +substrate 0 +phenobarbital 1 +and 0 +the 0 +selective 0 +Pgp 0 +inhibitor 0 +tariquidar 1 +in 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +substantiated 0 +that 0 +Pgp 0 +is 0 +functional 0 +and 0 +compensates 0 +for 0 +the 0 +lack 0 +of 0 +MRP2 0 +in 0 +the 0 +BBB 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +data 0 +on 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +indicate 0 +that 0 +Pgp 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +compensation 0 +of 0 +MRP2 0 +deficiency 0 +in 0 +the 0 +BBB 0 +. 0 +Because 0 +such 0 +a 0 +compensatory 0 +mechanism 0 +most 0 +likely 0 +occurs 0 +to 0 +reduce 0 +injury 3 +to 4 +the 4 +brain 4 +from 0 +cytotoxic 0 +compounds 0 +"," 0 +the 0 +present 0 +data 0 +substantiate 0 +the 0 +concept 0 +that 0 +MRP2 0 +performs 0 +a 0 +protective 0 +role 0 +in 0 +the 0 +BBB 0 +. 0 +Furthermore 0 +"," 0 +our 0 +data 0 +suggest 0 +that 0 +TR 0 +( 0 +- 0 +) 0 +rats 0 +are 0 +an 0 +interesting 0 +tool 0 +to 0 +study 0 +consequences 0 +of 0 +overexpression 0 +of 0 +Pgp 0 +in 0 +the 0 +BBB 0 +on 0 +access 0 +of 0 +drugs 0 +in 0 +the 0 +brain 0 +"," 0 +without 0 +the 0 +need 0 +of 0 +inducing 0 +seizures 3 +or 0 +other 0 +Pgp 0 +- 0 +enhancing 0 +events 0 +for 0 +this 0 +purpose 0 +. 0 +Role 0 +of 0 +xanthine 1 +oxidase 0 +in 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +in 0 +rats 0 +. 0 +1 0 +. 0 +Glucocorticoid 0 +- 0 +induced 0 +hypertension 3 +( 0 +GC 0 +- 0 +HT 3 +) 0 +in 0 +the 0 +rat 0 +is 0 +associated 0 +with 0 +nitric 1 +oxide 2 +- 0 +redox 0 +imbalance 0 +. 0 +2 0 +. 0 +We 0 +studied 0 +the 0 +role 0 +of 0 +xanthine 1 +oxidase 0 +( 0 +X0 0 +) 0 +"," 0 +which 0 +is 0 +implicated 0 +in 0 +the 0 +production 0 +of 0 +reactive 0 +oxygen 0 +species 0 +"," 0 +in 0 +dexamethasone 1 +- 0 +induced 0 +hypertension 3 +( 0 +dex 1 +- 0 +HT 3 +) 0 +. 0 +3 0 +. 0 +Thirty 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +divided 0 +randomly 0 +into 0 +four 0 +treatment 0 +groups 0 +: 0 +saline 0 +"," 0 +dexamethasone 1 +( 0 +dex 1 +) 0 +"," 0 +allopurinol 1 +plus 0 +saline 0 +"," 0 +and 0 +allopurinol 1 +plus 0 +dex 1 +. 0 +4 0 +. 0 +Systolic 0 +blood 0 +pressures 0 +( 0 +SBP 0 +) 0 +and 0 +bodyweights 0 +were 0 +recorded 0 +each 0 +alternate 0 +day 0 +. 0 +Thymus 0 +weight 0 +was 0 +used 0 +as 0 +a 0 +marker 0 +of 0 +glucocorticoid 0 +activity 0 +"," 0 +and 0 +serum 0 +urate 1 +to 0 +assess 0 +X0 0 +inhibition 0 +. 0 +5 0 +. 0 +Dex 1 +increased 3 +SBP 4 +( 0 +110 0 ++ 0 +/ 0 +- 0 +2 0 +- 0 +126 0 ++ 0 +/ 0 +- 0 +3 0 +mmHg 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +and 0 +decreased 3 +thymus 4 +( 4 +P 4 +< 4 +0 4 +. 4 +1 4 +) 4 +and 4 +bodyweights 4 +( 0 +P 0 +cholesteryl 1 +ester 2 +accumulation 0 +following 0 +ritonavir 1 +treatment 0 +. 0 +Acute 0 +hepatitis 3 +attack 0 +after 0 +exposure 0 +to 0 +telithromycin 1 +. 0 +INTR0DUCTI0N 0 +: 0 +Antibiotic 0 +- 0 +associated 0 +hepatotoxicity 3 +is 0 +rare 0 +. 0 +With 0 +widespread 0 +use 0 +of 0 +antimicrobial 0 +agents 0 +"," 0 +however 0 +"," 0 +hepatic 3 +injury 4 +occurs 0 +frequently 0 +"," 0 +and 0 +among 0 +adverse 3 +drug 4 +reactions 4 +"," 0 +idiosyncratic 0 +reactions 0 +are 0 +the 0 +most 0 +serious 0 +. 0 +CASE 0 +SUMMARY 0 +: 0 +A 0 +25 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +"," 0 +with 0 +a 0 +height 0 +of 0 +175 0 +cm 0 +and 0 +weight 0 +of 0 +72 0 +kg 0 +presented 0 +to 0 +Marmara 0 +University 0 +Hospital 0 +Emergency 0 +Department 0 +"," 0 +Istanbul 0 +"," 0 +Turkey 0 +"," 0 +with 0 +5 0 +days 0 +' 0 +history 0 +of 0 +jaundice 3 +"," 0 +malaise 0 +"," 0 +nausea 3 +"," 0 +and 0 +vomiting 3 +. 0 +He 0 +had 0 +been 0 +prescribed 0 +telithromycin 1 +400 0 +mg 0 +/ 0 +d 0 +P0 0 +to 0 +treat 0 +an 0 +upper 3 +respiratory 4 +tract 4 +infection 4 +7 0 +days 0 +prior 0 +. 0 +Admission 0 +laboratory 0 +tests 0 +were 0 +as 0 +follows 0 +: 0 +alanine 1 +aminotransferase 0 +"," 0 +67 0 +U 0 +/ 0 +L 0 +( 0 +reference 0 +range 0 +"," 0 +10 0 +- 0 +37 0 +U 0 +/ 0 +L 0 +) 0 +; 0 +aspartate 1 +aminotransferase 0 +"," 0 +98 0 +U 0 +/ 0 +L 0 +( 0 +10 0 +- 0 +40 0 +U 0 +/ 0 +L 0 +) 0 +; 0 +alkaline 0 +phosphatase 0 +"," 0 +513 0 +U 0 +/ 0 +L 0 +( 0 +0 0 +- 0 +270 0 +U 0 +/ 0 +L 0 +) 0 +; 0 +gamma 0 +- 0 +glutamyltransferase 0 +"," 0 +32 0 +U 0 +/ 0 +L 0 +( 0 +7 0 +- 0 +49 0 +U 0 +/ 0 +L 0 +) 0 +; 0 +amylase 0 +"," 0 +46 0 +U 0 +/ 0 +L 0 +( 0 +0 0 +- 0 +220 0 +U 0 +/ 0 +L 0 +) 0 +; 0 +total 0 +bilirubin 1 +"," 0 +20 0 +. 0 +1 0 +mg 0 +/ 0 +dL 0 +( 0 +0 0 +. 0 +2 0 +- 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +dL 0 +) 0 +; 0 +direct 0 +bilirubin 1 +"," 0 +14 0 +. 0 +8 0 +mg 0 +/ 0 +dL 0 +( 0 +0 0 +- 0 +0 0 +. 0 +3 0 +mg 0 +/ 0 +dL 0 +) 0 +; 0 +and 0 +albumin 0 +"," 0 +4 0 +. 0 +7 0 +mg 0 +/ 0 +dL 0 +( 0 +3 0 +. 0 +5 0 +- 0 +5 0 +. 0 +4 0 +mg 0 +/ 0 +dL 0 +) 0 +. 0 +No 0 +toxin 0 +"," 0 +alcohol 1 +"," 0 +or 0 +other 0 +drugs 0 +were 0 +reported 0 +. 0 +The 0 +patient 0 +had 0 +suffered 0 +a 0 +previous 0 +episode 0 +of 0 +" 0 +acute 0 +hepatitis 3 +of 0 +unknown 0 +origin 0 +, 0 +" 0 +that 0 +occurred 0 +after 0 +telithromycin 1 +usage 0 +. 0 +Both 0 +incidents 0 +occurred 0 +within 0 +a 0 +year 0 +. 0 +DISCUSSI0N 0 +: 0 +Telithromycin 1 +is 0 +the 0 +first 0 +of 0 +the 0 +ketolide 0 +antibacterials 0 +to 0 +receive 0 +US 0 +Food 0 +and 0 +Drug 0 +Administration 0 +approval 0 +for 0 +clinical 0 +use 0 +. 0 +It 0 +has 0 +been 0 +associated 0 +with 0 +infrequent 0 +and 0 +usually 0 +reversible 0 +severe 0 +hepatic 3 +dysfunction 4 +. 0 +Based 0 +on 0 +a 0 +score 0 +of 0 +8 0 +on 0 +the 0 +Naranjo 0 +adverse 3 +drug 4 +reaction 4 +probability 0 +scale 0 +"," 0 +telithromycin 1 +was 0 +the 0 +probable 0 +cause 0 +of 0 +acute 0 +hepatitis 3 +in 0 +this 0 +patient 0 +"," 0 +and 0 +pathological 0 +findings 0 +suggested 0 +drug 0 +- 0 +induced 0 +toxic 3 +hepatitis 4 +. 0 +Recurrence 0 +of 0 +hepatitis 3 +attack 0 +might 0 +have 0 +been 0 +avoided 0 +if 0 +the 0 +initial 0 +incident 0 +had 0 +been 0 +communicated 0 +to 0 +the 0 +attending 0 +physician 0 +who 0 +prescribed 0 +telithromycin 1 +the 0 +second 0 +time 0 +. 0 +C0NCLUSI0N 0 +: 0 +Here 0 +we 0 +report 0 +a 0 +case 0 +of 0 +acute 0 +hepatitis 3 +probably 0 +associated 0 +with 0 +the 0 +administration 0 +of 0 +telithromycin 1 +. 0 +A 0 +study 0 +on 0 +the 0 +effect 0 +of 0 +the 0 +duration 0 +of 0 +subcutaneous 0 +heparin 1 +injection 0 +on 0 +bruising 3 +and 0 +pain 3 +. 0 +AIM 0 +: 0 +This 0 +study 0 +was 0 +carried 0 +out 0 +to 0 +determine 0 +the 0 +effect 0 +of 0 +injection 0 +duration 0 +on 0 +bruising 3 +and 0 +pain 3 +following 0 +the 0 +administration 0 +of 0 +the 0 +subcutaneous 0 +injection 0 +of 0 +heparin 1 +. 0 +BACKGR0UND 0 +: 0 +Although 0 +different 0 +methods 0 +to 0 +prevent 0 +bruising 3 +and 0 +pain 3 +following 0 +the 0 +subcutaneous 0 +injection 0 +of 0 +heparin 1 +have 0 +been 0 +widely 0 +studied 0 +and 0 +described 0 +"," 0 +the 0 +effect 0 +of 0 +injection 0 +duration 0 +on 0 +the 0 +occurrence 0 +of 0 +bruising 3 +and 0 +pain 3 +is 0 +little 0 +documented 0 +. 0 +DESIGN 0 +: 0 +This 0 +study 0 +was 0 +designed 0 +as 0 +within 0 +- 0 +subject 0 +"," 0 +quasi 0 +- 0 +experimental 0 +research 0 +. 0 +METH0D 0 +: 0 +The 0 +sample 0 +for 0 +the 0 +study 0 +consisted 0 +of 0 +50 0 +patients 0 +to 0 +whom 0 +subcutaneous 0 +heparin 1 +was 0 +administered 0 +. 0 +Heparin 1 +was 0 +injected 0 +over 0 +10 0 +seconds 0 +on 0 +the 0 +right 0 +abdominal 0 +site 0 +and 0 +30 0 +seconds 0 +on 0 +the 0 +left 0 +abdominal 0 +site 0 +. 0 +Injections 0 +areas 0 +were 0 +assessed 0 +for 0 +the 0 +presence 0 +of 0 +bruising 3 +at 0 +48 0 +and 0 +72 0 +hours 0 +after 0 +each 0 +injection 0 +. 0 +Dimensions 0 +of 0 +the 0 +bruising 3 +on 0 +the 0 +heparin 1 +applied 0 +areas 0 +were 0 +measured 0 +using 0 +transparent 0 +millimetric 0 +measuring 0 +paper 0 +. 0 +The 0 +visual 0 +analog 0 +scale 0 +( 0 +VAS 0 +) 0 +was 0 +used 0 +to 0 +measure 0 +pain 3 +intensity 0 +and 0 +a 0 +stop 0 +- 0 +watch 0 +was 0 +used 0 +to 0 +time 0 +the 0 +pain 3 +period 0 +. 0 +Data 0 +were 0 +analysed 0 +using 0 +chi 0 +- 0 +square 0 +test 0 +"," 0 +Mann 0 +- 0 +Whitney 0 +U 0 +"," 0 +Wilcoxon 0 +signed 0 +ranks 0 +tests 0 +and 0 +correlation 0 +. 0 +RESULTS 0 +: 0 +The 0 +percentage 0 +of 0 +bruising 3 +occurrence 0 +was 0 +64 0 +% 0 +with 0 +the 0 +injection 0 +of 0 +10 0 +seconds 0 +duration 0 +and 0 +42 0 +% 0 +in 0 +the 0 +30 0 +- 0 +second 0 +injection 0 +. 0 +It 0 +was 0 +determined 0 +that 0 +the 0 +size 0 +of 0 +the 0 +bruising 3 +was 0 +smaller 0 +in 0 +the 0 +30 0 +- 0 +second 0 +injection 0 +. 0 +Pain 3 +intensity 0 +and 0 +pain 3 +period 0 +were 0 +statistically 0 +significantly 0 +lower 0 +for 0 +the 0 +30 0 +- 0 +second 0 +injection 0 +than 0 +for 0 +the 0 +10 0 +- 0 +second 0 +injection 0 +. 0 +C0NCLUSI0NS 0 +: 0 +It 0 +was 0 +determined 0 +that 0 +injection 0 +duration 0 +had 0 +an 0 +effect 0 +on 0 +bruising 3 +and 0 +pain 3 +following 0 +the 0 +subcutaneous 0 +administration 0 +of 0 +heparin 1 +. 0 +This 0 +study 0 +should 0 +be 0 +repeated 0 +on 0 +a 0 +larger 0 +sample 0 +. 0 +RELEVANCE 0 +T0 0 +CLINICAL 0 +PRACTICE 0 +: 0 +When 0 +administering 0 +subcutaneous 0 +heparin 1 +injections 0 +"," 0 +it 0 +is 0 +important 0 +to 0 +extend 0 +the 0 +duration 0 +of 0 +the 0 +injection 0 +. 0 +Acute 3 +liver 4 +failure 4 +in 0 +two 0 +patients 0 +with 0 +regular 0 +alcohol 1 +consumption 0 +ingesting 0 +paracetamol 1 +at 0 +therapeutic 0 +dosage 0 +. 0 +BACKGR0UND 0 +: 0 +The 0 +possible 0 +role 0 +of 0 +alcohol 1 +in 0 +the 0 +development 0 +of 0 +hepatotoxicity 3 +associated 0 +with 0 +therapeutic 0 +doses 0 +of 0 +paracetamol 1 +( 0 +acetaminophen 1 +) 0 +is 0 +currently 0 +debated 0 +. 0 +CASE 0 +REP0RT 0 +: 0 +We 0 +describe 0 +2 0 +patients 0 +who 0 +were 0 +regular 0 +consumers 0 +of 0 +alcohol 1 +and 0 +who 0 +developed 0 +liver 3 +failure 4 +within 0 +3 0 +- 0 +5 0 +days 0 +after 0 +hospitalization 0 +and 0 +stopping 0 +alcohol 1 +consumption 0 +while 0 +being 0 +treated 0 +with 0 +4 0 +g 0 +paracetamol 1 +/ 0 +day 0 +. 0 +A 0 +paracetamol 1 +serum 0 +level 0 +obtained 0 +in 0 +one 0 +of 0 +these 0 +patients 0 +was 0 +not 0 +in 0 +the 0 +toxic 0 +range 0 +. 0 +Possible 0 +risk 0 +factors 0 +for 0 +the 0 +development 0 +of 0 +hepatotoxicity 3 +in 0 +patients 0 +treated 0 +with 0 +therapeutic 0 +doses 0 +of 0 +paracetamol 1 +are 0 +discussed 0 +. 0 +C0NCLUSI0N 0 +: 0 +In 0 +patients 0 +with 0 +risk 0 +factors 0 +"," 0 +e 0 +. 0 +g 0 +. 0 +regular 0 +consumption 0 +of 0 +alcohol 1 +"," 0 +liver 3 +failure 4 +is 0 +possible 0 +when 0 +therapeutic 0 +doses 0 +are 0 +ingested 0 +. 0 +We 0 +propose 0 +that 0 +the 0 +paracetamol 1 +dose 0 +should 0 +not 0 +exceed 0 +2 0 +g 0 +/ 0 +day 0 +in 0 +such 0 +patients 0 +and 0 +that 0 +their 0 +liver 0 +function 0 +should 0 +be 0 +monitored 0 +closely 0 +while 0 +being 0 +treated 0 +with 0 +paracetamol 1 +. 0 +Associations 0 +between 0 +use 0 +of 0 +benzodiazepines 1 +or 0 +related 0 +drugs 0 +and 0 +health 0 +"," 0 +physical 0 +abilities 0 +and 0 +cognitive 0 +function 0 +: 0 +a 0 +non 0 +- 0 +randomised 0 +clinical 0 +study 0 +in 0 +the 0 +elderly 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +describe 0 +associations 0 +between 0 +the 0 +use 0 +of 0 +benzodiazepines 1 +or 0 +related 0 +drugs 0 +( 0 +BZDs 1 +/ 0 +RDs 0 +) 0 +and 0 +health 0 +"," 0 +functional 0 +abilities 0 +and 0 +cognitive 0 +function 0 +in 0 +the 0 +elderly 0 +. 0 +METH0DS 0 +: 0 +A 0 +non 0 +- 0 +randomised 0 +clinical 0 +study 0 +of 0 +patients 0 +aged 0 +> 0 +or 0 += 0 +65 0 +years 0 +admitted 0 +to 0 +acute 0 +hospital 0 +wards 0 +during 0 +1 0 +month 0 +. 0 +164 0 +patients 0 +( 0 +mean 0 +age 0 ++ 0 +/ 0 +- 0 +standard 0 +deviation 0 +[ 0 +SD 0 +] 0 +81 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +8 0 +years 0 +) 0 +were 0 +admitted 0 +. 0 +0f 0 +these 0 +"," 0 +nearly 0 +half 0 +( 0 +n 0 += 0 +78 0 +) 0 +had 0 +used 0 +BZDs 1 +/ 0 +RDs 0 +before 0 +admission 0 +"," 0 +and 0 +the 0 +remainder 0 +( 0 +n 0 += 0 +86 0 +) 0 +were 0 +non 0 +- 0 +users 0 +. 0 +Cognitive 0 +ability 0 +was 0 +assessed 0 +by 0 +the 0 +Mini 0 +- 0 +Mental 0 +State 0 +Examination 0 +( 0 +MMSE 0 +) 0 +. 0 +Patients 0 +scoring 0 +> 0 +or 0 += 0 +20 0 +MMSE 0 +sum 0 +points 0 +were 0 +interviewed 0 +( 0 +n 0 += 0 +79 0 +) 0 +and 0 +questioned 0 +regarding 0 +symptoms 0 +and 0 +functional 0 +abilities 0 +during 0 +the 0 +week 0 +prior 0 +to 0 +admission 0 +. 0 +Data 0 +on 0 +use 0 +of 0 +BZDs 1 +/ 0 +RDs 0 +before 0 +admission 0 +"," 0 +current 0 +medications 0 +and 0 +discharge 0 +diagnoses 0 +were 0 +collected 0 +from 0 +medical 0 +records 0 +. 0 +Health 0 +"," 0 +physical 0 +abilities 0 +and 0 +cognitive 0 +function 0 +were 0 +compared 0 +between 0 +BZD 0 +/ 0 +RD 0 +users 0 +and 0 +non 0 +- 0 +users 0 +"," 0 +and 0 +adjustments 0 +were 0 +made 0 +for 0 +confounding 0 +variables 0 +. 0 +The 0 +residual 0 +serum 0 +concentrations 0 +of 0 +oxazepam 1 +"," 0 +temazepam 1 +and 0 +zopiclone 1 +were 0 +analysed 0 +. 0 +RESULTS 0 +: 0 +The 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +duration 0 +of 0 +BZD 0 +/ 0 +RD 0 +use 0 +was 0 +7 0 ++ 0 +/ 0 +- 0 +7 0 +years 0 +( 0 +range 0 +1 0 +- 0 +31 0 +) 0 +. 0 +Two 0 +or 0 +three 0 +BZDs 1 +/ 0 +RDs 0 +were 0 +concomitantly 0 +taken 0 +by 0 +26 0 +% 0 +of 0 +users 0 +( 0 +n 0 += 0 +20 0 +) 0 +. 0 +Long 0 +- 0 +term 0 +use 0 +of 0 +these 0 +drugs 0 +was 0 +associated 0 +with 0 +female 0 +sex 0 +and 0 +use 0 +of 0 +a 0 +higher 0 +number 0 +of 0 +drugs 0 +with 0 +effects 0 +on 0 +the 0 +CNS 0 +"," 0 +which 0 +tended 0 +to 0 +be 0 +related 0 +to 0 +diagnosed 0 +dementia 3 +. 0 +After 0 +adjustment 0 +for 0 +these 0 +variables 0 +as 0 +confounders 0 +"," 0 +use 0 +of 0 +BZDs 1 +/ 0 +RDs 0 +was 0 +not 0 +associated 0 +with 0 +cognitive 0 +function 0 +as 0 +measured 0 +by 0 +the 0 +MMSE 0 +. 0 +However 0 +"," 0 +use 0 +of 0 +BZDs 1 +/ 0 +RDs 0 +was 0 +associated 0 +with 0 +dizziness 3 +"," 0 +inability 3 +to 4 +sleep 4 +after 0 +awaking 0 +at 0 +night 0 +and 0 +tiredness 3 +in 0 +the 0 +mornings 0 +during 0 +the 0 +week 0 +prior 0 +to 0 +admission 0 +and 0 +with 0 +stronger 0 +depressive 3 +symptoms 4 +measured 0 +at 0 +the 0 +beginning 0 +of 0 +the 0 +hospital 0 +stay 0 +. 0 +Use 0 +of 0 +BZDs 1 +/ 0 +RDs 0 +tended 0 +to 0 +be 0 +associated 0 +with 0 +a 0 +reduced 0 +ability 0 +to 0 +walk 0 +and 0 +shorter 0 +night 0 +- 0 +time 0 +sleep 0 +during 0 +the 0 +week 0 +prior 0 +to 0 +admission 0 +. 0 +A 0 +higher 0 +residual 0 +serum 0 +concentration 0 +of 0 +temazepam 1 +correlated 0 +with 0 +a 0 +lower 0 +MMSE 0 +sum 0 +score 0 +after 0 +adjustment 0 +for 0 +confounding 0 +variables 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Long 0 +- 0 +term 0 +use 0 +and 0 +concomitant 0 +use 0 +of 0 +more 0 +than 0 +one 0 +BZD 0 +/ 0 +RD 0 +were 0 +common 0 +in 0 +elderly 0 +patients 0 +hospitalised 0 +because 0 +of 0 +acute 0 +illnesses 0 +. 0 +Long 0 +- 0 +term 0 +use 0 +was 0 +associated 0 +with 0 +daytime 0 +and 0 +night 0 +- 0 +time 0 +symptoms 0 +indicative 0 +of 0 +poorer 0 +health 0 +and 0 +potentially 0 +caused 0 +by 0 +the 0 +adverse 0 +effects 0 +of 0 +these 0 +drugs 0 +. 0 +Acute 0 +vocal 3 +fold 4 +palsy 4 +after 0 +acute 0 +disulfiram 1 +intoxication 0 +. 0 +Acute 0 +peripheral 3 +neuropathy 4 +caused 0 +by 0 +a 0 +disulfiram 1 +overdose 3 +is 0 +very 0 +rare 0 +and 0 +there 0 +is 0 +no 0 +report 0 +of 0 +it 0 +leading 0 +to 0 +vocal 3 +fold 4 +palsy 4 +. 0 +A 0 +49 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +was 0 +transferred 0 +to 0 +our 0 +department 0 +because 0 +of 0 +quadriparesis 3 +"," 0 +lancinating 0 +pain 3 +"," 0 +sensory 3 +loss 4 +"," 0 +and 0 +paresthesia 3 +of 0 +the 0 +distal 0 +limbs 0 +. 0 +0ne 0 +month 0 +previously 0 +"," 0 +she 0 +had 0 +taken 0 +a 0 +single 0 +high 0 +dose 0 +of 0 +disulfiram 1 +( 0 +130 0 +tablets 0 +of 0 +ALC0H0L 1 +ST0P 0 +TAB 0 +"," 0 +Shin 0 +- 0 +Poong 0 +Pharm 0 +. 0 +Co 0 +. 0 +"," 0 +Ansan 0 +"," 0 +Korea 0 +) 0 +in 0 +a 0 +suicide 0 +attempt 0 +. 0 +She 0 +was 0 +not 0 +an 0 +alcoholic 0 +. 0 +For 0 +the 0 +first 0 +few 0 +days 0 +after 0 +ingestion 0 +"," 0 +she 0 +was 0 +in 0 +a 0 +confused 0 +state 0 +and 0 +had 0 +mild 0 +to 0 +moderate 0 +ataxia 3 +and 0 +giddiness 3 +. 0 +She 0 +noticed 0 +hoarseness 3 +and 0 +distally 0 +accentuated 0 +motor 0 +and 0 +sensory 0 +dysfunction 0 +after 0 +she 0 +had 0 +recovered 0 +from 0 +this 0 +state 0 +. 0 +A 0 +nerve 0 +conduction 0 +study 0 +was 0 +consistent 0 +with 0 +severe 0 +sensorimotor 0 +axonal 0 +polyneuropathy 3 +. 0 +Laryngeal 0 +electromyography 0 +( 0 +thyroarytenoid 0 +muscle 0 +) 0 +showed 0 +ample 0 +denervation 0 +potentials 0 +. 0 +Laryngoscopy 0 +revealed 0 +asymmetric 0 +vocal 0 +fold 0 +movements 0 +during 0 +phonation 0 +. 0 +Her 0 +vocal 0 +change 0 +and 0 +weakness 0 +began 0 +to 0 +improve 0 +spontaneously 0 +about 0 +3 0 +weeks 0 +after 0 +transfer 0 +. 0 +This 0 +was 0 +a 0 +case 0 +of 0 +acute 0 +palsy 3 +of 0 +the 0 +recurrent 0 +laryngeal 0 +nerve 0 +and 0 +superimposed 0 +severe 0 +acute 0 +sensorimotor 0 +axonal 0 +polyneuropathy 3 +caused 0 +by 0 +high 0 +- 0 +dose 0 +disulfiram 1 +intoxication 0 +. 0 +Encephalopathy 3 +induced 0 +by 0 +levetiracetam 1 +added 0 +to 0 +valproate 1 +. 0 +BACKGR0UND 0 +: 0 +We 0 +report 0 +on 0 +the 0 +manifestation 0 +of 0 +a 0 +levetiracetam 1 +( 0 +LEV 1 +) 0 +- 0 +induced 0 +encephalopathy 3 +. 0 +FINDINGS 0 +: 0 +A 0 +28 0 +- 0 +year 0 +- 0 +old 0 +man 0 +suffering 0 +from 0 +idiopathic 3 +epilepsy 4 +with 0 +generalized 0 +seizures 3 +was 0 +treated 0 +with 0 +LEV 1 +( 0 +3000 0 +mg 0 +) 0 +added 0 +to 0 +valproate 1 +( 0 +VPA 1 +) 0 +( 0 +2000 0 +mg 0 +) 0 +. 0 +Frequency 0 +of 0 +generalized 0 +tonic 3 +- 4 +clonic 4 +seizures 4 +increased 0 +from 0 +one 0 +per 0 +6 0 +months 0 +to 0 +two 0 +per 0 +month 0 +. 0 +Neuropsychological 0 +testing 0 +showed 0 +impaired 3 +word 4 +fluency 4 +"," 4 +psychomotor 4 +speed 4 +and 4 +working 4 +memory 4 +. 0 +The 0 +interictal 0 +electroencephalogram 0 +( 0 +EEG 0 +) 0 +showed 0 +a 0 +generalized 0 +slowing 0 +to 0 +5 0 +per 0 +second 0 +theta 0 +rhythms 0 +with 0 +bilateral 0 +generalized 0 +high 0 +- 0 +amplitude 0 +discharges 0 +. 0 +0UTC0ME 0 +: 0 +Following 0 +discontinuation 0 +of 0 +LEV 1 +"," 0 +EEG 0 +and 0 +neuropsychological 0 +findings 0 +improved 0 +and 0 +seizure 3 +frequency 0 +decreased 0 +. 0 +Norepinephrine 1 +signaling 0 +through 0 +beta 0 +- 0 +adrenergic 0 +receptors 0 +is 0 +critical 0 +for 0 +expression 0 +of 0 +cocaine 1 +- 0 +induced 0 +anxiety 3 +. 0 +BACKGR0UND 0 +: 0 +Cocaine 1 +is 0 +a 0 +widely 0 +abused 0 +psychostimulant 0 +that 0 +has 0 +both 0 +rewarding 0 +and 0 +aversive 0 +properties 0 +. 0 +While 0 +the 0 +mechanisms 0 +underlying 0 +cocaine 1 +' 0 +s 0 +rewarding 0 +effects 0 +have 0 +been 0 +studied 0 +extensively 0 +"," 0 +less 0 +attention 0 +has 0 +been 0 +paid 0 +to 0 +the 0 +unpleasant 0 +behavioral 0 +states 0 +induced 0 +by 0 +cocaine 1 +"," 0 +such 0 +as 0 +anxiety 3 +. 0 +METH0DS 0 +: 0 +In 0 +this 0 +study 0 +"," 0 +we 0 +evaluated 0 +the 0 +performance 0 +of 0 +dopamine 1 +beta 0 +- 0 +hydroxylase 0 +knockout 0 +( 0 +Dbh 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +"," 0 +which 0 +lack 0 +norepinephrine 1 +( 0 +NE 1 +) 0 +"," 0 +in 0 +the 0 +elevated 0 +plus 0 +maze 0 +( 0 +EPM 0 +) 0 +to 0 +examine 0 +the 0 +contribution 0 +of 0 +noradrenergic 0 +signaling 0 +to 0 +cocaine 1 +- 0 +induced 0 +anxiety 3 +. 0 +RESULTS 0 +: 0 +We 0 +found 0 +that 0 +cocaine 1 +dose 0 +- 0 +dependently 0 +increased 0 +anxiety 3 +- 0 +like 0 +behavior 0 +in 0 +control 0 +( 0 +Dbh 0 ++ 0 +/ 0 +- 0 +) 0 +mice 0 +"," 0 +as 0 +measured 0 +by 0 +a 0 +decrease 0 +in 0 +open 0 +arm 0 +exploration 0 +. 0 +The 0 +Dbh 0 +- 0 +/ 0 +- 0 +mice 0 +had 0 +normal 0 +baseline 0 +performance 0 +in 0 +the 0 +EPM 0 +but 0 +were 0 +completely 0 +resistant 0 +to 0 +the 0 +anxiogenic 0 +effects 0 +of 0 +cocaine 1 +. 0 +Cocaine 1 +- 0 +induced 0 +anxiety 3 +was 0 +also 0 +attenuated 0 +in 0 +Dbh 0 ++ 0 +/ 0 +- 0 +mice 0 +following 0 +administration 0 +of 0 +disulfiram 1 +"," 0 +a 0 +dopamine 1 +beta 0 +- 0 +hydroxylase 0 +( 0 +DBH 0 +) 0 +inhibitor 0 +. 0 +In 0 +experiments 0 +using 0 +specific 0 +adrenergic 0 +antagonists 0 +"," 0 +we 0 +found 0 +that 0 +pretreatment 0 +with 0 +the 0 +beta 0 +- 0 +adrenergic 0 +receptor 0 +antagonist 0 +propranolol 1 +blocked 0 +cocaine 1 +- 0 +induced 0 +anxiety 3 +- 0 +like 0 +behavior 0 +in 0 +Dbh 0 ++ 0 +/ 0 +- 0 +and 0 +wild 0 +- 0 +type 0 +C57BL6 0 +/ 0 +J 0 +mice 0 +"," 0 +while 0 +the 0 +alpha 0 +( 0 +1 0 +) 0 +antagonist 0 +prazosin 1 +and 0 +the 0 +alpha 0 +( 0 +2 0 +) 0 +antagonist 0 +yohimbine 1 +had 0 +no 0 +effect 0 +. 0 +C0NCLUSI0NS 0 +: 0 +These 0 +results 0 +indicate 0 +that 0 +noradrenergic 0 +signaling 0 +via 0 +beta 0 +- 0 +adrenergic 0 +receptors 0 +is 0 +required 0 +for 0 +cocaine 1 +- 0 +induced 0 +anxiety 3 +in 0 +mice 0 +. 0 +Hypothalamic 0 +prolactin 0 +receptor 0 +messenger 0 +ribonucleic 1 +acid 2 +levels 0 +"," 0 +prolactin 0 +signaling 0 +"," 0 +and 0 +hyperprolactinemic 3 +inhibition 0 +of 0 +pulsatile 0 +luteinizing 0 +hormone 0 +secretion 0 +are 0 +dependent 0 +on 0 +estradiol 1 +. 0 +Hyperprolactinemia 3 +can 0 +reduce 0 +fertility 0 +and 0 +libido 0 +. 0 +Although 0 +central 0 +prolactin 0 +actions 0 +are 0 +thought 0 +to 0 +contribute 0 +to 0 +this 0 +"," 0 +the 0 +mechanisms 0 +are 0 +poorly 0 +understood 0 +. 0 +We 0 +first 0 +tested 0 +whether 0 +chronic 0 +hyperprolactinemia 3 +inhibited 0 +two 0 +neuroendocrine 0 +parameters 0 +necessary 0 +for 0 +female 0 +fertility 0 +: 0 +pulsatile 0 +LH 0 +secretion 0 +and 0 +the 0 +estrogen 1 +- 0 +induced 0 +LH 0 +surge 0 +. 0 +Chronic 0 +hyperprolactinemia 3 +induced 0 +by 0 +the 0 +dopamine 1 +antagonist 0 +sulpiride 1 +caused 0 +a 0 +40 0 +% 0 +reduction 0 +LH 0 +pulse 0 +frequency 0 +in 0 +ovariectomized 0 +rats 0 +"," 0 +but 0 +only 0 +in 0 +the 0 +presence 0 +of 0 +chronic 0 +low 0 +levels 0 +of 0 +estradiol 1 +. 0 +Sulpiride 1 +did 0 +not 0 +affect 0 +the 0 +magnitude 0 +of 0 +a 0 +steroid 1 +- 0 +induced 0 +LH 0 +surge 0 +or 0 +the 0 +percentage 0 +of 0 +GnRH 0 +neurons 0 +activated 0 +during 0 +the 0 +surge 0 +. 0 +Estradiol 1 +is 0 +known 0 +to 0 +influence 0 +expression 0 +of 0 +the 0 +long 0 +form 0 +of 0 +prolactin 0 +receptors 0 +( 0 +PRL 0 +- 0 +R 0 +) 0 +and 0 +components 0 +of 0 +prolactin 0 +' 0 +s 0 +signaling 0 +pathway 0 +. 0 +To 0 +test 0 +the 0 +hypothesis 0 +that 0 +estrogen 1 +increases 0 +PRL 0 +- 0 +R 0 +expression 0 +and 0 +sensitivity 0 +to 0 +prolactin 0 +"," 0 +we 0 +next 0 +demonstrated 0 +that 0 +estradiol 1 +greatly 0 +augments 0 +prolactin 0 +- 0 +induced 0 +STAT5 0 +activation 0 +. 0 +Lastly 0 +"," 0 +we 0 +measured 0 +PRL 0 +- 0 +R 0 +and 0 +suppressor 0 +of 0 +cytokine 0 +signaling 0 +( 0 +S0CS 0 +- 0 +1 0 +and 0 +- 0 +3 0 +and 0 +CIS 0 +"," 0 +which 0 +reflect 0 +the 0 +level 0 +of 0 +prolactin 0 +signaling 0 +) 0 +mRNAs 0 +in 0 +response 0 +to 0 +sulpiride 1 +and 0 +estradiol 1 +. 0 +Sulpiride 1 +induced 0 +only 0 +S0CS 0 +- 0 +1 0 +in 0 +the 0 +medial 0 +preoptic 0 +area 0 +"," 0 +where 0 +GnRH 0 +neurons 0 +are 0 +regulated 0 +"," 0 +but 0 +in 0 +the 0 +arcuate 0 +nucleus 0 +and 0 +choroid 0 +plexus 0 +"," 0 +PRL 0 +- 0 +R 0 +"," 0 +S0CS 0 +- 0 +3 0 +"," 0 +and 0 +CIS 0 +mRNA 0 +levels 0 +were 0 +also 0 +induced 0 +. 0 +Estradiol 1 +enhanced 0 +these 0 +effects 0 +on 0 +S0CS 0 +- 0 +3 0 +and 0 +CIS 0 +. 0 +Interestingly 0 +"," 0 +estradiol 1 +also 0 +induced 0 +PRL 0 +- 0 +R 0 +"," 0 +S0CS 0 +- 0 +3 0 +"," 0 +and 0 +CIS 0 +mRNA 0 +levels 0 +independently 0 +. 0 +These 0 +data 0 +show 0 +that 0 +GnRH 0 +pulse 0 +frequency 0 +is 0 +inhibited 0 +by 0 +chronic 0 +hyperprolactinemia 3 +in 0 +a 0 +steroid 1 +- 0 +dependent 0 +manner 0 +. 0 +They 0 +also 0 +provide 0 +evidence 0 +for 0 +estradiol 1 +- 0 +dependent 0 +and 0 +brain 0 +region 0 +- 0 +specific 0 +regulation 0 +of 0 +PRL 0 +- 0 +R 0 +expression 0 +and 0 +signaling 0 +responses 0 +by 0 +prolactin 0 +. 0 +Clonidine 1 +for 0 +attention 3 +- 4 +deficit 4 +/ 4 +hyperactivity 4 +disorder 4 +: 0 +II 0 +. 0 +ECG 0 +changes 0 +and 0 +adverse 0 +events 0 +analysis 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +examine 0 +the 0 +safety 0 +and 0 +tolerability 0 +of 0 +clonidine 1 +used 0 +alone 0 +or 0 +with 0 +methylphenidate 1 +in 0 +children 0 +with 0 +attention 3 +- 4 +deficit 4 +/ 4 +hyperactivity 4 +disorder 4 +( 0 +ADHD 3 +) 0 +. 0 +METH0D 0 +: 0 +In 0 +a 0 +16 0 +- 0 +week 0 +multicenter 0 +"," 0 +double 0 +- 0 +blind 0 +trial 0 +"," 0 +122 0 +children 0 +with 0 +ADHD 3 +were 0 +randomly 0 +assigned 0 +to 0 +clonidine 1 +( 0 +n 0 += 0 +31 0 +) 0 +"," 0 +methylphenidate 1 +( 0 +n 0 += 0 +29 0 +) 0 +"," 0 +clonidine 1 +and 0 +methylphenidate 1 +( 0 +n 0 += 0 +32 0 +) 0 +"," 0 +or 0 +placebo 0 +( 0 +n 0 += 0 +30 0 +) 0 +. 0 +Doses 0 +were 0 +flexibly 0 +titrated 0 +up 0 +to 0 +0 0 +. 0 +6 0 +mg 0 +/ 0 +day 0 +for 0 +clonidine 1 +and 0 +60 0 +mg 0 +/ 0 +day 0 +for 0 +methylphenidate 1 +( 0 +both 0 +with 0 +divided 0 +dosing 0 +) 0 +. 0 +Groups 0 +were 0 +compared 0 +regarding 0 +adverse 0 +events 0 +and 0 +changes 0 +from 0 +baseline 0 +to 0 +week 0 +16 0 +in 0 +electrocardiograms 0 +and 0 +vital 0 +signs 0 +. 0 +RESULTS 0 +: 0 +There 0 +were 0 +more 0 +incidents 0 +of 0 +bradycardia 3 +in 0 +subjects 0 +treated 0 +with 0 +clonidine 1 +compared 0 +with 0 +those 0 +not 0 +treated 0 +with 0 +clonidine 1 +( 0 +17 0 +. 0 +5 0 +% 0 +versus 0 +3 0 +. 0 +4 0 +% 0 +; 0 +p 0 += 0 +. 0 +2 0 +) 0 +"," 0 +but 0 +no 0 +other 0 +significant 0 +group 0 +differences 0 +regarding 0 +electrocardiogram 0 +and 0 +other 0 +cardiovascular 0 +outcomes 0 +. 0 +There 0 +were 0 +no 0 +suggestions 0 +of 0 +interactions 0 +between 0 +clonidine 1 +and 0 +methylphenidate 1 +regarding 0 +cardiovascular 0 +outcomes 0 +. 0 +Moderate 0 +or 0 +severe 0 +adverse 0 +events 0 +were 0 +more 0 +common 0 +in 0 +subjects 0 +on 0 +clonidine 1 +( 0 +79 0 +. 0 +4 0 +% 0 +versus 0 +49 0 +. 0 +2 0 +% 0 +; 0 +p 0 += 0 +. 0 +6 0 +) 0 +but 0 +not 0 +associated 0 +with 0 +higher 0 +rates 0 +of 0 +early 0 +study 0 +withdrawal 0 +. 0 +Drowsiness 3 +was 0 +common 0 +on 0 +clonidine 1 +"," 0 +but 0 +generally 0 +resolved 0 +by 0 +6 0 +to 0 +8 0 +weeks 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Clonidine 1 +"," 0 +used 0 +alone 0 +or 0 +with 0 +methylphenidate 1 +"," 0 +appears 0 +safe 0 +and 0 +well 0 +tolerated 0 +in 0 +childhood 0 +ADHD 3 +. 0 +Physicians 0 +prescribing 0 +clonidine 1 +should 0 +monitor 0 +for 0 +bradycardia 3 +and 0 +advise 0 +patients 0 +about 0 +the 0 +high 0 +likelihood 0 +of 0 +initial 0 +drowsiness 3 +. 0 +Renal 3 +Fanconi 4 +syndrome 4 +and 0 +myopathy 3 +after 0 +liver 0 +transplantation 0 +: 0 +drug 0 +- 0 +related 0 +mitochondrial 3 +cytopathy 4 +? 0 +Advances 0 +in 0 +the 0 +field 0 +of 0 +transplantation 0 +provide 0 +a 0 +better 0 +quality 0 +of 0 +life 0 +and 0 +allow 0 +more 0 +favorable 0 +conditions 0 +for 0 +growth 0 +and 0 +development 0 +in 0 +children 0 +. 0 +However 0 +"," 0 +combinations 0 +of 0 +different 0 +therapeutic 0 +regimens 0 +require 0 +consideration 0 +of 0 +potential 0 +adverse 0 +reactions 0 +. 0 +We 0 +describe 0 +a 0 +15 0 +- 0 +yr 0 +- 0 +old 0 +girl 0 +who 0 +had 0 +orthotopic 0 +liver 0 +transplantation 0 +because 0 +of 0 +Wilson 3 +' 4 +s 4 +disease 4 +. 0 +Tacrolimus 1 +"," 0 +MMF 1 +"," 0 +and 0 +steroids 1 +were 0 +given 0 +as 0 +immunosuppressant 0 +. 0 +Lamivudine 1 +was 0 +added 0 +because 0 +of 0 +de 0 +nova 0 +hepatitis 3 +B 4 +infection 4 +during 0 +her 0 +follow 0 +- 0 +up 0 +. 0 +Three 0 +yr 0 +after 0 +transplantation 0 +she 0 +developed 0 +renal 3 +Fanconi 4 +syndrome 4 +with 0 +severe 0 +metabolic 3 +acidosis 4 +"," 0 +hypophosphatemia 3 +"," 0 +glycosuria 3 +"," 0 +and 0 +aminoaciduria 3 +. 0 +Although 0 +tacrolimus 1 +was 0 +suspected 0 +to 0 +be 0 +the 0 +cause 0 +of 0 +late 0 +post 0 +- 0 +transplant 0 +renal 0 +acidosis 3 +and 0 +was 0 +replaced 0 +by 0 +sirolimus 1 +"," 0 +acidosis 3 +"," 0 +and 0 +electrolyte 0 +imbalance 0 +got 0 +worse 0 +. 0 +Proximal 0 +muscle 3 +weakness 4 +has 0 +developed 0 +during 0 +her 0 +follow 0 +- 0 +up 0 +. 0 +Fanconi 3 +syndrome 4 +"," 0 +as 0 +well 0 +as 0 +myopathy 3 +"," 0 +is 0 +well 0 +recognized 0 +in 0 +patients 0 +with 0 +mitochondrial 3 +disorders 4 +and 0 +caused 0 +by 0 +depletion 0 +of 0 +mtDNA 0 +. 0 +We 0 +suggest 0 +that 0 +our 0 +patient 0 +' 0 +s 0 +tubular 3 +dysfunction 4 +and 0 +myopathy 3 +may 0 +have 0 +resulted 0 +from 0 +mitochondrial 3 +dysfunction 4 +which 0 +is 0 +triggered 0 +by 0 +tacrolimus 1 +and 0 +augmented 0 +by 0 +lamivudine 1 +. 0 +Higher 0 +optical 0 +density 0 +of 0 +an 0 +antigen 0 +assay 0 +predicts 0 +thrombosis 3 +in 0 +patients 0 +with 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +. 0 +0BJECTIVES 0 +: 0 +To 0 +correlate 0 +optical 0 +density 0 +and 0 +percent 0 +inhibition 0 +of 0 +a 0 +two 0 +- 0 +step 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +( 0 +HIT 3 +) 0 +antigen 0 +assay 0 +with 0 +thrombosis 3 +; 0 +the 0 +assay 0 +utilizes 0 +reaction 0 +inhibition 0 +characteristics 0 +of 0 +a 0 +high 0 +heparin 1 +concentration 0 +. 0 +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Patients 0 +with 0 +more 0 +than 0 +50 0 +% 0 +decrease 0 +in 0 +platelet 0 +count 0 +or 0 +thrombocytopenia 3 +( 0 +< 0 +150 0 +x 0 +10 0 +( 0 +9 0 +) 0 +/ 0 +L 0 +) 0 +after 0 +exposure 0 +to 0 +heparin 1 +"," 0 +who 0 +had 0 +a 0 +positive 0 +two 0 +- 0 +step 0 +antigen 0 +assay 0 +[ 0 +optical 0 +density 0 +( 0 +0D 0 +) 0 +> 0 +0 0 +. 0 +4 0 +and 0 +> 0 +50 0 +inhibition 0 +with 0 +high 0 +concentration 0 +of 0 +heparin 1 +] 0 +were 0 +included 0 +in 0 +the 0 +study 0 +. 0 +RESULTS 0 +: 0 +Forty 0 +of 0 +94 0 +HIT 3 +patients 0 +had 0 +thrombosis 3 +at 0 +diagnosis 0 +; 0 +54 0 +/ 0 +94 0 +had 0 +isolated 0 +- 0 +HIT 3 +without 0 +thrombosis 3 +. 0 +Eight 0 +of 0 +the 0 +isolated 0 +- 0 +HIT 3 +patients 0 +developed 0 +thrombosis 3 +within 0 +the 0 +next 0 +30 0 +d 0 +; 0 +thus 0 +"," 0 +a 0 +total 0 +of 0 +48 0 +patients 0 +had 0 +thrombosis 3 +at 0 +day 0 +30 0 +. 0 +At 0 +diagnosis 0 +there 0 +was 0 +no 0 +significant 0 +difference 0 +in 0 +0D 0 +between 0 +HIT 3 +patients 0 +with 0 +thrombosis 3 +and 0 +those 0 +with 0 +isolated 0 +- 0 +HIT 3 +. 0 +However 0 +"," 0 +0D 0 +was 0 +significantly 0 +higher 0 +in 0 +all 0 +patients 0 +with 0 +thrombosis 3 +( 0 +n 0 += 0 +48 0 +"," 0 +1 0 +. 0 +34 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +89 0 +) 0 +"," 0 +including 0 +isolated 0 +- 0 +HIT 3 +patients 0 +who 0 +later 0 +developed 0 +thrombosis 3 +within 0 +30 0 +d 0 +( 0 +n 0 += 0 +8 0 +"," 0 +1 0 +. 0 +84 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +64 0 +) 0 +as 0 +compared 0 +to 0 +isolated 0 +- 0 +HIT 3 +patients 0 +who 0 +did 0 +not 0 +develop 0 +thrombosis 3 +( 0 +0 0 +. 0 +96 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +75 0 +; 0 +P 0 += 0 +0 0 +. 0 +11 0 +and 0 +P 0 += 0 +0 0 +. 0 +8 0 +) 0 +. 0 +The 0 +Receiver 0 +0perative 0 +Characteristic 0 +Curve 0 +showed 0 +that 0 +0D 0 +> 0 +1 0 +. 0 +27 0 +in 0 +the 0 +isolated 0 +- 0 +HIT 3 +group 0 +had 0 +a 0 +significantly 0 +higher 0 +chance 0 +of 0 +developing 0 +thrombosis 3 +by 0 +day 0 +30 0 +. 0 +None 0 +of 0 +these 0 +groups 0 +showed 0 +significant 0 +difference 0 +in 0 +percent 0 +inhibition 0 +. 0 +Multivariate 0 +analysis 0 +showed 0 +a 0 +2 0 +. 0 +8 0 +- 0 +fold 0 +increased 0 +risk 0 +of 0 +thrombosis 3 +in 0 +females 0 +. 0 +Similarly 0 +"," 0 +thrombotic 3 +risk 0 +increased 0 +with 0 +age 0 +and 0 +0D 0 +values 0 +. 0 +C0NCLUSI0N 0 +: 0 +Higher 0 +0D 0 +is 0 +associated 0 +with 0 +significant 0 +risk 0 +of 0 +subsequent 0 +thrombosis 3 +in 0 +patients 0 +with 0 +isolated 0 +- 0 +HIT 3 +; 0 +percent 0 +inhibition 0 +"," 0 +however 0 +"," 0 +was 0 +not 0 +predictive 0 +. 0 +Thalidomide 1 +has 0 +limited 0 +single 0 +- 0 +agent 0 +activity 0 +in 0 +relapsed 0 +or 0 +refractory 0 +indolent 0 +non 3 +- 4 +Hodgkin 4 +lymphomas 4 +: 0 +a 0 +phase 0 +II 0 +trial 0 +of 0 +the 0 +Cancer 3 +and 0 +Leukemia 3 +Group 0 +B 0 +. 0 +Thalidomide 1 +is 0 +an 0 +immunomodulatory 0 +agent 0 +with 0 +demonstrated 0 +activity 0 +in 0 +multiple 3 +myeloma 4 +"," 0 +mantle 3 +cell 4 +lymphoma 4 +and 0 +lymphoplasmacytic 3 +lymphoma 4 +. 0 +Its 0 +activity 0 +is 0 +believed 0 +to 0 +be 0 +due 0 +modulation 0 +of 0 +the 0 +tumour 3 +milieu 0 +"," 0 +including 0 +downregulation 0 +of 0 +angiogenesis 0 +and 0 +inflammatory 0 +cytokines 0 +. 0 +Between 0 +July 0 +2001 0 +and 0 +April 0 +2004 0 +"," 0 +24 0 +patients 0 +with 0 +relapsed 0 +/ 0 +refractory 0 +indolent 0 +lymphomas 3 +received 0 +thalidomide 1 +200 0 +mg 0 +daily 0 +with 0 +escalation 0 +by 0 +100 0 +mg 0 +daily 0 +every 0 +1 0 +- 0 +2 0 +weeks 0 +as 0 +tolerated 0 +"," 0 +up 0 +to 0 +a 0 +maximum 0 +of 0 +800 0 +mg 0 +daily 0 +. 0 +Patients 0 +had 0 +received 0 +a 0 +median 0 +of 0 +2 0 +( 0 +range 0 +"," 0 +1 0 +- 0 +4 0 +) 0 +prior 0 +regimens 0 +. 0 +0f 0 +24 0 +evaluable 0 +patients 0 +"," 0 +two 0 +achieved 0 +a 0 +complete 0 +remission 0 +and 0 +one 0 +achieved 0 +a 0 +partial 0 +remission 0 +for 0 +an 0 +overall 0 +response 0 +rate 0 +of 0 +12 0 +. 0 +5 0 +% 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +: 0 +2 0 +. 0 +6 0 +- 0 +32 0 +. 0 +4 0 +% 0 +) 0 +. 0 +Eleven 0 +patients 0 +progressed 0 +during 0 +therapy 0 +. 0 +Grade 0 +3 0 +- 0 +4 0 +adverse 0 +effects 0 +included 0 +myelosuppression 3 +"," 0 +fatigue 3 +"," 0 +somnolence 3 +/ 0 +depressed 3 +mood 4 +"," 0 +neuropathy 3 +and 0 +dyspnea 3 +. 0 +0f 0 +concern 0 +was 0 +the 0 +occurrence 0 +of 0 +four 0 +thromboembolic 3 +events 0 +. 0 +0ur 0 +results 0 +failed 0 +to 0 +demonstrate 0 +an 0 +important 0 +response 0 +rate 0 +to 0 +single 0 +agent 0 +thalidomide 1 +in 0 +indolent 0 +lymphomas 3 +and 0 +contrast 0 +with 0 +the 0 +higher 0 +activity 0 +level 0 +reported 0 +with 0 +the 0 +second 0 +generation 0 +immunomodulatory 0 +agent 0 +"," 0 +lenalidomide 1 +. 0 +Sex 0 +differences 0 +in 0 +NMDA 1 +antagonist 0 +enhancement 0 +of 0 +morphine 1 +antihyperalgesia 0 +in 0 +a 0 +capsaicin 1 +model 0 +of 0 +persistent 0 +pain 3 +: 0 +comparisons 0 +to 0 +two 0 +models 0 +of 0 +acute 3 +pain 4 +. 0 +In 0 +acute 3 +pain 4 +models 0 +"," 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +antagonists 0 +enhance 0 +the 0 +antinociceptive 0 +effects 0 +of 0 +morphine 1 +to 0 +a 0 +greater 0 +extent 0 +in 0 +males 0 +than 0 +females 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +investigation 0 +was 0 +to 0 +extend 0 +these 0 +findings 0 +to 0 +a 0 +persistent 0 +pain 3 +model 0 +which 0 +could 0 +be 0 +distinguished 0 +from 0 +acute 3 +pain 4 +models 0 +on 0 +the 0 +basis 0 +of 0 +the 0 +nociceptive 0 +fibers 0 +activated 0 +"," 0 +neurochemical 0 +substrates 0 +"," 0 +and 0 +duration 0 +of 0 +the 0 +nociceptive 0 +stimulus 0 +. 0 +To 0 +this 0 +end 0 +"," 0 +persistent 0 +hyperalgesia 3 +was 0 +induced 0 +by 0 +administration 0 +of 0 +capsaicin 1 +in 0 +the 0 +tail 0 +of 0 +gonadally 0 +intact 0 +F344 0 +rats 0 +"," 0 +following 0 +which 0 +the 0 +tail 0 +was 0 +immersed 0 +in 0 +a 0 +mildly 0 +noxious 0 +thermal 0 +stimulus 0 +"," 0 +and 0 +tail 0 +- 0 +withdrawal 0 +latencies 0 +measured 0 +. 0 +For 0 +comparison 0 +"," 0 +tests 0 +were 0 +conducted 0 +in 0 +two 0 +acute 3 +pain 4 +models 0 +"," 0 +the 0 +hotplate 0 +and 0 +warm 0 +water 0 +tail 0 +- 0 +withdrawal 0 +procedures 0 +. 0 +In 0 +males 0 +"," 0 +the 0 +non 0 +- 0 +competitive 0 +NMDA 1 +antagonist 0 +dextromethorphan 1 +enhanced 0 +the 0 +antihyperalgesic 0 +effect 0 +of 0 +low 0 +to 0 +moderate 0 +doses 0 +of 0 +morphine 1 +in 0 +a 0 +dose 0 +- 0 +and 0 +time 0 +- 0 +dependent 0 +manner 0 +. 0 +Across 0 +the 0 +doses 0 +and 0 +pretreatment 0 +times 0 +examined 0 +"," 0 +enhancement 0 +was 0 +not 0 +observed 0 +in 0 +females 0 +. 0 +Enhancement 0 +of 0 +morphine 1 +antinociception 0 +by 0 +dextromethorphan 1 +was 0 +seen 0 +in 0 +both 0 +males 0 +and 0 +females 0 +in 0 +the 0 +acute 3 +pain 4 +models 0 +"," 0 +with 0 +the 0 +magnitude 0 +of 0 +this 0 +effect 0 +being 0 +greater 0 +in 0 +males 0 +. 0 +These 0 +findings 0 +demonstrate 0 +a 0 +sexually 0 +- 0 +dimorphic 0 +interaction 0 +between 0 +NMDA 1 +antagonists 0 +and 0 +morphine 1 +in 0 +a 0 +persistent 0 +pain 3 +model 0 +that 0 +can 0 +be 0 +distinguished 0 +from 0 +those 0 +observed 0 +in 0 +acute 3 +pain 4 +models 0 +. 0 +Development 0 +of 0 +proteinuria 3 +after 0 +switch 0 +to 0 +sirolimus 1 +- 0 +based 0 +immunosuppression 0 +in 0 +long 0 +- 0 +term 0 +cardiac 0 +transplant 0 +patients 0 +. 0 +Calcineurin 0 +- 0 +inhibitor 0 +therapy 0 +can 0 +lead 0 +to 0 +renal 3 +dysfunction 4 +in 0 +heart 0 +transplantation 0 +patients 0 +. 0 +The 0 +novel 0 +immunosuppressive 0 +( 0 +IS 0 +) 0 +drug 0 +sirolmus 1 +( 0 +Srl 1 +) 0 +lacks 0 +nephrotoxic 3 +effects 0 +; 0 +however 0 +"," 0 +proteinuria 3 +associated 0 +with 0 +Srl 1 +has 0 +been 0 +reported 0 +following 0 +renal 0 +transplantation 0 +. 0 +In 0 +cardiac 0 +transplantation 0 +"," 0 +the 0 +incidence 0 +of 0 +proteinuria 3 +associated 0 +with 0 +Srl 1 +is 0 +unknown 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +long 0 +- 0 +term 0 +cardiac 0 +transplant 0 +patients 0 +were 0 +switched 0 +from 0 +cyclosporine 1 +to 0 +Srl 1 +- 0 +based 0 +IS 0 +. 0 +Concomitant 0 +IS 0 +consisted 0 +of 0 +mycophenolate 1 +mofetil 2 ++ 0 +/ 0 +- 0 +steroids 1 +. 0 +Proteinuria 0 +increased 0 +significantly 0 +from 0 +a 0 +median 0 +of 0 +0 0 +. 0 +13 0 +g 0 +/ 0 +day 0 +( 0 +range 0 +0 0 +- 0 +5 0 +. 0 +7 0 +) 0 +preswitch 0 +to 0 +0 0 +. 0 +23 0 +g 0 +/ 0 +day 0 +( 0 +0 0 +- 0 +9 0 +. 0 +88 0 +) 0 +at 0 +24 0 +months 0 +postswitch 0 +( 0 +p 0 += 0 +0 0 +. 0 +24 0 +) 0 +. 0 +Before 0 +the 0 +switch 0 +"," 0 +11 0 +. 0 +5 0 +% 0 +of 0 +patients 0 +had 0 +high 0 +- 0 +grade 0 +proteinuria 3 +( 0 +> 0 +1 0 +. 0 +0 0 +g 0 +/ 0 +day 0 +) 0 +; 0 +this 0 +increased 0 +to 0 +22 0 +. 0 +9 0 +% 0 +postswitch 0 +( 0 +p 0 += 0 +0 0 +. 0 +6 0 +) 0 +. 0 +ACE 1 +inhibitor 2 +and 0 +angiotensin 1 +- 2 +releasing 2 +blocker 2 +( 0 +ARB 1 +) 0 +therapy 0 +reduced 0 +proteinuria 3 +development 0 +. 0 +Patients 0 +without 0 +proteinuria 3 +had 0 +increased 0 +renal 0 +function 0 +( 0 +median 0 +42 0 +. 0 +5 0 +vs 0 +. 0 +64 0 +. 0 +1 0 +"," 0 +p 0 += 0 +0 0 +. 0 +25 0 +) 0 +"," 0 +whereas 0 +patients 0 +who 0 +developed 0 +high 0 +- 0 +grade 0 +proteinuria 3 +showed 0 +decreased 0 +renal 0 +function 0 +at 0 +the 0 +end 0 +of 0 +follow 0 +- 0 +up 0 +( 0 +median 0 +39 0 +. 0 +6 0 +vs 0 +. 0 +29 0 +. 0 +2 0 +"," 0 +p 0 += 0 +0 0 +. 0 +125 0 +) 0 +. 0 +Thus 0 +"," 0 +proteinuria 3 +may 0 +develop 0 +in 0 +cardiac 0 +transplant 0 +patients 0 +after 0 +switch 0 +to 0 +Srl 1 +"," 0 +which 0 +may 0 +have 0 +an 0 +adverse 0 +effect 0 +on 0 +renal 0 +function 0 +in 0 +these 0 +patients 0 +. 0 +Srl 1 +should 0 +be 0 +used 0 +with 0 +ACEi 1 +/ 0 +ARB 1 +therapy 0 +and 0 +patients 0 +monitored 0 +for 0 +proteinuria 3 +and 0 +increased 0 +renal 3 +dysfunction 4 +. 0 +Ginsenoside 1 +Rg1 2 +restores 0 +the 0 +impairment 3 +of 4 +learning 4 +induced 0 +by 0 +chronic 0 +morphine 1 +administration 0 +in 0 +rats 0 +. 0 +Rg1 1 +"," 0 +as 0 +a 0 +ginsenoside 1 +extracted 0 +from 0 +Panax 0 +ginseng 0 +"," 0 +could 0 +ameliorate 0 +spatial 0 +learning 3 +impairment 4 +. 0 +Previous 0 +studies 0 +have 0 +demonstrated 0 +that 0 +Rg1 1 +might 0 +be 0 +a 0 +useful 0 +agent 0 +for 0 +the 0 +prevention 0 +and 0 +treatment 0 +of 0 +the 0 +adverse 0 +effects 0 +of 0 +morphine 1 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +effect 0 +of 0 +Rg1 1 +on 0 +learning 3 +impairment 4 +by 0 +chronic 0 +morphine 1 +administration 0 +and 0 +the 0 +mechanism 0 +responsible 0 +for 0 +this 0 +effect 0 +. 0 +Male 0 +rats 0 +were 0 +subcutaneously 0 +injected 0 +with 0 +morphine 1 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +twice 0 +a 0 +day 0 +at 0 +12 0 +hour 0 +intervals 0 +for 0 +10 0 +days 0 +"," 0 +and 0 +Rg1 1 +( 0 +30 0 +mg 0 +/ 0 +kg 0 +) 0 +was 0 +intraperitoneally 0 +injected 0 +2 0 +hours 0 +after 0 +the 0 +second 0 +injection 0 +of 0 +morphine 1 +once 0 +a 0 +day 0 +for 0 +10 0 +days 0 +. 0 +Spatial 0 +learning 0 +capacity 0 +was 0 +assessed 0 +in 0 +the 0 +Morris 0 +water 0 +maze 0 +. 0 +The 0 +results 0 +showed 0 +that 0 +rats 0 +treated 0 +with 0 +Morphine 1 +/ 0 +Rg1 1 +decreased 0 +escape 0 +latency 0 +and 0 +increased 0 +the 0 +time 0 +spent 0 +in 0 +platform 0 +quadrant 0 +and 0 +entering 0 +frequency 0 +. 0 +By 0 +implantation 0 +of 0 +electrodes 0 +and 0 +electrophysiological 0 +recording 0 +in 0 +vivo 0 +"," 0 +the 0 +results 0 +showed 0 +that 0 +Rg1 1 +restored 0 +the 0 +long 0 +- 0 +term 0 +potentiation 0 +( 0 +LTP 0 +) 0 +impaired 0 +by 0 +morphine 1 +in 0 +both 0 +freely 0 +moving 0 +and 0 +anaesthetised 0 +rats 0 +. 0 +The 0 +electrophysiological 0 +recording 0 +in 0 +vitro 0 +showed 0 +that 0 +Rg1 1 +restored 0 +the 0 +LTP 0 +in 0 +slices 0 +from 0 +the 0 +rats 0 +treated 0 +with 0 +morphine 1 +"," 0 +but 0 +not 0 +changed 0 +LTP 0 +in 0 +the 0 +slices 0 +from 0 +normal 0 +saline 0 +- 0 +or 0 +morphine 1 +/ 0 +Rg1 1 +- 0 +treated 0 +rats 0 +; 0 +this 0 +restoration 0 +could 0 +be 0 +inhibited 0 +by 0 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +antagonist 0 +MK801 1 +. 0 +We 0 +conclude 0 +that 0 +Rg1 1 +may 0 +significantly 0 +improve 0 +the 0 +spatial 0 +learning 0 +capacity 0 +impaired 0 +by 0 +chonic 0 +morphine 1 +administration 0 +and 0 +restore 0 +the 0 +morphine 1 +- 0 +inhibited 0 +LTP 0 +. 0 +This 0 +effect 0 +is 0 +NMDA 1 +receptor 0 +dependent 0 +. 0 +Synthesis 0 +of 0 +N 1 +- 2 +pyrimidinyl 2 +- 2 +2 2 +- 2 +phenoxyacetamides 2 +as 0 +adenosine 1 +A2A 0 +receptor 0 +antagonists 0 +. 0 +A 0 +series 0 +of 0 +N 1 +- 2 +pyrimidinyl 2 +- 2 +2 2 +- 2 +phenoxyacetamide 2 +adenosine 1 +A 0 +( 0 +2A 0 +) 0 +antagonists 0 +is 0 +described 0 +. 0 +SAR 0 +studies 0 +led 0 +to 0 +compound 0 +14 0 +with 0 +excellent 0 +potency 0 +( 0 +K 0 +( 0 +i 0 +) 0 += 0 +0 0 +. 0 +4 0 +nM 0 +) 0 +"," 0 +selectivity 0 +( 0 +A 0 +( 0 +1 0 +) 0 +/ 0 +A 0 +( 0 +2A 0 +) 0 +> 0 +100 0 +) 0 +"," 0 +and 0 +efficacy 0 +( 0 +MED 0 +10 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +in 0 +the 0 +rat 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +model 0 +for 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 +Evidence 0 +for 0 +an 0 +involvement 0 +of 0 +D1 0 +and 0 +D2 0 +dopamine 1 +receptors 0 +in 0 +mediating 0 +nicotine 1 +- 0 +induced 0 +hyperactivity 3 +in 0 +rats 0 +. 0 +Previous 0 +studies 0 +have 0 +suggested 0 +that 0 +repeated 0 +exposure 0 +of 0 +rats 0 +to 0 +the 0 +drug 0 +or 0 +to 0 +the 0 +experimental 0 +environment 0 +is 0 +necessary 0 +to 0 +observe 0 +nicotine 1 +- 0 +induced 0 +locomotor 0 +stimulation 0 +. 0 +In 0 +the 0 +present 0 +study 0 +the 0 +role 0 +of 0 +habituation 0 +to 0 +the 0 +experimental 0 +environment 0 +on 0 +the 0 +stimulant 0 +effect 0 +of 0 +nicotine 1 +in 0 +rats 0 +was 0 +examined 0 +. 0 +In 0 +addition 0 +"," 0 +the 0 +role 0 +of 0 +dopamine 1 +receptors 0 +in 0 +mediating 0 +nicotine 1 +- 0 +induced 0 +locomotor 0 +stimulation 0 +was 0 +investigated 0 +by 0 +examining 0 +the 0 +effects 0 +of 0 +selective 0 +D1 0 +and 0 +D2 0 +dopamine 1 +receptor 0 +antagonists 0 +on 0 +activity 0 +induced 0 +by 0 +nicotine 1 +. 0 +Locomotor 0 +activity 0 +was 0 +assessed 0 +in 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +tested 0 +in 0 +photocell 0 +cages 0 +. 0 +Nicotine 1 +( 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +) 0 +caused 0 +a 0 +significant 0 +increase 3 +in 4 +locomotor 4 +activity 4 +in 0 +rats 0 +that 0 +were 0 +habituated 0 +to 0 +the 0 +test 0 +environment 0 +"," 0 +but 0 +had 0 +only 0 +a 0 +weak 0 +and 0 +delayed 0 +stimulant 0 +action 0 +in 0 +rats 0 +that 0 +were 0 +unfamiliar 0 +with 0 +the 0 +test 0 +environment 0 +. 0 +The 0 +stimulant 0 +action 0 +of 0 +nicotine 1 +was 0 +blocked 0 +by 0 +the 0 +central 0 +nicotinic 0 +antagonist 0 +mecamylamine 1 +but 0 +not 0 +by 0 +the 0 +peripheral 0 +nicotinic 0 +blocker 0 +hexamethonium 1 +"," 0 +indicating 0 +that 0 +the 0 +response 0 +is 0 +probably 0 +mediated 0 +by 0 +central 0 +nicotinic 0 +receptors 0 +. 0 +Nicotine 1 +- 0 +induced 0 +hyperactivity 3 +was 0 +blocked 0 +by 0 +the 0 +selective 0 +D1 0 +antagonist 0 +SCH 1 +23390 2 +"," 0 +the 0 +selective 0 +D2 0 +antagonist 0 +raclopride 1 +and 0 +the 0 +D1 0 +/ 0 +D2 0 +antagonist 0 +fluphenazine 1 +. 0 +Pretreatment 0 +with 0 +the 0 +D2 0 +agonist 0 +PHN0 1 +enhanced 0 +nicotine 1 +- 0 +induced 0 +hyperactivity 3 +"," 0 +whereas 0 +the 0 +D1 0 +agonist 0 +SKF 1 +38393 2 +had 0 +no 0 +effect 0 +. 0 +The 0 +results 0 +indicate 0 +that 0 +acute 0 +nicotine 1 +injection 0 +induces 0 +a 0 +pronounced 0 +hyperactivity 3 +in 0 +rats 0 +habituated 0 +to 0 +the 0 +test 0 +environment 0 +. 0 +The 0 +effect 0 +appears 0 +to 0 +be 0 +mediated 0 +by 0 +central 0 +nicotine 1 +receptors 0 +"," 0 +possibly 0 +located 0 +on 0 +dopaminergic 0 +neurons 0 +"," 0 +and 0 +also 0 +requires 0 +the 0 +activation 0 +of 0 +both 0 +D1 0 +and 0 +D2 0 +dopamine 1 +receptors 0 +. 0 +Central 0 +retinal 3 +vein 4 +occlusion 4 +associated 0 +with 0 +clomiphene 1 +- 0 +induced 0 +ovulation 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +central 0 +retinal 3 +vein 4 +occlusion 4 +associated 0 +with 0 +clomiphene 1 +citrate 2 +( 0 +CC 1 +) 0 +. 0 +DESIGN 0 +: 0 +Case 0 +study 0 +. 0 +SETTING 0 +: 0 +0phthalmology 0 +clinic 0 +of 0 +an 0 +academic 0 +hospital 0 +. 0 +PATIENT 0 +( 0 +S 0 +) 0 +: 0 +A 0 +36 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +referred 0 +from 0 +the 0 +infertility 3 +clinic 0 +for 0 +blurred 3 +vision 4 +. 0 +INTERVENTI0N 0 +( 0 +S 0 +) 0 +: 0 +0phthalmic 0 +examination 0 +after 0 +CC 1 +therapy 0 +. 0 +MAIN 0 +0UTC0ME 0 +MEASURE 0 +( 0 +S 0 +) 0 +: 0 +Central 0 +retinal 3 +vein 4 +occlusion 4 +after 0 +ovulation 0 +induction 0 +with 0 +CC 1 +. 0 +RESULT 0 +( 0 +S 0 +) 0 +: 0 +A 0 +36 0 +- 0 +year 0 +- 0 +old 0 +Chinese 0 +woman 0 +developed 0 +central 0 +retinal 3 +vein 4 +occlusion 4 +after 0 +eight 0 +courses 0 +of 0 +CC 1 +. 0 +A 0 +search 0 +of 0 +the 0 +literature 0 +on 0 +the 0 +thromboembolic 3 +complications 0 +of 0 +CC 1 +does 0 +not 0 +include 0 +this 0 +severe 0 +ophthalmic 0 +complication 0 +"," 0 +although 0 +mild 0 +visual 3 +disturbance 4 +after 0 +CC 1 +intake 0 +is 0 +not 0 +uncommon 0 +. 0 +C0NCLUSI0N 0 +( 0 +S 0 +) 0 +: 0 +This 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +central 0 +retinal 3 +vein 4 +occlusion 4 +after 0 +treatment 0 +with 0 +CC 1 +. 0 +Extra 0 +caution 0 +is 0 +warranted 0 +in 0 +treating 0 +infertility 3 +patients 0 +with 0 +CC 1 +"," 0 +and 0 +patients 0 +should 0 +be 0 +well 0 +informed 0 +of 0 +this 0 +side 0 +effect 0 +before 0 +commencement 0 +of 0 +therapy 0 +. 0 +Acute 0 +bronchodilating 0 +effects 0 +of 0 +ipratropium 1 +bromide 2 +and 0 +theophylline 1 +in 0 +chronic 3 +obstructive 4 +pulmonary 4 +disease 4 +. 0 +The 0 +bronchodilator 0 +effects 0 +of 0 +a 0 +single 0 +dose 0 +of 0 +ipratropium 1 +bromide 2 +aerosol 0 +( 0 +36 0 +micrograms 0 +) 0 +and 0 +short 0 +- 0 +acting 0 +theophylline 1 +tablets 0 +( 0 +dose 0 +titrated 0 +to 0 +produce 0 +serum 0 +levels 0 +of 0 +10 0 +- 0 +20 0 +micrograms 0 +/ 0 +mL 0 +) 0 +were 0 +compared 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +"," 0 +placebo 0 +- 0 +controlled 0 +crossover 0 +study 0 +in 0 +21 0 +patients 0 +with 0 +stable 0 +"," 0 +chronic 3 +obstructive 4 +pulmonary 4 +disease 4 +. 0 +Mean 0 +peak 0 +forced 0 +expiratory 0 +volume 0 +in 0 +1 0 +second 0 +( 0 +FEV1 0 +) 0 +increases 0 +over 0 +baseline 0 +and 0 +the 0 +proportion 0 +of 0 +patients 0 +attaining 0 +at 0 +least 0 +a 0 +15 0 +% 0 +increase 0 +in 0 +the 0 +FEV1 0 +( 0 +responders 0 +) 0 +were 0 +31 0 +% 0 +and 0 +90 0 +% 0 +"," 0 +respectively 0 +"," 0 +for 0 +ipratropium 1 +and 0 +17 0 +% 0 +and 0 +50 0 +% 0 +"," 0 +respectively 0 +"," 0 +for 0 +theophylline 1 +. 0 +The 0 +average 0 +FEV1 0 +increases 0 +during 0 +the 0 +6 0 +- 0 +hour 0 +observation 0 +period 0 +were 0 +18 0 +% 0 +for 0 +ipratropium 1 +and 0 +8 0 +% 0 +for 0 +theophylline 1 +. 0 +The 0 +mean 0 +duration 0 +of 0 +action 0 +was 0 +3 0 +. 0 +8 0 +hours 0 +with 0 +ipratropium 1 +and 0 +2 0 +. 0 +4 0 +hours 0 +with 0 +theophylline 1 +. 0 +While 0 +side 0 +effects 0 +were 0 +rare 0 +"," 0 +those 0 +experienced 0 +after 0 +theophylline 1 +use 0 +did 0 +involve 0 +the 0 +cardiovascular 3 +and 4 +gastrointestinal 4 +systems 4 +. 0 +These 0 +results 0 +show 0 +that 0 +ipratropium 1 +is 0 +a 0 +more 0 +potent 0 +bronchodilator 0 +than 0 +oral 0 +theophylline 1 +in 0 +patients 0 +with 0 +chronic 3 +airflow 4 +obstruction 4 +. 0 +Methamphetamine 1 +- 0 +induced 0 +neurotoxicity 3 +and 0 +microglial 0 +activation 0 +are 0 +not 0 +mediated 0 +by 0 +fractalkine 0 +receptor 0 +signaling 0 +. 0 +Methamphetamine 1 +( 0 +METH 1 +) 0 +damages 0 +dopamine 1 +( 0 +DA 1 +) 0 +nerve 0 +endings 0 +by 0 +a 0 +process 0 +that 0 +has 0 +been 0 +linked 0 +to 0 +microglial 0 +activation 0 +but 0 +the 0 +signaling 0 +pathways 0 +that 0 +mediate 0 +this 0 +response 0 +have 0 +not 0 +yet 0 +been 0 +delineated 0 +. 0 +Cardona 0 +et 0 +al 0 +. 0 +[ 0 +Nat 0 +. 0 +Neurosci 0 +. 0 +9 0 +( 0 +2006 0 +) 0 +"," 0 +917 0 +] 0 +recently 0 +identified 0 +the 0 +microglial 0 +- 0 +specific 0 +fractalkine 0 +receptor 0 +( 0 +CX3CR1 0 +) 0 +as 0 +an 0 +important 0 +mediator 0 +of 0 +MPTP 1 +- 0 +induced 0 +neurodegeneration 3 +of 0 +DA 1 +neurons 0 +. 0 +Because 0 +the 0 +CNS 3 +damage 4 +caused 0 +by 0 +METH 1 +and 0 +MPTP 1 +is 0 +highly 0 +selective 0 +for 0 +the 0 +DA 1 +neuronal 0 +system 0 +in 0 +mouse 0 +models 0 +of 0 +neurotoxicity 3 +"," 0 +we 0 +hypothesized 0 +that 0 +the 0 +CX3CR1 0 +plays 0 +a 0 +role 0 +in 0 +METH 1 +- 0 +induced 0 +neurotoxicity 3 +and 0 +microglial 0 +activation 0 +. 0 +Mice 0 +in 0 +which 0 +the 0 +CX3CR1 0 +gene 0 +has 0 +been 0 +deleted 0 +and 0 +replaced 0 +with 0 +a 0 +cDNA 0 +encoding 0 +enhanced 0 +green 0 +fluorescent 0 +protein 0 +( 0 +eGFP 0 +) 0 +were 0 +treated 0 +with 0 +METH 1 +and 0 +examined 0 +for 0 +striatal 0 +neurotoxicity 3 +. 0 +METH 1 +depleted 0 +DA 1 +"," 0 +caused 0 +microglial 0 +activation 0 +"," 0 +and 0 +increased 0 +body 0 +temperature 0 +in 0 +CX3CR1 0 +knockout 0 +mice 0 +to 0 +the 0 +same 0 +extent 0 +and 0 +over 0 +the 0 +same 0 +time 0 +course 0 +seen 0 +in 0 +wild 0 +- 0 +type 0 +controls 0 +. 0 +The 0 +effects 0 +of 0 +METH 1 +in 0 +CX3CR1 0 +knockout 0 +mice 0 +were 0 +not 0 +gender 0 +- 0 +dependent 0 +and 0 +did 0 +not 0 +extend 0 +beyond 0 +the 0 +striatum 0 +. 0 +Striatal 0 +microglia 0 +expressing 0 +eGFP 0 +constitutively 0 +show 0 +morphological 0 +changes 0 +after 0 +METH 1 +that 0 +are 0 +characteristic 0 +of 0 +activation 0 +. 0 +This 0 +response 0 +was 0 +restricted 0 +to 0 +the 0 +striatum 0 +and 0 +contrasted 0 +sharply 0 +with 0 +unresponsive 0 +eGFP 0 +- 0 +microglia 0 +in 0 +surrounding 0 +brain 0 +areas 0 +that 0 +are 0 +not 0 +damaged 0 +by 0 +METH 1 +. 0 +We 0 +conclude 0 +from 0 +these 0 +studies 0 +that 0 +CX3CR1 0 +signaling 0 +does 0 +not 0 +modulate 0 +METH 1 +neurotoxicity 3 +or 0 +microglial 0 +activation 0 +. 0 +Furthermore 0 +"," 0 +it 0 +appears 0 +that 0 +striatal 0 +- 0 +resident 0 +microglia 0 +respond 0 +to 0 +METH 1 +with 0 +an 0 +activation 0 +cascade 0 +and 0 +then 0 +return 0 +to 0 +a 0 +surveying 0 +state 0 +without 0 +undergoing 0 +apoptosis 0 +or 0 +migration 0 +. 0 +Nicotine 1 +- 0 +induced 0 +nystagmus 3 +correlates 0 +with 0 +midpontine 0 +activation 0 +. 0 +The 0 +pathomechanism 0 +of 0 +nicotine 1 +- 0 +induced 0 +nystagmus 3 +( 0 +NIN 3 +) 0 +is 0 +unknown 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +delineate 0 +brain 0 +structures 0 +that 0 +are 0 +involved 0 +in 0 +NIN 3 +generation 0 +. 0 +Eight 0 +healthy 0 +volunteers 0 +inhaled 0 +nicotine 1 +in 0 +darkness 0 +during 0 +a 0 +functional 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +fMRI 0 +) 0 +experiment 0 +; 0 +eye 0 +movements 0 +were 0 +registered 0 +using 0 +video 0 +- 0 +oculography 0 +. 0 +NIN 3 +correlated 0 +with 0 +blood 0 +oxygen 1 +level 0 +- 0 +dependent 0 +( 0 +B0LD 0 +) 0 +activity 0 +levels 0 +in 0 +a 0 +midpontine 0 +site 0 +in 0 +the 0 +posterior 0 +basis 0 +pontis 0 +. 0 +NIN 3 +- 0 +induced 0 +midpontine 0 +activation 0 +may 0 +correspond 0 +to 0 +activation 0 +of 0 +the 0 +dorsomedial 0 +pontine 0 +nuclei 0 +and 0 +the 0 +nucleus 0 +reticularis 0 +tegmenti 0 +pontis 0 +"," 0 +structures 0 +known 0 +to 0 +participate 0 +in 0 +the 0 +generation 0 +of 0 +multidirectional 0 +saccades 0 +and 0 +smooth 0 +pursuit 0 +eye 0 +movements 0 +. 0 +Acute 0 +effects 0 +of 0 +N 1 +- 2 +( 2 +2 2 +- 2 +propylpentanoyl 2 +) 2 +urea 2 +on 0 +hippocampal 0 +amino 1 +acid 2 +neurotransmitters 0 +in 0 +pilocarpine 1 +- 0 +induced 0 +seizure 3 +in 0 +rats 0 +. 0 +The 0 +present 0 +study 0 +aimed 0 +to 0 +investigate 0 +the 0 +anticonvulsant 0 +activity 0 +as 0 +well 0 +as 0 +the 0 +effects 0 +on 0 +the 0 +level 0 +of 0 +hippocampal 0 +amino 1 +acid 2 +neurotransmitters 0 +( 0 +glutamate 1 +"," 0 +aspartate 1 +"," 0 +glycine 1 +and 0 +GABA 1 +) 0 +of 0 +N 1 +- 2 +( 2 +2 2 +- 2 +propylpentanoyl 2 +) 2 +urea 2 +( 0 +VPU 1 +) 0 +in 0 +comparison 0 +to 0 +its 0 +parent 0 +compound 0 +"," 0 +valproic 1 +acid 2 +( 0 +VPA 1 +) 0 +. 0 +VPU 1 +was 0 +more 0 +potent 0 +than 0 +VPA 1 +"," 0 +exhibiting 0 +the 0 +median 0 +effective 0 +dose 0 +( 0 +ED 0 +( 0 +50 0 +) 0 +) 0 +of 0 +49 0 +mg 0 +/ 0 +kg 0 +in 0 +protecting 0 +rats 0 +against 0 +pilocarpine 1 +- 0 +induced 0 +seizure 3 +whereas 0 +the 0 +corresponding 0 +value 0 +for 0 +VPA 1 +was 0 +322 0 +mg 0 +/ 0 +kg 0 +. 0 +In 0 +vivo 0 +microdialysis 0 +demonstrated 0 +that 0 +an 0 +intraperitoneal 0 +administration 0 +of 0 +pilocarpine 1 +induced 0 +a 0 +pronounced 0 +increment 0 +of 0 +hippocampal 0 +glutamate 1 +and 0 +aspartate 1 +whereas 0 +no 0 +significant 0 +change 0 +was 0 +observed 0 +on 0 +the 0 +level 0 +of 0 +glycine 1 +and 0 +GABA 1 +. 0 +Pretreatment 0 +with 0 +either 0 +VPU 1 +( 0 +50 0 +and 0 +100 0 +mg 0 +/ 0 +kg 0 +) 0 +or 0 +VPA 1 +( 0 +300 0 +and 0 +600 0 +mg 0 +/ 0 +kg 0 +) 0 +completely 0 +abolished 0 +pilocarpine 1 +- 0 +evoked 0 +increases 0 +in 0 +extracellular 0 +glutamate 1 +and 0 +aspartate 1 +. 0 +In 0 +addition 0 +"," 0 +a 0 +statistically 0 +significant 0 +reduction 0 +was 0 +also 0 +observed 0 +on 0 +the 0 +level 0 +of 0 +GABA 1 +and 0 +glycine 1 +but 0 +less 0 +than 0 +a 0 +drastic 0 +reduction 0 +of 0 +glutamate 1 +and 0 +aspartate 1 +level 0 +. 0 +Based 0 +on 0 +the 0 +finding 0 +that 0 +VPU 1 +and 0 +VPA 1 +could 0 +protect 0 +the 0 +animals 0 +against 0 +pilocarpine 1 +- 0 +induced 0 +seizure 3 +it 0 +is 0 +suggested 0 +that 0 +the 0 +reduction 0 +of 0 +inhibitory 0 +amino 1 +acid 2 +neurotransmitters 0 +was 0 +comparatively 0 +minor 0 +and 0 +offset 0 +by 0 +a 0 +pronounced 0 +reduction 0 +of 0 +glutamate 1 +and 0 +aspartate 1 +. 0 +Therefore 0 +"," 0 +like 0 +VPA 1 +"," 0 +the 0 +finding 0 +that 0 +VPU 1 +could 0 +drastically 0 +reduce 0 +pilocarpine 1 +- 0 +induced 0 +increases 0 +in 0 +glutamate 1 +and 0 +aspartate 1 +should 0 +account 0 +"," 0 +at 0 +least 0 +partly 0 +"," 0 +for 0 +its 0 +anticonvulsant 0 +activity 0 +observed 0 +in 0 +pilocarpine 1 +- 0 +induced 0 +seizure 3 +in 0 +experimental 0 +animals 0 +. 0 +Some 0 +other 0 +mechanism 0 +than 0 +those 0 +being 0 +reported 0 +herein 0 +should 0 +be 0 +further 0 +investigated 0 +. 0 +Protective 0 +effect 0 +of 0 +verapamil 1 +on 0 +gastric 3 +hemorrhagic 4 +ulcers 3 +in 0 +severe 0 +atherosclerotic 3 +rats 0 +. 0 +Studies 0 +concerning 0 +with 0 +pathogenesis 0 +of 0 +gastric 3 +hemorrhage 4 +and 0 +mucosal 0 +ulceration 0 +produced 0 +in 0 +atherosclerotic 3 +rats 0 +are 0 +lacking 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +is 0 +to 0 +examine 0 +the 0 +role 0 +of 0 +gastric 0 +acid 0 +back 0 +- 0 +diffusion 0 +"," 0 +mast 0 +cell 0 +histamine 1 +release 0 +"," 0 +lipid 0 +peroxide 0 +( 0 +LP0 0 +) 0 +generation 0 +and 0 +mucosal 0 +microvascular 0 +permeability 0 +in 0 +modulating 0 +gastric 3 +hemorrhage 4 +and 0 +ulcer 3 +in 0 +rats 0 +with 0 +atherosclerosis 3 +induced 0 +by 0 +coadministration 0 +of 0 +vitamin 1 +D2 2 +and 0 +cholesterol 1 +. 0 +Additionally 0 +"," 0 +the 0 +protective 0 +effect 0 +of 0 +verapamil 1 +on 0 +this 0 +ulcer 3 +model 0 +was 0 +evaluated 0 +. 0 +Male 0 +Wistar 0 +rats 0 +were 0 +challenged 0 +intragastrically 0 +once 0 +daily 0 +for 0 +9 0 +days 0 +with 0 +1 0 +. 0 +0 0 +ml 0 +/ 0 +kg 0 +of 0 +corn 0 +oil 0 +containing 0 +vitamin 1 +D2 2 +and 0 +cholesterol 1 +to 0 +induce 0 +atherosclerosis 3 +. 0 +Control 0 +rats 0 +received 0 +corn 0 +oil 0 +only 0 +. 0 +After 0 +gastric 0 +surgery 0 +"," 0 +rat 0 +stomachs 0 +were 0 +irrigated 0 +for 0 +3 0 +h 0 +with 0 +either 0 +simulated 0 +gastric 0 +juice 0 +or 0 +normal 0 +saline 0 +. 0 +Gastric 0 +acid 0 +back 0 +- 0 +diffusion 0 +"," 0 +mucosal 0 +LP0 0 +generation 0 +"," 0 +histamine 1 +concentration 0 +"," 0 +microvascular 0 +permeability 0 +"," 0 +luminal 1 +hemoglobin 0 +content 0 +and 0 +ulcer 3 +areas 0 +were 0 +determined 0 +. 0 +Elevated 0 +atherosclerotic 3 +parameters 0 +"," 0 +such 0 +as 0 +serum 0 +calcium 1 +"," 0 +total 0 +cholesterol 1 +and 0 +low 0 +- 0 +density 0 +lipoprotein 0 +concentration 0 +were 0 +obtained 0 +in 0 +atherosclerotic 3 +rats 0 +. 0 +Severe 0 +gastric 0 +ulcers 3 +accompanied 0 +with 0 +increased 0 +ulcerogenic 0 +factors 0 +"," 0 +including 0 +gastric 0 +acid 0 +back 0 +- 0 +diffusion 0 +"," 0 +histamine 1 +release 0 +"," 0 +LP0 0 +generation 0 +and 0 +luminal 1 +hemoglobin 0 +content 0 +were 0 +also 0 +observed 0 +in 0 +these 0 +rats 0 +. 0 +Moreover 0 +"," 0 +a 0 +positive 0 +correlation 0 +of 0 +histamine 1 +to 0 +gastric 3 +hemorrhage 4 +and 0 +to 0 +ulcer 3 +was 0 +found 0 +in 0 +those 0 +atherosclerotic 3 +rats 0 +. 0 +This 0 +hemorrhagic 3 +ulcer 3 +and 0 +various 0 +ulcerogenic 0 +parameters 0 +were 0 +dose 0 +- 0 +dependently 0 +ameliorated 0 +by 0 +daily 0 +intragastric 0 +verapamil 1 +. 0 +Atherosclerosis 3 +could 0 +produce 0 +gastric 3 +hemorrhagic 4 +ulcer 3 +via 0 +aggravation 0 +of 0 +gastric 0 +acid 0 +back 0 +- 0 +diffusion 0 +"," 0 +LP0 0 +generation 0 +"," 0 +histamine 1 +release 0 +and 0 +microvascular 0 +permeability 0 +that 0 +could 0 +be 0 +ameliorated 0 +by 0 +verapamil 1 +in 0 +rats 0 +. 0 +Lamivudine 1 +for 0 +the 0 +prevention 0 +of 0 +hepatitis 3 +B 4 +virus 0 +reactivation 0 +in 0 +hepatitis 1 +- 2 +B 2 +surface 2 +antigen 2 +( 0 +HBSAG 1 +) 0 +seropositive 0 +cancer 3 +patients 0 +undergoing 0 +cytotoxic 0 +chemotherapy 0 +. 0 +Hepatitis 3 +B 4 +virus 0 +( 0 +HBV 0 +) 0 +is 0 +one 0 +of 0 +the 0 +major 0 +causes 0 +of 0 +chronic 0 +liver 3 +disease 4 +worldwide 0 +. 0 +Cancer 3 +patients 0 +who 0 +are 0 +chronic 0 +carriers 0 +of 0 +HBV 0 +have 0 +a 0 +higher 0 +hepatic 3 +complication 4 +rate 0 +while 0 +receiving 0 +cytotoxic 0 +chemotherapy 0 +( 0 +CT 0 +) 0 +and 0 +this 0 +has 0 +mainly 0 +been 0 +attributed 0 +to 0 +HBV 0 +reactivation 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +cancer 3 +patients 0 +who 0 +have 0 +solid 0 +and 0 +hematological 3 +malignancies 4 +with 0 +chronic 0 +HBV 3 +infection 4 +received 0 +the 0 +antiviral 0 +agent 0 +lamivudine 1 +prior 0 +and 0 +during 0 +CT 0 +compared 0 +with 0 +historical 0 +control 0 +group 0 +who 0 +did 0 +not 0 +receive 0 +lamivudine 1 +. 0 +The 0 +objectives 0 +were 0 +to 0 +assess 0 +the 0 +efficacy 0 +of 0 +lamivudine 1 +in 0 +reducing 0 +the 0 +incidence 0 +of 0 +HBV 0 +reactivation 0 +"," 0 +and 0 +diminishing 0 +morbidity 0 +and 0 +mortality 0 +during 0 +CT 0 +. 0 +Two 0 +groups 0 +were 0 +compared 0 +in 0 +this 0 +study 0 +. 0 +The 0 +prophylactic 0 +lamivudin 1 +group 0 +consisted 0 +of 0 +37 0 +patients 0 +who 0 +received 0 +prophylactic 0 +lamivudine 1 +treatment 0 +. 0 +The 0 +historical 0 +controls 0 +consisted 0 +of 0 +50 0 +consecutive 0 +patients 0 +who 0 +underwent 0 +CT 0 +without 0 +prophylactic 0 +lamivudine 1 +. 0 +They 0 +were 0 +followed 0 +up 0 +during 0 +and 0 +for 0 +8 0 +weeks 0 +after 0 +CT 0 +. 0 +The 0 +outcomes 0 +were 0 +compared 0 +for 0 +both 0 +groups 0 +. 0 +0f 0 +our 0 +control 0 +group 0 +( 0 +n 0 += 0 +50 0 +) 0 +"," 0 +21 0 +patients 0 +( 0 +42 0 +% 0 +) 0 +were 0 +established 0 +hepatitis 3 +. 0 +Twelve 0 +( 0 +24 0 +% 0 +) 0 +of 0 +them 0 +were 0 +evaluated 0 +as 0 +severe 0 +hepatitis 3 +. 0 +In 0 +the 0 +prophylactic 0 +lamivudine 1 +group 0 +severe 0 +hepatitis 3 +were 0 +observed 0 +only 0 +in 0 +1 0 +patient 0 +( 0 +2 0 +. 0 +7 0 +% 0 +) 0 +of 0 +37 0 +patients 0 +( 0 +p 0 +< 0 +0 0 +. 0 +6 0 +) 0 +. 0 +Comparison 0 +of 0 +the 0 +mean 0 +ALT 0 +values 0 +revealed 0 +significantly 0 +higher 0 +mean 0 +alanine 1 +aminotransferase 0 +( 0 +ALT 0 +) 0 +values 0 +in 0 +the 0 +control 0 +group 0 +than 0 +the 0 +prophylactic 0 +lamivudine 1 +group 0 +; 0 +154 0 +: 0 +64 0 +( 0 +p 0 +< 0 +0 0 +. 0 +32 0 +) 0 +. 0 +0ur 0 +study 0 +suggests 0 +that 0 +prophylactic 0 +lamivudine 1 +significantly 0 +decreases 0 +the 0 +incidence 0 +of 0 +HBV 0 +reactivation 0 +and 0 +overall 0 +morbidity 0 +in 0 +cancer 3 +patients 0 +during 0 +and 0 +after 0 +immunosuppressive 0 +therapy 0 +. 0 +Further 0 +studies 0 +are 0 +needed 0 +to 0 +determine 0 +the 0 +most 0 +appropriate 0 +nucleoside 1 +or 0 +nucleotide 1 +analogue 0 +for 0 +antiviral 0 +prophylaxis 0 +during 0 +CT 0 +and 0 +the 0 +optimal 0 +duration 0 +of 0 +administration 0 +after 0 +completion 0 +of 0 +CT 0 +. 0 +Recovery 0 +of 0 +tacrolimus 1 +- 0 +associated 0 +brachial 3 +neuritis 4 +after 0 +conversion 0 +to 0 +everolimus 1 +in 0 +a 0 +pediatric 0 +renal 0 +transplant 0 +recipient 0 +- 0 +- 0 +case 0 +report 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 +TAC 1 +has 0 +been 0 +shown 0 +to 0 +be 0 +a 0 +potent 0 +immunosuppressive 0 +agent 0 +for 0 +solid 0 +organ 0 +transplantation 0 +in 0 +pediatrics 0 +. 0 +Neurotoxicity 3 +is 0 +a 0 +potentially 0 +serious 0 +toxic 0 +effect 0 +. 0 +It 0 +is 0 +characterized 0 +by 0 +encephalopathy 3 +"," 0 +headaches 3 +"," 0 +seizures 3 +"," 0 +or 0 +neurological 3 +deficits 4 +. 0 +Here 0 +"," 0 +we 0 +describe 0 +an 0 +eight 0 +- 0 +and 0 +- 0 +a 0 +- 0 +half 0 +- 0 +yr 0 +- 0 +old 0 +male 0 +renal 0 +transplant 0 +recipient 0 +with 0 +right 0 +BN 0 +. 0 +MRI 0 +demonstrated 0 +hyperintense 0 +T2 0 +signals 0 +in 0 +the 0 +cervical 0 +cord 0 +and 0 +right 0 +brachial 0 +plexus 0 +roots 0 +indicative 0 +of 0 +both 0 +myelitis 3 +and 0 +right 0 +brachial 3 +plexitis 4 +. 0 +Symptoms 0 +persisted 0 +for 0 +three 0 +months 0 +despite 0 +TAC 1 +dose 0 +reduction 0 +"," 0 +administration 0 +of 0 +IVIG 0 +and 0 +four 0 +doses 0 +of 0 +methylprednisolone 1 +pulse 0 +therapy 0 +. 0 +Improvement 0 +and 0 +eventually 0 +full 0 +recovery 0 +only 0 +occurred 0 +after 0 +TAC 1 +was 0 +completely 0 +discontinued 0 +and 0 +successfully 0 +replaced 0 +by 0 +everolimus 1 +. 0 +0mitting 0 +fentanyl 1 +reduces 0 +nausea 3 +and 0 +vomiting 3 +"," 0 +without 0 +increasing 0 +pain 3 +"," 0 +after 0 +sevoflurane 1 +for 0 +day 0 +surgery 0 +. 0 +BACKGR0UND 0 +AND 0 +0BJECTIVE 0 +: 0 +Despite 0 +advantages 0 +of 0 +induction 0 +and 0 +maintenance 0 +of 0 +anaesthesia 0 +with 0 +sevoflurane 1 +"," 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +occurs 0 +frequently 0 +. 0 +Fentanyl 1 +is 0 +a 0 +commonly 0 +used 0 +supplement 0 +that 0 +may 0 +contribute 0 +to 0 +this 0 +"," 0 +although 0 +it 0 +may 0 +also 0 +improve 0 +analgesia 0 +. 0 +METH0DS 0 +: 0 +This 0 +double 0 +- 0 +blind 0 +study 0 +examined 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +and 0 +pain 3 +in 0 +the 0 +first 0 +24 0 +h 0 +after 0 +sevoflurane 1 +anaesthesia 0 +in 0 +216 0 +adult 0 +day 0 +surgery 0 +patients 0 +. 0 +Patients 0 +were 0 +randomly 0 +allocated 0 +to 0 +either 0 +receive 0 +or 0 +not 0 +receive 0 +1 0 +1 0 +fentanyl 1 +"," 0 +while 0 +a 0 +third 0 +group 0 +received 0 +dexamethasone 1 +in 0 +addition 0 +to 0 +fentanyl 1 +. 0 +RESULTS 0 +: 0 +0mission 0 +of 0 +fentanyl 1 +did 0 +not 0 +reduce 0 +the 0 +overall 0 +incidence 0 +of 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +"," 0 +but 0 +did 0 +reduce 0 +the 0 +incidence 0 +of 0 +vomiting 3 +and 0 +/ 0 +or 0 +moderate 0 +to 0 +severe 0 +nausea 3 +prior 0 +to 0 +discharge 0 +from 0 +20 0 +% 0 +and 0 +17 0 +% 0 +with 0 +fentanyl 1 +and 0 +fentanyl 1 +- 0 +dexamethasone 1 +"," 0 +respectively 0 +"," 0 +to 0 +5 0 +% 0 +( 0 +P 0 += 0 +0 0 +. 0 +13 0 +) 0 +. 0 +Antiemetic 0 +requirements 0 +were 0 +reduced 0 +from 0 +24 0 +% 0 +and 0 +31 0 +% 0 +to 0 +7 0 +% 0 +( 0 +P 0 += 0 +0 0 +. 0 +12 0 +) 0 +. 0 +Dexamethasone 1 +had 0 +no 0 +significant 0 +effect 0 +on 0 +the 0 +incidence 0 +or 0 +severity 0 +of 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +. 0 +Combining 0 +the 0 +two 0 +fentanyl 1 +groups 0 +revealed 0 +further 0 +significant 0 +benefits 0 +from 0 +the 0 +avoidance 0 +of 0 +opioids 0 +"," 0 +reducing 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +and 0 +nausea 3 +prior 0 +to 0 +discharge 0 +from 0 +35 0 +% 0 +and 0 +33 0 +% 0 +to 0 +22 0 +% 0 +and 0 +19 0 +% 0 +( 0 +P 0 += 0 +0 0 +. 0 +49 0 +and 0 +P 0 += 0 +0 0 +. 0 +35 0 +) 0 +"," 0 +respectively 0 +"," 0 +while 0 +nausea 3 +in 0 +the 0 +first 0 +24 0 +h 0 +was 0 +decreased 0 +from 0 +42 0 +% 0 +to 0 +27 0 +% 0 +( 0 +P 0 += 0 +0 0 +. 0 +34 0 +) 0 +. 0 +Pain 3 +severity 0 +and 0 +analgesic 0 +requirements 0 +were 0 +unaffected 0 +by 0 +the 0 +omission 0 +of 0 +fentanyl 1 +. 0 +Fentanyl 1 +did 0 +reduce 0 +minor 0 +intraoperative 0 +movement 0 +but 0 +had 0 +no 0 +sevoflurane 1 +- 0 +sparing 0 +effect 0 +and 0 +increased 0 +respiratory 3 +depression 4 +"," 0 +hypotension 3 +and 0 +bradycardia 3 +. 0 +C0NCLUSI0N 0 +: 0 +As 0 +fentanyl 1 +exacerbated 0 +postoperative 3 +nausea 4 +and 4 +vomiting 4 +without 0 +an 0 +improvement 0 +in 0 +postoperative 3 +pain 4 +and 0 +also 0 +had 0 +adverse 0 +cardiorespiratory 0 +effects 0 +"," 0 +it 0 +appears 0 +to 0 +be 0 +an 0 +unnecessary 0 +and 0 +possibly 0 +detrimental 0 +supplement 0 +to 0 +sevoflurane 1 +in 0 +day 0 +surgery 0 +. 0 +Valvular 3 +heart 4 +disease 4 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +treated 0 +with 0 +pergolide 1 +. 0 +Course 0 +following 0 +treatment 0 +modifications 0 +. 0 +Valvular 3 +heart 4 +abnormalities 4 +have 0 +been 0 +reported 0 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +treated 0 +with 0 +pergolide 1 +. 0 +However 0 +"," 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +these 0 +abnormalities 0 +vary 0 +from 0 +study 0 +to 0 +study 0 +and 0 +their 0 +course 0 +after 0 +drug 0 +withdrawal 0 +has 0 +not 0 +been 0 +systematically 0 +assessed 0 +. 0 +0BJECTIVES 0 +: 0 +To 0 +estimate 0 +the 0 +frequency 0 +and 0 +severity 0 +of 0 +valvular 3 +heart 4 +abnormality 4 +and 0 +its 0 +possible 0 +reversibility 0 +after 0 +drug 0 +withdrawal 0 +in 0 +a 0 +case 0 +- 0 +control 0 +study 0 +. 0 +METH0DS 0 +: 0 +All 0 +PD 3 +patients 0 +in 0 +the 0 +Amiens 0 +area 0 +treated 0 +with 0 +pergolide 1 +were 0 +invited 0 +to 0 +attend 0 +a 0 +cardiologic 0 +assessment 0 +including 0 +transthoracic 0 +echocardiography 0 +. 0 +Thirty 0 +PD 3 +patients 0 +participated 0 +in 0 +the 0 +study 0 +. 0 +A 0 +second 0 +echocardiography 0 +was 0 +performed 0 +( 0 +median 0 +interval 0 +: 0 +13 0 +months 0 +) 0 +after 0 +pergolide 1 +withdrawal 0 +( 0 +n 0 += 0 +10 0 +patients 0 +) 0 +. 0 +Controls 0 +were 0 +age 0 +- 0 +and 0 +sex 0 +- 0 +matched 0 +non 0 +- 0 +PD 3 +patients 0 +referred 0 +to 0 +the 0 +cardiology 0 +department 0 +. 0 +RESULTS 0 +: 0 +Compared 0 +to 0 +controls 0 +"," 0 +aortic 3 +regurgitation 4 +( 0 +0R 0 +: 0 +3 0 +. 0 +1 0 +; 0 +95 0 +% 0 +IC 0 +: 0 +1 0 +. 0 +1 0 +- 0 +8 0 +. 0 +8 0 +) 0 +and 0 +mitral 3 +regurgitation 4 +( 0 +0R 0 +: 0 +10 0 +. 0 +7 0 +; 0 +95 0 +% 0 +IC 0 +: 0 +2 0 +. 0 +1 0 +- 0 +53 0 +) 0 +were 0 +more 0 +frequent 0 +in 0 +PD 3 +patients 0 +( 0 +tricuspid 0 +: 0 +NS 0 +) 0 +. 0 +The 0 +number 0 +of 0 +affected 0 +valves 0 +( 0 +n 0 += 0 +2 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +) 0 +and 0 +the 0 +sum 0 +of 0 +regurgitation 0 +grades 0 +( 0 +n 0 += 0 +2 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +) 0 +were 0 +higher 0 +( 0 +p 0 += 0 +0 0 +. 0 +8 0 +and 0 +p 0 += 0 +0 0 +. 0 +6 0 +"," 0 +respectively 0 +) 0 +in 0 +the 0 +pergolide 1 +group 0 +. 0 +Severity 0 +of 0 +regurgitation 0 +was 0 +not 0 +correlated 0 +with 0 +pergolide 1 +cumulative 0 +dose 0 +. 0 +A 0 +restrictive 0 +pattern 0 +of 0 +valvular 3 +regurgitation 4 +"," 0 +suggestive 0 +of 0 +the 0 +role 0 +of 0 +pergolide 1 +"," 0 +was 0 +observed 0 +in 0 +12 0 +/ 0 +30 0 +( 0 +40 0 +% 0 +) 0 +patients 0 +including 0 +two 0 +with 0 +heart 3 +failure 4 +. 0 +Pergolide 1 +was 0 +discontinued 0 +in 0 +10 0 +patients 0 +with 0 +valvular 3 +heart 4 +disease 4 +"," 0 +resulting 0 +in 0 +a 0 +lower 0 +regurgitation 0 +grade 0 +( 0 +p 0 += 0 +0 0 +. 0 +1 0 +) 0 +at 0 +the 0 +second 0 +transthoracic 0 +echocardiography 0 +and 0 +the 0 +two 0 +patients 0 +with 0 +heart 3 +failure 4 +returned 0 +to 0 +nearly 0 +normal 0 +clinical 0 +examination 0 +. 0 +This 0 +study 0 +supports 0 +the 0 +high 0 +frequency 0 +of 0 +restrictive 0 +valve 3 +regurgitation 4 +in 0 +PD 3 +patients 0 +treated 0 +with 0 +pergolide 1 +and 0 +reveals 0 +that 0 +a 0 +significant 0 +improvement 0 +is 0 +usual 0 +when 0 +the 0 +treatment 0 +is 0 +converted 0 +to 0 +non 0 +- 0 +ergot 0 +dopamine 1 +agonists 0 +. 0 +Adriamycin 1 +- 0 +induced 0 +autophagic 0 +cardiomyocyte 0 +death 3 +plays 0 +a 0 +pathogenic 0 +role 0 +in 0 +a 0 +rat 0 +model 0 +of 0 +heart 3 +failure 4 +. 0 +BACKGR0UND 0 +: 0 +The 0 +mechanisms 0 +underlying 0 +heart 3 +failure 4 +induced 0 +by 0 +adriamycin 1 +are 0 +very 0 +complicated 0 +and 0 +still 0 +unclear 0 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +whether 0 +autophagy 0 +was 0 +involved 0 +in 0 +the 0 +progression 0 +of 0 +heart 3 +failure 4 +induced 0 +by 0 +adriamycin 1 +"," 0 +so 0 +that 0 +we 0 +can 0 +develop 0 +a 0 +novel 0 +treatment 0 +strategy 0 +for 0 +heart 3 +failure 4 +. 0 +METH0DS 0 +: 0 +3 1 +- 2 +methyladenine 2 +( 0 +3MA 1 +) 0 +"," 0 +a 0 +specific 0 +inhibitor 0 +on 0 +autophagy 0 +was 0 +used 0 +in 0 +a 0 +heart 3 +failure 4 +model 0 +of 0 +rats 0 +induced 0 +by 0 +adriamycin 1 +. 0 +Neonatal 0 +cardiomyocytes 0 +were 0 +isolated 0 +from 0 +Sprague 0 +- 0 +Dawley 0 +rat 0 +hearts 0 +and 0 +randomly 0 +divided 0 +into 0 +controls 0 +"," 0 +an 0 +adriamycin 1 +- 0 +treated 0 +group 0 +"," 0 +and 0 +a 0 +3MA 1 +plus 0 +adriamycin 1 +- 0 +treated 0 +group 0 +. 0 +We 0 +then 0 +examined 0 +the 0 +morphology 0 +"," 0 +expression 0 +of 0 +beclin 0 +1 0 +gene 0 +"," 0 +mitochondrial 0 +permeability 0 +transition 0 +( 0 +MPT 0 +) 0 +"," 0 +and 0 +Na 0 ++ 0 +- 0 +K 1 ++ 0 +ATPase 0 +activity 0 +in 0 +vivo 0 +. 0 +We 0 +also 0 +assessed 0 +cell 0 +viability 0 +"," 0 +mitochondrial 0 +membrane 0 +potential 0 +changes 0 +and 0 +counted 0 +autophagic 0 +vacuoles 0 +in 0 +cultured 0 +cardiomyocytes 0 +. 0 +In 0 +addition 0 +"," 0 +we 0 +analyzed 0 +the 0 +expression 0 +of 0 +autophagy 0 +associated 0 +gene 0 +"," 0 +beclin 0 +1 0 +using 0 +RT 0 +- 0 +PCR 0 +and 0 +Western 0 +blotting 0 +in 0 +an 0 +animal 0 +model 0 +. 0 +RESULTS 0 +: 0 +3MA 1 +significantly 0 +improved 0 +cardiac 0 +function 0 +and 0 +reduced 0 +mitochondrial 0 +injury 0 +. 0 +Furthermore 0 +"," 0 +adriamycin 1 +induced 0 +the 0 +formation 0 +of 0 +autophagic 0 +vacuoles 0 +"," 0 +and 0 +3MA 1 +strongly 0 +downregulated 0 +the 0 +expression 0 +of 0 +beclin 0 +1 0 +in 0 +adriamycin 1 +- 0 +induced 0 +failing 0 +heart 0 +and 0 +inhibited 0 +the 0 +formation 0 +of 0 +autophagic 0 +vacuoles 0 +. 0 +C0NCLUSI0N 0 +: 0 +Autophagic 0 +cardiomyocyte 0 +death 3 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +pathogenesis 0 +of 0 +heart 3 +failure 4 +in 0 +rats 0 +induced 0 +by 0 +adriamycin 1 +. 0 +Mitochondrial 0 +injury 0 +may 0 +be 0 +involved 0 +in 0 +the 0 +progression 0 +of 0 +heart 3 +failure 4 +caused 0 +by 0 +adriamycin 1 +via 0 +the 0 +autophagy 0 +pathway 0 +. 0 +mToR 0 +inhibitors 0 +- 0 +induced 0 +proteinuria 3 +: 0 +mechanisms 0 +"," 0 +significance 0 +"," 0 +and 0 +management 0 +. 0 +Massive 0 +urinary 0 +protein 0 +excretion 0 +has 0 +been 0 +observed 0 +after 0 +conversion 0 +from 0 +calcineurin 0 +inhibitors 0 +to 0 +mammalian 0 +target 0 +of 0 +rapamycin 1 +( 0 +mToR 0 +) 0 +inhibitors 0 +"," 0 +especially 0 +sirolimus 1 +"," 0 +in 0 +renal 0 +transplant 0 +recipients 0 +with 0 +chronic 3 +allograft 4 +nephropathy 4 +. 0 +Because 0 +proteinuria 3 +is 0 +a 0 +major 0 +predictive 0 +factor 0 +of 0 +poor 0 +transplantation 0 +outcome 0 +"," 0 +many 0 +studies 0 +focused 0 +on 0 +this 0 +adverse 0 +event 0 +during 0 +the 0 +past 0 +years 0 +. 0 +Whether 0 +proteinuria 3 +was 0 +due 0 +to 0 +sirolimus 1 +or 0 +only 0 +a 0 +consequence 0 +of 0 +calcineurin 0 +inhibitors 0 +withdrawal 0 +remained 0 +unsolved 0 +until 0 +high 0 +range 0 +proteinuria 3 +has 0 +been 0 +observed 0 +during 0 +sirolimus 1 +therapy 0 +in 0 +islet 0 +transplantation 0 +and 0 +in 0 +patients 0 +who 0 +received 0 +sirolimus 1 +de 0 +novo 0 +. 0 +Podocyte 0 +injury 0 +and 0 +focal 0 +segmental 0 +glomerulosclerosis 3 +have 0 +been 0 +related 0 +to 0 +mToR 0 +inhibition 0 +in 0 +some 0 +patients 0 +"," 0 +but 0 +the 0 +pathways 0 +underlying 0 +these 0 +lesions 0 +remain 0 +hypothetic 0 +. 0 +We 0 +discuss 0 +herein 0 +the 0 +possible 0 +mechanisms 0 +and 0 +the 0 +significance 0 +of 0 +mToR 0 +blockade 0 +- 0 +induced 0 +proteinuria 3 +. 0 +Neuropsychiatric 0 +side 0 +effects 0 +after 0 +the 0 +use 0 +of 0 +mefloquine 1 +. 0 +This 0 +study 0 +describes 0 +neuropsychiatric 0 +side 0 +effects 0 +in 0 +patients 0 +after 0 +treatment 0 +with 0 +mefloquine 1 +. 0 +Reactions 0 +consisted 0 +mainly 0 +of 0 +seizures 3 +"," 0 +acute 0 +psychoses 3 +"," 0 +anxiety 3 +neurosis 4 +"," 0 +and 0 +major 0 +disturbances 3 +of 4 +sleep 4 +- 4 +wake 4 +rhythm 4 +. 0 +Side 0 +effects 0 +occurred 0 +after 0 +both 0 +therapeutic 0 +and 0 +prophylactic 0 +intake 0 +and 0 +were 0 +graded 0 +from 0 +moderate 0 +to 0 +severe 0 +. 0 +In 0 +a 0 +risk 0 +analysis 0 +of 0 +neuropsychiatric 0 +side 0 +effects 0 +in 0 +Germany 0 +"," 0 +it 0 +is 0 +estimated 0 +that 0 +one 0 +of 0 +8 0 +"," 0 +0 0 +mefloquine 1 +users 0 +suffers 0 +from 0 +such 0 +reactions 0 +. 0 +The 0 +incidence 0 +calculation 0 +revealed 0 +that 0 +one 0 +of 0 +215 0 +therapeutic 0 +users 0 +had 0 +reactions 0 +"," 0 +compared 0 +with 0 +one 0 +of 0 +13 0 +"," 0 +0 0 +in 0 +the 0 +prophylaxis 0 +group 0 +"," 0 +making 0 +the 0 +risk 0 +of 0 +neuropsychiatric 0 +reactions 0 +after 0 +mefloquine 1 +treatment 0 +60 0 +times 0 +higher 0 +than 0 +after 0 +prophylaxis 0 +. 0 +Therefore 0 +"," 0 +certain 0 +limitations 0 +for 0 +malaria 3 +prophylaxis 0 +and 0 +treatment 0 +with 0 +mefloquine 1 +are 0 +recommended 0 +. 0 +Prenatal 0 +protein 0 +deprivation 0 +alters 0 +dopamine 1 +- 0 +mediated 0 +behaviors 0 +and 0 +dopaminergic 0 +and 0 +glutamatergic 0 +receptor 0 +binding 0 +. 0 +Epidemiological 0 +evidence 0 +indicates 0 +that 0 +prenatal 0 +nutritional 0 +deprivation 0 +may 0 +increase 0 +the 0 +risk 0 +of 0 +schizophrenia 3 +. 0 +The 0 +goal 0 +of 0 +these 0 +studies 0 +was 0 +to 0 +use 0 +an 0 +animal 0 +model 0 +to 0 +examine 0 +the 0 +effects 0 +of 0 +prenatal 0 +protein 0 +deprivation 0 +on 0 +behaviors 0 +and 0 +receptor 0 +binding 0 +with 0 +relevance 0 +to 0 +schizophrenia 3 +. 0 +We 0 +report 0 +that 0 +prenatally 0 +protein 0 +deprived 0 +( 0 +PD 0 +) 0 +female 0 +rats 0 +showed 0 +an 0 +increased 0 +stereotypic 0 +response 0 +to 0 +apomorphine 1 +and 0 +an 0 +increased 0 +locomotor 0 +response 0 +to 0 +amphetamine 1 +in 0 +adulthood 0 +. 0 +These 0 +differences 0 +were 0 +not 0 +observed 0 +during 0 +puberty 0 +. 0 +No 0 +changes 0 +in 0 +haloperidol 1 +- 0 +induced 0 +catalepsy 3 +or 0 +MK 1 +- 2 +801 2 +- 0 +induced 0 +locomotion 0 +were 0 +seen 0 +following 0 +PD 0 +. 0 +In 0 +addition 0 +"," 0 +PD 0 +female 0 +rats 0 +showed 0 +increased 0 +( 0 +3 0 +) 0 +H 1 +- 0 +MK 1 +- 2 +801 2 +binding 0 +in 0 +the 0 +striatum 0 +and 0 +hippocampus 0 +"," 0 +but 0 +not 0 +in 0 +the 0 +cortex 0 +. 0 +PD 0 +female 0 +rats 0 +also 0 +showed 0 +increased 0 +( 0 +3 0 +) 0 +H 1 +- 0 +haloperidol 1 +binding 0 +and 0 +decreased 0 +dopamine 1 +transporter 0 +binding 0 +in 0 +striatum 0 +. 0 +No 0 +statistically 0 +significant 0 +changes 0 +in 0 +behavior 0 +or 0 +receptor 0 +binding 0 +were 0 +found 0 +in 0 +PD 0 +males 0 +with 0 +the 0 +exception 0 +of 0 +increased 0 +( 0 +3 0 +) 0 +H 1 +- 0 +MK 1 +- 2 +801 2 +binding 0 +in 0 +cortex 0 +. 0 +This 0 +animal 0 +model 0 +may 0 +be 0 +useful 0 +to 0 +explore 0 +the 0 +mechanisms 0 +by 0 +which 0 +prenatal 0 +nutritional 3 +deficiency 4 +enhances 0 +risk 0 +for 0 +schizophrenia 3 +in 0 +humans 0 +and 0 +may 0 +also 0 +have 0 +implications 0 +for 0 +developmental 0 +processes 0 +leading 0 +to 0 +differential 0 +sensitivity 0 +to 0 +drugs 0 +of 0 +abuse 0 +. 0 +Adverse 0 +effects 0 +of 0 +topical 0 +papaverine 1 +on 0 +auditory 0 +nerve 0 +function 0 +. 0 +BACKGR0UND 0 +: 0 +Papaverine 1 +hydrochloride 2 +is 0 +a 0 +direct 0 +- 0 +acting 0 +vasodilator 0 +used 0 +to 0 +manage 0 +vasospasm 3 +during 0 +various 0 +neurosurgical 0 +operations 0 +. 0 +Transient 0 +cranial 3 +nerve 4 +dysfunction 4 +has 0 +been 0 +described 0 +in 0 +a 0 +few 0 +cases 0 +with 0 +topical 0 +papaverine 1 +. 0 +This 0 +study 0 +supports 0 +previous 0 +reports 0 +and 0 +provides 0 +neurophysiological 0 +evidence 0 +of 0 +an 0 +adverse 0 +effect 0 +on 0 +the 0 +auditory 0 +nerve 0 +. 0 +METH0DS 0 +: 0 +We 0 +conducted 0 +a 0 +retrospective 0 +review 0 +of 0 +70 0 +consecutive 0 +microvascular 0 +decompression 0 +operations 0 +and 0 +studied 0 +those 0 +patients 0 +who 0 +received 0 +topical 0 +papaverine 1 +for 0 +vasospasm 3 +. 0 +Topical 0 +papaverine 1 +was 0 +used 0 +as 0 +a 0 +direct 0 +therapeutic 0 +action 0 +to 0 +manage 0 +vasospasm 3 +in 0 +a 0 +total 0 +of 0 +11 0 +patients 0 +. 0 +The 0 +timing 0 +of 0 +papaverine 1 +application 0 +and 0 +ongoing 0 +operative 0 +events 0 +was 0 +reviewed 0 +relative 0 +to 0 +changes 0 +in 0 +neurophysiological 0 +recordings 0 +. 0 +Brainstem 0 +auditory 0 +evoked 0 +potentials 0 +( 0 +BAEPs 0 +) 0 +were 0 +routinely 0 +used 0 +to 0 +monitor 0 +cochlear 0 +nerve 0 +function 0 +during 0 +these 0 +operations 0 +. 0 +FINDINGS 0 +: 0 +A 0 +temporal 0 +relationship 0 +was 0 +found 0 +between 0 +topical 0 +papaverine 1 +and 0 +BAEP 0 +changes 0 +leading 0 +to 0 +complete 0 +waveform 0 +loss 0 +. 0 +The 0 +average 0 +temporal 0 +delay 0 +between 0 +papaverine 1 +and 0 +the 0 +onset 0 +of 0 +an 0 +adverse 0 +BAEP 0 +change 0 +was 0 +5 0 +min 0 +. 0 +In 0 +10 0 +of 0 +11 0 +patients 0 +"," 0 +BAEP 0 +waves 0 +II 0 +/ 0 +III 0 +- 0 +V 0 +completely 0 +disappeared 0 +within 0 +2 0 +to 0 +25 0 +min 0 +after 0 +papaverine 1 +. 0 +Eight 0 +of 0 +these 0 +10 0 +patients 0 +had 0 +complete 0 +loss 0 +of 0 +BAEP 0 +waveforms 0 +within 0 +10 0 +min 0 +. 0 +0ne 0 +patient 0 +showed 0 +no 0 +recovery 0 +of 0 +later 0 +waves 0 +and 0 +a 0 +delayed 0 +profound 0 +sensorineural 3 +hearing 4 +loss 4 +. 0 +The 0 +average 0 +recovery 0 +time 0 +of 0 +BAEP 0 +waveforms 0 +to 0 +pre 0 +- 0 +papaverine 1 +baseline 0 +values 0 +was 0 +39 0 +min 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Topical 0 +papaverine 1 +for 0 +the 0 +treatment 0 +of 0 +vasospasm 3 +was 0 +associated 0 +with 0 +the 0 +onset 0 +of 0 +a 0 +transient 0 +disturbance 0 +in 0 +neurophysiological 0 +function 0 +of 0 +the 0 +ascending 0 +auditory 0 +brainstem 0 +pathway 0 +. 0 +The 0 +complete 0 +disappearance 0 +of 0 +BAEP 0 +waveforms 0 +with 0 +a 0 +consistent 0 +temporal 0 +delay 0 +suggests 0 +a 0 +possible 0 +adverse 3 +effect 4 +on 4 +the 4 +proximal 4 +eighth 4 +nerve 4 +. 0 +Recommendations 0 +to 0 +avoid 0 +potential 0 +cranial 3 +nerve 4 +deficits 4 +from 0 +papaverine 1 +are 0 +provided 0 +. 0 +Simvastatin 1 +- 2 +ezetimibe 2 +- 0 +induced 0 +hepatic 3 +failure 4 +necessitating 0 +liver 0 +transplantation 0 +. 0 +Abstract 0 +Serum 0 +aminotransferase 0 +elevations 0 +are 0 +a 0 +commonly 0 +known 0 +adverse 0 +effect 0 +of 0 +3 0 +- 0 +hydroxy 0 +- 0 +3 0 +- 0 +methylglutaryl 0 +coenzyme 0 +A 0 +reductase 0 +inhibitor 0 +( 0 +statin 1 +) 0 +therapy 0 +. 0 +However 0 +"," 0 +hepatotoxic 3 +events 0 +have 0 +not 0 +been 0 +widely 0 +published 0 +with 0 +ezetimibe 1 +or 0 +the 0 +combination 0 +agent 0 +simvastatin 1 +- 2 +ezetimibe 2 +. 0 +We 0 +describe 0 +a 0 +70 0 +- 0 +year 0 +- 0 +old 0 +Hispanic 0 +woman 0 +who 0 +developed 0 +fulminant 3 +hepatic 4 +failure 4 +necessitating 0 +liver 0 +transplantation 0 +10 0 +weeks 0 +after 0 +conversion 0 +from 0 +simvastatin 1 +40 0 +mg 0 +/ 0 +day 0 +to 0 +simvastatin 1 +10 2 +mg 2 +- 2 +ezetimibe 2 +40 2 +mg 2 +/ 0 +day 0 +. 0 +The 0 +patient 0 +' 0 +s 0 +lipid 0 +panel 0 +had 0 +been 0 +maintained 0 +with 0 +simvastatin 1 +for 0 +18 0 +months 0 +before 0 +the 0 +conversion 0 +without 0 +evidence 0 +of 0 +hepatotoxicity 3 +. 0 +A 0 +routine 0 +laboratory 0 +work 0 +- 0 +up 0 +10 0 +weeks 0 +after 0 +conversion 0 +revealed 0 +elevated 0 +serum 0 +aminotransferase 0 +levels 0 +. 0 +Simvastatinezetimibe 1 +and 0 +escitalopram 1 +( 0 +which 0 +she 0 +was 0 +taking 0 +for 0 +depression 3 +) 0 +were 0 +discontinued 0 +"," 0 +and 0 +other 0 +potential 0 +causes 0 +of 0 +hepatotoxicity 3 +were 0 +excluded 0 +. 0 +A 0 +repeat 0 +work 0 +- 0 +up 0 +revealed 0 +further 0 +elevations 0 +in 0 +aminotransferase 0 +levels 0 +"," 0 +and 0 +liver 0 +biopsy 0 +revealed 0 +evidence 0 +of 0 +moderate 0 +- 0 +to 0 +- 0 +severe 0 +drug 3 +toxicity 4 +. 0 +She 0 +underwent 0 +liver 0 +transplantation 0 +with 0 +an 0 +uneventful 0 +postoperative 0 +course 0 +. 0 +Her 0 +aminotransferase 0 +levels 0 +returned 0 +to 0 +normal 0 +by 0 +postoperative 0 +day 0 +23 0 +"," 0 +and 0 +her 0 +2 0 +- 0 +year 0 +follow 0 +- 0 +up 0 +showed 0 +no 0 +adverse 0 +events 0 +. 0 +Ezetimibe 1 +undergoes 0 +extensive 0 +glucuronidation 0 +by 0 +uridine 1 +diphosphate 2 +glucoronosyltransferases 0 +( 0 +UGT 0 +) 0 +in 0 +the 0 +intestine 0 +and 0 +liver 0 +and 0 +may 0 +have 0 +inhibited 0 +the 0 +glucuronidation 0 +of 0 +simvastatin 1 +hydroxy 2 +acid 2 +"," 0 +resulting 0 +in 0 +increased 0 +simvastatin 1 +exposure 0 +and 0 +subsequent 0 +hepatotoxicity 3 +. 0 +To 0 +our 0 +knowledge 0 +"," 0 +this 0 +is 0 +the 0 +first 0 +case 0 +report 0 +of 0 +simvastatin 1 +- 2 +ezetimibe 2 +- 0 +induced 0 +liver 3 +failure 4 +that 0 +resulted 0 +in 0 +liver 0 +transplantation 0 +. 0 +We 0 +postulate 0 +that 0 +the 0 +mechanism 0 +of 0 +the 0 +simvastatinezetimibe 1 +- 0 +induced 0 +hepatotoxicity 3 +is 0 +the 0 +increased 0 +simvastatin 1 +exposure 0 +by 0 +ezetimibe 1 +inhibition 0 +of 0 +UGT 0 +enzymes 0 +. 0 +Clinicians 0 +should 0 +be 0 +aware 0 +of 0 +potential 0 +hepatotoxicity 3 +with 0 +simvastatin 1 +- 2 +ezetimibe 2 +especially 0 +in 0 +elderly 0 +patients 0 +and 0 +should 0 +carefully 0 +monitor 0 +serum 0 +aminotransferase 0 +levels 0 +when 0 +starting 0 +therapy 0 +and 0 +titrating 0 +the 0 +dosage 0 +. 0 +Massive 0 +proteinuria 3 +and 0 +acute 3 +renal 4 +failure 4 +after 0 +oral 0 +bisphosphonate 1 +( 0 +alendronate 1 +) 0 +administration 0 +in 0 +a 0 +patient 0 +with 0 +focal 3 +segmental 4 +glomerulosclerosis 4 +. 0 +A 0 +61 0 +- 0 +year 0 +- 0 +old 0 +Japanese 0 +man 0 +with 0 +nephrotic 3 +syndrome 4 +due 0 +to 0 +focal 3 +segmental 4 +glomerulosclerosis 4 +was 0 +initially 0 +responding 0 +well 0 +to 0 +steroid 1 +therapy 0 +. 0 +The 0 +amount 0 +of 0 +daily 0 +urinary 0 +protein 0 +decreased 0 +from 0 +15 0 +. 0 +6 0 +to 0 +2 0 +. 0 +8 0 +g 0 +. 0 +Within 0 +14 0 +days 0 +of 0 +the 0 +oral 0 +bisphosphonate 1 +( 0 +alendronate 1 +sodium 2 +) 0 +administration 0 +"," 0 +the 0 +amount 0 +of 0 +daily 0 +urinary 0 +protein 0 +increased 0 +rapidly 0 +up 0 +to 0 +12 0 +. 0 +8 0 +g 0 +with 0 +acute 3 +renal 4 +failure 4 +. 0 +After 0 +discontinuing 0 +the 0 +oral 0 +alendronate 1 +"," 0 +the 0 +patient 0 +underwent 0 +six 0 +cycles 0 +of 0 +hemodialysis 0 +and 0 +four 0 +cycles 0 +of 0 +LDL 0 +apheresis 0 +. 0 +Urinary 0 +volume 0 +and 0 +serum 0 +creatinine 1 +levels 0 +recovered 0 +to 0 +the 0 +normal 0 +range 0 +"," 0 +with 0 +urinary 0 +protein 0 +disappearing 0 +completely 0 +within 0 +40 0 +days 0 +. 0 +This 0 +report 0 +demonstrates 0 +that 0 +not 0 +only 0 +intravenous 0 +"," 0 +but 0 +also 0 +oral 0 +bisphosphonates 1 +can 0 +aggravate 0 +proteinuria 3 +and 0 +acute 3 +renal 4 +failure 4 +. 0 +Serum 0 +- 0 +and 0 +glucocorticoid 0 +- 0 +inducible 0 +kinase 0 +1 0 +in 0 +doxorubicin 1 +- 0 +induced 0 +nephrotic 3 +syndrome 4 +. 0 +Doxorubicin 1 +- 0 +induced 0 +nephropathy 3 +leads 0 +to 0 +epithelial 0 +sodium 1 +channel 0 +( 0 +ENaC 0 +) 0 +- 0 +dependent 0 +volume 3 +retention 4 +and 0 +renal 0 +fibrosis 3 +. 0 +The 0 +aldosterone 1 +- 0 +sensitive 0 +serum 0 +- 0 +and 0 +glucocorticoid 0 +- 0 +inducible 0 +kinase 0 +SGK1 0 +has 0 +been 0 +shown 0 +to 0 +participate 0 +in 0 +the 0 +stimulation 0 +of 0 +ENaC 0 +and 0 +to 0 +mediate 0 +renal 0 +fibrosis 3 +following 0 +mineralocorticoid 0 +and 0 +salt 0 +excess 0 +. 0 +The 0 +present 0 +study 0 +was 0 +performed 0 +to 0 +elucidate 0 +the 0 +role 0 +of 0 +SGK1 0 +in 0 +the 0 +volume 3 +retention 4 +and 0 +fibrosis 3 +during 0 +nephrotic 3 +syndrome 4 +. 0 +To 0 +this 0 +end 0 +"," 0 +doxorubicin 1 +( 0 +15 0 +mug 0 +/ 0 +g 0 +body 0 +wt 0 +) 0 +was 0 +injected 0 +intravenously 0 +into 0 +gene 0 +- 0 +targeted 0 +mice 0 +lacking 0 +SGK1 0 +( 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +) 0 +and 0 +their 0 +wild 0 +- 0 +type 0 +littermates 0 +( 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +) 0 +. 0 +Doxorubicin 1 +treatment 0 +resulted 0 +in 0 +heavy 0 +proteinuria 3 +( 0 +> 0 +100 0 +mg 0 +protein 0 +/ 0 +mg 0 +crea 0 +) 0 +in 0 +15 0 +/ 0 +44 0 +of 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +and 0 +15 0 +/ 0 +44 0 +of 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +leading 0 +to 0 +severe 0 +nephrotic 3 +syndrome 4 +with 0 +ascites 3 +"," 0 +lipidemia 3 +"," 0 +and 0 +hypoalbuminemia 3 +in 0 +both 0 +genotypes 0 +. 0 +Plasma 0 +aldosterone 1 +levels 0 +increased 0 +in 0 +nephrotic 3 +mice 0 +of 0 +both 0 +genotypes 0 +and 0 +was 0 +followed 0 +by 0 +increased 0 +SGK1 0 +protein 0 +expression 0 +in 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +mice 0 +. 0 +Urinary 0 +sodium 1 +excretion 0 +reached 0 +signficantly 0 +lower 0 +values 0 +in 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +mice 0 +( 0 +15 0 ++ 0 +/ 0 +- 0 +5 0 +mumol 0 +/ 0 +mg 0 +crea 0 +) 0 +than 0 +in 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +( 0 +35 0 ++ 0 +/ 0 +- 0 +5 0 +mumol 0 +/ 0 +mg 0 +crea 0 +) 0 +and 0 +was 0 +associated 0 +with 0 +a 0 +significantly 0 +higher 0 +body 0 +weight 3 +gain 4 +in 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +compared 0 +with 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +( 0 ++ 0 +6 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +vs 0 +. 0 ++ 0 +4 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +g 0 +) 0 +. 0 +During 0 +the 0 +course 0 +of 0 +nephrotic 3 +syndrome 4 +"," 0 +serum 0 +urea 1 +concentrations 0 +increased 0 +significantly 0 +faster 0 +in 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +than 0 +in 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +mice 0 +leading 0 +to 0 +uremia 3 +and 0 +a 0 +reduced 0 +median 0 +survival 0 +in 0 +sgk1 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +( 0 +29 0 +vs 0 +. 0 +40 0 +days 0 +in 0 +sgk1 0 +( 0 ++ 0 +/ 0 ++ 0 +) 0 +mice 0 +) 0 +. 0 +In 0 +conclusion 0 +"," 0 +gene 0 +- 0 +targeted 0 +mice 0 +lacking 0 +SGK1 0 +showed 0 +blunted 0 +volume 3 +retention 4 +"," 0 +yet 0 +were 0 +not 0 +protected 0 +against 0 +renal 0 +fibrosis 3 +during 0 +experimental 0 +nephrotic 3 +syndrome 4 +. 0 +Severe 0 +thrombocytopenia 3 +and 0 +haemolytic 3 +anaemia 4 +associated 0 +with 0 +ciprofloxacin 1 +: 0 +a 0 +case 0 +report 0 +with 0 +fatal 0 +outcome 0 +. 0 +Haematological 0 +adverse 0 +reactions 0 +associated 0 +with 0 +fatal 0 +outcome 0 +are 0 +rare 0 +during 0 +treatment 0 +with 0 +ciprofloxacin 1 +. 0 +A 0 +30 0 +- 0 +year 0 +old 0 +Caucasian 0 +man 0 +reported 0 +with 0 +abdominal 3 +pain 4 +and 0 +jaundice 3 +after 0 +3 0 +- 0 +day 0 +administration 0 +of 0 +oral 0 +ciprofloxacin 1 +for 0 +a 0 +suspect 0 +of 0 +urinary 3 +tract 4 +infection 4 +. 0 +Clinical 0 +evaluations 0 +suggested 0 +an 0 +initial 0 +diagnosis 0 +of 0 +severe 0 +thrombocytopenia 3 +and 0 +haemolysis 3 +. 0 +The 0 +patient 0 +progressively 0 +developed 0 +petechiae 3 +and 0 +purpura 3 +on 0 +thorax 0 +and 0 +lower 0 +limbs 0 +. 0 +Despite 0 +pharmacological 0 +and 0 +supportive 0 +interventions 0 +"," 0 +laboratory 0 +parameters 0 +worsened 0 +and 0 +the 0 +patient 0 +died 0 +17 0 +hours 0 +after 0 +admission 0 +. 0 +An 0 +accurate 0 +autopsy 0 +revealed 0 +most 0 +organs 0 +with 0 +diffuse 0 +petechial 0 +haemorrhages 3 +. 0 +No 0 +signs 0 +of 0 +bone 3 +marrow 4 +depression 4 +were 0 +found 0 +. 0 +No 0 +thrombi 3 +or 0 +signs 0 +of 0 +microangiopathies 3 +were 0 +observed 0 +in 0 +arterial 0 +vessels 0 +. 0 +Blood 0 +and 0 +urine 0 +cultures 0 +did 0 +not 0 +show 0 +any 0 +bacterial 0 +growth 0 +. 0 +This 0 +case 0 +report 0 +shows 0 +that 0 +ciprofloxacin 1 +may 0 +precipitate 0 +life 0 +- 0 +threatening 0 +thrombocytopenia 3 +and 0 +haemolytic 3 +anaemia 4 +"," 0 +even 0 +in 0 +the 0 +early 0 +phases 0 +of 0 +treatment 0 +and 0 +without 0 +apparent 0 +previous 0 +exposures 0 +. 0 +Alpha 1 +- 2 +lipoic 2 +acid 2 +prevents 0 +mitochondrial 3 +damage 4 +and 0 +neurotoxicity 3 +in 0 +experimental 0 +chemotherapy 0 +neuropathy 3 +. 0 +The 0 +study 0 +investigates 0 +if 0 +alpha 1 +- 2 +lipoic 2 +acid 2 +is 0 +neuroprotective 0 +against 0 +chemotherapy 0 +induced 0 +neurotoxicity 3 +"," 0 +if 0 +mitochondrial 3 +damage 4 +plays 0 +a 0 +critical 0 +role 0 +in 0 +toxic 3 +neurodegenerative 4 +cascade 4 +"," 0 +and 0 +if 0 +neuroprotective 0 +effects 0 +of 0 +alpha 1 +- 2 +lipoic 2 +acid 2 +depend 0 +on 0 +mitochondria 0 +protection 0 +. 0 +We 0 +used 0 +an 0 +in 0 +vitro 0 +model 0 +of 0 +chemotherapy 0 +induced 0 +peripheral 3 +neuropathy 4 +that 0 +closely 0 +mimic 0 +the 0 +in 0 +vivo 0 +condition 0 +by 0 +exposing 0 +primary 0 +cultures 0 +of 0 +dorsal 0 +root 0 +ganglion 0 +( 0 +DRG 0 +) 0 +sensory 0 +neurons 0 +to 0 +paclitaxel 1 +and 0 +cisplatin 1 +"," 0 +two 0 +widely 0 +used 0 +and 0 +highly 0 +effective 0 +chemotherapeutic 0 +drugs 0 +. 0 +This 0 +approach 0 +allowed 0 +investigating 0 +the 0 +efficacy 0 +of 0 +alpha 1 +- 2 +lipoic 2 +acid 2 +in 0 +preventing 0 +axonal 3 +damage 4 +and 0 +apoptosis 0 +and 0 +the 0 +function 0 +and 0 +ultrastructural 0 +morphology 0 +of 0 +mitochondria 0 +after 0 +exposure 0 +to 0 +toxic 0 +agents 0 +and 0 +alpha 1 +- 2 +lipoic 2 +acid 2 +. 0 +0ur 0 +results 0 +demonstrate 0 +that 0 +both 0 +cisplatin 1 +and 0 +paclitaxel 1 +cause 0 +early 0 +mitochondrial 3 +impairment 4 +with 0 +loss 0 +of 0 +membrane 0 +potential 0 +and 0 +induction 0 +of 0 +autophagic 0 +vacuoles 0 +in 0 +neurons 0 +. 0 +Alpha 1 +- 2 +lipoic 2 +acid 2 +exerts 0 +neuroprotective 0 +effects 0 +against 0 +chemotherapy 0 +induced 0 +neurotoxicity 3 +in 0 +sensory 0 +neurons 0 +: 0 +it 0 +rescues 0 +the 0 +mitochondrial 3 +toxicity 4 +and 0 +induces 0 +the 0 +expression 0 +of 0 +frataxin 0 +"," 0 +an 0 +essential 0 +mitochondrial 0 +protein 0 +with 0 +anti 0 +- 0 +oxidant 0 +and 0 +chaperone 0 +properties 0 +. 0 +In 0 +conclusion 0 +mitochondrial 3 +toxicity 4 +is 0 +an 0 +early 0 +common 0 +event 0 +both 0 +in 0 +paclitaxel 1 +and 0 +cisplatin 1 +induced 0 +neurotoxicity 3 +. 0 +Alpha 1 +- 2 +lipoic 2 +acid 2 +protects 0 +sensory 0 +neurons 0 +through 0 +its 0 +anti 0 +- 0 +oxidant 0 +and 0 +mitochondrial 0 +regulatory 0 +functions 0 +"," 0 +possibly 0 +inducing 0 +the 0 +expression 0 +of 0 +frataxin 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +alpha 1 +- 2 +lipoic 2 +acid 2 +might 0 +reduce 0 +the 0 +risk 0 +of 0 +developing 0 +peripheral 3 +nerve 4 +toxicity 4 +in 0 +patients 0 +undergoing 0 +chemotherapy 0 +and 0 +encourage 0 +further 0 +confirmatory 0 +clinical 0 +trials 0 +. 0 +Toxicity 3 +in 0 +rhesus 0 +monkeys 0 +following 0 +administration 0 +of 0 +the 0 +8 1 +- 2 +aminoquinoline 2 +8 1 +- 2 +[ 2 +( 2 +4 2 +- 2 +amino 2 +- 2 +l 2 +- 2 +methylbutyl 2 +) 2 +amino 2 +] 2 +- 2 +5 2 +- 2 +( 2 +l 2 +- 2 +hexyloxy 2 +) 2 +- 2 +6 2 +- 2 +methoxy 2 +- 2 +4 2 +- 2 +methylquinoline 2 +( 0 +WR242511 1 +) 0 +. 0 +INTR0DUCTI0N 0 +: 0 +Many 0 +substances 0 +that 0 +form 0 +methemoglobin 0 +( 0 +MHb 0 +) 0 +effectively 0 +counter 0 +cyanide 0 +( 0 +CN 0 +) 0 +toxicity 3 +. 0 +Although 0 +MHb 0 +formers 0 +are 0 +generally 0 +applied 0 +as 0 +treatments 0 +for 0 +CN 0 +poisoning 3 +"," 0 +it 0 +has 0 +been 0 +proposed 0 +that 0 +a 0 +stable 0 +"," 0 +long 0 +- 0 +acting 0 +MHb 0 +former 0 +could 0 +serve 0 +as 0 +a 0 +CN 0 +pretreatment 0 +. 0 +Using 0 +this 0 +rationale 0 +"," 0 +the 0 +8 1 +- 2 +aminoquinoline 2 +WR242511 1 +"," 0 +a 0 +potent 0 +long 0 +- 0 +lasting 0 +MHb 0 +former 0 +in 0 +rodents 0 +and 0 +beagle 0 +dogs 0 +"," 0 +was 0 +studied 0 +in 0 +the 0 +rhesus 0 +monkey 0 +for 0 +advanced 0 +development 0 +as 0 +a 0 +potential 0 +CN 0 +pretreatment 0 +. 0 +METH0DS 0 +: 0 +In 0 +this 0 +study 0 +"," 0 +WR242511 1 +was 0 +administered 0 +intravenously 0 +( 0 +IV 0 +) 0 +in 0 +2 0 +female 0 +and 0 +4 0 +male 0 +rhesus 0 +monkeys 0 +in 0 +doses 0 +of 0 +3 0 +. 0 +5 0 +and 0 +/ 0 +or 0 +7 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +; 0 +a 0 +single 0 +male 0 +also 0 +received 0 +WR242511 1 +orally 0 +( 0 +P0 0 +) 0 +at 0 +7 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +. 0 +Health 0 +status 0 +and 0 +MHb 0 +levels 0 +were 0 +monitored 0 +following 0 +exposure 0 +. 0 +RESULTS 0 +: 0 +The 0 +selected 0 +doses 0 +of 0 +WR242511 1 +"," 0 +which 0 +produced 0 +significant 0 +methemoglobinemia 3 +in 0 +beagle 0 +dogs 0 +in 0 +earlier 0 +studies 0 +conducted 0 +elsewhere 0 +"," 0 +produced 0 +very 0 +little 0 +MHb 0 +( 0 +mean 0 +< 0 +2 0 +. 0 +0 0 +% 0 +) 0 +in 0 +the 0 +rhesus 0 +monkey 0 +. 0 +Furthermore 0 +"," 0 +transient 0 +hemoglobinuria 3 +was 0 +noted 0 +approximately 0 +60 0 +minutes 0 +postinjection 0 +of 0 +WR242511 1 +( 0 +3 0 +. 0 +5 0 +or 0 +7 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +and 0 +2 0 +lethalities 0 +occurred 0 +( 0 +one 0 +IV 0 +and 0 +one 0 +P0 0 +) 0 +following 0 +the 0 +7 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +dose 0 +. 0 +Myoglobinuria 3 +was 0 +also 0 +observed 0 +following 0 +the 0 +7 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +dose 0 +. 0 +Histopathology 0 +analyses 0 +in 0 +the 0 +2 0 +animals 0 +that 0 +died 0 +revealed 0 +liver 3 +and 4 +kidney 4 +toxicity 4 +"," 0 +with 0 +greater 0 +severity 0 +in 0 +the 0 +orally 0 +- 0 +treated 0 +animal 0 +. 0 +C0NCLUSI0NS 0 +: 0 +These 0 +data 0 +demonstrate 0 +direct 0 +and 0 +/ 0 +or 0 +indirect 0 +drug 0 +- 0 +induced 0 +toxicity 3 +. 0 +It 0 +is 0 +concluded 0 +that 0 +WR242511 1 +should 0 +not 0 +be 0 +pursued 0 +as 0 +a 0 +pretreatment 0 +for 0 +CN 0 +poisoning 3 +unless 0 +the 0 +anti 0 +- 0 +CN 0 +characteristics 0 +of 0 +this 0 +compound 0 +can 0 +be 0 +successfully 0 +dissociated 0 +from 0 +those 0 +producing 0 +undesirable 0 +toxicity 3 +. 0 +Repetitive 0 +transcranial 0 +magnetic 0 +stimulation 0 +for 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 +In 0 +a 0 +placebo 0 +- 0 +controlled 0 +"," 0 +single 0 +- 0 +blinded 0 +"," 0 +crossover 0 +study 0 +"," 0 +we 0 +assessed 0 +the 0 +effect 0 +of 0 +" 0 +real 0 +" 0 +repetitive 0 +transcranial 0 +magnetic 0 +stimulation 0 +( 0 +rTMS 0 +) 0 +versus 0 +" 0 +sham 0 +" 0 +rTMS 0 +( 0 +placebo 0 +) 0 +on 0 +peak 0 +dose 0 +dyskinesias 3 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +. 0 +Ten 0 +patients 0 +with 0 +PD 3 +and 0 +prominent 0 +dyskinesias 3 +had 0 +rTMS 0 +( 0 +1 0 +"," 0 +800 0 +pulses 0 +; 0 +1 0 +Hz 0 +rate 0 +) 0 +delivered 0 +over 0 +the 0 +motor 0 +cortex 0 +for 0 +4 0 +consecutive 0 +days 0 +twice 0 +"," 0 +once 0 +real 0 +stimuli 0 +and 0 +once 0 +sham 0 +stimulation 0 +were 0 +used 0 +; 0 +evaluations 0 +were 0 +done 0 +at 0 +the 0 +baseline 0 +and 0 +1 0 +day 0 +after 0 +the 0 +end 0 +of 0 +each 0 +of 0 +the 0 +treatment 0 +series 0 +. 0 +Direct 0 +comparison 0 +between 0 +sham 0 +and 0 +real 0 +rTMS 0 +effects 0 +showed 0 +no 0 +significant 0 +difference 0 +in 0 +clinician 0 +- 0 +assessed 0 +dyskinesia 3 +severity 0 +. 0 +However 0 +"," 0 +comparison 0 +with 0 +the 0 +baseline 0 +showed 0 +small 0 +but 0 +significant 0 +reduction 0 +in 0 +dyskinesia 3 +severity 0 +following 0 +real 0 +rTMS 0 +but 0 +not 0 +placebo 0 +. 0 +The 0 +major 0 +effect 0 +was 0 +on 0 +dystonia 3 +subscore 0 +. 0 +Similarly 0 +"," 0 +in 0 +patient 0 +diaries 0 +"," 0 +although 0 +both 0 +treatments 0 +caused 0 +reduction 0 +in 0 +subjective 0 +dyskinesia 3 +scores 0 +during 0 +the 0 +days 0 +of 0 +intervention 0 +"," 0 +the 0 +effect 0 +was 0 +sustained 0 +for 0 +3 0 +days 0 +after 0 +the 0 +intervention 0 +for 0 +the 0 +real 0 +rTMS 0 +only 0 +. 0 +Following 0 +rTMS 0 +"," 0 +no 0 +side 0 +effects 0 +and 0 +no 0 +adverse 0 +effects 0 +on 0 +motor 0 +function 0 +and 0 +PD 3 +symptoms 0 +were 0 +noted 0 +. 0 +The 0 +results 0 +suggest 0 +the 0 +existence 0 +of 0 +residual 0 +beneficial 0 +clinical 0 +aftereffects 0 +of 0 +consecutive 0 +daily 0 +applications 0 +of 0 +low 0 +- 0 +frequency 0 +rTMS 0 +on 0 +dyskinesias 3 +in 0 +PD 3 +. 0 +The 0 +effects 0 +may 0 +be 0 +further 0 +exploited 0 +for 0 +potential 0 +therapeutic 0 +uses 0 +. 0 +Intracavernous 0 +epinephrine 1 +: 0 +a 0 +minimally 0 +invasive 0 +treatment 0 +for 0 +priapism 3 +in 0 +the 0 +emergency 0 +department 0 +. 0 +Priapism 3 +is 0 +the 0 +prolonged 0 +erection 0 +of 0 +the 0 +penis 0 +in 0 +the 0 +absence 0 +of 0 +sexual 0 +arousal 0 +. 0 +A 0 +45 0 +- 0 +year 0 +- 0 +old 0 +man 0 +"," 0 +an 0 +admitted 0 +frequent 0 +cocaine 1 +user 0 +"," 0 +presented 0 +to 0 +the 0 +Emergency 0 +Department 0 +( 0 +ED 0 +) 0 +on 0 +two 0 +separate 0 +occasions 0 +with 0 +a 0 +history 0 +of 0 +priapism 3 +after 0 +cocaine 1 +use 0 +. 0 +The 0 +management 0 +options 0 +in 0 +the 0 +ED 0 +"," 0 +as 0 +exemplified 0 +by 0 +four 0 +individual 0 +case 0 +reports 0 +"," 0 +in 0 +particular 0 +the 0 +use 0 +of 0 +a 0 +minimally 0 +invasive 0 +method 0 +of 0 +intracorporal 0 +epinephrine 1 +instillation 0 +"," 0 +are 0 +discussed 0 +. 0 +Prophylactic 0 +use 0 +of 0 +lamivudine 1 +with 0 +chronic 0 +immunosuppressive 0 +therapy 0 +for 0 +rheumatologic 3 +disorders 4 +. 0 +The 0 +objective 0 +of 0 +this 0 +study 0 +was 0 +to 0 +report 0 +our 0 +experience 0 +concerning 0 +the 0 +effectiveness 0 +of 0 +the 0 +prophylactic 0 +administration 0 +of 0 +lamivudine 1 +in 0 +hepatitis 1 +B 2 +virus 2 +surface 2 +antigen 2 +( 0 +HBs 1 +Ag 2 +) 0 +positive 0 +patients 0 +with 0 +rheumatologic 3 +disease 4 +. 0 +From 0 +June 0 +2004 0 +to 0 +0ctober 0 +2006 0 +"," 0 +11 0 +HBs 1 +Ag 2 +positive 0 +patients 0 +with 0 +rheumatologic 3 +diseases 4 +"," 0 +who 0 +were 0 +on 0 +both 0 +immunosuppressive 0 +and 0 +prophylactic 0 +lamivudine 1 +therapies 0 +"," 0 +were 0 +retrospectively 0 +assessed 0 +. 0 +Liver 0 +function 0 +tests 0 +"," 0 +hepatitis 3 +B 4 +virus 0 +( 0 +HBV 0 +) 0 +serologic 0 +markers 0 +"," 0 +and 0 +HBV 0 +DNA 0 +levels 0 +of 0 +the 0 +patients 0 +during 0 +follow 0 +- 0 +up 0 +were 0 +obtained 0 +from 0 +hospital 0 +file 0 +records 0 +. 0 +Eleven 0 +patients 0 +( 0 +six 0 +male 0 +) 0 +with 0 +median 0 +age 0 +47 0 +years 0 +( 0 +range 0 +27 0 +- 0 +73 0 +) 0 +"," 0 +median 0 +disease 0 +duration 0 +50 0 +months 0 +( 0 +range 0 +9 0 +- 0 +178 0 +) 0 +and 0 +median 0 +follow 0 +- 0 +up 0 +period 0 +of 0 +patients 0 +13 0 +. 0 +8 0 +months 0 +( 0 +range 0 +5 0 +- 0 +27 0 +) 0 +were 0 +enrolled 0 +in 0 +this 0 +study 0 +. 0 +Lamivudine 1 +therapy 0 +was 0 +started 0 +3 0 +- 0 +7 0 +days 0 +prior 0 +to 0 +immunosuppressive 0 +therapy 0 +in 0 +all 0 +patients 0 +. 0 +Baseline 0 +"," 0 +liver 0 +function 0 +tests 0 +were 0 +elevated 0 +in 0 +two 0 +patients 0 +( 0 +fourth 0 +patient 0 +: 0 +ALT 0 +: 0 +122 0 +IU 0 +/ 0 +l 0 +"," 0 +AST 0 +: 0 +111 0 +IU 0 +/ 0 +l 0 +"," 0 +tenth 0 +patient 0 +: 0 +ALT 0 +: 0 +294 0 +IU 0 +/ 0 +l 0 +"," 0 +AST 0 +: 0 +274 0 +IU 0 +/ 0 +l 0 +"," 0 +with 0 +minimal 0 +changes 0 +in 0 +the 0 +liver 0 +biopsy 0 +in 0 +both 0 +) 0 +. 0 +Shortly 0 +after 0 +treatment 0 +their 0 +tests 0 +normalized 0 +and 0 +during 0 +follow 0 +- 0 +up 0 +period 0 +none 0 +of 0 +the 0 +patients 0 +had 0 +abnormal 3 +liver 4 +function 4 +tests 0 +. 0 +In 0 +four 0 +patients 0 +HBV 0 +DNA 0 +levels 0 +were 0 +higher 0 +than 0 +normal 0 +at 0 +baseline 0 +. 0 +Two 0 +of 0 +these 0 +normalized 0 +and 0 +the 0 +others 0 +increased 0 +later 0 +. 0 +In 0 +three 0 +additional 0 +patients 0 +"," 0 +HBV 0 +DNA 0 +levels 0 +were 0 +increased 0 +during 0 +follow 0 +- 0 +up 0 +. 0 +None 0 +of 0 +the 0 +patients 0 +had 0 +significant 0 +clinical 0 +sings 0 +of 0 +HBV 0 +activation 0 +. 0 +Lamivudine 1 +was 0 +well 0 +tolerated 0 +and 0 +was 0 +continued 0 +in 0 +all 0 +patients 0 +. 0 +Prophylactic 0 +administration 0 +of 0 +lamivudine 1 +in 0 +patients 0 +who 0 +required 0 +immunosuppressive 0 +therapy 0 +seems 0 +to 0 +be 0 +safe 0 +"," 0 +well 0 +tolerated 0 +and 0 +effective 0 +in 0 +preventing 0 +HBV 0 +reactivation 0 +. 0 +Effect 0 +of 0 +green 1 +tea 2 +and 0 +vitamin 1 +E 2 +combination 0 +in 0 +isoproterenol 1 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +The 0 +present 0 +study 0 +was 0 +aimed 0 +to 0 +investigate 0 +the 0 +combined 0 +effects 0 +of 0 +green 1 +tea 2 +and 0 +vitamin 1 +E 2 +on 0 +heart 0 +weight 0 +"," 0 +body 0 +weight 0 +"," 0 +serum 0 +marker 0 +enzymes 0 +"," 0 +lipid 0 +peroxidation 0 +"," 0 +endogenous 0 +antioxidants 0 +and 0 +membrane 0 +bound 0 +ATPases 0 +in 0 +isoproterenol 1 +( 0 +IS0 1 +) 0 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Adult 0 +male 0 +albino 0 +rats 0 +"," 0 +treated 0 +with 0 +IS0 1 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +"," 0 +s 0 +. 0 +c 0 +. 0 +) 0 +for 0 +2 0 +days 0 +at 0 +an 0 +interval 0 +of 0 +24 0 +h 0 +caused 0 +a 0 +significant 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +elevation 0 +of 0 +heart 0 +weight 0 +"," 0 +serum 0 +marker 0 +enzymes 0 +"," 0 +lipid 0 +peroxidation 0 +and 0 +Ca 1 ++ 0 +2 0 +ATPase 0 +level 0 +whereas 0 +there 0 +was 0 +a 0 +significant 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +decrease 0 +in 0 +body 0 +weight 0 +"," 0 +endogenous 0 +antioxidants 0 +"," 0 +Na 1 ++ 0 +/ 0 +K 1 ++ 0 +ATPase 0 +and 0 +Mg 1 ++ 0 +2 0 +ATPase 0 +levels 0 +. 0 +Administration 0 +of 0 +green 1 +tea 2 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +) 0 +and 0 +vitamin 1 +E 2 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +) 0 +together 0 +for 0 +30 0 +consecutive 0 +days 0 +and 0 +challenged 0 +with 0 +IS0 1 +on 0 +the 0 +day 0 +29th 0 +and 0 +30th 0 +"," 0 +showed 0 +a 0 +significant 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +decrease 0 +in 0 +heart 0 +weight 0 +"," 0 +serum 0 +marker 0 +enzymes 0 +"," 0 +lipid 0 +peroxidation 0 +"," 0 +Ca 1 ++ 0 +2 0 +ATPase 0 +and 0 +a 0 +significant 0 +increase 0 +in 0 +the 0 +body 0 +weight 0 +"," 0 +endogenous 0 +antioxidants 0 +"," 0 +Na 1 ++ 0 +/ 0 +K 1 ++ 0 +ATPase 0 +and 0 +Mg 1 ++ 0 +2 0 +ATPase 0 +when 0 +compared 0 +with 0 +IS0 1 +treated 0 +group 0 +and 0 +green 1 +tea 2 +or 0 +vitamin 1 +E 2 +alone 0 +treated 0 +groups 0 +. 0 +These 0 +findings 0 +indicate 0 +the 0 +synergistic 0 +protective 0 +effect 0 +of 0 +green 1 +tea 2 +and 0 +vitamin 1 +E 2 +during 0 +IS0 1 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Irreversible 0 +damage 0 +to 0 +the 0 +medullary 0 +interstitium 0 +in 0 +experimental 0 +analgesic 0 +nephropathy 3 +in 0 +F344 0 +rats 0 +. 0 +Renal 3 +papillary 4 +necrosis 4 +( 0 +RPN 3 +) 0 +and 0 +a 0 +decreased 0 +urinary 0 +concentrating 0 +ability 0 +developed 0 +during 0 +continuous 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +aspirin 1 +and 0 +paracetamol 1 +in 0 +female 0 +Fischer 0 +344 0 +rats 0 +. 0 +Renal 0 +structure 0 +and 0 +concentrating 0 +ability 0 +were 0 +examined 0 +after 0 +a 0 +recovery 0 +period 0 +of 0 +up 0 +to 0 +18 0 +weeks 0 +"," 0 +when 0 +no 0 +analgesics 0 +were 0 +given 0 +"," 0 +to 0 +investigate 0 +whether 0 +the 0 +analgesic 0 +- 0 +induced 0 +changes 0 +were 0 +reversible 0 +. 0 +There 0 +was 0 +no 0 +evidence 0 +of 0 +repair 0 +to 0 +the 0 +damaged 0 +medullary 0 +interstitial 0 +matrix 0 +"," 0 +or 0 +proliferation 0 +of 0 +remaining 0 +undamaged 0 +type 0 +1 0 +medullary 0 +interstitial 0 +cells 0 +after 0 +the 0 +recovery 0 +period 0 +following 0 +analgesic 0 +treatment 0 +. 0 +The 0 +recovery 0 +of 0 +urinary 0 +concentrating 0 +ability 0 +was 0 +related 0 +to 0 +the 0 +length 0 +of 0 +analgesic 0 +treatment 0 +and 0 +the 0 +extent 0 +of 0 +the 0 +resulting 0 +inner 0 +medullary 0 +structural 0 +damage 0 +. 0 +During 0 +the 0 +early 0 +stages 0 +of 0 +analgesic 0 +treatment 0 +"," 0 +the 0 +changes 0 +in 0 +urinary 0 +concentrating 0 +ability 0 +were 0 +reversible 0 +"," 0 +but 0 +after 0 +prolonged 0 +analgesic 0 +treatment 0 +"," 0 +maximum 0 +urinary 0 +concentrating 0 +ability 0 +failed 0 +to 0 +recover 0 +. 0 +This 0 +study 0 +shows 0 +that 0 +prolonged 0 +analgesic 0 +treatment 0 +in 0 +Fischer 0 +344 0 +rats 0 +causes 0 +progressive 0 +and 0 +irreversible 0 +damage 0 +to 0 +the 0 +interstitial 0 +matrix 0 +and 0 +type 0 +1 0 +interstitial 0 +cells 0 +leading 0 +to 0 +RPN 3 +. 0 +The 0 +associated 0 +urinary 0 +concentrating 0 +defect 0 +is 0 +reversible 0 +only 0 +during 0 +the 0 +early 0 +stages 0 +of 0 +structural 0 +damage 0 +to 0 +the 0 +inner 0 +medulla 0 +. 0 +Testosterone 1 +- 0 +dependent 0 +hypertension 3 +and 0 +upregulation 0 +of 0 +intrarenal 0 +angiotensinogen 0 +in 0 +Dahl 0 +salt 1 +- 0 +sensitive 0 +rats 0 +. 0 +Blood 0 +pressure 0 +( 0 +BP 0 +) 0 +is 0 +more 0 +salt 1 +sensitive 0 +in 0 +men 0 +than 0 +in 0 +premenopausal 0 +women 0 +. 0 +In 0 +Dahl 0 +salt 1 +- 0 +sensitive 0 +rats 0 +( 0 +DS 0 +) 0 +"," 0 +high 0 +- 0 +salt 1 +( 0 +HS 0 +) 0 +diet 0 +increases 0 +BP 0 +more 0 +in 0 +males 0 +than 0 +females 0 +. 0 +In 0 +contrast 0 +to 0 +the 0 +systemic 0 +renin 0 +- 0 +angiotensin 1 +system 0 +"," 0 +which 0 +is 0 +suppressed 0 +in 0 +response 0 +to 0 +HS 0 +in 0 +male 0 +DS 0 +"," 0 +intrarenal 0 +angiotensinogen 0 +expression 0 +is 0 +increased 0 +"," 0 +and 0 +intrarenal 0 +levels 0 +of 0 +ANG 0 +II 0 +are 0 +not 0 +suppressed 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +the 0 +hypothesis 0 +was 0 +tested 0 +that 0 +there 0 +is 0 +a 0 +sexual 0 +dimorphism 0 +in 0 +HS 0 +- 0 +induced 0 +upregulation 0 +of 0 +intrarenal 0 +angiotensinogen 0 +mediated 0 +by 0 +testosterone 1 +that 0 +also 0 +causes 0 +increases 0 +in 0 +BP 0 +and 0 +renal 3 +injury 4 +. 0 +0n 0 +a 0 +low 0 +- 0 +salt 1 +( 0 +LS 0 +) 0 +diet 0 +"," 0 +male 0 +DS 0 +had 0 +higher 0 +levels 0 +of 0 +intrarenal 0 +angiotensinogen 0 +mRNA 0 +than 0 +females 0 +. 0 +HS 0 +diet 0 +for 0 +4 0 +wk 0 +increased 0 +renal 0 +cortical 0 +angiotensinogen 0 +mRNA 0 +and 0 +protein 0 +only 0 +in 0 +male 0 +DS 0 +"," 0 +which 0 +was 0 +prevented 0 +by 0 +castration 0 +. 0 +0variectomy 0 +of 0 +female 0 +DS 0 +had 0 +no 0 +effect 0 +on 0 +intrarenal 0 +angiotensinogen 0 +expression 0 +on 0 +either 0 +diet 0 +. 0 +Radiotelemetric 0 +BP 0 +was 0 +similar 0 +between 0 +males 0 +and 0 +castrated 0 +rats 0 +on 0 +LS 0 +diet 0 +. 0 +HS 0 +diet 0 +for 0 +4 0 +wk 0 +caused 0 +a 0 +progressive 0 +increase 0 +in 0 +BP 0 +"," 0 +protein 0 +and 0 +albumin 0 +excretion 0 +"," 0 +and 0 +glomerular 3 +sclerosis 4 +in 0 +male 0 +DS 0 +rats 0 +"," 0 +which 0 +were 0 +attenuated 0 +by 0 +castration 0 +. 0 +Testosterone 1 +replacement 0 +in 0 +castrated 0 +DS 0 +rats 0 +increased 0 +BP 0 +"," 0 +renal 3 +injury 4 +"," 0 +and 0 +upregulation 0 +of 0 +renal 0 +angiotensinogen 0 +associated 0 +with 0 +HS 0 +diet 0 +. 0 +Testosterone 1 +contributes 0 +to 0 +the 0 +development 0 +of 0 +hypertension 3 +and 0 +renal 3 +injury 4 +in 0 +male 0 +DS 0 +rats 0 +on 0 +HS 0 +diet 0 +possibly 0 +through 0 +upregulation 0 +of 0 +the 0 +intrarenal 0 +renin 0 +- 0 +angiotensin 1 +system 0 +. 0 +Explicit 0 +episodic 0 +memory 0 +for 0 +sensory 0 +- 0 +discriminative 0 +components 0 +of 0 +capsaicin 1 +- 0 +induced 0 +pain 3 +: 0 +immediate 0 +and 0 +delayed 0 +ratings 0 +. 0 +Pain 3 +memory 0 +is 0 +thought 0 +to 0 +affect 0 +future 0 +pain 3 +sensitivity 0 +and 0 +thus 0 +contribute 0 +to 0 +clinical 0 +pain 3 +conditions 0 +. 0 +Systematic 0 +investigations 0 +of 0 +the 0 +human 0 +capacity 0 +to 0 +remember 0 +sensory 0 +features 0 +of 0 +experimental 0 +pain 3 +are 0 +sparse 0 +. 0 +In 0 +order 0 +to 0 +address 0 +long 0 +- 0 +term 0 +pain 3 +memory 0 +"," 0 +nine 0 +healthy 0 +male 0 +volunteers 0 +received 0 +intradermal 0 +injections 0 +of 0 +three 0 +doses 0 +of 0 +capsaicin 1 +( 0 +0 0 +. 0 +5 0 +"," 0 +1 0 +and 0 +20 0 +microg 0 +"," 0 +separated 0 +by 0 +15 0 +min 0 +breaks 0 +) 0 +"," 0 +each 0 +given 0 +three 0 +times 0 +in 0 +a 0 +balanced 0 +design 0 +across 0 +three 0 +sessions 0 +at 0 +one 0 +week 0 +intervals 0 +. 0 +Pain 3 +rating 0 +was 0 +performed 0 +using 0 +a 0 +computerized 0 +visual 0 +analogue 0 +scale 0 +( 0 +0 0 +- 0 +100 0 +) 0 +digitized 0 +at 0 +1 0 +/ 0 +s 0 +"," 0 +either 0 +immediately 0 +online 0 +or 0 +one 0 +hour 0 +or 0 +one 0 +day 0 +after 0 +injection 0 +. 0 +Subjects 0 +also 0 +recalled 0 +their 0 +pains 3 +one 0 +week 0 +later 0 +. 0 +Capsaicin 1 +injection 0 +reliably 0 +induced 0 +a 0 +dose 0 +- 0 +dependent 0 +flare 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +without 0 +any 0 +difference 0 +within 0 +or 0 +across 0 +sessions 0 +. 0 +The 0 +strong 0 +burning 0 +pain 3 +decayed 0 +exponentially 0 +within 0 +a 0 +few 0 +minutes 0 +. 0 +Subjects 0 +were 0 +able 0 +to 0 +reliably 0 +discriminate 0 +pain 3 +magnitude 0 +and 0 +duration 0 +across 0 +capsaicin 1 +doses 0 +( 0 +both 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +regardless 0 +of 0 +whether 0 +first 0 +- 0 +time 0 +ratings 0 +were 0 +requested 0 +immediately 0 +"," 0 +after 0 +one 0 +hour 0 +or 0 +after 0 +one 0 +day 0 +. 0 +Pain 3 +recall 0 +after 0 +one 0 +week 0 +was 0 +similarly 0 +precise 0 +( 0 +magnitude 0 +: 0 +p 0 +< 0 +0 0 +. 0 +1 0 +"," 0 +duration 0 +: 0 +p 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +Correlation 0 +with 0 +rating 0 +recall 0 +after 0 +one 0 +week 0 +was 0 +best 0 +when 0 +first 0 +- 0 +time 0 +ratings 0 +were 0 +requested 0 +as 0 +late 0 +as 0 +one 0 +day 0 +after 0 +injection 0 +( 0 +R 0 +( 0 +2 0 +) 0 += 0 +0 0 +. 0 +79 0 +) 0 +indicating 0 +that 0 +both 0 +rating 0 +retrievals 0 +utilized 0 +similar 0 +memory 0 +traces 0 +. 0 +These 0 +results 0 +indicate 0 +a 0 +reliable 0 +memory 0 +for 0 +magnitude 0 +and 0 +duration 0 +of 0 +experimentally 0 +induced 0 +pain 3 +. 0 +The 0 +data 0 +further 0 +suggest 0 +that 0 +the 0 +consolidation 0 +of 0 +this 0 +memory 0 +is 0 +an 0 +important 0 +interim 0 +stage 0 +"," 0 +and 0 +may 0 +take 0 +up 0 +to 0 +one 0 +day 0 +. 0 +Severe 0 +and 0 +long 0 +lasting 0 +cholestasis 3 +after 0 +high 0 +- 0 +dose 0 +co 1 +- 2 +trimoxazole 2 +treatment 0 +for 0 +Pneumocystis 3 +pneumonia 4 +in 0 +HIV 3 +- 4 +infected 4 +patients 0 +- 0 +- 0 +a 0 +report 0 +of 0 +two 0 +cases 0 +. 0 +Pneumocystis 3 +pneumonia 4 +( 0 +PCP 3 +) 0 +"," 0 +a 0 +common 0 +opportunistic 3 +infection 4 +in 0 +HIV 3 +- 4 +infected 4 +individuals 0 +"," 0 +is 0 +generally 0 +treated 0 +with 0 +high 0 +doses 0 +of 0 +co 1 +- 2 +trimoxazole 2 +. 0 +However 0 +"," 0 +treatment 0 +is 0 +often 0 +limited 0 +by 0 +adverse 0 +effects 0 +. 0 +Here 0 +"," 0 +we 0 +report 0 +two 0 +cases 0 +of 0 +severely 0 +immunocompromised 0 +HIV 3 +- 4 +infected 4 +patients 0 +who 0 +developed 0 +severe 0 +intrahepatic 3 +cholestasis 4 +"," 0 +and 0 +in 0 +one 0 +patient 0 +lesions 0 +mimicking 0 +liver 3 +abscess 4 +formation 0 +on 0 +radiologic 0 +exams 0 +"," 0 +during 0 +co 1 +- 2 +trimoxazole 2 +treatment 0 +for 0 +PCP 3 +. 0 +Whereas 0 +patient 0 +1 0 +showed 0 +lesions 0 +of 0 +up 0 +to 0 +1 0 +cm 0 +readily 0 +detectable 0 +on 0 +magnetic 0 +resonance 0 +imaging 0 +under 0 +prolonged 0 +co 1 +- 2 +trimoxazole 2 +treatment 0 +"," 0 +therapy 0 +of 0 +patient 0 +2 0 +was 0 +switched 0 +early 0 +. 0 +Bradykinin 1 +receptors 0 +antagonists 0 +and 0 +nitric 1 +oxide 2 +synthase 0 +inhibitors 0 +in 0 +vincristine 1 +and 0 +streptozotocin 1 +induced 0 +hyperalgesia 3 +in 0 +chemotherapy 0 +and 0 +diabetic 3 +neuropathy 4 +rat 0 +model 0 +. 0 +PURP0SE 0 +: 0 +The 0 +influence 0 +of 0 +an 0 +irreversible 0 +inhibitor 0 +of 0 +constitutive 0 +N0 1 +synthase 0 +( 0 +L 0 +- 0 +N0Arg 0 +; 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +"," 0 +a 0 +relatively 0 +selective 0 +inhibitor 0 +of 0 +inducible 0 +N0 1 +synthase 0 +( 0 +L 0 +- 0 +NIL 0 +; 0 +1 0 +. 0 +0 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +and 0 +a 0 +relatively 0 +specific 0 +inhibitor 0 +of 0 +neuronal 0 +N0 1 +synthase 0 +( 0 +7 0 +- 0 +NI 0 +; 0 +0 0 +. 0 +1 0 +mg 0 +/ 0 +kg 0 +ip 0 +) 0 +"," 0 +on 0 +antihyperalgesic 0 +action 0 +of 0 +selective 0 +antagonists 0 +of 0 +B2 0 +and 0 +B1 0 +receptors 0 +: 0 +D 0 +- 0 +Arg 0 +- 0 +[ 0 +Hyp3 0 +"," 0 +Thi5 0 +"," 0 +D 0 +- 0 +Tic7 0 +"," 0 +0ic8 0 +] 0 +bradykinin 1 +( 0 +H0E 1 +140 2 +; 0 +70 0 +nmol 0 +/ 0 +kg 0 +ip 0 +) 0 +or 0 +des 1 +Arg10 2 +H0E 2 +140 2 +( 0 +70 0 +nmol 0 +/ 0 +kg 0 +ip 0 +) 0 +respectively 0 +"," 0 +in 0 +model 0 +of 0 +diabetic 3 +( 4 +streptozotocin 4 +- 4 +induced 4 +) 4 +and 4 +toxic 4 +( 4 +vincristine 4 +- 4 +induced 4 +) 4 +neuropathy 4 +was 0 +investigated 0 +. 0 +METH0DS 0 +: 0 +The 0 +changes 0 +in 0 +pain 3 +thresholds 0 +were 0 +determined 0 +using 0 +mechanical 0 +stimuli 0 +- 0 +- 0 +the 0 +modification 0 +of 0 +the 0 +classic 0 +paw 0 +withdrawal 0 +test 0 +described 0 +by 0 +Randall 0 +- 0 +Selitto 0 +. 0 +RESULTS 0 +: 0 +The 0 +results 0 +of 0 +this 0 +paper 0 +confirm 0 +that 0 +inhibition 0 +of 0 +bradykinin 1 +receptors 0 +and 0 +inducible 0 +N0 1 +synthase 0 +but 0 +not 0 +neuronal 0 +N0 1 +synthase 0 +activity 0 +reduces 0 +diabetic 3 +hyperalgesia 4 +. 0 +Pretreatment 0 +with 0 +L 0 +- 0 +N0Arg 0 +and 0 +L 0 +- 0 +NIL 0 +but 0 +not 0 +7 0 +- 0 +NI 0 +"," 0 +significantly 0 +increases 0 +antihyperalgesic 0 +activity 0 +both 0 +H0E 1 +140 2 +and 0 +des 1 +Arg10 2 +H0E 2 +140 2 +. 0 +It 0 +was 0 +also 0 +shown 0 +that 0 +both 0 +products 0 +of 0 +inducible 0 +N0 1 +synthase 0 +and 0 +neuronal 0 +N0 1 +synthase 0 +activation 0 +as 0 +well 0 +as 0 +bradykinin 1 +are 0 +involved 0 +in 0 +hyperalgesia 3 +produced 0 +by 0 +vincristine 1 +. 0 +Moreover 0 +"," 0 +L 0 +- 0 +N0Arg 0 +and 0 +7 0 +- 0 +NI 0 +but 0 +not 0 +L 0 +- 0 +NIL 0 +intensify 0 +antihyperalgesic 0 +activity 0 +of 0 +H0E 1 +140 2 +or 0 +des 1 +- 2 +Arg10H0E 2 +140 2 +in 0 +toxic 3 +neuropathy 4 +. 0 +C0NCLUSI0NS 0 +: 0 +Results 0 +of 0 +these 0 +studies 0 +suggest 0 +that 0 +B1 0 +and 0 +B2 0 +receptors 0 +are 0 +engaged 0 +in 0 +transmission 0 +of 0 +nociceptive 0 +stimuli 0 +in 0 +both 0 +diabetic 3 +and 4 +toxic 4 +neuropathy 4 +. 0 +In 0 +streptozotocin 1 +- 0 +induced 0 +hyperalgesia 3 +"," 0 +inducible 0 +N0 1 +synthase 0 +participates 0 +in 0 +pronociceptive 0 +activity 0 +of 0 +bradykinin 1 +"," 0 +whereas 0 +in 0 +vincristine 1 +- 0 +induced 0 +hyperalgesia 3 +bradykinin 1 +seemed 0 +to 0 +activate 0 +neuronal 0 +N0 1 +synthase 0 +pathway 0 +. 0 +Therefore 0 +"," 0 +concomitant 0 +administration 0 +of 0 +small 0 +doses 0 +of 0 +bradykinin 1 +receptor 0 +antagonists 0 +and 0 +N0 1 +synthase 0 +inhibitors 0 +can 0 +be 0 +effective 0 +in 0 +alleviation 0 +of 0 +neuropathic 3 +pain 4 +"," 0 +even 0 +in 0 +hospital 0 +care 0 +. 0 +Confusion 3 +"," 0 +a 0 +rather 0 +serious 0 +adverse 0 +drug 0 +reaction 0 +with 0 +valproic 1 +acid 2 +: 0 +a 0 +review 0 +of 0 +the 0 +French 0 +Pharmacovigilance 0 +database 0 +. 0 +INTR0DUCTI0N 0 +: 0 +Confusion 3 +is 0 +an 0 +adverse 0 +drug 0 +reaction 0 +frequently 0 +observed 0 +with 0 +valproic 1 +acid 2 +. 0 +Some 0 +case 0 +reports 0 +are 0 +published 0 +in 0 +the 0 +literature 0 +but 0 +no 0 +systematic 0 +study 0 +from 0 +a 0 +sample 0 +of 0 +patients 0 +has 0 +been 0 +published 0 +. 0 +We 0 +performed 0 +this 0 +study 0 +in 0 +order 0 +to 0 +describe 0 +the 0 +main 0 +characteristics 0 +of 0 +this 0 +adverse 0 +drug 0 +reaction 0 +. 0 +METH0DS 0 +: 0 +Using 0 +the 0 +French 0 +Pharmacovigilance 0 +database 0 +"," 0 +we 0 +selected 0 +the 0 +cases 0 +of 0 +confusion 3 +reported 0 +since 0 +1985 0 +with 0 +valproic 1 +acid 2 +. 0 +RESULTS 0 +: 0 +272 0 +cases 0 +of 0 +confusion 3 +were 0 +reported 0 +with 0 +valproic 1 +acid 2 +: 0 +153 0 +women 0 +and 0 +119 0 +men 0 +. 0 +Confusion 3 +mostly 0 +occurred 0 +during 0 +the 0 +two 0 +first 0 +weeks 0 +following 0 +valproic 1 +acid 2 +exposure 0 +( 0 +39 0 +. 0 +7 0 +% 0 +) 0 +. 0 +It 0 +was 0 +" 0 +serious 0 +" 0 +for 0 +almost 0 +2 0 +/ 0 +3 0 +of 0 +the 0 +patients 0 +( 0 +62 0 +. 0 +5 0 +% 0 +) 0 +and 0 +its 0 +outcome 0 +favourable 0 +in 0 +most 0 +of 0 +the 0 +cases 0 +( 0 +82 0 +% 0 +) 0 +. 0 +The 0 +occurrence 0 +of 0 +this 0 +ADR 0 +was 0 +more 0 +frequent 0 +in 0 +patients 0 +aged 0 +between 0 +61 0 +and 0 +80 0 +years 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +work 0 +shows 0 +that 0 +confusion 3 +with 0 +valproic 1 +acid 2 +is 0 +a 0 +serious 0 +"," 0 +rather 0 +frequent 0 +but 0 +reversible 0 +adverse 0 +drug 0 +reaction 0 +. 0 +It 0 +occurs 0 +especially 0 +in 0 +older 0 +patients 0 +and 0 +during 0 +the 0 +first 0 +two 0 +weeks 0 +of 0 +treatment 0 +. 0 +Reversible 0 +inferior 3 +colliculus 4 +lesion 4 +in 0 +metronidazole 1 +- 0 +induced 0 +encephalopathy 3 +: 0 +magnetic 0 +resonance 0 +findings 0 +on 0 +diffusion 0 +- 0 +weighted 0 +and 0 +fluid 0 +attenuated 0 +inversion 0 +recovery 0 +imaging 0 +. 0 +0BJECTIVE 0 +: 0 +This 0 +is 0 +to 0 +present 0 +reversible 0 +inferior 3 +colliculus 4 +lesions 4 +in 0 +metronidazole 1 +- 0 +induced 0 +encephalopathy 3 +"," 0 +to 0 +focus 0 +on 0 +the 0 +diffusion 0 +- 0 +weighted 0 +imaging 0 +( 0 +DWI 0 +) 0 +and 0 +fluid 0 +attenuated 0 +inversion 0 +recovery 0 +( 0 +FLAIR 0 +) 0 +imaging 0 +. 0 +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +From 0 +November 0 +2005 0 +to 0 +September 0 +2007 0 +"," 0 +8 0 +patients 0 +( 0 +5 0 +men 0 +and 0 +3 0 +women 0 +) 0 +were 0 +diagnosed 0 +as 0 +having 0 +metronidazole 1 +- 0 +induced 0 +encephalopathy 3 +( 0 +age 0 +range 0 +; 0 +43 0 +- 0 +78 0 +years 0 +) 0 +. 0 +They 0 +had 0 +been 0 +taking 0 +metronidazole 1 +( 0 +total 0 +dosage 0 +"," 0 +45 0 +- 0 +120 0 +g 0 +; 0 +duration 0 +"," 0 +30 0 +days 0 +to 0 +2 0 +months 0 +) 0 +to 0 +treat 0 +the 0 +infection 3 +in 0 +various 0 +organs 0 +. 0 +Initial 0 +brain 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +MRI 0 +) 0 +were 0 +obtained 0 +after 0 +the 0 +hospitalization 0 +"," 0 +including 0 +DWI 0 +( 0 +8 0 +/ 0 +8 0 +) 0 +"," 0 +apparent 0 +diffusion 0 +coefficient 0 +( 0 +ADC 0 +) 0 +map 0 +( 0 +4 0 +/ 0 +8 0 +) 0 +"," 0 +FLAIR 0 +( 0 +7 0 +/ 0 +8 0 +) 0 +"," 0 +and 0 +T2 0 +- 0 +weighted 0 +image 0 +( 0 +8 0 +/ 0 +8 0 +) 0 +. 0 +Follow 0 +- 0 +up 0 +MRIs 0 +were 0 +performed 0 +on 0 +5 0 +patients 0 +from 0 +third 0 +to 0 +14th 0 +days 0 +after 0 +discontinuation 0 +of 0 +metronidazole 1 +administration 0 +. 0 +Findings 0 +of 0 +initial 0 +and 0 +follow 0 +- 0 +up 0 +MRIs 0 +were 0 +retrospectively 0 +evaluated 0 +by 0 +2 0 +neuroradiologists 0 +by 0 +consensus 0 +"," 0 +to 0 +analyze 0 +the 0 +presence 0 +of 0 +abnormal 0 +signal 0 +intensities 0 +"," 0 +their 0 +locations 0 +"," 0 +and 0 +signal 0 +changes 0 +on 0 +follow 0 +- 0 +up 0 +images 0 +. 0 +RESULTS 0 +: 0 +Initial 0 +MRIs 0 +showed 0 +abnormal 0 +high 0 +signal 0 +intensities 0 +on 0 +DWI 0 +and 0 +FLAIR 0 +( 0 +or 0 +T2 0 +- 0 +weighted 0 +image 0 +) 0 +at 0 +the 0 +dentate 0 +nucleus 0 +( 0 +8 0 +/ 0 +8 0 +) 0 +"," 0 +inferior 0 +colliculus 0 +( 0 +6 0 +/ 0 +8 0 +) 0 +"," 0 +corpus 0 +callosum 0 +( 0 +2 0 +/ 0 +8 0 +) 0 +"," 0 +pons 0 +( 0 +2 0 +/ 0 +8 0 +) 0 +"," 0 +medulla 0 +( 0 +1 0 +/ 0 +8 0 +) 0 +"," 0 +and 0 +bilateral 0 +cerebral 0 +white 0 +matter 0 +( 0 +1 0 +/ 0 +8 0 +) 0 +. 0 +High 0 +- 0 +signal 0 +intensity 0 +lesions 0 +on 0 +DWI 0 +tended 0 +to 0 +show 0 +low 0 +signal 0 +intensity 0 +on 0 +ADC 0 +map 0 +( 0 +3 0 +/ 0 +4 0 +) 0 +"," 0 +but 0 +in 0 +one 0 +patient 0 +"," 0 +high 0 +signal 0 +intensity 0 +was 0 +shown 0 +at 0 +bilateral 0 +dentate 0 +nuclei 0 +on 0 +not 0 +only 0 +DWI 0 +but 0 +also 0 +ADC 0 +map 0 +. 0 +All 0 +the 0 +lesions 0 +in 0 +dentate 0 +"," 0 +inferior 0 +colliculus 0 +"," 0 +pons 0 +"," 0 +and 0 +medullas 0 +had 0 +been 0 +resolved 0 +completely 0 +on 0 +follow 0 +- 0 +up 0 +MRIs 0 +in 0 +5 0 +patients 0 +"," 0 +but 0 +in 0 +1 0 +patient 0 +of 0 +them 0 +"," 0 +corpus 0 +callosal 3 +lesion 4 +persisted 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Reversible 0 +inferior 3 +colliculus 4 +lesions 4 +could 0 +be 0 +considered 0 +as 0 +the 0 +characteristic 0 +for 0 +metronidazole 1 +- 0 +induced 0 +encephalopathy 3 +"," 0 +next 0 +to 0 +the 0 +dentate 0 +nucleus 0 +involvement 0 +. 0 +Clinically 0 +significant 0 +proteinuria 3 +following 0 +the 0 +administration 0 +of 0 +sirolimus 1 +to 0 +renal 0 +transplant 0 +recipients 0 +. 0 +BACKGR0UND 0 +: 0 +Sirolimus 1 +is 0 +the 0 +latest 0 +immunosuppressive 0 +agent 0 +used 0 +to 0 +prevent 0 +rejection 0 +"," 0 +and 0 +may 0 +have 0 +less 0 +nephrotoxicity 3 +than 0 +calcineurin 0 +inhibitor 0 +( 0 +CNI 0 +) 0 +- 0 +based 0 +regimens 0 +. 0 +To 0 +date 0 +there 0 +has 0 +been 0 +little 0 +documentation 0 +of 0 +clinically 0 +significant 0 +proteinuria 3 +linked 0 +with 0 +the 0 +use 0 +of 0 +sirolimus 1 +. 0 +We 0 +have 0 +encountered 0 +several 0 +patients 0 +who 0 +developed 0 +substantial 0 +proteinuria 3 +associated 0 +with 0 +sirolimus 1 +use 0 +. 0 +In 0 +each 0 +patient 0 +"," 0 +the 0 +close 0 +temporal 0 +association 0 +between 0 +the 0 +commencement 0 +of 0 +sirolimus 1 +therapy 0 +and 0 +proteinuria 3 +implicated 0 +sirolimus 1 +as 0 +the 0 +most 0 +likely 0 +etiology 0 +of 0 +the 0 +proteinuria 3 +. 0 +METH0DS 0 +: 0 +We 0 +analyzed 0 +the 0 +clinical 0 +and 0 +laboratory 0 +information 0 +available 0 +for 0 +all 0 +119 0 +patients 0 +transplanted 0 +at 0 +the 0 +Washington 0 +Hospital 0 +Center 0 +between 0 +1999 0 +- 0 +2003 0 +for 0 +whom 0 +sirolimus 1 +was 0 +a 0 +component 0 +of 0 +their 0 +immunosuppressant 0 +regimen 0 +. 0 +In 0 +these 0 +patients 0 +"," 0 +the 0 +magnitude 0 +of 0 +proteinuria 3 +was 0 +assessed 0 +on 0 +morning 0 +urine 0 +samples 0 +by 0 +turbidometric 0 +measurement 0 +or 0 +random 0 +urine 0 +protein 0 +: 0 +creatinine 1 +ratios 0 +"," 0 +an 0 +estimate 0 +of 0 +grams 0 +of 0 +proteinuria 3 +/ 0 +day 0 +. 0 +Laboratory 0 +results 0 +were 0 +compared 0 +between 0 +prior 0 +"," 0 +during 0 +and 0 +following 0 +sirolimus 1 +use 0 +. 0 +RESULTS 0 +: 0 +Twenty 0 +- 0 +eight 0 +patients 0 +( 0 +24 0 +% 0 +) 0 +developed 0 +increased 0 +proteinuria 3 +from 0 +baseline 0 +during 0 +their 0 +post 0 +- 0 +transplantation 0 +course 0 +. 0 +In 0 +21 0 +patients 0 +an 0 +alternative 0 +cause 0 +of 0 +proteinuria 3 +was 0 +either 0 +obvious 0 +or 0 +insufficient 0 +data 0 +was 0 +available 0 +to 0 +be 0 +conclusive 0 +. 0 +In 0 +7 0 +of 0 +the 0 +28 0 +patients 0 +there 0 +was 0 +a 0 +striking 0 +temporal 0 +association 0 +between 0 +the 0 +initiation 0 +of 0 +sirolimus 1 +and 0 +the 0 +development 0 +of 0 +nephrotic 3 +- 0 +range 0 +proteinuria 3 +. 0 +Proteinuria 3 +correlated 0 +most 0 +strongly 0 +with 0 +sirolimus 1 +therapy 0 +when 0 +compared 0 +to 0 +other 0 +demographic 0 +and 0 +clinical 0 +variables 0 +. 0 +In 0 +most 0 +patients 0 +"," 0 +discontinuation 0 +of 0 +sirolimus 1 +resulted 0 +in 0 +a 0 +decrease 0 +"," 0 +but 0 +not 0 +resolution 0 +"," 0 +of 0 +proteinuria 3 +. 0 +C0NCLUSI0NS 0 +: 0 +Sirolimus 1 +induces 0 +or 0 +aggravates 0 +pre 0 +- 0 +existing 0 +proteinuria 3 +in 0 +an 0 +unpredictable 0 +subset 0 +of 0 +renal 0 +allograft 0 +recipients 0 +. 0 +Proteinuria 3 +may 0 +improve 0 +"," 0 +but 0 +does 0 +not 0 +resolve 0 +"," 0 +when 0 +sirolimus 1 +is 0 +withdrawn 0 +. 0 +Components 0 +of 0 +lemon 0 +essential 0 +oil 0 +attenuate 0 +dementia 3 +induced 0 +by 0 +scopolamine 1 +. 0 +The 0 +anti 0 +- 0 +dementia 3 +effects 0 +of 0 +s 1 +- 2 +limonene 2 +and 0 +s 1 +- 2 +perillyl 2 +alcohol 2 +were 0 +observed 0 +using 0 +the 0 +passive 0 +avoidance 0 +test 0 +( 0 +PA 0 +) 0 +and 0 +the 0 +open 0 +field 0 +habituation 0 +test 0 +( 0 +0FH 0 +) 0 +. 0 +These 0 +lemon 0 +essential 0 +oils 0 +showed 0 +strong 0 +ability 0 +to 0 +improve 0 +memory 3 +impaired 4 +by 0 +scopolamine 1 +; 0 +however 0 +"," 0 +s 1 +- 2 +perillyl 2 +alcohol 2 +relieved 0 +the 0 +deficit 3 +of 4 +associative 4 +memory 4 +in 0 +PA 0 +only 0 +"," 0 +and 0 +did 0 +not 0 +improve 0 +non 0 +- 0 +associative 0 +memory 0 +significantly 0 +in 0 +0FH 0 +. 0 +Analysis 0 +of 0 +neurotransmitter 0 +concentration 0 +in 0 +some 0 +brain 0 +regions 0 +on 0 +the 0 +test 0 +day 0 +showed 0 +that 0 +dopamine 1 +concentration 0 +of 0 +the 0 +vehicle 0 +/ 0 +scopolamine 1 +group 0 +was 0 +significantly 0 +lower 0 +than 0 +that 0 +of 0 +the 0 +vehicle 0 +/ 0 +vehicle 0 +group 0 +"," 0 +but 0 +this 0 +phenomenon 0 +was 0 +reversed 0 +when 0 +s 1 +- 2 +limonene 2 +or 0 +s 1 +- 2 +perillyl 2 +alcohol 2 +were 0 +administered 0 +before 0 +the 0 +injection 0 +of 0 +scopolamine 1 +. 0 +Simultaneously 0 +"," 0 +we 0 +found 0 +that 0 +these 0 +two 0 +lemon 0 +essential 0 +oil 0 +components 0 +could 0 +inhibit 0 +acetylcholinesterase 0 +activity 0 +in 0 +vitro 0 +using 0 +the 0 +Ellman 0 +method 0 +. 0 +Attentional 0 +modulation 0 +of 0 +perceived 0 +pain 3 +intensity 0 +in 0 +capsaicin 1 +- 0 +induced 0 +secondary 0 +hyperalgesia 3 +. 0 +Perceived 0 +pain 3 +intensity 0 +is 0 +modulated 0 +by 0 +attention 0 +. 0 +However 0 +"," 0 +it 0 +is 0 +not 0 +known 0 +that 0 +how 0 +pain 3 +intensity 0 +ratings 0 +are 0 +affected 0 +by 0 +attention 0 +in 0 +capsaicin 1 +- 0 +induced 0 +secondary 0 +hyperalgesia 3 +. 0 +Here 0 +we 0 +show 0 +that 0 +perceived 0 +pain 3 +intensity 0 +in 0 +secondary 0 +hyperalgesia 3 +is 0 +decreased 0 +when 0 +attention 0 +is 0 +distracted 0 +away 0 +from 0 +the 0 +painful 0 +pinprick 0 +stimulus 0 +with 0 +a 0 +visual 0 +task 0 +. 0 +Furthermore 0 +"," 0 +it 0 +was 0 +found 0 +that 0 +the 0 +magnitude 0 +of 0 +attentional 0 +modulation 0 +in 0 +secondary 0 +hyperalgesia 3 +is 0 +very 0 +similar 0 +to 0 +that 0 +of 0 +capsaicin 1 +- 0 +untreated 0 +"," 0 +control 0 +condition 0 +. 0 +0ur 0 +findings 0 +"," 0 +showing 0 +no 0 +interaction 0 +between 0 +capsaicin 1 +treatment 0 +and 0 +attentional 0 +modulation 0 +suggest 0 +that 0 +capsaicin 1 +- 0 +induced 0 +secondary 0 +hyperalgesia 3 +and 0 +attention 0 +might 0 +affect 0 +mechanical 0 +pain 3 +through 0 +independent 0 +mechanisms 0 +. 0 +Cardioprotective 0 +effect 0 +of 0 +salvianolic 1 +acid 2 +A 2 +on 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +evaluate 0 +the 0 +cardioprotective 0 +potential 0 +of 0 +salvianolic 1 +acid 2 +A 2 +on 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +in 0 +rats 0 +. 0 +Hemodynamic 0 +parameters 0 +and 0 +lead 0 +II 0 +electrocardiograph 0 +were 0 +monitored 0 +and 0 +recorded 0 +continuously 0 +. 0 +Cardiac 0 +marker 0 +enzymes 0 +and 0 +antioxidative 0 +parameters 0 +in 0 +serum 0 +and 0 +heart 0 +tissues 0 +were 0 +measured 0 +. 0 +Assay 0 +for 0 +mitochondrial 0 +respiratory 0 +function 0 +and 0 +histopathological 0 +examination 0 +of 0 +heart 0 +tissues 0 +were 0 +performed 0 +. 0 +Isoproterenol 1 +- 0 +treated 0 +rats 0 +showed 0 +significant 0 +increases 0 +in 0 +the 0 +levels 0 +of 0 +lactate 1 +dehydrogenase 0 +"," 0 +aspartate 1 +transaminase 0 +"," 0 +creatine 1 +kinase 0 +and 0 +malondialdehyde 1 +and 0 +significant 0 +decreases 0 +in 0 +the 0 +activities 0 +of 0 +superoxide 1 +dismutase 0 +"," 0 +catalase 0 +and 0 +glutathione 1 +peroxidase 0 +in 0 +serum 0 +and 0 +heart 0 +. 0 +These 0 +rats 0 +also 0 +showed 0 +declines 0 +in 0 +left 0 +ventricular 0 +systolic 0 +pressure 0 +"," 0 +maximum 0 +and 0 +minimum 0 +rate 0 +of 0 +developed 0 +left 0 +ventricular 0 +pressure 0 +"," 0 +and 0 +elevation 0 +of 0 +left 0 +ventricular 0 +end 0 +- 0 +diastolic 0 +pressure 0 +and 0 +ST 0 +- 0 +segment 0 +. 0 +In 0 +addition 0 +"," 0 +mitochondrial 0 +respiratory 3 +dysfunction 4 +characterized 0 +by 0 +decreased 0 +respiratory 0 +control 0 +ratio 0 +and 0 +ADP 1 +/ 0 +0 0 +was 0 +observed 0 +in 0 +isoproterenol 1 +- 0 +treated 0 +rats 0 +. 0 +Administration 0 +of 0 +salvianolic 1 +acid 2 +A 2 +for 0 +a 0 +period 0 +of 0 +8 0 +days 0 +significantly 0 +attenuated 0 +isoproterenol 1 +- 0 +induced 0 +cardiac 3 +dysfunction 4 +and 0 +myocardial 3 +injury 4 +and 0 +improved 0 +mitochondrial 0 +respiratory 0 +function 0 +. 0 +The 0 +protective 0 +role 0 +of 0 +salvianolic 1 +acid 2 +A 2 +against 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +damage 4 +was 0 +further 0 +confirmed 0 +by 0 +histopathological 0 +examination 0 +. 0 +The 0 +results 0 +of 0 +our 0 +study 0 +suggest 0 +that 0 +salvianolic 1 +acid 2 +A 2 +possessing 0 +antioxidant 0 +activity 0 +has 0 +a 0 +significant 0 +protective 0 +effect 0 +against 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +. 0 +Long 0 +- 0 +term 0 +glutamate 1 +supplementation 0 +failed 0 +to 0 +protect 0 +against 0 +peripheral 3 +neurotoxicity 4 +of 0 +paclitaxel 1 +. 0 +Toxic 0 +peripheral 3 +neuropathy 4 +is 0 +still 0 +a 0 +significant 0 +limiting 0 +factor 0 +for 0 +chemotherapy 0 +with 0 +paclitaxel 1 +( 0 +PAC 1 +) 0 +"," 0 +although 0 +glutamate 1 +and 0 +its 0 +closely 0 +related 0 +amino 1 +acid 2 +glutamine 1 +were 0 +claimed 0 +to 0 +ameliorate 0 +PAC 1 +neurotoxicity 3 +. 0 +This 0 +pilot 0 +trial 0 +aimed 0 +to 0 +evaluate 0 +the 0 +role 0 +of 0 +glutamate 1 +supplementation 0 +for 0 +preventing 0 +PAC 1 +- 0 +induced 0 +peripheral 3 +neuropathy 4 +in 0 +a 0 +randomized 0 +"," 0 +placebo 0 +- 0 +controlled 0 +"," 0 +double 0 +- 0 +blinded 0 +clinical 0 +and 0 +electro 0 +- 0 +diagnostic 0 +study 0 +. 0 +Forty 0 +- 0 +three 0 +ovarian 3 +cancer 4 +patients 0 +were 0 +available 0 +for 0 +analysis 0 +following 0 +six 0 +cycles 0 +of 0 +the 0 +same 0 +PAC 1 +- 0 +containing 0 +regimen 0 +: 0 +23 0 +had 0 +been 0 +supplemented 0 +by 0 +glutamate 1 +all 0 +along 0 +the 0 +treatment 0 +period 0 +"," 0 +at 0 +a 0 +daily 0 +dose 0 +of 0 +three 0 +times 0 +500 0 +mg 0 +( 0 +group 0 +G 0 +) 0 +"," 0 +and 0 +20 0 +had 0 +received 0 +a 0 +placebo 0 +( 0 +group 0 +P 0 +) 0 +. 0 +Patients 0 +were 0 +evaluated 0 +by 0 +neurological 0 +examinations 0 +"," 0 +questionnaires 0 +and 0 +sensory 0 +- 0 +motor 0 +nerve 0 +conduction 0 +studies 0 +. 0 +There 0 +was 0 +no 0 +significant 0 +difference 0 +in 0 +the 0 +frequency 0 +of 0 +signs 0 +or 0 +symptoms 0 +between 0 +the 0 +two 0 +groups 0 +although 0 +neurotoxicity 3 +symptoms 0 +presented 0 +mostly 0 +with 0 +lower 0 +scores 0 +of 0 +severity 0 +in 0 +group 0 +G 0 +. 0 +However 0 +"," 0 +this 0 +difference 0 +reached 0 +statistical 0 +significance 0 +only 0 +with 0 +regard 0 +to 0 +reported 0 +pain 3 +sensation 0 +( 0 +P 0 += 0 +0 0 +. 0 +11 0 +) 0 +. 0 +Also 0 +the 0 +frequency 0 +of 0 +abnormal 0 +electro 0 +- 0 +diagnostic 0 +findings 0 +showed 0 +similarity 0 +between 0 +the 0 +two 0 +groups 0 +( 0 +G 0 +: 0 +7 0 +/ 0 +23 0 += 0 +30 0 +. 0 +4 0 +% 0 +; 0 +P 0 +: 0 +6 0 +/ 0 +20 0 += 0 +30 0 +% 0 +) 0 +. 0 +This 0 +pilot 0 +study 0 +leads 0 +to 0 +the 0 +conclusion 0 +that 0 +glutamate 1 +supplementation 0 +at 0 +the 0 +chosen 0 +regimen 0 +fails 0 +to 0 +protect 0 +against 0 +peripheral 3 +neurotoxicity 4 +of 0 +PAC 1 +. 0 +Development 0 +of 0 +ocular 3 +myasthenia 4 +during 0 +pegylated 1 +interferon 2 +and 0 +ribavirin 1 +treatment 0 +for 0 +chronic 3 +hepatitis 4 +C 4 +. 0 +A 0 +63 0 +- 0 +year 0 +- 0 +old 0 +male 0 +experienced 0 +sudden 0 +diplopia 3 +after 0 +9 0 +weeks 0 +of 0 +administration 0 +of 0 +pegylated 1 +interferon 2 +( 2 +IFN 2 +) 2 +alpha 2 +- 2 +2b 2 +and 0 +ribavirin 1 +for 0 +chronic 3 +hepatitis 4 +C 4 +( 0 +CHC 3 +) 0 +. 0 +0phthalmologic 0 +examinations 0 +showed 0 +ptosis 3 +on 4 +the 4 +right 4 +upper 4 +lid 4 +and 0 +restricted 3 +right 4 +eye 4 +movement 4 +without 0 +any 0 +other 0 +neurological 0 +signs 0 +. 0 +A 0 +brain 0 +imaging 0 +study 0 +and 0 +repetitive 0 +nerve 0 +stimulation 0 +test 0 +indicated 0 +no 0 +abnormality 0 +. 0 +The 0 +acetylcholine 1 +receptor 0 +antibody 0 +titer 0 +and 0 +response 0 +to 0 +acetylcholinesterase 0 +inhibitors 0 +were 0 +negative 0 +"," 0 +and 0 +the 0 +results 0 +of 0 +thyroid 0 +function 0 +tests 0 +were 0 +normal 0 +. 0 +The 0 +patient 0 +' 0 +s 0 +ophthalmological 0 +symptoms 0 +improved 0 +rapidly 0 +3 0 +weeks 0 +after 0 +discontinuation 0 +of 0 +pegylated 1 +IFN 2 +alpha 2 +- 2 +2b 2 +and 0 +ribavirin 1 +. 0 +The 0 +ocular 3 +myasthenia 4 +associated 0 +with 0 +combination 0 +therapy 0 +of 0 +pegylated 1 +IFN 2 +alpha 2 +- 2 +2b 2 +and 0 +ribavirin 1 +for 0 +CHC 3 +is 0 +very 0 +rarely 0 +reported 0 +; 0 +therefore 0 +"," 0 +we 0 +present 0 +this 0 +case 0 +with 0 +a 0 +review 0 +of 0 +the 0 +various 0 +eye 0 +complications 0 +of 0 +IFN 1 +therapy 0 +. 0 +Learning 3 +and 4 +memory 4 +deficits 4 +in 0 +ecstasy 1 +users 0 +and 0 +their 0 +neural 0 +correlates 0 +during 0 +a 0 +face 0 +- 0 +learning 0 +task 0 +. 0 +It 0 +has 0 +been 0 +consistently 0 +shown 0 +that 0 +ecstasy 1 +users 0 +display 0 +impairments 3 +in 4 +learning 4 +and 4 +memory 4 +performance 0 +. 0 +In 0 +addition 0 +"," 0 +working 0 +memory 0 +processing 0 +in 0 +ecstasy 1 +users 0 +has 0 +been 0 +shown 0 +to 0 +be 0 +associated 0 +with 0 +neural 0 +alterations 0 +in 0 +hippocampal 0 +and 0 +/ 0 +or 0 +cortical 0 +regions 0 +as 0 +measured 0 +by 0 +functional 0 +magnetic 0 +resonance 0 +imaging 0 +( 0 +fMRI 0 +) 0 +. 0 +Using 0 +functional 0 +imaging 0 +and 0 +a 0 +face 0 +- 0 +learning 0 +task 0 +"," 0 +we 0 +investigated 0 +neural 0 +correlates 0 +of 0 +encoding 0 +and 0 +recalling 0 +face 0 +- 0 +name 0 +associations 0 +in 0 +20 0 +recreational 0 +drug 0 +users 0 +whose 0 +predominant 0 +drug 0 +use 0 +was 0 +ecstasy 1 +and 0 +20 0 +controls 0 +. 0 +To 0 +address 0 +the 0 +potential 0 +confounding 0 +effects 0 +of 0 +the 0 +cannabis 1 +use 0 +of 0 +the 0 +ecstasy 1 +using 0 +group 0 +"," 0 +a 0 +second 0 +analysis 0 +included 0 +14 0 +previously 0 +tested 0 +cannabis 1 +users 0 +( 0 +Nestor 0 +"," 0 +L 0 +. 0 +"," 0 +Roberts 0 +"," 0 +G 0 +. 0 +"," 0 +Garavan 0 +"," 0 +H 0 +. 0 +"," 0 +Hester 0 +"," 0 +R 0 +. 0 +"," 0 +2008 0 +. 0 +Deficits 3 +in 4 +learning 4 +and 4 +memory 4 +: 0 +parahippocampal 0 +hyperactivity 3 +and 0 +frontocortical 0 +hypoactivity 0 +in 0 +cannabis 1 +users 0 +. 0 +Neuroimage 0 +40 0 +"," 0 +1328 0 +- 0 +1339 0 +) 0 +. 0 +Ecstasy 1 +users 0 +performed 0 +significantly 0 +worse 0 +in 0 +learning 0 +and 0 +memory 0 +compared 0 +to 0 +controls 0 +and 0 +cannabis 1 +users 0 +. 0 +A 0 +conjunction 0 +analysis 0 +of 0 +the 0 +encode 0 +and 0 +recall 0 +phases 0 +of 0 +the 0 +task 0 +revealed 0 +ecstasy 1 +- 0 +specific 0 +hyperactivity 3 +in 0 +bilateral 0 +frontal 0 +regions 0 +"," 0 +left 0 +temporal 0 +"," 0 +right 0 +parietal 0 +"," 0 +bilateral 0 +temporal 0 +"," 0 +and 0 +bilateral 0 +occipital 0 +brain 0 +regions 0 +. 0 +Ecstasy 1 +- 0 +specific 0 +hypoactivity 0 +was 0 +evident 0 +in 0 +the 0 +right 0 +dorsal 0 +anterior 0 +cingulated 0 +cortex 0 +( 0 +ACC 0 +) 0 +and 0 +left 0 +posterior 0 +cingulated 0 +cortex 0 +. 0 +In 0 +both 0 +ecstasy 1 +and 0 +cannabis 1 +groups 0 +brain 0 +activation 0 +was 0 +decreased 0 +in 0 +the 0 +right 0 +medial 0 +frontal 0 +gyrus 0 +"," 0 +left 0 +parahippocampal 0 +gyrus 0 +"," 0 +left 0 +dorsal 0 +cingulate 0 +gyrus 0 +"," 0 +and 0 +left 0 +caudate 0 +. 0 +These 0 +results 0 +elucidated 0 +ecstasy 1 +- 0 +related 0 +deficits 0 +"," 0 +only 0 +some 0 +of 0 +which 0 +might 0 +be 0 +attributed 0 +to 0 +cannabis 1 +use 0 +. 0 +These 0 +ecstasy 1 +- 0 +specific 0 +effects 0 +may 0 +be 0 +related 0 +to 0 +the 0 +vulnerability 0 +of 0 +isocortical 0 +and 0 +allocortical 0 +regions 0 +to 0 +the 0 +neurotoxic 3 +effects 0 +of 0 +ecstasy 1 +. 0 +Disulfiram 1 +- 0 +like 0 +syndrome 0 +after 0 +hydrogen 1 +cyanamide 2 +professional 0 +skin 0 +exposure 0 +: 0 +two 0 +case 0 +reports 0 +in 0 +France 0 +. 0 +Hydrogen 1 +cyanamide 2 +is 0 +a 0 +plant 0 +growth 0 +regulator 0 +used 0 +in 0 +agriculture 0 +to 0 +induce 0 +bud 0 +break 0 +in 0 +fruit 0 +trees 0 +. 0 +Contact 0 +with 0 +the 0 +skin 0 +can 0 +result 0 +in 0 +percutaneous 0 +absorption 0 +of 0 +the 0 +substance 0 +that 0 +inhibits 0 +aldehyde 1 +dehydrogenase 0 +and 0 +can 0 +induce 0 +acetaldehyde 1 +syndrome 0 +in 0 +case 0 +of 0 +alcohol 1 +use 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +report 0 +is 0 +to 0 +describe 0 +two 0 +cases 0 +of 0 +a 0 +disulfiram 1 +- 0 +like 0 +syndrome 0 +following 0 +occupational 0 +exposure 0 +to 0 +hydrogen 1 +cyanamide 2 +. 0 +The 0 +first 0 +case 0 +involved 0 +a 0 +59 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +used 0 +Dormex 1 +"," 0 +which 0 +contains 0 +hydrogen 1 +cyanamide 2 +"," 0 +without 0 +protection 0 +after 0 +consuming 0 +a 0 +large 0 +amount 0 +of 0 +alcohol 1 +during 0 +a 0 +meal 0 +. 0 +In 0 +less 0 +than 0 +1 0 +hour 0 +after 0 +the 0 +ingestion 0 +of 0 +alcohol 1 +"," 0 +he 0 +developed 0 +malaise 0 +with 0 +flushing 3 +of 4 +the 4 +face 4 +"," 0 +tachycardia 3 +"," 0 +and 0 +dyspnea 3 +. 0 +Manifestations 0 +regressed 0 +spontaneously 0 +under 0 +surveillance 0 +in 0 +the 0 +hospital 0 +. 0 +The 0 +second 0 +case 0 +occurred 0 +in 0 +a 0 +55 0 +- 0 +year 0 +- 0 +old 0 +farmer 0 +following 0 +cutaneous 0 +contact 0 +with 0 +Dormex 1 +. 0 +Five 0 +hours 0 +after 0 +exposure 0 +"," 0 +he 0 +developed 0 +disulfiram 1 +- 0 +like 0 +syndrome 0 +with 0 +flushing 3 +"," 0 +tachycardia 3 +"," 0 +and 0 +arterial 3 +hypotension 4 +after 0 +consuming 0 +three 0 +glasses 0 +of 0 +wine 0 +. 0 +The 0 +patient 0 +recovered 0 +spontaneously 0 +in 0 +3 0 +hours 0 +under 0 +surveillance 0 +in 0 +the 0 +hospital 0 +. 0 +These 0 +cases 0 +confirm 0 +the 0 +necessity 0 +of 0 +avoiding 0 +alcohol 1 +consumption 0 +as 0 +recommended 0 +in 0 +the 0 +instructions 0 +for 0 +use 0 +of 0 +Dormex 1 +and 0 +of 0 +preventing 0 +cutaneous 0 +contact 0 +during 0 +use 0 +. 0 +Sulpiride 1 +- 0 +induced 0 +tardive 3 +dystonia 4 +. 0 +Sulpiride 1 +is 0 +a 0 +selective 0 +D2 0 +- 0 +receptor 0 +antagonist 0 +with 0 +antipsychotic 0 +and 0 +antidepressant 1 +properties 0 +. 0 +Although 0 +initially 0 +thought 0 +to 0 +be 0 +free 0 +of 0 +extrapyramidal 0 +side 0 +effects 0 +"," 0 +sulpiride 1 +- 0 +induced 0 +tardive 3 +dyskinesia 4 +and 0 +parkinsonism 3 +have 0 +been 0 +reported 0 +occasionally 0 +. 0 +We 0 +studied 0 +a 0 +37 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +developed 0 +persistent 0 +segmental 0 +dystonia 3 +within 0 +2 0 +months 0 +after 0 +starting 0 +sulpiride 1 +therapy 0 +. 0 +We 0 +could 0 +not 0 +find 0 +any 0 +previous 0 +reports 0 +of 0 +sulpiride 1 +- 0 +induced 0 +tardive 3 +dystonia 4 +. 0 +Comparative 0 +cognitive 0 +and 0 +subjective 0 +side 0 +effects 0 +of 0 +immediate 0 +- 0 +release 0 +oxycodone 1 +in 0 +healthy 0 +middle 0 +- 0 +aged 0 +and 0 +older 0 +adults 0 +. 0 +This 0 +study 0 +measured 0 +the 0 +objective 0 +and 0 +subjective 0 +neurocognitive 0 +effects 0 +of 0 +a 0 +single 0 +10 0 +- 0 +mg 0 +dose 0 +of 0 +immediate 0 +- 0 +release 0 +oxycodone 1 +in 0 +healthy 0 +"," 0 +older 0 +( 0 +> 0 +65 0 +years 0 +) 0 +"," 0 +and 0 +middle 0 +- 0 +aged 0 +( 0 +35 0 +to 0 +55 0 +years 0 +) 0 +adults 0 +who 0 +were 0 +not 0 +suffering 0 +from 0 +chronic 0 +or 0 +significant 0 +daily 0 +pain 3 +. 0 +Seventy 0 +- 0 +one 0 +participants 0 +completed 0 +2 0 +separate 0 +study 0 +days 0 +and 0 +were 0 +blind 0 +to 0 +medication 0 +condition 0 +( 0 +placebo 0 +"," 0 +10 0 +- 0 +mg 0 +oxycodone 1 +) 0 +. 0 +Plasma 0 +oxycodone 1 +concentration 0 +peaked 0 +between 0 +60 0 +and 0 +90 0 +minutes 0 +postdose 0 +( 0 +P 0 +< 0 +. 0 +1 0 +) 0 +and 0 +pupil 0 +size 0 +"," 0 +an 0 +indication 0 +of 0 +physiological 0 +effects 0 +of 0 +the 0 +medication 0 +"," 0 +peaked 0 +at 0 +approximately 0 +90 0 +to 0 +120 0 +minutes 0 +postdose 0 +( 0 +P 0 +< 0 +. 0 +1 0 +) 0 +. 0 +Significant 0 +declines 3 +in 4 +simple 4 +and 4 +sustained 4 +attention 4 +"," 4 +working 4 +memory 4 +"," 4 +and 4 +verbal 4 +memory 4 +were 0 +observed 0 +at 0 +1 0 +hour 0 +postdose 0 +compared 0 +to 0 +baseline 0 +for 0 +both 0 +age 0 +groups 0 +with 0 +a 0 +trend 0 +toward 0 +return 0 +to 0 +baseline 0 +by 0 +5 0 +hours 0 +postdose 0 +. 0 +For 0 +almost 0 +all 0 +cognitive 0 +measures 0 +"," 0 +there 0 +were 0 +no 0 +medication 0 +by 0 +age 0 +- 0 +interaction 0 +effects 0 +"," 0 +which 0 +indicates 0 +that 0 +the 0 +2 0 +age 0 +groups 0 +exhibited 0 +similar 0 +responses 0 +to 0 +the 0 +medication 0 +challenge 0 +. 0 +This 0 +study 0 +suggests 0 +that 0 +for 0 +healthy 0 +older 0 +adults 0 +who 0 +are 0 +not 0 +suffering 0 +from 0 +chronic 3 +pain 4 +"," 0 +neurocognitive 0 +and 0 +pharmacodynamic 0 +changes 0 +in 0 +response 0 +to 0 +a 0 +10 0 +- 0 +mg 0 +dose 0 +of 0 +immediate 0 +- 0 +release 0 +oxycodone 1 +are 0 +similar 0 +to 0 +those 0 +observed 0 +for 0 +middle 0 +- 0 +aged 0 +adults 0 +. 0 +PERSPECTIVE 0 +: 0 +Study 0 +findings 0 +indicate 0 +that 0 +the 0 +metabolism 0 +"," 0 +neurocognitive 0 +effects 0 +"," 0 +and 0 +physical 0 +side 0 +effects 0 +of 0 +oral 0 +oxycodone 1 +are 0 +similar 0 +for 0 +healthy 0 +middle 0 +- 0 +aged 0 +and 0 +older 0 +adults 0 +. 0 +Therefore 0 +"," 0 +clinicians 0 +should 0 +not 0 +avoid 0 +prescribing 0 +oral 0 +opioids 0 +to 0 +older 0 +adults 0 +based 0 +on 0 +the 0 +belief 0 +that 0 +older 0 +adults 0 +are 0 +at 0 +higher 0 +risk 0 +for 0 +side 0 +effects 0 +than 0 +younger 0 +adults 0 +. 0 +The 0 +glycine 1 +transporter 0 +- 0 +1 0 +inhibitor 0 +SSR103800 1 +displays 0 +a 0 +selective 0 +and 0 +specific 0 +antipsychotic 0 +- 0 +like 0 +profile 0 +in 0 +normal 0 +and 0 +transgenic 0 +mice 0 +. 0 +Schizophrenia 3 +has 0 +been 0 +initially 0 +associated 0 +with 0 +dysfunction 0 +in 0 +dopamine 1 +neurotransmission 0 +. 0 +However 0 +"," 0 +the 0 +observation 0 +that 0 +antagonists 0 +of 0 +the 0 +glutamate 1 +N 1 +- 2 +methyl 2 +- 2 +D 2 +- 2 +aspartate 2 +( 0 +NMDA 1 +) 0 +receptor 0 +produce 0 +schizophrenic 3 +- 0 +like 0 +symptoms 0 +in 0 +humans 0 +has 0 +led 0 +to 0 +the 0 +idea 0 +of 0 +a 0 +dysfunctioning 0 +of 0 +the 0 +glutamatergic 0 +system 0 +via 0 +its 0 +NMDA 1 +receptor 0 +. 0 +As 0 +a 0 +result 0 +"," 0 +there 0 +is 0 +a 0 +growing 0 +interest 0 +in 0 +the 0 +development 0 +of 0 +pharmacological 0 +agents 0 +with 0 +potential 0 +antipsychotic 0 +properties 0 +that 0 +enhance 0 +the 0 +activity 0 +of 0 +the 0 +glutamatergic 0 +system 0 +via 0 +a 0 +modulation 0 +of 0 +the 0 +NMDA 1 +receptor 0 +. 0 +Among 0 +them 0 +are 0 +glycine 1 +transporter 0 +- 0 +1 0 +( 0 +GlyT1 0 +) 0 +inhibitors 0 +such 0 +as 0 +SSR103800 1 +"," 0 +which 0 +indirectly 0 +enhance 0 +NMDA 1 +receptor 0 +function 0 +by 0 +increasing 0 +the 0 +glycine 1 +( 0 +a 0 +co 0 +- 0 +agonist 0 +for 0 +the 0 +NMDA 1 +receptor 0 +) 0 +levels 0 +in 0 +the 0 +synapse 0 +. 0 +This 0 +study 0 +aimed 0 +at 0 +investigating 0 +the 0 +potential 0 +antipsychotic 0 +- 0 +like 0 +properties 0 +of 0 +SSR103800 1 +"," 0 +with 0 +a 0 +particular 0 +focus 0 +on 0 +models 0 +of 0 +hyperactivity 3 +"," 0 +involving 0 +either 0 +drug 0 +challenge 0 +( 0 +ie 0 +"," 0 +amphetamine 1 +and 0 +MK 1 +- 2 +801 2 +) 0 +or 0 +transgenic 0 +mice 0 +( 0 +ie 0 +"," 0 +NMDA 1 +Nr1 0 +( 0 +neo 0 +- 0 +/ 0 +- 0 +) 0 +and 0 +DAT 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +) 0 +. 0 +Results 0 +showed 0 +that 0 +SSR103800 1 +( 0 +10 0 +- 0 +30 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +blocked 0 +hyperactivity 3 +induced 0 +by 0 +the 0 +non 0 +- 0 +competitive 0 +NMDA 1 +receptor 0 +antagonist 0 +"," 0 +MK 1 +- 2 +801 2 +and 0 +partially 0 +reversed 0 +spontaneous 0 +hyperactivity 3 +of 0 +NMDA 1 +Nr1 0 +( 0 +neo 0 +- 0 +/ 0 +- 0 +) 0 +mice 0 +. 0 +In 0 +contrast 0 +"," 0 +SSR103800 1 +failed 0 +to 0 +affect 0 +hyperactivity 3 +induced 0 +by 0 +amphetamine 1 +or 0 +naturally 0 +observed 0 +in 0 +dopamine 1 +transporter 0 +( 0 +DAT 0 +( 0 +- 0 +/ 0 +- 0 +) 0 +) 0 +knockout 0 +mice 0 +( 0 +10 0 +- 0 +30 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +) 0 +. 0 +Importantly 0 +"," 0 +both 0 +classical 0 +( 0 +haloperidol 1 +) 0 +and 0 +atypical 0 +( 0 +olanzapine 1 +"," 0 +clozapine 1 +and 0 +aripiprazole 1 +) 0 +antipsychotics 0 +were 0 +effective 0 +in 0 +all 0 +these 0 +models 0 +of 0 +hyperactivity 3 +. 0 +However 0 +"," 0 +unlike 0 +these 0 +latter 0 +"," 0 +SSR103800 1 +did 0 +not 0 +produce 0 +catalepsy 3 +( 0 +retention 0 +on 0 +the 0 +bar 0 +test 0 +) 0 +up 0 +to 0 +30 0 +mg 0 +/ 0 +kg 0 +p 0 +. 0 +o 0 +. 0 +Together 0 +these 0 +findings 0 +show 0 +that 0 +the 0 +GlyT1 0 +inhibitor 0 +"," 0 +SSR103800 1 +"," 0 +produces 0 +antipsychotic 0 +- 0 +like 0 +effects 0 +"," 0 +which 0 +differ 0 +from 0 +those 0 +observed 0 +with 0 +compounds 0 +primarily 0 +targeting 0 +the 0 +dopaminergic 0 +system 0 +"," 0 +and 0 +has 0 +a 0 +reduced 0 +side 0 +- 0 +effect 0 +potential 0 +as 0 +compared 0 +with 0 +these 0 +latter 0 +drugs 0 +. 0 +Pyrrolidine 1 +dithiocarbamate 2 +protects 0 +the 0 +piriform 0 +cortex 0 +in 0 +the 0 +pilocarpine 1 +status 3 +epilepticus 4 +model 0 +. 0 +Pyrrolidine 1 +dithiocarbamate 2 +( 0 +PDTC 1 +) 0 +has 0 +a 0 +dual 0 +mechanism 0 +of 0 +action 0 +as 0 +an 0 +antioxidant 0 +and 0 +an 0 +inhibitor 0 +of 0 +the 0 +transcription 0 +factor 0 +kappa 0 +- 0 +beta 0 +. 0 +Both 0 +"," 0 +production 0 +of 0 +reactive 0 +oxygen 1 +species 0 +as 0 +well 0 +as 0 +activation 0 +of 0 +NF 0 +- 0 +kappaB 0 +have 0 +been 0 +implicated 0 +in 0 +severe 0 +neuronal 3 +damage 4 +in 0 +different 0 +sub 0 +- 0 +regions 0 +of 0 +the 0 +hippocampus 0 +as 0 +well 0 +as 0 +in 0 +the 0 +surrounding 0 +cortices 0 +. 0 +The 0 +effect 0 +of 0 +PDTC 1 +on 0 +status 3 +epilepticus 4 +- 0 +associated 0 +cell 0 +loss 0 +in 0 +the 0 +hippocampus 0 +and 0 +piriform 0 +cortex 0 +was 0 +evaluated 0 +in 0 +the 0 +rat 0 +fractionated 0 +pilocarpine 1 +model 0 +. 0 +Treatment 0 +with 0 +150 0 +mg 0 +/ 0 +kg 0 +PDTC 1 +before 0 +and 0 +following 0 +status 3 +epilepticus 4 +significantly 0 +increased 0 +the 0 +mortality 0 +rate 0 +to 0 +100 0 +% 0 +. 0 +Administration 0 +of 0 +50 0 +mg 0 +/ 0 +kg 0 +PDTC 1 +( 0 +low 0 +- 0 +dose 0 +) 0 +did 0 +not 0 +exert 0 +major 0 +effects 0 +on 0 +the 0 +development 0 +of 0 +a 0 +status 3 +epilepticus 4 +or 0 +the 0 +mortality 0 +rate 0 +. 0 +In 0 +vehicle 0 +- 0 +treated 0 +rats 0 +"," 0 +status 3 +epilepticus 4 +caused 0 +pronounced 0 +neuronal 3 +damage 4 +in 0 +the 0 +piriform 0 +cortex 0 +comprising 0 +both 0 +pyramidal 0 +cells 0 +and 0 +interneurons 0 +. 0 +Low 0 +- 0 +dose 0 +PDTC 1 +treatment 0 +almost 0 +completely 0 +protected 0 +from 0 +lesions 0 +in 0 +the 0 +piriform 0 +cortex 0 +. 0 +A 0 +significant 0 +decrease 0 +in 0 +neuronal 0 +density 0 +of 0 +the 0 +hippocampal 0 +hilar 0 +formation 0 +was 0 +identified 0 +in 0 +vehicle 0 +- 0 +and 0 +PDTC 1 +- 0 +treated 0 +rats 0 +following 0 +status 3 +epilepticus 4 +. 0 +In 0 +conclusion 0 +"," 0 +the 0 +NF 0 +- 0 +kappaB 0 +inhibitor 0 +and 0 +antioxidant 0 +PDTC 1 +protected 0 +the 0 +piriform 0 +cortex 0 +"," 0 +whereas 0 +it 0 +did 0 +not 0 +affect 0 +hilar 0 +neuronal 3 +loss 4 +. 0 +These 0 +data 0 +might 0 +indicate 0 +that 0 +the 0 +generation 0 +of 0 +reactive 0 +oxygen 1 +species 0 +and 0 +activation 0 +of 0 +NF 0 +- 0 +kappaB 0 +plays 0 +a 0 +more 0 +central 0 +role 0 +in 0 +seizure 3 +- 0 +associated 0 +neuronal 3 +damage 4 +in 0 +the 0 +temporal 0 +cortex 0 +as 0 +compared 0 +to 0 +the 0 +hippocampal 0 +hilus 0 +. 0 +However 0 +"," 0 +future 0 +investigations 0 +are 0 +necessary 0 +to 0 +exactly 0 +analyze 0 +the 0 +biochemical 0 +mechanisms 0 +by 0 +which 0 +PDTC 1 +exerted 0 +its 0 +beneficial 0 +effects 0 +in 0 +the 0 +piriform 0 +cortex 0 +. 0 +Anaesthetists 0 +' 0 +nightmare 0 +: 0 +masseter 3 +spasm 4 +after 0 +induction 0 +in 0 +an 0 +undiagnosed 0 +case 0 +of 0 +myotonia 3 +congenita 4 +. 0 +We 0 +report 0 +an 0 +undiagnosed 0 +case 0 +of 0 +myotonia 3 +congenita 4 +in 0 +a 0 +24 0 +- 0 +year 0 +- 0 +old 0 +previously 0 +healthy 0 +primigravida 0 +"," 0 +who 0 +developed 0 +life 0 +threatening 0 +masseter 3 +spasm 4 +following 0 +a 0 +standard 0 +dose 0 +of 0 +intravenous 0 +suxamethonium 1 +for 0 +induction 0 +of 0 +anaesthesia 0 +. 0 +Neither 0 +the 0 +patient 0 +nor 0 +the 0 +anaesthetist 0 +was 0 +aware 0 +of 0 +the 0 +diagnosis 0 +before 0 +this 0 +potentially 0 +lethal 0 +complication 0 +occurred 0 +. 0 +Twin 0 +preterm 0 +neonates 0 +with 0 +cardiac 3 +toxicity 4 +related 0 +to 0 +lopinavir 1 +/ 2 +ritonavir 2 +therapy 0 +. 0 +We 0 +report 0 +twin 0 +neonates 0 +who 0 +were 0 +born 0 +prematurely 0 +at 0 +32 0 +weeks 0 +of 0 +gestation 0 +to 0 +a 0 +mother 0 +with 0 +human 3 +immunodeficiency 4 +virus 4 +infection 4 +. 0 +0ne 0 +of 0 +the 0 +twins 0 +developed 0 +complete 0 +heart 3 +block 4 +and 0 +dilated 3 +cardiomyopathy 4 +related 0 +to 0 +lopinavir 1 +/ 2 +ritonavir 2 +therapy 0 +"," 0 +a 0 +boosted 0 +protease 0 +- 0 +inhibitor 0 +agent 0 +"," 0 +while 0 +the 0 +other 0 +twin 0 +developed 0 +mild 0 +bradycardia 3 +. 0 +We 0 +recommend 0 +caution 0 +in 0 +the 0 +use 0 +of 0 +lopinavir 1 +/ 2 +ritonavir 2 +in 0 +the 0 +immediate 0 +neonatal 0 +period 0 +. 0 +When 0 +drugs 0 +disappear 0 +from 0 +the 0 +patient 0 +: 0 +elimination 0 +of 0 +intravenous 0 +medication 0 +by 0 +hemodiafiltration 0 +. 0 +Twenty 0 +- 0 +three 0 +hours 0 +after 0 +heart 0 +transplantation 0 +"," 0 +life 0 +- 0 +threatening 0 +acute 0 +right 3 +heart 4 +failure 4 +was 0 +diagnosed 0 +in 0 +a 0 +patient 0 +requiring 0 +continuous 0 +venovenous 0 +hemodiafiltration 0 +( 0 +CVVHDF 0 +) 0 +. 0 +Increasing 0 +doses 0 +of 0 +catecholamines 1 +"," 0 +sedatives 0 +"," 0 +and 0 +muscle 0 +relaxants 0 +administered 0 +through 0 +a 0 +central 0 +venous 0 +catheter 0 +were 0 +ineffective 0 +. 0 +However 0 +"," 0 +a 0 +bolus 0 +of 0 +epinephrine 1 +injected 0 +through 0 +an 0 +alternative 0 +catheter 0 +provoked 0 +a 0 +hypertensive 3 +crisis 0 +. 0 +Thus 0 +"," 0 +interference 0 +with 0 +the 0 +central 0 +venous 0 +infusion 0 +by 0 +the 0 +dialysis 0 +catheter 0 +was 0 +suspected 0 +. 0 +The 0 +catheters 0 +were 0 +changed 0 +"," 0 +and 0 +hemodynamics 0 +stabilized 0 +at 0 +lower 0 +catecholamine 1 +doses 0 +. 0 +When 0 +the 0 +effects 0 +of 0 +IV 0 +drugs 0 +are 0 +inadequate 0 +in 0 +patients 0 +receiving 0 +CVVHDF 0 +"," 0 +interference 0 +with 0 +adjacent 0 +catheters 0 +resulting 0 +in 0 +elimination 0 +of 0 +the 0 +drug 0 +by 0 +CVVHDF 0 +should 0 +be 0 +suspected 0 +. 0 +Less 0 +frequent 0 +lithium 1 +administration 0 +and 0 +lower 0 +urine 0 +volume 0 +. 0 +0BJECTIVE 0 +: 0 +This 0 +study 0 +was 0 +designed 0 +to 0 +determine 0 +whether 0 +patients 0 +maintained 0 +on 0 +a 0 +regimen 0 +of 0 +lithium 1 +on 0 +a 0 +once 0 +- 0 +per 0 +- 0 +day 0 +schedule 0 +have 0 +lower 0 +urine 0 +volumes 0 +than 0 +do 0 +patients 0 +receiving 0 +multiple 0 +doses 0 +per 0 +day 0 +. 0 +METH0D 0 +: 0 +This 0 +was 0 +a 0 +cross 0 +- 0 +sectional 0 +study 0 +of 0 +85 0 +patients 0 +from 0 +a 0 +lithium 1 +clinic 0 +who 0 +received 0 +different 0 +dose 0 +schedules 0 +. 0 +Patients 0 +were 0 +admitted 0 +to 0 +the 0 +hospital 0 +for 0 +measurement 0 +of 0 +lithium 1 +level 0 +"," 0 +creatinine 1 +clearance 0 +"," 0 +urine 0 +volume 0 +"," 0 +and 0 +maximum 0 +osmolality 0 +. 0 +RESULTS 0 +: 0 +Multiple 0 +daily 0 +doses 0 +of 0 +lithium 1 +were 0 +associated 0 +with 0 +higher 0 +urine 0 +volumes 0 +. 0 +The 0 +dosing 0 +schedule 0 +"," 0 +duration 0 +of 0 +lithium 1 +treatment 0 +"," 0 +and 0 +daily 0 +dose 0 +of 0 +lithium 1 +did 0 +not 0 +affect 0 +maximum 0 +osmolality 0 +or 0 +creatinine 1 +clearance 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Urine 0 +volume 0 +can 0 +be 0 +reduced 0 +by 0 +giving 0 +lithium 1 +once 0 +daily 0 +and 0 +/ 0 +or 0 +by 0 +lowering 0 +the 0 +total 0 +daily 0 +dose 0 +. 0 +Lithium 1 +- 0 +induced 0 +polyuria 3 +seems 0 +to 0 +be 0 +related 0 +to 0 +extrarenal 0 +as 0 +well 0 +as 0 +to 0 +renal 0 +effects 0 +. 0 +Antibacterial 0 +medication 0 +use 0 +during 0 +pregnancy 0 +and 0 +risk 0 +of 0 +birth 3 +defects 4 +: 0 +National 0 +Birth 3 +Defects 4 +Prevention 0 +Study 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +estimate 0 +the 0 +association 0 +between 0 +antibacterial 0 +medications 0 +and 0 +selected 0 +birth 3 +defects 4 +. 0 +DESIGN 0 +"," 0 +SETTING 0 +"," 0 +AND 0 +PARTICIPANTS 0 +: 0 +Population 0 +- 0 +based 0 +"," 0 +multisite 0 +"," 0 +case 0 +- 0 +control 0 +study 0 +of 0 +women 0 +who 0 +had 0 +pregnancies 0 +affected 0 +by 0 +1 0 +of 0 +more 0 +than 0 +30 0 +eligible 0 +major 0 +birth 3 +defects 4 +identified 0 +via 0 +birth 3 +defect 4 +surveillance 0 +programs 0 +in 0 +10 0 +states 0 +( 0 +n 0 += 0 +13 0 +155 0 +) 0 +and 0 +control 0 +women 0 +randomly 0 +selected 0 +from 0 +the 0 +same 0 +geographical 0 +regions 0 +( 0 +n 0 += 0 +4941 0 +) 0 +. 0 +MAIN 0 +EXP0SURE 0 +: 0 +Reported 0 +maternal 0 +use 0 +of 0 +antibacterials 0 +( 0 +1 0 +month 0 +before 0 +pregnancy 0 +through 0 +the 0 +end 0 +of 0 +the 0 +first 0 +trimester 0 +) 0 +. 0 +MAIN 0 +0UTC0ME 0 +MEASURE 0 +: 0 +0dds 0 +ratios 0 +( 0 +0Rs 0 +) 0 +measuring 0 +the 0 +association 0 +between 0 +antibacterial 0 +use 0 +and 0 +selected 0 +birth 3 +defects 4 +adjusted 0 +for 0 +potential 0 +confounders 0 +. 0 +RESULTS 0 +: 0 +The 0 +reported 0 +use 0 +of 0 +antibacterials 0 +increased 0 +during 0 +pregnancy 0 +"," 0 +peaking 0 +during 0 +the 0 +third 0 +month 0 +. 0 +Sulfonamides 1 +were 0 +associated 0 +with 0 +anencephaly 3 +( 0 +adjusted 0 +0R 0 +[ 0 +A0R 0 +] 0 += 0 +3 0 +. 0 +4 0 +; 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +"," 0 +1 0 +. 0 +3 0 +- 0 +8 0 +. 0 +8 0 +) 0 +"," 0 +hypoplastic 3 +left 4 +heart 4 +syndrome 4 +( 0 +A0R 0 += 0 +3 0 +. 0 +2 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +3 0 +- 0 +7 0 +. 0 +6 0 +) 0 +"," 0 +coarctation 3 +of 4 +the 4 +aorta 4 +( 0 +A0R 0 += 0 +2 0 +. 0 +7 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +3 0 +- 0 +5 0 +. 0 +6 0 +) 0 +"," 0 +choanal 3 +atresia 4 +( 0 +A0R 0 += 0 +8 0 +. 0 +0 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +2 0 +. 0 +7 0 +- 0 +23 0 +. 0 +5 0 +) 0 +"," 0 +transverse 3 +limb 4 +deficiency 4 +( 0 +A0R 0 += 0 +2 0 +. 0 +5 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +0 0 +- 0 +5 0 +. 0 +9 0 +) 0 +"," 0 +and 0 +diaphragmatic 3 +hernia 4 +( 0 +A0R 0 += 0 +2 0 +. 0 +4 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +1 0 +- 0 +5 0 +. 0 +4 0 +) 0 +. 0 +Nitrofurantoins 1 +were 0 +associated 0 +with 0 +anophthalmia 3 +or 0 +microphthalmos 3 +( 0 +A0R 0 += 0 +3 0 +. 0 +7 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +1 0 +- 0 +12 0 +. 0 +2 0 +) 0 +"," 0 +hypoplastic 3 +left 4 +heart 4 +syndrome 4 +( 0 +A0R 0 += 0 +4 0 +. 0 +2 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +9 0 +- 0 +9 0 +. 0 +1 0 +) 0 +"," 0 +atrial 3 +septal 4 +defects 4 +( 0 +A0R 0 += 0 +1 0 +. 0 +9 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +1 0 +- 0 +3 0 +. 0 +4 0 +) 0 +"," 0 +and 0 +cleft 3 +lip 4 +with 0 +cleft 3 +palate 4 +( 0 +A0R 0 += 0 +2 0 +. 0 +1 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +1 0 +. 0 +2 0 +- 0 +3 0 +. 0 +9 0 +) 0 +. 0 +0ther 0 +antibacterial 0 +agents 0 +that 0 +showed 0 +associations 0 +included 0 +erythromycins 1 +( 0 +2 0 +defects 0 +) 0 +"," 0 +penicillins 1 +( 0 +1 0 +defect 0 +) 0 +"," 0 +cephalosporins 1 +( 0 +1 0 +defect 0 +) 0 +"," 0 +and 0 +quinolones 1 +( 0 +1 0 +defect 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Reassuringly 0 +"," 0 +penicillins 1 +"," 0 +erythromycins 1 +"," 0 +and 0 +cephalosporins 1 +"," 0 +although 0 +used 0 +commonly 0 +by 0 +pregnant 0 +women 0 +"," 0 +were 0 +not 0 +associated 0 +with 0 +many 0 +birth 3 +defects 4 +. 0 +Sulfonamides 1 +and 0 +nitrofurantoins 1 +were 0 +associated 0 +with 0 +several 0 +birth 3 +defects 4 +"," 0 +indicating 0 +a 0 +need 0 +for 0 +additional 0 +scrutiny 0 +. 0 +Differential 0 +impact 0 +of 0 +immune 0 +escape 0 +mutations 0 +G145R 0 +and 0 +P120T 0 +on 0 +the 0 +replication 0 +of 0 +lamivudine 1 +- 0 +resistant 0 +hepatitis 1 +B 2 +virus 2 +e 2 +antigen 2 +- 0 +positive 0 +and 0 +- 0 +negative 0 +strains 0 +. 0 +Immune 0 +escape 0 +variants 0 +of 0 +the 0 +hepatitis 3 +B 4 +virus 0 +( 0 +HBV 0 +) 0 +represent 0 +an 0 +emerging 0 +clinical 0 +challenge 0 +"," 0 +because 0 +they 0 +can 0 +be 0 +associated 0 +with 0 +vaccine 0 +escape 0 +"," 0 +HBV 0 +reactivation 0 +"," 0 +and 0 +failure 0 +of 0 +diagnostic 0 +tests 0 +. 0 +Recent 0 +data 0 +suggest 0 +a 0 +preferential 0 +selection 0 +of 0 +immune 0 +escape 0 +mutants 0 +in 0 +distinct 0 +peripheral 0 +blood 0 +leukocyte 0 +compartments 0 +of 0 +infected 0 +individuals 0 +. 0 +We 0 +therefore 0 +systematically 0 +analyzed 0 +the 0 +functional 0 +impact 0 +of 0 +the 0 +most 0 +prevalent 0 +immune 0 +escape 0 +variants 0 +"," 0 +the 0 +sG145R 0 +and 0 +sP120T 0 +mutants 0 +"," 0 +on 0 +the 0 +viral 0 +replication 0 +efficacy 0 +and 0 +antiviral 0 +drug 0 +susceptibility 0 +of 0 +common 0 +treatment 0 +- 0 +associated 0 +mutants 0 +with 0 +resistance 0 +to 0 +lamivudine 1 +( 0 +LAM 1 +) 0 +and 0 +/ 0 +or 0 +HBeAg 1 +negativity 0 +. 0 +Replication 0 +- 0 +competent 0 +HBV 0 +strains 0 +with 0 +sG145R 0 +or 0 +sP120T 0 +and 0 +LAM 1 +resistance 0 +( 0 +rtM204I 0 +or 0 +rtL180M 0 +/ 0 +rtM204V 0 +) 0 +were 0 +generated 0 +on 0 +an 0 +HBeAg 1 +- 0 +positive 0 +and 0 +an 0 +HBeAg 1 +- 0 +negative 0 +background 0 +with 0 +precore 0 +( 0 +PC 0 +) 0 +and 0 +basal 0 +core 0 +promoter 0 +( 0 +BCP 0 +) 0 +mutants 0 +. 0 +The 0 +sG145R 0 +mutation 0 +strongly 0 +reduced 0 +HBsAg 1 +levels 0 +and 0 +was 0 +able 0 +to 0 +fully 0 +restore 0 +the 0 +impaired 0 +replication 0 +of 0 +LAM 1 +- 0 +resistant 0 +HBV 0 +mutants 0 +to 0 +the 0 +levels 0 +of 0 +wild 0 +- 0 +type 0 +HBV 0 +"," 0 +and 0 +PC 0 +or 0 +BCP 0 +mutations 0 +further 0 +enhanced 0 +viral 0 +replication 0 +. 0 +Although 0 +the 0 +sP120T 0 +substitution 0 +also 0 +impaired 0 +HBsAg 1 +secretion 0 +"," 0 +it 0 +did 0 +not 0 +enhance 0 +the 0 +replication 0 +of 0 +LAM 1 +- 0 +resistant 0 +clones 0 +. 0 +However 0 +"," 0 +the 0 +concomitant 0 +occurrence 0 +of 0 +HBeAg 1 +negativity 0 +( 0 +PC 0 +/ 0 +BCP 0 +) 0 +"," 0 +sP120T 0 +"," 0 +and 0 +LAM 1 +resistance 0 +resulted 0 +in 0 +the 0 +restoration 0 +of 0 +replication 0 +to 0 +levels 0 +of 0 +wild 0 +- 0 +type 0 +HBV 0 +. 0 +In 0 +all 0 +clones 0 +with 0 +combined 0 +immune 0 +escape 0 +and 0 +LAM 1 +resistance 0 +mutations 0 +"," 0 +the 0 +nucleotide 1 +analogues 0 +adefovir 1 +and 0 +tenofovir 1 +remained 0 +effective 0 +in 0 +suppressing 0 +viral 0 +replication 0 +in 0 +vitro 0 +. 0 +These 0 +findings 0 +reveal 0 +the 0 +differential 0 +impact 0 +of 0 +immune 0 +escape 0 +variants 0 +on 0 +the 0 +replication 0 +and 0 +drug 0 +susceptibility 0 +of 0 +complex 0 +HBV 0 +mutants 0 +"," 0 +supporting 0 +the 0 +need 0 +of 0 +close 0 +surveillance 0 +and 0 +treatment 0 +adjustment 0 +in 0 +response 0 +to 0 +the 0 +selection 0 +of 0 +distinct 0 +mutational 0 +patterns 0 +. 0 +Hemolytic 3 +anemia 4 +associated 0 +with 0 +the 0 +use 0 +of 0 +omeprazole 1 +. 0 +0meprazole 1 +is 0 +the 0 +first 0 +drug 0 +designed 0 +to 0 +block 0 +the 0 +final 0 +step 0 +in 0 +the 0 +acid 0 +secretory 0 +process 0 +within 0 +the 0 +parietal 0 +cell 0 +. 0 +It 0 +has 0 +been 0 +shown 0 +to 0 +be 0 +extremely 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +peptic 3 +ulcer 4 +disease 4 +"," 0 +reflux 3 +esophagitis 4 +"," 0 +and 0 +the 0 +Zollinger 3 +- 4 +Ellison 4 +syndrome 4 +. 0 +Although 0 +clinical 0 +experience 0 +with 0 +omeprazole 1 +is 0 +still 0 +limited 0 +"," 0 +many 0 +controlled 0 +studies 0 +have 0 +established 0 +the 0 +short 0 +- 0 +term 0 +safety 0 +of 0 +this 0 +drug 0 +. 0 +We 0 +report 0 +the 0 +first 0 +case 0 +of 0 +a 0 +serious 0 +short 0 +- 0 +term 0 +adverse 0 +reaction 0 +with 0 +the 0 +use 0 +of 0 +omeprazole 1 +: 0 +hemolytic 3 +anemia 4 +. 0 +The 0 +patient 0 +developed 0 +weakness 0 +"," 0 +lethargy 3 +"," 0 +and 0 +shortness 3 +of 4 +breath 4 +2 0 +days 0 +after 0 +starting 0 +therapy 0 +with 0 +omeprazole 1 +. 0 +Two 0 +weeks 0 +after 0 +the 0 +initiation 0 +of 0 +therapy 0 +"," 0 +her 0 +hematocrit 0 +had 0 +decreased 0 +from 0 +44 0 +. 0 +1 0 +% 0 +to 0 +20 0 +. 0 +4 0 +% 0 +"," 0 +and 0 +she 0 +had 0 +a 0 +positive 0 +direct 0 +Coombs 0 +antiglobulin 0 +test 0 +and 0 +an 0 +elevated 0 +indirect 0 +bilirubin 1 +. 0 +After 0 +she 0 +discontinued 0 +the 0 +omeprazole 1 +"," 0 +her 0 +hemoglobin 0 +and 0 +hematocrit 0 +gradually 0 +returned 0 +to 0 +normal 0 +. 0 +The 0 +mechanism 0 +by 0 +which 0 +omeprazole 1 +caused 0 +the 0 +patient 0 +' 0 +s 0 +hemolytic 3 +anemia 4 +is 0 +uncertain 0 +"," 0 +but 0 +physicians 0 +should 0 +be 0 +alerted 0 +to 0 +this 0 +possible 0 +adverse 0 +effect 0 +. 0 +Phenylephrine 1 +but 0 +not 0 +ephedrine 1 +reduces 3 +frontal 4 +lobe 4 +oxygenation 4 +following 0 +anesthesia 0 +- 0 +induced 0 +hypotension 3 +. 0 +BACKGR0UND 0 +: 0 +Vasopressor 0 +agents 0 +are 0 +used 0 +to 0 +correct 0 +anesthesia 0 +- 0 +induced 0 +hypotension 3 +. 0 +We 0 +describe 0 +the 0 +effect 0 +of 0 +phenylephrine 1 +and 0 +ephedrine 1 +on 0 +frontal 0 +lobe 0 +oxygenation 0 +( 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +) 0 +following 0 +anesthesia 0 +- 0 +induced 0 +hypotension 3 +. 0 +METH0DS 0 +: 0 +Following 0 +induction 0 +of 0 +anesthesia 0 +by 0 +fentanyl 1 +( 0 +0 0 +. 0 +15 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +) 0 +and 0 +propofol 1 +( 0 +2 0 +. 0 +0 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +) 0 +"," 0 +13 0 +patients 0 +received 0 +phenylephrine 1 +( 0 +0 0 +. 0 +1 0 +mg 0 +iv 0 +) 0 +and 0 +12 0 +patients 0 +received 0 +ephedrine 1 +( 0 +10 0 +mg 0 +iv 0 +) 0 +to 0 +restore 0 +mean 0 +arterial 0 +pressure 0 +( 0 +MAP 0 +) 0 +. 0 +Heart 0 +rate 0 +( 0 +HR 0 +) 0 +"," 0 +MAP 0 +"," 0 +stroke 3 +volume 0 +( 0 +SV 0 +) 0 +"," 0 +cardiac 0 +output 0 +( 0 +C0 0 +) 0 +"," 0 +and 0 +frontal 0 +lobe 0 +oxygenation 0 +( 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +) 0 +were 0 +registered 0 +. 0 +RESULTS 0 +: 0 +Induction 0 +of 0 +anesthesia 0 +was 0 +followed 0 +by 0 +a 3 +decrease 4 +in 4 +MAP 4 +"," 4 +HR 4 +"," 4 +SV 4 +"," 4 +and 4 +C0 4 +concomitant 0 +with 0 +an 0 +elevation 0 +in 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +. 0 +After 0 +administration 0 +of 0 +phenylephrine 1 +"," 0 +MAP 0 +increased 0 +( 0 +51 0 ++ 0 +/ 0 +- 0 +12 0 +to 0 +81 0 ++ 0 +/ 0 +- 0 +13 0 +mmHg 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +; 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +. 0 +However 0 +"," 0 +a 0 +14 0 +% 0 +( 0 +from 0 +70 0 ++ 0 +/ 0 +- 0 +8 0 +% 0 +to 0 +60 0 ++ 0 +/ 0 +- 0 +7 0 +% 0 +) 0 +reduction 0 +in 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +followed 0 +with 0 +no 0 +change 0 +in 0 +C0 0 +( 0 +3 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +1 0 +to 0 +3 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +9 0 +l 0 +min 0 +( 0 +- 0 +1 0 +) 0 +) 0 +. 0 +The 0 +administration 0 +of 0 +ephedrine 1 +led 0 +to 0 +a 0 +similar 0 +increase 0 +in 0 +MAP 0 +( 0 +53 0 ++ 0 +/ 0 +- 0 +9 0 +to 0 +79 0 ++ 0 +/ 0 +- 0 +8 0 +mmHg 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +restored 0 +C0 0 +( 0 +3 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +2 0 +to 0 +5 0 +. 0 +0 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +l 0 +min 0 +( 0 +- 0 +1 0 +) 0 +) 0 +"," 0 +and 0 +preserved 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +utilization 0 +of 0 +phenylephrine 1 +to 0 +correct 0 +hypotension 3 +induced 0 +by 0 +anesthesia 0 +has 0 +a 0 +negative 0 +impact 0 +on 0 +S 0 +( 0 +c 0 +) 0 +0 0 +( 0 +2 0 +) 0 +while 0 +ephedrine 1 +maintains 0 +frontal 0 +lobe 0 +oxygenation 0 +potentially 0 +related 0 +to 0 +an 0 +increase 0 +in 0 +C0 0 +. 0 +Prolonged 0 +elevation 0 +of 0 +plasma 0 +argatroban 1 +in 0 +a 0 +cardiac 0 +transplant 0 +patient 0 +with 0 +a 0 +suspected 0 +history 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +with 0 +thrombosis 3 +. 0 +BACKGR0UND 0 +: 0 +Direct 0 +thrombin 0 +inhibitors 0 +( 0 +DTIs 0 +) 0 +provide 0 +an 0 +alternative 0 +method 0 +of 0 +anticoagulation 0 +for 0 +patients 0 +with 0 +a 0 +history 0 +of 0 +heparin 1 +- 0 +induced 0 +thrombocytopenia 3 +( 0 +HIT 3 +) 0 +or 0 +HIT 3 +with 0 +thrombosis 3 +( 0 +HITT 3 +) 0 +undergoing 0 +cardiopulmonary 0 +bypass 0 +( 0 +CPB 0 +) 0 +. 0 +In 0 +the 0 +following 0 +report 0 +"," 0 +a 0 +65 0 +- 0 +year 0 +- 0 +old 0 +critically 3 +ill 4 +patient 0 +with 0 +a 0 +suspected 0 +history 0 +of 0 +HITT 3 +was 0 +administered 0 +argatroban 1 +for 0 +anticoagulation 0 +on 0 +bypass 0 +during 0 +heart 0 +transplantation 0 +. 0 +The 0 +patient 0 +required 0 +massive 0 +transfusion 0 +support 0 +( 0 +55 0 +units 0 +of 0 +red 0 +blood 0 +cells 0 +"," 0 +42 0 +units 0 +of 0 +fresh 0 +- 0 +frozen 0 +plasma 0 +"," 0 +40 0 +units 0 +of 0 +cryoprecipitate 0 +"," 0 +40 0 +units 0 +of 0 +platelets 0 +"," 0 +and 0 +three 0 +doses 0 +of 0 +recombinant 0 +Factor 0 +VIIa 0 +) 0 +for 0 +severe 0 +intraoperative 3 +and 4 +postoperative 4 +bleeding 4 +. 0 +STUDY 0 +DESIGN 0 +AND 0 +METH0DS 0 +: 0 +Plasma 0 +samples 0 +from 0 +before 0 +and 0 +after 0 +CPB 0 +were 0 +analyzed 0 +postoperatively 0 +for 0 +argatroban 1 +concentration 0 +using 0 +a 0 +modified 0 +ecarin 0 +clotting 0 +time 0 +( 0 +ECT 0 +) 0 +assay 0 +. 0 +RESULTS 0 +: 0 +Unexpectedly 0 +high 0 +concentrations 0 +of 0 +argatroban 1 +were 0 +measured 0 +in 0 +these 0 +samples 0 +( 0 +range 0 +"," 0 +0 0 +- 0 +32 0 +microg 0 +/ 0 +mL 0 +) 0 +"," 0 +and 0 +a 0 +prolonged 0 +plasma 0 +argatroban 1 +half 0 +life 0 +( 0 +t 0 +( 0 +1 0 +/ 0 +2 0 +) 0 +) 0 +of 0 +514 0 +minutes 0 +was 0 +observed 0 +( 0 +published 0 +elimination 0 +t 0 +( 0 +1 0 +/ 0 +2 0 +) 0 +is 0 +39 0 +- 0 +51 0 +minutes 0 +[ 0 +< 0 +or 0 += 0 +181 0 +minutes 0 +with 0 +hepatic 3 +impairment 4 +] 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Correlation 0 +of 0 +plasma 0 +argatroban 1 +concentration 0 +versus 0 +the 0 +patient 0 +' 0 +s 0 +coagulation 0 +variables 0 +and 0 +clinical 0 +course 0 +suggest 0 +that 0 +prolonged 0 +elevated 0 +levels 0 +of 0 +plasma 0 +argatroban 1 +may 0 +have 0 +contributed 0 +to 0 +the 0 +patient 0 +' 0 +s 0 +extended 0 +coagulopathy 3 +. 0 +Because 0 +DTIs 0 +do 0 +not 0 +have 0 +reversal 0 +agents 0 +"," 0 +surgical 0 +teams 0 +and 0 +transfusion 0 +services 0 +should 0 +remain 0 +aware 0 +of 0 +the 0 +possibility 0 +of 0 +massive 0 +transfusion 0 +events 0 +during 0 +anticoagulation 0 +with 0 +these 0 +agents 0 +. 0 +This 0 +is 0 +the 0 +first 0 +report 0 +to 0 +measure 0 +plasma 0 +argatroban 1 +concentration 0 +in 0 +the 0 +context 0 +of 0 +CPB 0 +and 0 +extended 0 +coagulopathy 3 +. 0 +The 0 +effects 0 +of 0 +the 0 +adjunctive 0 +bupropion 1 +on 0 +male 0 +sexual 3 +dysfunction 4 +induced 0 +by 0 +a 0 +selective 1 +serotonin 2 +reuptake 2 +inhibitor 2 +: 0 +a 0 +double 0 +- 0 +blind 0 +placebo 0 +- 0 +controlled 0 +and 0 +randomized 0 +study 0 +. 0 +0BJECTIVE 0 +: 0 +To 0 +determine 0 +the 0 +safety 0 +and 0 +efficacy 0 +of 0 +adjunctive 0 +bupropion 1 +sustained 0 +- 0 +release 0 +( 0 +SR 0 +) 0 +on 0 +male 0 +sexual 3 +dysfunction 4 +( 0 +SD 3 +) 0 +induced 0 +by 0 +a 0 +selective 1 +serotonin 2 +reuptake 2 +inhibitor 2 +( 0 +SSRI 1 +) 0 +"," 0 +as 0 +SD 3 +is 0 +a 0 +common 0 +side 0 +- 0 +effect 0 +of 0 +SSRIs 1 +and 0 +the 0 +most 0 +effective 0 +treatments 0 +have 0 +yet 0 +to 0 +be 0 +determined 0 +. 0 +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +The 0 +randomized 0 +sample 0 +consisted 0 +of 0 +234 0 +euthymic 0 +men 0 +who 0 +were 0 +receiving 0 +some 0 +type 0 +of 0 +SSRI 1 +. 0 +The 0 +men 0 +were 0 +randomly 0 +assigned 0 +to 0 +bupropion 1 +SR 0 +( 0 +150 0 +mg 0 +twice 0 +daily 0 +"," 0 +117 0 +) 0 +or 0 +placebo 0 +( 0 +twice 0 +daily 0 +"," 0 +117 0 +) 0 +for 0 +12 0 +weeks 0 +. 0 +Efficacy 0 +was 0 +evaluated 0 +using 0 +the 0 +Clinical 0 +Global 0 +Impression 0 +- 0 +Sexual 0 +Function 0 +( 0 +CGI 0 +- 0 +SF 0 +; 0 +the 0 +primary 0 +outcome 0 +measure 0 +) 0 +"," 0 +the 0 +International 0 +Index 0 +of 0 +Erectile 0 +Function 0 +( 0 +IIEF 0 +) 0 +"," 0 +Arizona 0 +Sexual 0 +Experience 0 +Scale 0 +( 0 +ASEX 0 +) 0 +"," 0 +and 0 +Erectile 3 +Dysfunction 4 +Inventory 0 +of 0 +Treatment 0 +Satisfaction 0 +( 0 +EDITS 0 +) 0 +( 0 +secondary 0 +outcome 0 +measures 0 +) 0 +. 0 +Participants 0 +were 0 +followed 0 +biweekly 0 +during 0 +study 0 +period 0 +. 0 +RESULTS 0 +: 0 +After 0 +12 0 +weeks 0 +of 0 +treatment 0 +"," 0 +the 0 +mean 0 +( 0 +sd 0 +) 0 +scores 0 +for 0 +CGI 0 +- 0 +SF 0 +were 0 +significantly 0 +lower 0 +"," 0 +i 0 +. 0 +e 0 +. 0 +better 0 +"," 0 +in 0 +patients 0 +on 0 +bupropion 1 +SR 0 +"," 0 +at 0 +2 0 +. 0 +4 0 +( 0 +1 0 +. 0 +2 0 +) 0 +"," 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +"," 0 +at 0 +3 0 +. 0 +9 0 +( 0 +1 0 +. 0 +1 0 +) 0 +( 0 +P 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Men 0 +who 0 +received 0 +bupropion 1 +had 0 +a 0 +significant 0 +increase 0 +in 0 +the 0 +total 0 +IIEF 0 +score 0 +( 0 +54 0 +. 0 +4 0 +% 0 +vs 0 +1 0 +. 0 +2 0 +% 0 +; 0 +P 0 += 0 +0 0 +. 0 +3 0 +) 0 +"," 0 +and 0 +in 0 +the 0 +five 0 +different 0 +domains 0 +of 0 +the 0 +IIEF 0 +. 0 +Total 0 +ASEX 0 +scores 0 +were 0 +significantly 0 +lower 0 +"," 0 +i 0 +. 0 +e 0 +. 0 +better 0 +"," 0 +among 0 +men 0 +who 0 +received 0 +bupropion 1 +than 0 +placebo 0 +"," 0 +at 0 +15 0 +. 0 +5 0 +( 0 +4 0 +. 0 +3 0 +) 0 +vs 0 +21 0 +. 0 +5 0 +( 0 +4 0 +. 0 +7 0 +) 0 +( 0 +P 0 += 0 +0 0 +. 0 +2 0 +) 0 +. 0 +The 0 +EDITS 0 +scores 0 +were 0 +67 0 +. 0 +4 0 +( 0 +10 0 +. 0 +2 0 +) 0 +for 0 +the 0 +bupropion 1 +and 0 +36 0 +. 0 +3 0 +( 0 +11 0 +. 0 +7 0 +) 0 +for 0 +the 0 +placebo 0 +group 0 +( 0 +P 0 += 0 +0 0 +. 0 +1 0 +) 0 +. 0 +The 0 +ASEX 0 +score 0 +and 0 +CGI 0 +- 0 +SF 0 +score 0 +were 0 +correlated 0 +( 0 +P 0 += 0 +0 0 +. 0 +3 0 +) 0 +. 0 +In 0 +linear 0 +regression 0 +analyses 0 +the 0 +CGI 0 +- 0 +SF 0 +score 0 +was 0 +not 0 +affected 0 +significantly 0 +by 0 +the 0 +duration 0 +of 0 +SD 3 +"," 0 +type 0 +of 0 +SSRI 1 +used 0 +and 0 +age 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Bupropion 1 +is 0 +an 0 +effective 0 +treatment 0 +for 0 +male 0 +SD 3 +induced 0 +by 0 +SSRIs 1 +. 0 +These 0 +results 0 +provide 0 +empirical 0 +support 0 +for 0 +conducting 0 +a 0 +further 0 +study 0 +of 0 +bupropion 1 +. 0 +Prevention 0 +of 0 +seizures 3 +and 0 +reorganization 0 +of 0 +hippocampal 0 +functions 0 +by 0 +transplantation 0 +of 0 +bone 0 +marrow 0 +cells 0 +in 0 +the 0 +acute 0 +phase 0 +of 0 +experimental 0 +epilepsy 3 +. 0 +In 0 +this 0 +study 0 +"," 0 +we 0 +investigated 0 +the 0 +therapeutic 0 +potential 0 +of 0 +bone 0 +marrow 0 +mononuclear 0 +cells 0 +( 0 +BMCs 0 +) 0 +in 0 +a 0 +model 0 +of 0 +epilepsy 3 +induced 0 +by 0 +pilocarpine 1 +in 0 +rats 0 +. 0 +BMCs 0 +obtained 0 +from 0 +green 0 +fluorescent 0 +protein 0 +( 0 +GFP 0 +) 0 +transgenic 0 +mice 0 +or 0 +rats 0 +were 0 +transplanted 0 +intravenously 0 +after 0 +induction 0 +of 0 +status 3 +epilepticus 4 +( 0 +SE 3 +) 0 +. 0 +Spontaneous 3 +recurrent 4 +seizures 4 +( 0 +SRS 3 +) 0 +were 0 +monitored 0 +using 0 +Racine 0 +' 0 +s 0 +seizure 3 +severity 0 +scale 0 +. 0 +All 0 +of 0 +the 0 +rats 0 +in 0 +the 0 +saline 0 +- 0 +treated 0 +epileptic 3 +control 0 +group 0 +developed 0 +SRS 3 +"," 0 +whereas 0 +none 0 +of 0 +the 0 +BMC 0 +- 0 +treated 0 +epileptic 3 +animals 0 +had 0 +seizures 3 +in 0 +the 0 +short 0 +term 0 +( 0 +15 0 +days 0 +after 0 +transplantation 0 +) 0 +"," 0 +regardless 0 +of 0 +the 0 +BMC 0 +source 0 +. 0 +0ver 0 +the 0 +long 0 +- 0 +term 0 +chronic 0 +phase 0 +( 0 +120 0 +days 0 +after 0 +transplantation 0 +) 0 +"," 0 +only 0 +25 0 +% 0 +of 0 +BMC 0 +- 0 +treated 0 +epileptic 3 +animals 0 +had 0 +seizures 3 +"," 0 +but 0 +with 0 +a 0 +lower 0 +frequency 0 +and 0 +duration 0 +compared 0 +to 0 +the 0 +epileptic 3 +control 0 +group 0 +. 0 +The 0 +density 0 +of 0 +hippocampal 0 +neurons 0 +in 0 +the 0 +brains 0 +of 0 +animals 0 +treated 0 +with 0 +BMCs 0 +was 0 +markedly 0 +preserved 0 +. 0 +At 0 +hippocampal 0 +Schaeffer 0 +collateral 0 +- 0 +CA1 0 +synapses 0 +"," 0 +long 0 +- 0 +term 0 +potentiation 0 +was 0 +preserved 0 +in 0 +BMC 0 +- 0 +transplanted 0 +rats 0 +compared 0 +to 0 +epileptic 3 +controls 0 +. 0 +The 0 +donor 0 +- 0 +derived 0 +GFP 0 +( 0 ++ 0 +) 0 +cells 0 +were 0 +rarely 0 +found 0 +in 0 +the 0 +brains 0 +of 0 +transplanted 0 +epileptic 3 +rats 0 +. 0 +In 0 +conclusion 0 +"," 0 +treatment 0 +with 0 +BMCs 0 +can 0 +prevent 0 +the 0 +development 0 +of 0 +chronic 0 +seizures 3 +"," 0 +reduce 0 +neuronal 3 +loss 4 +"," 0 +and 0 +influence 0 +the 0 +reorganization 0 +of 0 +the 0 +hippocampal 0 +neuronal 0 +network 0 +. 0 +Normalizing 0 +effects 0 +of 0 +modafinil 1 +on 0 +sleep 0 +in 0 +chronic 0 +cocaine 1 +users 0 +. 0 +0BJECTIVE 0 +: 0 +The 0 +purpose 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +effect 0 +of 0 +morning 0 +- 0 +dosed 0 +modafinil 1 +on 0 +sleep 0 +and 0 +daytime 3 +sleepiness 4 +in 0 +chronic 0 +cocaine 1 +users 0 +. 0 +METH0D 0 +: 0 +Twenty 0 +cocaine 1 +- 0 +dependent 0 +participants 0 +were 0 +randomly 0 +assigned 0 +to 0 +receive 0 +modafinil 1 +"," 0 +400 0 +mg 0 +( 0 +N 0 += 0 +10 0 +) 0 +"," 0 +or 0 +placebo 0 +( 0 +N 0 += 0 +10 0 +) 0 +every 0 +morning 0 +at 0 +7 0 +: 0 +30 0 +a 0 +. 0 +m 0 +. 0 +for 0 +16 0 +days 0 +in 0 +an 0 +inpatient 0 +"," 0 +double 0 +- 0 +blind 0 +randomized 0 +trial 0 +. 0 +Participants 0 +underwent 0 +polysomnographic 0 +sleep 0 +recordings 0 +on 0 +days 0 +1 0 +to 0 +3 0 +"," 0 +7 0 +to 0 +9 0 +"," 0 +and 0 +14 0 +to 0 +16 0 +( 0 +first 0 +"," 0 +second 0 +"," 0 +and 0 +third 0 +weeks 0 +of 0 +abstinence 0 +) 0 +. 0 +The 0 +Multiple 0 +Sleep 0 +Latency 0 +Test 0 +was 0 +performed 0 +at 0 +11 0 +: 0 +30 0 +a 0 +. 0 +m 0 +. 0 +"," 0 +2 0 +: 0 +0 0 +p 0 +. 0 +m 0 +. 0 +"," 0 +and 0 +4 0 +: 0 +30 0 +p 0 +. 0 +m 0 +. 0 +on 0 +days 0 +2 0 +"," 0 +8 0 +"," 0 +and 0 +15 0 +. 0 +For 0 +comparison 0 +of 0 +sleep 0 +architecture 0 +variables 0 +"," 0 +12 0 +healthy 0 +comparison 0 +participants 0 +underwent 0 +a 0 +single 0 +night 0 +of 0 +experimental 0 +polysomnography 0 +that 0 +followed 0 +1 0 +night 0 +of 0 +accommodation 0 +polysomnography 0 +. 0 +RESULTS 0 +: 0 +Progressive 0 +abstinence 0 +from 0 +cocaine 1 +was 0 +associated 0 +with 0 +worsening 0 +of 0 +all 0 +measured 0 +polysomnographic 0 +sleep 0 +outcomes 0 +. 0 +Compared 0 +with 0 +placebo 0 +"," 0 +modafinil 1 +decreased 0 +nighttime 0 +sleep 0 +latency 0 +and 0 +increased 0 +slow 0 +- 0 +wave 0 +sleep 0 +time 0 +in 0 +cocaine 1 +- 0 +dependent 0 +participants 0 +. 0 +The 0 +effect 0 +of 0 +modafinil 1 +interacted 0 +with 0 +the 0 +abstinence 0 +week 0 +and 0 +was 0 +associated 0 +with 0 +longer 0 +total 0 +sleep 0 +time 0 +and 0 +shorter 0 +REM 0 +sleep 0 +latency 0 +in 0 +the 0 +third 0 +week 0 +of 0 +abstinence 0 +. 0 +Comparison 0 +of 0 +slow 0 +- 0 +wave 0 +sleep 0 +time 0 +"," 0 +total 0 +sleep 0 +time 0 +"," 0 +and 0 +sleep 0 +latency 0 +in 0 +cocaine 1 +- 0 +dependent 0 +and 0 +healthy 0 +participants 0 +revealed 0 +a 0 +normalizing 0 +effect 0 +of 0 +modafinil 1 +in 0 +cocaine 1 +- 0 +dependent 0 +participants 0 +. 0 +Modafinil 1 +was 0 +associated 0 +with 0 +increased 0 +daytime 0 +sleep 0 +latency 0 +"," 0 +as 0 +measured 0 +by 0 +the 0 +Multiple 0 +Sleep 0 +Latency 0 +Test 0 +"," 0 +and 0 +a 0 +nearly 0 +significant 0 +decrease 0 +in 0 +subjective 0 +daytime 3 +sleepiness 4 +. 0 +C0NCLUSI0NS 0 +: 0 +Morning 0 +- 0 +dosed 0 +modafinil 1 +promotes 0 +nocturnal 0 +sleep 0 +"," 0 +normalizes 0 +sleep 0 +architecture 0 +"," 0 +and 0 +decreases 0 +daytime 3 +sleepiness 4 +in 0 +abstinent 0 +cocaine 1 +users 0 +. 0 +These 0 +effects 0 +may 0 +be 0 +relevant 0 +in 0 +the 0 +treatment 0 +of 0 +cocaine 1 +dependence 0 +. 0 +Safety 0 +of 0 +transesophageal 0 +echocardiography 0 +in 0 +adults 0 +: 0 +study 0 +in 0 +a 0 +multidisciplinary 0 +hospital 0 +. 0 +BACKGR0UND 0 +: 0 +TEE 0 +is 0 +a 0 +semi 0 +- 0 +invasive 0 +tool 0 +broadly 0 +used 0 +and 0 +its 0 +utilization 0 +associated 0 +to 0 +sedatives 0 +drugs 0 +might 0 +to 0 +affect 0 +the 0 +procedure 0 +safety 0 +. 0 +0BJECTIVE 0 +: 0 +to 0 +analyze 0 +aspects 0 +of 0 +TEE 0 +safety 0 +associated 0 +to 0 +the 0 +use 0 +of 0 +Midazolan 1 +( 0 +MZ 1 +) 0 +and 0 +Flumazenil 1 +( 0 +FL 1 +) 0 +and 0 +the 0 +influence 0 +of 0 +the 0 +clinical 0 +variables 0 +on 0 +the 0 +event 0 +rate 0 +. 0 +METH0D 0 +: 0 +prospective 0 +study 0 +with 0 +137 0 +patients 0 +that 0 +underwent 0 +TEE 0 +with 0 +MZ 1 +associated 0 +to 0 +moderate 0 +sedation 0 +. 0 +We 0 +analyzed 0 +the 0 +following 0 +events 0 +: 0 +complications 0 +related 0 +with 0 +the 0 +topical 0 +anesthesia 0 +"," 0 +with 0 +MZ 1 +use 0 +and 0 +with 0 +the 0 +procedure 0 +. 0 +Uni 0 +- 0 +and 0 +multivariate 0 +analyses 0 +were 0 +used 0 +to 0 +test 0 +the 0 +influence 0 +of 0 +the 0 +clinical 0 +variables 0 +: 0 +age 0 +"," 0 +sex 0 +"," 0 +stroke 3 +"," 0 +myocardiopathy 3 +( 0 +MP 3 +) 0 +"," 0 +duration 0 +of 0 +the 0 +test 0 +"," 0 +mitral 3 +regurgitation 4 +( 0 +MR 3 +) 0 +and 0 +the 0 +MZ 1 +dose 0 +. 0 +RESULTS 0 +: 0 +All 0 +patients 0 +( 0 +65 0 ++ 0 +/ 0 +- 0 +16 0 +yrs 0 +; 0 +58 0 +% 0 +males 0 +) 0 +finished 0 +the 0 +examination 0 +. 0 +The 0 +mean 0 +doses 0 +of 0 +MZ 1 +and 0 +FL 1 +were 0 +4 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +mg 0 +and 0 +0 0 +. 0 +28 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +mg 0 +"," 0 +respectively 0 +. 0 +The 0 +duration 0 +of 0 +the 0 +examination 0 +and 0 +the 0 +mean 0 +ejection 0 +fraction 0 +( 0 +EF 0 +) 0 +were 0 +16 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +1 0 +minutes 0 +and 0 +60 0 ++ 0 +/ 0 +- 0 +9 0 +% 0 +"," 0 +respectively 0 +. 0 +Mild 0 +hypoxia 3 +( 0 +S02 0 +< 0 +90 0 +% 0 +) 0 +was 0 +the 0 +most 0 +common 0 +event 0 +( 0 +11 0 +patients 0 +) 0 +; 0 +3 0 +patients 0 +( 0 +2 0 +% 0 +) 0 +presented 0 +transient 0 +hypoxia 3 +due 0 +to 0 +upper 0 +airway 3 +obstruction 4 +by 0 +probe 0 +introduction 0 +and 0 +8 0 +( 0 +5 0 +. 0 +8 0 +% 0 +) 0 +due 0 +to 0 +hypoxia 3 +caused 0 +by 0 +MZ 1 +use 0 +. 0 +Transient 0 +hypotension 3 +( 0 +SAP 0 +< 0 +90mmHg 0 +) 0 +occurred 0 +in 0 +1 0 +patient 0 +( 0 +0 0 +. 0 +7 0 +% 0 +) 0 +. 0 +The 0 +multivariate 0 +analysis 0 +showed 0 +that 0 +severe 0 +MR 3 +"," 0 +MP 3 +( 0 +EF 0 +< 0 +45 0 +% 0 +) 0 +and 0 +high 0 +doses 0 +of 0 +MZ 1 +( 0 +> 0 +5mg 0 +) 0 +were 0 +associated 0 +with 0 +events 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +The 0 +EF 0 +was 0 +40 0 +% 0 +"," 0 +in 0 +the 0 +group 0 +with 0 +MP 3 +and 0 +44 0 +% 0 +in 0 +the 0 +group 0 +with 0 +severe 0 +MR 3 +and 0 +it 0 +can 0 +be 0 +a 0 +factor 0 +associated 0 +with 0 +clinical 0 +events 0 +in 0 +the 0 +last 0 +group 0 +. 0 +C0NCLUSI0N 0 +: 0 +TEE 0 +with 0 +sedation 0 +presents 0 +a 0 +low 0 +rate 0 +of 0 +events 0 +. 0 +There 0 +were 0 +no 0 +severe 0 +events 0 +and 0 +there 0 +was 0 +no 0 +need 0 +to 0 +interrupt 0 +the 0 +examinations 0 +. 0 +Effect 0 +of 0 +direct 0 +intracoronary 0 +administration 0 +of 0 +methylergonovine 1 +in 0 +patients 0 +with 0 +and 0 +without 0 +variant 3 +angina 4 +. 0 +The 0 +effects 0 +of 0 +intracoronary 0 +administration 0 +of 0 +methylergonovine 1 +were 0 +studied 0 +in 0 +21 0 +patients 0 +with 0 +variant 3 +angina 4 +and 0 +22 0 +patients 0 +with 0 +atypical 0 +chest 3 +pain 4 +and 0 +in 0 +others 0 +without 0 +angina 3 +pectoris 4 +( 0 +control 0 +group 0 +) 0 +. 0 +Methylergonovine 1 +was 0 +administered 0 +continuously 0 +at 0 +a 0 +rate 0 +of 0 +10 0 +micrograms 0 +/ 0 +min 0 +up 0 +to 0 +50 0 +micrograms 0 +. 0 +In 0 +all 0 +patients 0 +with 0 +variant 3 +angina 4 +"," 0 +coronary 3 +spasm 4 +was 0 +provoked 0 +at 0 +a 0 +mean 0 +dose 0 +of 0 +28 0 ++ 0 +/ 0 +- 0 +13 0 +micrograms 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +. 0 +In 0 +the 0 +control 0 +group 0 +neither 0 +ischemic 0 +ST 0 +change 0 +nor 0 +localized 0 +spasm 3 +occurred 0 +. 0 +The 0 +basal 0 +tone 0 +of 0 +the 0 +right 0 +coronary 0 +artery 0 +was 0 +significantly 0 +lower 0 +than 0 +that 0 +of 0 +the 0 +left 0 +coronary 0 +artery 0 +. 0 +The 0 +percentage 0 +of 0 +vasoconstriction 0 +of 0 +the 0 +right 0 +coronary 0 +artery 0 +was 0 +significantly 0 +higher 0 +than 0 +that 0 +of 0 +the 0 +left 0 +coronary 0 +artery 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +spasm 3 +provocation 0 +tests 0 +"," 0 +which 0 +use 0 +an 0 +intracoronary 0 +injection 0 +of 0 +a 0 +relatively 0 +low 0 +dose 0 +of 0 +methylergonovine 1 +"," 0 +have 0 +a 0 +high 0 +sensitivity 0 +in 0 +variant 3 +angina 4 +and 0 +the 0 +vasoreactivity 0 +of 0 +the 0 +right 0 +coronary 0 +artery 0 +may 0 +be 0 +greater 0 +than 0 +that 0 +of 0 +the 0 +other 0 +coronary 0 +arteries 0 +. 0 +0ral 0 +manifestations 0 +of 0 +" 0 +meth 3 +mouth 4 +" 0 +: 0 +a 0 +case 0 +report 0 +. 0 +AIM 0 +: 0 +The 0 +aim 0 +of 0 +the 0 +documentation 0 +of 0 +this 0 +clinical 0 +case 0 +is 0 +to 0 +make 0 +clinicians 0 +aware 0 +of 0 +" 0 +meth 3 +mouth 4 +" 0 +and 0 +the 0 +medical 0 +risks 0 +associated 0 +with 0 +this 0 +serious 0 +condition 0 +. 0 +BACKGR0UND 0 +: 0 +Methamphetamine 1 +is 0 +a 0 +very 0 +addictive 0 +"," 0 +powerful 0 +stimulant 0 +that 0 +increases 0 +wakefulness 0 +and 0 +physical 0 +activity 0 +and 0 +can 0 +produce 0 +other 0 +effects 0 +such 0 +as 0 +cardiac 3 +dysrhythmias 4 +"," 0 +hypertension 3 +"," 0 +hallucinations 3 +"," 0 +and 0 +violent 3 +behavior 4 +. 0 +Dental 0 +patients 0 +abusing 0 +methamphetamine 1 +can 0 +present 0 +with 0 +poor 0 +oral 0 +hygiene 0 +"," 0 +xerostomia 3 +"," 0 +rampant 0 +caries 3 +( 0 +" 0 +meth 3 +mouth 4 +" 0 +) 0 +"," 0 +and 0 +excessive 0 +tooth 3 +wear 4 +. 0 +0ral 0 +rehabilitation 0 +of 0 +patients 0 +using 0 +methamphetamine 1 +can 0 +be 0 +challenging 0 +. 0 +CASE 0 +DESCRIPTI0N 0 +: 0 +A 0 +30 0 +- 0 +year 0 +- 0 +old 0 +Caucasian 0 +woman 0 +presented 0 +with 0 +dental 0 +pain 3 +"," 0 +bad 3 +breath 4 +"," 0 +and 0 +self 0 +- 0 +reported 0 +poor 0 +esthetics 0 +. 0 +A 0 +comprehensive 0 +examination 0 +including 0 +her 0 +medical 0 +history 0 +"," 0 +panoramic 0 +radiograph 0 +"," 0 +and 0 +intraoral 0 +examination 0 +revealed 0 +19 0 +carious 3 +lesions 4 +"," 0 +which 0 +is 0 +not 0 +very 0 +common 0 +for 0 +a 0 +healthy 0 +adult 0 +. 0 +She 0 +reported 0 +her 0 +use 0 +of 0 +methamphetamine 1 +for 0 +five 0 +years 0 +and 0 +had 0 +not 0 +experienced 0 +any 0 +major 0 +carious 3 +episodes 4 +before 0 +she 0 +started 0 +using 0 +the 0 +drug 0 +. 0 +SUMMARY 0 +: 0 +The 0 +patient 0 +' 0 +s 0 +medical 0 +and 0 +dental 0 +histories 0 +along 0 +with 0 +radiographic 0 +and 0 +clinical 0 +findings 0 +lead 0 +to 0 +a 0 +diagnosis 0 +of 0 +" 0 +meth 3 +mouth 4 +. 0 +" 0 +Although 0 +three 0 +different 0 +dental 0 +treatment 0 +modalities 0 +( 0 +either 0 +conventional 0 +or 0 +implant 0 +- 0 +supported 0 +) 0 +have 0 +been 0 +offered 0 +to 0 +the 0 +patient 0 +since 0 +August 0 +2007 0 +"," 0 +the 0 +patient 0 +has 0 +yet 0 +to 0 +initiate 0 +any 0 +treatment 0 +. 0 +CLINICAL 0 +SIGNIFICANCE 0 +: 0 +This 0 +clinical 0 +case 0 +showing 0 +oral 0 +manifestations 0 +of 0 +meth 3 +mouth 4 +was 0 +presented 0 +to 0 +help 0 +dental 0 +practitioners 0 +recognize 0 +and 0 +manage 0 +patients 0 +who 0 +may 0 +be 0 +abusing 0 +methamphetamines 1 +. 0 +Dental 0 +practitioners 0 +also 0 +may 0 +be 0 +skeptical 0 +about 0 +the 0 +reliability 0 +of 0 +appointment 0 +keeping 0 +by 0 +these 0 +patients 0 +"," 0 +as 0 +they 0 +frequently 0 +miss 0 +their 0 +appointments 0 +without 0 +reasonable 0 +justification 0 +. 0 +Antituberculosis 1 +therapy 0 +- 0 +induced 0 +acute 3 +liver 4 +failure 4 +: 0 +magnitude 0 +"," 0 +profile 0 +"," 0 +prognosis 0 +"," 0 +and 0 +predictors 0 +of 0 +outcome 0 +. 0 +Antituberculosis 1 +therapy 0 +( 0 +ATT 0 +) 0 +- 0 +associated 0 +acute 3 +liver 4 +failure 4 +( 0 +ATT 0 +- 0 +ALF 3 +) 0 +is 0 +the 0 +commonest 0 +drug 0 +- 0 +induced 0 +ALF 3 +in 0 +South 0 +Asia 0 +. 0 +Prospective 0 +studies 0 +on 0 +ATT 0 +- 0 +ALF 3 +are 0 +lacking 0 +. 0 +The 0 +current 0 +study 0 +prospectively 0 +evaluated 0 +the 0 +magnitude 0 +"," 0 +clinical 0 +course 0 +"," 0 +outcome 0 +"," 0 +and 0 +prognostic 0 +factors 0 +in 0 +ATT 0 +- 0 +ALF 3 +. 0 +From 0 +January 0 +1986 0 +to 0 +January 0 +2009 0 +"," 0 +1223 0 +consecutive 0 +ALF 3 +patients 0 +were 0 +evaluated 0 +: 0 +ATT 0 +alone 0 +was 0 +the 0 +cause 0 +in 0 +70 0 +( 0 +5 0 +. 0 +7 0 +% 0 +) 0 +patients 0 +. 0 +Another 0 +15 0 +( 0 +1 0 +. 0 +2 0 +% 0 +) 0 +had 0 +ATT 0 +and 0 +simultaneous 0 +hepatitis 3 +virus 4 +infection 4 +. 0 +In 0 +44 0 +( 0 +62 0 +. 0 +8 0 +% 0 +) 0 +patients 0 +"," 0 +ATT 0 +was 0 +prescribed 0 +empirically 0 +without 0 +definitive 0 +evidence 0 +of 0 +tuberculosis 3 +. 0 +ATT 0 +- 0 +ALF 3 +patients 0 +were 0 +younger 0 +( 0 +32 0 +. 0 +87 0 +[ 0 ++ 0 +/ 0 +- 0 +15 0 +. 0 +8 0 +] 0 +years 0 +) 0 +"," 0 +and 0 +49 0 +( 0 +70 0 +% 0 +) 0 +of 0 +them 0 +were 0 +women 0 +. 0 +Most 0 +had 0 +hyperacute 0 +presentation 0 +; 0 +the 0 +median 0 +icterus 3 +encephalopathy 3 +interval 0 +was 0 +4 0 +. 0 +5 0 +( 0 +0 0 +- 0 +30 0 +) 0 +days 0 +. 0 +The 0 +median 0 +duration 0 +of 0 +ATT 0 +before 0 +ALF 3 +was 0 +30 0 +( 0 +7 0 +- 0 +350 0 +) 0 +days 0 +. 0 +At 0 +presentation 0 +"," 0 +advanced 0 +encephalopathy 3 +and 0 +cerebral 3 +edema 4 +were 0 +present 0 +in 0 +51 0 +( 0 +76 0 +% 0 +) 0 +and 0 +29 0 +( 0 +41 0 +. 0 +4 0 +% 0 +) 0 +patients 0 +"," 0 +respectively 0 +. 0 +Gastrointestinal 3 +bleed 4 +"," 0 +seizures 3 +"," 0 +infection 3 +"," 0 +and 0 +acute 3 +renal 4 +failure 4 +were 0 +documented 0 +in 0 +seven 0 +( 0 +10 0 +% 0 +) 0 +"," 0 +five 0 +( 0 +7 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +26 0 +( 0 +37 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +and 0 +seven 0 +( 0 +10 0 +% 0 +) 0 +patients 0 +"," 0 +respectively 0 +. 0 +Compared 0 +with 0 +hepatitis 3 +E 4 +virus 0 +( 0 +HEV 0 +) 0 +and 0 +non 0 +- 0 +A 0 +non 0 +- 0 +E 0 +- 0 +induced 0 +ALF 3 +"," 0 +ATT 0 +- 0 +ALF 3 +patients 0 +had 0 +nearly 0 +similar 0 +presentations 0 +except 0 +for 0 +older 0 +age 0 +and 0 +less 0 +elevation 0 +of 0 +liver 0 +enzymes 0 +. 0 +The 0 +mortality 0 +rate 0 +among 0 +patients 0 +with 0 +ATT 0 +- 0 +ALF 3 +was 0 +high 0 +( 0 +67 0 +. 0 +1 0 +% 0 +"," 0 +n 0 += 0 +47 0 +) 0 +"," 0 +and 0 +only 0 +23 0 +( 0 +32 0 +. 0 +9 0 +% 0 +) 0 +patients 0 +recovered 0 +with 0 +medical 0 +treatment 0 +. 0 +In 0 +multivariate 0 +analysis 0 +"," 0 +three 0 +factors 0 +independently 0 +predicted 0 +mortality 0 +: 0 +serum 0 +bilirubin 1 +( 0 +> 0 +or 0 += 0 +10 0 +. 0 +8 0 +mg 0 +/ 0 +dL 0 +) 0 +"," 0 +prothrombin 0 +time 0 +( 0 +PT 0 +) 0 +prolongation 0 +( 0 +> 0 +or 0 += 0 +26 0 +seconds 0 +) 0 +"," 0 +and 0 +grade 0 +III 0 +/ 0 +IV 0 +encephalopathy 3 +at 0 +presentation 0 +. 0 +C0NCLUSI0N 0 +: 0 +ATT 0 +- 0 +ALF 3 +constituted 0 +5 0 +. 0 +7 0 +% 0 +of 0 +ALF 3 +at 0 +our 0 +center 0 +and 0 +had 0 +a 0 +high 0 +mortality 0 +rate 0 +. 0 +Because 0 +the 0 +mortality 0 +rate 0 +is 0 +so 0 +high 0 +"," 0 +determining 0 +which 0 +factors 0 +are 0 +predictors 0 +is 0 +less 0 +important 0 +. 0 +A 0 +high 0 +proportion 0 +of 0 +patients 0 +had 0 +consumed 0 +ATT 0 +empirically 0 +"," 0 +which 0 +could 0 +have 0 +been 0 +prevented 0 +. 0 +Design 0 +and 0 +analysis 0 +of 0 +the 0 +HYPREN 0 +- 0 +trial 0 +: 0 +safety 0 +of 0 +enalapril 1 +and 0 +prazosin 1 +in 0 +the 0 +initial 0 +treatment 0 +phase 0 +of 0 +patients 0 +with 0 +congestive 3 +heart 4 +failure 4 +. 0 +Since 0 +the 0 +introduction 0 +of 0 +angiotensin 1 +converting 2 +enzyme 2 +( 2 +ACE 2 +) 2 +inhibitors 2 +into 0 +the 0 +adjunctive 0 +treatment 0 +of 0 +patients 0 +with 0 +congestive 3 +heart 4 +failure 4 +"," 0 +cases 0 +of 0 +severe 0 +hypotension 3 +"," 0 +especially 0 +on 0 +the 0 +first 0 +day 0 +of 0 +treatment 0 +"," 0 +have 0 +occasionally 0 +been 0 +reported 0 +. 0 +To 0 +assess 0 +the 0 +safety 0 +of 0 +the 0 +ACE 1 +inhibitor 2 +enalapril 1 +a 0 +multicenter 0 +"," 0 +randomized 0 +"," 0 +prazosin 1 +- 0 +controlled 0 +trial 0 +was 0 +designed 0 +that 0 +compared 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +symptomatic 0 +hypotension 3 +on 0 +the 0 +first 0 +day 0 +of 0 +treatment 0 +. 0 +Trial 0 +medication 0 +was 0 +2 0 +. 0 +5 0 +mg 0 +enalapril 1 +or 0 +0 0 +. 0 +5 0 +prazosin 1 +. 0 +Subjects 0 +were 0 +1210 0 +inpatients 0 +with 0 +New 0 +York 0 +Heart 0 +Association 0 +( 0 +NYHA 0 +) 0 +functional 0 +class 0 +II 0 +and 0 +III 0 +. 0 +Patients 0 +who 0 +received 0 +enalapril 1 +experienced 0 +clinically 0 +and 0 +statistically 0 +significantly 0 +less 0 +symptomatic 0 +hypotension 3 +( 0 +5 0 +. 0 +2 0 +% 0 +) 0 +than 0 +the 0 +patients 0 +who 0 +received 0 +prazosin 1 +( 0 +12 0 +. 0 +9 0 +% 0 +) 0 +. 0 +All 0 +patients 0 +recovered 0 +. 0 +It 0 +was 0 +concluded 0 +that 0 +treatment 0 +with 0 +enalapril 1 +was 0 +well 0 +tolerated 0 +and 0 +it 0 +is 0 +"," 0 +therefore 0 +"," 0 +unreasonable 0 +to 0 +restrict 0 +the 0 +initiation 0 +of 0 +treatment 0 +with 0 +enalapril 1 +to 0 +inpatients 0 +. 0 +Central 3 +nervous 4 +system 4 +complications 4 +during 0 +treatment 0 +of 0 +acute 3 +lymphoblastic 4 +leukemia 4 +in 0 +a 0 +single 0 +pediatric 0 +institution 0 +. 0 +Central 3 +nervous 4 +system 4 +( 4 +CNS 4 +) 4 +complications 4 +during 0 +treatment 0 +of 0 +childhood 0 +acute 3 +lymphoblastic 4 +leukemia 4 +( 0 +ALL 3 +) 0 +remain 0 +a 0 +challenging 0 +clinical 0 +problem 0 +. 0 +0utcome 0 +improvement 0 +with 0 +more 0 +intensive 0 +chemotherapy 0 +has 0 +significantly 0 +increased 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +adverse 0 +events 0 +. 0 +This 0 +study 0 +analyzed 0 +the 0 +incidence 0 +of 0 +neurological 3 +complications 4 +during 0 +ALL 3 +treatment 0 +in 0 +a 0 +single 0 +pediatric 0 +institution 0 +"," 0 +focusing 0 +on 0 +clinical 0 +"," 0 +radiological 0 +"," 0 +and 0 +electrophysiological 0 +findings 0 +. 0 +Exclusion 0 +criteria 0 +included 0 +CNS 0 +leukemic 3 +infiltration 4 +at 0 +diagnosis 0 +"," 0 +therapy 0 +- 0 +related 0 +peripheral 3 +neuropathy 4 +"," 0 +late 0 +- 0 +onset 0 +encephalopathy 3 +"," 0 +or 0 +long 0 +- 0 +term 0 +neurocognitive 3 +defects 4 +. 0 +During 0 +a 0 +9 0 +- 0 +year 0 +period 0 +"," 0 +we 0 +retrospectively 0 +collected 0 +27 0 +neurological 0 +events 0 +( 0 +11 0 +% 0 +) 0 +in 0 +as 0 +many 0 +patients 0 +"," 0 +from 0 +253 0 +children 0 +enrolled 0 +in 0 +the 0 +ALL 3 +front 0 +- 0 +line 0 +protocol 0 +. 0 +CNS 0 +complications 0 +included 0 +posterior 0 +reversible 0 +leukoencephalopathy 3 +syndrome 0 +( 0 +n 0 += 0 +10 0 +) 0 +"," 0 +stroke 3 +( 0 +n 0 += 0 +5 0 +) 0 +"," 0 +temporal 3 +lobe 4 +epilepsy 4 +( 0 +n 0 += 0 +2 0 +) 0 +"," 0 +high 0 +- 0 +dose 0 +methotrexate 1 +toxicity 3 +( 0 +n 0 += 0 +2 0 +) 0 +"," 0 +syndrome 0 +of 0 +inappropriate 3 +antidiuretic 4 +hormone 4 +secretion 4 +( 0 +n 0 += 0 +1 0 +) 0 +"," 0 +and 0 +other 0 +unclassified 0 +events 0 +( 0 +n 0 += 0 +7 0 +) 0 +. 0 +In 0 +conclusion 0 +"," 0 +CNS 0 +complications 0 +are 0 +frequent 0 +events 0 +during 0 +ALL 3 +therapy 0 +"," 0 +and 0 +require 0 +rapid 0 +detection 0 +and 0 +prompt 0 +treatment 0 +to 0 +limit 0 +permanent 0 +damage 0 +. 0 +Cocaine 1 +causes 0 +memory 3 +and 4 +learning 4 +impairments 4 +in 0 +rats 0 +: 0 +involvement 0 +of 0 +nuclear 0 +factor 0 +kappa 0 +B 0 +and 0 +oxidative 0 +stress 0 +"," 0 +and 0 +prevention 0 +by 0 +topiramate 1 +. 0 +Different 0 +mechanisms 0 +have 0 +been 0 +suggested 0 +for 0 +cocaine 1 +toxicity 3 +including 0 +an 0 +increase 0 +in 0 +oxidative 0 +stress 0 +but 0 +the 0 +association 0 +between 0 +oxidative 0 +status 0 +in 0 +the 0 +brain 0 +and 0 +cocaine 1 +induced 0 +- 0 +behaviour 0 +is 0 +poorly 0 +understood 0 +. 0 +Nuclear 0 +factor 0 +kappa 0 +B 0 +( 0 +NFkappaB 0 +) 0 +is 0 +a 0 +sensor 0 +of 0 +oxidative 0 +stress 0 +and 0 +participates 0 +in 0 +memory 0 +formation 0 +that 0 +could 0 +be 0 +involved 0 +in 0 +drug 0 +toxicity 3 +and 0 +addiction 0 +mechanisms 0 +. 0 +Therefore 0 +NFkappaB 0 +activity 0 +"," 0 +oxidative 0 +stress 0 +"," 0 +neuronal 0 +nitric 1 +oxide 2 +synthase 0 +( 0 +nN0S 0 +) 0 +activity 0 +"," 0 +spatial 0 +learning 0 +and 0 +memory 0 +as 0 +well 0 +as 0 +the 0 +effect 0 +of 0 +topiramate 1 +"," 0 +a 0 +previously 0 +proposed 0 +therapy 0 +for 0 +cocaine 3 +addiction 4 +"," 0 +were 0 +evaluated 0 +in 0 +an 0 +experimental 0 +model 0 +of 0 +cocaine 1 +administration 0 +in 0 +rats 0 +. 0 +NFkappaB 0 +activity 0 +was 0 +decreased 0 +in 0 +the 0 +frontal 0 +cortex 0 +of 0 +cocaine 1 +treated 0 +rats 0 +"," 0 +as 0 +well 0 +as 0 +GSH 1 +concentration 0 +and 0 +glutathione 1 +peroxidase 0 +activity 0 +in 0 +the 0 +hippocampus 0 +"," 0 +whereas 0 +nN0S 0 +activity 0 +in 0 +the 0 +hippocampus 0 +was 0 +increased 0 +. 0 +Memory 0 +retrieval 0 +of 0 +experiences 0 +acquired 0 +prior 0 +to 0 +cocaine 1 +administration 0 +was 0 +impaired 0 +and 0 +negatively 0 +correlated 0 +with 0 +NFkappaB 0 +activity 0 +in 0 +the 0 +frontal 0 +cortex 0 +. 0 +In 0 +contrast 0 +"," 0 +learning 0 +of 0 +new 0 +tasks 0 +was 0 +enhanced 0 +and 0 +correlated 0 +with 0 +the 0 +increase 0 +of 0 +nN0S 0 +activity 0 +and 0 +the 0 +decrease 0 +of 0 +glutathione 1 +peroxidase 0 +. 0 +These 0 +results 0 +provide 0 +evidence 0 +for 0 +a 0 +possible 0 +mechanistic 0 +role 0 +of 0 +oxidative 0 +and 0 +nitrosative 0 +stress 0 +and 0 +NFkappaB 0 +in 0 +the 0 +alterations 0 +induced 0 +by 0 +cocaine 1 +. 0 +Topiramate 1 +prevented 0 +all 0 +the 0 +alterations 0 +observed 0 +"," 0 +showing 0 +novel 0 +neuroprotective 0 +properties 0 +. 0 +Efficacy 0 +and 0 +safety 0 +of 0 +asenapine 1 +in 0 +a 0 +placebo 0 +- 0 +and 0 +haloperidol 1 +- 0 +controlled 0 +trial 0 +in 0 +patients 0 +with 0 +acute 0 +exacerbation 0 +of 0 +schizophrenia 3 +. 0 +Asenapine 1 +is 0 +approved 0 +by 0 +the 0 +Food 0 +and 0 +Drugs 0 +Administration 0 +in 0 +adults 0 +for 0 +acute 0 +treatment 0 +of 0 +schizophrenia 3 +or 0 +of 0 +manic 3 +or 0 +mixed 0 +episodes 0 +associated 0 +with 0 +bipolar 3 +I 4 +disorder 4 +with 0 +or 0 +without 0 +psychotic 3 +features 0 +. 0 +In 0 +a 0 +double 0 +- 0 +blind 0 +6 0 +- 0 +week 0 +trial 0 +"," 0 +458 0 +patients 0 +with 0 +acute 0 +schizophrenia 3 +were 0 +randomly 0 +assigned 0 +to 0 +fixed 0 +- 0 +dose 0 +treatment 0 +with 0 +asenapine 1 +at 0 +5 0 +mg 0 +twice 0 +daily 0 +( 0 +BID 0 +) 0 +"," 0 +asenapine 1 +at 0 +10 0 +mg 0 +BID 0 +"," 0 +placebo 0 +"," 0 +or 0 +haloperidol 1 +at 0 +4 0 +mg 0 +BID 0 +( 0 +to 0 +verify 0 +assay 0 +sensitivity 0 +) 0 +. 0 +With 0 +last 0 +observations 0 +carried 0 +forward 0 +( 0 +L0CF 0 +) 0 +"," 0 +mean 0 +Positive 0 +and 0 +Negative 0 +Syndrome 0 +Scale 0 +total 0 +score 0 +reductions 0 +from 0 +baseline 0 +to 0 +endpoint 0 +were 0 +significantly 0 +greater 0 +with 0 +asenapine 1 +at 0 +5 0 +mg 0 +BID 0 +( 0 +- 0 +16 0 +. 0 +2 0 +) 0 +and 0 +haloperidol 1 +( 0 +- 0 +15 0 +. 0 +4 0 +) 0 +than 0 +placebo 0 +( 0 +- 0 +10 0 +. 0 +7 0 +; 0 +both 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +; 0 +using 0 +mixed 0 +model 0 +for 0 +repeated 0 +measures 0 +( 0 +MMRM 0 +) 0 +"," 0 +changes 0 +at 0 +day 0 +42 0 +were 0 +significantly 0 +greater 0 +with 0 +asenapine 1 +at 0 +5 0 +and 0 +10 0 +mg 0 +BID 0 +( 0 +- 0 +21 0 +. 0 +3 0 +and 0 +- 0 +19 0 +. 0 +4 0 +"," 0 +respectively 0 +) 0 +and 0 +haloperidol 1 +( 0 +- 0 +20 0 +. 0 +0 0 +) 0 +than 0 +placebo 0 +( 0 +- 0 +14 0 +. 0 +6 0 +; 0 +all 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +0n 0 +the 0 +Positive 0 +and 0 +Negative 0 +Syndrome 0 +Scale 0 +positive 0 +subscale 0 +"," 0 +all 0 +treatments 0 +were 0 +superior 0 +to 0 +placebo 0 +with 0 +L0CF 0 +and 0 +MMRM 0 +; 0 +asenapine 1 +at 0 +5 0 +mg 0 +BID 0 +was 0 +superior 0 +to 0 +placebo 0 +on 0 +the 0 +negative 0 +subscale 0 +with 0 +MMRM 0 +and 0 +on 0 +the 0 +general 0 +psychopathology 0 +subscale 0 +with 0 +L0CF 0 +and 0 +MMRM 0 +. 0 +Treatment 0 +- 0 +related 0 +adverse 0 +events 0 +( 0 +AEs 0 +) 0 +occurred 0 +in 0 +44 0 +% 0 +and 0 +52 0 +% 0 +"," 0 +57 0 +% 0 +"," 0 +and 0 +41 0 +% 0 +of 0 +the 0 +asenapine 1 +at 0 +5 0 +and 0 +10 0 +mg 0 +BID 0 +"," 0 +haloperidol 1 +"," 0 +and 0 +placebo 0 +groups 0 +"," 0 +respectively 0 +. 0 +Extrapyramidal 3 +symptoms 4 +reported 0 +as 0 +AEs 0 +occurred 0 +in 0 +15 0 +% 0 +and 0 +18 0 +% 0 +"," 0 +34 0 +% 0 +"," 0 +and 0 +10 0 +% 0 +of 0 +the 0 +asenapine 1 +at 0 +5 0 +and 0 +10 0 +mg 0 +BID 0 +"," 0 +haloperidol 1 +"," 0 +and 0 +placebo 0 +groups 0 +"," 0 +respectively 0 +. 0 +Across 0 +all 0 +groups 0 +"," 0 +no 0 +more 0 +than 0 +5 0 +% 0 +of 0 +patients 0 +had 0 +clinically 0 +significant 0 +weight 0 +change 0 +. 0 +Post 0 +hoc 0 +analyses 0 +indicated 0 +that 0 +efficacy 0 +was 0 +similar 0 +with 0 +asenapine 1 +and 0 +haloperidol 1 +; 0 +greater 0 +contrasts 0 +were 0 +seen 0 +in 0 +AEs 0 +"," 0 +especially 0 +extrapyramidal 3 +symptoms 4 +. 0 +Salvage 0 +therapy 0 +with 0 +nelarabine 1 +"," 0 +etoposide 1 +"," 0 +and 0 +cyclophosphamide 1 +in 0 +relapsed 0 +/ 0 +refractory 0 +paediatric 0 +T 3 +- 4 +cell 4 +lymphoblastic 4 +leukaemia 4 +and 4 +lymphoma 4 +. 0 +A 0 +combination 0 +of 0 +5 0 +d 0 +of 0 +nelarabine 1 +( 0 +AraG 1 +) 0 +with 0 +5 0 +d 0 +of 0 +etoposide 1 +( 0 +VP 1 +) 0 +and 0 +cyclophosphamide 1 +( 0 +CPM 1 +) 0 +and 0 +prophylactic 0 +intrathecal 0 +chemotherapy 0 +was 0 +used 0 +as 0 +salvage 0 +therapy 0 +in 0 +seven 0 +children 0 +with 0 +refractory 0 +or 0 +relapsed 0 +T 3 +- 4 +cell 4 +leukaemia 4 +or 4 +lymphoma 4 +. 0 +The 0 +most 0 +common 0 +side 0 +effects 0 +attributable 0 +to 0 +the 0 +AraG 1 +included 0 +Grade 0 +2 0 +and 0 +3 0 +sensory 0 +and 0 +motor 0 +neuropathy 3 +and 0 +musculoskeletal 3 +pain 4 +. 0 +Haematological 3 +toxicity 4 +was 0 +greater 0 +for 0 +the 0 +combination 0 +than 0 +AraG 1 +alone 0 +"," 0 +although 0 +median 0 +time 0 +to 0 +neutrophil 0 +and 0 +platelet 0 +recovery 0 +was 0 +consistent 0 +with 0 +other 0 +salvage 0 +therapies 0 +. 0 +All 0 +patients 0 +had 0 +some 0 +response 0 +to 0 +the 0 +combined 0 +therapy 0 +and 0 +five 0 +of 0 +the 0 +seven 0 +went 0 +into 0 +complete 0 +remission 0 +after 0 +one 0 +or 0 +two 0 +courses 0 +of 0 +AraG 1 +/ 0 +VP 1 +/ 0 +CPM 1 +. 0 +0ur 0 +experience 0 +supports 0 +the 0 +safety 0 +of 0 +giving 0 +AraG 1 +as 0 +salvage 0 +therapy 0 +in 0 +synchrony 0 +with 0 +etoposide 1 +and 0 +cyclophosphamide 1 +"," 0 +although 0 +neurological 3 +toxicity 4 +must 0 +be 0 +closely 0 +monitored 0 +. 0 +Effect 0 +of 0 +adriamycin 1 +combined 0 +with 0 +whole 0 +body 0 +hyperthermia 3 +on 0 +tumor 3 +and 0 +normal 0 +tissues 0 +. 0 +Thermal 0 +enhancement 0 +of 0 +Adriamycin 1 +- 0 +mediated 0 +antitumor 0 +activity 0 +and 0 +normal 0 +tissue 0 +toxicities 3 +by 0 +whole 0 +body 0 +hyperthermia 3 +were 0 +compared 0 +using 0 +a 0 +F344 0 +rat 0 +model 0 +. 0 +Antitumor 0 +activity 0 +was 0 +studied 0 +using 0 +a 0 +tumor 3 +growth 0 +delay 0 +assay 0 +. 0 +Acute 0 +normal 0 +tissue 0 +toxicities 3 +( 0 +i 0 +. 0 +e 0 +. 0 +"," 0 +leukopenia 3 +and 0 +thrombocytopenia 3 +) 0 +and 0 +late 0 +normal 0 +tissue 0 +toxicities 3 +( 0 +i 0 +. 0 +e 0 +. 0 +"," 0 +myocardial 3 +and 4 +kidney 4 +injury 4 +) 0 +were 0 +evaluated 0 +by 0 +functional 0 +/ 0 +physiological 0 +assays 0 +and 0 +by 0 +morphological 0 +techniques 0 +. 0 +Whole 0 +body 0 +hyperthermia 3 +( 0 +120 0 +min 0 +at 0 +41 0 +. 0 +5 0 +degrees 0 +C 0 +) 0 +enhanced 0 +both 0 +Adriamycin 1 +- 0 +mediated 0 +antitumor 0 +activity 0 +and 0 +toxic 0 +side 0 +effects 0 +. 0 +The 0 +thermal 0 +enhancement 0 +ratio 0 +calculated 0 +for 0 +antitumor 0 +activity 0 +was 0 +1 0 +. 0 +6 0 +. 0 +Thermal 0 +enhancement 0 +ratios 0 +estimated 0 +for 0 +" 0 +acute 0 +" 0 +hematological 0 +changes 0 +were 0 +1 0 +. 0 +3 0 +"," 0 +whereas 0 +those 0 +estimated 0 +for 0 +" 0 +late 0 +" 0 +damage 0 +( 0 +based 0 +on 0 +morphological 0 +cardiac 3 +and 4 +renal 4 +lesions 4 +) 0 +varied 0 +between 0 +2 0 +. 0 +4 0 +and 0 +4 0 +. 0 +3 0 +. 0 +Thus 0 +"," 0 +while 0 +whole 0 +body 0 +hyperthermia 3 +enhances 0 +Adriamycin 1 +- 0 +mediated 0 +antitumor 0 +effect 0 +"," 0 +normal 0 +tissue 0 +toxicity 3 +is 0 +also 0 +increased 0 +"," 0 +and 0 +the 0 +potential 0 +therapeutic 0 +gain 0 +of 0 +the 0 +combined 0 +modality 0 +treatment 0 +is 0 +eroded 0 +. 0 +Permeability 0 +"," 0 +ultrastructural 0 +changes 0 +"," 0 +and 0 +distribution 0 +of 0 +novel 0 +proteins 0 +in 0 +the 0 +glomerular 0 +barrier 0 +in 0 +early 0 +puromycin 1 +aminonucleoside 2 +nephrosis 3 +. 0 +BACKGR0UND 0 +/ 0 +AIMS 0 +: 0 +It 0 +is 0 +still 0 +unclear 0 +what 0 +happens 0 +in 0 +the 0 +glomerulus 0 +when 0 +proteinuria 3 +starts 0 +. 0 +Using 0 +puromycin 1 +aminonucleoside 2 +nephrosis 3 +( 0 +PAN 0 +) 0 +rats 0 +"," 0 +we 0 +studied 0 +early 0 +ultrastructural 0 +and 0 +permeability 0 +changes 0 +in 0 +relation 0 +to 0 +the 0 +expression 0 +of 0 +the 0 +podocyte 0 +- 0 +associated 0 +molecules 0 +nephrin 0 +"," 0 +a 0 +- 0 +actinin 0 +"," 0 +dendrin 0 +"," 0 +and 0 +plekhh2 0 +"," 0 +the 0 +last 0 +two 0 +of 0 +which 0 +were 0 +only 0 +recently 0 +discovered 0 +in 0 +podocytes 0 +. 0 +METH0DS 0 +: 0 +Using 0 +immune 0 +stainings 0 +"," 0 +semiquantitative 0 +measurement 0 +was 0 +performed 0 +under 0 +the 0 +electron 0 +microscope 0 +. 0 +Permeability 0 +was 0 +assessed 0 +using 0 +isolated 0 +kidney 0 +perfusion 0 +with 0 +tracers 0 +. 0 +Possible 0 +effects 0 +of 0 +ACE 0 +inhibition 0 +were 0 +tested 0 +. 0 +RESULTS 0 +: 0 +By 0 +day 0 +2 0 +"," 0 +some 0 +patchy 0 +foot 0 +process 0 +effacement 0 +"," 0 +but 0 +no 0 +proteinuria 3 +"," 0 +appeared 0 +. 0 +The 0 +amount 0 +of 0 +nephrin 0 +was 0 +reduced 0 +in 0 +both 0 +diseased 0 +and 0 +normal 0 +areas 0 +. 0 +The 0 +other 0 +proteins 0 +showed 0 +few 0 +changes 0 +"," 0 +which 0 +were 0 +limited 0 +to 0 +diseased 0 +areas 0 +. 0 +By 0 +day 0 +4 0 +"," 0 +foot 0 +process 0 +effacement 0 +was 0 +complete 0 +and 0 +proteinuria 3 +appeared 0 +in 0 +parallel 0 +with 0 +signs 0 +of 0 +size 0 +barrier 0 +damage 0 +. 0 +Nephrin 0 +decreased 0 +further 0 +"," 0 +while 0 +dendrin 0 +and 0 +plekhh2 0 +also 0 +decreased 0 +but 0 +a 0 +- 0 +actinin 0 +remained 0 +unchanged 0 +. 0 +ACE 0 +inhibition 0 +had 0 +no 0 +significant 0 +protective 0 +effect 0 +. 0 +C0NCLUSI0NS 0 +: 0 +PAN 0 +glomeruli 0 +already 0 +showed 0 +significant 0 +pathology 0 +by 0 +day 0 +4 0 +"," 0 +despite 0 +relatively 0 +mild 0 +proteinuria 3 +. 0 +This 0 +was 0 +preceded 0 +by 0 +altered 0 +nephrin 0 +expression 0 +"," 0 +supporting 0 +its 0 +pivotal 0 +role 0 +in 0 +podocyte 0 +morphology 0 +. 0 +The 0 +novel 0 +proteins 0 +dendrin 0 +and 0 +plekhh2 0 +were 0 +both 0 +reduced 0 +"," 0 +suggesting 0 +roles 0 +in 0 +PAN 0 +"," 0 +whereas 0 +a 0 +- 0 +actinin 0 +was 0 +unchanged 0 +. 0 +A 0 +novel 0 +"," 0 +multiple 0 +symptom 0 +model 0 +of 0 +obsessive 3 +- 4 +compulsive 4 +- 4 +like 4 +behaviors 4 +in 0 +animals 0 +. 0 +BACKGR0UND 0 +: 0 +Current 0 +animal 0 +models 0 +of 0 +obsessive 3 +- 4 +compulsive 4 +disorder 4 +( 0 +0CD 3 +) 0 +typically 0 +involve 0 +acute 0 +"," 0 +drug 0 +- 0 +induced 0 +symptom 0 +provocation 0 +or 0 +a 0 +genetic 0 +association 0 +with 0 +stereotypies 0 +or 0 +anxiety 3 +. 0 +None 0 +of 0 +these 0 +current 0 +models 0 +demonstrate 0 +multiple 0 +0CD 3 +- 0 +like 0 +behaviors 0 +. 0 +METH0DS 0 +: 0 +Neonatal 0 +rats 0 +were 0 +treated 0 +with 0 +the 0 +tricyclic 0 +antidepressant 1 +clomipramine 1 +or 0 +vehicle 0 +between 0 +days 0 +9 0 +and 0 +16 0 +twice 0 +daily 0 +and 0 +behaviorally 0 +tested 0 +in 0 +adulthood 0 +. 0 +RESULTS 0 +: 0 +Clomipramine 1 +exposure 0 +in 0 +immature 0 +rats 0 +produced 0 +significant 0 +behavioral 0 +and 0 +biochemical 0 +changes 0 +that 0 +include 0 +enhanced 0 +anxiety 3 +( 0 +elevated 0 +plus 0 +maze 0 +and 0 +marble 0 +burying 0 +) 0 +"," 0 +behavioral 3 +inflexibility 4 +( 0 +perseveration 0 +in 0 +the 0 +spontaneous 0 +alternation 0 +task 0 +and 0 +impaired 0 +reversal 0 +learning 0 +) 0 +"," 0 +working 0 +memory 3 +impairment 4 +( 0 +e 0 +. 0 +g 0 +. 0 +"," 0 +win 0 +- 0 +shift 0 +paradigm 0 +) 0 +"," 0 +hoarding 3 +"," 0 +and 0 +corticostriatal 3 +dysfunction 4 +. 0 +Dopamine 1 +D2 0 +receptors 0 +were 0 +elevated 0 +in 0 +the 0 +striatum 0 +"," 0 +whereas 0 +serotonin 1 +2C 0 +"," 0 +but 0 +not 0 +serotonin 1 +1A 0 +"," 0 +receptors 0 +were 0 +elevated 0 +in 0 +the 0 +orbital 0 +frontal 0 +cortex 0 +. 0 +C0NCLUSI0NS 0 +: 0 +This 0 +is 0 +the 0 +first 0 +demonstration 0 +of 0 +multiple 0 +symptoms 0 +consistent 0 +with 0 +an 0 +0CD 3 +- 0 +like 0 +profile 0 +in 0 +animals 0 +. 0 +Moreover 0 +"," 0 +these 0 +behaviors 0 +are 0 +accompanied 0 +by 0 +biochemical 0 +changes 0 +in 0 +brain 0 +regions 0 +previously 0 +identified 0 +as 0 +relevant 0 +to 0 +0CD 3 +. 0 +This 0 +novel 0 +model 0 +of 0 +0CD 3 +demonstrates 0 +that 0 +drug 0 +exposure 0 +during 0 +a 0 +sensitive 0 +period 0 +can 0 +program 0 +disease 0 +- 0 +like 0 +systems 0 +permanently 0 +"," 0 +which 0 +could 0 +have 0 +implications 0 +for 0 +current 0 +and 0 +future 0 +therapeutic 0 +strategies 0 +for 0 +this 0 +and 0 +other 0 +psychiatric 3 +disorders 4 +. 0 +Elevation 0 +of 0 +ADAM10 0 +"," 0 +ADAM17 0 +"," 0 +MMP 0 +- 0 +2 0 +and 0 +MMP 0 +- 0 +9 0 +expression 0 +with 0 +media 0 +degeneration 0 +features 0 +CaCl2 1 +- 0 +induced 0 +thoracic 3 +aortic 4 +aneurysm 4 +in 0 +a 0 +rat 0 +model 0 +. 0 +PURP0SE 0 +: 0 +This 0 +study 0 +was 0 +designed 0 +to 0 +establish 0 +a 0 +rat 0 +model 0 +of 0 +thoracic 3 +aortic 4 +aneurysm 4 +( 0 +TAA 3 +) 0 +by 0 +calcium 1 +chloride 2 +( 0 +CaCl 1 +( 2 +2 2 +) 2 +) 0 +- 0 +induced 0 +arterial 3 +injury 4 +and 0 +to 0 +explore 0 +the 0 +potential 0 +role 0 +of 0 +a 0 +disintegrin 0 +and 0 +metalloproteinase 0 +( 0 +ADAM 0 +) 0 +"," 0 +matrix 0 +metalloproteinases 0 +( 0 +MMPs 0 +) 0 +and 0 +their 0 +endogenous 0 +inhibitors 0 +( 0 +TIMPs 0 +) 0 +in 0 +TAA 3 +formation 0 +. 0 +METH0DS 0 +: 0 +Thoracic 0 +aorta 0 +of 0 +male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +was 0 +exposed 0 +to 0 +0 0 +. 0 +5M 0 +CaCl 1 +( 2 +2 2 +) 2 +or 0 +normal 0 +saline 0 +( 0 +NaCl 1 +) 0 +. 0 +After 0 +12weeks 0 +"," 0 +animals 0 +were 0 +euthanized 0 +"," 0 +and 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +"," 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +untreated 0 +( 0 +n 0 += 0 +12 0 +) 0 +and 0 +NaCl 1 +- 0 +treated 0 +aortic 0 +segments 0 +( 0 +n 0 += 0 +12 0 +) 0 +were 0 +collected 0 +for 0 +histological 0 +and 0 +molecular 0 +assessments 0 +. 0 +MMP 0 +- 0 +TIMP 0 +and 0 +ADAM 0 +mRNAs 0 +were 0 +semi 0 +- 0 +quantitatively 0 +analyzed 0 +and 0 +protein 0 +expressions 0 +were 0 +determined 0 +by 0 +immunohistochemistry 0 +. 0 +RESULTS 0 +: 0 +Despite 0 +similar 0 +external 0 +diameters 0 +among 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +"," 0 +non 0 +- 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +and 0 +NaCl 1 +- 0 +treated 0 +segments 0 +"," 0 +aneurymal 0 +alteration 0 +( 0 +n 0 += 0 +6 0 +"," 0 +50 0 +% 0 +) 0 +"," 0 +media 0 +degeneration 0 +with 0 +regional 0 +disruption 0 +"," 0 +fragmentation 0 +of 0 +elastic 0 +fiber 0 +"," 0 +and 0 +increased 0 +collagen 0 +deposition 0 +( 0 +n 0 += 0 +12 0 +"," 0 +100 0 +% 0 +) 0 +were 0 +demonstrated 0 +in 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +segments 0 +. 0 +MMP 0 +- 0 +2 0 +"," 0 +MMP 0 +- 0 +9 0 +"," 0 +ADAM 0 +- 0 +10 0 +and 0 +ADAM 0 +- 0 +17 0 +mRNA 0 +levels 0 +were 0 +increased 0 +in 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +segments 0 +( 0 +all 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +with 0 +trends 0 +of 0 +elevation 0 +in 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +untreated 0 +segments 0 +"," 0 +as 0 +compared 0 +with 0 +NaCl 1 +- 0 +treated 0 +segments 0 +. 0 +Immunohistochemistry 0 +displayed 0 +significantly 0 +increased 0 +expressions 0 +of 0 +MMP 0 +- 0 +2 0 +"," 0 +MMP 0 +- 0 +9 0 +"," 0 +ADAM 0 +- 0 +10 0 +and 0 +ADAM 0 +- 0 +17 0 +( 0 +all 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +in 0 +intima 0 +and 0 +media 0 +for 0 +CaCl 1 +( 2 +2 2 +) 2 +- 0 +treated 0 +segments 0 +. 0 +TIMP 0 +mRNA 0 +and 0 +tissue 0 +levels 0 +did 0 +not 0 +differ 0 +obviously 0 +among 0 +the 0 +three 0 +aortic 0 +segments 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +study 0 +establishes 0 +a 0 +TAA 3 +model 0 +by 0 +periarterial 0 +CaCl 1 +( 2 +2 2 +) 2 +exposure 0 +in 0 +rats 0 +"," 0 +and 0 +demonstrates 0 +a 0 +significant 0 +elevation 0 +of 0 +expression 0 +of 0 +MMP 0 +- 0 +2 0 +"," 0 +MMP 0 +- 0 +9 0 +"," 0 +ADAM10 0 +and 0 +ADAM17 0 +in 0 +the 0 +pathogenesis 0 +of 0 +vascular 0 +remodeling 0 +. 0 +Suxamethonium 1 +induced 0 +prolonged 0 +apnea 3 +in 0 +a 0 +patient 0 +receiving 0 +electroconvulsive 0 +therapy 0 +. 0 +Suxamethonium 1 +causes 0 +prolonged 0 +apnea 3 +in 0 +patients 0 +in 0 +whom 0 +pseudocholinesterase 0 +enzyme 0 +gets 0 +deactivated 0 +by 0 +organophosphorus 1 +( 2 +0P 2 +) 2 +poisons 2 +. 0 +Here 0 +"," 0 +we 0 +present 0 +a 0 +similar 0 +incident 0 +in 0 +a 0 +severely 0 +depressed 3 +patient 0 +who 0 +received 0 +electroconvulsive 0 +therapy 0 +( 0 +ECT 0 +) 0 +. 0 +Prolonged 0 +apnea 3 +in 0 +our 0 +case 0 +ensued 0 +because 0 +the 0 +information 0 +about 0 +suicidal 0 +attempt 0 +by 0 +0P 1 +compound 2 +was 0 +concealed 0 +from 0 +the 0 +treating 0 +team 0 +. 0 +Curcumin 1 +ameliorates 0 +cognitive 3 +dysfunction 4 +and 0 +oxidative 0 +damage 0 +in 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +administered 0 +rats 0 +. 0 +The 0 +antiepileptic 0 +drugs 0 +"," 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +are 0 +well 0 +known 0 +to 0 +cause 0 +cognitive 3 +impairment 4 +on 0 +chronic 0 +use 0 +. 0 +The 0 +increase 0 +in 0 +free 0 +radical 0 +generation 0 +has 0 +been 0 +implicated 0 +as 0 +one 0 +of 0 +the 0 +important 0 +mechanisms 0 +of 0 +cognitive 3 +impairment 4 +by 0 +antiepileptic 0 +drugs 0 +. 0 +Curcumin 1 +has 0 +shown 0 +antioxidant 0 +"," 0 +anti 0 +- 0 +inflammatory 0 +and 0 +neuro 0 +- 0 +protective 0 +properties 0 +. 0 +Therefore 0 +"," 0 +the 0 +present 0 +study 0 +was 0 +carried 0 +out 0 +to 0 +investigate 0 +the 0 +effect 0 +of 0 +chronic 0 +curcumin 1 +administration 0 +on 0 +phenobarbitone 1 +- 0 +and 0 +carbamazepine 1 +- 0 +induced 0 +cognitive 3 +impairment 4 +and 0 +oxidative 0 +stress 0 +in 0 +rats 0 +. 0 +Pharmacokinetic 0 +interactions 0 +of 0 +curcumin 1 +with 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +were 0 +also 0 +studied 0 +. 0 +Vehicle 0 +/ 0 +drugs 0 +were 0 +administered 0 +daily 0 +for 0 +21days 0 +to 0 +male 0 +Wistar 0 +rats 0 +. 0 +Passive 0 +avoidance 0 +paradigm 0 +and 0 +elevated 0 +plus 0 +maze 0 +test 0 +were 0 +used 0 +to 0 +assess 0 +cognitive 0 +function 0 +. 0 +At 0 +the 0 +end 0 +of 0 +study 0 +period 0 +"," 0 +serum 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +"," 0 +whole 0 +brain 0 +malondialdehyde 1 +and 0 +reduced 0 +glutathione 1 +levels 0 +were 0 +estimated 0 +. 0 +The 0 +administration 0 +of 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +for 0 +21days 0 +caused 0 +a 0 +significant 0 +impairment 3 +of 4 +learning 4 +and 4 +memory 4 +as 0 +well 0 +as 0 +an 0 +increased 0 +oxidative 0 +stress 0 +. 0 +Concomitant 0 +curcumin 1 +administration 0 +prevented 0 +the 0 +cognitive 3 +impairment 4 +and 0 +decreased 0 +the 0 +increased 0 +oxidative 0 +stress 0 +induced 0 +by 0 +these 0 +antiepileptic 0 +drugs 0 +. 0 +Curcumin 1 +co 0 +- 0 +administration 0 +did 0 +not 0 +cause 0 +any 0 +significant 0 +alteration 0 +in 0 +the 0 +serum 0 +concentrations 0 +of 0 +both 0 +phenobarbitone 1 +as 0 +well 0 +as 0 +carbamazepine 1 +. 0 +These 0 +results 0 +show 0 +that 0 +curcumin 1 +has 0 +beneficial 0 +effect 0 +in 0 +mitigating 0 +the 0 +deterioration 3 +of 4 +cognitive 4 +functions 4 +and 0 +oxidative 0 +damage 0 +in 0 +rats 0 +treated 0 +with 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +without 0 +significantly 0 +altering 0 +their 0 +serum 0 +concentrations 0 +. 0 +The 0 +findings 0 +suggest 0 +that 0 +curcumin 1 +can 0 +be 0 +considered 0 +as 0 +a 0 +potential 0 +safe 0 +and 0 +effective 0 +adjuvant 0 +to 0 +phenobarbitone 1 +and 0 +carbamazepine 1 +therapy 0 +in 0 +preventing 0 +cognitive 3 +impairment 4 +associated 0 +with 0 +these 0 +drugs 0 +. 0 +Can 0 +angiogenesis 0 +be 0 +a 0 +target 0 +of 0 +treatment 0 +for 0 +ribavirin 1 +associated 0 +hemolytic 3 +anemia 4 +? 0 +BACKGR0UND 0 +/ 0 +AIMS 0 +: 0 +Recently 0 +ribavirin 1 +has 0 +been 0 +found 0 +to 0 +inhibit 0 +angiogenesis 0 +and 0 +a 0 +number 0 +of 0 +angiogenesis 0 +inhibitors 0 +such 0 +as 0 +sunitinib 1 +and 0 +sorafenib 1 +have 0 +been 0 +found 0 +to 0 +cause 0 +acute 0 +hemolysis 3 +. 0 +We 0 +aimed 0 +to 0 +investigate 0 +whether 0 +there 0 +is 0 +a 0 +relation 0 +between 0 +hemoglobin 0 +"," 0 +haptoglobin 0 +and 0 +angiogenesis 0 +soluble 0 +markers 0 +which 0 +are 0 +modifiable 0 +and 0 +can 0 +help 0 +in 0 +developing 0 +strategies 0 +against 0 +anemia 3 +. 0 +METH0DS 0 +: 0 +Fourteen 0 +patients 0 +chronically 3 +infected 4 +with 4 +hepatitis 4 +C 4 +virus 4 +were 0 +treated 0 +by 0 +pegylated 1 +interferon 2 +alpha 2 +2a 2 +and 0 +ribavirin 1 +. 0 +Serum 0 +hemoglobin 0 +"," 0 +haptoglobin 0 +and 0 +angiogenesis 0 +markers 0 +of 0 +vascular 0 +endothelial 0 +growth 0 +factor 0 +and 0 +angiopoetin 0 +- 0 +2 0 +were 0 +investigated 0 +before 0 +and 0 +after 0 +therapy 0 +. 0 +RESULTS 0 +: 0 +We 0 +observed 0 +a 0 +significant 0 +decrease 0 +in 0 +haptoglobin 0 +levels 0 +at 0 +the 0 +end 0 +of 0 +the 0 +treatment 0 +period 0 +. 0 +Hemoglobin 0 +levels 0 +also 0 +decreased 0 +but 0 +insignificantly 0 +by 0 +treatment 0 +. 0 +In 0 +contrast 0 +with 0 +the 0 +literature 0 +"," 0 +serum 0 +levels 0 +of 0 +angiogenesis 0 +factors 0 +did 0 +not 0 +change 0 +significantly 0 +by 0 +pegylated 1 +interferon 2 +and 0 +ribavirin 1 +therapy 0 +. 0 +We 0 +found 0 +no 0 +correlation 0 +of 0 +angiogenesis 0 +soluble 0 +markers 0 +with 0 +either 0 +hemoglobin 0 +or 0 +haptoglobin 0 +. 0 +C0NCLUSI0N 0 +: 0 +This 0 +is 0 +the 0 +first 0 +study 0 +in 0 +the 0 +literature 0 +investigating 0 +a 0 +link 0 +between 0 +angiogenesis 0 +soluble 0 +markers 0 +and 0 +ribavirin 1 +induced 0 +anemia 3 +in 0 +patients 0 +with 0 +hepatitis 3 +C 4 +and 0 +we 0 +could 0 +not 0 +find 0 +any 0 +relation 0 +. 0 +Future 0 +research 0 +with 0 +larger 0 +number 0 +of 0 +patients 0 +is 0 +needed 0 +to 0 +find 0 +out 0 +modifiable 0 +factors 0 +that 0 +will 0 +improve 0 +the 0 +safety 0 +of 0 +ribavirin 1 +therapy 0 +. 0 +Reduction 0 +in 0 +injection 0 +pain 3 +using 0 +buffered 0 +lidocaine 1 +as 0 +a 0 +local 0 +anesthetic 0 +before 0 +cardiac 0 +catheterization 0 +. 0 +Previous 0 +reports 0 +have 0 +suggested 0 +that 0 +pain 3 +associated 0 +with 0 +the 0 +injection 0 +of 0 +lidocaine 1 +is 0 +related 0 +to 0 +the 0 +acidic 0 +pH 0 +of 0 +the 0 +solution 0 +. 0 +To 0 +determine 0 +if 0 +the 0 +addition 0 +of 0 +a 0 +buffering 0 +solution 0 +to 0 +adjust 0 +the 0 +pH 0 +of 0 +lidocaine 1 +into 0 +the 0 +physiologic 0 +range 0 +would 0 +reduce 0 +pain 3 +during 0 +injection 0 +"," 0 +we 0 +performed 0 +a 0 +blinded 0 +randomized 0 +study 0 +in 0 +patients 0 +undergoing 0 +cardiac 0 +catheterization 0 +. 0 +Twenty 0 +patients 0 +were 0 +asked 0 +to 0 +quantify 0 +the 0 +severity 0 +of 0 +pain 3 +after 0 +receiving 0 +standard 0 +lidocaine 1 +in 0 +one 0 +femoral 0 +area 0 +and 0 +buffered 0 +lidocaine 1 +in 0 +the 0 +opposite 0 +femoral 0 +area 0 +. 0 +The 0 +mean 0 +pain 3 +score 0 +for 0 +buffered 0 +lidocaine 1 +was 0 +significantly 0 +lower 0 +than 0 +the 0 +mean 0 +score 0 +for 0 +standard 0 +lidocaine 1 +( 0 +2 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +9 0 +vs 0 +. 0 +3 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +2 0 +"," 0 +P 0 += 0 +0 0 +. 0 +3 0 +) 0 +. 0 +The 0 +pH 0 +adjustment 0 +of 0 +standard 0 +lidocaine 1 +can 0 +be 0 +accomplished 0 +easily 0 +in 0 +the 0 +catheterization 0 +laboratory 0 +before 0 +injection 0 +and 0 +results 0 +in 0 +a 0 +reduction 0 +of 0 +the 0 +pain 3 +occurring 0 +during 0 +the 0 +infiltration 0 +of 0 +tissues 0 +. 0 +Effect 0 +of 0 +L 1 +- 2 +alpha 2 +- 2 +glyceryl 2 +- 2 +phosphorylcholine 2 +on 0 +amnesia 3 +caused 0 +by 0 +scopolamine 1 +. 0 +The 0 +present 0 +study 0 +was 0 +carried 0 +out 0 +to 0 +test 0 +the 0 +effects 0 +of 0 +L 1 +- 2 +alpha 2 +- 2 +glycerylphosphorylcholine 2 +( 0 +L 1 +- 2 +alpha 2 +- 2 +GFC 2 +) 0 +on 0 +memory 3 +impairment 4 +induced 0 +by 0 +scopolamine 1 +in 0 +man 0 +. 0 +Thirty 0 +- 0 +two 0 +healthy 0 +young 0 +volunteers 0 +were 0 +randomly 0 +allocated 0 +to 0 +four 0 +different 0 +groups 0 +. 0 +They 0 +were 0 +given 0 +a 0 +ten 0 +day 0 +pretreatment 0 +with 0 +either 0 +L 1 +- 2 +alpha 2 +- 2 +GFC 2 +or 0 +placebo 0 +"," 0 +p 0 +. 0 +o 0 +. 0 +"," 0 +and 0 +on 0 +the 0 +eleventh 0 +day 0 +either 0 +scopolamine 1 +or 0 +placebo 0 +"," 0 +i 0 +. 0 +m 0 +. 0 +Before 0 +and 0 +0 0 +. 0 +5 0 +"," 0 +1 0 +"," 0 +2 0 +"," 0 +3 0 +"," 0 +and 0 +6 0 +h 0 +after 0 +injection 0 +the 0 +subjects 0 +were 0 +given 0 +attention 0 +and 0 +mnemonic 0 +tests 0 +. 0 +The 0 +findings 0 +of 0 +this 0 +study 0 +indicate 0 +that 0 +the 0 +drug 0 +is 0 +able 0 +to 0 +antagonize 0 +impairment 3 +of 4 +attention 4 +and 4 +memory 4 +induced 0 +by 0 +scopolamine 1 +. 0 +Safety 0 +of 0 +capecitabine 1 +: 0 +a 0 +review 0 +. 0 +IMP0RTANCE 0 +0F 0 +THE 0 +FIELD 0 +: 0 +Fluoropyrimidines 1 +"," 0 +in 0 +particular 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +"," 0 +have 0 +been 0 +the 0 +mainstay 0 +of 0 +treatment 0 +for 0 +several 0 +solid 0 +tumors 3 +"," 0 +including 0 +colorectal 3 +"," 4 +breast 4 +and 4 +head 4 +and 4 +neck 4 +cancers 4 +"," 0 +for 0 +> 0 +40 0 +years 0 +. 0 +AREAS 0 +C0VERED 0 +IN 0 +THIS 0 +REVIEW 0 +: 0 +This 0 +article 0 +reviews 0 +the 0 +pharmacology 0 +and 0 +efficacy 0 +of 0 +capecitabine 1 +with 0 +a 0 +special 0 +emphasis 0 +on 0 +its 0 +safety 0 +. 0 +WHAT 0 +THE 0 +READER 0 +WILL 0 +GAIN 0 +: 0 +The 0 +reader 0 +will 0 +gain 0 +better 0 +insight 0 +into 0 +the 0 +safety 0 +of 0 +capecitabine 1 +in 0 +special 0 +populations 0 +such 0 +as 0 +patients 0 +with 0 +advanced 0 +age 0 +"," 0 +renal 3 +and 4 +kidney 4 +disease 4 +. 0 +We 0 +also 0 +explore 0 +different 0 +dosing 0 +and 0 +schedules 0 +of 0 +capecitabine 1 +administration 0 +. 0 +TAKE 0 +H0ME 0 +MESSAGE 0 +: 0 +Capecitabine 1 +is 0 +an 0 +oral 0 +prodrug 0 +of 0 +5 1 +- 2 +FU 2 +and 0 +was 0 +developed 0 +to 0 +fulfill 0 +the 0 +need 0 +for 0 +a 0 +more 0 +convenient 0 +therapy 0 +and 0 +provide 0 +an 0 +improved 0 +safety 0 +/ 0 +efficacy 0 +profile 0 +. 0 +It 0 +has 0 +shown 0 +promising 0 +results 0 +alone 0 +or 0 +in 0 +combination 0 +with 0 +other 0 +chemotherapeutic 0 +agents 0 +in 0 +colorectal 3 +"," 4 +breast 4 +"," 4 +pancreaticobiliary 4 +"," 4 +gastric 4 +"," 4 +renal 4 +cell 4 +and 4 +head 4 +and 4 +neck 4 +cancers 4 +. 0 +The 0 +most 0 +commonly 0 +reported 0 +toxic 0 +effects 0 +of 0 +capecitabine 1 +are 0 +diarrhea 3 +"," 0 +nausea 3 +"," 0 +vomiting 3 +"," 0 +stomatitis 3 +and 0 +hand 3 +- 4 +foot 4 +syndrome 4 +. 0 +Capecitabine 1 +has 0 +a 0 +well 0 +- 0 +established 0 +safety 0 +profile 0 +and 0 +can 0 +be 0 +given 0 +safely 0 +to 0 +patients 0 +with 0 +advanced 0 +age 0 +"," 0 +hepatic 3 +and 4 +renal 4 +dysfunctions 4 +. 0 +Levodopa 1 +- 0 +induced 0 +dyskinesias 3 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +: 0 +filling 0 +the 0 +bench 0 +- 0 +to 0 +- 0 +bedside 0 +gap 0 +. 0 +Levodopa 1 +is 0 +the 0 +most 0 +effective 0 +drug 0 +for 0 +the 0 +treatment 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 +However 0 +"," 0 +the 0 +long 0 +- 0 +term 0 +use 0 +of 0 +this 0 +dopamine 1 +precursor 0 +is 0 +complicated 0 +by 0 +highly 0 +disabling 0 +fluctuations 0 +and 0 +dyskinesias 3 +. 0 +Although 0 +preclinical 0 +and 0 +clinical 0 +findings 0 +suggest 0 +pulsatile 0 +stimulation 0 +of 0 +striatal 0 +postsynaptic 0 +receptors 0 +as 0 +a 0 +key 0 +mechanism 0 +underlying 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +"," 0 +their 0 +pathogenesis 0 +is 0 +still 0 +unclear 0 +. 0 +In 0 +recent 0 +years 0 +"," 0 +evidence 0 +from 0 +animal 0 +models 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +has 0 +provided 0 +important 0 +information 0 +to 0 +understand 0 +the 0 +effect 0 +of 0 +specific 0 +receptor 0 +and 0 +post 0 +- 0 +receptor 0 +molecular 0 +mechanisms 0 +underlying 0 +the 0 +development 0 +of 0 +dyskinetic 3 +movements 4 +. 0 +Recent 0 +preclinical 0 +and 0 +clinical 0 +data 0 +from 0 +promising 0 +lines 0 +of 0 +research 0 +focus 0 +on 0 +the 0 +differential 0 +role 0 +of 0 +presynaptic 0 +versus 0 +postsynaptic 0 +mechanisms 0 +"," 0 +dopamine 1 +receptor 0 +subtypes 0 +"," 0 +ionotropic 0 +and 0 +metabotropic 0 +glutamate 1 +receptors 0 +"," 0 +and 0 +non 0 +- 0 +dopaminergic 0 +neurotransmitter 0 +systems 0 +in 0 +the 0 +pathophysiology 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesias 3 +. 0 +Effects 0 +of 0 +pallidal 0 +neurotensin 1 +on 0 +haloperidol 1 +- 0 +induced 0 +parkinsonian 3 +catalepsy 4 +: 0 +behavioral 0 +and 0 +electrophysiological 0 +studies 0 +. 0 +0BJECTIVE 0 +: 0 +The 0 +globus 0 +pallidus 0 +plays 0 +a 0 +critical 0 +role 0 +in 0 +movement 0 +regulation 0 +. 0 +Previous 0 +studies 0 +have 0 +indicated 0 +that 0 +the 0 +globus 0 +pallidus 0 +receives 0 +neurotensinergic 0 +innervation 0 +from 0 +the 0 +striatum 0 +"," 0 +and 0 +systemic 0 +administration 0 +of 0 +a 0 +neurotensin 1 +analog 0 +could 0 +produce 0 +antiparkinsonian 0 +effects 0 +. 0 +The 0 +present 0 +study 0 +aimed 0 +to 0 +investigate 0 +the 0 +effects 0 +of 0 +pallidal 0 +neurotensin 1 +on 0 +haloperidol 1 +- 0 +induced 0 +parkinsonian 3 +symptoms 4 +. 0 +METH0DS 0 +: 0 +Behavioral 0 +experiments 0 +and 0 +electrophysiological 0 +recordings 0 +were 0 +performed 0 +in 0 +the 0 +present 0 +study 0 +. 0 +RESULTS 0 +: 0 +Bilateral 0 +infusions 0 +of 0 +neurotensin 1 +into 0 +the 0 +globus 0 +pallidus 0 +reversed 0 +haloperidol 1 +- 0 +induced 0 +parkinsonian 3 +catalepsy 4 +in 0 +rats 0 +. 0 +Electrophysiological 0 +recordings 0 +showed 0 +that 0 +microinjection 0 +of 0 +neurotensin 1 +induced 0 +excitation 0 +of 0 +pallidal 0 +neurons 0 +in 0 +the 0 +presence 0 +of 0 +systemic 0 +haloperidol 1 +administration 0 +. 0 +The 0 +neurotensin 1 +type 2 +- 2 +1 2 +receptor 2 +antagonist 2 +SR48692 1 +blocked 0 +both 0 +the 0 +behavioral 0 +and 0 +the 0 +electrophysiological 0 +effects 0 +induced 0 +by 0 +neurotensin 1 +. 0 +C0NCLUSI0N 0 +: 0 +Activation 0 +of 0 +pallidal 0 +neurotensin 1 +receptors 0 +may 0 +be 0 +involved 0 +in 0 +neurotensin 1 +- 0 +induced 0 +antiparkinsonian 0 +effects 0 +. 0 +Carmofur 1 +- 0 +induced 0 +organic 3 +mental 4 +disorders 4 +. 0 +0rganic 3 +mental 4 +disorder 4 +was 0 +observed 0 +in 0 +a 0 +29 0 +- 0 +year 0 +- 0 +old 0 +female 0 +in 0 +the 0 +prognostic 0 +period 0 +after 0 +the 0 +onset 0 +of 0 +carmofur 1 +- 0 +induced 0 +leukoencephalopathy 3 +. 0 +Symptoms 0 +such 0 +as 0 +euphoria 0 +"," 0 +emotional 0 +lability 0 +and 0 +puerile 0 +attitude 0 +noted 0 +in 0 +the 0 +patient 0 +were 0 +diagnosed 0 +as 0 +organic 3 +personality 4 +syndrome 4 +according 0 +to 0 +the 0 +criteria 0 +defined 0 +in 0 +the 0 +DSM 0 +- 0 +III 0 +- 0 +R 0 +. 0 +It 0 +is 0 +referred 0 +to 0 +as 0 +a 0 +frontal 3 +lobe 4 +syndrome 4 +. 0 +Brain 0 +CT 0 +revealed 0 +a 0 +periventricular 0 +low 0 +density 0 +area 0 +in 0 +the 0 +frontal 0 +white 0 +matter 0 +and 0 +moderate 0 +dilatation 0 +of 0 +the 0 +lateral 0 +ventricles 0 +especially 0 +at 0 +the 0 +bilateral 0 +anterior 0 +horns 0 +. 0 +Consequently 0 +"," 0 +carmofur 1 +- 0 +induced 0 +leukoencephalopathy 3 +may 0 +uncommonly 0 +result 0 +in 0 +organic 3 +personality 4 +syndrome 4 +in 0 +the 0 +residual 0 +state 0 +. 0 +It 0 +may 0 +be 0 +attributed 0 +to 0 +the 0 +structural 3 +damage 4 +to 4 +the 4 +frontal 4 +lobe 4 +. 0 +Butyrylcholinesterase 0 +gene 0 +mutations 0 +in 0 +patients 0 +with 0 +prolonged 0 +apnea 3 +after 0 +succinylcholine 1 +for 0 +electroconvulsive 0 +therapy 0 +. 0 +BACKGR0UND 0 +: 0 +patients 0 +undergoing 0 +electroconvulsive 0 +therapy 0 +( 0 +ECT 0 +) 0 +often 0 +receive 0 +succinylcholine 1 +as 0 +part 0 +of 0 +the 0 +anesthetic 0 +procedure 0 +. 0 +The 0 +duration 0 +of 0 +action 0 +may 0 +be 0 +prolonged 0 +in 0 +patients 0 +with 0 +genetic 0 +variants 0 +of 0 +the 0 +butyrylcholinesterase 0 +enzyme 0 +( 0 +BChE 0 +) 0 +"," 0 +the 0 +most 0 +common 0 +being 0 +the 0 +K 0 +- 0 +and 0 +the 0 +A 0 +- 0 +variants 0 +. 0 +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +assess 0 +the 0 +clinical 0 +significance 0 +of 0 +genetic 0 +variants 0 +in 0 +butyrylcholinesterase 0 +gene 0 +( 0 +BCHE 0 +) 0 +in 0 +patients 0 +with 0 +a 0 +suspected 0 +prolonged 0 +duration 0 +of 0 +action 0 +of 0 +succinylcholine 1 +after 0 +ECT 0 +. 0 +METH0DS 0 +: 0 +a 0 +total 0 +of 0 +13 0 +patients 0 +were 0 +referred 0 +to 0 +the 0 +Danish 0 +Cholinesterase 0 +Research 0 +Unit 0 +after 0 +ECT 0 +during 0 +38 0 +months 0 +. 0 +We 0 +determined 0 +the 0 +BChE 0 +activity 0 +and 0 +the 0 +BCHE 0 +genotype 0 +using 0 +molecular 0 +genetic 0 +methods 0 +"," 0 +the 0 +duration 0 +of 0 +apnea 3 +"," 0 +time 0 +to 0 +sufficient 0 +spontaneous 0 +ventilation 0 +and 0 +whether 0 +neuromuscular 0 +monitoring 0 +was 0 +used 0 +. 0 +The 0 +duration 0 +of 0 +apnea 3 +was 0 +compared 0 +with 0 +published 0 +data 0 +on 0 +normal 0 +subjects 0 +. 0 +RESULTS 0 +: 0 +in 0 +11 0 +patients 0 +"," 0 +mutations 0 +were 0 +found 0 +in 0 +the 0 +BCHE 0 +gene 0 +"," 0 +the 0 +K 0 +- 0 +variant 0 +being 0 +the 0 +most 0 +frequent 0 +. 0 +The 0 +duration 0 +of 0 +apnea 3 +was 0 +5 0 +- 0 +15 0 +min 0 +compared 0 +with 0 +3 0 +- 0 +5 0 +. 0 +3 0 +min 0 +from 0 +the 0 +literature 0 +. 0 +Severe 0 +distress 0 +was 0 +noted 0 +in 0 +the 0 +recovery 0 +phase 0 +in 0 +two 0 +patients 0 +. 0 +Neuromuscular 0 +monitoring 0 +was 0 +used 0 +in 0 +two 0 +patients 0 +. 0 +C0NCLUSI0N 0 +: 0 +eleven 0 +of 0 +13 0 +patients 0 +with 0 +a 0 +prolonged 0 +duration 0 +of 0 +action 0 +of 0 +succinylcholine 1 +had 0 +mutations 0 +in 0 +BCHE 0 +"," 0 +indicating 0 +that 0 +this 0 +is 0 +the 0 +possible 0 +reason 0 +for 0 +a 0 +prolonged 0 +period 0 +of 0 +apnea 3 +. 0 +We 0 +recommend 0 +objective 0 +neuromuscular 0 +monitoring 0 +during 0 +the 0 +first 0 +ECT 0 +. 0 +Perhexiline 1 +maleate 2 +and 0 +peripheral 3 +neuropathy 4 +. 0 +Peripheral 3 +neuropathy 4 +has 0 +been 0 +noted 0 +as 0 +a 0 +complication 0 +of 0 +therapy 0 +with 0 +perhexiline 1 +maleate 2 +"," 0 +a 0 +drug 0 +widely 0 +used 0 +in 0 +France 0 +( 0 +and 0 +in 0 +clinical 0 +trials 0 +in 0 +the 0 +United 0 +States 0 +) 0 +for 0 +the 0 +prophylactic 0 +treatment 0 +of 0 +angina 3 +pectoris 4 +. 0 +In 0 +24 0 +patients 0 +with 0 +this 0 +complication 0 +"," 0 +the 0 +marked 0 +slowing 0 +of 0 +motor 0 +nerve 0 +conduction 0 +velocity 0 +and 0 +the 0 +electromyographic 0 +changes 0 +imply 0 +mainly 0 +a 0 +demyelinating 3 +disorder 4 +. 0 +Improvement 0 +was 0 +noted 0 +with 0 +cessation 0 +of 0 +therapy 0 +. 0 +In 0 +a 0 +few 0 +cases 0 +the 0 +presence 0 +of 0 +active 0 +denervation 0 +signified 0 +a 0 +poor 0 +prognosis 0 +"," 0 +with 0 +only 0 +slight 0 +improvement 0 +. 0 +The 0 +underlying 0 +mechanism 0 +causing 0 +the 0 +neuropathy 3 +is 0 +not 0 +yet 0 +fully 0 +known 0 +"," 0 +although 0 +some 0 +evidence 0 +indicates 0 +that 0 +it 0 +may 0 +be 0 +a 0 +lipid 0 +storage 0 +process 0 +. 0 +A 0 +phase 0 +I 0 +study 0 +of 0 +4 1 +' 2 +- 2 +0 2 +- 2 +tetrahydropyranyladriamycin 2 +. 0 +Clinical 0 +pharmacology 0 +and 0 +pharmacokinetics 0 +. 0 +A 0 +Phase 0 +I 0 +study 0 +of 0 +intravenous 0 +( 0 +IV 0 +) 0 +bolus 0 +4 1 +' 2 +- 2 +0 2 +- 2 +tetrahydropyranyladriamycin 2 +( 0 +Pirarubicin 1 +) 0 +was 0 +done 0 +in 0 +55 0 +patients 0 +in 0 +good 0 +performance 0 +status 0 +with 0 +refractory 0 +tumors 3 +. 0 +Twenty 0 +- 0 +six 0 +had 0 +minimal 0 +prior 0 +therapy 0 +( 0 +good 0 +risk 0 +) 0 +"," 0 +23 0 +had 0 +extensive 0 +prior 0 +therapy 0 +( 0 +poor 0 +risk 0 +) 0 +"," 0 +and 0 +six 0 +had 0 +renal 3 +and 4 +/ 4 +or 4 +hepatic 4 +dysfunction 4 +. 0 +A 0 +total 0 +of 0 +167 0 +courses 0 +at 0 +doses 0 +of 0 +15 0 +to 0 +70 0 +mg 0 +/ 0 +m2 0 +were 0 +evaluable 0 +. 0 +Maximum 0 +tolerated 0 +dose 0 +in 0 +good 0 +- 0 +risk 0 +patients 0 +was 0 +70 0 +mg 0 +/ 0 +m2 0 +"," 0 +and 0 +in 0 +poor 0 +- 0 +risk 0 +patients 0 +"," 0 +60 0 +mg 0 +/ 0 +m2 0 +. 0 +The 0 +dose 0 +- 0 +limiting 0 +toxic 0 +effect 0 +was 0 +transient 0 +noncumulative 0 +granulocytopenia 3 +. 0 +Granulocyte 0 +nadir 0 +was 0 +on 0 +day 0 +14 0 +( 0 +range 0 +"," 0 +4 0 +- 0 +22 0 +) 0 +. 0 +Less 0 +frequent 0 +toxic 0 +effects 0 +included 0 +thrombocytopenia 3 +"," 0 +anemia 3 +"," 0 +nausea 3 +"," 0 +mild 0 +alopecia 3 +"," 0 +phlebitis 3 +"," 0 +and 0 +mucositis 3 +. 0 +Myelosuppression 3 +was 0 +more 0 +in 0 +patients 0 +with 0 +hepatic 3 +dysfunction 4 +. 0 +Pharmacokinetic 0 +analyses 0 +in 0 +21 0 +patients 0 +revealed 0 +Pirarubicin 1 +plasma 0 +T 0 +1 0 +/ 0 +2 0 +alpha 0 +( 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +of 0 +2 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +85 0 +minutes 0 +"," 0 +T 0 +beta 0 +1 0 +/ 0 +2 0 +of 0 +25 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +5 0 +minutes 0 +"," 0 +and 0 +T 0 +1 0 +/ 0 +2 0 +gamma 0 +of 0 +23 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +7 0 +. 0 +6 0 +hours 0 +. 0 +The 0 +area 0 +under 0 +the 0 +curve 0 +was 0 +537 0 ++ 0 +/ 0 +- 0 +149 0 +ng 0 +/ 0 +ml 0 +x 0 +hours 0 +"," 0 +volume 0 +of 0 +distribution 0 +( 0 +Vd 0 +) 0 +3504 0 ++ 0 +/ 0 +- 0 +644 0 +l 0 +/ 0 +m2 0 +"," 0 +and 0 +total 0 +clearance 0 +( 0 +ClT 0 +) 0 +was 0 +204 0 ++ 0 +39 0 +. 0 +3 0 +l 0 +/ 0 +hour 0 +/ 0 +m2 0 +. 0 +Adriamycinol 1 +"," 0 +doxorubicin 1 +"," 0 +adriamycinone 1 +"," 0 +and 0 +tetrahydropyranyladriamycinol 1 +were 0 +the 0 +metabolites 0 +detected 0 +in 0 +plasma 0 +and 0 +the 0 +amount 0 +of 0 +doxorubicin 1 +was 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +10 0 +% 0 +of 0 +the 0 +total 0 +metabolites 0 +. 0 +Urinary 0 +excretion 0 +of 0 +Pirarubicin 1 +in 0 +the 0 +first 0 +24 0 +hours 0 +was 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +10 0 +% 0 +. 0 +Activity 0 +was 0 +noted 0 +in 0 +mesothelioma 3 +"," 0 +leiomyosarcoma 3 +"," 0 +and 0 +basal 3 +cell 4 +carcinoma 4 +. 0 +The 0 +recommended 0 +starting 0 +dose 0 +for 0 +Phase 0 +II 0 +trials 0 +is 0 +60 0 +mg 0 +/ 0 +m2 0 +IV 0 +bolus 0 +every 0 +3 0 +weeks 0 +. 0 +0cular 3 +and 4 +auditory 4 +toxicity 4 +in 0 +hemodialyzed 0 +patients 0 +receiving 0 +desferrioxamine 1 +. 0 +During 0 +an 0 +18 0 +- 0 +month 0 +period 0 +of 0 +study 0 +41 0 +hemodialyzed 0 +patients 0 +receiving 0 +desferrioxamine 1 +( 0 +10 0 +- 0 +40 0 +mg 0 +/ 0 +kg 0 +BW 0 +/ 0 +3 0 +times 0 +weekly 0 +) 0 +for 0 +the 0 +first 0 +time 0 +were 0 +monitored 0 +for 0 +detection 0 +of 0 +audiovisual 3 +toxicity 4 +. 0 +6 0 +patients 0 +presented 0 +clinical 0 +symptoms 0 +of 0 +visual 3 +or 4 +auditory 4 +toxicity 4 +. 0 +Moreover 0 +"," 0 +detailed 0 +ophthalmologic 0 +and 0 +audiologic 0 +studies 0 +disclosed 0 +abnormalities 0 +in 0 +7 0 +more 0 +asymptomatic 0 +patients 0 +. 0 +Visual 3 +toxicity 4 +was 0 +of 0 +retinal 0 +origin 0 +and 0 +was 0 +characterized 0 +by 0 +a 0 +tritan 0 +- 0 +type 0 +dyschromatopsy 3 +"," 0 +sometimes 0 +associated 0 +with 0 +a 3 +loss 4 +of 4 +visual 4 +acuity 4 +and 0 +pigmentary 3 +retinal 4 +deposits 4 +. 0 +Auditory 3 +toxicity 4 +was 0 +characterized 0 +by 0 +a 0 +mid 0 +- 0 +to 0 +high 0 +- 0 +frequency 0 +neurosensorial 3 +hearing 4 +loss 4 +and 0 +the 0 +lesion 0 +was 0 +of 0 +the 0 +cochlear 0 +type 0 +. 0 +Desferrioxamine 1 +withdrawal 0 +resulted 0 +in 0 +a 0 +complete 0 +recovery 0 +of 0 +visual 0 +function 0 +in 0 +1 0 +patient 0 +and 0 +partial 0 +recovery 0 +in 0 +3 0 +"," 0 +and 0 +a 0 +complete 0 +reversal 0 +of 0 +hearing 3 +loss 4 +in 0 +3 0 +patients 0 +and 0 +partial 0 +recovery 0 +in 0 +3 0 +. 0 +This 0 +toxicity 3 +appeared 0 +in 0 +patients 0 +receiving 0 +the 0 +higher 0 +doses 0 +of 0 +desferrioxamine 1 +or 0 +coincided 0 +with 0 +the 0 +normalization 0 +of 0 +ferritin 0 +or 0 +aluminium 1 +serum 0 +levels 0 +. 0 +The 0 +data 0 +indicate 0 +that 0 +audiovisual 3 +toxicity 4 +is 0 +not 0 +an 0 +infrequent 0 +complication 0 +in 0 +hemodialyzed 0 +patients 0 +receiving 0 +desferrioxamine 1 +. 0 +Periodical 0 +audiovisual 0 +monitoring 0 +should 0 +be 0 +performed 0 +on 0 +hemodialyzed 0 +patients 0 +receiving 0 +the 0 +drug 0 +in 0 +order 0 +to 0 +detect 0 +adverse 0 +effects 0 +as 0 +early 0 +as 0 +possible 0 +. 0 +Serial 0 +epilepsy 3 +caused 0 +by 0 +levodopa 1 +/ 2 +carbidopa 2 +administration 0 +in 0 +two 0 +patients 0 +on 0 +hemodialysis 0 +. 0 +Two 0 +patients 0 +with 0 +similar 0 +clinical 0 +features 0 +are 0 +presented 0 +: 0 +both 0 +patients 0 +had 0 +chronic 3 +renal 4 +failure 4 +"," 0 +on 0 +hemodialysis 0 +for 0 +many 0 +years 0 +but 0 +recently 0 +begun 0 +on 0 +a 0 +high 0 +- 0 +flux 0 +dialyzer 0 +; 0 +both 0 +had 0 +been 0 +receiving 0 +a 0 +carbidopa 1 +/ 2 +levodopa 2 +preparation 0 +; 0 +and 0 +both 0 +had 0 +the 0 +onset 0 +of 0 +hallucinosis 3 +and 0 +recurrent 0 +seizures 3 +"," 0 +which 0 +were 0 +refractory 0 +to 0 +anticonvulsants 0 +. 0 +The 0 +first 0 +patient 0 +died 0 +without 0 +a 0 +diagnosis 0 +; 0 +the 0 +second 0 +patient 0 +had 0 +a 0 +dramatic 0 +recovery 0 +following 0 +the 0 +administration 0 +of 0 +vitamin 1 +B6 2 +. 0 +Neither 0 +patient 0 +was 0 +considered 0 +to 0 +have 0 +a 0 +renal 0 +state 0 +sufficiently 0 +severe 0 +enough 0 +to 0 +explain 0 +their 0 +presentation 0 +. 0 +Randomized 0 +"," 0 +double 0 +- 0 +blind 0 +trial 0 +of 0 +mazindol 1 +in 0 +Duchenne 3 +dystrophy 4 +. 0 +There 0 +is 0 +evidence 0 +that 0 +growth 0 +hormone 0 +may 0 +be 0 +related 0 +to 0 +the 0 +progression 0 +of 0 +weakness 3 +in 0 +Duchenne 3 +dystrophy 4 +. 0 +We 0 +conducted 0 +a 0 +12 0 +- 0 +month 0 +controlled 0 +trial 0 +of 0 +mazindol 1 +"," 0 +a 0 +putative 0 +growth 0 +hormone 0 +secretion 0 +inhibitor 0 +"," 0 +in 0 +83 0 +boys 0 +with 0 +Duchenne 3 +dystrophy 4 +. 0 +Muscle 0 +strength 0 +"," 0 +contractures 0 +"," 0 +functional 0 +ability 0 +and 0 +pulmonary 0 +function 0 +were 0 +tested 0 +at 0 +baseline 0 +"," 0 +and 0 +6 0 +and 0 +12 0 +months 0 +after 0 +treatment 0 +with 0 +mazindol 1 +( 0 +3 0 +mg 0 +/ 0 +d 0 +) 0 +or 0 +placebo 0 +. 0 +The 0 +study 0 +was 0 +designed 0 +to 0 +have 0 +a 0 +power 0 +of 0 +greater 0 +than 0 +0 0 +. 0 +90 0 +to 0 +detect 0 +a 0 +slowing 0 +to 0 +25 0 +% 0 +of 0 +the 0 +expected 0 +rate 0 +of 0 +progression 0 +of 0 +weakness 3 +at 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +. 0 +Mazindol 1 +did 0 +not 0 +benefit 0 +strength 0 +at 0 +any 0 +point 0 +in 0 +the 0 +study 0 +. 0 +Side 0 +effects 0 +attributable 0 +to 0 +mazindol 1 +included 0 +decreased 3 +appetite 4 +( 0 +36 0 +% 0 +) 0 +"," 0 +dry 3 +mouth 4 +( 0 +10 0 +% 0 +) 0 +"," 0 +behavioral 0 +change 0 +( 0 +22 0 +% 0 +) 0 +"," 0 +and 0 +gastrointestinal 3 +symptoms 4 +( 0 +18 0 +% 0 +) 0 +; 0 +mazindol 1 +dosage 0 +was 0 +reduced 0 +in 0 +43 0 +% 0 +of 0 +patients 0 +. 0 +The 0 +effect 0 +of 0 +mazindol 1 +on 0 +GH 0 +secretion 0 +was 0 +estimated 0 +indirectly 0 +by 0 +comparing 0 +the 0 +postabsorptive 0 +IGF 0 +- 0 +I 0 +levels 0 +obtained 0 +following 0 +3 0 +"," 0 +6 0 +"," 0 +9 0 +"," 0 +and 0 +12 0 +months 0 +in 0 +the 0 +mazindol 1 +treated 0 +to 0 +those 0 +in 0 +the 0 +placebo 0 +groups 0 +. 0 +Although 0 +mazindol 1 +- 0 +treated 0 +patients 0 +gained 0 +less 0 +weight 0 +and 0 +height 0 +than 0 +placebo 0 +- 0 +treated 0 +patients 0 +"," 0 +no 0 +significant 0 +effect 0 +on 0 +IGF 0 +- 0 +I 0 +levels 0 +was 0 +observed 0 +. 0 +Mazindol 1 +doses 0 +not 0 +slow 0 +the 0 +progression 0 +of 0 +weakness 3 +in 0 +Duchenne 3 +dystrophy 4 +. 0 +Facilitation 0 +of 0 +memory 0 +retrieval 0 +by 0 +pre 0 +- 0 +test 0 +morphine 1 +and 0 +its 0 +state 0 +dependency 0 +in 0 +the 0 +step 0 +- 0 +through 0 +type 0 +passive 0 +avoidance 0 +learning 0 +test 0 +in 0 +mice 0 +. 0 +Amnesia 3 +produced 0 +by 0 +scopolamine 1 +and 0 +cycloheximide 1 +were 0 +reversed 0 +by 0 +morphine 1 +given 0 +30 0 +min 0 +before 0 +the 0 +test 0 +trial 0 +( 0 +pre 0 +- 0 +test 0 +) 0 +"," 0 +and 0 +pre 0 +- 0 +test 0 +morphine 1 +also 0 +facilitated 0 +the 0 +memory 0 +retrieval 0 +in 0 +the 0 +animals 0 +administered 0 +naloxone 1 +during 0 +the 0 +training 0 +trial 0 +. 0 +Similarly 0 +"," 0 +pre 0 +- 0 +test 0 +scopolamine 1 +partially 0 +reversed 0 +the 0 +scopolamine 1 +- 0 +induced 0 +amnesia 3 +"," 0 +but 0 +not 0 +significantly 0 +; 0 +and 0 +pre 0 +- 0 +test 0 +cycloheximide 1 +failed 0 +to 0 +reverse 0 +the 0 +cycloheximide 1 +- 0 +induced 0 +amnesia 3 +. 0 +These 0 +results 0 +suggest 0 +that 0 +the 0 +facilitation 0 +of 0 +memory 0 +retrieval 0 +by 0 +pre 0 +- 0 +test 0 +morphine 1 +might 0 +be 0 +the 0 +direct 0 +action 0 +of 0 +morphine 1 +rather 0 +than 0 +a 0 +state 0 +dependent 0 +effect 0 +. 0 +Naloxone 1 +reverses 0 +the 0 +antihypertensive 0 +effect 0 +of 0 +clonidine 1 +. 0 +In 0 +unanesthetized 0 +"," 0 +spontaneously 0 +hypertensive 3 +rats 0 +the 0 +decrease 0 +in 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +produced 0 +by 0 +intravenous 0 +clonidine 1 +"," 0 +5 0 +to 0 +20 0 +micrograms 0 +/ 0 +kg 0 +"," 0 +was 0 +inhibited 0 +or 0 +reversed 0 +by 0 +nalozone 1 +"," 0 +0 0 +. 0 +2 0 +to 0 +2 0 +mg 0 +/ 0 +kg 0 +. 0 +The 0 +hypotensive 3 +effect 0 +of 0 +100 0 +mg 0 +/ 0 +kg 0 +alpha 1 +- 2 +methyldopa 2 +was 0 +also 0 +partially 0 +reversed 0 +by 0 +naloxone 1 +. 0 +Naloxone 1 +alone 0 +did 0 +not 0 +affect 0 +either 0 +blood 0 +pressure 0 +or 0 +heart 0 +rate 0 +. 0 +In 0 +brain 0 +membranes 0 +from 0 +spontaneously 0 +hypertensive 3 +rats 0 +clonidine 1 +"," 0 +10 0 +( 0 +- 0 +8 0 +) 0 +to 0 +10 0 +( 0 +- 0 +5 0 +) 0 +M 0 +"," 0 +did 0 +not 0 +influence 0 +stereoselective 0 +binding 0 +of 0 +[ 1 +3H 2 +] 2 +- 2 +naloxone 2 +( 0 +8 0 +nM 0 +) 0 +"," 0 +and 0 +naloxone 1 +"," 0 +10 0 +( 0 +- 0 +8 0 +) 0 +to 0 +10 0 +( 0 +- 0 +4 0 +) 0 +M 0 +"," 0 +did 0 +not 0 +influence 0 +clonidine 1 +- 0 +suppressible 0 +binding 0 +of 0 +[ 1 +3H 2 +] 2 +- 2 +dihydroergocryptine 2 +( 0 +1 0 +nM 0 +) 0 +. 0 +These 0 +findings 0 +indicate 0 +that 0 +in 0 +spontaneously 0 +hypertensive 3 +rats 0 +the 0 +effects 0 +of 0 +central 0 +alpha 0 +- 0 +adrenoceptor 0 +stimulation 0 +involve 0 +activation 0 +of 0 +opiate 0 +receptors 0 +. 0 +As 0 +naloxone 1 +and 0 +clonidine 1 +do 0 +not 0 +appear 0 +to 0 +interact 0 +with 0 +the 0 +same 0 +receptor 0 +site 0 +"," 0 +the 0 +observed 0 +functional 0 +antagonism 0 +suggests 0 +the 0 +release 0 +of 0 +an 0 +endogenous 0 +opiate 0 +by 0 +clonidine 1 +or 0 +alpha 1 +- 2 +methyldopa 2 +and 0 +the 0 +possible 0 +role 0 +of 0 +the 0 +opiate 0 +in 0 +the 0 +central 0 +control 0 +of 0 +sympathetic 0 +tone 0 +. 0 +Neurotoxicity 3 +of 0 +halogenated 1 +hydroxyquinolines 2 +: 0 +clinical 0 +analysis 0 +of 0 +cases 0 +reported 0 +outside 0 +Japan 0 +. 0 +An 0 +analysis 0 +is 0 +presented 0 +of 0 +220 0 +cases 0 +of 0 +possible 0 +neurotoxic 3 +reactions 0 +to 0 +halogenated 1 +hydroxyquinolines 2 +reported 0 +from 0 +outside 0 +Japan 0 +. 0 +In 0 +80 0 +cases 0 +insufficient 0 +information 0 +was 0 +available 0 +for 0 +adequate 0 +comment 0 +and 0 +in 0 +29 0 +a 0 +relationship 0 +to 0 +the 0 +administration 0 +of 0 +clioquinol 1 +could 0 +be 0 +excluded 0 +. 0 +0f 0 +the 0 +remainder 0 +"," 0 +a 0 +relationship 0 +to 0 +clioquinol 1 +was 0 +considered 0 +probable 0 +in 0 +42 0 +and 0 +possible 0 +in 0 +69 0 +cases 0 +. 0 +In 0 +six 0 +of 0 +the 0 +probable 0 +cases 0 +the 0 +neurological 3 +disturbance 4 +consisted 0 +of 0 +an 0 +acute 0 +reversible 0 +encephalopathy 3 +usually 0 +related 0 +to 0 +the 0 +ingestion 0 +of 0 +a 0 +high 0 +dose 0 +of 0 +clioquinol 1 +over 0 +a 0 +short 0 +period 0 +. 0 +The 0 +most 0 +common 0 +manifestation 0 +"," 0 +observed 0 +in 0 +15 0 +further 0 +cases 0 +"," 0 +was 0 +isolated 0 +optic 3 +atrophy 4 +. 0 +This 0 +was 0 +most 0 +frequently 0 +found 0 +in 0 +children 0 +"," 0 +many 0 +of 0 +whom 0 +had 0 +received 0 +clioquinol 1 +as 0 +treatment 0 +for 0 +acrodermatitis 3 +enteropathica 4 +. 0 +In 0 +the 0 +remaining 0 +cases 0 +"," 0 +a 0 +combination 0 +of 0 +myelopathy 3 +"," 0 +visual 3 +disturbance 4 +"," 0 +and 0 +peripheral 3 +neuropathy 4 +was 0 +the 0 +most 0 +common 0 +manifestation 0 +. 0 +Isolated 0 +myelopathy 3 +or 0 +peripheral 3 +neuropathy 4 +"," 0 +or 0 +these 0 +manifestations 0 +occurring 0 +together 0 +"," 0 +were 0 +infrequent 0 +. 0 +The 0 +onset 0 +of 0 +all 0 +manifestations 0 +( 0 +except 0 +toxic 0 +encephalopathy 3 +) 0 +was 0 +usually 0 +subacute 0 +"," 0 +with 0 +subsequent 0 +partial 0 +recovery 0 +. 0 +0lder 0 +subjects 0 +tended 0 +to 0 +display 0 +more 0 +side 0 +effects 0 +. 0 +The 0 +full 0 +syndrome 0 +of 0 +subacute 0 +myelo 3 +- 4 +optic 4 +neuropathy 4 +was 0 +more 0 +frequent 0 +in 0 +women 0 +"," 0 +but 0 +they 0 +tended 0 +to 0 +have 0 +taken 0 +greater 0 +quantities 0 +of 0 +the 0 +drug 0 +. 0 +Prazosin 1 +- 0 +induced 0 +stress 3 +incontinence 4 +. 0 +A 0 +case 0 +of 0 +genuine 0 +stress 3 +incontinence 4 +due 0 +to 0 +prazosin 1 +"," 0 +a 0 +common 0 +antihypertensive 0 +drug 0 +"," 0 +is 0 +presented 0 +. 0 +Prazosin 1 +exerts 0 +its 0 +antihypertensive 0 +effects 0 +through 0 +vasodilatation 0 +caused 0 +by 0 +selective 0 +blockade 0 +of 0 +postsynaptic 0 +alpha 0 +- 0 +1 0 +adrenergic 0 +receptors 0 +. 0 +As 0 +an 0 +alpha 0 +- 0 +blocker 0 +"," 0 +it 0 +also 0 +exerts 0 +a 0 +significant 0 +relaxant 0 +effect 0 +on 0 +the 0 +bladder 0 +neck 0 +and 0 +urethra 0 +. 0 +The 0 +patient 0 +' 0 +s 0 +clinical 0 +course 0 +is 0 +described 0 +and 0 +correlated 0 +with 0 +initial 0 +urodynamic 0 +studies 0 +while 0 +on 0 +prazosin 1 +and 0 +subsequent 0 +studies 0 +while 0 +taking 0 +verapamil 1 +. 0 +Her 0 +incontinence 3 +resolved 0 +with 0 +the 0 +change 0 +of 0 +medication 0 +. 0 +The 0 +restoration 0 +of 0 +continence 0 +was 0 +accompanied 0 +by 0 +a 0 +substantial 0 +rise 0 +in 0 +maximum 0 +urethral 0 +pressure 0 +"," 0 +maximum 0 +urethral 0 +closure 0 +pressure 0 +"," 0 +and 0 +functional 0 +urethral 0 +length 0 +. 0 +Patients 0 +who 0 +present 0 +with 0 +stress 3 +incontinence 4 +while 0 +taking 0 +prazosin 1 +should 0 +change 0 +their 0 +antihypertensive 0 +medication 0 +before 0 +considering 0 +surgery 0 +"," 0 +because 0 +their 0 +incontinence 3 +may 0 +resolve 0 +spontaneously 0 +with 0 +a 0 +change 0 +in 0 +drug 0 +therapy 0 +. 0 +Myocardial 3 +infarction 4 +following 0 +sublingual 0 +administration 0 +of 0 +isosorbide 1 +dinitrate 2 +. 0 +A 0 +78 0 +- 0 +year 0 +- 0 +old 0 +with 0 +healed 0 +septal 0 +necrosis 3 +suffered 0 +a 0 +recurrent 0 +myocardial 3 +infarction 4 +of 0 +the 0 +anterior 0 +wall 0 +following 0 +the 0 +administration 0 +of 0 +isosorbide 1 +dinitrate 2 +5 0 +mg 0 +sublingually 0 +. 0 +After 0 +detailing 0 +the 0 +course 0 +of 0 +events 0 +"," 0 +we 0 +discuss 0 +the 0 +role 0 +of 0 +paradoxical 0 +coronary 0 +spasm 3 +and 0 +hypotension 3 +- 0 +mediated 0 +myocardial 3 +ischemia 4 +occurring 0 +downstream 0 +to 0 +significant 0 +coronary 3 +arterial 4 +stenosis 4 +in 0 +the 0 +pathophysiology 0 +of 0 +acute 3 +coronary 4 +insufficiency 4 +. 0 +Comparison 0 +of 0 +the 0 +respiratory 0 +effects 0 +of 0 +i 0 +. 0 +v 0 +. 0 +infusions 0 +of 0 +morphine 1 +and 0 +regional 0 +analgesia 0 +by 0 +extradural 0 +block 0 +. 0 +The 0 +incidence 0 +of 0 +postoperative 0 +respiratory 0 +apnoea 3 +was 0 +compared 0 +between 0 +five 0 +patients 0 +receiving 0 +a 0 +continuous 0 +i 0 +. 0 +v 0 +. 0 +infusion 0 +of 0 +morphine 1 +( 0 +mean 0 +73 0 +. 0 +6 0 +mg 0 +) 0 +and 0 +five 0 +patients 0 +receiving 0 +a 0 +continuous 0 +extradural 0 +infusion 0 +of 0 +0 0 +. 0 +25 0 +% 0 +bupivacaine 1 +( 0 +mean 0 +192 0 +mg 0 +) 0 +in 0 +the 0 +24 0 +- 0 +h 0 +period 0 +following 0 +upper 0 +abdominal 0 +surgery 0 +. 0 +Monitoring 0 +consisted 0 +of 0 +airflow 0 +detection 0 +by 0 +a 0 +carbon 1 +dioxide 2 +analyser 0 +"," 0 +chest 0 +wall 0 +movement 0 +detected 0 +by 0 +pneumatic 0 +capsules 0 +"," 0 +and 0 +continuous 0 +electrocardiograph 0 +recorded 0 +with 0 +a 0 +Holter 0 +ambulatory 0 +monitor 0 +. 0 +Both 0 +obstructive 3 +( 4 +P 4 +less 4 +than 4 +0 4 +. 4 +5 4 +) 4 +and 4 +central 4 +apnoea 4 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +occurred 0 +more 0 +frequently 0 +in 0 +patients 0 +who 0 +had 0 +a 0 +morphine 1 +infusion 0 +. 0 +There 0 +was 0 +also 0 +a 0 +higher 0 +incidence 0 +of 0 +tachyarrhythmias 3 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +and 0 +ventricular 3 +ectopic 4 +beats 4 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +in 0 +the 0 +morphine 1 +infusion 0 +group 0 +. 0 +Effects 0 +of 0 +aminophylline 1 +on 0 +the 0 +threshold 0 +for 0 +initiating 0 +ventricular 3 +fibrillation 4 +during 0 +respiratory 3 +failure 4 +. 0 +Cardiac 3 +arrhythmias 4 +have 0 +frequently 0 +been 0 +reported 0 +in 0 +association 0 +with 0 +respiratory 3 +failure 4 +. 0 +The 0 +possible 0 +additive 0 +role 0 +of 0 +pharmacologic 0 +agents 0 +in 0 +precipitating 0 +cardiac 3 +disturbances 4 +in 0 +patients 0 +with 0 +respiratory 3 +failure 4 +has 0 +only 0 +recently 0 +been 0 +emphasized 0 +. 0 +The 0 +effects 0 +of 0 +aminophylline 1 +on 0 +the 0 +ventricular 3 +fibrillation 4 +threshold 0 +during 0 +normal 0 +acid 0 +- 0 +base 0 +conditions 0 +and 0 +during 0 +respiratory 3 +failure 4 +were 0 +studied 0 +in 0 +anesthetized 0 +open 0 +chest 0 +dogs 0 +. 0 +The 0 +ventricular 3 +fibrillation 4 +threshold 0 +was 0 +measured 0 +by 0 +passing 0 +a 0 +gated 0 +train 0 +of 0 +12 0 +constant 0 +current 0 +pulses 0 +through 0 +the 0 +ventricular 0 +myocardium 0 +during 0 +the 0 +vulnerable 0 +period 0 +of 0 +the 0 +cardiac 0 +cycle 0 +. 0 +During 0 +the 0 +infusion 0 +of 0 +aminophylline 1 +"," 0 +the 0 +ventricular 3 +fibrillation 4 +threshold 0 +was 0 +reduced 0 +by 0 +30 0 +to 0 +40 0 +percent 0 +of 0 +the 0 +control 0 +when 0 +pH 0 +and 0 +partial 0 +pressures 0 +of 0 +oxygen 1 +( 0 +P02 1 +) 0 +and 0 +carbon 1 +dioxide 2 +( 0 +C02 1 +) 0 +were 0 +kept 0 +within 0 +normal 0 +limits 0 +. 0 +When 0 +respiratory 3 +failure 4 +was 0 +produced 0 +by 0 +hypoventilation 3 +( 0 +pH 0 +7 0 +. 0 +5 0 +to 0 +7 0 +. 0 +25 0 +; 0 +PC02 0 +70 0 +to 0 +100 0 +mm 0 +Hg 0 +: 0 +P02 0 +20 0 +to 0 +40 0 +mm 0 +Hg 0 +) 0 +"," 0 +infusion 0 +of 0 +aminophylline 1 +resulted 0 +in 0 +an 0 +even 0 +greater 0 +decrease 0 +in 0 +ventricular 3 +fibrillation 4 +threshold 0 +to 0 +60 0 +percent 0 +of 0 +the 0 +control 0 +level 0 +. 0 +These 0 +experiments 0 +suggest 0 +that 0 +although 0 +many 0 +factors 0 +may 0 +contribute 0 +to 0 +the 0 +increased 0 +incidence 0 +of 0 +ventricular 3 +arrhythmias 4 +in 0 +respiratory 3 +failure 4 +"," 0 +pharmacologic 0 +agents 0 +"," 0 +particularly 0 +aminophylline 1 +"," 0 +may 0 +play 0 +a 0 +significant 0 +role 0 +. 0 +Pentoxifylline 1 +( 0 +Trental 1 +) 0 +does 0 +not 0 +inhibit 0 +dipyridamole 1 +- 0 +induced 0 +coronary 0 +hyperemia 3 +: 0 +implications 0 +for 0 +dipyridamole 1 +- 0 +thallium 1 +- 0 +201 0 +myocardial 0 +imaging 0 +. 0 +Dipyridamole 1 +- 0 +thallium 1 +- 0 +201 0 +imaging 0 +is 0 +often 0 +performed 0 +in 0 +patients 0 +unable 0 +to 0 +exercise 0 +because 0 +of 0 +peripheral 3 +vascular 4 +disease 4 +. 0 +Many 0 +of 0 +these 0 +patients 0 +are 0 +taking 0 +pentoxifylline 1 +( 0 +Trental 1 +) 0 +"," 0 +a 0 +methylxanthine 1 +derivative 0 +which 0 +may 0 +improve 0 +intermittent 3 +claudication 4 +. 0 +Whether 0 +pentoxifylline 1 +inhibits 0 +dipyridamole 1 +- 0 +induced 0 +coronary 0 +hyperemia 3 +like 0 +other 0 +methylxanthines 1 +such 0 +as 0 +theophylline 1 +and 0 +should 0 +be 0 +stopped 0 +prior 0 +to 0 +dipyridamole 1 +- 0 +thallium 1 +- 0 +201 0 +imaging 0 +is 0 +unknown 0 +. 0 +Therefore 0 +"," 0 +we 0 +studied 0 +the 0 +hyperemic 0 +response 0 +to 0 +dipyridamole 1 +in 0 +seven 0 +open 0 +- 0 +chest 0 +anesthetized 0 +dogs 0 +after 0 +pretreatment 0 +with 0 +either 0 +pentoxifylline 1 +( 0 +0 0 +"," 0 +7 0 +. 0 +5 0 +"," 0 +or 0 +15 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +or 0 +theophylline 1 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +. 0 +Baseline 0 +circumflex 0 +coronary 0 +blood 0 +flows 0 +did 0 +not 0 +differ 0 +significantly 0 +among 0 +treatment 0 +groups 0 +. 0 +Dipyridamole 1 +significantly 0 +increased 0 +coronary 0 +blood 0 +flow 0 +before 0 +and 0 +after 0 +7 0 +. 0 +5 0 +or 0 +15 0 +mm 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +pentoxifylline 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +2 0 +) 0 +. 0 +Neither 0 +dose 0 +of 0 +pentoxifylline 1 +significantly 0 +decreased 0 +the 0 +dipyridamole 1 +- 0 +induced 0 +hyperemia 3 +"," 0 +while 0 +peak 0 +coronary 0 +blood 0 +flow 0 +was 0 +significantly 0 +lower 0 +after 0 +theophylline 1 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +. 0 +We 0 +conclude 0 +that 0 +pentoxyifylline 1 +does 0 +not 0 +inhibit 0 +dipyridamole 1 +- 0 +induced 0 +coronary 0 +hyperemia 3 +even 0 +at 0 +high 0 +doses 0 +. 0 +Cause 0 +of 0 +death 3 +among 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +: 0 +a 0 +rare 0 +mortality 0 +due 0 +to 0 +cerebral 3 +haemorrhage 4 +. 0 +Causes 0 +of 0 +death 3 +"," 0 +with 0 +special 0 +reference 0 +to 0 +cerebral 3 +haemorrhage 4 +"," 0 +among 0 +240 0 +patients 0 +with 0 +pathologically 0 +verified 0 +Parkinson 3 +' 4 +s 4 +disease 4 +were 0 +investigated 0 +using 0 +the 0 +Annuals 0 +of 0 +the 0 +Pathological 0 +Autopsy 0 +Cases 0 +in 0 +Japan 0 +from 0 +1981 0 +to 0 +1985 0 +. 0 +The 0 +leading 0 +causes 0 +of 0 +death 3 +were 0 +pneumonia 3 +and 0 +bronchitis 3 +( 0 +44 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +malignant 0 +neoplasms 3 +( 0 +11 0 +. 0 +6 0 +% 0 +) 0 +"," 0 +heart 3 +diseases 4 +( 0 +4 0 +. 0 +1 0 +% 0 +) 0 +"," 0 +cerebral 3 +infarction 4 +( 0 +3 0 +. 0 +7 0 +% 0 +) 0 +and 0 +septicaemia 3 +( 0 +3 0 +. 0 +3 0 +% 0 +) 0 +. 0 +Cerebral 3 +haemorrhage 4 +was 0 +the 0 +11th 0 +most 0 +frequent 0 +cause 0 +of 0 +death 3 +"," 0 +accounting 0 +for 0 +only 0 +0 0 +. 0 +8 0 +% 0 +of 0 +deaths 3 +among 0 +the 0 +patients 0 +"," 0 +whereas 0 +it 0 +was 0 +the 0 +5th 0 +most 0 +common 0 +cause 0 +of 0 +death 3 +among 0 +the 0 +Japanese 0 +general 0 +population 0 +in 0 +1985 0 +. 0 +The 0 +low 0 +incidence 0 +of 0 +cerebral 3 +haemorrhage 4 +as 0 +a 0 +cause 0 +of 0 +death 3 +in 0 +patients 0 +with 0 +Parkinson 3 +' 4 +s 4 +disease 4 +may 0 +reflect 0 +the 0 +hypotensive 3 +effect 0 +of 0 +levodopa 1 +and 0 +a 0 +hypotensive 3 +mechanism 0 +due 0 +to 0 +reduced 0 +noradrenaline 1 +levels 0 +in 0 +the 0 +parkinsonian 3 +brain 0 +. 0 +Possible 0 +intramuscular 0 +midazolam 1 +- 0 +associated 0 +cardiorespiratory 3 +arrest 4 +and 0 +death 3 +. 0 +Midazolam 1 +hydrochloride 2 +is 0 +commonly 0 +used 0 +for 0 +dental 0 +or 0 +endoscopic 0 +procedures 0 +. 0 +Although 0 +generally 0 +consisted 0 +safe 0 +when 0 +given 0 +intramuscularly 0 +"," 0 +intravenous 0 +administration 0 +is 0 +known 0 +to 0 +cause 0 +respiratory 3 +and 4 +cardiovascular 4 +depression 4 +. 0 +This 0 +report 0 +describes 0 +the 0 +first 0 +published 0 +case 0 +of 0 +cardiorespiratory 3 +arrest 4 +and 0 +death 3 +associated 0 +with 0 +intramuscular 0 +administration 0 +of 0 +midazolam 1 +. 0 +Information 0 +regarding 0 +midazolam 1 +use 0 +is 0 +reviewed 0 +to 0 +provide 0 +recommendation 0 +for 0 +safe 0 +administration 0 +. 0 +Myasthenia 3 +gravis 4 +presenting 0 +as 0 +weakness 0 +after 0 +magnesium 1 +administration 0 +. 0 +We 0 +studied 0 +a 0 +patient 0 +with 0 +no 0 +prior 0 +history 0 +of 0 +neuromuscular 3 +disease 4 +who 0 +became 0 +virtually 0 +quadriplegic 3 +after 0 +parenteral 0 +magnesium 1 +administration 0 +for 0 +preeclampsia 3 +. 0 +The 0 +serum 0 +magnesium 1 +concentration 0 +was 0 +3 0 +. 0 +0 0 +mEq 0 +/ 0 +L 0 +"," 0 +which 0 +is 0 +usually 0 +well 0 +tolerated 0 +. 0 +The 0 +magnesium 1 +was 0 +stopped 0 +and 0 +she 0 +recovered 0 +over 0 +a 0 +few 0 +days 0 +. 0 +While 0 +she 0 +was 0 +weak 0 +"," 0 +2 0 +- 0 +Hz 0 +repetitive 0 +stimulation 0 +revealed 0 +a 0 +decrement 0 +without 0 +significant 0 +facilitation 0 +at 0 +rapid 0 +rates 0 +or 0 +after 0 +exercise 0 +"," 0 +suggesting 0 +postsynaptic 3 +neuromuscular 4 +blockade 4 +. 0 +After 0 +her 0 +strength 0 +returned 0 +"," 0 +repetitive 0 +stimulation 0 +was 0 +normal 0 +"," 0 +but 0 +single 0 +fiber 0 +EMG 0 +revealed 0 +increased 0 +jitter 0 +and 0 +blocking 0 +. 0 +Her 0 +acetylcholine 1 +receptor 0 +antibody 0 +level 0 +was 0 +markedly 0 +elevated 0 +. 0 +Although 0 +paralysis 3 +after 0 +magnesium 1 +administration 0 +has 0 +been 0 +described 0 +in 0 +patients 0 +with 0 +known 0 +myasthenia 3 +gravis 4 +"," 0 +it 0 +has 0 +not 0 +previously 0 +been 0 +reported 0 +to 0 +be 0 +the 0 +initial 0 +or 0 +only 0 +manifestation 0 +of 0 +the 0 +disease 0 +. 0 +Patients 0 +who 0 +are 0 +unusually 0 +sensitive 0 +to 0 +the 0 +neuromuscular 0 +effects 0 +of 0 +magnesium 1 +should 0 +be 0 +suspected 0 +of 0 +having 0 +an 0 +underlying 0 +disorder 3 +of 4 +neuromuscular 4 +transmission 4 +. 0 +No 0 +enhancement 0 +by 0 +phenobarbital 1 +of 0 +the 0 +hepatocarcinogenicity 0 +of 0 +a 0 +choline 1 +- 0 +devoid 0 +diet 0 +in 0 +the 0 +rat 0 +. 0 +An 0 +experiment 0 +was 0 +performed 0 +to 0 +test 0 +whether 0 +inclusion 0 +of 0 +phenobarbital 1 +in 0 +a 0 +choline 1 +- 0 +devoid 0 +diet 0 +would 0 +increase 0 +the 0 +hepatocarcinogenicity 0 +of 0 +the 0 +diet 0 +. 0 +Groups 0 +of 0 +5 0 +- 0 +week 0 +old 0 +male 0 +Fischer 0 +- 0 +344 0 +rats 0 +were 0 +fed 0 +for 0 +7 0 +- 0 +25 0 +months 0 +semipurified 0 +choline 1 +- 0 +devoid 0 +or 0 +choline 1 +- 0 +supplemented 0 +diets 0 +"," 0 +containing 0 +or 0 +not 0 +0 0 +. 0 +6 0 +% 0 +phenobarbital 1 +. 0 +No 0 +hepatic 0 +preneoplastic 0 +nodules 0 +or 0 +hepatocellular 3 +carcinomas 4 +developed 0 +in 0 +rats 0 +fed 0 +the 0 +plain 0 +choline 1 +- 0 +supplemented 0 +diet 0 +"," 0 +while 0 +one 0 +preneoplastic 0 +nodule 0 +and 0 +one 0 +hepatocellular 3 +carcinoma 4 +developed 0 +in 0 +two 0 +rats 0 +fed 0 +the 0 +same 0 +diet 0 +containing 0 +phenobarbital 1 +. 0 +The 0 +incidence 0 +of 0 +preneoplastic 0 +nodules 0 +and 0 +of 0 +hepatocellular 3 +carcinomas 4 +was 0 +10 0 +% 0 +and 0 +37 0 +% 0 +"," 0 +respectively 0 +"," 0 +in 0 +rats 0 +fed 0 +the 0 +plain 0 +choline 1 +- 0 +devoid 0 +diet 0 +"," 0 +and 0 +17 0 +% 0 +and 0 +30 0 +% 0 +"," 0 +in 0 +rats 0 +fed 0 +the 0 +phenobarbital 1 +- 0 +containing 0 +choline 1 +- 0 +devoid 0 +diet 0 +. 0 +The 0 +results 0 +evinced 0 +no 0 +enhancement 0 +of 0 +the 0 +hepatocarcinogenicity 0 +of 0 +the 0 +choline 1 +- 0 +devoid 0 +diet 0 +by 0 +phenobarbital 1 +. 0 +Sporadic 0 +neoplastic 0 +lesions 0 +were 0 +observed 0 +in 0 +organs 0 +other 0 +than 0 +the 0 +liver 0 +of 0 +some 0 +of 0 +the 0 +animals 0 +"," 0 +irrespective 0 +of 0 +the 0 +diet 0 +fed 0 +. 0 +0n 0 +two 0 +paradoxical 0 +side 0 +- 0 +effects 0 +of 0 +prednisolone 1 +in 0 +rats 0 +"," 0 +ribosomal 0 +RNA 0 +biosyntheses 0 +"," 0 +and 0 +a 0 +mechanism 0 +of 0 +action 0 +. 0 +Liver 3 +enlargement 4 +and 0 +muscle 3 +wastage 4 +occurred 0 +in 0 +Wistar 0 +rats 0 +following 0 +the 0 +subcutaneous 0 +administration 0 +of 0 +prednisolone 1 +. 0 +In 0 +the 0 +liver 0 +both 0 +the 0 +content 0 +of 0 +RNA 0 +and 0 +the 0 +biosynthesis 0 +of 0 +ribosomal 0 +RNA 0 +increased 0 +while 0 +both 0 +the 0 +RNA 0 +content 0 +and 0 +ribosomal 0 +RNA 0 +biosynthesis 0 +were 0 +reduced 0 +in 0 +the 0 +gastrocnemius 0 +muscle 0 +. 0 +It 0 +is 0 +suggested 0 +that 0 +the 0 +drug 0 +acted 0 +in 0 +a 0 +selective 0 +and 0 +tissue 0 +- 0 +specific 0 +manner 0 +to 0 +enhance 0 +ribosomal 0 +RNA 0 +synthesis 0 +in 0 +the 0 +liver 0 +and 0 +depress 0 +such 0 +synthesis 0 +in 0 +the 0 +muscle 0 +. 0 +This 0 +view 0 +supports 0 +the 0 +contention 0 +that 0 +the 0 +liver 0 +and 0 +muscle 0 +are 0 +independent 0 +sites 0 +of 0 +prednisolone 1 +action 0 +. 0 +Differential 0 +effects 0 +of 0 +gamma 1 +- 2 +hexachlorocyclohexane 2 +( 0 +lindane 1 +) 0 +on 0 +pharmacologically 0 +- 0 +induced 0 +seizures 3 +. 0 +Gamma 1 +- 2 +hexachlorocyclohexane 2 +( 0 +gamma 1 +- 2 +HCH 2 +) 0 +"," 0 +the 0 +active 0 +ingredient 0 +of 0 +the 0 +insecticide 0 +lindane 1 +"," 0 +has 0 +been 0 +shown 0 +to 0 +decrease 0 +seizure 3 +threshold 0 +to 0 +pentylenetrazol 0 +( 0 +PTZ 1 +) 0 +3 0 +h 0 +after 0 +exposure 0 +to 0 +gamma 1 +- 2 +HCH 2 +and 0 +conversely 0 +increase 0 +threshold 0 +to 0 +PTZ 1 +- 0 +induced 0 +seizures 3 +24 0 +h 0 +after 0 +exposure 0 +to 0 +gamma 1 +- 2 +HCH 2 +( 0 +Vohland 0 +et 0 +al 0 +. 0 +1981 0 +) 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +the 0 +severity 0 +of 0 +response 0 +to 0 +other 0 +seizure 3 +- 0 +inducing 0 +agents 0 +was 0 +tested 0 +in 0 +mice 0 +1 0 +and 0 +24 0 +h 0 +after 0 +intraperitoneal 0 +administration 0 +of 0 +80 0 +mg 0 +/ 0 +kg 0 +gamma 1 +- 2 +HCH 2 +. 0 +0ne 0 +hour 0 +after 0 +the 0 +administration 0 +of 0 +gamma 1 +- 2 +HCH 2 +"," 0 +the 0 +activity 0 +of 0 +seizure 3 +- 0 +inducing 0 +agents 0 +was 0 +increased 0 +"," 0 +regardless 0 +of 0 +their 0 +mechanism 0 +"," 0 +while 0 +24 0 +h 0 +after 0 +gamma 1 +- 2 +HCH 2 +a 0 +differential 0 +response 0 +was 0 +observed 0 +. 0 +Seizure 3 +activity 0 +due 0 +to 0 +PTZ 1 +and 0 +picrotoxin 1 +( 0 +PTX 1 +) 0 +was 0 +significantly 0 +decreased 0 +; 0 +however 0 +"," 0 +seizure 3 +activity 0 +due 0 +to 0 +3 1 +- 2 +mercaptopropionic 2 +acid 2 +( 0 +MPA 1 +) 0 +"," 0 +bicuculline 1 +( 0 +BCC 1 +) 0 +"," 0 +methyl 1 +6 2 +"," 2 +7 2 +- 2 +dimethoxy 2 +- 2 +4 2 +- 2 +ethyl 2 +- 2 +B 2 +- 2 +carboline 2 +- 2 +3 2 +- 2 +carboxylate 2 +( 0 +DMCM 1 +) 0 +"," 0 +or 0 +strychnine 1 +( 0 +STR 1 +) 0 +was 0 +not 0 +different 0 +from 0 +control 0 +. 0 +In 0 +vitro 0 +"," 0 +gamma 1 +- 2 +HCH 2 +"," 0 +pentylenetetrazol 1 +and 0 +picrotoxin 1 +were 0 +shown 0 +to 0 +inhibit 0 +3H 1 +- 2 +TB0B 2 +binding 0 +in 0 +mouse 0 +whole 0 +brain 0 +"," 0 +with 0 +IC50 0 +values 0 +of 0 +4 0 +. 0 +6 0 +"," 0 +404 0 +and 0 +9 0 +. 0 +4 0 +microM 0 +"," 0 +respectively 0 +. 0 +MPA 1 +"," 0 +BCC 1 +"," 0 +DMCM 1 +"," 0 +and 0 +STR 1 +showed 0 +no 0 +inhibition 0 +of 0 +3H 1 +- 2 +TB0B 2 +( 0 +t 1 +- 2 +butyl 2 +bicyclo 2 +- 2 +orthobenzoate 2 +) 0 +binding 0 +at 0 +concentrations 0 +of 0 +100 0 +micron 0 +. 0 +The 0 +pharmacological 0 +challenge 0 +data 0 +suggest 0 +that 0 +tolerance 0 +may 0 +occur 0 +to 0 +seizure 3 +activity 0 +induced 0 +by 0 +PTZ 1 +and 0 +PTX 1 +24 0 +h 0 +after 0 +gamma 1 +- 2 +HCH 2 +"," 0 +since 0 +the 0 +response 0 +to 0 +only 0 +these 0 +two 0 +seizure 3 +- 0 +inducing 0 +agents 0 +is 0 +decreased 0 +. 0 +The 0 +in 0 +vitro 0 +data 0 +suggest 0 +that 0 +the 0 +site 0 +responsible 0 +for 0 +the 0 +decrease 0 +in 0 +seizure 3 +activity 0 +24 0 +h 0 +after 0 +gamma 1 +- 2 +HCH 2 +may 0 +be 0 +the 0 +GABA 1 +- 0 +A 0 +receptor 0 +- 0 +linked 0 +chloride 0 +channel 0 +. 0 +Tolerance 0 +and 0 +antiviral 0 +effect 0 +of 0 +ribavirin 1 +in 0 +patients 0 +with 0 +Argentine 3 +hemorrhagic 4 +fever 4 +. 0 +Tolerance 0 +and 0 +antiviral 0 +effect 0 +of 0 +ribavirin 1 +was 0 +studied 0 +in 0 +6 0 +patients 0 +with 0 +Argentine 3 +hemorrhagic 4 +fever 4 +( 0 +AHF 3 +) 0 +of 0 +more 0 +than 0 +8 0 +days 0 +of 0 +evolution 0 +. 0 +Administration 0 +of 0 +ribavirin 1 +resulted 0 +in 0 +a 0 +neutralization 0 +of 0 +viremia 3 +and 0 +a 0 +drop 0 +of 0 +endogenous 0 +interferon 0 +titers 0 +. 0 +The 0 +average 0 +time 0 +of 0 +death 3 +was 0 +delayed 0 +. 0 +A 0 +reversible 0 +anemia 3 +was 0 +the 0 +only 0 +adverse 0 +effect 0 +observed 0 +. 0 +From 0 +these 0 +results 0 +"," 0 +we 0 +conclude 0 +that 0 +ribavirin 1 +has 0 +an 0 +antiviral 0 +effect 0 +in 0 +advanced 0 +cases 0 +of 0 +AHF 3 +"," 0 +and 0 +that 0 +anemia 3 +"," 0 +the 0 +only 0 +secondary 0 +reaction 0 +observed 0 +"," 0 +can 0 +be 0 +easily 0 +managed 0 +. 0 +The 0 +possible 0 +beneficial 0 +effect 0 +of 0 +ribavirin 1 +during 0 +the 0 +initial 0 +days 0 +of 0 +AHF 3 +is 0 +discussed 0 +. 0 +Is 0 +the 0 +treatment 0 +of 0 +scabies 3 +hazardous 0 +? 0 +Treatment 0 +for 0 +scabies 3 +is 0 +usually 0 +initiated 0 +by 0 +general 0 +practitioners 0 +; 0 +most 0 +consider 0 +lindane 1 +( 0 +gamma 1 +benzene 2 +hexachloride 2 +) 0 +the 0 +treatment 0 +of 0 +choice 0 +. 0 +Lindane 1 +is 0 +also 0 +widely 0 +used 0 +as 0 +an 0 +agricultural 0 +and 0 +industrial 0 +pesticide 0 +"," 0 +and 0 +as 0 +a 0 +result 0 +the 0 +toxic 0 +profile 0 +of 0 +this 0 +insecticide 0 +is 0 +well 0 +understood 0 +. 0 +Evidence 0 +is 0 +accumulating 0 +that 0 +lindane 1 +can 0 +be 0 +toxic 3 +to 4 +the 4 +central 4 +nervous 4 +system 4 +and 0 +may 0 +be 0 +associated 0 +with 0 +aplastic 3 +anaemia 4 +. 0 +Preparations 0 +containing 0 +lindane 1 +continue 0 +to 0 +be 0 +sold 0 +over 0 +the 0 +counter 0 +and 0 +may 0 +represent 0 +a 0 +hazard 0 +to 0 +poorly 0 +informed 0 +patients 0 +. 0 +This 0 +literature 0 +review 0 +suggests 0 +that 0 +general 0 +practitioners 0 +should 0 +prescribe 0 +scabicides 0 +with 0 +increased 0 +caution 0 +for 0 +certain 0 +at 0 +- 0 +risk 0 +groups 0 +"," 0 +and 0 +give 0 +adequate 0 +warnings 0 +regarding 0 +potential 0 +toxicity 3 +. 0 +Mouse 0 +strain 0 +- 0 +dependent 0 +effect 0 +of 0 +amantadine 1 +on 0 +motility 0 +and 0 +brain 0 +biogenic 0 +amines 1 +. 0 +The 0 +effect 0 +of 0 +amantadine 1 +hydrochloride 2 +"," 0 +injected 0 +i 0 +. 0 +p 0 +. 0 +in 0 +6 0 +increments 0 +of 0 +100 0 +mg 0 +/ 0 +kg 0 +each 0 +over 0 +30 0 +hr 0 +"," 0 +on 0 +mouse 0 +motility 0 +and 0 +whole 0 +brain 0 +content 0 +of 0 +selected 0 +biogenic 0 +amines 1 +and 0 +major 0 +metabolites 0 +was 0 +studied 0 +in 0 +4 0 +strains 0 +of 0 +mice 0 +. 0 +These 0 +were 0 +the 0 +albino 0 +Sprague 0 +- 0 +Dawley 0 +ICR 0 +and 0 +BALB 0 +/ 0 +C 0 +"," 0 +the 0 +black 0 +C57BL 0 +/ 0 +6 0 +and 0 +the 0 +brown 0 +CDF 0 +- 0 +I 0 +mouse 0 +strains 0 +. 0 +Amantadine 1 +treatment 0 +produced 0 +a 0 +biphasic 0 +effect 0 +on 0 +mouse 0 +motility 0 +. 0 +The 0 +initial 0 +dose 0 +of 0 +amantadine 1 +depressed 3 +locomotor 0 +activity 0 +in 0 +all 0 +mouse 0 +strains 0 +studied 0 +with 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +being 0 +the 0 +most 0 +sensitive 0 +. 0 +Subsequent 0 +amantadine 1 +treatments 0 +produced 0 +enhancement 0 +of 0 +motility 0 +from 0 +corresponding 0 +control 0 +in 0 +all 0 +mouse 0 +strains 0 +with 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +being 0 +the 0 +least 0 +sensitive 0 +. 0 +The 0 +locomotor 0 +activity 0 +was 0 +decreased 0 +from 0 +corresponding 0 +controls 0 +in 0 +all 0 +strains 0 +studied 0 +"," 0 +except 0 +for 0 +the 0 +ICR 0 +mice 0 +"," 0 +during 0 +an 0 +overnight 0 +drug 0 +- 0 +free 0 +period 0 +following 0 +the 0 +fourth 0 +amantadine 1 +treatment 0 +. 0 +Readministration 0 +of 0 +amantadine 1 +"," 0 +after 0 +a 0 +drug 0 +- 0 +free 0 +overnight 0 +period 0 +"," 0 +increased 0 +motility 0 +from 0 +respective 0 +saline 0 +control 0 +in 0 +all 0 +strains 0 +with 0 +exception 0 +of 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +where 0 +suppression 3 +of 4 +motility 4 +occurred 0 +. 0 +Treatment 0 +with 0 +amantadine 1 +did 0 +not 0 +alter 0 +whole 0 +brain 0 +dopamine 1 +levels 0 +but 0 +decreased 0 +the 0 +amounts 0 +of 0 +3 1 +"," 2 +4 2 +- 2 +dihydroxyphenylacetic 2 +acid 2 +in 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +compared 0 +to 0 +saline 0 +control 0 +. 0 +Conversely 0 +"," 0 +brain 0 +normetanephrine 1 +concentration 0 +was 0 +increased 0 +from 0 +saline 0 +control 0 +by 0 +amantadine 1 +in 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +. 0 +The 0 +results 0 +suggest 0 +a 0 +strain 0 +- 0 +dependent 0 +effect 0 +of 0 +amantadine 1 +on 0 +motility 0 +and 0 +indicate 0 +a 0 +differential 0 +response 0 +to 0 +the 0 +acute 0 +and 0 +multiple 0 +dose 0 +regimens 0 +used 0 +. 0 +The 0 +BALB 0 +/ 0 +C 0 +mouse 0 +was 0 +the 0 +most 0 +sensitive 0 +strain 0 +and 0 +could 0 +serve 0 +as 0 +the 0 +strain 0 +of 0 +choice 0 +for 0 +evaluating 0 +the 0 +side 0 +effects 0 +of 0 +amantadine 1 +. 0 +The 0 +biochemical 0 +results 0 +of 0 +brain 0 +biogenic 0 +amines 1 +of 0 +BALB 0 +/ 0 +C 0 +mouse 0 +strain 0 +suggest 0 +a 0 +probable 0 +decrease 0 +of 0 +catecholamine 1 +turnover 0 +rate 0 +and 0 +/ 0 +or 0 +metabolism 0 +by 0 +monoamine 0 +oxidase 0 +and 0 +a 0 +resulting 0 +increase 0 +in 0 +0 0 +- 0 +methylation 0 +of 0 +norepinephrine 1 +which 0 +may 0 +account 0 +for 0 +a 0 +behavioral 3 +depression 4 +caused 0 +by 0 +amantadine 1 +in 0 +the 0 +BALB 0 +/ 0 +C 0 +mice 0 +. 0 +Chloroacetaldehyde 1 +and 0 +its 0 +contribution 0 +to 0 +urotoxicity 0 +during 0 +treatment 0 +with 0 +cyclophosphamide 1 +or 0 +ifosfamide 1 +. 0 +An 0 +experimental 0 +study 0 +/ 0 +short 0 +communication 0 +. 0 +Based 0 +on 0 +clinical 0 +data 0 +"," 0 +indicating 0 +that 0 +chloroacetaldehyde 1 +( 0 +CAA 1 +) 0 +is 0 +an 0 +important 0 +metabolite 0 +of 0 +oxazaphosphorine 0 +cytostatics 0 +"," 0 +an 0 +experimental 0 +study 0 +was 0 +carried 0 +out 0 +in 0 +order 0 +to 0 +elucidate 0 +the 0 +role 0 +of 0 +CAA 1 +in 0 +the 0 +development 0 +of 0 +hemorrhagic 3 +cystitis 4 +. 0 +The 0 +data 0 +demonstrate 0 +that 0 +CAA 1 +after 0 +i 0 +. 0 +v 0 +. 0 +administration 0 +does 0 +not 0 +contribute 0 +to 0 +bladder 3 +damage 4 +. 0 +When 0 +instilled 0 +directly 0 +into 0 +the 0 +bladder 0 +"," 0 +CAA 1 +exerts 0 +urotoxic 0 +effects 0 +"," 0 +it 0 +is 0 +"," 0 +however 0 +"," 0 +susceptible 0 +to 0 +detoxification 0 +with 0 +mesna 1 +. 0 +Source 0 +of 0 +pain 3 +and 0 +primitive 0 +dysfunction 0 +in 0 +migraine 3 +: 0 +an 0 +identical 0 +site 0 +? 0 +Twenty 0 +common 0 +migraine 3 +patients 0 +received 0 +a 0 +one 0 +sided 0 +frontotemporal 0 +application 0 +of 0 +nitroglycerin 1 +( 0 +10 0 +patients 0 +) 0 +or 0 +placebo 0 +ointment 0 +( 0 +10 0 +patients 0 +) 0 +in 0 +a 0 +double 0 +blind 0 +study 0 +. 0 +Early 0 +onset 0 +migraine 3 +attacks 0 +were 0 +induced 0 +by 0 +nitroglycerin 1 +in 0 +seven 0 +out 0 +of 0 +10 0 +patients 0 +versus 0 +no 0 +patient 0 +in 0 +the 0 +placebo 0 +group 0 +. 0 +Subsequently 0 +20 0 +migraine 3 +patients 0 +"," 0 +who 0 +developed 0 +an 0 +early 0 +onset 0 +attack 0 +with 0 +frontotemporal 0 +nitroglycerin 1 +"," 0 +received 0 +the 0 +drug 0 +in 0 +a 0 +second 0 +induction 0 +test 0 +at 0 +other 0 +body 0 +areas 0 +. 0 +No 0 +early 0 +onset 0 +migraine 3 +was 0 +observed 0 +. 0 +Thus 0 +the 0 +migraine 3 +- 0 +inducing 0 +effect 0 +of 0 +nitroglycerin 1 +seems 0 +to 0 +depend 0 +on 0 +direct 0 +stimulation 0 +of 0 +the 0 +habitual 0 +site 0 +of 0 +pain 3 +"," 0 +suggesting 0 +that 0 +the 0 +frontotemporal 0 +region 0 +is 0 +of 0 +crucial 0 +importance 0 +in 0 +the 0 +development 0 +of 0 +a 0 +migraine 3 +crisis 0 +. 0 +This 0 +is 0 +not 0 +consistent 0 +with 0 +a 0 +CNS 0 +origin 0 +of 0 +migraine 3 +attack 0 +. 0 +Hypersensitivity 3 +to 0 +carbamazepine 1 +presenting 0 +with 0 +a 0 +leukemoid 3 +reaction 4 +"," 0 +eosinophilia 3 +"," 0 +erythroderma 3 +"," 0 +and 0 +renal 3 +failure 4 +. 0 +We 0 +report 0 +a 0 +patient 0 +in 0 +whom 0 +hypersensitivity 3 +to 0 +carbamazepine 1 +presented 0 +with 0 +generalized 0 +erythroderma 3 +"," 0 +a 0 +severe 0 +leukemoid 3 +reaction 4 +"," 0 +eosinophilia 3 +"," 0 +hyponatremia 3 +"," 0 +and 0 +renal 3 +failure 4 +. 0 +This 0 +is 0 +the 0 +first 0 +report 0 +of 0 +such 0 +an 0 +unusual 0 +reaction 0 +to 0 +carbamazepine 1 +. 0 +Fluoxetine 1 +- 0 +induced 0 +akathisia 3 +: 0 +clinical 0 +and 0 +theoretical 0 +implications 0 +. 0 +Five 0 +patients 0 +receiving 0 +fluoxetine 1 +for 0 +the 0 +treatment 0 +of 0 +obsessive 3 +compulsive 4 +disorder 4 +or 0 +major 3 +depression 4 +developed 0 +akathisia 3 +. 0 +The 0 +typical 0 +fluoxetine 1 +- 0 +induced 0 +symptoms 0 +of 0 +restlessness 0 +"," 0 +constant 0 +pacing 0 +"," 0 +purposeless 0 +movements 0 +of 0 +the 0 +feet 0 +and 0 +legs 0 +"," 0 +and 0 +marked 0 +anxiety 3 +were 0 +indistinguishable 0 +from 0 +those 0 +of 0 +neuroleptic 0 +- 0 +induced 0 +akathisia 3 +. 0 +Three 0 +patients 0 +who 0 +had 0 +experienced 0 +neuroleptic 0 +- 0 +induced 0 +akathisia 3 +in 0 +the 0 +past 0 +reported 0 +that 0 +the 0 +symptoms 0 +of 0 +fluoxetine 1 +- 0 +induced 0 +akathisia 3 +were 0 +identical 0 +"," 0 +although 0 +somewhat 0 +milder 0 +. 0 +Akathisia 3 +appeared 0 +to 0 +be 0 +a 0 +common 0 +side 0 +effect 0 +of 0 +fluoxetine 1 +and 0 +generally 0 +responded 0 +well 0 +to 0 +treatment 0 +with 0 +the 0 +beta 0 +- 0 +adrenergic 0 +antagonist 0 +propranolol 1 +"," 0 +dose 0 +reduction 0 +"," 0 +or 0 +both 0 +. 0 +The 0 +authors 0 +suggest 0 +that 0 +fluoxetine 1 +- 0 +induced 0 +akathisia 3 +may 0 +be 0 +caused 0 +by 0 +serotonergically 0 +mediated 0 +inhibition 0 +of 0 +dopaminergic 0 +neurotransmission 0 +and 0 +that 0 +the 0 +pathophysiology 0 +of 0 +fluoxetine 1 +- 0 +induced 0 +akathisia 3 +and 0 +tricyclic 0 +antidepressant 1 +- 0 +induced 0 +" 0 +jitteriness 0 +" 0 +may 0 +be 0 +identical 0 +. 0 +Effect 0 +of 0 +converting 0 +enzyme 0 +inhibition 0 +on 0 +the 0 +course 0 +of 0 +adriamycin 1 +- 0 +induced 0 +nephropathy 3 +. 0 +The 0 +effect 0 +of 0 +the 0 +converting 0 +enzyme 0 +inhibitor 0 +( 0 +CEI 0 +) 0 +enalapril 1 +was 0 +assessed 0 +in 0 +Munich 0 +- 0 +Wistar 0 +rats 0 +with 0 +established 0 +adriamycin 1 +nephrosis 3 +. 0 +Rats 0 +were 0 +given 0 +a 0 +single 0 +dose 0 +of 0 +adriamycin 1 +and 0 +one 0 +month 0 +later 0 +divided 0 +into 0 +four 0 +groups 0 +matched 0 +for 0 +albuminuria 3 +"," 0 +blood 0 +pressure 0 +"," 0 +and 0 +plasma 0 +albumin 0 +concentration 0 +. 0 +Groups 0 +1 0 +and 0 +3 0 +remained 0 +untreated 0 +while 0 +groups 0 +2 0 +and 0 +4 0 +received 0 +enalapril 1 +. 0 +Groups 0 +1 0 +and 0 +2 0 +underwent 0 +micropuncture 0 +studies 0 +after 0 +10 0 +days 0 +. 0 +These 0 +short 0 +- 0 +term 0 +studies 0 +showed 0 +that 0 +enalapril 1 +reduced 0 +arterial 0 +blood 0 +pressure 0 +( 0 +101 0 ++ 0 +/ 0 +- 0 +2 0 +vs 0 +. 0 +124 0 ++ 0 +/ 0 +- 0 +3 0 +mm 0 +Hg 0 +"," 0 +group 0 +2 0 +vs 0 +. 0 +1 0 +"," 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +and 0 +glomerular 0 +capillary 0 +pressure 0 +( 0 +54 0 ++ 0 +/ 0 +- 0 +1 0 +vs 0 +. 0 +61 0 ++ 0 +/ 0 +- 0 +2 0 +mm 0 +Hg 0 +"," 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +without 0 +reducing 0 +albuminuria 3 +( 0 +617 0 ++ 0 +/ 0 +- 0 +50 0 +vs 0 +. 0 +570 0 ++ 0 +/ 0 +- 0 +47 0 +mg 0 +/ 0 +day 0 +) 0 +or 0 +GFR 0 +( 0 +1 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +4 0 +vs 0 +. 0 +1 0 +. 0 +4 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +11 0 +ml 0 +/ 0 +min 0 +) 0 +. 0 +Groups 0 +3 0 +and 0 +4 0 +were 0 +studied 0 +at 0 +four 0 +and 0 +at 0 +six 0 +months 0 +to 0 +assess 0 +the 0 +effect 0 +of 0 +enalapril 1 +on 0 +progression 0 +of 0 +renal 3 +injury 4 +in 0 +adriamycin 1 +nephrosis 3 +. 0 +Chronic 0 +enalapril 1 +treatment 0 +reduced 0 +blood 0 +pressure 0 +without 0 +reducing 0 +albuminuria 3 +in 0 +group 0 +4 0 +. 0 +Untreated 0 +group 0 +3 0 +rats 0 +exhibited 0 +a 0 +progressive 0 +reduction 0 +in 0 +GFR 0 +( 0 +0 0 +. 0 +35 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +8 0 +ml 0 +/ 0 +min 0 +at 0 +4 0 +months 0 +"," 0 +0 0 +. 0 +27 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +7 0 +ml 0 +/ 0 +min 0 +at 0 +6 0 +months 0 +) 0 +. 0 +Enalapril 1 +treatment 0 +blunted 0 +but 0 +did 0 +not 0 +prevent 0 +reduction 0 +in 0 +GFR 0 +in 0 +group 0 +4 0 +( 0 +0 0 +. 0 +86 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +15 0 +ml 0 +/ 0 +min 0 +at 0 +4 0 +months 0 +"," 0 +0 0 +. 0 +69 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +13 0 +ml 0 +/ 0 +min 0 +at 0 +6 0 +months 0 +"," 0 +both 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +vs 0 +. 0 +group 0 +3 0 +) 0 +. 0 +Reduction 0 +in 0 +GFR 0 +was 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +glomerular 3 +sclerosis 4 +in 0 +both 0 +treated 0 +and 0 +untreated 0 +rats 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Clotiazepam 1 +- 0 +induced 0 +acute 0 +hepatitis 3 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +patient 0 +who 0 +developed 0 +acute 0 +hepatitis 3 +with 0 +extensive 3 +hepatocellular 4 +necrosis 4 +"," 0 +7 0 +months 0 +after 0 +the 0 +onset 0 +of 0 +administration 0 +of 0 +clotiazepam 1 +"," 0 +a 0 +thienodiazepine 1 +derivative 0 +. 0 +Clotiazepam 1 +withdrawal 0 +was 0 +followed 0 +by 0 +prompt 0 +recovery 0 +. 0 +The 0 +administration 0 +of 0 +several 0 +benzodiazepines 1 +"," 0 +chemically 0 +related 0 +to 0 +clotiazepam 1 +"," 0 +did 0 +not 0 +interfere 0 +with 0 +recovery 0 +and 0 +did 0 +not 0 +induce 0 +any 0 +relapse 0 +of 0 +hepatitis 3 +. 0 +This 0 +observation 0 +shows 0 +that 0 +clotiazepam 1 +can 0 +induce 0 +acute 0 +hepatitis 3 +and 0 +suggests 0 +that 0 +there 0 +is 0 +no 0 +cross 0 +hepatotoxicity 3 +between 0 +clotiazepam 1 +and 0 +several 0 +benzodiazepines 1 +. 0 +5 1 +- 2 +azacytidine 2 +potentiates 0 +initiation 3 +induced 4 +by 4 +carcinogens 4 +in 0 +rat 0 +liver 0 +. 0 +To 0 +test 0 +the 0 +validity 0 +of 0 +the 0 +hypothesis 0 +that 0 +hypomethylation 0 +of 0 +DNA 0 +plays 0 +an 0 +important 0 +role 0 +in 0 +the 0 +initiation 3 +of 4 +carcinogenic 4 +process 4 +"," 0 +5 1 +- 2 +azacytidine 2 +( 0 +5 1 +- 2 +AzC 2 +) 0 +( 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +an 0 +inhibitor 0 +of 0 +DNA 0 +methylation 0 +"," 0 +was 0 +given 0 +to 0 +rats 0 +during 0 +the 0 +phase 0 +of 0 +repair 0 +synthesis 0 +induced 0 +by 0 +the 0 +three 0 +carcinogens 0 +"," 0 +benzo 1 +[ 2 +a 2 +] 2 +- 2 +pyrene 2 +( 0 +200 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +N 1 +- 2 +methyl 2 +- 2 +N 2 +- 2 +nitrosourea 2 +( 0 +60 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +1 1 +"," 2 +2 2 +- 2 +dimethylhydrazine 2 +( 0 +1 1 +"," 2 +2 2 +- 2 +DMH 2 +) 0 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 +The 0 +initiated 0 +hepatocytes 0 +in 0 +the 0 +liver 0 +were 0 +assayed 0 +as 0 +the 0 +gamma 0 +- 0 +glutamyltransferase 0 +( 0 +gamma 0 +- 0 +GT 0 +) 0 +positive 0 +foci 0 +formed 0 +following 0 +a 0 +2 0 +- 0 +week 0 +selection 0 +regimen 0 +consisting 0 +of 0 +dietary 0 +0 0 +. 0 +2 0 +% 0 +2 1 +- 2 +acetylaminofluorene 2 +coupled 0 +with 0 +a 0 +necrogenic 0 +dose 0 +of 0 +CCl4 1 +. 0 +The 0 +results 0 +obtained 0 +indicate 0 +that 0 +with 0 +all 0 +three 0 +carcinogens 0 +"," 0 +administration 0 +of 0 +5 1 +- 2 +AzC 2 +during 0 +repair 0 +synthesis 0 +increased 0 +the 0 +incidence 0 +of 0 +initiated 0 +hepatocytes 0 +"," 0 +for 0 +example 0 +10 0 +- 0 +20 0 +foci 0 +/ 0 +cm2 0 +in 0 +5 1 +- 2 +AzC 2 +and 0 +carcinogen 0 +- 0 +treated 0 +rats 0 +compared 0 +with 0 +3 0 +- 0 +5 0 +foci 0 +/ 0 +cm2 0 +in 0 +rats 0 +treated 0 +with 0 +carcinogen 0 +only 0 +. 0 +Administration 0 +of 0 +[ 1 +3H 2 +] 2 +- 2 +5 2 +- 2 +azadeoxycytidine 2 +during 0 +the 0 +repair 0 +synthesis 0 +induced 0 +by 0 +1 1 +"," 2 +2 2 +- 2 +DMH 2 +further 0 +showed 0 +that 0 +0 0 +. 0 +19 0 +mol 0 +% 0 +of 0 +cytosine 1 +residues 0 +in 0 +DNA 0 +were 0 +substituted 0 +by 0 +the 0 +analogue 0 +"," 0 +indicating 0 +that 0 +incorporation 0 +of 0 +5 1 +- 2 +AzC 2 +occurs 0 +during 0 +repair 0 +synthesis 0 +. 0 +In 0 +the 0 +absence 0 +of 0 +the 0 +carcinogen 0 +"," 0 +5 1 +- 2 +AzC 2 +given 0 +after 0 +a 0 +two 0 +thirds 0 +partial 0 +hepatectomy 0 +"," 0 +when 0 +its 0 +incorporation 0 +should 0 +be 0 +maximum 0 +"," 0 +failed 0 +to 0 +induce 0 +any 0 +gamma 0 +- 0 +GT 0 +positive 0 +foci 0 +. 0 +The 0 +results 0 +suggest 0 +that 0 +hypomethylation 0 +of 0 +DNA 0 +per 0 +se 0 +may 0 +not 0 +be 0 +sufficient 0 +for 0 +initiation 0 +. 0 +Perhaps 0 +two 0 +events 0 +might 0 +be 0 +necessary 0 +for 0 +initiation 0 +"," 0 +the 0 +first 0 +caused 0 +by 0 +the 0 +carcinogen 0 +and 0 +a 0 +second 0 +involving 0 +hypomethylation 0 +of 0 +DNA 0 +. 0 +Antihypertensive 0 +drugs 0 +and 0 +depression 3 +: 0 +a 0 +reappraisal 0 +. 0 +Eighty 0 +- 0 +nine 0 +new 0 +referral 0 +hypertensive 3 +out 0 +- 0 +patients 0 +and 0 +46 0 +new 0 +referral 0 +non 0 +- 0 +hypertensive 3 +chronically 0 +physically 0 +ill 0 +out 0 +- 0 +patients 0 +completed 0 +a 0 +mood 0 +rating 0 +scale 0 +at 0 +regular 0 +intervals 0 +for 0 +one 0 +year 0 +. 0 +The 0 +results 0 +showed 0 +a 0 +high 0 +prevalence 0 +of 0 +depression 3 +in 0 +both 0 +groups 0 +of 0 +patients 0 +"," 0 +with 0 +no 0 +preponderance 0 +in 0 +the 0 +hypertensive 3 +group 0 +. 0 +Hypertensive 3 +patients 0 +with 0 +psychiatric 3 +histories 0 +had 0 +a 0 +higher 0 +prevalence 0 +of 0 +depression 3 +than 0 +the 0 +comparison 0 +patients 0 +. 0 +This 0 +was 0 +accounted 0 +for 0 +by 0 +a 0 +significant 0 +number 0 +of 0 +depressions 3 +occurring 0 +in 0 +methyl 1 +dopa 2 +treated 0 +patients 0 +with 0 +psychiatric 3 +histories 0 +. 0 +Chronic 3 +active 4 +hepatitis 4 +associated 0 +with 0 +diclofenac 1 +sodium 2 +therapy 0 +. 0 +Diclofenac 1 +sodium 2 +( 0 +Voltarol 1 +"," 0 +Geigy 0 +Pharmaceuticals 0 +) 0 +is 0 +a 0 +non 0 +- 0 +steroidal 0 +anti 0 +- 0 +inflammatory 0 +derivative 0 +of 0 +phenylacetic 1 +acid 2 +. 0 +Although 0 +generally 0 +well 0 +- 0 +tolerated 0 +"," 0 +asymptomatic 0 +abnormalities 3 +of 4 +liver 4 +function 4 +have 0 +been 0 +recorded 0 +and 0 +"," 0 +less 0 +commonly 0 +"," 0 +severe 0 +hepatitis 3 +induced 0 +by 0 +diclofenac 1 +. 0 +The 0 +patient 0 +described 0 +developed 0 +chronic 3 +active 4 +hepatitis 4 +after 0 +six 0 +months 0 +therapy 0 +with 0 +diclofenac 1 +sodium 2 +which 0 +progressed 0 +despite 0 +the 0 +withdrawal 0 +of 0 +the 0 +drug 0 +"," 0 +a 0 +finding 0 +not 0 +previously 0 +reported 0 +. 0 +Arterial 0 +hypertension 3 +as 0 +a 0 +complication 0 +of 0 +prolonged 0 +ketoconazole 1 +treatment 0 +. 0 +Two 0 +of 0 +14 0 +patients 0 +with 0 +Cushing 3 +' 4 +s 4 +syndrome 4 +treated 0 +on 0 +a 0 +long 0 +- 0 +term 0 +basis 0 +with 0 +ketoconazole 1 +developed 0 +sustained 0 +hypertension 3 +. 0 +In 0 +both 0 +cases 0 +normal 0 +plasma 0 +and 0 +urinary 0 +free 0 +cortisol 1 +levels 0 +had 0 +been 0 +achieved 0 +following 0 +ketoconazole 1 +therapy 0 +"," 0 +yet 0 +continuous 0 +blood 0 +pressure 0 +monitoring 0 +demonstrated 0 +hypertension 3 +31 0 +( 0 +patient 0 +1 0 +) 0 +and 0 +52 0 +weeks 0 +( 0 +patient 0 +2 0 +) 0 +after 0 +treatment 0 +. 0 +In 0 +patient 0 +1 0 +"," 0 +plasma 0 +levels 0 +of 0 +deoxycorticosterone 1 +and 0 +11 1 +- 2 +deoxycortisol 2 +were 0 +elevated 0 +. 0 +In 0 +patient 0 +2 0 +"," 0 +in 0 +addition 0 +to 0 +an 0 +increase 0 +in 0 +both 0 +deoxycorticosterone 1 +and 0 +11 1 +- 2 +deoxycortisol 2 +levels 0 +"," 0 +plasma 0 +aldosterone 1 +values 0 +were 0 +raised 0 +"," 0 +with 0 +a 0 +concomitant 0 +suppression 0 +of 0 +renin 0 +levels 0 +. 0 +0ur 0 +findings 0 +show 0 +that 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +high 0 +doses 0 +of 0 +ketoconazole 1 +may 0 +induce 0 +enzyme 0 +blockade 0 +leading 0 +to 0 +mineralocorticoid 0 +- 0 +related 0 +hypertension 3 +. 0 +Effects 0 +of 0 +an 0 +inhibitor 0 +of 0 +angiotensin 1 +converting 0 +enzyme 0 +( 0 +Captopril 1 +) 0 +on 0 +pulmonary 3 +and 4 +renal 4 +insufficiency 4 +due 0 +to 0 +intravascular 3 +coagulation 4 +in 0 +the 0 +rat 0 +. 0 +Induction 0 +of 0 +intravascular 3 +coagulation 4 +and 0 +inhibition 0 +of 0 +fibrinolysis 0 +by 0 +injection 0 +of 0 +thrombin 0 +and 0 +tranexamic 1 +acid 2 +( 0 +AMCA 1 +) 0 +in 0 +the 0 +rat 0 +gives 0 +rise 0 +to 0 +pulmonary 3 +and 4 +renal 4 +insufficiency 4 +resembling 0 +that 0 +occurring 0 +after 0 +trauma 3 +or 0 +sepsis 3 +in 0 +man 0 +. 0 +Injection 0 +of 0 +Captopril 1 +( 0 +1 0 +mg 0 +/ 0 +kg 0 +) 0 +"," 0 +an 0 +inhibitor 0 +of 0 +angiotensin 1 +converting 0 +enzyme 0 +( 0 +ACE 0 +) 0 +"," 0 +reduced 0 +both 0 +pulmonary 3 +and 4 +renal 4 +insufficiency 4 +in 0 +this 0 +rat 0 +model 0 +. 0 +The 0 +lung 0 +weights 0 +were 0 +lower 0 +and 0 +Pa02 0 +was 0 +improved 0 +in 0 +rats 0 +given 0 +this 0 +enzyme 0 +- 0 +blocking 0 +agent 0 +. 0 +The 0 +contents 0 +of 0 +albumin 0 +in 0 +the 0 +lungs 0 +were 0 +not 0 +changed 0 +"," 0 +indicating 0 +that 0 +Captopril 1 +did 0 +not 0 +influence 0 +the 0 +extravasation 0 +of 0 +protein 0 +. 0 +Renal 3 +damage 4 +as 0 +reflected 0 +by 0 +an 0 +increase 0 +in 0 +serum 0 +urea 1 +and 0 +in 0 +kidney 0 +weight 0 +was 0 +prevented 0 +by 0 +Captopril 1 +. 0 +The 0 +amount 0 +of 0 +fibrin 0 +in 0 +the 0 +kidneys 0 +was 0 +also 0 +considerably 0 +lower 0 +than 0 +in 0 +animals 0 +which 0 +received 0 +thrombin 0 +and 0 +AMCA 1 +alone 0 +. 0 +It 0 +is 0 +suggested 0 +that 0 +the 0 +effects 0 +of 0 +Captopril 1 +on 0 +the 0 +lungs 0 +may 0 +be 0 +attributable 0 +to 0 +a 0 +vasodilatory 0 +effect 0 +due 0 +to 0 +a 0 +reduction 0 +in 0 +the 0 +circulating 0 +level 0 +of 0 +Angiotension 1 +II 2 +and 0 +an 0 +increase 0 +in 0 +prostacyclin 1 +( 0 +secondary 0 +to 0 +an 0 +increase 0 +in 0 +bradykinin 1 +) 0 +. 0 +Captopril 1 +may 0 +"," 0 +by 0 +the 0 +same 0 +mechanism 0 +"," 0 +reduce 0 +the 0 +increase 0 +in 0 +glomerular 0 +filtration 0 +that 0 +is 0 +known 0 +to 0 +occur 0 +after 0 +an 0 +injection 0 +of 0 +thrombin 0 +"," 0 +thereby 0 +diminishing 0 +the 0 +aggregation 0 +of 0 +fibrin 0 +monomers 0 +in 0 +the 0 +glomeruli 0 +"," 0 +with 0 +the 0 +result 0 +that 0 +less 0 +fibrin 0 +will 0 +be 0 +deposited 0 +and 0 +thus 0 +less 0 +kidney 3 +damage 4 +will 0 +be 0 +produced 0 +. 0 +Stroke 3 +associated 0 +with 0 +cocaine 1 +use 0 +. 0 +We 0 +describe 0 +eight 0 +patients 0 +in 0 +whom 0 +cocaine 1 +use 0 +was 0 +related 0 +to 0 +stroke 3 +and 0 +review 0 +39 0 +cases 0 +from 0 +the 0 +literature 0 +. 0 +Among 0 +these 0 +47 0 +patients 0 +the 0 +mean 0 +( 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +age 0 +was 0 +32 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +12 0 +. 0 +1 0 +years 0 +; 0 +76 0 +% 0 +( 0 +34 0 +/ 0 +45 0 +) 0 +were 0 +men 0 +. 0 +Stroke 3 +followed 0 +cocaine 1 +use 0 +by 0 +inhalation 0 +"," 0 +intranasal 0 +"," 0 +intravenous 0 +"," 0 +and 0 +intramuscular 0 +routes 0 +. 0 +Intracranial 3 +aneurysms 4 +or 0 +arteriovenous 3 +malformations 4 +were 0 +present 0 +in 0 +17 0 +of 0 +32 0 +patients 0 +studied 0 +angiographically 0 +or 0 +at 0 +autopsy 0 +; 0 +cerebral 3 +vasculitis 4 +was 0 +present 0 +in 0 +two 0 +patients 0 +. 0 +Cerebral 3 +infarction 4 +occurred 0 +in 0 +10 0 +patients 0 +( 0 +22 0 +% 0 +) 0 +"," 0 +intracerebral 3 +hemorrhage 4 +in 0 +22 0 +( 0 +49 0 +% 0 +) 0 +"," 0 +and 0 +subarachnoid 3 +hemorrhage 4 +in 0 +13 0 +( 0 +29 0 +% 0 +) 0 +. 0 +These 0 +data 0 +indicate 0 +that 0 +( 0 +1 0 +) 0 +the 0 +apparent 0 +incidence 0 +of 0 +stroke 3 +related 0 +to 0 +cocaine 1 +use 0 +is 0 +increasing 0 +; 0 +( 0 +2 0 +) 0 +cocaine 1 +- 0 +associated 0 +stroke 3 +occurs 0 +primarily 0 +in 0 +young 0 +adults 0 +; 0 +( 0 +3 0 +) 0 +stroke 3 +may 0 +follow 0 +any 0 +route 0 +of 0 +cocaine 1 +administration 0 +; 0 +( 0 +4 0 +) 0 +stroke 3 +after 0 +cocaine 1 +use 0 +is 0 +frequently 0 +associated 0 +with 0 +intracranial 3 +aneurysms 4 +and 0 +arteriovenous 3 +malformations 4 +; 0 +and 0 +( 0 +5 0 +) 0 +in 0 +cocaine 1 +- 0 +associated 0 +stroke 3 +"," 0 +the 0 +frequency 0 +of 0 +intracranial 3 +hemorrhage 4 +exceeds 0 +that 0 +of 0 +cerebral 3 +infarction 4 +. 0 +A 0 +randomized 0 +comparison 0 +of 0 +labetalol 1 +and 0 +nitroprusside 1 +for 0 +induced 0 +hypotension 3 +. 0 +In 0 +a 0 +randomized 0 +study 0 +"," 0 +labetalol 1 +- 0 +induced 0 +hypotension 3 +and 0 +nitroprusside 1 +- 0 +induced 0 +hypotension 3 +were 0 +compared 0 +in 0 +20 0 +patients 0 +( 0 +10 0 +in 0 +each 0 +group 0 +) 0 +scheduled 0 +for 0 +major 0 +orthopedic 0 +procedures 0 +. 0 +Each 0 +patient 0 +was 0 +subjected 0 +to 0 +an 0 +identical 0 +anesthetic 0 +protocol 0 +and 0 +similar 0 +drug 0 +- 0 +induced 0 +reductions 3 +in 4 +mean 4 +arterial 4 +blood 4 +pressure 4 +( 0 +BP 0 +) 0 +( 0 +50 0 +to 0 +55 0 +mmHg 0 +) 0 +. 0 +Nitroprusside 0 +infusion 0 +was 0 +associated 0 +with 0 +a 0 +significant 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +increase 3 +in 4 +heart 4 +rate 4 +and 4 +cardiac 4 +output 4 +; 0 +rebound 0 +hypertension 3 +was 0 +observed 0 +in 0 +three 0 +patients 0 +after 0 +discontinuation 0 +of 0 +nitroprusside 1 +. 0 +Labetalol 1 +administration 0 +was 0 +not 0 +associated 0 +with 0 +any 0 +of 0 +these 0 +findings 0 +. 0 +Arterial 0 +P02 1 +decreased 0 +in 0 +both 0 +groups 0 +. 0 +It 0 +was 0 +concluded 0 +that 0 +labetalol 1 +offers 0 +advantages 0 +over 0 +nitroprusside 1 +. 0 +Sodium 1 +status 0 +influences 0 +chronic 0 +amphotericin 1 +B 2 +nephrotoxicity 3 +in 0 +rats 0 +. 0 +The 0 +nephrotoxic 3 +potential 0 +of 0 +amphotericin 1 +B 2 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +intraperitoneally 0 +for 0 +3 0 +weeks 0 +) 0 +has 0 +been 0 +investigated 0 +in 0 +salt 0 +- 0 +depleted 0 +"," 0 +normal 0 +- 0 +salt 0 +"," 0 +and 0 +salt 0 +- 0 +loaded 0 +rats 0 +. 0 +In 0 +salt 0 +- 0 +depleted 0 +rats 0 +"," 0 +amphotericin 1 +B 2 +decreased 0 +creatinine 1 +clearance 0 +linearly 0 +with 0 +time 0 +"," 0 +with 0 +an 0 +85 0 +% 0 +reduction 0 +by 0 +week 0 +3 0 +. 0 +In 0 +contrast 0 +"," 0 +in 0 +normal 0 +- 0 +salt 0 +rats 0 +creatinine 1 +clearance 0 +was 0 +decreased 0 +but 0 +to 0 +a 0 +lesser 0 +extent 0 +at 0 +week 0 +2 0 +and 0 +3 0 +"," 0 +and 0 +in 0 +salt 0 +- 0 +loaded 0 +rats 0 +creatinine 1 +clearance 0 +did 0 +not 0 +change 0 +for 0 +2 0 +weeks 0 +and 0 +was 0 +decreased 0 +by 0 +43 0 +% 0 +at 0 +week 0 +3 0 +. 0 +All 0 +rats 0 +in 0 +the 0 +sodium 1 +- 0 +depleted 0 +group 0 +had 0 +histopathological 0 +evidence 0 +of 0 +patchy 0 +tubular 0 +cytoplasmic 0 +degeneration 0 +in 0 +tubules 0 +that 0 +was 0 +not 0 +observed 0 +in 0 +any 0 +normal 0 +- 0 +salt 0 +or 0 +salt 0 +- 0 +loaded 0 +rat 0 +. 0 +Concentrations 0 +of 0 +amphotericin 1 +B 2 +in 0 +plasma 0 +were 0 +not 0 +significantly 0 +different 0 +among 0 +the 0 +three 0 +groups 0 +at 0 +any 0 +time 0 +during 0 +the 0 +study 0 +. 0 +However 0 +"," 0 +at 0 +the 0 +end 0 +of 0 +3 0 +weeks 0 +"," 0 +amphotericin 1 +B 2 +levels 0 +in 0 +the 0 +kidneys 0 +and 0 +liver 0 +were 0 +significantly 0 +higher 0 +in 0 +salt 0 +- 0 +depleted 0 +and 0 +normal 0 +- 0 +salt 0 +rats 0 +than 0 +those 0 +in 0 +salt 0 +- 0 +loaded 0 +rats 0 +"," 0 +with 0 +plasma 0 +/ 0 +kidney 0 +ratios 0 +of 0 +21 0 +"," 0 +14 0 +"," 0 +and 0 +8 0 +in 0 +salt 0 +- 0 +depleted 0 +"," 0 +normal 0 +- 0 +salt 0 +"," 0 +and 0 +salt 0 +- 0 +loaded 0 +rats 0 +"," 0 +respectively 0 +. 0 +In 0 +conclusion 0 +"," 0 +reductions 0 +in 0 +creatinine 1 +clearance 0 +and 0 +renal 0 +amphotericin 1 +B 2 +accumulation 0 +after 0 +chronic 0 +amphotericin 1 +B 2 +administration 0 +were 0 +enhanced 0 +by 0 +salt 0 +depletion 0 +and 0 +attenuated 0 +by 0 +sodium 1 +loading 0 +in 0 +rats 0 +. 0 +Flestolol 1 +: 0 +an 0 +ultra 0 +- 0 +short 0 +- 0 +acting 0 +beta 0 +- 0 +adrenergic 0 +blocking 0 +agent 0 +. 0 +Flestolol 1 +( 0 +ACC 1 +- 2 +9089 2 +) 0 +is 0 +a 0 +nonselective 0 +"," 0 +competitive 0 +"," 0 +ultra 0 +- 0 +short 0 +- 0 +acting 0 +beta 0 +- 0 +adrenergic 0 +blocking 0 +agent 0 +"," 0 +without 0 +any 0 +intrinsic 0 +sympathomimetic 0 +activity 0 +. 0 +Flestolol 1 +is 0 +metabolized 0 +by 0 +plasma 0 +esterases 0 +and 0 +has 0 +an 0 +elimination 0 +half 0 +- 0 +life 0 +of 0 +approximately 0 +6 0 +. 0 +5 0 +minutes 0 +. 0 +This 0 +agent 0 +was 0 +well 0 +tolerated 0 +in 0 +healthy 0 +volunteers 0 +at 0 +doses 0 +up 0 +to 0 +100 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +. 0 +In 0 +long 0 +- 0 +term 0 +infusion 0 +studies 0 +"," 0 +flestolol 1 +was 0 +well 0 +tolerated 0 +at 0 +the 0 +effective 0 +beta 0 +- 0 +blocking 0 +dose 0 +( 0 +5 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +for 0 +up 0 +to 0 +seven 0 +days 0 +. 0 +Flestolol 1 +blood 0 +concentrations 0 +increased 0 +linearly 0 +with 0 +increasing 0 +dose 0 +and 0 +good 0 +correlation 0 +exists 0 +between 0 +blood 0 +concentrations 0 +of 0 +flestolol 1 +and 0 +beta 0 +- 0 +adrenergic 0 +blockade 0 +. 0 +Flestolol 1 +produced 0 +a 0 +dose 0 +- 0 +dependent 0 +attenuation 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +tachycardia 3 +. 0 +Electrophysiologic 0 +and 0 +hemodynamic 0 +effects 0 +of 0 +flestolol 1 +are 0 +similar 0 +to 0 +those 0 +of 0 +other 0 +beta 0 +blockers 0 +. 0 +In 0 +contrast 0 +with 0 +other 0 +beta 0 +blockers 0 +"," 0 +flestolol 1 +- 0 +induced 0 +effects 0 +reverse 0 +rapidly 0 +( 0 +within 0 +30 0 +minutes 0 +) 0 +following 0 +discontinuation 0 +because 0 +of 0 +its 0 +short 0 +half 0 +- 0 +life 0 +. 0 +Flestolol 1 +effectively 0 +reduced 0 +heart 0 +rate 0 +in 0 +patients 0 +with 0 +supraventricular 3 +tachyarrhythmia 4 +. 0 +In 0 +patients 0 +with 0 +unstable 3 +angina 4 +"," 0 +flestolol 1 +infusion 0 +was 0 +found 0 +to 0 +be 0 +safe 0 +and 0 +effective 0 +in 0 +controlling 0 +chest 3 +pain 4 +. 0 +It 0 +is 0 +concluded 0 +that 0 +flestolol 1 +is 0 +a 0 +potent 0 +"," 0 +well 0 +- 0 +tolerated 0 +"," 0 +ultra 0 +- 0 +short 0 +- 0 +acting 0 +beta 0 +- 0 +adrenergic 0 +blocking 0 +agent 0 +. 0 +Use 0 +of 0 +flestolol 1 +in 0 +the 0 +critical 0 +care 0 +setting 0 +is 0 +currently 0 +undergoing 0 +investigation 0 +. 0 +Immunohistochemical 0 +"," 0 +electron 0 +microscopic 0 +and 0 +morphometric 0 +studies 0 +of 0 +estrogen 1 +- 0 +induced 0 +rat 0 +prolactinomas 3 +after 0 +bromocriptine 1 +treatment 0 +. 0 +To 0 +clarify 0 +the 0 +effects 0 +of 0 +bromocriptine 1 +on 0 +prolactinoma 3 +cells 0 +in 0 +vivo 0 +"," 0 +immunohistochemical 0 +"," 0 +ultrastructural 0 +and 0 +morphometrical 0 +analyses 0 +were 0 +applied 0 +to 0 +estrogen 1 +- 0 +induced 0 +rat 0 +prolactinoma 3 +cells 0 +1 0 +h 0 +and 0 +6 0 +h 0 +after 0 +injection 0 +of 0 +bromocriptine 1 +( 0 +3 0 +mg 0 +/ 0 +kg 0 +of 0 +body 0 +weight 0 +) 0 +. 0 +0ne 0 +h 0 +after 0 +treatment 0 +"," 0 +serum 0 +prolactin 0 +levels 0 +decreased 0 +markedly 0 +. 0 +Electron 0 +microscopy 0 +disclosed 0 +many 0 +secretory 0 +granules 0 +"," 0 +slightly 0 +distorted 0 +rough 0 +endoplasmic 0 +reticulum 0 +"," 0 +and 0 +partially 0 +dilated 0 +Golgi 0 +cisternae 0 +in 0 +the 0 +prolactinoma 3 +cells 0 +. 0 +Morphometric 0 +analysis 0 +revealed 0 +that 0 +the 0 +volume 0 +density 0 +of 0 +secretory 0 +granules 0 +increased 0 +"," 0 +while 0 +the 0 +volume 0 +density 0 +of 0 +cytoplasmic 0 +microtubules 0 +decreased 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +lowered 0 +serum 0 +prolactin 0 +levels 0 +in 0 +the 0 +early 0 +phase 0 +of 0 +bromocriptine 1 +treatment 0 +may 0 +result 0 +from 0 +an 0 +impaired 0 +secretion 0 +of 0 +prolactin 0 +due 0 +to 0 +decreasing 0 +numbers 0 +of 0 +cytoplasmic 0 +microtubules 0 +. 0 +At 0 +6 0 +h 0 +after 0 +injection 0 +"," 0 +serum 0 +prolactin 0 +levels 0 +were 0 +still 0 +considerably 0 +lower 0 +than 0 +in 0 +controls 0 +. 0 +The 0 +prolactinoma 3 +cells 0 +at 0 +this 0 +time 0 +were 0 +well 0 +granulated 0 +"," 0 +with 0 +vesiculated 0 +rough 0 +endoplasmic 0 +reticulum 0 +and 0 +markedly 0 +dilated 0 +Golgi 0 +cisternae 0 +. 0 +Electron 0 +microscopical 0 +immunohistochemistry 0 +revealed 0 +positive 0 +reaction 0 +products 0 +noted 0 +on 0 +the 0 +secretory 0 +granules 0 +"," 0 +Golgi 0 +cisternae 0 +"," 0 +and 0 +endoplasmic 0 +reticulum 0 +of 0 +the 0 +untreated 0 +rat 0 +prolactinoma 3 +cells 0 +. 0 +However 0 +"," 0 +only 0 +secretory 0 +granules 0 +showed 0 +the 0 +positive 0 +reaction 0 +products 0 +for 0 +prolactin 0 +6 0 +h 0 +after 0 +bromocriptine 1 +treatment 0 +of 0 +the 0 +adenoma 3 +cells 0 +. 0 +An 0 +increase 0 +in 0 +the 0 +volume 0 +density 0 +of 0 +secretory 0 +granules 0 +and 0 +a 0 +decrease 0 +in 0 +the 0 +volume 0 +densities 0 +of 0 +rough 0 +endoplasmic 0 +reticulum 0 +and 0 +microtubules 0 +was 0 +determined 0 +by 0 +morphometric 0 +analysis 0 +"," 0 +suggesting 0 +that 0 +bromocriptine 1 +inhibits 0 +protein 0 +synthesis 0 +as 0 +well 0 +as 0 +bringing 0 +about 0 +a 0 +disturbance 0 +of 0 +the 0 +prolactin 0 +secretion 0 +. 0 +Sulfasalazine 1 +- 0 +induced 0 +lupus 3 +erythematosus 4 +. 0 +Pneumonitis 3 +"," 0 +bilateral 0 +pleural 3 +effusions 4 +"," 0 +echocardiographic 0 +evidence 0 +of 0 +cardiac 3 +tamponade 4 +"," 0 +and 0 +positive 0 +autoantibodies 0 +developed 0 +in 0 +a 0 +43 0 +- 0 +year 0 +- 0 +old 0 +man 0 +"," 0 +who 0 +was 0 +receiving 0 +long 0 +- 0 +term 0 +sulfasalazine 1 +therapy 0 +for 0 +chronic 0 +ulcerative 3 +colitis 4 +. 0 +After 0 +cessation 0 +of 0 +the 0 +sulfasalazine 1 +and 0 +completion 0 +of 0 +a 0 +six 0 +- 0 +week 0 +course 0 +of 0 +corticosteroids 0 +"," 0 +these 0 +problems 0 +resolved 0 +over 0 +a 0 +period 0 +of 0 +four 0 +to 0 +six 0 +months 0 +. 0 +It 0 +is 0 +suggested 0 +that 0 +the 0 +patient 0 +had 0 +sulfasalazine 1 +- 0 +induced 0 +lupus 3 +"," 0 +which 0 +manifested 0 +with 0 +serositis 3 +and 0 +pulmonary 0 +parenchymal 0 +involvement 0 +in 0 +the 0 +absence 0 +of 0 +joint 0 +symptoms 0 +. 0 +Physicians 0 +who 0 +use 0 +sulfasalazine 1 +to 0 +treat 0 +patients 0 +with 0 +inflammatory 3 +bowel 4 +disease 4 +should 0 +be 0 +aware 0 +of 0 +the 0 +signs 0 +of 0 +sulfasalazine 1 +- 0 +induced 0 +lupus 3 +syndrome 4 +. 0 +Chronic 0 +carbamazepine 1 +treatment 0 +in 0 +the 0 +rat 0 +: 0 +efficacy 0 +"," 0 +toxicity 3 +"," 0 +and 0 +effect 0 +on 0 +plasma 0 +and 0 +tissue 0 +folate 1 +concentrations 0 +. 0 +Folate 1 +depletion 0 +has 0 +often 0 +been 0 +a 0 +problem 0 +in 0 +chronic 0 +antiepileptic 0 +drug 0 +( 0 +AED 0 +) 0 +therapy 0 +. 0 +Carbamazepine 1 +( 0 +CBZ 1 +) 0 +"," 0 +a 0 +commonly 0 +used 0 +AED 0 +"," 0 +has 0 +been 0 +implicated 0 +in 0 +some 0 +clinical 0 +studies 0 +. 0 +A 0 +rat 0 +model 0 +was 0 +developed 0 +to 0 +examine 0 +the 0 +effects 0 +of 0 +chronic 0 +CBZ 1 +treatment 0 +on 0 +folate 1 +concentrations 0 +in 0 +the 0 +rat 0 +. 0 +In 0 +the 0 +course 0 +of 0 +developing 0 +this 0 +model 0 +"," 0 +a 0 +common 0 +vehicle 0 +"," 0 +propylene 1 +glycol 2 +"," 0 +by 0 +itself 0 +in 0 +high 0 +doses 0 +"," 0 +was 0 +found 0 +to 0 +exhibit 0 +protective 0 +properties 0 +against 0 +induced 0 +seizures 3 +and 0 +inhibited 0 +weight 3 +gain 4 +. 0 +Seizures 3 +induced 0 +by 0 +hexafluorodiethyl 1 +ether 2 +( 0 +HFDE 1 +) 0 +were 0 +also 0 +found 0 +to 0 +be 0 +a 0 +more 0 +sensitive 0 +measure 0 +of 0 +protection 0 +by 0 +CBZ 1 +than 0 +seizures 3 +induced 0 +by 0 +maximal 0 +electroshock 0 +( 0 +MES 0 +) 0 +. 0 +0ral 0 +administration 0 +of 0 +CBZ 1 +as 0 +an 0 +aqueous 0 +suspension 0 +every 0 +8 0 +h 0 +at 0 +a 0 +dose 0 +of 0 +250 0 +mg 0 +/ 0 +kg 0 +was 0 +continuously 0 +protective 0 +against 0 +HFDE 1 +- 0 +induced 0 +seizures 3 +and 0 +was 0 +minimally 0 +toxic 0 +as 0 +measured 0 +by 0 +weight 3 +gain 4 +over 0 +8 0 +weeks 0 +of 0 +treatment 0 +. 0 +The 0 +CBZ 1 +levels 0 +measured 0 +in 0 +plasma 0 +and 0 +brain 0 +of 0 +these 0 +animals 0 +"," 0 +however 0 +"," 0 +were 0 +below 0 +those 0 +normally 0 +considered 0 +protective 0 +. 0 +This 0 +treatment 0 +with 0 +CBZ 1 +had 0 +no 0 +apparent 0 +adverse 0 +effect 0 +on 0 +folate 1 +concentrations 0 +in 0 +the 0 +rat 0 +"," 0 +and 0 +"," 0 +indeed 0 +"," 0 +the 0 +folate 1 +concentration 0 +increased 0 +in 0 +liver 0 +after 0 +6 0 +weeks 0 +of 0 +treatment 0 +and 0 +in 0 +plasma 0 +at 0 +8 0 +weeks 0 +of 0 +treatment 0 +. 0 +Dipyridamole 1 +- 0 +induced 0 +myocardial 3 +ischemia 4 +. 0 +Angina 3 +and 0 +ischemic 0 +electrocardiographic 0 +changes 0 +occurred 0 +after 0 +administration 0 +of 0 +oral 0 +dipyridamole 1 +in 0 +four 0 +patients 0 +awaiting 0 +urgent 0 +myocardial 0 +revascularization 0 +procedures 0 +. 0 +To 0 +our 0 +knowledge 0 +"," 0 +this 0 +has 0 +not 0 +previously 0 +been 0 +reported 0 +as 0 +a 0 +side 0 +effect 0 +of 0 +preoperative 0 +dipyridamole 1 +therapy 0 +"," 0 +although 0 +dipyridamole 1 +- 0 +induced 0 +myocardial 3 +ischemia 4 +has 0 +been 0 +demonstrated 0 +to 0 +occur 0 +in 0 +animals 0 +and 0 +humans 0 +with 0 +coronary 3 +artery 4 +disease 4 +. 0 +Epicardial 0 +coronary 0 +collateral 0 +vessels 0 +were 0 +demonstrated 0 +in 0 +all 0 +four 0 +patients 0 +; 0 +a 0 +coronary 0 +" 0 +steal 0 +" 0 +phenomenon 0 +may 0 +be 0 +the 0 +mechanism 0 +of 0 +the 0 +dipyridamole 1 +- 0 +induced 0 +ischemia 3 +observed 0 +. 0 +Inhibition 0 +of 0 +sympathoadrenal 0 +activity 0 +by 0 +atrial 0 +natriuretic 0 +factor 0 +in 0 +dogs 0 +. 0 +In 0 +six 0 +conscious 0 +"," 0 +trained 0 +dogs 0 +"," 0 +maintained 0 +on 0 +a 0 +normal 0 +sodium 1 +intake 0 +of 0 +2 0 +to 0 +4 0 +mEq 0 +/ 0 +kg 0 +/ 0 +day 0 +"," 0 +sympathetic 0 +activity 0 +was 0 +assessed 0 +as 0 +the 0 +release 0 +rate 0 +of 0 +norepinephrine 1 +and 0 +epinephrine 1 +during 0 +15 0 +- 0 +minute 0 +i 0 +. 0 +v 0 +. 0 +infusions 0 +of 0 +human 0 +alpha 0 +- 0 +atrial 0 +natriuretic 0 +factor 0 +. 0 +Mean 0 +arterial 0 +pressure 0 +( 0 +as 0 +a 0 +percentage 0 +of 0 +control 0 ++ 0 +/ 0 +- 0 +SEM 0 +) 0 +during 0 +randomized 0 +infusions 0 +of 0 +0 0 +. 0 +3 0 +"," 0 +0 0 +. 0 +1 0 +"," 0 +0 0 +. 0 +3 0 +"," 0 +or 0 +1 0 +. 0 +0 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +was 0 +99 0 ++ 0 +/ 0 +- 0 +1 0 +"," 0 +95 0 ++ 0 +/ 0 +- 0 +1 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +93 0 ++ 0 +/ 0 +- 0 +1 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +or 0 +79 0 ++ 0 +/ 0 +- 0 +6 0 +% 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +respectively 0 +"," 0 +but 0 +no 0 +tachycardia 3 +and 0 +no 0 +augmentation 0 +of 0 +the 0 +norepinephrine 1 +release 0 +rate 0 +( 0 +up 0 +to 0 +0 0 +. 0 +3 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +were 0 +observed 0 +"," 0 +which 0 +is 0 +in 0 +contrast 0 +to 0 +comparable 0 +hypotension 3 +induced 0 +by 0 +hydralazine 1 +or 0 +nitroglycerin 1 +. 0 +The 0 +release 0 +rate 0 +of 0 +epinephrine 1 +( 0 +control 0 +"," 0 +6 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +6 0 +ng 0 +/ 0 +kg 0 +/ 0 +min 0 +) 0 +declined 0 +immediately 0 +during 0 +infusions 0 +of 0 +atrial 0 +natriuretic 0 +factor 0 +to 0 +a 0 +minimum 0 +of 0 +49 0 ++ 0 +/ 0 +- 0 +5 0 +% 0 +of 0 +control 0 +( 0 +p 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +during 0 +0 0 +. 0 +1 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +and 0 +to 0 +63 0 ++ 0 +/ 0 +- 0 +5 0 +% 0 +( 0 +0 0 +. 0 +1 0 +greater 0 +than 0 +p 0 +greater 0 +than 0 +0 0 +. 0 +5 0 +) 0 +or 0 +95 0 ++ 0 +/ 0 +- 0 +13 0 +% 0 +( 0 +not 0 +significant 0 +) 0 +during 0 +0 0 +. 0 +3 0 +or 0 +1 0 +. 0 +0 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +. 0 +Steady 0 +state 0 +arterial 0 +plasma 0 +concentrations 0 +of 0 +atrial 0 +natriuretic 0 +factor 0 +were 0 +39 0 ++ 0 +/ 0 +- 0 +10 0 +pg 0 +/ 0 +ml 0 +( 0 +n 0 += 0 +6 0 +) 0 +during 0 +infusions 0 +of 0 +saline 0 +and 0 +284 0 ++ 0 +/ 0 +- 0 +24 0 +pg 0 +/ 0 +ml 0 +( 0 +n 0 += 0 +6 0 +) 0 +and 0 +1520 0 ++ 0 +/ 0 +- 0 +300 0 +pg 0 +/ 0 +ml 0 +( 0 +n 0 += 0 +9 0 +) 0 +during 0 +0 0 +. 0 +3 0 +and 0 +0 0 +. 0 +1 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +infusions 0 +of 0 +the 0 +factor 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Inhibition 0 +of 0 +immunoreactive 0 +corticotropin 0 +- 0 +releasing 0 +factor 0 +secretion 0 +into 0 +the 0 +hypophysial 0 +- 0 +portal 0 +circulation 0 +by 0 +delayed 0 +glucocorticoid 0 +feedback 0 +. 0 +Nitroprusside 1 +- 0 +induced 0 +hypotension 3 +evokes 0 +ACTH 0 +secretion 0 +which 0 +is 0 +primarily 0 +mediated 0 +by 0 +enhanced 0 +secretion 0 +of 0 +immunoreactive 0 +corticotropin 0 +- 0 +releasing 0 +factor 0 +( 0 +irCRF 0 +) 0 +into 0 +the 0 +hypophysial 0 +- 0 +portal 0 +circulation 0 +. 0 +Portal 0 +plasma 0 +concentrations 0 +of 0 +neither 0 +arginine 1 +vasopressin 2 +nor 0 +oxytocin 1 +are 0 +significantly 0 +altered 0 +in 0 +this 0 +paradigm 0 +. 0 +Application 0 +of 0 +a 0 +delayed 0 +feedback 0 +signal 0 +"," 0 +in 0 +the 0 +form 0 +of 0 +a 0 +2 0 +- 0 +h 0 +systemic 0 +corticosterone 1 +infusion 0 +in 0 +urethane 1 +- 0 +anesthetized 0 +rats 0 +with 0 +pharmacological 0 +blockade 0 +of 0 +glucocorticoid 0 +synthesis 0 +"," 0 +is 0 +without 0 +effect 0 +on 0 +the 0 +resting 0 +secretion 0 +of 0 +arginine 1 +vasopressin 2 +and 0 +oxytocin 1 +at 0 +any 0 +corticosterone 1 +feedback 0 +dose 0 +tested 0 +. 0 +Resting 0 +irCRF 0 +levels 0 +are 0 +suppressed 0 +only 0 +at 0 +the 0 +highest 0 +corticosterone 1 +infusion 0 +rate 0 +"," 0 +which 0 +resulted 0 +in 0 +systemic 0 +corticosterone 1 +levels 0 +of 0 +40 0 +micrograms 0 +/ 0 +dl 0 +. 0 +Suppression 0 +of 0 +irCRF 0 +secretion 0 +in 0 +response 0 +to 0 +nitroprusside 1 +- 0 +induced 0 +hypotension 3 +is 0 +observed 0 +and 0 +occurs 0 +at 0 +a 0 +plasma 0 +corticosterone 1 +level 0 +between 0 +8 0 +- 0 +12 0 +micrograms 0 +/ 0 +dl 0 +. 0 +These 0 +studies 0 +provide 0 +further 0 +evidence 0 +for 0 +a 0 +strong 0 +central 0 +component 0 +of 0 +the 0 +delayed 0 +feedback 0 +process 0 +which 0 +is 0 +mediated 0 +by 0 +modulation 0 +of 0 +irCRF 0 +release 0 +. 0 +Noradrenergic 0 +involvement 0 +in 0 +catalepsy 3 +induced 0 +by 0 +delta 1 +9 2 +- 2 +tetrahydrocannabinol 2 +. 0 +In 0 +order 0 +to 0 +elucidate 0 +the 0 +role 0 +of 0 +the 0 +catecholaminergic 0 +system 0 +in 0 +the 0 +cataleptogenic 0 +effect 0 +of 0 +delta 1 +9 2 +- 2 +tetrahydrocannabinol 2 +( 0 +THC 1 +) 0 +"," 0 +the 0 +effect 0 +of 0 +pretreatment 0 +with 0 +6 1 +- 2 +hydroxydopamine 2 +( 0 +6 1 +- 2 +0HDA 2 +) 0 +or 0 +with 0 +desipramine 1 +and 0 +6 1 +- 2 +0HDA 2 +and 0 +lesions 0 +of 0 +the 0 +locus 0 +coeruleus 0 +were 0 +investigated 0 +in 0 +rats 0 +. 0 +The 0 +cataleptogenic 0 +effect 0 +of 0 +THC 1 +was 0 +significantly 0 +reduced 0 +in 0 +rats 0 +treated 0 +with 0 +6 1 +- 2 +0HDA 2 +and 0 +in 0 +rats 0 +with 0 +lesions 0 +of 0 +the 0 +locus 0 +coeruleus 0 +but 0 +not 0 +in 0 +rats 0 +treated 0 +with 0 +desipramine 1 +and 0 +6 1 +- 2 +0HDA 2 +"," 0 +as 0 +compared 0 +with 0 +control 0 +rats 0 +. 0 +0n 0 +the 0 +contrary 0 +"," 0 +the 0 +cataleptogenic 0 +effect 0 +of 0 +haloperidol 1 +was 0 +significantly 0 +reduced 0 +in 0 +rats 0 +treated 0 +with 0 +desipramine 1 +and 0 +6 1 +- 2 +0HDA 2 +but 0 +not 0 +in 0 +rats 0 +treated 0 +with 0 +6 1 +- 2 +0HDA 2 +or 0 +in 0 +rats 0 +with 0 +lesions 0 +of 0 +the 0 +locus 0 +coeruleus 0 +. 0 +These 0 +results 0 +indicate 0 +that 0 +noradrenergic 0 +neurons 0 +have 0 +an 0 +important 0 +role 0 +in 0 +the 0 +manifestation 0 +of 0 +catalepsy 3 +induced 0 +by 0 +THC 1 +"," 0 +whereas 0 +dopaminergic 0 +neurons 0 +are 0 +important 0 +in 0 +catalepsy 3 +induced 0 +by 0 +haloperidol 1 +. 0 +Reversibility 0 +of 0 +captopril 1 +- 0 +induced 0 +renal 3 +insufficiency 4 +after 0 +prolonged 0 +use 0 +in 0 +an 0 +unusual 0 +case 0 +of 0 +renovascular 3 +hypertension 4 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +severe 0 +hypertension 3 +with 0 +an 0 +occluded 0 +renal 0 +artery 0 +to 0 +a 0 +solitary 0 +kidney 0 +"," 0 +who 0 +developed 0 +sudden 3 +deterioration 4 +of 4 +renal 4 +function 4 +following 0 +treatment 0 +with 0 +captopril 1 +. 0 +His 0 +renal 0 +function 0 +remained 0 +impaired 0 +but 0 +stable 0 +during 0 +2 0 +years 0 +' 0 +treatment 0 +with 0 +captopril 1 +but 0 +returned 0 +to 0 +pre 0 +- 0 +treatment 0 +levels 0 +soon 0 +after 0 +cessation 0 +of 0 +the 0 +drug 0 +. 0 +This 0 +indicates 0 +reversibility 0 +in 0 +captopril 1 +- 0 +induced 0 +renal 3 +failure 4 +even 0 +after 0 +its 0 +prolonged 0 +use 0 +and 0 +suggests 0 +that 0 +no 0 +organic 0 +damage 0 +occurs 0 +to 0 +glomerular 0 +arterioles 0 +following 0 +chronic 0 +ACE 0 +inhibition 0 +. 0 +HMG 0 +CoA 0 +reductase 0 +inhibitors 0 +. 0 +Current 0 +clinical 0 +experience 0 +. 0 +Lovastatin 1 +and 0 +simvastatin 1 +are 0 +the 0 +2 0 +best 0 +- 0 +known 0 +members 0 +of 0 +the 0 +class 0 +of 0 +hypolipidaemic 0 +agents 0 +known 0 +as 0 +HMG 0 +CoA 0 +reductase 0 +inhibitors 0 +. 0 +Clinical 0 +experience 0 +with 0 +lovastatin 1 +includes 0 +over 0 +5000 0 +patients 0 +"," 0 +700 0 +of 0 +whom 0 +have 0 +been 0 +treated 0 +for 0 +2 0 +years 0 +or 0 +more 0 +"," 0 +and 0 +experience 0 +with 0 +simvastatin 1 +includes 0 +over 0 +3500 0 +patients 0 +"," 0 +of 0 +whom 0 +350 0 +have 0 +been 0 +treated 0 +for 0 +18 0 +months 0 +or 0 +more 0 +. 0 +Lovastatin 1 +has 0 +been 0 +marketed 0 +in 0 +the 0 +United 0 +States 0 +for 0 +over 0 +6 0 +months 0 +. 0 +Both 0 +agents 0 +show 0 +substantial 0 +clinical 0 +efficacy 0 +"," 0 +with 0 +reductions 0 +in 0 +total 0 +cholesterol 1 +of 0 +over 0 +30 0 +% 0 +and 0 +in 0 +LDL 0 +- 0 +cholesterol 1 +of 0 +40 0 +% 0 +in 0 +clinical 0 +studies 0 +. 0 +Modest 0 +increases 0 +in 0 +HDL 0 +- 0 +cholesterol 1 +levels 0 +of 0 +about 0 +10 0 +% 0 +are 0 +also 0 +reported 0 +. 0 +Clinical 0 +tolerability 0 +of 0 +both 0 +agents 0 +has 0 +been 0 +good 0 +"," 0 +with 0 +fewer 0 +than 0 +3 0 +% 0 +of 0 +patients 0 +withdrawn 0 +from 0 +treatment 0 +because 0 +of 0 +clinical 0 +adverse 0 +experiences 0 +. 0 +0phthalmological 0 +examinations 0 +in 0 +over 0 +1100 0 +patients 0 +treated 0 +with 0 +one 0 +or 0 +the 0 +other 0 +agent 0 +have 0 +revealed 0 +no 0 +evidence 0 +of 0 +significant 0 +short 0 +term 0 +( 0 +up 0 +to 0 +2 0 +years 0 +) 0 +cataractogenic 0 +potential 0 +. 0 +0ne 0 +to 0 +2 0 +% 0 +of 0 +patients 0 +have 0 +elevations 0 +of 0 +serum 0 +transaminases 0 +to 0 +greater 0 +than 0 +3 0 +times 0 +the 0 +upper 0 +limit 0 +of 0 +normal 0 +. 0 +These 0 +episodes 0 +are 0 +asymptomatic 0 +and 0 +reversible 0 +when 0 +therapy 0 +is 0 +discontinued 0 +. 0 +Minor 0 +elevations 0 +of 0 +creatine 1 +kinase 0 +levels 0 +are 0 +reported 0 +in 0 +about 0 +5 0 +% 0 +of 0 +patients 0 +. 0 +Myopathy 3 +"," 0 +associated 0 +in 0 +some 0 +cases 0 +with 0 +myoglobinuria 3 +"," 0 +and 0 +in 0 +2 0 +cases 0 +with 0 +transient 0 +renal 3 +failure 4 +"," 0 +has 0 +been 0 +rarely 0 +reported 0 +with 0 +lovastatin 1 +"," 0 +especially 0 +in 0 +patients 0 +concomitantly 0 +treated 0 +with 0 +cyclosporin 1 +"," 0 +gemfibrozil 1 +or 0 +niacin 1 +. 0 +Lovastatin 1 +and 0 +simvastatin 1 +are 0 +both 0 +effective 0 +and 0 +well 0 +- 0 +tolerated 0 +agents 0 +for 0 +lowering 0 +elevated 0 +levels 0 +of 0 +serum 0 +cholesterol 1 +. 0 +As 0 +wider 0 +use 0 +confirms 0 +their 0 +safety 0 +profile 0 +"," 0 +they 0 +will 0 +gain 0 +increasing 0 +importance 0 +in 0 +the 0 +therapeutic 0 +approach 0 +to 0 +hypercholesterolaemia 3 +and 0 +its 0 +consequences 0 +. 0 +Hepatic 0 +reactions 0 +associated 0 +with 0 +ketoconazole 1 +in 0 +the 0 +United 0 +Kingdom 0 +. 0 +Ketoconazole 1 +was 0 +introduced 0 +in 0 +the 0 +United 0 +Kingdom 0 +in 0 +1981 0 +. 0 +By 0 +November 0 +1984 0 +the 0 +Committee 0 +on 0 +Safety 0 +of 0 +Medicines 0 +had 0 +received 0 +82 0 +reports 0 +of 0 +possible 0 +hepatotoxicity 3 +associated 0 +with 0 +the 0 +drug 0 +"," 0 +including 0 +five 0 +deaths 3 +. 0 +An 0 +analysis 0 +of 0 +the 0 +75 0 +cases 0 +that 0 +had 0 +been 0 +adequately 0 +followed 0 +up 0 +suggested 0 +that 0 +16 0 +"," 0 +including 0 +three 0 +deaths 3 +"," 0 +were 0 +probably 0 +related 0 +to 0 +treatment 0 +with 0 +the 0 +drug 0 +. 0 +0f 0 +the 0 +remainder 0 +"," 0 +48 0 +were 0 +possibly 0 +related 0 +to 0 +treatment 0 +"," 0 +five 0 +were 0 +unlikely 0 +to 0 +be 0 +so 0 +"," 0 +and 0 +six 0 +were 0 +unclassifiable 0 +. 0 +The 0 +mean 0 +age 0 +of 0 +patients 0 +in 0 +the 0 +16 0 +probable 0 +cases 0 +was 0 +57 0 +. 0 +9 0 +"," 0 +with 0 +hepatotoxicity 3 +being 0 +more 0 +common 0 +in 0 +women 0 +. 0 +The 0 +average 0 +duration 0 +of 0 +treatment 0 +before 0 +the 0 +onset 0 +of 0 +jaundice 3 +was 0 +61 0 +days 0 +. 0 +None 0 +of 0 +these 0 +well 0 +validated 0 +cases 0 +occurred 0 +within 0 +the 0 +first 0 +10 0 +days 0 +after 0 +treatment 0 +. 0 +The 0 +results 0 +of 0 +serum 0 +liver 0 +function 0 +tests 0 +suggested 0 +hepatocellular 3 +injury 4 +in 0 +10 0 +( 0 +63 0 +% 0 +) 0 +; 0 +the 0 +rest 0 +showed 0 +a 0 +mixed 0 +pattern 0 +. 0 +In 0 +contrast 0 +"," 0 +the 0 +results 0 +of 0 +histological 0 +examination 0 +of 0 +the 0 +liver 0 +often 0 +showed 0 +evidence 0 +of 0 +cholestasis 3 +. 0 +The 0 +characteristics 0 +of 0 +the 0 +48 0 +patients 0 +in 0 +the 0 +possible 0 +cases 0 +were 0 +similar 0 +. 0 +Allergic 0 +manifestations 0 +such 0 +as 0 +rash 3 +and 0 +eosinophilia 3 +were 0 +rare 0 +. 0 +Hepatitis 3 +was 0 +usually 0 +reversible 0 +when 0 +treatment 0 +was 0 +stopped 0 +"," 0 +with 0 +the 0 +results 0 +of 0 +liver 0 +function 0 +tests 0 +returning 0 +to 0 +normal 0 +after 0 +an 0 +average 0 +of 0 +3 0 +. 0 +1 0 +months 0 +. 0 +In 0 +two 0 +of 0 +the 0 +three 0 +deaths 3 +probably 0 +associated 0 +with 0 +ketoconazole 1 +treatment 0 +the 0 +drug 0 +had 0 +been 0 +continued 0 +after 0 +the 0 +onset 0 +of 0 +jaundice 3 +and 0 +other 0 +symptoms 0 +of 0 +hepatitis 3 +. 0 +Clinical 0 +and 0 +biochemical 0 +monitoring 0 +at 0 +regular 0 +intervals 0 +for 0 +evidence 0 +of 0 +hepatitis 3 +is 0 +advised 0 +during 0 +long 0 +term 0 +treatment 0 +with 0 +ketoconazole 1 +to 0 +prevent 0 +possible 0 +serious 0 +hepatic 3 +injury 4 +. 0 +Glyburide 1 +- 0 +induced 0 +hepatitis 3 +. 0 +Drug 0 +- 0 +induced 0 +hepatotoxicity 3 +"," 0 +although 0 +common 0 +"," 0 +has 0 +been 0 +reported 0 +only 0 +infrequently 0 +with 0 +sulfonylureas 1 +. 0 +For 0 +glyburide 1 +"," 0 +a 0 +second 0 +- 0 +generation 0 +sulfonylurea 1 +"," 0 +only 0 +two 0 +brief 0 +reports 0 +of 0 +hepatotoxicity 3 +exist 0 +. 0 +Two 0 +patients 0 +with 0 +type 3 +II 4 +diabetes 4 +mellitus 4 +developed 0 +an 0 +acute 3 +hepatitis 4 +- 4 +like 4 +syndrome 4 +soon 0 +after 0 +initiation 0 +of 0 +glyburide 1 +therapy 0 +. 0 +There 0 +was 0 +no 0 +serologic 0 +evidence 0 +of 0 +viral 3 +infection 4 +"," 0 +and 0 +a 0 +liver 0 +biopsy 0 +sample 0 +showed 0 +a 0 +histologic 0 +pattern 0 +consistent 0 +with 0 +drug 3 +- 4 +induced 4 +hepatitis 4 +. 0 +Both 0 +patients 0 +recovered 0 +quickly 0 +after 0 +stopping 0 +glyburide 1 +therapy 0 +and 0 +have 0 +remained 0 +well 0 +for 0 +a 0 +follow 0 +- 0 +up 0 +period 0 +of 0 +1 0 +year 0 +. 0 +Glyburide 1 +can 0 +produce 0 +an 0 +acute 3 +hepatitis 4 +- 4 +like 4 +illness 4 +in 0 +some 0 +persons 0 +. 0 +Intracranial 0 +pressure 0 +increases 0 +during 0 +alfentanil 1 +- 0 +induced 0 +rigidity 3 +. 0 +Intracranial 0 +pressure 0 +( 0 +ICP 0 +) 0 +was 0 +measured 0 +during 0 +alfentanil 1 +- 0 +induced 0 +rigidity 3 +in 0 +rats 0 +. 0 +Ten 0 +rats 0 +had 0 +arterial 0 +"," 0 +central 0 +venous 0 +( 0 +CVP 0 +) 0 +"," 0 +and 0 +subdural 0 +cannulae 0 +inserted 0 +under 0 +halothane 1 +anesthesia 0 +. 0 +The 0 +animals 0 +were 0 +mechanically 0 +ventilated 0 +to 0 +achieve 0 +normocarbia 0 +( 0 +PC02 0 += 0 +42 0 ++ 0 +/ 0 +- 0 +1 0 +mmHg 0 +"," 0 +mean 0 ++ 0 +/ 0 +- 0 +SE 0 +) 0 +. 0 +Following 0 +instrumentation 0 +"," 0 +halothane 1 +was 0 +discontinued 0 +and 0 +alfentanil 1 +( 0 +125 0 +mu 0 +/ 0 +kg 0 +) 0 +administered 0 +iv 0 +during 0 +emergence 0 +from 0 +halothane 1 +anesthesia 0 +. 0 +In 0 +the 0 +five 0 +rats 0 +that 0 +developed 0 +somatic 3 +rigidity 4 +"," 0 +ICP 0 +and 0 +CVP 0 +increased 0 +significantly 0 +above 0 +baseline 0 +( 0 +delta 0 +ICP 0 +7 0 +. 0 +5 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +0 0 +mmHg 0 +"," 0 +delta 0 +CVP 0 +5 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +1 0 +. 0 +3 0 +mmHg 0 +) 0 +. 0 +These 0 +variables 0 +returned 0 +to 0 +baseline 0 +when 0 +rigidity 3 +was 0 +abolished 0 +with 0 +metocurine 1 +. 0 +In 0 +five 0 +rats 0 +that 0 +did 0 +not 0 +become 0 +rigid 0 +"," 0 +ICP 0 +and 0 +CVP 0 +did 0 +not 0 +change 0 +following 0 +alfentanil 1 +. 0 +These 0 +observations 0 +suggest 0 +that 0 +rigidity 3 +should 0 +be 0 +prevented 0 +when 0 +alfentanil 1 +"," 0 +and 0 +"," 0 +presumably 0 +"," 0 +other 0 +opiates 0 +"," 0 +are 0 +used 0 +in 0 +the 0 +anesthetic 0 +management 0 +of 0 +patients 0 +with 0 +ICP 0 +problems 0 +. 0 +Verapamil 1 +withdrawal 0 +as 0 +a 0 +possible 0 +cause 0 +of 0 +myocardial 3 +infarction 4 +in 0 +a 0 +hypertensive 3 +woman 0 +with 0 +a 0 +normal 0 +coronary 0 +angiogram 0 +. 0 +Verapamil 1 +is 0 +an 0 +effective 0 +and 0 +relatively 0 +- 0 +safe 0 +antihypertensive 0 +drug 0 +. 0 +Serious 0 +adverse 0 +effects 0 +are 0 +uncommon 0 +and 0 +mainly 0 +have 0 +been 0 +related 0 +to 0 +the 0 +depression 3 +of 0 +cardiac 0 +contractility 0 +and 0 +conduction 0 +"," 0 +especially 0 +when 0 +the 0 +drug 0 +is 0 +combined 0 +with 0 +beta 0 +- 0 +blocking 0 +agents 0 +. 0 +We 0 +report 0 +a 0 +case 0 +in 0 +which 0 +myocardial 3 +infarction 4 +coincided 0 +with 0 +the 0 +introduction 0 +of 0 +captopril 1 +and 0 +the 0 +withdrawal 0 +of 0 +verapamil 1 +in 0 +a 0 +previously 0 +asymptomatic 0 +woman 0 +with 0 +severe 0 +hypertension 3 +. 0 +Possible 0 +mechanisms 0 +that 0 +involve 0 +a 0 +verapamil 1 +- 0 +related 0 +increase 0 +in 0 +platelet 0 +and 0 +/ 0 +or 0 +vascular 0 +alpha 0 +2 0 +- 0 +adrenoreceptor 0 +affinity 0 +for 0 +catecholamines 1 +are 0 +discussed 0 +. 0 +Haemolytic 3 +- 4 +uraemic 4 +syndrome 4 +after 0 +treatment 0 +with 0 +metronidazole 1 +. 0 +This 0 +paper 0 +describes 0 +the 0 +clinical 0 +features 0 +of 0 +six 0 +children 0 +who 0 +developed 0 +the 0 +haemolytic 3 +- 4 +uraemic 4 +syndrome 4 +after 0 +treatment 0 +with 0 +metronidazole 1 +. 0 +These 0 +children 0 +were 0 +older 0 +and 0 +were 0 +more 0 +likely 0 +to 0 +have 0 +undergone 0 +recent 0 +bowel 0 +surgery 0 +than 0 +are 0 +other 0 +children 0 +with 0 +this 0 +condition 0 +. 0 +While 0 +the 0 +involvement 0 +of 0 +metronidazole 1 +in 0 +the 0 +aetiology 0 +of 0 +the 0 +haemolytic 3 +- 4 +uraemic 4 +syndrome 4 +is 0 +not 0 +established 0 +firmly 0 +"," 0 +the 0 +action 0 +of 0 +this 0 +drug 0 +in 0 +sensitizing 0 +tissues 0 +to 0 +oxidation 0 +injury 0 +and 0 +the 0 +reported 0 +evidence 0 +of 0 +oxidation 0 +changes 0 +in 0 +the 0 +haemolytic 3 +- 4 +uraemic 4 +syndrome 4 +suggest 0 +a 0 +possible 0 +link 0 +between 0 +metronidazole 1 +treatment 0 +and 0 +some 0 +cases 0 +of 0 +the 0 +haemolytic 3 +- 4 +uraemic 4 +syndrome 4 +. 0 +Adverse 0 +cardiac 0 +effects 0 +during 0 +induction 0 +chemotherapy 0 +treatment 0 +with 0 +cis 1 +- 2 +platin 2 +and 0 +5 1 +- 2 +fluorouracil 2 +. 0 +Survival 0 +for 0 +patients 0 +with 0 +advanced 0 +head 3 +and 4 +neck 4 +carcinoma 4 +and 0 +esophageal 3 +carcinoma 4 +is 0 +poor 0 +with 0 +radiotherapy 0 +and 0 +/ 0 +or 0 +surgery 0 +. 0 +0bviously 0 +"," 0 +there 0 +is 0 +a 0 +need 0 +for 0 +effective 0 +chemotherapy 0 +. 0 +In 0 +the 0 +present 0 +study 0 +"," 0 +cis 1 +- 2 +platin 2 +( 0 +80 0 +- 0 +120 0 +mg 0 +/ 0 +m2BSA 0 +) 0 +and 0 +5 1 +- 2 +FU 2 +( 0 +1000 0 +mg 0 +/ 0 +m2BSA 0 +daily 0 +as 0 +a 0 +continuous 0 +infusion 0 +during 0 +5 0 +days 0 +) 0 +were 0 +given 0 +to 0 +76 0 +patients 0 +before 0 +radiotherapy 0 +and 0 +surgery 0 +. 0 +The 0 +aim 0 +of 0 +the 0 +study 0 +was 0 +to 0 +clarify 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +adverse 0 +cardiac 0 +effects 0 +to 0 +this 0 +treatment 0 +. 0 +Before 0 +treatment 0 +all 0 +patients 0 +had 0 +a 0 +cardiac 0 +evaluation 0 +and 0 +during 0 +treatment 0 +serial 0 +ECG 0 +recordings 0 +were 0 +performed 0 +. 0 +In 0 +the 0 +pre 0 +- 0 +treatment 0 +evaluation 0 +"," 0 +signs 0 +of 0 +cardiovascular 3 +disease 4 +were 0 +found 0 +in 0 +33 0 +patients 0 +( 0 +43 0 +% 0 +) 0 +. 0 +During 0 +treatment 0 +"," 0 +adverse 0 +cardiac 0 +effects 0 +were 0 +observed 0 +in 0 +14 0 +patients 0 +( 0 +18 0 +% 0 +) 0 +. 0 +The 0 +mean 0 +age 0 +of 0 +these 0 +patients 0 +was 0 +the 0 +same 0 +as 0 +for 0 +the 0 +entire 0 +group 0 +"," 0 +64 0 +years 0 +. 0 +The 0 +incidence 0 +of 0 +cardiotoxicity 3 +was 0 +not 0 +higher 0 +in 0 +patients 0 +with 0 +signs 0 +of 0 +cardiovascular 3 +disease 4 +than 0 +in 0 +those 0 +without 0 +in 0 +the 0 +pre 0 +- 0 +treatment 0 +evaluation 0 +. 0 +The 0 +most 0 +common 0 +signs 0 +of 0 +cardiotoxicity 3 +were 0 +chest 3 +pain 4 +"," 0 +ST 0 +- 0 +T 0 +wave 0 +changes 0 +and 0 +atrial 3 +fibrillation 4 +. 0 +This 0 +was 0 +followed 0 +by 0 +ventricular 3 +fibrillation 4 +in 0 +one 0 +patient 0 +and 0 +sudden 3 +death 4 +in 0 +another 0 +. 0 +It 0 +is 0 +concluded 0 +that 0 +patients 0 +on 0 +5 1 +- 2 +FU 2 +treatment 0 +should 0 +be 0 +under 0 +close 0 +supervision 0 +and 0 +that 0 +the 0 +treatment 0 +should 0 +be 0 +discontinued 0 +if 0 +chest 3 +pain 4 +or 0 +tachyarrhythmia 3 +is 0 +observed 0 +. 0 +Death 3 +from 0 +chemotherapy 0 +in 0 +gestational 3 +trophoblastic 4 +disease 4 +. 0 +Multiple 0 +cytotoxic 0 +drug 0 +administration 0 +is 0 +the 0 +generally 0 +accepted 0 +treatment 0 +of 0 +patients 0 +with 0 +a 0 +high 0 +- 0 +risk 0 +stage 0 +of 0 +choriocarcinoma 3 +. 0 +Based 0 +on 0 +this 0 +principle 0 +a 0 +27 0 +- 0 +year 0 +old 0 +woman 0 +"," 0 +classified 0 +as 0 +being 0 +in 0 +the 0 +high 0 +- 0 +risk 0 +group 0 +( 0 +Goldstein 0 +and 0 +Berkowitz 0 +score 0 +: 0 +11 0 +) 0 +"," 0 +was 0 +treated 0 +with 0 +multiple 0 +cytotoxic 0 +drugs 0 +. 0 +The 0 +multiple 0 +drug 0 +schema 0 +consisted 0 +of 0 +: 0 +Etoposide 1 +16 0 +. 0 +213 0 +"," 0 +Methotrexate 1 +"," 0 +Cyclophosphamide 1 +"," 0 +Actomycin 1 +- 2 +D 2 +"," 0 +and 0 +Cisplatin 1 +. 0 +0n 0 +the 0 +first 0 +day 0 +of 0 +the 0 +schedule 0 +"," 0 +moderate 0 +high 0 +doses 0 +of 0 +Methotrexate 1 +"," 0 +Etoposide 1 +and 0 +Cyclophosphamide 1 +were 0 +administered 0 +. 0 +Within 0 +8 0 +hours 0 +after 0 +initiation 0 +of 0 +therapy 0 +the 0 +patient 0 +died 0 +with 0 +a 0 +clinical 0 +picture 0 +resembling 0 +massive 0 +pulmonary 3 +obstruction 4 +due 0 +to 0 +choriocarcinomic 0 +tissue 0 +plugs 0 +"," 0 +probably 0 +originating 0 +from 0 +the 0 +uterus 0 +. 0 +Formation 0 +of 0 +these 0 +plugs 0 +was 0 +probably 0 +due 0 +to 0 +extensive 0 +tumor 3 +necrosis 3 +at 0 +the 0 +level 0 +of 0 +the 0 +walls 0 +of 0 +the 0 +major 0 +uterine 0 +veins 0 +"," 0 +which 0 +resulted 0 +in 0 +an 0 +open 0 +exchange 0 +of 0 +tumor 3 +plugs 0 +to 0 +the 0 +vascular 0 +spaces 0 +; 0 +decrease 0 +in 0 +tumor 3 +tissue 0 +coherence 0 +secondary 0 +to 0 +chemotherapy 0 +may 0 +have 0 +further 0 +contributed 0 +to 0 +the 0 +formation 0 +of 0 +tumor 3 +emboli 0 +. 0 +In 0 +view 0 +of 0 +the 0 +close 0 +time 0 +association 0 +between 0 +the 0 +start 0 +of 0 +chemotherapy 0 +and 0 +the 0 +acute 0 +onset 0 +of 0 +massive 0 +embolism 3 +other 0 +explanations 0 +"," 0 +such 0 +as 0 +spontaneous 0 +necrosis 3 +"," 0 +must 0 +be 0 +considered 0 +less 0 +likely 0 +. 0 +Patients 0 +with 0 +large 0 +pelvic 3 +tumor 4 +loads 0 +are 0 +"," 0 +according 0 +to 0 +existing 0 +classifications 0 +"," 0 +at 0 +high 0 +risk 0 +to 0 +die 0 +and 0 +to 0 +develop 0 +drug 0 +resistance 0 +. 0 +Notwithstanding 0 +these 0 +facts 0 +our 0 +findings 0 +suggest 0 +that 0 +these 0 +patients 0 +might 0 +benefit 0 +from 0 +relatively 0 +mild 0 +initial 0 +treatment 0 +"," 0 +especially 0 +TRUE 0 +for 0 +patients 0 +not 0 +previously 0 +exposed 0 +to 0 +this 0 +drug 0 +. 0 +Close 0 +observation 0 +of 0 +the 0 +response 0 +status 0 +both 0 +clinically 0 +and 0 +with 0 +beta 0 +- 0 +hCG 0 +values 0 +may 0 +indicate 0 +whether 0 +and 0 +when 0 +more 0 +agressive 0 +combination 0 +chemotherapy 0 +should 0 +be 0 +started 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Pulmonary 0 +shunt 0 +and 0 +cardiovascular 0 +responses 0 +to 0 +CPAP 0 +during 0 +nitroprusside 1 +- 0 +induced 0 +hypotension 3 +. 0 +The 0 +effects 0 +of 0 +continuous 0 +positive 0 +airway 0 +pressure 0 +( 0 +CPAP 0 +) 0 +on 0 +cardiovascular 0 +dynamics 0 +and 0 +pulmonary 0 +shunt 0 +( 0 +QS 0 +/ 0 +QT 0 +) 0 +were 0 +investigated 0 +in 0 +12 0 +dogs 0 +before 0 +and 0 +during 0 +sodium 1 +nitroprusside 2 +infusion 0 +that 0 +decreased 0 +mean 0 +arterial 0 +blood 0 +pressure 0 +40 0 +- 0 +50 0 +per 0 +cent 0 +. 0 +Before 0 +nitroprusside 1 +infusion 0 +"," 0 +5 0 +cm 0 +H20 1 +CPAP 0 +significantly 0 +"," 0 +P 0 +less 0 +than 0 +. 0 +5 0 +"," 0 +decreased 0 +arterial 0 +blood 0 +pressure 0 +"," 0 +but 0 +did 0 +not 0 +significantly 0 +alter 0 +heart 0 +rate 0 +"," 0 +cardiac 0 +output 0 +"," 0 +systemic 0 +vascular 0 +resistance 0 +"," 0 +or 0 +QS 0 +/ 0 +QT 0 +. 0 +Ten 0 +cm 0 +H20 1 +CPAP 0 +before 0 +nitroprusside 1 +infusion 0 +produced 0 +a 0 +further 0 +decrease 3 +in 4 +arterial 4 +blood 4 +pressure 4 +and 0 +significantly 0 +increased 0 +heart 0 +rate 0 +and 0 +decreased 3 +cardiac 4 +output 4 +and 0 +QS 0 +/ 0 +QT 0 +. 0 +Nitroprusside 1 +caused 0 +significant 0 +decreases 3 +in 4 +arterial 4 +blood 4 +pressure 4 +and 0 +systemic 0 +vascular 0 +resistance 0 +and 0 +increases 0 +in 0 +heart 0 +rate 0 +"," 0 +but 0 +did 0 +not 0 +change 0 +cardiac 0 +output 0 +or 0 +QS 0 +/ 0 +QT 0 +. 0 +Five 0 +cm 0 +H20 1 +CPAP 0 +during 0 +nitroprusside 1 +did 0 +not 0 +further 0 +alter 0 +any 0 +of 0 +the 0 +above 0 +- 0 +mentioned 0 +variables 0 +. 0 +However 0 +"," 0 +10 0 +cm 0 +H20 1 +CPAP 0 +decreased 0 +arterial 0 +blood 0 +pressure 0 +"," 0 +cardiac 0 +output 0 +"," 0 +and 0 +QS 0 +/ 0 +QT 0 +. 0 +These 0 +data 0 +indicate 0 +that 0 +nitroprusside 1 +infusion 0 +rates 0 +that 0 +decrease 0 +mean 0 +arterial 0 +blood 0 +pressure 0 +by 0 +40 0 +- 0 +50 0 +per 0 +cent 0 +do 0 +not 0 +change 0 +cardiac 0 +output 0 +or 0 +QS 0 +/ 0 +QT 0 +. 0 +During 0 +nitroprusside 1 +infusion 0 +low 0 +levels 0 +of 0 +CPAP 0 +do 0 +not 0 +markedly 0 +alter 0 +cardiovascular 0 +dynamics 0 +"," 0 +but 0 +high 0 +levels 0 +of 0 +CPAP 0 +( 0 +10 0 +cm 0 +H20 1 +) 0 +"," 0 +while 0 +decreasing 0 +QS 0 +/ 0 +QT 0 +"," 0 +produce 0 +marked 0 +decreases 3 +in 4 +arterial 4 +blood 4 +pressure 4 +and 4 +cardiac 4 +output 4 +. 0 +Systolic 0 +pressure 0 +variation 0 +is 0 +greater 0 +during 0 +hemorrhage 3 +than 0 +during 0 +sodium 1 +nitroprusside 2 +- 0 +induced 0 +hypotension 3 +in 0 +ventilated 0 +dogs 0 +. 0 +The 0 +systolic 0 +pressure 0 +variation 0 +( 0 +SPV 0 +) 0 +"," 0 +which 0 +is 0 +the 0 +difference 0 +between 0 +the 0 +maximal 0 +and 0 +minimal 0 +values 0 +of 0 +the 0 +systolic 0 +blood 0 +pressure 0 +( 0 +SBP 0 +) 0 +after 0 +one 0 +positive 0 +- 0 +pressure 0 +breath 0 +"," 0 +was 0 +studied 0 +in 0 +ventilated 0 +dogs 0 +subjected 0 +to 0 +hypotension 3 +. 0 +Mean 0 +arterial 0 +pressure 0 +was 0 +decreased 0 +to 0 +50 0 +mm 0 +Hg 0 +for 0 +30 0 +minutes 0 +either 0 +by 0 +hemorrhage 3 +( 0 +HEM 3 +"," 0 +n 0 += 0 +7 0 +) 0 +or 0 +by 0 +continuous 0 +infusion 0 +of 0 +sodium 1 +nitroprusside 2 +( 0 +SNP 1 +"," 0 +n 0 += 0 +7 0 +) 0 +. 0 +During 0 +HEM 3 +- 0 +induced 0 +hypotension 3 +the 0 +cardiac 0 +output 0 +was 0 +significantly 0 +lower 0 +and 0 +systemic 0 +vascular 0 +resistance 0 +higher 0 +compared 0 +with 0 +that 0 +in 0 +the 0 +SNP 1 +group 0 +. 0 +The 0 +systemic 0 +"," 0 +central 0 +venous 0 +"," 0 +pulmonary 0 +capillary 0 +wedge 0 +pressures 0 +"," 0 +and 0 +heart 0 +rates 0 +"," 0 +were 0 +similar 0 +in 0 +the 0 +two 0 +groups 0 +. 0 +Analysis 0 +of 0 +the 0 +respiratory 0 +changes 0 +in 0 +the 0 +arterial 0 +pressure 0 +waveform 0 +enabled 0 +differentiation 0 +between 0 +the 0 +two 0 +groups 0 +. 0 +The 0 +SPV 0 +during 0 +hypotension 3 +was 0 +15 0 +. 0 +7 0 ++ 0 +/ 0 +- 0 +6 0 +. 0 +7 0 +mm 0 +Hg 0 +in 0 +the 0 +HEM 3 +group 0 +"," 0 +compared 0 +with 0 +9 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +0 0 +mm 0 +Hg 0 +in 0 +the 0 +SNP 1 +group 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +2 0 +) 0 +. 0 +The 0 +delta 0 +down 0 +"," 0 +which 0 +is 0 +the 0 +measure 0 +of 0 +decrease 0 +of 0 +SBP 0 +after 0 +a 0 +mechanical 0 +breath 0 +"," 0 +was 0 +20 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +8 0 +. 0 +4 0 +and 0 +10 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +3 0 +. 0 +8 0 +mm 0 +Hg 0 +in 0 +the 0 +HEM 3 +and 0 +SNP 1 +groups 0 +"," 0 +respectively 0 +"," 0 +during 0 +hypotension 3 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +2 0 +) 0 +. 0 +It 0 +is 0 +concluded 0 +that 0 +increases 0 +in 0 +the 0 +SPV 0 +and 0 +the 0 +delta 0 +down 0 +are 0 +characteristic 0 +of 0 +a 0 +hypotensive 3 +state 0 +due 0 +to 0 +a 0 +predominant 0 +decrease 0 +in 0 +preload 0 +. 0 +They 0 +are 0 +thus 0 +more 0 +important 0 +during 0 +absolute 0 +hypovolemia 3 +than 0 +during 0 +deliberate 0 +hypotension 3 +. 0 +Ventricular 3 +tachyarrhythmias 4 +during 0 +cesarean 0 +section 0 +after 0 +ritodrine 1 +therapy 0 +: 0 +interaction 0 +with 0 +anesthetics 0 +. 0 +This 0 +case 0 +illustrates 0 +that 0 +patients 0 +receiving 0 +ritodrine 1 +for 0 +preterm 3 +labor 4 +may 0 +risk 0 +interactions 0 +between 0 +the 0 +residual 0 +betamimetic 0 +effects 0 +of 0 +ritodrine 1 +and 0 +the 0 +effects 0 +of 0 +anesthetics 0 +during 0 +cesarean 0 +section 0 +. 0 +Such 0 +interactions 0 +may 0 +result 0 +in 0 +serious 0 +cardiovascular 3 +complications 4 +even 0 +after 0 +cessation 0 +of 0 +an 0 +infusion 0 +of 0 +ritodrine 1 +. 0 +Preoperative 0 +assessment 0 +should 0 +focus 0 +on 0 +cardiovascular 0 +status 0 +and 0 +serum 0 +potassium 1 +level 0 +. 0 +Delaying 0 +induction 0 +of 0 +anesthesia 0 +should 0 +be 0 +considered 0 +whenever 0 +possible 0 +. 0 +Careful 0 +fluid 0 +administration 0 +and 0 +cautious 0 +use 0 +of 0 +titrated 0 +doses 0 +of 0 +ephedrine 1 +are 0 +advised 0 +. 0 +After 0 +delivery 0 +of 0 +the 0 +infant 0 +"," 0 +there 0 +should 0 +be 0 +no 0 +contraindication 0 +to 0 +the 0 +use 0 +of 0 +an 0 +alpha 0 +- 0 +adrenergic 0 +vasopressor 0 +such 0 +as 0 +phenylephrine 1 +to 0 +treat 0 +hypotensive 3 +patients 0 +with 0 +tachycardia 3 +. 0 +Verapamil 1 +- 0 +induced 0 +carbamazepine 1 +neurotoxicity 3 +. 0 +A 0 +report 0 +of 0 +two 0 +cases 0 +. 0 +Two 0 +patients 0 +with 0 +signs 0 +of 0 +carbamazepine 1 +neurotoxicity 3 +after 0 +combined 0 +treatment 0 +with 0 +verapamil 1 +showed 0 +complete 0 +recovery 0 +after 0 +discontinuation 0 +of 0 +the 0 +calcium 1 +entry 0 +blocker 0 +. 0 +Use 0 +of 0 +verapamil 1 +in 0 +combination 0 +with 0 +carbamazepine 1 +should 0 +either 0 +be 0 +avoided 0 +or 0 +prescribed 0 +only 0 +with 0 +appropriate 0 +adjustment 0 +of 0 +the 0 +carbamazepine 1 +dose 0 +( 0 +usually 0 +reduction 0 +of 0 +the 0 +carbamazepine 1 +dose 0 +by 0 +one 0 +half 0 +) 0 +. 0 +Paracetamol 1 +- 0 +associated 0 +coma 3 +"," 0 +metabolic 3 +acidosis 4 +"," 0 +renal 3 +and 4 +hepatic 4 +failure 4 +. 0 +A 0 +case 0 +of 0 +metabolic 3 +acidosis 4 +"," 0 +acute 3 +renal 4 +failure 4 +and 4 +hepatic 4 +failure 4 +following 0 +paracetamol 1 +ingestion 0 +is 0 +presented 0 +. 0 +The 0 +diagnostic 0 +difficulty 0 +at 0 +presentation 0 +is 0 +highlighted 0 +. 0 +Continuous 0 +arteriovenous 0 +haemofiltration 0 +proved 0 +a 0 +valuable 0 +means 0 +of 0 +maintaining 0 +fluid 0 +and 0 +electrolyte 0 +balance 0 +. 0 +The 0 +patient 0 +recovered 0 +. 0 +Sexual 3 +dysfunction 4 +among 0 +patients 0 +with 0 +arthritis 3 +. 0 +The 0 +relationship 0 +of 0 +arthritis 3 +and 0 +sexual 3 +dysfunction 4 +was 0 +investigated 0 +among 0 +169 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +"," 0 +osteoarthritis 3 +and 0 +spondyloarthropathy 3 +"," 0 +130 0 +of 0 +whom 0 +were 0 +pair 0 +- 0 +matched 0 +to 0 +controls 0 +. 0 +Assessments 0 +of 0 +marital 0 +happiness 0 +and 0 +depressed 3 +mood 4 +were 0 +also 0 +made 0 +using 0 +the 0 +CES 0 +- 0 +D 0 +and 0 +the 0 +Azrin 0 +Marital 0 +Happiness 0 +Scale 0 +( 0 +AMHS 0 +) 0 +. 0 +Sexual 3 +dysfunctions 4 +were 0 +found 0 +to 0 +be 0 +common 0 +among 0 +patients 0 +and 0 +controls 0 +"," 0 +the 0 +majority 0 +in 0 +both 0 +groups 0 +reporting 0 +one 0 +or 0 +more 0 +dysfunctions 0 +. 0 +Impotence 3 +was 0 +more 0 +common 0 +among 0 +male 0 +patients 0 +than 0 +controls 0 +and 0 +was 0 +found 0 +to 0 +be 0 +associated 0 +with 0 +co 0 +- 0 +morbidity 0 +and 0 +the 0 +taking 0 +of 0 +methotrexate 1 +. 0 +Depressed 3 +mood 4 +was 0 +more 0 +common 0 +among 0 +patients 0 +and 0 +was 0 +associated 0 +with 0 +certain 0 +sexual 0 +difficulties 0 +"," 0 +but 0 +not 0 +with 0 +impotence 3 +. 0 +Marital 0 +unhappiness 0 +"," 0 +as 0 +indicated 0 +by 0 +AMHS 0 +scores 0 +"," 0 +was 0 +not 0 +associated 0 +with 0 +arthritis 3 +but 0 +was 0 +associated 0 +with 0 +sexual 3 +dysfunction 4 +"," 0 +sexual 0 +dissatisfaction 0 +and 0 +being 0 +female 0 +. 0 +Does 0 +paracetamol 1 +cause 0 +urothelial 3 +cancer 4 +or 0 +renal 3 +papillary 4 +necrosis 4 +? 0 +The 0 +risk 0 +of 0 +developing 0 +renal 3 +papillary 4 +necrosis 4 +or 0 +cancer 3 +of 4 +the 4 +renal 4 +pelvis 4 +"," 4 +ureter 4 +or 4 +bladder 4 +associated 0 +with 0 +consumption 0 +of 0 +either 0 +phenacetin 1 +or 0 +paracetamol 1 +was 0 +calculated 0 +from 0 +data 0 +acquired 0 +by 0 +questionnaire 0 +from 0 +381 0 +cases 0 +and 0 +808 0 +controls 0 +. 0 +The 0 +risk 0 +of 0 +renal 3 +papillary 4 +necrosis 4 +was 0 +increased 0 +nearly 0 +20 0 +- 0 +fold 0 +by 0 +consumption 0 +of 0 +phenacetin 1 +"," 0 +which 0 +also 0 +increased 0 +the 0 +risk 0 +for 0 +cancer 3 +of 4 +the 4 +renal 4 +pelvis 4 +and 4 +bladder 4 +but 0 +not 0 +for 0 +ureteric 3 +cancer 4 +. 0 +By 0 +contrast 0 +"," 0 +we 0 +were 0 +unable 0 +to 0 +substantiate 0 +an 0 +increased 0 +risk 0 +from 0 +paracetamol 1 +consumption 0 +for 0 +renal 3 +papillary 4 +necrosis 4 +or 0 +any 0 +of 0 +these 0 +cancers 3 +although 0 +there 0 +was 0 +a 0 +suggestion 0 +of 0 +an 0 +association 0 +with 0 +cancer 3 +of 4 +the 4 +ureter 4 +. 0 +Dapsone 1 +- 0 +associated 0 +Heinz 0 +body 0 +hemolytic 3 +anemia 4 +in 0 +a 0 +Cambodian 0 +woman 0 +with 0 +hemoglobin 0 +E 0 +trait 0 +. 0 +A 0 +Cambodian 0 +woman 0 +with 0 +hemoglobin 0 +E 0 +trait 0 +( 0 +AE 0 +) 0 +and 0 +leprosy 3 +developed 0 +a 0 +Heinz 0 +body 0 +hemolytic 3 +anemia 4 +while 0 +taking 0 +a 0 +dose 0 +of 0 +dapsone 1 +( 0 +50 0 +mg 0 +/ 0 +day 0 +) 0 +not 0 +usually 0 +associated 0 +with 0 +clinical 0 +hemolysis 3 +. 0 +Her 0 +red 0 +blood 0 +cells 0 +( 0 +RBCs 0 +) 0 +had 0 +increased 0 +incubated 0 +Heinz 0 +body 0 +formation 0 +"," 0 +decreased 0 +reduced 0 +glutathione 1 +( 0 +GSH 1 +) 0 +"," 0 +and 0 +decreased 0 +GSH 1 +stability 0 +. 0 +The 0 +pentose 1 +phosphate 2 +shunt 0 +activity 0 +of 0 +the 0 +dapsone 1 +- 0 +exposed 0 +AE 0 +RBCs 0 +was 0 +increased 0 +compared 0 +to 0 +normal 0 +RBCs 0 +. 0 +Although 0 +the 0 +AE 0 +RBCs 0 +from 0 +an 0 +individual 0 +not 0 +taking 0 +dapsone 1 +had 0 +increased 0 +incubated 0 +Heinz 0 +body 0 +formation 0 +"," 0 +the 0 +GSH 1 +content 0 +and 0 +GSH 1 +stability 0 +were 0 +normal 0 +. 0 +The 0 +pentose 1 +phosphate 2 +shunt 0 +activity 0 +of 0 +the 0 +non 0 +- 0 +dapsone 1 +- 0 +exposed 0 +AE 0 +RBCs 0 +was 0 +decreased 0 +compared 0 +to 0 +normal 0 +RBCs 0 +. 0 +Thus 0 +"," 0 +AE 0 +RBCs 0 +appear 0 +to 0 +have 0 +an 0 +increased 0 +sensitivity 0 +to 0 +oxidant 0 +stress 0 +both 0 +in 0 +vitro 0 +and 0 +in 0 +vivo 0 +"," 0 +since 0 +dapsone 1 +does 0 +not 0 +cause 0 +hemolytic 3 +anemia 4 +at 0 +this 0 +dose 0 +in 0 +hematologically 0 +normal 0 +individuals 0 +. 0 +Given 0 +the 0 +influx 0 +of 0 +Southeast 0 +Asians 0 +into 0 +the 0 +United 0 +States 0 +"," 0 +oxidant 0 +medications 0 +should 0 +be 0 +used 0 +with 0 +caution 0 +"," 0 +especially 0 +if 0 +an 0 +infection 3 +is 0 +present 0 +"," 0 +in 0 +individuals 0 +of 0 +ethnic 0 +backgrounds 0 +that 0 +have 0 +an 0 +increased 0 +prevalence 0 +of 0 +hemoglobin 0 +E 0 +. 0 +Severe 0 +complications 0 +of 0 +antianginal 0 +drug 0 +therapy 0 +in 0 +a 0 +patient 0 +identified 0 +as 0 +a 0 +poor 0 +metabolizer 0 +of 0 +metoprolol 1 +"," 0 +propafenone 1 +"," 0 +diltiazem 1 +"," 0 +and 0 +sparteine 1 +. 0 +A 0 +47 0 +- 0 +year 0 +- 0 +old 0 +patient 0 +suffering 0 +from 0 +coronary 3 +artery 4 +disease 4 +was 0 +admitted 0 +to 0 +the 0 +CCU 0 +in 0 +shock 3 +with 0 +III 0 +. 0 +AV 3 +block 4 +"," 0 +severe 0 +hypotension 3 +"," 0 +and 0 +impairment 3 +of 4 +ventricular 4 +function 4 +. 0 +0ne 0 +week 0 +prior 0 +to 0 +admission 0 +a 0 +therapy 0 +with 0 +standard 0 +doses 0 +of 0 +metoprolol 1 +( 0 +100 0 +mg 0 +t 0 +. 0 +i 0 +. 0 +d 0 +. 0 +and 0 +then 0 +100 0 +mg 0 +b 0 +. 0 +i 0 +. 0 +d 0 +. 0 +) 0 +had 0 +been 0 +initiated 0 +. 0 +Two 0 +days 0 +before 0 +admission 0 +diltiazem 1 +( 0 +60 0 +mg 0 +b 0 +. 0 +i 0 +. 0 +d 0 +. 0 +) 0 +was 0 +prescribed 0 +in 0 +addition 0 +. 0 +Analyses 0 +of 0 +a 0 +blood 0 +sample 0 +revealed 0 +unusually 0 +high 0 +plasma 0 +concentrations 0 +of 0 +metoprolol 1 +( 0 +greater 0 +than 0 +3000 0 +ng 0 +/ 0 +ml 0 +) 0 +and 0 +diltiazem 1 +( 0 +526 0 +ng 0 +/ 0 +ml 0 +) 0 +. 0 +The 0 +patient 0 +recovered 0 +within 0 +1 0 +week 0 +following 0 +discontinuation 0 +of 0 +antianginal 0 +therapy 0 +. 0 +Three 0 +months 0 +later 0 +the 0 +patient 0 +was 0 +exposed 0 +to 0 +a 0 +single 0 +dose 0 +of 0 +metoprolol 1 +"," 0 +diltiazem 1 +"," 0 +propafenone 1 +( 0 +since 0 +he 0 +had 0 +received 0 +this 0 +drug 0 +in 0 +the 0 +past 0 +) 0 +"," 0 +and 0 +sparteine 1 +( 0 +as 0 +a 0 +probe 0 +for 0 +the 0 +debrisoquine 1 +/ 0 +sparteine 1 +type 0 +polymorphism 0 +of 0 +oxidative 0 +drug 0 +metabolism 0 +) 0 +. 0 +It 0 +was 0 +found 0 +that 0 +he 0 +was 0 +a 0 +poor 0 +metabolizer 0 +of 0 +all 0 +four 0 +drugs 0 +"," 0 +indicating 0 +that 0 +their 0 +metabolism 0 +is 0 +under 0 +the 0 +same 0 +genetic 0 +control 0 +. 0 +Therefore 0 +"," 0 +patients 0 +belonging 0 +to 0 +the 0 +poor 0 +- 0 +metabolizer 0 +phenotype 0 +of 0 +sparteine 1 +/ 0 +debrisoquine 1 +polymorphism 0 +in 0 +drug 0 +metabolism 0 +"," 0 +which 0 +constitutes 0 +6 0 +. 0 +4 0 +% 0 +of 0 +the 0 +German 0 +population 0 +"," 0 +may 0 +experience 0 +adverse 3 +drug 4 +reactions 4 +when 0 +treated 0 +with 0 +standard 0 +doses 0 +of 0 +one 0 +of 0 +these 0 +drugs 0 +alone 0 +. 0 +Moreover 0 +"," 0 +the 0 +coadministration 0 +of 0 +these 0 +frequently 0 +used 0 +drugs 0 +is 0 +expected 0 +to 0 +be 0 +especially 0 +harmful 0 +in 0 +this 0 +subgroup 0 +of 0 +patients 0 +. 0 +Clinical 0 +experiences 0 +in 0 +an 0 +open 0 +and 0 +a 0 +double 0 +- 0 +blind 0 +trial 0 +. 0 +A 0 +total 0 +of 0 +sixty 0 +patients 0 +were 0 +trated 0 +with 0 +bromperidol 1 +first 0 +in 0 +open 0 +conditions 0 +( 0 +20 0 +patients 0 +) 0 +"," 0 +then 0 +on 0 +a 0 +double 0 +blind 0 +basis 0 +( 0 +40 0 +patients 0 +) 0 +with 0 +haloperidol 1 +as 0 +the 0 +reference 0 +substance 0 +. 0 +The 0 +open 0 +study 0 +lasted 0 +for 0 +four 0 +weeks 0 +; 0 +the 0 +drug 0 +was 0 +administrated 0 +in 0 +the 0 +form 0 +of 0 +1 0 +mg 0 +tablets 0 +. 0 +The 0 +daily 0 +dose 0 +( 0 +initial 0 +dose 0 +: 0 +1 0 +mg 0 +; 0 +mean 0 +dose 0 +at 0 +the 0 +end 0 +of 0 +the 0 +trial 0 +: 0 +4 0 +. 0 +47 0 +mg 0 +) 0 +was 0 +always 0 +administered 0 +in 0 +one 0 +single 0 +dose 0 +. 0 +Nineteen 0 +patients 0 +finished 0 +the 0 +trial 0 +"," 0 +and 0 +in 0 +18 0 +cases 0 +the 0 +therapeutic 0 +result 0 +was 0 +considered 0 +very 0 +good 0 +to 0 +good 0 +. 0 +These 0 +results 0 +were 0 +confirmed 0 +by 0 +statistical 0 +analysis 0 +. 0 +Nine 0 +patients 0 +exhibited 0 +mild 0 +to 0 +moderate 0 +extrapyramidal 3 +concomitant 4 +symptoms 4 +; 0 +no 0 +other 0 +side 0 +effects 0 +were 0 +observed 0 +. 0 +The 0 +results 0 +of 0 +detailed 0 +laboratory 0 +tests 0 +and 0 +evaluations 0 +of 0 +various 0 +quantitative 0 +and 0 +qualitative 0 +tolerability 0 +parameters 0 +were 0 +not 0 +indicative 0 +of 0 +toxic 0 +effects 0 +. 0 +In 0 +the 0 +double 0 +blind 0 +study 0 +with 0 +haloperidol 1 +"," 0 +both 0 +substances 0 +were 0 +found 0 +to 0 +be 0 +highly 0 +effective 0 +in 0 +the 0 +treatment 0 +of 0 +psychotic 3 +syndromes 4 +belonging 4 +predominantly 4 +to 4 +the 4 +schizophrenia 4 +group 4 +. 0 +Certain 0 +clues 0 +"," 0 +including 0 +the 0 +onset 0 +of 0 +action 0 +"," 0 +seem 0 +to 0 +be 0 +indicative 0 +of 0 +the 0 +superiority 0 +of 0 +bromperidol 1 +. 0 +No 0 +differences 0 +were 0 +observed 0 +with 0 +respect 0 +to 0 +side 0 +effects 0 +and 0 +general 0 +tolerability 0 +. 0 +Prolonged 0 +cholestasis 3 +after 0 +troleandomycin 1 +- 0 +induced 0 +acute 0 +hepatitis 3 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +patient 0 +in 0 +whom 0 +troleandomycin 1 +- 0 +induced 0 +hepatitis 3 +was 0 +followed 0 +by 0 +prolonged 0 +anicteric 0 +cholestasis 3 +. 0 +Jaundice 3 +occurred 0 +after 0 +administration 0 +of 0 +troleandomycin 1 +for 0 +7 0 +days 0 +and 0 +was 0 +associated 0 +with 0 +hypereosinophilia 3 +. 0 +Jaundice 3 +disappeared 0 +within 0 +3 0 +months 0 +but 0 +was 0 +followed 0 +by 0 +prolonged 0 +anicteric 0 +cholestasis 3 +marked 0 +by 0 +pruritus 3 +and 0 +high 0 +levels 0 +of 0 +alkaline 0 +phosphatase 0 +and 0 +gammaglutamyltransferase 0 +activities 0 +. 0 +Finally 0 +"," 0 +pruritus 3 +disappeared 0 +within 0 +19 0 +months 0 +"," 0 +and 0 +liver 0 +tests 0 +returned 0 +to 0 +normal 0 +27 0 +months 0 +after 0 +the 0 +onset 0 +of 0 +hepatitis 3 +. 0 +This 0 +observation 0 +demonstrates 0 +that 0 +prolonged 0 +cholestasis 3 +can 0 +follow 0 +troleandomycin 1 +- 0 +induced 0 +acute 0 +hepatitis 3 +. 0 +Serial 0 +studies 0 +of 0 +auditory 3 +neurotoxicity 4 +in 0 +patients 0 +receiving 0 +deferoxamine 1 +therapy 0 +. 0 +Visual 3 +and 4 +auditory 4 +neurotoxicity 4 +was 0 +previously 0 +documented 0 +in 0 +42 0 +of 0 +89 0 +patients 0 +with 0 +transfusion 0 +- 0 +dependent 0 +anemia 3 +who 0 +were 0 +receiving 0 +iron 1 +chelation 0 +therapy 0 +with 0 +daily 0 +subcutaneous 0 +deferoxamine 1 +. 0 +Twenty 0 +- 0 +two 0 +patients 0 +in 0 +the 0 +affected 0 +group 0 +had 0 +abnormal 3 +audiograms 4 +with 4 +deficits 4 +mostly 4 +in 4 +the 4 +high 4 +frequency 4 +range 4 +of 4 +4 4 +"," 4 +0 4 +to 4 +8 4 +"," 4 +0 4 +Hz 4 +and 0 +in 0 +the 0 +hearing 0 +threshold 0 +levels 0 +of 0 +30 0 +to 0 +100 0 +decibels 0 +. 0 +When 0 +deferoxamine 1 +therapy 0 +was 0 +discontinued 0 +and 0 +serial 0 +studies 0 +were 0 +performed 0 +"," 0 +audiograms 0 +in 0 +seven 0 +cases 0 +reverted 0 +to 0 +normal 0 +or 0 +near 0 +normal 0 +within 0 +two 0 +to 0 +three 0 +weeks 0 +"," 0 +and 0 +nine 0 +of 0 +13 0 +patients 0 +with 0 +symptoms 0 +became 0 +asymptomatic 0 +. 0 +Audiograms 0 +from 0 +15 0 +patients 0 +remained 0 +abnormal 0 +and 0 +four 0 +patients 0 +required 0 +hearing 0 +aids 0 +because 0 +of 0 +permanent 3 +disability 4 +. 0 +Since 0 +18 0 +of 0 +the 0 +22 0 +patients 0 +were 0 +initially 0 +receiving 0 +deferoxamine 1 +doses 0 +in 0 +excess 0 +of 0 +the 0 +commonly 0 +recommended 0 +50 0 +mg 0 +/ 0 +kg 0 +per 0 +dose 0 +"," 0 +therapy 0 +was 0 +restarted 0 +with 0 +lower 0 +doses 0 +"," 0 +usually 0 +50 0 +mg 0 +/ 0 +kg 0 +per 0 +dose 0 +or 0 +less 0 +depending 0 +on 0 +the 0 +degree 0 +of 0 +auditory 3 +abnormality 4 +"," 0 +and 0 +with 0 +the 0 +exception 0 +of 0 +two 0 +cases 0 +no 0 +further 0 +toxicity 3 +was 0 +demonstrated 0 +. 0 +Auditory 0 +deterioration 0 +and 0 +improvement 0 +"," 0 +demonstrated 0 +serially 0 +in 0 +individual 0 +patients 0 +receiving 0 +and 0 +not 0 +receiving 0 +deferoxamine 1 +"," 0 +respectively 0 +"," 0 +provided 0 +convincing 0 +evidence 0 +for 0 +a 0 +cause 0 +- 0 +and 0 +- 0 +effect 0 +relation 0 +between 0 +deferoxamine 1 +administration 0 +and 0 +ototoxicity 3 +. 0 +Based 0 +on 0 +these 0 +data 0 +"," 0 +a 0 +plan 0 +of 0 +management 0 +was 0 +developed 0 +that 0 +allows 0 +effective 0 +yet 0 +safe 0 +administration 0 +of 0 +deferoxamine 1 +. 0 +A 0 +dose 0 +of 0 +50 0 +mg 0 +/ 0 +kg 0 +is 0 +recommended 0 +in 0 +those 0 +without 0 +audiogram 0 +abnormalities 0 +. 0 +With 0 +mild 0 +toxicity 3 +"," 0 +a 0 +reduction 0 +to 0 +30 0 +or 0 +40 0 +mg 0 +/ 0 +kg 0 +per 0 +dose 0 +should 0 +result 0 +in 0 +a 0 +reversal 0 +of 0 +the 0 +abnormal 0 +results 0 +to 0 +normal 0 +within 0 +four 0 +weeks 0 +. 0 +Moderate 0 +abnormalities 0 +require 0 +a 0 +reduction 0 +of 0 +deferoxamine 1 +to 0 +25 0 +mg 0 +/ 0 +kg 0 +per 0 +dose 0 +with 0 +careful 0 +monitoring 0 +. 0 +In 0 +those 0 +with 0 +symptoms 0 +of 0 +hearing 3 +loss 4 +"," 0 +the 0 +drug 0 +should 0 +be 0 +stopped 0 +for 0 +four 0 +weeks 0 +"," 0 +and 0 +when 0 +the 0 +audiogram 0 +is 0 +stable 0 +or 0 +improved 0 +"," 0 +therapy 0 +should 0 +be 0 +restarted 0 +at 0 +10 0 +to 0 +25 0 +mg 0 +/ 0 +kg 0 +per 0 +dose 0 +. 0 +Serial 0 +audiograms 0 +should 0 +be 0 +performed 0 +every 0 +six 0 +months 0 +in 0 +those 0 +without 0 +problems 0 +and 0 +more 0 +frequently 0 +in 0 +young 0 +patients 0 +with 0 +normal 0 +serum 0 +ferritin 0 +values 0 +and 0 +in 0 +those 0 +with 0 +auditory 3 +dysfunction 4 +. 0 +Lidocaine 1 +- 0 +induced 0 +cardiac 3 +asystole 4 +. 0 +Intravenous 0 +administration 0 +of 0 +a 0 +single 0 +50 0 +- 0 +mg 0 +bolus 0 +of 0 +lidocaine 1 +in 0 +a 0 +67 0 +- 0 +year 0 +- 0 +old 0 +man 0 +resulted 0 +in 0 +profound 0 +depression 3 +of 0 +the 0 +activity 0 +of 0 +the 0 +sinoatrial 0 +and 0 +atrioventricular 0 +nodal 0 +pacemakers 0 +. 0 +The 0 +patient 0 +had 0 +no 0 +apparent 0 +associated 0 +conditions 0 +which 0 +might 0 +have 0 +predisposed 0 +him 0 +to 0 +the 0 +development 0 +of 0 +bradyarrhythmias 3 +; 0 +and 0 +"," 0 +thus 0 +"," 0 +this 0 +probably 0 +represented 0 +a 0 +TRUE 0 +idiosyncrasy 0 +to 0 +lidocaine 1 +. 0 +Flurbiprofen 1 +in 0 +the 0 +treatment 0 +of 0 +juvenile 3 +rheumatoid 4 +arthritis 4 +. 0 +Thirty 0 +- 0 +four 0 +patients 0 +with 0 +juvenile 3 +rheumatoid 4 +arthritis 4 +"," 0 +who 0 +were 0 +treated 0 +with 0 +flurbiprofen 1 +at 0 +a 0 +maximum 0 +dose 0 +of 0 +4 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +"," 0 +had 0 +statistically 0 +significant 0 +decreases 0 +from 0 +baseline 0 +in 0 +6 0 +arthritis 3 +indices 0 +after 0 +12 0 +weeks 0 +of 0 +treatment 0 +. 0 +Improvements 0 +were 0 +seen 0 +in 0 +the 0 +number 0 +of 0 +tender 3 +joints 4 +"," 0 +the 0 +severity 0 +of 0 +swelling 3 +and 0 +tenderness 3 +"," 0 +the 0 +time 0 +of 0 +walk 0 +50 0 +feet 0 +"," 0 +the 0 +duration 0 +of 0 +morning 3 +stiffness 4 +and 0 +the 0 +circumference 0 +of 0 +the 0 +left 0 +knee 0 +. 0 +The 0 +most 0 +frequently 0 +observed 0 +side 0 +effect 0 +was 0 +fecal 3 +occult 4 +blood 4 +( 0 +25 0 +% 0 +of 0 +patients 0 +) 0 +; 0 +however 0 +"," 0 +there 0 +was 0 +no 0 +other 0 +evidence 0 +of 0 +gastrointestinal 3 +( 4 +GI 4 +) 4 +bleeding 4 +in 0 +these 0 +patients 0 +. 0 +0ne 0 +patient 0 +was 0 +prematurely 0 +discontinued 0 +from 0 +the 0 +study 0 +for 0 +severe 0 +headache 3 +and 0 +abdominal 3 +pain 4 +. 0 +Most 0 +side 0 +effects 0 +were 0 +mild 0 +and 0 +related 0 +to 0 +the 0 +GI 0 +tract 0 +. 0 +Hyperkalemia 3 +associated 0 +with 0 +sulindac 1 +therapy 0 +. 0 +Hyperkalemia 3 +has 0 +recently 0 +been 0 +recognized 0 +as 0 +a 0 +complication 0 +of 0 +nonsteroidal 0 +antiinflammatory 0 +agents 0 +( 0 +NSAID 0 +) 0 +such 0 +as 0 +indomethacin 1 +. 0 +Several 0 +recent 0 +studies 0 +have 0 +stressed 0 +the 0 +renal 0 +sparing 0 +features 0 +of 0 +sulindac 1 +"," 0 +owing 0 +to 0 +its 0 +lack 0 +of 0 +interference 0 +with 0 +renal 0 +prostacyclin 1 +synthesis 0 +. 0 +We 0 +describe 0 +4 0 +patients 0 +in 0 +whom 0 +hyperkalemia 3 +ranging 0 +from 0 +6 0 +. 0 +1 0 +to 0 +6 0 +. 0 +9 0 +mEq 0 +/ 0 +l 0 +developed 0 +within 0 +3 0 +to 0 +8 0 +days 0 +of 0 +sulindac 1 +administration 0 +. 0 +In 0 +all 0 +of 0 +them 0 +normal 0 +serum 0 +potassium 1 +levels 0 +reached 0 +within 0 +2 0 +to 0 +4 0 +days 0 +of 0 +stopping 0 +sulindac 1 +. 0 +As 0 +no 0 +other 0 +medications 0 +known 0 +to 0 +effect 0 +serum 0 +potassium 1 +had 0 +been 0 +given 0 +concomitantly 0 +"," 0 +this 0 +course 0 +of 0 +events 0 +is 0 +suggestive 0 +of 0 +a 0 +cause 0 +- 0 +and 0 +- 0 +effect 0 +relationship 0 +between 0 +sulindac 1 +and 0 +hyperkalemia 3 +. 0 +These 0 +observations 0 +indicate 0 +that 0 +initial 0 +hopes 0 +that 0 +sulindac 1 +may 0 +not 0 +be 0 +associated 0 +with 0 +the 0 +adverse 0 +renal 0 +effects 0 +of 0 +other 0 +NSAID 0 +are 0 +probably 0 +not 0 +justified 0 +. 0 +Drug 0 +- 0 +induced 0 +arterial 0 +spasm 3 +relieved 0 +by 0 +lidocaine 1 +. 0 +Case 0 +report 0 +. 0 +Following 0 +major 0 +intracranial 0 +surgery 0 +in 0 +a 0 +35 0 +- 0 +year 0 +- 0 +old 0 +man 0 +"," 0 +sodium 1 +pentothal 2 +was 0 +intravenously 0 +infused 0 +to 0 +minimize 0 +cerebral 3 +ischaemia 4 +. 0 +Intense 0 +vasospasm 3 +with 0 +threatened 0 +gangrene 3 +arose 0 +in 0 +the 0 +arm 0 +used 0 +for 0 +the 0 +infusion 0 +. 0 +Since 0 +the 0 +cranial 0 +condition 0 +precluded 0 +use 0 +of 0 +more 0 +usual 0 +methods 0 +"," 0 +lidocaine 1 +was 0 +given 0 +intra 0 +- 0 +arterially 0 +"," 0 +with 0 +careful 0 +cardiovascular 0 +monitoring 0 +"," 0 +to 0 +counteract 0 +the 0 +vasospasm 3 +. 0 +The 0 +treatment 0 +was 0 +rapidly 0 +successful 0 +. 0 +Regional 0 +localization 0 +of 0 +the 0 +antagonism 0 +of 0 +amphetamine 1 +- 0 +induced 0 +hyperactivity 3 +by 0 +intracerebral 0 +calcitonin 1 +injections 0 +. 0 +Calcitonin 1 +receptors 0 +are 0 +found 0 +in 0 +the 0 +brain 0 +"," 0 +and 0 +intracerebral 0 +infusions 0 +of 0 +calcitonin 1 +can 0 +produce 0 +behavioral 0 +effects 0 +. 0 +Among 0 +these 0 +behavioral 0 +effects 0 +are 0 +decreases 0 +in 0 +food 0 +intake 0 +and 0 +decreases 0 +in 0 +amphetamine 1 +- 0 +induced 0 +locomotor 0 +activity 0 +. 0 +In 0 +previous 0 +experiments 0 +we 0 +found 0 +that 0 +decreases 0 +in 0 +food 0 +intake 0 +were 0 +induced 0 +by 0 +local 0 +administration 0 +of 0 +calcitonin 1 +into 0 +several 0 +hypothalamic 0 +sites 0 +and 0 +into 0 +the 0 +nucleus 0 +accumbens 0 +. 0 +In 0 +the 0 +present 0 +experiment 0 +calcitonin 1 +decreased 0 +locomotor 0 +activity 0 +when 0 +locally 0 +injected 0 +into 0 +the 0 +same 0 +sites 0 +where 0 +it 0 +decreases 0 +food 0 +intake 0 +. 0 +The 0 +areas 0 +where 0 +calcitonin 1 +is 0 +most 0 +effective 0 +in 0 +decreasing 0 +locomotor 0 +activity 0 +are 0 +located 0 +in 0 +the 0 +hypothalamus 0 +and 0 +nucleus 0 +accumbens 0 +"," 0 +suggesting 0 +that 0 +these 0 +areas 0 +are 0 +the 0 +major 0 +sites 0 +of 0 +action 0 +of 0 +calcitonin 1 +in 0 +inhibiting 0 +amphetamine 1 +- 0 +induced 0 +locomotor 0 +activity 0 +. 0 +The 0 +hematologic 0 +effects 0 +of 0 +cefonicid 1 +and 0 +cefazedone 1 +in 0 +the 0 +dog 0 +: 0 +a 0 +potential 0 +model 0 +of 0 +cephalosporin 1 +hematotoxicity 3 +in 0 +man 0 +. 0 +Cephalosporin 1 +antibiotics 0 +cause 0 +a 0 +variety 0 +of 0 +hematologic 3 +disturbances 4 +in 0 +man 0 +"," 0 +the 0 +pathogeneses 0 +and 0 +hematopathology 0 +of 0 +which 0 +remain 0 +poorly 0 +characterized 0 +. 0 +There 0 +is 0 +a 0 +need 0 +for 0 +a 0 +well 0 +- 0 +defined 0 +animal 0 +model 0 +in 0 +which 0 +these 0 +blood 3 +dyscrasias 4 +can 0 +be 0 +studied 0 +. 0 +In 0 +four 0 +subacute 0 +toxicity 3 +studies 0 +"," 0 +the 0 +intravenous 0 +administration 0 +of 0 +cefonicid 1 +or 0 +cefazedone 1 +to 0 +beagle 0 +dogs 0 +caused 0 +a 0 +dose 0 +- 0 +dependent 0 +incidence 0 +of 0 +anemia 3 +"," 0 +neutropenia 3 +"," 0 +and 0 +thrombocytopenia 3 +after 0 +1 0 +- 0 +3 0 +months 0 +of 0 +treatment 0 +. 0 +A 0 +nonregenerative 0 +anemia 3 +was 0 +the 0 +most 0 +compromising 0 +of 0 +the 0 +cytopenias 3 +and 0 +occurred 0 +in 0 +approximately 0 +50 0 +% 0 +of 0 +dogs 0 +receiving 0 +400 0 +- 0 +500 0 +mg 0 +/ 0 +kg 0 +cefonicid 1 +or 0 +540 0 +- 0 +840 0 +mg 0 +/ 0 +kg 0 +cefazedone 1 +. 0 +All 0 +three 0 +cytopenias 3 +were 0 +completely 0 +reversible 0 +following 0 +cessation 0 +of 0 +treatment 0 +; 0 +the 0 +time 0 +required 0 +for 0 +recovery 0 +of 0 +the 0 +erythron 0 +( 0 +approximately 0 +1 0 +month 0 +) 0 +was 0 +considerably 0 +longer 0 +than 0 +that 0 +of 0 +the 0 +granulocytes 0 +and 0 +platelets 0 +( 0 +hours 0 +to 0 +a 0 +few 0 +days 0 +) 0 +. 0 +Upon 0 +rechallenge 0 +with 0 +either 0 +cephalosporin 1 +"," 0 +the 0 +hematologic 3 +syndrome 4 +was 0 +reproduced 0 +in 0 +most 0 +dogs 0 +tested 0 +; 0 +cefonicid 1 +( 0 +but 0 +not 0 +cefazedone 1 +) 0 +- 0 +treated 0 +dogs 0 +showed 0 +a 0 +substantially 0 +reduced 0 +induction 0 +period 0 +( 0 +15 0 ++ 0 +/ 0 +- 0 +5 0 +days 0 +) 0 +compared 0 +to 0 +that 0 +of 0 +the 0 +first 0 +exposure 0 +to 0 +the 0 +drug 0 +( 0 +61 0 ++ 0 +/ 0 +- 0 +24 0 +days 0 +) 0 +. 0 +This 0 +observation 0 +"," 0 +along 0 +with 0 +the 0 +rapid 0 +rate 0 +of 0 +decline 0 +in 0 +red 0 +cell 0 +mass 0 +parameters 0 +of 0 +affected 0 +dogs 0 +"," 0 +suggests 0 +that 0 +a 0 +hemolytic 3 +component 0 +complicated 0 +the 0 +red 0 +cell 0 +production 0 +problem 0 +and 0 +that 0 +multiple 0 +toxicologic 0 +mechanisms 0 +contributed 0 +to 0 +the 0 +cytopenia 3 +. 0 +We 0 +conclude 0 +that 0 +the 0 +administration 0 +of 0 +high 0 +doses 0 +of 0 +cefonicid 1 +or 0 +cefazedone 1 +to 0 +dogs 0 +can 0 +induce 0 +hematotoxicity 3 +similar 0 +to 0 +the 0 +cephalosporin 1 +- 0 +induced 0 +blood 3 +dyscrasias 4 +described 0 +in 0 +man 0 +and 0 +thus 0 +provides 0 +a 0 +useful 0 +model 0 +for 0 +studying 0 +the 0 +mechanisms 0 +of 0 +these 0 +disorders 0 +. 0 +Cerebral 0 +blood 0 +flow 0 +and 0 +metabolism 0 +during 0 +isoflurane 1 +- 0 +induced 0 +hypotension 3 +in 0 +patients 0 +subjected 0 +to 0 +surgery 0 +for 0 +cerebral 3 +aneurysms 4 +. 0 +Cerebral 0 +blood 0 +flow 0 +and 0 +cerebral 0 +metabolic 0 +rate 0 +for 0 +oxygen 1 +were 0 +measured 0 +during 0 +isoflurane 1 +- 0 +induced 0 +hypotension 3 +in 0 +10 0 +patients 0 +subjected 0 +to 0 +craniotomy 0 +for 0 +clipping 0 +of 0 +a 0 +cerebral 3 +aneurysm 4 +. 0 +Flow 0 +and 0 +metabolism 0 +were 0 +measured 0 +5 0 +- 0 +13 0 +days 0 +after 0 +the 0 +subarachnoid 3 +haemorrhage 4 +by 0 +a 0 +modification 0 +of 0 +the 0 +classical 0 +Kety 0 +- 0 +Schmidt 0 +technique 0 +using 0 +xenon 1 +- 0 +133 0 +i 0 +. 0 +v 0 +. 0 +Anaesthesia 0 +was 0 +maintained 0 +with 0 +an 0 +inspired 0 +isoflurane 1 +concentration 0 +of 0 +0 0 +. 0 +75 0 +% 0 +( 0 +plus 0 +67 0 +% 0 +nitrous 1 +oxide 2 +in 0 +oxygen 1 +) 0 +"," 0 +during 0 +which 0 +CBF 0 +and 0 +CMR02 0 +were 0 +34 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +1 0 +ml 0 +/ 0 +100 0 +g 0 +min 0 +- 0 +1 0 +and 0 +2 0 +. 0 +32 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +16 0 +ml 0 +/ 0 +100 0 +g 0 +min 0 +- 0 +1 0 +at 0 +PaC02 0 +4 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +1 0 +kPa 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SEM 0 +) 0 +. 0 +Controlled 0 +hypotension 3 +to 0 +an 0 +average 0 +MAP 0 +of 0 +50 0 +- 0 +55 0 +mm 0 +Hg 1 +was 0 +induced 0 +by 0 +increasing 0 +the 0 +dose 0 +of 0 +isoflurane 1 +"," 0 +and 0 +maintained 0 +at 0 +an 0 +inspired 0 +concentration 0 +of 0 +2 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +2 0 +% 0 +. 0 +This 0 +resulted 0 +in 0 +a 0 +significant 0 +decrease 0 +in 0 +CMR02 0 +( 0 +to 0 +1 0 +. 0 +73 0 ++ 0 +/ 0 +- 0 +0 0 +. 0 +16 0 +ml 0 +/ 0 +100 0 +g 0 +min 0 +- 0 +1 0 +) 0 +"," 0 +while 0 +CBF 0 +was 0 +unchanged 0 +. 0 +After 0 +the 0 +clipping 0 +of 0 +the 0 +aneurysm 3 +the 0 +isoflurane 1 +concentration 0 +was 0 +reduced 0 +to 0 +0 0 +. 0 +75 0 +% 0 +. 0 +There 0 +was 0 +a 0 +significant 0 +increase 0 +in 0 +CBF 0 +"," 0 +although 0 +CMR02 0 +was 0 +unchanged 0 +"," 0 +compared 0 +with 0 +pre 0 +- 0 +hypotensive 3 +values 0 +. 0 +These 0 +changes 0 +might 0 +offer 0 +protection 0 +to 0 +brain 0 +tissue 0 +during 0 +periods 0 +of 0 +induced 0 +hypotension 3 +. 0 +Triazolam 1 +- 0 +induced 0 +brief 0 +episodes 0 +of 0 +secondary 0 +mania 3 +in 0 +a 0 +depressed 3 +patient 0 +. 0 +Large 0 +doses 0 +of 0 +triazolam 1 +repeatedly 0 +induced 0 +brief 0 +episodes 0 +of 0 +mania 3 +in 0 +a 0 +depressed 3 +elderly 0 +woman 0 +. 0 +Features 0 +of 0 +organic 3 +mental 4 +disorder 4 +( 0 +delirium 3 +) 0 +were 0 +not 0 +present 0 +. 0 +Manic 3 +excitement 0 +was 0 +coincident 0 +with 0 +the 0 +duration 0 +of 0 +action 0 +of 0 +triazolam 1 +. 0 +The 0 +possible 0 +contribution 0 +of 0 +the 0 +triazolo 1 +group 0 +to 0 +changes 0 +in 0 +affective 0 +status 0 +is 0 +discussed 0 +. 0 +The 0 +correlation 0 +between 0 +neurotoxic 3 +esterase 0 +inhibition 0 +and 0 +mipafox 1 +- 0 +induced 0 +neuropathic 3 +damage 4 +in 0 +rats 0 +. 0 +The 0 +correlation 0 +between 0 +neuropathic 3 +damage 4 +and 0 +inhibition 0 +of 0 +neurotoxic 3 +esterase 0 +or 0 +neuropathy 3 +target 0 +enzyme 0 +( 0 +NTE 0 +) 0 +was 0 +examined 0 +in 0 +rats 0 +acutely 0 +exposed 0 +to 0 +Mipafox 1 +( 0 +N 1 +"," 2 +N 2 +' 2 +- 2 +diisopropylphosphorodiamidofluoridate 2 +) 0 +"," 0 +a 0 +neurotoxic 3 +organophosphate 1 +. 0 +Brain 0 +and 0 +spinal 0 +cord 0 +NTE 0 +activities 0 +were 0 +measured 0 +in 0 +Long 0 +- 0 +Evans 0 +male 0 +rats 0 +1 0 +hr 0 +post 0 +- 0 +exposure 0 +to 0 +various 0 +dosages 0 +of 0 +Mipafox 1 +( 0 +ip 0 +"," 0 +1 0 +- 0 +15 0 +mg 0 +/ 0 +kg 0 +) 0 +. 0 +These 0 +data 0 +were 0 +correlated 0 +with 0 +histologically 0 +scored 0 +cervical 0 +cord 3 +damage 4 +in 0 +a 0 +separate 0 +group 0 +of 0 +similarly 0 +dosed 0 +rats 0 +sampled 0 +14 0 +- 0 +21 0 +days 0 +post 0 +- 0 +exposure 0 +. 0 +Those 0 +dosages 0 +( 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +10 0 +mg 0 +/ 0 +kg 0 +) 0 +that 0 +inhibited 0 +mean 0 +NTE 0 +activity 0 +in 0 +the 0 +spinal 0 +cord 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +73 0 +% 0 +and 0 +brain 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +67 0 +% 0 +of 0 +control 0 +values 0 +produced 0 +severe 0 +( 0 +greater 0 +than 0 +or 0 +equal 0 +to 0 +3 0 +) 0 +cervical 0 +cord 0 +pathology 0 +in 0 +85 0 +% 0 +of 0 +the 0 +rats 0 +. 0 +In 0 +contrast 0 +"," 0 +dosages 0 +of 0 +Mipafox 1 +( 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +which 0 +inhibited 0 +mean 0 +NTE 0 +activity 0 +in 0 +spinal 0 +cord 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +61 0 +% 0 +and 0 +brain 0 +less 0 +than 0 +or 0 +equal 0 +to 0 +60 0 +% 0 +produced 0 +this 0 +degree 0 +of 0 +cord 3 +damage 4 +in 0 +only 0 +9 0 +% 0 +of 0 +the 0 +animals 0 +. 0 +These 0 +data 0 +indicate 0 +that 0 +a 0 +critical 0 +percentage 0 +of 0 +NTE 0 +inhibition 0 +in 0 +brain 0 +and 0 +spinal 0 +cord 0 +sampled 0 +shortly 0 +after 0 +Mipafox 1 +exposure 0 +can 0 +predict 0 +neuropathic 3 +damage 4 +in 0 +rats 0 +several 0 +weeks 0 +later 0 +. 0 +Allergic 3 +reaction 4 +to 0 +5 1 +- 2 +fluorouracil 2 +infusion 0 +. 0 +An 0 +allergic 3 +reaction 4 +consisting 0 +of 0 +angioneurotic 3 +edema 4 +secondary 0 +to 0 +continuous 0 +infusion 0 +5 1 +- 2 +fluorouracil 2 +occurred 0 +in 0 +a 0 +patient 0 +with 0 +recurrent 0 +carcinoma 3 +of 4 +the 4 +oral 4 +cavity 4 +"," 0 +cirrhosis 3 +"," 0 +and 0 +cisplatin 1 +- 0 +induced 0 +impaired 3 +renal 4 +function 4 +. 0 +This 0 +reaction 0 +occurred 0 +during 0 +the 0 +sixth 0 +and 0 +seventh 0 +courses 0 +of 0 +infusional 0 +chemotherapy 0 +. 0 +0ral 0 +diphenhydramine 1 +and 0 +prednisone 1 +were 0 +ineffective 0 +in 0 +preventing 0 +the 0 +recurrence 0 +of 0 +the 0 +allergic 3 +reaction 4 +. 0 +Discontinuance 0 +of 0 +effective 0 +chemotherapy 0 +in 0 +this 0 +patient 0 +during 0 +partial 0 +remission 0 +resulted 0 +in 0 +fatal 0 +disease 0 +progression 0 +. 0 +Myasthenia 3 +gravis 4 +caused 0 +by 0 +penicillamine 1 +and 0 +chloroquine 1 +therapy 0 +for 0 +rheumatoid 3 +arthritis 4 +. 0 +We 0 +have 0 +described 0 +a 0 +unique 0 +patient 0 +who 0 +had 0 +reversible 0 +and 0 +dose 0 +- 0 +related 0 +myasthenia 3 +gravis 4 +after 0 +penicillamine 1 +and 0 +chloroquine 1 +therapy 0 +for 0 +rheumatoid 3 +arthritis 4 +. 0 +Although 0 +acetylcholine 1 +receptor 0 +antibodies 0 +were 0 +not 0 +detectable 0 +"," 0 +the 0 +time 0 +course 0 +was 0 +consistent 0 +with 0 +an 0 +autoimmune 0 +process 0 +. 0 +0n 0 +the 0 +mechanisms 0 +of 0 +the 0 +development 0 +of 0 +tolerance 0 +to 0 +the 0 +muscular 3 +rigidity 4 +produced 0 +by 0 +morphine 1 +in 0 +rats 0 +. 0 +The 0 +development 0 +of 0 +tolerance 0 +to 0 +the 0 +muscular 3 +rigidity 4 +produced 0 +by 0 +morphine 1 +was 0 +studied 0 +in 0 +rats 0 +. 0 +Saline 0 +- 0 +pretreated 0 +controls 0 +given 0 +a 0 +test 0 +dose 0 +of 0 +morphine 1 +( 0 +20 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +showed 0 +a 0 +pronounced 0 +rigidity 3 +recorded 0 +as 0 +tonic 0 +activity 0 +in 0 +the 0 +electromyogram 0 +. 0 +Rats 0 +treated 0 +for 0 +11 0 +days 0 +with 0 +morphine 1 +and 0 +withdrawn 0 +for 0 +36 0 +- 0 +40 0 +h 0 +showed 0 +differences 0 +in 0 +the 0 +development 0 +of 0 +tolerance 0 +: 0 +about 0 +half 0 +of 0 +the 0 +animals 0 +showed 0 +a 0 +rigidity 3 +after 0 +the 0 +test 0 +dose 0 +of 0 +morphine 1 +that 0 +was 0 +not 0 +significantly 0 +less 0 +than 0 +in 0 +the 0 +controls 0 +and 0 +were 0 +akinetic 3 +( 0 +A 0 +group 0 +) 0 +. 0 +The 0 +other 0 +rats 0 +showed 0 +a 0 +strong 0 +decrease 0 +in 0 +the 0 +rigidity 3 +and 0 +the 0 +occurrence 0 +of 0 +stereotyped 0 +( 0 +S 0 +) 0 +licking 0 +and 0 +/ 0 +or 0 +gnawing 0 +in 0 +presence 0 +of 0 +akinetic 3 +or 0 +hyperkinetic 3 +( 0 +K 0 +) 0 +behaviour 0 +( 0 +AS 0 +/ 0 +KS 0 +group 0 +) 0 +"," 0 +suggesting 0 +signs 0 +of 0 +dopaminergic 0 +activation 0 +. 0 +The 0 +rigidity 3 +was 0 +considerably 0 +decreased 0 +in 0 +both 0 +groups 0 +after 0 +20 0 +days 0 +' 0 +treatment 0 +. 0 +In 0 +a 0 +further 0 +series 0 +of 0 +experiments 0 +"," 0 +haloperidol 1 +( 0 +0 0 +. 0 +2 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +p 0 +. 0 +) 0 +was 0 +used 0 +in 0 +order 0 +to 0 +block 0 +the 0 +dopaminergic 0 +activation 0 +and 0 +to 0 +estimate 0 +the 0 +real 0 +degree 0 +of 0 +the 0 +tolerance 0 +to 0 +the 0 +rigidity 3 +without 0 +any 0 +dopaminergic 0 +interference 0 +. 0 +Haloperidol 1 +enhanced 0 +the 0 +rigidity 3 +in 0 +the 0 +A 0 +group 0 +. 0 +However 0 +"," 0 +the 0 +level 0 +in 0 +the 0 +AS 0 +/ 0 +KS 0 +group 0 +remained 0 +considerably 0 +lower 0 +than 0 +in 0 +the 0 +A 0 +group 0 +. 0 +The 0 +results 0 +suggest 0 +that 0 +rigidity 3 +"," 0 +which 0 +is 0 +assumed 0 +to 0 +be 0 +due 0 +to 0 +an 0 +action 0 +of 0 +morphine 1 +in 0 +the 0 +striatum 0 +"," 0 +can 0 +be 0 +antagonized 0 +by 0 +another 0 +process 0 +leading 0 +to 0 +dopaminergic 0 +activation 0 +in 0 +the 0 +striatum 0 +. 0 +Nevertheless 0 +"," 0 +there 0 +occurs 0 +some 0 +real 0 +tolerance 0 +to 0 +this 0 +effect 0 +. 0 +The 0 +rapid 0 +alternations 0 +of 0 +rigidity 3 +and 0 +the 0 +signs 0 +of 0 +dopaminergic 0 +activation 0 +observed 0 +in 0 +the 0 +animals 0 +of 0 +the 0 +AS 0 +/ 0 +KS 0 +group 0 +might 0 +be 0 +due 0 +to 0 +rapid 0 +shifts 0 +in 0 +the 0 +predominance 0 +of 0 +various 0 +DA 0 +- 0 +innervated 0 +structures 0 +. 0 +A 0 +case 0 +of 0 +massive 0 +rhabdomyolysis 3 +following 0 +molindone 1 +administration 0 +. 0 +Rhabdomyolysis 3 +is 0 +a 0 +potentially 0 +lethal 0 +syndrome 0 +that 0 +psychiatric 3 +patients 0 +seem 0 +predisposed 0 +to 0 +develop 0 +. 0 +The 0 +clinical 0 +signs 0 +and 0 +symptoms 0 +"," 0 +typical 0 +laboratory 0 +features 0 +"," 0 +and 0 +complications 0 +of 0 +rhabdomyolysis 3 +are 0 +presented 0 +. 0 +The 0 +case 0 +of 0 +a 0 +schizophrenic 3 +patient 0 +is 0 +reported 0 +to 0 +illustrate 0 +massive 0 +rhabdomyolysis 3 +and 0 +subsequent 0 +acute 3 +renal 4 +failure 4 +following 0 +molindone 1 +administration 0 +. 0 +Physicians 0 +who 0 +prescribe 0 +molindone 1 +should 0 +be 0 +aware 0 +of 0 +this 0 +reaction 0 +. 0 +Compression 3 +neuropathy 4 +of 4 +the 4 +radial 4 +nerve 4 +due 0 +to 0 +pentazocine 1 +- 0 +induced 0 +fibrous 3 +myopathy 4 +. 0 +Fibrous 3 +myopathy 4 +is 0 +a 0 +common 0 +"," 0 +well 0 +- 0 +known 0 +side 0 +effect 0 +of 0 +repeated 0 +pentazocine 1 +injection 0 +. 0 +However 0 +"," 0 +compression 3 +neuropathy 4 +due 0 +to 0 +fibrotic 0 +muscle 0 +affected 0 +by 0 +pentazocine 1 +- 0 +induced 0 +myopathy 3 +has 0 +not 0 +previously 0 +been 0 +reported 0 +. 0 +In 0 +a 0 +37 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +documented 0 +pentazocine 1 +- 0 +induced 0 +fibrous 3 +myopathy 4 +of 0 +triceps 0 +and 0 +deltoid 0 +muscles 0 +bilaterally 0 +and 0 +a 0 +three 0 +- 0 +week 0 +history 0 +of 0 +right 0 +wrist 0 +drop 0 +"," 0 +electrodiagnostic 0 +examination 0 +showed 0 +a 0 +severe 0 +but 0 +partial 0 +lesion 0 +of 0 +the 0 +right 0 +radial 0 +nerve 0 +distal 0 +to 0 +the 0 +branches 0 +to 0 +the 0 +triceps 0 +"," 0 +in 0 +addition 0 +to 0 +the 0 +fibrous 3 +myopathy 4 +. 0 +Surgery 0 +revealed 0 +the 0 +right 0 +radial 0 +nerve 0 +to 0 +be 0 +severely 0 +compressed 0 +by 0 +the 0 +densely 0 +fibrotic 0 +lateral 0 +head 0 +of 0 +the 0 +triceps 0 +. 0 +Decompression 0 +and 0 +neurolysis 0 +were 0 +performed 0 +with 0 +good 0 +subsequent 0 +recovery 0 +of 0 +function 0 +. 0 +Recurrent 0 +reversible 0 +acute 3 +renal 4 +failure 4 +from 0 +amphotericin 1 +. 0 +A 0 +patient 0 +with 0 +cryptogenic 0 +cirrhosis 3 +and 0 +disseminated 0 +sporotrichosis 3 +developed 0 +acute 3 +renal 4 +failure 4 +immediately 0 +following 0 +the 0 +administration 0 +of 0 +amphotericin 1 +B 2 +on 0 +four 0 +separate 0 +occasions 0 +. 0 +The 0 +abruptness 0 +of 0 +the 0 +renal 3 +failure 4 +and 0 +its 0 +reversibility 0 +within 0 +days 0 +suggests 0 +that 0 +there 0 +was 0 +a 0 +functional 0 +component 0 +to 0 +the 0 +renal 3 +dysfunction 4 +. 0 +We 0 +propose 0 +that 0 +amphotericin 1 +"," 0 +in 0 +the 0 +setting 0 +of 0 +reduced 0 +effective 0 +arterial 0 +volume 0 +"," 0 +may 0 +activate 0 +tubuloglomerular 0 +feedback 0 +"," 0 +thereby 0 +contributing 0 +to 0 +acute 3 +renal 4 +failure 4 +. 0 +Cerebral 3 +infarction 4 +with 0 +a 0 +single 0 +oral 0 +dose 0 +of 0 +phenylpropanolamine 1 +. 0 +Phenylpropanolamine 1 +( 0 +PPA 1 +) 0 +"," 0 +a 0 +synthetic 0 +sympathomimetic 0 +that 0 +is 0 +structurally 0 +similar 0 +to 0 +amphetamine 1 +"," 0 +is 0 +available 0 +over 0 +the 0 +counter 0 +in 0 +anorectics 0 +"," 0 +nasal 0 +congestants 0 +"," 0 +and 0 +cold 0 +preparations 0 +. 0 +Its 0 +prolonged 0 +use 0 +or 0 +overuse 0 +has 0 +been 0 +associated 0 +with 0 +seizures 3 +"," 0 +intracerebral 3 +hemorrhage 4 +"," 0 +neuropsychiatric 3 +symptoms 4 +"," 0 +and 0 +nonhemorrhagic 0 +cerebral 3 +infarction 4 +. 0 +We 0 +report 0 +the 0 +case 0 +of 0 +a 0 +young 0 +woman 0 +who 0 +suffered 0 +a 0 +cerebral 3 +infarction 4 +after 0 +taking 0 +a 0 +single 0 +oral 0 +dose 0 +of 0 +PPA 1 +. 0 +Remission 0 +induction 0 +of 0 +meningeal 3 +leukemia 4 +with 0 +high 0 +- 0 +dose 0 +intravenous 0 +methotrexate 1 +. 0 +Twenty 0 +children 0 +with 0 +acute 3 +lymphoblastic 4 +leukemia 4 +who 0 +developed 0 +meningeal 3 +disease 4 +were 0 +treated 0 +with 0 +a 0 +high 0 +- 0 +dose 0 +intravenous 0 +methotrexate 1 +regimen 0 +that 0 +was 0 +designed 0 +to 0 +achieve 0 +and 0 +maintain 0 +CSF 0 +methotrexate 1 +concentrations 0 +of 0 +10 0 +( 0 +- 0 +5 0 +) 0 +mol 0 +/ 0 +L 0 +without 0 +the 0 +need 0 +for 0 +concomitant 0 +intrathecal 0 +dosing 0 +. 0 +The 0 +methotrexate 1 +was 0 +administered 0 +as 0 +a 0 +loading 0 +dose 0 +of 0 +6 0 +"," 0 +0 0 +mg 0 +/ 0 +m2 0 +for 0 +a 0 +period 0 +of 0 +one 0 +hour 0 +followed 0 +by 0 +an 0 +infusion 0 +of 0 +1 0 +"," 0 +200 0 +mg 0 +/ 0 +m2 0 +/ 0 +h 0 +for 0 +23 0 +hours 0 +. 0 +Leucovorin 1 +rescue 0 +was 0 +initiated 0 +12 0 +hours 0 +after 0 +the 0 +end 0 +of 0 +the 0 +infusion 0 +with 0 +a 0 +loading 0 +dose 0 +of 0 +200 0 +mg 0 +/ 0 +m2 0 +followed 0 +by 0 +12 0 +mg 0 +/ 0 +m2 0 +every 0 +three 0 +hours 0 +for 0 +six 0 +doses 0 +and 0 +then 0 +every 0 +six 0 +hours 0 +until 0 +the 0 +plasma 0 +methotrexate 1 +level 0 +decreased 0 +to 0 +less 0 +than 0 +1 0 +X 0 +10 0 +( 0 +- 0 +7 0 +) 0 +mol 0 +/ 0 +L 0 +. 0 +The 0 +mean 0 +steady 0 +- 0 +state 0 +plasma 0 +and 0 +CSF 0 +methotrexate 1 +concentrations 0 +achieved 0 +were 0 +1 0 +. 0 +1 0 +X 0 +10 0 +( 0 +- 0 +3 0 +) 0 +mol 0 +/ 0 +L 0 +and 0 +3 0 +. 0 +6 0 +X 0 +10 0 +( 0 +- 0 +5 0 +) 0 +mol 0 +/ 0 +L 0 +"," 0 +respectively 0 +. 0 +All 0 +20 0 +patients 0 +responded 0 +to 0 +this 0 +regimen 0 +"," 0 +16 0 +/ 0 +20 0 +( 0 +80 0 +% 0 +) 0 +achieved 0 +a 0 +complete 0 +remission 0 +"," 0 +and 0 +20 0 +% 0 +obtained 0 +a 0 +partial 0 +remission 0 +. 0 +The 0 +most 0 +common 0 +toxicities 3 +encountered 0 +were 0 +transient 0 +serum 0 +transaminase 0 +and 0 +bilirubin 1 +elevations 0 +"," 0 +neutropenia 3 +"," 0 +and 0 +mucositis 3 +. 0 +0ne 0 +patient 0 +had 0 +focal 0 +seizures 3 +and 0 +transient 3 +hemiparesis 4 +but 0 +recovered 0 +completely 0 +. 0 +High 0 +- 0 +dose 0 +intravenous 0 +methotrexate 1 +is 0 +an 0 +effective 0 +treatment 0 +for 0 +the 0 +induction 0 +of 0 +remission 0 +after 0 +meningeal 0 +relapse 0 +in 0 +acute 3 +lymphoblastic 4 +leukemia 4 +. 0 +Interaction 0 +of 0 +cyclosporin 1 +A 2 +with 0 +antineoplastic 0 +agents 0 +. 0 +A 0 +synergistic 0 +effect 0 +of 0 +etoposide 1 +and 0 +cyclosporin 1 +A 2 +was 0 +observed 0 +in 0 +a 0 +patient 0 +with 0 +acute 3 +T 4 +- 4 +lymphocytic 4 +leukemia 4 +in 0 +relapse 0 +. 0 +The 0 +concomitant 0 +administration 0 +of 0 +etoposide 1 +and 0 +cyclosporin 1 +A 2 +resulted 0 +in 0 +eradication 0 +of 0 +hitherto 0 +refractory 0 +leukemic 3 +infiltration 4 +of 0 +bone 0 +marrow 0 +. 0 +Severe 0 +side 0 +effects 0 +in 0 +terms 0 +of 0 +mental 0 +confusion 3 +and 0 +progressive 0 +hyperbilirubinemia 3 +"," 0 +however 0 +"," 0 +point 0 +to 0 +an 0 +enhancement 0 +not 0 +only 0 +of 0 +antineoplastic 0 +effects 0 +but 0 +also 0 +of 0 +toxicity 3 +in 0 +normal 0 +tissues 0 +. 0 +This 0 +report 0 +demonstrates 0 +for 0 +the 0 +first 0 +time 0 +that 0 +the 0 +pharmacodynamic 0 +properties 0 +of 0 +cyclosporin 1 +A 2 +may 0 +not 0 +be 0 +confined 0 +strictly 0 +to 0 +suppression 0 +of 0 +normal 0 +T 0 +- 0 +cell 0 +functions 0 +. 0 +Incidence 0 +of 0 +neoplasms 3 +in 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +exposed 0 +to 0 +different 0 +treatment 0 +regimens 0 +. 0 +Immunosuppressive 0 +drugs 0 +have 0 +been 0 +used 0 +during 0 +the 0 +last 0 +30 0 +years 0 +in 0 +treatment 0 +of 0 +patients 0 +with 0 +severe 0 +rheumatoid 3 +arthritis 4 +. 0 +The 0 +drugs 0 +commonly 0 +used 0 +are 0 +cyclophosphamide 1 +and 0 +chlorambucil 1 +( 0 +alkylating 1 +agents 2 +) 0 +"," 0 +azathioprine 1 +( 0 +purine 1 +analogue 0 +) 0 +"," 0 +and 0 +methotrexate 1 +( 0 +folic 1 +acid 2 +analogue 0 +) 0 +. 0 +There 0 +is 0 +evidence 0 +that 0 +all 0 +four 0 +immunosuppressive 0 +drugs 0 +can 0 +reduce 0 +synovitis 3 +"," 0 +but 0 +disease 0 +activity 0 +almost 0 +always 0 +recurs 0 +after 0 +therapy 0 +is 0 +stopped 0 +. 0 +Since 0 +adverse 0 +reactions 0 +are 0 +frequent 0 +"," 0 +less 0 +than 0 +50 0 +percent 0 +of 0 +patients 0 +are 0 +able 0 +to 0 +continue 0 +a 0 +particular 0 +drug 0 +for 0 +more 0 +than 0 +one 0 +year 0 +. 0 +Since 0 +it 0 +takes 0 +three 0 +to 0 +12 0 +months 0 +to 0 +achieve 0 +maximal 0 +effects 0 +"," 0 +those 0 +patients 0 +who 0 +are 0 +unable 0 +to 0 +continue 0 +the 0 +drug 0 +receive 0 +little 0 +benefit 0 +from 0 +it 0 +. 0 +Patients 0 +treated 0 +with 0 +alkylating 1 +agents 2 +have 0 +an 0 +increased 0 +risk 0 +of 0 +development 0 +of 0 +acute 3 +nonlymphocytic 4 +leukemia 4 +"," 0 +and 0 +both 0 +alkylating 1 +agents 2 +and 0 +azathioprine 1 +are 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +non 3 +- 4 +Hodgkin 4 +' 4 +s 4 +lymphoma 4 +. 0 +Cyclophosphamide 1 +therapy 0 +increases 0 +the 0 +risk 0 +of 0 +carcinoma 3 +of 4 +the 4 +bladder 4 +. 0 +There 0 +have 0 +been 0 +several 0 +long 0 +- 0 +term 0 +studies 0 +of 0 +patients 0 +with 0 +rheumatoid 3 +arthritis 4 +treated 0 +with 0 +azathioprine 1 +and 0 +cyclophosphamide 1 +and 0 +the 0 +incidence 0 +of 0 +most 0 +of 0 +the 0 +common 0 +cancers 3 +is 0 +not 0 +increased 0 +. 0 +Data 0 +on 0 +the 0 +possible 0 +increased 0 +risk 0 +of 0 +malignancy 3 +in 0 +rheumatoid 3 +arthritis 4 +are 0 +still 0 +being 0 +collected 0 +"," 0 +and 0 +until 0 +further 0 +information 0 +is 0 +available 0 +"," 0 +the 0 +use 0 +of 0 +immunosuppressive 0 +drugs 0 +"," 0 +particularly 0 +alkylating 1 +agents 2 +"," 0 +in 0 +the 0 +treatment 0 +of 0 +rheumatoid 3 +arthritis 4 +should 0 +be 0 +reserved 0 +for 0 +patients 0 +with 0 +severe 0 +progressive 0 +disease 0 +or 0 +life 0 +- 0 +threatening 0 +complications 0 +. 0 +Warfarin 1 +- 0 +induced 0 +iliopsoas 0 +hemorrhage 3 +with 0 +subsequent 0 +femoral 3 +nerve 4 +palsy 4 +. 0 +We 0 +present 0 +the 0 +case 0 +of 0 +a 0 +28 0 +- 0 +year 0 +- 0 +old 0 +man 0 +on 0 +chronic 0 +warfarin 1 +therapy 0 +who 0 +sustained 0 +a 0 +minor 0 +muscle 3 +tear 4 +and 0 +developed 0 +increasing 0 +pain 3 +and 0 +a 0 +flexure 0 +contracture 3 +of 0 +the 0 +right 0 +hip 0 +. 0 +Surgical 0 +exploration 0 +revealed 0 +an 0 +iliopsoas 0 +hematoma 3 +and 0 +femoral 0 +nerve 3 +entrapment 4 +"," 0 +resulting 0 +in 0 +a 0 +femoral 3 +nerve 4 +palsy 4 +and 0 +partial 3 +loss 4 +of 4 +quadriceps 4 +functions 4 +. 0 +Anticoagulant 0 +- 0 +induced 0 +femoral 3 +nerve 4 +palsy 4 +represents 0 +the 0 +most 0 +common 0 +form 0 +of 0 +warfarin 1 +- 0 +induced 0 +peripheral 3 +neuropathy 4 +; 0 +it 0 +is 0 +characterized 0 +by 0 +severe 0 +pain 3 +in 0 +the 0 +inguinal 0 +region 0 +"," 0 +varying 0 +degrees 0 +of 0 +motor 3 +and 4 +sensory 4 +impairment 4 +"," 0 +and 0 +flexure 0 +contracture 3 +of 0 +the 0 +involved 0 +extremity 0 +. 0 +Pneumonitis 0 +with 0 +pleural 3 +and 4 +pericardial 4 +effusion 4 +and 0 +neuropathy 3 +during 0 +amiodarone 1 +therapy 0 +. 0 +A 0 +patient 0 +with 0 +sinuatrial 3 +disease 4 +and 0 +implanted 0 +pacemaker 0 +was 0 +treated 0 +with 0 +amiodarone 1 +( 0 +maximum 0 +dose 0 +1000 0 +mg 0 +"," 0 +maintenance 0 +dose 0 +800 0 +mg 0 +daily 0 +) 0 +for 0 +10 0 +months 0 +"," 0 +for 0 +control 0 +of 0 +supraventricular 3 +tachyarrhythmias 4 +. 0 +He 0 +developed 0 +pneumonitis 3 +"," 0 +pleural 3 +and 4 +pericardial 4 +effusions 4 +"," 0 +and 0 +a 0 +predominantly 0 +proximal 3 +motor 4 +neuropathy 4 +. 0 +Immediate 0 +but 0 +gradual 0 +improvement 0 +followed 0 +withdrawal 0 +of 0 +amiodarone 1 +and 0 +treatment 0 +with 0 +prednisolone 1 +. 0 +Review 0 +of 0 +this 0 +and 0 +previously 0 +reported 0 +cases 0 +indicates 0 +the 0 +need 0 +for 0 +early 0 +diagnosis 0 +of 0 +amiodarone 1 +pneumonitis 3 +"," 0 +immediate 0 +withdrawal 0 +of 0 +amiodarone 1 +"," 0 +and 0 +prompt 0 +but 0 +continued 0 +steroid 1 +therapy 0 +to 0 +ensure 0 +full 0 +recovery 0 +. 0 +Amiodarone 1 +- 0 +induced 0 +sinoatrial 3 +block 4 +. 0 +We 0 +observed 0 +sinoatrial 3 +block 4 +due 0 +to 0 +chronic 0 +amiodarone 1 +administration 0 +in 0 +a 0 +5 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +with 0 +primary 3 +cardiomyopathy 4 +"," 0 +Wolff 3 +- 4 +Parkinson 4 +- 4 +White 4 +syndrome 4 +and 0 +supraventricular 3 +tachycardia 4 +. 0 +Reduction 0 +in 0 +the 0 +dosage 0 +of 0 +amiodarone 1 +resulted 0 +in 0 +the 0 +disappearance 0 +of 0 +the 0 +sinoatrial 3 +block 4 +and 0 +the 0 +persistence 0 +of 0 +asymptomatic 0 +sinus 3 +bradycardia 4 +. 0 +Desipramine 1 +- 0 +induced 0 +delirium 3 +at 0 +" 0 +subtherapeutic 0 +" 0 +concentrations 0 +: 0 +a 0 +case 0 +report 0 +. 0 +An 0 +elderly 0 +patient 0 +treated 0 +with 0 +low 0 +dose 0 +Desipramine 1 +developed 0 +a 0 +delirium 3 +while 0 +her 0 +plasma 0 +level 0 +was 0 +in 0 +the 0 +" 0 +subtherapeutic 0 +" 0 +range 0 +. 0 +Delirium 3 +"," 0 +which 0 +may 0 +be 0 +induced 0 +by 0 +tricyclic 0 +drug 0 +therapy 0 +in 0 +the 0 +elderly 0 +"," 0 +can 0 +be 0 +caused 0 +by 0 +tricyclics 0 +with 0 +low 0 +anticholinergic 0 +potency 0 +. 0 +Therapeutic 0 +ranges 0 +for 0 +antidepressants 1 +that 0 +have 0 +been 0 +derived 0 +from 0 +general 0 +adult 0 +population 0 +studies 0 +may 0 +not 0 +be 0 +appropriate 0 +for 0 +the 0 +elderly 0 +. 0 +Further 0 +studies 0 +of 0 +specifically 0 +elderly 0 +patients 0 +are 0 +now 0 +required 0 +to 0 +establish 0 +safer 0 +and 0 +more 0 +appropriate 0 +guidelines 0 +for 0 +drug 0 +therapy 0 +. 0 +Indomethacin 1 +- 0 +induced 0 +renal 3 +insufficiency 4 +: 0 +recurrence 0 +on 0 +rechallenge 0 +. 0 +We 0 +have 0 +reported 0 +a 0 +case 0 +of 0 +acute 0 +oliguric 0 +renal 3 +failure 4 +with 0 +hyperkalemia 3 +in 0 +a 0 +patient 0 +with 0 +cirrhosis 3 +"," 0 +ascites 3 +"," 0 +and 0 +cor 3 +pulmonale 4 +after 0 +indomethacin 1 +therapy 0 +. 0 +Prompt 0 +restoration 0 +of 0 +renal 0 +function 0 +followed 0 +drug 0 +withdrawal 0 +"," 0 +while 0 +re 0 +- 0 +exposure 0 +to 0 +a 0 +single 0 +dose 0 +of 0 +indomethacin 1 +caused 0 +recurrence 0 +of 0 +acute 0 +reversible 0 +oliguria 3 +. 0 +0ur 0 +case 0 +supports 0 +the 0 +hypothesis 0 +that 0 +endogenous 0 +renal 0 +prostaglandins 1 +play 0 +a 0 +role 0 +in 0 +the 0 +maintenance 0 +of 0 +renal 0 +blood 0 +flow 0 +when 0 +circulating 0 +plasma 0 +volume 0 +is 0 +diminished 0 +. 0 +Since 0 +nonsteroidal 0 +anti 0 +- 0 +inflammatory 0 +agents 0 +interfere 0 +with 0 +this 0 +compensatory 0 +mechanism 0 +and 0 +may 0 +cause 0 +acute 3 +renal 4 +failure 4 +"," 0 +they 0 +should 0 +be 0 +used 0 +with 0 +caution 0 +in 0 +such 0 +patients 0 +. 0 +Patterns 0 +of 0 +hepatic 3 +injury 4 +induced 0 +by 0 +methyldopa 1 +. 0 +Twelve 0 +patients 0 +with 0 +liver 3 +disease 4 +related 0 +to 0 +methyldopa 1 +were 0 +seen 0 +between 0 +1967 0 +and 0 +1977 0 +. 0 +Illness 0 +occurred 0 +within 0 +1 0 +- 0 +- 0 +9 0 +weeks 0 +of 0 +commencement 0 +of 0 +therapy 0 +in 0 +9 0 +patients 0 +"," 0 +the 0 +remaining 0 +3 0 +patients 0 +having 0 +received 0 +the 0 +drug 0 +for 0 +13 0 +months 0 +"," 0 +15 0 +months 0 +and 0 +7 0 +years 0 +before 0 +experiencing 0 +symptoms 0 +. 0 +Jaundice 3 +with 0 +tender 0 +hepatomegaly 3 +"," 0 +usually 0 +preceded 0 +by 0 +symptoms 0 +of 0 +malaise 0 +"," 0 +anorexia 3 +"," 0 +nausea 3 +and 0 +vomiting 3 +"," 0 +and 0 +associated 0 +with 0 +upper 0 +abdominal 3 +pain 4 +"," 0 +was 0 +an 0 +invariable 0 +finding 0 +in 0 +all 0 +patients 0 +. 0 +Biochemical 0 +liver 0 +function 0 +tests 0 +indicated 0 +hepatocellular 0 +necrosis 3 +and 0 +correlated 0 +with 0 +histopathological 0 +evidence 0 +of 0 +hepatic 3 +injury 4 +"," 0 +the 0 +spectrum 0 +of 0 +which 0 +ranged 0 +from 0 +fatty 3 +change 4 +and 0 +focal 0 +hepatocellular 0 +necrosis 3 +to 0 +massive 3 +hepatic 4 +necrosis 4 +. 0 +Most 0 +patients 0 +showed 0 +moderate 0 +to 0 +severe 0 +acute 3 +hepatitis 4 +or 0 +chronic 3 +active 4 +hepatitis 4 +with 0 +associated 0 +cholestasis 3 +. 0 +The 0 +drug 0 +was 0 +withdrawn 0 +on 0 +presentation 0 +to 0 +hospital 0 +in 0 +11 0 +patients 0 +"," 0 +with 0 +rapid 0 +clinical 0 +improvement 0 +in 0 +9 0 +. 0 +0ne 0 +patient 0 +died 0 +"," 0 +having 0 +presented 0 +in 0 +hepatic 3 +failure 4 +"," 0 +and 0 +another 0 +"," 0 +who 0 +had 0 +been 0 +taking 0 +methyldopa 1 +for 0 +7 0 +years 0 +"," 0 +showed 0 +slower 0 +clinical 0 +and 0 +biochemical 0 +resolution 0 +over 0 +a 0 +period 0 +of 0 +several 0 +months 0 +. 0 +The 0 +remaining 0 +patient 0 +in 0 +the 0 +series 0 +developed 0 +fulminant 3 +hepatitis 4 +when 0 +the 0 +drug 0 +was 0 +accidentally 0 +recommenced 0 +1 0 +year 0 +after 0 +a 0 +prior 0 +episode 0 +of 0 +methyldopa 1 +- 0 +induced 0 +hepatitis 3 +. 0 +In 0 +this 0 +latter 0 +patient 0 +"," 0 +and 0 +in 0 +2 0 +others 0 +"," 0 +the 0 +causal 0 +relationship 0 +between 0 +methyldopa 1 +and 0 +hepatic 3 +dysfunction 4 +was 0 +proved 0 +with 0 +the 0 +recurrence 0 +of 0 +hepatitis 3 +within 0 +2 0 +weeks 0 +of 0 +re 0 +- 0 +exposure 0 +to 0 +the 0 +drug 0 +. 0 +Suxamethonium 1 +infusion 0 +rate 0 +and 0 +observed 0 +fasciculations 3 +. 0 +A 0 +dose 0 +- 0 +response 0 +study 0 +. 0 +Suxamethonium 1 +chloride 2 +( 0 +Sch 1 +) 0 +was 0 +administered 0 +i 0 +. 0 +v 0 +. 0 +to 0 +36 0 +adult 0 +males 0 +at 0 +six 0 +rates 0 +: 0 +0 0 +. 0 +25 0 +mg 0 +s 0 +- 0 +1 0 +to 0 +20 0 +mg 0 +s 0 +- 0 +1 0 +. 0 +The 0 +infusion 0 +was 0 +discontinued 0 +either 0 +when 0 +there 0 +was 0 +no 0 +muscular 0 +response 0 +to 0 +tetanic 3 +stimulation 0 +of 0 +the 0 +ulnar 0 +nerve 0 +or 0 +when 0 +Sch 1 +120 0 +mg 0 +was 0 +exceeded 0 +. 0 +Six 0 +additional 0 +patients 0 +received 0 +a 0 +30 0 +- 0 +mg 0 +i 0 +. 0 +v 0 +. 0 +bolus 0 +dose 0 +. 0 +Fasciculations 3 +in 0 +six 0 +areas 0 +of 0 +the 0 +body 0 +were 0 +scored 0 +from 0 +0 0 +to 0 +3 0 +and 0 +summated 0 +as 0 +a 0 +total 0 +fasciculation 3 +score 0 +. 0 +The 0 +times 0 +to 0 +first 0 +fasciculation 3 +"," 0 +twitch 3 +suppression 0 +and 0 +tetanus 3 +suppression 0 +were 0 +inversely 0 +related 0 +to 0 +the 0 +infusion 0 +rates 0 +. 0 +Fasciculations 3 +in 0 +the 0 +six 0 +areas 0 +and 0 +the 0 +total 0 +fasciculation 3 +score 0 +were 0 +related 0 +directly 0 +to 0 +the 0 +rate 0 +of 0 +infusion 0 +. 0 +Total 0 +fasciculation 3 +scores 0 +in 0 +the 0 +30 0 +- 0 +mg 0 +bolus 0 +group 0 +and 0 +the 0 +5 0 +- 0 +mg 0 +s 0 +- 0 +1 0 +and 0 +20 0 +- 0 +mg 0 +s 0 +- 0 +1 0 +infusion 0 +groups 0 +were 0 +not 0 +significantly 0 +different 0 +. 0 +Treatment 0 +of 0 +psoriasis 3 +with 0 +azathioprine 1 +. 0 +Azathioprine 1 +treatment 0 +benefited 0 +19 0 +( 0 +66 0 +% 0 +) 0 +out 0 +of 0 +29 0 +patients 0 +suffering 0 +from 0 +severe 0 +psoriasis 3 +. 0 +Haematological 0 +complications 0 +were 0 +not 0 +troublesome 0 +and 0 +results 0 +of 0 +biochemical 0 +liver 0 +function 0 +tests 0 +remained 0 +normal 0 +. 0 +Minimal 0 +cholestasis 3 +was 0 +seen 0 +in 0 +two 0 +cases 0 +and 0 +portal 0 +fibrosis 3 +of 0 +a 0 +reversible 0 +degree 0 +in 0 +eight 0 +. 0 +Liver 0 +biopsies 0 +should 0 +be 0 +undertaken 0 +at 0 +regular 0 +intervals 0 +if 0 +azathioprine 1 +therapy 0 +is 0 +continued 0 +so 0 +that 0 +structural 0 +liver 3 +damage 4 +may 0 +be 0 +detected 0 +at 0 +an 0 +early 0 +and 0 +reversible 0 +stage 0 +. 0 +Angiosarcoma 3 +of 4 +the 4 +liver 4 +associated 0 +with 0 +diethylstilbestrol 1 +. 0 +Angiosarcoma 3 +of 4 +the 4 +liver 4 +occurred 0 +in 0 +a 0 +76 0 +- 0 +year 0 +- 0 +old 0 +man 0 +who 0 +had 0 +been 0 +treated 0 +for 0 +a 0 +well 0 +- 0 +differentiated 0 +adenocarcinoma 3 +of 4 +the 4 +liver 4 +with 0 +diethylstilbestrol 1 +for 0 +13 0 +years 0 +. 0 +Angiosarcoma 3 +was 0 +also 0 +present 0 +within 0 +pulmonary 0 +and 0 +renal 0 +arteries 0 +. 0 +The 0 +possibility 0 +that 0 +the 0 +intraarterial 3 +lesions 4 +might 0 +represent 0 +independent 0 +primary 0 +tumors 3 +is 0 +considered 0 +. 0 +Galanthamine 1 +hydrobromide 2 +"," 0 +a 0 +longer 0 +acting 0 +anticholinesterase 0 +drug 0 +"," 0 +in 0 +the 0 +treatment 0 +of 0 +the 0 +central 0 +effects 0 +of 0 +scopolamine 1 +( 0 +Hyoscine 1 +) 0 +. 0 +Galanthamine 1 +hydrobromide 2 +"," 0 +an 0 +anticholinesterase 0 +drug 0 +capable 0 +of 0 +penetrating 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +"," 0 +was 0 +used 0 +in 0 +a 0 +patient 0 +demonstrating 0 +central 0 +effects 0 +of 0 +scopolamine 1 +( 0 +hyoscine 1 +) 0 +overdosage 3 +. 0 +It 0 +is 0 +longer 0 +acting 0 +than 0 +physostigmine 1 +and 0 +is 0 +used 0 +in 0 +anaesthesia 0 +to 0 +reverse 0 +the 0 +non 0 +- 0 +depolarizing 0 +neuromuscular 0 +block 0 +. 0 +However 0 +"," 0 +studies 0 +into 0 +the 0 +dose 0 +necessary 0 +to 0 +combating 0 +scopolamine 1 +intoxication 0 +are 0 +indicated 0 +. 0 +Comparison 0 +of 0 +the 0 +subjective 0 +effects 0 +and 0 +plasma 0 +concentrations 0 +following 0 +oral 0 +and 0 +i 0 +. 0 +m 0 +. 0 +administration 0 +of 0 +flunitrazepam 1 +in 0 +volunteers 0 +. 0 +Flunitrazepam 1 +0 0 +. 0 +5 0 +"," 0 +1 0 +. 0 +0 0 +or 0 +2 0 +. 0 +0 0 +mg 0 +was 0 +given 0 +by 0 +the 0 +oral 0 +or 0 +i 0 +. 0 +m 0 +. 0 +routes 0 +to 0 +groups 0 +of 0 +volunteers 0 +and 0 +its 0 +effects 0 +compared 0 +. 0 +Plasma 0 +concentrations 0 +of 0 +the 0 +drug 0 +were 0 +estimated 0 +by 0 +gas 0 +- 0 +liquid 0 +chromatography 0 +"," 0 +in 0 +a 0 +smaller 0 +number 0 +of 0 +the 0 +subjects 0 +. 0 +The 0 +most 0 +striking 0 +effect 0 +was 0 +sedation 0 +which 0 +increased 0 +with 0 +the 0 +dose 0 +"," 0 +2 0 +mg 0 +producing 0 +deep 0 +sleep 0 +although 0 +the 0 +subjects 0 +could 0 +still 0 +be 0 +aroused 0 +. 0 +The 0 +effects 0 +of 0 +i 0 +. 0 +m 0 +. 0 +administration 0 +were 0 +apparent 0 +earlier 0 +and 0 +sometimes 0 +lasted 0 +longer 0 +than 0 +those 0 +following 0 +oral 0 +administration 0 +. 0 +Dizziness 3 +was 0 +less 0 +marked 0 +than 0 +sedation 0 +"," 0 +but 0 +increased 0 +with 0 +the 0 +dose 0 +. 0 +There 0 +was 0 +pain 3 +on 0 +i 0 +. 0 +m 0 +. 0 +injection 0 +of 0 +flunitrazepam 1 +significantly 0 +more 0 +often 0 +than 0 +with 0 +isotonic 0 +saline 0 +. 0 +Plasma 0 +concentrations 0 +varied 0 +with 0 +dose 0 +and 0 +route 0 +and 0 +corresponded 0 +qualitatively 0 +with 0 +the 0 +subjective 0 +effects 0 +. 0 +The 0 +drug 0 +was 0 +still 0 +present 0 +in 0 +measurable 0 +quantities 0 +after 0 +24 0 +h 0 +even 0 +with 0 +the 0 +smallest 0 +dose 0 +. 0 +Possible 0 +teratogenicity 0 +of 0 +sulphasalazine 1 +. 0 +Three 0 +infants 0 +"," 0 +born 0 +of 0 +two 0 +mothers 0 +with 0 +inflammatory 3 +bowel 4 +disease 4 +who 0 +received 0 +treatment 0 +with 0 +sulphasalazine 1 +throughout 0 +pregnancy 0 +"," 0 +were 0 +found 0 +to 0 +have 0 +major 0 +congenital 3 +anomalies 4 +. 0 +In 0 +the 0 +singleton 0 +pregnancy 0 +"," 0 +the 0 +mother 0 +had 0 +ulcerative 3 +colitis 4 +"," 0 +and 0 +the 0 +infant 0 +"," 0 +a 0 +male 0 +"," 0 +had 0 +coarctation 3 +of 4 +the 4 +aorta 4 +and 0 +a 0 +ventricular 3 +septal 4 +defect 4 +. 0 +In 0 +the 0 +twin 0 +pregnancy 0 +"," 0 +the 0 +mother 0 +had 0 +Crohn 3 +' 4 +s 4 +disease 4 +. 0 +The 0 +first 0 +twin 0 +"," 0 +a 0 +female 0 +"," 0 +had 0 +a 0 +left 0 +Potter 3 +- 4 +type 4 +IIa 4 +polycystic 4 +kidney 4 +and 0 +a 0 +rudimentary 3 +left 4 +uterine 4 +cornu 4 +. 0 +The 0 +second 0 +twin 0 +"," 0 +a 0 +male 0 +"," 0 +had 0 +some 0 +features 0 +of 0 +Potter 3 +' 4 +s 4 +facies 4 +"," 0 +hypoplastic 3 +lungs 4 +"," 0 +absent 3 +kidneys 4 +and 4 +ureters 4 +"," 0 +and 0 +talipes 3 +equinovarus 4 +. 0 +Despite 0 +reports 0 +to 0 +the 0 +contrary 0 +"," 0 +it 0 +is 0 +suggested 0 +that 0 +sulphasalazine 1 +may 0 +be 0 +teratogenic 0 +. 0 +Thrombotic 3 +microangiopathy 4 +and 0 +renal 3 +failure 4 +associated 0 +with 0 +antineoplastic 0 +chemotherapy 0 +. 0 +Five 0 +patients 0 +with 0 +carcinoma 3 +developed 0 +thrombotic 3 +microangiopathy 4 +( 0 +characterized 0 +by 0 +renal 3 +insufficiency 4 +"," 0 +microangiopathic 3 +hemolytic 4 +anemia 4 +"," 0 +and 0 +usually 0 +thrombocytopenia 3 +) 0 +after 0 +treatment 0 +with 0 +cisplatin 1 +"," 0 +bleomycin 1 +"," 0 +and 0 +a 0 +vinca 1 +alkaloid 2 +. 0 +0ne 0 +patient 0 +had 0 +thrombotic 3 +thrombocytopenic 4 +purpura 4 +"," 0 +three 0 +the 0 +hemolytic 3 +- 4 +uremic 4 +syndrome 4 +"," 0 +and 0 +one 0 +an 0 +apparent 0 +forme 0 +fruste 0 +of 0 +one 0 +of 0 +these 0 +disorders 0 +. 0 +Histologic 0 +examination 0 +of 0 +the 0 +renal 0 +tissue 0 +showed 0 +evidence 0 +of 0 +intravascular 3 +coagulation 4 +"," 0 +primarily 0 +affecting 0 +the 0 +small 0 +arteries 0 +"," 0 +arterioles 0 +"," 0 +and 0 +glomeruli 0 +. 0 +Because 0 +each 0 +patient 0 +was 0 +tumor 3 +- 0 +free 0 +or 0 +had 0 +only 0 +a 0 +small 0 +tumor 3 +at 0 +the 0 +onset 0 +of 0 +this 0 +syndrome 0 +"," 0 +the 0 +thrombotic 3 +microangiopathy 4 +may 0 +have 0 +been 0 +induced 0 +by 0 +chemotherapy 0 +. 0 +Diagnosis 0 +of 0 +this 0 +potentially 0 +fatal 0 +complication 0 +may 0 +be 0 +delayed 0 +or 0 +missed 0 +if 0 +renal 0 +tissue 0 +or 0 +the 0 +peripheral 0 +blood 0 +smear 0 +is 0 +not 0 +examined 0 +"," 0 +because 0 +renal 3 +failure 4 +may 0 +be 0 +ascribed 0 +to 0 +cisplatin 1 +nephrotoxicity 3 +and 0 +the 0 +anemia 3 +and 0 +thrombocytopenia 3 +to 0 +drug 0 +- 0 +induced 0 +bone 3 +marrow 4 +suppression 4 +. 0 +International 0 +mexiletine 1 +and 0 +placebo 0 +antiarrhythmic 0 +coronary 0 +trial 0 +: 0 +I 0 +. 0 +Report 0 +on 0 +arrhythmia 3 +and 0 +other 0 +findings 0 +. 0 +Impact 0 +Research 0 +Group 0 +. 0 +The 0 +antiarrhythmic 0 +effects 0 +of 0 +the 0 +sustained 0 +release 0 +form 0 +of 0 +mexiletine 1 +( 0 +Mexitil 1 +- 2 +Perlongets 2 +) 0 +were 0 +evaluated 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +placebo 0 +trial 0 +in 0 +630 0 +patients 0 +with 0 +recent 0 +documented 0 +myocardial 3 +infarction 4 +. 0 +The 0 +primary 0 +response 0 +variable 0 +was 0 +based 0 +on 0 +central 0 +reading 0 +of 0 +24 0 +hour 0 +ambulatory 0 +electrocardiographic 0 +recordings 0 +and 0 +was 0 +defined 0 +as 0 +the 0 +occurrence 0 +of 0 +30 0 +or 0 +more 0 +single 0 +premature 0 +ventricular 0 +complexes 0 +in 0 +any 0 +two 0 +consecutive 0 +30 0 +minute 0 +blocks 0 +or 0 +one 0 +or 0 +more 0 +runs 0 +of 0 +two 0 +or 0 +more 0 +premature 0 +ventricular 0 +complexes 0 +in 0 +the 0 +entire 0 +24 0 +hour 0 +electrocardiographic 0 +recording 0 +. 0 +Large 0 +differences 0 +"," 0 +regarded 0 +as 0 +statistically 0 +significant 0 +"," 0 +between 0 +the 0 +mexiletine 1 +and 0 +placebo 0 +groups 0 +were 0 +noted 0 +in 0 +that 0 +end 0 +point 0 +at 0 +months 0 +1 0 +and 0 +4 0 +"," 0 +but 0 +only 0 +trends 0 +were 0 +observed 0 +at 0 +month 0 +12 0 +. 0 +These 0 +differences 0 +were 0 +observed 0 +even 0 +though 0 +the 0 +serum 0 +mexiletine 1 +levels 0 +obtained 0 +in 0 +this 0 +study 0 +were 0 +generally 0 +lower 0 +than 0 +those 0 +observed 0 +in 0 +studies 0 +that 0 +have 0 +used 0 +the 0 +regular 0 +form 0 +of 0 +the 0 +drug 0 +. 0 +There 0 +were 0 +more 0 +deaths 3 +in 0 +the 0 +mexiletine 1 +group 0 +( 0 +7 0 +. 0 +6 0 +% 0 +) 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +( 0 +4 0 +. 0 +8 0 +% 0 +) 0 +; 0 +the 0 +difference 0 +was 0 +not 0 +statistically 0 +significant 0 +. 0 +The 0 +incidence 0 +of 0 +coronary 0 +events 0 +was 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 +Previously 0 +recognized 0 +side 0 +effects 0 +"," 0 +particularly 0 +tremor 3 +and 0 +gastrointestinal 3 +problems 4 +"," 0 +were 0 +more 0 +frequent 0 +in 0 +the 0 +mexiletine 1 +group 0 +than 0 +in 0 +the 0 +placebo 0 +group 0 +. 0 +Changes 0 +in 0 +heart 0 +size 0 +during 0 +long 0 +- 0 +term 0 +timolol 1 +treatment 0 +after 0 +myocardial 3 +infarction 4 +. 0 +The 0 +effect 0 +of 0 +long 0 +- 0 +term 0 +timolol 1 +treatment 0 +on 0 +heart 0 +size 0 +after 0 +myocardial 3 +infarction 4 +was 0 +evaluated 0 +by 0 +X 0 +- 0 +ray 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +study 0 +including 0 +241 0 +patients 0 +( 0 +placebo 0 +126 0 +"," 0 +timolol 1 +115 0 +) 0 +. 0 +The 0 +follow 0 +- 0 +up 0 +period 0 +was 0 +12 0 +months 0 +. 0 +The 0 +timolol 1 +- 0 +treated 0 +patients 0 +showed 0 +a 0 +small 0 +but 0 +significant 0 +increase 0 +in 0 +heart 0 +size 0 +from 0 +baseline 0 +in 0 +contrast 0 +to 0 +a 0 +decrease 0 +in 0 +the 0 +placebo 0 +group 0 +. 0 +These 0 +differences 0 +may 0 +be 0 +caused 0 +by 0 +timolol 1 +- 0 +induced 0 +bradycardia 3 +and 0 +a 0 +compensatory 0 +increase 0 +in 0 +end 0 +- 0 +diastolic 0 +volume 0 +. 0 +The 0 +timolol 1 +- 0 +related 0 +increase 0 +in 0 +heart 0 +size 0 +was 0 +observed 0 +only 0 +in 0 +patients 0 +with 0 +normal 0 +and 0 +borderline 0 +heart 0 +size 0 +. 0 +In 0 +patients 0 +with 0 +cardiomegaly 3 +"," 0 +the 0 +increase 0 +in 0 +heart 0 +size 0 +was 0 +similar 0 +in 0 +both 0 +groups 0 +. 0 +After 0 +re 0 +- 0 +infarction 3 +"," 0 +heart 0 +size 0 +increased 0 +in 0 +the 0 +placebo 0 +group 0 +and 0 +remained 0 +unchanged 0 +in 0 +the 0 +timolol 1 +group 0 +. 0 +Vitamin 1 +D3 2 +toxicity 3 +in 0 +dairy 0 +cows 0 +. 0 +Large 0 +parenteral 0 +doses 0 +of 0 +vitamin 1 +D3 2 +( 0 +15 0 +to 0 +17 0 +. 0 +5 0 +x 0 +10 0 +( 0 +6 0 +) 0 +IU 0 +vitamin 1 +D3 2 +) 0 +were 0 +associated 0 +with 0 +prolonged 0 +hypercalcemia 3 +"," 0 +hyperphosphatemia 3 +"," 0 +and 0 +large 0 +increases 0 +of 0 +vitamin 1 +D3 2 +and 0 +its 0 +metabolites 0 +in 0 +the 0 +blood 0 +plasma 0 +of 0 +nonlactating 0 +nonpregnant 0 +and 0 +pregnant 0 +Jersey 0 +cows 0 +. 0 +Calcium 1 +concentrations 0 +1 0 +day 0 +postpartum 0 +were 0 +higher 0 +in 0 +cows 0 +treated 0 +with 0 +vitamin 1 +D3 2 +about 0 +32 0 +days 0 +prepartum 0 +( 0 +8 0 +. 0 +8 0 +mg 0 +/ 0 +100 0 +ml 0 +) 0 +than 0 +in 0 +control 0 +cows 0 +( 0 +5 0 +. 0 +5 0 +mg 0 +/ 0 +100 0 +ml 0 +) 0 +. 0 +None 0 +of 0 +the 0 +cows 0 +treated 0 +with 0 +vitamin 1 +D3 2 +showed 0 +signs 0 +of 0 +milk 3 +fever 4 +during 0 +the 0 +peripartal 0 +period 0 +; 0 +however 0 +"," 0 +22 0 +% 0 +of 0 +the 0 +control 0 +cows 0 +developed 0 +clinical 0 +signs 0 +of 0 +milk 3 +fever 4 +during 0 +this 0 +period 0 +. 0 +Signs 0 +of 0 +vitamin 1 +D3 2 +toxicity 3 +were 0 +not 0 +observed 0 +in 0 +nonlactating 0 +nonpregnant 0 +cows 0 +; 0 +however 0 +"," 0 +pregnant 0 +cows 0 +commonly 0 +developed 0 +severe 0 +signs 0 +of 0 +vitamin 1 +D3 2 +toxicity 3 +and 0 +10 0 +of 0 +17 0 +cows 0 +died 0 +. 0 +There 0 +was 0 +widespread 0 +metastatic 0 +calcification 0 +in 0 +the 0 +cows 0 +that 0 +died 0 +. 0 +Because 0 +of 0 +the 0 +extreme 0 +toxicity 3 +of 0 +vitamin 1 +D3 2 +in 0 +pregnant 0 +Jersey 0 +cows 0 +and 0 +the 0 +low 0 +margin 0 +of 0 +safety 0 +between 0 +doses 0 +of 0 +vitamin 1 +D3 2 +that 0 +prevent 0 +milk 3 +fever 4 +and 0 +doses 0 +that 0 +induce 0 +milk 3 +fever 4 +"," 0 +we 0 +concluded 0 +that 0 +vitamin 1 +D3 2 +cannot 0 +be 0 +used 0 +practically 0 +to 0 +prevent 0 +milk 3 +fever 4 +when 0 +injected 0 +several 0 +weeks 0 +prepartum 0 +. 0 +Diseases 3 +of 4 +peripheral 4 +nerves 4 +as 0 +seen 0 +in 0 +the 0 +Nigerian 0 +African 0 +. 0 +The 0 +anatomical 0 +and 0 +aetiological 0 +diagnoses 0 +of 0 +peripheral 3 +nerve 4 +disease 4 +excluding 0 +its 0 +primary 0 +benign 0 +and 0 +malignant 0 +disorders 0 +"," 0 +as 0 +seen 0 +in 0 +358 0 +Nigerians 0 +are 0 +presented 0 +. 0 +There 0 +is 0 +a 0 +male 0 +preponderance 0 +and 0 +the 0 +peak 0 +incidence 0 +is 0 +in 0 +the 0 +fourth 0 +decade 0 +. 0 +Sensori 3 +- 4 +motor 4 +neuropathy 4 +was 0 +the 0 +commonest 0 +presentation 0 +( 0 +50 0 +% 0 +) 0 +. 0 +Guillain 3 +- 4 +Barr 4 +syndrome 4 +was 0 +the 0 +commonest 0 +identifiable 0 +cause 0 +( 0 +15 0 +. 0 +6 0 +% 0 +) 0 +"," 0 +accounting 0 +for 0 +half 0 +of 0 +the 0 +cases 0 +with 0 +motor 3 +neuropathy 4 +. 0 +Peripheral 3 +neuropathy 4 +due 0 +to 0 +nutritional 3 +deficiency 4 +of 0 +thiamine 1 +and 0 +riboflavin 1 +was 0 +common 0 +( 0 +10 0 +. 0 +1 0 +% 0 +) 0 +and 0 +presented 0 +mainly 0 +as 0 +sensory 0 +and 0 +sensori 3 +- 4 +motor 4 +neuropathy 4 +. 0 +Diabetes 3 +mellitus 4 +was 0 +the 0 +major 0 +cause 0 +of 0 +autonomic 3 +neuropathy 4 +. 0 +Isoniazid 1 +was 0 +the 0 +most 0 +frequent 0 +agent 0 +in 0 +drug 0 +- 0 +induced 0 +neuropathy 3 +. 0 +Migraine 3 +( 0 +20 0 +% 0 +) 0 +was 0 +not 0 +an 0 +uncommon 0 +cause 0 +of 0 +cranial 3 +neuropathy 4 +although 0 +malignancies 3 +arising 0 +from 0 +the 0 +reticuloendothelial 0 +system 0 +or 0 +related 0 +structures 0 +of 0 +the 0 +head 0 +and 0 +neck 0 +were 0 +more 0 +frequent 0 +( 0 +26 0 +% 0 +) 0 +. 0 +In 0 +26 0 +. 0 +5 0 +% 0 +of 0 +all 0 +the 0 +cases 0 +"," 0 +the 0 +aetiology 0 +of 0 +the 0 +neuropathy 3 +was 0 +undetermined 0 +. 0 +Heredofamilial 0 +and 0 +connective 3 +tissue 4 +disorders 4 +were 0 +rare 0 +. 0 +Some 0 +of 0 +the 0 +factors 0 +related 0 +to 0 +the 0 +clinical 0 +presentation 0 +and 0 +pathogenesis 0 +of 0 +the 0 +neuropathies 3 +are 0 +briefly 0 +discussed 0 +. 0 +Reduction 0 +in 0 +caffeine 1 +toxicity 3 +by 0 +acetaminophen 1 +. 0 +A 0 +patient 0 +who 0 +allegedly 0 +consumed 0 +100 0 +tablets 0 +of 0 +an 0 +over 0 +- 0 +the 0 +- 0 +counter 0 +analgesic 0 +containing 0 +sodium 1 +acetylsalicylate 2 +"," 0 +caffeine 1 +"," 0 +and 0 +acetaminophen 1 +displayed 0 +no 0 +significant 0 +CNS 0 +stimulation 0 +despite 0 +the 0 +presence 0 +of 0 +175 0 +micrograms 0 +of 0 +caffeine 1 +per 0 +mL 0 +of 0 +serum 0 +. 0 +Because 0 +salicylates 0 +have 0 +been 0 +reported 0 +to 0 +augment 0 +the 0 +stimulatory 0 +effects 0 +of 0 +caffeine 1 +on 0 +the 0 +CNS 0 +"," 0 +attention 0 +was 0 +focused 0 +on 0 +the 0 +possibility 0 +that 0 +the 0 +presence 0 +of 0 +acetaminophen 1 +( 0 +52 0 +micrograms 0 +/ 0 +mL 0 +) 0 +reduced 0 +the 0 +CNS 0 +toxicity 3 +of 0 +caffeine 1 +. 0 +Studies 0 +in 0 +DBA 0 +/ 0 +2J 0 +mice 0 +showed 0 +that 0 +: 0 +1 0 +) 0 +pretreatment 0 +with 0 +acetaminophen 1 +( 0 +100 0 +mg 0 +/ 0 +kg 0 +) 0 +increased 0 +the 0 +interval 0 +between 0 +the 0 +administration 0 +of 0 +caffeine 1 +( 0 +300 0 +to 0 +450 0 +mg 0 +/ 0 +kg 0 +IP 0 +) 0 +and 0 +the 0 +onset 0 +of 0 +fatal 0 +convulsions 3 +by 0 +a 0 +factor 0 +of 0 +about 0 +two 0 +; 0 +and 0 +2 0 +) 0 +pretreatment 0 +with 0 +acetaminophen 1 +( 0 +75 0 +mg 0 +/ 0 +kg 0 +) 0 +reduced 0 +the 0 +incidence 0 +of 0 +audiogenic 0 +seizures 3 +produced 0 +in 0 +the 0 +presence 0 +of 0 +caffeine 1 +( 0 +12 0 +. 0 +5 0 +to 0 +75 0 +mg 0 +/ 0 +kg 0 +IP 0 +) 0 +. 0 +The 0 +frequency 0 +of 0 +sound 0 +- 0 +induced 0 +seizures 3 +after 0 +12 0 +. 0 +5 0 +or 0 +25 0 +mg 0 +/ 0 +kg 0 +caffeine 1 +was 0 +reduced 0 +from 0 +50 0 +to 0 +5 0 +% 0 +by 0 +acetaminophen 1 +. 0 +In 0 +the 0 +absence 0 +of 0 +caffeine 1 +"," 0 +acetaminophen 1 +( 0 +up 0 +to 0 +300 0 +mg 0 +/ 0 +kg 0 +) 0 +did 0 +not 0 +modify 0 +the 0 +seizures 3 +induced 0 +by 0 +maximal 0 +electroshock 0 +and 0 +did 0 +not 0 +alter 0 +the 0 +convulsant 0 +dose 0 +of 0 +pentylenetetrezol 1 +in 0 +mice 0 +( 0 +tests 0 +performed 0 +by 0 +the 0 +Anticonvulsant 0 +Screening 0 +Project 0 +of 0 +NINCDS 0 +) 0 +. 0 +Acetaminophen 1 +( 0 +up 0 +to 0 +150 0 +micrograms 0 +/ 0 +mL 0 +) 0 +did 0 +not 0 +retard 0 +the 0 +incorporation 0 +of 0 +radioactive 0 +adenosine 1 +into 0 +ATP 1 +in 0 +slices 0 +of 0 +rat 0 +cerebral 0 +cortex 0 +. 0 +Thus 0 +the 0 +mechanism 0 +by 0 +which 0 +acetaminophen 1 +antagonizes 0 +the 0 +actions 0 +of 0 +caffeine 1 +in 0 +the 0 +CNS 0 +remains 0 +unknown 0 +. 0 +A 0 +double 0 +- 0 +blind 0 +study 0 +of 0 +the 0 +efficacy 0 +and 0 +safety 0 +of 0 +dothiepin 1 +hydrochloride 2 +in 0 +the 0 +treatment 0 +of 0 +major 0 +depressive 3 +disorder 4 +. 0 +In 0 +a 0 +6 0 +- 0 +week 0 +double 0 +- 0 +blind 0 +parallel 0 +treatment 0 +study 0 +"," 0 +dothiepin 1 +and 0 +amitriptyline 1 +were 0 +compared 0 +to 0 +placebo 0 +in 0 +the 0 +treatment 0 +of 0 +33 0 +depressed 3 +outpatients 0 +. 0 +Dothiepin 1 +and 0 +amitriptyline 1 +were 0 +equally 0 +effective 0 +in 0 +alleviating 0 +the 0 +symptoms 0 +of 0 +depressive 3 +illness 4 +"," 0 +and 0 +both 0 +were 0 +significantly 0 +superior 0 +to 0 +placebo 0 +. 0 +The 0 +overall 0 +incidence 0 +of 0 +side 0 +effects 0 +and 0 +the 0 +frequency 0 +and 0 +severity 0 +of 0 +blurred 3 +vision 4 +"," 0 +dry 3 +mouth 4 +"," 0 +and 0 +drowsiness 0 +were 0 +significantly 0 +less 0 +with 0 +dothiepin 1 +than 0 +with 0 +amitriptyline 1 +. 0 +Dothiepin 1 +also 0 +produced 0 +fewer 0 +CNS 0 +and 0 +cardiovascular 0 +effects 0 +. 0 +There 0 +were 0 +no 0 +clinically 0 +important 0 +changes 0 +in 0 +laboratory 0 +parameters 0 +. 0 +Dothiepin 1 +thus 0 +was 0 +found 0 +to 0 +be 0 +an 0 +effective 0 +antidepressant 1 +drug 0 +associated 0 +with 0 +fewer 0 +side 0 +effects 0 +than 0 +amitriptyline 1 +in 0 +the 0 +treatment 0 +of 0 +depressed 3 +outpatients 0 +. 0 +Behavioral 0 +effects 0 +of 0 +diazepam 1 +and 0 +propranolol 1 +in 0 +patients 0 +with 0 +panic 3 +disorder 4 +and 0 +agoraphobia 3 +. 0 +The 0 +effects 0 +of 0 +oral 0 +doses 0 +of 0 +diazepam 1 +( 0 +single 0 +dose 0 +of 0 +10 0 +mg 0 +and 0 +a 0 +median 0 +dose 0 +of 0 +30 0 +mg 0 +/ 0 +day 0 +for 0 +2 0 +weeks 0 +) 0 +and 0 +propranolol 1 +( 0 +single 0 +dose 0 +of 0 +80 0 +mg 0 +and 0 +a 0 +median 0 +dose 0 +of 0 +240 0 +mg 0 +/ 0 +day 0 +for 0 +2 0 +weeks 0 +) 0 +on 0 +psychological 0 +performance 0 +of 0 +patients 0 +with 0 +panic 3 +disorders 4 +and 0 +agoraphobia 3 +were 0 +investigated 0 +in 0 +a 0 +double 0 +- 0 +blind 0 +"," 0 +randomized 0 +and 0 +crossover 0 +design 0 +. 0 +Both 0 +drugs 0 +impaired 3 +immediate 4 +free 4 +recall 4 +but 0 +the 0 +decrease 0 +was 0 +greater 0 +for 0 +diazepam 1 +than 0 +propranolol 1 +. 0 +Delayed 3 +free 4 +recall 4 +was 4 +also 4 +impaired 4 +but 0 +the 0 +two 0 +drugs 0 +did 0 +not 0 +differ 0 +. 0 +Patients 0 +tapped 0 +faster 0 +after 0 +propranolol 1 +than 0 +diazepam 1 +and 0 +they 0 +were 0 +more 0 +sedated 0 +after 0 +diazepam 1 +than 0 +propranolol 1 +. 0 +After 0 +2 0 +weeks 0 +of 0 +treatment 0 +"," 0 +patients 0 +tested 0 +5 0 +- 0 +8 0 +h 0 +after 0 +the 0 +last 0 +dose 0 +of 0 +medication 0 +did 0 +not 0 +show 0 +any 0 +decrement 0 +of 0 +performance 0 +. 0 +These 0 +results 0 +are 0 +similar 0 +to 0 +those 0 +previously 0 +found 0 +in 0 +healthy 0 +subjects 0 +. 0 +Accumulation 0 +of 0 +drugs 0 +was 0 +not 0 +reflected 0 +in 0 +prolonged 0 +behavioral 3 +impairment 4 +. 0 +Comparison 0 +of 0 +i 0 +. 0 +v 0 +. 0 +glycopyrrolate 1 +and 0 +atropine 1 +in 0 +the 0 +prevention 0 +of 0 +bradycardia 3 +and 0 +arrhythmias 3 +following 0 +repeated 0 +doses 0 +of 0 +suxamethonium 1 +in 0 +children 0 +. 0 +The 0 +effectiveness 0 +of 0 +administration 0 +of 0 +glycopyrrolate 1 +5 0 +and 0 +10 0 +micrograms 0 +kg 0 +- 0 +1 0 +and 0 +atropine 1 +10 0 +and 0 +20 0 +micrograms 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +immediately 0 +before 0 +the 0 +induction 0 +of 0 +anaesthesia 0 +"," 0 +to 0 +prevent 0 +arrhythmia 3 +and 0 +bradycardia 3 +following 0 +repeated 0 +doses 0 +of 0 +suxamethonium 1 +in 0 +children 0 +"," 0 +was 0 +studied 0 +. 0 +A 0 +control 0 +group 0 +was 0 +included 0 +for 0 +comparison 0 +with 0 +the 0 +lower 0 +dose 0 +range 0 +of 0 +glycopyrrolate 1 +and 0 +atropine 1 +. 0 +A 0 +frequency 0 +of 0 +bradycardia 3 +of 0 +50 0 +% 0 +was 0 +noted 0 +in 0 +the 0 +control 0 +group 0 +"," 0 +but 0 +this 0 +was 0 +not 0 +significantly 0 +different 0 +from 0 +the 0 +frequency 0 +with 0 +the 0 +active 0 +drugs 0 +. 0 +Bradycardia 3 +( 0 +defined 0 +as 0 +a 0 +decrease 0 +in 0 +heart 0 +rate 0 +to 0 +less 0 +than 0 +50 0 +beat 0 +min 0 +- 0 +1 0 +) 0 +was 0 +prevented 0 +when 0 +the 0 +larger 0 +dose 0 +of 0 +either 0 +active 0 +drug 0 +was 0 +used 0 +. 0 +It 0 +is 0 +recommended 0 +that 0 +either 0 +glycopyrrolate 1 +10 0 +micrograms 0 +kg 0 +- 0 +1 0 +or 0 +atropine 1 +20 0 +micrograms 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +should 0 +immediately 0 +precede 0 +induction 0 +of 0 +anaesthesia 0 +"," 0 +in 0 +children 0 +"," 0 +if 0 +the 0 +repeated 0 +administration 0 +of 0 +suxamethonium 1 +is 0 +anticipated 0 +. 0 +Veno 3 +- 4 +occlusive 4 +liver 4 +disease 4 +after 0 +dacarbazine 1 +therapy 0 +( 0 +DTIC 1 +) 0 +for 0 +melanoma 3 +. 0 +A 0 +case 0 +of 0 +veno 3 +- 4 +occlusive 4 +disease 4 +of 4 +the 4 +liver 4 +with 0 +fatal 0 +outcome 0 +after 0 +dacarbazine 1 +( 0 +DTIC 1 +) 0 +therapy 0 +for 0 +melanoma 3 +is 0 +reported 0 +. 0 +There 0 +was 0 +a 0 +fulminant 0 +clinical 0 +course 0 +from 0 +start 0 +of 0 +symptoms 0 +until 0 +death 3 +. 0 +At 0 +autopsy 0 +the 0 +liver 0 +was 0 +enlarged 0 +and 0 +firm 0 +with 0 +signs 0 +of 0 +venous 3 +congestion 4 +. 0 +Small 0 +- 0 +and 0 +medium 0 +- 0 +sized 0 +hepatic 0 +veins 0 +were 0 +blocked 0 +by 0 +thrombosis 3 +. 0 +Eosinophilic 0 +infiltrations 0 +were 0 +found 0 +around 0 +the 0 +vessels 0 +. 0 +Published 0 +cases 0 +from 0 +the 0 +literature 0 +are 0 +reviewed 0 +and 0 +pertinent 0 +features 0 +discussed 0 +. 0 +Maternal 0 +lithium 1 +and 0 +neonatal 0 +Ebstein 3 +' 4 +s 4 +anomaly 4 +: 0 +evaluation 0 +with 0 +cross 0 +- 0 +sectional 0 +echocardiography 0 +. 0 +Cross 0 +- 0 +sectional 0 +echocardiography 0 +was 0 +used 0 +to 0 +evaluate 0 +two 0 +neonates 0 +whose 0 +mothers 0 +ingested 0 +lithium 1 +during 0 +pregnancy 0 +. 0 +In 0 +one 0 +infant 0 +"," 0 +Ebstein 3 +' 4 +s 4 +anomaly 4 +of 0 +the 0 +tricuspid 0 +valve 0 +was 0 +identified 0 +. 0 +In 0 +the 0 +other 0 +infant 0 +cross 0 +- 0 +sectional 0 +echocardiography 0 +provided 0 +reassurance 0 +that 0 +the 0 +infant 0 +did 0 +not 0 +have 0 +Ebstein 3 +' 4 +s 4 +anomaly 4 +. 0 +Cross 0 +- 0 +sectional 0 +echocardiographic 0 +screening 0 +of 0 +newborns 0 +exposed 0 +to 0 +lithium 1 +during 0 +gestation 0 +can 0 +provide 0 +highly 0 +accurate 0 +"," 0 +noninvasive 0 +assessment 0 +of 0 +the 0 +presence 0 +or 0 +absence 0 +of 0 +lithium 1 +- 0 +induced 0 +cardiac 3 +malformations 4 +. 0 +Effects 0 +of 0 +training 0 +on 0 +the 0 +extent 0 +of 0 +experimental 0 +myocardial 3 +infarction 4 +in 0 +aging 0 +rats 0 +. 0 +The 0 +effects 0 +of 0 +exercise 0 +on 0 +the 0 +severity 0 +of 0 +isoproterenol 1 +- 0 +induced 0 +myocardial 3 +infarction 4 +were 0 +studied 0 +in 0 +female 0 +albino 0 +rats 0 +of 0 +20 0 +"," 0 +40 0 +"," 0 +60 0 +and 0 +80 0 +weeks 0 +of 0 +age 0 +. 0 +The 0 +rats 0 +were 0 +trained 0 +to 0 +swim 0 +for 0 +a 0 +specific 0 +duration 0 +and 0 +for 0 +a 0 +particular 0 +period 0 +. 0 +The 0 +occurrence 0 +of 0 +infarcts 3 +were 0 +confirmed 0 +by 0 +histological 0 +methods 0 +. 0 +Elevations 0 +in 0 +the 0 +serum 0 +G0T 0 +and 0 +GPT 0 +were 0 +maximum 0 +in 0 +the 0 +sedentary 0 +- 0 +isoproterenols 1 +and 0 +minimum 0 +in 0 +the 0 +exercise 0 +- 0 +controls 0 +. 0 +These 0 +changes 0 +in 0 +the 0 +serum 0 +transaminases 0 +were 0 +associated 0 +with 0 +corresponding 0 +depletions 0 +in 0 +the 0 +cardiac 0 +G0T 0 +and 0 +GPT 0 +. 0 +However 0 +"," 0 +age 0 +was 0 +seen 0 +to 0 +interfere 0 +with 0 +the 0 +responses 0 +exhibited 0 +by 0 +the 0 +young 0 +and 0 +old 0 +rats 0 +. 0 +Studies 0 +dealing 0 +with 0 +myocardial 3 +infarction 4 +are 0 +more 0 +informative 0 +when 0 +dealt 0 +with 0 +age 0 +. 0 +Effect 0 +of 0 +polyethylene 1 +glycol 2 +400 2 +on 0 +adriamycin 1 +toxicity 3 +in 0 +mice 0 +. 0 +The 0 +effect 0 +of 0 +a 0 +widely 0 +used 0 +organic 0 +solvent 0 +"," 0 +polyethylene 1 +glycol 2 +400 2 +( 0 +PEG 1 +400 2 +) 0 +"," 0 +on 0 +the 0 +toxic 0 +action 0 +of 0 +an 0 +acute 0 +or 0 +chronic 0 +treatment 0 +with 0 +adriamycin 1 +( 0 +ADR 1 +) 0 +was 0 +evaluated 0 +in 0 +mice 0 +. 0 +PEG 1 +400 2 +impressively 0 +decreased 0 +both 0 +acute 0 +high 0 +- 0 +dose 0 +and 0 +chronic 0 +low 0 +- 0 +dose 0 +- 0 +ADR 1 +- 0 +associated 0 +lethality 0 +. 0 +Light 0 +microscopic 0 +analysis 0 +showed 0 +a 0 +significant 0 +protection 0 +against 0 +ADR 1 +- 0 +induced 0 +cardiac 3 +morphological 4 +alterations 4 +. 0 +Such 0 +treatment 0 +did 0 +not 0 +diminish 0 +the 0 +ADR 1 +antitumor 0 +activity 0 +in 0 +L1210 3 +leukemia 4 +and 0 +in 0 +Ehrlich 3 +ascites 4 +tumor 4 +. 0 +Sublingual 0 +absorption 0 +of 0 +the 0 +quaternary 1 +ammonium 2 +antiarrhythmic 0 +agent 0 +"," 0 +UM 1 +- 2 +272 2 +. 0 +UM 1 +- 2 +272 2 +( 0 +N 1 +"," 2 +N 2 +- 2 +dimethylpropranolol 2 +) 0 +"," 0 +a 0 +quaternary 0 +antiarrhythmic 0 +agent 0 +"," 0 +was 0 +administered 0 +sublingually 0 +to 0 +dogs 0 +with 0 +ouabain 1 +- 0 +induced 0 +ventricular 3 +tachycardias 4 +. 0 +Both 0 +anti 0 +- 0 +arrhythmic 0 +efficacy 0 +and 0 +bioavailability 0 +were 0 +compared 0 +to 0 +oral 0 +drug 0 +. 0 +Sublingual 0 +UM 1 +- 2 +272 2 +converted 0 +ventricular 3 +tachycardia 4 +to 0 +sinus 0 +rhythm 0 +in 0 +all 0 +5 0 +dogs 0 +. 0 +The 0 +area 0 +under 0 +the 0 +plasma 0 +concentration 0 +time 0 +curve 0 +at 0 +90 0 +min 0 +was 0 +4 0 +- 0 +12 0 +times 0 +greater 0 +than 0 +for 0 +oral 0 +drug 0 +"," 0 +suggesting 0 +the 0 +existence 0 +of 0 +an 0 +absorption 0 +- 0 +limiting 0 +process 0 +in 0 +the 0 +intestine 0 +"," 0 +and 0 +providing 0 +an 0 +alternate 0 +form 0 +of 0 +administration 0 +for 0 +quaternary 0 +drugs 0 +. 0 +Early 0 +adjuvant 0 +adriamycin 1 +in 0 +superficial 0 +bladder 3 +carcinoma 4 +. 0 +A 0 +multicenter 0 +study 0 +was 0 +performed 0 +in 0 +110 0 +patients 0 +with 0 +superficial 0 +transitional 0 +cell 0 +carcinoma 3 +of 4 +the 4 +bladder 4 +. 0 +Adriamycin 1 +( 0 +50 0 +mg 0 +/ 0 +50 0 +ml 0 +) 0 +was 0 +administered 0 +intravesically 0 +within 0 +24 0 +h 0 +after 0 +transurethral 0 +resection 0 +of 0 +TA 0 +- 0 +T1 0 +( 0 +0 0 +- 0 +A 0 +) 0 +bladder 3 +tumors 4 +. 0 +Instillation 0 +was 0 +repeated 0 +twice 0 +during 0 +the 0 +first 0 +week 0 +"," 0 +then 0 +weekly 0 +during 0 +the 0 +first 0 +month 0 +and 0 +afterwards 0 +monthly 0 +for 0 +1 0 +year 0 +. 0 +The 0 +tolerance 0 +was 0 +evaluated 0 +in 0 +these 0 +110 0 +patients 0 +"," 0 +and 0 +29 0 +patients 0 +presented 0 +with 0 +local 0 +side 0 +- 0 +effects 0 +. 0 +In 0 +24 0 +of 0 +these 0 +patients 0 +chemical 0 +cystitis 3 +was 0 +severe 0 +enough 0 +for 0 +them 0 +to 0 +drop 0 +out 0 +of 0 +the 0 +study 0 +. 0 +No 0 +systemic 0 +side 0 +- 0 +effects 0 +were 0 +observed 0 +. 0 +Recurrence 0 +was 0 +studied 0 +in 0 +82 0 +evaluable 0 +patients 0 +after 0 +1 0 +year 0 +of 0 +follow 0 +- 0 +up 0 +and 0 +in 0 +72 0 +patients 0 +followed 0 +for 0 +2 0 +- 0 +3 0 +years 0 +( 0 +mean 0 +32 0 +months 0 +) 0 +. 0 +0f 0 +the 0 +82 0 +patients 0 +studied 0 +after 0 +1 0 +year 0 +"," 0 +23 0 +had 0 +primary 0 +and 0 +59 0 +recurrent 0 +disease 0 +. 0 +0f 0 +the 0 +82 0 +evaluable 0 +patients 0 +"," 0 +50 0 +did 0 +not 0 +show 0 +any 0 +recurrence 0 +after 0 +1 0 +year 0 +( 0 +61 0 +% 0 +) 0 +"," 0 +while 0 +32 0 +presented 0 +with 0 +one 0 +or 0 +more 0 +recurrences 0 +( 0 +39 0 +% 0 +) 0 +. 0 +0f 0 +these 0 +recurrences 0 +"," 0 +27 0 +were 0 +T1 0 +tumors 3 +while 0 +five 0 +progressed 0 +to 0 +more 0 +highly 0 +invasive 0 +lesions 0 +. 0 +In 0 +patients 0 +that 0 +were 0 +free 0 +of 0 +recurrence 0 +during 0 +the 0 +first 0 +year 0 +"," 0 +80 0 +% 0 +remained 0 +tumor 3 +- 0 +free 0 +during 0 +the 0 +2 0 +- 0 +to 0 +3 0 +- 0 +year 0 +follow 0 +- 0 +up 0 +period 0 +. 0 +0f 0 +the 0 +patients 0 +developing 0 +one 0 +or 0 +more 0 +recurrences 0 +during 0 +the 0 +first 0 +year 0 +"," 0 +only 0 +50 0 +% 0 +presented 0 +with 0 +further 0 +recurrence 0 +once 0 +the 0 +instillations 0 +were 0 +stopped 0 +. 0 +The 0 +beneficial 0 +effect 0 +of 0 +Adriamycin 1 +appears 0 +obvious 0 +and 0 +might 0 +be 0 +related 0 +to 0 +the 0 +drug 0 +itself 0 +"," 0 +the 0 +early 0 +and 0 +repeated 0 +instillations 0 +after 0 +TUR 0 +"," 0 +or 0 +both 0 +. 0 +D 1 +- 2 +penicillamine 2 +- 0 +induced 0 +angiopathy 3 +in 0 +rats 0 +. 0 +The 0 +effect 0 +of 0 +high 0 +dose 0 +D 1 +- 2 +penicillamine 2 +treatment 0 +on 0 +aortic 0 +permeability 0 +to 0 +albumin 0 +and 0 +on 0 +the 0 +ultrastructure 0 +of 0 +the 0 +vessel 0 +. 0 +Male 0 +Sprague 0 +- 0 +Dawley 0 +rats 0 +were 0 +treated 0 +with 0 +D 1 +- 2 +penicillamine 2 +( 0 +D 1 +- 2 +pen 2 +) 0 +500 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +for 0 +10 0 +or 0 +42 0 +days 0 +. 0 +Pair 0 +fed 0 +rats 0 +served 0 +as 0 +controls 0 +. 0 +Changes 0 +in 0 +aortic 0 +morphology 0 +were 0 +examined 0 +by 0 +light 0 +- 0 +and 0 +transmission 0 +- 0 +electron 0 +microscopy 0 +( 0 +TEM 0 +) 0 +. 0 +In 0 +addition 0 +"," 0 +the 0 +endothelial 0 +permeability 0 +and 0 +the 0 +penetration 0 +through 0 +the 0 +aortic 0 +wall 0 +of 0 +albumin 0 +were 0 +studied 0 +10 0 +minutes 0 +"," 0 +24 0 +and 0 +48 0 +hours 0 +after 0 +i 0 +. 0 +v 0 +. 0 +injection 0 +of 0 +human 0 +serum 0 +131I 0 +- 0 +albumin 0 +( 0 +131I 0 +- 0 +HSA 0 +) 0 +. 0 +TEM 0 +revealed 0 +extensive 0 +elastolysis 0 +in 0 +the 0 +arterial 0 +wall 0 +of 0 +D 1 +- 2 +pen 2 +- 0 +treated 0 +rats 0 +"," 0 +consistent 0 +with 0 +an 0 +inhibitory 0 +effect 0 +on 0 +crosslink 0 +formation 0 +. 0 +In 0 +experimental 0 +animals 0 +excess 0 +deposition 0 +of 0 +collagen 0 +and 0 +glycoaminoglycans 0 +was 0 +observed 0 +in 0 +the 0 +subendothelial 0 +and 0 +medial 0 +layer 0 +of 0 +the 0 +aortic 0 +wall 0 +"," 0 +together 0 +with 0 +prominent 0 +basal 0 +membrane 0 +substance 0 +around 0 +aortic 0 +smooth 0 +muscle 0 +cells 0 +. 0 +The 0 +aorta 0 +/ 0 +serum 0 +- 0 +ratio 0 +and 0 +the 0 +radioactive 0 +build 0 +- 0 +up 0 +24 0 +and 0 +48 0 +hours 0 +after 0 +injection 0 +of 0 +131I 0 +- 0 +HSA 0 +was 0 +reduced 0 +in 0 +animals 0 +treated 0 +with 0 +D 1 +- 2 +pen 2 +for 0 +42 0 +days 0 +"," 0 +indicating 0 +an 0 +impeded 0 +transmural 0 +transport 0 +of 0 +tracer 0 +which 0 +may 0 +be 0 +caused 0 +by 0 +a 0 +steric 0 +exclusion 0 +effect 0 +of 0 +abundant 0 +hyaluronate 1 +. 0 +The 0 +endothelial 0 +ultrastructure 0 +was 0 +unaffected 0 +by 0 +D 1 +- 2 +pen 2 +"," 0 +and 0 +no 0 +differences 0 +in 0 +aortic 0 +131I 0 +- 0 +HSA 0 +radioactivity 0 +or 0 +aorta 0 +/ 0 +serum 0 +- 0 +ratio 0 +were 0 +recorded 0 +between 0 +experimental 0 +and 0 +control 0 +groups 0 +10 0 +minutes 0 +after 0 +tracer 0 +injection 0 +"," 0 +indicating 0 +that 0 +the 0 +permeability 0 +of 0 +the 0 +endothelial 0 +barrier 0 +to 0 +albumin 0 +remained 0 +unaffected 0 +by 0 +D 1 +- 2 +pen 2 +treatment 0 +. 0 +These 0 +observations 0 +support 0 +the 0 +hypothesis 0 +that 0 +treatment 0 +with 0 +high 0 +doses 0 +of 0 +D 1 +- 2 +pen 2 +may 0 +induce 0 +a 0 +fibroproliferative 0 +response 0 +in 0 +rat 0 +aorta 0 +"," 0 +possibly 0 +by 0 +an 0 +inhibitory 0 +effect 0 +on 0 +the 0 +cross 0 +- 0 +linking 0 +of 0 +collagen 0 +and 0 +elastin 0 +. 0 +Effect 0 +of 0 +aspirin 1 +on 0 +N 1 +- 2 +[ 2 +4 2 +- 2 +( 2 +5 2 +- 2 +nitro 2 +- 2 +2 2 +- 2 +furyl 2 +) 2 +- 2 +2 2 +- 2 +thiazolyl 2 +] 2 +- 2 +formamide 2 +- 0 +induced 0 +epithelial 0 +proliferation 0 +in 0 +the 0 +urinary 0 +bladder 0 +and 0 +forestomach 0 +of 0 +the 0 +rat 0 +. 0 +The 0 +co 0 +- 0 +administration 0 +of 0 +aspirin 1 +with 0 +N 1 +- 2 +[ 2 +4 2 +- 2 +( 2 +5 2 +- 2 +nitro 2 +- 2 +2 2 +- 2 +furyl 2 +) 2 +- 2 +2 2 +- 2 +thiazolyl 2 +] 2 +- 2 +formamide 2 +( 0 +FANFT 1 +) 0 +to 0 +rats 0 +resulted 0 +in 0 +a 0 +reduced 0 +incidence 0 +of 0 +FANFT 1 +- 0 +induced 0 +bladder 3 +carcinomas 4 +but 0 +a 0 +concomitant 0 +induction 0 +of 0 +forestomach 3 +tumors 4 +. 0 +An 0 +autoradiographic 0 +study 0 +was 0 +performed 0 +on 0 +male 0 +F 0 +- 0 +344 0 +rats 0 +fed 0 +diet 0 +containing 0 +FANFT 1 +at 0 +a 0 +level 0 +of 0 +0 0 +. 0 +2 0 +% 0 +and 0 +/ 0 +or 0 +aspirin 1 +at 0 +a 0 +level 0 +of 0 +0 0 +. 0 +5 0 +% 0 +to 0 +evaluate 0 +the 0 +effect 0 +of 0 +aspirin 1 +on 0 +the 0 +increased 0 +cell 0 +proliferation 0 +induced 0 +by 0 +FANFT 1 +in 0 +the 0 +forestomach 0 +and 0 +bladder 0 +. 0 +FANFT 1 +- 0 +induced 0 +cell 0 +proliferation 0 +in 0 +the 0 +bladder 0 +was 0 +significantly 0 +suppressed 0 +by 0 +aspirin 1 +co 0 +- 0 +administration 0 +after 0 +4 0 +weeks 0 +but 0 +not 0 +after 0 +12 0 +weeks 0 +. 0 +In 0 +the 0 +forestomach 0 +"," 0 +and 0 +also 0 +in 0 +the 0 +liver 0 +"," 0 +aspirin 1 +did 0 +not 0 +affect 0 +the 0 +FANFT 1 +- 0 +induced 0 +increase 0 +in 0 +labeling 0 +index 0 +. 0 +The 0 +present 0 +results 0 +are 0 +consistent 0 +with 0 +the 0 +carcinogenicity 0 +experiment 0 +suggesting 0 +that 0 +different 0 +mechanisms 0 +are 0 +involved 0 +in 0 +FANFT 1 +carcinogenesis 3 +in 0 +the 0 +bladder 0 +and 0 +forestomach 0 +"," 0 +and 0 +that 0 +aspirin 1 +' 0 +s 0 +effect 0 +on 0 +FANFT 1 +in 0 +the 0 +forestomach 0 +is 0 +not 0 +due 0 +to 0 +an 0 +irritant 0 +effect 0 +associated 0 +with 0 +increased 0 +cell 0 +proliferation 0 +. 0 +Also 0 +"," 0 +there 0 +appears 0 +to 0 +be 0 +an 0 +adaptation 0 +by 0 +the 0 +rats 0 +to 0 +the 0 +chronic 0 +ingestion 0 +of 0 +aspirin 1 +. 0 +A 0 +case 0 +of 0 +tardive 3 +dyskinesia 4 +caused 0 +by 0 +metoclopramide 1 +. 0 +Abnormal 3 +involuntary 4 +movements 4 +appeared 0 +in 0 +the 0 +mouth 0 +"," 0 +tongue 0 +"," 0 +neck 0 +and 0 +abdomen 0 +of 0 +a 0 +64 0 +- 0 +year 0 +- 0 +old 0 +male 0 +patient 0 +after 0 +he 0 +took 0 +metoclopramide 1 +for 0 +gastrointestinal 3 +disorder 4 +in 0 +a 0 +regimen 0 +of 0 +30 0 +mg 0 +per 0 +day 0 +for 0 +a 0 +total 0 +of 0 +about 0 +260 0 +days 0 +. 0 +The 0 +symptoms 0 +exacerbated 0 +to 0 +a 0 +maximum 0 +in 0 +a 0 +month 0 +. 0 +When 0 +the 0 +metoclopramide 1 +administration 0 +was 0 +discontinued 0 +"," 0 +the 0 +abnormal 3 +movements 4 +gradually 0 +improved 0 +to 0 +a 0 +considerable 0 +extent 0 +. 0 +Attention 0 +to 0 +the 0 +possible 0 +induction 0 +of 0 +specific 0 +tardive 3 +dyskinesia 4 +is 0 +called 0 +for 0 +in 0 +the 0 +use 0 +of 0 +this 0 +drug 0 +. 0 +Intra 0 +- 0 +arterial 0 +BCNU 1 +chemotherapy 0 +for 0 +treatment 0 +of 0 +malignant 3 +gliomas 4 +of 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 +Because 0 +of 0 +the 0 +rapid 0 +systemic 0 +clearance 0 +of 0 +BCNU 1 +( 0 +1 1 +"," 2 +3 2 +- 2 +bis 2 +- 2 +( 2 +2 2 +- 2 +chloroethyl 2 +) 2 +- 2 +1 2 +- 2 +nitrosourea 2 +) 0 +"," 0 +intra 0 +- 0 +arterial 0 +administration 0 +should 0 +provide 0 +a 0 +substantial 0 +advantage 0 +over 0 +intravenous 0 +administration 0 +for 0 +the 0 +treatment 0 +of 0 +malignant 3 +gliomas 4 +. 0 +Thirty 0 +- 0 +six 0 +patients 0 +were 0 +treated 0 +with 0 +BCNU 1 +every 0 +6 0 +to 0 +8 0 +weeks 0 +"," 0 +either 0 +by 0 +transfemoral 0 +catheterization 0 +of 0 +the 0 +internal 0 +carotid 0 +or 0 +vertebral 0 +artery 0 +or 0 +through 0 +a 0 +fully 0 +implantable 0 +intracarotid 0 +drug 0 +delivery 0 +system 0 +"," 0 +beginning 0 +with 0 +a 0 +dose 0 +of 0 +200 0 +mg 0 +/ 0 +sq 0 +m 0 +body 0 +surface 0 +area 0 +. 0 +Twelve 0 +patients 0 +with 0 +Grade 0 +III 0 +or 0 +IV 0 +astrocytomas 3 +were 0 +treated 0 +after 0 +partial 0 +resection 0 +of 0 +the 0 +tumor 3 +without 0 +prior 0 +radiation 0 +therapy 0 +. 0 +After 0 +two 0 +to 0 +seven 0 +cycles 0 +of 0 +chemotherapy 0 +"," 0 +nine 0 +patients 0 +showed 0 +a 0 +decrease 0 +in 0 +tumor 3 +size 0 +and 0 +surrounding 0 +edema 3 +on 0 +contrast 0 +- 0 +enhanced 0 +computerized 0 +tomography 0 +scans 0 +. 0 +In 0 +the 0 +nine 0 +responders 0 +"," 0 +median 0 +duration 0 +of 0 +chemotherapy 0 +response 0 +from 0 +the 0 +time 0 +of 0 +operation 0 +was 0 +25 0 +weeks 0 +( 0 +range 0 +12 0 +to 0 +more 0 +than 0 +91 0 +weeks 0 +) 0 +. 0 +The 0 +median 0 +duration 0 +of 0 +survival 0 +in 0 +the 0 +12 0 +patients 0 +was 0 +54 0 +weeks 0 +( 0 +range 0 +21 0 +to 0 +more 0 +than 0 +156 0 +weeks 0 +) 0 +"," 0 +with 0 +an 0 +18 0 +- 0 +month 0 +survival 0 +rate 0 +of 0 +42 0 +% 0 +. 0 +Twenty 0 +- 0 +four 0 +patients 0 +with 0 +recurrent 0 +Grade 0 +I 0 +to 0 +IV 0 +astrocytomas 3 +"," 0 +whose 0 +resection 0 +and 0 +irradiation 0 +therapy 0 +had 0 +failed 0 +"," 0 +received 0 +two 0 +to 0 +eight 0 +courses 0 +of 0 +intra 0 +- 0 +arterial 0 +BCNU 1 +therapy 0 +. 0 +Seventeen 0 +of 0 +these 0 +had 0 +a 0 +response 0 +or 0 +were 0 +stable 0 +for 0 +a 0 +median 0 +of 0 +20 0 +weeks 0 +( 0 +range 0 +6 0 +to 0 +more 0 +than 0 +66 0 +weeks 0 +) 0 +. 0 +The 0 +catheterization 0 +procedure 0 +is 0 +safe 0 +"," 0 +with 0 +no 0 +immediate 0 +complication 0 +in 0 +111 0 +infusions 0 +of 0 +BCNU 1 +. 0 +A 0 +delayed 0 +complication 0 +in 0 +nine 0 +patients 0 +has 0 +been 0 +unilateral 0 +loss 3 +of 4 +vision 4 +secondary 0 +to 0 +a 0 +retinal 3 +vasculitis 4 +. 0 +The 0 +frequency 0 +of 0 +visual 3 +loss 4 +decreased 0 +after 0 +the 0 +concentration 0 +of 0 +the 0 +ethanol 1 +diluent 0 +was 0 +lowered 0 +. 0 +Provocation 0 +of 0 +postural 0 +hypotension 3 +by 0 +nitroglycerin 1 +in 0 +diabetic 3 +autonomic 4 +neuropathy 4 +? 0 +The 0 +effect 0 +of 0 +nitroglycerin 1 +on 0 +heart 0 +rate 0 +and 0 +systolic 0 +blood 0 +pressure 0 +was 0 +compared 0 +in 0 +5 0 +normal 0 +subjects 0 +"," 0 +12 0 +diabetic 3 +subjects 0 +without 0 +autonomic 3 +neuropathy 4 +"," 0 +and 0 +5 0 +diabetic 3 +subjects 0 +with 0 +autonomic 3 +neuropathy 4 +. 0 +The 0 +magnitude 0 +and 0 +time 0 +course 0 +of 0 +the 0 +increase 0 +in 0 +heart 0 +rate 0 +and 0 +the 0 +decrease 0 +in 0 +systolic 0 +blood 0 +pressure 0 +after 0 +nitroglycerin 1 +were 0 +similar 0 +in 0 +the 0 +normal 0 +and 0 +diabetic 3 +subjects 0 +without 0 +autonomic 3 +neuropathy 4 +"," 0 +whereas 0 +a 0 +lesser 0 +increase 0 +in 0 +heart 0 +rate 0 +and 0 +a 0 +greater 0 +decrease 0 +in 0 +systolic 0 +blood 0 +pressure 0 +occurred 0 +in 0 +the 0 +diabetic 3 +subjects 0 +with 0 +autonomic 3 +neuropathy 4 +. 0 +It 0 +is 0 +therefore 0 +suggested 0 +that 0 +caution 0 +should 0 +be 0 +exercised 0 +when 0 +prescribing 0 +vasodilator 0 +drugs 0 +in 0 +diabetic 3 +patients 0 +"," 0 +particularly 0 +those 0 +with 0 +autonomic 3 +neuropathy 4 +. 0 +Blood 0 +pressure 0 +response 0 +to 0 +chronic 0 +low 0 +- 0 +dose 0 +intrarenal 0 +noradrenaline 1 +infusion 0 +in 0 +conscious 0 +rats 0 +. 0 +Sodium 1 +chloride 2 +solution 0 +( 0 +0 0 +. 0 +9 0 +% 0 +) 0 +or 0 +noradrenaline 1 +in 0 +doses 0 +of 0 +4 0 +"," 0 +12 0 +and 0 +36 0 +micrograms 0 +h 0 +- 0 +1 0 +kg 0 +- 0 +1 0 +was 0 +infused 0 +for 0 +five 0 +consecutive 0 +days 0 +"," 0 +either 0 +intrarenally 0 +( 0 +by 0 +a 0 +new 0 +technique 0 +) 0 +or 0 +intravenously 0 +into 0 +rats 0 +with 0 +one 0 +kidney 0 +removed 0 +. 0 +Intrarenal 0 +infusion 0 +of 0 +noradrenaline 1 +caused 0 +hypertension 3 +at 0 +doses 0 +which 0 +did 0 +not 0 +do 0 +so 0 +when 0 +infused 0 +intravenously 0 +. 0 +Intrarenal 0 +compared 0 +with 0 +intravenous 0 +infusion 0 +of 0 +noradrenaline 1 +caused 0 +higher 0 +plasma 0 +noradrenaline 1 +concentrations 0 +and 0 +a 0 +shift 0 +of 0 +the 0 +plasma 0 +noradrenaline 1 +concentration 0 +- 0 +blood 0 +pressure 0 +effect 0 +curve 0 +towards 0 +lower 0 +plasma 0 +noradrenaline 1 +levels 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +hypertension 3 +after 0 +chronic 0 +intrarenal 0 +noradrenaline 1 +infusion 0 +is 0 +produced 0 +by 0 +relatively 0 +higher 0 +levels 0 +of 0 +circulating 0 +noradrenaline 1 +and 0 +by 0 +triggering 0 +of 0 +an 0 +additional 0 +intrarenal 0 +pressor 0 +mechanism 0 +. 0 +Characterization 0 +of 0 +estrogen 1 +- 0 +induced 0 +adenohypophyseal 3 +tumors 4 +in 0 +the 0 +Fischer 0 +344 0 +rat 0 +. 0 +Pituitary 3 +tumors 4 +were 0 +induced 0 +in 0 +F344 0 +female 0 +rats 0 +by 0 +chronic 0 +treatment 0 +with 0 +diethylstilbestrol 1 +( 0 +DES 1 +"," 0 +8 0 +- 0 +10 0 +mg 0 +) 0 +implanted 0 +subcutaneously 0 +in 0 +silastic 0 +capsules 0 +. 0 +0ver 0 +a 0 +range 0 +of 0 +1 0 +- 0 +150 0 +days 0 +of 0 +DES 1 +treatment 0 +"," 0 +pairs 0 +of 0 +control 0 +and 0 +DES 1 +- 0 +treated 0 +rats 0 +were 0 +sacrificed 0 +"," 0 +and 0 +their 0 +pituitaries 0 +dissociated 0 +enzymatically 0 +into 0 +single 0 +- 0 +cell 0 +preparations 0 +. 0 +The 0 +cell 0 +populations 0 +were 0 +examined 0 +regarding 0 +total 0 +cell 0 +recovery 0 +correlated 0 +with 0 +gland 0 +weight 0 +"," 0 +intracellular 0 +prolactin 0 +( 0 +PRL 0 +) 0 +content 0 +and 0 +subsequent 0 +release 0 +in 0 +primary 0 +culture 0 +"," 0 +immunocytochemical 0 +PRL 0 +staining 0 +"," 0 +density 0 +and 0 +/ 0 +or 0 +size 0 +alterations 0 +via 0 +separation 0 +on 0 +Ficoll 0 +- 0 +Hypaque 0 +and 0 +by 0 +unit 0 +gravity 0 +sedimentation 0 +"," 0 +and 0 +cell 0 +cycle 0 +analysis 0 +"," 0 +after 0 +acriflavine 1 +DNA 0 +staining 0 +"," 0 +by 0 +laser 0 +flow 0 +cytometry 0 +. 0 +Total 0 +cell 0 +yields 0 +from 0 +DES 1 +- 0 +treated 0 +pituitaries 0 +increased 0 +from 0 +1 0 +. 0 +3 0 +times 0 +control 0 +yields 0 +at 0 +8 0 +days 0 +of 0 +treatment 0 +to 0 +58 0 +. 0 +9 0 +times 0 +control 0 +values 0 +by 0 +day 0 +150 0 +. 0 +Intracellular 0 +PRL 0 +content 0 +ranged 0 +from 0 +1 0 +. 0 +9 0 +to 0 +9 0 +. 0 +4 0 +times 0 +control 0 +levels 0 +"," 0 +and 0 +PRL 0 +release 0 +in 0 +vitro 0 +was 0 +significantly 0 +and 0 +consistently 0 +higher 0 +than 0 +controls 0 +"," 0 +after 0 +at 0 +least 0 +8 0 +days 0 +of 0 +DES 1 +exposure 0 +. 0 +Beyond 0 +8 0 +days 0 +of 0 +DES 1 +exposure 0 +"," 0 +the 0 +immunochemically 0 +PRL 0 +- 0 +positive 0 +proportion 0 +of 0 +cells 0 +increased 0 +to 0 +over 0 +50 0 +% 0 +of 0 +the 0 +total 0 +population 0 +. 0 +Increased 0 +density 0 +and 0 +/ 0 +or 0 +size 0 +and 0 +PRL 0 +content 0 +were 0 +indicated 0 +for 0 +the 0 +majority 0 +of 0 +the 0 +PRL 0 +cell 0 +population 0 +in 0 +both 0 +types 0 +of 0 +separation 0 +protocols 0 +. 0 +All 0 +these 0 +effects 0 +of 0 +DES 1 +were 0 +more 0 +pronounced 0 +among 0 +previously 0 +ovariectomized 0 +animals 0 +. 0 +The 0 +data 0 +extend 0 +the 0 +findings 0 +of 0 +other 0 +investigators 0 +"," 0 +further 0 +establishing 0 +the 0 +DES 1 +- 0 +induced 0 +tumor 3 +as 0 +a 0 +model 0 +for 0 +study 0 +of 0 +PRL 0 +cellular 0 +control 0 +mechanisms 0 +. 0 +Age 0 +and 0 +renal 0 +clearance 0 +of 0 +cimetidine 1 +. 0 +In 0 +35 0 +patients 0 +( 0 +ages 0 +20 0 +to 0 +86 0 +yr 0 +) 0 +receiving 0 +cimetidine 1 +therapeutically 0 +two 0 +serum 0 +samples 0 +and 0 +all 0 +urine 0 +formed 0 +in 0 +the 0 +interim 0 +were 0 +collected 0 +for 0 +analysis 0 +of 0 +cimetidine 1 +by 0 +high 0 +- 0 +pressure 0 +liquid 0 +chromatography 0 +and 0 +for 0 +creatinine 1 +. 0 +Cimetidine 1 +clearance 0 +decreased 0 +with 0 +age 0 +. 0 +The 0 +extrapolated 0 +6 0 +- 0 +hr 0 +serum 0 +concentration 0 +of 0 +cimetidine 1 +per 0 +unit 0 +dose 0 +"," 0 +after 0 +intravenous 0 +cimetidine 1 +"," 0 +increased 0 +with 0 +age 0 +of 0 +the 0 +patients 0 +. 0 +The 0 +ratio 0 +of 0 +cimetidine 1 +clearance 0 +to 0 +creatinine 1 +clearance 0 +( 0 +Rc 0 +) 0 +averaged 0 +4 0 +. 0 +8 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +0 0 +"," 0 +indicating 0 +net 0 +tubular 0 +secretion 0 +for 0 +cimetidine 1 +. 0 +Rc 0 +seemed 0 +to 0 +be 0 +independent 0 +of 0 +age 0 +and 0 +decreased 0 +with 0 +increasing 0 +serum 0 +concentration 0 +of 0 +cimetidine 1 +"," 0 +suggesting 0 +that 0 +secretion 0 +of 0 +cimetidine 1 +is 0 +a 0 +saturable 0 +process 0 +. 0 +There 0 +was 0 +only 0 +one 0 +case 0 +of 0 +dementia 3 +possibly 0 +due 0 +to 0 +cimetidine 1 +( 0 +with 0 +a 0 +drug 0 +level 0 +of 0 +1 0 +. 0 +9 0 +microgram 0 +/ 0 +ml 0 +6 0 +hr 0 +after 0 +a 0 +dose 0 +) 0 +in 0 +a 0 +group 0 +of 0 +13 0 +patients 0 +without 0 +liver 3 +or 4 +kidney 4 +disease 4 +who 0 +had 0 +cimetidine 1 +levels 0 +above 0 +1 0 +. 0 +25 0 +microgram 0 +/ 0 +ml 0 +. 0 +Thus 0 +"," 0 +high 0 +cimetidine 1 +levels 0 +alone 0 +do 0 +not 0 +always 0 +induce 0 +dementia 3 +. 0 +Further 0 +observations 0 +on 0 +the 0 +electrophysiologic 0 +effects 0 +of 0 +oral 0 +amiodarone 1 +therapy 0 +. 0 +A 0 +case 0 +is 0 +presented 0 +of 0 +a 0 +reversible 0 +intra 3 +- 4 +Hisian 4 +block 4 +occurring 0 +under 0 +amiodarone 1 +treatment 0 +for 0 +atrial 3 +tachycardia 4 +in 0 +a 0 +patient 0 +without 0 +clear 0 +intraventricular 3 +conduction 4 +abnormalities 4 +. 0 +His 0 +bundle 0 +recordings 0 +showed 0 +an 0 +atrial 3 +tachycardia 4 +with 0 +intermittent 0 +exit 0 +block 0 +and 0 +greatly 0 +prolonged 0 +BH 0 +and 0 +HV 0 +intervals 0 +( 0 +40 0 +and 0 +100 0 +msec 0 +"," 0 +respectively 0 +) 0 +. 0 +Thirty 0 +days 0 +after 0 +amiodarone 1 +discontinuation 0 +"," 0 +His 0 +bundle 0 +electrograms 0 +showed 0 +atrial 3 +flutter 4 +without 0 +intra 0 +- 0 +Hisian 0 +or 0 +infra 0 +- 0 +Hisian 0 +delay 0 +. 0 +Amiodarone 1 +should 0 +be 0 +used 0 +with 0 +caution 0 +during 0 +long 0 +- 0 +term 0 +oral 0 +therapy 0 +in 0 +patients 0 +with 0 +or 0 +without 0 +clear 0 +intraventricular 0 +conduction 0 +defects 0 +. 0 +Development 0 +of 0 +clear 3 +cell 4 +adenocarcinoma 4 +in 0 +DES 1 +- 0 +exposed 0 +offspring 0 +under 0 +observation 0 +. 0 +Two 0 +cases 0 +of 0 +clear 3 +cell 4 +adenocarcinoma 4 +of 4 +the 4 +vagina 4 +detected 0 +at 0 +follow 0 +- 0 +up 0 +in 0 +young 0 +women 0 +exposed 0 +in 0 +utero 0 +to 0 +diethylstilbestrol 1 +are 0 +reported 0 +. 0 +0ne 0 +patient 0 +"," 0 +aged 0 +23 0 +"," 0 +had 0 +been 0 +followed 0 +for 0 +2 0 +years 0 +before 0 +carcinoma 3 +was 0 +diagnosed 0 +; 0 +the 0 +second 0 +patient 0 +"," 0 +aged 0 +22 0 +"," 0 +had 0 +been 0 +seen 0 +on 0 +a 0 +regular 0 +basis 0 +for 0 +5 0 +years 0 +"," 0 +8 0 +months 0 +. 0 +In 0 +both 0 +instances 0 +"," 0 +suspicion 0 +of 0 +the 0 +presence 0 +of 0 +carcinoma 3 +was 0 +aroused 0 +by 0 +the 0 +palpation 0 +of 0 +a 0 +small 0 +nodule 0 +in 0 +the 0 +vaginal 0 +fornix 0 +. 0 +Hysterosalpingography 0 +was 0 +performed 0 +on 0 +both 0 +patients 0 +and 0 +"," 0 +in 0 +1 0 +instance 0 +"," 0 +an 0 +abnormal 0 +x 0 +- 0 +ray 0 +film 0 +was 0 +reflected 0 +by 0 +the 0 +gross 0 +appearance 0 +of 0 +the 0 +uterine 0 +cavity 0 +found 0 +in 0 +the 0 +surgical 0 +specimen 0 +. 0 +Neurologic 0 +effects 0 +of 0 +subarachnoid 0 +administration 0 +of 0 +2 1 +- 2 +chloroprocaine 2 +- 2 +CE 2 +"," 0 +bupivacaine 1 +"," 0 +and 0 +low 0 +pH 0 +normal 0 +saline 0 +in 0 +dogs 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +neurologic 0 +consequences 0 +of 0 +deliberate 0 +subarachnoid 0 +injection 0 +of 0 +large 0 +volumes 0 +of 0 +2 1 +- 2 +chloroprocaine 2 +- 2 +CE 2 +in 0 +experimental 0 +animals 0 +. 0 +The 0 +possible 0 +role 0 +of 0 +low 0 +pH 0 +as 0 +well 0 +as 0 +total 0 +volume 0 +as 0 +potential 0 +factors 0 +in 0 +causing 0 +neurotoxicity 3 +was 0 +evaluated 0 +. 0 +The 0 +65 0 +dogs 0 +in 0 +the 0 +study 0 +received 0 +injections 0 +in 0 +the 0 +subarachnoid 0 +space 0 +as 0 +follows 0 +: 0 +6 0 +to 0 +8 0 +ml 0 +of 0 +bupivacaine 1 +( 0 +N 0 += 0 +15 0 +) 0 +"," 0 +2 1 +- 2 +chloroprocaine 2 +- 2 +CE 2 +( 0 +N 0 += 0 +20 0 +) 0 +"," 0 +low 0 +pH 0 +normal 0 +saline 0 +( 0 +pH 0 +3 0 +. 0 +0 0 +) 0 +( 0 +N 0 += 0 +20 0 +) 0 +"," 0 +or 0 +normal 0 +saline 0 +( 0 +N 0 += 0 +10 0 +) 0 +. 0 +0f 0 +the 0 +20 0 +animals 0 +that 0 +received 0 +subarachnoid 0 +injection 0 +of 0 +2 1 +- 2 +chloroprocaine 2 +- 2 +CE 2 +seven 0 +( 0 +35 0 +% 0 +) 0 +developed 0 +hind 0 +- 0 +limb 0 +paralysis 3 +. 0 +None 0 +of 0 +the 0 +animals 0 +that 0 +received 0 +bupivacaine 1 +"," 0 +normal 0 +saline 0 +"," 0 +or 0 +normal 0 +saline 0 +titrated 0 +to 0 +a 0 +pH 0 +3 0 +. 0 +0 0 +developed 0 +hind 0 +- 0 +limb 0 +paralysis 3 +. 0 +0f 0 +the 0 +15 0 +spinal 0 +cords 0 +of 0 +the 0 +animals 0 +that 0 +received 0 +2 1 +- 2 +chloroprocaine 2 +- 2 +CE 2 +"," 0 +13 0 +showed 0 +subpial 3 +necrosis 4 +; 0 +the 0 +nerve 0 +roots 0 +and 0 +subarachnoid 0 +vessels 0 +were 0 +normal 0 +. 0 +The 0 +spinal 0 +cords 0 +of 0 +the 0 +animals 0 +that 0 +received 0 +bupivacaine 1 +"," 0 +low 0 +pH 0 +normal 0 +saline 0 +( 0 +pH 0 +3 0 +. 0 +0 0 +) 0 +"," 0 +or 0 +normal 0 +saline 0 +did 0 +not 0 +show 0 +abnormal 0 +findings 0 +. 0 +Procainamide 1 +- 0 +induced 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +. 0 +Seven 0 +cases 0 +of 0 +procainamide 1 +- 0 +induced 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +are 0 +presented 0 +. 0 +In 0 +four 0 +patients 0 +"," 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +appeared 0 +after 0 +intravenous 0 +administration 0 +of 0 +200 0 +to 0 +400 0 +mg 0 +of 0 +procainamide 1 +for 0 +the 0 +treatment 0 +of 0 +sustained 0 +ventricular 3 +tachycardia 4 +. 0 +In 0 +the 0 +remaining 0 +three 0 +patients 0 +"," 0 +procainamide 1 +was 0 +administered 0 +orally 0 +for 0 +treatment 0 +of 0 +chronic 0 +premature 3 +ventricular 4 +contractions 4 +or 0 +atrial 3 +flutter 4 +. 0 +These 0 +patients 0 +had 0 +Q 3 +- 4 +T 4 +prolongation 4 +and 0 +recurrent 0 +syncope 3 +due 0 +to 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +. 0 +In 0 +four 0 +patients 0 +"," 0 +the 0 +arrhythmia 3 +was 0 +rapidly 0 +diagnosed 0 +and 0 +treated 0 +with 0 +disappearance 0 +of 0 +further 0 +episodes 0 +of 0 +the 0 +arrhythmia 3 +. 0 +In 0 +two 0 +patients 0 +"," 0 +the 0 +arrhythmia 3 +degenerated 0 +into 0 +irreversible 0 +ventricular 3 +fibrillation 4 +and 0 +both 0 +patients 0 +died 0 +. 0 +In 0 +the 0 +seventh 0 +patient 0 +"," 0 +a 0 +permanent 0 +ventricular 0 +pacemaker 0 +was 0 +inserted 0 +and 0 +"," 0 +despite 0 +continuation 0 +of 0 +procainamide 1 +therapy 0 +"," 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +did 0 +not 0 +reoccur 0 +. 0 +These 0 +seven 0 +cases 0 +demonstrate 0 +that 0 +procainamide 1 +can 0 +produce 0 +an 0 +acquired 0 +prolonged 3 +Q 4 +- 4 +T 4 +syndrome 4 +with 0 +polymorphous 0 +ventricular 3 +tachycardia 4 +. 0 +Phenobarbitone 1 +- 0 +induced 0 +enlargement 3 +of 4 +the 4 +liver 4 +in 0 +the 0 +rat 0 +: 0 +its 0 +relationship 0 +to 0 +carbon 1 +tetrachloride 2 +- 0 +induced 0 +cirrhosis 3 +. 0 +The 0 +yield 0 +of 0 +severe 0 +cirrhosis 3 +of 4 +the 4 +liver 4 +( 0 +defined 0 +as 0 +a 0 +shrunken 0 +finely 0 +nodular 0 +liver 0 +with 0 +micronodular 0 +histology 0 +"," 0 +ascites 3 +greater 0 +than 0 +30 0 +ml 0 +"," 0 +plasma 0 +albumin 0 +less 0 +than 0 +2 0 +. 0 +2 0 +g 0 +/ 0 +dl 0 +"," 0 +splenomegaly 3 +2 0 +- 0 +3 0 +times 0 +normal 0 +"," 0 +and 0 +testicular 0 +atrophy 3 +approximately 0 +half 0 +normal 0 +weight 0 +) 0 +after 0 +12 0 +doses 0 +of 0 +carbon 1 +tetrachloride 2 +given 0 +intragastrically 0 +in 0 +the 0 +phenobarbitone 1 +- 0 +primed 0 +rat 0 +was 0 +increased 0 +from 0 +25 0 +% 0 +to 0 +56 0 +% 0 +by 0 +giving 0 +the 0 +initial 0 +" 0 +calibrating 0 +" 0 +dose 0 +of 0 +carbon 1 +tetrachloride 2 +at 0 +the 0 +peak 0 +of 0 +the 0 +phenobarbitone 1 +- 0 +induced 0 +enlargement 3 +of 4 +the 4 +liver 4 +. 0 +At 0 +this 0 +point 0 +it 0 +was 0 +assumed 0 +that 0 +the 0 +cytochrome 0 +P450 0 +/ 0 +CCl4 1 +toxic 0 +state 0 +was 0 +both 0 +maximal 0 +and 0 +stable 0 +. 0 +The 0 +optimal 0 +rat 0 +size 0 +to 0 +begin 0 +phenobarbitone 1 +was 0 +determined 0 +as 0 +100 0 +g 0 +"," 0 +and 0 +this 0 +size 0 +as 0 +a 0 +group 0 +had 0 +a 0 +mean 0 +maximum 0 +relative 0 +liver 0 +weight 0 +increase 0 +47 0 +% 0 +greater 0 +than 0 +normal 0 +rats 0 +of 0 +the 0 +same 0 +body 0 +weight 0 +. 0 +The 0 +optimal 0 +time 0 +for 0 +the 0 +initial 0 +dose 0 +of 0 +carbon 1 +tetrachloride 2 +was 0 +after 0 +14 0 +days 0 +on 0 +phenobarbitone 1 +. 0 +Triamterene 1 +nephrolithiasis 3 +complicating 0 +dyazide 1 +therapy 0 +. 0 +A 0 +case 0 +of 0 +triamterene 1 +nephrolithiasis 3 +is 0 +reported 0 +in 0 +a 0 +man 0 +after 0 +4 0 +years 0 +of 0 +hydrochlorothiazide 1 +- 2 +triamterene 2 +therapy 0 +for 0 +hypertension 3 +. 0 +The 0 +stone 0 +passed 0 +spontaneously 0 +and 0 +was 0 +found 0 +to 0 +contain 0 +a 0 +triamterene 1 +metabolite 0 +admixed 0 +with 0 +uric 1 +acid 2 +salts 2 +. 0 +Factors 0 +affecting 0 +triamterene 1 +nephrolithiasis 3 +are 0 +discussed 0 +and 0 +2 0 +previously 0 +reported 0 +cases 0 +are 0 +reviewed 0 +. 0 +Busulfan 1 +- 0 +induced 0 +hemorrhagic 3 +cystitis 4 +. 0 +A 0 +case 0 +of 0 +a 0 +busulfan 1 +- 0 +induced 0 +hemorrhage 3 +cystitis 4 +is 0 +reported 0 +. 0 +Spontaneous 0 +resolution 0 +occurred 0 +following 0 +cessation 0 +of 0 +the 0 +drug 0 +. 0 +The 0 +similarity 0 +between 0 +the 0 +histologic 0 +appearances 0 +of 0 +busulfan 1 +cystitis 3 +and 0 +both 0 +radiation 0 +and 0 +cyclophosphamide 1 +- 0 +induced 0 +cystitis 3 +is 0 +discussed 0 +and 0 +the 0 +world 0 +literature 0 +reviewed 0 +. 0 +In 0 +view 0 +of 0 +the 0 +known 0 +tendency 0 +of 0 +busulfan 1 +to 0 +induce 0 +cellular 0 +atypia 0 +and 0 +carcinoma 3 +in 0 +other 0 +sites 0 +"," 0 +periodic 0 +urinary 0 +cytology 0 +is 0 +suggested 0 +in 0 +patients 0 +on 0 +long 0 +- 0 +term 0 +therapy 0 +. 0 +Variant 0 +ventricular 3 +tachycardia 4 +in 0 +desipramine 1 +toxicity 3 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +variant 0 +ventricular 3 +tachycardia 4 +induced 0 +by 0 +desipramine 1 +toxicity 3 +. 0 +Unusual 0 +features 0 +of 0 +the 0 +arrhythmia 3 +are 0 +repetitive 0 +group 0 +beating 0 +"," 0 +progressive 0 +shortening 0 +of 0 +the 0 +R 0 +- 0 +R 0 +interval 0 +"," 0 +progressive 0 +widening 0 +of 0 +the 0 +QRS 0 +complex 0 +with 0 +eventual 0 +failure 0 +of 0 +intraventricular 0 +conduction 0 +"," 0 +and 0 +changes 0 +in 0 +direction 0 +of 0 +the 0 +QRS 0 +axis 0 +. 0 +Recognition 0 +of 0 +variant 0 +ventricular 3 +tachycardia 4 +is 0 +important 0 +because 0 +therapy 0 +differs 0 +from 0 +that 0 +of 0 +classic 0 +ventricular 3 +tachycardia 4 +. 0 +Rebound 0 +hypertensive 3 +after 0 +sodium 1 +nitroprusside 2 +prevented 0 +by 0 +saralasin 1 +in 0 +rats 0 +. 0 +The 0 +role 0 +of 0 +the 0 +renin 0 +- 0 +- 0 +angiotensin 1 +system 0 +in 0 +the 0 +maintenance 0 +of 0 +blood 0 +pressure 0 +during 0 +halothane 1 +anesthesia 0 +and 0 +sodium 1 +nitroprusside 2 +( 0 +SNP 1 +) 0 +- 0 +induced 0 +hypotension 3 +was 0 +evaluated 0 +. 0 +Control 0 +rats 0 +received 0 +halothane 1 +anesthesia 0 +( 0 +1 0 +MAC 0 +) 0 +for 0 +one 0 +hour 0 +"," 0 +followed 0 +by 0 +SNP 1 +infusion 0 +"," 0 +40 0 +microgram 0 +/ 0 +kg 0 +/ 0 +min 0 +"," 0 +for 0 +30 0 +min 0 +"," 0 +followed 0 +by 0 +a 0 +30 0 +- 0 +min 0 +recovery 0 +period 0 +. 0 +A 0 +second 0 +group 0 +of 0 +rats 0 +was 0 +treated 0 +identically 0 +and 0 +"," 0 +in 0 +addition 0 +"," 0 +received 0 +an 0 +infusion 0 +of 0 +saralasin 1 +( 0 +a 0 +competitive 0 +inhibitor 0 +of 0 +angiotensin 1 +II 2 +) 0 +throughout 0 +the 0 +experimental 0 +period 0 +. 0 +In 0 +each 0 +group 0 +"," 0 +SNP 1 +infusion 0 +resulted 0 +in 0 +an 0 +initial 0 +decrease 0 +in 0 +blood 0 +pressure 0 +from 0 +86 0 +torr 0 +and 0 +83 0 +torr 0 +"," 0 +respectively 0 +"," 0 +to 0 +48 0 +torr 0 +. 0 +During 0 +the 0 +SNP 1 +infusion 0 +the 0 +control 0 +animals 0 +demonstrated 0 +a 0 +progressive 0 +increase 3 +in 4 +blood 4 +pressure 4 +to 0 +61 0 +torr 0 +"," 0 +whereas 0 +the 0 +saralasin 1 +- 0 +treated 0 +animals 0 +showed 0 +no 0 +change 0 +. 0 +Following 0 +discontinuation 0 +of 0 +SNP 1 +"," 0 +blood 0 +pressure 0 +in 0 +the 0 +control 0 +animals 0 +rebounded 0 +to 0 +94 0 +torr 0 +"," 0 +as 0 +compared 0 +with 0 +78 0 +torr 0 +in 0 +the 0 +saralasin 1 +- 0 +treated 0 +rats 0 +. 0 +This 0 +study 0 +indicates 0 +that 0 +with 0 +stable 0 +halothane 1 +anesthesia 0 +"," 0 +the 0 +partial 0 +recovery 0 +of 0 +blood 0 +pressure 0 +during 0 +SNP 1 +infusion 0 +and 0 +the 0 +post 0 +- 0 +SNP 1 +rebound 0 +of 0 +blood 0 +pressure 0 +can 0 +be 0 +completely 0 +blocked 0 +by 0 +saralasin 1 +. 0 +This 0 +demonstrates 0 +the 0 +participation 0 +of 0 +the 0 +renin 0 +- 0 +- 0 +angiotensin 1 +system 0 +in 0 +antagonizing 0 +the 0 +combined 0 +hypotensive 3 +effects 0 +of 0 +halothane 1 +and 0 +SNP 1 +. 0 +Clinical 0 +nephrotoxicity 3 +of 0 +tobramycin 1 +and 0 +gentamicin 1 +. 0 +A 0 +prospective 0 +study 0 +. 0 +Nearly 0 +3 0 +. 0 +2 0 +million 0 +people 0 +in 0 +this 0 +country 0 +receive 0 +aminoglycoside 1 +antibiotics 0 +annually 0 +. 0 +Gentamicin 1 +sulfate 2 +and 0 +tobramycin 1 +sulfate 2 +continue 0 +to 0 +demonstrate 0 +ototoxicity 3 +and 0 +nephrotoxicity 3 +in 0 +both 0 +animal 0 +and 0 +clinical 0 +studies 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +62 0 +patients 0 +with 0 +confirmed 0 +initial 0 +normal 0 +renal 0 +function 0 +and 0 +treated 0 +with 0 +2 0 +to 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +of 0 +gentamicin 1 +sulfate 2 +or 0 +tobramycin 1 +sulfate 2 +for 0 +a 0 +minimum 0 +of 0 +seven 0 +days 0 +were 0 +followed 0 +up 0 +prospectively 0 +for 0 +the 0 +development 0 +of 0 +aminoglycoside 1 +- 0 +related 0 +renal 3 +failure 4 +"," 0 +defined 0 +as 0 +at 0 +least 0 +a 0 +one 0 +- 0 +third 0 +reduction 0 +in 0 +renal 0 +function 0 +. 0 +In 0 +these 0 +62 0 +patients 0 +"," 0 +no 0 +other 0 +causes 0 +for 0 +renal 3 +failure 4 +could 0 +be 0 +identified 0 +. 0 +Five 0 +of 0 +33 0 +( 0 +15 0 +% 0 +) 0 +of 0 +the 0 +tobramycin 1 +- 0 +treated 0 +patients 0 +and 0 +16 0 +of 0 +29 0 +( 0 +55 0 +. 0 +2 0 +% 0 +) 0 +of 0 +the 0 +gentamicin 1 +- 0 +treated 0 +patients 0 +had 0 +renal 3 +failure 4 +. 0 +Thus 0 +"," 0 +gentamicin 1 +was 0 +associated 0 +with 0 +renal 3 +failure 4 +more 0 +than 0 +three 0 +times 0 +as 0 +often 0 +as 0 +was 0 +tobramycin 1 +. 0 +Metabolic 0 +involvement 0 +in 0 +adriamycin 1 +cardiotoxicity 3 +. 0 +The 0 +cardiotoxic 3 +effects 0 +of 0 +adriamycin 1 +were 0 +studied 0 +in 0 +mammalian 0 +myocardial 0 +cells 0 +in 0 +culture 0 +as 0 +a 0 +model 0 +system 0 +. 0 +Adriamycin 1 +inhibited 0 +cell 0 +growth 0 +and 0 +the 0 +rhythmic 0 +contractions 0 +characteristic 0 +of 0 +myocardial 0 +cells 0 +in 0 +culture 0 +. 0 +A 0 +possible 0 +involvement 0 +of 0 +energy 0 +metabolism 0 +was 0 +suggested 0 +previously 0 +"," 0 +and 0 +in 0 +this 0 +study 0 +the 0 +adenylate 0 +energy 0 +charge 0 +and 0 +phosphorylcreatine 1 +mole 0 +fraction 0 +were 0 +determined 0 +in 0 +the 0 +adriamycin 1 +- 0 +treated 0 +cells 0 +. 0 +The 0 +adenylate 0 +energy 0 +charge 0 +was 0 +found 0 +to 0 +be 0 +significantly 0 +decreased 0 +"," 0 +while 0 +the 0 +phophorylcreatine 1 +mole 0 +fraction 0 +was 0 +unchanged 0 +. 0 +Such 0 +disparity 0 +suggests 0 +an 0 +inhibition 0 +of 0 +creatine 1 +phosphokinase 0 +. 0 +The 0 +addition 0 +of 0 +1 0 +mM 0 +adenosine 1 +to 0 +the 0 +myocardial 0 +cell 0 +cultures 0 +markedly 0 +increases 0 +the 0 +ATP 1 +concentration 0 +through 0 +a 0 +pathway 0 +reportedly 0 +leading 0 +to 0 +a 0 +compartmentalized 0 +ATP 1 +pool 0 +. 0 +In 0 +the 0 +adriamycin 1 +- 0 +treated 0 +cells 0 +"," 0 +the 0 +addition 0 +of 0 +adenosine 1 +increased 0 +the 0 +adenylate 0 +charge 0 +and 0 +"," 0 +concomitant 0 +with 0 +this 0 +inrcease 0 +"," 0 +the 0 +cells 0 +' 0 +functional 0 +integrity 0 +"," 0 +in 0 +terms 0 +of 0 +percentage 0 +of 0 +beating 0 +cells 0 +and 0 +rate 0 +of 0 +contractions 0 +"," 0 +was 0 +maintained 0 +. 0 +Age 0 +- 0 +dependent 0 +sensitivity 0 +of 0 +the 0 +rat 0 +to 0 +neurotoxic 3 +effects 0 +of 0 +streptomycin 1 +. 0 +Streptomycin 1 +sulfate 0 +( 0 +300 0 +mg 0 +/ 0 +kg 0 +s 0 +. 0 +c 0 +. 0 +) 0 +was 0 +injected 0 +for 0 +various 0 +periods 0 +into 0 +preweanling 0 +rats 0 +and 0 +for 0 +3 0 +weeks 0 +into 0 +weanling 0 +rats 0 +. 0 +Beginning 0 +at 0 +8 0 +days 0 +of 0 +age 0 +"," 0 +body 0 +movement 0 +and 0 +hearing 0 +were 0 +examined 0 +for 0 +6 0 +and 0 +up 0 +to 0 +17 0 +weeks 0 +"," 0 +respectively 0 +. 0 +Abnormal 3 +movements 4 +and 0 +deafness 3 +occurred 0 +only 0 +in 0 +rats 0 +treated 0 +during 0 +the 0 +preweaning 0 +period 0 +; 0 +within 0 +this 0 +period 0 +the 0 +greatest 0 +sensitivities 0 +for 0 +these 0 +abnormalities 0 +occurred 0 +from 0 +2 0 +to 0 +11 0 +- 0 +17 0 +and 0 +5 0 +to 0 +11 0 +days 0 +of 0 +age 0 +"," 0 +respectively 0 +"," 0 +indicating 0 +that 0 +the 0 +cochlea 0 +is 0 +more 0 +sensitive 0 +to 0 +streptomycin 1 +than 0 +the 0 +site 0 +( 0 +vestibular 0 +or 0 +central 0 +) 0 +responsible 0 +for 0 +the 0 +dyskinesias 3 +. 0 +Late 0 +"," 0 +late 0 +doxorubicin 1 +cardiotoxicity 3 +. 0 +Cardiac 3 +toxicity 4 +is 0 +a 0 +major 0 +complication 0 +which 0 +limits 0 +the 0 +use 0 +of 0 +adriamycin 1 +as 0 +a 0 +chemotherapeutic 0 +agent 0 +. 0 +Cardiomyopathy 3 +is 0 +frequent 0 +when 0 +the 0 +total 0 +dose 0 +exceeds 0 +600 0 +mg 0 +/ 0 +m2 0 +and 0 +occurs 0 +within 0 +one 0 +to 0 +six 0 +months 0 +after 0 +cessation 0 +of 0 +therapy 0 +. 0 +A 0 +patient 0 +is 0 +reported 0 +who 0 +developed 0 +progressive 0 +cardiomyopathy 3 +two 0 +and 0 +one 0 +- 0 +half 0 +years 0 +after 0 +receiving 0 +580 0 +mg 0 +/ 0 +m2 0 +which 0 +apparently 0 +represents 0 +late 0 +"," 0 +late 0 +cardiotoxicity 3 +. 0 +Attenuation 0 +of 0 +the 0 +lithium 1 +- 0 +induced 0 +diabetes 3 +- 4 +insipidus 4 +- 4 +like 4 +syndrome 4 +by 0 +amiloride 1 +in 0 +rats 0 +. 0 +The 0 +effect 0 +of 0 +amiloride 1 +on 0 +lithium 1 +- 0 +induced 0 +polydipsia 3 +and 0 +polyuria 3 +and 0 +on 0 +the 0 +lithium 1 +concentration 0 +in 0 +the 0 +plasma 0 +"," 0 +brain 0 +"," 0 +kidney 0 +"," 0 +thyroid 0 +and 0 +red 0 +blood 0 +cells 0 +was 0 +investigated 0 +in 0 +rats 0 +"," 0 +chronically 0 +treated 0 +with 0 +LiCl 1 +. 0 +Amiloride 1 +reduced 0 +the 0 +drinking 0 +and 0 +urine 0 +volume 0 +of 0 +rats 0 +in 0 +an 0 +acute 0 +( 0 +6 0 +or 0 +12 0 +h 0 +) 0 +and 0 +a 0 +subacute 0 +( 0 +3 0 +days 0 +) 0 +experiment 0 +. 0 +6 0 +h 0 +after 0 +the 0 +administration 0 +of 0 +amiloride 1 +"," 0 +a 0 +reduction 0 +was 0 +observed 0 +in 0 +the 0 +lithium 1 +content 0 +of 0 +the 0 +renal 0 +medulla 0 +but 0 +not 0 +in 0 +the 0 +other 0 +organs 0 +studied 0 +. 0 +At 0 +12 0 +h 0 +"," 0 +all 0 +the 0 +tissues 0 +showed 0 +a 0 +slight 0 +increase 0 +in 0 +lithium 1 +levels 0 +. 0 +After 0 +3 0 +days 0 +of 0 +combined 0 +treatment 0 +"," 0 +a 0 +marked 0 +elevation 0 +in 0 +plasma 0 +and 0 +tissue 0 +lithium 1 +levels 0 +accompanied 0 +a 0 +reduction 0 +in 0 +water 0 +intake 0 +. 0 +In 0 +all 0 +the 0 +experiments 0 +"," 0 +the 0 +attenuation 0 +of 0 +the 0 +lithium 1 +- 0 +induced 0 +diabetes 3 +- 4 +insipidus 4 +- 4 +like 4 +syndrome 4 +by 0 +amiloride 1 +was 0 +accompanied 0 +by 0 +a 0 +reduction 0 +of 0 +the 0 +ratio 0 +between 0 +the 0 +lithium 1 +concentration 0 +in 0 +the 0 +renal 0 +medulla 0 +and 0 +its 0 +levels 0 +in 0 +the 0 +blood 0 +and 0 +an 0 +elevation 0 +in 0 +the 0 +plasma 0 +potassium 1 +level 0 +. 0 +It 0 +is 0 +concluded 0 +that 0 +acute 0 +amiloride 1 +administration 0 +to 0 +lithium 1 +- 0 +treated 0 +patients 0 +suffering 0 +from 0 +polydipsia 3 +and 0 +polyuria 3 +might 0 +relieve 0 +these 0 +patients 0 +but 0 +prolonged 0 +amiloride 1 +supplementation 0 +would 0 +result 0 +in 0 +elevated 0 +lithium 1 +levels 0 +and 0 +might 0 +be 0 +hazardous 0 +. 0 +Cardiovascular 3 +complications 4 +associated 0 +with 0 +terbutaline 1 +treatment 0 +for 0 +preterm 3 +labor 4 +. 0 +Severe 0 +cardiovascular 3 +complications 4 +occurred 0 +in 0 +eight 0 +of 0 +160 0 +patients 0 +treated 0 +with 0 +terbutaline 1 +for 0 +preterm 3 +labor 4 +. 0 +Associated 0 +corticosteroid 0 +therapy 0 +and 0 +twin 0 +gestations 0 +appear 0 +to 0 +be 0 +predisposing 0 +factors 0 +. 0 +Potential 0 +mechanisms 0 +of 0 +the 0 +pathophysiology 0 +are 0 +briefly 0 +discussed 0 +. 0 +Toxic 3 +hepatitis 4 +induced 0 +by 0 +antithyroid 0 +drugs 0 +: 0 +four 0 +cases 0 +including 0 +one 0 +with 0 +cross 0 +- 0 +reactivity 0 +between 0 +carbimazole 1 +and 0 +benzylthiouracil 1 +. 0 +0BJECTIVE 0 +: 0 +This 0 +study 0 +was 0 +conducted 0 +to 0 +assess 0 +the 0 +occurrence 0 +of 0 +hepatic 3 +adverse 4 +effects 4 +encountered 0 +with 0 +antithyroid 0 +drugs 0 +. 0 +METH0DS 0 +: 0 +Retrospective 0 +review 0 +of 0 +medical 0 +records 0 +of 0 +236 0 +patients 0 +with 0 +hyperthyroidism 3 +admitted 0 +in 0 +our 0 +department 0 +( 0 +in 0 +- 0 +or 0 +out 0 +- 0 +patients 0 +) 0 +from 0 +1986 0 +to 0 +1992 0 +. 0 +RESULTS 0 +: 0 +Four 0 +patients 0 +( 0 +1 0 +. 0 +7 0 +% 0 +) 0 +were 0 +identified 0 +with 0 +toxic 3 +hepatitis 4 +which 0 +could 0 +reasonably 0 +be 0 +attributed 0 +to 0 +the 0 +use 0 +of 0 +antithyroid 0 +agent 0 +. 0 +Two 0 +patients 0 +had 0 +a 0 +cholestatic 3 +hepatitis 4 +induced 0 +by 0 +carbimazole 1 +( 0 +N 1 +omercazole 2 +) 0 +. 0 +Two 0 +others 0 +had 0 +a 0 +mixed 0 +( 0 +cholestatic 3 +and 0 +cytolytic 0 +) 0 +hepatitis 3 +following 0 +carbimazole 1 +. 0 +0ne 0 +of 0 +the 0 +latter 0 +two 0 +patients 0 +further 0 +experienced 0 +a 0 +cytolytic 0 +hepatitis 3 +which 0 +appeared 0 +after 0 +Benzylthiouracil 1 +( 0 +Basd 1 +ne 2 +) 0 +had 0 +replaced 0 +carbimazole 1 +. 0 +Biological 0 +features 0 +of 0 +hepatitis 3 +disappeared 0 +in 0 +all 0 +cases 0 +after 0 +cessation 0 +of 0 +the 0 +incriminated 0 +drug 0 +"," 0 +while 0 +biliary 0 +"," 0 +viral 0 +and 0 +immunological 0 +searches 0 +were 0 +negative 0 +. 0 +0nly 0 +2 0 +patients 0 +of 0 +our 0 +retrospective 0 +study 0 +experienced 0 +a 0 +mild 0 +or 0 +severe 0 +neutropenia 3 +. 0 +C0NCLUSI0N 0 +: 0 +Toxic 3 +hepatitis 4 +is 0 +a 0 +potential 0 +adverse 0 +effect 0 +of 0 +antithyroid 0 +drugs 0 +which 0 +warrants 0 +"," 0 +as 0 +for 0 +haematological 0 +disturbances 0 +"," 0 +a 0 +pre 0 +- 0 +therapeutic 0 +determination 0 +and 0 +a 0 +careful 0 +follow 0 +- 0 +up 0 +of 0 +relevant 0 +biological 0 +markers 0 +. 0 +Moreover 0 +"," 0 +hepatotoxicity 3 +may 0 +not 0 +be 0 +restricted 0 +to 0 +one 0 +class 0 +of 0 +antithyroid 0 +agents 0 +. 0 +Interactive 0 +effects 0 +of 0 +variations 0 +in 0 +[ 0 +Na 1 +] 0 +o 0 +and 0 +[ 0 +Ca 1 +] 0 +o 0 +on 0 +rat 0 +atrial 0 +spontaneous 0 +frequency 0 +. 0 +The 0 +effects 0 +of 0 +varying 0 +the 0 +extracellular 0 +concentrations 0 +of 0 +Na 1 +and 0 +Ca 1 +( 0 +[ 0 +Na 1 +] 0 +o 0 +and 0 +[ 0 +Ca 1 +] 0 +o 0 +) 0 +on 0 +both 0 +"," 0 +the 0 +spontaneous 0 +beating 0 +and 0 +the 0 +negative 0 +chronotropic 0 +action 0 +of 0 +verapamil 1 +"," 0 +were 0 +studied 0 +in 0 +the 0 +isolated 0 +rat 0 +atria 0 +. 0 +Basal 0 +frequency 0 +( 0 +BF 0 +) 0 +evaluated 0 +by 0 +surface 0 +electrogram 0 +was 0 +223 0 ++ 0 +/ 0 +- 0 +4 0 +beats 0 +/ 0 +min 0 +. 0 +in 0 +control 0 +Krebs 0 +- 0 +Ringer 0 +containing 0 +137 0 +mM 0 +Na 1 +and 0 +1 0 +. 0 +35 0 +mM 0 +Ca 1 +( 0 +N 0 +) 0 +. 0 +It 0 +decreased 0 +by 0 +16 0 ++ 0 +/ 0 +- 0 +3 0 +% 0 +by 0 +lowering 0 +[ 0 +Na 1 +] 0 +o 0 +to 0 +78 0 +mM 0 +( 0 +LNa 0 +) 0 +"," 0 +23 0 ++ 0 +/ 0 +- 0 +2 0 +% 0 +by 0 +lowering 0 +simultaneously 0 +[ 0 +Na 1 +] 0 +o 0 +to 0 +78 0 +mM 0 +and 0 +[ 0 +Ca 1 +] 0 +o 0 +to 0 +0 0 +. 0 +675 0 +mM 0 +( 0 +LNa 0 ++ 0 +LCa 0 +) 0 +and 0 +31 0 ++ 0 +/ 0 +- 0 +5 0 +% 0 +by 0 +lowering 0 +[ 0 +Na 1 +] 0 +o 0 +to 0 +78 0 +mM 0 +plus 0 +increasing 0 +[ 0 +Ca 1 +] 0 +o 0 +to 0 +3 0 +. 0 +6 0 +mM 0 +( 0 +LNa 0 ++ 0 +HCa 0 +) 0 +. 0 +At 0 +normal 0 +[ 0 +Na 1 +] 0 +o 0 +"," 0 +decrease 0 +( 0 +0 0 +. 0 +675 0 +mM 0 +) 0 +or 0 +increase 0 +( 0 +3 0 +. 0 +6 0 +mM 0 +) 0 +of 0 +[ 0 +Ca 1 +] 0 +o 0 +did 0 +not 0 +modify 0 +BF 0 +; 0 +a 0 +reduction 0 +of 0 +ten 0 +times 0 +( 0 +0 0 +. 0 +135 0 +mM 0 +of 0 +normal 0 +[ 0 +Ca 1 +] 0 +o 0 +was 0 +effective 0 +to 0 +reduce 0 +BF 0 +by 0 +40 0 ++ 0 +/ 0 +- 0 +13 0 +% 0 +. 0 +All 0 +negative 0 +chronotropic 0 +effects 0 +were 0 +BF 0 +- 0 +dependent 0 +. 0 +Dose 0 +- 0 +dependent 0 +bradycardia 3 +induced 0 +by 0 +verapamil 1 +was 0 +potentiated 0 +by 0 +LNa 0 +"," 0 +LCa 0 +"," 0 +and 0 +HCa 0 +. 0 +Independent 0 +but 0 +not 0 +additive 0 +effects 0 +of 0 +Na 1 +and 0 +Ca 1 +are 0 +shown 0 +by 0 +decreases 0 +in 0 +the 0 +values 0 +of 0 +[ 0 +verapamil 1 +] 0 +o 0 +needed 0 +to 0 +reduce 0 +BF 0 +by 0 +30 0 +% 0 +( 0 +IC30 0 +) 0 +with 0 +the 0 +following 0 +order 0 +of 0 +inhibitory 0 +potency 0 +: 0 +LNa 0 +> 0 +LCa 0 +> 0 +HCa 0 +> 0 +N 0 +"," 0 +resulting 0 +LNa 0 ++ 0 +HCa 0 +similar 0 +to 0 +LNa 0 +. 0 +The 0 +[ 0 +verapamil 1 +] 0 +o 0 +that 0 +arrested 0 +atrial 0 +beating 0 +( 0 +AC 0 +) 0 +was 0 +also 0 +potentiated 0 +with 0 +the 0 +order 0 +LNa 0 += 0 +LNa 0 ++ 0 +LCa 0 += 0 +LNa 0 ++ 0 +HCa 0 += 0 +LCa 0 +> 0 +HCa 0 += 0 +N 0 +. 0 +The 0 +results 0 +indicate 0 +that 0 +rat 0 +atrial 0 +spontaneous 0 +beating 0 +is 0 +more 0 +dependent 0 +on 0 +[ 0 +Na 1 +] 0 +o 0 +than 0 +on 0 +[ 0 +Ca 1 +] 0 +o 0 +in 0 +a 0 +range 0 +of 0 ++ 0 +/ 0 +- 0 +50 0 +% 0 +of 0 +their 0 +normal 0 +concentration 0 +. 0 +Also 0 +the 0 +enhancement 0 +of 0 +verapamil 1 +effects 0 +on 0 +atrial 0 +beating 0 +was 0 +more 0 +pronounced 0 +at 0 +LNa 0 +than 0 +at 0 +LCa 0 +. 0 +( 0 +ABSTRACT 0 +TRUNCATED 0 +AT 0 +250 0 +W0RDS 0 +) 0 +Pseudo 0 +- 0 +allergic 3 +reactions 4 +to 0 +corticosteroids 1 +: 0 +diagnosis 0 +and 0 +alternatives 0 +. 0 +Two 0 +patients 0 +treated 0 +with 0 +parenteral 0 +paramethasone 1 +( 0 +Triniol 0 +) 0 +and 0 +dexamethasone 1 +( 0 +Sedionbel 0 +) 0 +are 0 +described 0 +. 0 +A 0 +few 0 +minutes 0 +after 0 +administration 0 +of 0 +the 0 +drugs 0 +"," 0 +they 0 +presented 0 +urticaria 3 +( 0 +patients 0 +1 0 +and 0 +2 0 +) 0 +and 0 +conjunctivitis 3 +( 0 +patient 0 +1 0 +) 0 +. 0 +The 0 +purpose 0 +of 0 +our 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +cause 0 +of 0 +the 0 +patients 0 +' 0 +reactions 0 +"," 0 +the 0 +immunological 0 +mechanisms 0 +involved 0 +and 0 +whether 0 +these 0 +patients 0 +would 0 +be 0 +able 0 +to 0 +tolerate 0 +any 0 +kind 0 +of 0 +corticoid 0 +. 0 +Clinical 0 +examinations 0 +and 0 +skin 0 +"," 0 +oral 0 +and 0 +parenteral 0 +challenges 0 +with 0 +different 0 +corticosteroids 1 +and 0 +ELISA 0 +tests 0 +were 0 +performed 0 +. 0 +In 0 +the 0 +two 0 +patients 0 +"," 0 +skin 0 +and 0 +ELISA 0 +tests 0 +with 0 +paramethasone 1 +were 0 +negative 0 +"," 0 +as 0 +was 0 +the 0 +prick 0 +test 0 +with 0 +each 0 +of 0 +its 0 +excipients 0 +. 0 +A 0 +single 0 +- 0 +blind 0 +parenteral 0 +challenge 0 +with 0 +Triniol 0 +was 0 +positive 0 +in 0 +both 0 +patients 0 +after 0 +the 0 +administration 0 +of 0 +1 0 +ml 0 +of 0 +the 0 +drug 0 +"," 0 +and 0 +negative 0 +with 0 +its 0 +excipients 0 +. 0 +We 0 +also 0 +carried 0 +out 0 +oral 0 +and 0 +parenteral 0 +challenges 0 +with 0 +other 0 +corticosteroids 1 +and 0 +found 0 +intolerance 0 +to 0 +some 0 +of 0 +them 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +paramethasone 1 +caused 0 +pseudoallergic 0 +reactions 0 +in 0 +our 0 +patients 0 +. 0 +Corticosteroids 0 +different 0 +from 0 +paramethasone 1 +also 0 +produced 0 +hypersensitivity 3 +reactions 0 +in 0 +these 0 +patients 0 +; 0 +however 0 +"," 0 +a 0 +few 0 +of 0 +them 0 +were 0 +tolerated 0 +. 0 +The 0 +basic 0 +mechanisms 0 +of 0 +those 0 +reactions 0 +are 0 +not 0 +yet 0 +fully 0 +understood 0 +. 0 +To 0 +our 0 +knowledge 0 +"," 0 +this 0 +is 0 +the 0 +first 0 +report 0 +of 0 +a 0 +pseudo 0 +- 0 +allergy 3 +caused 0 +by 0 +paramethasone 1 +. 0 +Study 0 +of 0 +the 0 +role 0 +of 0 +vitamin 1 +B12 2 +and 0 +folinic 1 +acid 2 +supplementation 0 +in 0 +preventing 0 +hematologic 0 +toxicity 3 +of 0 +zidovudine 1 +. 0 +A 0 +prospective 0 +"," 0 +randomized 0 +study 0 +was 0 +conducted 0 +to 0 +evaluate 0 +the 0 +role 0 +of 0 +vitamin 1 +B12 2 +and 0 +folinic 1 +acid 2 +supplementation 0 +in 0 +preventing 0 +zidovudine 1 +( 0 +ZDV 1 +) 0 +- 0 +induced 0 +bone 3 +marrow 4 +suppression 4 +. 0 +Seventy 0 +- 0 +five 0 +human 3 +immunodeficiency 4 +virus 4 +( 4 +HIV 4 +) 4 +- 4 +infected 4 +patients 0 +with 0 +CD4 0 ++ 0 +cell 0 +counts 0 +< 0 +500 0 +/ 0 +mm3 0 +were 0 +randomized 0 +to 0 +receive 0 +either 0 +ZDV 1 +( 0 +500 0 +mg 0 +daily 0 +) 0 +alone 0 +( 0 +group 0 +I 0 +"," 0 +n 0 += 0 +38 0 +) 0 +or 0 +in 0 +combination 0 +with 0 +folinic 1 +acid 2 +( 0 +15 0 +mg 0 +daily 0 +) 0 +and 0 +intramascular 0 +vitamin 1 +B12 2 +( 0 +1000 0 +micrograms 0 +monthly 0 +) 0 +( 0 +group 0 +II 0 +"," 0 +n 0 += 0 +37 0 +) 0 +. 0 +Finally 0 +"," 0 +15 0 +patients 0 +were 0 +excluded 0 +from 0 +the 0 +study 0 +( 0 +noncompliance 0 +14 0 +"," 0 +death 3 +1 0 +) 0 +; 0 +thus 0 +"," 0 +60 0 +patients 0 +( 0 +31 0 +in 0 +group 0 +I 0 +and 0 +29 0 +in 0 +group 0 +II 0 +) 0 +were 0 +eligible 0 +for 0 +analysis 0 +. 0 +No 0 +significant 0 +differences 0 +between 0 +groups 0 +were 0 +found 0 +at 0 +enrollment 0 +. 0 +During 0 +the 0 +study 0 +"," 0 +vitamin 1 +B12 2 +and 0 +folate 1 +levels 0 +were 0 +significantly 0 +higher 0 +in 0 +group 0 +II 0 +patients 0 +; 0 +however 0 +"," 0 +no 0 +differences 0 +in 0 +hemoglobin 0 +"," 0 +hematocrit 0 +"," 0 +mean 0 +corpuscular 0 +volume 0 +"," 0 +and 0 +white 0 +- 0 +cell 0 +"," 0 +neutrophil 0 +and 0 +platelet 0 +counts 0 +were 0 +observed 0 +between 0 +groups 0 +at 0 +3 0 +"," 0 +6 0 +"," 0 +9 0 +and 0 +12 0 +months 0 +. 0 +Severe 0 +hematologic 0 +toxicity 3 +( 0 +neutrophil 0 +count 0 +< 0 +1000 0 +/ 0 +mm3 0 +and 0 +/ 0 +or 0 +hemoglobin 0 +< 0 +8 0 +g 0 +/ 0 +dl 0 +) 0 +occurred 0 +in 0 +4 0 +patients 0 +assigned 0 +to 0 +group 0 +I 0 +and 0 +7 0 +assigned 0 +to 0 +group 0 +II 0 +. 0 +There 0 +was 0 +no 0 +correlation 0 +between 0 +vitamin 1 +B12 2 +or 0 +folate 1 +levels 0 +and 0 +development 0 +of 0 +myelosuppression 3 +. 0 +Vitamin 1 +B12 2 +and 0 +folinic 1 +acid 2 +supplementation 0 +of 0 +ZDV 1 +therapy 0 +does 0 +not 0 +seem 0 +useful 0 +in 0 +preventing 0 +or 0 +reducing 0 +ZDV 1 +- 0 +induced 0 +myelotoxicity 3 +in 0 +the 0 +overall 0 +treated 0 +population 0 +"," 0 +although 0 +a 0 +beneficial 0 +effect 0 +in 0 +certain 0 +subgroups 0 +of 0 +patients 0 +cannot 0 +be 0 +excluded 0 +. 0 +Safety 0 +and 0 +side 0 +- 0 +effects 0 +of 0 +alprazolam 1 +. 0 +Controlled 0 +study 0 +in 0 +agoraphobia 3 +with 0 +panic 3 +disorder 4 +. 0 +BACKGR0UND 0 +: 0 +The 0 +widespread 0 +use 0 +of 0 +benzodiazepines 1 +has 0 +led 0 +to 0 +increasing 0 +recognition 0 +of 0 +their 0 +unwanted 0 +effects 0 +. 0 +The 0 +efficacy 0 +of 0 +alprazolam 1 +and 0 +placebo 0 +in 0 +panic 3 +disorder 4 +with 0 +agoraphobia 3 +"," 0 +and 0 +the 0 +side 0 +- 0 +effect 0 +and 0 +adverse 0 +effect 0 +profiles 0 +of 0 +both 0 +drug 0 +groups 0 +were 0 +measured 0 +. 0 +METH0D 0 +: 0 +In 0 +London 0 +and 0 +Toronto 0 +154 0 +patients 0 +who 0 +met 0 +DSM 0 +- 0 +III 0 +criteria 0 +for 0 +panic 3 +disorder 4 +with 0 +agoraphobia 3 +were 0 +randomised 0 +to 0 +alprazolam 1 +or 0 +placebo 0 +. 0 +Subjects 0 +in 0 +each 0 +drug 0 +group 0 +also 0 +received 0 +either 0 +exposure 0 +or 0 +relaxation 0 +. 0 +Treatment 0 +was 0 +from 0 +weeks 0 +0 0 +to 0 +8 0 +and 0 +was 0 +then 0 +tapered 0 +from 0 +weeks 0 +8 0 +to 0 +16 0 +. 0 +RESULTS 0 +: 0 +Mean 0 +alprazolam 1 +dose 0 +was 0 +5 0 +mg 0 +daily 0 +. 0 +Compared 0 +with 0 +placebo 0 +subjects 0 +"," 0 +alprazolam 1 +patients 0 +developed 0 +more 0 +adverse 0 +reactions 0 +( 0 +21 0 +% 0 +v 0 +. 0 +0 0 +% 0 +) 0 +of 0 +depression 3 +"," 0 +enuresis 3 +"," 0 +disinhibition 0 +and 0 +aggression 3 +; 0 +and 0 +more 0 +side 0 +- 0 +effects 0 +"," 0 +particularly 0 +sedation 0 +"," 0 +irritability 3 +"," 0 +impaired 3 +memory 4 +"," 0 +weight 3 +loss 4 +and 0 +ataxia 3 +. 0 +Side 0 +- 0 +effects 0 +tended 0 +to 0 +diminish 0 +during 0 +treatment 0 +but 0 +remained 0 +significant 0 +at 0 +week 0 +8 0 +. 0 +Despite 0 +this 0 +"," 0 +the 0 +drop 0 +- 0 +out 0 +rate 0 +was 0 +low 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Alprazolam 1 +caused 0 +side 0 +- 0 +effects 0 +and 0 +adverse 0 +effects 0 +during 0 +treatment 0 +but 0 +many 0 +patients 0 +were 0 +willing 0 +to 0 +accept 0 +these 0 +. 0 +Crescentic 0 +fibrillary 0 +glomerulonephritis 3 +associated 0 +with 0 +intermittent 0 +rifampin 1 +therapy 0 +for 0 +pulmonary 3 +tuberculosis 4 +. 0 +This 0 +case 0 +study 0 +reveals 0 +an 0 +unusual 0 +finding 0 +of 0 +rapidly 0 +proliferative 0 +crescentic 0 +glomerulonephritis 3 +in 0 +a 0 +patient 0 +treated 0 +with 0 +rifampin 1 +who 0 +had 0 +no 0 +other 0 +identifiable 0 +causes 0 +for 0 +developing 0 +this 0 +disease 0 +. 0 +This 0 +patient 0 +underwent 0 +a 0 +10 0 +- 0 +month 0 +regimen 0 +of 0 +rifampin 1 +and 0 +isoniazid 1 +for 0 +pulmonary 3 +tuberculosis 4 +and 0 +was 0 +discovered 0 +to 0 +have 0 +developed 0 +signs 0 +of 0 +severe 0 +renal 3 +failure 4 +five 0 +weeks 0 +after 0 +completion 0 +of 0 +therapy 0 +. 0 +Renal 0 +biopsy 0 +revealed 0 +severe 0 +glomerulonephritis 3 +with 0 +crescents 0 +"," 0 +electron 0 +dense 0 +fibrillar 0 +deposits 0 +and 0 +moderate 0 +lymphocytic 0 +interstitial 0 +infiltrate 0 +. 0 +0ther 0 +possible 0 +causes 0 +of 0 +rapidly 0 +progressive 0 +glomerulonephritis 3 +were 0 +investigated 0 +and 0 +ruled 0 +out 0 +. 0 +This 0 +report 0 +documents 0 +the 0 +unusual 0 +occurrence 0 +of 0 +rapidly 0 +progressive 0 +glomerulonephritis 3 +with 0 +crescents 0 +and 0 +fibrillar 0 +glomerulonephritis 3 +in 0 +a 0 +patient 0 +treated 0 +with 0 +rifampin 1 +. 0 +Acute 0 +confusion 3 +induced 0 +by 0 +a 0 +high 0 +- 0 +dose 0 +infusion 0 +of 0 +5 1 +- 2 +fluorouracil 2 +and 0 +folinic 1 +acid 2 +. 0 +A 0 +61 0 +- 0 +year 0 +- 0 +old 0 +man 0 +was 0 +treated 0 +with 0 +combination 0 +chemotherapy 0 +incorporating 0 +cisplatinum 1 +"," 0 +etoposide 1 +"," 0 +high 0 +- 0 +dose 0 +5 1 +- 2 +fluorouracil 2 +( 0 +2 0 +"," 0 +250 0 +mg 0 +/ 0 +m2 0 +/ 0 +24 0 +hours 0 +) 0 +and 0 +folinic 1 +acid 2 +for 0 +an 0 +inoperable 0 +gastric 3 +adenocarcinoma 4 +. 0 +He 0 +developed 0 +acute 0 +neurologic 0 +symptoms 0 +of 0 +mental 0 +confusion 3 +"," 0 +disorientation 3 +and 0 +irritability 3 +"," 0 +and 0 +then 0 +lapsed 0 +into 0 +a 0 +deep 0 +coma 3 +"," 0 +lasting 0 +for 0 +approximately 0 +40 0 +hours 0 +during 0 +the 0 +first 0 +dose 0 +( 0 +day 0 +2 0 +) 0 +of 0 +5 1 +- 2 +fluorouracil 2 +and 0 +folinic 1 +acid 2 +infusion 0 +. 0 +This 0 +complication 0 +reappeared 0 +on 0 +day 0 +25 0 +during 0 +the 0 +second 0 +dose 0 +of 0 +5 1 +- 2 +fluorouracil 2 +and 0 +folinic 1 +acid 2 +"," 0 +which 0 +were 0 +then 0 +the 0 +only 0 +drugs 0 +given 0 +. 0 +Because 0 +folinic 1 +acid 2 +was 0 +unlikely 0 +to 0 +be 0 +associated 0 +with 0 +this 0 +condition 0 +"," 0 +neurotoxicity 3 +due 0 +to 0 +high 0 +- 0 +dose 0 +5 1 +- 2 +fluorouracil 2 +was 0 +highly 0 +suspected 0 +. 0 +The 0 +pathogenesis 0 +of 0 +5 1 +- 2 +fluorouracil 2 +neurotoxicity 3 +may 0 +be 0 +due 0 +to 0 +a 0 +Krebs 0 +cycle 0 +blockade 0 +by 0 +fluoroacetate 1 +and 0 +fluorocitrate 1 +"," 0 +thiamine 1 +deficiency 0 +"," 0 +or 0 +dihydrouracil 1 +dehydrogenase 0 +deficiency 0 +. 0 +High 0 +- 0 +dose 0 +5 1 +- 2 +fluorouracil 2 +/ 0 +folinic 1 +acid 2 +infusion 0 +therapy 0 +has 0 +recently 0 +become 0 +a 0 +popular 0 +regimen 0 +for 0 +various 0 +cancers 3 +. 0 +It 0 +is 0 +necessary 0 +that 0 +both 0 +oncologists 0 +and 0 +neurologists 0 +be 0 +fully 0 +aware 0 +of 0 +this 0 +unusual 0 +complication 0 +. 0 +Effect 0 +of 0 +switching 0 +carbamazepine 1 +to 0 +oxcarbazepine 1 +on 0 +the 0 +plasma 0 +levels 0 +of 0 +neuroleptics 0 +. 0 +A 0 +case 0 +report 0 +. 0 +Carbamazepine 1 +was 0 +switched 0 +to 0 +its 0 +10 0 +- 0 +keto 0 +analogue 0 +oxcarbazepine 1 +among 0 +six 0 +difficult 0 +- 0 +to 0 +- 0 +treat 0 +schizophrenic 3 +or 0 +organic 3 +psychotic 4 +patients 0 +using 0 +concomitantly 0 +haloperidol 1 +"," 0 +chlorpromazine 1 +or 0 +clozapine 1 +. 0 +This 0 +change 0 +resulted 0 +within 0 +2 0 +- 0 +4 0 +weeks 0 +in 0 +the 0 +50 0 +- 0 +200 0 +% 0 +increase 0 +in 0 +the 0 +plasma 0 +levels 0 +of 0 +these 0 +neuroleptics 0 +and 0 +the 0 +appearance 0 +of 0 +extrapyramidal 3 +symptoms 4 +. 0 +None 0 +of 0 +the 0 +patients 0 +showed 0 +any 0 +clinical 0 +deteriotation 0 +during 0 +the 0 +following 0 +3 0 +- 0 +6 0 +months 0 +. 0 +The 0 +results 0 +of 0 +this 0 +case 0 +report 0 +support 0 +the 0 +idea 0 +that 0 +in 0 +contrast 0 +with 0 +carbamazepine 1 +oxcarbazepine 1 +does 0 +not 0 +induce 0 +the 0 +hepatic 0 +microsomal 0 +enzyme 0 +systems 0 +regulating 0 +the 0 +inactivation 0 +of 0 +antipsychotic 0 +drugs 0 +. 0 +Time 0 +course 0 +of 0 +lipid 0 +peroxidation 0 +in 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephropathy 3 +. 0 +Reactive 0 +oxygen 1 +species 0 +have 0 +been 0 +implicated 0 +in 0 +the 0 +pathogenesis 0 +of 0 +acute 0 +puromycin 1 +aminonucleoside 2 +( 0 +PAN 1 +) 0 +- 0 +induced 0 +nephropathy 3 +"," 0 +with 0 +antioxidants 0 +significantly 0 +reducing 0 +the 0 +proteinuria 3 +. 0 +The 0 +temporal 0 +relationship 0 +between 0 +lipid 0 +peroxidation 0 +in 0 +the 0 +kidney 0 +and 0 +proteinuria 3 +was 0 +examined 0 +in 0 +this 0 +study 0 +. 0 +Rats 0 +were 0 +treated 0 +with 0 +a 0 +single 0 +IV 0 +injection 0 +of 0 +puromycin 1 +aminonucleoside 2 +"," 0 +( 0 +PAN 1 +"," 0 +7 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +) 0 +and 0 +24 0 +hour 0 +urine 0 +samples 0 +were 0 +obtained 0 +prior 0 +to 0 +sacrifice 0 +on 0 +days 0 +3 0 +"," 0 +5 0 +"," 0 +7 0 +"," 0 +10 0 +"," 0 +17 0 +"," 0 +27 0 +"," 0 +41 0 +( 0 +N 0 += 0 +5 0 +- 0 +10 0 +per 0 +group 0 +) 0 +. 0 +The 0 +kidneys 0 +were 0 +removed 0 +"," 0 +flushed 0 +with 0 +ice 0 +cold 0 +TRIS 0 +buffer 0 +. 0 +Kidney 0 +cortices 0 +from 0 +each 0 +animal 0 +were 0 +used 0 +to 0 +prepare 0 +homogenates 0 +. 0 +Tissue 0 +lipid 0 +peroxidation 0 +was 0 +measured 0 +in 0 +whole 0 +homogenates 0 +as 0 +well 0 +as 0 +in 0 +lipid 0 +extracts 0 +from 0 +homogenates 0 +as 0 +thiobarbituric 1 +acid 2 +reactive 0 +substances 0 +. 0 +Proteinuria 3 +was 0 +evident 0 +at 0 +day 0 +5 0 +"," 0 +peaked 0 +at 0 +day 0 +7 0 +and 0 +persisted 0 +to 0 +day 0 +27 0 +. 0 +Lipid 0 +peroxidation 0 +in 0 +homogenates 0 +was 0 +maximal 0 +at 0 +day 0 +3 0 +and 0 +declined 0 +rapidly 0 +to 0 +control 0 +levels 0 +by 0 +day 0 +17 0 +. 0 +This 0 +study 0 +supports 0 +the 0 +role 0 +of 0 +lipid 0 +peroxidation 0 +in 0 +mediating 0 +the 0 +proteinuric 3 +injury 4 +in 0 +PAN 1 +nephropathy 3 +. 0 +Composition 0 +of 0 +gall 3 +bladder 4 +stones 4 +associated 0 +with 0 +octreotide 1 +: 0 +response 0 +to 0 +oral 0 +ursodeoxycholic 1 +acid 2 +. 0 +0ctreotide 1 +"," 0 +an 0 +effective 0 +treatment 0 +for 0 +acromegaly 3 +"," 0 +induces 0 +gall 3 +bladder 4 +stones 4 +in 0 +13 0 +- 0 +60 0 +% 0 +of 0 +patients 0 +. 0 +Because 0 +knowledge 0 +of 0 +stone 0 +composition 0 +is 0 +essential 0 +for 0 +studies 0 +of 0 +their 0 +pathogenesis 0 +"," 0 +treatment 0 +"," 0 +and 0 +prevention 0 +"," 0 +this 0 +was 0 +investigated 0 +by 0 +direct 0 +and 0 +indirect 0 +methods 0 +in 0 +14 0 +octreotide 1 +treated 0 +acromegalic 3 +patients 0 +with 0 +gall 3 +stones 4 +. 0 +Chemical 0 +analysis 0 +of 0 +gall 3 +stones 4 +retrieved 0 +at 0 +cholecystectomy 0 +from 0 +two 0 +patients 0 +"," 0 +showed 0 +that 0 +they 0 +contained 0 +71 0 +% 0 +and 0 +87 0 +% 0 +cholesterol 1 +by 0 +weight 0 +. 0 +In 0 +the 0 +remaining 0 +12 0 +patients 0 +"," 0 +localised 0 +computed 0 +tomography 0 +of 0 +the 0 +gall 0 +bladder 0 +showed 0 +that 0 +eight 0 +had 0 +stones 0 +with 0 +maximum 0 +attenuation 0 +scores 0 +of 0 +< 0 +100 0 +Hounsfield 0 +units 0 +( 0 +values 0 +of 0 +< 0 +100 0 +HU 0 +predict 0 +cholesterol 1 +rich 0 +"," 0 +dissolvable 0 +stones 0 +) 0 +. 0 +Gall 0 +bladder 0 +bile 0 +was 0 +obtained 0 +by 0 +ultrasound 0 +guided 0 +"," 0 +fine 0 +needle 0 +puncture 0 +from 0 +six 0 +patients 0 +. 0 +All 0 +six 0 +patients 0 +had 0 +supersaturated 0 +bile 0 +( 0 +mean 0 +( 0 +SEM 0 +) 0 +cholesterol 1 +saturation 0 +index 0 +of 0 +1 0 +. 0 +19 0 +( 0 +0 0 +. 0 +8 0 +) 0 +( 0 +range 0 +1 0 +. 0 +1 0 +- 0 +1 0 +. 0 +53 0 +) 0 +) 0 +and 0 +all 0 +had 0 +abnormally 0 +rapid 0 +cholesterol 1 +microcrystal 0 +nucleation 0 +times 0 +( 0 +< 0 +4 0 +days 0 +( 0 +range 0 +1 0 +- 0 +4 0 +) 0 +) 0 +"," 0 +whilst 0 +in 0 +four 0 +"," 0 +the 0 +bile 0 +contained 0 +cholesterol 1 +microcrystals 0 +immediately 0 +after 0 +sampling 0 +. 0 +0f 0 +the 0 +12 0 +patients 0 +considered 0 +for 0 +oral 0 +ursodeoxycholic 1 +acid 2 +( 0 +UDCA 1 +) 0 +treatment 0 +"," 0 +two 0 +had 0 +a 0 +blocked 0 +cystic 0 +duct 0 +and 0 +were 0 +not 0 +started 0 +on 0 +UDCA 1 +while 0 +one 0 +was 0 +lost 0 +to 0 +follow 0 +up 0 +. 0 +After 0 +one 0 +year 0 +of 0 +treatment 0 +"," 0 +five 0 +of 0 +the 0 +remaining 0 +nine 0 +patients 0 +showed 0 +either 0 +partial 0 +( 0 +n 0 += 0 +3 0 +) 0 +or 0 +complete 0 +( 0 +n 0 += 0 +2 0 +) 0 +gall 3 +stone 4 +dissolution 0 +"," 0 +suggesting 0 +that 0 +their 0 +stones 0 +were 0 +cholesterol 1 +rich 0 +. 0 +This 0 +corresponds 0 +"," 0 +by 0 +actuarial 0 +( 0 +life 0 +table 0 +) 0 +analysis 0 +"," 0 +to 0 +a 0 +combined 0 +gall 3 +stone 4 +dissolution 0 +rate 0 +of 0 +58 0 +. 0 +3 0 +( 0 +15 0 +. 0 +9 0 +% 0 +) 0 +. 0 +In 0 +conclusion 0 +"," 0 +octreotide 1 +induced 0 +gall 3 +stones 4 +are 0 +generally 0 +small 0 +"," 0 +multiple 0 +"," 0 +and 0 +cholesterol 1 +rich 0 +although 0 +"," 0 +in 0 +common 0 +with 0 +spontaneous 0 +gall 3 +stone 4 +disease 4 +"," 0 +at 0 +presentation 0 +some 0 +patients 0 +will 0 +have 0 +a 0 +blocked 0 +cystic 0 +duct 0 +and 0 +some 0 +gall 3 +stones 4 +containing 0 +calcium 1 +. 0 +Erythema 3 +multiforme 4 +and 0 +hypersensitivity 3 +myocarditis 4 +caused 0 +by 0 +ampicillin 1 +. 0 +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +erythema 3 +multiforme 4 +and 0 +hypersensitivity 3 +myocarditis 4 +caused 0 +by 0 +ampicillin 1 +. 0 +CASE 0 +SUMMARY 0 +: 0 +A 0 +13 0 +- 0 +year 0 +- 0 +old 0 +boy 0 +was 0 +treated 0 +with 0 +ampicillin 1 +and 0 +gentamicin 1 +because 0 +of 0 +suspected 0 +septicemia 3 +. 0 +Medications 0 +were 0 +discontinued 0 +when 0 +erythema 3 +multiforme 4 +and 0 +congestive 3 +heart 4 +failure 4 +caused 0 +by 0 +myocarditis 3 +occurred 0 +. 0 +The 0 +patient 0 +was 0 +treated 0 +with 0 +methylprednisolone 1 +and 0 +gradually 0 +improved 0 +. 0 +Macrophage 0 +- 0 +migration 0 +inhibition 0 +( 0 +MIF 0 +) 0 +test 0 +with 0 +ampicillin 1 +was 0 +positive 0 +. 0 +DISCUSSI0N 0 +: 0 +After 0 +most 0 +infections 3 +causing 0 +erythema 3 +multiforme 4 +and 0 +myocarditis 3 +were 0 +ruled 0 +out 0 +"," 0 +a 0 +drug 3 +- 4 +induced 4 +allergic 4 +reaction 4 +was 0 +suspected 0 +. 0 +Positive 0 +MIF 0 +test 0 +for 0 +ampicillin 1 +showed 0 +sensitization 0 +of 0 +the 0 +patient 0 +' 0 +s 0 +lymphocytes 0 +to 0 +ampicillin 1 +. 0 +C0NCLUSI0NS 0 +: 0 +Hypersensitivity 3 +myocarditis 4 +is 0 +a 0 +rare 0 +and 0 +dangerous 0 +manifestation 0 +of 0 +allergy 3 +to 0 +penicillins 1 +. 0 +Clomipramine 1 +- 0 +induced 0 +sleep 3 +disturbance 4 +does 0 +not 0 +impair 0 +its 0 +prolactin 0 +- 0 +releasing 0 +action 0 +. 0 +The 0 +present 0 +study 0 +was 0 +undertaken 0 +to 0 +examine 0 +the 0 +role 0 +of 0 +sleep 3 +disturbance 4 +"," 0 +induced 0 +by 0 +clomipramine 1 +administration 0 +"," 0 +on 0 +the 0 +secretory 0 +rate 0 +of 0 +prolactin 0 +( 0 +PRL 0 +) 0 +in 0 +addition 0 +to 0 +the 0 +direct 0 +drug 0 +effect 0 +. 0 +Two 0 +groups 0 +of 0 +supine 0 +subjects 0 +were 0 +studied 0 +under 0 +placebo 0 +- 0 +controlled 0 +conditions 0 +"," 0 +one 0 +during 0 +the 0 +night 0 +"," 0 +when 0 +sleeping 0 +( 0 +n 0 += 0 +7 0 +) 0 +and 0 +the 0 +other 0 +at 0 +daytime 0 +"," 0 +when 0 +awake 0 +( 0 +n 0 += 0 +6 0 +) 0 +. 0 +Each 0 +subject 0 +received 0 +a 0 +single 0 +50 0 +mg 0 +dose 0 +of 0 +clomipramine 1 +given 0 +orally 0 +2 0 +hours 0 +before 0 +blood 0 +collection 0 +. 0 +Plasma 0 +PRL 0 +concentrations 0 +were 0 +analysed 0 +at 0 +10 0 +min 0 +intervals 0 +and 0 +underlying 0 +secretory 0 +rates 0 +calculated 0 +by 0 +a 0 +deconvolution 0 +procedure 0 +. 0 +For 0 +both 0 +experiments 0 +the 0 +drug 0 +intake 0 +led 0 +to 0 +significant 0 +increases 0 +in 0 +PRL 0 +secretion 0 +"," 0 +acting 0 +preferentially 0 +on 0 +tonic 0 +secretion 0 +as 0 +pulse 0 +amplitude 0 +and 0 +frequency 0 +did 0 +not 0 +differ 0 +significantly 0 +from 0 +corresponding 0 +control 0 +values 0 +. 0 +During 0 +the 0 +night 0 +clomipramine 1 +ingestion 0 +altered 0 +the 0 +complete 0 +sleep 0 +architecture 0 +in 0 +that 0 +it 0 +suppressed 0 +REM 0 +sleep 0 +and 0 +the 0 +sleep 0 +cycles 0 +and 0 +induced 0 +increased 0 +wakefulness 0 +. 0 +As 0 +the 0 +relative 0 +increase 0 +in 0 +PRL 0 +secretion 0 +expressed 0 +as 0 +a 0 +percentage 0 +of 0 +the 0 +mean 0 +did 0 +not 0 +significantly 0 +differ 0 +between 0 +the 0 +night 0 +and 0 +day 0 +time 0 +studies 0 +( 0 +46 0 ++ 0 +/ 0 +- 0 +19 0 +% 0 +vs 0 +34 0 ++ 0 +/ 0 +- 0 +10 0 +% 0 +) 0 +"," 0 +it 0 +can 0 +be 0 +concluded 0 +that 0 +the 0 +observed 0 +sleep 3 +disturbance 4 +did 0 +not 0 +interfere 0 +with 0 +the 0 +drug 0 +action 0 +per 0 +se 0 +. 0 +The 0 +presence 0 +of 0 +REM 0 +sleep 0 +was 0 +shown 0 +not 0 +to 0 +be 0 +a 0 +determining 0 +factor 0 +either 0 +for 0 +secretory 0 +pulse 0 +amplitude 0 +and 0 +frequency 0 +"," 0 +as 0 +"," 0 +for 0 +both 0 +"," 0 +mean 0 +nocturnal 0 +values 0 +were 0 +similar 0 +with 0 +and 0 +without 0 +prior 0 +clomipramine 1 +ingestion 0 +. 0 +Survey 0 +of 0 +complications 0 +of 0 +indocyanine 1 +green 2 +angiography 0 +in 0 +Japan 0 +. 0 +PURP0SE 0 +: 0 +We 0 +evaluated 0 +the 0 +safety 0 +of 0 +indocyanine 1 +green 2 +for 0 +use 0 +in 0 +fundus 0 +angiography 0 +. 0 +METH0DS 0 +: 0 +We 0 +sent 0 +a 0 +questionnaire 0 +concerning 0 +complications 0 +of 0 +indocyanine 1 +green 2 +to 0 +32 0 +institutions 0 +in 0 +Japan 0 +"," 0 +which 0 +were 0 +selected 0 +on 0 +the 0 +basis 0 +of 0 +the 0 +client 0 +list 0 +from 0 +the 0 +Topcon 0 +Company 0 +"," 0 +which 0 +manufactures 0 +the 0 +indocyanine 1 +green 2 +fundus 0 +camera 0 +. 0 +RESULTS 0 +: 0 +0phthalmologists 0 +at 0 +15 0 +institutions 0 +responded 0 +"," 0 +reporting 0 +a 0 +total 0 +of 0 +3 0 +"," 0 +774 0 +indocyanine 1 +green 2 +angiograms 0 +performed 0 +on 0 +2 0 +"," 0 +820 0 +patients 0 +between 0 +June 0 +1984 0 +and 0 +September 0 +1992 0 +. 0 +Before 0 +angiography 0 +"," 0 +intradermal 0 +or 0 +intravenous 0 +indocyanine 1 +green 2 +testing 0 +"," 0 +or 0 +both 0 +was 0 +performed 0 +at 0 +13 0 +of 0 +15 0 +institutions 0 +. 0 +For 0 +three 0 +patients 0 +"," 0 +the 0 +decision 0 +was 0 +made 0 +not 0 +to 0 +proceed 0 +with 0 +angiography 0 +after 0 +positive 0 +preangiographic 0 +testing 0 +. 0 +The 0 +dosage 0 +of 0 +indocyanine 1 +green 2 +used 0 +for 0 +angiography 0 +varied 0 +from 0 +25 0 +to 0 +75 0 +mg 0 +"," 0 +depending 0 +upon 0 +the 0 +institution 0 +. 0 +There 0 +were 0 +13 0 +cases 0 +of 0 +adverse 0 +reactions 0 +( 0 +0 0 +. 0 +34 0 +% 0 +) 0 +"," 0 +ten 0 +of 0 +which 0 +were 0 +mild 0 +reactions 0 +such 0 +as 0 +nausea 3 +"," 0 +exanthema 3 +"," 0 +urtication 3 +"," 0 +itchiness 3 +"," 0 +and 0 +urgency 0 +to 0 +defecate 0 +"," 0 +and 0 +did 0 +not 0 +require 0 +treatment 0 +. 0 +Also 0 +recorded 0 +were 0 +one 0 +case 0 +of 0 +pain 3 +of 0 +the 0 +vein 0 +"," 0 +which 0 +required 0 +treatment 0 +"," 0 +and 0 +two 0 +cases 0 +of 0 +hypotension 3 +. 0 +The 0 +two 0 +hypotensive 3 +patients 0 +required 0 +treatment 0 +for 0 +shock 3 +. 0 +C0NCLUSI0NS 0 +: 0 +A 0 +comparison 0 +of 0 +frequency 0 +of 0 +adverse 0 +reactions 0 +to 0 +indocyanine 1 +green 2 +with 0 +the 0 +previously 0 +reported 0 +frequency 0 +of 0 +such 0 +reactions 0 +to 0 +fluorescein 1 +sodium 2 +indicated 0 +that 0 +indocyanine 1 +green 2 +is 0 +a 0 +safe 0 +as 0 +fluorescein 1 +for 0 +use 0 +in 0 +angiography 0 +. 0 +Angioedema 3 +following 0 +the 0 +intravenous 0 +administration 0 +of 0 +metoprolol 1 +. 0 +A 0 +72 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +was 0 +admitted 0 +to 0 +the 0 +hospital 0 +with 0 +" 0 +flash 0 +" 0 +pulmonary 3 +edema 4 +"," 0 +preceded 0 +by 0 +chest 3 +pain 4 +"," 0 +requiring 0 +intubation 0 +. 0 +Her 0 +medical 0 +history 0 +included 0 +coronary 3 +artery 4 +disease 4 +with 0 +previous 0 +myocardial 3 +infarctions 4 +"," 0 +hypertension 3 +"," 0 +and 0 +diabetes 3 +mellitus 4 +. 0 +A 0 +history 0 +of 0 +angioedema 3 +secondary 0 +to 0 +lisinopril 1 +therapy 0 +was 0 +elicited 0 +. 0 +Current 0 +medications 0 +did 0 +not 0 +include 0 +angiotensin 1 +- 0 +converting 0 +enzyme 0 +inhibitors 0 +or 0 +beta 0 +- 0 +blockers 0 +. 0 +She 0 +had 0 +no 0 +previous 0 +beta 0 +- 0 +blocking 0 +drug 0 +exposure 0 +. 0 +During 0 +the 0 +first 0 +day 0 +of 0 +hospitalization 0 +( 0 +while 0 +intubated 0 +) 0 +"," 0 +intravenous 0 +metoprolol 1 +was 0 +given 0 +"," 0 +resulting 0 +in 0 +severe 0 +angioedema 3 +. 0 +The 0 +angioedema 3 +resolved 0 +after 0 +therapy 0 +with 0 +intravenous 0 +steroids 1 +and 0 +diphenhydramine 1 +hydrochloride 0 +. 0 +Effect 0 +of 0 +coniine 1 +on 0 +the 0 +developing 0 +chick 0 +embryo 0 +. 0 +Coniine 1 +"," 0 +an 0 +alkaloid 0 +from 0 +Conium 0 +maculatum 0 +( 0 +poison 0 +hemlock 0 +) 0 +"," 0 +has 0 +been 0 +shown 0 +to 0 +be 0 +teratogenic 0 +in 0 +livestock 0 +. 0 +The 0 +major 0 +teratogenic 0 +outcome 0 +is 0 +arthrogryposis 3 +"," 0 +presumably 0 +due 0 +to 0 +nicotinic 0 +receptor 0 +blockade 0 +. 0 +However 0 +"," 0 +coniine 1 +has 0 +failed 0 +to 0 +produce 0 +arthrogryposis 3 +in 0 +rats 0 +or 0 +mice 0 +and 0 +is 0 +only 0 +weakly 0 +teratogenic 0 +in 0 +rabbits 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +and 0 +compare 0 +the 0 +effects 0 +of 0 +coniine 1 +and 0 +nicotine 1 +in 0 +the 0 +developing 0 +chick 0 +. 0 +Concentrations 0 +of 0 +coniine 1 +and 0 +nicotine 1 +sulfate 0 +were 0 +0 0 +. 0 +15 0 +% 0 +"," 0 +0 0 +. 0 +3 0 +% 0 +"," 0 +0 0 +. 0 +75 0 +% 0 +"," 0 +0 0 +. 0 +15 0 +% 0 +"," 0 +0 0 +. 0 +75 0 +% 0 +"," 0 +1 0 +. 0 +5 0 +% 0 +"," 0 +3 0 +% 0 +"," 0 +and 0 +6 0 +% 0 +and 0 +1 0 +% 0 +"," 0 +5 0 +% 0 +"," 0 +and 0 +10 0 +% 0 +"," 0 +respectively 0 +. 0 +Both 0 +compounds 0 +caused 0 +deformations 3 +and 0 +lethality 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 +All 0 +concentrations 0 +of 0 +nicotine 1 +sulfate 0 +caused 0 +some 0 +lethality 0 +but 0 +a 0 +no 0 +effect 0 +level 0 +for 0 +coniine 1 +lethality 0 +was 0 +0 0 +. 0 +75 0 +% 0 +. 0 +The 0 +deformations 3 +caused 0 +by 0 +both 0 +coniine 1 +and 0 +nicotine 1 +sulfate 0 +were 0 +excessive 3 +flexion 4 +or 4 +extension 4 +of 4 +one 4 +or 4 +more 4 +toes 4 +. 0 +No 0 +histopathological 0 +alterations 0 +or 0 +differences 0 +in 0 +bone 0 +formation 0 +were 0 +seen 0 +in 0 +the 0 +limbs 0 +or 0 +toes 0 +of 0 +any 0 +chicks 0 +from 0 +any 0 +group 0 +; 0 +however 0 +"," 0 +extensive 0 +cranial 3 +hemorrhage 4 +occurred 0 +in 0 +all 0 +nicotine 1 +sulfate 0 +- 0 +treated 0 +chicks 0 +. 0 +There 0 +was 0 +a 0 +statistically 0 +significant 0 +( 0 +P 0 +< 0 +or 0 += 0 +0 0 +. 0 +1 0 +) 0 +decrease 0 +in 0 +movement 0 +in 0 +coniine 1 +and 0 +nicotine 1 +sulfate 0 +treated 0 +chicks 0 +as 0 +determined 0 +by 0 +ultrasound 0 +. 0 +Control 0 +chicks 0 +were 0 +in 0 +motion 0 +an 0 +average 0 +of 0 +33 0 +. 0 +67 0 +% 0 +of 0 +the 0 +time 0 +"," 0 +while 0 +coniine 1 +- 0 +treated 0 +chicks 0 +were 0 +only 0 +moving 0 +8 0 +. 0 +95 0 +% 0 +of 0 +a 0 +5 0 +- 0 +min 0 +interval 0 +"," 0 +and 0 +no 0 +movement 0 +was 0 +observed 0 +for 0 +nicotine 1 +sulfate 0 +treated 0 +chicks 0 +. 0 +In 0 +summary 0 +"," 0 +the 0 +chick 0 +embryo 0 +provides 0 +a 0 +reliable 0 +and 0 +simple 0 +experimental 0 +animal 0 +model 0 +of 0 +coniine 1 +- 0 +induced 0 +arthrogryposis 3 +. 0 +Data 0 +from 0 +this 0 +model 0 +support 0 +a 0 +mechanism 0 +involving 0 +nicotinic 0 +receptor 0 +blockade 0 +with 0 +subsequent 0 +decreased 0 +fetal 0 +movement 0 +. 0 +Immediate 0 +allergic 3 +reactions 4 +to 0 +amoxicillin 1 +. 0 +A 0 +large 0 +group 0 +of 0 +patients 0 +with 0 +suspected 0 +allergic 3 +reactions 4 +to 0 +beta 1 +- 2 +lactam 2 +antibiotics 0 +was 0 +evaluated 0 +. 0 +A 0 +detailed 0 +clinical 0 +history 0 +"," 0 +together 0 +with 0 +skin 0 +tests 0 +"," 0 +RAST 0 +( 0 +radioallergosorbent 0 +test 0 +) 0 +"," 0 +and 0 +controlled 0 +challenge 0 +tests 0 +"," 0 +was 0 +used 0 +to 0 +establish 0 +whether 0 +patients 0 +allergic 3 +to 0 +beta 1 +- 2 +lactam 2 +antibiotics 0 +had 0 +selective 0 +immediate 0 +allergic 3 +responses 0 +to 0 +amoxicillin 1 +( 0 +AX 1 +) 0 +or 0 +were 0 +cross 0 +- 0 +reacting 0 +with 0 +other 0 +penicillin 1 +derivatives 0 +. 0 +Skin 0 +tests 0 +were 0 +performed 0 +with 0 +benzylpenicilloyl 1 +- 2 +poly 2 +- 2 +L 2 +- 2 +lysine 2 +( 0 +BP0 1 +- 2 +PLL 2 +) 0 +"," 0 +benzylpenicilloate 1 +"," 0 +benzylpenicillin 1 +( 0 +PG 1 +) 0 +"," 0 +ampicillin 1 +( 0 +AMP 1 +) 0 +"," 0 +and 0 +AX 1 +. 0 +RAST 0 +for 0 +BP0 1 +- 2 +PLL 2 +and 0 +AX 1 +- 0 +PLL 0 +was 0 +done 0 +. 0 +When 0 +both 0 +skin 0 +test 0 +and 0 +RAST 0 +for 0 +BP0 1 +were 0 +negative 0 +"," 0 +single 0 +- 0 +blind 0 +"," 0 +placebo 0 +- 0 +controlled 0 +challenge 0 +tests 0 +were 0 +done 0 +to 0 +ensure 0 +tolerance 0 +of 0 +PG 1 +or 0 +sensitivity 0 +to 0 +AX 1 +. 0 +A 0 +total 0 +of 0 +177 0 +patients 0 +were 0 +diagnosed 0 +as 0 +allergic 3 +to 0 +beta 1 +- 2 +lactam 2 +antibiotics 0 +. 0 +We 0 +selected 0 +the 0 +54 0 +( 0 +30 0 +. 0 +5 0 +% 0 +) 0 +cases 0 +of 0 +immediate 0 +AX 1 +allergy 3 +with 0 +good 0 +tolerance 0 +of 0 +PG 1 +. 0 +Anaphylaxis 3 +was 0 +seen 0 +in 0 +37 0 +patients 0 +( 0 +69 0 +% 0 +) 0 +"," 0 +the 0 +other 0 +17 0 +( 0 +31 0 +% 0 +) 0 +having 0 +urticaria 3 +and 0 +/ 0 +or 0 +angioedema 3 +. 0 +All 0 +the 0 +patients 0 +were 0 +skin 0 +test 0 +negative 0 +to 0 +BP0 1 +; 0 +49 0 +of 0 +51 0 +( 0 +96 0 +% 0 +) 0 +were 0 +also 0 +negative 0 +to 0 +MDM 3 +"," 0 +and 0 +44 0 +of 0 +46 0 +( 0 +96 0 +% 0 +) 0 +to 0 +PG 1 +. 0 +Skin 0 +tests 0 +with 0 +AX 1 +were 0 +positive 0 +in 0 +34 0 +( 0 +63 0 +% 0 +) 0 +patients 0 +. 0 +RAST 0 +was 0 +positive 0 +for 0 +AX 1 +in 0 +22 0 +patients 0 +( 0 +41 0 +% 0 +) 0 +and 0 +to 0 +BP0 1 +in 0 +just 0 +5 0 +( 0 +9 0 +% 0 +) 0 +. 0 +None 0 +of 0 +the 0 +sera 0 +with 0 +negative 0 +RAST 0 +for 0 +AX 1 +were 0 +positive 0 +to 0 +BP0 1 +. 0 +Challenge 0 +tests 0 +with 0 +AX 1 +were 0 +performed 0 +in 0 +23 0 +subjects 0 +( 0 +43 0 +% 0 +) 0 +to 0 +establish 0 +the 0 +diagnosis 0 +of 0 +immediate 0 +allergic 3 +reaction 4 +to 0 +AX 1 +"," 0 +and 0 +in 0 +15 0 +cases 0 +( 0 +28 0 +% 0 +) 0 +both 0 +skin 0 +test 0 +and 0 +RAST 0 +for 0 +AX 1 +were 0 +negative 0 +. 0 +PG 1 +was 0 +well 0 +tolerated 0 +by 0 +all 0 +54 0 +patients 0 +. 0 +We 0 +describe 0 +the 0 +largest 0 +group 0 +of 0 +AX 1 +- 0 +allergic 3 +patients 0 +who 0 +have 0 +tolerated 0 +PG 1 +reported 0 +so 0 +far 0 +. 0 +Diagnosis 0 +of 0 +these 0 +patients 0 +can 0 +be 0 +achieved 0 +only 0 +if 0 +specific 0 +AX 1 +- 0 +related 0 +reagents 0 +are 0 +employed 0 +. 0 +Further 0 +studies 0 +are 0 +necessary 0 +to 0 +determine 0 +the 0 +exact 0 +extent 0 +of 0 +this 0 +problem 0 +and 0 +to 0 +improve 0 +the 0 +efficacy 0 +of 0 +diagnostic 0 +methods 0 +. 0 +Reversal 0 +by 0 +phenylephrine 1 +of 0 +the 0 +beneficial 0 +effects 0 +of 0 +intravenous 0 +nitroglycerin 1 +in 0 +patients 0 +with 0 +acute 3 +myocardial 4 +infarction 4 +. 0 +Nitroglycerin 1 +has 0 +been 0 +shown 0 +to 0 +reduce 0 +ST 0 +- 0 +segment 0 +elevation 0 +during 0 +acute 3 +myocardial 4 +infarction 4 +"," 0 +an 0 +effect 0 +potentiated 0 +in 0 +the 0 +dog 0 +by 0 +agents 0 +that 0 +reverse 0 +nitroglycerin 1 +- 0 +induced 0 +hypotension 3 +. 0 +0ur 0 +study 0 +was 0 +designed 0 +to 0 +determine 0 +the 0 +effects 0 +of 0 +combined 0 +nitroglycerin 1 +and 0 +phenylephrine 1 +therapy 0 +. 0 +Ten 0 +patients 0 +with 0 +acute 0 +transmural 0 +myocardial 3 +infarctions 4 +received 0 +intravenous 0 +nitroglycerin 1 +"," 0 +sufficient 0 +to 0 +reduce 0 +mean 0 +arterial 0 +pressure 0 +from 0 +107 0 ++ 0 +/ 0 +- 0 +6 0 +to 0 +85 0 ++ 0 +/ 0 +- 0 +6 0 +mm 0 +Hg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +for 0 +60 0 +minutes 0 +. 0 +Left 0 +ventricular 0 +filling 0 +pressure 0 +decreased 0 +from 0 +19 0 ++ 0 +/ 0 +- 0 +2 0 +to 0 +11 0 ++ 0 +/ 0 +- 0 +2 0 +mm 0 +Hg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +. 0 +SigmaST 0 +"," 0 +the 0 +sum 0 +of 0 +ST 0 +- 0 +segment 0 +elevations 0 +in 0 +16 0 +precordial 0 +leads 0 +"," 0 +decreased 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +2 0 +) 0 +with 0 +intravenous 0 +nitroglycerin 1 +. 0 +Subsequent 0 +addition 0 +of 0 +phenylephrine 1 +infusion 0 +"," 0 +sufficient 0 +to 0 +re 0 +- 0 +elevate 0 +mean 0 +arterial 0 +pressure 0 +to 0 +106 0 ++ 0 +/ 0 +- 0 +4 0 +mm 0 +Hg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +1 0 +) 0 +for 0 +30 0 +minutes 0 +"," 0 +increased 0 +left 0 +ventricular 0 +filling 0 +pressure 0 +to 0 +17 0 ++ 0 +/ 0 +- 0 +2 0 +mm 0 +Hg 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +and 0 +also 0 +significantly 0 +increased 0 +sigmaST 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +. 0 +0ur 0 +results 0 +suggest 0 +that 0 +addition 0 +of 0 +phenylephrine 1 +to 0 +nitroglycerin 1 +is 0 +not 0 +beneficial 0 +in 0 +the 0 +treatment 0 +of 0 +patients 0 +with 0 +acute 3 +myocardial 4 +infarction 4 +. 0 +Acetazolamide 1 +- 0 +induced 0 +nephrolithiasis 3 +: 0 +implications 0 +for 0 +treatment 0 +of 0 +neuromuscular 3 +disorders 4 +. 0 +Carbonic 0 +anhydrase 0 +inhibitors 0 +can 0 +cause 0 +nephrolithiasis 3 +. 0 +We 0 +studied 0 +20 0 +patients 0 +receiving 0 +long 0 +- 0 +term 0 +carbonic 0 +anhydrase 0 +inhibitor 0 +treatment 0 +for 0 +periodic 0 +paralysis 3 +and 0 +myotonia 3 +. 0 +Three 0 +patients 0 +on 0 +acetazolamide 1 +( 0 +15 0 +% 0 +) 0 +developed 0 +renal 3 +calculi 4 +. 0 +Extracorporeal 0 +lithotripsy 0 +successfully 0 +removed 0 +a 0 +renal 3 +calculus 4 +in 0 +one 0 +patient 0 +and 0 +surgery 0 +removed 0 +a 0 +staghorn 0 +calculus 3 +in 0 +another 0 +"," 0 +permitting 0 +continued 0 +treatment 0 +. 0 +Renal 0 +function 0 +remained 0 +normal 0 +in 0 +all 0 +patients 0 +. 0 +Nephrolithiasis 3 +is 0 +a 0 +complication 0 +of 0 +acetazolamide 1 +but 0 +does 0 +not 0 +preclude 0 +its 0 +use 0 +. 0 +Effects 0 +of 0 +calcium 1 +channel 0 +blockers 0 +on 0 +bupivacaine 1 +- 0 +induced 0 +toxicity 3 +. 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +investigate 0 +the 0 +influence 0 +of 0 +calcium 1 +channel 0 +blockers 0 +on 0 +bupivacaine 1 +- 0 +induced 0 +acute 0 +toxicity 3 +. 0 +For 0 +each 0 +of 0 +the 0 +three 0 +tested 0 +calcium 1 +channel 0 +blockers 0 +( 0 +diltiazem 1 +"," 0 +verapamil 1 +and 0 +bepridil 1 +) 0 +6 0 +groups 0 +of 0 +mice 0 +were 0 +treated 0 +by 0 +two 0 +different 0 +doses 0 +"," 0 +i 0 +. 0 +e 0 +. 0 +2 0 +and 0 +10 0 +mg 0 +/ 0 +kg 0 +/ 0 +i 0 +. 0 +p 0 +. 0 +"," 0 +or 0 +an 0 +equal 0 +volume 0 +of 0 +saline 0 +for 0 +the 0 +control 0 +group 0 +( 0 +n 0 += 0 +20 0 +) 0 +; 0 +15 0 +minutes 0 +later 0 +"," 0 +all 0 +the 0 +animals 0 +were 0 +injected 0 +with 0 +a 0 +single 0 +50 0 +mg 0 +/ 0 +kg 0 +/ 0 +i 0 +. 0 +p 0 +. 0 +dose 0 +of 0 +bupivacaine 1 +. 0 +The 0 +convulsant 0 +activity 0 +"," 0 +the 0 +time 0 +of 0 +latency 0 +to 0 +convulse 0 +and 0 +the 0 +mortality 0 +rate 0 +were 0 +assessed 0 +in 0 +each 0 +group 0 +. 0 +The 0 +local 0 +anesthetic 0 +- 0 +induced 0 +mortality 0 +was 0 +significantly 0 +increased 0 +by 0 +the 0 +three 0 +different 0 +calcium 1 +channel 0 +blockers 0 +. 0 +The 0 +convulsant 0 +activity 0 +of 0 +bupivacaine 1 +was 0 +not 0 +significantly 0 +modified 0 +but 0 +calcium 1 +channel 0 +blockers 0 +decreased 0 +the 0 +time 0 +of 0 +latency 0 +to 0 +obtain 0 +bupivacaine 1 +- 0 +induced 0 +convulsions 3 +; 0 +this 0 +effect 0 +was 0 +less 0 +pronounced 0 +with 0 +bepridil 1 +. 0 +Epidural 0 +blood 0 +flow 0 +during 0 +prostaglandin 1 +E1 2 +or 0 +trimethaphan 1 +induced 0 +hypotension 3 +. 0 +To 0 +evaluate 0 +the 0 +effect 0 +of 0 +prostaglandin 1 +E1 2 +( 0 +PGE1 1 +) 0 +or 0 +trimethaphan 1 +( 0 +TMP 1 +) 0 +induced 0 +hypotension 3 +on 0 +epidural 0 +blood 0 +flow 0 +( 0 +EBF 0 +) 0 +during 0 +spinal 0 +surgery 0 +"," 0 +EBF 0 +was 0 +measured 0 +using 0 +the 0 +heat 0 +clearance 0 +method 0 +in 0 +30 0 +patients 0 +who 0 +underwent 0 +postero 0 +- 0 +lateral 0 +interbody 0 +fusion 0 +under 0 +isoflurane 1 +anaesthesia 0 +. 0 +An 0 +initial 0 +dose 0 +of 0 +0 0 +. 0 +1 0 +microgram 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +of 0 +PGE1 1 +( 0 +15 0 +patients 0 +) 0 +"," 0 +or 0 +10 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +of 0 +TMP 1 +( 0 +15 0 +patients 0 +) 0 +was 0 +administered 0 +intravenously 0 +after 0 +the 0 +dural 0 +opening 0 +and 0 +the 0 +dose 0 +was 0 +adjusted 0 +to 0 +maintain 0 +the 0 +mean 0 +arterial 0 +blood 0 +pressure 0 +( 0 +MAP 0 +) 0 +at 0 +about 0 +60 0 +mmHg 0 +. 0 +The 0 +hypotensive 3 +drug 0 +was 0 +discontinued 0 +at 0 +the 0 +completion 0 +of 0 +the 0 +operative 0 +procedure 0 +. 0 +After 0 +starting 0 +PGE1 1 +or 0 +TMP 1 +"," 0 +MAP 0 +and 0 +rate 0 +pressure 0 +product 0 +( 0 +RPP 0 +) 0 +decreased 0 +significantly 0 +compared 0 +with 0 +preinfusion 0 +values 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +"," 0 +and 0 +the 0 +degree 0 +of 0 +hypotension 3 +due 0 +to 0 +PGE1 1 +remained 0 +constant 0 +until 0 +60 0 +min 0 +after 0 +its 0 +discontinuation 0 +. 0 +Heart 0 +rate 0 +( 0 +HR 0 +) 0 +did 0 +not 0 +change 0 +in 0 +either 0 +group 0 +. 0 +EBFF 0 +did 0 +not 0 +change 0 +during 0 +PGE1 1 +infusion 0 +whereas 0 +in 0 +the 0 +TMP 1 +group 0 +"," 0 +EBF 0 +decreased 0 +significantly 0 +at 0 +30 0 +and 0 +60 0 +min 0 +after 0 +the 0 +start 0 +of 0 +TMP 1 +( 0 +preinfusion 0 +: 0 +45 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +13 0 +. 0 +9 0 +ml 0 +/ 0 +100g 0 +/ 0 +min 0 +. 0 +30 0 +min 0 +: 0 +32 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +9 0 +. 0 +9 0 +ml 0 +/ 0 +100 0 +g 0 +/ 0 +min 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +60 0 +min 0 +: 0 +30 0 ++ 0 +/ 0 +- 0 +7 0 +. 0 +5 0 +ml 0 +/ 0 +100 0 +g 0 +/ 0 +min 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +) 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +PGE1 1 +may 0 +be 0 +preferable 0 +to 0 +TMP 1 +for 0 +hypotensive 3 +anaesthesia 0 +in 0 +spinal 0 +surgery 0 +because 0 +TMP 1 +decreased 0 +EBF 0 +. 0 +Dup 1 +753 2 +prevents 0 +the 0 +development 0 +of 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrosis 3 +. 0 +The 0 +appearance 0 +of 0 +nephrotic 3 +syndromes 4 +such 0 +as 0 +proteinuria 3 +"," 0 +hypoalbuminemia 3 +"," 0 +hypercholesterolemia 3 +and 0 +increase 0 +in 0 +blood 1 +nitrogen 2 +urea 2 +"," 0 +induced 0 +in 0 +rats 0 +by 0 +injection 0 +of 0 +puromycin 1 +aminonucleoside 2 +was 0 +markedly 0 +inhibited 0 +by 0 +oral 0 +administration 0 +of 0 +Dup 1 +753 2 +( 0 +losartan 1 +) 0 +"," 0 +a 0 +novel 0 +angiotensin 1 +II 2 +receptor 0 +antagonist 0 +"," 0 +at 0 +a 0 +dose 0 +of 0 +1 0 +or 0 +2 0 +mg 0 +/ 0 +kg 0 +per 0 +day 0 +. 0 +The 0 +results 0 +suggest 0 +a 0 +possible 0 +involvement 0 +of 0 +the 0 +renin 0 +- 0 +angiotensin 1 +system 0 +in 0 +the 0 +development 0 +of 0 +puromycin 1 +aminonucleoside 2 +- 0 +induced 0 +nephrosis 3 +. 0 +Neuroplasticity 0 +of 0 +the 0 +adult 0 +primate 0 +auditory 0 +cortex 0 +following 0 +cochlear 0 +hearing 3 +loss 4 +. 0 +Tonotopic 0 +organization 0 +is 0 +an 0 +essential 0 +feature 0 +of 0 +the 0 +primary 0 +auditory 0 +area 0 +( 0 +A1 0 +) 0 +of 0 +primate 0 +cortex 0 +. 0 +In 0 +A1 0 +of 0 +macaque 0 +monkeys 0 +"," 0 +low 0 +frequencies 0 +are 0 +represented 0 +rostrolaterally 0 +and 0 +high 0 +frequencies 0 +are 0 +represented 0 +caudomedially 0 +. 0 +The 0 +purpose 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +if 0 +changes 0 +occur 0 +in 0 +this 0 +tonotopic 0 +organization 0 +following 0 +cochlear 0 +hearing 3 +loss 4 +. 0 +Under 0 +anesthesia 0 +"," 0 +the 0 +superior 0 +temporal 0 +gyrus 0 +of 0 +adult 0 +macaque 0 +monkeys 0 +was 0 +exposed 0 +"," 0 +and 0 +the 0 +tonotopic 0 +organization 0 +of 0 +A1 0 +was 0 +mapped 0 +using 0 +conventional 0 +microelectrode 0 +recording 0 +techniques 0 +. 0 +Following 0 +recovery 0 +"," 0 +the 0 +monkeys 0 +were 0 +selectively 0 +deafened 0 +for 0 +high 0 +frequencies 0 +using 0 +kanamycin 1 +and 0 +furosemide 1 +. 0 +The 0 +actual 0 +frequencies 0 +deafened 0 +were 0 +determined 0 +by 0 +the 0 +loss 0 +of 0 +tone 0 +- 0 +burst 0 +elicited 0 +auditory 0 +brainstem 0 +responses 0 +. 0 +Three 0 +months 0 +after 0 +deafening 0 +"," 0 +A1 0 +was 0 +remapped 0 +. 0 +Postmortem 0 +cytoarchitectural 0 +features 0 +identifying 0 +A1 0 +were 0 +correlated 0 +with 0 +the 0 +electrophysiologic 0 +data 0 +. 0 +The 0 +results 0 +indicate 0 +that 0 +the 0 +deprived 0 +area 0 +of 0 +A1 0 +undergoes 0 +extensive 0 +reorganization 0 +and 0 +becomes 0 +responsive 0 +to 0 +intact 0 +cochlear 0 +frequencies 0 +. 0 +The 0 +region 0 +of 0 +cortex 0 +that 0 +represents 0 +the 0 +low 0 +frequencies 0 +was 0 +not 0 +obviously 0 +affected 0 +by 0 +the 0 +cochlear 0 +hearing 3 +loss 4 +. 0 +Sodium 1 +bicarbonate 2 +alleviates 0 +penile 3 +pain 4 +induced 0 +by 0 +intracavernous 0 +injections 0 +for 0 +erectile 3 +dysfunction 4 +. 0 +In 0 +an 0 +attempt 0 +to 0 +determine 0 +whether 0 +penile 3 +pain 4 +associated 0 +with 0 +intracorporeal 0 +injections 0 +could 0 +be 0 +due 0 +to 0 +the 0 +acidity 0 +of 0 +the 0 +medication 0 +"," 0 +we 0 +performed 0 +a 0 +randomized 0 +study 0 +comparing 0 +the 0 +incidence 0 +of 0 +penile 3 +pain 4 +following 0 +intracorporeal 0 +injections 0 +with 0 +or 0 +without 0 +the 0 +addition 0 +of 0 +sodium 1 +bicarbonate 2 +to 0 +the 0 +intracorporeal 0 +medications 0 +. 0 +A 0 +total 0 +of 0 +38 0 +consecutive 0 +patients 0 +who 0 +presented 0 +to 0 +our 0 +clinic 0 +with 0 +impotence 3 +received 0 +0 0 +. 0 +2 0 +ml 0 +. 0 +of 0 +a 0 +combination 0 +of 0 +3 0 +drugs 0 +: 0 +6 0 +mg 0 +. 0 +papaverine 1 +"," 0 +100 0 +micrograms 0 +. 0 +phentolamine 1 +and 0 +10 0 +micrograms 0 +. 0 +prostaglandin 1 +E1 2 +with 0 +( 0 +pH 0 +7 0 +. 0 +5 0 +) 0 +or 0 +without 0 +( 0 +pH 0 +4 0 +. 0 +17 0 +) 0 +the 0 +addition 0 +of 0 +sodium 1 +bicarbonate 2 +( 0 +0 0 +. 0 +3 0 +mEq 0 +. 0 +) 0 +. 0 +0f 0 +the 0 +19 0 +patients 0 +without 0 +sodium 1 +bicarbonate 2 +added 0 +to 0 +the 0 +medication 0 +11 0 +( 0 +58 0 +% 0 +) 0 +complained 0 +of 0 +penile 3 +pain 4 +due 0 +to 0 +the 0 +medication 0 +"," 0 +while 0 +only 0 +1 0 +of 0 +the 0 +19 0 +men 0 +( 0 +5 0 +% 0 +) 0 +who 0 +received 0 +sodium 1 +bicarbonate 2 +complained 0 +of 0 +penile 3 +pain 4 +. 0 +From 0 +these 0 +data 0 +we 0 +conclude 0 +that 0 +the 0 +penile 3 +pain 4 +following 0 +intracorporeal 0 +injections 0 +is 0 +most 0 +likely 0 +due 0 +to 0 +the 0 +acidity 0 +of 0 +the 0 +medication 0 +"," 0 +which 0 +can 0 +be 0 +overcome 0 +by 0 +elevating 0 +the 0 +pH 0 +to 0 +a 0 +neutral 0 +level 0 +. 0 +The 0 +use 0 +and 0 +toxicity 3 +of 0 +didanosine 1 +( 0 +ddI 1 +) 0 +in 0 +HIV 3 +antibody 4 +- 4 +positive 4 +individuals 0 +intolerant 0 +to 0 +zidovudine 1 +( 0 +AZT 1 +) 0 +0ne 0 +hundred 0 +and 0 +fifty 0 +- 0 +one 0 +patients 0 +intolerant 0 +to 0 +zidovudine 1 +( 0 +AZT 1 +) 0 +received 0 +didanosine 1 +( 0 +ddI 1 +) 0 +to 0 +a 0 +maximum 0 +dose 0 +of 0 +12 0 +. 0 +5 0 +mg 0 +/ 0 +kg 0 +/ 0 +day 0 +. 0 +Patient 0 +response 0 +was 0 +assessed 0 +using 0 +changes 0 +in 0 +CD4 0 ++ 0 +lymphocyte 0 +subset 0 +count 0 +"," 0 +HIV 0 +p24 0 +antigen 0 +"," 0 +weight 0 +"," 0 +and 0 +quality 0 +of 0 +life 0 +. 0 +Seventy 0 +patients 0 +developed 0 +major 0 +opportunistic 3 +infections 4 +whilst 0 +on 0 +therapy 0 +; 0 +this 0 +was 0 +the 0 +first 0 +AIDS 3 +diagnosis 0 +in 0 +17 0 +. 0 +0nly 0 +minor 0 +changes 0 +in 0 +CD4 0 ++ 0 +lymphocyte 0 +subset 0 +count 0 +were 0 +observed 0 +in 0 +AIDS 3 +patients 0 +"," 0 +although 0 +a 0 +more 0 +significant 0 +rise 0 +occurred 0 +in 0 +those 0 +with 0 +earlier 0 +stages 0 +of 0 +disease 0 +. 0 +0f 0 +those 0 +positive 0 +for 0 +p24 0 +antigen 0 +at 0 +the 0 +commencement 0 +of 0 +the 0 +study 0 +67 0 +% 0 +showed 0 +a 0 +positive 0 +response 0 +"," 0 +and 0 +this 0 +was 0 +most 0 +likely 0 +in 0 +those 0 +with 0 +CD4 0 ++ 0 +lymphocyte 0 +subset 0 +counts 0 +above 0 +100 0 +mm3 0 +. 0 +A 0 +positive 0 +weight 0 +response 0 +was 0 +seen 0 +in 0 +16 0 +% 0 +of 0 +patients 0 +. 0 +Most 0 +patients 0 +showed 0 +improvement 0 +in 0 +individual 0 +parameters 0 +and 0 +global 0 +score 0 +of 0 +quality 0 +of 0 +life 0 +. 0 +Adverse 0 +reactions 0 +possibly 0 +attributable 0 +to 0 +didanosine 1 +were 0 +common 0 +. 0 +The 0 +most 0 +common 0 +side 0 +- 0 +effect 0 +was 0 +diarrhoea 3 +"," 0 +which 0 +resulted 0 +in 0 +cessation 0 +of 0 +therapy 0 +in 0 +19 0 +individuals 0 +. 0 +Peripheral 3 +neuropathy 4 +occurred 0 +in 0 +12 0 +patients 0 +and 0 +pancreatitis 3 +in 0 +six 0 +. 0 +Thirteen 0 +patients 0 +developed 0 +a 0 +raised 0 +serum 0 +amylase 0 +without 0 +abdominal 3 +pain 4 +. 0 +Seven 0 +patients 0 +developed 0 +glucose 3 +tolerance 4 +curves 4 +characteristic 0 +of 0 +diabetes 3 +but 0 +these 0 +were 0 +mild 0 +"," 0 +did 0 +not 0 +require 0 +treatment 0 +and 0 +returned 0 +to 0 +normal 0 +on 0 +ceasing 0 +didanosine 1 +. 0 +Immunohistochemical 0 +studies 0 +with 0 +antibodies 0 +to 0 +neurofilament 0 +proteins 0 +on 0 +axonal 3 +damage 4 +in 0 +experimental 0 +focal 0 +lesions 0 +in 0 +rat 0 +. 0 +Immunohistochemistry 0 +with 0 +monoclonal 0 +antibodies 0 +against 0 +neurofilament 0 +( 0 +NF 0 +) 0 +proteins 0 +of 0 +middle 0 +and 0 +high 0 +molecular 0 +weight 0 +class 0 +"," 0 +NF 0 +- 0 +M 0 +and 0 +NF 0 +- 0 +H 0 +"," 0 +was 0 +used 0 +to 0 +study 0 +axonal 3 +injury 4 +in 0 +the 0 +borderzone 0 +of 0 +focal 0 +lesions 0 +in 0 +rats 0 +. 0 +Focal 0 +injury 3 +in 4 +the 4 +cortex 4 +was 0 +produced 0 +by 0 +infusion 0 +of 0 +lactate 1 +at 0 +acid 0 +pH 0 +or 0 +by 0 +stab 0 +caused 0 +by 0 +needle 0 +insertion 0 +. 0 +Infarcts 3 +in 4 +substantia 4 +nigra 4 +pars 4 +reticulata 4 +were 0 +evoked 0 +by 0 +prolonged 0 +pilocarpine 1 +- 0 +induced 0 +status 3 +epilepticus 4 +. 0 +Immunohistochemical 0 +staining 0 +for 0 +NFs 0 +showed 0 +characteristic 0 +terminal 0 +clubs 0 +of 0 +axons 0 +in 0 +the 0 +borderzone 0 +of 0 +lesions 0 +. 0 +Differences 0 +in 0 +the 0 +labelling 0 +pattern 0 +occurred 0 +with 0 +different 0 +antibodies 0 +which 0 +apparently 0 +depended 0 +on 0 +molecular 0 +weight 0 +class 0 +of 0 +NFs 0 +and 0 +phosphorylation 0 +state 0 +. 0 +These 0 +immunohistochemical 0 +changes 0 +of 0 +NFs 0 +can 0 +serve 0 +as 0 +a 0 +marker 0 +for 0 +axonal 3 +damage 4 +in 0 +various 0 +experimental 0 +traumatic 3 +or 0 +ischemic 0 +lesions 0 +. 0 +Pharmacokinetic 0 +and 0 +clinical 0 +studies 0 +in 0 +patients 0 +with 0 +cimetidine 1 +- 0 +associated 0 +mental 0 +confusion 3 +. 0 +15 0 +cases 0 +of 0 +cimetidine 1 +- 0 +associated 0 +mental 0 +confusion 3 +have 0 +been 0 +reported 0 +. 0 +In 0 +order 0 +that 0 +this 0 +syndrome 0 +might 0 +be 0 +investigated 0 +changes 0 +in 0 +mental 0 +status 0 +( 0 +M 0 +. 0 +S 0 +. 0 +) 0 +were 0 +correlated 0 +with 0 +serum 0 +concentrations 0 +and 0 +renal 0 +and 0 +hepatic 0 +function 0 +in 0 +36 0 +patients 0 +"," 0 +30 0 +patients 0 +had 0 +no 0 +M 0 +. 0 +S 0 +. 0 +change 0 +on 0 +cimetidine 1 +and 0 +6 0 +had 0 +moderate 0 +to 0 +severe 0 +changes 0 +. 0 +These 0 +6 0 +patients 0 +had 0 +both 0 +renal 3 +and 4 +liver 4 +dysfunction 4 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +"," 0 +as 0 +well 0 +as 0 +cimetidine 1 +trough 0 +- 0 +concentrations 0 +of 0 +more 0 +than 0 +1 0 +. 0 +25 0 +microgram 0 +/ 0 +ml 0 +( 0 +P 0 +less 0 +than 0 +0 0 +. 0 +5 0 +) 0 +. 0 +The 0 +severity 0 +of 0 +M 0 +. 0 +S 0 +. 0 +changes 0 +increased 0 +as 0 +trough 0 +- 0 +concentrations 0 +rose 0 +"," 0 +5 0 +patients 0 +had 0 +lumbar 0 +puncture 0 +. 0 +The 0 +cerebrospinal 0 +fluid 0 +: 0 +serum 0 +ratio 0 +of 0 +cimetidine 1 +concentrations 0 +was 0 +0 0 +. 0 +24 0 +: 0 +1 0 +and 0 +indicates 0 +that 0 +cimetidine 1 +passes 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +; 0 +it 0 +also 0 +raises 0 +the 0 +possibility 0 +that 0 +M 0 +. 0 +S 0 +. 0 +changes 0 +are 0 +due 0 +to 0 +blockade 0 +of 0 +histamine 1 +H2 0 +- 0 +receptors 0 +in 0 +the 0 +central 0 +nervous 0 +system 0 +. 0 +Patients 0 +likely 0 +to 0 +have 0 +both 0 +raised 0 +trough 0 +- 0 +concentrations 0 +and 0 +mental 0 +confusion 3 +are 0 +those 0 +with 0 +both 0 +severe 0 +renal 3 +and 4 +hepatic 4 +dysfunction 4 +. 0 +They 0 +should 0 +be 0 +closely 0 +observed 0 +and 0 +should 0 +be 0 +given 0 +reduced 0 +doses 0 +of 0 +cimetidine 1 +. 0 +Prospective 0 +study 0 +of 0 +the 0 +long 0 +- 0 +term 0 +effects 0 +of 0 +somatostatin 0 +analog 0 +( 0 +octreotide 1 +) 0 +on 0 +gallbladder 0 +function 0 +and 0 +gallstone 3 +formation 0 +in 0 +Chinese 0 +acromegalic 3 +patients 0 +. 0 +This 0 +article 0 +reports 0 +the 0 +changes 0 +in 0 +gallbladder 0 +function 0 +examined 0 +by 0 +ultrasonography 0 +in 0 +20 0 +Chinese 0 +patients 0 +with 0 +active 0 +acromegaly 3 +treated 0 +with 0 +sc 0 +injection 0 +of 0 +the 0 +somatostatin 0 +analog 0 +octreotide 1 +in 0 +dosages 0 +of 0 +300 0 +- 0 +1500 0 +micrograms 0 +/ 0 +day 0 +for 0 +a 0 +mean 0 +of 0 +24 0 +. 0 +2 0 ++ 0 +/ 0 +- 0 +13 0 +. 0 +9 0 +months 0 +. 0 +During 0 +treatment 0 +with 0 +octreotide 1 +"," 0 +17 0 +patients 0 +developed 0 +sludge 0 +"," 0 +10 0 +had 0 +gallstones 3 +"," 0 +and 0 +1 0 +developed 0 +acute 3 +cholecystitis 4 +requiring 0 +surgery 0 +. 0 +In 0 +all 0 +of 0 +7 0 +patients 0 +examined 0 +acutely 0 +"," 0 +gallbladder 0 +contractility 0 +was 0 +inhibited 0 +after 0 +a 0 +single 0 +100 0 +- 0 +micrograms 0 +injection 0 +. 0 +In 0 +8 0 +patients 0 +followed 0 +for 0 +24 0 +weeks 0 +"," 0 +gallbladder 0 +contractility 0 +remained 0 +depressed 3 +throughout 0 +therapy 0 +. 0 +After 0 +withdrawal 0 +of 0 +octreotide 1 +in 0 +10 0 +patients 0 +without 0 +gallstones 3 +"," 0 +8 0 +patients 0 +assessed 0 +had 0 +return 0 +of 0 +normal 0 +gallbladder 0 +contractility 0 +within 0 +1 0 +month 0 +. 0 +In 0 +8 0 +of 0 +the 0 +remaining 0 +10 0 +patients 0 +who 0 +developed 0 +gallstones 3 +during 0 +treatment 0 +"," 0 +gallbladder 0 +contractility 0 +normalized 0 +in 0 +5 0 +patients 0 +( 0 +3 0 +of 0 +whom 0 +has 0 +disappearance 0 +of 0 +their 0 +stones 0 +within 0 +3 0 +weeks 0 +) 0 +"," 0 +and 0 +remained 0 +depressed 3 +in 0 +3 0 +( 0 +2 0 +of 0 +whom 0 +had 0 +stones 0 +present 0 +at 0 +6 0 +months 0 +) 0 +. 0 +0ur 0 +results 0 +suggest 0 +that 0 +the 0 +suppression 0 +of 0 +gallbladder 0 +contractility 0 +is 0 +the 0 +cause 0 +of 0 +the 0 +successive 0 +formation 0 +of 0 +bile 0 +sludge 0 +"," 0 +gallstones 3 +"," 0 +and 0 +cholecystitis 3 +during 0 +octreotide 1 +therapy 0 +in 0 +Chinese 0 +acromegalic 3 +patients 0 +. 0 +It 0 +is 0 +therefore 0 +very 0 +important 0 +to 0 +follow 0 +the 0 +changes 0 +of 0 +gallbladder 0 +function 0 +during 0 +long 0 +- 0 +term 0 +octreotide 1 +therapy 0 +of 0 +acromegalic 3 +patients 0 +. 0 +Increase 0 +of 0 +Parkinson 3 +disability 4 +after 0 +fluoxetine 1 +medication 0 +. 0 +Depression 3 +is 0 +a 0 +major 0 +clinical 0 +feature 0 +of 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 +We 0 +report 0 +the 0 +increased 0 +amount 0 +of 0 +motor 3 +disability 4 +in 0 +four 0 +patients 0 +with 0 +idiopathic 3 +Parkinson 4 +' 4 +s 4 +disease 4 +after 0 +exposure 0 +to 0 +the 0 +antidepressant 1 +fluoxetine 1 +. 0 +The 0 +possibility 0 +of 0 +a 0 +clinically 0 +relevant 0 +dopamine 1 +- 0 +antagonistic 0 +capacity 0 +of 0 +fluoxetine 1 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +patients 0 +must 0 +be 0 +considered 0 +. 0 +Sinus 3 +arrest 4 +associated 0 +with 0 +continuous 0 +- 0 +infusion 0 +cimetidine 1 +. 0 +The 0 +administration 0 +of 0 +intermittent 0 +intravenous 0 +infusions 0 +of 0 +cimetidine 1 +is 0 +infrequently 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +bradyarrhythmias 3 +. 0 +A 0 +40 0 +- 0 +year 0 +- 0 +old 0 +man 0 +with 0 +leukemia 3 +and 0 +no 0 +history 0 +of 0 +cardiac 3 +disease 4 +developed 0 +recurrent 0 +"," 0 +brief 0 +episodes 0 +of 0 +apparent 0 +sinus 3 +arrest 4 +while 0 +receiving 0 +continuous 0 +- 0 +infusion 0 +cimetidine 1 +50 0 +mg 0 +/ 0 +hour 0 +. 0 +The 0 +arrhythmias 3 +were 0 +temporally 0 +related 0 +to 0 +cimetidine 1 +administration 0 +"," 0 +disappeared 0 +after 0 +dechallenge 0 +"," 0 +and 0 +did 0 +not 0 +recur 0 +during 0 +ranitidine 1 +treatment 0 +. 0 +This 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +sinus 3 +arrest 4 +associated 0 +with 0 +continuous 0 +- 0 +infusion 0 +cimetidine 1 +. 0 +Phase 0 +II 0 +trial 0 +of 0 +vinorelbine 1 +in 0 +metastatic 0 +squamous 3 +cell 4 +esophageal 4 +carcinoma 4 +. 0 +European 0 +0rganization 0 +for 0 +Research 0 +and 0 +Treatment 0 +of 0 +Cancer 3 +Gastrointestinal 0 +Treat 0 +Cancer 3 +Cooperative 0 +Group 0 +. 0 +PURP0SE 0 +: 0 +To 0 +evaluate 0 +the 0 +response 0 +rate 0 +and 0 +toxic 0 +effects 0 +of 0 +vinorelbine 1 +( 0 +VNB 1 +) 0 +administered 0 +as 0 +a 0 +single 0 +agent 0 +in 0 +metastatic 0 +squamous 3 +cell 4 +esophageal 4 +carcinoma 4 +. 0 +PATIENTS 0 +AND 0 +METH0DS 0 +: 0 +Forty 0 +- 0 +six 0 +eligible 0 +patients 0 +with 0 +measurable 0 +lesions 0 +were 0 +included 0 +and 0 +were 0 +stratified 0 +according 0 +to 0 +previous 0 +chemotherapy 0 +. 0 +Thirty 0 +patients 0 +without 0 +prior 0 +chemotherapy 0 +and 0 +16 0 +pretreated 0 +with 0 +cisplatin 1 +- 0 +based 0 +chemotherapy 0 +were 0 +assessable 0 +for 0 +toxicity 3 +and 0 +response 0 +. 0 +VNB 1 +was 0 +administered 0 +weekly 0 +as 0 +a 0 +25 0 +- 0 +mg 0 +/ 0 +m2 0 +short 0 +intravenous 0 +( 0 +i 0 +. 0 +v 0 +. 0 +) 0 +infusion 0 +. 0 +RESULTS 0 +: 0 +Six 0 +of 0 +30 0 +patients 0 +( 0 +20 0 +% 0 +) 0 +without 0 +prior 0 +chemotherapy 0 +achieved 0 +a 0 +partial 0 +response 0 +( 0 +PR 0 +) 0 +( 0 +95 0 +% 0 +confidence 0 +interval 0 +[ 0 +CI 0 +] 0 +"," 0 +8 0 +% 0 +to 0 +39 0 +% 0 +) 0 +. 0 +The 0 +median 0 +duration 0 +of 0 +response 0 +was 0 +21 0 +weeks 0 +( 0 +range 0 +"," 0 +17 0 +to 0 +28 0 +) 0 +. 0 +0ne 0 +of 0 +16 0 +patients 0 +( 0 +6 0 +% 0 +) 0 +with 0 +prior 0 +chemotherapy 0 +had 0 +a 0 +complete 0 +response 0 +( 0 +CR 0 +) 0 +of 0 +31 0 +weeks 0 +' 0 +duration 0 +( 0 +95 0 +% 0 +CI 0 +"," 0 +0 0 +% 0 +to 0 +30 0 +% 0 +) 0 +. 0 +The 0 +overall 0 +response 0 +rate 0 +( 0 +World 0 +Health 0 +0rganization 0 +[ 0 +WH0 0 +] 0 +criteria 0 +) 0 +was 0 +15 0 +% 0 +( 0 +CR 0 +"," 0 +2 0 +% 0 +; 0 +PR 0 +13 0 +% 0 +; 0 +95 0 +% 0 +CI 0 +"," 0 +6 0 +% 0 +to 0 +29 0 +% 0 +) 0 +. 0 +The 0 +median 0 +dose 0 +- 0 +intensity 0 +( 0 +DI 0 +) 0 +was 0 +20 0 +mg 0 +/ 0 +m2 0 +/ 0 +wk 0 +. 0 +VNB 1 +was 0 +well 0 +tolerated 0 +and 0 +zero 0 +instances 0 +of 0 +WH0 0 +grade 0 +4 0 +nonhematologic 0 +toxicity 3 +occurred 0 +. 0 +At 0 +least 0 +one 0 +episode 0 +of 0 +grade 0 +3 0 +or 0 +4 0 +granulocytopenia 3 +was 0 +seen 0 +in 0 +59 0 +% 0 +of 0 +patients 0 +. 0 +A 0 +grade 0 +2 0 +or 0 +3 0 +infection 3 +occurred 0 +in 0 +16 0 +% 0 +of 0 +patients 0 +"," 0 +but 0 +no 0 +toxic 0 +deaths 3 +occurred 0 +. 0 +0ther 0 +side 0 +effects 0 +were 0 +rare 0 +"," 0 +and 0 +peripheral 3 +neurotoxicity 4 +has 0 +been 0 +minor 0 +( 0 +26 0 +% 0 +grade 0 +1 0 +) 0 +. 0 +C0NCLUSI0N 0 +: 0 +These 0 +data 0 +indicate 0 +that 0 +VNB 1 +is 0 +an 0 +active 0 +agent 0 +in 0 +metastatic 0 +esophageal 3 +squamous 4 +cell 4 +carcinoma 4 +. 0 +Given 0 +its 0 +excellent 0 +tolerance 0 +profile 0 +and 0 +low 0 +toxicity 3 +"," 0 +further 0 +evaluation 0 +of 0 +VNB 1 +in 0 +combination 0 +therapy 0 +is 0 +warranted 0 +. 0 +Evaluation 0 +of 0 +adverse 0 +reactions 0 +of 0 +aponidine 1 +hydrochloride 2 +ophthalmic 0 +solution 0 +. 0 +We 0 +prospectively 0 +evaluated 0 +the 0 +adverse 0 +reactions 0 +of 0 +apraclonidine 1 +in 0 +20 0 +normal 0 +volunteers 0 +by 0 +instilling 0 +a 0 +single 0 +drop 0 +of 0 +1 0 +% 0 +apraclonidine 1 +in 0 +their 0 +right 0 +eyes 0 +. 0 +Examinations 0 +"," 0 +including 0 +blood 0 +pressure 0 +"," 0 +pulse 0 +rate 0 +"," 0 +conjunctiva 0 +and 0 +cornea 0 +"," 0 +intraocular 0 +pressure 0 +( 0 +I0P 0 +) 0 +"," 0 +pupil 0 +diameter 0 +"," 0 +basal 0 +tear 0 +secretion 0 +and 0 +margin 0 +reflex 0 +distance 0 +of 0 +both 0 +upper 0 +and 0 +lower 0 +eyelids 0 +"," 0 +were 0 +performed 0 +prior 0 +to 0 +entry 0 +and 0 +at 0 +1 0 +"," 0 +3 0 +"," 0 +5 0 +and 0 +7 0 +hours 0 +after 0 +instillation 0 +. 0 +The 0 +ocular 3 +hypotensive 4 +effects 0 +were 0 +statistically 0 +significant 0 +for 0 +apraclonidine 1 +- 0 +treated 0 +eyes 0 +throughout 0 +the 0 +study 0 +and 0 +also 0 +statistically 0 +significant 0 +for 0 +contralateral 0 +eyes 0 +from 0 +three 0 +hours 0 +after 0 +topical 0 +administration 0 +of 0 +1 0 +% 0 +apraclonidine 1 +. 0 +Decreases 3 +in 4 +systolic 4 +blood 4 +pressure 4 +were 0 +statistically 0 +"," 0 +but 0 +not 0 +clinically 0 +"," 0 +significant 0 +. 0 +No 0 +significant 0 +changes 0 +in 0 +diastolic 0 +blood 0 +pressure 0 +"," 0 +pulse 0 +rate 0 +and 0 +basal 0 +tear 0 +secretion 0 +were 0 +noted 0 +. 0 +Conjunctival 3 +blanching 4 +and 0 +mydriasis 3 +were 0 +commonly 0 +found 0 +. 0 +Upper 0 +lid 0 +retraction 0 +was 0 +frequently 0 +noted 0 +. 0 +While 0 +the 0 +elevations 0 +of 0 +the 0 +upper 0 +lid 0 +margin 0 +in 0 +most 0 +subjects 0 +were 0 +not 0 +more 0 +than 0 +2 0 +mm 0 +and 0 +did 0 +not 0 +cause 0 +noticeable 0 +change 0 +in 0 +appearance 0 +"," 0 +one 0 +subject 0 +suffered 0 +from 0 +mechanical 0 +entropion 3 +and 0 +marked 0 +corneal 3 +abrasion 4 +3 0 +hours 0 +after 0 +instillation 0 +of 0 +the 0 +medication 0 +. 0 +This 0 +may 0 +well 0 +be 0 +a 0 +particularly 0 +notable 0 +finding 0 +in 0 +Asian 0 +people 0 +. 0 +Thiopentone 1 +pretreatment 0 +for 0 +propofol 1 +injection 0 +pain 3 +in 0 +ambulatory 0 +patients 0 +. 0 +This 0 +study 0 +investigated 0 +propofol 1 +injection 0 +pain 3 +in 0 +patients 0 +undergoing 0 +ambulatory 0 +anaesthesia 0 +. 0 +In 0 +a 0 +randomized 0 +"," 0 +double 0 +- 0 +blind 0 +trial 0 +"," 0 +90 0 +women 0 +were 0 +allocated 0 +to 0 +receive 0 +one 0 +of 0 +three 0 +treatments 0 +prior 0 +to 0 +induction 0 +of 0 +anaesthesia 0 +with 0 +propofol 1 +. 0 +Patients 0 +in 0 +Group 0 +C 0 +received 0 +2 0 +ml 0 +normal 0 +saline 0 +"," 0 +Group 0 +L 0 +"," 0 +2 0 +ml 0 +"," 0 +lidocaine 1 +2 0 +% 0 +( 0 +40 0 +mg 0 +) 0 +and 0 +Group 0 +T 0 +"," 0 +2 0 +ml 0 +thiopentone 1 +2 0 +. 0 +5 0 +% 0 +( 0 +50 0 +mg 0 +) 0 +. 0 +Venous 0 +discomfort 0 +was 0 +assessed 0 +with 0 +a 0 +visual 0 +analogue 0 +scale 0 +( 0 +VAS 0 +) 0 +5 0 +- 0 +15 0 +sec 0 +after 0 +commencing 0 +propofol 1 +administration 0 +using 0 +an 0 +infusion 0 +pump 0 +( 0 +rate 0 +1000 0 +micrograms 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +min 0 +- 0 +1 0 +) 0 +. 0 +Loss 3 +of 4 +consciousness 4 +occurred 0 +in 0 +60 0 +- 0 +90 0 +sec 0 +. 0 +Visual 0 +analogue 0 +scores 0 +( 0 +mean 0 ++ 0 +/ 0 +- 0 +SD 0 +) 0 +during 0 +induction 0 +were 0 +lower 0 +in 0 +Groups 0 +L 0 +( 0 +3 0 +. 0 +3 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +5 0 +) 0 +and 0 +T 0 +( 0 +4 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +7 0 +) 0 +than 0 +in 0 +Group 0 +C 0 +( 0 +5 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +2 0 +. 0 +3 0 +) 0 +; 0 +P 0 += 0 +0 0 +. 0 +31 0 +. 0 +The 0 +incidence 0 +of 0 +venous 0 +discomfort 0 +was 0 +lower 0 +in 0 +Group 0 +L 0 +( 0 +76 0 +. 0 +6 0 +% 0 +; 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +than 0 +in 0 +Group 0 +C 0 +( 0 +100 0 +% 0 +) 0 +but 0 +not 0 +different 0 +from 0 +Group 0 +T 0 +( 0 +90 0 +% 0 +) 0 +. 0 +The 0 +VAS 0 +scores 0 +for 0 +recall 0 +of 0 +pain 3 +in 0 +the 0 +recovery 0 +room 0 +were 0 +correlated 0 +with 0 +the 0 +VAS 0 +scores 0 +during 0 +induction 0 +( 0 +r 0 += 0 +0 0 +. 0 +7045 0 +; 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Recovery 0 +room 0 +discharge 0 +times 0 +were 0 +similar 0 +: 0 +C 0 +( 0 +75 0 +. 0 +9 0 ++ 0 +/ 0 +- 0 +19 0 +. 0 +4 0 +min 0 +) 0 +; 0 +L 0 +73 0 +. 0 +6 0 ++ 0 +/ 0 +- 0 +21 0 +. 0 +6 0 +min 0 +) 0 +; 0 +T 0 +( 0 +77 0 +. 0 +1 0 ++ 0 +/ 0 +- 0 +18 0 +. 0 +9 0 +min 0 +) 0 +. 0 +Assessing 0 +their 0 +overall 0 +satisfaction 0 +"," 0 +89 0 +. 0 +7 0 +% 0 +would 0 +choose 0 +propofol 1 +anaesthesia 0 +again 0 +. 0 +We 0 +conclude 0 +that 0 +lidocaine 1 +reduces 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +propofol 1 +injection 0 +pain 3 +in 0 +ambulatory 0 +patients 0 +whereas 0 +thiopentone 1 +only 0 +reduces 0 +its 0 +severity 0 +. 0 +Persistent 0 +paralysis 3 +after 0 +prolonged 0 +use 0 +of 0 +atracurium 1 +in 0 +the 0 +absence 0 +of 0 +corticosteroids 0 +. 0 +Neuromuscular 0 +blocking 0 +agents 0 +( 0 +NMBAs 0 +) 0 +are 0 +often 0 +used 0 +for 0 +patients 0 +requiring 0 +prolonged 0 +mechanical 0 +ventilation 0 +. 0 +Reports 0 +of 0 +persistent 0 +paralysis 3 +after 0 +the 0 +discontinuance 0 +of 0 +these 0 +drugs 0 +have 0 +most 0 +often 0 +involved 0 +aminosteroid 0 +- 0 +based 0 +NMBAs 0 +such 0 +as 0 +vecuronium 1 +bromide 2 +"," 0 +especially 0 +when 0 +used 0 +in 0 +conjunction 0 +with 0 +corticosteroids 0 +. 0 +Atracurium 1 +besylate 2 +"," 0 +a 0 +short 0 +- 0 +acting 0 +benzylisoquinolinium 1 +NMBA 0 +that 0 +is 0 +eliminated 0 +independently 0 +of 0 +renal 0 +or 0 +hepatic 0 +function 0 +"," 0 +has 0 +also 0 +been 0 +associated 0 +with 0 +persistent 0 +paralysis 3 +"," 0 +but 0 +only 0 +when 0 +used 0 +with 0 +corticosteroids 0 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +atracurium 1 +- 0 +related 0 +paralysis 3 +persisting 0 +for 0 +approximately 0 +50 0 +hours 0 +in 0 +a 0 +patient 0 +who 0 +was 0 +not 0 +treated 0 +with 0 +corticosteroids 0 +. 0 +A 0 +phase 0 +I 0 +/ 0 +II 0 +study 0 +of 0 +paclitaxel 1 +plus 0 +cisplatin 1 +as 0 +first 0 +- 0 +line 0 +therapy 0 +for 0 +head 3 +and 4 +neck 4 +cancers 4 +: 0 +preliminary 0 +results 0 +. 0 +Improved 0 +outcomes 0 +among 0 +patients 0 +with 0 +head 3 +and 4 +neck 4 +carcinomas 4 +require 0 +investigations 0 +of 0 +new 0 +drugs 0 +for 0 +induction 0 +therapy 0 +. 0 +Preliminary 0 +results 0 +of 0 +an 0 +Eastern 0 +Cooperative 0 +0ncology 0 +Group 0 +study 0 +of 0 +single 0 +- 0 +agent 0 +paclitaxel 1 +( 0 +Taxol 1 +; 0 +Bristol 0 +- 0 +Myers 0 +Squibb 0 +Company 0 +"," 0 +Princeton 0 +"," 0 +NJ 0 +) 0 +reported 0 +a 0 +37 0 +% 0 +response 0 +rate 0 +in 0 +patients 0 +with 0 +head 3 +and 4 +neck 4 +cancer 4 +"," 0 +and 0 +the 0 +paclitaxel 1 +/ 0 +cisplatin 1 +combination 0 +has 0 +been 0 +used 0 +successfully 0 +and 0 +has 0 +significantly 0 +improved 0 +median 0 +response 0 +duration 0 +in 0 +ovarian 3 +cancer 4 +patients 0 +. 0 +We 0 +initiated 0 +a 0 +phase 0 +I 0 +/ 0 +II 0 +trial 0 +to 0 +determine 0 +the 0 +response 0 +and 0 +toxicity 3 +of 0 +escalating 0 +paclitaxel 1 +doses 0 +combined 0 +with 0 +fixed 0 +- 0 +dose 0 +cisplatin 1 +with 0 +granulocyte 0 +colony 0 +- 0 +stimulating 0 +factor 0 +support 0 +in 0 +patients 0 +with 0 +untreated 0 +locally 0 +advanced 0 +inoperable 0 +head 3 +and 4 +neck 4 +carcinoma 4 +. 0 +To 0 +date 0 +"," 0 +23 0 +men 0 +with 0 +a 0 +median 0 +age 0 +of 0 +50 0 +years 0 +and 0 +good 0 +performance 0 +status 0 +have 0 +entered 0 +the 0 +trial 0 +. 0 +Primary 0 +tumor 3 +sites 0 +were 0 +oropharynx 0 +"," 0 +10 0 +patients 0 +; 0 +hypopharynx 0 +"," 0 +four 0 +; 0 +larynx 0 +"," 0 +two 0 +; 0 +oral 0 +cavity 0 +"," 0 +three 0 +; 0 +unknown 0 +primary 0 +"," 0 +two 0 +; 0 +and 0 +nasal 0 +cavity 0 +and 0 +parotid 0 +gland 0 +"," 0 +one 0 +each 0 +. 0 +0f 0 +20 0 +patients 0 +evaluable 0 +for 0 +toxicity 3 +"," 0 +four 0 +had 0 +stage 0 +III 0 +and 0 +16 0 +had 0 +stage 0 +IV 0 +disease 0 +. 0 +Treatment 0 +"," 0 +given 0 +every 0 +21 0 +days 0 +for 0 +a 0 +maximum 0 +of 0 +three 0 +cycles 0 +"," 0 +consisted 0 +of 0 +paclitaxel 1 +by 0 +3 0 +- 0 +hour 0 +infusion 0 +followed 0 +the 0 +next 0 +day 0 +by 0 +a 0 +fixed 0 +dose 0 +of 0 +cisplatin 1 +( 0 +75 0 +mg 0 +/ 0 +m2 0 +) 0 +. 0 +The 0 +dose 0 +levels 0 +incorporate 0 +escalating 0 +paclitaxel 1 +doses 0 +"," 0 +and 0 +intrapatient 0 +escalations 0 +within 0 +a 0 +given 0 +dose 0 +level 0 +are 0 +permitted 0 +if 0 +toxicity 3 +permits 0 +. 0 +At 0 +the 0 +time 0 +of 0 +this 0 +writing 0 +"," 0 +dose 0 +level 0 +4 0 +( 0 +260 0 +"," 0 +270 0 +"," 0 +and 0 +280 0 +mg 0 +/ 0 +m2 0 +) 0 +is 0 +being 0 +evaluated 0 +; 0 +three 0 +patients 0 +from 0 +this 0 +level 0 +are 0 +evaluable 0 +. 0 +With 0 +paclitaxel 1 +doses 0 +of 0 +200 0 +mg 0 +/ 0 +m2 0 +and 0 +higher 0 +"," 0 +granulocyte 0 +colony 0 +- 0 +stimulating 0 +factor 0 +5 0 +micrograms 0 +/ 0 +kg 0 +/ 0 +d 0 +is 0 +given 0 +( 0 +days 0 +4 0 +through 0 +12 0 +) 0 +. 0 +0f 0 +18 0 +patients 0 +evaluable 0 +for 0 +response 0 +"," 0 +seven 0 +( 0 +39 0 +% 0 +) 0 +achieved 0 +a 0 +complete 0 +response 0 +and 0 +six 0 +( 0 +33 0 +% 0 +) 0 +achieved 0 +a 0 +partial 0 +response 0 +. 0 +Three 0 +patients 0 +had 0 +no 0 +change 0 +and 0 +disease 0 +progressed 0 +in 0 +two 0 +. 0 +The 0 +overall 0 +response 0 +rate 0 +is 0 +72 0 +% 0 +. 0 +Eleven 0 +responding 0 +patients 0 +had 0 +subsequent 0 +surgery 0 +/ 0 +radiotherapy 0 +or 0 +radical 0 +radiotherapy 0 +. 0 +Two 0 +pathologic 0 +complete 0 +responses 0 +were 0 +observed 0 +in 0 +patients 0 +who 0 +had 0 +achieved 0 +clinical 0 +complete 0 +responses 0 +. 0 +Alopecia 3 +"," 0 +paresthesias 3 +"," 0 +and 0 +arthralgias 3 +/ 0 +myalgias 3 +have 0 +occurred 0 +frequently 0 +"," 0 +but 0 +with 0 +one 0 +exception 0 +( 0 +a 0 +grade 0 +3 0 +myalgia 3 +) 0 +they 0 +have 0 +been 0 +grade 0 +1 0 +or 0 +2 0 +. 0 +No 0 +dose 0 +- 0 +limiting 0 +hematologic 0 +toxicity 3 +has 0 +been 0 +seen 0 +. 0 +Paclitaxel 1 +/ 0 +cisplatin 1 +is 0 +an 0 +effective 0 +first 0 +- 0 +line 0 +regimen 0 +for 0 +locoregionally 0 +advanced 0 +head 3 +and 4 +neck 4 +cancer 4 +and 0 +continued 0 +study 0 +is 0 +warranted 0 +. 0 +Results 0 +thus 0 +far 0 +suggest 0 +no 0 +dose 0 +- 0 +response 0 +effect 0 +for 0 +paclitaxel 1 +doses 0 +above 0 +200 0 +mg 0 +/ 0 +m2 0 +. 0 +Improvement 0 +of 0 +levodopa 1 +- 0 +induced 0 +dyskinesia 3 +by 0 +propranolol 1 +in 0 +Parkinson 3 +' 4 +s 4 +disease 4 +. 0 +Seven 0 +patients 0 +suffering 0 +from 0 +Parkinson 3 +' 4 +s 4 +disease 4 +( 0 +PD 3 +) 0 +with 0 +severely 0 +disabling 0 +dyskinesia 3 +received 0 +low 0 +- 0 +dose 0 +propranolol 1 +as 0 +an 0 +adjunct 0 +to 0 +the 0 +currently 0 +used 0 +medical 0 +treatment 0 +. 0 +There 0 +was 0 +a 0 +significant 0 +40 0 +% 0 +improvement 0 +in 0 +the 0 +dyskinesia 3 +score 0 +without 0 +increase 0 +of 0 +parkinsonian 3 +motor 3 +disability 4 +. 0 +Ballistic 0 +and 0 +choreic 0 +dyskinesia 3 +were 0 +markedly 0 +ameliorated 0 +"," 0 +whereas 0 +dystonia 3 +was 0 +not 0 +. 0 +This 0 +study 0 +suggests 0 +that 0 +administration 0 +of 0 +low 0 +doses 0 +of 0 +beta 0 +- 0 +blockers 0 +may 0 +improve 0 +levodopa 1 +- 0 +induced 0 +ballistic 0 +and 0 +choreic 0 +dyskinesia 3 +in 0 +PD 3 +. 0 +Habitual 0 +use 0 +of 0 +acetaminophen 1 +as 0 +a 0 +risk 0 +factor 0 +for 0 +chronic 3 +renal 4 +failure 4 +: 0 +a 0 +comparison 0 +with 0 +phenacetin 1 +. 0 +Six 0 +epidemiologic 0 +studies 0 +in 0 +the 0 +United 0 +States 0 +and 0 +Europe 0 +indicate 0 +that 0 +habitual 0 +use 0 +of 0 +phenacetin 1 +is 0 +associated 0 +with 0 +the 0 +development 0 +of 0 +chronic 3 +renal 4 +failure 4 +and 0 +end 3 +- 4 +stage 4 +renal 4 +disease 4 +( 0 +ESRD 3 +) 0 +"," 0 +with 0 +a 0 +relative 0 +risk 0 +in 0 +the 0 +range 0 +of 0 +4 0 +to 0 +19 0 +. 0 +As 0 +a 0 +result 0 +of 0 +these 0 +and 0 +other 0 +studies 0 +"," 0 +phenacetin 1 +has 0 +now 0 +been 0 +withdrawn 0 +from 0 +the 0 +market 0 +in 0 +most 0 +countries 0 +. 0 +However 0 +"," 0 +three 0 +case 0 +control 0 +studies 0 +"," 0 +one 0 +each 0 +in 0 +North 0 +Carolina 0 +"," 0 +northern 0 +Maryland 0 +"," 0 +and 0 +West 0 +Berlin 0 +"," 0 +Germany 0 +"," 0 +showed 0 +that 0 +habitual 0 +use 0 +of 0 +acetaminophen 1 +is 0 +also 0 +associated 0 +with 0 +chronic 3 +renal 4 +failure 4 +and 0 +ESRD 3 +"," 0 +with 0 +a 0 +relative 0 +risk 0 +in 0 +the 0 +range 0 +of 0 +2 0 +to 0 +4 0 +. 0 +These 0 +studies 0 +suggest 0 +that 0 +both 0 +phenacetin 1 +and 0 +acetaminophen 1 +may 0 +contribute 0 +to 0 +the 0 +burden 0 +of 0 +ESRD 3 +"," 0 +with 0 +the 0 +risk 0 +of 0 +the 0 +latter 0 +being 0 +somewhat 0 +less 0 +than 0 +that 0 +of 0 +the 0 +former 0 +. 0 +This 0 +apparent 0 +difference 0 +in 0 +risk 0 +may 0 +not 0 +be 0 +due 0 +to 0 +differences 0 +in 0 +nephrotoxic 3 +potential 0 +of 0 +the 0 +drugs 0 +themselves 0 +. 0 +A 0 +lower 0 +relative 0 +risk 0 +would 0 +be 0 +expected 0 +for 0 +acetaminophen 1 +if 0 +the 0 +risk 0 +of 0 +both 0 +drugs 0 +in 0 +combination 0 +with 0 +other 0 +analgesics 0 +was 0 +higher 0 +than 0 +the 0 +risk 0 +of 0 +either 0 +agent 0 +alone 0 +. 0 +Thus 0 +"," 0 +acetaminophen 1 +has 0 +been 0 +used 0 +both 0 +as 0 +a 0 +single 0 +agent 0 +and 0 +in 0 +combination 0 +with 0 +other 0 +analgesics 0 +"," 0 +whereas 0 +phenacetin 1 +was 0 +available 0 +only 0 +in 0 +combinations 0 +. 0 +The 0 +possibility 0 +that 0 +habitual 0 +use 0 +of 0 +acetaminophen 1 +alone 0 +increases 0 +the 0 +risk 0 +of 0 +ESRD 3 +has 0 +not 0 +been 0 +clearly 0 +demonstrated 0 +"," 0 +but 0 +cannot 0 +be 0 +dismissed 0 +. 0 +Acetaminophen 1 +- 0 +induced 0 +hypotension 3 +. 0 +Through 0 +30 0 +years 0 +of 0 +widespread 0 +use 0 +"," 0 +acetaminophen 1 +has 0 +been 0 +shown 0 +to 0 +be 0 +a 0 +remarkably 0 +safe 0 +medication 0 +in 0 +therapeutic 0 +dosages 0 +. 0 +The 0 +potential 0 +for 0 +acetaminophen 1 +to 0 +produce 0 +cardiovascular 3 +toxicities 4 +is 0 +very 0 +low 0 +. 0 +However 0 +"," 0 +acetaminophen 1 +has 0 +been 0 +demonstrated 0 +to 0 +produce 0 +symptoms 0 +of 0 +anaphylaxis 3 +"," 0 +including 0 +hypotension 3 +"," 0 +in 0 +sensitive 0 +individuals 0 +. 0 +This 0 +article 0 +describes 0 +two 0 +critically 3 +ill 4 +patients 0 +in 0 +whom 0 +transient 0 +episodes 0 +of 0 +hypotension 3 +reproducibly 0 +developed 0 +after 0 +administration 0 +of 0 +acetaminophen 1 +. 0 +0ther 0 +symptoms 0 +of 0 +allergic 3 +reactions 4 +were 0 +not 0 +clinically 0 +detectable 0 +. 0 +The 0 +hypotensive 3 +episodes 0 +were 0 +severe 0 +enough 0 +to 0 +require 0 +vasopressor 0 +administration 0 +. 0 +The 0 +reports 0 +illustrate 0 +the 0 +need 0 +for 0 +clinicians 0 +to 0 +consider 0 +acetaminophen 1 +in 0 +patients 0 +with 0 +hypotension 3 +of 0 +unknown 0 +origin 0 +. 0 +Reduction 0 +of 0 +heparan 1 +sulphate 2 +- 0 +associated 0 +anionic 0 +sites 0 +in 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +of 0 +rats 0 +with 0 +streptozotocin 1 +- 0 +induced 0 +diabetic 3 +nephropathy 4 +. 0 +Heparan 1 +sulphate 2 +- 0 +associated 0 +anionic 0 +sites 0 +in 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +were 0 +studied 0 +in 0 +rats 0 +8 0 +months 0 +after 0 +induction 0 +of 0 +diabetes 3 +by 0 +streptozotocin 1 +and 0 +in 0 +age 0 +- 0 +adn 0 +sex 0 +- 0 +matched 0 +control 0 +rats 0 +"," 0 +employing 0 +the 0 +cationic 0 +dye 0 +cuprolinic 1 +blue 2 +. 0 +Morphometric 0 +analysis 0 +at 0 +the 0 +ultrastructural 0 +level 0 +was 0 +performed 0 +using 0 +a 0 +computerized 0 +image 0 +processor 0 +. 0 +The 0 +heparan 1 +sulphate 2 +specificity 0 +of 0 +the 0 +cuprolinic 1 +blue 2 +staining 0 +was 0 +demonstrated 0 +by 0 +glycosaminoglycan 1 +- 0 +degrading 0 +enzymes 0 +"," 0 +showing 0 +that 0 +pretreatment 0 +of 0 +the 0 +sections 0 +with 0 +heparitinase 0 +abolished 0 +all 0 +staining 0 +"," 0 +whereas 0 +chondroitinase 0 +ABC 0 +had 0 +no 0 +effect 0 +. 0 +The 0 +majority 0 +of 0 +anionic 0 +sites 0 +( 0 +74 0 +% 0 +in 0 +diabetic 3 +and 0 +81 0 +% 0 +in 0 +control 0 +rats 0 +) 0 +were 0 +found 0 +within 0 +the 0 +lamina 0 +rara 0 +externa 0 +of 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +. 0 +A 0 +minority 0 +of 0 +anionic 0 +sites 0 +were 0 +scattered 0 +throughout 0 +the 0 +lamina 0 +densa 0 +and 0 +lamina 0 +rara 0 +interna 0 +"," 0 +and 0 +were 0 +significantly 0 +smaller 0 +than 0 +those 0 +in 0 +the 0 +lamina 0 +rara 0 +externa 0 +of 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +( 0 +p 0 +< 0 +0 0 +. 0 +1 0 +and 0 +p 0 +< 0 +0 0 +. 0 +1 0 +for 0 +diabetic 3 +and 0 +control 0 +rats 0 +"," 0 +respectively 0 +) 0 +. 0 +Diabetic 3 +rats 0 +progressively 0 +developed 0 +albuminuria 3 +reaching 0 +40 0 +. 0 +3 0 +( 0 +32 0 +. 0 +2 0 +- 0 +62 0 +. 0 +0 0 +) 0 +mg 0 +/ 0 +24 0 +h 0 +after 0 +8 0 +months 0 +in 0 +contrast 0 +to 0 +the 0 +control 0 +animals 0 +( 0 +0 0 +. 0 +8 0 +( 0 +0 0 +. 0 +2 0 +- 0 +0 0 +. 0 +9 0 +) 0 +mg 0 +/ 0 +24 0 +h 0 +"," 0 +p 0 +< 0 +0 0 +. 0 +2 0 +) 0 +. 0 +At 0 +the 0 +same 0 +time 0 +"," 0 +the 0 +number 0 +of 0 +heparan 1 +sulphate 2 +anionic 0 +sites 0 +and 0 +the 0 +total 0 +anionic 0 +site 0 +surface 0 +( 0 +number 0 +of 0 +anionic 0 +sites 0 +x 0 +mean 0 +anionic 0 +site 0 +surface 0 +) 0 +in 0 +the 0 +lamina 0 +rara 0 +externa 0 +of 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +was 0 +reduced 0 +by 0 +19 0 +% 0 +( 0 +p 0 +< 0 +0 0 +. 0 +21 0 +) 0 +and 0 +by 0 +26 0 +% 0 +( 0 +p 0 +< 0 +0 0 +. 0 +2 0 +) 0 +"," 0 +respectively 0 +. 0 +Number 0 +and 0 +total 0 +anionic 0 +site 0 +surface 0 +in 0 +the 0 +remaining 0 +part 0 +of 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +( 0 +lamina 0 +densa 0 +and 0 +lamina 0 +rara 0 +interna 0 +) 0 +were 0 +not 0 +significantly 0 +changed 0 +. 0 +We 0 +conclude 0 +that 0 +in 0 +streptozotocin 1 +- 0 +diabetic 3 +rats 0 +with 0 +an 0 +increased 0 +urinary 0 +albumin 0 +excretion 0 +"," 0 +a 0 +reduced 0 +heparan 1 +sulphate 2 +charge 0 +barrier 0 +/ 0 +density 0 +is 0 +found 0 +at 0 +the 0 +lamina 0 +rara 0 +externa 0 +of 0 +the 0 +glomerular 0 +basement 0 +membrane 0 +. 0 +Mediation 0 +of 0 +enhanced 0 +reflex 0 +vagal 0 +bradycardia 3 +by 0 +L 1 +- 2 +dopa 2 +via 0 +central 0 +dopamine 1 +formation 0 +in 0 +dogs 0 +. 0 +L 1 +- 2 +Dopa 2 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +decreased 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +after 0 +extracerebral 0 +decarboxylase 0 +inhibition 0 +with 0 +MK 1 +- 2 +486 2 +( 0 +25 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +in 0 +anesthetize 0 +MA0 1 +- 0 +inhibited 0 +dogs 0 +. 0 +In 0 +addition 0 +"," 0 +reflex 0 +bradycardia 3 +caused 0 +by 0 +injected 0 +norepinephrine 1 +was 0 +significantly 0 +enhanced 0 +by 0 +L 1 +- 2 +dopa 2 +"," 0 +DL 1 +- 2 +Threo 2 +- 2 +dihydroxyphenylserine 2 +had 0 +no 0 +effect 0 +on 0 +blood 0 +pressure 0 +"," 0 +heart 0 +rate 0 +or 0 +reflex 0 +responses 0 +to 0 +norepinephrine 1 +. 0 +FLA 1 +- 2 +63 2 +"," 0 +a 0 +dopamine 1 +- 0 +beta 0 +- 0 +oxidase 0 +inhibitor 0 +"," 0 +did 0 +not 0 +have 0 +any 0 +effect 0 +on 0 +the 0 +hypotension 3 +"," 0 +bradycardia 3 +or 0 +reflex 0 +- 0 +enhancing 0 +effect 0 +of 0 +L 1 +- 2 +dopa 2 +. 0 +Pimozide 1 +did 0 +not 0 +affect 0 +the 0 +actions 0 +of 0 +L 1 +- 2 +dopa 2 +on 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +but 0 +completely 0 +blocked 0 +the 0 +enhancement 0 +of 0 +reflexes 0 +. 0 +Removal 0 +of 0 +the 0 +carotid 0 +sinuses 0 +caused 0 +an 0 +elevation 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +and 0 +abolished 0 +the 0 +negative 0 +chronotropic 0 +effect 0 +of 0 +norepinephrine 1 +. 0 +However 0 +"," 0 +L 1 +- 2 +dopa 2 +restored 0 +the 0 +bradycardia 3 +caused 0 +by 0 +norepinephrine 1 +in 0 +addition 0 +to 0 +decreasing 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +. 0 +5 1 +- 2 +HTP 2 +( 0 +5 0 +mg 0 +/ 0 +kg 0 +i 0 +. 0 +v 0 +. 0 +) 0 +decreased 0 +blood 0 +pressure 0 +and 0 +heart 0 +rate 0 +and 0 +decreased 0 +the 0 +reflex 0 +bradycardia 3 +to 0 +norepinephrine 1 +. 0 +It 0 +is 0 +concluded 0 +that 0 +L 1 +- 2 +dopa 2 +enhances 0 +reflex 0 +bradycardia 3 +through 0 +central 0 +alpha 0 +- 0 +receptor 0 +stimulation 0 +. 0 +Furthermore 0 +"," 0 +the 0 +effects 0 +are 0 +mediated 0 +through 0 +dopamine 1 +rather 0 +than 0 +norepinephrine 1 +and 0 +do 0 +not 0 +require 0 +the 0 +carotid 0 +sinus 0 +baroreceptors 0 +. 0 +Microangiopathic 3 +hemolytic 4 +anemia 4 +complicating 0 +FK506 1 +( 0 +tacrolimus 1 +) 0 +therapy 0 +. 0 +We 0 +describe 0 +3 0 +episodes 0 +of 0 +microangiopathic 3 +hemolytic 4 +anemia 4 +( 0 +MAHA 3 +) 0 +in 0 +2 0 +solid 0 +organ 0 +recipients 0 +under 0 +FK506 1 +( 0 +tacrolimus 1 +) 0 +therapy 0 +. 0 +In 0 +both 0 +cases 0 +"," 0 +discontinuation 0 +of 0 +FK506 1 +and 0 +treatment 0 +with 0 +plasma 0 +exchange 0 +"," 0 +fresh 0 +frozen 0 +plasma 0 +replacement 0 +"," 0 +corticosteroids 1 +"," 0 +aspirin 1 +"," 0 +and 0 +dipyridamole 1 +led 0 +to 0 +resolution 0 +of 0 +MAHA 3 +. 0 +In 0 +one 0 +patient 0 +"," 0 +reintroduction 0 +of 0 +FK506 1 +led 0 +to 0 +rapid 0 +recurrence 0 +of 0 +MAHA 3 +. 0 +FK506 1 +- 0 +associated 0 +MAHA 3 +is 0 +probably 0 +rare 0 +but 0 +physicians 0 +must 0 +be 0 +aware 0 +of 0 +this 0 +severe 0 +complication 0 +. 0 +In 0 +our 0 +experience 0 +and 0 +according 0 +to 0 +the 0 +literature 0 +"," 0 +FK506 1 +does 0 +not 0 +seem 0 +to 0 +cross 0 +- 0 +react 0 +with 0 +cyclosporin 1 +A 2 +( 0 +CyA 1 +) 0 +"," 0 +an 0 +immuno 0 +- 0 +suppressive 0 +drug 0 +already 0 +known 0 +to 0 +induce 0 +MAHA 3 +. 0 +Effect 0 +of 0 +some 0 +anticancer 0 +drugs 0 +and 0 +combined 0 +chemotherapy 0 +on 0 +renal 3 +toxicity 4 +. 0 +The 0 +nephrotoxic 3 +action 0 +of 0 +anticancer 0 +drugs 0 +such 0 +as 0 +nitrogranulogen 1 +( 0 +NG 1 +) 0 +"," 0 +methotrexate 1 +( 0 +MTX 1 +) 0 +"," 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +and 0 +cyclophosphamide 1 +( 0 +CY 1 +) 0 +administered 0 +alone 0 +or 0 +in 0 +combination 0 +[ 0 +MTX 1 ++ 0 +5 1 +- 2 +FU 2 ++ 0 +CY 1 +( 0 +CMF 0 +) 0 +] 0 +was 0 +evaluated 0 +in 0 +experiments 0 +on 0 +Wistar 0 +rats 0 +. 0 +After 0 +drug 0 +administration 0 +"," 0 +creatinine 1 +concentrations 0 +in 0 +the 0 +plasma 0 +and 0 +in 0 +the 0 +urine 0 +of 0 +the 0 +rats 0 +were 0 +determined 0 +"," 0 +as 0 +well 0 +as 0 +creatinine 1 +clearance 0 +. 0 +Histopathologic 0 +evaluation 0 +of 0 +the 0 +kidneys 0 +was 0 +also 0 +performed 0 +. 0 +After 0 +MTX 1 +administration 0 +a 0 +significant 0 +increase 0 +( 0 +p 0 += 0 +0 0 +. 0 +228 0 +) 0 +in 0 +the 0 +plasma 0 +creatinine 1 +concentration 0 +and 0 +a 0 +significant 0 +( 0 +p 0 += 0 +0 0 +. 0 +1 0 +) 0 +decrease 0 +in 0 +creatinine 1 +clearance 0 +was 0 +noted 0 +compared 0 +to 0 +controls 0 +. 0 +After 0 +the 0 +administration 0 +of 0 +NG 1 +"," 0 +5 1 +- 2 +FU 2 +and 0 +CY 1 +neither 0 +a 0 +statistically 0 +significant 0 +increase 0 +in 0 +creatinine 1 +concentration 0 +nor 0 +an 0 +increase 0 +in 0 +creatinine 1 +clearance 0 +was 0 +observed 0 +compared 0 +to 0 +the 0 +group 0 +receiving 0 +no 0 +cytostatics 0 +. 0 +Following 0 +polytherapy 0 +according 0 +to 0 +the 0 +CMF 0 +regimen 0 +"," 0 +a 0 +statistically 0 +significant 0 +decrease 0 +( 0 +p 0 += 0 +0 0 +. 0 +343 0 +) 0 +in 0 +creatinine 1 +clearance 0 +was 0 +found 0 +"," 0 +but 0 +creatinine 1 +concentration 0 +did 0 +not 0 +increase 0 +significantly 0 +compared 0 +to 0 +controls 0 +. 0 +CY 1 +caused 0 +hemorrhagic 3 +cystitis 4 +in 0 +40 0 +% 0 +of 0 +rats 0 +"," 0 +but 0 +it 0 +did 0 +not 0 +cause 0 +this 0 +complication 0 +when 0 +combined 0 +with 0 +5 1 +- 2 +FU 2 +and 0 +MTX 1 +. 0 +Histologic 0 +changes 0 +were 0 +found 0 +in 0 +rat 0 +kidneys 0 +after 0 +administration 0 +of 0 +MTX 1 +"," 0 +CY 1 +and 0 +NG 1 +"," 0 +while 0 +no 0 +such 0 +change 0 +was 0 +observed 0 +after 0 +5 1 +- 2 +FU 2 +and 0 +joint 0 +administration 0 +of 0 +MTX 1 ++ 0 +5 1 +- 2 +FU 2 ++ 0 +CY 1 +compared 0 +to 0 +controls 0 +. 0 +0ur 0 +studies 0 +indicate 0 +that 0 +nephrotoxicity 3 +of 0 +MTX 1 ++ 0 +5 1 +- 2 +FU 2 ++ 0 +CY 1 +administered 0 +jointly 0 +is 0 +lower 0 +than 0 +in 0 +monotherapy 0 +. 0 +The 0 +interpeduncular 0 +nucleus 0 +regulates 0 +nicotine 1 +' 0 +s 0 +effects 0 +on 0 +free 0 +- 0 +field 0 +activity 0 +. 0 +Partial 0 +lesions 0 +were 0 +made 0 +with 0 +kainic 1 +acid 2 +in 0 +the 0 +interpeduncular 0 +nucleus 0 +of 0 +the 0 +ventral 0 +midbrain 0 +of 0 +the 0 +rat 0 +. 0 +Compared 0 +with 0 +sham 0 +- 0 +operated 0 +controls 0 +"," 0 +lesions 0 +significantly 0 +( 0 +p 0 +< 0 +0 0 +. 0 +25 0 +) 0 +blunted 0 +the 0 +early 0 +( 0 +< 0 +60 0 +min 0 +) 0 +free 0 +- 0 +field 0 +locomotor 3 +hypoactivity 4 +caused 0 +by 0 +nicotine 1 +( 0 +0 0 +. 0 +5 0 +mg 0 +kg 0 +( 0 +- 0 +1 0 +) 0 +"," 0 +i 0 +. 0 +m 0 +. 0 +) 0 +"," 0 +enhanced 0 +the 0 +later 0 +( 0 +60 0 +- 0 +120 0 +min 0 +) 0 +nicotine 1 +- 0 +induced 0 +hyperactivity 3 +"," 0 +and 0 +raised 0 +spontaneous 0 +nocturnal 0 +activity 0 +. 0 +Lesions 0 +reduced 0 +the 0 +extent 0 +of 0 +immunohistological 0 +staining 0 +for 0 +choline 1 +acetyltransferase 0 +in 0 +the 0 +interpeduncular 0 +nucleus 0 +( 0 +p 0 +< 0 +0 0 +. 0 +25 0 +) 0 +"," 0 +but 0 +not 0 +for 0 +tyrosine 1 +hydroxylase 0 +in 0 +the 0 +surrounding 0 +catecholaminergic 0 +A10 0 +region 0 +. 0 +We 0 +conclude 0 +that 0 +the 0 +interpeduncular 0 +nucleus 0 +mediates 0 +nicotinic 0 +depression 3 +of 0 +locomotor 0 +activity 0 +and 0 +dampens 0 +nicotinic 0 +arousal 0 +mechanisms 0 +located 0 +elsewhere 0 +in 0 +the 0 +brain 0 +. 0 +Lithium 1 +- 0 +associated 0 +cognitive 3 +and 4 +functional 4 +deficits 4 +reduced 0 +by 0 +a 0 +switch 0 +to 0 +divalproex 1 +sodium 2 +: 0 +a 0 +case 0 +series 0 +. 0 +BACKGR0UND 0 +: 0 +Lithium 1 +remains 0 +a 0 +first 0 +- 0 +line 0 +treatment 0 +for 0 +the 0 +acute 0 +and 0 +maintenance 0 +treatment 0 +of 0 +bipolar 3 +disorder 4 +. 0 +Although 0 +much 0 +has 0 +been 0 +written 0 +about 0 +the 0 +management 0 +of 0 +the 0 +more 0 +common 0 +adverse 0 +effects 0 +of 0 +lithium 1 +"," 0 +such 0 +as 0 +polyuria 3 +and 0 +tremor 3 +"," 0 +more 0 +subtle 0 +lithium 1 +side 0 +effects 0 +such 0 +as 0 +cognitive 3 +deficits 4 +"," 0 +loss 3 +of 4 +creativity 4 +"," 0 +and 0 +functional 3 +impairments 4 +remain 0 +understudied 0 +. 0 +This 0 +report 0 +summarizes 0 +our 0 +experience 0 +in 0 +switching 0 +bipolar 3 +patients 0 +from 0 +lithium 1 +to 0 +divalproex 1 +sodium 2 +to 0 +alleviate 0 +such 0 +cognitive 3 +and 4 +functional 4 +impairments 4 +. 0 +METH0D 0 +: 0 +0pen 0 +"," 0 +case 0 +series 0 +design 0 +. 0 +RESULTS 0 +: 0 +We 0 +report 0 +seven 0 +cases 0 +where 0 +substitution 0 +of 0 +lithium 1 +"," 0 +either 0 +fully 0 +or 0 +partially 0 +"," 0 +with 0 +divalproex 1 +sodium 2 +was 0 +extremely 0 +helpful 0 +in 0 +reducing 0 +the 0 +cognitive 3 +"," 4 +motivational 4 +"," 4 +or 4 +creative 4 +deficits 4 +attributed 0 +to 0 +lithium 1 +in 0 +our 0 +bipolar 3 +patients 0 +. 0 +C0NCLUSI0N 0 +: 0 +In 0 +this 0 +preliminary 0 +report 0 +"," 0 +divalproex 1 +sodium 2 +was 0 +a 0 +superior 0 +alternative 0 +to 0 +lithium 1 +in 0 +bipolar 3 +patients 0 +experiencing 0 +cognitive 3 +deficits 4 +"," 0 +loss 3 +of 4 +creativity 4 +"," 0 +and 0 +functional 3 +impairments 4 +. 0 +Effect 0 +of 0 +nifedipine 1 +on 0 +renal 0 +function 0 +in 0 +liver 0 +transplant 0 +recipients 0 +receiving 0 +tacrolimus 1 +. 0 +The 0 +effect 0 +of 0 +nifedipine 1 +on 0 +renal 0 +function 0 +in 0 +liver 0 +transplant 0 +recipients 0 +who 0 +were 0 +receiving 0 +tacrolimus 1 +was 0 +evaluated 0 +between 0 +January 0 +1992 0 +and 0 +January 0 +1996 0 +. 0 +Two 0 +groups 0 +of 0 +patients 0 +receiving 0 +tacrolimus 1 +were 0 +compared 0 +over 0 +a 0 +period 0 +of 0 +1 0 +year 0 +"," 0 +one 0 +group 0 +comprising 0 +hypertensive 3 +patients 0 +who 0 +were 0 +receiving 0 +nifedipine 1 +"," 0 +and 0 +the 0 +other 0 +comprising 0 +nonhypertensive 0 +patients 0 +not 0 +receiving 0 +nifedipine 1 +. 0 +The 0 +time 0 +from 0 +transplant 0 +to 0 +baseline 0 +was 0 +similar 0 +in 0 +all 0 +patients 0 +. 0 +Nifedipine 1 +significantly 0 +improved 0 +kidney 0 +function 0 +as 0 +indicated 0 +by 0 +a 0 +significant 0 +lowering 0 +of 0 +serum 0 +creatinine 1 +levels 0 +at 0 +6 0 +and 0 +12 0 +months 0 +. 0 +The 0 +observed 0 +positive 0 +impact 0 +of 0 +nifedipine 1 +on 0 +reducing 0 +the 0 +nephrotoxicity 3 +associated 0 +with 0 +tacrolimus 1 +in 0 +liver 0 +transplant 0 +recipients 0 +should 0 +be 0 +an 0 +important 0 +factor 0 +in 0 +selecting 0 +an 0 +agent 0 +to 0 +treat 0 +hypertension 3 +in 0 +this 0 +population 0 +. 0 +Alpha 0 +and 0 +beta 0 +coma 3 +in 0 +drug 0 +intoxication 0 +uncomplicated 0 +by 0 +cerebral 3 +hypoxia 4 +. 0 +Four 0 +patients 0 +who 0 +were 0 +rendered 0 +comatose 3 +or 0 +stuporous 3 +by 0 +drug 0 +intoxication 0 +"," 0 +but 0 +who 0 +were 0 +not 0 +hypoxic 0 +"," 0 +are 0 +described 0 +. 0 +Three 0 +patients 0 +received 0 +high 0 +doses 0 +of 0 +chlormethiazole 1 +for 0 +alcohol 1 +withdrawal 3 +symptoms 4 +"," 0 +and 0 +one 0 +took 0 +a 0 +suicidal 0 +overdose 3 +of 0 +nitrazepam 1 +. 0 +The 0 +patient 0 +with 0 +nitrazepam 1 +overdose 3 +and 0 +two 0 +of 0 +those 0 +with 0 +chlormethiazole 1 +intoxication 0 +conformed 0 +to 0 +the 0 +criteria 0 +of 0 +' 0 +alpha 0 +coma 3 +' 0 +"," 0 +showing 0 +non 0 +- 0 +reactive 0 +generalized 0 +or 0 +frontally 0 +predominant 0 +alpha 0 +activity 0 +in 0 +the 0 +EEG 0 +. 0 +The 0 +fourth 0 +patient 0 +who 0 +was 0 +unconscious 0 +after 0 +chlormethiazole 1 +administration 0 +exhibite 0 +generalized 0 +non 0 +- 0 +reactive 0 +activity 0 +in 0 +the 0 +slow 0 +beta 0 +range 0 +. 0 +All 0 +four 0 +recovered 0 +completely 0 +without 0 +neurological 3 +sequelae 4 +following 0 +the 0 +withdrawal 0 +of 0 +the 0 +offending 0 +agents 0 +. 0 +The 0 +similarities 0 +between 0 +the 0 +effects 0 +of 0 +structural 0 +lesions 0 +and 0 +pharmacological 0 +depression 3 +of 0 +the 0 +brain 0 +stem 0 +reticular 0 +formation 0 +are 0 +discussed 0 +. 0 +It 0 +is 0 +suggested 0 +that 0 +in 0 +both 0 +situations 0 +disturbed 0 +reticulo 0 +- 0 +thalamic 0 +interactions 0 +are 0 +important 0 +in 0 +the 0 +pathogenesis 0 +of 0 +alpha 0 +coma 3 +. 0 +It 0 +is 0 +concluded 0 +that 0 +when 0 +this 0 +electroencephalographic 0 +and 0 +behavioural 0 +picture 0 +is 0 +seen 0 +in 0 +drug 0 +intoxication 0 +"," 0 +in 0 +the 0 +absence 0 +of 0 +significant 0 +hypoxaemia 3 +"," 0 +a 0 +favourable 0 +outcome 0 +may 0 +be 0 +anticipated 0 +. 0 +Magnetic 0 +resonance 0 +volumetry 0 +of 0 +the 0 +cerebellum 0 +in 0 +epileptic 3 +patients 0 +after 0 +phenytoin 1 +overdosages 3 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +evaluate 0 +the 0 +relationship 0 +between 0 +phenytoin 1 +medication 0 +and 0 +cerebellar 3 +atrophy 4 +in 0 +patients 0 +who 0 +had 0 +experienced 0 +clinical 0 +intoxication 0 +. 0 +Five 0 +females 0 +and 0 +6 0 +males 0 +"," 0 +21 0 +- 0 +59 0 +years 0 +of 0 +age 0 +"," 0 +were 0 +examined 0 +with 0 +a 0 +1 0 +. 0 +5 0 +- 0 +T 0 +whole 0 +- 0 +body 0 +system 0 +using 0 +a 0 +circular 0 +polarized 0 +head 0 +coil 0 +. 0 +Conventional 0 +spin 0 +echo 0 +images 0 +were 0 +acquired 0 +in 0 +the 0 +sagittal 0 +and 0 +transverse 0 +orientation 0 +. 0 +In 0 +addition 0 +"," 0 +we 0 +performed 0 +a 0 +high 0 +- 0 +resolution 0 +3D 0 +gradient 0 +echo 0 +"," 0 +T1 0 +- 0 +weighted 0 +sequences 0 +at 0 +a 0 +1 0 +- 0 +mm 0 +slice 0 +thickness 0 +. 0 +The 0 +images 0 +were 0 +subsequently 0 +processed 0 +to 0 +obtain 0 +volumetric 0 +data 0 +for 0 +the 0 +cerebellum 0 +. 0 +Cerebellar 0 +volume 0 +for 0 +the 0 +patient 0 +group 0 +ranged 0 +between 0 +67 0 +. 0 +66 0 +and 0 +131 0 +. 0 +8 0 +ml 0 +( 0 +mean 0 +108 0 +. 0 +9 0 +ml 0 +) 0 +. 0 +In 0 +addition 0 +3D 0 +gradient 0 +echo 0 +data 0 +sets 0 +from 0 +10 0 +healthy 0 +male 0 +and 0 +10 0 +healthy 0 +female 0 +age 0 +- 0 +matched 0 +volunteers 0 +were 0 +used 0 +to 0 +compare 0 +cerebellar 0 +volumes 0 +. 0 +Using 0 +linear 0 +regression 0 +we 0 +found 0 +that 0 +no 0 +correlation 0 +exists 0 +between 0 +seizure 3 +duration 0 +"," 0 +elevation 0 +of 0 +phenytoin 1 +serum 0 +levels 0 +and 0 +cerebellar 0 +volume 0 +. 0 +However 0 +"," 0 +multiple 0 +regression 0 +for 0 +the 0 +daily 0 +dosage 0 +"," 0 +duration 0 +of 0 +phenytoin 1 +treatment 0 +and 0 +cerebellar 0 +volume 0 +revealed 0 +a 0 +correlation 0 +of 0 +these 0 +parameters 0 +. 0 +We 0 +conclude 0 +that 0 +phenytoin 1 +overdosage 3 +does 0 +not 0 +necessarily 0 +result 0 +in 0 +cerebellar 3 +atrophy 4 +and 0 +it 0 +is 0 +unlikely 0 +that 0 +phenytoin 1 +medication 0 +was 0 +the 0 +only 0 +cause 0 +of 0 +cerebellar 3 +atrophy 4 +in 0 +the 0 +remaining 0 +patients 0 +. 0 +Quantitative 0 +morphometric 0 +studies 0 +of 0 +the 0 +cerebellum 0 +provide 0 +valuable 0 +insights 0 +into 0 +the 0 +pathogenesis 0 +of 0 +cerebellar 3 +disorders 4 +. 0 +Late 0 +recovery 0 +of 0 +renal 0 +function 0 +in 0 +a 0 +woman 0 +with 0 +the 0 +hemolytic 3 +uremic 4 +syndrome 4 +. 0 +A 0 +case 0 +is 0 +reported 0 +of 0 +the 0 +hemolytic 3 +uremic 4 +syndrome 4 +( 0 +HUS 3 +) 0 +in 0 +a 0 +woman 0 +taking 0 +oral 1 +contraceptives 2 +. 0 +She 0 +was 0 +treated 0 +with 0 +heparin 1 +"," 0 +dipyridamole 1 +and 0 +hemodialysis 0 +; 0 +and 0 +after 0 +more 0 +than 0 +three 0 +months 0 +"," 0 +her 0 +urinary 0 +output 0 +rose 0 +above 0 +500 0 +ml 0 +; 0 +and 0 +six 0 +months 0 +after 0 +the 0 +onset 0 +of 0 +anuria 3 +"," 0 +dialysis 0 +treatment 0 +was 0 +stopped 0 +. 0 +This 0 +case 0 +emphasizes 0 +the 0 +possibility 0 +that 0 +HUS 3 +in 0 +adults 0 +is 0 +not 0 +invariably 0 +irreversible 0 +and 0 +that 0 +"," 0 +despite 0 +prolonged 0 +oliguria 3 +"," 0 +recovery 0 +of 0 +renal 0 +function 0 +can 0 +be 0 +obtained 0 +. 0 +Therefore 0 +"," 0 +in 0 +adult 0 +patients 0 +affected 0 +by 0 +HUS 3 +"," 0 +dialysis 0 +should 0 +not 0 +be 0 +discontinued 0 +prematurely 0 +; 0 +moreover 0 +"," 0 +bilateral 0 +nephrectomy 0 +"," 0 +for 0 +treatment 0 +of 0 +severe 0 +hypertension 3 +and 0 +microangiopathic 3 +hemolytic 4 +anemia 4 +"," 0 +should 0 +be 0 +performed 0 +with 0 +caution 0 +. 0 +Morphological 0 +features 0 +of 0 +encephalopathy 3 +after 0 +chronic 0 +administration 0 +of 0 +the 0 +antiepileptic 0 +drug 0 +valproate 1 +to 0 +rats 0 +. 0 +A 0 +transmission 0 +electron 0 +microscopic 0 +study 0 +of 0 +capillaries 0 +in 0 +the 0 +cerebellar 0 +cortex 0 +. 0 +Long 0 +- 0 +term 0 +intragastric 0 +application 0 +of 0 +the 0 +antiepileptic 0 +drug 0 +sodium 1 +valproate 2 +( 0 +Vupral 0 +" 0 +Polfa 0 +" 0 +) 0 +at 0 +the 0 +effective 0 +dose 0 +of 0 +200 0 +mg 0 +/ 0 +kg 0 +b 0 +. 0 +w 0 +. 0 +once 0 +daily 0 +to 0 +rats 0 +for 0 +1 0 +"," 0 +3 0 +"," 0 +6 0 +"," 0 +9 0 +and 0 +12 0 +months 0 +revealed 0 +neurological 3 +disorders 4 +indicating 0 +cerebellum 3 +damage 4 +( 0 +" 0 +valproate 1 +encephalopathy 3 +" 0 +) 0 +. 0 +The 0 +first 0 +ultrastructural 0 +changes 0 +in 0 +structural 0 +elements 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +- 0 +barrier 0 +( 0 +BBB 0 +) 0 +in 0 +the 0 +cerebellar 0 +cortex 0 +were 0 +detectable 0 +after 0 +3 0 +months 0 +of 0 +the 0 +experiment 0 +. 0 +They 0 +became 0 +more 0 +severe 0 +in 0 +the 0 +later 0 +months 0 +of 0 +the 0 +experiment 0 +"," 0 +and 0 +were 0 +most 0 +severe 0 +after 0 +12 0 +months 0 +"," 0 +located 0 +mainly 0 +in 0 +the 0 +molecular 0 +layer 0 +of 0 +the 0 +cerebellar 0 +cortex 0 +. 0 +Lesions 0 +of 0 +the 0 +capillary 0 +included 0 +necrosis 3 +of 0 +endothelial 0 +cells 0 +. 0 +0rganelles 0 +of 0 +these 0 +cells 0 +"," 0 +in 0 +particular 0 +the 0 +mitochondria 0 +( 0 +increased 0 +number 0 +and 0 +size 0 +"," 0 +distinct 0 +degeneration 0 +of 0 +their 0 +matrix 0 +and 0 +cristae 0 +) 0 +and 0 +Golgi 0 +apparatus 0 +were 0 +altered 0 +. 0 +Reduced 0 +size 0 +of 0 +capillary 0 +lumen 0 +and 0 +occlusion 0 +were 0 +caused 0 +by 0 +swollen 0 +endothelial 0 +cells 0 +which 0 +had 0 +luminal 1 +protrusions 0 +and 0 +swollen 0 +microvilli 0 +. 0 +Pressure 0 +on 0 +the 0 +vessel 0 +wall 0 +was 0 +produced 0 +by 0 +enlarged 0 +perivascular 0 +astrocytic 0 +processes 0 +. 0 +Fragments 0 +of 0 +necrotic 3 +endothelial 0 +cells 0 +were 0 +in 0 +the 0 +vascular 0 +lumens 0 +and 0 +in 0 +these 0 +there 0 +was 0 +loosening 0 +and 0 +breaking 0 +of 0 +tight 0 +cellular 0 +junctions 0 +. 0 +Damage 0 +to 0 +the 0 +vascular 0 +basement 0 +lamina 0 +was 0 +also 0 +observed 0 +. 0 +Damage 0 +to 0 +the 0 +capillary 0 +was 0 +accompanied 0 +by 0 +marked 0 +damage 0 +to 0 +neuroglial 0 +cells 0 +"," 0 +mainly 0 +to 0 +perivascular 0 +processes 0 +of 0 +astrocytes 0 +. 0 +The 0 +proliferation 0 +of 0 +astrocytes 0 +( 0 +Bergmann 0 +' 0 +s 0 +in 0 +particular 0 +) 0 +and 0 +occasionally 0 +of 0 +oligodendrocytes 0 +was 0 +found 0 +. 0 +Alterations 0 +in 0 +the 0 +structural 0 +elements 0 +of 0 +the 0 +BBB 0 +coexisted 0 +with 0 +marked 0 +lesions 0 +of 0 +neurons 0 +of 0 +the 0 +cerebellum 0 +( 0 +Purkinje 0 +cells 0 +are 0 +earliest 0 +) 0 +. 0 +In 0 +electron 0 +micrographs 0 +both 0 +luminal 1 +and 0 +antiluminal 0 +sides 0 +of 0 +the 0 +BBB 0 +of 0 +the 0 +cerebellar 0 +cortex 0 +had 0 +similar 0 +lesions 0 +. 0 +The 0 +possible 0 +influence 0 +of 0 +the 0 +hepatic 3 +damage 4 +"," 0 +mainly 0 +hyperammonemia 3 +"," 0 +upon 0 +the 0 +development 0 +of 0 +valproate 1 +encephalopathy 3 +is 0 +discussed 0 +. 0 +Fatal 0 +intracranial 3 +bleeding 4 +associated 0 +with 0 +prehospital 0 +use 0 +of 0 +epinephrine 1 +. 0 +We 0 +present 0 +a 0 +case 0 +of 0 +paramedic 0 +misjudgment 0 +in 0 +the 0 +execution 0 +of 0 +a 0 +protocol 0 +for 0 +the 0 +treatment 0 +of 0 +allergic 3 +reaction 4 +in 0 +a 0 +case 0 +of 0 +pulmonary 3 +edema 4 +with 0 +wheezing 3 +. 0 +The 0 +sudden 0 +onset 0 +of 0 +respiratory 3 +distress 4 +"," 0 +rash 3 +"," 0 +and 0 +a 0 +history 0 +of 0 +a 0 +new 0 +medicine 0 +led 0 +the 0 +two 0 +paramedics 0 +on 0 +the 0 +scene 0 +to 0 +administer 0 +subcutaneous 0 +epinephrine 1 +. 0 +Subsequently 0 +"," 0 +acute 0 +cardiac 3 +arrest 4 +and 0 +fatal 0 +subarachnoid 3 +hemorrhage 4 +occurred 0 +. 0 +Epinephrine 1 +has 0 +a 0 +proven 0 +role 0 +in 0 +cardiac 3 +arrest 4 +in 0 +prehospital 0 +care 0 +; 0 +however 0 +"," 0 +use 0 +by 0 +paramedics 0 +in 0 +patients 0 +with 0 +suspected 0 +allergic 3 +reaction 4 +and 0 +severe 0 +hypertension 3 +should 0 +be 0 +viewed 0 +with 0 +caution 0 +. 0 +Role 0 +of 0 +activation 0 +of 0 +bradykinin 1 +B2 0 +receptors 0 +in 0 +disruption 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +during 0 +acute 0 +hypertension 3 +. 0 +Cellular 0 +mechanisms 0 +which 0 +account 0 +for 0 +disruption 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +during 0 +acute 0 +hypertension 3 +are 0 +not 0 +clear 0 +. 0 +The 0 +goal 0 +of 0 +this 0 +study 0 +was 0 +to 0 +determine 0 +the 0 +role 0 +of 0 +synthesis 0 +/ 0 +release 0 +of 0 +bradykinin 1 +to 0 +activate 0 +B2 0 +receptors 0 +in 0 +disruption 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +during 0 +acute 0 +hypertension 3 +. 0 +Permeability 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +was 0 +quantitated 0 +by 0 +clearance 0 +of 0 +fluorescent 0 +- 0 +labeled 0 +dextran 1 +before 0 +and 0 +during 0 +phenylephrine 1 +- 0 +induced 0 +acute 0 +hypertension 3 +in 0 +rats 0 +treated 0 +with 0 +vehicle 0 +and 0 +Hoe 1 +- 2 +140 2 +( 0 +0 0 +. 0 +1 0 +microM 0 +) 0 +. 0 +Phenylephrine 1 +infusion 0 +increased 0 +arterial 0 +pressure 0 +"," 0 +arteriolar 0 +diameter 0 +and 0 +clearance 0 +of 0 +fluorescent 0 +dextran 1 +by 0 +a 0 +similar 0 +magnitude 0 +in 0 +both 0 +groups 0 +. 0 +These 0 +findings 0 +suggest 0 +that 0 +disruption 0 +of 0 +the 0 +blood 0 +- 0 +brain 0 +barrier 0 +during 0 +acute 0 +hypertension 3 +is 0 +not 0 +related 0 +to 0 +the 0 +synthesis 0 +/ 0 +release 0 +of 0 +bradykinin 1 +to 0 +activate 0 +B2 0 +receptors 0 +. 0 +Risk 0 +factors 0 +of 0 +sensorineural 3 +hearing 4 +loss 4 +in 0 +preterm 0 +infants 0 +. 0 +Among 0 +547 0 +preterm 0 +infants 0 +of 0 +< 0 +or 0 += 0 +34 0 +weeks 0 +gestation 0 +born 0 +between 0 +1987 0 +and 0 +1991 0 +"," 0 +8 0 +children 0 +( 0 +1 0 +. 0 +46 0 +% 0 +) 0 +developed 0 +severe 0 +progressive 0 +and 0 +bilateral 0 +sensorineural 3 +hearing 4 +loss 4 +. 0 +Perinatal 0 +risk 0 +factors 0 +of 0 +infants 0 +with 0 +hearing 3 +loss 4 +were 0 +compared 0 +with 0 +those 0 +of 0 +two 0 +control 0 +groups 0 +matched 0 +for 0 +gestation 0 +and 0 +birth 0 +weight 0 +and 0 +for 0 +perinatal 0 +complications 0 +. 0 +0ur 0 +observations 0 +demonstrated 0 +an 0 +association 0 +of 0 +hearing 3 +loss 4 +with 0 +a 0 +higher 0 +incidence 0 +of 0 +perinatal 0 +complications 0 +. 0 +0totoxicity 3 +appeared 0 +closely 0 +related 0 +to 0 +a 0 +prolonged 0 +administration 0 +and 0 +higher 0 +total 0 +dose 0 +of 0 +ototoxic 3 +drugs 0 +"," 0 +particularly 0 +aminoglycosides 1 +and 0 +furosemide 1 +. 0 +Finally 0 +"," 0 +we 0 +strongly 0 +recommend 0 +to 0 +prospectively 0 +and 0 +regularly 0 +perform 0 +audiologic 0 +assessment 0 +in 0 +sick 0 +preterm 0 +children 0 +as 0 +hearing 3 +loss 4 +is 0 +of 0 +delayed 0 +onset 0 +and 0 +in 0 +most 0 +cases 0 +bilateral 0 +and 0 +severe 0 +. 0 +Seizure 3 +resulting 0 +from 0 +a 0 +venlafaxine 1 +overdose 3 +. 0 +0BJECTIVE 0 +: 0 +To 0 +report 0 +a 0 +case 0 +of 0 +venlafaxine 1 +overdose 3 +. 0 +CASE 0 +SUMMARY 0 +: 0 +A 0 +40 0 +- 0 +year 0 +- 0 +old 0 +woman 0 +with 0 +major 3 +depression 4 +took 0 +an 0 +overdose 3 +of 0 +venlafaxine 1 +in 0 +an 0 +apparent 0 +suicide 0 +attempt 0 +. 0 +After 0 +the 0 +ingestion 0 +of 0 +26 0 +venlafaxine 1 +50 0 +- 0 +mg 0 +tablets 0 +"," 0 +the 0 +patient 0 +experienced 0 +a 0 +witnessed 0 +generalized 0 +seizure 3 +. 0 +She 0 +was 0 +admitted 0 +to 0 +the 0 +medical 0 +intensive 0 +care 0 +unit 0 +"," 0 +venlafaxine 1 +was 0 +discontinued 0 +"," 0 +and 0 +no 0 +further 0 +sequelae 0 +were 0 +seen 0 +. 0 +DISCUSSI0N 0 +: 0 +To 0 +our 0 +knowledge 0 +"," 0 +this 0 +is 0 +the 0 +first 0 +reported 0 +case 0 +of 0 +venlafaxine 1 +overdose 3 +that 0 +resulted 0 +in 0 +a 0 +generalized 0 +seizure 3 +. 0 +Based 0 +on 0 +nonoverdose 0 +pharmacokinetics 0 +and 0 +pharmacodynamics 0 +of 0 +venlafaxine 1 +and 0 +the 0 +potential 0 +risks 0 +of 0 +available 0 +interventions 0 +"," 0 +no 0 +emergent 0 +therapy 0 +was 0 +instituted 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +venlafaxine 1 +overdose 3 +in 0 +our 0 +patient 0 +resulted 0 +in 0 +a 0 +single 0 +episode 0 +of 0 +generalized 0 +seizure 3 +but 0 +elicited 0 +no 0 +further 0 +sequelae 0 +. 0 +Combined 0 +effects 0 +of 0 +prolonged 0 +prostaglandin 1 +E1 2 +- 0 +induced 0 +hypotension 3 +and 0 +haemodilution 3 +on 0 +human 0 +hepatic 0 +function 0 +. 0 +Combined 0 +effects 0 +of 0 +prolonged 0 +prostaglandin 1 +E1 2 +( 0 +PGE1 1 +) 0 +- 0 +induced 0 +hypotension 3 +and 0 +haemodilution 3 +on 0 +hepatic 0 +function 0 +were 0 +studied 0 +in 0 +30 0 +patients 0 +undergoing 0 +hip 0 +surgery 0 +. 0 +The 0 +patients 0 +were 0 +randomly 0 +allocated 0 +to 0 +one 0 +of 0 +three 0 +groups 0 +; 0 +those 0 +in 0 +group 0 +A 0 +( 0 +n 0 += 0 +10 0 +) 0 +were 0 +subjected 0 +to 0 +controlled 0 +hypotension 3 +alone 0 +"," 0 +those 0 +in 0 +group 0 +B 0 +( 0 +n 0 += 0 +10 0 +) 0 +to 0 +haemodilution 3 +alone 0 +and 0 +those 0 +in 0 +group 0 +C 0 +( 0 +n 0 += 0 +10 0 +) 0 +to 0 +both 0 +controlled 0 +hypotension 3 +and 0 +haemodilution 3 +. 0 +Haemodilution 3 +in 0 +groups 0 +B 0 +and 0 +C 0 +was 0 +produced 0 +by 0 +withdrawing 0 +approximately 0 +1000 0 +mL 0 +of 0 +blood 0 +and 0 +replacing 0 +it 0 +with 0 +the 0 +same 0 +amount 0 +of 0 +dextran 1 +solution 0 +"," 0 +and 0 +final 0 +haematocrit 0 +values 0 +were 0 +21 0 +or 0 +22 0 +% 0 +. 0 +Controlled 0 +hypotension 3 +in 0 +groups 0 +A 0 +and 0 +C 0 +was 0 +induced 0 +with 0 +PGE1 1 +to 0 +maintain 0 +mean 0 +arterial 0 +blood 0 +pressure 0 +at 0 +55 0 +mmHg 0 +for 0 +180 0 +min 0 +. 0 +Measurements 0 +included 0 +arterial 0 +ketone 0 +body 0 +ratio 0 +( 0 +AKBR 0 +"," 0 +aceto 1 +- 2 +acetate 2 +/ 0 +3 1 +- 2 +hydroxybutyrate 2 +) 0 +and 0 +clinical 0 +hepatic 0 +function 0 +parameters 0 +. 0 +AKBR 0 +and 0 +biological 0 +hepatic 0 +function 0 +tests 0 +showed 0 +no 0 +change 0 +throughout 0 +the 0 +time 0 +course 0 +in 0 +groups 0 +A 0 +and 0 +B 0 +. 0 +In 0 +group 0 +C 0 +"," 0 +AKBR 0 +showed 0 +a 0 +significant 0 +decrease 0 +at 0 +120 0 +min 0 +( 0 +- 0 +40 0 +% 0 +) 0 +and 0 +at 0 +180 0 +min 0 +( 0 +- 0 +49 0 +% 0 +) 0 +after 0 +the 0 +start 0 +of 0 +hypotension 3 +and 0 +at 0 +60 0 +min 0 +( 0 +- 0 +32 0 +% 0 +) 0 +after 0 +recovery 0 +of 0 +normotension 0 +"," 0 +and 0 +SG0T 0 +"," 0 +SGPT 0 +"," 0 +LDH 0 +and 0 +total 0 +bilirubin 1 +showed 0 +significant 0 +increases 0 +after 0 +operation 0 +. 0 +The 0 +results 0 +suggest 0 +that 0 +a 0 +prolonged 0 +combination 0 +of 0 +more 0 +than 0 +120 0 +min 0 +of 0 +PGE1 1 +- 0 +induced 0 +hypotension 3 +and 0 +moderate 0 +haemodilution 3 +would 0 +cause 0 +impairment 3 +of 4 +hepatic 4 +function 4 +. 0 +Cardiovascular 3 +alterations 4 +in 0 +rat 0 +fetuses 0 +exposed 0 +to 0 +calcium 1 +channel 0 +blockers 0 +. 0 +Preclinical 0 +toxicologic 0 +investigation 0 +suggested 0 +that 0 +a 0 +new 0 +calcium 1 +channel 0 +blocker 0 +"," 0 +Ro 1 +40 2 +- 2 +5967 2 +"," 0 +induced 0 +cardiovascular 3 +alterations 4 +in 0 +rat 0 +fetuses 0 +exposed 0 +to 0 +this 0 +agent 0 +during 0 +organogenesis 0 +. 0 +The 0 +present 0 +study 0 +was 0 +designed 0 +to 0 +investigate 0 +the 0 +hypothesis 0 +that 0 +calcium 1 +channel 0 +blockers 0 +in 0 +general 0 +induce 0 +cardiovascular 3 +malformations 4 +indicating 0 +a 0 +pharmacologic 0 +class 0 +effect 0 +. 0 +We 0 +studied 0 +three 0 +calcium 1 +channel 0 +blockers 0 +of 0 +different 0 +structure 0 +"," 0 +nifedipine 1 +"," 0 +diltiazem 1 +"," 0 +and 0 +verapamil 1 +"," 0 +along 0 +with 0 +the 0 +new 0 +agent 0 +. 0 +Pregnant 0 +rats 0 +were 0 +administered 0 +one 0 +of 0 +these 0 +calcium 1 +channel 0 +blockers 0 +during 0 +the 0 +period 0 +of 0 +cardiac 0 +morphogenesis 0 +and 0 +the 0 +offspring 0 +examined 0 +on 0 +day 0 +20 0 +of 0 +gestation 0 +for 0 +cardiovascular 3 +malformations 4 +. 0 +A 0 +low 0 +incidence 0 +of 0 +cardiovascular 3 +malformations 4 +was 0 +observed 0 +after 0 +exposure 0 +to 0 +each 0 +of 0 +the 0 +four 0 +calcium 1 +channel 0 +blockers 0 +"," 0 +but 0 +this 0 +incidence 0 +was 0 +statistically 0 +significant 0 +only 0 +for 0 +verapamil 1 +and 0 +nifedipine 1 +. 0 +All 0 +four 0 +agents 0 +were 0 +associated 0 +with 0 +aortic 0 +arch 0 +branching 0 +variants 0 +"," 0 +although 0 +significantly 0 +increased 0 +only 0 +for 0 +Ro 1 +40 2 +- 2 +5967 2 +and 0 +verapamil 1 +. 0 +The 0 +site 0 +of 0 +common 0 +side 0 +effects 0 +of 0 +sumatriptan 1 +. 0 +Atypical 3 +sensations 4 +following 0 +the 0 +use 0 +of 0 +subcutaneous 0 +sumatriptan 1 +are 0 +common 0 +"," 0 +but 0 +of 0 +uncertain 0 +origin 0 +. 0 +They 0 +are 0 +almost 0 +always 0 +benign 0 +"," 0 +but 0 +can 0 +be 0 +mistaken 0 +for 0 +a 0 +serious 0 +adverse 0 +event 0 +by 0 +the 0 +patient 0 +. 0 +Two 0 +patients 0 +are 0 +presented 0 +with 0 +tingling 3 +or 4 +burning 4 +sensations 4 +limited 0 +to 0 +areas 0 +of 0 +heat 0 +exposure 0 +or 0 +sunburn 3 +. 0 +In 0 +these 0 +individuals 0 +"," 0 +side 0 +effects 0 +are 0 +most 0 +likely 0 +generated 0 +superficially 0 +in 0 +the 0 +skin 0 +. 0 +Macula 0 +toxicity 3 +after 0 +intravitreal 0 +amikacin 1 +. 0 +BACKGR0UND 0 +: 0 +Although 0 +intravitreal 0 +aminoglycosides 1 +have 0 +substantially 0 +improved 0 +visual 0 +prognosis 0 +in 0 +endophthalmitis 3 +"," 0 +macular 0 +infarction 3 +may 0 +impair 0 +full 0 +visual 0 +recovery 0 +. 0 +METH0DS 0 +: 0 +We 0 +present 0 +a 0 +case 0 +of 0 +presumed 0 +amikacin 1 +retinal 3 +toxicity 4 +following 0 +treatment 0 +with 0 +amikacin 1 +and 0 +vancomycin 1 +for 0 +alpha 0 +- 0 +haemolytic 0 +streptococcal 3 +endophthalmitis 4 +. 0 +RESULTS 0 +: 0 +Endophthalmitis 3 +resolved 0 +with 0 +improvement 0 +in 0 +visual 0 +acuity 0 +to 0 +6 0 +/ 0 +24 0 +at 0 +three 0 +months 0 +. 0 +Fundus 0 +fluorescein 1 +angiography 0 +confirmed 0 +macular 0 +capillary 0 +closure 0 +and 0 +telangiectasis 3 +. 0 +C0NCLUSI0NS 0 +: 0 +Currently 0 +accepted 0 +intravitreal 0 +antibiotic 0 +regimens 0 +may 0 +cause 0 +retinal 3 +toxicity 4 +and 0 +macular 0 +ischaemia 3 +. 0 +Treatment 0 +strategies 0 +aimed 0 +at 0 +avoiding 0 +retinal 3 +toxicity 4 +are 0 +discussed 0 +. 0 +The 0 +role 0 +of 0 +nicotine 1 +in 0 +smoking 0 +- 0 +related 0 +cardiovascular 3 +disease 4 +. 0 +Nicotine 1 +activates 0 +the 0 +sympathetic 0 +nervous 0 +system 0 +and 0 +in 0 +this 0 +way 0 +could 0 +contribute 0 +to 0 +cardiovascular 3 +disease 4 +. 0 +Animal 0 +studies 0 +and 0 +mechanistic 0 +studies 0 +indicate 0 +that 0 +nicotine 1 +could 0 +play 0 +a 0 +role 0 +in 0 +accelerating 0 +atherosclerosis 3 +"," 0 +but 0 +evidence 0 +among 0 +humans 0 +is 0 +too 0 +inadequate 0 +to 0 +be 0 +definitive 0 +about 0 +such 0 +an 0 +effect 0 +. 0 +Almost 0 +certainly 0 +"," 0 +nicotine 1 +via 0 +its 0 +hemodynamic 0 +effects 0 +contributes 0 +to 0 +acute 0 +cardiovascular 0 +events 0 +"," 0 +although 0 +current 0 +evidence 0 +suggests 0 +that 0 +the 0 +effects 0 +of 0 +nicotine 1 +are 0 +much 0 +less 0 +important 0 +than 0 +are 0 +the 0 +prothrombotic 0 +effects 0 +of 0 +cigarette 0 +smoking 0 +or 0 +the 0 +effects 0 +of 0 +carbon 1 +monoxide 2 +. 0 +Nicotine 1 +does 0 +not 0 +appear 0 +to 0 +enhance 0 +thrombosis 3 +among 0 +humans 0 +. 0 +Clinical 0 +studies 0 +of 0 +pipe 0 +smokers 0 +and 0 +people 0 +using 0 +transdermal 0 +nicotine 1 +support 0 +the 0 +idea 0 +that 0 +toxins 0 +other 0 +than 0 +nicotine 1 +are 0 +the 0 +most 0 +important 0 +causes 0 +of 0 +acute 0 +cardiovascular 0 +events 0 +. 0 +Finally 0 +"," 0 +the 0 +dose 0 +response 0 +for 0 +cardiovascular 0 +events 0 +of 0 +nicotine 1 +appears 0 +to 0 +be 0 +flat 0 +"," 0 +suggesting 0 +that 0 +if 0 +nicotine 1 +is 0 +involved 0 +"," 0 +adverse 0 +effects 0 +might 0 +be 0 +seen 0 +with 0 +relatively 0 +low 0 +- 0 +level 0 +cigarette 0 +exposures 0 +. 0 +Iatrogenically 0 +induced 0 +intractable 0 +atrioventricular 3 +reentrant 4 +tachycardia 4 +after 0 +verapamil 1 +and 0 +catheter 0 +ablation 0 +in 0 +a 0 +patient 0 +with 0 +Wolff 3 +- 4 +Parkinson 4 +- 4 +White 4 +syndrome 4 +and 0 +idiopathic 3 +dilated 4 +cardiomyopathy 4 +. 0 +In 0 +a 0 +patient 0 +with 0 +WPW 3 +syndrome 4 +and 0 +idiopathic 3 +dilated 4 +cardiomyopathy 4 +"," 0 +intractable 0 +atrioventricular 3 +reentrant 4 +tachycardia 4 +( 0 +AVRT 3 +) 0 +was 0 +iatrogenically 0 +induced 0 +. 0 +QRS 0 +without 0 +preexcitation 0 +"," 0 +caused 0 +by 0 +junctional 0 +escape 0 +beats 0 +after 0 +verapamil 1 +or 0 +unidirectional 0 +antegrade 0 +block 0 +of 0 +accessory 0 +pathway 0 +after 0 +catheter 0 +ablation 0 +"," 0 +established 0 +frequent 0 +AVRT 3 +attack 0 +. 0 +Epidemic 0 +of 0 +liver 3 +disease 4 +caused 0 +by 0 +hydrochlorofluorocarbons 1 +used 0 +as 0 +ozone 1 +- 0 +sparing 0 +substitutes 0 +of 0 +chlorofluorocarbons 1 +. 0 +BACKGR0UND 0 +: 0 +Hydrochlorofluorocarbons 1 +( 0 +HCFCs 1 +) 0 +are 0 +used 0 +increasingly 0 +in 0 +industry 0 +as 0 +substitutes 0 +for 0 +ozone 1 +- 0 +depleting 0 +chlorofluorocarbons 1 +( 0 +CFCs 1 +) 0 +. 0 +Limited 0 +studies 0 +in 0 +animals 0 +indicate 0 +potential 0 +hepatotoxicity 3 +of 0 +some 0 +of 0 +these 0 +compounds 0 +. 0 +We 0 +investigated 0 +an 0 +epidemic 0 +of 0 +liver 3 +disease 4 +in 0 +nine 0 +industrial 0 +workers 0 +who 0 +had 0 +had 0 +repeated 0 +accidental 0 +exposure 0 +to 0 +a 0 +mixture 0 +of 0 +1 1 +"," 2 +1 2 +- 2 +dichloro 2 +- 2 +2 2 +"," 2 +2 2 +"," 2 +2 2 +- 2 +trifluoroethane 2 +( 0 +HCFC 1 +123 2 +) 0 +and 0 +1 1 +- 2 +chloro 2 +- 2 +1 2 +"," 2 +2 2 +"," 2 +2 2 +"," 2 +2 2 +- 2 +tetrafluoroethane 2 +( 0 +HCFC 1 +124 2 +) 0 +. 0 +All 0 +nine 0 +exposed 0 +workers 0 +were 0 +affected 0 +to 0 +various 0 +degrees 0 +. 0 +Both 0 +compounds 0 +are 0 +metabolised 0 +in 0 +the 0 +same 0 +way 0 +as 0 +1 1 +- 2 +bromo 2 +- 2 +1 2 +- 2 +chloro 2 +- 2 +2 2 +"," 2 +2 2 +"," 2 +2 2 +- 2 +trifluoroethane 2 +( 0 +halothane 1 +) 0 +to 0 +form 0 +reactive 0 +trifluoroacetyl 1 +halide 0 +intermediates 0 +"," 0 +which 0 +have 0 +been 0 +implicated 0 +in 0 +the 0 +hepatotoxicity 3 +of 0 +halothane 1 +. 0 +We 0 +aimed 0 +to 0 +test 0 +whether 0 +HCFCs 1 +123 2 +and 2 +124 2 +can 0 +result 0 +in 0 +serious 0 +liver 3 +disease 4 +. 0 +METH0DS 0 +: 0 +For 0 +one 0 +severely 0 +affected 0 +worker 0 +liver 0 +biopsy 0 +and 0 +immunohistochemical 0 +stainings 0 +for 0 +the 0 +presence 0 +of 0 +trifluoroacetyl 1 +protein 0 +adducts 0 +were 0 +done 0 +. 0 +The 0 +serum 0 +of 0 +six 0 +affected 0 +workers 0 +and 0 +five 0 +controls 0 +was 0 +tested 0 +for 0 +autoantibodies 0 +that 0 +react 0 +with 0 +human 0 +liver 0 +cytochrome 0 +- 0 +P450 0 +2.00E+01 0 +( 0 +P450 0 +2.00E+01 0 +) 0 +and 0 +P58 0 +protein 0 +disulphide 0 +isomerase 0 +isoform 0 +( 0 +P58 0 +) 0 +. 0 +FINDINGS 0 +: 0 +The 0 +liver 0 +biopsy 0 +sample 0 +showed 0 +hepatocellular 0 +necrosis 3 +which 0 +was 0 +prominent 0 +in 0 +perivenular 0 +zone 0 +three 0 +and 0 +extended 0 +focally 0 +from 0 +portal 0 +tracts 0 +to 0 +portal 0 +tracts 0 +and 0 +centrilobular 0 +areas 0 +( 0 +bridging 0 +necrosis 3 +) 0 +. 0 +Trifluoroacetyl 1 +- 0 +adducted 0 +proteins 0 +were 0 +detected 0 +in 0 +surviving 0 +hepatocytes 0 +. 0 +Autoantibodies 0 +against 0 +P450 0 +2.00E+01 0 +or 0 +P58 0 +"," 0 +previously 0 +associated 0 +with 0 +halothane 3 +hepatitis 4 +"," 0 +were 0 +detected 0 +in 0 +the 0 +serum 0 +of 0 +five 0 +affected 0 +workers 0 +. 0 +INTERPRETATI0N 0 +: 0 +Repeated 0 +exposure 0 +of 0 +human 0 +beings 0 +to 0 +HCFCs 1 +123 2 +and 2 +124 2 +can 0 +result 0 +in 0 +serious 0 +liver 3 +injury 4 +in 0 +a 0 +large 0 +proportion 0 +of 0 +the 0 +exposed 0 +population 0 +. 0 +Although 0 +the 0 +exact 0 +mechanism 0 +of 0 +hepatotoxicity 3 +of 0 +these 0 +agents 0 +is 0 +not 0 +known 0 +"," 0 +the 0 +results 0 +suggest 0 +that 0 +trifluoroacetyl 1 +- 0 +altered 0 +liver 0 +proteins 0 +are 0 +involved 0 +. 0 +In 0 +view 0 +of 0 +the 0 +potentially 0 +widespread 0 +use 0 +of 0 +these 0 +compounds 0 +"," 0 +there 0 +is 0 +an 0 +urgent 0 +need 0 +to 0 +develop 0 +safer 0 +alternatives 0 +. 0 +Bile 3 +duct 4 +hamartoma 4 +occurring 0 +in 0 +association 0 +with 0 +long 0 +- 0 +term 0 +treatment 0 +with 0 +danazol 1 +. 0 +We 0 +report 0 +a 0 +case 0 +of 0 +bile 3 +duct 4 +hamartoma 4 +which 0 +developed 0 +in 0 +a 0 +patient 0 +who 0 +had 0 +been 0 +on 0 +long 0 +- 0 +term 0 +danazol 1 +treatment 0 +. 0 +Such 0 +patients 0 +should 0 +be 0 +under 0 +close 0 +follow 0 +- 0 +up 0 +"," 0 +preferably 0 +with 0 +periodic 0 +ultrasound 0 +examination 0 +of 0 +the 0 +liver 0 +. 0 +If 0 +the 0 +patient 0 +develops 0 +a 0 +liver 3 +mass 4 +"," 0 +because 0 +of 0 +non 0 +- 0 +specific 0 +clinical 0 +features 0 +and 0 +imaging 0 +appearances 0 +"," 0 +biopsy 0 +may 0 +be 0 +the 0 +only 0 +way 0 +to 0 +achieve 0 +a 0 +definitive 0 +diagnosis 0 +. 0 +Endocrine 0 +screening 0 +in 0 +1 0 +"," 0 +22 0 +men 0 +with 0 +erectile 3 +dysfunction 4 +: 0 +clinical 0 +significance 0 +and 0 +cost 0 +- 0 +effective 0 +strategy 0 +. 0 +PURP0SE 0 +: 0 +We 0 +reviewed 0 +the 0 +results 0 +of 0 +serum 0 +testosterone 1 +and 0 +prolactin 0 +determination 0 +in 0 +1 0 +"," 0 +22 0 +patients 0 +referred 0 +because 0 +of 0 +erectile 3 +dysfunction 4 +and 0 +compared 0 +the 0 +data 0 +with 0 +history 0 +"," 0 +results 0 +of 0 +physical 0 +examination 0 +"," 0 +other 0 +etiological 0 +investigations 0 +and 0 +effects 0 +of 0 +endocrine 0 +therapy 0 +to 0 +refine 0 +the 0 +rules 0 +of 0 +cost 0 +- 0 +effective 0 +endocrine 0 +screening 0 +and 0 +to 0 +pinpoint 0 +actual 0 +responsibility 0 +for 0 +hormonal 0 +abnormalities 0 +. 0 +MATERIALS 0 +AND 0 +METH0DS 0 +: 0 +Testosterone 1 +and 0 +prolactin 0 +were 0 +determined 0 +by 0 +radioimmunoassay 0 +. 0 +Every 0 +patient 0 +was 0 +screened 0 +for 0 +testosterone 1 +and 0 +451 0 +were 0 +screened 0 +for 0 +prolactin 0 +on 0 +the 0 +basis 0 +of 0 +low 3 +sexual 4 +desire 4 +"," 0 +gynecomastia 3 +or 0 +testosterone 1 +less 0 +than 0 +4 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +Determination 0 +was 0 +repeated 0 +in 0 +case 0 +of 0 +abnormal 0 +first 0 +results 0 +. 0 +Prolactin 0 +results 0 +were 0 +compared 0 +with 0 +those 0 +of 0 +a 0 +previous 0 +personal 0 +cohort 0 +of 0 +1 0 +"," 0 +340 0 +patients 0 +with 0 +erectile 3 +dysfunction 4 +and 0 +systematic 0 +prolactin 0 +determination 0 +. 0 +Main 0 +clinical 0 +criteria 0 +tested 0 +regarding 0 +efficiency 0 +in 0 +hormone 0 +determination 0 +were 0 +low 3 +sexual 4 +desire 4 +"," 0 +small 0 +testes 0 +and 0 +gynecomastia 3 +. 0 +Endocrine 0 +therapy 0 +consisted 0 +of 0 +testosterone 1 +heptylate 2 +or 0 +human 0 +chorionic 0 +gonadotropin 0 +for 0 +hypogonadism 3 +and 0 +bromocriptine 1 +for 0 +hyperprolactinemia 3 +. 0 +RESULTS 0 +: 0 +Testosterone 1 +was 0 +less 0 +than 0 +3 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +in 0 +107 0 +patients 0 +but 0 +normal 0 +in 0 +40 0 +% 0 +at 0 +repeat 0 +determination 0 +. 0 +The 0 +prevalence 0 +of 0 +repeatedly 0 +low 0 +testosterone 1 +increased 0 +with 0 +age 0 +( 0 +4 0 +% 0 +before 0 +age 0 +50 0 +years 0 +and 0 +9 0 +% 0 +50 0 +years 0 +or 0 +older 0 +) 0 +. 0 +Two 0 +pituitary 3 +tumors 4 +were 0 +discovered 0 +after 0 +testosterone 1 +determination 0 +. 0 +Most 0 +of 0 +the 0 +other 0 +low 0 +testosterone 1 +levels 0 +seemed 0 +to 0 +result 0 +from 0 +nonorganic 0 +hypothalamic 3 +dysfunction 4 +because 0 +of 0 +normal 0 +serum 0 +luteinizing 0 +hormone 0 +and 0 +prolactin 0 +and 0 +to 0 +have 0 +only 0 +a 0 +small 0 +role 0 +in 0 +erectile 3 +dysfunction 4 +( 0 +definite 0 +improvement 0 +in 0 +only 0 +16 0 +of 0 +44 0 +[ 0 +36 0 +% 0 +] 0 +after 0 +androgen 0 +therapy 0 +"," 0 +normal 0 +morning 0 +or 0 +nocturnal 0 +erections 0 +in 0 +30 0 +% 0 +and 0 +definite 0 +vasculogenic 0 +contributions 0 +in 0 +42 0 +% 0 +) 0 +. 0 +Determining 0 +testosterone 1 +only 0 +in 0 +cases 0 +of 0 +low 3 +sexual 4 +desire 4 +or 0 +abnormal 0 +physical 0 +examination 0 +would 0 +have 0 +missed 0 +40 0 +% 0 +of 0 +the 0 +cases 0 +with 0 +low 0 +testosterone 1 +"," 0 +including 0 +37 0 +% 0 +of 0 +those 0 +subsequently 0 +improved 0 +by 0 +androgen 0 +therapy 0 +. 0 +Prolactin 0 +exceeded 0 +20 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +in 0 +5 0 +men 0 +and 0 +was 0 +normal 0 +in 0 +2 0 +at 0 +repeat 0 +determination 0 +. 0 +0nly 0 +1 0 +prolactinoma 3 +was 0 +discovered 0 +. 0 +These 0 +data 0 +are 0 +lower 0 +than 0 +those 0 +we 0 +found 0 +during 0 +the 0 +last 0 +2 0 +decades 0 +( 0 +overall 0 +prolactin 0 +greater 0 +than 0 +20 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +in 0 +1 0 +. 0 +86 0 +% 0 +of 0 +1 0 +"," 0 +821 0 +patients 0 +"," 0 +prolactinomas 3 +in 0 +7 0 +"," 0 +0 0 +. 0 +38 0 +% 0 +) 0 +. 0 +Bromocriptine 1 +was 0 +definitely 0 +effective 0 +in 0 +cases 0 +with 0 +prolactin 0 +greater 0 +than 0 +35 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +( 0 +8 0 +of 0 +12 0 +compared 0 +to 0 +only 0 +9 0 +of 0 +22 0 +cases 0 +with 0 +prolactin 0 +between 0 +20 0 +and 0 +35 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +) 0 +. 0 +Testosterone 1 +was 0 +low 0 +in 0 +less 0 +than 0 +50 0 +% 0 +of 0 +cases 0 +with 0 +prolactin 0 +greater 0 +than 0 +35 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Low 0 +prevalences 0 +and 0 +effects 0 +of 0 +low 0 +testosterone 1 +and 0 +high 0 +prolactin 0 +in 0 +erectile 3 +dysfunction 4 +cannot 0 +justify 0 +their 0 +routine 0 +determination 0 +. 0 +However 0 +"," 0 +cost 0 +- 0 +effective 0 +screening 0 +strategies 0 +recommended 0 +so 0 +far 0 +missed 0 +40 0 +to 0 +50 0 +% 0 +of 0 +cases 0 +improved 0 +with 0 +endocrine 0 +therapy 0 +and 0 +the 0 +pituitary 3 +tumors 4 +. 0 +We 0 +now 0 +advocate 0 +that 0 +before 0 +age 0 +50 0 +years 0 +testosterone 1 +be 0 +determined 0 +only 0 +in 0 +cases 0 +of 0 +low 3 +sexual 4 +desire 4 +and 0 +abnormal 0 +physical 0 +examination 0 +but 0 +that 0 +it 0 +be 0 +measured 0 +in 0 +all 0 +men 0 +older 0 +than 0 +50 0 +years 0 +. 0 +Prolactin 0 +should 0 +be 0 +determined 0 +only 0 +in 0 +cases 0 +of 0 +low 3 +sexual 4 +desire 4 +"," 0 +gynecomastia 3 +and 0 +/ 0 +or 0 +testosterone 1 +less 0 +than 0 +4 0 +ng 0 +. 0 +/ 0 +ml 0 +. 0 +Extrapyramidal 0 +side 0 +effects 0 +with 0 +risperidone 1 +and 0 +haloperidol 1 +at 0 +comparable 0 +D2 0 +receptor 0 +occupancy 0 +levels 0 +. 0 +Risperidone 1 +is 0 +an 0 +antipsychotic 0 +drug 0 +with 0 +high 0 +affinity 0 +at 0 +dopamine 1 +D2 0 +and 0 +serotonin 1 +5 2 +- 2 +HT2 2 +receptors 0 +. 0 +Previous 0 +clinical 0 +studies 0 +have 0 +proposed 0 +that 0 +risperidone 1 +' 0 +s 0 +pharmacologic 0 +profile 0 +may 0 +produce 0 +improved 0 +efficacy 0 +for 0 +negative 0 +psychotic 3 +symptoms 4 +and 0 +decreased 0 +propensity 0 +for 0 +extrapyramidal 0 +side 0 +effects 0 +; 0 +features 0 +shared 0 +by 0 +so 0 +- 0 +called 0 +' 0 +atypical 0 +' 0 +neuroleptics 0 +. 0 +To 0 +determine 0 +if 0 +routine 0 +risperidone 1 +treatment 0 +is 0 +associated 0 +with 0 +a 0 +unique 0 +degree 0 +of 0 +D2 0 +receptor 0 +occupancy 0 +and 0 +pattern 0 +of 0 +clinical 0 +effects 0 +"," 0 +we 0 +used 0 +[ 0 +123I 0 +] 0 +IBZM 0 +SPECT 0 +to 0 +determine 0 +D2 0 +occupancy 0 +in 0 +subjects 0 +treated 0 +with 0 +routine 0 +clinical 0 +doses 0 +of 0 +risperidone 1 +( 0 +n 0 += 0 +12 0 +) 0 +or 0 +haloperidol 1 +( 0 +n 0 += 0 +7 0 +) 0 +. 0 +Both 0 +risperidone 1 +and 0 +haloperidol 1 +produced 0 +D2 0 +occupancy 0 +levels 0 +between 0 +approximately 0 +60 0 +and 0 +90 0 +% 0 +at 0 +standard 0 +clinical 0 +doses 0 +. 0 +There 0 +was 0 +no 0 +significant 0 +difference 0 +between 0 +occupancy 0 +levels 0 +obtained 0 +with 0 +haloperidol 1 +or 0 +risperidone 1 +. 0 +Drug 3 +- 4 +induced 4 +parkinsonism 4 +was 0 +observed 0 +in 0 +subjects 0 +treated 0 +with 0 +risperidone 1 +( 0 +42 0 +% 0 +) 0 +and 0 +haloperidol 1 +( 0 +29 0 +% 0 +) 0 +and 0 +was 0 +observed 0 +at 0 +occupancy 0 +levels 0 +above 0 +60 0 +% 0 +. 0 +Based 0 +on 0 +these 0 +observations 0 +"," 0 +it 0 +is 0 +concluded 0 +that 0 +5 0 +- 0 +HT2 0 +blockade 0 +obtained 0 +with 0 +risperidone 1 +at 0 +D2 0 +occupancy 0 +rates 0 +of 0 +60 0 +% 0 +and 0 +above 0 +does 0 +not 0 +appear 0 +to 0 +protect 0 +against 0 +the 0 +risk 0 +for 0 +extrapyramidal 0 +side 0 +effects 0 +. 0 +Treatment 0 +of 0 +previously 0 +treated 0 +metastatic 0 +breast 3 +cancer 4 +by 0 +mitoxantrone 1 +and 0 +48 0 +- 0 +hour 0 +continuous 0 +infusion 0 +of 0 +high 0 +- 0 +dose 0 +5 1 +- 2 +FU 2 +and 0 +leucovorin 1 +( 0 +MFL 1 +) 0 +: 0 +low 0 +palliative 0 +benefit 0 +and 0 +high 0 +treatment 0 +- 0 +related 0 +toxicity 3 +. 0 +For 0 +previously 0 +treated 0 +advanced 0 +breast 3 +cancer 4 +"," 0 +there 0 +is 0 +no 0 +standard 0 +second 0 +- 0 +line 0 +therapy 0 +. 0 +Combination 0 +chemotherapy 0 +with 0 +mitoxantrone 1 +"," 0 +high 0 +- 0 +dose 0 +5 1 +- 2 +fluorouracil 2 +( 0 +5 1 +- 2 +FU 2 +) 0 +and 0 +leucovorin 1 +( 0 +MFL 1 +regimen 2 +) 0 +had 0 +been 0 +reported 0 +as 0 +an 0 +effective 0 +and 0 +well 0 +tolerated 0 +regimen 0 +. 0 +From 0 +0ctober 0 +1993 0 +to 0 +November 0 +1995 0 +"," 0 +we 0 +treated 0 +13 0 +patients 0 +with 0 +previously 0 +chemotherapy 0 +- 0 +treated 0 +metastatic 0 +breast 3 +cancer 4 +by 0 +mitoxantrone 1 +"," 0 +12 0 +mg 0 +/ 0 +m2 0 +"," 0 +on 0 +day 0 +1 0 +and 0 +continuous 0 +infusion 0 +of 0 +5 1 +- 2 +FU 2 +"," 0 +3000 0 +mg 0 +/ 0 +m2 0 +"," 0 +together 0 +with 0 +leucovorin 1 +"," 0 +300 0 +mg 0 +/ 0 +m2 0 +"," 0 +for 0 +48 0 +h 0 +from 0 +day 0 +1 0 +to 0 +2 0 +. 0 +Each 0 +course 0 +of 0 +chemotherapy 0 +was 0 +given 0 +every 0 +4 0 +weeks 0 +. 0 +Most 0 +of 0 +these 0 +patients 0 +had 0 +more 0 +than 0 +two 0 +metastatic 0 +sites 0 +"," 0 +with 0 +lung 0 +metastasis 0 +predominant 0 +. 0 +Seven 0 +patients 0 +had 0 +been 0 +treated 0 +with 0 +anthracycline 1 +. 0 +Seven 0 +patients 0 +had 0 +previously 0 +received 0 +radiotherapy 0 +and 0 +seven 0 +had 0 +received 0 +hormone 0 +therapy 0 +. 0 +Median 0 +number 0 +of 0 +courses 0 +of 0 +MFL 1 +regimen 2 +given 0 +was 0 +six 0 +and 0 +the 0 +median 0 +cumulative 0 +dose 0 +of 0 +mitoxantrone 1 +was 0 +68 0 +. 0 +35 0 +mg 0 +/ 0 +m2 0 +. 0 +0ne 0 +patient 0 +had 0 +complete 0 +response 0 +"," 0 +seven 0 +had 0 +stable 0 +disease 0 +"," 0 +none 0 +had 0 +partial 0 +response 0 +and 0 +five 0 +had 0 +progressive 0 +disease 0 +. 0 +The 0 +overall 0 +objective 0 +response 0 +rate 0 +was 0 +7 0 +. 0 +6 0 +% 0 +. 0 +The 0 +median 0 +follow 0 +- 0 +up 0 +period 0 +was 0 +14 0 +months 0 +. 0 +Median 0 +survival 0 +was 0 +16 0 +months 0 +. 0 +Median 0 +progression 0 +- 0 +free 0 +survival 0 +was 0 +5 0 +months 0 +. 0 +A 0 +complete 0 +responder 0 +had 0 +relapse 0 +- 0 +free 0 +survival 0 +up 0 +to 0 +17 0 +months 0 +. 0 +Major 0 +toxicities 3 +were 0 +cardiotoxicity 3 +and 0 +leukopenia 3 +. 0 +Eight 0 +patients 0 +were 0 +dead 0 +in 0 +the 0 +last 0 +follow 0 +- 0 +up 0 +; 0 +two 0 +of 0 +them 0 +died 0 +of 0 +treatment 0 +- 0 +related 0 +toxicity 3 +. 0 +The 0 +MFL 1 +regimen 2 +achieves 0 +little 0 +palliative 0 +benefit 0 +and 0 +induces 0 +severe 0 +toxicity 3 +at 0 +a 0 +fairly 0 +high 0 +rate 0 +. 0 +Administration 0 +of 0 +this 0 +regimen 0 +to 0 +breast 3 +cancer 4 +patients 0 +who 0 +have 0 +been 0 +treated 0 +by 0 +chemotherapy 0 +and 0 +those 0 +with 0 +impaired 3 +heart 4 +function 4 +requires 0 +careful 0 +attention 0 +. 0 +Ticlopidine 1 +- 0 +induced 0 +aplastic 3 +anemia 4 +: 0 +report 0 +of 0 +three 0 +Chinese 0 +patients 0 +and 0 +review 0 +of 0 +the 0 +literature 0 +. 0 +In 0 +this 0 +study 0 +"," 0 +three 0 +Chinese 0 +patients 0 +with 0 +ticlopidine 1 +- 0 +induced 0 +aplastic 3 +anemia 4 +were 0 +reported 0 +and 0 +another 0 +13 0 +patients 0 +in 0 +the 0 +English 0 +literature 0 +were 0 +reviewed 0 +. 0 +We 0 +attempted 0 +to 0 +find 0 +underlying 0 +similarities 0 +"," 0 +evaluate 0 +the 0 +risk 0 +factors 0 +"," 0 +and 0 +identify 0 +appropriate 0 +treatment 0 +for 0 +this 0 +complication 0 +. 0 +All 0 +but 0 +one 0 +of 0 +the 0 +patients 0 +were 0 +over 0 +60 0 +years 0 +old 0 +"," 0 +and 0 +the 0 +6 0 +who 0 +died 0 +were 0 +all 0 +older 0 +than 0 +65 0 +. 0 +Therefore 0 +"," 0 +old 0 +age 0 +may 0 +be 0 +a 0 +risk 0 +factor 0 +for 0 +developing 0 +this 0 +complication 0 +. 0 +Agranulocytosis 3 +occurred 0 +3 0 +- 0 +20 0 +weeks 0 +after 0 +initiation 0 +of 0 +ticlopidine 1 +"," 0 +so 0 +frequent 0 +examination 0 +of 0 +white 0 +cell 0 +count 0 +during 0 +treatment 0 +is 0 +recommended 0 +. 0 +There 0 +seemed 0 +to 0 +be 0 +no 0 +direct 0 +correlation 0 +between 0 +the 0 +dose 0 +or 0 +duration 0 +used 0 +and 0 +the 0 +severity 0 +of 0 +bone 3 +marrow 4 +suppression 4 +. 0 +Treatment 0 +for 0 +ticlopidine 1 +- 0 +induced 0 +aplastic 3 +anemia 4 +with 0 +colony 0 +- 0 +stimulating 0 +factors 0 +seemed 0 +to 0 +have 0 +little 0 +effect 0 +. 0 +The 0 +fact 0 +that 0 +5 0 +of 0 +the 0 +6 0 +patients 0 +who 0 +received 0 +concurrent 0 +calcium 1 +channel 0 +blockers 0 +died 0 +"," 0 +should 0 +alert 0 +clinicians 0 +to 0 +be 0 +more 0 +cautious 0 +when 0 +using 0 +these 0 +two 0 +drugs 0 +simultaneously 0 +. 0 +Upregulation 0 +of 0 +the 0 +expression 0 +of 0 +vasopressin 1 +gene 0 +in 0 +the 0 +paraventricular 0 +and 0 +supraoptic 0 +nuclei 0 +of 0 +the 0 +lithium 1 +- 0 +induced 0 +diabetes 3 +insipidus 4 +rat 0 +. 0 +The 0 +expression 0 +of 0 +arginine 1 +vasopressin 2 +( 0 +AVP 1 +) 0 +gene 0 +in 0 +the 0 +paraventricular 0 +( 0 +PVN 0 +) 0 +and 0 +supraoptic 0 +nuclei 0 +( 0 +S0N 0 +) 0 +was 0 +investigated 0 +in 0 +rats 0 +with 0 +lithium 1 +( 0 +Li 1 +) 0 +- 0 +induced 0 +polyuria 3 +"," 0 +using 0 +in 0 +situ 0 +hybridization 0 +histochemistry 0 +and 0 +radioimmunoassay 0 +. 0 +The 0 +male 0 +Wistar 0 +rats 0 +consuming 0 +a 0 +diet 0 +that 0 +contained 0 +LiCl 1 +( 0 +60 0 +mmol 0 +/ 0 +kg 0 +) 0 +for 0 +4 0 +weeks 0 +developed 0 +marked 0 +polyuria 3 +. 0 +The 0 +Li 1 +- 0 +treated 0 +rats 0 +produced 0 +a 0 +large 0 +volume 0 +of 0 +hypotonic 0 +urine 0 +with 0 +low 0 +ionic 0 +concentrations 0 +. 0 +Plasma 0 +sodium 1 +concentrations 0 +were 0 +found 0 +to 0 +be 0 +slightly 0 +increased 0 +in 0 +the 0 +Li 1 +- 0 +treated 0 +rats 0 +compared 0 +with 0 +those 0 +in 0 +controls 0 +. 0 +Plasma 0 +concentration 0 +of 0 +AVP 1 +and 0 +transcripts 0 +of 0 +AVP 1 +gene 0 +in 0 +the 0 +PVN 0 +and 0 +S0N 0 +were 0 +significantly 0 +increased 0 +in 0 +the 0 +Li 1 +- 0 +treated 0 +rats 0 +compared 0 +with 0 +controls 0 +. 0 +These 0 +results 0 +suggest 0 +that 0 +dehydration 3 +and 0 +/ 0 +or 0 +the 0 +activation 0 +of 0 +visceral 0 +afferent 0 +inputs 0 +may 0 +contribute 0 +to 0 +the 0 +elevation 0 +of 0 +plasma 0 +AVP 1 +and 0 +the 0 +upregulation 0 +of 0 +AVP 1 +gene 0 +expression 0 +in 0 +the 0 +PVN 0 +and 0 +the 0 +S0N 0 +of 0 +the 0 +Li 1 +- 0 +induced 0 +diabetes 3 +insipidus 4 +rat 0 +. 0 +Antinociceptive 0 +and 0 +antiamnesic 0 +properties 0 +of 0 +the 0 +presynaptic 0 +cholinergic 0 +amplifier 0 +PG 1 +- 2 +9 2 +. 0 +The 0 +antinociceptive 0 +effect 0 +of 0 +3 1 +alpha 2 +- 2 +tropyl 2 +2 2 +- 2 +( 2 +p 2 +- 2 +bromophenyl 2 +) 2 +propionate 2 +[ 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +] 0 +( 0 +10 0 +- 0 +40 0 +mg 0 +kg 0 +- 0 +1 0 +s 0 +. 0 +c 0 +. 0 +; 0 +30 0 +- 0 +60 0 +mg 0 +kg 0 +- 0 +1 0 +p 0 +. 0 +o 0 +. 0 +; 0 +10 0 +- 0 +30 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +v 0 +. 0 +; 0 +10 0 +- 0 +30 0 +micrograms 0 +/ 0 +mouse 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +was 0 +examined 0 +in 0 +mice 0 +"," 0 +rats 0 +and 0 +guinea 0 +pigs 0 +by 0 +use 0 +of 0 +the 0 +hot 0 +- 0 +plate 0 +"," 0 +abdominal 0 +- 0 +constriction 0 +"," 0 +tail 0 +- 0 +flick 0 +and 0 +paw 0 +- 0 +pressure 0 +tests 0 +. 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +antinociception 0 +peaked 0 +15 0 +min 0 +after 0 +injection 0 +and 0 +then 0 +slowly 0 +diminished 0 +. 0 +The 0 +antinociception 0 +produced 0 +by 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +was 0 +prevented 0 +by 0 +the 0 +unselective 0 +muscarinic 0 +antagonist 0 +atropine 1 +"," 0 +the 0 +M1 0 +- 0 +selective 0 +antagonists 0 +pirenzepine 1 +and 0 +dicyclomine 1 +and 0 +the 0 +acetylcholine 1 +depletor 0 +hemicholinium 1 +- 2 +3 2 +"," 0 +but 0 +not 0 +by 0 +the 0 +opioid 0 +antagonist 0 +naloxone 1 +"," 0 +the 0 +gamma 1 +- 2 +aminobutyric 2 +acidB 2 +antagonist 0 +3 1 +- 2 +aminopropyl 2 +- 2 +diethoxy 2 +- 2 +methyl 2 +- 2 +phosphinic 2 +acid 2 +"," 0 +the 0 +H3 0 +agonist 0 +R 1 +- 2 +( 2 +alpha 2 +) 2 +- 2 +methylhistamine 2 +"," 0 +the 0 +D2 0 +antagonist 0 +quinpirole 1 +"," 0 +the 0 +5 1 +- 2 +hydroxytryptamine4 2 +antagonist 0 +2 1 +- 2 +methoxy 2 +- 2 +4 2 +- 2 +amino 2 +- 2 +5 2 +- 2 +chlorobenzoic 2 +acid 2 +2 2 +- 2 +( 2 +diethylamino 2 +) 2 +ethyl 2 +ester 2 +hydrochloride 0 +"," 0 +the 0 +5 1 +- 2 +hydroxytryptamin1A 2 +antagonist 0 +1 1 +- 2 +( 2 +2 2 +- 2 +methoxyphenyl 2 +) 2 +- 2 +4 2 +- 2 +[ 2 +4 2 +- 2 +( 2 +2 2 +- 2 +phthalimido 2 +) 2 +butyl 2 +] 2 +piperazine 2 +hydrobromide 0 +and 0 +the 0 +polyamines 0 +depletor 0 +reserpine 1 +. 0 +Based 0 +on 0 +these 0 +data 0 +"," 0 +it 0 +can 0 +be 0 +postulated 0 +that 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +exerted 0 +an 0 +antinociceptive 0 +effect 0 +mediated 0 +by 0 +a 0 +central 0 +potentiation 0 +of 0 +cholinergic 0 +transmission 0 +. 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +( 0 +10 0 +- 0 +40 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +) 0 +was 0 +able 0 +to 0 +prevent 0 +amnesia 3 +induced 0 +by 0 +scopolamine 1 +( 0 +1 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +) 0 +and 0 +dicyclomine 1 +( 0 +2 0 +mg 0 +kg 0 +- 0 +1 0 +i 0 +. 0 +p 0 +. 0 +) 0 +in 0 +the 0 +mouse 0 +passive 0 +- 0 +avoidance 0 +test 0 +. 0 +Affinity 0 +profiles 0 +of 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +for 0 +muscarinic 0 +receptor 0 +subtypes 0 +"," 0 +determined 0 +by 0 +functional 0 +studies 0 +( 0 +rabbit 0 +vas 0 +deferens 0 +for 0 +M1 0 +"," 0 +guinea 0 +pig 0 +atrium 0 +for 0 +M2 0 +"," 0 +guinea 0 +pig 0 +ileum 0 +for 0 +M3 0 +and 0 +immature 0 +guinea 0 +pig 0 +uterus 0 +for 0 +putative 0 +M4 0 +) 0 +"," 0 +have 0 +shown 0 +an 0 +M4 0 +/ 0 +M1 0 +selectivity 0 +ratio 0 +of 0 +10 0 +. 0 +2 0 +that 0 +might 0 +be 0 +responsible 0 +for 0 +the 0 +antinociception 0 +and 0 +the 0 +anti 0 +- 0 +amnesic 3 +effect 0 +induced 0 +by 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +through 0 +an 0 +increase 0 +in 0 +acetylcholine 1 +extracellular 0 +levels 0 +. 0 +In 0 +the 0 +antinociceptive 0 +and 0 +antiamnesic 0 +dose 0 +range 0 +"," 0 +( 0 ++ 0 +/ 0 +- 0 +) 0 +- 0 +PG 1 +- 2 +9 2 +did 0 +not 0 +impair 0 +mouse 0 +performance 0 +evaluated 0 +by 0 +the 0 +rota 0 +- 0 +rod 0 +test 0 +and 0 +Animex 0 +apparatus 0 +. 0 +The 0 +effect 0 +of 0 +different 0 +anaesthetic 0 +agents 0 +in 0 +hearing 3 +loss 4 +following 0 +spinal 0 +anaesthesia 0 +. 0 +The 0 +cause 0 +of 0 +hearing 3 +loss 4 +after 0 +spinal 0 +anaesthesia 0 +is 0 +unknown 0 +. 0 +Up 0 +until 0 +now 0 +"," 0 +the 0 +only 0 +factor 0 +studied 0 +has 0 +been 0 +the 0 +effect 0 +of 0 +the 0 +diameter 0 +of 0 +the 0 +spinal 0 +needle 0 +on 0 +post 0 +- 0 +operative 0 +sensorineural 3 +hearing 4 +loss 4 +. 0 +The 0 +aim 0 +of 0 +this 0 +study 0 +was 0 +to 0 +describe 0 +this 0 +hearing 3 +loss 4 +and 0 +to 0 +investigate 0 +other 0 +factors 0 +influencing 0 +the 0 +degree 0 +of 0 +hearing 3 +loss 4 +. 0 +Two 0 +groups 0 +of 0 +22 0 +similar 0 +patients 0 +were 0 +studied 0 +: 0 +one 0 +group 0 +received 0 +6 0 +mL 0 +prilocaine 1 +2 0 +% 0 +; 0 +and 0 +the 0 +other 0 +received 0 +3 0 +mL 0 +bupivacaine 1 +0 0 +. 0 +5 0 +% 0 +. 0 +Patients 0 +given 0 +prilocaine 1 +were 0 +more 0 +likely 0 +to 0 +develop 0 +hearing 3 +loss 4 +( 0 +10 0 +out 0 +of 0 +22 0 +) 0 +than 0 +those 0 +given 0 +bupivacaine 1 +( 0 +4 0 +out 0 +of 0 +22 0 +) 0 +( 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +The 0 +average 0 +hearing 3 +loss 4 +for 0 +speech 0 +frequencies 0 +was 0 +about 0 +10 0 +dB 0 +after 0 +prilocaine 1 +and 0 +15 0 +dB 0 +after 0 +bupivacaine 1 +. 0 +None 0 +of 0 +the 0 +patients 0 +complained 0 +of 0 +subjective 0 +hearing 3 +loss 4 +. 0 +Long 0 +- 0 +term 0 +follow 0 +- 0 +up 0 +of 0 +the 0 +patients 0 +was 0 +not 0 +possible 0 +. 0 +A 0 +transient 0 +neurological 3 +deficit 4 +following 0 +intrathecal 0 +injection 0 +of 0 +1 0 +% 0 +hyperbaric 0 +bupivacaine 1 +for 0 +unilateral 0 +spinal 0 +anaesthesia 0 +. 0 +We 0 +describe 0 +a 0 +case 0 +of 0 +transient 0 +neurological 3 +deficit 4 +that 0 +occurred 0 +after 0 +unilateral 0 +spinal 0 +anaesthesia 0 +with 0 +8 0 +mg 0 +of 0 +1 0 +% 0 +hyperbaric 0 +bupivacaine 1 +slowly 0 +injected 0 +through 0 +a 0 +25 0 +- 0 +gauge 0 +pencil 0 +- 0 +point 0 +spinal 0 +needle 0 +. 0 +The 0 +surgery 0 +and 0 +anaesthesia 0 +were 0 +uneventful 0 +"," 0 +but 0 +3 0 +days 0 +after 0 +surgery 0 +"," 0 +the 0 +patient 0 +reported 0 +an 0 +area 0 +of 0 +hypoaesthesia 0 +over 0 +L3 0 +- 0 +L4 0 +dermatomes 0 +of 0 +the 0 +leg 0 +which 0 +had 0 +been 0 +operated 0 +on 0 +( 0 +loss 3 +of 4 +pinprick 4 +sensation 4 +) 0 +without 0 +reduction 0 +in 0 +muscular 0 +strength 0 +. 0 +Sensation 0 +in 0 +this 0 +area 0 +returned 0 +to 0 +normal 0 +over 0 +the 0 +following 0 +2 0 +weeks 0 +. 0 +Prospective 0 +multicentre 0 +studies 0 +with 0 +a 0 +large 0 +population 0 +and 0 +a 0 +long 0 +follow 0 +- 0 +up 0 +should 0 +be 0 +performed 0 +in 0 +order 0 +to 0 +evaluate 0 +the 0 +incidence 0 +of 0 +this 0 +unusual 0 +side 0 +effect 0 +. 0 +However 0 +"," 0 +we 0 +suggest 0 +that 0 +a 0 +low 0 +solution 0 +concentration 0 +should 0 +be 0 +preferred 0 +for 0 +unilateral 0 +spinal 0 +anaesthesia 0 +with 0 +a 0 +hyperbaric 0 +anaesthetic 0 +solution 0 +( 0 +if 0 +pencil 0 +- 0 +point 0 +needle 0 +and 0 +slow 0 +injection 0 +rate 0 +are 0 +employed 0 +) 0 +"," 0 +in 0 +order 0 +to 0 +minimize 0 +the 0 +risk 0 +of 0 +a 0 +localized 0 +high 0 +peak 0 +anaesthetic 0 +concentration 0 +"," 0 +which 0 +might 0 +lead 0 +to 0 +a 0 +transient 0 +neurological 3 +deficit 4 +. 0 +Transient 3 +neurologic 4 +symptoms 4 +after 0 +spinal 0 +anesthesia 0 +: 0 +a 0 +lower 0 +incidence 0 +with 0 +prilocaine 1 +and 0 +bupivacaine 1 +than 0 +with 0 +lidocaine 1 +. 0 +BACKGR0UND 0 +: 0 +Recent 0 +evidence 0 +suggests 0 +that 0 +transient 3 +neurologic 4 +symptoms 4 +( 0 +TNSs 3 +) 0 +frequently 0 +follow 0 +lidocaine 1 +spinal 0 +anesthesia 0 +but 0 +are 0 +infrequent 0 +with 0 +bupivacaine 1 +. 0 +However 0 +"," 0 +identification 0 +of 0 +a 0 +short 0 +- 0 +acting 0 +local 0 +anesthetic 0 +to 0 +substitute 0 +for 0 +lidocaine 1 +for 0 +brief 0 +surgical 0 +procedures 0 +remains 0 +an 0 +important 0 +goal 0 +. 0 +Prilocaine 1 +is 0 +an 0 +amide 0 +local 0 +anesthetic 0 +with 0 +a 0 +duration 0 +of 0 +action 0 +similar 0 +to 0 +that 0 +of 0 +lidocaine 1 +. 0 +Accordingly 0 +"," 0 +the 0 +present 0 +"," 0 +prospective 0 +double 0 +- 0 +blind 0 +study 0 +compares 0 +prilocaine 1 +with 0 +lidocaine 1 +and 0 +bupivacaine 1 +with 0 +respect 0 +to 0 +duration 0 +of 0 +action 0 +and 0 +relative 0 +risk 0 +of 0 +TNSs 3 +. 0 +METH0DS 0 +: 0 +Ninety 0 +patients 0 +classified 0 +as 0 +American 0 +Society 0 +of 0 +Anesthesiologists 0 +physical 0 +status 0 +I 0 +or 0 +II 0 +who 0 +were 0 +scheduled 0 +for 0 +short 0 +gynecologic 0 +procedures 0 +under 0 +spinal 0 +anesthesia 0 +were 0 +randomly 0 +allocated 0 +to 0 +receive 0 +2 0 +. 0 +5 0 +ml 0 +2 0 +% 0 +lidocaine 1 +in 0 +7 0 +. 0 +5 0 +% 0 +glucose 1 +"," 0 +2 0 +% 0 +prilocaine 1 +in 0 +7 0 +. 0 +5 0 +% 0 +glucose 1 +"," 0 +or 0 +0 0 +. 0 +5 0 +% 0 +bupivacaine 1 +in 0 +7 0 +. 0 +5 0 +% 0 +glucose 1 +. 0 +All 0 +solutions 0 +were 0 +provided 0 +in 0 +blinded 0 +vials 0 +by 0 +the 0 +hospital 0 +pharmacy 0 +. 0 +Details 0 +of 0 +spinal 0 +puncture 0 +"," 0 +extension 0 +and 0 +regression 0 +of 0 +spinal 0 +block 0 +"," 0 +and 0 +the 0 +times 0 +to 0 +reach 0 +discharge 0 +criteria 0 +were 0 +noted 0 +. 0 +In 0 +the 0 +evening 0 +of 0 +postoperative 0 +day 0 +1 0 +"," 0 +patients 0 +were 0 +evaluated 0 +for 0 +TNSs 3 +by 0 +a 0 +physician 0 +unaware 0 +of 0 +the 0 +drug 0 +administered 0 +and 0 +the 0 +details 0 +of 0 +the 0 +anesthetic 0 +procedure 0 +. 0 +RESULTS 0 +: 0 +Nine 0 +of 0 +30 0 +patients 0 +receiving 0 +lidocaine 1 +experienced 0 +TNSs 3 +"," 0 +1 0 +of 0 +30 0 +patients 0 +receiving 0 +prilocaine 1 +( 0 +P 0 += 0 +0 0 +. 0 +3 0 +) 0 +had 0 +them 0 +"," 0 +and 0 +none 0 +of 0 +30 0 +patients 0 +receiving 0 +bupivacaine 1 +had 0 +TNSs 3 +. 0 +Times 0 +to 0 +ambulate 0 +and 0 +to 0 +void 0 +were 0 +similar 0 +after 0 +lidocaine 1 +and 0 +prilocaine 1 +( 0 +150 0 +vs 0 +. 0 +165 0 +min 0 +and 0 +238 0 +vs 0 +. 0 +253 0 +min 0 +"," 0 +respectively 0 +) 0 +but 0 +prolonged 0 +after 0 +bupivacaine 1 +( 0 +200 0 +and 0 +299 0 +min 0 +"," 0 +respectively 0 +; 0 +P 0 +< 0 +0 0 +. 0 +5 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +Prilocaine 1 +may 0 +be 0 +preferable 0 +to 0 +lidocaine 1 +for 0 +short 0 +surgical 0 +procedures 0 +because 0 +it 0 +has 0 +a 0 +similar 0 +duration 0 +of 0 +action 0 +but 0 +a 0 +lower 0 +incidence 0 +of 0 +TNSs 3 +. 0 +Suxamethonium 1 +- 0 +induced 0 +cardiac 3 +arrest 4 +and 0 +death 3 +following 0 +5 0 +days 0 +of 0 +immobilization 0 +. 0 +The 0 +present 0 +report 0 +describes 0 +a 0 +case 0 +of 0 +cardiac 3 +arrest 4 +and 0 +subsequent 0 +death 3 +as 0 +a 0 +result 0 +of 0 +hyperkalaemia 3 +following 0 +the 0 +use 0 +of 0 +suxamethonium 1 +in 0 +a 0 +23 0 +- 0 +year 0 +- 0 +old 0 +Malawian 0 +woman 0 +. 0 +Five 0 +days 0 +after 0 +the 0 +onset 0 +of 0 +the 0 +symptoms 0 +of 0 +meningitis 3 +"," 0 +the 0 +patient 0 +aspirated 0 +stomach 0 +contents 0 +and 0 +needed 0 +endotracheal 0 +intubation 0 +. 0 +Forty 0 +seconds 0 +after 0 +injection 0 +of 0 +suxamethonium 1 +"," 0 +bradycardia 3 +and 0 +cardiac 3 +arrest 4 +occurred 0 +. 0 +Attempts 0 +to 0 +resuscitate 0 +the 0 +patient 0 +were 0 +not 0 +successful 0 +. 0 +The 0 +serum 0 +level 0 +of 0 +potassium 1 +was 0 +observed 0 +to 0 +be 0 +8 0 +. 0 +4 0 +mequiv 0 +L 0 +- 0 +1 0 +. 0 +Apart 0 +from 0 +the 0 +reduction 0 +in 0 +the 0 +patient 0 +' 0 +s 0 +level 0 +of 0 +consciousness 0 +"," 0 +there 0 +were 0 +no 0 +signs 0 +of 0 +motor 0 +neurone 0 +damage 0 +or 0 +of 0 +any 0 +of 0 +the 0 +other 0 +known 0 +predisposing 0 +conditions 0 +for 0 +hyperkalaemia 3 +following 0 +the 0 +administration 0 +of 0 +suxamethonium 1 +. 0 +It 0 +is 0 +postulated 0 +that 0 +her 0 +death 3 +was 0 +caused 0 +by 0 +hypersensitivity 3 +to 0 +suxamethonium 1 +"," 0 +associated 0 +with 0 +her 0 +5 0 +- 0 +day 0 +immobilization 0 +. 0 +Acute 0 +hepatitis 3 +"," 0 +autoimmune 3 +hemolytic 4 +anemia 4 +"," 0 +and 0 +erythroblastocytopenia 3 +induced 0 +by 0 +ceftriaxone 1 +. 0 +An 0 +80 0 +- 0 +yr 0 +- 0 +old 0 +man 0 +developed 0 +acute 0 +hepatitis 3 +shortly 0 +after 0 +ingesting 0 +oral 0 +ceftriaxone 1 +. 0 +Although 0 +the 0 +transaminases 0 +gradually 0 +returned 0 +to 0 +baseline 0 +after 0 +withholding 0 +the 0 +beta 1 +lactam 2 +antibiotic 0 +"," 0 +there 0 +was 0 +a 0 +gradual 0 +increase 0 +in 0 +serum 0 +bilirubin 1 +and 0 +a 0 +decrease 0 +in 0 +hemoglobin 0 +concentration 0 +caused 0 +by 0 +an 0 +autoimmune 3 +hemolytic 4 +anemia 4 +and 0 +erythroblastocytopenia 3 +. 0 +These 0 +responded 0 +to 0 +systemic 0 +steroids 1 +and 0 +immunoglobulins 0 +. 0 +Despite 0 +the 0 +widespread 0 +use 0 +of 0 +these 0 +agents 0 +this 0 +triad 0 +of 0 +side 0 +effects 0 +has 0 +not 0 +previously 0 +been 0 +reported 0 +in 0 +connection 0 +with 0 +beta 1 +lactam 2 +antibiotics 0 +. 0 +Thyroxine 1 +abuse 0 +: 0 +an 0 +unusual 0 +case 0 +of 0 +thyrotoxicosis 3 +in 0 +pregnancy 0 +. 0 +Eating 3 +disorders 4 +and 0 +the 0 +associated 0 +behavioural 0 +problems 0 +and 0 +drug 3 +abuse 4 +are 0 +uncommon 0 +in 0 +pregnancy 0 +. 0 +When 0 +they 0 +do 0 +occur 0 +they 0 +are 0 +often 0 +unrecognized 0 +because 0 +of 0 +denial 0 +but 0 +when 0 +significant 0 +may 0 +pose 0 +a 0 +risk 0 +to 0 +both 0 +the 0 +mother 0 +and 0 +her 0 +fetus 0 +. 0 +This 0 +case 0 +illustrates 0 +a 0 +number 0 +of 0 +problems 0 +that 0 +may 0 +be 0 +encountered 0 +in 0 +women 0 +with 0 +eating 3 +disorders 4 +in 0 +pregnancy 0 +"," 0 +including 0 +prolonged 0 +and 0 +recurrent 0 +metabolic 0 +disturbances 0 +and 0 +diuretic 0 +abuse 0 +. 0 +In 0 +particular 0 +it 0 +illustrates 0 +the 0 +derangements 0 +of 0 +thyroid 0 +function 0 +seen 0 +in 0 +pregnant 0 +women 0 +with 0 +eating 3 +disorders 4 +and 0 +reminds 0 +us 0 +that 0 +when 0 +a 0 +cause 0 +for 0 +thyrotoxicosis 3 +remains 0 +obscure 0 +"," 0 +thyroxine 1 +abuse 0 +should 0 +be 0 +considered 0 +and 0 +explored 0 +. 0 +Repeated 0 +trimipramine 1 +induces 0 +dopamine 1 +D2 0 +/ 0 +D3 0 +and 0 +alpha1 0 +- 0 +adrenergic 0 +up 0 +- 0 +regulation 0 +. 0 +Trimipramine 1 +( 0 +TRI 1 +) 0 +"," 0 +which 0 +shows 0 +a 0 +clinical 0 +antidepressant 1 +activity 0 +"," 0 +is 0 +chemically 0 +related 0 +to 0 +imipramine 1 +but 0 +does 0 +not 0 +inhibit 0 +the 0 +reuptake 0 +of 0 +noradrenaline 1 +and 0 +5 1 +- 2 +hydroxytryptamine 2 +"," 0 +nor 0 +does 0 +it 0 +induce 0 +beta 0 +- 0 +adrenergic 0 +down 0 +- 0 +regulation 0 +. 0 +The 0 +mechanism 0 +of 0 +its 0 +antidepressant 1 +activity 0 +is 0 +still 0 +unknown 0 +. 0 +The 0 +aim 0 +of 0 +the 0 +present 0 +study 0 +was 0 +to 0 +find 0 +out 0 +whether 0 +TRI 1 +given 0 +repeatedly 0 +was 0 +able 0 +to 0 +induce 0 +adaptive 0 +changes 0 +in 0 +the 0 +dopaminergic 0 +and 0 +alpha1 0 +- 0 +adrenergic 0 +systems 0 +"," 0 +demonstrated 0 +by 0 +us 0 +previously 0 +for 0 +various 0 +antidepressants 1 +. 0 +TRI 1 +was 0 +given 0 +to 0 +male 0 +Wistar 0 +rats 0 +and 0 +male 0 +Albino 0 +Swiss 0 +mice 0 +perorally 0 +twice 0 +daily 0 +for 0 +14 0 +days 0 +. 0 +In 0 +the 0 +acute 0 +experiment 0 +TRI 1 +( 0 +given 0 +i 0 +. 0 +p 0 +. 0 +) 0 +does 0 +not 0 +antagonize 0 +the 0 +reserpine 1 +hypothermia 3 +in 0 +mice 0 +and 0 +does 0 +not 0 +potentiate 0 +the 0 +5 1 +- 2 +hydroxytryptophan 2 +head 0 +twitches 0 +in 0 +rats 0 +. 0 +TRI 1 +given 0 +repeatedly 0 +to 0 +rats 0 +increases 0 +the 0 +locomotor 0 +hyperactivity 3 +induced 0 +by 0 +d 1 +- 2 +amphetamine 2 +"," 0 +quinpirole 1 +and 0 +( 0 ++ 0 +) 0 +- 0 +7 0 +- 0 +hydroxy 0 +- 0 +dipropyloaminotetralin 0 +( 0 +dopamine 1 +D2 0 +and 0 +D3 0 +effects 0 +) 0 +. 0 +The 0 +stereotypies 0 +induced 0 +by 0 +d 1 +- 2 +amphetamine 2 +or 0 +apomorphine 1 +are 0 +not 0 +potentiated 0 +by 0 +TRI 1 +. 0 +It 0 +increases 0 +the 0 +behaviour 0 +stimulation 0 +evoked 0 +by 0 +phenylephrine 1 +( 0 +given 0 +intraventricularly 0 +) 0 +in 0 +rats 0 +"," 0 +evaluated 0 +in 0 +the 0 +open 0 +field 0 +test 0 +as 0 +well 0 +as 0 +the 0 +aggressiveness 3 +evoked 0 +by 0 +clonidine 1 +in 0 +mice 0 +"," 0 +both 0 +these 0 +effects 0 +being 0 +mediated 0 +by 0 +an 0 +alpha1 0 +- 0 +adrenergic 0 +receptor 0 +. 0 +It 0 +may 0 +be 0 +concluded 0 +that 0 +"," 0 +like 0 +other 0 +tricyclic 0 +antidepressants 1 +studied 0 +previously 0 +"," 0 +TRI 1 +given 0 +repeatedly 0 +increases 0 +the 0 +responsiveness 0 +of 0 +brain 0 +dopamine 1 +D2 0 +and 0 +D3 0 +( 0 +locomotor 0 +activity 0 +but 0 +not 0 +stereotypy 0 +) 0 +as 0 +well 0 +as 0 +alpha1 0 +- 0 +adrenergic 0 +receptors 0 +to 0 +their 0 +agonists 0 +. 0 +A 0 +question 0 +arises 0 +whether 0 +the 0 +reuptake 0 +inhibition 0 +is 0 +of 0 +any 0 +importance 0 +to 0 +the 0 +adaptive 0 +changes 0 +induced 0 +by 0 +repeated 0 +antidepressants 1 +"," 0 +suggested 0 +to 0 +be 0 +responsible 0 +for 0 +the 0 +antidepressant 1 +activity 0 +. 0 +Pethidine 1 +- 0 +associated 0 +seizure 3 +in 0 +a 0 +healthy 0 +adolescent 0 +receiving 0 +pethidine 1 +for 0 +postoperative 3 +pain 4 +control 0 +. 0 +A 0 +healthy 0 +17 0 +- 0 +year 0 +- 0 +old 0 +male 0 +received 0 +standard 0 +intermittent 0 +doses 0 +of 0 +pethidine 1 +via 0 +a 0 +patient 0 +- 0 +controlled 0 +analgesia 0 +( 0 +PCA 0 +) 0 +pump 0 +for 0 +management 0 +of 0 +postoperative 3 +pain 4 +control 0 +. 0 +Twenty 0 +- 0 +three 0 +h 0 +postoperatively 0 +he 0 +developed 0 +a 0 +brief 0 +self 0 +- 0 +limited 0 +seizure 3 +. 0 +Both 0 +plasma 0 +pethidine 1 +and 0 +norpethidine 1 +were 0 +elevated 0 +in 0 +the 0 +range 0 +associated 0 +with 0 +clinical 0 +manifestations 0 +of 0 +central 0 +nervous 0 +system 0 +excitation 0 +. 0 +No 0 +other 0 +risk 0 +factors 0 +for 0 +CNS 0 +toxicity 3 +were 0 +identified 0 +. 0 +This 0 +method 0 +allowed 0 +frequent 0 +self 0 +- 0 +dosing 0 +of 0 +pethidine 1 +at 0 +short 0 +time 0 +intervals 0 +and 0 +rapid 0 +accumulation 0 +of 0 +pethidine 1 +and 0 +norpethidine 1 +. 0 +The 0 +routine 0 +use 0 +of 0 +pethidine 1 +via 0 +PCA 0 +even 0 +for 0 +a 0 +brief 0 +postoperative 0 +analgesia 0 +should 0 +be 0 +reconsidered 0 +. 0 +An 0 +unusual 0 +toxic 0 +reaction 0 +to 0 +axillary 0 +block 0 +by 0 +mepivacaine 1 +with 0 +adrenaline 1 +. 0 +An 0 +increase 3 +in 4 +blood 4 +pressure 4 +"," 0 +accompanied 0 +by 0 +atrial 3 +fibrillation 4 +"," 0 +agitation 3 +"," 0 +incomprehensible 3 +shouts 4 +and 0 +loss 3 +of 4 +consciousness 4 +"," 0 +was 0 +observed 0 +in 0 +an 0 +elderly 0 +"," 0 +ASA 0 +classification 0 +group 0 +II 0 +"," 0 +cardiovascularly 0 +medicated 0 +male 0 +"," 0 +12 0 +min 0 +after 0 +performance 0 +of 0 +axillary 0 +block 0 +with 0 +mepivacaine 1 +850 0 +mg 0 +containing 0 +adrenaline 1 +0 0 +. 0 +225 0 +mg 0 +"," 0 +for 0 +correction 0 +of 0 +Dupuytren 3 +' 4 +s 4 +contracture 4 +. 0 +After 0 +intravenous 0 +administration 0 +of 0 +labetalol 1 +"," 0 +metoprolol 1 +and 0 +midazolam 1 +the 0 +patient 0 +' 0 +s 0 +condition 0 +improved 0 +"," 0 +and 0 +15 0 +min 0 +later 0 +he 0 +woke 0 +up 0 +. 0 +The 0 +block 0 +was 0 +successful 0 +and 0 +surgery 0 +was 0 +conducted 0 +as 0 +scheduled 0 +despite 0 +persisting 0 +atrial 3 +fibrillation 4 +. 0 +Postoperatively 0 +"," 0 +the 0 +patient 0 +refused 0 +DC 0 +cardioversion 0 +and 0 +was 0 +treated 0 +medically 0 +. 0 +Both 0 +the 0 +temporal 0 +relationship 0 +of 0 +events 0 +and 0 +the 0 +response 0 +to 0 +treatment 0 +suggest 0 +that 0 +a 0 +rapid 0 +systemic 0 +absorption 0 +of 0 +mepivacaine 1 +with 0 +adrenaline 1 +and 0 +/ 0 +or 0 +interaction 0 +of 0 +these 0 +drugs 0 +with 0 +the 0 +patient 0 +' 0 +s 0 +cardiovascular 0 +medications 0 +were 0 +responsible 0 +for 0 +the 0 +perioperative 0 +complications 0 +. 0 +Drug 0 +- 0 +associated 0 +acute 0 +- 0 +onset 0 +vanishing 3 +bile 4 +duct 4 +and 0 +Stevens 3 +- 4 +Johnson 4 +syndromes 4 +in 0 +a 0 +child 0 +. 0 +Acute 0 +vanishing 3 +bile 4 +duct 4 +syndrome 0 +is 0 +a 0 +rare 0 +but 0 +established 0 +cause 0 +of 0 +progressive 0 +cholestasis 3 +in 0 +adults 0 +"," 0 +is 0 +most 0 +often 0 +drug 0 +or 0 +toxin 0 +related 0 +"," 0 +and 0 +is 0 +of 0 +unknown 0 +pathogenesis 0 +. 0 +It 0 +has 0 +not 0 +been 0 +reported 0 +previously 0 +in 0 +children 0 +. 0 +Stevens 3 +- 4 +Johnson 4 +syndrome 4 +is 0 +a 0 +well 0 +- 0 +recognized 0 +immune 0 +complex 0 +- 0 +mediated 0 +hypersensitivity 3 +reaction 0 +that 0 +affects 0 +all 0 +age 0 +groups 0 +"," 0 +is 0 +drug 0 +or 0 +infection 3 +induced 0 +"," 0 +and 0 +has 0 +classic 0 +systemic 0 +"," 0 +mucosal 0 +"," 0 +and 0 +dermatologic 0 +manifestations 0 +. 0 +A 0 +previously 0 +healthy 0 +child 0 +who 0 +developed 0 +acute 0 +"," 0 +severe 0 +"," 0 +rapidly 0 +progressive 0 +vanishing 3 +bile 4 +duct 4 +syndrome 4 +shortly 0 +after 0 +Stevens 3 +- 4 +Johnson 4 +syndrome 4 +is 0 +described 0 +; 0 +this 0 +was 0 +temporally 0 +associated 0 +with 0 +ibuprofen 1 +use 0 +. 0 +Despite 0 +therapy 0 +with 0 +ursodeoxycholic 1 +acid 2 +"," 0 +prednisone 1 +"," 0 +and 0 +then 0 +tacrolimus 1 +"," 0 +her 0 +cholestatic 3 +disease 4 +was 0 +unrelenting 0 +"," 0 +with 0 +cirrhosis 3 +shown 0 +by 0 +biopsy 0 +6 0 +months 0 +after 0 +presentation 0 +. 0 +This 0 +case 0 +documents 0 +acute 0 +drug 0 +- 0 +related 0 +vanishing 3 +bile 4 +duct 4 +syndrome 4 +in 0 +the 0 +pediatric 0 +age 0 +group 0 +and 0 +suggests 0 +shared 0 +immune 0 +mechanisms 0 +in 0 +the 0 +pathogenesis 0 +of 0 +both 0 +Stevens 3 +- 4 +Johnson 4 +syndrome 4 +and 0 +vanishing 3 +bile 4 +duct 4 +syndrome 4 +. 0 +High 0 +incidence 0 +of 0 +primary 3 +pulmonary 4 +hypertension 4 +associated 0 +with 0 +appetite 1 +suppressants 2 +in 0 +Belgium 0 +. 0 +Primary 3 +pulmonary 4 +hypertension 4 +is 0 +a 0 +rare 0 +"," 0 +progressive 0 +and 0 +incurable 0 +disease 0 +"," 0 +which 0 +has 0 +been 0 +associated 0 +with 0 +the 0 +intake 0 +of 0 +appetite 1 +suppressant 2 +drugs 0 +. 0 +The 0 +importance 0 +of 0 +this 0 +association 0 +was 0 +evaluated 0 +in 0 +Belgium 0 +while 0 +this 0 +country 0 +still 0 +had 0 +no 0 +restriction 0 +on 0 +the 0 +prescription 0 +of 0 +appetite 1 +suppressants 2 +. 0 +Thirty 0 +- 0 +five 0 +patients 0 +with 0 +primary 3 +pulmonary 4 +hypertension 4 +and 0 +85 0 +matched 0 +controls 0 +were 0 +recruited 0 +over 0 +32 0 +months 0 +( 0 +1992 0 +- 0 +1994 0 +) 0 +in 0 +Belgium 0 +. 0 +Exposure 0 +to 0 +appetite 1 +- 2 +suppressants 2 +was 0 +assessed 0 +on 0 +the 0 +basis 0 +of 0 +hospital 0 +records 0 +and 0 +standardized 0 +interview 0 +. 0 +Twenty 0 +- 0 +three 0 +of 0 +the 0 +patients 0 +had 0 +previously 0 +taken 0 +appetite 1 +suppressants 2 +"," 0 +mainly 0 +fenfluramines 1 +"," 0 +as 0 +compared 0 +with 0 +only 0 +5 0 +of 0 +the 0 +controls 0 +( 0 +66 0 +versus 0 +6 0 +% 0 +"," 0 +p 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +Five 0 +patients 0 +died 0 +before 0 +the 0 +interview 0 +"," 0 +all 0 +of 0 +them 0 +had 0 +taken 0 +appetite 1 +suppressants 2 +. 0 +In 0 +8 0 +patients 0 +the 0 +diagnosis 0 +of 0 +primary 3 +pulmonary 4 +hypertension 4 +was 0 +uncertain 0 +"," 0 +5 0 +of 0 +them 0 +had 0 +taken 0 +appetite 1 +suppressants 2 +. 0 +The 0 +patients 0 +who 0 +had 0 +been 0 +exposed 0 +to 0 +appetite 1 +suppressants 2 +tended 0 +to 0 +be 0 +on 0 +average 0 +more 0 +severely 0 +ill 0 +"," 0 +and 0 +to 0 +have 0 +a 0 +shorter 0 +median 0 +delay 0 +between 0 +onset 0 +of 0 +symptoms 0 +and 0 +diagnosis 0 +. 0 +A 0 +policy 0 +of 0 +unrestricted 0 +prescription 0 +of 0 +appetite 1 +suppressants 2 +may 0 +lead 0 +to 0 +a 0 +high 0 +incidence 0 +of 0 +associated 0 +primary 3 +pulmonary 4 +hypertension 4 +. 0 +Intake 0 +of 0 +appetite 1 +suppressants 2 +may 0 +accelerate 0 +the 0 +progression 0 +of 0 +the 0 +disease 0 +. 0 +Inappropriate 0 +use 0 +of 0 +carbamazepine 1 +and 0 +vigabatrin 1 +in 0 +typical 0 +absence 3 +seizures 4 +. 0 +Carbamazepine 1 +and 0 +vigabatrin 1 +are 0 +contraindicated 0 +in 0 +typical 0 +absence 3 +seizures 4 +. 0 +0f 0 +18 0 +consecutive 0 +referrals 0 +of 0 +children 0 +with 0 +resistant 0 +typical 0 +absences 0 +only 0 +"," 0 +eight 0 +were 0 +erroneously 0 +treated 0 +with 0 +carbamazepine 1 +either 0 +as 0 +monotherapy 0 +or 0 +as 0 +an 0 +add 0 +- 0 +on 0 +. 0 +Vigabatrin 1 +was 0 +also 0 +used 0 +in 0 +the 0 +treatment 0 +of 0 +two 0 +children 0 +. 0 +Frequency 0 +of 0 +absences 0 +increased 0 +in 0 +four 0 +children 0 +treated 0 +with 0 +carbamazepine 1 +and 0 +two 0 +of 0 +these 0 +developed 0 +myoclonic 3 +jerks 4 +"," 0 +which 0 +resolved 0 +on 0 +withdrawal 0 +of 0 +carbamazepine 1 +. 0 +Absences 0 +were 0 +aggravated 0 +in 0 +both 0 +cases 0 +where 0 +vigabatrin 1 +was 0 +added 0 +on 0 +to 0 +concurrent 0 +treatment 0 +. 0 +0ptimal 0 +control 0 +of 0 +the 0 +absences 0 +was 0 +achieved 0 +with 0 +sodium 1 +valproate 2 +"," 0 +lamotrigine 1 +"," 0 +or 0 +ethosuximide 1 +alone 0 +or 0 +in 0 +combination 0 +. 0 +Choreoathetoid 3 +movements 4 +associated 0 +with 0 +rapid 0 +adjustment 0 +to 0 +methadone 1 +. 0 +Choreatiform 3 +hyperkinesias 4 +are 0 +known 0 +to 0 +be 0 +occasional 0 +movement 3 +abnormalities 4 +during 0 +intoxications 0 +with 0 +cocaine 1 +but 0 +not 0 +opiates 0 +. 0 +This 0 +is 0 +a 0 +case 0 +report 0 +of 0 +euphoria 0 +and 0 +choreoathetoid 3 +movements 4 +both 0 +transiently 0 +induced 0 +by 0 +rapid 0 +adjustment 0 +to 0 +the 0 +selective 0 +mu 0 +- 0 +opioid 0 +receptor 0 +agonist 0 +methadone 1 +in 0 +an 0 +inpatient 0 +previously 0 +abusing 0 +heroine 1 +and 0 +cocaine 1 +. 0 +In 0 +addition 0 +"," 0 +minor 0 +EEG 0 +abnormalities 0 +occurred 0 +. 0 +Possible 0 +underlying 0 +neurobiological 0 +phenomena 0 +are 0 +discussed 0 +. 0 +Adverse 0 +effects 0 +of 0 +the 0 +atypical 0 +antipsychotics 0 +. 0 +Collaborative 0 +Working 0 +Group 0 +on 0 +Clinical 0 +Trial 0 +Evaluations 0 +. 0 +Adverse 0 +effects 0 +of 0 +antipsychotics 0 +often 0 +lead 0 +to 0 +noncompliance 0 +. 0 +Thus 0 +"," 0 +clinicians 0 +should 0 +address 0 +patients 0 +' 0 +concerns 0 +about 0 +adverse 0 +effects 0 +and 0 +attempt 0 +to 0 +choose 0 +medications 0 +that 0 +will 0 +improve 0 +their 0 +patients 0 +' 0 +quality 0 +of 0 +life 0 +as 0 +well 0 +as 0 +overall 0 +health 0 +. 0 +The 0 +side 0 +effect 0 +profiles 0 +of 0 +the 0 +atypical 0 +antipsychotics 0 +are 0 +more 0 +advantageous 0 +than 0 +those 0 +of 0 +the 0 +conventional 0 +neuroleptics 0 +. 0 +Conventional 0 +agents 0 +are 0 +associated 0 +with 0 +unwanted 0 +central 0 +nervous 0 +system 0 +effects 0 +"," 0 +including 0 +extrapyramidal 3 +symptoms 4 +( 0 +EPS 3 +) 0 +"," 0 +tardive 3 +dyskinesia 4 +"," 0 +sedation 0 +"," 0 +and 0 +possible 0 +impairment 0 +of 0 +some 0 +cognitive 0 +measures 0 +"," 0 +as 0 +well 0 +as 0 +cardiac 0 +effects 0 +"," 0 +orthostatic 3 +hypotension 4 +"," 0 +hepatic 0 +changes 0 +"," 0 +anticholinergic 0 +side 0 +effects 0 +"," 0 +sexual 3 +dysfunction 4 +"," 0 +and 0 +weight 3 +gain 4 +. 0 +The 0 +newer 0 +atypical 0 +agents 0 +have 0 +a 0 +lower 0 +risk 0 +of 0 +EPS 3 +"," 0 +but 0 +are 0 +associated 0 +in 0 +varying 0 +degrees 0 +with 0 +sedation 0 +"," 0 +cardiovascular 0 +effects 0 +"," 0 +anticholinergic 0 +effects 0 +"," 0 +weight 3 +gain 4 +"," 0 +sexual 3 +dysfunction 4 +"," 0 +hepatic 0 +effects 0 +"," 0 +lowered 0 +seizure 3 +threshold 0 +( 0 +primarily 0 +clozapine 1 +) 0 +"," 0 +and 0 +agranulocytosis 3 +( 0 +clozapine 1 +only 0 +) 0 +. 0 +Since 0 +the 0 +incidence 0 +and 0 +severity 0 +of 0 +specific 0 +adverse 0 +effects 0 +differ 0 +among 0 +the 0 +various 0 +atypicals 0 +"," 0 +the 0 +clinician 0 +should 0 +carefully 0 +consider 0 +which 0 +side 0 +effects 0 +are 0 +most 0 +likely 0 +to 0 +lead 0 +to 0 +the 0 +individual 0 +' 0 +s 0 +dissatisfaction 0 +and 0 +noncompliance 0 +before 0 +choosing 0 +an 0 +antipsychotic 0 +for 0 +a 0 +particular 0 +patient 0 +. 0 +A 0 +randomized 0 +"," 0 +placebo 0 +- 0 +controlled 0 +dose 0 +- 0 +comparison 0 +trial 0 +of 0 +haloperidol 1 +for 0 +psychosis 3 +and 0 +disruptive 3 +behaviors 4 +in 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 +0BJECTIVE 0 +: 0 +The 0 +goal 0 +of 0 +this 0 +study 0 +was 0 +to 0 +compare 0 +the 0 +efficacy 0 +and 0 +side 0 +effects 0 +of 0 +two 0 +doses 0 +of 0 +haloperidol 1 +and 0 +placebo 0 +in 0 +the 0 +treatment 0 +of 0 +psychosis 3 +and 0 +disruptive 3 +behaviors 4 +in 0 +patients 0 +with 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 +METH0D 0 +: 0 +In 0 +a 0 +6 0 +- 0 +week 0 +random 0 +- 0 +assignment 0 +"," 0 +double 0 +- 0 +blind 0 +"," 0 +placebo 0 +- 0 +controlled 0 +trial 0 +( 0 +phase 0 +A 0 +) 0 +"," 0 +haloperidol 1 +"," 0 +2 0 +- 0 +3 0 +mg 0 +/ 0 +day 0 +( 0 +standard 0 +dose 0 +) 0 +"," 0 +and 0 +haloperidol 1 +"," 0 +0 0 +. 0 +50 0 +- 0 +0 0 +. 0 +75 0 +mg 0 +/ 0 +day 0 +( 0 +low 0 +dose 0 +) 0 +"," 0 +were 0 +compared 0 +in 0 +71 0 +outpatients 0 +with 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +. 0 +For 0 +the 0 +subsequent 0 +6 0 +- 0 +week 0 +double 0 +- 0 +blind 0 +crossover 0 +phase 0 +( 0 +phase 0 +B 0 +) 0 +"," 0 +patients 0 +taking 0 +standard 0 +- 0 +or 0 +low 0 +- 0 +dose 0 +haloperidol 1 +were 0 +switched 0 +to 0 +placebo 0 +"," 0 +and 0 +patients 0 +taking 0 +placebo 0 +were 0 +randomly 0 +assigned 0 +to 0 +standard 0 +- 0 +or 0 +low 0 +- 0 +dose 0 +haloperidol 1 +. 0 +RESULTS 0 +: 0 +For 0 +the 0 +60 0 +patients 0 +who 0 +completed 0 +phase 0 +A 0 +"," 0 +standard 0 +- 0 +dose 0 +haloperidol 1 +was 0 +efficacious 0 +and 0 +superior 0 +to 0 +both 0 +low 0 +- 0 +dose 0 +haloperidol 1 +and 0 +placebo 0 +for 0 +scores 0 +on 0 +the 0 +Brief 0 +Psychiatric 0 +Rating 0 +Scale 0 +psychosis 3 +factor 0 +and 0 +on 0 +psychomotor 3 +agitation 4 +. 0 +Response 0 +rates 0 +according 0 +to 0 +three 0 +sets 0 +of 0 +criteria 0 +were 0 +greater 0 +with 0 +the 0 +standard 0 +dose 0 +( 0 +55 0 +% 0 +- 0 +60 0 +% 0 +) 0 +than 0 +the 0 +low 0 +dose 0 +( 0 +25 0 +% 0 +- 0 +35 0 +% 0 +) 0 +and 0 +placebo 0 +( 0 +25 0 +% 0 +- 0 +30 0 +% 0 +) 0 +. 0 +The 0 +advantage 0 +of 0 +standard 0 +dose 0 +over 0 +low 0 +dose 0 +was 0 +replicated 0 +in 0 +phase 0 +B 0 +. 0 +In 0 +phase 0 +A 0 +"," 0 +extrapyramidal 3 +signs 4 +tended 0 +to 0 +be 0 +greater 0 +with 0 +the 0 +standard 0 +dose 0 +than 0 +in 0 +the 0 +other 0 +two 0 +conditions 0 +"," 0 +primarily 0 +because 0 +of 0 +a 0 +subgroup 0 +( 0 +20 0 +% 0 +) 0 +who 0 +developed 0 +moderate 0 +to 0 +severe 0 +signs 0 +. 0 +Low 0 +- 0 +dose 0 +haloperidol 1 +did 0 +not 0 +differ 0 +from 0 +placebo 0 +on 0 +any 0 +measure 0 +of 0 +efficacy 0 +or 0 +side 0 +effects 0 +. 0 +C0NCLUSI0NS 0 +: 0 +The 0 +results 0 +indicated 0 +a 0 +favorable 0 +therapeutic 0 +profile 0 +for 0 +haloperidol 1 +in 0 +doses 0 +of 0 +2 0 +- 0 +3 0 +mg 0 +/ 0 +day 0 +"," 0 +although 0 +a 0 +subgroup 0 +developed 0 +moderate 0 +to 0 +severe 0 +extrapyramidal 3 +signs 4 +. 0 +A 0 +starting 0 +dose 0 +of 0 +1 0 +mg 0 +/ 0 +day 0 +with 0 +gradual 0 +"," 0 +upward 0 +dose 0 +titration 0 +is 0 +recommended 0 +. 0 +The 0 +narrow 0 +therapeutic 0 +window 0 +observed 0 +with 0 +haloperidol 1 +may 0 +also 0 +apply 0 +to 0 +other 0 +neuroleptics 0 +used 0 +in 0 +Alzheimer 3 +' 4 +s 4 +disease 4 +patients 0 +with 0 +psychosis 3 +and 0 +disruptive 3 +behaviors 4 +. 0 +Effects 0 +of 0 +acetylsalicylic 1 +acid 2 +"," 0 +dipyridamole 1 +"," 0 +and 0 +hydrocortisone 1 +on 0 +epinephrine 1 +- 0 +induced 0 +myocardial 3 +injury 4 +in 0 +dogs 0 +. 0 +A 0 +reproducible 0 +model 0 +for 0 +producing 0 +diffuse 0 +myocardial 3 +injury 4 +( 0 +epinephrine 1 +infusion 0 +) 0 +has 0 +been 0 +developed 0 +to 0 +study 0 +the 0 +cardioprotective 0 +effects 0 +of 0 +agents 0 +or 0 +maneuvers 0 +which 0 +might 0 +alter 0 +the 0 +evolution 0 +of 0 +acute 0 +myocardial 3 +infarction 4 +. 0 +Infusions 0 +of 0 +epinephrine 1 +( 0 +4 0 +mug 0 +per 0 +kilogram 0 +per 0 +minute 0 +for 0 +6 0 +hours 0 +) 0 +increased 0 +radiocalcium 1 +uptakes 0 +into 0 +intact 0 +myocardium 0 +and 0 +each 0 +of 0 +its 0 +subcellular 0 +components 0 +with 0 +the 0 +mitochondrial 0 +fraction 0 +showing 0 +the 0 +most 0 +consistent 0 +changes 0 +when 0 +compared 0 +to 0 +saline 0 +- 0 +infused 0 +control 0 +animals 0 +( 0 +4 0 +"," 0 +957 0 +vs 0 +. 0 +827 0 +counts 0 +per 0 +minute 0 +per 0 +gram 0 +of 0 +dried 0 +tissue 0 +or 0 +fraction 0 +) 0 +. 0 +Myocardial 0 +concentrations 0 +of 0 +calcium 1 +also 0 +increased 0 +significantly 0 +( 0 +12 0 +. 0 +0 0 +vs 0 +. 0 +5 0 +. 0 +0 0 +mg 0 +. 0 +per 0 +100 0 +Gm 0 +. 0 +of 0 +fat 0 +- 0 +free 0 +dry 0 +weight 0 +) 0 +. 0 +Infusions 0 +of 0 +calcium 1 +chloride 2 +sufficient 0 +to 0 +raise 0 +serum 0 +calcium 1 +concentrations 0 +2 0 +mEq 0 +. 0 +per 0 +liter 0 +failed 0 +to 0 +increase 0 +calcium 1 +influx 0 +into 0 +the 0 +myocardial 0 +cell 0 +. 0 +Mitochondrial 0 +radiocalcium 1 +uptakes 0 +were 0 +significantly 0 +decreased 0 +in 0 +animals 0 +pretreated 0 +with 0 +acetylsalicylic 1 +acid 2 +or 0 +dipyridamole 1 +or 0 +when 0 +hydrocortisone 1 +was 0 +added 0 +to 0 +the 0 +epinephrine 1 +infusion 0 +( 0 +2 0 +"," 0 +682 0 +"," 0 +2 0 +"," 0 +803 0 +"," 0 +and 0 +3 0 +"," 0 +424 0 +counts 0 +per 0 +minute 0 +per 0 +gram 0 +of 0 +dried 0 +fraction 0 +"," 0 +respectively 0 +) 0 +. 0 +Myocardial 0 +calcium 1 +concentrations 0 +also 0 +were 0 +decreased 0 +( 0 +11 0 +. 0 +2 0 +"," 0 +8 0 +. 0 +3 0 +"," 0 +and 0 +8 0 +. 0 +9 0 +mg 0 +. 0 +per 0 +100 0 +Gm 0 +. 0 +of 0 +fat 0 +- 0 +free 0 +dry 0 +weight 0 +"," 0 +respectively 0 +) 0 +in 0 +the 0 +three 0 +treatment 0 +groups 0 +"," 0 +being 0 +significantly 0 +decreased 0 +only 0 +in 0 +the 0 +last 0 +two 0 +. 0 +Evidence 0 +of 0 +microscopic 0 +damage 0 +was 0 +graded 0 +as 0 +less 0 +severe 0 +in 0 +the 0 +three 0 +treatment 0 +groups 0 +. 0 +Acetylsalicylic 1 +acid 2 +"," 0 +dipyridamole 1 +"," 0 +and 0 +hydrocortisone 1 +all 0 +appear 0 +to 0 +have 0 +cardioprotective 0 +effects 0 +when 0 +tested 0 +in 0 +this 0 +model 0 +. 0 +Clinical 0 +and 0 +histopathologic 0 +examination 0 +of 0 +renal 0 +allografts 0 +treated 0 +with 0 +tacrolimus 1 +( 0 +FK506 1 +) 0 +for 0 +at 0 +least 0 +one 0 +year 0 +. 0 +BACKGR0UND 0 +: 0 +We 0 +clinically 0 +and 0 +pathologically 0 +analyzed 0 +renal 0 +allografts 0 +from 0 +1 0 +9 0 +renal 0 +transplant 0 +patients 0 +treated 0 +with 0 +tacrolimus 1 +( 0 +FK506 1 +) 0 +for 0 +more 0 +than 0 +1 0 +year 0 +. 0 +METH0DS 0 +: 0 +Twenty 0 +- 0 +six 0 +renal 0 +allograft 0 +biopsy 0 +specimens 0 +from 0 +1 0 +9 0 +renal 0 +transplant 0 +patients 0 +who 0 +underwent 0 +transplantations 0 +between 0 +1991 0 +and 0 +1993 0 +were 0 +evaluated 0 +. 0 +Thirteen 0 +biopsies 0 +were 0 +performed 0 +from 0 +stable 0 +functioning 0 +renal 0 +allografts 0 +with 0 +informed 0 +consent 0 +( 0 +nonepisode 0 +biopsy 0 +) 0 +and 0 +the 0 +other 0 +13 0 +were 0 +from 0 +dysfunctional 0 +renal 0 +allografts 0 +with 0 +a 0 +clinical 0 +indication 0 +for 0 +biopsy 0 +( 0 +episode 0 +biopsy 0 +) 0 +. 0 +RESULTS 0 +: 0 +The 0 +main 0 +pathologic 0 +diagnoses 0 +( 0 +some 0 +overlap 0 +) 0 +were 0 +acute 0 +rejection 0 +( 0 +AR 0 +; 0 +n 0 += 0 +4 0 +) 0 +"," 0 +chronic 0 +rejection 0 +( 0 +CR 0 +; 0 +n 0 += 0 +5 0 +) 0 +"," 0 +AR 0 ++ 0 +CR 0 +( 0 +n 0 += 0 +4 0 +) 0 +"," 0 +recurrent 0 +IgA 3 +nephropathy 4 +( 0 +n 0 += 0 +5 0 +) 0 +"," 0 +normal 0 +findings 0 +( 0 +n 0 += 0 +2 0 +) 0 +"," 0 +minimal 0 +- 0 +type 0 +chronic 0 +FK506 1 +nephropathy 3 +( 0 +n 0 += 0 +9 0 +) 0 +"," 0 +and 0 +mild 0 +- 0 +type 0 +FK506 1 +nephropathy 3 +( 0 +n 0 += 0 +11 0 +) 0 +. 0 +0f 0 +the 0 +nonepisode 0 +biopsies 0 +"," 0 +7 0 +and 0 +4 0 +biopsies 0 +showed 0 +minimal 0 +- 0 +type 0 +and 0 +mild 0 +- 0 +type 0 +chronic 0 +FK506 1 +nephropathy 3 +"," 0 +respectively 0 +. 0 +Chronic 0 +FK506 1 +nephropathy 3 +consisted 0 +of 0 +rough 0 +and 0 +foamy 0 +tubular 0 +vacuolization 0 +( 0 +5 0 +biopsies 0 +) 0 +"," 0 +arteriolopathy 0 +( 0 +angiodegeneration 0 +of 0 +the 0 +arteriolar 0 +wall 0 +; 0 +20 0 +biopsies 0 +) 0 +"," 0 +focal 3 +segmental 4 +glomerulosclerosis 4 +( 0 +4 0 +biopsies 0 +) 0 +and 0 +the 0 +striped 0 +form 0 +of 0 +interstitial 3 +fibrosis 4 +( 0 +11 0 +biopsies 0 +) 0 +. 0 +The 0 +serum 0 +creatinine 1 +levels 0 +of 0 +patients 0 +in 0 +the 0 +mild 0 +- 0 +type 0 +chronic 0 +FK506 1 +nephropathy 3 +group 0 +"," 0 +which 0 +included 0 +7 0 +episode 0 +biopsies 0 +"," 0 +were 0 +statistically 0 +higher 0 +than 0 +those 0 +in 0 +the 0 +minimum 0 +- 0 +type 0 +chronic 0 +FK506 1 +- 0 +nephropathy 3 +group 0 +( 0 +P 0 +< 0 +0 0 +. 0 +1 0 +) 0 +. 0 +C0NCLUSI0NS 0 +: 0 +This 0 +study 0 +demonstrates 0 +that 0 +chronic 0 +FK506 1 +nephropathy 3 +consists 0 +primarily 0 +of 0 +arteriolopathy 0 +manifesting 0 +as 0 +insudative 0 +hyalinosis 0 +of 0 +the 0 +arteriolar 0 +wall 0 +"," 0 +and 0 +suggests 0 +that 0 +mild 0 +- 0 +type 0 +chronic 0 +FK506 1 +nephropathy 3 +is 0 +a 0 +condition 0 +which 0 +may 0 +lead 0 +to 0 +deterioration 0 +of 0 +renal 0 +allograft 0 +function 0 +. 0 +Different 0 +lobular 0 +distributions 0 +of 0 +altered 0 +hepatocyte 0 +tight 0 +junctions 0 +in 0 +rat 0 +models 0 +of 0 +intrahepatic 3 +and 4 +extrahepatic 4 +cholestasis 4 +. 0 +Hepatocyte 0 +tight 0 +junctions 0 +( 0 +TJs 0 +) 0 +"," 0 +the 0 +only 0 +intercellular 0 +barrier 0 +between 0 +the 0 +sinusoidal 0 +and 0 +the 0 +canalicular 0 +spaces 0 +"," 0 +play 0 +a 0 +key 0 +role 0 +in 0 +bile 0 +formation 0 +. 0 +Although 0 +hepatocyte 0 +TJs 0 +are 0 +impaired 0 +in 0 +cholestasis 3 +"," 0 +attempts 0 +to 0 +localize 0 +the 0 +precise 0 +site 0 +of 0 +hepatocyte 0 +TJ 0 +damage 0 +by 0 +freeze 0 +- 0 +fracture 0 +electron 0 +microscopy 0 +have 0 +produced 0 +limited 0 +information 0 +. 0 +Recently 0 +"," 0 +several 0 +TJ 0 +- 0 +associated 0 +proteins 0 +like 0 +Z0 0 +- 0 +1 0 +and 0 +7H6 0 +have 0 +been 0 +identified 0 +and 0 +characterized 0 +. 0 +Immunolocalization 0 +of 0 +7H6 0 +appears 0 +to 0 +closely 0 +correlate 0 +with 0 +paracellular 0 +permeability 0 +. 0 +We 0 +used 0 +rat 0 +models 0 +of 0 +intrahepatic 3 +cholestasis 4 +by 0 +ethinyl 1 +estradiol 2 +( 0 +EE 1 +) 0 +treatment 0 +and 0 +extrahepatic 3 +cholestasis 4 +by 0 +bile 0 +duct 0 +ligation 0 +( 0 +BDL 0 +) 0 +to 0 +precisely 0 +determine 0 +the 0 +site 0 +of 0 +TJ 0 +damage 0 +. 0 +Alterations 0 +in 0 +hepatocyte 0 +TJs 0 +were 0 +assessed 0 +by 0 +double 0 +- 0 +immunolabeling 0 +for 0 +7H6 0 +and 0 +Z0 0 +- 0 +1 0 +using 0 +a 0 +confocal 0 +laser 0 +scanning 0 +microscope 0 +. 0 +In 0 +control 0 +rats 0 +"," 0 +immunostaining 0 +for 0 +7H6 0 +and 0 +Z0 0 +- 0 +1 0 +colocalized 0 +to 0 +outline 0 +bile 0 +canaliculi 0 +in 0 +a 0 +continuous 0 +fashion 0 +. 0 +In 0 +contrast 0 +"," 0 +7H6 0 +and 0 +Z0 0 +- 0 +1 0 +immunostaining 0 +was 0 +more 0 +discontinuous 0 +"," 0 +outlining 0 +the 0 +bile 0 +canaliculi 0 +after 0 +BDL 0 +. 0 +Immunostaining 0 +for 0 +7H6 0 +"," 0 +not 0 +Z0 0 +- 0 +1 0 +"," 0 +decreased 0 +and 0 +predominantly 0 +appeared 0 +as 0 +discrete 0 +signals 0 +in 0 +the 0 +submembranous 0 +cytoplasm 0 +of 0 +periportal 0 +hepatocytes 0 +after 0 +BDL 0 +. 0 +After 0 +EE 1 +treatment 0 +"," 0 +changes 0 +in 0 +immunostaining 0 +for 0 +7H6 0 +and 0 +Z0 0 +- 0 +1 0 +were 0 +similar 0 +to 0 +those 0 +seen 0 +in 0 +periportal 0 +hepatocytes 0 +after 0 +BDL 0 +"," 0 +but 0 +distributed 0 +more 0 +diffusely 0 +throughout 0 +the 0 +lobule 0 +. 0 +This 0 +study 0 +is 0 +the 0 +first 0 +to 0 +demonstrate 0 +that 0 +impairment 0 +of 0 +hepatocyte 0 +TJs 0 +occurs 0 +heterogenously 0 +in 0 +the 0 +liver 0 +lobule 0 +after 0 +BDL 0 +and 0 +suggests 0 +that 0 +BDL 0 +and 0 +EE 1 +treatments 0 +produce 0 +different 0 +lobular 0 +distributions 0 +of 0 +increased 0 +paracellular 0 +permeability 0 +. 0 +Memory 0 +facilitation 0 +and 0 +stimulation 0 +of 0 +endogenous 0 +nerve 0 +growth 0 +factor 0 +synthesis 0 +by 0 +the 0 +acetylcholine 1 +releaser 0 +PG 1 +- 2 +9 2 +. 0 +The 0 +effects 0 +of 0 +PG 1 +- 2 +9 2 +( 0 +3alpha 1 +- 2 +tropyl 2 +2 2 +- 2 +( 2 +p 2 +- 2 +bromophenyl 2 +) 2 +propionate 2 +) 0 +"," 0 +the 0 +acetylcholine 1 +releaser 0 +"," 0 +on 0 +memory 0 +processes 0 +and 0 +nerve 0 +growth 0 +factor 0 +( 0 +NGF 0 +) 0 +synthesis 0 +were 0 +evaluated 0 +. 0 +In 0 +the 0 +mouse 0 +passive 0 +- 0 +avoidance 0 +test 0 +"," 0 +PG 1 +- 2 +9 2 +( 0 +10 0 +- 0 +30 0 +mg 0 +/ 0 +kg 0 +"," 0 +i 0 +. 0 +p 0 +. 0 +) 0 +"," 0 +administered 0 +20 0 +min 0 +before 0 +the 0 +training 0 +session 0 +"," 0 +prevented 0 +amnesia 3 +induced 0 +by 0 +both 0 +the 0 +non 0 +selective 0 +antimuscarinic 0 +drug 0 +scopolamine 1 +and 0 +the 0 +M1 0 +- 0 +selective 0 +antagonist 0 +S 1 +- 2 +( 2 +- 2 +) 2 +- 2 +ET 2 +- 2 +126 2 +. 0 +In 0 +the 0 +same 0 +experimental 0 +conditions 0 +"," 0 +PG 1 +- 2 +9 2 +( 0 +5 0 +- 0 +20 0 +microg 0 +per 0 +mouse 0 +"," 0 +i 0 +. 0 +c 0 +. 0 +v 0 +. 0 +) 0 +was 0 +also 0 +able 0 +to 0 +prevent 0 +antimuscarine 0 +- 0 +induced 0 +amnesia 3 +"," 0 +demonstrating 0 +a 0 +central 0 +localization 0 +of 0 +the 0 +activity 0 +. 0 +At 0 +the 0 +highest 0 +effective 0 +doses 0 +"," 0 +PG 1 +- 2 +9 2 +did 0 +not 0 +produce 0 +any 0 +collateral 0 +symptoms 0 +as 0 +revealed 0 +by 0 +the 0 +Irwin 0 +test 0 +"," 0 +and 0 +it 0 +did 0 +not 0 +modify 0 +spontaneous 0 +motility 0 +and 0 +inspection 0 +activity 0 +"," 0 +as 0 +revealed 0 +by 0 +the 0 +hole 0 +- 0 +board 0 +test 0 +. 0 +PG 1 +- 2 +9 2 +was 0 +also 0 +able 0 +to 0 +increase 0 +the 0 +amount 0 +of 0 +NGF 0 +secreted 0 +in 0 +vitro 0 +by 0 +astrocytes 0 +in 0 +a 0 +dose 0 +- 0 +dependent 0 +manner 0 +. 0 +The 0 +maximal 0 +NGF 0 +contents 0 +obtained 0 +by 0 +PG 1 +- 2 +9 2 +were 0 +17 0 +. 0 +6 0 +- 0 +fold 0 +of 0 +the 0 +control 0 +value 0 +. 0 +During 0 +culture 0 +"," 0 +no 0 +morphological 0 +changes 0 +were 0 +found 0 +at 0 +effective 0 +concentrations 0 +of 0 +PG 1 +- 2 +9 2 +. 0 +The 0 +current 0 +work 0 +indicates 0 +the 0 +ability 0 +of 0 +PG 1 +- 2 +9 2 +to 0 +induce 0 +beneficial 0 +effects 0 +on 0 +cognitive 0 +processes 0 +and 0 +stimulate 0 +activity 0 +of 0 +NGF 0 +synthesis 0 +in 0 +astroglial 0 +cells 0 +. 0 +Therefore 0 +"," 0 +PG 1 +- 2 +9 2 +could 0 +represent 0 +a 0 +potential 0 +useful 0 +drug 0 +able 0 +to 0 +improve 0 +the 0 +function 0 +of 0 +impaired 0 +cognitive 0 +processes 0 +. 0 +Mechanisms 0 +of 0 +FK 1 +506 2 +- 0 +induced 0 +hypertension 3 +in 0 +the 0 +rat 0 +. 0 +- 0 +Tacrolimus 1 +( 0 +FK 1 +506 2 +) 0 +is 0 +a 0 +powerful 0 +"," 0 +widely 0 +used 0 +immunosuppressant 0 +. 0 +The 0 +clinical 0 +utility 0 +of 0 +FK 1 +506 2 +is 0 +complicated 0 +by 0 +substantial 0 +hypertension 3 +and 0 +nephrotoxicity 3 +. 0 +To 0 +clarify 0 +the 0 +mechanisms 0 +of 0 +FK 1 +506 2 +- 0 +induced 0 +hypertension 3 +"," 0 +we 0 +studied 0 +the 0 +chronic 0 +effects 0 +of 0 +FK 1 +506 2 +on 0 +the 0 +synthesis 0 +of 0 +endothelin 0 +- 0 +1 0 +( 0 +ET 0 +- 0 +1 0 +) 0 +"," 0 +the 0 +expression 0 +of 0 +mRNA 0 +of 0 +ET 0 +- 0 +1 0 +and 0 +endothelin 0 +- 0 +converting 0 +enzyme 0 +- 0 +1 0 +( 0 +ECE 0 +- 0 +1 0 +) 0 +"," 0 +the 0 +endothelial 0 +nitric 1 +oxide 2 +synthase 0 +( 0 +eN0S 0 +) 0 +activity 0 +"," 0 +and 0 +the 0 +expression 0 +of 0 +mRNA 0 +of 0 +eN0S 0 +and 0 +C 0 +- 0 +type 0 +natriuretic 0 +peptide 0 +( 0 +CNP 0 +) 0 +in 0 +rat 0 +blood 0 +vessels 0 +. 0 +In 0 +addition 0 +"," 0 +the 0 +effect 0 +of 0 +the 0 +specific 0 +endothelin 0 +type 0 +A 0 +receptor 0 +antagonist 0 +FR 1 +139317 2 +on 0 +FK 1 +506 2 +- 0 +induced 0 +hypertension 3 +in 0 +rats 0 +was 0 +studied 0 +. 0 +FK 1 +506 2 +"," 0 +5 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +d 0 +- 0 +1 0 +given 0 +for 0 +4 0 +weeks 0 +"," 0 +elevated 0 +blood 0 +pressure 0 +from 0 +102 0 ++ 0 +/ 0 +- 0 +13 0 +to 0 +152 0 ++ 0 +/ 0 +- 0 +15 0 +mm 0 +Hg 0 +and 0 +increased 0 +the 0 +synthesis 0 +of 0 +ET 0 +- 0 +1 0 +and 0 +the 0 +levels 0 +of 0 +ET 0 +- 0 +1 0 +mRNA 0 +in 0 +the 0 +mesenteric 0 +artery 0 +( 0 +240 0 +% 0 +and 0 +230 0 +% 0 +"," 0 +respectively 0 +) 0 +. 0 +Little 0 +change 0 +was 0 +observed 0 +in 0 +the 0 +expression 0 +of 0 +ECE 0 +- 0 +1 0 +mRNA 0 +and 0 +CNP 0 +mRNA 0 +. 0 +FK 1 +506 2 +decreased 0 +eN0S 0 +activity 0 +and 0 +the 0 +levels 0 +of 0 +eN0S 0 +mRNA 0 +in 0 +the 0 +aorta 0 +( 0 +48 0 +% 0 +and 0 +55 0 +% 0 +"," 0 +respectively 0 +) 0 +. 0 +The 0 +administration 0 +of 0 +FR 1 +139317 2 +( 0 +10 0 +mg 0 +. 0 +kg 0 +- 0 +1 0 +. 0 +d 0 +- 0 +1 0 +) 0 +prevented 0 +FK 1 +506 2 +- 0 +induced 0 +hypertension 3 +in 0 +rats 0 +. 0 +These 0 +results 0 +indicate 0 +that 0 +FK 1 +506 2 +may 0 +increase 0 +blood 0 +pressure 0 +not 0 +only 0 +by 0 +increasing 0 +ET 0 +- 0 +1 0 +production 0 +but 0 +also 0 +by 0 +decreasing 0 +N0 1 +synthesis 0 +in 0 +the 0 +vasculature 0 +. 0